<SEC-DOCUMENT>0000950170-24-023237.txt : 20240229
<SEC-HEADER>0000950170-24-023237.hdr.sgml : 20240229
<ACCEPTANCE-DATETIME>20240229170100
ACCESSION NUMBER:		0000950170-24-023237
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		125
CONFORMED PERIOD OF REPORT:	20231231
FILED AS OF DATE:		20240229
DATE AS OF CHANGE:		20240229

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Innoviva, Inc.
		CENTRAL INDEX KEY:			0001080014
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				943265960
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30319
		FILM NUMBER:		24704844

	BUSINESS ADDRESS:	
		STREET 1:		1350 OLD BAYSHORE HIGHWAY
		STREET 2:		SUITE 400
		CITY:			BURLINGAME
		STATE:			CA
		ZIP:			94010
		BUSINESS PHONE:		6502389600

	MAIL ADDRESS:	
		STREET 1:		1350 OLD BAYSHORE HIGHWAY
		STREET 2:		SUITE 400
		CITY:			BURLINGAME
		STATE:			CA
		ZIP:			94010

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	THERAVANCE INC
		DATE OF NAME CHANGE:	20020207

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADVANCED MEDICINE INC
		DATE OF NAME CHANGE:	20000302
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>inva-20231231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:inva="http://www.inva.com/20231231" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16">
 <head>
  <title>10-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_a7027fdd-0941-440c-9c9d-cdfbda79f29c" name="dei:EntityCentralIndexKey" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1">0001080014</ix:nonNumeric><ix:nonNumeric id="F_7f36bfc1-3e2a-4e7e-8df6-9c20266e1dfa" name="dei:AmendmentFlag" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1">false</ix:nonNumeric><ix:nonNumeric id="F_ea74df07-20a7-42c8-8e36-3fab5a27a4c1" name="dei:DocumentFiscalYearFocus" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1">2023</ix:nonNumeric><ix:nonNumeric id="F_2d907aa0-bc18-4de5-952b-9071c0e09061" name="dei:DocumentFiscalPeriodFocus" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1">FY</ix:nonNumeric><ix:nonFraction id="F_2f119708-881a-4577-8742-9ee60a34c0fc" name="us-gaap:CommitmentsAndContingencies" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_118b362a-f883-4a7d-b60c-4f79a2ad6875" name="us-gaap:CommitmentsAndContingencies" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_f0687ae1-b6c0-4b43-81f8-6dd3b3798531" name="us-gaap:AccountingStandardsUpdateExtensibleList" contextRef="C_0f0e0c31-e997-4327-b909-2d345a34ba21">http://fasb.org/us-gaap/2023#AccountingStandardsUpdate202006Member</ix:nonNumeric><ix:nonNumeric id="F_ef17ea9b-bf17-4735-b022-25e18ecf85bb" name="us-gaap:AccountingStandardsUpdateExtensibleList" contextRef="C_bd738e6b-a394-4de5-a04f-1f55e1ed3e59">http://fasb.org/us-gaap/2023#AccountingStandardsUpdate202006Member</ix:nonNumeric><ix:nonNumeric id="F_2dbed8c2-40ac-48d1-9ee8-996ed0f6f21a" name="us-gaap:AccountingStandardsUpdateExtensibleList" contextRef="C_5460cef4-c4cc-4668-99ef-fb2e26f72ba2">http://fasb.org/us-gaap/2023#AccountingStandardsUpdate202006Member</ix:nonNumeric><ix:nonNumeric id="F_16022dea-4c29-4456-a7e5-3f052ff36fa9" name="inva:ExtendedExpirationDate" contextRef="C_8591827b-2838-4d76-9be9-a5c2eecadbf7">2023-03-31</ix:nonNumeric><ix:nonNumeric id="F_4d9e1814-d90c-438a-b69f-2d0819d5112e" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e">http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric id="F_62616aa1-c408-4682-b198-b4aacc8031c4" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63">http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric id="F_8a36ba82-b9a3-4b23-adb9-3d2b758e3db2" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e">http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric id="F_fbfec351-c094-49d9-a03a-e641b11869bb" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63">http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric id="F_7da350c6-153c-485b-808f-be5a8394009e" name="us-gaap:LesseeOperatingLeaseTermOfContract" contextRef="C_b14e6b43-6384-43b6-9c33-6f1a35010333">P36M</ix:nonNumeric><ix:nonNumeric id="F_4335f0ee-8c74-4e0b-beba-133f49c7dc56" name="us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e">http://fasb.org/us-gaap/2023#LiabilitiesAndStockholdersEquity</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="inva-20231231.xsd"/></ix:references><ix:resources><xbrli:context id="C_b6abf77e-c226-4f1c-b9e9-b0f6f21c3bb2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d175404c-e239-4f30-bbd0-3bbf386d06ea"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:LaJollaPharmaceuticalCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_35f64b46-11ed-4d73-b48d-9b0294e79c59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ce2c65ac-3b0f-4cd6-a073-a6b687f80393"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7b934074-97f1-4177-96bc-6664a24ee9fa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-08-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b697daba-e91e-4352-8b6f-532cdaacd5fa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cdf38ae8-3488-4d9c-82c7-3e8d9ebc8c31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:NanoliveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b8a25da7-f0c7-4777-ac22-af038c29402e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0dca3067-b301-4dc8-acf3-6ddafb2e6e93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4e8c55ea-f6dc-4620-b986-2786c29cf612"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-08-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fb582b1b-defd-402a-8689-f3dd46cd150b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_175d99d3-70ac-4ebe-93be-8247d1fbe50e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:SarissaCapitalManagementLpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_eed06e0c-196c-43ba-8f27-6f6c2781e050"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_70752bbf-999a-40de-bb2c-738c0b7f7ada"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:IspFundLpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_69fb044e-5d2a-46bb-ae62-33b02683b43d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:CostReimbursementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:PaionAgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_19a3e0c0-9301-442d-a4f9-622a1ad048d2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4db40aa1-f9c9-4e8f-b9d8-1756f4712094"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:TheravanceRespiratoryCompanyLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-20</xbrli:startDate><xbrli:endDate>2022-07-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ed72a4a0-2d3e-42f5-b565-15482cc0126c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6d1cd716-967a-4cec-ae43-c48297ca0a77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a0b988e7-21ed-4760-8751-f6fa519d9c49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inva:CommercialSupplyAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:EverestMedicinesLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c1969bd2-5e89-423e-88e9-b5564c6afe10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:GSKMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bd738e6b-a394-4de5-a04f-1f55e1ed3e59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_21e1bf8d-0dfb-436e-a0f5-40401cbd051a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_30cc733a-2659-49f2-9019-387d5263bfd5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:GateNeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fa14f0b8-b80c-4b7b-b274-a48521a14a84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_45a2b910-f147-4239-a429-43ed79c4207b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_44f0f126-1c89-49be-aae9-85fa06e97ffc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">inva:PrivatelyNegotiatedCappedCallOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2014-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f0f3a5ea-44ff-44dc-9c12-7e3628fc5813"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ce39f75c-0185-4a4f-87c1-250c81cd12eb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cdba2e0f-32b5-4b89-bd92-54198cce3aa9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4c92ef07-b330-4a35-9de3-b077cb45c462"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:CreditAndSecurityAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-10</xbrli:startDate><xbrli:endDate>2023-07-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e78c50b6-10c0-4578-be27-2aad784b619e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:LongActingBeta2AgonistAnoroMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:GSKMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f6067cb4-1702-418f-8410-c3ff025f386d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inva:LabaCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:LongActingBeta2AgonistRelvarBreoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:GSKMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_48c187f6-6fef-4cb6-83d6-250ba457d99a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6f92e4e3-0288-40a0-9972-c89e1aac1433"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyEightNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_83a2b6b3-d55f-414b-a77a-bc247a02d235"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:EverestMedicinesLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c86331ec-9958-472c-9d3d-73034f0f043f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9ddbdfad-57e5-479b-ba9a-8f0e252307df"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:ZaiLabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:ResearchAndDevelopmentSupportMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1fd35541-50f5-4c16-a031-bd9cc78d2a09"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_75ab87a5-b754-4d3e-95be-4a5426c4c785"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_12a01e00-2ffc-4751-bfae-ab411878a4e9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6f3330be-9c77-42d3-931d-990047c9e84c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">inva:NewDebtInstrumentInterestRateAfterRepurchaseOfNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1c6f694e-9295-44ca-bb54-e10942065024"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:ParatekPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f4dfb9e5-6e91-41c1-a947-ccb6c551ac4d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ArmataTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_abc0a929-7e90-463f-b887-b58ca920de42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:HealthCareRoyaltyPartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:RoyaltyFinancingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_00bcfed5-5665-4a95-a3f4-d2ac0f6fdaa3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:IspFundLpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">inva:EquityInvestmentsAndMoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_90e80338-5725-4945-ba17-420b39d8a65d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9fea235d-92aa-406b-99d4-cef846711663"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8b18bfe1-7298-47b5-82af-99cfcef35fce"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:LaJollaPharmaceuticalCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f20a0f71-d04c-4707-b554-1102f62cf1a6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5f070bd2-c0df-4242-beff-e5f9b6727217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f018c1ca-e8f9-4a4f-9827-94816b25882f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:SecondNoteAmendmentAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:GateNeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_85e74837-f1dd-4956-a48b-f67a1bfe07cf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5c0f9d6a-daac-43d5-9697-46136da2e5eb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:LongActingBeta2AgonistAnoroMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:GSKMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_710dc59e-981c-4ad8-987e-bb49af565884"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_09977380-7092-418e-b4d3-d48f7caaae46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f08bc742-7ba2-448a-ba4b-b3bb674bb334"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:PutOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2013-01-01</xbrli:startDate><xbrli:endDate>2013-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c2c8ab67-08be-4854-91e3-98e911bef5b3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4b010911-360b-4122-a51a-2daa2012b8a9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">inva:TermLoanInvestmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6672ccef-5420-4f2f-9dd7-acb4111b0173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:CallOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2013-01-01</xbrli:startDate><xbrli:endDate>2013-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4e8f4a7f-a815-47e5-91cf-9d09535c48ce"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:LaJollaPharmaceuticalCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-01</xbrli:startDate><xbrli:endDate>2023-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f6a3bb99-253a-4791-914d-f4334dddf22a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c2081d77-3917-481a-aad9-38a97a27b3f4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ConsolidatedInvesteesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ImaginabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_441daf0e-a05d-414c-8eaa-feeb49fa7590"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">inva:LaboratoryEquipmentFurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4eb342bb-a67b-41a2-af3e-2b6b0a442022"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a97169bf-af91-4b94-a033-7619a6aaa930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ad1bdaae-2e73-4919-aef7-1bf53376deb1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ffbac92f-8341-4e52-864a-91ee3864a86e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:GSKMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_569e7525-942b-48c6-9703-ac849c3d278a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:IspFundLpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_105e2ff6-b00c-4d0f-80a9-99bc41fa4247"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IncardaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e112a83c-e5e4-49f5-9f29-958a211ef1b6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:IncardaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9fb8ce09-b755-456a-88b1-2a93a91dc1d0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inva:LabaCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:GSKMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2014-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3b5f86a2-e137-470e-ae05-ea4b9e220cfa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9c42d5a6-8705-438d-afbc-23f20a000d9b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5d7298e5-9f61-4332-aa3f-399d8b896265"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2e71015c-4917-4b0c-8a50-046d7e6f4812"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inva:CustomerOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:LaJollaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e3c81efe-d99a-4794-9295-046bab474ae8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fa7ab020-0f18-40e9-ae65-5d70aca1f021"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:InnovivaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bb2dfb4c-8159-49a4-8abd-85f592b904b8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:LaJollaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-22</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2357dcf9-e127-4ee9-a066-9899931c287f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ImaginabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:OneOfImaginabsCommonStockholderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-18</xbrli:startDate><xbrli:endDate>2021-03-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0c5dc7e3-2671-4634-a2ea-45c94c03c65f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c104561f-a325-42f1-b855-c5fa80ede0f4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b1399523-0285-44ab-8535-deb7616f55e6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_41328be9-6954-48ec-8905-bb9f765ccba2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8b89681a-3d4d-4507-960c-e611eee0ae68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2297939c-7913-4791-9563-25bbf6ee309c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inva:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_850c3b25-8c30-4a01-9de2-0ca85949a00e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:LaJollaPharmaceuticalCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dc1e896e-f118-48b0-8cb0-89c09e214ab6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c00f47a4-0506-4cb6-a19d-c4eb9dd56571"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ConsolidatedInvesteesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_73b7ce85-a0d4-4185-bb79-15359bd6b909"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ArmataConvertibleNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e3a16997-be95-4821-b76f-a08d875b0dcf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1ed70a12-64b7-49e4-b68e-70f274537beb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inva:CustomerOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:LaJollaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cff2e9b5-87f8-419f-9856-34ae17e4d036"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a48b0af5-32e5-4d70-8301-ead504e49b4c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4a4dcf17-e144-4065-bc02-636f5d4b60be"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:HarvardUniversityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9eec32d5-1f8c-44e6-9ec4-05156ada8af3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_919c050c-8a72-41cb-a13c-102eefa52e63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f7d458fe-e023-4486-aa27-fdd8c78f09fa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5cb2b0db-90a2-4560-b85e-87494f6a7282"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:CommonStockAndWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_eaa09fba-b20a-4958-908d-40cfb3339c00"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyEightNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9030a2c1-fd8e-4238-9d01-79bece46654e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IspFundLpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c8d0b01f-64b8-4438-8b36-9e1b99364b0b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_77a6d898-3c41-425f-bdce-0d730d09522d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:GateNeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6bed736f-3aa9-4d71-818d-93a8fca55527"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a5bd2f55-3e40-4db1-9698-8e328bebe397"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b0777350-8f02-402b-b8d8-33ebfbea0625"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f252cf15-a5b7-46ae-b4cf-f02a7d2a1bf9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:LaJollaPharmaceuticalCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a57ec5ea-103b-4914-89c8-f5cce009d3f2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:NanoliveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-18</xbrli:startDate><xbrli:endDate>2022-02-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_702028fe-7b13-49f6-bf9a-e4aaba3364f4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_68f79cad-95a1-43ef-b218-21108e820b17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c11bea0f-0ab6-46b3-9574-250a23feeefc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyEightNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_47540ae3-5ee1-428f-99db-8eab3bc7a785"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:HealthCareRoyaltyPartnersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_707fc4b5-3c6e-4394-b574-0e56dc4f8c0a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-11</xbrli:startDate><xbrli:endDate>2022-07-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d7474670-7c71-498e-a093-31edba908380"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IncardaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">inva:OptionPricingModelBacksolveValuationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6e16f944-8e12-42b7-84eb-4f21d332cd44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:TrelegyElliptaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:GSKMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_29193a89-f8bc-431f-9fc2-70fd8e836d0e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_109bc829-e421-4835-9aad-dedc4c375347"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:IncardaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_539783b3-bf29-4a63-8d24-99d7b7b79e81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:GSKMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3b21613e-2472-472e-b92e-7b218fb6aecc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:NoteAmendmentAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:GateNeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_809b9867-b962-4553-b6ab-8ca43d28920b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c1cee939-99f5-4170-95af-3c7cd8ef24ef"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:LicenseRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cb4e7215-9a5e-4dd4-aeee-e50dd4e2eb6b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5adfa42a-1fb9-4bab-ac06-149565b0b62c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">inva:EquityIncentivePlansAndESPPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d2367046-d399-4ddc-a17e-2f5ef1165e9e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_394439fc-7c8a-4379-be01-6a604b354293"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b628e0b4-4491-4cf0-9301-fd0c4a42318f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IncardaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">inva:OptionPricingModelBacksolveValuationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_20a1bbc0-a748-41da-a071-6972900ca7d7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:PaionAgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7595f3bf-096e-45fc-b68b-d690c0d2803e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:IspFundLpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">inva:EquityInvestmentsAndMoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2bff9226-01dd-49ce-8c00-439b9b368e4f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:AstrazenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_08e9488e-214d-4494-813d-28131fd90598"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:IspFundLpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5ca60e7e-4ba6-40eb-a454-386ec8c73923"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d7cf516f-572b-431a-8937-a3fa41621ee5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c6dfd9f2-8eeb-44c2-9621-2be87264e608"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0fcc5eab-dacf-4fd9-9338-7ce4c19eb6f1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:SeriesCPreferredStockAndWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IncardaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a602a058-063e-48c6-b5ce-d6c0d4fb1353"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ConsolidatedInvesteesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:NanoliveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a69ed80b-24cf-4fb0-939b-206e1bd2ef60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:GSKMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1e700f80-a869-46a2-ac03-43bec9ff60e2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IspFundLpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_81047951-2422-46bb-a073-86b99c1cee75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:IspFundLpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">inva:EquityInvestmentsAndMoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_61ec0a88-ce56-4964-8be3-32f048a015ef"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fdb40e49-15a5-44e8-ab56-25350fd9d665"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IncardaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_059975f4-4c4c-47fa-a5cc-efc7bf10d886"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IspFundLpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b3da9b9d-f2ab-400a-b73e-57b287e45c47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ArmataTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">inva:TermLoanInvestmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1d4ad1ec-0fb3-4d86-8793-4881afd79af0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:SeriesA1PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IncardaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-15</xbrli:startDate><xbrli:endDate>2022-06-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7b781f4e-2b96-403a-be95-189c21bfe845"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-09-01</xbrli:startDate><xbrli:endDate>2017-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_60737025-6027-4430-9a69-c41773b76a7a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ConsolidatedInvesteesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IncardaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5b63eaba-876c-4443-a190-0d776e3f0354"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5f1754a6-1e81-4cbd-8bf9-4f5f1ce7bd5f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c548651f-66c2-40f0-80ce-a318243d8cf7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:SeriesCWarrantsAndSeriesDWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IncardaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0180ad0a-b06f-4e53-948d-bb80d100090e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bcf921a3-2613-4901-bd57-bf22fbe5ef61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8e426da9-946c-40b8-bd70-2a6eaa29fe3d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:LicenseRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1d6c5f53-6c4d-4fe6-a55d-07940f638bd4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0608758b-b85d-4f54-a373-092e1463e6e6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:CommonStockAndWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_70e1c77f-fb08-4ab9-9457-0bc05d1bd9af"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b2abb502-4aea-4d3e-a1e8-7663f28b3e4a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:LaJollaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-22</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dec01f12-3f85-4d42-8b61-61f857a1419a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0e8b7755-7a30-43fc-8700-88f8cb2fb267"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f390186b-f0e1-423b-87da-2c37deb3557f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5610546b-710f-4b56-bca0-b9c532b6f95a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:IspFundLpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">inva:PrivatePlacementPositionsAndConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c985f900-3058-44b4-9093-ef23d5cbfa14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5294fbf9-d2f4-4cee-abd1-6e00044b2cfa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2013-01-01</xbrli:startDate><xbrli:endDate>2013-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7dd3ea38-7516-4e7e-9399-9f1920d9d119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:LicenseRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_01fb7c8c-6c66-4d02-b04d-546c5c407297"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-08-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9d6f1e1e-8a05-4f52-aabf-6ea93d745a22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ImaginabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b4844c4a-5218-4a44-b32f-7a91f6ba430d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:NanoliveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ec125de3-1e4e-4a75-b4bb-7673bacb9c03"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b58b4d47-eb88-4714-9e20-e846765b8a44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:CommonStockAndWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a0d0f17e-db42-4983-a7d4-03a17fcfd44f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_941dd2d3-13db-4e88-a246-2446d97b2a8e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:CommonStockAndWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1595673f-bb14-4c0c-b50c-19b1db664ef7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyEightNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b28442af-97a1-40c6-8f0f-8d7c9d6642b5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:GateNeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ffcfb827-8e39-4d8f-add9-6684b4c98b48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1a69ac4e-3663-4d1d-a457-2b4890fc09f6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_059f7bf6-1ef6-49bc-9ffa-a0a2a13282ed"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bc5da3bc-ba84-41b4-9714-69d7f9dcb276"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:IspFundLpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dc664211-9a49-4cc6-b77c-b76d951d8b6a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:WarrantsPurchasedIn2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f865e077-bfae-42a2-83e9-9bbaf0133b51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inva:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_03ba9ffa-87ef-489a-a311-42db1ae05203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IspFundLpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_71266bcb-340c-4b6f-bce7-ec001e02f542"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d5306868-e998-4382-9386-90e35c6d7f3a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ImaginabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6c28106a-1f5c-4375-9a90-9f5d3d7fd470"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a864ac08-9446-4d68-95de-31f94372d9f3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d809c37b-511d-4f0b-942b-be754908ee4d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_32d8d95b-c12c-46d1-98c1-3deb4b8cb129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5d098b39-13cc-4896-9cc3-c37b02ea18ac"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IncardaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-15</xbrli:startDate><xbrli:endDate>2022-06-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5783ed68-2473-492b-88b5-e1af30e3c0e7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:GSKMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e6d12e36-aff4-4dc6-81a3-899ea1f5910b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inva:CustomerTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:LaJollaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d05dfc5c-b948-4497-8849-a42784e9f325"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inva:CustomerTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:LaJollaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_23e66452-ee29-415e-90e3-ae16681b068e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c21ec5a1-610f-49e2-a459-1e404f26ba78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:GateNeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_825c0bd4-909c-4d86-9ae9-0ce6eb8cdcf2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:GateNeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-13</xbrli:startDate><xbrli:endDate>2024-02-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b40eac4f-f18e-4a85-95ce-6db8d48f14f2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7bb88b87-b326-4e6e-865b-16d3ceea75e6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ArmataTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7adc5fad-9ae2-4326-83c1-8d6394980f7e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyEightNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0baf8d0a-a93a-4dff-b66a-e5c5efa4d6d1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IspFundLpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-30</xbrli:startDate><xbrli:endDate>2022-03-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a6dc9592-99de-4df7-8a98-ca4fcda287d2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6c747ad1-5f7b-4926-8ac2-714e9199e239"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-08-07</xbrli:startDate><xbrli:endDate>2017-08-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f9f2e0b5-7d3e-40a6-b5ac-2fadf0d6e6e3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cd17c19c-ec63-4e2e-b6da-1c56d9be380d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inva:CustomerOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:LaJollaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a7bcde7c-16d0-44f6-bf9e-2ed901913ed0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ConsolidatedInvesteesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d10e57d1-8709-4825-a966-e724f8f4633f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_17f70e4b-90ed-432b-9c5b-4b6afd7a39ac"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IncardaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b7286a7d-74d3-4d92-a0a9-a2bb49f254d9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bf5886d1-1be6-4c7a-bfe3-1be3dd08388d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyEightNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e913bb79-80cf-4e4b-b05e-99a1cc469935"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:LaJollaPharmaceuticalCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_67050c7f-cb36-416c-aa88-59d5550ab95e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:CommonStockAndWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8e8b777f-2a9d-4fa4-b2ab-fe056ae69ce8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:TheravanceRespiratoryCompanyLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8e9e31d1-92be-49a8-9a9a-67c314bf7e73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b14e6b43-6384-43b6-9c33-6f1a35010333"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">inva:BurlingameCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9fac3855-4b00-44d6-b70c-185ef1d1eeb0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:GateNeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-02</xbrli:startDate><xbrli:endDate>2023-02-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3596ffd8-7703-4aa7-bc48-723fa485f9cd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:LongActingBeta2AgonistRelvarBreoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:GSKMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1ba9463a-d1f5-4a30-bbac-3bc5aad6339b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ImaginabConvertibleNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3325a2cf-7460-4b93-a664-ed1cbe345622"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IncardaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_140324d1-1834-455e-b137-0176d2de6d77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:IspFundLpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">inva:PrivatePlacementPositionsAndConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bda4cb66-7959-4b7c-926d-00e33cf8a0ad"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:NanoliveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_19d44124-af4c-4c1d-92f5-962be9ea56b6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d9c7ca7c-81fc-4272-b388-610e1b6444a8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f86d4e5c-570c-4de9-85a1-8a94d98944a1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_13a7a85f-17d1-43df-a359-948888dae445"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-07</xbrli:startDate><xbrli:endDate>2022-03-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d98c3729-ed3e-4b22-af22-60937a83a980"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8c8eca7f-7819-48ae-9938-c3c7153ffa73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:GSKMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1c3869dc-1179-4ea1-8b03-28655253f10d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IncardaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2ea14962-08db-4e80-a279-f2d275caee54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:IspFundLpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_195a4e8d-1787-4289-8f28-a87a026f6c66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fe183000-a690-4df9-a845-930c3241af02"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f3f69c9a-b63b-46c1-8d46-3c3cdfa265b1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_87231fad-8817-4c3e-8afb-e2378841555d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_76103f21-39aa-4d6c-bd6a-47f7c57f423e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inva:LabaCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:LongActingBeta2AgonistAnoroMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:GSKMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2f159654-f79f-4e47-806d-ec1adbda538c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:EverestMedicinesLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4fa6082e-52f0-4343-8a08-2384bb43f803"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IncardaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-15</xbrli:startDate><xbrli:endDate>2022-06-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0b1bdfd5-7193-40f2-af61-475bdb6831fa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IncardaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_99ee3dae-1eb1-48e4-a46a-c7e1dc1f16a3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2014-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_89169f0d-1765-42aa-9d7f-0ca1858b85d2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IncardaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f7344ab8-d158-462a-91a3-5ed1e74e6333"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7b140651-bbea-4d88-8a4f-fa197b5dfa55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_046580cc-7efc-42fb-b5c6-9fa3ae87d270"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:HealthCareRoyaltyPartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:RoyaltyFinancingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0882851d-0bed-4150-b837-2e1f74d8e460"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">inva:PrivatelyNegotiatedCappedCallOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyEightNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_274e3c4f-40cb-407c-aabb-e32137ff6f9d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inva:EmployeeStockPurchasePlanTwentyTwentyThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d81eb8e0-c039-48de-a07a-d8267be56862"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:TheravanceRespiratoryCompanyLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f20f052b-36df-4c4e-bd3b-191c89d3381d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ImaginabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:OneOfImaginabsCommonStockholderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5c9abf9d-1e31-4f48-9d0d-c57d10750153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inva:EquityIncentivePlan2012Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_11f17e9c-095d-4fae-8b57-328fa2b9ba57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IspFundLpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4c71a645-f25d-4cb5-8889-681f3449ecac"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_921dd0ce-2b9e-4442-9188-880568f7b1f1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8438a6b5-27b4-494b-a98e-519ed66169d5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c59027d6-af7f-4474-af78-da02d5338608"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:InnovivaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_972fc684-1125-4562-949a-c061a92ab4f3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">inva:OutstandingStockWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a6849091-06e9-4245-b57e-57668217a80b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ImaginabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5e685cc4-011a-4588-9181-90ecb3ccceb4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e2dfcab8-9a69-48b0-bbd8-dd20190bc830"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">inva:PrivatelyNegotiatedCappedCallOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyEightNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_308dae91-3293-4e16-bef8-42832c4675db"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1c9ae792-bfa8-4f96-9434-ec29ab1930a2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3f92b149-a39f-4e8f-96ab-6c3b86b4dbe7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:TrelegyElliptaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:GSKMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d68c6264-7526-47b4-8da2-c7ceccce0e57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:IncardaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_825f18bd-f7d5-4d67-9659-20286d27f1c0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b5db3709-c76a-4a08-8c44-b8f59cdb4608"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_81ea3387-bcc2-4cfe-a9e7-78fab40062ee"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_07eefa71-9b4d-4cdb-b27f-f192898d804e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">inva:EquityIncentivePlansAndESPPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_552da0c1-853f-4893-a1b0-a4223d212e95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4aa2cab4-fd43-44e4-87cc-bff3c5ce186b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:WarrantsPurchasedIn2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_743b7286-55b6-4101-852d-19e61fad9eaf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SecuredConvertibleCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_211cd3e4-b7d2-4255-9490-b9155f8d7b3d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:LaJollaPharmaceuticalCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_94027cba-de30-4b5d-a0ff-68cce2ec7cfa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ImaginabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:SeriesC2PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d3087254-4dbd-4e76-a116-2ba842506912"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">inva:OutstandingStockWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a0e6a86f-d6b7-4f77-89aa-49a1c8b20ae6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyEightNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fb34b57e-973b-4997-8a2c-2f01d3f8fa62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyEightNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6f107155-7e2c-410b-87ad-9c00bd1803a3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ConsolidatedInvesteesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:NanoliveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_de46daa9-d4c7-4d11-b729-3650d5f2b9cd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:IspFundLpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">inva:EquityInvestmentsAndMoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_32088045-eb75-4318-bbdc-77c7436faa52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:LongActingBeta2AgonistRelvarBreoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:GSKMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8b957e8d-7780-431f-93e1-471c1c7babcb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1c6acdd9-134f-4827-828c-e39c4849a9cf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:InnovivaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5f6a168b-c6ae-4f1b-a9d6-59d531bc1b72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_33ccc9ac-1bd0-4923-b096-29db8ac98a5e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:ZaiLabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:ResearchAndDevelopmentSupportMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9f19eb4c-29fe-474d-b77a-08e5bb571e8e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyEightNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4f37ea9f-306f-4950-a02c-a9b920bca4f3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">inva:PrivatelyNegotiatedCappedCallOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-07-01</xbrli:startDate><xbrli:endDate>2014-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cd8458e6-5f79-4d96-add0-064203ed13b2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9425c965-5f65-4fe2-b539-6c9acbd2b026"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:LaJollaPharmaceuticalCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_31fb851b-8f5e-4955-b085-ac6b0dd38b8d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inva:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a0c44c89-e8b9-4ab7-8450-da67ef9caaa2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a99937e1-764a-4db1-ae21-40947196ea5e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:HealthCareRoyaltyPartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:RoyaltyFinancingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f3734e2c-95b6-4b79-9206-0f8540ff6e11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:NanoliveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-18</xbrli:startDate><xbrli:endDate>2022-02-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e585cd60-cdd5-4401-bfcc-d855443a7706"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:SeriesDWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IncardaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b2c2c1ac-728c-4d23-a024-c459443d06d0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:TheravanceRespiratoryCompanyLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_455dfd10-363e-4652-a98d-acd8423476e5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:NoteAmendmentAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:GateNeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_51f40066-7e1b-48d8-8a38-42b77199fdd5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inva:LabaCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:GSKMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_07acd2a2-efee-41c9-bbd9-499920ef8206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ImaginabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-18</xbrli:startDate><xbrli:endDate>2021-03-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e414574e-4c06-4df7-8940-8de9bca1b108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inva:CustomerThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:LaJollaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9c87d87f-710c-4de3-a73e-9a9094727284"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:TheravanceRespiratoryCompanyLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_460b7389-fa51-4f4c-9e61-7e987dc6ad3e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:IspFundLpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3341913e-5e8a-43b4-af63-a752924ce8bc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_833ede43-b30a-4e04-a7aa-1d2f47880788"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inva:CustomerTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:LaJollaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f6f51154-4209-4901-acf6-2c40992c8eb9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b39ad5c9-17bf-4a35-b889-6bc388c60b7c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IspFundLpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fe55bf5e-1c8a-47f4-addb-d0f1f9a5891e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-02-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5058eabb-afd4-4dc1-a2f0-0ac8d38fabee"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7a07a415-eb4b-4dff-ab91-19dbbfc1a7cc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:TheravanceRespiratoryCompanyLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0d916e91-2dd2-468c-ab30-e90e2ac963b9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9d615842-43ad-4afe-b67a-2a588d4d0728"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0651f01e-b4f6-472e-bb04-bd2532da85ee"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:GateNeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_011ae41c-ec4e-43c1-8532-003573595646"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:ConvertiblePromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inva:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-17</xbrli:startDate><xbrli:endDate>2022-02-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a3c920a5-17f0-4dbc-8aff-02ec45493f70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IncardaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-15</xbrli:startDate><xbrli:endDate>2022-06-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_44d770d3-712a-4496-9e68-7b69a5f5d2bf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:IspFundLpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cce222e5-dac9-4c08-abb5-d90f2a3b1707"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_966fb9ea-4c8a-4b8b-b091-d09a286a05bf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">inva:TwoDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-09</xbrli:startDate><xbrli:endDate>2022-02-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d406fd03-b3d6-41fd-b4f9-74170c936a7a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cad461b3-85e0-44a5-b49c-2fdefdb8eb14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SecuredConvertibleCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-10</xbrli:startDate><xbrli:endDate>2023-01-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_45aa5dba-bae7-468a-aac4-f6723db99993"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6a99d93c-955d-4e2f-bcac-63e09ca2e6ef"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ImaginabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-18</xbrli:startDate><xbrli:endDate>2021-03-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_28748b0b-ed6b-4f26-be07-c4b34621cb5b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8ee91638-15d2-4e40-b682-b93f8c3d03b7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IncardaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3a82bed2-f816-4121-ae41-fc7fd838fa36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:SeriesD1WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IncardaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_067b241e-3eec-46f9-b23d-3e9d389993c0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b9a1435b-0390-4e98-b9e7-4a02063789ba"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_24b1825a-6f77-49e4-828c-3e33f531af0b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_be6668a0-7dd8-4ba3-acdc-f68ede2a4466"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dbf2c9ec-33a9-4f10-847f-e794f7585c7b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">inva:OneDirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-09</xbrli:startDate><xbrli:endDate>2022-02-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8591827b-2838-4d76-9be9-a5c2eecadbf7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IncardaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_102d957f-b55b-4b0c-b290-8ba82889bebc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d4a6dcc0-1cdb-48e6-9838-784bbf0081bc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IncardaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2f7d8e77-eb63-419b-ad16-1ac5905b61e3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inva:CustomerThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:LaJollaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1c07c08c-06ec-49dc-b790-0f2340f3ad4e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:WarrantsPurchasedIn2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f4a9e48d-00e5-43b6-9299-938496783a9d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:IncardaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d4042f8a-02bc-4c92-af62-098270afe2af"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-07-01</xbrli:startDate><xbrli:endDate>2014-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1a6354f8-d8d6-4e39-a8ca-ea30d3d87bc6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1a399c56-8380-4778-aa97-c511dc489262"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_36943c71-452d-4fbb-8d19-9e8b848cee67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inva:CustomerTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:LaJollaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ba1a82e3-49cc-4439-9ea4-1ade7ac73cb8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:LaJollaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-22</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_81c113da-ef79-4663-b552-0f93fc8926be"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:LaJollaPharmaceuticalCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_aab90c2e-843e-4eca-8999-f7ad6f6f31c9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4a240330-393d-4181-af3c-3ee7aca2c718"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:SeriesD1WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IncardaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-15</xbrli:startDate><xbrli:endDate>2022-06-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_126a8e06-61fd-494c-9ffd-58ea5c0bdea5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fe573d70-749d-4747-a2aa-7a4c9cb2488c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_101e59d3-6e14-4104-a1dd-021cb423fa02"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:ConvertiblePromissoryNotePurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:GateNeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_87ac8e26-9a2a-47e5-973e-54a32e529605"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inva:LabaCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:TrelegyElliptaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:GSKMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0de66d0f-6eb9-49fa-a5ec-9c7b513a7979"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:ConvertiblePromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inva:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2b0ee96a-cf29-4fd8-a358-2c59b280effd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:GeorgeWashingtonUniversityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c70d2786-9128-41e1-9dae-1423ff150cb0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:ConvertiblePromissoryNotePurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:GateNeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-24</xbrli:startDate><xbrli:endDate>2021-11-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5361a0f4-5547-4b13-aab7-9c5bf77f49a1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inva:CommercialSupplyAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:EverestMedicinesLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_40cc7194-3f29-4836-b18c-10aa722c5ee1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:SeriesD1AndD2PreferredStockAndCommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IncardaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1f21da09-fc29-466c-a31f-b632bcb5a795"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:SeriesD2PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IncardaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-15</xbrli:startDate><xbrli:endDate>2022-06-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_653aae1f-7476-41b2-a55d-7986566e9db4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inva:CustomerOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:LaJollaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_646bb33b-4ef6-4493-b542-00c92f556418"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_425efcfe-eac0-4b78-bf2f-d0ef757a0501"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:LongActingBeta2AgonistRelvarBreoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:GSKMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8c6a7bcf-3783-4f54-9341-3247cae07c70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_50bb996e-86f5-4158-a575-796da0e57247"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyEightNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b60e6976-6149-440a-b50d-539629e77c91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">inva:OutstandingStockWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9eac7308-f944-4333-bf01-4381430c8676"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:TheravanceRespiratoryCompanyLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_379884bb-ab3a-4a27-89b9-9b8365b16e1e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:GateNeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bfe82950-e87e-4ffb-ad0e-84e0026f5b0c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8e0a440d-9ea8-4152-85ec-508d2a5aa993"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9b30963d-d42c-4ba2-85ac-e1f548c6e616"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:LaJollaPharmaceuticalCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_300582a5-75c9-4125-aa9d-205955fffcd6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-09</xbrli:startDate><xbrli:endDate>2022-02-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cd95e6eb-db30-4b57-a111-4b45da383cf5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7087d489-2159-4c5e-b41f-f209f859c49e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyEightNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0c62ac1f-f870-4e92-add2-b1924f35420e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:IspFundLpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">inva:EquityInvestmentsAndMoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_adc3b151-5d38-4abe-9182-9e724c5ef29b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bd478d73-d23c-479d-ac02-32fc192ff66f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ArmataConvertibleNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_74b73320-f859-4046-baa9-7350be012c10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3810cd04-c006-4bfa-8397-c106caf901af"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d21494bc-80c8-4b9a-af3a-b8e82bfd6caf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:IspFundLpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">inva:EquityInvestmentsAndMoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ea704773-4bd5-40ed-9730-d6a668d17624"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:ConvertiblePromissoryNotePurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:GateNeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e6805147-9eff-450d-a94b-d8e4239b1dd2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fa01aae9-eeeb-459c-9277-c4cd33bb93d0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a89fb91f-9ba5-4dc8-a73e-32d0a623c796"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_54ed52d3-2763-46fa-a0e9-bfeb58272692"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:GiaprezaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:LaJollaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-22</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b6f84383-3742-4678-adab-90f14685e54b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3b8d2e0c-b8e8-465e-b685-f60604c8c298"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-01</xbrli:startDate><xbrli:endDate>2023-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2f78a803-3fe0-4245-b906-d2b1f794b7ad"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IncardaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_29561087-beae-414b-bf9d-e689e21a5ee7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b77a83ac-82c7-48f4-8088-fe346e76a70f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ConsolidatedInvesteesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IncardaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_825d28ed-6319-4ae7-9001-97f35281db61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:GateNeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_669beef7-e71d-4c69-83c1-57065488410a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">inva:WalthamMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a18d4683-905b-4297-962a-d6b053b48738"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6f7b5337-631f-48a7-b4c9-05cbb564473e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_886d4bf2-cc70-460c-8055-b20097a1c12e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c572fa7f-d00c-4858-9672-e4e0981286bf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_983ae2b6-5a3f-48bf-90f1-b4b741cfcbbe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3ac61c6b-9a4c-4283-b479-f0354fbd761b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-08-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_698952c3-354e-492f-acd8-4bebed0f9f6b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">inva:PrivatelyNegotiatedCappedCallOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2013-01-01</xbrli:startDate><xbrli:endDate>2013-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_29d8e0a4-1346-4e5a-9734-3d41d9fe9891"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b022e036-d13c-4fc8-94e9-00734a572b9c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inva:CustomerThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:LaJollaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5a9d38bb-6bc6-4e0d-b81a-0f669ce07277"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1dbbdaf4-e472-4d57-8ddc-ea01a7242c98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_76445fe9-d438-4d1c-a28d-613fef583510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4a4ab2a3-40c8-4d79-9cdf-f746af492718"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e4ffec73-53e1-424c-b35f-67a5034c0026"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:GateNeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-06</xbrli:startDate><xbrli:endDate>2023-10-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c84174e9-be04-42dd-b25c-92df750b79e8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:GateNeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d175b10d-c61c-4706-bba1-92ef6df9865b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-01</xbrli:startDate><xbrli:endDate>2024-02-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e1b05d91-a370-4fa6-955b-9c0c677f7d49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ea7c0a60-08f5-4a3e-a061-5a67602a1ec1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bf193f24-bfbe-419c-9802-eee6070d5ad5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ConsolidatedInvesteesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ImaginabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f3b6b1d2-3788-42e8-b1e9-0bae28c7d538"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e05740b2-e808-41d3-b26e-897ba3aa633c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:LaJollaPharmaceuticalCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-22</xbrli:startDate><xbrli:endDate>2022-08-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f2f66487-eef9-477e-a54f-358af57f70cc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9f56edf9-4d83-4ddd-b43e-19b470780c80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_052592af-355b-490c-9bea-1016c2ec7fe7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c9163898-48a1-4dcb-8fe2-b46eda3de475"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_55652f07-0e2e-4bb9-b4c3-618b5066831e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_344746bb-e636-4cfa-9204-6870353b5936"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8f8c6623-d626-4ff4-b287-9206e6e7485e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_85b04dbe-2493-4115-9d41-cfc1636e1d1c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:GateNeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-24</xbrli:startDate><xbrli:endDate>2021-11-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_94c529c4-f563-461a-9da8-262bcfe8bc37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:TrelegyElliptaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:GSKMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0287d352-8cf0-4411-9610-d97bd5f904bf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IspFundLpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b57cd753-71d3-4cff-8d5a-7f32594379ed"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">inva:TermLoanInvestmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a18abd1c-665b-4c52-b36b-be1bbd83b22e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3abefe6f-631c-4640-93e2-984c5ac20007"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IspFundLpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_00500ade-f7ea-4d89-9a06-fb25d9363802"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_74708c78-45e8-4732-9508-597695b3a0d5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2013-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6c4d4181-e8c1-43dd-85b3-83b9cf5f55dd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e3491d72-ab2a-429a-8f92-dd8be751aada"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">inva:OldDebtInstrumentInterestRateBeforeRepurchaseOfNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cd9243f5-5c45-4dc0-9b92-52023672ac79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2253537a-7271-4515-97f9-6f06ff495b9f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ImaginabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:SeriesC2PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e2357c2d-6a56-4a89-83af-cfa33770d462"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:SeriesD1PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IncardaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-15</xbrli:startDate><xbrli:endDate>2022-06-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_27cbe4a1-3bff-4bc8-b808-d5e97b10b96a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:GSKMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-13</xbrli:startDate><xbrli:endDate>2022-07-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0f8abff1-9020-483e-b333-8737df241e43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:SeriesD1AndD2PreferredStockAndCommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IncardaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6e065d89-351d-457c-ba2e-bc2d69edba60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5e106938-a0b0-4aeb-9126-1ce4d5e166fa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IncardaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_da2e5495-b09e-47a8-9a8c-ea82f08e7ead"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">inva:OneDirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-09</xbrli:startDate><xbrli:endDate>2022-02-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c3ca1f40-a3c1-4ba0-9cd7-3d664a62262a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ea272365-8aa7-4a80-8b19-6a8032d971c0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:IspFundLpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_96f1c8f6-d5af-40ca-aebd-5dd11479b360"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f00e797a-c719-4c90-a9dc-1bce4096970e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:GiaprezaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_64603e03-c98c-40b7-ae31-b9e79c20bc55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:LaJollaPharmaceuticalCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0647acf4-6f5c-4d39-86c2-fb4fddd549fb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2f32a53f-9c4b-4122-bfb3-3e89cba768ae"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_13fdb038-bf81-4c06-8c1d-9aabbf5a3705"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:IspFundLpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">inva:EquityInvestmentsAndMoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4744817d-5145-49fb-a6a0-1308e192a8f6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bfc65bb1-ad80-4e8a-8b46-7fb950cefb1b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inva:EmployeeStockPurchasePlanTwentyTwentyThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_49ef45bd-5ceb-448c-b5bf-998ea5bcd6a4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b4ac9910-3d92-4e1b-ac5f-f74c9dbdcfcd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d074e316-aefd-4e82-9593-cc19fd319a60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_53420953-7564-40c6-bee0-709280cf738f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inva:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b55f651c-8a37-4dd9-95c5-8086ccf211c2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">inva:PrivatelyNegotiatedCappedCallOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2013-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_47315d43-a153-47de-8273-33588b06dde8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inva:InnovivaCommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-17</xbrli:startDate><xbrli:endDate>2022-04-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9125c6de-8c86-4bde-9b04-80aa987c21cc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f526cd8e-6c2f-4f2c-bd9e-4e878cf8ba5f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:GateNeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9f8ff2b8-4656-4ea8-955a-c60a95c6b1c1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:GateNeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e037e13e-6e91-4a72-ba0c-e61af7067b1b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5c2cfa33-ca5f-465a-89ae-63a6b102f37a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e3e6ec1f-49a0-4fb9-9419-c9b6fcbc8855"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c174b897-ce7b-41b0-af4e-37c1c1527fe2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:TheravanceRespiratoryCompanyLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9d9fedca-43c3-4c3c-a148-a051b0151a35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1dafa801-a453-4e03-925d-1453c2c0f5f6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f0da2c05-1727-4786-acd0-b03e3dff2fa8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-01</xbrli:startDate><xbrli:endDate>2017-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_962daa42-70a2-4386-b932-c071d02f40c5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inva:CustomerThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:LaJollaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_593427ab-e2d7-4f72-ba54-456608483083"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7cde4835-b322-4448-9e0f-120e1bccc549"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:HealthCareRoyaltyPartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:RoyaltyFinancingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_acc8fa0e-9230-4a63-8d63-4ae6d91d60af"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2e2e6b99-d8c8-44b8-aabd-25fa00182b05"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inva:LabaCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:TrelegyElliptaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:GSKMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a332f0a6-0f9e-4712-97f0-f10d648bcf65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d5f73726-2a05-4be7-87fa-3fd6369578ba"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4ad76130-0d29-47d9-b811-82b396d4ef22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inva:LabaCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:LongActingBeta2AgonistAnoroMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:GSKMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5460cef4-c4cc-4668-99ef-fb2e26f72ba2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1007c8ce-c961-4336-8299-5ed88a88849d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">inva:LaboratoryEquipmentFurnitureAndFixturesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_676e8b46-96e2-42eb-927b-d2236a78f7f0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:LongActingBeta2AgonistAnoroMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:GSKMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e4d7581f-3285-4f94-bf60-7ad14f82c23d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2013-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b5138b8b-4530-41d2-a75c-4212efb677c1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0f0e0c31-e997-4327-b909-2d345a34ba21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e642beae-c7bf-4bc4-9ebd-c58d6623dfc5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">inva:SoftwareAndComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_98c23b09-7eaa-42d7-b41a-5b1541dea4a7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:LaJollaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:XeravaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-22</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_31010f98-5d41-43b8-8b09-e38bde00ec6d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c21ca759-25e6-4904-91dd-c322af1eeaf5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1cbdd9df-6a4a-4d82-9344-ffb61a7bc4cd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_11c3614e-b3bf-4d55-987c-21911b9b09fc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c20721f8-5014-4577-a717-6b5f4d10b69e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:LaJollaPharmaceuticalCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3d081474-bef5-49f9-9f8c-6d2a8ce28f36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:GateNeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c3fa46e4-5e22-4b74-a128-70da5649065e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:CommonStockAndWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-09</xbrli:startDate><xbrli:endDate>2022-02-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_51b5cb2e-4d34-4373-952e-14896dcb3ec0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d81c2107-a7a0-4ec4-8988-fc8409645f16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:IspFundLpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c2b5fc1d-7d57-4855-af69-696043e9626b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ImaginabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:SeriesC2PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-14</xbrli:startDate><xbrli:endDate>2023-03-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ca966b79-26e3-4d58-ae1b-26f1394533f5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:WarrantsPurchasedIn2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_96fef1ab-5fb4-4957-bed2-bbcbb49272d9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_25a18144-6924-42a5-a99d-aab05e77ca53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6d65900c-b10f-49a2-bba9-16040891a8f1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ConvertibleNoteAndWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IncardaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-09</xbrli:startDate><xbrli:endDate>2022-03-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_64d5bd90-3055-4f52-b86f-cb8d0deed43e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4c7b96af-5930-4df9-9e24-686f4186dd93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c5f941e0-b007-4ef9-bd80-53ea1e5f382a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_96ac591a-5f0a-4705-94d6-904d91058ae4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:XeravaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_44f330d4-92f5-4b09-a61f-569ed269bd6e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyEightNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dabbf05b-a0a7-405b-8376-1cdce909cd8e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:CreditAndSecurityAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-07-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3d517819-005b-4abf-9ea5-9aada251df67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">inva:TermLoanInvestmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_afca57b6-192a-41f3-9d82-5a1dd8586709"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:XacduroMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fa0aac3c-12ff-4c52-bf57-2b8f937d8ef4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a7cbb363-ce02-4f94-bf8b-d70a020aba6a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:LaJollaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1f2036f9-b56a-403d-9f98-ec7e12869b74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2c5b2d53-225f-409f-ad02-223827b8634c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_66b50de4-9da3-415d-8893-6426c4c9c73b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bae5ea2a-1d4e-43c0-924e-20e43f661014"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:GateNeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3824b03b-c4bb-4202-90b1-652ccf15674b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">inva:EquityIncentivePlansAndESPPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f0655569-45ea-4da7-be44-e42a72acf91f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8157d7d6-196c-4c46-bf54-22f1d9546346"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:ConvertiblePromissoryNotePurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:GateNeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6872c5a6-9354-4f1c-9344-b3b75b5392e8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyEightNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_29a8663f-3680-40ab-9728-c1d88380d314"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="U_Director"><xbrli:measure>inva:Director</xbrli:measure></xbrli:unit><xbrli:unit id="U_UsdItem"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>inva:Item</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_Item"><xbrli:measure>inva:Item</xbrli:measure></xbrli:unit><xbrli:unit id="U_Customer"><xbrli:measure>inva:Customer</xbrli:measure></xbrli:unit><xbrli:unit id="U_UnitedStatesOfAmericaDollarsShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_CHF"><xbrli:measure>iso4217:CHF</xbrli:measure></xbrli:unit><xbrli:unit id="U_Tranche"><xbrli:measure>inva:Tranche</xbrli:measure></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="U_Installment"><xbrli:measure>inva:Installment</xbrli:measure></xbrli:unit><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_e66ad88b-f785-4158-ae1c-5740243b0d71" fromRefs="F_f02c3cdb-acc9-4cbf-9957-678c00ecf7f0 F_f2a97274-1f4f-460d-ae0c-feb28444b496 F_10f70c8e-4f7f-4ca3-b77a-59255ab84f38 F_9f51a90b-d5b3-4baf-a592-557db4d38798 F_19514078-4d7f-46e4-9ec3-6baa01d8bc45 F_e397c611-ef5b-4261-b926-3631409061a6 F_fd0c3223-a52a-48b1-a54d-d2343a4454e1 F_c2d29a19-daed-4394-b61e-859713cd07bf"></ix:relationship><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_30a29ac4-a358-403f-922e-b22439018a34" fromRefs="F_e248727d-972b-4bb6-ab0b-09782adb2852 F_4a70ed61-c9ff-4827-8179-ace3ddd3bf0d F_b9ac7d88-0ec7-4a44-b18b-b9ac67c540d1 F_35d88796-82fe-4251-9612-1a4e04f63d2e F_64e8fe2d-9ccc-4d48-a246-d18907408dd4 F_e2184934-bd84-4125-9424-85c04dca4927 F_26a4b48a-8a57-4a41-bd9e-43886a8b595b F_5b257131-c564-45cc-91a5-088cab24c28e"></ix:relationship><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_24bb9798-5eb0-4e31-b65e-3441d7813ebf" fromRefs="F_163fe0cd-4268-4bdf-8328-6e0ab0363e8f F_b935334f-0493-4661-b36b-bead7c670f68 F_640cced8-8c0d-4ecb-b7e5-b8a0e34874d2 F_22478cef-8f79-4fb5-9e36-deaf9b1d90f8"></ix:relationship><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_4e3e88eb-3c93-45b2-a2dc-9cb89ab6791d" fromRefs="F_8a869d89-7a7a-45db-ada7-7a991d2546c3 F_16adad2a-1e35-499c-8549-470982d5bd2a F_007ca7f4-d174-4a7c-a703-836236edbe52 F_642b9e4b-f8ea-48f4-9e68-c69a54e91074"></ix:relationship></ix:resources></ix:header></div>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="border-top:3pt solid;padding-top:1pt;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">UNITED STATES</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:3pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Washington, D.C. 20549</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:3pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">FORM </span><span style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9d8199f0-bc2f-40bc-a725-ac21ef35f3f6" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">10-K</span></ix:nonNumeric></span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:13.42%;"/>
    <td style="width:86.58%;"/>
   </tr>
   <tr style="height:10.1pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;text-align:left;"><p style="text-indent:-10pt;padding-left:10pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Mark One)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;text-align:left;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_ecd0407c-f457-46aa-b4bb-58d621fdef80" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="dei:DocumentAnnualReport" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p></td>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="2" style="text-indent:10.1pt;vertical-align:top;"><p style="text-indent:-10.1pt;padding-left:10.1pt;font-size:8pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">For the fiscal year ended </span><span><ix:nonNumeric id="F_539de6f7-1998-48fe-9568-42d1ac90c08a" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span><ix:nonNumeric id="F_a934c2ed-de78-49cb-8600-984e39932e60" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_3a26652a-5373-4453-839b-41bc182ade18" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="dei:DocumentFiscalYearFocus"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></ix:nonNumeric></span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="2" style="text-indent:10pt;vertical-align:top;"><p style="text-indent:-10pt;padding-left:10pt;font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="2" style="text-indent:10.1pt;vertical-align:top;"><p style="text-indent:-10.1pt;padding-left:10.1pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">or</span></p></td>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;text-align:left;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_c215554b-f42a-4c00-bdf7-b632754f6ddf" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;text-align:left;"><p style="text-indent:-10pt;padding-left:10pt;font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="2" style="text-indent:10pt;vertical-align:top;"><p style="text-indent:-10pt;padding-left:10pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">For the transition period from              to</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Commission File No. </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_38cad768-6696-4a31-9d87-12e38ebeb9d8" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">000-30319</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:3pt;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_293de294-a3f8-45a4-bd40-37a1e489b669" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">INNOVIVA, INC.</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:3pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(Exact name of registrant as specified in its charter)</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50%;"/>
    <td style="width:50%;"/>
   </tr>
   <tr style="height:25.2pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="text-indent:10.1pt;vertical-align:top;"><p style="text-indent:-10.1pt;padding-left:10.1pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_9ffbfc6d-e491-41d4-931b-44e2d02cd28e" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Delaware</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><br/>(State or other jurisdiction of<br/>incorporation or organization)</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_eae683bb-fd79-4a1a-b6b0-451316b0ec21" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">94-3265960</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><br/>(I.R.S. Employer<br/>Identification No.)</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="text-indent:-10pt;padding-left:10pt;font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="text-indent:-10pt;padding-left:10pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_77428a60-6b8d-487f-874b-060751880f25" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">1350 Old Bayshore Highway, Suite 400</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><br/></span><span><ix:nonNumeric id="F_fae3ddec-42ab-484b-b3d9-de6ae72f52b9" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Burlingame</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_5588472b-4fe3-4fc1-b1a5-541c869442dd" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="dei:EntityAddressStateOrProvince"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">CA</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> <br/></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(Address of principal executive offices)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_1cf813d5-9e16-4a73-b5df-3dcdceb90b26" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">94010</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><br/>(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Registrant&#8217;s telephone number, including area code: </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_599456b4-2a75-42ec-a4fb-993d3eccf181" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">650</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">) </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e7a8a7c3-2e1b-4386-b548-97e82f106434" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">238-9600</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:3pt;text-align:center;"><span style="white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:34.167%;"/>
    <td style="width:1.66%;"/>
    <td style="width:25.345%;"/>
    <td style="width:1.48%;"/>
    <td style="width:37.347%;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="text-indent:10pt;vertical-align:top;border-bottom:0.5pt solid;"><p style="text-indent:-10pt;padding-left:10pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Title of Each Class</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">    </span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Trading Symbol(s)</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">    </span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Name of Each Exchange On Which Registered</span></p></td>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_73daf2d8-7d19-4a61-8020-3d200a77d75a" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common Stock $0.01 Par Value</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_d7416747-e3e4-4b2c-8c6a-e1c8cdd0cbd7" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">INVA</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">The </span><span style="font-size:8pt;"><ix:nonNumeric id="F_30e963d8-891d-40e6-b6b9-fec61602bd9c" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Nasdaq</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">&#160;Stock Market LLC</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:3pt;text-align:center;"><span style="white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">SECURITIES REGISTERED PURSUANT TO SECTION 12(g) OF THE ACT: </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">NONE</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark if the registrant is a well&#8209;known seasoned issuer, as defined in Rule 405 of the Securities Act. </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a4fd7dfe-4dbb-4673-b271-0e3cc192a449" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="dei:EntityWellKnownSeasonedIssuer"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> &#9746;   No &#9744;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes &#9744;   </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_beda6eae-dc59-437c-8bbc-5ef5f597984b" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="dei:EntityVoluntaryFilers"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> &#9746;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7e0fdca1-49ff-43cc-9d91-2ae85dd1a42d" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="dei:EntityCurrentReportingStatus"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> &#9746;   No &#9744;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_342fc646-5b85-4dd8-a7e0-27354d9d095a" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="dei:EntityInteractiveDataCurrent"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> &#9746;  No &#9744;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether registrant is a large accelerated filer, an accelerated filer or a non-accelerated filer. See definition of &#8220;accelerated filer and large accelerated filer&#8221; in Rule 12b-2 of the Exchange Act (Check One):</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:31.246%;"/>
    <td style="width:17.944%;"/>
    <td style="width:27.586%;"/>
    <td style="width:23.225%;"/>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10.1pt;vertical-align:bottom;"><p style="text-indent:-10.1pt;padding-left:10.1pt;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:3pt;text-align:left;"><span style="font-size:8pt;"><ix:nonNumeric id="F_fbbdce1d-ae76-4740-adc5-05012484e86e" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Large accelerated filer</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">&#160;&#9746;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accelerated filer &#9744;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non&#8209;accelerated filer &#9744;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">Smaller reporting company </span><span style="font-size:8pt;"><ix:nonNumeric id="F_7d9877bf-f4e2-42be-a37f-e766031c1201" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10.1pt;vertical-align:bottom;"><p style="text-indent:-10.1pt;padding-left:10.1pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">Emerging growth company </span><span style="font-size:8pt;"><ix:nonNumeric id="F_e2951440-ecc7-47fe-bd6d-2a93e11d12d3" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5da7c02c-55c2-4d54-bfc9-f52f2ef5d4e6" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c7956048-bdd7-429a-b895-fa7ca6dd656e" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive o&#64259;cers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:5pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b&#8209;2 of the Exchange Act). Yes </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e633c0ee-89ac-4494-96bc-0916e05aadbd" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">   No &#9746;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">The aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant based upon the closing price of the registrant&#8217;s Common Stock on The Nasdaq Global Select Market on June 30, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> was $</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_261b757c-58fe-45c5-994e-7d61a34ae25f" contextRef="C_b9a1435b-0390-4e98-b9e7-4a02063789ba" name="dei:EntityPublicFloat" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">731,926,690</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">. This calculation does not reflect a determination that persons are affiliates for any other purpose.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">On February 14, 2024,</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> there were </span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f1b95002-f83d-4e00-ac43-58a5f74ac9ab" contextRef="C_fe55bf5e-1c8a-47f4-addb-d0f1f9a5891e" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">63,227,333</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> shares of the registrant&#8217;s Common Stock outstanding.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8465d106-b3d9-4145-a6c8-8bf9f10c9caa" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="dei:DocumentsIncorporatedByReferenceTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">DOCUMENTS INCORPORATED BY REFERENCE</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Specified portions of the registrant&#8217;s definitive Proxy Statement to be issued in conjunction with the registrant&#8217;s 2023 Annual Meeting of Stockholders, which is expected to be filed not later than 120 days after the registrant&#8217;s fiscal year ended December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">, are incorporated by reference into Part III of this Annual Report. Except as expressly incorporated by reference, the registrant&#8217;s Proxy Statement shall not be deemed to be a part of this Annual Report on Form 10-K.</span></p></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="border-top:0.5pt solid;padding-top:1pt;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:3pt solid;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">INNOVIVA, INC.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2023 Form 10&#8209;K Annual Report</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="toc"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:7%;"/>
    <td style="width:88%;"/>
    <td style="width:5%;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Page</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:bottom;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">PART I</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:bottom;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 1.</span></p></td>
    <td style="text-indent:7.2pt;vertical-align:bottom;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1_business"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Business</span></a></p></td>
    <td style="text-indent:7.2pt;vertical-align:bottom;text-align:center;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:bottom;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 1A.</span></p></td>
    <td style="text-indent:7.2pt;vertical-align:bottom;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1a_risk_factors"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Risk Factors</span></a></p></td>
    <td style="text-indent:7.2pt;vertical-align:bottom;text-align:center;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">34</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:bottom;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 1B.</span></p></td>
    <td style="text-indent:7.2pt;vertical-align:bottom;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1b_unresolved_staff_comments"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Unresolved Staff Comments</span></a></p></td>
    <td style="text-indent:7.2pt;vertical-align:bottom;text-align:center;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">74</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:bottom;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 1C.</span></p></td>
    <td style="text-indent:7.2pt;vertical-align:bottom;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1c_cybersecurity"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Cybersecurity</span></a></p></td>
    <td style="text-indent:7.2pt;vertical-align:bottom;text-align:center;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">74</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:bottom;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 2.</span></p></td>
    <td style="text-indent:7.2pt;vertical-align:bottom;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_2_properties"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Properties</span></a></p></td>
    <td style="text-indent:7.2pt;vertical-align:bottom;text-align:center;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">75</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:bottom;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 3.</span></p></td>
    <td style="text-indent:7.2pt;vertical-align:bottom;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_3_legal_proceedings"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Legal Proceedings</span></a></p></td>
    <td style="text-indent:7.2pt;vertical-align:bottom;text-align:center;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">75</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:bottom;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 4.</span></p></td>
    <td style="text-indent:7.2pt;vertical-align:bottom;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_4_mine_safety_disclosures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Mine Safety Disclosures</span></a></p></td>
    <td style="text-indent:7.2pt;vertical-align:bottom;text-align:center;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">75</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:bottom;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:7.2pt;vertical-align:bottom;text-align:left;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">PART II</span></p></td>
    <td style="text-indent:7.2pt;vertical-align:bottom;text-align:center;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:bottom;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 5.</span></p></td>
    <td style="text-indent:7.2pt;vertical-align:bottom;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_5_market_for_registrant_s_common"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Market for the Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td>
    <td style="text-indent:7.2pt;vertical-align:bottom;text-align:center;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">76</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:bottom;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 6.</span></p></td>
    <td style="text-indent:7.2pt;vertical-align:bottom;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_6_selected_financial_data"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">[Reserved]</span></a></p></td>
    <td style="text-indent:7.2pt;vertical-align:bottom;text-align:center;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">77</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:bottom;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 7.</span></p></td>
    <td style="text-indent:7.2pt;vertical-align:bottom;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_7_management_s_discussion_and"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
    <td style="text-indent:7.2pt;vertical-align:bottom;text-align:center;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">78</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:bottom;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 7A.</span></p></td>
    <td style="text-indent:7.2pt;vertical-align:bottom;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_7a_quantitative_and_qualitative"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
    <td style="text-indent:7.2pt;vertical-align:bottom;text-align:center;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">91</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:bottom;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 8.</span></p></td>
    <td style="text-indent:7.2pt;vertical-align:bottom;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_8_financial_statements_and"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Financial Statements and Supplementary Data</span></a></p></td>
    <td style="text-indent:7.2pt;vertical-align:bottom;text-align:center;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">92</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:bottom;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 9.</span></p></td>
    <td style="text-indent:7.2pt;vertical-align:bottom;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9_changes_in_and_disagreements_with"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></p></td>
    <td style="text-indent:7.2pt;vertical-align:bottom;text-align:center;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">141</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:bottom;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 9A.</span></p></td>
    <td style="text-indent:7.2pt;vertical-align:bottom;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9a_controls_and_procedures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Controls and Procedures</span></a></p></td>
    <td style="text-indent:7.2pt;vertical-align:bottom;text-align:center;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">141</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:bottom;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 9B.</span></p></td>
    <td style="text-indent:7.2pt;vertical-align:bottom;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9b_other_information"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Other Information</span></a></p></td>
    <td style="text-indent:7.2pt;vertical-align:bottom;text-align:center;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">144</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:bottom;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 9C.</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9c_disclosure_regarding_foreign_jur"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td>
    <td style="text-indent:7.2pt;vertical-align:bottom;text-align:center;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">144</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:bottom;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:7.2pt;vertical-align:bottom;text-align:left;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">PART III</span></p></td>
    <td style="text-indent:7.2pt;vertical-align:bottom;text-align:center;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:bottom;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 10.</span></p></td>
    <td style="text-indent:7.2pt;vertical-align:bottom;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_10_directors_executive_officers_and"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Directors, Executive Officers and Corporate Governance</span></a></p></td>
    <td style="text-indent:7.2pt;vertical-align:bottom;text-align:center;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">145</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:bottom;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 11.</span></p></td>
    <td style="text-indent:7.2pt;vertical-align:bottom;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_11_executive_compensation"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Executive Compensation</span></a></p></td>
    <td style="text-indent:7.2pt;vertical-align:bottom;text-align:center;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">145</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:bottom;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 12.</span></p></td>
    <td style="text-indent:7.2pt;vertical-align:bottom;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_12_security_ownership_of_certain"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td>
    <td style="text-indent:7.2pt;vertical-align:bottom;text-align:center;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">145</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:bottom;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 13.</span></p></td>
    <td style="text-indent:7.2pt;vertical-align:bottom;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_13_certain_relationships_and"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td>
    <td style="text-indent:7.2pt;vertical-align:bottom;text-align:center;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">145</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:bottom;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 14.</span></p></td>
    <td style="text-indent:7.2pt;vertical-align:bottom;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_14_principal_accounting_fees_and"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Principal Accountant Fees and Services</span></a></p></td>
    <td style="text-indent:7.2pt;vertical-align:bottom;text-align:center;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">145</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:bottom;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:7.2pt;vertical-align:bottom;text-align:left;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">PART IV</span></p></td>
    <td style="text-indent:7.2pt;vertical-align:bottom;text-align:center;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:bottom;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 15.</span></p></td>
    <td style="text-indent:7.2pt;vertical-align:bottom;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_15_exhibits_and_financial_statement"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Exhibits and Financial Statement Schedules</span></a></p></td>
    <td style="text-indent:7.2pt;vertical-align:bottom;text-align:center;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">146</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:bottom;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 16.</span></p></td>
    <td style="text-indent:7.2pt;vertical-align:bottom;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_16_form_10_k_summary"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form 10&#8209;K Summary</span></a></p></td>
    <td style="text-indent:7.2pt;vertical-align:bottom;text-align:center;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">146</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="2" style="text-indent:10pt;vertical-align:bottom;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#exhibits"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Exhibits</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">147</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="2" style="text-indent:10pt;vertical-align:bottom;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#signatures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Signatures</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">150</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:center;" id="special_note_regarding_forward_looking"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Special Note Regarding Forward&#8209;Looking Statements</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">This Annual Report on Form 10&#8209;K contains forward&#8209;looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the &#8220;Securities Act&#8221;). Such forward&#8209;looking statements involve substantial risks, uncertainties and assumptions. All statements in this Annual Report on Form 10&#8209;K, other than statements of historical fact, including, without limitation, statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, intentions, expectations, goals and objectives may be forward&#8209;looking statements. The words &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;could,&#8221; &#8220;designed,&#8221; &#8220;estimates,&#8221; &#8220;expects,&#8221; &#8220;goal,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;objective,&#8221; &#8220;plans,&#8221; &#8220;projects,&#8221; &#8220;pursuing,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and similar expressions (including the negatives thereof) are intended to identify forward&#8209;looking statements, although not all forward&#8209;looking statements contain these identifying words. We may not actually achieve the plans, intentions, expectations or objectives disclosed in our forward&#8209;looking statements and the assumptions underlying our forward&#8209;looking statements may prove incorrect. Therefore, you should not place undue reliance on our forward&#8209;looking statements. Actual results or events could differ materially from the plans, intentions, expectations and objectives disclosed in the forward&#8209;looking statements that we make. All written and verbal forward&#8209;looking statements attributable to us or any person acting on our behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this section.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Important factors that we believe could cause actual results or events to differ materially from our forward&#8209;looking statements include, but are not limited to, risks related to: lower than expected future royalty revenue from respiratory products partnered with GSK, the commercialization of RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">, ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">, GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">, XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">, and XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> in the jurisdictions in which these products have been approved; the strategies, plans and objectives of the Company (including the Company's growth strategy and corporate development initiatives); the timing, manner, and amount of potential capital returns to shareholders; the status and timing of clinical studies, data analysis and communication of results; the potential benefits and mechanisms of action of product candidates; expectations for product candidates through development and commercialization; the timing of regulatory approval of product candidates; and projections of revenue, expenses and other financial items; the impact of the novel coronavirus (&#8220;COVID-19&#8221;); the timing, manner and amount of capital deployment, including potential capital returns to stockholders; and risks related to the Company&#8217;s growth strategy and risks discussed in &#8220;Risk Factors&#8221; in Item 1A of Part I, &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in Item 7 of Part II and elsewhere in this Annual Report on Form 10&#8209;K. Our forward&#8209;looking statements in this Annual Report on Form 10&#8209;K are based on current expectations as of the date hereof and we do not assume any obligation to update any forward&#8209;looking statements on account of new information, future events or otherwise, except as required by law.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We encourage you to read Management&#8217;s Discussion and Analysis of our Financial Condition and Results of Operations and our consolidated financial statements contained in this Annual Report on Form 10&#8209;K. We also encourage you to read Item 1A of Part I of this Annual Report on Form 10&#8209;K, entitled &#8220;Risk Factors,&#8221; which contains a more complete discussion of the risks and uncertainties associated with our business. In addition to the risks described above and in Item 1A of this report, other unknown or unpredictable factors also could affect our results. Therefore, the information in this report should be read together with other reports and documents that we file with the Securities and Exchange Commission (&#8220;SEC&#8221;) from time to time, including on Form 10&#8209;Q and Form 8&#8209;K, which may supplement, modify, supersede or update those risk factors. As a result of these factors, we cannot assure you that the forward&#8209;looking statements in this report will prove to be accurate. Furthermore, if our forward&#8209;looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward&#8209;looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:center;" id="part_i"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PART I</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;" id="item_1_business"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM 1.   BUSINESS</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Overview</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Innoviva, Inc. (&#8220;Innoviva&#8221;, the &#8220;Company&#8221;, the &#8220;Registrant&#8221; or &#8220;we&#8221; and other similar pronouns) is a company with a portfolio of royalties and innovative healthcare assets. We currently have three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our royalty portfolio contains respiratory assets partnered with Glaxo Group Limited (&#8220;GSK&#8221;), including RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (fluticasone furoate/vilanterol, &#8220;FF/VI&#8221;) and ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (umeclidinium bromide/vilanterol, &#8220;UMEC/VI&#8221;). Under the Long-Acting Beta2 Agonist (&#8220;LABA&#8221;) Collaboration Agreement, Innoviva is entitled to receive royalties from GSK on sales of RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> as follows: 15% on the first $3.0 billion of annual global net sales and 5% for all annual global net sales above $3.0 billion; and royalties from the sales of ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, which tier upward at a range from 6.5% to 10%.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expanded our portfolio through the acquisition of Entasis Therapeutics Holdings Inc. (&#8220;Entasis&#8221;) on July 11, 2022 and the acquisition of La Jolla Pharmaceutical Company (&#8220;La Jolla&#8221;) on August 22, 2022. Our commercial and marketed products include GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (angiotensin II), approved in the United States (&#8220;U.S.&#8221;) to increase blood pressure in adults with septic or other distributive shock, and XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (eravacycline) approved in the U.S. for the treatment of complicated intra-abdominal infections in adults. On May 23, 2023, XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (formerly known as sulbactam-durlobactam or SUL-DUR), was approved by the United States Food and Drug Administration (&#8220;FDA&#8221;) and we commenced commercial sales of XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in the third quarter of 2023. Our development pipeline includes zoliflodacin, an investigational treatment for uncomplicated gonorrhea that reported positive data in a pivotal Phase 3 clinical trial on November 1, 2023. As such, we have a wholly owned robust critical care and infectious disease operating platform with a hospital focus anchored by three differentiated products with significant growth potential and a promising drug candidate.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, we own other strategic healthcare assets, such as a large equity stake in Armata Pharmaceuticals, Inc., a leader in development of bacteriophages with potential use across a range of infectious and other serious diseases. We also have economic interests in other healthcare companies.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our focus on capital allocation and shareholder value maximization has led our company to a meaningful transformation, and 2023 was a significant transition year. In 2022 our financials contained royalty revenues from TRELEGY</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> which was divested mid-year in an economically accretive transaction. Additionally, our acquisition and integration of operating companies further changed the structure of our financials compared to prior years. Through these changes, we believe we are well-positioned to create significant long-term shareholder value.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our headquarters are located at 1350 Old Bayshore Highway, Suite 400, Burlingame, CA 94010. The Company was incorporated in Delaware in November 1996 under the name Advanced Medicine, Inc., and began operations in May 1997. It later changed its name to Theravance, Inc. in April 2002. In June 2014, we spun-off our research and development operations. In January 2016, we rebranded and changed our name to Innoviva, Inc.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Strategy</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our corporate strategy is currently focused on increasing stockholder value by, among other things, maximizing the potential value of our respiratory assets partnered with GSK, creating value through our critical care and infectious disease platform, optimizing our operations, and augmenting capital allocation. We continue to diversify our royalty management business through actively pursuing opportunistic acquisitions of promising companies and assets in the healthcare industry and enhancing the returns on our capital.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Royalty Product Portfolio</span></p>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Relationship with GSK</span></p>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">LABA Collaboration</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2002, we entered into our LABA Collaboration Agreement with GSK to develop and commercialize once&#8209;daily products for the treatment of chronic obstructive pulmonary disease (&#8220;COPD&#8221;) and asthma. The collaboration has developed three combination products, two of which we still retain rights in. Those two are as follows:</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (&#8220;FF/VI&#8221;) (BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> is the proprietary name in the U.S. and Canada and RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> is the proprietary name outside the U.S. and Canada), a once-daily combination medicine consisting of a LABA, vilanterol (&#8220;VI&#8221;), and an inhaled corticosteroid (&#8220;ICS&#8221;), fluticasone furoate (&#8220;FF&#8221;), and,</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (&#8220;UMEC/VI&#8221;), a once-daily medicine combining a long-acting muscarinic antagonist (&#8220;LAMA&#8221;), umeclidinium bromide (&#8220;UMEC&#8221;), with a LABA, VI.</span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a result of the launch and approval of RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in the U.S., Japan and Europe, in accordance with the LABA Collaboration Agreement, we paid milestone fees to GSK totaling $220.0 million during the year ended December 31, 2014. The milestone fees paid to GSK were recognized as capitalized fees paid, which are being amortized over their estimated useful lives commencing upon the commercial launch of the products.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Competition</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We anticipate that RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (FF/VI) and ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (UMEC/VI) will compete with a number of approved bronchodilator drugs alone or in combination, including each other and drug candidates under development that are designed to treat asthma and COPD. These include but are not limited to:</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Advair</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/Seretide&#153; Diskus</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/HFA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (salmeterol and fluticasone propionate as a combination) marketed by GSK</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Symbicort</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (formoterol and budesonide as a combination) marketed by AstraZeneca</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">AirDuo Respiclick</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (salmeterol and fluticasone propionate), a non-substitutable generic version of Advair, marketed by TEVA</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Spiriva</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Handihaler</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and Spiriva</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Respimat</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (tiotropium) marketed by Boehringer Ingelheim</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Dulera</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (formoterol and mometasone as a combination) marketed by Merck</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Tudorza</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Pressair</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (aclidinium) marketed by AstraZeneca and Seebri</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Breezehaler</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (glycopyrronium) marketed by Novartis outside the U.S. and Sunovion in the U.S.</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Incruse</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Ellipta</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (umeclidinium) and Arnuity</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Ellipta</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (fluticasone furoate) (Innoviva is not entitled to any royalties from either product)</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Foradil</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Aerolizer</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/Oxis</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Turbuhaler</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (formoterol) marketed by a number of companies</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Striverdi</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Respimat</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (olodaterol) marketed by Boehringer Ingelheim</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Onbrez</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Breezehaler</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (E.U.)/Arcapta</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Neohaler</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (U.S.) (indacaterol) marketed by Novartis</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Ultibro</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Breezehaler</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (E.U.)/Utibron</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Neohaler</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (U.S.) (indacaterol combined with glycopyrronium bromide) developed by Novartis and approved and launched in Europe and Japan in the year ended December 31, 2013 as a once-daily treatment for COPD. In the U.S., the product was approved in October 2015 at a lower strength as a twice-daily COPD treatment, and was licensed to Sunovion in December 2016, and launched in May 2017</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stiolto (U.S.)/Spiolto (E.U.) Respimat</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (tiotropium combined with olodaterol) marketed by Boehringer Ingelheim for the treatment of COPD</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Bevespi Aerosphere</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (glycopyrronium bromide in combination with formoterol fumarate) marketed by AstraZeneca</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Duaklir</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Genuair</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (aclidinium bromide in combination with formoterol fumarate) developed by AstraZeneca as a maintenance bronchodilator treatment for COPD and approved in November 2014 in the EU and March 2019 in the U.S.</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Atectura</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Breezhaler</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (indacaterol in combination with mometasone) marketed by Novartis</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Trimbow</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (a fixed-dose, twice daily combination of formoterol, beclomethasone and glycopyrronium) manufactured by Chiesi and indicated for use in COPD in the E.U.</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Foster (beclomethasone dipropionate in combination with formoterol fumarate) manufactured by Chiesi and indicated for use in asthma and COPD outside the U.S.</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Enerzair</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Breezehaler</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (a fixed-dose combination of indacaterol, mometasone and glycopyrronium) developed by Novartis as a triple therapy/single inhaler for the treatment of asthma and approved in the E.U., Canada, and Japan</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Breztri</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Aerosphere</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (fixed dose combination of formoterol, glycopyrronium and budesonide) developed by AstraZeneca as a triple therapy single inhaler twice-daily medication for COPD and approved in the U.S. in July 2020</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Nucala</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (mepolizumab; an interleukin-5 antagonist monoclonal antibody) developed by GSK for add on maintenance treatment of severe asthma in patients 12 years and older and approved in the U.S. in June 2019</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Xolair</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (omalizumab, an anti-IgE antibody) developed by Genentech for patients 6 years of age and older with moderate to severe persistent asthma uncontrolled by inhaled corticosteroids and approved in 2003. Single-dose pre-filled syringes were approved by the FDA in September 2018</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cinqair</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (anti-interleukin-5 monoclonal antibody for the add-on maintenance treatment of adults with severe asthma and an eosinophilic phenotype) marketed by TEVA Pharmaceutical Industries Ltd.</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Dupixent</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (dupilamab, an injectable IL-4 and IL-13 inhibitor) developed by Sanofi Genzyme and approved by the FDA in October 2018 as an add-on maintenance therapy in patients with moderate-to-severe asthma aged 12 years and older with an eosinophilic phenotype or with oral corticosteroid-dependent asthma</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fasenra</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (benralizumab, an injectable anti-IL-5 monoclonal antibody) for the treatment of severe asthma in patients 12 years of age and older marketed by AstraZeneca. Fasenra Pen pre-filled auto-injector was approved by the FDA for self-administration in November 2019</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Singulair</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (monteleukast), an orally active leukotriene receptor antagonist for the prophylaxis and treatment of asthma in patients 12 months of age and older marketed by Merck</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Tezspire</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (tezepelumab-ekko), an injectable monoclonal antibody designed to inhibit thymic stromal lymphopoietin (TSLP), an epithelial cytokine thought to be critical in the initiation and persistence of airway inflammation. Co-developed by Astra Zeneca and Amgen for the treatment of severe asthma. The FDA approved the Tezspire solution for subcutaneous injection in December 2021; it is indicated for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma.</span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, several firms have developed and launched new formulations of Advair/Seretide (salmeterol /fluticasone propionate) and Symbicort (formoterol fumerate/budesonide) which may be marketed as generics or branded generics relative to the existing products from GSK and AstraZeneca, respectively. All of these efforts represent potential competition for any of our partnered products. Efforts have intensified following the publication of FDA draft guidance for the approval of fully substitutable versions of Advair and Symbicort in late 2013 and mid-2015, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In general, these manufacturers are required to conduct a number of clinical efficacy, pharmacokinetic and device studies to demonstrate equivalence. These studies are designed to demonstrate that the generic product has the same active ingredient(s), dosage form, strength, exposure and clinical efficacy as the branded product. These generic equivalents, which must meet the same exacting quality standards as branded products, may be significantly less costly to bring to market, and companies that produce generic equivalents are generally able to offer their products at lower prices. Thus, after the introduction of a generic competitor, a significant percentage of the sales of any branded product and products that may compete with such branded product is typically lost to the generic product. In addition, in April 2016, the FDA issued a draft guidance document covering Fluticasone Furoate/Vilanterol Trifenatate (FF/VI), the active ingredients used in RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Integrated Critical Care / Infectious Disease Assets</span></p>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Commercial and Marketed Products</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our critical care and infectious disease portfolio was formed through the 2022 acquisitions of Entasis and La Jolla. It comprises  three differentiated commercial stage products and a pipeline. The following table summarizes our commercial and marketed products:</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img11953243_0.jpg" alt="img11953243_0.jpg" style="width:683px;height:290px;"/>&#160;</p>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;min-width:3.333%;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For U.S. and European approval</span></div></div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;min-width:3.333%;display:inline-flex;justify-content:flex-start;">(2)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">U.S.: GIAPREZA is a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock</span></div></div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;min-width:3.333%;display:inline-flex;justify-content:flex-start;">(3)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">European Union: GIAPREZA is indicated for the treatment of refractory hypotension in adults with septic or other distributive shock who remain hypotensive despite adequate volume restitution and application of catecholamines and other available vasopressor therapies</span></div></div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;min-width:3.333%;display:inline-flex;justify-content:flex-start;">(4)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">U.S.: XERAVA is a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections (&#8220;cIAI&#8221;) in patients 18 years of age and older</span></div></div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;min-width:3.333%;display:inline-flex;justify-content:flex-start;">(5)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">European Union: XERAVA is indicated for the treatment of cIAI in adults</span></div></div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;min-width:3.333%;display:inline-flex;justify-content:flex-start;">(6)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">U.S.: XACDURO is a co-packaged product containing sulbactam, a beta-lactam antibacterial and beta lactamase inhibitor, and durlobactam, a beta lactamase inhibitor, indicated in patients 18 years of age and older for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP), caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (angiotensin II)</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (angiotensin II) injection is approved by the U.S. FDA as a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. GIAPREZA is approved by the European Commission (&#8220;EC&#8221;) and by the Great Britain Medicines and Health Care Products Regulatory Agency (&#8220;MHRA&#8221;) for the treatment of refractory hypotension in adults with septic or other distributive shock who remain hypotensive despite adequate volume restitution and application of catecholamines and other available vasopressor therapies. GIAPREZA mimics the body&#8217;s endogenous angiotensin II peptide, which is central to the renin-angiotensin-aldosterone system (&#8220;RAAS&#8221;), which in turn regulates blood pressure. GIAPREZA is marketed in the U.S. by La Jolla and is marketed in Europe and Great Britain by PAION Deutschland GmbH on behalf of La Jolla. PAION AG and PAION Deutschland GmbH (together and individually &#8220;PAION&#8221;) filed for insolvency in Germany on October 27, 2023 and the insolvency proceedings were opened on January 1, 2024. PAION announced on December 22, 2023 that it concluded negotiations with Humanwell Healthcare Group and entered into an agreement on the sale of the essential business operations of PAION AG and PAION Deutschland GmbH with the approval of the insolvency administrator in both procedures. La Jolla did not oppose the sale and is in discussions with the acquirer regarding the continued business relationship.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Angiotensin II for the Treatment of High-Output Shock (&#8220;ATHOS-3&#8221;)</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">GIAPREZA was approved by the U.S. FDA, EC and MHRA based on the results of ATHOS-3, which were published in the New England Journal of Medicine in August 2017. ATHOS-3 was a multinational, randomized, double-blind, placebo-controlled study in which 321 adults with septic or other distributive shock who remained hypotensive despite fluid and vasopressor therapy received either GIAPREZA or placebo, both in addition to background vasopressor therapy. The primary endpoint was mean arterial pressure (&#8220;MAP&#8221;) response, defined as a MAP of 75 mm Hg or higher or an increase in MAP from baseline of at least 10 mm Hg without an increase in the dose of background vasopressors at Hour 3 (Khanna et al, New England Journal of Medicine 2017; 377:419&#8211;430).</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ATHOS-3 Study Design</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">(1)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img11953243_1.jpg" alt="img11953243_1.jpg" style="width:632px;height:261px;"/>&#160;</p>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">MAP=mean arterial pressure</span></p>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;min-width:3.333%;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Khanna et al, New England Journal of Medicine 2017; 377:419&#8211;430</span></div></div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;min-width:3.333%;display:inline-flex;justify-content:flex-start;">(2)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Standard-of-care vasopressors included norepinephrine, epinephrine, dopamine and vasopressin</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">GIAPREZA significantly improved blood pressure response. Specifically, the primary endpoint was achieved by 70% of GIAPREZA-treated patients compared to 23% of placebo-treated patients (p &lt;0.0001).</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ATHOS-3 Primary Endpoint Results</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img11953243_2.jpg" alt="img11953243_2.jpg" style="width:442px;height:338px;"/>&#160;</p>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;min-width:3.333%;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Charts, graphs and tables derived from FDA prescribing information</span></div></div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;min-width:3.333%;display:inline-flex;justify-content:flex-start;">(2)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">MAP response of 75 mm Hg or higher or an increase from baseline of at least 10 mm Hg at Hour 3 without an increase in the dose of background vasopressors</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">GIAPREZA provides the ability to rapidly achieve and adjust therapeutic response. GIAPREZA rapidly increased MAP with a median time to MAP response of approximately 5 minutes. The plasma half-life of GIAPREZA is less than 1 minute.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, a positive survival trend was observed. Mortality through Day 28 was 46% on GIAPREZA and 54% on placebo (hazard ratio 0.78; 95% confidence interval 0.57&#8211;1.07).</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Positive Survival Trend Observed (N=321)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">(1),(2)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img11953243_3.jpg" alt="img11953243_3.jpg" style="width:530px;height:304px;"/>&#160;</p>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;min-width:3.333%;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Charts, graphs and tables derived from FDA prescribing information</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;min-width:3.333%;display:inline-flex;justify-content:flex-start;">(2)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Khanna et al, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">New England Journal of Medicine 2017;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> 377:419&#8211;430</span></div></div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;min-width:3.333%;display:inline-flex;justify-content:flex-start;">(3)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Patients were treated with either GIAPREZA or placebo, both in addition to background vasopressor therapy</span></div></div>
  <p style="margin-left:4.267%;text-indent:3.482%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The most common adverse reactions that were reported in greater than 10% of GIAPREZA-treated patients were thromboembolic events.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Adverse Reactions Occurring in &#8805;4% of Patients Treated with GIAPREZA and &#8805;1.5% More Often than in Placebo-treated Patients</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">(1)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img11953243_4.jpg" alt="img11953243_4.jpg" style="width:542px;height:239px;"/>&#160;</p>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;min-width:3.333%;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Charts, graphs and tables derived from FDA prescribing information</span></div></div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;min-width:3.333%;display:inline-flex;justify-content:flex-start;">(2)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Including arterial and venous thrombotic events</span></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">XERAVA</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (eravacycline)</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (eravacycline) for injection is approved by the U.S. FDA and Singapore Health Sciences Authority (&#8220;HSA&#8221;) as a tetracycline class antibacterial indicated for the treatment of cIAI due to susceptible microorganisms in patients 18 years of age and older. XERAVA is approved by the EC, MHRA, and the Hong Kong Department of Health (&#8220;DoH&#8221;) for the treatment of cIAI in adults. XERAVA is marketed in the U.S. by our wholly owned subsidiary, Tetraphase Pharmaceuticals, Inc. (&#8220;Tetraphase&#8221;), and is marketed in Europe and Great Britain by PAION on behalf of Tetraphase and is marketed in mainland China, Taiwan, Hong Kong, Macau, South Korea, Singapore, the Malaysian Federation, the Kingdom of Thailand, the Republic of Indonesia, the Socialist Republic of Vietnam and the Republic of the Philippines by Everest Medicines Limited (&#8220;Everest&#8221;).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">cIAIs are the second most common source of severe sepsis in the ICU cIAIs are defined as consequences of perforations of the gastrointestinal tract that result in contamination of the peritoneal space.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Investigating Gram-negative Infections Treated with Eravacycline (&#8220;IGNITE&#8221;)</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">XERAVA was approved by the U.S. FDA, HSA, EC, MHRA, and DoH based on the results of IGNITE1 and IGNITE4, which were published in JAMA Surgery in March 2017 and Clinical Infectious Diseases in December 2018, respectively.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">IGNITE1 was a multinational, randomized, double-blind, active-controlled study in 538 patients with clinical evidence of cIAIs requiring urgent surgical or percutaneous intervention who received either XERAVA or ertapenem. The primary endpoint was clinical cure, defined as complete resolution or significant improvement of signs or symptoms of the index infection, at the test of cure (&#8220;TOC&#8221;) visit. The TOC visit was conducted 25 to 31 calendar days after the first dose of the study drug was administered.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">IGNITE4 was a multinational, randomized, double-blind, active controlled study in 499 patients with clinical evidence of cIAIs requiring urgent surgical or percutaneous intervention who received either XERAVA or meropenem. The primary endpoint was clinical cure, defined as complete resolution or significant improvement of signs or symptoms of the index infection, at the TOC visit. The TOC visit was conducted 25 to 31 calendar days after the first dose of the study drug was administered.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">11</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">IGNITE1 and IGNITE4 Study Design</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img11953243_5.jpg" alt="img11953243_5.jpg" style="width:608px;height:330px;"/>&#160;</p>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;min-width:3.333%;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Solomkin et al, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">JAMA Surgery</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> 2017; 152(3):224-232</span></div></div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;min-width:3.333%;display:inline-flex;justify-content:flex-start;">(2)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Solomkin et al, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Clinical Infectious Diseases</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> 2018; 69(6):921-9</span></div></div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;min-width:3.333%;display:inline-flex;justify-content:flex-start;">(3)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">TOC visit was conducted 25 to 31 calendar days after the first dose of the study drug was administered</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">XERAVA demonstrated statistical noninferiority in clinical cure rate in the micro-ITT population, which included all randomized subjects who had baseline bacterial pathogens that caused cIAIs and against at least one of which the investigational drug has in vitro (in a test tube) antibacterial activity (N=846).</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">IGNITE1 and IGNITE4 Primary Endpoint Results</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">(1)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img11953243_6.jpg" alt="img11953243_6.jpg" style="width:621px;height:238px;"/>&#160;</p>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;min-width:3.333%;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Charts, graphs and tables derived from FDA prescribing information</span></div></div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;min-width:3.333%;display:inline-flex;justify-content:flex-start;">(2)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Noninferiority margins of 10% and 12.5% were used for IGNITE1 and IGNITE4, respectively</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Clinical cure rates across patients with gram-negative, gram-positive and anaerobic pathogens, including those with resistant strains, are shown in the following tables.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Clinical Cure Rates at TOC by Selected Baseline Pathogens in the Micro-ITT Population</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">(1)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img11953243_7.jpg" alt="img11953243_7.jpg" style="width:516px;height:267px;"/>&#160;</p>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">N=Number of subjects in the micro-ITT Population; N1=Number of subjects with a specific pathogen; n=Number of subjects with a clinical cure at the TOC visit</span></p>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;min-width:3.333%;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Charts, graphs and tables derived from FDA prescribing information</span></div></div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;min-width:3.333%;display:inline-flex;justify-content:flex-start;">(2)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Comparators included ertapenem and meropenem for IGNITE1 and IGNITE4, respectively</span></div></div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;min-width:3.333%;display:inline-flex;justify-content:flex-start;">(3)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Includes </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Streptococcus anginosus, Streptococcus constellatus, and Streptococcus intermedius</span></div></div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;min-width:3.333%;display:inline-flex;justify-content:flex-start;">(4)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Includes </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Bacteroides caccae, Bacteroides fragilis, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Clostridium perfringens, and Parabacteroides distasonis</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The most common adverse reactions that were reported in XERAVA-treated patients in IGNITE1 and IGNITE4 were infusion site reactions.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Selected Adverse Reactions Reported in &#8805;1% of Patients Receiving XERAVA</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">(1)</span></p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img11953243_8.jpg" alt="img11953243_8.jpg" style="width:515px;height:154px;"/>&#160;</p>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;min-width:3.333%;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Charts, graphs and tables derived from FDA prescribing information</span></div></div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;min-width:3.333%;display:inline-flex;justify-content:flex-start;">(2)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Comparators included ertapenem and meropenem for IGNITE1 and IGNITE4, respectively</span></div></div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;min-width:3.333%;display:inline-flex;justify-content:flex-start;">(3)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Infusion site reactions include: catheter/vessel puncture site pain, infusion site extravasation, infusion site hypoaesthesia, infusion/injection site phlebitis, infusion site thrombosis, injection site/vessel puncture site erythema, phlebitis, phlebitis superficial, thrombophlebitis, and vessel puncture site swelling</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">XACDURO</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use (formerly known as sulbactam-durlobactam or SUL-DUR), was approved by the United States Food and Drug Administration (&#8220;FDA&#8221;) on May 23, 2023, and we commenced commercial sales of XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in the third quarter of 2023. XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> is a novel IV antibiotic. The product is a combination of sulbactam, a &#946;-lactam antibiotic, and durlobactam, a novel &#946;-lactamase inhibitor (&#8220;BLI&#8221;) with broad spectrum &#946;-lactamase coverage including Classes A, C and D, that was specifically developed for the treatment of a variety of serious infections caused by carbapenem-resistant </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Acinetobacter</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. We believe that XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> is addressing a large unmet medical need in treating patients with serious </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Acinetobacter </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">infections who prior to this launch have had few options for effective treatment.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">13</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Acinetobacter</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Acinetobacter</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> is a Gram-negative, opportunistic human pathogen that predominantly infects critically ill patients often resulting in severe pneumonia and bloodstream infections but also capable of infecting other body sites as well. Once thought to be mostly benign, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Acinetobacter</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> is now considered a global threat in the healthcare setting due in part to its ability to acquire multidrug resistance at rates not previously seen in other bacteria. In addition, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Acinetobacter</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> can remain viable for up to 100 days in dry conditions and easily spreads via air or water droplets, which explains why the pathogen can often be found in many locations in the intensive care unit, or ICU, including bedrails, bedside tables, monitors of mechanical ventilators, intravenous pumps, door handles, stethoscopes and many other locations. Of significant concern, one study reported greater than 98% of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Acinetobacter</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> isolates in an ICU from non-clinical sources, such as bedrails and door handles, were determined to be multidrug resistant.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pneumonia and bloodstream infections caused by drug-resistant </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Acinetobacter</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> can have mortality rates up to 50%. Antibiotic-resistance rates of Acinetobacter to current standard-of-care treatments are some of the highest reported, between 30% and 50% in the United States and greater than 90% in parts of Europe and Asia. Acinetobacter resistance to &#946;-lactams is primarily driven by the expression of Class&#8239;D &#946;-lactamases, often in combination with Class&#8239;A and/or Class&#8239;C &#946;-lactamases. There are currently no effective antibiotics specifically indicated for the treatment of multidrug-resistant </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Acinetobacter</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> infections. Durlobactam is the first clinical-stage BLI with sufficient broad-spectrum activity against class A, C, and D &#946;-lactamases to potentially restore the efficacy of &#946;-lactam antibiotics against multidrug-resistant </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Acinetobacter</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Sulbactam, the &#946;-lactam antibiotic used in XACDURO has superior microbiological potency against </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Acinetobacter</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> compared to other &#946;-lactam antibiotics based on </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> analyses. Historically, physicians used sulbactam to successfully treat </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Acinetobacter</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> infections before development of broad &#946;-lactamase mediated resistance rendered sulbactam on its own largely ineffective. We believe our data demonstrates that combining durlobactam with sulbactam can effectively restore the activity of sulbactam against multidrug-resistant strains of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Acinetobacter</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Acinetobacter Treatment Trial Against Colistin (&#8220;ATTACK&#8221;)</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We completed ATTACK, a Phase 3 registration trial of XACDURO for the treatment of patients with carbapenem-resistant </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Acinetobacter</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> infections, with positive top-line data announced in October 2021 and published in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The Lancet Infectious Diseases </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">in May 2023. ATTACK enrolled 207 patients at 95 clinical sites in 16 countries. This was a two-part trial with Part A being the randomized, comparative portion (XACDURO vs colistin) in patients with documented </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Acinetobacter</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> hospital-acquired bacterial pneumonia (HABP), ventilator-associated bacterial pneumonia (VAPB), ventilated pneumonia (VP), or bacteremia, and Part B being an open-labeled portion including </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Acinetobacter</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> infections resistant to, or having previously failed colistin or polymyxin B treatment. Baseline </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Acinetobacter</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> isolates tested were greater than 95% carbapenem resistant.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">XACDURO met the primary efficacy endpoint of 28-day all-cause mortality compared to colistin in the CRABC m-MITT population of Part A. XACDURO mortality was 19.0% (12/63) compared to 32.3% (20/62) in the colistin arm (treatment difference of -13.2%; 95% CI: -30.0, 3.5). Similar trends were demonstrated in 28-day and 14-day all-cause mortality favoring XACDURO across all study populations evaluated to date. A statistically significant difference in clinical cure at Test of Cure (TOC) was observed with 61.9% in the XACDURO arm compared to 40.3% in the colistin arm (95% CI 2.9-40.3). In Part B, the 28-day all-cause mortality was 17.9% (5/28) and consistent with that observed in Part A.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Safety analyses from a total of 177 patients treated with XACDURO suggested that XACDURO was generally well-tolerated with a favorable safety profile compared to colistin. XACDURO met the primary safety objective with a statistically significant lower incidence of nephrotoxicity as measured by the RIFLE classification for acute kidney injury. XACDURO nephrotoxicity was 13.2% (12/91) versus 37.6% (32/85) in the colistin arm (p = 0. 0002). Overall adverse events (AEs) in the safety population were comparable between treatment groups with 87.9% (80/91) in the XACDURO arm vs. 94.2% (81/86) in the colistin arm in Part A, 89.3% (25/28) in Part B. Drug related AEs were 12.1% (10.7% in Part B) with XACDURO compared to 30.2% with colistin. The most common non-infectious AEs (&#8805;10%) in the XACDURO arm were diarrhea (16.5%), allergic and hypersensitivity reactions (16.5%), anemia (13.2%) and hypokalemia (12.1%) in Part A. These AEs were also &gt;10% in the colistin arm as was acute kidney injury.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">14</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="margin-left:20%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:6pt;margin-right:26.667%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ATTACK Study Design</span></p>
  <p style="margin-left:20%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:6pt;margin-right:26.667%;text-align:center;"><img src="img11953243_9.jpg" alt="img11953243_9.jpg" style="width:405px;height:249px;"/>&#160;</p>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">IMI=Imipenem; TOC=Test of cure; HABP=hospital acquired bacterial pneumonia; VABP=ventilator associated bacterial pneumonia; VP=ventilated pneumonia; BSI=blood stream infection; ABC=</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Acinetobacter baumannii-calcoaceticus</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> complex</span></p>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;min-width:3.333%;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2-part study, Part A being the randomized, controlled portion of the study in patients with ABC HABP / VABP or bacteremia. Part B is the single-group portion of the study and includes ABC infections that are resistant to or have failed colistin or polymyxin B treatment, as detailed in the inclusion criteria. Part B is deemed as not relevant to the HABP / VABP indication</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ATTACK Primary Endpoint Results</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">(1)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img11953243_10.jpg" alt="img11953243_10.jpg" style="width:345px;height:223px;"/><img src="img11953243_11.jpg" alt="img11953243_11.jpg" style="width:346px;height:223px;"/>&#160;</p>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">IMI=Imipenem</span></p>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;min-width:3.333%;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Charts, graphs and tables derived from FDA prescribing information. Kaye et al. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Lancet Infect Dis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> 2023 May 11:S1473-3099(23)00184-6</span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">15</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Selected Adverse Reactions Occurring at a Frequency of &gt;5% in Trial 1</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">(1)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img11953243_12.jpg" alt="img11953243_12.jpg" style="width:590px;height:259px;"/>&#160;</p>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;min-width:3.333%;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Charts, graphs and tables derived from FDA prescribing information</span></div></div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;min-width:3.333%;display:inline-flex;justify-content:flex-start;">(2)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Liver test abnormalities includes the following adverse reactions: liver function test abnormal, hepatic function abnormal, increased transaminases, ALT increased, and AST increased; Acute kidney injury includes the following adverse reactions: renal impairment, blood Cr increased, toxic nephropathy, renal failure and acute kidney injury. </span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All-cause mortality: Kaplan-Meier analysis of time to death by day 28</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">(1)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img11953243_13.jpg" alt="img11953243_13.jpg" style="width:665px;height:243px;"/>&#160;</p>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;min-width:3.333%;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Kaye et al. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Lancet Infect Dis. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2023 May 11:S1473-3099(23)00184-6</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Competition</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">competes with catecholamines (primarily norepinephrine), which are available as generics and inexpensive and typically used first line to treat distributive shock, and vasopressin, including Vasostrict</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (Endo International plc) and vasopressin generic drugs, which are typically used second line. In the randomized, Phase 3 study ATHOS-3, GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> demonstrated clinical benefit in patients who were not adequately responding to available vasopressors, including catecholamines and vasopressin. GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8217;s principal competition as a treatment in patients not adequately responding to available vasopressors is the use of these same vasopressors at increased doses. If we are unable to successfully change treatment practices, the commercial prospects for GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> will be limited, and our business may suffer.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">16</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> competes with a number of antibiotics that are currently marketed for the treatment of cIAI and other multidrug resistant infections, including: AVYCAZ (ceftazidime and avibactam, marketed by AbbVie Inc.); MERREM IV</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (meropenem, marketed by AstraZeneca PLC); PRIMAXIN</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (imipenem and cilastatin, marketed by Merck &amp; Co., Inc.); RECARBRIO&#153; (imipenem, cilastatin, and relebactam, marketed by Merck &amp; Co., Inc.); TYGACIL</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (tigecycline, marketed by Pfizer Inc.); VABOMERE&#153; (meropenem and vaborbactam, marketed by Melinta Therapeutics, Inc.); ZERBAXA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (ceftolozane and tazobactam, marketed by Merck &amp; Co., Inc.); ZOSYN</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (piperacillin and tazobactam, marketed by Pfizer Inc.); and current and future generic versions of marketed antibiotics. If we are unable to successfully change treatment practices, the commercial prospects for XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> will be limited, and our business may suffer.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> competes with a number of antibiotics that are used to treat carbapenem-resistant </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Acinetobacter </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">infections in the absence of other products indicated for these infections, including: FETROJA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (cefiderocol, marketed by Shionogi &amp; Co., Ltd.), UNASYN</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (ampicillin and sulbactam, marketed by Pfizer Inc.), colistin (polymyxin E), and other current and future generic versions of marketed antibiotics. There are at least two additional early-stage clinical programs developing investigational therapies for multidrug-resistant </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Acinetobacter </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">infections. If we are unable to successfully change treatment practices, the commercial prospects for XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> will be limited, and our business may suffer.</span></p>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Regulatory Exclusivity</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> are New Chemical Entities (&#8220;NCEs&#8221;) approved by the U.S. FDA. In the U.S., NCEs approved by the FDA are eligible for market exclusivity under the U.S. Federal Food, Drug, and Cosmetic Act (&#8220;FDCA&#8221;), which can prevent the approval of generic versions of the NCE for 5 to 7.5 years from the date of the initial approval of the NCE. Specifically, the FDCA provides a 5-year period of marketing exclusivity within the U.S. to the applicant that gains approval of an NDA for an NCE. A drug is an NCE if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not accept for review an Abbreviated New Drug Application (&#8220;ANDA&#8221;) or a 505(b)(2) NDA submitted by another company for another version of such drug where the applicant does not own or have a legal right of reference to all of the data required for approval. However, an application may be submitted 4 years after the NDA approval of the NCE if it contains a certification of patent invalidity or non-infringement. Should the NDA holder commence litigation against the ANDA filer within 45 days of receipt of the certification notice, an automatic stay of the approval of any generic competition goes into effect until the earlier of: (i) 30 months from the receipt of the certification; or (ii) a court ruling of patent invalidity or non-infringement for the relevant patents. In the absence of a court ruling, the 30-month stay will be extended by such amount of time (if any) that is required for 7.5 years to have elapsed from the date of NDA approval of the NCE.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On February 15, 2022, La Jolla received a paragraph IV notice of certification (the &#8220;Notice Letter&#8221;) from Gland Pharma Limited (&#8220;Gland&#8221;) advising that Gland had submitted an Abbreviated New Drug Application (&#8220;ANDA&#8221;) to the FDA seeking approval to manufacture, use or sell a generic version of GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in the U.S. prior to the expiration of U.S. Patent Nos.: 9,220,745; 9,572,856; 9,867,863; 10,028,995; 10,335,451; 10,493,124; 10,500,247; 10,548,943; 11,096,983; and 11,219,662 (the &#8220;GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Patents&#8221;), which are listed in the FDA&#8217;s Approved Drug Products with Therapeutic Equivalence Evaluations (the &#8220;Orange Book&#8221;). The Notice Letter alleges that the GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Patents are invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of the generic product described in Gland&#8217;s ANDA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On March 29, 2022, La Jolla filed a complaint for patent infringement of the GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Patents against Gland and certain related entities in the United States District Court for the District of New Jersey in response to Gland&#8217;s ANDA filing. In accordance with the Hatch-Waxman Act, because GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> is a new chemical entity and La Jolla filed a complaint for patent infringement within 45 days of receipt of the Notice Letter, the FDA cannot approve Gland&#8217;s ANDA any earlier than 7.5 years from the approval of the GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> NDA unless the District Court finds that all of the asserted claims of the patents-in-suit are invalid, unenforceable and/or not infringed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On February 22, 2023, La Jolla received a paragraph IV notice of certification (the &#8220;Second Notice Letter&#8221;) from Gland advising that Gland had amended its ANDA filing to include a paragraph IV certification alleging that all claims of the newly-issued and Orange Book-listed U.S. Patent No. 11,559,559 (&#8220;the &#8217;559 Patent&#8221;), which covers GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, are invalid, unenforceable and/or not infringed.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">17</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On March 22, 2023, La Jolla filed a First Amended Complaint in this litigation adding Gland&#8217;s marketing and distribution partners for its ANDA angiotensin II product, Fresenius Kabi USA LLC and Fresenius Kabi SwissBiosim GmbH (collectively, the &#8220;Fresenius Kabi Defendants&#8221;), as co-defendants. On April 7, 2023, La Jolla filed a Second Amended Complaint in response to the Second Notice Letter, adding claims that the manufacture, use, sale, offer for sale, or import of Gland&#8217;s ANDA angiotensin II product will infringe the &#8217;559 Patent. On November 14, 2023, La Jolla filed a Third Amended Complaint adding additional infringement claims against the Fresenius Kabi Defendants. We intend to vigorously enforce our intellectual property rights relating to GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fact discovery is set to conclude on February 29, 2024 and expert discovery will be complete by July 12, 2024. A trial date has not yet been set in this matter.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the Generating Antibiotic Incentives Now (&#8220;GAIN&#8221;) provisions of the FDA Safety and Innovation Act (&#8220;FDASIA&#8221;), the FDA may designate a product as a qualified infectious disease product (&#8220;QIDP&#8221;). In order to receive this designation, a drug must qualify as an antibacterial or antifungal drug for human use intended to treat serious or life-threatening infections. We obtained a QIDP designation for the IV formulation of XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for cIAI in July 2013. Upon approving an application for a QIDP, the FDA will extend by an additional 5 years any non-patent marketing exclusivity period awarded, such as a 5-year exclusivity period awarded for an NCE. This extension is in addition to any pediatric exclusivity extension awarded. XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> has been awarded this 5-year exclusivity under FDASIA.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Pipeline</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes the status of our primary product candidate:</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><img src="img11953243_14.jpg" alt="img11953243_14.jpg" style="width:691px;height:80px;"/>&#160;</p>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;min-width:3.333%;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Global Antibiotic Research and Development Partnership (&#8220;GARDP&#8221;) fully funded the Phase&#8239;3 clinical trial and pharmaceutical development activities and has commercial rights in WHO defined low-income and specified middle-income countries. We have retained commercial rights in major markets in North America, Europe and Asia-Pacific</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Zoliflodacin</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Zoliflodacin is a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea caused by the bacterial pathogen </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">N. gonorrhoeae</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Gonorrhea is an area of significant medical need and zoliflodacin is the only novel single dose treatment in development that provides a potential monotherapy oral alternative to intramuscular injections of ceftriaxone for the treatment of gonorrhea, including infections caused by drug-resistant strains. Zoliflodacin targets the validated mechanism of action of the fluoroquinolone class of antibiotics but does so in a novel manner to avoid existing fluoroquinolone resistance. In November 2023, we reported positive top-line data results of a pivotal Phase 3 trial. The study demonstrated statistical non-inferiority of microbiological cure at the urogenital site when compared to treatment with intramuscular infection of ceftriaxone and oral azithromycin, a current global standard of care regimen. This trial was initiated in 2019 in collaboration with GARDP, who funded all the Phase 3 clinical trial and pharmaceutical development costs and in return received commercial rights for zoliflodacin in WHO-defined low-income and select middle-income countries. We retained commercial rights in all other countries, including the major markets in North America, Europe and Asia-Pacific.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Gonorrhea</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Uncomplicated gonorrhea is an </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">N.&#8239;gonorrhoeae</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> infection of the urethra, cervix, pharynx or rectum, and is more common than complicated gonorrhea, which includes spread of the infection to other tissues and potentially the bloodstream. Gonorrhea can be associated with serious complications, including pelvic inflammatory disease, ectopic pregnancy and infertility, as well as an increased risk of human immunodeficiency virus, or HIV. Despite the continued use of effective antibiotics, it remains one of the most common sexually transmitted bacterial infections in the world with an estimated 82&#8239;million people worldwide infected each year, including over 1 million people each year in the United States. The occasional absence of symptoms, more frequent in women, is thought to be one reason for sustained levels of infection. Antibiotics remain the mainstay for treating uncomplicated gonorrhea</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">caused by </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">N. gonorrhoeae.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">18</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">N. gonorrhoeae</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> is the bacterial pathogen responsible for gonorrhea and has a strong propensity for uptake of chromosomal DNA from other genera of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Neisseria</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> which allows the bacteria to accumulate many mutations in chromosomal genes leading to frequent resistance of antibiotics. For example, penicillin was introduced for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">N. gonorrhoeae </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">infections in 1943, and initial resistance was reported in 1945. Fluoroquinolone antibiotics were first used to treat gonorrhea in 1949 and have been one of the most successful classes of antibiotics against </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">N. gonorrhoeae</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, but even so resistance was identified in 1969. One member of this class, ciprofloxacin, was introduced in 1980 and resistance was identified in 1990. More recently cephalosporin antibiotics, notably cefixime, had been widely used for the treatment of gonorrhea due to their oral administration along with a favorable efficacy and safety profile, although resistance by </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">N. gonorrhoeae </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">has been reported since 2007. As widespread use of these antibiotics drove the emergence of drug-resistant </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">N. gonorrhoeae</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> strains, treatment guidelines have subsequently been amended. Ceftriaxone is currently the only CDC-recommended option for the treatment of gonorrhea and, until recently, was administered with azithromycin, a broad-spectrum antibiotic, to provide coverage against other sexually transmitted diseases that tend to occur concurrently with gonorrhea. However, rising resistance of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">N. gonorrhoeae</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to azithromycin recently prompted the CDC to now recommend 500mg ceftriaxone monotherapy. Ceftriaxone is administered by intramuscular injection, which can be painful and may require patient monitoring by a healthcare administrator. Although ceftriaxone remains effective in most of the U.S., in Hawaii and Massachusetts as well as in several countries, including China, Japan, Vietnam, South Korea, France and Spain, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">N. gonorrhoeae</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> strains with resistance to azithromycin and ceftriaxone have been reported, prompting concerns that multidrug-resistant gonorrhea may become a major community health issue.</span></p>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Market Opportunity</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">N. gonorrhoeae</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> is an immediate global public health threat with 82.4 million cases worldwide in 2020 (WHO estimate). Cases of gonorrhea in the United States have reached an estimated 1.6 million per year. The CDC estimates that the cases of gonorrhea in the United States have been increasing at least 10% per year since 2009.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The results of a 2017-2018 survey of countries reporting decreased susceptibility, DS, or resistance, R, of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">N. gonorrhoeae</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to current antibiotics are reflected in the table below.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><img src="img11953243_15.jpg" alt="img11953243_15.jpg" style="width:458px;height:168px;"/>&#160;</p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Historically, to reduce the risk of spreading drug-resistant </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">N. gonorrhoeae</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the CDC has changed treatment guidelines when resistance rates to recommended first-line treatments reach 5%. Since 2015, there has only been one recommended treatment on CDC guidelines for gonorrhea: 250mg intramuscular injection of ceftriaxone plus 1g of oral azithromycin. In 2020 the CDC once again updated its treatment guideline, now recommending a 500mg intramuscular injection of ceftriaxone for treatment of uncomplicated gonorrhea. This follows a 2019 update in the United Kingdom where recommended empirical treatment of gonorrhea is now 1 g intramuscular ceftriaxone monotherapy.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe that as resistance to ceftriaxone continues to grow both in the US and around the world, there is an increasing unmet medical need for drugs effective against resistant strains of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">N. gonorrhoeae</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and also for an oral therapy for those patients who cannot get an in-office intramuscular injection or prefer a more convenient option.</span></p>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Completed Clinical Trials</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Phase 3 registrational trial:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> We completed a global, multi-center Phase 3 registrational trial in collaboration with GARDP who conducted and funded all Phase 3 clinical trial and pharmaceutical development costs. The Phase 3 trial enrolled a total of 930 patients with uncomplicated gonorrhea, including women, adolescents, and people living with HIV, making it the largest clinical trial ever conducted for a new treatment against gonorrhea infection, with 16 trial sites in regions with a high prevalence of gonorrhea across five countries, including Belgium, the Netherlands, South Africa, Thailand, and the U.S. The trial compared a single, oral, 3g dose of zoliflodacin to a globally recognized standard of care regimen (500mg ceftriaxone IM plus 1g oral azithromycin) for the treatment of uncomplicated gonorrhea.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">19</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Zoliflodacin met the prespecified statistical test for non-inferiority when compared to ceftriaxone and oral azithromycin (5.31% (95%CI 1.38, 8.65%)). Non inferiority of zoliflodacin was demonstrated within the pre-specified margin of 12% and, furthermore, within the margin of 10% as specified in U.S. Food and Drug Administration guidance.<br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Phase 3 trial design</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><img src="img11953243_16.jpg" alt="img11953243_16.jpg" style="width:275px;height:268px;"/><img src="img11953243_17.jpg" alt="img11953243_17.jpg" style="width:289px;height:268px;"/>&#160;</p>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">TOC=Test of Cure; IM=intra-muscular; CRO-AZI=ceftriaxone and azithromycin</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Efficacy and safety results from Phase 3 trial</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">(1)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img11953243_18.jpg" alt="img11953243_18.jpg" style="width:331px;height:239px;"/><img src="img11953243_19.jpg" alt="img11953243_19.jpg" style="width:256px;height:236px;"/><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><br/></span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:3.35pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">TEAE=Treatment emergent adverse event; CRO-AZI=ceftriaxone and azithromycin</span></p>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;min-width:3.333%;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Company data, published on November 6, 2023</span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Phase&#8239;2 clinical proof-of-concept trial: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have completed a multi-center, randomized, open-label Phase&#8239;2 clinical trial comparing a single oral dose of 2.0g or 3.0g of zoliflodacin to 500mg intramuscular ceftriaxone for the treatment of uncomplicated gonorrhea. In this trial, 179 randomized patients received treatment and zoliflodacin was generally well tolerated, with efficacy outcomes comparable to ceftriaxone. Microbiological eradication and clinical cure in urogenital infections with a single dose of zoliflodacin, the primary endpoint of the trial, was comparable to ceftriaxone, with 100% cure rate in both the 3.0g zoliflodacin and ceftriaxone groups in the per-protocol population. The results of this clinical trial were published in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The New England Journal of Medicine</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in 2018.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">20</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Phase 1 clinical trial: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We evaluated zoliflodacin in two Phase&#8239;1 clinical trials studying 72 healthy volunteers in total. In one trial, we evaluated PKs and tolerability in 48 subjects and food effects in 18 subjects, and in the second trial, we evaluated absorption, distribution, metabolism and excretion in six subjects. Zoliflodacin was generally well tolerated in these trials at doses we would expect to be clinically active for treating uncomplicated gonorrhea. Administration of a high-fat meal was associated with an increase in zoliflodacin plasma concentration, suggesting that zoliflodacin could be administered with or without food.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Preclinical Data</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have generated biochemical, microbiological and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> data on zoliflodacin. The data suggest that zoliflodacin retains potent activity against contemporary clinical isolates in the U.S., Europe, China, Thailand and South Africa that are resistant to other antibiotic classes including fluroquinolones, which was expected given its novel mechanism of action. In addition, the data show significant resistance against two of the four standard antibiotics indicated for gonorrhea, ciprofloxacin, a fluoroquinolone, and azithromycin, a macrolide.</span></p>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Competition</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are initially developing zoliflodacin as a single oral dose treatment for uncomplicated gonorrhea. Gonorrhea is commonly treated with 500mg intramuscular ceftriaxone, a generically available agent. Additional generic cephalosporins and fluoroquinolones are also prescribed, but not recommended as primary treatment options given current resistance rates. Gepotidacin, currently under development for a variety of infections by GlaxoSmithKline&#8239;plc, is the only potentially competitive product candidate in late-stage clinical development that we are aware of that is being developed for the treatment of uncomplicated urogenital gonorrhea. A Phase 3 clinical trial (EAGLE-1) was initiated by GlaxoSmithKline in October 2019. A prior Phase 2 clinical trial revealed the emergence of resistance to gepotidacin in 2 urogenital microbiological failures following administration of a single oral dose. In an attempt to overcome this resistance, gepotidacin will be given in two oral doses in the EAGLE-1 clinical trial; a 4-tablet 3000 milligram (mg) oral dose at the study site followed by another 4-tablet 3000mg oral dose as an outpatient.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Manufacturing</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Manufacturing of RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (FF/VI) and ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (UMEC/VI) is performed by GSK.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We rely on third-party manufacturers to produce GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and expect to continue to do so in the foreseeable future to meet our development and commercial needs. In all of our manufacturing agreements, we require that contract manufacturers produce active pharmaceutical ingredients (&#8220;APIs&#8221;) and drug products in accordance with the FDA&#8217;s current Good Manufacturing Practices (&#8220;cGMPs&#8221;) and all other applicable laws and regulations. We maintain confidentiality agreements with potential and existing manufacturers in order to protect our proprietary rights related to GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The long-term commercial success of GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> will depend in part on the ability of our contract manufacturers to supply cGMP-compliant API and drug product without interruption.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">With respect to our product candidates, we currently rely on third-party contract manufacturers for our required raw materials, drug substance, and finished drug product for our preclinical research and clinical trials. Although we have contracts with these third parties to meet our current clinical supply needs, we do not have any current contractual relationships with these third parties for the manufacture of commercial supply of our product candidates after they are approved. As our product candidates approach potential approval by any regulatory agency, we intend to enter into agreements with third-party contract manufacturers for the commercial production of those products. We currently employ internal resources to manage our manufacturing vendor relationships and processes.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Government Regulation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Government authorities in the United States, at the federal, state and local level, and in other countries extensively regulate, among other things, the research, development, testing, manufacture, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing, post-approval monitoring and reporting, import and export of our products and reimbursement. The process of obtaining regulatory approvals and the subsequent compliance with applicable federal, state, local and foreign statutes and regulation require the expenditure of substantial time and financial resources.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">21</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">U.S. Government Regulation</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the United States, the process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local statutes and regulations requires the expenditure of substantial time and financial resources. The failure to comply with the applicable requirements at any time during the product development process, approval process or after approval may subject an applicant to a variety of administrative or judicial sanctions, such as the FDA&#8217;s refusal to approve pending applications, withdrawal of an approval, imposition of a clinical hold, issuance of warning letters and untitled letters, product recalls, product seizures, total or partial suspension of production or distribution injunctions, fines, refusals of government contracts, restitution, disgorgement of profits or civil or criminal penalties.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Approval Processes</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the United States, the FDA regulates drugs under the Federal Food, Drug and Cosmetic Act, or the FDCA, the Public Health Service Act, or PHSA, and implementing regulations. The process of obtaining regulatory approvals and the subsequent compliance with applicable federal, state, local and foreign statutes and regulation require the expenditure of substantial time and financial resources. Failure to comply with the FDCA and other applicable U.S. requirements at any time during the product development process, approval process or after approval may subject us to a variety of administrative or judicial sanctions, any of which could have a material adverse effect on us. These sanctions could include:</span></p>
  <div style="margin-left:4.269%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.481630819692681%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">refusal to approve pending applications;</span></div></div>
  <div style="margin-left:4.269%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.481630819692681%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">withdrawal of an approval;</span></div></div>
  <div style="margin-left:4.269%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.481630819692681%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">imposition of a clinical hold;</span></div></div>
  <div style="margin-left:4.269%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.481630819692681%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">warning letters, untitled letters and similar communications;</span></div></div>
  <div style="margin-left:4.269%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.481630819692681%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">product seizures or recalls; or</span></div></div>
  <div style="margin-left:4.269%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.481630819692681%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">total or partial suspension of production or distribution, or injunctions, fines, restitution, disgorgement of profits or civil or criminal investigations and penalties brought by the FDA and the Department of Justice, or DOJ, or other </span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The process required by the FDA before a drug may be marketed in the United States generally involves the following:</span></p>
  <div style="margin-left:4.269%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.481630819692681%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">completion of preclinical laboratory tests, animal studies and formulation studies conducted according to Good Laboratory Practices or other applicable regulations;</span></div></div>
  <div style="margin-left:4.269%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.481630819692681%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">submission to the FDA of an IND application, which must become effective before human clinical trials may begin;</span></div></div>
  <div style="margin-left:4.269%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.481630819692681%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">approval by an independent institutional review board, or IRB, representing each clinical site before each clinical trial may be initiated;</span></div></div>
  <div style="margin-left:4.269%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.481630819692681%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">performance of adequate and well-controlled human clinical trials to establish the safety and efficacy of the proposed drug for its intended use, conducted in accordance with current good clinical practices, or cGCP, which are ethical and scientific quality standards and FDA requirements for conducting, recording and reporting clinical trials to assure that the rights, safety and well-being of trial participants are protected;</span></div></div>
  <div style="margin-left:4.269%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.481630819692681%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">preparation and submission to the FDA of an NDA;</span></div></div>
  <div style="margin-left:4.269%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.481630819692681%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">satisfactory completion of one or more FDA inspections of the manufacturing facility or facilities at which the product is produced to assess compliance with current good manufacturing practices, or cGMP, requirements to assure that the facilities, methods and controls are adequate to preserve the drug&#8217;s safety, identity, strength, quality and purity; and</span></div></div>
  <div style="margin-left:4.269%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.481630819692681%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">FDA review and approval of the NDA.</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">22</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Once a pharmaceutical candidate is identified for development, it enters the preclinical testing stage. Preclinical tests include laboratory evaluations of product chemistry, toxicity and formulation, as well as animal studies. An IND sponsor must submit the results of the preclinical tests, together with manufacturing information and analytical data, to the FDA as part of the IND. Some preclinical or nonclinical testing may continue even after the IND is submitted. In addition to including the results of the preclinical studies, the IND will also include one or more protocols detailing, among other things, the objectives of the clinical trial, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated if the first phase lends itself to an efficacy determination. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day time period, places the IND on clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before clinical trials can begin. A clinical hold may occur at any time during the life of an IND and may affect one or more specific studies or all studies conducted under the IND.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All clinical trials must be conducted under the supervision of one or more qualified investigators in accordance with cGCP. They must be conducted under protocols detailing, among other things, the objectives of the trial, dosing procedures, subject selection and exclusion criteria and the safety and effectiveness criteria to be evaluated. Each protocol and any amendments must be submitted to the FDA as part of the IND, and progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and more frequently in other situations, including the occurrence of serious adverse events. An IRB at each institution participating in the clinical trial must review and approve the protocol and any amendments before a clinical trial commences or continues at that institution, approve the information regarding the clinical trial and the informed consent form that must be provided to each trial subject or his or her legal representative, monitor the study until completed and otherwise comply with IRB regulations. Information about certain clinical trials must be submitted within specific timeframes to the National Institutes of Health for public dissemination on their ClinicalTrials.gov website.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Human clinical trials are typically conducted in three sequential phases that may overlap or be combined:</span></p>
  <div style="margin-left:4.269%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.481630819692681%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Phase 1. The drug is initially introduced into healthy human subjects and tested for safety, dosage tolerance, absorption, distribution, metabolism and elimination. In the case of some products for severe or life-threatening diseases, such as multidrug-resistant infections, especially when the product may be inherently too toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in patients with the target disease or condition.</span></div></div>
  <div style="margin-left:4.269%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.481630819692681%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Phase 2. Clinical trials are initiated in a limited patient population intended to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage.</span></div></div>
  <div style="margin-left:4.269%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.481630819692681%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Phase 3. Clinical trials are undertaken to further evaluate dosage, clinical efficacy and safety in an expanded patient population at geographically dispersed clinical study sites. These studies are intended to establish the overall risk-benefit ratio of the product and provide an adequate basis for regulatory approval and product labeling.</span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Phase 1, Phase 2 and Phase 3 testing may not be completed successfully within any specified period, if at all. The FDA or the sponsor may suspend or terminate a clinical trial at any time for a variety of reasons, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the drug has been associated with unexpected serious harm to patients.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the development of a new drug, sponsors are given opportunities to meet with the FDA at certain points, including prior to submission of an IND, at the end of Phase 2 and before an NDA is submitted. Meetings at other times may also be requested. These meetings can provide an opportunity for the sponsor to share information about the data gathered to date, for the FDA to provide advice and for the sponsor and the FDA to reach agreement on the next phase of development. Sponsors typically use the end-of-Phase 2 meeting to discuss their Phase 2 clinical results and present their plans for the pivotal Phase 3 clinical trial or trials that they believe will support approval of the new drug.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Pediatric Research Equity Act, or PREA, requires a sponsor to conduct pediatric studies for certain drugs and biologics. Specifically, PREA requires original NDAs, biologic license applications, or BLAs, and supplements thereto for a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration to contain a pediatric assessment unless the sponsor has received a deferral or waiver.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">23</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Concurrent with clinical trials, companies usually complete additional animal safety studies and must also develop additional information about the chemistry and physical characteristics of the drug and finalize a process for manufacturing the product in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the drug candidate and the manufacturer must develop methods for testing the quality, purity and potency of the final drugs. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the drug candidate does not undergo unacceptable deterioration over its shelf-life.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The results of product development, preclinical studies and clinical trials, along with descriptions of the manufacturing process, analytical tests conducted on the chemistry of the drug, proposed labeling and other relevant information are submitted to the FDA as part of an NDA requesting approval to market the product for one or more indications. The submission of an NDA is subject to the payment of user fees, but a waiver of such fees may be obtained under specified circumstances. The FDA reviews all NDAs submitted to ensure that they are sufficiently complete for substantive review before it accepts them for filing. It may request additional information rather than accept an NDA for filing. In this event, the NDA must be resubmitted with the additional information. The resubmitted application also is subject to completeness review before the FDA accepts it for filing.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Once the submission is accepted for filing, the FDA begins an in-depth review. NDAs receive either standard or priority review. A drug that, if approved, would represent a significant improvement in the safety or effectiveness of the treatment, prevention or diagnosis of a serious disease or condition may receive priority review. Requests for priority review generally must be submitted at the time of NDA submission. The FDA has agreed to specified performance goals in the review process of NDAs. Under that agreement, 90% of applications seeking approval of new molecular entities, or NMEs, are meant to be reviewed within ten months from the date on which FDA accepts the NDA for filing, and 90% of applications for NMEs that have been designated for &#8220;priority review&#8221; are meant to be reviewed within six months of the filing date. For applications seeking approval of drugs that are not NMEs, the ten-month and six-month review periods run from the date that FDA receives the application. The review process may be extended by the FDA for three additional months to consider a major amendment to the application following the original submission.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA reviews an NDA to determine, among other things, whether a product is safe and effective for its intended use and whether its manufacturing complies with cGMP requirements to assure and preserve the product&#8217;s safety, identity, strength, quality and purity. The FDA may refer the NDA to an advisory committee for review and recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendation of an advisory committee, but it generally follows such recommendation.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Before approving an NDA, the FDA will typically inspect the facility or facilities where the product is manufactured and tested. These pre-approval inspections may cover all facilities associated with NDA submission, including drug component manufacturing (such as active pharmaceutical ingredients), finished drug product manufacturing, and control testing laboratories. Additionally, before approving an NDA, the FDA will typically inspect one or more clinical sites to assure compliance with cGCP. In addition, the FDA may require, as a condition of approval, risk evaluation and mitigation strategies, or REMS (which may include requirements for, restricted distribution and use), enhanced labeling, special packaging or labeling, expedited reporting of certain adverse events, pre-approval of promotional materials, restrictions on direct-to-consumer advertising or commitments to conduct additional research post-approval.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On the basis of the FDA&#8217;s evaluation of the NDA and accompanying information, the FDA may issue an approval letter or a complete response letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. If the FDA ultimately decides that the NDA does not satisfy the criteria for approval, the FDA will issue a complete response letter to indicate that the agency will not approve the NDA in its present form. The complete response letter usually describes all of the specific deficiencies in the NDA identified by the FDA. If a complete response letter is issued, the applicant may either resubmit the NDA, addressing all of the deficiencies identified in the letter, or withdraw the application.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">24</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Expedited Review and Approval</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA has various programs, including Fast Track and priority review, which are intended to expedite or simplify the process for developing and/or reviewing drugs. Even if a drug qualifies for one or more of these programs, the FDA may later decide that the drug no longer meets the conditions for qualification or that the time period for FDA review or approval will not be shortened. Generally, drugs that may be eligible for these programs are those for serious or life-threatening conditions, those with the potential to address unmet medical needs and those that offer meaningful benefits over existing treatments. For example, Fast Track is a process designed to facilitate the clinical development and expedite the review of drugs to treat serious diseases with the potential, based on nonclinical or clinical data, to fill an unmet medical need. Priority review is designed to give drugs that offer a significant improvement in safety or effectiveness of treatment for a serious condition an expedited review within eight months from the completed submission (six months from filing) as compared to a standard review time of twelve months from the completed submission (10 months from filing) for a standard new molecular entity NDA. Although Fast Track and priority review do not affect the standards for approval, the FDA will attempt to facilitate early and frequent meetings with a sponsor of a Fast Track designated drug and expedite review of the application for a drug designated for priority review.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Generating Antibiotic Incentives Now Act, or GAIN Act, is intended to provide incentives for the development of new QIDPs. A new drug that is designated as a QIDP after a request by the sponsor that is made before an NDA is submitted will be eligible, if approved, for an additional five years of exclusivity beyond any period of exclusivity to which it would have previously been eligible. In addition, a QIDP will receive priority review and qualify for a Fast Track designation. QIDPs are defined as antibacterial or antifungal drugs intended to treat serious or life-threatening infections, including those caused by an antibacterial or antifungal resistant pathogen or qualifying pathogens identified by the FDA. XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> have been designated by the FDA as a QIDP. Zoliflodacin has also been designated as a QIDP by the FDA for the treatment of uncomplicated gonorrhea.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Patent Term Restoration and Data Exclusivity</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Depending upon the timing, duration and specifics of FDA approval of the use of our drugs, some of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly referred to as the Hatch-Waxman Amendments. As noted above, the Hatch-Waxman Amendments permit a patent restoration term of up to five years for a single patent for an approved product as compensation for patent term lost during product development and the FDA regulatory review process. However, patent term restoration cannot extend the remaining term of a patent beyond a total of 14 years from the product&#8217;s approval date and only those claims covering such approved drug product, a method for using it or a method for manufacturing it may be extended. Only one patent applicable to an approved drug is eligible for the extension and the application for the extension must be submitted prior to the expiration of the patent. The USPTO, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. We have applied for restoration of patent term for one U.S. Patent covering XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and, in the future, we may apply for restoration of patent term for other currently owned or licensed patents to add patent life beyond its current expiration date, depending on the expected length of the clinical trials and other factors involved in the filing of the relevant NDA.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Data exclusivity provisions under the FDCA also can delay the submission or the approval of certain applications. The FDCA provides a five-year period of non-patent data exclusivity within the United States to the first applicant to gain approval of an NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not accept for review an abbreviated new drug application, or ANDA, or a 505(b)(2) NDA submitted by another company using the drug entitled to data exclusivity as the reference listed drug, or RLD. However, an application may be submitted after four years if it contains a certification of patent invalidity or non-infringement. The FDCA also provides three years of data exclusivity for an NDA, 505(b)(2) NDA or supplement to an existing NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example, for new indications, dosages or strengths of an existing drug. This three-year exclusivity covers only the use or conditions of use associated with the new clinical investigations and does not prohibit the FDA from approving ANDAs for drugs containing the original active agent for other uses or conditions of use. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct its own preclinical and clinical studies in support of its application or obtain a right of reference to all of the preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, as described above, under the GAIN Act a new drug that is designated as a QIDP is eligible for an additional five years of exclusivity to be added to certain other exclusivity periods that the application may qualify for upon approval, specifically five-year exclusivity, three-year exclusivity, and orphan exclusivity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">25</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Pediatric Exclusivity</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Best Pharmaceuticals for Children Act provides for an additional six months of exclusivity, which is added on to patent and exclusivity periods in effect at the time the pediatric exclusivity award is granted, if a sponsor conducts clinical trials in children in response to a written request from the FDA, or a Written Request. The FDA may request studies on approved indications in separate Written Requests. The issuance of a Written Request does not require the sponsor to undertake the described studies. To date, we have not received any Written Requests.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Post-approval Requirements</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems, including safety issues, with a product may result in restrictions on the product or even complete withdrawal of the product from the market. After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further FDA review and approval. In addition, the FDA may require testing and surveillance programs to monitor the effect of approved products that have been commercialized, and the FDA has the power to prevent or limit further marketing of a product based on the results of these post-marketing programs. The FDA and other authorities also strictly regulate the promotional claims that may be made about prescription products. Under the FDCA the sponsor of an approved drug in the United States may not promote that drug for unapproved, or off-label, uses, although a physician may prescribe a drug for an off-label use in accordance with the practice of medicine. If we are found to have promoted off-label uses, we may be subject to significant liability, including sanctions, civil and criminal fines and penalties, and injunctions prohibiting us from engaging in specified promotional conduct.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moreover, any drug products manufactured or distributed pursuant to FDA approvals are subject to continuing regulation by the FDA, including, among other things:</span></p>
  <div style="margin-left:4.269%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.481630819692681%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">record-keeping requirements;</span></div></div>
  <div style="margin-left:4.269%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.481630819692681%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">reporting of adverse experiences with the drug;</span></div></div>
  <div style="margin-left:4.269%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.481630819692681%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">providing the FDA with updated safety and efficacy information;</span></div></div>
  <div style="margin-left:4.269%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.481630819692681%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">drug sampling and distribution requirements;</span></div></div>
  <div style="margin-left:4.269%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.481630819692681%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">notifying the FDA and gaining its approval of specified manufacturing or labeling changes;</span></div></div>
  <div style="margin-left:4.269%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.481630819692681%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">complying with certain electronic records and signature requirements; and</span></div></div>
  <div style="margin-left:4.269%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.481630819692681%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">complying with FDA promotion and advertising requirements.</span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and some state agencies for compliance with cGMP requirements and other laws.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Failure to comply with the FDCA and other applicable U.S. requirements at any time during the product development process, approval process or after approval may subject us to a variety of administrative or judicial sanctions, any of which could have a material adverse effect on us. These sanctions could include:</span></p>
  <div style="margin-left:4.269%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.481630819692681%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">refusal to approve pending applications;</span></div></div>
  <div style="margin-left:4.269%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.481630819692681%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">withdrawal of an approval;</span></div></div>
  <div style="margin-left:4.269%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.481630819692681%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">imposition of a clinical hold;</span></div></div>
  <div style="margin-left:4.269%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.481630819692681%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">warning letters, untitled letters and similar communications;</span></div></div>
  <div style="margin-left:4.269%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.481630819692681%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">product seizures or recalls;</span></div></div>
  <div style="margin-left:4.269%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.481630819692681%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">total or partial suspension of production or distribution; or</span></div></div>
  <div style="margin-left:4.269%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.481630819692681%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">injunctions, fines, restitution, disgorgement of profits or civil or criminal investigations and penalties brought by the FDA and DOJ, or other governmental entities.</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">26</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From time to time, legislation is drafted, introduced and passed in Congress that could significantly change the statutory provisions governing the approval, manufacturing and marketing of products regulated by the FDA. In addition, FDA regulations and guidance are often revised or reinterpreted by the agency in ways that may significantly affect our business and our products. It is impossible to predict whether legislative changes will be enacted, or FDA regulations, guidance or interpretations changed or what the impact of such changes, if any, may be.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Foreign Regulation</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to regulations in the United States, we will be subject to a variety of foreign regulations governing clinical trials and commercial sales and distribution of our products. Whether or not we obtain FDA approval for a product, we must obtain approval by the comparable regulatory authorities of foreign countries or economic areas, such as the EU, before we may commence clinical trials or market products in those countries or areas. The approval process and requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary greatly from place to place, and the time may be longer or shorter than that required for FDA approval.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under EU regulatory systems, a company may submit marketing authorization applications under the centralized, decentralized or mutual recognition procedures, or under the purely national route of approval. The centralized procedure is compulsory for medicinal products produced by biotechnology or those medicinal products containing new active substances for specific indications such as the treatment of acquired immune deficiency syndrome, or AIDS, cancer, neurodegenerative disorders, diabetes, viral diseases, and designated orphan medicines, and is optional for other medicines that are highly innovative. Under the centralized procedure, a marketing application is submitted to the European Medicines Agency, or EMA, where it will be evaluated by the relevant scientific committee, in most cases the Committee for Medicinal Products for Human Use, and a favorable opinion typically results in the grant by the European Commission of a single marketing authorization that is valid for all EU member states and, by extension (after national implementing measures), in Norway, Iceland and Liechtenstein. In general, an initial marketing authorization is valid for five years, but once renewed is usually valid for an unlimited period. The decentralized procedure allows marketing authorization applications to be submitted simultaneously in two or more EU member states, whereas the mutual recognition procedure must be used if the product has already been authorized in at least one other EU member state. Both the decentralized and mutual recognition procedures provide for approval by one or more &#8220;concerned&#8221; member states based on an assessment of an application performed by one-member state, known as the &#8220;reference&#8221; member state.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the decentralized approval procedure, an applicant submits an application, or dossier, and related materials to the reference member state and concerned member states. The reference member state prepares a draft assessment and drafts of the related materials within 120 days after receipt of a valid application. Within 90 days of receiving the reference member state&#8217;s assessment report, each concerned member state must approve the assessment report and related materials, unless they identify a serious risk to public health. Under the mutual recognition procedure, the concerned member states have the same 90-day period to recognize the marketing authorization in the reference member state. In either case, concerns about serious risks to public health escalate through the relevant EMA scientific committees, and the disputed points may eventually result in a consensus opinion from the Committee for Medicinal Products for Human Use that is referred to the European Commission, whose decision is binding on all member states. The purely national procedure results in a marketing authorization in a single EU member state.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Following the result of a referendum in 2016, the United Kingdom left the EU on January 31, 2020, and as of January 1, 2021, the United Kingdom and EU operate separate regulatory regimes. The UK and EU announced on December 24, 2020, that they had agreed a Trade and Cooperation Agreement, or TCA, to govern their future relationship. The TCA remains provisional until formally ratified by the EU. The TCA sets out the new arrangements for trade of goods, including medicines and medical devices, which aims to ensure goods continue to flow between the EU and the UK and also has implications for product regulation and mutual recognition.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a result of the United Kingdom&#8217;s departure from the EU, if a company wishes to sell its products in the United Kingdom, it will need to seek and maintain appropriate national marketing authorizations. The TCA does not provide for wholesale mutual recognition of the regulatory regimes and so products exported from the UK to the EU must comply with the EU&#8217;s regulatory requirements. In the pharmaceutical context, this has had a number of implications. From January 31, 2020, the UK no longer participated in EU institutions and their decision-making, including approval decisions under the centralized procedure. Moreover, the movement of finished pharmaceutical products into the EU from the UK is treated as an import from a third country. Since the TCA does not provide for mutual recognition of batch testing and release, products must be quality control tested and released in the EU. However, the UK has unilaterally waived batch testing requirements for UK imports from the EU for products placed on the market prior to January 2023. It remains to be seen how these developments will impact regulatory requirements for product candidates and products in the United Kingdom.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">27</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Reimbursement</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Significant uncertainty exists as to the coverage and reimbursement status of products approved by the FDA and other government authorities. Sales of products will depend, in part, on the extent to which third-party payors, including government health programs in the United States such as Medicare and Medicaid, commercial health insurers and managed care organizations, provide coverage, and establish adequate reimbursement levels for, such products. The process for determining whether a payor will provide coverage for a product may be separate from the process for setting the price or reimbursement rate that the payor will pay for the product once coverage is approved. Third-party payors are increasingly challenging the prices charged, examining the medical necessity, and reviewing the cost-effectiveness of medical products and services and imposing controls to manage costs. Third-party payors may limit coverage to specific products on an approved list, or formulary, which might not include all the approved products for a particular indication. For example, in the U.S. and most major foreign markets, drugs like GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> that are administered in the hospital must be purchased by the hospital and generally are not reimbursed by third-party payors. Hospitals instead are reimbursed for patient cases based on patients&#8217; diagnosed conditions under the U.S. Medicare diagnosis-related group (&#8220;DRG&#8221;) system or other like systems for non-Medicare patients in the U.S. and in most major foreign markets. Adoption of new drugs that are administered in the hospital generally occurs more slowly than adoption of new drugs that are taken on an outpatient basis, which generally are paid for by third-party payors.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To secure coverage and reimbursement for any product that might be approved for sale, a company may need to conduct expensive pharmacoeconomic studies to demonstrate the medical necessity and cost effectiveness of the product, in addition to the costs required to obtain FDA or other comparable regulatory approvals. Nonetheless, product candidates may not be considered medically necessary or cost effective. Additionally, a payor&#8217;s decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved. Further, one payor&#8217;s determination to provide coverage for a drug product does not ensure that other payors will also provide coverage for the drug product. Third-party reimbursement may not be sufficient to maintain price levels high enough to realize an appropriate return on investment in product development.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Health Care Laws Governing Interactions with Healthcare Providers</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to FDA restrictions on marketing of pharmaceutical products, several other types of state and federal laws restrict our business activities, including certain marketing practices. These laws include, without limitation, anti-kickback laws, false claims laws, data privacy and security laws, as well as transparency laws regarding payments or other items of value provided to healthcare providers.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The federal Anti-Kickback Statute prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving remuneration to induce or in return for purchasing, leasing, ordering or arranging for the purchase, lease or order of any healthcare item, good, facility or service reimbursable under Medicare, Medicaid or other federal healthcare programs. The term &#8220;remuneration&#8221; has been broadly interpreted to include anything of value. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers and formulary managers, among others, on the other. Although there are several statutory exceptions and regulatory safe harbors protecting certain common activities from prosecution or other regulatory sanctions, the exceptions and safe harbors are drawn narrowly, and practices that involve remuneration that are alleged to be intended to induce prescriptions, purchases or recommendations may be subject to scrutiny if they do not qualify for an exception or safe harbor. Failure to meet all requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the federal Anti-Kickback Statute. Instead, the legality of the arrangement will be evaluated on a case-by-case basis based on a cumulative review of all its facts and circumstances. Several courts have interpreted the statute&#8217;s intent requirement to mean that if any one purpose of an arrangement involving remuneration is to induce referrals of federal healthcare covered business, the federal Anti-Kickback Statute has been violated. Additionally, the intent standard under the federal Anti-Kickback Statute was amended by the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010, collectively the Affordable Care Act, or ACA, to a stricter standard such that a person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. In addition, the ACA codified case law that a claim for payment for items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Federal false claims laws, including the civil False Claims Act, and civil monetary penalties laws prohibit any person or entity from, among other things, knowingly presenting, or causing to be presented, a false claim for payment to the federal government, or knowingly making, or causing to be made, a false statement to have a claim paid. Pharmaceutical and other healthcare companies have been prosecuted under these laws for, among other things, allegedly inflating drug prices they report to pricing services, which in turn were used by the government to set Medicare and Medicaid reimbursement rates, and for allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product. In addition, certain marketing practices, including off-label promotion, have also been alleged to violate false claims laws.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">28</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, created additional federal criminal and civil statutes that prohibit among other actions, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payors, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense, and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. As with the federal Anti-Kickback Statute, the ACA amended the intent standard for certain healthcare fraud under HIPAA such that a person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it to have committed a violation.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, we may be subject to data privacy and security regulations promulgated by both the federal government and the states in which we conduct our business. HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and its implementing regulations, impose certain requirements on covered entities (i.e., certain healthcare providers, health plans and healthcare clearinghouses) relating to the privacy, security and transmission of individually identifiable health information. Among other things, HITECH makes HIPAA&#8217;s security standards directly applicable to business associates, independent contractors or agents of covered entities that receive or obtain protected health information in connection with providing a service on behalf of a covered entity. HITECH also created four new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">What is more, the federal Physician Payments Sunshine Act, created under the ACA, and its implementing regulations, require certain manufacturers of drugs, devices, biologicals and medical supplies for which payment is available under Medicare, Medicaid or the children&#8217;s health insurance program (with certain exceptions) to annually report information related to certain payments or other transfers of value provided to covered recipients, including physicians, as defined by such law, and teaching hospitals, or to entities or individuals at the request of, or designated on behalf of, the physicians and teaching hospitals&#8217; covered recipients and information related to certain ownership and investment interests held by physicians and their immediate family members.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The majority of states also have statutes or regulations similar to the aforementioned federal laws, some of which are broader in scope and apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payor. Some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government. In addition, some state laws require drug manufacturers to report information related to payments to clinicians and other healthcare providers or marketing expenditures and drug pricing. Further, some state and local laws require the licensure of pharmaceutical sales representatives. State and foreign laws also govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Finally, in Europe, the European Union General Data Protection Regulation (2016/679) (&#8220;GDPR&#8221;) contains provisions specifically directed at the processing of health information. The GDPR provides for potentially significant sanctions and contains extraterritoriality measures intended to bring non-EU companies under the regulation. In addition to the GDPR, individual countries in Europe and elsewhere in the world have enacted similar data privacy legislation. This legislation imposes increased compliance obligations and regulatory risk, including the potential for significant fines for noncompliance.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Healthcare and Other Reform</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the United States, there have been and continue to be a number of significant legislative initiatives to contain healthcare costs. Federal and state governments continue to propose and pass legislation designed to reform delivery of, or payment for, healthcare, which include initiatives to reduce the cost of healthcare. For example, in March 2010, the United States Congress enacted the ACA, which expanded health care coverage through Medicaid expansion and the implementation of the individual mandate for health insurance coverage and which included changes to the coverage and reimbursement of drug products under government healthcare programs. Under the Trump administration, there were ongoing efforts to modify or repeal all or certain provisions of the ACA. For example, tax reform legislation was enacted at the end of 2017 that eliminated the tax penalty established under the ACA for individuals who do not maintain mandated health insurance coverage beginning in 2019. The ACA has also been subject to judicial challenge. In December 2018, a federal district court, in a challenge brought by a number of state attorneys general, found the ACA unconstitutional in its entirety because, once Congress repealed the individual mandate provision, there was no longer a basis to rely on Congressional taxing authority to support enactment of the law. In December 2019, the federal appellate court upheld the district court ruling that the individual mandate was unconstitutional and remanded the case back to the district court to determine whether the remaining provisions of the ACA are invalid as well. The case has been appealed to the U.S. Supreme Court where a ruling remains pending.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">29</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There were other reform initiatives under the former Trump Administration, including initiatives focused on drug pricing. For example, the Bipartisan Budget Act of 2018 contained various provisions that affect coverage and reimbursement of drugs, including an increase in the discount that manufacturers of Medicare Part D brand name drugs must provide to Medicare Part D beneficiaries during the coverage gap from 50% to 70% starting in 2019. As another example, in 2018, President Trump and the Secretary of the HHS, released a &#8220;blueprint&#8221; to lower prescription drug prices and out-of-pocket costs. Certain proposals in the blueprint, and related drug pricing measures proposed since the blueprint, could cause significant operational and reimbursement changes for the pharmaceutical industry. HHS has solicited feedback on some of these measures and, at the same, has implemented others under its existing authority. On November 20, 2020, CMS issued an interim final rule through the CMS Innovation Center whereby Medicare Part B reimbursement for &#8220;certain high-cost prescriptions drugs&#8221; would be no more than most-favored-nation price (i.e., the lowest price) after adjustments, for a pharmaceutical product that the drug manufacturer sells in a member country of the Organization for Economic Cooperation and Development that has a comparable per-capita gross domestic product. On December 28, 2020, the United States District Court in Northern California issued a nationwide preliminary injunction against implementation of the interim final rule. While some of these and other measures may require additional authorization to become effective, members of Congress and the new Biden administration have indicated that lowering prescription drug prices is a priority, but it is not yet clear what steps the Biden Administration will take or whether such steps will be successful.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There have also been recent state legislative efforts to address drug costs, which generally have focused on increasing transparency around drug costs or limiting drug prices and address price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In 2019, the DISARM Act of 2019 was introduced in Congress as new legislation to provide financial incentives for pharmaceutical companies to develop new antibiotics. This new legislation was guided by input from the IDSA and will help to ensure that patients can access new antibiotics when they are clinically appropriate, require hospitals to establish antibiotic stewardship programs, and spur improved reporting of antibiotic use and resistance to more rapidly identify challenges and inform best practices. More recently, this legislation was reintroduced in the U.S. House of Representatives in June 2021 which aims to amend title XVIII of the Social Security Act to encourage the development and use of DISARM antimicrobial drugs, and for other purposes.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">General legislative cost control measures may also affect reimbursement for our product candidates. The Budget Control Act, as amended, resulted in the imposition of 2% reductions in Medicare, but not Medicaid, payments to providers in 2013 and will remain in effect through 2029 unless additional Congressional action is taken. There was a temporary suspension of the 2% reduction during the pandemic; that temporary suspension is scheduled to expire on March 31, 2021. Any significant spending reductions affecting Medicare, Medicaid or other publicly funded or subsidized health programs that may be implemented and/or any significant taxes or fees that may be imposed on us could have an adverse impact on our results of operations.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Legislation was introduced to the U.S. Senate in September 2020 which aims to reinvigorate innovation for the development of new antibiotics through a subscription contract program managed by HHS. The PASTEUR Act was introduced to provide a mechanism for funding designated &#8216;critical need antimicrobial&#8217; drugs post FDA approval. In return, patients covered by federal insurance programs will receive these drugs at no cost. These Contracts under the PASTEUR Act could range from $750 million to $3 billion in value. It is unclear when or if the PASTEUR Act or similar incentive programs will become law. In October 2021, the PACCARB authored a letter to the Honorable Xavier Becerra, Secretary, Department of Health and Human Services recommending the passage of both DISARM and PASTEUR and the antimicrobial stewardship provisions contained within each act.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Adoption of new legislation at the federal or state level could affect demand for, or pricing of, our current or future products if approved for sale. We cannot, however, predict the ultimate content, timing or effect of any changes to the ACA or other federal and state reform efforts. There is no assurance that federal or state health care reform will not adversely affect our future business and financial results.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other Laws and Regulations</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are subject to a variety of financial disclosure and securities trading regulations as a public company in the U.S., including laws relating to the oversight activities of the SEC and the regulations of the Nasdaq Capital Market, on which our shares of common stock are traded. We are also subject to various laws and regulations relating to safe working conditions, laboratory practices and the experimental use of animals.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">30</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Intellectual Property</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our commercial success depends in part on our ability to obtain and maintain proprietary or intellectual property protection for our product candidates, our core technologies, and other know-how. To accomplish this we rely on the skills, knowledge and experience of our scientific and technical personnel, as well as that of our advisors, consultants and other contractors. To help protect our proprietary know-how that is not patentable, we rely on trade secret protection and confidentiality agreements to protect our interests. We require our employees, consultants and advisors to enter into confidentiality agreements prohibiting the disclosure of confidential information and requiring disclosure and assignment to us of the ideas, developments, discoveries and inventions important to our business. We file patent applications directed to our key product candidates to establish intellectual property positions. These patent applications are intended to protect new chemical entities relating to these product candidates as well as their manufacturing processes, intermediates and uses in the treatment of diseases.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The intellectual property portfolios for our commercial products, advanced product candidates, and various compounds are summarized below.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#174;</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of February 15, 2023, the licensed intellectual property portfolio relating to GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> included 12 issued U.S. patents, 2 pending U.S. patent applications, 9 issued foreign patents and 12 pending foreign patent applications. The issued U.S. patents, and patents that may issue from the pending U.S. patent applications, will expire between 2029 and 2034, absent any disclaimers, extensions, or adjustments of patent term. The foreign patents, and patents that may issue from the pending foreign patent applications, will expire in 2034, absent any disclaimers, extensions, or adjustments of patent term.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of February 15, 2023, the intellectual property portfolio relating to GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> also included 4 issued U.S. patents, 6 pending U.S. patent applications, 8 issued foreign patents and 10 pending foreign patent applications. The issued U.S. patents, and patents that may issue from the pending U.S. patent applications, will expire between 2034 and 2040, absent any disclaimers, extensions, or adjustments of patent term. The foreign patents, and patents that may issue from the pending foreign patent applications, will expire between 2034 and 2037, absent any disclaimers, extensions, or adjustments of patent term.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">XERAVA</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#174;</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of February 15, 2023, we owned 2 issued U.S. patents, 1 pending U.S. patent application, 17 issued foreign patents and 4 pending foreign patent applications relating to XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The issued U.S. patents, and the patent that may issue from the pending U.S. patent application, will have an expiration date of August 7, 2029, absent any disclaimers, extensions, or adjustments of patent term. The term of 1 of the U.S. patents has received 508 days of patent term adjustment. The foreign patents, and patents that may issue from the pending foreign applications, will likewise have an expiration date of August 7, 2029, absent any disclaimers, extensions, or adjustments of patent term.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of February 15, 2023, we also filed applications for Supplementary Protection Certificates based on European Patent No. 2323972 covering the composition of matter and use of XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Some applications have been granted and others are pending.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, as of February 15, 2023, we also owned 2 issued U.S. patent, 1 pending U.S. patent application, 2 granted foreign patents and 9 pending foreign patent applications that relate to crystalline forms of eravacycline, any U.S. patent that may issue from the pending patent application will expire in 2037 absent any disclaimers, extensions, or adjustments of patent term. Likewise, any foreign patents that may issue from the pending foreign patent applications will expire in 2037. We also owned 7 issued U.S. patents, 1 pending U.S. patent application, 39 issued foreign patents and 12 pending foreign patent applications relating to other tetracycline-related intellectual property.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#174;</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of February 15, 2023, we owned 4 issued U.S. patents, 115 issued foreign patents and 5 pending foreign patent applications (of which 1 is allowed) relating to XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The issued U.S. patents have an expiration date of April 2, 2033 and November 17, 2035, absent any disclaimers, extensions, or adjustments of patent term. The foreign patents, and patents that may issue from the pending foreign applications, will likewise have an expiration date of April 2, 2033 and November 17, 2035, absent any disclaimers, extensions, or adjustments of patent term.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">31</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:16.48%;"/>
    <td style="width:1.44%;"/>
    <td style="width:11.46%;"/>
    <td style="width:1.44%;"/>
    <td style="width:11.46%;"/>
    <td style="width:1.44%;"/>
    <td style="width:14.52%;"/>
    <td style="width:1.44%;"/>
    <td style="width:11.46%;"/>
    <td style="width:1.44%;"/>
    <td style="width:11.46%;"/>
    <td style="width:1.44%;"/>
    <td style="width:14.52%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="5" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">United States</span></p></td>
    <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="5" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Foreign</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Description</span></p></td>
    <td style="vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Issued</span></p></td>
    <td style="vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Pending</span></p></td>
    <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Expiration</span></p></td>
    <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Issued</span></p></td>
    <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Pending</span></p></td>
    <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Expiration</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">GIAPREZA</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">&#174;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2029 - 2040</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2034 - 2037</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">XERAVA</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">&#174;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2029 - 2037</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2029 - 2037</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">XACDURO</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">&#174;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2033 - 2035</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">115</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2033 - 2035</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2029 - 2037</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">39</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2039 - 2037</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Zoliflodacin</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our intellectual property portfolio for zoliflodacin contains patent applications directed to compositions of matter for zoliflodacin and other chemical analogs, as well as synthetic methods and methods of use and modes of treatment. As of February 15, 2023, we owned seven issued U.S. patents, 74 issued foreign patents as well as two pending foreign patent applications. The issued foreign patents are in several jurisdictions, including Australia, Brazil, Canada, China, Eurasia, the European Union, Hong Kong, India, Israel, Japan, Mexico, New Zealand, Philippines, Singapore, South Africa, South Korea, Taiwan and the United Kingdom. Issued U.S. and foreign patents and patents issuing from pending U.S. and foreign applications have expiration dates of October 2029, January 2034 and May 2035.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Trademarks, Trade Secrets and Know-How</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our trademark portfolio currently consists of various registered trademark and service mark rights in several jurisdictions, including the United States, the European Union, Japan, Argentina, Australia, Brazil, Canada, India, Mexico, Norway, the Russian Federation, South Korea, Switzerland, Taiwan, Turkey and the United Kingdom, and pending applications in other jurisdictions. In connection with the ongoing development and advancement of our products and services in the United States and various international jurisdictions, we routinely seek to create protection for our marks and enhance their value by pursuing trademarks and service marks where available and when appropriate. In addition to patents and trademark protection, we rely upon unpatented trade secrets and know-how and continuing technological innovation to develop and maintain our competitive position. We seek to protect our proprietary information, in part, using confidentiality agreements with our commercial partners, collaborators, employees, and consultants, and invention assignment agreements with our employees. These agreements are designed to protect our proprietary information and, in the case of the invention assignment agreements, to grant us ownership of technologies that are developed through a relationship with a third party. These agreements may be breached, and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors. To the extent that our commercial partners, collaborators, employees, and consultants use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Strategic Partnership with Sarissa Capital</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Strategic Advisory Agreement</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On December 11, 2020, we entered into a Strategic Advisory Agreement (the &#8220;Services Agreement&#8221;) with Sarissa Capital Management LP (&#8220;Sarissa Capital&#8221;), pursuant to which Sarissa Capital provides a variety of strategic services to us in order to assist us in the development and execution of our acquisition strategy intended to diversify our assets and the potential sources of revenue. Sarissa Capital is considered to be a related party due to its investment in Innoviva and its representation on our board of directors.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Partnership Agreement</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On December 11, 2020, Innoviva Strategic Partners LLC, our wholly owned subsidiary (&#8220;Strategic Partners&#8221;), entered into a subscription agreement and an Amended and Restated Limited Partnership Agreement (the &#8220;Partnership Agreement&#8221;) pursuant to which Strategic Partners became a limited partner of ISP Fund LP (the &#8220;Partnership&#8221;). The general partner of the Partnership is an affiliate of Sarissa Capital and, pursuant to an investment management agreement, Sarissa Capital acts as the investment adviser to the Partnership. Strategic Partners made a $300 million initial contribution to the Partnership. The Partnership was formed for the purposes of investing in equity securities in the healthcare, pharmaceutical and biotechnology industries.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In May 2021, Strategic Partners received a distribution of $110.0 million from the Partnership to provide funding to us for a strategic repurchase of shares held by GSK. Pursuant to the letter agreement entered into between Strategic Partners, the Partnership, and Sarissa Capital Fund GP LP on May 20, 2021, Strategic Partners agreed to make additional capital contributions to the Partnership in an aggregate amount equal to the amount of the May 2021 distribution prior to March 31, 2022. A $110.0 million contribution was made during the first quarter of 2022.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">32</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Human Capital</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we had 112 employees, all of whom were full-time employees. None of our employees are represented by a labor union or covered by a collective bargaining agreement, and we consider our relations with our employees to be good. We also hire consultants and contract with third parties, as needed, to provide additional resources to support our business activities.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our key human capital management objectives are to identify, recruit, integrate, retain and motivate our new and existing employees. We believe that our compensation and benefit programs are appropriately designed to attract and retain qualified talent. Employees receive an annual base salary and are eligible to earn performance-based cash bonuses. To create and maintain a successful work environment, we offer a comprehensive package of additional benefits that support the physical and mental health and wellness of all of our employees and their families and flexible working arrangements. Additionally, we grant equity awards in order to allow employees to share in the performance of the Company. The Chief Executive Officer regularly updates our board of directors and our committees on the operation and status of these human capital trends and activities.</span></p>
  <p style="margin-left:4.267%;text-indent:-3.608%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Diversity, Equity and Inclusion</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have created an environment that fosters individual development while maintaining consistency in our corporate values and code of conduct. We offer seminars from external resources on diversity, equity and inclusion, or DEI, best practices and promote the fair treatment and full participation of all people in our workplace.</span></p>
  <p style="margin-left:4.267%;text-indent:-3.608%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Health, Safety and Wellness</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We strive to provide pay, benefits and other employee services that are competitive to market in the life sciences industry and create incentives to attract and retain employees. Our compensation package includes market-competitive pay, stock options and restrictive stock units, bonuses, employee spot awards, health care and retirement benefits, paid time off and family leave. We utilize third party consultants to review and update our compensation practices annually. We are also committed to the continued development of our people, providing opportunities for employees to further their career development through internal training and education programs and third party online training programs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.267%;text-indent:-3.608%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Environmental, Social and Governance</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The management team and Board of Directors are keenly aware of the importance of environmental, social and governance issues, and the Company&#8217;s need to conduct business with high standards. Our mission as an organization is to be patient-centric and develop innovative treatments to find solutions for patients suffering from rare and underserved diseases.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We collectively believe that pursuing an environmental, social and governance agenda serves the interests of all of our stakeholders, which includes our stockholders. Our employees, partners, and investors expect us to honor our values and take action to promote a more equitable and sustainable world for future generations.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As we further build our organization behind our portfolio of royalties and innovative healthcare assets, we intend to strive to understand the perspectives of the diverse clients and communities we will serve, and as such, we are intensifying our efforts to drive diversity and inclusion and a culture of belonging throughout our organization. We will strive to comply with all applicable environmental laws, regulations and policies concerning environmental protection in all our business activities and in the selection of partners we choose to work with. We are committed to strengthening our local community by contributing through volunteerism and will continue, as we have been doing, to provide donations to parties we believe will support our goal of improving patient health and well-being. We are also committed to good corporate governance. All of our employees, officers and directors must conduct themselves according to the language and spirit of our Code of Conduct, and our Board of Directors is dedicated to providing effective corporate oversight including through oversight committees such as the Nominating and Governance Committee, the Audit Committee and the Compensation Committee. As our Company grows, we will continue to integrate policies and programs that further foster this effort.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Information about our Executive Officers</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table sets forth the name, age, and position of each of our executive officers as of February 29, 2024:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:54.189%;"/>
    <td style="width:1.84%;"/>
    <td style="width:9.318%;"/>
    <td style="width:1.84%;"/>
    <td style="width:32.813%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Name</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Age</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Positions Held</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Pavel Raifeld</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">40</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chief Executive Officer</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stephen Basso</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">58</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chief Financial Officer</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Marianne Zhen</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">55</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chief Accounting Officer</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">33</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Pavel Raifeld</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, CFA, was appointed Chief Executive Officer in May 2020. Prior to his appointment, Mr. Raifeld, served on the investment team at Sarissa Capital Management LP. Earlier, he was a senior member of the healthcare investment banking team at Credit Suisse Securities (USA) LLC. Previously, Mr. Raifeld worked as a consultant, primarily specializing in advising biopharmaceutical companies, at McKinsey &amp; Company, Inc. and The Boston Consulting Group Ltd. Mr. Raifeld earned an AB degree from Harvard University and an MBA degree from Columbia University.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stephen Basso </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">was appointed Chief Financial Officer of the Company in August 2023. Prior to joining Innoviva, Mr. Basso served as the Chief Financial Officer and Chief Operating Officer at Cybrexa Therapeutics and has held a variety of financial leadership positions at Inozyme Pharma, Alexion Pharmaceuticals and Pfizer. He received a BS in business from Providence College and an MBA from Boston College.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Marianne Zhen</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, CPA, was appointed Chief Accounting Officer in July 2018. Prior to joining Innoviva in October 2014, Ms. Zhen served as the Corporate Controller at Steelwedge Software Inc. from 2012 to 2014, Intelmate from 2011 to 2012 and Model N, Inc. from 2007 to 2011. Previously, Ms. Zhen served as a member of the board of directors of CalCPA Peninsula Silicon Valley Chapter. Ms. Zhen earned a Bachelor of Science degree in Business Administration with a concentration in Accounting from San Francisco State University. She is a member of the American Institute of Certified Public Accountants (AICPA) and a member of the California Society of Certified Public Accountants (CalCPA).</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Code of Business Conduct</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has adopted the Innoviva, Inc. Code of Business Conduct that applies to all directors, officers and employees. The Code of Business Conduct, as amended through January 24, 2023, is available on the corporate governance section of our website at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">www.inva.com</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. If the Company makes any substantive amendments to the Code of Business Conduct or grants a waiver from any provision of such code to any executive officer or director, the Company will promptly disclose the nature of the amendment or waiver, as required by applicable law.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Available Information</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our web page address is </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">www.inva.com</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Our investor relations website is located at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">http://investor.inva.com</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. We make available free of charge on our investor relations website under &#8220;SEC Filings&#8221; our Annual Reports on Form 10&#8209;K, Quarterly Reports on Form 10&#8209;Q, Current Reports on Form 8&#8209;K, our directors&#8217; and officers&#8217; Section 16 Reports and any amendments to those reports after filing or furnishing such materials to the SEC. The information found on our website is not part of this or any other report that we file with or furnish to the SEC. Innoviva and the Innoviva logo are registered trademarks of Innoviva, Inc. Trademarks, tradenames or service marks of other companies appearing in this report are the property of their respective owners.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;" id="item_1a_risk_factors"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM 1A.   RISK FACTORS</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Summary of Risk Factors</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is subject to a number of risks that if realized could affect its business, financial condition, results of operations, cash flows and access to liquidity materially. The Company&#8217;s business is subject to uncertainties and risks including:</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> face substantial competition for their intended uses in the targeted markets from products discovered, developed, launched and commercialized both by GSK and by other pharmaceutical companies, which could cause the royalties payable to us pursuant to the GSK Agreements to be less than expected, which in turn would harm our business and cause the price of our securities to fall.</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are dependent on GSK for the successful commercialization and development of the products developed under the GSK Agreements. If GSK does not devote sufficient resources to the commercialization and development of these products, is unsuccessful in its efforts, or chooses to reprioritize its commercial programs, our business would be materially harmed.</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our debt including our convertible subordinated notes and convertible senior notes are senior in capital structure and cash flow, respectively, to our common stockholders. Satisfying the obligations relating to our debt could adversely affect our liquidity or the amount or timing of potential distributions to our stockholders.</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">GSK has indicated to us that it believes its consent may be required before we can engage in certain royalty monetization transactions with third parties, which may inhibit our ability to engage in these transactions.</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">34</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If clinical trials of our product candidates fail to demonstrate safety and efficacy to the satisfaction of the FDA, the EMA or other comparable regulatory authorities, or do not otherwise produce favorable results, we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of that product candidate.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We rely on collaborations with third parties for the development of both our product and commercial candidates, and we may seek additional collaborations in the future. If those collaborations are not successful, we may not be able to capitalize on the market potential of these product or commercial candidates.</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if any of our product candidates receives marketing approval, such product candidate may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success.</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our operations could be disrupted by failure of our information systems or cyber-attacks.</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we engage in future acquisitions or strategic collaborations, this may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities and subject us to other risks.</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if we complete the necessary preclinical studies and clinical trials, the regulatory approval process is expensive, time-consuming and uncertain and may prevent us or any future collaborators from obtaining approvals for the commercialization of some or all of our product candidates. As a result, we cannot predict when or if, and in which territories, we, or any future collaborators, will obtain marketing approval to commercialize a product candidate.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to our Business</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Currently, we derive most of our revenues from GSK and our near-term success depends in large part on GSK&#8217;s ability to successfully develop and commercialize the products in the respiratory programs partnered with GSK.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the GSK Agreements, GSK is responsible for the development and commercialization of products in the partnered respiratory programs. Royalty revenues from RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> are expected to represent the majority of our foreseeable future revenues from GSK. The amount and timing of revenue from such royalties are unknown and highly uncertain. Our near-term success depends in large part upon the performance by GSK of its commercial obligations under the GSK Agreements and the commercial success of RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. We have no control over GSK&#8217;s marketing and sales efforts, and GSK might not be successful, which would harm our business and cause the price of our securities to fall.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our quarterly royalty revenues may fluctuate due to a variety of factors, many of which are outside of our control. The amount of royalties and milestone payments, if any, we receive will depend on many factors, including but not limited to the following:</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the extent and effectiveness of the sales and marketing and distribution support GSK provides to our partnered products;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">market acceptance and demand for our partnered products;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">changes in the treatment paradigm or standard of care for COPD or asthma, for instance through changes to the GOLD (Global Initiative for Chronic Obstructive Lung Disease) guidelines;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the competitive landscape of generic and branded products and developing therapies that compete with our products owned by GSK (such as Advair</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">) but which are not partnered with us and pricing pressure in the respiratory markets targeted by our partnered products;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the size of the market for our partnered products;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the mix of sales of our partnered products;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">decisions as to the timing of product launches, pricing and discounts;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">reprioritization of GSK&#8217;s commercial efforts on other products owned by GSK, which are not partnered with us;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">GSK&#8217;s ability to expand the indications for which our partnered products can be marketed;</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">35</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a satisfactory efficacy and safety profile as demonstrated in a broad patient population;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">acceptance of, and ongoing satisfaction with, our partnered products by the medical community, patients receiving therapy and third-party payors;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">timing and amounts of payor rebate adjustments and prior period rebate adjustments;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">seasonal fluctuations of demand;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the ability of patients to be able to afford our partnered products or obtain health care coverage that covers our partnered products;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">safety concerns in the marketplace for respiratory therapies in general and with our partnered products in particular;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulatory developments relating to the manufacture or continued use of our partnered products;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the requirement to conduct additional post&#8209;approval studies or trials for our partnered products;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">GSK&#8217;s ability to obtain regulatory approval of our partnered products in additional countries;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the unfavorable outcome of any potential litigation relating to our partnered products;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">general economic conditions in the jurisdictions where our partnered products are sold, including microeconomic disruptions or slowdowns; or</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">if our royalty revenue or operating results fall below the expectations of investors or securities analysts or below any guidance we may provide to the market, the price of our common stock could decline substantially.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">When the FDA or other applicable regulatory authorities approve generic products, including but not limited to generic forms of Advair, that compete with RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">, and ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> or a generic form of RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">, the royalties payable to us pursuant to the GSK Agreements will be less than anticipated, which in turn would harm our business and the price of our securities could fall.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Once an NDA or marketing authorization application outside the United States is approved, the product covered thereby becomes a &#8220;listed drug&#8221; that can, in turn, be cited by potential competitors in support of approval of an ANDA in the United States. Agency regulations and other applicable regulations and policies provide incentives to manufacturers to create modified, non-infringing versions of a drug to facilitate the approval of an ANDA or other application for generic substitutes in the United States and in nearly every pharmaceutical market around the world. Numerous companies have brought to market generic forms of the ICS/LABA drug Advair</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> since certain patents covering the Advair</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> delivery device expired in 2016. In general, these manufactures are required to conduct a number of clinical efficacy, pharmacokinetic and device studies to demonstrate equivalence to Advair, per FDA&#8217;s September 2013 draft guidance document. These studies are designed to demonstrate that the generic product has the same active ingredient(s), dosage form, strength, exposure and clinical efficacy as the branded product. These generic equivalents, which must meet the same exacting quality standards as branded products, may be significantly less costly to bring to market, and companies that produce generic equivalents are generally able to offer their products at lower prices. Thus, after the introduction of a generic competitor, a significant percentage of the sales of any branded product and products that may compete with such branded product is typically lost to the generic product.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In January 2019, Mylan announced that the FDA approved Wixela&#153; Inhu&#153; (fluticasone propionate and salmeterol inhalation powder, USP), the first generic of ADVAIR DISKUS</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. In that same month, Teva announced that the FDA approved two of their products for adolescent and adult patients with asthma, one of which is AirDuo&#153; RespiClick</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (fluticasone propionate and salmeterol inhalation powder), a non-AB substitutable generic version of Advair</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. In January 2020, Astra Zeneca launched an authorized generic version of Symbicort. In December 2020, Hikma/Vectura announced that it received FDA approval and launched its generic version of GSK&#8217;s Advair Diskus</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In April 2016, the FDA issued draft guidance documents covering Fluticasone Furoate/Vilanterol Trifenatate (FF/VI), the active ingredients used in RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Introduction of generic products that compete against ICS/LABA products, like RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, would materially adversely impact our future royalty revenue, profitability and cash flows. We cannot yet ascertain what impact these generic products and any future approved generic products will have on any sales of RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> or ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, if approved.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">36</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Reduced prices and reimbursement rates due to the actions of governments, payors, or competition or other healthcare cost containment initiatives such as restrictions on use, may negatively impact royalties generated under the GSK Agreements.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The continuing efforts of governments, pharmaceutical benefit management organizations (&#8220;PBMs&#8221;), insurance companies, managed care organizations and other payors of health care costs to contain or reduce costs of health care has adversely affected the price, market access, and total revenues of RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and may continue to adversely affect them in the future. These organizations, together with governments, have increasingly imposed utilization management tools favoring the use of generic products. As these practices expand, we may face difficulty in obtaining or maintaining timely or adequate pricing or formulary placement of our products. In addition, we have experienced and expect to continue to experience increased competitive activity, which has resulted in lower overall prices for our products.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (together, &#8220;PPACA&#8221;) and other legislative or regulatory requirements or potential legislative or regulatory actions regarding healthcare and insurance matters, along with the trend toward managed healthcare in the U.S., could adversely influence the purchase of healthcare products and reduce demand and prices for our partnered products. This could harm GSK&#8217;s ability to market our partnered products and significantly reduce future revenues. For example, when GSK launched RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for the treatment of COPD in the U.S. in October 2013, GSK experienced significant challenges gaining coverage at some of the largest PBMs, healthcare payors, and providers and lower overall prices than expected. Recent actions by U.S. PBMs in particular have increased discount levels for respiratory products resulting in lower net sales pricing realized for products in our collaboration. In addition, in certain foreign markets, the pricing of prescription drugs is subject to government control and reimbursement may in some cases be unavailable. We believe that pricing pressures will continue and may increase. This may make it difficult for GSK to sell our partnered products at a price acceptable to us or GSK or to generate revenues in line with our analysts&#8217; or investors&#8217; expectations, which may cause the price of our securities to fall.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">More recently, presidential administrations and the U.S. Congress have taken actions in an effort to modify or replace PPACA and to implement or pass other reforms to the healthcare system, including proposed legislation related to the pricing of pharmaceuticals. There is uncertainty with respect to any potential changes that may be proposed and what the impact, if any, will be on our business, including the impact on coverage and reimbursement for healthcare items and services covered by plans that were authorized by PPACA. However, we cannot predict the ultimate content, timing or effect of any healthcare reform legislation or the impact of potential legislation on us.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect that additional state and federal healthcare reform measures will be considered and potentially adopted, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our products once approved or additional pricing pressures and may adversely affect our operating results.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">A portion of our current revenues are from royalties derived from sales of our respiratory products partnered with GSK, RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174; </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">and ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">. If the treatment paradigm for the indications our partnered products are approved for change or if GSK is unable to, or does not devote sufficient resources to, maintain or continue increasing sales of these products, our results of operations will be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We currently depend, in part, on royalties from sales of our products partnered with GSK to support our existing operations. The treatment paradigm for COPD and asthma constantly evolves. For instance, in November 2018, the GOLD guidelines were revised to favorably position bronchodilator monotherapy and LABA/LAMA treatment ahead of ICS/LABA for the treatment of COPD unless the patient has frequent exacerbations, or an eosinophil count greater than 300 per cubic microliter. The use of ICS in COPD is also recommended for patients requiring triple therapy (LABA, LAMA, ICS). If the treatment paradigms were to change further, causing our partnered products to fall out of favor, or if GSK were unable, or did not devote sufficient resources, to maintain or continue increasing RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> sales, our results of operations would likely suffer, and the price of our securities could fall.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">37</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If the commercialization of RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174; </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">and ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> in the countries in which they have received regulatory approval encounters any delays or adverse developments, or perceived delays or adverse developments, or if sales or payor coverage does not meet investors&#8217;, analysts&#8217;, or our expectations, our business will be harmed, and the price of our securities could fall.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under our agreements with our collaborative partner GSK, GSK has full responsibility for commercialization of RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. GSK has launched RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in a number of countries, including the United States, Canada, Japan, the United Kingdom, and Germany, among others. The commercialization of the products in countries where they are already launched and the commercialization launch in new countries are still subject to fluctuating overall pricing levels and uncertain timeframes to obtain payor coverage. Any delays or adverse developments or perceived additional delays or adverse developments with respect to the commercialization of RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> including if sales or payor coverage does not meet investors&#8217;, analysts&#8217;, or our expectations, would significantly harm our business and the price of our securities could fall.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are dependent on GSK for the successful commercialization and development of products under the GSK Agreements. If GSK does not devote sufficient resources to the commercialization or development of these products, is unsuccessful in its efforts, or chooses to reprioritize its commercial programs, our business would be materially harmed.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">GSK is responsible for all clinical and other product development, regulatory, manufacturing and commercialization activities for products developed under the GSK Agreements, including RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Our royalty revenues under the GSK Agreements may not meet our, analysts&#8217;, or investors&#8217; expectations, due to a number of important factors. GSK has a substantial respiratory product portfolio in addition to the partnered products that are covered by the GSK Agreements. GSK may make respiratory product portfolio decisions or statements about its portfolio which may be, or may be perceived to be, harmful to the respiratory products partnered with us. For instance, GSK has wide discretion in determining the efforts and resources that it will apply to the development and commercialization of our partnered products. In addition, GSK may determine to focus its commercialization efforts on its own products. For example, in January 2015, GSK launched Incruse</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (UMEC) in the U.S., which is a LAMA for the treatment of COPD. GSK may determine to focus its marketing efforts on Incruse, which could have the effect of decreasing the potential market share of ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and lowering the royalties we may receive for such product. Alternatively, GSK may decide to market to eventually compete directly against sales of RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. In the event GSK does not devote sufficient resources to the commercialization of our partnered products or chooses to reprioritize its commercial programs, our business, operations and stock price would be negatively affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Any adverse change in FDA policy or guidance regarding the use of LABAs to treat asthma could significantly harm our royalty revenues and the price of our securities could fall.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On February 18, 2010, the FDA announced that LABAs should not be used alone in the treatment of asthma and it will require manufacturers to include this warning in the product labels of these drugs, along with taking other steps to reduce the overall use of these medicines. The FDA now requires that the product labels for LABA medicines reflect, among other things, that the use of LABAs is contraindicated without the use of an asthma controller medication such as an inhaled corticosteroid, that LABAs should only be used long term in patients whose asthma cannot be adequately controlled on asthma controller medications, and that LABAs should be used for the shortest duration of time required to achieve control of asthma symptoms and discontinued, if possible, once asthma control is achieved. In addition, in March 2010, the FDA held an Advisory Committee to discuss the design of medical research studies (known as &#8220;clinical trial design&#8221;) to evaluate serious asthma outcomes (such as hospitalizations, a procedure using a breathing tube known as intubation, or death) with the use of LABAs in the treatment of asthma in adults, adolescents, and children. Further, in April 2011, the FDA announced that to further evaluate the safety of LABAs, it required the manufacturers of currently marketed LABAs to conduct additional randomized, double blind, controlled clinical trials comparing the addition of LABAs to inhaled corticosteroids versus inhaled corticosteroids alone. These post&#8209;marketing studies have been completed and the FDA stated that treating asthma with LABAs in combination with ICS did not result in significantly more serious asthma-related side effects than treatment with ICS alone. The FDA subsequently removed the black box warning from the ICS/LABA package inserts. Although this concern appears to be resolved, it is unknown at this time what, if any, future concerns could impact the use of ICS/LABA and its potential impact on the prospects for FF/VI. Any adverse change in FDA policy or guidance regarding the use of LABAs to treat asthma could significantly harm our business and the price of our securities could fall.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">38</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Any adverse developments to the regulatory status of either RELVAR</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> or ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> in the countries in which they have received regulatory approval, including labeling restrictions, safety findings, or any other limitation to usage, would harm our business and may cause the price of our securities to fall.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Although RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> are approved and marketed in a number of countries, it is possible that adverse changes to the regulatory status of these products could occur in the event new safety issues are identified, treatment guidelines are changed, or new studies fail to demonstrate product benefits. A number of notable pharmaceutical products have experienced adverse developments during commercialization that have resulted in the product being withdrawn, approved uses being limited, or new warnings being included. In the event that any adverse regulatory changes were to occur to any of our products, our business would be harmed, and the price of our securities could fall.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Any adverse developments or results or perceived adverse developments or results with respect to the ongoing studies for FF/VI in asthma or COPD, for UMEC/VI in COPD, or any future studies would significantly harm our business and the price of our securities could fall, and if regulatory authorities in those countries in which approval has not yet been granted determine that the ongoing studies for FF/VI in asthma or COPD or the ongoing studies for UMEC/VI for COPD do not demonstrate adequate safety and efficacy, the continued development of FF/VI or UMEC/VI or both could be significantly delayed, they might not be approved by these regulatory authorities, and even if approved they may be subject to restrictive labeling, any of which might harm our business, and the price of our securities could fall.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Although we have announced the completion of, and reported certain top&#8209;line data from, the Phase 3 registrational program for FF/VI in COPD and asthma, additional studies of FF/VI are underway or may commence in the future. Any adverse developments or perceived adverse developments with respect to any prior, current or future studies in these programs could significantly harm our business and the price of our securities could fall.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Although the FDA, the European Medicines Agency, the Japanese Ministry of Health, Labour and Welfare and Health Canada and other jurisdictions have approved ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, it has not yet been approved in all jurisdictions.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any adverse developments or results or perceived adverse developments or results with respect to other pending or future regulatory submissions for the FF/VI program or the UMEC/VI program might significantly harm our business and the price of our securities could fall. Examples of such adverse developments include, but are not limited to:</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">not every study, nor every dose in every study, in the Phase 3 programs for FF/VI achieved its primary endpoint and regulatory authorities may determine that additional clinical studies are required;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">safety, efficacy or other concerns arising from clinical or non&#8209;clinical studies in these programs having to do with the LABA VI, which is a component of FF/VI and UMEC/VI;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">analysts adjusting their sales forecasts downward from previous projections based on results or interpretations of results of prior, current or future studies;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">safety, efficacy or other concerns arising from clinical or non&#8209;clinical studies in these programs;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulatory authorities determining that the Phase 3 programs in asthma or in COPD raise safety concerns or do not demonstrate adequate efficacy; or</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">any change in FDA (or comparable foreign regulatory agency) policy or guidance regarding the use of LABAs to treat asthma or the use of LABAs combined with a LAMA to treat COPD.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">RELVAR</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> and ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> face substantial competition for their intended uses in the targeted markets from products discovered, developed, launched and commercialized both by GSK and by other pharmaceutical companies, which could cause the royalties payable to us pursuant to the LABA Collaboration Agreement to be less than expected, which in turn would harm our business and cause the price of our securities to fall.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">GSK has responsibility for obtaining regulatory approval, launching and commercializing RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for their intended uses in the targeted markets around the world. While these products have received regulatory approval and have been launched and commercialized in the U.S. and certain other targeted markets, the products face substantial competition from existing products previously developed and commercialized both by GSK and by other competing pharmaceutical companies and can expect to face additional competition from new products that are discovered, developed and commercialized by the same pharmaceutical companies and other competitors going forward. For example, sales of generic Advair</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, GSK&#8217;s approved medicine for both COPD and asthma, continue to have a negative impact on sales of RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">39</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Many of the pharmaceutical companies competing in respiratory markets are international in scope with substantial financial, technical and personnel resources that permit them to discover, develop, obtain regulatory approval and commercialize new products in a highly efficient and low-cost manner at competitive prices to consumers. In addition, many of these competitors have substantial commercial infrastructure that facilitates commercializing their products in a highly efficient and low-cost manner at competitive prices to consumers. The market for products developed for treatment of COPD and asthma continues to experience significant innovation and reduced cost in bringing products to market over time. There can be no assurance that RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> will not be replaced by new products that are deemed more effective at lower cost to consumers. The ability of RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to succeed and achieve the anticipated level of sales depends on the commercial and development performance of GSK to achieve and maintain a competitive advantage over other products with the same intended use in the targeted markets.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If sales of RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> are less than anticipated because of existing or future competition in the markets in which they are commercialized, including competition from existing and new products that are perceived as lower cost or more effective, our royalty payments could be less than anticipated, which in turn would harm our business and cause the price of our securities to fall.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may not be able to utilize all of our net operating loss carryforwards.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have net operating loss carryforwards and other significant U.S. tax attributes that we believe could offset otherwise taxable income in the U.S. The net operating loss carryforwards available in any year to offset our net taxable income will be reduced following a more than 50% change in ownership during any period of 36 consecutive months (an &#8220;ownership change&#8221;) as determined under the Code. Transactions involving our common stock, even those outside our control, such as purchases or sales by investors, within the testing period could result in an ownership change. We have conducted an analysis to determine whether an ownership change had occurred since inception through December 31, 2023 and concluded that it is more likely than not that the Company did not experience an ownership change during the testing period. Subsequent changes in our ownership or sale of our stock could have the effect of limiting the use of our net operating losses in the future. There may be certain annual limitations for utilization based on the above-described ownership change provisions. In addition, we may not be able to have sufficient future taxable income prior to their expiration because net operating losses have carryforward periods. Future changes in federal and state tax laws pertaining to net operating loss carryforwards may also cause limitations or restrictions from us claiming such net operating losses. If the net operating loss carryforwards become unavailable to us or are fully utilized, our future taxable income will not be shielded from federal and state income taxation absent certain U.S. federal and state tax credits, and the funds otherwise available for general corporate purposes would be reduced.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If any product candidates in any respiratory program partnered with GSK were not approved by regulatory authorities or are determined to be unsafe or ineffective in humans, our business would be adversely affected and the price of our securities could fall.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA must approve any new medicine before it can be marketed and sold in the U.S. Our partner GSK must provide the FDA and similar foreign regulatory authorities with data from preclinical and clinical studies that demonstrate that the product candidates are safe and effective for a defined indication before they can be approved for commercial distribution. GSK will not obtain this approval for a partnered product candidate unless and until the FDA approves an NDA. The processes by which regulatory approvals are obtained from the FDA to market and sell a new product are complex, require a number of years and involve the expenditure of substantial resources. In order to market medicines in foreign countries, separate regulatory approvals must be obtained in each country. The approval procedure varies among countries and can involve additional testing, and the time required to obtain approval may differ from that required to obtain FDA approval. Approval by the FDA does not ensure approval by regulatory authorities in other countries, and approval by one foreign regulatory authority does not ensure approval by regulatory authorities in other foreign countries or by the FDA. Conversely, failure to obtain approval in one or more country may make approval in other countries more difficult.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Clinical studies involving product candidates partnered with GSK may reveal that those candidates are ineffective, inferior to existing approved medicines, unacceptably toxic, or that they have other unacceptable side effects. In addition, the results of preclinical studies do not necessarily predict clinical success, and larger and later&#8209;stage clinical studies may not produce the same results as earlier&#8209;stage clinical studies.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">40</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Frequently, product candidates that have shown promising results in early preclinical or clinical studies have subsequently suffered significant setbacks or failed in later clinical or non&#8209;clinical studies. In addition, clinical and non&#8209;clinical studies of potential products often reveal that it is not possible or practical to continue development efforts for these product candidates. If these studies are substantially delayed or fail to prove the safety and effectiveness of product candidates in development partnered with GSK, GSK may not receive regulatory approval for such product candidates and our business and financial condition could be materially harmed and the price of our securities might fall.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Several well&#8209;publicized Complete Response letters issued by the FDA and safety&#8209;related product withdrawals, suspensions, post&#8209;approval labeling revisions to include boxed warnings and changes in approved indications over the last several years, as well as growing public and governmental scrutiny of safety issues, have created a conservative regulatory environment. The implementation of new laws and regulations and revisions to FDA clinical trial design guidance have increased uncertainty regarding the approvability of a new drug. Further, there are additional requirements for approval of new drugs, including advisory committee meetings for new chemical entities, and formal risk evaluation and mitigation strategy at the FDA&#8217;s discretion. These laws, regulations, additional requirements and changes in interpretation could cause non&#8209;approval or further delays in the FDA&#8217;s review and approval of any product candidates in any respiratory program partnered with GSK.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Even if product candidates in any respiratory program partnered with GSK receive regulatory approval, as is the case with RELVAR</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> and ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">, commercialization of such products may be adversely affected by regulatory actions and oversight.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if GSK receives regulatory approval for product candidates in any respiratory program partnered with GSK, this approval may include limitations on the indicated uses for which GSK can market the medicines or the patient population that may utilize the medicines, which may limit the market for the medicines or put GSK at a competitive disadvantage relative to alternative therapies. These restrictions make it more difficult to market the approved products.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For example, at the joint meeting of the Pulmonary&#8209;Allergy Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee of the FDA regarding the sNDA for BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> as a treatment for asthma, the advisory committee recommended that a large LABA safety trial with BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> should be required in adults and in children ages 12&#8209;17, similar to the ongoing LABA safety trials being conducted as an FDA Post&#8209;Marketing Requirement by each of the manufacturers of LABA containing asthma treatments. The FDA did not concur with the recommendation. A pediatric program including patients 5&#8209;17 years of age is currently ongoing.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, the manufacturing, labeling, packaging, adverse event reporting, advertising, promotion and recordkeeping for the approved product remain subject to extensive and ongoing regulatory requirements. If we or GSK become aware of previously unknown problems with an approved product in the U.S. or overseas or at contract manufacturers&#8217; facilities, a regulatory authority may impose restrictions on the product, the contract manufacturers or on GSK, including requiring it to reformulate the product, conduct additional clinical studies, change the labeling of the product, withdraw the product from the market or require the contract manufacturer to implement changes to its facilities. GSK is also subject to regulation by regional, national, state and local agencies, including the Department of Justice, the Federal Trade Commission, the Office of Inspector General of the U.S. Department of Health and Human Services and other regulatory bodies, as well as governmental authorities in those foreign countries in which any of the product candidates in any respiratory program partnered with GSK are approved for commercialization. The Federal Food, Drug, and Cosmetic Act, the Public Health Service Act and other federal and state statutes and regulations govern to varying degrees the research, development, manufacturing and commercial activities relating to prescription pharmaceutical products, including non&#8209;clinical and clinical testing, approval, production, labeling, sale, distribution, import, export, post&#8209;market surveillance, advertising, dissemination of information and promotion. Any failure to maintain regulatory approval would limit GSK&#8217;s ability to commercialize the product candidates in any respiratory program partnered with GSK, which could materially and adversely affect our business and financial condition, and which may cause the price of our securities to fall.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Pharmaceutical research and development are very costly and highly uncertain; we may not succeed in developing, licensing, or acquiring commercially successful products.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There are many difficulties and uncertainties inherent in pharmaceutical research and development, the introduction of new products, and business development activities to enhance our product pipeline.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">41</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There is a high rate of failure inherent in new drug discovery and development. Failure can occur at any point in the process, including in later stages after substantial investment. New product candidates that appear promising in development may fail to reach the market or may have only limited commercial success because of efficacy or safety concerns, inability to obtain or maintain necessary regulatory approvals or payer reimbursement or coverage, the application of pricing controls, limited scope of approved uses, label changes, changes in the relevant treatment standards or the availability of new or better competitive products, difficulty or excessive costs to manufacture, or infringement of the patents or intellectual property rights of others. Regulatory agencies establish high hurdles for the efficacy and safety of new products and indications. Delays, uncertainties, unpredictability, and inconsistencies in drug approval processes across markets and agencies can result in delays in product launches, lost market opportunity, potential impairment of inventories, and other negative impacts. In addition, it can be very difficult to predict revenue growth rates of or variability in demand for new products and indications.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We cannot state with certainty when or whether our products now under development will be approved or launched; whether, if initially granted, such approval will be maintained; whether we will be able to develop, license, or otherwise acquire additional product candidates or products; or whether our products, once launched, will be commercially successful.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Failure to successfully develop and market new products in the short term or long term would have a material adverse effect on the Company&#8217;s business, results of operations, cash flow, financial condition and prospects.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Acquisitions or strategic investments we have made or may make could turn out to be unsuccessful.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As part of our strategy, we frequently monitor and analyze acquisition or investment opportunities that we believe will create value for our shareholders.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Existing or future acquisitions and investments could involve numerous risks that may prevent us from fully realizing the benefits that we anticipated as a result of the transaction. These risks include the failure to derive any commercial value from the acquired technology, products and intellectual property including as a result of the failure to obtain regulatory approval or to monetize products once approved, as well as risks from lengthy product development and high upfront development costs without guarantee of successful results. Patents and other intellectual property rights covering acquired technology and/or intellectual property may not be obtained, and if obtained, may not be sufficient to fully protect the technology or intellectual property. We may be subject to liabilities, including unanticipated litigation costs, that are not covered by indemnification protection we may obtain. As we pursue or consummate a strategic acquisition or investment, we may value the acquired or funded company incorrectly, fail to successfully manage our operations as our asset diversity increases, expend unforeseen costs during the acquisition or integration process, or encounter other unanticipated risks or challenges. Once an investment is made, we may fail to value it accurately, properly account for it in our consolidated financial statements, or successfully divest it or otherwise realize the value which we originally invested or have subsequently reflected in our consolidated financial statements. Any failure by us to effectively limit such risks as we implement our acquisitions or strategic investments could have a material adverse effect on our business, financial condition or results of operations and may negatively impact our net income and cause the price of our securities to fall.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We have a significant amount of debt including our convertible subordinated notes and convertible senior notes that are senior in capital structure and cash flow, respectively, to our common stockholders. Satisfying the obligations relating to our debt could adversely affect our liquidity or the amount or timing of potential distributions to our stockholders.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we had $453.5 million in total debt outstanding, comprised primarily of $192.5 million in principal outstanding under our convertible senior notes due 2025 (the &#8220;2025 Notes&#8221;) and $261.0 million in principal outstanding under our convertible notes due 2028 (the &#8220;2028 Notes&#8221;) (the 2025 Notes and 2028 Notes, hereinafter, the &#8220;Notes&#8221;). The Notes are unsecured debt and, with the exception of the 2028 Notes, are not redeemable by us prior to the maturity date. Holders of the Notes may require us to purchase all or any portion of their Notes at 100% of their principal amount, plus any unpaid interest, upon a fundamental change. A fundamental change is generally defined to include a merger involving us, an acquisition of a majority of our outstanding common stock. In addition, to the extent we pursue and complete a monetization transaction or a transaction that modifies our corporate structure, the structure of such transaction may qualify as a fundamental change under the Notes, which could trigger the put rights of the holders of the Notes, in which case we would be required to use a portion of the net proceeds from such transaction to repurchase any Notes put to us.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">42</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Satisfying the obligations of this debt could adversely affect the amount or timing of any distributions to our stockholders. We may choose to satisfy, repurchase, or refinance this debt through public or private equity or debt financings if we deem such financings available on favorable terms. If any or all of the Notes are not converted into shares of our common stock before the maturity date, we will have to pay the holders the full aggregate principal amount of the Notes then outstanding. Any of the above payments could have a material adverse effect on our cash position. If we fail to satisfy these obligations, it may result in a default under the indenture, which could result in a default under certain of our other debt instruments, if any. Any such default would harm our business and the price of our securities could fall.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we lose key management personnel, or if we fail to retain our key employees, our ability to manage our business may be impaired.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our performance is substantially dependent on the continued service and performance of our management team, who have extensive experience and specialized expertise in our business.  None of our employees have employment commitments for any fixed period of time and all may leave our employment at will. If we fail to retain our qualified personnel or to replace them when they leave, our ability to manage our business may be impaired, which may cause the price of our securities to fall.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To continue to commercialize our products, and advance the research, development, and commercialization of additional modalities, indications, and product candidates, we have expanded, and may need to further expand, our workforce. Our failure to compete effectively for talent could negatively affect sales of our current and any future approved products, and could result in material financial, legal, commercial, or reputational harm to our business.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Prolonged economic uncertainties or downturns, as well as unstable market, credit and financial conditions, may exacerbate certain risks affecting our business and have serious adverse consequences on our business.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The global economic downturn and market instability has made the business climate more volatile and more costly. These economic conditions, and uncertainty as to the general direction of the macroeconomic environment, are beyond our control and may make any necessary debt or equity financing more difficult, more costly, and more dilutive. While we believe we have adequate capital resources to meet current working capital and capital expenditure requirements, a lingering economic downturn or significant increase in our expenses could require additional financing at less than attractive rates or on terms that are excessively dilutive to existing stockholders. Failure to secure any necessary financing in a timely manner and on favorable terms could have a material adverse effect on our stock price and could require us to delay or abandon clinical development plans.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Sales of our partnered products will be dependent, in large part, on reimbursement from government health administration authorities, private health insurers, distribution partners and other organizations. As a result of negative trends in the general economy in the U.S. or other jurisdictions in which we may do business, these organizations may be unable to satisfy their reimbursement obligations or may delay payment. In addition, federal and state health authorities may reduce Medicare and Medicaid reimbursements, and private insurers may increase their scrutiny of claims. A reduction in the availability or extent of reimbursement could negatively affect our or our partners&#8217; product sales and revenue.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, we rely on third parties for several important aspects of our business. During challenging and uncertain economic times and in tight credit markets, there may be a disruption or delay in the performance of our third&#8209;party contractors, suppliers or partners. If such third parties are unable to satisfy their commitments to us, our business and results of operations would be adversely affected.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our success in preclinical studies or clinical trials may not be indicative of results in current or future clinical trials.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our success in preclinical testing and early clinical trials does not ensure that later clinical trials will generate the same results or otherwise provide adequate data to demonstrate the efficacy and safety of a product candidate. Certain product candidates may fail to show the necessary safety and efficacy in clinical development despite positive results in preclinical studies or having successfully advanced through initial clinical trials.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> In addition, the design of a clinical trial can determine whether its results will support approval of a product, and flaws in the design of a clinical trial may not become apparent until the clinical trial is well advanced. We have limited experience designing clinical trials and may be unable to design and execute a clinical trial to support regulatory approval. There is a high failure rate for drugs and biologic products proceeding through clinical trials. Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in late-stage clinical trials even after achieving promising results in preclinical testing and earlier-stage clinical trials. Data obtained from preclinical and clinical activities are subject to varying interpretations, which may delay, limit or prevent regulatory approval. In addition, we may experience regulatory delays or rejections because of many factors, including changes in regulatory policy during the period of our product candidate development. Any such delays could negatively impact our business, financial condition, results of operations and prospects.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">43</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If clinical trials of our product candidates fail to demonstrate safety and efficacy to the satisfaction of the FDA, the EMA or other comparable regulatory authorities, or do not otherwise produce favorable results, we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of that product candidate.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We, or our potential collaborators, may not commercialize, market, promote, or sell any product candidate without obtaining marketing approval from the FDA, the EMA or other comparable regulatory authority, and we may never receive such approvals. Even if our product candidates appear sufficiently effective and/or safe in patients in well-controlled clinical trials, it is impossible to predict if or when these product candidates will receive regulatory approval. Before obtaining marketing approval from regulatory authorities for the sale of any product candidate, we must complete preclinical development and then conduct extensive clinical trials to demonstrate the safety and efficacy of our product candidates in humans. Clinical testing is expensive, difficult to design and implement, can take many years to complete and is uncertain as to outcome. A failure of one or more clinical trials can occur at any stage of testing. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their products.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> We may experience numerous unforeseen events prior to, during, or because of, clinical trials that could delay or prevent our ability to receive marketing approval or commercialize our product candidates, including but not limited to:</span></p>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the FDA, the EMA or other comparable regulatory authority may change from the views they have expressed to us as to the design, implementation, and/or interpretation of our clinical trials;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the FDA may withdraw Fast Track designation if it believes that the designation is no longer supported by data from our clinical development program;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulators or institutional review boards may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may not reach agreement on acceptable terms with prospective contract research organizations, or CROs, and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical trial sites;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">clinical trials of product candidates may produce negative or inconclusive results;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may decide, or regulators may require us, to conduct additional clinical trials or abandon product development programs;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may not be able to complete our clinical trials in a timely manner, if at all, for example because the number of patients required for clinical trials of our product candidates may be larger than we anticipate;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">enrollment in these clinical trials may be slower than we anticipate, participants may drop out of these clinical trials at a higher rate than we anticipate, or we may fail to recruit suitable patients to participate in a trial;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may fail to comply with regulatory requirements applicable to them, to the FDA&#8217;s or other comparable regulatory authority&#8217;s, satisfaction;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulators may issue a clinical hold, or regulators or institutional review boards may require that we or our investigators suspend or terminate clinical research for various reasons, including noncompliance with regulatory requirements or a finding that the participants are being exposed to unacceptable health risks;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the cost of clinical trials of our product candidates may be greater than we anticipate;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the FDA, the EMA or other comparable regulatory authorities may fail to approve the manufacturing processes or facilities of third-party manufacturers with whom we enter into agreements for clinical and commercial supplies;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be insufficient or inadequate;</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">44</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our product candidates, once exposed to greater numbers of patients, may have undesirable side effects or other unexpected characteristics, causing us or our investigators, regulators or institutional review boards to suspend or terminate the clinical trials or cause regulatory authorities to refuse to approve our product candidates or approve them only with significant restrictions on distribution or use;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">even if our clinical trials are successful, the FDA, the EMA or other comparable regulatory authorities may determine that the overall risk-benefit profiles of our product candidates are insufficient to support marketing authorization; and</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the approval policies or regulations of the FDA, the EMA or other comparable regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval.</span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we are required to conduct additional clinical trials or other testing of our product candidates beyond those that we currently contemplate, if we are unable to successfully complete clinical trials or other testing of those product candidates, or if the results of these trials or tests are not positive or are only modestly positive or if there are safety concerns, we may:</span></p>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">be delayed in obtaining marketing approval for our product candidates;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">not obtain marketing approval at all;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">obtain approval for indications or patient populations that are not as broad as intended or desired;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">obtain approval with labeling that includes significant use or distribution restrictions or safety warnings, such as black box warnings or a REMS program;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">be subject to additional post-marketing testing requirements; or</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">be required to remove the product from the market after obtaining marketing approval.</span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our product development costs may also increase if we experience delays in testing and we may be required to obtain additional funds to complete clinical trials. We do not know whether any of our preclinical studies or clinical trials will begin as planned, will need to be restructured or will be completed on schedule, or at all. Significant preclinical study or clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our product candidates or allow our competitors to bring products to market before we do and impair our ability to successfully commercialize our product candidates. In addition, many of the factors that cause, or lead to, delays of clinical trials may ultimately lead to the denial of regulatory approval of a product candidate.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we are not successful in discovering, developing, and commercializing additional product candidates, our ability to expand and achieve our strategic objectives would be impaired.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have chosen to devote a substantial amount of our effort on the continued clinical testing and potential regulatory approval of our product candidates. However, an element of our strategy may include the development of novel product candidates in other therapeutic areas. Our efforts to identify and develop product candidates require substantial technical, financial and human resources, whether or not any product candidates are ultimately identified. Our research programs may initially show promise in identifying potential product candidates, yet fail to yield product candidates for clinical development for many reasons, including but not limited to the following:</span></p>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the research methodology used may not be successful in identifying potential product candidates;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">competitors may develop alternatives that render our product candidates obsolete or less attractive;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">product candidates we develop may nevertheless be covered by third parties&#8217; patents or other exclusive rights;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a product candidate may on further study be shown to have harmful side effects or other characteristics that indicate it is unlikely to be effective or otherwise does not meet applicable regulatory criteria;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a product candidate may not be accepted as safe and effective by patients, the medical community or third-party payors, if applicable; and</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">45</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the FDA, the EMA or other regulatory authorities may not approve or agree with the intended use of a new product candidate.</span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we fail to develop and successfully generate revenue from other current and future product candidates, our future prospects may be harmed, and we will be more vulnerable to any problems that we or potential collaborators may encounter in developing and commercializing our current product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we or our collaborators experience delays or difficulties in the enrollment of patients in clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may not be able to initiate, continue or complete clinical trials of our product candidates that we develop if we and our collaborators are unable to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA, the EMA or other comparable regulatory authority. We have limited experience enrolling patients in our clinical trials and cannot predict how successful we will be in enrolling patients in future clinical trials.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For instance, patients involved in our clinical trials are often in the hospital setting and the decision to participate can be made by the caregiver or doctor. Accordingly, seeking consent for patient participation may become difficult when the family and/or the patient may not be available to consider participation in a clinical trial and the providers/investigators seeking the consent often have no established relationship with the family or patient. In addition, some of our competitors have ongoing clinical trials to treat the same indications as our product candidates, and patients who would otherwise be eligible for our clinical trials may instead enroll in clinical trials of our competitors. If we are not successful at enrolling patients in one clinical trial, it may affect when we are able to initiate the next clinical trial, which could result in significant delays in our efforts to pursue regulatory approval of and commercialize our product candidates. Patient enrollment is affected by other factors including but not limited to:</span></p>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the size and nature of the patient population;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the severity of the disease under investigation;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the proximity and availability of clinical trial sites for prospective patients;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the eligibility criteria for participation in the clinical trial;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the design of the clinical trial;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the perceived risks and benefits of the product candidate under study;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to recruit clinical trial investigators with appropriate experience;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the availability of drugs approved to treat the diseases under study;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the patient referral practices of physicians;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to obtain and maintain patient consents;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the ability to monitor patients adequately during and after treatment;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the risk that patients enrolled in clinical trials will drop out of the trials before completion; and</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the impact of public health epidemics, such as the COVID-19 pandemic.</span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our inability to enroll a sufficient number of patients for clinical trials would result in significant delays and could require us to abandon one or more clinical trials altogether. Enrollment delays in these clinical trials may result in increased development costs for our product candidates, which would reduce the capital we have available to support current and future product candidates and may result in the need to raise additional capital earlier than planned and could cause the value of our common stock to decline and limit our ability to obtain additional financing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">46</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial potential or result in significant negative consequences following any potential marketing approval.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the conduct of clinical trials, patients report changes in their health, including illnesses, injuries and discomforts (generally referred to as adverse events), to their doctor. We are required to report adverse events to the FDA and other regulatory authorities. Often, it is not possible to determine whether the product candidate being studied caused these conditions. Regulatory authorities may draw different conclusions or require additional testing to confirm or refute these observations, if they occur. In addition, it is possible that as we test our product candidates in larger, longer and more extensive clinical programs, or as use of these product candidates becomes more widespread if they receive regulatory approval, illnesses, injuries, discomforts and other adverse events that were observed in earlier trials, as well as conditions that did not occur or went undetected in previous trials, will be reported by subjects. Many times, side effects are only detectable after investigational drugs are tested in large-scale, Phase&#8239;3 clinical trials or, in some cases, after they are made available to patients on a commercial scale after approval. If additional clinical experience indicates that any of our current product candidates or any future product candidates, have side effects or causes serious or life-threatening side effects, the development of the product candidate may fail or be delayed, or, if the product candidate has received regulatory approval, such approval may be revoked, which could harm our business, prospects, operating results and financial condition.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moreover, if we elect, or are required, to delay, suspend or terminate any clinical trial of our product candidates, the commercial prospects of our product candidates may be harmed and our ability to generate revenue through their sale may be delayed or eliminated. Any of these occurrences may significantly harm our business, financial condition and prospects.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, if any of our product candidates receive marketing approval, regulatory authorities may require the addition of labeling statements, such as a &#8220;black box&#8221; warning or a contraindication, or the adoption of a REMS program to ensure that the benefits outweigh its risks, which may include, among other things, a medication guide outlining the risks of the drug for distribution to patients and a communication plan to health care practitioners, and/or significant restrictions on distribution or use of the drug. Furthermore, if we or others later identify undesirable side effects caused by our product candidates, several potentially significant negative consequences could result, including but not limited to:</span></p>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulatory authorities may suspend or withdraw approvals of such product candidate;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulatory authorities may require additional warnings on the label or impose distribution or use restrictions;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may be required to change the way a product candidate is administered or conduct additional clinical trials, including one or more post-market studies;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we could be sued and held liable for harm caused to patients;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may be required to implement a REMS, including the creation of a medication guide outlining the risks of such side effects for distribution to patients, and/or other elements to assure safe use;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may need to conduct a recall; and</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our reputation may suffer.</span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any of these events could prevent us from achieving or maintaining market acceptance of the affected product candidate, if approved, or could substantially increase commercialization costs and expenses, which could delay or prevent us from generating revenue from the sale of our products and harm our business and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Interim &#8220;top-line&#8221; and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From time to time, we may announce interim top-line or preliminary data from our clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and/or more patient data become available. Preliminary or top-line data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, interim and preliminary data should be viewed with caution until the final data are available. Differences between preliminary or interim data and final data could significantly harm our business prospects and may cause the trading price of our common stock to fluctuate significantly.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">47</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our operations could be disrupted by failure of our information systems or cyber-attacks.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Our operations could be disrupted if our information systems fail, if we are unsuccessful in implementing necessary upgrades, or if we are subject to cyber-attacks. Our business depends on the efficient and uninterrupted operation of our computer and communications systems and networks, hardware and software systems and our other information technology. We collect and maintain information, which includes confidential and proprietary information as well as personal information regarding our employees, in digital form. Data maintained in digital form is subject to risk of cyber-attacks, which are increasing in frequency and sophistication. Cyber-attacks could include the deployment of harmful malware, viruses, worms, and other means to affect service reliability and threaten data confidentiality, integrity and availability. Despite our efforts to monitor and safeguard our systems to prevent data compromise, the possibility of a future data compromise cannot be eliminated entirely, and risks associated with intrusion, tampering, and theft remain. A failure of our systems, or an inability to successfully expand the capacity of these systems, or an inability to successfully integrate new technologies into our existing systems could have a material adverse effect on our business, results of operations, financial condition, and cash flows.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> The Company and its vendors&#8217; sophisticated information technology operations are spread across multiple, sometimes inconsistent, platforms, which pose difficulties in maintaining data integrity across systems. The ever-increasing use and evolution of technology, including cloud-based computing, creates opportunities for the unintentional or improper dissemination or destruction of confidential information stored in the Company&#8217;s systems.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, the California Consumer Privacy Act (&#8220;CCPA&#8221;) creates new individual privacy rights for consumers (as that word is broadly defined in the law) and places increased privacy and security obligations on entities handling personal data of consumers or households. Having gone into effect January 1, 2020, the CCPA requires covered companies to provide new disclosures to California consumers, provide such consumers new ways to opt-out of certain sales of personal information, and allow for a new cause of action for data breaches. The CCPA may significantly impact our business activities and require substantial compliance costs that adversely affect business, operating results, prospects and financial condition.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any breach of our security measures or the accidental loss, inadvertent disclosure, unapproved dissemination, misappropriation or misuse of trade secrets, proprietary information or other confidential information, whether as a result of theft, hacking, fraud, trickery or other forms of deception, or for any other cause, could adversely affect our business position. Further, any such interruption, security breach, loss or disclosure of confidential information could result in financial, legal, business and reputational harm to the Company and could have a material adverse effect on our business, financial condition, results of operations, cash flows and stock price.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could harm our business.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous materials, including chemicals and biological materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological or hazardous materials.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Increased scrutiny of our environmental, social or governance responsibilities will likely result in additional costs and risks and may adversely impact our reputation, employee retention and willingness of customers and suppliers to do business with us.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There is an increasing focus from certain customers, consumers, employees and other stakeholders concerning environmental, social and governance (&#8220;ESG&#8221;) matters, including corporate citizenship and sustainability. Additionally, public interest and legislative pressure related to public companies&#8217; ESG practices continues to grow. If our ESG practices fail to meet regulatory requirements or stakeholders&#8217; evolving expectations and standards for responsible corporate citizenship in areas including environmental stewardship, support for local communities, Board of Director and employee diversity, human capital management, employee health and safety practices, corporate governance and transparency and employing ESG strategies in our operations, our brand, reputation and employee retention may be negatively impacted, and customers and suppliers may be unwilling to do business with us.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">48</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The standards for tracking and reporting on ESG matters are relatively new, have not been harmonized and continue to evolve. The disclosure frameworks we choose to align with, if any, may change from time-to-time and may result in a lack of consistent or meaningful comparative data from period to period. Ensuring there are systems and processes in place to comply with various ESG tracking and reporting obligations will require management time and expense. In addition, our processes and controls may not always comply with evolving standards for identifying, measuring and reporting ESG metrics, our interpretation of reporting standards may differ from those of others and such standards may change over time, any of which could result in significant revisions to our goals or reported progress in achieving such goals.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we fail to adopt ESG standards or practices as quickly as stakeholders desire, fail, or be perceived to fail, in our achievement of such initiatives or goals, or fail in fully and accurately reporting our progress on such initiatives and goals, our reputation, business, financial performance and growth may be adversely impacted. In addition, we could be criticized for the scope of such initiatives or goals or perceived as not acting responsibly in connection with these matters. Our business could be negatively impacted by such matters. Any such matters, or related corporate citizenship and sustainability matters, could have a material adverse effect on our business.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Our Dependence on Third Parties</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We rely on third parties to conduct the clinical trials for our product candidates, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials or failing to comply with applicable regulatory requirements.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have engaged contract research organizations, or CROs, to conduct our ongoing and planned clinical trials. We also expect to engage CROs for any of our other product candidates that may progress to clinical development. We expect to rely on CROs, as well as other third parties, such as clinical data management organizations, medical institutions and clinical investigators, to conduct those clinical trials. Agreements with such third parties might terminate for a variety of reasons, including a failure to perform by the third parties. If we need to enter into alternative arrangements, our product development activities would be delayed.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our reliance on these third parties for research and development activities will reduce our control over these activities but will not relieve us of our responsibilities. For example, we will remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. Moreover, the FDA requires us to comply with regulatory standards, commonly referred to as good clinical practices, or GCPs, for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected. Similar regulatory requirements apply outside the United States, including the International Council for Harmonisation of Technical Requirements for the Registration of Pharmaceuticals for Human Use, or ICH.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are also required to register certain ongoing clinical trials and post the results of certain completed clinical trials on government-sponsored, publicly accessible databases, such as ClinicalTrials.gov, within specified timeframes. Failure to do so by us or by third parties can result in FDA refusal to approve applications based on the clinical data, enforcement actions, adverse publicity and civil and criminal sanctions.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Furthermore, these third parties may also have relationships with other entities, some of which may be our competitors. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our clinical trials in accordance with regulatory requirements or our stated protocols, we will not be able to obtain, or may be delayed in obtaining, marketing approvals for our product candidates and will not be able to, or may be delayed in our efforts to, successfully commercialize our product candidates.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and may receive cash or equity compensation in connection with such services. If these relationships and any related compensation result in perceived or actual conflicts of interest, or the FDA concludes that the financial relationship may have affected the results of the trial, the integrity of the data generated at the applicable clinical trial site may be questioned and the utility of the clinical trial itself may be jeopardized, which could result in the delay or rejection by the FDA of any NDA we submit. Any such delay or rejection could prevent us from commercializing our product candidates.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We also expect to rely on other third parties to store and distribute product supplies for our clinical trials. Any performance failure or regulatory noncompliance on the part of our distributors could delay clinical development or marketing approval of our product candidates or commercialization of our products, resulting in additional losses and depriving us of potential product revenue.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">49</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We rely on collaborations with third parties for the development of both our product and commercial candidates, and we may seek additional collaborations in the future. If those collaborations are not successful, we may not be able to capitalize on the market potential of these product or commercial candidates.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have limited capabilities for drug development, and our product development programs and the commercialization of our product candidates will require substantial additional cash to fund expenses. As a result of these factors, we are, and expect to continue to be, dependent on collaborations relating to the development of our existing and future product candidates. We have had and will continue to have discussions on potential partnering opportunities with various pharmaceutical companies. In addition, we may seek third-party collaborators for the development and commercialization of our product candidates, particularly for the commercialization of our product candidates outside the United States. Likely collaborators for any collaboration arrangements include large and mid-size pharmaceutical companies, regional and national pharmaceutical companies and biotechnology companies and we may face significant competition in seeking appropriate collaborators. If we fail to enter into or maintain collaborations on reasonable terms or at all, our ability to develop our existing or future product candidates could be delayed, the commercial potential of our products could change, and our costs of development and commercialization could increase. If we enter into any future collaboration arrangements with any third parties, we will likely have limited control over the amount and timing of resources that our collaborators dedicate to the development or commercialization of our product candidates. Our ability to generate revenues from these arrangements will depend on our collaborators&#8217; abilities to successfully perform the functions assigned to them in these arrangements.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our collaborations and any future collaborations we might enter into may pose a number of risks, including but not limited to:</span></p>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators often have significant discretion in determining the efforts and resources that they will apply to these collaborations;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators may not perform their obligations as expected or contractually obligated;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators may not pursue development and commercialization of any product candidates that achieve regulatory approval or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborators&#8217; strategic focus or available funding, or external factors, such as an acquisition, that divert resources or create competing priorities;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">product candidates discovered in collaboration with us may be viewed by our collaborators as competitive with their own product candidates or products, which may cause collaborators to cease to devote resources to the commercialization of our product candidates;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a collaborator with marketing and distribution rights to one or more of our product candidates that achieve regulatory approval may not commit sufficient resources to the marketing and distribution of such products;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">disagreements with collaborators, including disagreements over proprietary rights, contract interpretation or the preferred course of development, might cause delays or termination of the research, development or commercialization of product candidates, might lead to additional responsibilities for us with respect to product candidates, or might result in litigation or arbitration, any of which would be time-consuming and expensive;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators may not properly maintain or defend our or their intellectual property rights or may use our or their proprietary information in such a way as to invite litigation that could jeopardize or invalidate such intellectual property or proprietary information or expose us to potential litigation;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators may be subject to geo-political actions, natural disasters or other occurrences, including public health epidemics such as the COVID-19 pandemic;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborations may be terminated for the convenience of the collaborator and, if terminated, we could be required to raise additional capital to pursue further development or commercialization of the applicable product candidates; and</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">50</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators&#8217; decisions may limit the availability of the product supplies required for development, clinical and commercial activities.</span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Collaboration agreements may not lead to development or successful commercialization of product or commercial candidates in the most efficient manner or at all. If a present or future collaborator were to be involved in a business combination, the continued pursuit and emphasis on our drug development or commercialization program could be delayed, diminished or terminated.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our reliance on third parties to manufacture our product candidates increases the risk that we will not have sufficient quantities of our product candidates or products or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We do not own or operate manufacturing facilities to produce clinical or commercial supplies of the product candidates that we are developing or evaluating. We have limited personnel with experience in drug manufacturing and lack the resources and the capabilities to manufacture any of our product candidates on a clinical or commercial scale. We currently rely on third parties for supply of our product candidates, and our strategy is to outsource all manufacturing of our product candidates and approved products, if any, to third parties.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To conduct clinical trials of our product candidates, we will need to identify suitable manufacturers with the capabilities to manufacture our compounds in large quantities in a manner consistent with existing regulations. Our third-party manufacturers may be unable to successfully increase the manufacturing capacity for any of our product candidates in a timely or cost-effective manner, or at all. In addition, quality issues may arise during scale-up activities and at any other time. If our manufacturers are unable to successfully scale up the manufacture of our product candidates in sufficient quality and quantity, the development, testing and clinical trials of that product candidate may be delayed, or infeasible, and regulatory approval or commercial launch of that product candidate may be delayed or not obtained, which could significantly harm our business.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if we can establish and maintain arrangements with third-party manufacturers, reliance on third-party manufacturers entails risks, including but not limited to:</span></p>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">reliance on the third party for regulatory compliance and quality assurance;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the possible breach of the manufacturing agreement by the third party;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the possible misappropriation of our proprietary information, including our trade secrets and know-how;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us; and</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">supply chain disruptions due to geo-political actions, natural disasters or public healthy crises, including epidemics such as the COVID-19 pandemic.</span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Third-party manufacturers may not be able to comply with cGMP regulations or similar regulatory requirements outside the United States. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or products, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our product candidates.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our current and anticipated future dependence upon others for the manufacture of our product candidates may adversely affect our future profit margins and our ability to develop product candidates and commercialize any products that receive marketing approval on a timely and competitive basis.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">51</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may not be able to win government or non-profit contracts or grants to fund our product development activities.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Historically, we have relied in part on funding from contracts or grants from government agencies and non-profit entities and it is part of our strategy to continue to do so. Such contracts or grants can be highly attractive because they provide capital to fund the ongoing development of our product candidates without diluting our stockholders. However, there is often significant competition for these contracts or grants. Entities offering contracts or grants may have requirements to apply for or to otherwise be eligible to receive certain contracts or grants that our competitors may be able to satisfy that we cannot. In addition, such entities may make arbitrary decisions as to whether to offer contracts or make grants, to whom the contracts or grants will be awarded, and the size of the contracts or grants to each awardee. Even if we can satisfy the award requirements, there is no guarantee that we will be selected to receive any contract or grant. If we are not successful in achieving this form of funding for our clinical trials, we will need to seek alternative means of funding which may not be available to the same extent, if at all.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our reliance on government funding for certain of our programs adds uncertainty to our research, development and commercialization efforts with respect to those programs and may impose requirements that increase the costs of the research, development and commercialization of product candidates developed under those government-funded programs.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Aspects of certain of our development programs are currently being supported, in part, with funding from the NIH, NIAID, CARB-X and the DOD. Contracts and grants awarded by the U.S. government, its agencies and its partners, including our awards from the NIH, NIAID, CARB-X, and the DOD, include provisions that reflect the government&#8217;s substantial rights and remedies, many of which are not typically found in commercial contracts, including powers of the government to:</span></p>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">terminate agreements, in whole or in part, for any reason or no reason at all;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">provide grant support to potential competitor programs;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">reduce or modify the government&#8217;s obligations under such agreements without the consent of the other party;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">claim rights, including intellectual property rights, in products and data developed under such agreements;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">audit contract-related costs and fees, including allocated indirect costs;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">suspend the contractor or grantee from receiving new contracts pending resolution of alleged violations of procurement laws or regulations;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">impose U.S. manufacturing requirements for products that embody inventions conceived or first reduced to practice under such agreements;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">suspend or debar the contractor or grantee from doing future business with the government;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">control and potentially prohibit the export of products;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">pursue criminal or civil remedies under the False Claims Act, False Statements Act and similar remedy provisions specific to government agreements; and</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">limit the government&#8217;s financial liability to amounts appropriated by the U.S. Congress on a fiscal-year basis, thereby leaving some uncertainty about the future availability of funding for a program even after it has been funded for an initial period.</span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may not have the right to prohibit the U.S. government from using certain technologies developed by us, and may not be able to prohibit third-party companies, including our competitors, from using those technologies in providing products and services to the U.S. government. The U.S. government generally takes the position that it has the right to royalty-free use of technologies that are developed under U.S. government contracts.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, government contracts and grants, and subcontracts and subawards awarded in the performance of those contracts and grants, normally contain additional requirements that may increase our costs of doing business, reduce our profits, and expose us to liability for failure to comply with these terms and conditions. These requirements include, for example:</span></p>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">specialized accounting systems unique to government awards;</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">52</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">mandatory financial audits and potential liability for price adjustments or recoupment of government funds after such funds have been spent;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">adhering to stewardship principles imposed by CARB-X as a condition of the award;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">public disclosures of certain award information, which may enable competitors to gain insights into our research program; and</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">mandatory socioeconomic compliance requirements, including labor standards, non-discrimination and affirmative action programs and environmental compliance requirements.</span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As an organization, we are relatively new to government contracting and new to the regulatory compliance obligations that such contracting entails. If we fail to maintain compliance with those obligations, we may be subject to potential liability and termination of our contracts.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a U.S. government contractor, we are subject to financial audits and other reviews by the U.S. government of our costs and performance on our contracts, as well as our accounting and general business practices related to these contracts. Based on the results of its audits, the government may adjust our contract-related costs and fees, including allocated indirect costs.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to the Commercialization of Our Product Candidates</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Even if any of our product candidates receives marketing approval, such product candidate may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if we obtain approvals from the FDA, the EMA or other comparable regulatory agencies and can initiate commercialization of a product candidate we develop, the product candidate may not achieve market acceptance among physicians, patients, hospitals, including pharmacy directors, and third-party payors and, ultimately, may not be commercially successful. The degree of market acceptance of our product candidates, if approved for commercial sale, will depend on several factors, including but not limited to:</span></p>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the efficacy and potential advantages compared to alternative treatments;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the potential and perceived advantages and disadvantages of the product candidates, including cost and clinical benefit relative to alternative treatments;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the convenience and ease of administration compared to alternative treatments;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">acceptance by physicians, patients, operators of hospitals, including in-hospital formularies, and treatment facilities and parties responsible for coverage and reimbursement of the product;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the availability of coverage and adequate reimbursement by third-party payors and government authorities;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the ability to manufacture our product in sufficient quantities and yields;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the strength and effectiveness of marketing and distribution support;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the prevalence and severity of any side effects;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">limitations or warnings, including distribution or use restrictions, contained in the product&#8217;s approved labeling or an approved REMS;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">whether the product is designated under physician treatment guidelines as a first-line therapy or as a second- or third-line therapy for particular infections;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the approval of other new products for the same indications;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the timing of market introduction of the approved product as well as competitive products;</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">53</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the emergence of bacterial resistance to the product; and</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the rate at which resistance to other drugs in the target infections grow.</span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any failure by any of our product candidates that obtains regulatory approval to achieve market acceptance or commercial success could have a material adverse effect on our business prospects.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We face substantial competition, which may result in others discovering, developing, or commercializing products before or more successfully than we do.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The development and commercialization of new drug products is highly competitive. We face competition from major multi-national pharmaceutical companies, biotechnology companies, specialty pharmaceutical companies and generic drug companies with respect to our current and future product candidates. There are several large pharmaceutical and biotechnology companies that currently market and sell products or are pursuing the development of product candidates for the treatment of drug-resistant infections. Potential competitors also include academic institutions, government agencies and other public and private research organizations. Our competitors may succeed in developing, acquiring or licensing technologies and drug products that are more effective, more effectively marketed and sold or less costly than our product candidates, which could render our product candidates non-competitive and obsolete.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If our competitors obtain marketing approval from the FDA, the EMA or other comparable regulatory authorities for their product candidates more rapidly than we do, it could result in our competitors establishing a strong market position before we are able to enter the market.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Regulation of generic and biosimilar products varies around the world and such regulation is complex and subject to ongoing interpretation and implementation by regulatory agencies and courts. Particularly for biosimilars, health authority guidelines and legislative actions could make it less burdensome for competitor products to enter the market and further incentivize uptake of biosimilars. In the U.S., the FDA has issued several "interchangeability" designations for biosimilar products, and is expected to continue doing so in the future. These designations could &#8211; subject to state law requirements &#8211; enable pharmacies to substitute biosimilars for innovator biological products.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Many of such our competitors have greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do as an organization. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller and other early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any product candidates that we may develop. Our competitors also may obtain approval from the FDA, the EMA or other comparable regulatory agencies for their product candidates more rapidly than we may obtain approval for ours, which could result in product approval delays if a competitor obtains market exclusivity from the FDA or the EMA, or our competitors establish a strong market position before we are able to enter the market. In addition, our ability to compete may be affected in many cases by insurers or other third-party payors seeking to encourage the use of generic drugs. Additional drugs may become available on a generic basis over the coming years. If our product candidates achieve marketing approval, we expect that they will be priced at a significant premium over competitive generic drugs.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Counterfeit versions of our products could harm our patients and have a negative impact on our revenues, earnings, reputation and business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our industry continues to be challenged by the vulnerability of distribution channels to illegal counterfeiting and the presence of counterfeit products in a growing number of markets and over the Internet. Third parties may illegally distribute and sell counterfeit versions of our products. To distributors and patients, counterfeit products may be visually indistinguishable from the authentic version. Counterfeit medicines pose a risk to patient health and safety because of the conditions under which they are manufactured - often in unregulated, unlicensed, uninspected and unsanitary sites - as well as the lack of regulation of their contents.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The industry&#8217;s failure to mitigate the threat of counterfeit medicines could adversely impact our business and reputation by impacting patient confidence in our authentic products, potentially resulting in lost sales, product recalls, and an increased threat of litigation. In addition, diversion of our products from their authorized market into other channels may result in reduced revenues and negatively affect our profitability.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">54</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Coverage and adequate reimbursement may not be available for our current or any future product candidates, which could make it difficult for us to sell profitably, if approved.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Market acceptance and sales of any product candidates that we or our collaborators commercialize will depend in part on the extent to which reimbursement for these drugs and related treatments will be available from third-party payors, including government health care programs (such as Medicare and Medicaid), government health administration authorities, managed care organizations and other private health insurers. Third-party payors decide which therapies they will pay for and establish reimbursement levels. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own coverage and reimbursement policies. However, decisions regarding the extent of coverage and amount of reimbursement to be provided for any product candidates that we develop will be made on a payor-by-payor basis. One payor&#8217;s determination to provide coverage for a drug does not assure that other payors will also provide coverage and adequate reimbursement for the drug. Additionally, a third-party payor&#8217;s decision to provide coverage for a therapy does not imply that an adequate reimbursement rate will be approved. Each payor determines whether it will provide coverage for a therapy, what amount it will pay the manufacturer for the therapy, and on what tier of its list of covered drugs, or formulary, it will be placed. The position on a payor&#8217;s formulary generally determines the co-payment that a patient will need to make to obtain the therapy and can strongly influence the adoption of such therapy by patients and physicians. Patients who are prescribed treatments for their conditions and providers prescribing such services generally rely on third-party payors to reimburse all or part of the associated healthcare costs. Patients are unlikely to use our drugs, and providers are unlikely to prescribe our drugs, unless coverage is provided, and reimbursement is adequate to cover a significant portion of the cost of our drugs and their administration.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A primary trend in the United States healthcare industry and elsewhere is cost containment. Third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. We cannot be sure that coverage and reimbursement will be available for any drug that we commercialize and, if reimbursement is available, what the level of reimbursement will be. Inadequate coverage and reimbursement may impact the demand, or the price of, any drug for which we obtain marketing approval for. If coverage and adequate reimbursement are not available, or are available only to limited levels, we may not be able to successfully commercialize our current and any future product candidates that we develop.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of any products that we may develop.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We face an inherent risk of product liability exposure related to the testing of our product candidates in human clinical trials and will face an even greater risk if we commercially sell any drugs that we may develop. If we cannot successfully defend ourselves against claims that our product candidates or products caused injuries, we will incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</span></p>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">reduced resources of our management to pursue our business strategy;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">decreased demand for any product candidates or products that we may develop;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">injury to our reputation and significant negative media attention;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">withdrawal of clinical trial participants;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">initiation of investigations by regulators;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">product recalls, withdrawals or labeling, marketing or promotional restrictions;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">significant costs to defend the resulting litigation;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">substantial monetary awards paid to clinical trial participants or patients;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">loss of revenue; and</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the inability to commercialize any drugs that we may develop.</span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We currently hold product liability insurance coverage in an amount that may not be adequate to cover all liabilities that we may incur. We may need to increase our insurance coverage as we expand our clinical trials or if we commence commercialization of our product candidates. Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">55</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">There are a variety of risks associated with marketing our product candidates internationally, which could affect our business.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We or our collaborators may seek regulatory approval for our product candidates outside of the United States and, accordingly, we expect that we will be subject to additional risks related to operating in foreign countries if we obtain the necessary approvals, including but not limited to:</span></p>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">differing regulatory requirements in foreign countries;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the potential for so-called parallel importing, which is what happens when a local seller, faced with high or higher local prices, opts to import goods from a foreign market with low or lower prices rather than buying them locally;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">unexpected changes in tariffs, trade barriers, price and exchange controls and other regulatory requirements;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">economic weakness, including inflation, or political instability in foreign economies and markets;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">foreign taxes, including withholding of payroll taxes;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and other obligations incident to doing business in another country;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">difficulties staffing and managing foreign operations;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">workforce uncertainty in countries where labor unrest is more common than in the United States;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">reduced level of reimbursement, pricing and insurance regimes compared to the United States;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">potential liability under the Foreign Corrupt Practices Act of 1977 or comparable foreign regulations;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">challenges enforcing our contractual and intellectual property rights, especially in those foreign countries that do not respect and protect intellectual property rights to the same extent as the United States;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">business interruptions resulting from geo-political actions, including war and terrorism, or natural disasters including earthquakes, typhoons, floods, fires, and public health epidemics, such as the COVID-19 pandemic.</span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These and other risks associated with our international operations may compromise our ability to achieve or maintain profitability.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Managing Our Growth</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We have pursued and may continue to pursue acquisitions. Acquisitions could be difficult to integrate, divert the attention of key personnel, disrupt our business, dilute stockholder value and impair our financial results.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As part of our business strategy, we have pursued and intend to continue to pursue acquisitions of complementary businesses, products, services or technologies that we believe could accelerate our ability to compete in our existing markets or allow us to enter new markets. Any of these transactions could be material to our financial condition and results of operations. If we fail to properly evaluate or integrate acquisitions, we may not achieve the anticipated benefits of any such acquisitions, and we may incur costs in excess of what we anticipate. The failure to successfully evaluate and execute acquisitions or otherwise adequately address these risks could materially harm our business and financial results.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Acquisitions also frequently result in the recording of goodwill and other intangible assets which are subject to potential impairments which could harm our financial results. As a result, if we fail to properly evaluate acquisitions or investments, we may not achieve the anticipated benefits of any such acquisitions, and we may incur costs in excess of what we anticipate. The failure to successfully evaluate and execute acquisitions or investments or otherwise adequately address these risks could materially harm our business and financial results.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">56</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Failure to realize the anticipated benefits from our acquisition of Entasis and La Jolla may affect our future results of operations and financial operations.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with our acquisition of Entasis and La Jolla, we have integrated the research and development, commercial operations and personnel into our existing infrastructure. If there are unexpected difficulties in our integration of these acquired businesses, the anticipated benefits of the transaction may not be realized or may take longer to realize than expected. The anticipated benefits of the acquisition could be materially reduced by a number of factors, including but not limited to the following:</span></p>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the future revenue and gross margins of the acquired products may be materially different from those we originally anticipated;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we could incur material unanticipated expenses;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">claims or lawsuits may arise from the acquisition transaction or from their previous business operations;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may experience difficulties in implementing effective internal controls over financial reporting as part of our integration actions; and</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">potential growth, expected financial results, perceived synergies and anticipated opportunities may not be realized through the ongoing integration actions.</span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The occurrence of any or all of these events may have an adverse effect on our business and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we engage in future acquisitions or strategic collaborations, this may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities and subject us to other risks.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From time to time, we may evaluate various acquisitions and strategic collaborations, including licensing or acquiring complementary drugs, intellectual property rights, technologies or businesses, as deemed appropriate to carry out our business plan. Any potential acquisition or strategic collaboration may entail numerous risks, including but not limited to:</span></p>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">increased operating expenses and cash requirements;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the assumption of additional indebtedness or contingent liabilities;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">assimilation of operations, intellectual property and drugs of an acquired company, including challenges associated with integrating new personnel;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the diversion of our management&#8217;s attention from our existing drug programs and initiatives in pursuing such a strategic partnership, merger or acquisition;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">retention of key employees, the loss of key personnel and uncertainties in our ability to maintain key business relationships;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">risks and uncertainties associated with the other party to such a transaction, including the prospects of that party and their existing drugs or drug candidates and regulatory approvals; and</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our inability to generate revenue from acquired technology and/or drugs sufficient to meet our objectives in undertaking the acquisition or even to offset the associated acquisition and maintenance costs.</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">57</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Our Intellectual Property</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we are unable to obtain and maintain patent protection for our technology and product candidates, or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and drugs similar or identical to ours, and our ability to successfully commercialize our technology and product candidates may be adversely affected.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our success depends in large part on our ability to obtain and maintain patent protection in the United States and other countries with respect to our product candidates. We seek to protect our proprietary position by filing patent applications in the United States and abroad related to our technology and product candidates. If we do not adequately protect our intellectual property, competitors may be able to use our technologies and erode or negate any competitive advantage that we may have, which could harm our business and ability to achieve profitability. To protect our proprietary positions, we file patent applications in the United States and abroad related to our novel technologies and product candidates that are important to our business.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The patent application and prosecution process are expensive and time-consuming. We, our current licensees, or any future licensors and licensees may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. We or our current licensees, or any future licensors or licensees may also fail to identify patentable aspects of our research and development before it is too late to obtain patent protection.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Therefore, these and any of our patents and applications may not be prosecuted and enforced in a manner consistent with our best interests. It is possible that defects of form in the preparation or filing of our patents or patent applications may exist, or may arise in the future, such as with respect to proper priority claims, inventorship, claim scope or patent term adjustments. If our current licensees, or any future licensors or licensees, are not fully cooperative or disagree with us as to the prosecution, maintenance or enforcement of any patent rights, such patent rights could be compromised, and we might not be able to prevent third parties from making, using and selling competing products. If there are material defects in the form or preparation of our patents or patent applications, such patents or applications may be invalid and/or unenforceable. Moreover, our competitors may independently develop equivalent knowledge, methods and know-how. Any of these outcomes could impair our ability to prevent competition from third parties.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection. In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of the United States. No consistent policy regarding the breadth of claims allowed in biotechnology and pharmaceutical patents has emerged to date in the United States or in many foreign jurisdictions. For example, European patent law currently restricts the patentability of methods of treatment of the human body more than United States law does. In addition, the determination of patent rights with respect to pharmaceutical compounds and technologies commonly involves complex legal and factual questions, which has in recent years been the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Furthermore, recent changes in patent laws in the United States, including the America Invents Act of 2011, may affect the scope, strength and enforceability of our patent rights or the nature of proceedings that may be brought by us related to our patent rights.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may not be aware of all third-party intellectual property rights potentially relating to our current and future product candidates. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18&#8239;months after filing, or in some cases not at all. Therefore, we cannot be certain that we were the first to make the inventions claimed in our patents or pending patent applications, or that we were the first to file for patent protection of such inventions. Similarly, should we own any patents or patent applications in the future, we may not be certain that we were the first to file for patent protection for the inventions claimed in such patents or patent applications. As a result, the issuance, scope, validity and commercial value of our patent rights cannot be predicted with any certainty. Moreover, we may be subject to a third-party pre-issuance submission of prior art to the U.S. Patent and Trademark Office, or USPTO, or become involved in derivation, ex-parte reexamination, or inter partes review proceedings in the USPTO or similar proceedings elsewhere, challenging our patent rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or product candidates and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. If the breadth or strength of protection provided by our patents and patent applications is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">58</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our pending and future patent applications may not result in patents being issued that protect our technology or product candidates, in whole or in part, or which effectively prevent others from commercializing competitive technologies and products. Even if our patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection against competing products or processes sufficient to achieve our business objectives, prevent competitors from competing with us or otherwise provide us with any competitive advantage. Our competitors may be able to circumvent our owned or licensed patents by developing similar or alternative technologies or products in a non-infringing manner. Our competitors may seek to market generic versions of any approved products by submitting abbreviated new drug applications to the FDA in which they claim that patents owned or licensed by us are invalid, unenforceable and/or not infringed. Alternatively, our competitors may seek approval to market their own products similar to or otherwise competitive with our products. In these circumstances, we may need to defend and/or assert our patents, including by filing lawsuits alleging patent infringement. In any of these types of proceedings, a court or other agency with jurisdiction may find our patents invalid and/or unenforceable.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our owned and licensed patents may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in loss of exclusivity or freedom to operate, a patent being held unenforceable, and/or in one or more or in patent claims being narrowed or invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products or limit the duration of the patent protection of our technology and products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Patents have a limited lifespan. In the U.S., if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest filing date of a non-provisional application to which the patent claims priority. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired for a product candidate, we may be open to competition from competitive medications, including generic medications. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such product candidates might expire before or shortly after such product candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing product candidates similar or identical to ours.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting our candidates might expire before or shortly after our candidates are commercialized. Depending upon the timing, duration and conditions of any FDA marketing approval of our product candidates, one or more of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Amendments, and similar legislation in the European Union, as discussed above. As a result, our revenue from applicable products could be reduced. Further, if this occurs, our competitors may take advantage of our investment in development and trials by referencing our clinical and preclinical data and launch their product earlier than might otherwise be the case, and our competitive position, business, financial condition, results of operations, and prospects could be materially harmed.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may need to license intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A third party may hold intellectual property rights, including patent rights, that are important or necessary to the development of our product candidates. It may be necessary for us to use the patented or proprietary technology of third parties to commercialize our product candidates, in which case we would be required to obtain a license from these third parties. Such a license may not be available on commercially reasonable terms, or at all, and we could be forced to accept unfavorable contractual terms. If we are unable to obtain such licenses on commercially reasonable terms, our business could be harmed.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we are unable to obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have, we may be required to expend significant time and resources to redesign our technology, product candidates, or the methods for manufacturing them or to develop or license replacement technology, all of which may not be feasible on a technical or commercial basis. If we are unable to do so, we may be unable to develop or commercialize the affected technology and product candidates, which could materially harm our business, financial condition, results of operations, and prospects.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">59</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time-consuming and unsuccessful.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Competitors and other third parties may infringe our issued patents, trademarks, copyrights or other intellectual property. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming and divert the time and attention of our management and scientific personnel. Any claims we assert against perceived infringers could provoke these parties to assert counterclaims against us alleging that we infringe their patents, trademarks, copyrights or other intellectual property. In addition, in a patent infringement proceeding, there is a risk that a court will decide that a patent of ours is invalid or unenforceable or that one or more claims of a patent are invalid, in whole or in part, and that we do not have the right to stop the other party from using the invention at issue. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. There is also a risk that, even if the validity of such patents is upheld, the court will construe the patent&#8217;s claims narrowly or decide that we do not have the right to stop the other party from using the invention at issue on the basis that our patents do not cover the invention. An adverse outcome in a litigation or proceeding involving our patents could limit our ability to assert our patents against those parties or other competitors and may curtail or preclude our ability to exclude third parties from making and selling similar or competitive products. Similarly, if we assert trademark infringement claims, a court may determine that the marks we have asserted are invalid or unenforceable, or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In this case, we could ultimately be forced to cease use of such trademarks.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In any infringement litigation, any award of monetary damages we receive may not be commercially valuable. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Moreover, there can be no assurance that we will have sufficient financial or other resources to file and pursue such infringement claims, which typically last for years before they are concluded. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Even if we ultimately prevail in such claims, the monetary cost of such litigation and the diversion of the attention of our management and scientific personnel could outweigh any benefit we receive because of the proceedings. Accordingly, despite our efforts, we may not be able to prevent third parties from infringing, misappropriating or successfully challenging our intellectual property rights. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a negative impact on our ability to compete in the marketplace.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could significantly harm our business.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There is a substantial amount of intellectual property litigation in the biotechnology and pharmaceutical industries, and we may become party to, or threatened with, litigation or other adversarial proceedings regarding intellectual property rights with respect to our technology or product candidates, including interference proceedings before the USPTO. Intellectual property disputes arise in several areas including with respect to patents, use of other proprietary rights and the contractual terms of license arrangements. Third parties may assert claims against us based on existing or future intellectual property rights. The outcome of intellectual property litigation is subject to uncertainties that cannot be adequately quantified in advance.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we are found to infringe a third-party&#8217;s intellectual property rights, we could be forced, including by court order, to cease developing, manufacturing or commercializing the infringing product candidate or product. Alternatively, we may be required to obtain a license from such third party to use the infringing technology and continue developing, manufacturing or marketing the infringing product candidate. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#8217; fees if we are found to have willfully infringed a patent. A finding of infringement could prevent us from commercializing our product candidates or force us to cease some of our business operations. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative effect on our business.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">60</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may not be able to protect our intellectual property rights throughout the world.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States could be less extensive than those in the United States. In some cases, we may not be able to obtain patent protection for certain licensed technology outside the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States, even in jurisdictions where we do pursue patent protection. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, even in jurisdictions where we do pursue patent protection or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Competitors may use our technologies in jurisdictions where we have not pursued and obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our product candidates and preclinical programs and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents, if pursued and obtained, or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to seeking patent and trademark protection for our product candidates, we also rely on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain our competitive position. We seek to protect our trade secrets, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, contract manufacturers, consultants, advisors and other third parties prior to beginning research or disclosing proprietary information. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets. Despite these efforts and the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information due to our reliance on third parties, increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Monitoring unauthorized uses and disclosures of our intellectual property is difficult, and we do not know whether the steps we have taken to protect our intellectual property will be effective. In addition, we may not be able to obtain adequate remedies for any such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moreover, our competitors may independently develop knowledge, methods and know-how equivalent to our trade secrets. Competitors could purchase our products and replicate some or all the competitive advantages we derive from our development efforts for technologies on which we do not have patent protection. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive position would be harmed.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">61</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Regulatory Approval of Our Product Candidates and Other Legal Compliance Matters</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Even if we complete the necessary preclinical studies and clinical trials, the regulatory approval process is expensive, time-consuming and uncertain and may prevent us or any future collaborators from obtaining approvals for the commercialization of some or all of our product candidates. As a result, we cannot predict when or if, and in which territories, we, or any future collaborators, will obtain marketing approval to commercialize a product candidate.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our product candidates and the activities associated with their development and commercialization, including their design, research, testing, manufacture, safety, efficacy, quality control, recordkeeping, labeling, packaging, storage, approval, advertising, promotion, sale, distribution, import, export, and reporting of safety and other post-market information, are subject to comprehensive regulation by the FDA, the EMA and other foreign regulatory agencies. Failure to obtain marketing approval for a product candidate will prevent us or a potential collaborator from commercializing the product candidate. We will rely on third parties to assist us in the process of filing and supporting the applications necessary to gain marketing approvals. Securing marketing approval requires the submission of extensive preclinical and clinical data and supporting information to regulatory authorities for each therapeutic indication to establish the product candidate&#8217;s safety and efficacy. Securing marketing approval also requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities by, the regulatory authorities. Our product candidates may not be effective, may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude our obtaining marketing approval or prevent or limit commercial use. We may not be able to successfully manufacture our products in compliance with applicable requirements such as GMPs. If any of our product candidates receives marketing approval, the accompanying label may limit its approved use more narrowly than we anticipate, which could limit sales of the product.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The process of obtaining marketing approvals, both in the United States and abroad, is expensive and may take many years, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved. Securing marketing approval requires the submission of extensive preclinical and clinical data and supporting information to regulatory authorities for each therapeutic indication to establish the product candidate&#8217;s safety and efficacy. Securing marketing approval also requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities by, the regulatory authorities. The FDA, the EMA or other regulatory authorities may determine that our product candidates are not safe and effective, only moderately effective or have undesirable or unintended side effects, toxicities or other characteristics that preclude us from obtaining marketing approval or prevent or limit commercial use. Any marketing approval we ultimately obtain may be limited or subject to restrictions or post-approval commitments that render the approved product not commercially viable.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, changes in marketing approval policies during the development period, changes in or the enactment of additional statutes or regulations, or changes in regulatory review for each submitted product application, may cause delays in the approval or rejection of an application. Regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that our data is insufficient for approval and require additional preclinical, clinical or other studies. In addition, varying interpretations of the data obtained from preclinical and clinical testing could delay, limit or prevent marketing approval of a product candidate. Any marketing approval we ultimately obtain may be limited or subject to restrictions or post-approval commitments that render the approved product not commercially viable. Any marketing approval that we, or any future collaborators, ultimately obtain may be limited or subject to restrictions or post-approval commitments that render the approved product not commercially viable.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we experience delays in obtaining approval or if we fail to obtain approval of our product candidates, the commercial prospects for our product candidates may be harmed and our ability to generate revenues will be impaired.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">62</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Failure to obtain marketing approval in foreign jurisdictions would prevent certain of our product candidates from being marketed in these territories. Any approval we are granted for our product candidates in the United States would not assure approval of our product candidates in foreign jurisdictions.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To market and sell our products in the European Union, or EU, and any other jurisdictions, we must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can involve additional testing. The time required to obtain approval may differ substantially from that required to obtain approval from the FDA. The regulatory approval process outside the United States generally includes all the risks associated with obtaining approval from the FDA. In addition, in many countries outside the United States, it is required that the product be approved for reimbursement before the product can be approved for sale in that country. We may not obtain approvals from regulatory authorities outside the United States on a timely basis, if at all. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority outside the United States does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA. However, denial of approval in one jurisdiction may impact the ability to obtain approval elsewhere. We may not be able to file for marketing approvals and may not receive necessary approvals to commercialize our products in any market.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Even if we obtain marketing approvals for our product candidates, the terms of approvals and ongoing regulation of our products may limit how we or our collaborators manufacture and market our products and compliance with such requirements may involve substantial resources, which could materially impair our ability to generate revenue.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if marketing approval of a product candidate is granted, an approved product and its manufacturer and marketer are subject to ongoing review and extensive regulation, including the potential requirements to implement a REMS or to conduct costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of the product. We must also comply with requirements concerning advertising and promotion for any of our product candidates for which we obtain marketing approval. Promotional communications with respect to prescription drugs are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the product&#8217;s approved labeling. Thus, we will not be able to promote any products we develop for indications or uses for which they are not approved. In addition, manufacturers of approved products and those manufacturers&#8217; facilities are required to comply with extensive FDA requirements including ensuring that quality control and manufacturing procedures conform to cGMP, which include requirements relating to quality control and quality assurance as well as the corresponding maintenance of records and documentation and reporting requirements, among other things. We and our contract manufacturers could be subject to periodic unannounced inspections by the FDA to monitor and ensure compliance with cGMP. We must also comply with FDA requirements for adverse event reporting for commercial products.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accordingly, assuming we receive marketing approval for one or more of our product candidates, we and our contract manufacturers will continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production, product surveillance and quality control. If we are not able to comply with post-approval regulatory requirements, we could have the marketing approvals for our products withdrawn by regulatory authorities and our ability to market any future products could be limited, which could adversely affect our ability to achieve or sustain profitability. We could also be subject to other civil or criminal penalties. Thus, the cost of compliance with post-approval regulations may have a negative effect on our operating results and financial condition.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Any product candidate for which we obtain marketing approval could be subject to post-marketing restrictions or recall or withdrawal from the market, and we may be subject to penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our product candidates, when and if any of them are approved.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA and other federal and state agencies, including the U.S. DOJ, closely regulate compliance with all requirements governing prescription drug products, including requirements pertaining to marketing and promotion of drugs in accordance with the provisions of the approved labeling and manufacturing of products in accordance with cGMP requirements. The FDA and DOJ impose stringent restrictions on manufacturers&#8217; communications regarding off-label use and if we market our products for indications other than their approved indications, we may be subject to enforcement action for off-label marketing. Violations of such requirements may lead to investigations alleging violations of the Food, Drug and Cosmetic Act and other statutes, including the False Claims Act and other federal and state health care fraud and abuse laws as well as state consumer protection laws.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our failure to comply with all regulatory requirements, and later discovery of previously unknown adverse events or other problems with our products, manufacturers or manufacturing processes, may yield various results, including but not limited to:</span></p>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">litigation involving patients taking our products;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">restrictions on our products, manufacturers or manufacturing processes;</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">63</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">restrictions on the labeling or marketing of a product;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">restrictions on product distribution or use;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">requirements to conduct post-marketing studies or clinical trials;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">warning or untitled letters;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">withdrawal of the products from the market;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">refusal to approve pending applications or supplements to approve applications that we submit;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">recall of products;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">fines, restitution or disgorgement of profits or revenues;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">suspension or withdrawal of marketing approvals;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">damage to relationships with any potential collaborators;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">unfavorable press coverage and damage to our reputation;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">refusal to permit the import or export of our products;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">product seizure; or</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">injunctions or imposition of civil or criminal penalties.</span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Non-compliance by us or any future collaborator with regulatory requirements regarding safety monitoring or pharmacovigilance, and with requirements related to the development of products for the pediatric population, can also result in significant financial penalties. Similarly, failure to comply with regulatory requirements regarding the protection of personal information can also lead to significant penalties and sanctions.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Non-compliance with U.K. and EU requirements regarding safety monitoring or pharmacovigilance, and with requirements related to the development of products for the pediatric population, also can result in significant financial penalties. Similarly, failure to comply with the U.K.&#8217;s or EU&#8217;s requirements regarding the protection of personal information can also lead to significant penalties and sanctions.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our current and future relationships with healthcare professionals, principal investigators, consultants, customers and third-party payors in the United States and elsewhere may be subject, directly or indirectly, to applicable anti-kickback, fraud and abuse, false claims, physician payment transparency, health information privacy and security and other healthcare laws and regulations, which could expose us to penalties.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our current and future arrangements with healthcare professionals, principal investigators, consultants, customers and third-party payors may expose us to broadly applicable fraud and abuse and other healthcare laws, including, without limitation, the federal Anti-Kickback Statute and the federal False Claims Act, that may constrain the business or financial arrangements and relationships through which we research, sell, market and distribute any product candidates for which we obtain marketing approval. In addition, we may be subject to physician payment transparency laws and patient privacy and security regulation by the federal government and by the states and foreign jurisdictions in which we conduct our business. The applicable federal, state and foreign healthcare laws that may affect our ability to operate include the following:</span></p>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, lease, order or recommendation of, any good, facility, item or service, for which payment may be made, in whole or in part, under federal healthcare programs such as Medicare and Medicaid;</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">64</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">federal civil and criminal false claims laws, including the federal False Claims Act, which impose criminal and civil penalties, including through civil whistleblower or </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">qui tam</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> actions, against individuals or entities for, among other things, knowingly presenting, or causing to be presented, to the federal government, including the Medicare and Medicaid programs, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the civil monetary penalties statute, which imposes penalties against any person or entity who, among other things, is determined to have presented or caused to be presented a claim to a federal health program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">HIPAA, which created additional federal criminal and civil statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of whether the payor is public or private, knowingly and willfully embezzling or stealing from a health care benefit program, willfully obstructing a criminal investigation of a health care offense and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">HIPAA, as amended by the HITECH Act of 2009, and their respective implementing regulations, which impose obligations on &#8220;covered entities,&#8221; including certain healthcare providers, health plans, and healthcare clearinghouses, as well as their respective &#8220;business associates&#8221; that create, receive, maintain or transmit individually identifiable health information for or on behalf of a covered entity, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the federal Physician Payments Sunshine Act, created under Section&#8239;6002 of Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, the ACA, and its implementing regulations, which created annual reporting requirements for manufacturers of drugs, devices, biologicals and medical supplies for certain payments and &#8220;transfers of value&#8221; provided to covered recipients, including physicians, as defined by such law, and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members; and</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">analogous state and foreign laws, such as state anti-kickback and false claims laws, which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers; state and foreign laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government or to adopt compliance programs as prescribed by state laws and regulations, or that otherwise restrict payments that may be made to healthcare providers; state and foreign laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures and drug pricing; state and local laws requiring the licensure of pharmaceutical sales representatives; and state and foreign laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Further, the ACA, among other things, amended the intent requirement of the federal Anti-Kickback Statute and certain criminal statutes governing healthcare fraud. A person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it. In addition, the ACA provided that the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">65</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Efforts to ensure that our future business arrangements with third parties will comply with applicable healthcare laws and regulations may involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, including, without limitation, damages, monetary fines, disgorgement, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, additional reporting or oversight obligations if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with the law and curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and pursue our strategy. If any of the physicians or other healthcare providers or entities with whom we expect to do business, including future collaborators, are found not to be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from participation in government healthcare programs, which could also affect our business.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Future legislation, and/or regulations and policies adopted by the FDA, the EMA or comparable regulatory authorities, may increase the time and cost required for us or our collaborators to conduct and complete clinical trials of our current and future product candidates.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA and the EMA have each established regulations to govern the product development and approval process, as have other foreign regulatory authorities. The policies of the FDA, the EMA and other regulatory authorities may change. For example, in December&#8239;2016, the 21st&#8239;Century Cures Act, or Cures Act, was signed into law. The Cures Act, among other things, is intended to modernize the regulation of drugs and spur innovation, but not all its provisions have yet been implemented. Additionally, in August&#8239;2017, the FDA issued final guidance setting forth its current thinking with respect to development programs and clinical trial designs for antibacterial drugs to treat serious bacterial diseases in patients with an unmet medical need. We cannot predict what if any effect the Cures Act or any existing or future guidance from the FDA or other regulatory authorities will have on the development of our product candidates.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recently enacted and future legislation, including relevant provisions of the Inflation Reduction Act, may increase the difficulty and cost for us and our collaborators to obtain marketing approval of and commercialize our product candidates and affect the prices we may obtain.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the United States and some foreign jurisdictions, there have been several legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to profitably sell any product candidates for which we obtain marketing approval.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other federal health reform measures have been proposed and adopted in the United States. For example, the Medicare Access and CHIP Reauthorization Act of 2015 ended the use of the statutory formula for clinician payment and established a quality payment incentive program, also referred to as the Quality Payment Program. This program provides clinicians with two ways to participate, including through the Advanced Alternative Payment Models, or APMs, and the Merit-based Incentive Payment System, or MIPS. In November 2019, CMS issued a final rule finalizing the changes to the Quality Payment Program. It is unclear how payment reductions or the introduction of the Quality Payment Program will impact overall physician reimbursement under the Medicare program. It is also unclear if changes in Medicare payments to providers would impact such providers&#8217; willingness to prescribe and administer our products, if approved.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Further, there has been heightened governmental scrutiny over the way companies set prices for their marketed products. For example, there have been several recent Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and patient programs, and reform government program reimbursement methodologies for drug products. In particular, the recently passed Inflation Reduction Act contains provisions designed to limit the prices paid by Medicare for various prescription drugs.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect that the ACA, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved product. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us or our collaborators from being able to generate revenue, attain profitability, or commercialize our drugs.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">66</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for drugs. We cannot be sure whether additional legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of our product candidates, if any, may be. In addition, increased scrutiny by the U.S. Congress of the FDA&#8217;s approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing testing and other requirements.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our product candidates may be subject to government price controls that may affect our revenue.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There has been heightened governmental scrutiny in the United States and abroad of pharmaceutical pricing practices considering the rising cost of prescription drugs and biologics. In the United States, such scrutiny has resulted in several recent Congressional inquiries and proposed and enacted federal legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. At the federal level, the former Trump Administration&#8217;s budget proposal for fiscal year 2020 contained further drug price control measures that could be enacted during the 2020 budget process or in other future legislation, including, for example, measures to permit Medicare Part&#8239;D plans to negotiate the price of certain drugs under Medicare Part&#8239;B, to allow some states to negotiate drug prices under Medicaid, and to eliminate cost sharing for generic drugs for low-income patients. The former Trump Administration also released a &#8220;Blueprint&#8221;, or plan, to lower drug prices and reduce out-of-pocket costs of drugs that contains additional proposals to increase drug manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products, and reduce the out-of-pocket costs of drug products paid by consumers.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">HHS has solicited feedback on some of these measures and has implemented others under its existing authority. For example, in May 2019, CMS issued a final rule to allow Medicare Advantage plans the option to use step therapy for Part B drugs beginning January 1, 2020. This final rule codified CMS&#8217;s policy change that was effective January 1, 2019. On November 20, 2020, CMS issued an interim final rule through the CMS Innovation Center whereby Medicare Part B reimbursement for &#8220;certain high-cost prescriptions drugs&#8221; would be no more than most-favored-nation price (i.e., the lowest price) after adjustments, for a pharmaceutical product that the drug manufacturer sells in a member country of the Organization for Economic Cooperation and Development that has a comparable per-capita gross domestic product. On December 28, 2020, the United States District Court in Northern California issued a nationwide preliminary injunction against implementation of the interim final rule. While some of these and other measures may require additional authorization to become effective, members of Congress and the new Biden Administration have indicated that they will continue to seek new legislative and/or administrative measures to control drug costs. For example, the recently enacted Inflation Reduction Act contains provisions designed to limit the prices paid by Medicare for various prescription drugs. At the state level, legislatures have become increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Outside of the United States, particularly in the European Union, the pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product. To obtain coverage and reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidate to other available therapies. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be harmed.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to our Alliance with GSK</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Because a portion of our current revenues and near-term projected revenues have historically been derived from products under the GSK Agreements, disputes with GSK could harm our business and cause the price of our securities to fall.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Historically, all of our current and near-term projected revenues have been derived from products under the GSK Agreements. We expect royalties from such products will likely continue to comprise a portion of our revenues in the future. Any action or inaction by either GSK or us that results in a material dispute, allegation of breach, litigation, arbitration, or significant disagreement between the parties may be interpreted negatively by the market or by our investors, could harm our business and cause the price of our securities to fall. Examples of these kinds of issues include but are not limited to non&#8209;performance of contractual obligations and allegations of non&#8209;performance, disagreements over the relative marketing and sales efforts for our partnered products and other GSK respiratory products, disputes over public statements, and similar matters.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">67</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Because GSK is a strategic partner, it may take actions that in certain cases are materially harmful to our business or to our stockholders.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">GSK is a strategic partner with rights and obligations under the GSK Agreements that cause its interests to differ from our interests and those of our stockholders. In particular, GSK has a substantial respiratory product portfolio in addition to the partnered products that are covered by the GSK Agreements. GSK may make respiratory product portfolio decisions or statements about its portfolio which may be, or may be perceived to be, harmful to the respiratory products partnered with us. For example, GSK could promote its non&#8209;GSK/Innoviva respiratory products or a partnered product for which we are entitled to receive a lower percentage of royalties, delay or terminate the development or commercialization of the respiratory programs covered by the GSK Agreements, or take other actions, such as making public statements, that have a negative effect on our stock price. In this regard and by way of example, sales of Advair</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, GSK&#8217;s approved medicine for both COPD and asthma, continue to be significantly greater than sales of RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and GSK has indicated publicly that it intends to continue commercializing Advair</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Also, given the potential future royalty payments which GSK may be obligated to pay under the GSK Agreements, GSK may seek to acquire us in order to reduce those payment obligations. The timing of when GSK may seek to acquire us could potentially be when it possesses information regarding the status of drug programs covered by the GSK Agreements that has not been publicly disclosed and is not otherwise known to us. As a result of these differing interests, GSK may take actions that it believes are in its best interest but which might not be in our best interest or the best interest of our stockholders.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">GSK has also indicated to us that it believes its consent may be required before we can engage in certain royalty monetization transactions with third parties, which may inhibit our ability to engage in these transactions.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">GSK indicated to us that it believes that its consent may be required before we can engage in certain transactions designed to monetize the future value of royalties that may be payable to us from GSK under the GSK Agreements. GSK has informed us that it believes that there may be certain covenants included in these types of transactions that might violate certain provisions of the GSK Agreements. Although we believe that we can structure royalty monetization transactions in a manner that fully complies with the requirements of the GSK Agreements without GSK&#8217;s consent, a third party in a proposed monetization transaction may nonetheless insist that we obtain GSK&#8217;s consent for the transaction or restructure the transaction on less favorable terms. We have obtained GSK&#8217;s agreement that (i) we may grant certain pre&#8209;agreed covenants in connection with monetization of our interests in RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and vilanterol monotherapy, and (ii) it will not unreasonably withhold its consent to our requests to grant other covenants, provided among other conditions, that in each case, the covenants are not granted in favor of a pharmaceutical or biotechnology company with a product either being developed or commercialized for the treatment of respiratory disease. If we seek GSK&#8217;s consent to grant covenants other than pre&#8209;agreed covenants, we may not be able to obtain GSK&#8217;s consent on reasonable terms, or at all. If we proceed with a royalty monetization transaction that is not otherwise covered by the GSK Agreement without GSK&#8217;s consent, GSK could request that its consent be obtained or seek to enjoin or otherwise challenge the transaction as violating or allowing it to terminate the GSK Agreements. Regardless of the merit of any claims by GSK, we would incur significant cost and diversion of resources in defending against GSK&#8217;s claims or asserting our own claims and GSK may seek concessions from us in order to provide its consent. Any uncertainty about whether or when we could engage in a royalty monetization transaction, the potential impact on the enforceability of the GSK Agreements or the loss of potential royalties from the respiratory programs partnered with GSK, could impair our ability to pursue a return of capital strategy for our stockholders ahead of our receipt of significant royalties from GSK, result in significant reduction in the market price of our securities and cause other material harm to our business.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">General Risks Factors</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Unfavorable global economic conditions, whether brought about by material global crises, health epidemics, military conflicts or war, geopolitical and trade disputes or other factors, may adversely affect our business and financial results.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our business is sensitive to global economic conditions, which can be adversely affected by epidemics and other public health crises, political and military conflict, trade and other international disputes, significant natural disasters (including as a result of climate change) or other events that disrupt macroeconomic conditions. Adverse macroeconomic conditions, including inflation, slower growth or recession, new or increased tariffs and other barriers to trade, changes to fiscal and monetary policy or government budget dynamics (particularly in the pharmaceutical and biotech areas), tighter credit, higher interest rates, volatility in financial markets, high unemployment, labor availability constraints, currency fluctuations and other challenges in the global economy have in the past adversely affected, and may in the future adversely affect, us and our business partners and suppliers.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Further, military conflicts or wars (such as the ongoing conflicts between Russia and Ukraine and Israel and Palestine) can cause exacerbated volatility and disruptions to various aspects of the global economy. The uncertain nature, magnitude, and duration of hostilities stemming from such conflicts, including the potential effects of sanctions and counter-sanctions, or retaliatory cyber-attacks on the world economy and markets, have contributed to increased market volatility and uncertainty, which could have an adverse</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">68</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">impact on macroeconomic factors that affect our business and operations, such as worldwide supply chain issues. It is not possible to predict the short and long-term implications of military conflicts or wars or geopolitical tensions which could include further sanctions, uncertainty about economic and political stability, increases in inflation rate and energy prices, cyber-attacks, supply chain challenges and adverse effects on currency exchange rates and financial markets.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, the operations of our suppliers and manufacturers may be located in areas that are prone to earthquakes, wildfires and other natural disasters. Such operations and facilities are also subject to the risk of interruption by drought, power shortages, nuclear power plant accidents and other industrial accidents, terrorist attacks and other hostile acts, ransomware and other cybersecurity attacks, labor disputes, public health crises, and other events beyond the Company&#8217;s control. Global climate change is resulting in certain types of natural disasters occurring more frequently or with more intense effects. Such events can create delays or interruptions to the Company&#8217;s development efforts and inefficiencies in the Company&#8217;s supply and manufacturing chain. Significant delays in our development efforts could materially impact our ability to obtain regulatory approval and to commercialize our products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any public health crisis may affect our operations and those of third parties on which we rely, including our business partners and suppliers. The COVID-19 pandemic has had an adverse impact on the global economy, including as a result of impacts associated with protective health measures that we, other businesses and governments are taking or might have to take again in the future to manage the pandemic.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Without limiting the foregoing, we have experienced and/or may in the future experience:</span></p>
  <div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delays in receiving authorization from regulatory authorities to initiate any planned clinical trials, inspections, reviews and approvals of products;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delays or difficulties enrolling patients in our clinical trials;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delays in or disruptions to the conduct of preclinical programs and clinical trials;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">constraints on the movement of products and supplies through the supply chain, which can disrupt our ability to conduct clinical trials and develop our products;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">price increases in raw materials and capital equipment, as well as increasing price competition in our markets;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">adverse impacts on our workforce and/or key employees; and</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">increased risk that counterparties to our contractual arrangements will become insolvent or otherwise unable to fulfill their contractual obligations.</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">69</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we fail to maintain proper and effective internal control over financial reporting or if the interpretations, estimates or judgments utilized in preparing our financial statements prove to be incorrect, our operating results and our ability to operate our business could be harmed.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Sarbanes-Oxley Act requires, among other things, that we establish and maintain effective internal control over financial reporting and disclosure controls and procedures. Under the SEC&#8217;s current rules, we are required to perform system and process evaluation and testing of our internal control over financial reporting to allow management to report on the effectiveness of our internal control over financial reporting, as required by Section 404 of the Sarbanes-Oxley Act. Our independent registered public accounting firm is also required to report on our internal control over financial reporting. Our testing and our independent registered public accounting firm&#8217;s testing may reveal deficiencies in our internal control over financial reporting that are deemed to be material weaknesses and render our internal control over financial reporting ineffective. We have and expect to continue to incur substantial accounting and auditing expense and to expend significant management time in complying with the requirements of Section 404. If we are not able to maintain compliance with the requirements of Section 404 in a timely manner, or if we or our independent registered public accounting firm identify deficiencies in our internal control over financial reporting that are deemed to be material weaknesses, the market price of our stock could decline and we could be subject to investigations or sanctions by the SEC, FINRA, The Nasdaq Global Select Market or other regulatory authorities. In addition, we could be required to expend significant management time and financial resources to correct any material weaknesses that may be identified or to respond to any regulatory investigations or proceedings.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are also subject to complex tax laws, regulations, accounting principles and interpretations thereof. The preparation of our financial statements requires us to interpret accounting principles and guidance and make estimates and judgments that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenue generated, and expenses incurred during the reporting periods. Our interpretations, estimates and judgments are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for the preparation of our financial statements. U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) presentation is subject to interpretation by the SEC, the Financial Accounting Standards Board and various other bodies formed to interpret and create appropriate accounting principles and guidance. In the event that one of these bodies disagrees with our accounting recognition, measurement or disclosure or any of our accounting interpretations, estimates or assumptions, it may have a significant effect on our reported results and may retroactively affect previously reported results. The need to restate our financial results could, among other potential adverse effects, result in our incurring substantial costs, affect our ability to timely file our periodic reports until such restatement is completed, divert the attention of our management and employees from managing our business, result in material changes to our historical and future financial results, result in investors losing confidence in our operating results, subject us to securities class action litigation, and cause our stock price to decline.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our employees or third party providers, or employees or third party providers of our portfolio companies may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are exposed to the risk of fraud or other misconduct by employees, third party providers, or employees or third party providers of our portfolio companies. Misconduct by employees, third party providers, or employees or third party providers of our portfolio companies could include intentional failures to comply with applicable regulations, provide accurate information to regulatory authorities, comply with federal and state fraud and abuse laws and regulations, report financial information or data accurately or disclose unauthorized activities to us. In particular, the health care industry is subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. It is not always possible to identify and deter misconduct by employees, third party providers, or employees or third party providers of our portfolio companies, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">70</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We have incurred litigation and may incur additional litigation.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have been subject to various legal proceedings, and, in the future, we may be exposed to, or threatened with, litigation, claims and proceedings incident to the ordinary course of, or otherwise in connection with, our business. In addition, agreements entered into by us sometimes include indemnification provisions which may subject us to costs and damages in the event of a claim against an indemnified third party.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Regardless of the merit of particular claims, litigation may be expensive, time-consuming, disruptive to our operations and distracting to management. In recognition of these considerations, we may enter into agreements or other arrangements to settle litigation and resolve such disputes. No assurance can be given that such agreements can be obtained on acceptable terms or that litigation will not occur. These agreements may also significantly increase our operating expenses.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If one or more legal matters were resolved against us or an indemnified third party in a reporting period for amounts in excess of management&#8217;s expectations, our consolidated financial statements for that reporting period could be materially adversely affected. Further, such an outcome could result in significant compensatory, punitive or trebled monetary damages, disgorgement of revenue or profits, remedial corporate measures or injunctive relief against us that could materially adversely affect our financial condition and operating results.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">While we maintain insurance coverage for certain types of claims, such insurance coverage may be insufficient to cover all losses or all types of claims that may arise.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Failure to comply with the U.S. Foreign Corrupt Practices Act, or &#8220;FCPA&#8221;, as well as the anti-bribery laws of the nations in which we conduct business, could subject us to penalties and other adverse consequences.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are subject to the FCPA, which generally prohibits U.S. companies from engaging in bribery or other prohibited payments to foreign officials for the purpose of obtaining or retaining business and requires companies to maintain accurate books and records and internal controls. In addition, we are subject to the anti-bribery laws of other jurisdictions in which we conduct business. Our employees or other agents may engage in prohibited conduct without our knowledge under our policies and procedures and the FCPA and other anti-bribery laws that we may be subject to for which we may be held responsible. If our employees or other agents are found to have engaged in such practices, we could suffer severe penalties and other consequences that may have a material adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">U.S. federal income tax reform could adversely affect us.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On December 22, 2017, U.S. federal tax legislation, commonly referred to as the Tax Cuts and Jobs Act (TCJA), was signed into law, significantly reforming the U.S. Internal Revenue Code. The TCJA, among other things, includes changes to U.S. federal tax rates, imposes significant additional limitations on the deductibility of interest, allows for the expensing of capital expenditures, puts into effect the migration from a &#8220;worldwide&#8221; system of taxation to a territorial system and modifies or repeals many business deductions and credits.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The TCJA is a complex revision to the U.S. federal income tax laws with disparate and, in some cases, countervailing impacts on different categories of taxpayers and industries, and will require subsequent rulemaking and interpretation in a number of areas. The long-term impact of the TCJA on the overall economy, the industries in which we operate and our partners business cannot be reliably predicted at this early stage of the new law&#8217;s implementation. There can be no assurance that the TCJA will not negatively impact our operating results, financial condition, and future business operations. The estimated impact of the TCJA is based on our management&#8217;s current knowledge and assumptions, following consultation with our tax advisors, and recognized impacts could be materially different from current estimates based on our actual results and our further analysis of the new law. The impact of the TCJA on holders of common stock is uncertain and could be materially adverse. This Annual Report does not discuss any such tax legislation or the manner in which it might affect investors in common stock. Investors should consult with their own tax advisors with respect to such legislation and the potential tax consequences of investing in common stock.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">71</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are subject to evolving and complex tax laws, which may result in additional liabilities and affect our results of operations.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are subject to income taxes in the U.S. and other jurisdictions, and in the course of our business, we make judgments about the expected tax treatment of various transactions and events. Changes in tax laws, regulations, administrative practices, principles, and interpretations, as well as events that differ from our expectations, have affected and may adversely affect our effective tax rates, cash flows, and/or results of operations. Significant uncertainty currently exists regarding tax proposals introduced by the U.S., including modifications to certain aspects of the Tax Cuts and Jobs Act of 2017, such as the potential repeal or deferral of the provision requiring capitalization of research and development expenses. In addition, tax authorities in the U.S. and other jurisdictions in which we do business routinely examine our tax returns and are intensifying their scrutiny and examinations of profit allocations among jurisdictions, which could unfavorably impact our results of operations. Further actions taken with respect to tax-related matters by associations such as the Organization for Economic Co-operation and Development and the European Commission could influence tax laws in countries in which we operate. Modifications to key elements of the current U.S. or international tax framework could have a significant impact on our effective tax rate, results of operations, and cash flows.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The widespread outbreak of an illness or any other communicable disease, or any other public health crisis, could adversely affect our business, results of operations and financial condition.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The outbreak of COVID-19 has negatively impacted the global economy, disrupted global supply chains, and created significant volatility and disruption of financial markets. The Company is closely monitoring developments related to the COVID-19 pandemic to assess its impact on the Company&#8217;s business. It is possible that an extended period of global supply chain and economic disruption resulting from the COVID-19 pandemic could materially affect our results of operations and financial condition.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Under the Services Agreement with Sarissa Capital, we may rely on Sarissa Capital to assist in our strategic investing activity.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On December 11, 2020, we entered into the Services Agreement pursuant to which Sarissa Capital provides substantial assistance to us in connection with our acquisition strategy. Pursuant to the terms of the Services Agreement, and subject to the limitations set forth therein, Sarissa Capital will, among other things: (i) assist Innoviva in the development of an overall acquisition and investment process and strategy; (ii) advise Innoviva on market trends, market dynamics and merger and acquisition activity; (iii) identify potential transaction targets; (iv) assist in due diligence of transaction targets and the negotiation and execution of transactions; (v) advise on the growth and operational plans, performance and integration of target companies once an investment or acquisition is made; and (vi) assist in the identification of director and officer candidates for target companies. The services are provided by Sarissa Capital personnel and we have limited or no ability to control the manner upon which the services are provided. In the event that Sarissa Capital fails to adequately perform the required services, our investment activity operations and financial performance may be negatively impacted.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our investment into the Partnership, managed by Sarissa Capital, could subject us to various risks and uncertainties, any of which could impact our investment results and could materially and adversely affect our business, financial condition and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Historically, we have invested our cash reserves in short-term investments and marketable securities, primarily corporate notes, government securities, government agencies, and commercial papers. On December 11, 2020, we entered into the Partnership Agreement and invested $300 million of our cash reserves to be managed by Sarissa Capital as the investment manager to the Partnership.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">While we expect that a portion of our revenues will continue to be derived from our royalty management business and the sales of our products, as a result of this investment, we may derive a material portion of our income from assets managed by Sarissa Capital. The investment strategy of Sarissa Capital will focus on a concentrated portfolio of &#8220;long&#8221; positions in publicly or privately traded securities (debt or equity) and derivatives of, and other financial instruments related to, each of the foregoing, specifically in the areas of healthcare, pharmaceuticals and biotechnology. The risks associated with this investment strategy may be substantially greater than the risks associated with traditional fixed-income investment strategies or other low-yield strategies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have limited rights to remove the general partner of the Partnership and do not have any right to participate in the management of the Partnership or the investment activity of Sarissa Capital. We are solely dependent on Sarissa Capital&#8217;s management of our investment in the Partnership. We cannot provide assurance that Sarissa Capital will be successful in meeting our investment objectives. Unexpected market volatility or losses in the Partnership&#8217;s securities portfolio could significantly and negatively affect our investment in the Partnership and therefore our investment results, financial condition or results of operations.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">72</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The Partnership Agreement limits our ability to withdraw our invested funds from the Partnership.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the terms of the Partnership Agreement, subject to limited exceptions, we are able to make annual withdrawals subject to 25% gating provision such that we would receive our entire account in the Partnership over four fiscal quarters. Therefore, we are limited in our ability to obtain liquidity with respect to those funds and are further subjects to market fluctuations with respect thereto, particularly given the expected concentrated nature of the Partnership&#8217;s portfolio.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sarissa Capital intends to continue to manage other third party capital and is not required to dedicate any minimum amount of time to the Partnership.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to managing the Partnership, Sarissa Capital, its principals and their affiliates may engage in investment and trading activities for their own accounts and/or for the accounts of third parties and is not required to afford the Partnership exclusivity or priority with respect to investment or trading activities. Affiliates of Sarissa Capital manage and expect to continue to manage other client accounts which have objectives similar to the Partnership. The Partnership Agreement does not include any specific obligations or requirements concerning allocation of time, effort or investment opportunities to us or impose any restriction on the nature or timing of investments for accounts that Sarissa Capital or its affiliates may manage.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The price of our securities has been volatile and may continue to be so, and purchasers of our securities could incur substantial losses.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The price of our securities has been volatile and may continue to be so. Between January 1, 2023 and December 31, 2023, the high and low sales prices of our common stock as reported on The Nasdaq Global Select Market varied between $10.64 and $16.43 per share. The stock market in general and the market for biotechnology and biopharmaceutical companies in particular have experienced extreme volatility that has often been unrelated to the companies&#8217; operating performance, in particular during the last several years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may be unable to or elect not to return capital to our stockholders.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The payment of, or continuation of, capital returns to stockholders is at the discretion of our Board of Directors and is dependent upon our financial condition, results of operations, capital requirements, execution of our strategic initiatives, general business conditions, tax treatment of capital returns, potential future contractual restrictions contained in our credit agreement and other agreements and other factors deemed relevant by our Board of Directors. Future capital returns may also be affected by, among other factors: our views on potential future capital requirements for investments in acquisitions and our working capital and debt maintenance requirements; legal risks; stock or debt repurchase programs; changes in federal and state income tax laws or corporate laws; and changes to our business model. Our capital return programs may change from time to time, and we cannot provide assurance that we will continue to provide any particular amounts. Our announcement of future capital return programs does not obligate us to repurchase any specific dollar amount of debt or equity or number of shares of common stock. A reduction, suspension or change in our capital return programs could have a negative effect on our stock price.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Anti&#8209;takeover provisions in our charter and bylaws and in Delaware law could prevent or delay a change in control of our company.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Provisions of our Certificate of Incorporation and Bylaws may discourage, delay or prevent a merger or acquisition that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. These provisions include:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">requiring supermajority stockholder voting to effect certain amendments to our Certificate of Incorporation and Bylaws;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">restricting the ability of stockholders to call special meetings of stockholders;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">prohibiting stockholder action by written consent; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">establishing advance notice requirements for nominations for election to the board of directors or for proposing matters that can be acted on by stockholders at meetings.</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">73</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, some provisions of Delaware law may also discourage, delay or prevent someone from acquiring us or merging with us.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The enactment of proposed or future tax legislation may adversely impact our financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On August 16, 2022, President Biden signed the Inflation Reduction Act, or the IRA. The IRA contains a number of tax related provisions including a 15% minimum corporate income tax on certain large corporations as well as an exercise tax on stock repurchases, both provisions are effective for tax years beginning after December 31, 2022. We are in the process of evaluating the IRA to determine any impact on our financial condition and results of operations in the future.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1b_unresolved_staff_comments"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM 1B.   UNRESOLVED STAFF COMMENTS</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;" id="item_1c_cybersecurity"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM 1C.   CYBERSECURITY</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risk Management and Strategy</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have established policies and processes for assessing, identifying, and managing material risk from cybersecurity threats, and have integrated these processes into our overall risk management systems and processes. We routinely assess material risks from cybersecurity threats, including any potential unauthorized occurrence on or conducted through our information systems that may result in adverse effects on the confidentiality, integrity, or availability of our information systems or any information residing therein.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We conduct risk assessments to identify cybersecurity threats at least annually, as well as assessments in the event of a material change in our business practices that may affect information systems that are vulnerable to such cybersecurity threats.  These risk assessments include identification of reasonably foreseeable internal and external risks, the likelihood and potential damage that could result from such risks, and the sufficiency of existing policies, procedures, systems, and safeguards in place to manage such risks.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Following these risk assessments, we re-design, implement, and maintain reasonable safeguards to minimize identified risks; reasonably address any identified gaps in existing safeguards; and regularly monitor the effectiveness of our safeguards.  We devote internal and external resources and designate high-level personnel to manage the risk assessment and mitigation process.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As part of our overall risk management system, we monitor and test our safeguards and train our employees on these safeguards, in collaboration with human resources, IT, legal, and management. Personnel at all levels and departments are made aware of our cybersecurity policies through trainings.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We engage internal auditors and other third parties in connection with our risk assessment processes. These service providers assist us in designing and implementing our cybersecurity policies and procedures, as well as to monitor and test our safeguards.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the year ended December 31, 2023, we did not identify any risks from known cybersecurity threats, including because of any prior cybersecurity incidents, that have materially affected us. However, in the future, we may face certain ongoing cybersecurity risks or threats that, if realized, are reasonably likely to materially affect us. Additional information on cybersecurity risks we face is discussed in Part I, Item 1A, &#8220;Risk Factors,&#8221; under the heading &#8220;Our operations could be disrupted by failure of our information systems or cyber-attacks.&#8221; <br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Governance</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">One of the key functions of our board of directors is informed oversight of our risk management process, including risks from cybersecurity threats. Our board of directors is responsible for monitoring and assessing strategic risk exposure, and our executive officers are responsible for the day-to-day management of the material risks we face. Our board of directors administers its cybersecurity risk oversight function directly as a whole, as well as through the audit committee.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our executive team, primarily consisting of Chief Accounting Officer, Chief Financial Officer, and Chief Executive Officer, in conjunction with our information security team and third-party consultants, is primarily responsible in assessing and managing our material risks from cybersecurity threats. The qualifications of our executive and information security teams include a combination of formal education, current trainings and certifications in systems, network, and cybersecurity and over 50 years of combined experience in information technology and cybersecurity matters.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">74</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">They oversee our cybersecurity policies and processes, including those described in &#8220;Risk Management and Strategy&#8221; above.  The processes by which the executive team is informed about and monitors the prevention, detection, mitigation, and remediation of cybersecurity incidents includes the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">They provide briefings to the audit committee regarding our company&#8217;s cybersecurity risks and activities, including any recent cybersecurity incidents and related responses, cybersecurity systems testing, activities of third parties, and the like.  </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, they provide briefings of any significant cybersecurity matters to the board of directors as well as an annual update of cybersecurity risks and activities.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;" id="item_2_properties"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM 2.   PROPERTIES</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our headquarters consist of a lease of 2,111 square feet of office space in Burlingame, California, which expires in December 2027. Our other material leased property is a combination of office space and laboratory facility of approximately 20,000 square feet located in Waltham, Massachusetts, which expires in December 2025. We believe that these facilities are sufficient for our current operational needs and that suitable additional space will be available on commercially reasonable terms to accommodate expansion of our operations, if necessary.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;" id="item_3_legal_proceedings"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM 3.   LEGAL PROCEEDINGS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information called for by this Item is incorporated herein by reference in Item 8. &#8220;Financial Statements and Supplementary Data,&#8221; Note 13. &#8220;Commitments and Contingencies&#8221;.</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;" id="item_4_mine_safety_disclosures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM 4.   MINE SAFETY DISCLOSURES</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Not applicable.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">75</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:center;" id="part_ii"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PART II</span></p>
  <p style="text-indent:-9.17%;padding-left:8.4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;" id="item_5_market_for_registrant_s_common"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM 5.   MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Market Information</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our common stock was traded on Nasdaq under the symbol &#8220;THRX&#8221; from October 5, 2004 until January 8, 2016. Upon changing our corporate name to Innoviva, Inc. on January 7, 2016, we changed the stock ticker symbol to &#8220;INVA&#8221; effective January 11, 2016.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Holders</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of February 14, 2024, there were 63 stockholders of record of our common stock. As many of our shares of common stock are held by brokers and other institutions on behalf of stockholders, we are unable to estimate the total number of stockholders represented by these record holders.3</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Dividends</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have not paid any cash dividends on our common stock since September 30, 2015. The payment of cash dividends in the future will be dependent upon our revenues and earnings, capital requirements and general financial condition. The payment of any cash dividends will be within the discretion of our board of directors at such time. In addition, our board of directors is not currently contemplating and does not anticipate declaring any stock dividends in the foreseeable future. Further, our ability to declare dividends may be limited by restrictive covenants contained in any of our existing or future indebtedness.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Securities Authorized for Issuance Under Equity Compensation Plans</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Securities Authorized for Issuance Under Equity Compensation Plans: See Part III, Item 12 of this Form 10-K for additional information required.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Purchases of Equity Securities by the Issuer</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table reflects share repurchases of our common stock for the three months ended December 31, 2023:</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:38.308%;"/>
    <td style="width:1.38%;"/>
    <td style="width:1%;"/>
    <td style="width:12.002%;"/>
    <td style="width:1%;"/>
    <td style="width:1.84%;"/>
    <td style="width:1%;"/>
    <td style="width:11.542%;"/>
    <td style="width:1%;"/>
    <td style="width:1.38%;"/>
    <td style="width:1%;"/>
    <td style="width:12.162%;"/>
    <td style="width:1%;"/>
    <td style="width:1.84%;"/>
    <td style="width:1%;"/>
    <td style="width:11.542%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Period</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total Number of Shares Purchases</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Average Price Paid per Share</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs </span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;min-width:fit-content;">(1)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Approximate Dollar Value of Shares That May Yet Be Purchased Under the Plans or Programs </span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;min-width:fit-content;">(1)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">October 1, 2023 to October 31, 2023</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">556,406</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13.07</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">556,406</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23,131,237</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">November 1, 2023 to November 30, 2023</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">287,723</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13.61</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">287,723</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19,215,246</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">December 1, 2023 to December 31, 2023</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">277,706</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15.14</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">277,706</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,011,394</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,121,835</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13.72</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,121,835</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;min-width:3.333%;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On October 31, 2022, the Board of Directors of Innoviva authorized and approved a stock repurchase program pursuant to which we may purchase up to $100.0 million of our outstanding common stock. The timing and amount of any share repurchases under the share repurchase program will be determined by Innoviva&#8217;s management in its discretion based on ongoing assessments of the capital needs of the business, the market price of Innoviva&#8217;s common stock, prevailing stock prices, general market conditions and other considerations. Share repurchases under the program may be made through a variety of methods, which may include open market purchases, privately negotiated transactions, in block trades, accelerated share repurchase transactions, exchange transactions, or any combination thereof or by other means in accordance with federal securities laws. This program has no termination date, may be suspended or discontinued at any time at the Company&#8217;s discretion and does not obligate the Company to acquire any amount of common stock.</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">76</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock Performance Graph</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The graph set forth below compares the cumulative total stockholder return on our common stock for the period commencing on December 31, 2018 and ending on December 31, 2023, with the cumulative total return of (i) the Nasdaq Composite Index, (ii) the Nasdaq S&amp;P Small Cap 600 Pharma Index and (iii) the Nasdaq Biotechnology Index over the same period. This graph assumes the investment of $100.00 on December 31, 2017 in each of (1) our common stock, (2) the Nasdaq Composite Index, (3) the Nasdaq S&amp;P Small Cap 600 Pharma Index and (4) the Nasdaq Biotechnology Index, and assumes the reinvestment of dividends.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The comparisons shown in the graph below are based upon historical data. We caution that the stock price performance shown in the graph below is not necessarily indicative of, nor is it intended to forecast, the potential future performance of our common stock. Information used in the graph was obtained from sources believed to be reliable including Nasdaq, Bloomberg and Reuters, but we are not responsible for any errors or omissions in such information.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding anything to the contrary set forth in any of our previous or future filings under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, that might incorporate this Annual Report on Form 10&#8209;K or future filings made by us under those statutes, this Stock Performance Graph section shall not be deemed filed with the SEC and shall not be deemed incorporated by reference into any of those prior filings or into any future filings made by us under those statutes.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">COMPARISON OF 5 YEAR CUMULATIVE TOTAL RETURN*</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Among Innoviva, Inc., the Nasdaq Composite Index, Nasdaq Biotechnology Index, and Nasdaq S&amp;P Small Cap 600 Pharma Index.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img11953243_20.jpg" alt="img11953243_20.jpg" style="width:688px;height:406px;"/>&#160;</p>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">*    $100 invested on December 31, 2018 in stock or index, including reinvestment of dividends.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;" id="item_6_selected_financial_data"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM 6.   [</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Reserved]</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">77</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:-9.17%;padding-left:8.4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;" id="item_7_management_s_discussion_and"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM 7.   MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Management&#8217;s Discussion and Analysis (&#8220;MD&amp;A&#8221;) is intended to facilitate an understanding of our business and results of operations. This discussion and analysis should be read in conjunction with our consolidated financial statements and notes included in this Annual Report on Form 10&#8209;K. The information contained in this discussion and analysis or set forth elsewhere in this Annual Report on Form 10&#8209;K, including information with respect to our plans and strategy for our business, our operating expenses, and future payments under our collaboration agreements, includes forward&#8209;looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements are based upon current expectations that involve risks and uncertainties. You should review the section entitled &#8220;Risk Factors&#8221; in Item 1A of Part I above for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward&#8209;looking statements contained in the following discussion and analysis. See the section entitled &#8220;Special Note Regarding Forward Looking Statements&#8221; above for more information.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Management Overview</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Innoviva, Inc. (and where context requires, together with its subsidiaries referred to as &#8220;Innoviva&#8221;, the &#8220;Company&#8221;, the &#8220;Registrant&#8221; or &#8220;we&#8221; and other similar pronouns) is a company with a portfolio of royalties and innovative healthcare assets. We currently have three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our royalty portfolio contains respiratory assets partnered with Glaxo Group Limited (&#8220;GSK&#8221;), including RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (fluticasone furoate/vilanterol, &#8220;FF/VI&#8221;) and ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (umeclidinium bromide/vilanterol, &#8220;UMEC/VI&#8221;), and up until July 2022, TRELEGY</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (the combination FF/UMEC/VI). We sold our 15% ownership interest in Theravance Respiratory Company, LLC (&#8220;TRC&#8221;) on July 20, 2022, and are no longer entitled to receive royalties on sales of TRELEGY</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> products. Under the Long&#8209;Acting Beta2 Agonist (&#8220;LABA&#8221;) Collaboration Agreement, Innoviva is entitled to receive royalties from GSK on sales of RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> as follows: 15% on the first $3.0 billion of annual global net sales and 5% for all annual global net sales above $3.0 billion; and royalties from the sales of ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> which tier upward at a range from 6.5% to 10%.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expanded our portfolio through the acquisition of Entasis Therapeutics Holdings Inc. (&#8220;Entasis&#8221;) on July 11, 2022 and the acquisition of La Jolla Pharmaceutical Company (&#8220;La Jolla&#8221;) on August 22, 2022. Following the acquisitions, our commercial and marketed products include GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock, and XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (eravacycline) approved for the treatment of complicated intra-abdominal infections in adults. Our new commercial and marketed product, XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (formerly known as sulbactam-durlobactam or SUL-DUR), was approved by the United States Food and Drug Administration (&#8220;FDA&#8221;) on May 23, 2023 for the treatment of hospital-acquired and ventilator-associated pneumonias caused by </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Acinetobacter</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in adults. We commenced commercial sales of XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in the third quarter of 2023. Our development pipeline includes zoliflodacin, an investigational treatment for uncomplicated gonorrhea that reported positive data in a pivotal Phase 3 clinical trial on November 1, 2023. As such, we have a wholly owned robust critical care and infectious disease operating platform with hospital focus.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, we own other strategic healthcare assets, such as a large equity stake in Armata Pharmaceuticals (&#8220;Armata&#8221;), a leader in development of bacteriophage with potential use across a range of infectious and other serious diseases. We also have economic interests in other healthcare companies.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our focus on capital allocation and shareholder value maximization has led our company to a meaningful transformation, and 2023 was a significant transition year. In 2022 our financials contained royalty revenues from TRELEGY</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> which was divested mid-year in an economically accretive transaction. Additionally, our acquisition and integration of operating companies further changed the structure of our financials compared to prior years. Through these changes, we believe we are well-positioned to create significant long-term shareholder value.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our company structure and organization are tailored to our focused activities of managing our respiratory assets partnered with GSK, commercializing our marketed products, developing of our product candidates, optimizing capital allocation, and providing for certain essential reporting and management functions of a public company. As of December 31, 2023, we had 112 employees.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial Highlights</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Royalty revenue: Fourth quarter 2023 gross royalty revenue from GSK was $69.6 million and full year was $252.7 million, compared to $54.7 million for the fourth quarter of 2022 and $253.4 million for the full year 2022.</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">78</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net Product Sales: Fourth quarter 2023 net product sales and license revenue were $19.7 million, which included $13.1 million from GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, $5.2 million from XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and $1.4 million from XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, compared to $14.6 million for the fourth quarter of 2022. Full year 2023 net product sales and license revenue was $71.6 million, which included $41.3 million from GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, $17.3 million from XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, $2.0 million from XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and $11.0 million in milestone payments from our partners.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Equity and long-term investments: Fourth quarter and full year 2023 change in fair values of equity and long-term investments of $25.5 million and $88.5 million, respectively, was primarily attributable to Armata share price appreciation.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net income: Fourth quarter 2023 net income was $61.5 million, or $0.97 basic per share, compared to a net loss of $68.3 million, or $(0.98) basic per share, for the fourth quarter 2022, driven primarily by higher revenue and positive impact of change in fair values of equity. Full year 2023 net income was $179.7 million, or $2.75 basic per share, compared to net income of $213.9 million, or $3.07 basic per share, for the full year 2022.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Share repurchase: During the fourth quarter 2023, Innoviva repurchased 1,121,835 shares of its outstanding common stock for $15.4 million. During the year 2023, Innoviva repurchased 6,173,565 shares of its outstanding common stock for $76.5 million. Approximately $15 million of the authorized program remains outstanding as of year-end.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash and cash equivalents: Totaled $193.5 million. Royalty and net product sales receivables totaled $84.1 million as of December 31, 2023.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Key 2023 R&amp;D Highlights</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Zoliflodacin: potential first-in-class oral antibiotic to treat uncomplicated gonorrhea</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.989278055754109%;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2023, in collaboration with The Global Antibiotic Research &amp; Development Partnership (GARDP), Innoviva announced that zoliflodacin, a first-in-class antibiotic, met its primary endpoint in a global pivotal phase 3 clinical trial for the treatment of uncomplicated gonorrhea. The Company expects a New Drug Application to be submitted to the U.S. FDA in the next twelve months.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use: targeted antibacterial for HABP/VABP caused by </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Acinetobacter</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.989278055754109%;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In May 2023, the U.S. Food and Drug Administration (FDA) approved XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for use in patients 18 years of age and older for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible isolates of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Acinetobacter baumannii-calcoaceticus</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> complex.</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.989278055754109%;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Earlier in May, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The Lancet Infectious Diseases</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> published detailed results from the pivotal Phase 3 ATTACK trial of sulbactam-durlobactam.</span></div></div>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Update on Strategic Healthcare Assets</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our portfolio of strategic assets under the Company&#8217;s various subsidiaries was valued at $561.0 million as of December 31, 2023. In fourth quarter 2023, Innoviva invested an additional $5.0 million in one of our assets, Gate Neurosciences, to support its strategy of developing next generation targeted CNS therapies.</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">79</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Collaborative Arrangements with GSK</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">LABA Collaboration</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2002, we entered into the LABA Collaboration Agreement with GSK to develop and commercialize once&#8209;daily LABA products for the treatment of chronic obstructive pulmonary disorder (&#8220;COPD&#8221;) and asthma (the &#8220;LABA Collaboration Agreement&#8221;). For the treatment of COPD, the collaboration has developed three combination products:</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (&#8220;FF/VI&#8221;) (BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> is the proprietary name in the U.S. and Canada and RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> is the proprietary name outside the U.S. and Canada), a once&#8209;daily combination medicine consisting of a LABA, vilanterol (VI), and an inhaled corticosteroid (&#8220;ICS&#8221;), fluticasone furoate (&#8220;FF&#8221;),</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (&#8220;UMEC/VI&#8221;), a once&#8209;daily medicine combining a long&#8209;acting muscarinic antagonist (&#8220;LAMA&#8221;), umeclidinium bromide (&#8220;UMEC&#8221;), with a LABA, vilanterol (VI), and</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">TRELEGY</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (the combination FF/UMEC/VI), a once&#8209;daily combination medicine consisting of an ICS, LAMA and LABA.</span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a result of the launch and approval of RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in the U.S., Japan and Europe, in accordance with the LABA Collaboration Agreement, we paid approval and launch milestone payments to GSK totaling $220.0 million during the year ended December 31, 2014. Although we have no further milestone payment obligations to GSK pursuant to the LABA Collaboration Agreement, we continue to have ongoing commercialization activities under the LABA Collaboration Agreement, including participation in the joint steering committee that are expected to continue over the life of the agreement. The milestone fees paid to GSK were recognized as capitalized fees, which are being amortized over their estimated useful lives commencing upon the commercial launch of the products.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are entitled to receive royalties from GSK on sales of RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> as follows: 15% on the first $3.0 billion of annual global net sales and 5% for all annual global net sales above $3.0 billion. On sales of ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, royalties are upward tiering and range from 6.5% to 10%. We no longer receive royalties on sales of TRELEGY</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> after we sold our royalty rights along with the sale of our ownership in TRC in July 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As mentioned above, on July 20, 2022, we sold our ownership interest in TRC, which received royalty payments from GSK stemming from sales of TRELEGY</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. We retained our royalty rights with respect to RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Strategic Partnership with Sarissa Capital</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Strategic Advisory Agreement</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On December 11, 2020, we entered into a Strategic Advisory Agreement (the &#8220;Services Agreement&#8221;) with Sarissa Capital Management LP (&#8220;Sarissa Capital&#8221;), pursuant to which Sarissa Capital provides a variety of strategic services to us in order to assist us in the development and execution of our acquisition strategy. The services are provided free of charge to us. Sarissa Capital is considered to be a related party due to its investment in Innoviva&#8217;s common stock and its representation on our board of directors.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Partnership Agreement</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On December 11, 2020, Innoviva Strategic Partners LLC (&#8220;Strategic Partners&#8221;), our wholly owned subsidiary, entered into a subscription agreement (the &#8220;Subscription Agreement&#8221;) and an Amended and Restated Limited Partnership Agreement (the &#8220;Partnership Agreement&#8221;) pursuant to which Strategic Partners became a limited partner of ISP Fund LP (the &#8220;Partnership&#8221;). The general partner of the Partnership (the &#8220;General Partner&#8221;) is an affiliate of Sarissa Capital and, pursuant to an investment management agreement, Sarissa Capital acts as the investment adviser to the Partnership. Strategic Partners made a $300.0 million initial contribution into the Partnership. The Partnership was formed for the purposes of investing in equity securities in the healthcare, pharmaceutical and biotechnology industries. The Partnership Agreement provides for Sarissa Capital to receive a customary one percent management fee from the Partnership, payable quarterly in advance, measured based on the Net Asset Value of Strategic Partners&#8217; capital account in the Partnership. In addition, the General Partner is entitled to a customary 10% annual performance allocation based on the Net Profits of the Partnership during the annual measurement period. The Partnership Agreement includes a lock-up period of thirty-six months after which Strategic Partners is entitled to make withdrawals from the Partnership as of such lock-up expiration date and each anniversary thereafter, subject to certain limitations.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">80</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In May 2021, Strategic Partners received a distribution of $110.0 million from the Partnership to provide funding to Innoviva for a strategic repurchase of Innoviva common shares held by GSK. On March 30, 2022, Strategic Partners made an additional capital contribution of $110.0 million to the Partnership pursuant to the letter agreement entered into between Strategic Partners, the Partnership and Sarissa Capital Fund GP LP on May 20, 2021. The capital contribution is subject to a 36-month lock-up period from the contribution date.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The lock-up period for our initial contribution of $190.0 million expired in December 2023. Strategic Partners did not elect to make a withdrawal in 2023, thereby extending the lock-up period and withdrawal elections into subsequent years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Critical Accounting Policies and Estimates</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our management&#8217;s discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the financial statements, as well as the reported revenue generated and expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. We believe that the accounting policies discussed below are critical to understanding our historical and future performance, as these policies relate to the more significant areas involving management&#8217;s judgments and estimates.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Business Combinations</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> We use the acquisition method of accounting under Accounting Standards Codification (&#8220;ASC&#8221;) Topic 805, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Business Combinations</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Each acquired company&#8217;s operating results are included in our consolidated financial statements starting on the acquisition date. The purchase price is equivalent to the fair value of consideration transferred. Tangible and identifiable intangible assets acquired, liabilities assumed and any noncontrolling interest in the acquiree as of the acquisition date are recorded at the acquisition date fair value. Goodwill is recognized for the excess of purchase price over the net fair value of assets acquired and liabilities assumed.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Amounts allocated to assets and liabilities are based upon fair values. Such valuations require us to make significant estimates and assumptions, especially with respect to the identifiable intangible assets. We make estimates of fair value based upon assumptions believed to be reasonable and that of a market participant. Significant estimates and assumptions may involve projected future revenues, earnings, cash flows, estimated probabilities of certain milestone achievements, discount rates, asset lives, among other items. Our estimates may also impact our deferred tax assets and liabilities. Unanticipated events and circumstances may occur that may affect the accuracy and validity of such assumptions, estimates or actual results. Our estimates are based on available historical information as well as future expectations, and the estimates are inherently uncertain. The separately identifiable intangible assets generally include marketed products, in-process research and development and collaboration agreement.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue Recognition from Royalties</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We recognize the royalty revenue on net sales of products with respect to which we have contractual royalty rights in the period in which the royalties are earned. The net sales reports provided by our partner are based on its methodology and assumptions to estimate rebates and returns, which it monitors and adjusts regularly in light of contractual and legal obligations, historical trends, past experience and projected market conditions. Our partner may make significant adjustments to its sales based on actual results recorded, which could cause our royalty revenue to fluctuate. We conduct periodic royalty audits to evaluate the information provided by our partner. Royalties are recognized net of amortization of capitalized fees associated with any approval and launch milestone payments made to GSK.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">81</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue Recognition from Product Sales</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We started recognizing revenue from product sales as a result of our acquisition of La Jolla. We apply the guidance on principal versus agent considerations under ASC Topic 606, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue from Contracts with Customers</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, to determine the appropriate treatment for the transactions between us and third parties. The classification of transactions under our arrangements is determined based on the nature and contractual terms of the arrangement along with the nature of the operations of the participants. Any consideration related to activities in which we are considered the principal, which includ</span><span style="color:#252525;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">es being in control of the good or service before such good or service is transferred to the customer, are accounted for as product sales.</span><span style="color:#252525;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prior to recognizing any revenue from product sales, we identify the contract, performance obligations, and transaction price, and allocate the transaction price to the performance obligations. Revenue from product sales is recognized when our customers obtain control of the product and is recorded at the transaction price, net of estimates for variable consideration consisting of chargebacks, discounts, returns and rebates. Variable consideration is estimated using the expected-value amount method, which is the sum of probability-weighted amounts in a range of possible consideration amounts. Actual amounts of consideration ultimately received may differ from our estimates. If actual results vary materially from our estimates, we will adjust these estimates, which will affect revenue from product sales and earnings in the period such estimates are adjusted. These items may include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Chargebacks: Chargebacks are discounts we provide to distributors in the event that the sales prices to end users are below the distributors&#8217; acquisition price. This may occur due to a direct contract with a health system, a group purchasing organization (&#8220;GPO&#8221;) agreement or a sale to a government facility. Chargebacks are estimated based on known chargeback rates and recorded as a reduction of revenue on delivery to our customers.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Discounts: We offer customers various forms of incentives and consideration, including prompt-pay and other discounts. We estimate discounts primarily based on contractual terms. These discounts are recorded as a reduction of revenue on delivery to our customers. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Returns: We offer customers a limited right of return, generally for damaged or expired product. We estimate returns based on an internal analysis, which includes actual experience. The estimates for returns are recorded as a reduction of revenue on delivery to our customers. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Rebates: We participate in Medicaid rebate programs, which provide assistance to certain low-income patients based on each individual state&#8217;s guidelines regarding eligibility and services. Under the Medicaid rebate programs, we pay a rebate to each participating state, generally within three months after the quarter in which product was sold. Additionally, we may offer customer incentives and consideration in the form of volume-based or other rebates. The estimates for rebates are recorded as a reduction of revenue on delivery to our customers. </span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We continue to assess our estimates of variable consideration as we accumulate additional historical data and will adjust these estimates accordingly.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Capitalized Fees Paid</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We review our Capitalized Fees for impairment on a product&#8209;by&#8209;product basis for each major geographic area when events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. The recoverability of Capitalized Fees is measured by comparing the asset&#8217;s carrying amount to the expected undiscounted future cash flows that the asset is expected to generate. The determination of recoverability typically requires various estimates and assumptions, including estimating the useful life over which cash flows will occur, their amount, and the asset&#8217;s residual value, if any. We derive the required cash flow estimates from near&#8209;term forecasted product sales and long&#8209;term projected sales in the corresponding market. Based upon our analyses of past, current and future sales and trends, there have been no indicators of impairment and no impairment charges have been recorded on the Capitalized Fees as of December 31, 2023.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">82</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Variable Interest Entities</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The primary beneficiary of a variable interest entity (&#8220;VIE&#8217;) is required to consolidate the assets and liabilities of the VIE. When we obtain a variable interest in another entity, we assess at the inception of the relationship and upon occurrence of certain significant events whether the entity is a VIE and, if so, whether we are the primary beneficiary of the VIE based on our power to direct the activities of the VIE that most significantly impact the VIE&#8217;s economic performance and our obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE. To determine whether a variable interest that we hold could potentially be significant to the VIE, we consider both qualitative and quantitative factors regarding the nature, size and form of our involvement with the VIE.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To assess whether we have the power to direct the activities of a VIE that most significantly impact the VIE&#8217;s economic performance, we consider all the facts and circumstances, including our role in establishing the VIE and our ongoing rights and responsibilities. This assessment includes identifying the activities that most significantly impact the VIE&#8217;s economic performance and identifying which party, if any, has power over those activities. In general, the parties that make the most significant decisions affecting the VIE (management and representation on the Board of Directors) and have the right to unilaterally remove those decision-makers are deemed to have the power to direct the activities of a VIE.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To assess whether we have the obligation to absorb losses of the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE, we consider all of our economic interests that are deemed to be variable interests in the VIE. This assessment requires us to apply judgment in determining whether these interests, in the aggregate, are considered potentially significant to the VIE.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Equity and Long-Term Investments</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our investments in Armata include a convertible note (the &#8220;Armata Convertible Note&#8221;) and a term loan (the &#8220;Armata Term Loan&#8221;), both of which are classified as Level 3 financial instruments. The Armata Convertible Note is measured at fair value using a Monte Carlo simulation model with the probability of certain qualified events and the assumptions of risk-free rate, volatility of stock price and timing of certain qualified events. We measure the Armata Term Loan at fair value using an income approach based on the discounted value of expected future cash flows.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Level 3 financial instruments include the Gate Neurosciences Inc. (&#8220;Gate&#8221;) convertible promissory note and private placement positions held by ISP Fund LP as these securities are not publicly traded and the assumptions used in the valuation model for valuing these securities are based on significant unobservable and observable inputs including those of publicly traded peer companies. We measure the Gate convertible promissory note at fair value using a Monte Carlo simulation model with the probability of certain qualified events and the assumptions of equity value of Gate, risk-free rate, expected stock price, volatility of its peer companies, and the time until a financing is raised. Valuations models applied for the private placement positions held by ISP Fund LP may include the Black-Scholes-Merton pricing model, the Monte Carlo simulation model and other applicable valuation models. Key assumptions involve inputs to the Black-Scholes-Merton pricing model, probability rates of certain events and scenarios applied in the Monte Carlo simulation model and discount rates, as appropriate. </span><span style="color:#252525;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Monte Carlo simulation model also incorporates assumptions made based on transaction details such as the security&#8217;s stock price, the expected term, maturity, risk-free interest rates and dividend yield, as well as volatility.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We also hold preferred stock warrants in InCarda Therapeutics Inc. (&#8220;InCarda&#8221;), a privately held, clinical-stage biopharmaceutical company. The preferred stock warrants are classified as Level 3 financial instruments and recorded at fair value subject to remeasurement at each balance sheet date. We use the Black-Scholes-Merton pricing model to estimate the fair value of the warrants with the following input assumptions: the exercise price of the warrants, the risk-free interest rate computed based on the U.S. Treasury yield, the remaining contractual term as the expected term, and the expected stock price volatility calculated based on the historical volatility of the common stock of its public peer companies. As of December 31, 2023, the fair value of these warrants was minimal.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">83</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Factors Affecting Comparability</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Our historical financial condition and results of operations for the periods presented may not be comparable, either between periods or going forward due to the factors described below.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Adoption of Accounting Standards Update (&#8220;ASU&#8221;) 2020-06 effective January 1, 2022;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accounting consolidation of Entasis on February 17, 2022 and purchase of remaining minority interest in Entasis on July 11, 2022; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Sale of our 15% ownership interest in TRC on July 20, 2022; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Acquisition of La Jolla on August 22, 2022.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Refer to Note 12, &#8220;Debt&#8221;, to the Consolidated Financial Statements for more information related to the adoption of ASU 2020-06. Refer to Note 5, &#8220;Consolidated Entities and Acquisitions&#8221;, to the Consolidated Financial Statements for more information related to our acquisitions of Entasis and La Jolla and the sale of our ownership interest in TRC.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Results of Operations</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Net Revenue</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Royalty Revenue</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Total royalty revenue, net, as compared to the prior years, was as follows:</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:28.743%;"/>
    <td style="width:1.201%;"/>
    <td style="width:1%;"/>
    <td style="width:6.968%;"/>
    <td style="width:1%;"/>
    <td style="width:1.201%;"/>
    <td style="width:1%;"/>
    <td style="width:6.968%;"/>
    <td style="width:1%;"/>
    <td style="width:1.201%;"/>
    <td style="width:1%;"/>
    <td style="width:6.968%;"/>
    <td style="width:1%;"/>
    <td style="width:1.201%;"/>
    <td style="width:1%;"/>
    <td style="width:6.727%;"/>
    <td style="width:1%;"/>
    <td style="width:1.001%;"/>
    <td style="width:1%;"/>
    <td style="width:7.448%;"/>
    <td style="width:1%;"/>
    <td style="width:1.201%;"/>
    <td style="width:1%;"/>
    <td style="width:6.727%;"/>
    <td style="width:1%;"/>
    <td style="width:1.001%;"/>
    <td style="width:1%;"/>
    <td style="width:7.448%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Change</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">$</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">%</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">$</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">%</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Royalties &#8211; RELVAR/BREO</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">208,042</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">215,034</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">234,066</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(6,992</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(3</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(19,032</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(8</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Royalties &#8211; ANORO</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">44,627</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">38,405</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">44,935</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,222</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(6,530</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(15</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Royalties &#8211; TRELEGY</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">72,029</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">126,688</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(72,029</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(100</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(54,659</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(43</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total royalties</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">252,669</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">325,468</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">405,689</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(72,799</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(22</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(80,221</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(20</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: amortization of capitalized<br/>&#160;&#160;&#160;fees paid</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(13,823</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(13,823</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(13,823</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">*</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">*</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total net royalty revenue</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">238,846</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">311,645</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">391,866</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(72,799</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(23</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(80,221</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(20</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
   </tr>
  </table>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">*    Not Meaningful</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Total royalty revenue, net, decreased to $238.8 million for the year ended December 31, 2023, compared to $311.6 million for the year ended December 31, 2022. The decrease in total net royalty revenue was primarily due to the sale of our ownership interest in TRC, which received royalties stemming from sales of TRELEGY</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Total royalty revenue, net, decreased to $311.6 million for the year ended December 31, 2022, compared to the year ended December 31, 2021. The decrease in total net royalty revenue was primarily due to the sale of our ownership interest in TRC, which received royalties stemming from sales of TRELEGY</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Royalties for RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">decreased due to pricing pressures in the U.S. market and foreign currency rate changes.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net Product Sales</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net product sales for the year ended December 31, 2023 was $60.6 million, consisting of net sales of GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for $41.3 million, $17.3 million, and $2.0 million, respectively. We derived approximately 91% of our net product sales for the same period from customers located in the U.S. and 9% from the rest of the world.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net product sales we recognized from the date of acquisition of La Jolla, which occurred on August 22, 2022, to December 31, 2022 was $19.7 million, consisting of net sales of GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for $14.2 million and $5.5 million, respectively. We derived approximately 96% of our net product sales for the same period from customers located in the U.S. and 4% from the rest of the world.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">84</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">License Revenue</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We recognized $8.0 million in license revenue for the year ended December 31, 2023 as a result of achievement of a regulatory milestone under our license agreement with Everest. We also recognized $3.0 million in license revenue as a result of achievement of a regulatory milestone under our license and collaboration agreement with Zai Lab.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research &amp; Development</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development expenses, as compared to the prior year period, were as follows:</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:26.156%;"/>
    <td style="width:1.101%;"/>
    <td style="width:1%;"/>
    <td style="width:7.446%;"/>
    <td style="width:1%;"/>
    <td style="width:1.101%;"/>
    <td style="width:1%;"/>
    <td style="width:7.446%;"/>
    <td style="width:1%;"/>
    <td style="width:1.101%;"/>
    <td style="width:1%;"/>
    <td style="width:7.446%;"/>
    <td style="width:1%;"/>
    <td style="width:1.101%;"/>
    <td style="width:1%;"/>
    <td style="width:7.086%;"/>
    <td style="width:1%;"/>
    <td style="width:1.001%;"/>
    <td style="width:1%;"/>
    <td style="width:7.926%;"/>
    <td style="width:1%;"/>
    <td style="width:1.101%;"/>
    <td style="width:1%;"/>
    <td style="width:7.446%;"/>
    <td style="width:1%;"/>
    <td style="width:1.101%;"/>
    <td style="width:9.446%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="13" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Change</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="5" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">$</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">%</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">$</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">33,922</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">41,432</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">576</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(7,510</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(18</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">40,856</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">*</span></p></td>
   </tr>
  </table>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">*    Not Meaningful</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development expenses consisted of the following:</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:26.156%;"/>
    <td style="width:1.101%;"/>
    <td style="width:1%;"/>
    <td style="width:7.446%;"/>
    <td style="width:1%;"/>
    <td style="width:1.101%;"/>
    <td style="width:1%;"/>
    <td style="width:7.446%;"/>
    <td style="width:1%;"/>
    <td style="width:1.101%;"/>
    <td style="width:1%;"/>
    <td style="width:7.446%;"/>
    <td style="width:1%;"/>
    <td style="width:1.101%;"/>
    <td style="width:1%;"/>
    <td style="width:7.086%;"/>
    <td style="width:1%;"/>
    <td style="width:1.001%;"/>
    <td style="width:1%;"/>
    <td style="width:7.926%;"/>
    <td style="width:1%;"/>
    <td style="width:1.101%;"/>
    <td style="width:1%;"/>
    <td style="width:7.446%;"/>
    <td style="width:1%;"/>
    <td style="width:1.101%;"/>
    <td style="width:9.446%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="13" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Change</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="5" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">$</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">%</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">$</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">External services</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20,051</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24,666</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">576</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(4,615</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(19</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24,090</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">*</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Compensation and related personnel costs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,081</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,863</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(3,782</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(27</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,863</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">*</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Facilities related</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,483</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,255</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">228</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,255</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">*</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,307</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">648</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">659</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">102</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">648</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">*</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total research and development expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">33,922</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">41,432</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">576</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(7,510</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(18</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">40,856</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">*</span></p></td>
   </tr>
  </table>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">*    Not Meaningful</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development expenses for the year ended December 31, 2023 were mainly attributable to our product development efforts for XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Research and development expenses for the year ended December 31, 2022 were mainly attributable to product development efforts of Entasis that we recognized from February 17, 2022. Research and development expenses for the year ended December 31, 2023 decreased compared to the same period in 2022 primarily due to the FDA approval of XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in May 2023 and resource reallocation from the research development function to general and administrative function after the FDA approval. External services costs consist primarily of fees paid to consultants, contractors and contract manufacturing organizations.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development expenses for the year ended December 31, 2021 were attributable to the product development efforts of Pulmoquine Therapeutics Inc., which was dissolved at the end of 2021.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Selling, General &amp; Administrative</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Selling, general and administrative expenses, as compared to the prior years, were as follows:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:26.161%;"/>
    <td style="width:1.101%;"/>
    <td style="width:1%;"/>
    <td style="width:7.448%;"/>
    <td style="width:1%;"/>
    <td style="width:1.101%;"/>
    <td style="width:1%;"/>
    <td style="width:7.448%;"/>
    <td style="width:1%;"/>
    <td style="width:1.101%;"/>
    <td style="width:1%;"/>
    <td style="width:7.448%;"/>
    <td style="width:1%;"/>
    <td style="width:1.101%;"/>
    <td style="width:1%;"/>
    <td style="width:7.087999999999999%;"/>
    <td style="width:1%;"/>
    <td style="width:1.001%;"/>
    <td style="width:1%;"/>
    <td style="width:7.9079999999999995%;"/>
    <td style="width:1%;"/>
    <td style="width:1.101%;"/>
    <td style="width:1%;"/>
    <td style="width:7.087999999999999%;"/>
    <td style="width:1%;"/>
    <td style="width:1.001%;"/>
    <td style="width:1%;"/>
    <td style="width:7.9079999999999995%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Change</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">$</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">%</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">$</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">%</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Selling, general and administrative</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">98,232</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">63,538</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,187</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">34,694</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">55</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">47,351</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">293</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
  </table>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Selling, general and administrative expenses increased by $34.7 million for the year ended December 31, 2023, compared to the year ended December 31, 2022, mainly attributable to the resource reallocation from the research development function to general and administrative function after the FDA approval of XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Selling, general and administrative expenses for the year ended December 31, 2023 also reflect certain full-year expenses of Entasis which we started consolidating on February 17, 2022 and of La Jolla, which we acquired in August 22, 2022.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Selling, general and administrative expenses increased by $47.4 million for the year ended December 31, 2022, compared to the year ended December 31, 2021, mainly attributable to the consolidation of Entasis&#8217; operating expenses and La Jolla&#8217;s operating expenses as previously mentioned.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">85</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Interest and Dividend Income and Other Expense, Net</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Interest and dividend income and other expense, net, as compared to the prior years, were as follows:</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:27.375%;"/>
    <td style="width:1.16%;"/>
    <td style="width:1%;"/>
    <td style="width:7.218999999999999%;"/>
    <td style="width:1%;"/>
    <td style="width:1.16%;"/>
    <td style="width:1%;"/>
    <td style="width:7.218999999999999%;"/>
    <td style="width:1%;"/>
    <td style="width:1.16%;"/>
    <td style="width:1%;"/>
    <td style="width:7.218999999999999%;"/>
    <td style="width:1%;"/>
    <td style="width:1.16%;"/>
    <td style="width:1%;"/>
    <td style="width:6.899000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:7.699%;"/>
    <td style="width:1%;"/>
    <td style="width:1.16%;"/>
    <td style="width:1%;"/>
    <td style="width:6.899000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:7.678999999999999%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Change</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">$</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">%</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">$</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">%</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest and dividend income</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(15,818</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(6,369</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(1,839</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(9,449</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">148</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(4,530</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">246</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other expense, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,969</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,373</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,626</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,596</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">47</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(253</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">*</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">*    Not Meaningful</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Interest and dividend income increased for the year ended December 31, 2023, compared to the year ended December 31, 2022, due to higher interest rates and higher average balances of our cash equivalents, money market funds and other interest-bearing investments.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Interest and dividend income increased for the year ended December 31, 2022, compared to the year ended December 31, 2021, due to higher interest rates and higher average balances of our cash equivalents, money market funds and other interest-bearing investments. Other expense, net, primarily consisted of expenses incurred by ISP Fund LP.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Interest Expense</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Interest expense, as compared to the prior years, was as follows:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:27.375%;"/>
    <td style="width:1.16%;"/>
    <td style="width:1%;"/>
    <td style="width:7.218999999999999%;"/>
    <td style="width:1%;"/>
    <td style="width:1.16%;"/>
    <td style="width:1%;"/>
    <td style="width:7.218999999999999%;"/>
    <td style="width:1%;"/>
    <td style="width:1.16%;"/>
    <td style="width:1%;"/>
    <td style="width:7.218999999999999%;"/>
    <td style="width:1%;"/>
    <td style="width:1.16%;"/>
    <td style="width:1%;"/>
    <td style="width:6.899000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:7.699%;"/>
    <td style="width:1%;"/>
    <td style="width:1.16%;"/>
    <td style="width:1%;"/>
    <td style="width:6.899000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:7.678999999999999%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Change</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">$</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">%</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">$</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">%</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19,157</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,789</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19,070</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,368</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(3,281</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(17</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
   </tr>
  </table>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The interest expense included the contractual interest expense and the amortization of debt issuance costs for our convertible subordinated notes due 2023 (the &#8220;2023 Notes&#8221;), our convertible senior notes due 2025 (the &#8220;2025 Notes&#8221;) and our convertible senior notes due 2028 (the &#8220;2028 Notes&#8221;), as well as effective interest expense on our deferred royalty obligation. The increase in 2023, compared to the year ended December 31, 2022, was mainly due to the interest expense on our deferred royalty obligation from the acquisition of La Jolla.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The change in interest expense for the year ended December 31, 2022, compared to the year ended December 31, 2021, was primarily due to the adoption of ASU 2020-06, which simplifies the accounting for convertible debt instruments. As a result of the adoption, the debt discount associated with the cash settlement feature of the 2025 Notes was adjusted to zero as of January 1, 2022. Interest expense for the year ended December 31, 2022 included the contractual interest expense and the amortization of debt issuance costs for our 2023 Notes, the 2025 Notes and 2028 Notes. Interest expense for the year ended December 31, 2021 included the amortization of debt discount in addition to the contractual interest expense and the amortization of debt issuance costs for our 2023 Notes and 2025 Notes. The decrease in interest expense as a result of the adoption of ASU 2020-06 was partially offset by a higher debt balance and interest expense incurred for the deferred royalty obligation from the acquisition of La Jolla.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Loss on Debt Extinguishment</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the year ended December 31, 2022, we recognized a loss of $20.7 million due to the total premium payment of $20.4 million and the write-off of $0.3 million debt issuance costs in connection with the repurchase of $144.8 million aggregate principal amount of our 2023 Notes in March 2022.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Gain on Sale of TRC</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We recognized a net gain of $266.7 million for the year ended December 31, 2022 due to the sale of our ownership interest in TRC to Royalty Pharma, consummated on July 20, 2022.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">86</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Changes in Fair Values of Equity Method Investments and Equity and Long-Term Investments</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Changes in fair values of equity method investments and equity and long-term investments, net, as compared to the prior years, were as follows:</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:27.375%;"/>
    <td style="width:1.16%;"/>
    <td style="width:1%;"/>
    <td style="width:7.218999999999999%;"/>
    <td style="width:1%;"/>
    <td style="width:1.16%;"/>
    <td style="width:1%;"/>
    <td style="width:7.218999999999999%;"/>
    <td style="width:1%;"/>
    <td style="width:1.16%;"/>
    <td style="width:1%;"/>
    <td style="width:7.218999999999999%;"/>
    <td style="width:1%;"/>
    <td style="width:1.16%;"/>
    <td style="width:1%;"/>
    <td style="width:6.899000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:7.699%;"/>
    <td style="width:1%;"/>
    <td style="width:1.16%;"/>
    <td style="width:1%;"/>
    <td style="width:6.899000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:7.678999999999999%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Change</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">$</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">%</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">$</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">%</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Changes in fair values of equity<br/>&#160;&#160;&#160;method investments, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(77,392</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">161,749</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(84,392</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(239,141</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(148</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">246,141</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(292</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Changes in fair values of equity <br/>&#160;&#160;&#160;and long-term investments, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(11,129</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(8,462</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(6,638</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(2,667</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">32</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(1,824</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
  </table>
  <p style="text-indent:13.158%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The changes in fair values of equity method investments for the year ended December 31, 2023 were favorable mainly due to Armata&#8217;s higher stock prices during this period. We recorded $77.4 million in unrealized gains, $152.5 million in unrealized losses and $78.7 million in unrealized gains associated with our equity method investments in Armata for the years ended December 31, 2023, 2022 and 2021, respectively. The changes in fair values of equity method investments for the years ended December 31, 2022 and 2021 also include $9.2 million in unrealized losses and $5.7 million in unrealized gains, respectively, we recorded from our then equity method investments in Entasis. Refer to Note 6, &#8220;Equity and Long-Term Investments and Fair Value Measurements&#8221;, to the Consolidated Financial Statements for more information.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The changes in fair values of equity and long-term investments year over year reflect the realized gains and losses and net unrealized gains and losses in our strategic investments in Armata, InCarda, and Gate, and those investments managed by ISP Fund LP. We recorded $23.8 million in unrealized gain for the year ended December 31, 2023 related to other long-term investments we made in Armata in 2023.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Income tax expense, net, as compared to the prior years, was as follows:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:27.375%;"/>
    <td style="width:1.16%;"/>
    <td style="width:1%;"/>
    <td style="width:7.218999999999999%;"/>
    <td style="width:1%;"/>
    <td style="width:1.16%;"/>
    <td style="width:1%;"/>
    <td style="width:7.218999999999999%;"/>
    <td style="width:1%;"/>
    <td style="width:1.16%;"/>
    <td style="width:1%;"/>
    <td style="width:7.218999999999999%;"/>
    <td style="width:1%;"/>
    <td style="width:1.16%;"/>
    <td style="width:1%;"/>
    <td style="width:6.899000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:7.699%;"/>
    <td style="width:1%;"/>
    <td style="width:1.16%;"/>
    <td style="width:1%;"/>
    <td style="width:6.899000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:7.678999999999999%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Change</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">$</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">%</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">$</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">%</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Income tax expense, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,376</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">66,687</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">76,439</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(52,311</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(78</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(9,752</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(13</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
   </tr>
  </table>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, 2022 and 2021, we had net operating loss carryforwards for federal income taxes of $543.5 million, $411.5 million and $92.9 million, respectively. As of December 31, 2023, 2022 and 2021, we also had state net operating loss carryforwards of approximately $1.0 billion, $955.3 million and $648.6 million, respectively, which will expire beginning 2029. As of December 31, 2021, we had federal research and development tax credit carryforwards of $42.1 million. We did not have such federal research and development tax credit carryforwards as of December 31, 2023 and 2022. As of December 31, 2023, we had state research and development tax credits of $33.3 million.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the year ended December 31, 2023, 2022 and 2021, we recognized $14.4 million, $66.7 million and $76.4 million of income tax expense, respectively, mainly based on the taxable income generated during those years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We had total unrecognized tax benefits of $19.4 million as of December 31, 2023. Our total unrecognized tax benefits as of December 31, 2022 and December 31, 2021 were $16.3 million and $14.9 million, respectively.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Utilization of net operating loss and tax credit carryforwards is subject to rules, provided by the Internal Revenue Code and similar state provisions, governing annual limitations tied to ownership changes. We conducted an analysis of the Company through December 31, 2023 to determine whether an ownership change had occurred since inception. The study concluded that it is more likely than not that the Company did not experience an ownership change during the testing period. If we ever undergo an ownership change, the utilization of the pre-ownership change net operating loss carryforwards or pre-ownership change tax attributes, such as research tax credits, to offset the post-ownership change income may be subject to an annual limitation, pursuant to Sections 382 and 383 of the Internal Revenue Code of 1986, as amended. Similar rules may apply under state tax laws.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a result of the acquisition of Entasis, we conducted a study of Entasis&#8217; ownership changes and estimated that we will be able to utilize $155.6 million of its federal net operating losses, which are subject to annual limitations.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">87</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a result of the acquisition of La Jolla, we also performed an analysis of its ownership changes and estimated that we will be able to utilize $309.5 million of its federal net operating losses, which are subject to annual limitations. <br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2021, the Organization for Economic Cooperation and Development (&#8220;OECD&#8221;) enacted model rules for a new global minimum tax framework (&#8220;BEPS Pillar Two&#8221;), and various governments around the world have enacted, or are in the process of enacting legislation. We are in the process of evaluating whether and when these new rules may come into effect and apply to us.  We plan to treat the tax if any as a period cost. We do not believe that the Pillar Two rules apply to us yet.  As such, the potential future quantitative impact of the enacted or substantively enacted legislation is not yet reasonably estimable.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Net Income Attributable to Noncontrolling Interest</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net income attributable to noncontrolling interests, as compared to the prior years, was as follows:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:27.375%;"/>
    <td style="width:1.16%;"/>
    <td style="width:1%;"/>
    <td style="width:7.218999999999999%;"/>
    <td style="width:1%;"/>
    <td style="width:1.16%;"/>
    <td style="width:1%;"/>
    <td style="width:7.218999999999999%;"/>
    <td style="width:1%;"/>
    <td style="width:1.16%;"/>
    <td style="width:1%;"/>
    <td style="width:7.218999999999999%;"/>
    <td style="width:1%;"/>
    <td style="width:1.16%;"/>
    <td style="width:1%;"/>
    <td style="width:6.899000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:7.699%;"/>
    <td style="width:1%;"/>
    <td style="width:1.16%;"/>
    <td style="width:1%;"/>
    <td style="width:6.899000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:7.678999999999999%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Change</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;min-width:fit-content;">(1)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;min-width:fit-content;">(1)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">$</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">%</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">$</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">%</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net income attributable to<br/>&#160;&#160;&#160;noncontrolling interest</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,341</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">102,983</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(6,341</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(100</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(96,642</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(94</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
   </tr>
  </table>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">(1)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">   The year ended December 31, 2022 represents the period from the initial date of consolidation of Entasis on February 17, 2022 to the date of the acquisition of Entasis on July 11, 2022, and the period from January 1, 2022 through the date of the sale of our ownership interest in TRC on July 20, 2022.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net income attributable to noncontrolling interests for the year ended December 31, 2022 was $6.3 million compared to $103.0 million for the year ended December 31, 2021, or a decrease of $96.6 million, which was mainly due to lower net income attributable to the sale of our ownership interest in TRC, offset with net loss attributable to Entasis&#8217; noncontrolling interest.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Liquidity and Capital Resources</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Liquidity</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since our inception, we have financed our operations primarily through private placements and public offerings of equity and debt securities and payments received under collaborative arrangements. For the year ended December 31, 2023, we generated gross royalty revenues of $252.7 million and net product sales revenues of $60.6 million. Cash and cash equivalents totaled $193.5 million, royalties receivable from GSK totaled $69.6 million and accounts receivable associated with our product sales totaled $14.5 million, as of December 31, 2023.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we had two outstanding convertible notes, the 2025 Notes and the 2028 Notes, in an aggregate principal amount of $453.5 million, of which $192.5 million and $261.0 million will become due in August 2025 and March 2028, respectively. Future interest payments associated with these notes total $34.6 million.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On October 31, 2022, our Board of Directors authorized a share repurchase program under which we may repurchase up to $100.0 million of Innoviva&#8217;s outstanding shares of common stock. As of December 31, 2023, we have repurchased Innoviva common stock in the open market for total price of approximately $84.2 million. This program has no termination date, may be suspended or discontinued at any time at our discretion and does not obligate us to acquire any amount of common stock.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In May 2021, Strategic Partners received a distribution of $110.0 million from the Partnership to provide funding to Innoviva for a strategic repurchase of Innoviva common shares held by GSK. On March 30, 2022, Strategic Partners made an additional capital contribution of $110.0 million to the Partnership pursuant to the letter agreement entered into between Strategic Partners, the Partnership and Sarissa Capital Fund GP LP on May 20, 2021. The capital contribution is subject to a 36-month lock-up period from the contribution date.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The lock-up period for our initial contribution of $190.0 million expired in December 2023. Strategic Partners did not elect to make a withdrawal in 2023, thereby extending the lock-up period and withdrawal elections into subsequent years.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">88</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Adequacy of Cash Resources to Meet Future Needs</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe that our cash and cash equivalents will be sufficient to meet our anticipated debt service and operating needs, as well our ongoing share repurchase program, for at least the next 12 months based upon current operating plans and financial forecasts. Our long-term capital requirements will depend on many factors including the amount of our royalty revenues, sales growth of our currently marketed products, timing of regulatory approval of our product candidates and outcome of our acquisitions and strategic investments. If our current operating plans and financial forecasts change, we may require additional funding sooner in the form of public or private equity offerings or debt financings. Furthermore, if in our view favorable financing opportunities arise, we may seek additional funding in the form of public or private equity offerings or debt financings at any time. However, future financing may not be available in amounts or on terms acceptable to us, if at all. This could leave us without adequate financial resources to fund our operations as currently planned. In addition, from time to time we may restructure or reduce our debt, including through privately negotiated repurchases, tender offers, redemptions, amendments, or otherwise, all allowable with the terms of our debt agreements.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash Flows</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash flows, as compared to the prior years, were as follows:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:31.859%;"/>
    <td style="width:1.341%;"/>
    <td style="width:1%;"/>
    <td style="width:10.288%;"/>
    <td style="width:1%;"/>
    <td style="width:1.341%;"/>
    <td style="width:1%;"/>
    <td style="width:10.288%;"/>
    <td style="width:1%;"/>
    <td style="width:1.341%;"/>
    <td style="width:1%;"/>
    <td style="width:10.288%;"/>
    <td style="width:1%;"/>
    <td style="width:1.341%;"/>
    <td style="width:1%;"/>
    <td style="width:10.288%;"/>
    <td style="width:1%;"/>
    <td style="width:1.341%;"/>
    <td style="width:1%;"/>
    <td style="width:10.288%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Change</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash provided by operating activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">141,064</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">201,726</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">363,813</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(60,662</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(162,087</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash provided by (used in) investing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(66,761</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(56,634</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">43,722</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(10,127</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(100,356</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash used in financing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(171,839</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(55,568</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(452,497</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(116,271</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">396,929</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash Flows from Operating Activities</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash provided by operating activities for the year ended December 31, 2023 was $141.1 million, consisting primarily of our net income of $179.7 million, partially offset by net non-cash items of $13.9 million and net changes in operating assets and liabilities of $24.8 million. Non-cash items included a $88.5 million net increase in fair values of equity method investments and equity and long-term investments, partially offset by $27.2 million in inventory fair value adjustments included in cost of products sold, $21.8 million in amortization of acquired intangible assets, $13.9 million of amortization of capitalized fees and depreciation of property and equipment, $5.8 million in stock-based compensation expense, $4.4 million of deferred income taxes and $2.1 million in amortization of debt discount and issuance costs. The changes in operating assets and liabilities included increases in receivables from collaboration arrangements of $14.9 million, inventories of $12.0 million, accounts receivable of $5.1 million, other assets of $3.0 million and a decrease in personnel-related, interest and other accrued expenses of $2.4 million, partially offset by a decrease in prepaid expenses of $7.9 million and increases in accounts payable of $3.8 million and income tax payable of $1.7 million.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash provided by operating activities for the year ended December 31, 2022 was $201.7 million, consisting primarily of our net income of $220.3 million and net changes in operating assets and liabilities of $6.9 million, partially offset by net non-cash items of $25.4 million. Non-cash items included a net gain of $266.7 million recognized on the sale of TRC, partially offset by net non-cash charges of $241.3 million. Non-cash charges included a $153.3 million net decrease in fair values of equity method investments and equity and long-term investments, $25.0 of deferred income taxes, $13.9 million of amortization of capitalized fees and depreciation of property and equipment and $5.6 million in amortization of acquired intangible assets, $20.7 million in loss on the extinguishment of debt, $7.3 million in stock-based compensation expense, $10.0 million in inventory fair value adjustments included in cost of products sold and $2.1 million in the amortization of debt discount and issuance costs. The changes in operating assets and liabilities included an increase in prepaid expenses of $21.4 million, a decrease in receivables from collaboration arrangements of $13.3 million and increases of $11.9 million and $10.0 million in accrued personnel-related expenses and other accrued liabilities and in income tax payable, respectively.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash provided by operating activities for the year ended December 31, 2021 was $363.8 million, consisting primarily of our net income of $368.8 million, adjusted for non-cash items such as $76.4 million of deferred income taxes, $13.8 million of depreciation and amortization, $9.1 million amortization of debt discount and issuance costs, $2.0 million of stock-based compensation expense, partially offset by a $89.3 million net increase in fair values of equity method investments and equity and long-term investments and an increase in receivables from collaborative arrangements of $16.8 million.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">89</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash Flows from Investing Activities</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net cash used in investing activities for the year ended December 31, 2023 of $66.8 million included $65.1 million for purchases trading securities, $31.2 million for purchases of equity investments managed by ISP Fund LP, $41.3 million in net purchases and sales of other investments managed by ISP Fund LP and $1.2 million for purchases of equity and long-term investments. Net cash used in investing activities was partially offset by $72.5 million in sales of equity investments managed by ISP Fund LP.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net cash used in investing activities for the year ended December 31, 2022 of $56.6 million included $159.1 million in cash paid for the acquisition of La Jolla, net of cash acquired, $58.7 million in purchases of equity and long-term investments, $60.9 million in purchases of equity investments managed by ISP Fund LP, $50.0 million in purchases of a trading security managed by ISP Fund LP and $23.4 million in net purchases and sales of other investments managed by ISP Fund LP. Net cash used in investing activities was partially offset by $248.2 million in net proceeds from the sale of our ownership interest in TRC, $24.3 million in sales of equity investments managed by ISP Fund LP and $23.1 million in cash acquired through the consolidation of Entasis.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net cash provided by investing activities for the year ended December 31, 2021 of $43.7 million was primarily due to $110.0 million net cash inflow from $301.0 million sales and $191.0 million purchases of equity and other investments managed by ISP Fund LP, offset by $66.3 million in purchases of various investment instruments including, but not limited to, common stock, warrants, convertible debt investment, money market funds and other securities.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash Flows from Financing Activities</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net cash used in financing activities for the year ended December 31, 2023 of $171.8 million consist mainly of the repayments of $96.2 million upon maturity of the 2023 Notes in January 2023 and $75.7 million for the repurchases of our common stock under the current stock repurchase program.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net cash used in financing activities for the year ended December 31, 2022 of $55.6 million included $165.1 million for the repurchase of convertible subordinated notes due 2023, $69.8 million in distributions to noncontrolling interest, $43.9 million for the purchase of Entasis noncontrolling interest, $21.0 million for purchases of capped call options associated with our 2028 Notes and $8.5 million for the repurchase of common stock. Net cash used in financing activities was partially offset by $252.5 million in net proceeds from the issuance of our 2028 Notes.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net cash used in financing activities for the year ended December 31, 2021 of $452.5 million was primarily due to a $394.1 million repurchase of our common stock from GSK and $59.5 million in distributions to noncontrolling interest.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Contractual Obligations</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, our notes payable obligation included $192.5 million related to our 2025 Notes and $261.0 million related to our 2028 Notes, which are due in 2025 and 2028, respectively. Under the terms of the 2025 Notes and 2028 Notes, we will make interest payments of 2.5% and 2.125%, respectively, of outstanding principal. Refer to Note 12, &#8220;Debt&#8221; to the Consolidated Financial Statements for more information.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our short-term and long-term obligations also include contractual payments related to our operating leases amounting to $3.1 million, with approximately $1.4 million payable through December 31, 2024 and 2025 and approximately $0.1 million payable in each of the years 2026 and 2027. Refer to Note 13, &#8220;Commitments and Contingencies&#8221; to the Consolidated Financial Statements for more information.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As part of our acquisition of La Jolla, we recognized its deferred royalty obligation in connection with La Jolla Royalty Agreement with HCR. Under the terms of the Agreement, HCR is entitled to receive quarterly royalties on worldwide net sales of GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> until either January 1, 2031 or when the maximum aggregate royalty payments have been made, whichever occurs first. Quarterly payments to HCR under the Royalty Agreement start at a maximum royalty rate, with step-downs based on the achievement of annual net product sales thresholds. The current maximum royalty rate is 14%. Starting January 1, 2024, the maximum royalty rate was increased to 18% based on the terms of the Agreement. The La Jolla Royalty Agreement is subject to maximum aggregate royalty payments to HCR of $225.0 million.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, we have certain contingent payment obligations under various in-license agreements which we are required to make royalty payments or milestone payments upon successful completion and achievement of certain milestones. Refer to Note 4, &#8220;License and Collaboration Arrangements&#8221; to the Consolidated Financial Statements for more information.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We also enter into agreements in the normal course of business with vendors for manufacturing, clinical trials and preclinical studies, and other services and products for operating purposes.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">90</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;" id="item_7a_quantitative_and_qualitative"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM 7A.   QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, our debt bears fixed interest rates and we had no outstanding debt with variable interest rates. Our cash flows on these debt obligations are not subject to variability as a result of changes in interest rates.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are exposed to changes in the fair value of certain of our investments in equity and debt securities. Fluctuations in the underlying fair value of the investments could result in material gains or losses. Refer to Note 6 &#8220;Equity and Long-Term Investments and Fair Value Measurements&#8221; to the Consolidated Financial Statements for more information.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Inflation has increased during the period covered by this Annual Report on Form 10-K and could continue to increase for the near future. Inflationary factors, such as increases in the cost of our raw materials, supplies, interest rates and overhead costs may adversely affect our operating results. Although we do not believe that inflation has had a material impact on our financial position or results of operations to date, we may experience some effect in the near future if inflation rates continue to rise. Significant adverse changes in inflation and prices in the future could result in material losses.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may face foreign exchange risk as a result of entering into transactions denominated in currencies other than U.S. dollars, including contracts with international vendors related to raw material purchases. Our royalty revenue from RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> is also indirectly exposed to foreign exchange risk as GSK also markets and sells the products outside the U.S. The majority of our cash and cash equivalents, investments, and the majority of our vendor relationships are denominated in U.S. dollars. Therefore, we do not believe that the risk of a significant impact on our operating income from foreign currency fluctuations is substantial.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">91</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_8_financial_statements_and"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM 8.   FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:93.8%;"/>
    <td style="width:6.2%;"/>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:7.2pt;vertical-align:bottom;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="text-indent:7.2pt;vertical-align:bottom;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Page</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:bottom;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_balance_sheets"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Balance Sheets as of December 31, 2023 and December 31, 2022</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">93</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:bottom;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statements_of_income"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Statements of Income for each of the three years in the period ended December 31, 2023</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">94</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:bottom;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statements_of_comprehensive"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Statements of Comprehensive Income for each of the three years in the period ended December 31, 2023</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">95</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:bottom;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statements_of_stockholders"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Statements of Stockholders&#8217; Equity for each of the three years in the period ended December 31, 2023</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">96</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:bottom;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statements_of_cash_flows"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Statements of Cash Flows for each of the three years in the period ended December 31, 2023</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">97</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:bottom;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#notes_to_consolidated_financial"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Notes to Consolidated Financial Statements</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">98</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:bottom;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#reports_of_independent_registered_1"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Reports of Independent Registered Public Accounting Firm (PCAOB ID </span><span><ix:nonNumeric id="F_2cd0b950-111d-477e-a9ba-d4c1a94c21c9" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="dei:AuditorFirmId"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">34</span></ix:nonNumeric></span><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">)</span><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;"> </span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">138</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:bottom;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#report_of_independent_registered_public"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Report of Independent Registered Public Accounting Firm (PCAOB ID 248)</span><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;"> </span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">140</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">92</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">INNOVIVA, INC.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;" id="consolidated_balance_sheets"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CONSOLIDATED BALANCE SHEETS</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(In thousands, except per share data)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:67.313%;"/>
    <td style="width:1.5%;"/>
    <td style="width:1%;"/>
    <td style="width:12.843%;"/>
    <td style="width:1%;"/>
    <td style="width:1.5%;"/>
    <td style="width:1%;"/>
    <td style="width:12.843%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Assets</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current assets:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6ac4c0f1-adab-44d0-b107-740ee9ffbd09" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">193,513</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0df4558c-a777-48cc-bb99-d1aa36585f0a" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">291,049</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts receivable</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_33b5f858-eea1-4944-ace4-4c5f647b543b" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="us-gaap:AccountsReceivableNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,454</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_de89055c-b8f8-4253-9f20-2b89c9c7a58d" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" name="us-gaap:AccountsReceivableNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,401</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Receivables from collaboration arrangements</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_322eff37-92f7-42d5-a81e-3575a9a6d301" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="us-gaap:ReceivablesLongTermContractsOrPrograms" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">69,621</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_965ef5c0-67d4-4e4e-ae5c-d8d8a75e7c0b" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" name="us-gaap:ReceivablesLongTermContractsOrPrograms" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">54,672</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inventory</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_24c247a7-c62a-4db7-9079-2b6afbc75718" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="us-gaap:InventoryNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">40,737</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5d9b191c-25c9-46aa-aa60-4d4d2ce170bb" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" name="us-gaap:InventoryNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">55,897</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8a92eb3a-7374-49d5-abab-d35a0ed7f881" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,630</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d65e7613-be6a-41c8-a2cf-6ebd24df311c" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,559</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other current assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_abb7edbd-0cfc-4eb1-b1b9-fb3164490e34" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="us-gaap:OtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,264</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_60d78822-1734-4296-b287-9edea0d28e46" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" name="us-gaap:OtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,933</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total current assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_839956e0-e7f8-495d-8d9e-05b7a9b915e0" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">344,219</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4f252135-c0a1-4b6a-b884-eb9c9aa08d0f" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">443,511</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Property and equipment, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9fbe6eec-b125-4a99-be97-75d476aa4637" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">483</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c11071e2-8ab7-40b6-9d02-a3983c6f45bb" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">170</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Equity method investments</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_16c7945f-ba5c-4f33-a1b0-7627b764943c" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="inva:EquityMethodInvestment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">116,546</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8f03c343-882a-4517-a2a1-47643e212814" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" name="inva:EquityMethodInvestment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39,154</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Equity and long-term investments</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4df3af14-074c-41d1-b60c-21c7de70b9e4" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="us-gaap:LongTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">444,432</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_16d5bb42-6db6-40a6-969a-3188f1dc5fdf" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" name="us-gaap:LongTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">363,859</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Capitalized fees paid, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c26af50d-4111-424d-8ba3-e214ca4a9176" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="us-gaap:CapitalizedContractCostNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">83,784</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f386ca52-688c-495a-8293-4ad3d9dabe3d" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" name="us-gaap:CapitalizedContractCostNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">97,607</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Right-of-use assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5a82c365-03d6-43c5-ae7b-d7cf0b5d3054" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,536</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5144fc5e-6be8-45b0-b25e-f96d260b8fe2" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,265</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Goodwill</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_46d119e0-ec4e-47e4-a137-9675f05dbf47" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="us-gaap:Goodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,905</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d573b1e8-38a0-40af-a2e5-76655bd20267" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" name="us-gaap:Goodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,713</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Intangible assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0cc8c924-4e86-4335-9871-4370d7fc5e29" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">230,335</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8c013766-4a2e-4917-b877-bb13e329ee00" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">252,919</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_48328fb6-fabf-4d3a-b47b-a552f58c9711" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,267</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fd7317fd-fc77-4dd9-9e28-4fcdc12ef06d" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,299</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d428d075-b8f0-4e1f-b1a9-133202382fcd" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,243,507</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ff5aeb9c-1067-4b94-beb5-77e36415c02a" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,231,497</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:20pt;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Liabilities and Stockholders&#8217; Equity</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current liabilities:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_359e7c15-b159-4149-978f-577a95dae9dc" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,717</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4a8deb03-6125-4b5a-b47c-098bf2cf4d49" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,939</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued personnel-related expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0d7d98a1-27ee-478e-9485-bc56fc338b96" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,020</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6ea1852e-b684-4c54-bf8a-0623455ea578" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,022</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued interest payable</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_936cada9-6f44-411f-a39a-4ffe197946bc" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="us-gaap:InterestPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,422</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7e7913e3-68d5-4cd4-97e2-89db38fd2e14" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" name="us-gaap:InterestPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,359</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred revenue</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f8758f3d-42db-4781-9afd-e08c09e512a9" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="us-gaap:DeferredRevenueCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,277</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_18532002-cc6b-42e8-b252-9b48573e0b2f" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" name="us-gaap:DeferredRevenueCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,094</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Convertible subordinated notes due 2023, net of issuance costs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a76fd3ae-fe34-4598-a199-74f411f6f895" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="us-gaap:ConvertibleDebtCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0fcc9982-4494-45ee-92ea-803b236e0116" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" name="us-gaap:ConvertibleDebtCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">96,193</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Income tax payable</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ad2169d6-8d6b-4403-8ebd-b6e2a78dd286" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="us-gaap:AccruedIncomeTaxesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_19b96451-d485-45c9-91bd-95a40ebcb382" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" name="us-gaap:AccruedIncomeTaxesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">154</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other accrued liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0e7ff711-947b-4f6d-a2c6-880e8a43e480" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="us-gaap:OtherLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,698</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fd08744c-ae90-4749-9ede-5acb5aa12595" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" name="us-gaap:OtherLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,207</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total current liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cb8dc650-0635-4172-b4ee-4050db6730e4" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">38,134</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fa659918-2bdc-42e5-8a76-780ae748ee91" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">134,968</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Long-term debt, net of discount and issuance costs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_90f5edf1-b300-43e6-9954-bc6611638174" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="us-gaap:LongTermDebtNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">446,234</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_34f01195-4314-4996-8c3c-1220bd8e0136" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" name="us-gaap:LongTermDebtNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">444,180</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other long-term liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_17355e0a-5ce7-4b51-b12f-e7ee0d809964" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">71,870</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f4aee8ce-d07e-43b6-8abc-5476afb73cf8" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">70,918</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax liabilities, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_38659219-d82a-4334-9485-f9a0ced5bd50" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">563</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_482515ed-fac2-44fb-9a7b-b3331ff974ed" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,771</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Income tax payable, long-term</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2866fc83-30b2-46f3-b186-8e6083ea6723" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="inva:IncomeTaxPayableNonCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,751</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a5170ea8-f03b-42ad-a929-cedcc768d520" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" name="inva:IncomeTaxPayableNonCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,872</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_2f119708-881a-4577-8742-9ee60a34c0fc;"><span style="-sec-ix-hidden:F_118b362a-f883-4a7d-b60c-4f79a2ad6875;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commitments and contingencies (Note 13)</span></span></span></span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stockholders&#8217; equity:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Preferred stock: $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_89ba63b9-7f97-4418-b3e5-b9d25029efb0" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="F_6f702253-6e03-41a0-b4a2-534054d4342c" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.01</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;par value, </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1da1da43-fdbd-4701-8f82-de57eaf3ea80" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal"><ix:nonFraction id="F_5147ddfa-f749-46af-9f69-0ffce3d25d3a" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">230</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;shares authorized,<br/>&#160;&#160;&#160;</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9e42384a-1e82-4be5-8c45-929bc6cd2351" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_91661139-3a49-44a6-9bb7-551fa1260960" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_8431bcd9-7587-48cb-8f14-0145e4d040af" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_53a6b99f-673c-43d4-90b2-748d8d96293d" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;shares issued and outstanding</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c7a4140d-c22d-4d07-b573-8837655a8389" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="us-gaap:PreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f370b6ed-4f10-4a9a-afe2-2bfbf925e5a4" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" name="us-gaap:PreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common stock: $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_adbd1ab7-f315-4321-ad82-2fe2d1524279" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="F_80f550a6-2001-4446-a08a-db8cd8df1a24" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.01</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;par value, </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_db071206-fbb3-4422-882b-b7f1e6e5368e" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal"><ix:nonFraction id="F_7a1a3a30-b8ba-403f-b61a-eedcca4e0679" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">200,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;shares authorized, <br/>&#160;&#160;&#160;</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_32eb1f20-3dd8-4aef-9872-9cf725a9c140" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal"><ix:nonFraction id="F_72fcb6bc-e9b2-426d-bd76-475026b64160" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">63,307</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;and </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a17d3370-fd09-4e89-a0a2-c3d89a6102db" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal"><ix:nonFraction id="F_1d7940a8-6b79-4a28-84ee-8d2579de68aa" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">69,188</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;issued and outstanding as of<br/>&#160;&#160;&#160;December 31, 2023 and December 31, 2022 respectively</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1886baf2-8c65-4719-aaec-5eeeeecf1184" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">633</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1f978dac-0b72-46f9-80f4-cec896f55e4d" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">692</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Treasury stock: at cost, </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c18154d3-1a3b-43c5-9522-95c2426b0538" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="us-gaap:TreasuryStockCommonShares" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal"><ix:nonFraction id="F_b5b6c690-fce3-45aa-84cd-fd16d35b06ed" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" name="us-gaap:TreasuryStockCommonShares" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,005</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;shares as of December 31, 2023<br/>&#160;&#160;&#160;&#160;and 2022</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_62544135-b6f0-424b-80f4-1c0bf87ff9b7" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="us-gaap:TreasuryStockCommonValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">393,829</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fe9e44ac-9207-4c4e-984c-fc569f2500d8" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" name="us-gaap:TreasuryStockCommonValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">393,829</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Additional paid-in capital</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_823e248d-d81c-49d4-bcaf-e574bdd5f1ed" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,093,340</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5450d2f8-870b-420e-84ce-bb261ac31ba0" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,163,836</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accumulated deficit</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6059dd23-4731-486b-83bf-e91126cbc49a" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">25,189</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9e5e4bb6-6fc0-486e-82a7-5bac76b98321" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">204,911</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total stockholders&#8217; equity</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d81d6720-2c44-4935-9ba1-a5b38168d61d" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">674,955</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_543be034-0332-49c5-90e4-6022c66f1ef5" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">565,788</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total liabilities and stockholders&#8217; equity</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7610eb1d-937d-48ff-ade0-682be4ef1eaf" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,243,507</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_af6a1759-c94a-4d6f-b1d1-b5c57d87bbcf" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,231,497</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">See accompanying notes to consolidated financial statements.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">93</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">INNOVIVA, INC.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_statements_of_income"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CONSOLIDATED STATEMENTS OF INCOME</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(In thousands, except per share data)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:51.311%;"/>
    <td style="width:1.481%;"/>
    <td style="width:1%;"/>
    <td style="width:12.75%;"/>
    <td style="width:1%;"/>
    <td style="width:1.481%;"/>
    <td style="width:1%;"/>
    <td style="width:12.75%;"/>
    <td style="width:1%;"/>
    <td style="width:1.481%;"/>
    <td style="width:1%;"/>
    <td style="width:12.75%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Revenue:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Royalty revenue, net of amortization of <br/>&#160;&#160;&#160;capitalized fees paid of $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0ce36674-32d8-4f12-8b6f-3c6913d3d58a" contextRef="C_c1969bd2-5e89-423e-88e9-b5564c6afe10" name="us-gaap:CapitalizedContractCostAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal"><ix:nonFraction id="F_b87f44a1-eb35-4eeb-99dd-2bfc63f950f8" contextRef="C_8c8eca7f-7819-48ae-9938-c3c7153ffa73" name="us-gaap:CapitalizedContractCostAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal"><ix:nonFraction id="F_111332a3-5e76-4f5f-b629-f9ef59790d7a" contextRef="C_539783b3-bf29-4a63-8d24-99d7b7b79e81" name="us-gaap:CapitalizedContractCostAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,823</ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;in <br/>&#160;&#160;&#160;each of the years ended <br/>&#160;&#160;&#160;December 31, 2023, 2022 and 2021</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6ace803c-4529-4e04-ad8f-a072b40fcd8c" contextRef="C_81ea3387-bcc2-4cfe-a9e7-78fab40062ee" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">238,846</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f9f68ed6-7a62-4cfd-8614-cb403e1c5e3a" contextRef="C_cd95e6eb-db30-4b57-a111-4b45da383cf5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">311,645</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7095efc3-5287-4b3f-aaa8-8e0cfda542c0" contextRef="C_fa01aae9-eeeb-459c-9277-c4cd33bb93d0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">391,866</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net product sales</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_65178307-5042-4556-84af-a9a12bf3b0c1" contextRef="C_48c187f6-6fef-4cb6-83d6-250ba457d99a" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">60,617</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_07c8de9b-ad97-4a16-bd2c-a49b89ca362e" contextRef="C_809b9867-b962-4553-b6ab-8ca43d28920b" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,694</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b819c5d6-ab8c-4298-a9fe-a2f0803b64e3" contextRef="C_052592af-355b-490c-9bea-1016c2ec7fe7" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">License revenue</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_56a5fecd-8fa3-4eb0-a718-95f83a20e3b8" contextRef="C_c1cee939-99f5-4170-95af-3c7cd8ef24ef" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,000</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8f6bb527-292e-4791-8475-efb1673bfe8b" contextRef="C_7dd3ea38-7516-4e7e-9399-9f1920d9d119" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7dd129db-f981-4e41-bc43-54119f14c358" contextRef="C_8e426da9-946c-40b8-bd70-2a6eaa29fe3d" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total revenue</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e93661b1-366a-48ba-96e4-57963fb77fef" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">310,463</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2764ec9f-ffaa-4204-b689-56e049d2d76b" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">331,339</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_29d6158f-992d-40b2-a43f-702e42f54a0d" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">391,866</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expenses:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cost of products sold (inclusive of<br/>&#160;&#160;&#160;amortization of inventory fair value<br/>&#160;&#160;&#160;adjustments, excluding amortization<br/>&#160;&#160;&#160;of intangible assets)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0572e884-ce45-4c5d-bd3a-4d1d23cd91ee" contextRef="C_48c187f6-6fef-4cb6-83d6-250ba457d99a" name="us-gaap:CostOfGoodsAndServicesSold" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">41,040</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4820deb0-0128-44df-a84b-9fdd1d37d06a" contextRef="C_809b9867-b962-4553-b6ab-8ca43d28920b" name="us-gaap:CostOfGoodsAndServicesSold" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,793</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b5f89791-ee7b-42ec-aa72-ecb7f7b548f5" contextRef="C_052592af-355b-490c-9bea-1016c2ec7fe7" name="us-gaap:CostOfGoodsAndServicesSold" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cost of license revenue</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_43c9abb2-2d20-4740-af78-7412aba2ba41" contextRef="C_0180ad0a-b06f-4e53-948d-bb80d100090e" name="us-gaap:CostOfRevenue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,600</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8cc7bad5-1b56-4768-ad04-9f3494d4930e" contextRef="C_68f79cad-95a1-43ef-b218-21108e820b17" name="us-gaap:CostOfRevenue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4d596a86-a4ed-421a-adab-4a1a7da403db" contextRef="C_b6f84383-3742-4678-adab-90f14685e54b" name="us-gaap:CostOfRevenue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Selling, general and administrative</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f9d7011a-1705-4c4b-a260-da07bbde1172" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:SellingGeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">98,232</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_089c0d57-158f-4111-9906-374345fc07ec" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="us-gaap:SellingGeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">63,538</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fdc30bb8-fe67-49f5-b550-1ce1a66ef0ca" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="us-gaap:SellingGeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,187</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_063b408b-c6e4-4538-b51a-bd21f960a9a2" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,922</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_801ba661-b31a-43ec-8c0d-5419c16c0739" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">41,432</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d2599a69-56ee-40e9-885d-2becea5b5b62" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">576</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Amortization of acquired intangible assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cc1f5fed-f4db-4e57-93cd-79cab0fb1da9" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:AmortizationOfIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,784</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eaebbf5c-cfc1-4d92-8440-b93e3704dd2f" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="us-gaap:AmortizationOfIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,581</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a58802fd-3751-43ce-a285-b7fd9c81fec4" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="us-gaap:AmortizationOfIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Gain on sale of Theravance Respiratory<br/>&#160;&#160;&#160;Company, LLC (&#8220;TRC&#8221;)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eed60521-b4d8-4c79-987f-c6f2d7053022" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:DeconsolidationGainOrLossAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_54556125-635a-4603-bd79-535e11dc0d5a" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="us-gaap:DeconsolidationGainOrLossAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">266,696</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2101fc47-5362-4a5f-adb4-5694176d75ed" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="us-gaap:DeconsolidationGainOrLossAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss on extinguishment of debt</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4bcf478b-80fd-4c77-affb-6f0aa266ab15" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2d54f3d3-772f-425a-8cbe-d4004fa83642" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">20,662</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e098d7d3-ccc6-44dd-8a1e-a50d8cb4c323" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Changes in fair values of equity method<br/>&#160;&#160;&#160;investments, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fa210b4c-0cd5-4dcf-a3b1-1428c25729d5" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:IncomeLossFromEquityMethodInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">77,392</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a748eb5d-49ad-44ae-bb70-794df4794da7" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="us-gaap:IncomeLossFromEquityMethodInvestments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">161,749</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_564363d1-1724-463a-8ad2-03679528a871" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="us-gaap:IncomeLossFromEquityMethodInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">84,392</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Changes in fair value of equity and<br/>&#160;&#160;&#160;long-term investments, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9660f006-efb2-4921-9fc2-196389d0cfca" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="inva:GainLossOnOtherInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,129</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b4606d6f-3471-4352-9ae5-26ff294afeb5" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="inva:GainLossOnOtherInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,462</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9517a171-742b-4eda-a0b8-e247df322ece" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="inva:GainLossOnOtherInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,638</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest and dividend income</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_032dca0e-c49a-4ea2-898b-0763b64089cb" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:InterestAndDividendIncomeOperating" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,818</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d22e3e20-989f-469b-8738-4bab1f755d70" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="us-gaap:InterestAndDividendIncomeOperating" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,369</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eecd894d-1783-4dc9-a87f-65245f29094d" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="us-gaap:InterestAndDividendIncomeOperating" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,839</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7c455487-949c-4780-887a-bc47dcbefb3b" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,157</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2cadbd49-dc38-4f4f-b57b-c5e84f93d9c6" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,789</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_20a5e4a6-9d80-404b-9898-b705664fcee8" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,070</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other expense, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_696e038f-eec0-4663-ad61-37e14fb37442" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">4,969</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d73394f4-0805-4db0-93f3-6d880d57b4e8" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3,373</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b4d07642-0c47-47ce-ae82-d1c07b12bc6b" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3,626</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total expenses, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6e2a929b-3254-4024-b041-7a5d682848d4" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:CostsAndExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">116,365</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_59b5bf85-5e97-4d56-840d-1295eb8403a9" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="us-gaap:CostsAndExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">44,390</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2b3771e7-c5e7-4e29-9d91-42197d8234cf" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="us-gaap:CostsAndExpenses" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">53,410</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Income before income taxes</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a8567a4f-eb75-4a6e-a81b-7d184520b3e6" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">194,098</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6e0d44ce-a6a3-4b4d-bef6-ad46212556e1" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">286,949</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_15aace38-5902-43cb-9905-23aeadee3ede" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">445,276</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Income tax expense, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ebd3a7d5-7e15-4870-8305-7cb3b9076e20" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,376</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f3564cd1-bf7a-4e1a-bac0-db0fc038d6a6" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">66,687</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_607fef87-2e60-44a2-8dc1-b1be42ce23fd" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">76,439</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net income</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_48565d14-b120-4a75-840c-1d068c37fe7b" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">179,722</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2ed2b915-3077-4755-93f6-6f56a5a48ad6" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">220,262</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_978847b5-65f1-4a6f-859d-a793e634b8ee" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">368,837</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net income attributable to noncontrolling<br/>&#160;&#160;&#160;interests</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ae9ef733-d0d2-46ad-b1b6-c04dcc7837a5" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_143a3153-795b-42e6-a7e9-71783c6a1e42" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,341</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1727974a-2928-4c2c-a29d-48dad8dac934" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">102,983</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net income attributable to Innoviva<br/>&#160;&#160;&#160;stockholders</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cc800781-f4e8-4a12-aaac-07de135a0c87" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">179,722</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_724b0e01-3065-4847-8788-0c57a2eedfc3" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">213,921</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_395fc31b-8b56-43b5-856e-915a125b7fb9" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">265,854</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Basic net income per share attributable to<br/>&#160;&#160;&#160;Innoviva stockholders</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1f6f9ba6-5120-4b48-b05e-61eb901841ed" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.75</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7d8bab8e-07cf-4046-8156-8a5b62e2d381" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">3.07</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eba0b338-d27e-4808-bb35-8cea8d0c27d6" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">3.24</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Diluted net income per share attributable to<br/>&#160;&#160;&#160;Innoviva stockholders</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_432f13f4-cb8b-415b-a21a-ccee1eab53b6" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.20</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_82e9a375-5cac-463b-bd8b-947b49fecdf4" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.37</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_92f91e2e-396e-4e21-bc2d-1387a55f4b34" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.87</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shares used to compute Innoviva <br/>&#160;&#160;&#160;basic and diluted net income per share:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shares used to compute basic <br/>&#160;&#160;&#160;net income per share</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_98d3c986-ca42-4eaf-8790-fa235f7bfd49" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">65,435</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c363e2cd-5311-45e6-a415-25ffa7ba2ff7" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">69,644</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e25a13b3-4d61-42ac-8573-22a1bebc7456" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">82,062</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shares used to compute diluted <br/>&#160;&#160;&#160;net income per share</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d09fd4c3-2e66-41b1-b461-1a807a015b2f" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">86,876</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d5ff2fd8-8b2d-4031-9e1b-092a54748479" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">95,248</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b6349ab6-19b6-4485-8069-c8ea4a71ae31" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">94,310</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">See accompanying notes to consolidated financial statements.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">94</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">INNOVIVA, INC.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_statements_of_comprehensive"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(In thousands)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:51.311%;"/>
    <td style="width:1.481%;"/>
    <td style="width:1%;"/>
    <td style="width:12.75%;"/>
    <td style="width:1%;"/>
    <td style="width:1.481%;"/>
    <td style="width:1%;"/>
    <td style="width:12.75%;"/>
    <td style="width:1%;"/>
    <td style="width:1.481%;"/>
    <td style="width:1%;"/>
    <td style="width:12.75%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net income</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aab6e11e-1469-4bce-96f0-24bd64cc91d7" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">179,722</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6bbe29aa-fffc-4345-a718-3be240fe4141" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">220,262</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bb7f552f-d98b-4638-a5f0-9dfebcf2ac53" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">368,837</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Comprehensive income</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_95dd4bc1-bf0a-435c-b41b-b97083d4d121" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">179,722</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2cb98452-9653-4d53-b3c9-bf8857083e20" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">220,262</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_92739eec-3f1d-4a51-b3d2-328787ab803c" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">368,837</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Comprehensive income attributable to noncontrolling interests</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ab7014ea-3a72-4e2d-ba75-5521cc940cf9" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_38b3ef8f-9d6e-43e9-9f8b-0426668cbbc1" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,341</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4ea68774-6c9e-403f-bfeb-b818c71d14d1" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">102,983</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Comprehensive income attributable to Innoviva stockholders</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_642f9886-1ac0-47d1-8a12-809aaf22d834" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">179,722</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1ad9a681-78d4-4d92-abc6-19bd686ee294" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">213,921</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8875eadb-2474-4fc2-a95c-fb14c775bf12" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">265,854</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">See accompanying notes to consolidated financial statements.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">95</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.4in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">INNOVIVA, INC.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_statements_of_stockholders"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(In thousands)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:20.98%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:5.94%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:5.54%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:6.82%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:7.62%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:5.94%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:6.18%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:8.76%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:8.22%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Additional</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Common Stock</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Paid-In</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Accumulated</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Treasury Stock</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Noncontrolling</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Stockholders&#8217;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Capital</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Deficit</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Interest</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Equity</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balance as of January 1, 2021</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ab63fb30-dea3-49ab-9f6a-656c0af3f25a" contextRef="C_ce39f75c-0185-4a4f-87c1-250c81cd12eb" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" scale="3" decimals="INF" format="ixt:num-dot-decimal">101,392</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ce148201-e9fb-4b79-a5be-ec7b9d1a5a17" contextRef="C_ce39f75c-0185-4a4f-87c1-250c81cd12eb" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,014</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fec68995-61aa-4a09-8403-373781f1fdfd" contextRef="C_b5db3709-c76a-4a08-8c44-b8f59cdb4608" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,260,900</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b25f8fee-f1ca-486b-8121-abb620d79276" contextRef="C_29561087-beae-414b-bf9d-e689e21a5ee7" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">722,002</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b68ede1b-1e9f-4bf4-a940-56c80c70a626" contextRef="C_4c71a645-f25d-4cb5-8889-681f3449ecac" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" scale="3" decimals="INF" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3d32c251-5640-4d6c-a5c9-11a4a2dc7c8b" contextRef="C_4c71a645-f25d-4cb5-8889-681f3449ecac" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f73d69fa-5e1c-4777-b06a-a81c45a0ab02" contextRef="C_fa14f0b8-b80c-4b7b-b274-a48521a14a84" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">67,925</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a5076eda-6508-4f85-867b-c69b840cbe48" contextRef="C_646bb33b-4ef6-4493-b542-00c92f556418" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">607,837</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Distributions to noncontrolling interests</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fb5088f3-36af-4341-97e5-7169bb621bdb" contextRef="C_ec125de3-1e4e-4a75-b4bb-7673bacb9c03" name="inva:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersShares" unitRef="U_shares" scale="3" decimals="INF" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f65a99f4-d638-4786-b679-50c2e5a05580" contextRef="C_ec125de3-1e4e-4a75-b4bb-7673bacb9c03" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dbaf626b-25d1-4fd0-88c0-41503921abb3" contextRef="C_cb4e7215-9a5e-4dd4-aeee-e50dd4e2eb6b" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b780f6b9-c3f8-4473-bbe8-215c5e3f42c5" contextRef="C_ea7c0a60-08f5-4a3e-a061-5a67602a1ec1" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1b3ecc87-dda4-4768-8036-6d51872078fc" contextRef="C_d7cf516f-572b-431a-8937-a3fa41621ee5" name="inva:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersShares" unitRef="U_shares" scale="3" decimals="INF" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c978b0fa-7030-4a04-ab75-690f34e68426" contextRef="C_d7cf516f-572b-431a-8937-a3fa41621ee5" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_061100d7-21e9-4208-9294-40858bc3541e" contextRef="C_23e66452-ee29-415e-90e3-ae16681b068e" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">59,457</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9f8a4bd5-7baf-400b-af78-fff4beb9e993" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">59,457</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Equity activity of noncontrolling interests in <br/>&#160;&#160;&#160;a consolidated variable interest entity</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_480d5465-7bf5-457a-92dd-f9cc6bcf3752" contextRef="C_ec125de3-1e4e-4a75-b4bb-7673bacb9c03" name="inva:ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntityShares" unitRef="U_shares" scale="3" decimals="INF" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dbef375a-0735-4646-8a5e-0b9c5a439cc2" contextRef="C_ec125de3-1e4e-4a75-b4bb-7673bacb9c03" name="inva:ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f2a85f8a-a136-4a0f-9a18-d2f7ac942778" contextRef="C_cb4e7215-9a5e-4dd4-aeee-e50dd4e2eb6b" name="inva:ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_07c782f4-afcf-47f9-a70e-aec02cf625ea" contextRef="C_ea7c0a60-08f5-4a3e-a061-5a67602a1ec1" name="inva:ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8fe88257-ddfa-4887-a612-2453fb9c0bbd" contextRef="C_d7cf516f-572b-431a-8937-a3fa41621ee5" name="inva:ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntityShares" unitRef="U_shares" scale="3" decimals="INF" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d4a092be-77d5-4325-97cb-127c53cb615b" contextRef="C_d7cf516f-572b-431a-8937-a3fa41621ee5" name="inva:ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_062f119a-c63a-41a2-a6ed-1eec6aeb99c3" contextRef="C_23e66452-ee29-415e-90e3-ae16681b068e" name="inva:ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">259</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_15a4ff0a-2f4d-4667-81b9-34bfefd9f921" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="inva:ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">259</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercise of stock options and issuance of<br/>&#160;&#160;&#160;common stock units and stock awards, net of <br/>&#160;&#160;&#160;repurchase of shares to satisfy tax withholding</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2fa06984-ce02-4754-9cba-890ef461ce4d" contextRef="C_ec125de3-1e4e-4a75-b4bb-7673bacb9c03" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" unitRef="U_shares" scale="3" decimals="INF" format="ixt:num-dot-decimal">179</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3702c8b6-fc3e-4d6c-aa67-d602d60bf20c" contextRef="C_ec125de3-1e4e-4a75-b4bb-7673bacb9c03" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aa687969-aa53-4944-8790-417d80d51dfc" contextRef="C_cb4e7215-9a5e-4dd4-aeee-e50dd4e2eb6b" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,107</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_36229718-0708-4f34-b24c-867e5ec035d3" contextRef="C_ea7c0a60-08f5-4a3e-a061-5a67602a1ec1" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1d4819d2-f008-4c1e-a3a8-4a3d89c53ec2" contextRef="C_d7cf516f-572b-431a-8937-a3fa41621ee5" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" unitRef="U_shares" scale="3" decimals="INF" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7ebf8ad6-53ec-4e7e-9008-90e987a94b4b" contextRef="C_d7cf516f-572b-431a-8937-a3fa41621ee5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3bd44aec-d51c-47c8-99ad-f45ded4d37ec" contextRef="C_23e66452-ee29-415e-90e3-ae16681b068e" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_36838132-ccfb-45a9-baa1-48b871c24881" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,109</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Repurchase of common stock</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a7b98165-7dbe-4a37-bb60-5257c32a4bd7" contextRef="C_ec125de3-1e4e-4a75-b4bb-7673bacb9c03" name="us-gaap:TreasuryStockSharesAcquired" unitRef="U_shares" scale="3" decimals="INF" format="ixt:num-dot-decimal">32,005</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ecb72839-c23f-4686-8853-9412b6322551" contextRef="C_ec125de3-1e4e-4a75-b4bb-7673bacb9c03" name="us-gaap:TreasuryStockValueAcquiredCostMethod" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">320</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8466b306-fad6-42d1-a58f-a28be4590e2c" contextRef="C_cb4e7215-9a5e-4dd4-aeee-e50dd4e2eb6b" name="us-gaap:TreasuryStockValueAcquiredCostMethod" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8bbbabec-42a4-4f10-b3b9-3d43d55b3a1b" contextRef="C_ea7c0a60-08f5-4a3e-a061-5a67602a1ec1" name="us-gaap:TreasuryStockValueAcquiredCostMethod" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bc3cc2b9-6357-4bbd-9c17-660bce77ac27" contextRef="C_d7cf516f-572b-431a-8937-a3fa41621ee5" name="us-gaap:TreasuryStockSharesAcquired" unitRef="U_shares" scale="3" decimals="INF" sign="-" format="ixt:num-dot-decimal">32,005</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3bdbadcd-034a-4a6c-957d-d0b8e83c4a69" contextRef="C_d7cf516f-572b-431a-8937-a3fa41621ee5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">393,829</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_76aa2192-1161-4f6a-ba73-c4253701f85a" contextRef="C_23e66452-ee29-415e-90e3-ae16681b068e" name="us-gaap:TreasuryStockValueAcquiredCostMethod" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4c1c7be4-0cfb-454d-b031-971346004891" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="us-gaap:TreasuryStockValueAcquiredCostMethod" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">394,149</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bd5e3d74-3b08-4e0f-b740-b51ced915af9" contextRef="C_ec125de3-1e4e-4a75-b4bb-7673bacb9c03" name="inva:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares" unitRef="U_shares" scale="3" decimals="INF" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ca591670-eaa6-4635-a5d7-9087097baec9" contextRef="C_ec125de3-1e4e-4a75-b4bb-7673bacb9c03" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d034d5e1-5d4b-4bac-a0d8-bee59c3fc3c4" contextRef="C_cb4e7215-9a5e-4dd4-aeee-e50dd4e2eb6b" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,017</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5a4ae9ef-f498-43eb-a222-ef781bd9c1d2" contextRef="C_ea7c0a60-08f5-4a3e-a061-5a67602a1ec1" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b8d0ddfa-6d94-4873-a504-1ed37fb6d10b" contextRef="C_d7cf516f-572b-431a-8937-a3fa41621ee5" name="inva:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares" unitRef="U_shares" scale="3" decimals="INF" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_67ffd895-342f-4c13-91f7-5fff96f86d11" contextRef="C_d7cf516f-572b-431a-8937-a3fa41621ee5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_09b55a70-52c1-4ae6-8129-767bdc589be4" contextRef="C_23e66452-ee29-415e-90e3-ae16681b068e" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_974b865a-9565-4c37-873f-a34c0af40552" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,017</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net income</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f1d06376-9525-4d5d-a0e7-9a124404b8a4" contextRef="C_ec125de3-1e4e-4a75-b4bb-7673bacb9c03" name="inva:ProfitLossShares" unitRef="U_shares" scale="3" decimals="INF" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_69691171-4958-454d-9c15-bf2a1c9f5c60" contextRef="C_ec125de3-1e4e-4a75-b4bb-7673bacb9c03" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d7cafe7e-5926-45b6-920b-2e4b9cb63460" contextRef="C_cb4e7215-9a5e-4dd4-aeee-e50dd4e2eb6b" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c3b2c540-6a61-4683-833a-71768c733a2e" contextRef="C_ea7c0a60-08f5-4a3e-a061-5a67602a1ec1" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">265,854</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d278d794-ce1e-4cc7-8d5c-f10e1ff75adb" contextRef="C_d7cf516f-572b-431a-8937-a3fa41621ee5" name="inva:ProfitLossShares" unitRef="U_shares" scale="3" decimals="INF" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4a1d8fed-94c5-4471-a74c-4c6f764cf4af" contextRef="C_d7cf516f-572b-431a-8937-a3fa41621ee5" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7336ae14-f1b9-40d0-b7ae-bd94b2bc7e6a" contextRef="C_23e66452-ee29-415e-90e3-ae16681b068e" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">102,983</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f636e8ad-1f93-4334-9632-655833b657a2" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">368,837</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balance as of December 31, 2021</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1425463b-11ff-4f54-90e8-c1dd50ae576f" contextRef="C_b8a25da7-f0c7-4777-ac22-af038c29402e" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" scale="3" decimals="INF" format="ixt:num-dot-decimal">69,566</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4a6d5293-a1e6-4a20-ab98-c88e2b8d38de" contextRef="C_b8a25da7-f0c7-4777-ac22-af038c29402e" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">696</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_91e38050-d8ed-4d90-9288-90f41d0e4787" contextRef="C_c3ca1f40-a3c1-4ba0-9cd7-3d664a62262a" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,264,024</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_68ac1927-8781-44a7-bacb-8783d78605a2" contextRef="C_2c5b2d53-225f-409f-ad02-223827b8634c" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">456,148</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0e7de1aa-930c-4dc4-bed6-d8e1c2e64b8f" contextRef="C_25a18144-6924-42a5-a99d-aab05e77ca53" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" scale="3" decimals="INF" format="ixt:num-dot-decimal">32,005</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_58b38070-815a-4166-a8db-8f2f8b187b29" contextRef="C_25a18144-6924-42a5-a99d-aab05e77ca53" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">393,829</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_33e4149a-0b28-46a8-af8e-2d1ac68526ae" contextRef="C_d074e316-aefd-4e82-9593-cc19fd319a60" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">111,192</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_be2a2a8e-7cba-4e34-b0cf-4924e7f6c58b" contextRef="C_c2c8ab67-08be-4854-91e3-98e911bef5b3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">525,935</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:7.5pt;"><span style="-sec-ix-hidden:F_f0687ae1-b6c0-4b43-81f8-6dd3b3798531;"><span style="-sec-ix-hidden:F_ef17ea9b-bf17-4735-b022-25e18ecf85bb;"><span style="-sec-ix-hidden:F_2dbed8c2-40ac-48d1-9ee8-996ed0f6f21a;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cumulative adjustment due to adoption of <br/>   ASU 2020-06</span></span></span></span></span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e0d50866-8125-4de8-9155-0aa4cf11e724" contextRef="C_983ae2b6-5a3f-48bf-90f1-b4b741cfcbbe" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" scale="3" decimals="INF" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8f086191-4163-4e18-86af-c6c648c7a6ea" contextRef="C_983ae2b6-5a3f-48bf-90f1-b4b741cfcbbe" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_22075b8a-0e20-4961-aacc-e957deb35102" contextRef="C_4744817d-5145-49fb-a6a0-1308e192a8f6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">65,467</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4a4139e8-fa2f-406f-ad61-fad1c261b616" contextRef="C_f2f66487-eef9-477e-a54f-358af57f70cc" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">37,238</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7ae938d2-1d42-40ce-9389-6bcb494fcd84" contextRef="C_0d916e91-2dd2-468c-ab30-e90e2ac963b9" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" scale="3" decimals="INF" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a18e8b4e-6edc-4086-97b4-63aeb38db126" contextRef="C_0d916e91-2dd2-468c-ab30-e90e2ac963b9" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8f980827-bf03-4ac8-ac53-4c024c638360" contextRef="C_d10e57d1-8709-4825-a966-e724f8f4633f" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9c344607-abc5-4633-ab95-a8b5745b5163" contextRef="C_5058eabb-afd4-4dc1-a2f0-0ac8d38fabee" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">28,229</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Distributions to noncontrolling interests</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5ea4bc94-3690-43ad-b4c0-2e5f867f6509" contextRef="C_5f070bd2-c0df-4242-beff-e5f9b6727217" name="inva:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersShares" unitRef="U_shares" scale="3" decimals="INF" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_54677a5a-44fc-4579-9ef6-095df61753c7" contextRef="C_55652f07-0e2e-4bb9-b4c3-618b5066831e" name="inva:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersShares" unitRef="U_shares" scale="3" decimals="INF" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cfb5f56e-4f4d-4762-811e-974fb6465f43" contextRef="C_55652f07-0e2e-4bb9-b4c3-618b5066831e" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e3235ef3-5c91-4f3b-aa89-029fcce7f4a7" contextRef="C_921dd0ce-2b9e-4442-9188-880568f7b1f1" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">69,811</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5df9d25a-d7c0-4dcc-b4f4-7bbeae4ed5bf" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">69,811</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Recognition of noncontrolling interest upon<br/>&#160;&#160;&#160;initial consolidation of Entasis</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cacac36b-9e83-4970-b974-b38e8098f4df" contextRef="C_5f070bd2-c0df-4242-beff-e5f9b6727217" name="inva:RecognitionOfNoncontrollingInterestUponInitialConsolidationofEntasisShares" unitRef="U_shares" scale="3" decimals="INF" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d424a2cb-546b-4ced-96f8-6b43db228b0c" contextRef="C_5f070bd2-c0df-4242-beff-e5f9b6727217" name="inva:RecognitionOfNoncontrollingInterestUponInitialConsolidationOfEntasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_30780c8d-164c-4fb7-8a77-5a1f79e910b6" contextRef="C_bd738e6b-a394-4de5-a04f-1f55e1ed3e59" name="inva:RecognitionOfNoncontrollingInterestUponInitialConsolidationOfEntasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e3edfd5b-b494-4546-94dc-60136c343d84" contextRef="C_5460cef4-c4cc-4668-99ef-fb2e26f72ba2" name="inva:RecognitionOfNoncontrollingInterestUponInitialConsolidationOfEntasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8e3b29ee-1dc2-488b-b250-d1e5f1119937" contextRef="C_55652f07-0e2e-4bb9-b4c3-618b5066831e" name="inva:RecognitionOfNoncontrollingInterestUponInitialConsolidationofEntasisShares" unitRef="U_shares" scale="3" decimals="INF" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9c13da04-d511-4bcf-8d0c-93fcdd7d69ff" contextRef="C_55652f07-0e2e-4bb9-b4c3-618b5066831e" name="inva:RecognitionOfNoncontrollingInterestUponInitialConsolidationOfEntasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_61e22796-3bba-40cb-9010-f38b68410b8e" contextRef="C_921dd0ce-2b9e-4442-9188-880568f7b1f1" name="inva:RecognitionOfNoncontrollingInterestUponInitialConsolidationOfEntasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">38,471</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4834ba7a-5ed6-44ae-95bd-78c34585faef" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="inva:RecognitionOfNoncontrollingInterestUponInitialConsolidationOfEntasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">38,471</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Equity activity of noncontrolling interests in <br/>&#160;&#160;&#160;a consolidated variable interest entity</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_61eedcdd-75ea-45c3-8998-422caee86e7a" contextRef="C_55652f07-0e2e-4bb9-b4c3-618b5066831e" name="inva:ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntityShares" unitRef="U_shares" scale="3" decimals="INF" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_21278a54-f043-4596-b479-4e3fb1045ac4" contextRef="C_55652f07-0e2e-4bb9-b4c3-618b5066831e" name="inva:ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2642f7cc-e43f-4eb0-b58d-bcb10dc30346" contextRef="C_921dd0ce-2b9e-4442-9188-880568f7b1f1" name="inva:ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_25f0fcbb-3a12-487c-bd92-3090c8f66e85" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="inva:ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Derecognition of noncontrolling interests upon <br/>&#160;&#160;&#160;sale of TRC</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cc0e9919-1374-4d60-9c88-c7aa9703aab6" contextRef="C_5f070bd2-c0df-4242-beff-e5f9b6727217" name="inva:DerecognitionOfNoncontrollingInterestsUponSaleOfTrcShares" unitRef="U_shares" scale="3" decimals="INF" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6d791fe4-059e-440d-8567-43ade3591bad" contextRef="C_5f070bd2-c0df-4242-beff-e5f9b6727217" name="inva:DerecognitionOfNoncontrollingInterestsUponSaleOfTrc" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_55db6fa4-7005-4c36-809d-ffb0dc938c4e" contextRef="C_bd738e6b-a394-4de5-a04f-1f55e1ed3e59" name="inva:DerecognitionOfNoncontrollingInterestsUponSaleOfTrc" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a0a8e83f-fe64-4e40-9c6c-2d86bf03736c" contextRef="C_5460cef4-c4cc-4668-99ef-fb2e26f72ba2" name="inva:DerecognitionOfNoncontrollingInterestsUponSaleOfTrc" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">78</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_64e24ebb-9452-45a4-ac1f-7c8d0d517ec4" contextRef="C_55652f07-0e2e-4bb9-b4c3-618b5066831e" name="inva:DerecognitionOfNoncontrollingInterestsUponSaleOfTrcShares" unitRef="U_shares" scale="3" decimals="INF" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e83b21d5-316f-4076-9b25-ad9b54e2052f" contextRef="C_55652f07-0e2e-4bb9-b4c3-618b5066831e" name="inva:DerecognitionOfNoncontrollingInterestsUponSaleOfTrc" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1e23d3d1-fd93-4385-b9b5-fe5ee3b3ba23" contextRef="C_921dd0ce-2b9e-4442-9188-880568f7b1f1" name="inva:DerecognitionOfNoncontrollingInterestsUponSaleOfTrc" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">61,304</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_72af18d8-8420-44fd-84ec-2f472b9c4d56" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="inva:DerecognitionOfNoncontrollingInterestsUponSaleOfTrc" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">61,226</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Derecognition of noncontrolling interests upon <br/>&#160;&#160;&#160;acquisition of Entasis noncontrolling interest</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b675ce08-b8d7-4573-9910-623fe7f1656e" contextRef="C_5f070bd2-c0df-4242-beff-e5f9b6727217" name="inva:DerecognitionOfNoncontrollingInterestsUponAcquisitionOfEntasisMinorityInterestShares" unitRef="U_shares" scale="3" decimals="INF" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b3bd7a71-7bc3-49fd-8169-468f2c57cfc2" contextRef="C_5f070bd2-c0df-4242-beff-e5f9b6727217" name="inva:DerecognitionOfNonControllingInterestsUponAcquisitionOfEntasisMinorityInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_19eedc3f-bd71-4e36-a0e8-83af2b5b8e75" contextRef="C_bd738e6b-a394-4de5-a04f-1f55e1ed3e59" name="inva:DerecognitionOfNonControllingInterestsUponAcquisitionOfEntasisMinorityInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">14,153</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7b7f5260-e0ed-49c2-8aab-1bb425d60110" contextRef="C_5460cef4-c4cc-4668-99ef-fb2e26f72ba2" name="inva:DerecognitionOfNonControllingInterestsUponAcquisitionOfEntasisMinorityInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dc0c8b1b-f835-4d56-8d4d-51397bf991c4" contextRef="C_55652f07-0e2e-4bb9-b4c3-618b5066831e" name="inva:DerecognitionOfNoncontrollingInterestsUponAcquisitionOfEntasisMinorityInterestShares" unitRef="U_shares" scale="3" decimals="INF" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_707a47fb-835a-46ee-9156-90171445b869" contextRef="C_55652f07-0e2e-4bb9-b4c3-618b5066831e" name="inva:DerecognitionOfNonControllingInterestsUponAcquisitionOfEntasisMinorityInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e4c5614d-790d-4617-851b-f7085547cc9b" contextRef="C_921dd0ce-2b9e-4442-9188-880568f7b1f1" name="inva:DerecognitionOfNonControllingInterestsUponAcquisitionOfEntasisMinorityInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">28,009</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_61788997-53a1-40c3-9254-204b6919c618" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="inva:DerecognitionOfNonControllingInterestsUponAcquisitionOfEntasisMinorityInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">42,162</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercise of stock options and issuance of <br/>&#160;&#160;&#160;common stock units and stock awards, net of<br/>&#160;&#160;&#160;repurchase of shares to satisfy tax withholding</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_63e6e352-8530-40b0-941f-708a4854e660" contextRef="C_5f070bd2-c0df-4242-beff-e5f9b6727217" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" unitRef="U_shares" scale="3" decimals="INF" format="ixt:num-dot-decimal">269</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bee1df20-9ed5-49c2-839d-4d1426b83685" contextRef="C_5f070bd2-c0df-4242-beff-e5f9b6727217" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_035c3a19-2104-4f54-bd23-9e13647b29db" contextRef="C_bd738e6b-a394-4de5-a04f-1f55e1ed3e59" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">286</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a1efaa2a-59ca-4986-954b-31874630132f" contextRef="C_5460cef4-c4cc-4668-99ef-fb2e26f72ba2" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0db8f8f7-c46d-4f1d-8bbe-0af56bd3cab7" contextRef="C_55652f07-0e2e-4bb9-b4c3-618b5066831e" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" unitRef="U_shares" scale="3" decimals="INF" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9d752d02-e8ed-4a9d-98fc-fbccdce5e263" contextRef="C_55652f07-0e2e-4bb9-b4c3-618b5066831e" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_041aa176-7df0-48e5-b1be-c5e5330525b3" contextRef="C_921dd0ce-2b9e-4442-9188-880568f7b1f1" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fb664234-579e-4df4-8f2f-387c9635a4cb" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">288</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Capped call options associated with convertible <br/>&#160;&#160;&#160;senior notes due 2028</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f6e9ad19-bc0f-4c43-b795-f0253d36c447" contextRef="C_5f070bd2-c0df-4242-beff-e5f9b6727217" name="inva:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtInShares" unitRef="U_shares" scale="3" decimals="INF" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b6f659c4-207d-43ea-b683-bcd5a2325259" contextRef="C_5f070bd2-c0df-4242-beff-e5f9b6727217" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6e7d8cda-0ede-4411-9bd5-76c839bdffae" contextRef="C_bd738e6b-a394-4de5-a04f-1f55e1ed3e59" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">16,585</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b9d0ef2f-8213-4b4a-a3dd-e3ebb9fc6808" contextRef="C_5460cef4-c4cc-4668-99ef-fb2e26f72ba2" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cdca65b6-4d7c-4838-9251-89f4d496b640" contextRef="C_55652f07-0e2e-4bb9-b4c3-618b5066831e" name="inva:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtInShares" unitRef="U_shares" scale="3" decimals="INF" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c366df48-40da-4181-bea2-90a29499be32" contextRef="C_55652f07-0e2e-4bb9-b4c3-618b5066831e" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_10e75c0e-22df-446d-9164-43638799f5a9" contextRef="C_921dd0ce-2b9e-4442-9188-880568f7b1f1" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fabb8e5d-2b52-4092-b231-d334e700e1b9" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">16,585</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Conversion of convertible subordinated notes <br/>&#160;&#160;&#160;due 2023</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9d9061a2-07ee-415a-ad67-0c3334c1528b" contextRef="C_5f070bd2-c0df-4242-beff-e5f9b6727217" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" unitRef="U_shares" scale="3" decimals="INF" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6296ab0c-3e22-4303-b95e-a626dd506d38" contextRef="C_5f070bd2-c0df-4242-beff-e5f9b6727217" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9766cc9c-43dc-42a2-887f-435e66974feb" contextRef="C_bd738e6b-a394-4de5-a04f-1f55e1ed3e59" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_91005394-2b51-45d0-95d2-0cfadc620c47" contextRef="C_5460cef4-c4cc-4668-99ef-fb2e26f72ba2" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c5eb1507-cce0-4810-9bdf-a63a9ac1a0b4" contextRef="C_55652f07-0e2e-4bb9-b4c3-618b5066831e" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" unitRef="U_shares" scale="3" decimals="INF" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_81a4c356-902f-4f84-9de3-7334eb9bf44e" contextRef="C_55652f07-0e2e-4bb9-b4c3-618b5066831e" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_28b368eb-b589-447f-ab94-0c38e61b1505" contextRef="C_921dd0ce-2b9e-4442-9188-880568f7b1f1" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a3fb9f17-9823-4bed-9725-13c89debffbb" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Repurchase of common stock</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3e16b625-5b1c-4a29-902a-8cf3582d5f22" contextRef="C_5f070bd2-c0df-4242-beff-e5f9b6727217" name="us-gaap:TreasuryStockSharesAcquired" unitRef="U_shares" scale="3" decimals="INF" format="ixt:num-dot-decimal">647</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_29bf531f-d0da-4444-b73b-f73767b14b84" contextRef="C_5f070bd2-c0df-4242-beff-e5f9b6727217" name="us-gaap:TreasuryStockValueAcquiredCostMethod" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c7bdbfbb-19a4-4207-b411-86bf692be7ea" contextRef="C_bd738e6b-a394-4de5-a04f-1f55e1ed3e59" name="us-gaap:TreasuryStockValueAcquiredCostMethod" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,497</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_488f8e4f-b8dd-4fdf-8cf3-c4e2712a9e6f" contextRef="C_5460cef4-c4cc-4668-99ef-fb2e26f72ba2" name="us-gaap:TreasuryStockValueAcquiredCostMethod" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_40a6f8e0-4f8f-4c18-91d9-6ac4671779b3" contextRef="C_921dd0ce-2b9e-4442-9188-880568f7b1f1" name="us-gaap:TreasuryStockValueAcquiredCostMethod" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bda14e28-f109-40a4-a848-56f17f70cb1f" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="us-gaap:TreasuryStockValueAcquiredCostMethod" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,503</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0e066b7e-6d7f-4d4d-82e0-c3979079ef90" contextRef="C_5f070bd2-c0df-4242-beff-e5f9b6727217" name="inva:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares" unitRef="U_shares" scale="3" decimals="INF" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b15e97f1-3f64-41b1-afa7-17b558314115" contextRef="C_5f070bd2-c0df-4242-beff-e5f9b6727217" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_45051e1c-2469-4fdb-89e4-873c9770fbd2" contextRef="C_bd738e6b-a394-4de5-a04f-1f55e1ed3e59" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,225</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6a2201b5-94f8-4539-94f7-0e3f7d530978" contextRef="C_5460cef4-c4cc-4668-99ef-fb2e26f72ba2" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_54c687c1-0772-4a6c-b93b-ee7e1078bce0" contextRef="C_55652f07-0e2e-4bb9-b4c3-618b5066831e" name="inva:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares" unitRef="U_shares" scale="3" decimals="INF" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c246dcd0-7c5d-455a-9e9f-52a8c618fe9c" contextRef="C_55652f07-0e2e-4bb9-b4c3-618b5066831e" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_19f69174-7889-4a5d-b6ff-71ec41fa0c12" contextRef="C_921dd0ce-2b9e-4442-9188-880568f7b1f1" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,122</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ae7773a4-bd21-4e4f-9f2d-4f2d970b6267" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,347</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net income</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a527f1c2-2b64-449a-83e6-361bd8d9f18e" contextRef="C_5f070bd2-c0df-4242-beff-e5f9b6727217" name="inva:ProfitLossShares" unitRef="U_shares" scale="3" decimals="INF" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bbe72733-2508-4037-a8a5-375fd53a17b8" contextRef="C_5f070bd2-c0df-4242-beff-e5f9b6727217" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4e17f3dd-5e9f-40b3-ae68-6a256016bec9" contextRef="C_bd738e6b-a394-4de5-a04f-1f55e1ed3e59" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_657c359c-8f9c-4b47-bfd2-d6cf9feedad5" contextRef="C_5460cef4-c4cc-4668-99ef-fb2e26f72ba2" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">213,921</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_218604a2-b225-4a0e-9f5a-89dec4950d9a" contextRef="C_55652f07-0e2e-4bb9-b4c3-618b5066831e" name="inva:ProfitLossShares" unitRef="U_shares" scale="3" decimals="INF" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c2196d9f-6b1d-428b-9935-68569d7e77fd" contextRef="C_55652f07-0e2e-4bb9-b4c3-618b5066831e" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_76dd6ffa-074f-4abe-9837-78a9e6d77359" contextRef="C_921dd0ce-2b9e-4442-9188-880568f7b1f1" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,341</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_06ec7d0e-8c0d-4b83-bab8-8ba3aa7c433c" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">220,262</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balance as of December 31, 2022</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_02f43c37-9c34-4989-b316-11b45c762b3c" contextRef="C_f20a0f71-d04c-4707-b554-1102f62cf1a6" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" scale="3" decimals="INF" format="ixt:num-dot-decimal">69,188</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f9da50ba-d5f8-4a8b-9b84-25eb0d151568" contextRef="C_f20a0f71-d04c-4707-b554-1102f62cf1a6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">692</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7d48a12b-2874-4fbd-ae50-bd1ff31475bf" contextRef="C_19d44124-af4c-4c1d-92f5-962be9ea56b6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,163,836</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_373ee7a8-8d9c-457a-90fb-d26bac7c2ac3" contextRef="C_f0655569-45ea-4da7-be44-e42a72acf91f" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">204,911</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6734873e-577c-4e88-9de9-2bb3354c01cb" contextRef="C_ffcfb827-8e39-4d8f-add9-6684b4c98b48" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" scale="3" decimals="INF" format="ixt:num-dot-decimal">32,005</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_642a5b17-53b8-4e03-bbbf-87938c9020d2" contextRef="C_ffcfb827-8e39-4d8f-add9-6684b4c98b48" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">393,829</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5493223a-0451-4a52-8ad2-8b36b148c8fa" contextRef="C_2f32a53f-9c4b-4122-bfb3-3e89cba768ae" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0a978d70-9475-46ec-9d35-30a323353b20" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">565,788</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercise of stock options and <br/>&#160;&#160;&#160;issuance of common stock units <br/>&#160;&#160;&#160;and stock awards, net of <br/>&#160;&#160;&#160;repurchase of shares to satisfy <br/>&#160;&#160;&#160;tax withholding</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b03749cb-da16-41d7-8250-23cfd7869e9d" contextRef="C_102d957f-b55b-4b0c-b290-8ba82889bebc" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" unitRef="U_shares" scale="3" decimals="INF" format="ixt:num-dot-decimal">293</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_71f07903-3f3b-46c9-bdf7-cd89cb71e09e" contextRef="C_102d957f-b55b-4b0c-b290-8ba82889bebc" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7e6c1272-fd25-44f4-972d-043287395982" contextRef="C_ed72a4a0-2d3e-42f5-b565-15482cc0126c" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">89</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_06eab76b-f229-4f39-a7fe-15e29f42c860" contextRef="C_b7286a7d-74d3-4d92-a0a9-a2bb49f254d9" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ead41912-2b5c-4a71-aaff-d6bbd1aac063" contextRef="C_c104561f-a325-42f1-b855-c5fa80ede0f4" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" unitRef="U_shares" scale="3" decimals="INF" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bb4bc6b3-ddd7-49a1-a55e-f0b6e7350af5" contextRef="C_c104561f-a325-42f1-b855-c5fa80ede0f4" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_697e4a25-abe0-40d5-a7e8-84a631dc431e" contextRef="C_c572fa7f-d00c-4858-9672-e4e0981286bf" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_72eb33f9-0350-48c8-b550-4c2d072aa209" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">92</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Repurchase of common stock</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c6c1e66d-e9d1-44e5-a74b-fc356c0f6e73" contextRef="C_102d957f-b55b-4b0c-b290-8ba82889bebc" name="us-gaap:TreasuryStockSharesAcquired" unitRef="U_shares" scale="3" decimals="INF" format="ixt:num-dot-decimal">6,174</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0ac62294-dd97-4105-8ef6-5961c5c737ba" contextRef="C_102d957f-b55b-4b0c-b290-8ba82889bebc" name="us-gaap:TreasuryStockValueAcquiredCostMethod" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">62</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3b03654a-12f7-4b55-ae32-2a5ff628a7d0" contextRef="C_ed72a4a0-2d3e-42f5-b565-15482cc0126c" name="us-gaap:TreasuryStockValueAcquiredCostMethod" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">76,422</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_79031a19-7dc3-4a84-9d46-bd0442d7c738" contextRef="C_b7286a7d-74d3-4d92-a0a9-a2bb49f254d9" name="us-gaap:TreasuryStockValueAcquiredCostMethod" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ddc1aad7-8b78-47bd-ba33-61c68708aa4c" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:TreasuryStockValueAcquiredCostMethod" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">76,484</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_025df4db-787c-42bc-916a-0d2974471f5e" contextRef="C_102d957f-b55b-4b0c-b290-8ba82889bebc" name="inva:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares" unitRef="U_shares" scale="3" decimals="INF" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c876bb32-3e52-47f2-ac57-27ec8fd07d4b" contextRef="C_102d957f-b55b-4b0c-b290-8ba82889bebc" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8be98709-22a3-443a-82c5-3f94a3fb8e3b" contextRef="C_ed72a4a0-2d3e-42f5-b565-15482cc0126c" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,837</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f6b72e7a-b081-4fb3-8e12-55ff4b200d5a" contextRef="C_5a9d38bb-6bc6-4e0d-b81a-0f669ce07277" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d7f78835-ddf5-4205-9243-19574d3bcf15" contextRef="C_c104561f-a325-42f1-b855-c5fa80ede0f4" name="us-gaap:TreasuryStockSharesAcquired" unitRef="U_shares" scale="3" decimals="INF" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7918e0a1-764a-4da9-901a-783dddca4df3" contextRef="C_c104561f-a325-42f1-b855-c5fa80ede0f4" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_46a153ac-4033-4043-a62e-5041ecb887d0" contextRef="C_c572fa7f-d00c-4858-9672-e4e0981286bf" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_10f057e6-afb5-4297-836c-db46e7ecaa0b" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,837</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net income</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2b59120f-993c-487f-b4df-4509c4352c11" contextRef="C_102d957f-b55b-4b0c-b290-8ba82889bebc" name="inva:ProfitLossShares" unitRef="U_shares" scale="3" decimals="INF" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5111e09c-ea18-415f-9dda-6e91b2013053" contextRef="C_102d957f-b55b-4b0c-b290-8ba82889bebc" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9332b750-9fa3-4b7e-80eb-4a8a916666d6" contextRef="C_ed72a4a0-2d3e-42f5-b565-15482cc0126c" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_89efe26f-5dd3-4ce1-b0fa-7df0a64b4b79" contextRef="C_5a9d38bb-6bc6-4e0d-b81a-0f669ce07277" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">179,722</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c25b2150-b8cd-4692-b151-944688136dac" contextRef="C_c104561f-a325-42f1-b855-c5fa80ede0f4" name="inva:ProfitLossShares" unitRef="U_shares" scale="3" decimals="INF" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a6a63be3-a6b9-4732-9603-7da3263d01d6" contextRef="C_c104561f-a325-42f1-b855-c5fa80ede0f4" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_644d6a2e-d8c6-4b44-9d2b-8f5fcd7de068" contextRef="C_c572fa7f-d00c-4858-9672-e4e0981286bf" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_75423b6b-61fa-446a-ac52-90d65101019c" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">179,722</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balance as of December 31, 2023</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6cb58af0-4ced-45e6-a047-4cbe9b11c552" contextRef="C_195a4e8d-1787-4289-8f28-a87a026f6c66" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" scale="3" decimals="INF" format="ixt:num-dot-decimal">63,307</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1aafc340-64ee-4bf4-9a37-636bff73dfc8" contextRef="C_195a4e8d-1787-4289-8f28-a87a026f6c66" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">633</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ad1af4c8-e805-4b36-b6f2-c1a0456e079f" contextRef="C_3341913e-5e8a-43b4-af63-a752924ce8bc" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,093,340</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9884d00b-1de8-48e0-a541-b71b35840fd7" contextRef="C_71266bcb-340c-4b6f-bce7-ec001e02f542" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">25,189</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_305d06d4-642f-477a-a638-65720d78e64f" contextRef="C_9125c6de-8c86-4bde-9b04-80aa987c21cc" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" scale="3" decimals="INF" format="ixt:num-dot-decimal">32,005</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4f1df1c5-6348-4b00-a801-957af35b6609" contextRef="C_9125c6de-8c86-4bde-9b04-80aa987c21cc" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">393,829</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5448a0f0-f69b-4cb0-9777-c2d2639b9827" contextRef="C_41328be9-6954-48ec-8905-bb9f765ccba2" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5cb737f2-8c1a-41cf-93f4-614223b82344" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">674,955</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">See accompanying notes to consolidated financial statements.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.4in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">96</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.3in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">INNOVIVA, INC.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_statements_of_cash_flows"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(In thousands)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:4.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:52.619%;"/>
    <td style="width:1.359%;"/>
    <td style="width:1%;"/>
    <td style="width:12.435%;"/>
    <td style="width:1%;"/>
    <td style="width:1.359%;"/>
    <td style="width:1%;"/>
    <td style="width:12.435%;"/>
    <td style="width:1%;"/>
    <td style="width:1.359%;"/>
    <td style="width:1%;"/>
    <td style="width:12.435%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cash flows from operating activities</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net income</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_099e34d3-251a-4c11-85f7-f81213359770" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">179,722</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ba3feacc-98b1-4873-93e8-735b209e3a5a" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">220,262</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_46ac10ca-915f-4783-a5c5-ca74d3b036e8" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">368,837</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Adjustments to reconcile net income to net cash provided by operating activities:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred income taxes</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4f717117-4f69-4734-9d4f-e77dcabd0bd4" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,400</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6d270984-0b37-4370-9285-0357130aa846" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,006</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0e811414-44f0-4b39-96dd-5d03405611af" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">76,432</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Amortization of capitalized fees and depreciation of property and equipment</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b2d9156d-5365-495e-a34d-a712c6cbbe30" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="inva:AmortizationOfCapitalizedFeesAndDepreciationOfPropertyAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,921</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c6fa566a-52dc-4759-aaaf-d1d770baf660" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="inva:AmortizationOfCapitalizedFeesAndDepreciationOfPropertyAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,931</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0c085112-b065-435a-8300-a73c19b56c68" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="inva:AmortizationOfCapitalizedFeesAndDepreciationOfPropertyAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,832</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Amortization of acquired intangible assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7c6291eb-35c7-48ac-8213-ee890a331fe4" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:AmortizationOfIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,784</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_89bfc8b7-51c3-41bf-acf7-fc95d73d202a" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="us-gaap:AmortizationOfIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,581</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2765394e-2956-43eb-a5f5-0fa17d2a592b" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="us-gaap:AmortizationOfIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inventory fair value step-up adjustment included in cost of products sold</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_08600c29-d78c-411c-8d75-99e9be3c1862" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="inva:InventoryFairValueStepUpAdjustmentIncludedInCostOfProductSales" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,164</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6230ce41-7a5d-4f40-802b-5c9c0a0bd2de" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="inva:InventoryFairValueStepUpAdjustmentIncludedInCostOfProductSales" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,023</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b19d8611-315f-4f2a-baad-e1de52f13870" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="inva:InventoryFairValueStepUpAdjustmentIncludedInCostOfProductSales" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_52db40cf-cdea-402f-a66b-43789a5a2ce3" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,837</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_45138f7a-096c-4e09-a7c1-75498bb93bd5" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,347</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c61f05ed-a11d-43af-9524-5553b98e45d5" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,017</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Amortization of debt discount and issuance costs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_91d4232f-0001-4b54-b818-85c65f8279ac" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,065</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_78bb979d-bd73-441c-ae71-7dfa8fbf7bed" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,055</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1e4d08d1-30c3-467f-9606-cf4f8c5fd953" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,136</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Changes in fair values of equity method investments, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;min-width:fit-content;">(</span><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b9421a9a-386d-45e1-94fd-6c5d8f03697d" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:IncomeLossFromEquityMethodInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">77,392</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_83634127-35fa-4870-858a-11be4308f8b3" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="us-gaap:IncomeLossFromEquityMethodInvestments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">161,749</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;min-width:fit-content;">(</span><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bcd98d6c-8022-48d9-b62d-75443862c250" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="us-gaap:IncomeLossFromEquityMethodInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">84,392</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Changes in fair values of equity and long-term investments, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;min-width:fit-content;">(</span><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_31ad1343-abe7-4f90-b7b7-1166de964adb" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="inva:UnrealizedOtherGainLossOnInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,129</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;min-width:fit-content;">(</span><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d42433e4-e0d7-470e-9c06-75c6e6ad6bee" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="inva:UnrealizedOtherGainLossOnInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,462</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;min-width:fit-content;">(</span><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_18c28bba-0ae6-4366-bd68-5dc8081d4ebb" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="inva:UnrealizedOtherGainLossOnInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,917</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss on extinguishment of debt</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5c3dc769-2078-4420-b53e-64885eb06632" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_477103c2-a968-4071-a3db-08b2bbb255f6" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">20,662</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_095ea57c-0c07-4005-a905-1ae289f8c54f" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net gain on sale of TRC</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a23f3944-22d2-4bc0-89ca-74d44b8ce219" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:DeconsolidationGainOrLossAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;min-width:fit-content;">(</span><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ed357a98-b14b-4ed9-b1f8-a133b667d68d" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="us-gaap:DeconsolidationGainOrLossAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">266,696</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7d089644-64a2-403f-b41a-58928ca562d2" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="us-gaap:DeconsolidationGainOrLossAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other non-cash items</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;min-width:fit-content;">(</span><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8a479437-1b43-4d65-8791-06293eabafa3" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:OtherNoncashIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">517</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_66d1f9a4-03ff-4016-8cef-8b7392786b70" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="us-gaap:OtherNoncashIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3,402</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;min-width:fit-content;">(</span><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_66920ef6-0c13-42f5-8c73-e9dffaef28bc" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="us-gaap:OtherNoncashIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">259</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Changes in operating assets and liabilities:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts receivable</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;min-width:fit-content;">(</span><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9867e02d-8d42-4b47-9da8-16b4a85a1d89" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:IncreaseDecreaseInAccountsReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,053</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;min-width:fit-content;">(</span><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_303c7ef0-4583-4139-9235-71a12bd5eeda" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="us-gaap:IncreaseDecreaseInAccountsReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,525</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d8c7698c-1c29-42f5-829c-6fe823c1c11a" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="us-gaap:IncreaseDecreaseInAccountsReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Receivables from collaboration arrangements</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;min-width:fit-content;">(</span><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a5954a02-ef6c-48e7-ba0f-b1a5170b8a6e" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:IncreaseDecreaseInDueFromRelatedPartiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,949</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a0aad8d1-7c7a-4e61-8277-e2ac999f28ca" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="us-gaap:IncreaseDecreaseInDueFromRelatedPartiesCurrent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">13,319</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;min-width:fit-content;">(</span><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_01914e2e-03b8-454a-97a5-64f0c3c3ac17" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="us-gaap:IncreaseDecreaseInDueFromRelatedPartiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,780</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inventory</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;min-width:fit-content;">(</span><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_56ce69df-55b5-49bb-9831-f14978b24f2e" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:IncreaseDecreaseInInventories" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,004</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_99912eeb-c54d-4340-8deb-03567690f655" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="us-gaap:IncreaseDecreaseInInventories" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">280</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5944dacb-5138-4273-ab64-bd47c451eb76" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="us-gaap:IncreaseDecreaseInInventories" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b1cf2aa1-b186-4caf-83e9-5e0b1565411e" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:IncreaseDecreaseInPrepaidExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">7,929</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;min-width:fit-content;">(</span><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6bfbf710-7e08-46be-82bc-981ab922f506" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="us-gaap:IncreaseDecreaseInPrepaidExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,350</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e7eeb964-cac3-4b0b-8b7d-03bfd80a4e16" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="us-gaap:IncreaseDecreaseInPrepaidExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">203</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;min-width:fit-content;">(</span><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1bc79fd7-4974-40f2-94c5-b6cfa1b32458" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,965</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;min-width:fit-content;">(</span><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_880e84c6-0505-40bb-bc72-6e5223b36776" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,341</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7a43b4a9-5d0e-4eec-8798-85c0bf67c58a" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7506aa35-98d9-4ac2-9390-55d2c4f50367" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,778</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5a44fafd-06cf-46f3-9ba6-128549472a4e" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">92</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;min-width:fit-content;">(</span><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e9377ddd-46bd-4041-a62a-9a8d6adeb83a" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">39</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued personnel-related expenses and other accrued liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;min-width:fit-content;">(</span><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c4bb32b4-b43a-445b-accd-541dfd063664" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,498</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_884b17f6-c9cd-4a78-93e8-48b43662f9e8" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,913</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;min-width:fit-content;">(</span><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_921153b2-059c-4738-865b-8a9935e1192e" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">257</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued interest payable</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;min-width:fit-content;">(</span><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8dfed973-65ad-44b1-9272-f0a6297c02ba" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:IncreaseDecreaseInInterestPayableNet" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">937</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b4520b21-cccb-4531-a9a2-2987cdeb4f0e" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="us-gaap:IncreaseDecreaseInInterestPayableNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">207</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d9fd988d-f195-40bf-a18d-ed6b51f5bfbb" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="us-gaap:IncreaseDecreaseInInterestPayableNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred revenue</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;min-width:fit-content;">(</span><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_16dc0d05-79c2-468a-ac79-a44e1e22e127" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:IncreaseDecreaseInDeferredRevenue" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">817</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;min-width:fit-content;">(</span><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_90cb14e2-3a82-468d-ac51-36acd4e3c721" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="us-gaap:IncreaseDecreaseInDeferredRevenue" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">755</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_01f51ba3-ea31-4207-9079-9403892d8c4e" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="us-gaap:IncreaseDecreaseInDeferredRevenue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Income tax payable</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b02fb408-a3ec-4b71-a520-bbd63080c7ea" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,725</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4ff4d9e3-edd0-4edf-bdbe-78fb9294298e" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,026</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_606c4013-3f34-45e7-91a9-e5b6e10e9669" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30pt;text-indent:0;font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash provided by operating activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_82b0c9f6-dc1c-4431-9c3b-8cd03f2a7df6" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">141,064</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d1492c1b-6d1a-45e1-a6bf-58deb235a3c0" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">201,726</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_15716cf7-5478-42fd-8386-5da1a6fd0b4d" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">363,813</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cash flows from investing activities</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Purchases of equity method investments</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e7437122-9a7a-49db-b3d3-e805f94c4bf3" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;min-width:fit-content;">(</span><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eb3757df-b39d-4e4d-af9f-a9a5704b1bfd" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">45,000</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;min-width:fit-content;">(</span><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d230c72b-0e7c-4e57-984f-c3977354bd89" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">44,000</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Purchases of trading securities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;min-width:fit-content;">(</span><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_28561914-23a1-42e0-b574-abda35eae15a" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:PaymentsToAcquireMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">65,132</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_14852f1d-3a07-4ece-a93e-84571db9c580" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="us-gaap:PaymentsToAcquireMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;min-width:fit-content;">(</span><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1f8b769f-38f9-45d8-8068-a9b51651cd90" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="us-gaap:PaymentsToAcquireMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,905</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Purchases of equity and long-term investments</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;min-width:fit-content;">(</span><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ffbfc274-1691-4194-8fe1-be89ceb7337b" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:PaymentsToAcquireLongtermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,218</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;min-width:fit-content;">(</span><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0dd3f4e7-2399-4d4e-baa4-0a4498aa0c07" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="us-gaap:PaymentsToAcquireLongtermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,725</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;min-width:fit-content;">(</span><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_63d11917-2e35-4308-8550-1a942fbea229" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="us-gaap:PaymentsToAcquireLongtermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,373</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Purchases of equity investments managed by ISP Fund LP</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;min-width:fit-content;">(</span><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ac0d4dc3-a5c1-420c-b47c-5f95a6482d98" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="inva:PurchasesOfEquityInvestmentsManagedByIspFundLp" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">31,164</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;min-width:fit-content;">(</span><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8a519b40-3a4e-490a-b192-2c1a036873ec" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="inva:PurchasesOfEquityInvestmentsManagedByIspFundLp" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">60,910</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;min-width:fit-content;">(</span><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_20f9854e-5e31-43f9-b698-1262f7d26dd3" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="inva:PurchasesOfEquityInvestmentsManagedByIspFundLp" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">190,970</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Purchases of trading security managed by ISP Fund LP</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2c5ef212-8e5c-4a0c-9a51-8386728161e4" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="inva:PurchasesOfTradingSecurityManagedByIspFundLp" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;min-width:fit-content;">(</span><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_55b94717-9dc8-45bd-8db9-07980deaaf9f" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="inva:PurchasesOfTradingSecurityManagedByIspFundLp" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">50,000</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f991eb5f-3859-4e7a-ae80-ff854ad5df08" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="inva:PurchasesOfTradingSecurityManagedByIspFundLp" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Sales of equity investments managed by ISP Fund LP</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_35ef6511-2d12-4771-a568-443082fe774c" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="inva:SaleOfEquityInvestmentsManagedByIspFundLp" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">72,500</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eea0413d-bded-43ee-ad8e-f5ef27374065" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="inva:SaleOfEquityInvestmentsManagedByIspFundLp" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,281</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dbc744f9-d737-4cee-86f5-4df5d686f09f" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="inva:SaleOfEquityInvestmentsManagedByIspFundLp" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,440</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Purchase and sales of other investments managed by ISP Fund LP, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;min-width:fit-content;">(</span><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_94919e93-b049-4186-9a4b-96df45604543" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="inva:PurchaseAndSaleOfOtherInvestmentsManagedByIspFundLp" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">41,336</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;min-width:fit-content;">(</span><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ad894be0-98bf-4e65-8cf6-447ed6c48ebd" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="inva:PurchaseAndSaleOfOtherInvestmentsManagedByIspFundLp" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,371</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9a8f2c7f-8164-44c8-8cef-40a2ed6ce707" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="inva:PurchaseAndSaleOfOtherInvestmentsManagedByIspFundLp" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">279,530</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Purchases of property and equipment</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;min-width:fit-content;">(</span><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2b86fd11-a368-488e-86f9-ffba3744717f" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">411</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;min-width:fit-content;">(</span><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_58a0cb4a-ffe7-46d7-9f72-5ffe0bbf676a" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">67</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1e87f9f0-6889-4f20-ac9d-048350fef463" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proceeds from sale of ownership interest in TRC, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9a23f513-0d81-466e-bf86-a42ea96e7d11" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="inva:NetProceedsFromSaleOfVariableInterestEntityEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1fac6353-e37e-4efb-8860-715da3c49ff7" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="inva:NetProceedsFromSaleOfVariableInterestEntityEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">248,191</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ff52a95a-60fd-46fb-bd04-e35809c286f2" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="inva:NetProceedsFromSaleOfVariableInterestEntityEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash acquired through the consolidation of Entasis</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_498b0e35-0b0d-4349-8166-085318614adc" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:CashAcquiredFromAcquisition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ba0a6736-265c-468a-94f2-f0da8c34da57" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="us-gaap:CashAcquiredFromAcquisition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,070</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dc60a367-9ef0-40a0-a891-9d372457e945" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="us-gaap:CashAcquiredFromAcquisition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash paid for the acquisition of La Jolla, net of cash acquired</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6ce4214c-3def-49de-a706-e66d3b6f9e13" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="inva:CashPaidForTheAcquisitionOfLaJollaPharmaceuticalCompanyNetOfCashAcquired" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;min-width:fit-content;">(</span><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2d17242c-3239-4e4b-95bc-ee78dfac1ada" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="inva:CashPaidForTheAcquisitionOfLaJollaPharmaceuticalCompanyNetOfCashAcquired" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">159,103</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_976b0eac-d58c-4fff-a4b6-3184212d5163" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="inva:CashPaidForTheAcquisitionOfLaJollaPharmaceuticalCompanyNetOfCashAcquired" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30pt;text-indent:0;font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash provided by (used in) investing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;min-width:fit-content;">(</span><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7bd01cfc-7ca4-4163-b54f-77708cf847cc" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">66,761</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;min-width:fit-content;">(</span><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3478fb28-a218-4ea7-8cea-9e0cdc8c01ba" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">56,634</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9dd5b164-4f20-4071-8bc3-4406f8932edd" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43,722</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cash flows from financing activities</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Distributions to noncontrolling interests</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_58855024-da42-4625-9231-2cdd9e7b33c1" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:PaymentsToMinorityShareholders" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;min-width:fit-content;">(</span><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0a0b3336-c609-4c97-b72d-aa4d39be37dd" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="us-gaap:PaymentsToMinorityShareholders" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">69,811</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;min-width:fit-content;">(</span><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b14520d9-d3df-4d70-80d5-d45d62231513" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="us-gaap:PaymentsToMinorityShareholders" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">59,457</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Purchase of Entasis noncontrolling interest</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d0770d03-2f07-4267-a40e-9891f0cd60f8" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="inva:PurchaseOfEntasisNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;min-width:fit-content;">(</span><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_22b072c0-7e29-46d1-847e-89b046776afa" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="inva:PurchaseOfEntasisNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43,910</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_90f1eed6-82df-4a3e-93c4-cc3776d16bf5" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="inva:PurchaseOfEntasisNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Repurchase of common stock</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;min-width:fit-content;">(</span><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ea4e9ff3-9cda-4aa7-97b2-7f5e8f06709b" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:PaymentsForRepurchaseOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">75,728</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;min-width:fit-content;">(</span><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f0a62b60-176a-4f00-aafd-10632b0fb7b3" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="us-gaap:PaymentsForRepurchaseOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,503</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;min-width:fit-content;">(</span><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c3bf7417-e773-441a-8791-5acf3b6646cf" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="us-gaap:PaymentsForRepurchaseOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">394,149</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Repurchase of shares to satisfy tax withholding</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;min-width:fit-content;">(</span><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a82bd7c6-7961-40c4-b73e-057aee2f32b2" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">77</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;min-width:fit-content;">(</span><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d81e9a12-d118-4d18-9a81-7eb10533972d" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">82</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;min-width:fit-content;">(</span><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d9c9e230-7a0a-4c39-a078-8b27ae721a24" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">60</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proceeds from issuances of common stock, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_61dc1ae4-b5af-44b8-a444-367b54b1fd99" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">170</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7b8630a3-16c8-4c45-ac0a-021e95c73488" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">370</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_60a20b9f-d27d-4361-80e1-7a25f901f953" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,169</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Payment for repurchase of convertible subordinated notes due 2023</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;min-width:fit-content;">(</span><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_da5a2bc6-15fe-4156-a42d-da7d756609d7" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:RepaymentsOfUnsecuredDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">96,204</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;min-width:fit-content;">(</span><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_01b1ab99-16de-4ade-bc6a-5dccd13329f3" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="us-gaap:RepaymentsOfUnsecuredDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">165,131</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_42281ae2-a677-44f7-a04c-e698d429b8dd" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="us-gaap:RepaymentsOfUnsecuredDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Purchases of capped call options associated with convertible senior notes due 2028</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3725d517-0469-46cd-9307-6733f5e6e342" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="inva:PurchasesOfCappedCallOptionsAssociatedWithConvertibleSeniorNotes" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;min-width:fit-content;">(</span><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0fe3d0e3-ed3e-4fef-91ee-ded86971c4bb" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="inva:PurchasesOfCappedCallOptionsAssociatedWithConvertibleSeniorNotes" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,037</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_69279218-b5ac-48c6-ab02-a86f98e74d63" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="inva:PurchasesOfCappedCallOptionsAssociatedWithConvertibleSeniorNotes" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proceeds from issuance of convertible senior notes due 2028, net of issuance costs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4a993779-54b0-47d7-a481-74c85a8b1569" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:ProceedsFromIssuanceOfDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7317e2ce-240e-4f65-9f1e-e4d7357e05bb" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="us-gaap:ProceedsFromIssuanceOfDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">252,536</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_86e6394b-14b0-48c6-8880-526c0c59dc14" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="us-gaap:ProceedsFromIssuanceOfDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30pt;text-indent:0;font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash used in financing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;min-width:fit-content;">(</span><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aa8e4d3f-b20a-4ccc-899b-2ee85d057ffb" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">171,839</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;min-width:fit-content;">(</span><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_716937c0-3ac9-4190-88e6-68d60b82235b" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">55,568</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;min-width:fit-content;">(</span><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8537df26-9919-49af-bcae-6195428c7b3d" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">452,497</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Net increase (decrease) in cash and cash equivalents</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;min-width:fit-content;">(</span><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_63a8edcb-02f0-41f9-a450-08d114c1224d" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">97,536</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9e3bc0f1-0ce9-4cae-bfcc-bcd901dc6079" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">89,524</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;min-width:fit-content;">(</span><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_47227f66-1281-4ecd-9c5d-760c3c1f13b1" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">44,962</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cash and cash equivalents at beginning of period</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_22d81949-6c67-4403-bbb7-c7aa8ffd801b" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">291,049</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5e452d49-ac85-472f-97b0-84dad69f03e6" contextRef="C_c2c8ab67-08be-4854-91e3-98e911bef5b3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">201,525</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ee71aee1-87de-46ac-8cd2-508403b72c29" contextRef="C_646bb33b-4ef6-4493-b542-00c92f556418" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">246,487</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cash and cash equivalents at end of period</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_92d3b492-102f-4eb7-8f3f-c52e3b822d90" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">193,513</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2cb8d2fd-f91e-4144-8db3-d1be81e673cf" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">291,049</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_638db1cd-7a0e-48f8-bc52-deed850f7adc" contextRef="C_c2c8ab67-08be-4854-91e3-98e911bef5b3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">201,525</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:52.619%;"/>
    <td style="width:1.359%;"/>
    <td style="width:1%;"/>
    <td style="width:12.435%;"/>
    <td style="width:1%;"/>
    <td style="width:1.359%;"/>
    <td style="width:1%;"/>
    <td style="width:12.435%;"/>
    <td style="width:1%;"/>
    <td style="width:1.359%;"/>
    <td style="width:1%;"/>
    <td style="width:12.435%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Supplemental Disclosure of Cash Flow Information:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash paid for interest</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2f7d9d58-413a-49d6-bbab-e5571366aee2" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:InterestPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,381</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_66ccbcd5-025b-4e42-ae15-dc99b80f1f63" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="us-gaap:InterestPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,736</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bb918af0-39df-4906-bd40-6e6deab92a32" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="us-gaap:InterestPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,933</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash paid for income taxes</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_776e6bcb-c048-4e33-8f14-2adce6352a2d" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:IncomeTaxesPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_de1a6d53-dbc5-46cc-b2d7-c8f7bfd5f1ae" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="us-gaap:IncomeTaxesPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">53,855</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3d7f9bc3-7140-406e-bc39-dac5023eb8d2" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="us-gaap:IncomeTaxesPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Supplemental Disclosure of Non-cash Investing and Financing Activities:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued interest income converted to long-term investments</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e6aa03de-c79c-4c83-952c-c90371eb6fed" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="inva:AccruedInterestIncomeIncludedInLongTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,666</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_110528b5-db79-40e9-a2f6-aaa75c973c4e" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="inva:AccruedInterestIncomeIncludedInLongTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a893ee63-a1b7-4857-a6f6-dacca29d3498" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="inva:AccruedInterestIncomeIncludedInLongTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Adoption of ASU 2020-06</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c8300200-e02d-4e64-8c3e-83229294af6f" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="inva:NonCashActivity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;min-width:fit-content;">(</span><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3408fbce-b93b-4c56-b64f-6ed4d1a3bfd3" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="inva:NonCashActivity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">28,228</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9264ecc6-0038-41e5-9d0f-3f3da552798b" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="inva:NonCashActivity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">See accompanying notes to consolidated financial statements.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.3in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">97</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">INNOVIVA, INC.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="notes_to_consolidated_financial"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p>
  <div><ix:nonNumeric id="F_2750278b-b3ca-4ad4-a461-e6e75a001a48" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" escape="true"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1.  DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7b7cc444-2c88-4637-bcd6-1b6a2a675f16" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="inva:DescriptionOfOperationsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Description of Operations</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Innoviva, Inc. (and where context requires, together with its subsidiaries referred to as &#8220;Innoviva&#8221;, the &#8220;Company&#8221;, or &#8220;we&#8221; and other similar pronouns) is a company with a portfolio of royalties and innovative healthcare assets. Our royalty portfolio contains respiratory assets partnered with Glaxo Group Limited (&#8220;GSK&#8221;), including RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(fluticasone furoate/vilanterol, &#8220;FF/VI&#8221;) and ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(umeclidinium bromide/vilanterol, &#8220;UMEC/VI&#8221;), and up until July 2022, TRELEGY</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(the combination FF/UMEC/VI). We sold our </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8f5d0c75-3e54-4cfa-9848-e472efd28cfa" contextRef="C_c174b897-ce7b-41b0-af4e-37c1c1527fe2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">15</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% ownership interest in Theravance Respiratory Company, LLC (&#8220;TRC&#8221;) on July 20, 2022, and are no longer entitled to receive royalties on sales of TRELEGY</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> products. Under the Long-Acting Beta2 Agonist (&#8220;LABA&#8221;) Collaboration Agreement, Innoviva is entitled to receive royalties from GSK on sales of RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> as follows: </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_640254d7-8501-4ea0-b707-2725feb01ab5" contextRef="C_f6067cb4-1702-418f-8410-c3ff025f386d" name="inva:CollaborativeArrangementRoyaltyRateDefinedLevelOne" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">15</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% on the first $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_998046ac-17be-4028-87b5-663550d44e5d" contextRef="C_f6067cb4-1702-418f-8410-c3ff025f386d" name="inva:CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate" unitRef="U_USD" scale="9" decimals="-8" format="ixt:num-dot-decimal">3.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> billion of annual global net sales and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_71016d37-68c2-42c9-853d-f2b5325247e7" contextRef="C_f6067cb4-1702-418f-8410-c3ff025f386d" name="inva:CollaborativeArrangementRoyaltyRateDefinedLevelTwo" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% for all annual global net sales above $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7f0a0c8c-60d9-456a-8c83-7ceb3e41ce31" contextRef="C_f6067cb4-1702-418f-8410-c3ff025f386d" name="inva:CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate" unitRef="U_USD" scale="9" decimals="-8" format="ixt:num-dot-decimal">3.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> billion; and royalties from the sales of ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, which tier upward at a range from </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_19cf5fea-829d-41fa-a50e-269500fa025b" contextRef="C_4ad76130-0d29-47d9-b811-82b396d4ef22" name="inva:CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">6.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_76b41daf-5f41-4065-b768-a7b6a53cd714" contextRef="C_76103f21-39aa-4d6c-bd6a-47f7c57f423e" name="inva:CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">10</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expanded our portfolio through the acquisition of Entasis Therapeutics Holdings Inc. (&#8220;Entasis&#8221;) on July 11, 2022 and the acquisition of La Jolla Pharmaceutical Company (&#8220;La Jolla&#8221;) on August 22, 2022. Our commercial and marketed products include GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock, and XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (eravacycline) for the treatment of complicated intra-abdominal infections in adults. Our new product, XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(formerly known as sulbactam-durlobactam or SUL-DUR), was approved by the United States Food and Drug Administration (&#8220;FDA&#8221;) for the treatment of hospital-acquired and ventilator-associated pneumonias caused by </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Acinetobacter</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in adults on May 23, 2023. We commenced commercial sales of XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in the third quarter of 2023. Our development pipeline includes zoliflodacin, an investigational treatment for uncomplicated gonorrhea that reported positive data in a pivotal Phase 3 clinical trial on November 1, 2023. As such, we have a wholly owned robust critical care and infectious disease operating platform with a hospital focus anchored by three differentiated products with significant growth potential and a promising drug candidate.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, we own other strategic healthcare assets, such as a large equity stake in Armata Pharmaceuticals, a leader in development of bacteriophages with potential use across a range of infectious and other serious diseases.  We also have economic interests in other healthcare companies.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_47dc3248-be8d-422b-829d-29c6580d93bd" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:ConsolidationPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Principles of Consolidation</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying consolidated financial statements include the accounts of Innoviva, our wholly owned subsidiaries and certain variable interest entities (&#8220;VIE&#8221;) for which we are the primary beneficiary. All intercompany balances and transactions have been eliminated in consolidation. For consolidated entities where we own or are exposed to less than 100% of the economics, we record net income (loss) attributable to noncontrolling interest in our consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entity by the respective noncontrolling party.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_af53be47-b269-4e11-8df5-b5a8d3a88818" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="inva:PresentationReclassificationPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Presentation Reclassification</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Amounts in equity and long-term investments reported in the Company&#8217;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">s comparative financial statements have been reclassified to conform to the current year presentation. Certain reclassifications have been made to the consolidated statement of cash flows for the years ended December 31, 2022 and 2021 to conform to the current year&#8217;s presentation. These reclassifications had no net effect on the net income or net cash flows from operating, investing and financing activities as previously reported.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7208c56b-8e73-4abb-8b7a-b7498c4c313c" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="inva:FactorsAffectingComparabilityPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Factors Affecting Comparability</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our historical financial condition and results of operations for the periods presented may not be comparable, either between periods or going forward due to the factors below and as discussed in Note 5, &#8220;Consolidated Entities and Acquisitions&#8221;.</span></p><div style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Adoption of Accounting Standards Update 2020-06, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Debt-Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (&#8220;ASU 2020-06&#8221;) effective January 1, 2022;</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accounting consolidation of Entasis on February 17, 2022 and purchase of remaining noncontrolling interest in Entasis on July 11, 2022;</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Sale of our </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_752d2676-28b3-4d20-bbbb-39ed4e890c88" contextRef="C_c174b897-ce7b-41b0-af4e-37c1c1527fe2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">15</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% ownership interest in TRC on July 20, 2022; and</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Acquisition of La Jolla on August 22, 2022.</span></div></div></ix:nonNumeric></div><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">98</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e8d95709-9233-4f94-acd3-9f3aa79bf306" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:UseOfEstimates" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Management&#8217;s Estimates</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of consolidated financial statements in conformity with U.S. Generally Accepted Accounting Principles (&#8220;U.S. GAAP&#8221;) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ materially from those estimates. Management evaluates its significant accounting policies and estimates on an ongoing basis. We base our estimates on historical experience and other relevant assumptions that we believe to be reasonable under the circumstances. These estimates also form the basis for making judgments about the carrying values of assets and liabilities when these values are not readily apparent from other sources.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_70cd2a6b-6af1-487f-a6a3-dc3b3b569723" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:ConcentrationRiskCreditRisk" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk and of Significant Suppliers and Partners</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents and equity and long-term investments. Although we deposit our cash with multiple financial institutions, our deposits, at times, may exceed federally insured limits.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> We are dependent on third-party manufacturers to supply active pharmaceutical ingredients (&#8220;API&#8221;) and drug products for research and development and commercial programs. These programs could be adversely affected by significant interruption in the supply of API or drug products.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Currently, we derive most of our revenues from GSK and our near-term success depends in large part on GSK&#8217;s ability to successfully develop and commercialize the products in the respiratory programs partnered with GSK. Our near-term success depends in large part upon the performance by GSK of its commercial obligations under the GSK Agreements and the commercial success of RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. If GSK does not devote sufficient resources to the commercialization or development of these products, is unsuccessful in its efforts, or chooses to reprioritize its commercial programs, our business would be materially harmed. GSK is responsible for all clinical and other product development, regulatory, manufacturing and commercialization activities for products developed under the GSK Agreements, including RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Our royalty revenues may fluctuate due to a variety of factors, many of which are outside of our control. Our royalty revenues under the GSK Agreements may not meet our, analysts&#8217; or investors&#8217; expectations, due to a number of important factors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We started recognizing revenue from product sales of GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in 2022 as a result of our acquisition of La Jolla. In the current year, we also started recognizing revenue from product sales from XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, which was commercially launched in the third quarter of 2023. Hospitals and other healthcare organizations generally purchase our products through a network of specialty distributors. These specialty distributors, which are located in the U.S., are considered our customers for accounting purposes. We do not believe that loss of one of these distributors would significantly impact our ability to distribute our products, as we expect that sales volume would be absorbed by new or remaining distributors. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_08df0bb2-419d-420c-8c31-58812f567049" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="inva:NumberOfCustomers" unitRef="U_Customer" decimals="0" format="ixt-sec:numwordsen">Three</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of our customers each account for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9f0d2626-a35a-4d73-ab4a-a5d6b6d20392" contextRef="C_2e71015c-4917-4b0c-8a50-046d7e6f4812" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">31</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d741bc3b-4a84-43ae-8118-1b35cfd6615b" contextRef="C_d05dfc5c-b948-4497-8849-a42784e9f325" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">27</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_080c047a-9518-46ab-a307-d2d7a53dc005" contextRef="C_962daa42-70a2-4386-b932-c071d02f40c5" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">27</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%, respectively, of our net product sales for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. These same customers account for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cd11c345-76c6-4bee-8d20-91c0bc57d554" contextRef="C_cd17c19c-ec63-4e2e-b6da-1c56d9be380d" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">29</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3f20e9de-7d82-4914-a738-8b5986d57ba7" contextRef="C_e6d12e36-aff4-4dc6-81a3-899ea1f5910b" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">19</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_412ece57-8c86-4768-8fe0-fc760b7bdec3" contextRef="C_2f7d8e77-eb63-419b-ad16-1ac5905b61e3" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">15</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%, respectively, of our receivables from net product sales, which are included in &#8220;Accounts receivables, net&#8221; in our consolidated balance sheet as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Three of our customers each account for approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7660e461-485c-430c-986a-52778a270525" contextRef="C_653aae1f-7476-41b2-a55d-7986566e9db4" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">33</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3b93afe4-f15e-4e0e-9737-871a497390fa" contextRef="C_36943c71-452d-4fbb-8d19-9e8b848cee67" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">29</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4d2478b1-a04e-4a11-ba96-3c67561423ed" contextRef="C_e414574e-4c06-4df7-8940-8de9bca1b108" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">28</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%, respectively, of our net product sales from the time of our acquisition of La Jolla through December 31, 2022. These same customers account for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_39ae346a-6acc-478c-879c-b61e3f8348b4" contextRef="C_1ed70a12-64b7-49e4-b68e-70f274537beb" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">23</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5f015bc8-f371-4477-82b0-60cf502b9eeb" contextRef="C_833ede43-b30a-4e04-a7aa-1d2f47880788" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">37</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cfb785a2-8c9b-4af4-b6d3-af7b6931ff7d" contextRef="C_b022e036-d13c-4fc8-94e9-00734a572b9c" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">37</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%, respectively, of our receivables from net product sales, which are included in &#8220;Accounts receivables, net&#8221; in our consolidated balance sheet as of December 31, 2022.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2f042a3c-256e-4cd4-aa53-98d9bd532ab7" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Segment Reporting</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We operate in a single segment, which is to provide capital return to stockholders by maximizing the potential value of our portfolio of royalties and innovative healthcare assets. Our Chief Operating Decision Maker (&#8220;CODM&#8221;) is our Chief Executive Officer. The CODM allocates resources and evaluates the performance of Innoviva at the consolidated level using information about our revenues, operating results and other key financial data as needed. Our revenues are generated primarily from our collaborative arrangements and royalty payments from GSK, located in Great Britain. We also generate revenue from net product sales of GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Refer to Note 3, &#8220;Revenue Recognition&#8221;, for more information on our revenues for the periods presented. Our long-term assets are located within the United States.</span></p></ix:nonNumeric></div><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">99</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_750af2c7-4413-4369-9e6b-32fd5f03b7f7" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:ConsolidationVariableInterestEntityPolicy" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Variable Interest Entities</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The primary beneficiary of a variable interest entity (&#8220;VIE&#8221;) is required to consolidate the assets and liabilities of the VIE. When we obtain a variable interest in another entity, we assess at the inception of the relationship and upon occurrence of certain significant events whether the entity is a VIE and, if so, whether we are the primary beneficiary of the VIE based on our power to direct the activities of the VIE that most significantly impact the VIE&#8217;s economic performance and our obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To assess whether we have the power to direct the activities of a VIE that most significantly impact the VIE&#8217;s economic performance, we consider all the facts and circumstances, including our role in establishing the VIE and our ongoing rights and responsibilities. This assessment includes identifying the activities that most significantly impact the VIE&#8217;s economic performance and identifying which party, if any, has power over those activities. In general, the parties that make the most significant decisions affecting the VIE (management and representation on the Board of Directors) and have the right to unilaterally remove those decision-makers are deemed to have the power to direct the activities of a VIE.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To assess whether we have the obligation to absorb losses of the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE, we consider all of our economic interests that are deemed to be variable interests in the VIE. This assessment requires us to apply judgment in determining whether these interests, in the aggregate, are considered potentially significant to the VIE.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_60237007-3ab7-4e9d-9a49-1242e8557761" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:BusinessCombinationsPolicy" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Business Combination</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">When we acquire an entity in a business combination, we recognize the fair value of all assets acquired, liabilities assumed, and any non-controlling interest in the acquiree and establish the acquisition date as the fair value measurement point. We recognize and measure goodwill as of the acquisition date, as the excess of the fair value of the consideration paid over the fair value of the identified net assets acquired. Acquisition-related expenses and related restructuring costs are expensed as incurred.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Several valuation methods may be used to determine the fair value of assets acquired and liabilities assumed. For intangible assets, we typically use the income method. This method starts with a forecast of all of the expected future net cash flows for each asset. These cash flows are then adjusted to present value by applying an appropriate discount rate that reflects the risk factors associated with the cash flow streams. Some of the more significant estimates and assumptions inherent in the income method or other methods include the amount and timing of projected future cash flows, the discount rate selected to measure the risks inherent in the future cash flows and the assessment of the asset&#8217;s life cycle and the competitive trends impacting the asset, including consideration of any technical, legal, regulatory, or economic barriers to entry. Determining the useful life of an intangible asset also requires judgment as different types of intangible assets will have different useful lives and certain assets may even be considered to have indefinite useful lives.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bbe3fa22-84dd-4ed4-b1f6-a5e19d1ce9e0" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash and Cash Equivalents</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We consider all highly liquid investments purchased with a maturity of three months or less on the date of purchase to be cash equivalents. Cash equivalents are carried at cost, which approximates fair value.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f5f60045-8b03-4671-8bad-07bd15364b07" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Accounts Receivable</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accounts receivable are recorded net of estimates for prompt-pay discounts, chargebacks, returns and rebates. Allowances for prompt-pay discounts and chargebacks are based on contractual terms. We estimate the allowance for credit losses based on existing contractual payment terms, actual payment patterns of customers and individual customer circumstances.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_27ba5c5f-c74c-4ac2-8eb9-84e3ba818800" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:InventoryPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Inventory</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Inventory is stated at the lower of cost or estimated net realizable value on a first-in, first-out basis. We periodically analyze inventory levels and write down inventory as cost of products sold when the following occurs: inventory has become obsolete, inventory has a cost basis in excess of its estimated net realizable value, or inventory quantities are in excess of expected product sales.</span></p></ix:nonNumeric></div><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">100</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_68f130f2-5a67-4a4c-9cf6-9b46f8ed4127" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Property and Equipment</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment, which consisted of laboratory equipment, computer equipment, software, office furniture and fixtures, and leasehold improvements, were not material as of December 31, 2023 and 2022, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_28e3498e-d426-4875-940e-d44a23e1aae9" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="inva:PropertyPlantAndEquipmentUsefulLifeTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment are stated at cost less accumulated depreciation. Property and equipment are depreciated using the straight-line method </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">over the estimated useful lives of the respective assets as follows:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
        <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
         <tr style="visibility:collapse;">
          <td style="width:49.17%;"/>
          <td style="width:1.66%;"/>
          <td style="width:49.17%;"/>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Leasehold improvements</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shorter of remaining lease terms or useful life</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Laboratory equipment, furniture and fixtures</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_2b184ea1-eed9-43d8-8128-e1a13c46f0a1" contextRef="C_1007c8ce-c961-4336-8299-5ed88a88849d" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#8211; </span><span><ix:nonNumeric id="F_3c92dda5-0a4c-48a3-83b4-4dd8a79443c7" contextRef="C_441daf0e-a05d-414c-8eaa-feeb49fa7590" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7 years</span></ix:nonNumeric></span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Software and computer equipment</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_86319735-82e7-49c4-8b17-9a1a34f92f8b" contextRef="C_e642beae-c7bf-4bc4-9ebd-c58d6623dfc5" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3 years</span></ix:nonNumeric></span></p></td>
         </tr>
        </table></ix:nonNumeric></div></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2eb58c07-7a9a-446e-88dd-ab6ce9994009" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:EquityMethodInvestmentsPolicy" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Equity and Long-Term Investments</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We invest from time to time in equity and debt securities of private or public companies. If we determine that we have control over these companies under either voting or VIE models, we consolidate them in our consolidated financial statements. If we determine that we do not have control over these companies under either voting or VIE models, we then determine if we have an ability to exercise significant influence via voting interests, board representation or other business relationships.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may account for the investments where we exercise significant influence using either an equity method of accounting or at fair value by electing the fair value option under Accounting Standards Codification (&#8220;ASC&#8221;) Topic 825, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Financial Instruments</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. If the fair value option is applied to an investment that would otherwise be accounted for under the equity method, we apply it to all our financial interests in the same entity (equity and debt, including guarantees) that are eligible items. All gains and losses from fair value changes, unrealized and realized, are presented as changes in fair values of equity method investments, net, and changes in fair values of equity and long-term investments, net, within the consolidated statements of income.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we conclude that we do not have an ability to exercise significant influence over an investee, we may elect to account for the security without a readily determinable fair value using the measurement alternative method under ASC 321, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Investments &#8211; Equity Securities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. This measurement alternative method allows us to measure the equity investment at its cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We also invest in ISP Fund LP, which investments consist of money market funds and equity and debt securities in the healthcare, pharmaceutical and biotechnology industries. Pursuant to the Partnership Agreement entered in December 2020, we became a limited partner of this partnership, and our contributions are subject to a 36-month lock-up period, which restriction prevents us from having control and access to the contributions and related investments. The lock-up period for a certain portion of our contributions expired in December 2023. Strategic Partners did not elect to make a withdrawal in 2023, thereby extending the lock-up period and withdrawal elections into subsequent years. These investments are classified as long-term investments in the consolidated balance sheets.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e09aa6ff-8afc-4933-a18a-a9eadea24f10" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Value of Financial Instruments</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We define fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our valuation techniques are based on observable and unobservable inputs. Observable inputs reflect readily obtainable data from independent sources, while unobservable inputs reflect our market assumptions. We classify these inputs into the following hierarchy:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Level 1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8212;Quoted prices for identical instruments in active markets.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Level 2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8212;Quoted prices for similar instruments in active markets; quoted prices for identical 3or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Level 3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8212;Unobservable inputs and little, if any, market activity for the assets.</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">101</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments include cash equivalents, accounts receivable, receivables from collaborative arrangements, accounts payable, and accrued liabilities, equity investments and convertible promissory notes. The carrying values of cash equivalents, receivables from collaborative arrangements, accounts payable, and accrued liabilities approximate their estimated fair values due to the relatively short-term nature of these instruments.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_96873202-6912-4d6a-b263-9f78d2ceea15" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="inva:CapitalizedFeesPaidPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Capitalized Fees Paid</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We capitalize fees paid to licensors related to agreements for approved products or commercialized products. We capitalize these fees as capitalized fees paid (&#8220;Capitalized Fees&#8221;) and amortize them on a straight-line basis over their estimated useful lives upon the commercial launch of the product, shortly after its regulatory approval. The estimated useful lives of these Capitalized Fees are determined on a country-by-country and product-by-product basis, as the later of the expiration or termination of the last patent right covering the compound in such product in such country and </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ebd92070-d818-4ceb-b80e-4a89028114fc" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="inva:CapitalizedFeePaidEstimatedUsefulLife" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">15 years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> from first commercial sale of such product in such country, unless the Collaboration Agreement is terminated earlier. Consistent with our policy for classification of costs under the research and development collaborative arrangements, the amortization of these Capitalized Fees is recognized as a reduction of royalty revenue. We review our Capitalized Fees for impairment on a product-by-product basis for each major geographic area when events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. The recoverability of Capitalized Fees is measured by comparing the asset&#8217;s carrying amount to the expected undiscounted future cash flows that the asset is expected to generate. The determination of recoverability typically requires various estimates and assumptions, including estimating the useful life over which cash flows will occur, their amount, and the asset&#8217;s residual value, if any. We derive the required cash flow estimates from near-term forecasted product sales and long-term projected sales in the corresponding market.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d887635f-29a6-4e91-8d64-6c2fa3e8b97b" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Goodwill and Intangible Assets</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Goodwill is recognized as the excess of the purchase consideration of an acquired entity over the fair value assigned to assets acquired and liabilities assumed in a business combination. Goodwill and intangible assets with indefinite useful life are not amortized and are tested for impairment at least annually on the first day of December of each year</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> or more frequently if indicators for potential impairment exist or whenever events or changes in circumstances indicate that the asset&#8217;s carrying asset amount may not be recoverable. Intangible assets with definite useful lives are amortized on a straight-line basis over their respective remaining useful lives and are tested for impairment only if indicators for potential impairment exist or whenever events or changes in circumstances indicate that the asset&#8217;s carrying amount may not be recoverable. Significant judgment may be involved in determining if an indicator of impairment has occurred.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_45994672-35c0-45c0-a2eb-d03c927a3b71" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:LesseeLeasesPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Operating Leases</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Right-of-use assets represent our right to use an underlying asset over the lease term and include any lease payments made prior to the lease commencement date and are reduced by lease incentives. Lease liabilities represent the present value of the total lease payments over the lease term, calculated using an estimated incremental borrowing rate. Lease expense is recognized on a straight-line basis over the expected lease term.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fbfd1e4c-e97e-4272-bb50-f1cd739e15fc" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:RevenueRecognitionPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue Recognition</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We apply the guidance on principal versus agent considerations under ASC Topic 606, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue from Contracts with Customers</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, to determine the appropriate treatment for the transactions between us and third parties. The classification of transactions under our arrangements is determined based on the nature and contractual terms of the arrangement along with the nature of the operations of the participants. Any consideration related to activities in which we are considered the principal, which includ</span><span style="color:#252525;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">es being in control of the good or service before such good or service is transferred to the customer, are accounted for as product sales.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Revenue is recognized when our customer obtains control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. Revenue is recognized through a five-step process: (i) identify the contract with the customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price for the contract; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue as a performance obligation is satisfied.</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">102</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Royalty Revenue</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We recognize the royalty revenue on net sales of products with respect to which we have contractual royalty rights in the period in which the royalties are earned. The net sales reports provided by our partner are based on its methodology and assumptions to estimate rebates and returns, which it monitors and adjusts regularly in light of contractual and legal obligations, historical trends, past experience and projected market conditions. Our partner may make significant adjustments to its sales based on actual results recorded, which could cause our royalty revenue to fluctuate. We conduct periodic royalty audits to evaluate the information provided by our partner. Royalties are recognized net of amortization of capitalized fees associated with any approval and launch milestone payments made to GSK.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue from Product Sales</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Revenue from product sales is recognized when our customers obtain control of the product and is recorded at the transaction price, net of estimates for variable consideration consisting of chargebacks, discounts, returns and rebates. Variable consideration is estimated using the expected-value amount method, which is the sum of probability-weighted amounts in a range of possible consideration amounts. Actual amounts of consideration ultimately received may differ from our estimates. If actual results vary materially from our estimates, we will adjust these estimates, which will affect revenue from product sales and earnings in the period such estimates are adjusted. These items may include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Chargebacks: Chargebacks are discounts we provide to distributors in the event that the sales prices to end users are below the distributors&#8217; acquisition price. This may occur due to a direct contract with a health system, a group purchasing organization (&#8220;GPO&#8221;) agreement or a sale to a government facility. Chargebacks are estimated based on known chargeback rates and recorded as a reduction of revenue on delivery to our customers.</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Discounts: We offer customers various forms of incentives and consideration, including prompt-pay and other discounts. We estimate discounts primarily based on contractual terms. These discounts are recorded as a reduction of revenue on delivery to our customers.</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Returns: We offer customers a limited right of return, generally for damaged or expired product. We estimate returns based on an internal analysis, which includes actual experience. The estimates for returns are recorded as a reduction of revenue on delivery to our customers. </span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Rebates: We participate in Medicaid rebate programs, which provide assistance to certain low-income patients based on each individual state&#8217;s guidelines regarding eligibility and services. Under the Medicaid rebate programs, we pay a rebate to each participating state, generally within three months after the quarter in which product was sold. Additionally, we may offer customer incentives and consideration in the form of volume-based or other rebates. The estimates for rebates are recorded as a reduction of revenue on delivery to our customers. </span></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We continue to assess our estimates of variable consideration as we accumulate additional historical data and will adjust these estimates accordingly.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">License Revenue</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At the inception of a licensing arrangement that includes development and regulatory milestone payments, we evaluate whether the milestones are considered probable of being achieved and estimate the amount to be included in the transaction price. We generally recognize these milestone payments as revenues when they are achieved because there is considerable uncertainty in the research and development processes that trigger receipt of these payments under our agreements. Similarly, we recognize regulatory approval milestone payments as revenues once the product is approved by the applicable regulatory agency.</span></p></ix:nonNumeric></div><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">103</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8fe11a65-c96b-4a35-a205-c955a291a15a" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development Expenses</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development expenses are recognized in the period that services are rendered or goods are received. Research and development expenses consist of salaries and benefits, laboratory supplies, facilities and other overhead costs, research-related manufacturing costs, contract service and clinical-related service costs performed by third party research organizations, research institutions and other outside service providers. Non-refundable prepayments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are recognized as an expense as the related goods are delivered or the related services are performed. We also utilize significant judgment and estimates to record accruals for estimated ongoing research costs based on the progress of the studies and progress of research manufacturing activities.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_674ad6c0-0f51-41fb-ab78-32d3358e9c48" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:InterestExpensePolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Interest Expense on Deferred Royalty Obligation</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Interest expense related to the deferred royalty obligation is recognized over the expected repayment term of the deferred royalty obligation using the effective interest method. The assumptions used in determining the expected repayment term of the deferred royalty obligation require us to make estimates that could impact the effective interest rate. Each reporting period, we estimate the expected repayment term of the deferred royalty obligation based on forecasted net sales of GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Changes in interest expense resulting from changes in the effective interest rate, if any, are recorded on a prospective basis. Refer to Note 12, &#8220;Debt&#8221;, for more information.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0d447386-b511-4236-95ea-236d9a7671a8" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Value of Stock&#8209;Based Compensation Awards</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We use the Black-Scholes-Merton option pricing model to estimate the fair value of options granted under our equity incentive plans and rights to acquire stock granted under our employee stock purchase plan (&#8220;ESPP&#8221;). The Black-Scholes-Merton option valuation model requires the use of assumptions, including the expected term of the award and the expected stock price volatility. We use the &#8220;simplified&#8221; method as described in Staff Accounting Bulletin No. 107, &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Share-Based Payment</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">,&#8221; for the expected option term. We use our historical volatility to estimate expected stock price volatility.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Restricted stock units (&#8220;RSUs&#8221;) and restricted stock awards (&#8220;RSAs&#8221;) are measured based on the fair market values of the underlying stock on the dates of grant.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock-based compensation expense is calculated based on awards ultimately expected to vest and is reduced for estimated forfeitures at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differed from those estimates. Our estimated annual forfeiture rates for stock options, RSUs and RSAs are based on our historical forfeiture experience.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The estimated fair value of stock options, RSUs and RSAs is expensed on a ratable or straight-line basis over the expected term of the grant or expected term of the vesting. Compensation expense is recorded over the requisite service period based on management&#8217;s best estimate as to whether it is probable that the shares awarded are expected to vest.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Compensation expense for purchases under the ESPP is recognized based on the fair value of the common stock on the date of offering, less the purchase discount percentage provided for in the plan.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_64c72857-68f1-43d2-bb76-0335abec8aff" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:IncomeTaxPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We utilize the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and the tax basis of assets and liabilities and are measured using enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The recognition and measurement of tax benefits requires significant judgment. Our judgment might change as new information becomes available. We continue to evaluate our deferred tax assets each reporting period to determine whether adjustments to our valuation allowance are required and deferred tax assets will be realized based on the consideration of all available positive and negative evidence, including the differences between our anticipated and actual future operating results, using a &#8220;more likely than not&#8221; standard.</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">104</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We assess all material positions taken in any income tax return, including all significant uncertain positions, in all tax years that are still subject to assessment or challenge by relevant taxing authorities. Assessing an uncertain tax position begins with the initial determination of the position&#8217;s sustainability and is measured at the largest amount of benefit that is greater than 50% likely to be realized upon ultimate settlement. As of each balance sheet date, unresolved uncertain tax positions must be reassessed, and we determine whether the factors underlying the sustainability assertion have changed and whether the amount of the recognized tax benefit is still appropriate.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_82807c29-eedd-4d77-9512-f02652bc2d62" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="inva:RelatedPartyTransactionsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Related Parties</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Transactions with GSK were considered related party transactions up until May 2021, when we completed the share repurchase agreement with GSK to buy back all of its shares of common stock in Innoviva. GSK is no longer considered a related party after the completion of the share repurchase. Transactions with GSK are described in Note 3, &#8220;Revenue Recognition and Collaborative Arrangements.&#8221;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Sarissa Capital ow</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ned </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b23bbcc6-6ff7-4df7-84d9-a66bd22d97a1" contextRef="C_175d99d3-70ac-4ebe-93be-8247d1fbe50e" name="inva:RelatedPartyTransactionCommonStockOwnershipPercentageByRelatedParty" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">11.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of o</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ur outstanding common stock as of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Transactions with Sarissa Capital are described in Note 5, &#8220;Consolidated Entities and Acquisitions&#8221;. Sarissa Capital is considered to be a related party because two of its principals are members of our board of directors.</span></p></ix:nonNumeric></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><br/></span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_29d6250d-2087-410c-901a-06da38b802bb" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true" continuedAt="F_29d6250d-2087-410c-901a-06da38b802bb_1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recently Issued Accounting Pronouncements Not Yet Adopted</span></ix:nonNumeric></span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_29d6250d-2087-410c-901a-06da38b802bb_1"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In October 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued ASU 2023-06, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Disclosure Improvements: Codification Amendments in Response to the SEC&#8217;s Disclosure Update and Simplification Initiative</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The amendment modifies the disclosure or presentation requirements for a variety of topics. The effective date for each amendment will be the date on which the SEC&#8217;s removal of that related disclosure from Regulation S-X or Regulation S-K becomes effective. The Company does not expect the adoption of the amendments to have a significant impact on its financial statements.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2023, the FASB issued ASU 2023-07, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Improvements to Reportable Segment Disclosures (Topic 280).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> This ASU update requires enhanced segment disclosures, primarily related to significant segment expenses. The amendments are effective for fiscal years beginning after December 15, 2023, and interim periods beginning after December 15, 2024. The Company does not expect the adoption of the amendments to have a significant impact on its financial statements.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2023, the FASB issued ASU 2023-09, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Improvements to Income Tax Disclosures (Topic 740)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The ASU requires the disclosure of income taxes paid disaggregated by jurisdiction and enhanced disclosures for the entity&#8217;s effective tax rate reconciliation as well as other income tax related disclosures. The ASU is effective on a prospective basis for annual periods beginning after December 15, 2024. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company does not expect the adoption of the amendments to have a significant impact on its financial statements.</span></p></ix:continuation></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2211db62-b1a5-43a2-a723-e35e93a52a25" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:EarningsPerShareTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2.  NET INCOME PER SHARE</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basic net income per share attributable to Innoviva stockholders is computed by dividing net income attributable to Innoviva stockholders by the weighted-average number of shares of common stock outstanding. Diluted net income per share attributable to Innoviva stockholders is computed by dividing net income attributable to Innoviva stockholders by the weighted-average number of shares of common stock and dilutive potential common stock equivalents then outstanding. Dilutive potential common stock equivalents include the assumed exercise, vesting and issuance of employee stock awards using the treasury stock method, as well as common stock issuable upon assumed conversion of our convertible subordinated notes due 2023 (the &#8220;2023 Notes&#8221;) up until its maturity date on January 15, 2023, our convertible senior notes due 2025 (the &#8220;2025 Notes&#8221;), and our convertible senior notes due 2028 (the &#8220;2028 Notes&#8221;) using the if-converted method.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The 2025 Notes are convertible, based on the applicable conversion rate, into cash, shares of our common stock or a combination thereof, at our election. Our current intent is to settle the principal amount of th</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">e 2025 Notes in cash upon conversion. The impact of the assumed conversion premium to diluted net income per share was historically computed using the treasury stock method until the adoption of ASU 2020-06. As the average market price per share of our common stock as reported on The Nasdaq Global Select Market was lower than the initial conversion price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_886bd5c7-8216-45d9-a953-ca1cc69addbf" contextRef="C_fa0aac3c-12ff-4c52-bf57-2b8f937d8ef4" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">17.26</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, there was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ed457491-7443-4b22-8862-a2487aa82607" contextRef="C_e3e6ec1f-49a0-4fb9-9419-c9b6fcbc8855" name="inva:IncrementalCommonSharesAttributableToConversionOfDebtSecuritiesTreasuryStockMethod" unitRef="U_shares" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> dilutive effect of the assumed conversion premium for the year ended December 31, 2021.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">105</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bd18c9a0-14ee-4a92-a6fe-23533efc6046" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table shows the computation of basic and diluted net income per share for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023, 2022 and 2021:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:51.311%;"/>
        <td style="width:1.481%;"/>
        <td style="width:1%;"/>
        <td style="width:12.75%;"/>
        <td style="width:1%;"/>
        <td style="width:1.481%;"/>
        <td style="width:1%;"/>
        <td style="width:12.75%;"/>
        <td style="width:1%;"/>
        <td style="width:1.481%;"/>
        <td style="width:1%;"/>
        <td style="width:12.75%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands except per share data)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Numerator:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net income attributable to Innoviva stockholders, basic</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_762629b2-5320-4034-bdc1-29fdc72694ea" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">179,722</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_47185b1f-c5c0-487b-bc92-0f0d611754d1" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">213,921</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3347a5de-bb92-4ea1-bc86-94fdb3fe7f64" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">265,854</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Add: interest expense on 2023 Notes, net of tax effect</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0fedaeda-5eea-460b-8778-ce0aff33825c" contextRef="C_1d6c5f53-6c4d-4fe6-a55d-07940f638bd4" name="us-gaap:InterestOnConvertibleDebtNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">89</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_554101ee-8eee-4e32-abbc-bddd568d0604" contextRef="C_394439fc-7c8a-4379-be01-6a604b354293" name="us-gaap:InterestOnConvertibleDebtNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,439</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9ab0ca4c-65c4-4eb5-b14a-5662a7470ebe" contextRef="C_a0c44c89-e8b9-4ab7-8450-da67ef9caaa2" name="us-gaap:InterestOnConvertibleDebtNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,736</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Add: interest expense on 2025 Notes, net of tax effect</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dda584a0-7f9a-4c50-88ed-768905fe65e9" contextRef="C_d9c7ca7c-81fc-4272-b388-610e1b6444a8" name="us-gaap:InterestOnConvertibleDebtNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,116</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4ecffe49-3301-4887-9d55-bffb82d8ea2a" contextRef="C_a18abd1c-665b-4c52-b36b-be1bbd83b22e" name="us-gaap:InterestOnConvertibleDebtNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,583</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c2f023c5-84bc-449f-a2e0-74d1a029bc4a" contextRef="C_8b89681a-3d4d-4507-960c-e611eee0ae68" name="us-gaap:InterestOnConvertibleDebtNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Add: interest expense on 2028 Notes, net of tax effect</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b7bdb5f5-5425-45d8-bb3b-ec0d1550d608" contextRef="C_6f92e4e3-0288-40a0-9972-c89e1aac1433" name="us-gaap:InterestOnConvertibleDebtNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,377</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_24d8fca1-f4c0-4161-adeb-3bfbadf4873e" contextRef="C_eaa09fba-b20a-4958-908d-40cfb3339c00" name="us-gaap:InterestOnConvertibleDebtNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,626</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_497f880b-c292-4094-aa19-742b9f2e8aeb" contextRef="C_50bb996e-86f5-4158-a575-796da0e57247" name="us-gaap:InterestOnConvertibleDebtNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net income attributable to Innoviva stockholders, diluted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ad61e599-77d3-46f3-be60-97e76d1dc984" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">191,304</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a58cc639-04c8-4e48-a607-ac49f7881217" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">225,569</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4f0d2d78-2e47-4fea-89e9-d9abd824cd6e" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">270,590</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Denominator:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average shares used to compute basic net income<br/>&#160;&#160;&#160;per share attributable to Innoviva stockholders</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1f811c0d-117e-4960-84f0-8f5a913aea57" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">65,435</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ee9f6274-f28d-40fa-a601-755a5fe6a147" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">69,644</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2598cb0e-c3b7-4afd-b4e4-e9c8983e773d" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">82,062</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Dilutive effect of 2023 Notes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8b3af0d7-986e-4ae2-b7ff-dc7b342071dd" contextRef="C_1d6c5f53-6c4d-4fe6-a55d-07940f638bd4" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">187</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1e68f8a1-15a9-4c37-ba92-88f51dae86d0" contextRef="C_394439fc-7c8a-4379-be01-6a604b354293" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,188</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0df8d5bc-149a-4d00-b18d-a5a27209ab24" contextRef="C_a0c44c89-e8b9-4ab7-8450-da67ef9caaa2" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,189</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Dilutive effect of 2025 Notes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d4ae79ec-38ae-4166-be57-c181fbdb0442" contextRef="C_d9c7ca7c-81fc-4272-b388-610e1b6444a8" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,150</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c2550765-ade0-4b8d-b793-c8618a7cd077" contextRef="C_a18abd1c-665b-4c52-b36b-be1bbd83b22e" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,150</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9a99014c-4617-4d95-abcd-d315438efc25" contextRef="C_8b89681a-3d4d-4507-960c-e611eee0ae68" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" unitRef="U_shares" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Dilutive effect of 2028 Notes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_25dbe408-57f2-4ca0-874a-533c8ca2d6df" contextRef="C_6f92e4e3-0288-40a0-9972-c89e1aac1433" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,955</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f4143b56-5cb5-4334-944e-d8229b667c6a" contextRef="C_eaa09fba-b20a-4958-908d-40cfb3339c00" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,158</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_501661d3-150d-4468-acf3-4f68ca03e278" contextRef="C_50bb996e-86f5-4158-a575-796da0e57247" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" unitRef="U_shares" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Dilutive effect of options and awards granted under equity<br/>&#160;&#160;&#160;incentive plan and employee stock purchase plan</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a51727c0-f4b6-48ce-a6bb-e152df693b17" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">149</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_676ff6ee-6112-4f75-82bd-8fcb1485e7d4" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">108</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d7d56afb-7b14-4520-b65b-c3ecc7ca4032" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">59</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average shares used to compute diluted net income<br/>&#160;&#160;&#160;per share attributable to Innoviva stockholders</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7e4fa101-3650-44be-88b1-56464e8cc244" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">86,876</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c812195f-d2a1-4c97-afd8-90345c4c4d10" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">95,248</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2af6c265-0278-47e7-b8df-6918f5223703" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">94,310</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net income per share attributable to Innoviva stockholders</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Basic</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5080eb5e-4b9a-47e4-9c06-336a37fb6fa9" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.75</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_90ef21ee-81cd-425a-9b73-a2db240c41a7" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">3.07</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ad92ee33-b672-42b4-a0f2-924015a5c56b" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">3.24</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Diluted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_462e32f8-466d-4625-8255-8753693c593c" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.20</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d4d87396-efbd-42d6-a4dc-2e0f80a850c0" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.37</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9ef1e4a6-f0b3-4fee-a935-c3777fe7c935" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.87</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Anti&#8209;dilutive Securities</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2232223b-d5c9-4377-a7d3-fec6543358de" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following common stock equivalents were not included in the computation of diluted net income per share because their effect was anti&#8209;dilutive for the periods presented:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:51%;"/>
        <td style="width:1.8%;"/>
        <td style="width:1%;"/>
        <td style="width:13.2%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:13.2%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:12.799999999999999%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding options and awards granted under equity incentive<br/>&#160;&#160;&#160;plan and employee stock purchase plan</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8cf05da8-e9a7-40cd-bf51-0123dba8b00f" contextRef="C_3824b03b-c4bb-4202-90b1-652ccf15674b" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,333</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fc15029a-9a25-401b-bf07-3f510923bf0f" contextRef="C_5adfa42a-1fb9-4bab-ac06-149565b0b62c" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">648</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_33f85cc9-db6b-4c66-a0bd-328855c4902a" contextRef="C_07eefa71-9b4d-4cdb-b27f-f192898d804e" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">979</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding stock warrant</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_da1d1e96-7295-4383-bac1-13785cb78684" contextRef="C_b60e6976-6149-440a-b50d-539629e77c91" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">591</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ad67de70-389e-47f2-88ae-09ab3f35dd3b" contextRef="C_d3087254-4dbd-4e76-a116-2ba842506912" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">282</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9f5514b0-8099-4ec8-9152-dd784a111742" contextRef="C_972fc684-1125-4562-949a-c061a92ab4f3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fffcc53c-e259-49bc-8699-1581571480cf" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,924</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6cecc704-c476-4233-be91-b0bca7862710" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">930</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7b4f19da-649a-48e7-8f64-073569a402e5" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">979</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d10b5246-f64f-4285-a603-31f5b9ad03f1" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:RevenueFromContractWithCustomerTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3.  REVENUE RECOGNITION</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Net Revenue from Collaboration Arrangement</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On July 13, 2022, Innoviva&#8217;s wholly owned subsidiary, Innoviva TRC Holdings, LLC (&#8220;ITH&#8221;) entered into an equity purchase agreement (&#8220;TRC Equity Purchase Agreement&#8221;) with Royalty Pharma Investments 2019 ICAV (&#8220;Royalty Pharma&#8221;) to sell our ownership interest in TRC. As a result of the sale of our ownership interest in TRC, which was consummated on July 20, 2022, we are no longer entitled to receive </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7b758520-64e9-4fa6-b6db-d992a088b034" contextRef="C_27cbe4a1-3bff-4bc8-b808-d5e97b10b96a" name="inva:PercentageOfRoyaltyPaymentsNotEntitledToReceive" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">15</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of royalty payments made by GSK stemming from sales of TRELEGY</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. We retained our royalty rights with respect to RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">106</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9d253d8c-bdc7-46eb-9f93-f246715ebd92" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:DisaggregationOfRevenueTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net revenue recognized under our GSK Agreements was as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:51.311%;"/>
        <td style="width:1.481%;"/>
        <td style="width:1%;"/>
        <td style="width:12.75%;"/>
        <td style="width:1%;"/>
        <td style="width:1.481%;"/>
        <td style="width:1%;"/>
        <td style="width:12.75%;"/>
        <td style="width:1%;"/>
        <td style="width:1.481%;"/>
        <td style="width:1%;"/>
        <td style="width:12.75%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Royalties &#8211; RELVAR/BREO</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f05da76d-03bd-483f-a805-7e6d68725bd1" contextRef="C_32088045-eb75-4318-bbdc-77c7436faa52" name="inva:GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">208,042</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_19c2d7de-a5c0-44f4-8f35-ab38357c13ed" contextRef="C_3596ffd8-7703-4aa7-bc48-723fa485f9cd" name="inva:GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">215,034</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_96c9bcea-ba1f-42fa-954a-17ba06ee7c02" contextRef="C_425efcfe-eac0-4b78-bf2f-d0ef757a0501" name="inva:GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">234,066</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Royalties &#8211; ANORO</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a8d81c52-1b7f-4d65-8568-6dc34c8740f0" contextRef="C_e78c50b6-10c0-4578-be27-2aad784b619e" name="inva:GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">44,627</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c6d19d98-dde8-43be-a11b-f17b7b543918" contextRef="C_5c0f9d6a-daac-43d5-9697-46136da2e5eb" name="inva:GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">38,405</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_10a79183-dbc3-4918-bfdd-e090a5187961" contextRef="C_676e8b46-96e2-42eb-927b-d2236a78f7f0" name="inva:GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">44,935</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Royalties &#8211; TRELEGY</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(1)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b77bea76-072e-4367-b47f-c8d7a579d4d8" contextRef="C_6e16f944-8e12-42b7-84eb-4f21d332cd44" name="inva:GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fef7ca76-dc12-4482-8f29-1f59651c4359" contextRef="C_3f92b149-a39f-4e8f-96ab-6c3b86b4dbe7" name="inva:GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">72,029</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8bd0930b-e853-47a3-8715-a03895cd09ab" contextRef="C_94c529c4-f563-461a-9da8-262bcfe8bc37" name="inva:GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">126,688</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total royalties</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0a46b916-e927-4a4b-bbcf-565a95bcb326" contextRef="C_c1969bd2-5e89-423e-88e9-b5564c6afe10" name="inva:GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">252,669</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c7718fcb-15da-47ad-9408-ce32c7969ad9" contextRef="C_8c8eca7f-7819-48ae-9938-c3c7153ffa73" name="inva:GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">325,468</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7b335909-04aa-4116-a317-e7b61d33d447" contextRef="C_539783b3-bf29-4a63-8d24-99d7b7b79e81" name="inva:GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">405,689</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: amortization of capitalized<br/>&#160;&#160;&#160;fees paid</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_953bdfff-ff9b-46b2-8750-c514a013ede2" contextRef="C_c1969bd2-5e89-423e-88e9-b5564c6afe10" name="us-gaap:CapitalizedContractCostAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,823</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fbe41650-f196-4afa-81c6-b1dcf7a54420" contextRef="C_8c8eca7f-7819-48ae-9938-c3c7153ffa73" name="us-gaap:CapitalizedContractCostAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,823</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_741e51bb-5fb0-4d89-8108-a040d0e136b6" contextRef="C_539783b3-bf29-4a63-8d24-99d7b7b79e81" name="us-gaap:CapitalizedContractCostAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,823</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total royalty revenue</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cddcec21-ea9a-4af4-b3a2-9caa8b61badd" contextRef="C_a69ed80b-24cf-4fb0-939b-206e1bd2ef60" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">238,846</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2ea1c0d8-54c8-46b5-b0c0-84d040cbef6f" contextRef="C_ffbac92f-8341-4e52-864a-91ee3864a86e" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">311,645</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8ac0fd58-edde-4fad-8c67-b2372c7a9e04" contextRef="C_5783ed68-2473-492b-88b5-e1af30e3c0e7" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">391,866</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">(1)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">   The year ended December 31, 2022 represents the period from January 1, 2022 to July 20, 2022, the date of the sale of our ownership interest in TRC.</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">LABA Collaboration</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a result of the launch and approval of RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in the U.S., Japan and Europe, we paid milestone fees to GSK totaling $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1e1c1ae1-395a-40f7-bebf-a77c03b102d9" contextRef="C_9fb8ce09-b755-456a-88b1-2a93a91dc1d0" name="us-gaap:CapitalizedContractCostGross" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">220.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million during the year ended December 31, 2014. The milestone fees paid to GSK were recognized as capitalized fees paid, which are being amortized over their estimated useful lives commencing upon the commercial launch of the product. The amortization is recorded as a reduction to the royalties from GSK.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are entitled to receive annual royalties from GSK on sales of RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> as follows: </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_11023421-5436-4265-83fa-1596965edd86" contextRef="C_f6067cb4-1702-418f-8410-c3ff025f386d" name="inva:CollaborativeArrangementRoyaltyRateDefinedLevelOne" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">15</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% on the first $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_51c0337b-1b2a-47ce-ab1d-b1ec73d2bc7c" contextRef="C_f6067cb4-1702-418f-8410-c3ff025f386d" name="inva:CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate" unitRef="U_USD" scale="9" decimals="-8" format="ixt:num-dot-decimal">3.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> billion of annual global net sales and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d315d1fc-2843-4317-b200-95ac7358d994" contextRef="C_f6067cb4-1702-418f-8410-c3ff025f386d" name="inva:CollaborativeArrangementRoyaltyRateDefinedLevelTwo" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% for all annual global net sales above $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_71b8c505-4141-469e-ac3e-7854b3a44369" contextRef="C_f6067cb4-1702-418f-8410-c3ff025f386d" name="inva:CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate" unitRef="U_USD" scale="9" decimals="-8" format="ixt:num-dot-decimal">3.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> billion. Sales of single&#8209;agent LABA medicines and combination medicines would be combined for the purposes of this royalty calculation. For other products combined with a LABA from the LABA Collaboration, such as ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, royalties are upward tiering and range from </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_28409b73-e199-4c3a-bf74-d1332ddc64ef" contextRef="C_4ad76130-0d29-47d9-b811-82b396d4ef22" name="inva:CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">6.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8a37912e-71fa-434b-b803-83665e12379c" contextRef="C_76103f21-39aa-4d6c-bd6a-47f7c57f423e" name="inva:CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">10</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are also entitled to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_928ecbe5-11fc-41a2-baf5-670cb9aea5eb" contextRef="C_51f40066-7e1b-48d8-8a38-42b77199fdd5" name="inva:PercentageOfEconomicInterestOnFuturePaymentsUnderAgreements" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">15</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of royalty payments made by GSK under its agreements originally entered into with us, and since assigned to TRC in connection with the Spin-Off, including TRELEGY</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> through July 20, 2022, which royalties were upward tiering and ranged from </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c2a719e0-c7e3-4b4e-8c2d-0efdc7d8e4ca" contextRef="C_87ac8e26-9a2a-47e5-973e-54a32e529605" name="inva:CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">6.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7e2a50b5-bbc8-4ddf-ad63-4b5c3ee9d630" contextRef="C_2e2e6b99-d8c8-44b8-aabd-25fa00182b05" name="inva:CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">10</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Net Product Sales</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net product sales were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_12f0c5dd-bb35-4f3e-8dd2-300cacda0a6c" contextRef="C_a7cbb363-ce02-4f94-bf8b-d70a020aba6a" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">60.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, consisting of net sales of GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b2ed2db9-7aad-46d5-847a-5de4b7453b59" contextRef="C_f00e797a-c719-4c90-a9dc-1bce4096970e" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">41.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_adf8a4ff-defa-4848-ae5d-ffa82b4b1d01" contextRef="C_96ac591a-5f0a-4705-94d6-904d91058ae4" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">17.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3608c151-a861-4a5f-ab6d-3977299e61eb" contextRef="C_afca57b6-192a-41f3-9d82-5a1dd8586709" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively. We derived approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_934efe4a-0ba7-48d2-9461-2c9d7eca9f96" contextRef="C_29193a89-f8bc-431f-9fc2-70fd8e836d0e" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">91</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_819ef480-0301-478b-93b1-282a8d43deeb" contextRef="C_adc3b151-5d38-4abe-9182-9e724c5ef29b" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of our net product sales for the same period from customers located in the U.S. and the rest of the world, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From the date of acquisition of La Jolla to December 31, 2022, net product sales were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_85684c5e-6bec-4ec7-a80b-f22a1450a681" contextRef="C_b2abb502-4aea-4d3e-a1e8-7663f28b3e4a" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">19.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, consisting of net sales of GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_05ea2058-d91e-4e0e-8cbf-ee64da28a436" contextRef="C_54ed52d3-2763-46fa-a0e9-bfeb58272692" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">14.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_380494ee-df55-4e0e-992e-0e7978599960" contextRef="C_98c23b09-7eaa-42d7-b41a-5b1541dea4a7" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively. We derived approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_da8694fc-959b-4708-a060-b6a47e41bab6" contextRef="C_ba1a82e3-49cc-4439-9ea4-1ade7ac73cb8" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">96</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_45b22d6a-c190-4996-a7f0-e03fb6840aff" contextRef="C_bb2dfb4c-8159-49a4-8abd-85f592b904b8" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of our net product sales for the same period from customers located in the U.S. and the rest of the world, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">License Revenue</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Refer to the out-license agreement with Zai Lab and Everest in Note 4, &#8220;License and Collaboration Arrangements&#8221;.</span></p></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">107</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_491467b6-21ea-48ae-9d4a-5c795cc59005" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="inva:LicenseAndCollaborationArrangementsDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4. LICENSE AND COLLABORATION ARRANGEMENTS</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Out-License Agreements</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Zai Lab</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Entasis entered into a license and collaboration agreement with Zai Lab (Shanghai) Co., Ltd. (&#8220;Zai Lab&#8221;) (Nasdaq: ZLAB), pursuant to which Zai Lab licensed exclusive rights to durlobactam and SUL-DUR, in the Asia-Pacific region (&#8220;the Zai Agreement&#8221;). Under the terms of the Zai Agreement, Zai Lab will fund most of the registrational clinical trial costs in China for SUL-DUR, with the exception of Phase 3 patient drug supply of licensed products. Zai Lab will conduct development activities and plan and obtain regulatory approval in a specified number of countries in the Asia-Pacific region beyond China after receipt of regulatory approval of a licensed product in China. Zai Lab is also solely responsible for commercializing licensed products in the Asia-Pacific region and will commercialize licensed products for which it has obtained regulatory approval. We are obligated to supply Zai Lab with the licensed products for clinical development and, if the licensed product is approved, for commercial use for a certain period unless Zai Lab notifies otherwise. Zai Lab may take over manufacturing responsibilities for its own commercialization activities within a specified time period following the effective date of the Zai Agreement.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We ar</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">e eligible to receive up to an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c5d8bb5e-faf3-43da-89cc-40dcb126a516" contextRef="C_33ccc9ac-1bd0-4923-b096-29db8ac98a5e" name="inva:FuturePotentialMilestonePayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">91.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in research and development support payments and development, regulatory and sales milestone payments related to SUL-DUR, imipenem and other combinations with the licensed products. Zai Lab will pay us a tiered royalty equal to from a high-single digit to low-double digit percentage based on annual net sales of licensed products in the territory, subject to specified reductions for the market entry of competing products, loss of patent coverage of licensed products and for payments owed to third parties for additional rights necessary to commercialize licensed products in the territory.  Payments received for research support and reimbursable clinical trial costs are recorded as a reduction to research and development expense during the period in which the qualifying expenses are incurred. Such amounts recorded </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">for the year ended December 31, 2023 and from the date of acquisition of Entasis to December 31, 2022 are not material. Following the approval of XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> by the FDA in May 2023, we recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_470c8928-485d-4308-bfaa-c30e457d3b07" contextRef="C_9ddbdfad-57e5-479b-ba9a-8f0e252307df" name="inva:LicenseRevenueRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in license revenue for the year ended December 31, 2023.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">GARDP</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Entasis entered into a collaboration agreement with the Global Antibiotic Research and Development Partnership (&#8220;GARDP&#8221;) for the development, manufacture and commercialization of the product candidate zoliflodacin in certain countries (&#8220;the GARDP Collaboration Agreement&#8221;). Under the terms of the GARDP Collaboration Agreement, GARDP will use commercially reasonable endeavors to perform and fully fund the Phase 3 registrational trial, including the manufacture and supply of the product candidate containing zoliflodacin, in uncomplicated gonorrhea. We recorded reimbursements from GARDP under this agreement as reduction to research and development expense. Relevant amounts for the year ended December 31, 2023 and from the date of acquisition of Entasis to December 31, 2022 are not material.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, under the GARDP Collaboration Agreement, GARDP was granted a worldwide, fully paid, exclusive and royalty-free license, with the right to sublicense, to use our zoliflodacin technology in connection with GARDP&#8217;s development, manufacture and commercialization of zoliflodacin in low-income and specified middle-income countries. We retained commercial rights in all other countries worldwide, including the major markets in North America, Europe and Asia-Pacific. We also retained the right to use and grant licenses to our zoliflodacin technology to perform our obligations under the GARDP Collaboration Agreement and for any purpose other than gonorrhea or community-acquired indications. If we believe that the results of the Phase 3 registrational trial of zoliflodacin would be supportive of an application for marketing approval, we are obligated to use our best efforts to file an application for marketing approval with the FDA within six months of the completion of the trial and to use commercially reasonable endeavors to file an application for marketing approval with the European Medicines Agency (&#8220;EMA&#8221;). Each party is responsible for using commercially reasonable efforts to obtain marketing authorizations for the product candidate in their respective territories.</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">108</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">PAION AG</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the PAION AG and PAION Deutschland GmbH (together and individually &#8220;PAION&#8221;) License, La Jolla granted PAION an exclusive license to commercialize GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in the European Economic Area, the United Kingdom and Switzerland (collectively, the &#8220;PAION Territory&#8221;). We are entitled to receive potential commercial milestone payments of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f9f8a305-47ba-4a39-8939-5ae1c3cc9705" contextRef="C_20a1bbc0-a748-41da-a071-6972900ca7d7" name="inva:FuturePotentialMilestonePayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">109.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and double-digit tiered royalty payments. Royalties payable in a given jurisdiction under the PAION License will be subject to reduction on account of generic competition and after patent expiration in that jurisdiction. Pursuant to the PAION License, PAION will be solely responsible for the future development and commercialization of GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in the PAION Territory. PAION is required to use commercially reasonable efforts to commercialize GIAPREZA&#174; and XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in the PAION Territory. We have not recognized any revenue from PAION related to commercial milestones from the date of acquisition of La Jolla to December 31, 2023. Royalty revenue recognized under this agreement for the year ended December 31, 2023 and from the date of acquisition of La Jolla to December 31, 2022 are not material.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">La Jolla also entered into the PAION commercial supply agreement (the &#8220;PAION Supply Agreement&#8221;) whereby La Jolla will supply PAION a minimum quantity of GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> through July 13, 2024. The PAION supply agreement will automatically renew until the earlier of July 13, 2027, or until a new supply agreement is executed. During the initial term of the supply agreement, we will be reimbursed for direct and certain indirect manufacturing costs at cost. We recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9ced0058-bf18-48b7-8fa6-d074a278006b" contextRef="C_69fb044e-5d2a-46bb-ae62-33b02683b43d" name="us-gaap:Revenues" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in cost reimbursements under this agreement for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023. Amounts recognized under this agreement from the date of acquisition of La Jolla to December 31, 2022 were not material.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PAION AG and PAION Deutschland GmbH filed for insolvency in Germany on October 27, 2023 and the insolvency proceedings were opened on January 1, 2024. PAION announced on December 22, 2023 that it concluded negotiations with Humanwell Healthcare Group and entered into an agreement on the sale of the essential business operations of PAION AG and PAION Deutschland GmbH with the approval of the insolvency administrator in both procedures. La Jolla did not oppose the sale and is in discussions with the acquirer regarding the continued business relationship.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Everest Medicines Limited</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the Everest Medicines Limited (&#8220;Everest&#8221;) License, La Jolla granted Everest an exclusive license to develop and commercialize XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for the treatment of complicated intra-abdominal infections (&#8220;cIAI&#8221;) and other indications in mainland China, Taiwan, Hong Kong, Macau, South Korea, Singapore, the Malaysian Federation, the Kingdom of Thailand, the Republic of Indonesia, the Socialist Republic of Vietnam and the Republic of the Philippines (collectively, the &#8220;Everest Territory&#8221;). </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the Everest License, we recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2ea0d13e-696b-484a-88f4-98d0dd486fdd" contextRef="C_2f159654-f79f-4e47-806d-ec1adbda538c" name="inva:LicenseRevenueRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">8.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in license revenue for the year ended December 31, 2023 as a result of an achievement of a regulatory milestone during the period. We are eligible to receive additional sales milestone payments of up to an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aeabb2b8-6b26-4001-ae12-4a83f53cd89c" contextRef="C_83a2b6b3-d55f-414b-a77a-bc247a02d235" name="inva:SalesMilestonePaymentsReceivable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">20.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are also entitled to receive tiered royalties from Everest at percentages in the low double digits on sales, if any, in the Everest Territory of products containing eravacycline. Royalties are payable with respect to each jurisdiction in the Everest Territory until the latest to occur of: (i) the last-to-expire of specified patent rights in such jurisdiction in the Everest Territory; (ii) expiration of marketing or regulatory exclusivity in such jurisdiction in the Everest Territory; or (iii) </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f8cd0749-629d-404c-aa59-38f8ffa9b14e" contextRef="C_2f159654-f79f-4e47-806d-ec1adbda538c" name="inva:RoyaltiesPayablePeriodAfterFirstCommercialSaleOfProduct" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years after the first commercial sale of a product in such jurisdiction in the Everest Territory. Royalty revenue recognized under this agreement for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d2e69ce3-a072-4acd-bb4d-3c9f8acd7a89" contextRef="C_2f159654-f79f-4e47-806d-ec1adbda538c" name="us-gaap:Revenues" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. Royalty revenue recognized </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">from the date of acquisition of La Jolla to December 31, 2022 is not material.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">La Jolla also entered into the Everest commercial supply agreement (the &#8220;Everest Supply Agreement&#8221;) whereby La Jolla will supply Everest a minimum quantity of XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> through December 31, 2023 and will transfer to Everest certain XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">-related manufacturing know-how. We were eligible to be reimbursed for direct and certain indirect manufacturing costs at </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_708156e9-488f-4fa6-8346-3e098328d3ea" contextRef="C_a0b988e7-21ed-4760-8751-f6fa519d9c49" name="inva:PercentageOfReimbursedForDirectAndCertainIndirectManufacturingCosts" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">110</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of cost through December 31, 2023. We recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8779320b-069f-48d8-8eec-7fdc7f94fead" contextRef="C_a0b988e7-21ed-4760-8751-f6fa519d9c49" name="us-gaap:Revenues" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f2590fe0-9128-4cfd-9f4e-674a914142ee" contextRef="C_5361a0f4-5547-4b13-aab7-9c5bf77f49a1" name="us-gaap:Revenues" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in revenue under this agreement for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and from the acquisition of La Jolla to December 31, 2022, respectively.</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">109</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">In-License Agreements</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">George Washington University</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the George Washington University (&#8220;GW&#8221;) License, GW exclusively licensed to La Jolla certain intellectual property rights relating to GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, including the exclusive rights to certain issued patents and patent applications covering GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Under the GW License, we are obligated to use commercially reasonable efforts to develop, commercialize, market and sell GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. We are obligated to pay a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f29d2c6f-86e9-45a4-a6e9-f6e300790834" contextRef="C_2b0ee96a-cf29-4fd8-a358-2c59b280effd" name="inva:PercentageOfRoyaltyPayableOnNetSales" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% royalty on net sales of GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0ecf2817-bad3-4550-8023-f0e239444832" contextRef="C_2b0ee96a-cf29-4fd8-a358-2c59b280effd" name="inva:PercentageOfRoyaltyOnPaymentsReceivedFromSublicensees" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">15</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% on payments received from sublicensees. The obligation to pay royalties under this agreement extends through the last-to-expire patent covering GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d570177c-c96a-4d74-a735-e6f6605a0a4f" contextRef="C_2b0ee96a-cf29-4fd8-a358-2c59b280effd" name="inva:AccruedRoyaltyObligations" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the year ended December 31, 2023 under this agreement. Amounts recognized f</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">rom the date of acquisition of La Jolla to December 31, 2022 were not material.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Harvard University</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the Harvard University (&#8220;Harvard&#8221;) License, Harvard exclusively licensed to La Jolla certain intellectual property rights relating to tetracycline-based products, including XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, including the exclusive rights to certain issued patents and patent applications covering such products. Under the Harvard License, we are obligated to use commercially reasonable efforts to develop, commercialize, market and sell tetracycline-based products, including XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. For each product covered by the Harvard License, we are obligated to make certain payments for the following: (i) up to approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0aec8e11-9d90-476c-9414-77217ebd3725" contextRef="C_4a4dcf17-e144-4065-bc02-636f5d4b60be" name="inva:ClinicalDevelopmentAndRegulatoryMilestonesAmountPayable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">15.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million upon the achievement of certain clinical development and regulatory milestones; (ii) a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a6afe523-8212-4d94-8667-126dae3b56cb" contextRef="C_4a4dcf17-e144-4065-bc02-636f5d4b60be" name="inva:PercentageOfRoyaltyPayableOnNetSales" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% royalty on direct U.S. net sales of XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">; (iii) a single-digit tiered royalty on direct ex-U.S. net sales of XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, starting at a minimum royalty rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bbe8463d-8a50-4278-9180-96b8f5bba597" contextRef="C_4a4dcf17-e144-4065-bc02-636f5d4b60be" name="inva:PercentageOfMinimumRoyaltyRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">4.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%, with step-ups to a maximum royalty of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6226b28b-3130-4532-9f7f-56fc64e9d4c2" contextRef="C_4a4dcf17-e144-4065-bc02-636f5d4b60be" name="inva:PercentageOfMaximumRoyaltyBasedOnAchievementOfAnnualNetProductSalesThresholds" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">7.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% based on the achievement of annual net product sales thresholds; and (iv) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bc2b50fe-f3b7-418e-b91f-3f32fa7a4411" contextRef="C_4a4dcf17-e144-4065-bc02-636f5d4b60be" name="inva:PercentageOfRoyaltyOnPaymentsReceivedFromSublicensees" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">20</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% on payments received from sublicensees. The obligation to pay royalties under this agreement extends through the last-to-expire patent covering tetracycline-based products, including XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> For the year ended December 31, 2023, we recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_388cda57-c631-4829-8bfc-f5cd35a8408b" contextRef="C_4a4dcf17-e144-4065-bc02-636f5d4b60be" name="us-gaap:CostOfRevenue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as cost of license revenue under this agreement as a result of the license revenue we earned under the out-licensing agreement with Everest for the same period. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From the date of acquisition of La Jolla to December 31, 2022, amounts recognized under this agreement were not material.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Paratek Pharmaceuticals, Inc.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the Paratek Pharmaceuticals, Inc. (&#8220;Paratek&#8221;) License, Paratek non-exclusively licensed to La Jolla certain intellectual property rights relating to XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, including non-exclusive rights to certain issued patents and patent applications covering XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. We are obligated to pay Paratek a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bce8215b-1510-4cdf-8b5d-9d910b935257" contextRef="C_1c6f694e-9295-44ca-bb54-e10942065024" name="inva:PercentageOfRoyaltyPayableOnNetSales" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">2.25</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% royalty based on direct U.S. net sales of XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Our obligation to pay royalties with respect to the licensed product is retroactive to the date of the first commercial sale of XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and shall continue until there are no longer any valid claims of the Paratek patents, which expired in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_74217e46-2d1f-46a3-b56f-e778cc36373e" contextRef="C_1c6f694e-9295-44ca-bb54-e10942065024" name="inva:ClaimExpirationDate" format="ixt:date-monthname-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">October 2023</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. For the year ended December 31, 2023 and from the date of acquisition of La Jolla to December 31, 2022, amounts recognized under this agreement were not material.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Business Transfer and Subscription Agreement with AstraZeneca</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Entasis entered into a Business Transfer and Subscription Agreement with AstraZeneca, AstraZeneca UK Limited and AstraZeneca Pharmaceuticals LP (collectively, &#8220;AstraZeneca&#8221;) (the &#8220;AstraZeneca Agreement&#8221;) in 2015, which was amended and restated through 2018, pursuant to which Entasis obtained, among other things, worldwide rights to durlobactam and zoliflodacin. Under the AstraZeneca Agreement, we are obligated to pay AstraZeneca a one-time milestone payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d164b6ea-beb3-4a8e-a4de-8a8dba709268" contextRef="C_2bff9226-01dd-49ce-8c00-439b9b368e4f" name="inva:SubscriptionAgreementOneTimeMilestonePaymentOnNetSales" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million within </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5159c828-3599-4442-aff7-b15fca04de4f" contextRef="C_2bff9226-01dd-49ce-8c00-439b9b368e4f" name="inva:TermOfMilestonePaymentForNetSales" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three months</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of achieving a specified cumulative net sales milestone for durlobactam. We are also obligated to pay AstraZeneca a one-time milestone payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_38d2f6dd-6b05-4a87-ad24-11d91a657b78" contextRef="C_2bff9226-01dd-49ce-8c00-439b9b368e4f" name="inva:SubscriptionAgreementOneTimeMilestonePaymentOnCommercialSales" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">10.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million within </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_874230e9-c5c4-40a8-8d34-2e030acc69c6" contextRef="C_2bff9226-01dd-49ce-8c00-439b9b368e4f" name="inva:TermOfMilestonePaymentForCommercialSale" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">two years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of achieving the first commercial sale of zoliflodacin. Additionally, we are obligated to pay AstraZeneca tiered, single-digit royalties on the annual worldwide net sales of durlobactam and, the lesser of tiered, single-digit royalties on the worldwide annual net sales of zoliflodacin and a specified share of the royalties we receive from sublicensees of zoliflodacin. Royalties on sales of zoliflodacin do not include sales by GARDP in low-income and specified middle-income countries as discussed above. Our obligation to make these royalty payments expires with respect to each product on a country-by-country basis upon the later of (i) the 10-year anniversary of the first commercial sale of a product in each such country or (ii) when the last patent right covering a product expires in each such country.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Royalty expense on durlobactam arising from our net sales of XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for the year ended December 31, 2023 was immaterial.</span></p></ix:nonNumeric></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">110</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9a0e3283-2790-4dd2-998f-d09a43402847" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="inva:ConsolidatedEntitiesAndAcquisitionsTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5. CONSOLIDATED ENTITIES AND ACQUISITIONS</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Consolidated Entities</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Theravance Respiratory Company, LLC</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Up until July 20, 2022, we consolidated TRC under the VIE model as we determined that TRC was a VIE and we were the primary beneficiary of the entity because we had the power to direct the economically significant activities of TRC and the obligation to absorb losses of, or the right to receive benefits from, TRC. We held </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0565eeaa-14fc-4105-b44d-2a1384f965c8" contextRef="C_9eac7308-f944-4333-bf01-4381430c8676" name="inva:OwnershipInterestInConsolidatedEntities" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">15</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% ownership interest of TRC. The primary source of revenue for TRC is the royalties generated from the net sales of TRELEGY</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> by GSK.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As discussed in Note 3, &#8220;Revenue Recognition&#8221;, on July 13, 2022, ITH entered into the TRC Equity Purchase Agreement to sell our ownership interest in TRC. Upon the closing of the transaction on July 20, 2022, we received $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5d669584-4a16-43df-99b6-20165e629f13" contextRef="C_9c87d87f-710c-4de3-a73e-9a9094727284" name="inva:ProceedsFromSaleOfEconomicInterestUnderEquityPurchaseAgreement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">277.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in cash from Royalty Pharma. We are also entitled to receive up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c77a662a-0621-4eb3-ac39-eb72ccd64478" contextRef="C_4db40aa1-f9c9-4e8f-b9d8-1756f4712094" name="inva:ContingentSalesBasedMilestonePayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">50.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in contingent sales-based milestone payments in the future. In connection with the closing of the transaction, we also received our portion of TRC&#8217;s remaining cash balance of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_078fcb7a-3864-44ee-824e-36be1a16ba0c" contextRef="C_4db40aa1-f9c9-4e8f-b9d8-1756f4712094" name="inva:CashDistributionReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million from Royalty Pharma rather than through a cash distribution from TRC.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prior to the closing of the transaction and as part of the agreement, TRC distributed its ownership interests and investments in InCarda Therapeutics (&#8220;InCarda&#8221;), Inc., ImaginAb, Inc. (&#8220;ImaginAb&#8221;), Gate Neurosciences (&#8220;Gate&#8221;), Inc. and Nanolive SA (&#8220;Nanolive&#8221;), which had a total carrying value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1d6e1856-9f40-4f9c-8300-cf537fcb38c9" contextRef="C_9c87d87f-710c-4de3-a73e-9a9094727284" name="us-gaap:EquityMethodInvestments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">39.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, to ITH. We accounted for the transaction similar to an upstream sale between a parent and a VIE under ASC 810-10. As such, ITH recorded the transferred investments at their respective carrying values and no gain or loss was recognized in the consolidated statement of income.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8900d24b-05a0-4198-9a12-e0b2ee276469" contextRef="C_8e8b777f-2a9d-4fa4-b2ab-fe056ae69ce8" name="us-gaap:ScheduleOfVariableInterestEntitiesTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The summarized financial information of TRC </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">for the relevant periods through the sale date in 2022 are presented as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Income statements</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:61.232%;"/>
        <td style="width:1.78%;"/>
        <td style="width:1%;"/>
        <td style="width:15.603%;"/>
        <td style="width:1%;"/>
        <td style="width:1.78%;"/>
        <td style="width:1%;"/>
        <td style="width:15.603%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;min-width:fit-content;">&#160;(1)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Royalty revenue</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_10f70c8e-4f7f-4ca3-b77a-59255ab84f38" contextRef="C_b2c2c1ac-728c-4d23-a024-c459443d06d0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">72,029</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4c0cd5e1-664c-4c03-a810-77e21e9e9a94" contextRef="C_7a07a415-eb4b-4dff-ab91-19dbbfc1a7cc" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">126,688</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_19514078-4d7f-46e4-9ec3-6baa01d8bc45" contextRef="C_9eac7308-f944-4333-bf01-4381430c8676" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">332</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_71a44ba5-c899-4022-994d-2aa0cc5643bf" contextRef="C_d81eb8e0-c039-48de-a07a-d8267be56862" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3,956</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Income from operations</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9f51a90b-d5b3-4baf-a592-557db4d38798" contextRef="C_9eac7308-f944-4333-bf01-4381430c8676" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">71,697</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7f3cb076-04b4-4d3d-87b1-c333b3e454e0" contextRef="C_d81eb8e0-c039-48de-a07a-d8267be56862" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">122,732</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other income, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c2d29a19-daed-4394-b61e-859713cd07bf" contextRef="C_9eac7308-f944-4333-bf01-4381430c8676" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2f21832c-338f-4281-9f6b-759b8af2cef9" contextRef="C_d81eb8e0-c039-48de-a07a-d8267be56862" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Realized loss</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f2a97274-1f4f-460d-ae0c-feb28444b496" contextRef="C_9eac7308-f944-4333-bf01-4381430c8676" name="inva:RealizedLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">39,386</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e46ed95f-8618-4b08-972d-9ee0c9d9fd5d" contextRef="C_d81eb8e0-c039-48de-a07a-d8267be56862" name="inva:RealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Income tax expense, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fd0c3223-a52a-48b1-a54d-d2343a4454e1" contextRef="C_9eac7308-f944-4333-bf01-4381430c8676" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_080bc88e-12ec-4149-90d5-7bd8a47674c7" contextRef="C_d81eb8e0-c039-48de-a07a-d8267be56862" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Changes in fair values of equity and<br/>&#160;&#160;&#160;long-term investments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f02c3cdb-acc9-4cbf-9957-678c00ecf7f0" contextRef="C_9eac7308-f944-4333-bf01-4381430c8676" name="us-gaap:GainLossOnInvestments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">8,884</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e8d2f2cc-27a9-4411-9bd6-36f1e69c07d7" contextRef="C_d81eb8e0-c039-48de-a07a-d8267be56862" name="us-gaap:GainLossOnInvestments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,541</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net income</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e397c611-ef5b-4261-b926-3631409061a6" contextRef="C_9eac7308-f944-4333-bf01-4381430c8676" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,438</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_43adfe2b-634e-4aed-8e25-0f6e4e580cb0" contextRef="C_d81eb8e0-c039-48de-a07a-d8267be56862" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">121,191</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:footnote id="FNT_e66ad88b-f785-4158-ae1c-5740243b0d71" xml:lang="en-US"><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">(1)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">   The year ended December 31, 2022 represents the period from January 1, 2022 to July 20, 2022, the date of the sale of our ownership interest in TRC.</span></p></ix:footnote></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ISP Fund LP</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2020, Innoviva Strategic Partners LLC, our wholly owned subsidiary (&#8220;Strategic Partners&#8221;), contributed $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7fdbffc2-128f-47d4-a23f-3d31b2874a80" contextRef="C_1e700f80-a869-46a2-ac03-43bec9ff60e2" name="us-gaap:LimitedPartnersContributedCapital" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">300.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million to ISP Fund LP (the &#8220;Partnership&#8221;) for investing in &#8220;long&#8221; positions in the healthcare, pharmaceutical and biotechnology sectors and became a limited partner. The general partner of the Partnership (&#8220;General Partner&#8221;) is an affiliate of Sarissa Capital.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Partnership Agreement provides for Sarissa Capital to receive management fees from the Partnership, payable quarterly in advance, measured based on the Net Asset Value of Strategic Partners&#8217; capital account in the Partnership. In addition, General Partner is entitled to an annual performance fee based on the Net Profits of the Partnership during the annual measurement period.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">111</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Partnership Agreement includes a lock-up period of thirty-six months after which Strategic Partners is entitled to make withdrawals from the Partnership as of such lock-up expiration date and each anniversary thereafter, subject to certain limitations. The lock-up period for the initial contribution of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f5e048ab-9eec-4e63-9a25-d200726c9f15" contextRef="C_059975f4-4c4c-47fa-a5cc-efc7bf10d886" name="inva:LimitedPartnersInitialContribution" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">190.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">which excludes the amount discussed below, expired in December 2023. Strategic Partners did not elect to make a withdrawal in 2023, thereby extending the lock-up period and withdrawal elections into subsequent years.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In May 2021, Strategic Partners received a distribution of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_69fcbab7-42fe-4ba2-8211-853ec6669c3b" contextRef="C_9030a2c1-fd8e-4238-9d01-79bece46654e" name="us-gaap:LimitedPartnersCumulativeCashDistributions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">110.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million from the Partnership to provide funding to Innoviva for a strategic repurchase of shares held by GSK. On March 30, 2022, Strategic Partners made an additional capital contribution of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e6b3f107-faa4-4f27-a236-560d92621265" contextRef="C_11f17e9c-095d-4fae-8b57-328fa2b9ba57" name="us-gaap:LimitedPartnersContributedCapital" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">110.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million to the Partnership pursuant to the letter agreement entered into between Strategic Partners, the Partnership and Sarissa Capital Fund GP LP on May 20, 2021. The capital contribution is subject to a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5952750a-4747-4048-8cdc-ba21ff28db50" contextRef="C_0baf8d0a-a93a-4dff-b66a-e5c5efa4d6d1" name="inva:PartnershipAgreementLockUpPeriod" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">36-month</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> lock up period from the contribution date.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We consolidate ISP Fund LP under the VIE model as we have determined that ISP Fund LP is a VIE and we are the primary beneficiary of the entity via our related party relationships with Sarissa Capital entities. Our maximum exposure to loss is equal to the amount we invested in the entity.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ISP Fund LP is determined to be an investment company under ASC 946, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Financial Services &#8211; Investment Companies</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, as it meets all fundamental characteristics of an investment company, and its activities are consistent with those of an investment company. Since ISP Fund LP is subject to investment company industry specific guidance, we have retained the industry-specific guidance applied by the Partnership. In addition, as our investment in the Partnership is a passive investment for the Company and is not part of our main operations, the investments are presented as part of &#8220;Equity and long-term investments&#8221; in our consolidated balance sheets. We report in our consolidated statements of income any investment gains and losses by the Partnership as part of &#8220;Changes in fair value of equity and long-term investments, net&#8221;, any interest and dividend income as part of &#8220;Interest and dividend income&#8221; and any investment expenses as part of &#8220;Other expense, net&#8221;.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, we continued to hold </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_979e7540-9f16-4721-8b5a-6067157efbda" contextRef="C_059975f4-4c4c-47fa-a5cc-efc7bf10d886" name="inva:PercentageOfEconomicInterestInPartnership" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">100</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the economic interest of Partnership. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023 and 2022, total assets of the Partnership were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7e09e334-d1c2-4af9-8ac1-b3bdc917a5ed" contextRef="C_b39ad5c9-17bf-4a35-b889-6bc388c60b7c" name="us-gaap:Assets" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">311.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5cd98a1e-8b67-472d-a3d5-19ddd1f3398f" contextRef="C_3abefe6f-631c-4640-93e2-984c5ac20007" name="us-gaap:Assets" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">320.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively, of which the majority was attributable to equity and long-term investments. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023 and 2022, total liabilities of the Partnership w</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ere $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_addc67ae-9328-46b8-93f8-b7ad4c0d6bd7" contextRef="C_b39ad5c9-17bf-4a35-b889-6bc388c60b7c" name="us-gaap:Liabilities" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> mill</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ion and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5c36a5fe-b2c3-4311-966b-4cb72c1e5891" contextRef="C_3abefe6f-631c-4640-93e2-984c5ac20007" name="us-gaap:Liabilities" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively. The Partnership</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8217;s assets can only be used to settle its own obligations. During the year ended December 31, 2023, the Partnership incurred</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_34474073-836e-4ded-b229-5b44072f0e9c" contextRef="C_059975f4-4c4c-47fa-a5cc-efc7bf10d886" name="inva:NetInvestmentRelatedIncomeExpenseEarnedInccured" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">million in net investment-related expenses, generated $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0b2c65ea-8032-4d62-8963-32f321cf6967" contextRef="C_059975f4-4c4c-47fa-a5cc-efc7bf10d886" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million interest income, recorded $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_561de82e-5ef2-4244-9a3c-8543ec66908b" contextRef="C_059975f4-4c4c-47fa-a5cc-efc7bf10d886" name="us-gaap:GainLossOnInvestments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in net realized losses and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_32e0511f-7e5c-44fc-94c1-94e0f20b7ce7" contextRef="C_059975f4-4c4c-47fa-a5cc-efc7bf10d886" name="us-gaap:UnrealizedGainLossOnInvestments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in net unrealized losses as changes in fair values of equity and long-term investments, net, in the consolidated statement of income. During the year ended December 31, 2022, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the Partnership incurred $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d8a82c50-5826-4025-8d04-322b9936a799" contextRef="C_03ba9ffa-87ef-489a-a311-42db1ae05203" name="inva:NetInvestmentRelatedIncomeExpenseEarnedInccured" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in net investment-related expenses, generated $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_97ecde06-8713-4737-a93e-23658bfa9fc6" contextRef="C_03ba9ffa-87ef-489a-a311-42db1ae05203" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million interest income, recorded $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b0accbe7-c0cf-4ba7-8bf5-7123d0002c14" contextRef="C_03ba9ffa-87ef-489a-a311-42db1ae05203" name="us-gaap:GainLossOnInvestments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in net realized gains and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5a051022-3b58-4384-a4a0-44ecf8d09a85" contextRef="C_03ba9ffa-87ef-489a-a311-42db1ae05203" name="us-gaap:UnrealizedGainLossOnInvestments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">9.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in net unrealized losses as changes in fair values of equity and long-term investments, net, in the consolidated statement of income. During the year ended December 31, 2021, the Partnership incurred $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_91ea76ab-7fa6-43a6-946b-ecf55e6b3895" contextRef="C_0287d352-8cf0-4411-9610-d97bd5f904bf" name="inva:NetInvestmentRelatedIncomeExpenseEarnedInccured" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in net investment-related expense, generated $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dba588e7-5ff7-45ef-b8ee-8f9ed2dd98f8" contextRef="C_0287d352-8cf0-4411-9610-d97bd5f904bf" name="us-gaap:InvestmentIncomeInterestAndDividend" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million interest and dividend income, and recorded net $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_193b980a-a50d-4a50-9018-2ad221f1d1b7" contextRef="C_0287d352-8cf0-4411-9610-d97bd5f904bf" name="us-gaap:GainLossOnInvestments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">10.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million realized gains and net $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d5fee99c-b330-4f90-af14-b9125f109617" contextRef="C_0287d352-8cf0-4411-9610-d97bd5f904bf" name="us-gaap:UnrealizedGainLossOnInvestments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million unrealized losses as changes in fair values of equity and long-term investments, net, in the consolidated statement of income. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We account for the long-term investments held by ISP Fund LP as of December 31, 2023 and 2022 as equity investments measured at fair value and the investment in convertible notes as of December 31, 2022 as trading security.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Acquisitions</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Entasis Therapeutics Holdings Inc.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We started investing in Entasis in 2020 as part of our capital allocation strategy of deploying cash generated from royalty income and investing in different life sciences companies. Entasis at the time was an advanced, late clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products. Effective in June 2020, after certain conditions were met with respect to the sales of Entasis equity shares, Innoviva had the right to designate </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dfe2b84f-232e-435e-94ac-3fc38ae275d6" contextRef="C_8f8c6623-d626-4ff4-b287-9206e6e7485e" name="inva:SecuritiesPurchaseAgreementRightsToDesignateInvesteeBoardMembersNumberOfBoardMembers" unitRef="U_Director" decimals="0" format="ixt-sec:numwordsen">two</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> members to Entasis&#8217; board. Our investment in Entasis consisted of shares of common stock and warrants to purchase shares of Entasis common stock.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair value of Entasis&#8217; common stock was measured based on its closing market price at each balance sheet date. We used the Black-Scholes-Merton pricing model to estimate the fair value of the warrants.</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">112</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On February 17, 2022, Innoviva Strategic Opportunities, LLC (&#8220;ISO&#8221;)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> entered into a securities purchase agreement with Entasis pursuant to which ISO purchased a convertible promissory note for a total purchase price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_63d68d0c-8ac9-4c47-9d3c-f6d2bbc21be4" contextRef="C_0de66d0f-6eb9-49fa-a5ec-9c7b513a7979" name="us-gaap:DebtInstrumentCarryingAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">15.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The note bore an annual interest rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1f229d5a-3c41-4cbf-bfe8-4c0f25b8a743" contextRef="C_0de66d0f-6eb9-49fa-a5ec-9c7b513a7979" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">0.59</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% and was due to mature and become payable on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6ff7305f-44a8-48b8-ac53-12af7ec7e17f" contextRef="C_011ae41c-ec4e-43c1-8532-003573595646" name="us-gaap:DebtInstrumentMaturityDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">August 18, 2022</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> unless it was converted at a conversion price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_872cd0ac-bee1-4988-9b5d-812ad2f1a615" contextRef="C_0de66d0f-6eb9-49fa-a5ec-9c7b513a7979" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">1.48</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> before the maturity date. With this financing, we determined that we had both (i) the power to direct the economically significant activities of Entasis and (ii) the obligation to absorb the losses, or the right to receive the benefits, that could potentially be significant to Entasis and therefore, we were the primary beneficiary of Entasis. Accordingly, we consolidated Entasis&#8217; financial position and results of operations effective on February 17, 2022. Our equity ownership interest remained at </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5b38513e-6e0b-45a3-a161-0cbdb7c43d0c" contextRef="C_c00f47a4-0506-4cb6-a19d-c4eb9dd56571" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">59.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% as of February 17, 2022, and the fair values of our holdings of Entasis common stock and warrants were remeasured and estimated at $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d647bf54-6717-401d-b62b-71a859a50505" contextRef="C_c6dfd9f2-8eeb-44c2-9621-2be87264e608" name="us-gaap:EquitySecuritiesFvNi" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">64.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3bc72364-c8d2-4955-9d85-48ea3c3f10f2" contextRef="C_126a8e06-61fd-494c-9ffd-58ea5c0bdea5" name="us-gaap:EquitySecuritiesFvNi" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">31.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The remeasurement resulted in a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2ccab435-7a95-4957-b210-6897152e3380" contextRef="C_a864ac08-9446-4d68-95de-31f94372d9f3" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million loss in the first quarter of 2022 which was included in changes in fair values of equity method investments, net, in the consolidated statement of income for the year ended December 31, 2022.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We completed our acquisition of Entasis&#8217; minority interest on July 11, 2022. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_346d8b38-1fbd-43d4-8033-3e6f9e7303f3" contextRef="C_707fc4b5-3c6e-4394-b574-0e56dc4f8c0a" name="us-gaap:RepaymentsOfConvertibleDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> payments were made toward the convertible promissory note through the date of acquisition of Entasis. In connection with the acquisition, all of the Entasis warrants were replaced with Innoviva warrants (the &#8220;Replacement Warrants&#8221;) of equivalent value and bearing the same terms. The Replacement Warrants are classified as equity.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We recognized the difference between the acquisition price and the carrying value of the acquired minority interest on July 11, 2022 in our additional paid-in capital.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair values assigned to assets acquired and liabilities assumed as of February 17, 2022 were based on management&#8217;s best estimates and assumptions. After the acquisition in July 2022, we adjusted the purchase price allocation based on new and additional information related to product sales forecast provided by Entasis and deferred tax liabilities.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the year ended December 31, 2022, we recorded measurement period adjustments of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3eeea199-6a9c-4bed-ad7a-dce058f78f3a" contextRef="C_710dc59e-981c-4ad8-987e-bb49af565884" name="us-gaap:GoodwillPeriodIncreaseDecrease" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">4.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million decrease in goodwill, primarily related to a decrease in estimated purchase price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_acf239c5-1148-4a38-adba-880abd71a70b" contextRef="C_710dc59e-981c-4ad8-987e-bb49af565884" name="inva:MeasurementPeriodAdjustmentsIncreaseDecreaseInEstimatedPurchasePrice" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">1.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, an increase in noncontrolling interests of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b7c861aa-d43f-4ae0-9828-83904acd56c7" contextRef="C_710dc59e-981c-4ad8-987e-bb49af565884" name="us-gaap:MinorityInterestPeriodIncreaseDecrease" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, and an increase in intangible assets of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_920c87ec-9784-440a-9cfa-bcdff66ecb4a" contextRef="C_710dc59e-981c-4ad8-987e-bb49af565884" name="us-gaap:IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The cumulative impact of the measurement period adjustments included in the consolidated net income for the year ended December 31, 2022 was not material.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In February 2023, we recorded a measurement period adjustment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f3ba2403-4fa8-411a-888d-1f991744a29d" contextRef="C_3b8d2e0c-b8e8-465e-b685-f60604c8c298" name="us-gaap:GoodwillPeriodIncreaseDecrease" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million increase in goodwill, primarily related to a decrease in intangible assets of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_61241a22-2590-4213-9307-6b1c4312f351" contextRef="C_3b8d2e0c-b8e8-465e-b685-f60604c8c298" name="us-gaap:IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">0.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and an increase in deferred tax liabilities of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b277d103-6c0f-42c9-89ed-fb432f1cd03c" contextRef="C_3b8d2e0c-b8e8-465e-b685-f60604c8c298" name="inva:IncreaseDecreaseInDeferredTaxLiabilities" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The measurement period adjustment did not impact the consolidated net income for the year ended December 31, 2023.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a54dbd9a-1b7a-47b9-bf5a-a8b6c68614a7" contextRef="C_8f8c6623-d626-4ff4-b287-9206e6e7485e" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table represents the adjusted fair values of the assets acquired and liabilities assumed by us in the transaction:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:80.444%;"/>
        <td style="width:1.8%;"/>
        <td style="width:1%;"/>
        <td style="width:15.757%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">February 17, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_83d339a1-6454-45cb-8702-8fd2f21d8671" contextRef="C_1cbdd9df-6a4a-4d82-9344-ffb61a7bc4cd" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,070</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2c0f211a-95a0-478f-b09c-f265fe0e9065" contextRef="C_1cbdd9df-6a4a-4d82-9344-ffb61a7bc4cd" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,554</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other current assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5ec24488-b0a0-4f5b-a641-250cd8fe1b63" contextRef="C_1cbdd9df-6a4a-4d82-9344-ffb61a7bc4cd" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,959</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Property and equipment, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bed4bb33-192f-4382-b52a-40d14d20af5b" contextRef="C_1cbdd9df-6a4a-4d82-9344-ffb61a7bc4cd" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">185</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Right-of-use assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6bf47e06-d4c6-4f87-a63f-a68af80d7ce0" contextRef="C_1cbdd9df-6a4a-4d82-9344-ffb61a7bc4cd" name="inva:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">959</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Goodwill</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_87696f4c-9aba-4912-832b-a0805442542c" contextRef="C_1cbdd9df-6a4a-4d82-9344-ffb61a7bc4cd" name="us-gaap:Goodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,493</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Intangible assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_82f28d63-ee54-499d-84dd-996c1cb19e51" contextRef="C_1cbdd9df-6a4a-4d82-9344-ffb61a7bc4cd" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">106,700</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a5ab4c8c-27aa-4ceb-91b0-ca6beb320c07" contextRef="C_1cbdd9df-6a4a-4d82-9344-ffb61a7bc4cd" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">302</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets acquired</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5eeda392-7a15-4cd0-9c5c-bd002cc79418" contextRef="C_1cbdd9df-6a4a-4d82-9344-ffb61a7bc4cd" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">150,222</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts payable</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f0b72a82-4e04-4784-ac2f-d1e7eb74e4ea" contextRef="C_1cbdd9df-6a4a-4d82-9344-ffb61a7bc4cd" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,583</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued personnel-related expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7924b47f-2819-4328-97e2-078f0f041f63" contextRef="C_1cbdd9df-6a4a-4d82-9344-ffb61a7bc4cd" name="inva:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedPersonnelRelatedExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,058</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other accrued liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_975f56ed-35c2-4842-9688-f2b7f241d975" contextRef="C_1cbdd9df-6a4a-4d82-9344-ffb61a7bc4cd" name="inva:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,096</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ac340973-2cf7-4cbd-b121-2ea1affcfd4e" contextRef="C_1cbdd9df-6a4a-4d82-9344-ffb61a7bc4cd" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,769</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total liabilities assumed</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_44e69415-8d40-4d88-9180-25070284092f" contextRef="C_1cbdd9df-6a4a-4d82-9344-ffb61a7bc4cd" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,506</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets acquired, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6ff7849d-f9be-450a-9acf-782698ec24f8" contextRef="C_1cbdd9df-6a4a-4d82-9344-ffb61a7bc4cd" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">134,716</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">113</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The goodwill arising from the acquisition of Entasis is primarily attributable to Entasis&#8217; assembled workforce and the value associated with growing our business more efficiently. The goodwill from this acquisition is not expected to be deductible for tax purposes.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Refer to Note 8, &#8220;Goodwill and Intangible Assets&#8221;, for more discussion on the intangible assets recognized as part of this acquisition.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a result of the consolidation, we recognized a non-controlling interest of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6dfdf5f6-111f-4d18-b755-bcade717cccd" contextRef="C_1cbdd9df-6a4a-4d82-9344-ffb61a7bc4cd" name="us-gaap:MinorityInterest" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">38.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as of February 17, 2022. Our consolidated net income for the year ended December 31, 2022 included the net loss attributable to noncontrolling interest since the consolidation date until the date of acquisition of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_293aa7d6-0b2d-47ca-97f3-612fec869643" contextRef="C_710dc59e-981c-4ad8-987e-bb49af565884" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">13.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">La Jolla Pharmaceutical Company</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On August 22, 2022, ISO acquired La Jolla for a total consideration of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_96f8aca3-eacd-44c0-9b02-4f4a46a7f9fc" contextRef="C_e05740b2-e808-41d3-b26e-897ba3aa633c" name="us-gaap:BusinessCombinationConsiderationTransferred1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">206.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. ISO acquired La Jolla at a price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_67be033a-b16e-43e8-9533-23ca17d4bb06" contextRef="C_d175404c-e239-4f30-bbd0-3bbf386d06ea" name="us-gaap:BusinessAcquisitionSharePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">6.23</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share. La Jolla is dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases. La Jolla brought to Innoviva an established product portfolio, including GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock and XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (eravacycline) for the treatment of complicated intra-abdominal infections (cIAIs). We incurred approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_62700df4-7667-4b67-bd28-65464115f4ad" contextRef="C_64603e03-c98c-40b7-ae31-b9e79c20bc55" name="us-gaap:AcquisitionCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in acquisition-related costs in connection with this acquisition during the year ended December 31, 2022.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair values assigned to assets acquired and liabilities assumed as of August 22, 2022 were based on management&#8217;s best estimates and assumptions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the year ended December 31, 2022, we recorded measurement period adjustments of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dca6ae47-9c82-404f-9198-69f14203e6e6" contextRef="C_64603e03-c98c-40b7-ae31-b9e79c20bc55" name="us-gaap:GoodwillPeriodIncreaseDecrease" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million increase in goodwill, primarily related to a decrease in inventory and intangible assets of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4707052e-f63f-4c28-800d-ca0b0c075a90" contextRef="C_64603e03-c98c-40b7-ae31-b9e79c20bc55" name="us-gaap:IncreaseDecreaseInInventories" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">7.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d3c43416-a373-4344-9734-570165238862" contextRef="C_64603e03-c98c-40b7-ae31-b9e79c20bc55" name="us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">1.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively, and an increase in deferred tax liabilities of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b05ad8cd-f163-4ad2-b125-4fc2282faa95" contextRef="C_64603e03-c98c-40b7-ae31-b9e79c20bc55" name="inva:IncreaseDecreaseInDeferredTaxLiabilities" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, partially offset by a decrease in other long-term liabilities of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_541eff81-ec71-47c3-9e28-1be121f98b0d" contextRef="C_64603e03-c98c-40b7-ae31-b9e79c20bc55" name="inva:MeasurementPeriodAdjustmentsIncreaseDecreaseInLiabilities" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">8.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The cumulative impact of the measurement period adjustments included in the consolidated net income for the year ended December 31, 2022 was not material.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2023, we recorded a measurement period adjustment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_983cc8a2-be22-4682-913b-7e0325bafd90" contextRef="C_c20721f8-5014-4577-a717-6b5f4d10b69e" name="us-gaap:GoodwillPeriodIncreaseDecrease" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">13.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million decrease in goodwill, primarily related to an increase in deferred tax assets of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4ef55ebc-267e-4a78-85fd-6e9a5da9d06c" contextRef="C_c20721f8-5014-4577-a717-6b5f4d10b69e" name="inva:IncreaseDecreaseInDeferredTaxAssets" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">10.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and a decrease in deferred tax liabilities of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_177def64-2b39-45c1-8eb5-07e15273ecee" contextRef="C_c20721f8-5014-4577-a717-6b5f4d10b69e" name="inva:IncreaseDecreaseInDeferredTaxLiabilities" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">2.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. In August 2023, we recorded a measurement period adjustment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5c19a1e7-e70a-4141-bd97-2ccf6c4ae4b9" contextRef="C_4e8f4a7f-a815-47e5-91cf-9d09535c48ce" name="us-gaap:GoodwillPeriodIncreaseDecrease" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million increase in goodwill, primarily related to a decrease in deferred tax assets of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_48976b1d-19a6-46d9-8cea-8f691ef1d1dd" contextRef="C_4e8f4a7f-a815-47e5-91cf-9d09535c48ce" name="inva:IncreaseDecreaseInDeferredTaxAssets" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">2.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and an increase in deferred tax liabilities of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9b6ad3b1-08f6-4ca0-adaf-300d498e9204" contextRef="C_4e8f4a7f-a815-47e5-91cf-9d09535c48ce" name="inva:IncreaseDecreaseInDeferredTaxLiabilities" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The cumulative impact of the measurement period adjustments included did not impact the consolidated net income for the year ended December 31, 2023.</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">114</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9619c407-67cc-4053-a7ad-0d31806e86c0" contextRef="C_211cd3e4-b7d2-4255-9490-b9155f8d7b3d" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table represents the adjusted fair values of assets acquired and liabilities assumed by us in the transaction:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:80.444%;"/>
        <td style="width:1.8%;"/>
        <td style="width:1%;"/>
        <td style="width:15.757%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">August 22, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4f2c1f9c-a27c-465c-bdfa-0f5d80d9a3bc" contextRef="C_d175404c-e239-4f30-bbd0-3bbf386d06ea" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">47,415</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Short-term marketable securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4c953744-8bb4-4164-b1d7-aec440b1a20b" contextRef="C_d175404c-e239-4f30-bbd0-3bbf386d06ea" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">471</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts receivable</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_07b6c5fb-808c-4f27-9edf-274e05e392ab" contextRef="C_d175404c-e239-4f30-bbd0-3bbf386d06ea" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,876</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inventory</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_013e7152-a610-4c0f-823f-b18b3a0078ed" contextRef="C_d175404c-e239-4f30-bbd0-3bbf386d06ea" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">66,200</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b94a3fde-9910-4779-a1a3-11775c76f54b" contextRef="C_d175404c-e239-4f30-bbd0-3bbf386d06ea" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,261</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other current assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5dae0d2c-9253-44f4-9c89-eeeb4ba191bb" contextRef="C_d175404c-e239-4f30-bbd0-3bbf386d06ea" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">907</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Property and equipment, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7d02a06b-a5f4-47b7-83b3-c415adbffd55" contextRef="C_d175404c-e239-4f30-bbd0-3bbf386d06ea" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Right-of-use assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_95e5dbcd-98eb-4ce4-a3a3-f5d09f464b03" contextRef="C_d175404c-e239-4f30-bbd0-3bbf386d06ea" name="inva:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">226</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Goodwill</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ee97a437-896e-4267-874e-188a310adf52" contextRef="C_d175404c-e239-4f30-bbd0-3bbf386d06ea" name="us-gaap:Goodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,411</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Intangible assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4922cb69-48a6-4d36-a893-8532232c6cac" contextRef="C_d175404c-e239-4f30-bbd0-3bbf386d06ea" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">151,000</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6ea13c57-ec3b-4cd9-8bb1-e808b24dcc41" contextRef="C_d175404c-e239-4f30-bbd0-3bbf386d06ea" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,461</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3cf76fce-48fc-4b23-8baa-533bb6ceb5e0" contextRef="C_d175404c-e239-4f30-bbd0-3bbf386d06ea" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">710</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets acquired</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3d2205f0-21c7-491d-bb11-13f25ebe2ea4" contextRef="C_d175404c-e239-4f30-bbd0-3bbf386d06ea" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">287,951</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts payable</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_327e038b-83ef-4ab1-a8f2-ddd09130e064" contextRef="C_d175404c-e239-4f30-bbd0-3bbf386d06ea" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,237</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred revenue</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_68461bf3-5fcf-4036-83b1-e1dbcbe38e4c" contextRef="C_d175404c-e239-4f30-bbd0-3bbf386d06ea" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,849</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other accrued liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f5ca7f1e-e720-4dd6-9d43-656fcdc9443b" contextRef="C_d175404c-e239-4f30-bbd0-3bbf386d06ea" name="inva:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,362</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other long-term liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0c6ffa82-91c1-4ecd-844d-9b21438594ab" contextRef="C_d175404c-e239-4f30-bbd0-3bbf386d06ea" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">65,944</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total liabilities assumed</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_42c73cf9-98c7-43f4-bdac-e052ab203368" contextRef="C_d175404c-e239-4f30-bbd0-3bbf386d06ea" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">81,392</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets acquired, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d330552b-76d3-4f6a-8633-a92532fb1e5b" contextRef="C_d175404c-e239-4f30-bbd0-3bbf386d06ea" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">206,559</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The goodwill arising from the acquisition of La Jolla is primarily attributable to La Jolla&#8217;s assembled workforce and the value associated with leveraging the workforce to develop and commercialize new drug products in the future and growing our business more efficiently. The goodwill from this acquisition is not expected to be deductible for tax purposes.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Refer to Note 8, &#8220;Goodwill and Intangible Assets&#8221;, for more discussion on the intangible assets recognized as part of this acquisition.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Pro Forma Financial Information</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_82217721-0adc-4753-8d9e-37de7bb50fa9" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:BusinessAcquisitionProFormaInformationTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table presents certain unaudited pro-forma financial information for the years ended December 31, 2022 and 2021 as if the consolidation of Entasis and La Jolla occurred on January 1, 2021. The unaudited pro forma financial information is presented for informational purposes only, and is not indicative of the results of operations that would have been achieved if the acquisitions had taken place on January 1, 2021, or of results that may occur in the future. The unaudited pro forma financial information combines the historical results of the Entasis and La Jolla with the Company&#8217;s consolidated historical results and includes certain adjustments including, but not limited to, fair value adjustments to equity investments in Entasis&#8217; common stock and warrants, fair value adjustments to inventory, amortization of intangible assets, and interest expense on deferred royalty obligations and acquisition-related costs.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:53.88%;"/>
        <td style="width:2.26%;"/>
        <td style="width:1%;"/>
        <td style="width:18.799999999999997%;"/>
        <td style="width:1%;"/>
        <td style="width:2.26%;"/>
        <td style="width:1%;"/>
        <td style="width:18.799999999999997%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Revenue</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9eecbd1b-ba60-46f3-879e-2cb8615d4f80" contextRef="C_e913bb79-80cf-4e4b-b05e-99a1cc469935" name="us-gaap:BusinessAcquisitionsProFormaRevenue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">357,880</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3f4cd773-8589-485d-88ca-626ce038a829" contextRef="C_9425c965-5f65-4fe2-b539-6c9acbd2b026" name="us-gaap:BusinessAcquisitionsProFormaRevenue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">435,398</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net income</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_842c4329-80c7-474b-9ffc-3c57313f8b10" contextRef="C_e913bb79-80cf-4e4b-b05e-99a1cc469935" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">204,987</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ae7f430a-8088-4a61-8065-4be78029acc3" contextRef="C_9425c965-5f65-4fe2-b539-6c9acbd2b026" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">281,719</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net income attributable to Innoviva stockholders</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d2bef76e-8cab-4cf9-b38e-d76e324a92a9" contextRef="C_e913bb79-80cf-4e4b-b05e-99a1cc469935" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">214,390</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_659718fa-0c58-461c-9ae8-1ad69690d799" contextRef="C_9425c965-5f65-4fe2-b539-6c9acbd2b026" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">197,535</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">115</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9c01bd6c-a34a-4be5-96a6-fcec29d0860c" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:FinancialInstrumentsDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6. EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Equity and Other Investments in Armata</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the first quarter of 2020, Innoviva acquired </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9ac9cac2-de37-49ef-b7f0-75f42ea0ef18" contextRef="C_21e1bf8d-0dfb-436e-a0f5-40401cbd051a" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">8,710,800</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock as well as warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e839077f-756a-433c-993a-74c87486419e" contextRef="C_4aa2cab4-fd43-44e4-87cc-bff3c5ce186b" name="inva:SaleOfWarrantsNumberOfWarrantsIssuedInTransaction" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">8,710,800</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> additional shares of common stock of Armata Pharmaceuticals, Inc. (&#8220;Armata&#8221;) for approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ce353fc5-74ca-4884-b7d0-2d5489c9f883" contextRef="C_5cb2b0db-90a2-4560-b85e-87494f6a7282" name="inva:SecuritiesPurchaseAgreementAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">25.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in cash. Armata is a clinical stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the first quarter of 2021, ISO entered into a securities purchase agreement with Armata to acquire </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_15f23262-e4f7-4b16-b01f-458b875b0393" contextRef="C_49ef45bd-5ceb-448c-b5bf-998ea5bcd6a4" name="inva:SecuritiesPurchaseAgreementTotalNumberOfWarrantsToBePurchasedUnderAgreement" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">6,153,847</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Armata common stock and warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3f56dd32-67d0-47f4-a8e5-8bdf49095656" contextRef="C_29a8663f-3680-40ab-9728-c1d88380d314" name="inva:SecuritiesPurchaseAgreementTotalNumberOfWarrantsToBePurchasedUnderAgreement" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">6,153,847</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> additional shares of Armata common stock for approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6de8779f-cd07-4033-91aa-39596db1e5c8" contextRef="C_b58b4d47-eb88-4714-9e20-e846765b8a44" name="inva:SecuritiesPurchaseAgreementAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">20.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. Armata also entered into a voting agreement with the Company and ISO, pursuant to which the Company and ISO agreed not to vote or take any action by written consent with respect to any common shares held by the Company and ISO that represent, in the aggregate, more than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c03d3710-a02d-4e17-b39f-c5797495ea2f" contextRef="C_e037e13e-6e91-4a72-ba0c-e61af7067b1b" name="inva:VotingAgreementMaximumVotingRightsPercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">49.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the total number of shares of Armata&#8217;s common stock for voting on the matters related to election or removal of Armata&#8217;s board members. The voting agreement will expire the earlier of the second anniversary of the agreement effective date and approval by the FDA of any of Armata&#8217;s product candidates for marketing and commercial distribution. During the fourth quarter of 2021, ISO also purchased an additional </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_93928661-faf1-4515-9360-e8918247ac92" contextRef="C_1c9ae792-bfa8-4f96-9434-ec29ab1930a2" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,212,122</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Armata common stock for approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_14575c79-aac6-47ec-8b33-461ec0292f41" contextRef="C_1c9ae792-bfa8-4f96-9434-ec29ab1930a2" name="inva:SecuritiesPurchaseAgreementAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On February 9, 2022, ISO entered into a securities purchase agreement with Armata to acquire </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c8a58389-d3f5-4328-979d-92e1e5d42357" contextRef="C_5ca60e7e-4ba6-40eb-a454-386ec8c73923" name="inva:SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">9,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Armata common stock and warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f64b8299-39a6-49ce-ae32-eaab41485d94" contextRef="C_6c4d4181-e8c1-43dd-85b3-83b9cf5f55dd" name="inva:SecuritiesPurchaseAgreementTotalNumberOfWarrantsToBePurchasedUnderAgreement" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">4,500,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> additional shares of common stock with an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_542a0965-600b-4614-a9fd-62bfbc469171" contextRef="C_6c4d4181-e8c1-43dd-85b3-83b9cf5f55dd" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">5.00</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share for $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_25dcf38a-ac83-4e35-8beb-f9900d053bee" contextRef="C_c3fa46e4-5e22-4b74-a128-70da5649065e" name="inva:SecuritiesPurchaseAgreementAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">45.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The investment closed in </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e7565c97-1c88-47cf-871d-a449784904ee" contextRef="C_e037e13e-6e91-4a72-ba0c-e61af7067b1b" name="inva:SecuritiesPurchaseAgreementNumberOfTranches" unitRef="U_Tranche" decimals="0" format="ixt-sec:numwordsen">two</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> tranches on February 9, 2022 and March 31, 2022. The investment is intended to aid Armata in advancing its clinical pipeline and strengthening its bacteriophage platform. On February 9, 2022, Armata also entered a second amended and restated voting agreement with the Company and ISO, pursuant to which the Company and ISO agreed not to vote or take any action by written consent with respect to any common shares held by the Company and ISO that represent, in the aggregate, more than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e0b6c9f0-ab0f-43ab-a0e2-61241950e49f" contextRef="C_300582a5-75c9-4125-aa9d-205955fffcd6" name="inva:VotingAgreementMaximumVotingRightsPercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">49.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the total number of shares of Armata&#8217;s common stock for voting on the matters related to election or removal of Armata&#8217;s board members or amend the bylaws of Armata to reduce the maximum number of directors or set the number of directors who may serve on the board of Armata. The voting agreement will expire the earlier of the second anniversary of the agreement effective date and approval by the FDA of any of Armata&#8217;s product candidates for marketing and commercial distribution. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_42231e2a-406e-43d4-97fb-3c77377d04e0" contextRef="C_300582a5-75c9-4125-aa9d-205955fffcd6" name="inva:SpecialTermReDesignatingBoardMemberToBoardOfInvestee"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, as of February 9, 2022, Armata entered into an amended and restated investor rights agreement with the Company and ISO, pursuant to which for as long as the Company and ISO hold at least </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d591f73c-2640-41e6-9aac-5e8dfb680071" contextRef="C_966fb9ea-4c8a-4b8b-b091-d09a286a05bf" name="us-gaap:VariableInterestEntityOwnershipPercentage" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">12.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the outstanding shares of Armata&#8217;s common stock on a fully-diluted, the Company and ISO shall have the right to designate two directors to Armata&#8217;s board of directors, and for so long as the Company and ISO hold at least </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_954a0e66-01ac-47e9-9f0e-2bcd83619a34" contextRef="C_da2e5495-b09e-47a8-9a8c-ea82f08e7ead" name="us-gaap:VariableInterestEntityOwnershipPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%, but less than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e6469275-c1cb-4a34-864d-788da8f82e31" contextRef="C_dbf2c9ec-33a9-4f10-847f-e794f7585c7b" name="us-gaap:VariableInterestEntityOwnershipPercentage" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">12.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%, of the outstanding shares of Armata&#8217;s common stock on a fully-diluted basis, the Company and ISO shall have the right to designate one director to Armata&#8217;s board of directors, subject to certain conditions and qualifications set forth in the amended and restated investor rights agreement.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> On July 10, 2023, Armata entered into an amendment to the amended and restated investor rights agreement with the Company and ISO, pursuant to which the Company and ISO agreed that the voting agreement will expire on the earlier of the fifth anniversary of the original agreement's effective date, January 26, 2021, or the approval by the FDA of any of Armata&#8217;s product candidates for marketing and commercial distribution. A</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">s of December 31, 2023,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d559132b-6d52-4ab8-9fa7-2ba7bf208c59" contextRef="C_4a4ab2a3-40c8-4d79-9cdf-f746af492718" name="inva:NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee" unitRef="U_Director" decimals="0" format="ixt-sec:numwordsen">three</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of the eight </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">members of Armata&#8217;s board of directors are also members of the board of directors of Innoviva. As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and 2022, we owned approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c41ab8b1-32dc-4ef7-9e55-b0ab398457ac" contextRef="C_a7bcde7c-16d0-44f6-bf9e-2ed901913ed0" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">69.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of Armata&#8217;s common stock.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_251c67b6-d5bc-46a4-a44d-f50fa8eba7fa" contextRef="C_cad461b3-85e0-44a5-b49c-2fdefdb8eb14" name="us-gaap:DebtInstrumentDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On January 10, 2023, we entered into a Secured Convertible Credit Agreement (the &#8220;Credit Agreement&#8221;) with Armata, under which we invested in a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5f418be5-e9ae-4b6d-a421-e6f81f28da8e" contextRef="C_cad461b3-85e0-44a5-b49c-2fdefdb8eb14" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">one-year</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> convertible note (the &#8220;Armata Convertible Note&#8221;) in an aggregate amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_64fd8761-189a-490e-abda-3b904b2f6aa8" contextRef="C_743b7286-55b6-4101-852d-19e61fad9eaf" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">30.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million at an interest rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0c43860b-8017-4cc6-a0ee-cee373de7719" contextRef="C_743b7286-55b6-4101-852d-19e61fad9eaf" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">8.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% per annum.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Pursuant to the Credit Agreement, the balance on the Armata Convertible Note, including all accrued and unpaid interest thereon, will convert into shares of Armata's common stock upon the occurrence of a qualified financing, as defined in the Credit Agreement. Any portion of the balance on the Armata Convertible Note, including all accrued and unpaid interest thereon, may also be converted into shares of Armata's common stock at our option once a registration statement covering the resale of such securities has been declared effective by the SEC. The Armata Convertible Note is secured by substantially all of the assets of Armata and its domestic and foreign material subsidiaries. On July 10, 2023, ISO and Armata executed an amendment to the Armata Convertible Note extending the maturity date from January 10, 2024 to January 10, 2025.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On July 10, 2023, ISO and Armata entered into a Credit and Security Agreement (the &#8220;Credit and Security Agreement"), under which we extended a term loan to Armata (the &#8220;Armata Term Loan&#8221;) in an aggregate amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_80ac1a3b-7baf-4790-91a4-dd0c70c88ac1" contextRef="C_dabbf05b-a0a7-405b-8376-1cdce909cd8e" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">25.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The Armata Term Loan is subject to an interest rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3559dc50-4870-47d0-8236-0bbbf6d850f7" contextRef="C_dabbf05b-a0a7-405b-8376-1cdce909cd8e" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">14</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% per annum and is due to mature on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_56e2760c-b103-4262-a77b-bbe5ca6d5356" contextRef="C_4c92ef07-b330-4a35-9de3-b077cb45c462" name="us-gaap:DebtInstrumentMaturityDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">January 10, 2025</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Credit and Security Agreement is secured by substantially all of the assets of Armata and its domestic and foreign material subsidiaries.</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">116</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The investments in Armata's common stock and warrants provide Innoviva and ISO the ability to have significant influence, but not control over Armata&#8217;s operations. Armata&#8217;s business and affairs are managed under the direction of its board of directors, which Innoviva and ISO do not control. Based on our evaluation, we determined that Armata is a VIE, but Innoviva and ISO are not the primary beneficiaries of the VIE. We have not provided financial or other support that we were not previously contractually required to provide during the periods presented. Our maximum exposure to loss is equal to the amount we invested in the entity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We account for Armata&#8217;s common stock and warrants under the equity method using the fair value option. The fair value of Armata&#8217;s common stock is measured based on its closing market price. The warrants purchased in 2020, 2021 and 2022 have an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cf2676d0-941b-4d0f-bc41-3d298f4795ee" contextRef="C_ca966b79-26e3-4d58-ae1b-26f1394533f5" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.87</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9b0f5e9b-cd06-4d42-b949-9c087272b4ef" contextRef="C_dc664211-9a49-4cc6-b77c-b76d951d8b6a" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">3.25</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2452ff76-57d3-42b9-8861-55042e240564" contextRef="C_1c07c08c-06ec-49dc-b790-0f2340f3ad4e" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">5.00</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, respectively. All warrants are exercisable immediately within </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6676608e-44a7-4487-8ec6-7c1a0af8bd94" contextRef="C_ca966b79-26e3-4d58-ae1b-26f1394533f5" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:durwordsen"><ix:nonNumeric id="F_cf3f401e-4741-4c07-bd3a-390026042e7c" contextRef="C_dc664211-9a49-4cc6-b77c-b76d951d8b6a" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:durwordsen"><ix:nonNumeric id="F_a0bf8b7e-9513-4377-b4fd-f26730d5a6a4" contextRef="C_1c07c08c-06ec-49dc-b790-0f2340f3ad4e" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">five years</span></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> from the issuance date of the warrants and include a cashless exercise option. We use the Black-Scholes-Merton pricing model to estimate the fair value of these warrants with the following input assumptions: Armata&#8217;s closing market price on the valuation date, the risk-free interest rate computed based on the U.S. Treasury yield, the remaining contractual term as the expected term, and the expected stock price volatility calculated based on the historical volatility of the common stock of Armata and its peer companies. We account for the Armata Convertible Note as a trading security, measured at fair value using a Monte Carlo simulation model with the probability of certain qualified events and the assumptions of risk-free rate, volatility of stock price and timing of certain qualified events. We account for the Armata Term Loan as a trading security, measured at fair value using an income approach based on the discounted value of expected future cash flows.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the fair values of our holdings of Armata common stock, warrants, the Armata Convertible Note and the Armata Term Loan were estimated at $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ea64263f-2e2c-4d15-9377-bdbaf907cf0a" contextRef="C_6f7b5337-631f-48a7-b4c9-05cbb564473e" name="us-gaap:EquitySecuritiesFvNi" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">81.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a529c840-0f44-4cb8-b142-110bef451224" contextRef="C_f390186b-f0e1-423b-87da-2c37deb3557f" name="us-gaap:EquitySecuritiesFvNi" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">35.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c32ecff1-d6a9-46bd-8f5c-9ba8127a5bd0" contextRef="C_bd478d73-d23c-479d-ac02-32fc192ff66f" name="us-gaap:EquitySecuritiesFvNi" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">51.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_97382db8-ce68-45ae-9f03-2f18f3e23127" contextRef="C_f4dfb9e5-6e91-41c1-a947-ccb6c551ac4d" name="us-gaap:EquitySecuritiesFvNi" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">27.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. As of December 31, 2022 the fair values of our holdings of Armata common stock and warrants were estimated at $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8ea858a5-6168-4496-9e1f-78da67bfaa73" contextRef="C_8438a6b5-27b4-494b-a98e-519ed66169d5" name="us-gaap:EquitySecuritiesFvNi" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">31.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0f0c1f3e-e9f9-453a-875f-86990da30648" contextRef="C_19a3e0c0-9301-442d-a4f9-622a1ad048d2" name="us-gaap:EquitySecuritiesFvNi" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">8.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the Armata common stock and warrants, we recorded $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9ed3512b-bd3a-4b7b-b6d5-d6543b769583" contextRef="C_0608758b-b85d-4f54-a373-092e1463e6e6" name="us-gaap:EquitySecuritiesFvNiUnrealizedGain" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">77.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million unrealized gains, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3869fed2-7247-46e0-a469-22ebc2f3e6b7" contextRef="C_67050c7f-cb36-416c-aa88-59d5550ab95e" name="us-gaap:EquitySecuritiesFvNiUnrealizedLoss" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">152.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million unrealized losses and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a8dc1659-7eda-4bf4-9d19-149bd19db4b0" contextRef="C_941dd2d3-13db-4e88-a246-2446d97b2a8e" name="us-gaap:EquitySecuritiesFvNiUnrealizedGain" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">78.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million unrealized gains as changes in fair values of equity method investments, net, in the consolidated statements of income for the years ended December 31, 2023, 2022 and 2021, respectively. For the Armata Convertible Note and Term Loan, we recorded $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_65841340-dfa5-491b-98df-01b9e3560927" contextRef="C_73b7ce85-a0d4-4185-bb79-15359bd6b909" name="us-gaap:EquitySecuritiesFvNiUnrealizedGain" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">21.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7781aebf-db9e-4f67-a4b4-d93c65df7ecb" contextRef="C_7bb88b87-b326-4e6e-865b-16d3ceea75e6" name="us-gaap:EquitySecuritiesFvNiUnrealizedGain" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million unrealized gain, respectively, as changes in fair values of equity and long-term investments, net, in the consolidated statement of income for year ended December 31, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_caa5c2ed-e4ce-417b-805e-fab30250493d" contextRef="C_e037e13e-6e91-4a72-ba0c-e61af7067b1b" name="us-gaap:ScheduleOfVariableInterestEntitiesTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The summarized financial information, including the portion we do not own, is presented for Armata on a one quarter lag as follows:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Balance Sheet Information</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:53.88%;"/>
        <td style="width:2.26%;"/>
        <td style="width:1%;"/>
        <td style="width:18.799999999999997%;"/>
        <td style="width:1%;"/>
        <td style="width:2.26%;"/>
        <td style="width:1%;"/>
        <td style="width:18.799999999999997%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">September 30,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9fbc5032-dd6c-432f-9a15-705c8cc1dc4c" contextRef="C_4a4ab2a3-40c8-4d79-9cdf-f746af492718" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">36,585</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_632e256c-0cfe-4c83-be2a-574f7b3ec0e6" contextRef="C_6bed736f-3aa9-4d71-818d-93a8fca55527" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,245</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Noncurrent assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ca3800af-4529-4ede-91cd-d15552aaf914" contextRef="C_4a4ab2a3-40c8-4d79-9cdf-f746af492718" name="us-gaap:AssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">76,176</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4fb798bc-3351-4b12-a251-f87815b43485" contextRef="C_6bed736f-3aa9-4d71-818d-93a8fca55527" name="us-gaap:AssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">59,636</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_54fe305d-2c18-413e-b072-7709b4df6b18" contextRef="C_4a4ab2a3-40c8-4d79-9cdf-f746af492718" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,884</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c6df6857-2c83-41e3-93fa-4bf6d7afe8f4" contextRef="C_6bed736f-3aa9-4d71-818d-93a8fca55527" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,004</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Noncurrent liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4e1e851d-0837-4c90-b41c-79eaf73050e4" contextRef="C_4a4ab2a3-40c8-4d79-9cdf-f746af492718" name="us-gaap:LiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">103,263</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f530192f-a129-4cc5-a810-b6df92651682" contextRef="C_6bed736f-3aa9-4d71-818d-93a8fca55527" name="us-gaap:LiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">40,300</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Statement Information</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:51.311%;"/>
        <td style="width:1.481%;"/>
        <td style="width:1%;"/>
        <td style="width:12.75%;"/>
        <td style="width:1%;"/>
        <td style="width:1.481%;"/>
        <td style="width:1%;"/>
        <td style="width:12.75%;"/>
        <td style="width:1%;"/>
        <td style="width:1.481%;"/>
        <td style="width:1%;"/>
        <td style="width:12.75%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Twelve Months Ended</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">September 30,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Revenue</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2645524a-5d36-47bd-b51b-2095b81a7751" contextRef="C_a48b0af5-32e5-4d70-8301-ead504e49b4c" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,052</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1970b7b8-42ea-4604-ade9-7b94a51e7b08" contextRef="C_9c42d5a6-8705-438d-afbc-23f20a000d9b" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,446</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_11d66f51-cc9f-48c3-a10f-24e39abce7e7" contextRef="C_e3c81efe-d99a-4794-9295-046bab474ae8" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,989</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss from operations</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1d439cfe-f7e6-4a1c-9899-6548b3f1db1c" contextRef="C_a48b0af5-32e5-4d70-8301-ead504e49b4c" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">41,639</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_589da5ba-4ef9-4a60-82cb-25e6b1e6d64d" contextRef="C_9c42d5a6-8705-438d-afbc-23f20a000d9b" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">32,666</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_23ce54b6-5fba-45b7-8db8-20190242a1cc" contextRef="C_e3c81efe-d99a-4794-9295-046bab474ae8" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">24,227</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ca9f2b33-e587-4d65-a9ad-f4d3ed069adc" contextRef="C_a48b0af5-32e5-4d70-8301-ead504e49b4c" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">59,512</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5bc22a7e-bb51-4958-8ddb-94415a5c9079" contextRef="C_9c42d5a6-8705-438d-afbc-23f20a000d9b" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">32,650</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f768945a-8e34-40fd-9b03-47dda64fb831" contextRef="C_e3c81efe-d99a-4794-9295-046bab474ae8" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">23,732</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Equity Method Investment in Entasis</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prior to the consolidation of Entasis&#8217; financial position and results of operations in February 2022, we accounted for Entasis as an equity method investment. Refer to Note 5, &#8220;Consolidated Entities and Acquisitions&#8221;, for more information.</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">117</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7e7dc1ee-7f7e-4537-a683-f682745cc966" contextRef="C_a97169bf-af91-4b94-a033-7619a6aaa930" name="us-gaap:ScheduleOfVariableInterestEntitiesTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The summarized financial information, including the portion we did not own, is presented for Entasis on a one quarter lag regardless of the date of our investments as follows:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Statement Information</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:71.98%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:25.02%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Twelve Months Ended<br/>September 30,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss from operations</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d565b1b0-c872-42ae-bf3d-00fa37a80885" contextRef="C_e3a16997-be95-4821-b76f-a08d875b0dcf" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">52,323</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b7321a83-31f4-44ab-8565-44f53c6530ff" contextRef="C_e3a16997-be95-4821-b76f-a08d875b0dcf" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">125,413</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Equity Investment in InCarda</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the third quarter of 2020, TRC purchased </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_561308d0-ab56-4b1b-9ad3-4979d66100b0" contextRef="C_1c3869dc-1179-4ea1-8b03-28655253f10d" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">20,469,432</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Series C preferred stock and a warrant to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0a5b1194-4e49-43d7-875c-74703210de13" contextRef="C_5e106938-a0b0-4aeb-9126-1ce4d5e166fa" name="inva:SecuritiesPurchaseAgreementWarrantsNumberOfSecuritiesCalledByWarrants" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,117,358</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> additional shares of Series C preferred stock of InCarda Therapeutics, Inc. (&#8220;InCarda&#8221;) (the &#8220;InCarda 2020 Warrant&#8221;) for $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_79fe5249-7248-4739-89ee-f6715a94e9a0" contextRef="C_0fcc5eab-dacf-4fd9-9338-7ce4c19eb6f1" name="inva:SecuritiesPurchaseAgreementAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">15.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which included $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ce6d8aad-786c-46a1-9a6a-79c7d88a9186" contextRef="C_1c3869dc-1179-4ea1-8b03-28655253f10d" name="inva:DebtInstrumentTransactionCost" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of transaction costs. InCarda is a privately held biopharmaceutical company focused on developing inhaled therapies for cardiovascular diseases. The investment is intended to fund the ongoing clinical development of InRhythm</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (flecainide for inhalation), InCarda&#8217;s lead program, for the treatment of a recent-onset episode of paroxysmal atrial fibrillation. On July 20, 2022, under the terms of the TRC Equity Purchase Agreement, TRC transferred to Innoviva&#8217;s wholly-owned subsidiary, Innoviva TRC Holdings, LLC (&#8220;ITH&#8221;) all of TRC&#8217;s ownership interests and investments in InCarda. ITH has the right to designate one member to InCarda&#8217;s board of directors. As of December 31, 2023, no ITH designee is serving on InCarda&#8217;s </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_10164b0d-eda7-4ea3-9301-4c19affb0eb1" contextRef="C_3325a2cf-7460-4b93-a664-ed1cbe345622" name="inva:NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee" unitRef="U_Director" decimals="0" format="ixt-sec:numwordsen">six</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">-member board. We did not exercise the InCarda 2020 Warrant which expired in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_16022dea-4c29-4456-a7e5-3f052ff36fa9;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">March 2023</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and wrote off its carrying value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d9321537-4f96-498a-9dbd-6ae3547d956e" contextRef="C_89169f0d-1765-42aa-9d7f-0ca1858b85d2" name="inva:CarryingValueWroteOffWarrantExercise" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million during 2023.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On March 9, 2022, TRC entered into a Note and Warrant Purchase Agreement (the &#8220;InCarda Agreement&#8221;) with InCarda to acquire a convertible promissory note (the &#8220;InCarda Convertible Note&#8221;) and warrants (the &#8220;InCarda 2022 Warrant&#8221;) for $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c1ef15eb-accd-462c-bac2-cf52d5c3120d" contextRef="C_6d65900c-b10f-49a2-bba9-16040891a8f1" name="inva:SecuritiesPurchaseAgreementAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.  The InCarda 2022 Warrant expires on March 9, 2027 and is measured at fair value.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On June 15, 2022, the principal amount and the accrued interest of the InCarda Convertible Note were converted into equity securities. In addition, TRC participated in InCarda&#8217;s Series D preferred stock financing by investing $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_974079ac-a8ed-4551-8268-107e0d7e77ab" contextRef="C_5d098b39-13cc-4896-9cc3-c37b02ea18ac" name="us-gaap:PaymentsToAcquireEquitySecuritiesFvNi" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. In connection with the new round of financing, InCarda recapitalized its equity structure resulting in TRC owning </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e732ed37-8ca1-423e-8730-e71e6abbcf85" contextRef="C_a3c920a5-17f0-4dbc-8aff-02ec45493f70" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">4,093,886</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of InCarda&#8217;s common stock, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d30e931a-fef5-4ddc-a396-6eafbee319e6" contextRef="C_1d4ad1ec-0fb3-4d86-8793-4881afd79af0" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">37,350</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of its Series A-1 preferred stock, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_62fdf94d-fb94-4b51-b2fe-ceacd8338d14" contextRef="C_1c3869dc-1179-4ea1-8b03-28655253f10d" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">20,469,432</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of its Series C preferred stock, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e74819a3-edeb-4f35-9388-c6000dd37664" contextRef="C_e2357c2d-6a56-4a89-83af-cfa33770d462" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">8,771,780</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of its Series D-1 preferred stock, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_056280df-d651-470f-921a-6b86e2d827e0" contextRef="C_1f21da09-fc29-466c-a31f-b632bcb5a795" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,369,802</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of its Series D-2 preferred stock, a warrant to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_098b6cd5-c85a-4df3-8c6b-682b577ff992" contextRef="C_4fa6082e-52f0-4343-8a08-2384bb43f803" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,117,358</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of its Series C preferred stock at $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_829f46b8-9261-4700-8c70-c50df5c667e1" contextRef="C_d4a6dcc0-1cdb-48e6-9838-784bbf0081bc" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.73</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share and a warrant to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9d3e7903-0deb-4641-825a-23db895553f0" contextRef="C_4a240330-393d-4181-af3c-3ee7aca2c718" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,490,033</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of its Series D-1 preferred stock at $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_18f36aac-db97-4fc4-90fe-4cf21a2b3c1d" contextRef="C_3a82bed2-f816-4121-ae41-fc7fd838fa36" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.20</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023 and 2022, we held </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_97bb2bb8-6a77-4f71-8862-6c86fe8d953f" contextRef="C_60737025-6027-4430-9a69-c41773b76a7a" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">8.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f159f5f6-5289-4904-8c01-3186a82380e6" contextRef="C_b77a83ac-82c7-48f4-8088-fe346e76a70f" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">9.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of InCarda equity ownership, respectively. Our investment in InCarda does not provide us with the ability to control or have significant influence over InCarda&#8217;s operations. Based on our evaluation, we determined that InCarda is a VIE, but we are not the primary beneficiary of the VIE. We have not provided financial or other support that we were not previously contractually required to provide during the periods presented. Our maximum exposure to loss is equal to the amount we invested in the entity.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We account for our investments in InCarda under the measurement alternative. Under the measurement alternative, the equity investment is initially recorded at its allocated cost, but the carrying value may be adjusted through earnings upon an impairment or when there is an observable price change involving the same or a similar investment with the same issuer. Due to InCarda&#8217;s equity recapitalization in the second quarter of 2022, TRC reassessed the value of its investments in InCarda using the Option Pricing Model Backsolve valuation methodology. Key assumptions used in the valuation model included an expected holding period of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f51d4db1-f9f8-4eb7-b523-e02c037ff5cd" contextRef="C_b628e0b4-4491-4cf0-9301-fd0c4a42318f" name="inva:ExpectedHoldingPeriod" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">two years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, a risk free interest rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_adc21b81-07ce-4b7b-a002-dacb0f8efb2c" contextRef="C_b628e0b4-4491-4cf0-9301-fd0c4a42318f" name="inva:RiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">3.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%, a dividend yield of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6f97445d-6ed1-4ee8-8707-1dc132569411" contextRef="C_b628e0b4-4491-4cf0-9301-fd0c4a42318f" name="inva:DividendYield" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% and an estimated volatility of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c995c83c-7cad-4753-944e-625cd373d796" contextRef="C_b628e0b4-4491-4cf0-9301-fd0c4a42318f" name="inva:PercentageOfEstimatedVolatility" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">122.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%. The estimated volatility was calculated based on the historical volatility of a selected peer group of public companies comparable to InCarda. We recognized an impairment charge of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_38c6653b-1209-4899-a3ff-08e4f215cda7" contextRef="C_2f78a803-3fe0-4245-b906-d2b1f794b7ad" name="us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">9.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million during the second quarter of 2022.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Due to certain changes in InCarda&#8217;s business operations during the second quarter of 2023, ITH reassessed the value of its investments in InCarda using the Option Pricing Model methodology. Key assumptions used in the valuation model included an expected holding period of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f342b3ef-b8d4-4bd8-9ff6-0b1f26d80c1b" contextRef="C_d7474670-7c71-498e-a093-31edba908380" name="inva:ExpectedHoldingPeriod" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">two years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, a risk-free interest rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e40fbfcb-710b-402f-a617-7a03e5c33e8b" contextRef="C_d7474670-7c71-498e-a093-31edba908380" name="inva:RiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">4.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%, a dividend yield of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_61165f89-3354-47ce-a2c0-6d11b4f7cf1e" contextRef="C_d7474670-7c71-498e-a093-31edba908380" name="inva:DividendYield" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% and an estimated volatility of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_33a59cde-2c60-4e6d-9c21-8af8f5b4e526" contextRef="C_d7474670-7c71-498e-a093-31edba908380" name="inva:PercentageOfEstimatedVolatility" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">114.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%. The estimated volatility was calculated based on the historical volatility of a selected peer group of public companies comparable to InCarda. We recognized an impairment charge of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9a8ed939-65bb-46c0-a9a1-09af17d679f8" contextRef="C_105e2ff6-b00c-4d0f-80a9-99bc41fa4247" name="us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million during the second quarter of 2023.</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">118</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we recorded $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5e45238d-1059-4f82-a862-44559ce9bb8e" contextRef="C_17f70e4b-90ed-432b-9c5b-4b6afd7a39ac" name="us-gaap:EquitySecuritiesFvNi" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in fair value of InCarda&#8217;s Series C preferred stock and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_971466cb-dc0f-45b9-abd5-3fbae21da5bb" contextRef="C_e585cd60-cdd5-4401-bfcc-d855443a7706" name="us-gaap:EquitySecuritiesFvNi" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in fair value of Series D warrants</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2022, we recorded $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_862cb3b8-aaeb-4bf8-a4a2-6ef46cc137ec" contextRef="C_0b1bdfd5-7193-40f2-af61-475bdb6831fa" name="us-gaap:EquitySecuritiesFvNi" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in fair value of InCarda&#8217;s Series C preferred stock and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_06c4942f-2171-458c-9057-a7536bd4bdb3" contextRef="C_c548651f-66c2-40f0-80ce-a318243d8cf7" name="us-gaap:EquitySecuritiesFvNi" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in fair value of Series C warrants and Series D warrants</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. As of December 31, 2023 and 2022, we recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8a36e2c6-69b6-42c8-9c5d-e7a38d44cb76" contextRef="C_40cc7194-3f29-4836-b18c-10aa722c5ee1" name="us-gaap:EquitySecuritiesFvNi" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_61a0f8bf-7323-495b-bf99-3654e8e601d6" contextRef="C_0f8abff1-9020-483e-b333-8737df241e43" name="us-gaap:EquitySecuritiesFvNi" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively, for InCarda&#8217;s Series D-1 preferred stock, Series D-2 preferred stock, and common stock using the measurement alternative. We recorded $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1147bfca-8add-452a-8032-8bbb0b828bf1" contextRef="C_89169f0d-1765-42aa-9d7f-0ca1858b85d2" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d633aafd-3be4-4d65-b34b-4b822125bbed" contextRef="C_fdb40e49-15a5-44e8-ab56-25350fd9d665" name="us-gaap:EquitySecuritiesFvNiUnrealizedLoss" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">8.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4a1ab563-537b-4a96-881d-31c1e54c8f3e" contextRef="C_8ee91638-15d2-4e40-b682-b93f8c3d03b7" name="us-gaap:EquitySecuritiesFvNiUnrealizedLoss" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> milli</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">on unrealized loss as changes in fair values of equity and long-term investments, net, in the consolidated statements of income for the years ended December 31, 2023, 2022, 2021, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Equity Investment in ImaginAb</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On March 18, 2021, TRC entered into a securities purchase agreement with ImaginAb, Inc. (&#8220;ImaginAb&#8221;) to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6a68847f-adfc-435a-894b-561cf225d500" contextRef="C_a6849091-06e9-4245-b57e-57668217a80b" name="inva:SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">4,051,724</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of ImaginAb Series C preferred stock for $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_27912b1f-6711-41e3-8797-348b444d4899" contextRef="C_6a99d93c-955d-4e2f-bcac-63e09ca2e6ef" name="inva:SecuritiesPurchaseAgreementAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. On the same day, TRC also entered into a securities purchase agreement with one of ImaginAb&#8217;s common stockholders to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ce75bc49-9557-4e59-8d36-cad6f6a53147" contextRef="C_f20f052b-36df-4c4e-bd3b-191c89d3381d" name="inva:SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">4,097,157</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of ImaginAb common stock for $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_44e5f160-9d80-4eee-97e0-804c1c3f49a3" contextRef="C_2357dcf9-e127-4ee9-a066-9899931c287f" name="inva:SecuritiesPurchaseAgreementAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. ImaginAb is a privately held biotechnology company focused on clinically managing cancer and autoimmune diseases via molecular imaging. $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c6d0de17-0a5a-4da6-9f0e-3a9910c6e3a3" contextRef="C_07acd2a2-efee-41c9-bbd9-499920ef8206" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million was incurred for investment due diligence costs and execution and recorded as part of the equity investment in the consolidated balance sheets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On July 20, 2022, under the terms of the TRC Equity Purchase Agreement, TRC transferred to ITH all of TRC&#8217;s ownership interests and investments in ImaginAb.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On March 14, 2023, ITH entered into a securities purchase agreement with ImaginAb to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dcc9ef07-7732-42d7-a365-2d394a76c18a" contextRef="C_94027cba-de30-4b5d-a0ff-68cce2ec7cfa" name="inva:SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">270,568</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of ImaginAb Series C-2 preferred stock for $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_33f9e097-b7bd-40d5-be0a-499a2d17bbd0" contextRef="C_c2b5fc1d-7d57-4855-af69-696043e9626b" name="inva:SecuritiesPurchaseAgreementAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. On September 14, 2023, ITH entered into a securities purchase agreement with ImaginAb to purchase another </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4152cd33-ebea-43a2-a713-9429be0ca58d" contextRef="C_2253537a-7271-4515-97f9-6f06ff495b9f" name="inva:SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">405,852</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of ImaginAb Series C-2 preferred stock for $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d25119f3-2bf1-43d2-9727-29870d85633b" contextRef="C_c2b5fc1d-7d57-4855-af69-696043e9626b" name="inva:SecuritiesPurchaseAgreementAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. As of December 31, 2023, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d2cc1d17-7c0f-4ac2-9934-715c74fb7044" contextRef="C_d5306868-e998-4382-9386-90e35c6d7f3a" name="inva:NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee" unitRef="U_Director" decimals="0" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of ImaginAb&#8217;s six board members was designated by ITH. As of December 31, 2023 and 2022, we held </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fda0b1d8-6fce-4d7b-ba69-42f9bb47eb1a" contextRef="C_c2081d77-3917-481a-aad9-38a97a27b3f4" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">12.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5494d00b-c794-473c-a4a7-486dfd13a3d0" contextRef="C_bf193f24-bfbe-419c-9802-eee6070d5ad5" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">12.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%, respectively, of ImaginAb equity ownership.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Our investment in ImaginAb does not provide us with the ability to control or have significant influence over ImaginAb&#8217;s operations. Based on our evaluation, we determined that ImaginAb is a VIE, but we are not the primary beneficiary of the VIE. We have not provided financial or other support that we were not previously contractually required to provide during the periods presented. Our maximum exposure to loss is equal to the amount we invested in the entity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because ImaginAb&#8217;s equity securities are not publicly traded and do not have a readily determinable fair value, we account for our investment in ImaginAb&#8217;s Series C preferred stock and common stock using the measurement alternative. As of December 31, 2023 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and 2022, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4980b7c7-7f03-427c-a4fd-7608ecded216" contextRef="C_d5306868-e998-4382-9386-90e35c6d7f3a" name="us-gaap:EquitySecuritiesFvNi" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_27a1bc18-c37f-4554-89f9-09feb63af8ca" contextRef="C_9d6f1e1e-8a05-4f52-aabf-6ea93d745a22" name="us-gaap:EquitySecuritiesFvNi" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively, was recorded as equity and long-term investments in the consolidated balance sheets, respectively, and there was no change to the fair value of our investment in ImaginAb.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Convertible Promissory Note in Gate Neurosciences</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On November 24, 2021, TRC entered into a Convertible Promissory Note Purchase Agreement with Gate to acquire a convertible promissory note (the &#8220;Gate Convertible Note&#8221;) with a principal amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b67b8c4a-efd0-4495-a0b2-83054542a5d4" contextRef="C_c70d2786-9128-41e1-9dae-1423ff150cb0" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">15.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. Gate is a privately held biopharmaceutical company focused on developing the next generation of targeted nervous system therapies, leveraging precision medicine approaches to develop breakthrough drugs for psychiatric and neurologic diseases. The investment is intended to fund Gate's ongoing development and research. The Gate Convertible Note bears an annual interest rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_96eecc59-84bf-4cff-982a-264a650f727d" contextRef="C_8157d7d6-196c-4c46-bf54-22f1d9546346" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% and will convert into shares of common stock of Gate upon a qualified event or into shares of shadow preferred stock of Gate (&#8220;Shadow Preferred&#8221;) upon a qualified financing. A qualifying event can be a qualified initial price offering, a qualified merger, or a merger with a special-purpose acquisition company (&#8220;SPAC&#8221;). Shadow Preferred means preferred stock having identical rights, preferences and restrictions as the preferred stock that would be issued in a qualified financing.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ae4db676-60a6-4591-bbf9-177fcd309dcc" contextRef="C_85b04dbe-2493-4115-9d41-cfc1636e1d1c" name="inva:NumberOfCommonStockIssuedDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The number of common stock shares to be issued in a qualified event shall be equal to the amount due on the conversion date divided by the lesser of a capped conversion price (the &#8220;Capped Conversion Price&#8221;) and the qualified event price (the &#8220;Qualified Event Price&#8221;). The Capped Conversion Price is calculated as $50.0 million divided by the number of shares of common stock outstanding at such time on a fully diluted basis. The Qualified Event Price is the price per share determined by the qualified event. A qualified financing is a sale or series of sales of preferred stock where (i) at least 50 percent of counterparties are not existing shareholders, (ii) net proceeds to Gate are at least $35.0 million, and (iii) the stated or implied equity valuation of Gate is at least $80.0 million. </span></ix:nonNumeric></span><span style="font-size:10pt;font-family:Times New Roman;"></span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">119</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On July 20, 2022, under the terms of the TRC Equity Purchase Agreement, TRC transferred to ITH all of TRC's debt investments in Gate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On February 2, 2023, ITH entered into a Note Amendment Agreement with Gate to amend the Gate Convertible Note. Pursuant to the Note Amendment Agreement, the principal amount of the Gate Convertible Note was increased from $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eaa1d709-e2ca-45e4-b08a-891410d18cd6" contextRef="C_8157d7d6-196c-4c46-bf54-22f1d9546346" name="us-gaap:DebtInstrumentFaceAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">15.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7e1eb564-9720-4fea-a3df-e3e60b0f5665" contextRef="C_455dfd10-363e-4652-a98d-acd8423476e5" name="us-gaap:DebtInstrumentFaceAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">21.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which represents the original principal, accrued interest as of the amendment date and an additional cash investment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_392bd5b6-bc4c-422d-ad61-b4274be3c002" contextRef="C_9fac3855-4b00-44d6-b70c-185ef1d1eeb0" name="us-gaap:PaymentsToAcquireLongtermInvestments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. All other material terms of the Gate Convertible Note were unchanged.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On October 6, 2023, ITH entered into a Second Note Amendment Agreement with Gate to amend the Note Amendment Agreement. Pursuant to the Second Note Amendment Agreement, the principal amount of the Gate Convertible Note was increased from $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3cdc77ee-ef75-44dd-bf63-6f0fcf6024dd" contextRef="C_101e59d3-6e14-4104-a1dd-021cb423fa02" name="us-gaap:DebtInstrumentFaceAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">21.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4c835a65-d49d-4702-b7d2-738e3f8020a2" contextRef="C_f018c1ca-e8f9-4a4f-9827-94816b25882f" name="us-gaap:DebtInstrumentFaceAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">27.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which represents the amended principal as of February 2, 2023, accrued interest as of the second amendment date and an additional cash investment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dc8b23c2-7292-4807-a8c6-aac52ca3a008" contextRef="C_e4ffec73-53e1-424c-b35f-67a5034c0026" name="us-gaap:PaymentsToAcquireLongtermInvestments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. All other material terms of the Gate Convertible Note were unchanged.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have accounted for the Gate Convertible Note as a trading security, measured at fair value using a Monte Carlo simulation model with the probability of certain qualified events and the assumptions of equity value of Gate, risk-free rate, expected stock price, volatility of its peer companies, and the time until a financing is raised. As of December 31, 2023 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and 2022, the fair value of the Gate Convertible Note was estimated at $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1516d2b7-3b60-4e74-882d-9a1828f82ce0" contextRef="C_77a6d898-3c41-425f-bdce-0d730d09522d" name="us-gaap:EquitySecuritiesFvNi" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">28.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4598e52e-7fa4-4141-b265-05a47c7f1108" contextRef="C_30cc733a-2659-49f2-9019-387d5263bfd5" name="us-gaap:EquitySecuritiesFvNi" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">15.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively, and recorded as equity and long-term investments in the consolidated balance sheets. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We recorded $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_313f8f75-8c59-4274-94d2-1b644e26c1e3" contextRef="C_0651f01e-b4f6-472e-bb04-bd2532da85ee" name="us-gaap:EquitySecuritiesFvNiUnrealizedLoss" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of unrealized loss, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7f25e588-58ef-496a-aa2a-81b6dc69a1a3" contextRef="C_c21ec5a1-610f-49e2-a459-1e404f26ba78" name="us-gaap:EquitySecuritiesFvNiUnrealizedGain" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of unrealized gain, and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_50fa0bf1-59d0-4a46-a957-bed042a1b5d5" contextRef="C_c21ec5a1-610f-49e2-a459-1e404f26ba78" name="us-gaap:EquitySecuritiesFvNiUnrealizedLoss" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of unrealized loss as changes in fair values of other equity and long-term investments, net, in the consolidated statements of income for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023, 2022 and 2021, respectively.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Equity Investment in Nanolive</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On February 18, 2022, TRC entered into an investment and shareholders agreement with Nanolive to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a3aa22fa-45e9-4453-b193-1bf119b5757f" contextRef="C_b4844c4a-5218-4a44-b32f-7a91f6ba430d" name="inva:SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">18,750,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Nanolive Series C preferred stock for $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f6c16d6b-a29b-47d9-b473-63e761adf89a" contextRef="C_a57ec5ea-103b-4914-89c8-f5cce009d3f2" name="inva:SecuritiesPurchaseAgreementAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">9.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million (equivalent to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f8d0a016-1735-460b-be06-0f0888743e88" contextRef="C_a57ec5ea-103b-4914-89c8-f5cce009d3f2" name="inva:SecuritiesPurchaseAgreementAmount" unitRef="U_CHF" scale="6" decimals="-5" format="ixt:num-dot-decimal">9.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million CHF). Nanolive SA is a Swiss privately held life sciences company focused on developing breakthrough imaging solutions that accelerate research in growth industries such as drug discovery and cell therapy. $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_29e67c17-ea57-4849-8135-41f6eccccf81" contextRef="C_f3734e2c-95b6-4b79-9206-0f8540ff6e11" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million was incurred for investment due diligence costs and execution and recorded as part of the equity and long-term investment in the consolidated balance sheets. On July 20, 2022, under the terms of the TRC Equity Purchase Agreement, TRC transferred to ITH all of TRC&#8217;s ownership interests and investments in Nanolive. ITH has the right to designate one member to Nanolive&#8217;s board. ITH also has the right to designate another member, who will be mutually acceptable to ITH and another stockholder, to Nanolive&#8217;s board. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2aa87ec2-c14d-44ee-b483-6b8be6672e97" contextRef="C_cdf38ae8-3488-4d9c-82c7-3e8d9ebc8c31" name="inva:NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee" unitRef="U_Director" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Innoviva designee is serving on Nanolive&#8217;s </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fe5010ab-bb93-4bd9-9108-9a7103a387a4" contextRef="C_cdf38ae8-3488-4d9c-82c7-3e8d9ebc8c31" name="inva:NumberOfBoardMembersOfInvestee" unitRef="U_Director" decimals="0" format="ixt-sec:numwordsen">six</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">-member board. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, we held </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_072a5807-56b1-43a5-938b-542d2b01771b" contextRef="C_a602a058-063e-48c6-b5ce-d6c0d4fb1353" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">15.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b46de076-fc7f-4634-81bc-9681ae269797" contextRef="C_6f107155-7e2c-410b-87ad-9c00bd1803a3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">15.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of Nanolive equity ownership, respectively.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our investment in Nanolive does not provide us with the ability to control or have significant influence over Nanolive&#8217;s operations. Based on our evaluation, we determined that Nanolive is a VIE, but we are not the primary beneficiary of the VIE. We have not provided financial or other support that we were not previously contractually required to provide during the periods presented. Our maximum exposure to loss is equal to the amount we invested in the entity.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because Nanolive&#8217;s equity securities are not publicly traded and do not have a readily determinable fair value, we account for our investment in Nanolive&#8217;s Series C preferred stock using the measurement alternative. As of December 31, 2023 and 2022,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3f5c6074-b3c9-4aba-829f-538fbe2f4e58" contextRef="C_cdf38ae8-3488-4d9c-82c7-3e8d9ebc8c31" name="us-gaap:EquitySecuritiesFvNi" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_74fb4169-b481-413e-aa30-8e2d175b7e7f" contextRef="C_bda4cb66-7959-4b7c-926d-00e33cf8a0ad" name="us-gaap:EquitySecuritiesFvNi" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">10.6</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of investment in Nanolive was recorded as equity and long-term investments in the consolidated balance sheets, and there was no change to the carrying amount of our investment.</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">120</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Available-for-Sale Securities</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3766c498-0bcd-4acf-bfa9-a652c6e82ecc" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The estimated fair value of available-for-sale securities is based on quoted market prices for these or similar investments that were based on prices obtained from a commercial pricing service. Available-for-sale securities are summarized below:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:36.867%;"/>
        <td style="width:1.56%;"/>
        <td style="width:1%;"/>
        <td style="width:12.222000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.56%;"/>
        <td style="width:1%;"/>
        <td style="width:12.222000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.56%;"/>
        <td style="width:1%;"/>
        <td style="width:12.222000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.56%;"/>
        <td style="width:1%;"/>
        <td style="width:12.222000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gains</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Losses</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(1)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b9ac7d88-0ec7-4a44-b18b-b9ac67c540d1" contextRef="C_f86d4e5c-570c-4de9-85a1-8a94d98944a1" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">170,706</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_26a4b48a-8a57-4a41-bd9e-43886a8b595b" contextRef="C_f86d4e5c-570c-4de9-85a1-8a94d98944a1" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4a70ed61-c9ff-4827-8179-ace3ddd3bf0d" contextRef="C_f86d4e5c-570c-4de9-85a1-8a94d98944a1" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e2184934-bd84-4125-9424-85c04dca4927" contextRef="C_f86d4e5c-570c-4de9-85a1-8a94d98944a1" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">170,706</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_287da742-b209-48b2-9599-c3abb9941dd3" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">170,706</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d97563a5-dac2-4b2c-9903-8ae2ccf68d28" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9ee341c7-3961-4f76-af83-81db2b050ae4" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9b43ccbf-ace8-4b70-88f8-0b99711bcb15" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">170,706</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:9pt;font-family:Times New Roman;transform-origin:top left;min-width:3.333%;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Money market funds are included in cash and cash equivalents in the consolidated balance sheets.</span></div></div>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:36.867%;"/>
        <td style="width:1.56%;"/>
        <td style="width:1%;"/>
        <td style="width:12.222000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.56%;"/>
        <td style="width:1%;"/>
        <td style="width:12.222000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.56%;"/>
        <td style="width:1%;"/>
        <td style="width:12.222000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.56%;"/>
        <td style="width:1%;"/>
        <td style="width:12.222000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gains</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Losses</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(1)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5b257131-c564-45cc-91a5-088cab24c28e" contextRef="C_a0d0f17e-db42-4983-a7d4-03a17fcfd44f" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">263,469</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_64e8fe2d-9ccc-4d48-a246-d18907408dd4" contextRef="C_a0d0f17e-db42-4983-a7d4-03a17fcfd44f" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e248727d-972b-4bb6-ab0b-09782adb2852" contextRef="C_a0d0f17e-db42-4983-a7d4-03a17fcfd44f" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_35d88796-82fe-4251-9612-1a4e04f63d2e" contextRef="C_a0d0f17e-db42-4983-a7d4-03a17fcfd44f" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">263,469</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b7eab255-6060-4634-aa12-a62bd9f9e168" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">263,469</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a51b749c-6ae2-4d0d-baa4-ad8ddca62d00" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_47800e7c-af7c-408c-873c-4cf8d0a580bc" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_900b0718-f17a-4754-b039-e3e3f6a66900" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">263,469</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:9pt;font-family:Times New Roman;transform-origin:top left;min-width:3.333%;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><ix:footnote id="FNT_30a29ac4-a358-403f-922e-b22439018a34" xml:lang="en-US"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Money market funds are included in cash and cash equivalents in the consolidated balance sheets.</span></ix:footnote></div></div></ix:nonNumeric></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023 and 2022, all available-for-sale securities were money market funds, and there was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9c1eaf19-5d49-4e10-aa6c-c3f28bf7e427" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_0ceb0bd1-76d0-4545-b7be-9b75590587ce" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> credit loss recognized.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Value Measurements</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_17bca1d5-c0e6-4c3c-a110-9993c8b8d90e" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our available-for-sale securities, equity and long-term investments and contingent value rights are measured at fair value on a recurring basis and our debt is carried at amortized cost basis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:36.867%;"/>
        <td style="width:1.56%;"/>
        <td style="width:1%;"/>
        <td style="width:12.222000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.56%;"/>
        <td style="width:1%;"/>
        <td style="width:12.222000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.56%;"/>
        <td style="width:1%;"/>
        <td style="width:12.222000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.56%;"/>
        <td style="width:1%;"/>
        <td style="width:12.222000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated Fair Value Measurements as of December 31, 2023 Using:</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Quoted Price<br/>in Active<br/>Markets for</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant<br/>Other</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Identical</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Observable</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unobservable</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Types of Instruments</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Assets</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Inputs</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Inputs</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 1</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 2</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 3</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">Assets</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6d4fd783-ff34-4a94-99d3-408891549f33" contextRef="C_5e685cc4-011a-4588-9181-90ecb3ccceb4" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">170,706</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_18593713-57ed-4b50-bc90-ed0a6b10dc97" contextRef="C_c5f941e0-b007-4ef9-bd80-53ea1e5f382a" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_46e1034c-66f9-4f1b-84a9-df1d75fcecbb" contextRef="C_31010f98-5d41-43b8-8b09-e38bde00ec6d" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3f6865c3-54a3-4389-ba1e-3552c012b26c" contextRef="C_c21ca759-25e6-4904-91dd-c322af1eeaf5" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">170,706</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Investments held by ISP Fund LP </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(1)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_640cced8-8c0d-4ecb-b7e5-b8a0e34874d2" contextRef="C_569e7525-942b-48c6-9703-ac849c3d278a" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">251,207</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b935334f-0493-4661-b36b-bead7c670f68" contextRef="C_d21494bc-80c8-4b9a-af3a-b8e82bfd6caf" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_22478cef-8f79-4fb5-9e36-deaf9b1d90f8" contextRef="C_7595f3bf-096e-45fc-b68b-d690c0d2803e" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">60,605</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_163fe0cd-4268-4bdf-8328-6e0ab0363e8f" contextRef="C_13fdb038-bf81-4c06-8c1d-9aabbf5a3705" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">311,812</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Equity investment - Armata Common Stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_926336ea-4816-4d18-b707-61b4578c0b3a" contextRef="C_9f56edf9-4d83-4ddd-b43e-19b470780c80" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">81,249</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6c37fcd5-7e41-4773-940f-80bae2065315" contextRef="C_9d9fedca-43c3-4c3c-a148-a051b0151a35" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d58bd632-297a-4028-843b-bc0bdfc5fed4" contextRef="C_a18d4683-905b-4297-962a-d6b053b48738" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_17062d09-f91b-41b5-868f-aa1f688f683b" contextRef="C_51b5cb2e-4d34-4373-952e-14896dcb3ec0" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">81,249</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Equity investment - Armata Warrants</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b3b6233b-1d63-406a-835b-b9b6e151b613" contextRef="C_5f6a168b-c6ae-4f1b-a9d6-59d531bc1b72" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3ef17bf4-1732-47e0-9ad2-5137735f4051" contextRef="C_1a6354f8-d8d6-4e39-a8ca-ea30d3d87bc6" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,297</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_735fa536-272e-48e9-a5cc-5fd80c31bbed" contextRef="C_64d5bd90-3055-4f52-b86f-cb8d0deed43e" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fbddb451-b161-421e-bd94-935fb1e7f561" contextRef="C_45a2b910-f147-4239-a429-43ed79c4207b" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,297</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Convertible debt investment - Armata Note</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dd912b58-29c2-4422-9d89-e200a754d98c" contextRef="C_9fea235d-92aa-406b-99d4-cef846711663" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fe596701-6d46-468e-9e99-20193bd523f7" contextRef="C_ad1bdaae-2e73-4919-aef7-1bf53376deb1" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9a271439-ef47-42af-b7a6-a3db60a36c56" contextRef="C_c9163898-48a1-4dcb-8fe2-b46eda3de475" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">51,883</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c24bb2e3-87e0-4419-8e9c-8e06f4715566" contextRef="C_8b957e8d-7780-431f-93e1-471c1c7babcb" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">51,883</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Term loan investment - Armata Term Loan</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_71fb031a-ce16-4607-badb-8f4ddbd216cd" contextRef="C_b3da9b9d-f2ab-400a-b73e-57b287e45c47" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_24b37d32-67c4-4885-8747-569383971955" contextRef="C_b57cd753-71d3-4cff-8d5a-7f32594379ed" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_08bf71d5-d43d-438f-9561-cbb4c533b6bb" contextRef="C_4b010911-360b-4122-a51a-2daa2012b8a9" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,044</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bd7e535d-1cf1-4d79-a58c-2ea0ec435f92" contextRef="C_3d517819-005b-4abf-9ea5-9aada251df67" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,044</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Convertible debt investment - Gate Note</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8f57c6d3-ea73-4ffa-a4dc-ef6e6c00e245" contextRef="C_b28442af-97a1-40c6-8f0f-8d7c9d6642b5" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bc363f24-6946-4640-81d4-04ed59be1f2d" contextRef="C_f526cd8e-6c2f-4f2c-bd9e-4e878cf8ba5f" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f3176264-d32b-43d2-ada9-d508c897dae8" contextRef="C_379884bb-ab3a-4a27-89b9-9b8365b16e1e" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,972</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_17255b89-d487-44de-8a56-076d0c70b2d4" contextRef="C_bae5ea2a-1d4e-43c0-924e-20e43f661014" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,972</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets measured at estimated fair value</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d0c41cd4-8ca7-4d51-928c-30575a503886" contextRef="C_1a399c56-8380-4778-aa97-c511dc489262" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">503,162</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d2b4a620-c952-405d-b00c-c2f864bc4474" contextRef="C_c8d0b01f-64b8-4438-8b36-9e1b99364b0b" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,297</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4a371282-3d28-41f1-b10f-fb93d416dac6" contextRef="C_702028fe-7b13-49f6-bf9a-e4aaba3364f4" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">167,504</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dd38df39-be3a-416b-be8b-e9141a4db40e" contextRef="C_acc8fa0e-9230-4a63-8d63-4ae6d91d60af" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">705,963</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">Liabilities</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Debt</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025 Notes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_592ad3ff-d267-4ed0-aa12-1bb1126ffa22" contextRef="C_b697daba-e91e-4352-8b6f-532cdaacd5fa" name="inva:ConvertibleSeniorDebtFairValueDisclosures" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9d1d4112-6de6-4fa5-b7e8-21836e0725af" contextRef="C_1dbbdaf4-e472-4d57-8ddc-ea01a7242c98" name="inva:ConvertibleSeniorDebtFairValueDisclosures" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">200,407</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_65e8acca-db38-42d4-96e6-4d098081beca" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="inva:ConvertibleSeniorDebtFairValueDisclosures" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5d9e3ccd-ab76-431c-8f7b-c29c8e3baf67" contextRef="C_12a01e00-2ffc-4751-bfae-ab411878a4e9" name="inva:ConvertibleSeniorDebtFairValueDisclosures" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">200,407</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2028 Notes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_24ab3e6a-15ad-49ec-a791-91f0b012b51e" contextRef="C_b697daba-e91e-4352-8b6f-532cdaacd5fa" name="us-gaap:ConvertibleDebtFairValueDisclosures" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bf8d27f0-9bb2-41b0-8572-d2c30ad0891f" contextRef="C_d809c37b-511d-4f0b-942b-be754908ee4d" name="us-gaap:ConvertibleDebtFairValueDisclosures" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">227,070</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ca6f6cd8-b07a-4bbd-9537-74987c92bef4" contextRef="C_0e8b7755-7a30-43fc-8700-88f8cb2fb267" name="us-gaap:ConvertibleDebtFairValueDisclosures" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b2fb31ce-17dd-4f34-a228-4d291cedf0b3" contextRef="C_12a01e00-2ffc-4751-bfae-ab411878a4e9" name="us-gaap:ConvertibleDebtFairValueDisclosures" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">227,070</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;Total fair value of debt</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_417a3f83-c0b3-4c7c-b7a5-bf9fd5965ede" contextRef="C_b697daba-e91e-4352-8b6f-532cdaacd5fa" name="us-gaap:DebtInstrumentFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4561ab40-b068-422f-b7bc-2b076340fcec" contextRef="C_d809c37b-511d-4f0b-942b-be754908ee4d" name="us-gaap:DebtInstrumentFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">427,477</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7eee3b92-a798-4882-b825-74ddd16afe2a" contextRef="C_0e8b7755-7a30-43fc-8700-88f8cb2fb267" name="us-gaap:DebtInstrumentFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_89970358-edb1-48a3-aee1-a13be0efeaec" contextRef="C_12a01e00-2ffc-4751-bfae-ab411878a4e9" name="us-gaap:DebtInstrumentFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">427,477</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Contingent value rights</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f8a64d0b-4e94-4170-bbec-04f71b904ddd" contextRef="C_74b73320-f859-4046-baa9-7350be012c10" name="inva:ContingentValueRightsLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_30c35ce1-82c0-427d-ad05-bd2fdf4eb028" contextRef="C_d809c37b-511d-4f0b-942b-be754908ee4d" name="inva:ContingentValueRightsLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8d303717-78d2-4f23-bdaf-078f33d332f5" contextRef="C_1dafa801-a453-4e03-925d-1453c2c0f5f6" name="inva:ContingentValueRightsLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">359</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_34cd0973-2233-4132-b402-b3cf40c7f429" contextRef="C_f7d458fe-e023-4486-aa27-fdd8c78f09fa" name="inva:ContingentValueRightsLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">359</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total liabilities at estimated fair value</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_84918b1d-460b-47e7-bdf8-f10e925bac0e" contextRef="C_74b73320-f859-4046-baa9-7350be012c10" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9cbb6bb4-fb04-4332-8c86-905e06496680" contextRef="C_d809c37b-511d-4f0b-942b-be754908ee4d" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">427,477</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a9dcbda3-7044-4a23-ba44-ae21d6a525f6" contextRef="C_1dafa801-a453-4e03-925d-1453c2c0f5f6" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">359</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_28bc960d-d14d-47c3-9784-aed048363a4f" contextRef="C_f7d458fe-e023-4486-aa27-fdd8c78f09fa" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">427,836</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">121</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:9pt;font-family:Times New Roman;transform-origin:top left;min-width:3.333%;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><ix:footnote id="FNT_24bb9798-5eb0-4e31-b65e-3441d7813ebf" xml:lang="en-US"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The investments held by ISP Fund LP, consisted of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a0e347eb-99aa-437e-ad46-4cb50eaa1373" contextRef="C_08e9488e-214d-4494-813d-28131fd90598" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">248.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in equity investments, which included private placement positions of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5f8c1571-9f4c-4eda-ade7-9761134b8465" contextRef="C_5610546b-710f-4b56-bca0-b9c532b6f95a" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">60.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_90a60e5c-4b32-46c7-8263-4ff0b82e7275" contextRef="C_ea272365-8aa7-4a80-8b19-6a8032d971c0" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">62.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in money market funds. A certain portion of the total capital contribution of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b0006e36-35db-438b-aaab-1625e15887f7" contextRef="C_bc5da3bc-ba84-41b4-9714-69d7f9dcb276" name="us-gaap:LimitedPartnersContributedCapital" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">300.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million is no longer subject to a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_682ea2de-3876-4f8f-8634-46d4810ee084" contextRef="C_70752bbf-999a-40de-bb2c-738c0b7f7ada" name="inva:PartnershipAgreementLockUpPeriod" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">36-month</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> lock-up period from the date of such capital contribution. However, we did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_90a798ce-d1fa-420a-8d7a-49f3a9dc17ca" contextRef="C_70752bbf-999a-40de-bb2c-738c0b7f7ada" name="inva:WithdrawalFromInvestment" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t elect to make a withdrawal in 2023, thereby extending the lock-up period and withdrawal elections into subsequent years. </span></ix:footnote></div></div>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:36.867%;"/>
        <td style="width:1.56%;"/>
        <td style="width:1%;"/>
        <td style="width:12.222000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.56%;"/>
        <td style="width:1%;"/>
        <td style="width:12.222000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.56%;"/>
        <td style="width:1%;"/>
        <td style="width:12.222000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.56%;"/>
        <td style="width:1%;"/>
        <td style="width:12.222000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated Fair Value Measurements as of December 31, 2022 Using:</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Quoted Price</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">in Active</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Markets for</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Other</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Identical</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Observable</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unobservable</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Types of Instruments</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Assets</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Inputs</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Inputs</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 1</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 2</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 3</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">Assets</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_286af3e8-03af-4dfb-b52b-74d4fb73f81e" contextRef="C_be6668a0-7dd8-4ba3-acdc-f68ede2a4466" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">263,469</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f1d2d04c-d672-4ae7-b449-16be6028657e" contextRef="C_29d8e0a4-1346-4e5a-9734-3d41d9fe9891" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f5185b53-9452-4367-92ef-72f96dadd147" contextRef="C_f6a3bb99-253a-4791-914d-f4334dddf22a" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4be73e97-3670-4a91-bbaa-20aaba8b2f00" contextRef="C_24b1825a-6f77-49e4-828c-3e33f531af0b" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">263,469</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Investments held by ISP Fund LP </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(1)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_642b9e4b-f8ea-48f4-9e68-c69a54e91074" contextRef="C_81047951-2422-46bb-a073-86b99c1cee75" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">265,982</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_007ca7f4-d174-4a7c-a703-836236edbe52" contextRef="C_00bcfed5-5665-4a95-a3f4-d2ac0f6fdaa3" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_16adad2a-1e35-499c-8549-470982d5bd2a" contextRef="C_0c62ac1f-f870-4e92-add2-b1924f35420e" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">54,578</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8a869d89-7a7a-45db-ada7-7a991d2546c3" contextRef="C_de46daa9-d4c7-4d11-b729-3650d5f2b9cd" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">320,560</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Equity investment - Armata Common Stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_67646e81-ba7b-4418-b15b-f12f8b0823ca" contextRef="C_fe573d70-749d-4747-a2aa-7a4c9cb2488c" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">31,095</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_974fe0a0-0c59-4d2a-ac5f-566b6dc55ca4" contextRef="C_5c2cfa33-ca5f-465a-89ae-63a6b102f37a" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_702cf89d-d3a3-4575-aaa7-449f730d1c6d" contextRef="C_85e74837-f1dd-4956-a48b-f67a1bfe07cf" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_49ddd7ca-b9eb-4a90-93dd-c8ac8f0bdcbc" contextRef="C_35f64b46-11ed-4d73-b48d-9b0294e79c59" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">31,095</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Equity investment - Armata Warrants</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f8562e75-3573-4f9f-8045-70ff1c9c717f" contextRef="C_1f2036f9-b56a-403d-9f98-ec7e12869b74" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fd23a935-a558-4115-8a1c-47e476ea344a" contextRef="C_66b50de4-9da3-415d-8893-6426c4c9c73b" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,059</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cf44bd73-c9a3-4eea-bca5-2631979a8b8b" contextRef="C_f6f51154-4209-4901-acf6-2c40992c8eb9" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2d7deb3c-f6da-46c5-adb8-0c019fb6165d" contextRef="C_6e065d89-351d-457c-ba2e-bc2d69edba60" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,059</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Equity investment - InCarda Warrants</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5b34893e-f7f3-4d1e-a7b4-93dfa52c2771" contextRef="C_f4a9e48d-00e5-43b6-9299-938496783a9d" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0cfa3877-5005-406a-82fc-5e871e40cd2b" contextRef="C_e112a83c-e5e4-49f5-9f29-958a211ef1b6" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c90d0199-0a0e-45ea-9c85-9d661c80fd6c" contextRef="C_d68c6264-7526-47b4-8da2-c7ceccce0e57" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">605</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a75ac58c-7546-45bd-bbb5-c024080f98fd" contextRef="C_109bc829-e421-4835-9aad-dedc4c375347" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">605</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Convertible debt investment - Gate Note</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3c8089b1-d952-4259-9f7c-b5d7221ba929" contextRef="C_3d081474-bef5-49f9-9f8c-6d2a8ce28f36" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d8135559-e564-4e12-9218-e7b5445cb556" contextRef="C_c84174e9-be04-42dd-b25c-92df750b79e8" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_65e2036f-0e58-4c6f-a3b6-1650fa2b3cf6" contextRef="C_825d28ed-6319-4ae7-9001-97f35281db61" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,700</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e01c7de6-2529-4e16-ba0a-ee28c8dc3641" contextRef="C_9f8ff2b8-4656-4ea8-955a-c60a95c6b1c1" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,700</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets measured at estimated fair value</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4ec0538e-a183-4e20-8162-a781ac683c56" contextRef="C_0647acf4-6f5c-4d39-86c2-fb4fddd549fb" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">560,546</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b892ae12-65d9-437e-901b-bcdbab2736b9" contextRef="C_d2367046-d399-4ddc-a17e-2f5ef1165e9e" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,059</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9978330a-a1e0-4ba5-99f3-2d409d9cd256" contextRef="C_dc1e896e-f118-48b0-8cb0-89c09e214ab6" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">70,883</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b45f594e-51e3-4456-8b7b-15c3217d768e" contextRef="C_825f18bd-f7d5-4d67-9659-20286d27f1c0" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">639,488</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">Debt</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2023 Notes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_44a7684e-ec11-4dc4-848f-8799426c8aa4" contextRef="C_c86331ec-9958-472c-9d3d-73034f0f043f" name="inva:ConvertibleSubordinatedDebtFairValueDisclosures" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c55c9a2c-1409-47b1-8c4a-e21937939e27" contextRef="C_dec01f12-3f85-4d42-8b61-61f857a1419a" name="inva:ConvertibleSubordinatedDebtFairValueDisclosures" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">96,089</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7efb727b-ece1-4cd3-a513-007890eacfde" contextRef="C_b1399523-0285-44ab-8535-deb7616f55e6" name="inva:ConvertibleSubordinatedDebtFairValueDisclosures" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c627209e-d75c-4e6a-9408-d72732f00814" contextRef="C_d406fd03-b3d6-41fd-b4f9-74170c936a7a" name="inva:ConvertibleSubordinatedDebtFairValueDisclosures" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">96,089</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025 Notes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d4c2329e-733a-4717-8575-de6e9b7e617a" contextRef="C_c86331ec-9958-472c-9d3d-73034f0f043f" name="inva:ConvertibleSeniorDebtFairValueDisclosures" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fb741ad5-96ef-445a-92b6-309946c3176c" contextRef="C_dec01f12-3f85-4d42-8b61-61f857a1419a" name="inva:ConvertibleSeniorDebtFairValueDisclosures" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">197,807</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a5d11fc4-82bb-4b00-b1e4-85ede6904016" contextRef="C_b1399523-0285-44ab-8535-deb7616f55e6" name="inva:ConvertibleSeniorDebtFairValueDisclosures" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7cf2bc54-bf20-4d11-b78e-1c5dfa01a815" contextRef="C_d406fd03-b3d6-41fd-b4f9-74170c936a7a" name="inva:ConvertibleSeniorDebtFairValueDisclosures" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">197,807</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2028 Notes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_712778a4-be60-4c64-9e15-f8d2d2d8b653" contextRef="C_c86331ec-9958-472c-9d3d-73034f0f043f" name="us-gaap:ConvertibleDebtFairValueDisclosures" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b6c1a9f6-9df3-4645-9a54-275640e2ab3a" contextRef="C_dec01f12-3f85-4d42-8b61-61f857a1419a" name="us-gaap:ConvertibleDebtFairValueDisclosures" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">211,768</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e4dcf57d-e979-4f94-a11e-68df29740c51" contextRef="C_b1399523-0285-44ab-8535-deb7616f55e6" name="us-gaap:ConvertibleDebtFairValueDisclosures" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ed9b801c-6154-4ea9-954a-42db2b4ab1ee" contextRef="C_d406fd03-b3d6-41fd-b4f9-74170c936a7a" name="us-gaap:ConvertibleDebtFairValueDisclosures" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">211,768</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total fair value of debt</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2a26bc5b-c6c4-4752-b041-e69f3ce8793d" contextRef="C_c86331ec-9958-472c-9d3d-73034f0f043f" name="us-gaap:DebtInstrumentFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_538e3495-3ed2-4ff0-a9fd-91a7f57f7862" contextRef="C_dec01f12-3f85-4d42-8b61-61f857a1419a" name="us-gaap:DebtInstrumentFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">505,664</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_256cf4fa-aba2-4323-9a2e-fe8c730b3fc6" contextRef="C_b1399523-0285-44ab-8535-deb7616f55e6" name="us-gaap:DebtInstrumentFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7e366394-addb-4771-aae1-ee261f8bcf92" contextRef="C_d406fd03-b3d6-41fd-b4f9-74170c936a7a" name="us-gaap:DebtInstrumentFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">505,664</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Contingent value rights</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d7d442b1-2e94-4d0c-bdaa-01a94b916a8d" contextRef="C_76445fe9-d438-4d1c-a28d-613fef583510" name="inva:ContingentValueRightsLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7c1b951d-b971-45e6-a3a2-45fbbcc563c8" contextRef="C_344746bb-e636-4cfa-9204-6870353b5936" name="inva:ContingentValueRightsLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7652e3e7-3d3e-4473-8674-6403b51aae7d" contextRef="C_593427ab-e2d7-4f72-ba54-456608483083" name="inva:ContingentValueRightsLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">595</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3023a1e1-772a-4ea8-b210-34baa44fe992" contextRef="C_9d615842-43ad-4afe-b67a-2a588d4d0728" name="inva:ContingentValueRightsLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">595</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total liabilities at estimated fair value</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_be7fbe7a-9081-40fa-b64b-317eee1b6879" contextRef="C_76445fe9-d438-4d1c-a28d-613fef583510" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6081934f-07a3-41bb-a614-2a4d19488d6e" contextRef="C_344746bb-e636-4cfa-9204-6870353b5936" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">505,664</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_95b03b45-4f61-4df5-97c6-d588f88fa59f" contextRef="C_593427ab-e2d7-4f72-ba54-456608483083" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">595</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c24c0054-198d-4133-b239-71538de799c1" contextRef="C_9d615842-43ad-4afe-b67a-2a588d4d0728" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">506,259</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:9pt;font-family:Times New Roman;transform-origin:top left;min-width:3.333%;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><ix:footnote id="FNT_4e3e88eb-3c93-45b2-a2dc-9cb89ab6791d" xml:lang="en-US"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The investments held by ISP Fund LP, consisted of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4e1639e8-ea07-437b-af4d-0747aeabe994" contextRef="C_44d770d3-712a-4496-9e68-7b69a5f5d2bf" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">295.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in equity investments, which included private placement positions and convertible notes of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3fc536e8-cd2c-40b8-89d8-d86fae92ab64" contextRef="C_140324d1-1834-455e-b137-0176d2de6d77" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">54.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9b04e254-d076-4265-960b-cce81bdbabcc" contextRef="C_2ea14962-08db-4e80-a279-f2d275caee54" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">25.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in money market funds. Our total capital contribution of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_28b158c2-c17a-4709-a8e1-0316a16ee710" contextRef="C_460b7389-fa51-4f4c-9e61-7e987dc6ad3e" name="us-gaap:LimitedPartnersContributedCapital" unitRef="U_USD" scale="3" decimals="-2" format="ixt:num-dot-decimal">300.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million was subject to a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_786a8a9d-babc-4ba1-b400-bd668a9f7f70" contextRef="C_d81c2107-a7a0-4ec4-8988-fc8409645f16" name="inva:PartnershipAgreementLockUpPeriod" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">36-month</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> lock-up period from the date of such capital contributions.</span></ix:footnote></div></div></ix:nonNumeric></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair values of our equity investments in Armata&#8217;s common stock and publicly traded investments held by ISP Fund LP are based on the quoted prices in active markets and are classified as Level 1 financial instruments. The fair values in the warrants in Armata classified within Level 2 are based upon observable inputs that may include benchmark yields, reported trades, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids, offers, and reference data including market research publications.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The InCarda Warrants, the Gate Convertible Note, the Armata Convertible Note, the Armata Term Loan, private placement positions and convertible notes held by ISP Fund LP, and contingent value rights are classified as Level 3 financial instruments as these securities are not publicly traded and the assumptions used in the valuation model for valuing these securities are based on significant unobservable and observable inputs including those of publicly traded peer companies.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair values of our 2025 Notes and 2028 Notes are based on recent trading prices of the respective instruments. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair values of our 2023 Notes, which were fully paid off in January 2023, were also based on their trading prices.</span></p></ix:nonNumeric></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">122</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fdd4a155-309a-4dde-9813-cef9edc61d23" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="inva:CapitalizedFeesPaidDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7. CAPITALIZED FEES PAID</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9b205584-ae22-46d4-80f3-9d9d4e6e5696" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:CapitalizedContractCostTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Capitalized fees paid, which consist of registrational and launch-related milestone fees paid to GSK, were as follows:</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:51.311%;"/>
        <td style="width:1.481%;"/>
        <td style="width:14.749%;"/>
        <td style="width:1.481%;"/>
        <td style="width:1%;"/>
        <td style="width:12.75%;"/>
        <td style="width:1%;"/>
        <td style="width:1.481%;"/>
        <td style="width:1%;"/>
        <td style="width:12.75%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortization period</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">United States</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2013-2030</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5b3f8b79-aee6-41e3-9e91-e18334634e6a" contextRef="C_0dca3067-b301-4dc8-acf3-6ddafb2e6e93" name="us-gaap:CapitalizedContractCostGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">120,000</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4a746f43-2f79-43e7-994e-40a20ef26e91" contextRef="C_b0777350-8f02-402b-b8d8-33ebfbea0625" name="us-gaap:CapitalizedContractCostGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">120,000</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Europe</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2013-2029</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_95f447d7-78dc-409d-a6ff-de85877826cb" contextRef="C_9eec32d5-1f8c-44e6-9ec4-05156ada8af3" name="us-gaap:CapitalizedContractCostGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">60,000</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a21e1668-80a6-4dc8-87c5-f39ef4c779d1" contextRef="C_5d7298e5-9f61-4332-aa3f-399d8b896265" name="us-gaap:CapitalizedContractCostGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">60,000</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Japan</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2013-2029</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_748b1cab-650f-4566-9ea5-f4d85232eae3" contextRef="C_ce2c65ac-3b0f-4cd6-a073-a6b687f80393" name="us-gaap:CapitalizedContractCostGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">40,000</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_adf2f105-1d35-4d7f-9cb7-c29fe1506a15" contextRef="C_cd8458e6-5f79-4d96-add0-064203ed13b2" name="us-gaap:CapitalizedContractCostGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">40,000</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Gross carrying value</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_450762cc-1ad5-4676-b57d-498534b63e41" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="us-gaap:CapitalizedContractCostGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">220,000</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6af88f74-d5b3-4f68-9a3b-10ceba811f96" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" name="us-gaap:CapitalizedContractCostGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">220,000</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accumulated amortization</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_94bd15dc-6cf0-4094-a260-0c44987cd46b" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="us-gaap:CapitalizedContractCostAccumulatedAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">136,216</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8dfd5dd2-e092-489f-99ef-6d506134387b" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" name="us-gaap:CapitalizedContractCostAccumulatedAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">122,393</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net carrying value</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6b811829-e2f2-4282-9ee2-5a69f33621b7" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="us-gaap:CapitalizedContractCostNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">83,784</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9b5ab1b7-995a-4964-aa15-12fc69a90614" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" name="us-gaap:CapitalizedContractCostNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">97,607</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These milestone fees are amortized over their estimated useful lives commencing upon the commercial launch of the product in their respective regions with the amortization recorded as a reduction in revenue from collaborative arrangements. As of December 31, 2023, the weighted average remaining amortization period wa</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">s </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_beb5e9c4-ed8c-4782-8ca6-bd6927d247f3" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="inva:CapitalizedFeesPaidWeightedAverageUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6.2</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additional information regarding these milestone fees is included in Note 3, &#8220;Revenue Recognition&#8221;. Amortization for each of the years ended December 31, 2023, 2022 and 2021 was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5a607ae6-e230-4765-bca7-1281aeef1e58" contextRef="C_81ea3387-bcc2-4cfe-a9e7-78fab40062ee" name="us-gaap:CapitalizedContractCostAmortization" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_c4c68f29-ee54-4a60-aa3c-73710af8c287" contextRef="C_cd95e6eb-db30-4b57-a111-4b45da383cf5" name="us-gaap:CapitalizedContractCostAmortization" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_e6d0940a-362f-40d4-90c8-006b117c953a" contextRef="C_fa01aae9-eeeb-459c-9277-c4cd33bb93d0" name="us-gaap:CapitalizedContractCostAmortization" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">13.8</ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The remaining estimated amortization is </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cfa76036-2f56-473d-b2e1-b3e376a66303" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="inva:CapitalizedFeesPaidRemainingEstimatedAmortizationNextTwelveMonths" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_2251e42f-d132-41aa-80d4-1ddaae8e6f2e" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="inva:CapitalizedFeesPaidRemainingEstimatedAmortizationYearTwo" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_16d463be-e07e-490c-b561-41f58a9cce43" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="inva:CapitalizedFeesPaidRemainingEstimatedAmortizationYearthree" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_a3fbce11-8a41-4fdc-85e7-bfbf0f514840" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="inva:CapitalizedFeesPaidRemainingEstimatedAmortizationYearFour" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">13.8</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for each of the years from 2024 to 2027, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4564357e-549d-44b5-8e5d-3be78dc9c78a" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="inva:CapitalizedFeesPaidRemainingEstimatedAmortizationYearFive" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">13.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the year 2028, and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1142369f-e146-4772-8122-dcf9df3e096a" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="inva:CapitalizedFeesPaidRemainingEstimatedAmortizationAfterYearFive" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">14.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> thereafter.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div><ix:nonNumeric id="F_921c4e0c-9a12-4bee-a458-e44e418ff557" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8. GOODWILL AND INTANGIBLE ASSETS</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Goodwill and intangible assets acquired are recognized at fair value as of the acquisition date. The carrying amount of goodwill as of December 31, 2023 and 2022 was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4bef471e-f308-4778-aaa4-cc38b16e8dbd" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="us-gaap:Goodwill" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">17.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_266ce74b-de2b-495f-ac26-4a6ca264193e" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" name="us-gaap:Goodwill" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">26.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively. We have </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a5bd1532-c79d-4274-9c3b-2a0db2c3d6d2" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:GoodwillImpairmentLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t recognized any impairment losses related to goodwill and intangible assets during the periods presented.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Intangible assets with definite lives are amortized over their estimated useful lives. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fc9e1147-6d55-42d2-acfa-78a3d9ac51d7" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="inva:ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsTableTextBlock" escape="true" continuedAt="F_fc9e1147-6d55-42d2-acfa-78a3d9ac51d7_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The carrying basis and accumulated amortization of recognized intangible assets as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022 were as follows:</span></ix:nonNumeric></span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><ix:continuation id="F_fc9e1147-6d55-42d2-acfa-78a3d9ac51d7_1"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:36.86%;"/>
        <td style="width:1.56%;"/>
        <td style="width:14.24%;"/>
        <td style="width:1.56%;"/>
        <td style="width:1%;"/>
        <td style="width:12.22%;"/>
        <td style="width:1%;"/>
        <td style="width:1.56%;"/>
        <td style="width:1%;"/>
        <td style="width:12.22%;"/>
        <td style="width:1%;"/>
        <td style="width:1.56%;"/>
        <td style="width:1%;"/>
        <td style="width:12.22%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="12" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Useful Life</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Accumulated</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Net Carrying</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Years)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortization</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Marketed products</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_b7bd33d9-7335-4e47-b29f-82958a7fa4a7" contextRef="C_90e80338-5725-4945-ba17-420b39d8a65d" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span><span><ix:nonNumeric id="F_31083c62-6cd9-43e6-9680-8fa420fb43a8" contextRef="C_6d1cd716-967a-4cec-ae43-c48297ca0a77" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span></ix:nonNumeric></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b6d8b8eb-1948-4eaf-aeb4-6282a0a5fe4d" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="inva:IntangibleAssetsMarketedProductsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">219,700</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8a6e4bf6-f919-4d5e-a8c5-c28896121c9f" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="inva:IntangibleAssetsMarketedProductsAccumulatedAmortization" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">25,204</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a6ca964b-b3f6-47c1-b7e5-fb2b0900e039" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="inva:IntangibleAssetsMarketedProductsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">194,496</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">In-process research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_224e5497-33ce-4da8-b40f-3a17ea729467" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="inva:IntangibleAssetsInProcessResearchAndDevelopmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,600</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c868d534-08c1-4a61-8b32-95d92d11fc9a" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="inva:IntangibleAssetsInProcessResearchAndDevelopmentAccumulatedAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_393a1d81-55d7-407c-a273-2de0e122c44e" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="inva:IntangibleAssetsInProcessResearchAndDevelopmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,600</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Collaboration agreement</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_0c167f9c-a339-40e7-b02e-9335f42a3f59" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span></ix:nonNumeric></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dab77d17-373a-4338-bb2e-df50d59f3e49" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="inva:IntangibleAssetsCollaborationAgreementGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,400</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ed2f3a8f-64c4-4efb-a498-0a90182743cf" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="inva:IntangibleAssetsCollaborationAgreementAccumulatedAmortization" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,161</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_13312e85-2b95-4fdf-b2b6-1b384f1ad19e" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="inva:IntangibleAssetsCollaborationAgreementNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,239</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_849cc4e0-5fe6-429c-9fa4-f4db47ea0ddc" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">257,700</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_45b48927-22ff-4403-92b9-509ec52a1bf3" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">27,365</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0ea77f82-6b50-4327-94a6-49fcbe36f818" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">230,335</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:36.86%;"/>
        <td style="width:1.56%;"/>
        <td style="width:14.24%;"/>
        <td style="width:1.56%;"/>
        <td style="width:1%;"/>
        <td style="width:12.22%;"/>
        <td style="width:1%;"/>
        <td style="width:1.56%;"/>
        <td style="width:1%;"/>
        <td style="width:12.22%;"/>
        <td style="width:1%;"/>
        <td style="width:1.56%;"/>
        <td style="width:1%;"/>
        <td style="width:12.22%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="12" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Useful Life</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Accumulated</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Net Carrying</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Years)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortization</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Marketed products</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_fe07f1fa-33d0-4a01-a391-900dbf3ba0a1" contextRef="C_cd9243f5-5c45-4dc0-9b92-52023672ac79" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span><span><ix:nonNumeric id="F_6a4ab856-c446-41f2-ab23-162c16656ce4" contextRef="C_6d1cd716-967a-4cec-ae43-c48297ca0a77" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span></ix:nonNumeric></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_233a3454-f80f-4aa8-ba20-ef13085837fb" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" name="inva:IntangibleAssetsMarketedProductsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">151,000</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3cb4cfe6-3775-4bb1-a783-3d5c94426035" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" name="inva:IntangibleAssetsMarketedProductsAccumulatedAmortization" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">5,581</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5cbf0a69-2153-452f-a302-9c94cf6c5384" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" name="inva:IntangibleAssetsMarketedProductsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">145,419</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">In-process research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4cfa7373-e265-435a-b2ab-57f9886acb68" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" name="inva:IntangibleAssetsInProcessResearchAndDevelopmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">72,100</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e115b030-3f16-429f-b168-252f960e9e49" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" name="inva:IntangibleAssetsInProcessResearchAndDevelopmentAccumulatedAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7e2c1076-18ab-4bbc-9556-d8c752e96a27" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" name="inva:IntangibleAssetsInProcessResearchAndDevelopmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">72,100</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Collaboration agreement</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_348030ff-bc3f-4dc4-93f2-2533716f4ec0" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" name="inva:IntangibleAssetsCollaborationAgreementGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,400</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_08ea668c-50d6-4d51-a5a3-270d00709582" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" name="inva:IntangibleAssetsCollaborationAgreementAccumulatedAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8e8faa89-49a4-4597-9e87-c54de793e6d4" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" name="inva:IntangibleAssetsCollaborationAgreementNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,400</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a9e71439-4d46-48fd-924b-894fa89b0cec" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">258,500</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3599a021-6b00-433b-bd8e-7870a3ef5264" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">5,581</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b06d1916-ebea-472c-a019-2a703961e301" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">252,919</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Intangible assets recognized as a result of the acquisition of Entasis amounted to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9caa7bd0-d6d3-42b9-8d77-984b94720e7f" contextRef="C_8c6a7bcf-3783-4f54-9341-3247cae07c70" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">106.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which consisted of Entasis&#8217; in-process research and development related to its antibacterial therapeutic product candidates and a collaboration agreement amounting to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_55a358e1-7819-45a2-9475-cdbb4ff7a47d" contextRef="C_f9f2e0b5-7d3e-40a6-b5ac-2fadf0d6e6e3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">71.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cdb9f03d-122e-419c-9112-423275e49580" contextRef="C_0c5dc7e3-2671-4634-a2ea-45c94c03c65f" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">35.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively. Following the FDA approval of XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in May 2023, we started amortizing $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1ad0c74d-0639-4735-afa3-1315d4bc9a85" contextRef="C_059f7bf6-1ef6-49bc-9ffa-a0a2a13282ed" name="us-gaap:AmortizationOfIntangibleAssets" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">68.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of the then in-process research and development as a marketed product, as well as the collaboration agreement, over their estimated useful lives. The useful life of the remaining in-process research and development of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4f11930f-9df5-4f41-894b-07b98b151ff9" contextRef="C_067b241e-3eec-46f9-b23d-3e9d389993c0" name="us-gaap:AcquiredFiniteLivedIntangibleAssetResidualValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million will be determined upon commercialization of the underlying product candidate; thus, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_79b9e9d8-7f39-42b6-aa62-ff626d383c03" contextRef="C_308dae91-3293-4e16-bef8-42832c4675db" name="us-gaap:AmortizationOfIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> amortization expense for this intangible asset was recognized </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">for the periods presented.</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">123</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Intangible assets recognized as a result of the acquisition of La Jolla amounting to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ee0943fc-452a-4848-a988-132cca52d3c3" contextRef="C_9b30963d-d42c-4ba2-85ac-e1f548c6e616" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">151.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million pertain to product rights and developed technologies on La Jolla&#8217;s currently marketed products. These are intangible assets with determinable lives and are amortized over their estimated useful lives.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We recognized amortization expense of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f09b66e6-3b19-493a-8756-04446a2e875a" contextRef="C_f0f3a5ea-44ff-44dc-9c12-7e3628fc5813" name="us-gaap:AmortizationOfIntangibleAssets" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">21.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3623d45a-afb5-4d6f-bc0d-9e9c4fd7e517" contextRef="C_45aa5dba-bae7-468a-aac4-f6723db99993" name="us-gaap:AmortizationOfIntangibleAssets" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and 2022, respectively. Future amortization expense is expected to be $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_965900c8-fe92-4a35-be11-8d021dc20450" contextRef="C_9b30963d-d42c-4ba2-85ac-e1f548c6e616" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_3c0390cc-3da9-4e43-9e78-0e6d8d902ab4" contextRef="C_9b30963d-d42c-4ba2-85ac-e1f548c6e616" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_8b0f0a2a-48ea-4589-a8ba-a0876bf1bcd8" contextRef="C_9b30963d-d42c-4ba2-85ac-e1f548c6e616" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_677f31d2-2071-47e4-82c9-cd894bc3b687" contextRef="C_9b30963d-d42c-4ba2-85ac-e1f548c6e616" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_2ff5ac30-9726-4498-911a-b34b372955cf" contextRef="C_9b30963d-d42c-4ba2-85ac-e1f548c6e616" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">25.8</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for each of the years from 2024 to 2028 and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ef823452-8b1a-4631-b21c-f0400696cae5" contextRef="C_9b30963d-d42c-4ba2-85ac-e1f548c6e616" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">98.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million thereafter.</span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f2a8e4d5-5364-4e53-8ecb-1cceab476f49" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9. BALANCE SHEET COMPONENTS</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Inventory</span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><ix:nonNumeric id="F_dc3edbb6-eeda-4e39-ab00-99c32828f53d" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Inventory consisted of the following:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:67.313%;"/>
        <td style="width:1.5%;"/>
        <td style="width:1%;"/>
        <td style="width:12.843%;"/>
        <td style="width:1%;"/>
        <td style="width:1.5%;"/>
        <td style="width:1%;"/>
        <td style="width:12.843%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Raw materials</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9f14deaf-5d36-43cd-be8c-b9e820ee89f4" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="us-gaap:InventoryRawMaterialsNetOfReserves" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,257</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e4f00795-6977-43a1-9d19-a38b0ce30381" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" name="us-gaap:InventoryRawMaterialsNetOfReserves" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,757</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Work-in-process</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9aec7400-8b94-4fa4-9bc9-d6923e71d9ea" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="us-gaap:InventoryWorkInProcessNetOfReserves" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,670</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_58019c96-bf9e-4f62-9dca-d9c61f8dc59b" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" name="us-gaap:InventoryWorkInProcessNetOfReserves" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,052</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Finished goods</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c9d841cc-09fe-4e5a-9d36-bc190b858331" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="us-gaap:InventoryFinishedGoodsNetOfReserves" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,810</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_02953bfa-f7ff-4cf8-8d36-878c2a5b5778" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" name="us-gaap:InventoryFinishedGoodsNetOfReserves" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,088</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total inventory</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f4e0fa86-0391-4712-885a-ab724a935b78" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="us-gaap:InventoryNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">40,737</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_19bec129-7853-4c19-8338-eb406206a9ce" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" name="us-gaap:InventoryNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">55,897</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and 2022, total inventory included net fair value adjustments resulting from the acquisition of La Jolla of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dc61f6d5-a21e-4db7-9546-1c27b25c97f3" contextRef="C_850c3b25-8c30-4a01-9de2-0ca85949a00e" name="inva:FairValueAdjustmentsOfInventoryFromAcquistion" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">23.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8b0f9a60-24d2-4a2f-aaa3-21895c15717c" contextRef="C_f252cf15-a5b7-46ae-b4cf-f02a7d2a1bf9" name="inva:FairValueAdjustmentsOfInventoryFromAcquistion" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">49.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, which will be recognized as cost of products sold when sales occur in future periods. The fair value adjustments recorded as part of cost of products sold amounted to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_19870bd0-9eaf-444d-b6a8-27dfb75abe0c" contextRef="C_81c113da-ef79-4663-b552-0f93fc8926be" name="inva:AmortizationOfFairValueAdjustmentsOfCostOfProductsSold" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">27.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">million and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_37d35905-65ad-4e2f-bfb2-dafb09d23b47" contextRef="C_8b18bfe1-7298-47b5-82af-99cfcef35fce" name="inva:AmortizationOfFairValueAdjustmentsOfCostOfProductsSold" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">10.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other Accrued Liabilities</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fa224706-4186-46bc-88fc-93c730720f65" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other accrued liabilities consisted of the following:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:67.313%;"/>
        <td style="width:1.5%;"/>
        <td style="width:1%;"/>
        <td style="width:12.843%;"/>
        <td style="width:1%;"/>
        <td style="width:1.5%;"/>
        <td style="width:1%;"/>
        <td style="width:12.843%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued contract manufacturing expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5f11a578-aa4c-461c-aacf-353cc99fb8ca" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="inva:AccruedContractManufacturingLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,966</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_498709cf-9571-442e-a433-fd2d2afaa5f5" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" name="inva:AccruedContractManufacturingLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,382</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued clinical expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c23a3ffb-0b29-4973-8b8a-6cbe43957d41" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="inva:AccruedClinicalLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">591</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_340574a2-fc6e-46b9-abae-895ceaac7ef1" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" name="inva:AccruedClinicalLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">692</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued research expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3d6947b6-6d97-46de-993b-fb80faad00bc" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="inva:AccruedResearchLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">185</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_adec6c6d-0b89-45b0-af49-1a59447515a5" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" name="inva:AccruedResearchLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">349</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued professional services</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cf0d0519-d2ca-4528-ad81-72bd6862f587" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="inva:AccruedProfessionalServices" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,876</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_962f46d8-bea2-4d27-a6e6-de888e6a24cf" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" name="inva:AccruedProfessionalServices" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,977</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_4d9e1814-d90c-438a-b69f-2d0819d5112e;"><span style="-sec-ix-hidden:F_62616aa1-c408-4682-b198-b4aacc8031c4;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current portion of lease liabilities</span></span></span></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_980dcfb9-9399-42f4-b97d-458cf5331949" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,207</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c5bc1d83-a00f-4f4e-b937-a194d941526a" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,316</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Royalty obligation payable</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_97f26be4-0d40-476f-b72a-c8a76153516f" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="us-gaap:AccruedRoyaltiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,928</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a668cd0e-f41f-4450-9cef-d3e2932f98a7" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" name="us-gaap:AccruedRoyaltiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current portion of deferred royalty obligation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8a5db259-321a-44b9-9737-bfb1f9597b30" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="inva:DeferredRoyaltyObligationCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1791c14d-e871-4d03-b597-b05a2f65df42" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" name="inva:DeferredRoyaltyObligationCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,639</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued license fees and royalties</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f8c246f1-8a66-4775-a17f-71ea5ada1501" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="inva:AccruedLicenseFeesAndRoyalties" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,575</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1ee633d9-ca9b-4008-9dc8-e166b84f713c" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" name="inva:AccruedLicenseFeesAndRoyalties" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">943</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d0010a82-06e4-4745-b7b3-d296ef19b229" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="us-gaap:OtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,370</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ef841dfb-a14b-495f-930b-2a3cbddb7138" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" name="us-gaap:OtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,909</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total other accrued liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_905a4e5c-0d1f-41f2-914f-d39852545f3f" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,698</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6e736dff-17c4-4e5f-8d78-bbd27ca7af94" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,207</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other Long-Term Liabilities</span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><ix:nonNumeric id="F_574ebbdd-c8c0-4903-acf8-2555a066bd3d" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:OtherNoncurrentLiabilitiesTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other long-term liabilities consisted of the following:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:67.313%;"/>
        <td style="width:1.5%;"/>
        <td style="width:1%;"/>
        <td style="width:12.843%;"/>
        <td style="width:1%;"/>
        <td style="width:1.5%;"/>
        <td style="width:1%;"/>
        <td style="width:12.843%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Long-term portion of deferred royalty obligation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6241912c-3d39-424d-a60b-45eba89f440d" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="inva:DeferredRoyaltyObligationNonCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">69,876</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f4404e89-27c3-4e8e-8364-0ce1093f907c" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" name="inva:DeferredRoyaltyObligationNonCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">67,947</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_8a36ba82-b9a3-4b23-adb9-3d2b758e3db2;"><span style="-sec-ix-hidden:F_fbfec351-c094-49d9-a03a-e641b11869bb;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Long-term portion of lease liabilities</span></span></span></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eb1a5710-e43e-413a-86c2-20cbbc788fc9" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,635</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e5bd16f6-1687-4dd3-8e8d-c58608fdf048" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,376</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Contingent value rights liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_04058619-6b30-4bde-a95b-14fedca33c46" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="inva:ContingentValueRightsLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">359</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9f832710-b60e-4094-a95e-6d25399295d2" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" name="inva:ContingentValueRightsLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">595</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total other long-term liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d45f20c9-3169-4c42-9ad4-4c5a8f7b7e35" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">71,870</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bf98f80c-a20a-476c-930b-f89136c9c9b1" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">70,918</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">124</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:nonNumeric id="F_06ff81a8-e489-45fa-ac44-4fedaa7fb9d8" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10. STOCK&#8209;BASED COMPENSATION</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Equity Incentive Plans</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In May 2012, we adopted the 2012 Equity Incentive Plan (the &#8220;2012 Plan&#8221;). The 2012 Plan provides for the grant of incentive stock options, nonstatutory stock options, RSAs, RSUs and Stock Appreciation Rights to employees, non-employee directors and consultants. As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, total shares remaining available for issuance under the 2012 Plan were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_25096e86-be07-4e4f-b8fa-3cf2e3cb6739" contextRef="C_5c9abf9d-1e31-4f48-9d0d-c57d10750153" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,924,185</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Employee Stock Purchase Plan</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the 2004 Employee Stock Purchase Plan (the &#8220;2004 ESPP&#8221;), our employees may purchase common stock through payroll deductions at a price equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_39b87b14-80d5-4628-a876-15d602e094d8" contextRef="C_53420953-7564-40c6-bee0-709280cf738f" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">85</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the lower of the fair market value of the stock at the beginning of the offering period or at the end of each applicable purchase period. The 2004 ESPP provided for consecutive and overlapping offering periods of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_246c326c-ab98-46d6-9328-a54386ef4f48" contextRef="C_53420953-7564-40c6-bee0-709280cf738f" name="inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveAndOverlappingOfferingPeriod" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">24 months</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in duration, with each offering period composed of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a8a15ac9-14ac-45ce-95fc-7f0da4b518f2" contextRef="C_53420953-7564-40c6-bee0-709280cf738f" name="inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods" unitRef="U_Item" decimals="0" format="ixt-sec:numwordsen">four</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> consecutive </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b0500d38-ae42-4a47-9915-d7d5f0dc05c7" contextRef="C_53420953-7564-40c6-bee0-709280cf738f" name="inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">six-month</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> purchase periods. The purchase periods ended on either May 15 or November 15. The 2004 ESPP contributions were limited to a maximum of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_89abb7dd-6a2c-4fc8-bda9-8f2ef8d54278" contextRef="C_f865e077-bfae-42a2-83e9-9bbaf0133b51" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">15</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of an employee&#8217;s eligible compensation. The maximum number of shares that an employee may purchase in any purchase period was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1b648a63-314a-42ec-a86b-c91c0801f476" contextRef="C_53420953-7564-40c6-bee0-709280cf738f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,500</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. An employee may not purchase shares with a value greater than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d5429b78-e7ab-482b-985c-ed2f287cc89c" contextRef="C_53420953-7564-40c6-bee0-709280cf738f" name="inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountAsContributionOfEligibleCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in any calendar year.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On April 13, 2023, the Board of Directors adopted the 2023 ESPP (the &#8220;2023 ESPP&#8221;). The 2023 ESPP, which supersedes the 2004 ESPP, was approved by the Company&#8217;s stockholders on May 22, 2023. Under the 2023 ESPP, eligible employees may purchase common stock through payroll deductions at a price equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_12ab4973-24fc-4d98-abe2-9df9487ce5fc" contextRef="C_274e3c4f-40cb-407c-aabb-e32137ff6f9d" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">85</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the lower of the fair market value of the stock at the beginning or end of each applicable purchase period. The 2023 ESPP provides for offering periods of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d84885ff-a19b-48f9-b100-ba5f87e3320b" contextRef="C_274e3c4f-40cb-407c-aabb-e32137ff6f9d" name="inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveAndOverlappingOfferingPeriod" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">six months</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, which ends on either May 15 or November 15. The 2023 ESPP contributions are limited to a maximum of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b82281e0-e74e-4bae-a502-d6eabe0482ab" contextRef="C_bfc65bb1-ad80-4e8a-8b46-7fb950cefb1b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">15</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of an employee&#8217;s eligible compensation. The maximum number of shares that an employee may purchase in any purchase period is </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c467acbe-9ae7-4670-8547-5ee36a0b4c86" contextRef="C_274e3c4f-40cb-407c-aabb-e32137ff6f9d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,500</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. An employee may not purchase shares with a value greater than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2605b439-660a-48a2-b950-f892df258edf" contextRef="C_274e3c4f-40cb-407c-aabb-e32137ff6f9d" name="inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountAsContributionOfEligibleCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in any calendar year. A total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_031e54d0-3646-41d3-8807-e8f3fa26348b" contextRef="C_bfc65bb1-ad80-4e8a-8b46-7fb950cefb1b" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" scale="6" decimals="INF" format="ixt:num-dot-decimal">2.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million shares of our common stock was reserved and available for issuance under the 2023 ESPP.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, total shares remaining available for issuance under the 2023 ESPP were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a42b442e-88fe-4556-b55b-543cf1b6a120" contextRef="C_bfc65bb1-ad80-4e8a-8b46-7fb950cefb1b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,500,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Director Compensation Program</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our non-employee directors receive compensation for services provided as a director. Each member of our board of directors who is not an employee receives both cash and equity compensation for services as a director, member of a committee of the board of directors, lead independent director and chairman, as applicable. In October 2017, both the cash and equity components of the compensation program were amended, effective immediately (the &#8220;October 2017 Amendments&#8221;).</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Each of our independent directors receives periodic automatic grants of equity awards under a program implemented under the 2012 Plan. These grants are non&#8209;discretionary. Only our independent directors or affiliates of such directors are eligible to receive automatic grants under the 2012 Plan. Under the program, each individual who first became a non-employee director will, on the date such individual joins the board of directors, automatically be granted a one&#8209;time grant of RSUs covering a number of shares of our common stock calculated as $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f6475233-99a5-42a1-9a5f-11908568190a" contextRef="C_f0da2c05-1727-4786-acd0-b03e3dff2fa8" name="inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialEquityGrantValue" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">125,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ($</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_99780f76-5f60-4f33-99b8-688501dcd4ce" contextRef="C_7b781f4e-2b96-403a-be95-189c21bfe845" name="inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialEquityGrantValue" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">250,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> prior to the October 2017 Amendments) divided by our common stock closing share price on the date of grant as reported on The Nasdaq Global Select Market, rounded down to the nearest whole share (the &#8220;Initial RSUs&#8221;), plus a one&#8209;time grant of RSUs covering a number of shares of our common stock calculated as $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_55824172-3088-4061-aea9-8e5d6877388b" contextRef="C_f0da2c05-1727-4786-acd0-b03e3dff2fa8" name="inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalEquityGrantValue" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">225,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ($</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8f9db4d8-f7b8-45dc-b5d3-c949e30e1023" contextRef="C_7b781f4e-2b96-403a-be95-189c21bfe845" name="inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalEquityGrantValue" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">250,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> prior to the October 2017 Amendments) divided by our common stock closing share price on the date of grant as reported on The Nasdaq Global Select Market, which would be pro-rated for the number of whole months remaining until the anniversary of the prior year&#8217;s stockholders&#8217; meeting, rounded down to the nearest whole share (the &#8220;Pro Rata RSUs&#8221;). The Initial RSUs vest in </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7b107d20-441c-4a9e-bd0e-7d18b63e0d3d" contextRef="C_bcf921a3-2613-4901-bd57-bf22fbe5ef61" name="inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments" unitRef="U_Installment" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> equal annual installments, while Pro Rata RSUs vest in a single installment at the sooner of the next annual stockholder meeting or the one-year grant anniversary, in each case subject to the non-employee director&#8217;s continuous service through the applicable vesting date.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Annually, upon his or her re&#8209;election to the board of directors at the Annual Meeting of Stockholders, each non-employee director is automatically granted an RSU covering a number of shares of our common stock calculated as $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d17950a4-fe6e-4a82-a3d7-a0b1920c59e6" contextRef="C_11c3614e-b3bf-4d55-987c-21911b9b09fc" name="inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityGrantValue" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">225,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ($</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0d18f1e7-186e-4e08-907b-3f6f3b370d45" contextRef="C_28748b0b-ed6b-4f26-be07-c4b34621cb5b" name="inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityGrantValue" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">250,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> prior to the October 2017 Amendments) divided by our common stock closing share price on the date of grant as reported on The Nasdaq Global Select Market, rounded down to the nearest whole share. These RSUs will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the non-employee director&#8217;s continuous service through the applicable vesting date. Following the amendment to our non-employee director compensation program, both the annual RSUs and Initial RSUs described above remained unchanged with the exception that the number of shares of our common stock subject to each award has been reduced.</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">125</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These RSUs will vest in full upon the director&#8217;s death, the occurrence of a change in control or, with respect to awards made after the October 2017 Amendments, the director&#8217;s disability before the director&#8217;s service terminates. Director RSUs carry dividend equivalent rights to be credited with an amount equal to all cash dividends paid on the underlying shares of common stock while unvested. Dividend equivalents are subject to the same terms and conditions, including vesting, as the RSUs to which they attach and are paid in cash upon vesting.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock&#8209;Based Compensation Expense</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_825a894a-bf5a-4cb0-83d1-610f7471e575" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock&#8209;based compensation expense is included in the consolidated statements of income as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:51.01%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:13.203%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:13.203%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:13.583%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Selling, general and administrative</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8c42dfa1-f53a-4990-9805-30a9f5161df9" contextRef="C_3810cd04-c006-4bfa-8397-c106caf901af" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,645</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4ab60342-b2ee-4617-b3ab-14f98150502c" contextRef="C_a6dc9592-99de-4df7-8a98-ca4fcda287d2" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,305</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f83383c1-8cd1-4f72-92d2-a854e663d83e" contextRef="C_00500ade-f7ea-4d89-9a06-fb25d9363802" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,017</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3b862451-0441-4a1f-bb5f-1635634e4423" contextRef="C_75ab87a5-b754-4d3e-95be-4a5426c4c785" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,192</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_338902bf-f653-4158-854e-43ea6083a48c" contextRef="C_cdba2e0f-32b5-4b89-bd92-54198cce3aa9" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,042</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_79704afe-af46-4a69-90b4-b7c36057cfd2" contextRef="C_b6abf77e-c226-4f1c-b9e9-b0f6f21c3bb2" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_62172a6e-2be8-4e17-9cf4-f64ba96eb65d" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,837</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c5c2e9dd-c794-4e66-8f50-acbf58a8203e" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,347</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e31d4c4d-10bd-4606-b09f-10d972a61d7e" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,017</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_27494baa-3da4-4847-bf8b-a7a1de0f28da" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock&#8209;based compensation expense included in the consolidated statements of income by award type is as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:51.311%;"/>
        <td style="width:1.481%;"/>
        <td style="width:1%;"/>
        <td style="width:12.75%;"/>
        <td style="width:1%;"/>
        <td style="width:1.481%;"/>
        <td style="width:1%;"/>
        <td style="width:12.75%;"/>
        <td style="width:1%;"/>
        <td style="width:1.481%;"/>
        <td style="width:1%;"/>
        <td style="width:12.75%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock options</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fb813e96-95fe-41d7-96fb-d4469abee4db" contextRef="C_1fd35541-50f5-4c16-a031-bd9cc78d2a09" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,980</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_76c74957-1ed7-4d07-acd1-d6ffc431017b" contextRef="C_b40eac4f-f18e-4a85-95ce-6db8d48f14f2" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,057</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2345b731-a606-4e6b-a317-e945276878b6" contextRef="C_7b140651-bbea-4d88-8a4f-fa197b5dfa55" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">490</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">RSUs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_07cd61a7-bc57-4aaf-9692-31c065ee990f" contextRef="C_f3f69c9a-b63b-46c1-8d46-3c3cdfa265b1" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,663</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_679a9c37-96a5-4657-9f27-d15fc21dde81" contextRef="C_a332f0a6-0f9e-4712-97f0-f10d648bcf65" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,053</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9fb5c905-b605-48d2-9239-8ff290c399ed" contextRef="C_4eb342bb-a67b-41a2-af3e-2b6b0a442022" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,280</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">RSAs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ffa024ce-c52e-4c3e-956c-11d5208c8ad2" contextRef="C_fb582b1b-defd-402a-8689-f3dd46cd150b" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">168</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_06aa5e75-0fad-4d19-a51a-01d67f73576c" contextRef="C_b4ac9910-3d92-4e1b-ac5f-f74c9dbdcfcd" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">194</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7186cfc6-967b-485c-8bd8-6261631949ff" contextRef="C_70e1c77f-fb08-4ab9-9457-0bc05d1bd9af" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">200</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ESPP</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b529cdca-9fd8-4608-a482-fb9897704808" contextRef="C_53420953-7564-40c6-bee0-709280cf738f" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4cb78605-b808-4a71-8e2b-146d7a26eaac" contextRef="C_31fb851b-8f5e-4955-b085-ac6b0dd38b8d" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8350c294-8cdc-4d0f-b636-9cc3d29b13e7" contextRef="C_2297939c-7913-4791-9563-25bbf6ee309c" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">47</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total stock-based compensation expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dd2f6f15-2b30-444f-bc3d-b82009169a9b" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,837</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_54b49c22-4de8-454b-b926-a9cbb534f347" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,347</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a73bcec2-3fae-4bfa-859f-5cb126d13963" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,017</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e7eedd67-af55-417a-af70-810307361e3f" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023, the unrecognized stock-based compensation cost and the estimated weighted-average amortization period were as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:60.2%;"/>
        <td style="width:1.82%;"/>
        <td style="width:1%;"/>
        <td style="width:16.08%;"/>
        <td style="width:1%;"/>
        <td style="width:1.36%;"/>
        <td style="width:1%;"/>
        <td style="width:16.54%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrecognized Compensation Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-Average Amortization Period (Years)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock options</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5537f60a-e69e-4eb6-9f62-4c09dfab5876" contextRef="C_6c28106a-1f5c-4375-9a90-9f5d3d7fd470" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,861</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_64ed0e0b-149d-43c4-9bdf-5515a0bc1cf1" contextRef="C_1fd35541-50f5-4c16-a031-bd9cc78d2a09" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.9</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">RSUs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_25874670-cca4-4af4-8c11-f997fe4e1e03" contextRef="C_3b5f86a2-e137-470e-ae05-ea4b9e220cfa" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,430</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_ab4ef592-f345-4f95-a2ee-be76090adde8" contextRef="C_f3f69c9a-b63b-46c1-8d46-3c3cdfa265b1" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.4</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">RSAs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c6cd01f3-2440-4bc9-939b-ba9ccd7781cc" contextRef="C_f3b6b1d2-3788-42e8-b1e9-0bae28c7d538" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">220</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_dc406b22-b1b1-4d35-ad92-4c90a54d09ba" contextRef="C_fb582b1b-defd-402a-8689-f3dd46cd150b" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.9</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total unrecognized compensation expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_29a1849b-149a-4a73-bc63-5816436d6531" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,511</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Compensation Awards</span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><ix:nonNumeric id="F_51a9a1f7-5778-4852-acc2-4a99267e3a1d" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes equity award activity under the 2012 Plan and prior plans and related information:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:32.386%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:8.642%;"/>
        <td style="width:1%;"/>
        <td style="width:1.02%;"/>
        <td style="width:1%;"/>
        <td style="width:7.7219999999999995%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:8.642%;"/>
        <td style="width:1%;"/>
        <td style="width:1.02%;"/>
        <td style="width:1%;"/>
        <td style="width:7.7219999999999995%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:8.642%;"/>
        <td style="width:1%;"/>
        <td style="width:1.02%;"/>
        <td style="width:1%;"/>
        <td style="width:8.182%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands, except per share data)</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of outstanding options</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-Average Exercise Price of Outstanding Options</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of outstanding RSUs</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-Average Fair Value per Share at Grant</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of outstanding RSAs</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-Average Fair Value per Share at Grant</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance as of December 31, 2022</span></p></td>
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1699a7dc-5004-4b3a-aecc-12272be43fd8" contextRef="C_886d4bf2-cc70-460c-8055-b20097a1c12e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">948</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6c8d7e05-3a22-4c21-b8c0-e89b7321f9a5" contextRef="C_886d4bf2-cc70-460c-8055-b20097a1c12e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">15.56</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e38ca905-3ac9-4daf-b117-026e91972df6" contextRef="C_cff2e9b5-87f8-419f-9856-34ae17e4d036" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">518</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6b10463e-118c-4da3-aab9-308b667254de" contextRef="C_cff2e9b5-87f8-419f-9856-34ae17e4d036" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">12.16</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5687c969-a4d5-490f-96d4-a0d70cbe75b9" contextRef="C_8e0a440d-9ea8-4152-85ec-508d2a5aa993" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">30</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d8ef4316-0b0d-449e-bdcc-40dda8c866a1" contextRef="C_8e0a440d-9ea8-4152-85ec-508d2a5aa993" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">14.97</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1ca81e62-5e2c-4308-97bf-7a1ef22208a2" contextRef="C_1fd35541-50f5-4c16-a031-bd9cc78d2a09" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">828</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2290e929-82cd-43b8-82bd-453a3c3f615c" contextRef="C_1fd35541-50f5-4c16-a031-bd9cc78d2a09" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">12.77</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ce41e84e-dbad-4c6e-99b5-1392413b080e" contextRef="C_f3f69c9a-b63b-46c1-8d46-3c3cdfa265b1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">389</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_69bf4fad-de8a-48df-8bef-501fd67b187b" contextRef="C_f3f69c9a-b63b-46c1-8d46-3c3cdfa265b1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">12.85</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7d6895fa-7d8f-4f5e-b6f6-868f19d39913" contextRef="C_fb582b1b-defd-402a-8689-f3dd46cd150b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" unitRef="U_shares" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b32d5a95-6acb-4031-b304-29e73439ba59" contextRef="C_fb582b1b-defd-402a-8689-f3dd46cd150b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercised</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bcdd82f5-d40e-43eb-b799-705e315e0976" contextRef="C_1fd35541-50f5-4c16-a031-bd9cc78d2a09" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d5f99c69-2ec5-490f-ad68-28d79c052eec" contextRef="C_1fd35541-50f5-4c16-a031-bd9cc78d2a09" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">12.98</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0ed13725-6002-484c-a65b-de0b587cc2fb" contextRef="C_f3f69c9a-b63b-46c1-8d46-3c3cdfa265b1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" unitRef="U_shares" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_313216b2-4f56-4e05-a6f8-04c85ca3fd34" contextRef="C_f3f69c9a-b63b-46c1-8d46-3c3cdfa265b1" name="inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_454a0886-edeb-4f21-adfb-3ce83b68eeae" contextRef="C_fb582b1b-defd-402a-8689-f3dd46cd150b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" unitRef="U_shares" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2c210651-13a9-4ecc-b307-195f3ebc6150" contextRef="C_fb582b1b-defd-402a-8689-f3dd46cd150b" name="inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Released RSUs and RSAs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_27961c4f-22fe-4e4e-9a59-ac46f7c70135" contextRef="C_1fd35541-50f5-4c16-a031-bd9cc78d2a09" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" unitRef="U_shares" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_70b66271-a461-4d90-a2cf-075959133da6" contextRef="C_1fd35541-50f5-4c16-a031-bd9cc78d2a09" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7598cb2a-ee13-4893-b274-6dc77e2d67c7" contextRef="C_f3f69c9a-b63b-46c1-8d46-3c3cdfa265b1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">284</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9a98928f-7c3b-4be5-b271-2e695b9b9aac" contextRef="C_f3f69c9a-b63b-46c1-8d46-3c3cdfa265b1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">12.42</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e6469af1-5921-4e91-aad7-b3554c57c7bd" contextRef="C_fb582b1b-defd-402a-8689-f3dd46cd150b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">14</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_042aedb0-14ce-4754-a20e-dcdc0609822f" contextRef="C_fb582b1b-defd-402a-8689-f3dd46cd150b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">15.02</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeited</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5d1d58b1-aa2b-4f7f-8f3e-68ee975320d4" contextRef="C_1fd35541-50f5-4c16-a031-bd9cc78d2a09" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">275</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9fa58380-a18c-4c52-ae2f-faed246284d4" contextRef="C_1fd35541-50f5-4c16-a031-bd9cc78d2a09" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">15.22</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_973d2a14-25a1-48f8-b71c-a2f9cd1e9b6f" contextRef="C_f3f69c9a-b63b-46c1-8d46-3c3cdfa265b1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">141</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_38c0a7ab-efc9-4347-a7f1-86de0e4eea05" contextRef="C_f3f69c9a-b63b-46c1-8d46-3c3cdfa265b1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">11.98</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5d994358-7849-499f-94c4-77faf7875e42" contextRef="C_fb582b1b-defd-402a-8689-f3dd46cd150b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" unitRef="U_shares" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_186db3df-f11f-4fb3-9288-d5a03799f322" contextRef="C_fb582b1b-defd-402a-8689-f3dd46cd150b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance as of December 31, 2023</span></p></td>
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2d5a620d-de0b-4f36-a2b7-07f07b51f380" contextRef="C_6c28106a-1f5c-4375-9a90-9f5d3d7fd470" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,499</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_42018a6d-ac7d-4860-a070-fb325b5fcff1" contextRef="C_6c28106a-1f5c-4375-9a90-9f5d3d7fd470" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">14.09</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f738106f-187a-4c8f-8ae0-4351177ffe36" contextRef="C_3b5f86a2-e137-470e-ae05-ea4b9e220cfa" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">482</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_25b843ad-a1e5-4734-a37e-996ce3fada4b" contextRef="C_3b5f86a2-e137-470e-ae05-ea4b9e220cfa" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">12.62</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eef61b42-6e00-4d64-ba8a-c770f809692a" contextRef="C_f3b6b1d2-3788-42e8-b1e9-0bae28c7d538" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">16</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_63ba7b47-1b9e-47c2-93a2-d5f8d8c093da" contextRef="C_f3b6b1d2-3788-42e8-b1e9-0bae28c7d538" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">14.93</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vested and expected to vest <br/>&#160;&#160;&#160;as of December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f2aee846-3679-4e3a-9be6-2caa3a3fad1a" contextRef="C_6c28106a-1f5c-4375-9a90-9f5d3d7fd470" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,499</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cfe3d378-82a2-4a93-9f28-410cfda92a68" contextRef="C_6c28106a-1f5c-4375-9a90-9f5d3d7fd470" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">14.09</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4773acf5-7081-4cbc-94e5-d1f54f31645e" contextRef="C_3b5f86a2-e137-470e-ae05-ea4b9e220cfa" name="inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingNumber" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">482</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_646f528f-a63d-409c-8f53-defaef7556dc" contextRef="C_3b5f86a2-e137-470e-ae05-ea4b9e220cfa" name="inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingWeightedAverageFairValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">12.62</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_74543118-2be4-4ed9-8a54-5892278a56f4" contextRef="C_f3b6b1d2-3788-42e8-b1e9-0bae28c7d538" name="inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingNumber" unitRef="U_shares" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5176867a-4b83-45e4-89de-244758b2c4df" contextRef="C_f3b6b1d2-3788-42e8-b1e9-0bae28c7d538" name="inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingWeightedAverageFairValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">126</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude></ix:nonNumeric></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the aggregate intrinsic value of options outstanding and options exercisable was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ec962339-4e78-403b-9834-c2147714856a" contextRef="C_6c28106a-1f5c-4375-9a90-9f5d3d7fd470" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2ffa1bc9-1623-4bab-a77a-7c0d83a6aff7" contextRef="C_6c28106a-1f5c-4375-9a90-9f5d3d7fd470" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2022, the aggregate intrinsic value of options outstanding and options exercisable was not material. As of December 31, 2023, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7ef1477d-9d14-4ea1-aca6-8c1678e0d4ce" contextRef="C_6c28106a-1f5c-4375-9a90-9f5d3d7fd470" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">519,165</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> options were exercisable. The weighted average remaining contractual term of options outstanding was </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7414926f-ed91-4f8d-ac4d-d065d42e819d" contextRef="C_1fd35541-50f5-4c16-a031-bd9cc78d2a09" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7.96</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years and </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_71be8666-502e-4e51-89df-fe50d750db66" contextRef="C_b40eac4f-f18e-4a85-95ce-6db8d48f14f2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8.01</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years as of December 31, 2023 and 2022, respectively.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The total intrinsic value of the options exercised was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a025dbaa-aa7c-4bbd-91fe-b81f59ac718e" contextRef="C_1fd35541-50f5-4c16-a031-bd9cc78d2a09" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen"><ix:nonFraction id="F_6349e2a5-dce6-4ba0-9be1-e9fed92ffacb" contextRef="C_b40eac4f-f18e-4a85-95ce-6db8d48f14f2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen"><ix:nonFraction id="F_15f2f2cc-450a-448e-9b9a-fe6daf93765d" contextRef="C_7b140651-bbea-4d88-8a4f-fa197b5dfa55" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t material for the year ended December 31, 2023, 2022 and 2021. The total estimated fair value of options vested was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_60116b46-2e06-46d2-991f-3950808d714c" contextRef="C_1fd35541-50f5-4c16-a031-bd9cc78d2a09" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fae3e3f7-841f-4c9d-a6c1-28f08a773df3" contextRef="C_7b140651-bbea-4d88-8a4f-fa197b5dfa55" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the years ended December 31, 2023 and 2021, respectively. The total estimated fair value of options vested was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6f2290d1-f3d7-4c1c-a9da-0d2ea81702e8" contextRef="C_b40eac4f-f18e-4a85-95ce-6db8d48f14f2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t material for the year ended December 31, 2022.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The total estimated fair value of RSUs vested was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4b819e10-c195-4599-bfb2-6cec2bc6b88f" contextRef="C_f3f69c9a-b63b-46c1-8d46-3c3cdfa265b1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_89376dc9-ad99-4cd7-b476-c8c0a202e88f" contextRef="C_a332f0a6-0f9e-4712-97f0-f10d648bcf65" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d6c3745c-472b-4828-9654-58806b5c2de6" contextRef="C_4eb342bb-a67b-41a2-af3e-2b6b0a442022" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the years December 31, 2023, 2022 and 2021.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The total estimated fair value of RSAs vested was not material for the year ended December 31, 2023, 2022, and 2021.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Valuation Assumptions</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Black-Scholes-Merton</span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7ba97f2c-5c0b-40c8-a706-3e4a2d60eba6" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" escape="true" continuedAt="F_7ba97f2c-5c0b-40c8-a706-3e4a2d60eba6_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> assumptions used in calculating the estimated value of stock options granted by Innoviva on the date of grant were as follows:</span></ix:nonNumeric></span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_7ba97f2c-5c0b-40c8-a706-3e4a2d60eba6_1"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:51.311%;"/>
        <td style="width:1.481%;"/>
        <td style="width:1%;"/>
        <td style="width:12.748999999999999%;"/>
        <td style="width:1%;"/>
        <td style="width:1.481%;"/>
        <td style="width:1%;"/>
        <td style="width:12.748999999999999%;"/>
        <td style="width:1%;"/>
        <td style="width:1.481%;"/>
        <td style="width:1%;"/>
        <td style="width:12.748999999999999%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5eaa8900-abcd-4fe1-9761-894a8a82ff55" contextRef="C_1c6acdd9-134f-4827-828c-e39c4849a9cf" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">4.0</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_93009f1d-c05d-4b53-aeeb-a5d3d22f123b" contextRef="C_c59027d6-af7f-4474-af78-da02d5338608" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">3.6</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0f80bf81-b666-413f-a024-7404e635da5a" contextRef="C_fa7ab020-0f18-40e9-ae65-5d70aca1f021" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">1.1</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_88663f6c-a64b-47da-84c2-606d908d59ee" contextRef="C_1c6acdd9-134f-4827-828c-e39c4849a9cf" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.09</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_36fd9fb2-657f-4f20-960c-6ab4c1299bcd" contextRef="C_c59027d6-af7f-4474-af78-da02d5338608" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.04</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_d9f039bf-23c1-4d04-84d2-a9c1394ccc59" contextRef="C_fa7ab020-0f18-40e9-ae65-5d70aca1f021" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.11</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Volatility</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cfb9d116-50bb-4f73-bb8e-2e2aedd51c76" contextRef="C_1c6acdd9-134f-4827-828c-e39c4849a9cf" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">37.8</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f90fad7e-f19e-4a10-a253-d895a3847e66" contextRef="C_c59027d6-af7f-4474-af78-da02d5338608" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">38.6</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f86b5d2b-7804-4f9f-a1a9-8e31a0bec3a4" contextRef="C_fa7ab020-0f18-40e9-ae65-5d70aca1f021" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">44.9</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Dividend yield</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_63b28a3b-34da-4d58-a199-1507d7952cf7" contextRef="C_1c6acdd9-134f-4827-828c-e39c4849a9cf" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.0</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d0d90b90-55c7-47eb-a9df-beb16955f9db" contextRef="C_c59027d6-af7f-4474-af78-da02d5338608" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.0</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e3fe1e8f-32c7-4bae-8b5d-3a7000a32153" contextRef="C_fa7ab020-0f18-40e9-ae65-5d70aca1f021" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.0</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average estimated fair value of stock options granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ae9708c7-de97-4070-a7ff-440d90a6f453" contextRef="C_1c6acdd9-134f-4827-828c-e39c4849a9cf" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">5.57</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9106b0b3-e1bd-4f4e-ae75-b3d05f30eadc" contextRef="C_c59027d6-af7f-4474-af78-da02d5338608" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">6.43</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ab2cdf34-7fa3-49fd-8c67-21ca827a3e67" contextRef="C_fa7ab020-0f18-40e9-ae65-5d70aca1f021" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">5.84</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cc9ad91a-2b2b-4267-b845-fec36e9dee27" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">11. </span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stockholders&#8217; Equity</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On October 31, 2022, our board of directors authorized a share repurchase program under which we may repurchase up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1ed4741a-e219-4a0a-942b-c8c602aa4dad" contextRef="C_c985f900-3058-44b4-9093-ef23d5cbfa14" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">100.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of our outstanding shares of common stock. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The repurchase program authorizes the repurchase by the Company of its common stock in open market transactions, including pursuant to a trading plan in accordance with Rule 10b-18 promulgated under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;) privately negotiated transactions, in block trades, accelerated share repurchase transactions, exchange transactions, or any combination thereof or by other means in accordance with federal securities laws. The authorization permits the Company to repurchase shares of its common stock from time to time at management&#8217;s discretion. Repurchases may also be made pursuant to a trading plan under Rule 10b5-1 under the Exchange Act, which would permit shares to be repurchased when the Company might otherwise be precluded from doing so because of self-imposed trading blackout periods or other regulatory restrictions. The actual means and timing of any shares purchased under the program will depend on a variety of factors, including ongoing assessments of the capital needs of the business, the market price of our common stock, prevailing stock prices, general market conditions and other considerations. This program has no termination date, may be suspended or discontinued at any time at our discretion, and does not obligate us to acquire any amount of common stock. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From program inception through December 31, 2022, we repurchased </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c14eb4f6-0ccd-4858-a83b-408d72b6d578" contextRef="C_5f070bd2-c0df-4242-beff-e5f9b6727217" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">647,394</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares in the open market at an average price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_244eca2f-dff9-44f5-930e-67e01f23671b" contextRef="C_5f070bd2-c0df-4242-beff-e5f9b6727217" name="inva:CommonStockAcquiredAverageCostPerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">13.13</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share for a total amount of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8e29ce8f-aff0-4fbf-af12-354a977efd55" contextRef="C_5f070bd2-c0df-4242-beff-e5f9b6727217" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">8.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. For the year ended</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> December 31, 2023, we repurchased </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d797fcfa-2701-45a7-984b-ee570d0ae783" contextRef="C_102d957f-b55b-4b0c-b290-8ba82889bebc" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">6,173,565</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares in the open market at an average price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9684f598-7013-4ade-a431-7776a27c6ed0" contextRef="C_102d957f-b55b-4b0c-b290-8ba82889bebc" name="inva:CommonStockAcquiredAverageCostPerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">12.39</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share for a total amount of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_228f960b-88c7-47ca-8117-83e8d11169d8" contextRef="C_102d957f-b55b-4b0c-b290-8ba82889bebc" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">76.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. Subsequent to December 31, 2023 and through February 15, 2024, we have repurchased </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_44eb9190-4410-4c4e-a0e7-a6a62b8d6260" contextRef="C_d175b10d-c61c-4706-bba1-92ef6df9865b" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">131,826</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares in the open market at an average price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a48ffd31-fdfc-4308-8d66-a701beb105d6" contextRef="C_d175b10d-c61c-4706-bba1-92ef6df9865b" name="inva:CommonStockAcquiredAverageCostPerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">15.93</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share for a total amount of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_940af20c-ffd7-4cb2-9886-841f04c088a9" contextRef="C_d175b10d-c61c-4706-bba1-92ef6df9865b" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. All of the repurchased shares were retired.</span></p></ix:nonNumeric></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">127</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ce958e7c-bfd2-4be6-b740-8748ef1ca634" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:DebtDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12. DEBT</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fa8a086a-ba1f-4100-821f-2910de74f0cb" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our debt consists of the following:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:67.313%;"/>
        <td style="width:1.5%;"/>
        <td style="width:1%;"/>
        <td style="width:12.843%;"/>
        <td style="width:1%;"/>
        <td style="width:1.5%;"/>
        <td style="width:1%;"/>
        <td style="width:12.843%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2023 Notes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ec5a7034-ddd2-4c3b-b872-2bf46636c227" contextRef="C_1a69ac4e-3663-4d1d-a457-2b4890fc09f6" name="inva:DebtInstrumentPrincipalAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8b8c2db5-7a67-4d6c-b975-8f8870765436" contextRef="C_96fef1ab-5fb4-4957-bed2-bbcbb49272d9" name="inva:DebtInstrumentPrincipalAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">96,204</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025 Notes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c56d8e0b-3749-4fb2-b162-4ec7a3a25ea4" contextRef="C_aab90c2e-843e-4eca-8999-f7ad6f6f31c9" name="inva:DebtInstrumentPrincipalAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">192,500</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0d33f5e0-8fc0-4a58-8986-e8c6e1756765" contextRef="C_87231fad-8817-4c3e-8afb-e2378841555d" name="inva:DebtInstrumentPrincipalAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">192,500</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2028 Notes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f56738c2-2627-42c5-87bc-a5d708a35222" contextRef="C_c11bea0f-0ab6-46b3-9574-250a23feeefc" name="inva:DebtInstrumentPrincipalAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">261,000</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_913a9942-aa1a-4499-b39f-0c13d6eb0623" contextRef="C_fb34b57e-973b-4997-8a2c-2f01d3f8fa62" name="inva:DebtInstrumentPrincipalAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">261,000</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total debt</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_880047d0-f190-47a0-92b1-a6c0c988b595" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="us-gaap:DebtInstrumentCarryingAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">453,500</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bac5e71d-16f8-4c04-9040-bc6fcdb09360" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" name="us-gaap:DebtInstrumentCarryingAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">549,704</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;Less: Unamortized debt discount and issuance costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2c26d5c8-a2e1-4411-9152-96405e2e4efa" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,266</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8a81f3e7-69fc-4ed2-992c-0f834e07c505" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,331</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total debt, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_215c19c4-a3be-43ea-8fde-4875b3959577" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="us-gaap:DebtLongtermAndShorttermCombinedAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">446,234</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_44daf669-171c-437c-860b-34ecaee45ab1" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" name="us-gaap:DebtLongtermAndShorttermCombinedAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">540,373</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;Less: Current portion of long-term debt, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_328b2d75-568c-4e96-af39-fefde12f8390" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="us-gaap:DebtCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_75078810-d1f7-4cd1-bb52-d895d3068f06" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" name="us-gaap:DebtCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">96,193</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total long-term debt, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_55caac61-d6cc-4ab9-b787-d4c560453742" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="us-gaap:LongTermDebtNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">446,234</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9eec5908-1155-4308-ada4-62c6b55e84ad" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" name="us-gaap:LongTermDebtNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">444,180</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Convertible Subordinated Notes Due 2023</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In January 2013, we completed an underwritten public offering of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3fe221d0-9a35-4c33-a500-02c836838d89" contextRef="C_74708c78-45e8-4732-9508-597695b3a0d5" name="us-gaap:DebtInstrumentFaceAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">287.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million aggregate principal amount of our 2023 Notes, which matured on January 15, 2023. The 2023 Notes bore interest at the rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0cc62baf-bcd7-4934-a838-d8e2bbf4b99a" contextRef="C_74708c78-45e8-4732-9508-597695b3a0d5" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" unitRef="U_pure" scale="-2" decimals="5" format="ixt:num-dot-decimal">2.125</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% per year that is payable semi-annually in arrears in cash on January 15 and July 15 of each year, beginning on July 15, 2013.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The 2023 Notes were convertible, at the option of the holder, into shares of our common stock at an initial conversion rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3c244d44-f5a4-40cf-8651-2e6cc845a6a6" contextRef="C_5294fbf9-d2f4-4cee-abd1-6e00044b2cfa" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" unitRef="U_pure" scale="0" decimals="4" format="ixt:num-dot-decimal">35.9903</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares per $1,000 principal amount of the 2023 Notes, subject to adjustment in certain circumstances, which represented an initial conversion price of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_80c8a85c-0889-4309-b2d3-f4276c7bd987" contextRef="C_e4d7581f-3285-4f94-bf60-7ad14f82c23d" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">27.79</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the offering of the 2023 Notes, we entered into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eac88c43-42e2-4f56-b5cb-04d6c3a172e0" contextRef="C_b55f651c-8a37-4dd9-95c5-8086ccf211c2" name="inva:NumberOfDerivativeInstrumentsPurchased" unitRef="U_Item" decimals="0" format="ixt-sec:numwordsen">two</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> privately negotiated capped call option transactions with a single counterparty. The capped call option transaction was an integrated instrument consisting of a call option on our common stock purchased by us with a strike price equal to the initial conversion price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7778c823-134a-4a23-b452-d0dff7954d8c" contextRef="C_698952c3-354e-492f-acd8-4bebed0f9f6b" name="us-gaap:OptionIndexedToIssuersEquityStrikePrice1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">27.79</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share for the underlying number of shares and a cap price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_66599239-a8db-41e9-af5d-640b05003b62" contextRef="C_b55f651c-8a37-4dd9-95c5-8086ccf211c2" name="us-gaap:DerivativeCapPrice" unitRef="U_UsdItem" scale="0" decimals="2" format="ixt:num-dot-decimal">38.00</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, both of which were subject to adjustments consistent with the 2023 Notes. The cap component was economically equivalent to a call option sold by us for the underlying number of shares with an initial strike price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cab36d97-5eb7-4b91-a78b-09e4f7ce7843" contextRef="C_b55f651c-8a37-4dd9-95c5-8086ccf211c2" name="us-gaap:DerivativeCapPrice" unitRef="U_UsdItem" scale="0" decimals="2" format="ixt:num-dot-decimal">38.00</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share. As an integrated instrument, the settlement of the capped call coincided with the due date of the convertible debt. Upon settlement, we would receive from our hedge counterparty a number of shares of our common shares that would range from </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9cfbc176-81d8-4e30-bbf7-93617c4a5270" contextRef="C_6672ccef-5420-4f2f-9dd7-acb4111b0173" name="inva:NumberOfSharesReceivableOnSettlementOfDerivativeInstrument" unitRef="U_shares" decimals="0" format="ixt-sec:numwordsen">zero</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, if the stock price was below $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8dfa07ab-b7f3-44f1-aa20-b94a5218fd38" contextRef="C_698952c3-354e-492f-acd8-4bebed0f9f6b" name="us-gaap:OptionIndexedToIssuersEquityStrikePrice1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">27.79</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, to a maximum of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a1aa7d29-71ab-43b1-9ab5-41b9a74a44be" contextRef="C_f08bc742-7ba2-448a-ba4b-b3bb674bb334" name="inva:NumberOfSharesReceivableOnSettlementOfDerivativeInstrument" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,779,659</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares, if the stock price was above $38.00 per share. However, if the market price of our common stock, as measured under the terms of the capped call transactions, exceeded $38.00 per share, there was no incremental anti-dilutive benefit from the capped call.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a result of the partial conversion by certain holders of the 2023 Notes in July 2014, and dividends declared and paid in 2014 and 2015, the conversion rate with respect to our 2023 Notes was adjusted in total to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0e676deb-4658-414f-9ee1-dc3d434585c5" contextRef="C_d4042f8a-02bc-4c92-af62-098270afe2af" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" unitRef="U_pure" scale="0" decimals="4" format="ixt:num-dot-decimal">50.5818</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of our common stock per $1,000 principal amount of the 2023 Notes, which represented a conversion price of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c52b8164-9349-42a8-a045-e38b4dfcb8f2" contextRef="C_99ee3dae-1eb1-48e4-a46a-c7e1dc1f16a3" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">19.77</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share. As a result of the conversion rate adjustments, the capped call strike price and cap price were also adjusted to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c02b2c83-ce65-4bf3-9ba5-1d04a78167a8" contextRef="C_4f37ea9f-306f-4950-a02c-a9b920bca4f3" name="us-gaap:OptionIndexedToIssuersEquityStrikePrice1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">19.77</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8a004d60-618c-49db-ab6d-e61d79f33592" contextRef="C_44f0f126-1c89-49be-aae9-85fa06e97ffc" name="us-gaap:DerivativeCapPrice" unitRef="U_UsdItem" scale="0" decimals="2" format="ixt:num-dot-decimal">27.04</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the year ended December 31, 2016, we retired a portion of our 2023 Notes with a face value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fb43f992-a007-47a7-98d2-514e1175e16f" contextRef="C_fe183000-a690-4df9-a845-930c3241af02" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">14.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and carrying value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_29f523a3-1462-4bea-9917-42d40bdcc1b3" contextRef="C_fe183000-a690-4df9-a845-930c3241af02" name="us-gaap:DebtInstrumentRepurchaseAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">13.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million by way of purchase in the open market.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On March 7, 2022, we used $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c1d1e3f3-b51d-4492-afda-3b3abe1ca8ca" contextRef="C_13a7a85f-17d1-43df-a359-948888dae445" name="us-gaap:RepaymentsOfUnsecuredDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">165.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million from the sale of the 2028 Notes to repurchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_994d6106-be21-4196-be1f-58eb5d69f225" contextRef="C_13a7a85f-17d1-43df-a359-948888dae445" name="inva:DebtInstrumentRepurchasePercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">60</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the 2023 Notes with a face value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_71a61ed1-a3c6-4847-94d6-c8af665024a3" contextRef="C_d98c3729-ed3e-4b22-af22-60937a83a980" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">144.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The carrying value of the repurchased 2023 Notes was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_336b518d-48ba-428f-ae82-d0c621143608" contextRef="C_d98c3729-ed3e-4b22-af22-60937a83a980" name="us-gaap:DebtInstrumentRepurchaseAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">144.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. Accrued interest was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6223e942-a3f1-419f-9a24-7217dd742534" contextRef="C_d98c3729-ed3e-4b22-af22-60937a83a980" name="us-gaap:InterestPayableCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and unamortized debt issuance costs were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_678f9f36-927f-4887-9aae-cc374c67458d" contextRef="C_d98c3729-ed3e-4b22-af22-60937a83a980" name="us-gaap:UnamortizedDebtIssuanceExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million on the date of repurchase. We recognized a loss on the extinguishment of the 2023 Notes of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f090e74a-1554-4bfc-ae58-b219672ab00e" contextRef="C_13a7a85f-17d1-43df-a359-948888dae445" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">20.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in other expense, net, in the consolidated statement of operations. The repurchase reduced the outstanding principal balance to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_64c4fae7-bfe1-416b-9f70-2b350f7bfa49" contextRef="C_d98c3729-ed3e-4b22-af22-60937a83a980" name="inva:DebtInstrumentPrincipalAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">96.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and unamortized debt issuance costs to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0f36d212-9a21-4c28-9a5f-b507eb2fc793" contextRef="C_d98c3729-ed3e-4b22-af22-60937a83a980" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The annual effective interest rate of the 2023 Notes changed from </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3a1441c3-450f-435d-b971-426307f308b1" contextRef="C_e3491d72-ab2a-429a-8f92-dd8be751aada" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">2.36</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2cad4fe6-37d9-4994-b951-51af8dd8dfc9" contextRef="C_6f3330be-9c77-42d3-931d-990047c9e84c" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">2.37</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On April 18, 2022, certain 2023 Notes holders converted their notes of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_77b69027-cbea-4c0b-924c-5b5d4d852895" contextRef="C_47315d43-a153-47de-8273-33588b06dde8" name="us-gaap:DebtConversionConvertedInstrumentAmount1" unitRef="U_USD" scale="3" decimals="-2" format="ixt:num-dot-decimal">3.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> thousand into Innoviva&#8217;s common stock. The outstanding principal balance was reduced slightly to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2b222747-6f28-436e-8902-2ebfc7cd8963" contextRef="C_e1b05d91-a370-4fa6-955b-9c0c677f7d49" name="inva:DebtInstrumentPrincipalAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">96.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">128</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e8f947f8-c1c5-4b86-9310-f2859d6c945d" contextRef="C_1d6c5f53-6c4d-4fe6-a55d-07940f638bd4" name="us-gaap:ConvertibleDebtTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our outstanding 2023 Notes balance consisted of the following as of December 31, 2022:</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:77%;"/>
        <td style="width:1.98%;"/>
        <td style="width:1%;"/>
        <td style="width:19.02%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Principal</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e255a58d-7039-478f-ac53-d46a5e2541a3" contextRef="C_96fef1ab-5fb4-4957-bed2-bbcbb49272d9" name="inva:DebtInstrumentPrincipalAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">96,204</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Debt issuance costs, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ca74bb45-a323-42e1-ac24-92a435ec2efa" contextRef="C_96fef1ab-5fb4-4957-bed2-bbcbb49272d9" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net carrying amount</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9e3581cd-17ce-4d08-ab3b-09d6738af8c7" contextRef="C_96fef1ab-5fb4-4957-bed2-bbcbb49272d9" name="us-gaap:LongTermDebtCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">96,193</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:3.333%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The remaining balance of the 2023 Notes in the amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4ca80bf7-6bb7-470c-a74e-b6063ff60158" contextRef="C_61ec0a88-ce56-4964-8be3-32f048a015ef" name="us-gaap:DebtInstrumentFaceAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">96.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million was fully paid upon the maturity date in January 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5e80ee9a-b12b-4154-9a51-275422fce683" contextRef="C_1d6c5f53-6c4d-4fe6-a55d-07940f638bd4" name="us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table sets forth total interest expense recognized related to the 2023 Notes for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023, 2022 and 2021:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:51.311%;"/>
        <td style="width:1.481%;"/>
        <td style="width:1%;"/>
        <td style="width:12.75%;"/>
        <td style="width:1%;"/>
        <td style="width:1.481%;"/>
        <td style="width:1%;"/>
        <td style="width:12.75%;"/>
        <td style="width:1%;"/>
        <td style="width:1.481%;"/>
        <td style="width:1%;"/>
        <td style="width:12.75%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Contractual interest expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c07f93c0-e538-4a92-8b06-1e026412f0e7" contextRef="C_f7344ab8-d158-462a-91a3-5ed1e74e6333" name="us-gaap:InterestExpenseDebtExcludingAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">85</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fd65225a-2f6c-4499-9cca-b906266314fe" contextRef="C_a5bd2f55-3e40-4db1-9698-8e328bebe397" name="us-gaap:InterestExpenseDebtExcludingAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,617</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_90962992-1453-42ac-b5b4-7d347dc96dcc" contextRef="C_4c7b96af-5930-4df9-9e24-686f4186dd93" name="us-gaap:InterestExpenseDebtExcludingAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,121</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Amortization of debt issuance costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9947f9b6-1319-4f10-9442-3c96c06e2229" contextRef="C_f7344ab8-d158-462a-91a3-5ed1e74e6333" name="us-gaap:AmortizationOfFinancingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4a8ce0e4-70fa-460b-ac2e-4a45a9ee4e6e" contextRef="C_a5bd2f55-3e40-4db1-9698-8e328bebe397" name="us-gaap:AmortizationOfFinancingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">302</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e87dd506-613c-41e5-bf06-53c9b3bd0d18" contextRef="C_4c7b96af-5930-4df9-9e24-686f4186dd93" name="us-gaap:AmortizationOfFinancingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">580</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total interest and amortization expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b8d4e722-c3bd-4a7b-8801-0adbd6d729bf" contextRef="C_f7344ab8-d158-462a-91a3-5ed1e74e6333" name="us-gaap:InterestExpenseDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">96</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fa75a407-a58d-438c-b7fc-c8fc9c9a81c0" contextRef="C_a5bd2f55-3e40-4db1-9698-8e328bebe397" name="us-gaap:InterestExpenseDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,919</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_be7af684-75e4-473b-acb2-8ddcbcb2e34c" contextRef="C_4c7b96af-5930-4df9-9e24-686f4186dd93" name="us-gaap:InterestExpenseDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,701</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Convertible Senior Notes Due 2025</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On August 7, 2017, we completed a private placement of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2f953245-339a-4593-9918-614fd1aa9f20" contextRef="C_01fb7c8c-6c66-4d02-b04d-546c5c407297" name="us-gaap:DebtInstrumentFaceAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">192.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million aggregate principal amount of our 2025 Notes. The proceeds include the 2025 Notes sold pursuant to the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cb7df1d5-02db-451e-8193-8e633c9ebd23" contextRef="C_3ac61c6b-9a4c-4283-b479-f0354fbd761b" name="us-gaap:DebtInstrumentFaceAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_6d9f9034-1a6c-4330-b251-dde402764f91" contextRef="C_3ac61c6b-9a4c-4283-b479-f0354fbd761b" name="inva:PortionOfDebtInstrumentFaceAmountExercised" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">17.5</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million over-allotment option granted by us to the initial purchasers, which option was exercised in full. The 2025 Notes were sold in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act. The 2025 Notes are senior unsecured obligations and bear interest at a rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b584955e-aa41-422c-ada2-c8ec1bcf877f" contextRef="C_01fb7c8c-6c66-4d02-b04d-546c5c407297" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">2.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% per year, payable semi-annually in arrears on February 15 and August 15 of each year, beginning on February 15, 2018.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The 2025 Notes are convertible, based on the applicable conversion rate, into cash, shares of our common stock or a combination thereof, at our election. The initial conversion rate for the 2025 Notes is </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cc68a917-4dd7-45ac-95e6-2dbc73af8c94" contextRef="C_6c747ad1-5f7b-4926-8ac2-714e9199e239" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" unitRef="U_pure" scale="0" decimals="4" format="ixt:num-dot-decimal">57.9240</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of our common stock per $1,000 principal amount of the 2025 Notes (which is equivalent to an initial conversion price of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dc011ca6-5953-44f1-b660-8fba7ef4f07f" contextRef="C_7b934074-97f1-4177-96bc-6664a24ee9fa" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">17.26</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share), representing a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d8209cf8-0bc8-428a-989e-8793da566d81" contextRef="C_7b934074-97f1-4177-96bc-6664a24ee9fa" name="inva:DebtInstrumentConvertibleConversionPremium" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">30.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% conversion premium over the last reported sale price of the Company&#8217;s common stock on August 1, 2017, which was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1d0de603-0d3a-469c-a40a-ae047bc15c46" contextRef="C_4e8c55ea-f6dc-4620-b986-2786c29cf612" name="us-gaap:SharePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">13.28</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share. The conversion rate is subject to customary anti-dilution adjustments in certain circumstances. The 2025 Notes will mature on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e761b618-6f74-4d00-b319-55dc3aaaa1fb" contextRef="C_6c747ad1-5f7b-4926-8ac2-714e9199e239" name="us-gaap:DebtInstrumentMaturityDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">August 15, 2025</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, unless repurchased or converted in accordance with their terms prior to such date. Prior to February 15, 2025, the 2025 Notes will be convertible at the option of the holders only upon the occurrence of specified events and during certain periods, as described below. From, and including, February 15, 2025, until the close of business on the second scheduled trading day immediately preceding the maturity date, the 2025 Notes will be convertible at any time.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Holders of the 2025 Notes may convert all or a portion of their 2025 Notes prior to the close of business on February 15, 2025 only under the following circumstances:</span></p><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">after September 30, 2017, if our closing common stock price for at least 20 days out of the most recent 30 consecutive trading days of the preceding quarter is greater than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_361ad168-60a0-4fef-811d-09c2e2a68fb8" contextRef="C_d9c7ca7c-81fc-4272-b388-610e1b6444a8" name="inva:DebtConversionCommonStockPriceToConversionPriceRatioPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">130</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the current conversion price of the 2025 Notes;</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">for five consecutive business days, if the average trading price per $1,000 of Notes during the prior 10 consecutive trading days is less than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f34abc0c-97fc-4530-acac-75dc986bff0f" contextRef="C_d9c7ca7c-81fc-4272-b388-610e1b6444a8" name="inva:DebtConversionConvertedInstrumentAverageTradePricePercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">98</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the product of our closing common stock price and the conversion rate of the 2025 Notes on such day; and,</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">upon the occurrence of specified corporate events, including certain distributions, the occurrence of a fundamental changes (as defined in the indenture governing the 2025 Notes) or a transaction resulting in our common stock converting into other securities or property or assets. </span></div></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On or after February 15, 2025, holders of the 2025 Notes may convert their 2025 Notes at any time until the close of business on the second scheduled trading day immediately preceding the maturity date of the 2025 Notes.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the event of default or a fundamental change (as defined above), holders of the 2025 Notes may require us to repurchase all or a portion of their 2025 Notes at price equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cadca6db-3a81-4e0d-844c-dc84defaa481" contextRef="C_bfe82950-e87e-4ffb-ad0e-84e0026f5b0c" name="inva:DebtInstrumentRatioOfRepurchasePriceToThePrincipalAmount" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">100</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the principal amount of the 2025 Notes, plus any accrued and unpaid interest.</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">129</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Effective January 1, 2022, we adopted ASU 2020-06 using a modified retrospective method, under which financial results reported in prior periods were not adjusted.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Prior to the adoption of ASU 2020-06, we separately accounted for the liability and equity components of the 2025 Notes by allocating the proceeds between the liability component and the embedded conversion option (&#8220;equity component&#8221;) due to our ability to settle the conversion obligation of the 2025 Notes in cash, common stock or a combination of cash and common stock, at our option. The carrying amount of the liability component was calculated by measuring the fair value of a similar liability that does not have an associated convertible feature using the income approach. The allocation was performed in a manner that reflected our non-convertible debt borrowing rate for similar debt. The equity component of the 2025 Notes of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a119c076-3fcb-4315-8e2c-4e3ed9d2eed9" contextRef="C_5b63eaba-876c-4443-a190-0d776e3f0354" name="us-gaap:DebtInstrumentUnamortizedDiscount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">67.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million was recognized as a debt discount and represents the difference between the proceeds from the issuance of the 2025 Notes and the fair value of the liability of the 2025 Notes on the date of issuance. The excess of the principal amount of the liability component over its carrying amount (&#8220;debt discount&#8221;) was amortized to interest expense using the effective interest method over the term of the 2025 Notes. The equity component was not remeasured as long as it continued to meet the conditions for equity classification. Additionally, we separated the total issuance costs of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c6604ce3-ef80-4c7d-9546-2cada20f428a" contextRef="C_d9c7ca7c-81fc-4272-b388-610e1b6444a8" name="us-gaap:PaymentOfFinancingAndStockIssuanceCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million incurred into liability and equity components in proportion to the allocation of the initial proceeds, resulting in liability issuance costs of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1611ed7e-0b9a-41e7-9350-bb8f17ffab01" contextRef="C_d9c7ca7c-81fc-4272-b388-610e1b6444a8" name="us-gaap:PaymentsOfDebtIssuanceCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and equity issuance costs of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3c3eb0f8-a7ad-45bb-a8ac-986a9880c50c" contextRef="C_d9c7ca7c-81fc-4272-b388-610e1b6444a8" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. Issuance costs attributable to the liability component were amortized on a straight-line basis, which approximated the effective interest rate method, to interest expense over the term of the 2025 Notes. The issuance costs attributable to the equity component were netted against the equity component in additional paid-in capital. The annual effective interest rate of the liability component of the 2025 Notes was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e0d57e38-00fd-404d-9fd8-17fe0f1ddf46" contextRef="C_96f1c8f6-d5af-40ca-aebd-5dd11479b360" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">8.87</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Upon adoption of ASU 2020-06 on January 1, 2022, we combined the liability and equity components of the 2025 Notes assuming that the instrument was accounted for as a single liability from inception to the date of adoption. We similarly combined the liability and equity components of the issuance costs. The issuance costs are presented as a deduction from the outstanding principal balance of the 2025 Notes and are amortized on a straight-line basis over the term of the 2025 Notes under the effective interest rate method. As of January 1, 2022, the annual effective interest rate on the 2025 Notes was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2a62bc1a-cd04-4822-9432-05ed6346a4dd" contextRef="C_a89fb91f-9ba5-4dc8-a73e-32d0a623c796" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">2.88</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%. Beginning January 1, 2022, the annual effective interest rate on the 2025 Notes is </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3dc619e1-a033-4f91-a47b-f9c96304afd1" contextRef="C_e6805147-9eff-450d-a94b-d8e4239b1dd2" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">2.88</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0b4381c8-8b34-4c30-a4b6-766e0be51a3f" contextRef="C_d9c7ca7c-81fc-4272-b388-610e1b6444a8" name="us-gaap:ConvertibleDebtTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our outstanding 2025 Notes balances consisted of the following:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:53.88%;"/>
        <td style="width:2.26%;"/>
        <td style="width:1%;"/>
        <td style="width:18.799999999999997%;"/>
        <td style="width:1%;"/>
        <td style="width:2.26%;"/>
        <td style="width:1%;"/>
        <td style="width:18.799999999999997%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Principal</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c72d48b0-98f2-4cae-80cb-b81bc30f1516" contextRef="C_aab90c2e-843e-4eca-8999-f7ad6f6f31c9" name="inva:DebtInstrumentPrincipalAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">192,500</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_06e6178f-a61c-4481-a353-e6d4c134d3f5" contextRef="C_87231fad-8817-4c3e-8afb-e2378841555d" name="inva:DebtInstrumentPrincipalAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">192,500</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Debt discount and issuance costs, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bed37f89-c575-4d45-ab96-edeca82d2673" contextRef="C_aab90c2e-843e-4eca-8999-f7ad6f6f31c9" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,205</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_745fb5a1-ca61-4b7b-b9d3-09c21797bd2d" contextRef="C_87231fad-8817-4c3e-8afb-e2378841555d" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,917</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net carrying amount</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6b3ff789-89b0-4e20-80ae-e926aafc74df" contextRef="C_aab90c2e-843e-4eca-8999-f7ad6f6f31c9" name="us-gaap:LongTermDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">191,295</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4cee7335-3cb7-4bb3-9098-134c79623e86" contextRef="C_87231fad-8817-4c3e-8afb-e2378841555d" name="us-gaap:LongTermDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">190,583</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_08c14028-c203-4bad-a6c8-1df895dc6ee6" contextRef="C_d9c7ca7c-81fc-4272-b388-610e1b6444a8" name="us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table sets forth total interest expense recognized related to the 2025 Notes for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023, 2022 and 2021:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:51.01%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:13.203%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:13.203%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:13.583%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Contractual interest expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_25d65c4f-bb98-4082-9510-29b17a96a5ad" contextRef="C_bfe82950-e87e-4ffb-ad0e-84e0026f5b0c" name="us-gaap:InterestExpenseDebtExcludingAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,813</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_14f0624a-5b37-4353-86df-1e90dbf4882b" contextRef="C_32d8d95b-c12c-46d1-98c1-3deb4b8cb129" name="us-gaap:InterestExpenseDebtExcludingAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,813</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5af7e1b6-5577-4852-a1d1-1e5751ffa349" contextRef="C_e3e6ec1f-49a0-4fb9-9419-c9b6fcbc8855" name="us-gaap:InterestExpenseDebtExcludingAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,813</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Amortization of debt issuance costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d63c43b6-93c9-4697-9fa2-4f761394c185" contextRef="C_bfe82950-e87e-4ffb-ad0e-84e0026f5b0c" name="us-gaap:AmortizationOfFinancingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">712</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ea2bfe28-5996-424a-9624-327d497fbe9d" contextRef="C_32d8d95b-c12c-46d1-98c1-3deb4b8cb129" name="us-gaap:AmortizationOfFinancingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">692</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_93e7059f-53fe-4ff4-9d0c-bce6652c58d9" contextRef="C_e3e6ec1f-49a0-4fb9-9419-c9b6fcbc8855" name="us-gaap:AmortizationOfFinancingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">657</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Amortization of debt discount</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ff3a466e-7eaa-431f-98b5-02a26d4e1e22" contextRef="C_bfe82950-e87e-4ffb-ad0e-84e0026f5b0c" name="us-gaap:AmortizationOfDebtDiscountPremium" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f0176460-942a-43dd-bf59-169736db24bc" contextRef="C_32d8d95b-c12c-46d1-98c1-3deb4b8cb129" name="us-gaap:AmortizationOfDebtDiscountPremium" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f74ed6c1-9395-4764-9cf4-b7a3754e2f3d" contextRef="C_e3e6ec1f-49a0-4fb9-9419-c9b6fcbc8855" name="us-gaap:AmortizationOfDebtDiscountPremium" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,898</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total interest and amortization expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e410d43f-3d93-49b3-9c3c-ce22adb8f109" contextRef="C_bfe82950-e87e-4ffb-ad0e-84e0026f5b0c" name="us-gaap:InterestExpenseDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,525</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_11c8a395-d2d0-417e-b963-5c3a3857c2f2" contextRef="C_32d8d95b-c12c-46d1-98c1-3deb4b8cb129" name="us-gaap:InterestExpenseDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,505</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fc4f7d9d-64ec-4725-8a4a-8755f7291765" contextRef="C_e3e6ec1f-49a0-4fb9-9419-c9b6fcbc8855" name="us-gaap:InterestExpenseDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,368</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Convertible Senior Notes Due 2028</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In March 2022, we completed a private placement of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7aae06a5-df6f-4874-ae2c-0ea625d8d878" contextRef="C_6872c5a6-9354-4f1c-9344-b3b75b5392e8" name="us-gaap:DebtInstrumentFaceAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">261.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million aggregate principal amount of our 2028 Notes, which will mature on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_59170e43-d667-4e24-b275-75aacd90dd32" contextRef="C_a0e6a86f-d6b7-4f77-89aa-49a1c8b20ae6" name="us-gaap:DebtInstrumentMaturityDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">March 15, 2028</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The proceeds include the 2028 Notes sold pursuant to the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c09beff9-120c-4eac-b888-43c9f23a1cb1" contextRef="C_7087d489-2159-4c5e-b41f-f209f859c49e" name="us-gaap:DebtInstrumentFaceAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">45.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million over-allotment option granted by us to the initial purchasers, of which $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ae3ff1c5-ddf9-434d-aa12-9839a294b711" contextRef="C_7087d489-2159-4c5e-b41f-f209f859c49e" name="inva:PortionOfDebtInstrumentFaceAmountExercised" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">36.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million was exercised. The 2028 Notes were sold in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act.</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">130</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The net proceeds from the sale of the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e9c5b2f8-6ee9-4e43-9116-767b3f001251" contextRef="C_6872c5a6-9354-4f1c-9344-b3b75b5392e8" name="us-gaap:DebtInstrumentFaceAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">261.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million aggregate principal amount of 2028 Notes were approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_635fc246-6c33-4855-8cd2-dad7bb5602da" contextRef="C_a0e6a86f-d6b7-4f77-89aa-49a1c8b20ae6" name="us-gaap:ProceedsFromConvertibleDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">252.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million after deducting the initial purchasers&#8217; discounts and commissions and our estimated offering expenses. We used approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1bb96a0b-c393-4653-8f54-519e9ba6b4db" contextRef="C_0882851d-0bed-4150-b837-2e1f74d8e460" name="inva:PurchasesOfCappedCallsInConnectionWithConvertibleSeniorNotes" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">21.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of the net proceeds from the offering to fund the cost of entering into the capped call transactions described below. In addition, we used $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5b7e4b18-e899-415c-af4a-5fcbb96cf872" contextRef="C_cce222e5-dac9-4c08-abb5-d90f2a3b1707" name="us-gaap:RepaymentsOfUnsecuredDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">165.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of the remaining net proceeds to repurchase $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cb16d33d-9d1b-4d76-b9fc-3d4d80bda161" contextRef="C_eed06e0c-196c-43ba-8f27-6f6c2781e050" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">144.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million aggregate principal amount of the 2023 Notes in separate and individually negotiated transactions with certain holders of the 2023 Notes, which closed concurrently with the issuance of the 2028 Notes. We expect to use the remaining net proceeds for general corporate purposes.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The 2028 Notes bear interest at an annual rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a31b8813-7fee-4d2e-896a-9ba39fe3ecf0" contextRef="C_bf5886d1-1be6-4c7a-bfe3-1be3dd08388d" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" unitRef="U_pure" scale="-2" decimals="5" format="ixt:num-dot-decimal">2.125</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% that is payable semi-annually in arrears in cash on March 15 and September 15 of each year, beginning on September 15, 2022.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The 2028 Notes are convertible, based on the applicable conversion rate, into cash, shares of our common stock or a combination thereof, at our election. The initial conversion rate was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f719f987-dd86-420a-bb6e-7a6485ef407d" contextRef="C_44f330d4-92f5-4b09-a61f-569ed269bd6e" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" unitRef="U_pure" scale="0" decimals="4" format="ixt:num-dot-decimal">38.1432</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares per $1,000 principal amount of the 2028 Notes, subject to customary anti-dilution adjustment in certain circumstances, which represented an initial conversion price of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a2137393-4e88-48b3-984c-016886019ede" contextRef="C_7adc5fad-9ae2-4326-83c1-8d6394980f7e" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">26.22</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prior to September 15, 2027, the 2028 Notes will be convertible at the option of the holders only upon the occurrence of specified events and during certain periods, and will be convertible on or after September 15, 2027, at any time until the close of business on the second scheduled trading day immediately preceding the maturity date of the 2028 Notes.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Holders of the 2028 Notes may convert all or a portion of their 2028 Notes prior to the close of business on September 15, 2027, only under the following circumstances:</span></p><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">after March 31, 2022, if our closing common stock price for at least 20 days out of the most recent 30 consecutive trading days of the preceding quarter is greater than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fa80e96a-a03a-4289-bf7f-3f1d434737ea" contextRef="C_a0e6a86f-d6b7-4f77-89aa-49a1c8b20ae6" name="inva:DebtConversionCommonStockPriceToConversionPriceRatioPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">130</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the current conversion price of the 2028 Notes;</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">for five consecutive business days, if the average trading price per $1,000 of Notes during the prior 10 consecutive trading days is less than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0c26ec3c-7148-477d-9406-aae5ac69c096" contextRef="C_a0e6a86f-d6b7-4f77-89aa-49a1c8b20ae6" name="inva:DebtConversionConvertedInstrumentAverageTradePricePercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">98</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the product of our closing common stock price and the conversion rate of the 2028 Notes on such day; and,</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">upon the occurrence of specified corporate events, including certain distributions, the occurrence of a fundamental changes (as defined in the indenture governing the 2028 Notes) or a transaction resulting in our common stock converting into other securities or property or assets.</span></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On or after September 15, 2027, holders of the 2028 Notes may convert their 2028 Notes at any time until the close of the business on the second day immediately preceding the maturity date of the 2028 Notes.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The 2028 Notes will be redeemable, in whole or in part, at our option at any time, and from time to time, on or after March 20, 2025, and on or before the 75th scheduled trading day immediately before the maturity date but only if the last reported sale price per share of our common stock exceeds 130% of the conversion price for a specified period of time. The redemption price will be equal to the principal amount of the 2028 Notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date. In addition, calling any 2028 Note for redemption will constitute a make-whole fundamental change (as defined in the indenture governing the 2028 Notes) with respect to that 2028 Note, in which case the conversion rate applicable to the conversion of that 2028 Note will be increased in certain circumstances if it is converted after it is called for redemption.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we undergo a fundamental change, subject to certain conditions, holders may require us to purchase for cash all or any portion of their 2028 Notes. The fundamental change purchase price will be </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f329e02d-c6b5-46cd-8c05-6d02a562b184" contextRef="C_a0e6a86f-d6b7-4f77-89aa-49a1c8b20ae6" name="inva:DebtInstrumentRatioOfRepurchasePriceToThePrincipalAmount" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">100</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the principal amount of the 2028 Notes to be purchased plus any accrued and unpaid interest to, but excluding, the fundamental change purchase date.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e865c4e6-9fbd-431d-b34c-cc95e55b8b7c" contextRef="C_6f92e4e3-0288-40a0-9972-c89e1aac1433" name="us-gaap:LineOfCreditFacilityCovenantTerms"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The indenture governing the 2028 Notes contains customary terms and covenants, including a merger covenant and that upon certain events of default occurring and continuing, either the Trustee or the holders of at least 25% of the aggregate principal amount of the outstanding Notes may declare 100% of the principal of, and accrued and unpaid interest, if any, on, all the Notes to be due and payable immediately.</span></ix:nonNumeric></span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the offering of the 2028 Notes, we entered into privately negotiated capped call transactions. The cap price of the capped call transaction is initially $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_589df2ee-2c98-4bea-9258-d56ab07689f5" contextRef="C_e2dfcab8-9a69-48b0-bbd8-dd20190bc830" name="us-gaap:DerivativeCapPrice" unitRef="U_UsdItem" scale="0" decimals="4" format="ixt:num-dot-decimal">33.9850</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">share and is subject to certain adjustments under the terms of the capped call transactions. The capped call transactions cover, subject to customary adjustments, the number of shares of common stock initially</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">131</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">underlying </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the 2028 Notes. The capped call transactions are expected generally to reduce potential dilution to our common stock upon conversion of the 2028 Notes or at our election (subject to certain conditions) offset any cash payments we are required to make in excess of the aggregate principal amount of converted 2028 Notes, as the case may be, with such reduction or offset subject to a cap.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The annual effective interest rate on the 2028 Notes is </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ae011e47-6c0e-4c12-86bb-e41fed86c937" contextRef="C_c11bea0f-0ab6-46b3-9574-250a23feeefc" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">2.70</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><ix:nonNumeric id="F_59143c81-782e-4967-8f50-e9fc69973a57" contextRef="C_6f92e4e3-0288-40a0-9972-c89e1aac1433" name="us-gaap:ConvertibleDebtTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our outstanding 2028 Notes balance consisted of th</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">e following:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:67.313%;"/>
        <td style="width:1.5%;"/>
        <td style="width:1%;"/>
        <td style="width:12.843%;"/>
        <td style="width:1%;"/>
        <td style="width:1.5%;"/>
        <td style="width:1%;"/>
        <td style="width:12.843%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Principal</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_891e0afe-003d-4f50-8c3d-1956061a34e3" contextRef="C_c11bea0f-0ab6-46b3-9574-250a23feeefc" name="inva:DebtInstrumentPrincipalAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">261,000</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_25a0e1dd-ae3e-4a86-88c1-76e165f33497" contextRef="C_fb34b57e-973b-4997-8a2c-2f01d3f8fa62" name="inva:DebtInstrumentPrincipalAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">261,000</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Debt discount and issuance costs, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3423bdd8-dca1-46d1-bb93-4a1073626699" contextRef="C_c11bea0f-0ab6-46b3-9574-250a23feeefc" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,061</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d719cd5b-cc1f-419e-9245-6a9f3a0d3aac" contextRef="C_fb34b57e-973b-4997-8a2c-2f01d3f8fa62" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,403</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net carrying amount</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d268a315-a9d4-4355-9473-630ba2fd1e73" contextRef="C_c11bea0f-0ab6-46b3-9574-250a23feeefc" name="us-gaap:LongTermDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">254,939</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_352f3d8e-1ffd-48d7-a530-6ea77910939e" contextRef="C_fb34b57e-973b-4997-8a2c-2f01d3f8fa62" name="us-gaap:LongTermDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">253,597</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8a971575-7c20-4cfb-bce0-f291770bd156" contextRef="C_6f92e4e3-0288-40a0-9972-c89e1aac1433" name="us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table sets forth total interest expense recognized related to the 2028 Notes for the year ended December 31, 2023 and from the issuance through December 31, 2022:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:67.313%;"/>
        <td style="width:1.5%;"/>
        <td style="width:1%;"/>
        <td style="width:12.843%;"/>
        <td style="width:1%;"/>
        <td style="width:1.5%;"/>
        <td style="width:1%;"/>
        <td style="width:12.843%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Date of Issuance through</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Contractual interest expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_99e87089-2733-482b-86f2-fb95cf93c5e2" contextRef="C_9f19eb4c-29fe-474d-b77a-08e5bb571e8e" name="us-gaap:InterestExpenseDebtExcludingAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,546</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_32a3895b-df6f-4722-ba1b-fa8a9867cea0" contextRef="C_1595673f-bb14-4c0c-b50c-19b1db664ef7" name="us-gaap:InterestExpenseDebtExcludingAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,514</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Amortization of debt discount and issuance costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bd559644-15a4-4679-a2c3-c6616e5bb490" contextRef="C_9f19eb4c-29fe-474d-b77a-08e5bb571e8e" name="us-gaap:AmortizationOfFinancingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,342</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_108e2988-9a62-4086-a92e-80fee9ee57e0" contextRef="C_1595673f-bb14-4c0c-b50c-19b1db664ef7" name="us-gaap:AmortizationOfFinancingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,061</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total interest and amortization expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_53b0c67e-090d-47cd-a4d2-f84c42707df1" contextRef="C_9f19eb4c-29fe-474d-b77a-08e5bb571e8e" name="us-gaap:InterestExpenseDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,888</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_79c0a96b-b9ed-43de-b41b-28de0266cdb6" contextRef="C_1595673f-bb14-4c0c-b50c-19b1db664ef7" name="us-gaap:InterestExpenseDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,575</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Debt Maturities</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_efe95fd0-6b2f-4269-aeb5-245dfeeb4e53" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The aggregate scheduled maturities of our convertible debt as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 are as follows:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:80.444%;"/>
        <td style="width:1.8%;"/>
        <td style="width:1%;"/>
        <td style="width:15.757%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Year ending December 31,</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c83c3f98-5561-471a-9b96-3a4b19da82fa" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2f9f31e7-b197-4a90-850f-f0ab03920a9a" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">192,500</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2026</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_205f4cf8-dfd9-4d56-98e9-93f4bc23172a" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2027</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9d1a8422-edb0-4ace-96ae-629bbd1b04c8" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2028</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b0ca7900-0b8e-4ae9-916a-56add4eb2346" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">261,000</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_34f8728f-772a-416a-a036-b6bd1d1aed75" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="us-gaap:DebtInstrumentCarryingAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">453,500</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Deferred Royalty Obligation</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As part of our acquisition of La Jolla, we recorded the fair value of its deferred royalty obligation in connection with La Jolla&#8217;s royalty financing agreement (&#8220;La Jolla Royalty Agreement&#8221;) with HealthCare Royalty Partners (&#8220;HCR&#8221;). Under the terms of the La Jolla Royalty Agreement, HCR is entitled to receive quarterly royalties on worldwide net sales of GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> until either January 1, 2031 or when the maximum aggregate royalty payments have been made, whichever occurs first. Quarterly payments to HCR under the Royalty Agreement start at a maximum royalty rate, with step-downs based on the achievement of annual net product sales thresholds. The current maximum royalty rate is </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e244f9fc-2891-40b9-9bef-163739f814ef" contextRef="C_47540ae3-5ee1-428f-99db-8eab3bc7a785" name="inva:RoyaltyAgreementMaximumPotentialPayoutPercent" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">14</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Starting January 1, 2024, the maximum royalty rate was increased to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6601824d-b285-4a61-b866-0ec48258d069" contextRef="C_47540ae3-5ee1-428f-99db-8eab3bc7a785" name="inva:RoyaltyAgreementIncreaseInMaximumPotentialPayoutPercent" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">18</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% based on the terms of the Agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> The La Jolla Royalty Agreement is subject to maximum aggr</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">egate royalty payments to HCR of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0a631d63-7063-4a98-98a8-d5e97c66677a" contextRef="C_47540ae3-5ee1-428f-99db-8eab3bc7a785" name="inva:RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentTwo" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">225.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the years ended December 31, 2023, we recognized interest expense of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ac1df2eb-161a-4280-add1-8e04fe805781" contextRef="C_a99937e1-764a-4db1-ae21-40947196ea5e" name="us-gaap:InterestExpenseBorrowings" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million on the deferred royalty obligation. From the date of our acquisition of La Jolla through December 31, 2022, we recognized interest expense of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f0fb4fca-b836-44e0-a371-887cfbcb5893" contextRef="C_abc0a929-7e90-463f-b887-b58ca920de42" name="us-gaap:InterestExpenseBorrowings" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million on the deferred royalty obligation. The carrying value of the deferred royalty obligation as of December 31, 2023 and 2022 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_81db57c7-3087-4663-bd45-55a33e96d461" contextRef="C_7cde4835-b322-4448-9e0f-120e1bccc549" name="inva:DeferredRoyaltyObligations" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">69.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9692aec1-2f92-4b70-86d7-978ebbf3aa16" contextRef="C_046580cc-7efc-42fb-b5c6-9fa3ae87d270" name="inva:DeferredRoyaltyObligations" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">70.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively, (refer to Note 9 &#8220;Balance Sheet Components</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">). During the year ended December 31, 2023, we made royalty payments to HCR of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7cad6a2d-fea6-47ac-9a69-8cb76069695b" contextRef="C_a99937e1-764a-4db1-ae21-40947196ea5e" name="inva:RoyaltyPayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. From the date of acquisition of La Jolla through December 31, 2022, we made royalty payments to HCR of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_49c49ec4-e2bd-4fd1-b6fd-755a21122836" contextRef="C_abc0a929-7e90-463f-b887-b58ca920de42" name="inva:RoyaltyPayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The deferred royalty obligation was valued using Level 3 inputs, and its carrying value as of December 31, 2023 and 2022 approximates fair value. The fair value of the deferred royalty obligation was calculated as the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">132</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">discounted </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">deferred royalty obligations based on revenue projections for GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. As of December 31, 2023, the annual effective interest rate of the deferred royalty obligation is </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b4c501df-2806-491d-8f19-6be77571165f" contextRef="C_a99937e1-764a-4db1-ae21-40947196ea5e" name="inva:InterestRateOfDeferredRoyaltyObligation" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">16.46</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the terms of the La Jolla Royalty Agreement, if we are unable to meet certain obligations, including the obligation to use commercially reasonable and diligent efforts to commercialize GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, HCR would have the right to terminate the La Jolla Royalty Agreement and demand payment of either $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_97e7cc18-6045-4cc9-b34d-2e1f547ae367" contextRef="C_47540ae3-5ee1-428f-99db-8eab3bc7a785" name="inva:RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentOne" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">125.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million or $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d612a0ab-2c0a-480d-994a-e1b11f4daa13" contextRef="C_47540ae3-5ee1-428f-99db-8eab3bc7a785" name="inva:RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentTwo" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">225.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million (depending on which obligation we have failed to meet) less aggregate royalties already paid to HCR. As of December 31, 2023, inclusive of the aggregate royalties paid to HCR by La Jolla under the La Jolla Royalty Agreement prior to our acquisition, La Jolla paid $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dfb7d166-1e3d-46e1-b060-f80a71d63a0e" contextRef="C_47540ae3-5ee1-428f-99db-8eab3bc7a785" name="inva:PaymentsForRoyaltyAgreement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">18.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">aggregate royalties to HCR. In the event that we fail to pay such amount if and when due in a timely manner, HCR would have the right to foreclose on the GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">-related assets. HCR has no recourse against any asset other than GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Certain contract provisions within the La Jolla Royalty Agreement that could result in an acceleration of amounts due under the La Jolla Royalty Agreement are recognized as embedded derivatives that require bifurcation from the deferred royalty obligation and fair value recognition. We determined the fair value of each derivative by assessing the probability of each event occurring, as well as the potential repayment amounts and timing of such repayments that would result under various scenarios. As a result of this assessment, we determined that the fair value of the embedded derivatives is immaterial and, therefore, not recognized as of December 31, 2023 and 2022. We estimate the fair value of the embedded derivatives for each reporting period until either the features lapse or the La Jolla Royalty Agreement is terminated, whichever occurs first. Any material change in the fair value of the embedded derivatives will be recorded as either a gain or loss in the consolidated statements of income.</span></p></ix:nonNumeric></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d86927fb-decb-4a8c-8b28-8ca796d0a490" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">13. COMMITMENTS AND CONTINGENCIES</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Operating Lease</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have operating leases for our corporate headquarters, office spaces and laboratory facilities.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our operating leases include a facility lease consisting of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4d5e831e-7356-4e50-9e37-980a43ed330d" contextRef="C_669beef7-e71d-4c69-83c1-57065488410a" name="us-gaap:AreaOfRealEstateProperty" unitRef="U_sqft" decimals="INF" format="ixt:num-dot-decimal">20,062</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> square feet of office and laboratory space in Waltham, Massachusetts. Effective April 2022, we exercised our renewal option for to extend the lease term for three additional years through December 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In 2019, we entered into an operating lease for our headquarters in Burlingame, California for approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7b37f5db-77bf-403d-b066-d4c6715e30eb" contextRef="C_b14e6b43-6384-43b6-9c33-6f1a35010333" name="us-gaap:NetRentableArea" unitRef="U_sqft" decimals="INF" format="ixt:num-dot-decimal">2,111</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> rentable square feet. The lease commenced in November 2019 with an initial term of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_7da350c6-153c-485b-808f-be5a8394009e;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">thirty-six</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> calendar months, which was subsequently amended to expire in December 2027.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b5147742-247f-4521-b9f4-672ab51afec1" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:LeaseCostTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The components of lease costs are as follows:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:67.313%;"/>
        <td style="width:1.5%;"/>
        <td style="width:1%;"/>
        <td style="width:12.843%;"/>
        <td style="width:1%;"/>
        <td style="width:1.5%;"/>
        <td style="width:1%;"/>
        <td style="width:12.843%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Straight line operating lease costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f28a1787-7b21-43b4-8ad6-6977f7f2ee53" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,428</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_78e75855-de36-4672-ba3a-7f61275dd001" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,585</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Variable lease costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_714c2965-70ed-42bf-9d74-7852b7f9f81d" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:VariableLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">189</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_417a283d-c157-42af-ad3b-fef7a437e490" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="us-gaap:VariableLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">155</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total lease costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e079b7f4-f058-419b-b41d-1379ce4c99fb" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,617</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6e9d1d1a-0dae-420e-9eec-d96faaa22122" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,740</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_dc7a1280-1b19-4982-89fc-ef961e4a6c53" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Supplemental cash flow information related to leases are as follows:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:67.313%;"/>
        <td style="width:1.5%;"/>
        <td style="width:1%;"/>
        <td style="width:12.843%;"/>
        <td style="width:1%;"/>
        <td style="width:1.5%;"/>
        <td style="width:1%;"/>
        <td style="width:12.843%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash paid for amounts included in the measurement of <br/>&#160;&#160;&#160;operating lease liabilities:</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_95d54c3e-61d5-46d0-8778-350b1b293063" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,542</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a56bcd41-ca7d-41c9-ae0a-96d514786613" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">790</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease right-of-use assets obtained in exchange <br/>&#160;&#160;&#160;for operating lease obligations</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_67651e79-7caa-483a-8146-b345a86cd55d" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_65fbaebb-c969-4f74-8401-3d99075400ba" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,323</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Right-of-use assets obtained through acquisitions</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8a26630c-6581-4943-a94b-169a91ff761d" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="inva:RightOfUseAssetsObtainedThroughAcquistions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e2d60dd3-9141-44b4-aab1-efbfef1a4bac" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="inva:RightOfUseAssetsObtainedThroughAcquistions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,185</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, our operating leases have weighted-average remaining term of approximately </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_414ba284-c4ca-4eed-867a-f3107230dda8" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2.3</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years and the weighted-average discount rate on our operating lease liabilities was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b5c7853c-4ecb-409e-805a-d70207dfb13c" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="inva:OperatingLeaseWeightedAverageIncrementalBorrowingRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">7.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%.</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">133</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have not presented the comparative information above for the year ended December 31, 2021 as our operating lease during this year was not material.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2629987c-d234-4d83-9b43-64349c24656b" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Future minimum lease payments on our operating leases as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 are as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:80.444%;"/>
        <td style="width:1.8%;"/>
        <td style="width:1%;"/>
        <td style="width:15.757%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Year ending December 31,</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1bff0ed9-9c13-4ad8-9c8d-8f4cca630dba" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,373</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5013ae42-f574-49cf-bf04-bcb7bf1df8eb" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,428</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2026</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9fd43e5c-734d-491a-a079-3d411b31ff1b" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">143</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Thereafter</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cd930406-6595-4ea7-94aa-8b5d618f887a" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="inva:LesseeOperatingLeaseLiabilityToBePaidAfterYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">149</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total undiscounted lease payments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7159a43c-b3e1-4c1d-8c95-9ad811936b69" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,093</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: imputed interest</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e012dab2-3069-4c99-ad22-b9558f62002f" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">251</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">    </span><span><span style="-sec-ix-hidden:F_4335f0ee-8c74-4e0b-beba-133f49c7dc56;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  Total operating lease liabilities</span></span></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_82e888a1-4fa5-40f2-a4dc-801b92a5a357" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,842</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Legal Proceedings</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From time to time, the Company is involved in legal proceedings in the ordinary course of its business. We are not currently a party to any material legal proceedings except as discussed below.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On February 15, 2022, La Jolla received a paragraph IV notice of certification (the &#8220;First Notice Letter&#8221;) from Gland Pharma Limited (&#8220;Gland&#8221;) advising that Gland had submitted an Abbreviated New Drug Application (&#8220;ANDA&#8221;) to the FDA seeking approval to manufacture, use or sell a generic version of GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in the U.S. prior to the expiration of U.S. Patent Nos.: 9,220,745; 9,572,856; 9,867,863; 10,028,995; 10,335,451; 10,493,124; 10,500,247; 10,548,943; 11,096,983; and 11,219,662 (the &#8220;GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Patents&#8221;), which are listed in the FDA&#8217;s Approved Drug Products with Therapeutic Equivalence Evaluations (the &#8220;Orange Book&#8221;). The First Notice Letter alleges that the GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Patents are invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of the generic product described in Gland&#8217;s ANDA.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On March 29, 2022, La Jolla filed a complaint for patent infringement of the GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Patents against Gland and certain related entities in the United States District Court for the District of New Jersey in response to Gland&#8217;s ANDA filing. In accordance with the Hatch-Waxman Act, because GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> is a new chemical entity and La Jolla filed a complaint for patent infringement within 45 days of receipt of the First Notice Letter, the FDA cannot approve Gland&#8217;s ANDA any earlier than 7.5 years from the approval of the GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> NDA unless the District Court finds that all of the asserted claims of the patents-in-suit are invalid, unenforceable and/or not infringed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On February 22, 2023, La Jolla received a paragraph IV notice of certification (the &#8220;Second Notice Letter&#8221;) from Gland advising that Gland had amended its ANDA filing to include a paragraph IV certification alleging that all claims of the newly-issued and Orange Book-listed U.S. Patent No. 11,559,559 (&#8220;the &#8217;559 Patent&#8221;), which covers GIAPREZA&#174;, are invalid, unenforceable and/or not infringed.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On March 22, 2023, La Jolla filed a First Amended Complaint in this litigation adding Gland&#8217;s marketing and distribution partners for its ANDA angiotensin II product, Fresenius Kabi USA LLC and Fresenius Kabi SwissBiosim GmbH (collectively, the &#8220;Fresenius Kabi Defendants&#8221;), as co-defendants. On April 7, 2023, La Jolla filed a Second Amended Complaint in response to the Second Notice Letter, adding claims that the manufacture, use, sale, offer for sale, or import of Gland&#8217;s ANDA angiotensin II product will infringe the &#8217;559 Patent. On November 14, 2023, La Jolla filed a Third Amended Complaint adding additional infringement claims against the Fresenius Kabi Defendants. We intend to vigorously enforce our intellectual property rights relating to GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fact discovery is set to conclude on February 29, 2024 and expert discovery will be complete by July 12, 2024. A trial date has not yet been set in this matter.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Given the early stage of this matter, we cannot reasonably estimate a potential future loss or a range of potential future losses, if any, and have not recorded a contingent liability accrual as of December 31, 2023.</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">134</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Indemnifications and Other Contingencies</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the ordinary course of business, we may provide indemnifications of varying scope and terms to vendors, directors, officers, and other parties with respect to certain matters, including, but not limited to, losses arising out of breach of such agreements, services to be provided by us, our negligence or willful misconduct, violations of law, or intellectual property infringement claims made by third parties. In addition, we have entered into indemnification agreements with directors and certain officers and employees that will require us, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors, officers, or employees. No material demands have been made upon us to provide indemnification under such agreements, and thus, there are no claims that we are aware of that could have a material effect in our consolidated financial statements. We also maintain director and officer insurance, which may cover certain liabilities arising from our obligation to indemnify our directors. To date, we have not incurred any material costs and, as of December 31, 2023, we have not accrued any liabilities in the consolidated financial statements as a result of these provisions.</span></p></ix:nonNumeric></div>
  <div><ix:nonNumeric id="F_a4456011-4edd-4155-8c71-a146cbcec95a" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">14. INCOME TAXES</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d81c565b-640d-4b3c-b235-f608c4a72dab" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Income tax expense consists of the following:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:51.311%;"/>
        <td style="width:1.481%;"/>
        <td style="width:1%;"/>
        <td style="width:12.75%;"/>
        <td style="width:1%;"/>
        <td style="width:1.481%;"/>
        <td style="width:1%;"/>
        <td style="width:12.75%;"/>
        <td style="width:1%;"/>
        <td style="width:1.481%;"/>
        <td style="width:1%;"/>
        <td style="width:12.75%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cae0bbd3-a340-465d-92b9-6294c965c36c" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:CurrentFederalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,799</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3b00f08d-e101-4de2-bddc-fac52396cc34" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="us-gaap:CurrentFederalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">40,822</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ed9158b9-43cb-4145-b6f8-aec6907b5360" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="us-gaap:CurrentFederalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e107cc8e-42be-4532-9be9-a8a30fc8d31e" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,177</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b5edd728-145e-4e6f-848b-3e5b96badc2e" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">464</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b69e5108-f291-485f-9e6e-d13719aec7a4" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total current</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_240ed584-a314-4381-aa37-dea1225f1d1b" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:CurrentIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,976</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6f7928d5-8cc3-4720-be3d-d0ee3ea854a9" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="us-gaap:CurrentIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">41,286</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_52d44819-85c0-483b-b1db-9261a2421112" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="us-gaap:CurrentIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="text-indent:10pt;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a8ca3586-0255-45c2-b40b-144033664eea" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,594</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6148e256-6808-4395-8df5-ed5f8c17fc35" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,026</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_38cc2855-f555-498f-9382-5d78b98171da" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">70,893</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8430ea7c-47f5-46ee-9693-516b4c1a5b22" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,194</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8eb00778-a9b1-47b8-b5c4-9e622694f588" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">625</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_51155404-2c99-4457-b8f6-e261565c9469" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,539</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fd698089-9069-4a10-a5a6-865e6e4c80b8" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,400</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d9b3c4d8-eda9-4825-935f-328c1b70d0c7" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,401</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_52193b2f-eb58-4877-af65-6b7a6f09da93" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">76,432</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="text-indent:5pt;vertical-align:bottom;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total income tax expense, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b031e1ae-b46c-4960-b9ab-7f12945b9024" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,376</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_27ac999d-61c5-4b6f-b305-80b5b80bbea3" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">66,687</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fd0e3767-896d-4dcb-827b-b27a60a95179" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">76,439</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_304f787d-b60f-4005-b3b6-0ffac4a484b6" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The impacts of the differences between the expected U.S. federal statutory income tax to our income tax expense are as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:51.311%;"/>
        <td style="width:1.481%;"/>
        <td style="width:1%;"/>
        <td style="width:12.75%;"/>
        <td style="width:1%;"/>
        <td style="width:1.481%;"/>
        <td style="width:1%;"/>
        <td style="width:12.75%;"/>
        <td style="width:1%;"/>
        <td style="width:1.481%;"/>
        <td style="width:1%;"/>
        <td style="width:12.75%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected tax at federal statutory rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f010d9f0-353a-4a0b-8b54-e10adbb743e0" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">40,747</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8fcd81fe-abd8-4445-93eb-a664702e4cb9" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">58,928</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7b507b21-de11-40a0-84e5-cf4efb1da214" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">93,507</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State income tax, net of federal benefit</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4c4d1508-9912-47dd-aa6b-89230195599d" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,433</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dc74d82a-55af-4cf6-a0e7-9b65a8a73966" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,414</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5b43c2d3-0942-4eac-b141-132f4da191df" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">848</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal and state research credits</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a4671c0b-4c4f-43c7-878a-e80f1da27b29" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,582</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5224486e-c2b1-4ffb-871e-e6ed0afa192b" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,453</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_74abf689-d52c-4069-868b-0bde4c390cb8" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,260</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 250 deduction</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8a6461b2-ae92-44fe-bf66-c4b474a4d15c" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:IncomeTaxReconciliationDeductionsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,274</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_374a9e6d-e5b9-4c14-b5df-e80e23e6c922" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="us-gaap:IncomeTaxReconciliationDeductionsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_79118a2a-45e0-4ab0-bce5-9191a3a0b35b" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="us-gaap:IncomeTaxReconciliationDeductionsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Noncontrolling interest</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_14f47642-bb3b-4d47-82c8-2408656fb0ca" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:IncomeTaxReconciliationMinorityInterestIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_40e810a8-830f-4a0c-8a9c-a37ebae4e8d3" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="us-gaap:IncomeTaxReconciliationMinorityInterestIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">7,468</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f9360b69-e56e-4c71-a7b0-c05733fe7457" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="us-gaap:IncomeTaxReconciliationMinorityInterestIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,626</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Impact of consolidation and deconsolidation of subsidiaries</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c9d37bb1-2d12-4b62-8833-6d7b95215eaf" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_85d4fcee-0037-4de1-bb9b-8a2e5994c1ff" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="us-gaap:IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">8,897</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_11b12143-fe96-4e91-bd5a-b907ecabc32a" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="us-gaap:IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1fe5b857-ff9d-425f-8c4e-258c66188b9d" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,219</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ee8db7f3-73ed-4be2-bdbb-860707e1c6f1" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">125</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_441f228b-36ef-400f-862a-48d33de974ce" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,129</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3bf0413b-1753-492c-a020-fc4e7f6f245c" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">12,167</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fffb7dca-c234-4d19-ae37-2829c3835079" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,180</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5111b844-1563-4a41-83a1-41cad1559818" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,321</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total income tax expense, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2993d321-025b-46e6-8a5e-531c3bd54201" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,376</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5f70aded-57ec-444e-8e64-4af20a597208" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">66,687</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_758d085a-a9d5-4f6a-a516-06bfff3b1e91" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">76,439</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">135</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fee71e65-1ad7-4401-9973-4245d9ffb94f" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" escape="true" continuedAt="F_fee71e65-1ad7-4401-9973-4245d9ffb94f_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Significant components of our deferred tax assets and deferred tax liabilities are as follows:</span></ix:nonNumeric></span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_fee71e65-1ad7-4401-9973-4245d9ffb94f_1"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:56.36%;"/>
        <td style="width:2%;"/>
        <td style="width:1%;"/>
        <td style="width:17.82%;"/>
        <td style="width:1%;"/>
        <td style="width:2%;"/>
        <td style="width:1%;"/>
        <td style="width:17.82%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax assets</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a68e1546-b23e-41e2-8edb-6fbe1bc56e3d" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">182,013</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9ba58509-077c-4d13-8a9a-7c14c9bc8c1b" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">149,646</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development tax credit carryforwards</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_16fa89d1-46d8-4804-bfd1-2c3f31764b5b" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,357</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_af802ca1-3a41-4b0a-b52d-0cccc570495a" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,230</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unrealized loss on investment, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3d7d346b-8390-4f16-8ee4-853618f4a727" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="inva:DeferredTaxAssetsUnrealizedLossesOnInvestmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3ff87072-0b88-4c22-a4d5-5c6f2f7dff82" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" name="inva:DeferredTaxAssetsUnrealizedLossesOnInvestmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,032</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred royalty obligation, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_81da5f42-0b6e-45c7-82fc-85dc4df3e182" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="inva:DeferredTaxAssetsDeferredRoyaltyObligationNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,084</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3e01b464-f506-47a3-b005-114c52b717fb" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" name="inva:DeferredTaxAssetsDeferredRoyaltyObligationNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,404</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1ff7badb-7d28-4ff4-b342-a90806de2f0b" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,467</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_81f0a9a5-8def-4380-ad8a-9ae00c81c76d" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,527</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred tax assets before valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2105104e-8753-47dd-8ed8-5d3623582346" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">227,921</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a14a5fff-b4af-41b3-ab52-d5e8bf4e48d4" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">202,839</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_28ad28c8-736f-48a4-8571-49da3b912dc8" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">169,249</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eeddd89c-577f-4dd4-8407-fc9c27fe976f" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">144,808</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0286f692-ae0b-4775-b71f-973a2fb1ace4" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">58,672</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_75489f29-e08c-48d3-ae16-6b3dee39ac1d" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">58,031</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax liabilities</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Depreciation and amortization</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fe6da3dc-0e84-4852-9311-f9192c8b1624" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="inva:DeferredTaxLiabilitiesDepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">39,064</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4859a712-3da0-475a-af4e-f9a181a27b70" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" name="inva:DeferredTaxLiabilitiesDepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">50,587</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unrealized gain on investment, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_334ccf84-c8ef-4e20-81e5-43785a6ebf7c" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="us-gaap:DeferredTaxLiabilitiesInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,747</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_41e7df49-c874-41bf-862b-6482fd980bcc" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" name="us-gaap:DeferredTaxLiabilitiesInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inventory fair value adjustment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1651f3c2-c3d1-4f7d-a7a6-1d0353e6b22a" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="inva:DeferredTaxLiabilitiesInventoryFairValueAdjustment" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">6,424</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_562d2225-5687-4373-96c0-712ac451728d" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" name="inva:DeferredTaxLiabilitiesInventoryFairValueAdjustment" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">12,410</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1ccb0ca0-a8d6-4e6b-8386-1252ab6253e2" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="us-gaap:DeferredTaxLiabilitiesOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f9d451df-8648-46bd-b3c5-e790ce70c3d0" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" name="us-gaap:DeferredTaxLiabilitiesOther" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">805</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net deferred tax liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ff4be056-754f-4e7f-b0c9-6558242306ba" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">563</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4490f298-8e3b-4436-b079-58a89e034338" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,771</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></ix:continuation></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We record deferred tax assets if the realization of such assets is more likely than not to occur. Significant management judgment is required in determining whether a valuation allowance against the deferred tax assets is required. We have considered all available evidence, both positive and negative, such as our historical operating results and predictability of future taxable income, in making such determination. We are also required to exercise significant management&#8217;s judgment in forecasting future taxable income. Specifically, we evaluate the following criteria when considering a valuation allowance:</span></p><div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the history of tax net operating losses in recent years;</span></div></div><div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">predictability of operating results;</span></div></div><div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">profitability for a sustained period of time; and</span></div></div><div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">level of profitability on a quarterly basis.</span></div></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we had federal net operating loss carryforwards of approximately </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_81ac6b5d-e388-4636-b05e-87fc45efd0f7" contextRef="C_552da0c1-853f-4893-a1b0-a4223d212e95" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">543.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, which will expire beginning 2034. As of December 31, 2023, we also had state net operating loss carryforwards of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a8c2120b-b196-4bb2-9b80-f8f56dc66af2" contextRef="C_5f1754a6-1e81-4cbd-8bf9-4f5f1ce7bd5f" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="9" decimals="-8" format="ixt:num-dot-decimal">1.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> billion</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, which will expire beginning 2029 and state research tax credits of approximately </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fbab969c-a360-4a7f-8adb-c7fe38f24ab9" contextRef="C_8e9e31d1-92be-49a8-9a9a-67c314bf7e73" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">33.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, which do not expire.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Utilization of net operating loss and tax credit carryforwards may be subject to a substantial annual limitation due to ownership change limitations provided by the Internal Revenue Code and similar state provisions. Annual limitations may result in expiration of net operating loss and tax credit carryforwards before some or all of such amounts have been utilized.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We conducted an Internal Revenue Code of 1986, as amended, Section 382 (&#8220;Section 382&#8221;) analysis of the Company through December 31, 2022 to determine whether an ownership change had occurred since inception. The Section 382 study concluded that it is more likely than not that the Company did not experience an ownership change during the testing period. If we ever undergo an ownership change, the utilization of the pre-ownership change net operating loss carryforwards or pre-ownership change tax attributes, such as research tax credits, to offset the post-ownership change income may be subject to an annual limitation, pursuant to Sections 382 and 383 of the Internal Revenue Code of 1986, as amended. Similar rules may apply under state tax laws.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a result of the acquisition of Entasis, we conducted a study of Entasis&#8217; ownership changes and estimated that we will be able to utilize $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5ed97001-680f-41fb-938f-eb4d14751420" contextRef="C_09977380-7092-418e-b4d3-d48f7caaae46" name="inva:FederalNetOperatingLossesEstimatedUtilizationAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">155.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of its federal net operating losses, which are subject to annual limitations.</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">136</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a result of the acquisition of La Jolla, we also performed an analysis of its ownership changes and estimated that we will be able to utilize $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f526b038-626c-46ab-89f9-d1d19ee1cbf9" contextRef="C_9b30963d-d42c-4ba2-85ac-e1f548c6e616" name="inva:FederalNetOperatingLossesEstimatedUtilizationAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">309.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of its federal net operating losses, which are subject to annual limitations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our policy is to recognize interest and/or penalties related to income tax matters in income tax expense. As of December 31, 2023 and 2022, we had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d707e5a3-fea6-464f-bd99-31fd83fc546b" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_e2480865-8173-4b25-955f-a854f1b74535" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> accrued interest or penalties due to the Company</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8217;s net operating losses available to offset any tax adjustments.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Uncertain Tax Positions</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d109e6dd-7872-45ea-ab18-5cb6587c55d4" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A reconciliation of the beginning and ending balances of the total amounts of unrecognized tax benefits are as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:76.46%;"/>
        <td style="width:2.34%;"/>
        <td style="width:1%;"/>
        <td style="width:19.2%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unrecognized tax benefits as of December 31, 2020</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5279e76e-ddf3-4596-affe-d78519e490bd" contextRef="C_646bb33b-4ef6-4493-b542-00c92f556418" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,185</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net decrease in tax portions for 2021</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_66d4f817-b7ba-4935-a175-1f96945f8fc8" contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">313</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unrecognized tax benefits as of December 31, 2021</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e732bbbc-53f6-405a-a931-71b96be1fe93" contextRef="C_c2c8ab67-08be-4854-91e3-98e911bef5b3" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,872</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net increase in tax portions for 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_33419dca-cd50-4d3c-9c45-9be7f3912a5c" contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,452</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unrecognized tax benefits as of December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_95c4c416-662c-4c9e-b750-ee7a08bab147" contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,324</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net increase in tax portions for 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_55629020-4237-4ba8-9c41-02deaa428553" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,119</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unrecognized tax benefits as of December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_17040fe0-7815-4fda-8ee2-2339bc4bade4" contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,443</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are subject to taxation in the U.S. and various state jurisdictions. The tax years 2006 through 2013, 2015 and forward remain open to examination by the federal and most state tax authorities due to net operating loss and overall credit carryforward positions.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2021, the Organization for Economic Cooperation and Development (&#8220;OECD&#8221;) enacted model rules for a new global minimum tax framework (&#8220;BEPS Pillar Two&#8221;), and various governments around the world have enacted, or are in the process of enacting legislation. We are in the process of evaluating whether and when these new rules may come into effect and apply to us.  We plan to treat the tax if any as a period cost. We do not believe that the Pillar Two rules apply to us yet.  As such, the potential future quantitative impact of the enacted or substantively enacted legislation is not yet reasonably estimable.</span></p></ix:nonNumeric></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ed2bb416-e5ab-4d76-bca2-773282e576b4" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="us-gaap:SubsequentEventsTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">15. SUBSEQUENT EVENTS</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On February 13, 2024, ITH entered into a Third Note Amendment Agreement with Gate to amend the Gate Convertible Note. Pursuant to the Third Note Amendment Agreement, the principal amount of the Gate Convertible Note was increased from $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ff961027-d441-4045-9603-ba80fea6416e" contextRef="C_ea704773-4bd5-40ed-9730-d6a668d17624" name="us-gaap:DebtInstrumentFaceAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">27.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dd992304-852d-4b12-b9d1-de1e03725b42" contextRef="C_3b21613e-2472-472e-b92e-7b218fb6aecc" name="us-gaap:DebtInstrumentFaceAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">33.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which represents the principal and accrued interest as of the amendment date and an additional cash investment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3b127812-7f71-4b32-9902-796fd7ca45f2" contextRef="C_825c0bd4-909c-4d86-9ae9-0ce6eb8cdcf2" name="us-gaap:PaymentsToAcquireLongtermInvestments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. All other material terms of the Gate Convertible Note were unchanged.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On February 23, 2024, ITH purchased a subordinated convertible promissory note (the &#8220;ImaginAb Convertible Note&#8221;) from ImaginAb for a total purchase price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1e265029-1ed9-4a12-a74e-975d953f6153" contextRef="C_1ba9463a-d1f5-4a30-bbac-3bc5aad6339b" name="us-gaap:DebtInstrumentCarryingAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The ImaginAb Convertible Note bears an annual interest of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_470017ab-b51e-40e4-9a3e-96c1804827e1" contextRef="C_1ba9463a-d1f5-4a30-bbac-3bc5aad6339b" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">10</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% and shall be due and payable upon the earlier to occur of January 31, 2025 and certain events defined in the ImaginAb Convertible Note. Under certain circumstances, the ImaginAb Convertible Note is convertible at the option of ITH into ImaginAb&#8217;s equity securities at defined conversion prices. The ImaginAb Convertible Note is subordinate to certain existing indebtedness of ImaginAb as defined in the ImaginAb Convertible Note.</span></p></ix:nonNumeric></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">137</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:center;" id="reports_of_independent_registered_1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">REP</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To the Stockholders and the Board of Directors of Innoviva, Inc.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Opinion on the Financial Statements</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have audited the accompanying consolidated balance sheets of Innoviva, Inc. and subsidiaries (the &#8220;Company&#8221;) as of December 31, 2023 and 2022, the related consolidated statements of income, comprehensive income, shareholders&#8217; equity, and cash flows, for each of the two years in the period ended December 31, 2023, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2023 and 2022, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2023, in conformity with accounting principles generally accepted in the United States of America.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company&#8217;s internal control over financial reporting as of December 31, 2023, based on criteria established in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Internal Control&#8212;Integrated Framework (2013) </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report dated February 29, 2024, expressed an unqualified opinion on the Company&#8217;s internal control over financial reporting.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basis for Opinion</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Critical Audit Matter</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The critical audit matter communicated below is a matter arising from the current-period audit of the financial statements that was communicated or required to be communicated to the audit committee and that (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Consolidated Entities and Equity and Long-term Investments&#8212;Primary Beneficiary Determination for Variable Interest Entity&#8212;Refer to Notes 1, 5, and 6 to the consolidated financial statements.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Critical Audit Matter Description</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company invests in equity and debt securities of private and public companies. The Company evaluates its interests in these entities to determine whether they meet the definition of a variable interest entity (VIE) or a voting interest entity (VOE) and whether the Company is required to consolidate these entities. A VIE is consolidated by its primary beneficiary, which is the party that has both 1) the power to direct the activities that most significantly impact the economic performance of the VIE and 2) a variable interest that could potentially be significant to the VIE. To determine whether a variable interest that the Company holds could potentially be significant to the VIE, the Company considers both qualitative and quantitative factors regarding the nature, size, and form of the Company&#8217;s involvement with the VIE. The Company will reconsider whether an entity is a VIE and whether the Company is the primary beneficiary of the entity upon the occurrence of certain types of events. The determination of the primary beneficiary of a VIE requires significant management judgement.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">138</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We identified the primary beneficiary determination for the Company&#8217;s VIEs as a critical audit matter due to the complexity of the accounting principles related to the determination of the primary beneficiary of a VIE and the significant judgment required by management in evaluating the agreements and structure of the investments in determining the primary beneficiary of a VIE. This required a high degree of auditor judgment and an increased extent of effort, including the involvement of professionals with consolidation accounting expertise, when performing audit procedures to evaluate the Company&#8217;s determination of whether it is the primary beneficiary for its VIEs.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">How the Critical Audit Matter Was Addressed in the Audit</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our audit procedures related to the primary beneficiary determination for VIEs included the following, among others:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We tested the effectiveness of controls over the Company&#8217;s primary beneficiary determination for its VIEs, including management&#8217;s determination of the party that has the power to direct the activities that most significantly impact the economic performance of the VIE and a variable interest that could potentially be significant to the VIE.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We evaluated the appropriateness of the Company&#8217;s accounting conclusions for consolidated and unconsolidated VIEs through the following:</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.989278055754109%;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Evaluated the investment structures and terms of the agreements, including reading the purchase agreements and other related documents.</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.989278055754109%;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Tested whether the Company appropriately determined the primary beneficiary by evaluating the contractual arrangements of the entity to determine if the Company has the power to direct activities that most significantly impact the economic performance of the VIE and if the Company has the obligation to absorb losses of the entity or the right to receive benefits from the entity that could be significant to the VIE.</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.989278055754109%;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For certain VIEs, with the assistance of professionals with expertise in consolidation accounting, evaluated the appropriateness of the Company&#8217;s determination of the primary beneficiary of the VIE.</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.989278055754109%;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Evaluated the Company&#8217;s disclosures related to the primary beneficiary determination of its consolidated entities and equity and long-term investments.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/s/ Deloitte &amp; Touche LLP</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">San Jose, California</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">February 29, 2024</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have served as the Company's auditor since 2022.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">139</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:center;" id="report_of_independent_registered_public"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To the Stockholders and Board of Directors of Innoviva, Inc.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Opinion on the financial statements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have audited the consolidated balance sheet of Innoviva, Inc. (a Delaware corporation) and subsidiaries (the &#8220;Company&#8221;) as of December 31, 2021 (not presented herein), the related consolidated statements of income, comprehensive income, changes in stockholders&#8217; equity, and cash flows for the year then ended, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2021, and the results of its operations and its cash flows for the year then ended, in conformity with accounting principles generally accepted in the United States of America.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basis for opinion</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/s/ GRANT THORNTON LLP</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We served as the Company&#8217;s auditor from 2019 to 2021.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">San Francisco, California</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">February 29, 2024</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">140</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:-8.696%;padding-left:8%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;" id="item_9_changes_in_and_disagreements_with"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM 9.  CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;" id="item_9a_controls_and_procedures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM 9A. CONTROLS AND PROCEDURES</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Evaluation of Disclosure Controls and Procedures.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We conducted an evaluation as of December 31, 2023, under the supervision and with the participation of our management, including our chief executive officer and chief accounting officer, of the effectiveness of the design and operation of our disclosure controls and procedures, which are defined under SEC rules as controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files under the Securities Exchange Act of 1934 (Exchange Act) is recorded, processed, summarized and reported within required time periods specified in the Commission&#8217;s rules and forms and controls and procedures that are designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Exchange Act is accumulated and communicated to the issuer&#8217;s management including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decision regarding required disclosure. Based upon that evaluation, our principal executive officer and principal financial officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance levels.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Management&#8217;s Report on Internal Control over Financial Reporting</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rule 13a&#8209;15(f) of the Exchange Act. Internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting based on criteria established in the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Internal Control&#8212;Integrated Framework</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework). Management&#8217;s assessment included evaluation of such elements as the design and operating effectiveness of key financial reporting controls, process documentation, accounting policies, and our overall control environment. Based on this evaluation, our management concluded that our internal control over financial reporting was effective as of December 31, 2023.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our independent registered public accounting firm, Deloitte &amp; Touche LLP, has audited our internal control over financial reporting as of December 31, 2023. Their attestation report on the audit of our internal control over financial reporting is included below.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Limitations on the Effectiveness of Controls</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our management, including our principal executive officer and principal financial officer, does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent all errors and all frauds. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefit of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within Innoviva have been detected. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">141</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Changes in Internal Control over Financial Reporting</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We completed our acquisitions of Entasis and La Jolla in 2022. We integrated the acquired operations and processes into our internal control environment and implemented necessary changes to our internal control over financial reporting, including, but not limited, to the creation of new controls related to inventory management, research and development activities and product sales.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other than the above, there have been more material changes to our internal control over financial reporting (as defined in Rule 13a-15(f) of the Exchange Act) for the year ended December 31, 2023 which have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">142</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To the Stockholders and the Board of Directors of Innoviva, Inc.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Opinion on Internal Control over Financial Reporting</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have audited the internal control over financial reporting of Innoviva, Inc. and subsidiaries (the &#8220;Company&#8221;) as of December 31, 2023, based on criteria established in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Internal Control&#8212;Integrated Framework (2013)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2023, based on criteria established in</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> Internal Control&#8212;Integrated Framework (2013)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> issued by COSO.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated financial statements as of and for the year ended December 31, 2023, of the Company and our report dated February 29, 2024, expressed an unqualified opinion on those financial statements.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basis for Opinion</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management&#8217;s Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Definition and Limitations of Internal Control over Financial Reporting</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions or that the degree of compliance with the policies or procedures may deteriorate.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/s/ </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_47568f74-f4b9-4b5a-908a-352d18716ad9" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="dei:AuditorName"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Deloitte &amp; Touche LLP</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c1246bbf-3a43-430f-addb-10571caa5744" contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1" name="dei:AuditorLocation"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">San Jose, California</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">February 29, 2024</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">143</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;" id="item_9b_other_information"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM 9B. OTHER INFORMATION</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Trading Arrangements</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None of the Company&#8217;s directors or officers </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d7a62b0f-0b0c-4521-b31a-3153357f191b" contextRef="C_d5f73726-2a05-4be7-87fa-3fd6369578ba" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_27712b0b-3359-4939-92dd-bd559b24e741" contextRef="C_d5f73726-2a05-4be7-87fa-3fd6369578ba" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">adopted</span></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1bba5060-2cd3-4d71-b702-cdec62395141" contextRef="C_d5f73726-2a05-4be7-87fa-3fd6369578ba" name="inva:Rule10B51ArrModifiedFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_f521b277-acbb-4d90-bf98-bc45f037f7a8" contextRef="C_d5f73726-2a05-4be7-87fa-3fd6369578ba" name="inva:NonRule10B51ArrModifiedFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">modified</span></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, or </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f85b2d46-3cb9-4f9e-89c9-5b3cd1546844" contextRef="C_d5f73726-2a05-4be7-87fa-3fd6369578ba" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_2d7d9811-ad17-480c-9299-717f1011ae72" contextRef="C_d5f73726-2a05-4be7-87fa-3fd6369578ba" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">terminated</span></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement during the Company&#8217;s fiscal quarter ended December 31, 2023.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;" id="item_9c_disclosure_regarding_foreign_jur"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM 9C. DISCL</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">OSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Not applicable.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">144</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:center;" id="part_iii"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PART III</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;" id="item_10_directors_executive_officers_and"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information required by this Item is incorporated by reference from our proxy statement for our 2024 Annual Meeting of Stockholders to be filed with the SEC within 120 days after the end of our fiscal year ended December 31, 2023.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;" id="item_11_executive_compensation"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM 11. EXECUTIVE COMPENSATION</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information required by this Item is incorporated by reference from our proxy statement for our 2024 Annual Meeting of Stockholders to be filed with the SEC within 120 days after the end of our fiscal year ended December 31, 2023.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:-9.012%;padding-left:8.267%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;" id="item_12_security_ownership_of_certain"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other than with respect to the Securities Authorized for Issuance under Equity Compensation Plans below, the information required by this Item is incorporated by reference from our proxy statement for our 2024 Annual Meeting of Stockholders to be filed with the SEC within 120 days after the end of our fiscal year ended December 31, 2023.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Securities Authorized for Issuance under Equity Compensation Plans</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table provides certain information with respect to all of our equity compensation plans in effect as of December 31, 2023:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:55.418%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:10.816%;"/>
    <td style="width:1%;"/>
    <td style="width:1.559%;"/>
    <td style="width:1%;"/>
    <td style="width:10.816%;"/>
    <td style="width:1%;"/>
    <td style="width:1.559%;"/>
    <td style="width:1%;"/>
    <td style="width:10.816%;"/>
    <td style="width:1%;"/>
    <td style="width:2.019%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Plan Category</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of securities to be issued upon exercise of outstanding options and vesting of outstanding restricted stock units and restricted stock awards</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted&#8209;average exercise price of outstanding options</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a))</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(a)</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(b)</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(c)</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Equity compensation plans approved by security holders</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,981,403</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(1)</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14.09</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(2)</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,424,185</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">&#160;(3)</span></p></td>
   </tr>
  </table>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;min-width:3.333%;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Includes 1,499,312 shares issuable upon exercise of outstanding options and 482,091 shares issuable upon vesting of outstanding RSUs and RSAs.</span></div></div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;min-width:3.333%;display:inline-flex;justify-content:flex-start;">(2)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Does not take into account outstanding restricted stock units as these awards have no exercise price.</span></div></div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;min-width:3.333%;display:inline-flex;justify-content:flex-start;">(3)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Includes 2,500,00 shares of common stock available under our Employee Stock Purchase Plan.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;" id="item_13_certain_relationships_and"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information required by this Item is incorporated by reference from our proxy statement for our 2024 Annual Meeting of Stockholders to be filed with the SEC within 120 days after the end of our fiscal year ended December 31, 2023.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;" id="item_14_principal_accounting_fees_and"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information required by this Item is incorporated by reference from our proxy statement for our 2024 Annual Meeting of Stockholders to be filed with the SEC within 120 days after the end of our fiscal year ended December 31, 2023.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">145</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;" id="part_iv"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PART IV</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;" id="item_15_exhibits_and_financial_statement"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(a)   The following documents are filed as part of this Annual Report on Form 10&#8209;K:</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1.    Financial Statements:</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following financial statements and schedules of the Registrant are contained in Part II, Item 8, &#8220;Financial Statements and Supplementary Data&#8221; of this Annual Report on Form 10&#8209;K:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:93.8%;"/>
    <td style="width:6.2%;"/>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:7.2pt;vertical-align:bottom;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="text-indent:7.2pt;vertical-align:bottom;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Page</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_balance_sheets"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Balance Sheets as of December 31, 2023 and 2022</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">93</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statements_of_income"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Statements of Income for each of the three years in the period ended December 31, 2023</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">94</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statements_of_comprehensive"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Statements of Comprehensive Income for each of the three years in the period ended December 31, 2023</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">95</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statements_of_stockholders"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Statements of Stockholders&#8217; Equity for each of the three years in the period ended December 31, 2023</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">96</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statements_of_cash_flows"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Statements of Cash Flows for each of the three years in the period ended December 31, 2023</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">97</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#notes_to_consolidated_financial"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Notes to Consolidated Financial Statements</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">98</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#reports_of_independent_registered_1"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Reports of Independent Registered Public Accounting Firm (PCAOB ID 34)</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">138</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#report_of_independent_registered_public"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Report of Independent Registered Public Accounting Firm (PCAOB ID 248)</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">140</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2.    Financial Statement Schedules:</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All schedules have been omitted because of the absence of conditions under which they are required or because the required information, where material, is shown in the financial statements, financial notes or supplementary financial information.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(b)   Exhibits required by Item 601 of Regulation S&#8209;K:</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information required by this Item is set forth on the exhibit index that follows the signature page of this report.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;" id="item_16_form_10_k_summary"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM 16. FORM 10&#8209;K SUMMARY</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">146</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="exhibits"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibits</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:7.58%;"/>
    <td style="width:2%;"/>
    <td style="width:55%;"/>
    <td style="width:1.02%;"/>
    <td style="width:7%;"/>
    <td style="width:1%;"/>
    <td style="width:7%;"/>
    <td style="width:1%;"/>
    <td style="width:9%;"/>
    <td style="width:1%;"/>
    <td style="width:8.4%;"/>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="5" style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Incorporated by Reference</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Filed Herewith</span></p></td>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><br/></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">    </span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Description</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">    </span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Form</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">    </span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">    </span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Filing</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><br/></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Date/Period</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><br/></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">End Date</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;text-align:left;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.1</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000114036122020321/ny20004305x1_ex2-1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Agreement and Plan of Merger, dated as of May 23, 2022, by and among Innoviva, Inc., Innoviva Merger Sub, Inc. and Entasis Therapeutics</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.1</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5/24/2022</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;text-align:left;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.2</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000114036122025657/ny20004741x1_ex2-1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Agreement and Plan of Merger, dated as of July 10, 2022, by and among Innoviva, Inc., Innoviva Acquisition Sub, Inc. and La Jolla Pharmaceutical Company</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.1</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7/11/2022</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;text-align:left;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.1</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000110465916115299/a16-9600_1ex99d2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amended and Restated Certificate of Incorporation</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8&#8209;K</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">99.2</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4/28/2016</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;text-align:left;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.2</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000110465923000897/tm231444d1_ex3-1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amended and Restated Bylaws, amended and restated as of January 1, 2023</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8&#8209;K</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.1</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1/4/2023</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;text-align:left;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.1</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000110465907015079/a07-1942_1ex4d1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Specimen certificate representing the common stock of the registrant</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10&#8209;K</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.1</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12/31/2006</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;text-align:left;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.2</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000110465913004773/a12-25051_9ex4d1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Indenture, dated as of January 24, 2013 by and between Theravance, Inc. and The Bank of New York Mellon Trust Company, N.A., as trustee</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8&#8209;K</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.1</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1/25/2013</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;text-align:left;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.3</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000110465913004773/a12-25051_9ex4d1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of 2.125% Convertible Subordinated Note Due 2023 (included in Exhibit 4.4</span></a><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">)</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.2</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1/25/2013</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;text-align:left;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.4</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000110465917049927/a17-18560_4ex4d1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Indenture (including form of Note) with respect to Innoviva&#8217;s 2.50% Convertible Senior Notes due 2025, dated as of August 7, 2017, between Innoviva and The Bank of New York Mellon Trust Company, N.A., as trustee</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8&#8209;K</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.1</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8/7/2017</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;text-align:left;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.5</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000110465920022807/ex-4d9.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Description of Registrant&#8217;s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-K</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.9</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2/19/2020</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;text-align:left;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.6</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000110465922031613/tm228653d1_ex4-1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Indenture (including form of Note) with respect to Innoviva's 2.125% Convertible Senior Notes due 2028, dated as of March 7, 2022, between Innoviva, Inc. and The Bank of New York Mellon Trust Company, N.A., as trustee</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.1</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3/8/2022</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;text-align:left;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.2</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000110465914058343/a14-13984_1ex10d1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Collaboration Agreement between the registrant and Glaxo Group Limited, dated as of November 14, 2002</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10&#8209;Q</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.1</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6/30/2014</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;text-align:left;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.3</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000104746904020116/a2136994zex-10_13.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amended and Restated Investors&#8217; Rights Agreement by and among the registrant and the parties listed therein, dated as of May 11, 2004</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">S&#8209;1</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.13</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6/10/2004</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;text-align:left;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.4*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000104746914001691/a2218387zex-10_13.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Strategic Alliance Agreement between the registrant and Glaxo Group Limited, dated as of March 30, 2004</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10&#8209;K</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.13</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12/31/2013</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;text-align:left;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.5+</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000104746910001540/a2196645zex-10_22.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Description of Cash Bonus Program, as amended</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10&#8209;K</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.22</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12/31/2009</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;text-align:left;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.6+</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000104746910001540/a2196645zex-10_47.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amendment to Change in Control Severance Plan effective December 16, 2009</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10&#8209;K</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.47</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12/31/2009</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;text-align:left;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.7+</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000104746910001540/a2196645zex-10_48.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">2009 Change in Control Severance Plan adopted December 16, 2009</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10&#8209;K</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.48</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12/31/2009</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;text-align:left;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.8</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000110465910060202/a10-21843_1ex10d2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Second Amendment to Amended and Restated Governance Agreement among the registrant, Glaxo Group Limited, GlaxoSmithKline plc and GlaxoSmithKline LLC, dated as of November 29, 2010</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8&#8209;K</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.2</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11/29/2010</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;text-align:left;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.9</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000104746912001614/a2207068zex-10_34.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amendment to Strategic Alliance Agreement, dated October 3, 2011</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10&#8209;K</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.34</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12/31/2011</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;text-align:left;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.10+</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000110465912053222/a12-11849_1ex10d38.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">2012 Equity Incentive Plan, as approved by the board of directors February 8, 2012 and approved by stockholders May 16, 2012 and forms of equity award</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10&#8209;Q</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.38</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6/30/2012</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;text-align:left;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.11</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000110465913003879/a12-25051_8ex10d1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Base Capped Call Transaction, dated January 17, 2013</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8&#8209;K</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.1</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1/23/2013</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;text-align:left;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.12</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000110465913003879/a12-25051_8ex10d2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Additional Capped Call Transaction, dated January 18, 2013</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8&#8209;K</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.2</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1/23/2013</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;text-align:left;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.13</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000110465914017128/a14-7412_1ex10d1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Master Agreement by and among Theravance, Inc., Theravance Biopharma, Inc. and Glaxo Group Limited, dated March 3, 2014</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8&#8209;K/A</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.1</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3/6/2014</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;text-align:left;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.14*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000110465914017128/a14-7412_1ex10d2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Collaboration Agreement Amendment by and between Theravance, Inc. and Glaxo Group Limited, dated March 3, 2014</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8&#8209;K/A</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.2</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3/6/2014</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;text-align:left;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.15*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000110465914017128/a14-7412_1ex10d3.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Strategic Alliance Agreement Amendment by and between Theravance, Inc. and Glaxo Group Limited, dated March 3, 2014</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8&#8209;K/A</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.3</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3/6/2014</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;text-align:left;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.16</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000110465914044231/a14-14482_1ex10d2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Transition Services Agreement between Theravance and Theravance Biopharma, dated June 2, 2014</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8&#8209;K</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.2</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6/5/2014</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;text-align:left;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.17</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000110465914044231/a14-14482_1ex10d3.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Tax Matters Agreement between Theravance and Theravance Biopharma, dated June 2, 2014</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8&#8209;K</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.3</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6/5/2014</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">147</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:7.58%;"/>
    <td style="width:2%;"/>
    <td style="width:55%;"/>
    <td style="width:1.02%;"/>
    <td style="width:7%;"/>
    <td style="width:1%;"/>
    <td style="width:7%;"/>
    <td style="width:1%;"/>
    <td style="width:9%;"/>
    <td style="width:1%;"/>
    <td style="width:8.4%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;text-align:left;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.18</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000110465914044231/a14-14482_1ex10d4.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Employee Matters Agreement between Theravance and Theravance Biopharma, dated June 1, 2014</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8&#8209;K</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.4</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6/5/2014</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;text-align:left;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.19</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000110465914044231/a14-14482_1ex10d5.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Theravance Respiratory Company, LLC Limited Liability Company Agreement between Theravance and Theravance Biopharma, dated May 31, 2014</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8&#8209;K</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.5</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6/5/2014</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;text-align:left;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.20</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000110465915036218/a15-7167_1ex10d64.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amendment/Clarification to Transition Services Agreement between Theravance and Theravance Biopharma, dated March 2, 2015</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10&#8209;Q</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.64</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3/31/2015</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;text-align:left;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.21+</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000110465915054328/a15-16369_1ex10d2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">First Amendment to 2009 Change In Control Severance Plan (Renamed 2009 Severance Plan)</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8&#8209;K</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.2</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7/29/2015</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;text-align:left;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.22</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000104746918001016/a2234562zex-10_76.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Notice of Performance&#8209;Based Restricted Stock Award and Restricted Stock Award Agreement under 2012 Equity Incentive Plan (director form)</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10&#8209;K</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.76</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2/23/2018</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;text-align:left;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.23+</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000110465918047409/a18-14089_1ex10d81.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Second Amendment to 2009 Severance Plan</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10&#8209;Q</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.81</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7/26/2018</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;text-align:left;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.24+</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000089914018000502/i25948910b.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Offer Letter with Marianne Zhen, dated September 7, 2018</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8&#8209;K</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.1</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9/11/2018</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;text-align:left;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.25+</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000089914020000275/i35135265b.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Offer Letter between Innoviva, Inc. and Pavel Raifeld, dated May 20, 2020</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8&#8209;K</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.1</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5/26/2020</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;text-align:left;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.26+</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000089914022000493/i5271437b.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Offer Letter between Innoviva, Inc. and Pavel Raifeld, dated April 29, 2022</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.1</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5/2/2022</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;text-align:left;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.27</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000119312520316331/d69428dex101.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Strategic Advisory Agreement, dated as of December 11, 2020, by and between Sarissa Capital Management LP and Innoviva, Inc.</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8&#8209;K</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.1</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12/14/2020</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;text-align:left;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.28</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000119312520316331/d69428dex102.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amended and Restated Limited Partnership Agreement of ISP Fund LP, dated as of December 11, 2020, by and among ISP Fund LP, Sarissa Capital Fund GP LP, Innoviva Strategic Partners LLC and the other parties named therein</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8&#8209;K</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.2</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12/14/2020</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;text-align:left;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.29</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000089914021000501/i052021b.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Share Repurchase Agreement, dated as of May 2021, by and between Innoviva, Inc. and Glaxo Group Limited</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.1</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5/20/2021</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;text-align:left;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.30</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000089914021000501/i052021c.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Letter Agreement, dated as of May 20, 2021, by and among Innoviva Strategic Partners LLC, ISP Fund LP and Sarissa Capital Fung GP LP</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.2</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5/20/2021</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;text-align:left;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.31</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000110465922031613/tm228653d1_ex10-1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Capped Call Confirmation dated March 2, 2022, by and among Innoviva, Inc., Bank of America, N.A., Goldman Sachs &amp; Co. LLC and Deutsche Bank AG, London Branch</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.1</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3/8/2022</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;text-align:left;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.32</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000114036122020321/ny20004305x1_ex10-1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amendment No. 1 to the Investor Rights Agreement, dated May 23, 2022, by and among Innoviva, Inc. and Entasis Therapeutics Holdings Inc.</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.1</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5/24/2022</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;text-align:left;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.33</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000114036122025657/ny20004741x1_ex10-1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Support Agreement, dated July 10, 2022, by and among Innoviva, Inc., Innoviva Acquisition Sub, Inc., Tang Capital Partners, LP and Kevin C. Tang Foundation</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.1</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7/11/2022</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;text-align:left;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.34</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000114036122025945/ny20004764x1_ex10-1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Equity Purchase Agreement, dated July 13, 2022, by and among Innoviva, Inc., Innoviva TRC Holdings LLC and Royalty Pharma Investments 2019 ICAV</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.1</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7/13/2022</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;text-align:left;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.35</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000114036122025945/ny20004764x1_ex10-2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Third Amendment to Collaboration Agreement, dated July 13, 2022, by and among Innoviva, Inc., Glaxo Group Limited, and Theravance Respiratory Company, LLC.</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.2</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7/13/2022</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;text-align:left;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.36+</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000095017023019835/inva-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Transition Agreement between Larry Edwards and Innoviva Specialty Therapeutics, Inc., dated February 23, 2023, and Release of Claims form signed by Larry Edwards, dated April 5, 2023</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-Q</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.1</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5/9/2023</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;text-align:left;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.37</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/d488837ddef14a.htm/000119312523127442/0001193125-23-127442-index.html"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">2023 Employee Stock Purchase Plan</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">DEF 14A</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4/28/2023</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;text-align:left;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.38+</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000110465923095406/tm2324789d1_ex10-1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Offer Letter between Innoviva, Inc. and Stephen Basso dated July 28, 2023</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.1</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8/25/2023</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;text-align:left;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21.1</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="inva-ex21_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">List of Subsidiaries</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;text-align:left;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23.1</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="inva-ex23_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consent of Independent Registered Public Accounting Firm</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;text-align:left;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23.2</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="inva-ex23_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consent of Independent Registered Public Accounting Firm</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;text-align:left;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23.3</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Consent of Ernst &amp; Young LLP Independent Registered Public Accounting Firm of Armata Pharmaceuticals, Inc.**</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;text-align:left;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24.1</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#power_of_attorney"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Power of Attorney (see signature page to this Annual Report on Form 10&#8209;K)</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;text-align:left;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31.1</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="inva-ex31_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certification of Principal Executive Officer Pursuant to Rule 13a&#8209;14 under the Securities Exchange Act of 1934</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">X</span></p></td>
   </tr>
  </table>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">148</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:7.58%;"/>
    <td style="width:2%;"/>
    <td style="width:55%;"/>
    <td style="width:1.02%;"/>
    <td style="width:7%;"/>
    <td style="width:1%;"/>
    <td style="width:7%;"/>
    <td style="width:1%;"/>
    <td style="width:9%;"/>
    <td style="width:1%;"/>
    <td style="width:8.4%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;text-align:left;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31.2</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="inva-ex31_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certification of Principal Financial Officer Pursuant to Rule 13a&#8209;14 under the Securities Exchange Act of 1934</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;text-align:left;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">32#</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="inva-ex32.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certifications Pursuant to 18 U.S.C. Section 1350</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;text-align:left;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">97</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="inva-ex97.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Innoviva Clawback Policy (effective as of October 2, 2023)</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;text-align:left;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">99.1</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Audited Consolidated Financial Statements of Armata Pharmaceuticals, Inc. at December 31, 2023, for the year ended December 31, 2023**</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;text-align:left;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.INS</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;text-align:left;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.SCH</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inline XBRL Taxonomy Extension Schema Document</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;text-align:left;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.CAL</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;text-align:left;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.DEF</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;text-align:left;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.LAB</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inline XBRL Taxonomy Extension Label Linkbase Document</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;text-align:left;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.PRE</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;text-align:left;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">104</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">X</span></p></td>
   </tr>
  </table>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">+     Management contract or compensatory plan or arrangement required to be filed pursuant to Item 15(b) of Form 10&#8209;K.</span></p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">*     Confidential treatment has been granted for certain portions which are omitted in the copy of the exhibit electronically filed with the Securities and Exchange Commission. The omitted information has been filed separately with the Securities and Exchange Commission pursuant to Innoviva, Inc.&#8217;s application for confidential treatment.</span></p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">**   To be filed by amendment to this Annual Report on Form 10-K.</span></p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">#     Furnished herewith.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">149</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:center;" id="signatures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SIGNATURES</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:47.42%;"/>
    <td style="width:3.42%;"/>
    <td style="width:49.16%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">INNOVIVA, INC.</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: February 29, 2024</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;border-bottom:0.5pt solid;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ PAVEL RAIFELD</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Pavel Raifeld<br/></span><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">Chief Executive Officer</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:center;" id="power_of_attorney"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">POWER OF ATTORNEY</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Pavel Raifeld, as their true and lawful attorney&#8209;in&#8209;fact and agent, with full power of substitution and resubstitution, for such person and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to the Annual Report on Form 10&#8209;K, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney&#8209;in&#8209;fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she could do in person, hereby ratifying and confirming all that said attorney&#8209;in&#8209;fact and agent, or his substitutes, may lawfully do or cause to be done by virtue hereof.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:37.82%;"/>
    <td style="width:3%;"/>
    <td style="width:37.82%;"/>
    <td style="width:3%;"/>
    <td style="width:18.36%;"/>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Signature</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">    </span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Title</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">    </span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Date</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;border-bottom:0.5pt solid;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ PAVEL RAIFELD</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Pavel Raifeld</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chief Executive Officer<br/>(Principal Executive Officer)</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">February 29, 2024</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;border-bottom:0.5pt solid;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ STEPHEN BASSO</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stephen Basso</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chief Financial Officer (Principal<br/>Financial Officer)</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">February 29, 2024</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;border-bottom:0.5pt solid;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ MARK DIPAOLO</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Mark DiPaolo, Esq.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chairman of the Board</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">February 29, 2024</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;border-bottom:0.5pt solid;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ ODYSSEAS KOSTAS</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Odysseas Kostas, M.D.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">February 29, 2024</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;border-bottom:0.5pt solid;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ JULES HAIMOVITZ</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Jules Haimovitz.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">February 29, 2024</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;border-bottom:0.5pt solid;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ SARAH SCHLESINGER</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Sarah Schlesinger, M.D.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">February 29, 2024</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;border-bottom:0.5pt solid;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ SAPNA SRIVASTAVA</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Sapna Srivastava, Ph.D.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">February 29, 2024</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">150</span></p></div>
  <hr style="page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>2
<FILENAME>inva-ex21_1.htm
<DESCRIPTION>EX-21.1
<TEXT>
<html>
 <head>
  <title>EX-21.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 21.1</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">LIST OF SUBSIDIARIES</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:60.552%;"></td>
    <td style="width:1.64%;"></td>
    <td style="width:21.104%;"></td>
    <td style="width:1.64%;"></td>
    <td style="width:15.063%;"></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Name</font></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Jurisdiction</font></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Ownership<br>Interest</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Advanced Medicine East, Inc</font></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Delaware</font></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">100%</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Innoviva Strategic Partners LLC</font></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Delaware</font></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">100%</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Innoviva Royalty Sub LLC</font></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Delaware</font></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">100%</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Innoviva TRC Holdings LLC</font></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Delaware</font></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">100%</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Innoviva Strategic Opportunities LLC</font></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Delaware</font></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">100%</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ISP Fund LLP</font></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Delaware</font></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">100%</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Innoviva Specialty Therapeutics Holdings LLC</font></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Delaware</font></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">100%</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Innoviva Specialty Therapeutics Inc.</font></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Delaware</font></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">100%</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Entasis Therapeutics Holdings Inc.</font></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Delaware</font></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">100%</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Entasis Therapeutics Inc.</font></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Delaware</font></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">100%</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Entasis Therapeutics Limited</font></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">United Kingdom</font></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">100%</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Entasis Therapeutics Security Corporation</font></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Massachusetts</font></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">100%</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Entasis Therapeutics (Ireland) Limited</font></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Ireland</font></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">100%</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">La Jolla Pharmaceutical Company</font></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Delaware</font></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">100%</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">La Jolla Pharma, LLC</font></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Delaware</font></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">100%</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Tetraphase Pharmaceuticals, Inc.</font></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Delaware</font></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">100%</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">La Jolla Pharmaceutical Holdings, LLC</font></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Delaware</font></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">100%</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">La Jolla Pharmaceutical I B.V.</font></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Netherlands</font></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">100%</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">La Jolla Pharmaceutical II B.V.</font></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Netherlands</font></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">100%</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">La Jolla Pharmaceutical III B.V.</font></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Netherlands</font></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">100%</font></p></td>
   </tr>
  </table>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>inva-ex23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html>
 <head>
  <title>EX-23.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 23.1</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We consent to the incorporation by reference in Registration Statement Nos. 333-275502, 333-119559, 333-129669, 333-150753, 333-159042, 333-173923, 333-181763, and 333-197950 on Form S-8 of our reports dated February 29, 2024, relating to the financial statements of Innoviva, Inc. and the effectiveness of Innoviva, Inc.'s internal control over financial reporting appearing in this Annual Report on Form 10-K for the year ended December 31, 2023.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/s/ Deloitte &amp; Touche LLP</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">San Jose, California</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">February 29, 2024</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>4
<FILENAME>inva-ex23_2.htm
<DESCRIPTION>EX-23.2
<TEXT>
<html>
 <head>
  <title>EX-23.2</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="min-height:1in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 23.2</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have issued our report dated February 28, 2022, with respect to the consolidated financial statements included in the Annual Report of Innoviva, Inc. on Form 10-K for the year ended December 31, 2023. We consent to the incorporation by reference of said report in the Registration Statements of Innoviva, Inc. on Forms S-8 (File No. 333-119559, File No. 333-129669, File No. 333-150753, File No. 333-159042, File No. 333-173923, File No. 333-181763, File No. 333-197950, and File No. 333-275502).</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/s/ GRANT THORNTON LLP</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">San Francisco, California</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">February 29, 2024</font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>inva-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 31.1</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Certification of Principal Executive Officer</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to Section 302 of the Sarbanes&#x2011;Oxley Act of 2002</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I, Pavel Raifeld, certify that:</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1.           I have reviewed this Annual Report on Form 10&#x2011;K of Innoviva, Inc.;</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2.           Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3.           Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4.           The registrant&#x2019;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a&#x2011;15(e) and 15d&#x2011;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a&#x2011;15(f) and 15(d)&#x2011;15(f)) for the registrant and have:</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a)           Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">b)           Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">c)            Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">d)           Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5.            The registrant&#x2019;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a)           All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">b)           Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:5%;"></td>
    <td style="width:44%;"></td>
    <td style="width:2%;"></td>
    <td style="width:49%;"></td>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date:</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">February 29, 2024</font></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ PAVEL RAIFELD</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="2" style="text-indent:3pt;vertical-align:bottom;"><p style="margin-left:3pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Pavel Raifeld</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="2" style="text-indent:3pt;vertical-align:bottom;"><p style="margin-left:3pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">Chief Executive Officer</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="2" style="text-indent:3pt;vertical-align:bottom;"><p style="margin-left:3pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>inva-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html>
 <head>
  <title>EX-31.2</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 31.2</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Certification of Principal Accounting Officer</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to Section 302 of the Sarbanes&#x2011;Oxley Act of 2002</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I, Stephen Basso, certify that:</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1.           I have reviewed this Annual Report on Form 10&#x2011;K of Innoviva, Inc.;</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2.           Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3.           Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4.           The registrant&#x2019;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a&#x2011;15(e) and 15d&#x2011;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a&#x2011;15(f) and 15(d)&#x2011;15(f)) for the registrant and have:</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a)           Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">b)           Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">c)           Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">d)           Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5.           The registrant&#x2019;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a)           All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">b)          Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:5%;"></td>
    <td style="width:44.44%;"></td>
    <td style="width:1.78%;"></td>
    <td style="width:48.78%;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date:</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">February 29, 2024</font></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ STEPHEN BASSO</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="2" style="text-indent:3pt;vertical-align:bottom;"><p style="margin-left:3pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stephen Basso</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="2" style="text-indent:3pt;vertical-align:bottom;"><p style="margin-left:3pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">Chief Financial Officer</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="2" style="text-indent:3pt;vertical-align:bottom;"><p style="margin-left:3pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">(Principal Financial Officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>7
<FILENAME>inva-ex32.htm
<DESCRIPTION>EX-32
<TEXT>
<html>
 <head>
  <title>EX-32</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 32</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATIONS OF PRINCIPAL EXECUTIVE OFFICER</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">AND PRINCIPAL ACCOUNTING OFFICER</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">18 U.S.C. SECTION 1350,</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">AS ADOPTED PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SECTION 906 OF THE SARBANES&#x2011;OXLEY ACT OF 2002</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I, Pavel Raifeld, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes&#x2011;Oxley Act of 2002, that the Annual Report of Innoviva, Inc. on Form 10&#x2011;K for the fiscal year ended December 31, 2023 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended and that information contained in such Annual Report on Form 10&#x2011;K fairly presents in all material respects the financial condition of Innoviva, Inc. at the end of the periods covered by such Annual Report on Form 10&#x2011;K and results of operations of Innoviva, Inc. for the periods covered by such Annual Report on Form 10&#x2011;K.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50%;"></td>
    <td style="width:3%;"></td>
    <td style="width:47%;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: February 29, 2024</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</font></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ PAVEL RAIFELD</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Pavel Raifeld</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">Chief Executive Officer</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I, Stephen Basso, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes&#x2011;Oxley Act of 2002, that the Annual Report of Innoviva, Inc. on Form 10&#x2011;K for the fiscal year ended December 31, 2023 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended and that information contained in such Annual Report on Form 10&#x2011;K fairly presents in all material respects the financial condition of Innoviva, Inc. at the end of the periods covered by such Annual Report on Form 10&#x2011;K and results of operations of Innoviva, Inc. for the periods covered by such Annual Report on Form 10&#x2011;K.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50%;"></td>
    <td style="width:3%;"></td>
    <td style="width:47%;"></td>
   </tr>
   <tr style="height:0.7pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: February 29, 2024</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</font></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ STEPHEN BASSO</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:3pt;vertical-align:bottom;"><p style="margin-left:3pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stephen Basso</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:3pt;vertical-align:bottom;"><p style="margin-left:3pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">Chief Financial Officer</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:3pt;vertical-align:bottom;"><p style="margin-left:3pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">(Principal Financial Officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A signed original of this written statement required by Section 906 has been provided to Innoviva, Inc. and will be retained by it and furnished to the Securities and Exchange Commission or its staff upon request.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97
<SEQUENCE>8
<FILENAME>inva-ex97.htm
<DESCRIPTION>EX-97
<TEXT>
<html>
 <head>
  <title>EX-97</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 97</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">INNOVIVA, INC. <br>POLICY FOR THE<br>RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION</font></p>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Purpose</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.  The purpose of this Policy is to describe the circumstances in which Executives will be required to repay or return Erroneously Awarded Compensation to members of the Company Group.  Each Executive Officer shall be required to sign and return to the Company the Acknowledgement Form attached hereto as </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit A</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> pursuant to which such Executive Officer will agree to be bound by the terms and comply with this Policy.</font></div></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Administration</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.  This Policy shall be administered by the Committee.  Any determinations made by the Committee shall be final and binding on all affected individuals and their beneficiaries, heirs, executors, administrators, or other legal representatives.  The Committee shall have full power and authority to (i) administer and interpret this Policy; (ii) correct any defect, supply any omission and reconcile any inconsistency in this Policy; and (iii) make any other determination and take any other action that the Committee deems necessary or desirable for the administration of this Policy and to comply with applicable law (including Section 10D of the Exchange Act) and applicable stock market or exchange rules and regulations.  Notwithstanding anything to the contrary contained herein, to the extent permitted by Section 10D of the Exchange Act, the Board may, in its sole discretion, at any time and from time to time, administer this Policy in the same manner as the Committee.</font></div></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Definitions</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.  For purposes of this Policy, the following capitalized terms shall have the meanings set forth below.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Accounting Restatement</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; shall mean an accounting restatement (i) due to the material noncompliance of the Company with any financial reporting requirement under the securities laws, including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements (a &#x201c;Big R&#x201d; restatement), or (ii) that corrects an error that is not material to previously issued financial statements, but would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period (a &#x201c;little r&#x201d; restatement).</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Board</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; shall mean the Board of Directors of the Company.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Clawback Eligible Incentive Compensation</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; shall mean, in connection with an Accounting Restatement and with respect to each individual who served as an Executive Officer at any time during the applicable performance period for any Incentive-based Compensation (whether or not such individual is serving as an Executive Officer at the time the Erroneously Awarded Compensation is required to be repaid to the Company Group), all Incentive-based Compensation Received by such Executive (i) on or after the Effective Date, (ii) after beginning service as an Executive Officer, (iii) while the Company has a class of securities listed on a national securities exchange or a national securities association, and (iv) during the applicable Clawback Period.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Clawback Period</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; shall mean, with respect to any Accounting Restatement, the three completed fiscal years of the Company immediately preceding the Restatement Date and any transition period (that results from a change in the Company&#x2019;s fiscal year) of less than nine months within or immediately following those three completed fiscal years.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(e)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Committee</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; shall mean the Compensation Committee of the Board.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(f)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; shall mean Innoviva, Inc., a Delaware corporation.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(g)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Company Group</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; shall mean the Company, together with each of its direct and indirect subsidiaries.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(h)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Exchange Act</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the U.S. Securities Exchange Act of 1934, as amended.</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Effective Date</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; shall mean October 2, 2023.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(j)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Erroneously Awarded Compensation</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; shall mean, with respect to each Executive in connection with an Accounting Restatement, the amount of Clawback Eligible Incentive Compensation that exceeds the amount of Incentive-based Compensation that otherwise would have been Received had it been determined based on the restated amounts, computed without regard to any taxes paid.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(k)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Executive</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; shall mean any current or former Executive Officer.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(l)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Executive Officer</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; shall mean each individual who is designated as an &#x201c;officer&#x201d; of the Company in accordance with 17 C.F.R. 240.16a-1(f).  Identification of an Executive Officer for purposes of this Policy would include at a minimum executive officers identified pursuant to 17 C.F.R. 229.401(b). The determination as to an individual&#x2019;s status as an Executive Officer shall be made by the Committee and such determination shall be final, conclusive and binding on such individual and all other interested persons.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(m)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Financial Reporting Measures</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; shall mean measures that are determined and presented in accordance with the accounting principles used in preparing the Company&#x2019;s financial statements, and all other measures that are derived wholly or in part from such measures.  Stock price and total shareholder return (and any measures that are derived wholly or in part from stock price or total shareholder return) shall for purposes of this Policy be considered Financial Reporting Measures.  For the avoidance of doubt, a Financial Reporting Measure need not be presented in the Company&#x2019;s financial statements or included in a filing with the SEC.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(n)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Incentive-based Compensation</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; shall mean any compensation that is granted, earned or vested based wholly or in part upon the attainment of a Financial Reporting Measure.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(o)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Nasdaq</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; shall mean The Nasdaq Stock Market. </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(p)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Policy</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; shall mean this Policy for the Recovery of Erroneously Awarded Compensation, as the same may be amended and/or restated from time to time.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(q)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Received</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; shall, with respect to any Incentive-based Compensation, mean actual or deemed receipt, and Incentive-based Compensation shall be deemed received in the Company&#x2019;s fiscal period during which the Financial Reporting Measure specified in the Incentive-based Compensation award is attained, even if payment or grant of the Incentive-based Compensation occurs after the end of that period.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(r)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Restatement Date</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; shall mean the earlier to occur of (i) the date the Board, a committee of the Board or the officers of the Company authorized to take such action if Board action is not required, concludes, or reasonably should have concluded, that the Company is required to prepare an Accounting Restatement, or (ii) the date a court, regulator or other legally authorized body directs the Company to prepare an Accounting Restatement.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(s)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">SEC</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; shall mean the U.S. Securities and Exchange Commission.</font></div></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Repayment of Erroneously Awarded Compensation</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the event of an Accounting Restatement, the Committee shall promptly (and in all events within ninety (90) days after the Restatement Date) determine the amount of any Erroneously Awarded Compensation for each Executive in connection with such Accounting Restatement and shall promptly thereafter provide each Executive with a written notice containing the amount of Erroneously Awarded Compensation and a demand for repayment or return, as applicable.  For Incentive-based Compensation based on (or derived from) stock price or total shareholder return where the amount of Erroneously Awarded Compensation is not subject to mathematical recalculation directly from the information in the applicable Accounting Restatement, the amount shall be determined by the Committee based on a reasonable estimate of the effect of the Accounting Restatement on the stock price or total shareholder </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">return upon which the Incentive-based Compensation was Received (in which case, the Company shall maintain documentation of such determination of that reasonable estimate and provide such documentation to Nasdaq).</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Committee shall have broad discretion to determine the appropriate means of recovery of Erroneously Awarded Compensation based on all applicable facts and circumstances and taking into account the time value of money and the cost to shareholders of delaying recovery.  To the extent that the Committee determines that any method of recovery (other than repayment by the Executive in a lump sum in cash or property) is appropriate, the Company shall offer to enter into a repayment agreement (in a form reasonable acceptable to the Committee) with the Executive.  If the Executive accepts such offer and signs the repayment agreement within thirty (30) days after such offer is extended, the Company shall countersign such repayment agreement.  If the Executive fails to sign the repayment agreement within thirty (30) days after such offer is extended, the Executive will be required to repay the Erroneously Awarded Compensation in a lump sum in cash (or such property as the Committee agrees to accept with a value equal to such Erroneously Awarded Compensation) on or prior to the date that is one hundred twenty (120) days following the Restatement Date.  For the avoidance of doubt, except as set forth in Section &#x200e;4(d) below, in no event may the Company Group accept an amount that is less than the amount of Erroneously Awarded Compensation in satisfaction of an Executive&#x2019;s obligations hereunder.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To the extent that an Executive fails to repay all Erroneously Awarded Compensation to the Company Group when due (as determined in accordance with Section &#x200e;4(b) above), the Company shall, or shall cause one or more other members of the Company Group to, take all actions reasonable and appropriate to recover such Erroneously Awarded Compensation from the applicable Executive.  The applicable Executive shall be required to reimburse the Company Group for any and all expenses reasonably incurred (including legal fees) by the Company Group in recovering such Erroneously Awarded Compensation in accordance with the immediately preceding sentence.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding anything herein to the contrary, the Company shall not be required to take the actions contemplated by Section &#x200e;4(b) or &#x200e;&#x200e;4(c) above if the following conditions are met and the Committee determines that recovery would be impracticable:</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The direct expenses paid to a third party to assist in enforcing the Policy against an Executive would exceed the amount to be recovered, after the Company has made a reasonable attempt to recover the applicable Erroneously Awarded Compensation, documented such attempts and provided such documentation to Nasdaq;</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Recovery would violate home country law where that law was adopted prior to November 28, 2022, provided that, before determining that it would be impracticable to recover any amount of  Erroneously Awarded Compensation based on violation of home country law, the Company has obtained an opinion of home country counsel, acceptable to Nasdaq, that recovery would result in such a violation and a copy of the opinion is provided to Nasdaq; or</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(iii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Recovery would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of the Company Group, to fail to meet the requirements of 26 U.S.C. 401(a)(13) or 26 U.S.C. 411(a) and regulations thereunder.</font></div></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Reporting and Disclosure</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.  The Company shall file all disclosures with respect to this Policy in accordance with the requirement of the federal securities laws, including the disclosure required by the applicable SEC filings.</font></div></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">6.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Indemnification Prohibition</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.  No member of the Company Group shall be permitted to indemnify any Executive against (i) the loss of any Erroneously Awarded Compensation that is repaid, returned or recovered pursuant to the terms of this Policy, or (ii) any claims relating to the Company Group&#x2019;s enforcement of its rights under this Policy.  Further, no member of the Company Group shall enter into any agreement that exempts any Incentive-based Compensation from the application of this Policy or that waives the Company Group&#x2019;s right to recovery of any Erroneously Awarded Compensation and this Policy shall supersede any such agreement (whether entered into before, on or after the Effective Date).</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">7.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Interpretation</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.  The Committee is authorized to interpret and construe this Policy and to make all determinations necessary, appropriate, or advisable for the administration of this Policy.  Notwithstanding anything to the contrary herein, this Policy is intended to comply with the requirements of Section 10D of the Exchange Act (and any applicable regulations, administrative interpretations or stock market or exchange rules and regulations adopted in connection therewith).  The provisions of this Policy shall be interpreted in a manner that satisfies such requirements and this Policy shall be operated accordingly.  If any provision of this Policy would otherwise frustrate or conflict with this intent, the provision shall be interpreted and deemed amended so as to avoid such conflict.  If any provision of this Policy is determined to be unenforceable or invalid under any applicable law, such provision will be applied to the maximum extent permitted by applicable law and shall automatically be deemed amended in a manner consistent with its objectives to the extent necessary to conform to any limitations required under applicable law.</font></div></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">8.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Effective Date</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.  This Policy shall be effective as of the Effective Date.</font></div></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">9.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Amendment</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">; </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Termination</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.  The Committee may amend this Policy from time to time in its discretion and shall amend this Policy as it deems necessary, including as and when it determines that it is legally required by any federal securities laws, SEC rule or the rules of any national securities exchange or national securities association on which the Company&#x2019;s securities are listed.  The Committee may terminate this Policy at any time.  Notwithstanding anything in this Section &#x200e;9 to the contrary, no amendment or termination of this Policy shall be effective if such amendment or termination would (after taking into account any actions taken by the Company contemporaneously with such amendment or termination) cause the Company to violate any federal securities laws, SEC rule or the rules of any national securities exchange or national securities association on which the Company&#x2019;s securities are listed.</font></div></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">10.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other Recoupment Rights</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">; </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">No Additional Payments</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.  The Committee intends that this Policy will be applied to the fullest extent of the law.  The Committee may require that any employment agreement, equity award agreement, or any other agreement entered into on or after the Effective Date shall, as a condition to the grant of any benefit thereunder, require an Executive to agree to abide by the terms of this Policy.  Any right of recoupment under this Policy is in addition to, and not in lieu of, any other remedies or rights of recoupment that may be available to the Company Group under applicable law, regulation or rule or pursuant to the terms of any similar policy in any employment agreement, equity award agreement, or similar agreement and any other legal remedies available to the Company Group.  Any applicable award agreement or other document setting forth the terms and conditions of any compensation covered by this Policy shall be deemed to include the restrictions imposed herein and incorporate this Policy by reference and, in the event of any inconsistency, the terms of this Policy will govern. For the avoidance of doubt, this Policy applies to all compensation that is received on or after the Effective Date, regardless of the date on which the award agreement or other document setting forth the terms and conditions of the Executive&#x2019;s compensation became effective, including, without limitation, compensation received under the 2012 Equity Incentive Plan and any successor plan thereto.</font></div></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">11.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Successors</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.  This Policy shall be binding and enforceable against all Executives and their beneficiaries, heirs, executors, administrators, or other legal representatives.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">*	*	*</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This Policy was adopted by the Committee as of October 30, 2023.</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit A</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">INNOVIVA, INC.<br>POLICY FOR THE<br>RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ACKNOWLEDGEMENT FORM</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">By signing below, the undersigned acknowledges and confirms that the undersigned has received and reviewed a copy of the Innoviva, Inc. Policy for the Recovery of Erroneously Awarded Compensation (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Policy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).  Capitalized terms used but not otherwise defined in this Acknowledgement Form (this &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Acknowledgement Form</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) shall have the meanings ascribed to such terms in the Policy.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:30pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">By signing this Acknowledgement Form, the undersigned acknowledges and agrees that the undersigned is and will continue to be subject to the Policy and that the Policy will apply both during and after the undersigned&#x2019;s employment with the Company Group.  Further, by signing below, the undersigned agrees to abide by the terms of the Policy, including, without limitation, by returning any Erroneously Awarded Compensation (as defined in the Policy) to the Company Group to the extent required by, and in a manner permitted by, the Policy.</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">________________________________<br>Signature</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">________________________________<br>Print Name</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">________________________________<br>Date</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>img11953243_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img11953243_0.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" -G" (# 2(  A$! Q$!_\0
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MHKPC_A>UU_SZI^5'_"]KK_GU3\J/JM3L',CW>BO"/^%[77_/JGY4?\+VNO\
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M?E2'X[W0Q_HJ<D#I1]5J=@YD>\45E^']3;6-&M[UE"F50<"M2L&K.PPHHHI
M8_BK_D6;_P#ZY&OD.X_X_)O]\U]>>*O^19O_ /KD:^0[C_C\F_WS7H8+9D2(
MZ***[1!1110 4444 %%%% !1110 4444 %%%% !1110 445HV&@:MJJ%["T:
M95ZD4-I;@9U%;G_"%^)/^@:_Y53U#0=6TE ]]9R1J>^#24HO9@9]%'6BF 44
M44 %%%% !1110 45I:?X>U?5H?.L+1IH\XW"JEW9W-A.8+J,QRCJIHNM@(**
M** "BBB@ HHHH **#GLI/T&:!GNI'U&*!!1110,**** "BBB@ HHHH ****
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M67_L:YV8SG;VKU'X)^$X;F*;6+^ .R-MBW#]:[7Q7\3]'\+Z@-.E&^4<.HZ
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M (MZE8ZIXD$UA<I<1_WD/%<!731TIH3W"BBBM "BBB@ HHHH **** "BBB@
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M&4-UI:*!DC7-PT7DM.YC_NYXJ)5"C '%+10(0@$8-/$LHA\D2-Y7]W/%-HH
M88D/;]:<%"C I:*8 N4;<A*GV--,:G.1U]Z=12 :J*IX'ZTK*&'-+10!(+FX
M6 P"=Q$>J9XJ)5"# %+10 A 88/2G!Y!%Y0D;R_[N>*2B@ ' Q1110,****
M"BBB@ HHHH **** "BBB@ HHHH **** "FO]QOI3J:_W&^E,1ZS%_P D7;Z5
MY-'_ *M?I7K,7_)%V^E>31_ZM?I6-'[7J-CJ***U **** "BBB@ HHHH ***
M* "BBB@ HHHH 0@,,'I2*BH<@4ZB@0PQ(3DC]:>!@8'2BB@!GE)G./UI^.,=
MJ** '1R20HT<4C(C?> /6HS&I&"/UIU% "!0JX'2FB) <@?K3Z*8 1D8I\,\
M]N"()GC!Z@&F44@$QERYR6/4FAE##FEHH >\TTD0B>5FC'12:A\I/3]:?10
M 8&*6-GA),3LA;K@]:2B@!"H.<\YZTBQJIR!S]:=10 A4,,&I4N;B.$PI.ZQ
M'JH/!J.B@!JHJ=!0R!^HIU% #50+T%#(K]13J* $50HP*6BB@84444 %%%%
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MRL6=V))-1X/=W;_>;-+4TJ*IK0&[A1116H#0H#AQD,.AS4TUQ<7"A9YGD4=
M3TJ.B@0@ 48%#*&&#TI:* %+N8EB+L8UZ+G@4W:,@]".AI:* '2RRSX$TC.!
MTR>E1>4F<X_6GT4 &,C':E1WCC,<;LJ'JH/6DHH 3:,8[4HRJE58A3U&:**
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MH!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %-D_U;?2G4V3_5M]*8CUBZ_Y(Q']*\G3[B_2O6;I
M3_PI>,XXQ7DR?<7Z5C1V?J-CJ***U **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** #M7J?P[_Y$#5_HU>6=J]4^'2D^ -7('9JRK_ "/*A]Y_]
MX_SI:0?>?_>/\Z6M1!1110,**** "BBB@ HHHH **** "BBB@ HHHH ****
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MKZ2HH^MU Y4?-O\ PI;Q'_=3\Z/^%+>(_P"ZGYU])44?6Z@<J/FW_A2WB/\
MNI^='_"EO$?]U/SKZ2HH^MU Y4?-O_"EO$?]U/SH_P"%+>(_[J?G7TE11];J
M!RH^;?\ A2WB/^ZGYT?\*6\1_P!U/SKZ2HH^MU Y4?-O_"EO$?\ =3\Z/^%+
M>(_[J?G7TE11];J!RH^;?^%+>(_[J?G1_P *6\1_W4_.OI*BCZW4#E1\V_\
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MO$?]U/SKZ2HH^MU Y4?-O_"EO$?]U/SH_P"%+>(_[J?G7TE11];J!RH^;?\
MA2WB/^ZGYT?\*6\1_P!U/SKZ2HH^MU Y4?-O_"EO$?\ =3\Z/^%+>(_[J?G7
MTE11];J!RH^;?^%+>(_[J?G1_P *6\1_W4_.OI*BCZW4#E1\V_\ "EO$?]U/
MSH_X4MXC_NI^=?25%'UNH'*CYM_X4MXC_NI^=!^"WB(C!5/SKZ2HH^MU Y4?
M-/\ 8GB1)O\ A#=W7^'/%2#X+>(@,!4_.N\E)_X7.O->K5<\1.%K=0L?-O\
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M\Z/^%+>(_P"ZGYU])44?6Z@<J/FW_A2WB/\ NI^='_"EO$?]U/SKZ2HH^MU
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MN0^FOM4'N,T ='XV\>:=X&MK:?4(II1<.418ASFN:A^->FRD%M%U)(SSO9.
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M U:*\H@\2_$/5X'U"RT:*.TY:)7.&8#VKJ?!7C%_$UA<+<V_V>_MLB6(= :
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M:C;ZQH=TEOJ4. #)]T@5<UGPYK6O^"$TR^N8?[1+ O(OW3B@#3\&@#PC98
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MF9NAQ0 WQ3X1B\5>'M,"72VU_;QH]M(3T;:*Y>XUGQOX(MA-K*#5+&/B23'
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MLKVVN;D3K.VX,.M97_"#>(M&\8S:IX?OH8[.Y/[^.7KCVH @^(/_ ".^B?\
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M:\X\6^!-7N?%*>)?#=Y';ZB4"/YO0@59\=:QJF@^!K:669!J+ND<CIT+'TH
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M665]AX6GIX8^)[QK;S:W9B# 4[>N*ZGP;\/[/PM+)?/*]SJ,W^LFD.3^% '
M>(XM2NOC/;I9W*P78BQ$7'&,5T.J^'/&NHZ?-:7>L1>1)PVX<5N^,_!1UV>#
M5--E%OK%L/W,O;\:Y>X\/?$S74_L[5-3M8;(,-[P\,P^M &5XST2\T'P5X?T
M^XG\]!>#SG'3;7LFF"W72;86^WR!$-N.F,5DW?A&SO\ PH-"N7>1!'M$K'+
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MX9T2'P_H%KI\"@+&H+>Y/6M>BB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *0_=/TI:0_=/TH \J\!_P#)0M7^K5ZM7E/@/_DH
M6K_5J]6K:O\ $)!1116(SRWXK_\ (9\.?]=_ZUZ;:_\ 'K%_N"O,OBO_ ,AG
MPY_UW_K7IMK_ ,>L7^X*VG\$1=26BBBL1A1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 07=I!?6LEM<QB2&0893WIFGV$.FV
MJVUN-L2_=7TJU10 4444 %%%% '*^,?!%KXMBB9KB2UNH>8YX^JUR</PCO[F
M4)J_B>\N[13GR6/#?6O5J* *NG:?;:58165I&(X8EVJHJU110 4444 %%%%
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MPU/J_P!G,_E,H\L'KDUI:-J/]K:1:W_E^7Y\8?;Z9H O4444 %%%% !1110
M4444 %%%<UXP\5_\(K:VL_V8S^?+Y> >E '2T5!97/VRRAN-NWS%#8]*GH *
M*** "BBB@ HKDO%GB/5]%OK&'3]--U'/(%D8?PBNKC8M&K,-K$9(]* '4444
M %%%% !117)Z]XS_ +%\2V6D?9#)]I&?,STH ZRFNN]&4'&1C([4H.0#ZTM
M&+X?\-67AU;K[+DM<RF61CU)K:HHH **** "BBB@ HHHH **** "BBB@ KRG
MX@?\CWH_U%>K5Y3\0/\ D>]'^HK:A\0F>JI]Q?I2TB?<7Z4M8C"BL+Q=XB'A
M;0)M3,!F$0SLSUKSRR^+7B?4K*.\L_!LDEO)RC[CS0![!17%>$/%VMZ_>20Z
MGX??3D49#L2<UVM !1110 4444 %%%% !2,NY"OJ,4M% '-Z#X.M=!U>]U&"
M:1Y+K[RMT%=)110!SOB?PA:^)VMC<321^0P9=O>M^*,10I&#D(H4?A3Z* "B
MBB@ HHHH **\\\1_%*WT_4WTK1;)M4U!#AXTZ#\:H6WQ8OK2Y0>(O#\FFV[D
M 2DDB@#U*BH;6Z@O;6.YMY!)%(H96!ZBIJ "BBB@ HHHH **** "BB@]* "B
MN0TOQ+K%WXQN=*GTLQV4:Y6X]:Z^@ HHHH ***Y+7?$FKZ=XHL-/L],,]K-_
MK)?[M '6T4BDE02,''2EH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH ***R?$>M?V!HTVH>5YOEC[OK0!K45D^&M:_P"$@T*#4O*\KS<_
M)Z5K4 %%%% !1110 4A^Z?I2TA^Z?I0!Y5X#_P"2A:O]6KU:O*? ?_)0M7^K
M5ZM6U?XA(****Q&>6_%?_D,^'/\ KO\ UKTVU_X]8O\ <%>9?%?_ )#/AS_K
MO_6O3;7_ (]8O]P5M/X(BZDM%%%8C"BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQC% '*^&_%B^+?!UU.\9BNHHV2:,]B!UKD_AA<R6?PVUVXBQYD=Q*RY]:?\
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M-[ZTE^+&C6R$-<*@R1_#0![ OW%^E+49D2-%WNJY'<U(#D9% !1110 4444
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M_@B+J2T445B,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M=5@U*:+=<P?ZMC_#6E0 4444 %%%% !1110 4444 %%%% !1110 5Y3\0/\
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M_P"/6+_<%;3^"(NI+1116(PHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#RB7_DLZ_6O5Z\
MHE_Y+.OUKU>MJOV?02"BBBL1A1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'E%M_P EFDKU
M>O*+;_DLTE>KUM6Z>@D%(6 (!(&:6O-OBOKVHZ#;V4VGDF21@FWZGK6(STC>
MH;;N&[TS4-[,UM933( 61"P!KS#_ (0#Q-?:>NHMXGN$O7C$@C'0'&<5?\$>
M*+S7/#FIV.I_\?UENB9C_$!WH U_ GBF]\31W[7<2(;>78NWN*Z]G5/O,!]3
M7F'PM:5-.UQH%#S"8[%/<\XJ!/"7B?6;F6^USQ$=.9F/EVR/P!V/6@#U>@D
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MZ?INGRE+J_G$89>JCUKM=&MIK/1K2WN)#)-'& [GN: +U%%% !1110 4444
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M_AH<^+-?^O\ 6@"]XS^(5UINL1Z!X?M?M6JN,D$951[UF-XY\7^%[J!_%MA
M+*9@HDMQ]TGUJGIM[;>'_C%>?VN/*-Q%B*=Q\OTS6]\6/$&EV_@R>/?%=3.0
M42-@QSZ\4 >@6UQ'=6\<\3!HY%#*1Z&I:XWX6WDE]X T^>3.Y@>O:NRH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MI#]T_2EI#]T_2@#RKP'_ ,E"U?ZM7JU>4^ _^2A:O]6KU:MJ_P 0D%%%%8C/
M+?BO_P AGPY_UW_K7IMK_P >L7^X*\R^*_\ R&?#G_7?^M>FVO\ QZQ?[@K:
M?P1%U):***Q&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M#;@M &YX*TR32?"MG:RC:X7<1Z9YKH* ,# Z44 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 >46W_)9I*]7KRBV_Y+-)7J];5NGH)!5*_P!(L-4V
M?;;9)MARNX=#5VBL1B*H10JC  P!2T44 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110!Y1+_ ,EG7ZUZO7E$O_)9U^M>KUM5
M^SZ"04445B,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH \HMO^2S25ZO7E%M_R6:2O5ZVK
M=/02"BBBL1A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Y3\
M0/\ D>]'^HKU:O*?B!_R/>C_ %%;4/B$SU5/N+]*6D3[B_2EK$9PGQ>_Y)_?
M?[IJY\+O^2<:-_UQ_J:G^(.C2:YX,U"TBSYOEDJ!W-<S\+/%VEIX6MM%O;A+
M2]LE*.DS!<\]LT 7/C-_R3^Y_P!Y?YUE>-EW_!2T7_IT3_T$5#\4_%%EKEA%
MX9TF07EW=2 $Q'<%Y[U;^(UN^G?"".VE.'AMU1OJ * /,[/QA<>(M&T'PYA[
M31H<)<W!X#'/3-?2&D:=9:7ID%K81HENJC;M'7WKS_POX.TO7?A%I]F($1YH
M/,$BCG?S@U'\/?%5UIU_+X1\1/Y=Y;';!(YQYB]J /4JY#QUHFJZ[8I:V>HK
M96N<SOG!Q[&NOKR'XH:A=2^+]*T:XNY++2)U!EG4X&?0F@#(\4>'_#/A_0?M
M.F>))O[1MR"@,V=Y[UT7B75;N_\ @K)?/*R7'E*-ZGFL?Q[I7@O2/!TCPR07
M=YE1&R2!F)]>*O7\4EU\!Y1 A=O*#;5'.* .[\%.\G@/27D<NYM5)8]37$?#
M4S7_ (D\86MQ/(\9FV@$_=!]*U?!?C;08_ %B'O8TEMK<))"S8?<.V*P?@Q?
MQ:GXA\57D((CDG! ;K0!S-I\.M+N_B[J6C27EV($B$H</\Q)YQFNL^,]D;/P
M5H]C;.28[I(XV<Y/'K4$5_;:5\>=1EOY!;PR0*$DD.%)^M:'QKEC?P]HTBNI
M1KY"K \&@!A^$]K<Z$]Y<:G>_;WA\W<LGRA@,C%3_#OQ1=Q>#+UM5<R/IY90
MYZD#I7?1_P#(NY_Z=C_Z#7EO@BQ.K^&/$%C&WSR,V,4 1^%_"MS\03=:[K][
M<QJTI6"*)\#;ZU/#%=?#?QO9V4=W-/H][][SFR4-:?PQ\3V4&D3:3J,L=G=V
MDA7;,P7</49K,\4:G!XP^(.F:/I?[^&W.^:=.54@^M #/&$6H:K\1;/2;>[>
M&TNP/-VG!Q[5OZCX3MO!OP_UW^S[JY=VMV;?*^2#[5F:J57XP:7'D94!?RKL
M_B 0/ .M$]/LS4 8?@*Q&O?"ZRM;V>4B6/YG#?-^=<EXN^'?A;PMI,EW-J6I
M&X?Y88A,268^U=;\.-0M],^%=G?7#A88HBQ/TKBM$US2_&_C&36]:U&&/3[-
MC]E@=\9_"@#J?A;X0U+0/#LUW=74DE[=#=$)3D(O;-9Q\#6"7]U>^+/$;_:I
M6.U$EPJ+7::SXEMYO">IW.@W$=S<6\)*+$<X->?> ],\/ZQI#:IK^K)->2,3
M-!/( 8SZ8- %CX=7ZVGC#4]"L=2:^TS)$;LV2*PO%7@#3&^)%G:F[NMEV^7.
M[E<^E7OA\^E?\+0U*+1X@EJC$*1T-:OC2ZBL/B=I$]T?*@WC]XW"C\: -KQC
MIJ^'?A^]G93S;4X#LV6_.LO5O$]YH/PHTY[1FDO[H")">O/4UN_$FY@N?!,T
MT$J21GHRG(KD?$EG<R?"S1=2LXS,]J59D S\N>?Y4 :>F_"*VNM(2XU#5+YM
M0N$$CNLG"DC.*F^'NL7UOJ%_X3U.8RSVP+1.3R4]ZZC2/&FAW6@0WAU"",+$
M-Z.X# @<C%<5X"W>(/'.K>*HXF2VV-"A88W>XH R/!^AW/C77/$$>H7\Z6-O
M<%%2-\'-/6QG^'?Q0TRRL[Z:73M1.'29L[:U_@ZP;5?%>"#_ *;_ (U0^)C*
M/B?X8!(!+T >S]:X+XNWOV+P2Y+%5DE5#CT-=VGW%^@KAOBU9?;?!<@*;ECD
M5S[ 4 :GA"WCM/ EM'",(("1^5>5?#OP[>>,H]1CU74+@:?;7;F(1OAB<]#[
M5ZKX1N(KOP);20ME# 0#]!7G7P;\3:=92:OI=W*L$@NG8/(=JGD\9H =JNG7
M'PP\4V%[8WD\VFWL@BDBF?.&-:WQ U;4-:\2Z7X3TN9H8[M0UQ,AP5%4?B5J
M=OXGU[1]#TEQ=3Q7"S2-$=RJ ?45/XK=_"WQ)T?5IHV.GR($ED X0]* )-7^
M%,.EZ,]YI&I7HO[9=Z%I,AB.N:U=%\7WNK?#:_OX!OU*RB:-@.[BM7Q-XVT7
M3O#5Q=QWT$[/'B..-PS,3[5SWP^A7POX$O=4U"%_*NY#<&,+DX/M0!ROA'1/
M#_BG2OMFK>()TUFX)\V'SL>6W;BO1-&\(WD?A6ZT+5=0>>UD!"2HWSA3[US3
MZ/X!\2:=)J]E=P:=,ZLS$2!64_3-6/A%J=]=0ZA933RW5I;L1#<2?Q<T <?X
M!^'NEWGBB^#W=V/L<Q,>U\;L'O7L6L^+-$\+M!;:E>K S+\@;N!7GW@'4[33
M_&NKVU[,MO-)*VQ9#MW?2O2=5\,Z)KTD<NIZ?!=L@PC.,X% %'2O'GA[6KU;
M.PU".:=NBBO+OB;J1TCXI:9>"VDN2@4^5'U->M:=X.\/:3=+=6&DV]O.O1T!
MR*\K^(%];V'Q=TF:YE2-%"Y+'B@"_P"(/BMJ=QI,T%EX9O[9I5*--.ORH",9
MZ5T7PUT^TL/!+-;W23S2JSRLAZ$]JU]2\9>%WTZX6?4;::,QG=&&!+#%<9\*
M(G*Z_=0121:9+N-NC"@#G_ /A6?QM8ZE'JVHW(LH;QS$(WPV<UL>-]1,>K:9
MX$M=1:SM1$#+<LWS;1VSZU=^"+!M+U?!!_TU_P"=9?CK2H;'XI6.KZG 9=*D
MCV.QZ*QH AUCPMX=TC2_MVB>)Y1?VOSKOFR'QUR*[/1KG_A8WPX.^8I+(#'Y
MD?'S#O6;J^G_  ^TS3&O)9;:6,XPD<@8MGVKI]$OM!T3P;]OLH_LFF1J9-K#
M% 'GECXZO/#WANY\.7P<ZPCFWM >K#H#7:>$= NM#\'W4U]-(]_<0O)*6/W3
M@]*\LN]%U3Q9>3^/T4A;*;=%'C[\8[BO8M$\36OBGP;-?0.-YMW$D>>5.T]:
M .(^&FF_\)/X"O[/4+J<J]PX+JWS 9KG?A5X"TW4=3U&ZDNKI7L+PB-5? ;!
M[UU_P18-X2O-IS_I,G3ZUG?"/4[.QU77K*\F2WN9+QBB2G:6Y[4 =-\7K5;K
MP/(&ZI,C*?0BNA\(7$ESX7L9)3E_+ S]!7.?&"\6T\$-GEI)T51ZUTOA*V>U
M\,6,<@PWE@X^HH VJ1ONGZ52UF^;3-(N;U(S(84+[!U.*YW0?B'HNLZ(][+=
M16SQ@^9%*X5ACVH Y;X9_P#)0_%_^^/YU?\ $WA";6=?-YX@UO[+I48_=11/
MM)/O69\*)&O?%'BC5X4;[+</^Z8C[V#69II@\2^.]27Q+J9MA#D1VLK[5(]L
MT 074FF^$O&&G-X<UM[I9V"RP-)N K8^*4FHOXY\+6]A=-"\P(8 X!!-<]XM
MB\,:?XRTFUT9(VG,JEIHVR![9KI?B(P'Q+\' D9(/\Z *OC/X<1:'X8N=<L-
M3O!?6@\XEI.&.>:] \!:Q)KG@[3[R9MTS1@.?>H/B20/ASK))P/L_P#45E_!
ML@_#ZR(.1B@#T"D/W3]*6D/W3]* /*O ?_)0M7^K5ZM7E/@/_DH6K_5J]6K:
MO\0D%%%%8C/+?BO_ ,AGPY_UW_K7IMK_ ,>L7^X*\R^*_P#R&?#G_7?^M>FV
MO_'K%_N"MI_!$74EHHHK$84444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y1+_R6=?K7J]>4
M2_\ )9U^M>KUM5^SZ"04445B,**** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \HMO^2S25ZO
M7E%M_P EFDKU>MJW3T$@HHHK$84444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M]YB<L?QK<HH RY?#VF3:O'JDEL#>1_=D]*N7]C;ZE8S65U&)()EVNI[BK%%
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MO]P5M/X(BZDM%%%8C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /*)?^2SK]:]7KRB7_DL
MZ_6O5ZVJ_9]!(****Q&%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 >46W_ "6:2O5Z\HMO
M^2S25ZO6U;IZ"04445B,**** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "O*?B!_R/>C_45ZM7E/Q _Y'O1_J*VH?$)GJJ?<7Z4M(GW%^E+6(S%\
M5ZS+H7A^YO;>%I9U0^6@&<M7F^E>"/$?BG2AK=_K][97EP"Z6\;85?0&O7Y(
MHYEVR(&7T(KGO%WBBR\):*TK%?/8;8(5ZECTXH Y_P"''B/4+G4-1\.:JWF7
M>F]9/[PSBLGQ'J^L^+O&K>&-&N6M;2%=TUQ&<$5K_#7P]>VB7WB'5$V7^I#+
M)Z+U%9OPT4-XJUISR_FL,GK0!F:K9>(?A?=6VJ)JEQJ>FR.L<RS')7-=[XL\
M4RZ3X*;6-/@:>:1%\I%&>33?B/"DW@VZ#@8'S#/K2?#X?;? UB+I1)UX89Z4
M <?8^ /$6M::FKW/B.\MKV=1*MNK85<\X-;WPT\47NJQ:EI>IG=>:;+Y3-_>
M [UK>-/%UMX5TK;%A[^4;+:!>I;MQ6;\,O"]UHVG7>I:D,7^I2>=(O\ =SVH
M YWQKJWC#6?MUMI*&RT^VY>XZ,?I75?"ZZNKOP9 ]Y<//,KE3(YY-:OC!0GA
M6^V@#Y#TK%^%'_(F)_UU:@#N:*** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D/W3]*
M6D/W3]* /*O ?_)0M7^K5ZM7E/@/_DH6K_5J]6K:O\0D%%%%8C/+?BO_ ,AG
MPY_UW_K7IMK_ ,>L7^X*\R^*_P#R&?#G_7?^M>FVO_'K%_N"MI_!$74EHHHK
M$84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110!Y1+_R6=?K7J]>42_\ )9U^M>KUM5^SZ"04
M445B,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH \HMO^2S25ZO7E%M_P EFDKU>MJW3T$@
MHHHK$84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>4_$#_D>
M]'^HKU:O*?B!_P CWH_U%;4/B$SU5/N+]*6D3[B_2EK$9D>)?$-IX8T6?4KP
MGRXQD*.K'TKP[0_%WAWQ%XED\1^)[_"QM_HMJP.%'N*]_O;"TU&#R;RWCGBZ
M['&164?!7AICDZ)9?]^A0!!X?\;Z%XEF>VTNY$C(.0!C KS]KT_#KXCW,VH1
M.-(O5R)P.%8UZGI_A_2-)D:2PT^WMG;@F-,$U-J&EV.K0>1?VL5Q%_=D7(H
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MYD%SU6BO*O\ A%OB%_T'DH_X1;XA?]!Y*/91_F07/5:*\J_X1;XA?]!Y*/\
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MVDLTTLB?>,,>X#\: .XHK*T'Q%IOB.P6[TVX$D9ZC^(?45JT %%%% !1110
M444V218HR[G"CDDT .HJ&VNX+R,R6\BR(#C*FN?M_&^G7'BM_#RQS"[4$[BO
MR_G0!TU%%% !1110 4456M[^UNY)(X)DD>,X<*<[30!9HHHH **** "BBB@
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M5E'_  O[23@9^SM_*O2=0L],FN();U(O.5OW;-US[5YMJN?^%_:3G_GW;^5
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M9IC7=_ V%1:Z7PA8>)K&UN!XDO(;F0_<,785QGPM@A;Q[XMG9%,JS *W<#-
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M*6D3[B_2EK$9P?Q>_P"2?WW^Z:B^&VD:/+\/='::UM&=HLL6 SG)J?XMMM\
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MA1@2H' ^HH GHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M9O#OQ!\6+]CUVXCL+0GYS;ORP]*Z^X\,3Z)X#ET;PXJ_:-FU"_&XGJ377T4
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M&.K^.-'\1:KY*K#S+$&X3Z5TVN^%M3O_ !WIVK0!/LL!!?)YKO** "O/-?\
M">KZ]\1=,U";8-(M%.5SRQ^E>AT4 (   !T%>>3^$M6L?BBOB'3%B^Q31;)T
M)Q]3BO1** /*O$O@SQ+I_BX>(?"DD;O)S+#*< FL_4?!GC7Q)JFGZGJKPQO
M^6@5OE'TKV6B@#CO&7A2T\1Z)9VUU=):W5N0T$A;'S 5SDFC^.IM,DTZ\N8T
MM$0@W"O\S+CO^%=IXM\+Q^*--%N9WMYD.Z.53]TUPI\!>/9D:PG\7N;$C8>#
MDKZ4 +\&K6.SGUB"%_,C5_\ 6>IS7K-87A7PM9^%=)2RM1N;K)(>KGUK=H \
M.\3^%/B'K'C!M2\BUGLH'_T>"1QMQV./6MF*;XLAXU-C8K$" 0&' KUBB@#G
M?$_AI?%/ALV-RWEW)0%9%_A?';\:\_C@^*%AIO\ 8$-M;R0 >6EX6^8+7L5%
M ')^!/!Z^%=,?S6\R]N#OGD]36GXKTZXU;PU>6-KCSI4PN>E;-% ',^#-"N=
M(\,)IVH!?,P0P7I7%2>%O%O@K6+R[\*I'>VMV^]X93]T^U>MT4 >1KX9\7^-
MM5M9_%$<5E96YW"&(_>^M>L00K;V\<*?=10H^@J2B@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH *0_=/TI:0_=/TH \J\!_\E"U
M?ZM7JU>4^ _^2A:O]6KU:MJ_Q"04445B,\M^*_\ R&?#G_7?^M>FVO\ QZQ?
M[@KS+XK_ /(9\.?]=_ZUZ;:_\>L7^X*VG\$1=26BBBL1A1110 4444 %%%%
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MO'7@^YM[W7;:W?3))-LAC.2N36U\3KC6M0\ RW.BB,VDUOYEQO/.P\\4 /\
M#7CW4_$^K$V^E2QZ83A9F'#5Z)7D'P<_X2Q-*LC=K;KH7E'801NS6EJWC/Q%
MK7B*YT;PE:QN+7B>>7A1]#0!Z;17EVF^,_$OA[7+?3/&-K$L5TVRWGAY!/N:
MZ'QUXS'A>RBCM8Q/J-P0L,?7D]Z .PJ&[NHK&UDN9V"Q1C+$]A7E<^L?$O2;
M5-3N[*VE@X,D2') ^E6_'&JZWK_P[6]T2%4C=3]K67@@#'3\: /1-.U*VU2U
M%S:2!XCT(KG=+\93ZAXNO-$;2YHT@.!<$?*U<7\((_%J6T7VI8!I!'!!^;-=
M'HWB2XN_B!J&F-"BQ0GAP.30!WU%>9Z[XWUO4?$\WA[PG;QRSV_^OED^ZOXU
M!%XQ\4^%M4M;?Q9;0_8KE]D<T7.&/K0!ZG17$_$/Q=-X6T2WU"V D$CA5'KF
MN<U#7/B,=-_MJTL[86HC$GE'[VWOQ0!ZS17)>$O&L'B'P@VM2IL, (F7T8=:
MY6T\2^-_%<MS=:%!:II\3%8V<@%C0!ZL2 "3T%<]I_B%M0U>[CB'^AVZ\OZF
ML[PIXAU?4[/4+'6[)K?4+1&WL!A6X[5G_"B<W'A6\FNU"G[9(&+>F: +%QXW
MU&-YKA-(F-G Q#-CJ!WKK-&U6#6]+AU"VSY4HR,UR?C>'Q%-; Z(8/[+$9-S
MR,E<<X_"MGP//8W'A2T.G@B!01@^O>@#>FFCMX7FE8*B#))[5ROACQLGB35;
MNT2U>%8&(5F_C'J*H^.M;#75OH:,42=O](?T6J?A>[TVV\6_8K20,J1;%/K0
M!Z)/*(+>68](T+'\!FN'T[QKJ.LVS7=AI[26_F% P[X/-=M=H)+.:,D .A4D
M],$5YH?!MUX9T*:_TC6)#Y+F58@W[LY/- '7:WXBET2+3YI82R7+B-E'52:Z
M)6#*&!R#T-<)JEVGB#P/!>3G9,F"3_M>U=5X?=I-!LV<DL8QDF@#2HHHH **
M** "BBB@#RBV_P"2S25ZO7E%M_R6:2O5ZVK=/02"BBN7\;^+XO"FE>:J^;=R
MG;#%ZFL1G3DX4GT%<UX3\9VGBQ[Y;6"2/[',8FW]R*Y"'6/B-:6RZM?V=LUD
M4+R1I]X+CC JM\#[E;JUUN\QL66Z9R&[4 >O45Y9>>-?$GB77KO3?"5O$8+1
MMDTTOK[&IM*\::_HOB"VT;Q=;1)]I.V":+H3[T >FT5PGBGQ5?:3XKTVPMU4
MPW# ,:W?%^JSZ-X>GO;< R(.,T 7->UF'0-'FU&=&>.+JJ]32:#K,6O:5%?P
M(R))T#=:XK5M6FUKX03:A= "1TRP'L:YCPAKOB_6_#<<7ABVA6TAX\R;@DT
M>WUS3^,K1/%L?A\PR>>_1^U8'A#QUJ4VO/X;\3VR6^J@;HRGW7%9LX_XO3;?
M0T >K45YYXK\:ZL-?'ASPO;+<:B!F5G^[&*R_P#A*_&?A*\MF\46D,FFS.$\
MR#DJQ]: /5Z*B@N(KBWCGC8%' 93FI ZDX##/UH YO7?&5IH.KVFGSPR/)<L
M%5EZ#-=+7C?Q<U-=(\0Z5=%2[AQL4=S5VZUCXEI =7BLK4V842>2?O;._% '
MJ5U.MK:RSL"5C4L0/:N6T;QW;Z]X7U#6K*TEQ:,R>4>K%?2ET3Q5;^+?!US>
MPJ4E6)EEC/56 YKCOA=<M9?#C7+E%#-'<RL >] '>^$/$DOB?2?MLMA+9MNQ
MLDZUT-<#X=\3W-UX$O-6>)8Y(59@J].*P-(\6>-_%VCK=Z);0)&K$%Y.-V*
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M'^HK:A\0F>JI]Q?I2TB?<7Z4M8C,?Q-XAM_#&C2ZG<QL\<8R0O6O/H/C:MW
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M' S[UU/C/P;;>+-/2-G,5U"=T,HZJ: .AN)8(K9I)V00@98MTQ7,^)+FSN?
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MM_AW'X:-VIF5=OFXXH N?#?_ )$>P^AKJZQO"VC2:!X?M].EE$KQ9RX[ULT
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M )+.OUKU>MJOV?02"BBBL1A1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'E%M_R6:2O5Z\H
MMO\ DLTE>KUM6Z>@D%%%%8C"BC(SBB@ HHS03@9H **PM-\56&J:U<:7 V9X
M!EA6;XLUSQ!I>I6,6D:<MU!*P$K'^$4 =?138V+(I;AB 2*=0 4444 %%%%
M!1103CK0 4444 %%'6B@ HHR*0G )]* %HK"TOQ38:MJ]SIL#9GMQEA6[F@
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MD%%%%8C/+?BO_P AGPY_UW_K7IMK_P >L7^X*\R^*_\ R&?#G_7?^M>FVO\
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MKF&U6R&7D'1QZUVS:C9HQ5KJ(,.H+CBN$\'>$M(TKQ5>:C;:L;S4&79,I;)
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M]8V2J%:.)0WN<<T :M%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M4:* .6\'^"++PE!(4E>YNY?];<2=6KJ:** $90ZE6&01@BO.-8^%CR:I)?\
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MW%^E+6(RGJFEVNL6$MG>1"2&12"#7F<GPFU:Q?R]$\475I:,W,(/"_2O6**
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M]:]7K:K]GT$@HHHK$84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y1;?\ )9I*]7KRBV_Y
M+-)7J];5NGH)!1116(PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MAX3UF8RW%F,QS-U<4 >D>8G/SKQUYH5U<95@P]C7BIM];\4^.=0T)-1EM+)
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MU?ZM7JU;5_B$@HHHK$9Y;\5_^0SX<_Z[_P!:]-M?^/6+_<%>9?%?_D,^'/\
MKO\ UKTVU_X]8O\ <%;3^"(NI+1116(PHHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#RB7_
M )+.OUKU>O*)?^2SK]:]7K:K]GT$@HHHK$84444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y
M1;?\EFDKU>O*+;_DLTE>KUM6Z>@D%%%%8C"BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M)U/%:7AV"XMM M(KNZ^TS(GSS9^\?6@#5HJB^L:;'<>0][ )/0R"K@=&3>K
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% 'E%M_R6:2O5Z\HMO^2S25ZO
M6U;IZ"05C^)]?MO#>ASZA<, %&U!ZL>E;%>>?$SP5J_C!K*.PN42WA.Z1'.
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MJ:W)%J7Q;N[+Q+>R6>EQ1@VVYL(YK,^)S>$[:UTBWT5()+G[6N;B(YP,],T
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MR7<LK"?RE&]3@UD^.T\$:=X-D%B;:]N\@1LC;F^IK0O8)KWX$2+;QEW\H,$
MYH [GP0S-X"TAF8LQM%R3U-</\,E:\\3>,;>>61XVFVX+= ?2M#P9\0/#\/@
M.RBENTCN;: 1O;L?GW#MBL?X+7\>I^(/%5Y&K(LDX(5NHH YZT^'FAW?Q@U+
M1I6N?LJ1"08?YMQYZUU/QHLA:>#-'L;5BH2[2.-F.2,55_M*VT/X[:A<ZG(+
M:WF@54EDX4FM'XU3Q2^'-&E216C>^0JP/!% #O\ A4VDW'A][FYN+IK]X?,,
MBRG 8#(P*3X=>)+NT\%7YU*0RG3RP5B>2!TKT*,_\4[G_IV/_H->7>!;'^V/
M#6OV*-\TC-CZT ,\(>#SXZ6ZU[Q)/<,TDI$$:.0 E2&UE^&WCFR@M+B5]&O>
M'21MVTU?^&_BRRT[3)]&UF9+&ZM9"JB8[=R^HJAK^JQ>./B%IVEZ5^_L[4[Y
MKA.5!!]: &>,+2[UCXDV6F1W;Q6=T!YH5L$CVKHM6\):?X0^'VNKI;SJ7MV)
M9WR<UDZJ57XP:7'GE0%_*NT^(! \ ZV3T^S-0!A_#ZPCUOX76-I>O(Z21X9M
MWS'\:Y7QGX \%^%M):=S>O=R_+!$LQ)9C[5U'P[U.WTKX46FH7# 0Q0EB?7%
M<-H'B71?%OB^;7]?U*&.UMF/V2W=NGX4 =C\+_!-WX;\.37$UQ(;Z[&Y/,;.
MQ3T%9G_"$^'[.^NKOQ9KS37DK' 64@(OIBNOU7Q1:ZEX2U2;PY=1W-U#"=BQ
MG)!K@/ ,'A6[TAK_ %_4XY-1=B9X;E^5/H!0!/\ #B^M[;QGJ>CZ5?O=Z420
MA9LD5D^*O .B-\2;*U+7'EW3YD^?GGTJW\/[C3)OBAJ2Z3 (K16.S:.&K4\<
M7<6F?$K2+N\/E6N\9E;A10!N>-=+A\/_  _DL[!Y4C3@$MD_G6/K/B*]T3X3
MZ:MBS-?70$2L3R 3R:WOB->VU[X&FN+:9)83T=#D&N5\0Z?=7/PKT;4;",RS
M6I5R@&<KGG^5 &KI?P@TJ?1DDU"YNY+^= \D@E(PQ&:3X>ZI>6.K:CX0U"9I
M9+=2T+,<G971:3\0/#T^@Q74NHP0ND0#Q.X#!@.1BN4\ +)K_C+5O%ODM% 4
M:&,L/O#U% &-X*\/-XQU[Q"-4NYC9V]R46)'QZT^33?^%>?%/2K;3;J8Z?J!
MQ)'(^<5L?!UE;5?%>#G%[_C6?\3'4?$_PP">2] 'M Y&:X#XOWHLO!+L6(62
M54./0UWJ?ZM?H*XCXL6)O?!<HV;EBD$C>P% &GX2@CMO MM'$-J>02/RKRKX
M;>%I/%R:D-7NYWT^"[<PQJ^#NSWKU/PA=17O@.VEA.4,# 'Z"O-O@_XLT[3)
M-6TV_E6V_P!*=EFD.%;D\9H GUS23\,O%.GZCI5Q,;"\D$4L,C[N3WK4\?ZA
M?>(/%.E>%+"9HK:Y4/<R*<$"J/Q!U:V\8>(-(T317%V\,ZS22Q'*J![U:\7F
M7PK\0]'UQXF;3F0).X'W#TH GUKX3:;8:(]SI%Q=QZA;+OC<RD@D>M7=!\5W
M^L?#34+F#Y]3LHVB)'=Q6CXE^(.A6?AN>XM;^"YGDCQ'#$^68GVK(\!6Y\)^
M [O5+VVD873FY:$#YL'MB@#D?!VE>$?$6E&76]5F77)R?.1I2-C=L"O2-$\'
M/!X7N=#U"_:[L900C*WS!3[UR\B?#OQ-IDFIK/;Z;<NK%P&"R*?I4_P?O+V:
M'4+5I9I]/B8BWFEYW<T <KX ^'^B7?BF_$AN/]$F)BP^.A[UZSKWC+0_"3P6
MVI7/E,ZY0$9R!7 >!M7LM(\;ZK::C,MK--*?+$IQN^E>HZAH6D:RR2W]A;W1
M485I%S@4 8VC?$7P[KVH)96%YYD[]%Q7FGQ-OY=+^*.F74-H]W(@4B).K5[!
M9>&-#TZX%Q9Z7;02CHZ)@BO(_B'J-MIGQ;TJXNIEBC4*2S=J -#Q#\2?$MQI
M,T-OX5O+,2*5>>49" \$UT?PUL["S\$,;2Z6XF=&:9E[-CI5_4/B#X3:PG5]
M2MYU*',8;.[CI7*_"JWE*:]?QP/!IUQN-O&PQ@4 <_\ #OP@OC*RU-=9NYY+
M**\<Q1I(00<UI^.M0B77=,\#17S66G+$#)-NYP.V:T?@@RMI>KX.?]-?^=9W
MCO2X],^)MEKNH6WG:4\?ER$C(4^M %36_#G@W3M)^UZ'KTL>H6HW(QE)W8ZY
M%=IH%P/B+\-BMS(P>4&/S%X.1WK-U>?X=:=IINPUI<;L8BC8%FS[5T^EZKHN
MC>#/[3M[?[%IZ*7\MA@T ><6OC6^\-:#<>%;L.=6WF"SR>2IX!KN_"?AR;P_
MX.NFNI'>_GA=YF8YP<'I7ETWA_5/%KW'C_#"2TE\RWC_ +\8KUK0/%-MXJ\&
MSWD; 3BW<31]T.T]: .,^%^EQ>(_ 5_9:C+,\3W#@D/\V,^M8'PI\!Z-J.I:
ME=3&?S+"\(AVO@8!XS76?!%@_A*\VG/^DR?SK+^%&KV6E:SKNGZA,MK=2WC&
M-)3@OSVH ZKXNVR7/@:16ZK,C ^A%=!X/GDN/"UB\IRWE@9^@KF_C#>K:>"2
M.KRSHJBNG\*6KV?AFQBD^]Y0)_$4 ;-(WW3]*HZS>RZ=H]U>0Q&5X4+A!U;%
M<MH7Q-T/4]%DNKV[BL[B('S()6PPQ[4 <]\,_P#DH?B__?'\ZO\ B;PA;ZEX
M@.H>)M;\O3D'[J!'VD'WK-^$[2WWB/Q-K4<;"UNG_<L1][!K(TY['5_'NI?\
M)9J#6SQY$4$S;4(]J *UY/HGAOQGIK^%=5DE,S!982Y(K;^*8O;CQWX4M[2Y
M:!I00Q!P",\U@>+)O#,'C#2;70X8G;S5+3Q<@>V:Z3XB,J_$OP<">2#_ #H
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH \HE_P"2SK]:]7KRB7_DLZ_6O5ZVJ_9]!(****Q&%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 >46W_)9I*]7KRBV_Y+-)7J];5NGH)!1116(R"[M(+ZU>VN8Q)#(,
M,IZ&F6&GVNF6PM[.%8HAT5>E6J 0>AH R=;\-:3XB@$.J6:3J.F>H_&J>@^!
MO#_AR3S-.L$CE_YZ'DUT5% "$ @@C(/8UR6H?#/PIJ5\UY<:8AF8Y8J< FNN
MHH JZ?IUII=JMM90)#"O15%6J.E'6@!K_<;Z&O&O OA^SUSQ/XPMM5L6>!Y@
M 77&1[&O9ZC2**-F*1HK-U*@ F@# T'P+X?\-R&73K%$E/\ &W)K3UC1-.UZ
MR-IJ5LD\)YVM6A10!R%A\,?"FG2,\.F(6;^^2:Z6QTZTTVT%K:0K% ,X0=*M
M44 8,'@W0+;5SJL.GQI>$Y,BU>&B:<NJ?VD+5!=XQYO>M#('>B@#*UOPWI/B
M* 0ZI:).B],\$5EZ+\._#.@W(N;+3D$X.0[')%=32%U52Q8!1U.: *&JZ)IV
MM1QQZA:I.D;!T#=B.]7'@CDMS R@QE=I7VIR2)(NY'5AZJ<TZ@#.TG0]-T.)
MXM-M4MT=MS!>YJEJ/@S0-6U"._O-.BDN8R"LG0@UO44 >9^.M.N-8\=>';.*
M%FMHR3,W9>>*]*C01QJ@Z* !043=O*KN]<<TZ@"K?Z?:ZG;&WO(5EB;JK4MO
M86UI8BS@B5+<*5"#I@U9HH S=)T#2]"21--M$MUD8LP3N::/#VE#6?[6^QI]
MNQCSN^*U** ,?6_"NB^(@G]JV$=P4^Z6ZBJUMX&\.6D4<<.EPJL9RG?%=#10
M!G:CH6FZM%;Q7UJDR6[!X@W\)'>K5Q96]U:-:SQ+) PVE&'&*GHH QM%\*Z+
MX?,YTNR2W\__ %FTGYJGT_0-+TNVGM[*T2&*=BTBK_$36E02!U- %+3=(L=(
MC>.QMUA5VW,%[FH)?#NE3:S'J\EG&U]%]R8]16I10!B:_P"$M%\31JNJ623%
M?NMT(_&J%I\.?"]I:);)I<;(C[QO.3N]:ZJB@""2TMY;0VLD2M 5V[".,5F:
M+X3T7P]<3SZ78I;R3_ZPJ3SWK:HH SM,T+3=':=K"U2 SMOD*_Q'UJCX@\&:
M%XF*MJ=DLKKT<<&MQY8XR \BJ3T!.,T^@#"T'P?H?AH-_9=BD+-]Y^I-7;S0
M].O[N*ZNK5))XCE'/45H44 5KZPMM2M'M;N)987&&1NAJ&RT;3]/TL:;:VJ1
MV8!'E <<U?HH XY/A?X3CU(7R:8HE!W8#'&?7%;NF>'=)T?S_L%G'!YYS)M_
MBK4HR/6@#)72=/T:UO9K*V6)I48OM'+'%<=\)](N+:PO]0O(6BGGN& #?W<U
MZ,0",$9%"JJ#"J%'H!B@!:*** "BBB@ HHHH **** "BBB@ HHHH *\I^('_
M "/>C_45ZM7E/Q _Y'O1_J*VH?$)GJJ?<7Z4M(GW%^E+6(PKE];^'WAOQ!,T
M]]IR&=O^6B\&NHI"Z@X+ 'ZT <_H/@G0/#;;]-L$CE/5SR:U=3TJRUBS:TOX
M%G@;JC=#5R@D <G% %>QL;?3;**SM(A%!$-J(O0"J5_X<TG4[^"^N[..2Y@.
M8Y#U%:@96Z$'Z&EH 0   #H*S]9T'3?$%F;34[5)X3SANU:&]0<%AGZTM '(
M6'PR\*:?N\K3$;<>=Y)KIK;3[6TL_LD,*K!C&S'%620.M .>E '+'X=>%?MW
MVW^R(1/NW;AGK6OIF@:9H\T\MA:1P/.<R%!]ZM*B@#&UOPIHGB+9_:EA'<%.
MA/!J6[\.Z5?V%M975FDMO;$&)&Z*1TK4HH 8(4$/DA1Y>W;M]JIZ=HVGZ3YG
MV&V2'S#EMO<U?HH YK7O ?A[Q'<"XU&P5YA_&IP35[0_#.D>'(&BTNS2!6ZD
M<D_C6O10!GR:'ITNIIJ+VJ&[3[LO<59O+2"_LY;2YC$D$J[70]"*GHH S5T#
M3$T<:2MH@L0,>2.F*P#\+/!I.?[$A'T)%=C10!BZ)X3T7P[YG]EV*6_F##8Y
MS63>?##PG>Z@;V73%\UFW-M8@$UV%% &1IWAC1M)F$UC8QPR#^)1S4FL^'M+
M\06X@U2T2XC!R W:M.B@#*3PYI2:2-+%HGV,=(CTJ[;V-M:V2V<,*K;JNT)C
MC%6** .-N?A;X2NKXW<FF+O)W$!B 3]*ZFTL+6PM%M;6%8H5& BCBK-% &?I
MNAZ=I$EP]A:I"UPV^4K_ !'UIE]X>TK4K^"]N[..6Y@.8Y&ZK6G10  8&*J:
MG8QZEIES92C*31LA_$5;HH X+P-I6H^'M,U'1+E";:W#FW?^\#7)_#/PIIOB
M+0-3@UG3V;%ZY0N"I'/:O:,#T%-CBCB!$<:(#R=J@4 8OA_P?HGAE3_9EFL3
M-]Y^I-:>H:=::I9O:7L*S0N,,K"K5% ''V/PP\)Z?>B[ATQ?-4Y7<Q(%=:8H
MVA,113&1MVXXQ3Z* .-N_A;X1O+S[5)I:AR<L%8@,:ZC3M-L]*LTM+*!884Z
M*HJU10!A:EX.T'5M1CO[W3XY+J,Y63H16VB*B!%&% P!3J* "L+6O!V@>(9Q
M/JFG17$BC 9NHK=HH Y"+X8>#X9%D31H@RG(.374PVL%O;"VAB5(0NT(HXQ4
MU% &?I6B:=HL<B:?:I LC%W"]R>]3:AIUIJEH]K>P+-"_56%6J* .,MOA9X1
MM+S[3'I:[P<J&8D UTU_I%CJ6G&PN[=9+4@ Q]L5=HH K6NGVME8I96\*1VR
M+M6,#C%5;#P]I>E_:?L=HD/VG/FA?XLUIT4 4-*T73]$MV@TZV2")F+%5[DU
M0O/!GA^_U2/4[C3HFNXSN63H0:WJ* //_%FC7_B7Q=IUD\&[2(?GE?\ VA7?
M1H(XTC7HH 'X4[ HH 0@$$$ @]C7):A\,_"FIWK7=QIB&5CEBIP#7744 5-.
MTRSTFT6UL8$AA7HJBL;7O GA[Q).)]2L%DF QY@.#7244 <W9> O#6GQQI!I
MD0\L[E)Y.:T[W0M-U"^MKVZM4DN+;_4N>J?2M&B@"O?6-MJ5E+9W<2RV\J[7
M1NA%1Z9I=EH]FMI80+! O1%Z"KE% !2'[I^E+2'[I^E 'E7@/_DH6K_5J]6K
MRGP'_P E"U?ZM7JU;5_B$@HHHK$9Y;\5_P#D,^'/^N_]:]-M?^/6+_<%>9?%
M?_D,^'/^N_\ 6O3;7_CUB_W!6T_@B+J2T445B,**** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH \HE_Y+.OUKU>O*)?\ DLZ_6O5ZVJ_9]!(****Q&%%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M<UPGP\OKBQU#6_"5Q*TJV:,\;-V7L*R_A;X9T_Q"-<NM6C^U!;QHUC<G '-
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M(?NGZ4M(?NGZ4 >5> _^2A:O]6KU:O*? ?\ R4+5_JU>K5M7^(2"BBBL1GEO
MQ7_Y#/AS_KO_ %KTVU_X]8O]P5YE\5_^0SX<_P"N_P#6O3;7_CUB_P!P5M/X
M(BZDM%%%8C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** /*)?\ DLZ_6O5Z\HE_Y+.OUKU>
MMJOV?02"BBBL1A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% 'E%M_R6:2O5Z\HMO^2S25ZO
M6U;IZ"05YE\4=*O(-0TSQ391F5]..&0==I/)KTVFR1I*A210R-P5(R#6(SSY
MOBOH5YI)73YVEU-XOEM]ASNQS7.?!B*35-$\0174;127,[!U88P37J$'AG1+
M6[-U!I=JDY_C6,9J_;V=M:;OL\$<6XY;8H&30!Y'X6\2I\/M2O\ 1O$8:VMC
M(6MIMI((IFO:_P#\+&\4:;I>@H\VFP/NN;C:0*]7U'1=-U90M_90W '3S%!Q
M3[#2=/TM"EC9PVZGKY:@9H \N^)L5SH6IZ+JT=JTUE:,JR%1G:!4/C3XF:=K
MGA:2VT2&6ZFD'SKL(V5Z]/;PW41BN(DEC/57&0:J0:%I-MGR=.M8\]=L0&:
M/.0&_P"%&'Y6WF+[N.<YJE\._'UIH'A>.T\2E[-U.8W93\PKUW[);?9_L_D1
M^3_<V\?E5*]\/:1J$:I=:=;RJO0,@XH \OL;V7X@?$NWU.PC<:19+CS6&-QJ
M[<$_\+GMEV-MVE<XXKTVRT^STV'R;*VB@C_NQK@4\V=L;@7!@C\X='VC/YT
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M(T?4H-%^'UKJ%R2(;>V5FSZ8%:UMX>TBSMC;V^G6R0MR5$8P?K6)X_T^XO\
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M04445B,\M^*__(9\.?\ 7?\ K7IMK_QZQ?[@KS+XK_\ (9\.?]=_ZUZ;:_\
M'K%_N"MI_!$74EHHHK$84444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y1+_ ,EG7ZUZO7E$
MO_)9U^M>KUM5^SZ"04445B,**** "BBB@ HHHH **** "BBB@ HHHH ****
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M?^2SK]:]7K:K]GT$@HHHK$84444 %%%% !1110 4444 %%%% !1110 4444
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MH6K_ %:O5J\I\!_\E"U?ZM7JU;5_B$@HHHK$9Y;\5_\ D,^'/^N_]:]-M?\
MCUB_W!7F7Q7_ .0SX<_Z[_UKTVU_X]8O]P5M/X(BZDM%%%8C"BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** /*)?^2SK]:]7KRB7_DLZ_6O5ZVJ_9]!(****Q&%%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 >46W_)9I*]7KRBV_Y+-)7J];5NGH)!1116(PHHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "L;Q/I%[K>C26=AJ+V$S$?OE
M'(%;-% '(^"O T/A-)II+EKN^G_UMP_5JZZBB@ HHHH **** "BBB@ HHHH
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M:0_=/TH \J\!_P#)0M7^K5ZM7E/@/_DH6K_5J]6K:O\ $)!1116(SRWXK_\
M(9\.?]=_ZUZ;:_\ 'K%_N"O,OBO_ ,AGPY_UW_K7IMK_ ,>L7^X*VG\$1=26
MBBBL1A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% 'E$O_)9U^M>KUY1+_R6=?K7J];5?L^@
MD%%%%8C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** /*+;_ )+-)7J]>46W_)9I*]7K:MT]
M!(****Q&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7E/Q _
MY'O1_J*]6KRGX@?\CWH_U%;4/B$SU5/N+]*6D3[B_2EK$9PGQ=!/@"^ &3M-
M5OAOXET.S\ :1!/JUI'*L/S(T@!4Y-6OBXQ7P#>D=0IKEO ?PN\,ZQX(TR^N
M[5FN)H]SL&//- %_XM^(=%O_  )<PVNJ6LTQ9<(D@)/-=)%K]OX9^'-A?W/\
M%HFQ?[QV]*\^^)GPU\.Z!X/FO["V9)T9<$L3WJYX_2:3X=^%'7/DH\33>FW
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M?%>036>BRK]UY@P^AQ7H>E_\@JU_ZYBO-_B;_P @?P]_OI_(5Z1I?_(*M?\
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M&T0 @9D?N[=S6S0 4444 %%%% !1110 4A^Z?I2TA^Z?I0!Y5X#_ .2A:O\
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M%% !1110!Y1;?\EFDKU>O*+;_DLTE>KUM6Z>@D%%%%8C"BBB@ HHHH ****
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M /*)?AWXHT.[N/\ A%-<6ULKA\F%QG;GTKH_!/@-/##W%[=W'VO4KDYDF/\
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M1A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MC(%>?>,/%<\7@:UUS3N7D ;8.^>U4_"VC^+-3EL]>U#6]EK(@?[)CH* /3:
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** "O*?B!_R/>C_45ZM7E/Q
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MZ)AB/N]*]$\,^$+7PQ)<O;S22&=BS;NV:JZ]X"LM?\1V>LSW$J36N-JKT.*
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M!Y5X#_Y*%J_U:O5J\I\!_P#)0M7^K5ZM6U?XA(****Q&>6_%?_D,^'/^N_\
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M%SU:BO*?^%C^)_\ H6;G_OFC_A8_B?\ Z%FY_P"^:/83"YZM17E/_"Q_$_\
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ML)A<]6HKRG_A8_B?_H6;G_OFC_A8_B?_ *%FY_[YH]A,+GJU%>4_\+'\3_\
M0LW/_?-'_"Q_$_\ T+-S_P!\T>PF%SU:BO*?^%C^)_\ H6;G_OFC_A8_B?\
MZ%FY_P"^:/83"YZM17E/_"Q_$_\ T+-S_P!\T?\ "Q_$_P#T+-S_ -\T>PF%
MSU:BO*?^%C^)_P#H6;G_ +YH_P"%C^)_^A9N?^^:/83"YZM17E/_  L?Q/\
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M+'\3_P#0LW/_ 'S1_P +'\3_ /0LW/\ WS1["87/5J*\I_X6/XG_ .A9N?\
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M+3_#VF:7>SWEI;B.>?\ UC#O6I7E/_"Q_$__ $+-S_WS1_PL?Q/_ -"S<_\
M?-'L)A<]6HKRG_A8_B?_ *%FY_[YH_X6/XG_ .A9N?\ OFCV$PN>K45Y3_PL
M?Q/_ -"S<_\ ?-'_  L?Q/\ ]"S<_P#?-'L)A<]6HKRG_A8_B?\ Z%FY_P"^
M:/\ A8_B?_H6;G_OFCV$PN>K45Y3_P +'\3_ /0LW/\ WS1_PL?Q/_T+-S_W
MS1["87/5J*\I_P"%C^)_^A9N?^^:/^%C^)_^A9N?^^:/83"YZM17E/\ PL?Q
M/_T+-S_WS1_PL?Q/_P!"S<_]\T>PF%SU:BO*?^%C^)_^A9N?^^:/^%C^)_\
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M+1_+DD'(!H ZVBJUA?VVIV<=W:2"2&095AWINJ:G::/ITU_?2B*WA7<['L*
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MUZ_6O7*\C^/0SX:ME_O2A<^G-8C/3=$P-"T\9'_'O'T_W17FWQI4,F@$X/\
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MZ9X8NKBP0D"0 _./44SXJP-I?P_M=,MODA^56]#]:FT:_P#&]KHEC%::=:"
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M#+_%]*YZ_4?\+HC.!GRQ3?B-"EK\0?#-[:X2\9\$+U<9[TZ])/QB@)ZF)<T
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M!Y=X<\*Z]KOBQ/$_BJ,6\EO_ ,>UJ#D+6C=^&M4E^)J:PL2_8@@&[/->@44
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MV5$Q^%=5IM_)=:!'?.,.T1?'OB@#3HKA_!_BV[UZVU*2>,*;8L%QWQ7,V7Q
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MHLC #\:[;Q!ITFK:%>6,+!9)HRBL>@)KEO"6@7?@3P'<6MW.DD\8=PZ].>E
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MXI\0:I/.CQ:B?W:KU7ZU)X,\(7GAR_OY[F=)%N'+*%[9H Y#XF2M#\0]!9,
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M^_LIC=O/P\;GA3[5V5%'L5T8?VA-_%%/OIOZ_P# ...EZWI8_M"WG:XN)/\
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MM=+,]I<-AYA_#0!UM%<CJOB36;+QE;:7;Z49K"107N!_":ZZ@ HHHH ****
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M_P >L7^X*VG\$1=26N5^(NJW.B^"+^_M-OGQ ;=W3K755Q/Q:_Y)OJG^ZO\
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M*N?#GQ1::[H*6R1+;W=H/+FMQQM(]JYS5?$NO>)O&]YX8T61+>&T4--(3AJ
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MW/!'J:$^'5_8R27_ (3UZ1X)&+K"7^0&@#K/"6L:VVEWL?B"U9+FQ!S*!Q*
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M \J\!_\ )0M7^K5ZM7E/@/\ Y*%J_P!6KU:MJ_Q"04445B,\M^*__(9\.?\
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M1]T5/XU\+'Q?H1TLW;6\;.KL5'7':NCHH Y/7O!4>LZ+I^EK=-#!:!00!]\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MQ!<:-X7"6#D7MQ(J1XZX- '<@AAD$$4M9'ABUN+3P]9QW<QEG,8=V/J16O0
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M !1110 4444 %%%% !1110 4A^Z?I2TA^Z?I0!Y5X#_Y*%J_U:O5J\I\!_\
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M+;MM5JVO"O@;2_"BR-;%Y[B3[\\W+G\: .-E./V@R ?^7-?Y5;^.IQX!'/\
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M1H]A/L%T>FT5YE_PMIO^@+/^1H_X6TW_ $!9_P C1["?8+H]-HKS+_A;3?\
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M'IM%>9?\+:;_ * L_P"1H_X6TW_0%G_(T>PGV"Z/3:*\R_X6TW_0%G_(T?\
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M&CV$^P71Z+<V-K>-&UQ"LAC.5W#H:G "@ # %>9_\+:;_H"S_D:/^%M-_P!
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MM-_T!9_R-<7XG\93:MXDL+]=+E06Y&5*GFM:5*:E=H39] )]Q?I2UYB/BTP
M_P")+/T]#2_\+:;_ * L_P"1K+V$^P[H]-HKS+_A;3?] 6?\C1_PMIO^@+/^
M1H]A/L%T>FT5YE_PMIO^@+/^1H_X6TW_ $!9_P C1["?8+H]-HKS+_A;3?\
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MQ_Y](?\ O@44478!_9MC_P ^D/\ WP*/[-L?^?2'_O@44478!_9MC_SZ0_\
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M*/[-L?\ GTA_[X%%%%V ?V;8_P#/I#_WP*/[-L?^?2'_ +X%%%%V ?V;8_\
M/I#_ -\"C^S;'_GTA_[X%%%%V ?V;8_\^D/_ 'P*/[-L?^?2'_O@44478!_9
MMC_SZ0_]\"C^S;'_ )](?^^!111=@)_9=AG/V.#/KL%+_9MC_P ^D/\ WP**
M*+L _LVQ_P"?2'_O@4?V;8_\^D/_ 'P***+L _LVQ_Y](?\ O@4?V;8_\^D/
M_? HHHNP#^S;'_GTA_[X%']FV/\ SZ0_]\"BBB[ /[-L?^?2'_O@4?V;8_\
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M^?2'_O@4?V;8_P#/I#_WP***+L _LVQ_Y](?^^!1_9MC_P ^D/\ WP***+L
M_LVQ_P"?2'_O@4?V;8_\^D/_ 'P***+L _LVQ_Y](?\ O@4?V;8_\^D/_? H
MHHNP#^S;'_GTA_[X%']FV/\ SZ0_]\"BBB[ /[-L?^?2'_O@4?V;8_\ /I#_
M -\"BBB[ /[-L?\ GTA_[X%']FV/_/I#_P!\"BBB[ /[-L?^?2'_ +X%']FV
M/_/I#_WP***+L _LVQ_Y](?^^!1_9MC_ ,^D/_? HHHNP#^S;'_GTA_[X%']
MFV/_ #Z0_P#? HHHNP#^S;'_ )](?^^!2'2[ G)LX"?]P44478"_V;8_\^D/
M_? H_LVQ_P"?2'_O@44478!_9MC_ ,^D/_? H_LVQ_Y](?\ O@44478!_9MC
M_P ^D/\ WP*/[-L?^?2'_O@44478!_9MC_SZ0_\ ? H_LVQ_Y](?^^!111=@
M']FV/_/I#_WP*/[-L?\ GTA_[X%%%%V ?V;8_P#/I#_WP*/[-L?^?2'_ +X%
M%%%V ?V;8_\ /I#_ -\"C^S;'_GTA_[X%%%%V ?V;8_\^D/_ 'P*/[-L?^?2
M'_O@44478!_9MC_SZ0_]\"C^S;'_ )](?^^!111=@']FV/\ SZ0_]\"C^S;'
M_GTA_P"^!111=@']FV/_ #Z0_P#? H_LVQ_Y](?^^!111=@']FV/_/I#_P!\
M"C^S;'_GTA_[X%%%%V ?V;8_\^D/_? H_LVQ_P"?2'_O@44478!_9MC_ ,^D
M/_? H_LVQ_Y](?\ O@44478!_9MC_P ^D/\ WP*/[-L?^?2'_O@44478!_9M
MC_SZ0_\ ? H_LVQ_Y](?^^!111=@']FV/_/I#_WP*/[-L?\ GTA_[X%%%%V
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+4]%%( HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>img11953243_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img11953243_1.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,.!V<# 2(  A$! Q$!_\0
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MPOOP/_SVO_\ P%/^-/E8'IU%>8_\+[\#_P#/:_\ _ 4_XT?\+[\#_P#/:_\
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M.HKS'_A??@?_ )[7_P#X"G_&C_A??@?_ )[7_P#X"G_&CE8'IU%>8_\ "^_
M_P#SVO\ _P !3_C1_P +[\#_ //:_P#_  %/^-'*P/3J*\Q_X7WX'_Y[7_\
MX"G_ !H_X7WX'_Y[7_\ X"G_ !HY6!Z=17F/_"^_ _\ SVO_ /P%/^-'_"^_
M _\ SVO_ /P%/^-'*P/3J*\Q_P"%]^!_^>U__P" I_QH_P"%]^!_^>U__P"
MI_QHY6!Z=17F/_"^_ __ #VO_P#P%/\ C1_POOP/_P ]K_\ \!3_ (T<K ].
MHKS'_A??@?\ Y[7_ /X"G_&C_A??@?\ Y[7_ /X"G_&CE8'IU%>8_P#"^_ _
M_/:__P# 4_XT?\+[\#_\]K__ ,!3_C1RL#TZBO,?^%]^!_\ GM?_ /@*?\:/
M^%]^!_\ GM?_ /@*?\:.5@>G45YC_P +[\#_ //:_P#_  %/^-'_  OOP/\
M\]K_ /\  4_XT<K ].HKS'_A??@?_GM?_P#@*?\ &C_A??@?_GM?_P#@*?\
M&CE8'IU%>8_\+[\#_P#/:_\ _ 4_XT?\+[\#_P#/:_\ _ 4_XT<K ].HKS'_
M (7WX'_Y[7__ ("G_&C_ (7WX'_Y[7__ ("G_&CE8'IU%>8_\+[\#_\ /:__
M / 4_P"-'_"^_ __ #VO_P#P%/\ C1RL#TZBO,?^%]^!_P#GM?\ _@*?\:/^
M%]^!_P#GM?\ _@*?\:.5@>G45YC_ ,+[\#_\]K__ ,!3_C1_POOP/_SVO_\
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M R?J:]&I--;@%%%%( HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MI_<7\J/+3^XOY4ZBBP#?+3^XOY4>6G]Q?RIU%%@&^6G]Q?RH\M/[B_E3J*+
M-\M/[B_E1Y:?W%_*G446 ;Y:?W%_*CRT_N+^5.HHL WRT_N+^5'EI_<7\J=1
M18!OEI_<7\J/+3^XOY4ZBBP#?+3^XOY4>6G]Q?RIU%%@&^6G]Q?RH\M/[B_E
M3J*+ -\M/[B_E1Y:?W%_*G446 ;Y:?W%_*CRT_N+^5.HHL WRT_N+^5'EI_<
M7\J=118!OEI_<7\J/+3^XOY4ZBBP#?+3^XOY4>6G]Q?RIU%%@&^6G]Q?RH\M
M/[B_E3J*+ -\M/[B_E1Y:?W%_*G446 ;Y:?W%_*CRT_N+^5.HHL!9T%57QKX
M=P /^)C!T'_31:^SZ^,=#_Y'7PY_V$8/_1BU]G5YF+^,J.P4445RE!1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 5\M_&;_DKEW_UZP_^@5]2
M5\M_&;_DKEW_ ->L/_H%;X?^(A/8XNBBBO6("BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** +6A_\CKX<_[",'_HQ:^SJ^,=#_Y'7PY_V$8/_1BU]G5YF+^,J.P4445R
ME!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\#/^1XF_Z]&_G7T94XJ*C4LD..P4445SC"BBB@ HHHH **** "BBB@ HHHH
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M $RN!@9Z=ZQ*2:>P!1113 **** "BBB@ HHHH **** "BD+*#@D4M !1110
M45J:1X;UG7UF;2=/FNUA($ACQ\I/3.3[53OK&ZTV]EL[V!H+F(X>-^JFE=7L
M!7HHHI@%%%% !1110 4444 %%%% !1110 4444 %%%% %K0_^1U\.?\ 81@_
M]&+7V=7QCH?_ ".OAS_L(P?^C%K[.KS,7\94=@HHHKE*"BBB@ HHHH ****
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M6&&^*0V>_>/_ !CI?A#3(I;VT6\N9B1;VY ^8C&221P!D?G7G.G_ !&\>:O
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MT1K8[RBJ]A=&^TZVNRGE^=$LFS.=N1G&>]6*XR@HHHH **** "BBB@ HHHH
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M1ON&&&1S5"&&6XGC@@C:2:1@B(HR6)Z >]6-2U:_UN]-_J=T]U=.JJTK@9(
MXZ"M/P9J-[I/BNSO-.TT:E>)N$5L5)R2,9&.XZUVW:CKN2=-8?!;Q;>0"69+
M6TW %4EDRW/J!T-<YXE\$:_X2\MM6LPD,G"S1/OC)],^OM7KVH6/Q6\27<,R
M26_A^*)!B..X#AVSU. 3^%=%\2X&;X4ZJ+LI-/%;HQDV\;P5^8>G>N18B:DD
MVG?L.Q\Y:#X=U3Q+J'V+2;4SS8W,2<*H]2>U=1J_PB\4Z+IYOVA@N8H@'E6W
M?<Z#C/'?'MZ5Z7\#K*WM? T^H!?WUQ<R>8V.2$X KS^\^+OB:/QA+=Q70-A'
M<%%L64"-HP<<\9SCG/K6GM*DIN,-D%E8]2^*O_)*KS_<B_F*\#\.>#]<\5S/
M'I-D9%0?/-(=D:GT+>M>_?%QP_PNU"0# (C8#T^85HZ?HMYHWP[@TSP[Y,5]
M]F7RY)AP'89+MZGDUSTJOLZ>F[8VKL\6O_@OXLLK$W,<=M=,HRT,,GS_ (9Z
MFO/Y8989FAEC=)4;:R,,$'TQ7TIX-T7Q_I.L%M?UB#4-/D4[U+9=6QP5X'XU
MSGB?PS8R?';0BT:^5?+]HF3^])&&.<>AVK^M;0Q#NU+7T$T<1I/P?\5ZK8K=
M^3!:HZ!XUGDPS9]1V_&JUI\*?%MY?7EFEE!'-:,HD\V;:&W#(*G'S#WKU3XQ
M>,]3\-6=A9Z1.;>XNF9GF"@E5'89XY-6OA!XNU+Q3H=XFJL)KBRD6,7&,-(K
M#/S <9%3[:KR>TTL.RO8\0LO VN:AXGNO#MO';G4;4$RJTV$ &.C8YZBJWB7
MPMJGA*_BLM62%)Y8O-012;QMR1U^H->L>$_^3@/$'_7-_P#V6L'X]_\ (Y:;
M_P!@\?\ HQJUC5DZBCY"MH<WH_PQ\3:[HT6K6,-HUI*I92]P%; Z\8K TG0=
M3US5?[-TVU:XNLD,J]% ."2>P]Z^C/AA_P DLLO^N4G\S7E7PVUKQ!IFK:K;
M^'M!CU*:XES)+(=@B )X+= #4QK2?/Y!8!\$/%OV7S,V(F_YX^=_[-C%<7J7
MAW5='UI-(U"U:WO)'"(KGY7R=H(/=<]Z]WT+1_B3/XJBU;5]4AM+ RLTFGK(
M)%"=E&!CTYS6/\? ((?#UY$ EREQ)ME ^88 8<^QYI0KR<U%M._8&M#M/!_A
M,Z1X&M=-U"QM#?I$RN0H?+'/\6*^=/$W@_5_!\MO#K"0(\ZED\J7?P.N>.*^
MC? FJ7VI_#BRU"]N7GO'@=FF8#)(SSQQ7C/@6XU+Q]\0-+7Q!>/J$5FK3;9E
M&, 9 X'3=CK4492C*<GLMQLJ:%\)O%.NV<=XMO%:6\B[D-R^UF'8[>N#5'Q-
M\._$7A2 W5_:K)9AL?:(&W*/3=W%>\^.-,\::K+;P^&=2@T^V5<RN3B1VSTZ
M'C%7] TC6)?"4ND^+9H;Z=P\3RI_RT0],^_O2^M27O.WH%CS[]GW_CS\0?\
M7:'_ -!:N8\4>$-6\7?$_P 0PZ2+=I('1G6:8(<%1R/7_P#577? R!;27Q5;
M(24AO$C4DY.%W@?RK!DUU?#_ .T%=W,KA+>>86TQ*Y^5E&/_ !X+57:K3<=[
M?Y"Z'G&OZ!J'AG5GTS4XT2Y15<[&W*01D8/>MW1OAEXFUW18M6LH;46<JED:
M6X"$@=\8KO/CQH<MS<:+J5NCL\I-F2!E06.5S]2:Z?QQJ4?@KX5QV$0\NXEM
MULX0G&&*_,1].35>WDXQY=V%CYM8;6(R&P<94Y!^E)1176(**** "BBB@ HH
MHH **** "BBB@ HHHH M:'_R.OAS_L(P?^C%K[.KXQT/_D=?#G_81@_]&+7V
M=7F8OXRH[!1117*4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110!%+;03L&E@CD(& 70'%/1$C0(B
MJJCHJC %.HH 8(8A)Y@C3?\ WMHS^=+)''*A21%=3V89%.HH CBMX8,^3#''
MGKL4#/Y4Z2-)4*2(KJ>JL,BG44 5[:QM+,$6MK##GD^6@7/Y4Y;.U202+;0A
MP<A@@SGZU-11<"*6V@G(,T,<A'3>H./SIZ1I$@2-%1!T51@"G44 07-C:7@
MN;:&8#IYB!L?G2Q6EM!!Y$5O%'%C&Q4 7\JFHHN!#%:V\+;HH(HVZ95 #1):
M6TS[Y;>)V]60$U-11<!%4*H50 !T [5";.U+[S;0E\YW>6,YJ>B@!&174JZA
ME/!!&0:I0:-IEK<&X@T^UBF/\:1 &KU%.[ A>SM9'+O;0LYY+% 34U%%("I+
MI>GSRB6:QMI)!_$T2D_GBIWMX)$5)(8V1>BLH(%244[L!D4,4*[8HTC7KA%
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MU?VVOW-Y<RW$S3Q;I)6+,?E/<USU:4X4FF]!IW9BZ3K$&C_M!:D;ET2&YD>
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MJ-858J,VD-;!11168PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M; Q7Y@0.WUJ3XK>'-+\,>)[>STFW,$#VPD9=Q;YLD=ZCVBY^3J%NIPM%%%6
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MSI_PED\.@@WDEA(C>GF.#Q^N*\%\">*3X)\4B_FMFEC\MK>XC PX4D$XSW!
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ML=[>7) LH3/&0<9_6N-\3?\ )6]0_P"PRO\ Z,6O1/@-H,L4&H:[,C+'-B"
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M=\.G2-9\Y!"[/!*B[PP8YV^QSFG9SPZ4 ZF)\9]#L](\8I)91+"E[!YKH@P
MX."1]:]$N=0DU3]GW[7,29'L I).2=K;?Z5Y3XW\03?$+QHC:7;2LK*MO:Q$
M99O4D#ID_P J]C\0Z.= ^"=QI;,&>WL@KD=-V<G]2:JII&FI;W$NIP7P$_Y&
M74O^O4?^A5R7BW_DK.I?]A=?_0UKK?@)_P C+J7_ %ZC_P!"KDO%O_)6=2_[
M"Z_^AK6L?XTO0.AZ)\?M2F2'1],5B(92\[@'@E< 9_[ZKF_ GQ#\.^#]$%O+
MH%S<W\C%I[E=AW<\ 9.0 ,?CFNX^-WAJ[U;1+35;.-I6L"WFHHR?+;JP^A _
M"N5^'/C[PQI6@KI7B&RB#P,QBN3:B3<I.<'@G.2:RA9T$DK@]SC?'?B'2O$V
MN)J>DZ;-I[-'B96V_,XZ,-O0XKT3XB:]/>_!O0)'?+:@8Q(5S@[5)_F*J:O\
M5M.?6$M?#GA>PNX6PBF:W :1R>P X'UKK_B9H-YK7PTB:"Q6&ZM-EPUI",A0
M!\RKCT!/:B4K."DK <[\"O#]A<6.HZO<P13W E$$?F(&\L 9.,^N1^50_'3P
M]86::=K%I;)#/+(T,YC  <8&TD>O7FN<^%_Q#MO!KW5IJ,$CV-RP?S(AEHV'
M'3N#1\3O'">-3:MIUM<QZ99,5,DHP'D;V'L/K5<E3V_-T"ZL>A_ G_D3+G_K
M[;^0KU&O+O@3_P B9<_]?;?R%>HUQ5_XC*6P4445D,**** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "OEOXS?\ )7+O_KUA_P#0*^I*
M^6_C-_R5R[_Z]8?_ $"M\/\ Q$)['%T445ZQ 4444 %%%% 'L7P0T32M7L]8
M;4M-M+PQRH$,\*OM&WMD<5U=]=?#GP1JMU:W<-HM]<MYCHMMN\I2.!TPJ\=!
M6'^S_P#\>6M_]=H__0:\Y^)V3\2==Y_Y;+_Z M<7)[2M*+>@]D=U\.?A_I&H
M07?BO61')IPED:UA;B/RU)R[#N." .G!K>TSQG\./$6K1>'H='AVRMY<#26:
M+&Q'3&.1WQ6_X$NX)/A/8SVUHURL5HX-MQF1ESE?Q(/YUP]I\6]%FU".UM/
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MP_I?ARP%EI5G';PCD[>2Q]6)Y)^M9_B#P+X>\4W<=UJ]B;B:--BL)73 _P"
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MCJ+WVFBY\YX_+/FREACZ5U];5J[E.\&)+N16]M!:6\=O;0I##&-J1QJ%51Z
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M++C=(H.0 !T&:X;Q9K4?B+Q5J&KQ1-#'=.&6-CDKA0/Z5C4X8>"M)K4+G9>
M?B%>^"KQD*-<Z9,<RVV<%3_>3T/J.]>F)\8_!B'^T5TB==0926Q;H),],;_?
MZUX#153H0F[L5SJ/''CB^\;:G'<7$8M[: %8;=6R%YY8^I/'Y5VGB/XMZ3K7
M@6ZT"'3KZ.>:V6$2/LV C')P<XX]*\CHJG1@[:;!<Z7P'XDMO"7BR'5[J"::
M&.*1"D.-Q+# ZD"M'X@^.+?Q9K]CJ>F0W-HUK& #+MW!@V01@FN)HING%RY^
MH'N>C?''39M'\CQ#ITK72IM?RD#I-QZ'IGT/%,L_CII=O=R(-$N8=/5 L$,
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M_P">\7_?8H^U6_\ SWB_[[%<-_PI;X??]"^O_@5-_P#%T?\ "EOA]_T+Z_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MMJ*XG_A;W@+_ *&.W_[]2?\ Q-'_  M[P%_T,=O_ -^I/_B:.5]@.VHKB?\
MA;W@+_H8[?\ []2?_$T?\+>\!?\ 0QV__?J3_P")HY7V [:BN)_X6]X"_P"A
MCM_^_4G_ ,31_P +>\!?]#';_P#?J3_XFCE?8#MJ*XG_ (6]X"_Z&.W_ ._4
MG_Q-'_"WO 7_ $,=O_WZD_\ B:.5]@.VHKB?^%O> O\ H8[?_OU)_P#$T?\
M"WO 7_0QV_\ WZD_^)HY7V [:BN)_P"%O> O^ACM_P#OU)_\31_PM[P%_P!#
M';_]^I/_ (FCE?8#MJ*XG_A;W@+_ *&.W_[]2?\ Q-'_  M[P%_T,=O_ -^I
M/_B:.5]@.VHKB?\ A;W@+_H8[?\ []2?_$T?\+>\!?\ 0QV__?J3_P")HY7V
M [:BN)_X6]X"_P"ACM_^_4G_ ,31_P +>\!?]#';_P#?J3_XFCE?8#MJ*XG_
M (6]X"_Z&.W_ ._4G_Q-'_"WO 7_ $,=O_WZD_\ B:.5]@.VHKB?^%O> O\
MH8[?_OU)_P#$T?\ "WO 7_0QV_\ WZD_^)HY7V [:BN)_P"%O> O^ACM_P#O
MU)_\31_PM[P%_P!#';_]^I/_ (FCE?8#MJ*XG_A;W@+_ *&.W_[]2?\ Q-'_
M  M[P%_T,=O_ -^I/_B:.5]@.VHKB?\ A;W@+_H8[?\ []2?_$T?\+>\!?\
M0QV__?J3_P")HY7V [:BN)_X6]X"_P"ACM_^_4G_ ,31_P +>\!?]#';_P#?
MJ3_XFCE?8#MJ*XG_ (6]X"_Z&.W_ ._4G_Q-'_"WO 7_ $,=O_WZD_\ B:.5
M]@.VHKB?^%O> O\ H8[?_OU)_P#$T?\ "WO 7_0QV_\ WZD_^)HY7V [:BN)
M_P"%O> O^ACM_P#OU)_\31_PM[P%_P!#';_]^I/_ (FCE?8#MJ*XG_A;W@+_
M *&.W_[]2?\ Q-'_  M[P%_T,=O_ -^I/_B:.5]@.VHKB?\ A;W@+_H8[?\
M[]2?_$T?\+>\!?\ 0QV__?J3_P")HY7V [:BN)_X6]X"_P"ACM_^_4G_ ,31
M_P +>\!?]#';_P#?J3_XFCE?8#MJ*XG_ (6]X"_Z&.W_ ._4G_Q-'_"WO 7_
M $,=O_WZD_\ B:.5]@.VHKB?^%O> O\ H8[?_OU)_P#$T?\ "WO 7_0QV_\
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M*NP$7V:#_GDOY4?9H/\ GDOY5+11RKL!%]F@_P">2_E1]F@_YY+^52T4<J[
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MU[_V#G_]#CKZ6KR<1_$9:V"BBBL1A1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !7CT?_)T4W_8+_\ 9!7L->/1_P#)T4W_ &"__9!51Z@>
MPT445(!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MK'KV*'\-&;W"BBBM0"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** /'OC+_ ,CG\/?^PE_[4BKV&O'OC+_R.?P]_P"PE_[4BKV&J>R
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M-M%>6LMM.@>&5"CJ>A!&"*P_^$]\(?\ 0T:-_P"!L?\ C1_PGOA#_H:-&_\
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M;QIXZ\):=#HNN^#+W49+9?)AN[/D2A>%SVZ#K7H?_">^$/\ H:-&_P# V/\
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M#1HW_@;'_C0!T-%<]_PGOA#_ *&C1O\ P-C_ ,:/^$]\(?\ 0T:-_P"!L?\
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M]"MHW_@%'_A1_P *_P#!W_0K:-_X!1_X5T=% '.?\*_\'?\ 0K:-_P" 4?\
MA1_PK_P=_P!"MHW_ (!1_P"%='10!SG_  K_ ,'?]"MHW_@%'_A1_P *_P#!
MW_0K:-_X!1_X5T=% '.?\*_\'?\ 0K:-_P" 4?\ A1_PK_P=_P!"MHW_ (!1
M_P"%='10!SG_  K_ ,'?]"MHW_@%'_A1_P *_P#!W_0K:-_X!1_X5T=% '.?
M\*_\'?\ 0K:-_P" 4?\ A1_PK_P=_P!"MHW_ (!1_P"%='10!SG_  K_ ,'?
M]"MHW_@%'_A1_P *_P#!W_0K:-_X!1_X5T=% '.?\*_\'?\ 0K:-_P" 4?\
MA1_PK_P=_P!"MHW_ (!1_P"%='10!SG_  K_ ,'?]"MHW_@%'_A1_P *_P#!
MW_0K:-_X!1_X5T=% '.?\*_\'?\ 0K:-_P" 4?\ A1_PK_P=_P!"MHW_ (!1
M_P"%='10!SG_  K_ ,'?]"MHW_@%'_A1_P *_P#!W_0K:-_X!1_X5T=% '.?
M\*_\'?\ 0K:-_P" 4?\ A1_PK_P=_P!"MHW_ (!1_P"%='10!SG_  K_ ,'?
M]"MHW_@%'_A1_P *_P#!W_0K:-_X!1_X5T=% '.?\*_\'?\ 0K:-_P" 4?\
MA1_PK_P=_P!"MHW_ (!1_P"%='10!SG_  K_ ,'?]"MHW_@%'_A6GI>A:3H<
M<B:5IMI8I(076VA6,,1TS@<UH44 %%%% !1110!\?^-O^2F^)O\ K]?^=8];
M'C;_ )*;XF_Z_7_G6/7L4/X:,WN%%%%:@%%%% !1110 4444 %%%% !1110
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M)O\ PF!TMRFPI]E\X9Y7;G=C\>E<+11&A3C>RW"[/</^&@H/^A:F_P# M?\
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MCD$CH16#XJ\+ZSJ'QG\+:[:V1DTVRA*W$^]0$.7[$Y/4=!WH J?'[_D2+/\
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M_A47E:5GL!QY!!((((X(/4&BM#7K9+/Q%J5M$VY(KF15;U&XUGUNG=7 ]"^
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MI([V5U#<*C;7,3A@I]#B@"U1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 >/?&7_D<_A[_P!A+_VI%7L->/?&7_D<_A[_ -A+
M_P!J15[#5/9 %%%%2 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M)6!6]D)CQ[J.IKW/3/AIX>L-9N=7GM_MM]/,TV^XY6,DY^5>@KKP H    X
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MSWR .:7Q'J=S9? 3PO:P.R)>$1RD'&5&YL?F!5'XE:_I<&C:9X,T&X%Q9Z>
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MCR:/9FQV;!%Y0XXQD'KGWZUY+\'M*?0OBIXLTMY6E%J@BC=FW$H&^3)_W<4
M>PZ_XDTCPOIQOM9OHK6 <#<<LY]%4<D_2N9TKXQ>!]8O$M(-8$4TA"H+B)HP
MQ/N1C]:\\UC7O#&K_&K4'\8:@D>F:*HAL[>5&*/*#\V0 <\Y//M6YXM\2_"7
MQ'X>N[-]0TY;CR6%O-':LKQOC(*G9QS0![%7$:W\6_!>@:C)87FK;[F,XD2W
MB:4(?0E1C/M63\)M7U/Q#\(0&G8WT"S6L,[-EB0/D))]-P'X"N'^%'BKPEX4
ML[C1O$]K_9^MBX8S7%W;D[P3P,X)'\N] 'M?ASQ9HGBVS:ZT2_2ZC0X< %60
M^ZG!%,F\9:!;:U=Z1/J"17EI;_:9UD5E5(_[Q8C'?UK'\,>%_"J>([KQ5X<N
MD8W:&.6.VE!A)SR=HZ'->=ZSX=B\3_M%RZ?=LYL!:)+<Q*2!,JC(5O4;MN?I
M0!W4'QH\!W%^+1=:VDG E>!UCS_O$8_&N[#0W-MN!62&1,Y!R&4C_"L/6O!7
MA_7-#ETFYTRU6!D*QF.)5:(XX93C@BN*^!^JW$WA?4M$N6:0Z/=/;I(3G*')
M _#F@#7\!+X&TNSUVZ\+2-Y,4Y:^9E?Y"H)VC(' YZ9KS]OBUH[?&%=1.OW/
M_"-"SV!?+DV>;C^YC/XXK=^!"+):^*T=0RMJ; @C((YJH=,L/^&E!:_8K?[/
M_9N[RO+&W..N.E 'KVD:Q8Z[I,&J:=-YMG.NZ.0J5R/H0"*Y#4_C+X&TJ_DL
MIM7\R6,[7,$+R*#_ +P&#^%4OC+K!\-_#I[;3V6T:\E6U!1<!$.=V,=./YUD
M^%O$?PD\-^'[?3HM3L)&$?[Z26V=VD8CYLDI^E 'IVA^(-*\2:>+[1[Z*[M\
MX+1G[IQG!'4'V-:5> ^'=;T"P^.EG%X+NHWT?5H"EU;PJR1I( QR%( [ ].Y
M]:]^H K:AJ-GI5E)>W]S%;6T8R\LK;5'XUPH^-W@(W?D?VNX^;;YAMI-GYXZ
M>]:WC[POH/B7285\0WTEI96TGFEA.(U8^C9X/\ZY74/&GPCM-&?1]^GS6BH8
MQ!#:E@.W!V]??- 'I]E?6NI6<5Y97$5Q;2C<DL3!E8>Q%8?B?Q[X;\'F--:U
M%89I!N2%4+N1ZX4' ]S7!_ &_P!O@?5E<L+6TOI#&&ZHFT$C^=5OA'HUMXLU
M'6O&VM1"\O9[QX[<3#<L2#T!_ >V* +OC;Q[X<\9?"[Q NC7XFEBA!>%U*.!
MN'.T\D>]=G\-_P#DG&@?]>:5Q?QN\&:=+X0N=?L;>*UU&U \R6(;/-B/#*V.
MO'3-7X-=D\-?L^0:K ^R>'3%6%L9VNQVJ?S(H V_$'Q5\'^&=1.GZAJ@-TOW
MXX(VEV'T8J, ^W6M;PWXQT#Q;"\NB:C'=>7C>@!5TSZJ<$5Y+\-M>^&?ASPS
M!)J.JVDFLW:B:]DN(7=PYYVYVG@9QQ[UF^(O$7A&Q^(7AS7/ ]Y )Y+@07UO
M:QM$DB$CEA@#G/Z4 ?05Y>6VGV<MW>3I!;PJ7DDD.%4#N37"Q_&OP'+?+:KK
M!!9MOFM ZQY_WB.GO6#\7GDU_P 5>%?!2SR1VM_<>;=A#C* X ]_XC^ KT3_
M (0[P[_8O]CG1K,V&P)Y1B!X QG/7/OUH +'Q;HFI:_<:)9WHEU"W0221JC8
M"G&"&Q@]1T-.A\5:-/XFF\.QW>=5AC\QX/+;A?7=C'?UKR#X7:*?#WQG\1:2
M)6DBMH"D)9MQ$>X;1GV&*V-(_P"3E-7_ .O ?R% 'JFJ:I9Z+I=QJ5_+Y5I;
MH7E?:6VCUP.:;I.L6.N:3!JFGS>;9SKOCD*E<CZ'!%8'Q/\ ^2:>(/\ KT;^
ME9OPYL(=4^#>EV-P\B0SV9CD:-RC!23G!'2@";5_B_X)T6\>TN-8$DZ'#K;Q
M-*%/U Q^M;_ASQ;H?BRS-SHNH172K]]!PZ?[RGD5P6D7WPH^'EH^GQZE8RW"
M$^;*Z^?*Y]"RJ1[8Z5S'@G6=#N_C[)-X5C$.F7UBPE41E%9P,DA>W*C]: -#
MXQ?$:RMY[+2=)UFX@OK2^7[<D*NF$QR"V,'Z UZ9X5\:Z#XO@E.B7QNOLX42
MDQ.F"1_M 9KSSX\6-HEGH$R6T*RRZFHD<( 7'N>]>FW'V+P]X?O+^WM88!#;
M-*WEQA<E5R,XH S?$_Q%\+>$+A+;5]36.Y89$$:&1P/4A0<?C4GAGX@>&?%\
MC1:/J:2W"@DP.I23 [[2.1SVKQ_X:^(? EM#>:_XKU2VE\0ZA,[R"XB>3RDS
MP!\I _\ U5'\3O$O@AUL/$/@[4+5/$-I=JY-K$\1E0@YW' ST'X$B@#Z*K.U
MS7=/\.:5+J>J3-#:1$!Y%C9]N3CHH)JU93FZL+>X(P98E<CTR,U#K&F0:SH]
MYIMRBO#<Q-&P89'(H DT^_M=5TZWO[*42VUP@DB< C<IZ=:S=6\7:)HFL6&D
MW]X8[Z_.+>$1LQ?G'8''/K7#_!'5770;_P +7;$7NAW3PD$$9C+'!_/=^8K.
MT&-_&?QZU76S\VGZ GV2 YR/,Y4X]L[S^(H ]4UG7-,\/:;)J&K7D5K:Q]7D
M/4^@'4GV%<A:?&GP'>7JVJ:R49CA7E@=$)^I''XXKE]>M8O'OQRBT'42TNCZ
M/;><UO\ PO(0#S^)'Y5Z/J_@KP]K.BRZ7/I5HL#QE$*0JIC., J0.".* -Y'
M26-9(V#(PRK*<@CU%>/?L]?\@#7_ /L)M_Z *N? W4KXZ/K'AZ_G:=]%O6MX
MW8=$Y&WZ94_G5/\ 9Z_Y &O_ /83;_T 4 >DZ!XKT;Q.UZND7?V@V4ODS_NV
M78W/'S 9Z'I2^)/%6C>$;"*]UN[^S6\LHA1_+9\L03C"@GH#7FOP'_U_C'_L
M)_U>G_M&?\B+IO\ V$T_]%R4 >FZWX@TSPYI#ZKJEQY%FF TFQFQGIP 37.:
MU\6O!F@W$=O>:KF9T$FR&)G*@C(W8'!]CS69\:O^22WGUB_F*U/ ?A31[;P+
MI\<MC;W,EW;+)=2S1AVF9AD[B>M &A/\0/"UMX;B\03:Q;KITO$<@)+,W=0H
MY+#N,9%4?#WQ4\(>)]273M.U/_2W^Y'-&T9?V7(Y/M7G'PP\*Z2_Q+\3VL\'
MVBVTN=C9P2\QQ%B<D+TSCBM+XV:;8Z;>^%]8L[2*"_744C\Z(;"5!!P<=: /
M8KJZM[*UDN;J>.""-=SR2,%51ZDGI7!CXW> C=FW_MAQAMOF?9Y-GYXZ>]<U
M\:]:M9=1\-^&M1OC9Z7>2?:+^0 _ZL' Z GJ#6K'XP^#\6E)I@NM*:S10@B>
MT=@0/7*<GWH ]*L;ZUU.RAO;*XCN+:9=T<L;95A]:L5XE\&=5M(?&OBC0-&N
MVNM 4BZLF).$!."%![?-C_@(KVV@ HHHH **** "BBB@ HHHH **** "BBB@
M#Q[XR_\ (Y_#W_L)?^U(J]AKQ[XR_P#(Y_#W_L)?^U(J]AJGL@"BBBI ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *P)/^2@VW_8*E_\
M1L=;]8$G_)0;;_L%2_\ HV.JCU WZ***D HHHH **** "BBB@ HHHH ****
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MC63/RMC&>"*U$18T5$4*JC  & !0!XQXDNV^'WQKB\27Z,NAZM ()9U3(C<
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MG4XOART-^)05O;@3;Y@N.<#'H3],FO!>G%30M[UMNPV%%%%;B"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH ]"^ _P#R4Z]_[!S_ /H<=?2U?-/P'_Y*=>_]@Y__
M $..OI:O(Q'\1EK8****Q&%%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %>/1_\G13?]@O_ -D%>PUX]'_R=%-_V"__ &054>H'L-%%%2 4
M444 %%%(KJXRK!@#C@YH 6BD+!1EB />EH ***0,K9P0<>AH 6BBB@ HHHH
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M9)#PH'\_PKSCX/>*_%6M>+];T[Q)=R2-;6ZN('4#RV+#^AH ]HHHHH ****
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M/JSZQ*N^2>*<[4D)R<#N!5WX=^(=8L/%VJ^ O$-U]LN;!?.M+Q@=TT1P<-]
MP_4=JCC^#S2QK)'X\\2,C ,K"[)!![]:M^#?A_HOAWQK=7\7B:XU36(H/*GA
MN)U>1%;!!89W#@#&: /2:\<^-NK:AH^L^%+G3C(TZW+%81(RK(W& V.HS7L=
M>.?&F[M['Q+X+NKK'D17N^3/H"* +O\ PIV35K1KS7O$VJR:U.-[RPS;8X7/
M95]!_2G_  RU[6K'Q)K'@7Q+=_:K[3\2VMPQRTL1_GP5/MG':O4E97171@RL
M,@@Y!%>.:/-%JW[2^K7-H_F0V5AY,KKR!( JE?SR/P- &;XG77=4^/5UH>D:
MK+8B[L$227<2(H]@+E5SC<>QKNM"\):;\,=*U;5_[1O[Q5MO,G-S)NR$!.1Z
M$\US"?\ )TDG_8,_]IBNX^)EI->_#;7X8 [2?9'8*@R6QSC]* /._#?@[5_B
MC;MXJ\4:S>VUK=,?L-E:2% D08CG\OKWJ2=-4^#OB;2475[G4O#6J3&!XKHE
MFMV)X*GZ$?7FL_X=_#Z/Q3X)L-1MO&6O6V08Y+>&Y(6)E)!4 '@=#]#6U?\
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M0M4F'[_RUW1RGU(R.O?M[53MOA/JVM:M:W_CGQ-+K$=JP>&SB3RXMP_O#O\
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MI?\ T;'51Z@;]%%%2 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M=5_\!9/_ (FC^R]>_P"A=U7_ ,!9/_B:^TJ*/K=0.5'Q;_9>O?\ 0NZK_P"
MLG_Q-']EZ]_T+NJ_^ LG_P 37VE11];J!RH^+?[+U[_H7=5_\!9/_B:/[+U[
M_H7=5_\  63_ .)K[2HH^MU Y4?%O]EZ]_T+NJ_^ LG_ ,31_9>O?]"[JO\
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MZ]_T+NJ_^ LG_P 37VE11];J!RH^+?[+U[_H7=5_\!9/_B:/[+U[_H7=5_\
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M !1110 4444 %%%% !1110 5X]'_ ,G13?\ 8+_]D%>PUX]'_P G13?]@O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MX]9O]QOY5YCXST+5;WXT^#]3M=/N)K&U3$]PB92/YFZGMU%>GS@M;RJ!DE"
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MSY%I"D*9ZX48_I5RBB@ HHHH **** "BBB@ HHHH \<^-#I%XN\ RR,$CCU
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M9/\ PF'AK_H/Z;_X%)_C1_PF'AK_ *#^F_\ @4G^-:WD0_\ /)/^^11Y$/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M-MIUE=3A$V#^+:3S_C5OXB0?#B7P]/JGAS5M(L]>LMLUJ]C<J'<J?NA5/.:
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M@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MJ+2@B>5;PPX:,/TR"?E'/<]ZRK[P5\-O%NE'4_LNG)#.GF_:K:00E<C.3@@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>/1_P#)T4W_ &"_
M_9!7L->/1_\ )T4W_8+_ /9!51Z@>PT445(!1110 4444 %%%% !1110 444
M4 %%%% !1110 445YIH.JZAK_P :=<"S7 TK2+<6XB\PB,S'J=O<XSU]* /2
MZ*\Z\'>+M6UCXE>*=%O)8VLM.(%NJI@C)[GO7HM !1110 4457O[M+#3[F\D
M!*01-(P'< 9H L45YY\'KK4]5\,7>MZG/<2/J%Y))")9"VV('"@#H!U'X5Z'
M0 4444 %%8/C.WU^Y\*WL7AFX2#5B%\EWQZC(!/ .,X-6/#,.L6_ANQBU^>.
M?5%B N)(Q@,WX<9^E &M1110 4444 %9NN:#IGB/3S8:M:K<VI8.8V) )'3I
M6E10!'!!';01P0H$BC4(BCH . *DKS_XN^*]3\+^%[?^R'6*^OKE;9)V&?*!
MZD>]6? WA3Q#H4\MYK?BF?5C<0J/)=,+&V<Y!SSQ["@#MZ*** "BBB@ HHHH
M **** "BBB@ HHHH ***X_X@V?C&\T^Q7P=>Q6MPMP#<%\<I^(/ /44 =A14
M=N)5MXA.RM,$ D91@%L<D>V:DH **** $  Z#K2T44 %%%% !17GWQ7\5ZKX
M4TW29M*ECC>YO5AD+INRIKOHF+PHQZE030 ^BBB@ HJ"]6X>QN%M'5+DQL(F
M89 ?'!/XUS/P^M/%UGHDR>,;R.YO3,3$4P2J>Y  /M0!UM%%% !1110 4444
M %%%% !1110 4444 %%%% 'CWQE_Y'/X>_\ 82_]J15[#7CWQE_Y'/X>_P#8
M2_\ :D5>PU3V0!1114@%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %8$G_ "4&V_[!4O\ Z-CK?K D_P"2@VW_ &"I?_1L=5'J!OT445(!
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!XIKWQKU
MO3?%>JZ-8^&H;Q;"=HMXF;) . 2 .*I?\+S\5?\ 0EI_W]?_  KEKS_DJWC#
M_KY;_P!"J_7LX;+Z=6DIMGDXK,)T:K@DC:_X7GXJ_P"A+3_OZ_\ A1_PO/Q5
M_P!"6G_?U_\ "L6BNC^RJ7=G/_:U3^5&U_PO/Q5_T):?]_7_ ,*/^%Y^*O\
MH2T_[^O_ (5BT4?V52[L/[6J?RHVO^%Y^*O^A+3_ +^O_A1_PO/Q5_T):?\
M?U_\*Q:*/[*I=V']K5/Y4;7_  O/Q5_T):?]_7_PH_X7GXJ_Z$M/^_K_ .%8
MM%']E4N[#^UJG\J-K_A>?BK_ *$M/^_K_P"%'_"\_%7_ $):?]_7_P *Q:*/
M[*I=V']K5/Y4;7_"\_%7_0EI_P!_7_PH_P"%Y^*O^A+3_OZ_^%8M%']E4N[#
M^UJG\J-K_A>?BK_H2T_[^O\ X4?\+S\5?]"6G_?U_P#"L6BC^RJ7=A_:U3^5
M&U_PO/Q5_P!"6G_?U_\ "C_A>?BK_H2T_P"_K_X5BT4?V52[L/[6J?RHVO\
MA>?BK_H2T_[^O_A1_P +S\5?]"6G_?U_\*Q:*/[*I=V']K5/Y4;7_"\_%7_0
MEI_W]?\ PH_X7GXJ_P"A+3_OZ_\ A6+11_95+NP_M:I_*C:_X7GXJ_Z$M/\
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MBK_H2T_[^O\ X5BT4?V52[L/[6J?RHVO^%Y^*O\ H2T_[^O_ (4?\+S\5?\
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MG4=<N9X!>QM'>Q2,C74+NB[)0.I4ANN>&KVKP3>6M]X(T6:T=7B^QQ+D=B%
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M 4444 %8$G_)0;;_ +!4O_HV.M^L"3_DH-M_V"I?_1L=5'J!OT445(!1110
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MH **** "BBB@ HHHH **** "BBB@ HHHH *\>C_Y.BF_[!?_ +(*]AKQZ/\
MY.BF_P"P7_[(*J/4#V&BBBI **** "BBB@ KA=?\$7^K?$S0O$\-U;):Z<A6
M2)]V]LYZ8&.]=U10!C>+-'FU_P *:GI-O)''-=P-$CR9VJ3ZXYJOX'\/W'A?
MP=I^C74L4LULA5GBSM/)/&>:Z&B@#A;#P1?VOQ8OO%KW5L;.XM_)6$;O,!P.
M3QCMZU'X[^'+^)-2M=>T346TKQ!:#;'<KG:ZC. V/<]>>.,&N^HH \@OO!/Q
M,\56QTKQ#XDT^VTML+/]DB)>9>OH._N*]*T_0-,TKPU%H<<"'3HH/)9'Z,N,
M'/UYK5JKJ6GVVK:;<Z?>(7MKB,QR*"1E3UY% 'E-O\*];TFXDE\#^-)+#2KA
MR_D,/,5>>=IY!Z5ROC+P<GA_Q?X*A:_FU77+S4_M%W=S<.ZAX]HQGA0 V/QK
MK[?X7^+_  TS0>$?&\MMIQSMMKR$2^7SGC.1^0%:OA7X83:?XC_X2;Q/K4NM
MZTHQ"[+M2'C' ]>3Z#GI0!G^._,U_P"+/A+PZC)]GMMU_.">N#P".G0<?6O5
MJKBQM%O6O5M81=,NUIQ&-Y'INZXJQ0!POA7P/?:#X_\ $?B"XNK:2WU0@Q1Q
M[MZ8/\61C\JA\??#N;Q%J=AK^@W<.G:_9."+AP=LJCH&QSQ].AQ7H%% ',>(
M_#UCXE\(+IOBMK9795+S1-M5)>FY"WOV/K7$VGPO\;6L)TR/XA7,>D;2@58L
MRA>F,GIQ[UW7C/P9IWC?1AI^H/-$8W\R&:%L-&X[^AKB4\!?$NTA-C:_$+-E
MG"O+;!I0O^\<G]: ,3P%HEGHWQ^UBRTE";&QTU86?.27VQ9+'U+!B??-;W@C
MS/$'Q=\6:^[(T%D1I]O@YZ=QZ<#MZUT_@/X?V/@>TN"EQ+>ZE=MNN[V7[TA^
MG.!DD]3UZUT]I8VEBC):6L-NK-N98HPH)]3CO0!'JUF^H:/>6<;*KSPO&K-T
M!((YKG?AMX3N_!?@^+1[VX@GF25W+P9VX8Y'4 UUU% '"WG@B_N?BS9^+5NK
M86<%MY+0G=YA.#R.,8Y]:V/'7AZX\4^#K_1K2:*&:Y0*KRYVCD'G'-=%10!P
MNH>"+Z[^$:^$$NK87HM4A\X[O+RK D],XX]*M1^$KQ/A4OA0W$'VP6'V7SN?
M+W8QGIG'X5V%% '.>!/#MSX5\'6&C7<T4TUNI#/%G:<DGC/-9&O>"+_5?B9H
M7B>&ZMDM=.0K)$^[>V<],#'>NZHH *H:SH]EK^CW.EZC%YMK<H4=<X/U![$=
M:OT4 >/V/@;XD^$X'TWPWXDL;C2R<0K>H=\ )[<'^?X5T'@CX<SZ#K=UXDU_
M5#JNOW*;&FVX2->X7\@.W%>@44 <1\2O!5]XUT_3;>QN;>!K6[6=S/NP0.PP
M#S7:1*4B1#U50*?10 5P>G>!K^S^,&J>,7NK9K*\M! D*[O,4XC&3QC'R'OW
M%=Y10!A>,]#G\2>#]4T:VECBFNX?+1Y<[0<@\XY[5!X6\+_V1X!LO#6I^3="
M*W,$^S)1P2<]><8-=)10!Y!:_#OQSX-GFB\%^(;9M)DD+I9WZD^7GTX_PSZ5
MJ^%?AMJ47BA?%?C#5UU/6(U*P1Q+B* <XQG'3)[?G7I5% '"^._!%_XJUSP]
M?6EU;0QZ9<>=*LN[+C(.%P/;O7=444 >;^+_ (;7U[XE7Q3X3U4:3K>W;-N!
M\N?  ^;'L,=#GCZUDWW@;XC^+XOL'B;Q)8VVE,W[Z*QC.Z4#IVZ9]3^%>O44
M >??$?3+;1O@SJ>FV2%+:VM%CC4G)P".]<CX-\*^,=,\'Z5J/@O6;>."]MA+
M<6-^"R+*>K(<<9QTKU+QEH$GBCPG?Z-%.L#W2;!(RY"\]<5-X7T5O#OAC3M'
M:<3M:0B(R!=H;'?% '%>%OAKJB^*1XJ\9ZK'JFJQC;;11+^Z@'MD#D9.!CWR
M:U/B;X*OO&^D6%G8W-O;O;W0G8S[L$ =!@'FNXHH X+XG^!;_P <>&;#3+"Z
MMK>6VNEF9Y]VT@(RX& >[5W:+MC53U  IU% '">%/ U_H/Q!\2^(;BZMI+;5
M6S%''NWI\V?FR,?E4/CGX<3>(-6MO$.@:F=)\06R[5N!G;(O8-C_  /':O0:
M* /(KWP?\4?$ULVF:UXETZTTV3$<YM(SOE3'/;OW&174ZQH-GX9^$NH:/8AO
ML]M8.H+')8XY)]R>:[2LWQ!ICZSX>O\ 34D$;74+1!R,A<C&: /%/ASX6\40
M>"=/UKP9J\-M-=!A>6=Z"T,A!(5UXX.*ZK1?AKKFI^*;;Q)X[U:&_N+3YK2R
M@7]U&>O.1V/.!G/KQ78^!_#+^$/"=GHLERMRT&[,JIM!R<]*Z*@#B/B5X*OO
M&NGZ9;V-S;P-:7:SN9]V"!V& >:[6)2D2(>JJ!3J* .%\,^"+[1/B+XC\1SW
M5M);:H (HDW;TY!^;(QV[4W3? U_9?&#5?&+W5LUE>6H@2%=WF*<1C)XQCY#
MW[BN\HH @O(6N;&X@4@-)&R GH"1BN0^&G@R]\%>%Y]+OKFWGEDN'E#P;MH#
M <<@>E=M10!PWPW\$WW@N'6$O;FWG-]>&X3R-WR@]CD#FG?$KP7?>-=-TZVL
M;FW@:UNUG<S[L$#L, \UV]% &%XE\*V'BOPU)HNI*3&Z#:Z_>C<=&'TKS^R\
M)?%;0;9=*TOQ-IMS8(0L4UTA,D:>G0_UKUVB@#A/ 7P]E\+WM]K6L:F^J:]J
M  N+@Y"J!V7U[<X'0  5W=%% !1110 4444 %%%% !1110!X]\9?^1S^'O\
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M317 ^%?BMI7B+6O[$NK&]TG53G9;7:8WX'.#_2M;Q=XWLO!T^E1WMO+(NHW
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M]3TZ=9[2XTH/&X^G0^A!R,4 >W4450UG6M/\/Z5-J6IW*6]K",L[?R [D^E
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M3Z#H*JUKA<,Z*?,[MZLRQ6(59KE5DM$%%%%=1R!1110 4444 %%%% !1110
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M)-EXK\(ZEI'A,/>DVK37MR4*QP0J,L,D?>., 5T'PZTYM7^ EGIJ,%:[L;F
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M1>RC I\GQ ^'O@W6KZUT+3)KO4IY#]I72[?>68=>20..>!5'X&127/@'Q!!
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ME %*^T72]3(-]I]M<L.AEB#$?B:G^Q6NV-?LT.V+_5CRQA/IZ5/10!'-;P7
M430QRA3D;U#8/XU)110!1FT72KB<3S:;:22CH[0J3^>*N(BQH$10J@8  P!3
MJ* (Q;PB<SB&,2D8,FT;B/K3GC25"DB*Z,,%6&0:=10 V...&,1Q(J(.BJ,
M?A4-Q86=W(DES:03.GW6DC#%?IFK%% !T&!1110!1GT72KJZ6YGTZTEG4[A(
M\*EL^N<59-M TB2&",R(,(Q094>Q[5+10 51DT72I;D7,FFVC3CD2&%2WYXJ
M]10 @    P!T J"[L;2_B\J\MH;B/^[*@8?K5BB@"K9Z98:<NVRL[>W!&#Y4
M87/Y5:HI-RCJP_.@"C)HFE2W N)--M'F QO:%2?SQ5Y55%"J % P !P*-Z_W
MA^=+0!Y[X6\*ZG+\0=:\7Z];)!/)BWL80X?9$!C=GL2 ./K7H5)O7^\/SH#
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M*** *']AZ5]L%Y_9MI]I&?WODKNY]\5;^SPB<SB&/SB,>9M&['UIY('4@4M
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M"GU]L'K5'PQ'X<BMKF^UR9998_\ 56?/S\?K6IX?25/AGK\DH_<R9$62.3@
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MS?SCKZ%KY7&?QY>K/J\-_!AZ+\@HHHKF-PHHHH **** "BBB@ HHHH ****
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M\/?^PE_[4BKV&J>R ****D HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M.Z6J?1GH5AXR\/:1!=V-A87$5J\9"OM!>1R,9;)X'I2?"]VBCU=U^\D:D?4
MUY]73>%/$EOX?@U$3PR2M<H%0)]#U_.N6OA4J4U3NV['30Q3=6+GHE<TAJ'@
MG4G:^U&TN(+MLM+#'G8[=\<]_P *RO$_B@:TD%E9V_V73;;B*+NWH2/Z5SAY
M)-%;PPT(R4KMVVN]C&>)G*+C9*^]EN6=/N);34K6X@&Z6*5608SDYKOOB?JI
M M-+C^3<//F4>O1<_K^E8'ASQ!HVB6?F3:0USJ*.628D8Y]/3%8>JZG<ZQJ,
MM]=L#+(>@Z*.P'M4.FZE=3<;*/XEJHJ=!P4KN7X%.BBBNLXPHHHH **** +O
MPD_Y+1JO_8.;^<=?0M?/7PD_Y+1JO_8.;^<=?0M?*8S^/+U9];AOX,/1?D%%
M%%<QN%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>/1_\
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M/X5S?B?3-!/Q'\$>%/"D<*IIUTUU<+ 2X0ED8[CSSB/N>XH ]]HHHH ****
M"BBB@#Q[XR_\CG\/?^PE_P"U(J]AKQ[XR_\ (Y_#W_L)?^U(J]AJGL@"BBBI
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?\*)E_Z'G6OS/_Q5%EW ]AHKQ[_A1,O_ $/.M?F?_BJ/^%$R_P#0\ZU^9_\
MBJ++N![#17CW_"B9?^AYUK\S_P#%4?\ "B9?^AYUK\S_ /%467<#V&BO'O\
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M (43+_T/.M?F?_BJ/^%$R_\ 0\ZU^9_^*HLNX'L-%>/?\*)E_P"AYUK\S_\
M%4?\*)E_Z'G6OS/_ ,519=P/8:*\>_X43+_T/.M?F?\ XJC_ (43+_T/.M?F
M?_BJ++N![#17CW_"B9?^AYUK\S_\51_PHF7_ *'G6OS/_P 519=P/8:*\>_X
M43+_ -#SK7YG_P"*H_X43+_T/.M?F?\ XJBR[@>PT5X]_P *)E_Z'G6OS/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M (4IXX_Z&VS_ .^7_P */[5H]F']DU>Z_$R:*UO^%*>./^AML_\ OE_\*/\
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M .^7_P */[5H]F']DU>Z_$R:*UO^%*>./^AML_\ OE_\*/\ A2GCC_H;;/\
M[Y?_  H_M6CV8?V35[K\3)HK6_X4IXX_Z&VS_P"^7_PH_P"%*>./^AML_P#O
ME_\ "C^U:/9A_9-7NOQ,FBM;_A2GCC_H;;/_ +Y?_"C_ (4IXX_Z&VS_ .^7
M_P */[5H]F']DU>Z_$R:*UO^%*>./^AML_\ OE_\*/\ A2GCC_H;;/\ [Y?_
M  H_M6CV8?V35[K\3)HK6_X4IXX_Z&VS_P"^7_PH_P"%*>./^AML_P#OE_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M+_PO?P+_ ,_MS_X#M7H\L,<\3131K)&W#*XR#^%5/[&TK_H&V?\ WX7_  H
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MBL=)M8VM\,DOE@R;L?>W=<FOFSPU_P G!V__ &%I/YM7UDGW%^@KY-\- _\
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M_P#$1?%NK6\B6"W)O'F9<+(ZGY43U ./P6@"O^T'S\14_P"O./\ K76_'O\
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M7AG4=,T[4-=UR%H=6UF<SR1,,&-.P/IUSBL?3P?^&E[\X./[._H* /8****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M$CH2.E+10 W8F_?M7=ZXYIU%% ",JN,,H8>A&:1D1@ RJ0.@(Z4ZB@ HHHH
M*1D5QAE##W&:6B@ I" PP0"/0T$@ DG '<TB2)*"8W5P#@E3GF@"&&QM+>1G
MAM88W8Y+)& 2:L444 5I].LKJ59;BS@ED7[K/&&(_.K"JJ*%50JCH , 4M%
M'D7A&TN$_:$\87$EM*L$EH LC(0C?ZK@'H>]>K16-I#,TT5K"DK'+.L8!/XU
M/@9SBB@ J.:"&X39-$DB?W74$?K4E% $<%O#;1B.")(D' 5%  _*GLJN,,H8
M>A&:6B@ Z4T(H8L% 8]3CFG44 1S00W$9CGB21",%74$'\Z9;6=M9ILMK>*%
M?2- O\JGHH *KR6-G+,LTEK \J\!VC!(_&K%%    , 8%%%% !5=+&SCG,Z6
ML"RD8+K& Q_&K%% !2;%W;MHW>N.:6B@ HHHH **** "FJBIG:H7/7 Q3J*
M"BBB@" V5JTOFFVA,G]\QC/YU/110 T(H8L% )ZD#K2LBO\ >4'ZBEHH *14
M5,[5 SZ"EHH 145<[5 SUP*"BL064$CID=*6B@ (R,&D550850!Z 4M% !3=
MB[MVT;O7'-.HH *0HI8,5!(Z$CI2T4 <CX^U;Q5HVGVM[X:TR+4$BEW7D)YD
M,8[*/S]^E<O_ ,+QTK[+D>&]<_M(C M?LO\ %_=W=?TKU:F>5'OW^6F[.<XY
MH \R^$OAS6(;W7/%FOVWV:^UJ4/';G[T48)//IU''H!7J%%% !5?[!9_:/M'
MV6#SA_RT\L;OSJQ10 4T(H8L% )ZD#K3J* "BBB@"O=6%I?($N[6&=1T$J!L
M?G4JPQ*BHL2!%^ZH48'TI]% ",BN,,H8>A&:6BB@!H10Q8* 3U('6G444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110!Q/BOP?J6N>+M"U6U\136%O8R!I;56($
MH!SP <$GH<]J[5G52 S $],GK7CWQ0)_X6W\/^3_ *]O_0UJ/X\/<QZCX,-F
MP6Z-\XB9N0'/E@'\Z /8'N[:*01R7$22-T5G )_"INM>57?P(\/:A92O>7NH
MS:O+EWOWGRQ<^W3&>U'P0UO4;K2-9T/4[EKF31;OR$F8Y)7YAC/H"I_.@#U*
M66.",O+(D:#JSM@4D-Q#<+NAFCD7U1@?Y5XC9Z5/\:/%^L7.JWUQ%X9TJX-M
M;6D$F!*XS\Q_#G/7Y@ >*O:U\*KWPE<6FM?#J6YCO(90)K&2?,<R'KDL?YT
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MXSZT =:+VU,WDBYA,O\ <$@S^53UX_JWP1\'Z=H4LD5[=6>HQHTD5_)<_-O
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MYHLMP]NETFTRHH8KSGH:X>3X/&QM[:3P[XDO=*OXX%AFEA4!+C;P&91T..]
M&=\;KJ/4+_PQX<M1YVH3WRR^6ARR*"!DCWY_*G_$G4]:U#QIH7@;3-3?2[>\
MCW7%RAPSCIM!^@/'<FNA\&_"ZQ\,:M-K5]?SZOK$F<75R.8P>NT<\^]:/C?X
M?:9XWMX&N)9;2_MCFVO8/OQ\YQ[B@#D[SX-^$=)T>[O]6N]0O/L\+2-+<W9
MR!U.,#TXIG[/TL</PWNI9&"1I>2LS'H %4DU;M?A/J-Y,J^)_%U_J]C&<I:,
M-J,>Q?GG!P<>U=/X$\$6_@?P_+I$5V][%),TI:6,+]X $8';B@#F+KX<^ OB
M$TNO:1<-'+([*]UI\FT%QU.WIG/.<<U@:9-XC^'7Q0TCPQ+KDFKZ3JF=J3G,
MD0)QD]P>!['FMVZ^#TMAJ5Q=^$O$U[H<=P^^2UC&Z,$]2.?TK5\)_"VR\/:X
M^OZAJ5UK&LG(6ZN3]P$8X'KUY]Z /.?$WAG3;_\ :#N++7IKFVMM5ME>VEBE
M\O+A54#/I\C#'KBNQD^!OA:*)Y)-0U58T4LS-=D  =2:ZSQIX%TGQO810:@'
MBN(&W6]U"<21'V/I[5QK?![5KN$6.H>/-6N-,4X$&,%E[@G/^- &WX'T7POH
M_A#4_P#A%;XWMG/YC22F3?\ .%QBL3]G?_DF\_\ V$9?_0(Z]!TCPUIV@^'5
MT33(O(M5C9 >K$D<L3W-9W@'P5#X#\/OI$%[)=H]PT_F2(%()"C&!_N_K0!P
MWP9_Y&[QW_V$#_Z$].^#O_(W^./^O[^K5V?A#P+!X2U76[^*_EN6U6?SV1T"
MB,Y8X&.OWOTI?"7@:'PGJNLW\5]+<MJDWG,CH%$9R3@8Z]: .8^/W_).E_Z_
M(OYU4^,NGS7WP8LY849A:-;SR;>R["N3[?,*[CQUX.A\<: -)FO)+1!*LOF1
MH&/';!K;73H#I*Z;<(L]OY(@=7'#KC!R/>@#R?P]\(O"'B'0++5;34=4:*YB
M5^+LG:<<@^X-7=*^'7@;P]XYT]$U:Y?7(?W\%M-<EF(YYQZ=:/\ A34^E7,K
M>&/%NI:3;2L2ULOS*H/7'-;_ (.^&6F^%-0EU6:\N=4U>4%6O+HY('^R.<?G
M0!V]>._&1O[*\5^#/$$\;-96UV8YF'1,D$9_#)_"O8JS==T+3_$FCSZ7JENL
MUK,N"#U4]F![$>M %^&:.XA2:%UDC=0RNIR&!Z$&O(=+F3Q!^T=>7^G[9+73
M+#R)Y5Y4O@C&?7+8_P" FIT^#>IVD!T_3O'6JVVDL3_HX&2H] <_X5V_@_P5
MI/@G37M-,1R\S!YYY6W/*WJ3^?'O0!P/Q(_Y+'X$_P!]OYU[#7)^(? T'B#Q
M;HGB"2^EADTHDK"J B3)SR>U=90 5Y9XXT+7_$'B>2U?QI;Z+H0C0&W2<+*_
M][(R/UKU.N+\2?"SPMXKU=M4U2UF>Z9 A9)BH('3B@#&T+X>_#?1&65IK#4+
MKO/>W22$GUP3@5Z)9364T&;"6W>%3C]PRE1[<<5Y]_PHCP+_ ,^5U_X$-76^
M%O".D^#M/DL='CDC@DD\Q@[[CNQCK0!NT444 >/? K_7^+_^PF?ZTGQ?W:)X
MS\'>*GC;[)9W/E7$@Z %@?Y;J[7P3X%@\%OJK0WTMU_:%QY[;T"[#SP,=>M;
M>NZ%IWB31Y]+U2W$UK,,,.A![$'L1ZT 7HIX9[=+B*17A= ZR*>"I&0<^F*\
M=\&SQ^+/COK_ (BLV,FGV5N+6.7'RLV ORG_ ("3^-3O\$;Q+4Z?:>-]5ATP
M\?9B,A1Z#D<5Z'X4\*:7X.T5-+TJ(K$"6=W.7D8]2QH \[T+_DY#7?\ KR'\
MEJ_\?O\ DF<G_7U%_.NELO T-E\0KWQ<+Z5Y;J'RC;E %4<<YZ]JG\<^#X?'
M'AUM'GO)+1#*LGF(@8_+VP: -70?^1>TW_KUC_\ 017E_P '?^1N\;_]?W]6
MKUBQM18V%O:!RXAC6,,1@G QFN;\)>!H?">JZS?Q7TMRVIS><R.@41G).!CK
MUH XOX6_\E/\=_\ 7P/_ $(TOQX_X]O"W_847^E=GX9\#0^&O$FMZS'?2SOJ
MKAVB9 !'SG@CKUI?&_@>'QK'IB37TEK]AN1<+L0-O(['/2@#HKG_ )!DO_7$
M_P J\N^ 7_(JZK_V$9*]6DB$EL\.<!D*Y_#%<UX&\%0^!],N;*&]DNUGN#.6
MD0*03VXH ZFO%-: /[3FD @$?9!U'^PU>UUQUYX @N_B1:^,CJ$JS6\7EBV$
M8VG@C.>O>@#KO*C_ .>:_E7C_P 855?&O@,*H'^GCH/]M*]CKDO%O@6#Q9K.
MB:C+?RVS:5/YRHB!A(<@X)/3[OZT <W\<M)N[CPM8ZW8Q+++HMVMTRD?P=S^
M87(]/I7:^$_%.G>+M M]4T^97#J/-CS\T3]U8=JVI8HYHGBE17C<%65AD$'L
M17EM_P#!*PCU!KWPSK5_H4CL6>.!MR'Z#(Q^M %GQ_H7@'PUX9U'4[W0]*2Z
MDC?R<P+ODE;I@=SDYS4WP1TFXTGX960NHVC>YD>X"MP0K' _,#/XU2TWX)V'
M]L1:GXBUN^UV6(ADCN>$!]QDY'MQ7J*JJ*%4!5 P !@ 4 ,GD\F"27:6V*6P
M.^!7A/A/0]1^+MSJ6M:_X@O8K*&Y:&'3[278$'OZ#I]<5[U7F&I_"%X=9N=5
M\)^(;O09;HYFAB&8V.<DCGCZ4 >??%/P3X:\&-X>CTKSO[0N+U3(9IS(S1CO
M@GCDBO9_B)_R3?7?^O-JY*Y^"-KJ$%O+J&OWMUJJ7"SRWTJAF<*.(P"?E7))
MKT^ZLX+ZRFL[J)9;>:,QR(PX92,$4 <;\'R#\+=%P<_NC_Z$:[FO//#'PND\
M):]'=:7XEOQI2,S?V;( R$'MG/XYQ7H= 'C_ ,=_N>%/^PHO]*]>3_5K]!7*
M^-O T'C4:6)KZ2U^P7(N%V(&WD=CGI75J,*!Z"@#QWX:KO\ BUX_7UDQ_P"/
M&CX*7,>FZSXK\-W0\G4(KYI@CG#.F2,@>W!_X%7;>'/ L'AWQ7KFO1W\L[ZL
MVYH60 1\YX/>J7C'X8:=XIU.+6+:\N-*UF( "\M>"V.FX=_3- &C\1M6M-&\
M :S<7CH%DMGA16/WW<$ #WYS^%<%I^E7=A^S+=6\T3":2QDF"8Y 9MPX^E:=
MO\&_M^H177BOQ+J&N)"VY+>4[8SCIGGFO3I+6"6T:U>)6MV3RS&1P5QC'TQ0
M!Q?P?N89_A;HBPRHYBB9) ISM;<>#Z'FN'U?5+34OVGM!2TF67[);-;RE3D!
MPDK$?AN%:C? Q+.ZN?[#\5:EIEC<L?,MH^0!Z Y%;6G?"/2=(\6Z/KNGW<T0
MTV%H_(90QF9M^7=^I)\S]!0!A?%7_DI7@3_KY/\ Z$*]@KD_$_@:'Q-XBT35
MY+Z6!]*DWK&J B3D'DGITKK* "N9\0>.M)\,Z[IFE:F)XWU$XAF"?NP<XPS9
MXZC\ZZ:L+Q7X1TCQEI)T[5X"Z!MT<B'#Q-ZJ>U &V\<<J%7174CHPR"*\8^'
M0AL/C9XMT[1?^0/Y6]DCYB23*],<=2P_/TJZ/@SJB0?8T\?:P+$C:8\<X],[
MJ[OPCX,T?P5IKV>DPL/,;=--(VYY6]2?QH WS+&)!&74.>0I/)_"G5Y)=P3:
M[^T?;>5,_P!GT;3P\X4G;N.[:I]SY@/X5ZW0!!>VL=]8SVDPS'-&T;#V(Q7S
M&E_/;>$+OX7,\BZA)KZ6JEQC]RS @_\ ?2@_\"KZCKAI_A?I<_Q+C\:-.XF0
M!C:[!L:0*5#D^O3\10!SWQ-L!X9G\%Z]9!(K;2+I+63(/RQ, .3Z !OSIOPH
M3_A(_%OBGQI(,I<7!MK0D=(U[@_3%>@>+_#,'B_PS=Z+<3/ EQMQ*@R4((.<
M=^E1>"O"=MX*\-0Z+:SO.D;,YE=0I8L<G@4 >??$C_DM'@#_ *Z'_P!#%6/V
MB?\ DG%O_P!A*+_T"2NM\0^!8/$'B_0_$,E])#)I+;DA5 1)SGD]NE:WB;PW
MIWBS0I](U2,O;RX(*\,C#HP/8B@"]I__ "#;7_KBG\A7DOP)_P"/[QK_ -A/
M^KUV/@CP3?>#VG2;Q)>:G:L@2&"X48B Z$')^E2^"? D'@N;6)(;Z6Z_M.X^
MT,'0+L.6X&.OWJ .5_:$_P"2;+_U^Q?R:JWQEM97^&.C7\<3R)8S02RJO9=N
M,G\<#\:[GQYX,A\=>'AI$]Y):()EF\R- QXSQ@_6MMM,M9]'_LN[B6XMC"(9
M$D7(=<8Y% $>A:E:ZOH5E?V<BR030JRE3G''3ZCI7EOC.5-=^.OA'3;#;)-I
MFZ>Z9>=BY#8/IPO_ (]5H?!FZTN2:/PWXPU/2[&=LO:CY@H[X.174>"OAWI7
M@MI[F"6>]U*Y&)[VY;+N,YP/0=/RH XGQM+':?M$>#;FX=8H#:%/,<X7=^]&
M,_5A^=>F>+M4M-'\):I>7LR10K;NN6.,L5( 'N2:S?'7@#2_'FG0P7SR07%N
MQ:WN8OO1YZCW!P./:N;TOX.)'<++KGB._P!86&,I;0S_ .KC." Q4D[B,T 1
M?L^?\DS_ .WZ7^2U0\.$?\-.>*.?^8>O_H,%=[X$\&P^!?#O]CP7DEVGG--Y
MDB!3\P'&!]*R?%_PPM?$FM1:[I^IW.CZPB['N;;_ ):+T^89'.._TH [VBJ>
MDV<^GZ3:V=S>27LT,81[F08:0C^(^]7* "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **Q_%6H:GI7AJ]O=&L!?7\4>Z* YPQ_#D\<XJ/PAJ6JZOX6L;[6K 6.H
M3(3+ ,C;R0#@],C!Q[T ;E%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 444'.#@9- !17%^!O$7BC7+O5X_$&A+IT5M-LMW&1O&3QR>>,<CBNTH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M:EI$6GJ%\VTM(VW/\PQR??GKVKT;P_HMOXA^#^G:1=$K#=Z8D3,O5<KU'TH
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M:-7MK28!Y'7'!8D<$CM47Q] .@:&",@ZDG%>KVW%K#C^XO\ *@#@_AEX[O\
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MU^Q&)9'VD8WY3_%ZD3XC>+_&.K7UKX$T:T:PM)3$VHWC_(Q'<#(Z]<#)Y&:
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M&WCK7;RW\#1VEIH]D[1/?W2;O-;_ &<_T]>:]&\723Q>#M9>W.)5LY2I_P"
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M,8/?H .A'';->WT4 >#>,M ^(7CM-+U.[T9;6.WNU\K3(Y4+1KP6E=B1G/0
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M.9%ZC<3S^>*O^"?"?B?4/'D_CKQ=%!9W)@,%K8Q')C7I\V/;/<G)[8Q7JM%
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MS'9V,;;G'H6(SQR3UZ]A7K5% 'EFMVOC[PKXSNM:T6*3Q#I%Z,-8RSX:W/\
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M* /*/!OA3Q1JOC^3QSXNA@L9E@,-I8Q-EHQT^8C/8GN22>V,5ZO110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>img11953243_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img11953243_2.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" /U!2X# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#8\#^!].\7
MZ1<ZEJ5U?"X%TT9,4B_,-JMD[E)SEC73?\*>\/\ _/YJ?_?V/_XBCX/?\BE=
M_P#7\_\ Z+CKT&M)2:9$8IH\^_X4]X?_ .?S4_\ O['_ /$4?\*>\/\ _/YJ
M?_?V/_XBO0:*GGEW'RH\^_X4]X?_ .?S4_\ O['_ /$4?\*>\/\ _/YJ?_?V
M/_XBO0:*.>7<.5'GW_"GO#__ #^:G_W]C_\ B*/^%/>'_P#G\U/_ +^Q_P#Q
M%>@T4<\NX<J//O\ A3WA_P#Y_-3_ ._L?_Q%'_"GO#__ #^:G_W]C_\ B*]!
MHHYY=PY4>??\*>\/_P#/YJ?_ ']C_P#B*/\ A3WA_P#Y_-3_ ._L?_Q%>@T4
M<\NX<J//O^%/>'_^?S4_^_L?_P 11_PI[P__ ,_FI_\ ?V/_ .(KT&BCGEW#
ME1Y]_P *>\/_ //YJ?\ W]C_ /B*/^%/>'_^?S4_^_L?_P 17H-%'/+N'*CS
M[_A3WA__ )_-3_[^Q_\ Q%'_  I[P_\ \_FI_P#?V/\ ^(KT&BCGEW#E1Y]_
MPI[P_P#\_FI_]_8__B*/^%/>'_\ G\U/_O['_P#$5Z#11SR[ARH\^_X4]X?_
M .?S4_\ O['_ /$4?\*>\/\ _/YJ?_?V/_XBO0:*.>7<.5'GW_"GO#__ #^:
MG_W]C_\ B*/^%/>'_P#G\U/_ +^Q_P#Q%>@T4<\NX<J//O\ A3WA_P#Y_-3_
M ._L?_Q%'_"GO#__ #^:G_W]C_\ B*]!HHYY=PY4>??\*>\/_P#/YJ?_ ']C
M_P#B*/\ A3WA_P#Y_-3_ ._L?_Q%>@T4<\NX<J//O^%/>'_^?S4_^_L?_P 1
M1_PI[P__ ,_FI_\ ?V/_ .(KT&BCGEW#E1Y]_P *>\/_ //YJ?\ W]C_ /B*
M/^%/>'_^?S4_^_L?_P 17H-%'/+N'*CS[_A3WA__ )_-3_[^Q_\ Q%'_  I[
MP_\ \_FI_P#?V/\ ^(KT&BCGEW#E1Y]_PI[P_P#\_FI_]_8__B*/^%/>'_\
MG\U/_O['_P#$5Z#11SR[ARH\^_X4]X?_ .?S4_\ O['_ /$4?\*>\/\ _/YJ
M?_?V/_XBO0:*.>7<.5'GW_"GO#__ #^:G_W]C_\ B*/^%/>'_P#G\U/_ +^Q
M_P#Q%>@T4<\NX<J//O\ A3WA_P#Y_-3_ ._L?_Q%'_"GO#__ #^:G_W]C_\
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M'_\ G\U/_O['_P#$5Z#11SR[ARH\^_X4]X?_ .?S4_\ O['_ /$4?\*>\/\
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M^_L?_P 11_PI[P__ ,_FI_\ ?V/_ .(KT&BCGEW#E1Y]_P *>\/_ //YJ?\
MW]C_ /B*/^%/>'_^?S4_^_L?_P 17H-%'/+N'*CS[_A3WA__ )_-3_[^Q_\
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MW_"GO#__ #^:G_W]C_\ B*/^%/>'_P#G\U/_ +^Q_P#Q%>@T4<\NX<J//O\
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M_-3_ ._L?_Q%>@T4<\NX<J//O^%/>'_^?S4_^_L?_P 11_PI[P__ ,_FI_\
M?V/_ .(KT&BCGEW#E1Y]_P *>\/_ //YJ?\ W]C_ /B*/^%/>'_^?S4_^_L?
M_P 17H-%'/+N'*CS[_A3WA__ )_-3_[^Q_\ Q%'_  I[P_\ \_FI_P#?V/\
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M&I<R!LZX_%CQ?J?B")XKXVMK+.JB"*$%0N<=2,]*]\\3>)K+PIH,NJ7Q)5
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M_(VVO_7@G_HR2O;*\3^,'_(VVO\ UX)_Z,DK2E\1$]CJ_@]_R*5W_P!?S_\
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M7-_\(>G_ $'_ !!_X'M_A1_PAZ?]!_Q!_P"![?X46CW Z2BN;_X0]/\ H/\
MB#_P/;_"C_A#T_Z#_B#_ ,#V_P *+1[@=)17-_\ "'I_T'_$'_@>W^%'_"'I
M_P!!_P 0?^![?X46CW Z2BN;_P"$/3_H/^(/_ ]O\*/^$/3_ *#_ (@_\#V_
MPHM'N!TE%<W_ ,(>G_0?\0?^![?X4?\ "'I_T'_$'_@>W^%%H]P.DHKF_P#A
M#T_Z#_B#_P #V_PH_P"$/3_H/^(/_ ]O\*+1[@=)17-_\(>G_0?\0?\ @>W^
M%'_"'I_T'_$'_@>W^%%H]P.DHKF_^$/3_H/^(/\ P/;_  H_X0]/^@_X@_\
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M7-_\(>G_ $'_ !!_X'M_A1_PAZ?]!_Q!_P"![?X46CW Z2BN;_X0]/\ H/\
MB#_P/;_"C_A#T_Z#_B#_ ,#V_P *+1[@=)17-_\ "'I_T'_$'_@>W^%'_"'I
M_P!!_P 0?^![?X46CW Z2BN;_P"$/3_H/^(/_ ]O\*/^$/3_ *#_ (@_\#V_
MPHM'N!TE%<W_ ,(>G_0?\0?^![?X4?\ "'I_T'_$'_@>W^%%H]P.DHKF_P#A
M#T_Z#_B#_P #V_PH_P"$/3_H/^(/_ ]O\*+1[@=)17-_\(>G_0?\0?\ @>W^
M%'_"'I_T'_$'_@>W^%%H]P.DHKF_^$/3_H/^(/\ P/;_  H_X0]/^@_X@_\
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M'_$'_@>W^%'_  AZ?]!_Q!_X'M_A1:/<#I**YO\ X0]/^@_X@_\  ]O\*/\
MA#T_Z#_B#_P/;_"BT>X'245S?_"'I_T'_$'_ ('M_A1_PAZ?]!_Q!_X'M_A1
M:/<#I**YO_A#T_Z#_B#_ ,#V_P */^$/3_H/^(/_  /;_"BT>X'245S?_"'I
M_P!!_P 0?^![?X4?\(>G_0?\0?\ @>W^%%H]P.DHKF_^$/3_ *#_ (@_\#V_
MPH_X0]/^@_X@_P# ]O\ "BT>X'245S?_  AZ?]!_Q!_X'M_A1_PAZ?\ 0?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>)_&#_
M )&VU_Z\$_\ 1DE>V5XG\8/^1MM?^O!/_1DE:4OB(GL=7\'O^12N_P#K^?\
M]%QUZ#7GWP>_Y%*[_P"OY_\ T7'7H-3/XF..P4445)04444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7B?Q@_Y&VU
M_P"O!/\ T9)7ME>)_&#_ )&VU_Z\$_\ 1DE:4OB(GL=7\'O^12N_^OY__1<=
M>@UY]\'O^12N_P#K^?\ ]%QUZ#4S^)CCL%%%%24%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5XG\8/^1MM?^O!
M/_1DE>V5XG\8/^1MM?\ KP3_ -&25I2^(B>QU?P>_P"12N_^OY__ $7'7H->
M??![_D4KO_K^?_T7'7H-3/XF..P4445)04444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !7B?Q@_Y&VU_Z\$_]&25[
M97B?Q@_Y&VU_Z\$_]&25I2^(B>QU?P>_Y%*[_P"OY_\ T7'7H->??![_ )%*
M[_Z_G_\ 1<=>@U,_B8X[!1114E!1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %>)_&#_ )&VU_Z\$_\ 1DE>V5XG
M\8/^1MM?^O!/_1DE:4OB(GL=7\'O^12N_P#K^?\ ]%QUZ#7GWP>_Y%*[_P"O
MY_\ T7'7H-3/XF..P4445)04444 %9?B/6HO#OAV_P!7F4LEK$9-H[GL/SQ6
MI6/XJT.+Q)X7U'2)FV)<PE0V<;2.0?S H \7\,:1XW^*UM/KU]XGN=*L7D*0
M0VI*9 ],8X'3WJW;>(_$_P +/&UAH/B+46U71+[Y+>>3F11D#.>N02 <U0\"
M_$V+X>6L_A+7K9[H6<K>1/IX$@92>>_/.>:@DOG^-7Q-L&A5++2=);($[ 3.
M,@GY>Y)4# Z#- 'N?B?Q#:^%_#EWK%US% FX*/XF[#\37COA[0O&_P 4[-]?
MU+Q+<Z392N?LL%FQ3Y?PQQ]>M;_[0<TD7P_AMT.V.6Z0,/7'2N_\&VJ67@S1
M[:, )':1@8&.U 'F&@>)?%7@/QY;>%/%=TVH:;>D1V5ZPYR> <_H<UW7Q.\7
M2^#?!EQ?VP4WDK""VW= [=_P )K@_P!HE)(+'P]J,#F.6"Z8!@<$< @BM_XL
MZ-?^)/AM:7-A$TMS:217ODJ-Q<!3D?KG\* .8U/PMXK\,>$4\:VOB_4+G5(H
MEN;FWGDS 5898!3QP#7K?A77E\1^%-.UID$7VF 2.N>%/>O*?%?Q/T;6_A@=
M(TUI)M:O($M6L1$V]&P W&.GI5S6+R]\!_"/1O#-JI/B#4HUM4B#996;[[#V
M&<?C0!?T&_OO'GQ2N]3ANIH_#^B9MHXXY6"7$W<G!P<=>?:O5:Y?P?H>G^!O
M"5CI;W$43JN^625@I>0\L>??C\*Z=65U#*P93T(.0: %HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH *\3^,'_(VVO_ %X)_P"C)*]LKQ/XP?\
M(VVO_7@G_HR2M*7Q$3V.K^#W_(I7?_7\_P#Z+CKT&O/O@]_R*5W_ -?S_P#H
MN.O0:F?Q,<=@HHHJ2@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZ_X7_I'_ $!+_P#[[3_&C_A?^D?] 2__ .^T_P :\%HH^JTNP<S/>O\ A?\
MI'_0$O\ _OM/\:/^%_Z1_P! 2_\ ^^T_QKP6BCZK2[!S,]Z_X7_I'_0$O_\
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M_P C!IO_ %]1_P#H0K[)K@QNZ*B%%%%<)04444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %>)_&#_D;;7_KP3_T9)7ME>)_&#_D;;7_ *\$
M_P#1DE:4OB(GL=7\'O\ D4KO_K^?_P!%QUZ#7GWP>_Y%*[_Z_G_]%QUZ#4S^
M)CCL%%%%24%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110!B^+O^1.UG_KSE_]!-?'
M\?\ JU^@K[ \7?\ (G:S_P!><O\ Z":^/X_]6OT%>C@OA9$AU%%%=@@HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH OZ'_ ,C!IO\ U]1_^A"OLFOC;0_^1@TW_KZC_P#0
MA7V37!C=T5$****X2@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MU#4[\F8&X)81J2<<>IJIXX^'=]H?C+1_$7@;39$D\W_28;884<Y+'G@$9&*
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M1^%>K4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M&+XN_P"1.UG_ *\Y?_037Q_'_JU^@K[ \7?\B=K/_7G+_P"@FOC^/_5K]!7H
MX+X61(=11178(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** +^A_\ (P:;_P!?4?\ Z$*^
MR:^-M#_Y&#3?^OJ/_P!"%?9-<&-W140HHHKA*"BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MLIE?R(A%*@ZHPZ@CMZUQ/[1=U"_AK2M,5MUY->ATC')("D?S(H G_:!ECN/
M-A-$P>.2Y1E8="",@UZ7X754\*Z4JJ%46L> .W KSKXJZ'<W?P5M D8\[3X(
M)'!ZJ%4!JZ_X::Q%K?P^T>Y2=)I5MUCFV_PR*,$&@#@?VCHU;P]HLA'S)=L
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%% !1110 4444 %%%% !1110!B^+O^1.UG_KSE_]!-?'\?\ JU^@K[ \7?\
M(G:S_P!><O\ Z":^/X_]6OT%>C@OA9$AU%%%=@@HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH OZ'_ ,C!IO\ U]1_^A"OLFOC;0_^1@TW_KZC_P#0A7V37!C=T5$****X
M2@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?Q_ZM?H*]'!?"R)#J***[!!1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!?T/_ )&#3?\
MKZC_ /0A7V37QMH?_(P:;_U]1_\ H0K[)K@QNZ*B%%%%<)04444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %>)_&#_D;;7_ *\$_P#1DE>V
M5XG\8/\ D;;7_KP3_P!&25I2^(B>QU?P>_Y%*[_Z_G_]%QUZ#7GWP>_Y%*[_
M .OY_P#T7'7H-3/XF..P4445)04444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &+XN
M_P"1.UG_ *\Y?_037Q_'_JU^@K[ \7?\B=K/_7G+_P"@FOC^/_5K]!7HX+X6
M1(=11178(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** +^A_\ (P:;_P!?4?\ Z$*^R:^-
MM#_Y&#3?^OJ/_P!"%?9-<&-W140HHHKA*"BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
MOZ'_ ,C!IO\ U]1_^A"OLFOC;0_^1@TW_KZC_P#0A7V37!C=T5$****X2@HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\3^,'_(VVO\
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MBO?Z* /"_#OA_P 2?$GQW;^*_%-@;#2[$@VMHXP6P<@8/.,\DFO= ,# HHH
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M\?\ JU^@K[ \7?\ (G:S_P!><O\ Z":^/X_]6OT%>C@OA9$AU%%%=@@HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MKQ/XP?\ (VVO_7@G_HR2O;*\3^,'_(VVO_7@G_HR2M*7Q$3V.K^#W_(I7?\
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MG'!;;A@"?QK6^.IDN_AU874:LUL+R&6<IV0J?ZD5G_M&R*/#VB1<[GNVVCZ
M?XUZLFEVVH>&XM-U"!)H)+=8Y(V&0?E% '&^/=3L$^"=U,DR&">P2*$Y!R2H
MP/K6?HOB(^"/@-IVH7C#[0;4):Q@'+.WW%^O?\*MP?!#PU%>H\EUJ4]C&X>/
M3Y;@F!#["LJ]B'Q"^*UOI448/A[PU\T^W[DD_93VXQQ^- '2?"GPQ<:%X8-]
MJ67U?59#=W;MR<MT&?IC\2:[RO'6\2>,_'7BS5-+\)7UMI&F:6QB:Y>,.7<<
M8P?<'Z5T'P_\::IJ>KZEX8\20Q1:UIQR7B.%F3.-P'Y?G0!Z%1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110!B^+O\ D3M9_P"O.7_T
M$U\?Q_ZM?H*^P/%W_(G:S_UYR_\ H)KX_C_U:_05Z."^%D2'4445V""BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@"_H?_ ",&F_\ 7U'_ .A"OLFOC;0_^1@TW_KZC_\
M0A7V37!C=T5$****X2@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M]!KS[X/?\BE=_P#7\_\ Z+CKT&IG\3''8****DH**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@#%\7?\ (G:S_P!><O\ Z":^/X_]6OT%?8'B[_D3M9_Z\Y?_ $$U
M\?Q_ZM?H*]'!?"R)#J***[!!1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!?T/_D8--_Z^
MH_\ T(5]DU\;:'_R,&F_]?4?_H0K[)K@QNZ*B%%%%<)04444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %>)_&#_ )&VU_Z\$_\ 1DE>V5XG
M\8/^1MM?^O!/_1DE:4OB(GL=7\'O^12N_P#K^?\ ]%QUZ#7GWP>_Y%*[_P"O
MY_\ T7'7H-3/XF..P4445)04444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ KQ/XP?\ (VVO_7@G_HR2O;*\3^,'_(VVO_7@G_HR2M*7
MQ$3V.K^#W_(I7?\ U_/_ .BXZ]!KS[X/?\BE=_\ 7\__ *+CKT&IG\3''8**
M**DH**** "BBB@ HKB]=^*_@WP]=M:WNK(\Z_>2W4RE3G&#MZ&M;PWXS\/\
MBR'?HVHQ7#!=S1=)%'NIY% &]117%:]\5_!WAV]:TO=55IU.'2W0RE#Z';TH
M [6BL;P_XKT3Q3;&?1]0AN@H!=5/S)GU'45JSSQ6T$D\\BQQ1J6=V. H'4F@
M"2BN%LOC!X)O]7&FQ:N%F9BJR21E8R1Z.>*[H$$ @Y![T %%8=[XLTJP\2V?
MA^625M2NUWQQ1Q%L+ZL1T''>MR@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH Q?%W_(G:S_UYR_^@FOC^/\ U:_05]@>+O\ D3M9
M_P"O.7_T$U\?Q_ZM?H*]'!?"R)#J***[!!1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!?
MT/\ Y&#3?^OJ/_T(5]DU\;:'_P C!IO_ %]1_P#H0K[)K@QNZ*B%%%%<)044
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P!?4?\ Z$*^R:^-M#_Y&#3?^OJ/_P!"%?9-<&-W140HHHKA*"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBDW+ZC\Z %HHHH **
M0D#J0* 0>AS0 M%%0W-W;V<8DN9XX4)P&D8*,_C0!-145O<P7<?F6\T<J=-R
M,&'Z5+0 449!Z44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7B?Q@_Y&VU_P"O!/\
MT9)7ME>)_&#_ )&VU_Z\$_\ 1DE:4OB(GL=7\'O^12N_^OY__1<=>@UY]\'O
M^12N_P#K^?\ ]%QUZ#4S^)CCL%%%%24%%%% !6#XR\1-X4\+W>M+9M=BV +1
M*V#@D#/ZUO5#=6L%[:RVMS&LL,JE'1AD,#U% &/X.\46WC#PU:ZQ;+Y8F!#Q
M%@3&P)&#_/\ &O-/VB[NR;PUIE@=KZ@]V'B13\P7:03CT)(%22_!75=&U&2X
M\&^*I],AE9F:"7)49] .OU/-:7A;X.1V&M)KGB?59=;U.-@T1D)*(1T.#UQ^
M5 %+XC^'[J[^!5D@C'VBPMX)G4]0H4;A]:['X8ZU#KGP]TB>.X6::.!8I\=5
MD48((KJ[B"*ZMY+>=!)%(I1T;H0>HKQZ;X+ZQHVISS>#/%,NEVEQDO;R[F"D
M]ACT]3S0!G_'*Z37O$WAKPK9CSKOS][JC<C>0 #Z=,U[E"GEP1IC&U0/TKSO
MP'\*+?PKJ<NM:I?/JNM2?\O$F<)GJ1GG/N:]'H R_$6N6OAS0;S5KMU6*WC+
M88XW'L/Q/%<+\)-'NIK34/&6K1?\336I#(FY>8X?X0/8\?D*V_'O@R[\;?V;
M8M?I;Z1%.);R$*=\X'0 ]!780Q)!"D,2A8T4*J@< "@#Q[X)!)M;\8W4[(U\
M=1=6!'S!<G],\?A2>%)%A_:'\26UEM6V>U+3HG \P,O)]^3^9K8UCX8:G;^*
MKCQ%X-UU='N[L$743PAXV]P,=<Y/-;G@7P#;^$([F[GN6O\ 6+UM]W>R=7/7
M ]!0!V-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &
M+XN_Y$[6?^O.7_T$U\?Q_P"K7Z"OL#Q=_P B=K/_ %YR_P#H)KX_C_U:_05Z
M."^%D2'4445V""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"_H?\ R,&F_P#7U'_Z$*^R
M:^-M#_Y&#3?^OJ/_ -"%?9-<&-W140HHHKA*"BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** /G[XS_%+4[;69/"^@S/;"' N9XC\[L1G
M8/08/-<E_P *D^(1T7^VS(V_;YWV<W+>?ZYQTS^->]W7PJ\'7FM/J]QI.^]>
M43,YF?!;UQG%;GB3Q!8>%M!N-3U"5(X84.U2>7;'"CU)H \)^$7Q6U@>)8/#
MOB"Z>YM[EO*ADEY>.3L,]P3Q[5ZS\3/':> _#/VU(A->3OY-M&3QNP3N/L,5
M\]_"_2;KQ9\5X=1@B,<,%V;^8@95!N+!?Q/%?5.IZ+IFM1)'J=A;W:(<J)D#
M8/M0!\KZ/H_Q!^*TTMVM]-+#$Y'G7$Q2-2?X5Q44MYXX^$/B1(I[B1<_,%9R
M\-PF1G&:^@?$GC+PS\+XK6SDLF@AN-SI';1_*/7BO"_&OB/4?C+XML+/0],9
M8X T<"NPR=V"68] /EH ^FO#6N0^)/#ECK$ VI<Q!RO]T]Q^!S7S]/'=?%GX
MR7>EWU_-;Z=:>8(XT/W44XP/<GG->[^"O#P\+>#]-T8MN>WB^<_[9)9OU)KR
M'Q/X*\7^#/B#<^*O!UM]L@NMS/&%#%=WWDV]<>A% %/P')>^ /C3<^$$O9+K
M3YCM8..Y0,I]B,X-=[\6_&\^CV,/AS1"[Z]JA$<8C^]$AZM]3T'X^E<%H&@Z
MSX?UJ^^)7CW$!B0R00LXWRRD85<#ICC KI_A7X:OM?UBX^(7B16-]<L191."
M/*3^\,]L' _&@#N_ /AB3PKX6M[*YGDGO7'F7,DCELN>H&>PZ?A73T44 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !7B?Q@_P"1MM?^O!/_ $9)7ME>)_&#_D;;7_KP
M3_T9)6E+XB)['5_![_D4KO\ Z_G_ /1<=>@UY]\'O^12N_\ K^?_ -%QUZ#4
MS^)CCL%%%%24%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M#+&[?,5=1G[W<$=*]UKY]^%6DZMXJ^)MYXWO[)[6T&\H'! 9F& !GK@5]!4
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MC_\ 0A7V37!C=T5$****X2@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M;0_^1@TW_KZC_P#0A7V37!C=T5$****X2@HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBO*/BWJ=_8
M:IIBV=[<6ZO"Y812%03D=<5OAJ#KU%33L8UZRHTW-JYZO17S)_PD.M_]!B__
M / AO\:/^$AUO_H,7_\ X$-_C7I?V-/^='G_ -JP_E/INBOF3_A(=;_Z#%__
M .!#?XT?\)#K?_08O_\ P(;_ !H_L:?\Z#^U8?RGTW17S)_PD.M_]!B__P#
MAO\ &C_A(=;_ .@Q?_\ @0W^-']C3_G0?VK#^4^FZ*^9/^$AUO\ Z#%__P"!
M#?XT?\)#K?\ T&+_ /\  AO\:/[&G_.@_M6'\I]-T5\R?\)#K?\ T&+_ /\
M AO\:/\ A(=;_P"@Q?\ _@0W^-']C3_G0?VK#^4^FZ*^9/\ A(=;_P"@Q?\
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MAUO_ *#%_P#^!#?XT?V-/^=!_:L/Y3Z;HKYD_P"$AUO_ *#%_P#^!#?XT?\
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MC=T5$****X2@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P#K^?\ ]%QUZ#7GWP>_Y%*[_P"OY_\ T7'7H-3/XF..P4445)04444 %!(
M))P!WHKA_BOJFL:=X(N(]#M+FXO;MA;C[/$79%/WC@>P(_&@#D/'_P 5+F_U
M!O"'@A'NM3G;R9+J/D)ZA??W[5TWPV^&%GX(MS?7#FZUNX3$\['(7)R57^I[
MUX]X U?Q'X$MIO*^']Y=7LK$F[DMI-^W^Z..!7:GXP>-\<?#V\S_ -<9?\*
M-7]H*V>7X?).H)$%TA8 =CQ7=>"KQ=0\$:+=HI59;2-@#VXIVI:8GBWP:]C?
MQ& W]H-Z$<Q,RY_,&O'M!UCQ]\+8G\/WGAVXUJQ0LUI-;JS[1G@9&<#V/(H
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MD<.8_P"[OY?F>9T445]0?.!1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5W?PD_Y'-_\
MKT?^8KA*[OX2?\CF_P#UZ/\ S%<N-_W>?H=.$_CQ]3W*BBBOD3Z@**** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\3^,'_(VVO_ %X)_P"C
M)*]LKQ/XP?\ (VVO_7@G_HR2M*7Q$3V.K^#W_(I7?_7\_P#Z+CKT&O/O@]_R
M*5W_ -?S_P#HN.O0:F?Q,<=@HHHJ2@HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M9_$QQV"BBBI*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Q?%W_ ")VL_\ 7G+_
M .@FOC^/_5K]!7V!XN_Y$[6?^O.7_P!!-?'\?^K7Z"O1P7PLB0ZBBBNP0444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 7]#_Y&#3?^OJ/_ -"%?9-?&VA_\C!IO_7U'_Z$
M*^R:X,;NBHA1117"4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5X]\9O\ D+:5_P!<'_\ 0A7L->/?
M&;_D+:5_UP?_ -"%>AEG^\Q^?Y'#F/\ N[^7YGF=%%%?4'S@4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %=W\)/^1S?_ *]'_F*X2N[^$G_(YO\ ]>C_ ,Q7+C?]WGZ'
M3A/X\?4]RHHHKY$^H"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "O$_C!_R-MK_P!>"?\ HR2O;*\3^,'_ "-MK_UX)_Z,DK2E\1$]CJ_@
M]_R*5W_U_/\ ^BXZ]!KS[X/?\BE=_P#7\_\ Z+CKT&IG\3''8****DH****
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M +O/T.G"?QX^I[E1117R)]0%%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 8OB[_D3M9_Z\Y?_ $$U\?Q_ZM?H*^P/%W_(G:S_
M -><O_H)KX_C_P!6OT%>C@OA9$AU%%%=@@HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@"_H?_(P:;_U]1_^A"OLFOC;0_\
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M?DQ0 X 'IG'Y"O4Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MC;:_]>"?^C)*TI?$1/8ZOX/?\BE=_P#7\_\ Z+CKT&O/O@]_R*5W_P!?S_\
MHN.O0:F?Q,<=@HHHJ2@HHHH **** "BBB@#R']H?_D2+3_K[6O2/# "^%M+
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M;_\ 33_O@T?VG;_]-/\ O@U<P/2C ]*RO'L,I_VG;_\ 33_O@T?VG;_]-/\
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MO^_U'_"NO$7_ #RMO^_U?06!Z48'I1_:];L@_LRAYGS[_P *Z\1?\\K;_O\
M4?\ "NO$7_/*V_[_ %?06!Z48'I1_:];L@_LRAYGS[_PKKQ%_P \K;_O]1_P
MKKQ%_P \K;_O]7T%@>E&!Z4?VO6[(/[,H>9\^_\ "NO$7_/*V_[_ %'_  KK
MQ%_SRMO^_P!7T%@>E&!Z4?VO6[(/[,H>9\^_\*Z\1?\ /*V_[_4?\*Z\1?\
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M_P!-/^^#5S ]*,#THO'L!3_M.W_Z:?\ ?!H_M.W_ .FG_?!JY@>E&!Z47CV
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MD"(.C\#HOKWK=\#^ [/P;;W$IG>]U2[;?=7LOWI#UQ["NNHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "O$_C!_P C;:_]>"?^C)*]LKQ/XP?\C;:_]>"?^C)*
MTI?$1/8ZOX/?\BE=_P#7\_\ Z+CKT&O/O@]_R*5W_P!?S_\ HN.O0:F?Q,<=
M@HHHJ2@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHKQ_XA_$#6KKQ-'X'\%C_B9R<7-R.L7L
M#VP.2: /76FB0X:1%/NP%*KJXRC!AZ@YKQVS^!'VV/[1XE\2W][>R?-)L<[0
MW?!/)K'\2^!O$OPPLVU_PKX@N9K"V.Z>TF).U<^G1AZ]* /?*:9$5PA=0QZ
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MJ/8T =C1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5XG\8/\ D;;7_KP3_P!&25[97B?Q@_Y&VU_Z\$_]&25I2^(B>QU?P>_Y%*[_
M .OY_P#T7'7H->??![_D4KO_ *_G_P#1<=>@U,_B8X[!1114E!1110 4444
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M*\%?]#1I?_@0M>+2>'M-\3_M$:CINJQ-+:MO8HK;<D+Q7IP^"'@4'_D&2?\
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M'(]"/<5H44 >$6F@?$OX7M+!H21Z[H@;<D!&6&3SA1R#].*N:AXO^*OB*/\
ML[2?"<ND/*,-=3J1L^A;@?E7M=% 'GWPQ^&L7@>TFN[R5;G6+L?OYAT0==H_
M'J>]>@T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !7E'QZT+5=>\*Z;;Z3I]Q>RI>[W2!"Q5=C#)Q7J]%
M &7X:AEMO#&EP3QM'+':QJZ,,%2%&0:U*** &N,HP'H:\B^$.@:OI'BKQ//J
M.F7-I#<2DPO,FT.-QZ>M>OT4 >$:]X2\7>"?B1<^+?#.G#5;:ZR7BQN<;OO#
M Y[<&M676_B=XUC;2K70!X=MI5V3WERIW*IZ[0>O'\Z]BHH \5^"?AO6O"FO
M^(+#4["Z2!RODW;PE4F*D@D$^HP:M>-? .OZ5XQ7QKX((-VYS>6>['F^I'KG
MN/QKV"B@#P_5/$OQ4\6:<VBVGA2329)P4FNI 4 4]@3T^M=MX:^&MEI/PXE\
M*7LAN!=*QNI%&,N>>/H0,?2NZHH \'TJT^)'PKFFTS3]+.OZ&TA:#RP69 ?0
M#E?<4W5M&^(GQ6O+:'4[#^P=%ADRT4A*LWN1U)QG':O>J* .%\?Z!+_PJJ\T
M72+26=TMUBBAB7<S8]J\\\)0_$;X=:':+:Z)+JNFW2"5K0J1-;2'[PQU%>^T
M4 >&)X6\9_%+7["^\862:7HMF^];(J59^>1@G() '->I>,/"5GXN\*W&B3XC
M#*/(D SY3CH1_+Z&NAHH \+T;4?B=\/;==!D\.-KEC!D6\\"EB%[#([?6F6_
M@SQO\1_$^GZSXPB33=,M6#I9C(/!SC;U!.!DFO=Z* $50BA5& !@"EHHH *Q
MK#PIHFF:Y>:U9V*1:C>9\^8,Q+Y.3P3CK6S10 4444 4M7TNWUO1[O3+L$P7
M431/CJ 1C(]Z\+LO#7Q+^%M[-#X>B76=(D<LL6-WYKG*GZ=:^@:* /$G\<_%
MG5?]#LO!GV&60$?:)HG 3WRQP*Z/X8?#>X\+27.N:[/]IU^]SYK;MPC!.2 >
MY/<UZ510!S'CCP1IOCG0VL+U=DR9:WN%'S1-Z^X]17FNE77Q4^'\0TF31AX@
MTZ+_ %,L9+.$[ $?R->XT4 >):EJ?Q6\=6DNFV>A#0;23"2S3$I(5/7!/;Z"
MN[^'GP^LO 6DR01R_:;RX8-/<%<;CZ#VKLJ* .3\?^!;/QWH!L)W\BYC.^WN
M N2C>_J#WKSK3=1^+/@6./3KK1?[?LD^6*6++NJC@#(_K7N-% 'A.L/\4?B3
M$^E?V0- TISMG,P*LZ^ASR1[#%>J^#/"-AX*\/0Z58Y;!WRRMUD<]2?RKH:*
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KQ/XP
M?\C;:_\ 7@G_ *,DKVRO$_C!_P C;:_]>"?^C)*TI?$1/8ZOX/?\BE=_]?S_
M /HN.O0:\^^#W_(I7?\ U_/_ .BXZ]!J9_$QQV"BBBI*"BBB@ HHHH ****
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M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BD9@JEF(
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MG/R+SY?_ -<$_E0!W7QR_P"26ZA_UTB_]"%;7PQ_Y)IH/_7L/YFL+XVRI/\
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M,*Z3XN^!I]6T^V\4:(/+UK3%$A9.&DC SCW([>V: /5Z\,^%'_)8?&7^\_\
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MXZ]!J9_$QQV"BBBI*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% 'BW[1=L6T'0[S^&WNVS_ ," _P *]=TJ[2^TBSNHR"DT
M*N".G(KE_BMX=D\3?#[4+.$GSX@+B, 9W,G./QJI\'-?.N?#NQ65@;FR_P!%
ME7N-O S]10!P?Q[_ .1J\+_[_P#[,*]XC ,*@C(*CBO-/B=\/-6\9ZWHUYIT
M]I''9-F03,P)^8'C ->F(-J*IZ@ 4 >"^*;"[^$7Q"B\5Z;&\F@:A)MNX$X"
M$]1C]0?K2_!J]M]2^*?BN]M7WV\ZM)&V.H+@BO:=>T.R\1Z+<Z7J$*RP3J1A
MA]T]B/<5YO\ "GX7:OX#U[4+N_NK2:WGB\N/R68M][.3D#M0!T_C?Q7K_AR>
MU31O#5SJZRJ3(T*D[".QQ7)_\+1\<_\ 1.M1_P"_;_X5Z_10!Y=HWQ%\8ZAK
M5E9W?@2^M;::94EG=& C4GECGTKU&BB@#SSXV_\ )+=2_P!Y/_0JT?A1_P D
MPT'_ *]A_.K'Q%\-WGBWP9=Z/820QW$Q4JTQ(7@Y[ U:\$:'<^&_!NF:1>/&
M]Q:PA':,DJ3[9H K:G\0-$TCQ9:^&[R22.^N0I1F3$?/3YJZFN'^(GPWL_'5
MM!*+AK/4[7F"Y49]]I]L]^U<5'X5^,T=LNGKXBLUA5?+$_FG=CUSMSF@"KX@
MN!J/[26D1::H>6U55N2@!X );/T!JQ^T-)(8O#T$DCK8R7)\[G"]NOX9KLOA
M[\,[7P4T]_<W37^L77,URXZ9Z@?CW[UT'BWPGIOC+09=*U)#L8[HY%^]$XZ,
M/SH T-(AM(-&LHK$1_9%A3RO+QM*XX(QZ]:\P_:#M[$^!H+F8*M[%=*+=Q@/
MR#D9ZX[_ ("LNT\!_%/PNC:=H'B&VFTU6S"9F(91Z8(./H#5FP^$OB+Q%KEO
MJ?C_ %I+Z&WY2TB8E?IT&!ZXH ]'\#3W5SX&T6:]#>>UI'N+]3QP3]1BO)['
M=K'[3MU(N2+"-@Q!Z!0!_P"S5[;=7%MH^D2W#*([6TA+$*.%11T'X"O'_@?I
MUUJVKZ]XVO')^W3-%%_M<Y8GZ?** /:Z*** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\3^,'_(V
MVO\ UX)_Z,DKVRO$_C!_R-MK_P!>"?\ HR2M*7Q$3V.K^#W_ "*5W_U_/_Z+
MCKT&O/O@]_R*5W_U_/\ ^BXZ]!J9_$QQV"BBBI*"BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@#)\2^'K+Q3X?N]'OP3!<+@E3
MRI!R"/H0*7PWHQ\/>'[/2C>2W8MDV":;&XCMFM6B@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** .9\:^$%\::7%ID^H3VMF)!),L/64#^$^U;MA
M8V^F:?;V-I&L=O!&(T51C  Q5FB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH ****  C(P:Y3PSX%M/"FN:K?:==SBVU%O,
M>S;&R-\]5[UU=% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 8/
MB_PVWBO0)=(^WS64,Y EDA^\R_W?H>]7=!T2S\.Z):Z58)LM[= B^K>Y]2:T
M:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "O$_C!_R-MK_UX)_Z,DKVRO$_C!_R-MK_ ->"
M?^C)*TI?$1/8ZOX/?\BE=_\ 7\__ *+CKT&O/O@]_P BE=_]?S_^BXZ]!J9_
M$QQV"BBBI*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M63XN_P"@M_Y+1?\ Q-'_  LGQ=_T%O\ R6B_^)HHHY8]@YF'_"R?%W_06_\
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MO_B:/^%D^+O^@M_Y+1?_ !-%%'+'L',P_P"%D^+O^@M_Y+1?_$T?\+)\7?\
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M#F8?\+)\7?\ 06_\EHO_ (FC_A9/B[_H+?\ DM%_\3111RQ[!S,/^%D^+O\
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I_):+_P")JC)=ZCXPU7S=3O=\\<&U9/*4?*&Z87 ZL:**+):H+M[G_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>img11953243_3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img11953243_3.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" '( QL# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#[R^'/PYT;
MQAX:?5]7?5;O4+C4=0$DHUF\C!"WDR* JRA0 JJ   ,"NG_X4IX4_P">6K?^
M#V__ /CU'P4_Y)_%_P!A'4O_ $ON*[JM)2ES/4B*5D<+_P *4\*?\\M6_P#!
M[?\ _P >H_X4IX4_YY:M_P"#V_\ _CU=U12YY=RN5=CA?^%*>%/^>6K?^#V_
M_P#CU5+[X1^#]/C:6X;4+6!2 TL_B"^5020 ,F?&22!^(KT6OFO]M_P9;ZU\
M/M,UVZO]0!T?6=+>WL(KDQVKRM?P+YDD8_UK*"0 >!NSC(HYY=PY5V/4IO@W
MX5AC+NFJ*JC)8Z[? # Y/^NX_'I5+1?AOX#\26[7.DWEUJ=JK%#<6?B.\F3<
M.",K<'FN:_;(U$P? #Q7;QW6Q6^QK?*D@#K9O=PI.QP<A?+,F3TP#TK.^&VD
MZ3X7_:F\:Z1X2M+/3O#C>%M,NKRSTV-8[:.\\^=(V")\JLT 7I@D!?8DYY=P
MY5V/25^"OA4J#Y6J_P#@^O\ _P"/4O\ PI7PI_SRU;_P>W__ ,>K2^)'C2#X
M;^ =?\4W-O->6NC64M[+;PLHDE6-"Q52QQDX[USOPR^(WBOQS(6USX>:AX-L
MGMDN(;N\U&UN%F+8^0+$[$'!SSZ4<\NX<J[&A_PI3PK_ ,\M6_\ ![?_ /QZ
MAO@KX5P<1:L/^X[?_P#QZNY7.T9I&)VFESR[BY5V.";X+>%P0/+U;_P>7W_Q
MZB/X+^%BS IJQ]O[<OO_ (]7,?'O]H_3?@!'IEQJ_A_6-4L;YC']JTY$9(G[
M(Q9A\Q )'T-=C\+/BEH7Q<\'V'B'0;N*>VNH8Y7@$J/+;EU#>7(%)VN >AJO
M?Y7+6W4TE1E",9M64B(?!7PKC_5:M_X/;_\ ^/4O_"E/"G_/+5O_  >W_P#\
M>KMT;*@]?I3J7-+N9\J['#?\*4\*?\\M6_\ ![?_ /QZC_A2GA3_ )Y:M_X/
M;_\ ^/5W5%'/+N/E78X7_A2GA3_GEJW_ (/;_P#^/4?\*4\*?\\M6_\ ![?_
M /QZNZHHYY=PY5V.%_X4IX4_YY:M_P"#V_\ _CU'_"E/"G_/+5O_  >W_P#\
M>KNJ*.>7<.5=CA?^%*>%/^>6K?\ @]O_ /X]1_PI3PI_SRU;_P 'M_\ _'J[
MJBCGEW#E78X7_A2GA3_GEJW_ (/;_P#^/4?\*4\*?\\M6_\ ![?_ /QZNZHH
MYY=PY5V.%_X4IX4_YY:M_P"#V_\ _CU'_"E/"G_/+5O_  >W_P#\>KNJ*.>7
M<.5=CA?^%*>%/^>6K?\ @]O_ /X]1_PI3PI_SRU;_P 'M_\ _'J[JBCGEW#E
M78X7_A2GA3_GEJW_ (/;_P#^/4?\*4\*?\\M6_\ ![?_ /QZNZHHYY=PY5V.
M%_X4IX4_YY:M_P"#V_\ _CU'_"E/"G_/+5O_  >W_P#\>KNJ*.>7<.5=CA?^
M%*>%/^>6K?\ @]O_ /X]1_PI3PI_SRU;_P 'M_\ _'J[JBCGEW#E78X7_A2G
MA3_GEJW_ (/;_P#^/4?\*4\*?\\M6_\ ![?_ /QZNZHHYY=PY5V.%_X4IX4_
MYY:M_P"#V_\ _CU'_"E/"G_/+5O_  >W_P#\>KNJ*.>7<.5=CA?^%*>%/^>6
MK?\ @]O_ /X]1_PI3PI_SRU;_P 'M_\ _'J[JBCGEW#E78X7_A2GA3_GEJW_
M (/;_P#^/4?\*4\*?\\M6_\ ![?_ /QZNZHHYY=PY5V.%_X4IX4_YY:M_P"#
MV_\ _CU'_"E/"G_/+5O_  >W_P#\>KNJ*.>7<.5=CA?^%*>%/^>6K?\ @]O_
M /X]1_PI3PI_SRU;_P 'M_\ _'J[JBCGEW#E78X7_A2GA3_GEJW_ (/;_P#^
M/4?\*4\*?\\M6_\ ![?_ /QZNZHHYY=PY5V.%_X4IX4_YY:M_P"#V_\ _CU'
M_"E/"G_/+5O_  >W_P#\>KNJ*.>7<.5=CA?^%*>%/^>6K?\ @]O_ /X]1_PI
M3PI_SRU;_P 'M_\ _'J[JBCGEW#E78X7_A2GA3_GEJW_ (/;_P#^/4?\*4\*
M?\\M6_\ ![?_ /QZNZHHYY=PY5V.%_X4IX4_YY:M_P"#V_\ _CU'_"E/"G_/
M+5O_  >W_P#\>KNJ*.>7<.5=CA?^%*>%/^>6K?\ @]O_ /X]1_PI3PI_SRU;
M_P 'M_\ _'J[JBCGEW#E78X7_A2GA3_GEJW_ (/;_P#^/4?\*4\*?\\M6_\
M![?_ /QZNZHHYY=PY5V.%_X4IX4_YY:M_P"#V_\ _CU'_"E/"G_/+5O_  >W
M_P#\>KNJ*.>7<.5=CA?^%*>%/^>6K?\ @]O_ /X]1_PI3PI_SRU;_P 'M_\
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M_P"#V_\ _CU'_"E/"G_/+5O_  >W_P#\>KNJ*.>7<.5=CA?^%*>%/^>6K?\
M@]O_ /X]1_PI3PI_SRU;_P 'M_\ _'J[JBCGEW#E78X7_A2GA3_GEJW_ (/;
M_P#^/4?\*4\*?\\M6_\ ![?_ /QZNZHHYY=PY5V.%_X4IX4_YY:M_P"#V_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MB'XU\+^*/@_>W-_IEKX!^,'@;4K.ZG2V2VM[N>=2GFR_(,^5B1B3TSWK[O\
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MG"-:ZELW?\3YV5*IAVW'[F>U12!UR#3RU?/_ .S1^T%:?$.QD\'ZVAT7Q]H
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M%:R2;N]?%?AWQAXJ_8RTG6K75_A];P?#V[\6321:S;ZJ@2TM[F8!"8%0L%0
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MWXK[=VA6)4 'UKYW\4?L@RZQJOBB/2/BAXP\,>$O%5W->ZSX9TY[=H9Y)O\
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M +#6I_\ I=/6U/J1+<]*^"G_ "3^+_L(ZE_Z7W%=U7"_!3_DG\7_ &$=2_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MFOF7QYX9_:#\'^&9]6TGQ]:>*[RWDC8:1%H$-NTZ%P' =I, A=Q_"O4_@_\
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M!@>AKGN:CJ*8:533 =1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M!\W!P:X,?L?Z%R?^$R\='GOXDN?\:]\91N)[_6E4TK=3KABZ]./)&3L>!_\
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M!GG)_.@#O5SM&>M+2+P!2T %%%% !1110 4444 %%%% !1110 4444 %%%%
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ML=9^'$&AZ!_9%N/[837XKEL"!=A\E8P?FP.,\9H ]SHIJ<J#C'UIU !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% "44M% ";11BEHH :5#=:-@]*=10 S:!QBCR5ZXYI]% #/+
M Z"FO&K=5!J6B@9Q-_\ !GP-JUY->7GA#1;FZF8O)-+I\3.['DDDKDFH?^%'
M_#]<_P#%%:%_X+HO_B:[RDI61M[>KMS/[SY9_:@_9+TGXA^ [A/"FG6VBW]A
M')=)8Z7IT >_F"'RXBV 5&?YBL7X0^#_ -H/X1Z5)I]I#IOB_3)HK>2V3Q!J
M30S66(@&A"(C  -D=>U?7K*&)!Y%)L'/^14>S7-<]..;5_JWU6HE*-[ZJ[^\
M^8?$_P >?BG\*-0\.7?C[PWX7TCPUJ6J1:=<7UKJ\DAMPX)+G=&HP IZFO>/
M"7Q#\/>/+.:Z\.:W8ZU!"_ER265PLJH^,[25)P:T/$7AK2_%-F+/5].M=4M@
M=RPWD*RIN]<,#SC/YUX3XB_9(M8;CQ)J?@OQ;XA\(W^JEKE;#2KU;:T6X\L*
MAV*AP/E7/U-5KN1&>$Q,;3]R2[;'T8LA90>12F0#C//TKYR\,R_M':%X?T[3
MKG1?!NJ3VMND,E[/J=QOF95 +MB/J3S^-9U]^T9\0/A?XUT_3_B9X5LX-$O+
M665;_P ,Q75^8Y%( 1@$XSDT<W=$QRZI.3C3DI6[-:GU K9[TN?>N)\ _%;P
MW\2/"EEXAT6_#Z9>!C$UPOE/P2I!5N0001@^E=)_;NG_ //];?\ ?T?XU7HS
MSY4:L':46C0+T;CZ50_MW3_^?VW_ ._J_P"-+_;NG_\ /[;_ /?U?\:7S%[.
M?\I?W'TI-_M5#^W=._Y_;?\ [^K_ (T?VYIW_/[;_P#?U?\ &D'LY_RE_P R
MCS*H?VYIW_/[;_\ ?U?\:/[<T[_G]M_^_J_XT:A[.?\ *:&[VHW>U9_]N:=_
MS^V__?U?\:/[<T[_ )_;?_OZO^-&H>SG_*:&[\*-WO6?_;NG_P#/[;_]_5_Q
MI&US3^/]-@QW_>K_ (T:![.?\IH[LTOXU2M[R&X!,4JR*IP60[AGTX/^<U:'
MKFJ(LT[,?2U&?7-*OW:!#Z*0=*6@!,4;12T4 )M%&T4M% ";11M%+10 F*,4
MM% "8%&*6B@!,"C:*6BE9 )@4;12T4P&-&#_ #K-UKP]IGB.Q>PU73[74K*0
M@O;W<2R1M@Y&5(P>:U:2DKQ=T[":OHSP;Q1^RWX:U;XL>#_$-GX=\/VNA:3;
M7D5]IO\ 9Z#[4TH01$ +M.P@GGUXKO8_@E\/F12? _AXG'/_ !*X?_B:[HKR
M>*4=.:Z)5ZLDDY;&:HPCLCA/^%(_#X X\#>'L?\ 8,A_^)KA;[]F?06^-WAO
MQ;8:%H%EHFF:=<6TVGIIZ*\EP[QM%, %V_)L89//)KW3CFC:*4:]6#;4MR/8
MPENA(S\H/M7S_I?^MUG_ +#6I_\ I=/7T$HPM?/NE_Z[6?\ L-:G_P"ET]*G
MU-9=#TGX*_\ )/XO^PCJ7_I?/2>._@K\/OBA?07?C#P1X?\ %5U;QF*&?6-,
MBNGC3.=JET.T9)..F:=\%/\ DG\7_81U+_TON*\\_:B^$/PP\0:%?>/OB-!K
M,MMX;TZ1RVE:Q>69\I27VB."5%=BS8!/.2!FHE\3''9&_;_LG_!2UNHKF#X3
M>"8[F%@\<R:#:AD8'*D$)P0>>*]9AP!@5^8FGZ=X TWQ(8Y?V>_B?ILFF:M8
MV5W<7WCJX,5C+<F-[=IQ]L;:I#J2<$<X)SQ7Z=V^[8-PPV.14E$M<[XI^'OA
MOQQ):-XAT#3-<-G*)K8ZC:)/Y+C'S+N!P>.U=%10!C3>$](N;R[O)])L9KJ[
MM197$TENA>:W!8B)R1\R99OE/')XJ#PGX#\/>!;)[/P[H>GZ%9R.9)+?3[=(
M4=CP68*!DX Y-=!10!P7Q[_Y(=\0S_U+NH_^DTE:/PF4'X5^#2>IT6RR<_\
M3!*H_'@!O@?\0P?^A=U'_P!)I*O?"/\ Y)3X+_[ ME_Z(2@#JP O X%+110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 F*-HI:*
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M_@X !_P@U@?H7_\ BJ7_ (8W^#?_ $(EA_X__P#%4O>(Y,+_ #2^Y?YGJ_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH 3%&T4M% ";11M%+10 FT4;12T4 )M%&T4M% ";11M%+10 F!1M%+10
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MQAJWBOQ)XIT(ZAINNZGICVW]JHF_<[9)"280_+DGIZUV=O\ M1_#^X\8^/\
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MOA/#\0_#[ZQXET-[S^SWM]&TB>ZO8+@?>22W1=ZX')R !D>M 'MM%?/GPO\
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M\+[76K?Q1X5\ ?\ "%6T">)/!&@BYU>[NO+7=9/<K$\D(S@; 5 W9/7(X/\
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M^ OV^KCX?_LZ?##Q/\2_"'B:2\\0SV^G+J48MY&U!GBWF[CB1\^62<!,!N@
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M(Q5_;;^#=]XC_;5\->"_"^I?9M.^+5O9CQ5I=JHR8[*?>9WQT&Q,\G^$^HH
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M9OAW_P %*/C!IE_NCA\:^';/7=-D?Y1,(66)U7U(8M]-IH _.75/%OA#P_\
M"/5/'6I>)M=L?VJ-/\7,\BS37(E6%9<E7!_=B,#/'!+87IQ7U3^VAH/BW]H#
MXR?"2X/P<USXF>&+/P@-4N+'3YGL+::YN5W/&;M>$*;(SM!R<X .:W/'G[(G
M[1?Q6U+7/ 'BJ3PC?^$=6UN.ZNOB(T$*:Q/IZ.KI:$(H8X* X*\'^+;7NWQF
M\(?M'?#WXB:/K?P5O=)\4^#(=)CTR3P7KLJ6Z6TB+M6=9,J6X5?X^#N&W!!
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MV+R.TGAB[6W>YWA1B0E3D#''^]7F/_#&6O'K^T+\5_\ P<1__$5].8YSWHH
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M\P_\,8Z]_P!'"_%?_P '$?\ \11_PQCKW_1POQ7_ /!Q'_\ $5]/44 ?,/\
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M40 !5 \O@  "I/\ AC'7O^CA?BO_ .#B/_XBOIZB@#YA_P"&,=>_Z.%^*_\
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M] IH ].HJII>I0:OI]O>VLJSVUQ&LT4T?*NC %6'L00:MT %%%% !7SWI?\
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M!^;'BS7]9U#]B4_"WQ!J36OC/X>^.M(\+7=W;-^\V+>1_9+F/<. 864KD?\
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M< X%5]4\#^']8UNVUF_T'3;W5[:WDM8-0GM8WN(H9 1)$KD;@C D%0<'/(H
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M:VA01Q0PH$2-0,!5 X  ["@"<=*6BB@ HHHH **** "BBB@ HII;G&>V:-U
M#J*9N]Z-WS$9H ?13=V.XI<_+F@!:*;N'7M2>8/6@!]%,\P<G(Q^=!;:,D\4
M /HI@;/>G9H 6BBD+!>M "T4W=GZ4WS O5E_.@"2BF[N^>/I2;O4T /HIN\<
M#-.H **** "BBB@ HHHH **** &DFH;B218G,7S.!\H/3.*GZFFE%[\TD^HG
MJK'R_=?$S]J)+J=8?A-X7D@61A&[:W@LH)VDC/!(P:B_X6=^U/\ ]$C\+?\
M@\_^O7U(OZ4M>DL7!+^#%_?_ )G)[&3=^=_U\CY:_P"%G?M3_P#1(O"__@\_
M^O2'XH?M3J#CX1>%BV#@'7/;ZU]34QD#-R!^5/ZY#;V$?Q_S&Z4EJIO\#(\)
M7NKZAX9TR?7K.'3]9DMT:\M+:3S(X9L#>JMW .1FO ?VOI(=-\;? C5=<*IX
M+LO&2'4Y9R!;PS-!(MG)+GA5$Q'S'@$CD5]+CC%4?$/AW3/%FBWFD:SI]MJN
MEWD?E7-E>1++#*I[,C @BO.;N[V.I;'S#^W'XV\<> ?AQJOB6'2OA_XC\ 6
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M\PKS_7[#X[>&_CMX'^'FD_M!7_BG5+X?VOK<%UX4TV"&PTF-MK2.Z(6#RO\
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MG$3@<,25#@'H* /H]>5!/6G4B_=%+0 4444 %%%% !7SWI?^NUG_ +#6I_\
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M -D=VC@_*3$?+<8.=B'(P:]!AM(58R+"B2-]YE !/.>2.M3>6OIFE "@ =*
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M "BBB@ HHHH **** "OGO2_]=K/_ &&M3_\ 2Z>OH2OGO2_]=K/_ &&M3_\
M2Z>MJ?4B6YZ5\%/^2?Q?]A'4O_2^XKNJX7X*?\D_B_[".I?^E]Q7=5G+XF..
MR"BBBI*"OE_XH>'K;XI_'?QOH?B&\OH=+\-^#K>_TJ&VO9+98;J9[C?>?(PW
M.GDQJI.0.>.37U!7FWQ+^ _A3XK:M#?ZY#>Q7<=N;%Y]-OI;1[FU8Y>WF,9'
MF1$\[3ZG&,T 4?@OKWB'X@?LZ^#M7EO_ +'XDU;P_;RMJ+P"79<-"/WQC) ?
MYOFVYP<]JYC]D&RO]+\._$#3M2US4/$=U8>--4M3J6IRAYIMICYP %49SA0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7SWI?\
MKM9_[#6I_P#I=/7T)7SWI?\ KM9_[#6I_P#I=/6U/J1+<]*^"G_)/XO^PCJ7
M_I?<5W5<+\%/^2?Q?]A'4O\ TON*[JLY?$QQV04445)04F*6B@!-HSG'-&T>
ME+10!R7Q<_Y)3XT_[ M[_P"B'K._9_\ ^2$_#O\ [%ZP_P#2=*T?BW_R2OQE
M_P!@6]_]$/6;^S[_ ,D)^'?_ &+UA_Z3I0!W]%%)0 M%%)0 M%%% !112>M
M"T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%)2T
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MA=NS/(YS7;#Q]\;5SM^$>AX[?\5<O_R-0![317B__"??&WO\(]$S_P!C<O\
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M9-9N$G66ZP4)+,H3:,N#G  .+O[2NM?$>WT'2])^'NAZA?\ ]ISM%JVJZ3+
MMWI]J!\QMUF94,KYVACG:,M@D 5Y=XCA\>Z-\+?"7@WP#\,/$OA3P[<-<1ZZ
MUI?V;:S! &SB*1IBOG3LSL9MS,N6(&[H ?0WPA^)5G\6_ .F^)[&VGL8KHR1
M26=QM,EO+%(T4L98$AMKQN-P.#C-=HO2N)^#5A!I7PUT'3[7PG/X(M;.'[/%
MH5R\;R6JH2H#-&S*Q.-V[<2=V3R37;+TH *6BB@#EOB/XTD\ ^%+[68M)O\
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M5P .!TIU% "*H48 XI:** "BBB@!K(K=1FD\I?3BGT4 -,:GJ*4#;P.E+10
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MWW[9UA9VL7B!_ OB8?#B74UTD>,W6!+;S&G^SB40&3SC$93M#A3D<XQS7/\
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M_P#_ !FBBM_91EJ9<[6@?\+K\*?\]=6_\$5__P#&:/\ A=?A3_GKJW_@BO\
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M17__ ,9HHH]C$/:,;_PNCPG_ ,]-5_\ !%?_ /QFD_X7-X3'2;5O7_D!W_\
M\9HHH]C$/:,/^%S>$MN/,U7T_P"0%?\ _P 9K#\/^+?AAX3U'6+_ $71Y=)O
MM8N/M>I7-GX8O(I+V8Y_>3,L +MR>6SUHHH]C$/:,W/^%S>$BI!EU8@_]0._
M_P#C-(?C)X2*E?,U7;C&W^PK_'_HFBBCV,0]HP_X7-X3SGS=6S_V K[_ .,4
MO_"Y_">,>;JW_@BO_P#XS111[&(>T8?\+F\)\CS=6P>W]A7^/_1-)_PN;PGG
M/FZMG_L!7_\ \9HHH]C$/:,<OQH\)JN!+JW_ ((K_P#^,TC?&;PFV?WNJ_\
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M;_D!7_\ \9H_X7+X3_Y[:M_X(K__ .,T44>QB'M&'_"YO"?_ #VU;_P17_\
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..([T45,H*FKH%)R>I_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>img11953243_4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img11953243_4.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +.!ED# 2(  A$! Q$!_\0
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M: -.BLS^W[#^^_\ WS1_;]A_??\ [YH TZ*S/[?L/[[_ /?-']OV']]_^^:
M-.BLS^W[#^^__?-']OV']]_^^: -.BLS^W[#^^__ 'S1_;]A_??_ +YH TZ*
MS/[?L/[[_P#?-']OV']]_P#OF@#3HK,_M^P_OO\ ]\T?V_8?WW_[YH TZ*S/
M[?L/[[_]\T?V_8?WW_[YH TZ*S/[?L/[[_\ ?-']OV']]_\ OF@#3HK,_M^P
M_OO_ -\T?V_8?WW_ .^: -.BLS^W[#^^_P#WS1_;]A_??_OF@#3HK,_M^P_O
MO_WS1_;]A_??_OF@#3HK,_M^P_OO_P!\T?V_8?WW_P"^: -.BLS^W[#^^_\
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M#3HK,_M^P_OO_P!\T?V_8?WW_P"^: -.BLS^W[#^^_\ WS1_;]A_??\ [YH
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M5A='H-%>??\ "Z/!O_/U<_\ ?@T?\+H\&_\ /U<_]^#1[&I_*PNCT&BO/O\
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M'UJC_.OO.THKB_\ A:?A?_GXG_[\FC_A:?A?_GXG_P"_)H^J5_Y']P?6J/\
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M7_Y^)_\ OR:/^%I^%_\ GXG_ ._)H^J5_P"1_<'UJC_.OO.THKB_^%I^%_\
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M*XO_ (6GX7_Y^)_^_)H_X6GX7_Y^)_\ OR:/JE?^1_<'UJC_ #K[SM**XO\
MX6GX7_Y^)_\ OR:TM$\;:+XAOC9Z?+*TP0OAHRHP*4L-6BN:478<<12D[*2N
M=%1116!L%87B;_4V_P#O'^5;M87B;_4V_P#O'^5 '.4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!YI\<O^1VL_^P>G_H35YE7I
MOQR_Y':S_P"P>G_H35YE7L4/X:,WN%%%%:@%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 >:?'+_D=K/_ +!Z?^A-7F5>F_'+_D=K/_L'I_Z$U>95[%#^&C-[
MA1116H!1110 4444 %%%% !117JOP5\(6^LZI<:W?1"2"Q8+ C#*M*1G)'?
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MY"N8\ ?\E T'_K\C_G73^-_^1VU?_KX/\A6V$_COT_4\W,_X2]3 HHHKU3Q
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!YI\<O^1VL_P#L
M'I_Z$U>95Z;\<O\ D=K/_L'I_P"A-7F5>Q0_AHS>X4445J 4444 %%%% !11
M10 5]%? MXF\#3(C*95O'\P#J,XQG\*^=:],^#?C"V\/:W<:;J,XAL[_ &['
M; 5)1P,GMD<?@*PQ,7*F[#6YR/C-)5\=ZV+A65S?R$AN."W!^F*]:T[X;_#;
M45MHH]526ZF0?N8]14L6QD@*#GUK2\>_"6'Q9J3:QIM\MK>RH!(L@+1RD# .
M1R.!VSFE\!_">W\(:DVL:C>QW5W&A$>Q=J1 CYCSU-82K1=-6E9H=M3SSXI^
M"-'\&S:.-)68?:6?S/-D+?=*XQ^9KUWXA?\ ))]6_P"O%?\ V6O'/BQXNM?%
M'BJWAT]Q)96'[M91TD<M\Q'MT'X5['\0O^23ZM_UXK_[+2GS6I\VX+J>)_"7
M0_[:\?6CR)N@L0;F3*Y&1PH]CN(/X5Z?\9=)UW7K#3-/T;3;BY5)6GEDB8 *
M0,*"">3R3^%5_@3H@M/#=YK$BCS+V;8AYSY:<?\ H1:L?7?CCJ-CKU]9V&G6
MDMK!,T4<DC'+!3C/!QR13DYSK7@KV#H>BKIMWXD^&G]FZM:M!?3V7E21RX)6
M0#@G\0#7RS#&\.HPQ2 K(DZJP(P00P%?1WPT^(LWC66_MKVVAM[FW"N@B)PR
M'COWS7D_Q.T!M#^)#NL>VVOIDN8B.F2PW#\&S^E/#MPG*$A/N>_^+O#B>*_#
MEQI#W#6XFVGS%7.,'/2N4\(_"72_">JKJ\]])=W$(/EF10B1GNWUQ6C\6;B>
MT^'M]-;320RJR;7C8JP^;U%?-5QK.J7<)AN=2O)HCU22=F!_ FLZ%.<X-*5D
M-O4]#^-?C"RUZ]M])TZ59X+$NTLJ_=,A&, ]\#//O7MS:9;:UX-CTV[+"WN+
M-$<J<$#:.]?'\G^J?Z&OJ?Q:2/A)>X./^)<G\EJZ]-14(H$RIX>^$WA;1-4A
MU.W$]U/ VZ(RR[E1O7 ZFN!^,WCJUU=E\-Z?F2.VFWW,I! \Q<@(,^F3DU#\
M$_%PTW6)/#]Y+BWOCNMRW:;T_P"!#]0*=\;O"8T[5HO$5K&1;WI\NYQT67'!
M_P"!#]11"+5>U1W[!TT/5? )C'PTT<S8\H60WY'&W!S7'C4?@ICB+2?_  #D
M_P#B:Z[P)$9_ACI,*D!I+':">@)!%>4CX!^(@ /[6TO_ ,B?_$UE#DYI<TK:
M@87Q)N/!]Q>V!\(+:K"(V\_[/$R#=GC.0.U<WX>T"^\3:W;Z78)F64_,QZ1I
MW8^PK<\9?#K4_!%E;W5_>VDZ3N440;L@@9YR!7L_PF\&P>'/#46HR[);_48U
MF:0#[D9 *H#^.3[_ $KJE5C3I7B[BM=C_$6KZ;\*O <%G8Q[I]IAM8R>7DQR
M[>PZG\!7S5<W,]Y=2W-S*TL\SEY)'.2S'DDU[AXR^%WBSQAX@EU*YU72XXQ\
MEO"#(1''G@?=Z]S7&>(?A!K7AO0KK5KK4=/EAMU#,D6_<><<9&.]30E3BM7J
MP=RA\+=#_MSQ]8)(FZWM";J7*Y'R_=!]/FQ^5>L_&32];UW1]/TW1M.N+K]^
M9I7B8 )M&%!!/.=Q/X5F_ ;1!!HE_K<BC?=2^3&><[$Z^W4U1\1_&W4--\1W
M]AI^GVLMM;3&)))&.7QP3P<8S43<IUO<5[#Z'H%AIUYK_P -$TO6K5X+R:S-
MO-'+@D,!@$X^@-?*T\$EK<2V\P(EB<QN",<@X-?1_P -?B3/XTO+ZSOK:&WN
M($62,1$X9>AZ]\UY5\7M ;1?'5Q<)'MMM0'VB,CINZ./S_G3P[<*CA(3VN<%
M7U)X!86GPETN:,8*V!DXX.<$U\MU]0?"VZBU+X8:;$A/[J)[9\_W@2#_ #JL
M9\"]0CN?,D1S>(?68'_QZOJ?QW?W.E?#J^O[.4Q7-O#')&X/0AE__57R[+;R
M6FKO;3+MEBN=CKZ$/7TS\2_^25:M_P!>R?\ H2TL3K.']=@14<:7\7OAX<;(
M[K''<VUP!_+G\0:TM*LKC3OA7]BNXS'<0:=+'(I[$*P->"?#KQF_@WQ&LTA8
MZ=<XCNT SQV8>XS^6:^E=9ECG\+:A-$X>-[*1E93D$%#@UA6@Z;4>E]!K4^9
M?AQXLM_!OB!M3NK>6>-K5H=D1&<DJ<_^.UZG_P +\T?_ * ]]^:UYA\,O$&D
M^&O$;7VLJS6K6C1@"+S/F)4CCZ UZW_PMSP#_P \)/\ P!KHKQ3G\#8D4F^/
M>CLI']D7PR,9RM>"2$/([8ZL6'XFOH9_BWX",;;;>7=@X_T+O7STY#2.PZ%B
M1^=7AXI7]VP,]R_9^_Y!FN_]?$7_ *":\_\ BI_R4W4_]^/_ -!%>@?L_?\
M(,UW_KXB_P#037GOQ7Y^).K?5/\ T 5$/]XE_78'L?1>IP::_A!EU5-VG1VR
MO,@[JH!Q^E>;Z/\ '.PEU2WL9-$-GISN(TD64?NE/ )7 &/7'2NB\&:KIWQ
M^'!TBXF'VA;7[)=Q;OG7 P&]2" #GUS7$:1\"=4AUN!M2U&S>PBD#N8PQ:0
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M/<?RS7NNLNDOAN_DC8,C6DC*PZ$%#S7#BZ4Z$U3^RW='7AJL:T74^U:S/!O
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M !1110 4444 %%%% !7>?"3_ )'!_P#KV;^8K@Z[SX2?\C@__7LW\Q7+C?\
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MR/\ G73^-_\ D=M7_P"O@_R%;83^._3]3S<S_A+U,"BBBO5/$"BBB@ HHHH
M**** "BBB@ HHHH *V#XLU\V/V$ZK<?9?+\KRLC&S&,=.F*QZ*F4(R^)7*C.
M4?A=@HHHJB38M/%>O6%FEG::K<0VZ#"QJ1@#\JI:?JE_I5T;FPNY;>8C!>,X
MR/?UJI14>SAKHM=R_:3TUV.@U/QMXAU:V^SW6HOY)QE8U"[L>N.M5;WQ1KFI
M6;6=[JD\]NV,QN1@XZ=JR:*2HTXVM%:>0W6J/>3)K2\N;"Y2YM)Y()T.5>-L
M$5T3_$3Q2]MY']ILH_OJBA_SKEZ*)TJ<W>44PC5G!6BVB2>>6YG>>>5Y97.6
M=SDD_6K6F:SJ6C3-+IU[+;,WWMAX;ZCH:HT5;BFK-:$*33NGJ=+>_$#Q/?1&
M*34WC4C!\E0A/XBN<#NL@D#'>&W!N^>N:;14PIP@K1214ZDYN\G<V+SQ7K^H
M6QM[O5KF6$D$JQ'4'(/ ]:M-X[\3M:?9CJ\VS&-V!NQ]<5SM%3["E:W*ON*]
MM4WYG]XK,SL69BS$Y))R2:T-*U[5=$D+Z;?2V^X@LJGY6^H/%9U%:2BI*S5T
M0I.+NGJ=%J7CGQ'JL#07&I.L3##+$ FX>^*YVBBIA3A!6@K#G.4W>3N%>D?"
MGQ-!IUU<:1>S+%%<'S(7<X ?H5SVR/Y5YO145Z,:U-TY=2J%9T9J<3L/B+I4
M>F^*)+VSDC:WO#YRM&P(63^(<>_/XUCWGBO7]0LY+2[U6XFMY!AXV(PPZ^E9
M&2>I)^II**=%1A&,]6NMASJMR;CHGT"M>'Q3KL&GBPBU6X6T"&,19!&T]NG2
MLBBM)0C+XE<SC*4?A=@Z44451(4444 :&F:YJFC>9_9M]+;>9C?Y>/FQTZU7
MOK^[U.\>[O9WGN'P&D?J<# _2J]%2H14N:VI7/)KEOH6]/U.^TJX\_3[N6VE
M(P6C;&1[^M;5S\0/%%U (7U61%QM)C4*3]37-45,J5.3O**;*C5G%6BVD.=W
MD=GD=G=CDLQR2?<U-97]YIMP+BQNI;>4?Q1M@_CZU7HJVDU9D)M.Z.G/Q"\4
MF#RO[5?&,;PB[OSQ7/75W<WT[3W<\D\K=7D8L:AHJ(4H0UC%(J56<_B;9Z]\
M+;*TT?1;K5[ZX@ADN?N[Y!E8E[X[9.?R%>>>+==/B+Q)=:@!B(D1PC'.P=/Z
MG\:Q,G&,G'UHK&GAE&M*LW=O\#:IB'*E&DE9+\0HHHKJ.8**** "BBB@ HHH
MH **** "BBB@ KO/A)_R.#_]>S?S%<'7>?"3_D<'_P"O9OYBN7&_[O/T.G"?
MQX^I[C1117R)]0%87B;_ %-O_O'^5;M>2:A)XE\:^-]:T"SUJ/3+?275T=(2
MS.&&,'GMBKA#FOKL!MT5D?\ "L_%_P#T/+?^ Y_^*H_X5GXO_P"AY;_P'/\
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MO_Z'EO\ P'/_ ,51_P *S\7_ /0\M_X#G_XJCV<?YE^/^07->BLC_A6?B_\
MZ'EO_ <__%4?\*S\7_\ 0\M_X#G_ .*H]G'^9?C_ )!<UZ*R/^%9^+_^AY;_
M ,!S_P#%4?\ "L_%_P#T/+?^ Y_^*H]G'^9?C_D%S7HK(_X5GXO_ .AY;_P'
M/_Q5'_"L_%__ $/+?^ Y_P#BJ/9Q_F7X_P"07->BLC_A6?B__H>6_P# <_\
MQ5'_  K/Q?\ ]#RW_@.?_BJ/9Q_F7X_Y!<UZ*R/^%9^+_P#H>6_\!S_\51_P
MK/Q?_P!#RW_@.?\ XJCV<?YE^/\ D%S7HK(_X5GXO_Z'EO\ P'/_ ,51_P *
MS\7_ /0\M_X#G_XJCV<?YE^/^07->BLC_A6?B_\ Z'EO_ <__%4?\*S\7_\
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MO_Z'EO\ P'/_ ,51_P *S\7_ /0\M_X#G_XJCV<?YE^/^07->BLC_A6?B_\
MZ'EO_ <__%4?\*S\7_\ 0\M_X#G_ .*H]G'^9?C_ )!<UZ*R/^%9^+_^AY;_
M ,!S_P#%4?\ "L_%_P#T/+?^ Y_^*H]G'^9?C_D%S7HK(_X5GXO_ .AY;_P'
M/_Q5'_"L_%__ $/+?^ Y_P#BJ/9Q_F7X_P"07->BLC_A6?B__H>6_P# <_\
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MPS_=_P#0PP_^ Q_^*H^LTNX69XW17LG_  S_ '?_ $,,/_@,?_BJ/^&?[O\
MZ&&'_P !C_\ %4?6:7<+,\;HKV3_ (9_N_\ H88?_ 8__%4?\,_W?_0PP_\
M@,?_ (JCZS2[A9GC=%>R?\,_W?\ T,,/_@,?_BJ/^&?[O_H88?\ P&/_ ,51
M]9I=PLSQNBO9/^&?[O\ Z&&'_P !C_\ %4?\,_W?_0PP_P#@,?\ XJCZS2[A
M9GC=%>R?\,_W?_0PP_\ @,?_ (JC_AG^[_Z&&'_P&/\ \51]9I=PLSQNBO9/
M^&?[O_H88?\ P&/_ ,51_P ,_P!W_P!###_X#'_XJCZS2[A9GC=%>R?\,_W?
M_0PP_P#@,?\ XJC_ (9_N_\ H88?_ 8__%4?6:7<+,\;HKV3_AG^[_Z&&'_P
M&/\ \51_PS_=_P#0PP_^ Q_^*H^LTNX69XW17LG_  S_ '?_ $,,/_@,?_BJ
M/^&?[O\ Z&&'_P !C_\ %4?6:7<+,\;HKV3_ (9_N_\ H88?_ 8__%4?\,_W
M?_0PP_\ @,?_ (JCZS2[A9GC=%>R?\,_W?\ T,,/_@,?_BJ/^&?[O_H88?\
MP&/_ ,51]9I=PLSQNBO9/^&?[O\ Z&&'_P !C_\ %4?\,_W?_0PP_P#@,?\
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M_P#@,?\ XJCZS2[A9GC=%>R?\,_W?_0PP_\ @,?_ (JC_AG^[_Z&&'_P&/\
M\51]9I=PLSQNBO9/^&?[O_H88?\ P&/_ ,51_P ,_P!W_P!###_X#'_XJCZS
M2[A9GC=%>R?\,_W?_0PP_P#@,?\ XJC_ (9_N_\ H88?_ 8__%4?6:7<+,\;
MHKV3_AG^[_Z&&'_P&/\ \51_PS_=_P#0PP_^ Q_^*H^LTNX69XW17LG_  S_
M '?_ $,,/_@,?_BJ/^&?[O\ Z&&'_P !C_\ %4?6:7<+,\;HKV3_ (9_N_\
MH88?_ 8__%4?\,_W?_0PP_\ @,?_ (JCZS2[A9GGW@#_ )*!H/\ U^1_SKI_
M&_\ R.VK_P#7P?Y"M#4OA!J/A/3;CQ!;^(8_.T^,W";+<JV5YX.[BIM)^%^M
M>+-*MM?G\3@2WR><P> L<GU.>>E:4,52IS]HWI:QR8O#2KP48G%45Z#_ ,*-
MU;_H:(__  &/_P 51_PHW5O^AHC_ / 8_P#Q5=?]J4#S_P"RZO='GU%>@_\
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M ,!C_P#%4?VI0#^RZO='GU%>@_\ "C=6_P"AHC_\!C_\51_PHW5O^AHC_P#
M8_\ Q5']J4 _LNKW1Y]17H/_  HW5O\ H:(__ 8__%4?\*-U;_H:(_\ P&/_
M ,51_:E /[+J]T>?45Z#_P *-U;_ *&B/_P&/_Q5'_"C=6_Z&B/_ ,!C_P#%
M4?VI0#^RZO='GU%>@_\ "C=6_P"AHC_\!C_\51_PHW5O^AHC_P# 8_\ Q5']
MJ4 _LNKW1Y]17H/_  HW5O\ H:(__ 8__%4?\*-U;_H:(_\ P&/_ ,51_:E
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M_P"AHC_\!C_\51_PHW5O^AHC_P# 8_\ Q5']J4 _LNKW1Y]17H/_  HW5O\
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M-=UC1G=@J*,LS'  ]34%CJ-CJEN;C3[VWNX0Q4R6\JR+D=L@D9Y% %FBBB@
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M^OI^-;,<B2QK)&ZNC@,K*<@@]"#0 ZBJL^IV%K>0V=Q?6T5U/_J89)55Y/\
M=4G)_"J^O:Y9^'-)EU34/-%I#CS'C0N4!.,D#M0!I457L;VVU*Q@O;.59K:=
M!)'(O1E(R#5B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH YOX@?\D_U[_KRD_E3/AU_R3W0_P#KV'\S3_B!_P D_P!>_P"O*3^5
M,^'7_)/=#_Z]A_,UK_RZ^?Z"ZG3T445D,**** "BBB@ HHHH **** "BBB@
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MEU;PSJ#[$N)<EHFXR<DY!&1QG!% 'NU0W<DL-E/+#'YDJ1LR)_>8#@?G4U%
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M"\\D!>)%ZLZ$.H_$J!4OAOP3I'A;4=3OM.^T>=J4IEG\V3<-Q)/ QQR371T
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MWMH[:SBM4!,448C4-SP!CF@#EOAQXJL/$W@K3;B&>'[1% L5Q"&&8W48.1U
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MIS^9_I6EXG^$7ACQ;K<FKZG]M^U2*JMY4P5< 8'&#6-_PSYX)]=3_P# D?\
MQ- 'J$%U;W2EK>>*90<$QN& /X47/_'K-_N-_*N>\&^!-&\"V]U!H_VC9=.K
MR>?)O.0"!C@>M=(Z"2-D/1@0: /'OV=_^19UO_L)'_T!:]CKGO"/@O2O!5E<
MVFD_:/*N)O.?SI-YW8 XX'I70T 5[ZW%WI]S;-TEB9#^((KR;]GJX,?AC5])
MD&)K*_;>/]X =.O5#7L->/V2+X ^-UXMP!'I/B==\,QX5)\Y*D^I.?\ OL4
M>P5XOK/_ "=!HW_7A_[+)7M%<Y<^"=(NO&UMXLD^T?VG;Q>4F),1[<$<KC_:
M/>@#>N;F"RM9;FYE2&")2\DCG"J!U)->%W]^_P 9_%#6PU$:?X+TZ0!R\@C>
M[D'H#^F>@YZFO9]?T.S\2:'=:/?^9]ENE"R>6VUL @\'ZBO//^&?/!/KJ?\
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M8?S-:_\ +KY_H+J=/11160PHHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M;>&O!;M/I=FS7;#:;F=M\F/0'H/PH VM:UW3/"^CMJ&KW@M[6+"F1\DL>@
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M_N:]>H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]"HKSW_A=7@K_G\NO_ 1_P#"C_A=7@K_ )_+K_P$?_"CV-3^5A='H5%>>_\
M"ZO!7_/Y=?\ @(_^%'_"ZO!7_/Y=?^ C_P"%'L:G\K"Z/0J*\]_X75X*_P"?
MRZ_\!'_PH_X75X*_Y_+K_P !'_PH]C4_E871Z%17GO\ PNKP5_S^77_@(_\
MA1_PNKP5_P _EU_X"/\ X4>QJ?RL+H]"HKSW_A=7@K_G\NO_  $?_"C_ (75
MX*_Y_+K_ ,!'_P */8U/Y6%T>A45Y[_PNKP5_P _EU_X"/\ X4?\+J\%?\_E
MU_X"/_A1[&I_*PNCT*BO/?\ A=7@K_G\NO\ P$?_  H_X75X*_Y_+K_P$?\
MPH]C4_E871Z%17GO_"ZO!7_/Y=?^ C_X4?\ "ZO!7_/Y=?\ @(_^%'L:G\K"
MZ/0J*\]_X75X*_Y_+K_P$?\ PH_X75X*_P"?RZ_\!'_PH]C4_E871Z%17GO_
M  NKP5_S^77_ ("/_A1_PNKP5_S^77_@(_\ A1[&I_*PNCT*BO/?^%U>"O\
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M5X*_Y_+K_P !'_PH_P"%U>"O^?RZ_P# 1_\ "CV-3^5A='H5%>>_\+J\%?\
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M_P"?"U_[\K_A5NBB[ J?V5IW_/A:_P#?E?\ "C^RM._Y\+7_ +\K_A5NBB[
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M0<=,T >S45Y%H_CWQ9X8\66WAWX@6\#)?';::C:IA&;. #C (_ $9%;WQ?\
M%>J>#O!T&I:1+''<->QPLSQAQM*N3P?]T4 =_17D$.N?$WQQ'_:7A5[#2-''
MRP2WL?[RZP.7P5; )SC@5<\(>//$5EXM7P=XZMHH]2F7=9WL( 2?J<<<=N"
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MK:22@RSP%)@N<#KSTJ]\3O$WC/0+S1T\+Z0UY!,Y^T.L!ER<@!#C[H.>OZT
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M#;1^[2?+C\B3^%1_"?1)- ^&VDVLT1CN)4-Q*I.3ESD?IB@#M:*** "BBB@
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M_"C_ (1+XC_]#Q%_X#C_  KTNBCVTNR^Y!8\T_X1+XC_ /0\1?\ @./\*/\
MA$OB/_T/$7_@./\ "O2Z*/;2[+[D%CS3_A$OB/\ ]#Q%_P" X_PH_P"$2^(_
M_0\1?^ X_P *]+HH]M+LON06/-/^$2^(_P#T/$7_ (#C_"C_ (1+XC_]#Q%_
MX#C_  KTNBCVTNR^Y!8\T_X1+XC_ /0\1?\ @./\*/\ A$OB/_T/$7_@./\
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M1?\ @./\*/\ A$OB/_T/$7_@./\ "O2Z*/;2[+[D%CS3_A$OB/\ ]#Q%_P"
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M/$7_ (#C_"C_ (1+XC_]#Q%_X#C_  KTNBCVTNR^Y!8\T_X1+XC_ /0\1?\
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M^%'_  B7Q'_Z'B+_ ,!Q_A7I=%'MI=E]R"QYI_PB7Q'_ .AXB_\  <?X4?\
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M>(O_  ''^%'_  B7Q'_Z'B+_ ,!Q_A7I=%'MI=E]R"QYI_PB7Q'_ .AXB_\
M <?X4?\ ")?$?_H>(O\ P''^%>ET4>VEV7W(+'FG_")?$?\ Z'B+_P !Q_A1
M_P (E\1_^AXB_P# <?X5Z711[:79?<@L>:?\(E\1_P#H>(O_  ''^%'_  B7
MQ'_Z'B+_ ,!Q_A7I=%'MI=E]R"QYI_PB7Q'_ .AXB_\  <?X4?\ ")?$?_H>
M(O\ P''^%>ET4>VEV7W(+'FG_")?$?\ Z'B+_P !Q_A1_P (E\1_^AXB_P#
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M1?\ @./\*/\ A$OB/_T/$7_@./\ "O2Z*/;2[+[D%CS3_A$OB/\ ]#Q%_P"
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M/$7_ (#C_"C_ (1+XC_]#Q%_X#C_  KTNBCVTNR^Y!8\T_X1+XC_ /0\1?\
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M+XC_ /0\1?\ @./\*/\ A$OB/_T/$7_@./\ "O2Z*/;2[+[D%CS3_A$OB/\
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MX,W5W$08YS;2+@YX+J?ZTSP)\-O#U_X1T_4]=L8]5U&\MT>2:YRVU<?*JCL
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M"^'/ ^JZL&&Z. B(]B[?*OZD5RGPF\&06OPQ6WUBS28ZN3<W,4HSO4XV CZ
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MH_'> VOPEMK<L&,5U A([X5A7;^ -<M_$'@;2;ZW9"?LZ1RHA!\MU #*?Q%
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M37$B1PQJ6=W.%51U)/I4E<1XU^&6F^.=2MKO4=1U&%((_+\BW=51AG)ZJ>:
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M4X'>@"Y1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M=_8FE?\ 0,L_^_"_X4?V)I7_ $#+/_OPO^%%Z79_?_P U.1_X7'X)_Z"C?\
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M^_"_X4?V)I7_ $#+/_OPO^%%Z79_?_P U.1_X7'X)_Z"C?\ ?IJ/^%Q^"?\
MH*-_WZ:NN_L32O\ H&6?_?A?\*/[$TK_ *!EG_WX7_"B]+L_O_X :G(_\+C\
M$_\ 04;_ +]-1_PN/P3_ -!1O^_35UW]B:5_T#+/_OPO^%']B:5_T#+/_OPO
M^%%Z79_?_P  -3D?^%Q^"?\ H*-_WZ:C_A<?@G_H*-_WZ:NN_L32O^@99_\
M?A?\*/[$TK_H&6?_ 'X7_"B]+L_O_P" &IR/_"X_!/\ T%&_[]-1_P +C\$_
M]!1O^_35UW]B:5_T#+/_ +\+_A1_8FE?] RS_P"_"_X47I=G]_\ P U.1_X7
M'X)_Z"C?]^FH_P"%Q^"?^@HW_?IJZ[^Q-*_Z!EG_ -^%_P */[$TK_H&6?\
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M1_PN/P3_ -!1O^_35UW]B:5_T#+/_OPO^%']B:5_T#+/_OPO^%%Z79_?_P
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MV)I7_0,L_P#OPO\ A1>EV?W_ / #4Y'_ (7'X)_Z"C?]^FH_X7'X)_Z"C?\
M?IJZ[^Q-*_Z!EG_WX7_"C^Q-*_Z!EG_WX7_"B]+L_O\ ^ &IR/\ PN/P3_T%
M&_[]-1_PN/P3_P!!1O\ OTU==_8FE?\ 0,L_^_"_X4?V)I7_ $#+/_OPO^%%
MZ79_?_P U.1_X7'X)_Z"C?\ ?IJ/^%Q^"?\ H*-_WZ:NN_L32O\ H&6?_?A?
M\*/[$TK_ *!EG_WX7_"B]+L_O_X :G(_\+C\$_\ 04;_ +]-1_PN/P3_ -!1
MO^_35UW]B:5_T#+/_OPO^%']B:5_T#+/_OPO^%%Z79_?_P  -3D?^%Q^"?\
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M_P"%:5G3YW=,2N<C_P +C\$_]!1O^_34?\+C\$_]!1O^_35UW]B:5_T#+/\
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M^FH_X7'X)_Z"C?\ ?IJZ[^Q-*_Z!EG_WX7_"C^Q-*_Z!EG_WX7_"B]+L_O\
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MN/P3_P!!1O\ OTU==_8FE?\ 0,L_^_"_X4?V)I7_ $#+/_OPO^%%Z79_?_P
MU.1_X7'X)_Z"C?\ ?IJ/^%Q^"?\ H*-_WZ:NN_L32O\ H&6?_?A?\*/[$TK_
M *!EG_WX7_"B]+L_O_X :G(_\+C\$_\ 04;_ +]-1_PN/P3_ -!1O^_35UW]
MB:5_T#+/_OPO^%']B:5_T#+/_OPO^%%Z79_?_P  -3D?^%Q^"?\ H*-_WZ:C
M_A<?@G_H*-_WZ:NN_L32O^@99_\ ?A?\*/[$TK_H&6?_ 'X7_"B]+L_O_P"
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MC^Q-*_Z!EG_WX7_"B]+L_O\ ^ &IR/\ PN/P3_T%&_[]-1_PN/P3_P!!1O\
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M&6?_ 'X7_"C^Q-*_Z!EG_P!^%_PHO2[/[_\ @!J<C_PN/P3_ -!1O^_34?\
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M(_\ "X_!/_04;_OTU<;\2OB#X;\3>'[6RTN],LZWL4A4QD?*#R:]@_L32O\
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MZM DXS' %  PO0GC.3TKL:* /%O@M_R.WCS_ *_?_:DE>TUXO\%O^1V\>?\
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M8U<@%G*],\+^5>C?$OX=Z#J?A&_OK2PM['4;"!KF"XMT$9&P;B#MZY /XXH
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M"#3(;>&W4K!#'$I.2$4*#^5 'G/Q+\*:WKGPF&FI.^H:M;>5-(54!KAESN
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M:H>.?".J7GB+1?%7AP1?VMITFR6*1]@N(#U4MVZG\_:N]0L44LNUB.5SG!H
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ME/IX"Z!JK:H0%^RA!M+?[V<XS[9]JUOA;X8U9+W4_&/B:)H]9U5ODA?K!#U
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MZ <'H<_G6U%74EY?J)GN%%>9?\(U\5/^ART__P !O_L*/^$:^*G_ $.6G_\
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MKXJ?]#EI_P#X#?\ V%'_  C7Q4_Z'+3_ /P&_P#L*/9K^9?C_D%STVBO,O\
MA&OBI_T.6G_^ W_V%'_"-?%3_H<M/_\  ;_["CV:_F7X_P"07/3:*\R_X1KX
MJ?\ 0Y:?_P" W_V%'_"-?%3_ *'+3_\ P&_^PH]FOYE^/^07/3:*\R_X1KXJ
M?]#EI_\ X#?_ &%'_"-?%3_H<M/_ / ;_P"PH]FOYE^/^07/3:*\R_X1KXJ?
M]#EI_P#X#?\ V%'_  C7Q4_Z'+3_ /P&_P#L*/9K^9?C_D%STVBO,O\ A&OB
MI_T.6G_^ W_V%'_"-?%3_H<M/_\  ;_["CV:_F7X_P"07/3:*\R_X1KXJ?\
M0Y:?_P" W_V%'_"-?%3_ *'+3_\ P&_^PH]FOYE^/^07%^"/_(I:C_V$YOY+
M7IE>!?#C1_&]]H-W)X?\0VEA:K>R+)%+#N+28&6SM/!X_*NP_P"$:^*G_0Y:
M?_X#?_85I6IIS;YD),]-HKS+_A&OBI_T.6G_ /@-_P#84?\ "-?%3_H<M/\
M_ ;_ .PK/V:_F7X_Y#N>FT5YE_PC7Q4_Z'+3_P#P&_\ L*/^$:^*G_0Y:?\
M^ W_ -A1[-?S+\?\@N>FT5YE_P (U\5/^ART_P#\!O\ ["C_ (1KXJ?]#EI_
M_@-_]A1[-?S+\?\ (+GIM%>9?\(U\5/^ART__P !O_L*/^$:^*G_ $.6G_\
M@-_]A1[-?S+\?\@N>FT5YE_PC7Q4_P"ART__ ,!O_L*/^$:^*G_0Y:?_ . W
M_P!A1[-?S+\?\@N>FT5YE_PC7Q4_Z'+3_P#P&_\ L*/^$:^*G_0Y:?\ ^ W_
M -A1[-?S+\?\@N>FT5YE_P (U\5/^ART_P#\!O\ ["C_ (1KXJ?]#EI__@-_
M]A1[-?S+\?\ (+GIM%>9?\(U\5/^ART__P !O_L*/^$:^*G_ $.6G_\ @-_]
MA1[-?S+\?\@N>FT5YE_PC7Q4_P"ART__ ,!O_L*/^$:^*G_0Y:?_ . W_P!A
M1[-?S+\?\@N>FT5YE_PC7Q4_Z'+3_P#P&_\ L*/^$:^*G_0Y:?\ ^ W_ -A1
M[-?S+\?\@N>FT5YE_P (U\5/^ART_P#\!O\ ["C_ (1KXJ?]#EI__@-_]A1[
M-?S+\?\ (+GIM%>9?\(U\5/^ART__P !O_L*/^$:^*G_ $.6G_\ @-_]A1[-
M?S+\?\@N>FT5YE_PC7Q4_P"ART__ ,!O_L*/^$:^*G_0Y:?_ . W_P!A1[-?
MS+\?\@N>FT5YE_PC7Q4_Z'+3_P#P&_\ L*/^$:^*G_0Y:?\ ^ W_ -A1[-?S
M+\?\@N>FT5YE_P (U\5/^ART_P#\!O\ ["C_ (1KXJ?]#EI__@-_]A1[-?S+
M\?\ (+GIM%>9?\(U\5/^ART__P !O_L*/^$:^*G_ $.6G_\ @-_]A1[-?S+\
M?\@N>FT5YE_PC7Q4_P"ART__ ,!O_L*/^$:^*G_0Y:?_ . W_P!A1[-?S+\?
M\@N>FT5YE_PC7Q4_Z'+3_P#P&_\ L*/^$:^*G_0Y:?\ ^ W_ -A1[-?S+\?\
M@N>FT5YE_P (U\5/^ART_P#\!O\ ["C_ (1KXJ?]#EI__@-_]A1[-?S+\?\
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M_P# ;_["C_A&OBI_T.6G_P#@-_\ 84>S7\R_'_(+GIM%>9?\(U\5/^ART_\
M\!O_ +"C_A&OBI_T.6G_ /@-_P#84>S7\R_'_(+GIM%>9?\ "-?%3_H<M/\
M_ ;_ .PH_P"$:^*G_0Y:?_X#?_84>S7\R_'_ ""YZ;17F7_"-?%3_H<M/_\
M ;_["C_A&OBI_P!#EI__ (#?_84>S7\R_'_(+GIM%>9?\(U\5/\ H<M/_P#
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M_84>S7\R_'_(+GIM%>9?\(U\5/\ H<M/_P# ;_["C_A&OBI_T.6G_P#@-_\
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M_P"77S_074Z>BBBLAA1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MK62XTJ\CN8XI#%)MX*..H(/(-:= !1110 4444 %%%% !1110 4444 %%%%
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M>$M>OELM-UVTGN6^['DJ6]AN R?85;\4>(],\.:3)/J.H161E5T@>0XW/M)
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M^+7B?PI:32-I:Q^?%&S9VG(Q^.&Q^% 'M=%%% !1110 4444 %%%% !1110
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M[>O45RWP9TJ/0_B?XPTN.:29+5!&)9/O/A^I]S7NU>,?#3_DM7CS_?\ _9Z
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M-O\ =A_K7IM>9>#/^2Q>-O\ =A_K6M/X9>GZH3/3:***R&>+VO\ R=/??]>
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M\1[*R^(9\):E:M9.T>^"[ED CER,@#TSR/J,59\!?#[3?A_875MI]Q<W!NI
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MXBO8* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *\W^-/_ "*%G_V$(?YUZ17F_P :?^10L_\ L(0_SK6C_$0GL>B6_P#Q
M[1?[@_E4E1V__'M%_N#^525D,*\R\&?\EB\;?[L/]:]-KQK2O%.C>&?BWXPF
MU>]6VCF\M(R58Y8<D<#W%;4DVI)=OU$SV6BN*_X6UX(_Z#D?_?I_\*/^%M>"
M/^@Y'_WZ?_"I]E/^5A=':T5Q7_"VO!'_ $'(_P#OT_\ A1_PMKP1_P!!R/\
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M'(_^_3_X4>RG_*PNCM:*XK_A;7@C_H.1_P#?I_\ "C_A;7@C_H.1_P#?I_\
M"CV4_P"5A=':T5Q7_"VO!'_0<C_[]/\ X4?\+:\$?]!R/_OT_P#A1[*?\K"Z
M.UHKBO\ A;7@C_H.1_\ ?I_\*/\ A;7@C_H.1_\ ?I_\*/93_E871VM%<5_P
MMKP1_P!!R/\ []/_ (4?\+:\$?\ 0<C_ ._3_P"%'LI_RL+H[6BN*_X6UX(_
MZ#D?_?I_\*/^%M>"/^@Y'_WZ?_"CV4_Y6%T=K17%?\+:\$?]!R/_ +]/_A1_
MPMKP1_T'(_\ OT_^%'LI_P K"Z.UHKBO^%M>"/\ H.1_]^G_ ,*/^%M>"/\
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M 'Z?_"CV4_Y6%T=K17%?\+:\$?\ 0<C_ ._3_P"%'_"VO!'_ $'(_P#OT_\
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M:\$?]!R/_OT_^%'LI_RL+H[6BN*_X6UX(_Z#D?\ WZ?_  H_X6UX(_Z#D?\
MWZ?_  H]E/\ E871UE]IUEJEL;;4+.WNX"0QBGC#KD=#@\58551%1%"JHP !
M@ 5Q?_"VO!'_ $'(_P#OT_\ A1_PMKP1_P!!R/\ []/_ (4>RG_*PNCM:*XK
M_A;7@C_H.1_]^G_PH_X6UX(_Z#D?_?I_\*/93_E871VM%<5_PMKP1_T'(_\
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M_P"_3_X4>RG_ "L+H[6BN*_X6UX(_P"@Y'_WZ?\ PH_X6UX(_P"@Y'_WZ?\
MPH]E/^5A=':UYO\ &G_D4+/_ +"$/\ZT_P#A;7@C_H.1_P#?I_\ "N)^)WCO
MPWXB\.VMII6I+<3K>Q2% C#"@\GD5I1IS4TV@;T/9[?_ (]HO]P?RJ2HK8AK
M2%@<@HI'Y5+7.,*\H\,:;8ZA\7_&B7MG!<*@B*B6,, 3U(S7J]>9>#/^2Q>-
MO]V'^M;4_AEZ?JA,[C_A&-!_Z NG_P#@,G^%'_",:#_T!=/_ / 9/\*U:*RY
MGW&97_",:#_T!=/_ / 9/\*/^$8T'_H"Z?\ ^ R?X5JT4<S[@97_  C&@_\
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M_A6K11S/N!E?\(QH/_0%T_\ \!D_PH_X1C0?^@+I_P#X#)_A6K11S/N!E?\
M",:#_P! 73__  &3_"C_ (1C0?\ H"Z?_P" R?X5JT4<S[@97_",:#_T!=/_
M / 9/\*/^$8T'_H"Z?\ ^ R?X5JT4<S[@97_  C&@_\ 0%T__P !D_PH_P"$
M8T'_ * NG_\ @,G^%:M%',^X&5_PC&@_] 73_P#P&3_"C_A&-!_Z NG_ /@,
MG^%:M%',^X&5_P (QH/_ $!=/_\  9/\*/\ A&-!_P"@+I__ (#)_A6K11S/
MN!E?\(QH/_0%T_\ \!D_PH_X1C0?^@+I_P#X#)_A6K11S/N!E?\ ",:#_P!
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MQH/_ $!=/_\  9/\*/\ A&-!_P"@+I__ (#)_A6K11S/N!E?\(QH/_0%T_\
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M_P#0%T__ ,!D_P *U:*RYGW&97_",:#_ - 73_\ P&3_  H_X1C0?^@+I_\
MX#)_A6K11S/N!E?\(QH/_0%T_P#\!D_PH_X1C0?^@+I__@,G^%:M%',^X&5_
MPC&@_P#0%T__ ,!D_P */^$8T'_H"Z?_ . R?X5JT4<S[@97_",:#_T!=/\
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M5_PC&@_] 73_ /P&3_"C_A&-!_Z NG_^ R?X5JT4<S[@97_",:#_ - 73_\
MP&3_  H_X1C0?^@+I_\ X#)_A6K11S/N!E?\(QH/_0%T_P#\!D_PH_X1C0?^
M@+I__@,G^%:M%',^X&5_PC&@_P#0%T__ ,!D_P */^$8T'_H"Z?_ . R?X5J
MT4<S[@97_",:#_T!=/\ _ 9/\*/^$8T'_H"Z?_X#)_A6K11S/N!E?\(QH/\
MT!=/_P# 9/\ "C_A&-!_Z NG_P#@,G^%:M%',^X&5_PC&@_] 73_ /P&3_"C
M_A&-!_Z NG_^ R?X5JT4<S[@97_",:#_ - 73_\ P&3_  H_X1C0?^@+I_\
MX#)_A6K11S/N!E?\(QH/_0%T_P#\!D_PH_X1C0?^@+I__@,G^%:M%',^X&5_
MPC&@_P#0%T__ ,!D_P */^$8T'_H"Z?_ . R?X5JT4<S[@97_",:#_T!=/\
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M5_PC&@_] 73_ /P&3_"C_A&-!_Z NG_^ R?X5JT4<S[@97_",:#_ - 73_\
MP&3_  H_X1C0?^@+I_\ X#)_A6K11S/N!Q/CGP]HUMX%UN:#2;*.5+21E=(%
M!4XZ@XIG@'P_HUSX#T::?2K*65[<%G>!26.3U)%:OQ _Y)_KW_7E)_*F?#K_
M ))[H?\ U[#^9K7F?LM^HNII?\(QH/\ T!=/_P# 9/\ "C_A&-!_Z NG_P#@
M,G^%:M%9<S[C,K_A&-!_Z NG_P#@,G^%'_",:#_T!=/_ / 9/\*U:*.9]P,K
M_A&-!_Z NG_^ R?X4?\ ",:#_P! 73__  &3_"M6BCF?<#*_X1C0?^@+I_\
MX#)_A1_PC&@_] 73_P#P&3_"M6BCF?<#*_X1C0?^@+I__@,G^%'_  C&@_\
M0%T__P !D_PK5HHYGW RO^$8T'_H"Z?_ . R?X4?\(QH/_0%T_\ \!D_PK5H
MHYGW RO^$8T'_H"Z?_X#)_A1_P (QH/_ $!=/_\  9/\*U:*.9]P,K_A&-!_
MZ NG_P#@,G^%'_",:#_T!=/_ / 9/\*U:*.9]P,K_A&-!_Z NG_^ R?X4?\
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M\(QH/_0%T_\ \!D_PK5HHYGW RO^$8T'_H"Z?_X#)_A1_P (QH/_ $!=/_\
M 9/\*U:*.9]P,K_A&-!_Z NG_P#@,G^%'_",:#_T!=/_ / 9/\*U:*.9]P,K
M_A&-!_Z NG_^ R?X4?\ ",:#_P! 73__  &3_"M6BCF?<#*_X1C0?^@+I_\
MX#)_A1_PC&@_] 73_P#P&3_"M6BCF?<#*_X1C0?^@+I__@,G^%'_  C&@_\
M0%T__P !D_PK5HHYGW RO^$8T'_H"Z?_ . R?X4?\(QH/_0%T_\ \!D_PK5H
MHYGW RO^$8T'_H"Z?_X#)_A1_P (QH/_ $!=/_\  9/\*U:*.9]P,K_A&-!_
MZ NG_P#@,G^%'_",:#_T!=/_ / 9/\*U:*.9]P,K_A&-!_Z NG_^ R?X4?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110!YG\$?^12U'_L)S?R6O3*\S^"/_(I:C_V$
MYOY+7IE:U_XC$M@HHHK(84444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 9FOZ_IWAG1I]5U2X6&VA&23U8]E4=R?2O+X_B_XJU1?MVA
M_#Z^N=*ZK,Y;+J.I&%Q^6:C^.I%SJO@[3;L@:;/?$SDG'.5 _1FKV2&&*W@C
MAA18XHU"HBC 4#H!0!RG@;XA:7XYMI_LT<MI?VIQ<V<_WX_<>HSQG\P*ZZO#
M]>N+;P_^TMHTFG[4;4K=([Y$; 9WW+\P]<!&]R :]PH *X'Q-XPU$>/M'\(Z
M 8OM,V9[^9T#B&$>V>O_ -:N^) !)Z"O&OA+(_B+XA^,_%$N&4S"VA8CD)DX
MQZ?*JT >L:MJ TG1+[470RK:6\DY0'!;8I;'XXKRG3_C5K^JV:7FG_#?5+NV
M<D+-!*SJ<'!P1%BNQ^*]VUE\+M?E7[QMQ&/^!,%_K7$>"/B=X/\ !GP_T/2[
M[4&-TL&^6*"(R&,LQ;!QT/S4 =1X8^(/B'7==AL+_P !:II5O(&+7<Y;8F!G
MG,8Z_6O0:QO#GBK1?%=A]LT:^CN8QPZCAD/HRGD5LT %>1S?&?5)=;U+3](\
M"ZAJBV$[0O+;S%NA(!($9QG'K7K$\GDV\LIZ(A;\A7S[\*/'7AWPCHFNWVMW
M_E7%YJ+,D**7D=0!R .V2?RH [&V^*GBJ:ZBB?X8:U$CN%9RSX4$]?\ 5=J]
M(U?5+71-(N]4OGV6UK$99".N!V'OVK#\+?$3PSXQD>'2-0#W"C)@E4HY'J >
MH^E2_$#1;GQ#X"UG2[,G[3/;GRP/XF4A@OXXQ^- '"CXP:_%ID7B2\\%R0^%
MY751="Z4RA2<!MG4C/L![UZO;7<%Y917D$@:WEC$J/V*D9!_*O![WQM:ZG\)
M;;P1:Z?J#>)&M8;$V1MF!#*0I;.,8XS6]XHO=1@T70OAAHTV_6+NUCBOIU.?
MLT( #$XZ9Y_#ZT =GX3\<?\ "7ZQJD6GZ:XT>R?RDU)I.+B3N%7;T'/.?3UJ
M'XD>(=9\)Z-;ZYIHAEM+>=1?02)DM$QQE3V(K?\ #GA^Q\+Z#:Z1IT82WMUQ
M[LW=C[D\TOB738]8\,ZGITJ[DN+9TQ[XX_7% %O3K^WU73;:_M'WV]Q&LD;>
MJD9%6:\K^ >J2WG@&2QG<L^G7;P#/93A@/IR:]4H **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#F_B!_P D_P!>_P"O*3^5
M,^'7_)/=#_Z]A_,T_P"('_)/]>_Z\I/Y4SX=?\D]T/\ Z]A_,UK_ ,NOG^@N
MIT]%%%9#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ JIJ6IV.CV$M]J-U%;6L0W/+*V *MUS/BWP1IOC233%U9I&M+*5I6MU.!,2
M, ,1R /:@#C;'XYZ=J_C*QT33-(N)K2\N! E]+)Y8)S@D)@Y'U(/TKUBO#_'
M%C:Z;\:O %G96\5O;1!52*)0JJ/,/85[A0 5SWC?Q3!X/\*7FKRX:1%VP1D_
M?D/"C\_T%=#7C7Q>G?6O'7@[PG&P,<MR+F92..N!G\ ] 'I'@^?6+OPM8W>O
M-&=0N(Q+(D<>P1@\A<?2N5\7?%B+1=>_X1_0=(N-=UA?];#;YVQ>Q(!)/3CM
MGKVKNM5O5TK1;V^VY6TMY)MH'95)Q^E>7? +3!)X>U+Q+<@/?ZG>/NF/WB@[
M?]]%C^5 %G3OC!=66MVVD^,_#=QH4MRVV*X+;HCGIGCI[@FO5000"#D&N#^,
M&@PZ[\.-2#A?.LU^TPL>Q7K^8R*N?"W6)==^&^C7L[F280^4[DY+%"5R?RH
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M7))-=3\3_"$_C'PB]I8L%U&VE6YM"3@;U[9[9!(S0!RZ>-/BE%&L<?PYA5$
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MXK6T\WQ1\!R102R(D_SLB$A?WB=2.E 'LE%%% !1110 4444 %%%% !1110
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M#V_BKVBO+O@-I,ECX!?4)T=)M3NGN#N'5>@(]C@FO4: "BBB@ HHHH ****
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M9@CR+NAE(SY<@Y5JZ"B@#!\'6^MV?A>RM/$ A.H6Z>4[PR;UD X#9P.<5ND
M@@C(/4&EHH 155%"J  .@ Q2T44 %%%% #1%&)#($4.1C=CG'UIU%% !1110
M THK,&902.A(Z4ZBB@#@?"_@[4H_'6L>+_$!@^VW'[BRAADWB& 8ZG Y.!^O
MK7?444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 5YO\:?^10L_P#L(0_SKTBO-_C3_P BA9_]A"'^=:T?XB$]CT2W_P"/
M:+_<'\JDJ.W_ ./:+_<'\JDK(85XA;VGBB[^+'BY?#>H6MI,K1F9ITW!E_A
M]^M>WUYEX,_Y+%XV_P!V'^M;4792?E^HF+_8WQ6_Z&+2O^_'_P!:C^QOBM_T
M,6E?]^/_ *U>F44O:OLON"QYG_8WQ6_Z&+2O^_'_ -:C^QOBM_T,6E?]^/\
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M_H8M*_[\?_6H_L;XK?\ 0Q:5_P!^/_K5Z911[5]E]P6/,_[&^*W_ $,6E?\
M?C_ZU']C?%;_ *&+2O\ OQ_]:O3**/:OLON"QYG_ &-\5O\ H8M*_P"_'_UJ
M/[&^*W_0Q:5_WX_^M7IE%'M7V7W!8\S_ +&^*W_0Q:5_WX_^M1_8WQ6_Z&+2
MO^_'_P!:O3**/:OLON"QYG_8WQ6_Z&+2O^_'_P!:C^QOBM_T,6E?]^/_ *U>
MF44>U?9?<%CS/^QOBM_T,6E?]^/_ *U']C?%;_H8M*_[\?\ UJ],HH]J^R^X
M+'F?]C?%;_H8M*_[\?\ UJ/[&^*W_0Q:5_WX_P#K5Z911[5]E]P6/,_[&^*W
M_0Q:5_WX_P#K4?V-\5O^ABTK_OQ_]:O3**/:OLON"QYG_8WQ6_Z&+2O^_'_U
MJ/[&^*W_ $,6E?\ ?C_ZU>F44>U?9?<%CS/^QOBM_P!#%I7_ 'X_^M1_8WQ6
M_P"ABTK_ +\?_6KTRBCVK[+[@L>9_P!C?%;_ *&+2O\ OQ_]:C^QOBM_T,6E
M?]^/_K5Z911[5]E]P6/,_P"QOBM_T,6E?]^/_K4?V-\5O^ABTK_OQ_\ 6KTR
MBCVK[+[@L>9_V-\5O^ABTK_OQ_\ 6H_L;XK?]#%I7_?C_P"M7IE%'M7V7W!8
M\S_L;XK?]#%I7_?C_P"M1_8WQ6_Z&+2O^_'_ -:O3**/:OLON"QYG_8WQ6_Z
M&+2O^_'_ -:C^QOBM_T,6E?]^/\ ZU>F44>U?9?<%CS/^QOBM_T,6E?]^/\
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M ))[H?\ U[#^9K3VC]G>RW["MJ<U_8WQ6_Z&+2O^_'_UJ/[&^*W_ $,6E?\
M?C_ZU>F45G[5]E]P['F?]C?%;_H8M*_[\?\ UJ/[&^*W_0Q:5_WX_P#K5Z91
M1[5]E]P6/,_[&^*W_0Q:5_WX_P#K4?V-\5O^ABTK_OQ_]:O3**/:OLON"QYG
M_8WQ6_Z&+2O^_'_UJ/[&^*W_ $,6E?\ ?C_ZU>F44>U?9?<%CS/^QOBM_P!#
M%I7_ 'X_^M1_8WQ6_P"ABTK_ +\?_6KTRBCVK[+[@L>9_P!C?%;_ *&+2O\
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M\5O^ABTK_OQ_]:O3**/:OLON"QYG_8WQ6_Z&+2O^_'_UJ/[&^*W_ $,6E?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH \S^"/\ R*6H_P#83F_DM>F5YG\$?^12U'_L)S?R
M6O3*UK_Q&);!11160PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MCBG^4 .5'7/4#/XT >_T5YYX7^%%OX8UZ'58_$6L7C1!AY-S*"C9&.1BO0Z
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M.;^('_)/]>_Z\I/Y4SX=?\D]T/\ Z]A_,T_X@?\ )/\ 7O\ KRD_E3/AU_R3
MW0_^O8?S-:_\NOG^@NIT]%%%9#"BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHKC_'_BK5?#MG9VVA:2VI:MJ,C16Z _*A R6;V
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M<-PL;%',3AMK#L?0U:KQZ2Y_X0/X[+"H$6D>)HP2JC"K<9P#]2V>G]\5[#0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MA_\ 7L/YFM?^77S_ $%U.GHHHK(84444 %%%% !1110 4444 %%%% !1110
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M?^(Q+8****R&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** .;^('_)/]>_Z\I/Y4SX=?\D]T/\ Z]A_,T_X@?\ )/\ 7O\
MKRD_E3/AU_R3W0_^O8?S-:_\NOG^@NIT]%%%9#"BBB@ HHHH **** "BBB@
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M\/\ X5K?\(?X:_Z &F?^ J?X4?\ "'^&O^@!IG_@*G^%'[KS#4R?^%I^"?\
MH/P?]\/_ (4?\+3\$_\ 0?@_[X?_  K6_P"$/\-?] #3/_ 5/\*/^$/\-?\
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M J?X4?\ "'^&O^@!IG_@*G^%'[KS#4R?^%I^"?\ H/P?]\/_ (4?\+3\$_\
M0?@_[X?_  K6_P"$/\-?] #3/_ 5/\*/^$/\-?\ 0 TS_P !4_PH_=>8:F3_
M ,+3\$_]!^#_ +X?_"C_ (6GX)_Z#\'_ 'P_^%:W_"'^&O\ H :9_P" J?X4
M?\(?X:_Z &F?^ J?X4?NO,-3)_X6GX)_Z#\'_?#_ .%'_"T_!/\ T'X/^^'_
M ,*UO^$/\-?] #3/_ 5/\*/^$/\ #7_0 TS_ ,!4_P */W7F&ID_\+3\$_\
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M\/\ X5K?\(?X:_Z &F?^ J?X4?\ "'^&O^@!IG_@*G^%'[KS#4R?^%I^"?\
MH/P?]\/_ (4?\+3\$_\ 0?@_[X?_  K6_P"$/\-?] #3/_ 5/\*/^$/\-?\
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MN]Q*]C)_X6GX)_Z#\'_?#_X4?\+3\$_]!^#_ +X?_"M;_A#_  U_T -,_P#
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M?NO,-3)_X6GX)_Z#\'_?#_X4?\+3\$_]!^#_ +X?_"M;_A#_  U_T -,_P#
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M_P#A1_PM/P3_ -!^#_OA_P#"M;_A#_#7_0 TS_P%3_"C_A#_  U_T -,_P#
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M?NO,-3)_X6GX)_Z#\'_?#_X4?\+3\$_]!^#_ +X?_"M;_A#_  U_T -,_P#
M5/\ "C_A#_#7_0 TS_P%3_"C]UYAJ<;XQ^(OA+4O!NKV5GK4,MS/:ND<85LL
MQ' Z4SP5\1/">E^"])L;W688;F& +)&5;*G)XX%:OCCPOH%IX'UJXM]%T^*:
M.T=DD2W0,IQU! XIG@/PQH-YX%T>XN=%T^::2W!>22W1F8Y/))'-:?N_9]=P
MUN7?^%I^"?\ H/P?]\/_ (4?\+3\$_\ 0?@_[X?_  K6_P"$/\-?] #3/_ 5
M/\*/^$/\-?\ 0 TS_P !4_PK/]UYAJ9/_"T_!/\ T'X/^^'_ ,*/^%I^"?\
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M4_PH_=>8:F3_ ,+3\$_]!^#_ +X?_"C_ (6GX)_Z#\'_ 'P_^%:W_"'^&O\
MH :9_P" J?X4?\(?X:_Z &F?^ J?X4?NO,-3)_X6GX)_Z#\'_?#_ .%'_"T_
M!/\ T'X/^^'_ ,*UO^$/\-?] #3/_ 5/\*/^$/\ #7_0 TS_ ,!4_P */W7F
M&ID_\+3\$_\ 0?@_[X?_  H_X6GX)_Z#\'_?#_X5K?\ "'^&O^@!IG_@*G^%
M'_"'^&O^@!IG_@*G^%'[KS#4R?\ A:?@G_H/P?\ ?#_X4?\ "T_!/_0?@_[X
M?_"M;_A#_#7_ $ -,_\  5/\*/\ A#_#7_0 TS_P%3_"C]UYAJ9/_"T_!/\
MT'X/^^'_ ,*/^%I^"?\ H/P?]\/_ (5K?\(?X:_Z &F?^ J?X4?\(?X:_P"@
M!IG_ ("I_A1^Z\PU,G_A:?@G_H/P?]\/_A1_PM/P3_T'X/\ OA_\*UO^$/\
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MGX)_Z#\'_?#_ .%'_"T_!/\ T'X/^^'_ ,*UO^$/\-?] #3/_ 5/\*/^$/\
M#7_0 TS_ ,!4_P */W7F&ID_\+3\$_\ 0?@_[X?_  H_X6GX)_Z#\'_?#_X5
MK?\ "'^&O^@!IG_@*G^%'_"'^&O^@!IG_@*G^%'[KS#4R?\ A:?@G_H/P?\
M?#_X4?\ "T_!/_0?@_[X?_"M;_A#_#7_ $ -,_\  5/\*/\ A#_#7_0 TS_P
M%3_"C]UYAJ9/_"T_!/\ T'X/^^'_ ,*/^%I^"?\ H/P?]\/_ (5K?\(?X:_Z
M &F?^ J?X4?\(?X:_P"@!IG_ ("I_A1^Z\PU,G_A:?@G_H/P?]\/_A1_PM/P
M3_T'X/\ OA_\*UO^$/\ #7_0 TS_ ,!4_P */^$/\-?] #3/_ 5/\*/W7F&I
MD_\ "T_!/_0?@_[X?_"C_A:?@G_H/P?]\/\ X5K?\(?X:_Z &F?^ J?X4?\
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MKS#4R?\ A:?@G_H/P?\ ?#_X4?\ "T_!/_0?@_[X?_"M;_A#_#7_ $ -,_\
M 5/\*/\ A#_#7_0 TS_P%3_"C]UYAJ9/_"T_!/\ T'X/^^'_ ,*/^%I^"?\
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M4_PH_=>8:F3_ ,+3\$_]!^#_ +X?_"C_ (6GX)_Z#\'_ 'P_^%:W_"'^&O\
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M3?C:<=<#^5=-0 44V21(8GEE=4C12S,QP !U)KR6X^,&JZUJ\]EX'\+RZQ!
M2CWCL5C+>W'3TR1GTH ]<HKS/PO\5IKWQ(GAOQ5HDFA:K*!Y =B4E)Z#D<$]
MNOUKOM9U:UT+1KS5;UBMM:Q&60CK@=A[GI0!>HKQ\?%GQ3!H\7BB\\'+%X8E
M=0)EN@9E0M@/M[C\ .1SWKUBUO;>\L(;Z&0&VEC$J.>!M(R#^5 %BBN.\(>-
MY?&.KZI]ATW;H=F_E0Z@TAS<2=PJ[>@YYSZ>M1_$K7M:\+:);Z]I;1O;6LZ_
M;;=X]WF1$X)4]B* .UHJKIFHV^K:9:ZC:/OM[F-98V]01FK5 !1110 4444
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MOXW'COPQ_:+VZV]U%*T-Q$IR PP01[$$?K77G[I^E>,?L^?ZCQ4.W]H#^34
M='X&\;:KXB\=^*-'O5@%KICA8/+3#?>(Y.>>E'C[X@ZKH>N67AOPYHSW^L7B
M;E:12(T!SCGN>"3S@"N<^%'_ "5CQ[_UU'_H;5TGC'XI6N@:^F@Z1H]QK>N[
M<_9[<?ZO(S@D G..< 4 <[J?B/XN>$; ZSK5EI%_I\/,\5OPR+_>)';\Z]2\
M.:[:^)O#]EK%GD0W48<*>JGNI]P<BO+?$>L_%/6/#FIQR^%]+TO3FM9#,\\X
MDDV8). &ZX]5K?\ @5_R2?3?^NL__HQJ /1Z*** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \S^"/
M_(I:C_V$YOY+7IE>9_!'_D4M1_["<W\EKTRM:_\ $8EL%%%%9#"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KC_B9XM'@_P7=WL;
M8O9AY%HO<R-W_ 9/X5V%>)W_ /Q<WXT16"_O-!\.?-+W627/(]#R,?130!V'
MPD\)'PKX+A-RI_M&_/VJZ9NN3T4_0?J37>4=!BB@#DOB;K3Z#\.=:OHG*3>1
MY,;+U#.0@(^F<_A53X0Z7_9/PPT>-E423QFX?:.I<DC/OMQ6;\=]_P#PJR]V
MYQY\.['IN[_CBNM\$[/^$$\/^7C;_9UOT]?+7/ZT :M]>V^FV%Q?7<JQ6UO&
MTDLC=%4#)->#6]G<^/;+Q1\1-6B9+6*RFM](MVY55"D%_J#G\2?05K?%OQ/;
MZSXCL? :ZI!I]D[K+JMU+((PB#D(">,XYQZXKH/$/BGP3:?#C4=&TG7])V1Z
M>\%O!%=H2?E(  SDDT +\"?^2667_7>7_P!"KTJO)?@3KNDCP)8Z0=2M/[2,
MLK?9/-'FXW9SMZ]*]:H I:OID6LZ1=Z;/)+'#<QF)VA;:P4]<&J'A[0=(\%:
M%#I5BRP6J,Q#2N SL3DDGN:W*YKQEX)TWQO96]IJ<UU''!(9%^SN%).,<\&@
M#S/XJWMIXI\<>%=%\/21WFKVUUYDLD#[A"F5)#,.!TR?3%>G>/M$N/$?@36-
M*M"1<7$!\L XW,I#!?QQC\:\DU[P]?\ P0N(/$'AV_:YTFXG6*\M;I%9\'D?
M, ">_H1[U[Q:7*7EG!=19\N:-9%SUP1D?SH \'O/&0U/X5V_@2VT?5#XD-K%
M8M:M;, NW"E]WI@5N>)[K4!I>A_"W19M^IW-K''J%PIS]G@ &XG'KS^'UKO?
M''BNR\%^'9M6G17N6_=6T0QNED/W5'MW/L*\XLKB[^&FAKKFHV3:EXT\3W&!
M 6P%)Y"9YP!D9_+C% 'K/A_0K'PUH=KI.G1".WMTVCU8]V/N3DT>(]-CU?PW
MJ6GRJ&2XMG3!]2#C]<5Q&E_$#Q%8>+]/\/>,M"MK!]3!^R7-K-O0N!]T]><\
M=>I'8YKTH\#)H \J^ 6I2W7@.:PF<L^G7;P#/8'# ?3DUZK7B_P"!,GBQP#L
M.H<'M_%7M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 <W\0/^2?Z]_P!>4G\J9\.O^2>Z'_U[#^9I_P 0/^2?Z]_UY2?R
MIGPZ_P"2>Z'_ ->P_F:U_P"77S_074Z>BBBLAA1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 54U34K71M+N=1OI1%;6T9DD<]@*MU
MX?\ %'Q-9^(_&=CX&DU6WL-)A<3:K<2RB,<<B,,>^.WJ?:@#'&FW7C'PSXN^
M)&M1%3+8S0:7;MRL<0&-PS^(^I8UZ5\%_P#DE.C?23_T8U9OC3Q9X-'PQU?2
M-*U[26(T]H;>WAND).%P% !Y-.^"FO:1)X!TC2$U.T;4E21FM!*/- WL>5Z]
M.: /3JS]=U%=(T#4-1<X%M;O+GZ FM"N6^)._P#X5MXA\O.[[#)C'7I0!R7P
M$LY/^$+O-7N"&GU.]DF9L<G''7ZYKJ?&W@.U\<'3%O;V>&"QG\XPQ@%93QPV
M?;(_$UF?!7R_^%5Z3Y>W_EINQZ[SFO0* &@)%'@!411]  *\:^&31ZA\8/&F
MJ:4@_LACY?F)]QY-P.1]<,?QJ7Q_XSOO%6L_\(#X,=Y+F5MFHWT1^6%.C*#_
M #/X"O1/"'A/3O!GA^#2-.4E4^:25A\TKGJQ_P \#B@#>KFOB%=&R^'?B"8'
M!^PRKG./O+M_K72U4U/3++6=.FT_4;=+BTG $D3]&P<C]0#0!XG\//B=X2\%
M?#G2;#4+N5[UC))-#;Q;S'EVQGMTQ^=>K^%O&N@^,K5Y]&O1*4_UD+#;(GU7
M^M2Z9X/\.:/:FVL-%L88B<D"%22?4D\FO(_'&CV_P^^*?AK7]!7[)'J=P(+J
M",80Y90V![ALX]10!V?QG\/WVO>"$;3HI)[BPNDN_(C&3*J@@@#O@-G\*Y/Q
M5XFC^*;:'H.@V&H+<)>QSWKS0%!:JO7)/&>OY5[A7"?$CQ9+X>T^'2=%C$OB
M'5V\BSC3&5SP7/L,\'UH YSQ//+\2O&L7@FPD;^P=+99M7N4/$KC[L6?K^N3
M_#7K-M;0V=K%;6T:Q00H$CC48"J!@ 5Y%;W=Q\,XM)\$^&M,35O$NHJ;N[DF
MDVIN/WF8_P# 3CG@#OFND\(^/-3U#Q3=^%?$VDQZ;K,$7G1^3)OCF3U7_P#7
MZ],4 2?&'2DU;X8:NI4-);HMS&3V*$$G_OG=^=7/A?JTFM?#;0[R5R\OV?RG
M8]24)3)_[YK1\:,J^!?$!8@#^S;CK_US:N1^ P(^%MH2" ;B8C/<;J /2Z**
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KS?X
MT_\ (H6?_80A_G7I%>;_ !I_Y%"S_P"PA#_.M:/\1">QZ);_ /'M%_N#^525
M';_\>T7^X/Y5)60PKS+P9_R6+QM_NP_UKTVO,O!G_)8O&W^[#_6M:?PR]/U0
MF>FT445D,\>MK*['[3E[>&UG%J;$*)O+.PGRDXW8Q7L-%% 'CWQRLKN\O_!Q
MM;6><1WS,YBC+;1F/DX'%>P#H*6L/Q;X@F\,Z!+J5OI5UJDJ,JK;6RDLV3R<
M@'  YSB@#P3XFZ3JND_$*^T/36V6?BQX6*YSE@_/';YN?I7T1HNE0:'HEEI=
MJ,0VD*Q)[@#&3[UY;X1T?7O&GQ%_X3GQ%I4FEVEG'Y6GV<V=^<$;B"!ZGG R
M3[5[#0!X!\7+/4+_ .,GAJWTJ2.._,*M;M+]W>K,P!]CC'XUTD_QM:P@-I?^
M$M7CUM/D>U6/*E\=0W=<^U1^,=,OY_CSX2O8K*XDM8DQ).L1*+][JW05ZZ44
ML&*@L.AQS0!Y9\*_"NMC6]7\:^)X?L^IZH=L5N>L<>1U';HH ]![U!XWTC7_
M  GX\3Q[X=LFO[>2#RM2LT/S%1@9 '7@ ]\$>]>N44 >/WGQR^TV1@T;POJ\
MNK2+MCAEA^5&/ SCJ*[?P!'XI7PU'+XNG1]1E8N(U0*8E[*V.":Z<(@8L%4,
M>IQS3J /'O@%97=EIWB$7=K/;E[X,HFC*;A@\C(KU+6](M]>T.]TJ[SY%W$T
M3XZC/>K]0W@N393"S:-;DH?*,H)4-CC..V: /%/#^I^.?A; WA^]\-SZWID4
MA^R75H<X4GIT]^AZ5SWQ6N?%/B7PY#KFM:>VCZ9;W"1VE@Y!DD=LYD?TP.!]
M:ZJP^)WBWPCYMAXY\-7US()"8[VSC!1ESTX^4^W.>F15+7KSQ'\8[[3]*LO#
M]YI6@07(FN+N]4KY@'MQ[\#/..10!VOQ'@FN?@MJ$-O#)-*]G %2-2S'YTZ
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MGHHHK(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MY!<]-HKS+[%\7_\ H*Z%_P!^O_K4?8OB_P#]!70O^_/_ -:CV7]Y!<7X(_\
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M%>9?8OB__P!!70O^_7_UJ/L7Q?\ ^@KH7_?K_P"M6?LO[R"YZ;17F7V+XO\
M_05T+_OU_P#6H^Q?%_\ Z"NA?]^O_K4>R_O(+GIM%>9?8OB__P!!70O^_7_U
MJ/L7Q?\ ^@KH7_?K_P"M1[+^\@N>FT5YE]B^+_\ T%="_P"_7_UJ/L7Q?_Z"
MNA?]^O\ ZU'LO[R"YZ;17F7V+XO_ /05T+_OU_\ 6H^Q?%__ *"NA?\ ?K_Z
MU'LO[R"YZ;17F7V+XO\ _05T+_OU_P#6H^Q?%_\ Z"NA?]^O_K4>R_O(+GIM
M%>9?8OB__P!!70O^_7_UJ/L7Q?\ ^@KH7_?K_P"M1[+^\@N>FT5YE]B^+_\
MT%="_P"_7_UJ/L7Q?_Z"NA?]^O\ ZU'LO[R"YZ;17F7V+XO_ /05T+_OU_\
M6H^Q?%__ *"NA?\ ?K_ZU'LO[R"YZ;17F7V+XO\ _05T+_OU_P#6H^Q?%_\
MZ"NA?]^O_K4>R_O(+GIM%>9?8OB__P!!70O^_7_UJ/L7Q?\ ^@KH7_?K_P"M
M1[+^\@N>FT5YE]B^+_\ T%="_P"_7_UJ/L7Q?_Z"NA?]^O\ ZU'LO[R"YZ;1
M7F7V+XO_ /05T+_OU_\ 6H^Q?%__ *"NA?\ ?K_ZU'LO[R"YZ;17F7V+XO\
M_05T+_OU_P#6H^Q?%_\ Z"NA?]^O_K4>R_O(+GIM%>9?8OB__P!!70O^_7_U
MJ/L7Q?\ ^@KH7_?K_P"M1[+^\@N>FT5YE]B^+_\ T%="_P"_7_UJ/L7Q?_Z"
MNA?]^O\ ZU'LO[R"YZ;17F7V+XO_ /05T+_OU_\ 6H^Q?%__ *"NA?\ ?K_Z
MU'LO[R"YZ;17F7V+XO\ _05T+_OU_P#6H^Q?%_\ Z"NA?]^O_K4>R_O(+GIM
M%>9?8OB__P!!70O^_7_UJ/L7Q?\ ^@KH7_?K_P"M1[+^\@N>FT5YE]B^+_\
MT%="_P"_7_UJ/L7Q?_Z"NA?]^O\ ZU'LO[R"YZ;17F7V+XO_ /05T+_OU_\
M6H^Q?%__ *"NA?\ ?K_ZU'LO[R"YZ;17F7V+XO\ _05T+_OU_P#6H^Q?%_\
MZ"NA?]^O_K4>R_O(+GIM%>9?8OB__P!!70O^_7_UJ/L7Q?\ ^@KH7_?K_P"M
M1[+^\@N>FT5YE]B^+_\ T%="_P"_7_UJ/L7Q?_Z"NA?]^O\ ZU'LO[R"YZ;1
M7F7V+XO_ /05T+_OU_\ 6H^Q?%__ *"NA?\ ?K_ZU'LO[R"YZ;17F7V+XO\
M_05T+_OU_P#6H^Q?%_\ Z"NA?]^O_K4>R_O(+GIM%>9?8OB__P!!70O^_7_U
MJ/L7Q?\ ^@KH7_?K_P"M1[+^\@N>FT5YE]B^+_\ T%="_P"_7_UJ/L7Q?_Z"
MNA?]^O\ ZU'LO[R"YZ;17F7V+XO_ /05T+_OU_\ 6H^Q?%__ *"NA?\ ?K_Z
MU'LO[R"YZ;17F7V+XO\ _05T+_OU_P#6H^Q?%_\ Z"NA?]^O_K4>R_O(+GIM
M%>9?8OB__P!!70O^_7_UJ/L7Q?\ ^@KH7_?K_P"M1[+^\@N>FT5YE]B^+_\
MT%="_P"_7_UJ/L7Q?_Z"NA?]^O\ ZU'LO[R"YZ;7F_QI_P"10L_^PA#_ #J+
M[%\7_P#H*Z%_WZ_^M7)?$*W\?Q:%;-XDOM,FLOMD05;:/#;\\'ITK2E3M-/F
M0F]#W:W_ ./:+_<'\JDJ*US]DAW8W>6N<>N*EKF*"O,O!G_)8O&W^[#_ %KT
MVO,O!G_)8O&W^[#_ %K6G\,O3]4)GIM%%%9#"BBB@ HHHH **** "BBF3316
M\+S3R)%$@W.[L%51ZDGI0 ^BHX+B&Z@2>WFCFA<962-@RL/8CK4E !1110 4
M444 %%%% !1110 4444 %%%% !1110 45!-?6EO<0V\]U!%/,<11O(%:3_=!
MY/X5/0 4444 %%%% !1110 4444 %%%% !1110 4444 %%07-]:6;1+=74$#
M3-LC$L@4NWH,]34] !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 >9_!'_D4M1_["<W\EKTRO,_@C_R*6H_]A.;^2UZ96M?^
M(Q+8****R&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%45UG3GU9]*2\A:_1=[6X;+JOJ1VH O4444 %%%% !11
M3)9HH5W2R)&OJS "@!]%(CK(@=&#*>00<@TM !148GA,QA$J&4#)3<-P_"I*
M "BBJ5[J^G:=<VUO>WD-O+<MMA61MOF-Z#/>@"[1110 4444 %%%% !1110
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M,JZ'((]0:\NT_P"$GPYMM)6UO#;WMT4Q)=R79#LW=@ V!S61\/;E_!7Q-O/
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M.;^2UZ96M?\ B,2V"BBBLAA1110 4444 %%%% !1110 4444 %%%% !1110
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MK<6FB76JO-*4,=N#E!C.3@&@#R_4-.O?@OXRT>?3-2N;KP_JDPMY[6X;=L/
MR#Z\Y!QV(YKU+XB:Q<Z!\/\ 6M3LV*7,-OB-P.59B%!_#.:\?MM>3XG?$73H
M_%<L6BVNGR[K72Y599+AR>[''/ _I7ONIZ=;:OI=UIUXF^VN8FBD4'&5(P:
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M)\.:_::O;ZUK,\MLQ98YYE*-D$<@*/6N6\.^$?BQ:^%+'2K+4[#0[>TW!(R
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MHH **** "O-_C3_R*%G_ -A"'^=>D5YO\:?^10L_^PA#_.M:/\1">QZ);_\
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M3:B\#:2X<0"(,)<,&ZY&.F.AJYXV\#Z7XYTE;+4#)%+$Q>WN(CAXFQU]Q[4
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MFC6-#OM,,IB%W \)D"Y*[@1G'?K0!Q/P._Y)+I'^_/\ ^CGKF?%'_)ROAO\
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M@87!3SIPQZ2/R1^'3\*ZV@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?$7AO4-':<P+>0-"90NXIGOCO5;P=X:7PAX6L]$2Z:Z6VW8E9-A;+$],GUH
MW:YWQY9/J'@'7;6/[\EE(!S_ +.?Z5T5-DC26)XY%#(X*L#T(- 'G7P-O%NO
MA;8*.#!))$?P;/\ 6NWUO6]/\.Z1<:IJ=PL%K N69NY[ #N3V%>8_"E?^$3\
M8>)?!-TQ5Q-]LLP3P\1_NCZ;:Z/XC_#<?$--/CDUF:PBM"[&-(O,60MC!(W#
MD8/YF@#C/#N@:O\ %CQ'%XM\3H]OX?MGW:;IYX$@!X8CT]3WZ=*]M "@   #
M@ 5X['\#]5BC2./XB:PB(H555& 4#H /,KH_!GPXU#PIKAU&Y\7ZCJL9A:/[
M/< [<DCYN7/(QZ=Z .XN+^SM)8(KF[@ADG;;"DD@4R'T4'J?I6?XH\0P^%?#
M]SK-S;3SV]O@R+  6 ) S@GU(KF/'?POM_'&N:9J<FJSVC66%,:(&#KNSP<C
M:??FNXGM(+JR>SN8EGMY$\N1)!N#J1@@^M %30-<LO$FAVFKZ?)OMKF,.N>J
MGNI]"#P:\D^+T\&H_$;P7I5@XDU6&[6214P3&A=2,_D3CTK1?X*WFEW5PWA7
MQCJ6CVD[[C:+DJOK@AAGVR,^]=%X*^%^F^$;^75IKRYU369@1)>W)YYZX&3U
M]22: .ZKR/Q5<3?$KQO'X-T^0_V#IS"76)XW($C9XB!'^<Y]*]1U2VN;S3+F
MVL[S['<2H42X$8<QD]PI(R:Q_!7@ZR\$Z$-.M9&GE=S+<7,@PTSGN>M 'GOB
MO2X?$OQ?T3P;>>9'H%IIQG%I$Q19",@9QV&%'X>].\-V*>"OCE+X:T=YET>^
MT[[2UL\A98G&>1GIT_\ 'JZ[QG\/QXEU6PUO3M5FTG6[$%8KN) V5/9@>O4_
MF:9X/^'K:!K=WX@U?5YM8URZ3RVN)$"+&O'"J.G3V^E &I\0;Q+'X>>()Y"H
M7[#*G)[LI4?J:Y_X(6CVGPKTPR*RF=Y90",<%R!_+/XU1^-E_/<Z'I_A/3OG
MU#6[I(Q&!D^6IR2<=!G;S[&O0]$TJ'0]#L=*MRQAM($A4L<DA1C)H OT444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7F_P :
M?^10L_\ L(0_SKTBO-_C3_R*%G_V$(?YUK1_B(3V/1+?_CVB_P!P?RJ2H[?_
M (]HO]P?RJ2LAA7F7@S_ )+%XV_W8?ZUZ;7CVB>(M'T#XN^,9=5U"&T27RD1
MI&QN(ZC]:VI)M22[?JA,]AHKE/\ A9?@W_H8;+_ONC_A9?@W_H8;+_ONH]G/
MLPN=717*?\++\&_]##9?]]T?\++\&_\ 0PV7_?='LY]F%SJZ*Y3_ (67X-_Z
M&&R_[[H_X67X-_Z&&R_[[H]G/LPN=717*?\ "R_!O_0PV7_?='_"R_!O_0PV
M7_?='LY]F%SJZ*Y3_A9?@W_H8;+_ +[H_P"%E^#?^AALO^^Z/9S[,+G27ML+
MVPN+5F*B:)HRPZC((S^M<]X#\%P>!= ;2K>\ENE:9I2\BA3DXXP/I3/^%E^#
M?^AALO\ ONC_ (67X-_Z&&R_[[H]G/LPN=717*?\++\&_P#0PV7_ 'W1_P +
M+\&_]##9?]]T>SGV87.KHKE/^%E^#?\ H8;+_ONC_A9?@W_H8;+_ +[H]G/L
MPN=717*?\++\&_\ 0PV7_?='_"R_!O\ T,-E_P!]T>SGV87.KHKE/^%E^#?^
MAALO^^Z/^%E^#?\ H8;+_ONCV<^S"YU=%<I_PLOP;_T,-E_WW1_PLOP;_P!#
M#9?]]T>SGV87.KHKE/\ A9?@W_H8;+_ONC_A9?@W_H8;+_ONCV<^S"YU=%<I
M_P ++\&_]##9?]]T?\++\&_]##9?]]T>SGV87.KHKE/^%E^#?^AALO\ ONC_
M (67X-_Z&&R_[[H]G/LPN=717*?\++\&_P#0PV7_ 'W1_P ++\&_]##9?]]T
M>SGV87.KHKE/^%E^#?\ H8;+_ONC_A9?@W_H8;+_ +[H]G/LPN=717*?\++\
M&_\ 0PV7_?='_"R_!O\ T,-E_P!]T>SGV87.KHKE/^%E^#?^AALO^^Z/^%E^
M#?\ H8;+_ONCV<^S"YU=%<I_PLOP;_T,-E_WW1_PLOP;_P!##9?]]T>SGV87
M.KHKE/\ A9?@W_H8;+_ONC_A9?@W_H8;+_ONCV<^S"YU=%<I_P ++\&_]##9
M?]]T?\++\&_]##9?]]T>SGV87.KHKE/^%E^#?^AALO\ ONC_ (67X-_Z&&R_
M[[H]G/LPN=717*?\++\&_P#0PV7_ 'W1_P ++\&_]##9?]]T>SGV87.KHKE/
M^%E^#?\ H8;+_ONC_A9?@W_H8;+_ +[H]G/LPN=717*?\++\&_\ 0PV7_?='
M_"R_!O\ T,-E_P!]T>SGV87.KHKE/^%E^#?^AALO^^Z/^%E^#?\ H8;+_ONC
MV<^S"YU=%<I_PLOP;_T,-E_WW1_PLOP;_P!##9?]]T>SGV87.KHKE/\ A9?@
MW_H8;+_ONC_A9?@W_H8;+_ONCV<^S"YU=%<I_P ++\&_]##9?]]T?\++\&_]
M##9?]]T>SGV87.KHKE/^%E^#?^AALO\ ONC_ (67X-_Z&&R_[[H]G/LPN=71
M7*?\++\&_P#0PV7_ 'W1_P ++\&_]##9?]]T>SGV87.KHKE/^%E^#?\ H8;+
M_ONC_A9?@W_H8;+_ +[H]G/LPN=717*?\++\&_\ 0PV7_?='_"RO!O\ T,-E
M_P!]T>SGV87.>^"/_(I:C_V$YOY+7IE>,?"?QCX>T/PU>V^IZM;6LSW\LBI(
MV"5(7!_2N\_X67X-_P"AALO^^ZUK0DZCL@3T.KHKE/\ A9?@W_H8;+_ONC_A
M9?@W_H8;+_ONLO9S[,+G5T5RG_"R_!O_ $,-E_WW1_PLOP;_ -##9?\ ?='L
MY]F%SJZ*Y3_A9?@W_H8;+_ONC_A9?@W_ *&&R_[[H]G/LPN=717*?\++\&_]
M##9?]]T?\++\&_\ 0PV7_?='LY]F%SJZ*Y3_ (67X-_Z&&R_[[H_X67X-_Z&
M&R_[[H]G/LPN=717*?\ "R_!O_0PV7_?='_"R_!O_0PV7_?='LY]F%SJZ*Y3
M_A9?@W_H8;+_ +[H_P"%E^#?^AALO^^Z/9S[,+G5T5RG_"R_!O\ T,-E_P!]
MT?\ "R_!O_0PV7_?='LY]F%SJZ*Y3_A9?@W_ *&&R_[[H_X67X-_Z&&R_P"^
MZ/9S[,+G5T5RG_"R_!O_ $,-E_WW1_PLOP;_ -##9?\ ?='LY]F%SJZ*Y3_A
M9?@W_H8;+_ONC_A9?@W_ *&&R_[[H]G/LPN=717*?\++\&_]##9?]]T?\++\
M&_\ 0PV7_?='LY]F%SJZ*Y3_ (67X-_Z&&R_[[H_X67X-_Z&&R_[[H]G/LPN
M=76:N@:4FNOKB6,2ZF\?E/<J,,R^A]>@_*L;_A9?@W_H8;+_ +[H_P"%E^#?
M^AALO^^Z/9S[,+G5T5RG_"R_!O\ T,-E_P!]T?\ "R_!O_0PV7_?='LY]F%S
MJZ*Y3_A9?@W_ *&&R_[[H_X67X-_Z&&R_P"^Z/9S[,+G5T5RG_"R_!O_ $,-
ME_WW1_PLOP;_ -##9?\ ?='LY]F%SJZ*Y3_A9?@W_H8;+_ONC_A9?@W_ *&&
MR_[[H]G/LPN=717*?\++\&_]##9?]]T?\++\&_\ 0PV7_?='LY]F%SJZSM1T
M#2M7N[2ZU"QAN9K-]]NT@SY;>H'3/%8O_"R_!O\ T,-E_P!]T?\ "R_!O_0P
MV7_?='LY]F%SJZ*Y3_A9?@W_ *&&R_[[H_X67X-_Z&&R_P"^Z/9S[,+G5T5R
MG_"R_!O_ $,-E_WW1_PLOP;_ -##9?\ ?='LY]F%SJZ*Y3_A9?@W_H8;+_ON
MC_A9?@W_ *&&R_[[H]G/LPN=717*?\++\&_]##9?]]T?\++\&_\ 0PV7_?='
MLY]F%SJZ*Y3_ (67X-_Z&&R_[[H_X67X-_Z&&R_[[H]G/LPN=717*?\ "R_!
MO_0PV7_?='_"R_!O_0PV7_?='LY]F%SJZ*Y3_A9?@W_H8;+_ +[H_P"%E^#?
M^AALO^^Z/9S[,+G5T5RG_"R_!O\ T,-E_P!]T?\ "R_!O_0PV7_?='LY]F%S
MJZ*Y3_A9?@W_ *&&R_[[H_X67X-_Z&&R_P"^Z/9S[,+G5T5RG_"R_!O_ $,-
ME_WW1_PLOP;_ -##9?\ ?='LY]F%SJZ*Y3_A9?@W_H8;+_ONC_A9?@W_ *&&
MR_[[H]G/LPN=717*?\++\&_]##9?]]T?\++\&_\ 0PV7_?='LY]F%R?X@?\
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M  LOP;_T,-E_WW1_PLOP;_T,-E_WW1[.?9A<ZNBN4_X67X-_Z&&R_P"^Z/\
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M#/#=[?37MUHUI-<S',DCIDL:W:*:;6P'/?\ ""^%?^@#8_\ ?H4?\(+X5_Z
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M * -C_WZ%'_""^%?^@#8_P#?H5T-%'/+N%CGO^$%\*_] &Q_[]"C_A!?"O\
MT ;'_OT*Z&BCGEW"QSW_  @OA7_H V/_ 'Z%'_""^%?^@#8_]^A70T4<\NX6
M.>_X07PK_P! &Q_[]"C_ (07PK_T ;'_ +]"NAHHYY=PL<]_P@OA7_H V/\
MWZ%'_""^%?\ H V/_?H5T-%'/+N%CGO^$%\*_P#0!L?^_0H_X07PK_T ;'_O
MT*Z&BCGEW"QSW_""^%?^@#8_]^A1_P (+X5_Z -C_P!^A70T4<\NX6.>_P"$
M%\*_] &Q_P"_0H_X07PK_P! &Q_[]"NAHHYY=PL<]_P@OA7_ * -C_WZ%'_"
M"^%?^@#8_P#?H5T-%'/+N%CGO^$%\*_] &Q_[]"C_A!?"O\ T ;'_OT*Z&BC
MGEW"QSW_  @OA7_H V/_ 'Z%'_""^%?^@#8_]^A70T4<\NX6.>_X07PK_P!
M&Q_[]"C_ (07PK_T ;'_ +]"NAHHYY=PL<]_P@OA7_H V/\ WZ%'_""^%?\
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7BNBHHYY=PL( %    '  [4M%%2!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>img11953243_5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img11953243_5.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" /?!R$# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HH-)B@0M%)1WH&+113>M #J*;BEH 6BF_I
M29([B@!]%,SZ<TN.: '44S^(C'XT8]>: 'T4S\#03B@!]%1G&.:4'(IAK:X^
MBHVQCYC@]J!QUYI B2BF=&I0,9Q0 ZBFXXHQ2 =1113 **** "BBB@ HHHH
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ML0!-=2.E<7\,;>2+P;:LP*B1 RFNT XH 6BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M,#M31DGI]:>,=J %HHI.] "T444 %%%% !1110 4444 %%%% !1110 4444
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M3[]:DHQ0 @X%**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M]<":Z5RJ] 30!I?"B1660;QNYXKTF_!-A< #)*' KR#2_"?B70[P3VB/MZ$
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M9"T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#83'0=J,=J6BBX@[TM(*6@84444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **2DSD''6@!U%("<<XS1GG% "T4@SCG&:6@ HHHSB@ HI,\>] .
M: %HII;'/:@MC'J: '44@.?K2T %%%% !113=WS8H =132W/'0=: 2: '44F
M[YB*3=^O2@!35:Z\XQD09W59[44 <7?V'B2Z<I'/)$IZ%35:'X?27<R3:GJ$
MDX'6-^E=X"<T8YH K6-C:Z=;+!:Q+'&.RBK.T9R:7\!2T (!SFEHQ2$G/;%
M"T4@;- )SS0 M%%% !129Q0"<4 +129I&; S0 ZBD!R*6@ HHHH ***0].*
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M4Z)0LD[[C"BBBH **** "BLSQ#K"^'_#][JSPF9;6/S#&&VEO;/:N?\  7Q
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M_P 5>*[C3]3E@:W2U>51'$%.X.@'/T8U<:;E%R705SUZBBBH&%%%% !1110
M45B^+8]7E\*ZBF@OLU,Q?N"#@]1G![';G'OBL#X7VWBJVT&<>*))VD,Q, N9
M-\H7OD\G&>F3^F*M0]WFN!W-%%%0 4444 %%%% !17G?Q7\8ZMX0L=-ETEXE
M>XD=7,D>[@ 8Q^==+X*U:ZUSPAIVI7K*US/'N<JNT9R>U6Z;4%/H*YOT445
MPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH Y;XD?\DZUS_KV/\Q7S#;Z9=-HL^M0,1':W$<3E3AE+!BK
M_53^E?3WQ(_Y)UKG_7L?YBO+?A+HD7B/P;XLTF7 %R(E4D_=<!BI_!@#^%=V
M'GR4G+S)>YZ9IWC>UF^&B^*IW'[JU)F4X!,R_*5P.F7QCIPPZ5\TW%G?7FEW
M'B&Z=G6:]\EI&ZRRLI=S^'&?]ZICKFIV7AV[\,2,R6S70EDC;JKKD%?S"G_@
M->B?$/P^/#/PG\-Z:0?.6Y\R<G_GHR,S#Z G ]@*UA!4I675_@)ZFM9WEUI_
M[-*75E<S6UPF=DL,A1US>8.".1P2/QK2^".K:EJVD:J^I:A=WCI.@1KF9I"H
MV]!N)Q61'&\O[,)5%+$*6P/07F2?R!I/@1JEA;6&L6D]W#%.9$F"2-MR@&">
M?0_SK&:O3GZCZF1\3/$6N6'Q-GM+/6=1MK8>1B&&Z=$&57/R@XYK6_:"_P"9
M=_[>?_:5<;\2=1L]3^)]Q<6-Q'<0[X4\R,Y4E54'![\BNR_:"_YEW_MY_P#:
M5:15I4_3]!=S*\2:3K5Q\(=$U.VU#RM)MK)%NK7SG7S6:8!3L VM@D'D]JI?
M"?0/$>IW\=_I6K?9-.M+V%KRW^TR1^<H()&U1AOE!'-=AJ8+?LUH "3]F@/'
M_7=:9\ 73^R-8CW+O\]&VYYQMZXI.;5*7J/J<[\7/$>N:;X\FMK#6=1M8!!&
M1%!=.B@D<G .*Z7XY:SJFD?V#_9NI7EEYOVCS/LT[1[\>7C.TC.,G\ZXCXU?
M\E%G_P"O:+^5=3^T%T\._P#;S_[2HC%7I_/\A=S+M+#XE>,_"\6HVNIS16,$
M(2&$W;)+=%1AFR!EB6!^^1[5H_!WQQJ]SKC>'=4N9;N)XV>%YW+21,O5<GDC
M';MCBO1OAO\ \DZT/_KV'\S7C/PT_P"2R_\ ;2Z_]!:INIQG%K8?8['QRWQ"
MU[Q.=)T:WNM/TG>(5N8V*+)W+NZ\A?8=O7-<CXDA\;?#*^L)F\2S7,5P6:-?
MM#NC%<;@T;<=QS_*K4_B3Q5\0?'LVAV.LR:5:^9(L:12% J)G.=O+D@=,X^@
M%8_Q)\&KX2.G_:->FU2_N=Y?S5VE$&,'!9CR2>_8^]:4U9J$K>EA,[OX@-K/
MBWX<:7XAT^\^Q6:VCRZA:^<Z"7=L   R& (;&['6N"^&6@>)-:O;J70=7^P1
M6LD#7:_:9(O-4EL#" [N%;KZ^]>E*"W[.^ "3_9V>/\ >K#_ &?702>(8RRA
MV%NP7/) \S)Q^(_,5$9.-*5NC'U'_&W7-7TG6=+CT[5;ZS1[=BZVUP\88[NI
M"D9K;\1>/;KPK\,/#UQ$_G:OJ-C"(Y9R7P?+4O(V?O'D=>[9.>AY7X^_\AW2
M/^O9O_0JSOB;:S?\(?X$N^L!TJ.+I]UO+C/ZC^1HA",HP3!D^C^%/B+XKT;_
M (2&+Q#<(92SP1RWLB/)@G[H'"C.<=!]!@UT7PI^(>I7^JMX9UZ1Y[GYS;W$
MA^?<O+(WKP"0?8CGC'<^ =4L+GX>:1<0S1+#;6:13DL (V10'W>G0GGL<UXI
MX+8Z_P#&P7]H&\F2^N+S<,C;&=S#/UR!^-*_M%-26P;%WXB>*]=TCXJ7L=IJ
MFH+;02V[+:1W3K&W[N-BNT'&"<YX[T>*](^)=CI*^)-5U>X"9#/#;73*UMD\
M$JN%'.!\I/;-4?B+_P EJN?^OBU_]%QU[9\2/^2=:Y_U['^8JG+D4++<.YB?
M"SQE?^)/"EV;]3<WVGG874C=.""5R/7@C/?\ZX]M'^)OC?7)OMUS=:):KF1$
M+O'&H/ 50OWC]??UP:_PFUA] \%^+M5CB662V6)T1NA;#@9]LU!X4L?%WQ0E
MOKBZ\6W-I;P$*ZHS8);)&(U*KCKS_.ER\DI25D@(],\4>*O 7CY-#U?5)=1M
MUECBFC>9I5V.!AD+<J0"#CBKOQ]_Y#ND?]>S?^A5QNN:-;^'_B(FF6]^U]Y%
MS"))VQEI"5+ ^X)QU/-=E\??^0[I'_7LW_H5:)+VD&NJ%T/7_!O_ "(WA_\
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M*#Z-'(1_.G&;DIW6R#L?2U%%%>>4%%%% !1110 4444 %%%% !1110 4444
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ML7D! ?F8;N>GI70>%+.:V^ 6NRRA@MPTDD>[^[\J\>V5-+^S]_KO$'^[;_\
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MH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MGU;^V_LFZ-(_*^R>9C:.N=X_E6K\0?A]_P )W_9W_$T^P_8_-_Y=_-W[]O\
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MT\1_"7^W_&LOB+^V_(WR1/\ 9_LF[&Q57&[>.NWT[UVWB31O^$@\.WVD^?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MT"QPWP3@NO\ A#IKZ[GFE:ZN6,9D8M\JX7C/N&KTJJFEZ9::-IEOIUC'Y=M
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH ***Y?QUXSMO!6AB\DB\^ZF;R[>'.-S8Y)/H._U [TXQ<G9 =17
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M6?%".]B^#MG'J3%K]/LRW+%@29 OS'(Z\YIWP(MX$\%WEPBCSI;UED;OA47
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MPQ\4>$_$9U;P6[2P@DQ!77S(@V05(?AQTYY^G&:@B\ >.O'>O17?BMWM;9
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M\ S>&?AQJ^D1LESJE];3;S&<*SM&5506QQ[G'7M6'\(O!7B'POK.H7&L:?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH P_&&
MA3^)?#%WI%O>?9'N-H,NW=P&!(ZCKBG>$_#T?A;PU9Z1&XD,*G?(%QO8G)/Y
MFMJBJYGR\O0 HHHJ0"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M>_\ !C+_ (T?\)1XH_Z&O7O_  8R_P"-'U.8<R/L2BOCO_A*/%'_ $->O?\
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M7KW_ (,9?\:/^$H\4?\ 0UZ]_P"#&7_&CZG,.9'V)17QW_PE'BC_ *&O7O\
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MX,9?\:/^$H\4?]#7KW_@QE_QH^IS#F1]B45\=_\ "4>*/^AKU[_P8R_XT?\
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M+W7_ *-:OL2OCOQ1_P CQXF_["]U_P"C6KKP?QDRV,NBBBO2)"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MO/H/P!DM=9)%PECY95EY5G?"+CU&Y1^%9<WACPE\._!-KJ^J:&^L74YC61I
M& 9@6Z$[548(S@DD@=^,U4DX\M^MO4=C+UWX:>&]8\'2^(_!EU/MAC:3RI"Q
M654SO ##<'XX[' XYS77?!J+0HO"C?V3<22W;;&O]X8;)<?=&0!@<],_6M/P
M_J2:O\-+J]AT2/1K>2WG,-K%C;LVGYAA5ZG)Z>]<G\ ?^0/K/_7Q'_Z":SE*
M4J<DWLPZG-KH/A#5OBMI6G:+?7DT$QF:[<,T;I,BNP*DJ,<J.G'%4/&?@?'Q
M/M?#^DRW$KWJ1N9+J3S&7.=S$]2 JD^O!I_@*TN;/XUV275O+ S37+JLJ%25
M,<N",]N*]#N+BW@_:#MUG=5:;2_+BR.KY)Q[<!OY=ZVE.4):.^@C%O/!?PN\
M+SV^E:[J,SZA( 2SR..O0ML&U!]>W/O7)^,OAFOAGQ%I,4%Q-<:/J5PD*RD#
M?&20"I8#;D@Y![X/''/<>/?$-AHWBYK6]^'=MJLMRJM!>.5+7.% .!Y;'*_=
MQG. #T(JKXTUO7M03P[;:KX4_L>!=7MWCE-]'-DC(V!5 (X.?;&*F$JB:=]_
M-?@/0EUWX4^"M$GLKV_U&6QTQ2PF$LV6F?Y=B@XR!@/G'./3K67XY^&.A0^$
M#XA\+2EHH4\UU$IE6:,D LI)X(Z_0'O5K]H)V$?AY QVDW!*YX)'EX/ZG\ZU
M?#7_ ";I-_UX7O\ Z'+2C*:A&?-U#R-;X41:"G@8#1YY)"VUK\L&^2X,2;P,
M@<#VR/>O)5\(Z!XG^(%MI'A&_FDTQX1+<3R@YBQG=@,%)_AQUY;TZ>@? L$^
M"-5 &2;U\ ?]<TKRWP7:^)]-\96\FCZ;(VI6Z&4VT^(M\9^5@0Q&0<_U[54$
MU.=GJ'8]%F\'?"O2-63P]J%]<_VGPI:65Q\S<KEE 0'!'7VS7FWC[PI!X1\0
M+9VE\MW:RQ"6)]REU&2,-COD=>_YUZY-XKTC6?$5MX=\8>"7BU>;;&N8TN H
M;D%7'S;?4KG&#Z&N ^+W@_3/"VL6,NE)Y,%[&[-;Y)",I&2"3T.X<=L'\'1E
M)32DWK\Q,J_"SPWH?BO6KS3=82X,@@$T#12;1P<,#[_,,?0U?\._#BUO/BCJ
M?AV^,\EA8J\F]&PQ4X\O<<=<,"<#J#VKF_AWJTFC>/=(N%)V23K;R#=M!23Y
M#GU R&QZ@5]$:K:V_AN?Q)XK&%DEL4R>N7C#@<=R<H.?3M3K3E";2>ZT]02/
M&_&_PXM=&\<:)I6F&<66JLD8+MO9&WA7[= "I[]ZV=?^'WAC3/'OAK0K)KU'
MO&>6X(N!N5 /DQQQDJW/M^7?>'+>W\7Z+X0\1S3>;=:?&VY\8W.4,<@(Z??4
M'\..#SP-WJQU7]HRT </%:2_98\=ML;;A_WV7J(U)RTOLG<=AFO>&O"^A?%C
M3[;5KV^%G)9I<>9-*\KR3^8RJ"0"<84?EUKN/BK;^&9]#@/B.[FMRHE^QB(,
M=TNWC.%/MUP.:X/XQ_\ )4-$_P"O6#_T=)70_'>TN;G0]+>"WEE6*:1Y&C0L
M$7:.3CH*FSE*FVP[E[P1IW]K? J#3S.D"W$-Q&TS](P9GRQZ=!DUG:9\-/AY
MXCTN:#1-2EGN8557N4G+.A[$H0!@X/;UQ4F@$C]G&;!Q_H=W_P"C9*YWX!,?
M[?U=<G!M5)'_  *BTDIR3M9@>6:E82Z7JEWI\Y0S6LSP2%#E2RL5./;(KNOA
MG\.8O&/VC4-1N'ATVV?RRL9PTCX!(R1@  C/?FL+XB_\E#US_KZ:O7/A=G4O
MA!?Z?ISHM\!<PC=P!(RDJ3[?,O/M[5T5JDE237426IG0^ /AMXF-UI?A[59!
MJ5NF[S(Y6<'C&<,,.N2,[3Z<C-9OPAT>[T#XI:MI=\JK<VUA(K[3D']Y$00?
M0@@_C7)>$?!/B_4]5GCTL7.E30H1)<3F2W SCY<@9R>N,=J[/X6:=>Z3\6]9
ML=2NUN[V&P<33K(SAFWQ'[S $]<<^E9STC*/-?0#A_BA_P E(UK_ *ZK_P"@
M+7LXU"#X7_#C0XIPBRM-#',""<%VWS' Y.%WX_#Z5Q/]@KK_ .T)>0RH'M[>
M874P/]U$7'_CQ4?C7:>/M3^'U[J$>E^*M1D6XL_F$$8FPI< Y.Q2"<8Z],^]
M34ES<D+7TNQHY?X]:(FW2]?B5/F)M9F!.6X+)[=GY^GX:?P#_P"19U3_ *_/
M_9%KH-5CTGQQ\+KZTT&[>]ABAV0-EMYDB 958N,Y. "3U#9[YKG_ (!_\BSJ
MG_7Y_P"R+4.5Z#B^C#J<%\-?AU'XUDN[F^N9;?3[8A,PE=\CGG R#@ 8Y([C
MWKK;7PC\*_$KW&GZ-J4L%[&"0_FN.AQD>8-K#Z5S_P *+OQ=IGVVZT+1EU73
MY7"3Q-<)%AU&006.0<-Z$'\*[K0[SP7\2-0O;.X\)M;W\*EKAY+<(0?ND&1,
M'=G/#8Z5I5E-2;OHNWZH$>!ZMI[:3K%YI[RQRM;3-$9(SE6VG&15.MWQGHL/
MAWQ?J6E6\AD@@E_=D]0I 8 ^I .,^U85=D7=)DA1113 **** "BBB@ HHHH
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M:74MS$B6Z2AK>3RWW"&,#YNHZ]JZNX_Y+S:_]@4_^C#618?\G':K_P!>:_\
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M:@RW@UE+'[0RF0$"0+N*X Y[BMKP5!%XY^$-OI5XP?R9%MY-K8(6-U8#V^3
M_&MR/Q+%-\4+KPR9]T TY<Q;<#S,DD9ZY*./R]:YG5J+W4]5?[AV1Y=X)\ :
M)?> K[Q-KWVEUB\UXXX)-OR(/IU+ CKCI[U9T?P5IE[\&+C6FN+])S'-,8TN
M"(BR.P!*=#PH%=1\08X_!?PACT2U=@9G6WW(<$Y)=R?K@@_[U1>&O^3=Y_\
MKUNO_1CU3J2:YK[L+&Q\)HM!3P0/[(GDD=@IO]P;Y)_+7>!D#CZ9'O7(>!H/
M#4'Q<4>%KN:YL6L'+F4,"LFX9 W*#C&#^-:OP*!/@[5@!DF[;C_MFM<A\(+2
MYLOB48KJWE@D^RRG9*A4XR.<&ERV=34.QV_B7PGX-N/'5W?>*=61;B_\M;:S
M\W9@!53<Q'/)!QR!]>W"?%+X=VGA'[-J.ERM]@N&\LPR-N:-\9X/<$?E6?\
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MW\\0B:,H_E !57@;LYPH[UR%%/V4.P7.H;QYJC>.QXO-O9_V@/\ EGL;RO\
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M>3S&-RCL0<8XVL/2N0HI*E!+EMH%S4T#7KKPYK]OK-G'"]Q 6*K,"4.Y2IR
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 ?37P6_Y)-HOUG_\ 1\E=]7 _!;_DDVB_6?\
M]'R5WU>)+XF:!1114@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% 'AO[1'_'QX6^MW_**O&:]F_:(_P"/CPM];O\ E%7C->IA/X9$
MMPHHHKI$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^-4?\,[>$?\ H(ZW_P!_XO\ XU1]<CV#E/ Z*]\_X9V\(_\ 01UO_O\ Q?\
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M?_&J/^&=O"/_ $$=;_[_ ,7_ ,:H^N1[!RG@=%>^?\,[>$?^@CK?_?\ B_\
MC5'_  SMX1_Z".M_]_XO_C5'UR/8.4WO@M_R2;1?K/\ ^CY*[ZN!^"W'PFT4
M>\__ */DKOJX)?$RPHHHJ0"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MUO\ [_Q?_&J/KD>P<IX'17OG_#.WA'_H(ZW_ -_XO_C5'_#.WA'_ *".M_\
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M^-4?\,[>$?\ H(ZW_P!_XO\ XU1]<CV#E/ Z*]\_X9V\(_\ 01UO_O\ Q?\
MQJC_ (9V\(_]!'6_^_\ %_\ &J/KD>P<IX'17OG_  SMX1_Z".M_]_XO_C5'
M_#.WA'_H(ZW_ -_XO_C5'UR/8.4\#KT;X%_\E*G_ .P7)_Z,CKMO^&=O"/\
MT$=;_P"_\7_QJHO"/@G3? OQF73M,GNYH9M">=FN75F#&95XVJO&%%15Q"J0
M<4AI6/8:***X2@HHHH **** "BBB@ HHHH *X+X7_P#,Y_\ 8TWW_LE=[7!?
M"_\ YG/_ +&F^_\ 9*I;,#O:***D HHHH **** "BBB@ HHHH **** "BBB@
M HKC?&_CN7PAJ&C6%MHL^JW6JM*L,4,H0@ILXY!SG?\ I6)=?%/6M*C%UK'P
M^UBST]#F>Y619!$N0"Q 'OZB@#TVBJ6DZK9:YI-MJFG3":TN4$D3@8R/H>A[
M8J[0 445E:#XDTOQ+;W4^E3M-':W+VDK&-DQ(H!(Y S]X<T :M%<SIVO:[=>
M.M2T>Z\/26VD6T D@U)GRL[$J-HXQW;C.1MYZBNFH **** "BBLK7O$>E^&K
M>UGU6=H8[JY2TB81L^9&!(' ./NGF@#5HHHH **** "BBB@ HK$\6ZMJFB>&
M[F_T?2'U6]BQLM4."PSR<#DX'8<FIX]7-MX676M7@:R,=D+J[AY<P83<Z\==
MO(]\4 :E%4M)U6SUS2;;4]/E,MI<H)(G*E20?8\BLCP-XNB\;^&8]:BM'M%>
M1X_*=PY&TXSG H Z2BBB@ HHHH **YN?Q=%!\0[;PB;1S)/8&]%R'& -S+MV
MX_V>N:;IVO:[=>.M2T>Z\/26VD6\ D@U)GRL[$J-HXQW;C.1MYZB@#IJ***
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M */DKO:J7Q, HHHJ0"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@#@O%O_ "5?X>_[VH_^B!7>UP7BW_DJ_P /?][4?_1 KO:I[( H
MHHJ0"BBB@ HHHH **** "BBB@ HHHH ***@O;C['87%SLW^3$TFW.,X&<9H
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M5O;:.X$9;)0.H;&>^,T :%%%% !1110 45!>S36]A<3V]NUS-'$SQP*P4RL
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MYOPKK;?$[XC:!J>"]IX?TH37!Q@"]E&UE^G&1C^Y^%;GQ%_Y*C\-O^OJZ_\
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M@%%%%2 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M<%XM_P"2K_#W_>U'_P!$"N]K@O%O_)5_A[_O:C_Z(%=[5/9 %%%%2 4444 %
M%%% !1110 4444 %%%% !5'6O^0%J'_7M)_Z":O51UK_ ) 6H?\ 7M)_Z":
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M3%$IY56Z$GGGKCWQ3]5U+Q%?_!GQ''XHT_[+J=M \32JN$N5&,2*.V>X]1G
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MO7$W7P5\ W=VUPVA^66.62*XD1#_ ,!#8'T&*[^B@#/.AZ9_84FB)911:9)
M]NUM"/+7RV!# ;<8SD\CGFI-*TNST72[?3=/A\FTMDV11[BVU?3)))_$U<J.
M*>&??Y4J2;&*/L8':PZ@^A]J ,_3O#NE:3JNI:G96OE7FILCW<GF,WF%<[>"
M2!C<>@'6LCQ-\-O"GBZ]6]U?2EDNP-IGCD:-F'8-M(W?CTKJZ* ,;P[X4T/P
ME9O::'IT=G%(VY]I9F<^[,2QQVR>*K>*/ OASQB(O[;TU+B2'B.579'4>FY2
M"1['BNBHH YGPQ\/_#'@^22;1=+C@N)!M:=V:23'H&8D@>PQG S73444 96O
M^&]'\4:?]@UJPBO+;=N"OD%6]0P((//4&L3P]\+_  ?X7U!=0TO2%6\3.R:6
M5Y&3(Q\NXD#OR.>:["B@#,UWP]I?B6Q2RU>U^TVZ2K,J>8R8=<X.5(/<UIT4
M4 5[PW2P[K-8GE4Y,<A*AQZ9&<'WP>GXUP?B#X9Z=XDOY+_5-%TVXO" 7GBE
ME@:?IP=IPI&,;CNS@=.:]$HJ7&_4UA4Y5;E3_K^OZM;E-!\.3^%=/^PZ-IVE
MV]NC>8RQEU-P2,8).2" /O$MG Z533P2D&AZCHJ:=8G3[Z8W-W$EQ/']J=MN
M1NW%H\;1T)#8Z#)KMZ*.7S*]O_=7W?U_7HK8&GV&JZ/IUMI]E!IXM;*)8XHU
M9QO4# 3)R5P/XCNW<=,FJVNZ%=^(])ETO6+/3KZS)5WCWR1><0<@ @YC*GOD
M[NG&37444<OF'M_[J^[^OZ]%;D]0\-W.I_V:;^TLKQM)F2YM6:>96:1<8YR2
M"N.K;]W?&32>(/#$GB>S6UUS3-*U&*$EUW%XV<GJ%8',>/4$[L#IVZVBCE\P
M]O\ W5]W]?UZ*WGF@_#/3O"^I+J.EZ)I@NX1E)6EE8MD8PN\L(R.?FY)]LFN
M_A$HA03LC2X^<H,+GV]JDHII6(G4YELEZ?U_7W!1113,PHHHH **** "BBB@
M HHHH **** "BBB@#@O@O_R2?1OK<?\ H^2N]K@O@O\ \DGT;ZW'_H^2N]JI
M?$P"BBBI **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* ."\6_\E7^'O^]J/_H@5WM<%XM_Y*O\/?\ >U'_ -$"N]JGL@"BBBI ****
M "BBB@ HHHH **** "BBB@ IDT,=Q!)!*NZ.12CC.,@C!I]% &?HFAZ=X<TB
M'2M)M_L]E#N,<6]GV[F+'EB3U)/6M"BB@#EO%7P[\,>,IH[C6=.\VYB78L\<
MC1OM]"5/(],YQ^)J/3?AGX0TA]/DLM'2*73Y6FMY/.DW!V #,QW?-]T<'(';
M%=;10!EZ]X<T?Q1IWV#6K"*\MMVX*^05/J&!!!]P:SSX"\./X2B\+S6+RZ/$
MVY('GDR#N+?>#!NI/>NDHH AN;2WO+.6TN84FMY4,<D4B[E92,$$'K7#)\%?
M *7RW0T/E7#B)KB4QY]U+8(]NGX5W]% &9JOA_2M:T&30[ZS1],D54:W1C&N
MU2"H&T@@ J.GI5^W@CM;:*WA7;%$H1%R3@ 8 YJ2B@#+T3P[I7AR&ZBTJU^S
MI=7#7,P\QGW2, "WS$XZ#@<5G2^ /#,OBJ+Q-_9BQZM&Q?SXI&3<Q!&64'!/
M)YQSWS72T4 <UXF\ >&/%[K+K6EQSSH JSJS1R #/&Y2"1R>#3_#/@7PUX/\
MUM#TN.VEE $DI=I'8>FYB2![# KHJ* "LW7= TOQ-I4FF:Q:BYLY"&:,NR<@
MY!RI!'YUI44 5;;3K2TTN+3((%2RBA$"19) C VA>>>G%5/#_AO2/"VF_P!G
MZ+9BUM2YD*!V?+'J<L2?UK5J.6>&#9YTJ1[V"+O8#<QZ 9ZGVH S[;P[I5IX
M@O==@M=FI7J(EQ-YC'>J@!1M)VC  Z 51\4>!O#GC%8O[;TU+B2'B.569'4>
MFY2"1['BNBI&8*I9B H&23VH R;SPQH]_=Z5=W5H9)]))-DYE<&(D 'H?FX4
M?>STJ]J.GVNJZ=<:?>Q>;:W,9BECW%=RD8(R""/PJ:*6.>)9(9$DC;D,C9!_
M$4^@"KIFFVFCZ9;:=81>3:6T8CBCW%MJCH,DDG\:M444 <)?_!SP)J6I27UQ
MH:B20[G2*>2-"?7:K #\,5T[^'-'?PZWA_[!&FE-%Y1MHLHNWTRI!_'.:U**
M ,.^\(:%J?AF#P[=V/F:3 B)';^<XVJ@PHW!MW&/6K&K>'-*UR2PDU&U\]M/
MG6YM3YC+Y<BX(;Y2,]!P<BM2B@""^LK?4;"YL;N/S+:YB:&5,D;D8$$9'(X)
MZ5E2^$-"F\*?\(Q)8YT;8J?9O.?[JL& W;MW4 ]:W** ($L[:.Q6R$*FU$?E
M>4XW IC&#GJ,>M<1_P *6\ &^:Z.@@L6W^7]HE\L'.?N[L8]NGM7?44 5I-/
MLY=.;3GM86LFC\DVY0;-F,;=O3&.U<9I_P &O NFZI'J$&C$RQ,'C26>1T5@
M<@[2>?QS7>44 8%IX+\/6'AJ?P[;:?Y>E7&[S+?SI#NW<GYBVX?@:UM/L+;2
M].MM/LH_*M;:)888]Q;:BC &3DG@=ZLT4 %<'J/P;\":GJ,E[/H@661MSK#/
M)&C'_=5@!^&*[RB@"EI6DZ?H>G1:?IEI%:6D0PD42X ]_<GN3R:I:MX3T/7=
M4T_4]2L%GO-/??:R&1U\ML@@X! /(!YS6U10 R:&.X@DAE7='(I1AG&01@U2
MT30].\.:3#I>DV_V>RA+%(M[/C<Q8\L2>I/>M"B@#A]0^#_@74M0-[/H4:S,
M^]Q#*\:,<YY52!^0K>TOPEH6B:I/J6FZ=':W4\202-&S!2B *H"YVC  Z 5M
M44 <[XH\#>'/&*1#6]-2X>+B.569'4>FY2"1['BH_#/P^\+^$)9)M&TJ.&XD
M&UIW=I),>@9B<#V&,X&:Z:B@#+7P[I2>)'\0K:XU5[?[,T_F-S'D';MSMZ@<
MXS2ZYX>TOQ';06VK6OVB*"=;F-?,9-LBYPV5(SU/!XJ_+/# $,TJ1[V"+O8#
M<QZ 9ZGVJ2@"O?6%IJ5A+8WMO'<6LR[)(I%W*P]Q7%V/P:\!Z??)>1:$KR(^
M]%FGDD13_NLQ!_'-=Y10!#<VMO>6DMK<PQS6\J%)(G7*LIX((]*X9?@KX!2^
M6Z&A\JX<1FXE,>?=2V"/;I^%=_10 R&&*V@C@@C2**-0J(B@*H'0 #H*?110
M!PM_\'/ FI:E)?7&AJ))#N=8IY(T8^NU6 'X8KL-.TZSTFPAL=/MH[:UA7;'
M%&N%45:HH S--\/:5I&H:A?V-KY5SJ,@ENG\QF\QN><$D#J>F*TZ** .<U_1
M;CQ!93Z?J.GZ=?:>6R(IBRF3TPPYC9?[PSGVKFM'^%>D^']334;#0=,:Z@.Z
M-Y)IFW'_ &0S,(ROKAB?:O2**GE\S=5O[J^[^OZ]%;EM2T"[U34-/O[ZST^Z
MNM+=I+63S)(\LV,\ X7&!UW9QVJ./PU<0>)I?$8LK&75C#Y+3F:4>:G'RJI)
M6/&!R <\],FNMHHY?,/;_P!U?=_7]>BMDYU]/X;"39[LGFY[=]F/^!9]JRK/
MP[=:;KM]K5K9V(O[L*+J1)946ZP,#*9*H5]<$GGIDUU=%'+YA[?^ZON_K^O1
M6Y71/#USX9TTZ=I5EI\=HK,YBWR8F+=?O%BF/^!9]JYFZ^#N@7-W)<2^'=,=
MC@LL4\\"R_15;$>/;.?:O4**.7S#V_\ =7W?U_7HK8^A:=<:1;1:>EO8V]A;
MIMC6U0J#GG[O\..<\G.<\5L444TK&4Y<SO:P4444R0HHHH **** "BBB@ HH
MHH **** "N"F_P"2]VW_ &+C?^E%=[7!3?\ )>[;_L7&_P#2BJCU [VBBBI
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MM54QG<<].*X@_&KP0+M(?[0G\EY!&MT;600D_P"\1TZ\X[>E<Y\6KV:/X?\
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MVWCG^RZ*MQ$)%!"N&10<'T#&O6J "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** ."^"_P#R2?1OK<?^CY*[VN"^"_\
MR2?1OK<?^CY*[VJE\3 ****D HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH X+Q;_R5?X>_P"]J/\ Z(%=[7!>+?\ DJ_P]_WM1_\
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MKBWEBU")M25;8L&@.TD E3GANB\UZ)X?\1:?XFTW^T-,>5[?>4S)$T9R.O#
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M^IZ&75&NHL1NQ.%D4AD)QSC<HS7#>'[OXJPZ9;>'9M L;9[:-;;^VIKI9%"
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MT$#W6L3W,2%T</$RH ?E)ZX/!YK2\&>"(/"*WUS)?W&IZKJ#B2\OK@ -(PZ
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M,%^4G)R2.@-=+XILKC4?".M6-I'YES<V$\,29 W.T; #)X')'6M:B@#RR_\
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MHH *X*;_ )+W;?\ 8N-_Z45WM<%-_P E[MO^Q<;_ -**J/4#O:***D HHHH
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MQGO7=4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ME&H6=S;K&VPG&Y""2.3^'&<C. #UZBN)\<>-9M&\/::^@QQW>J:U+'!IRO\
M=)?!WGIP 1^8[9K#N_"_Q'TS36UB'QR;_4[>,S/8R6:K;RD*24&,?0' _#L
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M_,Y_]C3??^R52V8'>T445(!1110 4444 %%%% !1110 4444 %%%% !1110
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M:+816=L6W%4R2S>K,223QU)K5H \B^#W_)$+K_M[_D:W?@E_R2'0_P#MX_\
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M0"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M2!S*N<,S!LMC)X)QSTH /&TG@^]CTSP]XL6-AJ4I%JL@91O4=1(,;3R!UYW
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MM%<%_P 7;_ZDG_R;H_XNW_U)/_DW1R^8'>T5P7_%V_\ J2?_ ";H_P"+M_\
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M_P"I)_\ )NC_ (NW_P!23_Y-T<OF!WM%<%_Q=O\ ZDG_ ,FZ/^+M_P#4D_\
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M'+Y@=[17!?\ %V_^I)_\FZ/^+M_]23_Y-T<OF!WM%<%_Q=O_ *DG_P FZ/\
MB[?_ %)/_DW1R^8'>T5P7_%V_P#J2?\ R;H_XNW_ -23_P"3='+Y@=[17!?\
M7;_ZDG_R;H_XNW_U)/\ Y-T<OF!WM%<%_P 7;_ZDG_R;H_XNW_U)/_DW1R^8
M'>T5P7_%V_\ J2?_ ";H_P"+M_\ 4D_^3='+Y@=[17!?\7;_ .I)_P#)NC_B
M[?\ U)/_ )-T<OF!WM%<%_Q=O_J2?_)NC_B[?_4D_P#DW1R^8'>T5P7_ !=O
M_J2?_)NC_B[?_4D_^3='+Y@=[17!?\7;_P"I)_\ )NJ&CZO\4];TY;ZU7P:L
M1DDCQ*+H-E'*'H3QE3BCETN!Z917!?\ %V_^I)_\FZ/^+M_]23_Y-T<OF!WM
M%<%_Q=O_ *DG_P FZ/\ B[?_ %)/_DW1R^8'>T5P7_%V_P#J2?\ R;H_XNW_
M -23_P"3='+Y@=[17!?\7;_ZDG_R;H_XNW_U)/\ Y-T<OF!WM%<%_P 7;_ZD
MG_R;H_XNW_U)/_DW1R^8'>T5P7_%V_\ J2?_ ";H_P"+M_\ 4D_^3='+Y@=[
M17!?\7;_ .I)_P#)NC_B[?\ U)/_ )-T<OF!WM%<%_Q=O_J2?_)NC_B[?_4D
M_P#DW1R^8'>T5P7_ !=O_J2?_)NC_B[?_4D_^3='+Y@=[17!?\7;_P"I)_\
M)NC_ (NW_P!23_Y-T<OF!WM%<%_Q=O\ ZDG_ ,FZ/^+M_P#4D_\ DW1R^8'>
MT5P7_%V_^I)_\FZ/^+M_]23_ .3='+Y@=[17!?\ %V_^I)_\FZ/^+M_]23_Y
M-T<OF!WM%<%_Q=O_ *DG_P FZ/\ B[?_ %)/_DW1R^8'>T5P7_%V_P#J2?\
MR;H_XNW_ -23_P"3='+Y@=[17!?\7;_ZDG_R;H_XNW_U)/\ Y-T<OF!WM%<%
M_P 7;_ZDG_R;H_XNW_U)/_DW1R^8'>T5P7_%V_\ J2?_ ";H_P"+M_\ 4D_^
M3='+Y@=[17!?\7;_ .I)_P#)NC_B[?\ U)/_ )-T<OF!WM%<%_Q=O_J2?_)N
MC_B[?_4D_P#DW1R^8'>T5P7_ !=O_J2?_)NC_B[?_4D_^3='+Y@=[17!?\7;
M_P"I)_\ )NC_ (NW_P!23_Y-T<OF!WM%<%_Q=O\ ZDG_ ,FZ/^+M_P#4D_\
MDW1R^8'>UP4W_)>[;_L7&_\ 2BC_ (NW_P!23_Y-TF@>'?%[>/QXE\32:'A-
M-:Q1--:7O('!(<?7OZ<4TK =]1114 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M7+>,O^/OPM_V&XO_ $5+74URWC+_ (^_"W_8;B_]%2U</B!G4T445 !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %<M\/?^11C_ .ONZ_\ 1\E=37+?#W_D48_^ONZ_]'R5:^!_+]0.
MIHHHJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KEO&7_'WX6_[#<7_
M **EKJ:Y;QE_Q]^%O^PW%_Z*EJX?$#.IHHHJ "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y;X>_\
M(HQ_]?=U_P"CY*ZFN6^'O_(HQ_\ 7W=?^CY*M? _E^H'4T445 !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MX<>!M&^&VI:_X>TY$N81$UO=0WLL@!,J*2,N0>": /<:*9#_ *B/_='\J?0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M KS?4?\ DU0?]>D'_H]* /:X?]1'_NC^5/ID/^HC_P!T?RI] !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]L"TEC'I+P6\^,+,JLVYEXZ;RZY[[:]3U3PIX>UR83:IHFGWDP_Y:3VZL_\
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MM4+DYSDG'/XU?@TO3[:^FOH+&UBNYU599XX5620*,*&8#)   &>F* +=%%%
M!1110!Y^?^3A1_V*O_MU7H%>?G_DX4?]BK_[=5Z!0 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MINBR:D(M)N@JY2WMKMGF<]@$#Y'U. .]2>/'72_A3H,6CVM[H/A^ZNXOM\:
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MY.W'_P <H_X4E\//^A>_\G;C_P".5Z!10!Y__P *2^'G_0O?^3MQ_P#'*/\
MA27P\_Z%[_R=N/\ XY7H%% 'G_\ PI+X>?\ 0O?^3MQ_\<H_X4E\//\ H7O_
M "=N/_CE>@44 >?_ /"DOAY_T+W_ ).W'_QRC_A27P\_Z%[_ ,G;C_XY7H%%
M 'G_ /PI+X>?]"]_Y.W'_P <H_X4E\//^A>_\G;C_P".5Z!10!S'AOX>^%O"
M-]+>Z'I0M+F6/RGD\^20E,@X^=CCD#IZ5T]%% !1110 4444 %%%% !1110
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M?]"]_P"3MQ_\<H_X4E\//^A>_P#)VX_^.5Z!10!Y_P#\*2^'G_0O?^3MQ_\
M'*/^%)?#S_H7O_)VX_\ CE>@44 >?_\ "DOAY_T+W_D[<?\ QRC_ (4E\//^
MA>_\G;C_ ..5Z!10!Y__ ,*2^'G_ $+W_D[<?_'*/^%)?#S_ *%[_P G;C_X
MY7H%% 'G_P#PI+X>?]"]_P"3MQ_\<IR_!3X>(X8>'AD'(S>3D?D7YKOJ* $
M"@ < <"EHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH *Y;QE_Q]^%O^PW%_Z*EKJ:Y;QE_Q]^%O^PW%_P"BI:N'Q SJ
M:***@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "N6^'O\ R*,?_7W=?^CY*ZFN6^'O_(HQ_P#7W=?^
MCY*M? _E^H'4T445 !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %9VMZE+I6F&Z@MTN)3-#"D;
MR&-2TDBQC+!6P 6ST/2M&L3Q7_R!8O\ L(6/_I5%515V@#[5XH_Z ^C_ /@U
ME_\ D>C[5XH_Z ^C_P#@UE_^1ZVZ*+KL!B?:O%'_ $!]'_\ !K+_ /(]'VKQ
M1_T!]'_\&LO_ ,CUMT4778#$^U>*/^@/H_\ X-9?_D>C[5XH_P"@/H__ (-9
M?_D>MNBBZ[ 8GVKQ1_T!]'_\&LO_ ,CT?:O%'_0'T?\ \&LO_P CUMT4778#
M$^U>*/\ H#Z/_P"#67_Y'H^U>*/^@/H__@UE_P#D>MNBBZ[ 8GVKQ1_T!]'_
M /!K+_\ (]'VKQ1_T!]'_P#!K+_\CUMT4778#$^U>*/^@/H__@UE_P#D>C[5
MXH_Z ^C_ /@UE_\ D>MNBBZ[ 8GVKQ1_T!]'_P#!K+_\CT?:O%'_ $!]'_\
M!K+_ /(];=%%UV Q/M7BC_H#Z/\ ^#67_P"1Z/M7BC_H#Z/_ .#67_Y'K;HH
MNNP&)]J\4?\ 0'T?_P &LO\ \CT?:O%'_0'T?_P:R_\ R/6W11==@,3[5XH_
MZ ^C_P#@UE_^1Z/M7BC_ * ^C_\ @UE_^1ZVZ*+KL!B?:O%'_0'T?_P:R_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %8GBO_D"Q?]A"Q_\
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M(>6/Y]/;%?/MCJ\]AX]E\3IX0+*SM+'8_P!H(%CD8<MNVX(Y; P,9'I7>?\
M"ZM:_P"A&_\ *LG_ ,;KIQ-.M4LHP=O02Q%%?;7WH]BHKQW_ (75K7_0C?\
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MK7_0C?\ E63_ .-T?\+JUK_H1O\ RK)_\;H^J5_Y']P?6:/\Z^]'L5%>._\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *WOA?_P E:G_[ ;_^CTK!K>^%_P#R5J?_ + ;_P#H]*X<R_W=
MGH99_O"]&>Z4445\R?2!1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !7Q#:_P#'NOU/\S7V]7Q#:_\ 'NOU/\S7;@OB9,B:BBBO0)"BBB@
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M6F3RSV]JPC\R5U8E\#<.  ,'(Q[5[7\/%A\$_"*77+L8:8/>LK,.<_+&H/\
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M]G9G 45[%J$MOX1@M[+2_#DM\S+N=XXSCTRS!3D\5C^-=!L[OP\GB"ULC97
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MD_*#CG)IMAK^LZ5 T&G:O?V<+-O,=O<O&I; &<*1S@#GVJ'0E[/DN%]3O/\
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M*/\ =M?_ &I74?''_D5-'_[#5O\ ^@R5YC_WCYA/^&_0\[HHHKZH^/"BBB@
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M23733H.%:=2_Q6.>I74Z,*=OAN)11170<P4444 %%%% !1110 4444 %%%%
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MWM89)YY#M2.)"S,?0 <FHJ]3\-SIX)^%%UXHM0G]M:G<?9+69TW>4@)SC/\
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MV'+O_P!#J:H6_P"1G\5?]AR[_P#0ZFKWL)_ CZ'R^-_WB7J%%%%=!RA1110
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M,'H,XSC(]:WQ,6U&25[.YAAI).46[75A_P .9IX_%T,<1/ER1N)1G^$*2/U
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M'F2/SUP<8Y)_+IBN:K3#\_)[^_\ 6YGB.3G]S;^M@HHHK8P"BBB@ K>^%_\
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MW)SDC&&SCZG'&1DT--*4;7N!T&FQP1:]\4TMPHC%G/PIR =LF?USQ7F_P_\
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ME.I&I'FB9U*<J<N6044451 4444 %%%% !1110 4444 %%%% !1110 4444
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M46X%HDY_3M^-<%73@W^[^;U[^9S8Q?O/DM.WD%%%%=1R!1110 4444 %%%%
M!1110 4444 %%%% !1110 5O?"__ )*U/_V W_\ 1Z5@UO?"_P#Y*U/_ -@-
M_P#T>E<.9?[NST,L_P!X7HSW2BBBOF3Z0**** "BBB@ HHHH **** "BBB@
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M'G>L7<M_K=_>3H8YI[B21T/56+$D5W_B,B]^!WA:\E0>=!=26Z-C^'+C@_\
M %_*J?BKX;>(D\77*:9ID][9W<K36T\(W(4;Y@&;HI&<?-C...HJW\27@T+P
MSX=\&PRQ/<6,9GO1&Q8+*W.,GW+G'H1TJW*,G%1 \THHHK<04444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% 'L7[//_(0\4?[MK_[4KJ/CC_R*FC_]
MAJW_ /09*Y?]GG_D(>*/]VU_]J5U'QQ_Y%31_P#L-6__ *#)7F/_ 'CYA/\
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MQ?\ HJ6O6*\G_:"_Y$?3/^PO%_Z*EJZ7QH&?/]%%%>T9A1110 4444 %%%%
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MI2P7Z#H/PK.HI65[@%%%%, HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?_GI^AK[?HH^NR[!RGQ!]LM_^>GZ&C[9;_\ /3]#7V_11]=EV#E/B#[9;_\
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M^'^1\J?\)5HO_/[_ .0G_P */^$JT7_G]_\ (3_X5]5T4?VM5_E0?V31[O\
M#_(^5/\ A*M%_P"?W_R$_P#A1_PE6B_\_O\ Y"?_  KZKHH_M:K_ "H/[)H]
MW^'^1\J?\)5HO_/[_P"0G_PH_P"$JT7_ )_?_(3_ .%?5=%']K5?Y4']DT>[
M_#_(^5/^$JT7_G]_\A/_ (4?\)5HO_/[_P"0G_PKZKHH_M:K_*@_LFCW?X?Y
M'RI_PE6B_P#/[_Y"?_"C_A*M%_Y_?_(3_P"%?5=%']K5?Y4']DT>[_#_ "/E
M3_A*M%_Y_?\ R$_^%'_"5:+_ ,_O_D)_\*^JZ*/[6J_RH/[)H]W^'^1\J?\
M"5:+_P _O_D)_P#"C_A*M%_Y_?\ R$_^%?5=%']K5?Y4']DT>[_#_(^5/^$J
MT7_G]_\ (3_X4?\ "5:+_P _O_D)_P#"OJNBC^UJO\J#^R:/=_A_D?*G_"5:
M+_S^_P#D)_\ "C_A*M%_Y_?_ "$_^%?5=%']K5?Y4']DT>[_  _R/E3_ (2K
M1?\ G]_\A/\ X4?\)5HO_/[_ .0G_P *^JZ*/[6J_P J#^R:/=_A_D?*G_"5
M:+_S^_\ D)_\*/\ A*M%_P"?W_R$_P#A7U711_:U7^5!_9-'N_P_R/E3_A*M
M%_Y_?_(3_P"%'_"5:+_S^_\ D)_\*^JZ*/[6J_RH/[)H]W^'^1\J?\)5HO\
MS^_^0G_PH_X2K1?^?W_R$_\ A7U711_:U7^5!_9-'N_P_P CY4_X2K1?^?W_
M ,A/_A1_PE6B_P#/[_Y"?_"OJNBC^UJO\J#^R:/=_A_D?)E_XFTB;3KF*.[R
M[Q.JCRWY)!QVKZ0\ ?\ )._#G_8-@_\ 0!71T5R8G%RQ%N96L=>&PL,.FHMZ
MA1117*=(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_=!Z\TGQP\.:3I/Q"L/L-KY7]I+]IN_WC-YDCRMN;DG&?08% 'TA:>(-&O\
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MYCG:.I[#TKQ3P)XM\&1V][KGBJRN-2\0:G.\MQ(]@9TC7<=J)D$ 8';V'8
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MKGH#UKH_@_KUM8?&"73=!>Y&A:GYJ1PW'4!5+J2 <;AM(SSP3Z\ 'T'!XO\
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MKWNO)/8QPHJ:C<R8$H(RK;B3U'3FN&M_^39#_P!@H_SK.\=?\FTZ)_UZ6/\
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M[>@.1]YN0<9]9HH \-\;Z[KOC^TT/^R?".LP:5;:M!-)-=6Q$KMAL%47/[L
MMELXR5'%=;XCTV_G^-O@R_ALKF2RM[>Z6:X2)C'$3&X 9@,#)(QGUKT6B@ K
MS;QOHFLZ3XVTWQ[H-I+J)MH#::AIT7^LEA))W(.Y!/0=U7WKTFB@#RR\\?\
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M$S+U7(X(^AY_"N/3Q7\0D143X7 *HP ->M^!_P!\TO\ PEOQ#_Z)A_Y7[?\
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M"[M8K:!9)K>V>1$(G<D%@"!@$'\:[CXTZ;?:K\-KBUTZRN;RY,\1$-O$TCD
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MNL^!N(Z<9S0!8HKCO'GB^]\.'2=,T>SBNM:UBX\BT%P2(4QMW,^#N( 8=/\
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M;?:;>YD8/YZ\8"J!G)!R/6N;^+4GB"[^%TEW:S:>-.>RC>_25&\UBS(1Y9'
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M;R_+& B*H)+/G<6/  QW- 'K]4YM5T^WU*VTV:]@COKH,T%NS@/(%&6('4X
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MOSP:YW5M8^)_@^Q;7=6_L'5=-@P;NUM%>.2-">61F SCWS].X .[\2^*-/\
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M(&G:SIL%R=C*?)E:-"0Z9.2A(]>W7!!H W/"GB*+Q7X:L];AM9[6.Z#%8IP
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M^N4M7>R1D>%VS@\]>F>^<'I0!ZQ17'>.?&=UX=_L[3=%L5U#7M4<I9VS'"@
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M'!>63JJ7MLK?9[M2,[DSW'&?KT!! ZR@ HKR^#Q=XQ\;ZGJ*>#$TNST>QF,
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M'%JJI]G5X)4 QB0.2?SR&_X%6_X3\'Z/X,TQK+287'F-OFGF;=+,WJ[=_H,
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MY)>R&X920[A00, <?*/?WH XW4/^3DM*_P"Q?;_T;)2^*/\ DOG@7_KUO/\
MT5)78S>$["?QO;^+&EN1?P69LEC#+Y13<S9(QG.6/?'M5;QAX&TKQG%:F]DN
MK6\M&+6UY:2^7+$3C.#R,' [?3% '35YC\;_ /D >'/^Q@M?_09*]!TC3SI6
MD6FGFZN+O[/$L?GW+;I'P.K'N:S_ !3X3L/%UG96U_+<QI9WD=[&;=E4ET#
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M21I UPRL^6.3RH _2CQ5X1TGQAIR6FJ1R!HG\R"XA;9- _\ >1NQ_,<#C@4
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M,X)Z@CVH POC'<P6WPKUOSI40RHD<88\NQ=< >IX)^@/I4,/_)O@_P"Q7_\
M;6JR?!70)-.GM=2U/6=2>6/RTFN[D2-;C(.8P5VJ>,9P3@G&,UW.GZ-::=X>
MM=#4--9V]JMH!-@EXU7;\V  <@<\4 <_\*_^27^'_P#KU'\S7%_"RUFO?@/J
MEI;;O/G2]CCV#+;F4@8]\FNU\*?#RP\&:G/<:3J6I_8IHRHT^:??!&2P.Y1C
M(/4<D]36EX1\)V'@S0UTC3I;F6W61I-UPRLV6.3RH _2@#GO@Q?6MY\+M)6V
M54-N'AE0#&) Q))]SD-_P*LO4)(=1_:+TA+1XY9-/TF0W94@F/)8!3[_ #J<
M'^]6KJWPJTR]UBXU72]7UG0;JY.ZX_LJZ\E)3W)7'4\'C^=;7A/P1H_@Z"X7
M3EFEN;I_,N;RZ?S)IF_VFP/?\R>] ')_"G_D9/B!_P!AZ;_T)J7Q7_R7CP+_
M -<+K_T4]=CX?\)V'AN^UB[LY;EY-6NVO)Q,RD*[$DA< 8'/?/UHU#PG8:EX
MMTGQ)-+<K>:8DB0HC*(V#J5.X$9/!/0B@#=KRS39(]/_ &C-:BNU(DU+3(GL
MW9?X5"AE4^A*,?\ @)KU.N=\6>"M(\8VL,>I+-'/;MN@N[9_+FA)Z[6P>#Z'
M(H POC3>VEI\+-7CNI(U>X$<4*,1EWWJ< 'J0 3^%<YXDMI;+Q)\([6==LL/
MF1N/0B.(&NDTSX4:7:ZO:ZIJVKZSKUS:'=;#5;KSDB/J%QUXS^ XR*Z'6O"=
MAKNN:)JUU+<I<:/(\ENL3*%8N%!W@@DCY1T(H W:9++'!"\TTBQQ1J6=W. H
M')))Z"GTUT22-HY%5T8$,K#((/8B@#RRR^'<L$3:I\.O&]UIUE<LTJ6Y"W5J
M6)(.T'@#MDACQUIFE>+=4\1_#;QQ8:VD)U/2+:[M)Y[?_5S$1N-PXQV/3Z\9
MQ6D_P?TZ!Y$T?Q'XDT:SD<N]G87Y2+)ZX!!QZ<Y[5T.F>!-#T;PC=^&M/AD@
ML[N&2*>4,#*^]2K,6(Y;!XXP,#C'% 'F&LV=Q>?LN67V=)',5O#*ZH,DH'Y/
MT'4_2O8= U73]6\/66HZ?)$;.2!7381A!@?*?3'0CM5*#3],\&>!VLBEQ=:9
MI]HP9'02R21@'(*@ -D9[ >M>9Z=H'PBU2U.J6VN_8K&4B:?37U,0Q@GJKQ$
MY'I@'''% &A\*-1M-6^(GQ"OK%TDMI;F QNG1QF4;A]<9J]\$_\ D$>)O^P_
M<?\ H,=5?A$(;WQ/XUUG38@NC7%U%;V;J,*ZQ!Q\H],,OYUW?A?PG8>$K:^@
ML);F1;V\>\D,[*2'8 $# ''RCU^M '':G_R<;H__ & 6_P#1DE'AO_DO_C3_
M *\[3_T6E=C/X3L+CQK;>*GEN1?6]H;-(PR^44+%LD8SG+'O^%%EX3L+#Q?J
MGB:*6Y-[J,<<<T;,OEJ$4*-HQD' '4F@#CM'_P"3A_$/_8*A_P#9*/%?_)=O
M O\ UPNO_1;UV-MX4L+7QG>^*$EN3?7=NMO)&S+Y85<8(&,Y^4=Z-0\)V&I>
M+-)\1S2W*WFEI(D*(RB-@ZE3N!&3P3T(H XB\FBTO]HVSDOAA-0T<P6CN/E$
M@;) /8X5O3[WOSZ)K6N:9X=TU]0U>\CM+16"F23U/0 #DGZ>]4O%/A'2?&&F
MK9ZI$^8F\R"XA;9+ _\ >1NQ_,=..*YFR^$.E)?6EUK&M:YKPM&W06^IW?FP
MH>.=N/;UQZB@!GC;Q'X@N/%ND>#_  S<Q:=<7]N;J349XMVR,$C:BG^+Y3G(
M[CIUKAOBWX3U+1_ S7NL^-M3U2<S(B6TA6&&1B22?+'4@<CTKUCQ=X%TOQBE
MH]U+=6=[9OOMKVRD\N:(^@.#QG!_#@BN9G^"FD:G9O'KFO:]JMP0%2ZNKL.\
M*Y!(3<"%R1SW_6@"/XA_\E#^&W_7U<?^@QUTOQ._Y)GX@_Z]&_I5[6?"5AKF
MLZ'JES-<I/HTCR6ZQ,H5BP4'?E23]T="*NZ[HUOXAT.\TB[>5+>[C,;M$0&
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MS:I<F7R?]T>O/?/MBMS4?"=AJ7BS2?$<TMRMYI:R+"B,HC8.I4[@1D\$]"*
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M9_-D5>/E'ITZ]??'%:=EX3L+'QAJ?B:*6Y-[J,4<4L;,OEJ$4 ;1C(. .I-
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M?MT<MX9&0LPR2AY&" N??W%>A:SXM\/>'75-7UFRLY'^['+* Y'KMZX]\8H
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M>GF_M;VWN+,*6\^&0.F!U.1D4 6Z*\PTSXN:5/X_US3;S6=)CT2WBA:QNO,
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MMFN)M<MHI)3$I9TVR?*3C)' XKH?B)I]EIOPJ\10V-G;VL36K,4@B5%)X&<
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M2YC\J:=MRGS&CQ\OW3^?!/)K1^">FW^E?#J&UU&RN;.X%S*QBN(FC< G@X8
MT 9'PJT;2W\2^.)'TVS9[77I5MV,"DQ!7;:%./EQVQTKJ+&(Z7\7-6$I CUK
M3H)H&;^)X"R.H]P)$)^OUQS/AN;5/!'Q!U_3[_P_J5Q9:]JQN+;4;6+S(D\Q
MC@/C[N,\D^A.,5ZI+:6T\\$\UO%)-;DM#(Z M&2"I*D]"02..QH XZ/5_&^D
M7UU8W7APZW$TS-:7]M=0P@QDDA9%;&UE&.1G/;IS2;3)?!7P:OM/N#&]V\$Z
M1PP#Y!-<,VR)!QD!I OOR<#I7HE0W%I;7?E?:;>*;RI!+'YB!MCCHPST(]:
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M2S;I[B.265F39L4(3M7N23S@<=ZM:+%_:'Q+\0:K&<V]K!#IRL!PT@R[_EO
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!%<>>+:7[,(S<;#Y0E)"[L<;L<XSUQ7!>'O!WB2Y\80>*O&6H6$]Y:6
M[0V=K8(PCAW<,Q+8)."1WZ]>!7H5% !1110 4444 <9X'\*ZAX=U;Q5=WKP&
M/5=4DN[<1,20C$D;L@8//O79T44 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 5SC^%O-^(2>*9;K>(M/\ L<-OMP$)
M?<6SWST_Q[='10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
:444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>img11953243_6.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img11953243_6.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ++!T<# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 56U*P6X^SM>VPFW;?+,J[L^F,YS5JOG#4?\
MDOR_]A6/^8KT;XM^.KCPOIL.G::^S4+U6)E'6&,<9'N3D ]L'VKHE0=XI=17
M.]O-6TW3W5+W4+2V=AE5FF5"1ZC)J>"Y@NH_,MYHYDSC=&X8?F*^?/#7P?UG
MQ38)J^J:H+);H>8GF1M-*X/1F!(QGKU-4;K3O%'PE\40M:W!N(9 '_=!O+G3
M."K+V/'X9X-5]7@WRQEJ*Y])3W$%K'YEQ-'%'G&Z1@H_,TD%S!=1^9;S1S)G
M&Z-@PS]17G'Q6O4U+X3QWT:E4N6@E4$8(##/]:\[^$WCG_A&]8&E7TN-,O7
MW,V%AD/ ;Z'@'\#VJ8T'*FY+=#OJ?1D]Q!:Q^9<31Q1YQND8*/S-,BO;2>!Y
MX;J&2%,[Y$D!5<#)R1TXKA/C1S\.YO\ KXB_F:YSX<_\D2\1_P#7.[_]$U,:
M5X<]^M@OJ>N0ZC8W.[R+RWEV#<VR56VCU.#47]M:5_T$[+_O^O\ C7B'P-M_
MM=QXAMMVSS;58]V,XSN&<58U+X$?8-,O+W_A)-_V>%YMGV'&[:"<9\SCI5NC
M",W&4@NSV?\ MK2O^@G9?]_U_P :EAU&QN=WD7EO+L&YMDJM@>IP:^7O 7@C
M_A-]1NK3^T?L7V>(2;_(\S=SC&-PQ7K_ (9^&G_"#VNLW?\ :_VWS[)X]OV;
MR]N 3G.\YHJ480TYM039WO\ ;6E?]!.R_P"_Z_XT?VUI7_03LO\ O^O^-?,/
M@7P9_P )OK-S8?;_ +%Y4)EW^3YF?F QC</6O0/^&??^IG_\D/\ [93G1IP=
MI2_ 5V>UJRNH96#*1D$'((I:KV%K]ATZVM-^_P F)8]V,;L#&<5Q_P 4M>U/
M1/"H72(YC>W4@B$D*DM$N,EACH>@_&N>,>:7*BCJKC6=+L[C[/=:E9P3\?NY
M9U5N>G!.:MQ31SQ++#(DD;=&1@0?Q%>!>$?@X_B3P\NJZCJ<UG/<,_EQB+<5
MP2,ODCDD$X].]5? .H:OX+^)7_"-2S^9;27#6\\0.4)P=KKZ'H?H>?;H="+3
MY97:%<^BJ***Y1A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_!O_ "(WA_\ [!MO_P"BUKIJ_P &!*W-NBBBN4H**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_@YN_P#X[6W11SR[@8G_  BNG?\ /SK'_@YN_P#X[1_PBNG?\_.L?^#F[_\
MCM;=%'/+N!B?\(KIW_/SK'_@YN__ ([1_P (KIW_ #\ZQ_X.;O\ ^.UMT4<\
MNX&)_P (KIW_ #\ZQ_X.;O\ ^.T?\(KIW_/SK'_@YN__ ([6W11SR[@8G_"*
MZ=_S\ZQ_X.;O_P".T?\ "*Z=_P _.L?^#F[_ /CM;=%'/+N!B?\ "*Z=_P _
M.L?^#F[_ /CM'_"*Z=_S\ZQ_X.;O_P".UMT4<\NX&)_PBNG?\_.L?^#F[_\
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MBNG?\_.L?^#F[_\ CM'_  BNG?\ /SK'_@YN_P#X[6W11SR[@8G_  BNG?\
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M'_"*Z=_S\ZQ_X.;O_P".UMT4<\NX&)_PBNG?\_.L?^#F[_\ CM'_  BNG?\
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M6/\ P<W?_P =H_X173O^?G6/_!S=_P#QVMNBCGEW Q/^$5T[_GYUC_P<W?\
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M_!S=_P#QVC_A%=._Y^=8_P#!S=__ !VMNBCGEW Q/^$5T[_GYUC_ ,'-W_\
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M._Y^=8_\'-W_ /':/^$5T[_GYUC_ ,'-W_\ ':VZ*.>7<#$_X173O^?G6/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MB2+8:C)(IDN8=AQO )(8>IY.?;)S? &O6/AGX(:?K.I,ZVEM$S2%%W-S*5
M]R0* /2Z*J:7J5MK&EVNI6;,UM=1++$S*5)5AD'!YZ5;H *1F"J68@ #))[4
MM>-7!\.^-M9UC5/&^J01Z#97KV&F64UZ8(V:,#?+P06)+#'<#VQ0![+17G_@
M'PW'HFIW=SX;UN"\\'W4>ZWM5N&F-O,&Y"-D@+RV<G.<9Z'/H% ",P498@#.
M,FEKSL?"NRUW5;[5/&LC:Q=2S/\ 9HQ/(D-M ?NHJ@C!_$\\]>:B^%\KVNM>
M*="L[I[O0--N8TT^1Y#)Y>5.^(,2<JN% ';- 'I&X;BN1N R1WI:^>[U-*6*
M_DFF>+XB?V\/()D(GYF"J /^>7E=AQC':O0=4+>/_%8T!#')X>TB17U5NHN;
MD<K!]%X9O?C% 'H=%(    , 5YO\9?%NJ^&?"C#2;:_2>8KG4($!CMP&'#'G
M!/3IWZT >DT5S^A>)O[2T*?4]2TV]T6*W)$@U)1&2H4$OUQMYZ^QKGE^+-D8
M'OSX;\1#15/&I_8OW13C]YC.[9SG./PZX /0:*K:??VNJ:?;W]E,LUK<1B2*
M1>C*1D&N,^,MV+7X6:NO&^?RX4STR9%ZGMP#0!WE%>,:9\.O@_>3P:;%?6EW
MJ)4*4CU0EY& YP%;KUX%>R11)!"D48PB*%49Z 4 /I P)(!!(X(]*YSQGH.I
M^)--M]-L=3:PM9)P;YHF*2R08.45AG&>_P#^O/G?CCP;H/P\T6TUKPG')I^O
M1W,45LJW4C&\RPS$REOF!ZD#T% 'L[,%4LQ  &23VI:\]^* BDL- _M;>-!.
MH(=3P2$V[24WXYV[\>W3VK!\->(=*\*6?BV^T>4W'A];R.'2+9')26Y9 6CB
M]BY[= ": /8*A@N[:Z,HM[B*8PN8Y!&X;8XZJ<=#[5SG@GPY<:/8W&H:J8Y=
M>U-_/OYD'&?X8Q_LH#@?B>]8MI/_ ,(]\:;S3$"+9Z]9"]"YZ7"$JV!_M*,G
MZ#WH [B34[.+5(-,>8?;)XGFCB ))12 S' P!E@.>O;H:SSXP\.+K7]CMK5D
MNH>9Y7D&4 [^/E]-W(XZUF:-_I/Q+\33R_ZRU@M;6$'M&4,A(^K.?^^:H:UI
M]A)';^!_#UK;HWG1W=V0Y_T.,2"3>3U+L1P,YY)/% '9Q:A:S:C<:>DC?:K=
M$DD0HPPKYVD$C!!VL.,\@BK5<AJP^R_$WPU+&</<V5W!*?[RJ8F7]2?SKKZ
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***\\^)-Y
MJ&I:MH'@K3;M[7^VWD-[/%PZ6T:@N >VX9'X8[\@'H08$D @D'!QVI:\@\7>
M![#X=Z,OBWP;'/976F2127-LL[M'>0@A65PQ/9LY^O&2"/6K:=+JUAN(L^7*
M@=<C!P1D4 2T@8,,J01DCBO-OB?*;S7_  EX=O[N2TT#5;F9+YXW*&4JH,<3
M,.BNQQCO[8K(\0>&]-^'WB?PI-X-\VSO+[44M;G38YWD6ZMR/G<JQ.-H4?-V
MW9/2@#V L%&6( R!S2UYG\0DTE_&WAX>+"H\-_9[C'GMB#[5\H7?[[2V,^^.
M]97ASQ)<Z%\/4L]&D:[O-1U.XM/#4-RY)-N'PKDGG8BY8]N@XR* /8:*P_"?
MAN#PMH$6GQMYL[$S7=R1AKB=N7D/U/Y  =JW* (7N[>.ZCMGN(EN)06CB+@.
MX'4@=3BI'=(T+R.J*.I8X KS[P9(?$'Q&\7>(F9F@LY5T:S&<A1'AI<?5]IX
M_6L72-"L_B;XR\47GB8RW5EI.HG3[+3A.RQ1^7D&0A2,ECSS[CD8P >NT5Y?
MX<1/ OQ0/@RTO)I-%U&Q-[96LKES:2!B"@)YV$*Q&>X^I//^)]/\'^(?C%K0
M\77D$%EINGV\"":Y\@-*_P XP<@MA2>GK[4 >X4FX!@N1N(R!W_SS7%>!/!_
M@G1GEU?PBT4RS)Y#S0WAG4C(;;U(!Z>]>9>(UTE5\7S:G++%XY76C_9#"0BY
M\O<GV?R@/X"IQ^??% 'T'17GFNO/XW\11>#XI%;2K 17&O3H>)6SE+4?[Q&Y
ML= ,9!X/H,<:11K'&BHB@*JJ,  = !0 ZFET5U1G4,V=H)Y./2N8^(7B.Y\+
M^#[F]L$5]1E=+:S5B /-D.U3SQQRV#P<5S]O\%_#M[:>=XF>\UK5Y4_?7LUW
M("&/78%( 4$G (- 'I-%<5X+TCQ%X:U74-#NY9;_ ,.QHLFF7MQ*IEC]8&&=
MS =B0 ,>X Q?A5?6^E^!_$6H7;E+:UU6]GE8 DA%PQ.!UX!H ]/HK*\.>(;#
MQ5H5MK.F-(UI< [#(A1L@E2"#Z$$<<<5JT %%%>>7GP4\!W-S/=SZ9*'E=I9
M&^UR 9)R3][B@#T.BO(/@OX:TZ+4=>\4Z3;O;:3=RFTTR-G9B\*'#2$MS\S#
MH>A##TKU;4#>#3;HZ<(6OA"_V<3Y\LR8.W=CG;G&<=J +-(6"C+$ 9 YKQ<^
M']0T;XT^"KG6-;GU;4[Q+UII679%&%A;:D2#A5&3]3SWK=^(::2_C7P\/%A4
M>&_L]QCSVQ!]J^4+OQWVEL9]\=Z /3**\>\.>)+G0OAZMGHTC7=WJ.IW%IX:
MAN7))MP^%<D\[$7+'MT'&17HOA/PW!X6T"+3XV\VX8F:[N2,-<3M]^0_4_D
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MS3[>QLXQ%;6T:Q1(#G:JC '/L*K:YHFG^(]'N-*U.#SK2X7#KD@\'(((Z$$
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M2/E).TC&#R<Y'O76U@>&O"=MX<EU"Z^V75_J.HR+)=WMVP+R;1A!A0  HR
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M+Z5<Z)X:L;"]O[F_NXX_W]S<RM([N>3R23C)P!GH!0!KT444 %%%% !1110
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M ,YH [6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@#$TGYO$7B!_[L\*?E"A_]FK;K'TB&6/6-?DDB=$EO(S&S
M*0'46\0R/49!'U!K8JI;@%%%%2 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !4-Y'YME/&?XXV7\Q4U(PW*1ZC% &7X9?S?"VE2'^*TB/\
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M0OW1]*Y+XD^'M;\4^#Y='T*ZMK:>XE43/<.Z*8ADD J"<D[>V,9H J7/QB\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MRX(P2N>AYP1C\JT9?!B:Q\.K?PMXAN7O)!:QQ2W2GY_,4##J3SD$=3U[YR:
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0JQ7-*+2]&.-:E)VC)-^IK4445D:A1110 4444 %%%% !1110 4444 %%%%
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MW5NI.=J@ J<>I/?@#@5V?@CPA:>"/#<>DVTSW#EVFN+EQAII6QEB,G'   ]
M.IR2 6?%]K+?>"M>M(%W33Z=<11CU9HV _4USWP:G2?X3:$R'[J2(1Z$2N*U
M_"MCXIMEU-?%.HVE^LMP3:"! !'#_=;Y%R?S^M<C#X%\:^$[F\M_!.N:8FCW
M<K3"UU*)LV;-U\K:""/8X' X/)(!'H&VY_:0\3W$+J\<&DQPR%><.?)./3^$
M_P"<UOZO\+-!UC4KR[>XU.UCOV#W]I:W9C@NR,$&1<'TZ@CJ?6K7@3P3_P (
MA:W\]W?-J.L:G/\ :+Z\9-F]N<*%[ 9;\ST& -#QCIVL:OX7N]-T.Y@M;N[
MA:XF8CRHR<.5P#EMN0.G7.1B@#SF/4UDCUWQ_8V\1TK0+-].T"!<B,A<!Y1[
M$X4<=%QVJ*5O$7A#1?"OBN3Q1J.HR:E=6T>I6=TX:!UF!/[I?^697...#@'
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MA54>P' J6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MG_@7'_C1_P )1X?_ .@[IG_@7'_C1[*?\K#VD.Z-:BLG_A*/#_\ T'=,_P#
MN/\ QH_X2CP__P!!W3/_  +C_P :/93_ )6'M(=T:U%9/_"4>'_^@[IG_@7'
M_C1_PE'A_P#Z#NF?^!<?^-'LI_RL/:0[HUJ*R?\ A*/#_P#T'=,_\"X_\:T;
M:ZM[VW6XM9XIX7SMDB<,IP<'!''44G"4=6AJ<7LR6BBBI*"BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /*;3PEKNE:
MYJFH?#OQ/I,EA>71>[L;P>;'#*1EL,F2#R/EXX(SG K#M]%O++X_^''U+5O[
M3UI[2:YOY$39%$IC=$C11T ]^3G)ZUU%QX(\6>'];U;4/!&KZ;%;ZK,;B>RU
M*-BD<A^\Z,N3DGMC&/H*U?!/@:XT'4+_ %[7=1_M/Q%?_+-<@82./.1&@[#@
M>G0<#% '/_ 1&M?!FI6$PVW%GJLT,J^C!4_3_"D\0;;G]HWPJD3JSVNG3/,H
MYV@K*!GTZC_)%7K_ ,#>)]$\2W^M>!M6T^W34FWW>G:C&WDA_P"^A0$Y/I@=
M3DG@#1\%^!KW1=9U#Q'X@U1=4\07Z")YHX]D<,8Q\B#OG"\X'0<=20#MZ\J^
M%Z-:?$+XC6<PVS'4A< >J.TC*?R(_,5V1L_%7_"=B[&I6O\ PC'V?:;/:/-\
MW^]G9G'_  +\*P_$G@?6E\5'Q7X.U2VL=4EB$-W;7<9-O<J.A8J,AAZX/0<C
MG(!C_%?;<>-_AW:1NIG&JB;9WV*\9)_0_E[&NS\2>"=-\2WEK?RW-_8:C:*5
M@O=/G\J5%)R5S@@@\\$'J?6L/PYX%UG_ (2Y?%OC#5K>_P!5AA,-I!:1E(+9
M3G)4G!8X+#D=SG/&.]E,@A<PJKRA3L5VVJ3V!(!P/?!^E 'D\GAO3)/$%A\/
M=$C(TJPD75-:D=RSS/P8T=N,LW#?0#TJG WB'Q=I7BCQ5%XFU'2Y=-N)X].L
M[60>0JPKD^8I&'W>I''7GI7?^!_"]SX<TRZEU2XCN]:U&X>ZO[F,?*SD\*N0
M#M48 'UP!G%<M<^ ?%EA_;NE>'-8TV'0M;FDFD^U1N9[0R<2"+:,,",@9QCC
M'.20#M?!NM3>(O!NDZM<*JSW5LCRA1@;\?-@>F<UN50T32+?0=#LM*M ?(M(
M5B0GJ<#J?<]:OT %%%% !1110 4444 %%%% !1110 4444 ?+WQ=_P"2G:M]
M(?\ T2E<17;_ !=_Y*=JWTA_]$I7$5[5+^''T,WN%%%%6 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 ?7?@O_D1M!_[!\'_H K=K
M"\%_\B-H/_8/@_\ 0!6[7B3^)F@4445(!1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %<!\7O^10@_Z_4_\ 0'KOZX#XO?\ (H0?]?J?^@/75@O]
MXAZG-C/X$O0\1HHHKZX^7"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ KU3X,?Z[6?]V'_P!GKRNO5/@Q_KM9_P!V'_V>N',?]UE\
MOS1V8#_>(_/\F>LT445\J?2A1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%':@#Y=_X6YXY_Z#G_DI!_\ $4?\+<\<_P#0<_\ )2#_ .(K
MB:*]KV5/^5?<9W9VW_"W/'/_ $'/_)2#_P"(H_X6YXY_Z#G_ )*0?_$5Q-%'
MLJ?\J^X+L[;_ (6YXY_Z#G_DI!_\11_PMSQS_P!!S_R4@_\ B*XFBCV5/^5?
M<%V=M_PMSQS_ -!S_P E(/\ XBC_ (6YXY_Z#G_DI!_\17$T4>RI_P J^X+L
M[;_A;GCG_H.?^2D'_P 11_PMSQS_ -!S_P E(/\ XBN)HH]E3_E7W!=G;?\
M"W/'/_0<_P#)2#_XBC_A;GCG_H.?^2D'_P 17$T4>RI_RK[@NSMO^%N>.?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^SUY77JGP8_UVL_[L/\ [/7#F/\ NLOE^:.S ?[Q'Y_DSUFBBBOE3Z4****
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MW]* -6BBB@ HHHH **** "BBB@ HHHH **** "CM11VH ^)Z***]TS"BBB@
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MO9WIN;G4;E=\-C90F6:1>>0.@'!ZD9P?0XZBO)OAX@UCXM^/-;N?GGM+A;"
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M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?7?@O_ )$;0?\
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K;\&_\
M(\:!_P!A*W_]&+6)6WX-_P"1XT#_ +"5O_Z,6E+X6!]>T445X9H%%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %>)_&'_D;+3_KQ3_T9)7M
ME>)_&'_D;+3_ *\4_P#1DE>CE7^\+T9P9E_ ?JCSZBBBOISYT**** "BBB@
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M %%%% !1110 4444 %%%% !7 ?%[_D4(/^OU/_0'KOZX#XO?\BA!_P!?J?\
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M10 4444 %%%% !7T#\-/^1 TS_MK_P"C7KY^KZ!^&G_(@:9_VU_]&O7E9O\
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M'\%Q^*I9##IS6@NV+XW*"N=ONV?EP.IX%,\%ZGK&M>%K35-;M[:VN;P>?'!
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MBG_HR2O1RK_>%Z,X,R_@/U1Y]1117TY\Z%%%% !1110 4444 %%%% !1110
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MKM9_W8?_ &>N',?]UE\OS1V8#_>(_/\ )GK-%%%?*GTH4444 %%%% !1110
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M= K,I!7YE&>_(S7 ?#/QOHWA3PK)X6\37\>FZGHLLL4B7.5\Q"[.&3/WAAN
M.<8XY%>JV&DZ=I?G?V?I]K:>>_F2_9X5C\QO[S8 R?<U%J.@:-J\T4VIZ387
MLL7$;W-LDC)WX+ XH \Y^&AE\4>/O%'CP1LFG7&VPT]VCV^;&F-S#/./D3\2
M1_#@>A>)->M/"_AR^UJ^)\BTB+E1U=NBJ/<L0/QK31$BC6.-51% 5548  Z
M"H+W3[+4HDBOK.WNHT<2(D\2N%<=& (X(]: /,?^$5U2/X.>([B]B,OB+6[>
M2^O$6,AMQ&Y8@O7*J,;?7-8VLZ[I/B3P)X T;1+N&YU-KVRV6T1&^#RDQ(6
M^YM_D<C(YKW"L^UT+2+&^EOK32K&WO)?]9<16Z)(_P!6 R: -"BBB@ HHHH
M**** "BBB@ HHHH **** "CM11VH ^)Z***]TS"BBB@ HHHH **** "BBB@
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M0#]!BNFHHH **** "BBB@ HHHH **** "BBB@ HHHH ^7OB[_P E.U;Z0_\
MHE*XBNW^+O\ R4[5OI#_ .B4KB*]JE_#CZ&;W"BBBK **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** /KOP7_R(V@_]@^#_ - %;M87
M@O\ Y$;0?^P?!_Z *W:\2?Q,T"BBBI **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ K@/B]_R*$'_7ZG_H#UW]<!\7O^10@_Z_4_] >NK!?[Q#U.
M;&?P)>AXC1117UQ\N%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !7JGP8_P!=K/\ NP_^SUY77JGP8_UVL_[L/_L]<.8_[K+Y?FCL
MP'^\1^?Y,]9HHHKY4^E"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH *.U%':@#XGHHHKW3,**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "MOP;_R/&@?]A*W_ /1BUB5M^#?^1XT#_L)6_P#Z,6E+
MX6!]>T445X9H%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MU;Z0_P#HE*XBO:I?PX^AF]PHHHJP"BBB@ HHHH **** "BBB@ HHHH ****
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MW51Z 1K7!?"QF3XA?$JW4D0KJ:2!<\!F:;<?QP/RH ]4=TBC:21E1%!9F8X
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M5OZ=\4II9](FU;PQ>:9I&M2K#I]^\RR!V;.P2(!F/=@$=00<YP": /1:***
M"BBB@ HHHH **** "BBB@ HHHH *.U%':@#XGHHHKW3,**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "MOP;_R/&@?]A*W_P#1BUB5
MM^#?^1XT#_L)6_\ Z,6E+X6!]>T445X9H%%%% !1110 4444 %%%% !1110
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M*77B"W\;>'/!_A+2K>[_ +8MKNU.H0RP.OV)8%PY<D=^WK['BO<Z* "BBB@
MHHHH **** "BBB@ HHHH **** "CM11VH ^)Z***]TS"BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ K;\&_\ (\:!_P!A*W_]&+6)
M6WX-_P"1XT#_ +"5O_Z,6E+X6!]>T445X9H%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %>)_&'_D;+3_KQ3_T9)7ME>)_&'_D;+3_ *\4
M_P#1DE>CE7^\+T9P9E_ ?JCSZBBBOISYT**** "BBB@ HHHH **** "BBB@
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MQ%=O\7?^2G:M](?_ $2E<17M4OX<?0S>X44458!1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110!]=^"_P#D1M!_[!\'_H K=K"\%_\
M(C:#_P!@^#_T 5NUXD_B9H%%%%2 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !7 ?%[_D4(/^OU/_0'KOZX#XO?\BA!_P!?J?\ H#UU8+_>(>IS
M8S^!+T/$:***^N/EPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH *]4^#'^NUG_=A_]GKRNO5/@Q_KM9_W8?\ V>N',?\ =9?+\T=F
M _WB/S_)GK-%%%?*GTH4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1VHH[4 ?$]%%%>Z9A1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5M^#?^1XT#_L)6__ *,6L2MOP;_R/&@?]A*W_P#1BTI?
M"P/KVBBBO#- HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MKQ/XP_\ (V6G_7BG_HR2O;*\3^,/_(V6G_7BG_HR2O1RK_>%Z,X,R_@/U1Y]
M1117TY\Z%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !7T#\-/^1 TS_MK_P"C7KY^KZ!^&G_(@:9_VU_]&O7E9O\ P%Z_HSTLK_C/
MT_5'64445\X>^%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 ?+WQ=_Y*=JWTA_]$I7$5V_Q=_Y*=JWTA_\ 1*5Q
M%>U2_AQ]#-[A1115@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MW_@+U_1GI97_ !GZ?JCK****^</?"BBB@ HHHH **** "BBB@ HHHH ****
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MUE\OS1V8#_>(_/\ )GK-%%%?*GTH4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !63XFT&W\3^&M0T6Z;;%=Q&/?M#;&ZJV.Y# '\*UJ* /)=''Q7
M\,:+#X<BT+2]42VB\FUU3[8$5$&0H="0S;1@< <8ZG)K<\*?#:/2O"VL66MW
M9O\ 5-=#-JET&.')! 5>AP-S<\$DGH, =]10!Y+I4'Q3\):0GAJQT?2]6@MQ
MY=GJK7(C5(_X0\9(8D#T]N6QD]9\.O!C>"O#;6ES<)<ZE=3-<WMPG1Y&[+D
M[0 .O?)P,XKKJ* .:\+W/BC4(]4C\5:9:V:B=H[06[@^;#S\S8=L'\OI7%:5
MH_Q ^'BW6C>'](L==T629Y;%WNA"]H&.=KAB"P!.>"2>>1G ]:HH X;X>>#;
M_0)-6UO7IH)M>UF?SKCR/]7"HSMC4GGN<]N .<9.YXQ;71X7NXO#=OYNK3@0
MPL75!#N.#(22/NC)&,G..#S6[10!R8\"64'PTD\&VD@BB:R:W\_;UD(YD(SW
M;YB,^U<?'X=\:^(;+PYX;U[2+2QTW1[B*6YOXKM9/M:PKA B#E<]\@>HQTKU
MRB@ HHHH **** "BBB@ HHHH **** "BBB@ H[44=J /B>BBBO=,PHHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *V_!O_ "/&@?\
M82M__1BUB5M^#?\ D>- _P"PE;_^C%I2^%@?7M%%%>&:!1110 4444 %%%%
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MZMJB^%M,LM;T&_N#<1V;3K;R6SD<X+87& !WSA>!S6MX7\':[>>,I/&GC&2
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M'ZXR<9KE&\.^-_#MMXD\.Z)I-I?Z;K$\TUM?O=+']D$HPRR(>6P,X(SSSSG
M]<HH RO#.BIX<\,Z=H\<AD%I L1<_P 1 Y/XG-:M%% !1110 4444 %%%% !
M1110 4444 %%%% 'R]\7?^2G:M](?_1*5Q%=O\7?^2G:M](?_1*5Q%>U2_AQ
M]#-[A1115@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% 'UWX+_P"1&T'_ +!\'_H K=K"\%_\B-H/_8/@_P#0!6[7B3^)F@4445(!
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<!\7O^10@_P"OU/\
MT!Z[^N ^+W_(H0?]?J?^@/75@O\ >(>IS8S^!+T/$:***^N/EPHHHH ****
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M[4 ?$]%%%>Z9A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 5M^#?^1XT#_L)6_P#Z,6L2MOP;_P CQH'_ &$K?_T8M*7PL#Z]HHHK
MPS0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\3^,/_(V
M6G_7BG_HR2O;*\3^,/\ R-EI_P!>*?\ HR2O1RK_ 'A>C.#,OX#]4>?4445]
M.?.A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5]
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M** "BBB@ HHHH **** "BBB@ HHHH *X#XO?\BA!_P!?J?\ H#UW]<!\7O\
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M&RT_Z\4_]&25Z.5?[PO1G!F7\!^J//J***^G/G0HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *^@?AI_R(&F?]M?_ $:]?/U?0/PT
M_P"1 TS_ +:_^C7KRLW_ ("]?T9Z65_QGZ?JCK****^</?"BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N8\$^$/\
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M 'B'J<V,_@2]#Q&BBBOKCY<**** "BBB@ HHHH **** "BBB@ HHHH ****
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MW$B21YQN1P!N]^/7&<'%CQ-XSN=(URUT'1M$EUG6+B!KK[.LZP)'$IQN9V!
MR>!QU[B@#K:*P?"OBFV\56-S-%;RVMS9W+VEW:S8+PRH>5)'![<CBH]&\4G7
M/$^LZ;:V)-CI;K ]_P";\LD^,M&JX_A[G/7MWH Z*BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@#Y>^+O_ "4[5OI#_P"B4KB*[?XN_P#)3M6^D/\ Z)2N
M(KVJ7\./H9O<****L HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'I0![1X%L8M.\!:!:PJ BV$)..[% S'\22?QKB_A+*UMXK^(.C( +:UU<SQ
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M.---MYU)*S$;2Q4]#]P'Z.M>EZOJMGH>D7>J7\HBM;6(RR,?0=AZD] .Y(%
M'DW]F7D_ACPI\,IV:.1[=+S7&WY\BU5MQB+ <%FPH(/&WN#7>Z)X]\':IJ":
M+I&KVCSH-D,"(45@ >(R0%8 *?ND]*X?^S=2?X3>*_%MZC1ZWKMH]V0CDM!;
M;<I&#U "9)'O@]*K>)%TUOAM\.!I(MS=_;K$V(@ W[@N9,=_O?>S_%C/- 'M
M5%%% !1110 4444 %%%% !1110 4444 %':BCM0!\3T445[IF%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6WX-_Y'C0/^PE;_\
MHQ:Q*V_!O_(\:!_V$K?_ -&+2E\+ ^O:***\,T"BBB@ HHHH **** "BBB@
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M8,I&00<@BEKEOALMPGPW\/K=!UD%E&,.,$+CY?TQ74T %%%% !1110 4444
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M7%QQF96:.1L# !9""1CU-:6B>'='\-V9M-&TZWLH2<L(DP7/JQZL?<DUIT4
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MXN_\E.U;Z0_^B4KB*[?XN_\ )3M6^D/_ *)2N(KVJ7\./H9O<****L HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^N_!?_(C:#_V
M#X/_ $ 5NUA>"_\ D1M!_P"P?!_Z *W:\2?Q,T"BBBI **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ K@/B]_P BA!_U^I_Z ]=_7 ?%[_D4(/\
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M%% !1110 4444 %%%% !1110 4444 %;?@W_ )'C0/\ L)6__HQ:Q*V_!O\
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MZ_4_] >NK!?[Q#U.;&?P)>AXC1117UQ\N%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !7JGP8_P!=K/\ NP_^SUY77JGP8_UVL_[L
M/_L]<.8_[K+Y?FCLP'^\1^?Y,]9HHHKY4^E"BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH *BN;:"\MI+:Z@CG@E4I)%*@974]00>"*EK!\:>)8_"
M'A#4-<>,2FV0>7&3C>[$*H^F2,^V: */C/QGIG@+180(!->R@0:?IMN,-,W
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *.U%':@#XGHHHKW3,**** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "MOP;_P CQH'_ &$K?_T8M8E;?@W_ )'C0/\ L)6__HQ:
M4OA8'U[1117AF@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 5XG\8?^1LM/^O%/_1DE>V5XG\8?^1LM/\ KQ3_ -&25Z.5?[PO1G!F7\!^
MJ//J***^G/G0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M @8XS75>"_#,?A+PM::4'\VX4>9=3%BQFG;EVR>3D],\X H WZ*** "BBB@
MHHHH **** "BBB@ HHHH *.U%':@#XGHHHKW3,**** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "MOP;_P CQH'_ &$K?_T8M8E;?@W_
M )'C0/\ L)6__HQ:4OA8'U[1117AF@4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 5XG\8?^1LM/^O%/_1DE>V5XG\8?^1LM/\ KQ3_ -&2
M5Z.5?[PO1G!F7\!^J//J***^G/G0HHHH **** "BBB@ HHHH **** "BBB@
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M^\+T9P9E_ ?JCSZBBBOISYT**** "BBB@ HHHH **** "BBB@ HHHH ****
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M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Z[\%_P#(C:#_ -@^#_T
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ H[44=J /B>BBBO=,PHHHH **** "BBB@ HHHH **** "BBB@
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M 4444 %%%% !1110 4444 %':BCM0!\3T445[IF%%%% !1110 4444 %%%%
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M0!]=^"_^1&T'_L'P?^@"MVL+P7_R(V@_]@^#_P! %;M>)/XF:!1114@%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 5P'Q>_Y%"#_K]3_P! >N_K
M@/B]_P BA!_U^I_Z ]=6"_WB'J<V,_@2]#Q&BBBOKCY<**** "BBB@ HHHH
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MM44<S J^1=_\_G_D(4>1=_\ /Y_Y"%6J*.9@5?(N_P#G\_\ (0H\B[_Y_/\
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M/Y-M%G8FS=C))/))/4FM6BHGB*LU:<F_4J%&G!WC%(J^1=_\_G_D(4>1=_\
M/Y_Y"%6J*SYF:%7R+O\ Y_/_ "$*/(N_^?S_ ,A"K5%',P*OD7?_ #^?^0A1
MY%W_ ,_G_D(5:HHYF!5\B[_Y_/\ R$*/(N_^?S_R$*M44<S J^1=_P#/Y_Y"
M%'D7?_/Y_P"0A5JBCF8!1114@%%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110!Y5\!T^Q>%]9TF1E-Q8:M-#)@]>%Y_,'\J36"NH_M'^'X[8L[Z9IL
MLMSA>$#*X&?^^U_,5L:W\-IY_$=QX@\->)+O0-1NP!=[(A/%-CH2C$8;WS^
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M ,71_P *N\.?\^O_ )$D_P#BZ[6BCZY7_G?WA]6H_P B^Y'%?\*N\.?\^O\
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M472WUC3UU!CA;1KE!*3Z!,Y_2@#2HHHH **** "BBB@ HHHH **** "BBB@
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ME^)]3O;PZ!XAO9[**UDD<PV^&4(5&2H.[ S@=&]Z^A* "BBB@ HHHH ****
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M;N9=2@<QV\32,%&[)P >!ZUM_$:TN;[X=:Y:VEO+<7$EJ5CBB0N[GC@ <DT
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MR!^!IOPATS7;FXU'Q'XFLI[74&BAL(4N(FC?RXD&7VD#[QY^H.,4 4/AO?\
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M 7A^VN89(9XM/@22*12K(P0 @@\@CTH WZ*** "BBB@ HHHH **** "BBB@
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M=M8GQ<RZY!Y0&<_=<9&/=A^=>J4 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *\Q^*SOJNN^#O"@/^CZEJ'G72YP'CBP2A'0@@GC
MU4<5Z=7E_C,"'XV^ IYD_<LMS&K'&"VP_P!67\Z -+XTC'PBUT#H%@_]'QUR
M_P /;V\^'^MV7A/59G?1=7B%QH]P_.V1@"\1/0<GIZD'^*NI^-/_ "2/7?\
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M5$M$%P$SP@EZCCC(/X8JO\&M-L-,B\6:CIY":.^HO%:N9"X:*+/SY/.#G]*
M.7\"^-_!.C0:]?>([BV>\U'5YYHT-L9W$?&"<*<<EN_/YU[)X8U3PUKEB=1\
M.264L+'8SV\81@?1EP&![X(IGANV\)W.FO=>&[32S93LP=K.!%5F^Z00!Z<5
MPFG65MX<_:%FLM'2.&TU'2O/NK:)-J1N&P" . >,_P# S0!;\:./#OQ>\'Z[
M%P-2$FEW(!"[@2-F3W^9A_WR/:O4*\K^,1\S5O UK&^+B36HV0#.<!ER>/3(
MKU0=* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%H\D;>,=,'@<X QTG@SP/9^#H;R5;J>_U.^D\R\O[@_/,><?0#)_/KTQU-%
M'F?B!&\5_&70M)C'F6/AZ/\ M&]*_P ,S?ZI3[_*K#V)_#TRHH[:"&626*&-
M))2#(ZJ 7QZGO4M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% 'G7Q=TVX&DZ5XHL8#-=^';Q;
MPH!G=!D>8,?\!4GT -;WBG1;?XA> 9M.M-0$%MJ<4,L5T(BXV;TD!VDKG('J
M.M=,RAE*L 5(P0>AIL44<$2Q11K'&HPJH, ?04 16-M]BT^VM=^_R8ECW8QN
MP ,X_"N(\8?"RR\4^+=)\1Q7OV&\LI(VFQ!O%PJ,&4'YA@]1NYXQZ"N_HH *
M*** *VH07%UIMU;VET;2YEA=(K@(',3D$!]IZX.#COBO*M!^#WB7PQ#/%HWQ
M">T6X?S)2ND(S.WJ6:0D_GW/J:]>HH Y3POX=\2Z/?33:WXPDUN%X]B0M8I
M$;(.[*L<\#&/>N5OOA-KL_CB^\56?CAK6^N681DZ6DAAC/"HI+XX4!<@ GGU
M->JT4 <'I?@_QK9ZI:W-[\19KVUBD5Y;8Z7'&)5!Y7<&R,^M;'C/P7I_C338
M;:[EFMKBVE$UK=V[;9(''=3^'\CU -=)10!Y=-\+_$6NK#8^*_'5SJ>CPR!S
M:16BP&?!R [J<D<=\^Q!YKJO&&K0>#/ %]<VB1P?9;;R+*)%X#D;(U4#T)'
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
H@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>img11953243_7.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img11953243_7.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,A!@P# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBJ<VJV
M5O*T4LVUUZC:3_2@"Y16?_;>G?\ /Q_XXW^%']MZ=_S\?^.-_A0!H45G_P!M
MZ=_S\?\ CC?X4?VWIW_/Q_XXW^% &A16?_;>G?\ /Q_XXW^%']MZ=_S\?^.-
M_A0!H45G_P!MZ=_S\?\ CC?X4?VWIW_/Q_XXW^% &A16?_;>G?\ /Q_XXW^%
M']MZ=_S\?^.-_A0!H45G_P!MZ=_S\?\ CC?X4?VWIW_/Q_XXW^% &A16?_;>
MG?\ /Q_XXW^%']MZ=_S\?^.-_A0!H45G_P!MZ=_S\?\ CC?X4?VWIW_/Q_XX
MW^% &A16?_;>G?\ /Q_XXW^%']MZ=_S\?^.-_A0!H45G_P!MZ=_S\?\ CC?X
M4?VWIW_/Q_XXW^% &A16?_;>G?\ /Q_XXW^%']MZ=_S\?^.-_A0!H45G_P!M
MZ=_S\?\ CC?X4?VWIW_/Q_XXW^% &A16?_;>G?\ /Q_XXW^%']MZ=_S\?^.-
M_A0!H45G_P!MZ=_S\?\ CC?X4?VWIW_/Q_XXW^% &A16?_;>G?\ /Q_XXW^%
M']MZ=_S\?^.-_A0!H45G_P!MZ=_S\?\ CC?X4?VWIW_/Q_XXW^% &A16?_;>
MG?\ /Q_XXW^%']MZ=_S\?^.-_A0!H45G_P!MZ=_S\?\ CC?X4?VWIW_/Q_XX
MW^% &A16?_;>G?\ /Q_XXW^%']MZ=_S\?^.-_A0!H45G_P!MZ=_S\?\ CC?X
M4?VWIW_/Q_XXW^% &A16?_;>G?\ /Q_XXW^%']MZ=_S\?^.-_A0!H45G_P!M
MZ=_S\?\ CC?X4?VWIW_/Q_XXW^% &A16?_;>G?\ /Q_XXW^%']MZ=_S\?^.-
M_A0!H45G_P!MZ=_S\?\ CC?X4?VWIW_/Q_XXW^% &A16?_;>G?\ /Q_XXW^%
M']MZ=_S\?^.-_A0!H45G_P!MZ=_S\?\ CC?X4?VWIW_/Q_XXW^% &A16?_;>
MG?\ /Q_XXW^%']MZ=_S\?^.-_A0!H45G_P!MZ=_S\?\ CC?X4?VWIW_/Q_XX
MW^% &A16?_;>G?\ /Q_XXW^%']MZ=_S\?^.-_A0!H45G_P!MZ=_S\?\ CC?X
M4?VWIW_/Q_XXW^% &A16?_;>G?\ /Q_XXW^%']MZ=_S\?^.-_A0!H45G_P!M
MZ=_S\?\ CC?X4?VWIW_/Q_XXW^% &A16?_;>G?\ /Q_XXW^%']MZ=_S\?^.-
M_A0!H45G_P!MZ=_S\?\ CC?X4?VWIW_/Q_XXW^% &A16?_;>G?\ /Q_XXW^%
M']MZ=_S\?^.-_A0!H45G_P!MZ=_S\?\ CC?X4?VWIW_/Q_XXW^% &A16?_;>
MG?\ /Q_XXW^%']MZ=_S\?^.-_A0!H451_MFP\B>;[1^[@C:60[&^50,D].:Y
M?_A;G@;_ *#G_DK-_P#$5482ELK@=M17$_\ "W/ W_0<_P#)6;_XBC_A;G@;
M_H.?^2LW_P 15>RJ?RO[A71VU%<3_P +<\#?]!S_ ,E9O_B*/^%N>!O^@Y_Y
M*S?_ !%'LJG\K^X+H[:BN)_X6YX&_P"@Y_Y*S?\ Q%'_  MSP-_T'/\ R5F_
M^(H]E4_E?W!=';45Q/\ PMSP-_T'/_)6;_XBC_A;G@;_ *#G_DK-_P#$4>RJ
M?RO[@NCMJ*XG_A;G@;_H.?\ DK-_\11_PMSP-_T'/_)6;_XBCV53^5_<%T=M
M17$_\+<\#?\ 0<_\E9O_ (BC_A;G@;_H.?\ DK-_\11[*I_*_N"Z.VHKB?\
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M-_T'/_)6;_XBCV53^5_<%T=M17$_\+<\#?\ 0<_\E9O_ (BC_A;G@;_H.?\
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MD?6*/\Z^]'5T5RG_  LKPC_T%O\ R7E_^)H_X65X1_Z"W_DO+_\ $T?5:_\
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M+?\ DO+_ /$T?5:_\C^YA]8H_P Z^]'5T5RG_"RO"/\ T%O_ "7E_P#B:/\
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M8?6*/\Z^]'5T5RG_  LKPC_T%O\ R7E_^)H_X65X1_Z"W_DO+_\ $T?5:_\
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M+?\ DO+_ /$T?5:_\C^YA]8H_P Z^]'5T5RG_"RO"/\ T%O_ "7E_P#B:/\
MA97A'_H+?^2\O_Q-'U6O_(_N8?6*/\Z^]'5T56L+^VU.QBO;.7S;>4;D?:1D
M?0\U9K%IIV9JFFKH*XW6/^0M<?4?R%=E7&ZQ_P A:X^H_D*0RC1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110!-_P P/7/^P=-_Z":^8:^GO^8'KG_8.F_]!-?,->A@MF3(****[20H
MHHH **** "BBB@ HKHO"O@W4/&$L\.F7%F)X5#M#-*48KTW 8.1G@^F1ZBJG
MB3PWJ/A75VTW4T19PBR QMN5E/<'\Q]0:GGC?EOJ!D45U/A7X?Z[XPM;BYTQ
M(!! XC9YW*AFQG X.<#&?J*2U\!:Q>>+KGPS ]HU_;J6D/FGR^ "1G'4;@.G
M7-'M(W:OL%CEZ*])_P"%'^+O[VG?]_S_ /$U3U7X0^)M'TJZU&Z-B8+:,R2;
M)B3@=<#%2JU-Z7"S."HKL_#OPP\0>*-'CU33S9BWD9E7S92K9!P>,&M*;X)^
M+XX6=$L9649$:7&"WL,@#\S0ZL$[-A9GG5%7]8T74M OVL=5M)+6Y"AMCXY!
MZ$$<$>X]#5"M$[ZH HKT:/X)>+9(U?\ T!=P!PTY!'U^6O/)8I(97BE1DD1B
MK(PP5(Z@CL:F,XR^%@,HKM/#OPPU_P 3Z/%JFG26)MY&9<23$,I!P01CCU^A
M%<A=6TUE=S6MPFR>%VCD3.=K X(X]Z%.+;28$5%=%X4\%:OXRDNDTH0?Z,%,
MAF<J!NSCL?0U2\1>'[SPQK$FEW[P-<QJK.(7W!<C(!X'."#^-'/&_+?4#*HK
MHO"G@K5O&4MTFE"#_1@ID,SE0-V<=CZ&I?%?@+6O!T5M+JBPF.X9E1X'+ $8
MX)P,$YX]<'THYX\W+?4#F****H HKI?"/@;6/&D\Z::(8XX%!DGN&*H">BY
M))ZGIVJ:+X?ZK<^,+CPS;7-C/?6Z%Y&21A&,8R,E0<C([5+J13:OL%CE**W/
M%'A+5?"%_'::I&@:5/,1XR61AG! .!R.X]Q4?AKPU?\ BO5O[-TWRO/\LR?O
M6VC QGG!]:?-&W-?0#'HK:\4>%M0\(ZFFGZD83.\0F'DN6&TDCK@<\&L6A--
M70!1113 **?%%)/,D,,;22R,%1$&68G@  =37?W/P9\5VMA-=R"QVQ1-*R"?
MYL 9(Z8S^-3*<8_$P//:**[?1/A/XKUS3TOHK6*VA?E!=.8V8>H7!./KC/TH
ME.,5>3 XBBK.HV,VEZG=Z?<;?/M9GADVG(W*2#@^F17=VWP6\6W-K%.!8H)$
M#A6GY&1G!P",T2J1CJV%CSNBO2?^%'^+O[VG?]_S_P#$USGAKP1?^*-7O-+L
M[VPANK7)*W$C+Y@!P2N%.<<>G44E5@TVF%CF:*U?$7AZ_P#"^M3:5J*J)XL'
M<A)1U(R&4D#(_P#KCM655IIJZ **** "BBB@ HHHH **** /1OA'_P ?/B3_
M + \W]*Q*V_A'_Q\^)/^P/-_2L2NK _%/Y'CYI\4?F%%%%>B>4%%%*JL[!5!
M9B<  9)- "45V=A\+_$U]#YCP06H/07$N"?P4''XXJCKO@37O#\/VBYM1+;#
M[TUNV]5^O<?4C'-8+%47+E4E<V>'JJ/,XNQS5%%%;F(4444 %%%% !1110 4
M444 %%%% !1110 4444 %%*JL[!5!9B<  9)-6[K2=1L8A+=Z?=6\9.T/+"R
M GTR1[4FTG9C2;U*=%%%,04444 %%%% !1170^$?"<_BS4)8$G%M!"F^68KN
MVYZ#&1UY_*HJ5(TXN4G9(J$)3DHQ6K.>HKI]!\&S^)-6N8-.N@;"W;#WDL>P
M$=L+D\GKC/UQ6CJ?PZ\G1[C4]'UNTU6&VR9A%@%0!D\AB,@<XXXK*6*I1ER-
MZ_U]QJL-5E'F2T.'HKJ++P?_ &GX/NM=L;XRRVA(GM&AVE0,$D-NY !ST'0U
MR]:PJ1FVHO8SE3E!)OJ%%%=7I_P_U>_\/G6FFM+6S$;2_P"D,X;8.=V IXXX
M]:*E6%-7F[!"G*;M%7.4HKI/#_@C5O$UC)=Z>;?RHY3$?,D*G( /I[BN?N+>
M6TN9;>="DT3E'0]58'!%$:D)2<4]4$J<HQ4FM&1T5TGA[P1JWB:QDN[ VXBC
MD,1\V0J<@ ^GN*Y^XA:WN)('(+1L5)'3(.*(U(2DXIZH)4Y1BI-:,CHHHJR
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^1[M_P#KPC_]#>NI'C3XKX&/"%K_ . TG_QRNB,Y1IQY;?,74\V_X5AXT_Z
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M78A+;P0.\2&+S"91@KM'0-UP3@ ]Q7O_ ("\:-XVM=0O%M!;007'E0J6RQ7
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M/U?37Q+^;X/7Q;D^3;G)]?-CKYEIX1MT[=F$MPHHHKI$%%%% !1110 4444
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MV/B30$U0:K]G+,P\K[-OZ''7</Y5W^@O)KGPM7^TV8M+:2H[L"6PNX*W/4X
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M7@OP7_PE[7H^W_9/LNS_ )8^9NW;O]H8QM_6NFL_@^Y^T/>:H5C1F$02'YG
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M]5W1UQY)X>%*?VMO4M?![_D5KS_K];_T!*\L;2[W6/$-Y:Z?;M//YLC;%('
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M>2/45X9':7,P)BMY9 #@E$) /X4L!&G5PKIR?74,;*=/$\\4=G-\1?$^I>(
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M_P#;3&T%I"GE6T);.U<YR>VXGKCV'.,URU.A3<(6>XFPHHHK8 HHHH ****
M"BBB@#T;X1_\?/B3_L#S?TK$K;^$?_'SXD_[ \W]*Q*ZL#\4_D>/FGQ1^844
M45Z)Y05TG@OQ7)X4U<SLAELYEVW$:@;B!G!&>X)_4US=%14IQJ1<);,N$Y0D
MI1W1[O=Q>!?&ABO)KJTDF"GGSO)EP./F4D'\Q]*9/KOA+P%I,L.EF"2<\B""
M7>\C8XW-DX'U_ 5X717GK+5\+FW'L=SS!_$H)2[G3>'O&%QI/B^37+I#/]I+
M"Y"\$JQ!.WMD8&!TXQQUKTK5](\'^.I8M1.KJDJ1@,8;A%;;V#*P.#R>PKP^
MBMZV#4Y*<'RM::=C&EBG"+A-<R?<]A\9^+](TCPT_A[1)HYI3$+8B-MRQ1XP
M<MT+8XQG/.35KX;ZYI%CX-MX+O5+&WF$DA,<UPB,,L>Q->*45F\N@Z/LKO>[
M9HL?-5?:6Z6L=-X"NK>S\<Z?<74\4$"&3=)*X51F-@,D\=36I\5;^SU'Q+:R
MV-W!=1K9JI>"0. =[G&0>O(KA:*Z'ATZRK7U2L<ZKM472MN[GL][K>DO\)TL
MUU2R:Z_LZ)/(%PA?<%7(VYSGVK7^',@B^'5A(1D()FQ])'KP&O8?!OBO0M-\
M 065YJ445RB3;HB"2,NQ'0>A%>;C,(Z='EA=WE?\&>AA<4IUKSLK1M^*)]%T
M3P'%>)XCMM0B"@^8D-Q<($@?_=/(([ D_P JY[QMXXM+_P 3:6;$O/9Z9<+,
M[*V%F8,"<?0# /N>W7SD\DTE=D,"E4YYR<NBN<L\8W#DA%+O8]VU^'PSXZTJ
MUF;78X(H&+AEF5<9 R&5NAX[]/QJ?PQJ_A'2-+;3K#6+58K>5D+W%PJM*W!+
M#.,CG&1QQQ7@5%8O+$X>S<WR]$:+,&I\_(K]3TSX3:II^FRZR;Z_M;42>5L\
M^94W8WYQD\]1^=<IXYN8+OQEJ,]M-'-"[@K)&P96^4=".*YZBNN&&4:\JU]7
M_P #_(YI8ARHJE;8]I\(^(-$UOP4N@W=ZEI.MN;:1'D",5P1N4G@\<XYQWH\
M.Z?X/\&ZRP37(IKV:,KOFG0)&F<XR. 3QU.?0#FO%J*YY9>FY*,VE+H;K'-*
M+<4VNIW/Q'U6WF\:6]]IUU;W*Q11LKQ.'7<K$XR#7HE[<^%_'GA^.";5(TCW
M++A9ECDC89'(;ZD<C![>M>!454\"I0@E)IQV9,,:XRDW&ZENCOO OBJU\)ZU
M>Z;=3>;ITTNU;A!D*P. _P#ND=>O05V%UX5\%:KJIU]M2A*,_FRHMRGDNW4E
ML\C)!R,^M>(T4ZN"YI^TA)Q;W\Q4\7RPY)132V\CTSXD^-[+5;5=&TJ;SH0^
MZ>91\K$=%7U&><CCIBN@L=<TA/A:;-M5L5NO[,>/R3<('W>61MVYSGVKQ.BD
M\OI^SC33M9W&L=/GE-K=6+6G7,5GJ5O<3VZ7$,<@,D3C(=>X_*O6I]'\!>+;
M&W:RN[73Y$!;;"4BDQP"'5ADX]?\:\;HK:OAW5:E&3BUV,J-=4TXRBFF>Y77
MB+0? WA<:;::C]ON(T98HQ*KOELD;L<*HS^6.M>)0W$UM.L]O+)#*IRKQL58
M?0BHJ*6'PL:*>MV]PKXF55K2R6Q)-/+<S--/*\LKG+.[%F)]R:CHHKJ.<G:]
MNGLTLVN9FM4;<L)D)13SR%Z \G\Z@HHI));#;N:WA?45TGQ/IU])CRXYAO).
M,*>"?P!->H?%_36N=#LM13)%K*58#^ZX'/YJ/SKQFO1+7XB6=UX.;0M;M+F=
MS%Y/GQE3D#[K')'S# ^N,]ZX,51G[:%:"O;?T.W#58>RG1F[7V]39^%6LZ7I
MWANZBOM2L[61KQF"3SJA(V)S@GIP:\ON[EHM;FNK:7#I<&2.1#T(;((-4N_%
M%;T\,H5)U+_$8U,0YTXPM\)[]X8\>:5JVBQ3:AJ%I9WB?),DTJQY8#JH)Z&O
M(M,\1R^'?%5SJ=I'#<9:1<,3M*D]01]!7/45G1P-.DY6VET+JXRI44;[QZGI
M7_"Y-2_Z!=I_WVU5=2^*^H:EIEU8R:;;(EQ$T196;(!&,UY_15+ 8=.ZB)XV
MNU9R.A\/>,]5\,6TT&GBW*2OO;S4+'.,>HK>M_BOXADN8DD^Q+&S@,WE$8&>
M3UK@**N>%HS;E**N1#$U8)*,G8]S\9^.XM+TB"?0]2TZZN6F"NBRK+A<$YP#
MGJ!7%_#GQK;Z!--I^HC99W,GF"< GRWP!R/0X'T_EP%%8PR^E&DZ3UOU-IXZ
MI*JJBZ=#V^\\,> ]8OY-5?4+8AF+S+%>J(V/4D\Y'X$=:S?'OCK2TT270]%F
M2=Y%$;R0\QQIW ;H2>!QD8)[UY%14PR]*2<YN5MD5/'-Q:A%*^Y<TETCUFQD
MD951;B,LS'  ##DFO5/BEK.EZAX5@ALM2L[F47:,4AG5V V/S@'IR*\?HK>K
MAE4J1J-_"84\0Z=.5-+<[7X6Z<U[XRBGPVRTC:4D#C)&T G\2?PK2^,&HI/K
M=G8)@FVB+.0W1G[$=N #^-4O!?C32O">E7"FPN)[^<EF<%0O'W5SG./P[FN/
MU+4)]5U*XO[IMTT[EV]!GL/8=*PC1G/%NK)625D;.K"&%5*+U;NRK1117H'"
M%%%% 'T5X"_Y$C2_^N7]371USG@+_D2-+_ZY?U-='7QN(_BR]6?64/X4?1!7
M&ZQ_R%KCZC^0KLJXW6/^0M<?4?R%8FI1HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH F_Y@>N?]@Z;
M_P!!-?,-?3W_ # ]<_[!TW_H)KYAKT,%LR9!1117:2%%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !173_ /"N_%?]BQZNND,UE+&D
ML;I-&S,KXVX0-N).1QC/-:$?PD\:26)NAI(7C(B:=!(1],_H<'CI4>T@NJ"Q
MQ%:.BZ%J?B&_^PZ5:-<W.POL5@,*.IR2!W%49H9+>9X9HWCEC8JZ.N&4C@@@
M]#7L_P !-(7=JVN2;<J%M8SD\#AWSV_N?D>G=59\D'($CRJZ\-ZU9ZI<:;+I
MMPUY;[?.BB7S2F0",[<CH16=/!-;3-#/$\4J'#)(I5A]0:]V^%6K-KGCWQ=J
M1D\Q9V4QMC'R!F"#&!T4 <\TSXS^!OM=JWBC3HOW\*@7J(O+IT$GU7H?;G^&
MLEB+5.20[:7/$+2PO;]F6SM)[EE&6$,9<CZX%,N+:>TG:"YADAF7&Z.12K#(
MR,@^U>O? #_D)ZW_ -<8OYM46J:!IGB'XYZQ;ZS,8;"");F5A($!"QQ\,QZ+
MSR>..XZU3K6FXM;(+'EEII>H7Z,]G8W5PJG#-#"S@'T.!5:2.2&5XI49)$8J
MR,,%2.H([&OK7PCJWA_4+">U\-K&MC82>1^ZCVQEL9.WUZ]>_7FOF3QG_P C
MSX@_["5Q_P"C&HI5G.335K U8PZ***W$%%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% 'HWPC_X^?$G_8'F_I6)6W\(_P#CY\2?]@>;
M^E8E=6!^*?R/'S3XH_,****]$\H**** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBGPPR7$\<$2[I)&"(,XR2<"@!E%='=> _$]EY(
MFTF3,SB-!'(DA)QGHI.!P>3Q4U[\._$]A9FZET_=&JEG$<JLR#W //X9K'ZQ
M1T]]:^:-?85=?=>GD<M6OI/AC6==@DGTVQ:>*-MKOO50#C..2*R*]HT!1X7^
M$<]\'$<\\33AQD_._P J<'OC;[?SK/%UY48KDW;LC3"T8U9/FV2N>0V^FWUV
MA>VLKB9%.TM%$S 'TR!56O:_@\<^%KP_]/S?^@)7*?$OPA_9%^=7LHS]BNG)
MD51Q%(?Z'D^W3TK*&-3Q#H25NQI/!M4%6B[]SB+?3KZ\C,EM9W$Z X+11,P!
M],@57961RCJ593@@C!!KVKX/?\BK>?\ 7ZW_ * E<YX5TKPZ9]6USQ!)'Y=M
M=O''',1L8_>^[U8]>/T-'UVTYQ<?AMMUN/ZG>,&G\7?H<$NEZ@UO]H6QN3!M
MW>8(6VX]<XQBJE?1^IWT&I^ ]0O;4,()M/F:/<,''EG'%?.%7@\4\0I75K,C
M%894'&SO<****[#D"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH ^BO 7_(D:7_UR_J:Z.N<\!?\ (D:7_P!<OZFNCKXW$?Q9
M>K/K*'\*/H@KC=8_Y"UQ]1_(5V5<;K'_ "%KCZC^0K$U*-%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^BO
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MP17F7A;X?67C'PU9:_JVKZR]_>*6E9+E0"0Q48&T]E%>E^(_^17U;_KRF_\
M0#6%\+?^2:Z+_P!<W_\ 1C41DXTVUW-.ID_\*8T'_H*ZY_X%K_\ $4?\*8T'
M_H*ZY_X%K_\ $5Z-12]M4[A9'G/_  IC0?\ H*ZY_P"!:_\ Q%'_  IC0?\
MH*ZY_P"!:_\ Q%>C44>VJ=PLCSG_ (4QH/\ T%=<_P# M?\ XBC_ (4QH/\
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M (BC_A3&@_\ 05US_P "U_\ B*]&HH]M4[A9'G/_  IC0?\ H*ZY_P"!:_\
MQ%'_  IC0?\ H*ZY_P"!:_\ Q%>C44>VJ=PLCSG_ (4QH/\ T%=<_P# M?\
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M $%=<_\  M?_ (BC_A3&@_\ 05US_P "U_\ B*]&HH]M4[A9'G/_  IC0?\
MH*ZY_P"!:_\ Q%'_  IC0?\ H*ZY_P"!:_\ Q%>C44>VJ=PLCSG_ (4QH/\
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M_P 17HU%'MJG<+(\Y_X4QH/_ $%=<_\  M?_ (BC_A3&@_\ 05US_P "U_\
MB*]&HH]M4[A9'G/_  IC0?\ H*ZY_P"!:_\ Q%'_  IC0?\ H*ZY_P"!:_\
MQ%>C44>VJ=PLCSG_ (4QH/\ T%=<_P# M?\ XBC_ (4QH/\ T%=<_P# M?\
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M_"BO"O\ S]:K_P!_D_\ B*].HH]O4[A9'F/_  HKPK_S]:K_ -_D_P#B*/\
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M_P#"BO"O_/UJO_?Y/_B*/^%%>%?^?K5?^_R?_$5Z=11[>IW"R/,?^%%>%?\
MGZU7_O\ )_\ $4?\**\*_P#/UJO_ '^3_P"(KTZBCV]3N%D>8_\ "BO"O_/U
MJO\ W^3_ .(H_P"%%>%?^?K5?^_R?_$5Z=11[>IW"R/,?^%%>%?^?K5?^_R?
M_$4?\**\*_\ /UJO_?Y/_B*].HH]O4[A9'F/_"BO"O\ S]:K_P!_D_\ B*/^
M%%>%?^?K5?\ O\G_ ,17IU%'MZG<+(\Q_P"%%>%?^?K5?^_R?_$4?\**\*_\
M_6J_]_D_^(KTZBCV]3N%D>8_\**\*_\ /UJO_?Y/_B*/^%%>%?\ GZU7_O\
M)_\ $5Z=11[>IW"R/,?^%%>%?^?K5?\ O\G_ ,11_P **\*_\_6J_P#?Y/\
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MO^PU!7H?:M)5JB@FF+E3W/,_^%'>&/\ G]U?_P "$_\ B*/^%'>&/^?W5_\
MP(3_ .(KTRBH^L5?Y@Y(]CS/_A1WAC_G]U?_ ,"$_P#B*/\ A1WAC_G]U?\
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MVYGT_3&A2U2=PQ0'>3T ]J]'KSSP3_R4KQU_UUM_Y/7H=*M\=_3\AHS/$?\
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M6OA_1+O5KW?]FM(S))Y:Y; ]!2:%K-MXAT2TU:S$@MKJ/S(Q( &Q[@$UY_\
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M"XB66-P<AE89!_(T 3T444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M6-9L[O2!IHL-I6-BQD^8MPP(&" OI7HM>0_#+_DKGQ$_Z^E_]#DKT3Q=K/\
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M)0%G6&Z!F1<9R<$GC!/W1^%>A>%_$MAXM\/6NLZ:S>1.#E'&&C8'#*P]0?\
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MD@'N,EAR#C-1Z;\4=<TOQ)8:'XZ\,_V1+J+A+6Z@E$D3,3@ X)'4J#ACC(R
M#FNOM-,\+?#O2+RYA2'2[&2;SKB625FR[849+$GTX''ZUYGX_P!=M/BAJ6C>
M&O"#R7S6]XMU=WT2.L=LHRH^?CU)R/08.<T >M>)]?MO"_AJ_P!;NU+16D6_
M8#@NQ.%7/;+$#/O7 K\1O%>D)I6J>)_#MG:Z)J<Z1(]M.7EM]XRA<'C'KTZ'
MV%==\0?#EQXK\!ZIHEI(D=S<1J8R_0LCJX!],[<9[9S7GFHP>*_'.B:%X4N?
M"MWI9M)[>34+^=U\E5C!!\OGYB>"!SCH?6@#U7Q%K]CX8\/WFLZ@Y6WMH]Q
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M>F2>_'2MGQWI5_I?P&N]+BD,]U9Z=!#)(O&\(4$AY[;0QK9^%TME+\,_#_V
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M>'-0\2_#V:WTR*2:YMITN1!$,M* ""H'<X;..^..:9H_QA\&-H$<M[?IIES
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MX@92"ILV((Z'I2_"W_DF'A[_ *]%_F:W=:T.TUSP[>:).#':W,!@/E?*4!&
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MS*SS-M+$M+E0-QW9."><U'XI^'>LKXL;Q=X(U6+3=6E3;=V]P"8;G&!SP<9
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M@HHHK(84444 %%%% !1110 4444 4-9UG3_#^DW&IZG<I;VD"[GD;] !W)Z
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MIEE=8^TR*;B4 ?=9SNV_4 @?A0!V=%%% !1110 4444 %%%% !1110 4444
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M *#B_P#@--_\11_PMGP/_P!!Q?\ P&F_^(H]E/\ E?W!=':45Q?_  MGP/\
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M_P +9\#_ /0<7_P&F_\ B*/^%L^!_P#H.+_X#3?_ !%'LI_RO[@NCM**XO\
MX6SX'_Z#B_\ @--_\11_PMGP/_T'%_\  :;_ .(H]E/^5_<%T=I17%_\+9\#
M_P#0<7_P&F_^(H_X6SX'_P"@XO\ X#3?_$4>RG_*_N"Z.THKB_\ A;/@?_H.
M+_X#3?\ Q%'_  MGP/\ ]!Q?_ :;_P"(H]E/^5_<%T=I17%_\+9\#_\ 0<7_
M ,!IO_B*/^%L^!_^@XO_ (#3?_$4>RG_ "O[@NBA\5O]7X7_ .PW!_6O0Z\8
M^(/C[PQK::"-.U03FUU6*XF_<R+MC7.3RHS^'-=G_P +9\#_ /0<7_P&F_\
MB*TE3GR1T?4+G:45Q?\ PMGP/_T'%_\  :;_ .(H_P"%L^!_^@XO_@--_P#$
M5G[*?\K^X+H[2BN+_P"%L^!_^@XO_@--_P#$4?\ "V? _P#T'%_\!IO_ (BC
MV4_Y7]P71VE%<7_PMGP/_P!!Q?\ P&F_^(H_X6SX'_Z#B_\ @--_\11[*?\
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MV4_Y7]P71VE%<7_PMGP/_P!!Q?\ P&F_^(H_X6SX'_Z#B_\ @--_\11[*?\
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M'%_\!IO_ (BCV4_Y7]P71VE%<7_PMGP/_P!!Q?\ P&F_^(H_X6SX'_Z#B_\
M@--_\11[*?\ *_N"Z-S1/"^E>'[K4;NP@9;G49O.NII)"[2-SW/0#)X'')K8
MKB_^%L^!_P#H.+_X#3?_ !%'_"V? _\ T'%_\!IO_B*/93_E?W!=':45Q?\
MPMGP/_T'%_\  :;_ .(H_P"%L^!_^@XO_@--_P#$4>RG_*_N"Z.THKB_^%L^
M!_\ H.+_ . TW_Q%'_"V? __ $'%_P# :;_XBCV4_P"5_<%T=I17%_\ "V?
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MBOJW_7E-_P"@&L+X6_\ )-=%_P"N;_\ HQJ$_P!V_4.IT/\ 8FD_] NR_P#
M=/\ "C^Q-)_Z!=E_X#I_A5^BL[L90_L32?\ H%V7_@.G^%']B:3_ - NR_\
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MT_PJ_11=@4/[$TG_ *!=E_X#I_A1_8FD_P#0+LO_  '3_"K]%%V!0_L32?\
MH%V7_@.G^%']B:3_ - NR_\  =/\*OT478%#^Q-)_P"@79?^ Z?X4?V)I/\
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MR!@ORL<GGG\QZ5UWC#P1:>+/L=R+N?3]4L'WVE];8WQGC(/]X<=*XCQ!92^
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M;J*9>>^2G\G-=[H%T;[P[IMVV<SVL<ASUY4&@#1HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** ///!/\ R4KQU_UUM_Y/7H=>>>"?^2E>.O\ KK;_
M ,GKT.M*OQ?)?D)&9XC_ .17U;_KRF_] -87PM_Y)KHO_7-__1C5N^(_^17U
M;_KRF_\ 0#6%\+?^2:Z+_P!<W_\ 1C4U_#?J'4["BBBLAA1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MASIUB]W'LLHNJG:3PWIGD=3\QX]<L=7TS4V=;#4;2[9 "P@G60J/?!XKC/\
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M** "BBB@ HHHH **** "BBB@ KE?B58W>I?#C7;6QC>2X>V)5$^\P!#$#U.
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M (2SX@?]""/_  /2C_A+/B!_T((_\#TH]E+R^]!<]#HKSS_A+/B!_P!""/\
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M (2SX@?]""/_  /2CV4O+[T%ST.BO//^$L^('_0@C_P/2C_A+/B!_P!""/\
MP/2CV4O+[T%ST.BO//\ A+/B!_T((_\  ]*/^$L^('_0@C_P/2CV4O+[T%ST
M.BO//^$L^('_ $((_P# ]*/^$L^('_0@C_P/2CV4O+[T%ST.BO//^$L^('_0
M@C_P/2C_ (2SX@?]""/_  /2CV4O+[T%ST.BO//^$L^('_0@C_P/2C_A+/B!
M_P!""/\ P/2CV4O+[T%ST.BO//\ A+/B!_T((_\  ]*/^$L^('_0@C_P/2CV
M4O+[T%ST.BO//^$L^('_ $((_P# ]*/^$L^('_0@C_P/2CV4O+[T%ST.BO//
M^$L^('_0@C_P/2C_ (2SX@?]""/_  /2CV4O+[T%ST.BO//^$L^('_0@C_P/
M2C_A+/B!_P!""/\ P/2CV4O+[T%ST.BO//\ A+/B!_T((_\  ]*/^$L^('_0
M@C_P/2CV4O+[T%ST.BO//^$L^('_ $((_P# ]*/^$L^('_0@C_P/2CV4O+[T
M%ST.BO//^$L^('_0@C_P/2C_ (2SX@?]""/_  /2CV4O+[T%ST.BO//^$L^(
M'_0@C_P/2C_A+/B!_P!""/\ P/2CV4O+[T%ST.BO//\ A+/B!_T((_\  ]*/
M^$L^('_0@C_P/2CV4O+[T%ST.BO//^$L^('_ $((_P# ]*/^$L^('_0@C_P/
M2CV4O+[T%ST.BO//^$L^('_0@C_P/2C_ (2SX@?]""/_  /2CV4O+[T%ST.B
MO//^$L^('_0@C_P/2C_A+/B!_P!""/\ P/2CV4O+[T%ST.BO//\ A+/B!_T(
M(_\  ]*/^$L^('_0@C_P/2CV4O+[T%ST.BO//^$L^('_ $((_P# ]*/^$L^(
M'_0@C_P/2CV4O+[T%ST.BO//^$L^('_0@C_P/2C_ (2SX@?]""/_  /2CV4O
M+[T%ST.BO//^$L^('_0@C_P/2C_A+/B!_P!""/\ P/2CV4O+[T%ST.BO//\
MA+/B!_T((_\  ]*/^$L^('_0@C_P/2CV4O+[T%P^*O\ S*W_ &&H*]#[5X=X
MZU_Q;>_V%_:?A06/E:E%)!_I:OYT@Z)QTSZUUW_"6?$#_H01_P"!Z5<J;Y(K
M3KU07/0Z*\\_X2SX@?\ 0@C_ ,#TH_X2SX@?]""/_ ]*CV4O+[T%ST.BO//^
M$L^('_0@C_P/2C_A+/B!_P!""/\ P/2CV4O+[T%ST.BO//\ A+/B!_T((_\
M ]*/^$L^('_0@C_P/2CV4O+[T%ST.BO//^$L^('_ $((_P# ]*/^$L^('_0@
MC_P/2CV4O+[T%ST.BO//^$L^('_0@C_P/2C_ (2SX@?]""/_  /2CV4O+[T%
MST.BO//^$L^('_0@C_P/2C_A+/B!_P!""/\ P/2CV4O+[T%ST.BO//\ A+/B
M!_T((_\  ]*/^$L^('_0@C_P/2CV4O+[T%ST.BO//^$L^('_ $((_P# ]*/^
M$L^('_0@C_P/2CV4O+[T%ST.BO//^$L^('_0@C_P/2C_ (2SX@?]""/_  /2
MCV4O+[T%ST.BO//^$L^('_0@C_P/2C_A+/B!_P!""/\ P/2CV4O+[T%ST.BO
M//\ A+/B!_T((_\  ]*/^$L^('_0@C_P/2CV4O+[T%ST.BO//^$L^('_ $((
M_P# ]*/^$L^('_0@C_P/2CV4O+[T%ST.BO//^$L^('_0@C_P/2C_ (2SX@?]
M""/_  /2CV4O+[T%ST.BO//^$L^('_0@C_P/2C_A+/B!_P!""/\ P/2CV4O+
M[T%ST.BO//\ A+/B!_T((_\  ]*/^$L^('_0@C_P/2CV4O+[T%ST.BO//^$L
M^('_ $((_P# ]*/^$L^('_0@C_P/2CV4O+[T%ST.BO//^$L^('_0@C_P/2C_
M (2SX@?]""/_  /2CV4O+[T%ST.BO//^$L^('_0@C_P/2C_A+/B!_P!""/\
MP/2CV4O+[T%ST.BO//\ A+/B!_T((_\  ]*/^$L^('_0@C_P/2CV4O+[T%ST
M.BO//^$L^('_ $((_P# ]*/^$L^('_0@C_P/2CV4O+[T%ST.BO//^$L^('_0
M@C_P/2C_ (2SX@?]""/_  /2CV4O+[T%ST.BO//^$L^('_0@C_P/2C_A+/B!
M_P!""/\ P/2CV4O+[T%ST.BO//\ A+/B!_T((_\  ]*/^$L^('_0@C_P/2CV
M4O+[T%ST.BO//^$L^('_ $((_P# ]*/^$L^('_0@C_P/2CV4O+[T%ST.BO//
M^$L^('_0@C_P/2C_ (2SX@?]""/_  /2CV4O+[T%ST.BO//^$L^('_0@C_P/
M2C_A+/B!_P!""/\ P/2CV4O+[T%ST.BO//\ A+/B!_T((_\  ]*/^$L^('_0
M@C_P/2CV4O+[T%ST.BO//^$L^('_ $((_P# ]*/^$L^('_0@C_P/2CV4O+[T
M%ST.BO//^$L^('_0@C_P/2C_ (2SX@?]""/_  /2CV4O+[T%P\$_\E*\=?\
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M2)O1@"1TYR"1^M5O&'Q T#P1'"-5GD>YG&8;2W3?+(,XR!D #/<D9[5Y_P#
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M>>?%;_5^%_\ L-P?UKT.M9?!'YB"BBBLAA1110 4444 %%%% !1110 4444
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M=[QFX;4+J//RF- =N?KMD'X^]:_Q0\/:]XKL])T32]R:9/=J=5ECG5&6$%>
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M9]17/_ S38M&\7^/M+@9FAL[N.!"W4JKS*,_E71_"KP[=O'=^-]>^?7-<_>
M\_N;<X*H >G0?@%':LGX2?\ )2?B9_V$A_Z-GH ]@JMJ-[%INF7=_.<16T+S
M.?\ 94$G]!5FN6^)4KP_#;Q"\;%6^Q.N1Z$8(_(F@#E/@?:SW>A:MXJO3NO=
M<OGE=@, JI(  ]-Q>LGQ)9+\0OCLGAC4V8Z1HEF+EK=3M$K$(3D]>=Z ].%.
M,9Y[;X2Q+%\+=!522#;[N?4L3_6N?\>>&-?TCQE;^/\ PG;+>W4<7DW]@%^:
M>,#JO<G  P.?E7 /2@#;\1?"CPEK'AZ?3[;1+&QN/+(@N;6!4D1P/E)(P6'J
M">?8\U2^"OB6Y\1^ 46]E>6[T^9K1Y'.6<  J3SD\,!D]P:Q[OQMXX\96)T;
M1/!-_H\UTGE7-_J098[=3P^W*C<1Z]?]GT3]GVR:R\.:Y'N,D2ZH\:2[=OF;
M449Q0!F>$--T/Q-\3/']_P"(;.QN+>VO$@A:[4,@PSKD%N,X1?SKTC3/!O@=
MY(K_ $O1-&=H9%>.>WB1MKC!!!'<<&N:7X%^%Y=4O[S4;C4;Y;J9IO)DGV*C
M,<D_+@D^YKD?&/A0_!W4+#Q=X3N+B*P,ZP7UB\FX.IR<9/4$ CG)!P0?0 ]]
MK/UZZN;+P]J=W9IONH+262%?5U0E1^8%7HW$D22*058 @@U2UK5[/0-&N]5O
MW*6MK&9)"HR<>@'J3@?C0!Y1\&_"/AS7/!YU[5M/L]5U6\N9C<O=Q"4HV_IA
MLC. &SC/S57O],L?!GQ\\/0^&HUMH]2MV6\L;<';M^;YL=A\H. !C9GO67X.
M\%>*?$#W7B?PY?Q>#=,U$EH;.V=YO,&3\S*3M'MC'?"@=;6A6UU\,OB;;+XM
MBAU.;7&,-KKQE=I <@;65B0.2@XQ@'J1G !TWQJ=%M?"_P!M'_$I_MF$WV]<
MQ^6#SO\ ;&[K5;7TTX_&OP4^ABV,X@G^T_9<<0[#MW8X Y./P]J]2O\ 3[/5
M;*6SO[:*YMI1AXI5#*17F7BJ'1O EO#H'@G2K6U\3ZZ?L]NZ [XHR?FD+\D
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M$CC#*DAZ KTQA4(!X.TBM/5_C/I5YX?O!X0MKN_O8K=G9S;M'#9H%R9)&/0
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MR3T&T#N*[[XA>#;C5OA"=#TZ$-=6,$+00@?>\H %5Z\[=P'J<#O7H:J%4*H
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ME1SUQVJYX"\-M<_ BTT1\1OJ&G3?,PZ>=O96Z=@X/X5Z/10!XAX&^)^E>!=
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M/7X59FTK4TD;"YVJ><GG^\JC\:]:K.U[1K;Q#H-[I%X,P7<1C8^GH?P.#^%
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MT.<5U[*&4JP!!&"#WI: /$O"'Q7LO!>A6_ACQEIM[IFHZ:@A7$!994!(5A^
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M (#_ /V='_" ^*O^BBZC_P" _P#]G1R1_F_,#T.BO//^$!\5?]%%U'_P'_\
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M_P" _P#]G1R1_F_,#T.BO//^$!\5?]%%U'_P'_\ LZ/^$!\5?]%%U'_P'_\
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M (#_ /V='_" ^*O^BBZC_P" _P#]G1R1_F_,#T.BO//^$!\5?]%%U'_P'_\
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M_P" _P#]G1R1_F_,#T.BO//^$!\5?]%%U'_P'_\ LZ/^$!\5?]%%U'_P'_\
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M (#_ /V='_" ^*O^BBZC_P" _P#]G1R1_F_,#T.BO//^$!\5?]%%U'_P'_\
MLZ/^$!\5?]%%U'_P'_\ LZ.2/\WY@>AT5YY_P@/BK_HHNH_^ _\ ]G1_P@/B
MK_HHNH_^ _\ ]G1R1_F_,#T.BO//^$!\5?\ 11=1_P# ?_[.C_A ?%7_ $47
M4?\ P'_^SHY(_P WY@>AT5YY_P (#XJ_Z*+J/_@/_P#9T?\ " ^*O^BBZC_X
M#_\ V=')'^;\P#XJ_P#,K?\ 8:@KT/M7AWCKPIKNF_V%]L\87FH>?J4447F0
M[?)<]''S')%==_P@/BK_ **+J/\ X#__ &=7*$>2/O=^X'H=%>>?\(#XJ_Z*
M+J/_ (#_ /V='_" ^*O^BBZC_P" _P#]G4<D?YOS ]#HKSS_ (0'Q5_T474?
M_ ?_ .SH_P"$!\5?]%%U'_P'_P#LZ.2/\WY@>AT5YY_P@/BK_HHNH_\ @/\
M_9T?\(#XJ_Z*+J/_ (#_ /V=')'^;\P/0Z*\\_X0'Q5_T474?_ ?_P"SH_X0
M'Q5_T474?_ ?_P"SHY(_S?F!Z'17GG_" ^*O^BBZC_X#_P#V='_" ^*O^BBZ
MC_X#_P#V=')'^;\P/0Z*\\_X0'Q5_P!%%U'_ ,!__LZ/^$!\5?\ 11=1_P#
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M5_T474?_  '_ /LZ.2/\WY@>AT5YY_P@/BK_ **+J/\ X#__ &='_" ^*O\
MHHNH_P#@/_\ 9T<D?YOS ]#HKSS_ (0'Q5_T474?_ ?_ .SH_P"$!\5?]%%U
M'_P'_P#LZ.2/\WY@>AT5YY_P@/BK_HHNH_\ @/\ _9T?\(#XJ_Z*+J/_ (#_
M /V=')'^;\P/0Z*\\_X0'Q5_T474?_ ?_P"SH_X0'Q5_T474?_ ?_P"SHY(_
MS?F!Z'17GG_" ^*O^BBZC_X#_P#V='_" ^*O^BBZC_X#_P#V=')'^;\P/0Z*
M\\_X0'Q5_P!%%U'_ ,!__LZ/^$!\5?\ 11=1_P# ?_[.CDC_ #?F!Z'17GG_
M  @/BK_HHNH_^ __ -G1_P (#XJ_Z*+J/_@/_P#9T<D?YOS ]#HKSS_A ?%7
M_11=1_\  ?\ ^SH_X0'Q5_T474?_  '_ /LZ.2/\WY@>AT5YY_P@/BK_ **+
MJ/\ X#__ &='_" ^*O\ HHNH_P#@/_\ 9T<D?YOS ]#HKSS_ (0'Q5_T474?
M_ ?_ .SH_P"$!\5?]%%U'_P'_P#LZ.2/\WY@>AT5YY_P@/BK_HHNH_\ @/\
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M561B< 9(!!/&.,>_3/I- !17&^,?&5QH'B#PUHUC%;S7.KW?E2"7)\N($;F
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M /4**Q/%7B!O#.B-J,>F7>I,'5!;VB[I&SW ]JX3_A<]W_T3_P 2_P#@.?\
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M:0+N>1OT '<GH .M>:-\;)YXVO-,\"^(+W2E!;[:(2%*CJW"D8QSUH ]9HK
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M\2KWPEJ\-O%OA%SILL2L/.CYR&R<9&.W'RFNTH **** "BBB@ HHHH ****
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M'D&O(O@@XEU3QM-%_P >TFJ$Q@$8ZN> /8B@#V"BBB@ HHHH **** "BBB@
MHHHH \\^*O\ S*W_ &&H*]#[5YY\5?\ F5O^PU!7H?:M9?!'YB"BBBLAA111
M0 4444 %%%% !1110 56U&VDO=,N[6&X:WEGA>-)E4,8RRD!@#UQG-6:* .<
M\#^$+7P1X9BT>VE$Y61Y);@QA&E9CG) )Y POT45P'BAX]1_:&\,0Z4%>]L;
M=GOI(R/W:$-\K'L<-T/]\>M=1\0_'3^'8(M&T1/MGBC4,)96J+O*9_Y:,.P
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M;=4;@+G[I)R21ZBI?CMI-IIND:?XNL(8[;6K._CVW$:@&0$$X;'7!4=?<=Z
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MW^K\+_\ 8;@_K7H=>>?%;_5^%_\ L-P?UKT.M9?!'YB"BBBLAA1110 4444
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M!*,#H/H !@5W.F>(/BU-JMG%J/@O38+%YT6XF2[0F.,L-S >:<D#)Z&O3:*
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M_A6_@[_H7[3\C_C1^[\PU-#_ (2_PS_T,6D?^!L?_P 51_PE_AG_ *&+2/\
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MR/\ C1^[\PU-#_A+_#/_ $,6D?\ @;'_ /%4?\)?X9_Z&+2/_ V/_P"*K/\
M^%;^#O\ H7[3\C_C1_PK?P=_T+]I^1_QH_=^8:FA_P )?X9_Z&+2/_ V/_XJ
MC_A+_#/_ $,6D?\ @;'_ /%5G_\ "M_!W_0OVGY'_&C_ (5OX._Z%^T_(_XT
M?N_,-30_X2_PS_T,6D?^!L?_ ,51_P )?X9_Z&+2/_ V/_XJL_\ X5OX._Z%
M^T_(_P"-'_"M_!W_ $+]I^1_QH_=^8:FA_PE_AG_ *&+2/\ P-C_ /BJ/^$O
M\,_]#%I'_@;'_P#%5G_\*W\'?]"_:?D?\:/^%;^#O^A?M/R/^-'[OS#4T/\
MA+_#/_0Q:1_X&Q__ !5'_"7^&?\ H8M(_P# V/\ ^*K/_P"%;^#O^A?M/R/^
M-'_"M_!W_0OVGY'_ !H_=^8:FA_PE_AG_H8M(_\  V/_ .*H_P"$O\,_]#%I
M'_@;'_\ %5G_ /"M_!W_ $+]I^1_QH_X5OX._P"A?M/R/^-'[OS#4T/^$O\
M#/\ T,6D?^!L?_Q5'_"7^&?^ABTC_P #8_\ XJL__A6_@[_H7[3\C_C1_P *
MW\'?]"_:?D?\:/W?F&IH?\)?X9_Z&+2/_ V/_P"*H_X2_P ,_P#0Q:1_X&Q_
M_%5G_P#"M_!W_0OVGY'_ !H_X5OX._Z%^T_(_P"-'[OS#4T/^$O\,_\ 0Q:1
M_P"!L?\ \51_PE_AG_H8M(_\#8__ (JL_P#X5OX._P"A?M/R/^-'_"M_!W_0
MOVGY'_&C]WYAJ:'_  E_AG_H8M(_\#8__BJ/^$O\,_\ 0Q:1_P"!L?\ \56?
M_P *W\'?]"_:?D?\:/\ A6_@[_H7[3\C_C1^[\PU-#_A+_#/_0Q:1_X&Q_\
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M[_H7[3\C_C1_PK?P=_T+]I^1_P :/W?F&IH?\)?X9_Z&+2/_  -C_P#BJ/\
MA+_#/_0Q:1_X&Q__ !59_P#PK?P=_P!"_:?D?\:/^%;^#O\ H7[3\C_C1^[\
MPU-#_A+_  S_ -#%I'_@;'_\51_PE_AG_H8M(_\  V/_ .*K/_X5OX._Z%^T
M_(_XT?\ "M_!W_0OVGY'_&C]WYAJ:'_"7^&?^ABTC_P-C_\ BJ/^$O\ #/\
MT,6D?^!L?_Q59_\ PK?P=_T+]I^1_P :/^%;^#O^A?M/R/\ C1^[\PU-#_A+
M_#/_ $,6D?\ @;'_ /%4?\)?X9_Z&+2/_ V/_P"*K/\ ^%;^#O\ H7[3\C_C
M1_PK?P=_T+]I^1_QH_=^8:FA_P )?X9_Z&+2/_ V/_XJC_A+_#/_ $,6D?\
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M3\C_ (U<O9\D=^H:FA_PE_AG_H8M(_\  V/_ .*H_P"$O\,_]#%I'_@;'_\
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M%;^#O^A?M/R/^-'[OS#4T/\ A+_#/_0Q:1_X&Q__ !5'_"7^&?\ H8M(_P#
MV/\ ^*K/_P"%;^#O^A?M/R/^-'_"M_!W_0OVGY'_ !H_=^8:FA_PE_AG_H8M
M(_\  V/_ .*H_P"$O\,_]#%I'_@;'_\ %5G_ /"M_!W_ $+]I^1_QH_X5OX.
M_P"A?M/R/^-'[OS#4T/^$O\ #/\ T,6D?^!L?_Q5'_"7^&?^ABTC_P #8_\
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M_P#A6_@[_H7[3\C_ (T?\*W\'?\ 0OVGY'_&C]WYAJ:'_"7^&?\ H8M(_P#
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M_P!"_:?D?\:/W?F&IH?\)?X9_P"ABTC_ ,#8_P#XJC_A+_#/_0Q:1_X&Q_\
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MO^A?M/R/^-'[OS#4T/\ A+_#/_0Q:1_X&Q__ !5'_"7^&?\ H8M(_P# V/\
M^*K/_P"%;^#O^A?M/R/^-'_"M_!W_0OVGY'_ !H_=^8:FA_PE_AG_H8M(_\
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M_7-__1C4+^&_4.IV%%%%9#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0VSM& 28PR YSVPY..^*]',L8E$1D02$9"$\G\* 'T44UW2-"\CJBCJ6. *
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MHHH **** "BJFJ:A#I&DWFI7._R+2![B38,MM12QP/7 KP3QQ\0?B#?>'_\
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MJ')5%'4'!YR3V':N8^(5RW@GQ_X?\81,8[&\?^S]3)R4VG&UB/4 $_\  .]
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M+M3T>+3/#WAW_D/:U+Y,$F/]2F0"_0XZXSV&3VK.M/@+X9DLV;6KK4=3U.4
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M:3S#SN(&%//MGW[U-\)?&-Y>^"=3'B2Z9I]!FDBN+N0EBT2+NW,>K$889QR
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M):20HDA'[R1E(50#U)/\B>U9/P8L[NR^%.C1W:%&=9)8U/7RWD9E/X@Y^AH
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MB@ HHHH 9)%'*4,D:OL;<NX9VGU'H>:\D^*7_)4OAY_U]M_Z&E>O5Y#\4O\
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M/I7L_A__ )%S3/\ KUC_ /017A'Q/U#XF7/@F>/Q/HVBVFF>;&6DM7)DW9X
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MTHHM+N/VE+^3\7_7]+SOP-AH-CI?CB_\5PVNNPW=XF+RV&TP!, !]H&6;C.
M20=W'3.7\0O&^AWWAR]\,RNJZGJ&;1(&8.8G/W&8)N/##D $@C'7&?4JY;1?
MAQX1\/ZH=3T[1HTOBQ;[1++),X)SD@NS8)R<D=:+2[A[2E_)^+_K^EYWRO .
MCP>!/"\6E1Z=?M-N,][,8@22P'S#;G/0#:N2 #GWZ*[U&.\LY[2^T:]:WEC9
M+F-HMP\IACL?FR#RJY(Y]L[E%%I=P]I2_D_%_P!?TO._EOA'P)I?@K7)-1L$
M\1B/#%K25E>&)&_BPHRYX' )88.<\9TO&7AK1_&L<#:GI.JVM[:'>E[:J!-
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M@#SSXJ_\RM_V&H*]#[5YY\5?^96_[#4%>A]JUE\$?F(****R&%%%% !1110
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M\06T?P9IM@/"^N78A1AY]M;;HWR['@]^N*]1\1_\BOJW_7E-_P"@&L+X6_\
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M_"TW_P"A,\2_^ E'_"TW_P"A,\2_^ E>AT4<T/Y?Q \\_P"%IO\ ]"9XE_\
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MA_+^('GG_"TW_P"A,\2_^ E'_"TW_P"A,\2_^ E>AT4<T/Y?Q \\_P"%IO\
M]"9XE_\  2C_ (6F_P#T)GB7_P !*]#HHYH?R_B!YY_PM-_^A,\2_P#@)1_P
MM-_^A,\2_P#@)7H=%'-#^7\0///^%IO_ -"9XE_\!*/^%IO_ -"9XE_\!*]#
MHHYH?R_B!YY_PM-_^A,\2_\ @)1_PM-_^A,\2_\ @)7H=%'-#^7\0///^%IO
M_P!"9XE_\!*/^%IO_P!"9XE_\!*]#HHYH?R_B!YY_P +3?\ Z$SQ+_X"4?\
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M]#HHYH?R_B!YY_PM-_\ H3/$O_@)1_PM-_\ H3/$O_@)7H=%'-#^7\0///\
MA:;_ /0F>)?_  $H_P"%IO\ ]"9XE_\  2O0Z*.:'\OX@>>?\+3?_H3/$O\
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M4?\ "TW_ .A,\2_^ E>AT4<T/Y?Q \\_X6F__0F>)?\ P$H_X6F__0F>)?\
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M#^7\0///^%IO_P!"9XE_\!*/^%IO_P!"9XE_\!*]#HHYH?R_B!YY_P +3?\
MZ$SQ+_X"4?\ "TW_ .A,\2_^ E>AT4<T/Y?Q \\_X6F__0F>)?\ P$H_X6F_
M_0F>)?\ P$KT.BCFA_+^('GG_"TW_P"A,\2_^ E'_"TW_P"A,\2_^ E>AT4<
MT/Y?Q \\_P"%IO\ ]"9XE_\  2C_ (6F_P#T)GB7_P !*]#HHYH?R_B!YY_P
MM-_^A,\2_P#@)1_PM-_^A,\2_P#@)7H=%'-#^7\0/+_AEJ)U;QKXROC:SVIF
M>W;R;A=KI]_@CM7J%>>>"?\ DI7CK_KK;_R>O0Z*WQ_=^0(S/$?_ "*^K?\
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M_9M\JN0"<@*S?3<I_P"V9Z=:];H **** "BBB@ HHHH **** "BBB@ HHHH
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M:!R+'Q!&+^V7><+)@EL*>.2'Z=E'X>N4 %%%% !1110 4444 %%%% !1110
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M[I0<Y[>GOCFN7^&]C>^+_'FJ_$?4;22UM)4^S:5#*N"8\ ;^O]T8[@EVQT%
M%;XAZ;'XO^-OA?PY-+-]D@LWN;CR7P5!W$C(/R[MB ]#AA[5W/B[PYH,'PZU
MNT&EV<-I#I\SJL<"@1E8R0PP.H(!S[5R/AEAK'[17BF_"EH=/LEM4)_A?Y >
M_JLG_P"NNB^,E_\ V?\ "K6W5]KS(D"C.,[W4$?]\EJ ,SX/S/I/P3M;ZZD
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MAT3GJHYSUXS_ 'E- %?PYJ-EHQN?B5X\NTLKW5QLT^V?]XT%MU5451G)!!)
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M6['OMW8_]J&O7Z\>\5[-:_:%\+:<CAET^V-Q-QG:WSL!T]D_/UKV&@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH \\\$_P#)2O'7_76W_D]>AUYYX)_Y
M*5XZ_P"NMO\ R>O0ZTJ_%\E^0D9GB/\ Y%?5O^O*;_T UA?"W_DFNB_]<W_]
M&-6[XC_Y%?5O^O*;_P! -87PM_Y)KHO_ %S?_P!&-37\-^H=3L****R&%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MVF R>@ZU=HH *XU_!UU<_%=/%UU+;-;6MA]DM(@"9 Q))8G&!]]QQG@UV5%
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M:LC!A.YW;I0 >,9/49Y4]N/1:** "BBB@ HHHH **** "BBB@ HHHH ****
M///BK_S*W_8:@KT/M7GGQ5_YE;_L-05Z'VK67P1^8@HHHK(84444 %%%% !1
M110 4444 %%%% !1110 53O-)TW49[:>^T^TNIK5]]O)/"KM"V0<H2,J<@<C
MT%7** (YX(;JWDM[B))895*21R*&5U(P00>"".U8?_"">#_^A4T/_P %T/\
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M $%W9VNH6LEK>VT-S;2##PS('1A[@\&GV]O#:6T5M;0QPP1*$CBC4*J*!@
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M :POA;_R371?^N;_ /HQJJ,N6F_4.IF?V9\5?^@]H/\ WY;_ .(H_LSXJ_\
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M9GQ5_P"@]H/_ 'Y;_P"(H_LSXJ_]![0?^_+?_$5Z'11[5]E]P6///[,^*O\
MT'M!_P"_+?\ Q%']F?%7_H/:#_WY;_XBO0Z*/:OLON"QYY_9GQ5_Z#V@_P#?
MEO\ XBC^S/BK_P!![0?^_+?_ !%>AT4>U?9?<%CSS^S/BK_T'M!_[\M_\11_
M9GQ5_P"@]H/_ 'Y;_P"(KT.BCVK[+[@L>>?V9\5?^@]H/_?EO_B*/[,^*O\
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M:#_WY;_XBCXJ_P#,K?\ 8:@KT/M5RJ>Y'1=>@6///[,^*O\ T'M!_P"_+?\
MQ%']F?%7_H/:#_WY;_XBO0Z*CVK[+[@L>>?V9\5?^@]H/_?EO_B*/[,^*O\
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M0@Y!'M7F&D_&^_\ $6G?\23P9=WNJ^:0UM#.9(XHP!AWDV *6.\!2/X>O(R
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MQIN]49C'+$^-T4@QE3CZ@_0BN<\2_%!=.UR30/#FB7?B+6(1F>.U.([?MAW
M.".,C&.<9!XH ]!HKS+1OBM>+XFMM!\7^&I_#\]X=MI.\N^*1O[N< =<#()Y
M(Z5W'B+Q%IGA;19]6U:X$-M$/JSMV51W8^G],F@#5HKR6;XK>+9+&75[+X<7
MS:/$GF^=<7'EN\?7>%VYQCGC<.^<5W?A#Q?IOC/PY'K6GLR19*31R8#0N.2K
M=NA!SZ$&@#?HKR^X^+EUJNKW.G>"?"]UXA6U.V:\$PB@#?[+$$,#SC)&<<9'
M-7_"/Q*GUGQ1/X8U_09=$UE(_-CB:7S%E7J<' QQSW!P>>,4 =+XK\6Z5X,T
ME-2UB21+9YA"#&FXEB"1Q]%-0^,O&5AX(\/?VQJ,-Q)&94B6*%06+-DXZX&
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M97/90,GCN?;O7S1XPL;OQ7X.UCXCZO&\3W5Q';Z7;'I%;AOO>Y/KQ_$?XA@
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M&VX39GHV<8QWQ6#\$UNI?A5IR7\;-'OD\@2C.Z+>=O7MUQ[8[8H K_\ "_/
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M_5QS;G/)_AX*\^_H#B#PSK&FW?Q4\7>++2YC_P"$?@L8HYKX K&\@52<?WB
M#[\CU&0#T+Q'XLTOPN+)=0:5IKZ;R;:"",R22M[*.2!D?F/6KFM:A/IFAW>H
M6UD;R6WB,HMQ)L+@<D D'G&?Y5Y]X%T^[\9^)9?B'K=OY<)4PZ+:R#F&$$CS
M/JW//N2."*]1H QO"GB2T\6^'+36+/"I.GSQ[MQB<?>0^X-;->0_"IVT#Q[X
MP\&JY-G!<?:[1"OW%8X//T,?MP3WKUZ@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH \\\$_\E*\=?]=;?^3UZ'7GG@G_ )*5XZ_ZZV_\GKT.M*OQ?)?D
M)&9XC_Y%?5O^O*;_ - -87PM_P"2:Z+_ -<W_P#1C5N^(_\ D5]6_P"O*;_T
M UA?"W_DFNB_]<W_ /1C4U_#?J'4["O._CAJ!L/A5J:JQ5[IXH%(..K@D?BJ
ML/QKT2O)/CS9ZEJFC:'I]CI&H:E";[[1<)96SR$*B[>2H.TD.<9Z\^E9#*FA
M?!:[70-/SXUUVT9K=&>WMYBL<;%06"C(XR3VKM/!O@.7PG?7-U+XCU75C-&(
MPE[*65.<Y SUXKF5^+7B%5"K\+?$84#  ADP/_(==AX,\4ZEXH@NY=0\,W^A
MB!E5%O0P:7(.2 57@<<^_M0!P_AR"#7_ -HKQ-J<D:RQZ3:I;P;QDI)A5+#G
M /$H_'US70_&NXBM_A-K0E"L9?)C13W8RI_+!/X5F_"#2M4AU#QAK>K6%S93
M:IJ99([F)HV*J68$!OX?WF ?8\\4OQOTS4M>\/:/HVFV%W=-<ZE&TSP0LZQ1
MA6!+$ [1EP<GT- &_H>/#/P?LY6W(;'11/)U)#"+>WH>N:Q?@/8?8OA99R^7
ML:[N)ISQ@M\VP'\D%=1X[TJ\U?P#K6F:8J_:IK1DBCZ;N/NCTR!@=N>>*Y/X
M0Z_JITNV\*ZIX8U/3I=,M3NN[B)EBDPP 49 ^8AL_P# 2: ..U/7-4OOCKJN
MHV?A>7Q&-$C6VMH$F6-;9NI<G:V6W>9CN/\ @(KJ[SQYXYO+&XMF^%=WMFC:
M,[[]67!&.1Y?(YZ54UE->^'/Q'U7Q+8:#<ZUHNMI'YZVH)E@E48Z#)QU.2 /
MF SD<S3?$#QEXP"Z?X/\+7^EF5E#ZMJ<85(%S\Q"D%6/XD^WH 1>&+35O!O[
M/NK)J=O)9WT-O=M'')@E-V0IQR.IS@UT'P8T:+2/AAI3+&HFO%:ZE<+@L68[
M<^N%VC\*@^,-KJMS\*YM,M;:ZU.^N'@B<6EJSLY5@[-M4':,I]!D#/KVV@V(
MTOP[IFGJ"!:VD4 !ZC:@7^E 'F/B>V3Q=\>M$T*]7?IND69OVA(R)9">XSC&
M?+XP<X(Z'CUZO*_'FC:[H7C[3O'OA[2VU01P?9+^RC!:1DR?F0#G.#CCH0.#
MDU6OOB/XL\4VS:5X3\&ZK97=POEOJ&H(8H[7)P6'&"1SWR,?=/2@"'X47)LM
M8^)>HJH_LJ+4Y)(-N%3Y6E9L>GR^7[=*M_ NP:ZT#4O%M_LEU36;V5WGV@$(
M#]T>@W;CCIPOI76^"?!%KX2\$Q^']_FM*C-=RKQYDCC#D<#CL,\X KS/POKO
MB3X1)=>&M:\-:CJFE1S/+9W]C%N!4GI@9&"?FP2&4GOD8 /9-=\/:3XET\6&
MLV,5Y;!Q($DSPPS@@CD'!(_$UYE\0[8>)_B]X0\'SKG2XHCJ$\7 20#?A2/3
M$17Z.:U-#O?''C/Q;;:G=6EYX:\-6>2+2;"SWC^C@C(7('8<<#.21#\2?#_B
M"S\6:/X]\-6IO[K38C;W-BN=\L)+?= Z\.PX&1D$ XH ]150JA5 "@8 '05X
MQ\/[R"V^)OQ,U&V;-A;OYDH4D*SAG+'GCJLG/N<<5<N_BGXBU^V.F^%?!6L1
M:G/F,SWT7EQ6_'+%NF1[D=NO0]/\/_ B>$_!TFF7LOVB_OM\FH3JQ.]V&" 3
MSP.,]SD]Z .<^!=@UUH&I>+;_9+JFLWLKO/M (0'[H]!NW''3A?2O1==\/:3
MXET\6&LV,5Y;!Q($DSPPS@@CD'!(_$UXWX7UWQ)\(DNO#6M>&M1U32HYGEL[
M^QBW J3TP,C!/S8)#*3WR,=7H=[XX\9^+;;4[JTO/#7AJSR1:386>\?T<$9"
MY [#C@9R2 #,^($0\3?%[PCX.E"MID*'4;B'"E7V[\*1Z8CQCT>O7E4*H50
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MN@Q?M&^)=4DUO34T^;3$2*[:Z01.VVWX#YP3\K< ]CZ5WO\ PJ#P#_T+=O\
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M_LM>P5X_\+\>(?B;XS\61Q9M3*+.VG# AP#SC'LL9_$=:]@H **** "BBB@
MHHHH **** "BBB@ HHHH **** ///!/_ "4KQU_UUM_Y/7H=>>>"?^2E>.O^
MNMO_ ">O0ZTJ_%\E^0D9GB/_ )%?5O\ KRF_] -87PM_Y)KHO_7-_P#T8U;O
MB/\ Y%?5O^O*;_T UA?"W_DFNB_]<W_]&-37\-^H=3L****R&%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M >>?%;_5^%_^PW!_6O0Z\\^*W^K\+_\ 8;@_K7H=:R^"/S$%%%%9#"BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ K#U#PIIVI^*--\0737#7>FHRVT8?$
M:EL@L1C).#ZXX'%;E% !1110 4444 %%%% !1110!R>K^##>>.=(\5V%XMK>
M6BF&Y0Q;A<PGL3D$$9.#SV]*ZRBB@ HHHH **** "BBB@ HHHH **** "BBB
M@#D8_!DD_P 2&\7:E>K<?9[?[/IUJD>T6X.=S$Y^9CENW\1]!77444 %%%%
M!1110 4444 %%%% !1110 4444 >>?%7_F5O^PU!7H?:O//BK_S*W_8:@KT/
MM6LO@C\Q!11160PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L-
M/"FG+XQD\4LUP^HO;BV4,_[N./@X50.Y&>2>IK<HH **** "BBB@ HHHH **
M** .3TKP7_8OC[5O$-C=I'9ZK$OVJR\KK,I_U@8'C.6)R#DL:ZRBB@ HHHH
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M'_GG??\ @2?\*/\ A2WA'_GG??\ @2?\*]#HH]M4[A9'GG_"EO"/_/.^_P#
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MX1_YYWW_ ($G_"O0Z*/;5.X61YY_PI;PC_SSOO\ P)/^%'_"EO"/_/.^_P#
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M/_/.^_\  D_X5Z'11[:IW"R///\ A2WA'_GG??\ @2?\*/\ A2WA'_GG??\
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M/_/.^_\  D_X5Z'11[:IW"R///\ A2WA'_GG??\ @2?\*/\ A2WA'_GG??\
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M$<K 9"[=QV@XQR2.>F* /8**X?P+XUEU_P"&*>(]1\J.>WAE^TL.%)CSECT
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M\3:'/X:\-Q33W^JK]E66Z"00QA^"2SGKCI]>N< @'K^A:O;Z_H-CJ]J&$%Y
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MYW2$CD=",^@8]JXWQMX;M/">M?";1K, I;ZEAY-N#*_FV^YS[D\T >\T444
M%>&:E\8M9N?B?I^EZ,L T"74XM/\YXMQF8.@E*MGC[XQ[8/>NL^*WB6]AM;3
MPAX?S)X@UPF-%5L&&'G=(2.1T(SZ!CVKC?&WANT\)ZU\)]&LP"EOJ6'DVX,K
M^;;[G/N30![=JNH1:1H][J4X8PV=O)<.%ZE44L<?@*\A_P"$N^(D/@M?'TMW
MI4FFDK,=)2#!$)?;_K#R&Z>O7\*]=U?38]8T6_TN9W2*\MY+=V3&Y5=2I(SW
MYKR3_A#_ (A2>"QX DATD:9_JCK'G'=Y(D# >5C.[ QZ>^?FH ].NO$VGV'A
M(^)+R0Q6 M5N23UPP!"C.,L20 .Y(K*^'VI>(]<T1]9U]8K=+U_,LK-8\-##
MD[=S?Q$@CL. /6N--E%\1/%EMX<M@[>#O"^U+A]V5O;A0 L>>A"@<X]_[RD>
MOJJHH50%4#  ' % 'FFKZY?^$?C#IL-U?S2:#X@A,:1W$Q*VUPO]S/0$E!C/
M5SZ 5Z97E/Q_M'?P#;:C =D^GW\4RR <J"&7CTY*G\*]-TZZ%]IEI=K@K/"D
M@QT^8 _UH LT444 %%%% !1110 4444 %%%% !1110!YY\5?^96_[#4%>A]J
M\\^*O_,K?]AJ"O0^U:R^"/S$%%%%9#"BBB@ HHHH **** "BBB@ HHHH ***
M* "O#-4^,6LW'Q-L-+T58!H$NI1:>9GBW&9@Z"4JV>/OC'M@]ZZSXK>);V"U
MM/"/A_,GB#7"8HU5L&&'G<Y(Y'0C/H&/:N-\;^&[3PGJWPIT:S *0:EAY-N#
M*YE@W.?<F@#WAF"J68@*!DD]J\@M_&GCOXA7E\W@6+2[#1K28P+?7V2TS#G(
M&#@$%3C;QGKZ>N7$"7-M+;R9\N5"C8/8C!KP?P=XVMOA'/?^#O% W1PW#2V]
MU9LLN5;G#H#N7/!&>>>G<@'4:+XZ\5:#XRL/"OCJUL6>_4BTU"R)VR-DXW#W
M(QT&,CCG->J5X6NL+\8_B;HDVEJ+?1?#TIN6DFE19I6W*V1'DMM+*@SZ9R0<
M"O8?$>JKH?AK4]48C_1+:249[L%) _$X% '%^!]:U+Q'\1/%]X]Q<_V18RK8
MVD+/B,.O#D+ZG:#D\_-]:R=;\5^.]1^*&J^&/"4VFK%8P1RL;Q.!E4) (R3R
MWIV-;OP8TE]-^'%G<3MON-1=[Z5\Y+%SP2>YVA<UP.GZEXIT?XI^,KW2/"%]
MJ-Q=3^7$T@,,(C5B-Y8\'.!C!&>3VQ0!UUI;_&;[9!]JO/#GV?S%\W:&SMSS
MCY>N*]!UK6+30-%N]5U!RMM:QF20J,D^P'J3@#ZUYK8?%S5=*UZTTGQWX:;1
M3>8$-TC[X\].>O&<="<9&>.:]2N[.UU"TDM;RVAN;:48>*9 Z..O(/!H \DT
M[7/BMX[MSK'A\:1H>DNQ%LEZ"TDJY^\3L;^2CTSUK9\$^.?$$WBVZ\'>,-/A
MM]6AA,\-S;_ZNX3(Y'X'((]"" 1BMOQ3XY\-_#NWL;74%DMXI(RMM!:P9550
M ;0!@ <@ 5PW@N63XC_%)_'D<:6VEZ=";6UB=T:9C@C+JIRO#L>?8 D4 >ST
M45A^,]1.D^"=;OD8K)#92F,@9P^TA?U(H Y/P/K]]XS\<^(=8CO)AH%@PL+&
M!'/E3,#EI3ZGH1[.!V%-\<?$#6+7Q-;^$/!UA%>Z[*HDGDER4M5//S#@="#D
MG R."2*L?!/3TL?A;IC@$27)DGD)&,DN<?H!7-Z'<P:!^T5X@@U9HXI=4MT-
MC-)T?.T[ 3ZXQCIE,>E #[_6_BSX(M!K6NC2-:TM"/M4-H"LD*_WL[5_/YA[
M=Z]3T/6;/Q#HEGJU@Y:VNHQ(F>HSV/N#P?<5E>/M>T[P]X*U2ZU&6-4DMY(8
MHF?!F=E("+WR<]N@R>@KS[X/ZK-:_!#5;KS"OV#[6\1.3L 3?_,D\4 7+[QQ
MXM\8^)[_ $3X?II\-IIS;+G5+P[E9^>%P",$@] V<9R!2Z?XY\7>$O$]EHOQ
M M[*2UU!Q':ZI9@A _ PW XR1V7&<\CI<^ UDMM\,+:X7;F\N9IFP.20Y3G\
M$%)\>K*&Z^&%S-(H+VMQ%+&?0D[3^C&@#TZBL[0+HWWAW3;MLYGM8Y#GKRH-
M4/'.HRZ5X%UR^MV*S16<AC8#.UB, _@3F@#AKCQIXP\;ZW>V/P]2PM]-L',4
MVJWIW)+(.R !N/?!XY)&12:=XW\8>$?%=EH/CZ*QGM=08+;:K:92-6/\)X /
M.!T4C.>17._#_P ;7^G>$-,T#P7X:GUR^2,S7\[R>7%#([$[2Q !.#ZC '?G
M'3:9X\BU?Q):>&/B#X0AT[5"V^S>X19X9).Q0D$ ]@02,C&<\4 =3\1?%=QX
M1\+K>6,4<M_=7,=I:K*"4\Q\\M@CC /Z5S<?B#QGX1\4:!8>)[ZPU6SUEV@$
MEO!Y36\O&,8^\.1V'7VYZ/XC>$;CQCX76RL;I;:_M;A+NU=A\AD0$ -P>,,?
MQQ7+WNF^)]8UC2]>\:6^FZ/I'AS?=-]GN#(]P^T8(_NKE<X//;G.0 =1\0?%
M[^%-#C6QB^TZUJ$GV;3K8<EY#_%CT7(/U('&<UNZ/!J0T*WBUJX2>_:/_2)(
M%\L;CU"X.1C.,Y[9K@/ FG7'C+Q%-\0]:MWC1_W6BVDG_+" <>9C^\W/YDC@
MC'J% 'FOP]U_4+7Q9XB\%:W?27=SI\WG6=Q<2[I98&Y / R0"I_X%[5Z57D'
MC$-I'Q_\(ZFC!([ZW:UD&/OGYQR?^!)^0KU^@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH \\\$_\E*\=?\ 76W_ )/7H=>>>"?^2E>.O^NMO_)Z]#K2
MK\7R7Y"1F>(_^17U;_KRF_\ 0#6%\+?^2:Z+_P!<W_\ 1C5N^(_^17U;_KRF
M_P#0#6%\+?\ DFNB_P#7-_\ T8U-?PWZAU.PKRS]H"^:V^&WV1-Q>_O8H-J]
M3C+]._*#\<5ZG7$?$7P!<>/(]+2'6O[,^P3-.&%KYI9^-I'SKC&#ZYS[5D,W
M=)\,:3I^CV-E_9EH?L]O'%EH58_*H').2>GJ:TK:PL[-F:UM((&88)BC"D_D
M*\P_X5=XU_Z*MJG_ ("M_P#'JZ_P9X8U?PW!=KJ_BB[UZ2=E*/<(4$0 / !9
MNN>3["@#B_AV#JOQE^(&LN 6MY4L58KS@$J0./\ IBN?PK1^/&H_8?A;>0@X
M:]N(;<'./XMY_1"/QK<\!>!4\$6^J!K_ .W7&H79N9)O(\K (X7&XYP2QS[]
M*7QYX(/CB'2K:34C:6ME>+=2QB'>9L< 9W#;P6YYZT -UK=X4^$-U%D"33]%
M,"X&1O6+8OX9Q5/X-:>-/^%6BKD,TZ/.Q _ONQ'Y# _"NJU_1;7Q'H%]H][N
M^SW<1B8KU7/1A[@X(^E<GX \ :QX)N9(9O%4VI:0L+1VUB\&P1L6#;L[CTP1
M@?WB>* .!L?"][XL^,WC4KXBU+1KBV:,![&4H\D9  !((X 5>/<5TM_\+[FS
ML)I]1^*/B2"S5<2R7%^5C"GCYBS8QSCGUK7\7_#236_$">)- URXT+6P@BEG
MA3<LZ#^\ 02?NC))&% QP",R'X4:QK5S#)XW\87FLVL3AQI\2>5"Y'0M@\_@
M >>M #=?T:Q^'?P&UBPLKR6[@>%T29BN7,[!.,8&,-[\9Z]*ZOX::>-,^&OA
MZV"A2;))F &,&0;SGWRQS[TGCKP7_P )AX1'AZUOH],@\R,EEM_, 1.B!0R@
M<[?RZ=QTMK;K:6<%LGW8HUC'T Q0!Y7, _[3EO\ :U)*:,?LA8#C[V=N?K)T
M]_>O4[R\M]/LI[R[F2&V@0R2R.<!5 R2:Y3QS\/;3QD]E>Q7TVF:Q8MNM;^
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M 'GGQ6_U?A?_ +#<']:]#KSSXK?ZOPO_ -AN#^M>AUK+X(_,04445D,****
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M1M*,:QR6]J@E5>GF$9<_BQ8UY!JMYXNB^+]YXCN? FH:O;V.^UTU$W)&BJQ
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MXS\0ZOXI\&W=_P"";W3)["^\VVMY9BQO&WQ'8IV#!RJCH?O"OI:N/\8>!?\
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M8>)+OQ#<6AW6T$B;(8SZE<G/(![=.<UZ+?6%KJ=A/8WL"3VLZ&.6)QPRGJ*
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M /@,_P#A1[&I_*PNCOJ*X'_A<O@O_G_G_P# 9_\ "C_A<O@O_G_G_P# 9_\
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M_@,_^%'L:G\K"Z.^HK@?^%R^"_\ G_G_ / 9_P#"C_A<O@O_ )_Y_P#P&?\
MPH]C4_E871WU%<#_ ,+E\%_\_P#/_P" S_X4?\+E\%_\_P#/_P" S_X4>QJ?
MRL+H[ZBN!_X7+X+_ .?^?_P&?_"C_A<O@O\ Y_Y__ 9_\*/8U/Y6%T=]17 _
M\+E\%_\ /_/_ . S_P"%'_"Y?!?_ #_S_P#@,_\ A1[&I_*PNCOJ*X'_ (7+
MX+_Y_P"?_P !G_PH_P"%R^"_^?\ G_\  9_\*/8U/Y6%T=]17 _\+E\%_P#/
M_/\ ^ S_ .%'_"Y?!?\ S_S_ /@,_P#A1[&I_*PNCOJ*X'_A<O@O_G_G_P#
M9_\ "C_A<O@O_G_G_P# 9_\ "CV-3^5A='?45P/_  N7P7_S_P __@,_^%'_
M  N7P7_S_P __@,_^%'L:G\K"Z.^HK@?^%R^"_\ G_G_ / 9_P#"C_A<O@O_
M )_Y_P#P&?\ PH]C4_E871WU%<#_ ,+E\%_\_P#/_P" S_X4?\+E\%_\_P#/
M_P" S_X4>QJ?RL+H[ZBN!_X7+X+_ .?^?_P&?_"C_A<O@O\ Y_Y__ 9_\*/8
MU/Y6%T=]17 _\+E\%_\ /_/_ . S_P"%'_"Y?!?_ #_S_P#@,_\ A1[&I_*P
MNCOJ*X'_ (7+X+_Y_P"?_P !G_PH_P"%R^"_^?\ G_\  9_\*/8U/Y6%T=]1
M7 _\+E\%_P#/_/\ ^ S_ .%'_"Y?!?\ S_S_ /@,_P#A1[&I_*PNCOJ*X'_A
M<O@O_G_G_P# 9_\ "C_A<O@O_G_G_P# 9_\ "CV-3^5A='?45P/_  N7P7_S
M_P __@,_^%'_  N7P7_S_P __@,_^%'L:G\K"Z.^HK@?^%R^"_\ G_G_ / 9
M_P#"C_A<O@O_ )_Y_P#P&?\ PH]C4_E871WU%<#_ ,+E\%_\_P#/_P" S_X4
M?\+E\%_\_P#/_P" S_X4>QJ?RL+H[ZBN!_X7+X+_ .?^?_P&?_"C_A<O@O\
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M\_\ /_X#/_A1[&I_*PNCOJ*X'_A<O@O_ )_Y_P#P&?\ PH_X7+X+_P"?^?\
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M_ 9_\*/8U/Y6%T=]17 _\+E\%_\ /_/_ . S_P"%'_"Y?!?_ #_S_P#@,_\
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M_ 9_\*/8U/Y6%T=]17 _\+E\%_\ /_/_ . S_P"%'_"Y?!?_ #_S_P#@,_\
MA1[&I_*PNCOJ*X'_ (7+X+_Y_P"?_P !G_PH_P"%R^"_^?\ G_\  9_\*/8U
M/Y6%T=]17 _\+E\%_P#/_/\ ^ S_ .%'_"Y?!?\ S_S_ /@,_P#A1[&I_*PN
MCOJ*X'_A<O@O_G_G_P# 9_\ "C_A<O@O_G_G_P# 9_\ "CV-3^5A='?45P/_
M  N7P7_S_P __@,_^%'_  N7P7_S_P __@,_^%'L:G\K"Z.^HK@?^%R^"_\
MG_G_ / 9_P#"C_A<O@O_ )_Y_P#P&?\ PH]C4_E871WU%<#_ ,+E\%_\_P#/
M_P" S_X4?\+E\%_\_P#/_P" S_X4>QJ?RL+H[ZBN!_X7+X+_ .?^?_P&?_"C
M_A<O@O\ Y_Y__ 9_\*/8U/Y6%T=]17 _\+E\%_\ /_/_ . S_P"%'_"Y?!?_
M #_S_P#@,_\ A1[&I_*PNCOJ*X'_ (7+X+_Y_P"?_P !G_PH_P"%R^"_^?\
MG_\  9_\*/8U/Y6%T=]17 _\+E\%_P#/_/\ ^ S_ .%'_"Y?!?\ S_S_ /@,
M_P#A1[&I_*PNCLCI6GG5AJILH/[0$7DBYV#S-F<[=W7&:N5P/_"Y?!?_ #_S
M_P#@,_\ A1_PN7P7_P _\_\ X#/_ (4>QJ?RL+H[ZBN!_P"%R^"_^?\ G_\
M 9_\*/\ A<O@O_G_ )__  &?_"CV-3^5A='?45P/_"Y?!?\ S_S_ /@,_P#A
M1_PN7P7_ ,_\_P#X#/\ X4>QJ?RL+H[ZBN!_X7+X+_Y_Y_\ P&?_  H_X7+X
M+_Y_Y_\ P&?_  H]C4_E871WU%<#_P +E\%_\_\ /_X#/_A1_P +E\%_\_\
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M /@,_P#A1[&I_*PNCOJ*X'_A<O@O_G_G_P# 9_\ "C_A<O@O_G_G_P# 9_\
M"CV-3^5A='?45P/_  N7P7_S_P __@,_^%'_  N7P7_S_P __@,_^%'L:G\K
M"Z.^HK@?^%R^"_\ G_G_ / 9_P#"C_A<O@O_ )_Y_P#P&?\ PH]C4_E871%X
M)_Y*5XZ_ZZV_\GKT.O,/AGJEIK7C;QEJ-BY>VG>W:-F4J2/G[&O3Z=96G9^7
MY C,\1_\BOJW_7E-_P"@&N>^%T$+_#;1F:)"3&^25'_/1JZ'Q'_R*^K?]>4W
M_H!K"^%O_)-=%_ZYO_Z,:A?PWZAU.K^S0?\ /"/_ +X%'V:#_GA'_P!\"I:*
MR&1?9H/^>$?_ 'P*/LT'_/"/_O@5+10!%]F@_P">$?\ WP*/LT'_ #PC_P"^
M!4M% $7V:#_GA'_WP*/LT'_/"/\ [X%2T4 1?9H/^>$?_? H^S0?\\(_^^!4
MM% $7V:#_GA'_P!\"C[-!_SPC_[X%2T4 1?9H/\ GA'_ -\"C[-!_P \(_\
MO@5+10!%]F@_YX1_]\"C[-!_SPC_ .^!4M% $7V:#_GA'_WP*/LT'_/"/_O@
M5+10!%]F@_YX1_\ ? H^S0?\\(_^^!4M% $7V:#_ )X1_P#? H^S0?\ /"/_
M +X%2T4 1?9H/^>$?_? H^S0?\\(_P#O@5+10!%]F@_YX1_]\"C[-!_SPC_[
MX%2T4 1?9H/^>$?_ 'P*/LT'_/"/_O@5+10!%]F@_P">$?\ WP*/LT'_ #PC
M_P"^!4M% $7V:#_GA'_WP*/LT'_/"/\ [X%2T4 1?9H/^>$?_? H^S0?\\(_
M^^!4M% $7V:#_GA'_P!\"C[-!_SPC_[X%2T4 1?9H/\ GA'_ -\"C[-!_P \
M(_\ O@5+10!%]F@_YX1_]\"C[-!_SPC_ .^!4M% $7V:#_GA'_WP*/LT'_/"
M/_O@5+10!%]F@_YX1_\ ? H^S0?\\(_^^!4M% $7V:#_ )X1_P#? H^S0?\
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M\"C[-!_SPC_[X%2T4 1?9H/^>$?_ 'P*/LT'_/"/_O@5+10!%]F@_P">$?\
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M/_O@5+10!%]F@_YX1_\ ? H^S0?\\(_^^!4M% $7V:#_ )X1_P#? H^S0?\
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M\_\ 31N_7-4O!/AI/BO?WGC;Q>DES9-.T.F:>TC".-%(^; //(QCH2&)!R*
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M;1MZMD%QT[]>:[R@#RCXG?$:XLM2B\&^&KFWBUJ\ 6>\EF5$LU.>K$\-CGU
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MEOL\KQ*Q_P!U2!^0H XOQMJ-IXG^,WA"T\.31W=[ITV^]GMR76.,.I*EAD<
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MXWMG(W#'.:J,>:F_4.I[)17GG]N?%#_H4M,_\#%_^+H_MSXH?]"EIG_@8O\
M\72]D^Z^]!<]#HKSS^W/BA_T*6F?^!B__%T?VY\4/^A2TS_P,7_XNCV3[K[T
M%ST.BO//[<^*'_0I:9_X&+_\71_;GQ0_Z%+3/_ Q?_BZ/9/NOO07/0Z*\\_M
MSXH?]"EIG_@8O_Q=']N?%#_H4M,_\#%_^+H]D^Z^]!<[73M&TS2//_LZPMK3
M[1(99O(C";W/<XZFKU>>?VY\4/\ H4M,_P# Q?\ XNC^W/BA_P!"EIG_ (&+
M_P#%T>R?=?>@N>AT5YY_;GQ0_P"A2TS_ ,#%_P#BZ/[<^*'_ $*6F?\ @8O_
M ,71[)]U]Z"YZ'6;_P (]HG]K?VM_8^G_P!I9W?;/LR>=G&,[\;NG'7I7'?V
MY\4/^A2TS_P,7_XNC^W/BA_T*6F?^!B__%T>R?=?>@N>AT5YY_;GQ0_Z%+3/
M_ Q?_BZ/[<^*'_0I:9_X&+_\71[)]U]Z"YZ'17GG]N?%#_H4M,_\#%_^+H_M
MSXH?]"EIG_@8O_Q='LGW7WH+GH=%>>?VY\4/^A2TS_P,7_XNC^W/BA_T*6F?
M^!B__%T>R?=?>@N>AT5YY_;GQ0_Z%+3/_ Q?_BZ/[<^*'_0I:9_X&+_\71[)
M]U]Z"YZ'17GG]N?%#_H4M,_\#%_^+H_MSXH?]"EIG_@8O_Q='LGW7WH+GH=%
M>>?VY\4/^A2TS_P,7_XNC^W/BA_T*6F?^!B__%T>R?=?>@N>AT5YY_;GQ0_Z
M%+3/_ Q?_BZ/[<^*'_0I:9_X&+_\71[)]U]Z"YZ'17GG]N?%#_H4M,_\#%_^
M+H_MSXH?]"EIG_@8O_Q='LGW7WH+GH=%>>?VY\4/^A2TS_P,7_XNC^W/BA_T
M*6F?^!B__%T>R?=?>@N>AT5YY_;GQ0_Z%+3/_ Q?_BZ/[<^*'_0I:9_X&+_\
M71[)]U]Z"YZ'17GG]N?%#_H4M,_\#%_^+H_MSXH?]"EIG_@8O_Q='LGW7WH+
MGH=%>>?VY\4/^A2TS_P,7_XNC^W/BA_T*6F?^!B__%T>R?=?>@N>AT5YY_;G
MQ0_Z%+3/_ Q?_BZ/[<^*'_0I:9_X&+_\71[)]U]Z"YZ'17GG]N?%#_H4M,_\
M#%_^+H_MSXH?]"EIG_@8O_Q='LGW7WH+GH=%>>?VY\4/^A2TS_P,7_XNC^W/
MBA_T*6F?^!B__%T>R?=?>@N>AT5YY_;GQ0_Z%+3/_ Q?_BZ/[<^*'_0I:9_X
M&+_\71[)]U]Z"YZ'17GG]N?%#_H4M,_\#%_^+H_MSXH?]"EIG_@8O_Q='LGW
M7WH+GH=%>>?VY\4/^A2TS_P,7_XNC^W/BA_T*6F?^!B__%T>R?=?>@N>AT5Y
MY_;GQ0_Z%+3/_ Q?_BZ/[<^*'_0I:9_X&+_\71[)]U]Z"YZ'17GG]N?%#_H4
MM,_\#%_^+H_MSXH?]"EIG_@8O_Q='LGW7WH+GH=%>>?VY\4/^A2TS_P,7_XN
MC^W/BA_T*6F?^!B__%T>R?=?>@N>AT5YY_;GQ0_Z%+3/_ Q?_BZ/[<^*'_0I
M:9_X&+_\71[)]U]Z"YZ'17GG]N?%#_H4M,_\#%_^+H_MSXH?]"EIG_@8O_Q=
M'LGW7WH+GH=%>>?VY\4/^A2TS_P,7_XNC^W/BA_T*6F?^!B__%T>R?=?>@N>
MAT5YY_;GQ0_Z%+3/_ Q?_BZ/[<^*'_0I:9_X&+_\71[)]U]Z"YZ'17GG]N?%
M#_H4M,_\#%_^+H_MSXH?]"EIG_@8O_Q='LGW7WH+GH=%>>?VY\4/^A2TS_P,
M7_XNC^W/BA_T*6F?^!B__%T>R?=?>@N>AT5YY_;GQ0_Z%+3/_ Q?_BZ/[<^*
M'_0I:9_X&+_\71[)]U]Z"YZ'17GG]N?%#_H4M,_\#%_^+H_MSXH?]"EIG_@8
MO_Q='LGW7WH+GH=%>>?VY\4/^A2TS_P,7_XNC^W/BA_T*6F?^!B__%T>R?=?
M>@N'Q6_U?A?_ +#<']:]#KP[QWJ?C>X30_[8T"RM FIQ-;>5<!O,EYVJ?F.
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MX;U*73OV>(K^5MDL&CS&,Y[@,$YY_P!FK?P3T];#X4Z2=FV2Y,L[^Y+L ?\
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M+=';%=Q&/?MW;&ZJV.Y! /X4 <!\,?AGX;A\&:=J>IZ7::GJ&HP+=2RWD8F
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M^P:__H-Q0![!4%[96VHV<MG>0)/;2C;)%(,JP]"*GHH YC_A7'@O_H5])_\
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MH(F)R#D9&<=?3.,GI[1+%'/$T4L:R1L,,CC(/U%)#!#;QB.")(D'144*/R%
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M*(%+,22V!U.:RDT$H"!J5X QPX5@NY/[O X/^V/F.3STQ>LK-[0/YEW/<,V
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MUSHOQ<\5>-9M/DFT2.[?2[N6+YGB4D;9 O&0/)7/H&[FNK\2_%A/%6GMX?\
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M7JZ)#<K/J&IRQ[%7 QM'7G#' /)..,#->Z.B2(4D564]0PR#0D:1H$C144=
MHP!0!ROC[Q8? /A ZK!ISWOER1PK&'VJ@/\ $S<D#C'?DBK'VN]\6?#\7FFF
MXTJ^O[/S;??P\,A&5S[9QSW!KHV4,I5@"I&"#T-+0!XUX=^,D7AW3%T;Q];:
ME9Z[:$K)(\!83KDX<8]N_0]0><"3P\=0^*/Q"L_%ES82VGAG1@_]F"8$-<R'
MC?CTXSD< JHYP:]=E@AFQYL228Z;E!Q4E %/5M4M-$TF[U._E$5K:Q&61CZ#
ML/4GH!W) KS[X>:5>^)-<N?B+KL#1SWB>7I-NQ)^SVO8_5LYSWR3_%7IM% '
MC<&LZ?\ #[XO^*;SQ/,]I:ZM%%+8W;0LZ2!1\R@J"01D#'M[C.Q\'H9I[?Q+
MK@@D@T_5]7FNK%95VLT1/#;>P.<?A]*])DBCF7;+&KKG.&&12N66-BB[F )"
MYQD^E 'D.ME=?_:1T2RCWO'HUB9IP!]QR&89YX'SQ?GBO8*X?P!X/O\ 0[S6
M]<UQ[=]:UBY,LHMR6CAC!.U%)&>Y_ +Z9KN* "BBB@ HHHH **** "BBB@ H
MHHH **** ///BK_S*W_8:@KT/M7GGQ5_YE;_ +#4%>A]JUE\$?F(****R&%%
M%% !1110 4444 %%%% !1110 4444 >6>,O$_B?P+X\BUBX2ZO\ P=<0A)HX
M8@WV1\ %LCGJ ?F.#N8=1QE^)?C!8^*-$N?#_@RPU'4M6U&)K<!8"HB1AM9B
M?H>O0=21CGV>HXX(8<^5$B9Z[5 S0!RW@SP:GA_X=6WAJ[<R,]NZW3(W\4F2
MX4^@W$ X["O-_"OBZ3X0/=^$_%UI=K813-)I]]%&9$=&)./SYX[DY KW6FNB
M2(4=593U##(- 'AMWJT_QK\9:5::59W,7A;2I_M%U<SQ[?.D&/E'4=, #KAB
M3V%=!\9I$U-?#/A%&8/JVIQ^:$/(A7AB1_P+/_ 37J21I$@2-%11T"C KF[W
MP>E_X_T[Q3-?/_Q+[9H8;01C;EMP+EL]<-C@=A0!T<420Q)%&JHB*%55&  .
MP%>2ZGXV\0?#WQ[J/_"4+=WOA6].^SNHH01;$DD)QCU((// (]_7:1E#*58
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M_P 1_P#@2W_Q5'_"M=5_Z'_Q'_X$M_\ %4<D/YOP ]#HKSS_ (5KJO\ T/\
MXC_\"6_^*H_X5KJO_0_^(_\ P);_ .*HY(?S?@!Z'17GG_"M=5_Z'_Q'_P"!
M+?\ Q5'_  K75?\ H?\ Q'_X$M_\51R0_F_ #T.BO//^%:ZK_P!#_P"(_P#P
M);_XJC_A6NJ_]#_XC_\  EO_ (JCDA_-^ 'H=%>>?\*UU7_H?_$?_@2W_P 5
M1_PK75?^A_\ $?\ X$M_\51R0_F_ #T.BO//^%:ZK_T/_B/_ ,"6_P#BJ/\
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M(_\ P);_ .*HY(?S?@!Z'17GG_"M=5_Z'_Q'_P"!+?\ Q5'_  K75?\ H?\
MQ'_X$M_\51R0_F_ #T.BO//^%:ZK_P!#_P"(_P#P);_XJC_A6NJ_]#_XC_\
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M#_XC_P# EO\ XJC_ (5KJO\ T/\ XC_\"6_^*HY(?S?@!Z'17GG_  K75?\
MH?\ Q'_X$M_\51_PK75?^A_\1_\ @2W_ ,51R0_F_ #T.BO//^%:ZK_T/_B/
M_P "6_\ BJ/^%:ZK_P!#_P"(_P#P);_XJCDA_-^ 'H=%>>?\*UU7_H?_ !'_
M .!+?_%4?\*UU7_H?_$?_@2W_P 51R0_F_ #T.BO//\ A6NJ_P#0_P#B/_P)
M;_XJC_A6NJ_]#_XC_P# EO\ XJCDA_-^ 'H=%>>?\*UU7_H?_$?_ ($M_P#%
M4?\ "M=5_P"A_P#$?_@2W_Q5')#^;\ /0Z*\\_X5KJO_ $/_ (C_ / EO_BJ
M/^%:ZK_T/_B/_P "6_\ BJ.2'\WX >AT5YY_PK75?^A_\1_^!+?_ !5'_"M=
M5_Z'_P 1_P#@2W_Q5')#^;\ /0Z*\\_X5KJO_0_^(_\ P);_ .*H_P"%:ZK_
M -#_ .(__ EO_BJ.2'\WX >AT5YY_P *UU7_ *'_ ,1_^!+?_%4?\*UU7_H?
M_$?_ ($M_P#%4<D/YOP ]#HKSS_A6NJ_]#_XC_\  EO_ (JC_A6NJ_\ 0_\
MB/\ \"6_^*HY(?S?@!Z'17GG_"M=5_Z'_P 1_P#@2W_Q5'_"M=5_Z'_Q'_X$
MM_\ %4<D/YOP /BK_P RM_V&H*]#[5X=XZ\&7VD_V%YWBS6+[[3J44*_:)BW
MDD_QKSPPKKO^%:ZK_P!#_P"(_P#P);_XJKE&/)'WNX'H=%>>?\*UU7_H?_$?
M_@2W_P 51_PK75?^A_\ $?\ X$M_\54<D/YOP ]#HKSS_A6NJ_\ 0_\ B/\
M\"6_^*H_X5KJO_0_^(__  );_P"*HY(?S?@!Z'17GG_"M=5_Z'_Q'_X$M_\
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M  );_P"*H_X5KJO_ $/_ (C_ / EO_BJ.2'\WX >AT5YY_PK75?^A_\ $?\
MX$M_\51_PK75?^A_\1_^!+?_ !5')#^;\ /0Z*\\_P"%:ZK_ -#_ .(__ EO
M_BJ/^%:ZK_T/_B/_ ,"6_P#BJ.2'\WX >AT5YY_PK75?^A_\1_\ @2W_ ,51
M_P *UU7_ *'_ ,1_^!+?_%4<D/YOP ]#HKSS_A6NJ_\ 0_\ B/\ \"6_^*H_
MX5KJO_0_^(__  );_P"*HY(?S?@!Z'17GG_"M=5_Z'_Q'_X$M_\ %4?\*UU7
M_H?_ !'_ .!+?_%4<D/YOP ]#HKSS_A6NJ_]#_XC_P# EO\ XJC_ (5KJO\
MT/\ XC_\"6_^*HY(?S?@!Z'17GG_  K75?\ H?\ Q'_X$M_\51_PK75?^A_\
M1_\ @2W_ ,51R0_F_  \$_\ )2O'7_76W_D]>AUY?\,K"32_&OC*REO9[V2)
M[=3<7#;G?[_)->H45OC^[\@1F>(_^17U;_KRF_\ 0#6%\+?^2:Z+_P!<W_\
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M'->O6LK3VD,K !G16('3D4 2T5Y1J7Q)\6OXSUG0?#?A:#55TQU623S_ "R
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MP?X9N]9O3E8EVQ1CK)(?NJ/J?R&34_AJ\U74- M;S6K**RO9T\QK:-B?+!Y
M;(!W8ZCL: -:BN!\&>*-4D\:>(/"&OS_ &B^L6%Q:W B5/,MV"XR%XR-R_\
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M(?G,'SK$Y'5=P^;!]1SB@"]17"_#;Q7J&NPZMI.N,&UK1[MH+EU0*KJ6;:P
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M+*VGRHS#806 *C<Q8DG'.237K'@K^TT\(Z?;:S;M#J-K']FF!Y#F/Y0X/<,
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MR!7>5P'P7L9+'X5Z0)00\PDFQ[,[%?T(KOZ &NZ1QM)(RJB@EF8X  [FO'/
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MCF$_KZU[!7CWBUC=?M&>$+:)<F"S:1VYXXE/]!^=>PT %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M5-I+70-1G_"?^$?^ABT[_O\ "C_A/_"/_0Q:=_W^%/\ ^$&\*?\ 0N:7_P"
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MX4?N_,-1G_"?^$?^ABT[_O\ "C_A/_"/_0Q:=_W^%/\ ^$&\*?\ 0N:7_P"
MJ?X4?\(-X4_Z%S2__ 5/\*/W?F&HS_A/_"/_ $,6G?\ ?X4?\)_X1_Z&+3O^
M_P *?_P@WA3_ *%S2_\ P%3_  H_X0;PI_T+FE_^ J?X4?N_,-1G_"?^$?\
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MX4?N_,-1G_"?^$?^ABT[_O\ "C_A/_"/_0Q:=_W^%/\ ^$&\*?\ 0N:7_P"
MJ?X4?\(-X4_Z%S2__ 5/\*/W?F&HS_A/_"/_ $,6G?\ ?X4?\)_X1_Z&+3O^
M_P *?_P@WA3_ *%S2_\ P%3_  H_X0;PI_T+FE_^ J?X4?N_,-1G_"?^$?\
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MX4?N_,-1G_"?^$?^ABT[_O\ "C_A/_"/_0Q:=_W^%/\ ^$&\*?\ 0N:7_P"
MJ?X4?\(-X4_Z%S2__ 5/\*/W?F&HS_A/_"/_ $,6G?\ ?X4?\)_X1_Z&+3O^
M_P *?_P@WA3_ *%S2_\ P%3_  H_X0;PI_T+FE_^ J?X4?N_,-1G_"?^$?\
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MX4?N_,-1G_"?^$?^ABT[_O\ "C_A/_"/_0Q:=_W^%/\ ^$&\*?\ 0N:7_P"
MJ?X4?\(-X4_Z%S2__ 5/\*/W?F&HS_A/_"/_ $,6G?\ ?X4?\)_X1_Z&+3O^
M_P *?_P@WA3_ *%S2_\ P%3_  H_X0;PI_T+FE_^ J?X4?N_,-3E?A[>VVH^
M/_&MW9SI/;R26Y22,Y5A\_0UZ56=I>@:1HK3-I>FVUF9L>9Y$83=C.,X^I_.
MM&IJ24I70(****@84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
F4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>img11953243_8.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img11953243_8.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '/!@D# 2(  A$! Q$!_\0
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M=B\\84LI'#=.M87_  DEY_SR@_[Y/^- '445R_\ PDEY_P \H/\ OD_XT?\
M"27G_/*#_OD_XT =117+_P#"27G_ #R@_P"^3_C1_P ))>?\\H/^^3_C0!U%
M%<O_ ,))>?\ /*#_ +Y/^-'_  DEY_SR@_[Y/^- '445R_\ PDEY_P \H/\
MOD_XT?\ "27G_/*#_OD_XT =117+_P#"27G_ #R@_P"^3_C1_P ))>?\\H/^
M^3_C0!U%%<O_ ,))>?\ /*#_ +Y/^-'_  DEY_SR@_[Y/^- '445R_\ PDEY
M_P \H/\ OD_XT?\ "27G_/*#_OD_XT =117+_P#"27G_ #R@_P"^3_C1_P )
M)>?\\H/^^3_C0!U%%<O_ ,))>?\ /*#_ +Y/^-'_  DEY_SR@_[Y/^- '445
MR_\ PDEY_P \H/\ OD_XT?\ "27G_/*#_OD_XT =117+_P#"27G_ #R@_P"^
M3_C1_P ))>?\\H/^^3_C0!U%%<O_ ,))>?\ /*#_ +Y/^-'_  DEY_SR@_[Y
M/^- '445R_\ PDEY_P \H/\ OD_XT?\ "27G_/*#_OD_XT =117+_P#"27G_
M #R@_P"^3_C1_P ))>?\\H/^^3_C0!U%%<O_ ,))>?\ /*#_ +Y/^-'_  DE
MY_SR@_[Y/^- '445R_\ PDEY_P \H/\ OD_XT?\ "27G_/*#_OD_XT =117+
M_P#"27G_ #R@_P"^3_C1_P ))>?\\H/^^3_C0!U%%<O_ ,))>?\ /*#_ +Y/
M^-'_  DEY_SR@_[Y/^- '445R_\ PDEY_P \H/\ OD_XT?\ "27G_/*#_OD_
MXT =117+_P#"27G_ #R@_P"^3_C1_P ))>?\\H/^^3_C0!U%%<O_ ,))>?\
M/*#_ +Y/^-'_  DEY_SR@_[Y/^- '445R_\ PDEY_P \H/\ OD_XT?\ "27G
M_/*#_OD_XT =117+_P#"27G_ #R@_P"^3_C1_P ))>?\\H/^^3_C0!U%%<O_
M ,))>?\ /*#_ +Y/^-'_  DEY_SR@_[Y/^- '445R_\ PDEY_P \H/\ OD_X
MT?\ "27G_/*#_OD_XT =117+_P#"27G_ #R@_P"^3_C1_P ))>?\\H/^^3_C
M0!U%%<O_ ,))>?\ /*#_ +Y/^-'_  DEY_SR@_[Y/^- '445R_\ PDEY_P \
MH/\ OD_XT?\ "27G_/*#_OD_XT =117+_P#"27G_ #R@_P"^3_C1_P ))>?\
M\H/^^3_C0!U%%<O_ ,))>?\ /*#_ +Y/^-'_  DEY_SR@_[Y/^- '445R_\
MPDEY_P \H/\ OD_XT?\ "27G_/*#_OD_XT =117+_P#"27G_ #R@_P"^3_C1
M_P ))>?\\H/^^3_C0!U%%<O_ ,))>?\ /*#_ +Y/^-'_  DEY_SR@_[Y/^-
M'445R_\ PDEY_P \H/\ OD_XT?\ "27G_/*#_OD_XT =117+_P#"27G_ #R@
M_P"^3_C1_P ))>?\\H/^^3_C0!U%%<O_ ,))>?\ /*#_ +Y/^-'_  DEY_SR
M@_[Y/^- '445R_\ PDEY_P \H/\ OD_XT?\ "27G_/*#_OD_XT =117EGQ%^
M)>L^$-1T^WL+6PE2YM!.YN$<D,21QAAQQ7%_\+Y\4?\ /AH__?F7_P".5O'#
M3DN9"NCZ'HKYX_X7SXH_Y\-'_P"_,O\ \<H_X7SXH_Y\-'_[\R__ !RJ^J5
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MC_A?/BC_ )\-'_[\R_\ QRCZI4#F1]#T5\\?\+Y\4?\ /AH__?F7_P".4?\
M"^?%'_/AH_\ WYE_^.4?5*@<R/H>BOGC_A?/BC_GPT?_ +\R_P#QRC_A?/BC
M_GPT?_OS+_\ '*/JE0.9'T/17SQ_POGQ1_SX:/\ ]^9?_CE'_"^?%'_/AH__
M 'YE_P#CE'U2H',CZ'HKYX_X7SXH_P"?#1_^_,O_ ,<H_P"%\^*/^?#1_P#O
MS+_\<H^J5 YD?0]%?/'_  OGQ1_SX:/_ -^9?_CE'_"^?%'_ #X:/_WYE_\
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M'_[\R_\ QRC_ (7SXH_Y\-'_ ._,O_QRCZI4#F1]#T5\\?\ "^?%'_/AH_\
MWYE_^.4?\+Y\4?\ /AH__?F7_P".4?5*@<R/H>BOGC_A?/BC_GPT?_OS+_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MK_.N1H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** /.?C?_R'-%_[!R_^A-7EM>I?&_\ Y#FB_P#8
M.7_T)J\MKU\/_"1F]PHHHK8 HHHH **** "MGPKX@E\,^(+;4DC66-3MGA8
MB2,GYEY[^A]0*QJ*32:LP/HCXF^%+/Q7X-AUS15B,UK&;B,Q+Q-"1EAQWX!'
MT([UF_!?P4EOITOB34H5+W*[+5)%^['W?GCYCC''09SS4GP(U:_N='OM+FAD
M:RM7#P3G[JEN6C'X_-^)]16Q\7=1O="\ BUTFV$5M.PM9FCC&V&$J1M '"@\
M+Z8XZD5Y[<T_87ZE>9P\?B.V\5?&[2_LT,(TRVE:&W41@!P%;+GUR>1[8]Z]
M,\8>+_#W@E[-=2TR64W0<I]F@C;&W&<[F']X5X-\,?\ DI&B_P#79O\ T!J]
M]\:^"=$\7O9-K%[<VQM@XB\F5$W;L9SN4YZ#I3K1A&I&+VL"V./N?C+X,FM9
MHET74 SHR@FUAZD?[]9OP"@AG;Q#YL,<F/L^-Z@X_P!;4GB'X3>$=*\.:EJ%
MMJ]\\]M;/+&CW,1#, 2 0$!/-)^S[U\1?]NW_M6G+D]C)P\@ZG1ZS\4/!^C:
MU=:1>Z3=-)!(8I76UB9/<_>R1^%5/B!X$\/ZYX1G\1:)%;V\T,#7BRVR!4G0
M+N.0,<X&<]<U1\0_!B_\0>*-0U0ZO;6\-U,9%41L[*/?IVKI/&%YIG@GX7RZ
M-)<AY6L&LK="0))25V%MN>@SD^E0G%./LWJ'J?,U?6GA;P]9>'O"FE:=<06_
MG)$JR%AG=*WS-@GG[Q.*^>/AGHAUWQ[IL)5C#;O]JE((&%3D9SV+;1^/XUZ7
M\9O%DFD:KX?L[1@9K6<:C(O(.5.U!GI@_O 1_D[XB\YJFA+34XOXS:$-)\;&
MZAC"6]_$LJ@< ,/E8#\@?^!5H?!#5X8_$-SHEU'$\5Y&9(MZ@D2)R0,^JY/_
M  &N[^+NBQ>(/ 2:M I::Q N(R,<QMC?^F#_ ,!KP'0-6DT+Q!8:I'G-K.LA
M _B4'YA^(R/QIT_WM'EZ@]&=W\;- 32O%L.H01+'!J$.XA1@>8F%;CITV'\3
M3_@AH*:GXKN=1GC22'3X. W_ #TDRHXZ$;0_7V_#O?C-I@UGP%%JEL2XLY$G
M!7G=&XVD_JI^@-6/A-ID?AWX<+J%V?*^U;[V9G886/'RG/8;5#<^IK+VO^SV
MZ[#MJ><?&W4X)_%D&EVL<21V$/[S8FT^8^&()[_*$_6E^"&@IJ?BNYU&>-)(
M=/@X#9_UDF5''0C:'Z^WX<!K>J2ZWKE]J<V[S+J9I2I;=M!/"Y] , ?2OH+X
M6V,7A;X8MJM[NC$ZR7\Q/.$ ^7&/55!QUY_"M:O[NCRK?82U9L^.?#]IKO@C
M5K6T@A^T)&7C,:@'S$.[;^.,?C7RK7OGP4\2W&KRZ_:W9!DDN3?#!X!D)W@
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MKTSX4Z':VVAOKDR(UQ,S!)&',:+P<>F2#G\*HZ=\6+N[\3Q6TEE NFSSB),
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M8XK6EBZCJ2I5(VDE=6ZF=7"P4(U*<M&[:]#FK+POKNH0B:UTF\DB(!5Q$0K
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@LE*0EWQNE88..><*3_WT*2C[*G*4MV&[.O^/5S&GA/3K4NHDDO1(JD\D*C
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MGC:5IVYGS+KLCU[X?_\ ),[7_<G_ /1CUXIHT4$WB#3XKG;]G>ZC67<<#:7
M.?;%:&G^-/$&EZ8FG66H>5:(&"Q^3&V-Q)/)4GJ3WK ZUUX?#3ISJ2;^)Z?B
M<M?$1J1II+X5_D?0GC&;Q'9Z9;1^%[5"Q;:[(JEHU&-NU3QCKVXJ[X4CUJ/0
MT.OS>9?LQ9Q\OR#L/EXZ>GK7C-G\1_$]E9"U34!(JC"O+&KN/Q(Y_'-06WC[
MQ1:&8Q:M)F:0RN7C1\L0!QN4X& .!P*X'EM9T_9^[ZZW9VK,*2GS^]Z=$;7P
MFE2/QI.K'!DM)%7W.Y3_ "!K0^*^@:C)J?\ ;<< :PCA2.20.,H<XY'7J17F
M]K=W%E=)=6LSPSQG<LB'!!K?U7Q[X@UG2GTZ]NHW@DV^9B%07P01D@>H!XQ7
M=/#U/K*K0:ML[G'"O3^KNE.]]T>I^&98?%'PT73X9E686ALWS_ P7 )]NA^A
MKEO!/P_UO3O%<-[J4"P6]KN8,)%;S#@@ 8/OGGTKS_2M:U'0[HW.FW3V\I&"
M5P01Z$'@UT%W\3/%%W;&#[:D(8$,\,05B/KV^HP>*QEA*\'.-)KEEWW1LL51
MFHRJI\T>W4ZSQUJL%U\0O#>GQ-N>TNHS(0> SR+Q]< ?G5SXQ?\ (O6/_7U_
M[*:\?BO+B"_CODE;[3'*)5D;YCO!R"<]>?6M/6/%FMZ_;I;ZG>^?%&V]5\I%
MP<8S\H%7' RA.FXO2)$L8I0J*2UD6/!NA/K^L_9[?4_[/NHU\R*0*2QQUP01
M@BO1Y9/B+HM_]F@2'6K;Y2L\D:1D],CAACOR<UXU#/+;3)-!*\4J'*O&Q5E/
MJ".E=9;_ !.\4P1;#?1RXZ-)"I/Z 5>*P]6I*\;-=FOUW)PU>G"-I73[K_(]
M$^*B6C>#2]TJ"Y65/(YYW9Y ]1C->8Z5XPDL/#-[H%U9K=V5P#L^?8T1/.1P
M<\@'ZUD:MK>I:Y<BXU*[>XD484L  H]@.!5"GAL&J='V=376_IZ$XC%N=7GA
MII8****[CC.E\1^+Y=<TVQTR"S2RT^S4!(0Y<D@8!+$#H/Z]:YJBBHITXTX\
ML5H7.<IOFDSUKX-7>;?5;,@#:Z2@YY.00?RVC\ZX?QY:BT\;ZK&!C=-YG_?0
M#?UI? VO)X>\4074W_'O(##,?16QS^! /TS76_%K3HKB2RUJUE25"GDR['!Q
MW4\>N2,_2O/2=+'-O::_$[F_:X.RWB_P.H\=_P#),I_^N</_ *$M<5\,/%IT
MS4!HUY(QM+I@(23Q%)Z?1N/QQZDUS5_XS\0:GIC:;>7_ )EHP4&/R8QP"".0
MN>P[U@TZ.!M0E2J=7?0FMC+UHU:?1'T!\2@!X"OP.!F/_P!#6N \"?\ "'?V
M-/\ \)%]E^U?:#L\[=G9M7'3MG-<Y?>,_$&I:6=-O-0,MHP4%#$@) ((^8+G
ML.]8-&'P,H4'2E*VM[H=?&1G652,;Z6U/:?^+7_]0_\ \?KD/'O_  B/V.S_
M .$=^S^=O;S?)W?=P,9S7"T5K2P7LYJ7/)V[LSJ8OGBX\B7R/4?#?@3P_P")
M_"*7=M+/'J&PHY\SA)1ZKSP>#]#57PQ\-==M?$]K<:A!%%:6LPD,GFAO,VG(
MV@'/4#KC^E</I6M:EHES]HTV\EMI#][8?E;K]Y3P>IZBM^?XE^*9[;R3J"IV
M,D<*JQ_'''X8K.I1Q:<E"2<7WW1<*V&:BYQ::[=3?^,6I6]Q?Z=812*TULKO
M* <[=VW /H?ES^(K*^%'_(Z#_KV?^8KBI99)Y7EE=I)')9G8Y+$]235O2=8O
M]#O?MFG3^1/M*;]BMP>O# CM6JPKCAO81?0S>)YL1[:2ZG:_&'_D:;/_ *\E
M_P#0WIWPG\/_ &W5Y-8F7,-G\L7O(1]>P/IW]JXO6-=U+7[I+G4[GSYD3RU;
M8JX7).,* .I-7=+\:>(-&L%L=/U#R;=22$$,;<DY/)4FH>'JK"JC%J^Q2KTG
MB75DG;<V?B=X@_M?Q*;.)LVUAF)?=_XST]0!Z?+GO7$4$DDD]371>"='&L>)
M[5)&5;:!A-,S' PIR!^)P/SKHC&.&HVZ11A*4J]6_5L]:\0 :+\+)8'ZQ64=
MO@]22%7V]:\#KU'XL>)8KC[/H=G*KJA\VX9#D9Z*N1^)/U%>75RY;3E&DY2W
MD[G3F%12JJ,=DK!1117HG %=G\+?^1W@_P"N4G\JXRNS^%O_ ".\'_7*3^5<
M^+_@3]&;X7^-#U1[U1117QY]49NN_P#()E^J_P ZY&NM\0.J:/*SL%&5Y)QW
M%<;]I@_Y[Q_]]B@"6BHOM,'_ #WC_P"^Q1]I@_Y[Q_\ ?8HL!+147VF#_GO'
M_P!]BC[3!_SWC_[[%%@):*B^TP?\]X_^^Q1]I@_Y[Q_]]BBP$M%1?:8/^>\?
M_?8H^TP?\]X_^^Q18"6BHOM,'_/>/_OL4?:8/^>\?_?8HL!+147VF#_GO'_W
MV*/M,'_/>/\ [[%%@):*B^TP?\]X_P#OL4?:8/\ GO'_ -]BBP$M%1?:8/\
MGO'_ -]BC[3!_P ]X_\ OL46 EHJ+[3!_P ]X_\ OL4?:8/^>\?_ 'V*+ 2T
M5%]I@_Y[Q_\ ?8H^TP?\]X_^^Q18"6BHOM,'_/>/_OL4?:8/^>\?_?8HL!+1
M47VF#_GO'_WV*/M,'_/>/_OL46 EHJ+[3!_SWC_[[%'VF#_GO'_WV*+ 2T5%
M]I@_Y[Q_]]BC[3!_SWC_ .^Q18"6BHOM,'_/>/\ [[%'VF#_ )[Q_P#?8HL!
M+147VF#_ )[Q_P#?8H^TP?\ />/_ +[%%@):*B^TP?\ />/_ +[%'VF#_GO'
M_P!]BBP$M%1?:8/^>\?_ 'V*/M,'_/>/_OL46 EHJ+[3!_SWC_[[%'VF#_GO
M'_WV*+ 2T5%]I@_Y[Q_]]BC[3!_SWC_[[%%@):*B^TP?\]X_^^Q1]I@_Y[Q_
M]]BBP$M%1?:8/^>\?_?8H^TP?\]X_P#OL46 EHJ+[3!_SWC_ .^Q1]I@_P">
M\?\ WV*+ 2T5%]I@_P">\?\ WV*/M,'_ #WC_P"^Q18"6BHOM,'_ #WC_P"^
MQ1]I@_Y[Q_\ ?8HL!+147VF#_GO'_P!]BC[3!_SWC_[[%%@):*B^TP?\]X_^
M^Q1]I@_Y[Q_]]BBP$M%1?:8/^>\?_?8H^TP?\]X_^^Q18"6BHOM,'_/>/_OL
M4?:8/^>\?_?8HL!+147VF#_GO'_WV*/M,'_/>/\ [[%%@):*B^TP?\]X_P#O
ML4?:8/\ GO'_ -]BBP$M%1?:8/\ GO'_ -]BC[3!_P ]X_\ OL46 EHJ+[3!
M_P ]X_\ OL4?:8/^>\?_ 'V*+ 2T5%]I@_Y[Q_\ ?8H^TP?\]X_^^Q18"6BH
MOM,'_/>/_OL4?:8/^>\?_?8HL!+147VF#_GO'_WV*/M,'_/>/_OL46 EHJ+[
M3!_SWC_[[%'VF#_GO'_WV*+ >??&_P#Y#FB_]@Y?_0FKRVO3_C9+'+K>C&.1
M7 TY0=ISCYFKS"O7P_\ #1F]PHHHK8 HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /7/'G_'MX9_
M[ \/]:XZNN\=31/;>&MLB-C2(0<,#@\UQ^]?[P_.O1P7\")\YC4_;R'44W>O
M]X?G1O7^\/SKJN<UF.HIN]?[P_.C>O\ >'YT7"S'44W>O]X?G1O7^\/SHN%F
M.HIN]?[P_.C>O]X?G1<+,=13=Z_WA^=&]?[P_.BX68ZBF[U_O#\Z-Z_WA^=%
MPLQU:M_XFUO4[4VM[J=S/ 2"8W?@XZ9K(WK_ 'A^=&]?[P_.I<8MIM;#3DE9
M#J*;O7^\/SHWK_>'YU5Q68ZBF[U_O#\Z-Z_WA^=%PLQU%-WK_>'YT;U_O#\Z
M+A9CJ*;O7^\/SHWK_>'YT7"S'44W>O\ >'YT;U_O#\Z+A9CJ*;O7^\/SHWK_
M 'A^=%PLQU%-WK_>'YT;U_O#\Z+A9CJ*;O7^\/SHWK_>'YT7"S'44W>O]X?G
M1O7^\/SHN%F.HIN]?[P_.C>O]X?G1<+,=13=Z_WA^=&]?[P_.BX68ZBF[U_O
M#\Z-Z_WA^=%PLQU%-WK_ 'A^=&]?[P_.BX68ZBF[U_O#\Z-Z_P!X?G1<+,=1
M3=Z_WA^=&]?[P_.BX68ZBF[U_O#\Z-Z_WA^=%PLQU%-WK_>'YT;U_O#\Z+A9
MCJ*;O7^\/SHWK_>'YT7"S'44W>O]X?G1O7^\/SHN%F.HIN]?[P_.C>O]X?G1
M<+,=13=Z_P!X?G1O7^\/SHN%F.KL_A;_ ,CO!_URD_E7%;U_O#\Z[3X6,I\;
MP8(/[J3O[5S8M_N)^C-\*G[:/JCWNBBBOD#ZD\R\8V$>N_%/1M"OY;EM+NK!
MWGMDG=$D9"[*2 0,@@5H_P#"G?!7_0,E_P# J3_XJH-9_P"2Y>'/^P=-_)Z]
M#K>4Y145%VT$<'_PIWP5_P! R7_P*D_^*H_X4[X*_P"@9+_X%2?_ !5=Y14>
MVJ?S,+(X/_A3O@K_ *!DO_@5)_\ %4?\*=\%?] R7_P*D_\ BJ[RBCVU3^9A
M9'!_\*=\%?\ 0,E_\"I/_BJ/^%.^"O\ H&2_^!4G_P 57>44>VJ?S,+(X/\
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MDO\ X%2?_%5WE%'MJG\S"R.#_P"%.^"O^@9+_P"!4G_Q5'_"G?!7_0,E_P#
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M\+/]9XL_[#<_]*]#K2K5FIM)L$C@_P#A3O@K_H&2_P#@5)_\51_PIWP5_P!
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M2?\ Q5'_  IWP5_T#)?_  *D_P#BJ[RBCVU3^9A9'!_\*=\%?] R7_P*D_\
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M2?\ Q5'_  IWP5_T#)?_  *D_P#BJ[RBCVU3^9A9'!_\*=\%?] R7_P*D_\
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M0 4444 %%%% !1110 4444 %%%% !1110 51UK5[30=&O-5OW*6MK$99".I
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M?V)X>TS2?.\[[#:16WF[=N_8@7=C)QG&<9-<_P##CP+_ ,*_\/7&D_VC]O\
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M?0??A?\ J,@' (/ P17(W/PP\9ZW$UAK_P 0[B?2V $D4%J$:5>X)S_/=]*
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MEDP7E<_Q,0![#Z 4 ;U>1> /^2X>/O\ @'\Q7KM<AH'@?^P_'&O^)/[1\_\
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M&=I)YZ>@. ,D]:W/!?PUB\,ZQ=>(-3U:YUK7[I-DEY.,!5XX5<DC@ 9ST&
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M[$"@"S:W,%[:0W5M*DL$R+)'(ARKJ1D$'N"*\CTJ:/Q)^TAJ%]:,);71M/\
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M1_\  7_Z]=$J<I*+2Z"N>AT5YY_PN?PK_=U'_P !?_KT?\+G\*_W=1_\!?\
MZ]1[&IV"Z/0Z*\\_X7/X5_NZC_X"_P#UZ/\ A<_A7^[J/_@+_P#7H]C4[!='
MH=%>>?\ "Y_"O]W4?_ 7_P"O1_PN?PK_ '=1_P# 7_Z]'L:G8+H]#HKSS_A<
M_A7^[J/_ ("__7H_X7/X5_NZC_X"_P#UZ/8U.P71Z'17GG_"Y_"O]W4?_ 7_
M .O1_P +G\*_W=1_\!?_ *]'L:G8+H]#HKSS_A<_A7^[J/\ X"__ %Z/^%S^
M%?[NH_\ @+_]>CV-3L%T>AT5YY_PN?PK_=U'_P !?_KT?\+G\*_W=1_\!?\
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MP71Z'17GG_"Y_"O]W4?_  %_^O1_PN?PK_=U'_P%_P#KT>QJ=@NCT.BO//\
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MX5_NZC_X"_\ UZ/^%S^%?[NH_P#@+_\ 7H]C4[!='H=%>>?\+G\*_P!W4?\
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M=1_\!?\ Z]'L:G8+H]#HKSS_ (7/X5_NZC_X"_\ UZ/^%S^%?[NH_P#@+_\
M7H]C4[!='H=%>>?\+G\*_P!W4?\ P%_^O1_PN?PK_=U'_P !?_KT>QJ=@NCT
M.BO//^%S^%?[NH_^ O\ ]>C_ (7/X5_NZC_X"_\ UZ/8U.P71Z'17GG_  N?
MPK_=U'_P%_\ KT?\+G\*_P!W4?\ P%_^O1[&IV"Z/0Z*\\_X7/X5_NZC_P"
MO_UZ/^%S^%?[NH_^ O\ ]>CV-3L%T>AT5YY_PN?PK_=U'_P%_P#KT?\ "Y_"
MO]W4?_ 7_P"O1[&IV"Z/0Z*\\_X7/X5_NZC_ . O_P!>C_A<_A7^[J/_ ("_
M_7H]C4[!='H=%>>?\+G\*_W=1_\  7_Z]'_"Y_"O]W4?_ 7_ .O1[&IV"Z/0
MZ*\\_P"%S^%?[NH_^ O_ ->C_A<_A7^[J/\ X"__ %Z/8U.P71Z'574=,L=7
ML7LM1M(;NUDP6BF0,IP<C@^]<-_PN?PK_=U'_P !?_KT?\+G\*_W=1_\!?\
MZ]'L:G8+H]"551 B*%51@ #  I:\\_X7/X5_NZC_ . O_P!>C_A<_A7^[J/_
M ("__7H]C4[!='H=%>>?\+G\*_W=1_\  7_Z]'_"Y_"O]W4?_ 7_ .O1[&IV
M"Z/0Z*\\_P"%S^%?[NH_^ O_ ->C_A<_A7^[J/\ X"__ %Z/8U.P71Z'17GG
M_"Y_"O\ =U'_ ,!?_KT?\+G\*_W=1_\  7_Z]'L:G8+H]#IKHLD;(XRK @CV
MKS[_ (7/X5_NZC_X"_\ UZ/^%S^%?[NH_P#@+_\ 7H]C4[!=';Z9I6GZ-9BT
MTRR@M+<$L(H$"KD]3@5<KSS_ (7/X5_NZC_X"_\ UZ/^%S^%?[NH_P#@+_\
M7H]C4[!='H=%>>?\+G\*_P!W4?\ P%_^O1_PN?PK_=U'_P !?_KT>QJ=@NCT
M.BO//^%S^%?[NH_^ O\ ]>C_ (7/X5_NZC_X"_\ UZ/8U.P71Z'17GG_  N?
MPK_=U'_P%_\ KT?\+G\*_P!W4?\ P%_^O1[&IV"Z/0Z*\\_X7/X5_NZC_P"
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M_8.F_D]>AUK4VCZ"04445D,**** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@#SSX6?ZSQ9_V&Y_Z5Z'7GGPL_UGBS_L-S_TKT.M
M:WQL2"BBBLAA1110 4444 %%%% !1110 4444 %%%% !1110!RWQ!UK6M"\)
M7%UX>TR>_P!3=A%"D,+2F/.<N5 .0,?3)&:XJR^"<FIVD=_XG\5:[-KDHWRO
M;W*A(VZA1E22%Z<$#T KUZN#\;^(_'6D:AY/ACPI%J=L8%;[3)+G$A)!&P,"
M<#'YT 8WPPU?6].\6^(/ NO:D^I2:8J2VMTZMN:(XX8GV9" 2<9;!(%>JUX_
M\%CIU[?ZUJU[>RR^+;E\ZA;W$/DO ,]%7/*YQSVP!@5T_P 3_&$WAK0H[#2E
M>77]68VVGQ1C+!CP7_#(Q[D=LT >:?&+Q1JOB"YU&WT"ZEBT?PXJM>W,#E1)
M<.ZQA,@\[=Q_)O:O9? \CS> /#DDKL\CZ9;,S,<EB8ER2:\W\6^#X?!7[/.K
MZ:'$UVYAFO+@9_>RM/'D\]AP![#US7HW@/\ Y)YX:_[!5K_Z*6@#H:\^^,?B
M2XT#P-);V!<:CJLHL;<IC*[OO'_OD%<CD%@:]!KR'XGDWWQ5^'NFNJF)+IK@
M@DX8AD/(]MGZT >C^%M#A\->%M-T:%5"VD"HQ7HS]7;\6)/XUY99VFI?&K5]
M1O+C5KS3O"-E<&WM8+-@CW+J.7).>F5/0CG P037I_C&=[;P/K\\9Q)%IMPZ
MGW$;$5XC\,5\:^)O!MGI'AR]BT#2[%W%WJ!B#R74C2%\(,?PJ5'4?7'  -Z_
M\+>)/A7J^FZGX6O-;US1)91%?:8RFXEP<DLH5< 8'7 (. 20U>UCI7C%UK?C
M7X5:QIY\2ZPFO>&;R86[73Q[);=CW/4],G!+9"GH:]GZB@".XG2UMI;B3/EQ
M(7; R< 9-?/OPV^'\OCKPS)K>H^)=;M9)+J1$CM;G"!1CL<GKG]*]VUZUN;W
MP]J=I9%%NY[26.$N2%#LA"Y(Y R17D7AOX8?$73M @TU/&%OHT$#N4ALHC(7
M);)9W^4DGTY& />@#LO"GPQM_"NMC4T\0:U?,L;((;N<,G/?&.M9_P 5+BZO
M-9\)>%DN[BUL]9NY!=R6TA21D0+\F?0[SGZ"LWPIXM\4^&_'J>"/&LT=[]J0
MOI^HJ #(.2 <#G.".>01W!!KN?&'@NP\8VEJMQ+-:WEE,)[.]MR!+ X(.03V
M.!Q[#TH XG2;!O WQAT_P]I5[=OH^IZ<TKVMQ,9 DB;OF4MDC..V.OTQ:\::
MG=^,?%UMX"T*[DAAA*W.M7D)(,48.1$&'1CQ^GHPJEKM@?AXLGB"XU2]\1^,
M=0C_ +.TOSXQ\N3G"1KT )R?R&,G.[X4@T#X;Z,EKKVO:=%KNH/]JOY[FY57
MFF;DGYCG:.@/ ZG@DT =M_9UI_9?]F-"LEGY/V<Q2$N&CV[=ISG/''/6O,_A
M!?3Z3?:_X$O9)7ET:Z9K4R8YMV/'(]_F_P"!_@/55974,I#*1D$'((KR$*--
M_:?9DSG4]*R^#Z*!_P"TAZT >OT444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110!YY\*NOBK_L-3?TKT.O//A5U\5?]AJ;^E>AUK6^-B04445D
M,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JCK-[/INB7U[:VDE
MY<00/)%;1@EI6 )"C&3R>.!5ZB@#Q;1/AQKGCZQ.N>.];UFSN+AV:'3;9_)%
MNF3@%64X/MC.,9.<T_0AJWPV^*.G^$Y-9NM2T#5HG:U6ZR[P,,D#/_ <'&!\
MV2!7?^--8\3:/:6TOAOP^NL2,S"96F">6 ."!G)SST]*\P\$W;Z_\6_[0\=.
M]CXFMX/+T_37MS%$J8/*,6.\X9C@^I(SC@ ]VIDLJ0Q/+(P6-%+,Q[ =33ZY
MKXA73V7P[\031_>^PRH.<8W*5S^&<T <=\)7E\4:WXC\=7B'=>W'V2R#_>BM
MTYVC'&#\H/J4)^LWQ+\1ZU<^(M(\">&;E[34=2'FW-XG!@AY^Z<\'"L>QX !
MYK7^#UJMI\*]#554%XVE..Y9V/\ 6N9T_;<_M/ZMYP9?LVE*8<MPQ*Q=/^^F
M_*@!E_\ !>ZTBP?4?#'BO7$UN >:IGG#).X&=N !C//4L.<'-=?\,?&A\;^$
M(K^=52_@<V]VJ\#S  =P]B"#[9([5V=>1_!=RFN>.;5>(H]59E&3QDL/_910
M!ZY7EGC35=:\5^.4\ >'[Y].AC@^T:K?1C+JA PB\CKN7WY] <^IU\Y:+JOB
M:;XJ^-M+\,PP+JM]?LG]H3KN2SAB=P3@@\G*#N..GH =-K7PAOO"^E2ZQX*\
M1ZX-6M!YPAGF$HG5024"J@R?0$$'ICG->BZ!KM_J'@:'6-0TZXLK\6SO-:W,
M9C82)D'Y3R 2,CV(KSO6-)^)_@C37U^W\7+KL-LOG7ME<6X4; /FV]> ,DD%
M3QGVKTSPQKUIXO\ "MEJ\,8\B\BRT3?,%/*LA]<$$?A0!XQI_AUM>^%-[X_N
M]8U3_A(L3W<5P+I@L/E2, BKG&W"_AGCIBO1X_'L.D?";3_%6M2*;B6RC;:,
M SSLO"@#U()]AGTK-?X0010W>GVOB?5+/PY<OYLVF1E=OJ0'(R%..F*R-&2S
M\9>)%UN<Q6G@7PR/(TQ)OW<,TB<><2W&U<<9]!T.Z@#J_AOH.J6>FSZYXAGE
MDUK5G\^:)F8+;H>5C"DX&._'4XYQ6'\88I=#FT'QS8JRW.DW2Q7+1@;GMW/*
MG/49R!Z;R?<>AZ3K^CZ]&\FD:I9WRQD!_LTROLSTS@\=.]8/Q2LTO_ACX@A?
MH+4R]<<H0X_5: .HLKN*_L8+N!MT4\:R(?4$9%3UQWPJNC>?##P_(<_+:B+G
M_8)7^E=C0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Y
M_P#&;_DG=Q_UWB_G7H%>?_&;_DG=Q_UWB_G6E'^(O43V.]B_U*?[HI],B_U*
M?[HI]9C//-9_Y+EX<_[!TW\GKT.O/-9_Y+EX<_[!TW\GKT.M:FT?02"O&O ?
M_)P7C?\ ZX_^S1U[+6-8>%-$TSQ!?:]9V7EZG?#;<S^:[;QD'[I.T=!T K(9
MD?$?P/#XY\,O:JPBU*V)FL9\XV28Z$_W6Z'TX/:O(/ ?B+4_$7QQT>36K9X-
M4L]/DLKH.NTM(BR98CL3D9'KG'%?1]82>#/#\?BMO%":<JZRR[6N1(XR-NWE
M<[>G&<4 >2^*+73O$WQ^DT;QE=-%HMO8JVGP/*8HYV*J3D@CDEI>003L SV-
MWXJZ;X$\,> [VWTW2]*BU:[4):B")6FQN!=@V"R@+NR>!V[UZ9XG\%Z!XQMD
MAUO3TN?*!\J0,4>//7:P(/IQTXZ5BZ9\(O!6E6%Y9Q:29$O8Q%.\L[EV0$-M
M# @J,@?=QG SF@#(^R3WW[-Z6]NADE;0E94 R6P@) ]3@5)\*/&7AY_AKIL,
MNK6EM+I\ BNDN)EC,1!."<GH<9!_KD5Z#ING6ND:;;:=8Q>5:6T8BBCW%MJ@
M8 R22?QKC[SX.^!+[5'OYM"02NV]TCFD2,GUV*P ^@P* .$\-^(+?Q-^T?+J
M-DDGV(Z>T=O*Z%?.10 7 /8MNP?05WFJ>(_"&O\ BN?P5KUA&US"@FC&HPJ(
MY"1QY3$\G!/(QWQGG&[;>#O#]GK\>MVNF1P7\5N+:-XF952(# 4(#L _"H?%
M'@;PYXQ2(:WIL=Q)%_JYE8I(HYXW*0<<G@\=^M 'C'Q1\.^&_!$MAJO@J_?3
M_$$ET%6SL[@R>8IY^YDD#<%X^Z<XQ70?&S3O)O\ PIXGU#3TN],LYO(U*$J6
M 1RIZ ].'&?7;US7;>'?A5X.\,7:7EAI*O=QG<D]P[2LA[%0QP"/4#-=;=VE
MO?6DUI=PQSV\R%)(I%W*ZG@@B@#@+;PK\*+O2DU2&RT%K%UW"<R*J@8R<DG@
MCG(/(P<T_P  W_A.\T_7KSP/HAMOL[F RF#:ETZ E=IR<CD''!^89 R*)/@C
MX EO&N&T5@&))B6ZE5,GT ;CZ XKM]-TRQT>PCL=-M(;2UB&$BA0*H]>!W/<
M]Z /"OA)X<\)^+;'4-8\421ZGXA>Y;[3'>S$&(=CLR,Y]3G&,#&#1XHD\,Q_
M&3P5IWAJUL(4M+M?M+6,2JA=F3 )489@ ,\G&:])\1?"7P=XFU%]0OM,,=Y(
M<RRV\K1^8?5@."??&3W-7K;X<>$K-M*:VT:.)M*D:6S*2R#8Y()8_-\YR!RV
M>@H ZFBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \\^%G^L\6?\ 8;G_ *5Z
M'7GGPL_UGBS_ +#<_P#2O0ZUK?&Q(****R&%%%% !1110 4444 %%%% !111
M0 4444 %%%% ')_$/Q9?>"_#/]LV6DC45CF5)U\TIY2$'Y^ >,X'XUH:9XR\
M.:OIJ7]GK=B\#+N):=5*<9PP)RI /(-;,L4<\+PS1K)%(I5T<95@>""#U%<'
M=?!7P#=W;7#:'Y98Y9(KB1$/_ 0V!]!B@#E=$OK;Q+^T3<:OX=9)]/MM/\J^
MNHON2-MP.>_(4<?W/05H>+?AUXRU;XBGQ3HWB"QM?(18[);B/S# -F&P"C+R
MQ<Y]Z](T;0=*\/6"V.D6,-G;@YV1+C)]2>I/N:T: /G_ .(^A_$VS\ ZG/X@
M\66%]I:>5Y]M%:HC/F5 N"(P1AMIZ]J[GX2Z?XMM?#]A/K6LVUYI$VG0&PMH
MXE5X%V@J&(0$_+@<D]*[?6]$T[Q%I$^E:K;_ &BRGV^9%O9-VU@PY4@CD \&
MK%A8VVF:=;6%G'Y5K:Q+#"FXMM10 HR<D\ =: +%>0_%G=IOQ \ :V%_=)?&
MWE;(& 63'7V+_EUZ5Z]7&_%#PE_PF/@:]L(8PU]"/M%IQR9%_A'(^\,K^.>U
M '3ZI8KJ>CWM@X4I=6[PL&Z892.?SKR?X-^([#0-.N_!.M21:=K&G7,F$G;8
M)U)SN4MC)Z\?W<$<9QZ+X+U6ZUKP?IE[?6T]M>M"%N(YXFC82+\K'#<X)!(]
MC4'B;P!X8\7NLNM:7'/.@"K.K-'( ,\;E()')X/K0!YU\:M>L?$MCIO@W09X
MM2U>\O4;R[:0.(@ 1\Q' ZYYZ $G KU#7?$.D>#="2^U>[^SVD92%6(+,S'H
M !R3@$\=@3VJGX8^'_ACP?))-HNEQP7$@VM.[-))CT#,20/88S@9K2\0^'-*
M\4Z2^F:Q:BYM'8/MW%2&'0@@@@T 1W>NB3PG-KFB1)J8^RFXMHT?:)N,@ XX
M/MC.>*P_!'Q)T;QAH*7KW5M97BG;<6LDP!B.3CKU!QP:ZO3]/M-*T^WL+&!(
M+6W01Q1IT51TKDM:^$G@G7M0>_O-%1+F0DR-;R/$'/7)52!GWQD]Z .,U[4X
M?&_QP\,VF@3K=0:)NGO+J$[HTY!*[AP>BKQW;'8U[#?W]KI>GSW]].D%K;H9
M)9'Z*HZFJ'A_POHGA:S:UT338;.)B"^P$LY'3<QRS=>YJ37M TWQ-I3Z9J\#
MSV4C*SQ+,\88@Y&2A!(S@XZ9 ]* //\ P'I]QXU\33_$76(62'F#1+608,,(
MR/,([ELGUZG'&,9/@#1=&\2W7CJ\\565E=7JZG+%-)=QH6MXU!'!/* <\C'W
M?:O9H88K>&.&&-(XHU"HB#"JHX  '05R>O\ PP\(^)M5;4M3TK?=R*%E>*9X
MO- Z;@I&>@YZ\#T% &3\#KFZN?A;I_VEG=8Y)8X6?)S&'. ">H'('IC':L2Q
M']K_ +3>HRJRM'I6FA<[L_,548'/K(WY'O7I[_8?#6@-]GM&CLK&$[+>VCW-
MM4<*JCJ3T'J37#_"+PY>V=AJ?B;6K=H=8UVY:X=) 0T46254@CY<DL<>A7TH
M ])HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#SSX5=?%7_
M &&IOZ5Z'7GGPJZ^*O\ L-3?TKT.M:WQL2"BBBLAA1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %9GB&_O-+\/WU_I]E]MNK>(RI;;B#)CD@8!YQ
MG'')K3HH XWP9\2-#\6Z%#>&]L[.]QBXLY+@!XF'UP2/0XQ7"?$75;#Q-\3/
M!>F^')X;W5;*],EQ+;N&$*!D8AF'!P%<D9XQC'.*[C6OA-X)U^^DO;S1(UN9
M#EY+>1XMQ[DJI ).>3C)]:U_#?@OP]X1A:/1-,BM6<8>7):1QUY9B2?IG% &
M]6!XXL6U/P)KMI&NZ22QEV+G&6"D@?F!6_2,H92K %2,$'O0!P/P7OOMWPLT
MC/WX/,@89'\+D#],5S7CJX_X0CXR:'XON4QI%_ ;*ZE123&W3+=NFP^I"M@<
M5J_#S2;SP9XW\2>&3:3_ -D7+C4-/N%B/E@-PR%N0"/E'."=I/<5Z)J>EV&L
MV$EAJ5I%=6LF-\4J[E.#D?K0!B:[X_\ #>A:#)JLNJV<Z",O#'#<(S3G&0%P
M><^M<M\#]'O+/PC=:Q?QE+C6;IKQ5(Q^[(&TX]^2/8BM"T^"W@&SO4NDT,2,
MC;ECFN))$SGNI8@CV.17?*JHH5%"J!@ #  H P?#WC7P]XJNKVVT;48[F:S?
M;*J@COC<I/WEXZC(KS2TOK3X=?&[66UE4M=.\0J);>]8$1J^<D,QX&23DYX^
M7/!X]-T+P;X?\,WM]>:1IT=M/>OOG<,S9[X&2=HR2<# _2K6N^'M(\2Z>;'6
M;"*\M\[@D@.5.,9!'(.">0: .9^(/CGP_HO@[4O,U.TFN;BV>&"WBF5GD9E*
MC@9.!GD]*/A#H]WHGPSTJVOH7AN7#S-&_50[EER.QVD9!Y!I='^$/@C0]1CO
M[715>XB.Z-IY7E"'U"L2,^^..U=Q0!YC\1=7NO$6L6_PZT&?;=WHWZI.HS]E
MM>"<^A8$<>X'\59?Q(TBTTEOA_X9@A6+P\=2"3Q,?E?:4VAB>N=SYSUS7INE
M^&M(T;4+^_L;3R[N_?S+F9Y'D>0]N6)P.>@P!Z5)KF@Z7XDTN33=7LX[NTD(
M)C<D8(Z$$8(/N#0!YM=Z=I_A[X[>&[?P_:6]DEW8S+?6]F@1-@#%69%P!\P'
M)ZX%=+\7+]=/^%VNREPK20B%1G!)=@N!^!/Y&K_AGX?^&O"-S/=:/I_E7,P*
MO/)(TCE202,L3@9 -<K\3=/O/&7B+0/"%O;7)T_S_MFIW&PK$L:\!-X_B(+<
M>K*?H =+\--/;3/AOH%LV WV1)& /0N-Q_G75TR*)(8DBB14C10JJHP !T I
M] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7G_QF_P"2
M=W'_ %WB_G7H%>?_ !F_Y)W<?]=XOYUI1_B+U$]CO8O]2G^Z*?3(O]2G^Z*?
M68SSS6?^2Y>'/^P=-_)Z]#KRCQO+K47Q>T)]"@M9KX:=)Y27)(0\ONS@CMTK
M4_M#XK_] ;P[_P!_'_\ BZZ)0YE%W6PCT.BO//[0^*__ $!O#O\ W\?_ .+H
M_M#XK_\ 0&\._P#?Q_\ XNH]EYK[PN>AT5YY_:'Q7_Z WAW_ +^/_P#%T?VA
M\5_^@-X=_P"_C_\ Q='LO-?>%ST.BO//[0^*_P#T!O#O_?Q__BZ/[0^*_P#T
M!O#O_?Q__BZ/9>:^\+GH=%>>?VA\5_\ H#>'?^_C_P#Q=']H?%?_ * WAW_O
MX_\ \71[+S7WA<]#HKSS^T/BO_T!O#O_ '\?_P"+H_M#XK_] ;P[_P!_'_\
MBZ/9>:^\+GH=%>>?VA\5_P#H#>'?^_C_ /Q=']H?%?\ Z WAW_OX_P#\71[+
MS7WA<]#HKSS^T/BO_P! ;P[_ -_'_P#BZ/[0^*__ $!O#O\ W\?_ .+H]EYK
M[PN>AT5YY_:'Q7_Z WAW_OX__P 71_:'Q7_Z WAW_OX__P 71[+S7WA<]#HK
MSS^T/BO_ - ;P[_W\?\ ^+H_M#XK_P#0&\._]_'_ /BZ/9>:^\+GH=%>>?VA
M\5_^@-X=_P"_C_\ Q=']H?%?_H#>'?\ OX__ ,71[+S7WA<]#HKSS^T/BO\
M] ;P[_W\?_XNC^T/BO\ ] ;P[_W\?_XNCV7FOO"YZ'17GG]H?%?_ * WAW_O
MX_\ \71_:'Q7_P"@-X=_[^/_ /%T>R\U]X7/0Z*\\_M#XK_] ;P[_P!_'_\
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M?^_C_P#Q=1[+S7WA<]#HKSS^T/BO_P! ;P[_ -_'_P#BZ/[0^*__ $!O#O\
MW\?_ .+H]EYK[PN>AT5YY_:'Q7_Z WAW_OX__P 71_:'Q7_Z WAW_OX__P 7
M1[+S7WA<]#HKSS^T/BO_ - ;P[_W\?\ ^+H_M#XK_P#0&\._]_'_ /BZ/9>:
M^\+GH=%>>?VA\5_^@-X=_P"_C_\ Q=']H?%?_H#>'?\ OX__ ,71[+S7WA<]
M#HKSS^T/BO\ ] ;P[_W\?_XNC^T/BO\ ] ;P[_W\?_XNCV7FOO"YZ'17GG]H
M?%?_ * WAW_OX_\ \71_:'Q7_P"@-X=_[^/_ /%T>R\U]X7/0Z*\\_M#XK_]
M ;P[_P!_'_\ BZ/[0^*__0&\._\ ?Q__ (NCV7FOO"YZ'17GG]H?%?\ Z WA
MW_OX_P#\71_:'Q7_ .@-X=_[^/\ _%T>R\U]X7/0Z*\\_M#XK_\ 0&\._P#?
MQ_\ XNC^T/BO_P! ;P[_ -_'_P#BZ/9>:^\+GH=%>>?VA\5_^@-X=_[^/_\
M%T?VA\5_^@-X=_[^/_\ %T>R\U]X7/0Z*\\_M#XK_P#0&\._]_'_ /BZ/[0^
M*_\ T!O#O_?Q_P#XNCV7FOO"YZ'17GG]H?%?_H#>'?\ OX__ ,71_:'Q7_Z
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M*_\ T!O#O_?Q_P#XNC^T/BO_ - ;P[_W\?\ ^+H]EYK[PN>AT5YY_:'Q7_Z
MWAW_ +^/_P#%T?VA\5_^@-X=_P"_C_\ Q='LO-?>%ST.BO//[0^*_P#T!O#O
M_?Q__BZ/[0^*_P#T!O#O_?Q__BZ/9>:^\+GH=%>>?VA\5_\ H#>'?^_C_P#Q
M=']H?%?_ * WAW_OX_\ \71[+S7WA<]#HKSS^T/BO_T!O#O_ '\?_P"+H_M#
MXK_] ;P[_P!_'_\ BZ/9>:^\+GH=%>>?VA\5_P#H#>'?^_C_ /Q=']H?%?\
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M2\X5EQW^7G/<^E=30 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/W_(O^(/^PL__H"T 6+3XS3ZF;NTTKPG=:AJT%W) MG;W&X>6F,RN^SY 2<
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MU7]FW&_K]WRVSTKE/@87/PFTH-G:))PF1V\U_P"N: /1:*** "BBB@ HHHH
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M4C0*JCL ,8KE5\&27/Q(/BW4KU9Q;6_V?3[58]HMP<[F)S\S'+=OXCZ"NNH
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M $-WB7_P,_\ K4?\*I3_ *&[Q+_X&?\ UJ.6'\WX >AT5YY_PJE/^AN\2_\
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M'17GG_"J4_Z&[Q+_ .!G_P!:C_A5*?\ 0W>)?_ S_P"M1RP_F_ #T.BO//\
MA5*?]#=XE_\  S_ZU'_"J4_Z&[Q+_P"!G_UJ.6'\WX >AT5YY_PJE/\ H;O$
MO_@9_P#6H_X52G_0W>)?_ S_ .M1RP_F_ #T.BO//^%4I_T-WB7_ ,#/_K4?
M\*I3_H;O$O\ X&?_ %J.6'\WX >AT5YY_P *I3_H;O$O_@9_]:C_ (52G_0W
M>)?_  ,_^M1RP_F_ #T.BO//^%4I_P!#=XE_\#/_ *U'_"J4_P"AN\2_^!G_
M -:CEA_-^ 'H=%>>?\*I3_H;O$O_ (&?_6H_X52G_0W>)?\ P,_^M1RP_F_
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M4?\ "J4_Z&[Q+_X&?_6HY8?S?@!Z'17GG_"J4_Z&[Q+_ .!G_P!:C_A5*?\
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M_P"AN\2_^!G_ -:CEA_-^ 'H=>?_ !F_Y)W<?]=XOYTS_A5*?]#=XE_\#/\
MZU<G\1O 2Z!X0FOQXAUJ]VRHODW=QO0Y/7&*NE&'.K2_ 'L>V1?ZE/\ =%/I
MD7^I3_=%/KG&>>:S_P ER\.?]@Z;^3UZ'7GFL_\ )<O#G_8.F_D]>AUK4VCZ
M"0445Y%J'Q2\5R>.M7\->'_"T&I/I[$EO/*'9QR<X'5A60SUVBO(KCXI>-=
M'VGQ)\/;B+3P,R3VDV_RE[DX!'YE?K7H_ASQ'IGBK1H=5TFX\ZVDX.1AD; R
MK#L1F@#6HKC[;6/%[_$RZTN;185\,I 'CON=S-M!ZYP3N)!7&1C.?7L* "BB
MB@ HHHH **KW]R;/3KJZ50S0PO(%/0X!/]*YOX=>+I_&WA*/6;BUCMI'F>/R
MXV+ ;3CJ: .LHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MB@ HHHH **** "BN!\7_ !'ET?Q!'X:\/:++K>O-&)7ACD"I I&<N><'H<'
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M10 4444 %%%% !1110 4444 %%%% !1110 5Y_\ &;_DG=Q_UWB_G7H%>?\
MQF_Y)W<?]=XOYUI1_B+U$]CO8O\ 4I_NBGTR+_4I_NBGUF,\\UG_ )+EX<_[
M!TW\GKT.O/-9_P"2Y>'/^P=-_)Z]#K6IM'T$@KQKP'_R<%XW_P"N/_LT=>RU
MXUX#_P"3@O&__7'_ -FCK(9[(RAE*L 5(P0>AKQSP;;1^#OCOK_ANP!CTK4;
M07D4 48CD&#QZ*-T@ '^R.V:]DKQSPM<Q^*OVA-=UJP82Z;I=D+3[0ARKR'"
MX]P2)<$<$(#WH W+/Q1K,OQXU#PT]YG2(=.$Z6_E)P^(^=V-W\1[]Z3Q9J'Q
M#U7Q7_PC_A>S72M/2,-+K-U&'5NA.SJ,\XQC).?N@9K)T_\ Y.@U;_L$K_Z#
M%3[SQAXS\8>-M8\.^"FL;"RTF00W6HW2;V#YVD!2",Y5P!@@[<DC- %+7-7^
M(7PP>SU36==M-?T.6X6&X5[=8I(\]UVC/0'')''2NL^+GB/4_#7@"75=$NQ;
MW0GB590B2#:QYX8$5YA\7?#?BO3/!B7WB/QF^JH]VD:6:VJPIO(8[L@\X ;C
M'OVQ7:_&_P#Y(\/^NMO0!+HEO\2/$U_IOB&XUNVTK1I)(;A-+2,,\EOP2';;
MPS+VSP3T%4/%7C+QC;_%J7PMX?DBE^U6 ^S13(@CAE(W&5FV[B JMQG&<<'I
M7J.B?\@#3O\ KUB_]!%>8_\ -S__ '"/Z4 =%HNC>+-)T'Q _BGQ#'J[SVQ:
M$1Q!!"0C[\8 X.5[=O>O-?A.GC?6O J:=X;OK31K"WN)!-?31>;+*['.V-2"
MN ",DX.3QTKW;6_^0!J/_7K+_P"@FN ^ ?\ R2ZW_P"OJ;_T*@#/T7Q-XS\(
M_$+3O"OC"^MM4L]4!-I?1Q!&#<X7@ =1@@@GYEP>U=/\1O&UWX5M;"PT6S6^
MU_59?)LK=@2HQC<[8QP,@<D=<] :YCXG?\E:^'/_ %]-_P"AQUF?$^+5Y?C?
MX4CTS5(]-GDLVCM;F6$2K'*3*#\I!!+ JOL2#Q0!L?\ "-_&&SM1>P^,K"\O
M NY[*6V148XR5#;.N>!]T>XKK/A_XV3QOX;:^:U:VO[:0V]Y:GJDH )P#S@Y
MXSWR.V:Y[_A%_BS_ -%"LO\ P61?_$59\$>%+GX;:9XEU?7=4COC<$WUQ)!"
M5("*[.<>IR>!0!DPM\5?&FI7<L5PGA#2H)2D,<MN))Y>F"<@Y'N"!D\9QQ-X
M<\3>+O#_ ,1+7P9XOO+344OH&EL[Z) C$J"<,  /X6'(SG')K/T#5?B?\1[#
M^V-/U/3?#FCRNRP!8!/*X!VD_,#QD,,Y4Y'3'-8KZ-JVB_'KPC!K?B*36[R2
M%Y/->(1"-2L@"A03QD,<\9].* /?Z*** "BBB@ HHHH **** "BBB@ HHHH
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M57\]I8>S"O3J155%"J J@8 '0"EH QY?"VBS>)X?$DEBK:O#%Y,=R7;Y$Y&
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MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KS_XS?\D[N/\
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M^G;F127DE<#?*YZLV/P'L !VK%U3P9J'B/XA66K:S<6YT+2U#V-C$[$R3_\
M/20%0!CC !/W1ZD'N** .7\?>$%\:^%Y-,6<6]S'(MQ:S%<A)5SC(]""0?KW
MZ5S2>$_&GB7Q+HMWXPGT:+3]&G%S%%IOF%IY@/E8EN@# ''IQCN/3:* .$^,
M.N?V'\-=3V9,]^!8PJ!G<9,AA_WP'K9\!Z!)X7\#Z3H\Q4SV\'[W;T#L2S >
MO+'GO5K5?"^E:WJVFZEJ$#3SZ:_FVH,A"(_'S;1P3P.O3%;% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% 'GGPJZ^*O\ L-3?TKT.O//A
M5U\5?]AJ;^E>AUK6^-B04445D,**** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH \OU_X;ZW9>+;CQ5X%U:#3[ZZR;NTNE)AF8\D\ \D\X(ZY.
M1FL^^\&?$[QC$NF>)]?TRST<L&N$T]3YDPR/EY4<=>^,XR#V]@HH I:3I5IH
MFDVNF6$7E6MM&(XTR3@#W/6KM%% 'D?BF)_"GQQT#Q*546&LI_9UP_E_=DP
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MVOY-_A1_PLOP;_T'[7\F_P *U/\ A%/#G_0 TK_P#C_PH_X13PY_T -*_P#
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MVOY-_A1_PLOP;_T'[7\F_P *U/\ A%/#G_0 TK_P#C_PH_X13PY_T -*_P#
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M@W_H/VOY-_A1_P ++\&_]!^U_)O\*U/^$4\.?] #2O\ P#C_ ,*/^$4\.?\
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M@W_H/VOY-_A1_P ++\&_]!^U_)O\*U/^$4\.?] #2O\ P#C_ ,*/^$4\.?\
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M@W_H/VOY-_A1_P ++\&_]!^U_)O\*U/^$4\.?] #2O\ P#C_ ,*/^$4\.?\
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M*:[K'&SN<*H))] *\7TK4/''Q;FO-0TO6W\,>'893%;>7%OFF(QDD@@^F<'
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!YY\+/]9XL_[#<_\
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M.#]?6Z8(HQ*91&@D(P7QR?QH 5$6.-40 *HP .PIU%% !1110 4444 %%%%
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M ,17H=%'/'^7\_\ ,#SS_A//%W_1.;[_ ,#!_P#$4?\ ">>+O^B<WW_@8/\
MXBO0Z*.>/\OY_P"8'GG_  GGB[_HG-]_X&#_ .(H_P"$\\7?]$YOO_ P?_$5
MZ'11SQ_E_/\ S \\_P"$\\7?]$YOO_ P?_$4?\)YXN_Z)S??^!@_^(KT.BCG
MC_+^?^8'AW@;Q5X@TY]>-EX.NM0,^IRRRA+@+Y#GK&?E.2/7BNN_X3SQ=_T3
MF^_\#!_\11\+/]9XL_[#<_\ 2O0ZNK.*F_=_,$>>?\)YXN_Z)S??^!@_^(H_
MX3SQ=_T3F^_\#!_\17H=%1SQ_E_/_,#SS_A//%W_ $3F^_\  P?_ !%'_">>
M+O\ HG-]_P"!@_\ B*]#HHYX_P OY_Y@>>?\)YXN_P"B<WW_ (&#_P"(H_X3
MSQ=_T3F^_P# P?\ Q%>AT4<\?Y?S_P P///^$\\7?]$YOO\ P,'_ ,11_P )
MYXN_Z)S??^!@_P#B*]#HHYX_R_G_ )@>>?\ ">>+O^B<WW_@8/\ XBC_ (3S
MQ=_T3F^_\#!_\17H=%'/'^7\_P#,#SS_ (3SQ=_T3F^_\#!_\11_PGGB[_HG
M-]_X&#_XBO0Z*.>/\OY_Y@>>?\)YXN_Z)S??^!@_^(H_X3SQ=_T3F^_\#!_\
M17H=%'/'^7\_\P///^$\\7?]$YOO_ P?_$4?\)YXN_Z)S??^!@_^(KT.BCGC
M_+^?^8'GG_">>+O^B<WW_@8/_B*/^$\\7?\ 1.;[_P #!_\ $5Z'11SQ_E_/
M_,#SS_A//%W_ $3F^_\  P?_ !%'_">>+O\ HG-]_P"!@_\ B*]#HHYX_P O
MY_Y@>>?\)YXN_P"B<WW_ (&#_P"(H_X3SQ=_T3F^_P# P?\ Q%>AT4<\?Y?S
M_P P///^$\\7?]$YOO\ P,'_ ,11_P )YXN_Z)S??^!@_P#B*]#HHYX_R_G_
M )@>>?\ ">>+O^B<WW_@8/\ XBC_ (3SQ=_T3F^_\#!_\17H=%'/'^7\_P#,
M#SS_ (3SQ=_T3F^_\#!_\11_PGGB[_HG-]_X&#_XBO0Z*.>/\OY_Y@>>?\)Y
MXN_Z)S??^!@_^(H_X3SQ=_T3F^_\#!_\17H=%'/'^7\_\P///^$\\7?]$YOO
M_ P?_$4?\)YXN_Z)S??^!@_^(KT.BCGC_+^?^8'GG_">>+O^B<WW_@8/_B*/
M^$\\7?\ 1.;[_P #!_\ $5Z'11SQ_E_/_,#SS_A//%W_ $3F^_\  P?_ !%'
M_">>+O\ HG-]_P"!@_\ B*]#HHYX_P OY_Y@>>?\)YXN_P"B<WW_ (&#_P"(
MH_X3SQ=_T3F^_P# P?\ Q%>AT4<\?Y?S_P P///^$\\7?]$YOO\ P,'_ ,11
M_P )YXN_Z)S??^!@_P#B*]#HHYX_R_G_ )@>>?\ ">>+O^B<WW_@8/\ XBC_
M (3SQ=_T3F^_\#!_\17H=%'/'^7\_P#,#SS_ (3SQ=_T3F^_\#!_\11_PGGB
M[_HG-]_X&#_XBO0Z*.>/\OY_Y@>>?\)YXN_Z)S??^!@_^(H_X3SQ=_T3F^_\
M#!_\17H=%'/'^7\_\P///^$\\7?]$YOO_ P?_$4?\)YXN_Z)S??^!@_^(KT.
MBCGC_+^?^8'GG_">>+O^B<WW_@8/_B*/^$\\7?\ 1.;[_P #!_\ $5Z'11SQ
M_E_/_,#SS_A//%W_ $3F^_\  P?_ !%'_">>+O\ HG-]_P"!@_\ B*]#HHYX
M_P OY_Y@>>?\)YXN_P"B<WW_ (&#_P"(H_X3SQ=_T3F^_P# P?\ Q%>AT4<\
M?Y?S_P P/#O OBGQ!IO]N_8?!UUJ'GZE)++LN ODN<90_*<D>M==_P )YXN_
MZ)S??^!@_P#B*/A5U\5?]AJ;^E>AU=6<5-^[^8(\\_X3SQ=_T3F^_P# P?\
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MN_Z)S??^!@_^(H_X3SQ=_P!$YOO_  ,'_P 17H=%'/'^7\_\P///^$\\7?\
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M;>'=!O=8NTE>WM(S)(L(!<@>@) S^- &C16=H&M6WB+0;+6+1)4M[N,21K,
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MO;HKJXB[%PW(/\QS@9H \_\ V;K"V3P?JNH+&/M4M^8'D[E$C1E'YNWYU/\
M&2*.W\9> -0B4)=C4UC\T=2H>,@'U&2?S/K2_LX_\D\U#_L*R?\ HJ*G?&K_
M )&#P#_V%A_Z''0 ?M _\B_X?_["R?\ H#5L?&CPOJGB?P9 FD6YNKFRNUNC
M;9'[U0K @ ]3\W3J>0.36/\ M _\B_X?_P"PLG_H#5UWQ#\0>(?#&DVNJ:)I
M<>HVT5P#J$>UFE6#J2@'3H02<XR#C&2 #DH/C/X=O+-M'\7Z%?Z,TZF":"YM
MRT14_*PZ!@!SGY>*V/%=_I7AKX):E=^%&C33_LNRT>UD)"^:X0LISD$%R?7.
M>]8GB#XS^ ]:\-W-I]EN=4N+B,I%I[VIW-(P(49/ Y/4$D=LGBIO G@+4)O@
M==>'-762SN=1$LB1R@AH"<;-P[<J&(ZX..#F@#J/A7HEGHGPXT5;6%$>[M8[
MN=P.9'D4-DGO@$#V  J\_@;1CXXB\71K-#J:1&)Q$X6.8$%<NN/F."._\*^E
M><>#_BA!X(TF'PIXYM+W3[_308(Y_*,D<L:_=P1SP, 8R" #GM70>$_'6M^.
MO&S2Z19/;^#K:)M]S<V^UKF7D (V<=2#QT"\X+ 4 <3J7BS3K7X\:OJ.LZ3J
M>J1Z7$EO80VD F\AP%)D(+ #G=C_ 'O4 UM>*_BCH?B;PMJ6CS>$O$[_ &F!
MDC,FGKA),?(V=YQAL'..U.\5KJ/PW^*$WCF"QN;_ $'4X!#J,<'+0,H'S8Z8
MP@()XY89&15W5/COH,EDT'ABVO=6UF9=MK;+:OCS"#C<."0.X7)/3CJ #.L)
M+]OV7[M-1CECGALYHE65"C;%D(7@^@P/PKLOA%8V]C\+M#%O&J>="9I"!R[L
MQ))/?T^@ [56\9S:K<?!'5)];MX+?4Y-.W7$,!)2-C@[1DGIWY/.>3UK1^%O
M_),/#W_7HO\ ,T <99V\6G_M/70M(UA%WI9DG"# =B%))'N5!/J>>I-+-'#X
MI_:3DLK]/.MM TU9H(9#E/,.QMVWIG,H_%!Z"I/^;G_^X1_2D\=VFJ>"_B/:
M?$+3K*>_TZ6 6FJ00\NJ] V/3A3Z93DC(H ]-UW1+#Q'HMUI.I0B6UN4*,,#
M*^C+GHP/(/8BO/\ XB0)X!^"-UI6DS7/EJ%M8I)9-SJLDF6!/'&TLH]!BJNJ
M_'?1+C2C#X7M[[4=<N 4M;3[(QVOZL!U ]%R3^M=!J_AK6O&/PD?2-=EB37;
MFW$K%%V(DP;>B'&>!@*2,]R* .0\(?$WP[X6\+V&E67A+Q,JQ1+YDD>GIB:3
M W.3YG))Y_+L*S],UU==^/.CZWH>AZMI\%S;O;Z@;RT\L2D*YW'!([)SD?='
MXZGA;XP6/AO18= \:VM_INKZ;$(&+PF07"K\H8$<YXY/0]03GCHO"/Q!U7QO
MXME.DZ.8O"<,)!O[J-DDFE!QB,@[2/;&0 22"0M 'HE%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110!YY\+/\ 6>+/^PW/_2O0Z\\^%G^L\6?]AN?^E>AUK6^-B044
M45D,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KQOPTH^)/Q<OO
M%+GS-$T$_9=.'!6209R_7W+ X[IZ5T?Q?\43:#X1_L[3R3J^M/\ 8K1%.&^;
M =A] 0,]BZFN@\$>&(?"'A&PT>/!>)-TSC^.0\L>I[T =#1110!Y!HQ:X_:@
M\0B1V(M]*01CT!6#C\V)KU^O(-7(T#]I'2;V4E+?6; P>85X\P @+GURD?\
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M*NOBK_L-3?TKT.O//A5U\5?]AJ;^E>AUK6^-B04445D,**** "BBB@ HHHH
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M $_QH_X0_P >?]%!;_P 3_&O0Z*/:R\ON06///\ A#_'G_106_\  !/\:/\
MA#_'G_106_\  !/\:]#HH]K+R^Y!8\\_X0_QY_T4%O\ P 3_ !H_X0_QY_T4
M%O\ P 3_ !KT.BCVLO+[D%CSS_A#_'G_ $4%O_ !/\:/^$/\>?\ 106_\ $_
MQKT.BCVLO+[D%CSS_A#_ !Y_T4%O_ !/\:/^$/\ 'G_106_\ $_QKT.BCVLO
M+[D%CSS_ (0_QY_T4%O_   3_&C_ (0_QY_T4%O_   3_&O0Z*/:R\ON06//
M/^$/\>?]%!;_ , $_P :/^$/\>?]%!;_ , $_P :]#HH]K+R^Y!8\\_X0_QY
M_P!%!;_P 3_&C_A#_'G_ $4%O_ !/\:]#HH]K+R^Y!8\\_X0_P >?]%!;_P
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M#_'G_106_P# !/\ &C_A#_'G_106_P# !/\ &O0Z*/:R\ON06///^$/\>?\
M106_\ $_QH_X0_QY_P!%!;_P 3_&O0Z*/:R\ON06///^$/\ 'G_106_\ $_Q
MH_X0_P >?]%!;_P 3_&O0Z*/:R\ON06///\ A#_'G_106_\  !/\:/\ A#_'
MG_106_\  !/\:]#HH]K+R^Y!8\\_X0_QY_T4%O\ P 3_ !H_X0_QY_T4%O\
MP 3_ !KT.BCVLO+[D%CSS_A#_'G_ $4%O_ !/\:/^$/\>?\ 106_\ $_QKT.
MBCVLO+[D%CRW3/AMXMT@W1L?&X@-U,T\NVR!WN>K')X-7_\ A#_'G_106_\
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MC1_PA_CS_HH+?^ "?XUZ'11[67E]R"QYY_PA_CS_ **"W_@ G^-'_"'^//\
MHH+?^ "?XUZ'11[67E]R"QYY_P (?X\_Z*"W_@ G^-'_  A_CS_HH+?^ "?X
MUZ'11[67E]R"QYY_PA_CS_HH+?\ @ G^-'_"'^//^B@M_P" "?XUZ'11[67E
M]R"QYY_PA_CS_HH+?^ "?XT?\(?X\_Z*"W_@ G^->AT4>UEY?<@L>>?\(?X\
M_P"B@M_X )_C1_PA_CS_ **"W_@ G^->AT4>UEY?<@L>>?\ "'^//^B@M_X
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MON06///^$/\ 'G_106_\ $_QH_X0_P >?]%!;_P 3_&O0Z*/:R\ON06///\
MA#_'G_106_\  !/\:/\ A#_'G_106_\  !/\:]#HH]K+R^Y!8\\_X0_QY_T4
M%O\ P 3_ !H_X0_QY_T4%O\ P 3_ !KT.BCVLO+[D%CSS_A#_'G_ $4%O_ !
M/\:/^$/\>?\ 106_\ $_QKT.BCVLO+[D%CSS_A#_ !Y_T4%O_ !/\:/^$/\
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M?]%!;_P 3_&O0Z*/:R\ON06///\ A#_'G_106_\  !/\:/\ A#_'G_106_\
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MT4%O_ !/\:]#HH]K+R^Y!8\\_P"$/\>?]%!;_P  $_QH_P"$/\>?]%!;_P
M$_QKT.BCVLO+[D%CSS_A#_'G_106_P# !/\ &C_A#_'G_106_P# !/\ &O0Z
M*/:R\ON06///^$/\>?\ 106_\ $_QH_X0_QY_P!%!;_P 3_&O0Z*/:R\ON06
M///^$/\ 'G_106_\ $_QH_X0_P >?]%!;_P 3_&O0Z*/:R\ON06///\ A#_'
MG_106_\  !/\:/\ A#_'G_106_\  !/\:]#HH]K+R^Y!8\\_X0_QY_T4%O\
MP 3_ !H_X0_QY_T4%O\ P 3_ !KT.BCVLO+[D%CSS_A#_'G_ $4%O_ !/\:/
M^$/\>?\ 106_\ $_QKT.BCVLO+[D%CSS_A#_ !Y_T4%O_ !/\:HZO\-_%VN:
I>UEJ/C<7-NS!C&]D%!(Z<@YKU&BA5I+56^Y!81%VHJ^@Q2T45D,__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>img11953243_9.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img11953243_9.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +J!, # 2(  A$! Q$!_\0
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M78+GJM%>5?\ "_O"?]RZ_P"^*/\ A?WA/^Y=?]\4>SEV"YZK17E7_"_O"?\
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MPG_<NO\ OBC_ (7]X3_N77_?%'LY=@N>JT5Y5_PO[PG_ '+K_OBC_A?WA/\
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M_P"^*/\ A?WA/^Y=?]\4>SEV"YZK17E7_"_O"?\ <NO^^*/^%_>$_P"Y=?\
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MRI:* $VK_='Y4;5_NC\J6B@!-J_W1^5&U?[H_*EHH 3:O]T?E1M7^Z/RI:*
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MZX!1A0*TI1:<F^HF+1116H!1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%%  .M>U_L[_\@S6/^NXKQ0=:]K_9W_Y!FL?]
M=Q7+C/X8X[GMM%%%>86%%%% !1110 4444 ?*_Q<_P"2IWG_ %R%<?78?%S_
M )*G>?\ 7(5Q]>OA_P"&C-[A1116P!110>!0 45V_A'X?1^)M%;4YKSR(U;;
MUQ5^_P#A0_V.271K^.[F09,>[G%9NK!.S869YS13IHI+:9X9UV2(<,#ZTPG
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M\4""B@$$9%% PHHHH *1ON-]#2TC?<;Z&@1]!_ '_D0G_P"OAJ]6KRGX _\
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M?>K6DZO>Z%J"7VGRF.=.GI51XY(FVR(R-Z-3:=DU8#N[GXO>*)XD"2QI(.K
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M_'[/_OFO0?@]HGV_Q#)J<A AMU()/8UO.7+!R$CM?%>B:-=^$IM*M8%-]IL
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M Z72_'_B'2H5MX[O?;HN$1AG%96K:]J>O3"74KDS,#\H["L^D!!&1248IW2
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M'J*3"^@H=).^NX7-WQ9XCG\5:Z^H3H$ ^6,#LM8E%&:T225D 4444P"BBB@
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MW-U SO&"W$/Q<L/[,B0W0@0QH>A.*Q?$UGKNO^+?LMS;HNH'C:G05TNOD_\
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M?PPOAK546VW&QE0-&Y]ZYFO3/']W'J?PVT&_0[BS;"?I7F=52;<=084445H
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M8O\ 61L,5N>,?$D7B-[ 0*4BM(]@%<U2IQM'7J#/HB^2TL=.D\9K,BRW%GL
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MZ2KYM^/'_(_V'_7O6F&_B(3V/.:***]8S"BBB@84444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%%  .M>U_L[_\ (,UC_KN*\4'6O:_V=_\
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M1]=78.4^7_M$'_/5/SH^T0?\]4_.OJ#_ (4[X)_Z!0_[[H_X4[X)_P"@4/\
MONCZZNP<I\O_ &B#_GJGYT?:(/\ GJGYU]0?\*=\$_\ 0*'_ 'W1_P *=\$_
M] H?]]T?75V#E/E_[1!_SU3\Z/M$'_/5/SKZ@_X4[X)_Z!0_[[H_X4[X)_Z!
M0_[ZH^NKL'*?,!FB7&Z11GIDTGVB#_GJGYU[CX*^'/AC6+W6X[VQ\Q;6Z\N(
M$XVKS77_ /"G?!/_ $"A_P!]U4L6HNU@Y3Y?^T0?\]4_.C[1!_SU3\Z^H/\
MA3O@G_H%#_ONC_A3O@G_ *!0_P"^ZGZZNP<I\O\ VB#_ )ZI^='VB#_GJGYU
M]0?\*=\$_P#0*'_?='_"G?!/_0*'_?='UU=@Y3Y?^T0?\]4_.C[1!_SU3\Z^
MH/\ A3O@G_H%#_ONC_A3O@G_ *!0_P"^Z/KJ[!RGR_\ :(/^>J?G1]H@_P">
MJ?G7U!_PIWP3_P! H?\ ?='_  IWP3_T"A_WW1]=78.4^7_M$'_/5/SH^T0?
M\]4_.OJ#_A3O@G_H%#_ONC_A3O@G_H%#_ONCZZNP<I\O_:(/^>J?G1]H@_YZ
MI^=?4'_"G?!/_0*'_?='_"G?!/\ T"A_WW1]=78.4^7_ +1!_P ]4_.C[1!_
MSU3\Z^H/^%.^"?\ H%#_ +[H_P"%.^"?^@4/^^Z/KJ[!RGR_]H@_YZI^='VB
M#_GJGYU]0?\ "G?!/_0*'_?='_"G?!/_ $"A_P!]T?75V#E/E_[1!_SU3\Z/
MM$'_ #U3\Z^H/^%.^"?^@4/^^Z/^%.^"?^@4/^^Z/KJ[!RGR_P#:(/\ GJGY
MT?:(/^>J?G7U!_PIWP3_ - H?]]T?\*=\$_] H?]]T?75V#E/E_[1!_SU3\Z
M/M$'_/5/SKZ@_P"%.^"?^@4/^^Z/^%.^"?\ H%#_ +[H^NKL'*?+_P!H@_YZ
MI^='VB#_ )ZI^=?4'_"G?!/_ $"A_P!]T?\ "G?!/_0*'_?='UU=@Y3Y?^T0
M?\]4_.C[1!_SU3\Z^H/^%.^"?^@4/^^Z/^%.^"?^@4/^^Z/KJ[!RGR_]H@_Y
MZI^='VB#_GJGYU]0?\*=\$_] H?]]T?\*=\$_P#0*'_?='UU=@Y3Y?\ M$'_
M #U3\Z/M$'_/5/SKZ@_X4[X)_P"@4/\ ONC_ (4[X)_Z!0_[[H^NKL'*?+_V
MB#_GJGYT?:(/^>J?G7U!_P *=\$_] H?]]T?\*=\$_\ 0*'_ 'W1]=78.4^7
MQ<09_P!<GYU[=^SJP;3-8P0?WPKLO^%.^"?^@4/^^ZZ'PYX2T;PI#+%H]J($
ME.7&<Y-8UL0JD;6&E8VZ***Y2@HHHH **** "BBB@#Y5^+TB)\4[W<X7]V.I
MKC?M$'_/5/SKZPUOX;^%_$.IOJ.I:>);EQAGW8S6?_PIWP3_ - H?]]UVT\4
MH14;$N)\O_:(/^>J?G1]H@_YZI^=?4'_  IWP3_T"A_WW1_PIWP3_P! H?\
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M - H?]]T?75V#E/E_P"T0?\ /5/SH^T0?\]4_.OJ#_A3O@G_ *!0_P"^Z/\
MA3O@G_H%#_ONCZZNP<I\O_:(/^>J?G1]H@_YZI^=?4'_  IWP3_T"A_WW1_P
MIWP3_P! H?\ ?='UU=@Y3Y?^T0?\]4_.C[1!_P ]4_.OJ#_A3O@G_H%#_ONC
M_A3O@G_H%#_ONCZZNP<I\O\ VB#_ )ZI^='VB#_GJGYU]0?\*=\$_P#0*'_?
M='_"G?!/_0*'_?='UU=@Y3Y?^T0?\]4_.C[1!_SU3\Z^H/\ A3O@G_H%#_ON
MC_A3O@G_ *!0_P"^Z/KJ[!RGR_\ :(/^>J?G1]H@_P">J?G7U!_PIWP3_P!
MH?\ ?='_  IWP3_T"A_WW1]=78.4^7_M$'_/5/SH^T0?\]4_.OJ#_A3O@G_H
M%#_ONC_A3O@G_H%#_ONCZZNP<I\O_:(/^>J?G1]H@_YZI^=?4'_"G?!/_0*'
M_?='_"G?!/\ T"A_WW1]=78.4^7_ +1!_P ]4_.C[1!_SU3\Z^H/^%.^"?\
MH%#_ +[H_P"%.^"?^@4/^^Z/KJ[!RGR_]H@_YZI^='VB#_GJGYU]0?\ "G?!
M/_0*'_?='_"G?!/_ $"A_P!]T?75V#E/E_[1!_SU3\Z7SHMN[S%QZYKZ?_X4
M[X)_Z!0_[ZKC[+X<^%YOB7?:0]CFRBMPZ1YZ-51Q:=]-@Y3P_P"T0?\ /5/S
MH^T0?\]4_.OJ#_A3O@G_ *!0_P"^Z/\ A3O@G_H%#_ONI^NKL'*?+_VB#_GJ
MGYT?:(/^>J?G7U!_PIWP3_T"A_WW1_PIWP3_ - H?]]T?75V#E/E_P"T0?\
M/5/SH^T0?\]4_.OJ#_A3O@G_ *!0_P"^Z/\ A3O@G_H%#_ONCZZNP<I\O_:(
M/^>J?G1]H@_YZI^=?4'_  IWP3_T"A_WW1_PIWP3_P! H?\ ?='UU=@Y3Y?^
MT0?\]4_.C[1!_P ]4_.OJ#_A3O@G_H%#_ONC_A3O@G_H%#_ONCZZNP<I\O\
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MQ1_PCFC?] VW_P"^*=Z?9AJ8W_"PM#_Y['\J/^%A:'_SV/Y5L_\ ".:-_P!
MVW_[XH_X1S1O^@;;_P#?%%Z?9AJ8W_"PM#_Y['\J/^%A:'_SV/Y5L_\ ".:-
M_P! VW_[XH_X1S1O^@;;_P#?%%Z?9AJ8W_"PM#_Y['\J/^%A:'_SV/Y5L_\
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M $#;?_OBB]/LPU,;_A86A_\ /8_E1_PL+0_^>Q_*MG_A'-&_Z!MO_P!\4?\
M".:-_P! VW_[XHO3[,-3&_X6%H?_ #V/Y4?\+"T/_GL?RK9_X1S1O^@;;_\
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MZ"\/ZT?\+#\*_P#07A_6KG_"'^'?^@/:?]\4?\(?X=_Z ]I_WQ1^[\PU*?\
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M4HQIIW)3U.^HHHKC*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/\P?VA_=/>?^%Y^#_P#GK<?]^Z/^%Y^#_P#GK<?]^Z\&\N/_ )YI^5'EQ_\
M/-/RH_LV/\P?VA_=/>?^%Y^#_P#GK<?]^Z/^%Y^#_P#GK<?]^Z\&\N/_ )YI
M^5'EQ_\ /-/RH_LV/\P?VA_=/>?^%Y^#_P#GK<?]^Z/^%Y^#_P#GK<?]^Z\&
M\N/_ )YI^5'EQ_\ /-/RH_LV/\P?VA_=/>?^%Y^#_P#GK<?]^Z/^%Y^#_P#G
MK<?]^Z\&\N/_ )YI^5'EQ_\ /-/RH_LV/\P?VA_=/>?^%Y^#_P#GK<?]^Z/^
M%Y^#_P#GK<?]^Z\&\N/_ )YI^5'EQ_\ /-/RH_LV/\P?VA_=/>?^%Y^#_P#G
MK<?]^Z/^%Y^#_P#GK<?]^Z\&\N/_ )YI^5'EQ_\ /-/RH_LV/\P?VA_=/>?^
M%Y^#_P#GK<?]^Z/^%Y^#_P#GK<?]^Z\&\N/_ )YI^5'EQ_\ /-/RH_LV/\P?
MVA_=/>?^%Y^#_P#GK<?]^Z/^%Y^#_P#GK<?]^Z\&\N/_ )YI^5'EQ_\ /-/R
MH_LV/\P?VA_=/>?^%Y^#_P#GK<?]^Z/^%Y^#_P#GK<?]^Z\&\N/_ )YI^5'E
MQ_\ /-/RH_LV/\P?VA_=/>?^%Y^#_P#GK<?]^ZXN7QIX"D\=IKNV81A,D;.K
M^N*\Z\N/_GFGY4;$_P">:?E51R]1VD+^T/[I[S_PO+P?_P ];C_OW1_PO/P?
M_P ];C_OW7@WEQ_\\T_*CRX_^>:?E4_V;'^8?]H?W3WG_A>?@_\ YZW'_?NC
M_A>?@_\ YZW'_?NO!O+C_P">:?E1Y<?_ #S3\J/[-C_,']H?W3WG_A>?@_\
MYZW'_?NC_A>?@_\ YZW'_?NO!O+C_P">:?E1Y<?_ #S3\J/[-C_,']H?W3WG
M_A>?@_\ YZW'_?NC_A>?@_\ YZW'_?NO!O+C_P">:?E1Y<?_ #S3\J/[-C_,
M']H?W3WG_A>?@_\ YZW'_?NC_A>?@_\ YZW'_?NO!O+C_P">:?E1Y<?_ #S3
M\J/[-C_,']H?W3WG_A>?@_\ YZW'_?NC_A>?@_\ YZW'_?NO!O+C_P">:?E1
MY<?_ #S3\J/[-C_,']H?W3WG_A>?@_\ YZW'_?NC_A>?@_\ YZW'_?NO!O+C
M_P">:?E1Y<?_ #S3\J/[-C_,']H?W3WG_A>?@_\ YZW'_?NC_A>?@_\ YZW'
M_?NO!O+C_P">:?E1Y<?_ #S3\J/[-C_,']H?W3WG_A>?@_\ YZW'_?NC_A>?
M@_\ YZW'_?NO!O+C_P">:?E1Y<?_ #S3\J/[-C_,']H?W3WG_A>?@_\ YZW'
M_?NC_A>?@_\ YZW'_?NO!O+C_P">:?E1Y<?_ #S3\J/[-C_,']H?W3WG_A>?
M@_\ YZW'_?NC_A>?@_\ YZW'_?NO!O+C_P">:?E1Y<?_ #S3\J/[-C_,']H?
MW3WG_A>?@_\ YZW'_?NI;;XV>$;J\AMHYIQ),X1<Q\9-> ^7'_SS3\J2%$&M
M:3A%'^E+T'O45,OC"#E?8NGC>>:CR[GV(I#*".A&:6F1?ZE/]T4^O+.\Y+Q5
M\1-#\(7T-GJ;RB:9=R+&N<BL/_A=WA3_ *>_^_5<O\4U1OB=I&]%8?9SPPS6
M<8H=Q_<1=?[@JM$!W/\ PN[PI_T]_P#?JC_A=WA3_I[_ ._5<-Y4/_/"+_O@
M4>5#_P \(O\ O@47CV [G_A=WA3_ *>_^_5'_"[O"G_3W_WZKAO*A_YX1?\
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M_GK<?]^Z\ M$3[%!^[3[@[5-Y<?_ #S3\J]19;&WQ'FO,+.W*>\_\+S\'_\
M/6X_[]T?\+S\'_\ /6X_[]UX-Y<?_/-/RH\N/_GFGY4?V;'^8/[0_NGO/_"\
M_!__ #UN/^_='_"\_!__ #UN/^_=>#>7'_SS3\J/+C_YYI^5']FQ_F#^T/[I
M[S_PO/P?_P ];C_OW1_PO/P?_P ];C_OW7@WEQ_\\T_*CRX_^>:?E1_9L?Y@
M_M#^Z>\_\+S\'_\ /6X_[]T?\+S\'_\ /6X_[]UX-Y<?_/-/RH\N/_GFGY4?
MV;'^8/[0_NGO/_"\_!__ #UN/^_='_"\_!__ #UN/^_=>#>7'_SS3\J/+C_Y
MYI^5']FQ_F#^T/[I[S_PO/P?_P ];C_OW1_PO/P?_P ];C_OW7@WEQ_\\T_*
MCRX_^>:?E1_9L?Y@_M#^Z>\_\+S\'_\ /6X_[]T?\+S\'_\ /6X_[]UX-Y<?
M_/-/RH\N/_GFGY4?V;'^8/[0_NGO/_"\_!__ #UN/^_='_"\_!__ #UN/^_=
M>#>7'_SS3\J/+C_YYI^5']FQ_F#^T/[I[S_PO/P?_P ];C_OW1_PO/P?_P ]
M;C_OW7@WEQ_\\T_*CRX_^>:?E1_9L?Y@_M#^Z>\_\+S\'_\ /6X_[]T?\+S\
M'_\ /6X_[]UX-Y<?_/-/RH\N/_GFGY4?V;'^8/[0_NGO/_"\_!__ #UN/^_=
M5-4^,7@G5=-GLIWN&CE0J1Y=>(^7'_SS3\J/+C_YYI^5-9;%?:%_:']T[[X?
M>-?!OA-KNXF,XN)7(0A,_)7=_P#"\_!__/6X_P"_=>#[$/\ RS7\J3RX_P#G
MFGY4YY>IN[D"S#^Z>\_\+S\'_P#/6X_[]T?\+S\'_P#/6X_[]UX-Y<?_ #S3
M\J/+C_YYI^53_9L?YA_VA_=/>?\ A>?@_P#YZW'_ '[H_P"%Y^#_ /GK<?\
M?NO!O+C_ .>:?E1Y<?\ SS3\J/[-C_,']H?W3WG_ (7GX/\ ^>MQ_P!^Z/\
MA>?@_P#YZW'_ '[KP;RX_P#GFGY4>7'_ ,\T_*C^S8_S!_:']T]Y_P"%Y^#_
M /GK<?\ ?NC_ (7GX/\ ^>MQ_P!^Z\&\N/\ YYI^5'EQ_P#/-/RH_LV/\P?V
MA_=/>?\ A>?@_P#YZW'_ '[H_P"%Y^#_ /GK<?\ ?NO!O+C_ .>:?E1Y<?\
MSS3\J/[-C_,']H?W3WG_ (7GX/\ ^>MQ_P!^Z/\ A>?@_P#YZW'_ '[KP;RX
M_P#GFGY4>7'_ ,\T_*C^S8_S!_:']T]Y_P"%Y^#_ /GK<?\ ?NC_ (7GX/\
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M* "BBB@ HI,CUI: "BBB@ HHHH *2+_D-:3_ -?2_P Z6DB_Y#6D_P#7TO\
M.L<1_"EZ&V&_BQ/L"+_4I_NBGTR+_4I_NBGU\V>\>'_%+_DIVD?]>YJ@?O'Z
MU?\ BE_R4[2/^O<U0/WC]:J70!***,XJ0"BDR#WI: "BBB@ HI,CUI00>AH
M**** "BBDR,XS0 M%%% !1110 449STHR,XH **"0.M'6@ HHHR!WH **3(]
M:6@ HHHH **** "BBC(S0 4444 %%%% !10"#THH **** "BBC- !111D&@
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MG;XU_P#)1;+_ *]J^B:^=OC7_P E%LO^O:ML)_&B98C^%+T.&[T4=Z*^A/
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M*NY>6VGO1H&LQ^()IM-GLHEB*'80.10!PU%6=1M18ZC-;*<A#Q5:@#%\3?\
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M6QUQ4%"=]1-6$*@T!0.E+13 **** "BBB@ I" >M+10 @4"EHHH **** "D
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M1110 4444 %%%% !1110 4444 8OB;_CWT__ *^T_G7L/Q*_Y)9?_P#7NO\
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MT-L-_%B?8$7^I3_=%/ID7^I3_=%/KYL]X\/^*7_)3M(_Z]S5 _>/UJ_\4O\
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M86G6@OK^.V+A _5CT% %7/-+7?OHFD6^@SK;GS98P<O[UP,4<DT@CB1G<G
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MIGOVP8""_/:LWQGJUNUCIDEG<))+$P)"GIP*U-3\4VH\*[TG5[F2/:4!Y!H
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M_P E.TC_ *]S5 _>/UJ_\4O^2G:1_P!>YJ@?O'ZU4N@"4445(!1110 4444
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MNE<U1B@!H7 'J*7'.><_6EHH 3 SF@C/6EHH !Q1110 4444 %%%% !1110
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M8H DHJ/[3:_\_4/_ 'V*/M-K_P _4/\ WV* )**C^TVO_/U#_P!]BC[3:_\
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MX[(*Y3Q+\.O#WBR_2]U6W>2=%V!E?'%=714IM;#/.O\ A27@O_GSF_[^4?\
M"DO!?_/G-_W\KT6BGSR[BLCSK_A27@O_ )\YO^_E'_"DO!?_ #YS?]_*]%HH
MYY=PLCSK_A27@O\ Y\YO^_E'_"DO!?\ SYS?]_*]%HHYY=PLCSK_ (4EX+_Y
M\YO^_E'_  I+P7_SYS?]_*]%HHYY=PLCSK_A27@O_GSF_P"_E'_"DO!?_/G-
M_P!_*]%HHYY=PLCSK_A27@O_ )\YO^_E'_"DO!?_ #YS?]_*]%HHYY=PLCSK
M_A27@O\ Y\YO^_E'_"DO!?\ SYS?]_*]%HHYY=PLCSK_ (4EX+_Y\YO^_E'_
M  I+P7_SYS?]_*]%HHYY=PLCSK_A27@O_GSF_P"_E'_"DO!?_/G-_P!_*]%H
MHYY=PLCSK_A27@O_ )\YO^_E'_"DO!?_ #YS?]_*]%HHYY=PLCSK_A27@O\
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M'G__  I;P?\ \^]Q_P!_:/\ A2W@_P#Y][C_ +^UZ'16?,^XSSS_ (4MX/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "O+_$>I?V!\5;;4[BVFDMC:;-T:YP<5ZA3
M'ABD.7C1C_M*#5PERO4&<1_PM#3/^?&]_P"_9H_X6AIG_/C>_P#?LUVOV6W_
M .>$7_? H^RV_P#SPB_[X%/FAV_$6IQ7_"T-,_Y\;W_OV:/^%H:9_P ^-[_W
M[-=K]EM_^>$7_? H^RV__/"+_O@4<T.WXAJ<5_PM#3/^?&]_[]FC_A:&F?\
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MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *9+_ *E_]TT^F2_ZE_\
M=- '!?"G_D$ZI_U_/7H%>?\ PI_Y!.J?]?SUZ!6E;XV);!11168PHHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KD?B9_R(>H?1
M?YUUKL$1F8X &37G7Q#\4:1=^#[^UANE:8X 7OG-:4DW-6$SL?#7_(LZ;_U[
MI_*M6N3\+>)](FT;3;1+I3.($7;GOBNLJ9IIZC"BBBI **** "BBB@ HHHH
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MNO\ OBCV<NP7/5**\K_X7YX2]+K_ +XH_P"%^>$O2Z_[XH]G+L%SU2BO*_\
MA?GA+TNO^^*/^%^>$O2Z_P"^*/9R[!<]4HKRO_A?GA+TNO\ OBC_ (7YX2]+
MK_OBCV<NP7/5**\K_P"%^>$O2Z_[XH_X7YX2]+K_ +XH]G+L%SU2BO*_^%^>
M$O2Z_P"^*/\ A?GA+TNO^^*/9R[!<]4HKRO_ (7YX2]+K_OBC_A?GA+TNO\
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M**\K_P"%^>$O2Z_[XH_X7YX2]+K_ +XH]G+L%SU2BO*_^%^>$O2Z_P"^*/\
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M 'Q1_P +]\)?W;K_ +XH]G+L%SU2BL'PGXMT_P 8Z2=1TW?Y(<H=XP<BMZH
M*^;?CP ?']CD _Z/7TE7S;\>/^1_L/\ KWK?#?Q$)['G&U?[J_E1M7^ZOY4M
M%>L9B;5_NK^5&U?[J_E2T4 )M7^ZOY4;5_NK^5+10 FU?[J_E1M7^ZOY4M%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "G1-Y=S#*>D;AB/I3:* /H?P=\1K'Q%?6^F+8Q@J
MH4G ["K'C/XAV'A#5UT][&-RR[L[17EOPA _X3&/CO5SXX@?\)I!Q_RS'\JX
M?8P]MR]+%7T+G@70K+Q[XTO]=ND M86R8>QKJM7^*7A[P[J1TRULHF@C.URJ
MCBL?X"$&QUJ($;VZ"O*/$VFW>F>([ZWNX)!*\Q91M)XS5\BG5<9;(5[(]M\:
M>&-)\5^#6UW1K>..?9YA*CJ*SOA=X0TFR\/2>)-65)1S@/T7%=!X6@DTWX3W
M+79V"2!BN[CM5'1[2;4_@?<6MGEYF#X"GGK6/,U%POI<8D'Q;\/7.KC39+.,
M6K-Y8; Q7'_%K0M(MKFWO]&D@\MQF1(VKS:SL+F;4(].6&3[1OV?=/!KHO$?
M@O5/#-M'+J$TA$@R%9LUTQI1IS7*Q7N<R.110.11702%%%% PHHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "D;[C?0TM(WW&^AH$?0?P
M!_Y$)_\ KX:O5J\I^ /_ "(3_P#7PU>K5XM3XV:H*^;?CQ_R/]A_U[U])5\V
M_'C_ )'^P_Z]ZTPW\1">QYS1117K&84444#"BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***3<O]X?G0 M%(&!Z$&EH
M **** "BBD!!Z'- "T444 %%!('6D!!Z$&@!:*** "BCI1G/2@ HHHH ****
M .F\">([3POKRW]ZC/$.R]:G^(WBFR\8>((K^P1TB1-I#]<UR5%3R+FY^H&]
MX2\57?A/55NK<YC)^=?45ZLWQ9\%:B1<:AI6^Y5?F9D!KPNDP*B=&,W=A>QZ
M1X\^* \2:>-+TB,V]AW[&J?@'XCS>$2;:Z4RV+=5]*X3I2;E/ (-/V,.7DMH
M%SW5?BMX$B<WD>D8N,YW;!G->:>.?&MSXSU-96REM%Q$@]*Y7 ]*6E"C"#N@
MN%%%%:@%%%!('6@ HHHH **** "BBB@ HHHH ** 0>AHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH *1ON-]#2TC?<;Z&@1]!_ '_D0G_P"OAJ]6KRGX _\ (A/_ -?#
M5ZM7BU/C9J@KYM^/'_(_V'_7O7TE7S;\>/\ D?[#_KWK3#?Q$)['G-%%%>L9
MA1110,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@"WI<=M+J,27AQ 3\Q]J]*_L3X>!5S=C) SSWKRHC-=)X!\-?\)%X
MFA1D#6L)W3$]L5G46E[VL".E\?\ @W1=!\+VVIZ:?WDS< GJ*\VKM/B5K\>K
M:_\ 8K-B+*S'E!!TR*XL#+!1U)P**7-R>\# G S0.17=^"? ^IW'B73[B[M"
MU@3EPPX(JIXJ\%:K9:WJ5S':E;(2DI@<!:?M(\W+<+'.Z-ILFLZQ;V$1P9&&
M?IWK8\?:3I^A^(TL=-4K$L0WY[MWK2^%FFM<>)FU(_ZBU1MWUK)N;6_\8>+;
MY8"#*)6"Y]*7-[^^B0=#G:#P*ZV]^&VO:?:O<S^7Y:#)Q7)'J1Z'!JXR4MF!
MW'@GP1!K=A+K&IW"Q:='P<GJ:U]1\!Z%J^ERW?AF]5G@!+QYY.*\_&MW\>C#
M1XI&%NS9V+_$:]'\(67_  @?@Z\U?5AY<MTI$$)^\0?:L*G-'WK^B!'E3*4D
M>-OO(=I^M)W  ))Z 4Z5_-N)INTCE_SKT7X<:-I\>DWGB;4(UF$ (2)^A-;3
MERJ[!'+>%=".K>*+33KV)TBF&<D=:/&FC0^'O$DNGP<QJ.*]%\$_$&'7O%T=
MG=Z3;PDDB*2->5%8'C)K"+XJ>9J*/+ ASY:C):LE.7M+-= Z'GWD3_9S<>2_
MD@X+;346X8S@_E7MFEZ]?ZMK*6,7A..+2'8*#)'@D>M8RP:=HGQBDT=[.&2R
MF7D./N$^E-5MTUYA8\NSQFDW#&<'\17?W'@MX_BE'IT*@VS2^:RGILK4OXM#
MU?XJQ:0((;:SM0 2. Y]ZKVJZ=KA8\Q^S7!MA<>2_DG^/::C!R,U[;K&NWFA
MZS]@G\+QRZ*!CS(H\\>M>.ZM);3:Q=2V:E(&<E4/\(]**<W+H#*9./7\*DD@
MGAC626)U1NA(-='X*N=+L]3-QJ-I)=NH_=PHN037IOAJ\OO%5Q<VNK>&HK2P
M;(B8I@@>M*=3EZ: D>1^%]&_X2#7X=/W;5)RQQVKI_'5AX2T0#3M-MY/[07"
MN_;-:7@6\31?B'?:+%:QR1ASME8?,*I>.?%GE>,O*_LFV;R7'S$<MSWJ'*4J
MEEM8?0YG7_"MSX=M+6XGE\P7"!Q@=,UA %G"*I9CT &:]F^)7B4VOANS7^SH
M'\^ <D?<SZ4WPGX;30O!8U>VL$O]0N?FC609"TXUFH<TD%CQV:.2WE\J:-D?
MK@BF9^8* 23TP*]T_LNY\5>'-075]&BM+Z)"8I$7&:PO!_\ 9>@?#2^U#4[&
M*XNH+@HC.,G-'MM-M16/+)(98<>;&4STR*Z3P-X>@\2ZG/;7!PL:Y%4?$7B2
M7Q+.DTMI%;;.BQCJ*Z?X1?\ (?N_^N9_E5S;4&]F"W.*U>V6PUBZM$R5B?:,
M57EAF@C226)U1_NDJ>:[33KK3++Q[J5Q?V<EY(K'RX%7.37>>&[R^\57LEEJ
MOAF&UL2K>6S1X*CM4RJN*V"QX63TX)SZ"I9;:X@17EA=%;[I(/->@> ='L+C
MQ]K=K.L;BU+?9XY.C,.@K8OO$]RJW=AXC\,"*  K'-''P/2FZOO62"QY[X=\
M,W'B5;QK>7R_LJ[FR.M8\B&*=XCG*'!R*]8^$^MA;/6;9+.(I""RN1RP]#7G
MGB;5O[8UN6;[+';;#MVQC@TXSDYM/8#()P,U9L[.:XF@)B?R)'V[\&N@^'_A
MY/$'B-%N,?8X@6D'KBNKN/B-9Q^)$T>ST6V_LV*3RBQ7YN#UHE-I\L5<#FOB
M!X8M?"\NEI:_\O,(=_K7)PPS7#%88F<CK@5ZG\98H[[Q)X=AB^6*=%5?8&I?
M$>OV'P[CM='TK3;>YNE0-/)(.<&HA4?)'JV%CR3D,5((8<$$4^&":Y<I!$SL
M.P%>D^*[.P\5^!4\3:5;);72-MF11@&MNV6?0/!&F7_A_28-0EE3-S\N64TW
M6TVU"QXP0RL592K#J",4Z&*6Y<I!&SLHR0!VKN/$]W:^*KO3K6'3#IVHR.!,
MI7:#7>W]C=>%;"TM="T.&ZF*#S973.31*M9+35A8\(Y#%2"".H(HKUOX@>&X
M[OPK;ZZ;);*[C'[Z-!@$UY&IW*#ZU=.:FKH!:***L HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D;[C?0TM(WW&^AH
M$?0?P!_Y$)_^OAJ]6KRGX _\B$__ %\-7JU>+4^-FJ"OFWX\?\C_ &'_ %[U
M])5\V_'C_D?[#_KWK3#?Q$)['G-%%%>L9A1110,**** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4C?<;Z&EI&^XWT-
MCZ#^ /\ R(3_ /7PU>K5Y3\ ?^1"?_KX:O5J\6I\;-4%?-OQX_Y'^P_Z]Z^D
MJ^;/CV^SQ[8L58J+?J!FM,.[5$)['G5%0?:X_P"[+_WP:/M<?]V7_O@UZO-'
MN03T5!]KC_NR_P#?!H^UQ_W9?^^#1S1[@3T5!]KC_NR_]\&C[7'_ '9?^^#1
MS1[@3T5!]KC_ +LO_?!H^UQ_W9?^^#1S1[@3T5!]KC_NR_\ ?!H^UQ_W9?\
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MYH]P)Z*@^UQ_W9?^^#1]KC_NR_\ ?!HYH]P)Z*@^UQ_W9?\ O@T?:X_[LO\
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MFCW GHJ#[7'_ '9?^^#1]KC_ +LO_?!HYH]P)Z*@^UQ_W9?^^#1]KC_NR_\
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M_P#0)M/^_0H_X1G0_P#H$VG_ 'Z%:M%%P,K_ (1G0_\ H$VG_?H4?\(SH?\
MT";3_OT*U:*+@97_  C.A_\ 0)M/^_0H_P"$9T/_ *!-I_WZ%:M%%P,K_A&=
M#_Z!-I_WZ%'_  C.A_\ 0)M/^_0K5HHN!E?\(SH?_0)M/^_0H_X1G0_^@3:?
M]^A6K11<#*_X1G0_^@3:?]^A1_PC.A_] FT_[]"M6BBX&5_PC.A_] FT_P"_
M0H_X1G0_^@3:?]^A6K11<#*_X1G0_P#H$VG_ 'Z%'_",Z'_T";3_ +]"M6BB
MX&5_PC.A_P#0)M/^_0H_X1G0_P#H$VG_ 'Z%:M%%P,K_ (1G0_\ H$VG_?H4
M?\(SH?\ T";3_OT*U:*+@97_  C.A_\ 0)M/^_0H_P"$9T/_ *!-I_WZ%:M%
M%P,K_A&=#_Z!-I_WZ%'_  C.A_\ 0)M/^_0K5HHN!E?\(SH?_0)M/^_0H_X1
MG0_^@3:?]^A6K11<#*_X1G0_^@3:?]^A1_PC.A_] FT_[]"M6BBX&5_PC.A_
M] FT_P"_0H_X1G0_^@3:?]^A6K11<#*_X1G0_P#H$VG_ 'Z%'_",Z'_T";3_
M +]"M6BBX&5_PC.A_P#0)M/^_0H_X1G0_P#H$VG_ 'Z%:M%%P,K_ (1G0_\
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M_0)M/^_0K5HHN!E?\(SH?_0)M/\ OT*/^$9T/_H$VG_?H5JT47 RO^$9T/\
MZ!-I_P!^A1_PC.A_] FT_P"_0K5HHN!E?\(SH?\ T";3_OT*/^$9T/\ Z!-I
M_P!^A6K11<#*_P"$9T/_ *!-I_WZ%'_",Z'_ - FT_[]"M6BBX&5_P (SH?_
M $";3_OT*/\ A&=#_P"@3:?]^A6K11<#*_X1G0_^@3:?]^A1_P (SH?_ $";
M3_OT*U:*+@97_",Z'_T";3_OT*/^$9T/_H$VG_?H5JT47 RO^$9T/_H$VG_?
MH4?\(SH?_0)M/^_0K5HHN!E?\(SH?_0)M/\ OT*/^$9T/_H$VG_?H5JT47 R
MO^$9T/\ Z!-I_P!^A1_PC.A_] FT_P"_0K5HHN!E?\(SH?\ T";3_OT*/^$9
MT/\ Z!-I_P!^A6K11<#*_P"$9T/_ *!-I_WZ%'_",Z'_ - FT_[]"M6BBX&5
M_P (SH?_ $";3_OT*/\ A&=#_P"@3:?]^A6K11<#*_X1G0_^@3:?]^A1_P (
MSH?_ $";3_OT*U:*+@97_",Z'_T";3_OT*/^$9T/_H$VG_?H5JT47 RO^$9T
M/_H$VG_?H4?\(SH?_0)M/^_0K5HHN!E?\(SH?_0)M/\ OT*/^$9T/_H$VG_?
MH5JT47 RO^$9T/\ Z!-I_P!^A1_PC.A_] FT_P"_0K5HHN!E?\(SH?\ T";3
M_OT*/^$9T/\ Z!-I_P!^A6K11<#*_P"$9T/_ *!-I_WZ%'_",Z'_ - FT_[]
M"M6BBX&5_P (SH?_ $";3_OT*/\ A&=#_P"@3:?]^A6K11<#*_X1G0_^@3:?
M]^A1_P (SH?_ $";3_OT*U:*+@97_",Z'_T";3_OT*/^$9T/_H$VG_?H5JT4
M7 RO^$9T/_H$VG_?H4?\(SH?_0)M/^_0K5HHN!E?\(SH?_0)M/\ OT*/^$9T
M/_H$VG_?H5JT47 RO^$9T/\ Z!-I_P!^A1_PC.A_] FT_P"_0K5HHN!E?\(S
MH?\ T";3_OT*/^$9T/\ Z!-I_P!^A6K11<#*_P"$9T/_ *!-I_WZ%'_",Z'_
M - FT_[]"M6BBX&5_P (SH?_ $";3_OT*/\ A&=#_P"@3:?]^A6K11<#*_X1
MG0_^@3:?]^A1_P (SH?_ $";3_OT*U:*+@97_",Z'_T";3_OT*/^$9T/_H$V
MG_?H5JT47 @M+*UL(O*M+>.&/.=L:X%3T44 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M+K_WS7RY]G@_YXI^5'V>#_GBGY4?4EW#F/J/_A;_ (*_Z"Z_]\T?\+?\%?\
M077_ +YKY<^SP?\ /%/RH^SP?\\4_*CZDNX<Q]1_\+?\%?\ 077_ +YH_P"%
MO^"O^@NO_?-?+GV>#_GBGY4?9X/^>*?E1]27<.8^H_\ A;_@K_H+K_WS1_PM
M_P %?]!=?^^:^7/L\'_/%/RH^SP?\\4_*CZDNX<Q]1_\+?\ !7_077_OFC_A
M;_@K_H+K_P!\U\N?9X/^>*?E1]G@_P">*?E1]27<.8^H_P#A;_@K_H+K_P!\
MT?\ "W_!7_077_OFOES[/!_SQ3\J/L\'_/%/RH^I+N',?4?_  M_P5_T%U_[
MYH_X6_X*_P"@NO\ WS7RY]G@_P">*?E1]G@_YXI^5'U)=PYCZC_X6_X*_P"@
MNO\ WS1_PM_P5_T%U_[YKY<^SP?\\4_*C[/!_P \4_*CZDNX<Q]1_P#"W_!7
M_077_OFC_A;_ (*_Z"Z_]\U\N?9X/^>*?E1]G@_YXI^5'U)=PYCZC_X6_P""
MO^@NO_?-'_"W_!7_ $%U_P"^:^7/L\'_ #Q3\J/L\'_/%/RH^I+N',?4?_"W
M_!7_ $%U_P"^:/\ A;_@K_H+K_WS7RY]G@_YXI^5'V>#_GBGY4?4EW#F/J/_
M (6_X*_Z"Z_]\T?\+?\ !7_077_OFOES[/!_SQ3\J/L\'_/%/RH^I+N',?4?
M_"W_  5_T%U_[YH_X6_X*_Z"Z_\ ?-?+GV>#_GBGY4?9X/\ GBGY4?4EW#F/
MJ/\ X6_X*_Z"Z_\ ?-'_  M_P5_T%U_[YKY<^SP?\\4_*C[/!_SQ3\J/J2[A
MS'U'_P +?\%?]!=?^^:/^%O^"O\ H+K_ -\U\N?9X/\ GBGY4?9X/^>*?E1]
M27<.8^H_^%O^"O\ H+K_ -\T?\+?\%?]!=?^^:^7/L\'_/%/RH^SP?\ /%/R
MH^I+N',?4?\ PM_P5_T%U_[YH_X6_P""O^@NO_?-?+GV>#_GBGY4?9X/^>*?
ME1]27<.8^H_^%O\ @K_H+K_WS1_PM_P5_P!!=?\ OFOES[/!_P \4_*C[/!_
MSQ3\J/J2[AS'U'_PM_P5_P!!=?\ OFC_ (6_X*_Z"Z_]\U\N?9X/^>*?E1]G
M@_YXI^5'U)=PYCZC_P"%O^"O^@NO_?-'_"W_  5_T%U_[YKY<^SP?\\4_*C[
M/!_SQ3\J/J2[AS'U'_PM_P %?]!=?^^:/^%O^"O^@NO_ 'S7RY]G@_YXI^5'
MV>#_ )XI^5'U)=PYCZC_ .%O^"O^@NO_ 'S1_P +?\%?]!=?^^:^7/L\'_/%
M/RH^SP?\\4_*CZDNX<Q]1_\ "W_!7_077_OFC_A;_@K_ *"Z_P#?-?+GV>#_
M )XI^5'V>#_GBGY4?4EW#F/J/_A;_@K_ *"Z_P#?-'_"W_!7_077_OFOES[/
M!_SQ3\J/L\'_ #Q3\J/J2[AS'U'_ ,+?\%?]!=?^^:/^%O\ @K_H+K_WS7RY
M]G@_YXI^5'V>#_GBGY4?4EW#F/J/_A;_ (*_Z"Z_]\T?\+?\%?\ 077_ +YK
MY<^SP?\ /%/RH^SP?\\4_*CZDNX<Q]1_\+?\%?\ 077_ +YH_P"%O^"O^@NO
M_?-?+GV>#_GBGY4?9X/^>*?E1]27<.8^H_\ A;_@K_H+K_WS1_PM_P %?]!=
M?^^:^7/L\'_/%/RH^SP?\\4_*CZDNX<Q]1_\+?\ !7_077_OFC_A;_@K_H+K
M_P!\U\N?9X/^>*?E1]G@_P">*?E1]27<.8^H_P#A;_@K_H+K_P!\T?\ "W_!
M7_077_OFOES[/!_SQ3\J/L\'_/%/RH^I+N',?4?_  M_P5_T%U_[YH_X6_X*
M_P"@NO\ WS7RY]G@_P">*?E1]G@_YXI^5'U)=PYCZC_X6_X*_P"@NO\ WS1_
MPM_P5_T%U_[YKY<^SP?\\4_*C[/!_P \4_*CZDNX<Q]1_P#"W_!7_077_OFN
M=\:>.O GBCP]-9OJBF4#=$0O0U\_?9X/^>*?E2_9X!_RR3\J<<)RNZ8<Q] ^
M#/'?@7PQX>@LTU51*1F0E>IKH?\ A;_@K_H+K_WS7R[]G@/_ "R3\J3[/!_S
MQ3\J)812=VPYCZC_ .%O^"O^@NO_ 'S1_P +?\%?]!=?^^:^7/L\'_/%/RH^
MSP?\\4_*E]27<.8^H_\ A;_@K_H+K_WS1_PM_P %?]!=?^^:^7/L\'_/%/RH
M^SP?\\4_*CZDNX<Q]1_\+?\ !7_077_OFC_A;_@K_H+K_P!\U\N?9X/^>*?E
M1]G@_P">*?E1]27<.8^H_P#A;_@K_H+K_P!\T?\ "W_!7_077_OFOES[/!_S
MQ3\J/L\'_/%/RH^I+N',?4?_  M_P5_T%U_[YH_X6_X*_P"@NO\ WS7RY]G@
M_P">*?E1]G@_YXI^5'U)=PYCZC_X6_X*_P"@NO\ WS1_PM_P5_T%U_[YKY<^
MSP?\\4_*C[/!_P \4_*CZDNX<Q]1_P#"W_!7_077_OFC_A;_ (*_Z"Z_]\U\
MN?9X/^>*?E1]G@_YXI^5'U)=PYCZC_X6_P""O^@NO_?-'_"W_!7_ $%U_P"^
M:^7/L\'_ #Q3\J/L\'_/%/RH^I+N',?4?_"W_!7_ $%U_P"^:/\ A;_@K_H+
MK_WS7RY]G@_YXI^5'V>#_GBGY4?4EW#F/J/_ (6_X*_Z"Z_]\T?\+?\ !7_0
M77_OFOES[/!_SQ3\J/L\'_/%/RH^I+N',?4?_"W_  5_T%U_[YH_X6_X*_Z"
MZ_\ ?-?+GV>#_GBGY4?9X/\ GBGY4?4EW#F/J/\ X6_X*_Z"Z_\ ?-'_  M_
MP5_T%U_[YKY<^SP?\\4_*C[/!_SQ3\J/J2[AS'U'_P +?\%?]!=?^^:/^%O^
M"O\ H+K_ -\U\N?9X/\ GBGY4?9X/^>*?E1]27<.8^H_^%O^"O\ H+K_ -\T
M?\+?\%?]!=?^^:^7/L\'_/%/RH^SP?\ /%/RH^I+N',?4?\ PM_P5_T%U_[Y
MH_X6_P""O^@NO_?-?+GV>#_GBGY4?9X/^>*?E1]27<.8^H_^%O\ @K_H+K_W
MS1_PM_P5_P!!=?\ OFOES[/!_P \4_*C[/!_SQ3\J/J2[AS'U'_PM_P5_P!!
M=?\ OFC_ (6_X*_Z"Z_]\U\N?9X/^>*?E1]G@_YXI^5'U)=PYCZC_P"%O^"O
M^@NO_?-'_"W_  5_T%U_[YKY<^SP?\\4_*C[/!_SQ3\J/J2[AS'U'_PM_P %
M?]!=?^^:/^%O^"O^@NO_ 'S7RY]G@_YXI^5'V>#_ )XI^5'U)=PYCZC_ .%O
M^"O^@NO_ 'S1_P +?\%?]!=?^^:^7/L\'_/%/RH^SP?\\4_*CZDNX<Q]1_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %(WW&^AI:1ON-]#0(^@_@#_R(3_]?#5ZM7E/P!_Y
M$)_^OAJ]6KQ:GQLU05\V_'C_ )'^P_Z]Z^DJ^;?CQ_R/]A_U[UIAOXB$]CSF
MBBBO6,PHHHH&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MLH[BKA'DC9 :OA7PZ_BC59K$.T/EPF7=CKCM6,ZE)I8RK#RW*Y(ZXKV[X?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %(WW&^AI:1ON-]#0(
M^@_@#_R(3_\ 7PU>K5Y3\ ?^1"?_ *^&KU:O%J?&S5!7S;\>/^1_L/\ KWKZ
M2KYM^/'_ "/]A_U[UIAOXB$]CSFBBBO6,PHHHH&%%%% !1110 4444 %%%%
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MS&_VRWUR5.49C@^M0%%( (Z4ZJC!1=P/8_AMXNTA= EMM8FCADLU(@W]_I7
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MK0_X1KQ1_P!"_=_]\T?\(UXH_P"A?N_^^:/;4^X69GT5H?\ "->*/^A?N_\
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M^^:/;4^X69GT5H?\(UXH_P"A?N_^^:/^$:\4?]"_=_\ ?-'MJ?<+,SZ*T/\
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MI]PLS/I&^XWT-:/_  C7BC_H7[O_ +YH/AKQ1M/_ !3]WT_NT>VI]PLSW+X
M_P#(A/\ ]?#5ZM7F?P0TR_TKP2\&H6LEM*9V(208.*],KR9ZR9H@HHHJ "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
>**** "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>img11953243_10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img11953243_10.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" *<! P# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MY.H7/2J*IZ7-/<:=#-<)LD=0Q7TS5RLF,**** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH Y7QQX:U'Q/I0LK'439 G)8=36#X*^
M%<7AK41J-[=_;+M>CD5Z116BJR4>5;"L%%%%9C"BBB@ HHHH **** "BBB@
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M\(-XG_Z'&Y_[YKT*BCVLOZ06//?^$&\3_P#0XW/_ 'S1_P (-XG_ .AQN?\
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M-S_WS1_P@WB?_H<;G_OFO0J*/:R_I!8\]_X0;Q/_ -#C<_\ ?-'_  @WB?\
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M!O$__0XW/_?-'_"#>)_^AQN?^^:]"HH]K+^D%CSW_A!O$_\ T.-S_P!\T?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M:* .'^'_ (<U#3!>ZEJR"*\O)"YB'1,]J[BBB@ HHHH **** "BBB@ HHHH
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M<B&,)GUP*MT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@PZE >)HUP%/OCK7IDT?FP/'G&Y2,UY7=:)K6E7=S;KI5I=I<']W,R9(SZT
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!R?Q*_Y
M$/4?HO\ .M;PQSX7TS_KW3^59'Q*_P"1#U'Z+_.M?PQ_R*^F?]>Z?RK1_P -
M>HNIK4445F,**** "BBB@ HHHH **** "H[C_CVE_P!P_P JDJ.X_P"/:7_<
M/\J:W$]CY=OO^0G=_P#79OYU!4]]_P A.[_Z[-_.H*^VCLCY&6["BBBF2%%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 5T7@+_D=]/\ ]ZN=KHO
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M1M.\S"WV[Y@F<U[910!S<&GW?AGP@EMI-LMS=PQC",<;V[U;:TN-=\+&WU.
M6]S<0E9$'.QC6S10!XFGA_QWINAS^$+2QCDTZ1R%OBWS*I.37JGAG1$\/Z#;
M6"\NB#>WJW>MBB@#@];T'5_$'C6Q>YB"Z-:\D9^^>U5_%>B:[I?B"#7_  U9
MI>3L/+DA8X"KCBO1** .'^'_ (<U#3!>:CJR".]O)"[1#HF>U=Q110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10!R7Q*_Y$/4?HO\ZU_#'_(KZ9_U[I_*LCXE?\B'J/T7^=:_AC_D5],_Z]T_
ME6C_ (:]1=36HHHK,84444 %%%% !1110 4444 %1W'_ ![2_P"X?Y5)4=Q_
MQ[2_[A_E36XGL?+M]_R$[O\ Z[-_.H*GOO\ D)W?_79OYU!7VT=D?(RW8444
M4R0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "NB\!?\COI_^]7.
MUT7@+_D=]/\ ]ZL<1_"EZ,UH?Q8^J/HNBBBOC3ZP**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "LW7KZXTW1Y
M[NUA,TL8R$ ZUI54U/4;72=/EO;U]EO&,L<9H XS1?BGIFH2"WOK:XL9E'SF
M9=JYKMK2_M+^,26EQ',I&<HV:\LUGQ?8>*E-OH_ATZHK?+N*;36;HWPV\5VO
MFZA9ZK)I75DM,DX]J /;:*Y#P/XAO=4@FL=2B9;VUX=R/O>]=?0 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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ML+4SQRG[OFIM#?2MC7/%&G>'YK2&]=O,NGV1JHR2: -JBFQN)(U<9PPSS3J
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M:Z+P%_R.^G_[U8XC^%+T9K0_BQ]4?1=%%%?&GU@4444 %%%% !1110 4444
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M )"=W_UV;^=05]M'9'R,MV%%%%,D**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ KHO 7_([Z?_O5SM=%X"_Y'?3_ />K'$?PI>C-:'\6/JCZ+HHH
MKXT^L"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ K@/B)X=T>XTR:\U"5T#, 2.@KOZY_QII<FK^%[NSA@$\K
M %$/<T 8]A\/='?3;5DDE*F)2#GL16SHOA#2=#G:XMH09V_Y:,.17$:/-\0-
M*L([66R20( %W-T [5T?A[4/%MQJRQZKIZPVFWEP>] '9T444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !112!E;H0?H: %HI"0!DD >] (/0@_2@!:*** "BDWKG&
MX9],TM !136EC5@K.H)[$TZ@ HI P;H0?I2T %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110!R7Q*_P"1#U'Z+_.M?PQ_R*^F?]>Z?RK(^)7_ "(>
MH_1?YUK^&/\ D5],_P"O=/Y5H_X:]1=36HHHK,84444 %%%% !1110 4444
M%1W'_'M+_N'^525'<?\ 'M+_ +A_E36XGL?+M]_R$[O_ *[-_.H*GOO^0G=_
M]=F_G4%?;1V1\C+=A1113)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *Z+P%_R.^G_ .]7.UT7@+_D=]/_ -ZL<1_"EZ,UH?Q8^J/HNBBBOC3Z
MP**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MET'QY;:[J@L8[6>-B,[G4@5U'V.U_P"?:'_O@4J6T$;;DAC5O54 - $M%%%
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M#=ES)=OLC5!DYH W**;&XDC5P" PSS3J "BBB@ HHHH **** "BBB@ HHHH
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MFM-%T];'1[2"'4[Y@B^6@#%2<'I7+'P[_:.LV?A":YFM;6W3SF:%MK,Q'.:
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MF[FN#DRGL?6L";X=>(+K3)M(G\0?Z W0!>WI7IM% ',W_A"&]\)6^AF8@VZ
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M***Z1!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %':BCM0![_\
M /\ Y%.[_P"N_P#C7K->3? /_D4[O_KO_C7K->1B/XK+6P4445B,**** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "H[C_CVE_W#_*I*
MCN/^/:7_ '#_ "IK<3V/EV^_Y"=W_P!=F_G4%3WW_(3N_P#KLW\Z@K[:.R/D
M9;L****9(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !71> O^1W
MT_\ WJYVNB\!?\COI_\ O5CB/X4O1FM#^+'U1]%T445\:?6!1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5F:
M]:Z=?Z3-:ZFR"V<?-N8"M%W$<;.W11DUY/'IMQ\1/&%]]OGFBTFR;$*1MC?]
M: -"ZT_P[?\ A^+0_P"UPLD3YMIR?]6>U7?"O@!M.U9=8U35VU:[1=L,IZ(*
MMW/PTT&YL_LQ251C 96Y%87A2XN_"?B\^$[J=YH)P9+9G.2%% 'I]%%% !11
M10!FZ_.+;P_?S,<!(&.?PKR'X=^//"NCZ1*^H3E;B>4[CY6X=?6O7]=BL)]&
MN8=2E$=HZ$2,3C KG=*\)>$;;PD\5A;6TVGLCL)F 8_7- '4Z=?6>HV4=S8R
M(\#C*E*H>++PV/A;49U.&6!L'T.*\]^"DLWDZI!&[R6,=PPC9N@YZ"N_\86I
MO/">I1 9/D,0/PH X7X<Z=;WWPGGFN8TDDN?,9W89)QTYK+\)/=ZU\*M;M(R
MSRV\S(BY_A':M?X9WL$7PBE#N%\CS5<$]*F^"UB]OX;OY94(\^Z9AD=5H Y6
M/6+'7=*T/P_IL3IJEJ=TW[O;M Z\UT5@@\7>.A<7FT:=I"K]GD8_*SCK6[X\
MOK/PYHSR6%C!_:-TPA7RT ?#<$Y%<5/X>:*32/"<US+%;3MYTLB-AV)YQF@#
MVN-TD7,;JR^JG(IU>:> ?,T3Q%?^'8IY)[.)BRO(VXCVS7I= !1110 4444
M%%%% !1110 4444 %%%% !1110!Y;\=_^1)C_P"NXKYX'05]#_'?_D28_P#K
MN*^>!T%>IA/X9$MQ:***Z1!1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %':BCM0![_\ _\ D4[O_KO_ (UZS7DWP#_Y%.[_ .N_^->LUY&(_BLM
M;!1116(PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M *CN/^/:7_</\JDJ.X_X]I?]P_RIK<3V/EV^_P"0G=_]=F_G4%3WW_(3N_\
MKLW\Z@K[:.R/D9;L****9(4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !71> O\ D=]/_P!ZN=KHO 7_ ".^G_[U8XC^%+T9K0_BQ]4?1=%%%?&G
MU@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MUFO(Q'\5EK8****Q&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !4=Q_Q[2_[A_E4E1W'_'M+_N'^5-;B>Q\NWW_(3N_^NS?SJ"I[
M[_D)W?\ UV;^=05]M'9'R,MV%%%%,D**** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ KHO 7_([Z?_ +U<[71> O\ D=]/_P!ZL<1_"EZ,UH?Q8^J/
MHNBBBOC3ZP**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BFR2+%&TC'"J,FO,)-;\4^)M:O%TE!#8VIPC _?H
M Z;5O#-W?^*+;4XY46*+&5/6NKKQNWUSQ7XSNY]"61M,GMOOS)U-:GA;5=;\
M-^+8?"NMW37K7*&2&=SS@4 >H4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% 'EOQW_P"1)C_Z[BOG@=!7
MT/\ '?\ Y$F/_KN*^>!T%>IA/X9$MQ:***Z1!1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %':BCM0![_P# /_D4[O\ Z[_XUZS7DWP#_P"13N_^
MN_\ C7K->1B/XK+6P4445B,**** "BBB@ HHHH **** "BBB@ HHHH ****
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M_.BT>X%K<O\ >'YT;E_O#\ZJ_P!GQ>K_ )T?V?%ZO^=%H]P+6Y?[P_.C<O\
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MBD+!1EB />LJ_P#$FE:;?PV5W=I'<3?ZM#_%0!K44 Y (Z&B@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M]>\'6^J>#FT&V<0 (%C?'W2.]<GI_P ,-:6[TZ?5-;2Y^P8$8"D?*.U>J44
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
F4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>img11953243_11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img11953243_11.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" *>! T# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M$]I / .FS"%1(5)+8Y-3)Q^KK0.IVUQ ES;R02C,<BE6'J#7E_B?X5>$]/\
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M>B45YW_:'Q+_ .@;8_\ ?0H_M#XE_P#0-L?^^A1[)]U]X7/1**\[_M#XE_\
M0-L?^^A1_:'Q+_Z!MC_WT*/9/NOO"YZ)17G?]H?$O_H&V/\ WT*/[0^)?_0-
ML?\ OH4>R?=?>%ST2BO._P"T/B7_ - VQ_[Z%']H?$O_ *!MC_WT*/9/NOO"
MYZ)17G?]H?$O_H&V/_?0H_M#XE_] VQ_[Z%'LGW7WA<]$HKSO^T/B7_T#;'_
M +Z%']H?$O\ Z!MC_P!]"CV3[K[PN>B45YW_ &A\2_\ H&V/_?0H_M#XE_\
M0-L?^^A1[)]U]X7/1**\[_M#XE_] VQ_[Z%']H?$O_H&V/\ WT*/9/NOO"YZ
M)17G?]H?$O\ Z!MC_P!]"C^T/B7_ - VQ_[Z%'LGW7WA<]$HKSO^T/B7_P!
MVQ_[Z%']H?$O_H&V/_?0H]D^Z^\+GHE%>=_VA\2_^@;8_P#?0H_M#XE_] VQ
M_P"^A1[)]U]X7/1**XO1+SQS+J<:ZM8VD=H?OLAYKM*B4>5V&%%%%2 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M9K:T*XOKO1[>?4(UCN)$#,J]LT :5%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >5?%"]GU?6=*
M\+6KMY=U)_I&T]!FM;QU F@_#G[#;C$<:"+CN,5A^&\Z[\8=<F;!AL2-GYUV
MGC^P>_\ "-ZL:;W1"X4=\4 8&@PQ#X/B/8-GE,<8H^#=TUSX8N0<@1W!4#VK
M$T?Q;IUO\'Y$FGC2\B5HS;%OGSGTKIOAE9?V1X/^TW.(4N&\[Y^, ^M '0>+
MIVMO#%]*N<B,]*XSX6(A\#:@0H'F.Y;WX-=QJR0ZSX>N5MI$F22,[60Y!KS/
MX>>(K'2_">M6FH3QVMQ;N^(I#@L,'&!0 WX>0?VP/$ND#Y(PQ"^@YJF(/%,]
MJGA:71'CLH[C)O3TV>M='\(K-WM;_6#&4CO')7(Y/-=!X_\ $::'H31(_P#I
M5WF&-0>03WH XB-[:_\ $HFU"<)I.@ 9E)X8UZ3H7BO1/$.Y=*O4GV=5'&*\
MNU?0I-"T+1X;SFWG8-?,WW2#_>JW:)IL/Q1M%\-^4+8VX\P6_P!S\: /8:**
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ H(R"#WHHH S-/T#3=+OKF\M+<1SW/^M;^]6DRAE*L 0>"#2T
M4 <C/\,_"UQJAU"33\SEMQPWRY^E='=:9:W>FMI\L?\ HS)L*+QQ5NB@"CI.
MDVFBZ='86,92WCSM4G-8>K?#KPSK6H?;KRPW3]RK8!^HKJJ* (+*RM]/M([6
MUC$<,8PJCM5'4?#NF:M=PW-[;B66$Y0D]#6K10!1U72++6M-ET^^A$EM(,,O
MM6=X?\&:'X99FTNT\IFZL3DUOT4 %%%% !1110 4444 %%%% !1110 4444
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M*GM0!Z]H&OQZ_#+-!&1"K85C_%6Q5+2=-MM)TR"SM5 CB4*"._O5V@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M;3]& SLSWK3\7_#O2O&5Y:W5^\BR6Q!38>M;E[H%CJ.C#2[J(20! @W#H,4
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 444CNL:%W8*JC))["@!:*\[U/XP:-I^H3VL5E>7:0G#3
M0+E/SKK]&\1:=KFD#4K.=6@"Y?G[GJ#0!JT5YW/\8=#@U![<6MT\"/L:Z5?W
M8/UKOK2ZAO;2*Y@</%(H96'<4 3445P.L?%G1M)U.2R6VNKKRCB26!<JGUH
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M_NW'Y4>PJ?RA='J%%>7_ /"]?"_]VX_*C_A>OA?^[<?E1["I_*%T>H45Y?\
M\+U\+_W;C\J/^%Z^%_[MQ^5'L*G\H71ZA17E_P#PO7PO_=N/RH_X7KX7_NW'
MY4>PJ?RA='J%%>7_ /"]?"_]VX_*C_A>OA?^[<?E1["I_*%T>H45Q'ACXH:)
MXKU-["P67SD3>=P[5H6/C2WOM;?2UL+M'4D>8R_+4NG).S07.GHKET\:V[Z^
M=)^P78<-M\W;\GYTMUXTM[7Q$NCM87;2-_RU5?D_.CDEV'<Z>BN7UCQM;Z/K
M-OILFGW<KS$ 21KE1]:=K_C*#0)X(I;"ZG,V,&)<@9]:.26F@7.FHKG-:\7P
M:+!;2R6-U,)P"!&N2OUI-5\80:5IEM?/8W4JS]$C7++]:2A)] .DHKG+_P 7
MP6'AZ/6&L;IXW_Y9*OSC\*4>+8#X;;6?L5SY8&?)V_/^5')+L!T5%<YIWB^#
M4?#LFL+8W4<:'_5.N'/X4FD>,(-7TVYO4L;J)8,Y21<%OI1R2[!<Z2BN;T3Q
MC!K:W+1V-U#Y )/FKC=]*S&^)FFQV\\L]G<P+$VW,JXW?2G[.5[6%<[>BJ]E
M>17]G%=0L&CD4,"/>K%0,**** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ KD_B+J4FG>$[CRFVM./*SZ9KK*XCXJ6#:AX,GB&0 =Q8?PCU
MH YCPCXE\'>%/"\.DZC<I]H<$S;DW9S[UM:_%I/A_P"'UY+H 6*VO06W(<@[
MA4/A#PMX>N?AW&T]O!=9B;=<2*"V<>M<%X<-S=_#[Q!9%WFL[:X8QL>=JCL*
M .TT/1;-O@N]LT2LLB,S,1R3G/6M7X2W[7GA1HBY9;>3RUSV JGH-[;_ /"F
MOM&\>4L3 MZ<XJ?X/V9M?"TSX.V:8NI]10!U_B*\:PT&[N4.UD0X->>_#'3;
M:;P7K,DB+(]U(Y=F&2<@UWWBFV-WX;O80,DQFN&^%ES#_P (-J@5AB!W#^V
M: ,OP,);GP_K^A6;$BW8^6N>E9#:[I=SX8A\-Q1DZPMU@IY?.<]<UT_PBME-
M_K5_'S%/)\K=CS76>)DT70--N=5-C;)=[3Y<FP!B^..: .*NQ<>(]<TKP]N_
MT>Q -Z">/QKUBV2&&!(8-OEQJ% 4] *\0>&^MM'A6=FANM??]]*O#*,]JV-$
MM;CP3X_@T:&_GN[6XA#L)FR030!Z[1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M:XC4""<#F,BL;PK\/[C1]5.IZOJC:E=A=B.P^Z*[NB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 445!>7<5C:27,[!8XU+$T 3T5Y>WQ<2XURUL[73IEMYGV"9QP
MWTKIU\:VJ>*(]"N(7CFD3<LA^Z: .IHHZT4 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!X'\?O^0OI
M7^X:\CKUSX_?\A?2O]PUY'7KX?\ A(S>X4445L 4444 %%%% !1110 4444
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M"HDO)C@,>7Q]: .UC!6)%/4* :=2*=R@^HS2T %%%17,Z6MK+<2?<C4L?H*
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MY_\ #"PMY/!.L.RAVNI'+LPR3D&N]\4VQO/#=["!DF,UPWPLNH?^$&U4*PQ
M[A_; - &5X%62[T+Q!H5FQQ Q\M<]*R6U_3[KPW#X7BAD_M9;K!7R^^>N:ZC
MX16RF]UG4(N8;B3Y6['FNM\42:3H&E7.I&SMENRI$3^6 Q<CCF@#B+E9_$6O
MZ7H!?%MIP!O<G@_6O6+;[.D"16[(40!0$(. *\1EMKVUT:WCN&:*XUY_](E7
MAE&>,&M;1K&3P3\0;?1[2]GN;6XA#,LS9.30!Z]1110 4444 %%%% !1110
M4444 %%%% !1110 4444 >!_'[_D+Z5_N&O(Z]<^/W_(7TK_ '#7D=>OA_X2
M,WN%%%%; %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >B_
M!#_D?)?^N)_E7TG7S9\$/^1\E_ZXG^5?2=>9C/XA4=@HHHKE*"BBB@ HHHH
M**** "BBB@ KC?BC_P B)=_[Z?SKLJXWXH_\B)=_[Z?SJZ7QH3.@\/?\B[IW
M_7NG\JTJS?#W_(NZ=_U[I_*M*IENQA1112 **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ J.:".XC,<JAD/4&I*BN;F*TMWGG<
M)&@R2: ,\^'-()S]AB_*I(=!TRWE$D5I&KCH0*X9_B[9OKL&G6^G7#1S/L6X
M(^4_2NG3QC9?\)$FBRH\4[IN5FZ&@#HZ*** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \#^/W_(7T
MK_<->1UZY\?O^0OI7^X:\CKU\/\ PD9O<****V **** "BBB@ HHHH ****
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M  9JU]#X(U334E:6XL,A'ZG%<])I&BQ^$H=7AV#6VNLEP_SYSTQ71_":V/\
M;/B!W^>.1^ >G6M:_P#AUX9T6XN/$+B;?#NG$9?Y-WTH R_$VI7/B"#1_#,>
MYFNPOVHCJN/6O2]*TV'2=-@LH%PD2!?K7C5IJ=W;)<ZY;H%U/56VV)<<1]JZ
M;PWXC\2:;XI30O%$L4\DT?F))$.![4 >F4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% '@?Q^_P"0OI7^X:\CKUSX_?\ (7TK_<->1UZ^'_A(S>X4
M445L 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Z+\$/\
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M6NEVY^0=V->IO%'(<O&K'W&:<JJHPH 'H!0 *H50HZ 8I:** "BBB@ HHHH
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M%G4?^N)KYF3H?K7T&3?PY>IXF:_''T'4445[!Y(4444 %%%% !1110 4444
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MXR\/VEMJ]W=12VDN 8 .030!ZO17E6I:QXPT*;3=0N[V&:QO)%'E*.5! /\
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MVPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M _F-)D$]Z .GOM7UBZT.RN]+CA%Q)(!(LAP-OM69XS\8W6E:II&C6C0_:K_
M<EA\E<SXTEN(/ GA@K,Z2_;$#LAQNYJ/QYX<L+CXG>%FD,N;O_6X;T]* .K\
M8>+;CPGX>LB)(I+ZYE$6"W3/>NFT%KK^S%EOI49B,E@W%>9?&/PWIZVNB3?O
M=YNUA^]_#Q6QXUN6\-Z)9:+IGF;;D 9)R<?6@#T1+ZTE?9'=0N_]U9 33Y;F
M" XEGCC/^VX%>*SZ?'8QV=SHUI=KJ 8&1G8D'UJUKEG<^(_&NA07T\L4<BCS
MHU;&: /81/"T7F"5#'_>##'YTR.]M9GV17,+L>RN":\Q\>2R:):66A:69%@=
MP9LMR5],UE7%HNEW%I=^'[.[2Y1EW;V)!SUH ]EDN8(FVR3QH?1G I(;NVN"
M1#<12$=0C@_RKRG6["36_B):6UQ/+&CVZF5%;':K#>'X_"7C_2DTF:9;:=&:
M:.1]V2* /3IKJWM\>?/%%GIO<#^=/BFBG7=%(DB^JL#7F5GH\?C_ %R]NM3E
ME%I QCCB1]O(K<M]'E\&6%_/;7+26FTF.-SDJ: .MDO;2)]DES"C>C2 &IE9
M74,C!E/0@Y!KPS288=9M+N\U>"ZFO7<['C<X [5WGPYN=3>QN;:^C=(8&VP[
M^I% '<4444 %%%% &3XF_P"19U'_ *XFOF9.A^M?3/B;_D6=1_ZXFOF9.A^M
M?09-_#EZGB9K\<?0=1117L'DA1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% "'JO^\*^G= _Y %C_P!<5_E7S$>J_P"\*^G= _Y %C_UQ7^5
M>-G/P1]3ULJ^*1HT445X![84444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !6;KNLP:%I4M[<'A1\H]3V%:5<YXWL(K_PY*LH)
M\L[U [D4 <7;>*_B1JL9NM.T*U^R,?W9D."16MHNJ?$2;4HTU32+.*U/WG1N
M15'P[\1UBTU+6YTZ6-X?ER!@$"NAT[QW;:C>+;K:R*6[F@#K1G SUI: <@&B
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M$U\S)T/UKZ#)OX<O4\3-?CCZ#J***]@\D**** "BBB@ HHHH **** "BBB@
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M\-:;#/IE@Q6:23J<=<?E7?>+;AK;PQ?2KG(C/2N,^%D<9\#:@0H D=RWOP:
M.F\.^,[76?"8UJ0>7L!\U.ZD5Q:_$/Q6DXU&;3(!H33^6LH^]CUJM\/8/[73
MQ)HZG8@8A?0<U2"^)+BS3PI)H<L=M'<9-Z?N[?6@#TCQ3XN71O#:W]FJRW,V
M/(B/\6:V-"NKV\T>WN+^)8KB1 S(.V:\NC-OJ/B5'OYPFDZ !NE)^5C7I>B^
M)]%U\%=*OHI]G4+VH V**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@#P/X_?\A?2O]PUY'7KGQ^_Y"^E?[AKR.O7P_P#"1F]PHHHK8 HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#T7X(?\CY+_ -<3_*OI.OFS
MX(?\CY+_ -<3_*OI.O,QG\0J.P4445RE!1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 9/B;_ )%G4?\ KB:^9DZ'ZU],^)O^
M19U'_KB:^9DZ'ZU]!DW\.7J>)FOQQ]!U%%%>P>2%%%% !1110 4444 %%%%
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MMA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110!X'\?O^0OI7^X:\CKUSX_?\A?2O]PU
MY'7KX?\ A(S>X4445L 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110!Z+\$/^1\E_P"N)_E7TG7S9\$/^1\E_P"N)_E7TG7F8S^(5'8****Y
M2@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M,GQ-_P BSJ/_ %Q-?,R=#]:^F?$W_(LZC_UQ-?,R=#]:^@R;^'+U/$S7XX^@
MZBBBO8/)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $/5?
M]X5].Z!_R +'_KBO\J^8CU7_ 'A7T[H'_( L?^N*_P J\;.?@CZGK95\4C1H
MHHKP#VPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH \#^/W_(7TK_<->1UZY\?O^0O
MI7^X:\CKU\/_  D9O<****V **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH ]%^"'_(^2_\ 7$_RKZ3KYL^"'_(^2_\ 7$_RKZ3KS,9_$*CL
M%%%%<I04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M X>*10RL.XKS#0]"LG^##V[Q(WF(SLY'S$YSG-;'PFU!KWPH8BY9;:3RESV
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M[84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M1110 4444 %%%% !1110 4444 %%%% !1110 4444 (>J_[PKZ=T#_D 6/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 445B^*+#4M1T2:'2KPVMWM
M)1QZT ;5%>=?#CQI/J,=YHNMOLU/3B5D=^/, [UGIK.M^-?'30:-?/:Z/8GY
MY0.)2.HH ]5HJI?W26&FS7$K@".,G)]<5X]X#\::_-XHN)]<G86%U*8K:-N
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX2:POF"-"[RP@_W<&N)N8%N]/A\1A2)+V8JQ/4X-6OC!!J.F>/+&[LTD-K>
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MACCC/554 416MO C)%#&BM]X*H -344 0PVMO;9\B&.//78H&:FHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BC-&: "BC-&: "BC-&: "BC-&:
M"BC-&: "BC-&: "BC-&: "BC-&: "BC-&: "BC-&: "BC-&: "BC-&: "BC-
M&: "BC-&: "BC-&: "BC-&: "BC-&: "BC-&: "BC-&: "BC-&: "BC-&: "
MBC-&: "BC-&: "BC-&: "BC-&: "BC-&: "BC-&: "BC-&: "BC-&: "BC-&
M: "BC-&: "BC-&: "BC-&: "BC-&: "BC-&: "BC-&: "BC-&: "BC-&: "B
MC-&: "BC-&: "BC-&: "BC-&: "BC-&: "BC-&: "BC-&: "BC-&: "BC-&:
M "BC-&: "BC-&: "BC-&: "BC-&: "BC-&: "BC-&: "BC-&: "BC-&: "BC
M-&: "BC-&: "BC-&: "BC-&: "BC-&: "BC-&: "BC-&: "BC-&: "BC-&:
("BC-&: /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>img11953243_12.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img11953243_12.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,)!ND# 2(  A$! Q$!_\0
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M'_/05Q/GR?WC1Y\G]XT =M]K@_YZ"C[7!_ST%<3Y\G]XT>?)_>- ';?:X/\
MGH*/M<'_ #T%<3Y\G]XT>?)_>- ';?:X/^>@H^UP?\]!7$^?)_>-'GR?WC0!
MVWVN#_GH*/M<'_/05Q/GR?WC1Y\G]XT =M]K@_YZ"C[7!_ST%<3Y\G]XT>?)
M_>- ';?:X/\ GH*/M<'_ #T%<3Y\G]XT>?)_>- ';?:X/^>@H^UP?\]!7$^?
M)_>-'GR?WC0!VWVN#_GH*/M<'_/05Q/GR?WC1Y\G]XT =M]K@_YZ"C[7!_ST
M%<3Y\G]XT>?)_>- ';?:X/\ GH*/M<'_ #T%<3Y\G]XT>?)_>- ';?:X/^>@
MH^UP?\]!7$^?)_>-'GR?WC0!VWVN#_GH*/M<'_/05Q/GR?WC1Y\G]XT =M]K
M@_YZ"C[7!_ST%<3Y\G]XT>?)_>- ';?:X/\ GH*/M<'_ #T%<3Y\G]XT>?)_
M>- ';?:X/^>@H^UP?\]!7$^?)_>-'GR?WC0!VWVN#_GH*/M<'_/05Q/GR?WC
M1Y\G]XT =M]K@_YZ"C[7!_ST%<3Y\G]XT>?)_>- ';?:X/\ GH*'O((TWM(
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MZ/J7F',?6_\ PDND_P#/XGYT?\)+I/\ S^)^=?)']KWO_/=_SH_M>]_Y[O\
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MS_G1_:=W_P ]G_.C^QU_,']JO^4^DO[>TW_GZ3\Z/[>TW_GZ3\Z^;?[3N_\
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M^E @HJP-(U9AD6CD?2HY;.[M?^/F$Q_4470$=%(6 &2:FBL;ZY&ZW@9U]0*
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M?8?\>4?TJS5:P_X\H_I5FOC9;L^LCLC*UG_4URG\1KJ]9_U-<I_$:D84444
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ME/XC4C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M"]Q\RN>@_'#P[->JMW"ORK@G%;?P5N4&A-;%QN Z5N>(M5T;6/!\F^ZC,C1
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 AI-?\
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M%  >>3RWK3A=7P&T73A?3--HH "6;EFRWK3EN;V,CR[IU'H#3:* )Y-2U&1
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M /YYM^5'_"K;_P#YYM^5'M8=PLS@-R^M&Y?6N_\ ^%6W_P#SS;\J/^%6W_\
MSS;\J/:P[A9G ;E]:-R^M=__ ,*MO_\ GFWY4?\ "K;_ /YYM^5'M8=PLS@-
MR^M&Y?6N_P#^%6W_ /SS;\J/^%6W_P#SS;\J/:P[A9G ;E]:-R^M=_\ \*MO
M_P#GFWY4?\*MO_\ GFWY4>UAW"S. W+ZT;E]:[__ (5;?_\ /-ORH_X5;?\
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M /SS;\J/:P[A9G ;E]:-R^M=_P#\*MO_ /GFWY4?\*MO_P#GFWY4>UAW"S.
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M@-R^M&Y?6N__ .%6W_\ SS;\J/\ A5M__P \V_*CVL.X69P&Y?6C<OK7?_\
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MH_X0'4?^>;?E1]?H]P_LZL<YO7^\*-Z_WA71_P#" ZC_ ,\V_*C_ (0'4?\
MGFWY4?7Z/</[.K'.;U_O"C>O]X5T?_" ZC_SS;\J/^$!U'_GFWY4?7Z/</[.
MK'.;U_O"C>O]X5T?_" ZC_SS;\J/^$!U'_GFWY4?7Z/</[.K'.;U_O"C>O\
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MRH\F/_GFOY4^B@!GDQ_\\U_*CR8_^>:_E3Z* &>3'_SS7\J/)C_YYK^5/HH
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M%/+#TH ]CIID0=6 _&N<\*>)HO$&G#YAYZK\PKSOQ?XQU*P\3KI]L&(9L<4
M>QF[MPVTS)GTS4H((R#D5X_K-MK=OIR:E&S[\9*UT'P^\73:RGV6Y&)5X(-
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M: .3^(WC%= TTI;N&N/[HZUB?"KQ3>^()I#=,<C/!KGAILWBS6Y]6D)>T&<
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M+Q3X)T_4-&D1(@&7D<4 6_"FI?VMX+6Y)RQB;/Y5Y[X+6,^,+K>@8[SU%7_
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MJ>AZG)\-=3N+>:W+PRMR<5O:G\8;>2#RK"T<S,<9/- %KP%IE]H%K)/JORH
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M:ZI=>(-:32H4!A8[2WI7:_#ZX2?P?;6A/[U$*L*X+Q?97_AG7TU.-&>'=N(
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MZ8KTKP_JZ:QI<=P#\Q'->-)XB1/!!TD6K><6QG'->C_#NSFL_#B23 @$9P:
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MVLXT;U K49%="C#*D8(IU% %&TTBQL9FEM[=4=NI JW-#'/$8Y5#(>H-/HH
MQO\ A%='\S?]D3.<]*LWV++2Y([>/ V$*!VK0I&56&& (]Z /-?!6@SMK%S=
MWJ$C)*YKTL# P.E-2-(_N(%^@IU !1110 4444 %%%% !1110 4444 %%%%
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M3\&:";B=M3NH\3;N,BO0'19%VNH8>AHCC2)=J*%'H!0 ZBBB@ HHHH ****
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M1>GV#4Q?^$_M_P"ZU'_"?V_]UJVO^$0TC_GA1_PB&D?\\*+T^P:F+_PG]O\
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M  B&D?\ /"C_ (1#2/\ GA1>GV#4Q?\ A/[?^ZU'_"?V_P#=:MK_ (1#2/\
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M216C<.1"UN1_\)_;?W6H_P"$_M_[K5M?\(AI'_/"C_A$-(_YX5G>GV'J8O\
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M,7_A/[?^ZU'_  G]O_=:MK_A$-(_YX4?\(AI'_/"B]/L&IB_\)_;_P!UJ/\
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MT^P:F+_PG]O_ '6H_P"$_M_[K5M?\(AI'_/"C_A$-(_YX47I]@U,7_A/[?\
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M(+@W&[RINNX5D6_PFA^SO!/=NR,,=: .<^ LD<MQJIA_U>3@?C6!\0+\Z?\
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M\==CX_UJ\T+3([JUC,F3A@!VJYI_@^ST^^-U&?G)S6W?6,&H6SP7"!T88Y%
M'$:+K/A+7-,BN+]+47./G$@Y!KE?%&L6-WKL&FZ%&C0D@,8QQ6Y<?!ZR>ZDF
MANV02'[H[5M>&?ASI_AV8S!_.DZY:@#=T#3TTO2HT^[E037#^,O$3:M=II.G
MR9?=A@M>ERQ"6%H^@(Q7,:;X&LM/UI]2W;Y&.<&@#!OM);0?#:R0IMD9?WA%
M<]<3:*_@2\DB*-J/.#WS7L%_8Q:A926LH&UQCZ5PMO\ "JRM[AV6<M&YR5-
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M:T[_ )^H_P Z+,"_15#^VM._Y^H_SH_MK3O^?J/\Z+,"_15#^VM._P"?J/\
M.C^VM._Y^H_SHLP+]%4/[:T[_GZC_.C^VM._Y^H_SHLP+]%4/[:T[_GZC_.C
M^VM._P"?J/\ .BS OT50_MK3O^?J/\Z/[:T[_GZC_.BS OT50_MK3O\ GZC_
M #H_MK3O^?J/\Z+,"_15#^VM._Y^H_SH_MK3O^?J/\Z+,"_15#^VM._Y^H_S
MH_MK3O\ GZC_ #HLP+]%4/[:T[_GZC_.C^VM._Y^H_SHLP+]%4/[:T[_ )^H
M_P Z/[:T[_GZC_.BS OT50_MK3O^?J/\Z/[:T[_GZC_.BS OT50_MK3O^?J/
M\Z/[:T[_ )^H_P Z+,"_15#^VM._Y^H_SH_MK3O^?J/\Z+,"_15#^VM._P"?
MJ/\ .C^VM._Y^H_SHLP+]%4/[:T[_GZC_.C^VM._Y^H_SHLP+]%4/[:T[_GZ
MC_.C^VM._P"?J/\ .BS OT50_MK3O^?J/\Z/[:T[_GZC_.BS OT50_MK3O\
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MSK_A6MQ_S_M^='_"M;C_ )_V_.O1Z*S]M,+'G'_"M;C_ )_V_.C_ (5K<?\
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M4>VF%CSC_A6MQ_S_ +?G1_PK6X_Y_P!OSKT>BCVTPL><?\*UN/\ G_;\Z/\
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MO+29CY6XA0: /::* <C(HH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M HHHH **** "BBB@ HHHH **** "BBB@#A?'WWH*W_#'_(,3Z5@>/OO05O\
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M<]8HKR?S_'/H]'G^.?1Z/8^:"YZQ17D_G^.?1Z//\<^CT>Q\T%SUBBO)_/\
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MY_CGT>CS_'/H]'L?-!<]8HKR?S_'/H]'G^.?1Z/8^:"YZQ17D_G^.?1Z//\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "O.?$SYUQ>!]ZO1J\W\2_P#(<7_>
MK6EN)G>:4=VG1<#I5RJ6D_\ (-B^E7:S>XPHHHI %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 44C,J*68@ =2:KPZA:3N4
MBG1V'8&@"S115&YUG3[1]D]U&C>A- %ZBJMKJ-I>_P#'M.DG^Z:M4 %%%(S!
M%+,< 4 +16?::O;7ETT$3@LO6KTDB1(7=@JCJ30 ZBJT%_:W+$0SHY'H:LT
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MVZ***Q&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MX))-'F*0VIP0I]*]$M?#Z6GA"2PC0"5XB&/<FO+M/?6?!=M>VD%LTGGL><4
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MOW5 ^@J":QM;C_6P1L?4K5BB@"NEC:QKM6WCQ_NBIU54&%4 >@%+10 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %>;^)?\ D.+_ +U>D5YQXE!_MQ>/XJUI;B9W6D_\@V+Z5=JEI(QI
ML7TJ[6;W&%%%%( HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "FB.-3D(H/J!3J* &LB.,.H8>A&:B-E:GK;0_\ ? J>B@"O
M]AM!_P NT/\ WP*G550850!Z 4M% !69KFCPZU8-;S $=1GUK3HH X;P=I=_
MI6H2V\JD6PSMKN2 1S110 T1H#D(H/L*=110! ]E:R-E[>)CZE13DMH(SE(8
MU/LHJ6B@ IGE1[MWEKGUQ3Z* "H7M+>1MSPHQ]2M344 1L@CA81J%XX &*X'
M3_#UW>>)I9[Y"8025S7H5% #8XUBC5%& HP*=110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!POC[[T%;_AC_D&)
M]*P?'P.Z"M[PR#_9B?2MI?PT+J;=%%%8C"BBB@ HHHH **** "BBB@ HHHH
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MX1[3?^?=/RH_X1[3?^?=/RHYJ?8-3DO^%D'_ )\C^5'_  L@_P#/D?RKK?\
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M*CFI]@U.2_X60?\ GR/Y4?\ "R#_ ,^1_*NM_P"$>TW_ )]T_*C_ (1[3?\
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MD?RKK?\ A'M-_P"?=/RH_P"$>TW_ )]T_*CFI]@U.2_X60?^?(_E1_PL@_\
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MGY4<U/L&IR7_  L@_P#/D?RH_P"%D'_GR/Y5UO\ PCVF_P#/NGY4?\(]IO\
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MJ<E_PL@_\^1_*C_A9!_Y\C^5=;_PCVF_\^Z?E1_PCVF_\^Z?E1S4^P:G)?\
M"R#_ ,^1_*C_ (60?^?(_E76_P#"/:;_ ,^Z?E1_PCVF_P#/NGY4<U/L&IR7
M_"R#_P ^1_*C_A9!_P"?(_E76_\ "/:;_P ^Z?E1_P (]IO_ #[I^5'-3[!J
M<E_PL@_\^1_*C_A9!_Y\C^5=;_PCVF_\^Z?E1_PCVF_\^Z?E1S4^P:G)?\+(
M/_/D?RH_X60?^?(_E76_\(]IO_/NGY4?\(]IO_/NGY4<U/L&IR7_  L@_P#/
MD?RH_P"%D'_GR/Y5UO\ PCVF_P#/NGY4?\(]IO\ S[I^5'-3[!J<E_PL@_\
M/D?RH_X60?\ GR/Y5UO_  CVF_\ /NGY4?\ "/:;_P ^Z?E1S4^P:G)?\+(/
M_/D?RH_X60?^?(_E76_\(]IO_/NGY4?\(]IO_/NGY4<U/L&IR7_"R#_SY'\J
M/^%D'_GR/Y5UO_"/:;_S[I^5'_"/:;_S[I^5'-3[!J<E_P +(/\ SY'\J/\
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M\(]IO_/NGY4?\(]IO_/NGY4<U/L&IR7_  L@_P#/D?RH_P"%D'_GR/Y5UO\
MPCVF_P#/NGY4?\(]IO\ S[I^5'-3[!J<E_PL@_\ /D?RH_X60?\ GR/Y5UO_
M  CVF_\ /NGY4?\ "/:;_P ^Z?E1S4^P:G)?\+(/_/D?RH_X60?^?(_E76_\
M(]IO_/NGY4?\(]IO_/NGY4<U/L&IR7_"R#_SY'\J/^%D'_GR/Y5UO_"/:;_S
M[I^5'_"/:;_S[I^5'-3[!J<E_P +(/\ SY'\J/\ A9!_Y\C^5=;_ ,(]IO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *\W\2_P#(<7_>KTBO-_$O_(<7_>K6EN)G=Z3_ ,@V+Z5=JEI/
M_(-B^E7:S>XPHHHI %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 45FZSK$.C6OGS#(]*\>\0?%"]EUN&&S5TB9L4 >YT5EZ
M'>-<Z/%<2GDKDUQ/BWXC+8N]E9QL91_$* /2J*\Q^'?BR\UN^>&Z8\=C7IU
M!2,RH,L0![TM>>^/=>GVQV.GR8N-W.#0!WZ2K)]TYI]86A226?AJ*>\)\Q4W
M-FN \8_$N6.SF_LZ-U,75A0!ZY17"?"[Q'<>)-!>YN6)<''-7O&?B^/P[:8
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M%>RUY3\5_P#C^LOJ* .U\/QM/X;BB4X)051O?".G1VDUQ/$KS8)W8K3\*_\
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M%@./XZ /8HG\R)7]1FGU!9_\></^Z*GH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *YSQO\ \BY-71USGC?_ )%R
M:JA\2 S_ (>?\@@_6NSKC/AY_P @@_6NSIU/B8(\N/\ R'H?]X5Z?'_JU^@K
MS _\AZ'_ 'A7I\?^K7Z"KJ]!(=7E7Q:8B>RPI/(Z5ZK6?J.C66J%3=Q!RO2L
M1E#PB2=#@SD?*.M;K_ZMOH:CMK:*UB$<2[5'05,1D8H \"\#,Q^,=\"C ;SR
M17MFNV2ZAHUS;D9W(<5#:>&M+LM2?4(+<+<-R6J#Q1XD@\/:>\THW';P* /
M(+F?3->E\/-N,<SXQ7T#X7T=-%T1+=1C(W&O)_#%C%XQ\5#5_(*;&SDBO<L;
M8\#L,4 >">/+RYT_Q&L]N"55LMBNVTWXJ:.FC1^;N$T:8(]ZY_7[<77B;RI4
MS&S8-=?'\-M!GMHG$.-P!;WH \]L([SQKX\358E86JMWKI?B1H,]G##?Z>A+
M)][ KT/2-"L-$A\JRA""KES:Q7<+0S(&0]0: /-O#?Q1TF+2(K>]WK<1##"N
M6UNYN/'OC"UFTU6^S1,-Q]J]&NOAIH$\QE6WV,WWO>MO1?#6FZ"FVRA"D]30
M!Q_Q6C-I\.3$JD[ %P/I67X&\-6FO_#1%DA"S$':<<YKT_4M,M=6M#;7D8DB
M/44NFZ;:Z5:+:VD>R(=!0!X]X7UZ\\'ZZ=,U,.;=FVIFLCXF17,GC"RU5M_V
M+(8@=,5[9J/AK3-4N$GN;<-(AR#2ZAX<TW4K5;>Y@#(HP* .5L_B'X>73%2&
M,$QQCY=HY.*\W^&=\-3^*UW<QQ%$+'''%>L6_P .-#MY"RQ?*>U:>E>$='T6
MZ-S96PCE/5J /*_C2[)XHT8A&;YEZ#WKKO%^BO?>$K2Y@3=-'$IQCVKKM4\.
MZ;K$\<U[ )'C^Z3VK0^SQ_9Q 5!C"[<>U 'E'A'XB:9IFG_V?J<12X0]=O6K
MEQ\2K;4M2CL])M@QW8+%:Z._^'>@WTQF-OME/.15C2? VBZ/*)K>W'F_WJ *
M'C5G;P@7=?G*<@5G?"4DZ-/E2/F[UWEW8P7T!AG3<A[5'IVE6FEQ&.TC"*>H
MH \N\8L1XD7"$_/Z5Z%;_P#(I-Q_RQ-6[G0["[G\Z:$,^<YJX+>-;?R O[O&
M,>U 'D7PU8GQ3=90CYCU%8OB!V'QMMAL8C<.<5[58Z%8:=<-/;0A';J:BF\-
M:7<:HNI26X-RIR'H \V^,L%R4MIAO\E<9Q5WPS\0/#^G^';:V:/]ZJ?,,=37
MHNIZ39ZO;^1>1!T]*YI/AGH*3;Q#QZ4 >8/JZ:OX\@E@@*(7&,"O?XO]2G^Z
M*Q+;P=HUI,LT5L Z]#6\!@ #M0 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 5YOXE_P"0XO\ O5Z17F_B7_D.+_O5K2W$SN])_P"0;%]*NU2TG_D&Q?2K
MM9O<84444@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *\G^+!(OK+"D\CI7K%9^H:+8ZHZM=1!RO2@"GX4YT2#C'RBKFM?
M\@R;_=-6[>WCM8A'$NU1T%.EB2:,HXRIZT >/?#MB?&=T"A')Y(KV2LVRT'3
M["Y:XMX0LC=36E0 UU#H5/0C%>%6,4NF?&!Y),B OWZ5[O7FGCO0Y8+A-3MD
M)?=SB@#TE'61 RG(-<WX_)'@K4< G]WT%7O#,\EQH<#R@A\<YK1O+2&^M7MY
MUW1.,,* /+?@22WAZ[RI7]YWJ[\4O'+>'=.,-NK%VX;%=YI.B6.BPM%8Q"-&
M.2!535O">DZV2;ZW$F?6@#Q/P)XQ\,Z9*VHZ@C-=/R=PS@UZ7IWQ9\/:E>QV
MD#/YDAPN:G;X5^%6/_'C^M367PU\-Z?=I<V]IME0Y!S0!T>H:C%IUBUU+G8!
MFO*;(WGC;Q5BX#"RC?(STKUF[L8+VV^SS+NC]*BL-(L]-&+:()0!Y?\ %#3[
MBVN-+^RJWV>$C=CTJGKOB.PU06-E90XN%4!B!WKU^^TVVU&+R[B,,*QK7P/H
MMK=_:4M\R Y!H F\.PRV.@#[03D+GGZ5Y/X0\_4?BC=[P?)5S@UZEXQO9;'1
MML"DEN,#TK*\#^'EME_M-TQ++R<T =PHVJ .U+110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!POC[[T%;_AC_D&
M)]*P/'WWH*W_  Q_R#$^E;2_AH74VZ***Q&%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 0W2&2W=5^]CBO(3XNO?#/
MBJ1=7B9K$D@$BO9*Q]8\,:7KBXO;</[T <+K?Q0T6XTR2WL(BTTR[5^7I5CX
M7Z'<VT4][>*<RG*YK;M_AMX=MIED6VR5Y&:ZN&&.WB6*)0J*, "@"2J>J0"X
MTRYC/>-L?E5RFNN^-E/<8H \3^%9DT[Q;J45R2JLS!<U[<#D9%>2^(=(N-$\
M1PW-LA*R-D[:]2L9#+90N1@E!F@#S;XJDBVCPI/S=JZ[P,2?"MID$<=ZU-0T
M>RU-0+J(.!5FUM8K*W6"!=L:]!0!G^)?^1>O.,_NS7F_PN8F\N,J1\W>O6IX
M4N(6BD&488(JE8:'8::S-;0A">30 [5]4BTFQ>XES@ XQZUY=HD-WXT\3&>]
M#"TB;*YKU:^T^WU&'R;A-R>E-L-+M--3;;1!!0!Y3\2;.XM?$6F2PJWV2';N
M Z5!KOB"QUJ_M+73X=LJ@!B!WKUS4-*M-3C*7,8:LJR\$Z-877VF*W_>YSF@
M"UHL,MIH(6;.\(3S]*\GT*X;7O'4\(!Q$YKU7Q+?OI^EGRT)+ K@5RW@'PQ]
MBOYM5=,--D\T >@PIY<*)Z#%/HHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH *YSQO\ \BY-71USGC?_ )%R:JA\
M2 S_ (>?\@@_6NSKC/AY_P @@_6NSIU/B8(\N/\ R'H?]X5Z?'_JU^@KRFYO
M8++7(6G; S7?)XGTK8O^D#I6E1-V$C:HK'_X2C2O^?@4?\)1I7_/P*RY7V&;
M%%8__"4:5_S\"C_A*-*_Y^!1ROL!L5SGB'PNFO.HE8>6.H-6_P#A*-*_Y^!1
M_P )1I7_ #\"CE?8!^BZ!9:';"*UB5?4@5JGD5C_ /"4:5_S\"C_ (2C2O\
MGX%'*^P$-QX:@GO?M) W9S6W$@CB5!T48K*_X2C2O^?@4?\ "4:5_P _ HY7
MV V**Q_^$HTK_GX%'_"4:5_S\"CE?8#8HK'_ .$HTK_GX%'_  E&E?\ /P*.
M5]@-BBL?_A*-*_Y^!1_PE&E?\_ HY7V V**Q_P#A*-*_Y^!1_P )1I7_ #\"
MCE?8#8HK'_X2C2O^?@4?\)1I7_/P*.5]@-BBL?\ X2C2O^?@4?\ "4:5_P _
M HY7V V**Q_^$HTK_GX%'_"4:5_S\"CE?8#8HK'_ .$HTK_GX%'_  E&E?\
M/P*.5]@-BBL?_A*-*_Y^!1_PE&E?\_ HY7V V**Q_P#A*-*_Y^!1_P )1I7_
M #\"CE?8#8HK'_X2C2O^?@4?\)1I7_/P*.5]@-BBL?\ X2C2O^?@4?\ "4:5
M_P _ HY7V V**Q_^$HTK_GX%'_"4:5_S\"CE?8#8HK'_ .$HTK_GX%'_  E&
ME?\ /P*.5]@-BBL?_A*-*_Y^!1_PE&E?\_ HY7V V**Q_P#A*-*_Y^!1_P )
M1I7_ #\"CE?8#8HK'_X2C2O^?@4?\)1I7_/P*.5]@-BBL?\ X2C2O^?@4?\
M"4:5_P _ HY7V V**Q_^$HTK_GX%'_"4:5_S\"CE?8#8HK'_ .$HTK_GX%'_
M  E&E?\ /P*.5]@-BBL?_A*-*_Y^!1_PE&E?\_ HY7V V**Q_P#A*-*_Y^!1
M_P )1I7_ #\"CE?8#8HK'_X2C2O^?@4?\)1I7_/P*.5]@-BBL?\ X2C2O^?@
M4?\ "4:5_P _ HY7V V**Q_^$HTK_GX%'_"4:5_S\"CE?8#8HK'_ .$HTK_G
MX%'_  E&E?\ /P*.5]@-BBL?_A*-*_Y^!1_PE&E?\_ HY7V V**Q_P#A*-*_
MY^!1_P )1I7_ #\"CE?8#8HK'_X2C2O^?@4?\)1I7_/P*.5]@-BBL?\ X2C2
MO^?@4?\ "4:5_P _ HY7V V*\W\2_P#(<7_>KL/^$GTK_GX%<#XBURPEUE71
MP5W5I2B[["9Z3I/_ "#8OI5VN<TWQ-I:V$0,X! JW_PE&E?\_ K-Q=]AFQ16
M/_PE&E?\_ H_X2C2O^?@4<K[ ;%%8_\ PE&E?\_ H_X2C2O^?@4<K[ ;%%8_
M_"4:5_S\"C_A*-*_Y^!1ROL!L45C_P#"4:5_S\"C_A*-*_Y^!1ROL!L45C_\
M)1I7_/P*/^$HTK_GX%'*^P&Q16/_ ,)1I7_/P*/^$HTK_GX%'*^P&Q16/_PE
M&E?\_ H_X2C2O^?@4<K[ ;%%8_\ PE&E?\_ H_X2C2O^?@4<K[ ;%%8__"4:
M5_S\"C_A*-*_Y^!1ROL!L45C_P#"4:5_S\"C_A*-*_Y^!1ROL!L45C_\)1I7
M_/P*/^$HTK_GX%'*^P&Q16/_ ,)1I7_/P*/^$HTK_GX%'*^P&Q16/_PE&E?\
M_ H_X2C2O^?@4<K[ ;%%8_\ PE&E?\_ H_X2C2O^?@4<K[ ;%%8__"4:5_S\
M"C_A*-*_Y^!1ROL!L5'-!%<)LE0.OH:R_P#A*-*_Y^!1_P )1I7_ #\"CE?8
M#5BAC@0)&H51V%/K'_X2C2O^?@4?\)1I7_/P*.5]@-BBL?\ X2C2O^?@4?\
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M ,)1I7_/P*/^$HTK_GX%'*^P&Q16/_PE&E?\_ H_X2C2O^?@4<K[ ;%%8_\
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M]J/^$$']]J[VBCVL@L<%_P ((/[[4?\ ""#^^U=[11[606."_P"$$']]J/\
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M!8X+_A!!_?:C_A!!_?:N]HH]K(+'!?\ ""#^^U'_  @@_OM7>T4>UD%C@O\
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M]J/^$$']]J[VBCVL@L<%_P ((/[[4?\ ""#^^U=[11[606."_P"$$']]J/\
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M0!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MD((W1\&MG6+9;K2+F$@'<A%>4^"IAX=U^:SW?ZU^E 'LE%(#D ^M+0 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 <+X^^]!6_P"&/^08GTK \??>@K?\,?\ (,3Z5M+^&A=3;HHHK$84444
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MP_JFF:?X#^S:@@^V$X!(YS70:/XA&C:&S2L=LH_=T =7KGC!=-U2&R@42%R
M<<XK5UBYF31?M$*GS-H.!7$^"M&GU2\FU+4%)4G,>X5Z4T2-%Y; %<8Q0!R7
MA7Q9'J<ALI6'GJ<8KL*\.M%?1OB=)+DB)GZ=J]NAD$T2R+T(S0 ^BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M KG/&_\ R+DU='7.>-_^1<FJH?$@,_X>?\@@_6NSKC/AY_R"#]:[.G4^)@CR
MX_\ (>A_WA7I\?\ JU^@KS _\AZ'_>%>GQ_ZM?H*NKT$AU9NOW8L=#NYR<%8
MSCZUI5YA\6-?^Q00V"/S/P1FL1G)> O$-OJ'B"YN;X ^6QP6I?$VKZ?;>+XM
M4BP"&K7\+?#.2.Q%V&VF8;JA\9_#68Z1YT1)=#GB@#U+3=1&J>&_M:G(>)OY
M5XYX=T&UUCQE<-=$DJYQ79_#O58QX9ETMW!FA0C&?:N=\&D#QE=+GG>: /53
MI=M96#+$@&U>*\8TW0+34_B06N"3\_2O<[S_ (\7_P!VO'?#[*?B.PSSOH ]
M7?3[?3M*N%@0+^[/\J\:\+:+;ZKXON))^H<U[?J/_(-N?^N9_E7D'@-P?%-T
M ?XS0!W'C'PU977AJ2+:!M'!KG?AH[VD4VF DH<@9KN_$IQH<Q]JX'P"P.M-
M@_Q4 9%U9CP=XX^UL2!</_.NN\>ZP)/#BVROAKE?6JWQ3T1[Z.UO8Q_Q[G<Q
M'L:\^DU*?Q7KVGVUNQ*6Y 8#VH ]+^&7A\:9X?E64$F4]_2O*+:UB_X7%+%@
M;?,_K7T;96ZVUE%$HQM09_*OGE%%I\8)9KH^5$9.&;ZT >YZW$MOX2OEC& (
M":\?^#&@VNH:AJ5W,,LCGC\:]>URZM[CPE?M;RK(GD'E37FOP)8,=5P<_.?Y
MT ;OQ3\/6LGADS1KMD0\$58^'DTA\ S12$DQQL!GZ5H?$I@OA9R3WK,\ ,#X
M,NR#_ W\J .$^%.CV]_XVU6:<EF1F(%=;\4?#%A-IGGXVNO3%<_\''5O&.L
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MH6&W=7T#I%Q;W.F0/:D>5M&T"O,?B]?Z?=VEK'!+'-/NZ(<XKK?A];7$'A^
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M10 4444 %%%% !1110 4444 %%%% !1110 4444 <+X^^]!6_P"&/^08GTK
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M'9992XE=SU/:NKHH P?%'AN+Q'IIMF8(W9JY+3_A:( D=U<>;&AR 3FO2Z*
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MYB?WU_.CS$_OK^=>9;=;_O/1MUO^\]'LO,+GIOF)_?7\Z/,3^^OYUYEMUO\
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M-?RJ2B@"/R(O^>:_E1Y$7_/-?RJ2B@"/R(O^>:_E1Y$7_/-?RJ2B@"/R(O\
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MYF(4$UZQ<*'MY%/0BO%[DM9^/HXT.%+T >VCD44U/]6OT%.H **** "BBB@
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M!ND7NJZM)J=\6,#'* USUC$]_JHT=>+&-OO=J];TNXTNRMH[&WN8R4&,9YH
MM:CI\=_ILEFP^1EQ7D>A:B?#GCHZ+&2(W>O:0<C(KP[Q-:B/XGQW"\-OH ]Q
MHJ"S<R6D;'J14] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %<YXW_ .1<FKHZYSQO_P BY-50^) 9_P //^00?K79UQGP
M\_Y!!^M=G3J?$P1Y<?\ D/0_[PKT^/\ U:_05Y@?^0]#_O"O3X_]6OT%75Z"
M0ZN&^)6O#3-':T!PUPN!7<UY7\0?"FK^(M9M'@W>1$PS6(SB_!OA75[,2W42
MN!,<@TSQGX;UF*S6\PY8-DFO?M+LULM,M[?8 40 \=Z35=/BU&PDMW0'(XXH
M XOPA>-J'P\EMG;]^L1!'?I7%_!S%AXIU2*X.UV8A<UU'@_PWK&E>(;E;@-]
MA<G [8JEXN\%ZE9ZF=0T$$,3D[: /5KBXBM8&FF8+&HR2:I6NJV.I6\QLY ^
M%.<#VKQUXO'6K+]BN/,$+8#&O3?!WAK^PM+\N1B97'S9H \L^';!?BOJ(;@E
MFQFO5?'MQ%;^#M0\U@-T9 KS[Q?X(UFPUEM5\.AA.[9.VJ4FA^-O$&A7%KJN
M_>P(7- &Q\">="O2.ADKC9 S?&I\?\]/ZUZ3\)?"]_X7T6>VO@0[-D9K"\=^
M!-3;6O[8T13]H+9)% 'I'B.%I?"]VB_>$)Z?2O!_AGX1&L:IJ/G7#0N&.!G&
M>:]?\&0ZW+I9AUT-N9=IS7)>)/"&L:3J;7F@!E#')VT :=W\*K9H&,^HMY8Y
M.2:VO"'A73=$.ZSF$A]<UYY<+X^U51;2&41D\UZ?X.T:?2]+1;IF,W?- '35
MYA\4XC<1"%3@D8S7I]<1XT\/WFKS(UN"0* /';#P7<^'84U]29=ISCK7N?@W
MQ+#K^DQMD+,HP5I^DZ$&\/\ V"^3.1CD5P^E>$];T+Q:TMIN^Q%NG;% &9\9
M#CQ3H_\ O+_.K_CRT<:?IMXQ(A5%S5KXE>#M3\1:OIMS: D0D%J[+6/#ZZOX
M533Y1^\6( ?7% ">"+J&[\/1/"P*CBN$^-VI006ME"2&DW=/QK)L]*\8^&9V
MM;'S#;%N*;K?@7Q!XHE@N+O<2I!YH [O1#N^&6[UBK!^&!(O+CG^,UV%AHEQ
M:^"FTS'[S9M%8O@3PO?Z+<S/= @,V10!:^*1(\.K_O5G^'H&G^'UQLZB,UO>
M/M%NM;T5;>U!+ALT[P=HL^FZ%]BNQ]X8(- 'C'PV\(C6-9U$37#0N&.!G&>:
M]%N_A5;- QGU%O+')R36;XE\(:QI6IM>: &4,<G;6/<+X^U5!;2&41D\T >B
M>$?"NFZ(&^QS"3/!.:X_X@J_AW7[:_MTVJ[ L17>>#=&N-+TM!=LQF[YK,^)
MNGP7OA^0LRB55.W/6@#@]8GD\4^(],FMR61=N_%>WVD*P6L4:C 50*\>^#&D
M3@7$MZI;8?D+5[/0 5XA\:/^1DTC_>7^=>WUY9\3O!VI>(M;TVXL@2D+ MB@
M#0\;?\B):?\ 7,?RJ]\,23X8'^]3_%.A7>I>$[>Q@!\U$ /Y5:\":/<Z+H0M
MKH8DW9H XGXEDG5+;)_C%=)X@_Y)[%_US'\JI>./"M_K.H02VP)56R:T?%$/
MV7P*MO(P$B)@C- &=\,!GP_=_0US?AB5#\2GCSAM_?ZUTWPH^;1[A2.,XKG/
M&/@G7+77FU70 WFDYXH ]$\:W,-MH$K2L ""!7$?#A@^F:@Z_=.<5BQZ'XWU
M^V>#5_,VXXS78>!?"M]HFE7-O< [G!VT 8_AAB/%#X/\=>N$9!![UYSH7A:_
MLM>:YE!\LMFO1Z /'/B!&WAS7+:^MDVJS L16;K,\GBGQ!I<MLQ9%V[\5WOQ
M,L(+WP_(691*JG;GK7'_  8TBX!N9;U2P0_(30![%:0K!:11J,!5 J:BB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\W\2_\
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M#%M#(?WJ#D54\=>"4UY1>P#_ $N/E<4 =C:QP?8XC&B",H#P.,8KQ75Y;/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** .%\??>@K?\ #'_(,3Z5@>/OO05O^&/^08GTK:7\-"ZFW1116(PHHHH
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M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5YOXE_P"0XO\
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M?\)K)_=/Y5O_ /"+Z=_<H_X1?3O[E'-#L&I@?\)K)_=/Y4?\)K)_=/Y5O_\
M"+Z=_<H_X1?3O[E'-#L&I@?\)K)_=/Y4?\)K)_=/Y5O_ /"+Z=_<H_X1?3O[
ME'-#L&I@?\)K)_=/Y4?\)K)_=/Y5O_\ "+Z=_<H_X1?3O[E'-#L&I@?\)K)_
M=/Y4?\)K)_=/Y5O_ /"+Z=_<H_X1?3O[E'-#L&I@?\)K)_=/Y4?\)K)_=/Y5
MO_\ "+Z=_<H_X1?3O[E'-#L&I@?\)K)_=/Y4?\)K)_=/Y5O_ /"+Z=_<H_X1
M?3O[E'-#L&I@?\)K)_=/Y4?\)K)_=/Y5O_\ "+Z=_<H_X1?3O[E'-#L&I@?\
M)K)_=/Y4?\)K)_=/Y5O_ /"+Z=_<H_X1?3O[E'-#L&I@?\)K)_=/Y4?\)K)_
M=/Y5O_\ "+Z=_<H_X1?3O[E'-#L&I@?\)K)_=/Y4?\)K)_=/Y5O_ /"+Z=_<
MH_X1?3O[E'-#L&I@?\)K)_=/Y4?\)K)_=/Y5O_\ "+Z=_<H_X1?3O[E'-#L&
MI@?\)K)_=/Y4?\)K)_=/Y5O_ /"+Z=_<H_X1?3O[E'-#L&I@?\)K)_=/Y4?\
M)K)_=/Y5O_\ "+Z=_<H_X1?3O[E'-#L&I@?\)K)_=/Y4?\)K)_=/Y5O_ /"+
MZ=_<H_X1?3O[E'-#L&I@?\)K)_=/Y4?\)K)_=/Y5O_\ "+Z=_<H_X1?3O[E'
M-#L&I@?\)K)_=/Y4?\)K)_=/Y5O_ /"+Z=_<H_X1?3O[E'-#L&I@CQI(?X3^
M5<5K?B1Y]4$A!ZUZI_PB^GC^"N!\0Z%:0ZRJ*!C=6E-POHA,U=.\8R)8HNT\
M"K/_  FLG]T_E6KIOAFP;3XB5R2*M?\ "+Z=_<K-RA?8>I@?\)K)_=/Y4?\
M":R?W3^5;_\ PB^G?W*/^$7T[^Y1S0[!J8'_  FLG]T_E1_PFLG]T_E6_P#\
M(OIW]RC_ (1?3O[E'-#L&I@?\)K)_=/Y4?\ ":R?W3^5;_\ PB^G?W*/^$7T
M[^Y1S0[!J8'_  FLG]T_E1_PFLG]T_E6_P#\(OIW]RC_ (1?3O[E'-#L&I@?
M\)K)_=/Y4?\ ":R?W3^5;_\ PB^G?W*/^$7T[^Y1S0[!J8'_  FLG]T_E1_P
MFLG]T_E6_P#\(OIW]RC_ (1?3O[E'-#L&I@?\)K)_=/Y4?\ ":R?W3^5;_\
MPB^G?W*/^$7T[^Y1S0[!J8'_  FLG]T_E1_PFLG]T_E6_P#\(OIW]RC_ (1?
M3O[E'-#L&I@?\)K)_=/Y4?\ ":R?W3^5;_\ PB^G?W*/^$7T[^Y1S0[!J8'_
M  FLG]T_E1_PFLG]T_E6_P#\(OIW]RC_ (1?3O[E'-#L&I@?\)K)_=/Y4?\
M":R?W3^5;_\ PB^G?W*/^$7T[^Y1S0[!J8'_  FLG]T_E1_PFLG]T_E6_P#\
M(OIW]RC_ (1?3O[E'-#L&I@?\)K)_=/Y4?\ ":R?W3^5;_\ PB^G?W*/^$7T
M[^Y1S0[!J8'_  FLG]T_E1_PFLG]T_E6_P#\(OIW]RC_ (1?3O[E'-#L&I@?
M\)K)_=/Y4?\ ":R?W3^5;_\ PB^G?W*/^$7T[^Y1S0[!J8'_  FLG]T_E1_P
MFLG]T_E6_P#\(OIW]RC_ (1?3O[E'-#L&I@?\)K)_=/Y4?\ ":R?W3^5;_\
MPB^G?W*/^$7T[^Y1S0[!J8'_  FLG]T_E1_PFLG]T_E6_P#\(OIW]RC_ (1?
M3O[E'-#L&I@?\)K)_=/Y4?\ ":R?W3^5;_\ PB^G?W*/^$7T[^Y1S0[!J8'_
M  FLG]T_E1_PFLG]T_E6_P#\(OIW]RC_ (1?3O[E'-#L&I@?\)K)_=/Y4?\
M":R?W3^5;_\ PB^G?W*/^$7T[^Y1S0[!J8'_  FLG]T_E1_PFLG]T_E6_P#\
M(OIW]RC_ (1?3O[E'-#L&I@?\)K)_=/Y4?\ ":R?W3^5;_\ PB^G?W*/^$7T
M[^Y1S0[!J8'_  FLG]T_E1_PFLG]T_E6_P#\(OIW]RC_ (1?3O[E'-#L&I@?
M\)K)_=/Y4?\ ":R?W3^5;_\ PB^G?W*/^$7T[^Y1S0[!J8'_  FLG]T_E1_P
MFLG]T_E6_P#\(OIW]RC_ (1?3O[E'-#L&I@?\)K)_=/Y4?\ ":R?W3^5;_\
MPB^G?W*/^$7T[^Y1S0[!J8'_  FLG]T_E1_PFLG]T_E6_P#\(OIW]RC_ (1?
M3O[E'-#L&I@?\)K)_=/Y4?\ ":R?W3^5;_\ PB^G?W*/^$7T[^Y1S0[!J8'_
M  FLG]T_E1_PFLG]T_E6_P#\(OIW]RC_ (1?3O[E'-#L&I@?\)K)_=/Y4?\
M":R?W3^5;_\ PB^G?W*/^$7T[^Y1S0[!J8'_  FLG]T_E1_PFLG]T_E6_P#\
M(OIW]RC_ (1?3O[E'-#L&I@?\)K)_=/Y4?\ ":R?W3^5;_\ PB^G?W*/^$7T
M[^Y1S0[!J8'_  FLG]T_E1_PFLG]T_E6_P#\(OIW]RC_ (1?3O[E'-#L&I@?
M\)K)_=/Y4#QI)G[I_*M__A%]._N4O_"+Z?\ W*.:'8-3S;Q?XF>[>($'BM;0
MO%TD-DJ8/2E\;Z#9VY@*#&:V_#WANQDTY&9<G%:-PY%H+J5O^$TD_NG\J/\
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M %%%% !1110 444A. 30 M%>?W/C;4X?%B:6MGF MC?MKOU.5!/<4 +1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7
MF_B7_D.+_O5Z17F_B7_D.+_O5K2W$SN])_Y!L7TJ[5+2?^0;%]*NUF]QA111
M2 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **IZK?#3M/ENCT05YA-\6+MKAH[>UWA3C(6@#UNBO)8?BAJLEW%$;$
M@,<$[:]3LIVN;**9AAG7)% $]%%4M5U&+3+)IY6  '% %W(SUHKC?"^O7.L:
ME+N4^2,X-;^LZW:Z-:M+/( 0. : -.BO*IOB=J+2DVMGOA!^\%[5UOAOQE9Z
MVHB9PESW2@#J**P?$OB2#P_:AY"-[?=![UR6E?$>[NM36"YMO+B<\-B@#TNB
MHOM,0@$Q<!,9S7*Z=XP?4/$+Z?''F)3C=B@#KB0.II:P/$]W-861N8LX09-5
MO!WB=/$5M(0?FCX- '44444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% '"^/OO05O\ AC_D&)]*P/'WWH*W
M_#'_ "#$^E;2_AH74VZ***Q&%%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%1S3QV\9DD8*HZDT 245YSKGQ)-M=-
M!ID0G93C@9INB_$B6XO$@U&#R2WJ,4 >D45'#/'<1B2)@RGN*DH *,@4R618
M8FD8X51DUP[^*Y;SQ"EM:#=$&P2* .[HI%Y4?2J.KZK;Z/8275PX55&1F@"_
M17!^%/B'%XEU&2WB4;5. 17;7-S':6[32MA5% $U%>8:E\3+J#4O)M;;S(=V
M"P&:[C0=;CUBT5^!)CE: ->@D <FN9\0>*X]&O([88:1^U:37$USI7FA<.5R
M!0!J YZ45P?A[QE]JUUM*F.'4XYKO* "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KG/&_\ R+DU='7.>-_^
M1<FJH?$@,_X>?\@@_6NSKC/AY_R"#]:[.G4^)@CRX_\ (>A_WA7I\?\ JU^@
MKS _\AZ'_>%>GQ_ZM?H*NKT$AU4KK2[6[;,T:M]15VBL1GCGQ3T:UMK<&*-5
M^@K;^&>B6<WAL221*S9QDBJ7Q:_X]Q6[\+O^18'U% &KK]C!::+.8E"@*>E>
M4>"/$?V'5;R*#+2$D5[!XIYT.X'JIKRWX6:#:SZU>SRC+ DB@#HK?X@3VNH"
M'4 50G@FN[34XKC33>0,&0+NKA?BCH%K'X8FOXEVRQ="*3X;WDE[\.YVE))"
MD<T 1W/Q1A-Y+96_,RY  KH/"&N:AJD<TM^I6->A-><>!/#EC>^,[J68;F#$
MX->G>*Y8M!\)7DENNTA#C% &7X@^(%O9W7V.R;?-TXJC:^/KBQE4ZHI6-CQF
MN;^$VCV_B,7.JWV7D5^,UWGC'PK9:CI#$IM:,9&* .EM-1AO]/%Y;MNC*Y%<
M?J'Q#MK*\:T8_OLX K(^'FIRE+K32Q,<0(%81T>VOO&A>;J'_K0!T<GC^ZL)
MQ)>*1;GG)]*OR?$2VU*V)TH[Y .<4WXAZ%9-X2<[0"H !'TK&^%7ANPCL3-C
M<Q/>@#1T?XBA=0%GJAV.QP,U?^(K+)X<,RGY&7(-<#\8--@T[7]*GMOD=W&<
M?6NP\=!Y?AM;A#\YB'/X4 8/@GQ6+70I+:URTP/:M[3OB$;6Z$.KY3<<#-97
MP?\ #$"Z*]W<C=*6K3^(WA>SGL8[A%VR(>U 'H$5]!+8B\5P82N[/M7#ZU\0
MX5O/LFF$R2#@XK!MO$$UKX1FLRQR$*BF?"KPY;7J75_=@O+OXS0!NV?CZ6TF
M5=5!16/&:[VTO8;VS2ZA;,;#(-<3\0?#-I=:)YB+MD0\$51\(:T]GX7N;>0D
MF%#MH VO$GCNSTE_LT+[ISV%8D/CR]M6$]^C"W/<UR/P[L8O%WBF_N+\EQ"Y
M*@UZWJ_A.QU/3#:%  !Q0!'+XIM[C1A?6;;EZFI/#WB./604!&\=15#3O"8T
M[2)K,9*;3BN#\ 2SZ3XWO(+IB(26"YH ]5UW68M(LVD=@&QP*YT^)+G4- N+
MB$'(4XKE/B;J<MQXBLK& DQR$ XKT'3]'AT_PUY6.3%D_E0!\[>$M7U2'XDR
M3"5V8R?=S7TU:7K+I[7-T=H49.:\"\#6L4GQ<G1E!4.:]6^(FJG3-(^SIP)E
MP<4 4=2^(J7-VUMI&79#@XJ32?'K+>K;:EE"W&36?\,O"UDD$M\Z[I).>:G^
M)WAVVCT%KZV79<*W!% '>W.H1IIQO(V#1@9S7 GXHV\MW):0G,P. !3/#&H3
MW/@"2*X8F381FN7^&7A6UO/$=[<W0+,I) - '70>.[JTG#Z@I6 GJ:[S2]4M
MM7LUNK9PR&N;\:^&;2]\-SHB;74?*17'>!]6FT+2Y[.5B=N<9H Z_P 2>/++
M2V-K ^ZYSC K&@\=7\!6:\1A >Y%>=:7K.GMXXN)]2C:10Q('6NT\1^,-"N]
M GMX[,[@F%P* /2]&UNTURT^T6KAAWKCM4^)%OIOB-]+D/S X K ^"U[/(+F
M%HW6(Y(W5S1TN#5?C:T=R25W]* .YO?'E_9W(E=&^S'O[5V?AWQ):>(;7S+=
M@2H^854\0>'-/E\/W2-& $B)!_"O._@<[B^U:$L2B$@9^M '6ZEXAL+?QM'I
MS1IYQ;&<<UO>)O%-GX:M1)<'EONBO(O$P/\ PNZW()^^*]8\6:1I.HV8DU,C
M;'TR>M '*#QUJ5S']KMXV-MUSCM74>&?%UKKB%-V)5ZBN1F\:>'=)TJ33X;7
M<@4C(%<UX'U*"Z\1,]DK(C-TH ]ZHI%^XOTI: "BBB@ HHHH **** "BBB@
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M  Q_R#$^E;2_AH74VZ***Q&%%%% !1110 4444 %%%% !1110 4444 %%%%
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M444 %%%% !1110 4444 %>;^)?\ D.+_ +U>D5YOXE_Y#B_[U:TMQ,[O2?\
MD&Q?2KM4M)_Y!L7TJ[6;W&%%%%( HHHH **** "BBB@ HHHH **** "BBB@
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M_#32I9YKF]NE(;=E<_6@#U%!A%'L*=110 4444 %%%% !1110 4444 %%%%
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MYN:^E-"BG@TY!<L2X')-8FC>!+72-3EO$8%G.<5UCQAHB@XR,4 >?^./$OF
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M+_GHOYT?\)!9?\]%_.CE8&M163_PD%E_ST7\Z/\ A(++_GHOYT<K UJ*R?\
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M"R_YZ+^='*P-:BLG_A(++_GHOYT?\)!9?\]%_.CE8&M163_PD%E_ST7\Z/\
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M-+AU$ 3=!VJ2RL(+"+RX5"CVJG_PD%E_ST7\Z/\ A(++_GHOYT<K UJ*R?\
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M+_GHOYT?\)!9?\]%_.CE8&M163_PD%E_ST7\Z/\ A(++_GHOYT<K UJ*R?\
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M*/:R"QP'_"!W?_/S^M'_  @=W_S\_K7?T4>UD%C@/^$#N_\ GY_6C_A [O\
MY^?UKOZ*/:R"QP'_  @=W_S\_K1_P@=W_P _/ZUW]%'M9!8X#_A [O\ Y^?U
MH_X0.[_Y^?UKOZ*/:R"QP'_"!W?_ #\_K1_P@=W_ ,_/ZUW]%'M9!8X#_A [
MO_GY_6C_ (0.[_Y^?UKOZ*/:R"QP'_"!W?\ S\_K1_P@=W_S\_K7?T4>UD%C
M@/\ A [O_GY_6C_A [O_ )^?UKOZ*/:R"QP'_"!W?_/S^M'_  @=W_S\_K7?
MT4>UD%C@/^$#N_\ GY_6C_A [O\ Y^?UKOZ*/:R"QP'_  @=W_S\_K1_P@=W
M_P _/ZUW]%'M9!8X#_A [O\ Y^?UH_X0.[_Y^?UKOZ*/:R"QP'_"!W?_ #\_
MK1_P@=W_ ,_/ZUW]%'M9!8X#_A [O_GY_6C_ (0.[_Y^?UKOZ*/:R"QP'_"!
MW?\ S\_K1_P@=W_S\_K7?T4>UD%C@/\ A [O_GY_6C_A [O_ )^?UKOZ*/:R
M"QP'_"!W?_/S^M'_  @=W_S\_K7?T4>UD%C@/^$#N_\ GY_6C_A [O\ Y^?U
MKOZ*/:R"QP'_  @=W_S\_K1_P@=W_P _/ZUW]%'M9!8X#_A [O\ Y^?UH_X0
M.[_Y^?UKOZ*/:R"QP'_"!W?_ #\_K1_P@=W_ ,_/ZUW]%'M9!8X#_A [O_GY
M_6C_ (0.[_Y^?UKOZ*/:R"QP'_"!W?\ S\_K1_P@=W_S\_K7?T4>UD%C@/\
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M^?G]:/\ A [O_GY_6N_HH]K(+' ?\('=_P#/S^M'_"!W?_/S^M=_11[606.
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M<@T >B6]Q'<PK+$P96&014M>0>!=>U6Q\0/HU]&YC0X#&O5KN^M[&$RW$JH
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MQA1112 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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ME\.,^UCGBJ,=A\2-081732>23\U>_44 <9X+\&1:$GVJ89NG^\35/Q_X*?7
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M*3P]H$.A6S1Q  MUH V@, "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH X7Q]]Z"M_PQ_P @Q/I6!X^^
M]!6_X8_Y!B?2MI?PT+J;=%%%8C"BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "JFH6$6HVS02_=(JW10!XMJOA3Q1H>
MI22Z"S^6Q/2FVOAWQ7KUY$FL%_(&-P->UT4 9VC:/;Z+9+;6ZX7 S]:T:**
M,;Q39B[\/7BXRXC.WZUYW\);N6REO+2[RI+':#]:];=%D0HPRIX(KC[CP>Z:
M^E[:'9'G+ 4 7_%OAF'Q%IK1,/W@Y4UYBFD>.-%#6=B9/LPSMKW!1A0/:EH
M\=\,?#_4M1U0:CXBW%T.5W5ZS<QO'8F.W&&5<+5FB@#S+3/!^HS>+3J&H9:+
M=D ]*ZWQ1X?36=.\M!AT'R@5T%% 'B*^&_%;W)LI]_V/.!]*]/\ #FD1>'=(
M\L_+W:M^L[6K.:^TYX(6VNW>@#R'3+.XU/XHRS$$V^_@]J]M1 B!5Z"L#P[X
M<324,DH#3D_>KH: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ KG/&__ "+DU='7.>-_^1<FJH?$@,_X>?\
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M3W+ZBC<OJ*\L^U>*O^>3_E1]J\5?\\G_ "H]CYA<]3W+ZBC<OJ*\L^U>*O\
MGD_Y4?:O%7_/)_RH]CYA<]3W+ZBC<OJ*\L^U>*O^>3_E1]J\5?\ /)_RH]CY
MA<]3W+ZBC<OJ*\L^U>*O^>3_ )4?:O%7_/)_RH]CYA<]3W+ZBC<OJ*\L^U>*
MO^>3_E1]J\5?\\G_ "H]CYA<]3W+ZBC<OJ*\L^U>*O\ GD_Y4?:O%7_/)_RH
M]CYA<]3W+ZBC<OJ*\L^U>*O^>3_E1]J\5?\ /)_RH]CYA<]3W+ZBC<OJ*\L^
MU>*O^>3_ )4?:O%7_/)_RH]CYA<]3W+ZBO./$K+_ &XO/\55!=^*@?\ 5/\
ME6)>Z7XEO+KSFB?(.>E73IV>K!L]@TEE_LV+D=*N[E]17E%O-XIMX!$(GP/:
MI/M7BK_GD_Y5#I:[A<]3W+ZBC<OJ*\L^U>*O^>3_ )4?:O%7_/)_RH]CYA<]
M3W+ZBC<OJ*\L^U>*O^>3_E1]J\5?\\G_ "H]CYA<]3W+ZBC<OJ*\L^U>*O\
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ML^U>*O\ GD_Y4?:O%7_/)_RH]CYA<]3W+ZBC<OJ*\L^U>*O^>3_E1]J\5?\
M/)_RH]CYA<]3W+ZBC<OJ*\L^U>*O^>3_ )4?:O%7_/)_RH]CYA<]3W+ZBC<O
MJ*\L^U>*O^>3_E1]J\5?\\G_ "H]CYA<]3W+ZBC<OJ*\L^U>*O\ GD_Y4HN_
M%0/^J?\ *CV/F%S9\?,NZ#FM[PPR_P!F)SVKS+6;/Q/JKH7B?Y?:KMD/$]E
ML:1/P/2M'3]Q*XKGK>Y?44;E]17EGVOQ5_SR?\J/M7BK_GD_Y5G['S'<]3W+
MZBC<OJ*\L^U>*O\ GD_Y4?:O%7_/)_RH]CYA<]3W+ZBC<OJ*\L^U>*O^>3_E
M1]J\5?\ /)_RH]CYA<]3W+ZBC<OJ*\L^U>*O^>3_ )4?:O%7_/)_RH]CYA<]
M3W+ZBC<OJ*\L^U>*O^>3_E1]J\5?\\G_ "H]CYA<]3W+ZBC<OJ*\L^U>*O\
MGD_Y4?:O%7_/)_RH]CYA<]3W+ZBC<OJ*\L^U>*O^>3_E1]J\5?\ /)_RH]CY
MA<]3W+ZBC<OJ*\L^U>*O^>3_ )4?:O%7_/)_RH]CYA<]3W+ZBC<OJ*\L^U>*
MO^>3_E1]J\5?\\G_ "H]CYA<]3W+ZBC<OJ*\L^U>*O\ GD_Y4?:O%7_/)_RH
M]CYA<]3W+ZBC<OJ*\L^U>*O^>3_E1]J\5?\ /)_RH]CYA<]3W+ZBC<OJ*\L^
MU>*O^>3_ )4?:O%7_/)_RH]CYA<]3W+ZBC<OJ*\L^U>*O^>3_E1]J\5?\\G_
M "H]CYA<]3W+ZBC<OJ*\L^U>*O\ GD_Y4?:O%7_/)_RH]CYA<]3W+ZBC<OJ*
M\L^U>*O^>3_E1]J\5?\ /)_RH]CYA<]3W+ZBC<OJ*\L^U>*O^>3_ )4?:O%7
M_/)_RH]CYA<]3W+ZBC<OJ*\L^U>*O^>3_E1]J\5?\\G_ "H]CYA<]3W+ZBC<
MOJ*\L^U>*O\ GD_Y4?:O%7_/)_RH]CYA<]3W+ZBC<OJ*\L^U>*O^>3_E1]J\
M5?\ /)_RH]CYA<]3W+ZBC<OJ*\L^U>*O^>3_ )4?:O%7_/)_RH]CYA<]3W+Z
MBC<OJ*\L^U>*O^>3_E1]J\5?\\G_ "H]CYA<]3W+ZBC<OJ*\L^U>*O\ GD_Y
M4?:O%7_/)_RH]CYA<]3W+ZBC<OJ*\L^U>*O^>3_E1]J\5?\ /)_RH]CYA<]3
MW+ZBC<OJ*\L^U>*O^>3_ )4?:O%7_/)_RH]CYA<]3W+ZBC<OJ*\L^U>*O^>3
M_E1]J\5?\\G_ "H]CYA<]3W+ZBC<OJ*\L^U>*O\ GD_Y4?:O%7_/)_RH]CYA
M<]3W+ZBC<OJ*\L^U>*O^>3_E1]J\5?\ /)_RH]CYA<]3W+ZBC<OJ*\L^U>*O
M^>3_ )4?:O%7_/)_RH]CYA<]3W+ZBC<OJ*\L^U>*O^>3_E1]J\5?\\G_ "H]
MCYA<]3W+ZBC<OJ*\L^U>*O\ GD_Y4?:O%7_/)_RH]CYA<]3W+ZBC<OJ*\L^U
M>*O^>3_E1]J\5?\ /)_RH]CYA<]3W+ZBC<OJ*\L^U>*O^>3_ )4?:O%7_/)_
MRH]CYA<]3W+ZBC<OJ*\L^U>*O^>3_E1]J\5?\\G_ "H]CYA<]3W+ZBC<OJ*\
ML^U>*O\ GD_Y4?:O%7_/)_RH]CYA<]3W+ZBC<OJ*\L^U>*O^>3_E1]J\5?\
M/)_RH]CYA<]3W+ZBN<\;,O\ PCDW-<?]J\5?\\G_ "JCK*^*=1L/LYB?!//%
M.-*S3N%SK_AX<Z0?K79US'@?2Y]-T)$N1B4]173UG4=Y,:"C ]***@ P/2C
M]*** # ]*,#THHH ,#THP/2BB@ P/2C ]*** # ]*,#THHH ,#THP/2BB@ P
M/2C ]*** # ]*,#THHH ,#THP/2BB@ P/2C ]*** # ]*,#THHH ,#THP/2B
MB@ P/2C ]*** # ]*,#THHH ,#THP/2BB@ P/2C ]*** # ]*,#THHH ,#TH
MP/2BB@ P/2C ]*** # ]*,#THHH ,#THP/2BB@ P/2C ]*** # ]*,#THHH
M,#THP/2BB@ P/2C ]*** # ]*,#THHH ,#THP/2BB@ P/2C ]*** # ]*,#T
MHHH ,#THP/2BB@ P/2C ]*** # ]*,#THHH ,#THP/2BB@ P/2C ]*** # ]
M*,#THHH ,#THP/2BB@ P/2C ]*** # ]*,#THHH ,#THP/2BB@ P/2C ]***
M # ]*,#THHH ,#THP/2BB@ P/2C ]*** # ]*,#THHH ,#THP/2BB@ P/2C
M]*** # ]*,#THHH ,#THP/2BB@ P/2C ]*** # ]*,#THHH ,#THP/2BB@ P
M/2C ]*** # ]*,#THHH ,#THP/2BB@ P/2C ]*** # ]*,#THHH ,#THP/2B
MB@ P/2C ]*** # ]*,#THHH ,#THP/2BB@ P/2C ]*** # ]*,#THHH ,#TH
MP/2BB@ P/2C ]*** # ]*,#THHH ,#THP/2BB@ P/2C ]*** # ]*,#THHH
M,#THP/2BB@ P/2C ]*** # ]*,#THHH ,#THP/2BB@ P/2C ]*** # ]*,#T
MHHH ,#THP/2BB@ P/2C ]*** # ]*,#THHH ,#THP/2BB@ P/2C ]*** # ]
M*,#THHH ,#THP/2BB@ P/2C ]*** # ]*,#THHH ,#THP/2BB@ P/2C ]***
M # ]*,#THHH ,#THP/2BB@ P/2C ]*** # ]*,#THHH ,#THP/2BB@ P/2C
M]*** # ]*,#THHH ,#THP/2BB@ P/2C ]*** # ]*,#THHH ,#THP/2BB@ P
M/2C ]*** # ]*,#THHH ,#THP/2BB@ P/2C ]*** # ]*,#THHH ,#THP/2B
MB@ P/2C ]*** # ]*,#THHH ,#THP/2BB@ P/2C ]*** # ]*,#THHH ,#TH
3P/2BB@ P/2C ]*** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>img11953243_13.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img11953243_13.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +8!\H# 2(  A$! Q$!_\0
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M./\ R3S4/^PK)_Z*BKV"@#Q__AG'P?\ ]!+7/^_\/_QJC_AG'P?_ -!+7/\
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M_P"&<?!__02US_O_  __ !JO8** /'_^&<?!_P#T$M<_[_P__&J/^&<?!_\
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M$M<_[_P__&J/^&<?!_\ T$M<_P"_\/\ \:KV"B@#Q_\ X9Q\'_\ 02US_O\
MP_\ QJC_ (9Q\'_]!+7/^_\ #_\ &J]@HH \?_X9Q\'_ /02US_O_#_\:H_X
M9Q\'_P#02US_ +_P_P#QJO8** /'_P#AG'P?_P!!+7/^_P##_P#&J/\ AG'P
M?_T$M<_[_P /_P :KV"B@#Q__AG'P?\ ]!+7/^_\/_QJC_AG'P?_ -!+7/\
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M_P"&<?!__02US_O_  __ !JO8** /'_^&<?!_P#T$M<_[_P__&J/^&<?!_\
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M$M<_[_P__&J/^&<?!_\ T$M<_P"_\/\ \:KV"B@#Q_\ X9Q\'_\ 02US_O\
MP_\ QJC_ (9Q\'_]!+7/^_\ #_\ &J]@HH \?_X9Q\'_ /02US_O_#_\:H_X
M9Q\'_P#02US_ +_P_P#QJO8** /'_P#AG'P?_P!!+7/^_P##_P#&J/\ AG'P
M?_T$M<_[_P /_P :KV"B@#Q__AG'P?\ ]!+7/^_\/_QJC_AG'P?_ -!+7/\
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M_P"&<?!__02US_O_  __ !JO8** /'_^&<?!_P#T$M<_[_P__&J/^&<?!_\
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M$M<_[_P__&J/^&<?!_\ T$M<_P"_\/\ \:KV"B@#Q_\ X9Q\'_\ 02US_O\
MP_\ QJC_ (9Q\'_]!+7/^_\ #_\ &J]@HH \?_X9Q\'_ /02US_O_#_\:H_X
M9Q\'_P#02US_ +_P_P#QJO8** /'_P#AG'P?_P!!+7/^_P##_P#&J/\ AG'P
M?_T$M<_[_P /_P :KV"B@#Q__AG'P?\ ]!+7/^_\/_QJC_AG'P?_ -!+7/\
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M_P"&<?!__02US_O_  __ !JO8** /'_^&<?!_P#T$M<_[_P__&J/^&<?!_\
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M$M<_[_P__&J/^&<?!_\ T$M<_P"_\/\ \:KV"B@#Q_\ X9Q\'_\ 02US_O\
MP_\ QJC_ (9Q\'_]!+7/^_\ #_\ &J]@HH \?_X9Q\'_ /02US_O_#_\:H_X
M9Q\'_P#02US_ +_P_P#QJO8** /'_P#AG'P?_P!!+7/^_P##_P#&J/\ AG'P
M?_T$M<_[_P /_P :KV"B@#Q__AG'P?\ ]!+7/^_\/_QJC_AG'P?_ -!+7/\
MO_#_ /&J]@HH \?_ .&<?!__ $$M<_[_ ,/_ ,:H_P"&<?!__02US_O_  __
M !JO8** /'_^&<?!_P#T$M<_[_P__&J/^&<?!_\ T$M<_P"_\/\ \:KV"B@#
MQ_\ X9Q\'_\ 02US_O\ P_\ QJC_ (9Q\'_]!+7/^_\ #_\ &J]@HH \?_X9
MQ\'_ /02US_O_#_\:H_X9Q\'_P#02US_ +_P_P#QJO8** /'_P#AG'P?_P!!
M+7/^_P##_P#&J/\ AG'P?_T$M<_[_P /_P :KV"B@#Q__AG'P?\ ]!+7/^_\
M/_QJC_AG'P?_ -!+7/\ O_#_ /&J]@HH \?_ .&<?!__ $$M<_[_ ,/_ ,:H
M_P"&<?!__02US_O_  __ !JO8** /'_^&<?!_P#T$M<_[_P__&J/^&<?!_\
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M$M<_[_P__&J/^&<?!_\ T$M<_P"_\/\ \:KV"B@#Q_\ X9Q\'_\ 02US_O\
MP_\ QJC_ (9Q\'_]!+7/^_\ #_\ &J]@HH \?_X9Q\'_ /02US_O_#_\:H_X
M9Q\'_P#02US_ +_P_P#QJO8** /'_P#AG'P?_P!!+7/^_P##_P#&J/\ AG'P
M?_T$M<_[_P /_P :KV"B@#Q__AG'P?\ ]!+7/^_\/_QJC_AG'P?_ -!+7/\
MO_#_ /&J]@HH \?_ .&<?!__ $$M<_[_ ,/_ ,:H_P"&<?!__02US_O_  __
M !JO8** /'_^&<?!_P#T$M<_[_P__&J/^&<?!_\ T$M<_P"_\/\ \:KV"B@#
MQ_\ X9Q\'_\ 02US_O\ P_\ QJC_ (9Q\'_]!+7/^_\ #_\ &J]@HH \?_X9
MQ\'_ /02US_O_#_\:H_X9Q\'_P#02US_ +_P_P#QJO8** /'_P#AG'P?_P!!
M+7/^_P##_P#&J/\ AG'P?_T$M<_[_P /_P :KV"B@#Q__AG'P?\ ]!+7/^_\
M/_QJC_AG'P?_ -!+7/\ O_#_ /&J]@HH \?_ .&<?!__ $$M<_[_ ,/_ ,:H
M_P"&<?!__02US_O_  __ !JO8** /'_^&<?!_P#T$M<_[_P__&J/^&<?!_\
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M$M<_[_P__&J/^&<?!_\ T$M<_P"_\/\ \:KV"B@#Q_\ X9Q\'_\ 02US_O\
MP_\ QJC_ (9Q\'_]!+7/^_\ #_\ &J]@HH \?_X9Q\'_ /02US_O_#_\:H_X
M9Q\'_P#02US_ +_P_P#QJO8** /'_P#AG'P?_P!!+7/^_P##_P#&J/\ AG'P
M?_T$M<_[_P /_P :KV"B@#Q__AG'P?\ ]!+7/^_\/_QJC_AG'P?_ -!+7/\
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M_P"&<?!__02US_O_  __ !JO8** /'_^&<?!_P#T$M<_[_P__&J/^&<?!_\
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M#3HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** .?\ '?\ R3SQ+_V"KK_T4U?$%?;_ ([_ .2>>)?^P5=?^BFKX@H
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 <_X[_P"2>>)?^P5=?^BFKX@K[?\ '?\ R3SQ+_V"KK_T4U?$
M% 'T_P#LX_\ )/-0_P"PK)_Z*BKV"O'_ -G'_DGFH?\ 85D_]%15[!0 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7#ZE_R6#1O^P?+_,U
MW%</J7_)8-&_[!\O\S0!W%%%% !1110 4444 %%%% !1145S<PV=M)<3N$BC
M&68]A2;MJP2N2T5P0\>:MJ4CR>'_  [)?VBDCSFDV9^F:[#2KJXO-/BGN[4V
MT[#YHB<[356=K@]'8NT45S.H>+A8^,+'0#:,YNE)\W/"XI+5I+J'1OL=-16'
MI^MWMWKUU83:9)#!#]RX)X>MRCHF'5H**S+OQ!IUCJUMI=Q-MN[D$Q)C[U1>
M(=6N](LXYK33WO79PI1#@@>M'F%M;&Q145M*TUM'*Z%&902I[>U2T-6$G=7"
MBBB@84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 <_X[_Y)YXE_P"P5=?^BFKX@K[?\=_\D\\2_P#8*NO_ $4U?$%
M'T_^SC_R3S4/^PK)_P"BHJ]@KQ_]G'_DGFH?]A63_P!%15[!0 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MBHJ]@H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHKG->\86NA7 @>RO;F0]K
M>+=BDVD-*YT=%<YX?\::;XAG>WA6:WN4Y,%PNU\?2K.O^)['P]$AN!)+,_W(
M(5W.WT%-Z;B6NQM45@:!XNT_7W:*))K>X7DP7"[7Q]*WZ;30D[A7#ZE_R6#1
MO^P?+_,UW%</J7_)8-&_[!\O\S2&=Q1110 4444 %%%% !1110 4444 59M,
ML+E]\]C;2O\ WGB4G]14HMK<0>0((_)QCR]@V_E4M%'D!7M]/LK1BUM:00L>
MICC"_P JD:"%I5E:*,R+T<J,C\:DHH B^S6X9V$$6Y_O'8,M]?6HHM,L()?,
MAL;:.3^\D2@_GBK5% $-Q:V]TFRX@BF7TD0,/UI!96HA$(MH?*7D)L&T?A4]
M% $3V\$A0O#&Q3[I*@[?IZ4LL$,X EB20 Y =0<5)10   # Z4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !7)^-;:.]N-%M9MWER7>&VG!Z>M=97,>*
MO^0GH'_7Y_2LJVL&=F ;6(37G^3-+3/#]EI*S+;&;$PPV^0M^59Y\#:.V<FZ
MY.3^_-=+15.G!JUC-8NNI.2F[LR[W0+*_L(+.?SO*A^YMD(/XFH-/\*Z;IMZ
MMU;FX\Q1@;Y21^5;=%'LXWO82Q-91<%)V9@WOA'3+^\ENIC<>9(<MMF('Y5:
MM] LK;2I=-C\[[/)G=F0EOSK4HH]G%.]@>)K.*BY.R_0\^O_  OIMIXKT>WC
M-QLDW,=TI)R.G->@@8 'I7+ZR1_PFNA#_9D_E745%**3E;O^AT8VK.I"DYN^
MGZL****V. Y_QW_R3SQ+_P!@JZ_]%-7Q!7V_X[_Y)YXE_P"P5=?^BFKX@H ^
MG_V<?^2>:A_V%9/_ $5%7L%>/_LX_P#)/-0_["LG_HJ*O8* "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH *S-7U?3- MFOM1E6"/H7*Y)_*M.HI[:WND\NXACF3
M^[(H8?K2=^@U;J>9Z2T7B_XB)K^F#R[*VCV-)T,A^E6='D&J_%G5&G&X6<:B
M(-_"?:JVL01:#\2-+&C?NVN2%N((S\H7UQVJWJT4OA'QM+XB:"273KM DYC7
M<4([XJH-)1?2TE\Q33?,NON_<-\:L-+\=:'J$(VRR'RWV_Q GO7;:QKVF:!;
M)<:G=+;Q.VU68$Y/X5Q",WCKQ?8ZA;0RII5DI.^5"I9OH:]$N+6WNT"7$$4R
M@Y D0,!^="35-)]W]P2=YW79?><S_P +)\)?]!>/_OAO\*P(-?TOQ!\6M+ET
MNZ6X6*PE#D C!Y]:[W^Q]+_Z!MG_ -^%_P *X^ZM;:T^+VCK;6\4(-A+D1H%
MSR>N*0'>T444 1SSQ6T#33.$C099CVKGH?'_ (7N+H6T>K0F4G:%((Y_*N@N
M+>*ZA,4R[D;J/6N+^(.E:-:^#+MOL<$4JJ/):- &W9['K4MVU>Q48\S21T7B
M'7[;P_HTFHS?.@P%"_Q$]*Y.77O&-IIW]NSQ6K::%WM;JO[P+ZYJ==%.L?#&
MWM=6G\IQ$)!(_P##@9%<L_B[4KW0AH<]I)%9O_HYU(CAEZ9Q5--2E%;IJW:Q
M,6G&,GMU/5=%U:#6])M]0M\A)EW8/:M"LKPYI=OH^A6MG:R"2)$&'!^][U<U
M"]CT[3Y[N7[D2%C^ IU'&+;6PH7:7<FED$43R$$A03@5B>&/%-OXH@NI;>"2
M(6\QB8/W([UR%C<>+O%-A-K-IJD=G8MN\JV,>2ZCWJ'X7"];PSJZP,%O#=.-
MQZ!O6B*?O7Z):?,<K65N]CU.BO+-8U7Q-X/N+6\OM?M]0@DF$<EJJ ,N36RG
MB+4[/Q_!87DJG3;R'?#\N-K>F:(KFM;K?[UJ$M+W]?EL=U2$A5)/  R:XI]>
MU.[^)(T>TD5;*WB$DPVYS[9K;\6ZHND>&KRY+88H43ZD8%1)VAS]RDKSY"CH
M/CK3M?UZ^TBWCD2:T;!9NC^XKIW=8T9W8*JC))[5XO9V$GA.;0-?92KWI$5P
M<?WCWKM?B9J<EGX-E-NY5IRJ!AZ$U<TU%6WV^>Q,;2GY/5>@ES\0U>Z>+1M%
MO-62,D-);\*#6K+XI%KX7FUJ\L)[?RE+-;O]\>U6/"VF6^E^'K.&WC5<Q*S$
M#EB1DDUE_$1A_P (K-$2 )3L/XU-7W$TMP@^:TGL:7A7Q/:>+=$CU.S1TC<X
MV/U!K.UWQ[I^@^(K+1IH99)[HX#(>%^M<Q\, = O;G0),A!"+A"?>N5\1Q-J
M7B:[\0DDK;7<<<+=L9YK6R=:*7PO\MOS)C=TY=^GY_D>^ Y&:Y_1/%EMK>L7
MVG0V\L<EF<,S=&^E;L#^9;1OZJ#7C_AZ#6;OQKK]OI-PMID\W!&['/I6:^/E
M\G^A7V.;S7XGLE%<!X2\0:PGB6_\.:U<+=7$ W1SJNW</I2>(H?%=HESJ,7B
M.WM8HP72U=!\P';-)M))]'K<:3;<>IZ!17GUA>>(/%OA^VU.PUI-,V9$P,08
M''4U'X#U/Q'JNKW[7FI)=Z;;DI&XCV^8:KE?,XOH3S>ZI(]%HKS_ ,10^*[-
M+G48O$5O;11@NEJR#Y@.V:BO/'-]_P *T&O6Z*+M6"$=B:F^E_3\2K:I=_T/
M1:JZC>IIVGSWCJ66%"Q5>IKBK#Q!K]EH,VOZX(XX3%NBMUZY(XYK)N$\9:IX
M5N=9FU6-+>:(N++R^0OUI5+Q4O+\ A:37G^)WWAO7X?$NDKJ$$3Q(S%=K]>*
MUZXGX59_X0F'/!\QLU3\8>*==T[Q;8Z/H\*2FYC)(;^'WK6HDJG(B*;;AS,]
M"HKE9K+Q1+H\<(U.*VNNLDY0$*/I6!HVO:W9>+&\.ZCJL.H&:/,5Q&H&PX[@
M5"5WR]2GHN8[J'6=/N-3ETZ*Z1KN(9>(=5JG=^(3:^(8-)^P7$@E7/GK]Q?K
M7EFFZ1X@E^*&J16VNK#<KR\WE9W#TQ77WNNZM8^/M+T9KB.2!X09FV<L?6G!
M7Y'W_P""$]'-=O\ @?YG?T5P%SK.M^)_$%YI>@WBV$-GP]R4W;CZ8J71?$&J
M:5XF7PWKTZW,TJ%X;H+MW#Z4H^];SV\PE[M_+?R.ZZ5@3^-?#MMJ/V"74XEN
M<XV<]?KTJ'QYJLFC^$;VYA;;+MVJ?0FLW1?#&G2^!5$MM')// 96F907W$9S
MGK2OHY=$.VR[G;(ZR('1@RD9!'>L[6-?TO0($FU2\2VC<[5+]S7,?#/4WGT"
M:TN)MS6<ICW,>U5/B0]HVI>'!=-$83=Y/F8VXJG'WE%=?UU"&M[]+_@;UK\0
M/#%Y<I;P:K&\KG"J%;G]*NZQXKT3098XM3OX[>20916R21^%36=KHDV'LX-/
M=E_BA1"1^5<5K[:<?BOIJWYMO+%JW^OQMS^-%KR4?7\A1V;?1'4Z;XU\/:O=
MBUL=12:<]%"D?TK?JC9VNE$B:R@L_P#?A1?YBKU#$@HHHI#"BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "N8\5?\A/0/\ K\_I73UA:_IUS?7VD26Z!DM[GS),GHM9U4W'
M0ZL')1K)R=M'^3-VBBBM#E"BBB@ HHHH B>WADF29XE:2/[C$<K]*EHHH&VV
M%%%% CG_ !W_ ,D\\2_]@JZ_]%-7Q!7V_P"._P#DGGB7_L%77_HIJ^(* /I_
M]G'_ ))YJ'_85D_]%15[!7C_ .SC_P D\U#_ +"LG_HJ*O8* "BBB@ HHHH
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MOUA;S4-8M8-+M7_=0,^#(WJ?:O4I[>&ZA:&>-9(V&&5AD&L@^#O#AZZ+9?\
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MI_"^&.W#,\<22;1U.!TJI%XPTJY^'IM8Y@]\+?RVM%_U@;Z5Z,D4<<0B1 $
MP% XQ5"+P]H\%V;N+3;9+@\F18P":)^]SKI(4/=47UB<O\)[A9?!R( RNDK;
ME8<BLSQ$P'Q@T09Y\EJ]'M[2WM PMX4B#')V#&339+"TENDNI+>-KA!A9"OS
M#\:MRO44_P"MK$J-H2AW_P SS[Q_JL\7B/3-/N+U['2I"#+.. ?8FL"S73+'
MXK6$FGAWM)%P)^JN?8UZ[?:98ZG$([ZTAN$!R%D4$"FQ:1IT*1)'90(L7,8"
M#Y?I44_=:?:_X_Y%3]Y->7Y'FUIJ%IHWQ=U*34KA+5)U_=-(<!OI4NMS1S?%
MS2FC<,DD'RL.AS7H-]H>E:E*LM[I]O<2)]UI$!(J4:98B:.86D7FQ#:C[>5'
MH*(Z<E_L_P#!_P PGKSV^U_P/\CSOPW>6_@_Q5K-GJ\BVT,[^;%/+PK9/3-/
M=E\5?$NRO=//FV-E$0UPOW6/L:[^_P!(T[5%5;^SAN0O02(#BI++3[/3H?)L
M[:."/^[&N!3B[<K?V=%]U@EKS6^UO^IC^-](DUOPI>V<(S*5R@]Q7/Z1XRTR
MU\'"TNKA8M0@A,/V9CARP&!@5Z#69+X>T>:\^V2Z;;/<YSYIC&[\ZFVCCT8[
M[/JCD/!_A::?P;<17;RVDM^YD8IPRC-=+/X1TF_TJUL-3MQ?);#"-+U^M;H
M   P!6!X@M?$DSQOH-]:VY'WQ<)N!JI--[=OPT0HI]7W_'<X;Q!I,7@3Q#I=
MWH3O#%<2;);4,2&%=YJOA/0_$+QW&IZ?'/,%P';((K#T[P;J5WK4.K>)K^*[
MN+?_ %,<*[4'X5H:W9>+WOM^B:C8PVQ'*3QEB/I2^RD]7K\O(-Y-K31?,Y2S
MMW\'?$:WTK3II&T^[0$VY.1'[UZG7(>'?!\]EJLFLZS=B\U-UV[E&%4>PKKZ
MK[*3=W_7Y"WDVM@HHHJ1A1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M>/\ [./_ "3S4/\ L*R?^BHJ]@H **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "JFJ,R:5=LK%6$+D$=C@U;J"\,(LIS<?ZG
MRVW_ .[CFD]BH.TD9WA662;PQ822R-([1Y+,<D\FMBJ&BFR;1[8Z<,6FW]U]
M,U?I0^%&F(=ZLG:VK_,****HQ"BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Y_QW_P D\\2_]@JZ_P#1
M35\05]O^._\ DGGB7_L%77_HIJ^(* /I_P#9Q_Y)YJ'_ &%9/_145>P5X_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MW>YI75E&+C9I:^>K"BBBK.<**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** .?\ '?\ R3SQ+_V"KK_T4U?$
M%?;_ ([_ .2>>)?^P5=?^BFKX@H ^G_V<?\ DGFH?]A63_T5%7L%>/\ [./_
M "3S4/\ L*R?^BHJ]@H **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ K,\0V+:EH5W:I]^2,A1GJ<5IU
MGZZ&;0[S865A$Q4IU!QVJ9VY7<J'Q(XN\T&_MO"6DS6M@AO-.(=X /\ 6 =J
M7P6=9U/Q->ZO=::^F6CQA! QZD=ZQ=!^*;V&EI:7^EZA+-%E?,\H_,/6NR\*
M^-H?$]Q-#%87-OY0R3*A4&MKMR;6N_X[D-6CR[=/Q.KHHHK,84444 %%%% !
M1110 5P^I?\ )8-&_P"P?+_,UW%</J7_ "6#1O\ L'R_S- '<4444 -=%D1D
M=0RL,$$<&LQ_#.AR??TFS;ZPK6K10!5CTVQBL_L<=I"MM_SR"#;^51V>C:9I
M\A>SL+>!SU:.,*:O44=;AY'*^(_$GAFRN!9Z\B,0-RB2$N/Y5RFEPP^)O'EG
MJ>D67D:58*0) FT.3Z"O3Y;2VG;,UO%(?5T!_G3XX8X5VQ1HB^BJ *(>Z^;K
M_2"6JLNH^H);.VFG2:6"-Y4^X[*"5^AJ>B@"O=V-I?Q>5=VT4\?]V10P_6F1
MZ5I\4211V<"QH<HH084^U6Z* (([.VBN'N([>-9G&&<* 3^-'V*V-S]I^SQ^
M?C'F;1N_.IZ* ((;*UMS(8;>.,R'+[5 W'WI+2PM+%7%K;QPASN8(N,GUJQ1
M0!YAXC@6?XMZ,DL!DB,3!LKE?QKT.RTK3].+&RLX+<MU\M N?RJR8HRX<QJ7
M'1B.13Z:=HJ/:_XNX2UE?T_ ****0%.]TK3]2V_;;."XV]/-0-C\ZL000VT2
MQ01K'&O14& *DHH *H-H>E-=_:FTZV-QG/F&,;L_6K]%'F!GZQ;ZA<:<\>EW
M*6UU_!(ZY4?A7(GP9K^LW$(\3:S#<VL3!A#;H4W$>M=]10M'<'M8P]<T[5Y;
M*"+0+V&QDC(&9$W*5],5SO\ PA6N:S?02>)]8AN[>%MRPP1E 3[UWU%"T=PZ
M6.?UW3M>E6 :!J%O9^6NUA-'N!%8^G^"M1NM7BU/Q-J4=]- <PI$NU%/TKN*
M*%H[@]58**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!S_CO_ ))YXE_[!5U_Z*:OB"OM_P =_P#)//$O_8*NO_135\04
M ?3_ .SC_P D\U#_ +"LG_HJ*O8*\?\ V<?^2>:A_P!A63_T5%7L% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/KA]2_Y+!HW_ &#Y?YFD,[BBBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MOZSXJN]8U&PEL+5HPB0NV<D5MKSRU[_U\R+KDM_6^QZ%11168PHHHH ****
M"BBB@ KA]2_Y+!HW_8/E_F:[BN'U+_DL&C?]@^7^9H [BBBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* ,#PG?W.H:?<R7,OF.ES(@/H >!6_5/3FL6A<Z>8_+\P[O+Z;N_XU<J8*T4
MKFV(DI59-*WD%%%%48A1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MHKF6>?[B01[B:'I;S!:W\CI:*Y71_'=GK.H+9Q:=J4+L,[YH"J_G754[,+]
MKA]2_P"2P:-_V#Y?YFNXKA]2_P"2P:-_V#Y?YFD!W%%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445GG7=*60QG
M4+<.#M*^8,Y]*3:6Y482E\*N:%%0W%W;VD/G7$R11?WW.!45KJ=C>R%+6[AF
M=1DA&!(HNKV!0DUS):%NBJ5QJ^G6DIBN+V"*0#)5W -6$NH);;[0DJ-#C.\'
MC'UHNANG-)-K1DM%4(=:TR>58HK^W>1CA55P2:FNK^TL0INKF*'=]W>V,T<R
MWN#I33Y6G<LT57M;ZUOE9K6XCF53@E&SBH)-<TN*1HY+^W5U."I<9!HYEO<%
M2FW9)W+]%5;G4;*S5&N;J*)7^Z78#=]*;;:K87DOE6UY#+)C.U'!.*.97M</
M9SMS6=BY15"37-+BD:.34+=74X93(,@U+_:-E]C^U_:HOL__ #UW?+^=',NX
MW2FMXO[BU16?'KFE2R+&FH6[.QPJB09-27.JV%G+Y5S>0Q28SM=P#BCF7</9
M5+VY7?T+E%5;;4;*\5VMKJ*4)]XHV<?6J_\ ;^D#_F)6W_?P4<R[@J51NRB_
MN-*BJT^HV=M"DT]U%'%)]QV; ;Z5';ZOIUU,(;>]@ED/(5'!-',MKB]G-J]G
M8NT51EUK3()FBEOH$D4X96< BI4U&SDM&NDNHFMUZR!OE'XT<R[@Z4TKM,LT
M52M]7TZ[F$5O>P2R$9"HX)I]UJ=C9.J75W%"S#(#L 31S*U[A[*=^6SN6J*A
MM[NWNX?.MYDEC_O(<BJHUS2C)Y8U"WWD[=OF#.?2CF7<%3FVTD]#0HJ"YO+:
MRB$ES/'$A. SM@4RUU*ROF9;6ZBF*_>",#BBZO87)+EYK:%JBJ,^L:;:S-%/
M?01R+U5G (JR+F VWVD2IY&-WF9XQZYHNANG-)-K<QO"FG7.FZ?<Q7481WN7
MD !Z@G@UO5S_ (0U&?5-+GGFG\_%RZH_;:#Q705-*W(K&V,Y_;RY][A1115G
M,%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MF@D@,MW)(J2##8)XJ_9RA2ES+L1SQG4CRON==1117,= 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '/^._^2>>)?^P5=?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ KC_ W_'UX@_["#5V%<?X&XN_$(/\ T$&K:'\.7R_,QG_$C\SL
M****Q-@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .?\=_\ )//$O_8*NO\
MT4U?$%?;_CO_ ))YXE_[!5U_Z*:OB"@#Z?\ V<?^2>:A_P!A63_T5%7L%>/_
M +./_)/-0_["LG_HJ*O8* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 <_X[_P"2>>)?^P5=?^BFKX@K[?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ J*:Y@MP#/-'$#TWN%S^=2UPWB^PMM3\9>'K.\0R6[B0LFX@'BM
M*<%.5F14FXQNCK_[3T__ )_K;_O\O^-']IZ?_P _UM_W^7_&L3_A ?#/_0,3
M_OMO\:/^$!\,_P#0,3_OMO\ &JM1[O[O^"3>KV7W_P# -O\ M/3_ /G^MO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M44 %%%% !7#ZE_R6#1O^P?+_ #-=Q7#ZE_R6#1O^P?+_ #- '<4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M4UY$CQO=5R<#)QDT .HKGI_&FDV]Q)#)]IWQMM;$)(S5TZ_8C1_[4_>_9O\
MKF=WY5"J0?4Z'A:\;-P>NQJ45S]OXRTFYN8X(_M&^1MJYA(&:GU/Q-IVDW?V
M:Y\[S-N[Y(BPQ]:/:0M>X/"5U+DY'<V:*R]-\06.JPSRVWF[81E]\97\JSCX
MZT89_P"/K@X_U!H=2"5[@L)7DW%0=UN:7B#37U;1I[*.18VDQAFZ#!S5^WC,
M-M%$3DH@4GUP*YKQEJ:+X8_=>?YEUM$/EJ<]0>?2NCLP196X;.[RUSGZ4DTY
MNQ4X3CAXN6UWI]Q-1116ARA1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !7'^(/^1_\-_27^5=A7'^(/^1_\-_27^5;4/B?H_R,:WPKU7YG84445B;!
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110!S_CO_DGGB7_ +!5U_Z*:OB"OM_Q
MW_R3SQ+_ -@JZ_\ 135\04 ?3_[./_)/-0_["LG_ **BKV"O'_V<?^2>:A_V
M%9/_ $5%7L% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M (;^DO\ *MJ'Q/T?Y&-;X5ZK\SL****Q-@HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% '$1>+M?O[R]33- 2>"VF,)D:;;DBI_[=\8?]"S%_P"! H\!?\QS_L(R
M5V%=-24(2Y5%?C_F<U.,IQYG)_A_D<?_ &[XP_Z%F+_P(%']N^,/^A9B_P#
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M[!\O\S7<5P^I?\E@T;_L'R_S- '<4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110!P=OI+W?Q4NM16156UB4,IZMD5WE<QI'_ ".^M_\
M7..NGK&BDDWYL[L?4E*4$^D8I?=<****V.$**** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHIKND
M:%W8*HY+,< 4 .HI%974,I#*1D$'(-+0 4444 %%%% !1110 4444 %%%% !
M1110!Q_@+_F.?]A&2NPKC_ 7_,<_[",E=A6V(_B,QH?PT%%%%8FP4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 <_X[_Y)YXE_[!5U_P"B
MFKX@K[?\=_\ )//$O_8*NO\ T4U?$% 'T_\ LX_\D\U#_L*R?^BHJ]@KQ_\
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MU_T$/_(;?X4?\+!\-?\ 00_\AM_A1["I_*_N#VU/^9'3T5S'_"P?#7_00_\
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M-7Q!0!]/_LX_\D\U#_L*R?\ HJ*O8*\?_9Q_Y)YJ'_85D_\ 145>P4 %%%%
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MFBB["R*W]GV7_/G;_P#?I?\ "C^S[+_GSM_^_2_X59HHNPLBM_9]E_SYV_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MU[5Y+I(G\.W*1L^TR%Q@#UKFUU_4I_&5]J&G:%/>06Z_9&96 RP.<UZ/7'^
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %(5!Z@&EHH  ,=**** "N'U+_ )+!HW_8
M/E_F:[BN'U+_ )+!HW_8/E_F: .XHHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **YOQAJ]]I=O8)I[(DUU<K#O<9"YJ-]/\7E"$UF
MR#=B8/\ ZU#NFKK1]32,(RBWSJZZ:W_*WXG445RZ:?XO" /K-D6]1!_]:FOI
MWC$R KK5D%[@P?\ UJ2=Y./XCE22@I\R=[::W5_ETZG545S/]G^+?^@Q9_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MZ\2=_MR$K'D\5WU*SWO?R[&DVN6,>2S76V]]O4****#(**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?_PCFB?] FR_[\+_ (51S&;_ ,+ \)_]!RU_,_X4?\+ \)_]!RU_,_X5I?\
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M+7\S_A2?\+ \)_\ 0<M?S/\ A7.>%-$TJ7QMXLB?3;5DCGC"*8@0O!Z5VO\
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M)LO^_"_X4 9O_"P/"?\ T'+7\S_A1_PL#PG_ -!RU_,_X5I?\(YHG_0)LO\
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M+7\S_A1_PL#PG_T'+7\S_A6E_P (YHG_ $";+_OPO^%'_".:)_T";+_OPO\
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M,_X4?\+ \)_]!RU_,_X5I?\ ".:)_P! FR_[\+_A1_PCFB?] FR_[\+_ (4
M9O\ PL#PG_T'+7\S_A1_PL#PG_T'+7\S_A6E_P (YHG_ $";+_OPO^%'_".:
M)_T";+_OPO\ A0!F_P#"P/"?_0<M?S/^%'_"P/"?_0<M?S/^%:7_  CFB?\
M0)LO^_"_X4?\(YHG_0)LO^_"_P"% &;_ ,+ \)_]!RU_,_X4O_"P/">/^0Y:
M_F?\*T?^$<T3_H$V7_?A?\*XO1M$TE_BAX@A;3;4Q);0E4,0P#QT% '1?\+
M\)_]!RU_,_X4?\+ \)_]!RU_,_X5I?\ ".:)_P! FR_[\+_A1_PCFB?] FR_
M[\+_ (4 9O\ PL#PG_T'+7\S_A1_PL#PG_T'+7\S_A6E_P (YHG_ $";+_OP
MO^%'_".:)_T";+_OPO\ A0!F_P#"P/"?_0<M?S/^%'_"P/"?_0<M?S/^%:7_
M  CFB?\ 0)LO^_"_X4?\(YHG_0)LO^_"_P"% &;_ ,+ \)_]!RU_,_X4?\+
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M6E_PCFB?] FR_P"_"_X4?\(YHG_0)LO^_"_X4 9W_"P/"?\ T'+7\S_A2?\
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MK2_X1S1/^@39?]^%_P *QO%F@:/%X2U61-+LU=;9R"(5!!Q0!/\ \+ \)_\
M0<M?S/\ A1_PL#PG_P!!RU_,_P"%5?!V@:/-X.TF232[-G:V4EFA4DFMS_A'
M-$_Z!-E_WX7_  H S?\ A8'A/_H.6OYG_"C_ (6!X3_Z#EK^9_PK2_X1S1/^
M@39?]^%_PH_X1S1/^@39?]^%_P * ,W_ (6!X3_Z#EK^9_PH_P"%@>$_^@Y:
M_F?\*TO^$<T3_H$V7_?A?\*/^$<T3_H$V7_?A?\ "@#-_P"%@>$_^@Y:_F?\
M*/\ A8'A/_H.6OYG_"M+_A'-$_Z!-E_WX7_"C_A'-$_Z!-E_WX7_  H S?\
MA8'A/_H.6OYG_"C_ (6!X3_Z#EK^9_PK2_X1S1/^@39?]^%_PH_X1S1/^@39
M?]^%_P * ,W_ (6!X3_Z#EK^9_PH_P"%@>$_^@Y:_F?\*TO^$<T3_H$V7_?A
M?\*/^$<T3_H$V7_?A?\ "@#-_P"%@>$_^@Y:_F?\*/\ A8'A/_H.6OYG_"M+
M_A'-$_Z!-E_WX7_"C_A'-$_Z!-E_WX7_  H SO\ A8'A/_H.6OYG_"D_X6!X
M3_Z#EK^9_P *YWP+HFDSZKXH$FFVK!-1(0-$#M&.@KM/^$<T3_H$V7_?A?\
M"@#-_P"%@>$_^@Y:_F?\*/\ A8'A/_H.6OYG_"M+_A'-$_Z!-E_WX7_"C_A'
M-$_Z!-E_WX7_  H S?\ A8'A/_H.6OYG_"C_ (6!X3_Z#EK^9_PK2_X1S1/^
M@39?]^%_PH_X1S1/^@39?]^%_P * ,W_ (6!X3_Z#EK^9_PH_P"%@>$_^@Y:
M_F?\*TO^$<T3_H$V7_?A?\*/^$<T3_H$V7_?A?\ "@#-_P"%@>$_^@Y:_F?\
M*/\ A8'A/_H.6OYG_"M+_A'-$_Z!-E_WX7_"C_A'-$_Z!-E_WX7_  H S?\
MA8'A/_H.6OYG_"C_ (6!X3_Z#EK^9_PK2_X1S1/^@39?]^%_PH_X1S1/^@39
M?]^%_P * ,W_ (6!X3_Z#EK^9_PH_P"%@>$_^@Y:_F?\*TO^$<T3_H$V7_?A
M?\*/^$<T3_H$V7_?A?\ "@#._P"%@>$_^@Y:_B3_ (4G_"P/"?\ T'+7\S_A
M7._$G1-)MM%L&ATVT1CJ$()6(#(STXKM/^$<T3_H$V7_ 'X7_"@#-_X6!X3_
M .@Y:_F?\*/^%@>$_P#H.6OYG_"M+_A'-$_Z!-E_WX7_  H_X1S1/^@39?\
M?A?\* ,W_A8'A/\ Z#EK^9_PH_X6!X3_ .@Y:_F?\*TO^$<T3_H$V7_?A?\
M"C_A'-$_Z!-E_P!^%_PH S?^%@>$_P#H.6OYG_"C_A8'A/\ Z#EK^9_PK2_X
M1S1/^@39?]^%_P */^$<T3_H$V7_ 'X7_"@#-_X6!X3_ .@Y:_F?\*/^%@>$
M_P#H.6OYG_"M+_A'-$_Z!-E_WX7_  H_X1S1/^@39?\ ?A?\* ,W_A8'A/\
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M +"LG_HJ*O8*\?\ V<?^2>:A_P!A63_T5%7L% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !37C21=KHK+Z,,BG44 ,CBCB7;&BH/11BGT44 %<7J%M<-
M\6=(N%@<P+8RJT@'R@Y/&:[*21(8FDD8*BC))["N*F^)%LD[&'2;V>Q1L->H
MO[L>]'6P[:7.WHJO8WMOJ-G'=6L@DAD&Y6%6*&K:,2=PHHHH **** "BBB@
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M0$!CW)-9TJW?@KQG?ZM<6<]W87W.Z!-[H?3%591<8]$GK_7<+M\TNKMIY?\
M '>%<1^+IO\ A)5QKY7$3'[K)[5Z77FEM%=>,_&MGK45I/:6-ER&F3:[GTQ7
MI=-WY5?1_P!?F3IS.WE_7R.?\=_\D\\2_P#8*NO_ $4U?$%?;_CO_DGGB7_L
M%77_ **:OB"I&?3_ .SC_P D\U#_ +"LG_HJ*O8*\?\ V<?^2>:A_P!A63_T
M5%7L% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 86L>%;'6]5LM1N6D$UF<QA3@?C6[110M%8'J[A1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %84
MGA2QD\4Q^("TOVN-"@&?EP:W:*%H[ATL%%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 5C3^&K.?Q%%K;-)]IB7:
M#\M;-%'6X/56"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** .?\ '?\ R3SQ+_V"KK_T4U?$%?;_
M ([_ .2>>)?^P5=?^BFKX@H ^G_V<?\ DGFH?]A63_T5%7L%>/\ [./_ "3S
M4/\ L*R?^BHJ]@H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MG_"C[*?<'NUZ?B;M%9C^(M(C6V9[^$"Y_P!2<_?^E6+_ %.RTN 37MPD$9.
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M*V.F:(_!)>?Z#GJX^C_-'F?@=0+WQ;@#J].^&6AZ;/X1OII[6.9Y)) WF*&
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M1'6[7=A1114%!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M=@?$?B7!'^N;I]:.7WG'^ZG\]!3=KM=)6-KP9XTO_$*:KIFKVZ0ZA:*P;8,
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MZ&T76;/7=,AOK*59(I%!X/0^AK:6J;ZZ?+3]2'I*W37YZ_H:%%%%9E!1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110!FZMH=IK'DM<!EDA;='(APRFM%%V(
MJY)P,9-+11TL'F%%%% '/>)]"O=>2&VAO3;6N?WP7[S#TK6TS3;;2;"*SM4"
M11C ]_>K=%"T5D#UM?H%9NKZ+;:U%'%=,_EHX?:IP#CUK2HH ;'&D4:QHH5%
M& !VIU%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MC L,0_A6KE%"TV!ZF;/H&EW.JQZG-9QO>QC"3'J*=JFAZ;K21IJ-I'<+&VY
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M/X:I?#\QGQ/KJPJ%CC?8 .W-*GK*[ZIV_#4532*2Z-7_ !T/1J***!A1110
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MXKR/P#X7TK6YM;&K0>?*EVWR,2,>]$+\[?9#EI#U:1ZK:+8PVQ>Q2 18S^X
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M%$?=V!ZZ'#7_ (0UFRURYU3PSJ%O;/=C]^EPFX'Z5<T/P>^FV.HO<W"S:EJ
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M.M.9N;F^I'+:"BOZ_P" =&"",@Y!HI%4*H51@ 8 I:D84444 %%%% !1110
M4444 07L NK*: _\M$*_G7G?P_U.UT :GH^J2QVDL4[.AE(4.OL3UKTNLG5?
M#&BZW(LFI:=#<.O1F!S^E)73;756&[-6?34\^T#3VUOQ#XHN[12+&YB*1D#
M=L=JU/A_K-EHWAY]*U*XCM;FR=@R2L%+#/;/6N[LK&UTZV6WM($AA7HB#@5G
MZCX4T+5KI;F^TV">9>CL#G]*J]ERK:R7W=1/WM7O>_\ P#E/A[:276LZOKKQ
MLD<\I2(D?>7/6O0ZC@@BMH5AAC6.-1A54<"I*':R2V6@M;MO=ZA1112&%%%%
M !1110 4444 %8&O>#-%\23QSZE;L\L8PCJY4@?A6_7,Z]_PEZ7JG0EL'MRO
MS"Y)!!]J3L-7Z'(I!/X$\<Z=IUC=2RZ;J#;3!(Q8H?7-3SF/PQ\4FOKP;+34
M$XF8?*I'J>U:VB>$]3GUT:[XDGCEO$XBBBY1/I75ZCI=CJUL;>_MH[B(_P +
MBJNX\KW:O]SZ"=FY+H[?>NIYWXEE@U_Q]HT>D2)-);D22S1'("^A(KU"LS2O
M#VDZ&K#3;&*VW==@ZUIT:**BO/\ $'=RYGZ?<%%%%( HHHH **** "BBB@ J
M"\LX+^TEM;E-\,J[77U%3U3U-;TV,G]G%!=#[GF?=S[TI6MJ-;G Z]\.=+T7
M1Y]0T*2>QNK9=Z$2DKQ[53U'QM>2^ ;%WAN&GNCY4LL,98@#J?QK3O-'\=>(
M(#I^K2V%K92<2M;,=Q%=KI6EV^DZ9!8P*/+B4 9'7WIV?*TWU7_!^\5US)K?
M7_@?<>,>*_%.AKX7T[3--@O4$-PCN98"N?7GN:];\,:Y::[I$<]FDRH@"$3)
MM.:S/'7AB[\2:?:06+0QM%<+*Q<=0*ZBVB\FVCC( *J <"J4KQ=]VQ-:Q2Z+
M]26BBBI&%%%% !1110 4444 %%%% '.Z[X(T+Q'=I=ZC;.TZ+M61'*D#\*Y#
M3%N?!OC^#1+>ZDGTV[4%8W.2A^M=1K9\9I?'^Q%T][4C_EX)# U3T+PEJ":K
M-KVMW"3:HR;8T3[D?THINSOTUNOZ\PGK%KKT+7B+P!H_B&:2[N%E6[(^5Q(<
M CIQ6?\ #O6+N=M2T:\99&TZ7RDD48!6DN$^(TPE@7^RDB<E1*&.\+_C6UX2
M\+IX;LI \IFN[AM\\I_B:G#2_:WXA/6W?]#HJ***0!1110 4444 %%%% !11
M10!5U#3[;5+*2SNX_,@D&&7/6O.O$O@.P\-:--K&@33V5Q:+O \TLI'IBN_U
MD:F=.?\ LDQ"[!^7S?N_C7%W>A>-/$JK9:Y-8VVGD_O!:L=SCTJ;._NZ,I-+
MXM4;NE+#XS\%VQU-'*SQCS K%23]17'ZCIJ_#?7K"XTAS]ANY!'+"_S-D]\U
MUNHV7B/2[:TM?#"61MXD",MR<=*R[3PIKFLZY!J?BB>#;;<Q6]N<IGU-:)IU
M.:.BOKZ&=FJ?++5V_$[U3N4'U&:6CI14E!1110 4444 %%%% !1110 5RNK_
M  [\/:S?2WUS;R+=2_>DCD*FNJ/2N-U+_A/1?3)IJZ8UH3^[:4G>!2>Y2O8R
M/!MW>Z+XQOO"\UTUS:11^;$[G)0>A-4OB#JNG2>+O#I2_MF$<IWD2 [?KZ5U
M7A7PB^DR7-_J4WVG4;O_ %K=@/0>U3O\/_"DLCN^B6S.YRQ(/)_.KNU*#>K5
MOFR=/>ML[F_:W-O=0+);SQS)C[T;!A^E353TW2['2+46UA;I!".B+TJY2=KZ
M"5[:A1112&%%%% !1110 4444 %9.N^'-,\26JV^IP&6-3D -C!K6K#\0_\
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M8TBW\_.[?@]?SK>5510J@!0, #M5<WQ/N3;1+L+1114E!1110 4444 %%%%
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M7A#1I]!\.6UA=&-IHQ\S(.#6[6E5IR;1G334;!1116984444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Y_QW_R3SQ+_ -@JZ_\
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?!.)"<9/H:^?TTK49$5TL+ID8 JRPL01ZCBBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>img11953243_14.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img11953243_14.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #O"!H# 2(  A$! Q$!_\0
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MYX&CZK4[!S(][HKP3_A>=Q_SP-'_  O.X_YX&CZK4[!S(][HKP3_ (7G<?\
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M\\#1]5J=@YD>]T5X)_PO.X_YX&C_ (7G<?\ / T?5:G8.9'O=%>"?\+SN/\
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MP+>TB9Y#V H4DU=,1!171W/@'Q':6K7,MHWEJ,G KG.02&!4@X(-"DGLQB'
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M$]:T6+S;VV94]0*.97M<#&HK8M?"FLWMF+N"W9H3T.*L7'@;Q#:6IN9;1O+
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MP.A/T%='+X#\10W*6[VC>8_3BM;P;X9EL_'$.G:U /FP=C"FZD4KW X8'/\
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MM+OKR*!WR&#G!P:S? \^D>#OB'J5HMW&UI-DK+GC-4XI<Z2U#L<RQ3_A>.W
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MOAA)#]NB\YDXCSS7F7PN\4P^%_$3BX&(KAR"WH*TA3;C)I:A<[WQ)\6CHOC
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MU1FBCCX24' _.O1--73M)O!)!KL)L!T1GS1435K[V!'B/Q&8OX@D9[;R&/7
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MU9U:/B'_ )&&[_WJSJJ.R 0ANSNOT.*7\2?K113$'T)'N*0 CJ[-_O'-+10
MF&S_ *Q\>F[BE5I$)*2NN?1L444 )A\_ZZ3_ +Z-&&[2./HV*6B@ 9I7QOFD
M('3+&D(/9B#Z@XI:*  O*4V&>4KZ;C0..^?K110 A#'H[+_NG%)A_P#GO+_W
MV:=10 @W=Y';_>;-+110 5L^$?\ D9[>L:MGPC_R,]O2E\+&:WQ'_P"0Y%]*
MY"NO^(__ "'(OI7(5-/X$#$.>S,O^Z<4#/=F;ZG-+15B"D ;/,CD>A/%+10
MA#9XD=?8'%*"ZL&61U([@T44 (QD=MS32D_[QHPW]]\^N>:6B@ WR[-GGR[?
M3>:3''4_7/-+10 *TJ A9Y0#_MFD (ZL3]3FEHH *%:5"=LT@S_M&BB@! #G
M+.[?[QS2T44 %%%% SK?AS_R'I/I6;XP_P"1GGK2^'/_ "'I/I6;XP_Y&>>L
MU_$?H'0Q*0ANSLO^Z<4M%:  SW)/N:3#9_UCX]-W%+10(0AL\2R+[!L4F'[S
M2GZL:=10 F"!P2#Z@\T -GF1V_WCFEHH #ST)'T-(-W=V;_>.:6B@ HHHH&%
M%%% #6_A_P!X5Z=K7_)/8?\ =KS%OX?]X5Z=K7_)/8?]VLJF\01YBGW!]*=3
M4^X/I3JU$( V>9'(]"U+110 A#=G=?\ =.*6BB@8@WJVY9'7'HV*'WR'<\CL
M?]HYI:*!'IW@3Q7X?AL&TO5;7:&X,G2NO@\5^#O"-G/<:3^\F8' SFO 2 >M
M($ /?\ZQE0C)WN.YJ>(M9E\0:Q+?NS(6)Q@XK-&<<DM[GFBBMDK*R 57D0$)
M+(H/8-BF8?\ YZR?]]&G44"$PV?]8^/3=00W:1Q]&Q2T4 (0<<.P/J#0,]V+
M?4YI:* $.<Y#,I]CBE=I9""TTIQ_M&BB@!,''WC]<T8?O+(?JQI:*  -*JE5
MFD"GMN-( P/,CL/0MFEHH 0ANTCK_NMBC#8^^^?7/-+10 W#_P#/:3_OHTH!
MQR[-[DYI:* !&EC.4FD'_ C2#.<EV8^YS2T4 %%%% PHHHH **** "BBB@ H
MHHH **** "BBB@!K_=KT^3_DG _W:\P?[M>GR?\ ).!_NUE5Z>H(\PC^X*=3
M8_N"G5L(0@GHS+[@XI2TK*%,\N!_M&BBD @'X_6E5I(VRDTB_1C110 GS$DL
M[,3_ 'CFC#9_UCX]-W%+10 A#9XD<#T#<4$-V=E^AQ2T4 )AO^>C@^H:C#8^
M^V?7/-+10 @!QR[$^I- #=Y'8>A;-+10 *TB-N261?HU)\Q)+2.Q/]XYI:*
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MQKKP6[)D8O:O3_A%:7\ZW3V<I10IR!7F!Z5[/\"B1;WO^Z:ZL0[4V2MS#M_
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MOB/_ ,AR+Z5R%=?\1_\ D.1?2N0J:?P(&%%%%6 4444 %%%% !1110 4444
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MS!_NUZ?)_P DX'^[657IZ@CS"/[@IU-C^X*=6P@HHHI#"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ I#T-+2'H: /1O '_(N7G^Z:\^N?^/VX_WS7H/@#_D7+S_=->?7
M/_'[<?[YK.'QR A=MJDBOHWX.>&[;2?#K:C%*'ENQEA_=KYR?[IKZ)^#KNWA
MB8,Y("G /:LL7?V>@X[G,>/](GUSQ[9Z4][OCF[ YVUP_CCPDGA'7[;38WWB
M;'/UK;\-332_&R02RNX67Y=QZ<UK?&JPO)_&^F30V\DD8"@E1TI0;A.,+Z6
MSKWX6BUT.UU 2DM/CBM%?@PTMI;SI.%63&\L>!7?ZVKQ^#-+5P5;Y>#53X@7
M]S9?#Z/[-(T;.HRRG!K)5JCLD^H[(XCQ#\&GTW2GO-/G$Y09.#FN8\%^ ;WQ
M7=2!@4@B.)&/:O6OAK?W-]X%G6ZD:7:IY8YJ_P""XX[?0M7>RVF0EC\OKS3=
M:<4T]T%D97@WX:V_A?Q0+RVNTF&,%0V2*YGQ5;W%S\:$6V<HX Z5#\,;O6I/
MB5>)=FX,&\\/G K4U3CXX#Z"CWE4=W?0.AF?$#1+W4/%>G:??2EA<8 SVJVW
MP0C2\"/>(D/<LV*VO'9)^(^@?[PK&^.FJW]EJVF1VMS)"NY<A#C-$)3?+&+M
M="T.7\;_  TN?"L*W5NWF6I.W=[UJ>%_A#)JVD+?ZG,( XRN3CBNU\92O<?"
MG39)6+,S1Y)[TGQ,N=0LOAG8_P!EB3<T:!O+Z@;1356;2C?5L+(YI/@FDGFR
M+<AX5!*LISFO+-7L?[+U::QSGRSC-?0OPGDOF\$G[<9-V"<R=>E>$>,?^1OO
M?]XUI1G)S<9.]@:T,6BBBND04444 %%%% !1110 4444 %%%% !1110 4L7_
M !\P_P"^*2EB_P"/F'_?% CZT\#_ /(KVO\ NBNCKG/ _P#R*]K_ +HKHZ\2
M?Q,U(;S_ (\YO]PU\C^,/^1INO\ >-?7%Y_QYS?[AKY(\8?\C5=?[QKKP6[)
MD8G:N[^'GCVS\%Q3I=0-*91QBN$HQ7=**FK,D]1T7XJ:?I>NW.H26K,DV< =
MJY'5_$L&I>.H/$"1%88Y-Y2N<P**E4HIW07/1/''Q)M_$UUI]SIT#0RVASD_
M6NEA^-6C7&FQ0:MIQGF1<%BN>:\6Q1@>E)T(-)=@NSV'5_C)I6H:&^G0V+)G
MA>. *HP?%73HO",^C&U?S9%(#5Y9@>E&!Z4EAZ:5@NSTGP/\3X_#EE)INI0F
M>T=B0#SC-;M]\8]%M=.GMM%T[R9Y!P^W%>,XI,#TH="#=V%V>G^"OBJ-'2ZB
MUF(S"<DY6MRT^,?AS3+J1K33757^\<<YKQ7&:3 ]*'AZ;=V%V=Q)X]C7QS_P
MD%O$5B)Y3VKH_$OQ4\/^(K9 VG-]H3D.17DM&!Z53HP;3[!<]-U_XH6&L>$$
MT:*V=)E &^K?A;XLV5EH2:1K=J;A$7"DC/%>3XHQ2]A"U@NSUGQ!\7K*70Y=
M,\/V?V4N"I.,<5G>&/B78Z%X0NM'N+=WN)PWSCIDBO-\"C%'L(6L%V=;\/O%
MUMX-U:XO+J$RK*Q( [9JOXW\30>*M8:]MXC&A/0US5%7R1YN?J 44450!111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5S1_P#D.6G^^*IU
M<T?_ )#EI_OBA[ =A\2_NV?T%<'7>?$OI9_05P=9TO@0/<N:5J=SHVHQ7MHV
MUT8$_2O88_C)X?O[:%=3TWS)X@/F([UXE28%$Z49ZL+V/2?%/Q1CUZ_LGM;?
MRK2V;.S'6K?B/XJZ=K=O9QPVC*8,9SWQ7EF*,#TI>PAIIL%V>E>+?B;8>(M!
MM-.@M61X&!)/M4/C3XC6/BCPC;:-;V[1RQ*%+'IP *\[Q1BFJ,%:W0+L]&\-
M?$BQT/P-/H$ULSS2(5#CIR*F\,_$_3]"\*S:1-:L\DF<,.G->9XHP*3HP=[]
M0NST+P=\3?\ A&KJY^U1M+:SMG9Z5U<GQC\.V4,QT[3-EQ,#\VWO7B5)@4I4
M(2=V%V>E>%?BQ-I.I7$NIH98)B<*O85T,?Q?\-:?J!N;73G\QOOMBO%:3 ]*
M)4(-W"[/43\4]//BL:Q]E;RLYVUS?Q \6VWC'54N[6(Q*O8UR>!151I1B[H+
MA37^X:=37^X:U$>G:7_R3R7_ ':\Q3H?J:].TO\ Y)Y+_NUYBG0_4UC2WD-C
MJ***U **** "BBB@ HHHH **** "BBB@ HHHH **** "NW^&G_'Y=?0UQ%=O
M\-/^/RZ^AJ*OP,$<SXA_Y&&[_P!ZLZM'Q#_R,-W_ +U9U5'9 %%%%, HHHH
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MJ\8_\^-?5%%'UR?9!RGRO_PJKQC_ ,^-'_"JO&/_ #XU]444?7)]D'*?*_\
MPJKQC_SXT?\ "JO&/_/C7U111]<GV0<I\K_\*J\8_P#/C1_PJKQC_P ^-?5%
M%'UR?9!RGRO_ ,*J\8_\^-'_  JKQC_SXU]444?7)]D'*?*__"JO&/\ SXT?
M\*J\8_\ /C7U111]<GV0<I\K_P#"JO&/_/C2'X4>,6&/L/6OJFBCZY/L@Y3Y
MFCM/$UA9'PVU@/-?BL\?"CQB/^7'KS7KVJ.W_"Q(N>C5Z752Q,H6LMPY3Y7_
M .%5>,?^?&C_ (55XQ_Y\:^J**GZY/L@Y3Y7_P"%5>,?^?&C_A57C'_GQKZH
MHH^N3[(.4^5_^%5>,?\ GQH_X55XQ_Y\:^J**/KD^R#E/E?_ (55XQ_Y\:/^
M%5>,?^?&OJBBCZY/L@Y3Y7_X55XQ_P"?&C_A57C'_GQKZHHH^N3[(.4^5_\
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MU111]<GV0<I\K_\ "JO&/_/C1_PJKQC_ ,^-?5%%'UR?9!RGRO\ \*J\8_\
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MJO&/_/C7U111]<GV0<I\K_\ "JO&/_/C1_PJKQC_ ,^-?5%%'UR?9!RGRO\
M\*J\8_\ /C1_PJKQC_SXU]444?7)]D'*?*__  JKQC_SXT?\*J\8_P#/C7U1
M11]<GV0<I\K'X4>,3_RX].:T);3Q/J=D/#B6 \U.*^F3TKS317;_ (6%-SU8
MU4<3*=VUL%CR$?"CQBHQ]AZ4O_"JO&/_ #XU]445/UR?9!RGRO\ \*J\8_\
M/C1_PJKQC_SXU]444?7)]D'*?*__  JKQC_SXT?\*J\8_P#/C7U111]<GV0<
MI\K_ /"JO&/_ #XT?\*J\8_\^-?5%%'UR?9!RGRO_P *J\8_\^-'_"JO&/\
MSXU]444?7)]D'*?*_P#PJKQC_P ^-'_"JO&/_/C7U111]<GV0<I\K_\ "JO&
M/_/C1_PJKQC_ ,^-?5%%'UR?9!RGRO\ \*J\8_\ /C1_PJKQC_SXU]444?7)
M]D'*?*__  JKQC_SXT?\*J\8_P#/C7U111]<GV0<I\K_ /"JO&/_ #XT?\*J
M\8_\^-?5%%'UR?9!RGRO_P *J\8_\^-'_"JO&/\ SXU]444?7)]D'*?*_P#P
MJKQC_P ^-'_"JO&/_/C7U111]<GV0<I\K_\ "JO&/_/C1_PJKQC_ ,^-?5%%
M'UR?9!RGRO\ \*J\8_\ /C1_PJKQC_SXU]444?7)]D'*?*__  JKQC_SXT?\
M*J\8_P#/C7U111]<GV0<I\K_ /"JO&/_ #XT?\*J\8_\^-?5%%'UR?9!RGRO
M_P *J\8_\^-'_"JO&/\ SXU]444?7)]D'*?*_P#PJKQC_P ^-'_"JO&/_/C7
MU111]<GV0<I\K_\ "JO&/_/C1_PJKQC_ ,^-?5%%'UR?9!RGRO\ \*J\8_\
M/C1_PJKQC_SXU]444?7)]D'*?*__  JKQC_SXT?\*J\8_P#/C7U111]<GV0<
MI\K_ /"JO&/_ #XT?\*J\8_\^-?5%%'UR?9!RGRL?A1XQ88^PUH&U\3/8_\
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MJO&/_/C7U111]<GV0<I\K_\ "JO&/_/C1_PJKQC_ ,^-?5%%'UR?9!RGRO\
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MK'.CW7_7,TUN!Q_PWZ7G^]_6N^K@OAPA"WA/3=_6N]JZOQL2"BBBLQA1110
M4444 %%%% !1110 4444 %%%% !1110!YGJG_)0X_P#>KTRO-=4C8_$2+W;U
MKTJM:FR$@HHHK(84444 %%%% !1110 4444 %%%% !1110 4444 %<-\2/\
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M.O&?_0;D_,T?\)UXS_Z#<GYFL6BG["GV"[-K_A.O&?\ T&Y/S-'_  G7C/\
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MK\4Z?&8K35GC0\X!JQ_PG7C/_H-R?F:Q:*?L:?8+LVO^$Z\9_P#0;D_,T?\
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M[1\7M7MR" ]MC./:H?#.LVWA+7;[3M5S;H6)C<CAN:],6PM$O6O%@07##!D
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M_NK#X@:'#]M)>0+R5KM_AS\1O^$CW6%^!'>Q\;?6FX]1*1Z32%E7JP'U-!.
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M^!O^1FO?J:](K6M\0D<A\1/^0"O^]6EX/_Y%NV^E9OQ$_P"0"O\ O5I>#_\
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M0:99/=7#!8T'-+87L>H6<=S%_JW&5I6=K@6:***0!7F4?_)1C_O5Z;7F4?\
MR48_[U:TNHF>FT445D,**P]9\4Z?HSB*2023_P#/)3S1H_BK3]7=HT?RY1_
MQY-5R2M>P&Y163K'B*PT4!;B4>:WW8P>3532?%^GZI<_9P3%,>BOU-'+*U[
M=#169>:Y:V-XEK*?WC]*EU'5;?3(%FG.%;I2LP+U%9-UX@LK.RCNYGVQ2=":
MR)/B!I<<B[@WE$X\SM34)/9 =;17.>(_$BZ=X>>_LR)"R%D(K!^''C:Z\26#
M+?H3<"0C<.F*:IR<>85ST&HI;F"%E669$9N@9@":P-0\:Z7IU_-92OFXC&2@
M/)K%U>YTS7;S3KJ=I89$.47.,T*F^H7.^!R,BBLZ]U6STC3UGN90B!> 3R:Q
M[+QUIEU<"-]T*L<*[]#246]4AG4T51U'5[/3+47%S,JHWW>?O5BV?CG3;FZ6
M"0-"7.%9^AH46U=(#;U'5+;3(@\[<GHHZFL_4_$NF:7';W-SUEP%..16/XC<
M2>+M'C/S1OV[&H_B#IELFB+<!?G65<>U7&"NK]1'2_V]:"\AMCN#2J&4GIBM
M2N"\5N;;0='NH@%FRB[O; KN+<EK6(GJ4!_2IE&R30R6BBBH **** "BBB@
MHHHH **** "BBB@ HHHH **** /./'G_ ",%C]17H-K_ ,>D/^X/Y5Y]X\_Y
M&"Q^HKT&U_X](?\ <'\JUG\$1$U%%5-2>1-.G:+[X4XK(90U'Q5I.ESB&YN5
M5SQC-:-I>V^H6PE@</&P[5\@>.-2U.3Q)-]HED7:QVC->M_!'Q%<7>GSV<\I
M=E'RY-:.%E<A3.M\4^"/#6K7):Z\N.5NN*XF?P;/X#NTUG1G,ENIRP'I3O$U
MY??VQ*)'=<,<<UUOAJ::\\,7D=^-T.PX+?2MYT>2'-<\K#YE[;$>RY;"6?CC
MPIX@@CDU!(A<CA@WK7<Z5+82VBM8%/*[;:^,=>86VOW:VLK*@<[<&O<O@AJ&
MI7,!2Y+M$!P36,HZ'J1M?8]%\=RM%X6O"IP?+->?_!"TA^R7%P5!E,A^:N^\
M??\ (JW?_7,UP_P1XTFY;N'-2OA93^(]<GA6X@>)P"K#&#7F6B_#1M(\;-K$
M1*QLV2!TIGB?QUK>F:DT5O8RO&IZ@5'X.^*,^N:^FEW$)1R<<T)-(&U<]*UB
M]73]*GN&.-J&OGS3]$/C/6M1N)%W*F2M>J?%75Q8>&7A5L22\"L_X1Z*;?1)
M+N5>9O6A:*X/5V,;X0ZF;;5[W196QY1(4&O3/%G_ "+=Y_N&O%[G?X6^+!E^
MY%</C]:]F\2,)?"UPX/#1Y_2B6]Q+:QY/\'<C7[O']XU[C+M\I]^-N#G-?+W
MA'6=4TK7KHZ?;O*=Q^Z/>M[5_BCK@N3I<L$D,\WRC/%5*+;%&22&7:0K\5T^
MPX_UG.VM/XN9_MK2=WWLK6[\/?A_-!=KKFI-OFD^89K"^,+9\2Z<.P<#]:+Z
MA;0]C\/G.A6G_7,5Q7Q>LH9_#YD= 74<&NU\/?\ ("M/]P5R/Q8_Y%Q_H:B.
MY;V*WP8F>3PHR,<A6XI_QD_Y%9?]ZH?@K_R*\G^_4_QC&?"@/HU/[8OLCOA&
M3_PCF.U=GKMO%=:-<QS*"FP]?I7BG@'XAPZ+I)MY(BV*T/$7Q1NM3T^2QTVU
M<RR_+D"FXNXE)6*'PH)M_%5_!"?W8E/ KWNO+?A1X0N=*MY-0OE(FF.[!KU*
MIF[L<5H%%%%24%1W'_'M+_N'^525'<?\>TO^X?Y4 >=^!O\ D9KWZFO2*\W\
M#?\ (S7OU->D5K6^(2.0^(G_ " 5_P!ZM+P?_P BW;?2LWXB?\@%?]ZM+P?_
M ,BW;?2A_P ,.INUY_\ %!@FGV[,<+Y@YKT"L'Q=X?7Q%H<EITDSN0^XJ:;2
MDFP9HZ1SH]F1T\E?Y5PGB @>/;;_ 'A52RU_Q=X>METZ31S<I$-L<G/(JUX:
M\/ZOJOB)M?UM# ?X(3VK51Y&Y-@5M8L+>_\ B! MR"RC&!4WCS2+*UU#3[B"
M/9*I&"/K6C=Z)J,GC9+U8<VP/WJL^-](OM2FM&LXMX0_-[<TU+6.H&!XYN)+
MQ-+TN0MY,H4N0>M=:?"&E7&B16GDA0(QANX.*SO%/AFYU70+9[;Y;ZW4$ =_
M:L3_ (2'QC-9)IBZ08I]H0RX[>M)7E%<KV J^.HI=*M=%T%78PS3!6;/49KL
MKWPEI2>'9+180%5/O=\UD:SX1O[_ ,,6@EE,^I6S>8K'KGTK-;7_ !?=6)TI
M]((D9=C38Z>]/627*]A#=!NY9O!^JV3N6CMR53GM5WP9H6GR>%KQGBW,P8DG
MZ&M"U\+3:9X1GMHAONYQEQ[U;\*:9>6'ARXM[F/9*RG _ TI25G;N-'*_#;0
M[!Y+YGC+GS",,<\5-X1MX['XIZ[:V^5@5<A<\#FMCP'HU_I;7?VV'R]\A*_2
MH]"T34;7XEZQJ4T.VTG7$;^M.4KN6O01SWA+0[35?B-X@N;I2YA?Y03QUK0\
M<Z9!H^HV6JV?[N96 V@]>:Y[2KK5[+XA:_<Z7 9T5CYB>M;D5EKOC/7+>XU.
MT-G9PD'9ZU<KJ7,WI8"34)#-X^TF9OO/$I-.L&\OXQZE)R=MMT_"M#4M"OW\
M=6-W!#FTA0 MZ46&B:A'\4KW4Y(<6,D&U7]3475OD!C>%+&'7_&NJWFH*9&0
MGRU)X'-=A<>#[-M9M]3M_P!U)%U Z&N4O],UOPGXHN=5TJU-U;7)^=/[M7=/
ME\4>(M<@NKF)K"RB4@I_?HE=^\GI89'K-[H=MKQFM+ WUZ/OA><&N>TS4);W
MXD12-I[V.0 4/&:NI8:YX0\37=Y;:<;R"=\[SSBI[&R\1ZQXWBUB]L/L\"@
M#':K5DOD(I>,[2#_ (3NP38,,XS6G\4[U["UTVPAB9X)CM:->XJ;Q_H.J&_M
M-8TFV^TSQ,"8JNZOI6H>*/#EO>W%M]GU*'YEB]#4J2]UL#GI)VD\/C3X?#,O
MW?E;'>F?:]7TCX;S_;(GBD:78J'J%-7QXG\8QV:V":+B=1L$N/UKHWT.]UCP
MF]KJ;9N7&X#T-#E;?N!#X2\,Z<OAB/,66G7<Q/7)KE?A]81Z9\2=;M86R@4D
M'-6M)U/Q5HT']CMI9E4$JLV.@IW@'PWK.E>,M4OM1B/E3KE'/>AW2E=[@>H4
M445RE!1110 4444 %%%% !1110 4444 %8/C3_D3-6_Z]VK>K!\:?\B9JW_7
MNU-;@?'ME_Q[G_?-6*KV7_'N?]\U8KVX[(S"BBBF 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1102 ,GI0 $@
M#)Z5I>&/"]_XTU9+.T1A;!OGEQQBCPQX8U#QGJR6EFC"V#?O)<=*^I_"?A2P
M\*:5':6D2A\?.^.2:X\1B.7W8C2.1UCPM9>%/!<%G:@[@0&8GJ:[#PA_R+=M
M]*S?B)_R E_WJTO"'_(MVWTKD>M,KJ;M%%%8C"BBB@ HHHH **** "BBB@ H
MHHH ****  ]*\ST7_DH,W^]7IAZ5YGHO_)09O]ZM:>S$STRHKC_CWD_W34M1
MSJ6@=1U(XK(9YOX-_P"0]KOT-5/#F?[,\0\G[QK;\+Z)J-EK.KS7$.V.8'RS
MZU5T/0-4MK#6HYH-K3L3&/6NIR6OR)%\!Z'I\FB74CQ;F<G)/XU2\(HNF7^K
MI:DK&BLP&>]=1X-TR\T[1IX;N/9(Q.!^=9OAW0;^#6[Y[J';!," :ERNY78S
MBO"VJ/+J%WJ$NC27DQD9=_45I6$6K2>-+>[M-)EM+9V_>D\#%7Q#K_@O5+D:
M=I_VNRE)(XZ5K>'[WQ/K&K&>_M_LEHOW4QUK24MY+81W+'",?05Y5I,">(OB
M!-<7ZEO()55)XKU8C(Q7FNNZ/J^@>)UUK1[<W$3#YXA6%)[KJ-E3XI^'[*WM
M;&_MU\J83!20>"*W=7DT8>%[#^V/GPH\M ?O&N7\2VGB?QFMF38F"&*0,4K4
M\9>%=1O=+TFXMHS+-98+1>N*VTM%28C!\7:SGPM+#;>'Y(8N-D^,;>>M=#J\
M2S_"&SDE^=Q$I#'\:SO$&H>*O$7AF73(-%\HMA3QV%=7_P (_<77PYMM)E79
M<)" 5]QFAM)*_<"K\/(+:+PF974*"N';VQ61%J6C6=U.='T=[YBQWN!GFI_"
M5OX@73[S0;[3S!;%&5)_6LSPU_PD'@M9]-CT@SJ\I83>M*VLM0'?#6[ENO'&
MML]NUJN.(&_AKUD]#7FW@32M<C\8:OJVK6ODK<CY..M>DGH:SK-.>@T>4Z=I
M-GJ/Q F>Z0N5)P,\5)\4+EK*VM-.MH3Y)<$HO&?:MC1]$U&W\8S7DL.(&)PU
M:'CCP[+K>G)):?\ 'U V]??':KYUSJ^PNAR%W=/+X=>QM_#$H9H@%;'.<=:F
MBBU&U^$>H0:C$T4BKA5;J!4P\3^,FLA81Z+MN0-ADQT'K6IK\5Y#\+[U=2?=
M<F++$U3;5D^X#?A]X7TZ+P99R-%O>>/<Q//6L/3)6\,^)=1L;4EX9(V;;G.#
M57PIKGB?2?"=I%#IINHY%Q&WH*Z3PAX7N\W6I:N"+FY! 0_P@TI>ZY.3 SOA
MII5MJ]M>:O>H9;AIV4%CT%)JMM'X=\<VDM@2GVE]KJ#Q45O#XA\$7US%86!N
MK*5RX'H36AHVCZIXAU\:SK%N;98^8XC3;]YROH!0U'3+74?B)']J4L 00*TO
MBAIEG;>!;AHH54JZX(%3MHNHGQN+WR?]&!^]6UXVT637_#%Q8P_ZQL,H]<5'
M/:4=1F3X7V6/P\6ZB3]X+8G(^E<-X*U-VAN;Z719+V=IB/-QGBNT\%?VV=+?
M1M5TWR($C,:R?WAC%9%HOB'P/<3VECIWVNQ=RRG'>K3UDNHBC8?VM;^)9]3M
M=*EM(&!W ]*T/ VGP:UKNJW]\IDD#_*">G-;7AV?Q'K.IS3ZM;_9;0C"Q8K%
M-CKO@WQ!>7>G69N[.Y.2O]VAN]X]0*?C;1+6P\56$]K^[WD%ESUKU:S_ ./*
M'_<'\J\GU#1_$OB;7;;59[4PQQ$8C]J]:M59+6)6&&"@$5G5^%*XT>>_%0[9
MM!/_ $]C^E-\9:7<Z-J5MXDTQ2%0#[0B_P 0J_\ $71=0U=]'-A#Y@AN0\GL
M.*[.6VCN;(V\ZAD=-K T*?+&/S \OU;5;?6/'OAJ\MVY*;BOI4EG;1^(OB+-
M+?*66W.U%)XXK/MO VL:;\4+:^BC+Z8IZ]E%;OB+1]7T;Q.NNZ+;FX5O]9"*
MU;BK*+Z"&_$72;?3K.SU"Q'DW*S ;@<9%'C.SDO]$TK64)62UVNY'>JEW%X@
M\=W5M;7EB;*SA<.S>IKT&_TN.XT*73U4;3%L K-RY.5/<9P/BW6?[=L-'LK=
MLK>D!\5Z)I-B--TNWLUZ1(%KS7P/X2U6VUR4ZM"5MK5B;8FO5JFJTK10(***
M*Q&%>91_\E&/^]7IM>91_P#)1C_O5K2ZB9Z;45U(8K661>JH2/RJ6FNH=&0]
M&&#60SRWPA8PZ]XKO=1OD+RJ2%!/%=A+X/LQK$.HVW[IT/S =ZY6]TW7/"?B
M2;4=)M#=VLP^:/TJYI<WBCQ#K<-S<QM86<1SL_OUTRN_>3T$9.EPQ^)OB'>F
M_5F6T?$8)XJ]\1],MM'L;?6+(>5<I,J\'J*=KNCZMH/B3^VM%MC.K\RQCO5:
M:+7O'-W!;:C8&TLHV#-]:I/523T$+KSM/K&CS,3NDC5C]:VOB""=#MOJ*K>-
M?#VH"&RO-)C\Z>U  C]0*P=6/C#Q7;P6]QI1LUB.3_M4HI.SOL!<\3Q+/X2T
MR)\[3C.*T]2\/Z9_P@*#R>B @]\T:YH>HW/A_3K>&'=+%C>/2MN_T^ZE\'+9
MI'FXV ;?>IYM%9]1G-:7$DOPYO%D&X1QD+GM1\';:$>%Y)@@\SSV&:U_#^A7
M2^$[K3[Q/+DE4@5B> ;?Q!X=N)-%N--_T'S2PN/K3;O&23Z@5-*TFSU3XNZT
M;Q#)Y2Y09X%7?'=M%;ZYHRPKL&[H/K5_0M$U&U^).KZE-#MM)TQ&_K4GC71M
M0U+6-+FM(=\<39<^G-'-[ZUZ <GXXU*6?QCI5B;5YX-@)@7^*I/$$EQJ6G16
MMIX;EB>-@58#&*Z/Q;X?OFO++7-,CWWMLH&SUK/D\2^,=2$=K#I'V=BPWRXJ
MHNZ5N@BKK^@:UJ?A73YY8W>6V8,8 >2!VJ2VUG1]0GLX-9TIK&2/ 4D8Y%;W
MB"#Q%9V%K=::YGG0@R18ZUS.L'7?%TUM!-HGDE2-TN/NTHOF6H'6:]9N;W3M
M2LQYD,&,8]*T=>TEO$FB1P!_*+,KY-7]+L?L>E06DAWE% .:N@!1@# %8.6U
MNA1QFLV,VHW-AH^TF.W"L7]2*[*-/+B1/[J@4>6GF>9M&[UIU)RNK %%%%2
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M@3=?]\&CVD.X68E%+]FU/_H$W7_?!H^S:G_T";K_ +X-'M(=PLQ**7[-J?\
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MM@L,!()<=:%3DVPN>C@ # &**Y#PMXLDU&^DTG44\O4(QEE]177TI1<79C$
M Z"EHHJ0"D(!ZBEHH **** "BBB@!,#.<<^M9/B;2VUKP_=Z>APTRX%:]%-.
MSN!E^'=-;2= L[!SEH$VYK4HHH;N[@! /44444@"BBB@ H(!ZC-%% !00",$
M9%%% !THHHH **** "BBB@!  !@#%+110 4444 %%%% !7F4?_)1C_O5Z;7F
M4?\ R48_[U:TNHF>FT445D,*  !@# HHH *  .@Q110 4444 %%%% !1110
M4444 %  '0444 %  '0444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% 'G'CS_D8+'ZBO0;7_CTA_P!P?RKS[QY_R,%C]17H-K_Q
MZ0_[@_E6L_@B(FHHJ.>400M(>U9#,C4?"VFZG.)9X@6!STK2M+&"RMA!"@5
M,8K"/B0K,22/+!QBIY/%5FCHH/WJJ[>A*C%.Z1G:U\.-$UJ[^T3Q /G/ K=T
M;0K/0[406D85?I4)\16KRA(V!)J!_%%M'=K W4]Z6H]";4_"^G:I,)9X@6'?
M%:-E806$ B@0*HK-N/$UE$"%;+5%;>*+6=MI(!IW;5A*,4[I'05#/:6]R,31
M(X_VA66_B:Q5MH;)J2;6X19-/$=Q Z5)1-%HFFPON2TC!]<5?"*J[0 %]!7+
MZ9XNBN)&2<;<&M7^W['./,&?K0!=CLK:%R\<*JQZD"IZRQK]D20'SBH(?$EM
M+=>3ZG - &TZ*ZE6 *GJ#4,5G;PJ5CB50>N!6)+XFBBU?[&W?H:9=^(FMKS:
M<>70!T$5K!"Q,<2J3U(%2UDP^(;*5-P?'K43^)K-9@H;(]: -5K2W>3S&A0O
M_>QS3;BRMKH 3PJX'J*I'Q#8 <R#/UIJ^([$Y^?&* )O[!TP_P#+G'^568+&
MUMO]3 B?050;Q'8JN=V15+5/$RVL:20J64T]0.DJ.6".==LJ!AZ&L>U\2VDM
ML'<X?&2*DC\26,BD[B/K2L!J10QPKMC0*/05)64/$%D02'SBJJ>*+5YS&/SH
M WZ*HVNK6MX^R)P6'6KU !1110 5'<?\>TO^X?Y5)4=Q_P >TO\ N'^5 'G?
M@;_D9KWZFO2*\W\#?\C->_4UZ16M;XA(Y#XB?\@%?]ZM+P?_ ,BW;?2LWXB?
M\@%?]ZM+P?\ \BW;?2A_PPZF[7&>/M=N+&S2QL)/+NYR K>U=G7G_P 1=.GW
M6VJ00F4P$9 ]*5)+F5P96E\*:K:Z"]_#>-]N\K>QSUXS5/P?XHNH/"5_>7K$
MW$>0N?6MNX\=::_AETMW\R\\C:8<<@XQ7(>%]-GU7P7J'RGS@68(.];J[B^?
MN(V- T'5?%%B=7O[PAIB?+4'I6CX/UB_MM4O-%U)_,:,GRF]A47@KQCI5CX?
M2RU"<6US 2'1A5?PN)=;\67NJ(A6T3.Q\?>I2O[RDM *.DV^JZ_XAU"V:Z*V
MB2$;<U9THZCX=\?+ICW!>SD4'!/2K/@1]WB;5<9_UI[4FK$'XI0(<X*"FW[S
MCTL S6]2U'Q+XQ?0-/G\N" ;I&!ZBFZK8ZGX.N+:]MKDM:Y'G*3UJ#S4\'_$
MBZO[P%;2[3:']*M^,O$-GX@MX-,TF47,LK8;:.E"3NDEH [QUJ=Y=:?83:;*
M8FG P<UJ:'X?N-,T^74;JX:2X-N6Z]\9K$\4V[6&GZ/:R9WQ@ UWA/\ Q3#G
M_IU;_P!!-1)VBDAGF?@?2M5\2Q3WUW>'[.MPP1,^E'B*PNV\7065M+MR0&:M
M_P"$+;O#-SU_X^6ZU5U9L?$.(<_>]*OF?M&NPNA6U[3-1\*7%MJ-M=,T8($@
M)ZU>\8>*YTTZPM;:X6WGO%!+MV%:'Q+;;H(Z_>%<KXHTI)['0M5N(FDM88P'
M I0M*SD [4((M+TN._MM<1KQ &<;NM=78:G?^)_!JW%C.L,Y!5G/M6#/<_#^
M.P20*)G8 ",$YS4OB>ZETWP5:OHL#6MM(_[Q1V6AKFLK:^8&=>64&E:+-=2Z
MZC:DG(&_J:[CP1JL^J^'H9KEMTH&"WK7GU^O@U_"$D[RF:^*9')SNKLOAH<^
M&(L @=@:*B]R_F".THHHKE*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "J.LX.CW>1D>6>#5ZJ.L_\@>Z_P"N9IK<#C/AU!;NMX&MXC\W
M4J/6N[^QVW_/O#_WP*X?X;]+S_>_K7?5=7XV)$/V.V_Y]X?^^!1]CMO^?>'_
M +X%345F,A^QVW_/O#_WP*/L=M_S[P_]\"IJ* (?L=M_S[P_]\"C[';?\^\/
M_? J:B@"'[';?\^\/_? H^QVW_/O#_WP*FHH A^QVW_/O#_WP*/L=M_S[P_]
M\"IJ* (?L=M_S[P_]\"C[';?\^\/_? J:B@"'[';?\^\/_? H^QVW_/O#_WP
M*FHH A^QVW_/O#_WP*/L=M_S[P_]\"IJ* /,=3B@'Q"B'V:+&[IM%>D?8[;_
M )]X?^^!7G.J?\E#C_WJ],K6ILA(A^QVW_/O#_WP*/L=M_S[P_\ ? J:BLAD
M/V.V_P"?>'_O@4?8[;_GWA_[X%344 0_8[;_ )]X?^^!1]CMO^?>'_O@5-10
M!#]CMO\ GWA_[X%'V.V_Y]X?^^!4U% $/V.V_P"?>'_O@4?8[;_GWA_[X%34
M4 0_8[;_ )]X?^^!1]CMO^?>'_O@5-10!#]CMO\ GWA_[X%'V.V_Y]X?^^!4
MU% $/V.V_P"?>'_O@4?8[;_GWA_[X%344 0_8[;_ )]X?^^!7$?$6"W2QM@M
MO$/GZA!7>UPWQ(_X\K;_ 'JTI?&A,Z'0;:V?0[0FVA^X/X!6E]CMO^?>'_O@
M52\/?\@*T_W*TZB6XR'[';?\^\/_ 'P*/L=M_P ^\/\ WP*FHI 0_8[;_GWA
M_P"^!1]CMO\ GWA_[X%344 0_8[;_GWA_P"^!1]CMO\ GWA_[X%344 0_8[;
M_GWA_P"^!1]CMO\ GWA_[X%344 0_8[;_GWA_P"^!1]CMO\ GWA_[X%344 0
M_8[;_GWA_P"^!1]CMO\ GWA_[X%344 0_8[;_GWA_P"^!1]CMO\ GWA_[X%3
M44 0_8[;_GWA_P"^!1]CMO\ GWA_[X%344 0_8[;_GWA_P"^!6+XJMK9/#MT
M1;0YQ_<%=!6)XM_Y%RY^E5'XD!B_#VWMWT-]UO$3OZ[!77_8[;_GWA_[X%<I
M\.O^0(_^_78TZGQL$0_8[;_GWA_[X%'V.V_Y]X?^^!4U%0!#]CMO^?>'_O@4
M?8[;_GWA_P"^!4U% $/V.V_Y]X?^^!1]CMO^?>'_ +X%344 0_8[;_GWA_[X
M%'V.V_Y]X?\ O@5-10!#]CMO^?>'_O@4?8[;_GWA_P"^!4U% $/V.V_Y]X?^
M^!1]CMO^?>'_ +X%344 0_8[;_GWA_[X%'V.V_Y]X?\ O@5-10!&D$,1S'$B
M'U50*DHHH **** .0^(G_("7_>K2\(?\BW;?2LWXB?\ ("7_ 'JTO"'_ "+=
MM]*U?\-"ZF[11160PHHHH **** "BBB@ HHHH **** "BBB@ /2O,]%_Y*#-
M_O5Z8>E>9Z+_ ,E!F_WJUI[,3/3*1E#*0>AI:0D*"3T%9#,V#3--TB2>^5%B
M9QF21JX&(R>,?B#;ZA;IMM=..!)CAZI>./&UI?ZTGA];PVT"M^_DQU%=7X<\
M1>$K"&'3-.OXVDQCIRQKH491CS6U8C&N%6^^+-N\PW")<(#TKJ?&MM%/X<G\
MQ =@++QT-<KXFWZ!X[L]<*$V)7#D=JG\6^--/U'2TLM*E^TW$YVE%'0&GRMN
M+0&CX-M8M:\'PQWH\Q0Q !J[XGU6Q\->'W@C5?,9=L4(ZFH;*XB\&^"Q-=#!
M1=^WU/I7 :#XAT+7=:EUG7M2P$;]S PX6DH\S<N@';^ ]#E@T::>[4K]M^8Q
M^@JUKFL1>#;3%EI,EQN&2(AW]ZNP>)+'5=*GGT.9;DPC&$%8NC?$+3;A9H-6
M=;:YC."CKU%3:4FVU\@,3P'-_;OB^YUZZ8073(4%L>"!7JE>3:1+%J_Q,DOM
M'C(M N&D P#7K(Z45OB0(****Q&%%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>91_\E&/^]7I
MM>91_P#)1C_O5K2ZB9Z;11160PHHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@#SCQY_R,%C]17H-K_QZ0_[@_E7GWCS_ )&"Q^HKT&U_X](?]P?RK6?P1$34
MV1!(A1NAIU%9#,*3PQ:R2EST/:HF\)6;'/-=%10!A6WABUMY?,!)-.F\-6DT
MID(^:MNBG<#!/A:T8Y-,'A.T5MPR*Z&BBX'/_P#"*VG/7-6H-"MX(C'U4^M:
MU%(# ?PK9%RRC!/I33X4M2P;<>*Z&BBX&#%X7M8\X)YJ6+P[:QR!P.16S10!
MB3>&K6:]6Y;[ZTZX\/6UPY9ZV:* ,%/"]J@(!.#2#PK:!".<FM^BBX')KX/3
M[5N9CL^M7I/"]HZXY%;U%.X&$OABT$83GBK/]A6IB$;*"!6I12N!A_\ ",V@
MG\P>F,4C>&+1@1TS6[13N!A0^&;6)2 3S2?\(O: ,5^\>];U%(# T;P^--F>
M0L3D\5OT44 %%%% !4=Q_P >TO\ N'^525'<?\>TO^X?Y4 >=^!O^1FO?J:]
M(KS?P-_R,U[]37I%:UOB$CD/B)_R 5_WJTO!_P#R+=M]*S?B)_R 5_WJT/"#
MH/#=M\Z]/6A_PPZF_6+XGN[VSTIGLK07+?Q(1VK8\Q/[Z_G2&2,C!=<?6LUH
M[C/+9]5T^/3W>ST-5U*52K?+T)KI?AYHUSI>@DWR;9YF+%?05THL[ /O$,.[
MKG JSYD?]]?SK252ZLA6,.[\':'>W/VB6QC\PG+$#[U:UI8VMA (;6%8HQ_"
MHJ;S$_OK^='F)_?7\ZS<F]&,KVVFV=I*\L%ND;N<L0.M#Z;9R78NWMT,XZ.1
MS5CS$_OK^='F)_?7\Z+L"GJ.CV&K1^7>VR2@=,CI533?"VCZ5+YMI9HDG][O
M6OYB?WU_.CS$_OK^=',[6 @N=/M+QE:X@20KT+#I4WE)Y7E;1LQMV^U+YB?W
MU_.CS$_OK^=&H$%EI]KIT1BM($A0G<54=Z:^FV<ER+E[=#,/XR.:L^8G]]?S
MH\Q/[Z_G1=@0W=E;7T?EW,*RIZ,*233[6:S%I) C0 8"$<5/YB?WU_.CS$_O
MK^=%V!@1^"/#\<_G+I\>0<@'H#6S-8VL]K]EEA1H<8V$<8J;S$_OK^='F)_?
M7\Z;DWN!@1^"= CE9QI\9!_A(X%;5K9V]E$(K:)8T'9:E\Q/[Z_G1YB?WU_.
MAR;W =13?,3^^OYT>8G]]?SJ0'44WS$_OK^='F)_?7\Z '44WS$_OK^='F)_
M?7\Z '44WS$_OK^='F)_?7\Z '44WS$_OK^='F)_?7\Z '44WS$_OK^='F)_
M?7\Z '44WS$_OK^='F)_?7\Z '44WS$_OK^='F)_?7\Z '44WS$_OK^='F)_
M?7\Z '44WS$_OK^='F)_?7\Z '51UG_D#W7_ %S-7/,3^^OYU1UB1#H]U\Z_
MZL]Z:W Y'X;]+S_>_K7?5Y_\.'0"\RZ_>]?>N^\Q/[Z_G5U?C8D.HIOF)_?7
M\Z/,3^^OYUF,=13?,3^^OYT>8G]]?SH =13?,3^^OYT>8G]]?SH =13?,3^^
MOYT>8G]]?SH =13?,3^^OYT>8G]]?SH =13?,3^^OYT>8G]]?SH =13?,3^^
MOYT>8G]]?SH =13?,3^^OYT>8G]]?SH \UU3_DH<?^]7IE>9:HR?\+#B^=<;
MO6O2_,3^^OYUK4V0D.HIOF)_?7\Z/,3^^OYUD,=13?,3^^OYT>8G]]?SH =1
M3?,3^^OYT>8G]]?SH =13?,3^^OYT>8G]]?SH =13?,3^^OYT>8G]]?SH =1
M3?,3^^OYT>8G]]?SH =13?,3^^OYT>8G]]?SH =13?,3^^OYT>8G]]?SH =7
M#?$C_CRMO]ZNW\Q/[Z_G7#?$=T-E;?.OWO6M*7QH3.H\/?\ ("M/]RM.LKP^
MZ#0K3YU^YZUI^8G]]?SJ);C'44WS$_OK^='F)_?7\Z0#J*;YB?WU_.CS$_OK
M^= #J*;YB?WU_.CS$_OK^= #J*;YB?WU_.CS$_OK^= #J*;YB?WU_.CS$_OK
M^= #J*;YB?WU_.CS$_OK^= #J*;YB?WU_.CS$_OK^= #J*;YB?WU_.CS$_OK
M^= #JQ/%O_(N7/TK9\Q/[Z_G6)XL=#X<N?G7IZU4?B0&7\.O^0(_^_78UQGP
M[=!H;_.OW_6NQ\Q/[Z_G3J?&P0ZBF^8G]]?SH\Q/[Z_G4 .HIOF)_?7\Z/,3
M^^OYT .HIOF)_?7\Z/,3^^OYT .HIOF)_?7\Z/,3^^OYT .HIOF)_?7\Z/,3
M^^OYT .HIOF)_?7\Z/,3^^OYT .HIOF)_?7\Z/,3^^OYT .HIOF)_?7\Z/,3
M^^OYT .HIOF)_?7\Z/,3^^OYT <E\1/^0$O^]6EX0_Y%NV^E9?Q#=#H*_.OW
MO6M/PBZ#PW;?.O3UK5_PT+J;U%-\Q/[Z_G1YB?WU_.LACJ*;YB?WU_.CS$_O
MK^= #J*;YB?WU_.CS$_OK^= #J*;YB?WU_.CS$_OK^= #J*;YB?WU_.CS$_O
MK^= #J*;YB?WU_.CS$_OK^= #J*;YB?WU_.CS$_OK^= #CTKS/1?^2@S?[U>
ME>8F/OK^=>::*R?\+!F.]<;CWK6GLQ,]-I" 00>AI/,3^^OYT>8G]]?SK(9B
MW/@_0+N=II],@DD;JQ')IMMX,\/6EPL\&EPI*O1@.16YYB?WU_.CS$_OK^=5
MS2[@07FGVM_;?9[J%98O[K"L^S\*:)83B>WL(DE'1L<UK^8G]]?SH\Q/[Z_G
M2NUH!!>V%KJ$/DW<*RQ_W6Z5C'P+X:;KI%O^5=!YB?WU_.CS$_OK^=-2DMF!
M1TO0]-T6-X].M([=7.6"=ZJW7A/0[V<S3Z?$TC=6QR:V/,3^^OYT>8G]]?SH
MYI7O<"IIVD6&E1E+&V2%3UVBKM-\Q/[Z_G1YB?WU_.D[L!U%-\Q/[Z_G1YB?
MWU_.D ZBF^8G]]?SH\Q/[Z_G0 ZBF^8G]]?SH\Q/[Z_G0 ZBF^8G]]?SH\Q/
M[Z_G0 ZBF^8G]]?SH\Q/[Z_G0 ZBF^8G]]?SH\Q/[Z_G0 ZBF^8G]]?SH\Q/
M[Z_G0 ZBF^8G]]?SH\Q/[Z_G0 ZBF^8G]]?SH\Q/[Z_G0 ZBF^8G]]?SH\Q/
M[Z_G0 ZBF^8G]]?SH\Q/[Z_G0 ZBF^8G]]?SH\Q/[Z_G0 ZBF^8G]]?SH\Q/
M[Z_G0 ZBF^8G]]?SH\Q/[Z_G0 ZBF^8G]]?SH\Q/[Z_G0 ZBF^8G]]?SH\Q/
M[Z_G0 ZO,H_^2C'_ 'J]+\Q/[Z_G7F<;)_PL8_.N-W7-:TNHF>G44WS$_OK^
M='F)_?7\ZR&.HIOF)_?7\Z/,3^^OYT .HIOF)_?7\Z/,3^^OYT .HIOF)_?7
M\Z/,3^^OYT .HIOF)_?7\Z/,3^^OYT .HIOF)_?7\Z/,3^^OYT .HIOF)_?7
M\Z/,3^^OYT .HIOF)_?7\Z/,3^^OYT .HIOF)_?7\Z/,3^^OYT .HIOF)_?7
M\Z/,3^^OYT .HIOF)_?7\Z/,3^^OYT .HIOF)_?7\Z/,3^^OYT .HIOF)_?7
M\Z/,3^^OYT .HIOF)_?7\Z/,3^^OYT .HIOF)_?7\Z/,3^^OYT .HIOF)_?7
M\Z/,3^^OYT .HIOF)_?7\Z/,3^^OYT .HIOF)_?7\Z/,3^^OYT .HIOF)_?7
M\Z/,3^^OYT >=>//^1@L?J*]!M?^/2'_ '!_*O/?'C(=?L?G7J.]>@VLB"TA
M^=?N#O[5K/X(B)Z*;YB?WU_.CS$_OK^=9#'44WS$_OK^='F)_?7\Z '44WS$
M_OK^='F)_?7\Z '44WS$_OK^='F)_?7\Z '44WS$_OK^='F)_?7\Z '44WS$
M_OK^='F)_?7\Z '44WS$_OK^='F)_?7\Z '44WS$_OK^='F)_?7\Z '44WS$
M_OK^='F)_?7\Z '44WS$_OK^='F)_?7\Z '44WS$_OK^='F)_?7\Z '44WS$
M_OK^='F)_?7\Z '44WS$_OK^='F)_?7\Z '44WS$_OK^='F)_?7\Z '44WS$
M_OK^='F)_?7\Z '5'<?\>TO^X?Y4[S$_OK^=1W$B?9I?G7[A[^U 'GO@;_D9
MKWZFO2*\W\#$'Q+>X.>37I%:UOB$C"\5Z++KND-:PL%?.037%6?@SQ796P@C
MOD" \?-7J5%*-1Q5D%CS7_A%O%W_ #_K_P!]4?\ "+>+O^?]?^^J]*HI^VD%
MCS7_ (1;Q=_S_K_WU1_PBWB[_G_7_OJO2J*/;2"QYK_PBWB[_G_7_OJC_A%O
M%W_/^O\ WU7I5%'MI!8\U_X1;Q=_S_K_ -]4?\(MXN_Y_P!?^^J]*HH]M(+'
MFO\ PBWB[_G_ %_[ZH_X1;Q=_P _Z_\ ?5>E44>VD%CS7_A%O%W_ #_K_P!]
M4?\ "+>+O^?]?^^J]*HH]M(+'FO_  BWB[_G_7_OJC_A%O%W_/\ K_WU7I5%
M'MI!8\U_X1;Q=_S_ *_]]4?\(MXN_P"?]?\ OJO2J*/;2"QYK_PBWB[_ )_U
M_P"^J/\ A%O%W_/^O_?5>E44>VD%CS7_ (1;Q=_S_K_WU1_PBWB[_G_7_OJO
M2J*/;2"QYK_PBWB[_G_7_OJC_A%O%W_/^O\ WU7I5%'MI!8\U_X1;Q=_S_K_
M -]4?\(MXN_Y_P!?^^J]*HH]M(+'FO\ PBWB[_G_ %_[ZH_X1;Q=_P _Z_\
M?5>E44>VD%CS7_A%O%W_ #_K_P!]4?\ "+>+O^?]?^^J]*HH]M(+'FO_  BW
MB[_G_7_OJC_A%O%W_/\ K_WU7I5%'MI!8\U_X1;Q=_S_ *_]]4?\(MXN_P"?
M]?\ OJO2J*/;2"QYK_PBWB[_ )_U_P"^J/\ A%O%W_/^O_?5>E44>VD%CS7_
M (1;Q=_S_K_WU1_PBWB[_G_7_OJO2J*/;2"QYK_PBWB[_G_7_OJC_A%O%W_/
M^O\ WU7I5%'MI!8\U_X1;Q=_S_K_ -]4?\(MXN_Y_P!?^^J]*HH]M(+'FO\
MPBWB[_G_ %_[ZIDWA+Q;- \37R;6&#\U>FT4>VD%CR73/ /B?2]_DWJ#?U^:
MM#_A%O%W_/\ K_WU7I5%-UI,+'FO_"+>+O\ G_7_ +ZH_P"$6\7?\_Z_]]5Z
M512]M(+'FO\ PBWB[_G_ %_[ZH_X1;Q=_P _Z_\ ?5>E44>VD%CS7_A%O%W_
M #_K_P!]4?\ "+>+O^?]?^^J]*HH]M(+'FO_  BWB[_G_7_OJC_A%O%W_/\
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ME44>VD%CS7_A%O%W_/\ K_WU1_PBWB[_ )_U_P"^J]*HH]M(+'FO_"+>+O\
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M #_K_P!]4?\ "+>+O^?]?^^J]*HH]M(+'FO_  BWB[_G_7_OJC_A%O%W_/\
MK_WU7I5%'MI!8\U_X1;Q=_S_ *_]]4?\(MXN_P"?]?\ OJO2J*/;2"QYK_PB
MWB[_ )_U_P"^J/\ A%O%W_/^O_?5>E44>VD%CS7_ (1;Q=_S_K_WU1_PBWB[
M_G_7_OJO2J*/;2"QYK_PBWB[_G_7_OJC_A%O%W_/^O\ WU7I5%'MI!8\U_X1
M;Q=_S_K_ -]4C>%?%S(R_;T^88^]7I=%'MI!8XGP5X2OM GEGOIED=\]#7;4
)45$I.3NQG__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>img11953243_15.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img11953243_15.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 'Y!5T# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBD+ =2
M* %HI-R_WA^=&Y?[P_.@!:*3<O\ >'YT;E_O#\Z %HI-R_WA^=&Y?[P_.@!:
M*3<O]X?G1N7^\/SH 6BDW+_>'YT;E_O#\Z %HI-R_P!X?G1N7^\/SH 6BDW+
M_>'YT;E_O#\Z %HI-R_WA^=&Y?[P_.@!:*3<O]X?G1N7^\/SH 6BDW+_ 'A^
M=&Y?[P_.@!:*3<O]X?G1N7^\/SH 6BDW+_>'YT;E_O#\Z %HI-R_WA^=&Y?[
MP_.@!:*3<O\ >'YT;E_O#\Z %HI-R_WA^=&Y?[P_.@!:*3<O]X?G1N7^\/SH
M 6BDW+_>'YT;E_O#\Z %HI-R_P!X?G1N7^\/SH 6BDW+_>'YT;E_O#\Z %HI
M-R_WA^=&Y?[P_.@!:*3<O]X?G1N7^\/SH 6BDW+_ 'A^=&Y?[P_.@!:*3<O]
MX?G1N7^\/SH 6BDW+_>'YT;E_O#\Z %HI-R_WA^=&Y?[P_.@!:*3<O\ >'YT
M;E_O#\Z %HI-R_WA^=&Y?[P_.@!:*3<O]X?G1N7^\/SH 6BDW+_>'YT;E_O#
M\Z %HI-R_P!X?G1N7^\/SH 6BDW+_>'YT;E_O#\Z %HI-R_WA^=&Y?[P_.@!
M:*3<O]X?G1N7^\/SH 6BDW+_ 'A^=&Y?[P_.@!:*3<O]X?G1N7^\/SH 6BDW
M+_>'YT;E_O#\Z %HI-R_WA^=&Y?[P_.@!:*3<O\ >'YT9'J* %HI-R_WA^=&
MY?[P_.@!:*3<O]X?G1N7^\/SH 6BDW+_ 'A^=&Y?[P_.@!:*3<O]X?G1N7^\
M/SH 6BDW+_>'YT;E_O#\Z %HI-R_WA^=&Y?[P_.@!:*3<O\ >'YT;E_O#\Z
M%HI-R_WA^=&Y?[P_.@!:*3<O]X?G1N7^\/SH 6BDW+_>'YT;E_O#\Z %HI-R
M_P!X?G1N7^\/SH 6BDW+_>'YT;E_O#\Z %HI-R_WA^=&Y?[P_.@!:*3<O]X?
MG1N7^\/SH 6BDW+_ 'A^=&Y?[P_.@!:*3<O]X?G1N7^\/SH 6BDW+_>'YT;E
M_O#\Z %HI-R_WA^=&Y?[P_.@!:*3<O\ >'YT;E_O#\Z %HI-R_WA^=&Y?[P_
M.@!:*3<O]X?G1N7^\/SH 6BDW+_>'YT;E_O#\Z %HI-R_P!X?G1N7^\/SH 6
MBDW+_>'YT;E_O#\Z %HI-R_WA^=&Y?[P_.@!:*3<O]X?G1N7^\/SH 6BDW+_
M 'A^=&Y?[P_.@!:*3<O]X?G1N7^\/SH 6BDW+_>'YT;E_O#\Z %HI-R_WA^=
M&Y?[P_.@!:*3<O\ >'YT;E_O#\Z %HI-R_WA^=&Y?[P_.@!:*3<O]X?G1N7^
M\/SH 6BDW+_>'YT;E_O#\Z %HI-R_P!X?G1N7^\/SH 6BDW+_>'YT;E_O#\Z
M %HI-R_WA^=&Y?[P_.@!:*3<O]X?G1N7^\/SH 6BDW+_ 'A^=&Y?[P_.@!:*
M3<O]X?G1N7^\/SH 6BDW+_>'YT;E_O#\Z %HI-R_WA^=&Y?[P_.@!:*3<O\
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M^7_.N>HHY(=@.A_X6'XF_P"?E_SH_P"%A^)O^?E_SKGJ*.2'8#H?^%A^)O\
MGY?\Z/\ A8?B;_GY?\ZYZBCDAV Z'_A8?B;_ )^7_.C_ (6'XF_Y^7_.N>HH
MY(=@.A_X6'XF_P"?E_SH_P"%A^)O^?E_SKGJ*.2'8#H?^%A^)O\ GY?\Z/\
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M+,\\HKNKWX0:U80M*^XA1FN*NK6:QG:&="I7CFG&<9?"P(J***H HI,CUI:
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MRHZG%8\,#W5P+91^\)QBOKBTFTCQ-8,(XXV#CG@<5XCXQ\*IX2\6Q7T2Y@+
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MK_R*1_W*\;7_ (^(O]ZO9+7_ )%(_P"Y6-?H"/'KC_C_ )O]ZFTZX_X_YO\
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MV:L#V/+['3[O47"6L)D'J!750?#G5)H#(86!QG&*]H\#>#;#PYHD=S<1JS%
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M_P!W0+<K_''_ )!L?TKP6'_5+7O?QQ4_V9&<<8KP2'_5+6F%_AH);G3?#O\
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MT'L*  .@I*E!/F2U"[% Q1115@%%%% !1110 4444 .M_P#C^B^M?4?PZ_Y
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M%:_\^\7_ 'R*GHHN!!]BM?\ GWB_[Y%'V*U_Y]XO^^14]%%P(/L5K_S[Q?\
M?(H^Q6O_ #[Q?]\BIZ*+@0?8K7_GWB_[Y%'V*U_Y]XO^^14]%%P(/L5K_P ^
M\7_?(H^Q6O\ S[Q?]\BIZ*+@0?8K7_GWB_[Y%'V*U_Y]XO\ OD5/11<"#[%:
M_P#/O%_WR*/L5K_S[Q?]\BIZ*+@0?8K7_GWB_P"^11]BM?\ GWB_[Y%3T47
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MH:\=N_\ D;1_OUM1ZB9ZS;V=J;:/%O'C:/X14GV*U_Y]XO\ OD4ZU_X]8O\
M=%2UC<9!]BM?^?>+_OD4?8K7_GWB_P"^14]%%P(/L5K_ ,^\7_?(H^Q6O_/O
M%_WR*GHHN!!]BM?^?>+_ +Y%'V*U_P"?>+_OD5/11<"#[%:_\^\7_?(H^Q6O
M_/O%_P!\BIZ*+@0?8K7_ )]XO^^11]BM?^?>+_OD5/11<"#[%:_\^\7_ 'R*
M/L5K_P ^\7_?(J>BBX$'V*U_Y]XO^^11]BM?^?>+_OD5/11<"#[%:_\ /O%_
MWR*/L5K_ ,^\7_?(J>BBX$'V*U_Y]XO^^11]BM?^?>+_ +Y%3T47 @^Q6O\
MS[Q?]\BC[%:_\^\7_?(J>BBX$'V*U_Y]XO\ OD4?8K7_ )]XO^^14]%%P(/L
M5K_S[Q?]\BC[%:_\^\7_ 'R*GHHN!!]BM?\ GWB_[Y%'V*U_Y]XO^^14]%%P
M(/L5K_S[Q?\ ?(H^Q6O_ #[Q?]\BIZ*+@0?8K7_GWB_[Y%'V*U_Y]XO^^14]
M%%P(/L5K_P ^\7_?(H^Q6O\ S[Q?]\BIZ*+@0?8K7_GWB_[Y%'V*U_Y]XO\
MOD5/11<"#[%:_P#/O%_WR*/L5K_S[Q?]\BIZ*+@0?8K7_GWB_P"^11]BM?\
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M10 4444 %%%% !1110 V3_5O]#7CMW_R-H_WZ]BD_P!6_P!#7CMW_P C:/\
M?K>AU$SU^U_X]8O]T5+45K_QZQ?[HJ6L!A1110 4444 %%%% !1110 4444
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M@2,>%Y_]^O2M4U2VTFT:YNG"HHSUKS;X$_\ (K3G_II7.?$?7KK7=>70[-R
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MU=W\XR4<X)KUV?3+.Y</+ C-ZD5R'PRT?^R]&9@N!+\U=U0!GG2-.C!<VT8
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MM_H:\=N_^1M'^_6]#J)GK]K_ ,>L7^Z*EJ*U_P"/6+_=%2U@,**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JO>W*6EI+-(P
M 52:L5Y9\7?%3:;I2V=KN,LAVG% '"IY_P 0/'A1LM#;O_*OH6QMDL[*&!
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M">^E!^_QF@#V6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[HJ6L!A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %8FI^%=*U>82WD&]@<C-;=% $-K;16=ND$*A8T& *FHHH *S]6T6RUJ
MW\B]B#K6A10!Y[)\'O#;W D$) SDBNMT?P]IVAPB.R@" =ZU:* ,#Q=<30Z-
M*L()9U*\5P_PK\-RZ9J-W>S(0TN3S7J<L$<Z[9$##T-$4$4(Q&@4>U $E9NL
M:'9:Y;B"^CWH.U:5% %'3-(L](MA!9Q!$%7J** "H;FUAO(&AF0,C=0:FHH
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M)^='L%_,@N>VT5XE_9WQ#_YZ2?G1_9WQ#_YZ2?G1[!?S(+GMM%>)?V=\0_\
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M3\Z/8+^9!<]MHKQ+^SOB'_STD_.C^SOB'_STD_.CV"_F07/;:*\2_L[XA_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH :YQ&Q]C7C]VY_X2X'_;KV"3_5O]#7CMW_R-
MH_WZWH]1,]?MSNMHR?[HJ6HK7_CUB_W14M8#"BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MX->G:'#<0:7$MTQ,FT9)H TJ**3(SC/- "T444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 V3_5O]#7CMW_R-H_WZ]BD_U;_0UX[=_P#(VC_?
MK>AU$SU^U_X]8O\ =%2U%:_\>L7^Z*EK 84444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 0W?\
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MI% 'JL5])_PC#7LRX<0ER#]*X/P'XY;Q!J=Y;A-OE,17H6N*J>'[U5  $+
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M'^_7L4G^K?Z&O';O_D;1_OUO0ZB9Z_:_\>L7^Z*EJ*U_X]8O]T5+6 PHHHH
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M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #9/]6_T->.W?\
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M3?[=TO\ Y_X/^^J/[=TO_G_@_P"^J\R_X4_=_P#04?\ [ZH_X4_=_P#04?\
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M3?[=TO\ Y_X/^^J/[=TO_G_@_P"^J\R_X4_=_P#04?\ [ZH_X4_=_P#04?\
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M"VC_ -.AQM'5JD_MW2_^?^#_ +ZKS"+X0W;0(W]IN"1G&ZG?\*?N_P#H*/\
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M=TO_ )_X/^^J/[=TO_G_ (/^^J\R_P"%/W?_ $%'_P"^J/\ A3]W_P!!1_\
MOJCV=+^8+L]-_MW2_P#G_@_[ZH_MW2_^?^#_ +ZKS+_A3]W_ -!1_P#OJC_A
M3]W_ -!1_P#OJCV=+^8+L]-_MW2_^?\ @_[ZH_MW2_\ G_@_[ZKS+_A3]W_T
M%'_[ZH_X4_=_]!1_^^J/9TOY@NSTW^W=+_Y_X/\ OJC^W=+_ .?^#_OJO,O^
M%/W?_04?_OJC_A3]W_T%'_[ZH]G2_F"[/3?[=TO_ )_X/^^J/[=TO_G_ (/^
M^J\R_P"%/W?_ $%'_P"^J/\ A3]W_P!!1_\ OJCV=+^8+L]-_MW2_P#G_@_[
MZH_MW2_^?^#_ +ZKS+_A3]W_ -!1_P#OJC_A3]W_ -!1_P#OJCV=+^8+L]-_
MMW2_^?\ @_[ZH_MW2_\ G_@_[ZKS+_A3]W_T%'_[ZH_X4_=_]!1_^^J/9TOY
M@NSTW^W=+_Y_X/\ OJC^W=+_ .?^#_OJO,O^%/W?_04?_OJC_A3]W_T%'_[Z
MH]G2_F"[/3?[=TO_ )_X/^^J/[=TO_G_ (/^^J\R_P"%/W?_ $%'_P"^J/\
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M=TO_ )_X/^^J/[=TO_G_ (/^^J\R_P"%/W?_ $%'_P"^J/\ A3]W_P!!1_\
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MH]G2_F"[/3?[=TO_ )_X/^^J/[=TO_G_ (/^^J\R_P"%/W?_ $%'_P"^J/\
MA3]W_P!!1_\ OJCV=+^8+L]-_MW2_P#G_@_[ZH_MW2_^?^#_ +ZKS+_A3]W_
M -!1_P#OJC_A3]W_ -!1_P#OJCV=+^8+L]-_MW2_^?\ @_[ZH_MW2_\ G_@_
M[ZKS+_A3]W_T%'_[ZH_X4_=_]!1_^^J/9TOY@NSTW^W=+_Y_X/\ OJC^W=+_
M .?^#_OJO,O^%/W?_04?_OJC_A3]W_T%'_[ZH]G2_F"[/2+G6]*-K+F^AQM/
M1J\MTZZMIO%F8I58%^,&IYOA#=K;NW]IN2!G&ZN=\-^'9--\4HKS%MK>M:PC
M!)V8M3Z C_U:_04ZFQ_ZI/H*=7&4<G\1/^16G^E9GPE/_%-/_OUI_$3_ )%:
M?Z5E_"7_ )%I_P#?K=?P7ZBZGH%%%%8#"BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &R?ZMOH:\>NR?^$M
M'^_7L,G^K?Z&O';O_D;1_OUO1ZB9Z_;<VL7^Z*EJ*U_X]8O]T5+6 PHHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MUK7!G1[G_<->'_"  ?$#4<>K4 ?0-%%% !1110 4444 %%%% !1110 4444
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MF* /F?Q__P E&L_^N@_G7MWB^QDU+X=M;1#+-"G'_ :\[\7?#;6=6\9VVHP
M^2C@G\Z]KM;?&FPV\HSB,*P/TH \'^%<6G0WKZ1?1KYV_'S"O9&\*:4H+&!
M ,]*X#QC\.[R*_;5=!RMSG.%KDY)OB9*IM&\W!&* /4([GPI!JBVFV+[3G Q
M7;1(J1@(,+CBO'_ WPWOEOEU/7'?SP<@&O8E&U0!T Q0 M%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 -D_U;_0UX[=_P#(VC_?KV*3_5O]#7CMW_R-H_WZWH=1,]?M?^/6+_=%
M2U%:_P#'K%_NBI:P&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !T 'TI:* "BBB@ HHHH ****  \C%>;>-_ [ZKK5OJ5J-K1D$XKTF@@$8-
M&?HWF#3XTESN4 5H4@4+T&*6@ HHHH **** "BBB@ HHHH **** $P,YP,TM
M%% 'FOBCPQ>>(-;5923;*V<5WFD:>FF:9#:1C"H,5=VKG.!FEH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M(;O_ (])?]TUY%9?\C:?]^O7;O\ X])?]TUY%9?\C:?]^MZ.S$SV%/\ 5K]!
M3J:G^K7Z"G5@,Y#XBR*OAB=3U(KA_A[X^T;1=$>UNF*R!\\5W/Q%13X8G8]0
M*XGX=>!M&UC19+J[BWR%L5U0Y?9/F)>YU?\ PM7P[_SU>C_A:OAW_GJ]2?\
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M5\._\]7J3_A5WAW_ )XFC_A5WAW_ )XFC]SYAJ1_\+5\._\ /5Z/^%J^'?\
MGJ]2?\*N\._\\31_PJ[P[_SQ-'[GS#4C_P"%J^'?^>KT?\+5\._\]7J3_A5W
MAW_GB:/^%7>'?^>)H_<^8:D?_"U?#O\ SU>C_A:OAW_GJ]2?\*N\._\ /$T?
M\*N\._\ /$T?N?,-2/\ X6KX=_YZO1_PM7P[_P ]7J3_ (5=X=_YXFC_ (5=
MX=_YXFC]SYAJ1_\ "U?#O_/5Z/\ A:OAW_GJ]2?\*N\._P#/$T?\*N\._P#/
M$T?N?,-2/_A:OAW_ )ZO1_PM7P[_ ,]7J3_A5WAW_GB:/^%7>'?^>)H_<^8:
MD?\ PM7P[_SU>C_A:OAW_GJ]2?\ "KO#O_/$T?\ "KO#O_/$T?N?,-2/_A:O
MAW_GJ]'_  M7P[_SU>I/^%7>'?\ GB:/^%7>'?\ GB:/W/F&I'_PM7P[_P ]
M7H_X6KX=_P">KU)_PJ[P[_SQ-'_"KO#O_/$T?N?,-2/_ (6KX=_YZO1_PM7P
M[_SU>I/^%7>'?^>)H_X5=X=_YXFC]SYAJ1_\+5\._P#/5Z/^%J^'?^>KU)_P
MJ[P[_P \31_PJ[P[_P \31^Y\PU(_P#A:OAW_GJ]'_"U?#O_ #U>I/\ A5WA
MW_GB:/\ A5WAW_GB:/W/F&I'_P +5\._\]7H_P"%J^'?^>KU)_PJ[P[_ ,\3
M1_PJ[P[_ ,\31^Y\PU(_^%J^'?\ GJ]'_"U?#O\ SU>I/^%7>'?^>)H_X5=X
M=_YXFC]SYAJ1_P#"U?#O_/5Z/^%J^'?^>KU)_P *N\._\\31_P *N\._\\31
M^Y\PU(_^%J^'?^>KT?\ "U?#O_/5ZD_X5=X=_P">)H_X5=X=_P">)H_<^8:D
M?_"U?#O_ #U>C_A:OAW_ )ZO4G_"KO#O_/$T?\*N\._\\31^Y\PU(_\ A:OA
MW_GJ]'_"U?#O_/5ZD_X5=X=_YXFC_A5WAW_GB:/W/F&I'_PM7P[_ ,]7H_X6
MKX=_YZO4G_"KO#O_ #Q-'_"KO#O_ #Q-'[GS#4C_ .%J^'?^>KT?\+5\._\
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MO1_PM7P[_P ]7J3_ (5=X=_YXFC_ (5=X=_YXFC]SYAJ1_\ "U?#O_/5Z/\
MA:OAW_GJ]2?\*N\._P#/$T?\*N\._P#/$T?N?,-2/_A:OAW_ )ZO1_PM7P[_
M ,]7J3_A5WAW_GB:/^%7>'?^>)H_<^8:D?\ PM7P[_SU>C_A:OAW_GJ]2?\
M"KO#O_/$T?\ "KO#O_/$T?N?,-2/_A:OAW_GJ]'_  M7P[_SU>I/^%7>'?\
MGB:/^%7>'?\ GB:/W/F&I'_PM7P[_P ]7H_X6KX=_P">KU)_PJ[P[_SQ-'_"
MKO#O_/$T?N?,-2/_ (6KX=_YZO1_PM7P[_SU>I/^%7>'?^>)H_X5=X=_YXFC
M]SYAJ1_\+5\._P#/5Z/^%J^'?^>KU)_PJ[P[_P \31_PJ[P[_P \31^Y\PU(
M_P#A:OAW_GJ]'_"U?#O_ #U>I/\ A5WAW_GB:/\ A5WAW_GB:/W/F&I'_P +
M5\._\]7H_P"%J^'?^>KU)_PJ[P[_ ,\31_PJ[P[_ ,\31^Y\PU(_^%J^'?\
MGJ]'_"U?#O\ SU>I/^%7>'?^>)H_X5=X=_YXFC]SYAJ1_P#"U?#O_/5Z/^%J
M^'?^>KU)_P *N\._\\31_P *N\._\\31^Y\PU(_^%J^'?^>KT?\ "U?#O_/5
MZD_X5=X=_P">)H_X5=X=_P">)H_<^8:D$_Q4\/- X$C$E2,5PVBZ_9ZCXK#0
M=&?BN\G^&'AY;:0B$@A20:X31-#L]/\ %06%<!6XK6'L[/E%J>Y1_P"K7Z"G
M4V/_ %:_04ZN,HY/XB?\BM/]*R_A+_R+3_[]:GQ$_P"16G^E9?PE_P"1:?\
MWZW7\%^HNIZ!1116 PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@!LG^K;Z&O';O_D;1_OU[%)_JW^AKQV[
M_P"1M'^_6]#J)GK]K_QZQ?[HJ6HK7_CUB_W14M8#"BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH AN_\ CTE_W37D5E_R-I_WZ]=N
M_P#CTE_W37D5E_R-I_WZWH[,3/84_P!6OT%.IJ?ZM?H*=6 SD_B)_P BM/\
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M&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MR?:@#WK3K466G06P'^K0+5JLCPYJZZSI,-P#\Y4%JUZ (YVV6\C>BDU\[ZW
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M14M16PQ:Q _W14M8#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "D9=RE?6EHH PO^$6L#J(O6
M0&4'.<5NT44 %%%% !1110 4444 %%%% !1110 5G:UI,.LZ;+:3 $..M:-%
M '+^%?#?_"-1O;Q',;'-=1110 4444 %%%% !1110 4444 %%%% !5>^B:>T
M>->K"K%% '':+X)@L-7.I. 92<Y-=C110 4444 %%%% !1110 4444 %%%%
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(H **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>img11953243_16.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img11953243_16.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,D SH# 2(  A$! Q$!_\0
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M./\ R3S4/^PK)_Z*BKV"@#Q__AG'P?\ ]!+7/^_\/_QJC_AG'P?_ -!+7/\
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MI] 'C_\ PSCX/_Z"6N?]_P"'_P"-4?\ #./@_P#Z"6N?]_X?_C5>P44 >/\
M_#./@_\ Z"6N?]_X?_C5'_#./@__ *"6N?\ ?^'_ .-5[!10!X__ ,,X^#_^
M@EKG_?\ A_\ C5'_  SCX/\ ^@EKG_?^'_XU7L%% 'C_ /PSCX/_ .@EKG_?
M^'_XU1_PSCX/_P"@EKG_ '_A_P#C5>P44 >/_P##./@__H):Y_W_ (?_ (U1
M_P ,X^#_ /H):Y_W_A_^-5[!10!X_P#\,X^#_P#H):Y_W_A_^-4?\,X^#_\
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M?]_X?_C5'_#./@__ *"6N?\ ?^'_ .-5[!10!X__ ,,X^#_^@EKG_?\ A_\
MC5'_  SCX/\ ^@EKG_?^'_XU7L%% 'C_ /PSCX/_ .@EKG_?^'_XU1_PSCX/
M_P"@EKG_ '_A_P#C5>P44 >/_P##./@__H):Y_W_ (?_ (U1_P ,X^#_ /H)
M:Y_W_A_^-5[!10!X_P#\,X^#_P#H):Y_W_A_^-4?\,X^#_\ H):Y_P!_X?\
MXU7L%% 'C_\ PSCX/_Z"6N?]_P"'_P"-4?\ #./@_P#Z"6N?]_X?_C5>P44
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M/@__ *"6N?\ ?^'_ .-5[!10!X__ ,,X^#_^@EKG_?\ A_\ C5'_  SCX/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M'_"0>-O^A2B_\"Q7:T4<Z_E7XA8XK_A(/&W_ $*47_@6*/\ A(/&W_0I1?\
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M\)!XV_Z%*+_P+%'_  D'C;_H4HO_  +%=K11SK^5?B%CBO\ A(/&W_0I1?\
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M+N\&_P#/S<_]^37S;11]3I^8<S/I+_A=W@W_ )^;G_OR:/\ A=W@W_GYN?\
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M*FH?]?9_E65?#PA#F0TSUJBBBN$H**** "BBB@ HHHH **** "BBB@ HHHH
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M&-;GK5%%%>86%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110!S_CO_ ))YXE_[!5U_Z*:OB"OM_P =_P#)
M//$O_8*NO_135\04 ?3_ .SC_P D\U#_ +"LG_HJ*O8*\?\ V<?^2>:A_P!A
M63_T5%7L% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110!E^)?^18U3_KUD_\ 037C7P+3
MS+'7$W!=T!&X]![U[+XE_P"18U3_ *]9/_037S[\+O%NC^&;#5H]4G:)KF(I
M& N<GFNNBFZ4DO(E[FUX*T_1_ >L:AKU_P"(K"Y=4<);VSY+9/3ZU1\'6FG:
MW/JVIOH,E[<WDKR12W(Q;0CK\QKS"1(S<2NJC#2,P..Q->F>%/%7A\?#FY\+
M:Q?S:>\CD^?$"2P/:NJ<&E?=NPD:/C_0=&T;PQHWB*UT^Q:8SJLL5N<PR\UL
M?%'4[5+?PO:RZ1:S+>!,,W!A! X6N:\9>(_"FH?#VR\/:/?R,]C(K1[H\;P#
M4GBGQ+X7\3:?X?F_M62"[TP)N@\K.[&,\UG&,O=;3Z_\ #I=9^'>C7_BK2;.
MUMEMK?RA+.%8G>/3FI(/"&F:SJ.J:1-X233;:-#]DOQU8CUK+UCXJ:1%XETN
M_P!+D:X@CC$=R"N./:J&H:_X(FNM1U%]>U2\:<;K>R5V01MZ9J5&I97N/0G\
M+>'-"L_ .M7VI:;%>7-A.Z"1NIQTJ'7-)T6^^&5EXHM-$@M;I909(HONN,]#
M6;H7C'1K/X::OHUQ-)'?W3LT41&[@],FG_\ "9:)_P *CC\/?:'_ +2'6/;Q
MU]:OEGS7UW_ 6AVGC?5K6'X:Z3))I=J\5RBKL;A801U'THB\&Z-8^&=,O=-T
M&TUF#8'N7)S*ZG^[[UR6H>*_#7B'X>V&DWU_):7EHO,(3<),=L^]2:'X@\':
M>^FW]AK=]H\L(Q/9MF1&'H/2HY)*-E?=CN<'XMAM(/$MS'8V-Q8V^ 1;W PZ
M&NO\%>']+\0_#O6(1:1OK41+13'[R@FL?XD^*K/Q9XC^U6$0%O&H59<8,GUI
MWPS\5VGA/Q&]QJ#$6<Z;)"!G;[XKHDI.EIN3U/0=2^%NFCX<PVMK"@UI55C<
M_P 9/<'VJM/X9\/6GBCPEH+6$'VMXR]Z%)!?Y>_XT67Q;TM/'UY-<3-_8;QX
MBEVY^;'I7-?\)OIUS\8H/$EQ*RZ="&02;>=N..*PC&KK?U'H>A>"%LM-\;^)
M],M-/ABB@8E&'+8QT^E97PUU""\\1>,KH6$-M$B%7AB^ZV.I^IK"T/Q]HEC\
M3=<U6>=UTN^4B.8+SGZ4SPIXH\,^&-5\3'^TWGMM0C)@E\O!+$'*XI.G*STW
M2'<M6=CH/B[X?:_JMOH%O8W%D["%H>K8/>O);2$W-S;VY.UI7"$^F:]#\$^+
MM'T3P'KFE7T[)>7;L84"YR#G'->>12M!<I/']^-]Z_45TTTTY+[B6>P>)M/\
M,^!+#1;2718;V>X9#/._WER1R*N_$O0&\4^,O"^F0OY44MOEF[JGM[UD:SXI
M\(>,=,T>76;^6UO;(J9HUCSYF,<9J'QI\1;"3Q3H6K^')6G6PCV2HRXROI7/
M&,[K>^HR[<CPSIWCRV\(#PY:RVAC$;WC_P"M+8QN_.F:7\);>W\=W4-[,TND
M6JF>-?XI!UVM[5%/KO@B_P#&-OXMFU::&9(PSZ?Y><R8Z;OK532?BU.OCBXU
M+48/^)7<CRC$#S$GK[T[5+>[VU]0T,S4?$?A*]M-7T^^\/1Z?*CE;.XLA\W'
M]ZMW5/#FCP_!^PU2.PB6^DV[IQ]X\UAWL?P^M;;5[P7L^L7ERQ:U@VF,1$^I
M[XK7TWQAX=U?X<Q^'-;O9-.G@?".J;LJ#D&K:=DXWW T/%/AC0[/POX;N;;3
MHHYKF6,3..K@]<ULZSI?A;2O'&CZ#%X:M'2^7]X[9^4>H]ZY[Q9XX\-ZCHFB
M66GW,CFQF0R93'RKU--\0>.O#^H?$G1-:M[EVL;10)GV8(_"LU&;M>_4>AT*
M:5X4/Q$;PHGARV:'RB[SM]X-CC%8_ACX=V7]MZ[>W5I]KMK-F%K9G^,]@?:J
ML7CG0$^+DGB%KE_[.:+:)-G.<>E2Z;\2M+@\1ZS!<7$BZ/?@^5<(,-$?6CEJ
M):7V0M"36/"=IK'@"[U67P^N@:C9.28U/$J@U=UC3/#>@>$]!U$>'[6XN+H(
MKA\X;/4GWKD->U/PM#X:-M8ZMJ6L:G(_,LLK*JKGT[UI>*_&NA:KX4T*PM+E
MWN+-D,RE, 8ZU7+-VWM<#<UW0](\-^//#][I^F0B&\V@PL/E0GN/>M+QW86W
MB;QWIGAZ6SA3>HD:Z'WPHZJ*Y3QSX]T;4YM"N-*D>X>Q93(A7;TQFKFO^/?#
M[^)=-\3:7?O-=P*(Y+1H\#:>IS[5"A/1VULPT.@C\(Z5?:_>:(_A!+73DBVP
MZCGYBX[USWA_P)IVA:7X@U;5X(M0:R++;PL?D/IFC4?$7@>_U6ZU6?7]4D2:
M/*Z>CLH63ZUF>%/'.E)H^L:#K4LEM8W@/D3'YVC],^M-*IRZ7Z!H=/8ZC::K
M\$-0NK2PCL59B&@B^Z#GM5SX _\ (J:A_P!?9_E7,+XF\(Z/\-+OPSIVIRW5
MP^2KF/&\FNG^ /\ R*FH?]?9_E4U%:G+U&MSUJBBBN$H**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#G
M_'?_ "3SQ+_V"KK_ -%-7Q!7V_X[_P"2>>)?^P5=?^BFKX@H ^G_ -G'_DGF
MH?\ 85D_]%15[!7C_P"SC_R3S4/^PK)_Z*BKV"@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M35\05]O^._\ DGGB7_L%77_HIJ^(* /I_P#9Q_Y)YJ'_ &%9/_145>P5X_\
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MR$DG##!ZUY3HOB;6O#IE.DWSV_F_ZP8W!OSJU?>-_$FIV4EE>:D9+67EXPH
M--T9<WSN%ST'XC/(O@?P.BLRH\L>X#H>!5[XC2S?\+(\%0^8_E[5;9G@G/6O
M);_Q'K&J6EG:7MXTL%D0;="/]61TIU]XHUO4]0M+^]OFEN[,8MY"/N4U1:M\
M_P 0N?0,2V</Q<U!I"!=S6BB('J<#M7-:7J$&CW'B%M+\+ZO,&++=O<2?)N]
M1FO([OQ1KE]JT>JW-^[W\8 28<$8J[?^/O%.J6<EI>:J[P2??55"[OJ14+#R
M"YWMVMS??L_LFG*S2"X9I8HN64;CP<5I>(XYH_@98K,K*PC7 8<@5Y'HOBC6
M_#B2II-\T"3',BD;@?P-3ZEXT\1ZO9-97^I--;,<F/: *OV,K^5[A<P5^Z/I
M2T=**Z"0HHHH&%%%% !1110 5[]\ O\ D5-0_P"OL_RKP&O?O@%_R*FH?]?9
M_E7/BOX3''<]:HHHKRBPHHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** .?\=_\D\\2_P#8*NO_ $4U?$%?
M;_CO_DGGB7_L%77_ **:OB"@#Z?_ &<?^2>:A_V%9/\ T5%7L%>/_LX_\D\U
M#_L*R?\ HJ*O8* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#+\2_P#(L:I_UZR?^@FO
MCNWBEF4+#%)*W/"+DU]B>)?^18U3_KUD_P#037@7P. /BV4,JL/+/49KNPLN
M6G*1+W//%M[AV*);3,Z_>54)(^HH2WN),^7;3/C@[4)Q]:]W\$!3\2/$X*(1
MSQM'%1?#MA%I'BR4(A9))&7*@X/.*W=>U].WXBL>&RVUS;@&>UGA4\ R(5!_
M.B*WN+C/V>VFFQU\M"V/RKV:"\D\5?!K4[C6$CN+BTD/ER%0",'@\4W66D\"
M_"_3)M"VPW%T%DGN=H);VI^V>UM;V"QXS(DD+;)HWB?^[(NT_E4ALKT1^:;&
MZ$>,[S$<8]<UZ5X;U2+XF>,M.CUK3;:-K4 LZ+@SX[&ME?%&HGXNS:$[(^CL
M/(^Q%!M"XQ3=5IVMK:XK'C,44T^?(ADFQU\M2V/RJ0V-\N-UC=#/3,1YKWOP
MIHEEX<\?>*K6PC00+9B5$(R$/I5/P9XGU#5? GB34;[RIY]/F?[.60?+C.*E
MUWNEII^(['ATMK=08\^UGA!Z&2,K_.E2RO9 "EC<N#R"L1.:]:N=0N?$?P&E
MU75"L]ZMP=LI4 J,CCBM#QCKU]X>^%OAZXTQU@N)=BF4("0/2G[9WM;6]A6/
M&]/M#+K=C9W44D:S3I&ZL-K8)KT?7/!_@_P_\04TN^2Z72VMA)A"6;=^%;/C
MW3[>['A'7C&([V26(2E1CS.G)KH[I5;XX1AE5A]A'!&:SE6;LUV8['@6NV=@
MOB*Y@T6*:6U!_<J5)?'TJC+;7-N ;BUGA!Z&5"N?SKW?3+&WM=4\:Z\D,3W]
MJ2(&V_ZO@]J\NN?B#JNN:%_8VJ6T%ZTLH,=RZ8>,D]!BM85'+1+85CFX[.\F
M3?#97,J?WDB)'YUI>'O#.I>)=673K*!P^?WC,,>6/4U[/:7,_A\:!8ZS=1:>
M\CJEM8Z>@;S0>\F:6SE&F?'FZL+5E@@NK8221*.';'6H==V=ET'8\0UO1KG1
M-<N-+D221XGV*VPCS/\ =]:IRVMU;KNGM)X5_O21E1^M>[>&H#KOQ%U^]U.5
M;A]-9ELUD VP^]59KZTF\+Z[8>*O$&EZBYWO9^4/F0C.!Q[TU7>UNP6/$X;:
MYN2OD6L\R[@"8T+ ?E7HGC;P1HV@>!]/U:RCF6\GQYF]LCWXK<UK4YO!7PIT
M!]$CCMYM0D7SI0H)YJU\59C<?#/2IF #/M)QZXI.I*4HVT5PL>(5/]@O]H;[
M!=X/0^2>:Z#X<Z?;:KX_TRSO(A+ Q+%#T)'(KU?2/$^H7OQFO]$EV?V=;+LC
M@V# QWJZE5Q=DNEQ)'@?E2^;Y7DR>:?^6>T[ORI\MI=P+NGM+B%?[TD94?K7
MN^D:;9_\)IXLUB6"&:YLHRT (^X<$]*Q?A[XAN_'LVM:-XA2*ZMQ$TT;% #&
M<XP*7MW9NVB'8\A2VN95#16L\BGHR(2#1+;W%OC[1;S0YZ>8A7/YU[EX7E.F
M_"/5);=$$EO+((F*@E<'@U7\2$^(/@]8:CJ")+=HZ_OMH!Y.,TO;^]:VE[!8
M\6BM;JX&Z"TGF4=XXRP_2F&*59?*:*19?^>97#?E7L'C[6[GX?Z3H.G>'4CM
M4N(1/+($!+GTJ]XHL;6YNO!^OB"&*]NV7SR!CS.!VIJL]';1BL>+?8;X*6-A
M=!1U)B.!0MC?-@_8+K;W/E' %>R?%'7]3L/&FF:99W ALIT7SHE08?ZT_P"+
MVNZEHL&BVVF7 MH[B+$P1!\XQT-$:TGRZ;A8Y?QEX&T_2/!>C:II-I=2WEWC
MSMN7XQZ#I7G;QR1/LEC>-_[KK@_E7N7C7Q!J7A[X>^&)],N/)DD=%<X!W#CC
MFIO%6@V&K_$'PL;B!!]IMQ+-M&/,(]:BG6:7O>?X#:/"S97HC\PV-R(^N_RC
MC\Z9%%+.VV"&25O[L:EC7T7=:@MAXPGBU+7-*CT,Q>4=/8?.@QUZ5ROAG3Y]
M/O=?OM$-E%HGFX.H2C]XB'KY=4J]U>P6/'Y;>XMR!<6\T)/3S$*Y_.O>O@%_
MR*FH?]?9_E57Q_'I^J?"A-1C=[MX'Q#=3* Y]^*M? '_ )%._P#^OK^E9UJG
M/1;\P2U/6J***\XL**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@#G_'?_ "3SQ+_V"KK_ -%-7Q!7V_X[
M_P"2>>)?^P5=?^BFKX@H ^G_ -G'_DGFH?\ 85D_]%15[!7C_P"SC_R3S4/^
MPK)_Z*BKV"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M;_OV:/\ A0&J_P#0=MO^_9H^L4NX69Y'17KG_"@-5_Z#MM_W[-'_  H#5?\
MH.VW_?LT?6*7<+,\CHKUS_A0&J_]!VV_[]FLFP^#VH:AKFI:4FK0(]ALW2%#
MA]PSQ35>F^H69YS17KG_  H#5?\ H.VW_?LT?\* U7_H.VW_ '[-+ZQ2[A9G
MD=%>N?\ "@-5_P"@[;?]^S1_PH#5?^@[;?\ ?LT?6*7<+,\CHKUS_A0&J_\
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M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '/\ CO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M#7;5]%EB:PL;G@9DT\3*P4445WG"%%%% !1110 4444 %%%% !1110 4444
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M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .?\ '?\
MR3SQ+_V"KK_T4U?$%?;_ ([_ .2>>)?^P5=?^BFKX@H ^G_V<?\ DGFH?]A6
M3_T5%7L%>/\ [./_ "3S4/\ L*R?^BHJ]@H **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** (WMX9#EXD8^
MZ@UQWAW;)X\\2P-&ABB\KRUVC"Y7G%=K7%>&O^2B>*O^V/\ Z#51C&TM/ZN/
MF?<[4  8 P****D04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% '/^._^2>>)?^P5=?\ HIJ^(*^W_'?_ "3SQ+_V"KK_
M -%-7Q!0!]/_ +./_)/-0_["LG_HJ*O8*\?_ &<?^2>:A_V%9/\ T5%7L% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%9?B2_FTOPWJ%];X\Z"!G3/3(KEM+
MMO&VHZ5:7O\ ;%DOGQ+)M\L\9&:M0NKW [VBN-_LKQM_T&[+_OT:/[*\;?\
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M=E_WZ-1R+N@N=E17&_V5XV_Z#=E_WZ-']E>-O^@W9?\ ?HT<B[H+G945QO\
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M)?\ L%77_HIJ^(*^W_'?_)//$O\ V"KK_P!%-7Q!0!]/_LX_\D\U#_L*R?\
MHJ*O8*\?_9Q_Y)YJ'_85D_\ 145>P4 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0!@^-?\ D2M8_P"O9ZG\+?\ (J:3_P!>L?\ Z"*\Q^-%QKNE*DUI<-_9ERIC
MF7T/I4OP:N-=U:)[J^N6.GVZB.!.QQ73[+]SS7%?4]@HHHKF&%%%% !1110
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M->544?5Z78+L]5_X7WKW_0)L_P#OHT?\+[U[_H$V?_?1KRJBCZO2[!=GJO\
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M-^LZ?90VD&CV0BA0(N"1P*L?\+[U[_H$V?\ WT:\JHI>PI]@NSU7_A?>O?\
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M3"!YK/$ H/<9K/TWX=0:KXBU&&WOY!H6G ^?>,/F)'9?6I]M"[3Z!8X&M/\
MX1[5CH7]N?8V_LS=M\_/&:ZAO NE:UX;O-5\):A<W;V3$3P7*[25'4KZUOC/
M_#.(4Y4_:,$'MS2E56EN]@L>=:CX:UG2+&VO;^Q>&VNB! ^<[R>E7)_ GB>U
MMX9Y],,<<Q58\N,L3TXKTFZT58++PG-K>O7=W:RR+Y-N8QM1L"K?Q-^PKXU\
M,[;NY%Z)XPD _P!65SU/O6:KMM)>8['C&KZ+J.@7WV+5;8V]SM#["<\'O5&O
M9?'_ (3N_%_Q9^QV[K''':(TTC'[JUB6OP]\-:W=WVFZ!KUQ<:I:J2$E7".1
MUP:N-:/*FQ6/-:U;;PUK-WH\VKV]DSZ?#_K)L\+73^%?AP-8L=2U#6;QK.RL
M2R.T7)++U%=U8VNG6GP7UD:3=R7-HX8JT@PPY[BB=9+2/<$CPD$$ CH:*[_P
MYX!T74M"M;J[U6XENYB%-M8KO,8]6]*9XA^&-[IGBVRT33)6N$NP"DL@QM]<
MU7M87L%C@ZUK'POK>IZ5+JEE8M+8Q9WR@\#%=A/X&\(Q:S<Z"?$5Q#JL$6XM
M.H6$OCIFKOA;1-2/PYU>:'7I8(+=W5[>$9CDQWS[U,JJM=!8\L_I17HD7P_T
M*#P-:>)]5U>YACG;YT1<XR2.*S?'?@JU\)VNF7EC>R75KJ"[D,@PPXS_ %JE
M5BW9!8W_ (#_ /(XZA_UZC^=>Z^(/^1<U+_KVD_]!->%? ?_ )''4/\ KU'\
MZ]U\0?\ (N:E_P!>TG_H)K@Q/\;[BH['QO']W\3_ #IU-C^[^)_G3J]0@***
M*0PK6\+7\.E^*],OKAML,,P+'T%9-!&10U=6 ]&^,6E2#Q1%K5LDEQ;:A$K(
M\2EAP/:L+2_#E_HVIZ3JFN60@TR:12K2GKZ97K573/&WB/1[)+*RU';;I]U)
M$#X^F:H:QKVJ^(+I;G5;Q[B5%VKV4#V'2LHQFER] /=/%S6"^.='NDTC5;[4
M%C#VKVDF(BH['MBH_"E]+JGQ4UBYFT]K&7[*%:!F#$''4XKR.S^(/BO3[2.U
MMM69(8UVH"H)4>@-4-.\3ZWI-_<7UC?R1W5Q_K9#R6K+ZO+EMY#N>N?#AU'C
MCQ1 %.\ACU^M4OA2LD,WCC*O&P$A&X$'H:\OL/$NLZ7JLNJ65ZT5],,22@?>
M_"K2^-O$:7=W=)J)6:\39<,J ;UQBG*C)WMUM^ 7.O\ @86?QAJ<C$L[0,23
MR3R:Z&RTA=/\-ZSXC+7-ZPFD T^-LQYSU9:\AT;7=3\/7,ESI-T;::1=K,!G
M(JYIGC'Q#H[W+V&HO$;EM\P(W!C]#53I2<FUY"3/6/'K3W_PDTJ5[18IY-I6
M*)" A/3 [5U/A:#4[+P/:Z5>7L:ZW):DV_F?>48XS7@T_C_Q3<QB*;5"\8;<
M%*# -5KCQEXBNM4@U.;4Y&O(!MBD'&T?2LWAY./+IW'<])^%5I>:;K_BNRU#
MY-5>)MN[@NV.HJK\(;35K'Q5K4^J)/%:)&XG:;(4MD^O7BO.KCQ-K5UK2ZS-
M?.=14 "9>.![5=U#QYXHU6S>TO-49X)/OJJA=WU(JY4I.^VH7/5/#SY^%7B%
MX2=C32[2/3-5I%+_  'B+EB$=<9[#=7E%IXHUNPT=])M;YH["3[\..M*?%.M
MG1?[&-\W]G?\\,<4O8.]_.X7/9_&G]E/:>%KJXTO4=05(X_(-B^$#X& V*X#
MXL:Q)JFO6ZW6DR:==QQ#<LC!F9>V2*P-+\<^)M%L4LK#4VCMH^41E#;?IFL>
M_O[O5+R2\OIVGN)#EG8\FJIT7%W?0&SUOX)@G1M>P"?E/\JOZ1J$^E_""2[@
M.UTU,\GTWC->1:1XEUG08IHM+O6MTG&) !G=1_PDNL_V.^D?;6_L]W\QH<=6
MZYI2HN4F_-!<^CM>O;71+*UG@7#ZO.BL1W) KR_XY*4UW3P1C$5<-<^+_$%Y
M#:17.HO)'9L&MP1]PCH:KZQX@U7Q#.DVK7;7,B#"L1C I4J#A)-L&[F;1117
M2(**** "OH#X!_\ (H7O_7V?Y5\_U] ? /\ Y%"]_P"OL_RKGQ?\(<=SUBBB
MBO*+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#G_ !W_ ,D\\2_]@JZ_
M]%-7Q!7V_P"._P#DGGB7_L%77_HIJ^(* /I_]G'_ ))YJ'_85D_]%15[!7C_
M .SC_P D\U#_ +"LG_HJ*O8* "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** ,WQ!_R+FI?]>TG_ *":^/M.NY=/O;>\A.)(I-P/X\U]@^(/
M^1<U+_KVD_\ 037QO']W\3_.O0P7PR)D>P^---C^)%A8ZWX<NH)+J!!%<6TK
MA#G'7FE>XM/AO\.+K2Y;R*;6[Y"3'$0P4'MD5X^"R_=D=/\ =8C^5!R3EF9C
MZL2:W5'11OHB;GK^KSPM\!].C$\1EW E XW#D]JM>%+:,_"Z*7PV;)-=+[7F
ME8+(JD\X)KQ;+?WVQZ;CC\J 6'W9'7_=8BCV.EK];A<]\\<,D6E>$X9+^*YF
MANU6:02 DGC)-<M\<)H9M9TPPS1R@1<E&!Q7EF6/620_5B:,D]69O]XDTH4>
M5IWV"YZO\(=8M&T_5?#]Q(L$L\9,4CM@,3VK9\)Z!+X8\!^*8=1NK5;BZ$CK
M&LH)Q@XKP_GLS*?4'%*6<]993]7-.5&[=GN%SUO3;^+QI\('T&Q>)-7M<?Z/
M(P7</4$TNHZA;^"_AC'X;OI8Y-4O\%XHF#"%<\DD5Y$"0<JS*?56(_E022<L
MS,?5B31[%7WTO<+GO&BW7B%-/TF%+S3/$.@2H$GCDVH\0'KGKBFZ9K'A?1_B
M[?6VG2PP17-MY!*C$8EZX^E>$AG'"RR*/17(%'ODY]<\_G4_5UKKN.Y[AJ%Y
MXET32]9NKS4=$TZT#%(A;Q!FN0<XZ5X@"T\Z[N&E< GTR>M(68\-)(P]&<D4
M9]ZUIT^039]$2Z3/X>^&ZZ1X9:TGO[A )I!,JGD<FN9\"W7]F:9JG@?6)8K?
M4YT+PR&0,LA([M7CP:0=)I?PD-(2Q.2[EO[VXY_.LE0T:;W'<]C\*H?AKX2U
MB\UZ2!;BX9H[>WCD#F0GZ55DNX9_V?Y,R1K-)=[_ "MPW#+>E>3%F/WY';_>
M8G^=&3TW-CTW''Y57L;N[>M[BN>Y^)KBW;0_! 6XA)25-P#CY>!U]*S_ (F3
MP2?$GPN\<\3HLB;F5P0/J:\<RW=W/IECQ1EN[L3ZEB2*4:%G>_?\0N?0EYXC
MTO3/BY>Q75W&L=_8)"DJD$!OK6!X)\+/X$\4ZEKVJWUK_9\2/Y;I("9 V3P*
M\:Y/5F)]223^=!9R,&60CT+DBDJ%E9/<=SVSPKJ]EXK\*^(M%CN(X+F:5Y8M
MS!0P/(J6STH^'?@WJ]A>75M]K<%FB24$CGI[UX<,C[K,I_V3BC<YZRR'ZN33
M=#71Z7N%SW2*U2Z\#:&_@Z>TMU9D-[('$<I ^]S6MXJ\2V.@>,-$OY[B*6RD
M4123(X;9VR<5\Z@N/NR2*/17(%&6/WG9A_M,32^KJ^K"YZKXF^'LVO>,]1U*
M34;2UT5X_/6[,@8GC.-M:/@N2SM_A)KMO'>1.H=Q&Q8*7'J!7C.Y\8,LI'IO
M.*,L. [ >@8@?E5.DW'E;["N>J>*)H7^ FCQ+-&THG0E P+#YCVJU\3Y;>7P
M#X<"2Q22)&,A6!*_**\AR>A9B/0L<?E1EN[L1Z%B:%1LT[[-L+GJ/P&_Y'#4
M/^O4?SKW7Q!_R+FI?]>TG_H)KPKX#_\ (XZA_P!>H_G7NOB#_D7-2_Z]I/\
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MJ,#(ZYK.=+73NAIF]+XT\.>*?#^D+JFM7NC7MFJI(EN3B1 .G'K61:>.]/\
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MW\Z%WBDC*>2O]TUS/PIB5/%_B35G^Y9M*S&N?N?BMJTR7IM]+T^SNKQ=LUU
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M_$_SK[(\0?\ (N:E_P!>TG_H)KXWC^[^)_G7H8+9DR'4445VDA1110 4444
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M5L=<&K'PNUBPTSQAKMK>7"0F_0Q1.W3-:O@7PK=>!O%&IZ_K5Q;Q6,2.$99
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M$_N!CC\J-\A7:99"G92QP/PI**!DT!CEG2.]N)Q;$X<ABQ4>PKT/Q)X[T5O
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M%9/_ $5%7L% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MUC))A4DG:/:G];7+>PN4^2=W^R__ 'R:-W^R_P#WR:^S/[%TK_H&VG_?E?\
M"C^Q=*_Z!MI_WY7_  I?75V'RGQGN_V7_P"^31N_V7_[Y-?9G]BZ5_T#;3_O
MRO\ A1_8NE?] VT_[\K_ (4?75V#E/C/=_LO_P!\FC=_LO\ ]\FOLS^Q=*_Z
M!MI_WY7_  H_L72O^@;:?]^5_P */KJ[!RGQGN_V7_[Y-&[_ &7_ .^37V9_
M8NE?] VT_P"_*_X4?V+I7_0-M/\ ORO^%'UU=@Y3XSW?[+_]\FC=_LO_ -\F
MOLS^Q=*_Z!MI_P!^5_PH_L72O^@;:?\ ?E?\*/KJ[!RGQGN_V7_[Y-&[_9?_
M +Y-?9G]BZ5_T#;3_ORO^%']BZ5_T#;3_ORO^%'UU=@Y3XSW?[+_ /?)HW?[
M+_\ ?)K[,_L72O\ H&VG_?E?\*/[%TK_ *!MI_WY7_"CZZNP<IX1\!8Y#XLU
M"7RV\O[-C<1@9S7NFO*7\/:BJ@EC;2  =_E-6K>QM+3/V:UAASU\M N?RJ8@
M,"" 0>H-<E6KSSYK#2L?$P#1ED='5E8@@J>.:-W^R_\ WR:^S#HVELQ)TZT)
M/4F%?\*/[%TK_H&VG_?E?\*Z_KJ["Y3XSW?[+_\ ?)HW?[+_ /?)K[,_L72O
M^@;:?]^5_P */[%TK_H&VG_?E?\ "CZZNP<I\9[O]E_^^31N_P!E_P#ODU]F
M?V+I7_0-M/\ ORO^%']BZ5_T#;3_ +\K_A1]=78.4^,]W^R__?)HW?[+_P#?
M)K[,_L72O^@;:?\ ?E?\*/[%TK_H&VG_ 'Y7_"CZZNP<I\9[O]E_^^31N_V7
M_P"^37V9_8NE?] VT_[\K_A1_8NE?] VT_[\K_A1]=78.4^,]W^R_P#WR:-W
M^R__ 'R:^S/[%TK_ *!MI_WY7_"C^Q=*_P"@;:?]^5_PH^NKL'*?&>[_ &7_
M .^31N_V7_[Y-?9G]BZ5_P! VT_[\K_A1_8NE?\ 0-M/^_*_X4?75V#E/C/=
M_LO_ -\FEW>S?]\FOLO^Q=*_Z!MI_P!^5_PKD?%.F:=%K^C(EA:JK2?,!$!G
MFG'&)NUA<I\P[O\ 9?\ [Y-&[_9?_ODU]F?V+I7_ $#;3_ORO^%']BZ5_P!
MVT_[\K_A2^NKL/E/C/=_LO\ ]\FC=_LO_P!\FOLS^Q=*_P"@;:?]^5_PH_L7
M2O\ H&VG_?E?\*/KJ[!RGQGN_P!E_P#ODT;O]E_^^37V9_8NE?\ 0-M/^_*_
MX4?V+I7_ $#;3_ORO^%'UU=@Y3XSW?[+_P#?)HW?[+_]\FOLS^Q=*_Z!MI_W
MY7_"C^Q=*_Z!MI_WY7_"CZZNP<I\9[O]E_\ ODT;O]E_^^37V9_8NE?] VT_
M[\K_ (4?V+I7_0-M/^_*_P"%'UU=@Y3XSW?[+_\ ?)HW?[+_ /?)K[,_L72O
M^@;:?]^5_P */[%TK_H&VG_?E?\ "CZZNP<I\9[O]E_^^31N_P!E_P#ODU]F
M?V+I7_0-M/\ ORO^%']BZ5_T#;3_ +\K_A1]=78.4^,]_P#LO_WR:^A/@+'(
MG@^[+HRAKHE<C&1BO2/[%TK_ *!MI_WY7_"K4%O#;1^7!#'$G]U%"C]*RK8E
M5(\M@2L24445R%!1110 4444 %%%% !1110 4444 %%%% !1110!S_CO_DGG
MB7_L%77_ **:OB"OM_QW_P D\\2_]@JZ_P#135\04 ?3_P"SC_R3S4/^PK)_
MZ*BKV"O'_P!G'_DGFH?]A63_ -%15[!0 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% &#XU_Y$K6/^O9JG\*_P#(IZ3_ ->L?_H(J#QK_P B5K'_ %[-4_A8$>%-
M)!_Y]8__ $$5I_R[^8NIKT445F,**** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KC?%O_ ",6B_\ 70?S
MKLJX[Q:#_P )#HI[>;_6KI_$#.QHHHJ "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .?\ '?\
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ML^X6.+_X5Y'_ -!_6/\ O_7#6NEWDWQ7NO#3:_JGV"*$2+B;YLXSUKVVO);
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MT5\^?\+[U[_H$V?_ 'T:/^%]Z]_T";/_ +Z-/ZI5[!S(^@Z*^?/^%]Z]_P!
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M\^?\+[U[_H$V?_?1H_X7WKW_ $";/_OHT?5*O8.9'T'17SY_POO7O^@39_\
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MQ!9Q)I#VRR?9P/D8D=35U*JAN)*Y\_;UV[MPQZUU=CX1L[SP1+XA;6H8IT)
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M^*RX[!1116 PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH Y_QW_R3SQ+_ -@JZ_\ 135\05]O^._^2>>)?^P5
M=?\ HIJ^(* /I_\ 9Q_Y)YJ'_85D_P#145>P5X_^SC_R3S4/^PK)_P"BHJ]@
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** /EKXL_P#)3-2_W4_E7&5V?Q9_Y*9J7^ZG
M\JXRO:I? O0S844458!1110 4444 %=!JO@S5=&\-6WB"Z:$V5R0(PC9;GUK
MGB<<GH.:]E\76T^K?!30(["%[AGD0 (N<<]_2LZDW%Q\V!YYK?@K5M ATN6]
M:$KJ946^QLXSC&?SK=?X0>(HKR.SEO-.CN)1NC1I,%OI74?%2&2WM? T,J[9
M$EC5AZ$ 5;\=-(/C5X34,P&T<#ZUBJLVE;S_  '8\DF\,ZK#XD_X1_[,SZAN
MV[$&?Q^E;UU\+]<M[>\DAN["\ELUW3VUO)ND4?2O3K*YL;;X[ZG%<LJ7,MLO
MDL_';M7F%WX=\4W'C+Q!_8\5S \<C-/+N,:LG^\>M5&K*3WMHF%C/T'P-K'B
M&SFO8?)M+2(X::Z;:N?8T:]X'UGP\MO)<B*>WN" EQ;G<G/3FN]U&&?4O@-:
MP:6CRRPR_P"D11G<V03G(%+"D^E? ^&SU@M'=SW2M;Q2GYMNX8X[4>UE>_G:
MP6.:?X1>(8FMUGO-.A-P 8M\F-Q/;ZT[_A3_ (C6Y6VDNM/BN'SY<3R89\>E
M=O\ $'?_ ,)1X)0EMN4.WWJ?76D;X]:.I9BJQ J#T'%9JM4:3OT;"R/*-+\!
MZWJ_B.[T& 11WMH,R>8<+CVK1G^%>OPVEU.EQ8SM:@F:&*3+K^%>GZ)%Y?QN
MUK;D,]KGGUK'^&=CJ6G>*?$]QJBR1VZLYE>7[K#MSWINO+5KL@L4? <<9^#6
MO,\2%U=AEE&167XC.NO\*].CN--LDL"ZB*:(YF<Y.,BND\./%-\-/%LMO@P-
M<N4*CC&:?J3)%\+_  M)-Q$MY&7)Z8S4\UIW\_T#H<':?"KQ!=06TCW-C;27
M(S%!/)MD;\*S[+P!X@OM>N-&6W6*XMQF220X0#US7<?%?1-;U3QQIUYHRSS1
MSPJMLT.=JL.^1TJ;P1X0U$3ZE=>([FZEU"T&X6L5QEI!Z'VK3VSY.9M!8XC5
M/ASK.EZ2=3^U65U:!_+:2!\A3[UT^L?#"TT[X>6=W#J%F=0E<227,LF%9?[B
M>M=6EU>:I\(-7FN].2T)9PL"1;<*/4>OO7-^,H9+GX*^%O)@>01S+NV*6VC)
MZXJ54G)I-]0L<K8?#/6[ZQM[N2YLK);AML*73[6<^PK*3P?K;^)CX>^R,+X-
MCD?+C^]]*]D\;#3IH?"]W)H5YJY1$$#VDF%1\#AL5/HVO/>_%"6+4K!=.OC9
M[(T:0.2?KZT*O.UPL97PQ\#WOAOQ-=?VA-8W.(B'2)@YC/H?2O'-> 'B35
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M&!7(5Y(R!CZU#;6-[>AC9V<]R%X8Q(6Q56CO8#9G\=>*;J*6&;69GBE&V1,
M!A4%KXN\066GG3[;4Y$LR"/*P".:R98I8)C#-$\4PZQN,-^56#I.JK'YC:7>
M"/&=QA.*.6/8#1T_QGXDTFU%K8:M-# "6"8!P3]:SAJE^-4.J"[D^WE]YGSS
MN]:J>W>BGRKL!TA^(7B\OO\ [<GW8QD =*YZ662>>2:5B\LC;G8]SZTRBA12
MV0!1113 **** "BBB@ HHHH ]J_9]_YCG^\G\J]NKQ']GW_F.?[R?RKVZO)Q
M/\5EQV"BBBL!A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!S_ ([_ .2>>)?^P5=?^BFKX@K[?\=_\D\\2_\
M8*NO_135\04 ?3_[./\ R3S4/^PK)_Z*BKV"O'_V<?\ DGFH?]A63_T5%7L%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110!\M?%G_DIFI?[J?RKC*[/XL_\ )3-2_P!U
M/Y5QE>U2^!>AFPHHHJP"BBB@ HHHH **** "D/;W(%+0: /;/$MU-X+^$VF?
MV&QA>;;(\R@$D^AJYXN1?$GASP0M^%47DZF7 QV%8VER^(U^'-NEWX?@U[3
MX,.R7+J>W'H*L?%[4I(_#/AV/Y;348R)3;H>8N!7"E[R76[U*&^-]>U#PWXW
MT31-&E^PZ="RK]GC4!9 >N?6M74=%L-.^-.@WMI&D+W:%I8E'&<=<5P8^)<%
MX-/N-<\/1:EJ5B/W=V7VDGMD5EQ>/=1/CN+Q5>(+F6+(C@S@*IZ#\*M4IVM;
MH_F*YZSH6NW][\9=>T.XD#Z<L9Q"0,5B^ ])LK&#Q5KD<2/?6\LBPY&?)Z]*
MXK3?B+-IOCV_\5#3E>2\4J;??@+^-4] \<WV@:[?W\40EM+]V:XLV/RL#VS1
M[&5FEV07.\^'MW-XX\-ZUI_B.07T<6Z2*:4#,;#/0U>T>_N-$^!\\]BX66*=
MXT?'(&>M>?WGCY$\/7&C>'M'31HKI]UPZ/N9QW&>U1P>/)8/ '_")BP5H]V[
M[06Y_*FZ4GTTNM N>A^ =<U%_A7K>ISW!GO$=B)7 S3?A#K6I:C8^(+V^NGN
M)XP2K/VKSW0O'<NA>#[[PZM@LR79),Q;!7/M1X.\=R^#[+4+:.P6Y%Z""Q;&
MVB5%M2LMV%STK0KRZ\3?#?7QJL@N665]AD ^4>@H.G+HWPPTK^R=9MM"EFD$
MDMS*/]:0>E>>Z'\19M$\/:AI"Z:DRWC,QD+8*YIND_$'[-X>&B:UI$>KV<<F
M^ 2-CR_:DZ4[NVUPN=CXH.G^(O%'APZ#)97^LXQ<.R$(Y4=3^-=EH6IQ7/C"
M[T>]OGN]02V_TF")1]FC]@/6O&KSXB7L_B>RUBSLK>RBLE"PVT2@ #OD]\UO
MP_&*"UU6;5+;PM!%>3C$T@DY<5,J,W%)+H%SS[7+=+77K^&/[@G;'MS5"KNK
MWZZIJUQ?) (!,Q;RP<X-4J[%MJ(****8!1110 4444 %%%% !1110![5^S[_
M ,QS_>3^5>W5XC^S[_S'/]Y/Y5[=7DXG^*RX[!1116 PHHHH **** "BBB@
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MC;_H!O\ ]]BC_A5_C;_H!O\ ]]BOJRBH^NS[(.4^4_\ A5_C;_H!O_WV*/\
MA5_C;_H!O_WV*^K**/KL^R#E/E/_ (5?XV_Z ;_]]BC_ (5?XV_Z ;_]]BOJ
MRBCZ[/L@Y3Y3_P"%7^-O^@&__?8H_P"%7^-O^@&__?8KZLHH^NS[(.4^4_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 <_X[_P"2>>)?^P5=?^BFKX@K[?\
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M44>T?E]P6.+_ .$>\8_]#6G_ (#"C_A'O&/_ $-:?^ PKM**/:/R^X+'%_\
M"/>,?^AK3_P&%'_"/>,?^AK3_P !A7:44>T?E]P6.+_X1[QC_P!#6G_@,*/^
M$>\8_P#0UI_X#"NTHH]H_+[@L<7_ ,(]XQ_Z&M/_  &%'_"/>,?^AK3_ ,!A
M7:44>T?E]P6.+_X1[QC_ -#6G_@,*/\ A'O&/_0UI_X#"NTHH]H_+[@L<7_P
MCWC'_H:T_P# 84_PA>ZS_;6J:7JU^EZ;8*4E5-O6NQKC?#G_ "/.O?[J4U+F
MB[@=E11160PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** .?\=_\ )//$O_8*NO\ T4U?$%?;_CO_ ))YXE_[!5U_Z*:OB"@#
MZ?\ V<?^2>:A_P!A63_T5%7L%>/_ +./_)/-0_["LG_HJ*O8* "BBB@ HHHH
M ***RM<\1Z3X;MH[C5KQ+:*1MBLW<^E-)MV0&K17'_\ "TO!G_0;@_(_X4?\
M+2\&?]!N#\C_ (57LY]F*Z.PHKC_ /A:7@S_ *#<'Y'_  H_X6EX,_Z#<'Y'
M_"CV<^S"Z.PHKC_^%I>#/^@W!^1_PH_X6EX,_P"@W!^1_P */9S[,+H["BN/
M_P"%I>#/^@W!^1_PH_X6EX,_Z#<'Y'_"CV<^S"Z.PHKC_P#A:7@S_H-P?D?\
M*/\ A:7@S_H-P?D?\*/9S[,+H["BN/\ ^%I>#/\ H-P?D?\ "C_A:7@S_H-P
M?D?\*/9S[,+H["BN/_X6EX,_Z#<'Y'_"C_A:7@S_ *#<'Y'_  H]G/LPNCL*
M*X__ (6EX,_Z#<'Y'_"C_A:7@S_H-P?D?\*/9S[,+H["BN/_ .%I>#/^@W!^
M1_PH_P"%I>#/^@W!^1_PH]G/LPNCL**X_P#X6EX,_P"@W!^1_P */^%I>#/^
M@W!^1_PH]G/LPNCJ+UITLIGME#3*I* ]S7SU?_%;5$\9Q:E+I*K=6D;VH@W?
M>R>M>N_\+2\&?]!N#\C_ (5Y?K#^";_XEVNLIK,(LF'FS84X#CH/QKHH1LWS
MQ$SV[0;R[U#1;:[OH!#/,@<Q@] :TJXY?BAX+10JZU  !@  _P"%+_PM+P9_
MT&X/R/\ A6#IS;^$=SL**X__ (6EX,_Z#<'Y'_"C_A:7@S_H-P?D?\*7LY]F
M%T=A17'_ /"TO!G_ $&X/R/^%'_"TO!G_0;@_(_X4>SGV871V%%<?_PM+P9_
MT&X/R/\ A1_PM+P9_P!!N#\C_A1[.?9A='845Q__  M+P9_T&X/R/^%'_"TO
M!G_0;@_(_P"%'LY]F%T=A17'_P#"TO!G_0;@_(_X4?\ "TO!G_0;@_(_X4>S
MGV871V%%<?\ \+2\&?\ 0;@_(_X4?\+2\&?]!N#\C_A1[.?9A='845Q__"TO
M!G_0;@_(_P"%'_"TO!G_ $&X/R/^%'LY]F%T=A17'_\ "TO!G_0;@_(_X4?\
M+2\&?]!N#\C_ (4>SGV871V%%<?_ ,+2\&?]!N#\C_A1_P +2\&?]!N#\C_A
M1[.?9A='845Q_P#PM+P9_P!!N#\C_A70Z/K.GZ]IZ7^F7"W%LY(61>A(ZTG"
M2U:'<OT445(!116)KOB[0_#4L,6KW\=L\P)C#9^8"FDV[(#;HKC_ /A:7@S_
M *#<'Y'_  H_X6EX,_Z#<'Y'_"J]G/LQ71V%%<?_ ,+2\&?]!N#\C_A1_P +
M2\&?]!N#\C_A1[.?9A='845Q_P#PM+P9_P!!N#\C_A1_PM+P9_T&X/R/^%'L
MY]F%T=A17'_\+2\&?]!N#\C_ (4?\+2\&?\ 0;@_(_X4>SGV871V%%<?_P +
M2\&?]!N#\C_A1_PM+P9_T&X/R/\ A1[.?9A='845Q_\ PM+P9_T&X/R/^%'_
M  M+P9_T&X/R/^%'LY]F%T=A17'_ /"TO!G_ $&X/R/^%'_"TO!G_0;@_(_X
M4>SGV871V%%<?_PM+P9_T&X/R/\ A1_PM+P9_P!!N#\C_A1[.?9A='845Q__
M  M+P9_T&X/R/^%'_"TO!G_0;@_(_P"%'LY]F%T=A17'_P#"TO!G_0;@_(_X
M4?\ "TO!G_0;@_(_X4>SGV871K>*M3O]'T"XU#3[=;B6 ;VC8XRHZUXCX=^*
M6JS>*Y9+;2DDN-194,>[[N#UKU67XG>"9HFCDUFW9&&&4@X(_*O-/"<W@K0O
M'6HZI+K4#V^=]J=IP,]1^%=%&-HRYHZB9[W"7,*&0 .0-P'8T^N/_P"%I>#/
M^@W!^1_PH_X6EX,_Z#<'Y'_"N?V<^S'='845Q_\ PM+P9_T&X/R/^%'_  M+
MP9_T&X/R/^%'LY]F%T=A17'_ /"TO!G_ $&X/R/^%'_"TO!G_0;@_(_X4>SG
MV871V%%<?_PM+P9_T&X/R/\ A1_PM+P9_P!!N#\C_A1[.?9A='845Q__  M+
MP9_T&X/R/^%'_"TO!G_0;@_(_P"%'LY]F%T=A17'_P#"TO!G_0;@_(_X4?\
M"TO!G_0;@_(_X4>SGV871V%%<?\ \+2\&?\ 0;@_(_X4?\+2\&?]!N#\C_A1
M[.?9A='845Q__"TO!G_0;@_(_P"%'_"TO!G_ $&X/R/^%'LY]F%T=A17'_\
M"TO!G_0;@_(_X4?\+2\&?]!N#\C_ (4>SGV871V%%<?_ ,+2\&?]!N#\C_A1
M_P +2\&?]!N#\C_A1[.?9A='845QQ^*?@P DZY!@>Q_PKJ;&]M]1LH;RTD$E
MO,NZ-QT84G"4=T,L4445('/^._\ DGGB7_L%77_HIJ^(*^W_ !W_ ,D\\2_]
M@JZ_]%-7Q!0!]/\ [./_ "3S4/\ L*R?^BHJ]@KQ_P#9Q_Y)YJ'_ &%9/_14
M5>P4 %%%% !1110 5Y'\?P#X7TW(!_TO^E>N5Y'\?O\ D5]-_P"OO^E;8?\
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M;_U]_P!*]<KR/X_?\BOIO_7W_2ML/_%0GL>!T445ZY 5U'PZT^TU7QW865]
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M,/E-)<Z/J=G80W]S92Q6<_\ JIF'RO\ 2O6O",9\=_#6Z\.2R$7MK<AY=PZ
MGH*R_C+?BT;2O"]N,6MI"'_X$*:JMSY+:_H*QY=%')/,D,*,\LC;411DL?2M
M:]\)^(M-M)+N]T>Y@MXQEY&'"CWK9^&>E:CJGBY!IES':S11EO.DCWA?P]:]
M=\-7FG:A_P ))91&XO'BA87=S.Q*228Y 4]**M9P=D-(\$L_#FMZC;+<V6ES
MSP.<+(@X)J/5-#U;1 AU73YK02?<,@X:O9/#UQ+;?!;4V@D:-E9PK*<%>>U1
MZVTVJ_!339[IQ-<B5%2609()..M+V[YK6TO8+'E-IX1\1ZA:I=6>C7,T#C*.
MHX8>U;GPUT."]^(<6EZU9!T$3EX)1T('>O26G.@:WX<TS6+NXU'4Y67[/';9
MBC@3U8#K52%$3]I1U0  V9) ]=M2ZSDFO)A8\Q\4>'+VVUW6+BSTV1-)M[AD
M$BCY$'I62FB:K)IG]II83-8?\_ 'RU[-X=N(M<U7QIX0N"<33,ZDGU["L_X@
M-'X/\$:-X6MP[NS^88P>7 /2G&L[J%M?T"QYI;>#_$MY;+<VVBW4L+C*N!PP
M]JT_ MM;P>*Y;?6-"GU()$0;1$RRMZD5ZS!XBTGQ%%I5A:7UUHFMPQC[.DB%
M4!QR"#PU9OA73=6TSXV78U>:.>::U9EFC7;Y@]<=J3K-Q:DK!8\B.C7^L:WJ
M$6CZ9/(J3-^X4<Q+G@&H-2T'5]&"'4]/FM0YPID'!KU3P?XITS1+WQ-;:M:W
M44$UTX-Y#&3D9Y&1TI/'>CZI<>"([W3M:34M"1Q)%'(OSQK_ +W4FJ]JU)1:
MT"QY7>:'JVG6L=U>Z?-!;RC,<CCAA[50KH];\4>)M8T>ULM6606,2@0EHMH(
MQQSWKG*WC>VH@HHHI@':OI;X*_\ )-K3_KK)_,5\T]J^EO@K_P DVM/^NLG\
MQ7+C/X?S''<]"HHHKS"PKP;]H#_D+Z)_UR?^=>\UX-^T!_R%]$_ZY/\ SKHP
MO\5"EL>04445ZI 4444 %%%% "-G'%>]^'M+NQ\)XI/"$T7V\MOD?:"S$=5K
MP4G S7?:!;>//!VFQZQHT8FL+H@F.+]Z#[8[&L:T;I:@C-\7>)-5\4:A!I^H
MZ+%;:M;D1'RUP[GT-:'_  J?6 ZP-J>GK?M%YPL2W[TC&<8]:]$\5W=E)-X0
MU:^M8;#4IKM))T; 95]ZDUK=:?$Q+VP\)37NH-#NBO\ SR(BN/R%8JLTDHJV
MX['C6@^#=8\0:G-800_9W@)$SS<+'CUJ_J_PZU32M%?5H;VSU&TC;:YM6R5^
MM>G^&=1&OV'BZS5(K;5IW8^5&^<_0]Z\PL/"?BBSLVU.=);;1X)LSI+(4#@'
MGY>]:*I)MW=K!833OA[J-[I$&IWE_9Z5!</L@%XVTR>A%4-2\'ZKI/B6VT.[
M15FNG"P3_P#+.3/<'TKT3XJ6\NO:/X;O='@>[LB451 NX1GCJ!TK3\97=K%>
M>#-)F97U6.:,L!RR#T/I4JM)V?>_R"QQ;_!_68]3739-5TY;MUW1Q%N7'M7-
MVGA#5[WQ6_AR"'=>QOLE;^&/W/M7JVLEC^T?IH)) ME('IQ5[09+6U^,GB*#
M>L=S<QG9N.-Q]J2K32N^UPL5OACX6?PW-K<4U_97SF,AQ =WED#H:\VM/!=_
MXDO=5OHKBWL[*WE.^><X7.>E>A?"S2M2T[5_%S7MK-%N9\&12-_7IZU!HN@6
MUAX8U'Q%'#-J5]%<LR6J,2@Y_B3O4\[C*3OKH%CSS7O >J^'Q8R2S0W5M>G;
M'<0?<!]ZUKOX3ZGIT4$FH:UIEHL^/*\UL;B>U>A>/#=R?#W19+R%8IFN8V9$
M7 3/08[5A?' ,NFZ Q'* ,N?454*LY-+O<+'!ZYX%U30-=T[2+F6&6;4/]0\
M?W357Q3X6N_".HK87US!+.5#$1'[H/K7N_A'[#XP\/:/K-WY;W>G+AV/.W%>
M%>--7?7/&&H7KC&)#&OT'2KI5)2EROIN#0OAGPAJ/BIK@VCQ6]O;KNEN)CA%
M]JM:WX"U#1-%CU@7MK>V#OL\VW.0#[UU7PQT6UN/"NJ:T\,]W=V;DQ6<<A D
M^J]ZZ#Q*VJW?P/>74K%;:Z:X5C!%'M"+GCBE*K)3LMKV"VAPP^%6JBSLKJXU
M73[:.] \GS6QDGM]:Q]:\$ZQH6OV^C7*))/<$"%T^Z^?2O0?BAN7P#X1(R")
M8\$=CQ6OXVTBWUOQMX1L[NX:")[7)<-M)/H#ZTHUI:-^?X!8X7_A4&M&66W3
M5-/>\BC\Q[96RX%=%\+H6M_ WBJ*>("6,LI#+R#@BNW\/"[L_&M_I,.FM!I]
MM!E;B5=SRD_[?>L'PO&PL/'8*$$2MQCV-9RJRE%I^0['E6N^!]5T33K+4Y7B
MGM;YL(T7.PG^]4^J?#K6-(33?.F@DFU%@L,*'YAGUKT+X>F#QKX)F\.W,Q%Q
M8W*R[B.@SD"L7QAK5SJ'Q?L4TG8T^EL(D21]J%A6JJSYN7M?_@"L9+_"'6@U
MQ#'J>GRW=O'YDEJK?.!C.*P_#_@C5O$)O&0QV5O9Y\Z>Y.$4^F:]C46WC#Q#
M-IOB/0+O2-3MXRZ75NY5)%QR2XZX]ZS?"L%F/ 'B725B.KB&ZDW01R8>9/7-
M2J\[:[Z!8\MU_P %:GH%K:78EAU"SNN([BU.4SZ?6MR'X2:S(MHLNI6%O<W:
M;XK:5L.?;ZUOZOJVH6O@"PL;/PVNDV<DZFU-S-EU?/4J><5U4=[=ZU/8:'XL
M\.2(\L8\K4+5MW..H8=*)59I!8\=TGP-JNL>*;KP[&\,-];*6D,A^7BL34K"
M72]2GL9V5I86*,5/!(KM]>\%ZC_PL*[TKPO>R37&SS&)FPR+Z%N]</J%K=66
MH36U[G[5&Q63)R<_6MX2YNHBM1116@!1110 4444 ,E_U3_2OKGP%_R(>B_]
M>RU\C2_ZI_I7USX"_P"1#T7_ *]EKCQOP(<=SHJ***\XLY_QW_R3SQ+_ -@J
MZ_\ 135\05]O^._^2>>)?^P5=?\ HIJ^(* /I_\ 9Q_Y)YJ'_85D_P#145>P
M5X_^SC_R3S4/^PK)_P"BHJ]@H **** "BBB@ KR/X_?\BOIO_7W_ $KURO(_
MC]_R*^F_]??]*VP_\5">QX'112!U8D YQ7KF8M:6@:W<^&];@U:S1'GASM5^
MAS68S*O4XHW#(&>30U=68S3U[6[GQ%K$VIW:(D\QRRIT%2^&O$5WX4UM-6L8
MXY)U0H%DZ8-9%%+E5N7H!L6_B6\MO%__  DR1QF]\XS;#]S)K=M?BCK=GK&I
M:G';6IFU  2J1P,#'%<512<(O= =7I?Q"U;2-)OM-MX+=H;UF:0L.03UQ3+?
MQ[JEMX4E\.)! ;.7.7(^;FN6#!NAS06"C).*/9Q[!<[RV^*^KP6=E;S:;873
M62[;>:9<LG&.*@N/B?K5UXAM=<DM;7[9;)L7 X(]ZXN@D 9/2E[*'8+FSJ-U
MJOC?Q+)<I;J=0N?^6<9P!7JOQ#U:?0?ACI6A32J][/&L<ZALE0*\2BE>-A)#
M*\;=F1L'\Z=)--.VZ>>64^LC%J4J=VNR"Y%C:F,9Q7KOA[4I;'PY#I]QXET"
M[MFQ((+U2QC/7'X5Y)3&6,<LJ\^U.<.=6 ]:U0RZOXBLM:N/&FAB6R8-#"JX
M1<=J2\4WOC&/Q1)XOT(7J*JA #LP.E>3^6G]Q?RH\M/[B_E4^R\_P"YZ_<W$
MEUXM@\2OXNT$7D(VJ@!VFB*ZNH/%5QX@B\;:(D]P,2P 'RW^HKR#RT_N+^5)
MMBW;=JY],4O8^?X!<]IU#5)+S2I].MO$_AO3HIVWR-;(06/K4\&OW$=E:V]Q
MXF\-W<EJ,17$RDNOOFO$/+3^XOY4>6G]Q?RI>P7<=SUS6Y9]<UBTU9_&FB6M
M[:XV2P9!(]#6E+KCLUU/!XA\,6U_=1[);V)#YA]_K7B/EI_<7\J/+3^XOY4_
M8+:XKGOGPQ\)R>';BYUY_$5G>V$ZLSR1'&XCJ37!>-=+M-3U/4]=7Q;I]UN8
MO%;+G?C^Z*X5)[B.+RH[F9(O^>:N0OY5$$0'(4 _2B-)J;DV%S8\->);_P +
M:JNI:?M\T+M*/T(/K761_&'6;=9UMM)TV 7&3*(UQO)ZDUY[15RIQD[M =3;
M>/\ 5;3PQ<>'XX+<VDY8LQ'S#)S22^/=5E\*1>'## MI$P99 /GR.E<O13]G
M'L!Z GQ?UL+;M)IMA-<VZ!([EURX'UK/;XD:LWBZ/Q-]CM1?I$8B /E88QS7
M'T4E2@N@7/2_AO::UX@^(7_"3C9!:&8R7;!@%;_9%9'Q-\1G7/&\TMK<![>T
M;;!(G8CK7(1W-S"A2&ZGB0]5CD*@U%25/W^8+G=Q?%?5A%:BZTO3[R>U&(KB
M9/G%4+3XBZW:>+)O$9$4UW*AC\N3[B+[5R=)N&[;GGTI^RAV"YU>C?$'5]%G
MOV2*WN8+YR\MM,N4!/7%&N?$#4];T:/25M;;3[)&W>7:C ;V-<K13]G&][ =
M/KWCO4_$6BVNE7=O;QP6RA4:,8)P,<US%%(6 ;&>:<8J*L@%HHHI@':OI;X*
M_P#)-K3_ *ZR?S%?-/:OI;X*_P#)-K3_ *ZR?S%<N,_A_,<=ST*BBBO,+"O!
MOV@/^0OHG_7)_P"=>\UX-^T!_P A?1/^N3_SKHPO\5"EL>044JHTCA$4LQX"
MCJ:FNK*\L75+VUFMG<9595VDCU%>J00458@T^^NHFEMK*>:).6>-,A?K3397
M:VPN3:RBW)P)2ORD^F:+H"&BBB@ K4T[Q-KNCVWV;3=5N+:#.?+0\9K+I0"S
M!5&6)P .YH:3W M:CJFH:Q<"?4KR6ZE48#R'D"M!?&/B9+7[*NMW0@V[-F[^
M'IBLFXM+FSD\N[MY()",[9%P<4L%G=W22/;6TLR1\R,BY"?6E:-@'6-_>:7<
MBYL+F2WG'21#S5S4?$NNZQ;_ &?4M5N+F#.?+<\9K+J6WMKB[E\FU@DGE(SL
MC&30TMV!?TWQ+KFC6YM]-U2>V@)W>6AXS5274;V?4O[2ENI'OMV[SV/S9]:@
M='C=HY%*.IPRD<@TVBRW T)->U>755U6349FU!!M6Y)^8#TJ*35=1FU-=3DO
M96OU;<+C/S ^M5*F@L[NZ1WM[669(QEV1<A1[T62 UW\;>*9/OZ[='C'7M5:
MP\2ZYI8D%AJEQ;B1MSA#]X^M9=%'+'L!JWGB;7M0@$%[JMQ/$&#A'/ ;UJ"_
MUG5-8$,>HW\MRJ$!/,.0E4:FFLKNWA2:>UEBBD^X[K@-]*+) >J:=J^A>!OA
MOJ%E9ZPFH:GJ!&5@/^K)'7\*\E!8\NVYCR2>YI J@Y"@'Z4M3""C=]P+^FZW
MJNC,S:9?S6I;[WEGK5FY\6^(KR)XKK6+F6.3[Z,>#6/15<JO>P%Z\UK5-0MH
M;:\OI9X(#F*-SPA]J6[US5M0GMY[S4)II;;_ %#L>8_I5"BBR WF\;^*V*DZ
M]=DKT.ZJ:>(];A%SY>ISK]J.;C!_UGUK-HHY8]@/6/AS?:-X-TS4]4N]=M9;
MJYB_=6R?>5L=Z\ON[Z>^U*:_E8B>60N6![YXJJP13D@ ^N*=4Q@DW+JP-Q_&
MGB>2W-N^N71A*["N>J],5G:;JNHZ+,TVF7LMK*PPS1GJ*J457*MK 7M4UG5-
M;>-]5OIKMHQA#(?NCVJ[;^,O$UI;I;V^MW4<*#"H#T%8E%'*K6L!>MM;U6RU
M&34;74)HKV08>=6^9JJSSRW4[SSR-)*YRSMU)J+<"V,\^E+3L@"BIK>TNKQF
M6UMI9V4;F$:Y('J:A(()!&"."/2@ HHHH **** &2_ZI_I7USX"_Y$/1?^O9
M:^1I?]4_TKZY\!?\B'HO_7LM<>-^!#CN=%1117G%G/\ CO\ Y)YXE_[!5U_Z
M*:OB"OM_QW_R3SQ+_P!@JZ_]%-7Q!0!]/_LX_P#)/-0_["LG_HJ*O8*\?_9Q
M_P"2>:A_V%9/_145>P4 %%%% !1110 5Y'\?O^17TW_K[_I7KE>1_'[_ )%?
M3?\ K[_I6V'_ (J$]CPFS :_MU894R $'O7L7Q*\.:4?"-M/I]K!;W-G$LTW
ME+@LI'>O';+_ )"-M_UU%>Z7,D%S\0&T*YP4U328XP#TR!7?6;4DUT)1C_"+
MP[83>'[W4-6T^*=I7Q;B5<Y7'45S,RQQ>"O$$:Z!O5;HA=1&,0C/2O1=+C&A
M^)M,\,0ON2VLI#*?5N<5S4&T_#'Q(KG]V=1 ;/3&[FLU)N3EWL!P.E^"/$FL
MV2W=AIID@;A79PN[Z9J.Q\(Z_J<]S!9Z<\DMJVV=2<;#7:_$^ZO]/OO#L>E2
M2PVBVJM ("0I?CTZUI^"KC6WT7Q?=:R)8[]X5RSKM8C'!K1U9<O-H*QYR/!W
MB!M6.EKI^Z\"[RBN" /4GI4.J>'-7\/W5LFK69@$QRASN5A]17<^#Y)%^$'B
M&Y@D=K_)#2;B7"9]>M+922WGP3WZD=ZQW2BVDE.6]^3S3]I)/YV"Q:\<^![W
M4H-(?P]I,0!MD:4H0FXX]^M<QX)L[C3O$NHVE[X>?4IX[9@UL?\ EF?[W-=+
M\2[O5()?"BP231P;(C&8R1N;C(XKL?E_X6.S+@3MHQ,V.#G'>LE-JG9];CMJ
M>'Z?X:UGQ%>WO]DV!D$,AW@G:$SVR:TO#WA^[TSXAZ1INMV.S?+\T4G*L*ZS
MQ,[V7PEA?269(WNW-Q)&<-NSQDBMEF>XL_ -U>8-^TH!=OOE<=ZMU6UY:H+'
M!>+] N+_ .)%_I>AV )'*Q1C"J/Z5A:SX7UOP]'')JEB88Y#A7#;@?Q%>R2?
MNY_'D]IS>J ,]U7O@UROAZ>2^^"FH->N9DCN@(GE.2#NY )HA5=EVT06.-L/
M!/B/5+!;ZSTXO;.,HS.%+?0'K70^$M(O]"U?4+/5?##7]P;;>(21F)2/O5L_
M$&>ZMM?\'1V3O'&(D\E(B0K'CTZUV3M*?B1JS29$IT<;OKMJ959..O4+'A>D
M^&-:\0/.VEV1F2-V#$L%"\],FH=0T'5=*U1-,O;*2.\?&R,#.[/3!KT#7'>U
M^"UD]@QCWW9\]XC@YSW(K+\-)XJU_P 2:-;WES/;*$;[)=21@G:.N">M:JH]
M9=!6,6^\ ^*=.L9KNYTLK#"NZ0JX8J/4@<UT5YI]B/@=9WZVD0O&FP9]OSD9
M]:[3PC;Z3'K/B1+74-2U*\$#)=27:D1YYZ5S.K@#X'1@< 7C8_[ZK/VCDTGW
M0['ERJSNJ(I9V("J!DDUT-UX"\465DUW<:65A1=[8<%@/7'6K_PLBMY?'UB)
MU1B-Q0/TW8INJZGXH3QUJZZ<]RU\VY)(DRP\O/ITK:4GS<J$8-[H.JZ;9VEW
M>6C16]V<0.3]^IY?"FNP7]I8R6#+=7B[[>//WQZUWOQ'68^#?"!D5MXE ?CH
MWI70:P'7XE>"@V0PM!P>W%9^V=D_7\!V/)M1\&^(=)C1[[3S'O?8JA@6+>F.
MM2WG@/Q/I]C)>W.F%8(UW.5<,5'N!S7=Z5-)=_'Z1;J5I$!?:CME01TP.E7]
M/U;P]I?CS6I8[C6]2OI-R7-GY6Y%X_E2=6:Z=+A8\4SQFMS2O!OB'7++[9I^
MGF2W+;0[L$R?;/6L:^93>7CA2JF9R%/4#/2O5I])M;+0_#C:_KNIMYY5[2SL
MT^4<\9Q6M2;BE82.;\'> [C5_&#Z-K-M+"D(_?A6P5^GK7/^)=%F\/>(KS39
MH]BQN3$"V28^Q->W:@0GQFT<C,>^U&1G&[CO[UX?XE=G\5ZP6=F(NW&6.<<]
M*BE.4Y7>U@8V/0=4ET=]72T8Z>C;6FSP#2KX?U9]+M]36S8V5R_EPRYX9O2N
M_P!,)D^!NH;"6"7/S =JL012P_"/PLDJ-&WV]2%;CC=0ZK_&P6.%OO _B33+
M-[N]TTPPI]XEQG\NM2+X!\4M8?;AI3?9]GF9W#=MZYQUKO/&<IF^-&D0W,K&
MV*J&1F(4].HK5US4-'T[XFK/+?ZTU]$%"64$68F7T Z$5/MIV7FKCL<3X(\
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MI:-KEMJXLFVW$<*X*>IKH/B*V[X<>%.>,5U.DVLD/@GQ,%\.Q:&I1\1*V6F
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M5-\1+.TAU%M"\.0Z7>Z@NV6X5]V![#M7"T5,H1D[L!& <DN Q)R21WH"J!@
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M: %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ':OI;X*_\
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M J]_[\FBZ IT5<_LC5O^@5>_]^31_9&K?] J]_[\FBZ IT5<_LC5O^@5>_\
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M_P#9Q_Y)YJ'_ &%9/_145>P5X_\ LX_\D\U#_L*R?^BHJ]@H **** "BBB@
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M]<_\&,W_ ,5110 ?\)WXP_Z&O7/_  8S?_%4?\)WXP_Z&O7/_!C-_P#%444
M'_"=^,/^AKUS_P &,W_Q5'_"=^,/^AKUS_P8S?\ Q5%% !_PG?C#_H:]<_\
M!C-_\51_PG?C#_H:]<_\&,W_ ,5110 ?\)WXP_Z&O7/_  8S?_%4?\)WXP_Z
M&O7/_!C-_P#%444 '_"=^,/^AKUS_P &,W_Q5'_"=^,/^AKUS_P8S?\ Q5%%
M !_PG?C#_H:]<_\ !C-_\51_PG?C#_H:]<_\&,W_ ,5110 ?\)WXP_Z&O7/_
M  8S?_%4?\)WXP_Z&O7/_!C-_P#%444 '_"=^,/^AKUS_P &,W_Q5'_"=^,/
M^AKUS_P8S?\ Q5%% !_PG?C#_H:]<_\ !C-_\51_PG?C#_H:]<_\&,W_ ,51
M10 ?\)WXP_Z&O7/_  8S?_%4?\)WXP_Z&O7/_!C-_P#%444 '_"=^,/^AKUS
M_P &,W_Q5'_"=^,/^AKUS_P8S?\ Q5%% !_PG?C#_H:]<_\ !C-_\51_PG?C
M#_H:]<_\&,W_ ,5110 ?\)WXP_Z&O7/_  8S?_%4?\)WXP_Z&O7/_!C-_P#%
M444 '_"=^,/^AKUS_P &,W_Q5'_"=^,/^AKUS_P8S?\ Q5%% !_PG?C#_H:]
M<_\ !C-_\51_PG?C#_H:]<_\&,W_ ,5110 ?\)WXP_Z&O7/_  8S?_%4?\)W
MXP_Z&O7/_!C-_P#%444 '_"=^,/^AKUS_P &,W_Q5'_"=^,/^AKUS_P8S?\
MQ5%% !_PG?C#_H:]<_\ !C-_\51_PG?C#_H:]<_\&,W_ ,5110 ?\)WXP_Z&
MO7/_  8S?_%4?\)WXP_Z&O7/_!C-_P#%444 '_"=^,/^AKUS_P &,W_Q5'_"
M=^,/^AKUS_P8S?\ Q5%% !_PG?C#_H:]<_\ !C-_\51_PG?C#_H:]<_\&,W_
M ,5110 ?\)WXP_Z&O7/_  8S?_%4?\)WXP_Z&O7/_!C-_P#%444 '_"=^,/^
MAKUS_P &,W_Q5'_"=^,/^AKUS_P8S?\ Q5%% !_PG?C#_H:]<_\ !C-_\51_
MPG?C#_H:]<_\&,W_ ,5110 ?\)WXP_Z&O7/_  8S?_%4?\)WXP_Z&O7/_!C-
M_P#%444 '_"=^,/^AKUS_P &,W_Q5'_"=^,/^AKUS_P8S?\ Q5%% !_PG?C#
M_H:]<_\ !C-_\51_PG?C#_H:]<_\&,W_ ,5110 ?\)WXP_Z&O7/_  8S?_%4
M?\)WXP_Z&O7/_!C-_P#%444 '_"=^,/^AKUS_P &,W_Q5'_"=^,/^AKUS_P8
MS?\ Q5%% !_PG?C#_H:]<_\ !C-_\51_PG?C#_H:]<_\&,W_ ,5110 ?\)WX
MP_Z&O7/_  8S?_%4?\)WXP_Z&O7/_!C-_P#%444 '_"=^,/^AKUS_P &,W_Q
M5'_"=^,/^AKUS_P8S?\ Q5%% !_PG?C#_H:]<_\ !C-_\51_PG?C#_H:]<_\
M&,W_ ,5110 ?\)WXP_Z&O7/_  8S?_%4?\)WXP_Z&O7/_!C-_P#%444 '_"=
M^,/^AKUS_P &,W_Q5'_"=^,/^AKUS_P8S?\ Q5%% !_PG?C#_H:]<_\ !C-_
M\51_PG?C#_H:]<_\&,W_ ,5110 ?\)WXP_Z&O7/_  8S?_%4?\)WXP_Z&O7/
M_!C-_P#%444 1S^-/%5U;RV]QXEUF:"5"DD<E_*RNI&"""V"".,5NV'@S3KK
53K6X>:Z#RQ([!67 ) /'RT44 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>img11953243_17.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img11953243_17.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,D V(# 2(  A$! Q$!_\0
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M./\ R3S4/^PK)_Z*BKV"@#Q__AG'P?\ ]!+7/^_\/_QJC_AG'P?_ -!+7/\
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M_P"&<?!__02US_O_  __ !JO8** /'_^&<?!_P#T$M<_[_P__&J/^&<?!_\
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M$M<_[_P__&J/^&<?!_\ T$M<_P"_\/\ \:KV"B@#Q_\ X9Q\'_\ 02US_O\
MP_\ QJC_ (9Q\'_]!+7/^_\ #_\ &J]@HH \?_X9Q\'_ /02US_O_#_\:H_X
M9Q\'_P#02US_ +_P_P#QJO8** /'_P#AG'P?_P!!+7/^_P##_P#&J/\ AG'P
M?_T$M<_[_P /_P :KV"B@#Q__AG'P?\ ]!+7/^_\/_QJC_AG'P?_ -!+7/\
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M_P"&<?!__02US_O_  __ !JO8** /'_^&<?!_P#T$M<_[_P__&J/^&<?!_\
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M$M<_[_P__&J/^&<?!_\ T$M<_P"_\/\ \:KV"B@#Q_\ X9Q\'_\ 02US_O\
MP_\ QJC_ (9Q\'_]!+7/^_\ #_\ &J]@HH \?_X9Q\'_ /02US_O_#_\:H_X
M9Q\'_P#02US_ +_P_P#QJO8** /'_P#AG'P?_P!!+7/^_P##_P#&J/\ AG'P
M?_T$M<_[_P /_P :KV"B@#Q__AG'P?\ ]!+7/^_\/_QJC_AG'P?_ -!+7/\
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M_P"&<?!__02US_O_  __ !JO8** /'_^&<?!_P#T$M<_[_P__&J/^&<?!_\
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M$M<_[_P__&J/^&<?!_\ T$M<_P"_\/\ \:KV"B@#Q_\ X9Q\'_\ 02US_O\
MP_\ QJC_ (9Q\'_]!+7/^_\ #_\ &J]@HH \?_X9Q\'_ /02US_O_#_\:K+\
M2_ +PKHWA75]4M]0UEI[*RFN(UDFB*ED0L <1@XR/45[I7/^._\ DGGB7_L%
M77_HIJ /C./Q%K<4:QQZQ?HB *JK<N  .@ S16910!]/_LX_\D\U#_L*R?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y_QW_R3SQ+_ -@JZ_\ 135T
M%<_X[_Y)YXE_[!5U_P"BFH ^(**** /I_P#9Q_Y)YJ'_ &%9/_145>P5X_\
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M_P"IEUG_ +_4?\*X_P"IEUG_ +_4<L/YOP [BBN'_P"%<?\ 4RZS_P!_J/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %<_X[_Y)YXE_[!5U_P"BFKH*Y_QW_P D\\2_]@JZ_P#134 ?$%%%% 'T
M_P#LX_\ )/-0_P"PK)_Z*BKV"O'_ -G'_DGFH?\ 85D_]%15[!0!6U"X:TTZ
MYN4 +11,X![D#->!#X]>(26_XE=GPQ'4^M>\:U_R [__ *]Y/_037QHO5_\
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MOGQ#_P! RT_,UY;11["EV"[/4O\ A?/B'_H&6GYFNW^&7Q(U/QKJU[:7UG!
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M@CPG91Z)<>(VT^*\N[MC)!$PX0'I4OB_PI;:]X-EO)M.@L-4C("E"!D9KF?
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MV#3F:30;R,*TQ_AKDCS<CLGS,?4ZO0O$'A;QWK%[X:_L:&)45A ZI@@#K2^
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M)X7\$:M/L-S=BV+"20_=/M7SY$28E)ZXKLPW)9\FQ+'T445TB"D  Z "EHH
M3:,YP,T8'I2T4 )M7T'Y48&,8&*6B@!  !@ 4;5_NC\J6B@!  .@%&T>G'I2
MT4"$(!&"!00#U J:VM;B]F\FUA>:3^Z@R:?=V%YI\@CO;:2!ST#BB_0"L5!Z
M@48'H*FMK2YO9A#:0/-*?X4%/N["\T^0)>VTD#D9 <=:+] *Q53U _*@*HZ
M#\*L6EE=ZA*8K.WDGD49*H.E-N;6XLYC#=0O#*.JN,&B_0"' SD<'U%   P
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MUC_KV:OD2'_4K]*]'!?"R)#Z***[!!1110 4444 :.@:/)X@UVVTJ*4123G
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MJ9&#T)/M7,?%V^^UZQI<$DRRW-K;[)BO0,>U9TOBC9?\$;//:***ZA!1110
M4444 %>L? +_ )&35O\ K@O\Z\GKUCX!?\C)JW_7!?YUCB/X3!;GT!1117D&
M@4444 %<_P"._P#DGGB7_L%77_HIJZ"N?\=_\D\\2_\ 8*NO_134 ?$%%%%
M'T_^SC_R3S4/^PK)_P"BHJ]@KQ_]G'_DGFH?]A63_P!%15[!0!1UK_D!W_\
MU[R?^@FOC1>K_P"^W\Z^R]:_Y =__P!>\G_H)KXT7J_^^W\Z]#!;2)D+1117
M:2%%%% !1110!9LM1O-.,QLKAH3.GER[?XE]*73]3OM)=WT^Y:W9QM8KW%5:
M*+(!68N[.QRS')/J:3\3^!HHH ,>Y_.BBB@"W8ZK?Z8)!8W+0"5=K[?XAZ5'
M9WMUIURMS93-#.IR'7K4%%%D!NZEXT\1ZO:FUO=3DDMV&&3&-WY5AHS1.CH<
M,A!4^A%)1222T0%J_P!2O=4G$]_<-/*!@,WI3H-7U"VL)+""Z=+27[\0Z-5.
MBG9;  &!@4444 %%%% !1110 5[)^S[_ ,?>M_1*\;KV3]GW_C[UOZ)6.)_A
M,%N>Z4445Y!H%%%% !1110 4444 <_XX_P"1'UC_ *]FKY$A_P!2OTKZ[\<?
M\B/K'_7LU?(D/^I7Z5Z."^%D2'T445V""BBB@ HHHH GL[RYT^[2ZLY3#<)]
MUUZBGKJ=\FH?V@MPPO,Y\WOFJM%%D!+=74]]=275U(99Y#EW/4FHOQ(^E%%
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MF0RBBBNXD**** "BBB@!58JP93AE.0?2K-_J5[JKQO?W#3M$NU"W\(]*JT4
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M['4 <U%7$4Y0:3!)GH=%%%>:6%%%% '$:;_R5K5_^O*/^8KMZXC3?^2M:O\
M]>4?\Q7;UI4W7HA(****S&07O_'C<?\ 7)OY5\8S_P#'Y<_]=G_G7VE-&)H)
M(B<!U*Y^HKR!_@!ISS22?VU= NY;&T<9-=>%JQIWYB6KGA-%>Z_\,_:=_P!!
MJZ_[Y%'_  S]IW_0:NO^^175]:I=Q<K/"J*]U_X9^T[_ *#5U_WR*/\ AG[3
MO^@U=?\ ?(H^M4NX<K/"J*]U_P"&?M._Z#5U_P!\BC_AG[3O^@U=?]\BCZU2
M[ARL\*HKW7_AG[3O^@U=?]\BC_AG[3O^@U=?]\BCZU2[ARL\*HKW7_AG[3O^
M@U=?]\BC_AG[3O\ H-77_?(H^M4NX<K/"J*]U_X9^T[_ *#5U_WR*/\ AG[3
MO^@U=?\ ?(H^M4NX<K/"J*]U_P"&?M._Z#5U_P!\BC_AG[3O^@U=?]\BCZU2
M[ARL\*HKW7_AG[3O^@U=?]\BC_AG[3O^@U=?]\BCZU2[ARL\*HKW7_AG[3O^
M@U=?]\BC_AG[3O\ H-77_?(H^M4NX<K/"J*]U_X9^T[_ *#5U_WR*/\ AG[3
MO^@U=?\ ?(H^M4NX<K/"J*]U_P"&?M._Z#5U_P!\BC_AG[3O^@U=?]\BCZU2
M[ARL\*HKW7_AG[3O^@U=?]\BC_AG[3O^@U=?]\BCZU2[ARL\*KUCX!?\C)JW
M_7!?YUN_\,_:=_T&KK_OD5U'@;X9VO@?4;J[M[^:Y:X0(5D&,5G6Q%.4&DP2
M=SNZ***\XL**** "N?\ '?\ R3SQ+_V"KK_T4U=!7/\ CO\ Y)YXE_[!5U_Z
M*:@#X@HHHH ^G_V<?^2>:A_V%9/_ $5%7L%>/_LX_P#)/-0_["LG_HJ*O8*
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M* "BBB@ HHHH **** &R2)$C/(RHBC)9C@"J?]LZ6?\ F(VG_?Y?\:S?'/\
MR(^L\D?Z,W2OD.('RE_>2=/[YKIH8=54W<3=C[/_ +9TO_H(VG_?Y?\ &C^V
M=+_Z"-I_W^7_ !KXSP?^>DG_ 'V:,'_GI)_WV:W^I+^8GF/LS^V=+_Z"-I_W
M^7_&C^V=+_Z"-I_W^7_&OC/!_P">DG_?9HP?^>DG_?9H^I+^8.8^S/[9TO\
MZ"-I_P!_E_QH_MG2_P#H(VG_ '^7_&OC/!_YZ2?]]FC!_P">DG_?9H^I+^8.
M8^S/[9TO_H(VG_?Y?\:/[9TO_H(VG_?Y?\:^,\'_ )Z2?]]FC!_YZ2?]]FCZ
MDOY@YC[,_MG2_P#H(VG_ '^7_&C^V=+_ .@C:?\ ?Y?\:^,\'_GI)_WV:,'_
M )Z2?]]FCZDOY@YC[,_MG2_^@C:?]_E_QK-UUM&US1KFPFO[-EE0@9F7@]CU
MKY%P?^>DG_?9HP?^>DG_ 'V:%@TG=2#F/9?A5X8L=,U^_O[^]M,6TABA#2 <
M^HKV?^V=+_Z"-I_W^7_&OC/!_ON/HQHP?^>DG_?9JZF&]I+F<@3L?9G]LZ7_
M -!&T_[_ "_XT?VSI?\ T$;3_O\ +_C7QG@_\])/^^S1@_\ /23_ +[-1]27
M\P<Q]F?VSI?_ $$;3_O\O^-']LZ7_P!!&T_[_+_C7QG@_P#/23_OLT8/_/23
M_OLT?4E_,',?9G]LZ7_T$;3_ +_+_C1_;.E_]!&T_P"_R_XU\9X/_/23_OLT
M8/\ STD_[[-'U)?S!S'V9_;.E_\ 01M/^_R_XT?VSI?_ $$;3_O\O^-?&>#_
M ,])/^^S1@_\])/^^S1]27\P<Q]F?VSI?_01M/\ O\O^-']LZ7_T$;3_ +_+
M_C7QG@_\])/^^S1@_P#/23_OLT?4E_,',?9G]LZ7_P!!&T_[_+_C4D&HV5U)
MY=O=P2OC.U) Q_2OB_!_YZ2?]]FO1O@?G_A8;99S_HK=6)J)X11BY7V&I'TG
M1117$4%%%% '$:;_ ,E:U?\ Z\H_YBNWKB--_P"2M:O_ ->4?\Q7;UI4W7HA
M(****S&!( ))P!5+^V-,!(_M&TR.#^^7_&IKW_CQN/\ KDW\J^,)P?MES^\D
M_P!<_P#&?6NBA0]K?6UA-V/LG^V=+_Z"-I_W^7_&C^V=+_Z"-I_W^7_&OC/!
M_P">DG_?9HP?^>DG_?9KH^I+^8GF/LS^V=+_ .@C:?\ ?Y?\:/[9TO\ Z"-I
M_P!_E_QKXSP?^>DG_?9HP?\ GI)_WV:/J2_F#F/LS^V=+_Z"-I_W^7_&C^V=
M+_Z"-I_W^7_&OC/!_P">DG_?9HP?^>DG_?9H^I+^8.8^S/[9TO\ Z"-I_P!_
ME_QH_MG2_P#H(VG_ '^7_&OC/!_YZ2?]]FC!_P">DG_?9H^I+^8.8^S/[9TO
M_H(VG_?Y?\:/[9TO_H(VG_?Y?\:^,\'_ )Z2?]]FC!_YZ2?]]FCZDOY@YC[,
M_MG2_P#H(VG_ '^7_&C^V=+_ .@C:?\ ?Y?\:^,\'_GI)_WV:,'_ )Z2?]]F
MCZDOY@YC[,_MG2_^@C:?]_E_QH_MG2_^@C:?]_E_QKXSP?\ GI)_WV:,'_GI
M)_WV:/J2_F#F/LS^V=+_ .@C:?\ ?Y?\:/[9TO\ Z"-I_P!_E_QKXSP?^>DG
M_?9HP?\ GI)_WV:/J2_F#F/LS^V=+_Z"-I_W^7_&C^V=+_Z"-I_W^7_&OC/!
M_P">DG_?9HP?^>DG_?9H^I+^8.8^S/[9TO\ Z"-I_P!_E_QH_MG2_P#H(VG_
M '^7_&OC/!_YZ2?]]FC!_P">DG_?9H^I+^8.8^S/[9TO_H(VG_?Y?\:/[9TO
M_H(VG_?Y?\:^,\'_ )Z2?]]FC!_YZ2?]]FCZDOY@YC[,_MG2_P#H(VG_ '^7
M_&C^V=+_ .@C:?\ ?Y?\:^,\'_GI)_WV:,'_ )Z2?]]FCZDOY@YC[,_MG2_^
M@C:?]_E_QJ6WO[.[8K;W4,S#DB.0,1^5?%V#_P ])/\ OLUZQ\ L_P#"2:ME
MF/[A>K$]ZSJ850@Y7&I'T#1117&4%%%% !7/^._^2>>)?^P5=?\ HIJZ"N?\
M=_\ )//$O_8*NO\ T4U 'Q!1110!]/\ [./_ "3S4/\ L*R?^BHJ]@KQ_P#9
MQ_Y)YJ'_ &%9/_145>P4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <_X
MX_Y$?6/^O9J^1(?]2OTKZ[\<?\B/K'_7LU?(D/\ J5^E>C@OA9$A]=7\//"]
MMXO\22:;=NR1+"9,KUS7*5Z3\#?^1]G_ .O4UT56XP;0D=')\'_#,\DEG8ZR
M/MR\!"W0UY/XCT*Y\,ZW-I=T=TL?.Y1U%>YZ5\-K>U\=S^(O[?-P4F:8VR-]
MSV-<?J6O)XD^+/GZ?I']J1VX\M8B,98=<UA2JROO=6&T>7/9W<5LEP]M*L+_
M '7*'FH?F[(Y^BDU]4Z-#=:F\]OK&GV$,#+A;5-I:.N5^&^G:?#<>)(GLX9(
MH+AMH= 2 .U-8G1NVP6/!3:W(MA<FWE$+' <H:;%#+<2B.&-I'/91FOH;PGX
MHLO&;:[I$NC6\$-BC!2$'-9O@&PTWPYX(U#Q&UHDT[2R<,N<8/ %-XAJ]UK_
M )A8XCP1\/[?Q+HFJ7E\TD,]F2%7&.U<++;NM]);1(TC*Y4!1G-?1'@OQ;#X
MN\+:S>II\=I)'N1@@X;@\UA^%=.T_P *>#-6\5S6L=W>!F(WC( STJ56DG+F
M7R"QXC<6\]I,8KB%XG SAE(I@5V8*L4C$\#"G!KWFSN;'XG_  ]O[F[L(H+J
M&-F#HH!X&>M);ZO9^%/@UIVKOI5O=21D)AD&2=QY)J_;O:VM[!8\+>UN8YEB
M>WE$C=%V'FDEMYK:X2*YB>(DC(88XKZ.UCQ!96W@BS\5?V/;M<2*I";!QFL#
MXI6]EJ?@[1M8-I'%<.Z.-B@=<<&E'$-M)KR"QYSXLTKPM8:;8R:!=2SW,B S
MJP/!Q7)8D_YXR_\ ?LU[M\1I;70M!T348+"WW(B,P$8&[@=:W?"WB*/4O#\^
MNZUH]EI]A&N4W1KEQZBDJS4.:UPL?-G(ZJP/H1S^5326=W% L\EM*L3_ '6*
M'FO6/!$>D_$#XE:AJ<EG&MK:+N@C485N>I%>CP_Z9>W-IJEOI:::ZE$4.N4I
MSQ'*[6!(^6T1Y9%CC1G=C@!1G)KOO /P_A\4->KJ/FP/;J2%QCFN_P#"'AK2
M?#"^(M76**[6U9F@SA@!@G K3^'?C.W\90W]T-.CM)T4@E!U%34KR<7R+;J"
M1\Z7T(M-0N[=>5AD9!]!7H?A#X<:=J?AU=<U[4!;6DS!8<>M<#JX+:]J"#DM
M<LH'N37T)X)T..#P'8:7XF,:J[B2&)VQCN*TKS<8*S!(\9\>>#SX.U>*W283
M6UPGF1-Z"N6KV/Q[X7UCQ/=:AJUW_HEKI2%($_YZ+7C:MN4'UJZ4^:.KU$Q:
M]%^"'_)0V_Z]6KSJO1?@A_R4-O\ KU:BM_#D"W/I.BBBO&- HHHH XC3?^2M
M:O\ ]>4?\Q7;UQ&F_P#)6M7_ .O*/^8KMZTJ;KT0D%%%%9C(+W_CQN/^N3?R
MKXQG_P"/RY_Z[/\ SK[.O?\ CQN/^N3?RKXQG_X_+G_KL_\ .N_!?:)D,HHH
MKN)"BBB@ HHHH **0L!U(%+D$9S0 44W>O\ >'YTX$'H: "BD) ZG% (/0@T
M +1110 44A8#J0*7K0 44FY1_$/SHW+_ 'A^= A:*3(SC(S2T#"BBB@ HHHH
M *]8^ 7_ ",FK?\ 7!?YUY/7K'P"_P"1DU;_ *X+_.L<1_"8+<^@****\@T"
MBBB@ KG_ !W_ ,D\\2_]@JZ_]%-705S_ ([_ .2>>)?^P5=?^BFH ^(****
M/I_]G'_DGFH?]A63_P!%15[!7C_[./\ R3S4/^PK)_Z*BKV"@ HHHH ****
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M@ KUCX!?\C)JW_7!?YUY/7K'P"_Y&35O^N"_SK'$?PF"W/H"BBBO(- HHHH
M*Y_QW_R3SQ+_ -@JZ_\ 135T%<_X[_Y)YXE_[!5U_P"BFH ^(**** /I_P#9
MQ_Y)YJ'_ &%9/_145>P5X_\ LX_\D\U#_L*R?^BHJ]@H **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M.?\ ''_(CZQ_U[-7R)#_ *E?I7UWXX_Y$?6/^O9J^1(?]2OTKT<%\+(D/HHH
MKL$%%%% !1110 =*0'<"5Y ZD=JTO#]O%=^(+.WG0/$[@,I[BO2-9UGP[X;\
M7QZ!:>'+>6"0HDSOU^;N*B4[.R5P/)@01D45TOCW1K;0_%,\%F-MN^'1/[N>
MU9FA:?::GJ:6U[="UA;K(>U4I)QY@,VBO16\!^%!NQXG0XZ?-7!ZA;Q6NH30
M02^;$APLG]ZE&:EL!I>&?"]]XHOF@M<)#&-TLS'"H*VM=^'-SI6ERZA8WT6H
M00_ZWRSDK^%;'P]EAU#P7J_A^"9(=3G!,98XW#TS6S\-O!NIZ!'JIUEU5)H&
M18F;)8@>E8SJN+>NW3N-(\Y\+>$;WQ3)*\;""SA_UMPYP%-7/$O@*[T'3QJ-
MM<I?66=KR1G.TUE?VYJ$%C?Z):LRV]Q<'*)U8@\"NV"-X(^&TUIJ!+7^IG<D
M#G)13WQ52E--?D(SM.^'5K?Z=#=MK\$1D4,4)'%0>)/AX?#VAKJJZDES"QPH
M'?Z5S?A[1[C7=;M-,A>7]Z_S%6/RBNI^)6JP-?6WA^P(^PZ<H4%6SN;OFA\R
MFE<#A1R****V **** "BBB@ KT7X(?\ )0V_Z]6KSJO1?@A_R4-O^O5JSK?P
MY MSZ3HHHKQC0**** "BBB@ HHHH @O?^/&X_P"N3?RKXQG_ ./RY_Z[/_.O
MLZ]_X\;C_KDW\J^,9_\ C\N?^NS_ ,Z[\%]HF0RBBBNXD**** "BBB@#KOAG
M)'%XVA:618U\L_,QP*DL7C'QE@D,B>6+W.\GY?SKC>>Q(/J#BCG^\<^N>:AP
MNV^ZL!I^)65O%NL,K!E-TY!'0\U;\+WFBVEQ(=:BEDC/W?+?;BL'ZDGW-%5R
MZ6 ]#N-9\#-;2K%:WGF%3LS,<9KSZ0J97*#"D_**;@>E%*,5$#M/#GA*T\0^
M')9K#44AUR(\0N^S(]C72V%A-X/\$:NGB:]BFENN(H?-\T@^OM7DP+*<J[J?
M56(I7>21LR2R.?\ :8FIE3<MWH!Z7H\8\<_#C^PENHH-2LIM\*2-@2+Z9I);
M"'P/\/-0L]1FA.K:F-ABB<-@#WKS56=&#([(P[JQ%#,[MN=W<^K,32]GKOIN
M%SU+[%/XM^'.DVOARZCM;JS!%Q;&787]\TW6(1X<^&;Z1KEW'>ZG/,'B17WF
M(?6O+T>2-LQRNA_V6(I"6)RSNQ_VF)H]EKOI>X7 =****U **** "BBB@ KU
MCX!?\C)JW_7!?YUY/7K'P"_Y&35O^N"_SK'$?PF"W/H"BBBO(- HHHH *Y_Q
MW_R3SQ+_ -@JZ_\ 135T%<_X[_Y)YXE_[!5U_P"BFH ^(**** /I_P#9Q_Y)
MYJ'_ &%9/_145>P5X_\ LX_\D\U#_L*R?^BHJ]@H **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH Y_QQ_R(^L?]>S5\B0_ZE?I7UWXYX\#ZSG_GV:OD*%T\
MI?F'3UKT<%\+(D2T4W>G]X?G1O3^\/SKM)'44W>G]X?G1O3^\/SH =13=Z?W
MA^=&]/[P_.@#4\/316WB&RFG<)$C@LQZ"MOQ;?V=Y\2DOK:X62T$L1\T=,#K
M7(%T(P67\Z0-&!@,N/K4.-W<9V/Q'U"SU+Q-Y]C<+/%L WKTZ5A:'J,&EZDE
MS<VJ740ZQN,@UEAHU& RC\:7>G]X?G0HVCR@>AMX^T [L>&+49Z?)7#7]PEY
M?S7$42Q(YR(UZ+57>G]X?G1O3^\/SHC!1V"YVO@631)HKNRU&Y^P7A7-O>$X
M"FNC_M.+PAH][-<^(TUO5+A-D&QLB,>M>3%HV&"5(^M ,8.05S]:F5+F=VPN
M>C_#>RT!)[C6M8U2UAOE)-O#-]T,>YJOXHT)M3GNM8O?&&G7<X!*P1GM_=6O
M/V\ICEBI^M $(.1LS1[-\W-<+GH7@74M+\.>&]3UI[J/^UY$,<%NW4>]<'+*
M]Q-)/(<R2L7;ZFHMT9;=E<^N:7>G]X?G5*-FWW =13=Z?WA^=&]/[P_.K$.H
MIN]/[P_.C>G]X?G0 ZBF[T_O#\Z-Z?WA^= #J]%^"'_)0V_Z]6KSC>G]X?G7
MHWP/93\0VPP/^BMWK*M_#D-;GTI1117C&@4444 %%%% !1110!!>_P#'C<?]
M<F_E7QC/_P ?ES_UV?\ G7V=>_\ 'C<?]<F_E7Q?.Z?;+KYA_KG[^]=^"^T3
M(2BF[T_O#\Z-Z?WA^==Y ZBF[T_O#\Z-Z?WA^= #J*;O3^\/SHWI_>'YT .H
MIN]/[P_.C>G]X?G0 ZBF[T_O#\Z-Z?WA^= #J*;O3^\/SHWI_>'YT .HIN]/
M[P_.C>G]X?G0 ZBF[T_O#\Z-Z?WA^= #J*;O3^\/SHWI_>'YT .HIN]/[P_.
MC>G]X?G0 ZBF[T_O#\Z-Z?WA^= #J*;O3^\/SHWI_>'YT .KUCX!?\C)JW_7
M!?YUY+O3^\/SKUGX LI\2:M@@_N%Z?6L<1_"8UN?0-%%%>.:!1110 5S_CO_
M ))YXE_[!5U_Z*:N@KG_ !W_ ,D\\2_]@JZ_]%-0!\04444 ?3_[./\ R3S4
M/^PK)_Z*BKV"O'_V<?\ DGFH?]A63_T5%7L% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% $%[9P:C936=U&)()E*NA[BN3'PI\&* !HT6![FNSHJHSE'9
M@<9_PJKP;_T!HOS-'_"JO!O_ $!HOS-=G13]K/NQ61QG_"JO!O\ T!HOS-'_
M  JKP;_T!HOS-=G11[6?=A9'&?\ "JO!O_0&B_,T?\*J\&_] :+\S79T4>UG
MW861QG_"JO!O_0&B_,T?\*J\&_\ 0&B_,UV=%'M9]V%D<9_PJKP;_P! :+\S
M1_PJKP;_ - :+\S79T4>UGW861QG_"JO!O\ T!HOS-'_  JKP;_T!HOS-=G1
M1[6?=A9'&?\ "JO!O_0&B_,T?\*J\&_] :+\S79T4>UGW861QG_"JO!O_0&B
M_,T?\*J\&_\ 0&B_,UV=%'M9]V%D<9_PJKP;_P! :+\S1_PJKP;_ - :+\S7
M9T4>UGW861QG_"JO!O\ T!HOS-'_  JKP;_T!HOS-=G11[6?=A9'&?\ "JO!
MO_0&B_,T?\*J\&_] :+\S79T4>UGW861QG_"JO!O_0&B_,T?\*J\&_\ 0&B_
M,UV=%'M9]V%D<9_PJKP;_P! :+\S6CHO@7P[X>O_ +=IFG)!<;2F\$]#7144
M.I-JS86"BBBH&%%%% !1110 4444 -=%D1D895@01[5Q[?"OP:SLYT>+<Q+$
MY/)-=E151E*.S XS_A57@W_H#1?F:/\ A57@W_H#1?F:[.BG[6?=BLCC/^%5
M>#?^@-%^9H_X55X-_P"@-%^9KLZ*/:S[L+(XS_A57@W_ * T7YFC_A57@W_H
M#1?F:[.BCVL^["R.,_X55X-_Z T7YFC_ (55X-_Z T7YFNSHH]K/NPLCC/\
MA57@W_H#1?F:/^%5>#?^@-%^9KLZ*/:S[L+(XS_A57@W_H#1?F:/^%5>#?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KG_'?_)//$O\
MV"KK_P!%-705S_CO_DGGB7_L%77_ **:@#X@HHHH ^G_ -G'_DGFH?\ 85D_
M]%15[!7C_P"SC_R3S4/^PK)_Z*BKV"@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *Y_QW_R3SQ+_P!@JZ_]%-705S_CO_DGGB7_ +!5U_Z*:@#X@HHH
MH ^G_P!G'_DGFH?]A63_ -%15[!7C_[./_)/-0_["LG_ **BKV"@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH *Y_P =_P#)//$O_8*NO_135T%<_P".
M_P#DGGB7_L%77_HIJ /B"BBB@#Z?_9Q_Y)YJ'_85D_\ 145>P5X_^SC_ ,D\
MU#_L*R?^BHJ]@H **0G )/:O%K_Q1XC\8>.+K0=(O8]/@M2?G?@FM(4W._D)
ML]JHKS+PI<>,])\3/I.M+]LL'7*W2]![T[0=0T_1]5U[4)?$WVU%SF Y/DGT
MINE:^H7/2Z*\P\"?$]?$.JW5EJ,L:/O(MPJ_>&:Z[7_&NA^&Y!%J%V%F(R(U
M&32E2G&7+;4+G0T5E:-XCTK7[0W.G7:2QJ,MV*_6L2\^)WA>ROC:27X+*<.R
MJ2%/N:E0DW9(9V%%5[*^MM1M$NK29987&5=3D&JVLZ[IN@69NM2N4@BZ GJ:
M5G>P&C17-Z#XZT#Q'.8+"\5IQSY;#!Q7F'Q-\:O=>)[?1['5FM+-/EN94R"I
MK2%&4I<NPFSW.BL?PS +?P]:J+QKQ2@*SMU<>M<MX4^S1^+]8E7Q)]NZEK7_
M )XXZU*AOY#/0:*Y*3XE^%$MYIEU2-UA;8X4'(-7;;QEHE[H<VK6MZCVT2DL
MPZ@_2ATY+H%SH**\ \)Z[=>+/'SO=:_) OFG[-;KG$H]*];USQSH/AR9;>_O
M )\#]VHR:N=&47R[L29TE%9VCZ[INO6?VO3KE9H>Y';ZUAZA\2O#&FZA]BGU
M!?,4[7*C(7ZFLU"3=DAG6T5R7BOQK9:-X4;5;2ZC=I5_T<CD.:Q/#?CF#Q9X
M/NEN[];6^\M@[*N/+]ZI4I-<W05STBBN-\!2VMGX6>0ZZ-3BC8E[ICT]J=#\
M3O"L^H_8TU%=Y.T,1\I/IFDZ<KM+6P7.PHK+U;Q%I6B6\=QJ%XD,4APC'H:Q
M7^)GA6/4([,ZDA=^ V.,_6DH2>R&==138Y$EC62-@R,,@CN*\T^*OB>\LFL-
M#TR0I<7D@#NIY5<TX0<Y<J!GIM%<RWB#2/"5EIUAJ^I".>9 $,F27/>F6OQ#
M\-W>KG3(M07[1G !& 31R2W2"YU-%9FL^(-,T"T^TZE=)#&>F>I^@K-T/QYX
M?\07(MK*]!N#TC88)I*$FKVT Z6BN:O?'WAJPOKFQN-2C6ZMAF2+N*Y3QY\4
MXM%TVQDT:5)+J=@S1NO2/UJHTIR:20KGJ%%><>)-;T[Q-X-M;FW\1#30Q4M.
M 1\W<5U4>LZ=HGAFVN[[45:W6,#SV_C]Z3IM+S"YNT5S&B>/_#NOW7V6ROE,
MY/RHW!;Z5C 6X^*#2?\ "29?9_R#>>W>A4WJGH%ST"BN7G^(GAB!;@MJ<9:W
M.V10#D'TK0T'Q1I/B6W,NF72R[?O+W6DX22NT,V**Y?6/B%X<T2[^RW5\IG!
MPR(-VWZUI6OB;2+W2'U2WO$>S09:0=OK1R22O8#6HKD+KXG>%+6W28ZFCJYX
MV@FGZ_XXTS3_  =+K=K=QNKJ1;MC(9^PI^SGV%<ZRBN#^&_CU/%FCC[;+&NI
MH298E& J]C5R]^)OA>QOC:2WX+J<.RJ2%/N:;I34G&P7.PHJO8WUKJ5HEU9S
M)-"XRKJ<@U2USQ%I?AVU%QJ=TD*'@ ]3^%19MV&:M%<]H'C;0O$CF+3[U7F'
M6)N&I=?\::'X;=8]0O%29ND:\M3Y)7M;4#H**RM#\2:5XBMC/IETDRC[P'4?
M44S2O%&CZW=W=KI]ZD\UH<3*O\%'*^P&Q17.R^*M+OH=2M-/O4DO;:%RR#JI
M -<K\'?$-]K'AO4;O5;G>8;EEWL>BC-5[-\KEV%<],HKA=2^)'AZX@OK*RU%
M3=HA"$#@MZ9JK\)M:O\ 6=+NY+^8RNDA )/:CV4E%R87/1**\H^)OB34=%\:
M>&[>VN3#:SM^^&>",UU]K\0O#=WK!TN+4$^TYV@'@$^U#I2Y5)=0N=116?JV
MMZ=H=H;K4;E((O5N_P!*RM"\>:!XAN?LUE> S]HW&"1[5*C)JZ0SI:*IZJ5&
ME71:;R%\LYE_N>]<5X+U/3-#\.7=U=>)!J-N)B6N&S\GM34+JZ ]!HKC[CXG
M>%+9H@VIHPDZ,HX%=3:7<%_:QW-M(LD,@RK+T(I.,EN@)Z*P]5\8:%HFHQZ?
MJ.H1P74B[DC;J15&T^(OAB\DG2+44W0_>##%"A)J]@N=517.:'XYT#Q#>O9Z
M?>J\ZY^0C!(J?7_%NC>&D4ZE=K&S_=0<D_A1R2O:VH&Y16+H/BO1_$D+R:;=
MK+L&77H5_"J$_P 1?"]N9E;4XS)"VQT .0:.25[6"YU-%8>H>+M&TK3(;^]N
MUBBF7=&#U;\*9H'C+1/$A9-/NP\JC+1L,$4<DK7L!OT51UC5+;1=*N+^[E$4
M,2DEB,X]*\Z\!_$\^)%U*VU*6.*Z4M]E55QN3!P?Y4XTY2BY+H*YZG17C?@W
MQ]]CU#5I/$%_M@BD*Q \UZ;H/B?2?$EJ;C3+I9D7[P[K]:<Z4H;@F:]%<EJ/
MQ(\,:9??9)K\-(IP^P9"?6M<^)=(_L;^U_ML?V'_ )ZCI4N$ET'<UJ*X^Z^)
MWA.T$1;4T828P5!.!ZUU%E?6VHVD=U:2K+#(,JZ]#0X26K0%BBL[6==TW0+3
M[5J5TD$7;/4_05F:%XZT#Q%<&WL;U3./^6;<$_2A1DU>V@'245S]_P"-O#VF
M7TEE=ZC'%<1C+1G.0*9H7CG0/$5VUKI]ZKSKGY#P31R2M>P7.CHK!U_QCHOA
MK:NHW825AE8UY8U/H7B;2?$<!ETRZ6;;]Y>A7ZBCEE:]M ->BH;JZ@LK9[BY
MD6.&,99F/ %<M:_$WPI=O,$U-%$6<LPP#]*%&3V0'7T5A/XPT*/1EU=[^,6+
M-M$O.":CT_QKH>JZDMC8WBSRLN[Y>F*.278#H:*Y+4OB1X8TN_\ L<^H*90<
M/M&0GUK9E\1:5#HXU9[R,6)&?-'(H<)+H!J45E)XCTJ31'UE+M#8(NYINP%5
MQXPT$Z"FMC4(_P"SG;:LW.":.678#=HKD9_B9X5MYH8VU)#YO1@.!3/'L<^H
M^#9K_2KQD>%/.1XF^\/2FJ;ND]+BN=C17'_#7Q/)XH\)07-R1]JC_=R#OQWK
ML*4HN+:8PHHHJ0"BBB@ HHHH *Y_QW_R3SQ+_P!@JZ_]%-705S_CO_DGGB7_
M +!5U_Z*:@#X@HHHH ^G_P!G'_DGFH?]A63_ -%15[!7C_[./_)/-0_["LG_
M **BKV"@!'8*C,>@&37CVH:!X4\:>)+J71-9DT_5H6_?@?+DU[%7GNO_  GT
MW5=6DU2SO)["[DY8P\!C[UM1DHMW=A,YCPYXAUOPW\0(O"FH7ZZE;W"'9(#G
M9QZU5\ V-O=>*_%EO<1*\7SD@CKBN[\*_#+2_#5ZU^T\UY>,/];-R5/M5OP]
MX!L?#NL:AJ4-S-*]Z29$?H,UK*K#6W85CSOX/6%C)K.L2/'&9X96\G/4<]JQ
M-*75M4^(>M/'I\.HW4;D;+A\!1[9KU&Q^%VGZ9XF;6K+4+J%F?>8%^X:7Q%\
M-+/5]5;5+&]FTZ\<8=H. _UJO;0YF[[H+')^#?#&L6NNZI+<-:6-I=1E9(XI
M@=AQZ=JYR#2-0\+1:CYVF6FKZ:[EGE#@G&?6O6?#7P\TWP_%<[IIKR:Y&)9)
MF.36%)\';43S+:ZU>P6<Y+20 Y'X4E6CS.[T] L;GPUO](U#PP)-'M6M80V&
MB+9VM7!_$$"_^,&C:;J4A&DLJEE8X7->L>'_  _8^&]+CL+%-L:]2>K'U-9W
MBWP1IOBZ!%NB\,\9RD\?WA64*D54<N@[:'F'Q(LK#0O%_AZ?0 D5S+*J2K">
MJY]J;XXTFQ/Q4T> VZ^7<!#*N/O&NW\._"K3]&U1-1O+V?4+A.$\[D+Z5IZQ
MX!L=9\46>O374Z3VN-L:_=.*U5:*:5]DQ6.H@@BM;9((4"11KM51V%>*_#Y0
M/B#XH( ^Y)_*O;^U<AH?P_L=#UO4=4ANIY);X,'5NBY]*QIS2C)/J-GF'PE\
M.Z7K$'B::_MEE:*=U4'H.M7OA;8VSW'B&P:/-JN[$9Z=Z]#\(^ K'PA#J45K
M=33"_<NYD_ASGI^=+X;\!6/AJZOY[>ZFE:\SO#_PY]*UG63YM=[6$D>=?"+3
M+-_$6NS&!3+:LWD''W/I6#X636=5\4ZY,FFP:E=)*RD7+XV+GL#7LGA7P)9>
M%+Z_NK6YFF:\;<XDZ#Z5F:]\,+34=4?4M-OY]-N9.'\G@-ZYI^VBY/S"QQ>A
M:/XAT"#Q#= 6\%O)"Q\B"7=Y9^E3?#/0?#FK>!KNZU;RGN)7832R,-RBO0_"
M_@33?#-M<1I)+=27 Q+),<E@:YF^^#-A->2O9ZI=6EM.V9((S\N/:CVL975[
M>86*FJ:-H,'PLU"/39_MEM;Y,3L<[#[50\'6-BOPCO+I(X_M31.&8=:])L/!
MVE:?X7;0(HR;1U(;/4GUK T?X5V.C6]W;0ZG=O!<J5,;=%SZ5*JQLTWU"QY6
M+BZM/@:YLBR%[[;(5X^7-=5K_A_PU;_!^.ZME@%U'"LL<BL-YD[UWFC_  ^T
MO2?#$^@L\EU:S,6)E'()]*YJ+X*:>MRHDU:\DLD;<MNQXSZ?2K]M!O>VM_4+
M''>(9KB_^#OA^2^RTSOM);KBK'Q#\-:3IGPGL=0M+54O,Q_O1UYZUZCXC\!Z
M=XATFUTUI)+6WMB"@B]J3Q%X$LO$?A.#P_<7,T<$)4B1/O'%2J\4UZA8T?"!
M+>$-)+$DFV3)/TKRWQB _P :=,68'RMJXSTS7L&E:?'I6E6MA$[.EO&(U9NI
M KS?XL>'-1FNM-U[28))I[:4>8D8R2OM449+VC\[C>QA_&V*&;Q5X6CFP(6;
M:Y]%S4/Q7T;0]&T?3+O1!&M]YJA#&V2R\<T?%,MK&L^#7DMY4$^%DC8<KD\Y
MKL8OA!I2ZS%J$U_=SI$P:.W<Y1?:ME-0C!M]Q&+XOU?33_8&GW.D_P!I:Q)
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M[AXK_.\MU7Z4G5ARV3[!9G ^!/"VCW_PZU2\NK199U5V5CV(!Z55\#VT-_\
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M?O &K?A+PS;^$?#\.D6LTDT43%@\G4YK*I54HM7ZC2/+OB$!?_$_2;'4W(L
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M_"4>,?\ H3C_ .! H]F_+[T%SN**X?\ X2CQC_T)Q_\  @4?\)1XQ_Z$X_\
M@0*/9OR^]!<[BBN'_P"$H\8_]"<?_ @4?\)1XQ_Z$X_^! H]F_+[T%SN**X?
M_A*/&/\ T)Q_\"!1_P )1XQ_Z$X_^! H]F_+[T%SN**X?_A*/&/_ $)Q_P#
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M$H\8_P#0G'_P(%'LWY?>@N=Q17#_ /"4>,?^A./_ ($"C_A*/&/_ $)Q_P#
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M>UW_ )]+6C_A;VN_\^EK1_96([+[P_M*AW9[=17B/_"WM=_Y]+6C_A;VN_\
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MX@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!5_0?^1BTW_KX7^=4*OZ#_R,6F_]?"_SJ*GP/T+I_&CZ>HHHKXH^N"BBB@ H
MHHH **** "O(?C/_ ,?NE?[C?SKUZO(?C/\ \?NE?[C?SKORS_>8_/\ (XLP
M_P!W9YA1117U)\V%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4#[Z?[P_G10/OI_O#^= UN?4FF_P#(+M/^N*?^@BK-5M-_
MY!=I_P!<4_\ 015FOB);L^OCL@HHHI#"N?\ '?\ R3SQ+_V"KK_T4U=!7/\
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MW%4PG+!23W=CBLBMC2/#5_KEG=75F%\NU&9,UZ39^#?">M1O9V4=Q^[7*S]
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MU>_0\LM?"FIWFCOJD2K]F09.>M88(->Y^&X;*7P/=1&0I9%FW,>H&>:YZ_\
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MSR5W&N.KA92J.I3ERMZ,ZZ6)C&"A.-TMCTOQ3K]KJ7C_ $6VM9E:WMI0';/
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MU-M+^&.I7$$\<=U&SM&&(SGCM7%ZAX[\1:K9-;W5X/*<?,$&W-<_E@,!V ]
M>**Y886$9RG)7;=_0Z9XF;@H+1)6/7_#D\"_"R>-IX@Y1OE+#/Y5C^"98H_A
MQKZ-+&CMG"E@"?PKSG<V,!V ] W%)E@,!F ] >*S>"TDN;=IFGUOX=-E8]F\
M-16;>!83H+VD=_\ QR3 ;@>_6IO%]RLG@NV66\@FN!/'O*,.N>>*\6CFFA!$
M4KH&ZA6(II9SUD<_5C4?V?\ O.?FZWV_4OZ][G+R]+'J'Q5FAFTW3A'-'(0@
MR%8'%5?A7J"S/>:%/CR)5W >]><$L>KLWU.:[GP?XHT#PUI[R2VK2ZGDD28[
M>E%7#NGA?91]YBIUU/$>T>B-7XI:A'%<Z;H]NVU8&4NHJW\1YH)? =DD<T3L
M ORJP)KS76]6FUS5YM0GX>0\#T%426/!=B/0G-53P?+&G=ZQU%/%WE.R^(]2
M\17T5K\//#LL<D;O Z,8U89_*M/Q%ING^.=)TZ\34HK4PX+"0@9]J\:#,"#N
M8@'(!/%>AVGBOPE=:9;1:KISI/#C_59P<=ZQJX:5+EE"[:;V\_(UI8B-1M3L
ME9;^1UOBZZ32?#&G31MOCA= 6]0.IJU?W&H:V+.]T+5K2*V9!YBR $CWKS;Q
MGXUCU^&*PL(C%8Q#C/4UR,5Q/ K+%/(BL,$!C44<!*5-.6DM=U?<JKC8J;4=
M5IY;'K1GMG\96UEKVKP:@J#=$ H"JWO746KW-KXBD,M[91:<P_<Q)M%?//.<
M[FSZYYJ1YYY<;YY#CI\QK6>7<VG-TMM^78SAC^77EZ]SV?PS<6Z^,?$3-<1*
MK-\I+C!^E>1ZZ0WB"^*D$&4X([U1W.#D2.#ZAC2?4YKIH8;V4W.][I+[CGK8
MCVD%&VS;^\****ZCF"@??3_>'\Z*!]]/]X?SH&MSZDTW_D%VG_7%/_015FJV
MF_\ (+M/^N*?^@BK-?$2W9]?'9!1112&%<_X[_Y)YXE_[!5U_P"BFKH*Y_QW
M_P D\\2_]@JZ_P#134 ?$%%%% 'T_P#LX_\ )/-0_P"PK)_Z*BKV"O'_ -G'
M_DGFH?\ 85D_]%15[!0!4U7_ )!%Y_UP?^1KY<_B;_>/\Z^H]5_Y!%Y_UP?^
M1KY<_B;_ 'C_ #KWLF^&?R/%S;>/S%HHHKVCR HHHH **** "BI;:VFO+J*V
MMTWS2MM1?4UT,?@'7GBE8P(LL?'E%QN-9SJPA\3L7"G.?PJYS-%.EBD@E:*5
M"DB'#*>QI K,<*K,?0#-:$"44[RI?^>,G_?)II[CI0 F?8_E1GV/Y5U6C^++
M#2]-2VGTE+ATZR$=:Z/7+O3SX(%]-I<=O/<G$*@8./6N6>(E&2BX;NVYTQH1
ME%M2V1YG1GZUK>&M#EUW5H[<#$"'=,_9172_$:STZV@TMM.B5$(*L0/O$=ZN
M5>*JJEU9$:$G3=3HCA*,UL>&M&;6]66,_+;Q#S)F[!1UKH_B-9:=:K9/IL2I
M$R###^(>M$J\555+JPC1;INIT1PE%%%;F(4444 %%%% !7J/P8_X^=5^BUY=
M7J/P8_X^=5^BUQ9C_NTOZZG9@/\ >(GKE%%%?*'TH4444 %%%% !1110 5\O
MZU_R']1_Z^&_G7U!7R_K7_(?U'_KX;^=>UDWQ3]$>3FOPQ*5%%%>\>(%%%%
M!1110 445H:9H>I:PDCV%N95B.'.>E*4E%7;L.,7)V1GT5OZGX.U?2K-;N2)
M7AQ\[(V=A]#6!4PG&:O%W'.$H.TE8**<$D896-V'J%S2%'49:-U'J5Q5BL)2
M9J2)!+,D;/L5C@L>U>D:58>&FT/4;>Q7[3<Q0AI)STS[5C6K*DKM7-:5%U'O
M8\TS174^&+;P_'*MQJTIEE:4+%;+]>]1^/+:"T\1NEO&(XR,A1VH5=.I[.P.
MBU3Y[G-45W'P_P##MO>3_P!JZFG^BH=L2M_&WI6)XR@AMO%-S' @2+@A1VI1
MKQE5=)= E0E&FJCZF%1116YB%%%% !1110 5?T'_ )&+3?\ KX7^=4*OZ#_R
M,6F_]?"_SJ*GP/T+I_&CZ>HHHKXH^N"BBB@ HHHH **** "O(?C/_P ?NE?[
MC?SKUZO(?C/_ ,?NE?[C?SKORS_>8_/\CBS#_=V>84445]2?-A1110 4444
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MI--_Y!=I_P!<4_\ 015FJVF_\@NT_P"N*?\ H(JS7Q$MV?7QV04444AA7/\
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M='UG%=U]P?V?0\STS_A4OB3^_:_]]T?\*E\2?W[7_ONO,_\ A+_$W_0>O?\
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MI<NJJ'X STKOP-2I!R]FU\SGQ%"%9)3Z'>_\*E\2?W[7_ONC_A4OB3^_:_\
M?=>9_P#"7^)O^@]>_P#?='_"7^)O^@]>_P#?=>C]9Q7=?<<O]GT/,],_X5+X
MD_OVO_?='_"I?$G]^U_[[KS/_A+_ !-_T'KW_ONC_A+_ !-_T'KW_ONCZSBN
MZ^X/[/H>9Z9_PJ7Q)_?M?^^Z/^%2^)/[]K_WW7F?_"7^)O\ H/7O_?='_"7^
M)O\ H/7O_?='UG%=U]P?V?0\STS_ (5+XD_OVO\ WW1_PJ7Q)_?M?^^Z\S_X
M2_Q-_P!!Z]_[[H_X2_Q-_P!!Z]_[[H^LXKNON#^SZ'F>F?\ "I?$G]^U_P"^
MZ/\ A4OB3^_:_P#?=>9_\)?XF_Z#U[_WW1_PE_B;_H/7O_?='UG%=U]P?V?0
M\STS_A4OB3^_:_\ ?='_  J7Q)_?M?\ ONO,_P#A+_$W_0>O?^^Z/^$O\3?]
M!Z]_[[H^LXKNON#^SZ'F>F?\*E\2?W[7_ONC_A4OB3^_:_\ ?=>9_P#"7^)O
M^@]>_P#?='_"7^)O^@]>_P#?='UG%=U]P?V?0\STS_A4OB3^_:_]]T?\*E\2
M?W[7_ONO,_\ A+_$W_0>O?\ ONC_ (2_Q-_T'KW_ +[H^LXKNON#^SZ'F>F?
M\*E\2?W[7_ONC_A4OB3^_:_]]UYG_P )?XF_Z#U[_P!]T?\ "7^)O^@]>_\
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MH&*FJII;M)I-F[L69H$))[G:*MUX#W/16B"BBBD,*Y_QW_R3SQ+_ -@JZ_\
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MBW-Z(C"J\*?[P-3S?#SPY%K[:"-?G.I[2R)L^4X&>M+VL>H6/-Z*?/&8+J>
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M EO'OE=H\*/;-9NE>$=.N;&]U;4=3:VT>&0QPS*,M*1[4O:1"QR0!8X52Q]
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MPO*]P/5=0TO2_$?B2R\1P:Y:06VT23PRM\ZD=A45YXGT[5K;Q=(LRQ^9''#
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M%CJ=AX7TK2M ?4+>YE:7=/-$<H@S4IUK2O/\7'[?#B=0(3G_ %G':O(0B@'
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M2?X;:3:17"/<QWDK/$#RH/0FJWB&ZMI_"'AJ"&97FA1A*@/*?6N8  .<<T
M$G')JE"P"T4450!6EX;_ .1LTC_KZ3^=9M:7AO\ Y&S2/^OI/YTI;,#[&HHH
MKPS0**** "BBB@ HHHH *\(_:!_Y".B?[C_S->[UX1^T#_R$=$_W'_F:Z,+_
M !4*6QX]1117JD!6MX<LM*U'5A;:Q<O;6[KA)4.,-VS[5DTA (P:&KH#TS2;
M&P\$V&MSOK=I?K<PF*&")]Q/UK%TO0--U/1H;[3==CTW5-Q\Y+AL #MMKC!&
MBG(4 T,BL<D UGR/>^H'I/BJ>RU&TT+09=3@NKR+Y9]0S\H'UKA];TZ+2=4E
MM+>ZCNX4/RRQG(-9P10, #%* %& ,"JC#ETN!ZAX/L--TSPK/>P:S8Q:W=#8
MOFM_JAZU5\,RV_AG6+JPU'5+:YBU)&WW$39",?4UYP8T)R5&: B@8P,5#I7O
M=[A<]'T[3=/\$6>KZA-K%K>S7<#P0Q6[9.&[FM-=8TL:OX.?[?#LMX\3-G_5
MG'>O)@H&..G2DV+SQUZT.E?5L+G=6E_9+H'CV)KF,274V;=<\RC/:KT>MV%G
M\.=& N$>YM;A)'@!^; -><;1D''3I1M&[=CGUINFF%SU&YT32=1\70>*[;7K
M2.UE<3SPRO\ .IQT%6Y/%.F^,(-9T:6YCLMWRVTTAPK?6O(BBGC''6E*AA@C
M.*7L;[O8+GI3Z?I/ASP%=:?)JUO=W<UQ&98XFR"H/:NLM+RU@N]-NM(U33+/
M1DV^<I/SYQS^->$[1G..?6C;\A3^ G)7MFDZ-]V%ST[3]8T[4;CQ-H4UY'!%
M=S,]O<N<*Q/J:Y^[\-Z3X=BT^2;5X[O4#<(0+=LHJ@]37(E5(P1P* H!SBJ5
M.ST8'LDNN:2=2\5/_:$.V>)1$<_?.WM7&:'?6D/PZU"UDN$2X>8E8B>2*XW8
MO' XZ4N 3G'-)4DE:_;\ N"_=%+116H@I/XX_P#KHO\ .EI/XX_^NB_SH ^S
M=)_Y UC_ ->\?_H(JY5/2?\ D#6/_7O'_P"@BKE>&]S4****0!7/^._^2>>)
M?^P5=?\ HIJZ"N?\=_\ )//$O_8*NO\ T4U 'Q!1110!]/\ [./_ "3S4/\
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M(KZVAN(XK>-9AF-99 K,/I7, E6##@CD&NT\)R6OB'5K6YU_6Y8I;4A8?FP
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M%-0!\04444 ?3_[./_)/-0_["LG_ **BKV"O'_V<?^2>:A_V%9/_ $5%7L%
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MX3D\*6NA3V-_&D9W2M"V/,;W]JS],U[PUH/B2SU/2;.\$42LLJ2G).?2N/\
M,3^\OYT>8G]Y?SI>S6H7+VKWJ:CJ]S>1J525BP4]15.F^8G]Y?SH\Q/[R_G5
MI6 =13?,3^\OYT>8G]Y?SH$.I/XX_P#KHO\ .D\Q/[R_G2>8GF1_,O\ K%[^
M] 'V?I/_ "!K'_KWC_\ 015RJ>D_\@:Q_P"O>/\ ]!%7*\-[FH4444@"N?\
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M]2E@<)5^";/.J8W$T_B@>\_\+"\+_P#05B_(T?\ "PO"_P#T%8OR-?.^%SC
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M*X)2E)WD[G=&*BK)!1114C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "J5[I-AJ*%;NUCE!&.15VBFFT[H32:LSSS
M6?A1IMV"]C(T#_W>U<!J_P /-=TMF*P^?&.ACYXKZ"HKOHYE7IZ-W7F<57+Z
M,]4K'RQ]CNO/\C[-)YW]S'-=-I'P[UW5&0M#]GC/),G'%>[?V98^?Y_V2'S?
M[^P9JW734SB;5H1L<]/*XI^^[GGFC?"G3;,![Z1IW_N]J[>RTJQTY MK;1Q
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M.BE?<"?457LU;<+GI-,DFCBQYDBKG@;CBGUY=KB>'FUJ[DUC6KJ>YY\N"V)
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M[@%%%%2 4444 %<_X[_Y)YXE_P"P5=?^BFKH*Y_QW_R3SQ+_ -@JZ_\ 134
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M15[!7C_[./\ R3S4/^PK)_Z*BKV"@ HHHH **** "BBJ>JZC'I.E7-_*C/'
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MXS1\,IKUO<S0:E>P7UK_ ,LIXL<>QKIZ\S\$QR?\)7,VC17,.@+&04GR#O\
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MM;20JSPQA21WQ5^BJ<VX\O0 QFBBBI ,#THP*** # ]*1E5EVLH(]"*6B@!
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M%%3-&CD%D4D="13J*0!2,JL,,H(]"*6B@!%547:JA1Z 4M%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 5S_CO_DGGB7_ +!5U_Z*:N@KG_'?_)//$O\
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M]<_\&,W_ ,5110 ?\)WXP_Z&O7/_  8S?_%4?\)WXP_Z&O7/_!C-_P#%444
M'_"=^,/^AKUS_P &,W_Q5'_"=^,/^AKUS_P8S?\ Q5%% !_PG?C#_H:]<_\
M!C-_\51_PG?C#_H:]<_\&,W_ ,5110 ?\)WXP_Z&O7/_  8S?_%4?\)WXP_Z
M&O7/_!C-_P#%444 '_"=^,/^AKUS_P &,W_Q5'_"=^,/^AKUS_P8S?\ Q5%%
M !_PG?C#_H:]<_\ !C-_\51_PG?C#_H:]<_\&,W_ ,5110 ?\)WXP_Z&O7/_
M  8S?_%4?\)WXP_Z&O7/_!C-_P#%444 '_"=^,/^AKUS_P &,W_Q5'_"=^,/
M^AKUS_P8S?\ Q5%% !_PG?C#_H:]<_\ !C-_\51_PG?C#_H:]<_\&,W_ ,51
M10 ?\)WXP_Z&O7/_  8S?_%4?\)WXP_Z&O7/_!C-_P#%444 '_"=^,/^AKUS
M_P &,W_Q5'_"=^,/^AKUS_P8S?\ Q5%% !_PG?C#_H:]<_\ !C-_\51_PG?C
M#_H:]<_\&,W_ ,5110 ?\)WXP_Z&O7/_  8S?_%4?\)WXP_Z&O7/_!C-_P#%
M444 '_"=^,/^AKUS_P &,W_Q5'_"=^,/^AKUS_P8S?\ Q5%% !_PG?C#_H:]
M<_\ !C-_\51_PG?C#_H:]<_\&,W_ ,5110 ?\)WXP_Z&O7/_  8S?_%4?\)W
MXP_Z&O7/_!C-_P#%444 '_"=^,/^AKUS_P &,W_Q5'_"=^,/^AKUS_P8S?\
MQ5%% !_PG?C#_H:]<_\ !C-_\51_PG?C#_H:]<_\&,W_ ,5110 ?\)WXP_Z&
MO7/_  8S?_%4?\)WXP_Z&O7/_!C-_P#%444 '_"=^,/^AKUS_P &,W_Q5'_"
M=^,/^AKUS_P8S?\ Q5%% !_PG?C#_H:]<_\ !C-_\51_PG?C#_H:]<_\&,W_
M ,5110 ?\)WXP_Z&O7/_  8S?_%4?\)WXP_Z&O7/_!C-_P#%444 '_"=^,/^
MAKUS_P &,W_Q5'_"=^,/^AKUS_P8S?\ Q5%% !_PG?C#_H:]<_\ !C-_\51_
MPG?C#_H:]<_\&,W_ ,5110 ?\)WXP_Z&O7/_  8S?_%4?\)WXP_Z&O7/_!C-
M_P#%444 '_"=^,/^AKUS_P &,W_Q5'_"=^,/^AKUS_P8S?\ Q5%% !_PG?C#
M_H:]<_\ !C-_\51_PG?C#_H:]<_\&,W_ ,5110 ?\)WXP_Z&O7/_  8S?_%4
M?\)WXP_Z&O7/_!C-_P#%444 '_"=^,/^AKUS_P &,W_Q5'_"=^,/^AKUS_P8
MS?\ Q5%% !_PG?C#_H:]<_\ !C-_\51_PG?C#_H:]<_\&,W_ ,5110 ?\)WX
MP_Z&O7/_  8S?_%4?\)WXP_Z&O7/_!C-_P#%444 '_"=^,/^AKUS_P &,W_Q
M5'_"=^,/^AKUS_P8S?\ Q5%% !_PG?C#_H:]<_\ !C-_\51_PG?C#_H:]<_\
M&,W_ ,5110 ?\)WXP_Z&O7/_  8S?_%4?\)WXP_Z&O7/_!C-_P#%444 '_"=
M^,/^AKUS_P &,W_Q5'_"=^,/^AKUS_P8S?\ Q5%% !_PG?C#_H:]<_\ !C-_
M\51_PG?C#_H:]<_\&,W_ ,5110 ?\)WXP_Z&O7/_  8S?_%4?\)WXP_Z&O7/
M_!C-_P#%444 '_"=^,/^AKUS_P &,W_Q5'_"=^,/^AKUS_P8S?\ Q5%% !_P
MG?C#_H:]<_\ !C-_\51_PG?C#_H:]<_\&,W_ ,5110 ?\)WXP_Z&O7/_  8S
M?_%4?\)WXP_Z&O7/_!C-_P#%444 '_"=^,/^AKUS_P &,W_Q5'_"=^,/^AKU
MS_P8S?\ Q5%% !_PG?C#_H:]<_\ !C-_\51_PG?C#_H:]<_\&,W_ ,5110 ?
M\)WXP_Z&O7/_  8S?_%4?\)WXP_Z&O7/_!C-_P#%444 '_"=^,/^AKUS_P &
M,W_Q5'_"=^,/^AKUS_P8S?\ Q5%% !_PG?C#_H:]<_\ !C-_\51_PG?C#_H:
M]<_\&,W_ ,5110 ?\)WXP_Z&O7/_  8S?_%4?\)WXP_Z&O7/_!C-_P#%444
M'_"=^,/^AKUS_P &,W_Q5'_"=^,/^AKUS_P8S?\ Q5%% !_PG?C#_H:]<_\
M!C-_\54<_C3Q5=6\MO<>)=9F@E0I)')?RLKJ1@@@M@@CC%%% &[8>#-.NM.M
4;AYKH/+$CL%9< D \?+1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>img11953243_18.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img11953243_18.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +- ^$# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M&BU\/KJQN(;QSK1.)(.P7UKR>M*<^>*D)A1115@%%%% !1110 4444 %%%%
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MISZK_:DEY(;_ #GSP<'-4J#DM>U@N>@VGPM\3W/C*]9]]C;B1G%Z3PP]JV/
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MN'*CPC_A05Y_T&5_[XH_X4%>?]!E?^^*]WHH^M5>X<J/"/\ A05Y_P!!E?\
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MN'*CPC_A05Y_T&5_[XH_X4%>?]!E?^^*]WHH^M5>X<J/"/\ A05Y_P!!E?\
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MV/W1G/K74>#R3X0TO)S_ *.O\J4XQ2NNX(W****R&%%%% 'C7QE .MZ9D?\
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MRJBYV>Y]JS=3$ ^*NCBP"B41/]K$8_AQ\N<5!X%MK=]*\42-#&SF]G!8J"2
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MN7AD&& ]:WJX.ZABA^+%HT2*C/:X;:,9'O7>5G-)6L-"/]QOI63X9_Y D?\
MOO\ ^A&M9_N-]*R?#/\ R!(_]]__ $(TE\(&O1114@)1110 M%%% !7-:5_R
M/&N?]<X?Y5TM<UI7_(\:Y_USA_E51V8'2T445(!1110 4444 %%%% !1110
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M:.42HKR%L,/>M#4M%L-7M8;:]A\R*%UD09QAATK0HHYGO<#/&B6 U==5$/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 C_<;Z5D^&?\ D"1_[[_^A&M9_N-]*R?#
M/_($C_WW_P#0C5+X0->BBBI 2BBB@!:*** "N:TK_D>-<_ZYP_RKI:YK2O\
MD>-<_P"N</\ *JCLP.EHHHJ0"BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M$UZI^PP$QZ?$PX([N11*DEKT"YWM%%%8C"BBB@ HHHH **** "BBB@ HHHH
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MGL3VKN5974,I!4C(([UG.-GH,6BBBH **:CI(,HP89QD'-.H **** "BBB@
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M\Z-H]_SI:* $VCW_ #HVCW_.EHH 3:/?\Z-H]_SI:* $VCW_ #HVCW_.EHH
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MYU:(L:A44*HZ # IU<E_PLOPG_T%X?SH_P"%E^$_^@O#^='LY]@N=;17)?\
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MHHH **** "BBB@ HHHH **** $;[A^E?4_PN_P"1#L?H:^6&^X?I7U/\+O\
MD0['Z&N3&? AQ.RHHHKS2PHHHH ^7-6_Y#5__P!?#_SJI5O5O^0U?_\ 7P_\
MZJ5]M#X4?(3^)A1115$A1110 4444 %%%% !1110 4444 %%%%  /O+]:^FO
M#?\ R+>G_P#7%:^91]Y?K7TUX;_Y%O3_ /KBM>-G'P1]3ULJ^.1J4445X![8
M4444 %%%% !1110 C_<;Z5D^&?\ D"1_[[_^A&M9_N-]*R?#/_($C_WW_P#0
MC5+X0->BBBI 2BBB@!:*** "N:TK_D>-<_ZYP_RKI:YK2O\ D>-<_P"N</\
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M?W1^5.HH ;L3^Z/RHV)_='Y4ZB@!NQ/[H_*D=$V'Y1T]*?2-]P_2F!]2?"H
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M "&K_P#Z^'_G52K>K?\ (:O_ /KX?^=5*^VA\*/D)_$PHHHJB0HHHH ****
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M4 %%%% !1110 4444 %%%% !2-]P_2EI&^X?I0!]2?"O_D0[+\:[6N*^%?\
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M_P#.O:R;XI_(\G-?AC\RE1117O'B!1110 4444 %%%% !1110 4444 %%%%
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M\2O^2A:I_O"N5KVJ?P+T,V%%%%6 4444 %%%% !1110 4444 %%%% !1110
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M 4444 ?*/Q*_Y*%JG^\*Y6NJ^)7_ "4+5/\ >%<K7M4_@7H9L****L HHHH
M**** "BBB@ HHHH **** "BBB@!&^X?I7U/\+O\ D0['Z&OEAON'Z5]3_"[_
M )$.Q^AKDQGP(<3LJ***\TL**** /ES5O^0U?_\ 7P_\ZJ5;U;_D-7__ %\/
M_.JE?;0^%'R$_B844451(4444 %%%% !1110 4444 %%%% !1110 #[R_6OI
MKPW_ ,BWI_\ UQ6OF4?>7ZU]->&_^1;T_P#ZXK7C9Q\$?4];*OCD:E%%%> >
MV%%%% !1110 4444 (_W&^E9/AG_ ) D?^^__H1K6?[C?2LGPS_R!(_]]_\
MT(U2^$#7HHHJ0$HHHH 6BBB@ KFM*_Y'C7/^N</\JZ6N:TK_ )'C7/\ KG#_
M "JH[,#I:***D HHHH **"0!DG KD;KXC^'[6YDB,TCQQ-MEF1"40_6JC%RV
M0'745375;%M+_M(7,?V/9YGFYXVUS<'Q+\/37")Y\B0R-LCG="$8_6A0D]D!
MV%%96L>(+'1;:*6X?<TQVPQIR9#[5%HWB:SUBXEM%5X+R(;G@D'S >M'*[7
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MHHH **** "BBB@ HHHH **** $;[A^E?4_PN_P"1#L?H:^6&^X?I7U/\+O\
MD0['Z&N3&? AQ.RHHHKS2PHHHH ^7-6_Y#5__P!?#_SJI5O5O^0U?_\ 7P_\
MZJ5]M#X4?(3^)A1115$A1110 4444 %%%% !1110 4444 %%%%  /O+]:^FO
M#?\ R+>G_P#7%:^91]Y?K7TUX;_Y%O3_ /KBM>-G'P1]3ULJ^.1J4445X![8
M4444 %%%% !1110 C_<;Z5D^&?\ D"1_[[_^A&M9_N-]*R?#/_($C_WW_P#0
MC5+X0->BBBI 2BBB@!:*** "N:TK_D>-<_ZYP_RKI:YK2O\ D>-<_P"N</\
M*JCLP.EHHHJ0"BBB@ JE)I&FS3^=)86SRYSO:($U=K"E\9>'8)7BDU>U5T.&
M!?H::3>P&YM4+MVC;C&,<8JFFD:;%<>?'86RR]=XB&:FBO+>:T%U',A@*[O,
MSQCUK)@\9>'[B\%K'J<!D)VJ=W#'T!II2Z ;C*KH5894C!![TR&&*WB$4,:Q
MQKT51@"J^I:K9Z3;>?>3+&AX7/5CZ#UJ'2]=T_6 XM)LNGWHVX9?PI6=K@6)
M-,L99_/DLX&E_OF,$U:Z# JB^K6<>JIIIES=NF\1CG"^IJ]0[]0"FR?ZMOH:
M=39/]6WT-(#'\,_\@Z7_ *[O6U6+X9_Y!TO_ %W>MJ@ HHHH *^4_B;_ ,E#
MU/ZBOJROE/XF_P#)0]3^HKLP?QLF1R=%%%>B2%%%% !1110 4444 %%%% !1
M110 4444 %(WW#]*6D;[A^E 'U)\*_\ D0[+\:[6N*^%?_(AV7XUVM>-5^-E
MK8****S&%?+VL?\ (=U#_KX?^=?4-?+VL?\ (=U#_KX?^=>UDWQ3^1Y.:_#'
MYE*BBBO>/$"BBB@ HHHH **** "BBB@ HHHH **** "@?>'UHH'WA]: /ICP
MQ_R+.G?]<5K6K)\,?\BSIW_7%:UJ^*J_'+U/KJ?P+T"BBBH+"BBB@ HHHH *
M*** /E'XE?\ )0M4_P!X5RM=5\2O^2A:I_O"N5KVJ?P+T,V%%%%6 4444 %%
M%% !1110 4444 %%%% !1110 C?</TKZG^%W_(AV/T-?+#?</TKZG^%W_(AV
M/T-<F,^!#B=E1117FEA1110!\N:M_P AJ_\ ^OA_YU4JWJW_ "&K_P#Z^'_G
M52OMH?"CY"?Q,****HD**** "BBB@ HHHH **** "BBB@ HHHH !]Y?K7TUX
M;_Y%O3_^N*U\RC[R_6OIKPW_ ,BWI_\ UQ6O&SCX(^IZV5?'(U****\ ]L**
M** "BBB@ HHHH 1_N-]*R?#/_($C_P!]_P#T(UK/]QOI63X9_P"0)'_OO_Z$
M:I?"!KT445("4444 +1110 5S6E?\CQKG_7.'^5=+7-:5_R/&N?]<X?Y54=F
M!TM%%%2 4444 5[^X^RZ?<3_ //.,M^E>/>$=:\*:?H);5]+::>2YD::X:TW
MJ,MQ\U>O:I<I::7<W$D)F2.,LT8&2P]*Y.3Q#X;OO 5W-"UM!;/"X-L2H8-Z
M;?7-;4WI:PF4?B+J,7_"&V5KI4BI!J$T<2M%P-AZ@8JUXC\%:6G@&6UM[2**
M:U@\R.9% <,HSG-<:^G7B_!_2[MXI&>SO!.$(Y\K.?Y5W'B/Q?IC> Y[N&[B
MEDNK?9'$C@N688QCK6EG&RCW$<U'>2ZAHW@_6[V*2YM+8D76%W8.,!B.]7&U
MBSM_%UYXBM8'AT^"R\IF*;/.DSP ._:NH\"::VE^"-/M[E=K>5OD5NV>>:Q!
M_P 5AX@E>)!_8NDEO+4#B:<?S%+F3;[(9?\ "%D()9=6U>:(:QJ!W^6S#=&G
M90*[*O)+.+3[WP9J6IZC>E-7#L23)AXB#P%%>B>&+BYNO#EE-=Y\YHQG/4^A
MK.K'J"->FR?ZMOH:=39/]6WT-9#,?PS_ ,@Z7_KN];58OAG_ )!TO_7=ZVJ
M"BBB@ KY3^)O_)0]3^HKZLKY3^)O_)0]3^HKLP?QLF1R=%%%>B2%%%% !111
M0 4444 %%%% !1110 4444 %(WW#]*6D;[A^E 'U)\*_^1#LOQKM:XKX5_\
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M/P5X>M=7^'.EP:C$6 'F1,#AEYX(-4-3TBS.K-X?TC?O=/-U.Z+$D1#^'/\
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M* $?[C?2LGPS_P @2/\ WW_]"-:S_<;Z5D^&?^0)'_OO_P"A&J7P@:]%%%2
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M*%JG^\*Y6NJ^)7_)0M4_WA7*U[5/X%Z&;"BBBK **** "BBB@ HHHH ****
M"BBB@ HHHH 1ON'Z5]3_  N_Y$.Q^AKY8;[A^E?4_P +O^1#L?H:Y,9\"'$[
M*BBBO-+"BBB@#Y<U;_D-7_\ U\/_ #JI5O5O^0U?_P#7P_\ .JE?;0^%'R$_
MB844451(4444 %%%% !1110 4444 %%%% !1110 #[R_6OIKPW_R+>G_ /7%
M:^91]Y?K7TUX;_Y%O3_^N*UXV<?!'U/6RKXY&I1117@'MA1110 4444 %%%%
M "/]QOI63X9_Y D?^^__ *$:UG^XWTK)\,_\@2/_ 'W_ /0C5+X0->BBBI 2
MBBB@!:*** "N:TK_ )'C7/\ KG#_ "KI:YK2O^1XUS_KG#_*JCLP.EHHHJ0"
MBBB@"*ZN$M+66XD!*1J6.T9/%>?_ /"<^(9=/FUJ#P\PTN(DXD;#L@ZMBO12
M 1@C(K@/B1=>((=,>VTRQ5]-D0B[E'WD3OBM:5F[-"9NR^,M-A\(+XC<G[,R
M!@O<L?X?K7.2>/-?L=/BUJ_T QZ5(020X+QJ>C&L3Q,VGMX \-VVER&33GNH
ME)/<@\YKT;Q':P/X/U"!E'E"U; [<+Q5<L8VNMV!1UGQ9Y,.EQZ3$+FYU3_C
MW)/ &,Y-&C>(;XZ_)H6KP*ET(O.CE3[KKFN5\,:->ZQX+\/:C93K%?Z<6,7F
M#*LO3!I^L+JVGZH+ZZFADUN^B^R6D$(XB7NQ_6GR1^$#K+/Q#-JGBJXT^QC#
M65HN+B?MYG]T5T=>>Z+X@TOPUIK6T%M/<6T#?Z9?J./,/4GUKO;>XBNK>.>%
MP\4BAE8=P:SG&SVT!$M-D_U;?0TZFR?ZMOH:S&8_AG_D'2_]=WK:K%\,_P#(
M.E_Z[O6U0 4444 %?*?Q-_Y*'J?U%?5E?*?Q-_Y*'J?U%=F#^-DR.3HHHKT2
M0HHHH **** "BBB@ HHHH **** "BBB@ I&^X?I2TC?</TH ^I/A7_R(=E^-
M=K7%?"O_ )$.R_&NUKQJOQLM;!11168PKY>UC_D.ZA_U\/\ SKZAKY>UC_D.
MZA_U\/\ SKVLF^*?R/)S7X8_,I4445[QX@4444 %%%% !1110 4444 %%%%
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M **** "OE/XF_P#)0]3^HKZLKY3^)O\ R4/4_J*[,'\;)D<G1117HDA1110
M4444 %%%% !1110 4444 %%%% !2-]P_2EI&^X?I0!]2?"O_ )$.R_&NUKBO
MA7_R(=E^-=K7C5?C9:V"BBBLQA7R]K'_ "'=0_Z^'_G7U#7R]K'_ "'=0_Z^
M'_G7M9-\4_D>3FOPQ^92HHHKWCQ HHHH **** "BBB@ HHHH **** "BBB@
MH'WA]:*!]X?6@#Z8\,?\BSIW_7%:UJR?#'_(LZ=_UQ6M:OBJOQR]3ZZG\"]
MHHHJ"PHHHH **** "BBB@#Y1^)7_ "4+5/\ >%<K75?$K_DH6J?[PKE:]JG\
M"]#-A1115@%%%% !1110 4444 %%%% !1110 4444 (WW#]*^I_A=_R(=C]#
M7RPWW#]*^I_A=_R(=C]#7)C/@0XG94445YI84444 ?+FK?\ (:O_ /KX?^=5
M*MZM_P AJ_\ ^OA_YU4K[:'PH^0G\3"BBBJ)"BBB@ HHHH **** "BBB@ HH
MHH ****  ?>7ZU]->&_^1;T__KBM?,H^\OUKZ:\-_P#(MZ?_ -<5KQLX^"/J
M>ME7QR-2BBBO /;"BBB@ HHHH **** $?[C?2LGPS_R!(_\ ??\ ]"-:S_<;
MZ5D^&?\ D"1_[[_^A&J7P@:]%%%2 E%%% "T444 %<UI7_(\:Y_USA_E72US
M6E?\CQKG_7.'^55'9@=+1114@%%%% $<\\=M \\SA(XU+,Q["N&/Q+22*6]M
M=&OI],B8AKE8^"!U(]J[J:*.>%XI5#1N,,IZ$5Q?C#Q!8^']).AZ;;K-J%TA
MCAM(1]W/<CL*TII-VM<3-\>*-*/AS^WOM %CLW[CU^GUKFE^)L*1Q7EUI%]!
MIDS!4N63@9Z$^U<OK^C3Z!\.M#T*Y;+7%ZC3@=!DYQ7HOB;3+>7P1?63(ODI
M:G:,<#:.*OE@O.[#4=K?BBWTN"S\A#=3WQQ;1Q\[^^?I4>B^)S?ZI+I-]:M:
MW\:>9L/W67U!KC- L=2U+PIX8UFP19KG3=P\F0XWKTZU/JEWJMEK#:_>6J0W
MD\/V.PM4;<SL3RQ^E/V:^'J%SLH_$277B=]&M8C+Y";IYOX4/]WZUN5P?A[4
M]%\,6[6EQ<M+>R-OO;H+E/,/8MV]*[I'62-71@R,,@CH164XV>@(=39/]6WT
M-.ILG^K;Z&H&8_AG_D'2_P#7=ZVJQ?#/_(.E_P"N[UM4 %%%% !7RG\3?^2A
MZG]17U97RG\3?^2AZG]179@_C9,CDZ***]$D**** "BBB@ HHHH **** "BB
MB@ HHHH *1ON'Z4M(WW#]* /J3X5_P#(AV7XUVM<5\*_^1#LOQKM:\:K\;+6
MP4445F,*^7M8_P"0[J'_ %\/_.OJ&OE[6/\ D.ZA_P!?#_SKVLF^*?R/)S7X
M8_,I4445[QX@4444 %%%% !1110 4444 %%%% !1110 4#[P^M% ^\/K0!],
M>&/^19T[_KBM:U9/AC_D6=._ZXK6M7Q57XY>I]=3^!>@4445!84444 %%%%
M!1110!\H_$K_ )*%JG^\*Y6NJ^)7_)0M4_WA7*U[5/X%Z&;"BBBK **** "B
MBB@ HHHH **** "BBB@ HHHH 1ON'Z5]3_"[_D0['Z&OEAON'Z5]3_"[_D0[
M'Z&N3&? AQ.RHHHKS2PHHHH ^7-6_P"0U?\ _7P_\ZJ5;U;_ )#5_P#]?#_S
MJI7VT/A1\A/XF%%%%42%%%% !1110 4444 %%%% !1110 4444  ^\OUKZ:\
M-_\ (MZ?_P!<5KYE'WE^M?37AO\ Y%O3_P#KBM>-G'P1]3ULJ^.1J4445X![
M84444 %%%% !1110 C_<;Z5D^&?^0)'_ +[_ /H1K6?[C?2LGPS_ ,@2/_??
M_P!"-4OA UZ***D!**** %HHHH *YK2O^1XUS_KG#_*NEKFM*_Y'C7/^N</\
MJJ.S Z6BBBI **** *.M7LFFZ+>7D432R0Q%UC49+'TKR7P=XET_3/.U76-+
MU.;6KERSR-;%MB]@/2O:*,#TK2$U%--". \41OXX\#I?Z5;S)<03":*.9-K'
M:>1BL_5?'+ZOX6.E66G7W]L7,8@:-X"%0G@DGTKT^FA%#%@HW'J<<TU42TML
M%C&\-:9_PCGA2TLY?O6\.9-O.3U-8&AV5UXDUB[\17T3QQHK0Z?#(,;1_?QZ
MUW1 (P>12  # &!4\[U?5C/)K6ZATOPCJ.@7VF7$FIL[*<0EA*Q/!S7HGAFT
MN+'P[96]T29DC&[)Z>U:I52P8J-PZ'%+3G/F%8*;)_JV^AIU-D_U;?0UF,Q_
M#/\ R#I?^N[UM5B^&?\ D'2_]=WK:H **** "OE/XF_\E#U/ZBOJROE/XF_\
ME#U/ZBNS!_&R9')T445Z)(4444 %%%% !1110 4444 %%%% !1110 4C?</T
MI:1ON'Z4 ?4GPK_Y$.R_&NUKBOA7_P B'9?C7:UXU7XV6M@HHHK,85\O:Q_R
M'=0_Z^'_ )U]0U\O:Q_R'=0_Z^'_ )U[63?%/Y'DYK\,?F4J***]X\0****
M"BBB@ HHHH **** "BBB@ HHHH *!]X?6B@?>'UH ^F/#'_(LZ=_UQ6M:LGP
MQ_R+.G?]<5K6KXJK\<O4^NI_ O0****@L**** "BBB@ HHHH ^4?B5_R4+5/
M]X5RM=5\2O\ DH6J?[PKE:]JG\"]#-A1115@%%%% !1110 4444 %%%% !11
M10 4444 (WW#]*^I_A=_R(=C]#7RPWW#]*^I_A=_R(=C]#7)C/@0XG94445Y
MI84444 ?+FK?\AJ__P"OA_YU4JWJW_(:O_\ KX?^=5*^VA\*/D)_$PHHHJB0
MHHHH **** "BBB@ HHHH **** "BBB@ 'WE^M?37AO\ Y%O3_P#KBM?,H^\O
MUKZ:\-_\BWI__7%:\;./@CZGK95\<C4HHHKP#VPHHHH **** "BBB@!'^XWT
MK)\,_P#($C_WW_\ 0C6L_P!QOI63X9_Y D?^^_\ Z$:I?"!KT445("4444 +
M1110 5S6E?\ (\:Y_P!<X?Y5TM<UI7_(\:Y_USA_E51V8'2T445(!1110 57
MFOK6WE2*6XB21SA4+#)/TI]Q&\MO)''(8W92 XZ@^M>0>)?"RZ)XF\/W<NH7
M5[=S7B[Y)FZ#/05I3@I.S8F>QDA022 !U)K/BUW2IKHVT=_;M-G&T..37,?%
M'4[BS\-1VEI*T4U[.D&]>H4GFJ.O> -+M/ S_8H!#?V<(F2Y4G?O49)S3C!6
M3D]PN=_>7MM86YGNIEBC'=C45AJEEJD9>SN$E"G! /(_"O,IM3.K:9X.U35-
MTE@K$7;<E=V, MCWJ[%JFFV/C6^U?3VVZ9#8XG900C29X ]^E/V6GF%ST.34
M+6.]2S:91<.-RQ]\>M6:XWP?I\T]S-XBU4A;^]_U,3'F*+LN*[*LY))V&%-D
M_P!6WT-.ILG^K;Z&I Q_#/\ R#I?^N[UM5B^&?\ D'2_]=WK:H **** "OE/
MXF_\E#U/ZBOJROE/XF_\E#U/ZBNS!_&R9')T445Z)(4444 %%%% !1110 44
M44 %%%% !1110 4C?</TI:1ON'Z4 ?4GPK_Y$.R_&NUKBOA7_P B'9?C7:UX
MU7XV6M@HHHK,85\O:Q_R'=0_Z^'_ )U]0U\O:Q_R'=0_Z^'_ )U[63?%/Y'D
MYK\,?F4J***]X\0**** "BBB@ HHHH **** "BBB@ HHHH *!]X?6B@?>'UH
M ^F/#'_(LZ=_UQ6M:LGPQ_R+.G?]<5K6KXJK\<O4^NI_ O0****@L**** "B
MBB@ HHHH ^4?B5_R4+5/]X5RM=5\2O\ DH6J?[PKE:]JG\"]#-A1115@%%%%
M !1110 4444 %%%% !1110 4444 (WW#]*^I_A=_R(=C]#7RPWW#]*^I_A=_
MR(=C]#7)C/@0XG94445YI84444 ?+FK?\AJ__P"OA_YU4JWJW_(:O_\ KX?^
M=5*^VA\*/D)_$PHHHJB0HHHH **** "BBB@ HHHH **** "BBB@ 'WE^M?37
MAO\ Y%O3_P#KBM?,H^\OUKZ:\-_\BWI__7%:\;./@CZGK95\<C4HHHKP#VPH
MHHH **** "BBB@!'^XWTK)\,_P#($C_WW_\ 0C6L_P!QOI63X9_Y D?^^_\
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M_(.E_P"N[UM5B^&?^0=+_P!=WK:H **** "OE/XF_P#)0]3^HKZLKY3^)O\
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M6_Y#5_\ ]?#_ ,ZJ5]M#X4?(3^)A1115$A1110 4444 %%%% !1110 4444
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M "T444 %<UI7_(\:Y_USA_E72US6E?\ (\:Y_P!<X?Y54=F!TM%%%2 4444
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M444 %%%% !1110 4444 (_W&^E9/AG_D"1_[[_\ H1K6?[C?2LGPS_R!(_\
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MI$Z-%((@"H7H*KVD>:]^HK&3 B7/Q@M5N@&\G3D:!6Z XY(JS\3$2#5/#-U
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M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "/\
M<;Z5D^&?^0)'_OO_ .A&M9_N-]*R?#/_ "!(_P#??_T(U2^$#7HHHJ0$HHHH
M 6BBB@ KFM*_Y'C7/^N</\JZ6N:TK_D>-<_ZYP_RJH[,#I:***D HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "HY)XHB!)*B9Z;F S4E>9?%3/V
MO3<$CY6Z'% 'H_VRU_Y^8?\ OL4?;+7_ )^8?^^Q7SQS_??_ +Z-'/\ ??\
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M1S_??_OHT!8^A_MEK_S\P_\ ?8H^V6O_ #\P_P#?8KYXY_OO_P!]&CG^^_\
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M/]LM?^?F'_OL4?;+7_GYA_[[%?/'/]]_^^C1S_??_OHT!8^A_MEK_P _,/\
MWV*/MEK_ ,_,/_?8KYXY_OO_ -]&CG^^_P#WT: L?0_VRU_Y^8?^^Q1]LM?^
M?F'_ +[%?/'/]]_^^C1S_??_ +Z- 6/H?[9:_P#/S#_WV*/MEK_S\P_]]BOG
MCG^^_P#WT:.?[[_]]&@+'T/]LM?^?F'_ +[%'VRU_P"?F'_OL5\\<_WW_P"^
MC1S_ 'W_ .^C0%CZ'^V6O_/S#_WV*/MEK_S\P_\ ?8KYXY_OO_WT:.?[[_\
M?1H"Q]#_ &RU_P"?F'_OL4?;+7_GYA_[[%?/'/\ ??\ [Z--?.QOG?I_>- 6
M/HX,&4%2"#T(I:S?#_\ R+VG_P#7!?Y5I4""BBB@ HHHH **** "BBB@!'^X
MWTK)\,_\@2/_ 'W_ /0C6L_W&^E9/AG_ ) D?^^__H1JE\(&O1114@)1110
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M#ZF@+G*T5U,&CV.GZ;#>7\$UQ)<'*11CA5]:+GP[;1ZKIYB+_8KSH'&"I]*
MN<MFBNQ73?#K:U)HH$WG$E5FQP&Q_*LS3-"B>\OFOI2MI9 ERO5O:@#!HK>N
MTT&\T^26Q9[>XC/$;]'%7CHVG:3;VZZA;W%Q<3*&?8.$!Z8H Y.BM;Q!I"Z1
M?*D3,T$JAXRW49[&LF@84444 %%%% !1110!Z%\*_P#7ZG]$KTNO-/A7_K]3
M^B5Z73)84444""BBB@ HHHH **** "BBB@ KQCX@?\CC<?\ 7-/Y5[/7C'Q
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M<%>&8?TH"YQM%2W,#6MW-;O]Z)RA_"HJ!A1110 4444 %-?[C?2G4U_N-]*
M/??#_P#R+VG_ /7!?Y5I5F^'_P#D7M/_ .N"_P JTJ9 4444 %%%% !1110
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M 6)KF3S;N:3>9-SD[SU;WJ*BB@84444 %%%% !37^XWTIU-?[C?2@#WWP_\
M\B]I_P#UP7^5:59OA_\ Y%[3_P#K@O\ *M*F0%%%% !1110 4444 %%%% "/
M]QOI63X9_P"0)'_OO_Z$:UG^XWTK)\,_\@2/_??_ -"-4OA UZ***D!****
M%HHHH *YK2O^1XUS_KG#_*NEKFM*_P"1XUS_ *YP_P JJ.S Z6BBBI ****
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MQOI3J:_W&^E 'OOA_P#Y%[3_ /K@O\JTJS?#_P#R+VG_ /7!?Y5I4R HHHH
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M^^#1M?\ YYR?]\&@18O;ZZU&;S;R=IG]6[4V:ZN+B*.*:9GCC&$4]%J':_\
MSSD_[X-&U_\ GG)_WP:!E[^V=1-E]C^UR?9\8V>WI5&C:_\ SSD_[X-&U_\
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MK_\ /.3_ +X- 'H7PK_U^I_1*]+KS3X5@B?4\JPX7J,5Z73)84444""BBB@
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M@B)=W+RJG0&J>U_^><G_ 'P:-K_\\Y/^^#0 44;7_P"><G_?!HVO_P \Y/\
MO@T %%&U_P#GG)_WP:-K_P#/.3_O@T %-?[C?2G;7_YYR?\ ?!I'5]A_=R=/
M[AH ]\\/_P#(O:?_ -<%_E6E6;X?_P"1>L.W[A?Y5I4R HHHH **** "BBB@
M HHHH 1_N-]*R?#/_($C_P!]_P#T(UK/]QOI63X9_P"0)'_OO_Z$:I?"!KT4
M45("4444 +1110 5S6E?\CQKG_7.'^5=+7-:5_R/&N?]<X?Y54=F!TM%%%2
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !3'BCDQOC1L=-RYI]%
M $7V6W_YX1?]\"C[+;_\\(O^^!4M% $7V6W_ .>$7_? H^RV_P#SPB_[X%2T
M4 1?9;?_ )X1?]\"C[+;_P#/"+_O@5+10!%]EM_^>$7_ 'P*/LMO_P \(O\
MO@5+10!%]EM_^>$7_? H^RV__/"+_O@5+10!%]EM_P#GA%_WP*/LMO\ \\(O
M^^!4M% $7V6W_P">$7_? H^RV_\ SPB_[X%2T4 1?9;?_GA%_P!\"C[+;_\
M/"+_ +X%2T4 1?9;?_GA%_WP*/LMO_SPB_[X%2T4 1?9;?\ YX1?]\"C[+;_
M //"+_O@5+10!%]EM_\ GA%_WP*/LMO_ ,\(O^^!4M% $7V6W_YX1?\ ? H^
MRV__ #PB_P"^!4M% $7V6W_YX1?]\"C[+;_\\(O^^!4M% $7V6W_ .>$7_?
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MO_?XT67<#9HK&_X1NV_Y^KW_ +_&C_A&[;_GZO?^_P :++N!LT5C?\(W;?\
M/U>_]_C1_P (W;?\_5[_ -_C19=P-FBL;_A&[;_GZO?^_P :/^$;MO\ GZO?
M^_QHLNX&S16-_P (W;?\_5[_ -_C1_PC=M_S]7O_ '^-%EW V:*QO^$;MO\
MGZO?^_QH_P"$;MO^?J]_[_&BR[@;-%8W_"-VW_/U>_\ ?XT?\(W;?\_5[_W^
M-%EW V:*QO\ A&[;_GZO?^_QH_X1NV_Y^KW_ +_&BR[@;-%8W_"-VW_/U>_]
M_C1_PC=M_P _5[_W^-%EW V:*QO^$;MO^?J]_P"_QH_X1NV_Y^KW_O\ &BR[
M@;-%8W_"-VW_ #]7O_?XT?\ "-VW_/U>_P#?XT67<#9HK&_X1NV_Y^KW_O\
M&C_A&[;_ )^KW_O\:++N!L/]QOI61X9_Y D?^^__ *$:3_A&[;_GZO?^_P :
:T[6VBL[=8(5PB]!1I:P$U%%%2 E%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>img11953243_19.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img11953243_19.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +$ P$# 2(  A$! Q$!_\0
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M?I/^^A1_PF.C?\_2?]]"OE/+?WV_[Z-&6_OM_P!]&CZG'N',?5G_  F.C?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5&O0OC6/^+CR?]>L?\J\]KJIRYHJ3$PHHHJ@"BBB@ KL_A;_ ,CM%_UQD_\
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MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 1ON'Z5UOBS_ ) >A?\
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MW;%Q.IR"WH#[5Z!\0D74/A7X=U&09FA0)D]3QBJ<VG'6Z8CR"BBBM@"BBB@
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M_P"@)<_E5\\>X'/T5T'_  @OBK_H"7/Y4?\ ""^*O^@)<_E1SQ[@<_170?\
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M)I.-M&!M_P!NI_SQ-']NI_SQ-8M%*P&U_;J?\\31_;J?\\36+118#:_MU/\
MGB:/[=3_ )XFL6BBP&U_;J?\\31_;J?\\36+118#:_MU/^>)H_MU/^>)K%HH
ML!M?VZG_ #Q-']NI_P \36+118#:_MU/^>)H_MU/^>)K%HHL!M?VZG_/$T?V
MZG_/$UBT46 VO[=3_GB:/[=3_GB:Q:*+ ;7]NI_SQ-']NI_SQ-8M%%@-K^W4
M_P">)H_MU/\ GB:Q:*+ ;7]NI_SQ-']NI_SQ-8M%%@-K^W4_YXFI9=72)$;R
MB=PK /2K5U_J8/I18#0_MU/^>)H_MU/^>)K%HHL!M?VZG_/$T?VZG_/$UBT4
M6 VO[=3_ )XFC^W4_P">)K%HHL!M?VZG_/$T?VZG_/$UBT$@ DG ')-%@-K^
MW4_YXFC^W4_YXFO/9?&,ADG>QT>XN[.W8K+<HP &.N!6I+K]C%H(UDN3:E01
MCJ2>@^M4Z;70+G7?VZG_ #Q-']NI_P \37GT'B^1;BW74M'N+&WN3B&>1@02
M>F:T=:UU-(DAMX[:2[O9_P#56\?4^]'LW>PKG8?VZG_/$T?VZG_/$UQ>C^(#
MJ-Y+8W=C-8WL8R8I.<CU!K99E1&=SA5&23VI.-G9C-O^W4_YXFC^W4_YXFN2
MT/5'UFT>[\K9"9"L6>I .,U3U;Q;9Z3K5GI30O-/<MMRAXC/O3Y&W8+G<_VZ
MG_/$T?VZG_/$URNL:Q!HMF)YE:1W;9%$OWG;T%9UAXGEFU**PU+2KC3YIAF$
MR'(?\J%!M7"YW?\ ;J?\\31_;J?\\36([+&CNYPJ LQ] *Y4^-79&NX=&N9-
M,5MINP1CZX]*(P<M@/1?[=3_ )XFC^W4_P">)KC-2UY+&TLK]%$EC.P#2#MG
MI6S[@Y!I.-@-K^W4_P">)H_MU/\ GB:Q:*5@-K^W4_YXFC^W4_YXFL6BBP&U
M_;J?\\31_;J?\\36+118#:_MU/\ GB:FMM62XF\L1$<9S7/U<TS_ (_!]#_*
MBP%\ZXF2/)-)_;J?\\36,?O'ZFDHL!M?VZG_ #Q-']NI_P \36+118#:_MU/
M^>)H_MU/^>)K%IKNL<;2.=J*,D^@HL!N?VZG_/$T?VZG_/$UP>G^,;/4]?&E
M6UO,0R,ZW##"MCK@5LZA?0Z;837EPV(HEW'W]A5.#3LT!T?]NI_SQ-']NI_S
MQ-<?X>U^'Q%IIOH8'A0$C:_7ZUFR^,)6>:2QT6YN[. XDN%( XZX%'LW>PKG
MH7]NI_SQ-']NI_SQ-<YIU_!JEA#>VS;HI1D5!K6JIHVF/=NNY@0J)W8DXI<N
MMAG5?VZG_/$T?VZG_/$U@V[2-:QR3@(Y7<X["L32?%EIK.N7FF6T,@-L,F4G
MY7^E"@W>W0#N?[=3_GB:/[=3_GB:XC4_$;VNH'3M/TZ;4;Q5W.D1QL'N:LZ)
MK<6M02,(9+>>)MLL,G533Y&E<+G7?VZG_/$T?VZG_/$UBU@3>+;.+Q,FA)"\
MLS#+2*?E7VI*+>P'<_VZG_/$T?VZG_/$UR,FK&W\1)I<Z!5FC+PR>N.U:E#C
M8#:_MU/^>)H_MU/^>)K%HI6 VO[=3_GB:/[=3_GB:Q:*+ ;L>M))*J>41DXJ
MS)_K&^M<];?\?4?^\*Z&3_6-]:3 ;1112 IZK_QY1_\ 72L>MC5?^/*/_KI6
M/5(#C?'FIP1?V?IDSLL4\H>;8NXA1R.!4'A75K!/&5Y8V#L;2Z421!D*?/\
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M?V9);VY3?'-)PS#UVU+=:QXKBN95@\.6LD",=LK7.,KZD=JK, /BJ@   M0
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M;:[&LIJTFD-!1114@%%%% !1110 5-;?Z[\#4-36W^N_ T 0GJ?K10>I^M%
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M_GHWYT>?-_ST;\ZCHH D\^;_ )Z-^=6].FD:[ 9V(P>_M5"KFF?\?@^A_E2
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M?EGC8XZ T 5SU/UHI^(<G_2(OSHQ#_S\1?G0 RBGXA_Y^(OSHQ#_ ,_$7YT
M,HI^(?\ GXB_.C$/_/Q%^= #**?B'_GXB_.C$/\ S\1?G0 RBGXA_P"?B+\Z
M,0_\_$7YT ,I'571D=0RL,$'N*DQ#_S\1?G1B'_GXB_.@#E$^'^@)>"<)<%
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M(V5=?1AP:N4+"N:>!Z48'I114## ]*,#THHH ,#THP/2BB@ P/2C ]*** #
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MYIG_ !^#Z'^54ZN:9_Q^#Z'^5("H?O'ZFDI3]X_4TE, HHHH **** "BBB@
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M7/19[VUMH4FFG1(I"%5R>"?K446K6$UO+/'=(8HCAWS@ UP&H6%S%X+TJQU
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MT 4Z*N?V7=_W!^=']EW?]P?G0!3HJY_9=W_<'YT?V7=_W!^= %.BKG]EW?\
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M?Q9HEO?&S>\4RJ<,5Y53[GM4\KO:PS;W-_>-&YO[QJII^HVNJV@NK*420,2
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M1R7D#0'#MI_E<K'G^]ZXKM["\CU#3[>]A_U<Z!UJY0<0+.YO[QHW-_>-)14
M+N;^\:-S?WC244 +N;^\:-S?WC244 +N;^\:-S?WC244 +N;^\:-S?WC244
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M^S/ZK^='V9_5?SIOVRV_Y[I^='VRV_Y[I^=&H#OLS^J_G1]F?U7\Z;]LMO\
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MI/[3NO\ GI1]9J]PY4>7?\,_ZA_T,$'_ 'Y-'_#/^H?]#!!_WY->H_VG=?\
M/2C^T[K_ )Z4?6:O<.5'EW_#/^H?]#!!_P!^31_PS_J'_0P0?]^37J7]IW?]
M^D_M.Z_YZ4?6:O<.5'EW_#/^H?\ 0P0?]^31_P ,_P"H?]#!!_WY->H_VG=?
M\]*/[3NO^>E'UFKW#E1Y=_PS_J'_ $,$'_?DT?\ #/\ J'_0P0?]^37J/]IW
M7_/2C^T[K_GI1]9J]PY4>7?\,_ZA_P!#!!_WY-'_  S_ *A_T,$'_?DUZC_:
M=U_STH_M.Z_YZ4?6:O<.5'G6D_ N^T[5[6];7876"0.5$)&<&O89#F1JQX-1
MN7G12_!/-:\G^L;ZUE4J2G\0)6&T445F,IZK_P >4?\ UTK'K8U7_CRC_P"N
ME8]4@,.35+M?&B:4I7[*8!(1CG/UH\6:I=Z-IL,]H5#O.D9W#(P3@UB:U82:
MA\0HHHKI[9A:@[UZU1\6:%<Z?8VL\NIRW"BZC^1NGWJZ(QBW$5SNM2U2RTI%
M>\G$>[[J]V^@HL-4LM3@::TG5T7[W/*_7TKD-86^G^([QP003[+=#"DYXSCG
M%26%K<:9JVJZA>BVBC%ONGM8&&< =<5/LUR[ZA<W_P#A*=&^U?9_MBEMVW</
MNY],U=OM2L]-MQ/=SK'&?NG/WOI7G6K?:[CP9->PZ;96.GN-\;9!<^A^M:Q6
M*Z\2^&XM0 :W.G[HU?[K/CC\:;IK<+FBWB@77B/3K/3YD>UFC9I5(^8$=/I6
MG>^)-)L+DV\]T/,7[P7G;]?2N?U*WLK?XDZ8+9(XYC QE5!_.HHYIM5DU2?3
M-*LX[8,RS7,Y!9B,]J.2+L^E@N=F;VU%E]L-Q']FV[O-S\N/K5/3_$.E:E="
MWM[D&0]%;C=]/6N MW+>!M$BG?\ T1K\I/Z;,_RKO+FPT.*ZTZ22.&&97'V8
MI\I8_P!:4H*.C"YE6GBU(=4U>#4YT6.VN/+A5%^;;CO716U_:7=F+R"=&M\9
M+YX'UKE_#5C:W'B;Q)+/;QR/]J*Y<9XQ7/3F6V\*>(;>U&V%=2VX' 5<]/I5
M.$9.R\A7.\M?$ND7ET+:&[4R$X7/ ;Z'O6M7GVHZ3J-QI5HK0:=9PJZ-%<*X
M!'T/O7?Q[O*3><OM&36<XI;#0ZBBBH&%%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%%  >E6KK_4P?2JIZ5:NO\ 4P?2D!5HHHI@%%%%
M !1110 4444 %17-PEI:37,GW(D+G\*EK+\21R2^&[]8AE_)8@?A32N[ <\E
M]XGO[7^U+:]M84?YX+!T&Z1/K6S>ZIJBZ7;-9Z>6OIU^96.!$>^:YBP\/Z:_
M@1=2>^F^TQP&02^;CRV'1:ZWP[=W%[X8M;BYR96BY8_Q>]:SLM5T8D5_!^J7
MVKZ%]HU%D:Y69XV*# X-7==U+^R=%N;P<NB_NQZMVK(\!?\ (O3?]?DO\Z?X
MZ!_L",_PBX0M]*EI>TMYAT(KS5M0TGP_IT<>)M3OV"H6Z*6YY^E,:^U[P]?6
M8UBZAO+2[D$19$V&-S_.I_$MM:7.DZ<9+K[).KH;6;' ?' -8/B"TUBXO-(B
MU2_CED-ROEP1+U_VS5Q2?XB/1"0JLW8 M^%<;;7WB3Q +F^TV[@M+.)B(HWC
MW&7'OVKKA)%DP&13(J?,@/.,<UQ=C9W\"7_]@ZM"NG%V,BR*,P'N*B%M1LN_
MVS>:IX1GO8/W-_:-B51R,CK^E=#IEZFI:7;7J?=F0-7)^#;86GA/6'>0RQ2O
M(ZR-_&,'FM7P.''@^QW=U)7Z9-.<4KVZ,$=#11160PHHHH **** "BBB@ JY
MIG_'X/H?Y53JYIG_ !^#Z'^5("H?O'ZFDI3]X_4TE, HHHH **** "J&L7EU
M960>RM3<W#ML1,X /J:OTH.,_2A <WX1U74]3BOUU4QF>WFV#RQ@ >E0^,?$
MEUH\"P:6JR7[#>VX9$:9ZFHO"LI@_P"$AF"%REQD*.I.*Y=]9(TK5[F_TR_&
MH7?&]H3MC7/3/I70H)S;L3?0]+TNXDN]+MKB8@R2("Q'3-4O$VJ/I.BR30\W
M#L(XA[DXIGA._6_\/6[+#+%Y8"8D7&?<>U4?&WW-)9O]6+H;JS4??LQ]#?M0
M;+2XS=R[C''NDD/YUR^A^*-1U;Q3+;.B)II7=!\OS./[V:?XXOKE(;33XK6Y
MDMIR#<20)N(4=JQ[37[8>-;;R--O(HA L21M$05]\>E7"%XMVW"YZ.2%!9N@
M&37$:;J'B;6EN)X-9L;6,7#Q11/""V >*[&66!EFC:1250F15/(%<>?#7AR;
M0KR\L;B9%3<XE\X_(]1"W4&:VO3:CINA17GGA[BW=6G95P'7OQ6Y;SK=6L-P
MGW)4#CZ&N4BO9;SX974UX=S_ &=T#'^(#H:V_#0=?#.G!\[O(7KZ8HDK1^8&
MI11168PHHHH **** );;_CZC_P!X5T,G^L;ZUSUM_P ?4?\ O"NAD_UC?6I8
M#:***0%/5?\ CRC_ .NE8];U[;/=6J*C*"'S\QJA_9-Q_?B_[ZJD!B-I=HVJ
MC4RA^UA-@;/&/I1J6EVFK0)!>(7C1Q( #CD<BMO^R;C^_%_WU1_9-Q_?B_[Z
MI\P'/:OH-CK80W2NLD?W)8FVL/QIFF^'--TJ*=((W<SC;*\K;F8>F372?V3<
M?WXO^^J/[)N/[\7_ 'U3YW:UPL<4? >AN'21;EX'_P"6)F.T?05IW_A_3]2L
M(+.XC;R[=0L3*V&0#I@UT7]DW']^+_OJC^R;C^_%_P!]4>TD^H6.5L/">E:?
M=1W422O<QC EDD+$CWJ.X\&Z3<7KW)$Z&0YDCCE*HQ^E==_9-Q_?B_[ZH_LF
MX_OQ?]]4>TEO<+'.0^'M+M]'.DI;_P"AG/R,<D?C5;3O".E:;>)=1B>66/\
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MPKH9/]8WUJ6 VBBBD!3U7_CRC_ZZ5CUT-U!'/;*LCE0&SP*I?V=:_P#/9O\
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MK00,P+",=0#G%7HHD@A2*-0J(H50.PHE)-/S8#Z***S&%%%% !1110 4444
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M'_SU6C,?_/5: $HI<Q_\]5HS'_SU6@!**7,?_/5:,Q_\]5H =%_K5^M69/\
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MGZ24 245']ML_22C[;9^DE $E%1_;;/TDH^VV?I)0!)14?VVS])*/MMGZ24
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MB@ HHHH ****  ]*M77^I@^E53TJU=?ZF#Z4@*M%%%, HHHH **** "BBB@
MHHJ*XCDEMI(XI/+=E(5_[OO0 \2Q&0QB5#(.J!AD?A3)+JVA;;+=01M_=>0
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MHH **** "BBB@ HHHH #TJU=?ZF#Z55/2K5U_J8/I2 JT444P"BBB@ HHHH
M**** "BBB@#F&BD_X6,LOEOY7V<#?CC\Z=/XL;2-3N+;5K.98QS!)#%O#CT.
M*Z7/&*.#U /U%7S)[H1S'@RTG2*^OI8#;I=REXXCP0/7'O2^.8F;1+><#BVN
MDF;V KILYJ*ZMXKRUEMIUW12KM8>HHY_?Y@L8/B?Q%+I.APSV=O+//<J-AC0
ML$!'WC6;X4U32;5DM42]DO[ILS3RP,-S?4]!776-JFGVD=M"S&.,87><G%6-
MQ/I^5',E'EL%C(.I-?WVH:3#')!-"A N&7Y3GTKD;WPOXATGPQ>6\6K6\T!^
M9T6 [Y"3ZUZ)FC-$:CCL%CFK%KS2_ \LFI3I*X@(7:NW:", 'WJSX/M6M/"=
MA&XPY3<1Z9-:&I:;!JUK]FN2WE%@Q"G&<>M6U54554 *HP *'*Z 6BBBH&%%
M%% !1110 4444 %7-,_X_!]#_*J=7-,_X_!]#_*D!4/WC]324'[Q^IHI@%%%
M% !1110 5%<SK:VLMPRLRQJ6*J,DU+1F@#S6R\0VM]K+:MK=M?!HFQ:VPMV*
MQCU/O71>)O$\ECHL4UA;3R2W7"L(B?+'J174[S[?E1N(K1SBVG85CC/">IZ1
M;%+&W2\>\N#NEGE@(WM[DUV$R%X)8QU9&4?B*>6)]*3.#4RE=W&<QX(D$.CW
M=N^=UI<,CKWXYIOAVWFU/6[W7KN)D^;R;9'&"%'\6/>MRWTNVM=1GOH=RR3C
M$BY^4GUQZU=)S3<]6UU%8SKG5UMM8MM.-O*YG!/FJ/E7'K63XYBEETVQ$4;R
M$7D9(49P,]:Z?- .*496::&<OXY)G@TVP09DFNT<#V!YKJ-NP!1T Q5*72[:
M;58=1DW-/"I6,$_*,]>*NT-Z) %%%%2 4444 %%%% $MM_Q]1_[PKH9/]8WU
MKGK;_CZC_P!X5T,G^L;ZU+ ;1112 D^S17,(649 .13/[*M/^>9_.BB@ _LJ
MT_YYG\Z/[*M/^>9_.BB@ _LJT_YYG\Z/[*M/^>9_.BB@ _LJT_YYG\Z/[*M/
M^>9_.BB@ _LJT_YYG\Z/[*M/^>9_.BB@ _LJT_YYG\Z/[*M/^>9_.BB@ _LJ
MT_YYG\Z/[*M/^>9_.BB@ _LJT_YYG\Z/[*M/^>9_.BB@ _LJT_YYG\Z/[*M/
M^>9_.BB@ _LJT_YYG\Z/[*M/^>9_.BB@ _LJT_YYG\Z/[*M/^>9_.BB@ _LJ
MT_YYG\Z/[*M/^>9_.BB@ _LJT_YYG\Z/[*M/^>9_.BB@ _LJT_YYG\Z/[*M/
M^>9_.BB@ _LJT_YYG\Z/[*M/^>9_.BB@ _LJT_YYG\Z/[*M/^>9_.BB@ _LJ
MT_YYG\Z/[*M/^>9_.BB@ _LJT_YYG\Z/[*M/^>9_.BB@ _LJT_YYG\Z/[*M/
M^>9_.BB@ _LJT_YYG\Z>^G6SJH9#A>G-%% #/[*M/^>9_.C^RK3_ )YG\Z**
M #^RK3_GF?SH_LJT_P">9_.BB@ _LJT_YYG\Z/[*M/\ GF?SHHH /[*M/^>9
M_.C^RK3_ )YG\Z** #^RK3_GF?SH_LJT_P">9_.BB@ _LJT_YYG\Z/[*M/\
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,K&^M%% #:*** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>img11953243_20.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img11953243_20.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 5U"3T# 2(  A$! Q$!_\0
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MJ]10!1_LJ#^_)^8_PH_LJ#^_)^8_PJ]10!1_LJ#^_)^8_P */[*@_OR?F/\
M"KU% %'^RH/[\GYC_"C^RH/[\GYC_"KU% %'^RH/[\GYC_"C^RH/[\GYC_"K
MU% %'^RH/[\GYC_"C^RH/[\GYC_"KU% %'^RH/[\GYC_  H_LJ#^_)^8_P *
MO44 4?[*@_OR?F/\*/[*@_OR?F/\*O44 4?[*@_OR?F/\*/[*@_OR?F/\*O4
M4 4?[*@_OR?F/\*/[*@_OR?F/\*O44 4?[*@_OR?F/\ "C^RH/[\GYC_  J]
M10!1_LJ#^_)^8_PH_LJ#^_)^8_PJ]10!1_LJ#^_)^8_PH_LJ#^_)^8_PJ]10
M!1_LJ#^_)^8_PH_LJ#^_)^8_PJ]10!1_LJ#^_)^8_P */[*@_OR?F/\ "KU%
M %'^RH/[\GYC_"C^RH/[\GYC_"KU% %'^RH/[\GYC_"C^RH/[\GYC_"KU% %
M'^RH/[\GYC_"C^RH/[\GYC_"KU% %'^RH/[\GYC_  H_LJ#^_)^8_P *O44
M4?[*@_OR?F/\*/[*@_OR?F/\*O44 4?[*@_OR?F/\*/[*@_OR?F/\*O44 4?
M[*@_OR?F/\*/[*@_OR?F/\*O44 4?[*@_OR?F/\ "C^RH/[\GYC_  J]10!1
M_LJ#^_)^8_PH_LJ#^_)^8_PJ]10!1_LJ#^_)^8_PH_LJ#^_)^8_PJ]10!1_L
MJ#^_)^8_PH_LJ#^_)^8_PJ]10!1_LJ#^_)^8_P */[*@_OR?F/\ "KU% %'^
MRH/[\GYC_"C^RH/[\GYC_"KU% %'^RH/[\GYC_"C^RH/[\GYC_"KU% %'^RH
M/[\GYC_"C^RH/[\GYC_"KU% %'^RH/[\GYC_  H_LJ#^_)^8_P *O44 4?[*
M@_OR?F/\*/[*@_OR?F/\*O44 4?[*@_OR?F/\*/[*@_OR?F/\*O44 4?[*@_
MOR?F/\*/[*@_OR?F/\*O44 4?[*@_OR?F/\ "C^RH/[\GYC_  J]10!1_LJ#
M^_)^8_PH_LJ#^_)^8_PJ]10!1_LJ#^_)^8_PH_LJ#^_)^8_PJ]10!1_LJ#^_
M)^8_PH_LJ#^_)^8_PJ]10!1_LJ#^_)^8_P */[*@_OR?F/\ "KU% %'^RH/[
M\GYC_"C^RH/[\GYC_"KU% %'^RH/[\GYC_"C^RH/[\GYC_"KU% %'^RH/[\G
MYC_"C^RH/[\GYC_"KU% %'^RH/[\GYC_  H_LJ#^_)^8_P *O44 4?[*@_OR
M?F/\*/[*@_OR?F/\*O44 4?[*@_OR?F/\*/[*@_OR?F/\*O44 4?[*@_OR?F
M/\*/[*@_OR?F/\*O44 4?[*@_OR?F/\ "C^RH/[\GYC_  J]10!1_LJ#^_)^
M8_PH_LJ#^_)^8_PJ]10!1_LJ#^_)^8_PH_LJ#^_)^8_PJ]10!1_LJ#^_)^8_
MPH_LJ#^_)^8_PJ]10!1_LJ#^_)^8_P */[*@_OR?F/\ "KU% %'^RH/[\GYC
M_"C^RH/[\GYC_"KU% %'^RH/[\GYC_"C^RH/[\GYC_"KU% %'^RH/[\GYC_"
MC^RH/[\GYC_"KU% %'^RH/[\GYC_  H_LJ#^_)^8_P *O44 4?[*@_OR?F/\
M*/[*@_OR?F/\*O44 4?[*@_OR?F/\*/[*@_OR?F/\*O44 4?[*@_OR?F/\*/
M[*@_OR?F/\*O44 4?[*@_OR?F/\ "C^RH/[\GYC_  J]10!1_LJ#^_)^8_PH
M_LJ#^_)^8_PJ]10!1_LJ#^_)^8_PH_LJ#^_)^8_PJ]10!1_LJ#^_)^8_PH_L
MJ#^_)^8_PJ]10!1_LJ#^_)^8_P */[*@_OR?F/\ "KU% %'^RH/[\GYC_"C^
MRH/[\GYC_"KU% %'^RH/[\GYC_"C^RH/[\GYC_"KU% %'^RH/[\GYC_"C^RH
M/[\GYC_"KU% %'^RH/[\GYC_  H_LJ#^_)^8_P *O44 4?[*@_OR?F/\*/[*
M@_OR?F/\*O44 4?[*@_OR?F/\*/[*@_OR?F/\*O44 4?[*@_OR?F/\*/[*@_
MOR?F/\*O44 4?[*@_OR?F/\ "C^RH/[\GYC_  J]10!1_LJ#^_)^8_PH_LJ#
M^_)^8_PJ]10!1_LJ#^_)^8_PH_LJ#^_)^8_PJ]10!1_LJ#^_)^8_PH_LJ#^_
M)^8_PJ]10!1_LJ#^_)^8_P */[*@_OR?F/\ "KU% %'^RH/[\GYC_"C^RH/[
M\GYC_"KU% %'^RH/[\GYC_"C^RH/[\GYC_"KU% %'^RH/[\GYC_"C^RH/[\G
MYC_"KU% %'^RH/[\GYC_  H_LJ#^_)^8_P *O44 4?[*@_OR?F/\*/[*@_OR
M?F/\*O44 4?[*@_OR?F/\*/[*@_OR?F/\*O44 4?[*@_OR?F/\*/[*@_OR?F
M/\*O44 4?[*@_OR?F/\ "C^RH/[\GYC_  J]10!1_LJ#^_)^8_PH_LJ#^_)^
M8_PJ]10!1_LJ#^_)^8_PH_LJ#^_)^8_PJ]10!1_LJ#^_)^8_PH_LJ#^_)^8_
MPJ]10!1_LJ#^_)^8_P */[*@_OR?F/\ "KU% %'^RH/[\GYC_"C^RH/[\GYC
M_"KU% %'^RH/[\GYC_"C^RH/[\GYC_"KU% %'^RH/[\GYC_"C^RH/[\GYC_"
MKU% %'^RH/[\GYC_  H_LJ#^_)^8_P *O44 4?[*@_OR?F/\*/[*@_OR?F/\
M*O44 4?[*@_OR?F/\*/[*@_OR?F/\*O44 4?[*@_OR?F/\*/[*@_OR?F/\*O
M44 4?[*@_OR?F/\ "C^RH/[\GYC_  J]10!1_LJ#^_)^8_PH_LJ#^_)^8_PJ
M]10!1_LJ#^_)^8_PH_LJ#^_)^8_PJ]10!1_LJ#^_)^8_PH_LJ#^_)^8_PJ]1
M0!1_LJ#^_)^8_P */[*@_OR?F/\ "KU% %'^RH/[\GYC_"C^RH/[\GYC_"KU
M% %'^RH/[\GYC_"C^RH/[\GYC_"KU% %'^RH/[\GYC_"C^RH/[\GYC_"KU%
M%'^RH/[\GYC_  H_LJ#^_)^8_P *O44 4?[*@_OR?F/\*/[*@_OR?F/\*O44
M 4?[*@_OR?F/\*/[*@_OR?F/\*O44 4?[*@_OR?F/\*/[*@_OR?F/\*O44 4
M?[*@_OR?F/\ "C^RH/[\GYC_  J]10!1_LJ#^_)^8_PH_LJ#^_)^8_PJ]10!
M1_LJ#^_)^8_PH_LJ#^_)^8_PJ]10!1_LJ#^_)^8_PH_LJ#^_)^8_PJ]10!1_
MLJ#^_)^8_P */[*@_OR?F/\ "KU% %'^RH/[\GYC_"C^RH/[\GYC_"KU% %'
M^RH/[\GYC_"C^RH/[\GYC_"KU% %'^RH/[\GYC_"C^RH/[\GYC_"KU% %'^R
MH/[\GYC_  H_LJ#^_)^8_P *O44 4?[*@_OR?F/\*/[*@_OR?F/\*O44 4?[
M*@_OR?F/\*/[*@_OR?F/\*O44 4?[*@_OR?F/\*/[*@_OR?F/\*O44 4?[*@
M_OR?F/\ "C^RH/[\GYC_  J]10!1_LJ#^_)^8_PH_LJ#^_)^8_PJ]10!1_LJ
M#^_)^8_PH_LJ#^_)^8_PJ]10!1_LJ#^_)^8_PH_LJ#^_)^8_PJ]10!1_LJ#^
M_)^8_P */[*@_OR?F/\ "KU% %'^RH/[\GYC_"C^RH/[\GYC_"KU% %'^RH/
M[\GYC_"C^RH/[\GYC_"KU% %'^RH/[\GYC_"C^RH/[\GYC_"KU% %'^RH/[\
MGYC_  H_LJ#^_)^8_P *O44 4?[*@_OR?F/\*/[*@_OR?F/\*O44 4?[*@_O
MR?F/\*/[*@_OR?F/\*O44 4?[*@_OR?F/\*/[*@_OR?F/\*O44 4?[*@_OR?
MF/\ "C^RH/[\GYC_  J]10!1_LJ#^_)^8_PH_LJ#^_)^8_PJ]10!1_LJ#^_)
M^8_PH_LJ#^_)^8_PJ]10!1_LJ#^_)^8_PH_LJ#^_)^8_PJ]10!1_LJ#^_)^8
M_P */[*@_OR?F/\ "KU% %'^RH/[\GYC_"C^RH/[\GYC_"KU% %'^RH/[\GY
MC_"C^RH/[\GYC_"KU% %'^RH/[\GYC_"C^RH/[\GYC_"KU% %'^RH/[\GYC_
M  H_LJ#^_)^8_P *O44 4?[*@_OR?F/\*/[*@_OR?F/\*O44 4?[*@_OR?F/
M\*/[*@_OR?F/\*O44 4?[*@_OR?F/\*/[*@_OR?F/\*O44 4?[*@_OR?F/\
M"C^RH/[\GYC_  J]10!1_LJ#^_)^8_PH_LJ#^_)^8_PJ]10!1_LJ#^_)^8_P
MH_LJ#^_)^8_PJ]10!1_LJ#^_)^8_PH_LJ#^_)^8_PJ]10!1_LJ#^_)^8_P *
MSKA/LUR\<;L%&._M6_6'J'_'])^'\A0!>TK_ (]6_P!\_P A5ZJ.E?\ 'JW^
M^?Y"KU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %8>H?\?TGX?R%;E8>H?\?TGX?R% %[2O\ CU;_ 'S_ "%7JHZ5_P >
MK?[Y_D*O4 %%%% &;K&OZ7H,"RZE=I &^ZN"6;Z*.37!>'/'6G?\)3K,^H:G
M.EI<N@M%EW%% SGCHO:F:F]F/C%C70AM/*46WG?ZL'8,9SQC=N_&O0KK1=)U
M&V\JYL+6:(CC,8X'L>WX4 73+&L1E+J(PNXN3QCKG/I7'W?Q0\-VLYB22YN,
M'!>&+Y?S)&:ZR2T@EL7LGC!MWC,3)DCY",8SUZ5'9Z;8:;9_9[2UA@MPN"JJ
M "/?U_&@"KH?B/3/$5N\VG7'F;,"1&&UDSTR*NWU_:Z99R7=[.D,$8RSL>!_
MB?:O-?!<4+?$S69=*4#341U)3[G++@#VR#CV%7/B S:MXIT#PX21!*XFF /4
M%L?H%;\Z +__  M7PYY_E_Z9MS_K/)&W^>?TKK[*^MM1LX[NSF2:"091U/!J
M-]+L9-,.FM:Q&SV;/)V_*!7"_#&62ROM=T)V+):7!*9]02K?^@K0!U6O>+M'
M\.%4O[@^<XRL,:[GQZX[#ZU0T?XB:!K-XEI'+-;S2'"+<(%W'T!!(S7/^ 8(
M_$'B76?$=W&)'68+;[N=F<]/HH4 _6M#XI:3!<>&CJ8C5;JTD0B4##%2=N,_
M4@_A0!W=%9OA^_?4_#VGWLG^LF@1GQ_>QS^N:LZA=BPTVZO&&1;PO*1Z[03_
M $H Q-=\<Z'X?N3;74[R7(&6B@7<5^O0#Z9I=!\<:)XAN/LUK-)'<D96&==K
M-ZXY(/YU@?"[3DFL;O7KI1)?75PX$K<D+QG'IDD_D*@^*%FFG2Z7XBM(UCNX
MKD(SJ,;SC<N?7&T_G0!Z+--%;0///(L<4:EG=S@*!W)KC9_BIX;AG,:F[F4'
M'F1P_+^I!_2J7Q.U*2;0]+T^W.#J4H/7JHQ@?FR_E7:Z?I%EINE1Z;!;Q_9E
M3:4*@A_4MZD]Z #2M7L=;LEO-/N%FA)P2."I]"#R#5ZO-?"*#0?B5K6APC;:
MRKYB)G[N,,H'X.17I5 !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 5AZA_Q_2?A_(5N5AZA_Q_2?A_(4 7M*_P"/
M5O\ ?/\ (5>JCI7_ !ZM_OG^0J]0 4444 8^O>&=+\1P+'J$&73[DR':Z?0_
MT.17!:GHGB'P! =2TC57N=-B8>9;S=%!..5Z$9/48/-;NJ^+M?\ #VHWGV[0
M&N=,5R8;F D;4[;CR/SQ65JFN:_XWTW^S=)T&>VM+G!>ZN#A2N0>#@#MVS0!
MWNAZJFMZ)::E&FP3IN*YSM/0C\P:YC5_AX^K7-U,WB#4%6>1G$+'<B9.< 9'
M':MN#3[KP[X06RTF-+F[M8?W:R<"1LY/<=23WKGD^),L \K4/#>I0W0X*(F0
M3[9 - %3PQ?WGA/Q*GA+48K9H9AN@N(8PA8D'!;'7.TCGG(ZFD\0Y3XQZ&SG
MY6A3;^<@_G4FBZ?JWB?QK%XEU.Q>PL[5-MO#(/F;&<<'GJQ.<>F*O?$+0;^]
M%AK.D1F2^T]]VQ1EF7((P.^".GN: .WKS7P4IF\=>+98FX\R10?<R-@_I4[?
M$B]GLS!;>';\ZH5VA/+)16]>F<>V*U_ 7ARXT'29IK__ )"%Z_F3#.=H[ GU
MY)_&@#$^$!']CZBG\0N 2/\ @/\ ]:M[XBNJ>!-2W'J(P/KYBUR^W4_A_P"*
M[^YBTV:[T:^8O^X7.SDD#V(R1SU%&L:CJOQ#:VTO3M+NK/3O,$EQ<W"X''Z<
M9SC.3QTH [+P2AC\%Z2K=3 &_/)_K5CQ4K-X2U<)G/V.7I_NFG:D\NB>&I3I
MEMYTEI %@AP6R%  &!R>*K>&=0O/$'AP3ZO9+!),71H@C*&3IG!YP: ,OX7L
M#X)A /(FD!_.JGQ;=1X4MU)Y:\7 _P" /6-I%]JGPYN[S3KW3+F[TR20R0S0
MKGVSGIR ,CC&*L7"ZE\1->L1)IL]EH=H^]VG7:9#W'N3C'&<<T 1>.XV@N?!
MOF$[4PI/H08\UZG7*>/_  [-XAT +9H&O+:3S8AG!88P5!]^OX"L6S^(][!8
MI:WWA_4'U-%VD+&0'8<9(QD9X[&@!MH/-^-]ZR'B.W&[_OV@_K7H]<1X%T'4
M(;N_\0:S'Y5_?GY8B,%$)R<CMDXX[ 5V] !1110 5'.LK18A8*^>IJ2B@"CY
M6H_\_$?Y?_6H\K4?^?B/\O\ ZU7J* */E:C_ ,_$?Y?_ %J/*U'_ )^(_P O
M_K5>HH H^5J/_/Q'^7_UJ/*U'_GXC_+_ .M5ZB@"CY6H_P#/Q'^7_P!:CRM1
M_P"?B/\ +_ZU7J* */E:C_S\1_E_]:CRM1_Y^(_R_P#K5>HH H^5J/\ S\1_
ME_\ 6H\K4?\ GXC_ "_^M5ZB@"CY6H_\_$?Y?_6H\K4?^?B/\O\ ZU7J* */
ME:C_ ,_$?Y?_ %J/*U'_ )^(_P O_K5>HH H^5J/_/Q'^7_UJ/*U'_GXC_+_
M .M5ZB@"CY6H_P#/Q'^7_P!:CRM1_P"?B/\ +_ZU7J* */E:C_S\1_E_]:CR
MM1_Y^(_R_P#K5>HH H^5J/\ S\1_E_\ 6H\K4?\ GXC_ "_^M5ZB@"CY6H_\
M_$?Y?_6H\K4?^?B/\O\ ZU7J* */E:C_ ,_$?Y?_ %J/*U'_ )^(_P O_K5>
MHH H^5J/_/Q'^7_UJ/*U'_GXC_+_ .M5ZB@"CY6H_P#/Q'^7_P!:CRM1_P"?
MB/\ +_ZU7J* */E:C_S\1_E_]:CRM1_Y^(_R_P#K5>HH H^5J/\ S\1_E_\
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M^5J/_/Q'^7_UJ/*U'_GXC_+_ .M5ZB@"CY6H_P#/Q'^7_P!:CRM1_P"?B/\
M+_ZU7J* */E:C_S\1_E_]:CRM1_Y^(_R_P#K5>HH H^5J/\ S\1_E_\ 6H\K
M4?\ GXC_ "_^M5ZB@"CY6H_\_$?Y?_6H\K4?^?B/\O\ ZU7J* */E:C_ ,_$
M?Y?_ %J/*U'_ )^(_P O_K5>HH H^5J/_/Q'^7_UJ/*U'_GXC_+_ .M5ZB@"
MCY6H_P#/Q'^7_P!:CRM1_P"?B/\ +_ZU7J* */E:C_S\1_E_]:CRM1_Y^(_R
M_P#K5>HH H^5J/\ S\1_E_\ 6H\K4?\ GXC_ "_^M5ZB@"CY6H_\_$?Y?_6H
M\K4?^?B/\O\ ZU7J* */E:C_ ,_$?Y?_ %J/*U'_ )^(_P O_K5>HH H^5J/
M_/Q'^7_UJ/*U'_GXC_+_ .M5ZB@"CY6H_P#/Q'^7_P!:CRM1_P"?B/\ +_ZU
M7J* */E:C_S\1_E_]:CRM1_Y^(_R_P#K5>HH H^5J/\ S\1_E_\ 6H\K4?\
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M^7_UJ/*U'_GXC_+_ .M5ZB@"CY6H_P#/Q'^7_P!:CRM1_P"?B/\ +_ZU7J*
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MJ/\ S\1_E_\ 6H\K4?\ GXC_ "_^M5ZB@"CY6H_\_$?Y?_6H\K4?^?B/\O\
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MCRM1_P"?B/\ +_ZU7J* */E:C_S\1_E_]:CRM1_Y^(_R_P#K5>HH H^5J/\
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MB/\ +_ZU7J* */E:C_S\1_E_]:CRM1_Y^(_R_P#K5>HH H^5J/\ S\1_E_\
M6H\K4?\ GXC_ "_^M5ZB@"CY6H_\_$?Y?_6H\K4?^?B/\O\ ZU7J* */E:C_
M ,_$?Y?_ %J/*U'_ )^(_P O_K5>HH H^5J/_/Q'^7_UJ/*U'_GXC_+_ .M5
MZB@"CY6H_P#/Q'^7_P!:CRM1_P"?B/\ +_ZU7J* */E:C_S\1_E_]:CRM1_Y
M^(_R_P#K5>HH H^5J/\ S\1_E_\ 6H\K4?\ GXC_ "_^M5ZB@"CY6H_\_$?Y
M?_6H\K4?^?B/\O\ ZU7J* */E:C_ ,_$?Y?_ %J/*U'_ )^(_P O_K5>HH H
M^5J/_/Q'^7_UJ/*U'_GXC_+_ .M5ZB@"CY6H_P#/Q'^7_P!:CRM1_P"?B/\
M+_ZU7J* */E:C_S\1_E_]:CRM1_Y^(_R_P#K5>HH H^5J/\ S\1_E_\ 6H\K
M4?\ GXC_ "_^M5ZB@"CY6H_\_$?Y?_6H\K4?^?B/\O\ ZU7J* */E:C_ ,_$
M?Y?_ %J/*U'_ )^(_P O_K5>HH H^5J/_/Q'^7_UJ/*U'_GXC_+_ .M5ZB@"
MCY6H_P#/Q'^7_P!:CRM1_P"?B/\ +_ZU7J* */E:C_S\1_E_]:CRM1_Y^(_R
M_P#K5>HH H^5J/\ S\1_E_\ 6H\K4?\ GXC_ "_^M5ZB@"CY6H_\_$?Y?_6H
M\K4?^?B/\O\ ZU7J* */E:C_ ,_$?Y?_ %J/*U'_ )^(_P O_K5>HH H^5J/
M_/Q'^7_UJ/*U'_GXC_+_ .M5ZB@"CY6H_P#/Q'^7_P!:CRM1_P"?B/\ +_ZU
M7J* */E:C_S\1_E_]:CRM1_Y^(_R_P#K5>HH H^5J/\ S\1_E_\ 6JW$'$2B
M0@OCDBGT4 %%%% !1110 5AZA_Q_2?A_(5N5AZA_Q_2?A_(4 7M*_P"/5O\
M?/\ (5>JCI7_ !ZM_OG^0J]0 4444 9OB#2WUK0;O3HYQ TZA?,*[L<@],CT
MQ5C3+(:;I5G8A]XMX4BW8QNVJ!G'X5:HH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH *P]0_X_I/P_D*W*P]0_P"/Z3\/Y"@"]I7_ !ZM
M_OG^0J]5'2O^/5O]\_R%7J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH *P]0_X_I/P_D*W*P]0_P"/Z3\/Y"@"]I7_ !ZM
M_OG^0J]5'2O^/5O]\_R%7J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH *P]0_X_I/P_D*W*P]0_P"/Z3\/Y"@"]I7_ !ZM
M_OG^0J]5'2O^/5O]\_R%7J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH *P]0_X_I/P_D*W*P]0_P"/Z3\/Y"@"]I7_ !ZM
M_OG^0J]5'2O^/5O]\_R%7J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH *P]0_X_I/P_D*W*P]0_P"/Z3\/Y"@"]I7_ !ZM
M_OG^0J]5'2O^/5O]\_R%7J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH *P]0_X_I/P_D*W*P]0_P"/Z3\/Y"@"]I7_ !ZM
M_OG^0J]5'2O^/5O]\_R%7J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH *P]0_X_I/P_D*W*P]0_P"/Z3\/Y"@"]I7_ !ZM
M_OG^0J]5'2O^/5O]\_R%7J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH *P]0_X_I/P_D*W*P]0_P"/Z3\/Y"@"]I7_ !ZM
M_OG^0J]5'2O^/5O]\_R%7J "BBB@ HK)UOQ)I7AZ)7U&Z$;/]R-1N=OH!V]^
ME<!X=\>:;%XIUF[O[NYCMKMT^S;U+*BC/4#..U 'JM%1M/$MN9VD40A=Y<G@
M+C.<^F*XN[^*OA^WG,<,=Y=*I^:2*,!<>HW$']* .XHK'T#Q/I?B2!Y-/F8M
M'CS(I%VNF>F1_A2>(_$MCX8LH[J^69UDD\M5A4%B<9[D#MZT ;-%<#_PMW0/
M^?/4O^_4?_Q==?HNKV^NZ3!J5JLBPS9VB5<,,$@YP3W% %^BN?\ $'C+2/#D
MB0W;R2W+C*P0+N?'J>0!^=4=*^(VC:E?I8RI<V5PYVJ+E H)[#()_7% '744
M44 %%<QKGCS1]#O?L+>?=7@ZPVR!BI]"20/PY-&A>/-'UZ\%E'Y]M=G[L-PH
M4MZX()']: .GHJ*XN(;2VDN+B58H8U+.[' 45Q<OQ4T1)&\JTU">!#AITB&W
M\,D'\\4 =S16?HVMV&OV(O-/F$D>=K C#(?0CL:T* "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MPHVZC_STC_S^% %ZBJ.W4?\ GI'_ )_"C;J/_/2/_/X4 7J*H[=1_P">D?\
MG\*-NH_\](_\_A0!>HJCMU'_ )Z1_P"?PHVZC_STC_S^% %ZBJ.W4?\ GI'_
M )_"C;J/_/2/_/X4 7J*H[=1_P">D?\ G\*-NH_\](_\_A0!>HJCMU'_ )Z1
M_P"?PHVZC_STC_S^% %ZBJ.W4?\ GI'_ )_"C;J/_/2/_/X4 7J*H[=1_P">
MD?\ G\*-NH_\](_\_A0!>HJCMU'_ )Z1_P"?PHVZC_STC_S^% %ZBJ.W4?\
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MPHVZC_STC_S^% %ZBJ.W4?\ GI'_ )_"C;J/_/2/_/X4 7J*H[=1_P">D?\
MG\*-NH_\](_\_A0!>HJCMU'_ )Z1_P"?PHVZC_STC_S^% %ZBJ.W4?\ GI'_
M )_"C;J/_/2/_/X4 7J*H[=1_P">D?\ G\*-NH_\](_\_A0!>HJCMU'_ )Z1
M_P"?PHVZC_STC_S^% %ZBJ.W4?\ GI'_ )_"C;J/_/2/_/X4 7J*H[=1_P">
MD?\ G\*-NH_\](_\_A0!>HJCMU'_ )Z1_P"?PHVZC_STC_S^% %ZBJ.W4?\
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MPHVZC_STC_S^% %ZBJ.W4?\ GI'_ )_"C;J/_/2/_/X4 7J*H[=1_P">D?\
MG\*-NH_\](_\_A0!>HJCMU'_ )Z1_P"?PHVZC_STC_S^% %ZBJ.W4?\ GI'_
M )_"C;J/_/2/_/X4 7J*H[=1_P">D?\ G\*-NH_\](_\_A0!>HJCMU'_ )Z1
M_P"?PHVZC_STC_S^% %ZBJ.W4?\ GI'_ )_"C;J/_/2/_/X4 7J*H[=1_P">
MD?\ G\*-NH_\](_\_A0!>HJCMU'_ )Z1_P"?PHVZC_STC_S^% %ZBJ.W4?\
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M=%2]TI6+131-M*IVW$9QCW%9FH:IXG\=::MA8:&;"PN<%[F=\ADR",' XZ=
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5AZA
M_P ?TGX?R%;E8>H?\?TGX?R% %[2O^/5O]\_R%7JHZ5_QZM_OG^0J]0 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M26-@R. RL.A%/KM.'8**** "BBB@ HHHH **** "L/4/^/Z3\/Y"MRL/4/\
MC^D_#^0H O:5_P >K?[Y_D*O51TK_CU;_?/\A5Z@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ J*XN8;2%IKB58XUZLQP*Q=9\56>F;H8<7%R
M.-BGY5/N?Z5P6HZK>:K-YEU*6Q]U!PJ_05P8G,*=+W8ZL]'"Y=4K>]+2)T6L
M^-))=T&F QIT,S#YC]!V_G]*Y%F:1R[L69CDDG))JYINDWFJS>7:Q%@/O.>%
M7ZFN^T;PK9Z7MEE N+D<[V'"GV']:\R-+$8V7-+;\/D>I.KAL#'EBM?Q^9S&
MC>$+J_VS7>ZVMSS@CYV'L.WU-=W8Z=::=;^1:PJB'[W<M]3WJU17L8?"4Z"]
MU:]SQ,3C*M=^\].Q1;1=+9][:?;%LY_U0J+4]!L=4MA%)$(V08C>, %/_K>U
M:=%;.C3::<5J8JM434E)W1Y1J^AW>CS;9UW1$_)*OW6_P/M4.G:G=Z7<":UD
M*G^)3RK#T(KUF:"*XA:&:-9(V&&5AD&N%UWP?+:[KG3@TL/5HNK)]/4?K7BX
MG 3HOVE';\4>YALPA67LZ^_X,Z71/$=IK"A,B*Z YB8]?=3WK9KQ=6:-PRDJ
MRG((."#79Z%XR^[;:H?9;C'_ *%_C71A,R4O<JZ/N<^+RQQ]^CJNQVM%(K*Z
M!T8,K#((.012UZQXX4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 5P_CN^D\^WL58B/9YK =SD@?E@_G7<5YOXPOK6^U93;
M-O\ *C\MW'0D$GC\ZX,RGRT&K[GHY7#FQ"=MCGJ***^;/ICO/ M])-:7%H[$
MK"0R9[ YR/S'ZUUM<KX(T^2WL)KN1<?:"-@/]T9Y_$G]*ZJOJ<#S?5X\W]=C
MY/'\OUB7+_7<****ZCD"BBB@ HHHH **** "L/4/^/Z3\/Y"MRL/4/\ C^D_
M#^0H O:5_P >K?[Y_D*O51TK_CU;_?/\A5Z@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **0D*"20 .237*ZSXS@MMT&G!9Y>AE/W%^GK_*LJU>%&/--FU&
MA4K2Y8*YT-_J-IIL'G74RQKV'=O8#O7!ZSXNN]0W0VN;:W/'!^=A[GM]!6'=
M7EQ?3F>YE:60]V/\O2KVD>'[W5V#1)Y<&>9G''X>M>)6QM;$2]G25E^)[E'
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%(S!5+,0%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MR.W-<-_R_C\_\S?HHHKV3Q HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHJGJ6IVNE6IGN7P.BJ/O,?0"E*2B
MKR>A48N3Y8J[)[BYAM('GN)%CB09+-7G?B#Q/-JK-!!NBLP?N]W]S_A5+6=<
MNM9GW2G9"I^2('A?\3[U'I6D76KW/E6Z_*/OR'[J#W_PKP<5C9UY>RI;?F>_
MA,###Q]K6W_!%>TLY[ZY6WMHS)(W0#^9]!7HV@^&X-'02R8ENR.9,<+[+_C5
MS2=&M='MO+@7+G[\I^\Q_P /:M"N[!X"-+WYZR_(X<;F$JWN0TC^84445Z)Y
M@4444 %%%% !1110!#/:V]TFRX@CE7T=0?YUB7?@W2;C)C22W;_IFW'Y'-=#
M1652C3J?'%,UIUZE/X)-' W?@6\CR;6YBF'HPV'^HK"N]&U&QS]HLY44?Q 9
M7\QQ7K=%<53*Z,OA;1WT\VK1^-)GBU%>GZ_HEO?:9<-#:Q?:PNY'50&)'.,^
M_3\:\PZ'!KR,5A98>23=[GLX3%1Q,7)*U@JQ80)=:A;V\C%$ED5&8=0"<57K
M3\/V<E[KEJB D(XD<^BJ<G_#\:QI1YIJ/F;U9<L'*^R/3[2T@L;9+>WC"1H.
M /YGWJ>BBOKDDE9'QC;;NPHHHIB"BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "L/4/^/Z3\/Y"MRL/4/\ C^D_#^0H O:5_P >K?[Y_D*O
M51TK_CU;_?/\A5Z@ HHHH Q=>\4Z5X;1#J$Y$DG*0QKN=AZX]/<UP.@>-["Q
M\4:S?ZB+V&WOY$\@O'D(HS]X \<8Z9[U-J=S;Z5\8?M>M "T>)?L\D@RJ?(
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M9X8LEE).<8 )&"3@X(P:-27Q'X_GM[&32)M(TN.0/,]QD,WT! SP3@ =>IH
MZ[P7$8?!FDJ>IMPWY\_UJQXHC,OA35T&<FSEQC_<-2:L;NP\/W']D0![F&'%
MO%C(XX Q]*I^&)M5U+PXIU^W\NYD+(Z,FPLG;([4 97PN=7\%1*#DI/(I]CG
M/]153XMR*OA6VC)^9KQ<#Z(]9FFP^(OA]J%W:V^D3ZMI4[[XS "6!]> <'&
M01V&#5D6.N^./$%C=ZIICZ;I-D^\039W2'(."" 3G [  4 5?'T7V.;P>\AP
ML1"MGMM,?^?PKU*N9\<^&G\3:%Y-N5%W _F0[C@,<8*Y[9'Z@5@6GB_Q79V"
MV5SX2O;B]C41B<*VQCT!.%(^N#S[4 -L@+CXW7SIR(;?D_\ ;-!_,UZ/7'^!
M_#E]IKWVK:P5.IW[[G4$'RUSG&1QR3T'H*["@ HHHH *CG$IC_<D!\]ZDHH
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MPHVZC_STC_S^%7J* *.W4?\ GI'_ )_"C;J/_/2/_/X5>HH H[=1_P">D?\
MG\*-NH_\](_\_A5ZB@"CMU'_ )Z1_P"?PHVZC_STC_S^%7J* *.W4?\ GI'_
M )_"C;J/_/2/_/X5>HH H[=1_P">D?\ G\*-NH_\](_\_A5ZB@"CMU'_ )Z1
M_P"?PHVZC_STC_S^%7J* *.W4?\ GI'_ )_"C;J/_/2/_/X5>HH H[=1_P">
MD?\ G\*-NH_\](_\_A5ZB@"CMU'_ )Z1_P"?PHVZC_STC_S^%7J* *.W4?\
MGI'_ )_"C;J/_/2/_/X5>HH H[=1_P">D?\ G\*-NH_\](_\_A5ZB@"CMU'_
M )Z1_P"?PHVZC_STC_S^%7J* *.W4?\ GI'_ )_"C;J/_/2/_/X5>HH H[=1
M_P">D?\ G\*-NH_\](_\_A5ZB@"CMU'_ )Z1_P"?PHVZC_STC_S^%7J* *.W
M4?\ GI'_ )_"C;J/_/2/_/X5>HH H[=1_P">D?\ G\*-NH_\](_\_A5ZB@"C
MMU'_ )Z1_P"?PHVZC_STC_S^%7J* *.W4?\ GI'_ )_"C;J/_/2/_/X5>HH
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MX5>HH H[=1_YZ1_Y_"C;J/\ STC_ ,_A5ZB@"CMU'_GI'_G\*-NH_P#/2/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L/4/^/Z3\/Y
M"MRL/4/^/Z3\/Y"@"]I7_'JW^^?Y"KU4=*_X]6_WS_(5>H **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !7GOC'1OL5[]MA7$%P?F _A?O\
MGU_.O0JK7]E%J-C+:S#Y)!C/<'L1]*YL7AU7IN/7H=6#Q#H55+IU/,M!U5M(
MU-)\DPM\LJCNO^(ZUZHCK)&KHP9& *D="*\?O;26PO);688DC;!]_>NS\%:Q
MYL)TR=OGC&Z$GNO<?A_GI7F9;B'";HS_ *9ZN9X=5(*O#^D=?1117N'@!111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/_$^]3^'O#<6D1B>;;)>,.6[)[#_ !K?K7!8#D_>5-^W8RQV8.I>G2V[]_\
M@!1117JGD!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 5AZA_Q_2?A_(5N5AZA_Q_2?A_(4 7M*_X]6_W
MS_(5>JCI7_'JW^^?Y"KU !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MIJT(XJE'VBMU]#V2WN8;J$2V\J2QGHR'(J6O)]&U>?2+Y)HV8Q$_O(\\,/\
M&O58I4GA26-MR.H93Z@U[N$Q:Q$7I9H\#&8-X:2UNF/HHHKL.(**** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHJ.XN(K6!Y
MYY%CB099CVI-I*[&DV[(=)(D,;22.J(HRS,< "O//$?B=]29K6T)2T!Y/0R?
M7V]JA\0^(Y=7D,,6Z.S4\+W?W/\ A67I^GW.IW:V]LFYSR2>BCU)]*\/&8V5
M9^RH[?F>_@L#&BO:UM_R&6EI/?7*6]M&7D<\ ?S/M7I.@^'X-&@W<273#YY/
M3V'M_.IM&T2VT:VV1#?,W^LE(Y;_  'M6G79@L"J/OS^+\CBQV/=9\D-(_F%
M%%%>B>8%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 5AZA_Q_2?A_(5N5AZA_P ?TGX?R% %[2O^
M/5O]\_R%7JHZ5_QZM_OG^0J]0 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M+6PCWW,RQCL#U/T%<MJ/C"5\QV$?EK_ST<9;\!T'ZT =7=7EM91>9<S)&O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MOXHL=+W1J?/N1_RS0\ ^Y[5PFJ:[?:L_^D2XBSQ$G"C_ !_&LY59V"J"S$X
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !6'J'_'])^'\A6Y6'J'_ !_2?A_(4 7M*_X]6_WS_(5>JCI7_'JW^^?Y
M"KU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 $ C!Y%<?JW@A9I3+ILBQ9Y,4F=H^A[?2NPHK&M0IUE::
M-J&(J4)7@SS^W\"W[R@7$\$<?<J2Q_ 8%=GIFEVVDVOV>V4@$Y9F.2Q]35VB
MHH82E1=X+4TKXRM75IO0****Z3E"BBB@!ABC8DF-"3ZBHS8VC##6L!'H8Q4]
M%)Q3W0U)K9E1M*TY_O6%JV/6%3_2HVT/2F.3IUK^$0%7Z*ETX/=(M59K:3^\
MRSX<T=LYT^'GT!%<=XI\/_V;<"YM(B+1QR!D^6W^!KT6D95=2K ,I&"",@US
MU\'3JPY4K/N=&'QM6E/F;;7:YXO4]G9SW]TEO;H7D<XX[>Y]J](E\)Z-+(7-
MIM)ZA'8#\LUH66G6>G1E+2W2('KCJ?J3R:\V&53YO?:L>G4S>GR^Y%W\Q=.L
MDT[3X+2,Y6)<9]3W/YYJS117N1BHI)'@RDY-M[L****8@HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH *P]0_X_I/P_D*W*P]0_P"/Z3\/Y"@"]I7_ !ZM_OG^0J]5
M'2O^/5O]\_R%7J "BBB@ HK"\0^+M*\->6MZ\CSR#*00KN=ATSV 'U-<%HGB
M^VTGQ-K&J:I8W\$.I2)Y3M%]Q1GK^G3/2@#UJBFQR++$DB'<C@,I]0:YOQ)X
MYTGPYF&1S<WG_/O"1E?]X_P_S]J .FHJCHVI+K&CVNH)&8UN$#A&.2*H>*?%
M%OX6L8;FX@DG\V3RU6,@=B<DF@#=HK@?^%G?]2YJ7_?/_P!:NOT74_[8TF"_
M^S2VWF[OW4PPRX)'/Y9H OT5S'B#QO8:%>IIZ03WVH.,BWMQDCTR?4^@R:H6
M/Q'M7U..PU;3+O2I9" C7 XYZ9R 1]<8H [:BBB@ HKD=8\?6=AJCZ986-UJ
ME\G#QVRY"GN,\DD>PHT3Q_9ZIJ@TN\L[C3;YCA([@<,?3/!!^HH ZZBJ]]?6
MVFV4MY>2K%;Q+N=V["N);XF^9&]S9>'=2N+)#S<;<*,=>@('YT =]163X?\
M$>G^); W5B[?*=LD3C#QGW']:UJ "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P!LO_1J4 6O!'_(EZ3_ -<!_,US'Q@_Y FG_P#7R?\ T$UT_@C_ )$O2?\
MK@/YFM+4M)L-7A2'4+6.XC1MRJXZ'IF@"I:^)]!G$<4>L6)D( "^>H)/MS6Q
M7):K\._#U[8RI!9):3[3Y<L1(VGMD9P16=\+=1N=1\,W-I<2,XMI/+C<]0I&
M<9]CG\Z *OPU1=6U;6_$%PH:XEFV1L1]P')('X;1^%:GQ1L(KKP=+<L@,MI(
MCHV.0"P4CZ<_H*S/A"P72]3A/$B7"EAZ97']#6[\1I%C\":B&/+^6H]SYBT
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M[K_G\;]: +U%4?L=U_S^-^M'V.Z_Y_&_6@"]15'['=?\_C?K1]CNO^?QOUH
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M/V.Z_P"?QOUH^QW7_/XWZT 7J*H_8[K_ )_&_6C['=?\_C?K0!>HJC]CNO\
MG\;]:/L=U_S^-^M %ZBJ/V.Z_P"?QOUH^QW7_/XWZT 7J*H_8[K_ )_&_6D:
MUN%4LUZ0!R2>WZT 7ZBN+B&UB,L\BQH.I8XKE-1\0_9F,=K=-<..K#(4?XUS
MEU>W-[)ON9GD(Z;CP/I0!T>J>+V?=%IZ[1T\UQS^ _QKF)99)I&DE=G=N2S'
M)-6+#3+O4I-EM$6 ZN>%7ZFNILO"26^UY9EDE'JORB@# TSP_>ZEAPOE0'_E
MHXZ_0=Z[/3=#LM, :--\W>5^3^'I4GV.Y'_+VWY4?8[K_G\;]: +U%4?L=U_
MS^-^M'V.Z_Y_&_6@"]15'['=?\_C?K1]CNO^?QOUH O451^QW7_/XWZT?8[K
M_G\;]: +U%4?L=U_S^-^M'V.Z_Y_&_6@"]15'['=?\_C?K1]CNO^?QOUH O4
M51^QW7_/XWZT?8[K_G\;]: +U%4?L=U_S^-^M'V.Z_Y_&_6@"]15'['=?\_C
M?K1]CNO^?QOUH O451^QW7_/XWZT?8[K_G\;]: +U%4?L=U_S^-^M'V.Z_Y_
M&_6@"]15'['=?\_C?K1]CNO^?QOUH O451^QW7_/XWZT?8[K_G\;]: +U%4?
ML=U_S^-^M'V.Z_Y_&_6@"]15'['=?\_C?K1]CNO^?QOUH O451^QW7_/XWZT
M?8[K_G\;]: +U%4?L=U_S^-^M'V.Z_Y_&_6@"]15'['=?\_C?K1]CNO^?QOU
MH O451^QW7_/XWZT?8[K_G\;]: +U%4?L=U_S^-^M'V.Z_Y_&_6@"]15'['=
M?\_C?K1]CNO^?QOUH O451^QW7_/XWZT?8[K_G\;]: +U%4?L=U_S^-^M'V.
MZ_Y_&_6@"]15'['=?\_C?K1]CNO^?QOUH O451^QW7_/XWZT?8[K_G\;]: +
MU%4?L=U_S^-^M'V.Z_Y_&_6@"]15'['=?\_C?K1]CNO^?QOUH O451^QW7_/
MXWZT?8[K_G\;]: +DD:2QM'(BNC#!5AD&N6U7PB&W3:<<'J86/'X'_&MW['=
M?\_C?K1]CNO^?QOUH \VFAD@E:*9&1UZJPP16GI7B"[TPA,^;;_\\V/3Z'M7
M67FA"_3%Q-O(Z-CD?C7+:IX<O-.!D4>? /XT'*_44 =GIVKVFIQY@DPX'S1M
MPPJ]7D\<CQ2+)&[(ZG(93@BM_3_$DQ98[VXD5>GFCG'U% '<T5G10S3Q+)%?
M[T;D,IR#^M/^QW7_ #^-^M %ZBJ/V.Z_Y_&_6C['=?\ /XWZT 7J*H_8[K_G
M\;]:/L=U_P _C?K0!>HJC]CNO^?QOUH^QW7_ #^-^M %ZBJ/V.Z_Y_&_6C['
M=?\ /XWZT 7J*H_8[K_G\;]:/L=U_P _C?K0!>HJC]CNO^?QOUH^QW7_ #^-
M^M %ZBJ/V.Z_Y_&_6C['=?\ /XWZT 7J*H_8[K_G\;]:/L=U_P _C?K0!>HJ
MC]CNO^?QOUH^QW7_ #^-^M %ZBJ/V.Z_Y_&_6C['=?\ /XWZT 7J*H_8[K_G
M\;]:/L=U_P _C?K0!>HJC]CNO^?QOUH^QW7_ #^-^M %ZBJ/V.Z_Y_&_6C['
M=?\ /XWZT 7J*H_8[K_G\;]:/L=U_P _C?K0!>HJC]CNO^?QOUH^QW7_ #^-
M^M %ZBJ/V.Z_Y_&_6C['=?\ /XWZT 7J*H_8[K_G\;]:/L=U_P _C?K0!>HJ
MC]CNO^?QOUH^QW7_ #^-^M %ZBJ/V.Z_Y_&_6C['=?\ /XWZT 7J*H_8[K_G
M\;]:/L=U_P _C?K0!>HJC]CNO^?QOUH^QW7_ #^-^M %ZBJ/V.Z_Y_&_6C['
M=?\ /XWZT 7J*H_8[K_G\;]:/L=U_P _C?K0!>HJC]CNO^?QOUH^QW7_ #^-
M^M %ZBJ/V.Z_Y_&_6C['=?\ /XWZT 7J*H_8[K_G\;]:/L=U_P _C?K0!>HJ
MC]CNO^?QOUH^QW7_ #^-^M %ZBJ/V.Z_Y_&_6C['=?\ /XWZT 7J*H_8[K_G
M\;]:/L=U_P _C?K0!>HJC]CNO^?QOUH^QW7_ #^-^M %ZBJ/V.Z_Y_&_6C['
M=?\ /XWZT 7J*H_8[K_G\;]:/L=U_P _C?K0!>HJC]CNO^?QOUH^QW7_ #^-
M^M %ZBJ/V.Z_Y_&_6C['=?\ /XWZT 7J*H_8[K_G\;]:/L=U_P _C?K0!>HJ
MC]CNO^?QOUH^QW7_ #^-^M %ZBJ/V.Z_Y_&_6C['=?\ /XWZT 7J*H_8[K_G
M\;]:/L=U_P _C?K0!>HJC]CNO^?QOUH^QW7_ #^-^M %ZBJ/V.Z_Y_&_6C['
M=?\ /XWZT 7J*H_8[K_G\;]:/L=U_P _C?K0!>HJC]CNO^?QOUH^QW7_ #^-
M^M %ZBJ/V.Z_Y_&_6C['=?\ /XWZT 7J*H_8[K_G\;]:/L=U_P _C?K0!>HJ
MC]CNO^?QOUJE?7*:<N;C4B&[(,EC^% "^(]6?3+-1 P%Q*<*<9V@=35C0]2_
MM/34E8CSE.V0#U]?QK@M2OI-0NVF=F*@;4W=0*M:#>/;:@L0F,4<Y"L1TSV/
M^?6@#T6BJ/V.Z_Y_&_6C['=?\_C?K0!>HJC]CNO^?QOUH^QW7_/XWZT 7J*H
M_8[K_G\;]:MQ*R1*K-N8#D^M #Z*** "BBB@ K#U#_C^D_#^0K<K#U#_ (_I
M/P_D* +VE?\ 'JW^^?Y"KU4=*_X]6_WS_(5>H **** .#UO5?&7AV[OKP6]K
M?Z0&,B%B%:)/3@@_H:S[@^,?'>FQ6YL[;3=*N KM,7R9%X(XSG'0]!]:[W6=
M+CUK2+C3II)(XYP%9X\;A@@]_I4]C:1Z?I]M9Q$F.WB6)2W4A0 ,_E0!'I>G
M0Z1I5O86V3%!&$7/4^Y^IKS_ ,1:GXKU_0[G2V\)S0K-M_>"7=C:P;ICVKTR
MB@#@/"NI>);"WTW2)_#,J6\>V)[EI<;5SRV,=JW/$=_XDT^[@FT?3HK^SV$3
M1%L.&SU'/I[&NCHH \]O->\9ZW:O8V/AI]/:9=CSSR?=!ZD9 Q^M=)X1\-IX
M8T1;/>))W8R3N.A<@#CV  %;U% 'F]WI'B#PCXIO-6T.R^WV%Z2TMNAY!)SC
M'7@DX(SP:9?VOB?QY<VUK>Z8VD:3%)YDN]\NY_'!)QG'&.?I7I=% &;K'VVU
MT"Y&CQ*;N.+%NF!@$=, \=*J^%GUBY\/H?$$8%XS,&#*H)7MD#BMRB@#S&RL
M?$W@+4KJ+3],;5=)N)-Z+&WS*?PR0<<'C!P*LQ:5X@\8^(;*_P!;L1IVF63;
MX[9FRSMP>1UY(&20..E>BT4 <[XT\.'Q-H+6L3*MS&XEA9NFX<8/U!/Z5SEI
MXD\;65DNGS>&)+B[C78MR6.TX'!..#]017HM% '(^"/#5YI"WFI:LZOJE^^^
M7!!V#).,CC))YQQP*ZZBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MYSPIJH@N9+2XEQ'+\RLYX#?_ %_Z5[Y\Z=K140N8&.%FC)]F%2*RM]U@?H:
M%HHHH **** "BBB@ HHHH ***Q=?UPZ2L20HCS.<D-T"T ;5%9DFO6$5A%=R
M2@"1=RQCEC[8^O%<KJ?B>[OLQP9MX3V4_,?J?\* .FU/Q#9Z;E-WG3C_ )9H
M>GU/:N-U+6[S4V(EDVQ9XB3A?_KUG@%F  ))/ '>NBTSPG<7.V6])@BZ[/XS
M_A0!@06\UU*(H(VD<]%49KJ]+\(*NV746W'KY*'C\3_A716=A;6$7EVT2H.Y
M'4_4]ZLT ,BBC@C6.)%1%Z*HP!3Z** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** ,'5?"]M>[I;;$$YYX'RM]1V_"N,O;"YT^;RKF(H>Q[-]#7J-1
M7%M!=PF&XB62,]0PH \VT_5+O3)=]O)A3]Y#RK?45VNE>([34=L;GR;@_P #
M'AOH:Q-5\)RP;I; F6/J8C]X?3UKFB"K%6!# X(/44 >LT5PFE>*+FRVQ769
MX!QDGYE^A[_C7965_;:A#YMM*'7N.Z_4=J +-%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !17!^(]6DGU<""0A+4X0@_Q=S_3\*[+3KU-0L(KE,?.
M/F'H>XH M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 445F:AKMAIV5DEWRC_EG'R?Q]* -.J%_K-CIH(GF!D_YYIRWY=OQKD-0\4W
MUYE(3]FB/9#\Q_'_  K$))))))/4T ;^H>++RZREL/LT9[@Y<_CV_"L!F9V+
M,Q9CR23DFM?3_#=_?X<IY$)_CD&,_0=36]_PAEEL4&XGW <D8Y_2@#B:*[7_
M (0RR_Y^9_T_PH_X0RR_Y^9_T_PH TM!U'^T=+CD8YE3Y)/J._XUIUFZ3HL&
MD>;Y,LC^9C.\CC&?3ZUI4 %%%% !1110 4444 %%%% !6'J'_'])^'\A6Y6'
MJ'_'])^'\A0!>TK_ (]6_P!\_P A5ZJ.E?\ 'JW^^?Y"KU !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !117)ZMXUAMI3#81K<,O#2,<+GV]:RK5Z=%7F[&U&A4K2
MY::N=917!V_CR[$@^TVD#IW\O*G]2:['3]1MM4M1<6K[DS@@C!4^A%9T<72K
M.T'J77PE:@KS6A;HHHKI.8**** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBN7\5^(?L$1L;5_])<?.P/^K4_U-95JT:,'.1K1HRK34(F;XN\0^<S:;:/^
M[4XF<'[Q_NCV]:Y>RLYK^[CMK=-TCG ]![GVJ)$>61412SL<  9)->F>'-!3
M1[3?( UW*/WC?W1_=%>%3A4QU;FEM_6A]!5J4\!0Y8[_ )ON7-(TJ#2+%;>+
MENLCXY=O6KY( R3@"@D 9)P!7%>(?$)NBUG9OB </(/X_8>W\Z^@C%0BHQV1
M\Y.<IR<I/5E/Q)JBZCJ&V)LP0_*I'1CW/^?2L:BBJ)"BMKPVEE<WQM+R!9/,
M&8R<@@CMQ[?RKJV\-:0QR;,?@[#^M 'G@D=1@.P'H#4@N[D'(N)0?9S7=GPM
MI))Q;L/I(W^-1GPEI9& LP]P] '&+J5\OW;VY'TE;_&GKK&I*,"_N/QD)KK6
M\'::>DEROT<?X5&?!ECGY;BX ]RI_I0!S0UW5!C%[+QZG-/'B/5U.1>-^**?
MZ5O'P7;\XNY1Z944QO!*8^6_8'WBS_6@#(7Q1JXZW(;ZQK_A3QXLU4#!DC/N
M8Q6@W@EOX;\'ZQ8_K3#X*N,\7D1'NIH K#QAJ0(RMN?JA_QK)O[Z;4;MKF?;
MO8 87H .PJQJND2:2T:2S1N[@G:F>!ZG-9U !6MIGAZ]U+#[?)@/_+1QU^@[
MUF0R&&9)5 )1@P##(.*]0L[J.\LXKB+[DBY ]/:@"IINB66F*#$F^7O*_+?A
MZ5I444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M];\* .1T_P ,7U[AY5^SQ'^)Q\Q^@_QQ75Z?H%AIV&2/S)1_RTDY/X>E:E%
M!1110 4444 %%%% !1110 4444 %%%% !1110 5AZA_Q_2?A_(5N5AZA_P ?
MTGX?R% %[2O^/5O]\_R%7JHZ5_QZM_OG^0J]0 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!14<\\5M$TL\B1QKU9S@"N4U3QO%'F+38_-;IYL@PH^@ZG]*QK8BG15YLWHX
M:K6=H(T?%U])9:$_E-M>9Q%D=0""3^@Q^->:59O=0NM0F\V[G>5NV3P/H.@J
MM7SF+Q'MZG,MCZ7!X;ZO3Y7N%=%X-OI+?6TMPQ\JX!5A[@$@_P"?6N=J:TNI
MK*ZCN8&VRQG*G&:RHU/9U(S[,VKT_:TY0[H]CHKF]%\76NH;8;O;;W!X!)^1
MOH>WT-=)7U5*M"K'F@[GR56C.E+EFK!1116AD%%%% !1110 4444 %%%% !1
M110 4452U34X-)L7N9STX51U9NP%3*2BG*6Q48N348[LJ>(=<31K/Y<-=2#$
M2>G^T?85YC++)/*\LKEY'.YF/4FIK^^GU*\DNKALNYZ=E'8#VKHO"7A[[7(N
MH7:?N$/[I"/OGU^@KY^K4GC:RC#;^M3Z.C3IX&BYSW_K1&EX2\/?98UU&[3]
M^X_=(1]P>OU-=82 ,DX H) &2< 5Q7B'Q";HM9V;X@'#R#^/V'M_.O=HT8T8
M*$3P*]>5:;G(/$/B$W1:SLWQ .'D'\?L/;^=<_;V\MW.D$"%Y'. !1;V\MW.
MD$"%Y'. !7H.BZ+%I,'9[AQ\\G]![5J8D.F^&[*TM0MQ%'<3'EV89 ]A[5<_
ML;3/^?&#_O@5>HH JPZ98V\HEAM(4D'1E0 BK5%% !1110 4444 %%%% !11
M10!SNK>&9-3U![D7@0,  I3.W ^M4?\ A"I/^?Y/^_9_QKL** ./_P"$*D_Y
M_D_[]G_&M_1=,?2K)K=Y_-RY8'& /:M&B@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M:&"*VB$4,:QH.BJ,"@#F].\'Q1XDOY/,;_GFAPOXGJ:VO[&TT_\ +C;_ /?
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M1++5X\7$>) /EE7AA_B/:N UCPY>Z0Q=E\VW[3(./Q':O+JX:OA)<]-Z=_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M[5J444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M./Y5M6O@G1[?!DCEN"/^>C\?D,5T5%=$<+2CLC54H+H5K;3K*S'^C6L,7NB
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M\=:5/@3K-;MW++N'YCG]*W+75+"^Q]FNX92?X5<9_+K7D5S8W=FV+FVEA/\
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M_E5I/$>DR=+Q1_O*P_F*WCE,?M2,)9Q+[,/Q.*A\':S+C=#'%_OR#^F:OP^
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M]XLO]#7C^SQ4>_WG7RUD31?$*X'^MT^)_P#<D*_T-7(OB#:'_6V,R_[C!O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %8>H
M?\?TGX?R%;E8>H?\?TGX?R% %[2O^/5O]\_R%7JHZ5_QZM_OG^0J]0 4444
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M_3_&NXM;2"R@6&WC"(.P[^Y]: *.D:%;:4@8#S+@CYI2/T'H*U*** "BBB@
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MZAE8,IY!!R#61<>)M+MM46PDF(D)PS@?(A]":WE.,=6S1M+<V****H84444
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M&'V%MVWVSWIFN:Y9>']->^OG*Q@[551EG;L /6J7@C_D2])_ZX#^9KE_&_\
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ML#W_ )5Z/0 =**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0FE1O[TAL<:0Q+'$BHBC"JHP *=117IG4%%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MGA*KJP]Z,K7TU6G3O9W_ *U./%T?:+FCN4J=;:CH=MK5O8:W>FS%PI,<A'R
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M7 Q>.=8C^\8)?]^/_ BK\7Q"N!_KM/B?_<D*_P P:U6-I/R+5>!U_P!CNO\
MG\;]:/L=U_S^-^M<_%\0+%O]=9W"?[A5OZBKT/C31)<;KAXB?[\9_IFM5B*3
MVD6JL'U-+['=?\_C?K1]CNO^?QOUID.OZ1/C9J-MSV9PI_6KL<\4PS%*CCU5
M@:T4HO9E)I[%7['=?\_C?K1]CNO^?QOUJ]7$^(?&;PW/V;2G7Y#^\FP&!/H,
M]O>E.HH+4F<U!79U'V.Z_P"?QOUKCM?\32P.]G87CR,.'F4\#V7_ !JIJ_C*
MZU*Q2VA3[/N7$[*>6/H/05SL$$MS.D,,;22.<*JC))KS\1C.;W:9A4K7TB-
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MS^-^M7J* */V.Z_Y_&_6C['=?\_C?K5ZB@"C]CNO^?QOUH^QW7_/XWZU>HH
MH_8[K_G\;]:/L=U_S^-^M7J* */V.Z_Y_&_6C['=?\_C?K5ZB@"C]CNO^?QO
MUH^QW7_/XWZU>HH H_8[K_G\;]:/L=U_S^-^M7J* /+/'WQ*E\#ZU!I@M)+V
M22 3L_G^4%!8@#[IS]TURG_"_+C_ * ;_P#@?_\ :ZS/CU_R/UM_V#H__0Y*
M\NK]%RO(<OKX.G5J4[R:N]9?HSDG5FI-)GLG_"_+C_H!O_X'_P#VNNW^'OCR
M;QX]_&()+&2T"-@S>8&#9[X&.E?,E='X4\;:OX->[?23 'NE57,L>[ 4DC'/
MN:TQW#.$EAY+"PM/2SO+OYM]!1K2O[ST/K'['=?\_C?K1]CNO^?QOUKYBN?B
M[XXN@0=;,:GM%!&OZA<_K6-<^-_%5X3Y_B+5"#U5;IU'Y @5XD.#\4_CJ17W
MO]$:/$1['UJUK<(I9KTA0,DGH/UK-N=8TRR)%UXFL(".OFW2+C\VKY$N+RYN
MSFYN)ICZR.6_G4-=D.#8_;K?<O\ @DO$=D?4]S\0O"EH#YGBVV;'_/(-)_Z"
M#6/<_&+PK 3Y>JWMSC_GE;,,_P#?6*^<*MVNEZA>X^R6%U/GIY4+/_(5UQX2
MP,%>I.3^:7Z"]O)['M=S\=M,7/V6SU.7T\THG\F:LBX^/5^21;:2$'8R71;]
M HKA+;X?^+[O'E>'-2&?^>D!C_\ 0L5LVOP;\;W&"VE1P ]Y;F/^08FJ_LK(
M:/QN/SG_ ,$7/5>Q<NOC?XJG5DC2RA4C&51R?U;'Z5YM7JD'P$\3,A>XOM,A
M4#) D=F_+;C]:\KKU<L_L_WE@;=+V^=OU(GS_:"BBBO5,ST?PE\&]<\2V=OJ
M%Q<0:?83J'C=CYDCJ>A"C^I'TKUC0?@_X>T,K)Y0O;E>?-NUWX/LOW1^6?>N
M@\ ?\D^T#_KQB_\ 0171U^6YIG>-KU9TG.T4VK+3K]YW0IQ2N4!97*J%6[(
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M?L=U_P _C?K1]CNO^?QOUJ]10!1^QW7_ #^-^M'V.Z_Y_&_6KU% %'['=?\
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ME;);V\8CB08514S5*KB76I*T?S?=&^%IR2YI$U%%%;'<%%%% !1110 4444
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MKYNIPI-<2#_5MRL8]/K[UU1 .,C..E+4*D]%-W2V3Z&4,/",G(Q)?".AR_\
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MKLZFBO*O^%_>%?\ H'ZS_P!^8O\ XY1_PO[PK_T#]9_[\Q?_ !RO0_L/,?\
MGTR/:P[GJM%<5X1^*&A>,]5DT[3X+Z&X2(R_Z3&JAE! ."K'GD=:[6N'$8:K
MAY^SK1Y7YEIIJZ"BBBL!A1110 4444 %%%% !28&0<<CO2T4 %%%% !1110
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M^//^@[_Y*0?_ !%>=B^$*WM6\--<OG>Z^Y,N.(5O>/JJBOE7_A</CS_H._\
MDI!_\17TEX3U&XU?PEI.HW94W%S:QR2%1@%BHR<=J\3,LDQ&70C.JTTW;2_Z
MI&D*BGHC8HHHKQS0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** (KFVAO+9[>XC$D3C#*:
MSM'\.V.BF1[<.\C_ /+20@D#T%:U%2X1;4FM4+E3=PHHHJAA1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% "%0P(8 @]C5"XT/2KG/FZ?;DG
MJ0@4_F*T**3BI;H32>YS=QX'T>8'RUF@/;9)G_T+-<)K6BW.BWAAF&Y&YCE
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M7C0B[.3L3*7*KGI=%?'/_":>*O\ H9M9_P# ^7_XJC_A-/%7_0S:S_X'R_\
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MHX^:SG8!C_N'HP^G/L*[.OS'$8>KAYNG6BXM=SM335T%%%%8C"BBB@ HHHH
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M!Z?=IO\ PS]X?_Z"VI_G'_\ $UZY17K_ -O9C_S]?X?Y&?LH=CR/_AG[P_\
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M!2JGJQSC.:^=:*RS#*:.,H.BDH[:I(<*CB[GV3)XO\,PD"7Q%I*$] U[&/\
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M7JHZ5_QZM_OG^0J]0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MCKQ1KVY=0UN[DC;K$C^7&?\ @*X'Z5<\'_#O7/&L<L^G?9H[:*3RWFGDP V
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MD3[" 4445\X;!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MS?VT.Y[C17AW_#1/_4K?^5#_ .U5TVB_&OP[>Z'+?ZK_ ,2V=)3&+17,SN,
M@C"CCG'( XZUC5R',:4>:5)_)I_@FV-58/J>ETV21(HVDD=411EF8X 'N:\)
M\0?'^XDW1>']+6%>@N+P[F_!%. ?J37EVN>+->\22%M6U2XN1G(C+8C'T084
M?E7H8/A3%UM:S4%][^Y?YD2KQ6VI]&>(/B_X2T/=''>'4;@?\L[(!QGW?[OY
M$UY9X@^.GB+4MT6E0PZ7">-R_O9?^^B,#\!^->8P6\UU.D%O#)-*YPL<:EF8
M^P'6O0?#_P %_%6L[);N&/2[<\[KH_/CV0<Y^N*^AAD^4Y;'GQ#3?]Y_DO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MF-L\1Q;,G;NM#G'O\U-_X9YN_P#H8X?_  %/_P 57O%%>]_K+F?_ #\_"/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M6KCKR"P_5*T_A?,LG@F%%/,4TB-]<Y_D15#XN2J?#UC;#F62\#*HZD!&!_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !6'J'_'])^'\A6Y6'J'_'])^'\A0!>TK_CU;_?/
M\A5ZJ.E?\>K?[Y_D*O4 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 5AZA_Q_2?A_(5N5AZA_Q_2?A_(4 7M*_X]6_WS_(5
M>JCI7_'JW^^?Y"KU !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %8>H?\?TGX?R%;E8>H?\?TGX?R% %[2O^/5O]\_R%7JH
MZ5_QZM_OG^0J]0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !6'J'_'])^'\A6Y6'J'_'])^'\A0!>TK_CU;_?/\A5ZJ.E?
M\>K?[Y_D*O4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 5AZA_Q_2?A_(5N5AZA_Q_2?A_(4 7M*_X]6_WS_(5>JCI7_'J
MW^^?Y"KU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %8>H?\?TGX?R%;E8>H?\?TGX?R% %[2O^/5O]\_R%7JHZ5_QZM_O
MG^0J]0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !6'J'_'])^'\A6Y6'J'_'])^'\A0!>TK_CU;_?/\A5ZJ.E?\>K?[Y_D
M*O4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 5AZA_Q_2?A_(5N5AZA_Q_2?A_(4 7M*_X]6_WS_(5>JCI7_'JW^^?Y"KU
M !1110 4444 %%%% !1110 45"]W;1W,=M)<1+<2@F.)G 9P.N!U-34 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M]E0?WY/S'^%']E0?WY/S'^%7J* */]E0?WY/S'^%']E0?WY/S'^%7J* */\
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M"C_94']^3\Q_A1_94']^3\Q_A5ZB@"C_ &5!_?D_,?X4?V5!_?D_,?X5>HH
MH_V5!_?D_,?X4?V5!_?D_,?X5>HH H_V5!_?D_,?X4?V5!_?D_,?X5>HH H_
MV5!_?D_,?X4?V5!_?D_,?X5>HH H_P!E0?WY/S'^%']E0?WY/S'^%7J* */]
ME0?WY/S'^%']E0?WY/S'^%7J* */]E0?WY/S'^%']E0?WY/S'^%7J* */]E0
M?WY/S'^%']E0?WY/S'^%7J* */\ 94']^3\Q_A1_94']^3\Q_A5ZB@"C_94'
M]^3\Q_A1_94']^3\Q_A5ZB@"C_94']^3\Q_A1_94']^3\Q_A5ZB@"C_94']^
M3\Q_A1_94']^3\Q_A5ZB@"C_ &5!_?D_,?X4?V5!_?D_,?X5>HH H_V5!_?D
M_,?X4?V5!_?D_,?X5>HH H_V5!_?D_,?X4?V5!_?D_,?X5>HH H_V5!_?D_,
M?X4?V5!_?D_,?X5>HH H_P!E0?WY/S'^%']E0?WY/S'^%7J* */]E0?WY/S'
M^%']E0?WY/S'^%7J* */]E0?WY/S'^%']E0?WY/S'^%7J* */]E0?WY/S'^%
M']E0?WY/S'^%7J* */\ 94']^3\Q_A1_94']^3\Q_A5ZB@"C_94']^3\Q_A1
M_94']^3\Q_A5ZB@"C_94']^3\Q_A1_94']^3\Q_A5ZB@"C_94']^3\Q_A1_9
M4']^3\Q_A5ZB@"C_ &5!_?D_,?X4?V5!_?D_,?X5>HH H_V5!_?D_,?X4?V5
M!_?D_,?X5>HH H_V5!_?D_,?X4?V5!_?D_,?X5>HH H_V5!_?D_,?X4?V5!_
M?D_,?X5>HH H_P!E0?WY/S'^%']E0?WY/S'^%7J* */]E0?WY/S'^%']E0?W
MY/S'^%7J* */]E0?WY/S'^%']E0?WY/S'^%7J* */]E0?WY/S'^%']E0?WY/
MS'^%7J* */\ 94']^3\Q_A1_94']^3\Q_A5ZB@"C_94']^3\Q_A1_94']^3\
MQ_A5ZB@"C_94']^3\Q_A1_94']^3\Q_A5ZB@"C_94']^3\Q_A1_94']^3\Q_
MA5ZB@"C_ &5!_?D_,?X4?V5!_?D_,?X5>HH H_V5!_?D_,?X4?V5!_?D_,?X
M5>HH H_V5!_?D_,?X4?V5!_?D_,?X5>HH H_V5!_?D_,?X4?V5!_?D_,?X5>
MHH H_P!E0?WY/S'^%']E0?WY/S'^%7J* */]E0?WY/S'^%']E0?WY/S'^%7J
M* */]E0?WY/S'^%']E0?WY/S'^%7J* */]E0?WY/S'^%']E0?WY/S'^%7J*
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *P]0_X_I/P_D*W*P]0_X_I/
MP_D* +VE?\>K?[Y_D*O51TK_ (]6_P!\_P A5Z@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***S==UJU\/
MZ3-J%V243A47J['HHH TJ*\UN+SXB7=DVM6_D6ML!YB6(52Y3KT()/'N#Z 5
MU_A37AXDT"'4"@CE)*2HO0..N/;H?QH VZ*** "BBB@ HHHH **** "BBB@
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MP057\:PXO$'BGP;JMO#XFD6[TZX;;YZX.WU(; /'7![=*].5@RAE(((R".]
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M0>M=[7G'BR:'Q)XVT32-.(EELI3+<S)R(URI(SZC;^9 ZUZ/0 4444 %%%%
M!1110 45E^(=<M_#NC3:A< L$^5(P<%W/0?Y[ UP9'Q'U2U_MF"XCMD8>9%9
MKM#%>WRD'/\ P(YH ZS6?#DNK>*](U"61'L;(.S0MUW]5(]><?\ ?-'CK4[/
M3O"5\MT5+7,30Q1GJSD8&/IU_"F>"O%1\3:=*+F,0W]JP2>,# /H0#R.AX]1
M6K?:!INI:E:7]W;B6>TSY6XG:,^HZ&@#SK1M4\::/X8M5T_P^AT^W0L6F!,C
MY)8G:&!Q\W&!7=>%?$UOXHTG[7$GE3(VR:'.=C?7N#6CJFJ6FCZ?+>WLRQPQ
MC.2>6/H!W)]*X_X8V,Z6>IZK)$88=0GWPQ^B@MR/;YL?A0!WE%%% !1110 4
M444 %%%% !1110 5AZA_Q_2?A_(5N5AZA_Q_2?A_(4 7M*_X]6_WS_(5>JCI
M7_'JW^^?Y"KU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%175Q':6DUS*2(X4:1L>@&30 ]W5%W.P4>I.*KZC!)?:5=
M6]O*J23P.B2=0I*D _K7G.EZ!<?$5)-:UN^GBM&D9+6UMV " <9Y!'MTR:AN
MM-\0?#>87NG7+W^C;OWL3_P_4=O]X?B.U '51>![.?P5:Z%?!3+"A(GCY*2$
MDDJ3U&3^(KG?#_B"^\%ZH/#GB,G[)TM;H\JJ]N?[O_H/TZ=YH>N6?B#3([ZR
M?*-PR'[R-W4^]4?&6GZ/?^'ISK+K##$"R3_Q1MVV^N>F.] &M?2V*V#F_D@6
MTD&QS,P",&XP2>.<URT?PO\ #27OV@Q7#IG(@:7]V/TS^M<OX-\-:CXEM+23
M6;B9]#M&)M;=^/-_^Q'_ -85ZTJA5"J  !@ =J &Q11PQ+%$BQQH-JHHP /0
M"GT44 %%%% !1110 4WS$W[-Z[QSMSS7'^.-;O[>73]"TE_*OM2?;YV<>6F0
M,CW.>O;![XK)N/A0D=N)['6;I=37YO-DX5F_#YE^N30!U&I:!-?^,-)U9I4-
MK91R9B.<[ST(_3_OFN;\5>%;S2=0_P"$G\,9CN8R7N+9!PX[D#OGN/Q'-+X9
M\97UCJG_  CWBE3%>*=L5P_ ?T#'H<]F[UZ'0!@>%?%5GXHT_P V+$=U& )X
M">4/J/4'L:TKIQ?07=E9:@D-XJ8+1E7>$D<$K_C7F7BZS33/&UJWA69TUFX)
M\ZW@ *KGN>PSU(/'?BNW\)^%4\/6TDT\IN-3N?FN;AB3D]<#/;/?O_( 3PWX
M/MM!EEO9KB2^U.;_ %EU+U^@ZX_G72444 %%%% !1110 4C,%4LQ  ZDT$@
MDG '4UYC96%S\3;RZO[Z]FM]&@E,5O;PD L0 <G(QG!')!Z^U 'IA/F1'RG
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M/RKO+6Z@O;6*YMI5EAE4,CJ>"#7F+>(;3PSX^\3WESEBT:+%$O61\*<>WUH
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MGD=_8 ]#O[./4-.N;.4 QSQM&V?<8KCOA5.[^%)8).MO=O&!Z#"M_,FNY!!
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M-<$#?:R)(I[\D*1_X]^E-\&^-'U:9M(UB/[/J\.00R[?-QUX[-ZC\1[:'C\
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M,Z+H6E31M<#9<SRGY8E[C(_F>?09KT#1=,CT;1K33HFW+!&%W8QN/4G\3DT
M0^'_  ]8^&].%G9)UYDE;[TC>I_P[5JT44 %%%% !112.ZQHSNP55&2Q. !Z
MT +534-5L-*B$M_>0VR-PIE<#=]/6A=3M)-+;4H9EFM5C:3S(SD$+G./R->>
M>'?#8\<2S^(_$+220S.RVUNKE55 <=1V'3CT)- ';W@L?%/AV\MK.\AFBN(F
MC$D;A@K8XSCT..*Y/X=Z\;4/X5U0>1?6CL(0_&\9R5^HR2/4'VK.N]-;X=>+
MK"\L99#I-\_E2QNV=O/(/KC.0>O!'UZ7QGX+7Q J7UC(+?58,%) <!\= 2.A
M'8_Y !U5S;07EM);7,2RPR*5=&&017G/AR.;PA\0IO#HD9M.OD,MN&.<'!(/
MU^5E/K@5'9_$75-!_P! \3Z5.;B,865 %+_4=#]0:T?#=CJ7B+Q3_P )9JMJ
M;2&*/RK*W;[V,$9/M\S=N<\=* -S4_!>EZOXA@UB[5W>) K0G[DA'W21[>G?
MC\>B P,#I110 4444 %%%% !15>6^M8+J"UEN(TGGSY4;-\SX&3@5R?C_4KT
MC3_#^F.8[O5)-C2 XVQC&>?QY]@: -\^)=#%]]C.K6?VC.W9YPZ^GU]JY#X@
M6UWI&N:9XMLX_,%KB*=?1<G&?8AF&?I4\_PIT5M(-O"\RWP7BY9R<M[KTQ].
M?>I/A]J$NJ:+?Z%JRB6:P<V\BR<[D.1M/KC:P^F* .LTG5;36M-BO[*3?#(/
MQ4]P1V(KF_B!X9BU;2)-1MUV:E9)YD<B\%E7DKG\R/?ZUSUWH>O> =2EU#P^
MKWFE2',EL06*CT('/'9A^/O+<_$&\\2V#Z5H>CW'VZX4QR,Q!6('@G/Y\G&*
M .G\+WX\5^"8_MV6::)[:XQP6ZJ3]2,'\:M>&O"NG^%[1XK0,\LAS)/)C<WH
M/8#TJ3POH@\/>'[;3MX>1 6D<=&<G)Q[=OPK8H **** "BBB@ HHJO:7UK?P
MF:TN(YX@Q0O&V1D<$9H 2]U"STVW\^]NHK>+.-\KA1GTY[U7AO=,\0Z?<16E
MY#<PR(8Y/*<$J&&.1V_&N"TK2O\ A8FLWFLZJ\ITJ"0PVENK%<@?RXP3CJ3[
M57\0Z%_PK_5;+Q!HK2"S,@BG@9L\'G&3U! /7H0* +7@757\-ZK<^$M7Q$XF
M+6TAX5R>V?0\$?B*]*DC26-HY$5T8%65AD$'L17,^+/"=IXMTZ.6)UBO$7=;
MW&."#SAO;^7YYY:R\<:WX4(T[Q1ITTRH-L=ROWF';GH_USGUH ?!;-X&^(]M
M:VK,-*U8A1$3D*Q. /J&(Y]&KK=?\':;XBU&RO+WS,VW!13@2+UP?Q]/4US>
MEQ:CXV\4VFO7EFUGI5AS:QR?>E;J#^>#GIP!SR:]%H ;'&D4:QQHJ(H"JJC
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MA_(5N5AZA_Q_2?A_(4 7M*_X]6_WS_(5>JCI7_'JW^^?Y"KU !1110 4444
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MIG'_ 'R,?5*]&H X&S46_P 9[_' GL03[\)_\36SK'C"WT[7+/1K2V>^OII
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M;Q9HX$690MS"O"L3W^C<@^^#UKJO%6DQ^*?",B0C=(T8N+8XYW8R!^()'XT
M='351$+%552QRQ QD^IKFO 6MMK?A> RD_:;4_9YL]25 P?Q&/QS73T %%%%
M !1110 445'+/##M\V5(]QPN]@,GVH R_%&N+X=T"YU'8'D0!8D/1G)P/P[_
M (5Q<'@#4/$=E'JNLZW<+?SJ)455RL0(R!C/Z#&*ZOQOHTNN>%;NUMQNN%Q+
M$O\ >9><?B,C\:H^ /$T6M:-'92L$U"S01RQG@LHX##^OH?J* .>LO$6N>!M
M4CTOQ(7NM-D.(KOEBH]0>I [J>1V]^YUW3(/$OANXM%=&2XC#0RCD!NJL#Z9
MQ^%6-8T>SUW39;&]C#Q..#W1NS ]B*XSX>W5YI>KZGX3O9#(;/,D#?[.1G'L
M=RD#W- %_P"&^L27VA/IMUN%[IK^0ZMUV\[?RP5_X#78NB2+M=593V89%>=Z
MT#X2^(MIK" BPU3]S<8Z*W )_P#06_[ZKT:@ HHHH **** "BBB@ KA?B#KF
MKV-SIFG:&SB[F+S,L:@LRIR!CN/O9'?%=M'<0S,RQ31NR_>"L"1]:RI?#Z2^
M+X->><DPVI@2$KPI)/S _0D4 4_"'B^V\3V6"%AU"(?OH,_^/+[?R_GTM>?^
M+_"%S!>_\))X;+0ZA$=\L48_UGJ0/7U'?Z]=OPAXOMO$]E@A8=0B'[Z#/_CR
M^W\OY@&!XUC?PWXJTWQ7;JQB9A!>*O<8Q^JY_%17H4<B31)+&P9'4,K#H0>A
MK"U!])\7:9JFC6]W%-)&-DFW_EF_53[X([>A%9/PVU6:?1Y]'O 5O-+D\EE;
MKMR<?D01^ H Z^&TM[>6:6&"*.29MTK(@!<^I/>IJ** "BBB@ HHHH *1B%4
MLQP ,DFFRS10+NED2-2<9=@!FH[N 7EA/;B0H)HF0.O)7(QD?G0!Y9H_Q#U.
MUU9KS5TD?1KZ5A%($XBP<?+Z@#&1U[_7U>&:*X@2:&19(I%#(ZG(8'H0:P;7
MPC8IX1A\/WBB>%$.7 VG>23N7T.2:XS3]0U'X;:P-+U0O<:'.Q,,X&=GN/ZK
M^(]P#TK4["'5=,N;"X&8IXRC>V>X]QUKC?AQJ$UNE]X9OB?M6G2-LSW3/./8
M'GZ,*ZV\UK3;#3DU"YO8H[1]NR7.0V>F,=?PKB/&:GP_XGTOQ=: M!(1#=;.
MC+C@^^5S_P!\B@#T5T61"CJ&5A@J1D$4H&!@=*:CK)&KH0RL 01W%.H ****
M "BBB@ HHJ-9X7E:))4:1?O*&!(^HH XSQ=JVI7FN6GA719_L]Q<IYEQ<@X,
M:<\#TX!/'L*RKKX;:GI2_;M UNX-\GS%7.WS#]<_H>*E\;K<^'?%^F^*X8C+
M; "&X4=NH_53Q[BN^L+^VU.QBO+.598)5W*P_P \'VH Y/P=XW;5YVTC5XOL
MVKQ9!!7:)<=>.S>H_+VJ?$.TFTR]TWQ79*?.LY%CG _B0GC/MR5_X$*G^(7A
MI;FQ;7[#,.I6($ID3@NB\_F.H/MCTK8T:YC\8>"8FNU&+N!HI@!T894D>G(R
M/PH VK*[AO[&"\MVW0SQB1#[$9J78GF>9M7?C;NQSCTS7"?#B]GM#J'AB]S]
MHTZ0F//="><>V>?^!5WM !1110 4444 %%%,DECA0O+(J(.K,< 4 ,O+J.QL
MI[N8XB@C:1S[ 9/\J\UL="U+XBP/J^K:C+:V,C,MK:P\@ '&3VZC&<9..W%>
MBZA:QZII-U:;QLN87BW#GA@1G]:X3X=ZR=,EG\)ZH/(N[>5O(W<!P3DK_4>H
M- %"5O$GPWN4=YGU/0V;!W9^3\\[#^AKT6QOK#Q'HPG@836ERA5E(YP>"I'8
MU;N+>&[MY+>XB66&12KHPR&![5YOH\,O@GXA#14D9M+U(;XE8YVGG'X@C;[@
M@T 6O D\F@Z_J?A*Z=B(W,UJS?Q+W_,8/YUZ&0""",@]17 ?$6SFT^XT[Q59
M*?/L9%28#^)">,^V25_X%7<65W%?V-O>0',4\:R)GT(S0!,JJB!$4*JC  &
M!2T44 %%%% !1110 5S'CW6;G1O#+R63E+NXE6")AU!.2<>^ :Z/[1#Y_D^=
M'YN,[-PW?E63KOA]-<N=+EDG*)8W(G,>W(DQV/\ GUH P?!OC*6\G.A:ZIM]
M7@.P%QCSL?\ LW\^HKN*Y3QEX-B\10"ZM6%OJL S%,#C=CD*Q_D>U4O!OC*6
M\G.A:ZIM]7@.P%QCSL?^S?SZB@!WQ)TF6?28-:L\K>Z9()59>NS(S^1 /X&N
MFT+5HM<T2UU&+ $R990?NMT8?@0:275-+GU)]$DN8GNWB):W/4H1R#VZ=NN.
M:XSP0\GAWQ1J?A2X+>46-Q:,W=?_ *ZX/U4T =]]DM_M?VOR(OM.S9YVP;]O
M7&>N/:IJ** "BBB@ HHHH **:[K&A=V"J.2S' %$<B2H'C=70]&4Y!H \PUO
MQOK&G>,KV>WC:?1[!TMYX@/ERPY)/9L@@'VQWKT32M5L]:T^*^L91)#(/Q4]
MP1V(K.T;PQ!ID>K).ZW8U&Y>:3>G56_A/KU/YUQ%]8ZC\-=8.HZ<'N-"N& F
MA)SL]CZ'T;\#[@'JI (((R#U%><^&R?"?CV^\/2$BROOW]IGH#R0/R!7ZJ*[
M6RUW3;_1AJT-TGV/:69V.-F.H;T(KDO'4$6L^'+/Q-H\PDDL6\Z*6,=4SS[\
M$ \],&@#OJ:B)&@1%55'0*,"J.AZI'K6B6FHQC"SQABO]UNC#\""*T* "BBB
M@ HHHH ***C,\*RB)I4$AY"%AD_A0!S7C?Q#<Z+I]M;:<H.HW\ODV^?X>F3]
M>0/QKGI?A?>R0B\_X2"X.KXW&5L[=WINSN_']*TOB9IEU<:79ZM9 M/IDOFX
M SA3C)_ JI^F:Z'PWXAM?$FD1WMNP#X"S19YC?N/IZ'O0!R'AWQEJ.DZL/#_
M (L4I/D+%=-WSTW'H0>S?G6U\0M$;5O#3SP _:[$_:(BO7 ^\!^'/U J[XM\
M,6_B?26@<*MU&"UO-W5O0^Q[_P#UJS/AQK-QJF@26EZ2UU82>0Q;DE<<9]^H
M_"@#8\)ZVOB#PY:WV?WVWRYAZ2#@_GU_&MAD1F5F525.5)'0].*\[\/ ^$_B
M#>Z P(L=1'GVOH#R<#_QY?\ @(KT:@ HHHH **** "BBD)"@DD #DDT +7FT
MHU#XA:[?6D5])9:'8OY9\K[TS<\^_3//3CC->C1313IOBD21/[R,"*\RT:]'
M@;QSJ.F:C^[L-0D$D$Y^Z.3MR?3D@^A'I0!'>>'/$7@3_B8Z%?R7EC'S-;N.
MB]R5Z$>XP17<>%_$]GXHTW[3;_NYDPLT!/*-_4'L:W.M>7>);(^!?%5GXATW
M]W8W4GEW,"_=&>2 /0C)'H10!:B_XH_XFM%RNFZT,KV59"?Z,<?1Q7H]<I\0
M-$.L^&9)( 3=69^T0E>IQ]X#ZC]0*O\ A'6_[?\ #=K>M_KMOES#_;7@_GU_
M&@#:5$3.Q57)).!C)]:=110 4444 %%%% !6?KFH?V5H5]?C&Z"%G4'H6QP/
MSQ5R2XAB=4DFC1F^ZK, 3]*SO$>CG7]!N=,%P8#,%_>!<XPP/(].* .#\)^.
MK^RNHK'Q.7$=VHFM[N48P&Y&3TVGL>W3IT]1!R,CI6%K?A/3M;T./394V>0@
M6WE4?-$0,#'MP,CO7(>&_$E[X3U,>&O$IVPCBVNB<J%[<]U]#VZ'V .O\7Z&
M/$'ANZLP,S@>9!_UT7I^?(_&J/P^UPZSX9CCF8_:[,^1,&ZG'W3^7Z@UNWNL
MZ=IT]K!=W<<4MT^R%6/+G_#W/%<,X/A#XG+(H*Z=K?RGT60G^C'\GH ]!FM+
M>XDBDG@BD>%M\3.@)1O49Z&IJ** "BBB@ HHHH ***CBGBG!,4J2 '!*,#@T
M <#X\\2ZSIVNV=EHI8M!";N=%3=N7)&&]L _GGTKIO#'B>R\3Z:+BW.R=,":
M GYHS_4'L:=!X?6'Q==Z\TY=I[=8%C*_<QC.#[X'ZUR'B?PQ>^'-2/B?PP"F
MS+7-JHXQW('=3W';J/8 ])KSC7/^*0^(EIK2Y73]3_=7..BMP"3_ ..M^#5U
M?ACQ/9>)]-%Q;D),F!/ 3S&?ZCT-4M>AT_QMX9O[73[F.XE@8[&0_=E7D#Z'
MD9Z<T =3351%9F55!8Y8@=3[US'P_P!;;6?#$2S9^U69^SR[NIP.#^6/Q!KJ
M: "BBB@ HHHH ***CEGBAV^;*D>XX&]@,F@#-\2ZVOA_0+G42@=HP!&A_B8G
M '^?2N(MO >H>)[&/5M:UJ=;VX42Q(BY6($948S^@Q77>,]'DUSPK>6< S/@
M21#^\RG./Q&1^-9GP]\2Q:MHT>FSG9J%B@B>-N"RKP&'Z ^_UH Y^TU[7O >
MI1Z=XB9[S2Y#B*Y!+%1Z@GDX[J>1V]^\UG3[;Q+X<GM5D1XKJ+=%*.0#U5A^
M.*LZMI-IK>FRV-[&'AD'XJ>S ]B*XGP!<7FCZ[J?A*]D,@M<RP,>RY&<>Q#*
M<?6@"]\-M7DNM%ETF[RM[IC^2RMUV<X_+!'X"NS=$D4JZJRGJ&&17G>O@^$O
MB%9:Z@*V.H_N;K'0-P"?_06_ UZ-0 4444 %%%% !1110 5P?B34-3U[Q0/"
M>DW)M$2/S;VX7[P4X.!^!7IUSZ9KN(YXI698Y4=E.&"L"1]:\W\223>$?B'!
MXC:-GT^]413E1G;P 1]<*K#UP: &W?P]UC0!]O\ #6KW#W"?,\+_ "F3U]F^
MA%=!X-\:)XA5K*\C%OJL(_>1D8#XZD ]".X[5U-M<PWEM'<V\JRPR*&1U.0P
M-<%\0] :U">*M*/D7]HRM,4XWC. WU'0^H^E #?&T3^'/%.F>++=3Y1807:J
M/O#']5R/JHKT&*5)X4EB8-&ZAE8="#R#6&\</C+P4HD 07UL&_W'Z_HP_2LC
MX;:K-/H\^CW@9;S2Y/)96Z[<G'Y$$?@* .T"*'+A0&8 %L<D#I3J** "BBB@
M HHHH *.@R:CEGB@3?-*D:]-SL /UI)XQ=6DL0D*B5"H=>HR,9% 'E.G?$'5
MK369=2U!))M"N[AHHR%XBV]-OT!&1WYKU:VN8+RVCN;:5989%#(ZG((K%T[P
MG8VOA./0+I5N8 &WL5VEF))W#T(SQ]*XFVN=1^&6L"TNS)=:!<OF.0#)0^H]
M&'<=^HH ]-OK.'4;">SN%W0SQF-Q[$8KB/AU>3:?<:CX5O6/GV,C/"3_ !(3
MSCVR0W_ JZZYUW2[32EU2>]B6R< K-G(;/3&.3]*XOQNC:/K>D^,; >9&"L=
MQL/#H1P?Q4D9_P!V@#T"YM;>\@:"Y@CFA;[T<BAE/X&I0   !@#H*9#*EQ!'
M-$VZ.10ZGU!&13Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
MP]0_X_I/P_D*W*P]0_X_I/P_D* +VE?\>K?[Y_D*O51TK_CU;_?/\A5Z@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH *"<#)Z455U.R74M+NK%G9!<1-
M&64\C(QF@!]Q>06UA+>NX,$41E9E.1M SD?A7F^G^&[KXA!]<UN\G@M9&9;.
MVA(^50<9YR.H],G'TK1^'UV;C3-0\+:HBM-8L\31M_'$201[@'/X$5V4<,.C
MZ0(K2W=H;6'$<,?+,%' &>I- ' >#X[_ ,+>-KGPS-<-/8O"9HB>B]PV.W<'
MWKTE)$E7=&ZNO3*G(KS2P\(ZEXPU&YUO799[""Y 5+2([7,8Z!LC@<#J.3SQ
MQ5.]TJ?X<^)M-N-.NYY=/O9/+EAD(R>0"#C /7(./_K@'H^OOIB:)='6/+^P
M[/W@?OZ8]\],<YKS+P;X,;7)#=737*>'XYFDMK:5N9CT!('&,  D=>@KU:_T
M^TU2T:UOK=)X&()1QQD<BIT18T5$4*B@!548 'H* (Y;.VGM#:2P1O;%=AB9
M1MV^F/2I5541410JJ,  8 %+10 4444 %%%% #2ZAU0L S9(4GDXZUR/C76;
M^.>QT#1GV:CJ+$>:#@Q1CJ?;OSV /?%9_P 0%N='U?2/%-L79;5_)F3/&TY_
M+(+#/TKL([/3M0N[/6TC6298<03@_P ##/\ 7]30!YQK?PV;1-'DU?3]4N'O
M[13-(S?+NQRQ4CD'J>IKO?"NK2:OX8TZ^NBHGFC(;MN8$J3CWQG\:R_'%QJU
MU!#H&DV4CR:@"LER1^[C3^($]CC].F2:QV^$UM+IZB;5KM[](PJ.<>6N.@VX
MSC\: /1J\P^(UO8WNMV-OI22/XC+K_Q[G&%Z@N>Q'4'L.O&*V?AOJ][>Z9>:
M?J#M)<:=-Y6]CDD'/!/?!!_#%=7%I=C#J4VHQVL:WDRA9)@/F8#_ "/R% &-
MX4\*1Z!"]Q<2?:=5N/FN+EN22>2 3V_G^6-T6=LMZUZ((Q=,@C,NT;BH.<9]
M*GHH **** "BBB@ IGFQF(RAU,8!)8'CCK1-$L\$D+%@LBE25." 1C@]JX#P
M!<2:;?:IX0U AGMG9X=W\:'K^!R&_P"!&@"G;Z9=_$N[N-0OKR:VT6*4QVL$
M?5\?Q<\9]\'J1VIN@V=]X*^($&AK<O<:=?H74-VX)SCLP*X/J/T]%T_3[71]
M/2SL8?+MXMQ6-3GJ23U]S7GL>@:KXZUN;5]1-QI5@JFWAA VS,@)R.>F23DG
MZ=* .G\7>$[7Q78@I(L5]!GR9QS_ ,!;';^7\^5T_P =ZKX6<:7XJL+B3RQB
M.YCP68#IUP'^N?KFJ>O:!-\.;JSUK1;V=[9I1%-%*1EN"<'  ((![<5ZP5CN
M85WQAD8 [7&: /.K62\^(/B?3]2%G):Z+IK^9&TOWI7R#_-1TR  >>:]&FAC
MN(9(9D5XI%*NK#(8'@@TX *    . !2T 1P016T"001K'%&H5$08"CT J2BB
M@ HHHH *:SJI4,P!8X4$]3UXIU<-\2;2ZBLK#7K)V\[2Y@Y7)QM)'./J /H3
M0!H^-M>NM)L+:STT9U/4)?(M_P#9Z9;Z\@?C[5RVH?"V2/2Y;]-6GFU= 9F9
MONNPYP#US[YKNK5--\1VVE:UY*R/&/.MVSS&6&&'X?S%4?&>H:G;:9'9:392
MW%W?DP+(H^6($<DGL<$XSQP3VH 9X%UB;6?"5O/?N'E#- SO_P M,="?4X_.
MN:U?PSJW@_5GUSPLK2VC\SV8&[ ZXQW7Z<BI;7X36\FF1QZCJMTURB$((B/*
MC)YP 1DC)]1FK'P[OM0MM0U3PYJ$S3_8&_=.3G S@C)[="/3F@" ?%>*XLQ#
M::/=OJS_ "K#PR;OJ/F/TQ6_X%\/7&@Z-(U\?].NY#-, <[?1?Y_B:Z40Q"4
MR"-!(>"P49/XT^@"%[.V>[CNW@C:XC4HDI7YE!Z@&IJ** "BBB@ HHHH :KH
M^=C*VTX.#G!]*\XN+:[^(NOWD#74EMH.GR>4!'UFD'4^GOST&..34OA:63PS
MXYU+PY<R$V]XQN;5F.<D\]?4C(/NE=SI^F6>EQS1V4"PI-*TSJO0N<9/MT%
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M71X[E[G3=04D*W&.#SCH&!'7N/T]%T[3;31[!;.QA\J!"S*@)/)))Z_6O/\
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MS,8AMC.V)NA)SUQ^7J:[965T#JP96&00>"*C2V@BFDFCAC263[[JH#-]3WH
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M6\TR0/N Y*9'YX.#]":ZO1]3AUG1[748/N3QAL?W3T(_ Y'X5:G@CN;>2"9
M\4BE'4]"",$5P'@2>30=?U/PE=.Q$;F:U9OXE[_F,'\Z .YU'4;72;"6]O9?
M*MX@-[[2V,G X'/6O/KR_O/B3>1Z?I\$UMH,4@>XN9!@R$=A_0<^IKTET26-
MHY$5T8896&01Z$41QI%&L<:*B*,!5& !]* $AB2W@CAB7;'&H11Z # I]%%
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MI_/],T>'_#UCX;T_['9!\,=TCNQ)=L8SZ#\*U%97&58, <<'- ''?#C67O\
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M45VNA:Q!KVC6^HV_"RKRA/*,."#]#7-?$G299](AUFS)6]TQQ*K*.=F1G\B
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M/^/Z3\/Y"MRL/4/^/Z3\/Y"@"]I7_'JW^^?Y"KU4=*_X]6_WS_(5>H ****
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M[:]N"( W&Y022?U _.NNU;1['7+1;74(1-"LBR!<D<CZ?B/QH OT4@
MZ 4M !1110 4444 %%<QX]UBXT;PO++9R&.ZGD6")EZ@GKCWP#63X.\8W#79
M\/>(@T&J0G8DDG'F^Q_VO0]_Y@&_I/AM-,\1:MJYF\Z2^*[05P8U[C/<9Q^0
MJ;Q78IJ'A34[=P#FW=UR.C*-P_4"MBJNI_\ ()O/^N#_ /H)H P?AY<M=>!]
M.9SEHP\?X*Q _3%:>LV5GXATN_T@SQ-(4 =0P+1-U4D=1R :\S\.^+)M/\'V
MNBZ/";C6KB60(H&1$"?O'W_08R>.O>>$?"J^'K:2>XE-QJ=U\US.23D]<#/;
M/?O0!G?#;599](FT:\RM[IDAB96/.S)Q^1!'X"NVJC;:-86>IW>HP6ZK=W6/
M-DSR<#].G;K5Z@ HHHH **** "BBB@#'\3Z(?$6@SZ:MP8#(5._&1P0<$>G%
M6[BXL=!TCS9G6"SM8PN3V4#  ]3T&*NU!>65MJ-J]K>0)/ ^-R.,@XYH \KT
M*'Q9JEWJNKZ%#!80ZA,9!/<#DJ"2%4$'UY..O>M_PMXHUA?$,GAOQ*B_;=I:
M&55 WX&<<<$8!((]"#7:3W%IIMF99Y8K:VB7&6(55 Z"N!T=SXO^(IU^WB9=
M-TZ+R8I6&/-;#?\ Q1/TQGK0 [QM&_ASQ3IGBNW5O*9A!>*H^\,?U7(^JBO0
M8I4FB26-@T;J&5AT(/0U7U/3+36-/EL;V/S+>7&Y<XZ'(Y^HJ>""*VMXX(4"
M11*$11T50, 4 24444 %%%% !1110 5PGQ.M;A+#3=9MEW-IMR)",9P"1R?;
M*J/QKNZCG@BN8)()XUDBD4HZ,,A@>H- '":QXFN/$S:=HWAJY\N2^B\ZXN >
M8(^A''0Y!S^'K6=JGPXN-#LSJN@ZI=&_ME,CAR 7QR=N/Y'.:KW6DZC\-]>?
M5].MS>:1*-D@(RT:$@[2>W.,-T]:VKSXH:3-I;#3HKF;4)5V16YBY#'@9QP?
MPSF@#7\/ZC%XV\&,+Q &E1K>X"]FQU'IU!'I61\.;Z:S?4/"]\Q^TZ?(S19[
MH3SCVR<_\"K8\!Z%-H'AB*WN5"W,KF:5?[I. !]< 5KIHMA'K<FL+ /MTD0B
M:3)^Z/;UZ<^U %^BBB@ HHHH **** "JFJ6KWVD7MI&VQYX'B5O0LI&?UJW1
M0!YO\/?$MGIM@_AW5G2QN[25POG$*&R22,GC(.?KQBI?%6H0>,-3LO#&E2"X
MC\X37EQ$05C1>H!Z9Y_/ [FNDUSP;HGB&83WML1< 8\Z)MC$>A['\:MZ-H&E
M>';5X]/MUA4\R2,<LV/5C_\ JH X_P $7%UX?\1WOA"]E\R- 9K1SW'7 ^H.
M<=B#4OQ%LIK"?3O%5B#]HL9%27'\2$\9]LDC_@51Z;,GB3XIR:K9$O8Z=;^2
M9A]UV(88'K]YO^^:[R]LX-0L9[.Y3?#,A1U]0: $L+V'4;"WO;=MT,\8D0^Q
M%6*KV-C;Z;8PV=I&(X(5VHH.<"K% !1110 4444 %%4=:O\ ^R]#OKX8W00.
MZ@]"P' _/%><^%?'.HZ9=0VGB<R?9[T":WNY?X0WO_=_E].@!V]SX;2Y\8VF
MOR3EOL]N8EA*\!LG# _1C^E;<D:31/%(H9'4JRGH0>HI00RAE((/(([TM '
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M;R:G)NBB(Y5,DY_'(_+/>NHO=%L-0U"ROKJ 27%FQ:%B3\I./SZ"@"_1110
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MCDG\ZXCP;X,.N3->70N(M 69I+:UE?F8] 3CC&.">_2O7418T5$4*B@!548
M'H* !$6-%1%"HH 55& !Z"G444 %%%% !1110 4444 %%%% !4%[:17]E-:3
M[O*F0HVUBIP?0CI4]% &%H'A#1_#F7L8"TY&#/*=SD>F>@_ "MVBB@ HHHH
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MC#C/T-%K9VMC#Y-I;0V\6<[(D"#\A4]% !1110 4444 %%%% !1110 4444
M%<[=>#-+O_$/]L7IGN9!C9!+)NB0CT'].E=%10 4444 %%%% !1110 4444
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MQ[]_R  )/#7@W3/#!FDM=\L\I(\Z7!95[*,=OYUT5%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *:Z)+&T<BAD8%65AD$'L:=10!!9V5MI]JEK9P)! GW40
M8 J>BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@"M:Z?9V+SO:VT4+3OYDI1<%V]35FBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"LNGV:
MZ@]^MM$+MT$;3!1N*^F:LT44 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 5I]/L[JZM[F>VBDGMR3#(RY*$^E
M6:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** *U[86FI6_V>]MX[B+<&V2+D9'0U9    & .@HHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "L/4/^/Z3\/Y"MRL/4/^/Z3\/Y"@"]I7_'JW^^?Y"KU4=*_P"/5O\ ?/\
M(5>H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ K#U#_C^D_#^0K<K#U#_C^D_#^0H O:5_QZM_OG^0J]5'2O\ CU;_ 'S_
M "%7J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *P]0_X_I/P_D*W*P]0_X_I/P_D* +VE?\>K?[Y_D*O51TK_ (]6_P!\
M_P A5Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "L/4/^/Z3\/Y"MRL/4/^/Z3\/Y"@"]I7_'JW^^?Y"KU4=*_P"/5O\
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MD5];OLGC4$#V8 ],\_B#5;X@>)+_ ,-:;:3V'E;Y9MC>8N[C!/K6!K2GP/\
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MJ[;7'Q'N[6&YB_LTQRHLBY !P1D5:^*__(GI_P!?2?R:NJT+_D7]-_Z]8O\
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MUC_:&&_F_!_Y&_\ 9N*_E_%?YG:4C,J(7=@J@9))P *XS_A/_P#J&?\ D?\
M^QK+UOQ5-K%JMLD'V>+.7 DW;_0=!Q4SS*@HMQ=W\RZ>68B4DI*R[Z'2W7C7
M3+>4QQK-/CJT8&W]35C3?%6FZE*(@[0RGHLH W?0]*\QHKS5FE;FN[6['IO*
M:'+97OW/::*X*Q\<36UG%!/9^?(@V^9YNTL.V1@U9_X3_P#ZAG_D?_[&O368
MX=J[E^#/*>6XE.RC?YK_ #.THKB_^$__ .H9_P"1_P#[&C_A/_\ J&?^1_\
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MVU>?_%?3TDT*VU- 5N;6<*'7@[6_^N!78:%>/J'A_3[R0YDFMXW?_>*C/ZT
M8GCKQ)=Z!96<.FJKZA>3>7$K+NX'7 ]<E1^-2^!O$DOB703/<[!=PR&.4(,
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MTL5M&K1)$Y;<%&1TQ^N*H> -.O+KQ%JWB:>V>UM[PN((W&"P9PQ./P'/?)H
M]$HHHH **** "BN;OO%\%M</#!;M/L."V_:,^W!JM_PFW_4/_P#(W_V- '6T
M5R7_  FW_4/_ /(W_P!C1_PFW_4/_P#(W_V- '6U7OKR.PLI;F7E4'3U/85S
M7_";?]0__P C?_8UEZUX@DU>*.(0^3&AW$;]VX]NP]Z .RTG5(]6L_/1=C [
M70G.TU?KSC1M8DT>=W$?FHZX9-VWGL<_YZUM?\)M_P!0_P#\C?\ V- '6T5R
M7_";?]0__P C?_8T?\)M_P!0_P#\C?\ V- '6T5R7_";?]0__P C?_8TZ/QL
MA<"2Q95[E9<G\L"@#JZ\NU_XBZMI'BZZM([>"2PM75738=Q7C)W9X.3QVZ5Z
M9;W$=U;QSPMNC<94UY?;:;#K'Q/\2Z?<#]W/:NI/]TYCP?J#@_A0!Z?:W4-[
M:0W5NX>&9 Z,.X/-<KI_B6_N?B/J&AR>5]B@BW( OS9 4]<_[1K-^'6ISV%S
M>^%-1.+FS=C!GNN?F ]N0P]C4&C_ /):=7_ZX'^4= 'I->9>*/B#JFF>)9[?
M3HXI+&R9$G+)G<QZC/;T^HKT+5=0CTK2KJ_E^Y;Q-(1ZX' _$\5Y[X7\-OJ_
M@'5[BY7=>:LSRJQZDJ25/_?>?P- 'I-O/'=6T5Q"VZ*5 Z-Z@C(-<YXP\5MX
M=CM;>TMOM6HWC;((CG'89..O) Q5+X8ZL;_PL+20GS[%S"0>NWJO]1_P&JOQ
M%T?47N=-U_3(C-+I[;GC R< A@<=QD'./6@!&F^)-LGVMH=.N!C)M5QD#T[?
MS-=+J&KW5KX.FU<VWDW:VGG>1)GY'*YP>AX-9?A[XB:-K?EP32?8KQN/*F/R
ML?\ 9;H?QP:T?&?_ ")NK?\ 7LU '(Z/K'Q UG38M1LUTZ2WDW;0X"DX)![^
MHJW;^/=2TC44L/%NF"S,GW+B#E/J>3D>X/'I6I\-?^1$L/\ >E_]&-4_CW38
MM2\'7X=,O;QFXC/=2HR?TR/QH Z16#*&4@@C(([UB^+-</A[PY<WZ;3, $A5
MAD%R<#\N3^%9_P .+Z6^\%VGG,6>!FAW$]@>/R! _"L?QJ?[?\8Z)X:3YHE;
M[1<@=,>A_P" AO\ OH4 7/ ?BR_UV>^L-65$O+<*ZA4VDJ>#D>QQ^==O7FOB
M/_BF?B9IFLJ-EK?*(I\<#/"G\@4/X5Z%?7'V33[FY'_+*)I/R!- ''Z]XXND
MUK^PO#EDM[J(.V1V^XA[CJ.G<D@"JTLOQ*LHC=,NGW2J-QMT4$X].,$_@:B^
M$EHKZ;J.J29:YGN/++MU( #'\RWZ5Z-0!S7@_P 7P^*+64-#]GO;<@30DY'/
M<>W'X5TM>8N@TCXUQ>1E([Y,R*.AW(<_^/*#]:].H Y_QIK5SH'AF>^LPAG5
MD52XR!DXSBN:LM0^(MUI\-_!#IL\4T:R1J< D$9'<<_C6I\3_P#D2+C_ *ZQ
M_P#H59^A_$/P[IWAO3[6:YF,\%M'&Z+"Q^8* 0#TH UO"'B]_$$EU8WUI]DU
M.T_UL8S@C."1GD8/&*L:M_PE'_"4:=_9OE?V/A?M6[9G[QW=>?NXQCO7.?#Z
M%M6\2:QXG)CCCN"T<<(D#, 6!RP'3[HZ]>:O>(]8U"T^(>@V%O=/':SA?-B&
M,/EB.?RH [BBL#QAXD7PQHC7819+B1A'!&W0MZGV S^GK7/6WAWQGJ5HE[=^
M*)+.X<;UMHX_E7/.#@C'Y&@#T"L*^\46UAXIL=!>"5IKN/>LBXVKDL!G_ODU
MB>$?$FJ/K5WX;U\H=0MUW1S*,>8.OT/!!!P..M<AJ^C:U!\0=+L9]=>:^EB#
M17ACP8QE^,9]C^= 'L]%8F@:=J6DVMQ_:VL-J!)W*[IM\M0.>]<M97OB#QW>
M74^GZFVDZ/!(8HWC3,DI]>W;'?C(ZT >B45YXNIZ[X.\26&GZOJ/]I:;?MLC
MG=,.C9 _F1GD\5T7C+Q*/#&AFZ15>ZE;RX$;H6[D^P']* .AKGO'$\MMX,U*
M6"5XI%1=KHQ4CYAT(K @\-^-+VT2^G\4O;WCC>+81_(I/(!QQ_XZ?QJWXB.J
M'X77O]LK&M^(]LOED8;$@ /''(P?Q[=* -?P5-+<>#M,EFD>21HOF=V))Y/4
MFMZO+O"]EXIUWPY:16VH?V/IT"%(W1-TDYR<MVP,\=?SK2\*:WK-GXKNO"^N
M7 NG1"\,^.3P#U[@@YYY!H [^BN&^(NNW^AOHTME-(JO.QEC3_EJ!M^7I]?S
MJ"31/&^JVS:E)KGV"Y9=T5A$N%4=E8YZ_4&@#T"BN3\ ^)+GQ#H\HO@/MEK)
MY<C 8WC'!(]>N?I5#Q!XAU?4O$X\,^'9$@EC4-<W3#.SN0.O3(_$XXH [NJ.
MM.T>A:@Z,5=;:0JRG!!"GD5P^IZ3XR\.63ZK;>(WU$0#S)H)H\ J.N 2<CZ8
MXKH+?7(_$/@&ZU%%",]I*LB#^%PI!'^>QH J?#.ZN+OPB)+F>6:3[0XW2.6.
M..YKL:XGX5_\B:/^OF3^E4[K6]=\5^)+K2?#]TMC961Q/=[<ECTX_$'&,=,Y
MH ]"HKS75H_%W@J%=476CJUBC 31SI@@'@=R<9[@^G%=E+XAME\*-K\:EX?L
MWGJF<$G'W?SXH V**\ZTG3?%/BC2UUB;Q++8&XRT-O!'\JC.!G!'I[U#X(F\
M07_B*\AU#79B=-E*3VS*&67[R\'ZCT]* /2Z*X/P;K.HIXGUCP_J]V]Q- V^
M!Y,9*@_U!4_G5GXB:[>:5IMG::9*T=_>SA$*?>VCKCZDJ/QH [.LSQ%?S:7X
M=O[ZWV^=!"SIN&1FKMG%+!9013RF:5(U5Y#U=@.3^)K(\9_\B;JW_7LU ">#
M=6NM<\+VFH7A0SR%PQ1<#AR!Q]!6]7)_#7_D1+#_ 'I?_1C5R?AW6/%WB,7>
MFV=X8PL[-+?RC)B3H$48Z\'_ .M0!ZQ17F5Q?>(O ^OZ?'J&JMJFFWC["TB_
M,.0#U)((R#UP:[GQ%K,>@:%=:BZAC$OR(3]YCP!^9H U*X%[Z[_X7(EI]JF^
MS?9O]3YAV?ZLG[O3KS572M-\:>(+!-9?Q$;%I@9(+=8_D*GID=A]0>*S=!FU
M2;XM0_VS"L=]'"T<FP?*^(SAA]1S0!ZU17+>,_$MQHD-I9:;&LNJ7\GEP*PR
M%[;L?4@#_P"M69+X8\8PVC7<7BR66^5=WD>7^[8_W1SC\=OY4 =Y17*>&==G
M\8>%)SYIM-07="\D0QL?&0P!^HX^M9W@WQ3<QRZCHWB.?;?6!:0RR'&Z,<GG
MOCK[@^U '>45Q'A'4M5\2ZW?:S)/+#HZ,8K6VZ!SZGZ#]3[5V] '#77_  L4
MW<WV<::(-[>7G'W<\=?:L31O$7CO7I;N.Q:P+6CA)=Z!>3GIZ_=->J5YS\+_
M /D(>)?^OE/YR4 =3X:_X23R[C_A(1:[LKY/D>G.<_I7'6?B;QGKNL:G!I L
M1%:3%2LB@87<0.3U^[7IU>2^"=>TO0]?\1'4KM;<33C9N4G=AGST!]10!KCQ
MMKV@:I!:^*M-@CMYVPMS;G@>_4@@=QP:]#ZC(KRKQ9JD?CZ[L='\/QR7*QR^
M9+<F,JB C'?G'7],9KU**,10I&"2$4*"?:@!]%%% !1161KGB&VT.-/-1I9I
M.5C4XX]2>PJ934%S2V$VDKLUZ*X?_A8G_4+_ /)C_P"QH_X6)_U"_P#R8_\
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M]>#Q]<&HO&+!?B?X;9B !Y>2?^NAKK/$^MZ;IWA^]:YN(3YD+QI%N!,A((
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M-QEA^/)^N *V/#VO^('U?^R/$.E""5HR\=S#]Q@.H/)'Y'\*ZU5"J%4  #
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M_7T-W7;?QCX4M%UK_A(#?QHZ_:(7CPBY..G3&<#C!YH ].HJEI]__:6C6]_
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M !_2?A_(5N5AZA_Q_2?A_(4 7M*_X]6_WS_(5>JCI7_'JW^^?Y"KU !1110
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M?XT?\(EKG_/C_P"14_QKT^BN?^RJ/=_A_D=/]KU^R_'_ #/,/^$2US_GQ_\
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M[-4>MJ?!/CZ#7(E(TS4B4N0.BL?O?T;\ZZ+P9X5N/#/]H^?<13?:I0Z>6",
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MOZ#VH Q/ ;B+QUXJMYB/M#3LXSU($C9/_CRUV/BB:*#PKJTDQ 3[)(O/<E2
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M "(FI_[L?_HQ:Z>LGQ/I,FN^'+S389$CDG"A7?.!A@><?2@"MX(_Y$O2?^N
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M#\NG03)%([JP:3..#GM6GIEHUAI5G9LP9H($B+#H2J@9_2@#@_!W_)2_$_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &7XBT5?
M$.ASZ8\YA$I4^8%W8PP/3\*L:38#2M)M+!9#(+>)8PY&-V!C.*N44 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !6'J'_'])^'\A6Y6'J'_'])^'\A0!>TK_ (]6_P!\_P A5ZJ.E?\
M'JW^^?Y"KU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %8>H?\?TGX?R%;E8>H?\?TGX?R% %[2O\ CU;_ 'S_ "%7JHZ5
M_P >K?[Y_D*O4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 5AZA_Q_2?A_(5N5AZA_Q_2?A_(4 ,2YFMMT<<F!N/84_P#M
M"Z_YZ_\ CH_PHHH /[0NO^>O_CH_PH_M"Z_YZ_\ CH_PHHH /[0NO^>O_CH_
MPH_M"Z_YZ_\ CH_PHHH /[0NO^>O_CH_PH_M"Z_YZ_\ CH_PHHH /[0NO^>O
M_CH_PH_M"Z_YZ_\ CH_PHHH /[0NO^>O_CH_PH_M"Z_YZ_\ CH_PHHH /[0N
MO^>O_CH_PH_M"Z_YZ_\ CH_PHHH /[0NO^>O_CH_PH_M"Z_YZ_\ CH_PHHH
M/[0NO^>O_CH_PH_M"Z_YZ_\ CH_PHHH /[0NO^>O_CH_PH_M"Z_YZ_\ CH_P
MHHH /[0NO^>O_CH_PH_M"Z_YZ_\ CH_PHHH /[0NO^>O_CH_PH_M"Z_YZ_\
MCH_PHHH /[0NO^>O_CH_PH_M"Z_YZ_\ CH_PHHH /[0NO^>O_CH_PH_M"Z_Y
MZ_\ CH_PHHH /[0NO^>O_CH_PH_M"Z_YZ_\ CH_PHHH /[0NO^>O_CH_PH_M
M"Z_YZ_\ CH_PHHH /[0NO^>O_CH_PH_M"Z_YZ_\ CH_PHHH /[0NO^>O_CH_
MPH_M"Z_YZ_\ CH_PHHH /[0NO^>O_CH_PH_M"Z_YZ_\ CH_PHHH /[0NO^>O
M_CH_PH_M"Z_YZ_\ CH_PHHH /[0NO^>O_CH_PH_M"Z_YZ_\ CH_PHHH /[0N
MO^>O_CH_PH_M"Z_YZ_\ CH_PHHH /[0NO^>O_CH_PH_M"Z_YZ_\ CH_PHHH
M/[0NO^>O_CH_PH_M"Z_YZ_\ CH_PHHH /[0NO^>O_CH_PH_M"Z_YZ_\ CH_P
MHHH /[0NO^>O_CH_PH_M"Z_YZ_\ CH_PHHH /[0NO^>O_CH_PH_M"Z_YZ_\
MCH_PHHH /[0NO^>O_CH_PH_M"Z_YZ_\ CH_PHHH /[0NO^>O_CH_PH_M"Z_Y
MZ_\ CH_PHHH /[0NO^>O_CH_PH_M"Z_YZ_\ CH_PHHH /[0NO^>O_CH_PH_M
M"Z_YZ_\ CH_PHHH /[0NO^>O_CH_PH_M"Z_YZ_\ CH_PHHH /[0NO^>O_CH_
MPH_M"Z_YZ_\ CH_PHHH /[0NO^>O_CH_PH_M"Z_YZ_\ CH_PHHH /[0NO^>O
M_CH_PH_M"Z_YZ_\ CH_PHHH /[0NO^>O_CH_PH_M"Z_YZ_\ CH_PHHH /[0N
MO^>O_CH_PH_M"Z_YZ_\ CH_PHHH /[0NO^>O_CH_PH_M"Z_YZ_\ CH_PHHH
M/[0NO^>O_CH_PH_M"Z_YZ_\ CH_PHHH /[0NO^>O_CH_PH_M"Z_YZ_\ CH_P
MHHH /[0NO^>O_CH_PH_M"Z_YZ_\ CH_PHHH /[0NO^>O_CH_PH_M"Z_YZ_\
MCH_PHHH /[0NO^>O_CH_PH_M"Z_YZ_\ CH_PHHH /[0NO^>O_CH_PH_M"Z_Y
MZ_\ CH_PHHH /[0NO^>O_CH_PH_M"Z_YZ_\ CH_PHHH /[0NO^>O_CH_PH_M
M"Z_YZ_\ CH_PHHH /[0NO^>O_CH_PH_M"Z_YZ_\ CH_PHHH /[0NO^>O_CH_
MPH_M"Z_YZ_\ CH_PHHH /[0NO^>O_CH_PH_M"Z_YZ_\ CH_PHHH /[0NO^>O
M_CH_PH_M"Z_YZ_\ CH_PHHH /[0NO^>O_CH_PH_M"Z_YZ_\ CH_PHHH /[0N
MO^>O_CH_PH_M"Z_YZ_\ CH_PHHH /[0NO^>O_CH_PH_M"Z_YZ_\ CH_PHHH
M/[0NO^>O_CH_PH_M"Z_YZ_\ CH_PHHH /[0NO^>O_CH_PH_M"Z_YZ_\ CH_P
MHHH /[0NO^>O_CH_PH_M"Z_YZ_\ CH_PHHH /[0NO^>O_CH_PH_M"Z_YZ_\
MCH_PHHH /[0NO^>O_CH_PH_M"Z_YZ_\ CH_PHHH /[0NO^>O_CH_PH_M"Z_Y
MZ_\ CH_PHHH /[0NO^>O_CH_PH_M"Z_YZ_\ CH_PHHH /[0NO^>O_CH_PH_M
M"Z_YZ_\ CH_PHHH /[0NO^>O_CH_PH_M"Z_YZ_\ CH_PHHH /[0NO^>O_CH_
MPH_M"Z_YZ_\ CH_PHHH /[0NO^>O_CH_PH_M"Z_YZ_\ CH_PHHH /[0NO^>O
M_CH_PH_M"Z_YZ_\ CH_PHHH /[0NO^>O_CH_PH_M"Z_YZ_\ CH_PHHH /[0N
MO^>O_CH_PH_M"Z_YZ_\ CH_PHHH /[0NO^>O_CH_PH_M"Z_YZ_\ CH_PHHH
M/[0NO^>O_CH_PH_M"Z_YZ_\ CH_PHHH /[0NO^>O_CH_PH_M"Z_YZ_\ CH_P
MHHH /[0NO^>O_CH_PH_M"Z_YZ_\ CH_PHHH /[0NO^>O_CH_PH_M"Z_YZ_\
MCH_PHHH /[0NO^>O_CH_PH_M"Z_YZ_\ CH_PHHH /[0NO^>O_CH_PH_M"Z_Y
MZ_\ CH_PHHH /[0NO^>O_CH_PH_M"Z_YZ_\ CH_PHHH /[0NO^>O_CH_PH_M
M"Z_YZ_\ CH_PHHH /[0NO^>O_CH_PH_M"Z_YZ_\ CH_PHHH /[0NO^>O_CH_
MPH_M"Z_YZ_\ CH_PHHH /[0NO^>O_CH_PH_M"Z_YZ_\ CH_PHHH /[0NO^>O
M_CH_PH_M"Z_YZ_\ CH_PHHH /[0NO^>O_CH_PH_M"Z_YZ_\ CH_PHHH /[0N
MO^>O_CH_PH_M"Z_YZ_\ CH_PHHH /[0NO^>O_CH_PH_M"Z_YZ_\ CH_PHHH
M/[0NO^>O_CH_PH_M"Z_YZ_\ CH_PHHH /[0NO^>O_CH_PH_M"Z_YZ_\ CH_P
MHHH /[0NO^>O_CH_PH_M"Z_YZ_\ CH_PHHH /[0NO^>O_CH_PH_M"Z_YZ_\
MCH_PHHH /[0NO^>O_CH_PH_M"Z_YZ_\ CH_PHHH /[0NO^>O_CH_PH_M"Z_Y
MZ_\ CH_PHHH /[0NO^>O_CH_PH_M"Z_YZ_\ CH_PHHH /[0NO^>O_CH_PH_M
M"Z_YZ_\ CH_PHHH /[0NO^>O_CH_PH_M"Z_YZ_\ CH_PHHH /[0NO^>O_CH_
MPH_M"Z_YZ_\ CH_PHHH /[0NO^>O_CH_PH_M"Z_YZ_\ CH_PHHH /[0NO^>O
M_CH_PH_M"Z_YZ_\ CH_PHHH /[0NO^>O_CH_PH_M"Z_YZ_\ CH_PHHH /[0N
MO^>O_CH_PH_M"Z_YZ_\ CH_PHHH /[0NO^>O_CH_PH_M"Z_YZ_\ CH_PHHH
M/[0NO^>O_CH_PH_M"Z_YZ_\ CH_PHHH /[0NO^>O_CH_PH_M"Z_YZ_\ CH_P
MHHH /[0NO^>O_CH_PH_M"Z_YZ_\ CH_PHHH /[0NO^>O_CH_PH_M"Z_YZ_\
MCH_PHHH /[0NO^>O_CH_PH_M"Z_YZ_\ CH_PHHH /[0NO^>O_CH_PH_M"Z_Y
MZ_\ CH_PHHH /[0NO^>O_CH_PH_M"Z_YZ_\ CH_PHHH /[0NO^>O_CH_PH_M
M"Z_YZ_\ CH_PHHH /[0NO^>O_CH_PH_M"Z_YZ_\ CH_PHHH /[0NO^>O_CH_
MPH_M"Z_YZ_\ CH_PHHH /[0NO^>O_CH_PH_M"Z_YZ_\ CH_PHHH /[0NO^>O
M_CH_PH_M"Z_YZ_\ CH_PHHH /[0NO^>O_CH_PH_M"Z_YZ_\ CH_PHHH /[0N
MO^>O_CH_PH_M"Z_YZ_\ CH_PHHH /[0NO^>O_CH_PH_M"Z_YZ_\ CH_PHHH
M/[0NO^>O_CH_PH_M"Z_YZ_\ CH_PHHH /[0NO^>O_CH_PH_M"Z_YZ_\ CH_P
MHHH /[0NO^>O_CH_PH_M"Z_YZ_\ CH_PHHH /[0NO^>O_CH_PH_M"Z_YZ_\
MCH_PHHH /[0NO^>O_CH_PH_M"Z_YZ_\ CH_PHHH /[0NO^>O_CH_PH_M"Z_Y
MZ_\ CH_PHHH /[0NO^>O_CH_PH_M"Z_YZ_\ CH_PHHH /[0NO^>O_CH_PH_M
M"Z_YZ_\ CH_PHHH /[0NO^>O_CH_PH_M"Z_YZ_\ CH_PHHH /[0NO^>O_CH_
MPH_M"Z_YZ_\ CH_PHHH /[0NO^>O_CH_PH_M"Z_YZ_\ CH_PHHH /[0NO^>O
M_CH_PH_M"Z_YZ_\ CH_PHHH /[0NO^>O_CH_PH_M"Z_YZ_\ CH_PHHH /[0N
MO^>O_CH_PH_M"Z_YZ_\ CH_PHHH /[0NO^>O_CH_PH_M"Z_YZ_\ CH_PHHH
M/[0NO^>O_CH_PH_M"Z_YZ_\ CH_PHHH /[0NO^>O_CH_PH_M"Z_YZ_\ CH_P
MHHH /[0NO^>O_CH_PH_M"Z_YZ_\ CH_PHHH /[0NO^>O_CH_PH_M"Z_YZ_\
MCH_PHHH /[0NO^>O_CH_PH_M"Z_YZ_\ CH_PHHH /[0NO^>O_CH_PH_M"Z_Y
MZ_\ CH_PHHH /[0NO^>O_CH_PH_M"Z_YZ_\ CH_PHHH /[0NO^>O_CH_PH_M
M"Z_YZ_\ CH_PHHH /[0NO^>O_CH_PH_M"Z_YZ_\ CH_PHHH /[0NO^>O_CH_
MPH_M"Z_YZ_\ CH_PHHH /[0NO^>O_CH_PH_M"Z_YZ_\ CH_PHHH /[0NO^>O
M_CH_PH_M"Z_YZ_\ CH_PHHH /[0NO^>O_CH_PH_M"Z_YZ_\ CH_PHHH /[0N
MO^>O_CH_PH_M"Z_YZ_\ CH_PHHH /[0NO^>O_CH_PH_M"Z_YZ_\ CH_PHHH
M/[0NO^>O_CH_PH_M"Z_YZ_\ CH_PHHH /[0NO^>O_CH_PH_M"Z_YZ_\ CH_P
MHHH /[0NO^>O_CH_PH_M"Z_YZ_\ CH_PHHH /[0NO^>O_CH_PH_M"Z_YZ_\
?CH_PHHH /[0NO^>O_CH_PJ/Y[F1G=_FXR<444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>30
<FILENAME>inva-20231231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-02-29T16:52:42.9870+00:00 -->
<!-- Copyright (c) 2024 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.inva.com/20231231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:inva="http://www.inva.com/20231231" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2023" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" namespace="http://xbrl.sec.gov/dei/2023"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" namespace="http://xbrl.org/2020/extensible-enumerations-2.0"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-sub-2023.xsd" namespace="http://xbrl.sec.gov/ecd-sub/2023"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" namespace="http://fasb.org/us-gaap/2023"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" namespace="http://xbrl.sec.gov/country/2023"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" namespace="http://www.xbrl.org/dtr/type/2022-03-31"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd" namespace="http://xbrl.sec.gov/ecd/2023"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" namespace="http://fasb.org/srt/2023"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" namespace="http://fasb.org/srt-types/2023"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.inva.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets" id="StatementConsolidatedBalanceSheets">
        <link:definition>100010 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails2" id="DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails2">
        <link:definition>100020 - Disclosure - COMMITMENTS AND CONTINGENCIES - Schedule of Future Minimum Lease Payments (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails2" id="DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails2">
        <link:definition>100030 - Disclosure - CONSOLIDATED ENTITIES AND ACQUISITIONS - Theravance Respiratory Company, LLC (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails2" id="DisclosureDebtScheduleOfDebtDetails2">
        <link:definition>100040 - Disclosure - DEBT - Schedule of Debt (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet1" id="DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet1">
        <link:definition>100050 - Disclosure - EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Schedule of Available-for-Sale Securities Measured at Fair Value on a Recurring Basis (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails2" id="DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails2">
        <link:definition>100060 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Summary of Accumulated Amortization of Recognized Intangible Assets (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails2" id="DisclosureIncomeTaxesDeferredTaxesDetails2">
        <link:definition>100070 - Disclosure - INCOME TAXES - Deferred Taxes (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" id="StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>100080 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfIncome" id="StatementConsolidatedStatementsOfIncome">
        <link:definition>100090 - Statement - CONSOLIDATED STATEMENTS OF INCOME</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfIncomeParenthetical" id="StatementConsolidatedStatementsOfIncomeParenthetical">
        <link:definition>100100 - Statement - CONSOLIDATED STATEMENTS OF INCOME (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveIncome" id="StatementConsolidatedStatementsOfComprehensiveIncome">
        <link:definition>100110 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" id="StatementConsolidatedStatementsOfStockholdersEquity">
        <link:definition>100120 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" id="StatementConsolidatedStatementsOfCashFlows">
        <link:definition>100130 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPolicies" id="DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPolicies">
        <link:definition>995455 - Disclosure - DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureNetIncomePerShare" id="DisclosureNetIncomePerShare">
        <link:definition>995465 - Disclosure - NET INCOME PER SHARE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureRevenueRecognition1" id="DisclosureRevenueRecognition1">
        <link:definition>995475 - Disclosure - REVENUE RECOGNITION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureLicenseAndCollaborationArrangements" id="DisclosureLicenseAndCollaborationArrangements">
        <link:definition>995485 - Disclosure - LICENSE AND COLLABORATION ARRANGEMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitions1" id="DisclosureConsolidatedEntitiesAndAcquisitions1">
        <link:definition>995495 - Disclosure - CONSOLIDATED ENTITIES AND ACQUISITIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurements" id="DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurements">
        <link:definition>995505 - Disclosure - EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureCapitalizedFeesPaid1" id="DisclosureCapitalizedFeesPaid1">
        <link:definition>995515 - Disclosure - CAPITALIZED FEES PAID</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureGoodwillAndIntangibleAssets" id="DisclosureGoodwillAndIntangibleAssets">
        <link:definition>995525 - Disclosure - GOODWILL AND INTANGIBLE ASSETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureBalanceSheetComponents" id="DisclosureBalanceSheetComponents">
        <link:definition>995535 - Disclosure - BALANCE SHEET COMPONENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensation" id="DisclosureStockBasedCompensation">
        <link:definition>995545 - Disclosure - STOCK-BASED COMPENSATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureStockholdersEquity" id="DisclosureStockholdersEquity">
        <link:definition>995555 - Disclosure - STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureDebt" id="DisclosureDebt">
        <link:definition>995565 - Disclosure - DEBT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingencies">
        <link:definition>995575 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>995585 - Disclosure - INCOME TAXES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>995595 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" id="DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>995605 - Disclosure - DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesTables" id="DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>995615 - Disclosure - DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureNetIncomePerShareTables" id="DisclosureNetIncomePerShareTables">
        <link:definition>995625 - Disclosure - NET INCOME PER SHARE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureRevenueRecognitionTables" id="DisclosureRevenueRecognitionTables">
        <link:definition>995635 - Disclosure - REVENUE RECOGNITION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTables" id="DisclosureConsolidatedEntitiesAndAcquisitionsTables">
        <link:definition>995645 - Disclosure - CONSOLIDATED ENTITIES AND ACQUISITIONS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsTables" id="DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsTables">
        <link:definition>995655 - Disclosure - EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureCapitalizedFeesPaidTables" id="DisclosureCapitalizedFeesPaidTables">
        <link:definition>995665 - Disclosure - CAPITALIZED FEES PAID (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsTables" id="DisclosureGoodwillAndIntangibleAssetsTables">
        <link:definition>995675 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsTables" id="DisclosureBalanceSheetComponentsTables">
        <link:definition>995685 - Disclosure - BALANCE SHEET COMPONENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationTables" id="DisclosureStockBasedCompensationTables">
        <link:definition>995695 - Disclosure - STOCK-BASED COMPENSATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureDebtTables" id="DisclosureDebtTables">
        <link:definition>995705 - Disclosure - DEBT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" id="DisclosureCommitmentsAndContingenciesTables">
        <link:definition>995715 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesTables" id="DisclosureIncomeTaxesTables">
        <link:definition>995725 - Disclosure - INCOME TAXES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails" id="DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails">
        <link:definition>995735 - Disclosure - DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Description of Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" id="DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails">
        <link:definition>995745 - Disclosure - DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesRelatedPartyTransactionsDetails" id="DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesRelatedPartyTransactionsDetails">
        <link:definition>995755 - Disclosure - DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureNetIncomePerShareDetails" id="DisclosureNetIncomePerShareDetails">
        <link:definition>995765 - Disclosure - NET INCOME PER SHARE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails" id="DisclosureNetIncomePerShareBasicAndDilutedEpsDetails">
        <link:definition>995775 - Disclosure - NET INCOME PER SHARE - Basic and Diluted EPS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureNetIncomePerShareAntiDilutiveSecuritiesDetails" id="DisclosureNetIncomePerShareAntiDilutiveSecuritiesDetails">
        <link:definition>995785 - Disclosure - NET INCOME PER SHARE - Anti-Dilutive Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfNetRevenueFromCollaborativeArrangementsDetails" id="DisclosureRevenueRecognitionScheduleOfNetRevenueFromCollaborativeArrangementsDetails">
        <link:definition>995795 - Disclosure - REVENUE RECOGNITION - Schedule of net revenue from collaborative arrangements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureRevenueRecognitionDetails" id="DisclosureRevenueRecognitionDetails">
        <link:definition>995805 - Disclosure - REVENUE RECOGNITION (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureLicenseAndCollaborationArrangementsAdditionalInformationDetails" id="DisclosureLicenseAndCollaborationArrangementsAdditionalInformationDetails">
        <link:definition>995815 - Disclosure - LICENSE AND COLLABORATION ARRANGEMENTS - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails" id="DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails">
        <link:definition>995825 - Disclosure - CONSOLIDATED ENTITIES AND ACQUISITIONS - Theravance Respiratory Company, LLC (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsIspFundLpDetails" id="DisclosureConsolidatedEntitiesAndAcquisitionsIspFundLpDetails">
        <link:definition>995835 - Disclosure - CONSOLIDATED ENTITIES AND ACQUISITIONS - ISP Fund LP (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails" id="DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails">
        <link:definition>995845 - Disclosure - CONSOLIDATED ENTITIES AND ACQUISITIONS - Entasis Therapeutics Holdings, Inc. (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails" id="DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails">
        <link:definition>995855 - Disclosure - CONSOLIDATED ENTITIES AND ACQUISITIONS - Schedule of Recognized Identified Assets Acquired and Liabilities Assumed (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsLaJollaPharmaceuticalCompanyDetails" id="DisclosureConsolidatedEntitiesAndAcquisitionsLaJollaPharmaceuticalCompanyDetails">
        <link:definition>995865 - Disclosure - CONSOLIDATED ENTITIES AND ACQUISITIONS - La Jolla Pharmaceutical Company (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsProFormaInformationDetails" id="DisclosureConsolidatedEntitiesAndAcquisitionsProFormaInformationDetails">
        <link:definition>995875 - Disclosure - CONSOLIDATED ENTITIES AND ACQUISITIONS - Pro Forma Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails" id="DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails">
        <link:definition>995885 - Disclosure - EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Equity Investment in Armata (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsSummarizedFinancialDataDetails" id="DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsSummarizedFinancialDataDetails">
        <link:definition>995895 - Disclosure - EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Summarized Financial Data (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails" id="DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails">
        <link:definition>995905 - Disclosure - EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Equity Investment in InCarda (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInImaginabDetails" id="DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInImaginabDetails">
        <link:definition>995915 - Disclosure - EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Equity Investment in ImaginAb (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInGateNeurosciencesDetails" id="DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInGateNeurosciencesDetails">
        <link:definition>995925 - Disclosure - EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Convertible Promissory Note in Gate Neurosciences (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInNanoliveDetails" id="DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInNanoliveDetails">
        <link:definition>995935 - Disclosure - EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Equity Investment in Nanolive (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsAvailableforsaleSecuritiesDetails" id="DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsAvailableforsaleSecuritiesDetails">
        <link:definition>995945 - Disclosure - EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Available-for-Sale Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet" id="DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet">
        <link:definition>995955 - Disclosure - EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Schedule of Available-for-Sale Securities Measured at Fair Value on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails" id="DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails">
        <link:definition>995965 - Disclosure - CAPITALIZED FEES PAID - Schedule of Capitalized Fees Paid (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails" id="DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails">
        <link:definition>995975 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails" id="DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails">
        <link:definition>995985 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Summary of Accumulated Amortization of Recognized Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoryNetDetails" id="DisclosureBalanceSheetComponentsScheduleOfInventoryNetDetails">
        <link:definition>995995 - Disclosure - BALANCE SHEET COMPONENTS - Schedule of Inventory, net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails" id="DisclosureBalanceSheetComponentsAdditionalInformationDetails">
        <link:definition>996005 - Disclosure - BALANCE SHEET COMPONENTS - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherAccruedLiabilitiesDetails" id="DisclosureBalanceSheetComponentsScheduleOfOtherAccruedLiabilitiesDetails">
        <link:definition>996015 - Disclosure - BALANCE SHEET COMPONENTS - Schedule Of Other Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherLongtermLiabilitiesDetails" id="DisclosureBalanceSheetComponentsScheduleOfOtherLongtermLiabilitiesDetails">
        <link:definition>996025 - Disclosure - BALANCE SHEET COMPONENTS -Schedule of Other Long-term Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensation2012PlanAndEsppDetails" id="DisclosureStockBasedCompensation2012PlanAndEsppDetails">
        <link:definition>996035 - Disclosure - STOCK-BASED COMPENSATION - 2012 Plan and ESPP (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationDirectorCompensationProgramDetails" id="DisclosureStockBasedCompensationDirectorCompensationProgramDetails">
        <link:definition>996045 - Disclosure - STOCK-BASED COMPENSATION - Director Compensation Program (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" id="DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails">
        <link:definition>996055 - Disclosure - STOCK-BASED COMPENSATION - Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationCompensationAwardsDetails" id="DisclosureStockBasedCompensationCompensationAwardsDetails">
        <link:definition>996065 - Disclosure - STOCK-BASED COMPENSATION - Compensation Awards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationValuationAssumptionsDetails" id="DisclosureStockBasedCompensationValuationAssumptionsDetails">
        <link:definition>996075 - Disclosure - STOCK-BASED COMPENSATION - Valuation Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureStockholdersEquityDetails" id="DisclosureStockholdersEquityDetails">
        <link:definition>996085 - Disclosure - STOCKHOLDERS' EQUITY (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails" id="DisclosureDebtScheduleOfDebtDetails">
        <link:definition>996095 - Disclosure - DEBT - Schedule of Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails" id="DisclosureDebtConvertibleSubordinatedNotesDetails">
        <link:definition>996105 - Disclosure - DEBT - Convertible Subordinated Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails" id="DisclosureDebtConvertibleSeniorNotesDetails">
        <link:definition>996115 - Disclosure - DEBT - Convertible Senior Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureDebtDebtMaturitiesDetails" id="DisclosureDebtDebtMaturitiesDetails">
        <link:definition>996125 - Disclosure - DEBT - Debt Maturities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" id="DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
        <link:definition>996135 - Disclosure - COMMITMENTS AND CONTINGENCIES - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeastCostDetails" id="DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeastCostDetails">
        <link:definition>996145 - Disclosure - COMMITMENTS AND CONTINGENCIES - Schedule of Components of Least Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalCashFlowInformationRelatedToLeaseDetails" id="DisclosureCommitmentsAndContingenciesScheduleOfSupplementalCashFlowInformationRelatedToLeaseDetails">
        <link:definition>996155 - Disclosure - COMMITMENTS AND CONTINGENCIES - Schedule of Supplemental Cash Flow Information Related to Lease (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails" id="DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails">
        <link:definition>996165 - Disclosure - COMMITMENTS AND CONTINGENCIES - Schedule of Future Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails" id="DisclosureIncomeTaxesIncomeTaxExpenseDetails">
        <link:definition>996175 - Disclosure - INCOME TAXES - Income tax expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails" id="DisclosureIncomeTaxesReconciliationDetails">
        <link:definition>996185 - Disclosure - INCOME TAXES - Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails" id="DisclosureIncomeTaxesDeferredTaxesDetails">
        <link:definition>996195 - Disclosure - INCOME TAXES - Deferred Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalTaxDisclosuresDetails" id="DisclosureIncomeTaxesAdditionalTaxDisclosuresDetails">
        <link:definition>996205 - Disclosure - INCOME TAXES - Additional Tax Disclosures (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" id="DisclosureSubsequentEventsAdditionalInformationDetails">
        <link:definition>996215 - Disclosure - SUBSEQUENT EVENTS - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="inva-20231231.xsd#DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets" xlink:href="inva-20231231.xsd#StatementConsolidatedBalanceSheets" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:href="inva-20231231.xsd#StatementConsolidatedBalanceSheetsParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfIncome" xlink:href="inva-20231231.xsd#StatementConsolidatedStatementsOfIncome" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfIncomeParenthetical" xlink:href="inva-20231231.xsd#StatementConsolidatedStatementsOfIncomeParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveIncome" xlink:href="inva-20231231.xsd#StatementConsolidatedStatementsOfComprehensiveIncome" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" xlink:href="inva-20231231.xsd#StatementConsolidatedStatementsOfStockholdersEquity" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:href="inva-20231231.xsd#StatementConsolidatedStatementsOfCashFlows" xlink:type="simple"/>
        <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingArrangements" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPolicies" xlink:href="inva-20231231.xsd#DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureNetIncomePerShare" xlink:href="inva-20231231.xsd#DisclosureNetIncomePerShare" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureRevenueRecognition1" xlink:href="inva-20231231.xsd#DisclosureRevenueRecognition1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureLicenseAndCollaborationArrangements" xlink:href="inva-20231231.xsd#DisclosureLicenseAndCollaborationArrangements" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitions1" xlink:href="inva-20231231.xsd#DisclosureConsolidatedEntitiesAndAcquisitions1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurements" xlink:href="inva-20231231.xsd#DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurements" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureCapitalizedFeesPaid1" xlink:href="inva-20231231.xsd#DisclosureCapitalizedFeesPaid1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureGoodwillAndIntangibleAssets" xlink:href="inva-20231231.xsd#DisclosureGoodwillAndIntangibleAssets" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureBalanceSheetComponents" xlink:href="inva-20231231.xsd#DisclosureBalanceSheetComponents" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensation" xlink:href="inva-20231231.xsd#DisclosureStockBasedCompensation" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureStockholdersEquity" xlink:href="inva-20231231.xsd#DisclosureStockholdersEquity" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureDebt" xlink:href="inva-20231231.xsd#DisclosureDebt" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingencies" xlink:href="inva-20231231.xsd#DisclosureCommitmentsAndContingencies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxes" xlink:href="inva-20231231.xsd#DisclosureIncomeTaxes" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureSubsequentEvents" xlink:href="inva-20231231.xsd#DisclosureSubsequentEvents" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="inva-20231231.xsd#DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesTables" xlink:href="inva-20231231.xsd#DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureNetIncomePerShareTables" xlink:href="inva-20231231.xsd#DisclosureNetIncomePerShareTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureRevenueRecognitionTables" xlink:href="inva-20231231.xsd#DisclosureRevenueRecognitionTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTables" xlink:href="inva-20231231.xsd#DisclosureConsolidatedEntitiesAndAcquisitionsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsTables" xlink:href="inva-20231231.xsd#DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureCapitalizedFeesPaidTables" xlink:href="inva-20231231.xsd#DisclosureCapitalizedFeesPaidTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsTables" xlink:href="inva-20231231.xsd#DisclosureGoodwillAndIntangibleAssetsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsTables" xlink:href="inva-20231231.xsd#DisclosureBalanceSheetComponentsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationTables" xlink:href="inva-20231231.xsd#DisclosureStockBasedCompensationTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureDebtTables" xlink:href="inva-20231231.xsd#DisclosureDebtTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" xlink:href="inva-20231231.xsd#DisclosureCommitmentsAndContingenciesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesTables" xlink:href="inva-20231231.xsd#DisclosureIncomeTaxesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails" xlink:href="inva-20231231.xsd#DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" xlink:href="inva-20231231.xsd#DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesRelatedPartyTransactionsDetails" xlink:href="inva-20231231.xsd#DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesRelatedPartyTransactionsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureNetIncomePerShareDetails" xlink:href="inva-20231231.xsd#DisclosureNetIncomePerShareDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails" xlink:href="inva-20231231.xsd#DisclosureNetIncomePerShareBasicAndDilutedEpsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureNetIncomePerShareAntiDilutiveSecuritiesDetails" xlink:href="inva-20231231.xsd#DisclosureNetIncomePerShareAntiDilutiveSecuritiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfNetRevenueFromCollaborativeArrangementsDetails" xlink:href="inva-20231231.xsd#DisclosureRevenueRecognitionScheduleOfNetRevenueFromCollaborativeArrangementsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureRevenueRecognitionDetails" xlink:href="inva-20231231.xsd#DisclosureRevenueRecognitionDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureLicenseAndCollaborationArrangementsAdditionalInformationDetails" xlink:href="inva-20231231.xsd#DisclosureLicenseAndCollaborationArrangementsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails" xlink:href="inva-20231231.xsd#DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsIspFundLpDetails" xlink:href="inva-20231231.xsd#DisclosureConsolidatedEntitiesAndAcquisitionsIspFundLpDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails" xlink:href="inva-20231231.xsd#DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails" xlink:href="inva-20231231.xsd#DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsLaJollaPharmaceuticalCompanyDetails" xlink:href="inva-20231231.xsd#DisclosureConsolidatedEntitiesAndAcquisitionsLaJollaPharmaceuticalCompanyDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsProFormaInformationDetails" xlink:href="inva-20231231.xsd#DisclosureConsolidatedEntitiesAndAcquisitionsProFormaInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails" xlink:href="inva-20231231.xsd#DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsSummarizedFinancialDataDetails" xlink:href="inva-20231231.xsd#DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsSummarizedFinancialDataDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails" xlink:href="inva-20231231.xsd#DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInImaginabDetails" xlink:href="inva-20231231.xsd#DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInImaginabDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInGateNeurosciencesDetails" xlink:href="inva-20231231.xsd#DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInGateNeurosciencesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInNanoliveDetails" xlink:href="inva-20231231.xsd#DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInNanoliveDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsAvailableforsaleSecuritiesDetails" xlink:href="inva-20231231.xsd#DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsAvailableforsaleSecuritiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet" xlink:href="inva-20231231.xsd#DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails" xlink:href="inva-20231231.xsd#DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails" xlink:href="inva-20231231.xsd#DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails" xlink:href="inva-20231231.xsd#DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoryNetDetails" xlink:href="inva-20231231.xsd#DisclosureBalanceSheetComponentsScheduleOfInventoryNetDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails" xlink:href="inva-20231231.xsd#DisclosureBalanceSheetComponentsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherAccruedLiabilitiesDetails" xlink:href="inva-20231231.xsd#DisclosureBalanceSheetComponentsScheduleOfOtherAccruedLiabilitiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherLongtermLiabilitiesDetails" xlink:href="inva-20231231.xsd#DisclosureBalanceSheetComponentsScheduleOfOtherLongtermLiabilitiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensation2012PlanAndEsppDetails" xlink:href="inva-20231231.xsd#DisclosureStockBasedCompensation2012PlanAndEsppDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationDirectorCompensationProgramDetails" xlink:href="inva-20231231.xsd#DisclosureStockBasedCompensationDirectorCompensationProgramDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" xlink:href="inva-20231231.xsd#DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationCompensationAwardsDetails" xlink:href="inva-20231231.xsd#DisclosureStockBasedCompensationCompensationAwardsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationValuationAssumptionsDetails" xlink:href="inva-20231231.xsd#DisclosureStockBasedCompensationValuationAssumptionsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureStockholdersEquityDetails" xlink:href="inva-20231231.xsd#DisclosureStockholdersEquityDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails" xlink:href="inva-20231231.xsd#DisclosureDebtScheduleOfDebtDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails" xlink:href="inva-20231231.xsd#DisclosureDebtConvertibleSubordinatedNotesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails" xlink:href="inva-20231231.xsd#DisclosureDebtConvertibleSeniorNotesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureDebtDebtMaturitiesDetails" xlink:href="inva-20231231.xsd#DisclosureDebtDebtMaturitiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="inva-20231231.xsd#DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeastCostDetails" xlink:href="inva-20231231.xsd#DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeastCostDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalCashFlowInformationRelatedToLeaseDetails" xlink:href="inva-20231231.xsd#DisclosureCommitmentsAndContingenciesScheduleOfSupplementalCashFlowInformationRelatedToLeaseDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails" xlink:href="inva-20231231.xsd#DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails" xlink:href="inva-20231231.xsd#DisclosureIncomeTaxesIncomeTaxExpenseDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails" xlink:href="inva-20231231.xsd#DisclosureIncomeTaxesReconciliationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails" xlink:href="inva-20231231.xsd#DisclosureIncomeTaxesDeferredTaxesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalTaxDisclosuresDetails" xlink:href="inva-20231231.xsd#DisclosureIncomeTaxesAdditionalTaxDisclosuresDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" xlink:href="inva-20231231.xsd#DisclosureSubsequentEventsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails2" xlink:href="inva-20231231.xsd#DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails2" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails2" xlink:href="inva-20231231.xsd#DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails2" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails2" xlink:href="inva-20231231.xsd#DisclosureDebtScheduleOfDebtDetails2" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet1" xlink:href="inva-20231231.xsd#DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails2" xlink:href="inva-20231231.xsd#DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails2" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails2" xlink:href="inva-20231231.xsd#DisclosureIncomeTaxesDeferredTaxesDetails2" xlink:type="simple"/>
        <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd#eedm" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_IncreaseToConvertibleNotes" xlink:label="inva_IncreaseToConvertibleNotes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillLineItems" xlink:label="us-gaap_GoodwillLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_DebtConversionConvertedInstrumentAverageTradePricePercentage" xlink:label="inva_DebtConversionConvertedInstrumentAverageTradePricePercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebtAbstract" xlink:label="us-gaap_InterestExpenseDebtAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostAbstract" xlink:label="us-gaap_CapitalizedContractCostAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestOnConvertibleDebtNetOfTax" xlink:label="us-gaap_InterestOnConvertibleDebtNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_CollaborativeArrangementRoyaltyRateDefinedLevelTwo" xlink:label="inva_CollaborativeArrangementRoyaltyRateDefinedLevelTwo"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_AccruedRoyaltyObligations" xlink:label="inva_AccruedRoyaltyObligations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="us-gaap_UnrealizedGainLossOnInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="us-gaap_NoncontrollingInterestMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesLongTermContractsOrPrograms" xlink:label="us-gaap_ReceivablesLongTermContractsOrPrograms"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SecuritiesPurchaseAgreementNumberOfTranches" xlink:label="inva_SecuritiesPurchaseAgreementNumberOfTranches"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_WeightedAverageMember" xlink:label="srt_WeightedAverageMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_DebtInstrumentRatioOfRepurchasePriceToThePrincipalAmount" xlink:label="inva_DebtInstrumentRatioOfRepurchasePriceToThePrincipalAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseBorrowings" xlink:label="us-gaap_InterestExpenseBorrowings"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_EquityMethodInvestment" xlink:label="inva_EquityMethodInvestment"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_CustomerTwoMember" xlink:label="inva_CustomerTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_RelatedPartyTransactionsPolicyTextBlock" xlink:label="inva_RelatedPartyTransactionsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_InventoryFairValueStepUpAdjustmentIncludedInCostOfProductSales" xlink:label="inva_InventoryFairValueStepUpAdjustmentIncludedInCostOfProductSales"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_IntangibleAssetsInProcessResearchAndDevelopmentGross" xlink:label="inva_IntangibleAssetsInProcessResearchAndDevelopmentGross"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_IncomeTaxesTable" xlink:label="inva_IncomeTaxesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_RiskFreeInterestRate" xlink:label="inva_RiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_PurchaseOfEntasisNoncontrollingInterest" xlink:label="inva_PurchaseOfEntasisNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_DeferredRoyaltyObligations" xlink:label="inva_DeferredRoyaltyObligations"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_LimitedPartnersInitialContribution" xlink:label="inva_LimitedPartnersInitialContribution"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_NumberOfDerivativeInstrumentsPurchased" xlink:label="inva_NumberOfDerivativeInstrumentsPurchased"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ClaimExpirationDate" xlink:label="inva_ClaimExpirationDate"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_NetIncomeLossPerShareAbstract" xlink:label="inva_NetIncomeLossPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestPeriodIncreaseDecrease" xlink:label="us-gaap_MinorityInterestPeriodIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EuropeMember" xlink:label="srt_EuropeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonValue" xlink:label="us-gaap_TreasuryStockCommonValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_HealthCareRoyaltyPartnersMember" xlink:label="inva_HealthCareRoyaltyPartnersMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_PaymentOfManagementAndIncentiveFee" xlink:label="inva_PaymentOfManagementAndIncentiveFee"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_CommonStockAndWarrantsMember" xlink:label="inva_CommonStockAndWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_NonCashActivity" xlink:label="inva_NonCashActivity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="us-gaap_ScheduleOfGoodwillTable"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_CashPaidForTheAcquisitionOfLaJollaPharmaceuticalCompanyNetOfCashAcquired" xlink:label="inva_CashPaidForTheAcquisitionOfLaJollaPharmaceuticalCompanyNetOfCashAcquired"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares" xlink:label="inva_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ReductionToAdditionalPaidInCapital" xlink:label="inva_ReductionToAdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SeriesD1PreferredStockMember" xlink:label="inva_SeriesD1PreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_DerecognitionOfNoncontrollingInterestsUponSaleOfTrc" xlink:label="inva_DerecognitionOfNoncontrollingInterestsUponSaleOfTrc"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_DescriptionOfOperationsPolicyTextBlock" xlink:label="inva_DescriptionOfOperationsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_DividendYield" xlink:label="inva_DividendYield"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_CashDistributionReceived" xlink:label="inva_CashDistributionReceived"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_RoyaltyAgreementMaximumPotentialPayoutPercent" xlink:label="inva_RoyaltyAgreementMaximumPotentialPayoutPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_NameOfEventDomain" xlink:label="inva_NameOfEventDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_BurlingameCaliforniaMember" xlink:label="inva_BurlingameCaliforniaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_AstrazenecaMember" xlink:label="inva_AstrazenecaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:label="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ConsolidatedInvesteesMember" xlink:label="inva_ConsolidatedInvesteesMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_PercentageOfEstimatedVolatility" xlink:label="inva_PercentageOfEstimatedVolatility"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_RightOfUseAssetsObtainedThroughAcquistions" xlink:label="inva_RightOfUseAssetsObtainedThroughAcquistions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentsPolicy" xlink:label="us-gaap_EquityMethodInvestmentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ScheduleOfBalanceSheetInformationRelatedToOperatingLeaseTableTextBlock" xlink:label="inva_ScheduleOfBalanceSheetInformationRelatedToOperatingLeaseTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNet" xlink:label="us-gaap_AccountsReceivableNet"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_TwoDirectorsMember" xlink:label="inva_TwoDirectorsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesInvestments" xlink:label="us-gaap_DeferredTaxLiabilitiesInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_BalanceSheetDisclosuresOfVariableInterestEntityAbstract" xlink:label="inva_BalanceSheetDisclosuresOfVariableInterestEntityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ConvertiblePromissoryNotePurchaseAgreementMember" xlink:label="inva_ConvertiblePromissoryNotePurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveAndOverlappingOfferingPeriod" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveAndOverlappingOfferingPeriod"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_CostReimbursements" xlink:label="inva_CostReimbursements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:label="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersShares" xlink:label="inva_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_LaboratoryEquipmentFurnitureAndFixturesMember" xlink:label="inva_LaboratoryEquipmentFurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_EverestMedicinesLimitedMember" xlink:label="inva_EverestMedicinesLimitedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonUsMember" xlink:label="us-gaap_NonUsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:label="us-gaap_BusinessAcquisitionsProFormaRevenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_WalthamMassachusettsMember" xlink:label="inva_WalthamMassachusettsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="us-gaap_CashAcquiredFromAcquisition"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_OtherAccruedLiabilitiesMember" xlink:label="inva_OtherAccruedLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:label="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:label="us-gaap_ScheduleOfVariableInterestEntitiesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_DeferredTaxLiabilitiesInventoryFairValueAdjustment" xlink:label="inva_DeferredTaxLiabilitiesInventoryFairValueAdjustment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_PriorPeriodImmaterialCorrectionPolicyTextBlock" xlink:label="inva_PriorPeriodImmaterialCorrectionPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayableMember" xlink:label="us-gaap_LoansPayableMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="us-gaap_TreasuryStockCommonShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ConvertibleNoteAndWarrantsMember" xlink:label="inva_ConvertibleNoteAndWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee" xlink:label="inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_CommercialSupplyAgreementMember" xlink:label="inva_CommercialSupplyAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_RegulatoryMilestonePaymentsReceivable" xlink:label="inva_RegulatoryMilestonePaymentsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_IntangibleAssetsMarketedProductsAccumulatedAmortization" xlink:label="inva_IntangibleAssetsMarketedProductsAccumulatedAmortization"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_DebtInstrumentConvertibleConversionPremium" xlink:label="inva_DebtInstrumentConvertibleConversionPremium"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_PercentageOfReimbursedForDirectAndCertainIndirectManufacturingCosts" xlink:label="inva_PercentageOfReimbursedForDirectAndCertainIndirectManufacturingCosts"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_LongActingBeta2AgonistRelvarBreoMember" xlink:label="inva_LongActingBeta2AgonistRelvarBreoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_TheravanceRespiratoryCompanyLlcMember" xlink:label="inva_TheravanceRespiratoryCompanyLlcMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ImaginabConvertibleNoteMember" xlink:label="inva_ImaginabConvertibleNoteMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_RecognitionOfNoncontrollingInterestUponInitialConsolidationofEntasisShares" xlink:label="inva_RecognitionOfNoncontrollingInterestUponInitialConsolidationofEntasisShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US" xlink:label="country_US"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SeriesD2PreferredStockMember" xlink:label="inva_SeriesD2PreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_OperatingLossCarryforwardsIndefinitePeriod" xlink:label="inva_OperatingLossCarryforwardsIndefinitePeriod"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_RoyaltyPayments" xlink:label="inva_RoyaltyPayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtByMaturityAbstract" xlink:label="us-gaap_LongTermDebtByMaturityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MembersEquity" xlink:label="us-gaap_MembersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_AccruedContractManufacturingLiability" xlink:label="inva_AccruedContractManufacturingLiability"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedPersonnelRelatedExpenses" xlink:label="inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedPersonnelRelatedExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_IntangibleAssetsMarketedProductsGross" xlink:label="inva_IntangibleAssetsMarketedProductsGross"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_RelatedPartyTransactionCommonStockOwnershipPercentageByRelatedParty" xlink:label="inva_RelatedPartyTransactionCommonStockOwnershipPercentageByRelatedParty"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_DerecognitionOfNoncontrollingInterestsUponSaleOfTrcShares" xlink:label="inva_DerecognitionOfNoncontrollingInterestsUponSaleOfTrcShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_DerecognitionOfNonControllingInterestsUponAcquisitionOfEntasisMinorityInterest" xlink:label="inva_DerecognitionOfNonControllingInterestsUponAcquisitionOfEntasisMinorityInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ArmataConvertibleNoteMember" xlink:label="inva_ArmataConvertibleNoteMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ReductionToResearchAndDevelopmentExpense" xlink:label="inva_ReductionToResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ShareRepurchaseAgreementWithGlaxoGroupLimitedMember" xlink:label="inva_ShareRepurchaseAgreementWithGlaxoGroupLimitedMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_WarrantsAcquiredInSecondQuarterOf2021Member" xlink:label="inva_WarrantsAcquiredInSecondQuarterOf2021Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PutOptionMember" xlink:label="us-gaap_PutOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_AccruedClinicalLiability" xlink:label="inva_AccruedClinicalLiability"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_PercentageOfMinimumRoyaltyRate" xlink:label="inva_PercentageOfMinimumRoyaltyRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate" xlink:label="inva_CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SecuritiesPurchaseAgreementWarrantsNumberOfSecuritiesCalledByWarrants" xlink:label="inva_SecuritiesPurchaseAgreementWarrantsNumberOfSecuritiesCalledByWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity" xlink:label="inva_ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_NumberOfSharesReceivableOnSettlementOfDerivativeInstrument" xlink:label="inva_NumberOfSharesReceivableOnSettlementOfDerivativeInstrument"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdateExtensibleList" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDilutedLineItems" xlink:label="us-gaap_EarningsPerShareDilutedLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_AccruedInterestIncomeIncludedInLongTermInvestments" xlink:label="inva_AccruedInterestIncomeIncludedInLongTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SeriesD1WarrantMember" xlink:label="inva_SeriesD1WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeconsolidationGainOrLossAmount" xlink:label="us-gaap_DeconsolidationGainOrLossAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_XeravaMember" xlink:label="inva_XeravaMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_LicenseAndCollaborationArrangementsDisclosureTextBlock" xlink:label="inva_LicenseAndCollaborationArrangementsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_LabaCollaborationMember" xlink:label="inva_LabaCollaborationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyMember" xlink:label="us-gaap_RoyaltyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoanRestructuringModificationDomain" xlink:label="us-gaap_LoanRestructuringModificationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense" xlink:label="us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SeriesD2WarrantMember" xlink:label="inva_SeriesD2WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_DeferredTaxLiabilitiesDepreciationAndAmortization" xlink:label="inva_DeferredTaxLiabilitiesDepreciationAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="us-gaap_ValuationTechniqueDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ArmataPharmaceuticalsIncMember" xlink:label="inva_ArmataPharmaceuticalsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_EquityInvestmentsAndMoneyMarketFundsMember" xlink:label="inva_EquityInvestmentsAndMoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SubscriptionAgreementOneTimeMilestonePaymentOnCommercialSales" xlink:label="inva_SubscriptionAgreementOneTimeMilestonePaymentOnCommercialSales"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostTable" xlink:label="us-gaap_CapitalizedContractCostTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementRelatedDisclosuresAbstract" xlink:label="us-gaap_IncomeStatementRelatedDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyAllegations" xlink:label="us-gaap_LossContingencyAllegations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_CreditAndSecurityAgreementMember" xlink:label="inva_CreditAndSecurityAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostLineItems" xlink:label="us-gaap_CapitalizedContractCostLineItems"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_DilutiveEpsOfNotes" xlink:label="inva_DilutiveEpsOfNotes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_WarrantsPurchasedIn2022Member" xlink:label="inva_WarrantsPurchasedIn2022Member"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_NumberOfBoardMembersOfInvestee" xlink:label="inva_NumberOfBoardMembersOfInvestee"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_NoteAmendmentAgreementMember" xlink:label="inva_NoteAmendmentAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ConvertiblePromissoryNoteMember" xlink:label="inva_ConvertiblePromissoryNoteMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_GainLossOnOtherInvestments" xlink:label="inva_GainLossOnOtherInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SeriesA1PreferredStockMember" xlink:label="inva_SeriesA1PreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_EntasisLeaseMember" xlink:label="inva_EntasisLeaseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="us-gaap_SeriesDPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ScheduleOfConsolidatedEntitiesAndBusinessAcquisitionsByAcquisitionTable" xlink:label="inva_ScheduleOfConsolidatedEntitiesAndBusinessAcquisitionsByAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_CapitalizedFeesPaidPolicyTextBlock" xlink:label="inva_CapitalizedFeesPaidPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_OutstandingStockWarrantMember" xlink:label="inva_OutstandingStockWarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_PaymentsForRoyaltyAgreement" xlink:label="inva_PaymentsForRoyaltyAgreement"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_StrategicAllianceAgreementMember" xlink:label="inva_StrategicAllianceAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_PrivatelyNegotiatedCappedCallOptionMember" xlink:label="inva_PrivatelyNegotiatedCappedCallOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_EntasisTherapeuticsHoldingsIncMember" xlink:label="inva_EntasisTherapeuticsHoldingsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_DeferredTaxAssetsDeferredRoyaltyObligationNet" xlink:label="inva_DeferredTaxAssetsDeferredRoyaltyObligationNet"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_AccruedProfessionalServices" xlink:label="inva_AccruedProfessionalServices"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_IntangibleAssetsCollaborationAgreementNet" xlink:label="inva_IntangibleAssetsCollaborationAgreementNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:label="us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SaleOfWarrantsNumberOfWarrantsIssuedInTransaction" xlink:label="inva_SaleOfWarrantsNumberOfWarrantsIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_NetProceedsFromSaleOfVariableInterestEntityEquity" xlink:label="inva_NetProceedsFromSaleOfVariableInterestEntityEquity"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_DerecognitionOfNoncontrollingInterestsUponAcquisitionOfEntasisMinorityInterestShares" xlink:label="inva_DerecognitionOfNoncontrollingInterestsUponAcquisitionOfEntasisMinorityInterestShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:label="us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_IntangibleAssetsCollaborationAgreementGross" xlink:label="inva_IntangibleAssetsCollaborationAgreementGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_DeferredRoyaltyObligationCurrent" xlink:label="inva_DeferredRoyaltyObligationCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationDeductionsOther" xlink:label="us-gaap_IncomeTaxReconciliationDeductionsOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_UnrecognizedTaxBenefitsDecreaseResultingFromCurrentPeriodTaxPositionsNet" xlink:label="inva_UnrecognizedTaxBenefitsDecreaseResultingFromCurrentPeriodTaxPositionsNet"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_OwnershipInterestInConsolidatedEntities" xlink:label="inva_OwnershipInterestInConsolidatedEntities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtCurrent" xlink:label="us-gaap_DebtCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ProceedsFromSaleOfEconomicInterestUnderEquityPurchaseAgreement" xlink:label="inva_ProceedsFromSaleOfEconomicInterestUnderEquityPurchaseAgreement"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_WarrantsPurchasedIn2020Member" xlink:label="inva_WarrantsPurchasedIn2020Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SeriesDWarrantsMember" xlink:label="inva_SeriesDWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:label="us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcquisitionCosts" xlink:label="us-gaap_AcquisitionCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ResearchAndDevelopmentSupportMember" xlink:label="inva_ResearchAndDevelopmentSupportMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareRepurchaseProgramAxis" xlink:label="us-gaap_ShareRepurchaseProgramAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_UnrecognizedTaxBenefitsIncreaseResultingFromCurrentPeriodTaxPositionsNet" xlink:label="inva_UnrecognizedTaxBenefitsIncreaseResultingFromCurrentPeriodTaxPositionsNet"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_CarryingValueWroteOffWarrantExercise" xlink:label="inva_CarryingValueWroteOffWarrantExercise"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalEquityGrantValue" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalEquityGrantValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees" xlink:label="inva_GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SpecialTermReDesignatingBoardMemberToBoardOfInvestee" xlink:label="inva_SpecialTermReDesignatingBoardMemberToBoardOfInvestee"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToMinorityShareholders" xlink:label="us-gaap_PaymentsToMinorityShareholders"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_EquityIncentivePlansAndESPPMember" xlink:label="inva_EquityIncentivePlansAndESPPMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_IntangibleAssetsInProcessResearchAndDevelopmentNet" xlink:label="inva_IntangibleAssetsInProcessResearchAndDevelopmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpensePolicyTextBlock" xlink:label="us-gaap_InterestExpensePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentDescription" xlink:label="us-gaap_DebtInstrumentDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_TermLoanInvestmentMember" xlink:label="inva_TermLoanInvestmentMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtInShares" xlink:label="inva_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtInShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_DecreaseToAccumulatedDeficit" xlink:label="inva_DecreaseToAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:label="us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_AccruedLicenseFeesAndRoyalties" xlink:label="inva_AccruedLicenseFeesAndRoyalties"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="us-gaap_EquitySecuritiesFvNi"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_DebtInstrumentPrincipalAmount" xlink:label="inva_DebtInstrumentPrincipalAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingNumber" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest" xlink:label="us-gaap_MinorityInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_RealizedLoss" xlink:label="inva_RealizedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_IncomeStatementDisclosuresOfVariableInterestEntityAbstract" xlink:label="inva_IncomeStatementDisclosuresOfVariableInterestEntityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:label="us-gaap_OtherNoncurrentLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SaleOfEquityInvestmentsManagedByIspFundLp" xlink:label="inva_SaleOfEquityInvestmentsManagedByIspFundLp"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement" xlink:label="inva_SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_EmployeeStockPurchasePlanMember" xlink:label="inva_EmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_OldDebtInstrumentInterestRateBeforeRepurchaseOfNotesMember" xlink:label="inva_OldDebtInstrumentInterestRateBeforeRepurchaseOfNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_RecognitionOfNoncontrollingInterestUponInitialConsolidationOfEntasis" xlink:label="inva_RecognitionOfNoncontrollingInterestUponInitialConsolidationOfEntasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:label="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_Rule10B51ArrModifiedFlag" xlink:label="inva_Rule10B51ArrModifiedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_RoyaltyAgreementIncreaseInMaximumPotentialPayoutPercent" xlink:label="inva_RoyaltyAgreementIncreaseInMaximumPotentialPayoutPercent"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_FairValueAdjustmentsOfInventoryFromAcquistion" xlink:label="inva_FairValueAdjustmentsOfInventoryFromAcquistion"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_TrelegyElliptaMember" xlink:label="inva_TrelegyElliptaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_PercentageOfEconomicInterestInPartnership" xlink:label="inva_PercentageOfEconomicInterestInPartnership"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ConvertibleSubordinatedDebtFairValueDisclosures" xlink:label="inva_ConvertibleSubordinatedDebtFairValueDisclosures"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LimitedPartnersCumulativeCashDistributions" xlink:label="us-gaap_LimitedPartnersCumulativeCashDistributions"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_OptionPricingModelBacksolveValuationMember" xlink:label="inva_OptionPricingModelBacksolveValuationMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_AccruedResearchLiability" xlink:label="inva_AccruedResearchLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseBorrowingsAbstract" xlink:label="us-gaap_InterestExpenseBorrowingsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_PartnershipAgreementLockUpPeriod" xlink:label="inva_PartnershipAgreementLockUpPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ConvertibleSeniorDebtFairValueDisclosures" xlink:label="inva_ConvertibleSeniorDebtFairValueDisclosures"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityCovenantTerms" xlink:label="us-gaap_LineOfCreditFacilityCovenantTerms"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_IncreaseDecreaseInDeferredTaxAssets" xlink:label="inva_IncreaseDecreaseInDeferredTaxAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostTableTextBlock" xlink:label="us-gaap_CapitalizedContractCostTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SecuritiesPurchaseAgreementRightsToDesignateInvesteeBoardMembersNumberOfBoardMembers" xlink:label="inva_SecuritiesPurchaseAgreementRightsToDesignateInvesteeBoardMembersNumberOfBoardMembers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryLineItems" xlink:label="us-gaap_InventoryLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_GiaprezaMember" xlink:label="inva_GiaprezaMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_WarrantsAcquiredInSecondQuarterOf2020Member" xlink:label="inva_WarrantsAcquiredInSecondQuarterOf2020Member"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_Percent2.50ConvertibleDebtMember" xlink:label="inva_Percent2.50ConvertibleDebtMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SecuritiesPurchaseAgreementTotalNumberOfWarrantsToBePurchasedUnderAgreement" xlink:label="inva_SecuritiesPurchaseAgreementTotalNumberOfWarrantsToBePurchasedUnderAgreement"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_PurchaseAndSaleOfOtherInvestmentsManagedByIspFundLp" xlink:label="inva_PurchaseAndSaleOfOtherInvestmentsManagedByIspFundLp"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_PurchasesOfCappedCallOptionsAssociatedWithConvertibleSeniorNotes" xlink:label="inva_PurchasesOfCappedCallOptionsAssociatedWithConvertibleSeniorNotes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_WarrantsPurchasedIn2021Member" xlink:label="inva_WarrantsPurchasedIn2021Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:label="us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_TermOfMilestonePaymentForNetSales" xlink:label="inva_TermOfMilestonePaymentForNetSales"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_PercentageOfMaximumRoyaltyBasedOnAchievementOfAnnualNetProductSalesThresholds" xlink:label="inva_PercentageOfMaximumRoyaltyBasedOnAchievementOfAnnualNetProductSalesThresholds"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_IncrementalCommonSharesAttributableToConversionOfDebtSecuritiesTreasuryStockMethod" xlink:label="inva_IncrementalCommonSharesAttributableToConversionOfDebtSecuritiesTreasuryStockMethod"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFour" xlink:label="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityGrantValue" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityGrantValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_IspFundLpMember" xlink:label="inva_IspFundLpMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ContingentValueRightsLiability" xlink:label="inva_ContingentValueRightsLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SecuredConvertibleCreditAgreementMember" xlink:label="inva_SecuredConvertibleCreditAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_DebtConversionCommonStockPriceToConversionPriceRatioPercentage" xlink:label="inva_DebtConversionCommonStockPriceToConversionPriceRatioPercentage"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntityShares" xlink:label="inva_ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntityShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetResidualValue" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetResidualValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:label="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRepurchaseAmount" xlink:label="us-gaap_DebtInstrumentRepurchaseAmount"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_PaionAgMember" xlink:label="inva_PaionAgMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_EquityIncentivePlan2012Member" xlink:label="inva_EquityIncentivePlan2012Member"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_PercentageOfRoyaltyOnPaymentsReceivedFromSublicensees" xlink:label="inva_PercentageOfRoyaltyOnPaymentsReceivedFromSublicensees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnInvestments" xlink:label="us-gaap_GainLossOnInvestments"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearthree" xlink:label="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearthree"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_WarrantsAcquiredInThirdQuarterOf2020Member" xlink:label="inva_WarrantsAcquiredInThirdQuarterOf2020Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_JP" xlink:label="country_JP"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_PreferredStockWarrantsMember" xlink:label="inva_PreferredStockWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_DebtInstrumentRepurchasePercentage" xlink:label="inva_DebtInstrumentRepurchasePercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:label="us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityStrikePrice1" xlink:label="us-gaap_OptionIndexedToIssuersEquityStrikePrice1"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_MeasurementPeriodAdjustmentsIncreaseDecreaseInEstimatedPurchasePrice" xlink:label="inva_MeasurementPeriodAdjustmentsIncreaseDecreaseInEstimatedPurchasePrice"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_OneOfImaginabsCommonStockholderMember" xlink:label="inva_OneOfImaginabsCommonStockholderMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_CustomerThreeMember" xlink:label="inva_CustomerThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostAccumulatedAmortization" xlink:label="us-gaap_CapitalizedContractCostAccumulatedAmortization"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_NanoliveMember" xlink:label="inva_NanoliveMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_DeferredTaxAssetsUnrealizedLossesOnInvestmentNet" xlink:label="inva_DeferredTaxAssetsUnrealizedLossesOnInvestmentNet"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_IncomeTaxesLineItems" xlink:label="inva_IncomeTaxesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_DenominatorAbstract" xlink:label="inva_DenominatorAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ExpectedHoldingPeriod" xlink:label="inva_ExpectedHoldingPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:label="us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_CollaborativeArrangementsMember" xlink:label="inva_CollaborativeArrangementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtTableTextBlock" xlink:label="us-gaap_ConvertibleDebtTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_IncreaseInDeferredTaxAssets" xlink:label="inva_IncreaseInDeferredTaxAssets"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_PercentageOfEconomicInterestOnFuturePaymentsUnderAgreements" xlink:label="inva_PercentageOfEconomicInterestOnFuturePaymentsUnderAgreements"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_VotingAgreementMaximumVotingRightsPercent" xlink:label="inva_VotingAgreementMaximumVotingRightsPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="us-gaap_DebtInstrumentFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_DeferredRoyaltyObligationNonCurrent" xlink:label="inva_DeferredRoyaltyObligationNonCurrent"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SeriesCWarrantsAndSeriesDWarrantsMember" xlink:label="inva_SeriesCWarrantsAndSeriesDWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_Incarda2020WarrantsMember" xlink:label="inva_Incarda2020WarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_PropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:label="inva_PropertyPlantAndEquipmentUsefulLifeTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_PresentationReclassificationPolicyTextBlock" xlink:label="inva_PresentationReclassificationPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_LaJollaMember" xlink:label="inva_LaJollaMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SecuritiesPurchaseAgreementAmount" xlink:label="inva_SecuritiesPurchaseAgreementAmount"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_TwoThousandTwentyEightNotesMember" xlink:label="inva_TwoThousandTwentyEightNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeAccountsReceivableMember" xlink:label="us-gaap_TradeAccountsReceivableMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:label="us-gaap_ConsolidationVariableInterestEntityPolicy"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_PercentageOfRoyaltyPaymentsNotEntitledToReceive" xlink:label="inva_PercentageOfRoyaltyPaymentsNotEntitledToReceive"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_DemandLettersSentByStockholders" xlink:label="inva_DemandLettersSentByStockholders"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_NonRule10B51ArrModifiedFlag" xlink:label="inva_NonRule10B51ArrModifiedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="us-gaap_ShareRepurchaseProgramDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ConsolidatedEntitiesAndAcquisitionsDisclosureAbstract" xlink:label="inva_ConsolidatedEntitiesAndAcquisitionsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SeriesCPreferredStockAndWarrantsMember" xlink:label="inva_SeriesCPreferredStockAndWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_CollaborativeArrangementRoyaltyRateDefinedLevelOne" xlink:label="inva_CollaborativeArrangementRoyaltyRateDefinedLevelOne"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_CommonStockAcquiredAverageCostPerShare" xlink:label="inva_CommonStockAcquiredAverageCostPerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentPrincipal"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostNet" xlink:label="us-gaap_CapitalizedContractCostNet"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SeriesC2PreferredStockMember" xlink:label="inva_SeriesC2PreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_InCardaConvertibleNoteMember" xlink:label="inva_InCardaConvertibleNoteMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFive" xlink:label="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_FuturePotentialMilestonePayment" xlink:label="inva_FuturePotentialMilestonePayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:label="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_InterestRateOfDeferredRoyaltyObligation" xlink:label="inva_InterestRateOfDeferredRoyaltyObligation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="us-gaap_TreasuryStockSharesAcquired"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="us-gaap_ConvertibleDebtCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_PurchasesOfCappedCallsInConnectionWithConvertibleSeniorNotes" xlink:label="inva_PurchasesOfCappedCallsInConnectionWithConvertibleSeniorNotes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CallOptionMember" xlink:label="us-gaap_CallOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_IntangibleAssetsMarketedProductsNet" xlink:label="inva_IntangibleAssetsMarketedProductsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_EmployeeStockPurchasePlanTwentyTwentyThreeMember" xlink:label="inva_EmployeeStockPurchasePlanTwentyTwentyThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SalesMilestonePaymentsReceivable" xlink:label="inva_SalesMilestonePaymentsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary" xlink:label="us-gaap_IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableInterestEntityLineItems" xlink:label="us-gaap_VariableInterestEntityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostAmortization" xlink:label="us-gaap_CapitalizedContractCostAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SeniorUnsecuredConvertibleNotesMember" xlink:label="inva_SeniorUnsecuredConvertibleNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentTwo" xlink:label="inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_RoyaltyFinancingAgreementMember" xlink:label="inva_RoyaltyFinancingAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:label="inva_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_LicenseRevenueRecognized" xlink:label="inva_LicenseRevenueRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeCapPrice" xlink:label="us-gaap_DerivativeCapPrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_PercentageOfRoyaltyPayableOnNetSales" xlink:label="inva_PercentageOfRoyaltyPayableOnNetSales"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_PrivatePlacementPositionsAndConvertibleNotesMember" xlink:label="inva_PrivatePlacementPositionsAndConvertibleNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember" xlink:label="inva_InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_PortionOfDebtInstrumentFaceAmountExercised" xlink:label="inva_PortionOfDebtInstrumentFaceAmountExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfUnsecuredDebt" xlink:label="us-gaap_RepaymentsOfUnsecuredDebt"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_IntangibleAssetsInProcessResearchAndDevelopmentAccumulatedAmortization" xlink:label="inva_IntangibleAssetsInProcessResearchAndDevelopmentAccumulatedAmortization"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_NewDebtInstrumentInterestRateAfterRepurchaseOfNotesMember" xlink:label="inva_NewDebtInstrumentInterestRateAfterRepurchaseOfNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilities" xlink:label="us-gaap_OtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SeriesD1AndD2PreferredStockAndCommonStockMember" xlink:label="inva_SeriesD1AndD2PreferredStockAndCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleSubordinatedDebtMember" xlink:label="us-gaap_ConvertibleSubordinatedDebtMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ConsolidatedEntitiesAndAcquisitionsTextBlock" xlink:label="inva_ConsolidatedEntitiesAndAcquisitionsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent" xlink:label="us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ContingentSalesBasedMilestonePayment" xlink:label="inva_ContingentSalesBasedMilestonePayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:label="us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_IntangibleAssetsCollaborationAgreementAccumulatedAmortization" xlink:label="inva_IntangibleAssetsCollaborationAgreementAccumulatedAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="us-gaap_CollaborativeArrangementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableInterestEntityOwnershipPercentage" xlink:label="us-gaap_VariableInterestEntityOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_AmortizationOfCapitalizedFeesAndDepreciationOfPropertyAndEquipment" xlink:label="inva_AmortizationOfCapitalizedFeesAndDepreciationOfPropertyAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_GateNeuroscienceMember" xlink:label="inva_GateNeuroscienceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:label="us-gaap_DebtLongtermAndShorttermCombinedAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_CapitalizedFeesPaidRemainingEstimatedAmortizationAfterYearFive" xlink:label="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationAfterYearFive"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_CapitalizedFeesPaidWeightedAverageUsefulLife" xlink:label="inva_CapitalizedFeesPaidWeightedAverageUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_MeasurementPeriodAdjustmentsIncreaseDecreaseInLiabilities" xlink:label="inva_MeasurementPeriodAdjustmentsIncreaseDecreaseInLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_OneDirectorMember" xlink:label="inva_OneDirectorMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:label="us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ArmataTermLoanMember" xlink:label="inva_ArmataTermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_GSKMember" xlink:label="inva_GSKMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestAndDividendIncomeOperating" xlink:label="us-gaap_InterestAndDividendIncomeOperating"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_NetOperatingLossEstimatingDate" xlink:label="inva_NetOperatingLossEstimatingDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_LaJollaPharmaceuticalCompanyMember" xlink:label="inva_LaJollaPharmaceuticalCompanyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_CapitalizedFeesPaidDisclosureTextBlock" xlink:label="inva_CapitalizedFeesPaidDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ProfitLossShares" xlink:label="inva_ProfitLossShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsNonrecurringMember" xlink:label="us-gaap_FairValueMeasurementsNonrecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_FederalNetOperatingLossesEstimatedUtilizationAmount" xlink:label="inva_FederalNetOperatingLossesEstimatedUtilizationAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestments" xlink:label="us-gaap_EquityMethodInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_BusinessAcquisitionsOfChangeInFairValueOfInvestment" xlink:label="inva_BusinessAcquisitionsOfChangeInFairValueOfInvestment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralPartnerMember" xlink:label="us-gaap_GeneralPartnerMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialEquityGrantValue" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialEquityGrantValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_DebtInstrumentTransactionCost" xlink:label="inva_DebtInstrumentTransactionCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:label="us-gaap_TreasuryStockValueAcquiredCostMethod"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="inva_SummaryOfSignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SecuritiesPurchaseAgreementMember" xlink:label="inva_SecuritiesPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesMember" xlink:label="us-gaap_EquitySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGain" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedGain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:label="us-gaap_PaymentsToAcquireEquitySecuritiesFvNi"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_LicenseRevenueMember" xlink:label="inva_LicenseRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_NumeratorAbstract" xlink:label="inva_NumeratorAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:label="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonMember" xlink:label="us-gaap_TreasuryStockCommonMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_IncomeTaxPayableNonCurrent" xlink:label="inva_IncomeTaxPayableNonCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_XacduroMember" xlink:label="inva_XacduroMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ImaginabMember" xlink:label="inva_ImaginabMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_UnrecognizedTaxBenefitsDecreaseResultingFromPriorPeriodTaxPositionsNet" xlink:label="inva_UnrecognizedTaxBenefitsDecreaseResultingFromPriorPeriodTaxPositionsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_LongActingBeta2AgonistAnoroMember" xlink:label="inva_LongActingBeta2AgonistAnoroMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SummaryOfSignificantAccountingPoliciesTable" xlink:label="inva_SummaryOfSignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_NumberOfCommonStockIssuedDescription" xlink:label="inva_NumberOfCommonStockIssuedDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts" xlink:label="inva_CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetRentableArea" xlink:label="us-gaap_NetRentableArea"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="us-gaap_BusinessAcquisitionSharePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:label="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_CapitalizedFeePaidEstimatedUsefulLife" xlink:label="inva_CapitalizedFeePaidEstimatedUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_UnrealizedOtherGainLossOnInvestments" xlink:label="inva_UnrealizedOtherGainLossOnInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfTreasuryStockTable" xlink:label="us-gaap_ClassOfTreasuryStockTable"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ConvertibleDebtInstrumentLiabilityComponentAbstract" xlink:label="inva_ConvertibleDebtInstrumentLiabilityComponentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="us-gaap_BusinessCombinationsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtMember" xlink:label="us-gaap_DebtMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate202006Member" xlink:label="us-gaap_AccountingStandardsUpdate202006Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryCurrentTable" xlink:label="us-gaap_InventoryCurrentTable"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_WithdrawalFromInvestment" xlink:label="inva_WithdrawalFromInvestment"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAccruedLiabilities" xlink:label="inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingWeightedAverageFairValuePerShare" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingWeightedAverageFairValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ConsolidatedEntitiesDisclosureAbstract" xlink:label="inva_ConsolidatedEntitiesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_OperatingLeaseWeightedAverageIncrementalBorrowingRate" xlink:label="inva_OperatingLeaseWeightedAverageIncrementalBorrowingRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LimitedPartnersContributedCapital" xlink:label="us-gaap_LimitedPartnersContributedCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_PurchasesOfTradingSecurityManagedByIspFundLp" xlink:label="inva_PurchasesOfTradingSecurityManagedByIspFundLp"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_StrategicAllianceMabaProgram" xlink:label="inva_StrategicAllianceMabaProgram"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_TwoThousandTwentyThreeNotesMember" xlink:label="inva_TwoThousandTwentyThreeNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_CapitalizedFeesPaidToRelatedPartyPolicyTextBlock" xlink:label="inva_CapitalizedFeesPaidToRelatedPartyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryGross" xlink:label="us-gaap_InventoryGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_RoyaltiesPayablePeriodAfterFirstCommercialSaleOfProduct" xlink:label="inva_RoyaltiesPayablePeriodAfterFirstCommercialSaleOfProduct"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_QualifiedFinancingMember" xlink:label="inva_QualifiedFinancingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_CapitalizedFeesPaidRemainingEstimatedAmortizationNextTwelveMonths" xlink:label="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree" xlink:label="inva_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountAsContributionOfEligibleCompensation" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountAsContributionOfEligibleCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ParatekPharmaceuticalsIncMember" xlink:label="inva_ParatekPharmaceuticalsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeographicConcentrationRiskMember" xlink:label="us-gaap_GeographicConcentrationRiskMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_PurchasesOfEquityInvestmentsManagedByIspFundLp" xlink:label="inva_PurchasesOfEquityInvestmentsManagedByIspFundLp"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_FactorsAffectingComparabilityPolicyTextBlock" xlink:label="inva_FactorsAffectingComparabilityPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInvestmentExpense" xlink:label="us-gaap_InvestmentIncomeInvestmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_InnovivaCommonStockMember" xlink:label="inva_InnovivaCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_NumberOfCustomers" xlink:label="inva_NumberOfCustomers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterestAndDividend" xlink:label="us-gaap_InvestmentIncomeInterestAndDividend"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SarissaCapitalManagementLpMember" xlink:label="inva_SarissaCapitalManagementLpMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SoftwareAndComputerEquipmentMember" xlink:label="inva_SoftwareAndComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_CustomerOneMember" xlink:label="inva_CustomerOneMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_StateNetOperatingLossesEstimatedUtilizationAmount" xlink:label="inva_StateNetOperatingLossesEstimatedUtilizationAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SecondNoteAmendmentAgreementMember" xlink:label="inva_SecondNoteAmendmentAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="us-gaap_RepaymentsOfConvertibleDebt"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_CapitalizedFeesPaidFutureAmortizationAbstract" xlink:label="inva_CapitalizedFeesPaidFutureAmortizationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtMember" xlink:label="us-gaap_ConvertibleDebtMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_NameOfEventAxis" xlink:label="inva_NameOfEventAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_TwoThousandTwentyFiveNotesMember" xlink:label="inva_TwoThousandTwentyFiveNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:label="us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_IncardaMember" xlink:label="inva_IncardaMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" xlink:label="inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_GeorgeWashingtonUniversityMember" xlink:label="inva_GeorgeWashingtonUniversityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_NewPrincipalAmountMember" xlink:label="inva_NewPrincipalAmountMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_NetInvestmentRelatedIncomeExpenseEarnedInccured" xlink:label="inva_NetInvestmentRelatedIncomeExpenseEarnedInccured"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireLongtermInvestments" xlink:label="us-gaap_PaymentsToAcquireLongtermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ClinicalDevelopmentAndRegulatoryMilestonesAmountPayable" xlink:label="inva_ClinicalDevelopmentAndRegulatoryMilestonesAmountPayable"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ExtendedExpirationDate" xlink:label="inva_ExtendedExpirationDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoanRestructuringModificationAxis" xlink:label="us-gaap_LoanRestructuringModificationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SubscriptionAgreementOneTimeMilestonePaymentOnNetSales" xlink:label="inva_SubscriptionAgreementOneTimeMilestonePaymentOnNetSales"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_InnovivaMember" xlink:label="inva_InnovivaMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_TermOfMilestonePaymentForCommercialSale" xlink:label="inva_TermOfMilestonePaymentForCommercialSale"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="us-gaap_ValuationTechniqueAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearTwo" xlink:label="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_AmortizationOfFairValueAdjustmentsOfCostOfProductsSold" xlink:label="inva_AmortizationOfFairValueAdjustmentsOfCostOfProductsSold"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_IncreaseDecreaseInDeferredTaxLiabilities" xlink:label="inva_IncreaseDecreaseInDeferredTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostGross" xlink:label="us-gaap_CapitalizedContractCostGross"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_CostReimbursementMember" xlink:label="inva_CostReimbursementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillPeriodIncreaseDecrease" xlink:label="us-gaap_GoodwillPeriodIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentOne" xlink:label="inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentOne"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ConsolidatedEntitiesAndAcquisitionsLineItems" xlink:label="inva_ConsolidatedEntitiesAndAcquisitionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ZaiLabMember" xlink:label="inva_ZaiLabMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_HarvardUniversityMember" xlink:label="inva_HarvardUniversityMember"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IncreaseToConvertibleNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase to convertible notes.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IncreaseToConvertibleNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase To Convertible Notes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IncreaseToConvertibleNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in convertible notes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm ID</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Interest Payable, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued interest payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DebtConversionConvertedInstrumentAverageTradePricePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The average trading price per $1,000 of Notes with respect to product of the closing common stock price and the conversion rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DebtConversionConvertedInstrumentAverageTradePricePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Conversion, Converted Instrument, Average Trade Price Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DebtConversionConvertedInstrumentAverageTradePricePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Average trading price percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Arrangements and Non-arrangement Transactions [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining contractual term of options outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseDebtAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense, Debt [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseDebtAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money market funds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalizedContractCostAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capitalized Contract Cost [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transaction costs to acquire equity securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments of Stock Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Equity issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestOnConvertibleDebtNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest on Convertible Debt, Net of Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestOnConvertibleDebtNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Add: interest expense on Notes, net of tax effect</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CollaborativeArrangementRoyaltyRateDefinedLevelTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the royalty rate which the entity will receive under the collaboration agreement on sales which exceed the first defined level of annual global net sales.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CollaborativeArrangementRoyaltyRateDefinedLevelTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement, Royalty Rate Defined, Level Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CollaborativeArrangementRoyaltyRateDefinedLevelTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty rate for sales above first level of annual global net sales (as a percent)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AccruedRoyaltyObligations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Obligation to pay royalties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AccruedRoyaltyObligations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Royalty Obligations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AccruedRoyaltyObligations_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Obligations incurred through that date and payable for royalties.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrealizedGainLossOnInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Unrealized Gain (Loss) on Investments, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrealizedGainLossOnInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrealized Gain (Loss) on Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrealizedGainLossOnInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Unrealized loss on other equity investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrealizedGainLossOnInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Changes in fair values of other equity and long-term investments, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoncontrollingInterestMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Noncontrolling Interest [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoncontrollingInterestMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostOfRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost of license revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostOfRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cost of Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostOfRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cost of Revenue, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-sale, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReceivablesLongTermContractsOrPrograms_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Receivables, Long-Term Contracts or Programs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReceivablesLongTermContractsOrPrograms_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Receivables from collaboration arrangements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other long-term liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other long-term liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units (RSUs) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">RSUs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Future amortization expense, 2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 1 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Quoted Price in Active Markets for Identical Assets, Level 1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SecuritiesPurchaseAgreementNumberOfTranches_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The number of tranches in which the Company agreed to purchase common stock and warrants upon satisfaction of certain closing conditions under the terms of the securities purchase agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SecuritiesPurchaseAgreementNumberOfTranches_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Purchase Agreement, Number of Tranches</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SecuritiesPurchaseAgreementNumberOfTranches_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of tranches</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SecuritiesPurchaseAgreementNumberOfTranches_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of tranches</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_WeightedAverageMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_WeightedAverageMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DebtInstrumentRatioOfRepurchasePriceToThePrincipalAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt Instrument, Ratio of repurchase price to the principal amount of debt instrument that was repurchased.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DebtInstrumentRatioOfRepurchasePriceToThePrincipalAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Ratio of repurchase price to the principal amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DebtInstrumentRatioOfRepurchasePriceToThePrincipalAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ratio of repurchase price to the principal amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Useful Life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated useful life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total royalty revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">License revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total net revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseBorrowings_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Interest Expense, Borrowings, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseBorrowings_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense, Borrowings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseBorrowings_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_EquityMethodInvestment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity method investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_EquityMethodInvestment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_EquityMethodInvestment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Equity method investment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CustomerTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Customer two.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CustomerTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Customer Two [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CustomerTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Customer Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized compensation cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation of Revenue [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of net revenue from collaborative arrangements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermDebtTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Debt, Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ICFR Auditor Attestation Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RelatedPartyTransactionsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Describes the entity's accounting policies for transactions entered with related parties.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RelatedPartyTransactionsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RelatedPartyTransactionsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Parties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capped call options associated with convertible senior notes due 2028</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_InventoryFairValueStepUpAdjustmentIncludedInCostOfProductSales_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventory fair value step-up adjustment included in cost of products sold</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_InventoryFairValueStepUpAdjustmentIncludedInCostOfProductSales_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Fair Value Step Up Adjustment Included In Cost Of Product Sales</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_InventoryFairValueStepUpAdjustmentIncludedInCostOfProductSales_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Inventory fair value step-up adjustment included in cost of product sales.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IntangibleAssetsInProcessResearchAndDevelopmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Gross amount of In-process research and development.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IntangibleAssetsInProcessResearchAndDevelopmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets In-process Research and Development, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IntangibleAssetsInProcessResearchAndDevelopmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">In-process research and development, gross carrying amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IncomeTaxesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of income taxes.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IncomeTaxesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of stock-based compensation expense included in the consolidated statements of operations by award type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of Individual [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Relationship to Entity [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">SUBSEQUENT EVENTS</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Risk free interest rate.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Risk Free Interest Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk free interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Debt, Fair Value Disclosures</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2028 Notes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PurchaseOfEntasisNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Purchase of entasis noncontrolling interest.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PurchaseOfEntasisNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchase Of Entasis noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PurchaseOfEntasisNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of Entasis noncontrolling interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term portion of lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DeferredRoyaltyObligations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred royalty obligations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DeferredRoyaltyObligations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Royalty Obligations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DeferredRoyaltyObligations_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred royalty obligations.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_LimitedPartnersInitialContribution_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial contribution</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_LimitedPartnersInitialContribution_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Limited Partners Initial Contribution</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_LimitedPartnersInitialContribution_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Limited partners initial contribution.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NumberOfDerivativeInstrumentsPurchased_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the number of derivative instruments purchased.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NumberOfDerivativeInstrumentsPurchased_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Derivative Instruments Purchased</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NumberOfDerivativeInstrumentsPurchased_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of derivative instruments purchased</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ClaimExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Claim expiration date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ClaimExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Claim Expiration Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NetIncomeLossPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">No definition available.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NetIncomeLossPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Per Share [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NetIncomeLossPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net income per share attributable to Innoviva stockholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MinorityInterestPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Noncontrolling Interest, Period Increase (Decrease), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MinorityInterestPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Noncontrolling Interest, Period Increase (Decrease)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MinorityInterestPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement period adjustments for change in value of noncontrolling interests</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_EuropeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Europe [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_EuropeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Europe</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss) Attributable to Noncontrolling Interest, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss attributable to noncontrolling interests</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Net loss attributable to noncontrolling interests</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockCommonValue_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Treasury stock: at cost, 32,005 shares as of December 31, 2023 and 2022</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockCommonValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Treasury Stock, Common, Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_HealthCareRoyaltyPartnersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Health care royalty partners member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_HealthCareRoyaltyPartnersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Health Care Royalty Partners [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_HealthCareRoyaltyPartnersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">HealthCare Royalty Partners</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PaymentOfManagementAndIncentiveFee_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment for management and annual performance incentive fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PaymentOfManagementAndIncentiveFee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment of Management and Incentive fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PaymentOfManagementAndIncentiveFee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment of management and Incentive fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total liabilities measured at estimated fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities at estimated fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Fair Value Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CommonStockAndWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information pertaining to common stock and warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CommonStockAndWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock And Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CommonStockAndWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock and warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Instrument, Unamortized Discount, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Unamortized Discount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Unamortized Debt discount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NonCashActivity_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non cash activity.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NonCashActivity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Cash Activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NonCashActivity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adoption of ASU 2020-06</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfGoodwillTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Goodwill [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CashPaidForTheAcquisitionOfLaJollaPharmaceuticalCompanyNetOfCashAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash paid for the acquisition of La Jolla Pharmaceutical Company, net of cash acquired.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CashPaidForTheAcquisitionOfLaJollaPharmaceuticalCompanyNetOfCashAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Paid for the Acquisition of La Jolla Pharmaceutical Company, Net of Cash Acquired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CashPaidForTheAcquisitionOfLaJollaPharmaceuticalCompanyNetOfCashAcquired_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Cash paid for the acquisition of La Jolla, net of cash acquired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Adjustments to additional paid in capital share based compensation requisite service period recognition shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Share based Compensation Requisite Service Period Recognition Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ReductionToAdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Reduction to additional paid in capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ReductionToAdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reduction to Additional Paid in Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ReductionToAdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reduction to Additional Paid in Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SeriesD1PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series D 1 preferred stock member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SeriesD1PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series D 1 Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SeriesD1PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series D 1 Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DerecognitionOfNoncontrollingInterestsUponSaleOfTrc_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Derecognition of noncontrolling interestsupon sale of TRC.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DerecognitionOfNoncontrollingInterestsUponSaleOfTrc_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derecognition of Noncontrolling Interests Upon Sale of TRC</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DerecognitionOfNoncontrollingInterestsUponSaleOfTrc_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Derecognition of noncontrolling interests upon sale of TRC</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DescriptionOfOperationsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description of Operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DescriptionOfOperationsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Description of Operations [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DescriptionOfOperationsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Description of operations.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DividendYield_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Dividend yield.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DividendYield_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Dividend Yield</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Deferred</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CashDistributionReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of cash distribution received.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CashDistributionReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Distribution Received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CashDistributionReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash distribution</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RoyaltyAgreementMaximumPotentialPayoutPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalty agreement, maximum potential payout, percent.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RoyaltyAgreementMaximumPotentialPayoutPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty Agreement Maximum Potential Payout Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RoyaltyAgreementMaximumPotentialPayoutPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum potential royalty payout</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance at the end of the period (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance at the beginning of the period (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NameOfEventDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Name Of Event [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NameOfEventDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Name Of Event [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_BurlingameCaliforniaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information pertaining to Burlingame, California.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_BurlingameCaliforniaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Burlingame California [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_BurlingameCaliforniaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Burlingame, California</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average estimated fair value of shares granted (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive income attributable to Innoviva stockholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AstrazenecaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">AstraZeneca</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AstrazenecaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AstraZeneca [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AstrazenecaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">AstraZeneca.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill and Intangible Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net of Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payment of Financing and Stock Issuance Costs, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment of Financing and Stock Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Shares, Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Available-for-Sale Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Maturity, Year Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total estimated fair value of equity instruments vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Income and Interest Expense Disclosure [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Components of Interest Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConsolidatedInvesteesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Consolidated investees.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConsolidatedInvesteesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidated Investees [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConsolidatedInvesteesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consolidated Investees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PercentageOfEstimatedVolatility_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of estimated volatility.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PercentageOfEstimatedVolatility_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of Estimated Volatility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PercentageOfEstimatedVolatility_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated volatility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Prepaid expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RightOfUseAssetsObtainedThroughAcquistions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Right of Use Assets Obtained Through Acquistions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RightOfUseAssetsObtainedThroughAcquistions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Right of Use Assets Obtained Through Acquistions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RightOfUseAssetsObtainedThroughAcquistions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use assets obtained through acquisitions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ConsolidatedEntitiesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidated Entities [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ConsolidatedEntitiesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consolidated Entities [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investments [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity and Long-Term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ScheduleOfBalanceSheetInformationRelatedToOperatingLeaseTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule Of Balance sheet Information Related To Operating Lease Table Text Block</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ScheduleOfBalanceSheetInformationRelatedToOperatingLeaseTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Balance sheet Information Related To Operating Lease Table Text Block</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ScheduleOfBalanceSheetInformationRelatedToOperatingLeaseTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Operating Lease Information Presented In Balance Sheet</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Receivable, after Allowance for Credit Loss, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable, after Allowance for Credit Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_TwoDirectorsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two Directors.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_TwoDirectorsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Directors [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_TwoDirectorsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Two Directors</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Unrealized Gain on Investment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Long-Term Debt Instruments [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary or Equity Method Investee [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AOCI Attributable to Parent [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Number of Shares Per Employee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum number of shares an employee may purchase during any purchase period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Components of Deferred Tax Liabilities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_BalanceSheetDisclosuresOfVariableInterestEntityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance sheets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_BalanceSheetDisclosuresOfVariableInterestEntityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">No definition available.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_BalanceSheetDisclosuresOfVariableInterestEntityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Disclosures of Variable Interest Entity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Current Maturities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Carrying Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConvertiblePromissoryNotePurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Promissory Note Purchase Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConvertiblePromissoryNotePurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible promissory note purchase agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConvertiblePromissoryNotePurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Promissory Note Purchase Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Parties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveAndOverlappingOfferingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the consecutive and overlapping offering period for the offering of share-based payment awards.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveAndOverlappingOfferingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement by Share Based Payment Award Consecutive and Overlapping Offering Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveAndOverlappingOfferingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total duration of consecutive and overlapping offering periods</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CostReimbursements_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost reimbursements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CostReimbursements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cost Reimbursements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CostReimbursements_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cost reimbursements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Incremental Common Shares Attributable to Conversion of Debt Securities, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dilutive effect</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Income Taxes Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">DEBT</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Distributions to noncontrolling interest (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Minority interest decrease from distributions to noncontrolling interest holders shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minority Interest Decrease From Distributions To Noncontrolling Interest Holders Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net increase in tax portions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_LaboratoryEquipmentFurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Laboratory equipment, furniture and fixtures.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_LaboratoryEquipmentFurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Laboratory Equipment, Furniture And Fixtures [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_LaboratoryEquipmentFurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Laboratory equipment furniture and fixtures</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_EverestMedicinesLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Everest Medicines Limited [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_EverestMedicinesLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Everest Medicines Limited [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_EverestMedicinesLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Everest Medicines Limited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid-in Capital [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-In Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Schedule of components of the income tax expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonUsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non-US [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonUsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rest of the world</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionsProFormaRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition, Pro Forma Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionsProFormaRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_WalthamMassachusettsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Waltham Massachusetts Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_WalthamMassachusettsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Waltham Massachusetts Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAcquiredFromAcquisition_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Acquired from Acquisition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAcquiredFromAcquisition_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash acquired through the consolidation of Entasis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_OtherAccruedLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Other Accrued Liabilities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_OtherAccruedLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_OtherAccruedLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Accrued Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested and expected to vest at the end of the period (in dollars per shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current portion of lease liabilities included within Other accrued liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Current portion of lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments in Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible subordinated notes due 2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument maturity date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Maturity Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Debt instrument maturity date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net carrying amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Net, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Net, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, Plant and Equipment, Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Deferred Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax expense recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfVariableInterestEntitiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Balance Sheets and Income Statements of VIE</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfVariableInterestEntitiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Variable Interest Entities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DeferredTaxLiabilitiesInventoryFairValueAdjustment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax liabilities inventory fair value adjustment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DeferredTaxLiabilitiesInventoryFairValueAdjustment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Inventory Fair Value Adjustment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DeferredTaxLiabilitiesInventoryFairValueAdjustment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventory fair value adjustment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income, Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment Income, Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the duration of each purchase period within each consecutive and overlapping purchase period for offering of share-based payment awards.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement by Share Based Payment Award Purchase Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Duration of purchase period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PriorPeriodImmaterialCorrectionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of accounting policy for reporting prior period immaterial correction.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PriorPeriodImmaterialCorrectionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prior Period Immaterial Correction [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PriorPeriodImmaterialCorrectionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prior Period Immaterial Correction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LoansPayableMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loans Payable [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LoansPayableMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loans Payable [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Comprehensive Income [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockCommonShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Treasury stock, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockCommonShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Treasury Stock, Common, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CIK</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConvertibleNoteAndWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible note and warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConvertibleNoteAndWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Note and Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConvertibleNoteAndWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">In Carda Convertible Note</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConvertibleNoteAndWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Convertible note and warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Investee's Board members currently representing the Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of the Company's Board Members Currently Serving on the Board of Investee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The number of the Company's Board members currently serving on the Investee's Board.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CommercialSupplyAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commercial supply agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CommercialSupplyAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Supply Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CommercialSupplyAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial Supply Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total assets measured at estimated fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Assets, Fair Value Disclosure, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Other Operating Assets, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Operating Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Shares Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Shares Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Forfeited (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RegulatoryMilestonePaymentsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Regulatory milestone payments receivable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RegulatoryMilestonePaymentsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Regulatory Milestone Payments Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RegulatoryMilestonePaymentsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional regulatory milestone payments receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IntangibleAssetsMarketedProductsAccumulatedAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accumulated amortization amount of Marketed Products.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IntangibleAssetsMarketedProductsAccumulatedAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets Marketed Products, Accumulated Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IntangibleAssetsMarketedProductsAccumulatedAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketed products, Accumulated amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DebtInstrumentConvertibleConversionPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The percentage above the last reported sale price of the Company's common stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DebtInstrumentConvertibleConversionPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Convertible, Conversion Premium</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DebtInstrumentConvertibleConversionPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion premium (as a percent)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income before income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory, Finished Goods, Net of Reserves</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finished goods</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Capital [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments of Debt Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liability issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instruments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PercentageOfReimbursedForDirectAndCertainIndirectManufacturingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of reimbursed for direct and certain indirect manufacturing costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PercentageOfReimbursedForDirectAndCertainIndirectManufacturingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Reimbursed For Direct And Certain Indirect Manufacturing Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PercentageOfReimbursedForDirectAndCertainIndirectManufacturingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of reimbursed for direct and certain indirect manufacturing costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_LongActingBeta2AgonistRelvarBreoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents Long-Acting Beta2 Agonist, RELVAR/BREO, which is being developed and commercialized by entering into a strategic alliance with GSK</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_LongActingBeta2AgonistRelvarBreoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long Acting Beta2 Agonist Relvar Breo [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_LongActingBeta2AgonistRelvarBreoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">RELVAR/BREO</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment, Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument, term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income Tax Examination, Penalties and Interest Accrued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Examination, Penalties and Interest Accrued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued interest and penalties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">RSAs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_TheravanceRespiratoryCompanyLlcMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information pertaining to the variable interest entity, Theravance Respiratory Company, LLC ("TRC").</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_TheravanceRespiratoryCompanyLlcMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Theravance Respiratory Company Llc [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_TheravanceRespiratoryCompanyLlcMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Theravance Respiratory Company, LLC</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the number of purchase periods having duration of six months each.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement by Share Based Payment Award Number of Purchase Periods</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of offering periods</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ImaginabConvertibleNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ImaginAb Convertible Note</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ImaginabConvertibleNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ImaginAb Convertible Note [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ImaginabConvertibleNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">ImaginAb Convertible Note.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Term of Contract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RecognitionOfNoncontrollingInterestUponInitialConsolidationofEntasisShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recognition of noncontrolling interest upon initial consolidation of Entasis (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RecognitionOfNoncontrollingInterestUponInitialConsolidationofEntasisShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Recognition Of Noncontrolling Interest Upon Initial ConsolidationOf Entasis, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RecognitionOfNoncontrollingInterestUponInitialConsolidationofEntasisShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Recognition of noncontrolling interest upon initial consolidation of Entasis, Shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_US_lbl" xlink:role="http://www.xbrl.org/2003/role/label">UNITED STATES</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_US_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">United States</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SeriesD2PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series D 2 preferred stock member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SeriesD2PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series D 2 Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SeriesD2PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series D 2 Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_OperatingLossCarryforwardsIndefinitePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Net operating loss carryforwards which can be carry forward indefinitely.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_OperatingLossCarryforwardsIndefinitePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards, Indefinite Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_OperatingLossCarryforwardsIndefinitePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards, indefinite period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RoyaltyPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalty Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RoyaltyPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RoyaltyPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Components of Deferred Tax Assets [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from Issuance or Sale of Equity, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance or Sale of Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross Proceeds from sale of equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party, Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Retained Earnings (Accumulated Deficit), Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Retained Earnings (Accumulated Deficit), Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtByMaturityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Fiscal Year Maturity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtByMaturityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term debt maturities for years ending December 31:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MembersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">LLC members' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MembersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Members' Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MembersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Members' Equity, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosure of cash flow information:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory, Raw Materials, Net of Reserves</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Raw materials</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AccruedContractManufacturingLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued contract manufacturing liability.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AccruedContractManufacturingLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Contract Manufacturing Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AccruedContractManufacturingLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued contract manufacturing expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedPersonnelRelatedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of accrued personnel-related expenses due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedPersonnelRelatedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accrued Personnel- Related Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedPersonnelRelatedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued personnel-related expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected tax at federal statutory rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Liabilities, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liabilities, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax (liabilities)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IntangibleAssetsMarketedProductsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Gross amount of Marketed products.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IntangibleAssetsMarketedProductsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets Marketed Products, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IntangibleAssetsMarketedProductsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketed products, gross carrying amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RelatedPartyTransactionCommonStockOwnershipPercentageByRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The percentage of ownership of common stock in the reporting entity owned by related parties.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RelatedPartyTransactionCommonStockOwnershipPercentageByRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction, Common Stock Ownership Percentage By Related Party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RelatedPartyTransactionCommonStockOwnershipPercentageByRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of common stock owned by a related party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DerecognitionOfNoncontrollingInterestsUponSaleOfTrcShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Derecognition of noncontrolling interests upon sale of TRC (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DerecognitionOfNoncontrollingInterestsUponSaleOfTrcShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derecognition Of Noncontrolling Interests Upon Sale Of Trc Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DerecognitionOfNoncontrollingInterestsUponSaleOfTrcShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Derecognition of noncontrolling interests upon sale of trc shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Revenues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Revenues_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Revenues, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Revenues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance at the end of the period (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance at the beginning of the period (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Fair Value Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DerecognitionOfNonControllingInterestsUponAcquisitionOfEntasisMinorityInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Derecognition of non controlling interests upon acquisition of entasis minority interest.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DerecognitionOfNonControllingInterestsUponAcquisitionOfEntasisMinorityInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derecognition Of Non Controlling Interests Upon Acquisition Of Entasis Minority Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DerecognitionOfNonControllingInterestsUponAcquisitionOfEntasisMinorityInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Derecognition of noncontrolling interests upon acquisition of Entasis noncontrolling interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Income Taxes, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ArmataConvertibleNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Armata Convertible Note</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ArmataConvertibleNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Armata Convertible Note [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ArmataConvertibleNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Armata convertible note member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ReductionToResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Reduction to Research and Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ReductionToResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reduction to Research and Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ReductionToResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reduction to research and development expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareRepurchaseAgreementWithGlaxoGroupLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share repurchase agreement with GSK</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareRepurchaseAgreementWithGlaxoGroupLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Repurchase Agreement With Glaxo Group Limited [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareRepurchaseAgreementWithGlaxoGroupLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information pertaining to share repurchase agreement with Glaxo Group Limited.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_WarrantsAcquiredInSecondQuarterOf2021Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Information related to warrants acquired in the second quarter of 2021</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_WarrantsAcquiredInSecondQuarterOf2021Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Acquired In Second Quarter Of2021 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_WarrantsAcquiredInSecondQuarterOf2021Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants acquired in second quarter of 2021</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortization of Debt Issuance Costs and Discounts, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amortization of Debt Issuance Costs and Discounts</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of debt discount and issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Valuation Assumptions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Investment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net income to net cash provided by operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: Unamortized debt discount and issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt discount and issuance costs, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Debt discount and issuance costs, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price of Outstanding Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net income attributable to Innoviva stockholders, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PutOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Put Option [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PutOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock prices above $38.00 per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Research and Development Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AccruedClinicalLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued Clinical Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AccruedClinicalLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Clinical Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AccruedClinicalLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued clinical expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PercentageOfMinimumRoyaltyRate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of minimum royalty rate.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PercentageOfMinimumRoyaltyRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Minimum Royalty Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PercentageOfMinimumRoyaltyRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of minimum royalty rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, by Balance Sheet Grouping [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the annual global net sales amount which determines the royalty rate applied under the collaboration arrangement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement, Specified Sales Level for Determining Royalty Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual global sales level used to determine royalty rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax (liabilities)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Net deferred tax (liabilities)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SecuritiesPurchaseAgreementWarrantsNumberOfSecuritiesCalledByWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The maximum number of additional common stock shares into which the warrants may be converted.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SecuritiesPurchaseAgreementWarrantsNumberOfSecuritiesCalledByWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Purchase Agreement, Warrants, Number of Securities Called by Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SecuritiesPurchaseAgreementWarrantsNumberOfSecuritiesCalledByWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum number of additional shares into which warrants may be converted under the securities purchase agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SecuritiesPurchaseAgreementWarrantsNumberOfSecuritiesCalledByWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Maximum number of additional shares into which warrants may be converted under the securities purchase agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Conversion, Converted Instrument, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Notes converted into common stock, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Changes to noncontrolling interest from a consolidated variable interest entity.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Changes to noncontrolling interest from a consolidated variable interest entity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity activity of noncontrolling interest in a consolidated variable interest entity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NumberOfSharesReceivableOnSettlementOfDerivativeInstrument_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the number of shares payable to the entity on settlement of derivative instruments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NumberOfSharesReceivableOnSettlementOfDerivativeInstrument_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Shares Receivable on Settlement of Derivative Instrument</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NumberOfSharesReceivableOnSettlementOfDerivativeInstrument_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net shares settlement payable to the entity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of equity award activity and related information</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuances of common stock, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amortization of Intangible Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of acquired intangible assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Amortization expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDilutedLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDilutedLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net Income Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares remaining available for issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AccruedInterestIncomeIncludedInLongTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued interest income added to long-term investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AccruedInterestIncomeIncludedInLongTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Interest Income Included in Long-term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AccruedInterestIncomeIncludedInLongTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued interest income included in long-term investments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Repurchased and Retired During Period, Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock repurchased and retired during period, value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SeriesD1WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series D1 Warrant [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SeriesD1WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series D1 Warrant [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SeriesD1WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series D1 Warrant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock: $0.01 par value, 200,000 shares authorized, 69,307 and 69,188 issued and outstanding as of December 31, 2023 and December 31, 2022 respectively</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Value, Issued, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Value, Issued, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Value, Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Convertible, Conversion Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion price (dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Conversion price of convertible notes into common stock (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Noncash Income (Expense), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Noncash Income (Expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other non-cash items</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeconsolidationGainOrLossAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deconsolidation, Gain (Loss), Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeconsolidationGainOrLossAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net gain on sale of TRC</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeconsolidationGainOrLossAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Net gain on sale of TRC</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeconsolidationGainOrLossAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Gain on sale of Theravance Respiratory Company, LLC ("TRC")</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Payment Arrangement, Noncash Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Noncash Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income from operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Loss from operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repayments of Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_XeravaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">XERAVA.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_XeravaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">XERAVA [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_XeravaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">XERAVA</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_LicenseAndCollaborationArrangementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License and collaboration arrangements disclosure.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_LicenseAndCollaborationArrangementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License and Collaboration Arrangements Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_LicenseAndCollaborationArrangementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">LICENSE AND COLLABORATION ARRANGEMENTS</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Consideration Transferred</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total consideration paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total consideration paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_LabaCollaborationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the collaboration with GSK to develop and commercialize once-daily LABA products and combination products RELVAR.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_LabaCollaborationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Laba Collaboration [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_LabaCollaborationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Acting Beta2 Agonist (LABA) Collaboration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Income Tax Expense (Benefit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total income tax expense, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Total income tax expense, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax expense, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Income tax expense, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Income tax expense, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Maturity, Year Four</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Net decrease in tax portions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Leases [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RoyaltyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RoyaltyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RoyaltyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Royalty revenue from a related party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk, Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration Risk, Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Repurchase of shares to satisfy tax withholding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LoanRestructuringModificationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loan Restructuring Modification [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation of Revenue [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Noncontrolling Interest Income (Loss), Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SeriesD2WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series D2 Warrant.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SeriesD2WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series D2 Warrant [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SeriesD2WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series D2 Warrant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DeferredTaxLiabilitiesDepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax liabilities depreciation and amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DeferredTaxLiabilitiesDepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Depreciation and Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DeferredTaxLiabilitiesDepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Revenue, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationTechniqueDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Approach and Technique [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">REVENUE RECOGNITION</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized gain loss from fair value changes in equity investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Securities, FV-NI, Unrealized Gain (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Equity Securities, FV-NI, Unrealized Gain (Loss), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value of options outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible notes Face Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Face Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">New principal amount convertible note</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ArmataPharmaceuticalsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information pertaining to Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on the development of precisely targeted bacteriophage therapeutics for the treatment of antibiotic-resistant infections.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ArmataPharmaceuticalsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Armata Pharmaceuticals Inc [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ArmataPharmaceuticalsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Armata</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cumulative Effect, Period of Adoption, Adjustment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cumulative effect period of adoption adjustment member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_EquityInvestmentsAndMoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information pertaining to equity investments and money market funds.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_EquityInvestmentsAndMoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Investments And Money Market Funds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_EquityInvestmentsAndMoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity investments and Money market funds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SubscriptionAgreementOneTimeMilestonePaymentOnCommercialSales_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subscription agreement one-time milestone payment on first commercial sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SubscriptionAgreementOneTimeMilestonePaymentOnCommercialSales_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subscription Agreement One-time Milestone Payment on Commercial Sales</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SubscriptionAgreementOneTimeMilestonePaymentOnCommercialSales_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Subscription agreement one-time milestone payment on commercial sales.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other expense, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Other income, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Nonoperating Income (Expense), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income (Expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other expense, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalizedContractCostTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capitalized Contract Cost [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementRelatedDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Related Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementRelatedDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Information</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingencyAllegations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingency, Allegations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingencyAllegations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Complaints filed by stockholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive income attributable to noncontrolling interests</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expenses:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term Debt, Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CreditAndSecurityAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credit and Security Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CreditAndSecurityAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Credit and Security Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CreditAndSecurityAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Credit and security agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of amortized cost and estimated fair values for available-for-sale securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalizedContractCostLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capitalized Contract Cost [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalizedContractCostLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalized Fees paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DilutiveEpsOfNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount of net income (loss) for the period available to convertible notes.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DilutiveEpsOfNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Dilutive EPS of Notes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DilutiveEpsOfNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dilutive EPS of note</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Differences between the expected U.S. federal statutory income tax to income tax expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Assets, Noncurrent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_WarrantsPurchasedIn2022Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants purchased in 2022 member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_WarrantsPurchasedIn2022Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Purchased In 2022 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_WarrantsPurchasedIn2022Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants Purchased in 2022</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NumberOfBoardMembersOfInvestee_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of the Investee's Board members</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NumberOfBoardMembersOfInvestee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Board Members of the Investee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NumberOfBoardMembersOfInvestee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The total number of Board members of the Investee.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Granted (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">STOCKHOLDERS' EQUITY</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NoteAmendmentAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Note amendment agreement member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NoteAmendmentAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Note Amendment Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NoteAmendmentAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Note Amendment Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConvertiblePromissoryNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertable promissory note</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConvertiblePromissoryNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Promissory Note [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConvertiblePromissoryNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible promissory note member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Future amortization expense, 2027</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Future amortization expense, 2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_GainLossOnOtherInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Changes in fair value of equity and long-term investments, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_GainLossOnOtherInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Gain loss on other investments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_GainLossOnOtherInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain (Loss) on Other Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_GainLossOnOtherInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in fair value of other equity and long-term investments, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross Unrealized Gains</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SeriesA1PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A1 preferred stock member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SeriesA1PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A1 preferred stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SeriesA1PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A1 preferred stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_EntasisLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Entasis Lease [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_EntasisLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entasis Lease [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_EntasisLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entasis Lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stockholders' equity:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesDPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series D Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesDPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series D Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Components of Lease Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Federal, State and Local, Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">All Entities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term loan facility in aggregate amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ScheduleOfConsolidatedEntitiesAndBusinessAcquisitionsByAcquisitionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of consolidated entities and business acquisitions by acquisition.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ScheduleOfConsolidatedEntitiesAndBusinessAcquisitionsByAcquisitionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Consolidated Entities and Business Acquisitions by Acquisition [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CapitalizedFeesPaidPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Capitalized fees paid.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CapitalizedFeesPaidPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capitalized Fees Paid [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CapitalizedFeesPaidPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalized Fees Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total estimated fair value of options vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost of products sold (inclusive of amortization of inventory fair value adjustments, excluding amortization of intangible assets)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cost of Goods and Services Sold</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cost of products sold (inclusive of amortization of inventory fair value adjustments, excluding depreciation and amortization of intangible assets)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseContractualTermDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Contractual Term [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_OutstandingStockWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Outstanding stock warrant member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_OutstandingStockWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Outstanding Stock Warrant [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_OutstandingStockWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding Stock Warrant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Supplemental Cash Flow Information Related to Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Future Minimum Lease Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PaymentsForRoyaltyAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payments For Royalty Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PaymentsForRoyaltyAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments For Royalty Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PaymentsForRoyaltyAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment for royalty agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_StrategicAllianceAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the strategic alliance with GSK for initiating three new full discovery programs and giving GSK option to license exclusive development and commercialization rights of products.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_StrategicAllianceAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Strategic Alliance Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_StrategicAllianceAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Strategic alliance - MABA program</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_EquityMethodInvesteeNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PrivatelyNegotiatedCappedCallOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the capped call option entered in connection with the offering of convertible debt.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PrivatelyNegotiatedCappedCallOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Privately Negotiated Capped Call Option [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PrivatelyNegotiatedCappedCallOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Privately-negotiated capped call option</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Future amortization expense, 2028</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">In Process Research and Development [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">In-process research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_EntasisTherapeuticsHoldingsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information pertaining to Entasis Therapeutics Holdings Inc.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_EntasisTherapeuticsHoldingsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entasis Therapeutics Holdings Inc [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_EntasisTherapeuticsHoldingsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entasis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_EntasisTherapeuticsHoldingsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entasis Therapeutics Holdings Inc</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DeferredTaxAssetsDeferredRoyaltyObligationNet_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets deferred royalty obligation, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DeferredTaxAssetsDeferredRoyaltyObligationNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Deferred Royalty Obligation, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DeferredTaxAssetsDeferredRoyaltyObligationNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred royalty obligation, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AccruedProfessionalServices_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued Professional Services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AccruedProfessionalServices_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AccruedProfessionalServices_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued professional services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentrations of Credit Risk and of Significant Suppliers and Partners</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IntangibleAssetsCollaborationAgreementNet_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Intangible assets collaboration agreement net.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IntangibleAssetsCollaborationAgreementNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets Collaboration Agreement Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IntangibleAssetsCollaborationAgreementNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration agreement, net carrying amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition, Pro Forma Information [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pro Forma Information</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets acquired, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Interest Rate, Effective Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Effective interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Distributions to noncontrolling interests</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SaleOfWarrantsNumberOfWarrantsIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Maximum number of additional shares into which warrants may be converted under the securities purchase agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SaleOfWarrantsNumberOfWarrantsIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Warrants, Number of Warrants Issued in Transaction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SaleOfWarrantsNumberOfWarrantsIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The number of warrants issued or sold by the subsidiary or equity method investee per stock transaction.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SaleOfWarrantsNumberOfWarrantsIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of warrants purchased under the securities purchase agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NetProceedsFromSaleOfVariableInterestEntityEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Net Proceeds from sale of variable interest entity equity.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NetProceedsFromSaleOfVariableInterestEntityEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Proceeds from Sale of Variable Interest Entity Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NetProceedsFromSaleOfVariableInterestEntityEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from sale of ownership interest in TRC, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DerecognitionOfNoncontrollingInterestsUponAcquisitionOfEntasisMinorityInterestShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Derecognition of noncontrolling interests upon acquisition of Entasis noncontrolling interest (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DerecognitionOfNoncontrollingInterestsUponAcquisitionOfEntasisMinorityInterestShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derecognition Of NonControlling Interests Upon Acquisition Of Entasis Minority Interest Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DerecognitionOfNoncontrollingInterestsUponAcquisitionOfEntasisMinorityInterestShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Derecognition of nonControlling interests upon acquisition of entasis minority interest shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investment, Other than Temporary Impairment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of equity investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IntangibleAssetsCollaborationAgreementGross_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Intangible assets collaboration agreement gross.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IntangibleAssetsCollaborationAgreementGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets Collaboration Agreement Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IntangibleAssetsCollaborationAgreementGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration agreement, gross carrying amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basic net income per share attributable to Innoviva stockholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Basic net income per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DeferredRoyaltyObligationCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Current portion of deferred royalty obligation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DeferredRoyaltyObligationCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Royalty Obligation, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DeferredRoyaltyObligationCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current portion of deferred royalty obligation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Customer Concentration Risk [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Customer Concentration Risk</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Commitments and contingencies (Note 13)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationDeductionsOther_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Section 250 deduction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationDeductionsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Deduction, Other, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_UnrecognizedTaxBenefitsDecreaseResultingFromCurrentPeriodTaxPositionsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net decrease in tax portions for 2021</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_UnrecognizedTaxBenefitsDecreaseResultingFromCurrentPeriodTaxPositionsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Decrease Resulting from Current Period Tax Positions, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_UnrecognizedTaxBenefitsDecreaseResultingFromCurrentPeriodTaxPositionsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Net amount of decrease in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_OwnershipInterestInConsolidatedEntities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Ownership interest in consolidated entities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_OwnershipInterestInConsolidatedEntities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Ownership Interest in Consolidated Entities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_OwnershipInterestInConsolidatedEntities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ownership interest in LLC</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less: Current portion of long-term debt, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party, Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ProceedsFromSaleOfEconomicInterestUnderEquityPurchaseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from sale of economic interest under Equity Purchase Agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ProceedsFromSaleOfEconomicInterestUnderEquityPurchaseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from sale of economic interest under Equity Purchase Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ProceedsFromSaleOfEconomicInterestUnderEquityPurchaseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from sale of economic interest under Equity Purchase Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_WarrantsPurchasedIn2020Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information pertaining to warrants purchased in 2020.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_WarrantsPurchasedIn2020Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Purchased In2020 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_WarrantsPurchasedIn2020Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants purchased in 2020</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Straight line operating lease costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Prepaid Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SeriesDWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series D Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SeriesDWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series D Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SeriesDWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series D warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested and expected to vest at the end of the period (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Range [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of convertible senior notes due 2028, net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfVariableInterestEntitiesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Variable Interest Entities [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AcquisitionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Acquisition Costs, Period Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AcquisitionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquisition-related costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">COMMITMENTS AND CONTINGENCIES</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ResearchAndDevelopmentSupportMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and Development Support [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ResearchAndDevelopmentSupportMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Support [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ResearchAndDevelopmentSupportMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Support</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for amounts included in the measurement of operating lease liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareRepurchaseProgramAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Repurchase Program [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Diluted net income per share attributable to Innoviva stockholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Diluted net income per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_UnrecognizedTaxBenefitsIncreaseResultingFromCurrentPeriodTaxPositionsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unrecognized tax benefits increase resulting from current period tax positions Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_UnrecognizedTaxBenefitsIncreaseResultingFromCurrentPeriodTaxPositionsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits Increase Resulting From Current Period Tax Positions Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_UnrecognizedTaxBenefitsIncreaseResultingFromCurrentPeriodTaxPositionsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net increase in tax portions for 2022</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CarryingValueWroteOffWarrantExercise_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Carrying value wrote off warrant exercise</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CarryingValueWroteOffWarrantExercise_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Carrying Value Wrote off Warrant Exercise</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CarryingValueWroteOffWarrantExercise_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Carrying value wrote off warrant exercise.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Products and Services [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Operating Loss Carryforwards, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Unrecognized Tax Benefits, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Unrecognized Tax Benefits, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized tax benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized loss from fair value changes in equity investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Unrealized loss from fair value changes in equity investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Securities, FV-NI, Unrealized Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Unrealized loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Benchmark [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalEquityGrantValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The additional value of shares granted to newly appointed non-employee director on the date that such individual joins the Board.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalEquityGrantValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation, Arrangement by Share Based Payment Award, Additional Equity Grant Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalEquityGrantValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pro rata shares grant, value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Gross Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer before amortization of capitalized fees.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gross Revenue from Contract with Customer, Excluding Assessed Tax, Before Amortization Of Capitalized Fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SpecialTermReDesignatingBoardMemberToBoardOfInvestee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Special Terms on amended and restated investor rights agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SpecialTermReDesignatingBoardMemberToBoardOfInvestee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Special Term Re Designating Board Member To Board Of Investee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SpecialTermReDesignatingBoardMemberToBoardOfInvestee_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Special terms on re-designating board member to board of investee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToMinorityShareholders_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Noncontrolling Interests</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToMinorityShareholders_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Distributions to noncontrolling interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_EquityIncentivePlansAndESPPMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information pertaining to options, Equity Incentive Plans and Employee Stock Purchase Plans.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_EquityIncentivePlansAndESPPMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Incentive Plans And E S P P [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_EquityIncentivePlansAndESPPMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity incentive plans and ESPP</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IntangibleAssetsInProcessResearchAndDevelopmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Net amount of In-process research and development.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IntangibleAssetsInProcessResearchAndDevelopmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets In-process Research and Development, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IntangibleAssetsInProcessResearchAndDevelopmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">In-process research and development, net carrying amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercisable option</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpensePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpensePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest Expense on Deferred Royalty Obligation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Volatility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument, description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recurring basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_TermLoanInvestmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term Loan Investment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_TermLoanInvestmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Term Loan Investment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_TermLoanInvestmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Term loan investment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtInShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capped call options associated with convertible senior notes due 2028 (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtInShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt in Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtInShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Adjustments to additional paid in capital equity component of convertible debt in shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Additional Paid in Capital, Common Stock, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Additional Paid in Capital, Common Stock, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital, Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DecreaseToAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Decrease to accumulated deficit.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DecreaseToAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Decrease to Accumulated Deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DecreaseToAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Decrease to accumulated deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Scheduled Maturities of Convertible Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Maturities of Long-Term Debt [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesFvNiRealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Equity Securities, FV-NI, Realized Gain (Loss), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesFvNiRealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Securities, FV-NI, Realized Gain (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesFvNiRealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remeasurement loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of outstanding options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AccruedLicenseFeesAndRoyalties_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued license fees and royalties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AccruedLicenseFeesAndRoyalties_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued License Fees and Royalties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AccruedLicenseFeesAndRoyalties_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued license fees and royalties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Components of Deferred Tax Assets and Liabilities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Components of deferred tax assets and deferred tax liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesFvNi_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Securities, FV-NI, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesFvNi_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity and long-term investments at fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesFvNi_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Fair value of equity securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DebtInstrumentPrincipalAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt Instrument Principal Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DebtInstrumentPrincipalAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Principal Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DebtInstrumentPrincipalAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DebtInstrumentPrincipalAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Principal</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments for Repurchase of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Repurchase of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of fully vested and expected to vest non-option equity instruments outstanding that can be converted into shares under award activity.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Vested And Expected To Vest Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested and expected to vest at the end of the period (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MinorityInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Stockholders' Equity Attributable to Noncontrolling Interest, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MinorityInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Stockholders' Equity Attributable to Noncontrolling Interest, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MinorityInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Stockholders' Equity Attributable to Noncontrolling Interest, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MinorityInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MinorityInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Noncontrolling interests</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RealizedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Realized loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RealizedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Realized Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RealizedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Realized loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Exercised (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidation, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Principles of Consolidation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IncomeStatementDisclosuresOfVariableInterestEntityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income statements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IncomeStatementDisclosuresOfVariableInterestEntityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">No definition available.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IncomeStatementDisclosuresOfVariableInterestEntityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Disclosures of Variable Interest Entity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Liabilities and Stockholders Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Noncurrent Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Other Long-term Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SaleOfEquityInvestmentsManagedByIspFundLp_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of equity investments managed by ISP FUND LP</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SaleOfEquityInvestmentsManagedByIspFundLp_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sale of equity investments managed by ISP FUND LP</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SaleOfEquityInvestmentsManagedByIspFundLp_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales of equity investments managed by ISP Fund LP</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The total number of shares to be purchased under the terms of a securities purchase agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Purchase Agreement, Total Number of Shares To Be Purchased Under the Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Securities to be purchased</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of shares to be purchased under the securities purchase agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentConvertibleConversionRatio1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Convertible, Conversion Ratio</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentConvertibleConversionRatio1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion rate for shares of common stock per $1,000 principal</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Private Placement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Private Placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_EmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information pertaining to the Company's Employee Stock Purchase Plan (the "ESPP").</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_EmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Purchase Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_EmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ESPP</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_OldDebtInstrumentInterestRateBeforeRepurchaseOfNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Old debt instrument interest rate before repurchase of notes member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_OldDebtInstrumentInterestRateBeforeRepurchaseOfNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Old Debt Instrument Interest Rate Before Repurchase Of Notes [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_OldDebtInstrumentInterestRateBeforeRepurchaseOfNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Old Rate [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized tax benefits would affect the effective income tax rate if recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Over-Allotment Option [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Over-Allotment Option</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Future amortization expense, 2026</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RecognitionOfNoncontrollingInterestUponInitialConsolidationOfEntasis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Recognition Of Noncontrolling Interest Upon Initial Consolidation Of Entasis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RecognitionOfNoncontrollingInterestUponInitialConsolidationOfEntasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Recognition of noncontrolling interest upon initial consolidation of Entasis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less: imputed interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: imputed interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well-known Seasoned Issuer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition, Pro Forma Net Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Business acquisition, net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_Rule10B51ArrModifiedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rule 10b51Arrangement Modified</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_Rule10B51ArrModifiedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Rule 10b51 Arr Modified Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_Rule10B51ArrModifiedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Rule 10b51 Arr Modified Flag.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Debt Securities, Available-for-sale, Allowance for Credit Loss, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Debt Securities, Available-for-sale, Allowance for Credit Loss, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-sale, Allowance for Credit Loss, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Allowance for Credit Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Credit loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee exercised the right during the reporting period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercised in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercised (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Exercised (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RoyaltyAgreementIncreaseInMaximumPotentialPayoutPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalty agreement increase in maximum potential payout percent.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RoyaltyAgreementIncreaseInMaximumPotentialPayoutPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty Agreement Increase In Maximum Potential Payout Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RoyaltyAgreementIncreaseInMaximumPotentialPayoutPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in maximum potential payout percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_FairValueAdjustmentsOfInventoryFromAcquistion_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Value of net fair value adjustment of inventory resulting from the acquisition.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_FairValueAdjustmentsOfInventoryFromAcquistion_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Adjustments Of Inventory From Acquistion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_FairValueAdjustmentsOfInventoryFromAcquistion_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net fair value adjustment of inventory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_TrelegyElliptaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information pertaining to Trelegy Ellipta.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_TrelegyElliptaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trelegy Ellipta [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_TrelegyElliptaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">TRELEGY</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Schedule of unrecognized stock-based compensation cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PercentageOfEconomicInterestInPartnership_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Economic interest of the Partnership (in percent)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PercentageOfEconomicInterestInPartnership_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of economic interest held in Partnership.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PercentageOfEconomicInterestInPartnership_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of Economic Interest In Partnership</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts receivable, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accounts receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConvertibleSubordinatedDebtFairValueDisclosures_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value portion of subordinated debt obligations which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConvertibleSubordinatedDebtFairValueDisclosures_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Subordinated Debt, Fair Value Disclosures</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConvertibleSubordinatedDebtFairValueDisclosures_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023 Notes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LimitedPartnersCumulativeCashDistributions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Distribution from partnership</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LimitedPartnersCumulativeCashDistributions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Limited Partners' Cumulative Cash Distributions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_OptionPricingModelBacksolveValuationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Option Pricing Model Backsolve valuation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_OptionPricingModelBacksolveValuationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Option Pricing Model Backsolve Valuation [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_OptionPricingModelBacksolveValuationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Backsolve Valuation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AccruedResearchLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued Research Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AccruedResearchLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Research Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AccruedResearchLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued research expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseBorrowingsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense, Borrowings [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseBorrowingsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Released RSUs and RSAs (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, equipment and leasehold improvements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PartnershipAgreementLockUpPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The period of time in which contributors to an investment fund have waived the right of redemption, as defined in the partnership agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PartnershipAgreementLockUpPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Partnership Agreement, Lock-Up Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PartnershipAgreementLockUpPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lock-up period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Conversion, Converted Instrument, Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Conversion, Converted Instrument, Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Deferred Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Federal Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research Tax Credit Carryforward [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Goodwill, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Goodwill, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Goodwill, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConvertibleSeniorDebtFairValueDisclosures_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value portion of long-term notes which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock. Senior debt has the highest claim on the assets of the issuer in case of bankruptcy or liquidation, due within one year or the normal operating cycle, if longer. Senior note holders are paid off in full before any payments are made to debt holders having a lesser priority of repayment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConvertibleSeniorDebtFairValueDisclosures_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Senior Debt, Fair Value Disclosures</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConvertibleSeniorDebtFairValueDisclosures_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025 Notes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityCovenantTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility, Covenant Terms</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityCovenantTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument, covenant terms description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IncreaseDecreaseInDeferredTaxAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase (decrease) in deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IncreaseDecreaseInDeferredTaxAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) In Deferred Tax Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IncreaseDecreaseInDeferredTaxAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase (Decrease) in deferred tax assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalizedContractCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capitalized Contract Cost [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalizedContractCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Capitalized Fees Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive Income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SecuritiesPurchaseAgreementRightsToDesignateInvesteeBoardMembersNumberOfBoardMembers_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The number of the investee's board members which the Company has the right to designate.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SecuritiesPurchaseAgreementRightsToDesignateInvesteeBoardMembersNumberOfBoardMembers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Purchase Agreement Rights To Designate Investee Board Members Number Of Board Members</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SecuritiesPurchaseAgreementRightsToDesignateInvesteeBoardMembersNumberOfBoardMembers_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of investee's board members which may be designated by the Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_DirectorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Director [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_DirectorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-employee director</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Repurchased and Retired During Period, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock repurchased and retired during period, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Benchmark [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_GiaprezaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">GIAPREZA.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_GiaprezaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">GIAPREZA [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_GiaprezaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">GIAPREZA</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_WarrantsAcquiredInSecondQuarterOf2020Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information pertaining to warrants acquired in the second quarter of 2020.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_WarrantsAcquiredInSecondQuarterOf2020Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Acquired In Second Quarter Of2020 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_WarrantsAcquiredInSecondQuarterOf2020Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants acquired in second quarter of 2020</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award number of annual installments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of annual installments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The number of annual installments that RSUs granted to newly appointed independent directors will vest.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Interest Rate, Stated Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Debt Instrument, annual interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument, annual interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cumulative Effect, Period of Adoption [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Amortization Period (Years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_Percent2.50ConvertibleDebtMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the information pertaining to 2.50% convertible senior notes due 2025.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_Percent2.50ConvertibleDebtMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percent2.50 Convertible Debt [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_Percent2.50ConvertibleDebtMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025 Notes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SecuritiesPurchaseAgreementTotalNumberOfWarrantsToBePurchasedUnderAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of warrants to be purchased under the securities purchase agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SecuritiesPurchaseAgreementTotalNumberOfWarrantsToBePurchasedUnderAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Purchase Agreement, Total Number of Warrants To Be Purchased Under Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SecuritiesPurchaseAgreementTotalNumberOfWarrantsToBePurchasedUnderAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The total number of warrants to be purchased under the terms of a securities purchase agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PurchaseAndSaleOfOtherInvestmentsManagedByIspFundLp_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchase and sale of other investments managed by ISP FUND LP</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PurchaseAndSaleOfOtherInvestmentsManagedByIspFundLp_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Purchase and sale of other investments managed by ISP FUND LP</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PurchaseAndSaleOfOtherInvestmentsManagedByIspFundLp_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase and sales of other investments managed by ISP Fund LP, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PurchaseAndSaleOfOtherInvestmentsManagedByIspFundLp_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase and sales of other investments managed by ISP Fund LP, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PurchasesOfCappedCallOptionsAssociatedWithConvertibleSeniorNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Purchases of capped call options associated with convertible senior notes.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PurchasesOfCappedCallOptionsAssociatedWithConvertibleSeniorNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchases of Capped Call Options Associated with Convertible Senior Notes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PurchasesOfCappedCallOptionsAssociatedWithConvertibleSeniorNotes_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of capped call options associated with convertible senior notes due 2028</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of changes in unrecognized tax benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 3 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Unobservable Inputs, Level 3</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Fair Value, Inputs, Level 3</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring and Nonrecurring [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermDebtTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Debt, Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net increase (decrease) in cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_WarrantsPurchasedIn2021Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants purchased in 2021</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_WarrantsPurchasedIn2021Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Purchased In2021 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_WarrantsPurchasedIn2021Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information pertaining to warrants purchased in 2021.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Convertible, Carrying Amount of Equity Component</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity component, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_TermOfMilestonePaymentForNetSales_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term of the milestone payment on net sales</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_TermOfMilestonePaymentForNetSales_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Term of Milestone Payment for Net Sales</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_TermOfMilestonePaymentForNetSales_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Term of milestone payment for net sales.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory, Work in Process, Net of Reserves</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Work-in-process</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Assets, Noncurrent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Noncurrent assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PercentageOfMaximumRoyaltyBasedOnAchievementOfAnnualNetProductSalesThresholds_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of maximum royalty based on achievement of annual net product sales thresholds.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PercentageOfMaximumRoyaltyBasedOnAchievementOfAnnualNetProductSalesThresholds_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Maximum Royalty Based On Achievement Of Annual Net Product Sales Thresholds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PercentageOfMaximumRoyaltyBasedOnAchievementOfAnnualNetProductSalesThresholds_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of maximum royalty based on achievement of annual net product sales thresholds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IncrementalCommonSharesAttributableToConversionOfDebtSecuritiesTreasuryStockMethod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the treasury stock method.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IncrementalCommonSharesAttributableToConversionOfDebtSecuritiesTreasuryStockMethod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Incremental Common Shares Attributable To Conversion Of Debt Securities, Treasury Stock Method</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IncrementalCommonSharesAttributableToConversionOfDebtSecuritiesTreasuryStockMethod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dilutive effect of the assumed conversion premium</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated amortization for the year 2027</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of estimated amortization for assets expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capitalized Fees Paid Remaining Estimated Amortization Year Four</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets, Gross (Excluding Goodwill)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total gross carrying amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total gross carrying amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityGrantValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The value of shares granted annually to independent directors upon re-election the to Board.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityGrantValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award, Annual Equity Grant, Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityGrantValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual grant of shares, value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Noncash Investing and Financing Items [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental Disclosure of Non-cash Investing and Financing Activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IspFundLpMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information pertaining to ISP Fund LP, an investment managed by Sarissa Capital.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IspFundLpMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Isp Fund Lp [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IspFundLpMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ISP Fund LP</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Incremental Common Shares Attributable to Share-based Payment Arrangements, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dilutive effect of options and awards granted under equity incentive plan and employee stock purchase plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Forfeited (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Financial Statement Error Correction [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Financial Statement Error Correction [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ContingentValueRightsLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contingent value rights liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ContingentValueRightsLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent value rights liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ContingentValueRightsLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent value rights liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of anti-dilutive securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SecuredConvertibleCreditAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Secured convertible credit agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SecuredConvertibleCreditAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Secured Convertible Credit Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SecuredConvertibleCreditAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Secured Convertible Credit Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Inventory, Current [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Inventory, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred State and Local Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">State</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total inventory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DebtConversionCommonStockPriceToConversionPriceRatioPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The value of common stock price as a percentage of conversion price.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DebtConversionCommonStockPriceToConversionPriceRatioPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Conversion, Common Stock Price to Conversion Price Ratio, Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DebtConversionCommonStockPriceToConversionPriceRatioPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock price to current conversion price ratio</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntityShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity activity of noncontrolling interests in a consolidated variable interest entity (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntityShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Changes To Noncontrolling Interest From A Consolidated Variable Interest Entity Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntityShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Changes to noncontrolling interest from a consolidated variable interest entity shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetResidualValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Acquired Finite-Lived Intangible Asset, Residual Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentRepurchaseAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Repurchase Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentRepurchaseAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Portion of debt retired, carrying value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PaionAgMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">PAION AG [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PaionAgMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">PAION AG [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PaionAgMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">PAION AG</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_EquityIncentivePlan2012Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the 2012 Equity Incentive Plan as approved by shareowners.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_EquityIncentivePlan2012Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Incentive Plan2012 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_EquityIncentivePlan2012Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2012 Equity Incentive Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PercentageOfRoyaltyOnPaymentsReceivedFromSublicensees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Royalty On Payments Received From Sublicensees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PercentageOfRoyaltyOnPaymentsReceivedFromSublicensees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of royalty on payments received from sublicensees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PercentageOfRoyaltyOnPaymentsReceivedFromSublicensees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the royalty payable as a percentage of payments received from sublicensees.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Acquisition [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Indefinite-Lived Intangible Assets, Period Increase (Decrease), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Indefinite-Lived Intangible Assets, Period Increase (Decrease)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement period adjustments for change in value of intangible assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Changes in fair values of equity and long-term investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Realized gain on equity investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Gain (Loss) on Investments, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain (Loss) on Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Changes in fair values of equity and long-term investments, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearthree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated amortization for the year 2026</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearthree_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of estimated amortization for assets expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearthree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capitalized Fees Paid Remaining Estimated Amortization YearThree</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_WarrantsAcquiredInThirdQuarterOf2020Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information pertaining to warrants acquired in the third quarter of 2020.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_WarrantsAcquiredInThirdQuarterOf2020Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Acquired In Third Quarter Of2020 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_WarrantsAcquiredInThirdQuarterOf2020Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants acquired in third quarter of 2020</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_NameOfMajorCustomerDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Customer [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_JP_lbl" xlink:role="http://www.xbrl.org/2003/role/label">JAPAN</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_JP_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Japan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Selling, General and Administrative Expenses [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Selling, general and administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares used to compute basic net income per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted-average shares used to compute basic net income per share attributable to Innoviva stockholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PreferredStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Preferred stock warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PreferredStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Warrants Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PreferredStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred Stock Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DebtInstrumentRepurchasePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Portion of debt Instrument, repurchased.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DebtInstrumentRepurchasePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Repurchase Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DebtInstrumentRepurchasePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of notes repurchased</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireEquityMethodInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of equity method investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireEquityMethodInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Equity Method Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument principal amount percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OptionIndexedToIssuersEquityStrikePrice1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Option Indexed to Issuer's Equity, Strike Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OptionIndexedToIssuersEquityStrikePrice1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Strike price for the underlying number of shares (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_MeasurementPeriodAdjustmentsIncreaseDecreaseInEstimatedPurchasePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of increase (decrease) in estimated purchase price during measurement period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_MeasurementPeriodAdjustmentsIncreaseDecreaseInEstimatedPurchasePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Period Adjustments, Increase Decrease In estimated Purchase Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_MeasurementPeriodAdjustmentsIncreaseDecreaseInEstimatedPurchasePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement period adjustments for change in estimated purchase price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_OneOfImaginabsCommonStockholderMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">One of ImaginAb's Common Stockholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_OneOfImaginabsCommonStockholderMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">One Of Imaginabs Common Stockholder [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_OneOfImaginabsCommonStockholderMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information pertaining to one of ImaginAb's common stockholders.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CustomerThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Customer three.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CustomerThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Customer Three [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CustomerThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Customer Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Gain (Loss) on Extinguishment of Debt, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain (Loss) on Extinguishment of Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Loss on extinguishment of debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss on extinguishment of debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalizedContractCostAccumulatedAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capitalized Contract Cost, Accumulated Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalizedContractCostAccumulatedAmortization_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accumulated amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NanoliveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Nanolive [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NanoliveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nanolive [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NanoliveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nanolive</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Summary of weighted-average assumptions used to calculate estimated value of stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DeferredTaxAssetsUnrealizedLossesOnInvestmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets unrealized losses on investment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DeferredTaxAssetsUnrealizedLossesOnInvestmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Unrealized Losses On Investment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DeferredTaxAssetsUnrealizedLossesOnInvestmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized loss on investment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IncomeTaxesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IncomeTaxesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IncomeTaxesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DenominatorAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">No definition available.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DenominatorAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Denominator [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DenominatorAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Denominator:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Liabilities, Noncurrent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Noncurrent liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Equity Method Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in fair values of equity method investments, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Changes in fair values of equity method investments, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ExpectedHoldingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Expected holding period of equity method investment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ExpectedHoldingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Expected Holding Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ExpectedHoldingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected holding period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CollaborativeArrangementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue from collaborative arrangements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CollaborativeArrangementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information pertaining to collaborative arrangements.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CollaborativeArrangementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Subsequent Events</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertibleDebtTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Debt [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertibleDebtTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Liability and Equity Components of Convertible Notes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IncreaseInDeferredTaxAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase in deferred tax assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IncreaseInDeferredTaxAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase in Deferred Tax Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IncreaseInDeferredTaxAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in Deferred Tax Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PercentageOfEconomicInterestOnFuturePaymentsUnderAgreements_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the percentage of economic interest in any future payments made under the agreements.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PercentageOfEconomicInterestOnFuturePaymentsUnderAgreements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of Economic Interest on Future Payments Under Agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PercentageOfEconomicInterestOnFuturePaymentsUnderAgreements_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of economic interest in any future payments made under the agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_VotingAgreementMaximumVotingRightsPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of maximum voting rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_VotingAgreementMaximumVotingRightsPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Voting Agreement, Maximum Voting Rights, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_VotingAgreementMaximumVotingRightsPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the percentage of maximum voting rights under voting agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Long-Term Debt Instruments [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Decrease Resulting from Current Period Tax Positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Gross decrease in tax portions from current year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total fair value of debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Anti-dilutive securities (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DeferredRoyaltyObligationNonCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Long-term portion of deferred royalty obligation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DeferredRoyaltyObligationNonCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Royalty Obligation, Non Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DeferredRoyaltyObligationNonCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term portion of deferred royalty obligation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SeriesCWarrantsAndSeriesDWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series C warrants and Series D warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SeriesCWarrantsAndSeriesDWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series C warrants and Series D warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SeriesCWarrantsAndSeriesDWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series C Warrants and Series D Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of deferred tax assets and deferred tax liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cumulative Effect, Period of Adoption [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MajorCustomersAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Customer [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_Incarda2020WarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">InCarda 2020 Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_Incarda2020WarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">InCarda 2020 Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_Incarda2020WarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Incarda 2020 Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and Cash Equivalents, at Carrying Value, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and Cash Equivalents, at Carrying Value, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, at Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Cash balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PropertyPlantAndEquipmentUsefulLifeTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tabular disclosure of the useful life of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PropertyPlantAndEquipmentUsefulLifeTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment Useful Life [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PropertyPlantAndEquipmentUsefulLifeTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of property, equipment and leasehold improvements useful lives</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Schedule of stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PresentationReclassificationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Presentation reclassification.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PresentationReclassificationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Presentation Reclassification [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PresentationReclassificationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Presentation Reclassification</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value of options exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_LaJollaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">La Jolla</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_LaJollaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">La Jolla [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_LaJollaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">La Jolla [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_LaJollaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">La Jolla [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SecuritiesPurchaseAgreementAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount the Company agreed to pay for common stock and warrants upon satisfaction of certain closing conditions under the terms of the securities purchase agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SecuritiesPurchaseAgreementAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Purchase Agreement, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SecuritiesPurchaseAgreementAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount of securities purchase agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SecuritiesPurchaseAgreementAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Payments for acquire variable interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_TwoThousandTwentyEightNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty eight notes.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_TwoThousandTwentyEightNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Eight Notes [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_TwoThousandTwentyEightNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2028 Notes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value of Financial Instruments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TradeAccountsReceivableMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trade Accounts Receivable [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TradeAccountsReceivableMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Receivables from Net Product Sales</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConsolidationVariableInterestEntityPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidation, Variable Interest Entity, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConsolidationVariableInterestEntityPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable Interest Entities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PercentageOfRoyaltyPaymentsNotEntitledToReceive_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of royalty payments the company is not entitled to receive.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PercentageOfRoyaltyPaymentsNotEntitledToReceive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of royalty payments not entitled to receive</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DemandLettersSentByStockholders_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of demand letters that were sent to the Company by purported stockholders.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DemandLettersSentByStockholders_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Demand Letters Sent By Stockholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DemandLettersSentByStockholders_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Demand letters sent by stockholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Selling, General and Administrative Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Selling, General and Administrative Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Selling, general and administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NonRule10B51ArrModifiedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non Rule 10b51 Arrangement Modified</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NonRule10B51ArrModifiedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Rule 10B51 Arr Modified Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NonRule10B51ArrModifiedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non Rule 10B51 Arr Modified Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareRepurchaseProgramDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Repurchase Program [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConsolidatedEntitiesAndAcquisitionsDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Consolidated entities and acquisitions disclosure abstract.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConsolidatedEntitiesAndAcquisitionsDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidated Entities and Acquisitions Disclosure Abstract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SeriesCPreferredStockAndWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information pertaining to series C preferred stock and warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SeriesCPreferredStockAndWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series C Preferred Stock And Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SeriesCPreferredStockAndWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series C preferred stock and warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CollaborativeArrangementRoyaltyRateDefinedLevelOne_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the royalty rate which the entity will receive under the collaboration agreement on the first defined level of annual global net sales.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CollaborativeArrangementRoyaltyRateDefinedLevelOne_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement, Royalty Rate Defined, Level One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CollaborativeArrangementRoyaltyRateDefinedLevelOne_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty rate for first level of annual global net sales (as a percent)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CommonStockAcquiredAverageCostPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common Stock Acquired Average Cost Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CommonStockAcquiredAverageCostPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Acquired Average Cost Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CommonStockAcquiredAverageCostPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares repurchased average price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income Taxes Paid, Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes Paid, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentPrincipal_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument, Principal Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentPrincipal_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Periodic Payment, Principal</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Option Indexed to Issuer's Equity, Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option Indexed to Issuer's Equity, Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Payable, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Accrued interest payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalizedContractCostNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capitalized Contract Cost, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalizedContractCostNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net carrying value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalizedContractCostNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalized fees paid, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SeriesC2PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series C2 Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SeriesC2PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series C-2 Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SeriesC2PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series C-2 Preferred Stock member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value of Stock-Based Compensation Awards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Granted (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_InCardaConvertibleNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">In Carda Convertible note.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_InCardaConvertibleNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">In Carda Convertible Note [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_InCardaConvertibleNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">InCarda Convertible Note</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated amortization for the year 2028</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of estimated amortization for assets expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capitalized Fees Paid Remaining Estimated Amortization Year Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity and long-term investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Long-term Investments, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Tax Authority [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_FuturePotentialMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Future potential milestone payment receivable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_FuturePotentialMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Future Potential Milestone Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_FuturePotentialMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Future potential milestone payment receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Issued Accounting Pronouncements Not Yet Adopted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Shares Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Interest Entity, Not Primary Beneficiary [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable Interest Entity, Not Primary Beneficiary</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Released RSUs/RSAs (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_InterestRateOfDeferredRoyaltyObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Interest rate of deferred royalty obligation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_InterestRateOfDeferredRoyaltyObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Rate of Deferred Royalty Obligation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_InterestRateOfDeferredRoyaltyObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">State</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current State and Local Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">State</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right-of-use assets obtained in exchange for operating lease obligations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockSharesAcquired_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Repurchase of common stock (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockSharesAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Repurchase of common stock (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockSharesAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Treasury Stock, Shares, Acquired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Forfeited (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition, Acquiree [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertibleDebtCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Debt, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertibleDebtCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible subordinated notes due 2023, net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LegalEntityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Legal Entity:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LegalEntityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Legal Entity [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PurchasesOfCappedCallsInConnectionWithConvertibleSeniorNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Purchases of capped calls In connection with convertible senior notes.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PurchasesOfCappedCallsInConnectionWithConvertibleSeniorNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchases Of Capped Calls In Connection With Convertible Senior Notes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PurchasesOfCappedCallsInConnectionWithConvertibleSeniorNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchases of capped calls in connection with convertible senior notes due 2028</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CallOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Call Option [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CallOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock prices below $27.79 per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares used to compute Innoviva basic and diluted net income per share:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants and Rights Outstanding, Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term of warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Term of warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IntangibleAssetsMarketedProductsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Net amount of Marketed Products.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IntangibleAssetsMarketedProductsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets Marketed Products, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IntangibleAssetsMarketedProductsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketed products, net carrying amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Additional General Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional disclosures</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Convertible Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of convertible notes, net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total intrinsic value of options exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_EmployeeStockPurchasePlanTwentyTwentyThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023 ESPP</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_EmployeeStockPurchasePlanTwentyTwentyThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Purchase Plan Twenty Twenty Three [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_EmployeeStockPurchasePlanTwentyTwentyThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee Stock Purchase Plan Twenty Twenty Three [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Components of Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforward amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SalesMilestonePaymentsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sales milestone payments receivable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SalesMilestonePaymentsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sales Milestone Payments Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SalesMilestonePaymentsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales milestone payments receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Equity in Earnings (Losses) of Unconsolidated Subsidiary, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impact of consolidation and deconsolidation of subsidiaries</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Impact of consolidation and deconsolidation of subsidiaries</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Accrued Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Other Accrued Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableInterestEntityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Interest Entity [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableInterestEntityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CONSOLIDATED ENTITIES</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalizedContractCostAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capitalized Contract Cost, Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalizedContractCostAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Amortization expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalizedContractCostAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of capitalized fees paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalizedContractCostAmortization_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: amortization of capitalized fees paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SeniorUnsecuredConvertibleNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Borrowing which takes priority over other debt securities and can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SeniorUnsecuredConvertibleNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Senior Unsecured Convertible Notes [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SeniorUnsecuredConvertibleNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible senior notes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalty agreement required payment for breach of agreement payment two.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty Agreement Required Payment For Breach Of Agreement Payment Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum aggregate royalty payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Gross Unrealized Losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal and state research credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Federal and state research credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RoyaltyFinancingAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalty financing agreement member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RoyaltyFinancingAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty Financing Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RoyaltyFinancingAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty Financing Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investment, Ownership Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Equity investment ownership percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity method investment ownership percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule Of finite and indefinite lived intangible assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Finite and Indefinite Lived Intangible Assets[Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Accumulated Amortization of Recognized Intangible Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_LicenseRevenueRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License revenue recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_LicenseRevenueRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Revenue Recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_LicenseRevenueRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License revenue recognized.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeCapPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative, Cap Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeCapPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cap price for the underlying number of shares (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Expected Amortization, after Year Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Future amortization expense, thereafter</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableRateDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Rate [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PercentageOfRoyaltyPayableOnNetSales_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the royalty payable, as a percentage of net sales.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PercentageOfRoyaltyPayableOnNetSales_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Royalty Payable On Net Sales</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PercentageOfRoyaltyPayableOnNetSales_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of royalty payable on net sales</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PrivatePlacementPositionsAndConvertibleNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Private Placement Positions And Convertible Notes.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PrivatePlacementPositionsAndConvertibleNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Private Placement Positions And Convertible Notes [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PrivatePlacementPositionsAndConvertibleNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Private Placement Positions And Convertible Notes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Innoviva Strategic Opportunities, LLC</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Innoviva Strategic Opportunities Limited Liability Corporation [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information pertaining to Innoviva Strategic Opportunities, LLC.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other long-term liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PortionOfDebtInstrumentFaceAmountExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Portion of debt instrument face amount, exercised.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PortionOfDebtInstrumentFaceAmountExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Portion of Debt Instrument Face Amount, Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PortionOfDebtInstrumentFaceAmountExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Portion of debt instrument face amount, Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfUnsecuredDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repayments of Unsecured Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfUnsecuredDebt_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payment for repurchase of convertible subordinated notes due 2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfUnsecuredDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment for repurchase of debt instrument</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IntangibleAssetsInProcessResearchAndDevelopmentAccumulatedAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">In-process research and development, accumulated amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IntangibleAssetsInProcessResearchAndDevelopmentAccumulatedAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets In Process Research And Development Accumulated Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IntangibleAssetsInProcessResearchAndDevelopmentAccumulatedAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Intangible sssets in process research and development accumulated amortization.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NewDebtInstrumentInterestRateAfterRepurchaseOfNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">New debt instrument interest rate after repurchase of notes member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NewDebtInstrumentInterestRateAfterRepurchaseOfNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Debt Instrument Interest Rate After Repurchase Of Notes [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NewDebtInstrumentInterestRateAfterRepurchaseOfNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">New Rate [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax assets before valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Liabilities, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term debt, net of discount and issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Excluding Current Maturities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total long-term debt, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total long-term debt, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and cash equivalents at beginning of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total cash, cash equivalents and restricted cash at end of period shown in the consolidated statements of cash flows</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total cash, cash equivalents and restricted cash at end of period shown in the condensed consolidated statements of cash flows</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and cash equivalents at end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Related Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Information</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SeriesD1AndD2PreferredStockAndCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series D 1 and D 2 preferred stock and common stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SeriesD1AndD2PreferredStockAndCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series D 1 And D 2 Preferred Stock And Common Stock Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SeriesD1AndD2PreferredStockAndCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series D 1 And D 2 Preferred Stock And Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities assumed</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of outstanding RSUs and PSUs/RSAs and PSAs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertibleSubordinatedDebtMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Subordinated Debt [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertibleSubordinatedDebtMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible subordinated notes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance at the end of the period (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance at the beginning of the period (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConsolidatedEntitiesAndAcquisitionsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Consolidated entities and acquisitions text block.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConsolidatedEntitiesAndAcquisitionsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidated Entities and Acquisitions [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConsolidatedEntitiesAndAcquisitionsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CONSOLIDATED ENTITIES AND ACQUISITIONS</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Valuation Allowance, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2028</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Maturity, Year Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostsAndExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total expenses, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostsAndExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Costs and Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostsAndExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Due from Related Parties, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Due from Related Parties, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Receivables from collaborative arrangements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ContingentSalesBasedMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contingent sales based milestone payment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ContingentSalesBasedMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Sales Based Milestone Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ContingentSalesBasedMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent sales based milestone payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Maturity, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Interest Entity, Primary Beneficiary [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable Interest Entity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IntangibleAssetsCollaborationAgreementAccumulatedAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration agreement, accumulated amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IntangibleAssetsCollaborationAgreementAccumulatedAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets Collaboration Agreement Accumulated Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IntangibleAssetsCollaborationAgreementAccumulatedAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Intangible assets collaboration agreement accumulated amortization.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities and Other Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other accrued liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term (in years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableInterestEntityOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableInterestEntityOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Armata outstanding shares percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Value, Issued, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Value, Issued, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Value, Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock: $0.01 par value, 230 shares authorized, no shares issued and outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AmortizationOfCapitalizedFeesAndDepreciationOfPropertyAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amortization of capitalized fees and depreciation of property and equipment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AmortizationOfCapitalizedFeesAndDepreciationOfPropertyAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amortization of Capitalized Fees and Depreciation of Property and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AmortizationOfCapitalizedFeesAndDepreciationOfPropertyAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of capitalized fees and depreciation of property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of Individual [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of shares to be purchased under the securities purchase agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares purchased under the securities purchase agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Number of Shares Issued in Transaction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_GateNeuroscienceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gate Neuroscience [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_GateNeuroscienceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Gate Neuroscience [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_GateNeuroscienceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gate Neurosciences Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtLongtermAndShorttermCombinedAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt, Long-Term and Short-Term, Combined Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtLongtermAndShorttermCombinedAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total debt, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtLongtermAndShorttermCombinedAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total debt, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise price of warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Exercise price of warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated amortization after 2028</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of estimated amortization for assets expected to be recognized after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capitalized Fees Paid Remaining Estimated Amortization After Year Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CapitalizedFeesPaidWeightedAverageUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Capitalized fees paid weighted average useful life.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CapitalizedFeesPaidWeightedAverageUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capitalized Fees Paid Weighted Average Useful Life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CapitalizedFeesPaidWeightedAverageUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining amortization period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_MeasurementPeriodAdjustmentsIncreaseDecreaseInLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement period adjustments increase decrease in liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_MeasurementPeriodAdjustmentsIncreaseDecreaseInLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Measurement period adjustments increase decrease In liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_MeasurementPeriodAdjustmentsIncreaseDecreaseInLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Period Adjustments Increase Decrease In liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Fair Value per Share at Grant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">NET INCOME PER SHARE</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_OneDirectorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">One Director.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_OneDirectorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">One Director [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_OneDirectorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">One Director</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Benchmark [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Product Sales</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Finite-Lived Intangible Assets, Period Increase (Decrease), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Period Increase (Decrease)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement period adjustments for change in value of intangible assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Option Indexed to Issuer's Equity, Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ArmataTermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Armata Term Loan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ArmataTermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Armata Term Loan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ArmataTermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Armata term loan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Liabilities, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other accrued liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_GSKMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents GSK, with whom the entity has agreements and arrangements, such as those for developing and commercializing different products.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_GSKMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">G S K [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_GSKMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">GSK</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">BALANCE SHEET COMPONENTS</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestAndDividendIncomeOperating_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest and dividend income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestAndDividendIncomeOperating_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest and Dividend Income, Operating</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestAndDividendIncomeOperating_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Interest and Dividend Income, Operating, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestAndDividendIncomeOperating_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Interest and dividend income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NetOperatingLossEstimatingDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Net Operating Loss Estimating Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NetOperatingLossEstimatingDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Operating Loss Estimating Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NetOperatingLossEstimatingDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss estimating date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_LaJollaPharmaceuticalCompanyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">La jolla pharmaceutical company member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_LaJollaPharmaceuticalCompanyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">La Jolla Pharmaceutical Company [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_LaJollaPharmaceuticalCompanyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">La Jolla Pharmaceutical Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable lease costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CapitalizedFeesPaidDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The entire disclosure for information about capitalized fees paid.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CapitalizedFeesPaidDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capitalized Fees Paid Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CapitalizedFeesPaidDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CAPITALIZED FEES PAID</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Maturity, Year Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amortization of Debt Discount (Premium)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of debt discount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ProfitLossShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net income (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ProfitLossShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Profit Loss Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ProfitLossShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Profit Loss Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Dividend yield</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsNonrecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Nonrecurring [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsNonrecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nonrecurring basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series C Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series C preferred stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 2 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Other Observable Inputs, Level 2</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProductMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProductMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net product sales</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_FederalNetOperatingLossesEstimatedUtilizationAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Federal net operating losses estimated utilization amount.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_FederalNetOperatingLossesEstimatedUtilizationAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Federal Net Operating Losses Estimated Utilization Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_FederalNetOperatingLossesEstimatedUtilizationAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal net operating losses estimated utilization amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total carrying value of investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_BusinessAcquisitionsOfChangeInFairValueOfInvestment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Business acquisitions of change in fair value of investment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_BusinessAcquisitionsOfChangeInFairValueOfInvestment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisitions of Change in Fair Value of Investment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralPartnerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General Partner [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralPartnerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General Partner</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialEquityGrantValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The value of shares granted to newly appointed non-employee director on the date that such individual joins the Board.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialEquityGrantValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation, Arrangement by Share Based Payment Award, Initial Equity Grant Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialEquityGrantValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">One time grant of shares, value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Principal</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement period adjustments for change in value of deferred tax liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense (Benefit), Continuing Operations, Adjustment of Deferred Tax (Asset) Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DebtInstrumentTransactionCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Transaction Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DebtInstrumentTransactionCost_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument transaction cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DebtInstrumentTransactionCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transaction cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockValueAcquiredCostMethod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Repurchase of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockValueAcquiredCostMethod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Treasury Stock, Value, Acquired, Cost Method</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockValueAcquiredCostMethod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Repurchase of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary of Significant Accounting Policies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SecuritiesPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Securities purchase agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SecuritiesPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Purchase Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SecuritiesPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Securities purchase agreement member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State income tax, net of federal benefit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Exercise of stock options, and issuance of common stock units and stock awards, net of repurchase of shares to satisfy tax withholding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity investment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedGain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Securities, FV-NI, Unrealized Gain</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedGain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized gain from fair value changes in equity investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedGain_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Unrealized gain</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payments to acquire equity securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Equity Securities, FV-NI</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_LicenseRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_LicenseRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Revenue [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_LicenseRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License revenue member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseContractualTermAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Contractual Term [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum contributions as a percentage of employee's eligible compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NumeratorAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">No definition available.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NumeratorAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Numerator [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NumeratorAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Numerator:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Subsidiary or Equity Method Investee [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockCommonMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Treasury Stock, Common [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockCommonMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Treasury Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amortization of Debt Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of debt issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IncomeTaxPayableNonCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax payable non current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IncomeTaxPayableNonCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Payable Non Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IncomeTaxPayableNonCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax payable, long-term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Exercised (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">State and Local Jurisdiction [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_XacduroMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">XACDURO</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_XacduroMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">XACDURO [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_XacduroMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">XACDURO [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ImaginabMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ImaginAb</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ImaginabMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Imaginab [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ImaginabMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information pertaining to ImaginAb.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill, impairment losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill, Impairment Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_UnrecognizedTaxBenefitsDecreaseResultingFromPriorPeriodTaxPositionsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net decrease in tax portions for 2020</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_UnrecognizedTaxBenefitsDecreaseResultingFromPriorPeriodTaxPositionsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_UnrecognizedTaxBenefitsDecreaseResultingFromPriorPeriodTaxPositionsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Net amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Reporting</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_LongActingBeta2AgonistAnoroMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents Long-Acting Beta2 Agonist, ANORO, which is being developed and commercialized by entering into a strategic alliance with GSK</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_LongActingBeta2AgonistAnoroMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long Acting Beta2 Agonist Anoro [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_LongActingBeta2AgonistAnoroMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ANORO</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Information related to various accounting policies of the entity.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary of Significant Accounting Policies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, Plant and Equipment, Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NumberOfCommonStockIssuedDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of common stock issued description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NumberOfCommonStockIssuedDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Common Stock Issued Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NumberOfCommonStockIssuedDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of common stock issued description.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the royalty rate for combination products.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Annual Royalties as Percentage of Net Sales for Combination Products</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty rate for combination products (as a percent)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetRentableArea_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Rentable Area</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetRentableArea_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rentable square feet</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionSharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition, Share Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionSharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquisition share price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Inventories, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Inventories</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement period adjustments for change in value of Inventory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Inventory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Change in inventory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense, Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total interest and amortization expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining contractual term of options exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Repurchase Program, Remaining Authorized Repurchase Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount of shares repurchased</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">STOCK-BASED COMPENSATION</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Forfeited (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedRoyaltiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty obligation payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedRoyaltiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Royalties, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CapitalizedFeePaidEstimatedUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Capitalized fee paid estimated useful life.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CapitalizedFeePaidEstimatedUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capitalized Fee Paid Estimated Useful Life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CapitalizedFeePaidEstimatedUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalized fees paid, estimated useful life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_UnrealizedOtherGainLossOnInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Changes in fair values of equity and long-term investments, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_UnrealizedOtherGainLossOnInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unrealized other gain loss on investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_UnrealizedOtherGainLossOnInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrealized Other Gain Loss on Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfTreasuryStockTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Treasury Stock [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConvertibleDebtInstrumentLiabilityComponentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">n/a</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConvertibleDebtInstrumentLiabilityComponentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Debt Instrument, Liability Component [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConvertibleDebtInstrumentLiabilityComponentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liability component</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combinations Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Combination</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of available-for-sale securities measured at fair value on a recurring basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Uncertain Tax Positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unamortized Debt Issuance Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unamortized debt issuance cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible subordinated notes due 2023 (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate202006Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update 2020-06 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate202006Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU 2020-06</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets, Net (Excluding Goodwill) [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible Assets Abstract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryCurrentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory, Current [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_WithdrawalFromInvestment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Withdrawal from investment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_WithdrawalFromInvestment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Withdrawal From Investment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_WithdrawalFromInvestment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Withdrawal From Investment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Business combination recognized identifiable assets acquired and liabilities assumed other accrued liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Other Accrued Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other accrued liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingWeightedAverageFairValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Weighted Average Fair Value per Share of fully vested and expected to vest non-option equity instruments outstanding that can be converted into shares under award activity.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingWeightedAverageFairValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Vested And Expected To Vest Outstanding, Weighted-Average Fair Value per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingWeightedAverageFairValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested and expected to vest at the end of the period (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by (used in) investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConsolidatedEntitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">No definition available.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConsolidatedEntitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidated Entities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">GOODWILL AND INTANGIBLE ASSETS</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Released RSUs/RSAs (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_OperatingLeaseWeightedAverageIncrementalBorrowingRate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating Lease Weighted Average Incremental Borrowing Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_OperatingLeaseWeightedAverageIncrementalBorrowingRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Weighted Average Incremental Borrowing Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_OperatingLeaseWeightedAverageIncrementalBorrowingRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, weighted average incremental borrowing rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LimitedPartnersContributedCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Limited Partners' Contributed Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LimitedPartnersContributedCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contributed to partnership for investing</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LimitedPartnersContributedCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Capital contribution</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss attributable to noncontrolling interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net income attributable to Innoviva stockholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net income attributable to Innoviva stockholders, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PurchasesOfTradingSecurityManagedByIspFundLp_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Purchases of trading security managed by Isp fund Lp.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PurchasesOfTradingSecurityManagedByIspFundLp_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchases of Trading Security Managed by Isp Fund Lp</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PurchasesOfTradingSecurityManagedByIspFundLp_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of trading security managed by ISP Fund LP</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_StrategicAllianceMabaProgram_lbl" xlink:role="http://www.xbrl.org/2003/role/label">strategic alliance - MABA program</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_StrategicAllianceMabaProgram_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">strategic alliance - MABA program</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_StrategicAllianceMabaProgram_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Strategic alliance - MABA program</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_TwoThousandTwentyThreeNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty three notes.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_TwoThousandTwentyThreeNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Three Notes [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_TwoThousandTwentyThreeNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023 Notes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CapitalizedFeesPaidToRelatedPartyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of accounting policy for capitalized fees paid to a related party.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CapitalizedFeesPaidToRelatedPartyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capitalized Fees Paid To A Related Party [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CapitalizedFeesPaidToRelatedPartyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalized Fees Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Inventory, Gross, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RoyaltiesPayablePeriodAfterFirstCommercialSaleOfProduct_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalties payable period after first commercial sale of product.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RoyaltiesPayablePeriodAfterFirstCommercialSaleOfProduct_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalties Payable Period After First Commercial Sale Of Product</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RoyaltiesPayablePeriodAfterFirstCommercialSaleOfProduct_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalties payable period after first commercial sale of product</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_QualifiedFinancingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Qualified Financing [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_QualifiedFinancingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Qualified Financing [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_QualifiedFinancingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Qualified Financing</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated amortization for the year 2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capitalized Fees Paid Remaining Estimated Amortization Next Twelve Months</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of estimated amortization for assets expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, after Year Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee, operating lease, liability, to be paid, after year three.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development tax credit carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountAsContributionOfEligibleCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum amount the employee may contribute of employee's eligible compensation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountAsContributionOfEligibleCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement By Share-Based Payment Award Maximum Amount As A Contribution Of Eligible Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountAsContributionOfEligibleCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum value of shares an employee may purchase in a calendar year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accrued Liabilities, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accrued Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued personnel-related expenses and other accrued liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ParatekPharmaceuticalsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Paratek Pharmaceuticals, Inc.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ParatekPharmaceuticalsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Paratek Pharmaceuticals, Inc [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ParatekPharmaceuticalsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Paratek Pharmaceuticals, Inc</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeographicConcentrationRiskMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographic Concentration Risk [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeographicConcentrationRiskMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographic Concentration Risk</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PurchasesOfEquityInvestmentsManagedByIspFundLp_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Purchases of Equity Investments Managed by Isp Fund Lp</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PurchasesOfEquityInvestmentsManagedByIspFundLp_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchases of Equity Investments Managed by Isp Fund Lp</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PurchasesOfEquityInvestmentsManagedByIspFundLp_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of equity investments managed by ISP Fund LP</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableRateAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Rate [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of trading securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Marketable Securities, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_FactorsAffectingComparabilityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Factors affecting comparability.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_FactorsAffectingComparabilityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Factors Affecting Comparability Policy [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_FactorsAffectingComparabilityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Factors Affecting Comparability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInvestmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment-related expenses, net of investment-related income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInvestmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income, Investment Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_InnovivaCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Innoviva's Common Stock Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_InnovivaCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Innoviva Common Stock Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_InnovivaCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Innoviva's Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Liabilities, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NumberOfCustomers_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of customers.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NumberOfCustomers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Customers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NumberOfCustomers_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of customers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterestAndDividend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income, Interest and Dividend</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterestAndDividend_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Investment Income, Interest and Dividend, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SarissaCapitalManagementLpMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">This member stands for Sarissa Capital.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SarissaCapitalManagementLpMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sarissa Capital Management Lp [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SarissaCapitalManagementLpMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sarissa Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Useful Life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketed products, Useful Life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SoftwareAndComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Software and computer equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SoftwareAndComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Software And Computer Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SoftwareAndComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Software and computer equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CustomerOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Customer one.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CustomerOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Customer One [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CustomerOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Customer One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_StateNetOperatingLossesEstimatedUtilizationAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">State net operating losses estimated utilization amount.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_StateNetOperatingLossesEstimatedUtilizationAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">State Net Operating Losses Estimated Utilization Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_StateNetOperatingLossesEstimatedUtilizationAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State net operating losses estimated utilization amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ConsolidatedEntitiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidated Entities [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated by Reference [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets, Net (Excluding Goodwill)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net carrying amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net income attributable to Innoviva stockholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase (Decrease) in Stockholders' Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Interest Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Interest expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SecondNoteAmendmentAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Second Note Amendment Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SecondNoteAmendmentAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Second Note Amendment Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SecondNoteAmendmentAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Second note amendment agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfConvertibleDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repayments of Convertible Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfConvertibleDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment towards convertible promissory note</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CapitalizedFeesPaidFutureAmortizationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Capitalized fees paid future amortization.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CapitalizedFeesPaidFutureAmortizationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capitalized Fees Paid Future Amortization [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CapitalizedFeesPaidFutureAmortizationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalized Fees paid, Future amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertibleDebtMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible debt investment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertibleDebtMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Debt [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NameOfEventAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Name Of Event [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NameOfEventAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Name Of Event [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_TwoThousandTwentyFiveNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty five notes.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_TwoThousandTwentyFiveNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Five Notes [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_TwoThousandTwentyFiveNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Two Thousand Twenty Five Notes [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_TwoThousandTwentyFiveNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025 Notes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AreaOfRealEstateProperty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Area of Real Estate Property</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AreaOfRealEstateProperty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease space</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Exercise of stock options, and issuance of common stock units and stock awards, net of repurchase of shares to satisfy tax withholding (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares used to compute diluted net income per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted-average shares used to compute diluted net income per share attributable to Innoviva stockholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of differences between expected U.S. federal statutory income tax to income tax expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentRepurchasedFaceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Repurchased Face Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentRepurchasedFaceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument, Repurchased Face Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentRepurchasedFaceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Portion of debt retired, face value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Federal Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Federal</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IncardaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information pertaining to InCarda.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IncardaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Incarda [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IncardaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">InCarda</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Business combination recognized identifiable assets acquired and liabilities assumed operating lease right-of-use assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Operating Lease Right-of-Use Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Remaining Lease Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, Weighted average remaining lease term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase price as a percentage of fair market value of stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use of Estimates, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Management's Estimates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_GeorgeWashingtonUniversityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">George Washington University.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_GeorgeWashingtonUniversityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">George Washington University [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_GeorgeWashingtonUniversityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">George Washington University</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">INCOME TAXES</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NewPrincipalAmountMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">New principal amount.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NewPrincipalAmountMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Principal Amount [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NewPrincipalAmountMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">New Principal Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">'Total assets acquired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NetInvestmentRelatedIncomeExpenseEarnedInccured_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net investment-related income (expense) earned (incurred)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NetInvestmentRelatedIncomeExpenseEarnedInccured_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Investment Related Income Expense Earned Inccured</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NetInvestmentRelatedIncomeExpenseEarnedInccured_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Net investment related income (expense) earned (inccured).</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance at the end of the period (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance at the beginning of the period (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireLongtermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional cash investment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireLongtermInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Purchases of equity and long term investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireLongtermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Long-Term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireLongtermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Initial contribution</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ClinicalDevelopmentAndRegulatoryMilestonesAmountPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Clinical development and regulatory milestones amount payable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ClinicalDevelopmentAndRegulatoryMilestonesAmountPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Clinical Development And Regulatory Milestones Amount Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ClinicalDevelopmentAndRegulatoryMilestonesAmountPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Clinical development and regulatory milestones amount payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ExtendedExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Extended expiration date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ExtendedExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Extended Expiration Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ExtendedExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Extended expiration date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LoanRestructuringModificationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loan Restructuring Modification [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of computation of basic and diluted net income per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SubscriptionAgreementOneTimeMilestonePaymentOnNetSales_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subscription agreement one-time milestone payment on net sales</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SubscriptionAgreementOneTimeMilestonePaymentOnNetSales_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subscription Agreement One-time Milestone Payment on Net Sales</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SubscriptionAgreementOneTimeMilestonePaymentOnNetSales_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Subscription agreement one-time milestone payment on net sales.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_InnovivaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Innoviva [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_InnovivaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Innoviva [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_InnovivaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Innoviva [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_TermOfMilestonePaymentForCommercialSale_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term of the milestone payment on first commercial sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_TermOfMilestonePaymentForCommercialSale_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Term of Milestone Payment for Commercial Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_TermOfMilestonePaymentForCommercialSale_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Term of milestone payment for commercial sale.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense, Debt, Excluding Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contractual interest expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationTechniqueAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Approach and Technique [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation of Revenue [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Recognition and Collaborative Arrangements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Anti-Dilutive Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Measurement Frequency [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated amortization for the year 2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capitalized Fees Paid Remaining Estimated Amortization Year Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of estimated amortization for assets expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Noncurrent Liabilities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Noncurrent Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Other Long Term Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AmortizationOfFairValueAdjustmentsOfCostOfProductsSold_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amortization of fair value adjustments of cost of products sold.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AmortizationOfFairValueAdjustmentsOfCostOfProductsSold_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amortization of Fair Value Adjustments of Cost of Products Sold</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AmortizationOfFairValueAdjustmentsOfCostOfProductsSold_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of fair value adjustments of Cost of products sold</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IncreaseDecreaseInDeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Increase (decrease) in deferred tax liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IncreaseDecreaseInDeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase (decrease) in deferred tax liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IncreaseDecreaseInDeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Deferred Tax Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IncreaseDecreaseInDeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement period adjustments increase decrease in deferred tax liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalizedContractCostGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capitalized Contract Cost, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalizedContractCostGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone fees paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalizedContractCostGross_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Gross carrying value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CostReimbursementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost Reimbursement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CostReimbursementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cost Reimbursement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CostReimbursementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cost reimbursement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Released RSUs and RSAs (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Employee-related Liabilities, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee-related Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued personnel-related expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Revenue, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Goodwill, Period Increase (Decrease), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill, Period Increase (Decrease)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement period adjustments for change in value of goodwill</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Decrease in goodwill</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentOne_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalty agreement required payment for breach of agreement payment one.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentOne_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty Agreement Required Payment For Breach Of Agreement Payment One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentOne_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Required payment for breach of agreement, payment one</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConsolidatedEntitiesAndAcquisitionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Consolidated entities and acquisitions.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConsolidatedEntitiesAndAcquisitionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidated Entities and Acquisitions [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConsolidatedEntitiesAndAcquisitionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consolidated Entities and Acquisitions [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ZaiLabMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Zai Lab.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ZaiLabMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Zai Lab [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ZaiLabMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Zai Lab</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Loss Carryforwards, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_HarvardUniversityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Harvard University.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_HarvardUniversityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Harvard University [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_HarvardUniversityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Harvard University</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_IncreaseToConvertibleNotes" xlink:to="inva_IncreaseToConvertibleNotes_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_GoodwillLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_DebtConversionConvertedInstrumentAverageTradePricePercentage" xlink:to="inva_DebtConversionConvertedInstrumentAverageTradePricePercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebtAbstract" xlink:to="us-gaap_InterestExpenseDebtAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedContractCostAbstract" xlink:to="us-gaap_CapitalizedContractCostAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestOnConvertibleDebtNetOfTax" xlink:to="us-gaap_InterestOnConvertibleDebtNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_CollaborativeArrangementRoyaltyRateDefinedLevelTwo" xlink:to="inva_CollaborativeArrangementRoyaltyRateDefinedLevelTwo_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_AccruedRoyaltyObligations" xlink:to="inva_AccruedRoyaltyObligations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrealizedGainLossOnInvestments" xlink:to="us-gaap_UnrealizedGainLossOnInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncontrollingInterestMember" xlink:to="us-gaap_NoncontrollingInterestMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesLongTermContractsOrPrograms" xlink:to="us-gaap_ReceivablesLongTermContractsOrPrograms_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_SecuritiesPurchaseAgreementNumberOfTranches" xlink:to="inva_SecuritiesPurchaseAgreementNumberOfTranches_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_WeightedAverageMember" xlink:to="srt_WeightedAverageMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_DebtInstrumentRatioOfRepurchasePriceToThePrincipalAmount" xlink:to="inva_DebtInstrumentRatioOfRepurchasePriceToThePrincipalAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseBorrowings" xlink:to="us-gaap_InterestExpenseBorrowings_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_EquityMethodInvestment" xlink:to="inva_EquityMethodInvestment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_CustomerTwoMember" xlink:to="inva_CustomerTwoMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_RelatedPartyTransactionsPolicyTextBlock" xlink:to="inva_RelatedPartyTransactionsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_InventoryFairValueStepUpAdjustmentIncludedInCostOfProductSales" xlink:to="inva_InventoryFairValueStepUpAdjustmentIncludedInCostOfProductSales_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_IntangibleAssetsInProcessResearchAndDevelopmentGross" xlink:to="inva_IntangibleAssetsInProcessResearchAndDevelopmentGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_IncomeTaxesTable" xlink:to="inva_IncomeTaxesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_RiskFreeInterestRate" xlink:to="inva_RiskFreeInterestRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtFairValueDisclosures" xlink:to="us-gaap_ConvertibleDebtFairValueDisclosures_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_PurchaseOfEntasisNoncontrollingInterest" xlink:to="inva_PurchaseOfEntasisNoncontrollingInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_DeferredRoyaltyObligations" xlink:to="inva_DeferredRoyaltyObligations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_LimitedPartnersInitialContribution" xlink:to="inva_LimitedPartnersInitialContribution_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_NumberOfDerivativeInstrumentsPurchased" xlink:to="inva_NumberOfDerivativeInstrumentsPurchased_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ClaimExpirationDate" xlink:to="inva_ClaimExpirationDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_NetIncomeLossPerShareAbstract" xlink:to="inva_NetIncomeLossPerShareAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestPeriodIncreaseDecrease" xlink:to="us-gaap_MinorityInterestPeriodIncreaseDecrease_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_EuropeMember" xlink:to="srt_EuropeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonValue" xlink:to="us-gaap_TreasuryStockCommonValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_HealthCareRoyaltyPartnersMember" xlink:to="inva_HealthCareRoyaltyPartnersMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_PaymentOfManagementAndIncentiveFee" xlink:to="inva_PaymentOfManagementAndIncentiveFee_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_CommonStockAndWarrantsMember" xlink:to="inva_CommonStockAndWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_NonCashActivity" xlink:to="inva_NonCashActivity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfGoodwillTable" xlink:to="us-gaap_ScheduleOfGoodwillTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_CashPaidForTheAcquisitionOfLaJollaPharmaceuticalCompanyNetOfCashAcquired" xlink:to="inva_CashPaidForTheAcquisitionOfLaJollaPharmaceuticalCompanyNetOfCashAcquired_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares" xlink:to="inva_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ReductionToAdditionalPaidInCapital" xlink:to="inva_ReductionToAdditionalPaidInCapital_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_SeriesD1PreferredStockMember" xlink:to="inva_SeriesD1PreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_DerecognitionOfNoncontrollingInterestsUponSaleOfTrc" xlink:to="inva_DerecognitionOfNoncontrollingInterestsUponSaleOfTrc_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_DescriptionOfOperationsPolicyTextBlock" xlink:to="inva_DescriptionOfOperationsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_DividendYield" xlink:to="inva_DividendYield_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_CashDistributionReceived" xlink:to="inva_CashDistributionReceived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_RoyaltyAgreementMaximumPotentialPayoutPercent" xlink:to="inva_RoyaltyAgreementMaximumPotentialPayoutPercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_NameOfEventDomain" xlink:to="inva_NameOfEventDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_BurlingameCaliforniaMember" xlink:to="inva_BurlingameCaliforniaMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_AstrazenecaMember" xlink:to="inva_AstrazenecaMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:to="us-gaap_PaymentOfFinancingAndStockIssuanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:to="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ConsolidatedInvesteesMember" xlink:to="inva_ConsolidatedInvesteesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_PercentageOfEstimatedVolatility" xlink:to="inva_PercentageOfEstimatedVolatility_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_RightOfUseAssetsObtainedThroughAcquistions" xlink:to="inva_RightOfUseAssetsObtainedThroughAcquistions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="srt_ConsolidatedEntitiesDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentsPolicy" xlink:to="us-gaap_EquityMethodInvestmentsPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ScheduleOfBalanceSheetInformationRelatedToOperatingLeaseTableTextBlock" xlink:to="inva_ScheduleOfBalanceSheetInformationRelatedToOperatingLeaseTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNet" xlink:to="us-gaap_AccountsReceivableNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_TwoDirectorsMember" xlink:to="inva_TwoDirectorsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesInvestments" xlink:to="us-gaap_DeferredTaxLiabilitiesInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_BalanceSheetDisclosuresOfVariableInterestEntityAbstract" xlink:to="inva_BalanceSheetDisclosuresOfVariableInterestEntityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtCurrent" xlink:to="us-gaap_LongTermDebtCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ConvertiblePromissoryNotePurchaseAgreementMember" xlink:to="inva_ConvertiblePromissoryNotePurchaseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveAndOverlappingOfferingPeriod" xlink:to="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveAndOverlappingOfferingPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_CostReimbursements" xlink:to="inva_CostReimbursements_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:to="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersShares" xlink:to="inva_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_LaboratoryEquipmentFurnitureAndFixturesMember" xlink:to="inva_LaboratoryEquipmentFurnitureAndFixturesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_EverestMedicinesLimitedMember" xlink:to="inva_EverestMedicinesLimitedMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonUsMember" xlink:to="us-gaap_NonUsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:to="us-gaap_BusinessAcquisitionsProFormaRevenue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_WalthamMassachusettsMember" xlink:to="inva_WalthamMassachusettsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAcquiredFromAcquisition" xlink:to="us-gaap_CashAcquiredFromAcquisition_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_OtherAccruedLiabilitiesMember" xlink:to="inva_OtherAccruedLiabilitiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:to="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:to="us-gaap_ScheduleOfVariableInterestEntitiesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_DeferredTaxLiabilitiesInventoryFairValueAdjustment" xlink:to="inva_DeferredTaxLiabilitiesInventoryFairValueAdjustment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:to="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_PriorPeriodImmaterialCorrectionPolicyTextBlock" xlink:to="inva_PriorPeriodImmaterialCorrectionPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansPayableMember" xlink:to="us-gaap_LoansPayableMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonShares" xlink:to="us-gaap_TreasuryStockCommonShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ConvertibleNoteAndWarrantsMember" xlink:to="inva_ConvertibleNoteAndWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee" xlink:to="inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_CommercialSupplyAgreementMember" xlink:to="inva_CommercialSupplyAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_RegulatoryMilestonePaymentsReceivable" xlink:to="inva_RegulatoryMilestonePaymentsReceivable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_IntangibleAssetsMarketedProductsAccumulatedAmortization" xlink:to="inva_IntangibleAssetsMarketedProductsAccumulatedAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_DebtInstrumentConvertibleConversionPremium" xlink:to="inva_DebtInstrumentConvertibleConversionPremium_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_PercentageOfReimbursedForDirectAndCertainIndirectManufacturingCosts" xlink:to="inva_PercentageOfReimbursedForDirectAndCertainIndirectManufacturingCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_LongActingBeta2AgonistRelvarBreoMember" xlink:to="inva_LongActingBeta2AgonistRelvarBreoMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_TheravanceRespiratoryCompanyLlcMember" xlink:to="inva_TheravanceRespiratoryCompanyLlcMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods" xlink:to="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ImaginabConvertibleNoteMember" xlink:to="inva_ImaginabConvertibleNoteMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_RecognitionOfNoncontrollingInterestUponInitialConsolidationofEntasisShares" xlink:to="inva_RecognitionOfNoncontrollingInterestUponInitialConsolidationofEntasisShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_SeriesD2PreferredStockMember" xlink:to="inva_SeriesD2PreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_OperatingLossCarryforwardsIndefinitePeriod" xlink:to="inva_OperatingLossCarryforwardsIndefinitePeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_RoyaltyPayments" xlink:to="inva_RoyaltyPayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtByMaturityAbstract" xlink:to="us-gaap_LongTermDebtByMaturityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MembersEquity" xlink:to="us-gaap_MembersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_AccruedContractManufacturingLiability" xlink:to="inva_AccruedContractManufacturingLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedPersonnelRelatedExpenses" xlink:to="inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedPersonnelRelatedExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_IntangibleAssetsMarketedProductsGross" xlink:to="inva_IntangibleAssetsMarketedProductsGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_RelatedPartyTransactionCommonStockOwnershipPercentageByRelatedParty" xlink:to="inva_RelatedPartyTransactionCommonStockOwnershipPercentageByRelatedParty_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_DerecognitionOfNoncontrollingInterestsUponSaleOfTrcShares" xlink:to="inva_DerecognitionOfNoncontrollingInterestsUponSaleOfTrcShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_DerecognitionOfNonControllingInterestsUponAcquisitionOfEntasisMinorityInterest" xlink:to="inva_DerecognitionOfNonControllingInterestsUponAcquisitionOfEntasisMinorityInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedIncomeTaxesCurrent" xlink:to="us-gaap_AccruedIncomeTaxesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ArmataConvertibleNoteMember" xlink:to="inva_ArmataConvertibleNoteMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ReductionToResearchAndDevelopmentExpense" xlink:to="inva_ReductionToResearchAndDevelopmentExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ShareRepurchaseAgreementWithGlaxoGroupLimitedMember" xlink:to="inva_ShareRepurchaseAgreementWithGlaxoGroupLimitedMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_WarrantsAcquiredInSecondQuarterOf2021Member" xlink:to="inva_WarrantsAcquiredInSecondQuarterOf2021Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PutOptionMember" xlink:to="us-gaap_PutOptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_AccruedClinicalLiability" xlink:to="inva_AccruedClinicalLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_PercentageOfMinimumRoyaltyRate" xlink:to="inva_PercentageOfMinimumRoyaltyRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate" xlink:to="inva_CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_SecuritiesPurchaseAgreementWarrantsNumberOfSecuritiesCalledByWarrants" xlink:to="inva_SecuritiesPurchaseAgreementWarrantsNumberOfSecuritiesCalledByWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity" xlink:to="inva_ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_NumberOfSharesReceivableOnSettlementOfDerivativeInstrument" xlink:to="inva_NumberOfSharesReceivableOnSettlementOfDerivativeInstrument_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdateExtensibleList" xlink:to="us-gaap_AccountingStandardsUpdateExtensibleList_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDilutedLineItems" xlink:to="us-gaap_EarningsPerShareDilutedLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_AccruedInterestIncomeIncludedInLongTermInvestments" xlink:to="inva_AccruedInterestIncomeIncludedInLongTermInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:to="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_SeriesD1WarrantMember" xlink:to="inva_SeriesD1WarrantMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashIncomeExpense" xlink:to="us-gaap_OtherNoncashIncomeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeconsolidationGainOrLossAmount" xlink:to="us-gaap_DeconsolidationGainOrLossAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebt" xlink:to="us-gaap_RepaymentsOfDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_XeravaMember" xlink:to="inva_XeravaMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_LicenseAndCollaborationArrangementsDisclosureTextBlock" xlink:to="inva_LicenseAndCollaborationArrangementsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_LabaCollaborationMember" xlink:to="inva_LabaCollaborationMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyMember" xlink:to="us-gaap_RoyaltyMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoanRestructuringModificationDomain" xlink:to="us-gaap_LoanRestructuringModificationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense" xlink:to="us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_SeriesD2WarrantMember" xlink:to="inva_SeriesD2WarrantMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_DeferredTaxLiabilitiesDepreciationAndAmortization" xlink:to="inva_DeferredTaxLiabilitiesDepreciationAndAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_DeferredRevenue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationTechniqueDomain" xlink:to="us-gaap_ValuationTechniqueDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:to="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseMember" xlink:to="us-gaap_LicenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ArmataPharmaceuticalsIncMember" xlink:to="inva_ArmataPharmaceuticalsIncMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_EquityInvestmentsAndMoneyMarketFundsMember" xlink:to="inva_EquityInvestmentsAndMoneyMarketFundsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_SubscriptionAgreementOneTimeMilestonePaymentOnCommercialSales" xlink:to="inva_SubscriptionAgreementOneTimeMilestonePaymentOnCommercialSales_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedContractCostTable" xlink:to="us-gaap_CapitalizedContractCostTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementRelatedDisclosuresAbstract" xlink:to="us-gaap_IncomeStatementRelatedDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyAllegations" xlink:to="us-gaap_LossContingencyAllegations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LongtermDebtTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_CreditAndSecurityAgreementMember" xlink:to="inva_CreditAndSecurityAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedContractCostLineItems" xlink:to="us-gaap_CapitalizedContractCostLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_DilutiveEpsOfNotes" xlink:to="inva_DilutiveEpsOfNotes_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_WarrantsPurchasedIn2022Member" xlink:to="inva_WarrantsPurchasedIn2022Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_NumberOfBoardMembersOfInvestee" xlink:to="inva_NumberOfBoardMembersOfInvestee_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_NoteAmendmentAgreementMember" xlink:to="inva_NoteAmendmentAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ConvertiblePromissoryNoteMember" xlink:to="inva_ConvertiblePromissoryNoteMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_GainLossOnOtherInvestments" xlink:to="inva_GainLossOnOtherInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_SeriesA1PreferredStockMember" xlink:to="inva_SeriesA1PreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_EntasisLeaseMember" xlink:to="inva_EntasisLeaseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesDPreferredStockMember" xlink:to="us-gaap_SeriesDPreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ScheduleOfConsolidatedEntitiesAndBusinessAcquisitionsByAcquisitionTable" xlink:to="inva_ScheduleOfConsolidatedEntitiesAndBusinessAcquisitionsByAcquisitionTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_CapitalizedFeesPaidPolicyTextBlock" xlink:to="inva_CapitalizedFeesPaidPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="us-gaap_LeaseContractualTermDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_OutstandingStockWarrantMember" xlink:to="inva_OutstandingStockWarrantMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_PaymentsForRoyaltyAgreement" xlink:to="inva_PaymentsForRoyaltyAgreement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_StrategicAllianceAgreementMember" xlink:to="inva_StrategicAllianceAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="srt_EquityMethodInvesteeNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_PrivatelyNegotiatedCappedCallOptionMember" xlink:to="inva_PrivatelyNegotiatedCappedCallOptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="us-gaap_InProcessResearchAndDevelopmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_EntasisTherapeuticsHoldingsIncMember" xlink:to="inva_EntasisTherapeuticsHoldingsIncMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_DeferredTaxAssetsDeferredRoyaltyObligationNet" xlink:to="inva_DeferredTaxAssetsDeferredRoyaltyObligationNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_AccruedProfessionalServices" xlink:to="inva_AccruedProfessionalServices_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_IntangibleAssetsCollaborationAgreementNet" xlink:to="inva_IntangibleAssetsCollaborationAgreementNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:to="us-gaap_BusinessAcquisitionProFormaInformationTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:to="us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_SaleOfWarrantsNumberOfWarrantsIssuedInTransaction" xlink:to="inva_SaleOfWarrantsNumberOfWarrantsIssuedInTransaction_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_NetProceedsFromSaleOfVariableInterestEntityEquity" xlink:to="inva_NetProceedsFromSaleOfVariableInterestEntityEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_DerecognitionOfNoncontrollingInterestsUponAcquisitionOfEntasisMinorityInterestShares" xlink:to="inva_DerecognitionOfNoncontrollingInterestsUponAcquisitionOfEntasisMinorityInterestShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:to="us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_IntangibleAssetsCollaborationAgreementGross" xlink:to="inva_IntangibleAssetsCollaborationAgreementGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_DeferredRoyaltyObligationCurrent" xlink:to="inva_DeferredRoyaltyObligationCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationDeductionsOther" xlink:to="us-gaap_IncomeTaxReconciliationDeductionsOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_UnrecognizedTaxBenefitsDecreaseResultingFromCurrentPeriodTaxPositionsNet" xlink:to="inva_UnrecognizedTaxBenefitsDecreaseResultingFromCurrentPeriodTaxPositionsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_OwnershipInterestInConsolidatedEntities" xlink:to="inva_OwnershipInterestInConsolidatedEntities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtCurrent" xlink:to="us-gaap_DebtCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ProceedsFromSaleOfEconomicInterestUnderEquityPurchaseAgreement" xlink:to="inva_ProceedsFromSaleOfEconomicInterestUnderEquityPurchaseAgreement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_WarrantsPurchasedIn2020Member" xlink:to="inva_WarrantsPurchasedIn2020Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_SeriesDWarrantsMember" xlink:to="inva_SeriesDWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:to="us-gaap_ScheduleOfVariableInterestEntitiesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AcquisitionCosts" xlink:to="us-gaap_AcquisitionCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ResearchAndDevelopmentSupportMember" xlink:to="inva_ResearchAndDevelopmentSupportMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareRepurchaseProgramAxis" xlink:to="us-gaap_ShareRepurchaseProgramAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_UnrecognizedTaxBenefitsIncreaseResultingFromCurrentPeriodTaxPositionsNet" xlink:to="inva_UnrecognizedTaxBenefitsIncreaseResultingFromCurrentPeriodTaxPositionsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_CarryingValueWroteOffWarrantExercise" xlink:to="inva_CarryingValueWroteOffWarrantExercise_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCostAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:to="us-gaap_EquitySecuritiesFvNiUnrealizedLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalEquityGrantValue" xlink:to="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalEquityGrantValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees" xlink:to="inva_GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_SpecialTermReDesignatingBoardMemberToBoardOfInvestee" xlink:to="inva_SpecialTermReDesignatingBoardMemberToBoardOfInvestee_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToMinorityShareholders" xlink:to="us-gaap_PaymentsToMinorityShareholders_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_EquityIncentivePlansAndESPPMember" xlink:to="inva_EquityIncentivePlansAndESPPMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_IntangibleAssetsInProcessResearchAndDevelopmentNet" xlink:to="inva_IntangibleAssetsInProcessResearchAndDevelopmentNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpensePolicyTextBlock" xlink:to="us-gaap_InterestExpensePolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentDescription" xlink:to="us-gaap_DebtInstrumentDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_TermLoanInvestmentMember" xlink:to="inva_TermLoanInvestmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtInShares" xlink:to="inva_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtInShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_DecreaseToAccumulatedDeficit" xlink:to="inva_DecreaseToAccumulatedDeficit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:to="us-gaap_EquitySecuritiesFvNiRealizedGainLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_AccruedLicenseFeesAndRoyalties" xlink:to="inva_AccruedLicenseFeesAndRoyalties_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesFvNi" xlink:to="us-gaap_EquitySecuritiesFvNi_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_DebtInstrumentPrincipalAmount" xlink:to="inva_DebtInstrumentPrincipalAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingNumber" xlink:to="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterest" xlink:to="us-gaap_MinorityInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_RealizedLoss" xlink:to="inva_RealizedLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_IncomeStatementDisclosuresOfVariableInterestEntityAbstract" xlink:to="inva_IncomeStatementDisclosuresOfVariableInterestEntityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:to="us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_SaleOfEquityInvestmentsManagedByIspFundLp" xlink:to="inva_SaleOfEquityInvestmentsManagedByIspFundLp_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement" xlink:to="inva_SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionRatio1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_EmployeeStockPurchasePlanMember" xlink:to="inva_EmployeeStockPurchasePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_OldDebtInstrumentInterestRateBeforeRepurchaseOfNotesMember" xlink:to="inva_OldDebtInstrumentInterestRateBeforeRepurchaseOfNotesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_RecognitionOfNoncontrollingInterestUponInitialConsolidationOfEntasis" xlink:to="inva_RecognitionOfNoncontrollingInterestUponInitialConsolidationOfEntasis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:to="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_Rule10B51ArrModifiedFlag" xlink:to="inva_Rule10B51ArrModifiedFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" xlink:to="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_RoyaltyAgreementIncreaseInMaximumPotentialPayoutPercent" xlink:to="inva_RoyaltyAgreementIncreaseInMaximumPotentialPayoutPercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_FairValueAdjustmentsOfInventoryFromAcquistion" xlink:to="inva_FairValueAdjustmentsOfInventoryFromAcquistion_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_TrelegyElliptaMember" xlink:to="inva_TrelegyElliptaMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_PercentageOfEconomicInterestInPartnership" xlink:to="inva_PercentageOfEconomicInterestInPartnership_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ConvertibleSubordinatedDebtFairValueDisclosures" xlink:to="inva_ConvertibleSubordinatedDebtFairValueDisclosures_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LimitedPartnersCumulativeCashDistributions" xlink:to="us-gaap_LimitedPartnersCumulativeCashDistributions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_OptionPricingModelBacksolveValuationMember" xlink:to="inva_OptionPricingModelBacksolveValuationMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_AccruedResearchLiability" xlink:to="inva_AccruedResearchLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseBorrowingsAbstract" xlink:to="us-gaap_InterestExpenseBorrowingsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_PartnershipAgreementLockUpPeriod" xlink:to="inva_PartnershipAgreementLockUpPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ConvertibleSeniorDebtFairValueDisclosures" xlink:to="inva_ConvertibleSeniorDebtFairValueDisclosures_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityCovenantTerms" xlink:to="us-gaap_LineOfCreditFacilityCovenantTerms_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_IncreaseDecreaseInDeferredTaxAssets" xlink:to="inva_IncreaseDecreaseInDeferredTaxAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedContractCostTableTextBlock" xlink:to="us-gaap_CapitalizedContractCostTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_SecuritiesPurchaseAgreementRightsToDesignateInvesteeBoardMembersNumberOfBoardMembers" xlink:to="inva_SecuritiesPurchaseAgreementRightsToDesignateInvesteeBoardMembersNumberOfBoardMembers_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:to="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_InventoryLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_GiaprezaMember" xlink:to="inva_GiaprezaMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_WarrantsAcquiredInSecondQuarterOf2020Member" xlink:to="inva_WarrantsAcquiredInSecondQuarterOf2020Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments" xlink:to="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_Percent2.50ConvertibleDebtMember" xlink:to="inva_Percent2.50ConvertibleDebtMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_SecuritiesPurchaseAgreementTotalNumberOfWarrantsToBePurchasedUnderAgreement" xlink:to="inva_SecuritiesPurchaseAgreementTotalNumberOfWarrantsToBePurchasedUnderAgreement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_PurchaseAndSaleOfOtherInvestmentsManagedByIspFundLp" xlink:to="inva_PurchaseAndSaleOfOtherInvestmentsManagedByIspFundLp_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_PurchasesOfCappedCallOptionsAssociatedWithConvertibleSeniorNotes" xlink:to="inva_PurchasesOfCappedCallOptionsAssociatedWithConvertibleSeniorNotes_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ShortTermDebtTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_WarrantsPurchasedIn2021Member" xlink:to="inva_WarrantsPurchasedIn2021Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:to="us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_TermOfMilestonePaymentForNetSales" xlink:to="inva_TermOfMilestonePaymentForNetSales_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_PercentageOfMaximumRoyaltyBasedOnAchievementOfAnnualNetProductSalesThresholds" xlink:to="inva_PercentageOfMaximumRoyaltyBasedOnAchievementOfAnnualNetProductSalesThresholds_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_IncrementalCommonSharesAttributableToConversionOfDebtSecuritiesTreasuryStockMethod" xlink:to="inva_IncrementalCommonSharesAttributableToConversionOfDebtSecuritiesTreasuryStockMethod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFour" xlink:to="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFour_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsGrossExcludingGoodwill_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityGrantValue" xlink:to="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityGrantValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_IspFundLpMember" xlink:to="inva_IspFundLpMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ContingentValueRightsLiability" xlink:to="inva_ContingentValueRightsLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_SecuredConvertibleCreditAgreementMember" xlink:to="inva_SecuredConvertibleCreditAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_DebtConversionCommonStockPriceToConversionPriceRatioPercentage" xlink:to="inva_DebtConversionCommonStockPriceToConversionPriceRatioPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntityShares" xlink:to="inva_ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntityShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AcquiredFiniteLivedIntangibleAssetResidualValue" xlink:to="us-gaap_AcquiredFiniteLivedIntangibleAssetResidualValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:to="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRepurchaseAmount" xlink:to="us-gaap_DebtInstrumentRepurchaseAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_PaionAgMember" xlink:to="inva_PaionAgMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_EquityIncentivePlan2012Member" xlink:to="inva_EquityIncentivePlan2012Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_PercentageOfRoyaltyOnPaymentsReceivedFromSublicensees" xlink:to="inva_PercentageOfRoyaltyOnPaymentsReceivedFromSublicensees_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnInvestments" xlink:to="us-gaap_GainLossOnInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearthree" xlink:to="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearthree_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_WarrantsAcquiredInThirdQuarterOf2020Member" xlink:to="inva_WarrantsAcquiredInThirdQuarterOf2020Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="srt_NameOfMajorCustomerDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_JP" xlink:to="country_JP_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_PreferredStockWarrantsMember" xlink:to="inva_PreferredStockWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_DebtInstrumentRepurchasePercentage" xlink:to="inva_DebtInstrumentRepurchasePercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:to="us-gaap_PaymentsToAcquireEquityMethodInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:to="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityStrikePrice1" xlink:to="us-gaap_OptionIndexedToIssuersEquityStrikePrice1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_MeasurementPeriodAdjustmentsIncreaseDecreaseInEstimatedPurchasePrice" xlink:to="inva_MeasurementPeriodAdjustmentsIncreaseDecreaseInEstimatedPurchasePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_OneOfImaginabsCommonStockholderMember" xlink:to="inva_OneOfImaginabsCommonStockholderMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_CustomerThreeMember" xlink:to="inva_CustomerThreeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedContractCostAccumulatedAmortization" xlink:to="us-gaap_CapitalizedContractCostAccumulatedAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_NanoliveMember" xlink:to="inva_NanoliveMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_DeferredTaxAssetsUnrealizedLossesOnInvestmentNet" xlink:to="inva_DeferredTaxAssetsUnrealizedLossesOnInvestmentNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_IncomeTaxesLineItems" xlink:to="inva_IncomeTaxesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_DenominatorAbstract" xlink:to="inva_DenominatorAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ExpectedHoldingPeriod" xlink:to="inva_ExpectedHoldingPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:to="us-gaap_FinancialInstrumentsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_CollaborativeArrangementsMember" xlink:to="inva_CollaborativeArrangementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtTableTextBlock" xlink:to="us-gaap_ConvertibleDebtTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_IncreaseInDeferredTaxAssets" xlink:to="inva_IncreaseInDeferredTaxAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_PercentageOfEconomicInterestOnFuturePaymentsUnderAgreements" xlink:to="inva_PercentageOfEconomicInterestOnFuturePaymentsUnderAgreements_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_VotingAgreementMaximumVotingRightsPercent" xlink:to="inva_VotingAgreementMaximumVotingRightsPercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFairValue" xlink:to="us-gaap_DebtInstrumentFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_DeferredRoyaltyObligationNonCurrent" xlink:to="inva_DeferredRoyaltyObligationNonCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_SeriesCWarrantsAndSeriesDWarrantsMember" xlink:to="inva_SeriesCWarrantsAndSeriesDWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_Incarda2020WarrantsMember" xlink:to="inva_Incarda2020WarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_PropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:to="inva_PropertyPlantAndEquipmentUsefulLifeTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_PresentationReclassificationPolicyTextBlock" xlink:to="inva_PresentationReclassificationPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_LaJollaMember" xlink:to="inva_LaJollaMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_SecuritiesPurchaseAgreementAmount" xlink:to="inva_SecuritiesPurchaseAgreementAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_TwoThousandTwentyEightNotesMember" xlink:to="inva_TwoThousandTwentyEightNotesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAccountsReceivableMember" xlink:to="us-gaap_TradeAccountsReceivableMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:to="us-gaap_ConsolidationVariableInterestEntityPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_PercentageOfRoyaltyPaymentsNotEntitledToReceive" xlink:to="inva_PercentageOfRoyaltyPaymentsNotEntitledToReceive_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_DemandLettersSentByStockholders" xlink:to="inva_DemandLettersSentByStockholders_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_NonRule10B51ArrModifiedFlag" xlink:to="inva_NonRule10B51ArrModifiedFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareRepurchaseProgramDomain" xlink:to="us-gaap_ShareRepurchaseProgramDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ConsolidatedEntitiesAndAcquisitionsDisclosureAbstract" xlink:to="inva_ConsolidatedEntitiesAndAcquisitionsDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_SeriesCPreferredStockAndWarrantsMember" xlink:to="inva_SeriesCPreferredStockAndWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_CollaborativeArrangementRoyaltyRateDefinedLevelOne" xlink:to="inva_CollaborativeArrangementRoyaltyRateDefinedLevelOne_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_CommonStockAcquiredAverageCostPerShare" xlink:to="inva_CommonStockAcquiredAverageCostPerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentPrincipal_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedContractCostNet" xlink:to="us-gaap_CapitalizedContractCostNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_SeriesC2PreferredStockMember" xlink:to="inva_SeriesC2PreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_InCardaConvertibleNoteMember" xlink:to="inva_InCardaConvertibleNoteMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFive" xlink:to="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFive_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermInvestments" xlink:to="us-gaap_LongTermInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_FuturePotentialMilestonePayment" xlink:to="inva_FuturePotentialMilestonePayment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:to="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_InterestRateOfDeferredRoyaltyObligation" xlink:to="inva_InterestRateOfDeferredRoyaltyObligation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockSharesAcquired" xlink:to="us-gaap_TreasuryStockSharesAcquired_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtCurrent" xlink:to="us-gaap_ConvertibleDebtCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_PurchasesOfCappedCallsInConnectionWithConvertibleSeniorNotes" xlink:to="inva_PurchasesOfCappedCallsInConnectionWithConvertibleSeniorNotes_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CallOptionMember" xlink:to="us-gaap_CallOptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_IntangibleAssetsMarketedProductsNet" xlink:to="inva_IntangibleAssetsMarketedProductsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_EmployeeStockPurchasePlanTwentyTwentyThreeMember" xlink:to="inva_EmployeeStockPurchasePlanTwentyTwentyThreeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_SalesMilestonePaymentsReceivable" xlink:to="inva_SalesMilestonePaymentsReceivable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary" xlink:to="us-gaap_IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="us-gaap_VariableInterestEntityLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedContractCostAmortization" xlink:to="us-gaap_CapitalizedContractCostAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_SeniorUnsecuredConvertibleNotesMember" xlink:to="inva_SeniorUnsecuredConvertibleNotesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentTwo" xlink:to="inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentTwo_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_RoyaltyFinancingAgreementMember" xlink:to="inva_RoyaltyFinancingAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:to="inva_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_LicenseRevenueRecognized" xlink:to="inva_LicenseRevenueRecognized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeCapPrice" xlink:to="us-gaap_DerivativeCapPrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_VariableRateDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_PercentageOfRoyaltyPayableOnNetSales" xlink:to="inva_PercentageOfRoyaltyPayableOnNetSales_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_PrivatePlacementPositionsAndConvertibleNotesMember" xlink:to="inva_PrivatePlacementPositionsAndConvertibleNotesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember" xlink:to="inva_InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_PortionOfDebtInstrumentFaceAmountExercised" xlink:to="inva_PortionOfDebtInstrumentFaceAmountExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfUnsecuredDebt" xlink:to="us-gaap_RepaymentsOfUnsecuredDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_IntangibleAssetsInProcessResearchAndDevelopmentAccumulatedAmortization" xlink:to="inva_IntangibleAssetsInProcessResearchAndDevelopmentAccumulatedAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_NewDebtInstrumentInterestRateAfterRepurchaseOfNotesMember" xlink:to="inva_NewDebtInstrumentInterestRateAfterRepurchaseOfNotesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilities" xlink:to="us-gaap_OtherLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_LongTermDebtNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_BalanceSheetRelatedDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_SeriesD1AndD2PreferredStockAndCommonStockMember" xlink:to="inva_SeriesD1AndD2PreferredStockAndCommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleSubordinatedDebtMember" xlink:to="us-gaap_ConvertibleSubordinatedDebtMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ConsolidatedEntitiesAndAcquisitionsTextBlock" xlink:to="inva_ConsolidatedEntitiesAndAcquisitionsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent" xlink:to="us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ContingentSalesBasedMilestonePayment" xlink:to="inva_ContingentSalesBasedMilestonePayment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:to="us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_IntangibleAssetsCollaborationAgreementAccumulatedAmortization" xlink:to="inva_IntangibleAssetsCollaborationAgreementAccumulatedAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementMember" xlink:to="us-gaap_CollaborativeArrangementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableInterestEntityOwnershipPercentage" xlink:to="us-gaap_VariableInterestEntityOwnershipPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_AmortizationOfCapitalizedFeesAndDepreciationOfPropertyAndEquipment" xlink:to="inva_AmortizationOfCapitalizedFeesAndDepreciationOfPropertyAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_GateNeuroscienceMember" xlink:to="inva_GateNeuroscienceMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:to="us-gaap_DebtLongtermAndShorttermCombinedAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationAfterYearFive" xlink:to="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationAfterYearFive_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_CapitalizedFeesPaidWeightedAverageUsefulLife" xlink:to="inva_CapitalizedFeesPaidWeightedAverageUsefulLife_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_MeasurementPeriodAdjustmentsIncreaseDecreaseInLiabilities" xlink:to="inva_MeasurementPeriodAdjustmentsIncreaseDecreaseInLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_OneDirectorMember" xlink:to="inva_OneDirectorMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:to="us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ArmataTermLoanMember" xlink:to="inva_ArmataTermLoanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_GSKMember" xlink:to="inva_GSKMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestAndDividendIncomeOperating" xlink:to="us-gaap_InterestAndDividendIncomeOperating_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_NetOperatingLossEstimatingDate" xlink:to="inva_NetOperatingLossEstimatingDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_LaJollaPharmaceuticalCompanyMember" xlink:to="inva_LaJollaPharmaceuticalCompanyMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_CapitalizedFeesPaidDisclosureTextBlock" xlink:to="inva_CapitalizedFeesPaidDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ProfitLossShares" xlink:to="inva_ProfitLossShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsNonrecurringMember" xlink:to="us-gaap_FairValueMeasurementsNonrecurringMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesCPreferredStockMember" xlink:to="us-gaap_SeriesCPreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductMember" xlink:to="us-gaap_ProductMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_FederalNetOperatingLossesEstimatedUtilizationAmount" xlink:to="inva_FederalNetOperatingLossesEstimatedUtilizationAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestments" xlink:to="us-gaap_EquityMethodInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_BusinessAcquisitionsOfChangeInFairValueOfInvestment" xlink:to="inva_BusinessAcquisitionsOfChangeInFairValueOfInvestment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralPartnerMember" xlink:to="us-gaap_GeneralPartnerMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialEquityGrantValue" xlink:to="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialEquityGrantValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" xlink:to="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_DebtInstrumentTransactionCost" xlink:to="inva_DebtInstrumentTransactionCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="us-gaap_TreasuryStockValueAcquiredCostMethod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="inva_SummaryOfSignificantAccountingPoliciesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_SecuritiesPurchaseAgreementMember" xlink:to="inva_SecuritiesPurchaseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesMember" xlink:to="us-gaap_EquitySecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesFvNiUnrealizedGain" xlink:to="us-gaap_EquitySecuritiesFvNiUnrealizedGain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:to="us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_LicenseRevenueMember" xlink:to="inva_LicenseRevenueMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_NumeratorAbstract" xlink:to="inva_NumeratorAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonMember" xlink:to="us-gaap_TreasuryStockCommonMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_IncomeTaxPayableNonCurrent" xlink:to="inva_IncomeTaxPayableNonCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_XacduroMember" xlink:to="inva_XacduroMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ImaginabMember" xlink:to="inva_ImaginabMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairmentLoss" xlink:to="us-gaap_GoodwillImpairmentLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_UnrecognizedTaxBenefitsDecreaseResultingFromPriorPeriodTaxPositionsNet" xlink:to="inva_UnrecognizedTaxBenefitsDecreaseResultingFromPriorPeriodTaxPositionsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_LongActingBeta2AgonistAnoroMember" xlink:to="inva_LongActingBeta2AgonistAnoroMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_SummaryOfSignificantAccountingPoliciesTable" xlink:to="inva_SummaryOfSignificantAccountingPoliciesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_NumberOfCommonStockIssuedDescription" xlink:to="inva_NumberOfCommonStockIssuedDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts" xlink:to="inva_CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetRentableArea" xlink:to="us-gaap_NetRentableArea_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionSharePrice" xlink:to="us-gaap_BusinessAcquisitionSharePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:to="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedRoyaltiesCurrent" xlink:to="us-gaap_AccruedRoyaltiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_CapitalizedFeePaidEstimatedUsefulLife" xlink:to="inva_CapitalizedFeePaidEstimatedUsefulLife_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_UnrealizedOtherGainLossOnInvestments" xlink:to="inva_UnrealizedOtherGainLossOnInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfTreasuryStockTable" xlink:to="us-gaap_ClassOfTreasuryStockTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ConvertibleDebtInstrumentLiabilityComponentAbstract" xlink:to="inva_ConvertibleDebtInstrumentLiabilityComponentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsPolicy" xlink:to="us-gaap_BusinessCombinationsPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnamortizedDebtIssuanceExpense" xlink:to="us-gaap_UnamortizedDebtIssuanceExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ConcentrationRiskTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtMember" xlink:to="us-gaap_DebtMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate202006Member" xlink:to="us-gaap_AccountingStandardsUpdate202006Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryCurrentTable" xlink:to="us-gaap_InventoryCurrentTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_WithdrawalFromInvestment" xlink:to="inva_WithdrawalFromInvestment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAccruedLiabilities" xlink:to="inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAccruedLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingWeightedAverageFairValuePerShare" xlink:to="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingWeightedAverageFairValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ConsolidatedEntitiesDisclosureAbstract" xlink:to="inva_ConsolidatedEntitiesDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_OperatingLeaseWeightedAverageIncrementalBorrowingRate" xlink:to="inva_OperatingLeaseWeightedAverageIncrementalBorrowingRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LimitedPartnersContributedCapital" xlink:to="us-gaap_LimitedPartnersContributedCapital_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_PurchasesOfTradingSecurityManagedByIspFundLp" xlink:to="inva_PurchasesOfTradingSecurityManagedByIspFundLp_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_StrategicAllianceMabaProgram" xlink:to="inva_StrategicAllianceMabaProgram_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_TwoThousandTwentyThreeNotesMember" xlink:to="inva_TwoThousandTwentyThreeNotesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_CapitalizedFeesPaidToRelatedPartyPolicyTextBlock" xlink:to="inva_CapitalizedFeesPaidToRelatedPartyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryGross" xlink:to="us-gaap_InventoryGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesOther" xlink:to="us-gaap_DeferredTaxLiabilitiesOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_RoyaltiesPayablePeriodAfterFirstCommercialSaleOfProduct" xlink:to="inva_RoyaltiesPayablePeriodAfterFirstCommercialSaleOfProduct_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_QualifiedFinancingMember" xlink:to="inva_QualifiedFinancingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationNextTwelveMonths" xlink:to="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationNextTwelveMonths_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree" xlink:to="inva_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountAsContributionOfEligibleCompensation" xlink:to="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountAsContributionOfEligibleCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ParatekPharmaceuticalsIncMember" xlink:to="inva_ParatekPharmaceuticalsIncMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeographicConcentrationRiskMember" xlink:to="us-gaap_GeographicConcentrationRiskMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_PurchasesOfEquityInvestmentsManagedByIspFundLp" xlink:to="inva_PurchasesOfEquityInvestmentsManagedByIspFundLp_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_FactorsAffectingComparabilityPolicyTextBlock" xlink:to="inva_FactorsAffectingComparabilityPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInvestmentExpense" xlink:to="us-gaap_InvestmentIncomeInvestmentExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_InnovivaCommonStockMember" xlink:to="inva_InnovivaCommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_NumberOfCustomers" xlink:to="inva_NumberOfCustomers_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterestAndDividend" xlink:to="us-gaap_InvestmentIncomeInterestAndDividend_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_SarissaCapitalManagementLpMember" xlink:to="inva_SarissaCapitalManagementLpMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_SoftwareAndComputerEquipmentMember" xlink:to="inva_SoftwareAndComputerEquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_CustomerOneMember" xlink:to="inva_CustomerOneMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_StateNetOperatingLossesEstimatedUtilizationAmount" xlink:to="inva_StateNetOperatingLossesEstimatedUtilizationAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_SecondNoteAmendmentAgreementMember" xlink:to="inva_SecondNoteAmendmentAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfConvertibleDebt" xlink:to="us-gaap_RepaymentsOfConvertibleDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_CapitalizedFeesPaidFutureAmortizationAbstract" xlink:to="inva_CapitalizedFeesPaidFutureAmortizationAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtMember" xlink:to="us-gaap_ConvertibleDebtMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_NameOfEventAxis" xlink:to="inva_NameOfEventAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_TwoThousandTwentyFiveNotesMember" xlink:to="inva_TwoThousandTwentyFiveNotesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfRealEstateProperty" xlink:to="us-gaap_AreaOfRealEstateProperty_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:to="us-gaap_DebtInstrumentRepurchasedFaceAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_IncardaMember" xlink:to="inva_IncardaMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" xlink:to="inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_GeorgeWashingtonUniversityMember" xlink:to="inva_GeorgeWashingtonUniversityMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_NewPrincipalAmountMember" xlink:to="inva_NewPrincipalAmountMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_NetInvestmentRelatedIncomeExpenseEarnedInccured" xlink:to="inva_NetInvestmentRelatedIncomeExpenseEarnedInccured_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireLongtermInvestments" xlink:to="us-gaap_PaymentsToAcquireLongtermInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ClinicalDevelopmentAndRegulatoryMilestonesAmountPayable" xlink:to="inva_ClinicalDevelopmentAndRegulatoryMilestonesAmountPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ExtendedExpirationDate" xlink:to="inva_ExtendedExpirationDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoanRestructuringModificationAxis" xlink:to="us-gaap_LoanRestructuringModificationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_SubscriptionAgreementOneTimeMilestonePaymentOnNetSales" xlink:to="inva_SubscriptionAgreementOneTimeMilestonePaymentOnNetSales_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_InnovivaMember" xlink:to="inva_InnovivaMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_TermOfMilestonePaymentForCommercialSale" xlink:to="inva_TermOfMilestonePaymentForCommercialSale_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebtExcludingAmortization" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearTwo" xlink:to="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearTwo_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncurrentLiabilitiesMember" xlink:to="us-gaap_OtherNoncurrentLiabilitiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_AmortizationOfFairValueAdjustmentsOfCostOfProductsSold" xlink:to="inva_AmortizationOfFairValueAdjustmentsOfCostOfProductsSold_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_IncreaseDecreaseInDeferredTaxLiabilities" xlink:to="inva_IncreaseDecreaseInDeferredTaxLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedContractCostGross" xlink:to="us-gaap_CapitalizedContractCostGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_CostReimbursementMember" xlink:to="inva_CostReimbursementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillPeriodIncreaseDecrease" xlink:to="us-gaap_GoodwillPeriodIncreaseDecrease_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentOne" xlink:to="inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentOne_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ConsolidatedEntitiesAndAcquisitionsLineItems" xlink:to="inva_ConsolidatedEntitiesAndAcquisitionsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ZaiLabMember" xlink:to="inva_ZaiLabMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_HarvardUniversityMember" xlink:to="inva_HarvardUniversityMember_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://www.inva.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="73.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" order="74.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="75.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="76.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="77.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="78.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="79.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="80.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="81.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="82.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="83.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName" order="84.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation" order="85.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId" order="86.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNet" xlink:label="us-gaap_AccountsReceivableNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesLongTermContractsOrPrograms" xlink:label="us-gaap_ReceivablesLongTermContractsOrPrograms"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_EquityMethodInvestment" xlink:label="inva_EquityMethodInvestment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonValue" xlink:label="us-gaap_TreasuryStockCommonValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="us-gaap_ConvertibleDebtCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostNet" xlink:label="us-gaap_CapitalizedContractCostNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_IncomeTaxPayableNonCurrent" xlink:label="inva_IncomeTaxPayableNonCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNet" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LongTermDebtNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_InterestPayableCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ReceivablesLongTermContractsOrPrograms" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="inva_EquityMethodInvestment" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_TreasuryStockCommonValue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_LongTermInvestments" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ConvertibleDebtCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_CapitalizedContractCostNet" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="inva_IncomeTaxPayableNonCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedIncomeTaxesCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Goodwill" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="us-gaap_TreasuryStockCommonShares"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TreasuryStockCommonShares" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfIncome" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyMember" xlink:label="us-gaap_RoyaltyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_CollaborativeArrangementsMember" xlink:label="inva_CollaborativeArrangementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_LicenseRevenueMember" xlink:label="inva_LicenseRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeconsolidationGainOrLossAmount" xlink:label="us-gaap_DeconsolidationGainOrLossAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_GainLossOnOtherInvestments" xlink:label="inva_GainLossOnOtherInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestAndDividendIncomeOperating" xlink:label="us-gaap_InterestAndDividendIncomeOperating"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_RoyaltyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_CostOfRevenue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="inva_CollaborativeArrangementsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="inva_LicenseRevenueMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfitLoss" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_DeconsolidationGainOrLossAmount" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="inva_GainLossOnOtherInvestments" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_InterestAndDividendIncomeOperating" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_InterestExpense" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_CostsAndExpenses" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfIncomeParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_GSKMember" xlink:label="inva_GSKMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyMember" xlink:label="us-gaap_RoyaltyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostAmortization" xlink:label="us-gaap_CapitalizedContractCostAmortization"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="inva_GSKMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_RoyaltyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CapitalizedContractCostAmortization" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveIncome" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_ProfitLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdateExtensibleList" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:label="us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonMember" xlink:label="us-gaap_TreasuryStockCommonMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersShares" xlink:label="inva_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="us-gaap_NoncontrollingInterestMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_RecognitionOfNoncontrollingInterestUponInitialConsolidationOfEntasis" xlink:label="inva_RecognitionOfNoncontrollingInterestUponInitialConsolidationOfEntasis"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_RecognitionOfNoncontrollingInterestUponInitialConsolidationofEntasisShares" xlink:label="inva_RecognitionOfNoncontrollingInterestUponInitialConsolidationofEntasisShares"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity" xlink:label="inva_ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntityShares" xlink:label="inva_ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntityShares"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_DerecognitionOfNoncontrollingInterestsUponSaleOfTrc" xlink:label="inva_DerecognitionOfNoncontrollingInterestsUponSaleOfTrc"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_DerecognitionOfNoncontrollingInterestsUponSaleOfTrcShares" xlink:label="inva_DerecognitionOfNoncontrollingInterestsUponSaleOfTrcShares"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_DerecognitionOfNonControllingInterestsUponAcquisitionOfEntasisMinorityInterest" xlink:label="inva_DerecognitionOfNonControllingInterestsUponAcquisitionOfEntasisMinorityInterest"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_DerecognitionOfNoncontrollingInterestsUponAcquisitionOfEntasisMinorityInterestShares" xlink:label="inva_DerecognitionOfNoncontrollingInterestsUponAcquisitionOfEntasisMinorityInterestShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtInShares" xlink:label="inva_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtInShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:label="us-gaap_TreasuryStockValueAcquiredCostMethod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="us-gaap_TreasuryStockSharesAcquired"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares" xlink:label="inva_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ProfitLossShares" xlink:label="inva_ProfitLossShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_25"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_26"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_CommonStockSharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_AccountingStandardsUpdateExtensibleList" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_TreasuryStockCommonMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="inva_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersShares" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_NoncontrollingInterestMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="inva_RecognitionOfNoncontrollingInterestUponInitialConsolidationOfEntasis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="inva_RecognitionOfNoncontrollingInterestUponInitialConsolidationofEntasisShares" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="inva_ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="inva_ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntityShares" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="inva_DerecognitionOfNoncontrollingInterestsUponSaleOfTrc" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="inva_DerecognitionOfNoncontrollingInterestsUponSaleOfTrcShares" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="inva_DerecognitionOfNonControllingInterestsUponAcquisitionOfEntasisMinorityInterest" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="inva_DerecognitionOfNoncontrollingInterestsUponAcquisitionOfEntasisMinorityInterestShares" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="inva_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtInShares" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_TreasuryStockValueAcquiredCostMethod" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_TreasuryStockSharesAcquired" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="inva_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_ProfitLoss" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="inva_ProfitLossShares" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_25" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_CommonStockSharesOutstanding_26" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_AccruedInterestIncomeIncludedInLongTermInvestments" xlink:label="inva_AccruedInterestIncomeIncludedInLongTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToMinorityShareholders" xlink:label="us-gaap_PaymentsToMinorityShareholders"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:label="us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent" xlink:label="us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_AmortizationOfCapitalizedFeesAndDepreciationOfPropertyAndEquipment" xlink:label="inva_AmortizationOfCapitalizedFeesAndDepreciationOfPropertyAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_NonCashActivity" xlink:label="inva_NonCashActivity"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_PurchaseOfEntasisNoncontrollingInterest" xlink:label="inva_PurchaseOfEntasisNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireLongtermInvestments" xlink:label="us-gaap_PaymentsToAcquireLongtermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_InventoryFairValueStepUpAdjustmentIncludedInCostOfProductSales" xlink:label="inva_InventoryFairValueStepUpAdjustmentIncludedInCostOfProductSales"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_PurchasesOfEquityInvestmentsManagedByIspFundLp" xlink:label="inva_PurchasesOfEquityInvestmentsManagedByIspFundLp"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_PurchasesOfTradingSecurityManagedByIspFundLp" xlink:label="inva_PurchasesOfTradingSecurityManagedByIspFundLp"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfUnsecuredDebt" xlink:label="us-gaap_RepaymentsOfUnsecuredDebt"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SaleOfEquityInvestmentsManagedByIspFundLp" xlink:label="inva_SaleOfEquityInvestmentsManagedByIspFundLp"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_PurchasesOfCappedCallOptionsAssociatedWithConvertibleSeniorNotes" xlink:label="inva_PurchasesOfCappedCallOptionsAssociatedWithConvertibleSeniorNotes"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_PurchaseAndSaleOfOtherInvestmentsManagedByIspFundLp" xlink:label="inva_PurchaseAndSaleOfOtherInvestmentsManagedByIspFundLp"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_UnrealizedOtherGainLossOnInvestments" xlink:label="inva_UnrealizedOtherGainLossOnInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_NetProceedsFromSaleOfVariableInterestEntityEquity" xlink:label="inva_NetProceedsFromSaleOfVariableInterestEntityEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeconsolidationGainOrLossAmount" xlink:label="us-gaap_DeconsolidationGainOrLossAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="us-gaap_CashAcquiredFromAcquisition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_CashPaidForTheAcquisitionOfLaJollaPharmaceuticalCompanyNetOfCashAcquired" xlink:label="inva_CashPaidForTheAcquisitionOfLaJollaPharmaceuticalCompanyNetOfCashAcquired"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="inva_AccruedInterestIncomeIncludedInLongTermInvestments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsToMinorityShareholders" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireEquityMethodInvestments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaidNet" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="inva_AmortizationOfCapitalizedFeesAndDepreciationOfPropertyAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="inva_NonCashActivity" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="inva_PurchaseOfEntasisNoncontrollingInterest" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireLongtermInvestments" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="inva_InventoryFairValueStepUpAdjustmentIncludedInCostOfProductSales" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="inva_PurchasesOfEquityInvestmentsManagedByIspFundLp" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="inva_PurchasesOfTradingSecurityManagedByIspFundLp" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfUnsecuredDebt" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="inva_SaleOfEquityInvestmentsManagedByIspFundLp" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="inva_PurchasesOfCappedCallOptionsAssociatedWithConvertibleSeniorNotes" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="inva_PurchaseAndSaleOfOtherInvestmentsManagedByIspFundLp" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="inva_UnrealizedOtherGainLossOnInvestments" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="inva_NetProceedsFromSaleOfVariableInterestEntityEquity" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DeconsolidationGainOrLossAmount" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_CashAcquiredFromAcquisition" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="inva_CashPaidForTheAcquisitionOfLaJollaPharmaceuticalCompanyNetOfCashAcquired" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingArrLineItems" xlink:label="ecd_InsiderTradingArrLineItems"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_Rule10B51ArrModifiedFlag" xlink:label="inva_Rule10B51ArrModifiedFlag"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_NonRule10B51ArrModifiedFlag" xlink:label="inva_NonRule10B51ArrModifiedFlag"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="inva_Rule10B51ArrModifiedFlag" order="13.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="inva_NonRule10B51ArrModifiedFlag" order="14.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureNetIncomePerShare" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureRevenueRecognition1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureLicenseAndCollaborationArrangements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_LicenseAndCollaborationArrangementsDisclosureTextBlock" xlink:label="inva_LicenseAndCollaborationArrangementsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="inva_LicenseAndCollaborationArrangementsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitions1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ConsolidatedEntitiesDisclosureAbstract" xlink:label="inva_ConsolidatedEntitiesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ConsolidatedEntitiesAndAcquisitionsTextBlock" xlink:label="inva_ConsolidatedEntitiesAndAcquisitionsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_ConsolidatedEntitiesDisclosureAbstract" xlink:to="inva_ConsolidatedEntitiesAndAcquisitionsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:label="us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FinancialInstrumentsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureCapitalizedFeesPaid1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostAbstract" xlink:label="us-gaap_CapitalizedContractCostAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_CapitalizedFeesPaidDisclosureTextBlock" xlink:label="inva_CapitalizedFeesPaidDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CapitalizedContractCostAbstract" xlink:to="inva_CapitalizedFeesPaidDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureGoodwillAndIntangibleAssets" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureBalanceSheetComponents" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureStockholdersEquity" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureDebt" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingencies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxes" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureSubsequentEvents" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_DescriptionOfOperationsPolicyTextBlock" xlink:label="inva_DescriptionOfOperationsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_PriorPeriodImmaterialCorrectionPolicyTextBlock" xlink:label="inva_PriorPeriodImmaterialCorrectionPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_PresentationReclassificationPolicyTextBlock" xlink:label="inva_PresentationReclassificationPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_FactorsAffectingComparabilityPolicyTextBlock" xlink:label="inva_FactorsAffectingComparabilityPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:label="us-gaap_ConsolidationVariableInterestEntityPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="us-gaap_BusinessCombinationsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentsPolicy" xlink:label="us-gaap_EquityMethodInvestmentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_CapitalizedFeesPaidToRelatedPartyPolicyTextBlock" xlink:label="inva_CapitalizedFeesPaidToRelatedPartyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_CapitalizedFeesPaidPolicyTextBlock" xlink:label="inva_CapitalizedFeesPaidPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpensePolicyTextBlock" xlink:label="us-gaap_InterestExpensePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_RelatedPartyTransactionsPolicyTextBlock" xlink:label="inva_RelatedPartyTransactionsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="inva_DescriptionOfOperationsPolicyTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="inva_PriorPeriodImmaterialCorrectionPolicyTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="inva_PresentationReclassificationPolicyTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="inva_FactorsAffectingComparabilityPolicyTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_UseOfEstimates" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ConsolidationVariableInterestEntityPolicy" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_BusinessCombinationsPolicy" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_MarketableSecuritiesPolicy" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_EquityMethodInvestmentsPolicy" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="inva_CapitalizedFeesPaidToRelatedPartyPolicyTextBlock" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="inva_CapitalizedFeesPaidPolicyTextBlock" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_InterestExpensePolicyTextBlock" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="inva_RelatedPartyTransactionsPolicyTextBlock" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_PropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:label="inva_PropertyPlantAndEquipmentUsefulLifeTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="inva_PropertyPlantAndEquipmentUsefulLifeTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureNetIncomePerShareTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureRevenueRecognitionTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_TheravanceRespiratoryCompanyLlcMember" xlink:label="inva_TheravanceRespiratoryCompanyLlcMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ScheduleOfConsolidatedEntitiesAndBusinessAcquisitionsByAcquisitionTable" xlink:label="inva_ScheduleOfConsolidatedEntitiesAndBusinessAcquisitionsByAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ConsolidatedEntitiesAndAcquisitionsDisclosureAbstract" xlink:label="inva_ConsolidatedEntitiesAndAcquisitionsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_EntasisTherapeuticsHoldingsIncMember" xlink:label="inva_EntasisTherapeuticsHoldingsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ConsolidatedEntitiesAndAcquisitionsLineItems" xlink:label="inva_ConsolidatedEntitiesAndAcquisitionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:label="us-gaap_ScheduleOfVariableInterestEntitiesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_LaJollaPharmaceuticalCompanyMember" xlink:label="inva_LaJollaPharmaceuticalCompanyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="inva_TheravanceRespiratoryCompanyLlcMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_ScheduleOfConsolidatedEntitiesAndBusinessAcquisitionsByAcquisitionTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_ConsolidatedEntitiesAndAcquisitionsDisclosureAbstract" xlink:to="inva_ScheduleOfConsolidatedEntitiesAndBusinessAcquisitionsByAcquisitionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="inva_EntasisTherapeuticsHoldingsIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_ConsolidatedEntitiesAndAcquisitionsLineItems" xlink:to="us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_ScheduleOfConsolidatedEntitiesAndBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="inva_LaJollaPharmaceuticalCompanyMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_ConsolidatedEntitiesAndAcquisitionsLineItems" xlink:to="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_ScheduleOfConsolidatedEntitiesAndBusinessAcquisitionsByAcquisitionTable" xlink:to="inva_ConsolidatedEntitiesAndAcquisitionsLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_ConsolidatedEntitiesAndAcquisitionsLineItems" xlink:to="us-gaap_BusinessAcquisitionProFormaInformationTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:label="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:label="us-gaap_ScheduleOfVariableInterestEntitiesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ArmataPharmaceuticalsIncMember" xlink:label="inva_ArmataPharmaceuticalsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_EntasisTherapeuticsHoldingsIncMember" xlink:label="inva_EntasisTherapeuticsHoldingsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:to="inva_ArmataPharmaceuticalsIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:to="inva_EntasisTherapeuticsHoldingsIncMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureCapitalizedFeesPaidTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostAbstract" xlink:label="us-gaap_CapitalizedContractCostAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostTableTextBlock" xlink:label="us-gaap_CapitalizedContractCostTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CapitalizedContractCostAbstract" xlink:to="us-gaap_CapitalizedContractCostTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:label="inva_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="inva_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:label="us-gaap_OtherNoncurrentLiabilitiesTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureDebtTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_TwoThousandTwentyThreeNotesMember" xlink:label="inva_TwoThousandTwentyThreeNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_Percent2.50ConvertibleDebtMember" xlink:label="inva_Percent2.50ConvertibleDebtMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtTableTextBlock" xlink:label="us-gaap_ConvertibleDebtTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_TwoThousandTwentyFiveNotesMember" xlink:label="inva_TwoThousandTwentyFiveNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:label="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_TwoThousandTwentyEightNotesMember" xlink:label="inva_TwoThousandTwentyEightNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_TwoThousandTwentyThreeNotesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ScheduleOfDebtInstrumentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_Percent2.50ConvertibleDebtMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ConvertibleDebtTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_TwoThousandTwentyFiveNotesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_TwoThousandTwentyEightNotesMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ScheduleOfBalanceSheetInformationRelatedToOperatingLeaseTableTextBlock" xlink:label="inva_ScheduleOfBalanceSheetInformationRelatedToOperatingLeaseTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="inva_ScheduleOfBalanceSheetInformationRelatedToOperatingLeaseTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_LabaCollaborationMember" xlink:label="inva_LabaCollaborationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_LaJollaMember" xlink:label="inva_LaJollaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_GSKMember" xlink:label="inva_GSKMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_TheravanceRespiratoryCompanyLlcMember" xlink:label="inva_TheravanceRespiratoryCompanyLlcMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_LongActingBeta2AgonistRelvarBreoMember" xlink:label="inva_LongActingBeta2AgonistRelvarBreoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_TwoThousandTwentyFiveNotesMember" xlink:label="inva_TwoThousandTwentyFiveNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SummaryOfSignificantAccountingPoliciesTable" xlink:label="inva_SummaryOfSignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_CustomerOneMember" xlink:label="inva_CustomerOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate202006Member" xlink:label="us-gaap_AccountingStandardsUpdate202006Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="inva_SummaryOfSignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SarissaCapitalManagementLpMember" xlink:label="inva_SarissaCapitalManagementLpMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_LongActingBeta2AgonistAnoroMember" xlink:label="inva_LongActingBeta2AgonistAnoroMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeAccountsReceivableMember" xlink:label="us-gaap_TradeAccountsReceivableMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_CustomerTwoMember" xlink:label="inva_CustomerTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_CollaborativeArrangementRoyaltyRateDefinedLevelOne" xlink:label="inva_CollaborativeArrangementRoyaltyRateDefinedLevelOne"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_CustomerThreeMember" xlink:label="inva_CustomerThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate" xlink:label="inva_CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_CollaborativeArrangementRoyaltyRateDefinedLevelTwo" xlink:label="inva_CollaborativeArrangementRoyaltyRateDefinedLevelTwo"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts" xlink:label="inva_CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_NumberOfCustomers" xlink:label="inva_NumberOfCustomers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_CapitalizedFeePaidEstimatedUsefulLife" xlink:label="inva_CapitalizedFeePaidEstimatedUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_RelatedPartyTransactionCommonStockOwnershipPercentageByRelatedParty" xlink:label="inva_RelatedPartyTransactionCommonStockOwnershipPercentageByRelatedParty"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_DecreaseToAccumulatedDeficit" xlink:label="inva_DecreaseToAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ReductionToAdditionalPaidInCapital" xlink:label="inva_ReductionToAdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_IncreaseToConvertibleNotes" xlink:label="inva_IncreaseToConvertibleNotes"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_IncreaseInDeferredTaxAssets" xlink:label="inva_IncreaseInDeferredTaxAssets"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="inva_LabaCollaborationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="inva_LaJollaMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="inva_GSKMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="inva_TheravanceRespiratoryCompanyLlcMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="inva_LongActingBeta2AgonistRelvarBreoMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_TwoThousandTwentyFiveNotesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="inva_SummaryOfSignificantAccountingPoliciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="inva_CustomerOneMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate202006Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="inva_SarissaCapitalManagementLpMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="inva_LongActingBeta2AgonistAnoroMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_TradeAccountsReceivableMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="inva_CustomerTwoMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="inva_CollaborativeArrangementRoyaltyRateDefinedLevelOne" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="inva_CustomerThreeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="inva_CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_ProductOrServiceAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="inva_CollaborativeArrangementRoyaltyRateDefinedLevelTwo" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="inva_CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_DebtInstrumentAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="inva_NumberOfCustomers" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="inva_CapitalizedFeePaidEstimatedUsefulLife" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="inva_RelatedPartyTransactionCommonStockOwnershipPercentageByRelatedParty" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_MajorCustomersAxis" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="inva_DecreaseToAccumulatedDeficit" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="inva_ReductionToAdditionalPaidInCapital" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="inva_IncreaseToConvertibleNotes" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_SummaryOfSignificantAccountingPoliciesTable" xlink:to="inva_SummaryOfSignificantAccountingPoliciesLineItems" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="inva_IncreaseInDeferredTaxAssets" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_LaboratoryEquipmentFurnitureAndFixturesMember" xlink:label="inva_LaboratoryEquipmentFurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SoftwareAndComputerEquipmentMember" xlink:label="inva_SoftwareAndComputerEquipmentMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="inva_LaboratoryEquipmentFurnitureAndFixturesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="inva_SoftwareAndComputerEquipmentMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesRelatedPartyTransactionsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_RelatedPartyTransactionCommonStockOwnershipPercentageByRelatedParty" xlink:label="inva_RelatedPartyTransactionCommonStockOwnershipPercentageByRelatedParty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SarissaCapitalManagementLpMember" xlink:label="inva_SarissaCapitalManagementLpMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="inva_RelatedPartyTransactionCommonStockOwnershipPercentageByRelatedParty" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="inva_SarissaCapitalManagementLpMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureNetIncomePerShareDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SeniorUnsecuredConvertibleNotesMember" xlink:label="inva_SeniorUnsecuredConvertibleNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:label="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_TwoThousandTwentyFiveNotesMember" xlink:label="inva_TwoThousandTwentyFiveNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_IncrementalCommonSharesAttributableToConversionOfDebtSecuritiesTreasuryStockMethod" xlink:label="inva_IncrementalCommonSharesAttributableToConversionOfDebtSecuritiesTreasuryStockMethod"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_DilutiveEpsOfNotes" xlink:label="inva_DilutiveEpsOfNotes"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="inva_SeniorUnsecuredConvertibleNotesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_TwoThousandTwentyFiveNotesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:to="us-gaap_DebtInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_IncrementalCommonSharesAttributableToConversionOfDebtSecuritiesTreasuryStockMethod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_DilutiveEpsOfNotes" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_NetIncomeLossPerShareAbstract" xlink:label="inva_NetIncomeLossPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDilutedLineItems" xlink:label="us-gaap_EarningsPerShareDilutedLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:label="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_TwoThousandTwentyThreeNotesMember" xlink:label="inva_TwoThousandTwentyThreeNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_DenominatorAbstract" xlink:label="inva_DenominatorAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_NumeratorAbstract" xlink:label="inva_NumeratorAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_IncrementalCommonSharesAttributableToConversionOfDebtSecuritiesTreasuryStockMethod" xlink:label="inva_IncrementalCommonSharesAttributableToConversionOfDebtSecuritiesTreasuryStockMethod"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_TwoThousandTwentyFiveNotesMember" xlink:label="inva_TwoThousandTwentyFiveNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:label="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestOnConvertibleDebtNetOfTax" xlink:label="us-gaap_InterestOnConvertibleDebtNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_TwoThousandTwentyEightNotesMember" xlink:label="inva_TwoThousandTwentyEightNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_NetIncomeLossPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareDilutedLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_TwoThousandTwentyThreeNotesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:to="us-gaap_DebtInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_DenominatorAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_NumeratorAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_NetIncomeLossPerShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareDilutedLineItems" xlink:to="inva_IncrementalCommonSharesAttributableToConversionOfDebtSecuritiesTreasuryStockMethod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_TwoThousandTwentyFiveNotesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_DenominatorAbstract" xlink:to="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_NumeratorAbstract" xlink:to="us-gaap_InterestOnConvertibleDebtNetOfTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareDilutedLineItems" xlink:to="inva_NumeratorAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_TwoThousandTwentyEightNotesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:to="us-gaap_EarningsPerShareDilutedLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_DenominatorAbstract" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_NumeratorAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareDilutedLineItems" xlink:to="inva_DenominatorAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_DenominatorAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareDilutedLineItems" xlink:to="inva_NetIncomeLossPerShareAbstract" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureNetIncomePerShareAntiDilutiveSecuritiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_EquityIncentivePlansAndESPPMember" xlink:label="inva_EquityIncentivePlansAndESPPMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_OutstandingStockWarrantMember" xlink:label="inva_OutstandingStockWarrantMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="inva_EquityIncentivePlansAndESPPMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="inva_OutstandingStockWarrantMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfNetRevenueFromCollaborativeArrangementsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_StrategicAllianceAgreementMember" xlink:label="inva_StrategicAllianceAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_GSKMember" xlink:label="inva_GSKMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyMember" xlink:label="us-gaap_RoyaltyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees" xlink:label="inva_GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_LongActingBeta2AgonistRelvarBreoMember" xlink:label="inva_LongActingBeta2AgonistRelvarBreoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostAmortization" xlink:label="us-gaap_CapitalizedContractCostAmortization"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_LongActingBeta2AgonistAnoroMember" xlink:label="inva_LongActingBeta2AgonistAnoroMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_TrelegyElliptaMember" xlink:label="inva_TrelegyElliptaMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_StrategicAllianceMabaProgram" xlink:label="inva_StrategicAllianceMabaProgram"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_CollaborativeArrangementsMember" xlink:label="inva_CollaborativeArrangementsMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="inva_StrategicAllianceAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="inva_GSKMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_RoyaltyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="inva_GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="inva_LongActingBeta2AgonistRelvarBreoMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_CapitalizedContractCostAmortization" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="inva_LongActingBeta2AgonistAnoroMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="inva_TrelegyElliptaMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="inva_StrategicAllianceMabaProgram" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="inva_CollaborativeArrangementsMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureRevenueRecognitionDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_StrategicAllianceAgreementMember" xlink:label="inva_StrategicAllianceAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US" xlink:label="country_US"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_GSKMember" xlink:label="inva_GSKMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyMember" xlink:label="us-gaap_RoyaltyMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_LongActingBeta2AgonistRelvarBreoMember" xlink:label="inva_LongActingBeta2AgonistRelvarBreoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeographicConcentrationRiskMember" xlink:label="us-gaap_GeographicConcentrationRiskMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_PercentageOfRoyaltyPaymentsNotEntitledToReceive" xlink:label="inva_PercentageOfRoyaltyPaymentsNotEntitledToReceive"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_LabaCollaborationMember" xlink:label="inva_LabaCollaborationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonUsMember" xlink:label="us-gaap_NonUsMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_LaJollaMember" xlink:label="inva_LaJollaMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_LongActingBeta2AgonistAnoroMember" xlink:label="inva_LongActingBeta2AgonistAnoroMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_CollaborativeArrangementsMember" xlink:label="inva_CollaborativeArrangementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_TrelegyElliptaMember" xlink:label="inva_TrelegyElliptaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostGross" xlink:label="us-gaap_CapitalizedContractCostGross"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_GiaprezaMember" xlink:label="inva_GiaprezaMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_CollaborativeArrangementRoyaltyRateDefinedLevelOne" xlink:label="inva_CollaborativeArrangementRoyaltyRateDefinedLevelOne"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_XeravaMember" xlink:label="inva_XeravaMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate" xlink:label="inva_CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_XacduroMember" xlink:label="inva_XacduroMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_CollaborativeArrangementRoyaltyRateDefinedLevelTwo" xlink:label="inva_CollaborativeArrangementRoyaltyRateDefinedLevelTwo"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts" xlink:label="inva_CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_PercentageOfEconomicInterestOnFuturePaymentsUnderAgreements" xlink:label="inva_PercentageOfEconomicInterestOnFuturePaymentsUnderAgreements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="inva_StrategicAllianceAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="inva_GSKMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RoyaltyMember" xlink:to="inva_LongActingBeta2AgonistRelvarBreoMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_RoyaltyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_GeographicConcentrationRiskMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="inva_PercentageOfRoyaltyPaymentsNotEntitledToReceive" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="inva_LabaCollaborationMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="us-gaap_NonUsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="inva_LaJollaMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RoyaltyMember" xlink:to="inva_LongActingBeta2AgonistAnoroMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="inva_CollaborativeArrangementsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RoyaltyMember" xlink:to="inva_TrelegyElliptaMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_CapitalizedContractCostGross" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RoyaltyMember" xlink:to="inva_GiaprezaMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_RangeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="inva_CollaborativeArrangementRoyaltyRateDefinedLevelOne" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RoyaltyMember" xlink:to="inva_XeravaMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="inva_CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RoyaltyMember" xlink:to="inva_XacduroMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="inva_CollaborativeArrangementRoyaltyRateDefinedLevelTwo" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_StatementGeographicalAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="inva_CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueLineItems" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="inva_PercentageOfEconomicInterestOnFuturePaymentsUnderAgreements" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureLicenseAndCollaborationArrangementsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_CommercialSupplyAgreementMember" xlink:label="inva_CommercialSupplyAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ResearchAndDevelopmentSupportMember" xlink:label="inva_ResearchAndDevelopmentSupportMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ZaiLabMember" xlink:label="inva_ZaiLabMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_CostReimbursementMember" xlink:label="inva_CostReimbursementMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_FuturePotentialMilestonePayment" xlink:label="inva_FuturePotentialMilestonePayment"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_PaionAgMember" xlink:label="inva_PaionAgMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_CostReimbursements" xlink:label="inva_CostReimbursements"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_EverestMedicinesLimitedMember" xlink:label="inva_EverestMedicinesLimitedMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ReductionToResearchAndDevelopmentExpense" xlink:label="inva_ReductionToResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_GeorgeWashingtonUniversityMember" xlink:label="inva_GeorgeWashingtonUniversityMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_RegulatoryMilestonePaymentsReceivable" xlink:label="inva_RegulatoryMilestonePaymentsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_HarvardUniversityMember" xlink:label="inva_HarvardUniversityMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SalesMilestonePaymentsReceivable" xlink:label="inva_SalesMilestonePaymentsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ParatekPharmaceuticalsIncMember" xlink:label="inva_ParatekPharmaceuticalsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_AstrazenecaMember" xlink:label="inva_AstrazenecaMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_LicenseRevenueRecognized" xlink:label="inva_LicenseRevenueRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_RoyaltiesPayablePeriodAfterFirstCommercialSaleOfProduct" xlink:label="inva_RoyaltiesPayablePeriodAfterFirstCommercialSaleOfProduct"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_PercentageOfReimbursedForDirectAndCertainIndirectManufacturingCosts" xlink:label="inva_PercentageOfReimbursedForDirectAndCertainIndirectManufacturingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_AccruedRoyaltyObligations" xlink:label="inva_AccruedRoyaltyObligations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_PercentageOfRoyaltyPayableOnNetSales" xlink:label="inva_PercentageOfRoyaltyPayableOnNetSales"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_PercentageOfRoyaltyOnPaymentsReceivedFromSublicensees" xlink:label="inva_PercentageOfRoyaltyOnPaymentsReceivedFromSublicensees"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ClinicalDevelopmentAndRegulatoryMilestonesAmountPayable" xlink:label="inva_ClinicalDevelopmentAndRegulatoryMilestonesAmountPayable"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_PercentageOfMinimumRoyaltyRate" xlink:label="inva_PercentageOfMinimumRoyaltyRate"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_PercentageOfMaximumRoyaltyBasedOnAchievementOfAnnualNetProductSalesThresholds" xlink:label="inva_PercentageOfMaximumRoyaltyBasedOnAchievementOfAnnualNetProductSalesThresholds"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ClaimExpirationDate" xlink:label="inva_ClaimExpirationDate"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SubscriptionAgreementOneTimeMilestonePaymentOnNetSales" xlink:label="inva_SubscriptionAgreementOneTimeMilestonePaymentOnNetSales"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_TermOfMilestonePaymentForNetSales" xlink:label="inva_TermOfMilestonePaymentForNetSales"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SubscriptionAgreementOneTimeMilestonePaymentOnCommercialSales" xlink:label="inva_SubscriptionAgreementOneTimeMilestonePaymentOnCommercialSales"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_TermOfMilestonePaymentForCommercialSale" xlink:label="inva_TermOfMilestonePaymentForCommercialSale"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="inva_CommercialSupplyAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="inva_ResearchAndDevelopmentSupportMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_Revenues" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="inva_ZaiLabMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="inva_CostReimbursementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_FuturePotentialMilestonePayment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="inva_PaionAgMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_CostReimbursements" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="inva_EverestMedicinesLimitedMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_ReductionToResearchAndDevelopmentExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="inva_GeorgeWashingtonUniversityMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_RegulatoryMilestonePaymentsReceivable" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="inva_HarvardUniversityMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_SalesMilestonePaymentsReceivable" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="inva_ParatekPharmaceuticalsIncMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="inva_AstrazenecaMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_LicenseRevenueRecognized" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CostOfRevenue" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_RoyaltiesPayablePeriodAfterFirstCommercialSaleOfProduct" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_PercentageOfReimbursedForDirectAndCertainIndirectManufacturingCosts" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RepaymentsOfDebt" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_AccruedRoyaltyObligations" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenue" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_PercentageOfRoyaltyPayableOnNetSales" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_PercentageOfRoyaltyOnPaymentsReceivedFromSublicensees" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_ClinicalDevelopmentAndRegulatoryMilestonesAmountPayable" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_PercentageOfMinimumRoyaltyRate" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_PercentageOfMaximumRoyaltyBasedOnAchievementOfAnnualNetProductSalesThresholds" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_ClaimExpirationDate" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_SubscriptionAgreementOneTimeMilestonePaymentOnNetSales" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_TermOfMilestonePaymentForNetSales" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_SubscriptionAgreementOneTimeMilestonePaymentOnCommercialSales" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_TermOfMilestonePaymentForCommercialSale" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_StrategicAllianceAgreementMember" xlink:label="inva_StrategicAllianceAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:label="us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_BalanceSheetDisclosuresOfVariableInterestEntityAbstract" xlink:label="inva_BalanceSheetDisclosuresOfVariableInterestEntityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:label="us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyMember" xlink:label="us-gaap_RoyaltyMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_IncomeStatementDisclosuresOfVariableInterestEntityAbstract" xlink:label="inva_IncomeStatementDisclosuresOfVariableInterestEntityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableInterestEntityLineItems" xlink:label="us-gaap_VariableInterestEntityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_OwnershipInterestInConsolidatedEntities" xlink:label="inva_OwnershipInterestInConsolidatedEntities"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_TheravanceRespiratoryCompanyLlcMember" xlink:label="inva_TheravanceRespiratoryCompanyLlcMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ConsolidatedEntitiesDisclosureAbstract" xlink:label="inva_ConsolidatedEntitiesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_CollaborativeArrangementsMember" xlink:label="inva_CollaborativeArrangementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MembersEquity" xlink:label="us-gaap_MembersEquity"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ProceedsFromSaleOfEconomicInterestUnderEquityPurchaseAgreement" xlink:label="inva_ProceedsFromSaleOfEconomicInterestUnderEquityPurchaseAgreement"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_IspFundLpMember" xlink:label="inva_IspFundLpMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ContingentSalesBasedMilestonePayment" xlink:label="inva_ContingentSalesBasedMilestonePayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_CashDistributionReceived" xlink:label="inva_CashDistributionReceived"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_RealizedLoss" xlink:label="inva_RealizedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestments" xlink:label="us-gaap_EquityMethodInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnInvestments" xlink:label="us-gaap_GainLossOnInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="inva_StrategicAllianceAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_BalanceSheetDisclosuresOfVariableInterestEntityAbstract" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_RoyaltyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_IncomeStatementDisclosuresOfVariableInterestEntityAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="inva_OwnershipInterestInConsolidatedEntities" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:to="inva_TheravanceRespiratoryCompanyLlcMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_ConsolidatedEntitiesDisclosureAbstract" xlink:to="us-gaap_ScheduleOfVariableInterestEntitiesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_BalanceSheetDisclosuresOfVariableInterestEntityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:to="srt_ProductOrServiceAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="inva_CollaborativeArrangementsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_IncomeStatementDisclosuresOfVariableInterestEntityAbstract" xlink:to="us-gaap_OperatingExpenses" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_MembersEquity" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="inva_ProceedsFromSaleOfEconomicInterestUnderEquityPurchaseAgreement" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:to="inva_IspFundLpMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_LongTermInvestments" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_IncomeStatementDisclosuresOfVariableInterestEntityAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="inva_ContingentSalesBasedMilestonePayment" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:to="us-gaap_VariableInterestEntityLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_IncomeStatementDisclosuresOfVariableInterestEntityAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="inva_CashDistributionReceived" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_IncomeStatementDisclosuresOfVariableInterestEntityAbstract" xlink:to="inva_RealizedLoss" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="us-gaap_EquityMethodInvestments" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_IncomeStatementDisclosuresOfVariableInterestEntityAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="inva_BalanceSheetDisclosuresOfVariableInterestEntityAbstract" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_IncomeStatementDisclosuresOfVariableInterestEntityAbstract" xlink:to="us-gaap_GainLossOnInvestments" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="inva_IncomeStatementDisclosuresOfVariableInterestEntityAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_IncomeStatementDisclosuresOfVariableInterestEntityAbstract" xlink:to="us-gaap_ProfitLoss" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsIspFundLpDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:label="us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralPartnerMember" xlink:label="us-gaap_GeneralPartnerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:label="us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableInterestEntityLineItems" xlink:label="us-gaap_VariableInterestEntityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LimitedPartnersCumulativeCashDistributions" xlink:label="us-gaap_LimitedPartnersCumulativeCashDistributions"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_IspFundLpMember" xlink:label="inva_IspFundLpMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ConsolidatedEntitiesDisclosureAbstract" xlink:label="inva_ConsolidatedEntitiesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LimitedPartnersContributedCapital" xlink:label="us-gaap_LimitedPartnersContributedCapital"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_LimitedPartnersInitialContribution" xlink:label="inva_LimitedPartnersInitialContribution"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_PercentageOfEconomicInterestInPartnership" xlink:label="inva_PercentageOfEconomicInterestInPartnership"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_NetInvestmentRelatedIncomeExpenseEarnedInccured" xlink:label="inva_NetInvestmentRelatedIncomeExpenseEarnedInccured"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInvestmentExpense" xlink:label="us-gaap_InvestmentIncomeInvestmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="us-gaap_UnrealizedGainLossOnInvestments"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_PaymentOfManagementAndIncentiveFee" xlink:label="inva_PaymentOfManagementAndIncentiveFee"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_PartnershipAgreementLockUpPeriod" xlink:label="inva_PartnershipAgreementLockUpPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterestAndDividend" xlink:label="us-gaap_InvestmentIncomeInterestAndDividend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnInvestments" xlink:label="us-gaap_GainLossOnInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_GeneralPartnerMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="us-gaap_LimitedPartnersCumulativeCashDistributions" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:to="inva_IspFundLpMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_ConsolidatedEntitiesDisclosureAbstract" xlink:to="us-gaap_ScheduleOfVariableInterestEntitiesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="us-gaap_LimitedPartnersContributedCapital" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:to="us-gaap_VariableInterestEntityLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="inva_LimitedPartnersInitialContribution" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="inva_PercentageOfEconomicInterestInPartnership" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="us-gaap_Liabilities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="inva_NetInvestmentRelatedIncomeExpenseEarnedInccured" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="us-gaap_InvestmentIncomeInvestmentExpense" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="us-gaap_InvestmentIncomeInterest" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="us-gaap_UnrealizedGainLossOnInvestments" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="inva_PaymentOfManagementAndIncentiveFee" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="inva_PartnershipAgreementLockUpPeriod" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="us-gaap_InvestmentIncomeInterestAndDividend" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="us-gaap_GainLossOnInvestments" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="us-gaap_Assets" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SecuritiesPurchaseAgreementMember" xlink:label="inva_SecuritiesPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember" xlink:label="inva_InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ConsolidatedInvesteesMember" xlink:label="inva_ConsolidatedInvesteesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ConvertiblePromissoryNoteMember" xlink:label="inva_ConvertiblePromissoryNoteMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_EntasisTherapeuticsHoldingsIncMember" xlink:label="inva_EntasisTherapeuticsHoldingsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:label="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ConsolidatedEntitiesDisclosureAbstract" xlink:label="inva_ConsolidatedEntitiesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SecuritiesPurchaseAgreementRightsToDesignateInvesteeBoardMembersNumberOfBoardMembers" xlink:label="inva_SecuritiesPurchaseAgreementRightsToDesignateInvesteeBoardMembersNumberOfBoardMembers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SaleOfWarrantsNumberOfWarrantsIssuedInTransaction" xlink:label="inva_SaleOfWarrantsNumberOfWarrantsIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_CommonStockAndWarrantsMember" xlink:label="inva_CommonStockAndWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:label="us-gaap_PaymentsToAcquireEquitySecuritiesFvNi"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_WarrantsAcquiredInSecondQuarterOf2021Member" xlink:label="inva_WarrantsAcquiredInSecondQuarterOf2021Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_WarrantsAcquiredInThirdQuarterOf2020Member" xlink:label="inva_WarrantsAcquiredInThirdQuarterOf2020Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_WarrantsAcquiredInSecondQuarterOf2020Member" xlink:label="inva_WarrantsAcquiredInSecondQuarterOf2020Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="us-gaap_EquitySecuritiesFvNi"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:label="us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="us-gaap_RepaymentsOfConvertibleDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillPeriodIncreaseDecrease" xlink:label="us-gaap_GoodwillPeriodIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_MeasurementPeriodAdjustmentsIncreaseDecreaseInEstimatedPurchasePrice" xlink:label="inva_MeasurementPeriodAdjustmentsIncreaseDecreaseInEstimatedPurchasePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestPeriodIncreaseDecrease" xlink:label="us-gaap_MinorityInterestPeriodIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_IncreaseDecreaseInDeferredTaxLiabilities" xlink:label="inva_IncreaseDecreaseInDeferredTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest" xlink:label="us-gaap_MinorityInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:label="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_BusinessAcquisitionsOfChangeInFairValueOfInvestment" xlink:label="inva_BusinessAcquisitionsOfChangeInFairValueOfInvestment"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="inva_SecuritiesPurchaseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="inva_InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="inva_ConsolidatedInvesteesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_ConvertiblePromissoryNoteMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="inva_EntasisTherapeuticsHoldingsIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_ConsolidatedEntitiesDisclosureAbstract" xlink:to="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="inva_SecuritiesPurchaseAgreementRightsToDesignateInvesteeBoardMembersNumberOfBoardMembers" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_WarrantMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="inva_SaleOfWarrantsNumberOfWarrantsIssuedInTransaction" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_CommonStockAndWarrantsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="dei_LegalEntityAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_WarrantsAcquiredInSecondQuarterOf2021Member" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_WarrantsAcquiredInThirdQuarterOf2020Member" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="us-gaap_DebtInstrumentAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_WarrantsAcquiredInSecondQuarterOf2020Member" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_EquitySecuritiesFvNi" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_EquitySecuritiesFvNiRealizedGainLoss" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_RepaymentsOfConvertibleDebt" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_GoodwillPeriodIncreaseDecrease" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="inva_MeasurementPeriodAdjustmentsIncreaseDecreaseInEstimatedPurchasePrice" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_MinorityInterestPeriodIncreaseDecrease" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="inva_IncreaseDecreaseInDeferredTaxLiabilities" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_MinorityInterest" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="inva_BusinessAcquisitionsOfChangeInFairValueOfInvestment" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ConsolidatedEntitiesAndAcquisitionsDisclosureAbstract" xlink:label="inva_ConsolidatedEntitiesAndAcquisitionsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_EntasisTherapeuticsHoldingsIncMember" xlink:label="inva_EntasisTherapeuticsHoldingsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_LaJollaPharmaceuticalCompanyMember" xlink:label="inva_LaJollaPharmaceuticalCompanyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" xlink:label="inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedPersonnelRelatedExpenses" xlink:label="inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedPersonnelRelatedExpenses"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAccruedLiabilities" xlink:label="inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_ConsolidatedEntitiesAndAcquisitionsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="inva_EntasisTherapeuticsHoldingsIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="inva_LaJollaPharmaceuticalCompanyMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_Goodwill" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedPersonnelRelatedExpenses" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAccruedLiabilities" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsLaJollaPharmaceuticalCompanyDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_LaJollaPharmaceuticalCompanyMember" xlink:label="inva_LaJollaPharmaceuticalCompanyMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ConsolidatedEntitiesDisclosureAbstract" xlink:label="inva_ConsolidatedEntitiesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="us-gaap_BusinessAcquisitionSharePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillPeriodIncreaseDecrease" xlink:label="us-gaap_GoodwillPeriodIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_IncreaseDecreaseInDeferredTaxAssets" xlink:label="inva_IncreaseDecreaseInDeferredTaxAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:label="us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_MeasurementPeriodAdjustmentsIncreaseDecreaseInLiabilities" xlink:label="inva_MeasurementPeriodAdjustmentsIncreaseDecreaseInLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcquisitionCosts" xlink:label="us-gaap_AcquisitionCosts"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_IncreaseDecreaseInDeferredTaxLiabilities" xlink:label="inva_IncreaseDecreaseInDeferredTaxLiabilities"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="inva_LaJollaPharmaceuticalCompanyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_ConsolidatedEntitiesDisclosureAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionSharePrice" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_GoodwillPeriodIncreaseDecrease" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="inva_IncreaseDecreaseInDeferredTaxAssets" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="inva_MeasurementPeriodAdjustmentsIncreaseDecreaseInLiabilities" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_AcquisitionCosts" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="inva_IncreaseDecreaseInDeferredTaxLiabilities" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsProFormaInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_EntasisTherapeuticsHoldingsIncMember" xlink:label="inva_EntasisTherapeuticsHoldingsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:label="us-gaap_BusinessAcquisitionsProFormaRevenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_LaJollaPharmaceuticalCompanyMember" xlink:label="inva_LaJollaPharmaceuticalCompanyMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ConsolidatedEntitiesDisclosureAbstract" xlink:label="inva_ConsolidatedEntitiesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:label="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="inva_EntasisTherapeuticsHoldingsIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionsProFormaRevenue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="inva_LaJollaPharmaceuticalCompanyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_ConsolidatedEntitiesDisclosureAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_NetIncomeLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_OneDirectorMember" xlink:label="inva_OneDirectorMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:label="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_CommonStockAndWarrantsMember" xlink:label="inva_CommonStockAndWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement" xlink:label="inva_SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SecuredConvertibleCreditAgreementMember" xlink:label="inva_SecuredConvertibleCreditAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember" xlink:label="inva_InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ConsolidatedInvesteesMember" xlink:label="inva_ConsolidatedInvesteesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_CreditAndSecurityAgreementMember" xlink:label="inva_CreditAndSecurityAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ArmataPharmaceuticalsIncMember" xlink:label="inva_ArmataPharmaceuticalsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_TwoDirectorsMember" xlink:label="inva_TwoDirectorsMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_WarrantsPurchasedIn2020Member" xlink:label="inva_WarrantsPurchasedIn2020Member"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SaleOfWarrantsNumberOfWarrantsIssuedInTransaction" xlink:label="inva_SaleOfWarrantsNumberOfWarrantsIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_WarrantsPurchasedIn2021Member" xlink:label="inva_WarrantsPurchasedIn2021Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_WarrantsPurchasedIn2022Member" xlink:label="inva_WarrantsPurchasedIn2022Member"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SecuritiesPurchaseAgreementTotalNumberOfWarrantsToBePurchasedUnderAgreement" xlink:label="inva_SecuritiesPurchaseAgreementTotalNumberOfWarrantsToBePurchasedUnderAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SecuritiesPurchaseAgreementAmount" xlink:label="inva_SecuritiesPurchaseAgreementAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SecuritiesPurchaseAgreementNumberOfTranches" xlink:label="inva_SecuritiesPurchaseAgreementNumberOfTranches"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ArmataConvertibleNoteMember" xlink:label="inva_ArmataConvertibleNoteMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ArmataTermLoanMember" xlink:label="inva_ArmataTermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentDescription" xlink:label="us-gaap_DebtInstrumentDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_VotingAgreementMaximumVotingRightsPercent" xlink:label="inva_VotingAgreementMaximumVotingRightsPercent"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee" xlink:label="inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_NumberOfBoardMembersOfInvestee" xlink:label="inva_NumberOfBoardMembersOfInvestee"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="us-gaap_EquitySecuritiesFvNi"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGain" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedGain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableInterestEntityOwnershipPercentage" xlink:label="us-gaap_VariableInterestEntityOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SpecialTermReDesignatingBoardMemberToBoardOfInvestee" xlink:label="inva_SpecialTermReDesignatingBoardMemberToBoardOfInvestee"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="inva_OneDirectorMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_CommonStockAndWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="dei_LegalEntityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="inva_SecuredConvertibleCreditAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="inva_InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="inva_ConsolidatedInvesteesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_CreditAndSecurityAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:to="inva_ArmataPharmaceuticalsIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="inva_TwoDirectorsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_WarrantsPurchasedIn2020Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_SaleOfWarrantsNumberOfWarrantsIssuedInTransaction" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_WarrantsPurchasedIn2021Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_WarrantsPurchasedIn2022Member" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_SecuritiesPurchaseAgreementTotalNumberOfWarrantsToBePurchasedUnderAgreement" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_WarrantMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_SecuritiesPurchaseAgreementAmount" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="srt_TitleOfIndividualAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommonStockMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_SecuritiesPurchaseAgreementNumberOfTranches" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_ArmataConvertibleNoteMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_ArmataTermLoanMember" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_DebtInstrumentDescription" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_DebtInstrumentAxis" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_DebtInstrumentTerm" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_VotingAgreementMaximumVotingRightsPercent" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_NumberOfBoardMembersOfInvestee" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_EquitySecuritiesFvNi" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_EquitySecuritiesFvNiUnrealizedGain" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_EquitySecuritiesFvNiUnrealizedLoss" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_VariableInterestEntityOwnershipPercentage" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_SpecialTermReDesignatingBoardMemberToBoardOfInvestee" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsSummarizedFinancialDataDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:label="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementRelatedDisclosuresAbstract" xlink:label="us-gaap_IncomeStatementRelatedDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ArmataPharmaceuticalsIncMember" xlink:label="inva_ArmataPharmaceuticalsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_EntasisTherapeuticsHoldingsIncMember" xlink:label="inva_EntasisTherapeuticsHoldingsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementRelatedDisclosuresAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_BalanceSheetRelatedDisclosuresAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:to="inva_ArmataPharmaceuticalsIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_AssetsCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementRelatedDisclosuresAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_IncomeStatementRelatedDisclosuresAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:to="inva_EntasisTherapeuticsHoldingsIncMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_AssetsNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementRelatedDisclosuresAbstract" xlink:to="us-gaap_ProfitLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_LiabilitiesNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_NameOfEventDomain" xlink:label="inva_NameOfEventDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_QualifiedFinancingMember" xlink:label="inva_QualifiedFinancingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_IncardaMember" xlink:label="inva_IncardaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SeriesCPreferredStockAndWarrantsMember" xlink:label="inva_SeriesCPreferredStockAndWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="us-gaap_ValuationTechniqueDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_OptionPricingModelBacksolveValuationMember" xlink:label="inva_OptionPricingModelBacksolveValuationMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ConsolidatedInvesteesMember" xlink:label="inva_ConsolidatedInvesteesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_NameOfEventAxis" xlink:label="inva_NameOfEventAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="us-gaap_ValuationTechniqueAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_Incarda2020WarrantsMember" xlink:label="inva_Incarda2020WarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_InCardaConvertibleNoteMember" xlink:label="inva_InCardaConvertibleNoteMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SecuritiesPurchaseAgreementWarrantsNumberOfSecuritiesCalledByWarrants" xlink:label="inva_SecuritiesPurchaseAgreementWarrantsNumberOfSecuritiesCalledByWarrants"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ConvertibleNoteAndWarrantsMember" xlink:label="inva_ConvertibleNoteAndWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SecuritiesPurchaseAgreementAmount" xlink:label="inva_SecuritiesPurchaseAgreementAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_DebtInstrumentTransactionCost" xlink:label="inva_DebtInstrumentTransactionCost"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SeriesA1PreferredStockMember" xlink:label="inva_SeriesA1PreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee" xlink:label="inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SeriesD1PreferredStockMember" xlink:label="inva_SeriesD1PreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_NumberOfBoardMembersOfInvestee" xlink:label="inva_NumberOfBoardMembersOfInvestee"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SeriesD2PreferredStockMember" xlink:label="inva_SeriesD2PreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SeriesD1WarrantMember" xlink:label="inva_SeriesD1WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:label="us-gaap_PaymentsToAcquireEquitySecuritiesFvNi"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SeriesD2WarrantMember" xlink:label="inva_SeriesD2WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="us-gaap_EquitySecuritiesFvNi"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SeriesCWarrantsAndSeriesDWarrantsMember" xlink:label="inva_SeriesCWarrantsAndSeriesDWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ExpectedHoldingPeriod" xlink:label="inva_ExpectedHoldingPeriod"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SeriesDWarrantsMember" xlink:label="inva_SeriesDWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_RiskFreeInterestRate" xlink:label="inva_RiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="us-gaap_SeriesDPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_DividendYield" xlink:label="inva_DividendYield"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SeriesD1AndD2PreferredStockAndCommonStockMember" xlink:label="inva_SeriesD1AndD2PreferredStockAndCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_PercentageOfEstimatedVolatility" xlink:label="inva_PercentageOfEstimatedVolatility"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:label="us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ExtendedExpirationDate" xlink:label="inva_ExtendedExpirationDate"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_CarryingValueWroteOffWarrantExercise" xlink:label="inva_CarryingValueWroteOffWarrantExercise"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGain" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedGain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_NameOfEventDomain" xlink:to="inva_QualifiedFinancingMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="inva_IncardaMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_SeriesCPreferredStockAndWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationTechniqueDomain" xlink:to="inva_OptionPricingModelBacksolveValuationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="inva_ConsolidatedInvesteesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_NameOfEventAxis" xlink:to="inva_NameOfEventDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_Incarda2020WarrantsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_ValuationTechniqueAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="inva_InCardaConvertibleNoteMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_WarrantMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_SecuritiesPurchaseAgreementWarrantsNumberOfSecuritiesCalledByWarrants" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_ConvertibleNoteAndWarrantsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_SecuritiesPurchaseAgreementAmount" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommonStockMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_DebtInstrumentTransactionCost" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_SeriesA1PreferredStockMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="inva_NameOfEventAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_SeriesD1PreferredStockMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_NumberOfBoardMembersOfInvestee" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_SeriesD2PreferredStockMember" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_SeriesD1WarrantMember" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_SeriesD2WarrantMember" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_EquitySecuritiesFvNi" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_SeriesCWarrantsAndSeriesDWarrantsMember" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_ExpectedHoldingPeriod" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_SeriesDWarrantsMember" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_RiskFreeInterestRate" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_SeriesDPreferredStockMember" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_DividendYield" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_SeriesD1AndD2PreferredStockAndCommonStockMember" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_PercentageOfEstimatedVolatility" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_ExtendedExpirationDate" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_CarryingValueWroteOffWarrantExercise" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_EquitySecuritiesFvNiUnrealizedLoss" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_EquitySecuritiesFvNiUnrealizedGain" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInImaginabDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ImaginabMember" xlink:label="inva_ImaginabMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement" xlink:label="inva_SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ConsolidatedInvesteesMember" xlink:label="inva_ConsolidatedInvesteesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_OneOfImaginabsCommonStockholderMember" xlink:label="inva_OneOfImaginabsCommonStockholderMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SeriesC2PreferredStockMember" xlink:label="inva_SeriesC2PreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SecuritiesPurchaseAgreementAmount" xlink:label="inva_SecuritiesPurchaseAgreementAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee" xlink:label="inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_NumberOfBoardMembersOfInvestee" xlink:label="inva_NumberOfBoardMembersOfInvestee"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="us-gaap_EquitySecuritiesFvNi"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="inva_ImaginabMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="srt_CounterpartyNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="inva_ConsolidatedInvesteesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="inva_OneOfImaginabsCommonStockholderMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_SeriesC2PreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_SecuritiesPurchaseAgreementAmount" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommonStockMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_NumberOfBoardMembersOfInvestee" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_EquitySecuritiesFvNi" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInGateNeurosciencesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_GateNeuroscienceMember" xlink:label="inva_GateNeuroscienceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentPrincipal"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_GateNeuroscienceMember" xlink:label="inva_GateNeuroscienceMember_0"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ConvertiblePromissoryNotePurchaseAgreementMember" xlink:label="inva_ConvertiblePromissoryNotePurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_NoteAmendmentAgreementMember" xlink:label="inva_NoteAmendmentAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_NumberOfCommonStockIssuedDescription" xlink:label="inva_NumberOfCommonStockIssuedDescription"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SecondNoteAmendmentAgreementMember" xlink:label="inva_SecondNoteAmendmentAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireLongtermInvestments" xlink:label="us-gaap_PaymentsToAcquireLongtermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="us-gaap_EquitySecuritiesFvNi"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGain" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedGain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedLoss"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="inva_GateNeuroscienceMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentPrincipal" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_DebtInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="inva_GateNeuroscienceMember_0" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_ConvertiblePromissoryNotePurchaseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_NoteAmendmentAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_NumberOfCommonStockIssuedDescription" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_SecondNoteAmendmentAgreementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_PaymentsToAcquireLongtermInvestments" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_EquitySecuritiesFvNi" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_EquitySecuritiesFvNiUnrealizedGain" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_EquitySecuritiesFvNiUnrealizedLoss" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInNanoliveDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_NanoliveMember" xlink:label="inva_NanoliveMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement" xlink:label="inva_SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ConsolidatedInvesteesMember" xlink:label="inva_ConsolidatedInvesteesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SecuritiesPurchaseAgreementAmount" xlink:label="inva_SecuritiesPurchaseAgreementAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee" xlink:label="inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_NumberOfBoardMembersOfInvestee" xlink:label="inva_NumberOfBoardMembersOfInvestee"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="us-gaap_EquitySecuritiesFvNi"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="inva_NanoliveMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="inva_ConsolidatedInvesteesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_SecuritiesPurchaseAgreementAmount" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_NumberOfBoardMembersOfInvestee" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_EquitySecuritiesFvNi" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsAvailableforsaleSecuritiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:label="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ConvertibleSubordinatedDebtFairValueDisclosures" xlink:label="inva_ConvertibleSubordinatedDebtFairValueDisclosures"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ArmataPharmaceuticalsIncMember" xlink:label="inva_ArmataPharmaceuticalsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtMember" xlink:label="us-gaap_ConvertibleDebtMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesMember" xlink:label="us-gaap_EquitySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_IspFundLpMember" xlink:label="inva_IspFundLpMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ConvertibleSeniorDebtFairValueDisclosures" xlink:label="inva_ConvertibleSeniorDebtFairValueDisclosures"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_EntasisTherapeuticsHoldingsIncMember" xlink:label="inva_EntasisTherapeuticsHoldingsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_TermLoanInvestmentMember" xlink:label="inva_TermLoanInvestmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsNonrecurringMember" xlink:label="us-gaap_FairValueMeasurementsNonrecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ArmataTermLoanMember" xlink:label="inva_ArmataTermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_IncardaMember" xlink:label="inva_IncardaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_EquityInvestmentsAndMoneyMarketFundsMember" xlink:label="inva_EquityInvestmentsAndMoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ContingentValueRightsLiability" xlink:label="inva_ContingentValueRightsLiability"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_GateNeuroscienceMember" xlink:label="inva_GateNeuroscienceMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_PrivatePlacementPositionsAndConvertibleNotesMember" xlink:label="inva_PrivatePlacementPositionsAndConvertibleNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtMember" xlink:label="us-gaap_DebtMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="us-gaap_DebtInstrumentFairValue"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_PreferredStockWarrantsMember" xlink:label="inva_PreferredStockWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_PartnershipAgreementLockUpPeriod" xlink:label="inva_PartnershipAgreementLockUpPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LimitedPartnersContributedCapital" xlink:label="us-gaap_LimitedPartnersContributedCapital"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_WithdrawalFromInvestment" xlink:label="inva_WithdrawalFromInvestment"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="inva_ConvertibleSubordinatedDebtFairValueDisclosures" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="inva_ArmataPharmaceuticalsIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ConvertibleDebtMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_EquitySecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="inva_IspFundLpMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommonStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="inva_ConvertibleSeniorDebtFairValueDisclosures" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="inva_EntasisTherapeuticsHoldingsIncMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="inva_TermLoanInvestmentMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsNonrecurringMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_ArmataTermLoanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ConvertibleDebtFairValueDisclosures" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="inva_IncardaMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="inva_EquityInvestmentsAndMoneyMarketFundsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_WarrantMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="inva_ContingentValueRightsLiability" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="inva_GateNeuroscienceMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="inva_PrivatePlacementPositionsAndConvertibleNotesMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_DebtMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DebtInstrumentFairValue" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_PreferredStockWarrantsMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="srt_CounterpartyNameAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="inva_PartnershipAgreementLockUpPeriod" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LimitedPartnersContributedCapital" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="inva_WithdrawalFromInvestment" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostAbstract" xlink:label="us-gaap_CapitalizedContractCostAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostTable" xlink:label="us-gaap_CapitalizedContractCostTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US" xlink:label="country_US"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_GSKMember" xlink:label="inva_GSKMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostLineItems" xlink:label="us-gaap_CapitalizedContractCostLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostGross" xlink:label="us-gaap_CapitalizedContractCostGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyMember" xlink:label="us-gaap_RoyaltyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_CapitalizedFeesPaidFutureAmortizationAbstract" xlink:label="inva_CapitalizedFeesPaidFutureAmortizationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_CapitalizedFeesPaidRemainingEstimatedAmortizationNextTwelveMonths" xlink:label="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EuropeMember" xlink:label="srt_EuropeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostAccumulatedAmortization" xlink:label="us-gaap_CapitalizedContractCostAccumulatedAmortization"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearTwo" xlink:label="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_JP" xlink:label="country_JP"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostNet" xlink:label="us-gaap_CapitalizedContractCostNet"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearthree" xlink:label="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearthree"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_CapitalizedFeesPaidWeightedAverageUsefulLife" xlink:label="inva_CapitalizedFeesPaidWeightedAverageUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFour" xlink:label="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostAmortization" xlink:label="us-gaap_CapitalizedContractCostAmortization"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFive" xlink:label="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFive"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_CapitalizedFeesPaidRemainingEstimatedAmortizationAfterYearFive" xlink:label="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationAfterYearFive"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CapitalizedContractCostAbstract" xlink:to="us-gaap_CapitalizedContractCostTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="inva_GSKMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CapitalizedContractCostTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CapitalizedContractCostLineItems" xlink:to="us-gaap_CapitalizedContractCostGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_RoyaltyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_CapitalizedFeesPaidFutureAmortizationAbstract" xlink:to="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_EuropeMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CapitalizedContractCostTable" xlink:to="srt_StatementGeographicalAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CapitalizedContractCostLineItems" xlink:to="us-gaap_CapitalizedContractCostAccumulatedAmortization" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_CapitalizedFeesPaidFutureAmortizationAbstract" xlink:to="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_JP" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CapitalizedContractCostTable" xlink:to="srt_ProductOrServiceAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CapitalizedContractCostLineItems" xlink:to="us-gaap_CapitalizedContractCostNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_CapitalizedFeesPaidFutureAmortizationAbstract" xlink:to="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearthree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CapitalizedContractCostTable" xlink:to="us-gaap_CapitalizedContractCostLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CapitalizedContractCostLineItems" xlink:to="inva_CapitalizedFeesPaidWeightedAverageUsefulLife" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_CapitalizedFeesPaidFutureAmortizationAbstract" xlink:to="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFour" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CapitalizedContractCostLineItems" xlink:to="us-gaap_CapitalizedContractCostAmortization" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_CapitalizedFeesPaidFutureAmortizationAbstract" xlink:to="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFive" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CapitalizedContractCostLineItems" xlink:to="inva_CapitalizedFeesPaidFutureAmortizationAbstract" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_CapitalizedFeesPaidFutureAmortizationAbstract" xlink:to="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationAfterYearFive" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillLineItems" xlink:label="us-gaap_GoodwillLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="us-gaap_CollaborativeArrangementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="us-gaap_ScheduleOfGoodwillTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_EntasisTherapeuticsHoldingsIncMember" xlink:label="inva_EntasisTherapeuticsHoldingsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_LaJollaPharmaceuticalCompanyMember" xlink:label="inva_LaJollaPharmaceuticalCompanyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetResidualValue" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetResidualValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_Goodwill" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_CollaborativeArrangementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfGoodwillTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="inva_EntasisTherapeuticsHoldingsIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_InProcessResearchAndDevelopmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="inva_LaJollaPharmaceuticalCompanyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfGoodwillTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_GoodwillImpairmentLoss" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfGoodwillTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfGoodwillTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="us-gaap_AcquiredFiniteLivedIntangibleAssetResidualValue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfGoodwillTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfGoodwillTable" xlink:to="us-gaap_GoodwillLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_IntangibleAssetsMarketedProductsGross" xlink:label="inva_IntangibleAssetsMarketedProductsGross"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_IntangibleAssetsInProcessResearchAndDevelopmentGross" xlink:label="inva_IntangibleAssetsInProcessResearchAndDevelopmentGross"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_IntangibleAssetsCollaborationAgreementGross" xlink:label="inva_IntangibleAssetsCollaborationAgreementGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_IntangibleAssetsMarketedProductsAccumulatedAmortization" xlink:label="inva_IntangibleAssetsMarketedProductsAccumulatedAmortization"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_IntangibleAssetsInProcessResearchAndDevelopmentAccumulatedAmortization" xlink:label="inva_IntangibleAssetsInProcessResearchAndDevelopmentAccumulatedAmortization"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_IntangibleAssetsCollaborationAgreementAccumulatedAmortization" xlink:label="inva_IntangibleAssetsCollaborationAgreementAccumulatedAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_IntangibleAssetsMarketedProductsNet" xlink:label="inva_IntangibleAssetsMarketedProductsNet"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_IntangibleAssetsInProcessResearchAndDevelopmentNet" xlink:label="inva_IntangibleAssetsInProcessResearchAndDevelopmentNet"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_IntangibleAssetsCollaborationAgreementNet" xlink:label="inva_IntangibleAssetsCollaborationAgreementNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="inva_IntangibleAssetsMarketedProductsGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="inva_IntangibleAssetsInProcessResearchAndDevelopmentGross" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="inva_IntangibleAssetsCollaborationAgreementGross" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_IntangibleAssetsGrossExcludingGoodwill" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="inva_IntangibleAssetsMarketedProductsAccumulatedAmortization" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="inva_IntangibleAssetsInProcessResearchAndDevelopmentAccumulatedAmortization" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="inva_IntangibleAssetsCollaborationAgreementAccumulatedAmortization" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="inva_IntangibleAssetsMarketedProductsNet" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="inva_IntangibleAssetsInProcessResearchAndDevelopmentNet" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="inva_IntangibleAssetsCollaborationAgreementNet" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoryNetDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryNet" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_LaJollaPharmaceuticalCompanyMember" xlink:label="inva_LaJollaPharmaceuticalCompanyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryLineItems" xlink:label="us-gaap_InventoryLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryGross" xlink:label="us-gaap_InventoryGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryCurrentTable" xlink:label="us-gaap_InventoryCurrentTable"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_FairValueAdjustmentsOfInventoryFromAcquistion" xlink:label="inva_FairValueAdjustmentsOfInventoryFromAcquistion"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_AmortizationOfFairValueAdjustmentsOfCostOfProductsSold" xlink:label="inva_AmortizationOfFairValueAdjustmentsOfCostOfProductsSold"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="inva_LaJollaPharmaceuticalCompanyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_InventoryGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_InventoryCurrentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryCurrentTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryLineItems" xlink:to="inva_FairValueAdjustmentsOfInventoryFromAcquistion" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryCurrentTable" xlink:to="us-gaap_InventoryLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryLineItems" xlink:to="inva_AmortizationOfFairValueAdjustmentsOfCostOfProductsSold" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherAccruedLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_AccruedContractManufacturingLiability" xlink:label="inva_AccruedContractManufacturingLiability"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_AccruedClinicalLiability" xlink:label="inva_AccruedClinicalLiability"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_AccruedResearchLiability" xlink:label="inva_AccruedResearchLiability"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_AccruedProfessionalServices" xlink:label="inva_AccruedProfessionalServices"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_DeferredRoyaltyObligationCurrent" xlink:label="inva_DeferredRoyaltyObligationCurrent"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_AccruedLicenseFeesAndRoyalties" xlink:label="inva_AccruedLicenseFeesAndRoyalties"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilities" xlink:label="us-gaap_OtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="inva_AccruedContractManufacturingLiability" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="inva_AccruedClinicalLiability" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="inva_AccruedResearchLiability" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="inva_AccruedProfessionalServices" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_AccruedRoyaltiesCurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="inva_DeferredRoyaltyObligationCurrent" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="inva_AccruedLicenseFeesAndRoyalties" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_OtherLiabilities" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherLongtermLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_DeferredRoyaltyObligationNonCurrent" xlink:label="inva_DeferredRoyaltyObligationNonCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ContingentValueRightsLiability" xlink:label="inva_ContingentValueRightsLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="inva_DeferredRoyaltyObligationNonCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="inva_ContingentValueRightsLiability" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensation2012PlanAndEsppDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_EquityIncentivePlan2012Member" xlink:label="inva_EquityIncentivePlan2012Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_EmployeeStockPurchasePlanMember" xlink:label="inva_EmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveAndOverlappingOfferingPeriod" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveAndOverlappingOfferingPeriod"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_EmployeeStockPurchasePlanTwentyTwentyThreeMember" xlink:label="inva_EmployeeStockPurchasePlanTwentyTwentyThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountAsContributionOfEligibleCompensation" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountAsContributionOfEligibleCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="inva_EquityIncentivePlan2012Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="inva_EmployeeStockPurchasePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveAndOverlappingOfferingPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="inva_EmployeeStockPurchasePlanTwentyTwentyThreeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountAsContributionOfEligibleCompensation" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationDirectorCompensationProgramDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialEquityGrantValue" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialEquityGrantValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalEquityGrantValue" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalEquityGrantValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityGrantValue" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityGrantValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_DirectorMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialEquityGrantValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalEquityGrantValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityGrantValue" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_EmployeeStockPurchasePlanMember" xlink:label="inva_EmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="inva_EmployeeStockPurchasePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="5.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationCompensationAwardsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_5"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingNumber" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingWeightedAverageFairValuePerShare" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingWeightedAverageFairValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="5.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:to="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingNumber" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingWeightedAverageFairValuePerShare" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationValuationAssumptionsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_InnovivaMember" xlink:label="inva_InnovivaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_WeightedAverageMember" xlink:label="srt_WeightedAverageMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="inva_InnovivaMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_WeightedAverageMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="dei_LegalEntityAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureStockholdersEquityDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfTreasuryStockTable" xlink:label="us-gaap_ClassOfTreasuryStockTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:label="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="us-gaap_ShareRepurchaseProgramDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ShareRepurchaseAgreementWithGlaxoGroupLimitedMember" xlink:label="inva_ShareRepurchaseAgreementWithGlaxoGroupLimitedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareRepurchaseProgramAxis" xlink:label="us-gaap_ShareRepurchaseProgramAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_CommonStockAcquiredAverageCostPerShare" xlink:label="inva_CommonStockAcquiredAverageCostPerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ClassOfTreasuryStockTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareRepurchaseProgramDomain" xlink:to="inva_ShareRepurchaseAgreementWithGlaxoGroupLimitedMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfTreasuryStockTable" xlink:to="us-gaap_ShareRepurchaseProgramAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfTreasuryStockTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareRepurchaseProgramAxis" xlink:to="us-gaap_ShareRepurchaseProgramDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="inva_CommonStockAcquiredAverageCostPerShare" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfTreasuryStockTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfTreasuryStockTable" xlink:to="us-gaap_StatementLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleSubordinatedDebtMember" xlink:label="us-gaap_ConvertibleSubordinatedDebtMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_TwoThousandTwentyThreeNotesMember" xlink:label="inva_TwoThousandTwentyThreeNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_HealthCareRoyaltyPartnersMember" xlink:label="inva_HealthCareRoyaltyPartnersMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SeniorUnsecuredConvertibleNotesMember" xlink:label="inva_SeniorUnsecuredConvertibleNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_TwoThousandTwentyFiveNotesMember" xlink:label="inva_TwoThousandTwentyFiveNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_DebtInstrumentPrincipalAmount" xlink:label="inva_DebtInstrumentPrincipalAmount"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_OtherAccruedLiabilitiesMember" xlink:label="inva_OtherAccruedLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayableMember" xlink:label="us-gaap_LoansPayableMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_TwoThousandTwentyEightNotesMember" xlink:label="inva_TwoThousandTwentyEightNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_RoyaltyFinancingAgreementMember" xlink:label="inva_RoyaltyFinancingAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:label="us-gaap_DebtLongtermAndShorttermCombinedAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtCurrent" xlink:label="us-gaap_DebtCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_RoyaltyAgreementMaximumPotentialPayoutPercent" xlink:label="inva_RoyaltyAgreementMaximumPotentialPayoutPercent"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_RoyaltyAgreementIncreaseInMaximumPotentialPayoutPercent" xlink:label="inva_RoyaltyAgreementIncreaseInMaximumPotentialPayoutPercent"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentTwo" xlink:label="inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseBorrowings" xlink:label="us-gaap_InterestExpenseBorrowings"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_DeferredRoyaltyObligations" xlink:label="inva_DeferredRoyaltyObligations"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_RoyaltyPayments" xlink:label="inva_RoyaltyPayments"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_InterestRateOfDeferredRoyaltyObligation" xlink:label="inva_InterestRateOfDeferredRoyaltyObligation"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentOne" xlink:label="inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentOne"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_PaymentsForRoyaltyAgreement" xlink:label="inva_PaymentsForRoyaltyAgreement"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_ConvertibleSubordinatedDebtMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_TwoThousandTwentyThreeNotesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="inva_HealthCareRoyaltyPartnersMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherNoncurrentLiabilitiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="inva_SeniorUnsecuredConvertibleNotesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_TwoThousandTwentyFiveNotesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_DebtInstrumentPrincipalAmount" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="inva_OtherAccruedLiabilitiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_CounterpartyNameAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LoansPayableMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_TwoThousandTwentyEightNotesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_RoyaltyFinancingAgreementMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtLongtermAndShorttermCombinedAmount" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtNoncurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_RoyaltyAgreementMaximumPotentialPayoutPercent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_RoyaltyAgreementIncreaseInMaximumPotentialPayoutPercent" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentTwo" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseBorrowings" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_DeferredRoyaltyObligations" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_RoyaltyPayments" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_InterestRateOfDeferredRoyaltyObligation" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentOne" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_PaymentsForRoyaltyAgreement" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebtAbstract" xlink:label="us-gaap_InterestExpenseDebtAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_InnovivaCommonStockMember" xlink:label="inva_InnovivaCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleSubordinatedDebtMember" xlink:label="us-gaap_ConvertibleSubordinatedDebtMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_PrivatelyNegotiatedCappedCallOptionMember" xlink:label="inva_PrivatelyNegotiatedCappedCallOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CallOptionMember" xlink:label="us-gaap_CallOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_TwoThousandTwentyThreeNotesMember" xlink:label="inva_TwoThousandTwentyThreeNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_OldDebtInstrumentInterestRateBeforeRepurchaseOfNotesMember" xlink:label="inva_OldDebtInstrumentInterestRateBeforeRepurchaseOfNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PutOptionMember" xlink:label="us-gaap_PutOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_NumberOfDerivativeInstrumentsPurchased" xlink:label="inva_NumberOfDerivativeInstrumentsPurchased"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_NewDebtInstrumentInterestRateAfterRepurchaseOfNotesMember" xlink:label="inva_NewDebtInstrumentInterestRateAfterRepurchaseOfNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityStrikePrice1" xlink:label="us-gaap_OptionIndexedToIssuersEquityStrikePrice1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeCapPrice" xlink:label="us-gaap_DerivativeCapPrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:label="us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRepurchaseAmount" xlink:label="us-gaap_DebtInstrumentRepurchaseAmount"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_NumberOfSharesReceivableOnSettlementOfDerivativeInstrument" xlink:label="inva_NumberOfSharesReceivableOnSettlementOfDerivativeInstrument"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfUnsecuredDebt" xlink:label="us-gaap_RepaymentsOfUnsecuredDebt"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_DebtInstrumentRepurchasePercentage" xlink:label="inva_DebtInstrumentRepurchasePercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_DebtInstrumentPrincipalAmount" xlink:label="inva_DebtInstrumentPrincipalAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InterestExpenseDebtAbstract" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="inva_InnovivaCommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_ConvertibleSubordinatedDebtMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_PrivatelyNegotiatedCappedCallOptionMember" xlink:to="us-gaap_CallOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_TwoThousandTwentyThreeNotesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="inva_PrivatelyNegotiatedCappedCallOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateDomain" xlink:to="inva_OldDebtInstrumentInterestRateBeforeRepurchaseOfNotesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InterestExpenseDebtAbstract" xlink:to="us-gaap_AmortizationOfFinancingCosts" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_PrivatelyNegotiatedCappedCallOptionMember" xlink:to="us-gaap_PutOptionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_NumberOfDerivativeInstrumentsPurchased" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateDomain" xlink:to="inva_NewDebtInstrumentInterestRateAfterRepurchaseOfNotesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InterestExpenseDebtAbstract" xlink:to="us-gaap_InterestExpenseDebt" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_VariableRateAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionRatio1" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_RangeAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_OptionIndexedToIssuersEquityStrikePrice1" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DerivativeCapPrice" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentRepurchasedFaceAmount" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentRepurchaseAmount" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_NumberOfSharesReceivableOnSettlementOfDerivativeInstrument" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_RepaymentsOfUnsecuredDebt" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_DebtInstrumentRepurchasePercentage" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestPayableCurrent" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_UnamortizedDebtIssuanceExpense" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_DebtInstrumentPrincipalAmount" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtCurrent" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseDebtAbstract" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SeniorUnsecuredConvertibleNotesMember" xlink:label="inva_SeniorUnsecuredConvertibleNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_TwoThousandTwentyThreeNotesMember" xlink:label="inva_TwoThousandTwentyThreeNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseBorrowingsAbstract" xlink:label="us-gaap_InterestExpenseBorrowingsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_PrivatelyNegotiatedCappedCallOptionMember" xlink:label="inva_PrivatelyNegotiatedCappedCallOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate202006Member" xlink:label="us-gaap_AccountingStandardsUpdate202006Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ConvertibleDebtInstrumentLiabilityComponentAbstract" xlink:label="inva_ConvertibleDebtInstrumentLiabilityComponentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleSubordinatedDebtMember" xlink:label="us-gaap_ConvertibleSubordinatedDebtMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_TwoThousandTwentyFiveNotesMember" xlink:label="inva_TwoThousandTwentyFiveNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_DebtInstrumentPrincipalAmount" xlink:label="inva_DebtInstrumentPrincipalAmount"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_TwoThousandTwentyEightNotesMember" xlink:label="inva_TwoThousandTwentyEightNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeCapPrice" xlink:label="us-gaap_DerivativeCapPrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_PurchasesOfCappedCallsInConnectionWithConvertibleSeniorNotes" xlink:label="inva_PurchasesOfCappedCallsInConnectionWithConvertibleSeniorNotes"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_DebtInstrumentConvertibleConversionPremium" xlink:label="inva_DebtInstrumentConvertibleConversionPremium"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_DebtConversionCommonStockPriceToConversionPriceRatioPercentage" xlink:label="inva_DebtConversionCommonStockPriceToConversionPriceRatioPercentage"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_DebtConversionConvertedInstrumentAverageTradePricePercentage" xlink:label="inva_DebtConversionConvertedInstrumentAverageTradePricePercentage"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_DebtInstrumentRatioOfRepurchasePriceToThePrincipalAmount" xlink:label="inva_DebtInstrumentRatioOfRepurchasePriceToThePrincipalAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityCovenantTerms" xlink:label="us-gaap_LineOfCreditFacilityCovenantTerms"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_PortionOfDebtInstrumentFaceAmountExercised" xlink:label="inva_PortionOfDebtInstrumentFaceAmountExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:label="us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfUnsecuredDebt" xlink:label="us-gaap_RepaymentsOfUnsecuredDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:label="us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="inva_SeniorUnsecuredConvertibleNotesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_TwoThousandTwentyThreeNotesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InterestExpenseBorrowingsAbstract" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="inva_PrivatelyNegotiatedCappedCallOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate202006Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_ConvertibleDebtInstrumentLiabilityComponentAbstract" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_ConvertibleSubordinatedDebtMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_TwoThousandTwentyFiveNotesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InterestExpenseBorrowingsAbstract" xlink:to="us-gaap_AmortizationOfFinancingCosts" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_ConvertibleDebtInstrumentLiabilityComponentAbstract" xlink:to="inva_DebtInstrumentPrincipalAmount" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_TwoThousandTwentyEightNotesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InterestExpenseBorrowingsAbstract" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionRatio1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_ConvertibleDebtInstrumentLiabilityComponentAbstract" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InterestExpenseBorrowingsAbstract" xlink:to="us-gaap_InterestExpenseDebt" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_ConvertibleDebtInstrumentLiabilityComponentAbstract" xlink:to="us-gaap_LongTermDebt" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DerivativeCapPrice" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_PurchasesOfCappedCallsInConnectionWithConvertibleSeniorNotes" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_DebtInstrumentConvertibleConversionPremium" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_SharePrice" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_DebtConversionCommonStockPriceToConversionPriceRatioPercentage" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_DebtConversionConvertedInstrumentAverageTradePricePercentage" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_DebtInstrumentRatioOfRepurchasePriceToThePrincipalAmount" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityCovenantTerms" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_PortionOfDebtInstrumentFaceAmountExercised" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentRepurchasedFaceAmount" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_RepaymentsOfUnsecuredDebt" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_ConvertibleDebtInstrumentLiabilityComponentAbstract" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseBorrowingsAbstract" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureDebtDebtMaturitiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtByMaturityAbstract" xlink:label="us-gaap_LongTermDebtByMaturityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermDebtByMaturityAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebtByMaturityAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermDebtByMaturityAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermDebtByMaturityAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermDebtByMaturityAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermDebtByMaturityAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermDebtByMaturityAbstract" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_BurlingameCaliforniaMember" xlink:label="inva_BurlingameCaliforniaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetRentableArea" xlink:label="us-gaap_NetRentableArea"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_EntasisLeaseMember" xlink:label="inva_EntasisLeaseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_WalthamMassachusettsMember" xlink:label="inva_WalthamMassachusettsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_OperatingLeaseWeightedAverageIncrementalBorrowingRate" xlink:label="inva_OperatingLeaseWeightedAverageIncrementalBorrowingRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyAllegations" xlink:label="us-gaap_LossContingencyAllegations"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_DemandLettersSentByStockholders" xlink:label="inva_DemandLettersSentByStockholders"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="inva_BurlingameCaliforniaMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_NetRentableArea" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="inva_EntasisLeaseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_StatementGeographicalAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="inva_WalthamMassachusettsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LeaseContractualTermAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="inva_OperatingLeaseWeightedAverageIncrementalBorrowingRate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LossContingencyAllegations" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="inva_DemandLettersSentByStockholders" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeastCostDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_VariableLeaseCost" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCost" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalCashFlowInformationRelatedToLeaseDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_RightOfUseAssetsObtainedThroughAcquistions" xlink:label="inva_RightOfUseAssetsObtainedThroughAcquistions"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="inva_RightOfUseAssetsObtainedThroughAcquistions" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree" xlink:label="inva_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="inva_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationDeductionsOther" xlink:label="us-gaap_IncomeTaxReconciliationDeductionsOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense" xlink:label="us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary" xlink:label="us-gaap_IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationDeductionsOther" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_DeferredTaxLiabilitiesDepreciationAndAmortization" xlink:label="inva_DeferredTaxLiabilitiesDepreciationAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesInvestments" xlink:label="us-gaap_DeferredTaxLiabilitiesInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_DeferredTaxLiabilitiesInventoryFairValueAdjustment" xlink:label="inva_DeferredTaxLiabilitiesInventoryFairValueAdjustment"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_DeferredTaxAssetsUnrealizedLossesOnInvestmentNet" xlink:label="inva_DeferredTaxAssetsUnrealizedLossesOnInvestmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_DeferredTaxAssetsDeferredRoyaltyObligationNet" xlink:label="inva_DeferredTaxAssetsDeferredRoyaltyObligationNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="inva_DeferredTaxLiabilitiesDepreciationAndAmortization" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesInvestments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="inva_DeferredTaxLiabilitiesInventoryFairValueAdjustment" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="inva_DeferredTaxAssetsUnrealizedLossesOnInvestmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesOther" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="inva_DeferredTaxAssetsDeferredRoyaltyObligationNet" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalTaxDisclosuresDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_IncomeTaxesTable" xlink:label="inva_IncomeTaxesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_IncomeTaxesLineItems" xlink:label="inva_IncomeTaxesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:label="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_EntasisTherapeuticsHoldingsIncMember" xlink:label="inva_EntasisTherapeuticsHoldingsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_LaJollaPharmaceuticalCompanyMember" xlink:label="inva_LaJollaPharmaceuticalCompanyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_OperatingLossCarryforwardsIndefinitePeriod" xlink:label="inva_OperatingLossCarryforwardsIndefinitePeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_NetOperatingLossEstimatingDate" xlink:label="inva_NetOperatingLossEstimatingDate"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_UnrecognizedTaxBenefitsDecreaseResultingFromPriorPeriodTaxPositionsNet" xlink:label="inva_UnrecognizedTaxBenefitsDecreaseResultingFromPriorPeriodTaxPositionsNet"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_FederalNetOperatingLossesEstimatedUtilizationAmount" xlink:label="inva_FederalNetOperatingLossesEstimatedUtilizationAmount"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_UnrecognizedTaxBenefitsDecreaseResultingFromCurrentPeriodTaxPositionsNet" xlink:label="inva_UnrecognizedTaxBenefitsDecreaseResultingFromCurrentPeriodTaxPositionsNet"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_StateNetOperatingLossesEstimatedUtilizationAmount" xlink:label="inva_StateNetOperatingLossesEstimatedUtilizationAmount"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_UnrecognizedTaxBenefitsIncreaseResultingFromCurrentPeriodTaxPositionsNet" xlink:label="inva_UnrecognizedTaxBenefitsIncreaseResultingFromCurrentPeriodTaxPositionsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_IncomeTaxesTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_IncomeTaxesLineItems" xlink:to="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="inva_EntasisTherapeuticsHoldingsIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="inva_IncomeTaxesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_IncomeTaxesTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_IncomeTaxesLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="inva_LaJollaPharmaceuticalCompanyMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_IncomeTaxesTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_IncomeTaxesLineItems" xlink:to="inva_OperatingLossCarryforwardsIndefinitePeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_IncomeTaxesTable" xlink:to="inva_IncomeTaxesLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_IncomeTaxesLineItems" xlink:to="inva_NetOperatingLossEstimatingDate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="inva_UnrecognizedTaxBenefitsDecreaseResultingFromPriorPeriodTaxPositionsNet" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_IncomeTaxesLineItems" xlink:to="inva_FederalNetOperatingLossesEstimatedUtilizationAmount" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="inva_UnrecognizedTaxBenefitsDecreaseResultingFromCurrentPeriodTaxPositionsNet" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_IncomeTaxesLineItems" xlink:to="inva_StateNetOperatingLossesEstimatedUtilizationAmount" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="inva_UnrecognizedTaxBenefitsIncreaseResultingFromCurrentPeriodTaxPositionsNet" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_IncomeTaxesLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_IncomeTaxesLineItems" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_IncomeTaxesLineItems" xlink:to="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ArmataPharmaceuticalsIncMember" xlink:label="inva_ArmataPharmaceuticalsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoanRestructuringModificationDomain" xlink:label="us-gaap_LoanRestructuringModificationDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_NewPrincipalAmountMember" xlink:label="inva_NewPrincipalAmountMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_InCardaConvertibleNoteMember" xlink:label="inva_InCardaConvertibleNoteMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SecuredConvertibleCreditAgreementMember" xlink:label="inva_SecuredConvertibleCreditAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoanRestructuringModificationAxis" xlink:label="us-gaap_LoanRestructuringModificationAxis"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_GateNeuroscienceMember" xlink:label="inva_GateNeuroscienceMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ImaginabConvertibleNoteMember" xlink:label="inva_ImaginabConvertibleNoteMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ConvertiblePromissoryNotePurchaseAgreementMember" xlink:label="inva_ConvertiblePromissoryNotePurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_NoteAmendmentAgreementMember" xlink:label="inva_NoteAmendmentAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireLongtermInvestments" xlink:label="us-gaap_PaymentsToAcquireLongtermInvestments"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="inva_ArmataPharmaceuticalsIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LoanRestructuringModificationDomain" xlink:to="inva_NewPrincipalAmountMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="inva_InCardaConvertibleNoteMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_SecuredConvertibleCreditAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LoanRestructuringModificationAxis" xlink:to="us-gaap_LoanRestructuringModificationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="inva_GateNeuroscienceMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="inva_ImaginabConvertibleNoteMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_ConvertiblePromissoryNotePurchaseAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_NoteAmendmentAgreementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_DebtInstrumentAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_PaymentsToAcquireLongtermInvestments" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_RangeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_LoanRestructuringModificationAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfIncome">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyMember" xlink:label="us-gaap_RoyaltyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_CollaborativeArrangementsMember" xlink:label="inva_CollaborativeArrangementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_LicenseRevenueMember" xlink:label="inva_LicenseRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeconsolidationGainOrLossAmount" xlink:label="us-gaap_DeconsolidationGainOrLossAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_GainLossOnOtherInvestments" xlink:label="inva_GainLossOnOtherInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestAndDividendIncomeOperating" xlink:label="us-gaap_InterestAndDividendIncomeOperating"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_CostOfGoodsAndServicesSold" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_RoyaltyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_CostOfRevenue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="inva_CollaborativeArrangementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="inva_LicenseRevenueMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfitLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_DeconsolidationGainOrLossAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="inva_GainLossOnOtherInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_InterestAndDividendIncomeOperating" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_InterestExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_CostsAndExpenses" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfIncomeParenthetical">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_GSKMember" xlink:label="inva_GSKMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyMember" xlink:label="us-gaap_RoyaltyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostAmortization" xlink:label="us-gaap_CapitalizedContractCostAmortization"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="inva_GSKMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_RoyaltyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CapitalizedContractCostAmortization" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdateExtensibleList" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:label="us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonMember" xlink:label="us-gaap_TreasuryStockCommonMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersShares" xlink:label="inva_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="us-gaap_NoncontrollingInterestMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_RecognitionOfNoncontrollingInterestUponInitialConsolidationOfEntasis" xlink:label="inva_RecognitionOfNoncontrollingInterestUponInitialConsolidationOfEntasis"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_RecognitionOfNoncontrollingInterestUponInitialConsolidationofEntasisShares" xlink:label="inva_RecognitionOfNoncontrollingInterestUponInitialConsolidationofEntasisShares"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity" xlink:label="inva_ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntityShares" xlink:label="inva_ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntityShares"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_DerecognitionOfNoncontrollingInterestsUponSaleOfTrc" xlink:label="inva_DerecognitionOfNoncontrollingInterestsUponSaleOfTrc"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_DerecognitionOfNoncontrollingInterestsUponSaleOfTrcShares" xlink:label="inva_DerecognitionOfNoncontrollingInterestsUponSaleOfTrcShares"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_DerecognitionOfNonControllingInterestsUponAcquisitionOfEntasisMinorityInterest" xlink:label="inva_DerecognitionOfNonControllingInterestsUponAcquisitionOfEntasisMinorityInterest"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_DerecognitionOfNoncontrollingInterestsUponAcquisitionOfEntasisMinorityInterestShares" xlink:label="inva_DerecognitionOfNoncontrollingInterestsUponAcquisitionOfEntasisMinorityInterestShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtInShares" xlink:label="inva_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtInShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:label="us-gaap_TreasuryStockValueAcquiredCostMethod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="us-gaap_TreasuryStockSharesAcquired"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares" xlink:label="inva_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ProfitLossShares" xlink:label="inva_ProfitLossShares"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_AccountingStandardsUpdateExtensibleList" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_TreasuryStockCommonMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="inva_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_NoncontrollingInterestMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="inva_RecognitionOfNoncontrollingInterestUponInitialConsolidationOfEntasis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="inva_RecognitionOfNoncontrollingInterestUponInitialConsolidationofEntasisShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="inva_ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="inva_ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntityShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="inva_DerecognitionOfNoncontrollingInterestsUponSaleOfTrc" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="inva_DerecognitionOfNoncontrollingInterestsUponSaleOfTrcShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="inva_DerecognitionOfNonControllingInterestsUponAcquisitionOfEntasisMinorityInterest" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="inva_DerecognitionOfNoncontrollingInterestsUponAcquisitionOfEntasisMinorityInterestShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="inva_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtInShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_TreasuryStockValueAcquiredCostMethod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_TreasuryStockSharesAcquired" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="inva_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_ProfitLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="inva_ProfitLossShares" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTables">
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ConsolidatedEntitiesAndAcquisitionsLineItems" xlink:label="inva_ConsolidatedEntitiesAndAcquisitionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ScheduleOfConsolidatedEntitiesAndBusinessAcquisitionsByAcquisitionTable" xlink:label="inva_ScheduleOfConsolidatedEntitiesAndBusinessAcquisitionsByAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_TheravanceRespiratoryCompanyLlcMember" xlink:label="inva_TheravanceRespiratoryCompanyLlcMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_EntasisTherapeuticsHoldingsIncMember" xlink:label="inva_EntasisTherapeuticsHoldingsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:label="us-gaap_ScheduleOfVariableInterestEntitiesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_LaJollaPharmaceuticalCompanyMember" xlink:label="inva_LaJollaPharmaceuticalCompanyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="inva_ConsolidatedEntitiesAndAcquisitionsLineItems" xlink:to="inva_ScheduleOfConsolidatedEntitiesAndBusinessAcquisitionsByAcquisitionTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="inva_TheravanceRespiratoryCompanyLlcMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="inva_ScheduleOfConsolidatedEntitiesAndBusinessAcquisitionsByAcquisitionTable" xlink:to="srt_ConsolidatedEntitiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="inva_EntasisTherapeuticsHoldingsIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_ConsolidatedEntitiesAndAcquisitionsLineItems" xlink:to="us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="inva_ScheduleOfConsolidatedEntitiesAndBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="inva_LaJollaPharmaceuticalCompanyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_ConsolidatedEntitiesAndAcquisitionsLineItems" xlink:to="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_ConsolidatedEntitiesAndAcquisitionsLineItems" xlink:to="us-gaap_BusinessAcquisitionProFormaInformationTextBlock" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsTables">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:label="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:label="us-gaap_ScheduleOfVariableInterestEntitiesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ArmataPharmaceuticalsIncMember" xlink:label="inva_ArmataPharmaceuticalsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_EntasisTherapeuticsHoldingsIncMember" xlink:label="inva_EntasisTherapeuticsHoldingsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="srt_ConsolidatedEntitiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:to="inva_ArmataPharmaceuticalsIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:to="inva_EntasisTherapeuticsHoldingsIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureDebtTables">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_TwoThousandTwentyThreeNotesMember" xlink:label="inva_TwoThousandTwentyThreeNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_Percent2.50ConvertibleDebtMember" xlink:label="inva_Percent2.50ConvertibleDebtMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtTableTextBlock" xlink:label="us-gaap_ConvertibleDebtTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_TwoThousandTwentyFiveNotesMember" xlink:label="inva_TwoThousandTwentyFiveNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:label="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_TwoThousandTwentyEightNotesMember" xlink:label="inva_TwoThousandTwentyEightNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_TwoThousandTwentyThreeNotesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ScheduleOfDebtInstrumentsTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_Percent2.50ConvertibleDebtMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ConvertibleDebtTableTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_TwoThousandTwentyFiveNotesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_TwoThousandTwentyEightNotesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails">
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="inva_SummaryOfSignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SummaryOfSignificantAccountingPoliciesTable" xlink:label="inva_SummaryOfSignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_LabaCollaborationMember" xlink:label="inva_LabaCollaborationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_LaJollaMember" xlink:label="inva_LaJollaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_GSKMember" xlink:label="inva_GSKMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_TheravanceRespiratoryCompanyLlcMember" xlink:label="inva_TheravanceRespiratoryCompanyLlcMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_LongActingBeta2AgonistRelvarBreoMember" xlink:label="inva_LongActingBeta2AgonistRelvarBreoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_TwoThousandTwentyFiveNotesMember" xlink:label="inva_TwoThousandTwentyFiveNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_CustomerOneMember" xlink:label="inva_CustomerOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate202006Member" xlink:label="us-gaap_AccountingStandardsUpdate202006Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SarissaCapitalManagementLpMember" xlink:label="inva_SarissaCapitalManagementLpMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_LongActingBeta2AgonistAnoroMember" xlink:label="inva_LongActingBeta2AgonistAnoroMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeAccountsReceivableMember" xlink:label="us-gaap_TradeAccountsReceivableMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_CustomerTwoMember" xlink:label="inva_CustomerTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_CollaborativeArrangementRoyaltyRateDefinedLevelOne" xlink:label="inva_CollaborativeArrangementRoyaltyRateDefinedLevelOne"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_CustomerThreeMember" xlink:label="inva_CustomerThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate" xlink:label="inva_CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_CollaborativeArrangementRoyaltyRateDefinedLevelTwo" xlink:label="inva_CollaborativeArrangementRoyaltyRateDefinedLevelTwo"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts" xlink:label="inva_CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_NumberOfCustomers" xlink:label="inva_NumberOfCustomers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_CapitalizedFeePaidEstimatedUsefulLife" xlink:label="inva_CapitalizedFeePaidEstimatedUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_RelatedPartyTransactionCommonStockOwnershipPercentageByRelatedParty" xlink:label="inva_RelatedPartyTransactionCommonStockOwnershipPercentageByRelatedParty"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_DecreaseToAccumulatedDeficit" xlink:label="inva_DecreaseToAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ReductionToAdditionalPaidInCapital" xlink:label="inva_ReductionToAdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_IncreaseToConvertibleNotes" xlink:label="inva_IncreaseToConvertibleNotes"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_IncreaseInDeferredTaxAssets" xlink:label="inva_IncreaseInDeferredTaxAssets"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="inva_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="inva_SummaryOfSignificantAccountingPoliciesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="inva_LabaCollaborationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="inva_LaJollaMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="inva_GSKMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="inva_TheravanceRespiratoryCompanyLlcMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="inva_LongActingBeta2AgonistRelvarBreoMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_TwoThousandTwentyFiveNotesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="inva_CustomerOneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate202006Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="inva_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="inva_SarissaCapitalManagementLpMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="inva_LongActingBeta2AgonistAnoroMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_TradeAccountsReceivableMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="inva_CustomerTwoMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="inva_CollaborativeArrangementRoyaltyRateDefinedLevelOne" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="inva_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="inva_CustomerThreeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="inva_CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="inva_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="inva_CollaborativeArrangementRoyaltyRateDefinedLevelTwo" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="inva_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="inva_CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="inva_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="inva_NumberOfCustomers" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="inva_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="inva_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="inva_CapitalizedFeePaidEstimatedUsefulLife" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="inva_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_ConsolidatedEntitiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="inva_RelatedPartyTransactionCommonStockOwnershipPercentageByRelatedParty" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="inva_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_MajorCustomersAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="inva_DecreaseToAccumulatedDeficit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="inva_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="inva_ReductionToAdditionalPaidInCapital" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="inva_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="inva_IncreaseToConvertibleNotes" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="inva_IncreaseInDeferredTaxAssets" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_LaboratoryEquipmentFurnitureAndFixturesMember" xlink:label="inva_LaboratoryEquipmentFurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SoftwareAndComputerEquipmentMember" xlink:label="inva_SoftwareAndComputerEquipmentMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="inva_LaboratoryEquipmentFurnitureAndFixturesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="inva_SoftwareAndComputerEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesRelatedPartyTransactionsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_RelatedPartyTransactionCommonStockOwnershipPercentageByRelatedParty" xlink:label="inva_RelatedPartyTransactionCommonStockOwnershipPercentageByRelatedParty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SarissaCapitalManagementLpMember" xlink:label="inva_SarissaCapitalManagementLpMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="inva_RelatedPartyTransactionCommonStockOwnershipPercentageByRelatedParty" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="inva_SarissaCapitalManagementLpMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureNetIncomePerShareDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:label="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SeniorUnsecuredConvertibleNotesMember" xlink:label="inva_SeniorUnsecuredConvertibleNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_TwoThousandTwentyFiveNotesMember" xlink:label="inva_TwoThousandTwentyFiveNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_IncrementalCommonSharesAttributableToConversionOfDebtSecuritiesTreasuryStockMethod" xlink:label="inva_IncrementalCommonSharesAttributableToConversionOfDebtSecuritiesTreasuryStockMethod"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_DilutiveEpsOfNotes" xlink:label="inva_DilutiveEpsOfNotes"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="inva_SeniorUnsecuredConvertibleNotesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_TwoThousandTwentyFiveNotesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_IncrementalCommonSharesAttributableToConversionOfDebtSecuritiesTreasuryStockMethod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:to="us-gaap_LongtermDebtTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_DilutiveEpsOfNotes" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDilutedLineItems" xlink:label="us-gaap_EarningsPerShareDilutedLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:label="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_NetIncomeLossPerShareAbstract" xlink:label="inva_NetIncomeLossPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_TwoThousandTwentyThreeNotesMember" xlink:label="inva_TwoThousandTwentyThreeNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_DenominatorAbstract" xlink:label="inva_DenominatorAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_NumeratorAbstract" xlink:label="inva_NumeratorAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_IncrementalCommonSharesAttributableToConversionOfDebtSecuritiesTreasuryStockMethod" xlink:label="inva_IncrementalCommonSharesAttributableToConversionOfDebtSecuritiesTreasuryStockMethod"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_TwoThousandTwentyFiveNotesMember" xlink:label="inva_TwoThousandTwentyFiveNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:label="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestOnConvertibleDebtNetOfTax" xlink:label="us-gaap_InterestOnConvertibleDebtNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_TwoThousandTwentyEightNotesMember" xlink:label="inva_TwoThousandTwentyEightNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EarningsPerShareDilutedLineItems" xlink:to="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_NetIncomeLossPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareDilutedLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_TwoThousandTwentyThreeNotesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_DenominatorAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_NumeratorAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_NetIncomeLossPerShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareDilutedLineItems" xlink:to="inva_IncrementalCommonSharesAttributableToConversionOfDebtSecuritiesTreasuryStockMethod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_TwoThousandTwentyFiveNotesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_DenominatorAbstract" xlink:to="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_NumeratorAbstract" xlink:to="us-gaap_InterestOnConvertibleDebtNetOfTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareDilutedLineItems" xlink:to="inva_NumeratorAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_TwoThousandTwentyEightNotesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_DenominatorAbstract" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_NumeratorAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareDilutedLineItems" xlink:to="inva_DenominatorAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_DenominatorAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareDilutedLineItems" xlink:to="inva_NetIncomeLossPerShareAbstract" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureNetIncomePerShareAntiDilutiveSecuritiesDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_EquityIncentivePlansAndESPPMember" xlink:label="inva_EquityIncentivePlansAndESPPMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_OutstandingStockWarrantMember" xlink:label="inva_OutstandingStockWarrantMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="inva_EquityIncentivePlansAndESPPMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="inva_OutstandingStockWarrantMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfNetRevenueFromCollaborativeArrangementsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_StrategicAllianceAgreementMember" xlink:label="inva_StrategicAllianceAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_GSKMember" xlink:label="inva_GSKMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyMember" xlink:label="us-gaap_RoyaltyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees" xlink:label="inva_GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_LongActingBeta2AgonistRelvarBreoMember" xlink:label="inva_LongActingBeta2AgonistRelvarBreoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostAmortization" xlink:label="us-gaap_CapitalizedContractCostAmortization"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_LongActingBeta2AgonistAnoroMember" xlink:label="inva_LongActingBeta2AgonistAnoroMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_TrelegyElliptaMember" xlink:label="inva_TrelegyElliptaMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_StrategicAllianceMabaProgram" xlink:label="inva_StrategicAllianceMabaProgram"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_CollaborativeArrangementsMember" xlink:label="inva_CollaborativeArrangementsMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="inva_StrategicAllianceAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="inva_GSKMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_RoyaltyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="inva_GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="inva_LongActingBeta2AgonistRelvarBreoMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_CapitalizedContractCostAmortization" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="inva_LongActingBeta2AgonistAnoroMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="inva_TrelegyElliptaMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="inva_StrategicAllianceMabaProgram" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="inva_CollaborativeArrangementsMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureRevenueRecognitionDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_StrategicAllianceAgreementMember" xlink:label="inva_StrategicAllianceAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US" xlink:label="country_US"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_GSKMember" xlink:label="inva_GSKMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyMember" xlink:label="us-gaap_RoyaltyMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_LongActingBeta2AgonistRelvarBreoMember" xlink:label="inva_LongActingBeta2AgonistRelvarBreoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeographicConcentrationRiskMember" xlink:label="us-gaap_GeographicConcentrationRiskMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_PercentageOfRoyaltyPaymentsNotEntitledToReceive" xlink:label="inva_PercentageOfRoyaltyPaymentsNotEntitledToReceive"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_LabaCollaborationMember" xlink:label="inva_LabaCollaborationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonUsMember" xlink:label="us-gaap_NonUsMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_LaJollaMember" xlink:label="inva_LaJollaMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_LongActingBeta2AgonistAnoroMember" xlink:label="inva_LongActingBeta2AgonistAnoroMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_CollaborativeArrangementsMember" xlink:label="inva_CollaborativeArrangementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_TrelegyElliptaMember" xlink:label="inva_TrelegyElliptaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostGross" xlink:label="us-gaap_CapitalizedContractCostGross"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_GiaprezaMember" xlink:label="inva_GiaprezaMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_CollaborativeArrangementRoyaltyRateDefinedLevelOne" xlink:label="inva_CollaborativeArrangementRoyaltyRateDefinedLevelOne"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_XeravaMember" xlink:label="inva_XeravaMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate" xlink:label="inva_CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_XacduroMember" xlink:label="inva_XacduroMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_CollaborativeArrangementRoyaltyRateDefinedLevelTwo" xlink:label="inva_CollaborativeArrangementRoyaltyRateDefinedLevelTwo"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts" xlink:label="inva_CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_PercentageOfEconomicInterestOnFuturePaymentsUnderAgreements" xlink:label="inva_PercentageOfEconomicInterestOnFuturePaymentsUnderAgreements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="inva_StrategicAllianceAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="inva_GSKMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RoyaltyMember" xlink:to="inva_LongActingBeta2AgonistRelvarBreoMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_RoyaltyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_GeographicConcentrationRiskMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="inva_PercentageOfRoyaltyPaymentsNotEntitledToReceive" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="inva_LabaCollaborationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="us-gaap_NonUsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="inva_LaJollaMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RoyaltyMember" xlink:to="inva_LongActingBeta2AgonistAnoroMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="inva_CollaborativeArrangementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RoyaltyMember" xlink:to="inva_TrelegyElliptaMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_CapitalizedContractCostGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RoyaltyMember" xlink:to="inva_GiaprezaMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="inva_CollaborativeArrangementRoyaltyRateDefinedLevelOne" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RoyaltyMember" xlink:to="inva_XeravaMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="inva_CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RoyaltyMember" xlink:to="inva_XacduroMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="inva_CollaborativeArrangementRoyaltyRateDefinedLevelTwo" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="inva_CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="inva_PercentageOfEconomicInterestOnFuturePaymentsUnderAgreements" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureLicenseAndCollaborationArrangementsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_CommercialSupplyAgreementMember" xlink:label="inva_CommercialSupplyAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ResearchAndDevelopmentSupportMember" xlink:label="inva_ResearchAndDevelopmentSupportMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ZaiLabMember" xlink:label="inva_ZaiLabMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_CostReimbursementMember" xlink:label="inva_CostReimbursementMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_FuturePotentialMilestonePayment" xlink:label="inva_FuturePotentialMilestonePayment"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_PaionAgMember" xlink:label="inva_PaionAgMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_CostReimbursements" xlink:label="inva_CostReimbursements"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_EverestMedicinesLimitedMember" xlink:label="inva_EverestMedicinesLimitedMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ReductionToResearchAndDevelopmentExpense" xlink:label="inva_ReductionToResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_GeorgeWashingtonUniversityMember" xlink:label="inva_GeorgeWashingtonUniversityMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_RegulatoryMilestonePaymentsReceivable" xlink:label="inva_RegulatoryMilestonePaymentsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_HarvardUniversityMember" xlink:label="inva_HarvardUniversityMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SalesMilestonePaymentsReceivable" xlink:label="inva_SalesMilestonePaymentsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ParatekPharmaceuticalsIncMember" xlink:label="inva_ParatekPharmaceuticalsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_AstrazenecaMember" xlink:label="inva_AstrazenecaMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_LicenseRevenueRecognized" xlink:label="inva_LicenseRevenueRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_RoyaltiesPayablePeriodAfterFirstCommercialSaleOfProduct" xlink:label="inva_RoyaltiesPayablePeriodAfterFirstCommercialSaleOfProduct"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_PercentageOfReimbursedForDirectAndCertainIndirectManufacturingCosts" xlink:label="inva_PercentageOfReimbursedForDirectAndCertainIndirectManufacturingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_AccruedRoyaltyObligations" xlink:label="inva_AccruedRoyaltyObligations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_PercentageOfRoyaltyPayableOnNetSales" xlink:label="inva_PercentageOfRoyaltyPayableOnNetSales"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_PercentageOfRoyaltyOnPaymentsReceivedFromSublicensees" xlink:label="inva_PercentageOfRoyaltyOnPaymentsReceivedFromSublicensees"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ClinicalDevelopmentAndRegulatoryMilestonesAmountPayable" xlink:label="inva_ClinicalDevelopmentAndRegulatoryMilestonesAmountPayable"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_PercentageOfMinimumRoyaltyRate" xlink:label="inva_PercentageOfMinimumRoyaltyRate"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_PercentageOfMaximumRoyaltyBasedOnAchievementOfAnnualNetProductSalesThresholds" xlink:label="inva_PercentageOfMaximumRoyaltyBasedOnAchievementOfAnnualNetProductSalesThresholds"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ClaimExpirationDate" xlink:label="inva_ClaimExpirationDate"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SubscriptionAgreementOneTimeMilestonePaymentOnNetSales" xlink:label="inva_SubscriptionAgreementOneTimeMilestonePaymentOnNetSales"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_TermOfMilestonePaymentForNetSales" xlink:label="inva_TermOfMilestonePaymentForNetSales"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SubscriptionAgreementOneTimeMilestonePaymentOnCommercialSales" xlink:label="inva_SubscriptionAgreementOneTimeMilestonePaymentOnCommercialSales"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_TermOfMilestonePaymentForCommercialSale" xlink:label="inva_TermOfMilestonePaymentForCommercialSale"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="inva_CommercialSupplyAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="inva_ResearchAndDevelopmentSupportMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_Revenues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="inva_ZaiLabMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="inva_CostReimbursementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_FuturePotentialMilestonePayment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="inva_PaionAgMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_CostReimbursements" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="inva_EverestMedicinesLimitedMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_ReductionToResearchAndDevelopmentExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="inva_GeorgeWashingtonUniversityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_RegulatoryMilestonePaymentsReceivable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="inva_HarvardUniversityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_SalesMilestonePaymentsReceivable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="inva_ParatekPharmaceuticalsIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="inva_AstrazenecaMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_LicenseRevenueRecognized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CostOfRevenue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_RoyaltiesPayablePeriodAfterFirstCommercialSaleOfProduct" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_PercentageOfReimbursedForDirectAndCertainIndirectManufacturingCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RepaymentsOfDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_AccruedRoyaltyObligations" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_PercentageOfRoyaltyPayableOnNetSales" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_PercentageOfRoyaltyOnPaymentsReceivedFromSublicensees" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_ClinicalDevelopmentAndRegulatoryMilestonesAmountPayable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_PercentageOfMinimumRoyaltyRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_PercentageOfMaximumRoyaltyBasedOnAchievementOfAnnualNetProductSalesThresholds" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_ClaimExpirationDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_SubscriptionAgreementOneTimeMilestonePaymentOnNetSales" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_TermOfMilestonePaymentForNetSales" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_SubscriptionAgreementOneTimeMilestonePaymentOnCommercialSales" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_TermOfMilestonePaymentForCommercialSale" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableInterestEntityLineItems" xlink:label="us-gaap_VariableInterestEntityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:label="us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_StrategicAllianceAgreementMember" xlink:label="inva_StrategicAllianceAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:label="us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_BalanceSheetDisclosuresOfVariableInterestEntityAbstract" xlink:label="inva_BalanceSheetDisclosuresOfVariableInterestEntityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyMember" xlink:label="us-gaap_RoyaltyMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_IncomeStatementDisclosuresOfVariableInterestEntityAbstract" xlink:label="inva_IncomeStatementDisclosuresOfVariableInterestEntityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_OwnershipInterestInConsolidatedEntities" xlink:label="inva_OwnershipInterestInConsolidatedEntities"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_TheravanceRespiratoryCompanyLlcMember" xlink:label="inva_TheravanceRespiratoryCompanyLlcMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_CollaborativeArrangementsMember" xlink:label="inva_CollaborativeArrangementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MembersEquity" xlink:label="us-gaap_MembersEquity"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ProceedsFromSaleOfEconomicInterestUnderEquityPurchaseAgreement" xlink:label="inva_ProceedsFromSaleOfEconomicInterestUnderEquityPurchaseAgreement"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_IspFundLpMember" xlink:label="inva_IspFundLpMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ContingentSalesBasedMilestonePayment" xlink:label="inva_ContingentSalesBasedMilestonePayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_CashDistributionReceived" xlink:label="inva_CashDistributionReceived"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_RealizedLoss" xlink:label="inva_RealizedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestments" xlink:label="us-gaap_EquityMethodInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnInvestments" xlink:label="us-gaap_GainLossOnInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="us-gaap_ScheduleOfVariableInterestEntitiesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="inva_StrategicAllianceAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_BalanceSheetDisclosuresOfVariableInterestEntityAbstract" xlink:to="us-gaap_AssetsAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:to="srt_ConsolidatedEntitiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_RoyaltyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_IncomeStatementDisclosuresOfVariableInterestEntityAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="inva_OwnershipInterestInConsolidatedEntities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:to="inva_TheravanceRespiratoryCompanyLlcMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_BalanceSheetDisclosuresOfVariableInterestEntityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="inva_CollaborativeArrangementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_IncomeStatementDisclosuresOfVariableInterestEntityAbstract" xlink:to="us-gaap_OperatingExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_MembersEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="inva_ProceedsFromSaleOfEconomicInterestUnderEquityPurchaseAgreement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:to="inva_IspFundLpMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_LongTermInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_IncomeStatementDisclosuresOfVariableInterestEntityAbstract" xlink:to="us-gaap_OperatingIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="inva_ContingentSalesBasedMilestonePayment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_IncomeStatementDisclosuresOfVariableInterestEntityAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="inva_CashDistributionReceived" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_IncomeStatementDisclosuresOfVariableInterestEntityAbstract" xlink:to="inva_RealizedLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="us-gaap_EquityMethodInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_IncomeStatementDisclosuresOfVariableInterestEntityAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="inva_BalanceSheetDisclosuresOfVariableInterestEntityAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_IncomeStatementDisclosuresOfVariableInterestEntityAbstract" xlink:to="us-gaap_GainLossOnInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="inva_IncomeStatementDisclosuresOfVariableInterestEntityAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_IncomeStatementDisclosuresOfVariableInterestEntityAbstract" xlink:to="us-gaap_ProfitLoss" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsIspFundLpDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableInterestEntityLineItems" xlink:label="us-gaap_VariableInterestEntityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:label="us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:label="us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralPartnerMember" xlink:label="us-gaap_GeneralPartnerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LimitedPartnersCumulativeCashDistributions" xlink:label="us-gaap_LimitedPartnersCumulativeCashDistributions"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_IspFundLpMember" xlink:label="inva_IspFundLpMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LimitedPartnersContributedCapital" xlink:label="us-gaap_LimitedPartnersContributedCapital"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_LimitedPartnersInitialContribution" xlink:label="inva_LimitedPartnersInitialContribution"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_PercentageOfEconomicInterestInPartnership" xlink:label="inva_PercentageOfEconomicInterestInPartnership"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_NetInvestmentRelatedIncomeExpenseEarnedInccured" xlink:label="inva_NetInvestmentRelatedIncomeExpenseEarnedInccured"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInvestmentExpense" xlink:label="us-gaap_InvestmentIncomeInvestmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="us-gaap_UnrealizedGainLossOnInvestments"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_PaymentOfManagementAndIncentiveFee" xlink:label="inva_PaymentOfManagementAndIncentiveFee"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_PartnershipAgreementLockUpPeriod" xlink:label="inva_PartnershipAgreementLockUpPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterestAndDividend" xlink:label="us-gaap_InvestmentIncomeInterestAndDividend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnInvestments" xlink:label="us-gaap_GainLossOnInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="us-gaap_ScheduleOfVariableInterestEntitiesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_GeneralPartnerMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:to="srt_ConsolidatedEntitiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="us-gaap_LimitedPartnersCumulativeCashDistributions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:to="inva_IspFundLpMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="us-gaap_LimitedPartnersContributedCapital" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="inva_LimitedPartnersInitialContribution" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="inva_PercentageOfEconomicInterestInPartnership" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="us-gaap_Liabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="inva_NetInvestmentRelatedIncomeExpenseEarnedInccured" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="us-gaap_InvestmentIncomeInvestmentExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="us-gaap_InvestmentIncomeInterest" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="us-gaap_UnrealizedGainLossOnInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="inva_PaymentOfManagementAndIncentiveFee" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="inva_PartnershipAgreementLockUpPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="us-gaap_InvestmentIncomeInterestAndDividend" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="us-gaap_GainLossOnInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="us-gaap_Assets" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:label="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SecuritiesPurchaseAgreementMember" xlink:label="inva_SecuritiesPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember" xlink:label="inva_InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ConsolidatedInvesteesMember" xlink:label="inva_ConsolidatedInvesteesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ConvertiblePromissoryNoteMember" xlink:label="inva_ConvertiblePromissoryNoteMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_EntasisTherapeuticsHoldingsIncMember" xlink:label="inva_EntasisTherapeuticsHoldingsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SecuritiesPurchaseAgreementRightsToDesignateInvesteeBoardMembersNumberOfBoardMembers" xlink:label="inva_SecuritiesPurchaseAgreementRightsToDesignateInvesteeBoardMembersNumberOfBoardMembers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SaleOfWarrantsNumberOfWarrantsIssuedInTransaction" xlink:label="inva_SaleOfWarrantsNumberOfWarrantsIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_CommonStockAndWarrantsMember" xlink:label="inva_CommonStockAndWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:label="us-gaap_PaymentsToAcquireEquitySecuritiesFvNi"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_WarrantsAcquiredInSecondQuarterOf2021Member" xlink:label="inva_WarrantsAcquiredInSecondQuarterOf2021Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_WarrantsAcquiredInThirdQuarterOf2020Member" xlink:label="inva_WarrantsAcquiredInThirdQuarterOf2020Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_WarrantsAcquiredInSecondQuarterOf2020Member" xlink:label="inva_WarrantsAcquiredInSecondQuarterOf2020Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="us-gaap_EquitySecuritiesFvNi"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:label="us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="us-gaap_RepaymentsOfConvertibleDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillPeriodIncreaseDecrease" xlink:label="us-gaap_GoodwillPeriodIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_MeasurementPeriodAdjustmentsIncreaseDecreaseInEstimatedPurchasePrice" xlink:label="inva_MeasurementPeriodAdjustmentsIncreaseDecreaseInEstimatedPurchasePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestPeriodIncreaseDecrease" xlink:label="us-gaap_MinorityInterestPeriodIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_IncreaseDecreaseInDeferredTaxLiabilities" xlink:label="inva_IncreaseDecreaseInDeferredTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest" xlink:label="us-gaap_MinorityInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:label="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_BusinessAcquisitionsOfChangeInFairValueOfInvestment" xlink:label="inva_BusinessAcquisitionsOfChangeInFairValueOfInvestment"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="inva_SecuritiesPurchaseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="inva_InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="inva_ConsolidatedInvesteesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_ConvertiblePromissoryNoteMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="inva_EntasisTherapeuticsHoldingsIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="inva_SecuritiesPurchaseAgreementRightsToDesignateInvesteeBoardMembersNumberOfBoardMembers" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_WarrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="inva_SaleOfWarrantsNumberOfWarrantsIssuedInTransaction" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_CommonStockAndWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="dei_LegalEntityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_WarrantsAcquiredInSecondQuarterOf2021Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_WarrantsAcquiredInThirdQuarterOf2020Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_WarrantsAcquiredInSecondQuarterOf2020Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_EquitySecuritiesFvNi" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_EquitySecuritiesFvNiRealizedGainLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_RepaymentsOfConvertibleDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_GoodwillPeriodIncreaseDecrease" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="inva_MeasurementPeriodAdjustmentsIncreaseDecreaseInEstimatedPurchasePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_MinorityInterestPeriodIncreaseDecrease" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="inva_IncreaseDecreaseInDeferredTaxLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_MinorityInterest" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="inva_BusinessAcquisitionsOfChangeInFairValueOfInvestment" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_EntasisTherapeuticsHoldingsIncMember" xlink:label="inva_EntasisTherapeuticsHoldingsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_LaJollaPharmaceuticalCompanyMember" xlink:label="inva_LaJollaPharmaceuticalCompanyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" xlink:label="inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedPersonnelRelatedExpenses" xlink:label="inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedPersonnelRelatedExpenses"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAccruedLiabilities" xlink:label="inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="inva_EntasisTherapeuticsHoldingsIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="inva_LaJollaPharmaceuticalCompanyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_Goodwill" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedPersonnelRelatedExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAccruedLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsLaJollaPharmaceuticalCompanyDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_LaJollaPharmaceuticalCompanyMember" xlink:label="inva_LaJollaPharmaceuticalCompanyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="us-gaap_BusinessAcquisitionSharePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillPeriodIncreaseDecrease" xlink:label="us-gaap_GoodwillPeriodIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_IncreaseDecreaseInDeferredTaxAssets" xlink:label="inva_IncreaseDecreaseInDeferredTaxAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:label="us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_MeasurementPeriodAdjustmentsIncreaseDecreaseInLiabilities" xlink:label="inva_MeasurementPeriodAdjustmentsIncreaseDecreaseInLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcquisitionCosts" xlink:label="us-gaap_AcquisitionCosts"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_IncreaseDecreaseInDeferredTaxLiabilities" xlink:label="inva_IncreaseDecreaseInDeferredTaxLiabilities"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="inva_LaJollaPharmaceuticalCompanyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionSharePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_GoodwillPeriodIncreaseDecrease" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="inva_IncreaseDecreaseInDeferredTaxAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_IncreaseDecreaseInInventories" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="inva_MeasurementPeriodAdjustmentsIncreaseDecreaseInLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_AcquisitionCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="inva_IncreaseDecreaseInDeferredTaxLiabilities" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsProFormaInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_EntasisTherapeuticsHoldingsIncMember" xlink:label="inva_EntasisTherapeuticsHoldingsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:label="us-gaap_BusinessAcquisitionsProFormaRevenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_LaJollaPharmaceuticalCompanyMember" xlink:label="inva_LaJollaPharmaceuticalCompanyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:label="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="srt_ConsolidatedEntitiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="inva_EntasisTherapeuticsHoldingsIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionsProFormaRevenue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="inva_LaJollaPharmaceuticalCompanyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_OneDirectorMember" xlink:label="inva_OneDirectorMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:label="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_CommonStockAndWarrantsMember" xlink:label="inva_CommonStockAndWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement" xlink:label="inva_SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SecuredConvertibleCreditAgreementMember" xlink:label="inva_SecuredConvertibleCreditAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember" xlink:label="inva_InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ConsolidatedInvesteesMember" xlink:label="inva_ConsolidatedInvesteesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_CreditAndSecurityAgreementMember" xlink:label="inva_CreditAndSecurityAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ArmataPharmaceuticalsIncMember" xlink:label="inva_ArmataPharmaceuticalsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_TwoDirectorsMember" xlink:label="inva_TwoDirectorsMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_WarrantsPurchasedIn2020Member" xlink:label="inva_WarrantsPurchasedIn2020Member"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SaleOfWarrantsNumberOfWarrantsIssuedInTransaction" xlink:label="inva_SaleOfWarrantsNumberOfWarrantsIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_WarrantsPurchasedIn2021Member" xlink:label="inva_WarrantsPurchasedIn2021Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_WarrantsPurchasedIn2022Member" xlink:label="inva_WarrantsPurchasedIn2022Member"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SecuritiesPurchaseAgreementTotalNumberOfWarrantsToBePurchasedUnderAgreement" xlink:label="inva_SecuritiesPurchaseAgreementTotalNumberOfWarrantsToBePurchasedUnderAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SecuritiesPurchaseAgreementAmount" xlink:label="inva_SecuritiesPurchaseAgreementAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SecuritiesPurchaseAgreementNumberOfTranches" xlink:label="inva_SecuritiesPurchaseAgreementNumberOfTranches"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ArmataConvertibleNoteMember" xlink:label="inva_ArmataConvertibleNoteMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ArmataTermLoanMember" xlink:label="inva_ArmataTermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentDescription" xlink:label="us-gaap_DebtInstrumentDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_VotingAgreementMaximumVotingRightsPercent" xlink:label="inva_VotingAgreementMaximumVotingRightsPercent"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee" xlink:label="inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_NumberOfBoardMembersOfInvestee" xlink:label="inva_NumberOfBoardMembersOfInvestee"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="us-gaap_EquitySecuritiesFvNi"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGain" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedGain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableInterestEntityOwnershipPercentage" xlink:label="us-gaap_VariableInterestEntityOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SpecialTermReDesignatingBoardMemberToBoardOfInvestee" xlink:label="inva_SpecialTermReDesignatingBoardMemberToBoardOfInvestee"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="inva_OneDirectorMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_CommonStockAndWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="dei_LegalEntityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="inva_SecuredConvertibleCreditAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="inva_InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="inva_ConsolidatedInvesteesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_CreditAndSecurityAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:to="inva_ArmataPharmaceuticalsIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="inva_TwoDirectorsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_WarrantsPurchasedIn2020Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_SaleOfWarrantsNumberOfWarrantsIssuedInTransaction" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_WarrantsPurchasedIn2021Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="srt_ConsolidatedEntitiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_WarrantsPurchasedIn2022Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_SecuritiesPurchaseAgreementTotalNumberOfWarrantsToBePurchasedUnderAgreement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_WarrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_SecuritiesPurchaseAgreementAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="srt_TitleOfIndividualAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_SecuritiesPurchaseAgreementNumberOfTranches" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_ArmataConvertibleNoteMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_LongtermDebtTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_ArmataTermLoanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_DebtInstrumentDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_DebtInstrumentTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_VotingAgreementMaximumVotingRightsPercent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_NumberOfBoardMembersOfInvestee" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_EquitySecuritiesFvNi" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_EquitySecuritiesFvNiUnrealizedGain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_EquitySecuritiesFvNiUnrealizedLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_VariableInterestEntityOwnershipPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_SpecialTermReDesignatingBoardMemberToBoardOfInvestee" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsSummarizedFinancialDataDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:label="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementRelatedDisclosuresAbstract" xlink:label="us-gaap_IncomeStatementRelatedDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ArmataPharmaceuticalsIncMember" xlink:label="inva_ArmataPharmaceuticalsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_EntasisTherapeuticsHoldingsIncMember" xlink:label="inva_EntasisTherapeuticsHoldingsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementRelatedDisclosuresAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_BalanceSheetRelatedDisclosuresAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="srt_ConsolidatedEntitiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:to="inva_ArmataPharmaceuticalsIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_AssetsCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementRelatedDisclosuresAbstract" xlink:to="us-gaap_OperatingIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_IncomeStatementRelatedDisclosuresAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:to="inva_EntasisTherapeuticsHoldingsIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_AssetsNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementRelatedDisclosuresAbstract" xlink:to="us-gaap_ProfitLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_LiabilitiesCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_LiabilitiesNoncurrent" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_NameOfEventDomain" xlink:label="inva_NameOfEventDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_QualifiedFinancingMember" xlink:label="inva_QualifiedFinancingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_IncardaMember" xlink:label="inva_IncardaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SeriesCPreferredStockAndWarrantsMember" xlink:label="inva_SeriesCPreferredStockAndWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="us-gaap_ValuationTechniqueDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_OptionPricingModelBacksolveValuationMember" xlink:label="inva_OptionPricingModelBacksolveValuationMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ConsolidatedInvesteesMember" xlink:label="inva_ConsolidatedInvesteesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_NameOfEventAxis" xlink:label="inva_NameOfEventAxis"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_NameOfEventDomain" xlink:label="inva_NameOfEventDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="us-gaap_ValuationTechniqueAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="us-gaap_ValuationTechniqueDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_Incarda2020WarrantsMember" xlink:label="inva_Incarda2020WarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_InCardaConvertibleNoteMember" xlink:label="inva_InCardaConvertibleNoteMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SecuritiesPurchaseAgreementWarrantsNumberOfSecuritiesCalledByWarrants" xlink:label="inva_SecuritiesPurchaseAgreementWarrantsNumberOfSecuritiesCalledByWarrants"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ConvertibleNoteAndWarrantsMember" xlink:label="inva_ConvertibleNoteAndWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SecuritiesPurchaseAgreementAmount" xlink:label="inva_SecuritiesPurchaseAgreementAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_DebtInstrumentTransactionCost" xlink:label="inva_DebtInstrumentTransactionCost"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SeriesA1PreferredStockMember" xlink:label="inva_SeriesA1PreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee" xlink:label="inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SeriesD1PreferredStockMember" xlink:label="inva_SeriesD1PreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_NumberOfBoardMembersOfInvestee" xlink:label="inva_NumberOfBoardMembersOfInvestee"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SeriesD2PreferredStockMember" xlink:label="inva_SeriesD2PreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SeriesD1WarrantMember" xlink:label="inva_SeriesD1WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:label="us-gaap_PaymentsToAcquireEquitySecuritiesFvNi"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SeriesD2WarrantMember" xlink:label="inva_SeriesD2WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="us-gaap_EquitySecuritiesFvNi"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SeriesCWarrantsAndSeriesDWarrantsMember" xlink:label="inva_SeriesCWarrantsAndSeriesDWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ExpectedHoldingPeriod" xlink:label="inva_ExpectedHoldingPeriod"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SeriesDWarrantsMember" xlink:label="inva_SeriesDWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_RiskFreeInterestRate" xlink:label="inva_RiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="us-gaap_SeriesDPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_DividendYield" xlink:label="inva_DividendYield"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SeriesD1AndD2PreferredStockAndCommonStockMember" xlink:label="inva_SeriesD1AndD2PreferredStockAndCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_PercentageOfEstimatedVolatility" xlink:label="inva_PercentageOfEstimatedVolatility"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:label="us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ExtendedExpirationDate" xlink:label="inva_ExtendedExpirationDate"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_CarryingValueWroteOffWarrantExercise" xlink:label="inva_CarryingValueWroteOffWarrantExercise"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGain" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedGain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_NameOfEventDomain" xlink:to="inva_QualifiedFinancingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="inva_IncardaMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_SeriesCPreferredStockAndWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationTechniqueDomain" xlink:to="inva_OptionPricingModelBacksolveValuationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="inva_ConsolidatedInvesteesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="inva_NameOfEventAxis" xlink:to="inva_NameOfEventDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="inva_NameOfEventAxis" xlink:to="inva_NameOfEventDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_Incarda2020WarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_ValuationTechniqueAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="inva_InCardaConvertibleNoteMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_WarrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_SecuritiesPurchaseAgreementWarrantsNumberOfSecuritiesCalledByWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_ConvertibleNoteAndWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_SecuritiesPurchaseAgreementAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_DebtInstrumentTransactionCost" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="srt_ConsolidatedEntitiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_SeriesA1PreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="inva_NameOfEventAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_SeriesD1PreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_NumberOfBoardMembersOfInvestee" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_SeriesD2PreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_SeriesD1WarrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_SeriesD2WarrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_EquitySecuritiesFvNi" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_SeriesCWarrantsAndSeriesDWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_ExpectedHoldingPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_SeriesDWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_RiskFreeInterestRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_SeriesDPreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_DividendYield" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_SeriesD1AndD2PreferredStockAndCommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_PercentageOfEstimatedVolatility" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_ExtendedExpirationDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_CarryingValueWroteOffWarrantExercise" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_EquitySecuritiesFvNiUnrealizedLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_EquitySecuritiesFvNiUnrealizedGain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInImaginabDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ImaginabMember" xlink:label="inva_ImaginabMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement" xlink:label="inva_SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ConsolidatedInvesteesMember" xlink:label="inva_ConsolidatedInvesteesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_OneOfImaginabsCommonStockholderMember" xlink:label="inva_OneOfImaginabsCommonStockholderMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SeriesC2PreferredStockMember" xlink:label="inva_SeriesC2PreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SecuritiesPurchaseAgreementAmount" xlink:label="inva_SecuritiesPurchaseAgreementAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee" xlink:label="inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_NumberOfBoardMembersOfInvestee" xlink:label="inva_NumberOfBoardMembersOfInvestee"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="us-gaap_EquitySecuritiesFvNi"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="inva_ImaginabMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="inva_ConsolidatedInvesteesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="inva_OneOfImaginabsCommonStockholderMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_SeriesC2PreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_SecuritiesPurchaseAgreementAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="srt_ConsolidatedEntitiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_NumberOfBoardMembersOfInvestee" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_EquitySecuritiesFvNi" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInGateNeurosciencesDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_GateNeuroscienceMember" xlink:label="inva_GateNeuroscienceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentPrincipal"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ConvertiblePromissoryNotePurchaseAgreementMember" xlink:label="inva_ConvertiblePromissoryNotePurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_NoteAmendmentAgreementMember" xlink:label="inva_NoteAmendmentAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_NumberOfCommonStockIssuedDescription" xlink:label="inva_NumberOfCommonStockIssuedDescription"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SecondNoteAmendmentAgreementMember" xlink:label="inva_SecondNoteAmendmentAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireLongtermInvestments" xlink:label="us-gaap_PaymentsToAcquireLongtermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="us-gaap_EquitySecuritiesFvNi"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGain" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedGain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedLoss"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="inva_GateNeuroscienceMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentPrincipal" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_ConvertiblePromissoryNotePurchaseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="srt_ConsolidatedEntitiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_NoteAmendmentAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_NumberOfCommonStockIssuedDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_SecondNoteAmendmentAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_PaymentsToAcquireLongtermInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_EquitySecuritiesFvNi" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_EquitySecuritiesFvNiUnrealizedGain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_EquitySecuritiesFvNiUnrealizedLoss" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInNanoliveDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_NanoliveMember" xlink:label="inva_NanoliveMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement" xlink:label="inva_SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ConsolidatedInvesteesMember" xlink:label="inva_ConsolidatedInvesteesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SecuritiesPurchaseAgreementAmount" xlink:label="inva_SecuritiesPurchaseAgreementAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee" xlink:label="inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_NumberOfBoardMembersOfInvestee" xlink:label="inva_NumberOfBoardMembersOfInvestee"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="us-gaap_EquitySecuritiesFvNi"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="inva_NanoliveMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="srt_ConsolidatedEntitiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="inva_ConsolidatedInvesteesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_SecuritiesPurchaseAgreementAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_NumberOfBoardMembersOfInvestee" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_EquitySecuritiesFvNi" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsAvailableforsaleSecuritiesDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:label="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ConvertibleSubordinatedDebtFairValueDisclosures" xlink:label="inva_ConvertibleSubordinatedDebtFairValueDisclosures"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ArmataPharmaceuticalsIncMember" xlink:label="inva_ArmataPharmaceuticalsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtMember" xlink:label="us-gaap_ConvertibleDebtMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesMember" xlink:label="us-gaap_EquitySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_IspFundLpMember" xlink:label="inva_IspFundLpMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ConvertibleSeniorDebtFairValueDisclosures" xlink:label="inva_ConvertibleSeniorDebtFairValueDisclosures"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_EntasisTherapeuticsHoldingsIncMember" xlink:label="inva_EntasisTherapeuticsHoldingsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_TermLoanInvestmentMember" xlink:label="inva_TermLoanInvestmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsNonrecurringMember" xlink:label="us-gaap_FairValueMeasurementsNonrecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ArmataTermLoanMember" xlink:label="inva_ArmataTermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_IncardaMember" xlink:label="inva_IncardaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_EquityInvestmentsAndMoneyMarketFundsMember" xlink:label="inva_EquityInvestmentsAndMoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ContingentValueRightsLiability" xlink:label="inva_ContingentValueRightsLiability"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_GateNeuroscienceMember" xlink:label="inva_GateNeuroscienceMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_PrivatePlacementPositionsAndConvertibleNotesMember" xlink:label="inva_PrivatePlacementPositionsAndConvertibleNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtMember" xlink:label="us-gaap_DebtMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="us-gaap_DebtInstrumentFairValue"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_PreferredStockWarrantsMember" xlink:label="inva_PreferredStockWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_PartnershipAgreementLockUpPeriod" xlink:label="inva_PartnershipAgreementLockUpPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LimitedPartnersContributedCapital" xlink:label="us-gaap_LimitedPartnersContributedCapital"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_WithdrawalFromInvestment" xlink:label="inva_WithdrawalFromInvestment"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="inva_ConvertibleSubordinatedDebtFairValueDisclosures" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="inva_ArmataPharmaceuticalsIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ConvertibleDebtMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_EquitySecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="inva_IspFundLpMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="inva_ConvertibleSeniorDebtFairValueDisclosures" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="inva_EntasisTherapeuticsHoldingsIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="srt_ConsolidatedEntitiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="inva_TermLoanInvestmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsNonrecurringMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_ArmataTermLoanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ConvertibleDebtFairValueDisclosures" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="inva_IncardaMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="inva_EquityInvestmentsAndMoneyMarketFundsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_WarrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="inva_ContingentValueRightsLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="inva_GateNeuroscienceMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="inva_PrivatePlacementPositionsAndConvertibleNotesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_DebtMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DebtInstrumentFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_PreferredStockWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="inva_PartnershipAgreementLockUpPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LimitedPartnersContributedCapital" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="inva_WithdrawalFromInvestment" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostLineItems" xlink:label="us-gaap_CapitalizedContractCostLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostTable" xlink:label="us-gaap_CapitalizedContractCostTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US" xlink:label="country_US"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_GSKMember" xlink:label="inva_GSKMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostGross" xlink:label="us-gaap_CapitalizedContractCostGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyMember" xlink:label="us-gaap_RoyaltyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_CapitalizedFeesPaidFutureAmortizationAbstract" xlink:label="inva_CapitalizedFeesPaidFutureAmortizationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_CapitalizedFeesPaidRemainingEstimatedAmortizationNextTwelveMonths" xlink:label="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EuropeMember" xlink:label="srt_EuropeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostAccumulatedAmortization" xlink:label="us-gaap_CapitalizedContractCostAccumulatedAmortization"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearTwo" xlink:label="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_JP" xlink:label="country_JP"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostNet" xlink:label="us-gaap_CapitalizedContractCostNet"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearthree" xlink:label="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearthree"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_CapitalizedFeesPaidWeightedAverageUsefulLife" xlink:label="inva_CapitalizedFeesPaidWeightedAverageUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFour" xlink:label="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostAmortization" xlink:label="us-gaap_CapitalizedContractCostAmortization"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFive" xlink:label="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFive"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_CapitalizedFeesPaidRemainingEstimatedAmortizationAfterYearFive" xlink:label="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationAfterYearFive"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CapitalizedContractCostLineItems" xlink:to="us-gaap_CapitalizedContractCostTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="inva_GSKMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_CapitalizedContractCostTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CapitalizedContractCostLineItems" xlink:to="us-gaap_CapitalizedContractCostGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_RoyaltyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_CapitalizedFeesPaidFutureAmortizationAbstract" xlink:to="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationNextTwelveMonths" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_EuropeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_CapitalizedContractCostTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CapitalizedContractCostLineItems" xlink:to="us-gaap_CapitalizedContractCostAccumulatedAmortization" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_CapitalizedFeesPaidFutureAmortizationAbstract" xlink:to="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearTwo" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_JP" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_CapitalizedContractCostTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CapitalizedContractCostLineItems" xlink:to="us-gaap_CapitalizedContractCostNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_CapitalizedFeesPaidFutureAmortizationAbstract" xlink:to="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearthree" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CapitalizedContractCostLineItems" xlink:to="inva_CapitalizedFeesPaidWeightedAverageUsefulLife" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_CapitalizedFeesPaidFutureAmortizationAbstract" xlink:to="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFour" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CapitalizedContractCostLineItems" xlink:to="us-gaap_CapitalizedContractCostAmortization" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_CapitalizedFeesPaidFutureAmortizationAbstract" xlink:to="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFive" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CapitalizedContractCostLineItems" xlink:to="inva_CapitalizedFeesPaidFutureAmortizationAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_CapitalizedFeesPaidFutureAmortizationAbstract" xlink:to="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationAfterYearFive" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillLineItems" xlink:label="us-gaap_GoodwillLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="us-gaap_ScheduleOfGoodwillTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="us-gaap_CollaborativeArrangementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_EntasisTherapeuticsHoldingsIncMember" xlink:label="inva_EntasisTherapeuticsHoldingsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_LaJollaPharmaceuticalCompanyMember" xlink:label="inva_LaJollaPharmaceuticalCompanyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetResidualValue" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetResidualValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_ScheduleOfGoodwillTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_Goodwill" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_CollaborativeArrangementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfGoodwillTable" xlink:to="srt_ConsolidatedEntitiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="inva_EntasisTherapeuticsHoldingsIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_InProcessResearchAndDevelopmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="inva_LaJollaPharmaceuticalCompanyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_GoodwillImpairmentLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfGoodwillTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfGoodwillTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="us-gaap_AcquiredFiniteLivedIntangibleAssetResidualValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfGoodwillTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_IntangibleAssetsMarketedProductsGross" xlink:label="inva_IntangibleAssetsMarketedProductsGross"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_IntangibleAssetsInProcessResearchAndDevelopmentGross" xlink:label="inva_IntangibleAssetsInProcessResearchAndDevelopmentGross"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_IntangibleAssetsCollaborationAgreementGross" xlink:label="inva_IntangibleAssetsCollaborationAgreementGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_IntangibleAssetsMarketedProductsAccumulatedAmortization" xlink:label="inva_IntangibleAssetsMarketedProductsAccumulatedAmortization"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_IntangibleAssetsInProcessResearchAndDevelopmentAccumulatedAmortization" xlink:label="inva_IntangibleAssetsInProcessResearchAndDevelopmentAccumulatedAmortization"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_IntangibleAssetsCollaborationAgreementAccumulatedAmortization" xlink:label="inva_IntangibleAssetsCollaborationAgreementAccumulatedAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_IntangibleAssetsMarketedProductsNet" xlink:label="inva_IntangibleAssetsMarketedProductsNet"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_IntangibleAssetsInProcessResearchAndDevelopmentNet" xlink:label="inva_IntangibleAssetsInProcessResearchAndDevelopmentNet"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_IntangibleAssetsCollaborationAgreementNet" xlink:label="inva_IntangibleAssetsCollaborationAgreementNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="inva_IntangibleAssetsMarketedProductsGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="inva_IntangibleAssetsInProcessResearchAndDevelopmentGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="inva_IntangibleAssetsCollaborationAgreementGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_IntangibleAssetsGrossExcludingGoodwill" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="inva_IntangibleAssetsMarketedProductsAccumulatedAmortization" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="inva_IntangibleAssetsInProcessResearchAndDevelopmentAccumulatedAmortization" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="inva_IntangibleAssetsCollaborationAgreementAccumulatedAmortization" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="inva_IntangibleAssetsMarketedProductsNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="inva_IntangibleAssetsInProcessResearchAndDevelopmentNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="inva_IntangibleAssetsCollaborationAgreementNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryLineItems" xlink:label="us-gaap_InventoryLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryCurrentTable" xlink:label="us-gaap_InventoryCurrentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_LaJollaPharmaceuticalCompanyMember" xlink:label="inva_LaJollaPharmaceuticalCompanyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryGross" xlink:label="us-gaap_InventoryGross"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_FairValueAdjustmentsOfInventoryFromAcquistion" xlink:label="inva_FairValueAdjustmentsOfInventoryFromAcquistion"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_AmortizationOfFairValueAdjustmentsOfCostOfProductsSold" xlink:label="inva_AmortizationOfFairValueAdjustmentsOfCostOfProductsSold"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_InventoryCurrentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="inva_LaJollaPharmaceuticalCompanyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_InventoryGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_InventoryCurrentTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryLineItems" xlink:to="inva_FairValueAdjustmentsOfInventoryFromAcquistion" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryLineItems" xlink:to="inva_AmortizationOfFairValueAdjustmentsOfCostOfProductsSold" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensation2012PlanAndEsppDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_EquityIncentivePlan2012Member" xlink:label="inva_EquityIncentivePlan2012Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_EmployeeStockPurchasePlanMember" xlink:label="inva_EmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveAndOverlappingOfferingPeriod" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveAndOverlappingOfferingPeriod"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_EmployeeStockPurchasePlanTwentyTwentyThreeMember" xlink:label="inva_EmployeeStockPurchasePlanTwentyTwentyThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountAsContributionOfEligibleCompensation" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountAsContributionOfEligibleCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="inva_EquityIncentivePlan2012Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="inva_EmployeeStockPurchasePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveAndOverlappingOfferingPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="inva_EmployeeStockPurchasePlanTwentyTwentyThreeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountAsContributionOfEligibleCompensation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationDirectorCompensationProgramDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialEquityGrantValue" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialEquityGrantValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalEquityGrantValue" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalEquityGrantValue"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityGrantValue" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityGrantValue"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_DirectorMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialEquityGrantValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalEquityGrantValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityGrantValue" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_EmployeeStockPurchasePlanMember" xlink:label="inva_EmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="inva_EmployeeStockPurchasePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationCompensationAwardsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingNumber" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingWeightedAverageFairValuePerShare" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingWeightedAverageFairValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:to="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingWeightedAverageFairValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationValuationAssumptionsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_InnovivaMember" xlink:label="inva_InnovivaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_WeightedAverageMember" xlink:label="srt_WeightedAverageMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="inva_InnovivaMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_WeightedAverageMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="dei_LegalEntityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureStockholdersEquityDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfTreasuryStockTable" xlink:label="us-gaap_ClassOfTreasuryStockTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareRepurchaseProgramAxis" xlink:label="us-gaap_ShareRepurchaseProgramAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="us-gaap_ShareRepurchaseProgramDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="us-gaap_ShareRepurchaseProgramDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:label="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ShareRepurchaseAgreementWithGlaxoGroupLimitedMember" xlink:label="inva_ShareRepurchaseAgreementWithGlaxoGroupLimitedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_CommonStockAcquiredAverageCostPerShare" xlink:label="inva_CommonStockAcquiredAverageCostPerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfTreasuryStockTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShareRepurchaseProgramAxis" xlink:to="us-gaap_ShareRepurchaseProgramDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShareRepurchaseProgramAxis" xlink:to="us-gaap_ShareRepurchaseProgramDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareRepurchaseProgramDomain" xlink:to="inva_ShareRepurchaseAgreementWithGlaxoGroupLimitedMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfTreasuryStockTable" xlink:to="us-gaap_ShareRepurchaseProgramAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfTreasuryStockTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="inva_CommonStockAcquiredAverageCostPerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfTreasuryStockTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleSubordinatedDebtMember" xlink:label="us-gaap_ConvertibleSubordinatedDebtMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_TwoThousandTwentyThreeNotesMember" xlink:label="inva_TwoThousandTwentyThreeNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_HealthCareRoyaltyPartnersMember" xlink:label="inva_HealthCareRoyaltyPartnersMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SeniorUnsecuredConvertibleNotesMember" xlink:label="inva_SeniorUnsecuredConvertibleNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_TwoThousandTwentyFiveNotesMember" xlink:label="inva_TwoThousandTwentyFiveNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_DebtInstrumentPrincipalAmount" xlink:label="inva_DebtInstrumentPrincipalAmount"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_OtherAccruedLiabilitiesMember" xlink:label="inva_OtherAccruedLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayableMember" xlink:label="us-gaap_LoansPayableMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_TwoThousandTwentyEightNotesMember" xlink:label="inva_TwoThousandTwentyEightNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_RoyaltyFinancingAgreementMember" xlink:label="inva_RoyaltyFinancingAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:label="us-gaap_DebtLongtermAndShorttermCombinedAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtCurrent" xlink:label="us-gaap_DebtCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_RoyaltyAgreementMaximumPotentialPayoutPercent" xlink:label="inva_RoyaltyAgreementMaximumPotentialPayoutPercent"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_RoyaltyAgreementIncreaseInMaximumPotentialPayoutPercent" xlink:label="inva_RoyaltyAgreementIncreaseInMaximumPotentialPayoutPercent"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentTwo" xlink:label="inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseBorrowings" xlink:label="us-gaap_InterestExpenseBorrowings"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_DeferredRoyaltyObligations" xlink:label="inva_DeferredRoyaltyObligations"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_RoyaltyPayments" xlink:label="inva_RoyaltyPayments"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_InterestRateOfDeferredRoyaltyObligation" xlink:label="inva_InterestRateOfDeferredRoyaltyObligation"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentOne" xlink:label="inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentOne"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_PaymentsForRoyaltyAgreement" xlink:label="inva_PaymentsForRoyaltyAgreement"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_ConvertibleSubordinatedDebtMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_TwoThousandTwentyThreeNotesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="inva_HealthCareRoyaltyPartnersMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherNoncurrentLiabilitiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="inva_SeniorUnsecuredConvertibleNotesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_TwoThousandTwentyFiveNotesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_DebtInstrumentPrincipalAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="inva_OtherAccruedLiabilitiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LoansPayableMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_TwoThousandTwentyEightNotesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_BalanceSheetLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_RoyaltyFinancingAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtLongtermAndShorttermCombinedAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_RoyaltyAgreementMaximumPotentialPayoutPercent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_RoyaltyAgreementIncreaseInMaximumPotentialPayoutPercent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentTwo" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseBorrowings" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_DeferredRoyaltyObligations" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_RoyaltyPayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_InterestRateOfDeferredRoyaltyObligation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentOne" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_PaymentsForRoyaltyAgreement" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebtAbstract" xlink:label="us-gaap_InterestExpenseDebtAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_InnovivaCommonStockMember" xlink:label="inva_InnovivaCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleSubordinatedDebtMember" xlink:label="us-gaap_ConvertibleSubordinatedDebtMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_PrivatelyNegotiatedCappedCallOptionMember" xlink:label="inva_PrivatelyNegotiatedCappedCallOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CallOptionMember" xlink:label="us-gaap_CallOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_TwoThousandTwentyThreeNotesMember" xlink:label="inva_TwoThousandTwentyThreeNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_OldDebtInstrumentInterestRateBeforeRepurchaseOfNotesMember" xlink:label="inva_OldDebtInstrumentInterestRateBeforeRepurchaseOfNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PutOptionMember" xlink:label="us-gaap_PutOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_NumberOfDerivativeInstrumentsPurchased" xlink:label="inva_NumberOfDerivativeInstrumentsPurchased"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_NewDebtInstrumentInterestRateAfterRepurchaseOfNotesMember" xlink:label="inva_NewDebtInstrumentInterestRateAfterRepurchaseOfNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityStrikePrice1" xlink:label="us-gaap_OptionIndexedToIssuersEquityStrikePrice1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeCapPrice" xlink:label="us-gaap_DerivativeCapPrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:label="us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRepurchaseAmount" xlink:label="us-gaap_DebtInstrumentRepurchaseAmount"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_NumberOfSharesReceivableOnSettlementOfDerivativeInstrument" xlink:label="inva_NumberOfSharesReceivableOnSettlementOfDerivativeInstrument"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfUnsecuredDebt" xlink:label="us-gaap_RepaymentsOfUnsecuredDebt"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_DebtInstrumentRepurchasePercentage" xlink:label="inva_DebtInstrumentRepurchasePercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_DebtInstrumentPrincipalAmount" xlink:label="inva_DebtInstrumentPrincipalAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InterestExpenseDebtAbstract" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="inva_InnovivaCommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_ConvertibleSubordinatedDebtMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_PrivatelyNegotiatedCappedCallOptionMember" xlink:to="us-gaap_CallOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_TwoThousandTwentyThreeNotesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="inva_PrivatelyNegotiatedCappedCallOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableRateDomain" xlink:to="inva_OldDebtInstrumentInterestRateBeforeRepurchaseOfNotesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InterestExpenseDebtAbstract" xlink:to="us-gaap_AmortizationOfFinancingCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_PrivatelyNegotiatedCappedCallOptionMember" xlink:to="us-gaap_PutOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_NumberOfDerivativeInstrumentsPurchased" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableRateDomain" xlink:to="inva_NewDebtInstrumentInterestRateAfterRepurchaseOfNotesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InterestExpenseDebtAbstract" xlink:to="us-gaap_InterestExpenseDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_VariableRateAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionRatio1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_OptionIndexedToIssuersEquityStrikePrice1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DerivativeCapPrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentRepurchasedFaceAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentRepurchaseAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_NumberOfSharesReceivableOnSettlementOfDerivativeInstrument" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_RepaymentsOfUnsecuredDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_DebtInstrumentRepurchasePercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestPayableCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_UnamortizedDebtIssuanceExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_DebtInstrumentPrincipalAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseDebtAbstract" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SeniorUnsecuredConvertibleNotesMember" xlink:label="inva_SeniorUnsecuredConvertibleNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_TwoThousandTwentyThreeNotesMember" xlink:label="inva_TwoThousandTwentyThreeNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseBorrowingsAbstract" xlink:label="us-gaap_InterestExpenseBorrowingsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_PrivatelyNegotiatedCappedCallOptionMember" xlink:label="inva_PrivatelyNegotiatedCappedCallOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate202006Member" xlink:label="us-gaap_AccountingStandardsUpdate202006Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ConvertibleDebtInstrumentLiabilityComponentAbstract" xlink:label="inva_ConvertibleDebtInstrumentLiabilityComponentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleSubordinatedDebtMember" xlink:label="us-gaap_ConvertibleSubordinatedDebtMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_TwoThousandTwentyFiveNotesMember" xlink:label="inva_TwoThousandTwentyFiveNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_DebtInstrumentPrincipalAmount" xlink:label="inva_DebtInstrumentPrincipalAmount"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_TwoThousandTwentyEightNotesMember" xlink:label="inva_TwoThousandTwentyEightNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeCapPrice" xlink:label="us-gaap_DerivativeCapPrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_PurchasesOfCappedCallsInConnectionWithConvertibleSeniorNotes" xlink:label="inva_PurchasesOfCappedCallsInConnectionWithConvertibleSeniorNotes"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_DebtInstrumentConvertibleConversionPremium" xlink:label="inva_DebtInstrumentConvertibleConversionPremium"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_DebtConversionCommonStockPriceToConversionPriceRatioPercentage" xlink:label="inva_DebtConversionCommonStockPriceToConversionPriceRatioPercentage"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_DebtConversionConvertedInstrumentAverageTradePricePercentage" xlink:label="inva_DebtConversionConvertedInstrumentAverageTradePricePercentage"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_DebtInstrumentRatioOfRepurchasePriceToThePrincipalAmount" xlink:label="inva_DebtInstrumentRatioOfRepurchasePriceToThePrincipalAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityCovenantTerms" xlink:label="us-gaap_LineOfCreditFacilityCovenantTerms"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_PortionOfDebtInstrumentFaceAmountExercised" xlink:label="inva_PortionOfDebtInstrumentFaceAmountExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:label="us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfUnsecuredDebt" xlink:label="us-gaap_RepaymentsOfUnsecuredDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:label="us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="inva_SeniorUnsecuredConvertibleNotesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_TwoThousandTwentyThreeNotesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InterestExpenseBorrowingsAbstract" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="inva_PrivatelyNegotiatedCappedCallOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate202006Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_ConvertibleDebtInstrumentLiabilityComponentAbstract" xlink:to="us-gaap_DebtInstrumentCarryingAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_ConvertibleSubordinatedDebtMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_TwoThousandTwentyFiveNotesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InterestExpenseBorrowingsAbstract" xlink:to="us-gaap_AmortizationOfFinancingCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_ConvertibleDebtInstrumentLiabilityComponentAbstract" xlink:to="inva_DebtInstrumentPrincipalAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_TwoThousandTwentyEightNotesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InterestExpenseBorrowingsAbstract" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionRatio1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_ConvertibleDebtInstrumentLiabilityComponentAbstract" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InterestExpenseBorrowingsAbstract" xlink:to="us-gaap_InterestExpenseDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_ConvertibleDebtInstrumentLiabilityComponentAbstract" xlink:to="us-gaap_LongTermDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DerivativeCapPrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromConvertibleDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_PurchasesOfCappedCallsInConnectionWithConvertibleSeniorNotes" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_DebtInstrumentConvertibleConversionPremium" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_SharePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_DebtConversionCommonStockPriceToConversionPriceRatioPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_DebtConversionConvertedInstrumentAverageTradePricePercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_DebtInstrumentRatioOfRepurchasePriceToThePrincipalAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityCovenantTerms" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_PortionOfDebtInstrumentFaceAmountExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentRepurchasedFaceAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_RepaymentsOfUnsecuredDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_ConvertibleDebtInstrumentLiabilityComponentAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseBorrowingsAbstract" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_BurlingameCaliforniaMember" xlink:label="inva_BurlingameCaliforniaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetRentableArea" xlink:label="us-gaap_NetRentableArea"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_EntasisLeaseMember" xlink:label="inva_EntasisLeaseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_WalthamMassachusettsMember" xlink:label="inva_WalthamMassachusettsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_OperatingLeaseWeightedAverageIncrementalBorrowingRate" xlink:label="inva_OperatingLeaseWeightedAverageIncrementalBorrowingRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyAllegations" xlink:label="us-gaap_LossContingencyAllegations"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_DemandLettersSentByStockholders" xlink:label="inva_DemandLettersSentByStockholders"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="inva_BurlingameCaliforniaMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_NetRentableArea" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="inva_EntasisLeaseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="inva_WalthamMassachusettsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LeaseContractualTermAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="inva_OperatingLeaseWeightedAverageIncrementalBorrowingRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LossContingencyAllegations" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="inva_DemandLettersSentByStockholders" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalTaxDisclosuresDetails">
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_IncomeTaxesLineItems" xlink:label="inva_IncomeTaxesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_IncomeTaxesTable" xlink:label="inva_IncomeTaxesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:label="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_EntasisTherapeuticsHoldingsIncMember" xlink:label="inva_EntasisTherapeuticsHoldingsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_LaJollaPharmaceuticalCompanyMember" xlink:label="inva_LaJollaPharmaceuticalCompanyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_OperatingLossCarryforwardsIndefinitePeriod" xlink:label="inva_OperatingLossCarryforwardsIndefinitePeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_NetOperatingLossEstimatingDate" xlink:label="inva_NetOperatingLossEstimatingDate"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_UnrecognizedTaxBenefitsDecreaseResultingFromPriorPeriodTaxPositionsNet" xlink:label="inva_UnrecognizedTaxBenefitsDecreaseResultingFromPriorPeriodTaxPositionsNet"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_FederalNetOperatingLossesEstimatedUtilizationAmount" xlink:label="inva_FederalNetOperatingLossesEstimatedUtilizationAmount"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_UnrecognizedTaxBenefitsDecreaseResultingFromCurrentPeriodTaxPositionsNet" xlink:label="inva_UnrecognizedTaxBenefitsDecreaseResultingFromCurrentPeriodTaxPositionsNet"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_StateNetOperatingLossesEstimatedUtilizationAmount" xlink:label="inva_StateNetOperatingLossesEstimatedUtilizationAmount"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_UnrecognizedTaxBenefitsIncreaseResultingFromCurrentPeriodTaxPositionsNet" xlink:label="inva_UnrecognizedTaxBenefitsIncreaseResultingFromCurrentPeriodTaxPositionsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="inva_IncomeTaxesLineItems" xlink:to="inva_IncomeTaxesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="inva_IncomeTaxesTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_IncomeTaxesLineItems" xlink:to="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="inva_EntasisTherapeuticsHoldingsIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_UnrecognizedTaxBenefits" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="inva_IncomeTaxesTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_IncomeTaxesLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="inva_LaJollaPharmaceuticalCompanyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="inva_IncomeTaxesTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_IncomeTaxesLineItems" xlink:to="inva_OperatingLossCarryforwardsIndefinitePeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_IncomeTaxesLineItems" xlink:to="inva_NetOperatingLossEstimatingDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="inva_UnrecognizedTaxBenefitsDecreaseResultingFromPriorPeriodTaxPositionsNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_IncomeTaxesLineItems" xlink:to="inva_FederalNetOperatingLossesEstimatedUtilizationAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="inva_UnrecognizedTaxBenefitsDecreaseResultingFromCurrentPeriodTaxPositionsNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_IncomeTaxesLineItems" xlink:to="inva_StateNetOperatingLossesEstimatedUtilizationAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="inva_UnrecognizedTaxBenefitsIncreaseResultingFromCurrentPeriodTaxPositionsNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_IncomeTaxesLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_IncomeTaxesLineItems" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_IncomeTaxesLineItems" xlink:to="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ArmataPharmaceuticalsIncMember" xlink:label="inva_ArmataPharmaceuticalsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoanRestructuringModificationDomain" xlink:label="us-gaap_LoanRestructuringModificationDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_NewPrincipalAmountMember" xlink:label="inva_NewPrincipalAmountMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_InCardaConvertibleNoteMember" xlink:label="inva_InCardaConvertibleNoteMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SecuredConvertibleCreditAgreementMember" xlink:label="inva_SecuredConvertibleCreditAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoanRestructuringModificationAxis" xlink:label="us-gaap_LoanRestructuringModificationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoanRestructuringModificationDomain" xlink:label="us-gaap_LoanRestructuringModificationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_GateNeuroscienceMember" xlink:label="inva_GateNeuroscienceMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ImaginabConvertibleNoteMember" xlink:label="inva_ImaginabConvertibleNoteMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ConvertiblePromissoryNotePurchaseAgreementMember" xlink:label="inva_ConvertiblePromissoryNotePurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_NoteAmendmentAgreementMember" xlink:label="inva_NoteAmendmentAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireLongtermInvestments" xlink:label="us-gaap_PaymentsToAcquireLongtermInvestments"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="inva_ArmataPharmaceuticalsIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LoanRestructuringModificationDomain" xlink:to="inva_NewPrincipalAmountMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="inva_InCardaConvertibleNoteMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_SecuredConvertibleCreditAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LoanRestructuringModificationAxis" xlink:to="us-gaap_LoanRestructuringModificationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LoanRestructuringModificationAxis" xlink:to="us-gaap_LoanRestructuringModificationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="inva_GateNeuroscienceMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="inva_ImaginabConvertibleNoteMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_ConvertiblePromissoryNotePurchaseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_ConsolidatedEntitiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_NoteAmendmentAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_PaymentsToAcquireLongtermInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_LoanRestructuringModificationAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAbstract" xlink:label="us-gaap_LiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate202006Member" xlink:label="us-gaap_AccountingStandardsUpdate202006Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate202006Member" priority="2" use="optional"/>
        </link:definitionLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_PreferredStockValue" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNet" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LongTermDebtNoncurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_CommonStockValue" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_ReceivablesLongTermContractsOrPrograms" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_InterestPayableCurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="inva_EquityMethodInvestment" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_TreasuryStockCommonValue" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_InventoryNet" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DeferredRevenueCurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_LongTermInvestments" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="inva_IncomeTaxPayableNonCurrent" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_ConvertibleDebtCurrent" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_CapitalizedContractCostNet" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedIncomeTaxesCurrent" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Goodwill" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="7" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="9" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNet" xlink:label="us-gaap_AccountsReceivableNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesLongTermContractsOrPrograms" xlink:label="us-gaap_ReceivablesLongTermContractsOrPrograms"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_EquityMethodInvestment" xlink:label="inva_EquityMethodInvestment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonValue" xlink:label="us-gaap_TreasuryStockCommonValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_IncomeTaxPayableNonCurrent" xlink:label="inva_IncomeTaxPayableNonCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="us-gaap_ConvertibleDebtCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostNet" xlink:label="us-gaap_CapitalizedContractCostNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails2">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails2">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="inva_RealizedLoss" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="3" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_GainLossOnInvestments" order="4" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_RealizedLoss" xlink:label="inva_RealizedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnInvestments" xlink:label="us-gaap_GainLossOnInvestments"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails2">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:to="us-gaap_DebtCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:to="us-gaap_LongTermDebtNoncurrent" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:label="us-gaap_DebtLongtermAndShorttermCombinedAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtCurrent" xlink:label="us-gaap_DebtCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet1">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="inva_ContingentValueRightsLiability" order="0" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ContingentValueRightsLiability" xlink:label="inva_ContingentValueRightsLiability"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails2">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="inva_IntangibleAssetsMarketedProductsNet" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="inva_IntangibleAssetsCollaborationAgreementNet" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="inva_IntangibleAssetsInProcessResearchAndDevelopmentNet" order="2" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_IntangibleAssetsMarketedProductsNet" xlink:label="inva_IntangibleAssetsMarketedProductsNet"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_IntangibleAssetsCollaborationAgreementNet" xlink:label="inva_IntangibleAssetsCollaborationAgreementNet"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_IntangibleAssetsInProcessResearchAndDevelopmentNet" xlink:label="inva_IntangibleAssetsInProcessResearchAndDevelopmentNet"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails2">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredTaxAssetsNet" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesOther" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="inva_DeferredTaxLiabilitiesDepreciationAndAmortization" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="inva_DeferredTaxAssetsDeferredRoyaltyObligationNet" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="inva_DeferredTaxLiabilitiesInventoryFairValueAdjustment" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="inva_DeferredTaxAssetsUnrealizedLossesOnInvestmentNet" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesInvestments" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOther" order="4" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_DeferredTaxLiabilitiesDepreciationAndAmortization" xlink:label="inva_DeferredTaxLiabilitiesDepreciationAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_DeferredTaxAssetsDeferredRoyaltyObligationNet" xlink:label="inva_DeferredTaxAssetsDeferredRoyaltyObligationNet"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_DeferredTaxLiabilitiesInventoryFairValueAdjustment" xlink:label="inva_DeferredTaxLiabilitiesInventoryFairValueAdjustment"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_DeferredTaxAssetsUnrealizedLossesOnInvestmentNet" xlink:label="inva_DeferredTaxAssetsUnrealizedLossesOnInvestmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesInvestments" xlink:label="us-gaap_DeferredTaxLiabilitiesInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfIncome">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_CostsAndExpenses" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_ProfitLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostOfRevenue" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_DeconsolidationGainOrLossAmount" order="5" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="6" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" order="7" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="inva_GainLossOnOtherInvestments" order="8" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_InterestAndDividendIncomeOperating" order="9" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_InterestExpense" order="10" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="11" weight="-1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeconsolidationGainOrLossAmount" xlink:label="us-gaap_DeconsolidationGainOrLossAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_GainLossOnOtherInvestments" xlink:label="inva_GainLossOnOtherInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestAndDividendIncomeOperating" xlink:label="us-gaap_InterestAndDividendIncomeOperating"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveIncome">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_ProfitLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" order="1" weight="-1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireEquityMethodInvestments" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsToMinorityShareholders" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="inva_PurchaseOfEntasisNoncontrollingInterest" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="inva_AmortizationOfCapitalizedFeesAndDepreciationOfPropertyAndEquipment" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireLongtermInvestments" order="3" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" order="3" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="inva_InventoryFairValueStepUpAdjustmentIncludedInCostOfProductSales" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="inva_PurchasesOfEquityInvestmentsManagedByIspFundLp" order="4" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="inva_PurchasesOfTradingSecurityManagedByIspFundLp" order="5" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfUnsecuredDebt" order="6" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="7" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts" order="8" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="inva_SaleOfEquityInvestmentsManagedByIspFundLp" order="8" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="inva_PurchasesOfCappedCallOptionsAssociatedWithConvertibleSeniorNotes" order="8" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="inva_PurchaseAndSaleOfOtherInvestmentsManagedByIspFundLp" order="9" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt" order="9" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="10" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="10" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="inva_UnrealizedOtherGainLossOnInvestments" order="11" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="inva_NetProceedsFromSaleOfVariableInterestEntityEquity" order="11" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="inva_AccruedInterestIncomeIncludedInLongTermInvestments" order="12" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_CashAcquiredFromAcquisition" order="12" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" order="13" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="inva_CashPaidForTheAcquisitionOfLaJollaPharmaceuticalCompanyNetOfCashAcquired" order="14" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="18" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="19" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DeconsolidationGainOrLossAmount" order="20" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="23" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="24" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent" order="26" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="27" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" order="28" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="31" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="33" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" order="34" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="35" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet" order="36" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:label="us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToMinorityShareholders" xlink:label="us-gaap_PaymentsToMinorityShareholders"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_PurchaseOfEntasisNoncontrollingInterest" xlink:label="inva_PurchaseOfEntasisNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_AmortizationOfCapitalizedFeesAndDepreciationOfPropertyAndEquipment" xlink:label="inva_AmortizationOfCapitalizedFeesAndDepreciationOfPropertyAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireLongtermInvestments" xlink:label="us-gaap_PaymentsToAcquireLongtermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_InventoryFairValueStepUpAdjustmentIncludedInCostOfProductSales" xlink:label="inva_InventoryFairValueStepUpAdjustmentIncludedInCostOfProductSales"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_PurchasesOfEquityInvestmentsManagedByIspFundLp" xlink:label="inva_PurchasesOfEquityInvestmentsManagedByIspFundLp"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_PurchasesOfTradingSecurityManagedByIspFundLp" xlink:label="inva_PurchasesOfTradingSecurityManagedByIspFundLp"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfUnsecuredDebt" xlink:label="us-gaap_RepaymentsOfUnsecuredDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_SaleOfEquityInvestmentsManagedByIspFundLp" xlink:label="inva_SaleOfEquityInvestmentsManagedByIspFundLp"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_PurchasesOfCappedCallOptionsAssociatedWithConvertibleSeniorNotes" xlink:label="inva_PurchasesOfCappedCallOptionsAssociatedWithConvertibleSeniorNotes"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_PurchaseAndSaleOfOtherInvestmentsManagedByIspFundLp" xlink:label="inva_PurchaseAndSaleOfOtherInvestmentsManagedByIspFundLp"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_UnrealizedOtherGainLossOnInvestments" xlink:label="inva_UnrealizedOtherGainLossOnInvestments"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_NetProceedsFromSaleOfVariableInterestEntityEquity" xlink:label="inva_NetProceedsFromSaleOfVariableInterestEntityEquity"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_AccruedInterestIncomeIncludedInLongTermInvestments" xlink:label="inva_AccruedInterestIncomeIncludedInLongTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="us-gaap_CashAcquiredFromAcquisition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_CashPaidForTheAcquisitionOfLaJollaPharmaceuticalCompanyNetOfCashAcquired" xlink:label="inva_CashPaidForTheAcquisitionOfLaJollaPharmaceuticalCompanyNetOfCashAcquired"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeconsolidationGainOrLossAmount" xlink:label="us-gaap_DeconsolidationGainOrLossAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent" xlink:label="us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_InterestOnConvertibleDebtNetOfTax" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" order="2" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestOnConvertibleDebtNetOfTax" xlink:label="us-gaap_InterestOnConvertibleDebtNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:label="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfNetRevenueFromCollaborativeArrangementsDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_CapitalizedContractCostAmortization" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="inva_GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostAmortization" xlink:label="us-gaap_CapitalizedContractCostAmortization"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees" xlink:label="inva_GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_MembersEquity" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_LongTermInvestments" order="3" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MembersEquity" xlink:label="us-gaap_MembersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="us-gaap_Goodwill" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAccruedLiabilities" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedPersonnelRelatedExpenses" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" order="7" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" order="8" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" order="9" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" order="11" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets" order="12" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAccruedLiabilities" xlink:label="inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" xlink:label="inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedPersonnelRelatedExpenses" xlink:label="inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedPersonnelRelatedExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsAvailableforsaleSecuritiesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="2" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentFairValue" xlink:to="inva_ConvertibleSubordinatedDebtFairValueDisclosures" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentFairValue" xlink:to="inva_ConvertibleSeniorDebtFairValueDisclosures" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentFairValue" xlink:to="us-gaap_ConvertibleDebtFairValueDisclosures" order="2" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="us-gaap_DebtInstrumentFairValue"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ConvertibleSubordinatedDebtFairValueDisclosures" xlink:label="inva_ConvertibleSubordinatedDebtFairValueDisclosures"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ConvertibleSeniorDebtFairValueDisclosures" xlink:label="inva_ConvertibleSeniorDebtFairValueDisclosures"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CapitalizedContractCostNet" xlink:to="us-gaap_CapitalizedContractCostGross" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CapitalizedContractCostNet" xlink:to="us-gaap_CapitalizedContractCostAccumulatedAmortization" order="1" weight="-1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostNet" xlink:label="us-gaap_CapitalizedContractCostNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostGross" xlink:label="us-gaap_CapitalizedContractCostGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostAccumulatedAmortization" xlink:label="us-gaap_CapitalizedContractCostAccumulatedAmortization"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="inva_IntangibleAssetsCollaborationAgreementGross" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="inva_IntangibleAssetsMarketedProductsAccumulatedAmortization" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsGrossExcludingGoodwill" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="inva_IntangibleAssetsInProcessResearchAndDevelopmentGross" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="inva_IntangibleAssetsInProcessResearchAndDevelopmentAccumulatedAmortization" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="inva_IntangibleAssetsMarketedProductsGross" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="inva_IntangibleAssetsCollaborationAgreementAccumulatedAmortization" order="2" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_IntangibleAssetsCollaborationAgreementGross" xlink:label="inva_IntangibleAssetsCollaborationAgreementGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_IntangibleAssetsMarketedProductsAccumulatedAmortization" xlink:label="inva_IntangibleAssetsMarketedProductsAccumulatedAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_IntangibleAssetsInProcessResearchAndDevelopmentGross" xlink:label="inva_IntangibleAssetsInProcessResearchAndDevelopmentGross"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_IntangibleAssetsInProcessResearchAndDevelopmentAccumulatedAmortization" xlink:label="inva_IntangibleAssetsInProcessResearchAndDevelopmentAccumulatedAmortization"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_IntangibleAssetsMarketedProductsGross" xlink:label="inva_IntangibleAssetsMarketedProductsGross"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_IntangibleAssetsCollaborationAgreementAccumulatedAmortization" xlink:label="inva_IntangibleAssetsCollaborationAgreementAccumulatedAmortization"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoryNetDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves" order="2" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherAccruedLiabilitiesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="inva_AccruedContractManufacturingLiability" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="inva_AccruedClinicalLiability" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="inva_AccruedResearchLiability" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="inva_AccruedProfessionalServices" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedRoyaltiesCurrent" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="inva_DeferredRoyaltyObligationCurrent" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="inva_AccruedLicenseFeesAndRoyalties" order="7" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_OtherLiabilities" order="8" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_AccruedContractManufacturingLiability" xlink:label="inva_AccruedContractManufacturingLiability"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_AccruedClinicalLiability" xlink:label="inva_AccruedClinicalLiability"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_AccruedResearchLiability" xlink:label="inva_AccruedResearchLiability"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_AccruedProfessionalServices" xlink:label="inva_AccruedProfessionalServices"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_DeferredRoyaltyObligationCurrent" xlink:label="inva_DeferredRoyaltyObligationCurrent"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_AccruedLicenseFeesAndRoyalties" xlink:label="inva_AccruedLicenseFeesAndRoyalties"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilities" xlink:label="us-gaap_OtherLiabilities"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherLongtermLiabilitiesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="inva_DeferredRoyaltyObligationNonCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="inva_ContingentValueRightsLiability" order="2" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_DeferredRoyaltyObligationNonCurrent" xlink:label="inva_DeferredRoyaltyObligationNonCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_ContingentValueRightsLiability" xlink:label="inva_ContingentValueRightsLiability"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" order="1" weight="-1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:label="us-gaap_DebtLongtermAndShorttermCombinedAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_AmortizationOfFinancingCosts" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebtCurrent" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_AmortizationOfFinancingCosts" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="2" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureDebtDebtMaturitiesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" order="5" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeastCostDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_OperatingLeaseCost" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_VariableLeaseCost" order="2" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="inva_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="3" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree" xlink:label="inva_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationDeductionsOther" order="3" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense" order="4" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary" order="5" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="7" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationDeductionsOther" xlink:label="us-gaap_IncomeTaxReconciliationDeductionsOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense" xlink:label="us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary" xlink:label="us-gaap_IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="inva_DeferredTaxLiabilitiesDepreciationAndAmortization" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxLiabilitiesInvestments" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="inva_DeferredTaxAssetsUnrealizedLossesOnInvestmentNet" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="inva_DeferredTaxLiabilitiesInventoryFairValueAdjustment" order="3" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="inva_DeferredTaxAssetsDeferredRoyaltyObligationNet" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxLiabilitiesOther" order="4" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOther" order="4" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_DeferredTaxLiabilitiesDepreciationAndAmortization" xlink:label="inva_DeferredTaxLiabilitiesDepreciationAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesInvestments" xlink:label="us-gaap_DeferredTaxLiabilitiesInvestments"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_DeferredTaxAssetsUnrealizedLossesOnInvestmentNet" xlink:label="inva_DeferredTaxAssetsUnrealizedLossesOnInvestmentNet"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_DeferredTaxLiabilitiesInventoryFairValueAdjustment" xlink:label="inva_DeferredTaxLiabilitiesInventoryFairValueAdjustment"/>
          <link:loc xlink:type="locator" xlink:href="inva-20231231.xsd#inva_DeferredTaxAssetsDeferredRoyaltyObligationNet" xlink:label="inva_DeferredTaxAssetsDeferredRoyaltyObligationNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
        </link:calculationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="inva_PercentageOfReimbursedForDirectAndCertainIndirectManufacturingCosts" name="PercentageOfReimbursedForDirectAndCertainIndirectManufacturingCosts" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_TwoDirectorsMember" name="TwoDirectorsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_IncomeTaxesTable" name="IncomeTaxesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_InnovivaCommonStockMember" name="InnovivaCommonStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_IntangibleAssetsMarketedProductsGross" name="IntangibleAssetsMarketedProductsGross" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_OutstandingStockWarrantMember" name="OutstandingStockWarrantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_SoftwareAndComputerEquipmentMember" name="SoftwareAndComputerEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_PropertyPlantAndEquipmentUsefulLifeTableTextBlock" name="PropertyPlantAndEquipmentUsefulLifeTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_DerecognitionOfNoncontrollingInterestsUponSaleOfTrcShares" name="DerecognitionOfNoncontrollingInterestsUponSaleOfTrcShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingNumber" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="inva_SeniorUnsecuredConvertibleNotesMember" name="SeniorUnsecuredConvertibleNotesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_PresentationReclassificationPolicyTextBlock" name="PresentationReclassificationPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_SubscriptionAgreementOneTimeMilestonePaymentOnNetSales" name="SubscriptionAgreementOneTimeMilestonePaymentOnNetSales" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_NonRule10B51ArrModifiedFlag" name="NonRule10B51ArrModifiedFlag" type="xbrli:booleanItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_IncomeTaxPayableNonCurrent" name="IncomeTaxPayableNonCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_DeferredTaxLiabilitiesDepreciationAndAmortization" name="DeferredTaxLiabilitiesDepreciationAndAmortization" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_SalesMilestonePaymentsReceivable" name="SalesMilestonePaymentsReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFour" name="CapitalizedFeesPaidRemainingEstimatedAmortizationYearFour" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_PercentageOfEstimatedVolatility" name="PercentageOfEstimatedVolatility" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_PaymentOfManagementAndIncentiveFee" name="PaymentOfManagementAndIncentiveFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_PercentageOfMaximumRoyaltyBasedOnAchievementOfAnnualNetProductSalesThresholds" name="PercentageOfMaximumRoyaltyBasedOnAchievementOfAnnualNetProductSalesThresholds" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_SeriesDWarrantsMember" name="SeriesDWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_IncreaseDecreaseInDeferredTaxLiabilities" name="IncreaseDecreaseInDeferredTaxLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_SarissaCapitalManagementLpMember" name="SarissaCapitalManagementLpMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_ExpectedHoldingPeriod" name="ExpectedHoldingPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_UnrecognizedTaxBenefitsDecreaseResultingFromCurrentPeriodTaxPositionsNet" name="UnrecognizedTaxBenefitsDecreaseResultingFromCurrentPeriodTaxPositionsNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_GeorgeWashingtonUniversityMember" name="GeorgeWashingtonUniversityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_SummaryOfSignificantAccountingPoliciesTable" name="SummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_NewDebtInstrumentInterestRateAfterRepurchaseOfNotesMember" name="NewDebtInstrumentInterestRateAfterRepurchaseOfNotesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_RecognitionOfNoncontrollingInterestUponInitialConsolidationofEntasisShares" name="RecognitionOfNoncontrollingInterestUponInitialConsolidationofEntasisShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_Incarda2020WarrantsMember" name="Incarda2020WarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_LongActingBeta2AgonistAnoroMember" name="LongActingBeta2AgonistAnoroMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_AccruedResearchLiability" name="AccruedResearchLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntityShares" name="ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntityShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_AstrazenecaMember" name="AstrazenecaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_OldDebtInstrumentInterestRateBeforeRepurchaseOfNotesMember" name="OldDebtInstrumentInterestRateBeforeRepurchaseOfNotesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationNextTwelveMonths" name="CapitalizedFeesPaidRemainingEstimatedAmortizationNextTwelveMonths" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_DeferredTaxLiabilitiesInventoryFairValueAdjustment" name="DeferredTaxLiabilitiesInventoryFairValueAdjustment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_IncreaseInDeferredTaxAssets" name="IncreaseInDeferredTaxAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_LaJollaMember" name="LaJollaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearthree" name="CapitalizedFeesPaidRemainingEstimatedAmortizationYearthree" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_BalanceSheetDisclosuresOfVariableInterestEntityAbstract" name="BalanceSheetDisclosuresOfVariableInterestEntityAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_SpecialTermReDesignatingBoardMemberToBoardOfInvestee" name="SpecialTermReDesignatingBoardMemberToBoardOfInvestee" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_GateNeuroscienceMember" name="GateNeuroscienceMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_IntangibleAssetsCollaborationAgreementAccumulatedAmortization" name="IntangibleAssetsCollaborationAgreementAccumulatedAmortization" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_ExtendedExpirationDate" name="ExtendedExpirationDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_AccruedLicenseFeesAndRoyalties" name="AccruedLicenseFeesAndRoyalties" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_ProfitLossShares" name="ProfitLossShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_SeriesD1PreferredStockMember" name="SeriesD1PreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_IncreaseDecreaseInDeferredTaxAssets" name="IncreaseDecreaseInDeferredTaxAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersShares" name="MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_WarrantsPurchasedIn2020Member" name="WarrantsPurchasedIn2020Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_DebtInstrumentPrincipalAmount" name="DebtInstrumentPrincipalAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_RelatedPartyTransactionsPolicyTextBlock" name="RelatedPartyTransactionsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalEquityGrantValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalEquityGrantValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_EquityIncentivePlan2012Member" name="EquityIncentivePlan2012Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_DerecognitionOfNoncontrollingInterestsUponSaleOfTrc" name="DerecognitionOfNoncontrollingInterestsUponSaleOfTrc" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_DebtConversionConvertedInstrumentAverageTradePricePercentage" name="DebtConversionConvertedInstrumentAverageTradePricePercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_OneDirectorMember" name="OneDirectorMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_IncomeStatementDisclosuresOfVariableInterestEntityAbstract" name="IncomeStatementDisclosuresOfVariableInterestEntityAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_IntangibleAssetsCollaborationAgreementNet" name="IntangibleAssetsCollaborationAgreementNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_IspFundLpMember" name="IspFundLpMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_WarrantsAcquiredInSecondQuarterOf2021Member" name="WarrantsAcquiredInSecondQuarterOf2021Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_FederalNetOperatingLossesEstimatedUtilizationAmount" name="FederalNetOperatingLossesEstimatedUtilizationAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_AccruedProfessionalServices" name="AccruedProfessionalServices" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_RoyaltiesPayablePeriodAfterFirstCommercialSaleOfProduct" name="RoyaltiesPayablePeriodAfterFirstCommercialSaleOfProduct" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_SecuredConvertibleCreditAgreementMember" name="SecuredConvertibleCreditAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_PercentageOfRoyaltyPayableOnNetSales" name="PercentageOfRoyaltyPayableOnNetSales" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember" name="InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_SecuritiesPurchaseAgreementWarrantsNumberOfSecuritiesCalledByWarrants" name="SecuritiesPurchaseAgreementWarrantsNumberOfSecuritiesCalledByWarrants" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="inva_DerecognitionOfNonControllingInterestsUponAcquisitionOfEntasisMinorityInterest" name="DerecognitionOfNonControllingInterestsUponAcquisitionOfEntasisMinorityInterest" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_NetInvestmentRelatedIncomeExpenseEarnedInccured" name="NetInvestmentRelatedIncomeExpenseEarnedInccured" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_PortionOfDebtInstrumentFaceAmountExercised" name="PortionOfDebtInstrumentFaceAmountExercised" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_EmployeeStockPurchasePlanTwentyTwentyThreeMember" name="EmployeeStockPurchasePlanTwentyTwentyThreeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_DebtInstrumentRepurchasePercentage" name="DebtInstrumentRepurchasePercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_BusinessAcquisitionsOfChangeInFairValueOfInvestment" name="BusinessAcquisitionsOfChangeInFairValueOfInvestment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_OwnershipInterestInConsolidatedEntities" name="OwnershipInterestInConsolidatedEntities" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_StrategicAllianceAgreementMember" name="StrategicAllianceAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_CustomerTwoMember" name="CustomerTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_NetIncomeLossPerShareAbstract" name="NetIncomeLossPerShareAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_BurlingameCaliforniaMember" name="BurlingameCaliforniaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_UnrecognizedTaxBenefitsIncreaseResultingFromCurrentPeriodTaxPositionsNet" name="UnrecognizedTaxBenefitsIncreaseResultingFromCurrentPeriodTaxPositionsNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_DeferredTaxAssetsDeferredRoyaltyObligationNet" name="DeferredTaxAssetsDeferredRoyaltyObligationNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_IntangibleAssetsMarketedProductsAccumulatedAmortization" name="IntangibleAssetsMarketedProductsAccumulatedAmortization" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFive" name="CapitalizedFeesPaidRemainingEstimatedAmortizationYearFive" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_AccruedContractManufacturingLiability" name="AccruedContractManufacturingLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_ConsolidatedEntitiesAndAcquisitionsTextBlock" name="ConsolidatedEntitiesAndAcquisitionsTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_DeferredRoyaltyObligationNonCurrent" name="DeferredRoyaltyObligationNonCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_NumberOfCustomers" name="NumberOfCustomers" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_ConsolidatedEntitiesAndAcquisitionsLineItems" name="ConsolidatedEntitiesAndAcquisitionsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_CollaborativeArrangementRoyaltyRateDefinedLevelOne" name="CollaborativeArrangementRoyaltyRateDefinedLevelOne" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_PercentageOfEconomicInterestInPartnership" name="PercentageOfEconomicInterestInPartnership" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_ResearchAndDevelopmentSupportMember" name="ResearchAndDevelopmentSupportMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_DenominatorAbstract" name="DenominatorAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingWeightedAverageFairValuePerShare" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingWeightedAverageFairValuePerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="inva_EntasisTherapeuticsHoldingsIncMember" name="EntasisTherapeuticsHoldingsIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationAfterYearFive" name="CapitalizedFeesPaidRemainingEstimatedAmortizationAfterYearFive" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_NonCashActivity" name="NonCashActivity" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_SeriesCWarrantsAndSeriesDWarrantsMember" name="SeriesCWarrantsAndSeriesDWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_RightOfUseAssetsObtainedThroughAcquistions" name="RightOfUseAssetsObtainedThroughAcquistions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_ClaimExpirationDate" name="ClaimExpirationDate" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityGrantValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityGrantValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_RoyaltyAgreementIncreaseInMaximumPotentialPayoutPercent" name="RoyaltyAgreementIncreaseInMaximumPotentialPayoutPercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_SeriesD2WarrantMember" name="SeriesD2WarrantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_PurchasesOfCappedCallsInConnectionWithConvertibleSeniorNotes" name="PurchasesOfCappedCallsInConnectionWithConvertibleSeniorNotes" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_StrategicAllianceMabaProgram" name="StrategicAllianceMabaProgram" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_CapitalizedFeesPaidWeightedAverageUsefulLife" name="CapitalizedFeesPaidWeightedAverageUsefulLife" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_IntangibleAssetsInProcessResearchAndDevelopmentNet" name="IntangibleAssetsInProcessResearchAndDevelopmentNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_IncreaseToConvertibleNotes" name="IncreaseToConvertibleNotes" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee" name="NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="inva_WarrantsPurchasedIn2021Member" name="WarrantsPurchasedIn2021Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares" name="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_TermLoanInvestmentMember" name="TermLoanInvestmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_ReductionToResearchAndDevelopmentExpense" name="ReductionToResearchAndDevelopmentExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_PrivatePlacementPositionsAndConvertibleNotesMember" name="PrivatePlacementPositionsAndConvertibleNotesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_DeferredTaxAssetsUnrealizedLossesOnInvestmentNet" name="DeferredTaxAssetsUnrealizedLossesOnInvestmentNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_PercentageOfMinimumRoyaltyRate" name="PercentageOfMinimumRoyaltyRate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialEquityGrantValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialEquityGrantValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_SeriesD2PreferredStockMember" name="SeriesD2PreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_SecuritiesPurchaseAgreementNumberOfTranches" name="SecuritiesPurchaseAgreementNumberOfTranches" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_ScheduleOfConsolidatedEntitiesAndBusinessAcquisitionsByAcquisitionTable" name="ScheduleOfConsolidatedEntitiesAndBusinessAcquisitionsByAcquisitionTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_DeferredRoyaltyObligationCurrent" name="DeferredRoyaltyObligationCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_TwoThousandTwentyEightNotesMember" name="TwoThousandTwentyEightNotesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_CarryingValueWroteOffWarrantExercise" name="CarryingValueWroteOffWarrantExercise" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_WarrantsAcquiredInThirdQuarterOf2020Member" name="WarrantsAcquiredInThirdQuarterOf2020Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_VotingAgreementMaximumVotingRightsPercent" name="VotingAgreementMaximumVotingRightsPercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_Rule10B51ArrModifiedFlag" name="Rule10B51ArrModifiedFlag" type="xbrli:booleanItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts" name="CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_NewPrincipalAmountMember" name="NewPrincipalAmountMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_WarrantsAcquiredInSecondQuarterOf2020Member" name="WarrantsAcquiredInSecondQuarterOf2020Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_DemandLettersSentByStockholders" name="DemandLettersSentByStockholders" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_StateNetOperatingLossesEstimatedUtilizationAmount" name="StateNetOperatingLossesEstimatedUtilizationAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_MeasurementPeriodAdjustmentsIncreaseDecreaseInEstimatedPurchasePrice" name="MeasurementPeriodAdjustmentsIncreaseDecreaseInEstimatedPurchasePrice" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_RiskFreeInterestRate" name="RiskFreeInterestRate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtInShares" name="AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtInShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_CustomerOneMember" name="CustomerOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_NetProceedsFromSaleOfVariableInterestEntityEquity" name="NetProceedsFromSaleOfVariableInterestEntityEquity" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_SaleOfWarrantsNumberOfWarrantsIssuedInTransaction" name="SaleOfWarrantsNumberOfWarrantsIssuedInTransaction" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_Percent2.50ConvertibleDebtMember" name="Percent2.50ConvertibleDebtMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_PriorPeriodImmaterialCorrectionPolicyTextBlock" name="PriorPeriodImmaterialCorrectionPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_CashDistributionReceived" name="CashDistributionReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_NameOfEventDomain" name="NameOfEventDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_ArmataConvertibleNoteMember" name="ArmataConvertibleNoteMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_AccruedInterestIncomeIncludedInLongTermInvestments" name="AccruedInterestIncomeIncludedInLongTermInvestments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_InventoryFairValueStepUpAdjustmentIncludedInCostOfProductSales" name="InventoryFairValueStepUpAdjustmentIncludedInCostOfProductSales" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_AccruedClinicalLiability" name="AccruedClinicalLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_SummaryOfSignificantAccountingPoliciesLineItems" name="SummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_ConvertibleNoteAndWarrantsMember" name="ConvertibleNoteAndWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_DebtInstrumentTransactionCost" name="DebtInstrumentTransactionCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_DescriptionOfOperationsPolicyTextBlock" name="DescriptionOfOperationsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_ParatekPharmaceuticalsIncMember" name="ParatekPharmaceuticalsIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_FuturePotentialMilestonePayment" name="FuturePotentialMilestonePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_PartnershipAgreementLockUpPeriod" name="PartnershipAgreementLockUpPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_QualifiedFinancingMember" name="QualifiedFinancingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_NetOperatingLossEstimatingDate" name="NetOperatingLossEstimatingDate" type="dtr-types:gYearListItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="inva_CollaborativeArrangementsMember" name="CollaborativeArrangementsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_XeravaMember" name="XeravaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_ConvertibleDebtInstrumentLiabilityComponentAbstract" name="ConvertibleDebtInstrumentLiabilityComponentAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_CapitalizedFeesPaidFutureAmortizationAbstract" name="CapitalizedFeesPaidFutureAmortizationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_ClinicalDevelopmentAndRegulatoryMilestonesAmountPayable" name="ClinicalDevelopmentAndRegulatoryMilestonesAmountPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_ConvertibleSeniorDebtFairValueDisclosures" name="ConvertibleSeniorDebtFairValueDisclosures" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_PaionAgMember" name="PaionAgMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_PercentageOfEconomicInterestOnFuturePaymentsUnderAgreements" name="PercentageOfEconomicInterestOnFuturePaymentsUnderAgreements" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_RegulatoryMilestonePaymentsReceivable" name="RegulatoryMilestonePaymentsReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_ImaginabConvertibleNoteMember" name="ImaginabConvertibleNoteMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_NoteAmendmentAgreementMember" name="NoteAmendmentAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_CapitalizedFeePaidEstimatedUsefulLife" name="CapitalizedFeePaidEstimatedUsefulLife" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="inva_ConsolidatedEntitiesAndAcquisitionsDisclosureAbstract" name="ConsolidatedEntitiesAndAcquisitionsDisclosureAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_NumeratorAbstract" name="NumeratorAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_IncrementalCommonSharesAttributableToConversionOfDebtSecuritiesTreasuryStockMethod" name="IncrementalCommonSharesAttributableToConversionOfDebtSecuritiesTreasuryStockMethod" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_OtherAccruedLiabilitiesMember" name="OtherAccruedLiabilitiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_CostReimbursements" name="CostReimbursements" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_ZaiLabMember" name="ZaiLabMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_FactorsAffectingComparabilityPolicyTextBlock" name="FactorsAffectingComparabilityPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentTwo" name="RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentTwo" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_SecuritiesPurchaseAgreementTotalNumberOfWarrantsToBePurchasedUnderAgreement" name="SecuritiesPurchaseAgreementTotalNumberOfWarrantsToBePurchasedUnderAgreement" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="inva_TwoThousandTwentyFiveNotesMember" name="TwoThousandTwentyFiveNotesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_NanoliveMember" name="NanoliveMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_SeriesC2PreferredStockMember" name="SeriesC2PreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountAsContributionOfEligibleCompensation" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountAsContributionOfEligibleCompensation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedPersonnelRelatedExpenses" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedPersonnelRelatedExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_DerecognitionOfNoncontrollingInterestsUponAcquisitionOfEntasisMinorityInterestShares" name="DerecognitionOfNoncontrollingInterestsUponAcquisitionOfEntasisMinorityInterestShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveAndOverlappingOfferingPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveAndOverlappingOfferingPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_NumberOfCommonStockIssuedDescription" name="NumberOfCommonStockIssuedDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_SeriesCPreferredStockAndWarrantsMember" name="SeriesCPreferredStockAndWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_CustomerThreeMember" name="CustomerThreeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_DebtInstrumentConvertibleConversionPremium" name="DebtInstrumentConvertibleConversionPremium" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="inva_InnovivaMember" name="InnovivaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_GSKMember" name="GSKMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_LongActingBeta2AgonistRelvarBreoMember" name="LongActingBeta2AgonistRelvarBreoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_WithdrawalFromInvestment" name="WithdrawalFromInvestment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_OptionPricingModelBacksolveValuationMember" name="OptionPricingModelBacksolveValuationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_GainLossOnOtherInvestments" name="GainLossOnOtherInvestments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_CreditAndSecurityAgreementMember" name="CreditAndSecurityAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_CommonStockAcquiredAverageCostPerShare" name="CommonStockAcquiredAverageCostPerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_ArmataPharmaceuticalsIncMember" name="ArmataPharmaceuticalsIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_CommonStockAndWarrantsMember" name="CommonStockAndWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_IntangibleAssetsInProcessResearchAndDevelopmentGross" name="IntangibleAssetsInProcessResearchAndDevelopmentGross" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_IntangibleAssetsMarketedProductsNet" name="IntangibleAssetsMarketedProductsNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity" name="ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_PurchaseOfEntasisNoncontrollingInterest" name="PurchaseOfEntasisNoncontrollingInterest" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_PurchasesOfTradingSecurityManagedByIspFundLp" name="PurchasesOfTradingSecurityManagedByIspFundLp" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_RoyaltyPayments" name="RoyaltyPayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_ShareRepurchaseAgreementWithGlaxoGroupLimitedMember" name="ShareRepurchaseAgreementWithGlaxoGroupLimitedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_EverestMedicinesLimitedMember" name="EverestMedicinesLimitedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_PurchasesOfEquityInvestmentsManagedByIspFundLp" name="PurchasesOfEquityInvestmentsManagedByIspFundLp" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_RecognitionOfNoncontrollingInterestUponInitialConsolidationOfEntasis" name="RecognitionOfNoncontrollingInterestUponInitialConsolidationOfEntasis" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_TermOfMilestonePaymentForNetSales" name="TermOfMilestonePaymentForNetSales" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_NameOfEventAxis" name="NameOfEventAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_ConvertiblePromissoryNoteMember" name="ConvertiblePromissoryNoteMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate" name="CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_HarvardUniversityMember" name="HarvardUniversityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_CashPaidForTheAcquisitionOfLaJollaPharmaceuticalCompanyNetOfCashAcquired" name="CashPaidForTheAcquisitionOfLaJollaPharmaceuticalCompanyNetOfCashAcquired" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_ImaginabMember" name="ImaginabMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_LaboratoryEquipmentFurnitureAndFixturesMember" name="LaboratoryEquipmentFurnitureAndFixturesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_RelatedPartyTransactionCommonStockOwnershipPercentageByRelatedParty" name="RelatedPartyTransactionCommonStockOwnershipPercentageByRelatedParty" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="inva_SeriesA1PreferredStockMember" name="SeriesA1PreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_RealizedLoss" name="RealizedLoss" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_LicenseRevenueMember" name="LicenseRevenueMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_XacduroMember" name="XacduroMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_ConsolidatedEntitiesDisclosureAbstract" name="ConsolidatedEntitiesDisclosureAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_OperatingLeaseWeightedAverageIncrementalBorrowingRate" name="OperatingLeaseWeightedAverageIncrementalBorrowingRate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_CostReimbursementMember" name="CostReimbursementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_InterestRateOfDeferredRoyaltyObligation" name="InterestRateOfDeferredRoyaltyObligation" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_NumberOfSharesReceivableOnSettlementOfDerivativeInstrument" name="NumberOfSharesReceivableOnSettlementOfDerivativeInstrument" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_EquityIncentivePlansAndESPPMember" name="EquityIncentivePlansAndESPPMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_SeriesD1WarrantMember" name="SeriesD1WarrantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_OneOfImaginabsCommonStockholderMember" name="OneOfImaginabsCommonStockholderMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_ContingentValueRightsLiability" name="ContingentValueRightsLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_ConvertiblePromissoryNotePurchaseAgreementMember" name="ConvertiblePromissoryNotePurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_LicenseAndCollaborationArrangementsDisclosureTextBlock" name="LicenseAndCollaborationArrangementsDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_UnrecognizedTaxBenefitsDecreaseResultingFromPriorPeriodTaxPositionsNet" name="UnrecognizedTaxBenefitsDecreaseResultingFromPriorPeriodTaxPositionsNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_ScheduleOfBalanceSheetInformationRelatedToOperatingLeaseTableTextBlock" name="ScheduleOfBalanceSheetInformationRelatedToOperatingLeaseTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_PercentageOfRoyaltyOnPaymentsReceivedFromSublicensees" name="PercentageOfRoyaltyOnPaymentsReceivedFromSublicensees" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_RoyaltyAgreementMaximumPotentialPayoutPercent" name="RoyaltyAgreementMaximumPotentialPayoutPercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_RoyaltyFinancingAgreementMember" name="RoyaltyFinancingAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_GiaprezaMember" name="GiaprezaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_DilutiveEpsOfNotes" name="DilutiveEpsOfNotes" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_NumberOfBoardMembersOfInvestee" name="NumberOfBoardMembersOfInvestee" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="inva_MeasurementPeriodAdjustmentsIncreaseDecreaseInLiabilities" name="MeasurementPeriodAdjustmentsIncreaseDecreaseInLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_PercentageOfRoyaltyPaymentsNotEntitledToReceive" name="PercentageOfRoyaltyPaymentsNotEntitledToReceive" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearTwo" name="CapitalizedFeesPaidRemainingEstimatedAmortizationYearTwo" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_ProceedsFromSaleOfEconomicInterestUnderEquityPurchaseAgreement" name="ProceedsFromSaleOfEconomicInterestUnderEquityPurchaseAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_AmortizationOfCapitalizedFeesAndDepreciationOfPropertyAndEquipment" name="AmortizationOfCapitalizedFeesAndDepreciationOfPropertyAndEquipment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_WarrantsPurchasedIn2022Member" name="WarrantsPurchasedIn2022Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_CommercialSupplyAgreementMember" name="CommercialSupplyAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentOne" name="RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentOne" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_CollaborativeArrangementRoyaltyRateDefinedLevelTwo" name="CollaborativeArrangementRoyaltyRateDefinedLevelTwo" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_NumberOfDerivativeInstrumentsPurchased" name="NumberOfDerivativeInstrumentsPurchased" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="inva_PurchasesOfCappedCallOptionsAssociatedWithConvertibleSeniorNotes" name="PurchasesOfCappedCallOptionsAssociatedWithConvertibleSeniorNotes" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_IncardaMember" name="IncardaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_IntangibleAssetsInProcessResearchAndDevelopmentAccumulatedAmortization" name="IntangibleAssetsInProcessResearchAndDevelopmentAccumulatedAmortization" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_ReductionToAdditionalPaidInCapital" name="ReductionToAdditionalPaidInCapital" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_DeferredRoyaltyObligations" name="DeferredRoyaltyObligations" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_SecuritiesPurchaseAgreementRightsToDesignateInvesteeBoardMembersNumberOfBoardMembers" name="SecuritiesPurchaseAgreementRightsToDesignateInvesteeBoardMembersNumberOfBoardMembers" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_LimitedPartnersInitialContribution" name="LimitedPartnersInitialContribution" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_TrelegyElliptaMember" name="TrelegyElliptaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_TheravanceRespiratoryCompanyLlcMember" name="TheravanceRespiratoryCompanyLlcMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_DebtConversionCommonStockPriceToConversionPriceRatioPercentage" name="DebtConversionCommonStockPriceToConversionPriceRatioPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree" name="LesseeOperatingLeaseLiabilityToBePaidAfterYearThree" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_UnrealizedOtherGainLossOnInvestments" name="UnrealizedOtherGainLossOnInvestments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_AmortizationOfFairValueAdjustmentsOfCostOfProductsSold" name="AmortizationOfFairValueAdjustmentsOfCostOfProductsSold" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_PurchaseAndSaleOfOtherInvestmentsManagedByIspFundLp" name="PurchaseAndSaleOfOtherInvestmentsManagedByIspFundLp" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_IntangibleAssetsCollaborationAgreementGross" name="IntangibleAssetsCollaborationAgreementGross" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_SubscriptionAgreementOneTimeMilestonePaymentOnCommercialSales" name="SubscriptionAgreementOneTimeMilestonePaymentOnCommercialSales" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_IncomeTaxesLineItems" name="IncomeTaxesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_LabaCollaborationMember" name="LabaCollaborationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_EntasisLeaseMember" name="EntasisLeaseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="inva_InCardaConvertibleNoteMember" name="InCardaConvertibleNoteMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_CapitalizedFeesPaidPolicyTextBlock" name="CapitalizedFeesPaidPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_PaymentsForRoyaltyAgreement" name="PaymentsForRoyaltyAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_EmployeeStockPurchasePlanMember" name="EmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_FairValueAdjustmentsOfInventoryFromAcquistion" name="FairValueAdjustmentsOfInventoryFromAcquistion" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_ConsolidatedInvesteesMember" name="ConsolidatedInvesteesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_ContingentSalesBasedMilestonePayment" name="ContingentSalesBasedMilestonePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_SaleOfEquityInvestmentsManagedByIspFundLp" name="SaleOfEquityInvestmentsManagedByIspFundLp" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_SeriesD1AndD2PreferredStockAndCommonStockMember" name="SeriesD1AndD2PreferredStockAndCommonStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_DebtInstrumentRatioOfRepurchasePriceToThePrincipalAmount" name="DebtInstrumentRatioOfRepurchasePriceToThePrincipalAmount" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_OperatingLossCarryforwardsIndefinitePeriod" name="OperatingLossCarryforwardsIndefinitePeriod" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_CapitalizedFeesPaidDisclosureTextBlock" name="CapitalizedFeesPaidDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAccruedLiabilities" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAccruedLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees" name="GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_CapitalizedFeesPaidToRelatedPartyPolicyTextBlock" name="CapitalizedFeesPaidToRelatedPartyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_SecuritiesPurchaseAgreementAmount" name="SecuritiesPurchaseAgreementAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_SecuritiesPurchaseAgreementMember" name="SecuritiesPurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_LicenseRevenueRecognized" name="LicenseRevenueRecognized" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_SecondNoteAmendmentAgreementMember" name="SecondNoteAmendmentAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsTableTextBlock" name="ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_EquityInvestmentsAndMoneyMarketFundsMember" name="EquityInvestmentsAndMoneyMarketFundsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_DecreaseToAccumulatedDeficit" name="DecreaseToAccumulatedDeficit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_DividendYield" name="DividendYield" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement" name="SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="inva_PreferredStockWarrantsMember" name="PreferredStockWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_PrivatelyNegotiatedCappedCallOptionMember" name="PrivatelyNegotiatedCappedCallOptionMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_TwoThousandTwentyThreeNotesMember" name="TwoThousandTwentyThreeNotesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_EquityMethodInvestment" name="EquityMethodInvestment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_HealthCareRoyaltyPartnersMember" name="HealthCareRoyaltyPartnersMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_ArmataTermLoanMember" name="ArmataTermLoanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_WalthamMassachusettsMember" name="WalthamMassachusettsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_LaJollaPharmaceuticalCompanyMember" name="LaJollaPharmaceuticalCompanyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_AccruedRoyaltyObligations" name="AccruedRoyaltyObligations" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_ConvertibleSubordinatedDebtFairValueDisclosures" name="ConvertibleSubordinatedDebtFairValueDisclosures" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_TermOfMilestonePaymentForCommercialSale" name="TermOfMilestonePaymentForCommercialSale" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430387971408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Feb. 14, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">INNOVIVA, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-30319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">94-3265960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1350 Old Bayshore Highway, Suite 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Burlingame<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">238-9600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock $0.01 Par Value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">INVA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 731,926,690<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,227,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001080014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">DOCUMENTS INCORPORATED BY REFERENCE</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Specified portions of the registrant&#8217;s definitive Proxy Statement to be issued in conjunction with the registrant&#8217;s 2023 Annual Meeting of Stockholders, which is expected to be filed not later than 120 days after the registrant&#8217;s fiscal year ended December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">, are incorporated by reference into Part III of this Annual Report. Except as expressly incorporated by reference, the registrant&#8217;s Proxy Statement shall not be deemed to be a part of this Annual Report on Form 10-K.</span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Deloitte & Touche LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">San Jose, California<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430388125680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 193,513<span></span>
</td>
<td class="nump">$ 291,049<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts receivable</a></td>
<td class="nump">14,454<span></span>
</td>
<td class="nump">9,401<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesLongTermContractsOrPrograms', window );">Receivables from collaboration arrangements</a></td>
<td class="nump">69,621<span></span>
</td>
<td class="nump">54,672<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">40,737<span></span>
</td>
<td class="nump">55,897<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses</a></td>
<td class="nump">21,630<span></span>
</td>
<td class="nump">29,559<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">4,264<span></span>
</td>
<td class="nump">2,933<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">344,219<span></span>
</td>
<td class="nump">443,511<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">483<span></span>
</td>
<td class="nump">170<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_EquityMethodInvestment', window );">Equity method investments</a></td>
<td class="nump">116,546<span></span>
</td>
<td class="nump">39,154<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Equity and long-term investments</a></td>
<td class="nump">444,432<span></span>
</td>
<td class="nump">363,859<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostNet', window );">Capitalized fees paid, net</a></td>
<td class="nump">83,784<span></span>
</td>
<td class="nump">97,607<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">2,536<span></span>
</td>
<td class="nump">3,265<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">17,905<span></span>
</td>
<td class="nump">26,713<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets</a></td>
<td class="nump">230,335<span></span>
</td>
<td class="nump">252,919<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">3,267<span></span>
</td>
<td class="nump">4,299<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">1,243,507<span></span>
</td>
<td class="nump">1,231,497<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">6,717<span></span>
</td>
<td class="nump">2,939<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued personnel-related expenses</a></td>
<td class="nump">7,020<span></span>
</td>
<td class="nump">8,022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest payable</a></td>
<td class="nump">3,422<span></span>
</td>
<td class="nump">4,359<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue</a></td>
<td class="nump">1,277<span></span>
</td>
<td class="nump">2,094<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtCurrent', window );">Convertible subordinated notes due 2023, net of issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">96,193<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income tax payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">154<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other accrued liabilities</a></td>
<td class="nump">19,698<span></span>
</td>
<td class="nump">21,207<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">38,134<span></span>
</td>
<td class="nump">134,968<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net of discount and issuance costs</a></td>
<td class="nump">446,234<span></span>
</td>
<td class="nump">444,180<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">71,870<span></span>
</td>
<td class="nump">70,918<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liabilities, net</a></td>
<td class="nump">563<span></span>
</td>
<td class="nump">5,771<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_IncomeTaxPayableNonCurrent', window );">Income tax payable, long-term</a></td>
<td class="nump">11,751<span></span>
</td>
<td class="nump">9,872<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 13)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock: $0.01 par value, 230 shares authorized, no shares issued and outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock: $0.01 par value, 200,000 shares authorized, 69,307 and 69,188 issued and outstanding as of December 31, 2023 and December 31, 2022 respectively</a></td>
<td class="nump">633<span></span>
</td>
<td class="nump">692<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonValue', window );">Treasury stock: at cost, 32,005 shares as of December 31, 2023 and 2022</a></td>
<td class="num">(393,829)<span></span>
</td>
<td class="num">(393,829)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">1,093,340<span></span>
</td>
<td class="nump">1,163,836<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(25,189)<span></span>
</td>
<td class="num">(204,911)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total stockholders' equity</a></td>
<td class="nump">674,955<span></span>
</td>
<td class="nump">565,788<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 1,243,507<span></span>
</td>
<td class="nump">$ 1,231,497<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_EquityMethodInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity method investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_EquityMethodInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_IncomeTaxPayableNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax payable non current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_IncomeTaxPayableNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480833/946-310-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(5)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481058/954-310-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479483/340-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesLongTermContractsOrPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount to be collected within one year of the balance sheet date (or one operating cycle, if longer) from customers in accordance with the contractual provisions of long-term contracts or programs including amounts billed and unbilled as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesLongTermContractsOrPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 38: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 41: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-15<br><br>Reference 42: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-16<br><br>Reference 43: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481520/505-30-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.30)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430385879440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">230<span></span>
</td>
<td class="nump">230<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">63,307<span></span>
</td>
<td class="nump">69,188<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">63,307<span></span>
</td>
<td class="nump">69,188<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock, shares</a></td>
<td class="nump">32,005<span></span>
</td>
<td class="nump">32,005<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430388928448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF INCOME - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 310,463<span></span>
</td>
<td class="nump">$ 331,339<span></span>
</td>
<td class="nump">$ 391,866<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">98,232<span></span>
</td>
<td class="nump">63,538<span></span>
</td>
<td class="nump">16,187<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">33,922<span></span>
</td>
<td class="nump">41,432<span></span>
</td>
<td class="nump">576<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of acquired intangible assets</a></td>
<td class="nump">21,784<span></span>
</td>
<td class="nump">5,581<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeconsolidationGainOrLossAmount', window );">Gain on sale of Theravance Respiratory Company, LLC ("TRC")</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(266,696)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">20,662<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Changes in fair values of equity method investments, net</a></td>
<td class="num">(77,392)<span></span>
</td>
<td class="nump">161,749<span></span>
</td>
<td class="num">(84,392)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_GainLossOnOtherInvestments', window );">Changes in fair value of equity and long-term investments, net</a></td>
<td class="num">(11,129)<span></span>
</td>
<td class="num">(8,462)<span></span>
</td>
<td class="num">(6,638)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestAndDividendIncomeOperating', window );">Interest and dividend income</a></td>
<td class="num">(15,818)<span></span>
</td>
<td class="num">(6,369)<span></span>
</td>
<td class="num">(1,839)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">19,157<span></span>
</td>
<td class="nump">15,789<span></span>
</td>
<td class="nump">19,070<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="nump">4,969<span></span>
</td>
<td class="nump">3,373<span></span>
</td>
<td class="nump">3,626<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total expenses, net</a></td>
<td class="nump">116,365<span></span>
</td>
<td class="nump">44,390<span></span>
</td>
<td class="num">(53,410)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before income taxes</a></td>
<td class="nump">194,098<span></span>
</td>
<td class="nump">286,949<span></span>
</td>
<td class="nump">445,276<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense, net</a></td>
<td class="nump">14,376<span></span>
</td>
<td class="nump">66,687<span></span>
</td>
<td class="nump">76,439<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">179,722<span></span>
</td>
<td class="nump">220,262<span></span>
</td>
<td class="nump">368,837<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to noncontrolling interests</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,341<span></span>
</td>
<td class="nump">102,983<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net income attributable to Innoviva stockholders</a></td>
<td class="nump">$ 179,722<span></span>
</td>
<td class="nump">$ 213,921<span></span>
</td>
<td class="nump">$ 265,854<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net income per share attributable to Innoviva stockholders</a></td>
<td class="nump">$ 2.75<span></span>
</td>
<td class="nump">$ 3.07<span></span>
</td>
<td class="nump">$ 3.24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net income per share attributable to Innoviva stockholders</a></td>
<td class="nump">$ 2.2<span></span>
</td>
<td class="nump">$ 2.37<span></span>
</td>
<td class="nump">$ 2.87<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Shares used to compute Innoviva basic and diluted net income per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Shares used to compute basic net income per share</a></td>
<td class="nump">65,435<span></span>
</td>
<td class="nump">69,644<span></span>
</td>
<td class="nump">82,062<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares used to compute diluted net income per share</a></td>
<td class="nump">86,876<span></span>
</td>
<td class="nump">95,248<span></span>
</td>
<td class="nump">94,310<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalty revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 238,846<span></span>
</td>
<td class="nump">$ 311,645<span></span>
</td>
<td class="nump">$ 391,866<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Net product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">60,617<span></span>
</td>
<td class="nump">19,694<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of products sold (inclusive of amortization of inventory fair value adjustments, excluding amortization of intangible assets)</a></td>
<td class="nump">41,040<span></span>
</td>
<td class="nump">13,793<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=inva_LicenseRevenueMember', window );">License revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">11,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of license revenue</a></td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_GainLossOnOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain loss on other investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_GainLossOnOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeconsolidationGainOrLossAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeconsolidationGainOrLossAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481664/323-10-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndDividendIncomeOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the total of interest and dividend income, including any amortization and accretion (as applicable) of discounts and premiums, earned from (1) loans and leases whether held-for-sale or held-in-portfolio; (2) investment securities; (3) federal funds sold; (4) securities purchased under agreements to resell; (5) investments in banker's acceptances, commercial paper, or certificates of deposit; (6) dividend income; or (7) other investments not otherwise specified herein.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 39<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480228/946-830-45-39<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.1-5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndDividendIncomeOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=inva_LicenseRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=inva_LicenseRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430389398672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF INCOME (Parenthetical) - Royalty revenue - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAmortization', window );">Amortization of capitalized fees paid</a></td>
<td class="nump">$ 13,800<span></span>
</td>
<td class="nump">$ 13,800<span></span>
</td>
<td class="nump">$ 13,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">GSK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAmortization', window );">Amortization of capitalized fees paid</a></td>
<td class="nump">$ 13,823<span></span>
</td>
<td class="nump">$ 13,823<span></span>
</td>
<td class="nump">$ 13,823<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479483/340-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inva_GSKMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inva_GSKMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430387604656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 179,722<span></span>
</td>
<td class="nump">$ 220,262<span></span>
</td>
<td class="nump">$ 368,837<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive income</a></td>
<td class="nump">179,722<span></span>
</td>
<td class="nump">220,262<span></span>
</td>
<td class="nump">368,837<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Comprehensive income attributable to noncontrolling interests</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,341<span></span>
</td>
<td class="nump">102,983<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income attributable to Innoviva stockholders</a></td>
<td class="nump">$ 179,722<span></span>
</td>
<td class="nump">$ 213,921<span></span>
</td>
<td class="nump">$ 265,854<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430384861488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Cumulative effect period of adoption adjustment member</div></th>
<th class="th"><div>Common stock</div></th>
<th class="th">
<div>Common stock </div>
<div>Cumulative effect period of adoption adjustment member</div>
</th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th">
<div>Additional Paid-In Capital </div>
<div>Cumulative effect period of adoption adjustment member</div>
</th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th">
<div>Accumulated Deficit </div>
<div>Cumulative effect period of adoption adjustment member</div>
</th>
<th class="th"><div>Treasury Stock</div></th>
<th class="th">
<div>Treasury Stock </div>
<div>Cumulative effect period of adoption adjustment member</div>
</th>
<th class="th"><div>Noncontrolling Interest</div></th>
<th class="th">
<div>Noncontrolling Interest </div>
<div>Cumulative effect period of adoption adjustment member</div>
</th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 607,837<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,260,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (722,002)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 67,925<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101,392,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distributions to noncontrolling interests</a></td>
<td class="num">(59,457)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(59,457)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersShares', window );">Distributions to noncontrolling interest (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity', window );">Equity activity of noncontrolling interest in a consolidated variable interest entity</a></td>
<td class="num">(259)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(259)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntityShares', window );">Equity activity of noncontrolling interests in a consolidated variable interest entity (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Exercise of stock options, and issuance of common stock units and stock awards, net of repurchase of shares to satisfy tax withholding</a></td>
<td class="nump">1,109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Exercise of stock options, and issuance of common stock units and stock awards, net of repurchase of shares to satisfy tax withholding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">179,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock</a></td>
<td class="num">(394,149)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (320)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (393,829)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(32,005,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,005,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">2,017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares', window );">Stock-based compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">368,837<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">265,854<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,983<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ProfitLossShares', window );">Net income (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">525,935<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,264,024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (456,148)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (393,829)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">111,192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,566,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,005,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingStandardsUpdateExtensibleList', window );">Accounting Standards Update [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Accounting Standards Update 2020-06 [Member]<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Accounting Standards Update 2020-06 [Member]<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Accounting Standards Update 2020-06 [Member]<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distributions to noncontrolling interests</a></td>
<td class="num">(69,811)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(69,811)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersShares', window );">Distributions to noncontrolling interest (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_RecognitionOfNoncontrollingInterestUponInitialConsolidationOfEntasis', window );">Recognition of noncontrolling interest upon initial consolidation of Entasis</a></td>
<td class="nump">38,471<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,471<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_RecognitionOfNoncontrollingInterestUponInitialConsolidationofEntasisShares', window );">Recognition of noncontrolling interest upon initial consolidation of Entasis (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity', window );">Equity activity of noncontrolling interest in a consolidated variable interest entity</a></td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntityShares', window );">Equity activity of noncontrolling interests in a consolidated variable interest entity (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_DerecognitionOfNoncontrollingInterestsUponSaleOfTrc', window );">Derecognition of noncontrolling interests upon sale of TRC</a></td>
<td class="num">(61,226)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(61,304)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_DerecognitionOfNoncontrollingInterestsUponSaleOfTrcShares', window );">Derecognition of noncontrolling interests upon sale of TRC (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_DerecognitionOfNonControllingInterestsUponAcquisitionOfEntasisMinorityInterest', window );">Derecognition of noncontrolling interests upon acquisition of Entasis noncontrolling interest</a></td>
<td class="num">(42,162)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,153)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28,009)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_DerecognitionOfNoncontrollingInterestsUponAcquisitionOfEntasisMinorityInterestShares', window );">Derecognition of noncontrolling interests upon acquisition of Entasis noncontrolling interest (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Exercise of stock options, and issuance of common stock units and stock awards, net of repurchase of shares to satisfy tax withholding</a></td>
<td class="nump">288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Exercise of stock options, and issuance of common stock units and stock awards, net of repurchase of shares to satisfy tax withholding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">269,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt', window );">Capped call options associated with convertible senior notes due 2028</a></td>
<td class="num">(16,585)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,585)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtInShares', window );">Capped call options associated with convertible senior notes due 2028 (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature', window );">Conversion of convertible subordinated notes due 2023</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of convertible subordinated notes due 2023 (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock</a></td>
<td class="num">(8,503)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,497)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(647,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">7,347<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares', window );">Stock-based compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">220,262<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">213,921<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ProfitLossShares', window );">Net income (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 565,788<span></span>
</td>
<td class="num">$ (28,229)<span></span>
</td>
<td class="nump">$ 692<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,163,836<span></span>
</td>
<td class="num">$ (65,467)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(204,911)<span></span>
</td>
<td class="nump">$ 37,238<span></span>
</td>
<td class="num">$ (393,829)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">69,188,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,188,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,005,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Exercise of stock options, and issuance of common stock units and stock awards, net of repurchase of shares to satisfy tax withholding</a></td>
<td class="nump">$ 92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Exercise of stock options, and issuance of common stock units and stock awards, net of repurchase of shares to satisfy tax withholding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">293,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock</a></td>
<td class="num">(76,484)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (62)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(76,422)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,174,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">5,837<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,837<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares', window );">Stock-based compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">179,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">179,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ProfitLossShares', window );">Net income (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 674,955<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,093,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (25,189)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (393,829)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Dec. 31, 2023</a></td>
<td class="nump">63,307,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,307,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,005,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtInShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments to additional paid in capital equity component of convertible debt in shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtInShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments to additional paid in capital share based compensation requisite service period recognition shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Changes to noncontrolling interest from a consolidated variable interest entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntityShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Changes to noncontrolling interest from a consolidated variable interest entity shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntityShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_DerecognitionOfNonControllingInterestsUponAcquisitionOfEntasisMinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derecognition of non controlling interests upon acquisition of entasis minority interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_DerecognitionOfNonControllingInterestsUponAcquisitionOfEntasisMinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_DerecognitionOfNoncontrollingInterestsUponAcquisitionOfEntasisMinorityInterestShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derecognition of nonControlling interests upon acquisition of entasis minority interest shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_DerecognitionOfNoncontrollingInterestsUponAcquisitionOfEntasisMinorityInterestShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_DerecognitionOfNoncontrollingInterestsUponSaleOfTrc">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derecognition of noncontrolling interestsupon sale of TRC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_DerecognitionOfNoncontrollingInterestsUponSaleOfTrc</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_DerecognitionOfNoncontrollingInterestsUponSaleOfTrcShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derecognition of noncontrolling interests upon sale of trc shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_DerecognitionOfNoncontrollingInterestsUponSaleOfTrcShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minority interest decrease from distributions to noncontrolling interest holders shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_ProfitLossShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Profit Loss Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_ProfitLossShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_RecognitionOfNoncontrollingInterestUponInitialConsolidationOfEntasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Recognition Of Noncontrolling Interest Upon Initial Consolidation Of Entasis</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_RecognitionOfNoncontrollingInterestUponInitialConsolidationOfEntasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_RecognitionOfNoncontrollingInterestUponInitialConsolidationofEntasisShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Recognition of noncontrolling interest upon initial consolidation of Entasis, Shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_RecognitionOfNoncontrollingInterestUponInitialConsolidationofEntasisShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingStandardsUpdateExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates amendment to accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147477123/405-50-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482477/820-10-65-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482477/820-10-65-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483482/832-10-65-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483482/832-10-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 66: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 67: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 68: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 69: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 70: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2<br><br>Reference 71: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2<br><br>Reference 72: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingStandardsUpdateExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in additional paid in capital (APIC) resulting from recognition of deferred taxes for convertible debt with a beneficial conversion feature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 51<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482663/740-10-55-51<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481284/470-20-25-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 38: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 41: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-15<br><br>Reference 42: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-16<br><br>Reference 43: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430388219056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 179,722<span></span>
</td>
<td class="nump">$ 220,262<span></span>
</td>
<td class="nump">$ 368,837<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="nump">4,400<span></span>
</td>
<td class="nump">25,006<span></span>
</td>
<td class="nump">76,432<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_AmortizationOfCapitalizedFeesAndDepreciationOfPropertyAndEquipment', window );">Amortization of capitalized fees and depreciation of property and equipment</a></td>
<td class="nump">13,921<span></span>
</td>
<td class="nump">13,931<span></span>
</td>
<td class="nump">13,832<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of acquired intangible assets</a></td>
<td class="nump">21,784<span></span>
</td>
<td class="nump">5,581<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_InventoryFairValueStepUpAdjustmentIncludedInCostOfProductSales', window );">Inventory fair value step-up adjustment included in cost of products sold</a></td>
<td class="nump">27,164<span></span>
</td>
<td class="nump">10,023<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">5,837<span></span>
</td>
<td class="nump">7,347<span></span>
</td>
<td class="nump">2,017<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt discount and issuance costs</a></td>
<td class="nump">2,065<span></span>
</td>
<td class="nump">2,055<span></span>
</td>
<td class="nump">9,136<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Changes in fair values of equity method investments, net</a></td>
<td class="num">(77,392)<span></span>
</td>
<td class="nump">161,749<span></span>
</td>
<td class="num">(84,392)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_UnrealizedOtherGainLossOnInvestments', window );">Changes in fair values of equity and long-term investments, net</a></td>
<td class="num">(11,129)<span></span>
</td>
<td class="num">(8,462)<span></span>
</td>
<td class="num">(4,917)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">20,662<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeconsolidationGainOrLossAmount', window );">Net gain on sale of TRC</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(266,696)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other non-cash items</a></td>
<td class="num">(517)<span></span>
</td>
<td class="nump">3,402<span></span>
</td>
<td class="num">(259)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(5,053)<span></span>
</td>
<td class="num">(3,525)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent', window );">Receivables from collaborative arrangements</a></td>
<td class="num">(14,949)<span></span>
</td>
<td class="nump">13,319<span></span>
</td>
<td class="num">(16,780)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(12,004)<span></span>
</td>
<td class="nump">280<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="nump">7,929<span></span>
</td>
<td class="num">(21,350)<span></span>
</td>
<td class="nump">203<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="num">(2,965)<span></span>
</td>
<td class="num">(3,341)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">3,778<span></span>
</td>
<td class="nump">92<span></span>
</td>
<td class="num">(39)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued personnel-related expenses and other accrued liabilities</a></td>
<td class="num">(1,498)<span></span>
</td>
<td class="nump">11,913<span></span>
</td>
<td class="num">(257)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInterestPayableNet', window );">Accrued interest payable</a></td>
<td class="num">(937)<span></span>
</td>
<td class="nump">207<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="num">(817)<span></span>
</td>
<td class="num">(755)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Income tax payable</a></td>
<td class="nump">1,725<span></span>
</td>
<td class="nump">10,026<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">141,064<span></span>
</td>
<td class="nump">201,726<span></span>
</td>
<td class="nump">363,813<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Purchases of equity method investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(45,000)<span></span>
</td>
<td class="num">(44,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of trading securities</a></td>
<td class="num">(65,132)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(15,905)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireLongtermInvestments', window );">Purchases of equity and long term investments</a></td>
<td class="num">(1,218)<span></span>
</td>
<td class="num">(13,725)<span></span>
</td>
<td class="num">(6,373)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_PurchasesOfEquityInvestmentsManagedByIspFundLp', window );">Purchases of equity investments managed by ISP Fund LP</a></td>
<td class="num">(31,164)<span></span>
</td>
<td class="num">(60,910)<span></span>
</td>
<td class="num">(190,970)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_PurchasesOfTradingSecurityManagedByIspFundLp', window );">Purchases of trading security managed by ISP Fund LP</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(50,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_SaleOfEquityInvestmentsManagedByIspFundLp', window );">Sales of equity investments managed by ISP Fund LP</a></td>
<td class="nump">72,500<span></span>
</td>
<td class="nump">24,281<span></span>
</td>
<td class="nump">21,440<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_PurchaseAndSaleOfOtherInvestmentsManagedByIspFundLp', window );">Purchase and sales of other investments managed by ISP Fund LP, net</a></td>
<td class="num">(41,336)<span></span>
</td>
<td class="num">(23,371)<span></span>
</td>
<td class="nump">279,530<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(411)<span></span>
</td>
<td class="num">(67)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_NetProceedsFromSaleOfVariableInterestEntityEquity', window );">Proceeds from sale of ownership interest in TRC, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">248,191<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAcquiredFromAcquisition', window );">Cash acquired through the consolidation of Entasis</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">23,070<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_CashPaidForTheAcquisitionOfLaJollaPharmaceuticalCompanyNetOfCashAcquired', window );">Cash paid for the acquisition of La Jolla, net of cash acquired</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(159,103)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="num">(66,761)<span></span>
</td>
<td class="num">(56,634)<span></span>
</td>
<td class="nump">43,722<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToMinorityShareholders', window );">Distributions to noncontrolling interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(69,811)<span></span>
</td>
<td class="num">(59,457)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_PurchaseOfEntasisNoncontrollingInterest', window );">Purchase of Entasis noncontrolling interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(43,910)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchase of common stock</a></td>
<td class="num">(75,728)<span></span>
</td>
<td class="num">(8,503)<span></span>
</td>
<td class="num">(394,149)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Repurchase of shares to satisfy tax withholding</a></td>
<td class="num">(77)<span></span>
</td>
<td class="num">(82)<span></span>
</td>
<td class="num">(60)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuances of common stock, net</a></td>
<td class="nump">170<span></span>
</td>
<td class="nump">370<span></span>
</td>
<td class="nump">1,169<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfUnsecuredDebt', window );">Payment for repurchase of convertible subordinated notes due 2023</a></td>
<td class="num">(96,204)<span></span>
</td>
<td class="num">(165,131)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_PurchasesOfCappedCallOptionsAssociatedWithConvertibleSeniorNotes', window );">Purchases of capped call options associated with convertible senior notes due 2028</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(21,037)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of convertible senior notes due 2028, net of issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">252,536<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(171,839)<span></span>
</td>
<td class="num">(55,568)<span></span>
</td>
<td class="num">(452,497)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="num">(97,536)<span></span>
</td>
<td class="nump">89,524<span></span>
</td>
<td class="num">(44,962)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">291,049<span></span>
</td>
<td class="nump">201,525<span></span>
</td>
<td class="nump">246,487<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">193,513<span></span>
</td>
<td class="nump">291,049<span></span>
</td>
<td class="nump">201,525<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">11,381<span></span>
</td>
<td class="nump">11,736<span></span>
</td>
<td class="nump">9,933<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for income taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">53,855<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental Disclosure of Non-cash Investing and Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_AccruedInterestIncomeIncludedInLongTermInvestments', window );">Accrued interest income added to long-term investments</a></td>
<td class="nump">2,666<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_NonCashActivity', window );">Adoption of ASU 2020-06</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (28,228)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_AccruedInterestIncomeIncludedInLongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued interest income included in long-term investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_AccruedInterestIncomeIncludedInLongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_AmortizationOfCapitalizedFeesAndDepreciationOfPropertyAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortization of capitalized fees and depreciation of property and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_AmortizationOfCapitalizedFeesAndDepreciationOfPropertyAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_CashPaidForTheAcquisitionOfLaJollaPharmaceuticalCompanyNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash paid for the acquisition of La Jolla Pharmaceutical Company, net of cash acquired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_CashPaidForTheAcquisitionOfLaJollaPharmaceuticalCompanyNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_InventoryFairValueStepUpAdjustmentIncludedInCostOfProductSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventory fair value step-up adjustment included in cost of product sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_InventoryFairValueStepUpAdjustmentIncludedInCostOfProductSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_NetProceedsFromSaleOfVariableInterestEntityEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Proceeds from sale of variable interest entity equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_NetProceedsFromSaleOfVariableInterestEntityEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_NonCashActivity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non cash activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_NonCashActivity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_PurchaseAndSaleOfOtherInvestmentsManagedByIspFundLp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase and sale of other investments managed by ISP FUND LP</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_PurchaseAndSaleOfOtherInvestmentsManagedByIspFundLp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_PurchaseOfEntasisNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase of entasis noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_PurchaseOfEntasisNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_PurchasesOfCappedCallOptionsAssociatedWithConvertibleSeniorNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchases of capped call options associated with convertible senior notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_PurchasesOfCappedCallOptionsAssociatedWithConvertibleSeniorNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_PurchasesOfEquityInvestmentsManagedByIspFundLp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchases of Equity Investments Managed by Isp Fund Lp</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_PurchasesOfEquityInvestmentsManagedByIspFundLp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_PurchasesOfTradingSecurityManagedByIspFundLp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchases of trading security managed by Isp fund Lp.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_PurchasesOfTradingSecurityManagedByIspFundLp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_SaleOfEquityInvestmentsManagedByIspFundLp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of equity investments managed by ISP FUND LP</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_SaleOfEquityInvestmentsManagedByIspFundLp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_UnrealizedOtherGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unrealized other gain loss on investments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_UnrealizedOtherGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAcquiredFromAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAcquiredFromAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeconsolidationGainOrLossAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeconsolidationGainOrLossAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481664/323-10-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate increase (decrease) during the reporting period in the amount due from the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInterestPayableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInterestPayableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireLongtermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, beyond the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the long-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireLongtermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfUnsecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to repay long-term debt that is not secured by collateral. Excludes repayments of tax exempt unsecured debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfUnsecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430385891152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_Rule10B51ArrModifiedFlag', window );">Rule 10b51Arrangement Modified</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_NonRule10B51ArrModifiedFlag', window );">Non Rule 10b51 Arrangement Modified</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_NonRule10B51ArrModifiedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non Rule 10B51 Arr Modified Flag</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_NonRule10B51ArrModifiedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_Rule10B51ArrModifiedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rule 10b51 Arr Modified Flag.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_Rule10B51ArrModifiedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430387610528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1.  DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Description of Operations</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Innoviva, Inc. (and where context requires, together with its subsidiaries referred to as &#8220;Innoviva&#8221;, the &#8220;Company&#8221;, or &#8220;we&#8221; and other similar pronouns) is a company with a portfolio of royalties and innovative healthcare assets. Our royalty portfolio contains respiratory assets partnered with Glaxo Group Limited (&#8220;GSK&#8221;), including RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(fluticasone furoate/vilanterol, &#8220;FF/VI&#8221;) and ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(umeclidinium bromide/vilanterol, &#8220;UMEC/VI&#8221;), and up until July 2022, TRELEGY</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(the combination FF/UMEC/VI). We sold our </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">15</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% ownership interest in Theravance Respiratory Company, LLC (&#8220;TRC&#8221;) on July 20, 2022, and are no longer entitled to receive royalties on sales of TRELEGY</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> products. Under the Long-Acting Beta2 Agonist (&#8220;LABA&#8221;) Collaboration Agreement, Innoviva is entitled to receive royalties from GSK on sales of RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> as follows: </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">15</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% on the first $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> billion of annual global net sales and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% for all annual global net sales above $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> billion; and royalties from the sales of ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, which tier upward at a range from </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">6.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expanded our portfolio through the acquisition of Entasis Therapeutics Holdings Inc. (&#8220;Entasis&#8221;) on July 11, 2022 and the acquisition of La Jolla Pharmaceutical Company (&#8220;La Jolla&#8221;) on August 22, 2022. Our commercial and marketed products include GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock, and XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (eravacycline) for the treatment of complicated intra-abdominal infections in adults. Our new product, XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(formerly known as sulbactam-durlobactam or SUL-DUR), was approved by the United States Food and Drug Administration (&#8220;FDA&#8221;) for the treatment of hospital-acquired and ventilator-associated pneumonias caused by </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Acinetobacter</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in adults on May 23, 2023. We commenced commercial sales of XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in the third quarter of 2023. Our development pipeline includes zoliflodacin, an investigational treatment for uncomplicated gonorrhea that reported positive data in a pivotal Phase 3 clinical trial on November 1, 2023. As such, we have a wholly owned robust critical care and infectious disease operating platform with a hospital focus anchored by three differentiated products with significant growth potential and a promising drug candidate.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, we own other strategic healthcare assets, such as a large equity stake in Armata Pharmaceuticals, a leader in development of bacteriophages with potential use across a range of infectious and other serious diseases.  We also have economic interests in other healthcare companies.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Principles of Consolidation</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying consolidated financial statements include the accounts of Innoviva, our wholly owned subsidiaries and certain variable interest entities (&#8220;VIE&#8221;) for which we are the primary beneficiary. All intercompany balances and transactions have been eliminated in consolidation. For consolidated entities where we own or are exposed to less than 100% of the economics, we record net income (loss) attributable to noncontrolling interest in our consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entity by the respective noncontrolling party.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Presentation Reclassification</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Amounts in equity and long-term investments reported in the Company&#8217;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">s comparative financial statements have been reclassified to conform to the current year presentation. Certain reclassifications have been made to the consolidated statement of cash flows for the years ended December 31, 2022 and 2021 to conform to the current year&#8217;s presentation. These reclassifications had no net effect on the net income or net cash flows from operating, investing and financing activities as previously reported.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Factors Affecting Comparability</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our historical financial condition and results of operations for the periods presented may not be comparable, either between periods or going forward due to the factors below and as discussed in Note 5, &#8220;Consolidated Entities and Acquisitions&#8221;.</span></p><div style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Adoption of Accounting Standards Update 2020-06, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Debt-Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (&#8220;ASU 2020-06&#8221;) effective January 1, 2022;</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accounting consolidation of Entasis on February 17, 2022 and purchase of remaining noncontrolling interest in Entasis on July 11, 2022;</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Sale of our </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">15</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% ownership interest in TRC on July 20, 2022; and</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Acquisition of La Jolla on August 22, 2022.</span></div></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Management&#8217;s Estimates</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of consolidated financial statements in conformity with U.S. Generally Accepted Accounting Principles (&#8220;U.S. GAAP&#8221;) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ materially from those estimates. Management evaluates its significant accounting policies and estimates on an ongoing basis. We base our estimates on historical experience and other relevant assumptions that we believe to be reasonable under the circumstances. These estimates also form the basis for making judgments about the carrying values of assets and liabilities when these values are not readily apparent from other sources.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk and of Significant Suppliers and Partners</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents and equity and long-term investments. Although we deposit our cash with multiple financial institutions, our deposits, at times, may exceed federally insured limits.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> We are dependent on third-party manufacturers to supply active pharmaceutical ingredients (&#8220;API&#8221;) and drug products for research and development and commercial programs. These programs could be adversely affected by significant interruption in the supply of API or drug products.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Currently, we derive most of our revenues from GSK and our near-term success depends in large part on GSK&#8217;s ability to successfully develop and commercialize the products in the respiratory programs partnered with GSK. Our near-term success depends in large part upon the performance by GSK of its commercial obligations under the GSK Agreements and the commercial success of RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. If GSK does not devote sufficient resources to the commercialization or development of these products, is unsuccessful in its efforts, or chooses to reprioritize its commercial programs, our business would be materially harmed. GSK is responsible for all clinical and other product development, regulatory, manufacturing and commercialization activities for products developed under the GSK Agreements, including RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Our royalty revenues may fluctuate due to a variety of factors, many of which are outside of our control. Our royalty revenues under the GSK Agreements may not meet our, analysts&#8217; or investors&#8217; expectations, due to a number of important factors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We started recognizing revenue from product sales of GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in 2022 as a result of our acquisition of La Jolla. In the current year, we also started recognizing revenue from product sales from XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, which was commercially launched in the third quarter of 2023. Hospitals and other healthcare organizations generally purchase our products through a network of specialty distributors. These specialty distributors, which are located in the U.S., are considered our customers for accounting purposes. We do not believe that loss of one of these distributors would significantly impact our ability to distribute our products, as we expect that sales volume would be absorbed by new or remaining distributors. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">Three</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of our customers each account for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">31</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">27</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">27</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%, respectively, of our net product sales for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. These same customers account for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">29</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">19</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">15</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%, respectively, of our receivables from net product sales, which are included in &#8220;Accounts receivables, net&#8221; in our consolidated balance sheet as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Three of our customers each account for approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">33</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">29</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">28</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%, respectively, of our net product sales from the time of our acquisition of La Jolla through December 31, 2022. These same customers account for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">23</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">37</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">37</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%, respectively, of our receivables from net product sales, which are included in &#8220;Accounts receivables, net&#8221; in our consolidated balance sheet as of December 31, 2022.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Segment Reporting</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We operate in a single segment, which is to provide capital return to stockholders by maximizing the potential value of our portfolio of royalties and innovative healthcare assets. Our Chief Operating Decision Maker (&#8220;CODM&#8221;) is our Chief Executive Officer. The CODM allocates resources and evaluates the performance of Innoviva at the consolidated level using information about our revenues, operating results and other key financial data as needed. Our revenues are generated primarily from our collaborative arrangements and royalty payments from GSK, located in Great Britain. We also generate revenue from net product sales of GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Refer to Note 3, &#8220;Revenue Recognition&#8221;, for more information on our revenues for the periods presented. Our long-term assets are located within the United States.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Variable Interest Entities</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The primary beneficiary of a variable interest entity (&#8220;VIE&#8221;) is required to consolidate the assets and liabilities of the VIE. When we obtain a variable interest in another entity, we assess at the inception of the relationship and upon occurrence of certain significant events whether the entity is a VIE and, if so, whether we are the primary beneficiary of the VIE based on our power to direct the activities of the VIE that most significantly impact the VIE&#8217;s economic performance and our obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To assess whether we have the power to direct the activities of a VIE that most significantly impact the VIE&#8217;s economic performance, we consider all the facts and circumstances, including our role in establishing the VIE and our ongoing rights and responsibilities. This assessment includes identifying the activities that most significantly impact the VIE&#8217;s economic performance and identifying which party, if any, has power over those activities. In general, the parties that make the most significant decisions affecting the VIE (management and representation on the Board of Directors) and have the right to unilaterally remove those decision-makers are deemed to have the power to direct the activities of a VIE.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To assess whether we have the obligation to absorb losses of the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE, we consider all of our economic interests that are deemed to be variable interests in the VIE. This assessment requires us to apply judgment in determining whether these interests, in the aggregate, are considered potentially significant to the VIE.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Business Combination</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">When we acquire an entity in a business combination, we recognize the fair value of all assets acquired, liabilities assumed, and any non-controlling interest in the acquiree and establish the acquisition date as the fair value measurement point. We recognize and measure goodwill as of the acquisition date, as the excess of the fair value of the consideration paid over the fair value of the identified net assets acquired. Acquisition-related expenses and related restructuring costs are expensed as incurred.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Several valuation methods may be used to determine the fair value of assets acquired and liabilities assumed. For intangible assets, we typically use the income method. This method starts with a forecast of all of the expected future net cash flows for each asset. These cash flows are then adjusted to present value by applying an appropriate discount rate that reflects the risk factors associated with the cash flow streams. Some of the more significant estimates and assumptions inherent in the income method or other methods include the amount and timing of projected future cash flows, the discount rate selected to measure the risks inherent in the future cash flows and the assessment of the asset&#8217;s life cycle and the competitive trends impacting the asset, including consideration of any technical, legal, regulatory, or economic barriers to entry. Determining the useful life of an intangible asset also requires judgment as different types of intangible assets will have different useful lives and certain assets may even be considered to have indefinite useful lives.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash and Cash Equivalents</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We consider all highly liquid investments purchased with a maturity of three months or less on the date of purchase to be cash equivalents. Cash equivalents are carried at cost, which approximates fair value.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Accounts Receivable</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accounts receivable are recorded net of estimates for prompt-pay discounts, chargebacks, returns and rebates. Allowances for prompt-pay discounts and chargebacks are based on contractual terms. We estimate the allowance for credit losses based on existing contractual payment terms, actual payment patterns of customers and individual customer circumstances.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Inventory</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Inventory is stated at the lower of cost or estimated net realizable value on a first-in, first-out basis. We periodically analyze inventory levels and write down inventory as cost of products sold when the following occurs: inventory has become obsolete, inventory has a cost basis in excess of its estimated net realizable value, or inventory quantities are in excess of expected product sales.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Property and Equipment</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment, which consisted of laboratory equipment, computer equipment, software, office furniture and fixtures, and leasehold improvements, were not material as of December 31, 2023 and 2022, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment are stated at cost less accumulated depreciation. Property and equipment are depreciated using the straight-line method </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">over the estimated useful lives of the respective assets as follows:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
        <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
         <tr style="visibility:collapse;">
          <td style="width:49.17%;"></td>
          <td style="width:1.66%;"></td>
          <td style="width:49.17%;"></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Leasehold improvements</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shorter of remaining lease terms or useful life</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Laboratory equipment, furniture and fixtures</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#8211; </span><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7 years</span></span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Software and computer equipment</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3 years</span></span></p></td>
         </tr>
        </table></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Equity and Long-Term Investments</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We invest from time to time in equity and debt securities of private or public companies. If we determine that we have control over these companies under either voting or VIE models, we consolidate them in our consolidated financial statements. If we determine that we do not have control over these companies under either voting or VIE models, we then determine if we have an ability to exercise significant influence via voting interests, board representation or other business relationships.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may account for the investments where we exercise significant influence using either an equity method of accounting or at fair value by electing the fair value option under Accounting Standards Codification (&#8220;ASC&#8221;) Topic 825, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Financial Instruments</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. If the fair value option is applied to an investment that would otherwise be accounted for under the equity method, we apply it to all our financial interests in the same entity (equity and debt, including guarantees) that are eligible items. All gains and losses from fair value changes, unrealized and realized, are presented as changes in fair values of equity method investments, net, and changes in fair values of equity and long-term investments, net, within the consolidated statements of income.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we conclude that we do not have an ability to exercise significant influence over an investee, we may elect to account for the security without a readily determinable fair value using the measurement alternative method under ASC 321, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Investments &#8211; Equity Securities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. This measurement alternative method allows us to measure the equity investment at its cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We also invest in ISP Fund LP, which investments consist of money market funds and equity and debt securities in the healthcare, pharmaceutical and biotechnology industries. Pursuant to the Partnership Agreement entered in December 2020, we became a limited partner of this partnership, and our contributions are subject to a 36-month lock-up period, which restriction prevents us from having control and access to the contributions and related investments. The lock-up period for a certain portion of our contributions expired in December 2023. Strategic Partners did not elect to make a withdrawal in 2023, thereby extending the lock-up period and withdrawal elections into subsequent years. These investments are classified as long-term investments in the consolidated balance sheets.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Value of Financial Instruments</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We define fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our valuation techniques are based on observable and unobservable inputs. Observable inputs reflect readily obtainable data from independent sources, while unobservable inputs reflect our market assumptions. We classify these inputs into the following hierarchy:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Level 1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8212;Quoted prices for identical instruments in active markets.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Level 2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8212;Quoted prices for similar instruments in active markets; quoted prices for identical 3or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Level 3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8212;Unobservable inputs and little, if any, market activity for the assets.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments include cash equivalents, accounts receivable, receivables from collaborative arrangements, accounts payable, and accrued liabilities, equity investments and convertible promissory notes. The carrying values of cash equivalents, receivables from collaborative arrangements, accounts payable, and accrued liabilities approximate their estimated fair values due to the relatively short-term nature of these instruments.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Capitalized Fees Paid</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We capitalize fees paid to licensors related to agreements for approved products or commercialized products. We capitalize these fees as capitalized fees paid (&#8220;Capitalized Fees&#8221;) and amortize them on a straight-line basis over their estimated useful lives upon the commercial launch of the product, shortly after its regulatory approval. The estimated useful lives of these Capitalized Fees are determined on a country-by-country and product-by-product basis, as the later of the expiration or termination of the last patent right covering the compound in such product in such country and </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">15 years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> from first commercial sale of such product in such country, unless the Collaboration Agreement is terminated earlier. Consistent with our policy for classification of costs under the research and development collaborative arrangements, the amortization of these Capitalized Fees is recognized as a reduction of royalty revenue. We review our Capitalized Fees for impairment on a product-by-product basis for each major geographic area when events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. The recoverability of Capitalized Fees is measured by comparing the asset&#8217;s carrying amount to the expected undiscounted future cash flows that the asset is expected to generate. The determination of recoverability typically requires various estimates and assumptions, including estimating the useful life over which cash flows will occur, their amount, and the asset&#8217;s residual value, if any. We derive the required cash flow estimates from near-term forecasted product sales and long-term projected sales in the corresponding market.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Goodwill and Intangible Assets</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Goodwill is recognized as the excess of the purchase consideration of an acquired entity over the fair value assigned to assets acquired and liabilities assumed in a business combination. Goodwill and intangible assets with indefinite useful life are not amortized and are tested for impairment at least annually on the first day of December of each year</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> or more frequently if indicators for potential impairment exist or whenever events or changes in circumstances indicate that the asset&#8217;s carrying asset amount may not be recoverable. Intangible assets with definite useful lives are amortized on a straight-line basis over their respective remaining useful lives and are tested for impairment only if indicators for potential impairment exist or whenever events or changes in circumstances indicate that the asset&#8217;s carrying amount may not be recoverable. Significant judgment may be involved in determining if an indicator of impairment has occurred.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Operating Leases</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Right-of-use assets represent our right to use an underlying asset over the lease term and include any lease payments made prior to the lease commencement date and are reduced by lease incentives. Lease liabilities represent the present value of the total lease payments over the lease term, calculated using an estimated incremental borrowing rate. Lease expense is recognized on a straight-line basis over the expected lease term.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue Recognition</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We apply the guidance on principal versus agent considerations under ASC Topic 606, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue from Contracts with Customers</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, to determine the appropriate treatment for the transactions between us and third parties. The classification of transactions under our arrangements is determined based on the nature and contractual terms of the arrangement along with the nature of the operations of the participants. Any consideration related to activities in which we are considered the principal, which includ</span><span style="color:#252525;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">es being in control of the good or service before such good or service is transferred to the customer, are accounted for as product sales.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Revenue is recognized when our customer obtains control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. Revenue is recognized through a five-step process: (i) identify the contract with the customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price for the contract; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue as a performance obligation is satisfied.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Royalty Revenue</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We recognize the royalty revenue on net sales of products with respect to which we have contractual royalty rights in the period in which the royalties are earned. The net sales reports provided by our partner are based on its methodology and assumptions to estimate rebates and returns, which it monitors and adjusts regularly in light of contractual and legal obligations, historical trends, past experience and projected market conditions. Our partner may make significant adjustments to its sales based on actual results recorded, which could cause our royalty revenue to fluctuate. We conduct periodic royalty audits to evaluate the information provided by our partner. Royalties are recognized net of amortization of capitalized fees associated with any approval and launch milestone payments made to GSK.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue from Product Sales</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Revenue from product sales is recognized when our customers obtain control of the product and is recorded at the transaction price, net of estimates for variable consideration consisting of chargebacks, discounts, returns and rebates. Variable consideration is estimated using the expected-value amount method, which is the sum of probability-weighted amounts in a range of possible consideration amounts. Actual amounts of consideration ultimately received may differ from our estimates. If actual results vary materially from our estimates, we will adjust these estimates, which will affect revenue from product sales and earnings in the period such estimates are adjusted. These items may include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Chargebacks: Chargebacks are discounts we provide to distributors in the event that the sales prices to end users are below the distributors&#8217; acquisition price. This may occur due to a direct contract with a health system, a group purchasing organization (&#8220;GPO&#8221;) agreement or a sale to a government facility. Chargebacks are estimated based on known chargeback rates and recorded as a reduction of revenue on delivery to our customers.</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Discounts: We offer customers various forms of incentives and consideration, including prompt-pay and other discounts. We estimate discounts primarily based on contractual terms. These discounts are recorded as a reduction of revenue on delivery to our customers.</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Returns: We offer customers a limited right of return, generally for damaged or expired product. We estimate returns based on an internal analysis, which includes actual experience. The estimates for returns are recorded as a reduction of revenue on delivery to our customers. </span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Rebates: We participate in Medicaid rebate programs, which provide assistance to certain low-income patients based on each individual state&#8217;s guidelines regarding eligibility and services. Under the Medicaid rebate programs, we pay a rebate to each participating state, generally within three months after the quarter in which product was sold. Additionally, we may offer customer incentives and consideration in the form of volume-based or other rebates. The estimates for rebates are recorded as a reduction of revenue on delivery to our customers. </span></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We continue to assess our estimates of variable consideration as we accumulate additional historical data and will adjust these estimates accordingly.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">License Revenue</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At the inception of a licensing arrangement that includes development and regulatory milestone payments, we evaluate whether the milestones are considered probable of being achieved and estimate the amount to be included in the transaction price. We generally recognize these milestone payments as revenues when they are achieved because there is considerable uncertainty in the research and development processes that trigger receipt of these payments under our agreements. Similarly, we recognize regulatory approval milestone payments as revenues once the product is approved by the applicable regulatory agency.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development Expenses</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development expenses are recognized in the period that services are rendered or goods are received. Research and development expenses consist of salaries and benefits, laboratory supplies, facilities and other overhead costs, research-related manufacturing costs, contract service and clinical-related service costs performed by third party research organizations, research institutions and other outside service providers. Non-refundable prepayments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are recognized as an expense as the related goods are delivered or the related services are performed. We also utilize significant judgment and estimates to record accruals for estimated ongoing research costs based on the progress of the studies and progress of research manufacturing activities.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Interest Expense on Deferred Royalty Obligation</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Interest expense related to the deferred royalty obligation is recognized over the expected repayment term of the deferred royalty obligation using the effective interest method. The assumptions used in determining the expected repayment term of the deferred royalty obligation require us to make estimates that could impact the effective interest rate. Each reporting period, we estimate the expected repayment term of the deferred royalty obligation based on forecasted net sales of GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Changes in interest expense resulting from changes in the effective interest rate, if any, are recorded on a prospective basis. Refer to Note 12, &#8220;Debt&#8221;, for more information.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Value of Stock&#8209;Based Compensation Awards</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We use the Black-Scholes-Merton option pricing model to estimate the fair value of options granted under our equity incentive plans and rights to acquire stock granted under our employee stock purchase plan (&#8220;ESPP&#8221;). The Black-Scholes-Merton option valuation model requires the use of assumptions, including the expected term of the award and the expected stock price volatility. We use the &#8220;simplified&#8221; method as described in Staff Accounting Bulletin No. 107, &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Share-Based Payment</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">,&#8221; for the expected option term. We use our historical volatility to estimate expected stock price volatility.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Restricted stock units (&#8220;RSUs&#8221;) and restricted stock awards (&#8220;RSAs&#8221;) are measured based on the fair market values of the underlying stock on the dates of grant.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock-based compensation expense is calculated based on awards ultimately expected to vest and is reduced for estimated forfeitures at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differed from those estimates. Our estimated annual forfeiture rates for stock options, RSUs and RSAs are based on our historical forfeiture experience.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The estimated fair value of stock options, RSUs and RSAs is expensed on a ratable or straight-line basis over the expected term of the grant or expected term of the vesting. Compensation expense is recorded over the requisite service period based on management&#8217;s best estimate as to whether it is probable that the shares awarded are expected to vest.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Compensation expense for purchases under the ESPP is recognized based on the fair value of the common stock on the date of offering, less the purchase discount percentage provided for in the plan.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We utilize the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and the tax basis of assets and liabilities and are measured using enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The recognition and measurement of tax benefits requires significant judgment. Our judgment might change as new information becomes available. We continue to evaluate our deferred tax assets each reporting period to determine whether adjustments to our valuation allowance are required and deferred tax assets will be realized based on the consideration of all available positive and negative evidence, including the differences between our anticipated and actual future operating results, using a &#8220;more likely than not&#8221; standard.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We assess all material positions taken in any income tax return, including all significant uncertain positions, in all tax years that are still subject to assessment or challenge by relevant taxing authorities. Assessing an uncertain tax position begins with the initial determination of the position&#8217;s sustainability and is measured at the largest amount of benefit that is greater than 50% likely to be realized upon ultimate settlement. As of each balance sheet date, unresolved uncertain tax positions must be reassessed, and we determine whether the factors underlying the sustainability assertion have changed and whether the amount of the recognized tax benefit is still appropriate.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Related Parties</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Transactions with GSK were considered related party transactions up until May 2021, when we completed the share repurchase agreement with GSK to buy back all of its shares of common stock in Innoviva. GSK is no longer considered a related party after the completion of the share repurchase. Transactions with GSK are described in Note 3, &#8220;Revenue Recognition and Collaborative Arrangements.&#8221;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Sarissa Capital ow</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ned </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">11.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of o</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ur outstanding common stock as of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Transactions with Sarissa Capital are described in Note 5, &#8220;Consolidated Entities and Acquisitions&#8221;. Sarissa Capital is considered to be a related party because two of its principals are members of our board of directors.</span></p></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><br/></span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recently Issued Accounting Pronouncements Not Yet Adopted</span></span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In October 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued ASU 2023-06, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Disclosure Improvements: Codification Amendments in Response to the SEC&#8217;s Disclosure Update and Simplification Initiative</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The amendment modifies the disclosure or presentation requirements for a variety of topics. The effective date for each amendment will be the date on which the SEC&#8217;s removal of that related disclosure from Regulation S-X or Regulation S-K becomes effective. The Company does not expect the adoption of the amendments to have a significant impact on its financial statements.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2023, the FASB issued ASU 2023-07, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Improvements to Reportable Segment Disclosures (Topic 280).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> This ASU update requires enhanced segment disclosures, primarily related to significant segment expenses. The amendments are effective for fiscal years beginning after December 15, 2023, and interim periods beginning after December 15, 2024. The Company does not expect the adoption of the amendments to have a significant impact on its financial statements.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2023, the FASB issued ASU 2023-09, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Improvements to Income Tax Disclosures (Topic 740)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The ASU requires the disclosure of income taxes paid disaggregated by jurisdiction and enhanced disclosures for the entity&#8217;s effective tax rate reconciliation as well as other income tax related disclosures. The ASU is effective on a prospective basis for annual periods beginning after December 15, 2024. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company does not expect the adoption of the amendments to have a significant impact on its financial statements.</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430386778416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET INCOME PER SHARE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">NET INCOME PER SHARE</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2.  NET INCOME PER SHARE</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basic net income per share attributable to Innoviva stockholders is computed by dividing net income attributable to Innoviva stockholders by the weighted-average number of shares of common stock outstanding. Diluted net income per share attributable to Innoviva stockholders is computed by dividing net income attributable to Innoviva stockholders by the weighted-average number of shares of common stock and dilutive potential common stock equivalents then outstanding. Dilutive potential common stock equivalents include the assumed exercise, vesting and issuance of employee stock awards using the treasury stock method, as well as common stock issuable upon assumed conversion of our convertible subordinated notes due 2023 (the &#8220;2023 Notes&#8221;) up until its maturity date on January 15, 2023, our convertible senior notes due 2025 (the &#8220;2025 Notes&#8221;), and our convertible senior notes due 2028 (the &#8220;2028 Notes&#8221;) using the if-converted method.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The 2025 Notes are convertible, based on the applicable conversion rate, into cash, shares of our common stock or a combination thereof, at our election. Our current intent is to settle the principal amount of th</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">e 2025 Notes in cash upon conversion. The impact of the assumed conversion premium to diluted net income per share was historically computed using the treasury stock method until the adoption of ASU 2020-06. As the average market price per share of our common stock as reported on The Nasdaq Global Select Market was lower than the initial conversion price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">17.26</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, there was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> dilutive effect of the assumed conversion premium for the year ended December 31, 2021.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table shows the computation of basic and diluted net income per share for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023, 2022 and 2021:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:51.311%;"></td>
        <td style="width:1.481%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.75%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.481%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.75%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.481%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.75%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands except per share data)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Numerator:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net income attributable to Innoviva stockholders, basic</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">179,722</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">213,921</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">265,854</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Add: interest expense on 2023 Notes, net of tax effect</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">89</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,439</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,736</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Add: interest expense on 2025 Notes, net of tax effect</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,116</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,583</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Add: interest expense on 2028 Notes, net of tax effect</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,377</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,626</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net income attributable to Innoviva stockholders, diluted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">191,304</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">225,569</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">270,590</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Denominator:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average shares used to compute basic net income<br/>&#160;&#160;&#160;per share attributable to Innoviva stockholders</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">65,435</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">69,644</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">82,062</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Dilutive effect of 2023 Notes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">187</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,188</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,189</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Dilutive effect of 2025 Notes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,150</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,150</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Dilutive effect of 2028 Notes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,955</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,158</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Dilutive effect of options and awards granted under equity<br/>&#160;&#160;&#160;incentive plan and employee stock purchase plan</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">149</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">108</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">59</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average shares used to compute diluted net income<br/>&#160;&#160;&#160;per share attributable to Innoviva stockholders</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">86,876</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">95,248</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">94,310</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net income per share attributable to Innoviva stockholders</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Basic</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.75</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.07</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.24</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Diluted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.20</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.37</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.87</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Anti&#8209;dilutive Securities</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following common stock equivalents were not included in the computation of diluted net income per share because their effect was anti&#8209;dilutive for the periods presented:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:51%;"></td>
        <td style="width:1.8%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.2%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.2%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.799999999999999%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding options and awards granted under equity incentive<br/>&#160;&#160;&#160;plan and employee stock purchase plan</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,333</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">648</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">979</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding stock warrant</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">591</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">282</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,924</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">930</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">979</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430393262560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE RECOGNITION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">REVENUE RECOGNITION</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3.  REVENUE RECOGNITION</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Net Revenue from Collaboration Arrangement</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On July 13, 2022, Innoviva&#8217;s wholly owned subsidiary, Innoviva TRC Holdings, LLC (&#8220;ITH&#8221;) entered into an equity purchase agreement (&#8220;TRC Equity Purchase Agreement&#8221;) with Royalty Pharma Investments 2019 ICAV (&#8220;Royalty Pharma&#8221;) to sell our ownership interest in TRC. As a result of the sale of our ownership interest in TRC, which was consummated on July 20, 2022, we are no longer entitled to receive </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">15</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of royalty payments made by GSK stemming from sales of TRELEGY</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. We retained our royalty rights with respect to RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net revenue recognized under our GSK Agreements was as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:51.311%;"></td>
        <td style="width:1.481%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.75%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.481%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.75%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.481%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.75%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Royalties &#8211; RELVAR/BREO</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">208,042</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">215,034</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">234,066</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Royalties &#8211; ANORO</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">44,627</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">38,405</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">44,935</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Royalties &#8211; TRELEGY</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(1)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">72,029</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">126,688</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total royalties</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">252,669</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">325,468</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">405,689</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: amortization of capitalized<br/>&#160;&#160;&#160;fees paid</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,823</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,823</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,823</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total royalty revenue</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">238,846</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">311,645</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">391,866</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">(1)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">   The year ended December 31, 2022 represents the period from January 1, 2022 to July 20, 2022, the date of the sale of our ownership interest in TRC.</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">LABA Collaboration</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a result of the launch and approval of RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in the U.S., Japan and Europe, we paid milestone fees to GSK totaling $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">220.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million during the year ended December 31, 2014. The milestone fees paid to GSK were recognized as capitalized fees paid, which are being amortized over their estimated useful lives commencing upon the commercial launch of the product. The amortization is recorded as a reduction to the royalties from GSK.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are entitled to receive annual royalties from GSK on sales of RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> as follows: </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">15</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% on the first $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> billion of annual global net sales and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% for all annual global net sales above $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> billion. Sales of single&#8209;agent LABA medicines and combination medicines would be combined for the purposes of this royalty calculation. For other products combined with a LABA from the LABA Collaboration, such as ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, royalties are upward tiering and range from </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">6.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are also entitled to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">15</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of royalty payments made by GSK under its agreements originally entered into with us, and since assigned to TRC in connection with the Spin-Off, including TRELEGY</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> through July 20, 2022, which royalties were upward tiering and ranged from </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">6.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Net Product Sales</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net product sales were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">60.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, consisting of net sales of GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">41.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">17.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively. We derived approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">91</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of our net product sales for the same period from customers located in the U.S. and the rest of the world, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From the date of acquisition of La Jolla to December 31, 2022, net product sales were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">19.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, consisting of net sales of GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">14.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively. We derived approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">96</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of our net product sales for the same period from customers located in the U.S. and the rest of the world, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">License Revenue</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Refer to the out-license agreement with Zai Lab and Everest in Note 4, &#8220;License and Collaboration Arrangements&#8221;.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-15<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430386532912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LICENSE AND COLLABORATION ARRANGEMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_LicenseAndCollaborationArrangementsDisclosureTextBlock', window );">LICENSE AND COLLABORATION ARRANGEMENTS</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4. LICENSE AND COLLABORATION ARRANGEMENTS</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Out-License Agreements</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Zai Lab</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Entasis entered into a license and collaboration agreement with Zai Lab (Shanghai) Co., Ltd. (&#8220;Zai Lab&#8221;) (Nasdaq: ZLAB), pursuant to which Zai Lab licensed exclusive rights to durlobactam and SUL-DUR, in the Asia-Pacific region (&#8220;the Zai Agreement&#8221;). Under the terms of the Zai Agreement, Zai Lab will fund most of the registrational clinical trial costs in China for SUL-DUR, with the exception of Phase 3 patient drug supply of licensed products. Zai Lab will conduct development activities and plan and obtain regulatory approval in a specified number of countries in the Asia-Pacific region beyond China after receipt of regulatory approval of a licensed product in China. Zai Lab is also solely responsible for commercializing licensed products in the Asia-Pacific region and will commercialize licensed products for which it has obtained regulatory approval. We are obligated to supply Zai Lab with the licensed products for clinical development and, if the licensed product is approved, for commercial use for a certain period unless Zai Lab notifies otherwise. Zai Lab may take over manufacturing responsibilities for its own commercialization activities within a specified time period following the effective date of the Zai Agreement.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We ar</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">e eligible to receive up to an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">91.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in research and development support payments and development, regulatory and sales milestone payments related to SUL-DUR, imipenem and other combinations with the licensed products. Zai Lab will pay us a tiered royalty equal to from a high-single digit to low-double digit percentage based on annual net sales of licensed products in the territory, subject to specified reductions for the market entry of competing products, loss of patent coverage of licensed products and for payments owed to third parties for additional rights necessary to commercialize licensed products in the territory.  Payments received for research support and reimbursable clinical trial costs are recorded as a reduction to research and development expense during the period in which the qualifying expenses are incurred. Such amounts recorded </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">for the year ended December 31, 2023 and from the date of acquisition of Entasis to December 31, 2022 are not material. Following the approval of XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> by the FDA in May 2023, we recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in license revenue for the year ended December 31, 2023.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">GARDP</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Entasis entered into a collaboration agreement with the Global Antibiotic Research and Development Partnership (&#8220;GARDP&#8221;) for the development, manufacture and commercialization of the product candidate zoliflodacin in certain countries (&#8220;the GARDP Collaboration Agreement&#8221;). Under the terms of the GARDP Collaboration Agreement, GARDP will use commercially reasonable endeavors to perform and fully fund the Phase 3 registrational trial, including the manufacture and supply of the product candidate containing zoliflodacin, in uncomplicated gonorrhea. We recorded reimbursements from GARDP under this agreement as reduction to research and development expense. Relevant amounts for the year ended December 31, 2023 and from the date of acquisition of Entasis to December 31, 2022 are not material.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, under the GARDP Collaboration Agreement, GARDP was granted a worldwide, fully paid, exclusive and royalty-free license, with the right to sublicense, to use our zoliflodacin technology in connection with GARDP&#8217;s development, manufacture and commercialization of zoliflodacin in low-income and specified middle-income countries. We retained commercial rights in all other countries worldwide, including the major markets in North America, Europe and Asia-Pacific. We also retained the right to use and grant licenses to our zoliflodacin technology to perform our obligations under the GARDP Collaboration Agreement and for any purpose other than gonorrhea or community-acquired indications. If we believe that the results of the Phase 3 registrational trial of zoliflodacin would be supportive of an application for marketing approval, we are obligated to use our best efforts to file an application for marketing approval with the FDA within six months of the completion of the trial and to use commercially reasonable endeavors to file an application for marketing approval with the European Medicines Agency (&#8220;EMA&#8221;). Each party is responsible for using commercially reasonable efforts to obtain marketing authorizations for the product candidate in their respective territories.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">PAION AG</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the PAION AG and PAION Deutschland GmbH (together and individually &#8220;PAION&#8221;) License, La Jolla granted PAION an exclusive license to commercialize GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in the European Economic Area, the United Kingdom and Switzerland (collectively, the &#8220;PAION Territory&#8221;). We are entitled to receive potential commercial milestone payments of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">109.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and double-digit tiered royalty payments. Royalties payable in a given jurisdiction under the PAION License will be subject to reduction on account of generic competition and after patent expiration in that jurisdiction. Pursuant to the PAION License, PAION will be solely responsible for the future development and commercialization of GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in the PAION Territory. PAION is required to use commercially reasonable efforts to commercialize GIAPREZA&#174; and XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in the PAION Territory. We have not recognized any revenue from PAION related to commercial milestones from the date of acquisition of La Jolla to December 31, 2023. Royalty revenue recognized under this agreement for the year ended December 31, 2023 and from the date of acquisition of La Jolla to December 31, 2022 are not material.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">La Jolla also entered into the PAION commercial supply agreement (the &#8220;PAION Supply Agreement&#8221;) whereby La Jolla will supply PAION a minimum quantity of GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> through July 13, 2024. The PAION supply agreement will automatically renew until the earlier of July 13, 2027, or until a new supply agreement is executed. During the initial term of the supply agreement, we will be reimbursed for direct and certain indirect manufacturing costs at cost. We recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in cost reimbursements under this agreement for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023. Amounts recognized under this agreement from the date of acquisition of La Jolla to December 31, 2022 were not material.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PAION AG and PAION Deutschland GmbH filed for insolvency in Germany on October 27, 2023 and the insolvency proceedings were opened on January 1, 2024. PAION announced on December 22, 2023 that it concluded negotiations with Humanwell Healthcare Group and entered into an agreement on the sale of the essential business operations of PAION AG and PAION Deutschland GmbH with the approval of the insolvency administrator in both procedures. La Jolla did not oppose the sale and is in discussions with the acquirer regarding the continued business relationship.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Everest Medicines Limited</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the Everest Medicines Limited (&#8220;Everest&#8221;) License, La Jolla granted Everest an exclusive license to develop and commercialize XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for the treatment of complicated intra-abdominal infections (&#8220;cIAI&#8221;) and other indications in mainland China, Taiwan, Hong Kong, Macau, South Korea, Singapore, the Malaysian Federation, the Kingdom of Thailand, the Republic of Indonesia, the Socialist Republic of Vietnam and the Republic of the Philippines (collectively, the &#8220;Everest Territory&#8221;). </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the Everest License, we recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">8.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in license revenue for the year ended December 31, 2023 as a result of an achievement of a regulatory milestone during the period. We are eligible to receive additional sales milestone payments of up to an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">20.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are also entitled to receive tiered royalties from Everest at percentages in the low double digits on sales, if any, in the Everest Territory of products containing eravacycline. Royalties are payable with respect to each jurisdiction in the Everest Territory until the latest to occur of: (i) the last-to-expire of specified patent rights in such jurisdiction in the Everest Territory; (ii) expiration of marketing or regulatory exclusivity in such jurisdiction in the Everest Territory; or (iii) </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years after the first commercial sale of a product in such jurisdiction in the Everest Territory. Royalty revenue recognized under this agreement for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. Royalty revenue recognized </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">from the date of acquisition of La Jolla to December 31, 2022 is not material.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">La Jolla also entered into the Everest commercial supply agreement (the &#8220;Everest Supply Agreement&#8221;) whereby La Jolla will supply Everest a minimum quantity of XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> through December 31, 2023 and will transfer to Everest certain XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">-related manufacturing know-how. We were eligible to be reimbursed for direct and certain indirect manufacturing costs at </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">110</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of cost through December 31, 2023. We recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in revenue under this agreement for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and from the acquisition of La Jolla to December 31, 2022, respectively.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">In-License Agreements</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">George Washington University</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the George Washington University (&#8220;GW&#8221;) License, GW exclusively licensed to La Jolla certain intellectual property rights relating to GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, including the exclusive rights to certain issued patents and patent applications covering GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Under the GW License, we are obligated to use commercially reasonable efforts to develop, commercialize, market and sell GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. We are obligated to pay a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% royalty on net sales of GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">15</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% on payments received from sublicensees. The obligation to pay royalties under this agreement extends through the last-to-expire patent covering GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the year ended December 31, 2023 under this agreement. Amounts recognized f</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">rom the date of acquisition of La Jolla to December 31, 2022 were not material.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Harvard University</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the Harvard University (&#8220;Harvard&#8221;) License, Harvard exclusively licensed to La Jolla certain intellectual property rights relating to tetracycline-based products, including XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, including the exclusive rights to certain issued patents and patent applications covering such products. Under the Harvard License, we are obligated to use commercially reasonable efforts to develop, commercialize, market and sell tetracycline-based products, including XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. For each product covered by the Harvard License, we are obligated to make certain payments for the following: (i) up to approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">15.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million upon the achievement of certain clinical development and regulatory milestones; (ii) a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% royalty on direct U.S. net sales of XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">; (iii) a single-digit tiered royalty on direct ex-U.S. net sales of XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, starting at a minimum royalty rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%, with step-ups to a maximum royalty of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">7.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% based on the achievement of annual net product sales thresholds; and (iv) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">20</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% on payments received from sublicensees. The obligation to pay royalties under this agreement extends through the last-to-expire patent covering tetracycline-based products, including XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> For the year ended December 31, 2023, we recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as cost of license revenue under this agreement as a result of the license revenue we earned under the out-licensing agreement with Everest for the same period. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From the date of acquisition of La Jolla to December 31, 2022, amounts recognized under this agreement were not material.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Paratek Pharmaceuticals, Inc.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the Paratek Pharmaceuticals, Inc. (&#8220;Paratek&#8221;) License, Paratek non-exclusively licensed to La Jolla certain intellectual property rights relating to XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, including non-exclusive rights to certain issued patents and patent applications covering XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. We are obligated to pay Paratek a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.25</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% royalty based on direct U.S. net sales of XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Our obligation to pay royalties with respect to the licensed product is retroactive to the date of the first commercial sale of XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and shall continue until there are no longer any valid claims of the Paratek patents, which expired in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">October 2023</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. For the year ended December 31, 2023 and from the date of acquisition of La Jolla to December 31, 2022, amounts recognized under this agreement were not material.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Business Transfer and Subscription Agreement with AstraZeneca</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Entasis entered into a Business Transfer and Subscription Agreement with AstraZeneca, AstraZeneca UK Limited and AstraZeneca Pharmaceuticals LP (collectively, &#8220;AstraZeneca&#8221;) (the &#8220;AstraZeneca Agreement&#8221;) in 2015, which was amended and restated through 2018, pursuant to which Entasis obtained, among other things, worldwide rights to durlobactam and zoliflodacin. Under the AstraZeneca Agreement, we are obligated to pay AstraZeneca a one-time milestone payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million within </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three months</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of achieving a specified cumulative net sales milestone for durlobactam. We are also obligated to pay AstraZeneca a one-time milestone payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million within </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">two years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of achieving the first commercial sale of zoliflodacin. Additionally, we are obligated to pay AstraZeneca tiered, single-digit royalties on the annual worldwide net sales of durlobactam and, the lesser of tiered, single-digit royalties on the worldwide annual net sales of zoliflodacin and a specified share of the royalties we receive from sublicensees of zoliflodacin. Royalties on sales of zoliflodacin do not include sales by GARDP in low-income and specified middle-income countries as discussed above. Our obligation to make these royalty payments expires with respect to each product on a country-by-country basis upon the later of (i) the 10-year anniversary of the first commercial sale of a product in each such country or (ii) when the last patent right covering a product expires in each such country.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Royalty expense on durlobactam arising from our net sales of XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for the year ended December 31, 2023 was immaterial.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_LicenseAndCollaborationArrangementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License and collaboration arrangements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_LicenseAndCollaborationArrangementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430386651344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED ENTITIES AND ACQUISITIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ConsolidatedEntitiesDisclosureAbstract', window );"><strong>Consolidated Entities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ConsolidatedEntitiesAndAcquisitionsTextBlock', window );">CONSOLIDATED ENTITIES AND ACQUISITIONS</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5. CONSOLIDATED ENTITIES AND ACQUISITIONS</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Consolidated Entities</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Theravance Respiratory Company, LLC</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Up until July 20, 2022, we consolidated TRC under the VIE model as we determined that TRC was a VIE and we were the primary beneficiary of the entity because we had the power to direct the economically significant activities of TRC and the obligation to absorb losses of, or the right to receive benefits from, TRC. We held </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">15</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% ownership interest of TRC. The primary source of revenue for TRC is the royalties generated from the net sales of TRELEGY</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> by GSK.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As discussed in Note 3, &#8220;Revenue Recognition&#8221;, on July 13, 2022, ITH entered into the TRC Equity Purchase Agreement to sell our ownership interest in TRC. Upon the closing of the transaction on July 20, 2022, we received $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">277.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in cash from Royalty Pharma. We are also entitled to receive up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">50.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in contingent sales-based milestone payments in the future. In connection with the closing of the transaction, we also received our portion of TRC&#8217;s remaining cash balance of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million from Royalty Pharma rather than through a cash distribution from TRC.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prior to the closing of the transaction and as part of the agreement, TRC distributed its ownership interests and investments in InCarda Therapeutics (&#8220;InCarda&#8221;), Inc., ImaginAb, Inc. (&#8220;ImaginAb&#8221;), Gate Neurosciences (&#8220;Gate&#8221;), Inc. and Nanolive SA (&#8220;Nanolive&#8221;), which had a total carrying value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">39.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, to ITH. We accounted for the transaction similar to an upstream sale between a parent and a VIE under ASC 810-10. As such, ITH recorded the transferred investments at their respective carrying values and no gain or loss was recognized in the consolidated statement of income.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The summarized financial information of TRC </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">for the relevant periods through the sale date in 2022 are presented as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Income statements</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:61.232%;"></td>
        <td style="width:1.78%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.603%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.78%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.603%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;min-width:fit-content;">&#160;(1)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Royalty revenue</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">72,029</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">126,688</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">332</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,956</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Income from operations</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">71,697</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">122,732</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other income, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Realized loss</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">39,386</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Income tax expense, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Changes in fair values of equity and<br/>&#160;&#160;&#160;long-term investments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,884</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,541</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net income</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23,438</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">121,191</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">(1)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">   The year ended December 31, 2022 represents the period from January 1, 2022 to July 20, 2022, the date of the sale of our ownership interest in TRC.</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ISP Fund LP</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2020, Innoviva Strategic Partners LLC, our wholly owned subsidiary (&#8220;Strategic Partners&#8221;), contributed $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">300.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million to ISP Fund LP (the &#8220;Partnership&#8221;) for investing in &#8220;long&#8221; positions in the healthcare, pharmaceutical and biotechnology sectors and became a limited partner. The general partner of the Partnership (&#8220;General Partner&#8221;) is an affiliate of Sarissa Capital.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Partnership Agreement provides for Sarissa Capital to receive management fees from the Partnership, payable quarterly in advance, measured based on the Net Asset Value of Strategic Partners&#8217; capital account in the Partnership. In addition, General Partner is entitled to an annual performance fee based on the Net Profits of the Partnership during the annual measurement period.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Partnership Agreement includes a lock-up period of thirty-six months after which Strategic Partners is entitled to make withdrawals from the Partnership as of such lock-up expiration date and each anniversary thereafter, subject to certain limitations. The lock-up period for the initial contribution of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">190.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">which excludes the amount discussed below, expired in December 2023. Strategic Partners did not elect to make a withdrawal in 2023, thereby extending the lock-up period and withdrawal elections into subsequent years.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In May 2021, Strategic Partners received a distribution of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">110.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million from the Partnership to provide funding to Innoviva for a strategic repurchase of shares held by GSK. On March 30, 2022, Strategic Partners made an additional capital contribution of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">110.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million to the Partnership pursuant to the letter agreement entered into between Strategic Partners, the Partnership and Sarissa Capital Fund GP LP on May 20, 2021. The capital contribution is subject to a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">36-month</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> lock up period from the contribution date.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We consolidate ISP Fund LP under the VIE model as we have determined that ISP Fund LP is a VIE and we are the primary beneficiary of the entity via our related party relationships with Sarissa Capital entities. Our maximum exposure to loss is equal to the amount we invested in the entity.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ISP Fund LP is determined to be an investment company under ASC 946, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Financial Services &#8211; Investment Companies</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, as it meets all fundamental characteristics of an investment company, and its activities are consistent with those of an investment company. Since ISP Fund LP is subject to investment company industry specific guidance, we have retained the industry-specific guidance applied by the Partnership. In addition, as our investment in the Partnership is a passive investment for the Company and is not part of our main operations, the investments are presented as part of &#8220;Equity and long-term investments&#8221; in our consolidated balance sheets. We report in our consolidated statements of income any investment gains and losses by the Partnership as part of &#8220;Changes in fair value of equity and long-term investments, net&#8221;, any interest and dividend income as part of &#8220;Interest and dividend income&#8221; and any investment expenses as part of &#8220;Other expense, net&#8221;.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, we continued to hold </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">100</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the economic interest of Partnership. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023 and 2022, total assets of the Partnership were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">311.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">320.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively, of which the majority was attributable to equity and long-term investments. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023 and 2022, total liabilities of the Partnership w</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ere $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> mill</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ion and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively. The Partnership</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8217;s assets can only be used to settle its own obligations. During the year ended December 31, 2023, the Partnership incurred</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">million in net investment-related expenses, generated $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">6.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million interest income, recorded $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in net realized losses and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">6.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in net unrealized losses as changes in fair values of equity and long-term investments, net, in the consolidated statement of income. During the year ended December 31, 2022, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the Partnership incurred $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in net investment-related expenses, generated $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million interest income, recorded $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">6.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in net realized gains and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">9.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in net unrealized losses as changes in fair values of equity and long-term investments, net, in the consolidated statement of income. During the year ended December 31, 2021, the Partnership incurred $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in net investment-related expense, generated $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million interest and dividend income, and recorded net $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million realized gains and net $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million unrealized losses as changes in fair values of equity and long-term investments, net, in the consolidated statement of income. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We account for the long-term investments held by ISP Fund LP as of December 31, 2023 and 2022 as equity investments measured at fair value and the investment in convertible notes as of December 31, 2022 as trading security.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Acquisitions</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Entasis Therapeutics Holdings Inc.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We started investing in Entasis in 2020 as part of our capital allocation strategy of deploying cash generated from royalty income and investing in different life sciences companies. Entasis at the time was an advanced, late clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products. Effective in June 2020, after certain conditions were met with respect to the sales of Entasis equity shares, Innoviva had the right to designate </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">two</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> members to Entasis&#8217; board. Our investment in Entasis consisted of shares of common stock and warrants to purchase shares of Entasis common stock.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair value of Entasis&#8217; common stock was measured based on its closing market price at each balance sheet date. We used the Black-Scholes-Merton pricing model to estimate the fair value of the warrants.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On February 17, 2022, Innoviva Strategic Opportunities, LLC (&#8220;ISO&#8221;)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> entered into a securities purchase agreement with Entasis pursuant to which ISO purchased a convertible promissory note for a total purchase price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">15.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The note bore an annual interest rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.59</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% and was due to mature and become payable on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">August 18, 2022</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> unless it was converted at a conversion price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.48</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> before the maturity date. With this financing, we determined that we had both (i) the power to direct the economically significant activities of Entasis and (ii) the obligation to absorb the losses, or the right to receive the benefits, that could potentially be significant to Entasis and therefore, we were the primary beneficiary of Entasis. Accordingly, we consolidated Entasis&#8217; financial position and results of operations effective on February 17, 2022. Our equity ownership interest remained at </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">59.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% as of February 17, 2022, and the fair values of our holdings of Entasis common stock and warrants were remeasured and estimated at $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">64.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">31.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The remeasurement resulted in a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">7.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million loss in the first quarter of 2022 which was included in changes in fair values of equity method investments, net, in the consolidated statement of income for the year ended December 31, 2022.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We completed our acquisition of Entasis&#8217; minority interest on July 11, 2022. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> payments were made toward the convertible promissory note through the date of acquisition of Entasis. In connection with the acquisition, all of the Entasis warrants were replaced with Innoviva warrants (the &#8220;Replacement Warrants&#8221;) of equivalent value and bearing the same terms. The Replacement Warrants are classified as equity.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We recognized the difference between the acquisition price and the carrying value of the acquired minority interest on July 11, 2022 in our additional paid-in capital.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair values assigned to assets acquired and liabilities assumed as of February 17, 2022 were based on management&#8217;s best estimates and assumptions. After the acquisition in July 2022, we adjusted the purchase price allocation based on new and additional information related to product sales forecast provided by Entasis and deferred tax liabilities.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the year ended December 31, 2022, we recorded measurement period adjustments of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million decrease in goodwill, primarily related to a decrease in estimated purchase price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, an increase in noncontrolling interests of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, and an increase in intangible assets of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The cumulative impact of the measurement period adjustments included in the consolidated net income for the year ended December 31, 2022 was not material.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In February 2023, we recorded a measurement period adjustment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million increase in goodwill, primarily related to a decrease in intangible assets of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and an increase in deferred tax liabilities of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The measurement period adjustment did not impact the consolidated net income for the year ended December 31, 2023.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table represents the adjusted fair values of the assets acquired and liabilities assumed by us in the transaction:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:80.444%;"></td>
        <td style="width:1.8%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.757%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">February 17, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23,070</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,554</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other current assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,959</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Property and equipment, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">185</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Right-of-use assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">959</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Goodwill</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,493</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Intangible assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">106,700</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">302</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets acquired</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">150,222</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts payable</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,583</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued personnel-related expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,058</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other accrued liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,096</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,769</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total liabilities assumed</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,506</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets acquired, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">134,716</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The goodwill arising from the acquisition of Entasis is primarily attributable to Entasis&#8217; assembled workforce and the value associated with growing our business more efficiently. The goodwill from this acquisition is not expected to be deductible for tax purposes.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Refer to Note 8, &#8220;Goodwill and Intangible Assets&#8221;, for more discussion on the intangible assets recognized as part of this acquisition.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a result of the consolidation, we recognized a non-controlling interest of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">38.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as of February 17, 2022. Our consolidated net income for the year ended December 31, 2022 included the net loss attributable to noncontrolling interest since the consolidation date until the date of acquisition of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">13.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">La Jolla Pharmaceutical Company</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On August 22, 2022, ISO acquired La Jolla for a total consideration of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">206.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. ISO acquired La Jolla at a price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">6.23</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share. La Jolla is dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases. La Jolla brought to Innoviva an established product portfolio, including GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock and XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (eravacycline) for the treatment of complicated intra-abdominal infections (cIAIs). We incurred approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in acquisition-related costs in connection with this acquisition during the year ended December 31, 2022.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair values assigned to assets acquired and liabilities assumed as of August 22, 2022 were based on management&#8217;s best estimates and assumptions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the year ended December 31, 2022, we recorded measurement period adjustments of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million increase in goodwill, primarily related to a decrease in inventory and intangible assets of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">7.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively, and an increase in deferred tax liabilities of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, partially offset by a decrease in other long-term liabilities of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">8.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The cumulative impact of the measurement period adjustments included in the consolidated net income for the year ended December 31, 2022 was not material.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2023, we recorded a measurement period adjustment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">13.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million decrease in goodwill, primarily related to an increase in deferred tax assets of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and a decrease in deferred tax liabilities of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. In August 2023, we recorded a measurement period adjustment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million increase in goodwill, primarily related to a decrease in deferred tax assets of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and an increase in deferred tax liabilities of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The cumulative impact of the measurement period adjustments included did not impact the consolidated net income for the year ended December 31, 2023.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table represents the adjusted fair values of assets acquired and liabilities assumed by us in the transaction:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:80.444%;"></td>
        <td style="width:1.8%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.757%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">August 22, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">47,415</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Short-term marketable securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">471</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts receivable</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,876</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inventory</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">66,200</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,261</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other current assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">907</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Property and equipment, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Right-of-use assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">226</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Goodwill</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,411</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Intangible assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">151,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,461</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">710</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets acquired</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">287,951</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts payable</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,237</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred revenue</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,849</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other accrued liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,362</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other long-term liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">65,944</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total liabilities assumed</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">81,392</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets acquired, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">206,559</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The goodwill arising from the acquisition of La Jolla is primarily attributable to La Jolla&#8217;s assembled workforce and the value associated with leveraging the workforce to develop and commercialize new drug products in the future and growing our business more efficiently. The goodwill from this acquisition is not expected to be deductible for tax purposes.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Refer to Note 8, &#8220;Goodwill and Intangible Assets&#8221;, for more discussion on the intangible assets recognized as part of this acquisition.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Pro Forma Financial Information</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table presents certain unaudited pro-forma financial information for the years ended December 31, 2022 and 2021 as if the consolidation of Entasis and La Jolla occurred on January 1, 2021. The unaudited pro forma financial information is presented for informational purposes only, and is not indicative of the results of operations that would have been achieved if the acquisitions had taken place on January 1, 2021, or of results that may occur in the future. The unaudited pro forma financial information combines the historical results of the Entasis and La Jolla with the Company&#8217;s consolidated historical results and includes certain adjustments including, but not limited to, fair value adjustments to equity investments in Entasis&#8217; common stock and warrants, fair value adjustments to inventory, amortization of intangible assets, and interest expense on deferred royalty obligations and acquisition-related costs.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:53.88%;"></td>
        <td style="width:2.26%;"></td>
        <td style="width:1%;"></td>
        <td style="width:18.799999999999997%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.26%;"></td>
        <td style="width:1%;"></td>
        <td style="width:18.799999999999997%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Revenue</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">357,880</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">435,398</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net income</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">204,987</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">281,719</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net income attributable to Innoviva stockholders</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">214,390</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">197,535</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_ConsolidatedEntitiesAndAcquisitionsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Consolidated entities and acquisitions text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_ConsolidatedEntitiesAndAcquisitionsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_ConsolidatedEntitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_ConsolidatedEntitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430386532912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsDisclosureTextBlock', window );">EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6. EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Equity and Other Investments in Armata</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the first quarter of 2020, Innoviva acquired </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">8,710,800</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock as well as warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">8,710,800</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> additional shares of common stock of Armata Pharmaceuticals, Inc. (&#8220;Armata&#8221;) for approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">25.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in cash. Armata is a clinical stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the first quarter of 2021, ISO entered into a securities purchase agreement with Armata to acquire </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">6,153,847</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Armata common stock and warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">6,153,847</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> additional shares of Armata common stock for approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">20.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. Armata also entered into a voting agreement with the Company and ISO, pursuant to which the Company and ISO agreed not to vote or take any action by written consent with respect to any common shares held by the Company and ISO that represent, in the aggregate, more than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">49.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the total number of shares of Armata&#8217;s common stock for voting on the matters related to election or removal of Armata&#8217;s board members. The voting agreement will expire the earlier of the second anniversary of the agreement effective date and approval by the FDA of any of Armata&#8217;s product candidates for marketing and commercial distribution. During the fourth quarter of 2021, ISO also purchased an additional </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,212,122</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Armata common stock for approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On February 9, 2022, ISO entered into a securities purchase agreement with Armata to acquire </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">9,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Armata common stock and warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4,500,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> additional shares of common stock with an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.00</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share for $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">45.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The investment closed in </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">two</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> tranches on February 9, 2022 and March 31, 2022. The investment is intended to aid Armata in advancing its clinical pipeline and strengthening its bacteriophage platform. On February 9, 2022, Armata also entered a second amended and restated voting agreement with the Company and ISO, pursuant to which the Company and ISO agreed not to vote or take any action by written consent with respect to any common shares held by the Company and ISO that represent, in the aggregate, more than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">49.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the total number of shares of Armata&#8217;s common stock for voting on the matters related to election or removal of Armata&#8217;s board members or amend the bylaws of Armata to reduce the maximum number of directors or set the number of directors who may serve on the board of Armata. The voting agreement will expire the earlier of the second anniversary of the agreement effective date and approval by the FDA of any of Armata&#8217;s product candidates for marketing and commercial distribution. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, as of February 9, 2022, Armata entered into an amended and restated investor rights agreement with the Company and ISO, pursuant to which for as long as the Company and ISO hold at least </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">12.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the outstanding shares of Armata&#8217;s common stock on a fully-diluted, the Company and ISO shall have the right to designate two directors to Armata&#8217;s board of directors, and for so long as the Company and ISO hold at least </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%, but less than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">12.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%, of the outstanding shares of Armata&#8217;s common stock on a fully-diluted basis, the Company and ISO shall have the right to designate one director to Armata&#8217;s board of directors, subject to certain conditions and qualifications set forth in the amended and restated investor rights agreement.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> On July 10, 2023, Armata entered into an amendment to the amended and restated investor rights agreement with the Company and ISO, pursuant to which the Company and ISO agreed that the voting agreement will expire on the earlier of the fifth anniversary of the original agreement's effective date, January 26, 2021, or the approval by the FDA of any of Armata&#8217;s product candidates for marketing and commercial distribution. A</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">s of December 31, 2023,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">three</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of the eight </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">members of Armata&#8217;s board of directors are also members of the board of directors of Innoviva. As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and 2022, we owned approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">69.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of Armata&#8217;s common stock.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On January 10, 2023, we entered into a Secured Convertible Credit Agreement (the &#8220;Credit Agreement&#8221;) with Armata, under which we invested in a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">one-year</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> convertible note (the &#8220;Armata Convertible Note&#8221;) in an aggregate amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">30.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million at an interest rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">8.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% per annum.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Pursuant to the Credit Agreement, the balance on the Armata Convertible Note, including all accrued and unpaid interest thereon, will convert into shares of Armata's common stock upon the occurrence of a qualified financing, as defined in the Credit Agreement. Any portion of the balance on the Armata Convertible Note, including all accrued and unpaid interest thereon, may also be converted into shares of Armata's common stock at our option once a registration statement covering the resale of such securities has been declared effective by the SEC. The Armata Convertible Note is secured by substantially all of the assets of Armata and its domestic and foreign material subsidiaries. On July 10, 2023, ISO and Armata executed an amendment to the Armata Convertible Note extending the maturity date from January 10, 2024 to January 10, 2025.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On July 10, 2023, ISO and Armata entered into a Credit and Security Agreement (the &#8220;Credit and Security Agreement"), under which we extended a term loan to Armata (the &#8220;Armata Term Loan&#8221;) in an aggregate amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">25.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The Armata Term Loan is subject to an interest rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">14</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% per annum and is due to mature on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">January 10, 2025</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Credit and Security Agreement is secured by substantially all of the assets of Armata and its domestic and foreign material subsidiaries.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The investments in Armata's common stock and warrants provide Innoviva and ISO the ability to have significant influence, but not control over Armata&#8217;s operations. Armata&#8217;s business and affairs are managed under the direction of its board of directors, which Innoviva and ISO do not control. Based on our evaluation, we determined that Armata is a VIE, but Innoviva and ISO are not the primary beneficiaries of the VIE. We have not provided financial or other support that we were not previously contractually required to provide during the periods presented. Our maximum exposure to loss is equal to the amount we invested in the entity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We account for Armata&#8217;s common stock and warrants under the equity method using the fair value option. The fair value of Armata&#8217;s common stock is measured based on its closing market price. The warrants purchased in 2020, 2021 and 2022 have an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.87</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.25</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.00</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, respectively. All warrants are exercisable immediately within </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">five years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> from the issuance date of the warrants and include a cashless exercise option. We use the Black-Scholes-Merton pricing model to estimate the fair value of these warrants with the following input assumptions: Armata&#8217;s closing market price on the valuation date, the risk-free interest rate computed based on the U.S. Treasury yield, the remaining contractual term as the expected term, and the expected stock price volatility calculated based on the historical volatility of the common stock of Armata and its peer companies. We account for the Armata Convertible Note as a trading security, measured at fair value using a Monte Carlo simulation model with the probability of certain qualified events and the assumptions of risk-free rate, volatility of stock price and timing of certain qualified events. We account for the Armata Term Loan as a trading security, measured at fair value using an income approach based on the discounted value of expected future cash flows.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the fair values of our holdings of Armata common stock, warrants, the Armata Convertible Note and the Armata Term Loan were estimated at $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">81.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">35.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">51.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">27.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. As of December 31, 2022 the fair values of our holdings of Armata common stock and warrants were estimated at $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">31.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">8.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the Armata common stock and warrants, we recorded $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">77.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million unrealized gains, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">152.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million unrealized losses and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">78.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million unrealized gains as changes in fair values of equity method investments, net, in the consolidated statements of income for the years ended December 31, 2023, 2022 and 2021, respectively. For the Armata Convertible Note and Term Loan, we recorded $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">21.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million unrealized gain, respectively, as changes in fair values of equity and long-term investments, net, in the consolidated statement of income for year ended December 31, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The summarized financial information, including the portion we do not own, is presented for Armata on a one quarter lag as follows:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Balance Sheet Information</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:53.88%;"></td>
        <td style="width:2.26%;"></td>
        <td style="width:1%;"></td>
        <td style="width:18.799999999999997%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.26%;"></td>
        <td style="width:1%;"></td>
        <td style="width:18.799999999999997%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">September 30,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">36,585</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">33,245</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Noncurrent assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">76,176</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">59,636</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21,884</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,004</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Noncurrent liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">103,263</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">40,300</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Statement Information</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:51.311%;"></td>
        <td style="width:1.481%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.75%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.481%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.75%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.481%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.75%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Twelve Months Ended</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">September 30,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Revenue</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,052</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,446</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,989</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss from operations</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">41,639</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">32,666</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24,227</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">59,512</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">32,650</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23,732</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Equity Method Investment in Entasis</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prior to the consolidation of Entasis&#8217; financial position and results of operations in February 2022, we accounted for Entasis as an equity method investment. Refer to Note 5, &#8220;Consolidated Entities and Acquisitions&#8221;, for more information.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The summarized financial information, including the portion we did not own, is presented for Entasis on a one quarter lag regardless of the date of our investments as follows:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Statement Information</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:71.98%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:25.02%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Twelve Months Ended<br/>September 30,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss from operations</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">52,323</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">125,413</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Equity Investment in InCarda</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the third quarter of 2020, TRC purchased </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">20,469,432</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Series C preferred stock and a warrant to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5,117,358</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> additional shares of Series C preferred stock of InCarda Therapeutics, Inc. (&#8220;InCarda&#8221;) (the &#8220;InCarda 2020 Warrant&#8221;) for $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">15.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which included $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of transaction costs. InCarda is a privately held biopharmaceutical company focused on developing inhaled therapies for cardiovascular diseases. The investment is intended to fund the ongoing clinical development of InRhythm</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (flecainide for inhalation), InCarda&#8217;s lead program, for the treatment of a recent-onset episode of paroxysmal atrial fibrillation. On July 20, 2022, under the terms of the TRC Equity Purchase Agreement, TRC transferred to Innoviva&#8217;s wholly-owned subsidiary, Innoviva TRC Holdings, LLC (&#8220;ITH&#8221;) all of TRC&#8217;s ownership interests and investments in InCarda. ITH has the right to designate one member to InCarda&#8217;s board of directors. As of December 31, 2023, no ITH designee is serving on InCarda&#8217;s </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">six</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">-member board. We did not exercise the InCarda 2020 Warrant which expired in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_16022dea-4c29-4456-a7e5-3f052ff36fa9;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">March 2023</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and wrote off its carrying value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million during 2023.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On March 9, 2022, TRC entered into a Note and Warrant Purchase Agreement (the &#8220;InCarda Agreement&#8221;) with InCarda to acquire a convertible promissory note (the &#8220;InCarda Convertible Note&#8221;) and warrants (the &#8220;InCarda 2022 Warrant&#8221;) for $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.  The InCarda 2022 Warrant expires on March 9, 2027 and is measured at fair value.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On June 15, 2022, the principal amount and the accrued interest of the InCarda Convertible Note were converted into equity securities. In addition, TRC participated in InCarda&#8217;s Series D preferred stock financing by investing $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. In connection with the new round of financing, InCarda recapitalized its equity structure resulting in TRC owning </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4,093,886</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of InCarda&#8217;s common stock, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">37,350</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of its Series A-1 preferred stock, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">20,469,432</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of its Series C preferred stock, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">8,771,780</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of its Series D-1 preferred stock, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3,369,802</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of its Series D-2 preferred stock, a warrant to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5,117,358</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of its Series C preferred stock at $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.73</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share and a warrant to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,490,033</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of its Series D-1 preferred stock at $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.20</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023 and 2022, we held </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">8.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">9.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of InCarda equity ownership, respectively. Our investment in InCarda does not provide us with the ability to control or have significant influence over InCarda&#8217;s operations. Based on our evaluation, we determined that InCarda is a VIE, but we are not the primary beneficiary of the VIE. We have not provided financial or other support that we were not previously contractually required to provide during the periods presented. Our maximum exposure to loss is equal to the amount we invested in the entity.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We account for our investments in InCarda under the measurement alternative. Under the measurement alternative, the equity investment is initially recorded at its allocated cost, but the carrying value may be adjusted through earnings upon an impairment or when there is an observable price change involving the same or a similar investment with the same issuer. Due to InCarda&#8217;s equity recapitalization in the second quarter of 2022, TRC reassessed the value of its investments in InCarda using the Option Pricing Model Backsolve valuation methodology. Key assumptions used in the valuation model included an expected holding period of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">two years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, a risk free interest rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%, a dividend yield of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% and an estimated volatility of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">122.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%. The estimated volatility was calculated based on the historical volatility of a selected peer group of public companies comparable to InCarda. We recognized an impairment charge of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">9.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million during the second quarter of 2022.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Due to certain changes in InCarda&#8217;s business operations during the second quarter of 2023, ITH reassessed the value of its investments in InCarda using the Option Pricing Model methodology. Key assumptions used in the valuation model included an expected holding period of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">two years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, a risk-free interest rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%, a dividend yield of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% and an estimated volatility of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">114.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%. The estimated volatility was calculated based on the historical volatility of a selected peer group of public companies comparable to InCarda. We recognized an impairment charge of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million during the second quarter of 2023.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we recorded $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in fair value of InCarda&#8217;s Series C preferred stock and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in fair value of Series D warrants</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2022, we recorded $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">6.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in fair value of InCarda&#8217;s Series C preferred stock and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in fair value of Series C warrants and Series D warrants</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. As of December 31, 2023 and 2022, we recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively, for InCarda&#8217;s Series D-1 preferred stock, Series D-2 preferred stock, and common stock using the measurement alternative. We recorded $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">8.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> milli</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">on unrealized loss as changes in fair values of equity and long-term investments, net, in the consolidated statements of income for the years ended December 31, 2023, 2022, 2021, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Equity Investment in ImaginAb</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On March 18, 2021, TRC entered into a securities purchase agreement with ImaginAb, Inc. (&#8220;ImaginAb&#8221;) to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4,051,724</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of ImaginAb Series C preferred stock for $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. On the same day, TRC also entered into a securities purchase agreement with one of ImaginAb&#8217;s common stockholders to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4,097,157</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of ImaginAb common stock for $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. ImaginAb is a privately held biotechnology company focused on clinically managing cancer and autoimmune diseases via molecular imaging. $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million was incurred for investment due diligence costs and execution and recorded as part of the equity investment in the consolidated balance sheets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On July 20, 2022, under the terms of the TRC Equity Purchase Agreement, TRC transferred to ITH all of TRC&#8217;s ownership interests and investments in ImaginAb.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On March 14, 2023, ITH entered into a securities purchase agreement with ImaginAb to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">270,568</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of ImaginAb Series C-2 preferred stock for $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. On September 14, 2023, ITH entered into a securities purchase agreement with ImaginAb to purchase another </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">405,852</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of ImaginAb Series C-2 preferred stock for $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. As of December 31, 2023, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of ImaginAb&#8217;s six board members was designated by ITH. As of December 31, 2023 and 2022, we held </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">12.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">12.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%, respectively, of ImaginAb equity ownership.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Our investment in ImaginAb does not provide us with the ability to control or have significant influence over ImaginAb&#8217;s operations. Based on our evaluation, we determined that ImaginAb is a VIE, but we are not the primary beneficiary of the VIE. We have not provided financial or other support that we were not previously contractually required to provide during the periods presented. Our maximum exposure to loss is equal to the amount we invested in the entity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because ImaginAb&#8217;s equity securities are not publicly traded and do not have a readily determinable fair value, we account for our investment in ImaginAb&#8217;s Series C preferred stock and common stock using the measurement alternative. As of December 31, 2023 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and 2022, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">7.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">6.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively, was recorded as equity and long-term investments in the consolidated balance sheets, respectively, and there was no change to the fair value of our investment in ImaginAb.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Convertible Promissory Note in Gate Neurosciences</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On November 24, 2021, TRC entered into a Convertible Promissory Note Purchase Agreement with Gate to acquire a convertible promissory note (the &#8220;Gate Convertible Note&#8221;) with a principal amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">15.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. Gate is a privately held biopharmaceutical company focused on developing the next generation of targeted nervous system therapies, leveraging precision medicine approaches to develop breakthrough drugs for psychiatric and neurologic diseases. The investment is intended to fund Gate's ongoing development and research. The Gate Convertible Note bears an annual interest rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% and will convert into shares of common stock of Gate upon a qualified event or into shares of shadow preferred stock of Gate (&#8220;Shadow Preferred&#8221;) upon a qualified financing. A qualifying event can be a qualified initial price offering, a qualified merger, or a merger with a special-purpose acquisition company (&#8220;SPAC&#8221;). Shadow Preferred means preferred stock having identical rights, preferences and restrictions as the preferred stock that would be issued in a qualified financing.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The number of common stock shares to be issued in a qualified event shall be equal to the amount due on the conversion date divided by the lesser of a capped conversion price (the &#8220;Capped Conversion Price&#8221;) and the qualified event price (the &#8220;Qualified Event Price&#8221;). The Capped Conversion Price is calculated as $50.0 million divided by the number of shares of common stock outstanding at such time on a fully diluted basis. The Qualified Event Price is the price per share determined by the qualified event. A qualified financing is a sale or series of sales of preferred stock where (i) at least 50 percent of counterparties are not existing shareholders, (ii) net proceeds to Gate are at least $35.0 million, and (iii) the stated or implied equity valuation of Gate is at least $80.0 million. </span></span><span style="font-size:10pt;font-family:Times New Roman;"></span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On July 20, 2022, under the terms of the TRC Equity Purchase Agreement, TRC transferred to ITH all of TRC's debt investments in Gate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On February 2, 2023, ITH entered into a Note Amendment Agreement with Gate to amend the Gate Convertible Note. Pursuant to the Note Amendment Agreement, the principal amount of the Gate Convertible Note was increased from $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">15.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">21.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which represents the original principal, accrued interest as of the amendment date and an additional cash investment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. All other material terms of the Gate Convertible Note were unchanged.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On October 6, 2023, ITH entered into a Second Note Amendment Agreement with Gate to amend the Note Amendment Agreement. Pursuant to the Second Note Amendment Agreement, the principal amount of the Gate Convertible Note was increased from $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">21.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">27.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which represents the amended principal as of February 2, 2023, accrued interest as of the second amendment date and an additional cash investment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. All other material terms of the Gate Convertible Note were unchanged.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have accounted for the Gate Convertible Note as a trading security, measured at fair value using a Monte Carlo simulation model with the probability of certain qualified events and the assumptions of equity value of Gate, risk-free rate, expected stock price, volatility of its peer companies, and the time until a financing is raised. As of December 31, 2023 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and 2022, the fair value of the Gate Convertible Note was estimated at $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">28.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">15.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively, and recorded as equity and long-term investments in the consolidated balance sheets. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We recorded $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of unrealized loss, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of unrealized gain, and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of unrealized loss as changes in fair values of other equity and long-term investments, net, in the consolidated statements of income for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023, 2022 and 2021, respectively.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Equity Investment in Nanolive</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On February 18, 2022, TRC entered into an investment and shareholders agreement with Nanolive to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">18,750,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Nanolive Series C preferred stock for $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">9.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million (equivalent to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">9.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million CHF). Nanolive SA is a Swiss privately held life sciences company focused on developing breakthrough imaging solutions that accelerate research in growth industries such as drug discovery and cell therapy. $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million was incurred for investment due diligence costs and execution and recorded as part of the equity and long-term investment in the consolidated balance sheets. On July 20, 2022, under the terms of the TRC Equity Purchase Agreement, TRC transferred to ITH all of TRC&#8217;s ownership interests and investments in Nanolive. ITH has the right to designate one member to Nanolive&#8217;s board. ITH also has the right to designate another member, who will be mutually acceptable to ITH and another stockholder, to Nanolive&#8217;s board. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Innoviva designee is serving on Nanolive&#8217;s </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">six</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">-member board. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, we held </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">15.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">15.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of Nanolive equity ownership, respectively.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our investment in Nanolive does not provide us with the ability to control or have significant influence over Nanolive&#8217;s operations. Based on our evaluation, we determined that Nanolive is a VIE, but we are not the primary beneficiary of the VIE. We have not provided financial or other support that we were not previously contractually required to provide during the periods presented. Our maximum exposure to loss is equal to the amount we invested in the entity.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because Nanolive&#8217;s equity securities are not publicly traded and do not have a readily determinable fair value, we account for our investment in Nanolive&#8217;s Series C preferred stock using the measurement alternative. As of December 31, 2023 and 2022,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of investment in Nanolive was recorded as equity and long-term investments in the consolidated balance sheets, and there was no change to the carrying amount of our investment.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Available-for-Sale Securities</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The estimated fair value of available-for-sale securities is based on quoted market prices for these or similar investments that were based on prices obtained from a commercial pricing service. Available-for-sale securities are summarized below:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:36.867%;"></td>
        <td style="width:1.56%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.222000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.56%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.222000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.56%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.222000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.56%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.222000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gains</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Losses</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(1)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">170,706</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">170,706</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">170,706</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">170,706</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:9pt;font-family:Times New Roman;transform-origin:top left;min-width:3.333%;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Money market funds are included in cash and cash equivalents in the consolidated balance sheets.</span></div></div>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:36.867%;"></td>
        <td style="width:1.56%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.222000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.56%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.222000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.56%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.222000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.56%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.222000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gains</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Losses</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(1)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">263,469</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">263,469</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">263,469</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">263,469</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:9pt;font-family:Times New Roman;transform-origin:top left;min-width:3.333%;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Money market funds are included in cash and cash equivalents in the consolidated balance sheets.</span></div></div></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023 and 2022, all available-for-sale securities were money market funds, and there was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> credit loss recognized.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Value Measurements</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our available-for-sale securities, equity and long-term investments and contingent value rights are measured at fair value on a recurring basis and our debt is carried at amortized cost basis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:36.867%;"></td>
        <td style="width:1.56%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.222000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.56%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.222000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.56%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.222000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.56%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.222000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated Fair Value Measurements as of December 31, 2023 Using:</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Quoted Price<br/>in Active<br/>Markets for</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant<br/>Other</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Identical</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Observable</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unobservable</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Types of Instruments</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Assets</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Inputs</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Inputs</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 1</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 2</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 3</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">Assets</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">170,706</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">170,706</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Investments held by ISP Fund LP </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(1)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">251,207</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">60,605</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">311,812</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Equity investment - Armata Common Stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">81,249</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">81,249</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Equity investment - Armata Warrants</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35,297</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35,297</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Convertible debt investment - Armata Note</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">51,883</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">51,883</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Term loan investment - Armata Term Loan</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27,044</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27,044</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Convertible debt investment - Gate Note</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27,972</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27,972</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets measured at estimated fair value</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">503,162</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35,297</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">167,504</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">705,963</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">Liabilities</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Debt</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025 Notes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">200,407</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">200,407</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2028 Notes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">227,070</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">227,070</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;Total fair value of debt</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">427,477</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">427,477</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Contingent value rights</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">359</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">359</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total liabilities at estimated fair value</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">427,477</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">359</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">427,836</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:9pt;font-family:Times New Roman;transform-origin:top left;min-width:3.333%;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The investments held by ISP Fund LP, consisted of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">248.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in equity investments, which included private placement positions of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">60.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">62.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in money market funds. A certain portion of the total capital contribution of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">300.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million is no longer subject to a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">36-month</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> lock-up period from the date of such capital contribution. However, we did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t elect to make a withdrawal in 2023, thereby extending the lock-up period and withdrawal elections into subsequent years. </span></div></div>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:36.867%;"></td>
        <td style="width:1.56%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.222000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.56%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.222000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.56%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.222000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.56%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.222000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated Fair Value Measurements as of December 31, 2022 Using:</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Quoted Price</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">in Active</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Markets for</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Other</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Identical</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Observable</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unobservable</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Types of Instruments</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Assets</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Inputs</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Inputs</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 1</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 2</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 3</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">Assets</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">263,469</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">263,469</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Investments held by ISP Fund LP </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(1)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">265,982</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">54,578</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">320,560</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Equity investment - Armata Common Stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31,095</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31,095</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Equity investment - Armata Warrants</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,059</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,059</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Equity investment - InCarda Warrants</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">605</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">605</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Convertible debt investment - Gate Note</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,700</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,700</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets measured at estimated fair value</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">560,546</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,059</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">70,883</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">639,488</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">Debt</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2023 Notes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">96,089</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">96,089</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025 Notes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">197,807</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">197,807</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2028 Notes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">211,768</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">211,768</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total fair value of debt</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">505,664</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">505,664</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Contingent value rights</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">595</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">595</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total liabilities at estimated fair value</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">505,664</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">595</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">506,259</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:9pt;font-family:Times New Roman;transform-origin:top left;min-width:3.333%;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The investments held by ISP Fund LP, consisted of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">295.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in equity investments, which included private placement positions and convertible notes of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">54.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">25.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in money market funds. Our total capital contribution of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">300.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million was subject to a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">36-month</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> lock-up period from the date of such capital contributions.</span></div></div></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair values of our equity investments in Armata&#8217;s common stock and publicly traded investments held by ISP Fund LP are based on the quoted prices in active markets and are classified as Level 1 financial instruments. The fair values in the warrants in Armata classified within Level 2 are based upon observable inputs that may include benchmark yields, reported trades, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids, offers, and reference data including market research publications.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The InCarda Warrants, the Gate Convertible Note, the Armata Convertible Note, the Armata Term Loan, private placement positions and convertible notes held by ISP Fund LP, and contingent value rights are classified as Level 3 financial instruments as these securities are not publicly traded and the assumptions used in the valuation model for valuing these securities are based on significant unobservable and observable inputs including those of publicly traded peer companies.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair values of our 2025 Notes and 2028 Notes are based on recent trading prices of the respective instruments. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair values of our 2023 Notes, which were fully paid off in January 2023, were also based on their trading prices.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430386692688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CAPITALIZED FEES PAID<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAbstract', window );"><strong>Capitalized Contract Cost [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_CapitalizedFeesPaidDisclosureTextBlock', window );">CAPITALIZED FEES PAID</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7. CAPITALIZED FEES PAID</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Capitalized fees paid, which consist of registrational and launch-related milestone fees paid to GSK, were as follows:</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:51.311%;"></td>
        <td style="width:1.481%;"></td>
        <td style="width:14.749%;"></td>
        <td style="width:1.481%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.75%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.481%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.75%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortization period</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">United States</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2013-2030</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">120,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">120,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Europe</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2013-2029</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">60,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">60,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Japan</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2013-2029</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">40,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">40,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Gross carrying value</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">220,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">220,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accumulated amortization</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">136,216</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">122,393</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net carrying value</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">83,784</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">97,607</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These milestone fees are amortized over their estimated useful lives commencing upon the commercial launch of the product in their respective regions with the amortization recorded as a reduction in revenue from collaborative arrangements. As of December 31, 2023, the weighted average remaining amortization period wa</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">s </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6.2</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additional information regarding these milestone fees is included in Note 3, &#8220;Revenue Recognition&#8221;. Amortization for each of the years ended December 31, 2023, 2022 and 2021 was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">13.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The remaining estimated amortization is </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">13.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for each of the years from 2024 to 2027, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">13.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the year 2028, and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">14.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> thereafter.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_CapitalizedFeesPaidDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about capitalized fees paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_CapitalizedFeesPaidDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430386562800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOODWILL AND INTANGIBLE ASSETS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">GOODWILL AND INTANGIBLE ASSETS</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8. GOODWILL AND INTANGIBLE ASSETS</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Goodwill and intangible assets acquired are recognized at fair value as of the acquisition date. The carrying amount of goodwill as of December 31, 2023 and 2022 was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">17.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">26.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively. We have </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t recognized any impairment losses related to goodwill and intangible assets during the periods presented.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Intangible assets with definite lives are amortized over their estimated useful lives. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The carrying basis and accumulated amortization of recognized intangible assets as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022 were as follows:</span></span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:36.86%;"></td>
        <td style="width:1.56%;"></td>
        <td style="width:14.24%;"></td>
        <td style="width:1.56%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.56%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.56%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.22%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="12" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Useful Life</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Accumulated</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Net Carrying</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Years)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortization</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Marketed products</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">219,700</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,204</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">194,496</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">In-process research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,600</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,600</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Collaboration agreement</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35,400</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,161</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">33,239</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">257,700</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27,365</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">230,335</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:36.86%;"></td>
        <td style="width:1.56%;"></td>
        <td style="width:14.24%;"></td>
        <td style="width:1.56%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.56%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.56%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.22%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="12" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Useful Life</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Accumulated</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Net Carrying</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Years)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortization</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Marketed products</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">151,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,581</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">145,419</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">In-process research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">72,100</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">72,100</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Collaboration agreement</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35,400</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35,400</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">258,500</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,581</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">252,919</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Intangible assets recognized as a result of the acquisition of Entasis amounted to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">106.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which consisted of Entasis&#8217; in-process research and development related to its antibacterial therapeutic product candidates and a collaboration agreement amounting to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">71.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">35.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively. Following the FDA approval of XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in May 2023, we started amortizing $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">68.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of the then in-process research and development as a marketed product, as well as the collaboration agreement, over their estimated useful lives. The useful life of the remaining in-process research and development of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million will be determined upon commercialization of the underlying product candidate; thus, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> amortization expense for this intangible asset was recognized </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">for the periods presented.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Intangible assets recognized as a result of the acquisition of La Jolla amounting to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">151.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million pertain to product rights and developed technologies on La Jolla&#8217;s currently marketed products. These are intangible assets with determinable lives and are amortized over their estimated useful lives.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We recognized amortization expense of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">21.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and 2022, respectively. Future amortization expense is expected to be $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">25.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for each of the years from 2024 to 2028 and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">98.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million thereafter.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//350/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430386712480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BALANCE SHEET COMPONENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">BALANCE SHEET COMPONENTS</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9. BALANCE SHEET COMPONENTS</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Inventory</span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Inventory consisted of the following:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:67.313%;"></td>
        <td style="width:1.5%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.843%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.5%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.843%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Raw materials</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,257</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,757</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Work-in-process</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,670</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,052</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Finished goods</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,810</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,088</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total inventory</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">40,737</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">55,897</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and 2022, total inventory included net fair value adjustments resulting from the acquisition of La Jolla of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">23.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">49.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, which will be recognized as cost of products sold when sales occur in future periods. The fair value adjustments recorded as part of cost of products sold amounted to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">27.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">million and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other Accrued Liabilities</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other accrued liabilities consisted of the following:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:67.313%;"></td>
        <td style="width:1.5%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.843%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.5%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.843%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued contract manufacturing expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,966</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,382</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued clinical expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">591</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">692</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued research expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">185</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">349</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued professional services</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,876</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,977</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_4d9e1814-d90c-438a-b69f-2d0819d5112e;"><span style="-sec-ix-hidden:F_62616aa1-c408-4682-b198-b4aacc8031c4;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current portion of lease liabilities</span></span></span></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,207</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,316</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Royalty obligation payable</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,928</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current portion of deferred royalty obligation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,639</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued license fees and royalties</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,575</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">943</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,370</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,909</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total other accrued liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19,698</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21,207</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other Long-Term Liabilities</span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other long-term liabilities consisted of the following:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:67.313%;"></td>
        <td style="width:1.5%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.843%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.5%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.843%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Long-term portion of deferred royalty obligation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">69,876</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">67,947</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_8a36ba82-b9a3-4b23-adb9-3d2b758e3db2;"><span style="-sec-ix-hidden:F_fbfec351-c094-49d9-a03a-e641b11869bb;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Long-term portion of lease liabilities</span></span></span></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,635</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,376</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Contingent value rights liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">359</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">595</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total other long-term liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">71,870</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">70,918</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//210/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430386602480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK-BASED COMPENSATION</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10. STOCK&#8209;BASED COMPENSATION</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Equity Incentive Plans</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In May 2012, we adopted the 2012 Equity Incentive Plan (the &#8220;2012 Plan&#8221;). The 2012 Plan provides for the grant of incentive stock options, nonstatutory stock options, RSAs, RSUs and Stock Appreciation Rights to employees, non-employee directors and consultants. As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, total shares remaining available for issuance under the 2012 Plan were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,924,185</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Employee Stock Purchase Plan</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the 2004 Employee Stock Purchase Plan (the &#8220;2004 ESPP&#8221;), our employees may purchase common stock through payroll deductions at a price equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">85</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the lower of the fair market value of the stock at the beginning of the offering period or at the end of each applicable purchase period. The 2004 ESPP provided for consecutive and overlapping offering periods of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">24 months</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in duration, with each offering period composed of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">four</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> consecutive </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">six-month</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> purchase periods. The purchase periods ended on either May 15 or November 15. The 2004 ESPP contributions were limited to a maximum of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">15</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of an employee&#8217;s eligible compensation. The maximum number of shares that an employee may purchase in any purchase period was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,500</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. An employee may not purchase shares with a value greater than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">25,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in any calendar year.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On April 13, 2023, the Board of Directors adopted the 2023 ESPP (the &#8220;2023 ESPP&#8221;). The 2023 ESPP, which supersedes the 2004 ESPP, was approved by the Company&#8217;s stockholders on May 22, 2023. Under the 2023 ESPP, eligible employees may purchase common stock through payroll deductions at a price equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">85</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the lower of the fair market value of the stock at the beginning or end of each applicable purchase period. The 2023 ESPP provides for offering periods of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">six months</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, which ends on either May 15 or November 15. The 2023 ESPP contributions are limited to a maximum of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">15</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of an employee&#8217;s eligible compensation. The maximum number of shares that an employee may purchase in any purchase period is </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,500</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. An employee may not purchase shares with a value greater than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">25,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in any calendar year. A total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million shares of our common stock was reserved and available for issuance under the 2023 ESPP.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, total shares remaining available for issuance under the 2023 ESPP were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,500,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Director Compensation Program</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our non-employee directors receive compensation for services provided as a director. Each member of our board of directors who is not an employee receives both cash and equity compensation for services as a director, member of a committee of the board of directors, lead independent director and chairman, as applicable. In October 2017, both the cash and equity components of the compensation program were amended, effective immediately (the &#8220;October 2017 Amendments&#8221;).</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Each of our independent directors receives periodic automatic grants of equity awards under a program implemented under the 2012 Plan. These grants are non&#8209;discretionary. Only our independent directors or affiliates of such directors are eligible to receive automatic grants under the 2012 Plan. Under the program, each individual who first became a non-employee director will, on the date such individual joins the board of directors, automatically be granted a one&#8209;time grant of RSUs covering a number of shares of our common stock calculated as $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">125,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ($</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">250,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> prior to the October 2017 Amendments) divided by our common stock closing share price on the date of grant as reported on The Nasdaq Global Select Market, rounded down to the nearest whole share (the &#8220;Initial RSUs&#8221;), plus a one&#8209;time grant of RSUs covering a number of shares of our common stock calculated as $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">225,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ($</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">250,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> prior to the October 2017 Amendments) divided by our common stock closing share price on the date of grant as reported on The Nasdaq Global Select Market, which would be pro-rated for the number of whole months remaining until the anniversary of the prior year&#8217;s stockholders&#8217; meeting, rounded down to the nearest whole share (the &#8220;Pro Rata RSUs&#8221;). The Initial RSUs vest in </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">two</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> equal annual installments, while Pro Rata RSUs vest in a single installment at the sooner of the next annual stockholder meeting or the one-year grant anniversary, in each case subject to the non-employee director&#8217;s continuous service through the applicable vesting date.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Annually, upon his or her re&#8209;election to the board of directors at the Annual Meeting of Stockholders, each non-employee director is automatically granted an RSU covering a number of shares of our common stock calculated as $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">225,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ($</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">250,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> prior to the October 2017 Amendments) divided by our common stock closing share price on the date of grant as reported on The Nasdaq Global Select Market, rounded down to the nearest whole share. These RSUs will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the non-employee director&#8217;s continuous service through the applicable vesting date. Following the amendment to our non-employee director compensation program, both the annual RSUs and Initial RSUs described above remained unchanged with the exception that the number of shares of our common stock subject to each award has been reduced.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These RSUs will vest in full upon the director&#8217;s death, the occurrence of a change in control or, with respect to awards made after the October 2017 Amendments, the director&#8217;s disability before the director&#8217;s service terminates. Director RSUs carry dividend equivalent rights to be credited with an amount equal to all cash dividends paid on the underlying shares of common stock while unvested. Dividend equivalents are subject to the same terms and conditions, including vesting, as the RSUs to which they attach and are paid in cash upon vesting.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock&#8209;Based Compensation Expense</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock&#8209;based compensation expense is included in the consolidated statements of income as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:51.01%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.203%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.203%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.583%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Selling, general and administrative</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,645</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,305</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,017</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,192</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,042</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,837</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,347</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,017</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock&#8209;based compensation expense included in the consolidated statements of income by award type is as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:51.311%;"></td>
        <td style="width:1.481%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.75%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.481%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.75%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.481%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.75%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock options</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,980</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,057</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">490</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">RSUs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,663</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,053</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,280</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">RSAs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">168</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">194</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">200</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ESPP</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">26</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">43</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">47</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total stock-based compensation expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,837</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,347</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,017</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023, the unrecognized stock-based compensation cost and the estimated weighted-average amortization period were as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:60.2%;"></td>
        <td style="width:1.82%;"></td>
        <td style="width:1%;"></td>
        <td style="width:16.08%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.36%;"></td>
        <td style="width:1%;"></td>
        <td style="width:16.54%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrecognized Compensation Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-Average Amortization Period (Years)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock options</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,861</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.9</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">RSUs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,430</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.4</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">RSAs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">220</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.9</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total unrecognized compensation expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,511</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Compensation Awards</span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes equity award activity under the 2012 Plan and prior plans and related information:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:32.386%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.642%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.02%;"></td>
        <td style="width:1%;"></td>
        <td style="width:7.7219999999999995%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.642%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.02%;"></td>
        <td style="width:1%;"></td>
        <td style="width:7.7219999999999995%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.642%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.02%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.182%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands, except per share data)</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of outstanding options</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-Average Exercise Price of Outstanding Options</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of outstanding RSUs</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-Average Fair Value per Share at Grant</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of outstanding RSAs</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-Average Fair Value per Share at Grant</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance as of December 31, 2022</span></p></td>
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">948</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15.56</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">518</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12.16</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">30</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14.97</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">828</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12.77</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">389</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12.85</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercised</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12.98</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Released RSUs and RSAs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">284</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12.42</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15.02</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeited</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">275</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15.22</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">141</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11.98</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance as of December 31, 2023</span></p></td>
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,499</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14.09</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">482</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12.62</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14.93</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vested and expected to vest <br/>&#160;&#160;&#160;as of December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,499</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14.09</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">482</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12.62</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the aggregate intrinsic value of options outstanding and options exercisable was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2022, the aggregate intrinsic value of options outstanding and options exercisable was not material. As of December 31, 2023, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">519,165</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> options were exercisable. The weighted average remaining contractual term of options outstanding was </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7.96</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years and </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8.01</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years as of December 31, 2023 and 2022, respectively.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The total intrinsic value of the options exercised was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t material for the year ended December 31, 2023, 2022 and 2021. The total estimated fair value of options vested was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the years ended December 31, 2023 and 2021, respectively. The total estimated fair value of options vested was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t material for the year ended December 31, 2022.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The total estimated fair value of RSUs vested was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the years December 31, 2023, 2022 and 2021.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The total estimated fair value of RSAs vested was not material for the year ended December 31, 2023, 2022, and 2021.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Valuation Assumptions</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Black-Scholes-Merton</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> assumptions used in calculating the estimated value of stock options granted by Innoviva on the date of grant were as follows:</span></span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:51.311%;"></td>
        <td style="width:1.481%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.748999999999999%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.481%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.748999999999999%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.481%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.748999999999999%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.6</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.09</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.04</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.11</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Volatility</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">37.8</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">38.6</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">44.9</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Dividend yield</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average estimated fair value of stock options granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.57</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.43</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.84</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430386609680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS' EQUITY</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">11. </span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stockholders&#8217; Equity</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On October 31, 2022, our board of directors authorized a share repurchase program under which we may repurchase up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">100.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of our outstanding shares of common stock. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The repurchase program authorizes the repurchase by the Company of its common stock in open market transactions, including pursuant to a trading plan in accordance with Rule 10b-18 promulgated under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;) privately negotiated transactions, in block trades, accelerated share repurchase transactions, exchange transactions, or any combination thereof or by other means in accordance with federal securities laws. The authorization permits the Company to repurchase shares of its common stock from time to time at management&#8217;s discretion. Repurchases may also be made pursuant to a trading plan under Rule 10b5-1 under the Exchange Act, which would permit shares to be repurchased when the Company might otherwise be precluded from doing so because of self-imposed trading blackout periods or other regulatory restrictions. The actual means and timing of any shares purchased under the program will depend on a variety of factors, including ongoing assessments of the capital needs of the business, the market price of our common stock, prevailing stock prices, general market conditions and other considerations. This program has no termination date, may be suspended or discontinued at any time at our discretion, and does not obligate us to acquire any amount of common stock. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From program inception through December 31, 2022, we repurchased </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">647,394</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares in the open market at an average price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">13.13</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share for a total amount of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">8.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. For the year ended</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> December 31, 2023, we repurchased </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">6,173,565</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares in the open market at an average price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">12.39</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share for a total amount of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">76.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. Subsequent to December 31, 2023 and through February 15, 2024, we have repurchased </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">131,826</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares in the open market at an average price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">15.93</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share for a total amount of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. All of the repurchased shares were retired.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430386549280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">DEBT</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12. DEBT</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our debt consists of the following:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:67.313%;"></td>
        <td style="width:1.5%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.843%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.5%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.843%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2023 Notes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">96,204</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025 Notes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">192,500</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">192,500</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2028 Notes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">261,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">261,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total debt</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">453,500</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">549,704</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;Less: Unamortized debt discount and issuance costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,266</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,331</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total debt, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">446,234</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">540,373</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;Less: Current portion of long-term debt, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">96,193</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total long-term debt, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">446,234</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">444,180</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Convertible Subordinated Notes Due 2023</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In January 2013, we completed an underwritten public offering of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">287.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million aggregate principal amount of our 2023 Notes, which matured on January 15, 2023. The 2023 Notes bore interest at the rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.125</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% per year that is payable semi-annually in arrears in cash on January 15 and July 15 of each year, beginning on July 15, 2013.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The 2023 Notes were convertible, at the option of the holder, into shares of our common stock at an initial conversion rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">35.9903</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares per $1,000 principal amount of the 2023 Notes, subject to adjustment in certain circumstances, which represented an initial conversion price of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">27.79</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the offering of the 2023 Notes, we entered into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">two</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> privately negotiated capped call option transactions with a single counterparty. The capped call option transaction was an integrated instrument consisting of a call option on our common stock purchased by us with a strike price equal to the initial conversion price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">27.79</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share for the underlying number of shares and a cap price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">38.00</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, both of which were subject to adjustments consistent with the 2023 Notes. The cap component was economically equivalent to a call option sold by us for the underlying number of shares with an initial strike price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">38.00</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share. As an integrated instrument, the settlement of the capped call coincided with the due date of the convertible debt. Upon settlement, we would receive from our hedge counterparty a number of shares of our common shares that would range from </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">zero</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, if the stock price was below $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">27.79</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, to a maximum of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,779,659</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares, if the stock price was above $38.00 per share. However, if the market price of our common stock, as measured under the terms of the capped call transactions, exceeded $38.00 per share, there was no incremental anti-dilutive benefit from the capped call.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a result of the partial conversion by certain holders of the 2023 Notes in July 2014, and dividends declared and paid in 2014 and 2015, the conversion rate with respect to our 2023 Notes was adjusted in total to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">50.5818</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of our common stock per $1,000 principal amount of the 2023 Notes, which represented a conversion price of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">19.77</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share. As a result of the conversion rate adjustments, the capped call strike price and cap price were also adjusted to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">19.77</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">27.04</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the year ended December 31, 2016, we retired a portion of our 2023 Notes with a face value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">14.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and carrying value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">13.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million by way of purchase in the open market.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On March 7, 2022, we used $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">165.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million from the sale of the 2028 Notes to repurchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">60</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the 2023 Notes with a face value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">144.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The carrying value of the repurchased 2023 Notes was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">144.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. Accrued interest was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and unamortized debt issuance costs were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million on the date of repurchase. We recognized a loss on the extinguishment of the 2023 Notes of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">20.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in other expense, net, in the consolidated statement of operations. The repurchase reduced the outstanding principal balance to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">96.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and unamortized debt issuance costs to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The annual effective interest rate of the 2023 Notes changed from </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.36</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.37</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On April 18, 2022, certain 2023 Notes holders converted their notes of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> thousand into Innoviva&#8217;s common stock. The outstanding principal balance was reduced slightly to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">96.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our outstanding 2023 Notes balance consisted of the following as of December 31, 2022:</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:77%;"></td>
        <td style="width:1.98%;"></td>
        <td style="width:1%;"></td>
        <td style="width:19.02%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Principal</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">96,204</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Debt issuance costs, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net carrying amount</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">96,193</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:3.333%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The remaining balance of the 2023 Notes in the amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">96.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million was fully paid upon the maturity date in January 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table sets forth total interest expense recognized related to the 2023 Notes for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023, 2022 and 2021:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:51.311%;"></td>
        <td style="width:1.481%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.75%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.481%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.75%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.481%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.75%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Contractual interest expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">85</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,617</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,121</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Amortization of debt issuance costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">302</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">580</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total interest and amortization expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">96</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,919</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,701</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Convertible Senior Notes Due 2025</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On August 7, 2017, we completed a private placement of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">192.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million aggregate principal amount of our 2025 Notes. The proceeds include the 2025 Notes sold pursuant to the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">17.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million over-allotment option granted by us to the initial purchasers, which option was exercised in full. The 2025 Notes were sold in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act. The 2025 Notes are senior unsecured obligations and bear interest at a rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% per year, payable semi-annually in arrears on February 15 and August 15 of each year, beginning on February 15, 2018.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The 2025 Notes are convertible, based on the applicable conversion rate, into cash, shares of our common stock or a combination thereof, at our election. The initial conversion rate for the 2025 Notes is </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">57.9240</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of our common stock per $1,000 principal amount of the 2025 Notes (which is equivalent to an initial conversion price of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">17.26</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share), representing a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">30.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% conversion premium over the last reported sale price of the Company&#8217;s common stock on August 1, 2017, which was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">13.28</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share. The conversion rate is subject to customary anti-dilution adjustments in certain circumstances. The 2025 Notes will mature on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">August 15, 2025</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, unless repurchased or converted in accordance with their terms prior to such date. Prior to February 15, 2025, the 2025 Notes will be convertible at the option of the holders only upon the occurrence of specified events and during certain periods, as described below. From, and including, February 15, 2025, until the close of business on the second scheduled trading day immediately preceding the maturity date, the 2025 Notes will be convertible at any time.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Holders of the 2025 Notes may convert all or a portion of their 2025 Notes prior to the close of business on February 15, 2025 only under the following circumstances:</span></p><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">after September 30, 2017, if our closing common stock price for at least 20 days out of the most recent 30 consecutive trading days of the preceding quarter is greater than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">130</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the current conversion price of the 2025 Notes;</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">for five consecutive business days, if the average trading price per $1,000 of Notes during the prior 10 consecutive trading days is less than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">98</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the product of our closing common stock price and the conversion rate of the 2025 Notes on such day; and,</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">upon the occurrence of specified corporate events, including certain distributions, the occurrence of a fundamental changes (as defined in the indenture governing the 2025 Notes) or a transaction resulting in our common stock converting into other securities or property or assets. </span></div></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On or after February 15, 2025, holders of the 2025 Notes may convert their 2025 Notes at any time until the close of business on the second scheduled trading day immediately preceding the maturity date of the 2025 Notes.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the event of default or a fundamental change (as defined above), holders of the 2025 Notes may require us to repurchase all or a portion of their 2025 Notes at price equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">100</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the principal amount of the 2025 Notes, plus any accrued and unpaid interest.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Effective January 1, 2022, we adopted ASU 2020-06 using a modified retrospective method, under which financial results reported in prior periods were not adjusted.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Prior to the adoption of ASU 2020-06, we separately accounted for the liability and equity components of the 2025 Notes by allocating the proceeds between the liability component and the embedded conversion option (&#8220;equity component&#8221;) due to our ability to settle the conversion obligation of the 2025 Notes in cash, common stock or a combination of cash and common stock, at our option. The carrying amount of the liability component was calculated by measuring the fair value of a similar liability that does not have an associated convertible feature using the income approach. The allocation was performed in a manner that reflected our non-convertible debt borrowing rate for similar debt. The equity component of the 2025 Notes of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">67.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million was recognized as a debt discount and represents the difference between the proceeds from the issuance of the 2025 Notes and the fair value of the liability of the 2025 Notes on the date of issuance. The excess of the principal amount of the liability component over its carrying amount (&#8220;debt discount&#8221;) was amortized to interest expense using the effective interest method over the term of the 2025 Notes. The equity component was not remeasured as long as it continued to meet the conditions for equity classification. Additionally, we separated the total issuance costs of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million incurred into liability and equity components in proportion to the allocation of the initial proceeds, resulting in liability issuance costs of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and equity issuance costs of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. Issuance costs attributable to the liability component were amortized on a straight-line basis, which approximated the effective interest rate method, to interest expense over the term of the 2025 Notes. The issuance costs attributable to the equity component were netted against the equity component in additional paid-in capital. The annual effective interest rate of the liability component of the 2025 Notes was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">8.87</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Upon adoption of ASU 2020-06 on January 1, 2022, we combined the liability and equity components of the 2025 Notes assuming that the instrument was accounted for as a single liability from inception to the date of adoption. We similarly combined the liability and equity components of the issuance costs. The issuance costs are presented as a deduction from the outstanding principal balance of the 2025 Notes and are amortized on a straight-line basis over the term of the 2025 Notes under the effective interest rate method. As of January 1, 2022, the annual effective interest rate on the 2025 Notes was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.88</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%. Beginning January 1, 2022, the annual effective interest rate on the 2025 Notes is </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.88</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our outstanding 2025 Notes balances consisted of the following:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:53.88%;"></td>
        <td style="width:2.26%;"></td>
        <td style="width:1%;"></td>
        <td style="width:18.799999999999997%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.26%;"></td>
        <td style="width:1%;"></td>
        <td style="width:18.799999999999997%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Principal</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">192,500</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">192,500</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Debt discount and issuance costs, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,205</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,917</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net carrying amount</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">191,295</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">190,583</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table sets forth total interest expense recognized related to the 2025 Notes for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023, 2022 and 2021:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:51.01%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.203%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.203%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.583%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Contractual interest expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,813</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,813</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,813</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Amortization of debt issuance costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">712</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">692</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">657</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Amortization of debt discount</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,898</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total interest and amortization expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,525</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,505</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,368</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Convertible Senior Notes Due 2028</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In March 2022, we completed a private placement of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">261.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million aggregate principal amount of our 2028 Notes, which will mature on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">March 15, 2028</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The proceeds include the 2028 Notes sold pursuant to the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">45.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million over-allotment option granted by us to the initial purchasers, of which $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">36.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million was exercised. The 2028 Notes were sold in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The net proceeds from the sale of the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">261.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million aggregate principal amount of 2028 Notes were approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">252.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million after deducting the initial purchasers&#8217; discounts and commissions and our estimated offering expenses. We used approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">21.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of the net proceeds from the offering to fund the cost of entering into the capped call transactions described below. In addition, we used $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">165.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of the remaining net proceeds to repurchase $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">144.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million aggregate principal amount of the 2023 Notes in separate and individually negotiated transactions with certain holders of the 2023 Notes, which closed concurrently with the issuance of the 2028 Notes. We expect to use the remaining net proceeds for general corporate purposes.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The 2028 Notes bear interest at an annual rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.125</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% that is payable semi-annually in arrears in cash on March 15 and September 15 of each year, beginning on September 15, 2022.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The 2028 Notes are convertible, based on the applicable conversion rate, into cash, shares of our common stock or a combination thereof, at our election. The initial conversion rate was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">38.1432</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares per $1,000 principal amount of the 2028 Notes, subject to customary anti-dilution adjustment in certain circumstances, which represented an initial conversion price of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">26.22</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prior to September 15, 2027, the 2028 Notes will be convertible at the option of the holders only upon the occurrence of specified events and during certain periods, and will be convertible on or after September 15, 2027, at any time until the close of business on the second scheduled trading day immediately preceding the maturity date of the 2028 Notes.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Holders of the 2028 Notes may convert all or a portion of their 2028 Notes prior to the close of business on September 15, 2027, only under the following circumstances:</span></p><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">after March 31, 2022, if our closing common stock price for at least 20 days out of the most recent 30 consecutive trading days of the preceding quarter is greater than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">130</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the current conversion price of the 2028 Notes;</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">for five consecutive business days, if the average trading price per $1,000 of Notes during the prior 10 consecutive trading days is less than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">98</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the product of our closing common stock price and the conversion rate of the 2028 Notes on such day; and,</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">upon the occurrence of specified corporate events, including certain distributions, the occurrence of a fundamental changes (as defined in the indenture governing the 2028 Notes) or a transaction resulting in our common stock converting into other securities or property or assets.</span></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On or after September 15, 2027, holders of the 2028 Notes may convert their 2028 Notes at any time until the close of the business on the second day immediately preceding the maturity date of the 2028 Notes.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The 2028 Notes will be redeemable, in whole or in part, at our option at any time, and from time to time, on or after March 20, 2025, and on or before the 75th scheduled trading day immediately before the maturity date but only if the last reported sale price per share of our common stock exceeds 130% of the conversion price for a specified period of time. The redemption price will be equal to the principal amount of the 2028 Notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date. In addition, calling any 2028 Note for redemption will constitute a make-whole fundamental change (as defined in the indenture governing the 2028 Notes) with respect to that 2028 Note, in which case the conversion rate applicable to the conversion of that 2028 Note will be increased in certain circumstances if it is converted after it is called for redemption.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we undergo a fundamental change, subject to certain conditions, holders may require us to purchase for cash all or any portion of their 2028 Notes. The fundamental change purchase price will be </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">100</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the principal amount of the 2028 Notes to be purchased plus any accrued and unpaid interest to, but excluding, the fundamental change purchase date.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The indenture governing the 2028 Notes contains customary terms and covenants, including a merger covenant and that upon certain events of default occurring and continuing, either the Trustee or the holders of at least 25% of the aggregate principal amount of the outstanding Notes may declare 100% of the principal of, and accrued and unpaid interest, if any, on, all the Notes to be due and payable immediately.</span></span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the offering of the 2028 Notes, we entered into privately negotiated capped call transactions. The cap price of the capped call transaction is initially $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">33.9850</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">share and is subject to certain adjustments under the terms of the capped call transactions. The capped call transactions cover, subject to customary adjustments, the number of shares of common stock initially</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">underlying </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the 2028 Notes. The capped call transactions are expected generally to reduce potential dilution to our common stock upon conversion of the 2028 Notes or at our election (subject to certain conditions) offset any cash payments we are required to make in excess of the aggregate principal amount of converted 2028 Notes, as the case may be, with such reduction or offset subject to a cap.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The annual effective interest rate on the 2028 Notes is </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.70</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our outstanding 2028 Notes balance consisted of th</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">e following:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:67.313%;"></td>
        <td style="width:1.5%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.843%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.5%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.843%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Principal</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">261,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">261,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Debt discount and issuance costs, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,061</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,403</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net carrying amount</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">254,939</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">253,597</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table sets forth total interest expense recognized related to the 2028 Notes for the year ended December 31, 2023 and from the issuance through December 31, 2022:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:67.313%;"></td>
        <td style="width:1.5%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.843%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.5%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.843%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Date of Issuance through</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Contractual interest expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,546</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,514</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Amortization of debt discount and issuance costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,342</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,061</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total interest and amortization expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,888</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,575</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Debt Maturities</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The aggregate scheduled maturities of our convertible debt as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 are as follows:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:80.444%;"></td>
        <td style="width:1.8%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.757%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Year ending December 31,</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">192,500</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2026</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2027</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2028</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">261,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">453,500</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Deferred Royalty Obligation</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As part of our acquisition of La Jolla, we recorded the fair value of its deferred royalty obligation in connection with La Jolla&#8217;s royalty financing agreement (&#8220;La Jolla Royalty Agreement&#8221;) with HealthCare Royalty Partners (&#8220;HCR&#8221;). Under the terms of the La Jolla Royalty Agreement, HCR is entitled to receive quarterly royalties on worldwide net sales of GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> until either January 1, 2031 or when the maximum aggregate royalty payments have been made, whichever occurs first. Quarterly payments to HCR under the Royalty Agreement start at a maximum royalty rate, with step-downs based on the achievement of annual net product sales thresholds. The current maximum royalty rate is </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">14</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Starting January 1, 2024, the maximum royalty rate was increased to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">18</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% based on the terms of the Agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> The La Jolla Royalty Agreement is subject to maximum aggr</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">egate royalty payments to HCR of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">225.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the years ended December 31, 2023, we recognized interest expense of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">6.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million on the deferred royalty obligation. From the date of our acquisition of La Jolla through December 31, 2022, we recognized interest expense of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million on the deferred royalty obligation. The carrying value of the deferred royalty obligation as of December 31, 2023 and 2022 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">69.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">70.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively, (refer to Note 9 &#8220;Balance Sheet Components</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">). During the year ended December 31, 2023, we made royalty payments to HCR of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. From the date of acquisition of La Jolla through December 31, 2022, we made royalty payments to HCR of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The deferred royalty obligation was valued using Level 3 inputs, and its carrying value as of December 31, 2023 and 2022 approximates fair value. The fair value of the deferred royalty obligation was calculated as the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">discounted </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">deferred royalty obligations based on revenue projections for GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. As of December 31, 2023, the annual effective interest rate of the deferred royalty obligation is </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">16.46</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the terms of the La Jolla Royalty Agreement, if we are unable to meet certain obligations, including the obligation to use commercially reasonable and diligent efforts to commercialize GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, HCR would have the right to terminate the La Jolla Royalty Agreement and demand payment of either $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">125.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million or $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">225.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million (depending on which obligation we have failed to meet) less aggregate royalties already paid to HCR. As of December 31, 2023, inclusive of the aggregate royalties paid to HCR by La Jolla under the La Jolla Royalty Agreement prior to our acquisition, La Jolla paid $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">18.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">aggregate royalties to HCR. In the event that we fail to pay such amount if and when due in a timely manner, HCR would have the right to foreclose on the GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">-related assets. HCR has no recourse against any asset other than GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Certain contract provisions within the La Jolla Royalty Agreement that could result in an acceleration of amounts due under the La Jolla Royalty Agreement are recognized as embedded derivatives that require bifurcation from the deferred royalty obligation and fair value recognition. We determined the fair value of each derivative by assessing the probability of each event occurring, as well as the potential repayment amounts and timing of such repayments that would result under various scenarios. As a result of this assessment, we determined that the fair value of the embedded derivatives is immaterial and, therefore, not recognized as of December 31, 2023 and 2022. We estimate the fair value of the embedded derivatives for each reporting period until either the features lapse or the La Jolla Royalty Agreement is terminated, whichever occurs first. Any material change in the fair value of the embedded derivatives will be recorded as either a gain or loss in the consolidated statements of income.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//470/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430386529680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">13. COMMITMENTS AND CONTINGENCIES</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Operating Lease</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have operating leases for our corporate headquarters, office spaces and laboratory facilities.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our operating leases include a facility lease consisting of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">20,062</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> square feet of office and laboratory space in Waltham, Massachusetts. Effective April 2022, we exercised our renewal option for to extend the lease term for three additional years through December 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In 2019, we entered into an operating lease for our headquarters in Burlingame, California for approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,111</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> rentable square feet. The lease commenced in November 2019 with an initial term of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_7da350c6-153c-485b-808f-be5a8394009e;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">thirty-six</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> calendar months, which was subsequently amended to expire in December 2027.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The components of lease costs are as follows:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:67.313%;"></td>
        <td style="width:1.5%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.843%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.5%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.843%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Straight line operating lease costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,428</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,585</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Variable lease costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">189</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">155</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total lease costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,617</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,740</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Supplemental cash flow information related to leases are as follows:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:67.313%;"></td>
        <td style="width:1.5%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.843%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.5%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.843%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash paid for amounts included in the measurement of <br/>&#160;&#160;&#160;operating lease liabilities:</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,542</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">790</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease right-of-use assets obtained in exchange <br/>&#160;&#160;&#160;for operating lease obligations</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,323</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Right-of-use assets obtained through acquisitions</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,185</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, our operating leases have weighted-average remaining term of approximately </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2.3</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years and the weighted-average discount rate on our operating lease liabilities was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">7.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have not presented the comparative information above for the year ended December 31, 2021 as our operating lease during this year was not material.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Future minimum lease payments on our operating leases as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 are as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:80.444%;"></td>
        <td style="width:1.8%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.757%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Year ending December 31,</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,373</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,428</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2026</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">143</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Thereafter</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">149</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total undiscounted lease payments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,093</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: imputed interest</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">251</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">    </span><span><span style="-sec-ix-hidden:F_4335f0ee-8c74-4e0b-beba-133f49c7dc56;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  Total operating lease liabilities</span></span></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,842</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Legal Proceedings</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From time to time, the Company is involved in legal proceedings in the ordinary course of its business. We are not currently a party to any material legal proceedings except as discussed below.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On February 15, 2022, La Jolla received a paragraph IV notice of certification (the &#8220;First Notice Letter&#8221;) from Gland Pharma Limited (&#8220;Gland&#8221;) advising that Gland had submitted an Abbreviated New Drug Application (&#8220;ANDA&#8221;) to the FDA seeking approval to manufacture, use or sell a generic version of GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in the U.S. prior to the expiration of U.S. Patent Nos.: 9,220,745; 9,572,856; 9,867,863; 10,028,995; 10,335,451; 10,493,124; 10,500,247; 10,548,943; 11,096,983; and 11,219,662 (the &#8220;GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Patents&#8221;), which are listed in the FDA&#8217;s Approved Drug Products with Therapeutic Equivalence Evaluations (the &#8220;Orange Book&#8221;). The First Notice Letter alleges that the GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Patents are invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of the generic product described in Gland&#8217;s ANDA.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On March 29, 2022, La Jolla filed a complaint for patent infringement of the GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Patents against Gland and certain related entities in the United States District Court for the District of New Jersey in response to Gland&#8217;s ANDA filing. In accordance with the Hatch-Waxman Act, because GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> is a new chemical entity and La Jolla filed a complaint for patent infringement within 45 days of receipt of the First Notice Letter, the FDA cannot approve Gland&#8217;s ANDA any earlier than 7.5 years from the approval of the GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> NDA unless the District Court finds that all of the asserted claims of the patents-in-suit are invalid, unenforceable and/or not infringed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On February 22, 2023, La Jolla received a paragraph IV notice of certification (the &#8220;Second Notice Letter&#8221;) from Gland advising that Gland had amended its ANDA filing to include a paragraph IV certification alleging that all claims of the newly-issued and Orange Book-listed U.S. Patent No. 11,559,559 (&#8220;the &#8217;559 Patent&#8221;), which covers GIAPREZA&#174;, are invalid, unenforceable and/or not infringed.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On March 22, 2023, La Jolla filed a First Amended Complaint in this litigation adding Gland&#8217;s marketing and distribution partners for its ANDA angiotensin II product, Fresenius Kabi USA LLC and Fresenius Kabi SwissBiosim GmbH (collectively, the &#8220;Fresenius Kabi Defendants&#8221;), as co-defendants. On April 7, 2023, La Jolla filed a Second Amended Complaint in response to the Second Notice Letter, adding claims that the manufacture, use, sale, offer for sale, or import of Gland&#8217;s ANDA angiotensin II product will infringe the &#8217;559 Patent. On November 14, 2023, La Jolla filed a Third Amended Complaint adding additional infringement claims against the Fresenius Kabi Defendants. We intend to vigorously enforce our intellectual property rights relating to GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fact discovery is set to conclude on February 29, 2024 and expert discovery will be complete by July 12, 2024. A trial date has not yet been set in this matter.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Given the early stage of this matter, we cannot reasonably estimate a potential future loss or a range of potential future losses, if any, and have not recorded a contingent liability accrual as of December 31, 2023.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Indemnifications and Other Contingencies</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the ordinary course of business, we may provide indemnifications of varying scope and terms to vendors, directors, officers, and other parties with respect to certain matters, including, but not limited to, losses arising out of breach of such agreements, services to be provided by us, our negligence or willful misconduct, violations of law, or intellectual property infringement claims made by third parties. In addition, we have entered into indemnification agreements with directors and certain officers and employees that will require us, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors, officers, or employees. No material demands have been made upon us to provide indemnification under such agreements, and thus, there are no claims that we are aware of that could have a material effect in our consolidated financial statements. We also maintain director and officer insurance, which may cover certain liabilities arising from our obligation to indemnify our directors. To date, we have not incurred any material costs and, as of December 31, 2023, we have not accrued any liabilities in the consolidated financial statements as a result of these provisions.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430386532912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">14. INCOME TAXES</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Income tax expense consists of the following:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:51.311%;"></td>
        <td style="width:1.481%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.75%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.481%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.75%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.481%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.75%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,799</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">40,822</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,177</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">464</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total current</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,976</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">41,286</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="text-indent:10pt;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,594</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">26,026</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">70,893</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,194</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">625</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,539</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,400</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,401</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">76,432</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="text-indent:5pt;vertical-align:bottom;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total income tax expense, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,376</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">66,687</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">76,439</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The impacts of the differences between the expected U.S. federal statutory income tax to our income tax expense are as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:51.311%;"></td>
        <td style="width:1.481%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.75%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.481%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.75%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.481%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.75%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected tax at federal statutory rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">40,747</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">58,928</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">93,507</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State income tax, net of federal benefit</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,433</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,414</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">848</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal and state research credits</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,582</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,453</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,260</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 250 deduction</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,274</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Noncontrolling interest</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,468</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21,626</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Impact of consolidation and deconsolidation of subsidiaries</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,897</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,219</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">125</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,129</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,167</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,180</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,321</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total income tax expense, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,376</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">66,687</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">76,439</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Significant components of our deferred tax assets and deferred tax liabilities are as follows:</span></span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:56.36%;"></td>
        <td style="width:2%;"></td>
        <td style="width:1%;"></td>
        <td style="width:17.82%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2%;"></td>
        <td style="width:1%;"></td>
        <td style="width:17.82%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax assets</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">182,013</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">149,646</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development tax credit carryforwards</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21,357</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21,230</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unrealized loss on investment, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,032</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred royalty obligation, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,084</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17,404</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,467</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,527</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred tax assets before valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">227,921</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">202,839</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">169,249</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">144,808</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">58,672</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">58,031</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax liabilities</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Depreciation and amortization</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">39,064</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">50,587</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unrealized gain on investment, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,747</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inventory fair value adjustment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,424</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,410</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">805</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net deferred tax liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">563</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,771</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We record deferred tax assets if the realization of such assets is more likely than not to occur. Significant management judgment is required in determining whether a valuation allowance against the deferred tax assets is required. We have considered all available evidence, both positive and negative, such as our historical operating results and predictability of future taxable income, in making such determination. We are also required to exercise significant management&#8217;s judgment in forecasting future taxable income. Specifically, we evaluate the following criteria when considering a valuation allowance:</span></p><div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the history of tax net operating losses in recent years;</span></div></div><div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">predictability of operating results;</span></div></div><div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">profitability for a sustained period of time; and</span></div></div><div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">level of profitability on a quarterly basis.</span></div></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we had federal net operating loss carryforwards of approximately </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">543.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, which will expire beginning 2034. As of December 31, 2023, we also had state net operating loss carryforwards of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> billion</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, which will expire beginning 2029 and state research tax credits of approximately </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">33.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, which do not expire.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Utilization of net operating loss and tax credit carryforwards may be subject to a substantial annual limitation due to ownership change limitations provided by the Internal Revenue Code and similar state provisions. Annual limitations may result in expiration of net operating loss and tax credit carryforwards before some or all of such amounts have been utilized.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We conducted an Internal Revenue Code of 1986, as amended, Section 382 (&#8220;Section 382&#8221;) analysis of the Company through December 31, 2022 to determine whether an ownership change had occurred since inception. The Section 382 study concluded that it is more likely than not that the Company did not experience an ownership change during the testing period. If we ever undergo an ownership change, the utilization of the pre-ownership change net operating loss carryforwards or pre-ownership change tax attributes, such as research tax credits, to offset the post-ownership change income may be subject to an annual limitation, pursuant to Sections 382 and 383 of the Internal Revenue Code of 1986, as amended. Similar rules may apply under state tax laws.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a result of the acquisition of Entasis, we conducted a study of Entasis&#8217; ownership changes and estimated that we will be able to utilize $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">155.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of its federal net operating losses, which are subject to annual limitations.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a result of the acquisition of La Jolla, we also performed an analysis of its ownership changes and estimated that we will be able to utilize $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">309.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of its federal net operating losses, which are subject to annual limitations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our policy is to recognize interest and/or penalties related to income tax matters in income tax expense. As of December 31, 2023 and 2022, we had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> accrued interest or penalties due to the Company</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8217;s net operating losses available to offset any tax adjustments.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Uncertain Tax Positions</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A reconciliation of the beginning and ending balances of the total amounts of unrecognized tax benefits are as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:76.46%;"></td>
        <td style="width:2.34%;"></td>
        <td style="width:1%;"></td>
        <td style="width:19.2%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unrecognized tax benefits as of December 31, 2020</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,185</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net decrease in tax portions for 2021</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">313</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unrecognized tax benefits as of December 31, 2021</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,872</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net increase in tax portions for 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,452</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unrecognized tax benefits as of December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,324</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net increase in tax portions for 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,119</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unrecognized tax benefits as of December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19,443</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are subject to taxation in the U.S. and various state jurisdictions. The tax years 2006 through 2013, 2015 and forward remain open to examination by the federal and most state tax authorities due to net operating loss and overall credit carryforward positions.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2021, the Organization for Economic Cooperation and Development (&#8220;OECD&#8221;) enacted model rules for a new global minimum tax framework (&#8220;BEPS Pillar Two&#8221;), and various governments around the world have enacted, or are in the process of enacting legislation. We are in the process of evaluating whether and when these new rules may come into effect and apply to us.  We plan to treat the tax if any as a period cost. We do not believe that the Pillar Two rules apply to us yet.  As such, the potential future quantitative impact of the enacted or substantively enacted legislation is not yet reasonably estimable.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430386504048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">15. SUBSEQUENT EVENTS</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On February 13, 2024, ITH entered into a Third Note Amendment Agreement with Gate to amend the Gate Convertible Note. Pursuant to the Third Note Amendment Agreement, the principal amount of the Gate Convertible Note was increased from $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">27.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">33.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which represents the principal and accrued interest as of the amendment date and an additional cash investment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. All other material terms of the Gate Convertible Note were unchanged.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On February 23, 2024, ITH purchased a subordinated convertible promissory note (the &#8220;ImaginAb Convertible Note&#8221;) from ImaginAb for a total purchase price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The ImaginAb Convertible Note bears an annual interest of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% and shall be due and payable upon the earlier to occur of January 31, 2025 and certain events defined in the ImaginAb Convertible Note. Under certain circumstances, the ImaginAb Convertible Note is convertible at the option of ITH into ImaginAb&#8217;s equity securities at defined conversion prices. The ImaginAb Convertible Note is subordinate to certain existing indebtedness of ImaginAb as defined in the ImaginAb Convertible Note.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430379351328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_DescriptionOfOperationsPolicyTextBlock', window );">Description of Operations</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Description of Operations</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Innoviva, Inc. (and where context requires, together with its subsidiaries referred to as &#8220;Innoviva&#8221;, the &#8220;Company&#8221;, or &#8220;we&#8221; and other similar pronouns) is a company with a portfolio of royalties and innovative healthcare assets. Our royalty portfolio contains respiratory assets partnered with Glaxo Group Limited (&#8220;GSK&#8221;), including RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(fluticasone furoate/vilanterol, &#8220;FF/VI&#8221;) and ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(umeclidinium bromide/vilanterol, &#8220;UMEC/VI&#8221;), and up until July 2022, TRELEGY</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(the combination FF/UMEC/VI). We sold our </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">15</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% ownership interest in Theravance Respiratory Company, LLC (&#8220;TRC&#8221;) on July 20, 2022, and are no longer entitled to receive royalties on sales of TRELEGY</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> products. Under the Long-Acting Beta2 Agonist (&#8220;LABA&#8221;) Collaboration Agreement, Innoviva is entitled to receive royalties from GSK on sales of RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> as follows: </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">15</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% on the first $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> billion of annual global net sales and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% for all annual global net sales above $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> billion; and royalties from the sales of ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, which tier upward at a range from </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">6.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expanded our portfolio through the acquisition of Entasis Therapeutics Holdings Inc. (&#8220;Entasis&#8221;) on July 11, 2022 and the acquisition of La Jolla Pharmaceutical Company (&#8220;La Jolla&#8221;) on August 22, 2022. Our commercial and marketed products include GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock, and XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (eravacycline) for the treatment of complicated intra-abdominal infections in adults. Our new product, XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(formerly known as sulbactam-durlobactam or SUL-DUR), was approved by the United States Food and Drug Administration (&#8220;FDA&#8221;) for the treatment of hospital-acquired and ventilator-associated pneumonias caused by </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Acinetobacter</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in adults on May 23, 2023. We commenced commercial sales of XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in the third quarter of 2023. Our development pipeline includes zoliflodacin, an investigational treatment for uncomplicated gonorrhea that reported positive data in a pivotal Phase 3 clinical trial on November 1, 2023. As such, we have a wholly owned robust critical care and infectious disease operating platform with a hospital focus anchored by three differentiated products with significant growth potential and a promising drug candidate.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, we own other strategic healthcare assets, such as a large equity stake in Armata Pharmaceuticals, a leader in development of bacteriophages with potential use across a range of infectious and other serious diseases.  We also have economic interests in other healthcare companies.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Principles of Consolidation</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying consolidated financial statements include the accounts of Innoviva, our wholly owned subsidiaries and certain variable interest entities (&#8220;VIE&#8221;) for which we are the primary beneficiary. All intercompany balances and transactions have been eliminated in consolidation. For consolidated entities where we own or are exposed to less than 100% of the economics, we record net income (loss) attributable to noncontrolling interest in our consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entity by the respective noncontrolling party.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_PresentationReclassificationPolicyTextBlock', window );">Presentation Reclassification</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Presentation Reclassification</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Amounts in equity and long-term investments reported in the Company&#8217;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">s comparative financial statements have been reclassified to conform to the current year presentation. Certain reclassifications have been made to the consolidated statement of cash flows for the years ended December 31, 2022 and 2021 to conform to the current year&#8217;s presentation. These reclassifications had no net effect on the net income or net cash flows from operating, investing and financing activities as previously reported.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_FactorsAffectingComparabilityPolicyTextBlock', window );">Factors Affecting Comparability</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Factors Affecting Comparability</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our historical financial condition and results of operations for the periods presented may not be comparable, either between periods or going forward due to the factors below and as discussed in Note 5, &#8220;Consolidated Entities and Acquisitions&#8221;.</span></p><div style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Adoption of Accounting Standards Update 2020-06, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Debt-Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (&#8220;ASU 2020-06&#8221;) effective January 1, 2022;</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accounting consolidation of Entasis on February 17, 2022 and purchase of remaining noncontrolling interest in Entasis on July 11, 2022;</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Sale of our </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">15</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% ownership interest in TRC on July 20, 2022; and</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Acquisition of La Jolla on August 22, 2022.</span></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Management's Estimates</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Management&#8217;s Estimates</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of consolidated financial statements in conformity with U.S. Generally Accepted Accounting Principles (&#8220;U.S. GAAP&#8221;) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ materially from those estimates. Management evaluates its significant accounting policies and estimates on an ongoing basis. We base our estimates on historical experience and other relevant assumptions that we believe to be reasonable under the circumstances. These estimates also form the basis for making judgments about the carrying values of assets and liabilities when these values are not readily apparent from other sources.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk and of Significant Suppliers and Partners</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk and of Significant Suppliers and Partners</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents and equity and long-term investments. Although we deposit our cash with multiple financial institutions, our deposits, at times, may exceed federally insured limits.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> We are dependent on third-party manufacturers to supply active pharmaceutical ingredients (&#8220;API&#8221;) and drug products for research and development and commercial programs. These programs could be adversely affected by significant interruption in the supply of API or drug products.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Currently, we derive most of our revenues from GSK and our near-term success depends in large part on GSK&#8217;s ability to successfully develop and commercialize the products in the respiratory programs partnered with GSK. Our near-term success depends in large part upon the performance by GSK of its commercial obligations under the GSK Agreements and the commercial success of RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. If GSK does not devote sufficient resources to the commercialization or development of these products, is unsuccessful in its efforts, or chooses to reprioritize its commercial programs, our business would be materially harmed. GSK is responsible for all clinical and other product development, regulatory, manufacturing and commercialization activities for products developed under the GSK Agreements, including RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Our royalty revenues may fluctuate due to a variety of factors, many of which are outside of our control. Our royalty revenues under the GSK Agreements may not meet our, analysts&#8217; or investors&#8217; expectations, due to a number of important factors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We started recognizing revenue from product sales of GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in 2022 as a result of our acquisition of La Jolla. In the current year, we also started recognizing revenue from product sales from XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, which was commercially launched in the third quarter of 2023. Hospitals and other healthcare organizations generally purchase our products through a network of specialty distributors. These specialty distributors, which are located in the U.S., are considered our customers for accounting purposes. We do not believe that loss of one of these distributors would significantly impact our ability to distribute our products, as we expect that sales volume would be absorbed by new or remaining distributors. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">Three</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of our customers each account for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">31</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">27</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">27</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%, respectively, of our net product sales for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. These same customers account for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">29</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">19</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">15</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%, respectively, of our receivables from net product sales, which are included in &#8220;Accounts receivables, net&#8221; in our consolidated balance sheet as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Three of our customers each account for approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">33</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">29</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">28</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%, respectively, of our net product sales from the time of our acquisition of La Jolla through December 31, 2022. These same customers account for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">23</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">37</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">37</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%, respectively, of our receivables from net product sales, which are included in &#8220;Accounts receivables, net&#8221; in our consolidated balance sheet as of December 31, 2022.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Segment Reporting</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We operate in a single segment, which is to provide capital return to stockholders by maximizing the potential value of our portfolio of royalties and innovative healthcare assets. Our Chief Operating Decision Maker (&#8220;CODM&#8221;) is our Chief Executive Officer. The CODM allocates resources and evaluates the performance of Innoviva at the consolidated level using information about our revenues, operating results and other key financial data as needed. Our revenues are generated primarily from our collaborative arrangements and royalty payments from GSK, located in Great Britain. We also generate revenue from net product sales of GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Refer to Note 3, &#8220;Revenue Recognition&#8221;, for more information on our revenues for the periods presented. Our long-term assets are located within the United States.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationVariableInterestEntityPolicy', window );">Variable Interest Entities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Variable Interest Entities</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The primary beneficiary of a variable interest entity (&#8220;VIE&#8221;) is required to consolidate the assets and liabilities of the VIE. When we obtain a variable interest in another entity, we assess at the inception of the relationship and upon occurrence of certain significant events whether the entity is a VIE and, if so, whether we are the primary beneficiary of the VIE based on our power to direct the activities of the VIE that most significantly impact the VIE&#8217;s economic performance and our obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To assess whether we have the power to direct the activities of a VIE that most significantly impact the VIE&#8217;s economic performance, we consider all the facts and circumstances, including our role in establishing the VIE and our ongoing rights and responsibilities. This assessment includes identifying the activities that most significantly impact the VIE&#8217;s economic performance and identifying which party, if any, has power over those activities. In general, the parties that make the most significant decisions affecting the VIE (management and representation on the Board of Directors) and have the right to unilaterally remove those decision-makers are deemed to have the power to direct the activities of a VIE.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To assess whether we have the obligation to absorb losses of the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE, we consider all of our economic interests that are deemed to be variable interests in the VIE. This assessment requires us to apply judgment in determining whether these interests, in the aggregate, are considered potentially significant to the VIE.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Business Combination</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Business Combination</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">When we acquire an entity in a business combination, we recognize the fair value of all assets acquired, liabilities assumed, and any non-controlling interest in the acquiree and establish the acquisition date as the fair value measurement point. We recognize and measure goodwill as of the acquisition date, as the excess of the fair value of the consideration paid over the fair value of the identified net assets acquired. Acquisition-related expenses and related restructuring costs are expensed as incurred.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Several valuation methods may be used to determine the fair value of assets acquired and liabilities assumed. For intangible assets, we typically use the income method. This method starts with a forecast of all of the expected future net cash flows for each asset. These cash flows are then adjusted to present value by applying an appropriate discount rate that reflects the risk factors associated with the cash flow streams. Some of the more significant estimates and assumptions inherent in the income method or other methods include the amount and timing of projected future cash flows, the discount rate selected to measure the risks inherent in the future cash flows and the assessment of the asset&#8217;s life cycle and the competitive trends impacting the asset, including consideration of any technical, legal, regulatory, or economic barriers to entry. Determining the useful life of an intangible asset also requires judgment as different types of intangible assets will have different useful lives and certain assets may even be considered to have indefinite useful lives.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash and Cash Equivalents</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We consider all highly liquid investments purchased with a maturity of three months or less on the date of purchase to be cash equivalents. Cash equivalents are carried at cost, which approximates fair value.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Accounts Receivable</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accounts receivable are recorded net of estimates for prompt-pay discounts, chargebacks, returns and rebates. Allowances for prompt-pay discounts and chargebacks are based on contractual terms. We estimate the allowance for credit losses based on existing contractual payment terms, actual payment patterns of customers and individual customer circumstances.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Inventory</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Inventory is stated at the lower of cost or estimated net realizable value on a first-in, first-out basis. We periodically analyze inventory levels and write down inventory as cost of products sold when the following occurs: inventory has become obsolete, inventory has a cost basis in excess of its estimated net realizable value, or inventory quantities are in excess of expected product sales.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Property and Equipment</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment, which consisted of laboratory equipment, computer equipment, software, office furniture and fixtures, and leasehold improvements, were not material as of December 31, 2023 and 2022, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment are stated at cost less accumulated depreciation. Property and equipment are depreciated using the straight-line method </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">over the estimated useful lives of the respective assets as follows:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
        <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
         <tr style="visibility:collapse;">
          <td style="width:49.17%;"></td>
          <td style="width:1.66%;"></td>
          <td style="width:49.17%;"></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Leasehold improvements</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shorter of remaining lease terms or useful life</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Laboratory equipment, furniture and fixtures</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#8211; </span><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7 years</span></span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Software and computer equipment</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3 years</span></span></p></td>
         </tr>
        </table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsPolicy', window );">Equity and Long-Term Investments</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Equity and Long-Term Investments</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We invest from time to time in equity and debt securities of private or public companies. If we determine that we have control over these companies under either voting or VIE models, we consolidate them in our consolidated financial statements. If we determine that we do not have control over these companies under either voting or VIE models, we then determine if we have an ability to exercise significant influence via voting interests, board representation or other business relationships.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may account for the investments where we exercise significant influence using either an equity method of accounting or at fair value by electing the fair value option under Accounting Standards Codification (&#8220;ASC&#8221;) Topic 825, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Financial Instruments</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. If the fair value option is applied to an investment that would otherwise be accounted for under the equity method, we apply it to all our financial interests in the same entity (equity and debt, including guarantees) that are eligible items. All gains and losses from fair value changes, unrealized and realized, are presented as changes in fair values of equity method investments, net, and changes in fair values of equity and long-term investments, net, within the consolidated statements of income.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we conclude that we do not have an ability to exercise significant influence over an investee, we may elect to account for the security without a readily determinable fair value using the measurement alternative method under ASC 321, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Investments &#8211; Equity Securities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. This measurement alternative method allows us to measure the equity investment at its cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We also invest in ISP Fund LP, which investments consist of money market funds and equity and debt securities in the healthcare, pharmaceutical and biotechnology industries. Pursuant to the Partnership Agreement entered in December 2020, we became a limited partner of this partnership, and our contributions are subject to a 36-month lock-up period, which restriction prevents us from having control and access to the contributions and related investments. The lock-up period for a certain portion of our contributions expired in December 2023. Strategic Partners did not elect to make a withdrawal in 2023, thereby extending the lock-up period and withdrawal elections into subsequent years. These investments are classified as long-term investments in the consolidated balance sheets.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Value of Financial Instruments</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We define fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our valuation techniques are based on observable and unobservable inputs. Observable inputs reflect readily obtainable data from independent sources, while unobservable inputs reflect our market assumptions. We classify these inputs into the following hierarchy:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Level 1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8212;Quoted prices for identical instruments in active markets.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Level 2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8212;Quoted prices for similar instruments in active markets; quoted prices for identical 3or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Level 3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8212;Unobservable inputs and little, if any, market activity for the assets.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments include cash equivalents, accounts receivable, receivables from collaborative arrangements, accounts payable, and accrued liabilities, equity investments and convertible promissory notes. The carrying values of cash equivalents, receivables from collaborative arrangements, accounts payable, and accrued liabilities approximate their estimated fair values due to the relatively short-term nature of these instruments.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_CapitalizedFeesPaidPolicyTextBlock', window );">Capitalized Fees Paid</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Capitalized Fees Paid</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We capitalize fees paid to licensors related to agreements for approved products or commercialized products. We capitalize these fees as capitalized fees paid (&#8220;Capitalized Fees&#8221;) and amortize them on a straight-line basis over their estimated useful lives upon the commercial launch of the product, shortly after its regulatory approval. The estimated useful lives of these Capitalized Fees are determined on a country-by-country and product-by-product basis, as the later of the expiration or termination of the last patent right covering the compound in such product in such country and </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">15 years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> from first commercial sale of such product in such country, unless the Collaboration Agreement is terminated earlier. Consistent with our policy for classification of costs under the research and development collaborative arrangements, the amortization of these Capitalized Fees is recognized as a reduction of royalty revenue. We review our Capitalized Fees for impairment on a product-by-product basis for each major geographic area when events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. The recoverability of Capitalized Fees is measured by comparing the asset&#8217;s carrying amount to the expected undiscounted future cash flows that the asset is expected to generate. The determination of recoverability typically requires various estimates and assumptions, including estimating the useful life over which cash flows will occur, their amount, and the asset&#8217;s residual value, if any. We derive the required cash flow estimates from near-term forecasted product sales and long-term projected sales in the corresponding market.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Goodwill and Intangible Assets</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Goodwill and Intangible Assets</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Goodwill is recognized as the excess of the purchase consideration of an acquired entity over the fair value assigned to assets acquired and liabilities assumed in a business combination. Goodwill and intangible assets with indefinite useful life are not amortized and are tested for impairment at least annually on the first day of December of each year</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> or more frequently if indicators for potential impairment exist or whenever events or changes in circumstances indicate that the asset&#8217;s carrying asset amount may not be recoverable. Intangible assets with definite useful lives are amortized on a straight-line basis over their respective remaining useful lives and are tested for impairment only if indicators for potential impairment exist or whenever events or changes in circumstances indicate that the asset&#8217;s carrying amount may not be recoverable. Significant judgment may be involved in determining if an indicator of impairment has occurred.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Operating Leases</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Operating Leases</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Right-of-use assets represent our right to use an underlying asset over the lease term and include any lease payments made prior to the lease commencement date and are reduced by lease incentives. Lease liabilities represent the present value of the total lease payments over the lease term, calculated using an estimated incremental borrowing rate. Lease expense is recognized on a straight-line basis over the expected lease term.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue Recognition</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We apply the guidance on principal versus agent considerations under ASC Topic 606, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue from Contracts with Customers</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, to determine the appropriate treatment for the transactions between us and third parties. The classification of transactions under our arrangements is determined based on the nature and contractual terms of the arrangement along with the nature of the operations of the participants. Any consideration related to activities in which we are considered the principal, which includ</span><span style="color:#252525;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">es being in control of the good or service before such good or service is transferred to the customer, are accounted for as product sales.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Revenue is recognized when our customer obtains control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. Revenue is recognized through a five-step process: (i) identify the contract with the customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price for the contract; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue as a performance obligation is satisfied.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Royalty Revenue</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We recognize the royalty revenue on net sales of products with respect to which we have contractual royalty rights in the period in which the royalties are earned. The net sales reports provided by our partner are based on its methodology and assumptions to estimate rebates and returns, which it monitors and adjusts regularly in light of contractual and legal obligations, historical trends, past experience and projected market conditions. Our partner may make significant adjustments to its sales based on actual results recorded, which could cause our royalty revenue to fluctuate. We conduct periodic royalty audits to evaluate the information provided by our partner. Royalties are recognized net of amortization of capitalized fees associated with any approval and launch milestone payments made to GSK.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue from Product Sales</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Revenue from product sales is recognized when our customers obtain control of the product and is recorded at the transaction price, net of estimates for variable consideration consisting of chargebacks, discounts, returns and rebates. Variable consideration is estimated using the expected-value amount method, which is the sum of probability-weighted amounts in a range of possible consideration amounts. Actual amounts of consideration ultimately received may differ from our estimates. If actual results vary materially from our estimates, we will adjust these estimates, which will affect revenue from product sales and earnings in the period such estimates are adjusted. These items may include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Chargebacks: Chargebacks are discounts we provide to distributors in the event that the sales prices to end users are below the distributors&#8217; acquisition price. This may occur due to a direct contract with a health system, a group purchasing organization (&#8220;GPO&#8221;) agreement or a sale to a government facility. Chargebacks are estimated based on known chargeback rates and recorded as a reduction of revenue on delivery to our customers.</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Discounts: We offer customers various forms of incentives and consideration, including prompt-pay and other discounts. We estimate discounts primarily based on contractual terms. These discounts are recorded as a reduction of revenue on delivery to our customers.</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Returns: We offer customers a limited right of return, generally for damaged or expired product. We estimate returns based on an internal analysis, which includes actual experience. The estimates for returns are recorded as a reduction of revenue on delivery to our customers. </span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Rebates: We participate in Medicaid rebate programs, which provide assistance to certain low-income patients based on each individual state&#8217;s guidelines regarding eligibility and services. Under the Medicaid rebate programs, we pay a rebate to each participating state, generally within three months after the quarter in which product was sold. Additionally, we may offer customer incentives and consideration in the form of volume-based or other rebates. The estimates for rebates are recorded as a reduction of revenue on delivery to our customers. </span></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We continue to assess our estimates of variable consideration as we accumulate additional historical data and will adjust these estimates accordingly.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">License Revenue</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At the inception of a licensing arrangement that includes development and regulatory milestone payments, we evaluate whether the milestones are considered probable of being achieved and estimate the amount to be included in the transaction price. We generally recognize these milestone payments as revenues when they are achieved because there is considerable uncertainty in the research and development processes that trigger receipt of these payments under our agreements. Similarly, we recognize regulatory approval milestone payments as revenues once the product is approved by the applicable regulatory agency.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development Expenses</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development expenses are recognized in the period that services are rendered or goods are received. Research and development expenses consist of salaries and benefits, laboratory supplies, facilities and other overhead costs, research-related manufacturing costs, contract service and clinical-related service costs performed by third party research organizations, research institutions and other outside service providers. Non-refundable prepayments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are recognized as an expense as the related goods are delivered or the related services are performed. We also utilize significant judgment and estimates to record accruals for estimated ongoing research costs based on the progress of the studies and progress of research manufacturing activities.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpensePolicyTextBlock', window );">Interest Expense on Deferred Royalty Obligation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Interest Expense on Deferred Royalty Obligation</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Interest expense related to the deferred royalty obligation is recognized over the expected repayment term of the deferred royalty obligation using the effective interest method. The assumptions used in determining the expected repayment term of the deferred royalty obligation require us to make estimates that could impact the effective interest rate. Each reporting period, we estimate the expected repayment term of the deferred royalty obligation based on forecasted net sales of GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Changes in interest expense resulting from changes in the effective interest rate, if any, are recorded on a prospective basis. Refer to Note 12, &#8220;Debt&#8221;, for more information.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Fair Value of Stock-Based Compensation Awards</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Value of Stock&#8209;Based Compensation Awards</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We use the Black-Scholes-Merton option pricing model to estimate the fair value of options granted under our equity incentive plans and rights to acquire stock granted under our employee stock purchase plan (&#8220;ESPP&#8221;). The Black-Scholes-Merton option valuation model requires the use of assumptions, including the expected term of the award and the expected stock price volatility. We use the &#8220;simplified&#8221; method as described in Staff Accounting Bulletin No. 107, &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Share-Based Payment</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">,&#8221; for the expected option term. We use our historical volatility to estimate expected stock price volatility.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Restricted stock units (&#8220;RSUs&#8221;) and restricted stock awards (&#8220;RSAs&#8221;) are measured based on the fair market values of the underlying stock on the dates of grant.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock-based compensation expense is calculated based on awards ultimately expected to vest and is reduced for estimated forfeitures at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differed from those estimates. Our estimated annual forfeiture rates for stock options, RSUs and RSAs are based on our historical forfeiture experience.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The estimated fair value of stock options, RSUs and RSAs is expensed on a ratable or straight-line basis over the expected term of the grant or expected term of the vesting. Compensation expense is recorded over the requisite service period based on management&#8217;s best estimate as to whether it is probable that the shares awarded are expected to vest.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Compensation expense for purchases under the ESPP is recognized based on the fair value of the common stock on the date of offering, less the purchase discount percentage provided for in the plan.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We utilize the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and the tax basis of assets and liabilities and are measured using enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The recognition and measurement of tax benefits requires significant judgment. Our judgment might change as new information becomes available. We continue to evaluate our deferred tax assets each reporting period to determine whether adjustments to our valuation allowance are required and deferred tax assets will be realized based on the consideration of all available positive and negative evidence, including the differences between our anticipated and actual future operating results, using a &#8220;more likely than not&#8221; standard.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We assess all material positions taken in any income tax return, including all significant uncertain positions, in all tax years that are still subject to assessment or challenge by relevant taxing authorities. Assessing an uncertain tax position begins with the initial determination of the position&#8217;s sustainability and is measured at the largest amount of benefit that is greater than 50% likely to be realized upon ultimate settlement. As of each balance sheet date, unresolved uncertain tax positions must be reassessed, and we determine whether the factors underlying the sustainability assertion have changed and whether the amount of the recognized tax benefit is still appropriate.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_RelatedPartyTransactionsPolicyTextBlock', window );">Related Parties</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Related Parties</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Transactions with GSK were considered related party transactions up until May 2021, when we completed the share repurchase agreement with GSK to buy back all of its shares of common stock in Innoviva. GSK is no longer considered a related party after the completion of the share repurchase. Transactions with GSK are described in Note 3, &#8220;Revenue Recognition and Collaborative Arrangements.&#8221;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Sarissa Capital ow</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ned </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">11.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of o</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ur outstanding common stock as of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Transactions with Sarissa Capital are described in Note 5, &#8220;Consolidated Entities and Acquisitions&#8221;. Sarissa Capital is considered to be a related party because two of its principals are members of our board of directors.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Pronouncements Not Yet Adopted</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recently Issued Accounting Pronouncements Not Yet Adopted</span><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In October 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued ASU 2023-06, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Disclosure Improvements: Codification Amendments in Response to the SEC&#8217;s Disclosure Update and Simplification Initiative</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The amendment modifies the disclosure or presentation requirements for a variety of topics. The effective date for each amendment will be the date on which the SEC&#8217;s removal of that related disclosure from Regulation S-X or Regulation S-K becomes effective. The Company does not expect the adoption of the amendments to have a significant impact on its financial statements.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2023, the FASB issued ASU 2023-07, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Improvements to Reportable Segment Disclosures (Topic 280).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> This ASU update requires enhanced segment disclosures, primarily related to significant segment expenses. The amendments are effective for fiscal years beginning after December 15, 2023, and interim periods beginning after December 15, 2024. The Company does not expect the adoption of the amendments to have a significant impact on its financial statements.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2023, the FASB issued ASU 2023-09, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Improvements to Income Tax Disclosures (Topic 740)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The ASU requires the disclosure of income taxes paid disaggregated by jurisdiction and enhanced disclosures for the entity&#8217;s effective tax rate reconciliation as well as other income tax related disclosures. The ASU is effective on a prospective basis for annual periods beginning after December 15, 2024. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company does not expect the adoption of the amendments to have a significant impact on its financial statements.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_CapitalizedFeesPaidPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Capitalized fees paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_CapitalizedFeesPaidPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_DescriptionOfOperationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_DescriptionOfOperationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_FactorsAffectingComparabilityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Factors affecting comparability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_FactorsAffectingComparabilityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_PresentationReclassificationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Presentation reclassification.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_PresentationReclassificationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_RelatedPartyTransactionsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Describes the entity's accounting policies for transactions entered with related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_RelatedPartyTransactionsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479515/805-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480981/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationVariableInterestEntityPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-5A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2AA<br> -Subparagraph a<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-2AA<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationVariableInterestEntityPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21D<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-21D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 60<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482053/820-10-60-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpensePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing interest expense, including the method of amortizing debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 3<br> -SubTopic 10<br> -Topic 835<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482914/835-10-05-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpensePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 330<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482105/912-330-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//330/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482989/270-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481569/310-20-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-11B<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-6<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430386648864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_PropertyPlantAndEquipmentUsefulLifeTableTextBlock', window );">Schedule of property, equipment and leasehold improvements useful lives</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment are stated at cost less accumulated depreciation. Property and equipment are depreciated using the straight-line method </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">over the estimated useful lives of the respective assets as follows:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
        <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
         <tr style="visibility:collapse;">
          <td style="width:49.17%;"></td>
          <td style="width:1.66%;"></td>
          <td style="width:49.17%;"></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Leasehold improvements</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shorter of remaining lease terms or useful life</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Laboratory equipment, furniture and fixtures</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#8211; </span><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7 years</span></span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Software and computer equipment</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3 years</span></span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_PropertyPlantAndEquipmentUsefulLifeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the useful life of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_PropertyPlantAndEquipmentUsefulLifeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430386669392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET INCOME PER SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of computation of basic and diluted net income per share</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table shows the computation of basic and diluted net income per share for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023, 2022 and 2021:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:51.311%;"></td>
        <td style="width:1.481%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.75%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.481%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.75%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.481%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.75%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands except per share data)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Numerator:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net income attributable to Innoviva stockholders, basic</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">179,722</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">213,921</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">265,854</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Add: interest expense on 2023 Notes, net of tax effect</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">89</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,439</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,736</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Add: interest expense on 2025 Notes, net of tax effect</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,116</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,583</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Add: interest expense on 2028 Notes, net of tax effect</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,377</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,626</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net income attributable to Innoviva stockholders, diluted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">191,304</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">225,569</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">270,590</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Denominator:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average shares used to compute basic net income<br/>&#160;&#160;&#160;per share attributable to Innoviva stockholders</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">65,435</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">69,644</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">82,062</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Dilutive effect of 2023 Notes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">187</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,188</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,189</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Dilutive effect of 2025 Notes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,150</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,150</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Dilutive effect of 2028 Notes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,955</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,158</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Dilutive effect of options and awards granted under equity<br/>&#160;&#160;&#160;incentive plan and employee stock purchase plan</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">149</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">108</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">59</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average shares used to compute diluted net income<br/>&#160;&#160;&#160;per share attributable to Innoviva stockholders</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">86,876</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">95,248</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">94,310</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net income per share attributable to Innoviva stockholders</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Basic</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.75</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.07</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.24</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Diluted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.20</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.37</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.87</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of anti-dilutive securities</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following common stock equivalents were not included in the computation of diluted net income per share because their effect was anti&#8209;dilutive for the periods presented:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:51%;"></td>
        <td style="width:1.8%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.2%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.2%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.799999999999999%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding options and awards granted under equity incentive<br/>&#160;&#160;&#160;plan and employee stock purchase plan</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,333</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">648</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">979</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding stock warrant</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">591</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">282</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,924</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">930</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">979</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430386589072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE RECOGNITION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of net revenue from collaborative arrangements</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net revenue recognized under our GSK Agreements was as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:51.311%;"></td>
        <td style="width:1.481%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.75%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.481%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.75%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.481%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.75%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Royalties &#8211; RELVAR/BREO</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">208,042</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">215,034</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">234,066</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Royalties &#8211; ANORO</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">44,627</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">38,405</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">44,935</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Royalties &#8211; TRELEGY</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(1)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">72,029</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">126,688</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total royalties</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">252,669</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">325,468</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">405,689</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: amortization of capitalized<br/>&#160;&#160;&#160;fees paid</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,823</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,823</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,823</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total royalty revenue</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">238,846</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">311,645</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">391,866</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">(1)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">   The year ended December 31, 2022 represents the period from January 1, 2022 to July 20, 2022, the date of the sale of our ownership interest in TRC.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430388081296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED ENTITIES AND ACQUISITIONS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ConsolidatedEntitiesAndAcquisitionsLineItems', window );"><strong>Consolidated Entities and Acquisitions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock', window );">Pro Forma Information</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table presents certain unaudited pro-forma financial information for the years ended December 31, 2022 and 2021 as if the consolidation of Entasis and La Jolla occurred on January 1, 2021. The unaudited pro forma financial information is presented for informational purposes only, and is not indicative of the results of operations that would have been achieved if the acquisitions had taken place on January 1, 2021, or of results that may occur in the future. The unaudited pro forma financial information combines the historical results of the Entasis and La Jolla with the Company&#8217;s consolidated historical results and includes certain adjustments including, but not limited to, fair value adjustments to equity investments in Entasis&#8217; common stock and warrants, fair value adjustments to inventory, amortization of intangible assets, and interest expense on deferred royalty obligations and acquisition-related costs.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:53.88%;"></td>
        <td style="width:2.26%;"></td>
        <td style="width:1%;"></td>
        <td style="width:18.799999999999997%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.26%;"></td>
        <td style="width:1%;"></td>
        <td style="width:18.799999999999997%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Revenue</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">357,880</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">435,398</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net income</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">204,987</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">281,719</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net income attributable to Innoviva stockholders</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">214,390</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">197,535</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=inva_EntasisTherapeuticsHoldingsIncMember', window );">Entasis Therapeutics Holdings Inc</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ConsolidatedEntitiesAndAcquisitionsLineItems', window );"><strong>Consolidated Entities and Acquisitions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table represents the adjusted fair values of the assets acquired and liabilities assumed by us in the transaction:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:80.444%;"></td>
        <td style="width:1.8%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.757%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">February 17, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23,070</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,554</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other current assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,959</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Property and equipment, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">185</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Right-of-use assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">959</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Goodwill</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,493</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Intangible assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">106,700</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">302</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets acquired</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">150,222</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts payable</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,583</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued personnel-related expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,058</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other accrued liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,096</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,769</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total liabilities assumed</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,506</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets acquired, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">134,716</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=inva_LaJollaPharmaceuticalCompanyMember', window );">La Jolla Pharmaceutical Company</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ConsolidatedEntitiesAndAcquisitionsLineItems', window );"><strong>Consolidated Entities and Acquisitions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table represents the adjusted fair values of assets acquired and liabilities assumed by us in the transaction:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:80.444%;"></td>
        <td style="width:1.8%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.757%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">August 22, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">47,415</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Short-term marketable securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">471</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts receivable</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,876</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inventory</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">66,200</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,261</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other current assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">907</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Property and equipment, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Right-of-use assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">226</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Goodwill</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,411</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Intangible assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">151,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,461</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">710</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets acquired</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">287,951</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts payable</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,237</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred revenue</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,849</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other accrued liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,362</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other long-term liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">65,944</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total liabilities assumed</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">81,392</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets acquired, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">206,559</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=inva_TheravanceRespiratoryCompanyLlcMember', window );">Theravance Respiratory Company, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ConsolidatedEntitiesAndAcquisitionsLineItems', window );"><strong>Consolidated Entities and Acquisitions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock', window );">Schedule of Balance Sheets and Income Statements of VIE</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The summarized financial information of TRC </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">for the relevant periods through the sale date in 2022 are presented as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Income statements</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:61.232%;"></td>
        <td style="width:1.78%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.603%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.78%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.603%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;min-width:fit-content;">&#160;(1)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Royalty revenue</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">72,029</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">126,688</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">332</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,956</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Income from operations</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">71,697</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">122,732</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other income, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Realized loss</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">39,386</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Income tax expense, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Changes in fair values of equity and<br/>&#160;&#160;&#160;long-term investments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,884</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,541</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net income</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23,438</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">121,191</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">(1)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">   The year ended December 31, 2022 represents the period from January 1, 2022 to July 20, 2022, the date of the sale of our ownership interest in TRC.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_ConsolidatedEntitiesAndAcquisitionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Consolidated entities and acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_ConsolidatedEntitiesAndAcquisitionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -SubTopic 10<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -SubTopic 10<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Paragraph 1<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-5A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-9<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfVariableInterestEntitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=inva_EntasisTherapeuticsHoldingsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=inva_EntasisTherapeuticsHoldingsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=inva_LaJollaPharmaceuticalCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=inva_LaJollaPharmaceuticalCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=inva_TheravanceRespiratoryCompanyLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=inva_TheravanceRespiratoryCompanyLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430384351952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Schedule of amortized cost and estimated fair values for available-for-sale securities</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The estimated fair value of available-for-sale securities is based on quoted market prices for these or similar investments that were based on prices obtained from a commercial pricing service. Available-for-sale securities are summarized below:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:36.867%;"></td>
        <td style="width:1.56%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.222000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.56%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.222000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.56%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.222000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.56%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.222000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gains</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Losses</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(1)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">170,706</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">170,706</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">170,706</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">170,706</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:9pt;font-family:Times New Roman;transform-origin:top left;min-width:3.333%;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Money market funds are included in cash and cash equivalents in the consolidated balance sheets.</span></div></div>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:36.867%;"></td>
        <td style="width:1.56%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.222000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.56%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.222000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.56%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.222000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.56%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.222000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gains</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Losses</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(1)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">263,469</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">263,469</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">263,469</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">263,469</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:9pt;font-family:Times New Roman;transform-origin:top left;min-width:3.333%;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Money market funds are included in cash and cash equivalents in the consolidated balance sheets.</span></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Schedule of available-for-sale securities measured at fair value on a recurring basis</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our available-for-sale securities, equity and long-term investments and contingent value rights are measured at fair value on a recurring basis and our debt is carried at amortized cost basis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:36.867%;"></td>
        <td style="width:1.56%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.222000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.56%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.222000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.56%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.222000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.56%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.222000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated Fair Value Measurements as of December 31, 2023 Using:</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Quoted Price<br/>in Active<br/>Markets for</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant<br/>Other</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Identical</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Observable</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unobservable</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Types of Instruments</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Assets</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Inputs</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Inputs</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 1</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 2</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 3</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">Assets</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">170,706</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">170,706</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Investments held by ISP Fund LP </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(1)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">251,207</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">60,605</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">311,812</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Equity investment - Armata Common Stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">81,249</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">81,249</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Equity investment - Armata Warrants</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35,297</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35,297</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Convertible debt investment - Armata Note</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">51,883</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">51,883</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Term loan investment - Armata Term Loan</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27,044</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27,044</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Convertible debt investment - Gate Note</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27,972</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27,972</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets measured at estimated fair value</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">503,162</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35,297</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">167,504</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">705,963</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">Liabilities</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Debt</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025 Notes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">200,407</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">200,407</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2028 Notes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">227,070</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">227,070</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;Total fair value of debt</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">427,477</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">427,477</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Contingent value rights</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">359</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">359</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total liabilities at estimated fair value</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">427,477</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">359</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">427,836</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:9pt;font-family:Times New Roman;transform-origin:top left;min-width:3.333%;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The investments held by ISP Fund LP, consisted of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">248.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in equity investments, which included private placement positions of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">60.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">62.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in money market funds. A certain portion of the total capital contribution of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">300.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million is no longer subject to a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">36-month</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> lock-up period from the date of such capital contribution. However, we did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t elect to make a withdrawal in 2023, thereby extending the lock-up period and withdrawal elections into subsequent years. </span></div></div>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:36.867%;"></td>
        <td style="width:1.56%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.222000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.56%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.222000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.56%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.222000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.56%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.222000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated Fair Value Measurements as of December 31, 2022 Using:</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Quoted Price</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">in Active</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Markets for</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Other</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Identical</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Observable</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unobservable</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Types of Instruments</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Assets</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Inputs</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Inputs</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 1</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 2</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 3</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">Assets</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">263,469</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">263,469</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Investments held by ISP Fund LP </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(1)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">265,982</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">54,578</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">320,560</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Equity investment - Armata Common Stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31,095</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31,095</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Equity investment - Armata Warrants</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,059</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,059</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Equity investment - InCarda Warrants</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">605</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">605</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Convertible debt investment - Gate Note</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,700</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,700</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets measured at estimated fair value</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">560,546</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,059</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">70,883</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">639,488</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">Debt</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2023 Notes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">96,089</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">96,089</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025 Notes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">197,807</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">197,807</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2028 Notes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">211,768</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">211,768</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total fair value of debt</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">505,664</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">505,664</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Contingent value rights</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">595</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">595</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total liabilities at estimated fair value</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">505,664</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">595</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">506,259</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:9pt;font-family:Times New Roman;transform-origin:top left;min-width:3.333%;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The investments held by ISP Fund LP, consisted of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">295.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in equity investments, which included private placement positions and convertible notes of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">54.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">25.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in money market funds. Our total capital contribution of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">300.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million was subject to a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">36-month</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> lock-up period from the date of such capital contributions.</span></div></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=inva_ArmataPharmaceuticalsIncMember', window );">Armata</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock', window );">Schedule of Balance Sheets and Income Statements of VIE</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The summarized financial information, including the portion we do not own, is presented for Armata on a one quarter lag as follows:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Balance Sheet Information</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:53.88%;"></td>
        <td style="width:2.26%;"></td>
        <td style="width:1%;"></td>
        <td style="width:18.799999999999997%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.26%;"></td>
        <td style="width:1%;"></td>
        <td style="width:18.799999999999997%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">September 30,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">36,585</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">33,245</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Noncurrent assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">76,176</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">59,636</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21,884</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,004</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Noncurrent liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">103,263</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">40,300</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Statement Information</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:51.311%;"></td>
        <td style="width:1.481%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.75%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.481%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.75%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.481%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.75%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Twelve Months Ended</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">September 30,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Revenue</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,052</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,446</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,989</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss from operations</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">41,639</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">32,666</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24,227</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">59,512</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">32,650</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23,732</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=inva_EntasisTherapeuticsHoldingsIncMember', window );">Entasis</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock', window );">Schedule of Balance Sheets and Income Statements of VIE</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The summarized financial information, including the portion we did not own, is presented for Entasis on a one quarter lag regardless of the date of our investments as follows:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Statement Information</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:71.98%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:25.02%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Twelve Months Ended<br/>September 30,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss from operations</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">52,323</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">125,413</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2C<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2C<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-5A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-9<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfVariableInterestEntitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=inva_ArmataPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=inva_ArmataPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=inva_EntasisTherapeuticsHoldingsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=inva_EntasisTherapeuticsHoldingsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430386534496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CAPITALIZED FEES PAID (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAbstract', window );"><strong>Capitalized Contract Cost [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostTableTextBlock', window );">Schedule of Capitalized Fees Paid</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Capitalized fees paid, which consist of registrational and launch-related milestone fees paid to GSK, were as follows:</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:51.311%;"></td>
        <td style="width:1.481%;"></td>
        <td style="width:14.749%;"></td>
        <td style="width:1.481%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.75%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.481%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.75%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortization period</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">United States</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2013-2030</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">120,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">120,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Europe</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2013-2029</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">60,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">60,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Japan</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2013-2029</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">40,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">40,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Gross carrying value</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">220,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">220,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accumulated amortization</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">136,216</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">122,393</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net carrying value</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">83,784</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">97,607</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost capitalized in obtaining or fulfilling contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479483/340-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430386462416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOODWILL AND INTANGIBLE ASSETS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsTableTextBlock', window );">Summary of Accumulated Amortization of Recognized Intangible Assets</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The carrying basis and accumulated amortization of recognized intangible assets as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022 were as follows:</span><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:36.86%;"></td>
        <td style="width:1.56%;"></td>
        <td style="width:14.24%;"></td>
        <td style="width:1.56%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.56%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.56%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.22%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="12" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Useful Life</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Accumulated</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Net Carrying</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Years)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortization</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Marketed products</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">219,700</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,204</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">194,496</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">In-process research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,600</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,600</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Collaboration agreement</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35,400</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,161</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">33,239</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">257,700</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27,365</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">230,335</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:36.86%;"></td>
        <td style="width:1.56%;"></td>
        <td style="width:14.24%;"></td>
        <td style="width:1.56%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.56%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.56%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.22%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="12" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Useful Life</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Accumulated</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Net Carrying</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Years)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortization</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Marketed products</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">151,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,581</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">145,419</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">In-process research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">72,100</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">72,100</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Collaboration agreement</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35,400</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35,400</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">258,500</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,581</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">252,919</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of finite and indefinite lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430385876016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BALANCE SHEET COMPONENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory, net</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Inventory consisted of the following:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:67.313%;"></td>
        <td style="width:1.5%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.843%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.5%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.843%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Raw materials</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,257</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,757</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Work-in-process</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,670</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,052</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Finished goods</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,810</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,088</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total inventory</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">40,737</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">55,897</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Other Accrued Liabilities</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other accrued liabilities consisted of the following:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:67.313%;"></td>
        <td style="width:1.5%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.843%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.5%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.843%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued contract manufacturing expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,966</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,382</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued clinical expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">591</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">692</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued research expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">185</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">349</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued professional services</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,876</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,977</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_4d9e1814-d90c-438a-b69f-2d0819d5112e;"><span style="-sec-ix-hidden:F_62616aa1-c408-4682-b198-b4aacc8031c4;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current portion of lease liabilities</span></span></span></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,207</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,316</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Royalty obligation payable</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,928</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current portion of deferred royalty obligation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,639</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued license fees and royalties</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,575</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">943</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,370</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,909</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total other accrued liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19,698</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21,207</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock', window );">Schedule of Other Long-term Liabilities</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other long-term liabilities consisted of the following:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:67.313%;"></td>
        <td style="width:1.5%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.843%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.5%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.843%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Long-term portion of deferred royalty obligation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">69,876</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">67,947</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_8a36ba82-b9a3-4b23-adb9-3d2b758e3db2;"><span style="-sec-ix-hidden:F_fbfec351-c094-49d9-a03a-e641b11869bb;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Long-term portion of lease liabilities</span></span></span></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,635</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,376</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Contingent value rights liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">359</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">595</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total other long-term liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">71,870</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">70,918</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other noncurrent liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430380122224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of stock-based compensation expense</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock&#8209;based compensation expense is included in the consolidated statements of income as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:51.01%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.203%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.203%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.583%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Selling, general and administrative</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,645</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,305</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,017</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,192</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,042</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,837</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,347</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,017</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Schedule of stock-based compensation expense included in the consolidated statements of operations by award type</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock&#8209;based compensation expense included in the consolidated statements of income by award type is as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:51.311%;"></td>
        <td style="width:1.481%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.75%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.481%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.75%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.481%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.75%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock options</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,980</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,057</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">490</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">RSUs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,663</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,053</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,280</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">RSAs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">168</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">194</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">200</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ESPP</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">26</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">43</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">47</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total stock-based compensation expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,837</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,347</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,017</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock', window );">Schedule of unrecognized stock-based compensation cost</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023, the unrecognized stock-based compensation cost and the estimated weighted-average amortization period were as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:60.2%;"></td>
        <td style="width:1.82%;"></td>
        <td style="width:1%;"></td>
        <td style="width:16.08%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.36%;"></td>
        <td style="width:1%;"></td>
        <td style="width:16.54%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrecognized Compensation Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-Average Amortization Period (Years)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock options</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,861</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.9</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">RSUs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,430</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.4</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">RSAs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">220</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.9</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total unrecognized compensation expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,511</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Summary of equity award activity and related information</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes equity award activity under the 2012 Plan and prior plans and related information:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:32.386%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.642%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.02%;"></td>
        <td style="width:1%;"></td>
        <td style="width:7.7219999999999995%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.642%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.02%;"></td>
        <td style="width:1%;"></td>
        <td style="width:7.7219999999999995%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.642%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.02%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.182%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands, except per share data)</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of outstanding options</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-Average Exercise Price of Outstanding Options</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of outstanding RSUs</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-Average Fair Value per Share at Grant</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of outstanding RSAs</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-Average Fair Value per Share at Grant</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance as of December 31, 2022</span></p></td>
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">948</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15.56</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">518</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12.16</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">30</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14.97</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">828</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12.77</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">389</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12.85</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercised</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12.98</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Released RSUs and RSAs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">284</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12.42</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15.02</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeited</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">275</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15.22</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">141</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11.98</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance as of December 31, 2023</span></p></td>
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,499</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14.09</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">482</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12.62</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14.93</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vested and expected to vest <br/>&#160;&#160;&#160;as of December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,499</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14.09</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">482</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12.62</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of weighted-average assumptions used to calculate estimated value of stock options</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> assumptions used in calculating the estimated value of stock options granted by Innoviva on the date of grant were as follows:</span><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:51.311%;"></td>
        <td style="width:1.481%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.748999999999999%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.481%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.748999999999999%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.481%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.748999999999999%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.6</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.09</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.04</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.11</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Volatility</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">37.8</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">38.6</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">44.9</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Dividend yield</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average estimated fair value of stock options granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.57</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.43</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.84</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost not yet recognized and weighted-average period over which cost is expected to be recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (i)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430384646736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Debt</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our debt consists of the following:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:67.313%;"></td>
        <td style="width:1.5%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.843%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.5%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.843%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2023 Notes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">96,204</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025 Notes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">192,500</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">192,500</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2028 Notes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">261,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">261,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total debt</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">453,500</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">549,704</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;Less: Unamortized debt discount and issuance costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,266</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,331</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total debt, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">446,234</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">540,373</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;Less: Current portion of long-term debt, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">96,193</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total long-term debt, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">446,234</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">444,180</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Aggregate Scheduled Maturities of Convertible Debt</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The aggregate scheduled maturities of our convertible debt as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 are as follows:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:80.444%;"></td>
        <td style="width:1.8%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.757%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Year ending December 31,</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">192,500</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2026</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2027</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2028</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">261,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">453,500</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyThreeNotesMember', window );">2023 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtTableTextBlock', window );">Summary of Liability and Equity Components of Convertible Notes</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our outstanding 2023 Notes balance consisted of the following as of December 31, 2022:</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:77%;"></td>
        <td style="width:1.98%;"></td>
        <td style="width:1%;"></td>
        <td style="width:19.02%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Principal</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">96,204</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Debt issuance costs, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net carrying amount</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">96,193</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock', window );">Schedule of Components of Interest Expense</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table sets forth total interest expense recognized related to the 2023 Notes for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023, 2022 and 2021:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:51.311%;"></td>
        <td style="width:1.481%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.75%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.481%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.75%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.481%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.75%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Contractual interest expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">85</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,617</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,121</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Amortization of debt issuance costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">302</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">580</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total interest and amortization expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">96</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,919</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,701</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyFiveNotesMember', window );">2025 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtTableTextBlock', window );">Summary of Liability and Equity Components of Convertible Notes</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our outstanding 2025 Notes balances consisted of the following:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:53.88%;"></td>
        <td style="width:2.26%;"></td>
        <td style="width:1%;"></td>
        <td style="width:18.799999999999997%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.26%;"></td>
        <td style="width:1%;"></td>
        <td style="width:18.799999999999997%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Principal</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">192,500</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">192,500</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Debt discount and issuance costs, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,205</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,917</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net carrying amount</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">191,295</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">190,583</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock', window );">Schedule of Components of Interest Expense</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table sets forth total interest expense recognized related to the 2025 Notes for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023, 2022 and 2021:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:51.01%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.203%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.203%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.583%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Contractual interest expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,813</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,813</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,813</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Amortization of debt issuance costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">712</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">692</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">657</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Amortization of debt discount</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,898</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total interest and amortization expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,525</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,505</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,368</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyEightNotesMember', window );">2028 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtTableTextBlock', window );">Summary of Liability and Equity Components of Convertible Notes</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our outstanding 2028 Notes balance consisted of th</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">e following:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:67.313%;"></td>
        <td style="width:1.5%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.843%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.5%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.843%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Principal</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">261,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">261,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Debt discount and issuance costs, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,061</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,403</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net carrying amount</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">254,939</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">253,597</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock', window );">Schedule of Components of Interest Expense</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table sets forth total interest expense recognized related to the 2028 Notes for the year ended December 31, 2023 and from the issuance through December 31, 2022:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:67.313%;"></td>
        <td style="width:1.5%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.843%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.5%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.843%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Date of Issuance through</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Contractual interest expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,546</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,514</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Amortization of debt discount and issuance costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,342</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,061</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total interest and amortization expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,888</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,575</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480848/942-470-50-3<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-8<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-6<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyThreeNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyThreeNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyFiveNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyFiveNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyEightNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyEightNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430384344320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Components of Lease Cost</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The components of lease costs are as follows:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:67.313%;"></td>
        <td style="width:1.5%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.843%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.5%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.843%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Straight line operating lease costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,428</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,585</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Variable lease costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">189</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">155</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total lease costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,617</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,740</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock', window );">Schedule of Supplemental Cash Flow Information Related to Leases</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Supplemental cash flow information related to leases are as follows:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:67.313%;"></td>
        <td style="width:1.5%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.843%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.5%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.843%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash paid for amounts included in the measurement of <br/>&#160;&#160;&#160;operating lease liabilities:</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,542</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">790</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease right-of-use assets obtained in exchange <br/>&#160;&#160;&#160;for operating lease obligations</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,323</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Right-of-use assets obtained through acquisitions</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,185</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Lease Payments</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Future minimum lease payments on our operating leases as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 are as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:80.444%;"></td>
        <td style="width:1.8%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.757%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Year ending December 31,</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,373</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,428</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2026</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">143</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Thereafter</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">149</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total undiscounted lease payments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,093</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: imputed interest</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">251</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">    </span><span><span style="-sec-ix-hidden:F_4335f0ee-8c74-4e0b-beba-133f49c7dc56;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  Total operating lease liabilities</span></span></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,842</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental cash flow information for the periods presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430387890704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of components of the income tax expense</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Income tax expense consists of the following:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:51.311%;"></td>
        <td style="width:1.481%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.75%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.481%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.75%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.481%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.75%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,799</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">40,822</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,177</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">464</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total current</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,976</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">41,286</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="text-indent:10pt;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,594</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">26,026</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">70,893</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,194</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">625</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,539</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,400</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,401</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">76,432</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="text-indent:5pt;vertical-align:bottom;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total income tax expense, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,376</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">66,687</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">76,439</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of differences between expected U.S. federal statutory income tax to income tax expense</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The impacts of the differences between the expected U.S. federal statutory income tax to our income tax expense are as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:51.311%;"></td>
        <td style="width:1.481%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.75%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.481%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.75%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.481%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.75%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected tax at federal statutory rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">40,747</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">58,928</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">93,507</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State income tax, net of federal benefit</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,433</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,414</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">848</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal and state research credits</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,582</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,453</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,260</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 250 deduction</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,274</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Noncontrolling interest</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,468</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21,626</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Impact of consolidation and deconsolidation of subsidiaries</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,897</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,219</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">125</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,129</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,167</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,180</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,321</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total income tax expense, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,376</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">66,687</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">76,439</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of deferred tax assets and deferred tax liabilities</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Significant components of our deferred tax assets and deferred tax liabilities are as follows:</span><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:56.36%;"></td>
        <td style="width:2%;"></td>
        <td style="width:1%;"></td>
        <td style="width:17.82%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2%;"></td>
        <td style="width:1%;"></td>
        <td style="width:17.82%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax assets</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">182,013</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">149,646</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development tax credit carryforwards</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21,357</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21,230</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unrealized loss on investment, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,032</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred royalty obligation, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,084</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17,404</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,467</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,527</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred tax assets before valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">227,921</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">202,839</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">169,249</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">144,808</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">58,672</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">58,031</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax liabilities</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Depreciation and amortization</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">39,064</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">50,587</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unrealized gain on investment, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,747</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inventory fair value adjustment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,424</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,410</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">805</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net deferred tax liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">563</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,771</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Summary of changes in unrecognized tax benefits</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A reconciliation of the beginning and ending balances of the total amounts of unrecognized tax benefits are as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:76.46%;"></td>
        <td style="width:2.34%;"></td>
        <td style="width:1%;"></td>
        <td style="width:19.2%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unrecognized tax benefits as of December 31, 2020</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,185</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net decrease in tax portions for 2021</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">313</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unrecognized tax benefits as of December 31, 2021</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,872</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net increase in tax portions for 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,452</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unrecognized tax benefits as of December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,324</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net increase in tax portions for 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,119</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unrecognized tax benefits as of December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19,443</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 9<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 12<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430379605920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Description of Operations (Details)<br> $ in Billions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>Customer</div>
</th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jul. 20, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_NumberOfCustomers', window );">Number of customers | Customer</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_CapitalizedFeePaidEstimatedUsefulLife', window );">Capitalized fees paid, estimated useful life</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_TheravanceRespiratoryCompanyLlcMember', window );">Theravance Respiratory Company, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk | Net Product Sales | La Jolla [Member] | Customer One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">31.00%<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk | Net Product Sales | La Jolla [Member] | Customer Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">27.00%<span></span>
</td>
<td class="nump">29.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk | Net Product Sales | La Jolla [Member] | Customer Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">27.00%<span></span>
</td>
<td class="nump">28.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk | Receivables from Net Product Sales | La Jolla [Member] | Customer One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">29.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk | Receivables from Net Product Sales | La Jolla [Member] | Customer Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">19.00%<span></span>
</td>
<td class="nump">37.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk | Receivables from Net Product Sales | La Jolla [Member] | Customer Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">37.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inva_SarissaCapitalManagementLpMember', window );">Sarissa Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_RelatedPartyTransactionCommonStockOwnershipPercentageByRelatedParty', window );">Percentage of common stock owned by a related party</a></td>
<td class="nump">11.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=inva_LabaCollaborationMember', window );">Long-Acting Beta2 Agonist (LABA) Collaboration | GSK | RELVAR/BREO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_CollaborativeArrangementRoyaltyRateDefinedLevelOne', window );">Royalty rate for first level of annual global net sales (as a percent)</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate', window );">Annual global sales level used to determine royalty rate | $</a></td>
<td class="nump">$ 3.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_CollaborativeArrangementRoyaltyRateDefinedLevelTwo', window );">Royalty rate for sales above first level of annual global net sales (as a percent)</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=inva_LabaCollaborationMember', window );">Long-Acting Beta2 Agonist (LABA) Collaboration | GSK | ANORO | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts', window );">Royalty rate for combination products (as a percent)</a></td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=inva_LabaCollaborationMember', window );">Long-Acting Beta2 Agonist (LABA) Collaboration | GSK | ANORO | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts', window );">Royalty rate for combination products (as a percent)</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_CapitalizedFeePaidEstimatedUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Capitalized fee paid estimated useful life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_CapitalizedFeePaidEstimatedUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the royalty rate for combination products.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_CollaborativeArrangementRoyaltyRateDefinedLevelOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the royalty rate which the entity will receive under the collaboration agreement on the first defined level of annual global net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_CollaborativeArrangementRoyaltyRateDefinedLevelOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_CollaborativeArrangementRoyaltyRateDefinedLevelTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the royalty rate which the entity will receive under the collaboration agreement on sales which exceed the first defined level of annual global net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_CollaborativeArrangementRoyaltyRateDefinedLevelTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the annual global net sales amount which determines the royalty rate applied under the collaboration arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_NumberOfCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of customers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_NumberOfCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_RelatedPartyTransactionCommonStockOwnershipPercentageByRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock in the reporting entity owned by related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_RelatedPartyTransactionCommonStockOwnershipPercentageByRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_TheravanceRespiratoryCompanyLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_TheravanceRespiratoryCompanyLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=inva_LaJollaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=inva_LaJollaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=inva_CustomerOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=inva_CustomerOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=inva_CustomerTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=inva_CustomerTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=inva_CustomerThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=inva_CustomerThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_TradeAccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_TradeAccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inva_SarissaCapitalManagementLpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inva_SarissaCapitalManagementLpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=inva_LabaCollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=inva_LabaCollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inva_GSKMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inva_GSKMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=inva_LongActingBeta2AgonistRelvarBreoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=inva_LongActingBeta2AgonistRelvarBreoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=inva_LongActingBeta2AgonistAnoroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=inva_LongActingBeta2AgonistAnoroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430389383008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=inva_LaboratoryEquipmentFurnitureAndFixturesMember', window );">Laboratory equipment furniture and fixtures | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=inva_LaboratoryEquipmentFurnitureAndFixturesMember', window );">Laboratory equipment furniture and fixtures | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=inva_SoftwareAndComputerEquipmentMember', window );">Software and computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=inva_LaboratoryEquipmentFurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=inva_LaboratoryEquipmentFurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=inva_SoftwareAndComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=inva_SoftwareAndComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430391767104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Related Party Transactions (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inva_SarissaCapitalManagementLpMember', window );">Sarissa Capital</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Parties</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_RelatedPartyTransactionCommonStockOwnershipPercentageByRelatedParty', window );">Percentage of common stock owned by a related party</a></td>
<td class="nump">11.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_RelatedPartyTransactionCommonStockOwnershipPercentageByRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock in the reporting entity owned by related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_RelatedPartyTransactionCommonStockOwnershipPercentageByRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inva_SarissaCapitalManagementLpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inva_SarissaCapitalManagementLpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430384862672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET INCOME PER SHARE (Details) - 2025 Notes - Convertible senior notes - $ / shares<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Aug. 07, 2017</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_IncrementalCommonSharesAttributableToConversionOfDebtSecuritiesTreasuryStockMethod', window );">Dilutive effect of the assumed conversion premium</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyFiveNotesMember', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.26<span></span>
</td>
<td class="nump">$ 17.26<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_IncrementalCommonSharesAttributableToConversionOfDebtSecuritiesTreasuryStockMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_IncrementalCommonSharesAttributableToConversionOfDebtSecuritiesTreasuryStockMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyFiveNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyFiveNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=inva_SeniorUnsecuredConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=inva_SeniorUnsecuredConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430384597920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET INCOME PER SHARE - Basic and Diluted EPS (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_NumeratorAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net income attributable to Innoviva stockholders, basic</a></td>
<td class="nump">$ 179,722<span></span>
</td>
<td class="nump">$ 213,921<span></span>
</td>
<td class="nump">$ 265,854<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net income attributable to Innoviva stockholders, diluted</a></td>
<td class="nump">$ 191,304<span></span>
</td>
<td class="nump">$ 225,569<span></span>
</td>
<td class="nump">$ 270,590<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_DenominatorAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares used to compute basic net income per share attributable to Innoviva stockholders</a></td>
<td class="nump">65,435<span></span>
</td>
<td class="nump">69,644<span></span>
</td>
<td class="nump">82,062<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Dilutive effect of options and awards granted under equity incentive plan and employee stock purchase plan</a></td>
<td class="nump">149<span></span>
</td>
<td class="nump">108<span></span>
</td>
<td class="nump">59<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares used to compute diluted net income per share attributable to Innoviva stockholders</a></td>
<td class="nump">86,876<span></span>
</td>
<td class="nump">95,248<span></span>
</td>
<td class="nump">94,310<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_NetIncomeLossPerShareAbstract', window );"><strong>Net income per share attributable to Innoviva stockholders</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net income per share</a></td>
<td class="nump">$ 2.75<span></span>
</td>
<td class="nump">$ 3.07<span></span>
</td>
<td class="nump">$ 3.24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net income per share</a></td>
<td class="nump">$ 2.2<span></span>
</td>
<td class="nump">$ 2.37<span></span>
</td>
<td class="nump">$ 2.87<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyThreeNotesMember', window );">2023 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_NumeratorAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestOnConvertibleDebtNetOfTax', window );">Add: interest expense on Notes, net of tax effect</a></td>
<td class="nump">$ 89<span></span>
</td>
<td class="nump">$ 2,439<span></span>
</td>
<td class="nump">$ 4,736<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_DenominatorAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities', window );">Dilutive effect</a></td>
<td class="nump">187<span></span>
</td>
<td class="nump">6,188<span></span>
</td>
<td class="nump">12,189<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyFiveNotesMember', window );">2025 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_NumeratorAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestOnConvertibleDebtNetOfTax', window );">Add: interest expense on Notes, net of tax effect</a></td>
<td class="nump">$ 5,116<span></span>
</td>
<td class="nump">$ 4,583<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_DenominatorAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities', window );">Dilutive effect</a></td>
<td class="nump">11,150<span></span>
</td>
<td class="nump">11,150<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyEightNotesMember', window );">2028 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_NumeratorAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestOnConvertibleDebtNetOfTax', window );">Add: interest expense on Notes, net of tax effect</a></td>
<td class="nump">$ 6,377<span></span>
</td>
<td class="nump">$ 4,626<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_DenominatorAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities', window );">Dilutive effect</a></td>
<td class="nump">9,955<span></span>
</td>
<td class="nump">8,158<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_DenominatorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_DenominatorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_NetIncomeLossPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_NetIncomeLossPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_NumeratorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_NumeratorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-42<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480454/718-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-22<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-28A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestOnConvertibleDebtNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of interest recognized on convertible debt instrument excluding interest on principal required to be paid in cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestOnConvertibleDebtNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-40<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-40<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyThreeNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyThreeNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyFiveNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyFiveNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyEightNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyEightNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430388893120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET INCOME PER SHARE - Anti-Dilutive Securities (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Anti-Dilutive Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities (in shares)</a></td>
<td class="nump">1,924<span></span>
</td>
<td class="nump">930<span></span>
</td>
<td class="nump">979<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=inva_EquityIncentivePlansAndESPPMember', window );">Equity incentive plans and ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Anti-Dilutive Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities (in shares)</a></td>
<td class="nump">1,333<span></span>
</td>
<td class="nump">648<span></span>
</td>
<td class="nump">979<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=inva_OutstandingStockWarrantMember', window );">Outstanding Stock Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Anti-Dilutive Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities (in shares)</a></td>
<td class="nump">591<span></span>
</td>
<td class="nump">282<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=inva_EquityIncentivePlansAndESPPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=inva_EquityIncentivePlansAndESPPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=inva_OutstandingStockWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=inva_OutstandingStockWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430384870544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE RECOGNITION - Schedule of net revenue from collaborative arrangements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition and Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total royalty revenue</a></td>
<td class="nump">$ 310,463<span></span>
</td>
<td class="nump">$ 331,339<span></span>
</td>
<td class="nump">$ 391,866<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalty revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition and Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAmortization', window );">Less: amortization of capitalized fees paid</a></td>
<td class="num">(13,800)<span></span>
</td>
<td class="num">(13,800)<span></span>
</td>
<td class="num">(13,800)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total royalty revenue</a></td>
<td class="nump">238,846<span></span>
</td>
<td class="nump">311,645<span></span>
</td>
<td class="nump">391,866<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inva_GSKMember', window );">GSK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition and Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total royalty revenue</a></td>
<td class="nump">238,846<span></span>
</td>
<td class="nump">311,645<span></span>
</td>
<td class="nump">391,866<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inva_GSKMember', window );">GSK | Royalty revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition and Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees', window );">Royalties</a></td>
<td class="nump">252,669<span></span>
</td>
<td class="nump">325,468<span></span>
</td>
<td class="nump">405,689<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAmortization', window );">Less: amortization of capitalized fees paid</a></td>
<td class="num">(13,823)<span></span>
</td>
<td class="num">(13,823)<span></span>
</td>
<td class="num">(13,823)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inva_GSKMember', window );">GSK | RELVAR/BREO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition and Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees', window );">Royalties</a></td>
<td class="nump">208,042<span></span>
</td>
<td class="nump">215,034<span></span>
</td>
<td class="nump">234,066<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inva_GSKMember', window );">GSK | ANORO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition and Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees', window );">Royalties</a></td>
<td class="nump">44,627<span></span>
</td>
<td class="nump">38,405<span></span>
</td>
<td class="nump">44,935<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inva_GSKMember', window );">GSK | TRELEGY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition and Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees', window );">Royalties</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 72,029<span></span>
</td>
<td class="nump">$ 126,688<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer before amortization of capitalized fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479483/340-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inva_GSKMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inva_GSKMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=inva_LongActingBeta2AgonistRelvarBreoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=inva_LongActingBeta2AgonistRelvarBreoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=inva_LongActingBeta2AgonistAnoroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=inva_LongActingBeta2AgonistAnoroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=inva_TrelegyElliptaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=inva_TrelegyElliptaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430374826672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE RECOGNITION (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">4 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 13, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition and Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total net revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 310,463<span></span>
</td>
<td class="nump">$ 331,339<span></span>
</td>
<td class="nump">$ 391,866<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostGross', window );">Milestone fees paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 220,000<span></span>
</td>
<td class="nump">220,000<span></span>
</td>
<td class="nump">220,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition and Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostGross', window );">Milestone fees paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
<td class="nump">$ 120,000<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Net Product Sales | Geographic Concentration Risk | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition and Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Net Product Sales | Geographic Concentration Risk | Rest of the world</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition and Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalty revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition and Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total net revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 238,846<span></span>
</td>
<td class="nump">311,645<span></span>
</td>
<td class="nump">391,866<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=inva_GiaprezaMember', window );">GIAPREZA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition and Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total net revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=inva_XeravaMember', window );">XERAVA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition and Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total net revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=inva_XacduroMember', window );">XACDURO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition and Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total net revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inva_GSKMember', window );">GSK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition and Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_PercentageOfRoyaltyPaymentsNotEntitledToReceive', window );">Percentage of royalty payments not entitled to receive</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total net revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 238,846<span></span>
</td>
<td class="nump">$ 311,645<span></span>
</td>
<td class="nump">$ 391,866<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inva_GSKMember', window );">GSK | Long-Acting Beta2 Agonist (LABA) Collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition and Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostGross', window );">Milestone fees paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 220,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_PercentageOfEconomicInterestOnFuturePaymentsUnderAgreements', window );">Percentage of economic interest in any future payments made under the agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inva_GSKMember', window );">GSK | RELVAR/BREO | Long-Acting Beta2 Agonist (LABA) Collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition and Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_CollaborativeArrangementRoyaltyRateDefinedLevelOne', window );">Royalty rate for first level of annual global net sales (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate', window );">Annual global sales level used to determine royalty rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_CollaborativeArrangementRoyaltyRateDefinedLevelTwo', window );">Royalty rate for sales above first level of annual global net sales (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inva_GSKMember', window );">GSK | ANORO | Long-Acting Beta2 Agonist (LABA) Collaboration | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition and Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts', window );">Royalty rate for combination products (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inva_GSKMember', window );">GSK | ANORO | Long-Acting Beta2 Agonist (LABA) Collaboration | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition and Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts', window );">Royalty rate for combination products (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inva_GSKMember', window );">GSK | TRELEGY | Long-Acting Beta2 Agonist (LABA) Collaboration | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition and Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts', window );">Royalty rate for combination products (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inva_GSKMember', window );">GSK | TRELEGY | Long-Acting Beta2 Agonist (LABA) Collaboration | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition and Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts', window );">Royalty rate for combination products (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inva_LaJollaMember', window );">La Jolla</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition and Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total net revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,700<span></span>
</td>
<td class="nump">$ 60,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inva_LaJollaMember', window );">La Jolla | Net Product Sales | Geographic Concentration Risk | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition and Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inva_LaJollaMember', window );">La Jolla | Net Product Sales | Geographic Concentration Risk | Rest of the world</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition and Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inva_LaJollaMember', window );">La Jolla | GIAPREZA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition and Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total net revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inva_LaJollaMember', window );">La Jolla | XERAVA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition and Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total net revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the royalty rate for combination products.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_CollaborativeArrangementRoyaltyRateDefinedLevelOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the royalty rate which the entity will receive under the collaboration agreement on the first defined level of annual global net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_CollaborativeArrangementRoyaltyRateDefinedLevelOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_CollaborativeArrangementRoyaltyRateDefinedLevelTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the royalty rate which the entity will receive under the collaboration agreement on sales which exceed the first defined level of annual global net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_CollaborativeArrangementRoyaltyRateDefinedLevelTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the annual global net sales amount which determines the royalty rate applied under the collaboration arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_PercentageOfEconomicInterestOnFuturePaymentsUnderAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of economic interest in any future payments made under the agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_PercentageOfEconomicInterestOnFuturePaymentsUnderAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_PercentageOfRoyaltyPaymentsNotEntitledToReceive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of royalty payments the company is not entitled to receive.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_PercentageOfRoyaltyPaymentsNotEntitledToReceive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479483/340-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=inva_GiaprezaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=inva_GiaprezaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=inva_XeravaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=inva_XeravaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=inva_XacduroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=inva_XacduroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inva_GSKMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inva_GSKMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=inva_LabaCollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=inva_LabaCollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=inva_LongActingBeta2AgonistRelvarBreoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=inva_LongActingBeta2AgonistRelvarBreoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=inva_LongActingBeta2AgonistAnoroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=inva_LongActingBeta2AgonistAnoroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=inva_TrelegyElliptaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=inva_TrelegyElliptaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inva_LaJollaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inva_LaJollaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430388933248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LICENSE AND COLLABORATION ARRANGEMENTS - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">License revenue</a></td>
<td class="num">$ (310,463)<span></span>
</td>
<td class="num">$ (331,339)<span></span>
</td>
<td class="num">$ (391,866)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=inva_ZaiLabMember', window );">Zai Lab | Research and Development Support</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_FuturePotentialMilestonePayment', window );">Future potential milestone payment receivable</a></td>
<td class="nump">91,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_LicenseRevenueRecognized', window );">License revenue recognized</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=inva_PaionAgMember', window );">PAION AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_FuturePotentialMilestonePayment', window );">Future potential milestone payment receivable</a></td>
<td class="nump">109,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=inva_PaionAgMember', window );">PAION AG | Cost Reimbursement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=inva_EverestMedicinesLimitedMember', window );">Everest Medicines Limited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_SalesMilestonePaymentsReceivable', window );">Sales milestone payments receivable</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_LicenseRevenueRecognized', window );">License revenue recognized</a></td>
<td class="nump">$ 8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_RoyaltiesPayablePeriodAfterFirstCommercialSaleOfProduct', window );">Royalties payable period after first commercial sale of product</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=inva_EverestMedicinesLimitedMember', window );">Everest Medicines Limited | Commercial Supply Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 2,400<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_PercentageOfReimbursedForDirectAndCertainIndirectManufacturingCosts', window );">Percentage of reimbursed for direct and certain indirect manufacturing costs</a></td>
<td class="nump">110.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=inva_GeorgeWashingtonUniversityMember', window );">George Washington University</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_AccruedRoyaltyObligations', window );">Obligation to pay royalties</a></td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_PercentageOfRoyaltyPayableOnNetSales', window );">Percentage of royalty payable on net sales</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_PercentageOfRoyaltyOnPaymentsReceivedFromSublicensees', window );">Percentage of royalty on payments received from sublicensees</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=inva_HarvardUniversityMember', window );">Harvard University</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of license revenue</a></td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_PercentageOfRoyaltyPayableOnNetSales', window );">Percentage of royalty payable on net sales</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_PercentageOfRoyaltyOnPaymentsReceivedFromSublicensees', window );">Percentage of royalty on payments received from sublicensees</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ClinicalDevelopmentAndRegulatoryMilestonesAmountPayable', window );">Clinical development and regulatory milestones amount payable</a></td>
<td class="nump">$ 15,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_PercentageOfMinimumRoyaltyRate', window );">Percentage of minimum royalty rate</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_PercentageOfMaximumRoyaltyBasedOnAchievementOfAnnualNetProductSalesThresholds', window );">Percentage of maximum royalty based on achievement of annual net product sales thresholds</a></td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=inva_ParatekPharmaceuticalsIncMember', window );">Paratek Pharmaceuticals, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_PercentageOfRoyaltyPayableOnNetSales', window );">Percentage of royalty payable on net sales</a></td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ClaimExpirationDate', window );">Claim Expiration Date</a></td>
<td class="text">2023-10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=inva_AstrazenecaMember', window );">AstraZeneca</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_SubscriptionAgreementOneTimeMilestonePaymentOnNetSales', window );">Subscription agreement one-time milestone payment on net sales</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_TermOfMilestonePaymentForNetSales', window );">Term of the milestone payment on net sales</a></td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_SubscriptionAgreementOneTimeMilestonePaymentOnCommercialSales', window );">Subscription agreement one-time milestone payment on first commercial sale</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_TermOfMilestonePaymentForCommercialSale', window );">Term of the milestone payment on first commercial sale</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_AccruedRoyaltyObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Obligations incurred through that date and payable for royalties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_AccruedRoyaltyObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_ClaimExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Claim expiration date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_ClaimExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_ClinicalDevelopmentAndRegulatoryMilestonesAmountPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Clinical development and regulatory milestones amount payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_ClinicalDevelopmentAndRegulatoryMilestonesAmountPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_FuturePotentialMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future potential milestone payment receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_FuturePotentialMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_LicenseRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License revenue recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_LicenseRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_PercentageOfMaximumRoyaltyBasedOnAchievementOfAnnualNetProductSalesThresholds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of maximum royalty based on achievement of annual net product sales thresholds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_PercentageOfMaximumRoyaltyBasedOnAchievementOfAnnualNetProductSalesThresholds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_PercentageOfMinimumRoyaltyRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of minimum royalty rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_PercentageOfMinimumRoyaltyRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_PercentageOfReimbursedForDirectAndCertainIndirectManufacturingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of reimbursed for direct and certain indirect manufacturing costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_PercentageOfReimbursedForDirectAndCertainIndirectManufacturingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_PercentageOfRoyaltyOnPaymentsReceivedFromSublicensees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the royalty payable as a percentage of payments received from sublicensees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_PercentageOfRoyaltyOnPaymentsReceivedFromSublicensees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_PercentageOfRoyaltyPayableOnNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the royalty payable, as a percentage of net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_PercentageOfRoyaltyPayableOnNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_RoyaltiesPayablePeriodAfterFirstCommercialSaleOfProduct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalties payable period after first commercial sale of product.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_RoyaltiesPayablePeriodAfterFirstCommercialSaleOfProduct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_SalesMilestonePaymentsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales milestone payments receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_SalesMilestonePaymentsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_SubscriptionAgreementOneTimeMilestonePaymentOnCommercialSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Subscription agreement one-time milestone payment on commercial sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_SubscriptionAgreementOneTimeMilestonePaymentOnCommercialSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_SubscriptionAgreementOneTimeMilestonePaymentOnNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Subscription agreement one-time milestone payment on net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_SubscriptionAgreementOneTimeMilestonePaymentOnNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_TermOfMilestonePaymentForCommercialSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of milestone payment for commercial sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_TermOfMilestonePaymentForCommercialSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_TermOfMilestonePaymentForNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of milestone payment for net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_TermOfMilestonePaymentForNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=inva_ZaiLabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=inva_ZaiLabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=inva_ResearchAndDevelopmentSupportMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=inva_ResearchAndDevelopmentSupportMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=inva_PaionAgMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=inva_PaionAgMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=inva_CostReimbursementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=inva_CostReimbursementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=inva_EverestMedicinesLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=inva_EverestMedicinesLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=inva_CommercialSupplyAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=inva_CommercialSupplyAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=inva_GeorgeWashingtonUniversityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=inva_GeorgeWashingtonUniversityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=inva_HarvardUniversityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=inva_HarvardUniversityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=inva_ParatekPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=inva_ParatekPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=inva_AstrazenecaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=inva_AstrazenecaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430384411264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED ENTITIES AND ACQUISITIONS - Theravance Respiratory Company, LLC (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 20, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 193,513<span></span>
</td>
<td class="nump">$ 291,049<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,630<span></span>
</td>
<td class="nump">29,559<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Equity and long-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">444,432<span></span>
</td>
<td class="nump">363,859<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,243,507<span></span>
</td>
<td class="nump">1,231,497<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract', window );"><strong>Liabilities and Stockholders Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,134<span></span>
</td>
<td class="nump">134,968<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,243,507<span></span>
</td>
<td class="nump">1,231,497<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_IncomeStatementDisclosuresOfVariableInterestEntityAbstract', window );"><strong>Income statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total net revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">310,463<span></span>
</td>
<td class="nump">331,339<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 391,866<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,969)<span></span>
</td>
<td class="num">(3,373)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(3,626)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,376<span></span>
</td>
<td class="nump">66,687<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">76,439<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">179,722<span></span>
</td>
<td class="nump">220,262<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">368,837<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalty revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_IncomeStatementDisclosuresOfVariableInterestEntityAbstract', window );"><strong>Income statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total net revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">238,846<span></span>
</td>
<td class="nump">$ 311,645<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">391,866<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=inva_TheravanceRespiratoryCompanyLlcMember', window );">Theravance Respiratory Company, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>CONSOLIDATED ENTITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_OwnershipInterestInConsolidatedEntities', window );">Ownership interest in LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ProceedsFromSaleOfEconomicInterestUnderEquityPurchaseAgreement', window );">Proceeds from sale of economic interest under Equity Purchase Agreement</a></td>
<td class="nump">$ 277,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ContingentSalesBasedMilestonePayment', window );">Contingent sales based milestone payment</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_CashDistributionReceived', window );">Cash distribution</a></td>
<td class="nump">4,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Total carrying value of investments</a></td>
<td class="nump">$ 39,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_IncomeStatementDisclosuresOfVariableInterestEntityAbstract', window );"><strong>Income statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (332)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(3,956)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income from operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,697<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">122,732<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_RealizedLoss', window );">Realized loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(39,386)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Changes in fair values of equity and long-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,884)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(1,541)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,438<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">121,191<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=inva_TheravanceRespiratoryCompanyLlcMember', window );">Theravance Respiratory Company, LLC | Royalty revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_IncomeStatementDisclosuresOfVariableInterestEntityAbstract', window );"><strong>Income statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total net revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,029<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">126,688<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=inva_IspFundLpMember', window );">ISP Fund LP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">311,800<span></span>
</td>
<td class="nump">320,600<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_IncomeStatementDisclosuresOfVariableInterestEntityAbstract', window );"><strong>Income statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Changes in fair values of equity and long-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400<span></span>
</td>
<td class="nump">$ 6,800<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 10,500<span></span>
</td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">(1)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">   The year ended December 31, 2022 represents the period from January 1, 2022 to July 20, 2022, the date of the sale of our ownership interest in TRC.</span></p></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_CashDistributionReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash distribution received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_CashDistributionReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_ContingentSalesBasedMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent sales based milestone payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_ContingentSalesBasedMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_IncomeStatementDisclosuresOfVariableInterestEntityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_IncomeStatementDisclosuresOfVariableInterestEntityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_OwnershipInterestInConsolidatedEntities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ownership interest in consolidated entities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_OwnershipInterestInConsolidatedEntities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_ProceedsFromSaleOfEconomicInterestUnderEquityPurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from sale of economic interest under Equity Purchase Agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_ProceedsFromSaleOfEconomicInterestUnderEquityPurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_RealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Realized loss</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_RealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481664/323-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(c),9(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 860<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481420/860-30-50-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 860<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481420/860-30-50-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 860<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481420/860-30-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=inva_TheravanceRespiratoryCompanyLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=inva_TheravanceRespiratoryCompanyLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=inva_IspFundLpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=inva_IspFundLpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430389355984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED ENTITIES AND ACQUISITIONS - ISP Fund LP (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>CONSOLIDATED ENTITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,243,507<span></span>
</td>
<td class="nump">$ 1,231,497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=inva_IspFundLpMember', window );">ISP Fund LP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>CONSOLIDATED ENTITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LimitedPartnersCumulativeCashDistributions', window );">Distribution from partnership</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 110,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LimitedPartnersContributedCapital', window );">Capital contribution</a></td>
<td class="nump">$ 110,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_LimitedPartnersInitialContribution', window );">Initial contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 190,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_PercentageOfEconomicInterestInPartnership', window );">Economic interest of the Partnership (in percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_NetInvestmentRelatedIncomeExpenseEarnedInccured', window );">Net investment-related income (expense) earned (incurred)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,300<span></span>
</td>
<td class="nump">5,200<span></span>
</td>
<td class="nump">$ 3,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Investment Income, Interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,300<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized loss on other equity investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,700<span></span>
</td>
<td class="nump">9,900<span></span>
</td>
<td class="nump">2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_PartnershipAgreementLockUpPeriod', window );">Lock-up period</a></td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterestAndDividend', window );">Investment Income, Interest and Dividend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Realized gain on equity investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400<span></span>
</td>
<td class="nump">6,800<span></span>
</td>
<td class="nump">$ 10,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 311,800<span></span>
</td>
<td class="nump">$ 320,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_LimitedPartnersInitialContribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Limited partners initial contribution.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_LimitedPartnersInitialContribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_NetInvestmentRelatedIncomeExpenseEarnedInccured">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net investment related income (expense) earned (inccured).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_NetInvestmentRelatedIncomeExpenseEarnedInccured</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_PartnershipAgreementLockUpPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The period of time in which contributors to an investment fund have waived the right of redemption, as defined in the partnership agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_PartnershipAgreementLockUpPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_PercentageOfEconomicInterestInPartnership">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of economic interest held in Partnership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_PercentageOfEconomicInterestInPartnership</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(c),9(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterestAndDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterestAndDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LimitedPartnersContributedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of capital contributed by the limited partners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB TOPIC 4.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LimitedPartnersContributedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LimitedPartnersCumulativeCashDistributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate cumulative cash distributions made to the limited partners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 4.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LimitedPartnersCumulativeCashDistributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 860<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481420/860-30-50-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 860<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481420/860-30-50-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 860<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481420/860-30-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=inva_IspFundLpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=inva_IspFundLpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430379430800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED ENTITIES AND ACQUISITIONS - Entasis Therapeutics Holdings, Inc. (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jul. 11, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 17, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Feb. 28, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>Director</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 453,500<span></span>
</td>
<td class="nump">$ 549,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to noncontrolling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">179,722<span></span>
</td>
<td class="nump">213,921<span></span>
</td>
<td class="nump">$ 265,854<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to noncontrolling interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(6,341)<span></span>
</td>
<td class="num">$ (102,983)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=inva_EntasisTherapeuticsHoldingsIncMember', window );">Entasis Therapeutics Holdings Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_SecuritiesPurchaseAgreementRightsToDesignateInvesteeBoardMembersNumberOfBoardMembers', window );">Number of investee's board members which may be designated by the Company | Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss', window );">Remeasurement loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Payment towards convertible promissory note</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillPeriodIncreaseDecrease', window );">Measurement period adjustments for change in value of goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,700)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_MeasurementPeriodAdjustmentsIncreaseDecreaseInEstimatedPurchasePrice', window );">Measurement period adjustments for change in estimated purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,400)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestPeriodIncreaseDecrease', window );">Measurement period adjustments for change in value of noncontrolling interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease', window );">Measurement period adjustments for change in value of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(800)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_IncreaseDecreaseInDeferredTaxLiabilities', window );">Measurement period adjustments increase decrease in deferred tax liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to noncontrolling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=inva_EntasisTherapeuticsHoldingsIncMember', window );">Entasis Therapeutics Holdings Inc | Consolidated Investees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=inva_EntasisTherapeuticsHoldingsIncMember', window );">Entasis Therapeutics Holdings Inc | Securities purchase agreement | Convertable promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, annual interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.59%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt instrument maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aug. 18,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=inva_EntasisTherapeuticsHoldingsIncMember', window );">Entasis Therapeutics Holdings Inc | Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Fair value of equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=inva_EntasisTherapeuticsHoldingsIncMember', window );">Entasis Therapeutics Holdings Inc | Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Fair value of equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_IncreaseDecreaseInDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in deferred tax liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_IncreaseDecreaseInDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_MeasurementPeriodAdjustmentsIncreaseDecreaseInEstimatedPurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in estimated purchase price during measurement period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_MeasurementPeriodAdjustmentsIncreaseDecreaseInEstimatedPurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_SecuritiesPurchaseAgreementRightsToDesignateInvesteeBoardMembersNumberOfBoardMembers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of the investee's board members which the Company has the right to designate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_SecuritiesPurchaseAgreementRightsToDesignateInvesteeBoardMembersNumberOfBoardMembers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482736/825-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Increase or Decrease in balance of noncontrolling interest in the subsidiary during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=inva_EntasisTherapeuticsHoldingsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=inva_EntasisTherapeuticsHoldingsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_ConsolidatedInvesteesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_ConsolidatedInvesteesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=inva_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=inva_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inva_ConvertiblePromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inva_ConvertiblePromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430379550544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED ENTITIES AND ACQUISITIONS - Schedule of Recognized Identified Assets Acquired and Liabilities Assumed (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Aug. 22, 2022</div></th>
<th class="th"><div>Feb. 17, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 17,905<span></span>
</td>
<td class="nump">$ 26,713<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=inva_EntasisTherapeuticsHoldingsIncMember', window );">Entasis Therapeutics Holdings Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,070<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets', window );">Prepaid expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,554<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther', window );">Other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,959<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Property and equipment, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">185<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets', window );">Right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">959<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,493<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets', window );">Other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">302<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">'Total assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,222<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,583<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedPersonnelRelatedExpenses', window );">Accrued personnel-related expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,058<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAccruedLiabilities', window );">Other accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,096<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,769<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Total liabilities assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,506<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Total assets acquired, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 134,716<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=inva_LaJollaPharmaceuticalCompanyMember', window );">La Jolla Pharmaceutical Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47,415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities', window );">Short-term marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">471<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,876<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory', window );">Inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets', window );">Prepaid expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther', window );">Other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">907<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Property and equipment, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets', window );">Right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">226<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,411<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">Intangible assets</a></td>
<td class="nump">$ 151,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">151,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,461<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets', window );">Other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">'Total assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">287,951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,849<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAccruedLiabilities', window );">Other accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,362<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther', window );">Other long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,944<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Total liabilities assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,392<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Total assets acquired, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 206,559<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedPersonnelRelatedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued personnel-related expenses due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedPersonnelRelatedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business combination recognized identifiable assets acquired and liabilities assumed operating lease right-of-use assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business combination recognized identifiable assets acquired and liabilities assumed other accrued liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments in debt and equity securities, including, but not limited to, held-to-maturity, trading and available-for-sale expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred revenue expected to be recognized as such within one year or the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax asset attributable to deductible temporary differences and carryforwards acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of inventory recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479303/805-10-55-37<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479303/805-10-55-37<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of property, plant, and equipment recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479303/805-10-55-37<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=inva_EntasisTherapeuticsHoldingsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=inva_EntasisTherapeuticsHoldingsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=inva_LaJollaPharmaceuticalCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=inva_LaJollaPharmaceuticalCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430373873824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED ENTITIES AND ACQUISITIONS - La Jolla Pharmaceutical Company (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 22, 2022</div></th>
<th class="th"><div>Aug. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Change in inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,004<span></span>
</td>
<td class="num">$ (280)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=inva_LaJollaPharmaceuticalCompanyMember', window );">La Jolla Pharmaceutical Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total consideration paid</a></td>
<td class="nump">$ 206,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Acquisition share price</a></td>
<td class="nump">$ 6.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillPeriodIncreaseDecrease', window );">Measurement period adjustments for change in value of goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="num">$ (13,100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_IncreaseDecreaseInDeferredTaxAssets', window );">Increase (decrease) in deferred tax assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,400)<span></span>
</td>
<td class="nump">10,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Change in inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,700)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease', window );">Measurement period adjustments for change in value of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_MeasurementPeriodAdjustmentsIncreaseDecreaseInLiabilities', window );">Measurement period adjustments increase decrease in liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,300)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquisitionCosts', window );">Acquisition-related costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_IncreaseDecreaseInDeferredTaxLiabilities', window );">Increase (decrease) in deferred tax liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="num">$ (2,600)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_IncreaseDecreaseInDeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_IncreaseDecreaseInDeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_IncreaseDecreaseInDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in deferred tax liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_IncreaseDecreaseInDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_MeasurementPeriodAdjustmentsIncreaseDecreaseInLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Measurement period adjustments increase decrease In liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_MeasurementPeriodAdjustmentsIncreaseDecreaseInLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquisitionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The capitalized costs incurred during the period (excluded from amortization) to purchase, lease or otherwise acquire an unproved property, including costs of lease bonuses and options to purchase or lease properties, the portion of costs applicable to minerals when land including mineral rights is purchased in fee, brokers' fees, recording fees, legal costs, and other costs incurred in acquiring properties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 932<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-10(c)(7)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479664/932-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 932<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-10(c)(3)(ii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479664/932-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquisitionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 8<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 7<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in carrying value of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=inva_LaJollaPharmaceuticalCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=inva_LaJollaPharmaceuticalCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430384349696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED ENTITIES AND ACQUISITIONS - Pro Forma Information (Details) - Entasis Therapeutics Holdings Inc - La Jolla Pharmaceutical Company - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaRevenue', window );">Revenue</a></td>
<td class="nump">$ 357,880<span></span>
</td>
<td class="nump">$ 435,398<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss', window );">Net income</a></td>
<td class="nump">204,987<span></span>
</td>
<td class="nump">281,719<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Innoviva stockholders</a></td>
<td class="nump">$ 214,390<span></span>
</td>
<td class="nump">$ 197,535<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=inva_EntasisTherapeuticsHoldingsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=inva_EntasisTherapeuticsHoldingsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=inva_LaJollaPharmaceuticalCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=inva_LaJollaPharmaceuticalCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430383269392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Equity Investment in Armata (Details) - Armata<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 10, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 10, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 09, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>Director </div>
<div>Tranche</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 01, 2024 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_SecuritiesPurchaseAgreementNumberOfTranches', window );">Number of tranches | Tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_VotingAgreementMaximumVotingRightsPercent', window );">Percentage of maximum voting rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee', window );">Number of Investee's Board members currently representing the Company | Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_SpecialTermReDesignatingBoardMemberToBoardOfInvestee', window );">Special terms on re-designating board member to board of investee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In addition, as of February 9, 2022, Armata entered into an amended and restated investor rights agreement with the Company and ISO, pursuant to which for as long as the Company and ISO hold at least 12.5% of the outstanding shares of Armata&#8217;s common stock on a fully-diluted, the Company and ISO shall have the right to designate two directors to Armata&#8217;s board of directors, and for so long as the Company and ISO hold at least 8%, but less than 12.5%, of the outstanding shares of Armata&#8217;s common stock on a fully-diluted basis, the Company and ISO shall have the right to designate one director to Armata&#8217;s board of directors, subject to certain conditions and qualifications set forth in the amended and restated investor rights agreement.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=inva_ArmataPharmaceuticalsIncMember', window );">Credit and Security Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Term loan facility in aggregate amount</a></td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, annual interest rate</a></td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt instrument maturity date</a></td>
<td class="text">Jan. 10,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=inva_ArmataPharmaceuticalsIncMember', window );">Secured Convertible Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescription', window );">Debt instrument, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On January 10, 2023, we entered into a Secured Convertible Credit Agreement (the &#8220;Credit Agreement&#8221;) with Armata, under which we invested in a one-year convertible note (the &#8220;Armata Convertible Note&#8221;) in an aggregate amount of $30.0 million at an interest rate of 8.0% per annum.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Term loan facility in aggregate amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, annual interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=inva_ArmataPharmaceuticalsIncMember', window );">Consolidated Investees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=inva_ArmataPharmaceuticalsIncMember', window );">Two Directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityOwnershipPercentage', window );">Armata outstanding shares percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=inva_ArmataPharmaceuticalsIncMember', window );">Common stock and warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_SecuritiesPurchaseAgreementAmount', window );">Amount of securities purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGain', window );">Unrealized gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 77.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss', window );">Unrealized loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 152.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=inva_ArmataPharmaceuticalsIncMember', window );">Warrants purchased in 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_SaleOfWarrantsNumberOfWarrantsIssuedInTransaction', window );">Number of warrants purchased under the securities purchase agreement | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,710,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.87<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Term of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=inva_ArmataPharmaceuticalsIncMember', window );">Warrants purchased in 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Term of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=inva_ArmataPharmaceuticalsIncMember', window );">Warrants Purchased in 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Term of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=inva_ArmataPharmaceuticalsIncMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity and long-term investments at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.3<span></span>
</td>
<td class="nump">8.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=inva_ArmataPharmaceuticalsIncMember', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares to be purchased under the securities purchase agreement | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,710,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity and long-term investments at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81.2<span></span>
</td>
<td class="nump">$ 31.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=inva_ArmataPharmaceuticalsIncMember', window );">Armata Convertible Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity and long-term investments at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGain', window );">Unrealized gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=inva_ArmataPharmaceuticalsIncMember', window );">Armata Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity and long-term investments at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGain', window );">Unrealized gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | One Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityOwnershipPercentage', window );">Armata outstanding shares percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | One Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityOwnershipPercentage', window );">Armata outstanding shares percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=inva_InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember', window );">Innoviva Strategic Opportunities, LLC | Common stock and warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_SecuritiesPurchaseAgreementAmount', window );">Amount of securities purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=inva_InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember', window );">Innoviva Strategic Opportunities, LLC | Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_SecuritiesPurchaseAgreementTotalNumberOfWarrantsToBePurchasedUnderAgreement', window );">Number of warrants to be purchased under the securities purchase agreement | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,153,847<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=inva_InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember', window );">Innoviva Strategic Opportunities, LLC | Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement', window );">Number of shares to be purchased under the securities purchase agreement | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares to be purchased under the securities purchase agreement | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,212,122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_SecuritiesPurchaseAgreementTotalNumberOfWarrantsToBePurchasedUnderAgreement', window );">Number of warrants to be purchased under the securities purchase agreement | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,153,847<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_SecuritiesPurchaseAgreementAmount', window );">Amount of securities purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of the Company's Board members currently serving on the Investee's Board.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_SaleOfWarrantsNumberOfWarrantsIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of warrants issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_SaleOfWarrantsNumberOfWarrantsIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_SecuritiesPurchaseAgreementAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount the Company agreed to pay for common stock and warrants upon satisfaction of certain closing conditions under the terms of the securities purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_SecuritiesPurchaseAgreementAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_SecuritiesPurchaseAgreementNumberOfTranches">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of tranches in which the Company agreed to purchase common stock and warrants upon satisfaction of certain closing conditions under the terms of the securities purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_SecuritiesPurchaseAgreementNumberOfTranches</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total number of shares to be purchased under the terms of a securities purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_SecuritiesPurchaseAgreementTotalNumberOfWarrantsToBePurchasedUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total number of warrants to be purchased under the terms of a securities purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_SecuritiesPurchaseAgreementTotalNumberOfWarrantsToBePurchasedUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_SpecialTermReDesignatingBoardMemberToBoardOfInvestee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Special Terms on amended and restated investor rights agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_SpecialTermReDesignatingBoardMemberToBoardOfInvestee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_VotingAgreementMaximumVotingRightsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of maximum voting rights under voting agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_VotingAgreementMaximumVotingRightsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480848/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482736/825-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized loss on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the Variable Interest Entity's (VIE) voting interest owned by (or beneficial interest in) the reporting entity (directly or indirectly).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-5A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=inva_ArmataPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=inva_ArmataPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inva_CreditAndSecurityAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inva_CreditAndSecurityAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=inva_SecuredConvertibleCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=inva_SecuredConvertibleCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_ConsolidatedInvesteesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_ConsolidatedInvesteesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=inva_TwoDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=inva_TwoDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=inva_CommonStockAndWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=inva_CommonStockAndWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=inva_WarrantsPurchasedIn2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=inva_WarrantsPurchasedIn2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=inva_WarrantsPurchasedIn2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=inva_WarrantsPurchasedIn2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=inva_WarrantsPurchasedIn2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=inva_WarrantsPurchasedIn2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=inva_ArmataConvertibleNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=inva_ArmataConvertibleNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=inva_ArmataTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=inva_ArmataTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=inva_OneDirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=inva_OneDirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=inva_InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=inva_InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430384599232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Summarized Financial Data (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="6">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Current assets</a></td>
<td class="nump">$ 344,219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 443,511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Current liabilities</a></td>
<td class="nump">38,134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">134,968<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementRelatedDisclosuresAbstract', window );"><strong>Income Statement Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">310,463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">331,339<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 391,866<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="nump">179,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">220,262<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 368,837<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=inva_ArmataPharmaceuticalsIncMember', window );">Armata</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Current assets</a></td>
<td class="nump">36,585<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Noncurrent assets</a></td>
<td class="nump">76,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Current liabilities</a></td>
<td class="nump">21,884<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Noncurrent liabilities</a></td>
<td class="nump">$ 103,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementRelatedDisclosuresAbstract', window );"><strong>Income Statement Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,052<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,446<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,989<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(41,639)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(32,666)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24,227)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (59,512)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (32,650)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23,732)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=inva_EntasisTherapeuticsHoldingsIncMember', window );">Entasis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementRelatedDisclosuresAbstract', window );"><strong>Income Statement Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(52,323)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (125,413)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 23: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=inva_ArmataPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=inva_ArmataPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=inva_EntasisTherapeuticsHoldingsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=inva_EntasisTherapeuticsHoldingsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430379183712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Equity Investment in InCarda (Details) - InCarda<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 15, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 09, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>Director</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee', window );">Number of Investee's Board members currently representing the Company | Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized gain loss from fair value changes in equity investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_CarryingValueWroteOffWarrantExercise', window );">Carrying value wrote off warrant exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss', window );">Unrealized loss from fair value changes in equity investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.7<span></span>
</td>
<td class="nump">$ 0.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_ConsolidatedInvesteesMember', window );">Consolidated Investees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity investment ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.10%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=inva_SeriesCPreferredStockAndWarrantsMember', window );">Series C preferred stock and warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_SecuritiesPurchaseAgreementAmount', window );">Amount of securities purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_SecuritiesPurchaseAgreementWarrantsNumberOfSecuritiesCalledByWarrants', window );">Maximum number of additional shares into which warrants may be converted under the securities purchase agreement | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,117,358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ExtendedExpirationDate', window );">Extended expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=inva_ConvertibleNoteAndWarrantsMember', window );">Convertible note and warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_SecuritiesPurchaseAgreementAmount', window );">Amount of securities purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommonStockMember', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt Conversion, Converted Instrument, Shares Issued | shares</a></td>
<td class="nump">4,093,886<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=inva_SeriesA1PreferredStockMember', window );">Series A1 preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt Conversion, Converted Instrument, Shares Issued | shares</a></td>
<td class="nump">37,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=inva_SeriesD1PreferredStockMember', window );">Series D 1 Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt Conversion, Converted Instrument, Shares Issued | shares</a></td>
<td class="nump">8,771,780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=inva_SeriesD2PreferredStockMember', window );">Series D 2 Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt Conversion, Converted Instrument, Shares Issued | shares</a></td>
<td class="nump">3,369,802<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=inva_SeriesD1WarrantMember', window );">Series D1 Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt Conversion, Converted Instrument, Shares Issued | shares</a></td>
<td class="nump">2,490,033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants | $ / shares</a></td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares to be purchased under the securities purchase agreement | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,469,432<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt Conversion, Converted Instrument, Shares Issued | shares</a></td>
<td class="nump">5,117,358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_DebtInstrumentTransactionCost', window );">Transaction cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity and long-term investments at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.8<span></span>
</td>
<td class="nump">$ 6.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment', window );">Impairment of equity investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.9<span></span>
</td>
<td class="nump">$ 9.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants | $ / shares</a></td>
<td class="nump">$ 0.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=inva_SeriesCWarrantsAndSeriesDWarrantsMember', window );">Series C Warrants and Series D Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity and long-term investments at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=inva_SeriesDWarrantsMember', window );">Series D Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity and long-term investments at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_SeriesDPreferredStockMember', window );">Series D Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi', window );">Payments to acquire equity securities</a></td>
<td class="nump">$ 2.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=inva_SeriesD1AndD2PreferredStockAndCommonStockMember', window );">Series D 1 And D 2 Preferred Stock And Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity and long-term investments at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.7<span></span>
</td>
<td class="nump">$ 3.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs, Level 3 | Backsolve Valuation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ExpectedHoldingPeriod', window );">Expected Holding Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_RiskFreeInterestRate', window );">Risk Free Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_DividendYield', window );">Dividend Yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_PercentageOfEstimatedVolatility', window );">Estimated volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">122.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">114.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_CarryingValueWroteOffWarrantExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value wrote off warrant exercise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_CarryingValueWroteOffWarrantExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_DebtInstrumentTransactionCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument transaction cost</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_DebtInstrumentTransactionCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_DividendYield">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Dividend yield.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_DividendYield</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_ExpectedHoldingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected holding period of equity method investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_ExpectedHoldingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_ExtendedExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Extended expiration date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_ExtendedExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of the Company's Board members currently serving on the Investee's Board.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_PercentageOfEstimatedVolatility">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of estimated volatility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_PercentageOfEstimatedVolatility</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_RiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Risk free interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_RiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_SecuritiesPurchaseAgreementAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount the Company agreed to pay for common stock and warrants upon satisfaction of certain closing conditions under the terms of the securities purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_SecuritiesPurchaseAgreementAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_SecuritiesPurchaseAgreementWarrantsNumberOfSecuritiesCalledByWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of additional common stock shares into which the warrants may be converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_SecuritiesPurchaseAgreementWarrantsNumberOfSecuritiesCalledByWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents an other than temporary decline in value that has been recognized against an investment accounted for under the equity method of accounting. The excess of the carrying amount over the fair value of the investment represents the amount of the write down which is or was reflected in earnings. The written down value is a new cost basis with the adjusted value of the investment becoming its new carrying value subject to the equity accounting method. Evidence of a loss in value might include, but would not necessarily be limited to, absence of an ability to recover the carrying amount of the investment or inability of the investee to sustain an earnings capacity which would justify the carrying amount of the investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481664/323-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482736/825-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized loss on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-19<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 321<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479567/321-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=inva_IncardaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=inva_IncardaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_ConsolidatedInvesteesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_ConsolidatedInvesteesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=inva_SeriesCPreferredStockAndWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=inva_SeriesCPreferredStockAndWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=inva_ConvertibleNoteAndWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=inva_ConvertibleNoteAndWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=inva_SeriesA1PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=inva_SeriesA1PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=inva_SeriesD1PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=inva_SeriesD1PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=inva_SeriesD2PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=inva_SeriesD2PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=inva_SeriesD1WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=inva_SeriesD1WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=inva_SeriesCWarrantsAndSeriesDWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=inva_SeriesCWarrantsAndSeriesDWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=inva_SeriesDWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=inva_SeriesDWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_SeriesDPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_SeriesDPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=inva_SeriesD1AndD2PreferredStockAndCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=inva_SeriesD1AndD2PreferredStockAndCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=inva_OptionPricingModelBacksolveValuationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=inva_OptionPricingModelBacksolveValuationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430385887312">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Equity Investment in ImaginAb (Details) - Imaginab [Member]<br> $ in Millions</strong></div></th>
<th class="th">
<div>Mar. 14, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 18, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>Director</div>
</th>
<th class="th">
<div>Sep. 14, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Transaction costs to acquire equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee', window );">Number of Investee's Board members currently representing the Company | Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity and long-term investments at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=inva_ImaginabMember', window );">Consolidated Investees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.70%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement', window );">Number of shares to be purchased under the securities purchase agreement | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,051,724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_SecuritiesPurchaseAgreementAmount', window );">Amount of securities purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=inva_SeriesC2PreferredStockMember', window );">Series C2 Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement', window );">Number of shares to be purchased under the securities purchase agreement | shares</a></td>
<td class="nump">270,568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">405,852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_SecuritiesPurchaseAgreementAmount', window );">Amount of securities purchase agreement</a></td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=inva_OneOfImaginabsCommonStockholderMember', window );">One of ImaginAb's Common Stockholders | Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement', window );">Number of shares to be purchased under the securities purchase agreement | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,097,157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_SecuritiesPurchaseAgreementAmount', window );">Amount of securities purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of the Company's Board members currently serving on the Investee's Board.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_SecuritiesPurchaseAgreementAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount the Company agreed to pay for common stock and warrants upon satisfaction of certain closing conditions under the terms of the securities purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_SecuritiesPurchaseAgreementAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total number of shares to be purchased under the terms of a securities purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482736/825-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=inva_ImaginabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=inva_ImaginabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_ConsolidatedInvesteesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_ConsolidatedInvesteesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=inva_SeriesC2PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=inva_SeriesC2PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=inva_OneOfImaginabsCommonStockholderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=inva_OneOfImaginabsCommonStockholderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430387675424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Convertible Promissory Note in Gate Neurosciences (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 06, 2023</div></th>
<th class="th"><div>Feb. 02, 2023</div></th>
<th class="th"><div>Nov. 24, 2021</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireLongtermInvestments', window );">Additional cash investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,218<span></span>
</td>
<td class="nump">$ 13,725<span></span>
</td>
<td class="nump">$ 6,373<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=inva_GateNeuroscienceMember', window );">Gate Neurosciences Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_NumberOfCommonStockIssuedDescription', window );">Number of common stock issued description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The number of common stock shares to be issued in a qualified event shall be equal to the amount due on the conversion date divided by the lesser of a capped conversion price (the &#8220;Capped Conversion Price&#8221;) and the qualified event price (the &#8220;Qualified Event Price&#8221;). The Capped Conversion Price is calculated as $50.0 million divided by the number of shares of common stock outstanding at such time on a fully diluted basis. The Qualified Event Price is the price per share determined by the qualified event. A qualified financing is a sale or series of sales of preferred stock where (i) at least 50 percent of counterparties are not existing shareholders, (ii) net proceeds to Gate are at least $35.0 million, and (iii) the stated or implied equity valuation of Gate is at least $80.0 million. <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireLongtermInvestments', window );">Additional cash investment</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity and long-term investments at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,000<span></span>
</td>
<td class="nump">$ 15,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGain', window );">Unrealized gain from fair value changes in equity investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss', window );">Unrealized loss from fair value changes in equity investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inva_ConvertiblePromissoryNotePurchaseAgreementMember', window );">Convertible Promissory Note Purchase Agreement | Gate Neurosciences Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Debt Instrument, Principal Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, annual interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Convertible notes Face Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,500<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inva_NoteAmendmentAgreementMember', window );">Note Amendment Agreement | Gate Neurosciences Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Convertible notes Face Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inva_SecondNoteAmendmentAgreementMember', window );">Second Note Amendment Agreement | Gate Neurosciences Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Convertible notes Face Value</a></td>
<td class="nump">$ 27,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_NumberOfCommonStockIssuedDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common stock issued description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_NumberOfCommonStockIssuedDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments applied to principal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPaymentPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482736/825-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized loss on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireLongtermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, beyond the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the long-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireLongtermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=inva_GateNeuroscienceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=inva_GateNeuroscienceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inva_ConvertiblePromissoryNotePurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inva_ConvertiblePromissoryNotePurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inva_NoteAmendmentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inva_NoteAmendmentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inva_SecondNoteAmendmentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inva_SecondNoteAmendmentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430384787648">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Equity Investment in Nanolive (Details) - Nanolive [Member]<br> SFr in Millions, $ in Millions</strong></div></th>
<th class="th">
<div>Feb. 18, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 18, 2022 </div>
<div>CHF (SFr) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>Director</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Transaction costs to acquire equity securities | $</a></td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee', window );">Number of Investee's Board members currently representing the Company | Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_NumberOfBoardMembersOfInvestee', window );">Number of the Investee's Board members | Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Fair value of equity securities | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.6<span></span>
</td>
<td class="nump">$ 10.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=inva_NanoliveMember', window );">Consolidated Investees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity investment ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.30%<span></span>
</td>
<td class="nump">15.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=inva_NanoliveMember', window );">Series C preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement', window );">Number of shares to be purchased under the securities purchase agreement | shares</a></td>
<td class="nump">18,750,000<span></span>
</td>
<td class="nump">18,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_SecuritiesPurchaseAgreementAmount', window );">Amount of securities purchase agreement</a></td>
<td class="nump">$ 9.8<span></span>
</td>
<td class="nump">SFr 9.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_NumberOfBoardMembersOfInvestee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total number of Board members of the Investee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_NumberOfBoardMembersOfInvestee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of the Company's Board members currently serving on the Investee's Board.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_SecuritiesPurchaseAgreementAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount the Company agreed to pay for common stock and warrants upon satisfaction of certain closing conditions under the terms of the securities purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_SecuritiesPurchaseAgreementAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total number of shares to be purchased under the terms of a securities purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482736/825-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=inva_NanoliveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=inva_NanoliveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_ConsolidatedInvesteesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_ConsolidatedInvesteesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430391308192">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Available-for-Sale Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-Sale Securities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 170,706<span></span>
</td>
<td class="nump">$ 263,469<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">170,706<span></span>
</td>
<td class="nump">263,469<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Credit loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-Sale Securities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">170,706<span></span>
</td>
<td class="nump">263,469<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 170,706<span></span>
</td>
<td class="nump">$ 263,469<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Money market funds are included in cash and cash equivalents in the consolidated balance sheets.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430379761120">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Schedule of Available-for-Sale Securities Measured at Fair Value on a Recurring Basis (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Dec. 31, 2023</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ConvertibleSeniorDebtFairValueDisclosures', window );">2025 Notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ContingentValueRightsLiability', window );">Contingent value rights liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 359,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 595,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=inva_IspFundLpMember', window );">ISP Fund LP</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_PartnershipAgreementLockUpPeriod', window );">Lock-up period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">36 months<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">36 months<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LimitedPartnersContributedCapital', window );">Contributed to partnership for investing</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 300,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_WithdrawalFromInvestment', window );">Withdrawal from investment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | ISP Fund LP</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">62,900,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">25,100,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember', window );">Equity investment | ISP Fund LP</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">248,500,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">295,400,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=inva_PrivatePlacementPositionsAndConvertibleNotesMember', window );">Private Placement Positions And Convertible Notes | ISP Fund LP</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">60,600,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">54,600,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">705,963,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">639,488,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Money market funds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">170,706,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">263,469,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Term Loan Investment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">27,044,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Term Loan Investment | Armata Term Loan</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Equity investments and Money market funds | ISP Fund LP</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">311,812,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">320,560,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Quoted Price in Active Markets for Identical Assets, Level 1</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">503,162,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">560,546,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Quoted Price in Active Markets for Identical Assets, Level 1 | ISP Fund LP</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">251,207,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Quoted Price in Active Markets for Identical Assets, Level 1 | Money market funds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">170,706,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">263,469,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Quoted Price in Active Markets for Identical Assets, Level 1 | Equity investments and Money market funds | ISP Fund LP</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">265,982,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Significant Other Observable Inputs, Level 2</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">35,297,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">8,059,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Significant Other Observable Inputs, Level 2 | Money market funds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Significant Other Observable Inputs, Level 2 | Term Loan Investment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Significant Other Observable Inputs, Level 2 | Equity investments and Money market funds | ISP Fund LP</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Significant Unobservable Inputs, Level 3</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">167,504,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">70,883,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Significant Unobservable Inputs, Level 3 | Money market funds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Significant Unobservable Inputs, Level 3 | Term Loan Investment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">27,044,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Significant Unobservable Inputs, Level 3 | Equity investments and Money market funds | ISP Fund LP</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">60,605,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">54,578,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember', window );">Nonrecurring basis</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ContingentValueRightsLiability', window );">Contingent value rights liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">359,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">595,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities at estimated fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">427,836,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">506,259,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember', window );">Nonrecurring basis | Debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ConvertibleSubordinatedDebtFairValueDisclosures', window );">2023 Notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">96,089,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ConvertibleSeniorDebtFairValueDisclosures', window );">2025 Notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">200,407,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">197,807,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">2028 Notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">227,070,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">211,768,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Total fair value of debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">427,477,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">505,664,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember', window );">Nonrecurring basis | Quoted Price in Active Markets for Identical Assets, Level 1</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ContingentValueRightsLiability', window );">Contingent value rights liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities at estimated fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember', window );">Nonrecurring basis | Quoted Price in Active Markets for Identical Assets, Level 1 | Debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ConvertibleSubordinatedDebtFairValueDisclosures', window );">2023 Notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ConvertibleSeniorDebtFairValueDisclosures', window );">2025 Notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">2028 Notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Total fair value of debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember', window );">Nonrecurring basis | Significant Other Observable Inputs, Level 2</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">2028 Notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">227,070,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ContingentValueRightsLiability', window );">Contingent value rights liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Total fair value of debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">427,477,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities at estimated fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">427,477,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">505,664,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember', window );">Nonrecurring basis | Significant Other Observable Inputs, Level 2 | Debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ConvertibleSubordinatedDebtFairValueDisclosures', window );">2023 Notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">96,089,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ConvertibleSeniorDebtFairValueDisclosures', window );">2025 Notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">200,407,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">197,807,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">2028 Notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">211,768,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Total fair value of debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">505,664,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember', window );">Nonrecurring basis | Significant Unobservable Inputs, Level 3</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ContingentValueRightsLiability', window );">Contingent value rights liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">359,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">595,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities at estimated fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">359,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">595,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember', window );">Nonrecurring basis | Significant Unobservable Inputs, Level 3 | Debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ConvertibleSubordinatedDebtFairValueDisclosures', window );">2023 Notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ConvertibleSeniorDebtFairValueDisclosures', window );">2025 Notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">2028 Notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Total fair value of debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_ArmataPharmaceuticalsIncMember', window );">Armata | Recurring basis | Convertible debt investment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">51,883,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_ArmataPharmaceuticalsIncMember', window );">Armata | Recurring basis | Equity investment | Common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">81,249,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">31,095,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_ArmataPharmaceuticalsIncMember', window );">Armata | Recurring basis | Equity investment | Warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">35,297,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">8,059,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_ArmataPharmaceuticalsIncMember', window );">Armata | Recurring basis | Quoted Price in Active Markets for Identical Assets, Level 1 | Convertible debt investment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_ArmataPharmaceuticalsIncMember', window );">Armata | Recurring basis | Quoted Price in Active Markets for Identical Assets, Level 1 | Equity investment | Common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">81,249,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">31,095,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_ArmataPharmaceuticalsIncMember', window );">Armata | Recurring basis | Quoted Price in Active Markets for Identical Assets, Level 1 | Equity investment | Warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_ArmataPharmaceuticalsIncMember', window );">Armata | Recurring basis | Significant Other Observable Inputs, Level 2 | Convertible debt investment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_ArmataPharmaceuticalsIncMember', window );">Armata | Recurring basis | Significant Other Observable Inputs, Level 2 | Equity investment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_ArmataPharmaceuticalsIncMember', window );">Armata | Recurring basis | Significant Other Observable Inputs, Level 2 | Equity investment | Common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_ArmataPharmaceuticalsIncMember', window );">Armata | Recurring basis | Significant Other Observable Inputs, Level 2 | Equity investment | Warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">35,297,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">8,059,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_ArmataPharmaceuticalsIncMember', window );">Armata | Recurring basis | Significant Unobservable Inputs, Level 3 | Convertible debt investment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">51,883,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_ArmataPharmaceuticalsIncMember', window );">Armata | Recurring basis | Significant Unobservable Inputs, Level 3 | Equity investment | Common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_ArmataPharmaceuticalsIncMember', window );">Armata | Recurring basis | Significant Unobservable Inputs, Level 3 | Equity investment | Warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_IncardaMember', window );">InCarda | Recurring basis | Equity investment | Warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">605,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_IncardaMember', window );">InCarda | Recurring basis | Quoted Price in Active Markets for Identical Assets, Level 1 | Equity investment | Warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_IncardaMember', window );">InCarda | Recurring basis | Significant Other Observable Inputs, Level 2 | Equity investment | Warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_IncardaMember', window );">InCarda | Recurring basis | Significant Unobservable Inputs, Level 3 | Equity investment | Warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">605,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_GateNeuroscienceMember', window );">Gate Neurosciences Member | Recurring basis | Convertible debt investment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">27,972,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">15,700,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_GateNeuroscienceMember', window );">Gate Neurosciences Member | Recurring basis | Quoted Price in Active Markets for Identical Assets, Level 1 | Convertible debt investment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_GateNeuroscienceMember', window );">Gate Neurosciences Member | Recurring basis | Significant Other Observable Inputs, Level 2 | Convertible debt investment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_GateNeuroscienceMember', window );">Gate Neurosciences Member | Recurring basis | Significant Unobservable Inputs, Level 3 | Convertible debt investment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 27,972,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 15,700,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The investments held by ISP Fund LP, consisted of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">248.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in equity investments, which included private placement positions of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">60.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">62.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in money market funds. A certain portion of the total capital contribution of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">300.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million is no longer subject to a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">36-month</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> lock-up period from the date of such capital contribution. However, we did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t elect to make a withdrawal in 2023, thereby extending the lock-up period and withdrawal elections into subsequent years. </span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The investments held by ISP Fund LP, consisted of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">295.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in equity investments, which included private placement positions and convertible notes of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">54.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">25.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in money market funds. Our total capital contribution of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">300.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million was subject to a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">36-month</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> lock-up period from the date of such capital contributions.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_ContingentValueRightsLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent value rights liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_ContingentValueRightsLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_ConvertibleSeniorDebtFairValueDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of long-term notes which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock. Senior debt has the highest claim on the assets of the issuer in case of bankruptcy or liquidation, due within one year or the normal operating cycle, if longer. Senior note holders are paid off in full before any payments are made to debt holders having a lesser priority of repayment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_ConvertibleSeniorDebtFairValueDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_ConvertibleSubordinatedDebtFairValueDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of subordinated debt obligations which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_ConvertibleSubordinatedDebtFairValueDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_PartnershipAgreementLockUpPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The period of time in which contributors to an investment fund have waived the right of redemption, as defined in the partnership agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_PartnershipAgreementLockUpPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_WithdrawalFromInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Withdrawal From Investment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_WithdrawalFromInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtFairValueDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtFairValueDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LimitedPartnersContributedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of capital contributed by the limited partners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB TOPIC 4.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LimitedPartnersContributedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=inva_IspFundLpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=inva_IspFundLpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=inva_PrivatePlacementPositionsAndConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=inva_PrivatePlacementPositionsAndConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=inva_TermLoanInvestmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=inva_TermLoanInvestmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=inva_ArmataTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=inva_ArmataTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=inva_EquityInvestmentsAndMoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=inva_EquityInvestmentsAndMoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_DebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_DebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_ArmataPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_ArmataPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_IncardaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_IncardaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_GateNeuroscienceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_GateNeuroscienceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430378729840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CAPITALIZED FEES PAID - Schedule of Capitalized Fees Paid (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostLineItems', window );"><strong>Capitalized Fees paid</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostGross', window );">Gross carrying value</a></td>
<td class="nump">$ 220,000<span></span>
</td>
<td class="nump">$ 220,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(136,216)<span></span>
</td>
<td class="num">(122,393)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostNet', window );">Net carrying value</a></td>
<td class="nump">$ 83,784<span></span>
</td>
<td class="nump">97,607<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_CapitalizedFeesPaidWeightedAverageUsefulLife', window );">Weighted average remaining amortization period</a></td>
<td class="text">6 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_CapitalizedFeesPaidFutureAmortizationAbstract', window );"><strong>Capitalized Fees paid, Future amortization</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_CapitalizedFeesPaidRemainingEstimatedAmortizationNextTwelveMonths', window );">Estimated amortization for the year 2024</a></td>
<td class="nump">$ 13,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearTwo', window );">Estimated amortization for the year 2025</a></td>
<td class="nump">13,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearthree', window );">Estimated amortization for the year 2026</a></td>
<td class="nump">13,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFour', window );">Estimated amortization for the year 2027</a></td>
<td class="nump">13,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFive', window );">Estimated amortization for the year 2028</a></td>
<td class="nump">13,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_CapitalizedFeesPaidRemainingEstimatedAmortizationAfterYearFive', window );">Estimated amortization after 2028</a></td>
<td class="nump">14,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalty revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostLineItems', window );"><strong>Capitalized Fees paid</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAmortization', window );">Amortization expense</a></td>
<td class="nump">13,800<span></span>
</td>
<td class="nump">13,800<span></span>
</td>
<td class="nump">$ 13,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostLineItems', window );"><strong>Capitalized Fees paid</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostGross', window );">Gross carrying value</a></td>
<td class="nump">120,000<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostLineItems', window );"><strong>Capitalized Fees paid</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostGross', window );">Gross carrying value</a></td>
<td class="nump">60,000<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_JP', window );">Japan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostLineItems', window );"><strong>Capitalized Fees paid</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostGross', window );">Gross carrying value</a></td>
<td class="nump">40,000<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inva_GSKMember', window );">GSK | Royalty revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostLineItems', window );"><strong>Capitalized Fees paid</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAmortization', window );">Amortization expense</a></td>
<td class="nump">$ 13,823<span></span>
</td>
<td class="nump">$ 13,823<span></span>
</td>
<td class="nump">$ 13,823<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_CapitalizedFeesPaidFutureAmortizationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Capitalized fees paid future amortization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_CapitalizedFeesPaidFutureAmortizationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_CapitalizedFeesPaidRemainingEstimatedAmortizationAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of estimated amortization for assets expected to be recognized after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_CapitalizedFeesPaidRemainingEstimatedAmortizationAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_CapitalizedFeesPaidRemainingEstimatedAmortizationNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of estimated amortization for assets expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_CapitalizedFeesPaidRemainingEstimatedAmortizationNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of estimated amortization for assets expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of estimated amortization for assets expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of estimated amortization for assets expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearthree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of estimated amortization for assets expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearthree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_CapitalizedFeesPaidWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Capitalized fees paid weighted average useful life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_CapitalizedFeesPaidWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated amortization of asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479483/340-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479483/340-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479483/340-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479483/340-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479483/340-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inva_GSKMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inva_GSKMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430378743552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOODWILL AND INTANGIBLE ASSETS (Additional Information) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Aug. 22, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,905<span></span>
</td>
<td class="nump">$ 26,713<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill, impairment losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible Assets Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,784<span></span>
</td>
<td class="nump">5,581<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaboration agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible Assets Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,800<span></span>
</td>
<td class="nump">5,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible Assets Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetResidualValue', window );">Acquired Finite-Lived Intangible Asset, Residual Value</a></td>
<td class="nump">$ 2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In-process research and development | Collaboration agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible Assets Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">$ 68,700<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=inva_LaJollaPharmaceuticalCompanyMember', window );">La Jolla Pharmaceutical Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,411<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">Future amortization expense, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">Future amortization expense, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">Future amortization expense, 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">Future amortization expense, 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">Future amortization expense, 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Future amortization expense, thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible Assets Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 151,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 151,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=inva_EntasisTherapeuticsHoldingsIncMember', window );">Entasis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible Assets Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=inva_EntasisTherapeuticsHoldingsIncMember', window );">Entasis | Collaboration agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible Assets Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=inva_EntasisTherapeuticsHoldingsIncMember', window );">Entasis | In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible Assets Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 71,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetResidualValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expected value at the end of their useful life of a major finite-lived intangible asset class acquired during the period either individually or as part of a group of assets (in either an asset acquisition or business combination). A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetResidualValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=inva_LaJollaPharmaceuticalCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=inva_LaJollaPharmaceuticalCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=inva_EntasisTherapeuticsHoldingsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=inva_EntasisTherapeuticsHoldingsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430388193648">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>GOODWILL AND INTANGIBLE ASSETS - Summary of Accumulated Amortization of Recognized Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Marketed products, Useful Life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_IntangibleAssetsMarketedProductsGross', window );">Marketed products, gross carrying amount</a></td>
<td class="nump">$ 219,700<span></span>
</td>
<td class="nump">$ 151,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_IntangibleAssetsInProcessResearchAndDevelopmentGross', window );">In-process research and development, gross carrying amount</a></td>
<td class="nump">2,600<span></span>
</td>
<td class="nump">72,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_IntangibleAssetsCollaborationAgreementGross', window );">Collaboration agreement, gross carrying amount</a></td>
<td class="nump">35,400<span></span>
</td>
<td class="nump">35,400<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Total gross carrying amount</a></td>
<td class="nump">257,700<span></span>
</td>
<td class="nump">258,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_IntangibleAssetsMarketedProductsAccumulatedAmortization', window );">Marketed products, Accumulated amortization</a></td>
<td class="num">(25,204)<span></span>
</td>
<td class="num">(5,581)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_IntangibleAssetsInProcessResearchAndDevelopmentAccumulatedAmortization', window );">In-process research and development, accumulated amortization</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_IntangibleAssetsCollaborationAgreementAccumulatedAmortization', window );">Collaboration agreement, accumulated amortization</a></td>
<td class="num">(2,161)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(27,365)<span></span>
</td>
<td class="num">(5,581)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_IntangibleAssetsMarketedProductsNet', window );">Marketed products, net carrying amount</a></td>
<td class="nump">194,496<span></span>
</td>
<td class="nump">145,419<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_IntangibleAssetsInProcessResearchAndDevelopmentNet', window );">In-process research and development, net carrying amount</a></td>
<td class="nump">2,600<span></span>
</td>
<td class="nump">72,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_IntangibleAssetsCollaborationAgreementNet', window );">Collaboration agreement, net carrying amount</a></td>
<td class="nump">33,239<span></span>
</td>
<td class="nump">35,400<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net carrying amount</a></td>
<td class="nump">$ 230,335<span></span>
</td>
<td class="nump">$ 252,919<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Marketed products, Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Marketed products, Useful Life</a></td>
<td class="text">8 years<span></span>
</td>
<td class="text">8 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_IntangibleAssetsCollaborationAgreementAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intangible assets collaboration agreement accumulated amortization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_IntangibleAssetsCollaborationAgreementAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_IntangibleAssetsCollaborationAgreementGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intangible assets collaboration agreement gross.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_IntangibleAssetsCollaborationAgreementGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_IntangibleAssetsCollaborationAgreementNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intangible assets collaboration agreement net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_IntangibleAssetsCollaborationAgreementNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_IntangibleAssetsInProcessResearchAndDevelopmentAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intangible sssets in process research and development accumulated amortization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_IntangibleAssetsInProcessResearchAndDevelopmentAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_IntangibleAssetsInProcessResearchAndDevelopmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross amount of In-process research and development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_IntangibleAssetsInProcessResearchAndDevelopmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_IntangibleAssetsInProcessResearchAndDevelopmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net amount of In-process research and development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_IntangibleAssetsInProcessResearchAndDevelopmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_IntangibleAssetsMarketedProductsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amortization amount of Marketed Products.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_IntangibleAssetsMarketedProductsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_IntangibleAssetsMarketedProductsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross amount of Marketed products.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_IntangibleAssetsMarketedProductsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_IntangibleAssetsMarketedProductsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net amount of Marketed Products.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_IntangibleAssetsMarketedProductsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430391584224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEET COMPONENTS - Schedule of Inventory, net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 11,257<span></span>
</td>
<td class="nump">$ 5,757<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work-in-process</a></td>
<td class="nump">15,670<span></span>
</td>
<td class="nump">25,052<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">13,810<span></span>
</td>
<td class="nump">25,088<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventory</a></td>
<td class="nump">$ 40,737<span></span>
</td>
<td class="nump">$ 55,897<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480581/330-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480581/330-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480581/330-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430386499088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BALANCE SHEET COMPONENTS - Additional Information (Details) - La Jolla Pharmaceutical Company - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_FairValueAdjustmentsOfInventoryFromAcquistion', window );">Fair Value Adjustments Of Inventory From Acquistion</a></td>
<td class="nump">$ 23.0<span></span>
</td>
<td class="nump">$ 49.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_AmortizationOfFairValueAdjustmentsOfCostOfProductsSold', window );">Amortization of fair value adjustments of Cost of products sold</a></td>
<td class="nump">$ 27.2<span></span>
</td>
<td class="nump">$ 10.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_AmortizationOfFairValueAdjustmentsOfCostOfProductsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortization of fair value adjustments of cost of products sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_AmortizationOfFairValueAdjustmentsOfCostOfProductsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_FairValueAdjustmentsOfInventoryFromAcquistion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of net fair value adjustment of inventory resulting from the acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_FairValueAdjustmentsOfInventoryFromAcquistion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inva_LaJollaPharmaceuticalCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inva_LaJollaPharmaceuticalCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430389324160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEET COMPONENTS - Schedule Of Other Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_AccruedContractManufacturingLiability', window );">Accrued contract manufacturing expenses</a></td>
<td class="nump">$ 1,966<span></span>
</td>
<td class="nump">$ 8,382<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_AccruedClinicalLiability', window );">Accrued clinical expenses</a></td>
<td class="nump">591<span></span>
</td>
<td class="nump">692<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_AccruedResearchLiability', window );">Accrued research expenses</a></td>
<td class="nump">185<span></span>
</td>
<td class="nump">349<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_AccruedProfessionalServices', window );">Accrued professional services</a></td>
<td class="nump">$ 8,876<span></span>
</td>
<td class="nump">$ 3,977<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other Liabilities, Current<span></span>
</td>
<td class="text">Other Liabilities, Current<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of lease liabilities</a></td>
<td class="nump">$ 1,207<span></span>
</td>
<td class="nump">$ 1,316<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Royalty obligation payable</a></td>
<td class="nump">1,928<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_DeferredRoyaltyObligationCurrent', window );">Current portion of deferred royalty obligation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,639<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_AccruedLicenseFeesAndRoyalties', window );">Accrued license fees and royalties</a></td>
<td class="nump">1,575<span></span>
</td>
<td class="nump">943<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilities', window );">Other</a></td>
<td class="nump">3,370<span></span>
</td>
<td class="nump">2,909<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Total other accrued liabilities</a></td>
<td class="nump">$ 19,698<span></span>
</td>
<td class="nump">$ 21,207<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_AccruedClinicalLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Clinical Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_AccruedClinicalLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_AccruedContractManufacturingLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued contract manufacturing liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_AccruedContractManufacturingLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_AccruedLicenseFeesAndRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued license fees and royalties</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_AccruedLicenseFeesAndRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_AccruedProfessionalServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Professional Services</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_AccruedProfessionalServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_AccruedResearchLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Research Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_AccruedResearchLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_DeferredRoyaltyObligationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current portion of deferred royalty obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_DeferredRoyaltyObligationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430391237984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEET COMPONENTS -Schedule of Other Long-term Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_DeferredRoyaltyObligationNonCurrent', window );">Long-term portion of deferred royalty obligation</a></td>
<td class="nump">$ 69,876<span></span>
</td>
<td class="nump">$ 67,947<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Total other long-term liabilities<span></span>
</td>
<td class="text">Total other long-term liabilities<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term portion of lease liabilities</a></td>
<td class="nump">$ 1,635<span></span>
</td>
<td class="nump">$ 2,376<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ContingentValueRightsLiability', window );">Contingent value rights liability</a></td>
<td class="nump">359<span></span>
</td>
<td class="nump">595<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Total other long-term liabilities</a></td>
<td class="nump">$ 71,870<span></span>
</td>
<td class="nump">$ 70,918<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_ContingentValueRightsLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent value rights liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_ContingentValueRightsLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_DeferredRoyaltyObligationNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-term portion of deferred royalty obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_DeferredRoyaltyObligationNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430384940816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - 2012 Plan and ESPP (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>Item </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=inva_EquityIncentivePlan2012Member', window );">2012 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares remaining available for issuance</a></td>
<td class="nump">2,924,185<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=inva_EmployeeStockPurchasePlanMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Purchase price as a percentage of fair market value of stock</a></td>
<td class="nump">85.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveAndOverlappingOfferingPeriod', window );">Total duration of consecutive and overlapping offering periods</a></td>
<td class="text">24 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods', window );">Number of offering periods | Item</a></td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod', window );">Duration of purchase period</a></td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate', window );">Maximum contributions as a percentage of employee's eligible compensation</a></td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee', window );">Maximum number of shares an employee may purchase during any purchase period</a></td>
<td class="nump">2,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountAsContributionOfEligibleCompensation', window );">Maximum value of shares an employee may purchase in a calendar year | $</a></td>
<td class="nump">$ 25,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=inva_EmployeeStockPurchasePlanTwentyTwentyThreeMember', window );">2023 ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Purchase price as a percentage of fair market value of stock</a></td>
<td class="nump">85.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveAndOverlappingOfferingPeriod', window );">Total duration of consecutive and overlapping offering periods</a></td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate', window );">Maximum contributions as a percentage of employee's eligible compensation</a></td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee', window );">Maximum number of shares an employee may purchase during any purchase period</a></td>
<td class="nump">2,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountAsContributionOfEligibleCompensation', window );">Maximum value of shares an employee may purchase in a calendar year | $</a></td>
<td class="nump">$ 25,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common Stock, Capital Shares Reserved for Future Issuance</a></td>
<td class="nump">2,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares remaining available for issuance</a></td>
<td class="nump">2,500,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveAndOverlappingOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the consecutive and overlapping offering period for the offering of share-based payment awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveAndOverlappingOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountAsContributionOfEligibleCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum amount the employee may contribute of employee's eligible compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountAsContributionOfEligibleCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of purchase periods having duration of six months each.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the duration of each purchase period within each consecutive and overlapping purchase period for offering of share-based payment awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The highest quantity of shares an employee can purchase under the plan per period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=inva_EquityIncentivePlan2012Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=inva_EquityIncentivePlan2012Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=inva_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=inva_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=inva_EmployeeStockPurchasePlanTwentyTwentyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=inva_EmployeeStockPurchasePlanTwentyTwentyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430388127392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Director Compensation Program (Details) - RSUs - Non-employee director<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>Installment</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialEquityGrantValue', window );">One time grant of shares, value</a></td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalEquityGrantValue', window );">Pro rata shares grant, value</a></td>
<td class="nump">225,000<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments', window );">Number of annual installments | Installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityGrantValue', window );">Annual grant of shares, value</a></td>
<td class="nump">$ 225,000<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalEquityGrantValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The additional value of shares granted to newly appointed non-employee director on the date that such individual joins the Board.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalEquityGrantValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityGrantValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of shares granted annually to independent directors upon re-election the to Board.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityGrantValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialEquityGrantValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of shares granted to newly appointed non-employee director on the date that such individual joins the Board.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialEquityGrantValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of annual installments that RSUs granted to newly appointed independent directors will vest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430387721984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 5,837<span></span>
</td>
<td class="nump">$ 7,347<span></span>
</td>
<td class="nump">$ 2,017<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost</a></td>
<td class="nump">9,511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=inva_EmployeeStockPurchasePlanMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">43<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">1,980<span></span>
</td>
<td class="nump">3,057<span></span>
</td>
<td class="nump">490<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost</a></td>
<td class="nump">$ 4,861<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-Average Amortization Period (Years)</a></td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 3,663<span></span>
</td>
<td class="nump">4,053<span></span>
</td>
<td class="nump">1,280<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost</a></td>
<td class="nump">$ 4,430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-Average Amortization Period (Years)</a></td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">RSAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 168<span></span>
</td>
<td class="nump">194<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost</a></td>
<td class="nump">$ 220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-Average Amortization Period (Years)</a></td>
<td class="text">1 year 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 4,645<span></span>
</td>
<td class="nump">5,305<span></span>
</td>
<td class="nump">2,017<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 1,192<span></span>
</td>
<td class="nump">$ 2,042<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=inva_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=inva_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430374776672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Compensation Awards (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of outstanding options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance at the beginning of the period (in shares)</a></td>
<td class="nump">948,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">828,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(2,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Released RSUs/RSAs (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(275,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance at the end of the period (in shares)</a></td>
<td class="nump">1,499,000<span></span>
</td>
<td class="nump">948,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest at the end of the period (in shares)</a></td>
<td class="nump">1,499,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Exercise Price of Outstanding Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance at the beginning of the period (in dollars per share)</a></td>
<td class="nump">$ 15.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">12.77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">12.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Released RSUs/RSAs (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">15.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance at the end of the period (in dollars per share)</a></td>
<td class="nump">14.09<span></span>
</td>
<td class="nump">$ 15.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest at the end of the period (in dollars per shares)</a></td>
<td class="nump">$ 14.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Additional disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value of options outstanding</a></td>
<td class="nump">$ 3.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value of options exercisable</a></td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable option</a></td>
<td class="nump">519,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual term of options exercisable</a></td>
<td class="text">7 years 11 months 15 days<span></span>
</td>
<td class="text">8 years 3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Total intrinsic value of options exercised</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Total estimated fair value of options vested</a></td>
<td class="nump">$ 1.9<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward', window );"><strong>Number of outstanding RSUs and PSUs/RSAs and PSAs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Balance at the beginning of the period (in shares)</a></td>
<td class="nump">518,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Granted (in shares)</a></td>
<td class="nump">389,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Released RSUs and RSAs (in shares)</a></td>
<td class="num">(284,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures', window );">Forfeited (in shares)</a></td>
<td class="num">(141,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Balance at the end of the period (in shares)</a></td>
<td class="nump">482,000<span></span>
</td>
<td class="nump">518,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest at the end of the period (in shares)</a></td>
<td class="nump">482,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Fair Value per Share at Grant</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Balance at the beginning of the period (in dollars per share)</a></td>
<td class="nump">$ 12.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">12.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue', window );">Exercised (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Released RSUs and RSAs (in dollars per share)</a></td>
<td class="nump">12.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">11.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Balance at the end of the period (in dollars per share)</a></td>
<td class="nump">12.62<span></span>
</td>
<td class="nump">$ 12.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingWeightedAverageFairValuePerShare', window );">Vested and expected to vest at the end of the period (in dollars per share)</a></td>
<td class="nump">$ 12.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Additional disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Total estimated fair value of equity instruments vested</a></td>
<td class="nump">$ 3.9<span></span>
</td>
<td class="nump">$ 2.3<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">RSAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward', window );"><strong>Number of outstanding RSUs and PSUs/RSAs and PSAs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Balance at the beginning of the period (in shares)</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Released RSUs and RSAs (in shares)</a></td>
<td class="num">(14,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures', window );">Forfeited (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Balance at the end of the period (in shares)</a></td>
<td class="nump">16,000<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest at the end of the period (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Fair Value per Share at Grant</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Balance at the beginning of the period (in dollars per share)</a></td>
<td class="nump">$ 14.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue', window );">Exercised (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Released RSUs and RSAs (in dollars per share)</a></td>
<td class="nump">15.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Balance at the end of the period (in dollars per share)</a></td>
<td class="nump">14.93<span></span>
</td>
<td class="nump">$ 14.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingWeightedAverageFairValuePerShare', window );">Vested and expected to vest at the end of the period (in dollars per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee exercised the right during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest non-option equity instruments outstanding that can be converted into shares under award activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingWeightedAverageFairValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Fair Value per Share of fully vested and expected to vest non-option equity instruments outstanding that can be converted into shares under award activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingWeightedAverageFairValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430392156608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Valuation Assumptions (Details) - Employee Stock Option - Innoviva [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Valuation Assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">3.60%<span></span>
</td>
<td class="nump">1.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 1 month 2 days<span></span>
</td>
<td class="text">6 years 14 days<span></span>
</td>
<td class="text">6 years 1 month 9 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Volatility</a></td>
<td class="nump">37.80%<span></span>
</td>
<td class="nump">38.60%<span></span>
</td>
<td class="nump">44.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average estimated fair value of shares granted (in dollars per share)</a></td>
<td class="nump">$ 5.57<span></span>
</td>
<td class="nump">$ 6.43<span></span>
</td>
<td class="nump">$ 5.84<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rate of weighted-average expected volatility for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=inva_InnovivaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=inva_InnovivaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430379526304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Details) - Common Stock [Member] - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 15, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Oct. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Amount of shares repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Stock repurchased and retired during period, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,173,565<span></span>
</td>
<td class="nump">647,394<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_CommonStockAcquiredAverageCostPerShare', window );">Shares repurchased average price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.39<span></span>
</td>
<td class="nump">$ 13.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Stock repurchased and retired during period, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 76.5<span></span>
</td>
<td class="nump">$ 8.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Stock repurchased and retired during period, shares</a></td>
<td class="nump">131,826<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_CommonStockAcquiredAverageCostPerShare', window );">Shares repurchased average price per share</a></td>
<td class="nump">$ 15.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Stock repurchased and retired during period, value</a></td>
<td class="nump">$ 2.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_CommonStockAcquiredAverageCostPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock Acquired Average Cost Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_CommonStockAcquiredAverageCostPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount remaining of a stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased and retired during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430391255312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT - Schedule of Debt (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Apr. 18, 2022</div></th>
<th class="th"><div>Mar. 07, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total debt</a></td>
<td class="nump">$ 453,500<span></span>
</td>
<td class="nump">$ 549,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Less: Unamortized debt discount and issuance costs</a></td>
<td class="num">(7,266)<span></span>
</td>
<td class="num">(9,331)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtLongtermAndShorttermCombinedAmount', window );">Total debt, net</a></td>
<td class="nump">446,234<span></span>
</td>
<td class="nump">540,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Less: Current portion of long-term debt, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">96,193<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Total long-term debt, net</a></td>
<td class="nump">$ 446,234<span></span>
</td>
<td class="nump">444,180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=inva_HealthCareRoyaltyPartnersMember', window );">HealthCare Royalty Partners</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_RoyaltyAgreementMaximumPotentialPayoutPercent', window );">Maximum potential royalty payout</a></td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_RoyaltyAgreementIncreaseInMaximumPotentialPayoutPercent', window );">Increase in maximum potential payout percent</a></td>
<td class="nump">18.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentTwo', window );">Maximum aggregate royalty payments</a></td>
<td class="nump">$ 225,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentOne', window );">Required payment for breach of agreement, payment one</a></td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_PaymentsForRoyaltyAgreement', window );">Payment for royalty agreement</a></td>
<td class="nump">18,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyThreeNotesMember', window );">2023 Notes | Convertible subordinated notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_DebtInstrumentPrincipalAmount', window );">Total debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">96,204<span></span>
</td>
<td class="nump">$ 96,200<span></span>
</td>
<td class="nump">$ 96,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Less: Unamortized debt discount and issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (200)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyFiveNotesMember', window );">2025 Notes | Convertible senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_DebtInstrumentPrincipalAmount', window );">Total debt</a></td>
<td class="nump">192,500<span></span>
</td>
<td class="nump">192,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Less: Unamortized debt discount and issuance costs</a></td>
<td class="num">(1,205)<span></span>
</td>
<td class="num">(1,917)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyEightNotesMember', window );">2028 Notes | Convertible senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_DebtInstrumentPrincipalAmount', window );">Total debt</a></td>
<td class="nump">261,000<span></span>
</td>
<td class="nump">261,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Less: Unamortized debt discount and issuance costs</a></td>
<td class="num">(6,061)<span></span>
</td>
<td class="num">(7,403)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inva_RoyaltyFinancingAgreementMember', window );">Royalty Financing Agreement | Loans Payable [Member] | HealthCare Royalty Partners</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseBorrowings', window );">Interest expense</a></td>
<td class="nump">6,500<span></span>
</td>
<td class="nump">1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_DeferredRoyaltyObligations', window );">Deferred royalty obligations</a></td>
<td class="nump">69,900<span></span>
</td>
<td class="nump">70,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_RoyaltyPayments', window );">Royalty Payments</a></td>
<td class="nump">$ 5,400<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_InterestRateOfDeferredRoyaltyObligation', window );">Percentage of interest rate</a></td>
<td class="nump">16.46%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_DebtInstrumentPrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Principal Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_DebtInstrumentPrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_DeferredRoyaltyObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred royalty obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_DeferredRoyaltyObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_InterestRateOfDeferredRoyaltyObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest rate of deferred royalty obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_InterestRateOfDeferredRoyaltyObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_PaymentsForRoyaltyAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments For Royalty Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_PaymentsForRoyaltyAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_RoyaltyAgreementIncreaseInMaximumPotentialPayoutPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty agreement increase in maximum potential payout percent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_RoyaltyAgreementIncreaseInMaximumPotentialPayoutPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_RoyaltyAgreementMaximumPotentialPayoutPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty agreement, maximum potential payout, percent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_RoyaltyAgreementMaximumPotentialPayoutPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty agreement required payment for breach of agreement payment one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty agreement required payment for breach of agreement payment two.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_RoyaltyPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_RoyaltyPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtLongtermAndShorttermCombinedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the aggregate of total long-term debt, including current maturities and short-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtLongtermAndShorttermCombinedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate amount of interest expense on all borrowings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.7,8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=inva_HealthCareRoyaltyPartnersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=inva_HealthCareRoyaltyPartnersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyThreeNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyThreeNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleSubordinatedDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleSubordinatedDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyFiveNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyFiveNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=inva_SeniorUnsecuredConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=inva_SeniorUnsecuredConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyEightNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyEightNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inva_RoyaltyFinancingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inva_RoyaltyFinancingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430373635136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT - Convertible Subordinated Notes (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 18, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 07, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2014 </div>
<div>$ / shares </div>
<div>$ / Item</div>
</th>
<th class="th">
<div>Jan. 31, 2013 </div>
<div>USD ($) </div>
<div>Item </div>
<div>$ / shares </div>
<div>$ / Item </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfUnsecuredDebt', window );">Payment for repurchase of debt instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 96,204,000<span></span>
</td>
<td class="nump">$ 165,131,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,422,000<span></span>
</td>
<td class="nump">4,359,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(20,662,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Debt discount and issuance costs, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,266,000)<span></span>
</td>
<td class="num">(9,331,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyThreeNotesMember', window );">2023 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Convertible notes Face Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyThreeNotesMember', window );">2023 Notes | Convertible subordinated notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Convertible notes Face Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 287,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, annual interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Portion of debt retired, face value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 144,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 144,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchaseAmount', window );">Portion of debt retired, carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">144,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,900,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfUnsecuredDebt', window );">Payment for repurchase of debt instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 165,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 165,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_DebtInstrumentRepurchasePercentage', window );">Percentage of notes repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnamortizedDebtIssuanceExpense', window );">Unamortized debt issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_DebtInstrumentPrincipalAmount', window );">Principal</a></td>
<td class="nump">$ 96,200,000<span></span>
</td>
<td class="nump">96,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">96,204,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Debt discount and issuance costs, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (200,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Net Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,193,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtAbstract', window );"><strong>Interest expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtExcludingAmortization', window );">Contractual interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,000<span></span>
</td>
<td class="nump">2,617,000<span></span>
</td>
<td class="nump">5,121,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,000<span></span>
</td>
<td class="nump">302,000<span></span>
</td>
<td class="nump">580,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Total interest and amortization expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 96,000<span></span>
</td>
<td class="nump">$ 2,919,000<span></span>
</td>
<td class="nump">$ 5,701,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyThreeNotesMember', window );">2023 Notes | Convertible subordinated notes | Privately-negotiated capped call option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_NumberOfDerivativeInstrumentsPurchased', window );">Number of derivative instruments purchased | Item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityStrikePrice1', window );">Strike price for the underlying number of shares (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19.77<span></span>
</td>
<td class="nump">$ 27.79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeCapPrice', window );">Cap price for the underlying number of shares (in dollars per share) | $ / Item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27.04<span></span>
</td>
<td class="nump">38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyThreeNotesMember', window );">2023 Notes | Convertible subordinated notes | Stock prices below $27.79 per share | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_NumberOfSharesReceivableOnSettlementOfDerivativeInstrument', window );">Net shares settlement payable to the entity | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyThreeNotesMember', window );">2023 Notes | Convertible subordinated notes | Stock prices above $38.00 per share | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_NumberOfSharesReceivableOnSettlementOfDerivativeInstrument', window );">Net shares settlement payable to the entity | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,779,659<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyThreeNotesMember', window );">2023 Notes | Old Rate [Member] | Convertible subordinated notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.36%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyThreeNotesMember', window );">2023 Notes | New Rate [Member] | Convertible subordinated notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.37%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=inva_InnovivaCommonStockMember', window );">Innoviva's Common Stock | 2023 Notes | Convertible subordinated notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Notes converted into common stock, Amount</a></td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common stock | 2023 Notes | Convertible subordinated notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Conversion rate for shares of common stock per $1,000 principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.5818<span></span>
</td>
<td class="nump">35.9903<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19.77<span></span>
</td>
<td class="nump">$ 27.79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_DebtInstrumentPrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Principal Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_DebtInstrumentPrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_DebtInstrumentRepurchasePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Portion of debt Instrument, repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_DebtInstrumentRepurchasePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_NumberOfDerivativeInstrumentsPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of derivative instruments purchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_NumberOfDerivativeInstrumentsPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_NumberOfSharesReceivableOnSettlementOfDerivativeInstrument">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of shares payable to the entity on settlement of derivative instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_NumberOfSharesReceivableOnSettlementOfDerivativeInstrument</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-7<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRepurchaseAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value amount of debt instrument that was repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRepurchaseAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRepurchasedFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of the original debt instrument that was repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRepurchasedFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeCapPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cap rate on a price risk derivative such as a cap or collar. A payment or receipt is triggered if the market rate exceeds the cap rate on the contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeCapPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:perUnitItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebtAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebtAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebtExcludingAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebtExcludingAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityStrikePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise or strike price stated in the contract for options indexed to the issuer's equity shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481648/480-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)(2)<br> -SubTopic 40<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityStrikePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfUnsecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to repay long-term debt that is not secured by collateral. Excludes repayments of tax exempt unsecured debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfUnsecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnamortizedDebtIssuanceExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnamortizedDebtIssuanceExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyThreeNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyThreeNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleSubordinatedDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleSubordinatedDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityTypeAxis=inva_PrivatelyNegotiatedCappedCallOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityTypeAxis=inva_PrivatelyNegotiatedCappedCallOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_CallOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_CallOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_PutOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_PutOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=inva_OldDebtInstrumentInterestRateBeforeRepurchaseOfNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=inva_OldDebtInstrumentInterestRateBeforeRepurchaseOfNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=inva_NewDebtInstrumentInterestRateAfterRepurchaseOfNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=inva_NewDebtInstrumentInterestRateAfterRepurchaseOfNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=inva_InnovivaCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=inva_InnovivaCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430376853056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT - Convertible Senior Notes (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 07, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 07, 2017 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jul. 31, 2014 </div>
<div>$ / shares </div>
<div>$ / Item</div>
</th>
<th class="th">
<div>Jan. 31, 2013 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>$ / Item</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>$ / Item</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 18, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jan. 01, 2022</div></th>
<th class="th">
<div>Aug. 01, 2017 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfUnsecuredDebt', window );">Payment for repurchase of debt instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 96,204<span></span>
</td>
<td class="nump">$ 165,131<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ConvertibleDebtInstrumentLiabilityComponentAbstract', window );"><strong>Liability component</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">453,500<span></span>
</td>
<td class="nump">549,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Debt discount and issuance costs, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,266)<span></span>
</td>
<td class="num">(9,331)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyThreeNotesMember', window );">2023 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Convertible notes Face Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 96,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyFiveNotesMember', window );">2025 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_DebtConversionCommonStockPriceToConversionPriceRatioPercentage', window );">Common stock price to current conversion price ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_DebtConversionConvertedInstrumentAverageTradePricePercentage', window );">Average trading price percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.87%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentOfFinancingAndStockIssuanceCosts', window );">Total issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Liability issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Equity issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyFiveNotesMember', window );">2025 Notes | ASU 2020-06</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized Debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 67,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.88%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyFiveNotesMember', window );">2025 Notes | Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyEightNotesMember', window );">2028 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCovenantTerms', window );">Debt instrument, covenant terms description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The indenture governing the 2028 Notes contains customary terms and covenants, including a merger covenant and that upon certain events of default occurring and continuing, either the Trustee or the holders of at least 25% of the aggregate principal amount of the outstanding Notes may declare 100% of the principal of, and accrued and unpaid interest, if any, on, all the Notes to be due and payable immediately.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=inva_SeniorUnsecuredConvertibleNotesMember', window );">Convertible senior notes | 2025 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_DebtInstrumentRatioOfRepurchasePriceToThePrincipalAmount', window );">Ratio of repurchase price to the principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.88%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ConvertibleDebtInstrumentLiabilityComponentAbstract', window );"><strong>Liability component</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_DebtInstrumentPrincipalAmount', window );">Principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 192,500<span></span>
</td>
<td class="nump">192,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Debt discount and issuance costs, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,205)<span></span>
</td>
<td class="num">(1,917)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Net carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">191,295<span></span>
</td>
<td class="nump">190,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseBorrowingsAbstract', window );"><strong>Interest expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtExcludingAmortization', window );">Contractual interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,813<span></span>
</td>
<td class="nump">4,813<span></span>
</td>
<td class="nump">4,813<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">712<span></span>
</td>
<td class="nump">692<span></span>
</td>
<td class="nump">657<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Total interest and amortization expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,525<span></span>
</td>
<td class="nump">5,505<span></span>
</td>
<td class="nump">13,368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=inva_SeniorUnsecuredConvertibleNotesMember', window );">Convertible senior notes | 2025 Notes | Over-Allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Convertible notes Face Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_PortionOfDebtInstrumentFaceAmountExercised', window );">Portion of debt instrument face amount, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=inva_SeniorUnsecuredConvertibleNotesMember', window );">Convertible senior notes | 2025 Notes | Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Convertible notes Face Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 192,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, annual interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=inva_SeniorUnsecuredConvertibleNotesMember', window );">Convertible senior notes | 2025 Notes | Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Conversion rate for shares of common stock per $1,000 principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57.924<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt instrument maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aug. 15,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_DebtInstrumentConvertibleConversionPremium', window );">Conversion premium (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=inva_SeniorUnsecuredConvertibleNotesMember', window );">Convertible senior notes | 2028 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Convertible notes Face Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 261,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt instrument maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar. 15,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of convertible notes, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 252,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_DebtConversionCommonStockPriceToConversionPriceRatioPercentage', window );">Common stock price to current conversion price ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_DebtConversionConvertedInstrumentAverageTradePricePercentage', window );">Average trading price percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_DebtInstrumentRatioOfRepurchasePriceToThePrincipalAmount', window );">Ratio of repurchase price to the principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ConvertibleDebtInstrumentLiabilityComponentAbstract', window );"><strong>Liability component</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_DebtInstrumentPrincipalAmount', window );">Principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 261,000<span></span>
</td>
<td class="nump">261,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Debt discount and issuance costs, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,061)<span></span>
</td>
<td class="num">(7,403)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Net carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">254,939<span></span>
</td>
<td class="nump">253,597<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseBorrowingsAbstract', window );"><strong>Interest expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtExcludingAmortization', window );">Contractual interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,546<span></span>
</td>
<td class="nump">4,514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,342<span></span>
</td>
<td class="nump">1,061<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Total interest and amortization expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,888<span></span>
</td>
<td class="nump">5,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=inva_SeniorUnsecuredConvertibleNotesMember', window );">Convertible senior notes | 2028 Notes | Privately-negotiated capped call option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeCapPrice', window );">Cap price for the underlying number of shares (in dollars per share) | $ / Item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.985<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_PurchasesOfCappedCallsInConnectionWithConvertibleSeniorNotes', window );">Purchases of capped calls in connection with convertible senior notes due 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=inva_SeniorUnsecuredConvertibleNotesMember', window );">Convertible senior notes | 2028 Notes | Over-Allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Convertible notes Face Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_PortionOfDebtInstrumentFaceAmountExercised', window );">Portion of debt instrument face amount, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=inva_SeniorUnsecuredConvertibleNotesMember', window );">Convertible senior notes | 2028 Notes | Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, annual interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=inva_SeniorUnsecuredConvertibleNotesMember', window );">Convertible senior notes | 2028 Notes | Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Conversion rate for shares of common stock per $1,000 principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38.1432<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleSubordinatedDebtMember', window );">Convertible subordinated notes | 2023 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Convertible notes Face Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 287,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, annual interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Debt Instrument, Repurchased Face Amount</a></td>
<td class="nump">$ 144,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 144,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfUnsecuredDebt', window );">Payment for repurchase of debt instrument</a></td>
<td class="nump">165,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 165,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ConvertibleDebtInstrumentLiabilityComponentAbstract', window );"><strong>Liability component</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_DebtInstrumentPrincipalAmount', window );">Principal</a></td>
<td class="nump">96,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">96,204<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 96,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Debt discount and issuance costs, net</a></td>
<td class="num">$ (200)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseBorrowingsAbstract', window );"><strong>Interest expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtExcludingAmortization', window );">Contractual interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85<span></span>
</td>
<td class="nump">2,617<span></span>
</td>
<td class="nump">5,121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="nump">302<span></span>
</td>
<td class="nump">580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Total interest and amortization expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 96<span></span>
</td>
<td class="nump">$ 2,919<span></span>
</td>
<td class="nump">$ 5,701<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleSubordinatedDebtMember', window );">Convertible subordinated notes | 2023 Notes | Privately-negotiated capped call option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeCapPrice', window );">Cap price for the underlying number of shares (in dollars per share) | $ / Item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27.04<span></span>
</td>
<td class="nump">38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleSubordinatedDebtMember', window );">Convertible subordinated notes | 2023 Notes | Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Conversion rate for shares of common stock per $1,000 principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.5818<span></span>
</td>
<td class="nump">35.9903<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19.77<span></span>
</td>
<td class="nump">$ 27.79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_ConvertibleDebtInstrumentLiabilityComponentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>n/a</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_ConvertibleDebtInstrumentLiabilityComponentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_DebtConversionCommonStockPriceToConversionPriceRatioPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of common stock price as a percentage of conversion price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_DebtConversionCommonStockPriceToConversionPriceRatioPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_DebtConversionConvertedInstrumentAverageTradePricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average trading price per $1,000 of Notes with respect to product of the closing common stock price and the conversion rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_DebtConversionConvertedInstrumentAverageTradePricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_DebtInstrumentConvertibleConversionPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage above the last reported sale price of the Company's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_DebtInstrumentConvertibleConversionPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_DebtInstrumentPrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Principal Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_DebtInstrumentPrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_DebtInstrumentRatioOfRepurchasePriceToThePrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Ratio of repurchase price to the principal amount of debt instrument that was repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_DebtInstrumentRatioOfRepurchasePriceToThePrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_PortionOfDebtInstrumentFaceAmountExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Portion of debt instrument face amount, exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_PortionOfDebtInstrumentFaceAmountExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_PurchasesOfCappedCallsInConnectionWithConvertibleSeniorNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchases of capped calls In connection with convertible senior notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_PurchasesOfCappedCallsInConnectionWithConvertibleSeniorNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-7<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRepurchasedFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of the original debt instrument that was repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRepurchasedFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeCapPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cap rate on a price risk derivative such as a cap or collar. A payment or receipt is triggered if the market rate exceeds the cap rate on the contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeCapPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:perUnitItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseBorrowingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseBorrowingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebtExcludingAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebtExcludingAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCovenantTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the conditions for borrowing under the credit facility including the nature of any restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCovenantTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentOfFinancingAndStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentOfFinancingAndStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfUnsecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to repay long-term debt that is not secured by collateral. Excludes repayments of tax exempt unsecured debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfUnsecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyThreeNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyThreeNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyFiveNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyFiveNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyEightNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyEightNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=inva_SeniorUnsecuredConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=inva_SeniorUnsecuredConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityTypeAxis=inva_PrivatelyNegotiatedCappedCallOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityTypeAxis=inva_PrivatelyNegotiatedCappedCallOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleSubordinatedDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleSubordinatedDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430391546960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DEBT - Debt Maturities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtByMaturityAbstract', window );"><strong>Long-term debt maturities for years ending December 31:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2025</a></td>
<td class="nump">192,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2026</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2027</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">2028</a></td>
<td class="nump">261,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total</a></td>
<td class="nump">$ 453,500<span></span>
</td>
<td class="nump">$ 549,704<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtByMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtByMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430391234960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES - Additional Information (Details) - ft&#178;<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Nov. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating lease, Weighted average remaining lease term</a></td>
<td class="text">2 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_OperatingLeaseWeightedAverageIncrementalBorrowingRate', window );">Operating lease, weighted average incremental borrowing rate</a></td>
<td class="nump">7.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=inva_BurlingameCaliforniaMember', window );">Burlingame, California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetRentableArea', window );">Rentable square feet</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,111<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=inva_WalthamMassachusettsMember', window );">Waltham Massachusetts Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Lease space</a></td>
<td class="nump">20,062<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_OperatingLeaseWeightedAverageIncrementalBorrowingRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease Weighted Average Incremental Borrowing Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_OperatingLeaseWeightedAverageIncrementalBorrowingRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetRentableArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net rentable area for properties owned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetRentableArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=inva_BurlingameCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=inva_BurlingameCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=inva_WalthamMassachusettsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=inva_WalthamMassachusettsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430386487744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES - Schedule of Components of Least Cost (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease, Cost [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Straight line operating lease costs</a></td>
<td class="nump">$ 1,428<span></span>
</td>
<td class="nump">$ 1,585<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease costs</a></td>
<td class="nump">189<span></span>
</td>
<td class="nump">155<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease costs</a></td>
<td class="nump">$ 1,617<span></span>
</td>
<td class="nump">$ 1,740<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430388881744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES - Schedule of Supplemental Cash Flow Information Related to Lease (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included in the measurement of operating lease liabilities:</a></td>
<td class="nump">$ 1,542<span></span>
</td>
<td class="nump">$ 790<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease right-of-use assets obtained in exchange for operating lease obligations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,323<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_RightOfUseAssetsObtainedThroughAcquistions', window );">Right-of-use assets obtained through acquisitions</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,185<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_RightOfUseAssetsObtainedThroughAcquistions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Right of Use Assets Obtained Through Acquistions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_RightOfUseAssetsObtainedThroughAcquistions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430387864080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES - Schedule of Future Minimum Lease Payments (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 1,373<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">1,428<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree', window );">Thereafter</a></td>
<td class="nump">149<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total</a></td>
<td class="nump">3,093<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">$ (251)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Liabilities and Equity<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 2,842<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, operating lease, liability, to be paid, after year three.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430392167072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Income tax expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 7,799<span></span>
</td>
<td class="nump">$ 40,822<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">2,177<span></span>
</td>
<td class="nump">464<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current</a></td>
<td class="nump">9,976<span></span>
</td>
<td class="nump">41,286<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">6,594<span></span>
</td>
<td class="nump">26,026<span></span>
</td>
<td class="nump">70,893<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="num">(2,194)<span></span>
</td>
<td class="num">(625)<span></span>
</td>
<td class="nump">5,539<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit', window );">Total deferred</a></td>
<td class="nump">4,400<span></span>
</td>
<td class="nump">25,401<span></span>
</td>
<td class="nump">76,432<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total income tax expense, net</a></td>
<td class="nump">$ 14,376<span></span>
</td>
<td class="nump">$ 66,687<span></span>
</td>
<td class="nump">$ 76,439<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal, state, and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national, regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430387889008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Reconciliation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract', window );"><strong>Differences between the expected U.S. federal statutory income tax to income tax expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Expected tax at federal statutory rate</a></td>
<td class="nump">$ 40,747<span></span>
</td>
<td class="nump">$ 58,928<span></span>
</td>
<td class="nump">$ 93,507<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State income tax, net of federal benefit</a></td>
<td class="nump">1,433<span></span>
</td>
<td class="num">(1,414)<span></span>
</td>
<td class="nump">848<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Federal and state research credits</a></td>
<td class="num">(1,582)<span></span>
</td>
<td class="num">(2,453)<span></span>
</td>
<td class="nump">1,260<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationDeductionsOther', window );">Section 250 deduction</a></td>
<td class="num">(15,274)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense', window );">Noncontrolling Interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,468<span></span>
</td>
<td class="num">(21,626)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary', window );">Impact of consolidation and deconsolidation of subsidiaries</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(8,897)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">1,219<span></span>
</td>
<td class="num">(125)<span></span>
</td>
<td class="nump">1,129<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(12,167)<span></span>
</td>
<td class="nump">13,180<span></span>
</td>
<td class="nump">1,321<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total income tax expense, net</a></td>
<td class="nump">$ 14,376<span></span>
</td>
<td class="nump">$ 66,687<span></span>
</td>
<td class="nump">$ 76,439<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationDeductionsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other deductions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationDeductionsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to equity in earnings (loss) of unconsolidated subsidiaries exempt from income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to noncontrolling interest income (loss) exempt from income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430392110832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INCOME TAXES - Deferred Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 182,013<span></span>
</td>
<td class="nump">$ 149,646<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development tax credit carryforwards</a></td>
<td class="nump">21,357<span></span>
</td>
<td class="nump">21,230<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_DeferredTaxAssetsUnrealizedLossesOnInvestmentNet', window );">Unrealized loss on investment, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,032<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_DeferredTaxAssetsDeferredRoyaltyObligationNet', window );">Deferred royalty obligation, net</a></td>
<td class="nump">18,084<span></span>
</td>
<td class="nump">17,404<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">6,467<span></span>
</td>
<td class="nump">8,527<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets before valuation allowance</a></td>
<td class="nump">227,921<span></span>
</td>
<td class="nump">202,839<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(169,249)<span></span>
</td>
<td class="num">(144,808)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets</a></td>
<td class="nump">58,672<span></span>
</td>
<td class="nump">58,031<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_DeferredTaxLiabilitiesDepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="num">(39,064)<span></span>
</td>
<td class="num">(50,587)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesInvestments', window );">Unrealized Gain on Investment, net</a></td>
<td class="num">(13,747)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_DeferredTaxLiabilitiesInventoryFairValueAdjustment', window );">Inventory fair value adjustment</a></td>
<td class="num">(6,424)<span></span>
</td>
<td class="num">(12,410)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(805)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Net deferred tax (liabilities)</a></td>
<td class="num">$ (563)<span></span>
</td>
<td class="num">$ (5,771)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_DeferredTaxAssetsDeferredRoyaltyObligationNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets deferred royalty obligation, net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_DeferredTaxAssetsDeferredRoyaltyObligationNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_DeferredTaxAssetsUnrealizedLossesOnInvestmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets unrealized losses on investment, net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_DeferredTaxAssetsUnrealizedLossesOnInvestmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_DeferredTaxLiabilitiesDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities depreciation and amortization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_DeferredTaxLiabilitiesDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_DeferredTaxLiabilitiesInventoryFairValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities inventory fair value adjustment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_DeferredTaxLiabilitiesInventoryFairValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from investments (excludes investments in subsidiaries and equity method investments).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430387726432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Additional Tax Disclosures (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_IncomeTaxesLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued', window );">Accrued interest and penalties</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Uncertain Tax Positions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">19,443<span></span>
</td>
<td class="nump">16,324<span></span>
</td>
<td class="nump">$ 14,872<span></span>
</td>
<td class="nump">$ 15,185<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Net decrease in tax portions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (313)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Net increase in tax portions</a></td>
<td class="nump">3,119<span></span>
</td>
<td class="nump">$ 1,452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=inva_EntasisTherapeuticsHoldingsIncMember', window );">Entasis Therapeutics Holdings Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_IncomeTaxesLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_FederalNetOperatingLossesEstimatedUtilizationAmount', window );">Federal net operating losses estimated utilization amount</a></td>
<td class="nump">155,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=inva_LaJollaPharmaceuticalCompanyMember', window );">La Jolla Pharmaceutical Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_IncomeTaxesLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_FederalNetOperatingLossesEstimatedUtilizationAmount', window );">Federal net operating losses estimated utilization amount</a></td>
<td class="nump">309,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_IncomeTaxesLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">543,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_IncomeTaxesLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_IncomeTaxesLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward amount</a></td>
<td class="nump">$ 33,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_FederalNetOperatingLossesEstimatedUtilizationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Federal net operating losses estimated utilization amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_FederalNetOperatingLossesEstimatedUtilizationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_IncomeTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_IncomeTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=inva_EntasisTherapeuticsHoldingsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=inva_EntasisTherapeuticsHoldingsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=inva_LaJollaPharmaceuticalCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=inva_LaJollaPharmaceuticalCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430384881136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 13, 2024</div></th>
<th class="th"><div>Oct. 06, 2023</div></th>
<th class="th"><div>Feb. 02, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Feb. 23, 2024</div></th>
<th class="th"><div>Nov. 24, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 453,500<span></span>
</td>
<td class="nump">$ 549,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireLongtermInvestments', window );">Additional cash investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,218<span></span>
</td>
<td class="nump">$ 13,725<span></span>
</td>
<td class="nump">$ 6,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=inva_GateNeuroscienceMember', window );">Gate Neurosciences Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireLongtermInvestments', window );">Additional cash investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=inva_GateNeuroscienceMember', window );">Gate Neurosciences Member | Convertible Promissory Note Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, annual interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Convertible notes Face Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=inva_GateNeuroscienceMember', window );">Gate Neurosciences Member | Note Amendment Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Convertible notes Face Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | ImaginAb Convertible Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, annual interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Gate Neurosciences Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireLongtermInvestments', window );">Additional cash investment</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Gate Neurosciences Member | Convertible Promissory Note Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Convertible notes Face Value</a></td>
<td class="nump">27,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Gate Neurosciences Member | Note Amendment Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Convertible notes Face Value</a></td>
<td class="nump">$ 33,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireLongtermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, beyond the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the long-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireLongtermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=inva_GateNeuroscienceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=inva_GateNeuroscienceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inva_ConvertiblePromissoryNotePurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inva_ConvertiblePromissoryNotePurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inva_NoteAmendmentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inva_NoteAmendmentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_ImaginabConvertibleNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_ImaginabConvertibleNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>118
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MJAU0GCZX=2,ZA2%P2T/@'IFVW_FG,4WD_.-W@KEVN\(1N?-SVSEW;24VHX[
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MBR)'1J8CO-0+[XO><@E5^+!:V""FY@R2>)Z1IA')*+4#S$: F1?@G="L>@/
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M]G+9W]74/\K;<0,Q41KQ4]HH5G?LV:54B4E1L*OF"V.Q F'@2!PR,1GQ,QD
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M\TC\TWUTXE2([P[;D-[2H;QUP]:*2>(6DR>;Z7O[CE:@,9SG]<5CXB@<<_Q
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M<.V@]E/&Y'JA#VA[;O 74$L#!!0    ( !B(75A987X'$@,  $X)   8
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MVPL'-[1F6,R<0GT1-$/*.=P!4J=X+E+10\)\MOOTA(^4"]G@T F.E(NEHTM
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M*"V TD+"6NB8[:2@YKD3$R%!J?:3O7/0$;&##G5[NEAF\'($N^4;:ZBB+XI
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M_XJ0'2PZP'@BWG3IM@%2J\5TT6F#NMWYK,ATK!U9](ARTLRO7U*R18L\HAW
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M[*++#.$PM)D.T.'$&KPR0#1U]P:"L!^"[AJ^S4NUWOBA<0Y>;6$73.+4F?<
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M(F<"  "_!P  &    'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;)V56T_;,!2
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M=_180,QTPX!^K%@GL-W39J^ (!SR9=,OLK.<8 06A-WM/E^]C )AYWF7-4G
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MD^\F2=M^6D#,)+![WX+[WTHM_0_M6Z*LF4XX@,)HO@-VIJ'M!?3&'5U64S%
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MTWG6Z:0^@RZ)-84T/0*V7*>BS)3ZPUL)ZR\=N6:!E1C<Q?;W@'!=](P/F^Y
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M%4"A. 8%HCRJ>%SHS2)4WPJZIB4ZXRZ[&'A/Z]9MM [266V7U,DKDVEX%>Z
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M*EV!JRYMJ%T9T&O9 [PS' 2,I 7@C$+$B5IDWC)B:,LE($%A QZI (4W 7=
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M%%VPP^,AF=<Y5LD8-):[&68UUZJ>S=GO-9 :'M)VCP;L7=C"&M^T-J0,!;+
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M?"@;-;&1Z.U.&./R[P0Q%S:I80O:+8>')CL(,V# 9EMH15(\19\F\$U"9Q.
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MH59PBN9A2.CT9VK!F@<F!@,:L4JG=1"VPZGUFN[H_,*?'#2:A&"!USQ9X@F
M:)8(R+PO$RC"N"H1]R"P=&T5#!M7C3 "D::AZ2I)L'$R?<3NRGONG:GZE>I3
M/4#BC#TF5RK$UI&I=UW],2P *S2J#* <*V4Z&@E6XX,0@JUO7 4(P4*PTO"
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M=3?W(SUQT_\:R1XS%=X^PD.B)K[QQ+1S\2,()S^[DVE3B;)?EV03'"^KMV;
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MX6L% H=MB>>%2( =@7>G-#?877B3U-"+OW^R.;'W#8T8VT'4P&/[+HTSM_T
M3I?DX(-( >X]MA)RP[#/*9A5MZBVWF$^UO,1WJT>H^S!?83O"0"P#E/IUCF-
M7 )@"A,V.C(5 "#7IA1TG!K ="C'ZWW5VZ_FS5?_QNMP/(UFLSX"@>$8XLBL
M]3IH?Q3-9U.*?G$TC>?AXW8D\#D\R0_OKK'Q!Z;&(Z#<IW>GIM%X.&9=/P)R
M'OQ>"WCY-?TJ#5H,Q%KSTRW^6__#-Q?F]U[JX>97<W[AQ1I; 3.Q@JG]WG1\
M:GH6W(=2[>C77Y:J+-66_MP(#NSB 'B^4N"Q[0=<P/\<T.O_!E!+ P04
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M3@4L'-=U\;_'JH"Q,U$ [M;DA -027Y&JL/+VRP*) Y[(D SNV(+%*9WB2I
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MJN/I+<OUA57<36!E!58&Q"4X_YEVY2NN53&5&J4\+8L'(2:("BUDP%IES(K
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M E!VH%[$Y:$FX]GUH8=49FJ^DBG-8.!QL!ACLJC_STHQS3C#VN3*%U*:FKC
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M:]&X'MB3<SU\"%JG0>$%ZEFCU"C6T3*V(6611IM-28<K.-,J;B,?S!KH>4K
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M\@?-P*@#X/43\$Y V4N6$]50I+G1K.+R]$QC/A#--:$^3/(6*4!G4\$K1).
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MJ3DI-][2J20]OSQ;75U^7OU^^=?%.;R_N+B!J]7E^7SH"9H%AED+<]K )$_
MC!+X:+0O'%SH'//' $/BM">6W!,[39Y%/,=L .FH#TF<I,_@I7M'TX"7/N6H
MJ*072O[ ',Z(JJ5ZH(GS\/=J[<+RGT-^-ZCCPZA\94Y<)3)<1'0G'-I;C):O
M7HPF\;MG.(_WG,?/H?__Y#P+<YCD=  'X:$;J VB@TK(O ^[0F8%9(:N(\7,
M;.A&;B7'C2^74"!T#DK4.BO>6%3"DW8I%5(!:WS  6_@P\UO!(<603C8&$7O
M@COI4;ZQ7*/EG/=>7VKPA:D=H;HC6)7&>ODCF((*K31Y* O^2WI?M&1K-YZ,
M.MH:I6^2.(WA)8R2N!_'G5GOHK;TGMT+)<<P:22:H?>KJ(3NG(Z;TV;H?;#&
M.<B$M7=2;^%6J)J@6AOMV%ME65W630!$E_=K&*63?C*:P!'/DZ2?'J=PU/M$
M+^]/F"]AEO:GLS%-CJ?]23R%SP7E[>> "@YA8X*,F5L*GB]06B A608&M<--
MK4#1RT?,34G/:<9VZLIPA+'9LYFD##;9X]3R065-7M,5D;H%I<JI,+RA(?54
M"/14^2((/W+48F9LSNX315HQ#.]+/KI%30YNK"G)M%)B;;B""),B(/06B2 U
M&5@YYM&MB9#P?K"V"T\M&R"7J7,0++<?]DL<J)2=  >300)W*"QCY[ELBU;J
MIJTUM+?"Y@SB#P5;TD]GJF;'R)-/QB,0GU<O9I3Y=]>M8]?D^U8'^' R>C=X
M7+UD#U \A#EP N1'\Y"[7.#A:M%D1)XXKN5T,&-VBO$&7!J= #RD_E$HY'\4
M#Q,)B2%;8[ZH-$[[C=[TD=Z]/$O,^H$?28T[Z"1!GP@;CW8 AQ["8:=C4?UM
M0U_F"JVU;YK7?G??^E=-QWL0;[X;/@J[E52,"C>D&@^F;R.P32]N%MY4H?^M
MC:=N&J8%?;Z@90$ZWQC*9;M@ _L/HN6_4$L#!!0    ( !B(75AY%M6VN04
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MG<L<A[O>WWLDN_?5(3P7<V#O%=+()BTX%[CKG#2(]UY/2PQ0UAKMZS?L]9_
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MR-)).GT&;[KU<QKPIM_ N[KSPFW8W^>9=093X9^GG(P0LZ<AJ#S>V(;G<#;
M_+=@[F&P>/4B.9B</$-PMB4X>P[]?POQ/$J2C-C2Z?RVTK( 8U^].$J3PQ/6
MNG^MV'7N= :FBVTZ9-IC8FMN"J97K! &ZT4;R[AWE3;B7R@89[;B!K (&V_R
M"HN -4:7AM?,H]Z&K2N15VP-F)F;_B[?,*?92Y9,)J,)IJ^45(EX#)V)+<(Z
MK@JARHAO:277=8U[+#DQ8I^K)T_=<K/,[>_(-F'F4M<-5QL"%,[N@3*!#+"G
M(5=SBUT/TT%9'GJ$'>)B+GV@A)#6<^7( TZ[XJSDBA!XGFM3<)4#%JRKV(V7
M@&YFKY,C8EE[67*'H8OQ(4I+R+T13B#GJP<DJTI@Y[DCBLGQ=#9D'&..[0[K
MA_U,!J1=.CGI;PY3R<DO>(2X1WRY80I*[40XZVM/6";)7Z(..(&4L1F:L/61
MGONVT)VY/ZT-HZ!B-#.A>.BJ2-0 "6HH])J&K 8T>BI(*\!@<,GL+A22KVV4
MN=,TXC9@:E*N+R8*T6.\2YE'"J]0 .;P[B"3\,T=RJWPEL$ N[8H+":[S0W0
M>2-VLT6V(8NYM)IEE-$%/)<+4>!._OGKI"=Y7[IA5R3:RZ)UK_/!A9-VOA6X
M%]2>[S7=+C&^:T%Y3L4 E*NX._A;Z%!(!)5SCULP,GC[K5Z+NM$VID>@G4F>
MWV+Q$0FA"TO:1>$,E%YRK'XJ8NR3(@K?ZI,[C]I%<;%L*; $A\<0P=:5G0N[
M,'15N\;ZQQL3:P];#68'N^=&@ M5NN*AZ_0+4*LRN,0M:F))N* V(>:\$0[)
M*(!B.YEYB]W0(@:-VNK&0LFAZSC])!E2_.ZYD"%J(6W"7C0O084T;2%RC3TJ
M!"*X'4.%DU90-F\C).S640P 4YAY)');)P66W3 D%BIGO6UBH6/H*0GQ[A3*
M4Z=U(9A=SA+I79(.P_F%!D+'Q4P*:C+,APSB.?9X+&JRY[7VRCUNI^\H43J6
M&&EHVB(VVI<5PTL7ZOW+8;V?EP>SP^'T>-:I+6*2]MMI\(#Q>PQ-";OPXQTP
M'253RKFV^:RHFR!QTG''ES=([T'4L;F]9$>C>7=O('T=$VH#W+ 8P*\I3Q]3
M'B:'T^'\8/Y#I-/1]/B[21\>]%DO?6;ASD-L'X\(QUIJ%7@'F?'X.&;)/*S.
M@CL5,MOS*4'CH_3@ASR:CXZ_7X9TE.P<.L<R;FNN3ZHELX9PLSC,Q6+TU,-H
MW'NMUF#*\":G#HYGQX?K=G;[[#^/K]W=]OB?X2,WI<"ZE+!"T\GH<#Y@)K[#
MX\#I)KQ],^WP)1U^5OC7!0QMP/65UJX;T ';/T.+_P!02P,$%     @ &(A=
M6$+UP1T]&0  \5H  !D   !X;"]W;W)K<VAE971S+W-H965T,C$N>&ULY3QI
MD]LVEM_]*U ]SI1=1<LB=?NJ:MO)Q*EDXK6=2>UN[0>*A"3&%*D!R)9[?OV^
M P#!0U)W,MGL[%8EEEK$\?#N"WQQ+-5GO9.R$E_V>:%?7NVJZO#LZ5.=[.0^
MUJ/R( MXLBG5/J[@3[5]J@]*QBE-VN=/H_%X_G0?9\75JQ?TVWOUZD595WE6
MR/=*Z'J_C]7M:YF7QY=7X97]X4.VW57XP]-7+P[Q5GZ4U4^']PK^>NI62;.]
M+'16%D+)S<NKZ_#9ZRF.IP%_R^11>]\%GF1=EI_QCW?IRZLQ B1SF52X0@P?
M-_*-S'-<",#XNUGSRFV)$_WO=O5OZ.QPEG6LY9LR_SE+J]W+J^652.4FKO/J
M0WG\5IKSS'"]I,PU_2N./#9:7(FDUE6Y-Y,!@GU6\&?\Q>#!F[ <GY@0F0D1
MP<T;$91OXRI^]4*51Z%P-*R&7^BH-!N RPHDRL=*P=,,YE6OWG[]^M.+IQ6L
MA'\_3<RLUSPK.C$KC,0/95'MM/BZ2&7:7N I@.#@B"P<KZ.S*[Z5R4A,PD!$
MXVAR9KV).]>$UIN<7&]=B;>93O)2UTJ*_[Q>ZTH!#_S7T&EYK>GP6B@7S_0A
M3N3+*V!\+=6-O'KUYS^%\_'S,Y!.':33<ZN?I,#Y66$T$CA3_%@KX$(X;%*"
MI.A*BW(CJIT4FS('B<N*[;,'@%RY7TN%"'[PZ%T!S\M:QT6J'Q.^\9_H 7W[
M:UE)+1Z*/_]I&871<_BVF@?1>(I/9^9IN(J"V7AL/_'1TCR*YF$PAD?F\\&G
MLHISAF\ZF]"LV705+&#![Z76S\1/1;PO597]0Z8\+ 6:E751"0!/9%K7<9%(
M.!R>[)%8!-%\+A[#MU4PF83BL;=#( I08M,IP#N9PC;C8+*8F&W>U$I)6/2
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M^W=U3M]A>1D#L+AN(-9RFQ4%X:"P0P)"80_B(X"* F'I$5BHRX,E/_ZU*W/
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M,W:IPN9A Z&!  59&Q463D=AXYP1X$J1/O0'348K-PC8[AC?X@-K@8C(Y+"
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MGK[NP)1(A0/@^:8$"3!_X ;N+=>O_AM02P,$%     @ &(A=6$+,9W-K#
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MH2P-P/NI076H;VB!]I/TV1]02P,$%     @ &(A=6&DZY2V2"P  1!X  !D
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MM9)(05J ]TL#R[1_B$'_X?CBOU!+ P04    "  8B%U8MK":6NL#   A"0
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M#LR0C?_5BT$S$9K44L9]S_S71#=S[Q?5P2]R\K_11UM\2 L'AP'ZL4/U'6\
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MNQ\E; 1E<9;?I>Y?E,@'PQIC0B%'14*?GI(\ ;<%BA75H20?I^0?X" .B@,
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MW+8=D,TI;A@M-O;\+82F];9D3E\OE$:!WJ^$T ?&.#A^#P?_ E!+ P04
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M3XF<-(F!6=HC$8ICQW=[2,YS_-CK)[G,388I+NAE.-^/]PP7@Q=>'\%%P#:
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MD>CFG-$IRW !S,\$W'+*#C*HOJV>_@]02P,$%     @ &(A=6-?C9T,# P
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MT."T_\8#7?>R>F)54?6/A;+4C2HSH_:/VCG0_E(INYVX!+L_E-%?4$L#!!0
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MB[Y=R^H%H]%AX/7[A7VL/GB!4Y#P'3P;2K.YC3M,7[@Z[8#B.J2.%K#$SWL
MMO>Y)PD$ZR00O#8);&=2A?%8"CA7!<>0)6%.L;61@I=&85554H5*79K8RZ4^
M36RSP *A8F$RQ_QE+C KA8HUPU66B66\9""*0H,J#)I@AFR?%+L*B6>5PTVL
M[H^FDE,AHQ$#/2D)&+T([\!M^_BTVS:\PPBH/,YE"@>XFT=S<(!/#L>'AP_;
M;MP)VF!"6<_MM0-""0R,AQI"G O,B!%'"3W&/(G ,@MM/!O?GOOSIY6FE!A>
M,!66(FU3]/AM+&&HAS%5I[C.QN4RY7)FKM *CZ\\T\4]<_UU?4L?%I?3G\.+
M*_YG)F<Q<DCX%*=:[1[6F[*X-A<=+1;FJCH1&B^^ICGG#,\$&H"_3X7058<6
M6/]W,?@74$L#!!0    ( !B(75@;/_+;P04   X7   9    >&PO=V]R:W-H
M965T<R]S:&5E=#,U+GAM;,U86V_;-A1^]Z\@W*!( *T6=9>;&$C2%"O0=D&3
M;M@C+=&V4$ET2:II]NMW2,F2DDA,ZJS%'FQ2(L^%/!\_G</C&\:_B VE$GTO
M\E*<3#=2;N>SF4@VM"#B%=O2$D96C!=$PB-?S\264Y)JH2*?.;8=S J2E=/%
ML7YWR1?'K))Y5M)+CD15%(3?GM&<W9Q,\73WXE.VWDCU8K8XWI(UO:+R\_:2
MP].LU9)F!2U%QDK$Z>ID>HKG9SA4 GK&GQF]$;T^4DM9,O9%/;Q+3Z:V\HCF
M-)%*!8'F&SVG>:XT@1]?&Z73UJ82[/=WVM_JQ<-BED30<Y;_E:5R<S*-IBBE
M*U+E\A.[^9TV"_*5OH3E0O^CFWINX$U14@G)BD88/"BRLF[)]V8C>@*1/2+@
M- *.]KLVI+U\0R19''-V@[B:#=I41R]52X-S6:FB<B4YC&8@)Q=O+LZNT>$U
M6>94'!W/)*A4 [.D$3^KQ9T1<>R@#ZR4&X$NRI2F=Q7,P)?6(6?GT)ECU/B&
M)J^0BRWDV(YKT.>V"W2U/G=4WU(.K:N6\H:EU%F8BRU)Z,D4P"XH_T:GBY<O
M<&"_-OCDM3YY)NV+*SA;:953Q%9HS#^CAF'__J@X '(I4<+@U @IE'ZYH6C%
M<CA]6;F>3V![:;&D7&WQY/!=">.L$J1,Q9'><?7G3'3O(Y-4H /T\D7D8.<U
M].+ <FQ/C?K-*(X=R[?M7:N&HF;(";!EPU#33JZ9)'GMG^>[6LKW8BL$A>^I
M$'/TN20%XS+[AZ;UM#03":M*B< ]E E1D3*AL#BULD,46DX0H"/HQ9;K8G34
MLV"A$@C-\\!?UP,SMN6&;F/FO.*<@M*ML@6\ 'N4LW+]FZ2\Z GO5@UKQK';
MZ!Z:>-#:43W/PI&-#!CQ6XSX1HR<KM><KHFD:(>6%'T@LN*9S*B.[#DKOU%8
M QS=4109;0RCZ!H 0UKCHC5>W#'. &M)SP$=,")J1'<0JS%%.%5C-0S%_#[N
M3@L5Y<G?E'!$RQ1P>D>' I77X;"&7P]P07\D[#]$]\!WT"+/$*"@#5!@#%!W
M1H8VWBB[)[V$K6?A7I07_@2?HM:GR$QY]5=?X>-]1I99GLE;?:XOOE:J>\Z*
M+2OA7#Z ]N@6&PV.,R2D)D*2&F8]GEN2O*$7S9T ^/OD.0)OYP&>'\R87/*L
M3+*MAF!#HBI(]TBMYI-#A!69?81N0CB_U9;U":F%@8U,\(W;@,1/_@;=W?QW
M)3 <%1)=?(?<3]"AO3?J'N>5;B^ERCB0H%+1 I<;)/4)S7:V:6T;$K^$K4O]
M3> T)RHNDNFX]&('&O2K6V 0H2@$9CU@H3H4&G/0P?.:;RX>3![]*FJQ"4!3
M<L@EJR%O#U#DPY]C!3B$UK<P2)S67S6R^]JD#R.O0N[:#O*C'56UJI6_I*^A
MLQ4'VE:,8VTKM+$)&-CN4D+[,6;SQX^=67A/&L&]?!7O16Z-V'_LEM.YY?QJ
M?C-;?#+!^7<)3A@8[JGI89_.=AE@VZN9S9"[M30'/.CK! X#AL-1SL,QS(Q]
MW;,M/S+2'^[J FQ,\9])@&;EOXP!_?\? WI6A-W[[9-(,(1J,HCAYX?#\UM0
M[9+S71M:41S] '/ZEN_X=6MK8+F6&T1&7'6U'387=UT)-(B;/>JZQVFJ*RJP
MOQ][[E$H/.Y6ETIC<R[],]ASCPQ\@#TC<WJ(GLF>NR*Y[3V9/0/+#K!FS]#R
M;'>4/1W?LV(WUCVH?>+0B/*NQ,#&:N&Y[+E'*?(3V#,:8,\Q\M2A6'%6Z)EM
M3.2&LVJ]&:H*^NRJ2FFU-_?$'JL<W(%:XA'Z!4KS DV[/O8>H=&!>Q5LN9X#
M_P"N'^#3P(JBJ#8>^H, F_6N* O*U_HB5N4BX$=]6]F^;2][3^LKSFYZ?5/\
M@?!U5@J4TQ6(VJ]"X"Y>7[[6#Y)M]87GDDG)"MW=4))2KB; ^(I!U)L'9:"]
M E_\"U!+ P04    "  8B%U8^U870/8#  ">"0  &0   'AL+W=O<FMS:&5E
M=',O<VAE970S-BYX;6RM5E%OXC@0?N=76-G3JI78AB0$* M(+6WWD!9:%6Y/
MI],]F&0@UMIQUG:6[K^_L9-F@:-H'^XEB1W/]\W,-V-[M)/JJ\X #'D1/-=C
M+S.F&/J^3C(05%_) G+\LY%*4(-#M?5UH8"FSDAP/^QT>KZ@+/<F(S?WI"8C
M61K.<GA21)="4/7C%KC<C;W >YUX9MO,V E_,BKH%I9@_BB>%([\!B5E G+-
M9$X4;,;>33"\[=GU;L$7!CN]]TUL)&LIO]K!+!U['>L0<$B,1:#X^@Y3X-P"
MH1O?:DROH;2&^]^OZ \N=HQE335,)?^3I28;>P./I+"A)3?/<O<[U/'$%B^1
M7+LGV55K>[%'DE(;*6IC]$"PO'K3ESH/>P:#SAL&86T0.K\K(N?E'35T,E)R
M1Y1=C6CVPX7JK-$YEEM1ED;A7X9V9C)]G,]GJ_G]8K4D-XL[,GU<K&:+3_>+
MZ>Q^22Y6=,U!7XY\@US6PD]JW-L*-WP#-PC)7.8FT^0^3R$]!/#1R<;3\-73
MV_ LXATD5R0*VB3LA-$9O*B)/')XT5N12R&8P?HRFM \)5-TE^5;R!,&FMPQ
MG7"I2P7D[YNU-@K+YY]3::A(NJ=);$L-=4$3&'O8,QK4=_ F[]\%O<[',R%T
MFQ"ZY] G2VS1M.1 Y ;=%X7,730X^@Q8J3BGS2F?SZ*>]GF5 4D.*+BC2) "
M\X=IHIIL),<FU\/67T!5)3Q!V4"L05GI6A>SG)A,EAH3KB^=DO81MI"?VOXA
MUAF"6XZB5HP#DM](T.Z& _>.!W'K"U7,EN?!HF!P38(X;JVDH?P_YKV@[][]
M;H><R7_<Y#_^Y?PORZ+@8,L)>:=49^0!<T%F>;5QVAWH&3@UF!(C*WWT*6W.
M,I[6YH ZL=0;2\WVJ-5/:I>3_T$R%V-!68H8BE A2UL8+$]X:4&8-0,BD V;
MR#IGL^2TZX;X[E]W6H]'.BM; A_DYD.IK7,:;*6M#1XM%2"\)!G%%B7OWPW"
M(/Q(HG841JWG<V8F4[+<9KC]?RN99C8;NK$/VL$@/E<)O:82>K]<"0^EL=O&
MG.5,E*)NQ2?ZPVTUIR0_"WU:\II#U!Q5^HJ:@Z#@LE3';:2MWNC?OKR5GL>U
M<*3YC=.VJA#(4PMX4"*(T77*1OW(#N*J4>UGCP3=J(6;!UX8-@;7!]WKNC=+
M1-*)14:5C@*(VIWKJ/49M!X2)HK2./W1'K0A%R2, W)9PQSO%1SW!,919[ M
M'[8'6&VG!/;WSDP!:NMN!IHXAZKCLYEM+A\WU9G[<WEU<YE3M65851PV:-JY
MZF,/J^HV4 V,+-P)O)8&SW/WF>$%"I1=@/\W4IK7@25HKF23?P%02P,$%
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M1$W7[3YU'MN=SZC7O6^[[;L!^H@PC4:"A<EP\@GJAE20^")")YA*PKSH%'U
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MJZ59I(>_T@O)P^0XU)!+R?WDWQDE8RKB!NK[">?RY2)^P/H(7N-?4$L#!!0
M   ( !B(75@.\O4!OP(  $ )   9    >&PO=V]R:W-H965T<R]S:&5E=#,Y
M+GAM;+66:V_:,!2&_XJ52=,F=<V%6]M!) JTBU0@(NVF:=H'$T[ JA.GMM.
MM!\_.X242I!*5?F2^'9>/^=BV=V<\4>Q I!H'=-$](R5E.F5:8IP!3$6YRR%
M1,U$C,=8JBY?FB+E@!>%44Q-Q[+:9HQ)8KC=8LSG;I=EDI($?(Y$%L>8;ZZ!
MLKQGV,9N8$:6*ZD'3+>;XB4$(!]2GZN>6:DL2 R)("Q!'**>T;>OKFU+&Q0K
M?A+(Q5X;:5?FC#WJCK?H&98F @JAU!)8_9YA )1J)<7Q5(H:U9[:<+^]4[\I
MG%?.S+&  :._R$*N>L:%@180X8S*&<M_0.E02^N%C(KBB_)RK66@,!.2Q:6Q
M(HA)LOWC=1F(/0.[><3 *0V<@GN[44$YQ!*[7<YRQ/5JI:8;A:N%M8(CB<Y*
M(+F:)<I.NL-1,)AY_KTWG:#I#9KZHUE?=P+4GPQ1\# >]V>_]4S@W4Z\&V_0
MG]RC_F P?9C<>Y-;Y$_OO($W"M WY'-5*UQN$$X6:/24D51E3Z(O0Y"84/&U
M:TH%K+<UPQ+N>@OG'(.#\!PU[#/D6$[CM;FI_*R<=2IGG4*O>43O#L\9QY+Q
M#8**+\IX0F3&H>".R%JW!?J'QB0A<18?PJ[=1A^D*Y'B$'J&.BD"^#,8[N=/
M=MOZ7N-$HW*B4:@WCCBQ"_,9\BE6_*^C_:<_%Y*K6O][B+MQ NYFQ=VL#?Y(
M2*).$2Q0)B#***(D@D.0]3(MM ',10U0JP)J?60UX/6Q:JC=YIU1;5=.M$]6
M#>T3<'<J[L['5$.]3.?-:KBH@"YJE0(6R1R7>0]9G&82^$MA'$*K%7QG_"XK
MW,N3Y?WR!-RV]7+A6!^3^3=T&L=3;^[=A_IM,<9\21*!*$1*RCKOJ!/+M]?U
MMB-96ER1<R;5A5LT5^J) UPO4/,18W+7T;=N]6AR_P-02P,$%     @ &(A=
M6">7<(]5 @  !P4  !D   !X;"]W;W)K<VAE971S+W-H965T-# N>&ULM53O
M;]HP$/U73IXT;=)&?D"[B85(-+1=I!4B0C?MHPD'6'7BS#:D_>]G.VG$).BW
M?2$^^]Z[]\R=HT;()[5'U/!<\DI-R%[K>NQYJMAC2=5 U%B9DZV0)=4FE#M/
MU1+IQH%*[H6^?^V5E%4DCMQ>)N-('#1G%682U*$LJ7RY02Z:"0G(Z\:2[?;:
M;GAQ5-,=YJ@?ZTR:R.M9-JS$2C%1@<3MA$R#\<W(YKN$GPP;=;(&ZV0MQ),-
MTLV$^%80<BRT9:#F<\0$.;=$1L:?CI/T)2WP=/W*?N>\&R]KJC 1_!?;Z/V$
M?"6PP2T]<+T4S7?L_%Q9OD)PY7ZAZ7)] L5!:5%V8*.@9%7[I<_=/9P @M$%
M0-@!0J>[+>14SJBF<21% ])F&S:[<%8=VHACE?U3<BW-*3,X'<]N\V299JMT
M,8?%'2RRV^74!CE,YS/('Q\>ILO?]B1/[^?I79I,YRN8)LGB<;Y*Y_>0+7ZD
M27J;PV=8(J<:-Y!1J5]@)6FEJ+MZ!1]FJ"GCZF/D:2/:EO:*3N!-*S"\)!"+
M 0R#3Q#ZX?!?N&>\]H;#WG#H^$87^'(JF5(4$EHS3?DY06\2V"D9JYH6."%F
M#!3*(Y+X_;O@VO_VAKQA+V_HV(<7Y)U>(D-U3M[P/\@;]?)&;]Y>AK+ 2IMQ
M!;&%0I2EF2S3I,43B*8RNM<O0,VPMB9JVPGG++1% M]5L>_&,?8'07 5><=3
M<=Y)7]LGXH'*'3/MQ'%K</[@RQ4!V8Y=&VA1NU9?"VT&QRWWYJ5":1/,^58(
M_1K8Z>G?OO@O4$L#!!0    ( !B(75BC>V[Q]0(  &\*   9    >&PO=V]R
M:W-H965T<R]S:&5E=#0Q+GAM;*U6;6_:,!#^*Z=LFCII(R] F#J(1 E3D=8.
MT;U\F/;!)!=B-8F9[4#W[V<[:093H*V4+\1GW_/X[L$^WWC/^+U($24\Y%DA
M)E8JY?;2MD648DY$CVVQ4"L)XSF1RN0;6VPYDMB \LSV',>W<T(+*QB;N24/
MQJR4&2UPR4&4>4[XGRO,V'YBN=;CQ(IN4JDG[&"\)1N\0_EMN^3*LAN6F.98
M",H*X)A,K*E[&8ZTOW'X3G$O#L:@,UDS=J^-13RQ'!T09AA)S4#49X<SS#)-
MI,+X77-:S98:>#A^9/]D<E>YK(G &<M^T%BF$^N#!3$FI,SDBNVOL<YGJ/DB
ME@GS"_O:U[$@*H5D>0U6$>2TJ+[DH=;A .#Z)P!>#?#^!PQ. /HUH/]<P* &
M#(PR52I&AY!($HPYVP/7WHI-#XR8!JW2IX7^V^\D5ZM4X61P._\*B]O9EYLY
M+.<KN+N>KN9P$:(D-!-OX3UXCC>$6R91*&/&BAUR2=<9@L"",@Y%O?0:;! I
MX2C&ME2!:7H[JH.XJH+P3@3A>G##"ID*F!<QQL<$MLJH2<M[3.O*.\L88M2#
MOOM.A^^V!#1[/KS? @_/PZ?EI@?.2,/=T9EL^LV?U#=\_9/AK"4L"B%YJ6Z<
MA)^?E0,L).;B5YO:%=N@G4T7DDNQ)1%.+%4I!/(=6L&;5Z[O?&Q3JDNRL".R
M(Q4'C8J#<^Q!2+-2%QG )%%5!U@",D4@0I4\C"$R9]N4,[5Y3LN\3=IJ"]]L
MH4OJ+G#&]NY0K[-!O%2OCLB.]!HV>@W/ZC5C>:[$4"4HNF^3XBSZI:>L2[*P
M([(CU?Q&-;_3N^IWJ6*79&%'9$<JCAH51T^<O8/+2".$BYAE&>$"MLBK=^9M
MFYIG65^J9D4V.KCK[JCG^<?W/7S*J\K?/GBB<^0;T^H(573*0E:O=3/;=%-3
MTT38_]RK5NR&\ TM!&28**C3&ZGCSJOVIC(DVYH'?\VD:A_,,%4=(7+MH-83
MIM[LVM ;-#UF\!=02P,$%     @ &(A=6/8!]Y.8!0  :Q\  !D   !X;"]W
M;W)K<VAE971S+W-H965T-#(N>&ULO5E=3^,X%/TK5A>M9B2&QLXW"Y6 L!H>
M8!$,.\^F<=N(),XX3@O_?IT/DL9Q,J!:^](FZ;DGOL?7UT?UV8ZREWQ#" >O
M29SFY[,-Y]GI?)XO-R3!^0G-2"I^65&68"YNV7J>9XS@L I*XCDR#&>>X"B=
M+<ZJ9_=L<48+'D<IN6<@+Y($L[=+$M/=^0S.WA\\1.L-+Q_,%V<97I-'PI^R
M>R;NYBU+&"4DS2.: D96Y[,+>!H@MPRH$/]&9)?O78,RE6=*7\J;F_!\9I0C
M(C%9\I("BZ\MN2)Q7#*)<?QJ2&?M.\O _>MW]K^KY$4RSS@G5S3^&85\<S[S
M9B D*US$_('NOI,F(;OD6](XKS[!KL$:,[ L<DZ3)EB,((G2^AN_-D+L!4!G
M)  U 4@.L$8"S"; _&B U018E3)U*I4. >9X<<;H#K 2+=C*BTK,*EJD'Z7E
MO#]R)GZ-1!Q?W%W_ #=W5__<7H/[ZP?P^/WBX1I\ Y<XCY8 IR$(HKC@) 37
M]X_@2T XCN+\JT \/0;@R]%7< 3F(-]@1G(0I> IC7A^O/?@QX86N> 1#X]Z
M]V=S+H9?#F*^;(9Z60\5C0P5(G!+4[[)P74:DK!/,!=YM\FC]^0OT21C0)8G
MP(3' !G(5 SHZN/A2!$>?#P<3F1CME-I5GSFV%06"6&84W:JTK:.M=2Q97<Y
MS3.\).<ST3YRPK9DMOCS#^@8?ZETT4D6:"+K:6:UFEE3[(L[T5FC=$D3 C#G
M+'HN.'Z."> 4W*0IW49;#,0:7+YL:!P2)JKXN5P9*H'K%]G5B\INNUU UW?+
MPMCN2S>$(6CZ90'LPP(%S+$]VVIAO73M-EU;<[IAO?Q5"=O#A'UH&I:4\!"&
MD&T[OI2P N8:MF^H$W;:A)W)-1&0E(JN.;HJ')VK0B=9H(FLIYK;JN9.ELG/
M:K<DX3>\%1UE3=[[>9&+C4#4BBB@3%1%O19 VA551EB-_5AYJ6:D'IFS5P>.
M;9FV5%0*E.]84ND%0Y2'# >I2\IKQ?$FQ:DV1.%5 %FMA'D!= 5H5GJ8O-HO
M\0ZS, =KAM-RVRS$5L4 ^55$_*U4B:15;!;CM(*3)(OI&R&U+B KV'(C;$P%
M4,GC#5*"EK24KA08PY.D&6)L7ZV+W^KB:RF:IJ-H+AM_.-6.YSJ2,D.4;R-+
MUD:!LDPXTHF@T3DM8WI_UIIP\S)-K4LK6Z"+K2_TGJ6%DY5X.=J6E$+69.[^
MSG/BR@U'@3)/#%>J'"4*C6S:$'4)H=^WG)$EHTRIIO-Z*<E&I 'U\S8'&:E0
MGCN246=5X:2K6Y2&&]Q13M2UK=6L:F4+=+'UA>O\*K0.,/EPTNU^6CB=;($N
MMKYPG?.%T];W(@Q/Q>+A1)!S0%XSDHIMEJ9U%1Y7:TMLY1R_-AN[4M^A2_7D
MW5>!098IVUT%RG)-9V1==787'N9WH5;#JY4MT,76EZ[SO'#:]$J^3JG>T%!"
MSY7G7^%-H2=[#!45@MZ(!X.=.873[E0T5GNBL4X&?WKZ=;(%NMCZPG7N%?J'
M--9)[_MIX72R!;K8^G^A=;863;HY/8VU><=^.[0AE.V[ F79GBDM+05JQ+NC
MSE(B>%!?19..]+/UH94MT,76EZXSK^@#YG6ZKS8,O68(H6W(T_\A6*" C<U_
MYU?1;_VJ-]Y6IX,_/?M:_:HNMKYPG5]%A_A5I-6O:F4+=+'UA>O\*OH?_"H:
MNDS'=&7'HD!9#G+D935$C2VKSJZBP^PJTFI7M;(%NMCZTG5V%1UL5]'08_J^
M+?^SH4!YT);]J@(ES_Y\[Q12+/IU=9J;@R4M4EZ?R;5/VQ/CB^J<5'I^"4^#
M^MRWHZF/H6\Q6T=I#F*R$I3&B2NJD=4GN_4-IUEUUOE,.:=)=;DA."2L!(C?
M5U2LGN:F?$%[OK[X#U!+ P04    "  8B%U8ZNAZERH#  !I#0  &0   'AL
M+W=O<FMS:&5E=',O<VAE970T,RYX;6RU5UUOVC 4_2M6)DVKM#9?$*"#2$"8
MVH>V"+KUV4T,L9K8F>U ^^]G.R$E$% KI2_$=NXYN>?$-UP/MY2]\!@A 5[3
MA/"1$0N179LF#V.40GY%,T3DG15E*11RRM8FSQB"D0:EB>E8EF>F$!/#'^JU
M.?.'-!<))FC. ,_3%+*W"4KH=F38QFYA@=>Q4 NF/\S@&BV1^)/-F9R9%4N$
M4T0XI@0PM!H98_LZL"T%T!%_,=KRO3%04IXI?5&3VVAD6"HCE*!0* HH+QLT
M14FBF&0>_TI2HWJF NZ/=^R_M7@IYAER-*7)$XY$/#+Z!HC0"N:)6-#M#2H%
M=15?2!.N?\&VC+4,$.9<T+0$RPQ23(HK?"V-V /8W@F 4P*<0T#G!, M >Y'
M 9T2T-'.%%*T#P$4T!\RN@5,14LV-=!F:K24CXEZ[TO!Y%TL<<*_GSV"V_OI
MP]T,S&<+L+P9+V;@$HR)P)<!3G+U5L 2A3G# B,.?@1(0)SP"QG$8\CD4GG!
M!#S&-.>01'QH"IF;>H(9EGE,BCR<$WG8#KBC1,0<S$B$HCJ!*455RIR=LHES
MEC% X15P[9_ L1RW(:'IQ^%. SSX.-P^H\:MWI.K^=P3?*=>2)/3!5.GF4E]
M2*YY!D,T,N27@B.V08;__9OM6;^:7&J3+&B)K.9@IW*P<XZ]<##:.<CWMK3<
MN<4>OFARLV#U-*OZBFY\>^!TAN9FWZ7CH(%KU6."AIC>H(JI:>I6FKIG-<W^
MY5B\R=(+$=&RL@02#F0)@MER/F^2<Y;PLYNC3;*@);*:D5YEI-=:>7EM.M@F
M6= 26<W!7N5@[TO*JW=<7J[K'I37<9#7Z1^4UW',R?+J5YKZ9S4]Y((+64R8
MK,%2T/ %/$'&(!%-0LY2?79;M$D6M$16LW!063AHK; &;3K8)EG0$EG-0=MZ
M;]&L+RFMDG:_)+H#^Z"T&H*<OG-06PU!UD%IF7L]:(K86O?R'(0T)Z)HVJK5
MZKPPUEWRP?I$G2-T;_M.4QQ"[B!;8_GWEJ"5I+2N>O(?@Q5]?3$1--.=[C,5
MLF_6PUB>A1!3 ?+^BE*QFZ@'5*<K_S]02P,$%     @ &(A=6*"G)Z#$!
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MZD$<)OD_^5X0L94 O3T)J$A S01W3X)3)#C')KA%0D:UE9>2\8"))*,!9VO
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M5*=X?LB6WTBVS(Z=7IB4+,XN%Y0$E*<!ZOV,,;FY21LHCSI'_P-02P,$%
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M]0KG__+Y)O;N.\<"JHFA- :E<2A-H&AFR+1/#DZQOCF FF,HC4)I#$KC4)I
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MS'V<OO-=)QC+J'O<9F)*Y[N^/]'3A:9T$_=D/-ZDTUHRVK1D9&W)7YBB*_R
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M)ASEK&$F58N6VPJV.VS0Z;&@K@)*34>E7(5O=Q4M5/BKAJK<V1VC:IOXBLJ
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M:4%%:W0^AY/=2PA129NJJH?@+>.0ZF&JTLVV."V:9*NUT(=E_H"+Y]V/->C
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MC6H.JKFHYJ&:CVH!JH64IH:N+109P^_?D&&@/2)4LU#-1C4'U5Q4\U#-1[4
MU4)*4Q/6EH\,??MH:[GQL-I3-<V3NVI'4F?8T-[1,S/W+A5R.;3>[?K8.S\4
M#_'6/E>QRU>S^*G:#U;M9C/[OVS_L;[9^.7GU=[8U1ZY0[%,9W'>['J5@S8[
MNF?U)I]J-]Z++W&45WOBUH.F61DK S7[B#=G[*V\SWJ\BOIZ U*U^^^'0;_7
M%XO540C5_DUY/V7-N+K3<:__H[B3,UFM.B^Z=MM9Z.MEHYJ#:BZJ>:CFHUJ
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M8>K[&>?KCE^Q.OM!4BT5+O/I;53$[4DX.G.'%C10S4(U&]4<5'/-KXLMV\O
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MXZI5W0)\DT7=R4%[%:AFH9J-:@ZJN:CFH9J/:@&JA92F!JSM58Q&P#H56IU
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MN8^$O#$JXYMD*M[=W65YN4SKXZ\.Q9LW%W*I<?/8XWJ_E^[D3?HQ]\X:VMY
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MTOP">?Z)<_&VDPO4"Y<7_P)02P,$%     @ &(A=6&Z)&FVM#0  ;ZP  !D
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MWL;O=%,21J4B(TL[$FH?3=-!(4QL*.P' :&=R[@B[$<LE:[0^+OF201=_AY
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M[.Z7"@>:H%FF<UBQSDO @$($3$BMLD!]PX!*<TO:QQU96'UKNJ\*U)<'J+0
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MH0O _24'U94GNH+JBYKKOP!02P,$%     @ &(A=6$:':T]Z!   N18  !D
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M<R]S:&5E=#4Y+GAM;*U7:6_C-A#]*X2Z*':!)CI\):EMP%?2 '&:^DA1%/U
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MWGN"\'DPX<.-[@%W#=2D&19:VWF"0WK)U%A')818:.T#$8(0^G!6[:6Q_M:
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M.QI<QX\2#YVL_$YQI=_1X#JF2JS2MOJ[88#Q'E$KVR#5DN3?J4'__6=N#OG
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ME>M.VF\N,26Z),YL!\II?_R<CR8$C!N0]TO)A]\G[_/8?O/$]6A+V7>^)D2
MERB,^;BS%B*YMBR^7),(\RN:D%C>65$682%/V;/%$T:PGP=%H05MV[,B',2=
MR2B_-F>3$4U%&,1DS@!/HPBSW0T)Z7;<<3JO%QZ"Y[7(+EB348*?R8*(QV3.
MY)E5H?A!1&(>T!@PLAIWILXU@L,L(&_Q5T"V?.\89%2>*/V>G=S[XXZ=941"
MLA09!)8_&S(C89@AR3S^*4$[U3.SP/WC5_2[G+PD\X0YF='P6^"+];@SZ "?
MK' :B@>Z_964A'H9WI*&//\+MF5;NP.6*1<T*H-E!E$0%[_XI11B+P#V3@3
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M?S)4V0#T)U*:U<)N4/VVPK]02P,$%     @ &(A=6 (VED+G P  @PP  !D
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MN8+FPDWUXEK3SJIR6R=F=+YA6\R\D_(K&=M')T1]//^*Q99F$@H\ 3_G-@0
M49YXRX7BN3DTKKF"(ZBYW,%7 A': )XGG*NWA3Z'UM\=XW\!4$L#!!0    (
M !B(75C*56V,*@,  +$(   9    >&PO=V]R:W-H965T<R]S:&5E=#8W+GAM
M;*U6;4_;,!#^*U8V34P"DB9-0UD;B;Y,F\2@HK!]0/O@IM?6PK$SVVGIO]_9
M+:&%P)C$E\2.[QX_]]R=G<Y*JCN] ##D/N="=[V%,<6I[^ML 3G5Q[( @2LS
MJ7)J<*KFOBX4T*ESRKD?!D'+SRD37MIQWT8J[<C2<"9@I(@N\YRJ=0^X7'6]
MAO?PX8K-%\9^\--.0><P!G-3C!3._ IERG(0FDE!%,RZWEGCM)]8>V?PD\%*
M[XR)C60BY9V=?)]VO< 2 @Z9L0@47TOH ^<6"&G\V6)ZU9;6<7?\@/[5Q8ZQ
M3*B&ON2_V-0LNMZ)1Z8PHR4W5W+U#;;QQ!8ODUR[)UEM;0./9*4V,M\Z(X.<
MB<V;WF]UV'&(FB\XA%N'\*T.T=8A<H%NF+FP!M30M*/DBBAKC6AVX+1QWA@-
M$S:+8Z-PE:&?27MGYV<7_2$9?QL.KTG_\L?H\F)X<3TF1V,LF&G)@<@9N30+
M4.1<BOF1 963<T8GC#/#0).# 1C*N/Y,CLC->$ ./GXF'PD3Y'HA2TW%5'=\
M@TSM?GZV9=7;L I?8#6 [)A$C4,2!F%4X]Y_NWNX[^ZC/I5(8252Z/"BET2B
MG(H,R-CUU15P:F!*!DQG7.I2H0BW9Q-M%-;D[[I@-^C->G3;IZ>ZH!ET/6Q$
M#6H)7OKI0Z,5?*D+_9W ]H2(*B&BU]#3QPHHI')MB,6!30-*H2!*KBDW:R(G
MG,VI7:X38[-#[':P9\PR;;5/DE;'7^Y&66.5M)M)9;5'OUG1;[Y*_[( A;S$
MG)P#MOYA5<?K0W(A159B&,(<DK'!!.-196QX7YG Y#/*R4AJYH*^'=X;>Y!-
ML#N&HLP=JA2UN7^=T;4T""Q=>_%*7/[87G45\*Z0>T+&E9#Q_]<!MYK^@WLO
M?I;71BN*GR3_N5$8[53('N561;GU*N6^%#;S-JE+RDL@RA[PNN*[KF.[@6SM
M$(GB]A.RSVWB=ES/-:FX)N]>%;WDF6A)XR0)GK"ML0K:C9,G?/V="\5>YC^H
MFC.!8L$,_8+C! '4YH+<3(PLW!TSD09O+#=<X#\%*&N ZS,IS</$7EO57TKZ
M%U!+ P04    "  8B%U8L9BG[5X$  !M$0  &0   'AL+W=O<FMS:&5E=',O
M<VAE970V."YX;6RU6&U/XS@0_BM6#MWM2@N)W3?8:RM!RVK1":@H>_?93::M
M11)G;:>ETO[XLYV0="$QW![]TL9)9N;Q>.9Y[ RW7#S(-8!"CTF<RI&W5BK[
M[/LR7$-"Y0G/(-5/EEPD5.FA6/DR$T C:Y3$/@F"OI]0EGKCH;TW$^,ASU7,
M4I@))/,DH6)W 3'?CCSL/=VX8ZNU,C?\\3"C*YB#^I;-A![YE9>()9!*QE,D
M8#GRSO'G"](Q!O:-OQELY=XU,E-9</Y@!E?1R L,(H@A5,8%U7\;F$ <&T\:
MQ_?2J5?%-(;[UT_>O]C)Z\DLJ(0)C_]AD5J/O%,/1;"D>:SN^/8KE!/J&7\A
MCZ7]1=OBW<' 0V$N%4]*8XT@86GQ3Q_+1.P9=+HM!J0T(!9W$<BBG%)%QT/!
MMTB8M[4W<V&G:JTU.)::59DKH9\R;:?&\_O;R5_'%^?SRRF:W%[/+F_FY_=7
MMS?H&)$ $S2+J4Y=&J'+^6R&/DQ!41;+C^@(L13=KWDN]4,Y])7&8CSZ81GW
MHHA+6N)JU]<\56N)+M,(HI\=^'H2U4S(TTPNB-/C%,(3U,&?-&[20=_F4_3A
MZ".Z4I @N:8"I"-&I\I6Q\;HML2P*;G\GC.U0U=I"*DI*9NCI@PX?9EV^RPS
M&L+(T_TD06S &__^&^X'?SJ0=BND7>N]T[:NBH</QZ9>(Q3R1#>QI*8-FG!V
M#X"S5^'L.3,ZMTNC^]LP"$M7B&YT@=%%#$A3#F)2YE0GN@EVX;AO'1ORV8S)
M&>GBT][0WS0@ZE>(^DY$IM";PCFM?C%+@PK3X-U6<W  G*<5SE-G[F:Y"-<:
M)<H$"P%1B2C*0)A&T12/^!(M*1.:O\2#%IP-C7-[4YKI-<VEB':VM\3!2=OZ
MGE48SYP8[[FB,8IR83-HPH<\E1#FMI<-U?$-B)AFF2E'OER",!=Z&HPW,YT[
M'NFBQ#*=([\XJ.DZ<'J[R9,%"(/Z.3+TPY)=(Q4'+UJEVYQ$O*<;V EDNI?
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MP8]S'YQ].0=?0)B AQ7=<)P$?&@*.<;T3.:B&,]U/AYT8#P0@5N:B!4'-TE
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M6\Y\N << E,&\OF64G&:J VJ?S(6_P%02P,$%     @ &(A=6"JLHAGA!@
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MAHI=J_SN1/)-T0L^XU+RI#A<,[I@(C=0]Y=<2=/R)!^@^@\+DW\!4$L#!!0
M   ( !B(75B2^;$Z[ P  %N=   9    >&PO=V]R:W-H965T<R]S:&5E=#<U
M+GAM;+6=;7.;.AJ&_XK&V]GMF6EC7OW233/3!A!HMMU,>WKVP\Y^(+82,\7@
M!9RT.^?'K\#$6$963,Y]OB0VEBX!OA_QP"W)EX]Y\;U<<5Z1'^LT*]^/5E6U
M>3<>EXL57\?E1;[AF?CD+B_6<27>%O?C<E/P>-E46J=CRS FXW6<9*.KRV;;
M37%UF6^K-,GX34'*[7H=%S\_\C1_?#\R1T\;OB3WJZK>,+ZZW,3W_"NOOFUN
M"O%NO*<LDS7/RB3/2,'OWH\^F.^8:]45FA*_)?RQ/'A-ZD.YS?/O]9MH^7YD
MU'O$4[ZH:D0L_CWP:YZF-4GLQW];Z&C?9EWQ\/43/6@.7AS,;5SRZSS]5[*L
M5N]'LQ%9\KMXFU9?\L>0MP?DUKQ%GI;-7_+8EC5&9+$MJWS=5A9[L$ZRW?_X
M1WLB#BI8UHD*5EO!.K>"W5:PCRK8SHD*3EO!.:K@GJK@MA7<<W=ITE:8G%MA
MVE:8GEMAUE:8G5MAWE:8GUO!-)Z^.:-1T.XK;_3BQ55\=5GDCZ2HRPM>_:(1
M75-?R"3)ZOCX6A7BTT34JZX\_^.OY"VYSK,'7E3);<K)U^UM7BR3+*[XDGS.
M*UZ2UQZOXB0M?[D<5Z+1NNIXT3;@[1JP3C1@DD]Y5JU*XF=+OE34#_3U[>?J
MTV?:MS2 L3A;^U-F/9VRCY:6^&%37!!S]H98AF61;U\]\OJ5ZL1<ZS&?8H$Q
MIL]B/#V&;=,+8ILUQG3(*S(FY2HNQ'=6OXPJOE8@_6>0<;9'VD][UK!4_/:]
MZIL]XP3LFM&> *K'>'RQQ]@:3'@^1K<WT?D84X-A9V/,B1HC:=?>A[O=<.V3
MW-M*L3<?=[4<=:WZ&OVNW,0+_GXD+L(E+Q[XZ.JO?S$GQM]5ND?"/"3,1\("
M)(PB82$2%B%A# 23M._LM>_HZ%<W\4^1V%5$))4BL]MLB\5*)%8DOQ/YU&U%
MDJRLBFU=0A4@6O30 $'"/"3,1\(")(SN8&X#JY/^AZOYQ#(<PS NQP^'XN\7
M-">N:9N]DE&_Y%$)!CH"2:[N7JZN5JX?%HMB*S*P)*NXH%=D$_^,17ZF4J>6
M-%2=2)B'A/E(6("$T1UL<B EV[&LOCC[Y1S;G?>EB=PY!H))*I[L53S1JO@?
M>5D2<1_,?U1)=K]-RE73![>=KDK+6MY0+2-A'A+F(V$!$D8G/8T>J[A?XJUE
M3"9]O4?/LAAHUR5Q3O?BG&K%66?#9)F4BWPK-!EGHK,MRVV<+3A9Y&55OB$9
M5VI4BQVJ423,0\)\)"Q PNBTK\"I-9GT.UQ%P;FM2@:0N\= ,$G4L[VH9UI1
M-[?!S6,;E7*U=8<J%PGSD# ?"0N0,(J$A4A8A(0Q$$R*@/D^ N8O>L@Q1VH?
M"?.0,!\)"Y PBH2%2%B$A#$03-*^:70/] UM_W_X*#]KGMX'HC'R6YQNE?>.
M>MS0L(#2/"C-A]("*(VVM,-$9=XDU+V,!MIN!*4Q%$V6_H&799Z9^I#?)4NK
M/+2TLE.YD9X^.!*0- ]*\Z&T $JC4%H(I450&D/1Y&BQNFBQ7I0FM=5088"D
M>5":#Z4%4!J%TD(H+8+2&(HFAT'GB)I:TVEXO@3U2J$T#TKS6]JA06+-IJXB
M*0F@#5,H+832(BB-H6BR]CM'U-1;HLT#T&AO?+XA<99MX[3SG J1,2F# .J'
M0FD>E.:W--,Y?(9]85BFY1[' -3OA-)"*"V"TAB*)L= 9[.:>I_U)B^:D9I/
MXP *7B4%7[XA=_5EX.'D90#JN;8TR;5VG)FBJ_6@#?M06G#^85!HPR&4%D%I
M3'E23/F<R-KMS%53[ZZ>U.XB+HJ?27:OT2_49S7[1I_XXE6I@@=MV(?2 BB-
M0FDAE!9!::RE21*WYSJ)=Q:MJ?=H_]"H+3U[L,BGJJ%%$Z7(H3XLE!:<?Q@4
MVG (I450&D/19)5WGJVI-VUO>+$0&H[O&V7O;D,[M:N&O7_4$P=K>T>;2UGN
MY%C54(\62@N@- JEA5!:!*4Q%$T6?F?5FEHW;- H1SUJL.+GO6[047;E4',6
M2@N@- JEA5!:!*4Q%$V>/]19M);>HOV6Q>LZ<_^?$/XNBSD<=J:2OAXX5/I6
MWVRT5=*'MNI#:0&41J&T$$J+H#2&HLG2[RQ:2V_1#A\/K <.EK[9D[YE3)7B
MASJN4%H I5$H+832(BB-H6BR^#O'U=):65<W19(MDDV<*G5N]?(1]0B0Z[;D
M\V-%//W^#-8PU"Z%TJCBG!P/G#EQVOI3B"+HKC$4319=YV]:>G_SQ8/<]=S!
M'6_?3'RKUBS4PX32 BB-0FEA2Y.&NIN*@>[05AF*)HN[,S MO8'YF5?D^NE9
M]X=U+7&EE*%V)93F06D^E!9 :11*"UN:W)V;<UNA>*A=B:+)BN_L2FMG%YT:
MM14]/2CA/S8\*Y4/2BRH-PFE>5":#Z4%4!J%TD(H+8+2&(HFAT3G@EIZ%_0Z
MSZHB7E32R!5=>$"M3RC-@])\*"V TJC5MXQG;G^XNZ*8-3&GBEZ^7] UK7X"
MQ%"'(:NU,S0MO:'Y8??H+Y:,>SDE5XH6:F5":1Z4YD-I 91&K?Y\4D6.'2J*
MV89B>K2BG#OKWQ,QU$'(DNW<24OO3OZ:5X==:WT/&1^J6-?70EU**,V#TGPH
M+8#2:$N3GRTI9-LO9LU-Q?(4BH+NU%#UM7^&NVAU[J*E=Q<'3 @2!6Z*Y$%L
M2'^^S?A]7B7-AXMXLVG^I2G)-[7<E3*'6I-0F@>E^5!: *51*"V$TB(HC:%H
M\B)RG8%I&]J;T)/+R$%M2BC-@])\*"V TBB4%D)I$93&4#0Y##HST]:;F9^W
MZUM>[)+XYMJ1//"#$8DEV0_@$E>7$VMQ?M2W,3AFH+-.H33?5GBO1W,HH U2
M*"V$TB(HC:%H<B!TQJ:M-S;%Z^0[)YLB$;>P]4C=:L7)-A-1D39/YK-]H+2+
MQ[Y.,K+,TS0N1)"(3YK-OX@HZ1:85<8*=&HJE.:UM.GAK>'\8CJ5%>XKBEG3
MB^G\.!"@[BB4%D)I$93&4#0Y$ Z6UWUF,FF\047!R>L%=JU>[&*].YIIR^HV
MG.,@Z'N5]NPX K#KZV(7V,6NL(M=8O?/<&3MSI&U]8[LL%ONKU6^^+Z+F)+<
MUK_60%XUW6$7#Z+4IR1+UEMU-$"=72C-@])\*"V TBB4%D)I$93&4#0YNCKW
MU]:[OR=OO*&.+Y3F06D^E!9 :11*"Z&T"$IC*)H<!IWC:^L=WWK83YM#E;RJ
M4MX,(FZGCI J;S(OL2FI?HK+A^9^ NH$0VD>E.;;SZ[$&T ;I%!:"*5%4!I#
MT>18Z/QD6^\G_X&$*[[-'SAY9<\N#$-.N.(?)Q,NJ \-I7E0F@^E!5 :A=)"
M*"V"TAB*)D=79WW;LY<E7%!?&TKSH#0?2@N@- JEA5!:!*4Q%$T.@\Y(M_5&
M.BSA@OKD4)H'I?DM33([IM/YQ.T]Z85:X%!:"*5%4!I#T>3?DNHL<$<_AU=*
MN_Z9+LD7D6>1?W_B]3/>_[QH_5E]BT.# TKSH#0?2@N@- JEA5!:!*4Q%$V.
MH,X]=\P7I58.U!"'TCPHS8?2 BB-0FDAE!9!:0Q%D\.@\\X=O7?NW]WQ13MR
MY)E5-_6DP9&QH]5KMG?/A"[$9>UXV1]HLSZ4%D!I%$H+H;0(2F,HFBSZSB=W
M]#ZYE#U]YH^([ GJBT-I'I3F0VD!E$:AM!!*BZ TAJ+)$73P8[;.R[(GJ"$.
MI7E0F@^E!5 :A=)"*"V"TAB*)H=!9X@[^M6;AV1/4(^\I?6SI^EQ]@2UOZ&T
M $JC4%H(I450&D/19-%W]K>CM[^C+,L?DH?X;Z7(D];K/&MMO=_)'_P%)'V[
M@T,$ZH=#:3Z4%D!I%$H+H;0(2F,HFAQ'G77N3%^60T$];BC-@])\*"V TBB4
M%D)I$93&4#0Y##J/V]%/[]Y=+Q:[J\5N+=Y<O&TN+&5]87FC65K)Z4\%[B_!
M<ZW?@\$Q #6XH;0 2J-06@BE15 :0]'D&.@,;D=O<%\?R!V01T%M;BC-@])\
M*"V TBB4%D)I$93&4#0I>-S."W=?-AW<A1K:4)H'I?E06@"E42@MA-(B*(VA
M:'(8=(:VJY\.OKM.E/6*./4SJ&8*8#MH*K^3$JIFL.TK\XU1C[O5+0JL;W%P
M!$&]\)9F2JO &!?NS#R:RN>K2MKNQ7QNV$>#H:![2*&T$$J+H#2&HLG*[SQL
M5^]A'RA_-_OU]0LF=^O;&*QUZ.1N][S)W8IBJLG=T'VC4%H(I450&D/1=BH?
MERO.*R^NXJO+-2_N^35/T_H^6-SIUKG.P592\+OZMVS>?;!&X]YVSWSGFXKM
MU'P7-=O''?[J<A/?\T]Q<9]D)4GYG6C*N)B*GK%([E?[-U6^$?WEB-SF596O
MFY<K'B]Y41<0G]_EXM:C?5,W\)@7WYO#N?H_4$L#!!0    ( !B(75B7-_-?
MK1H  !RE 0 9    >&PO=V]R:W-H965T<R]S:&5E=#<V+GAM;+W=:W.C1J+&
M\:]"^>2<2JIF;(&$+CF3J9H,--?>3.6RYS4C85L527@1RF2V]L,?D+!1(]02
MSG_W33*VX0>6_""0'KK??<GRW[>/:5H8?ZY7F^T/-X]%\?3]W=UV_IBND^UM
M]I1NRI_<9_DZ*<HO\X>[[5.>)HO]2NO5G348C._6R7)S\_[=_GN?\O?OLEVQ
M6F[23[FQW:W72?[UQW25??GAQKQY_L;/RX?'HOK&W?MW3\E#^DM:_/;T*2^_
MNGM1%LMUNMDNLXV1I_<_W'PPOY?F8%*ML5_D[\OTR_;HWT;UNWS.LM^K+X+%
M#S>#:I?253HO*B,I__='^C%=K2JJW)%_U.K-RT:K%8___:R+_6]?_C:?DVWZ
M,5O]WW)1//YP,[TQ%NE]LEL5/V=?_+3^C>S*FV>K[?Z_QI=ZV<&-,=]MBVQ=
MKUSNP7JY.?P_^;-^)(Y6L*PS*UCU"E9KA>'PS K#>H5A>X71F15&]0JCU@JC
M<[MDURO8UZXPKE<8MU8X^RA-ZA4FUSY*TWJ%Z;4KS.H59M>N8 Z>G[E!:Q7S
MW -KOCS9)\^V?6Z5YZ?;;#_?YW?L^0DW]\_XW>%O<?^'["1%\OY=GGTQ\FKY
MTJO^L4_#?OWR[W>YJ9+[2Y&7/UV6ZQ7O'??'7XVWQL=L\T>:%\O/J]3X)=TL
ML]SX6U:D6^-;)RV2Y6K[G?&-<6=L'Y.\_.9R8_RV61;;-^4WRW__^ICMMLEF
ML7UW5Y2[5,%W\WKSSF'SUIG-FX;,-L7CUG WBW31L;[0KS^\M+YW8?N6!K@K
M'\N7!]1Z?D!_M+2B3/);8S!Y8U@#RS)^^\4QOOWFNXX=^ZAG/NP>GAES\LP<
M/0==#[5>#'>K6V-H[L71\;-9_3,HTG4'Z5X@D\T+.>S821TMKG@8#W3S,%Y)
M>WK:2><O=-=>=XC^]:+N.0^N9TP-$U[XTWDJ'SIS>G%OHBN>W$']2W6L'E_S
M!VS6?\#:1U=>_;"8X^[?1TGJ\.70-]R[P[/NYZ)C;WX\K#7J7JLZD_I^^Y3,
MTQ]NRE.E;9K_D=Z\_Y__,L>#_^U*.8DY).:2F" QC\1\$@M(+"2QB,1B$I,0
MID1\]!+QD4Y__RGY6EYE%$9YA5->9CSM\OEC>9)O9/?EN?WGHCQWV1;YKEJB
MZSB@I?L>!TC,(3&7Q 2)>0?,WF/5%>@?[V=C:S!Z=_?'<<!/ES+'MCDTU<6"
MT\4&ZA(AN>\1B<4D)B%,R:/]DD=;^Y(;+Y//R]6R^&K,L_53MCF3/)M,'HDY
M).:2F" QC\1\$@M(+"2QB,1B$I,0IB1^_)+XL?X5.%]NYLNG9-65<^VJ?7-.
M8@Z)N20F2,P[8..C%\61/;0'K5=&_W0Q>S2;M%^) W+70A*+2"PF,0EA2C8G
M+]F<:+-970 ;B^5VGNW*<^1DLS"6V^TNV<S3\N5Y6[V]MTD[7Y^U;-_<DIA#
M8BZ)"1+S)B>!?#NQQN-6;#N6F@U/3HS)'0M)+"*QF,0DA"FIG;ZD=JI-[?Y=
MR_V;\UW1U*[;-YHDYI"82V*"Q#P2\TDL(+&0Q"(2BTE,0I@2]-E+T&>O>G]Z
M1D:<Q!P2<TE,D)A'8CZ)!206DEA$8C&)20A3(FX.FH_?!]I7\^,/WC?[3]Q%
MN3'C[\EJEW:%7\_U33^J.:CFHII -:_6VF]-MZ^;T8T&J!:B6H1J,:I)2E,3
M?E2P,2^=K]OGS]?U*_?.,ZDYJ.:BFD U#]5\5 M0+42U"-5B5).4IL;>:F)O
MO>KLO5Z-"CRI.:CFHII -0_5?%0+4"U$M0C58E23E*8&OFF3F=HF2WDFOUYG
M&V-;9//?C:=\69[%%YDQW^5YU4"9[\_S]WWWP\_RI%AFG0<(M'^&:@ZJN:@F
M4,VKM=EQK>1VV#Z_1\MEJ!:B6H1J,:I)2E-SWU3,3&UCYOV',M?)0QGV/%DL
M-P]UO)_2?%[FOOQ!9\;)1L]'5'-0S44U@6I>K1UG?' [F[9#3FXS0+40U2)4
MBU%-4IH:\J:W9FI+,N_=^_MT?XN9L=P4:;F%HGH![\XVVEY#-0?57%03J.;5
M6O7>SU&X!]/II!UOM)Z&:B&J1:@6HYJD-#7>34G-U+?4?LV*9-5JOW1F&VVL
MH9J#:BZJ"53S:NWXW7=[=/KF.[G- -5"5(M0+48U26EJL)N&FZFON#6%\RO"
MC=;:4,U!-1?5!*IYYFEKK:.1BFXS0+40U2)4BU%-4IH:[J8(9^J;<.X_=E<F
M&VW%H9J#:BZJ"53S:NTXV>;L--EHYPW50E2+4"U&-4EI:K*;YINI;=T<?69N
M_,OX\,MOU3WH@[>#<6>XT3X<JCFHYJ*:0#4/U7Q4"U M1+4(U6)4DY2FCJ/2
M5..LP:L^0;?0"ARJ.:CFHII -0_5?%0+4"U$M0C58E23E*8&OFG*6?JFW&^;
M9)WEQ?*?Z<)0[DWK/ J@Q3E4<U#-136!:EZM';\5-YX,3T[JT8T&J!:B6H1J
M,:I)2E/CW33B+&T!I\]G:'JI=[C1DARJN:@F4,U#-1_5 E0+42VJM?9GC]:T
M52V(T<U*2E/CW?3?+'W_3;EF/R[#=08<+;FAFH-J+JH)5/-0S4>U -5"5(M0
M+48U26GJ4:!IPUFCUUVTDVV@CZCFH)J+:@+5/%3S42U M1#5(E2+44U2FAKX
MIAEGZ9MQOU2CNAJ?]J77?^G'>?U13_4^"*#5.%1S44V@FH=J/JH%J!:B6H1J
M<:U-CC\-'=Y:K4L$26U437=3C+/TQ;CRI'YZ_N95_<J]\XS6X5#-136!:AZJ
M^:@6H%J(:A&JQ:@F*4V-?5.;LR:O.XM'*W*HYJ":BVH"U3Q4\U$M0+40U2)4
MBU%-4IH:^*9*9^FK=(XZ'/H;8Y[]D6Z236$4:;[>&HMT.\^73]5<2YW'!;1@
MAVH.JKFH)E#-N_ <__I8??*R*)_>77G%]E ^P?FFNF&Q*+_?G.=5=RH72?FG
M4,\_E.1?Z[^!:H#0YS^+[9N2FJ]V^SL>$V.=Y@]IWOS15(L6CTEA[)ZRC3%/
M\THTTO*GQ?8P^OY^9BTCFU?W1^^-/;XIEIM=^>4;(UV6NY7O]^W7O-R1-#6R
MPY>/V6J1YGNFW, J3;:%8=G_77U=_3AY>,C3AZ1(JQLQ#T,/&\EZ/\)IO42V
M*[9%N;UJLX=?>9U\+7=IOJJN9,W!X,5JA.S^S7X7D_D\WZ6+_;]WFZ=DN7CY
M,*M\1,H]VGQ]8V2;<N'5:D\<-E!DQN?46.S2_8I/R=>D&N]IN5ZGBV6YJZNO
MMYU'9K0*B6HAJD6H%J.:I#3UR-Q4(2U]%?)X@+#M86:N3?TABWYD(;W;^YB,
M]B)1S44U@6H>JOFH%J!:B&H1JL6H)BE-G;6JZ44.7]>+'**]2%1S4,U%-8%J
M'JKYJ!:@6HAJ$:K%J"8I30U\TXL<ZGN1/U=#!57GI$=36+T,,*2>IQ[.=#N/
M#FA?$M4<5'-13:":5VO*L$*MKB2ZP0#50E2+4"U&-4EI:N2;KN00ZTKJI=[!
M1KN2J.:BFD U#]5\5 M0+42U:'AM5Q+=K*0T-=Y',\_JIYZ]<AZ\(3L5+3L7
M+3L9+3L;+3L=+3L?+3LA+3LC+3LE+3LG+3LI[;^C)3EL6I)#;2E+/RN>?MW>
MJ2<U!]5<5!.HYM6:,J_LS#H=B:1>;GQAN0#=NQ#5(E2+44U2FIK4IMXXU-<;
M7SU'GM[MG6*TZXAJ+JH)5/-J39D#S[0&=CO$78O-S$D[PV@[$=4B5(M135*:
MFN&FQ#C4EQC_EA;&/,GSK_L/FL^_0X:V&5'-0347U02J></3R6;+)%JSD\AV
M+3>PI\-V9M$&(JI%J!:CFJ0T-;-- W&H;R &SV][I7\^I9MM]SM?:!L1U1Q4
M<U%-H)J':CZJ!:@6HEJ$:C&J24I3P]^T$8?ZIMK';%/DR;S858/R7G,@0.N'
MJ.:@FHMJ M6\X>GX?J.IV9XSXZJE@JN6"M']CU M1C5):6H@FQ+:4%]"^W 8
MEZ?Z''ISZ&]6=>&+XV[JU=ZY1"MHJ.:BFD UK]:.LS0QK78L3Q<:SZQV*CL6
MLB?M4*(],%2+44U2FA+*4=,#&^FGCNT,I6[(++W7-XZHYJ":BVH"U;Q:.PY1
M^SWERXL$'8M,INVY:T)TSR-4BU%-4IJ:Q::B-=)7M.H)))[/5?>W"AS'4W/R
MJI=[IQ(M9J&:BVH"U;S1Z4!VMFVUWW2JEQHK2[7?30XZEC*'P_%).-$R%:K%
MJ"8I30UG4Z8:Z<M45]U"47[Q4[G4VP^K5594]\ 9/YV]W4V_O=Z112M7J.:B
MFD U#]5\5 M0+42U"-5B5).4IAXIFE[62-_+.G=KQ0@M8J&:@VHNJ@E4\U#-
M1[4 U4)4BU M1C5):6K@FR+62%_$.CXU.)P3B')CQM^3U:[[9!WM9HTZ.D:3
MD^J0@V[4136!:AZJ^:@6H%J(:A&JQ:@F*4U->%/@&ND+7)^JJ_#C=ZU?!KDP
M[JNH'_H@;PSWSS2?+[?IHC/V:)EK=-HVZHP]VM)"-8%J'JKYJ!:@6HAJ$:K%
MJ"8I38U]T_D:Z3M?UU[S?\J7?U2#A7Q:E?NR/G,?AGY;O>./-L-0S44U@6H>
MJOFH%J!:B&H1JL6H)BE-/4HT+;/1Z\:Y&Z'-,E1S4,U%-8%J'JKYJ!:@6HAJ
M$:K%J"8I30U\TRP;76R6];O>1YMEM7;IGB('W:J+:@+5/%3S42U M1#5(E2+
M44U2FAKQIJLVTG?5]G=L!4=#62:;C5(D/3>0@M[MG?6#=G)CN]W..MI#0S6!
M:AZJ^:@6H%J(:A&JQ:@F*4W)NMU4X&Q]!>[:J_Q+TU'I-],W^JCFH)J+:@+5
M/%3S42U M1#5(E2+44U2FGJ :'IYMOFJ"WP;+=VAFH-J+JH)5/-0S4>U -5"
M5(M0+48U26EJX)NNGWU-UV];?>)7G><;]^4IP6%"JNH3P/G1>8#QE.;&-^:;
MP6#0#*#8>:Q VWZU9BH=TLGMS!JU+@S0S;JH)E#-0S4?U0)4"U$M0K48U22E
MJ8>!ILAGZR>C/3H,'$9*_7:1K59)OMVG?G] ^.[B='7Z;?0._D%3)OR:W%KC
M=NS1.A^J"53SKGM ?'2C :J%J!:A6HQJDM+4/#<]/5O;$FK/3V.LDV*75^,G
M+LZ\F:?W>F=7OW<?=@^WAFF_,?;O.G2>TY.[XZ*:0#4/U7Q4"U M1+4(U6)4
MDY2FAK^I\-GZ"I_R8IZNE[NU\6VR-9+JM7Q>'@V^ZSP H)6]6CL>MWMP.VR_
M=*.%/503J.:AFH]J :J%J!:A6HQJDM+4D#>%/?NO%/8TD]#JW=Y!1\MYJ.:B
MFD U#]5\5 M0+42U"-5B5).4IAX1FG*>_;IRGHV6\U#-0347U02J>:CFHUJ
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M'A.:)MQ$WX2[]GV%G\JEWGY8K;)B/QS-3^??14 ;<JCFH)J+:@+5/%3S42U
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MD0SF=%7H6['Y#DT]H?%+1:&J7[*I8T,,3E=*B[(1(T')>'VE3TT?=@1N\(;
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M^LK)SV;YW7P^>YS?+AZ7<+V80GZW>)PMOMPN\MGM$BY@2653M@)!K6'9-HU
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M3PD[W.AS&819H-^O.%>'B3DJBI,^_ M02P,$%     @ &(A=6$_-CVQ3 P
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M/C8QR;JWKP=:[*IN=RVTZ9VKR]Q\#X&T!N;^1@C],K /:+^PYO\#4$L#!!0
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M0@>D6ZEX5B5K!!G-RW_\5 W$20(,.A)0E8!>F^!7"7Y!M$16T)IAA2<CP?=
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M=0%17DK*AN*;XEP_YTK?$HK'M;[($6$"]/<EY^JY8:X*]=5P\C]02P,$%
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MK]_G^AM1/R@'V%[P;?8?4$L#!!0    ( !B(75CDZ&F5; ,  '$7   -
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MCZCU^6V:;]>5:%_:.TT-TVKWY.X.>;[4YZ)B5:;9TR_WGGYU^/9?4$L#!!0
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M\PM02P$"% ,4    "  8B%U8!T%-8H$   "Q    $               @ $
M    9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( !B(75C$LG=)[@   "L"
M   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0
M   ( !B(75B97)PC$ 8  )PG   3              "  <P!  !X;"]T:&5M
M92]T:&5M93$N>&UL4$L! A0#%     @ &(A=6"@^)MCH"   <#4  !@
M         ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0
M   ( !B(75A.8W8L9P<  (,?   8              " @2L1  !X;"]W;W)K
M<VAE971S+W-H965T,BYX;6Q02P$"% ,4    "  8B%U87G*U2!D#  "L"@
M&               @('(&   >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L!
M A0#%     @ &(A=6,I!S73V!P  [2D  !@              ("!%QP  'AL
M+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( !B(75CXJ--9G (
M '\'   8              " @4,D  !X;"]W;W)K<VAE971S+W-H965T-2YX
M;6Q02P$"% ,4    "  8B%U866%^!Q(#  !."0  &               @($5
M)P  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ &(A=6-'@
M->9-$0  .]H  !@              ("!72H  'AL+W=O<FMS:&5E=',O<VAE
M970W+GAM;%!+ 0(4 Q0    ( !B(75B]S!O]O@L  +0Z   8
M  " @> [  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    "  8
MB%U8F^[O(F<"  "_!P  &               @('41P  >&PO=V]R:W-H965T
M<R]S:&5E=#DN>&UL4$L! A0#%     @ &(A=6*:&!(PC+   -(@  !D
M         ("!<4H  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4
M    "  8B%U8+;RG<V@&  !"$0  &0              @('+=@  >&PO=V]R
M:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( !B(75B(8,I:>P<  (,2
M   9              " @6I]  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL
M4$L! A0#%     @ &(A=6(\2;T3S$0  GST  !D              ("!'(4
M 'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    "  8B%U8$3;[
M?H$6   :2   &0              @(%&EP  >&PO=V]R:W-H965T<R]S:&5E
M=#$T+GAM;%!+ 0(4 Q0    ( !B(75A2[1WUZ1X  %MX   9
M  " @?ZM  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @
M&(A=6)WB+',>!   ' D  !D              ("!'LT  'AL+W=O<FMS:&5E
M=',O<VAE970Q-BYX;6Q02P$"% ,4    "  8B%U8>1;5MKD%  #N#@  &0
M            @(%ST0  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4
M Q0    ( !B(75@!"GN*M00  -\*   9              " @6/7  !X;"]W
M;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ &(A=6-"(M[I*#0
M82D  !D              ("!3]P  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX
M;6Q02P$"% ,4    "  8B%U8\B@8CH,%   8#0  &0              @('0
MZ0  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( !B(75A"
M]<$=/1D  /%:   9              " @8KO  !X;"]W;W)K<VAE971S+W-H
M965T,C$N>&UL4$L! A0#%     @ &(A=6$+,9W-K#   GAX  !D
M     ("!_@@! 'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4
M"  8B%U8:3KE+9(+  !$'@  &0              @(&@%0$ >&PO=V]R:W-H
M965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( !B(75BVL)I:ZP,  "$)   9
M              " @6DA 0!X;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L!
M A0#%     @ &(A=6%%3"RVI+P  =YP  !D              ("!BR4! 'AL
M+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4    "  8B%U8D1AG:S4#
M  "W!@  &0              @(%K50$ >&PO=V]R:W-H965T<R]S:&5E=#(V
M+GAM;%!+ 0(4 Q0    ( !B(75C%MJ#5CP0  &4+   9              "
M@==8 0!X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ &(A=
M6 3PT0]V P  &P<  !D              ("!G5T! 'AL+W=O<FMS:&5E=',O
M<VAE970R."YX;6Q02P$"% ,4    "  8B%U85(A!8.4'  !V%P  &0
M        @(%*80$ >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0
M   ( !B(75ABJ5?BK @  &<=   9              " @69I 0!X;"]W;W)K
M<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ &(A=6-?C9T,# P  7 8
M !D              ("!27(! 'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q0
M2P$"% ,4    "  8B%U8$[,I#G,#  #U!P  &0              @(&#=0$
M>&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( !B(75CWI17H
M# 0  #$*   9              " @2UY 0!X;"]W;W)K<VAE971S+W-H965T
M,S,N>&UL4$L! A0#%     @ &(A=6"PI>.GX!0  QQ   !D
M ("!<'T! 'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4    "  8
MB%U8&S_RV\$%   .%P  &0              @(&?@P$ >&PO=V]R:W-H965T
M<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( !B(75C[5A= ]@,  )X)   9
M          " @9>) 0!X;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#
M%     @ &(A=6%@-ILD?!@  5A   !D              ("!Q(T! 'AL+W=O
M<FMS:&5E=',O<VAE970S-RYX;6Q02P$"% ,4    "  8B%U8K>GP#"H'  ".
M-P  &0              @($:E $ >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM
M;%!+ 0(4 Q0    ( !B(75@.\O4!OP(  $ )   9              " @7N;
M 0!X;"]W;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @ &(A=6">7
M<(]5 @  !P4  !D              ("!<9X! 'AL+W=O<FMS:&5E=',O<VAE
M970T,"YX;6Q02P$"% ,4    "  8B%U8HWMN\?4"  !O"@  &0
M    @(']H $ >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    (
M !B(75CV ?>3F 4  &L?   9              " @2FD 0!X;"]W;W)K<VAE
M971S+W-H965T-#(N>&UL4$L! A0#%     @ &(A=6.KH>I<J P  :0T  !D
M             ("!^*D! 'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"
M% ,4    "  8B%U8H*<GH,0$  #V'   &0              @(%9K0$ >&PO
M=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( !B(75BWK.Q-9@L
M  >1   9              " @52R 0!X;"]W;W)K<VAE971S+W-H965T-#4N
M>&UL4$L! A0#%     @ &(A=6.%"#3I/"   [#T  !D              ("!
M\;T! 'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q02P$"% ,4    "  8B%U8
MU/G$#,\(  #3/0  &0              @(%WQ@$ >&PO=V]R:W-H965T<R]S
M:&5E=#0W+GAM;%!+ 0(4 Q0    ( !B(75C\O@'[<P4  %(E   9
M      " @7W/ 0!X;"]W;W)K<VAE971S+W-H965T-#@N>&UL4$L! A0#%
M  @ &(A=6%;&*?OK"   0E,  !D              ("!)]4! 'AL+W=O<FMS
M:&5E=',O<VAE970T.2YX;6Q02P$"% ,4    "  8B%U8*?Q4PY('  "E/0
M&0              @(%)W@$ >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+
M 0(4 Q0    ( !B(75A_G3YR)04  ,,@   9              " @1+F 0!X
M;"]W;W)K<VAE971S+W-H965T-3$N>&UL4$L! A0#%     @ &(A=6"<,B=H%
M P  :P<  !D              ("!;NL! 'AL+W=O<FMS:&5E=',O<VAE970U
M,BYX;6Q02P$"% ,4    "  8B%U82AQ7_9L2   J!0$ &0
M@(&J[@$ >&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    ( !B(
M75B_E*\2S04  ,0L   9              " @7P! @!X;"]W;W)K<VAE971S
M+W-H965T-30N>&UL4$L! A0#%     @ &(A=6&Z)&FVM#0  ;ZP  !D
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M=#4Y+GAM;%!+ 0(4 Q0    ( !B(75@-N>FX*A(  %6Q   9
M  " @90K @!X;"]W;W)K<VAE971S+W-H965T-C N>&UL4$L! A0#%     @
M&(A=6 L YLY"!0  :R,  !D              ("!]3T" 'AL+W=O<FMS:&5E
M=',O<VAE970V,2YX;6Q02P$"% ,4    "  8B%U8,O-$H^\&  "%0@  &0
M            @(%N0P( >&PO=V]R:W-H965T<R]S:&5E=#8R+GAM;%!+ 0(4
M Q0    ( !B(75BU;\&[3P0  !$4   9              " @91* @!X;"]W
M;W)K<VAE971S+W-H965T-C,N>&UL4$L! A0#%     @ &(A=6/HHA(*I @
M]08  !D              ("!&D\" 'AL+W=O<FMS:&5E=',O<VAE970V-"YX
M;6Q02P$"% ,4    "  8B%U8QN6$<=0"  #"!@  &0              @('Z
M40( >&PO=V]R:W-H965T<R]S:&5E=#8U+GAM;%!+ 0(4 Q0    ( !B(75@"
M-I9"YP,  (,,   9              " @055 @!X;"]W;W)K<VAE971S+W-H
M965T-C8N>&UL4$L! A0#%     @ &(A=6,I5;8PJ P  L0@  !D
M     ("!(UD" 'AL+W=O<FMS:&5E=',O<VAE970V-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( !B(75@='&^D9P,  &8*   9              "
M@5%S @!X;"]W;W)K<VAE971S+W-H965T-S(N>&UL4$L! A0#%     @ &(A=
M6)<I$QZP P  U1   !D              ("![W8" 'AL+W=O<FMS:&5E=',O
M<VAE970W,RYX;6Q02P$"% ,4    "  8B%U8*JRB&>$&  "\,   &0
M        @('6>@( >&PO=V]R:W-H965T<R]S:&5E=#<T+GAM;%!+ 0(4 Q0
M   ( !B(75B2^;$Z[ P  %N=   9              " @>Z! @!X;"]W;W)K
M<VAE971S+W-H965T-S4N>&UL4$L! A0#%     @ &(A=6)<W\U^M&@  '*4!
M !D              ("!$8\" 'AL+W=O<FMS:&5E=',O<VAE970W-BYX;6Q0
M2P$"% ,4    "  8B%U8CB216YH"  "H"   &0              @('UJ0(
M>&PO=V]R:W-H965T<R]S:&5E=#<W+GAM;%!+ 0(4 Q0    ( !B(75BDD2_&
M@0,  &P-   9              " @<:L @!X;"]W;W)K<VAE971S+W-H965T
M-S@N>&UL4$L! A0#%     @ &(A=6!"=0+F_ @  &0<  !D
M ("!?K " 'AL+W=O<FMS:&5E=',O<VAE970W.2YX;6Q02P$"% ,4    "  8
MB%U8AU[69S #  #>!P  &0              @(%TLP( >&PO=V]R:W-H965T
M<R]S:&5E=#@P+GAM;%!+ 0(4 Q0    ( !B(75B8)-F3# ,  /4'   9
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M970X-2YX;6Q02P$"% ,4    "  8B%U8@%51'=\&  #\30  &0
M    @(&<RP( >&PO=V]R:W-H965T<R]S:&5E=#@V+GAM;%!+ 0(4 Q0    (
M !B(75CDZ&F5; ,  '$7   -              "  ;+2 @!X;"]S='EL97,N
M>&UL4$L! A0#%     @ &(A=6)>*NQS     $P(   L              ( !
M2=8" %]R96QS+RYR96QS4$L! A0#%     @ &(A=6-1SE2Q1!@  ^3@   \
M             ( !,M<" 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( !B(
M75A2-<:CB@(  +DR   :              "  ;#= @!X;"]?<F5L<R]W;W)K
M8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( !B(75B#T:P!+@(  $0Q   3
M          "  7+@ @!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !> %X
*R1D  -'B @    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>496</ContextCount>
  <ElementCount>604</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>146</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>12</UnitCount>
  <MyReports>
    <Report instance="inva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="inva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="inva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100080 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="inva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100090 - Statement - CONSOLIDATED STATEMENTS OF INCOME</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfIncome</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF INCOME</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="inva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100100 - Statement - CONSOLIDATED STATEMENTS OF INCOME (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfIncomeParenthetical</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF INCOME (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="inva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100110 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveIncome</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="inva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100120 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="inva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100130 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="inva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="inva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995455 - Disclosure - DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="inva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995465 - Disclosure - NET INCOME PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20231231/taxonomy/role/DisclosureNetIncomePerShare</Role>
      <ShortName>NET INCOME PER SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="inva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995475 - Disclosure - REVENUE RECOGNITION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20231231/taxonomy/role/DisclosureRevenueRecognition1</Role>
      <ShortName>REVENUE RECOGNITION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="inva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995485 - Disclosure - LICENSE AND COLLABORATION ARRANGEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20231231/taxonomy/role/DisclosureLicenseAndCollaborationArrangements</Role>
      <ShortName>LICENSE AND COLLABORATION ARRANGEMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="inva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995495 - Disclosure - CONSOLIDATED ENTITIES AND ACQUISITIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitions1</Role>
      <ShortName>CONSOLIDATED ENTITIES AND ACQUISITIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="inva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995505 - Disclosure - EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurements</Role>
      <ShortName>EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="inva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995515 - Disclosure - CAPITALIZED FEES PAID</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20231231/taxonomy/role/DisclosureCapitalizedFeesPaid1</Role>
      <ShortName>CAPITALIZED FEES PAID</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="inva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995525 - Disclosure - GOODWILL AND INTANGIBLE ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20231231/taxonomy/role/DisclosureGoodwillAndIntangibleAssets</Role>
      <ShortName>GOODWILL AND INTANGIBLE ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="inva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995535 - Disclosure - BALANCE SHEET COMPONENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20231231/taxonomy/role/DisclosureBalanceSheetComponents</Role>
      <ShortName>BALANCE SHEET COMPONENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="inva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995545 - Disclosure - STOCK-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensation</Role>
      <ShortName>STOCK-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="inva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995555 - Disclosure - STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20231231/taxonomy/role/DisclosureStockholdersEquity</Role>
      <ShortName>STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="inva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995565 - Disclosure - DEBT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20231231/taxonomy/role/DisclosureDebt</Role>
      <ShortName>DEBT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="inva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995575 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="inva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995585 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxes</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="inva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995595 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20231231/taxonomy/role/DisclosureSubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="inva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995605 - Disclosure - DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="inva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995615 - Disclosure - DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="inva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995625 - Disclosure - NET INCOME PER SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20231231/taxonomy/role/DisclosureNetIncomePerShareTables</Role>
      <ShortName>NET INCOME PER SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inva.com/20231231/taxonomy/role/DisclosureNetIncomePerShare</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="inva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995635 - Disclosure - REVENUE RECOGNITION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20231231/taxonomy/role/DisclosureRevenueRecognitionTables</Role>
      <ShortName>REVENUE RECOGNITION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inva.com/20231231/taxonomy/role/DisclosureRevenueRecognition1</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="inva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995645 - Disclosure - CONSOLIDATED ENTITIES AND ACQUISITIONS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTables</Role>
      <ShortName>CONSOLIDATED ENTITIES AND ACQUISITIONS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitions1</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="inva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>995655 - Disclosure - EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsTables</Role>
      <ShortName>EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurements</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="inva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>995665 - Disclosure - CAPITALIZED FEES PAID (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20231231/taxonomy/role/DisclosureCapitalizedFeesPaidTables</Role>
      <ShortName>CAPITALIZED FEES PAID (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inva.com/20231231/taxonomy/role/DisclosureCapitalizedFeesPaid1</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="inva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>995675 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20231231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsTables</Role>
      <ShortName>GOODWILL AND INTANGIBLE ASSETS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inva.com/20231231/taxonomy/role/DisclosureGoodwillAndIntangibleAssets</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="inva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>995685 - Disclosure - BALANCE SHEET COMPONENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsTables</Role>
      <ShortName>BALANCE SHEET COMPONENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inva.com/20231231/taxonomy/role/DisclosureBalanceSheetComponents</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="inva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>995695 - Disclosure - STOCK-BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationTables</Role>
      <ShortName>STOCK-BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensation</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="inva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>995705 - Disclosure - DEBT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20231231/taxonomy/role/DisclosureDebtTables</Role>
      <ShortName>DEBT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inva.com/20231231/taxonomy/role/DisclosureDebt</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="inva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>995715 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inva.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="inva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>995725 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxes</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="inva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>995735 - Disclosure - DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Description of Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails</Role>
      <ShortName>DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Description of Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="inva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>995745 - Disclosure - DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails</Role>
      <ShortName>DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="inva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>995755 - Disclosure - DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesRelatedPartyTransactionsDetails</Role>
      <ShortName>DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="inva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>995765 - Disclosure - NET INCOME PER SHARE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20231231/taxonomy/role/DisclosureNetIncomePerShareDetails</Role>
      <ShortName>NET INCOME PER SHARE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inva.com/20231231/taxonomy/role/DisclosureNetIncomePerShareTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="inva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>995775 - Disclosure - NET INCOME PER SHARE - Basic and Diluted EPS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20231231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails</Role>
      <ShortName>NET INCOME PER SHARE - Basic and Diluted EPS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="inva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>995785 - Disclosure - NET INCOME PER SHARE - Anti-Dilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20231231/taxonomy/role/DisclosureNetIncomePerShareAntiDilutiveSecuritiesDetails</Role>
      <ShortName>NET INCOME PER SHARE - Anti-Dilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="inva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>995795 - Disclosure - REVENUE RECOGNITION - Schedule of net revenue from collaborative arrangements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20231231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfNetRevenueFromCollaborativeArrangementsDetails</Role>
      <ShortName>REVENUE RECOGNITION - Schedule of net revenue from collaborative arrangements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="inva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>995805 - Disclosure - REVENUE RECOGNITION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20231231/taxonomy/role/DisclosureRevenueRecognitionDetails</Role>
      <ShortName>REVENUE RECOGNITION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inva.com/20231231/taxonomy/role/DisclosureRevenueRecognitionTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="inva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>995815 - Disclosure - LICENSE AND COLLABORATION ARRANGEMENTS - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20231231/taxonomy/role/DisclosureLicenseAndCollaborationArrangementsAdditionalInformationDetails</Role>
      <ShortName>LICENSE AND COLLABORATION ARRANGEMENTS - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="inva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>995825 - Disclosure - CONSOLIDATED ENTITIES AND ACQUISITIONS - Theravance Respiratory Company, LLC (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails</Role>
      <ShortName>CONSOLIDATED ENTITIES AND ACQUISITIONS - Theravance Respiratory Company, LLC (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="inva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>995835 - Disclosure - CONSOLIDATED ENTITIES AND ACQUISITIONS - ISP Fund LP (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsIspFundLpDetails</Role>
      <ShortName>CONSOLIDATED ENTITIES AND ACQUISITIONS - ISP Fund LP (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="inva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>995845 - Disclosure - CONSOLIDATED ENTITIES AND ACQUISITIONS - Entasis Therapeutics Holdings, Inc. (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails</Role>
      <ShortName>CONSOLIDATED ENTITIES AND ACQUISITIONS - Entasis Therapeutics Holdings, Inc. (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="inva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>995855 - Disclosure - CONSOLIDATED ENTITIES AND ACQUISITIONS - Schedule of Recognized Identified Assets Acquired and Liabilities Assumed (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails</Role>
      <ShortName>CONSOLIDATED ENTITIES AND ACQUISITIONS - Schedule of Recognized Identified Assets Acquired and Liabilities Assumed (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="inva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>995865 - Disclosure - CONSOLIDATED ENTITIES AND ACQUISITIONS - La Jolla Pharmaceutical Company (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsLaJollaPharmaceuticalCompanyDetails</Role>
      <ShortName>CONSOLIDATED ENTITIES AND ACQUISITIONS - La Jolla Pharmaceutical Company (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="inva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>995875 - Disclosure - CONSOLIDATED ENTITIES AND ACQUISITIONS - Pro Forma Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsProFormaInformationDetails</Role>
      <ShortName>CONSOLIDATED ENTITIES AND ACQUISITIONS - Pro Forma Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="inva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>995885 - Disclosure - EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Equity Investment in Armata (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails</Role>
      <ShortName>EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Equity Investment in Armata (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="inva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>995895 - Disclosure - EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Summarized Financial Data (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsSummarizedFinancialDataDetails</Role>
      <ShortName>EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Summarized Financial Data (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="inva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>995905 - Disclosure - EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Equity Investment in InCarda (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails</Role>
      <ShortName>EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Equity Investment in InCarda (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="inva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>995915 - Disclosure - EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Equity Investment in ImaginAb (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInImaginabDetails</Role>
      <ShortName>EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Equity Investment in ImaginAb (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="inva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>995925 - Disclosure - EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Convertible Promissory Note in Gate Neurosciences (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInGateNeurosciencesDetails</Role>
      <ShortName>EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Convertible Promissory Note in Gate Neurosciences (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="inva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>995935 - Disclosure - EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Equity Investment in Nanolive (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInNanoliveDetails</Role>
      <ShortName>EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Equity Investment in Nanolive (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="inva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>995945 - Disclosure - EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Available-for-Sale Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsAvailableforsaleSecuritiesDetails</Role>
      <ShortName>EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Available-for-Sale Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="inva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>995955 - Disclosure - EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Schedule of Available-for-Sale Securities Measured at Fair Value on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet</Role>
      <ShortName>EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Schedule of Available-for-Sale Securities Measured at Fair Value on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="inva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>995965 - Disclosure - CAPITALIZED FEES PAID - Schedule of Capitalized Fees Paid (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20231231/taxonomy/role/DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails</Role>
      <ShortName>CAPITALIZED FEES PAID - Schedule of Capitalized Fees Paid (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="inva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>995975 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20231231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails</Role>
      <ShortName>GOODWILL AND INTANGIBLE ASSETS (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inva.com/20231231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="inva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>995985 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Summary of Accumulated Amortization of Recognized Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20231231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails</Role>
      <ShortName>GOODWILL AND INTANGIBLE ASSETS - Summary of Accumulated Amortization of Recognized Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="inva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>995995 - Disclosure - BALANCE SHEET COMPONENTS - Schedule of Inventory, net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoryNetDetails</Role>
      <ShortName>BALANCE SHEET COMPONENTS - Schedule of Inventory, net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="inva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>996005 - Disclosure - BALANCE SHEET COMPONENTS - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails</Role>
      <ShortName>BALANCE SHEET COMPONENTS - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="inva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>996015 - Disclosure - BALANCE SHEET COMPONENTS - Schedule Of Other Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherAccruedLiabilitiesDetails</Role>
      <ShortName>BALANCE SHEET COMPONENTS - Schedule Of Other Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="inva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>996025 - Disclosure - BALANCE SHEET COMPONENTS -Schedule of Other Long-term Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherLongtermLiabilitiesDetails</Role>
      <ShortName>BALANCE SHEET COMPONENTS -Schedule of Other Long-term Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="inva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>996035 - Disclosure - STOCK-BASED COMPENSATION - 2012 Plan and ESPP (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensation2012PlanAndEsppDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - 2012 Plan and ESPP (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="inva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>996045 - Disclosure - STOCK-BASED COMPENSATION - Director Compensation Program (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationDirectorCompensationProgramDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Director Compensation Program (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="inva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>996055 - Disclosure - STOCK-BASED COMPENSATION - Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="inva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>996065 - Disclosure - STOCK-BASED COMPENSATION - Compensation Awards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationCompensationAwardsDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Compensation Awards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="inva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>996075 - Disclosure - STOCK-BASED COMPENSATION - Valuation Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationValuationAssumptionsDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Valuation Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="inva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>996085 - Disclosure - STOCKHOLDERS' EQUITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20231231/taxonomy/role/DisclosureStockholdersEquityDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inva.com/20231231/taxonomy/role/DisclosureStockholdersEquity</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="inva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>996095 - Disclosure - DEBT - Schedule of Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20231231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails</Role>
      <ShortName>DEBT - Schedule of Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="inva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>996105 - Disclosure - DEBT - Convertible Subordinated Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails</Role>
      <ShortName>DEBT - Convertible Subordinated Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="inva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>996115 - Disclosure - DEBT - Convertible Senior Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails</Role>
      <ShortName>DEBT - Convertible Senior Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="inva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>996125 - Disclosure - DEBT - Debt Maturities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20231231/taxonomy/role/DisclosureDebtDebtMaturitiesDetails</Role>
      <ShortName>DEBT - Debt Maturities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="inva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>996135 - Disclosure - COMMITMENTS AND CONTINGENCIES - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="inva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>996145 - Disclosure - COMMITMENTS AND CONTINGENCIES - Schedule of Components of Least Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeastCostDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES - Schedule of Components of Least Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="inva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>996155 - Disclosure - COMMITMENTS AND CONTINGENCIES - Schedule of Supplemental Cash Flow Information Related to Lease (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalCashFlowInformationRelatedToLeaseDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES - Schedule of Supplemental Cash Flow Information Related to Lease (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="inva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>996165 - Disclosure - COMMITMENTS AND CONTINGENCIES - Schedule of Future Minimum Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES - Schedule of Future Minimum Lease Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="inva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>996175 - Disclosure - INCOME TAXES - Income tax expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails</Role>
      <ShortName>INCOME TAXES - Income tax expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="inva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>996185 - Disclosure - INCOME TAXES - Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails</Role>
      <ShortName>INCOME TAXES - Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="inva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>996195 - Disclosure - INCOME TAXES - Deferred Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails</Role>
      <ShortName>INCOME TAXES - Deferred Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="inva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>996205 - Disclosure - INCOME TAXES - Additional Tax Disclosures (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalTaxDisclosuresDetails</Role>
      <ShortName>INCOME TAXES - Additional Tax Disclosures (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="inva-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>996215 - Disclosure - SUBSEQUENT EVENTS - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails</Role>
      <ShortName>SUBSEQUENT EVENTS - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="inva-20231231.htm">inva-20231231.htm</File>
    <File>inva-20231231.xsd</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img11953243_0.jpg</File>
    <File>img11953243_1.jpg</File>
    <File>img11953243_10.jpg</File>
    <File>img11953243_11.jpg</File>
    <File>img11953243_12.jpg</File>
    <File>img11953243_13.jpg</File>
    <File>img11953243_14.jpg</File>
    <File>img11953243_15.jpg</File>
    <File>img11953243_16.jpg</File>
    <File>img11953243_17.jpg</File>
    <File>img11953243_18.jpg</File>
    <File>img11953243_19.jpg</File>
    <File>img11953243_2.jpg</File>
    <File>img11953243_20.jpg</File>
    <File>img11953243_3.jpg</File>
    <File>img11953243_4.jpg</File>
    <File>img11953243_5.jpg</File>
    <File>img11953243_6.jpg</File>
    <File>img11953243_7.jpg</File>
    <File>img11953243_8.jpg</File>
    <File>img11953243_9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1280">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="39">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>125
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "inva-20231231.htm": {
   "nsprefix": "inva",
   "nsuri": "http://www.inva.com/20231231",
   "dts": {
    "inline": {
     "local": [
      "inva-20231231.htm"
     ]
    },
    "schema": {
     "local": [
      "inva-20231231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-sub-2023.xsd"
     ]
    }
   },
   "keyStandard": 435,
   "keyCustom": 169,
   "axisStandard": 37,
   "axisCustom": 0,
   "memberStandard": 51,
   "memberCustom": 86,
   "hidden": {
    "total": 16,
    "http://fasb.org/us-gaap/2023": 11,
    "http://xbrl.sec.gov/dei/2023": 4,
    "http://www.inva.com/20231231": 1
   },
   "contextCount": 496,
   "entityCount": 1,
   "segmentCount": 146,
   "elementCount": 1084,
   "unitCount": 12,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 1280,
    "http://xbrl.sec.gov/dei/2023": 39,
    "http://xbrl.sec.gov/ecd/2023": 4
   },
   "report": {
    "R1": {
     "role": "http://www.inva.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_b5138b8b-4530-41d2-a75c-4212efb677c1",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b5138b8b-4530-41d2-a75c-4212efb677c1",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets",
     "longName": "100010 - Statement - CONSOLIDATED BALANCE SHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "C_89447e67-fc05-4e77-9ac9-db6d75b7d66e",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_89447e67-fc05-4e77-9ac9-db6d75b7d66e",
      "name": "us-gaap:AccountsReceivableNet",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical",
     "longName": "100080 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "C_89447e67-fc05-4e77-9ac9-db6d75b7d66e",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_89447e67-fc05-4e77-9ac9-db6d75b7d66e",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfIncome",
     "longName": "100090 - Statement - CONSOLIDATED STATEMENTS OF INCOME",
     "shortName": "CONSOLIDATED STATEMENTS OF INCOME",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "C_b5138b8b-4530-41d2-a75c-4212efb677c1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b5138b8b-4530-41d2-a75c-4212efb677c1",
      "name": "us-gaap:SellingGeneralAndAdministrativeExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfIncomeParenthetical",
     "longName": "100100 - Statement - CONSOLIDATED STATEMENTS OF INCOME (Parenthetical)",
     "shortName": "CONSOLIDATED STATEMENTS OF INCOME (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "C_81ea3387-bcc2-4cfe-a9e7-78fab40062ee",
      "name": "us-gaap:CapitalizedContractCostAmortization",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "inva:CapitalizedFeesPaidDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R6": {
     "role": "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveIncome",
     "longName": "100110 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME",
     "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "C_b5138b8b-4530-41d2-a75c-4212efb677c1",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b5138b8b-4530-41d2-a75c-4212efb677c1",
      "name": "us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
     "longName": "100120 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "C_646bb33b-4ef6-4493-b542-00c92f556418",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_646bb33b-4ef6-4493-b542-00c92f556418",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
     "longName": "100130 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "8",
     "firstAnchor": {
      "contextRef": "C_b5138b8b-4530-41d2-a75c-4212efb677c1",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b5138b8b-4530-41d2-a75c-4212efb677c1",
      "name": "us-gaap:DeferredIncomeTaxExpenseBenefit",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "unique": true
     }
    },
    "R9": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "C_d5f73726-2a05-4be7-87fa-3fd6369578ba",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_d5f73726-2a05-4be7-87fa-3fd6369578ba",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPolicies",
     "longName": "995455 - Disclosure - DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "shortName": "DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "C_b5138b8b-4530-41d2-a75c-4212efb677c1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b5138b8b-4530-41d2-a75c-4212efb677c1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.inva.com/20231231/taxonomy/role/DisclosureNetIncomePerShare",
     "longName": "995465 - Disclosure - NET INCOME PER SHARE",
     "shortName": "NET INCOME PER SHARE",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "C_b5138b8b-4530-41d2-a75c-4212efb677c1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b5138b8b-4530-41d2-a75c-4212efb677c1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.inva.com/20231231/taxonomy/role/DisclosureRevenueRecognition1",
     "longName": "995475 - Disclosure - REVENUE RECOGNITION",
     "shortName": "REVENUE RECOGNITION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "C_b5138b8b-4530-41d2-a75c-4212efb677c1",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b5138b8b-4530-41d2-a75c-4212efb677c1",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.inva.com/20231231/taxonomy/role/DisclosureLicenseAndCollaborationArrangements",
     "longName": "995485 - Disclosure - LICENSE AND COLLABORATION ARRANGEMENTS",
     "shortName": "LICENSE AND COLLABORATION ARRANGEMENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "C_b5138b8b-4530-41d2-a75c-4212efb677c1",
      "name": "inva:LicenseAndCollaborationArrangementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b5138b8b-4530-41d2-a75c-4212efb677c1",
      "name": "inva:LicenseAndCollaborationArrangementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitions1",
     "longName": "995495 - Disclosure - CONSOLIDATED ENTITIES AND ACQUISITIONS",
     "shortName": "CONSOLIDATED ENTITIES AND ACQUISITIONS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "C_b5138b8b-4530-41d2-a75c-4212efb677c1",
      "name": "inva:ConsolidatedEntitiesAndAcquisitionsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b5138b8b-4530-41d2-a75c-4212efb677c1",
      "name": "inva:ConsolidatedEntitiesAndAcquisitionsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurements",
     "longName": "995505 - Disclosure - EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS",
     "shortName": "EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "C_b5138b8b-4530-41d2-a75c-4212efb677c1",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b5138b8b-4530-41d2-a75c-4212efb677c1",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.inva.com/20231231/taxonomy/role/DisclosureCapitalizedFeesPaid1",
     "longName": "995515 - Disclosure - CAPITALIZED FEES PAID",
     "shortName": "CAPITALIZED FEES PAID",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "C_b5138b8b-4530-41d2-a75c-4212efb677c1",
      "name": "inva:CapitalizedFeesPaidDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b5138b8b-4530-41d2-a75c-4212efb677c1",
      "name": "inva:CapitalizedFeesPaidDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.inva.com/20231231/taxonomy/role/DisclosureGoodwillAndIntangibleAssets",
     "longName": "995525 - Disclosure - GOODWILL AND INTANGIBLE ASSETS",
     "shortName": "GOODWILL AND INTANGIBLE ASSETS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "C_b5138b8b-4530-41d2-a75c-4212efb677c1",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b5138b8b-4530-41d2-a75c-4212efb677c1",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.inva.com/20231231/taxonomy/role/DisclosureBalanceSheetComponents",
     "longName": "995535 - Disclosure - BALANCE SHEET COMPONENTS",
     "shortName": "BALANCE SHEET COMPONENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "C_b5138b8b-4530-41d2-a75c-4212efb677c1",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b5138b8b-4530-41d2-a75c-4212efb677c1",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensation",
     "longName": "995545 - Disclosure - STOCK-BASED COMPENSATION",
     "shortName": "STOCK-BASED COMPENSATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "C_b5138b8b-4530-41d2-a75c-4212efb677c1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b5138b8b-4530-41d2-a75c-4212efb677c1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.inva.com/20231231/taxonomy/role/DisclosureStockholdersEquity",
     "longName": "995555 - Disclosure - STOCKHOLDERS' EQUITY",
     "shortName": "STOCKHOLDERS' EQUITY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "C_b5138b8b-4530-41d2-a75c-4212efb677c1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b5138b8b-4530-41d2-a75c-4212efb677c1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.inva.com/20231231/taxonomy/role/DisclosureDebt",
     "longName": "995565 - Disclosure - DEBT",
     "shortName": "DEBT",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "C_b5138b8b-4530-41d2-a75c-4212efb677c1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b5138b8b-4530-41d2-a75c-4212efb677c1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.inva.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingencies",
     "longName": "995575 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "C_b5138b8b-4530-41d2-a75c-4212efb677c1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b5138b8b-4530-41d2-a75c-4212efb677c1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxes",
     "longName": "995585 - Disclosure - INCOME TAXES",
     "shortName": "INCOME TAXES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "C_b5138b8b-4530-41d2-a75c-4212efb677c1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b5138b8b-4530-41d2-a75c-4212efb677c1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.inva.com/20231231/taxonomy/role/DisclosureSubsequentEvents",
     "longName": "995595 - Disclosure - SUBSEQUENT EVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "C_b5138b8b-4530-41d2-a75c-4212efb677c1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b5138b8b-4530-41d2-a75c-4212efb677c1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "995605 - Disclosure - DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "shortName": "DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "25",
     "firstAnchor": {
      "contextRef": "C_b5138b8b-4530-41d2-a75c-4212efb677c1",
      "name": "inva:DescriptionOfOperationsPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b5138b8b-4530-41d2-a75c-4212efb677c1",
      "name": "inva:DescriptionOfOperationsPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesTables",
     "longName": "995615 - Disclosure - DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "shortName": "DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "C_b5138b8b-4530-41d2-a75c-4212efb677c1",
      "name": "inva:PropertyPlantAndEquipmentUsefulLifeTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b5138b8b-4530-41d2-a75c-4212efb677c1",
      "name": "inva:PropertyPlantAndEquipmentUsefulLifeTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.inva.com/20231231/taxonomy/role/DisclosureNetIncomePerShareTables",
     "longName": "995625 - Disclosure - NET INCOME PER SHARE (Tables)",
     "shortName": "NET INCOME PER SHARE (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "C_b5138b8b-4530-41d2-a75c-4212efb677c1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b5138b8b-4530-41d2-a75c-4212efb677c1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.inva.com/20231231/taxonomy/role/DisclosureRevenueRecognitionTables",
     "longName": "995635 - Disclosure - REVENUE RECOGNITION (Tables)",
     "shortName": "REVENUE RECOGNITION (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "C_b5138b8b-4530-41d2-a75c-4212efb677c1",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b5138b8b-4530-41d2-a75c-4212efb677c1",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTables",
     "longName": "995645 - Disclosure - CONSOLIDATED ENTITIES AND ACQUISITIONS (Tables)",
     "shortName": "CONSOLIDATED ENTITIES AND ACQUISITIONS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "C_b5138b8b-4530-41d2-a75c-4212efb677c1",
      "name": "us-gaap:BusinessAcquisitionProFormaInformationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "inva:ConsolidatedEntitiesAndAcquisitionsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b5138b8b-4530-41d2-a75c-4212efb677c1",
      "name": "us-gaap:BusinessAcquisitionProFormaInformationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "inva:ConsolidatedEntitiesAndAcquisitionsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsTables",
     "longName": "995655 - Disclosure - EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS (Tables)",
     "shortName": "EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "C_b5138b8b-4530-41d2-a75c-4212efb677c1",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FinancialInstrumentsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b5138b8b-4530-41d2-a75c-4212efb677c1",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FinancialInstrumentsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.inva.com/20231231/taxonomy/role/DisclosureCapitalizedFeesPaidTables",
     "longName": "995665 - Disclosure - CAPITALIZED FEES PAID (Tables)",
     "shortName": "CAPITALIZED FEES PAID (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "C_b5138b8b-4530-41d2-a75c-4212efb677c1",
      "name": "us-gaap:CapitalizedContractCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "inva:CapitalizedFeesPaidDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b5138b8b-4530-41d2-a75c-4212efb677c1",
      "name": "us-gaap:CapitalizedContractCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "inva:CapitalizedFeesPaidDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.inva.com/20231231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsTables",
     "longName": "995675 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Tables)",
     "shortName": "GOODWILL AND INTANGIBLE ASSETS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "C_b5138b8b-4530-41d2-a75c-4212efb677c1",
      "name": "inva:ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b5138b8b-4530-41d2-a75c-4212efb677c1",
      "name": "inva:ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.inva.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsTables",
     "longName": "995685 - Disclosure - BALANCE SHEET COMPONENTS (Tables)",
     "shortName": "BALANCE SHEET COMPONENTS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "C_b5138b8b-4530-41d2-a75c-4212efb677c1",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b5138b8b-4530-41d2-a75c-4212efb677c1",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationTables",
     "longName": "995695 - Disclosure - STOCK-BASED COMPENSATION (Tables)",
     "shortName": "STOCK-BASED COMPENSATION (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "C_b5138b8b-4530-41d2-a75c-4212efb677c1",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b5138b8b-4530-41d2-a75c-4212efb677c1",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtTables",
     "longName": "995705 - Disclosure - DEBT (Tables)",
     "shortName": "DEBT (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "C_b5138b8b-4530-41d2-a75c-4212efb677c1",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b5138b8b-4530-41d2-a75c-4212efb677c1",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.inva.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables",
     "longName": "995715 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "C_b5138b8b-4530-41d2-a75c-4212efb677c1",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b5138b8b-4530-41d2-a75c-4212efb677c1",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesTables",
     "longName": "995725 - Disclosure - INCOME TAXES (Tables)",
     "shortName": "INCOME TAXES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "C_b5138b8b-4530-41d2-a75c-4212efb677c1",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b5138b8b-4530-41d2-a75c-4212efb677c1",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails",
     "longName": "995735 - Disclosure - DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Description of Operations (Details)",
     "shortName": "DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Description of Operations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "C_b5138b8b-4530-41d2-a75c-4212efb677c1",
      "name": "inva:NumberOfCustomers",
      "unitRef": "U_Customer",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:ConcentrationRiskCreditRisk",
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b5138b8b-4530-41d2-a75c-4212efb677c1",
      "name": "inva:NumberOfCustomers",
      "unitRef": "U_Customer",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:ConcentrationRiskCreditRisk",
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails",
     "longName": "995745 - Disclosure - DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment (Details)",
     "shortName": "DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "C_1007c8ce-c961-4336-8299-5ed88a88849d",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "inva:PropertyPlantAndEquipmentUsefulLifeTableTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1007c8ce-c961-4336-8299-5ed88a88849d",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "inva:PropertyPlantAndEquipmentUsefulLifeTableTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesRelatedPartyTransactionsDetails",
     "longName": "995755 - Disclosure - DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Related Party Transactions (Details)",
     "shortName": "DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Related Party Transactions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "C_175d99d3-70ac-4ebe-93be-8247d1fbe50e",
      "name": "inva:RelatedPartyTransactionCommonStockOwnershipPercentageByRelatedParty",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "inva:RelatedPartyTransactionsPolicyTextBlock",
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R41": {
     "role": "http://www.inva.com/20231231/taxonomy/role/DisclosureNetIncomePerShareDetails",
     "longName": "995765 - Disclosure - NET INCOME PER SHARE (Details)",
     "shortName": "NET INCOME PER SHARE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "C_e3e6ec1f-49a0-4fb9-9419-c9b6fcbc8855",
      "name": "inva:IncrementalCommonSharesAttributableToConversionOfDebtSecuritiesTreasuryStockMethod",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e3e6ec1f-49a0-4fb9-9419-c9b6fcbc8855",
      "name": "inva:IncrementalCommonSharesAttributableToConversionOfDebtSecuritiesTreasuryStockMethod",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.inva.com/20231231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails",
     "longName": "995775 - Disclosure - NET INCOME PER SHARE - Basic and Diluted EPS (Details)",
     "shortName": "NET INCOME PER SHARE - Basic and Diluted EPS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "C_b5138b8b-4530-41d2-a75c-4212efb677c1",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b5138b8b-4530-41d2-a75c-4212efb677c1",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.inva.com/20231231/taxonomy/role/DisclosureNetIncomePerShareAntiDilutiveSecuritiesDetails",
     "longName": "995785 - Disclosure - NET INCOME PER SHARE - Anti-Dilutive Securities (Details)",
     "shortName": "NET INCOME PER SHARE - Anti-Dilutive Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "C_b5138b8b-4530-41d2-a75c-4212efb677c1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b5138b8b-4530-41d2-a75c-4212efb677c1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.inva.com/20231231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfNetRevenueFromCollaborativeArrangementsDetails",
     "longName": "995795 - Disclosure - REVENUE RECOGNITION - Schedule of net revenue from collaborative arrangements (Details)",
     "shortName": "REVENUE RECOGNITION - Schedule of net revenue from collaborative arrangements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "C_b5138b8b-4530-41d2-a75c-4212efb677c1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_c1969bd2-5e89-423e-88e9-b5564c6afe10",
      "name": "inva:GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "div",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.inva.com/20231231/taxonomy/role/DisclosureRevenueRecognitionDetails",
     "longName": "995805 - Disclosure - REVENUE RECOGNITION (Details)",
     "shortName": "REVENUE RECOGNITION (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "C_b5138b8b-4530-41d2-a75c-4212efb677c1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_29193a89-f8bc-431f-9fc2-70fd8e836d0e",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.inva.com/20231231/taxonomy/role/DisclosureLicenseAndCollaborationArrangementsAdditionalInformationDetails",
     "longName": "995815 - Disclosure - LICENSE AND COLLABORATION ARRANGEMENTS - Additional Information (Details)",
     "shortName": "LICENSE AND COLLABORATION ARRANGEMENTS - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "C_b5138b8b-4530-41d2-a75c-4212efb677c1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_33ccc9ac-1bd0-4923-b096-29db8ac98a5e",
      "name": "inva:FuturePotentialMilestonePayment",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "inva:LicenseAndCollaborationArrangementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails",
     "longName": "995825 - Disclosure - CONSOLIDATED ENTITIES AND ACQUISITIONS - Theravance Respiratory Company, LLC (Details)",
     "shortName": "CONSOLIDATED ENTITIES AND ACQUISITIONS - Theravance Respiratory Company, LLC (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "C_89447e67-fc05-4e77-9ac9-db6d75b7d66e",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_9eac7308-f944-4333-bf01-4381430c8676",
      "name": "inva:OwnershipInterestInConsolidatedEntities",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "inva:ConsolidatedEntitiesAndAcquisitionsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsIspFundLpDetails",
     "longName": "995835 - Disclosure - CONSOLIDATED ENTITIES AND ACQUISITIONS - ISP Fund LP (Details)",
     "shortName": "CONSOLIDATED ENTITIES AND ACQUISITIONS - ISP Fund LP (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "C_89447e67-fc05-4e77-9ac9-db6d75b7d66e",
      "name": "us-gaap:Assets",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_9030a2c1-fd8e-4238-9d01-79bece46654e",
      "name": "us-gaap:LimitedPartnersCumulativeCashDistributions",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "inva:ConsolidatedEntitiesAndAcquisitionsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails",
     "longName": "995845 - Disclosure - CONSOLIDATED ENTITIES AND ACQUISITIONS - Entasis Therapeutics Holdings, Inc. (Details)",
     "shortName": "CONSOLIDATED ENTITIES AND ACQUISITIONS - Entasis Therapeutics Holdings, Inc. (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "C_89447e67-fc05-4e77-9ac9-db6d75b7d66e",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_8f8c6623-d626-4ff4-b287-9206e6e7485e",
      "name": "inva:SecuritiesPurchaseAgreementRightsToDesignateInvesteeBoardMembersNumberOfBoardMembers",
      "unitRef": "U_Director",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "inva:ConsolidatedEntitiesAndAcquisitionsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails",
     "longName": "995855 - Disclosure - CONSOLIDATED ENTITIES AND ACQUISITIONS - Schedule of Recognized Identified Assets Acquired and Liabilities Assumed (Details)",
     "shortName": "CONSOLIDATED ENTITIES AND ACQUISITIONS - Schedule of Recognized Identified Assets Acquired and Liabilities Assumed (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "C_89447e67-fc05-4e77-9ac9-db6d75b7d66e",
      "name": "us-gaap:Goodwill",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1cbdd9df-6a4a-4d82-9344-ffb61a7bc4cd",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "div",
       "inva:ConsolidatedEntitiesAndAcquisitionsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsLaJollaPharmaceuticalCompanyDetails",
     "longName": "995865 - Disclosure - CONSOLIDATED ENTITIES AND ACQUISITIONS - La Jolla Pharmaceutical Company (Details)",
     "shortName": "CONSOLIDATED ENTITIES AND ACQUISITIONS - La Jolla Pharmaceutical Company (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "C_b5138b8b-4530-41d2-a75c-4212efb677c1",
      "name": "us-gaap:IncreaseDecreaseInInventories",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e05740b2-e808-41d3-b26e-897ba3aa633c",
      "name": "us-gaap:BusinessCombinationConsiderationTransferred1",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "inva:ConsolidatedEntitiesAndAcquisitionsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsProFormaInformationDetails",
     "longName": "995875 - Disclosure - CONSOLIDATED ENTITIES AND ACQUISITIONS - Pro Forma Information (Details)",
     "shortName": "CONSOLIDATED ENTITIES AND ACQUISITIONS - Pro Forma Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "C_e913bb79-80cf-4e4b-b05e-99a1cc469935",
      "name": "us-gaap:BusinessAcquisitionsProFormaRevenue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:BusinessAcquisitionProFormaInformationTextBlock",
       "div",
       "inva:ConsolidatedEntitiesAndAcquisitionsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e913bb79-80cf-4e4b-b05e-99a1cc469935",
      "name": "us-gaap:BusinessAcquisitionsProFormaRevenue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:BusinessAcquisitionProFormaInformationTextBlock",
       "div",
       "inva:ConsolidatedEntitiesAndAcquisitionsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
     "longName": "995885 - Disclosure - EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Equity Investment in Armata (Details)",
     "shortName": "EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Equity Investment in Armata (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "C_e037e13e-6e91-4a72-ba0c-e61af7067b1b",
      "name": "inva:SecuritiesPurchaseAgreementNumberOfTranches",
      "unitRef": "U_Tranche",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:FinancialInstrumentsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e037e13e-6e91-4a72-ba0c-e61af7067b1b",
      "name": "inva:SecuritiesPurchaseAgreementNumberOfTranches",
      "unitRef": "U_Tranche",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:FinancialInstrumentsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsSummarizedFinancialDataDetails",
     "longName": "995895 - Disclosure - EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Summarized Financial Data (Details)",
     "shortName": "EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Summarized Financial Data (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "C_89447e67-fc05-4e77-9ac9-db6d75b7d66e",
      "name": "us-gaap:AssetsCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4a4ab2a3-40c8-4d79-9cdf-f746af492718",
      "name": "us-gaap:AssetsCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfVariableInterestEntitiesTextBlock",
       "div",
       "us-gaap:FinancialInstrumentsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails",
     "longName": "995905 - Disclosure - EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Equity Investment in InCarda (Details)",
     "shortName": "EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Equity Investment in InCarda (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "C_3325a2cf-7460-4b93-a664-ed1cbe345622",
      "name": "inva:NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee",
      "unitRef": "U_Director",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:FinancialInstrumentsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3325a2cf-7460-4b93-a664-ed1cbe345622",
      "name": "inva:NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee",
      "unitRef": "U_Director",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:FinancialInstrumentsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInImaginabDetails",
     "longName": "995915 - Disclosure - EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Equity Investment in ImaginAb (Details)",
     "shortName": "EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Equity Investment in ImaginAb (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "C_07acd2a2-efee-41c9-bbd9-499920ef8206",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:FinancialInstrumentsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_07acd2a2-efee-41c9-bbd9-499920ef8206",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:FinancialInstrumentsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInGateNeurosciencesDetails",
     "longName": "995925 - Disclosure - EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Convertible Promissory Note in Gate Neurosciences (Details)",
     "shortName": "EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Convertible Promissory Note in Gate Neurosciences (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "C_b5138b8b-4530-41d2-a75c-4212efb677c1",
      "name": "us-gaap:PaymentsToAcquireLongtermInvestments",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_85b04dbe-2493-4115-9d41-cfc1636e1d1c",
      "name": "inva:NumberOfCommonStockIssuedDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:FinancialInstrumentsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInNanoliveDetails",
     "longName": "995935 - Disclosure - EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Equity Investment in Nanolive (Details)",
     "shortName": "EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Equity Investment in Nanolive (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "C_f3734e2c-95b6-4b79-9206-0f8540ff6e11",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:FinancialInstrumentsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f3734e2c-95b6-4b79-9206-0f8540ff6e11",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:FinancialInstrumentsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsAvailableforsaleSecuritiesDetails",
     "longName": "995945 - Disclosure - EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Available-for-Sale Securities (Details)",
     "shortName": "EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Available-for-Sale Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "C_89447e67-fc05-4e77-9ac9-db6d75b7d66e",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "div",
       "us-gaap:FinancialInstrumentsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_89447e67-fc05-4e77-9ac9-db6d75b7d66e",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "div",
       "us-gaap:FinancialInstrumentsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet",
     "longName": "995955 - Disclosure - EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Schedule of Available-for-Sale Securities Measured at Fair Value on a Recurring Basis (Details)",
     "shortName": "EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Schedule of Available-for-Sale Securities Measured at Fair Value on a Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "C_89447e67-fc05-4e77-9ac9-db6d75b7d66e",
      "name": "inva:ConvertibleSeniorDebtFairValueDisclosures",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "div",
       "us-gaap:FinancialInstrumentsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_89447e67-fc05-4e77-9ac9-db6d75b7d66e",
      "name": "inva:ConvertibleSeniorDebtFairValueDisclosures",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "div",
       "us-gaap:FinancialInstrumentsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.inva.com/20231231/taxonomy/role/DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails",
     "longName": "995965 - Disclosure - CAPITALIZED FEES PAID - Schedule of Capitalized Fees Paid (Details)",
     "shortName": "CAPITALIZED FEES PAID - Schedule of Capitalized Fees Paid (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "C_89447e67-fc05-4e77-9ac9-db6d75b7d66e",
      "name": "us-gaap:CapitalizedContractCostGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:CapitalizedContractCostTableTextBlock",
       "div",
       "inva:CapitalizedFeesPaidDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_89447e67-fc05-4e77-9ac9-db6d75b7d66e",
      "name": "us-gaap:CapitalizedContractCostAccumulatedAmortization",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:CapitalizedContractCostTableTextBlock",
       "div",
       "inva:CapitalizedFeesPaidDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.inva.com/20231231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails",
     "longName": "995975 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Additional Information) (Details)",
     "shortName": "GOODWILL AND INTANGIBLE ASSETS (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "C_89447e67-fc05-4e77-9ac9-db6d75b7d66e",
      "name": "us-gaap:Goodwill",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b5138b8b-4530-41d2-a75c-4212efb677c1",
      "name": "us-gaap:GoodwillImpairmentLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.inva.com/20231231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails",
     "longName": "995985 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Summary of Accumulated Amortization of Recognized Intangible Assets (Details)",
     "shortName": "GOODWILL AND INTANGIBLE ASSETS - Summary of Accumulated Amortization of Recognized Intangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "C_89447e67-fc05-4e77-9ac9-db6d75b7d66e",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_89447e67-fc05-4e77-9ac9-db6d75b7d66e",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.inva.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoryNetDetails",
     "longName": "995995 - Disclosure - BALANCE SHEET COMPONENTS - Schedule of Inventory, net (Details)",
     "shortName": "BALANCE SHEET COMPONENTS - Schedule of Inventory, net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "C_89447e67-fc05-4e77-9ac9-db6d75b7d66e",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_89447e67-fc05-4e77-9ac9-db6d75b7d66e",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.inva.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails",
     "longName": "996005 - Disclosure - BALANCE SHEET COMPONENTS - Additional Information (Details)",
     "shortName": "BALANCE SHEET COMPONENTS - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "C_850c3b25-8c30-4a01-9de2-0ca85949a00e",
      "name": "inva:FairValueAdjustmentsOfInventoryFromAcquistion",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_850c3b25-8c30-4a01-9de2-0ca85949a00e",
      "name": "inva:FairValueAdjustmentsOfInventoryFromAcquistion",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.inva.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherAccruedLiabilitiesDetails",
     "longName": "996015 - Disclosure - BALANCE SHEET COMPONENTS - Schedule Of Other Accrued Liabilities (Details)",
     "shortName": "BALANCE SHEET COMPONENTS - Schedule Of Other Accrued Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "C_89447e67-fc05-4e77-9ac9-db6d75b7d66e",
      "name": "inva:AccruedContractManufacturingLiability",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_89447e67-fc05-4e77-9ac9-db6d75b7d66e",
      "name": "inva:AccruedContractManufacturingLiability",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.inva.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherLongtermLiabilitiesDetails",
     "longName": "996025 - Disclosure - BALANCE SHEET COMPONENTS -Schedule of Other Long-term Liabilities (Details)",
     "shortName": "BALANCE SHEET COMPONENTS -Schedule of Other Long-term Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "C_89447e67-fc05-4e77-9ac9-db6d75b7d66e",
      "name": "inva:DeferredRoyaltyObligationNonCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_89447e67-fc05-4e77-9ac9-db6d75b7d66e",
      "name": "inva:DeferredRoyaltyObligationNonCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensation2012PlanAndEsppDetails",
     "longName": "996035 - Disclosure - STOCK-BASED COMPENSATION - 2012 Plan and ESPP (Details)",
     "shortName": "STOCK-BASED COMPENSATION - 2012 Plan and ESPP (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "C_5c9abf9d-1e31-4f48-9d0d-c57d10750153",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5c9abf9d-1e31-4f48-9d0d-c57d10750153",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R69": {
     "role": "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationDirectorCompensationProgramDetails",
     "longName": "996045 - Disclosure - STOCK-BASED COMPENSATION - Director Compensation Program (Details)",
     "shortName": "STOCK-BASED COMPENSATION - Director Compensation Program (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "C_f0da2c05-1727-4786-acd0-b03e3dff2fa8",
      "name": "inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialEquityGrantValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f0da2c05-1727-4786-acd0-b03e3dff2fa8",
      "name": "inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialEquityGrantValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R70": {
     "role": "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails",
     "longName": "996055 - Disclosure - STOCK-BASED COMPENSATION - Stock-Based Compensation Expense (Details)",
     "shortName": "STOCK-BASED COMPENSATION - Stock-Based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "C_b5138b8b-4530-41d2-a75c-4212efb677c1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b5138b8b-4530-41d2-a75c-4212efb677c1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R71": {
     "role": "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationCompensationAwardsDetails",
     "longName": "996065 - Disclosure - STOCK-BASED COMPENSATION - Compensation Awards (Details)",
     "shortName": "STOCK-BASED COMPENSATION - Compensation Awards (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "C_886d4bf2-cc70-460c-8055-b20097a1c12e",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1fd35541-50f5-4c16-a031-bd9cc78d2a09",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "unique": true
     }
    },
    "R72": {
     "role": "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationValuationAssumptionsDetails",
     "longName": "996075 - Disclosure - STOCK-BASED COMPENSATION - Valuation Assumptions (Details)",
     "shortName": "STOCK-BASED COMPENSATION - Valuation Assumptions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "C_1c6acdd9-134f-4827-828c-e39c4849a9cf",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1c6acdd9-134f-4827-828c-e39c4849a9cf",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R73": {
     "role": "http://www.inva.com/20231231/taxonomy/role/DisclosureStockholdersEquityDetails",
     "longName": "996085 - Disclosure - STOCKHOLDERS' EQUITY (Details)",
     "shortName": "STOCKHOLDERS' EQUITY (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "C_c985f900-3058-44b4-9093-ef23d5cbfa14",
      "name": "us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_c985f900-3058-44b4-9093-ef23d5cbfa14",
      "name": "us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R74": {
     "role": "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails",
     "longName": "996095 - Disclosure - DEBT - Schedule of Debt (Details)",
     "shortName": "DEBT - Schedule of Debt (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "C_89447e67-fc05-4e77-9ac9-db6d75b7d66e",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_89447e67-fc05-4e77-9ac9-db6d75b7d66e",
      "name": "us-gaap:DebtLongtermAndShorttermCombinedAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "unique": true
     }
    },
    "R75": {
     "role": "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails",
     "longName": "996105 - Disclosure - DEBT - Convertible Subordinated Notes (Details)",
     "shortName": "DEBT - Convertible Subordinated Notes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "C_b5138b8b-4530-41d2-a75c-4212efb677c1",
      "name": "us-gaap:RepaymentsOfUnsecuredDebt",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_d98c3729-ed3e-4b22-af22-60937a83a980",
      "name": "us-gaap:DebtInstrumentRepurchaseAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "unique": true
     }
    },
    "R76": {
     "role": "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails",
     "longName": "996115 - Disclosure - DEBT - Convertible Senior Notes (Details)",
     "shortName": "DEBT - Convertible Senior Notes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "C_b5138b8b-4530-41d2-a75c-4212efb677c1",
      "name": "us-gaap:RepaymentsOfUnsecuredDebt",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_d9c7ca7c-81fc-4272-b388-610e1b6444a8",
      "name": "inva:DebtConversionCommonStockPriceToConversionPriceRatioPercentage",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "unique": true
     }
    },
    "R77": {
     "role": "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtDebtMaturitiesDetails",
     "longName": "996125 - Disclosure - DEBT - Debt Maturities (Details)",
     "shortName": "DEBT - Debt Maturities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "C_89447e67-fc05-4e77-9ac9-db6d75b7d66e",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_89447e67-fc05-4e77-9ac9-db6d75b7d66e",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R78": {
     "role": "http://www.inva.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
     "longName": "996135 - Disclosure - COMMITMENTS AND CONTINGENCIES - Additional Information (Details)",
     "shortName": "COMMITMENTS AND CONTINGENCIES - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "C_89447e67-fc05-4e77-9ac9-db6d75b7d66e",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_89447e67-fc05-4e77-9ac9-db6d75b7d66e",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R79": {
     "role": "http://www.inva.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeastCostDetails",
     "longName": "996145 - Disclosure - COMMITMENTS AND CONTINGENCIES - Schedule of Components of Least Cost (Details)",
     "shortName": "COMMITMENTS AND CONTINGENCIES - Schedule of Components of Least Cost (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "C_b5138b8b-4530-41d2-a75c-4212efb677c1",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b5138b8b-4530-41d2-a75c-4212efb677c1",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R80": {
     "role": "http://www.inva.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalCashFlowInformationRelatedToLeaseDetails",
     "longName": "996155 - Disclosure - COMMITMENTS AND CONTINGENCIES - Schedule of Supplemental Cash Flow Information Related to Lease (Details)",
     "shortName": "COMMITMENTS AND CONTINGENCIES - Schedule of Supplemental Cash Flow Information Related to Lease (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "C_b5138b8b-4530-41d2-a75c-4212efb677c1",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b5138b8b-4530-41d2-a75c-4212efb677c1",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R81": {
     "role": "http://www.inva.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails",
     "longName": "996165 - Disclosure - COMMITMENTS AND CONTINGENCIES - Schedule of Future Minimum Lease Payments (Details)",
     "shortName": "COMMITMENTS AND CONTINGENCIES - Schedule of Future Minimum Lease Payments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "C_89447e67-fc05-4e77-9ac9-db6d75b7d66e",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_89447e67-fc05-4e77-9ac9-db6d75b7d66e",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R82": {
     "role": "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails",
     "longName": "996175 - Disclosure - INCOME TAXES - Income tax expense (Details)",
     "shortName": "INCOME TAXES - Income tax expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "82",
     "firstAnchor": {
      "contextRef": "C_b5138b8b-4530-41d2-a75c-4212efb677c1",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b5138b8b-4530-41d2-a75c-4212efb677c1",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R83": {
     "role": "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails",
     "longName": "996185 - Disclosure - INCOME TAXES - Reconciliation (Details)",
     "shortName": "INCOME TAXES - Reconciliation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "83",
     "firstAnchor": {
      "contextRef": "C_b5138b8b-4530-41d2-a75c-4212efb677c1",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b5138b8b-4530-41d2-a75c-4212efb677c1",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R84": {
     "role": "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails",
     "longName": "996195 - Disclosure - INCOME TAXES - Deferred Taxes (Details)",
     "shortName": "INCOME TAXES - Deferred Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "84",
     "firstAnchor": {
      "contextRef": "C_89447e67-fc05-4e77-9ac9-db6d75b7d66e",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_89447e67-fc05-4e77-9ac9-db6d75b7d66e",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R85": {
     "role": "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalTaxDisclosuresDetails",
     "longName": "996205 - Disclosure - INCOME TAXES - Additional Tax Disclosures (Details)",
     "shortName": "INCOME TAXES - Additional Tax Disclosures (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "85",
     "firstAnchor": {
      "contextRef": "C_89447e67-fc05-4e77-9ac9-db6d75b7d66e",
      "name": "us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_89447e67-fc05-4e77-9ac9-db6d75b7d66e",
      "name": "us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R86": {
     "role": "http://www.inva.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
     "longName": "996215 - Disclosure - SUBSEQUENT EVENTS - Additional Information (Details)",
     "shortName": "SUBSEQUENT EVENTS - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "86",
     "firstAnchor": {
      "contextRef": "C_89447e67-fc05-4e77-9ac9-db6d75b7d66e",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1ba9463a-d1f5-4a30-bbac-3bc5aad6339b",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20231231.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingStandardsUpdate202006Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingStandardsUpdate202006Member",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update 2020-06 [Member]",
        "terseLabel": "ASU 2020-06",
        "documentation": "Accounting Standards Update 2020-06 Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity."
       }
      }
     },
     "auth_ref": [
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672"
     ]
    },
    "us-gaap_AccountingStandardsUpdateExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingStandardsUpdateExtensibleList",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update [Extensible Enumeration]",
        "documentation": "Indicates amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r309",
      "r310",
      "r311",
      "r383",
      "r384",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r465",
      "r591",
      "r592",
      "r593",
      "r626",
      "r627",
      "r638",
      "r639",
      "r640",
      "r649",
      "r650",
      "r651",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r682",
      "r683",
      "r687",
      "r688",
      "r689",
      "r690",
      "r698",
      "r699",
      "r703",
      "r704",
      "r705",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r1135"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Accounts Payable, Current, Total",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r999"
     ]
    },
    "us-gaap_AccountsReceivableNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableNet",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Accounts Receivable, after Allowance for Credit Loss, Total",
        "label": "Accounts Receivable, after Allowance for Credit Loss",
        "terseLabel": "Accounts receivable",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business."
       }
      }
     },
     "auth_ref": [
      "r873",
      "r936",
      "r1005",
      "r1231"
     ]
    },
    "inva_AccruedClinicalLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "AccruedClinicalLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Clinical Liability",
        "label": "Accrued Clinical Liability",
        "terseLabel": "Accrued clinical expenses"
       }
      }
     },
     "auth_ref": []
    },
    "inva_AccruedContractManufacturingLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "AccruedContractManufacturingLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued contract manufacturing liability.",
        "label": "Accrued Contract Manufacturing Liability",
        "terseLabel": "Accrued contract manufacturing expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedIncomeTaxesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Income Taxes, Current",
        "terseLabel": "Income tax payable",
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r224"
     ]
    },
    "inva_AccruedInterestIncomeIncludedInLongTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "AccruedInterestIncomeIncludedInLongTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued interest income added to long-term investments",
        "label": "Accrued Interest Income Included in Long-term Investments",
        "documentation": "Accrued interest income included in long-term investments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesAndOtherLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherAccruedLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities and Other Liabilities",
        "totalLabel": "Total other accrued liabilities",
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "inva_AccruedLicenseFeesAndRoyalties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "AccruedLicenseFeesAndRoyalties",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued license fees and royalties",
        "label": "Accrued License Fees and Royalties",
        "terseLabel": "Accrued license fees and royalties"
       }
      }
     },
     "auth_ref": []
    },
    "inva_AccruedProfessionalServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "AccruedProfessionalServices",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Professional Services",
        "label": "Accrued Professional Services",
        "terseLabel": "Accrued professional services"
       }
      }
     },
     "auth_ref": []
    },
    "inva_AccruedResearchLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "AccruedResearchLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Research Liability",
        "label": "Accrued Research Liability",
        "terseLabel": "Accrued research expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedRoyaltiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedRoyaltiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty obligation payable",
        "label": "Accrued Royalties, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r958"
     ]
    },
    "inva_AccruedRoyaltyObligations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "AccruedRoyaltyObligations",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureLicenseAndCollaborationArrangementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Obligation to pay royalties",
        "label": "Accrued Royalty Obligations",
        "documentation": "Obligations incurred through that date and payable for royalties."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r17",
      "r49",
      "r654",
      "r657",
      "r724",
      "r827",
      "r828",
      "r1121",
      "r1122",
      "r1123",
      "r1132",
      "r1133",
      "r1134"
     ]
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetResidualValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AcquiredFiniteLivedIntangibleAssetResidualValue",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquired Finite-Lived Intangible Asset, Residual Value",
        "documentation": "The aggregate expected value at the end of their useful life of a major finite-lived intangible asset class acquired during the period either individually or as part of a group of assets (in either an asset acquisition or business combination). A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "us-gaap_AcquisitionCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AcquisitionCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsLaJollaPharmaceuticalCompanyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquisition Costs, Period Cost",
        "terseLabel": "Acquisition-related costs",
        "documentation": "The capitalized costs incurred during the period (excluded from amortization) to purchase, lease or otherwise acquire an unproved property, including costs of lease bonuses and options to purchase or lease properties, the portion of costs applicable to minerals when land including mineral rights is purchased in fee, brokers' fees, recording fees, legal costs, and other costs incurred in acquiring properties."
       }
      }
     },
     "auth_ref": [
      "r220",
      "r221"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r1056"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Additional Paid in Capital, Common Stock, Ending Balance",
        "periodStartLabel": "Additional Paid in Capital, Common Stock, Beginning Balance",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r164"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r591",
      "r592",
      "r593",
      "r845",
      "r1132",
      "r1133",
      "r1134",
      "r1213",
      "r1238"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r1062"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r1062"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r1062"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r1062"
     ]
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update [Axis]",
        "documentation": "Information by amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r309",
      "r310",
      "r311",
      "r312",
      "r321",
      "r383",
      "r384",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r465",
      "r591",
      "r592",
      "r593",
      "r624",
      "r625",
      "r626",
      "r627",
      "r638",
      "r639",
      "r640",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r682",
      "r683",
      "r687",
      "r688",
      "r689",
      "r690",
      "r698",
      "r699",
      "r703",
      "r704",
      "r705",
      "r706",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r769",
      "r770",
      "r771",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature",
        "terseLabel": "Conversion of convertible subordinated notes due 2023",
        "documentation": "Amount of increase (decrease) in additional paid in capital (APIC) resulting from recognition of deferred taxes for convertible debt with a beneficial conversion feature."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r205",
      "r623"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt",
        "terseLabel": "Capped call options associated with convertible senior notes due 2028",
        "documentation": "Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "inva_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtInShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtInShares",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capped call options associated with convertible senior notes due 2028 (in shares)",
        "label": "Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt in Shares",
        "documentation": "Adjustments to additional paid in capital equity component of convertible debt in shares."
       }
      }
     },
     "auth_ref": []
    },
    "inva_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation (in shares)",
        "documentation": "Adjustments to additional paid in capital share based compensation requisite service period recognition shares.",
        "label": "Adjustments To Additional Paid In Capital Share based Compensation Requisite Service Period Recognition Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r102",
      "r553"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1026",
      "r1038",
      "r1048",
      "r1074"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r1029",
      "r1041",
      "r1051",
      "r1077"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r1062"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r1069"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r1033",
      "r1042",
      "r1052",
      "r1069",
      "r1078",
      "r1082",
      "r1090"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r1088"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Total stock-based compensation expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r586",
      "r598"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "inva_AmortizationOfCapitalizedFeesAndDepreciationOfPropertyAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "AmortizationOfCapitalizedFeesAndDepreciationOfPropertyAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortization of capitalized fees and depreciation of property and equipment.",
        "label": "Amortization of Capitalized Fees and Depreciation of Property and Equipment",
        "terseLabel": "Amortization of capitalized fees and depreciation of property and equipment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfDebtDiscountPremium",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails": {
       "parentTag": "us-gaap_InterestExpenseDebt",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of Debt Discount (Premium)",
        "terseLabel": "Amortization of debt discount",
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r140",
      "r181",
      "r504"
     ]
    },
    "inva_AmortizationOfFairValueAdjustmentsOfCostOfProductsSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "AmortizationOfFairValueAdjustmentsOfCostOfProductsSold",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortization of fair value adjustments of cost of products sold.",
        "label": "Amortization of Fair Value Adjustments of Cost of Products Sold",
        "terseLabel": "Amortization of fair value adjustments of Cost of products sold"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfFinancingCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails": {
       "parentTag": "us-gaap_InterestExpenseDebt",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails": {
       "parentTag": "us-gaap_InterestExpenseDebt",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of Debt Issuance Costs",
        "terseLabel": "Amortization of debt issuance costs",
        "documentation": "Amount of amortization expense attributable to debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r173",
      "r504",
      "r701",
      "r1127"
     ]
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Amortization of Debt Issuance Costs and Discounts, Total",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of debt discount and issuance costs",
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r504",
      "r701",
      "r978",
      "r979",
      "r1127"
     ]
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfIncome": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails",
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization of acquired intangible assets",
        "verboseLabel": "Amortization expense",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r76",
      "r81"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureNetIncomePerShareAntiDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Anti-dilutive securities (in shares)",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r342"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureNetIncomePerShareAntiDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureNetIncomePerShareAntiDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Anti-Dilutive Securities",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureNetIncomePerShareAntiDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "us-gaap_AreaOfRealEstateProperty": {
     "xbrltype": "areaItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AreaOfRealEstateProperty",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Area of Real Estate Property",
        "terseLabel": "Lease space",
        "documentation": "Area of a real estate property."
       }
      }
     },
     "auth_ref": []
    },
    "inva_ArmataConvertibleNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "ArmataConvertibleNoteMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Armata Convertible Note",
        "label": "Armata Convertible Note [Member]",
        "documentation": "Armata convertible note member."
       }
      }
     },
     "auth_ref": []
    },
    "inva_ArmataPharmaceuticalsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "ArmataPharmaceuticalsIncMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsSummarizedFinancialDataDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsTables",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on the development of precisely targeted bacteriophage therapeutics for the treatment of antibiotic-resistant infections.",
        "label": "Armata Pharmaceuticals Inc [Member]",
        "terseLabel": "Armata"
       }
      }
     },
     "auth_ref": []
    },
    "inva_ArmataTermLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "ArmataTermLoanMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Armata Term Loan",
        "label": "Armata Term Loan [Member]",
        "documentation": "Armata term loan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureLicenseAndCollaborationArrangementsAdditionalInformationDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureRevenueRecognitionDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfNetRevenueFromCollaborativeArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Arrangements and Non-arrangement Transactions [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r641"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsIspFundLpDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails",
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets",
        "verboseLabel": "Total assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r222",
      "r266",
      "r300",
      "r351",
      "r367",
      "r371",
      "r420",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r643",
      "r647",
      "r686",
      "r795",
      "r878",
      "r999",
      "r1015",
      "r1169",
      "r1170",
      "r1221"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails",
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsSummarizedFinancialDataDetails",
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current",
        "terseLabel": "Current assets",
        "totalLabel": "Total current assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r258",
      "r274",
      "r300",
      "r420",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r643",
      "r647",
      "r686",
      "r999",
      "r1169",
      "r1170",
      "r1221"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Total assets measured at estimated fair value",
        "totalLabel": "Assets, Fair Value Disclosure, Total",
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r133"
     ]
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsFairValueDisclosureAbstract",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsSummarizedFinancialDataDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Assets, Noncurrent, Total",
        "label": "Assets, Noncurrent",
        "terseLabel": "Noncurrent assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r300",
      "r420",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r643",
      "r647",
      "r686",
      "r1169",
      "r1170",
      "r1221"
     ]
    },
    "inva_AstrazenecaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "AstrazenecaMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureLicenseAndCollaborationArrangementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AstraZeneca",
        "label": "AstraZeneca [Member]",
        "documentation": "AstraZeneca."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r1020",
      "r1021",
      "r1034"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r1020",
      "r1021",
      "r1034"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorName",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r1020",
      "r1021",
      "r1034"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsAvailableforsaleSecuritiesDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r389"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsAvailableforsaleSecuritiesDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross Unrealized Losses",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r390"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsAvailableforsaleSecuritiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r386",
      "r436",
      "r794"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsAvailableforsaleSecuritiesDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Debt Securities, Available-for-sale, Total",
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Estimated Fair Value",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r387",
      "r436",
      "r786",
      "r1138"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r1085"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r1086"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r1081"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r1081"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r1081"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r1081"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r1081"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r1081"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationCompensationAwardsDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationDirectorCompensationProgramDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationValuationAssumptionsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r557",
      "r558",
      "r559",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r1084"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r1083"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r1082"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r1082"
     ]
    },
    "inva_BalanceSheetDisclosuresOfVariableInterestEntityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "BalanceSheetDisclosuresOfVariableInterestEntityAbstract",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance sheets",
        "documentation": "No definition available.",
        "label": "Balance Sheet Disclosures of Variable Interest Entity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BalanceSheetLocationAxis",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Location [Axis]",
        "documentation": "Information by location on balance sheet (statement of financial position)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BalanceSheetLocationDomain",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Location [Domain]",
        "documentation": "Location in the balance sheet (statement of financial position)."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r130"
     ]
    },
    "us-gaap_BalanceSheetRelatedDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BalanceSheetRelatedDisclosuresAbstract",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsSummarizedFinancialDataDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Related Disclosures [Abstract]",
        "terseLabel": "Balance Sheet Information"
       }
      }
     },
     "auth_ref": []
    },
    "inva_BurlingameCaliforniaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "BurlingameCaliforniaMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Burlingame, California.",
        "label": "Burlingame California [Member]",
        "terseLabel": "Burlingame, California"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsLaJollaPharmaceuticalCompanyDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsProFormaInformationDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTables",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalTaxDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition, Acquiree [Domain]",
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "auth_ref": [
      "r637",
      "r991",
      "r992"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsLaJollaPharmaceuticalCompanyDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsProFormaInformationDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTables",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalTaxDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r109",
      "r637",
      "r991",
      "r992"
     ]
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionLineItems",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsLaJollaPharmaceuticalCompanyDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsProFormaInformationDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r637"
     ]
    },
    "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionProFormaInformationTextBlock",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition, Pro Forma Information [Table Text Block]",
        "terseLabel": "Pro Forma Information",
        "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate."
       }
      }
     },
     "auth_ref": [
      "r1100",
      "r1101"
     ]
    },
    "us-gaap_BusinessAcquisitionSharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionSharePrice",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsLaJollaPharmaceuticalCompanyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition, Share Price",
        "terseLabel": "Acquisition share price",
        "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination."
       }
      }
     },
     "auth_ref": []
    },
    "inva_BusinessAcquisitionsOfChangeInFairValueOfInvestment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "BusinessAcquisitionsOfChangeInFairValueOfInvestment",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business acquisitions of change in fair value of investment.",
        "label": "Business Acquisitions of Change in Fair Value of Investment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionsProFormaNetIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsProFormaInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition, Pro Forma Net Income (Loss)",
        "terseLabel": "Net income",
        "verboseLabel": "Business acquisition, net loss",
        "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period."
       }
      }
     },
     "auth_ref": [
      "r635",
      "r636"
     ]
    },
    "us-gaap_BusinessAcquisitionsProFormaRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionsProFormaRevenue",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsProFormaInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition, Pro Forma Revenue",
        "terseLabel": "Revenue",
        "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period."
       }
      }
     },
     "auth_ref": [
      "r635",
      "r636"
     ]
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationConsiderationTransferred1",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsLaJollaPharmaceuticalCompanyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Consideration Transferred",
        "totalLabel": "Total consideration paid",
        "terseLabel": "Total consideration paid",
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r3",
      "r15"
     ]
    },
    "inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedPersonnelRelatedExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedPersonnelRelatedExpenses",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accrued personnel-related expenses due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accrued Personnel- Related Expenses",
        "terseLabel": "Accrued personnel-related expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets",
        "totalLabel": "'Total assets acquired",
        "documentation": "Amount of assets acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "terseLabel": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Marketable Securities",
        "terseLabel": "Short-term marketable securities",
        "documentation": "Amount of investments in debt and equity securities, including, but not limited to, held-to-maturity, trading and available-for-sale expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other",
        "terseLabel": "Other current assets",
        "documentation": "Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets",
        "terseLabel": "Prepaid expenses",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables",
        "terseLabel": "Accounts receivable",
        "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable",
        "terseLabel": "Accounts payable",
        "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue",
        "terseLabel": "Deferred revenue",
        "documentation": "Amount of deferred revenue expected to be recognized as such within one year or the normal operating cycle, if longer, assumed at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets",
        "label": "Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets",
        "documentation": "Amount of deferred tax asset attributable to deductible temporary differences and carryforwards acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities",
        "terseLabel": "Deferred tax liabilities",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets",
        "terseLabel": "Intangible assets",
        "documentation": "Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory",
        "terseLabel": "Inventory",
        "documentation": "The amount of inventory recognized as of the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r111"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities",
        "totalLabel": "Total liabilities assumed",
        "documentation": "Amount of liabilities assumed at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net",
        "totalLabel": "Total assets acquired, net",
        "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r111"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Assets",
        "totalLabel": "Other assets",
        "terseLabel": "Other assets",
        "documentation": "Amount of assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other",
        "terseLabel": "Other long-term liabilities",
        "documentation": "Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business combination recognized identifiable assets acquired and liabilities assumed operating lease right-of-use assets.",
        "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Operating Lease Right-of-Use Assets",
        "terseLabel": "Right-of-use assets"
       }
      }
     },
     "auth_ref": []
    },
    "inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAccruedLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business combination recognized identifiable assets acquired and liabilities assumed other accrued liabilities",
        "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Other Accrued Liabilities",
        "terseLabel": "Other accrued liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment",
        "totalLabel": "Property and equipment, net",
        "terseLabel": "Property and equipment, net",
        "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r111"
     ]
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationsPolicy",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations Policy [Policy Text Block]",
        "terseLabel": "Business Combination",
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy."
       }
      }
     },
     "auth_ref": [
      "r107"
     ]
    },
    "us-gaap_CallOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CallOptionMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Call Option [Member]",
        "terseLabel": "Stock prices below $27.79 per share",
        "documentation": "Financial contract between two parties, the buyer and the seller of the option, where the buyer has the right but not the obligation to buy an agreed quantity of a particular commodity or financial instrument (the underlying instrument) from the seller of the option for a certain price (the strike price). Seller is obligated to sell the asset to the buyer, if the buyer exercises the option."
       }
      }
     },
     "auth_ref": [
      "r922",
      "r923"
     ]
    },
    "us-gaap_CapitalizedContractCostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CapitalizedContractCostAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Capitalized Contract Cost [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalizedContractCostAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CapitalizedContractCostAccumulatedAmortization",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails": {
       "parentTag": "us-gaap_CapitalizedContractCostNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capitalized Contract Cost, Accumulated Amortization",
        "negatedLabel": "Accumulated amortization",
        "documentation": "Amount of accumulated amortization of asset recognized from cost incurred to obtain or fulfill contract with customer."
       }
      }
     },
     "auth_ref": [
      "r1160"
     ]
    },
    "us-gaap_CapitalizedContractCostAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CapitalizedContractCostAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfNetRevenueFromCollaborativeArrangementsDetails": {
       "parentTag": "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfNetRevenueFromCollaborativeArrangementsDetails",
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfIncomeParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capitalized Contract Cost, Amortization",
        "verboseLabel": "Amortization expense",
        "terseLabel": "Amortization of capitalized fees paid",
        "negatedLabel": "Less: amortization of capitalized fees paid",
        "documentation": "Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer."
       }
      }
     },
     "auth_ref": [
      "r446"
     ]
    },
    "us-gaap_CapitalizedContractCostGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CapitalizedContractCostGross",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails": {
       "parentTag": "us-gaap_CapitalizedContractCostNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capitalized Contract Cost, Gross",
        "terseLabel": "Milestone fees paid",
        "verboseLabel": "Gross carrying value",
        "documentation": "Amount, before accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer."
       }
      }
     },
     "auth_ref": [
      "r1160"
     ]
    },
    "us-gaap_CapitalizedContractCostLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CapitalizedContractCostLineItems",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capitalized Contract Cost [Line Items]",
        "terseLabel": "Capitalized Fees paid",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r445"
     ]
    },
    "us-gaap_CapitalizedContractCostNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CapitalizedContractCostNet",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.inva.com/20231231/taxonomy/role/DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails",
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capitalized Contract Cost, Net",
        "totalLabel": "Net carrying value",
        "terseLabel": "Capitalized fees paid, net",
        "documentation": "Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer."
       }
      }
     },
     "auth_ref": [
      "r445"
     ]
    },
    "us-gaap_CapitalizedContractCostTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CapitalizedContractCostTable",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capitalized Contract Cost [Table]",
        "documentation": "Disclosure of information about cost capitalized in obtaining or fulfilling contract with customer."
       }
      }
     },
     "auth_ref": [
      "r445"
     ]
    },
    "us-gaap_CapitalizedContractCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CapitalizedContractCostTableTextBlock",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureCapitalizedFeesPaidTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capitalized Contract Cost [Table Text Block]",
        "terseLabel": "Schedule of Capitalized Fees Paid",
        "documentation": "Tabular disclosure of cost capitalized in obtaining or fulfilling contract with customer."
       }
      }
     },
     "auth_ref": [
      "r1159"
     ]
    },
    "inva_CapitalizedFeePaidEstimatedUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "CapitalizedFeePaidEstimatedUsefulLife",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capitalized fee paid estimated useful life.",
        "label": "Capitalized Fee Paid Estimated Useful Life",
        "terseLabel": "Capitalized fees paid, estimated useful life"
       }
      }
     },
     "auth_ref": []
    },
    "inva_CapitalizedFeesPaidDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "CapitalizedFeesPaidDisclosureTextBlock",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureCapitalizedFeesPaid1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about capitalized fees paid.",
        "label": "Capitalized Fees Paid Disclosure [Text Block]",
        "terseLabel": "CAPITALIZED FEES PAID"
       }
      }
     },
     "auth_ref": []
    },
    "inva_CapitalizedFeesPaidFutureAmortizationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "CapitalizedFeesPaidFutureAmortizationAbstract",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capitalized fees paid future amortization.",
        "label": "Capitalized Fees Paid Future Amortization [Abstract]",
        "terseLabel": "Capitalized Fees paid, Future amortization"
       }
      }
     },
     "auth_ref": []
    },
    "inva_CapitalizedFeesPaidPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "CapitalizedFeesPaidPolicyTextBlock",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capitalized fees paid.",
        "label": "Capitalized Fees Paid [Policy Text Block]",
        "terseLabel": "Capitalized Fees Paid"
       }
      }
     },
     "auth_ref": []
    },
    "inva_CapitalizedFeesPaidRemainingEstimatedAmortizationAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "CapitalizedFeesPaidRemainingEstimatedAmortizationAfterYearFive",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated amortization after 2028",
        "documentation": "Amount of estimated amortization for assets expected to be recognized after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Capitalized Fees Paid Remaining Estimated Amortization After Year Five"
       }
      }
     },
     "auth_ref": []
    },
    "inva_CapitalizedFeesPaidRemainingEstimatedAmortizationNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "CapitalizedFeesPaidRemainingEstimatedAmortizationNextTwelveMonths",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated amortization for the year 2024",
        "label": "Capitalized Fees Paid Remaining Estimated Amortization Next Twelve Months",
        "documentation": "Amount of estimated amortization for assets expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date."
       }
      }
     },
     "auth_ref": []
    },
    "inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "CapitalizedFeesPaidRemainingEstimatedAmortizationYearFive",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated amortization for the year 2028",
        "documentation": "Amount of estimated amortization for assets expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Capitalized Fees Paid Remaining Estimated Amortization Year Five"
       }
      }
     },
     "auth_ref": []
    },
    "inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "CapitalizedFeesPaidRemainingEstimatedAmortizationYearFour",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated amortization for the year 2027",
        "documentation": "Amount of estimated amortization for assets expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Capitalized Fees Paid Remaining Estimated Amortization Year Four"
       }
      }
     },
     "auth_ref": []
    },
    "inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "CapitalizedFeesPaidRemainingEstimatedAmortizationYearTwo",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated amortization for the year 2025",
        "label": "Capitalized Fees Paid Remaining Estimated Amortization Year Two",
        "documentation": "Amount of estimated amortization for assets expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date."
       }
      }
     },
     "auth_ref": []
    },
    "inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearthree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "CapitalizedFeesPaidRemainingEstimatedAmortizationYearthree",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated amortization for the year 2026",
        "documentation": "Amount of estimated amortization for assets expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Capitalized Fees Paid Remaining Estimated Amortization YearThree"
       }
      }
     },
     "auth_ref": []
    },
    "inva_CapitalizedFeesPaidToRelatedPartyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "CapitalizedFeesPaidToRelatedPartyPolicyTextBlock",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for capitalized fees paid to a related party.",
        "label": "Capitalized Fees Paid To A Related Party [Policy Text Block]",
        "terseLabel": "Capitalized Fees Paid"
       }
      }
     },
     "auth_ref": []
    },
    "inva_CapitalizedFeesPaidWeightedAverageUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "CapitalizedFeesPaidWeightedAverageUsefulLife",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capitalized fees paid weighted average useful life.",
        "label": "Capitalized Fees Paid Weighted Average Useful Life",
        "terseLabel": "Weighted average remaining amortization period"
       }
      }
     },
     "auth_ref": []
    },
    "inva_CarryingValueWroteOffWarrantExercise": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "CarryingValueWroteOffWarrantExercise",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Carrying value wrote off warrant exercise",
        "label": "Carrying Value Wrote off Warrant Exercise",
        "documentation": "Carrying value wrote off warrant exercise."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAcquiredFromAcquisition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAcquiredFromAcquisition",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Acquired from Acquisition",
        "terseLabel": "Cash acquired through the consolidation of Entasis",
        "documentation": "The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business)."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails",
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance",
        "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance",
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash balance",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r261",
      "r955"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodStartLabel": "Cash and cash equivalents at beginning of period",
        "terseLabel": "Total cash, cash equivalents and restricted cash at end of period shown in the consolidated statements of cash flows",
        "totalLabel": "Total cash, cash equivalents and restricted cash at end of period shown in the condensed consolidated statements of cash flows",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r185",
      "r297"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r185"
     ]
    },
    "inva_CashDistributionReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "CashDistributionReceived",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash distribution received.",
        "label": "Cash Distribution Received",
        "terseLabel": "Cash distribution"
       }
      }
     },
     "auth_ref": []
    },
    "inva_CashPaidForTheAcquisitionOfLaJollaPharmaceuticalCompanyNetOfCashAcquired": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "CashPaidForTheAcquisitionOfLaJollaPharmaceuticalCompanyNetOfCashAcquired",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash paid for the acquisition of La Jolla Pharmaceutical Company, net of cash acquired.",
        "label": "Cash Paid for the Acquisition of La Jolla Pharmaceutical Company, Net of Cash Acquired",
        "negatedLabel": "Cash paid for the acquisition of La Jolla, net of cash acquired"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r1060"
     ]
    },
    "inva_ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Changes to noncontrolling interest from a consolidated variable interest entity.",
        "label": "Changes to noncontrolling interest from a consolidated variable interest entity",
        "terseLabel": "Equity activity of noncontrolling interest in a consolidated variable interest entity"
       }
      }
     },
     "auth_ref": []
    },
    "inva_ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntityShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntityShares",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity activity of noncontrolling interests in a consolidated variable interest entity (in shares)",
        "label": "Changes To Noncontrolling Interest From A Consolidated Variable Interest Entity Shares",
        "documentation": "Changes to noncontrolling interest from a consolidated variable interest entity shares."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "inva_ClaimExpirationDate": {
     "xbrltype": "gYearMonthItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "ClaimExpirationDate",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureLicenseAndCollaborationArrangementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Claim expiration date.",
        "label": "Claim Expiration Date"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfTreasuryStockTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfTreasuryStockTable",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Treasury Stock [Table]",
        "documentation": "Disclosure of information about treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r94",
      "r95",
      "r96"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Exercise price of warrants",
        "verboseLabel": "Exercise price of warrants",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r529"
     ]
    },
    "inva_ClinicalDevelopmentAndRegulatoryMilestonesAmountPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "ClinicalDevelopmentAndRegulatoryMilestonesAmountPayable",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureLicenseAndCollaborationArrangementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical development and regulatory milestones amount payable.",
        "label": "Clinical Development And Regulatory Milestones Amount Payable",
        "terseLabel": "Clinical development and regulatory milestones amount payable"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r1061"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r1061"
     ]
    },
    "inva_CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the royalty rate for combination products.",
        "label": "Collaborative Arrangement Annual Royalties as Percentage of Net Sales for Combination Products",
        "terseLabel": "Royalty rate for combination products (as a percent)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement [Member]",
        "terseLabel": "Collaboration agreement",
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity."
       }
      }
     },
     "auth_ref": [
      "r641"
     ]
    },
    "inva_CollaborativeArrangementRoyaltyRateDefinedLevelOne": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "CollaborativeArrangementRoyaltyRateDefinedLevelOne",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the royalty rate which the entity will receive under the collaboration agreement on the first defined level of annual global net sales.",
        "label": "Collaborative Arrangement, Royalty Rate Defined, Level One",
        "terseLabel": "Royalty rate for first level of annual global net sales (as a percent)"
       }
      }
     },
     "auth_ref": []
    },
    "inva_CollaborativeArrangementRoyaltyRateDefinedLevelTwo": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "CollaborativeArrangementRoyaltyRateDefinedLevelTwo",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the royalty rate which the entity will receive under the collaboration agreement on sales which exceed the first defined level of annual global net sales.",
        "label": "Collaborative Arrangement, Royalty Rate Defined, Level Two",
        "terseLabel": "Royalty rate for sales above first level of annual global net sales (as a percent)"
       }
      }
     },
     "auth_ref": []
    },
    "inva_CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the annual global net sales amount which determines the royalty rate applied under the collaboration arrangement.",
        "label": "Collaborative Arrangement, Specified Sales Level for Determining Royalty Rate",
        "terseLabel": "Annual global sales level used to determine royalty rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureLicenseAndCollaborationArrangementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r641"
     ]
    },
    "inva_CollaborativeArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "CollaborativeArrangementsMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureRevenueRecognitionDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfNetRevenueFromCollaborativeArrangementsDetails",
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from collaborative arrangements",
        "documentation": "Represents information pertaining to collaborative arrangements.",
        "label": "Collaborative Arrangements [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "inva_CommercialSupplyAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "CommercialSupplyAgreementMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureLicenseAndCollaborationArrangementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial supply agreement.",
        "label": "Commercial Supply Agreement [Member]",
        "terseLabel": "Commercial Supply Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "verboseLabel": "Commitments and contingencies (Note 13)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r147",
      "r797",
      "r864"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "verboseLabel": "COMMITMENTS AND CONTINGENCIES",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r195",
      "r467",
      "r468",
      "r938",
      "r1165"
     ]
    },
    "inva_CommonStockAcquiredAverageCostPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "CommonStockAcquiredAverageCostPerShare",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Acquired Average Cost Per Share",
        "label": "Common Stock Acquired Average Cost Per Share",
        "terseLabel": "Shares repurchased average price per share"
       }
      }
     },
     "auth_ref": []
    },
    "inva_CommonStockAndWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "CommonStockAndWarrantsMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to common stock and warrants.",
        "label": "Common Stock And Warrants [Member]",
        "terseLabel": "Common stock and warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensation2012PlanAndEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock, Capital Shares Reserved for Future Issuance",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInGateNeurosciencesDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInImaginabDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureNetIncomePerShareDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockholdersEquityDetails",
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common stock",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r1002",
      "r1003",
      "r1004",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1132",
      "r1133",
      "r1213",
      "r1235",
      "r1238"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r163"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r865"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Common Stock, Shares, Issued, Total",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r163"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)",
        "terseLabel": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r163",
      "r865",
      "r884",
      "r1238",
      "r1239"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock: $0.01 par value, 200,000 shares authorized, 69,307 and 69,188 issued and outstanding as of December 31, 2023 and December 31, 2022 respectively",
        "periodEndLabel": "Common Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance",
        "totalLabel": "Common Stock, Value, Issued, Total",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r799",
      "r999"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r1066"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r1065"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r1067"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r1064"
     ]
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets [Abstract]",
        "terseLabel": "Deferred tax assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets and Liabilities [Abstract]",
        "terseLabel": "Components of deferred tax assets and deferred tax liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Liabilities [Abstract]",
        "terseLabel": "Deferred tax liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveIncome": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income attributable to Innoviva stockholders",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r276",
      "r278",
      "r287",
      "r789",
      "r813"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveIncome": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest, Total",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "terseLabel": "Comprehensive income attributable to noncontrolling interests",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r114",
      "r128",
      "r276",
      "r278",
      "r286",
      "r788",
      "r812"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveIncome": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Comprehensive income",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r216",
      "r276",
      "r278",
      "r285",
      "r787",
      "r811"
     ]
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Income",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Domain]",
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r69",
      "r137",
      "r138",
      "r376",
      "r937"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r69",
      "r137",
      "r138",
      "r376",
      "r837",
      "r937"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r69",
      "r137",
      "r138",
      "r376",
      "r937",
      "r1099"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentrations of Credit Risk and of Significant Suppliers and Partners",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r243"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration Risk, Percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r69",
      "r137",
      "r138",
      "r376"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Domain]",
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r69",
      "r137",
      "r138",
      "r376",
      "r937"
     ]
    },
    "inva_ConsolidatedEntitiesAndAcquisitionsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "ConsolidatedEntitiesAndAcquisitionsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consolidated entities and acquisitions disclosure abstract.",
        "label": "Consolidated Entities and Acquisitions Disclosure Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "inva_ConsolidatedEntitiesAndAcquisitionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "ConsolidatedEntitiesAndAcquisitionsLineItems",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consolidated entities and acquisitions.",
        "label": "Consolidated Entities and Acquisitions [Line Items]",
        "terseLabel": "Consolidated Entities and Acquisitions [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "inva_ConsolidatedEntitiesAndAcquisitionsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "ConsolidatedEntitiesAndAcquisitionsTextBlock",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitions1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consolidated entities and acquisitions text block.",
        "label": "Consolidated Entities and Acquisitions [Text Block]",
        "terseLabel": "CONSOLIDATED ENTITIES AND ACQUISITIONS"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ConsolidatedEntitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ConsolidatedEntitiesAxis",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsIspFundLpDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsProFormaInformationDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTables",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInGateNeurosciencesDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInImaginabDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInNanoliveDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsSummarizedFinancialDataDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsTables",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Axis]"
       }
      }
     },
     "auth_ref": [
      "r304",
      "r643",
      "r644",
      "r647",
      "r648",
      "r728",
      "r948",
      "r1168",
      "r1171",
      "r1172"
     ]
    },
    "inva_ConsolidatedEntitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "ConsolidatedEntitiesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Consolidated Entities"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ConsolidatedEntitiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ConsolidatedEntitiesDomain",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsIspFundLpDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsProFormaInformationDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTables",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInGateNeurosciencesDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInImaginabDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInNanoliveDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsSummarizedFinancialDataDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsTables",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Domain]",
        "terseLabel": "Consolidated Entities [Domain]"
       }
      }
     },
     "auth_ref": [
      "r304",
      "r643",
      "r644",
      "r647",
      "r648",
      "r728",
      "r948",
      "r1168",
      "r1171",
      "r1172"
     ]
    },
    "inva_ConsolidatedInvesteesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "ConsolidatedInvesteesMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInImaginabDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInNanoliveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consolidated investees.",
        "label": "Consolidated Investees [Member]",
        "terseLabel": "Consolidated Investees"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r965"
     ]
    },
    "us-gaap_ConsolidationVariableInterestEntityPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConsolidationVariableInterestEntityPolicy",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation, Variable Interest Entity, Policy [Policy Text Block]",
        "terseLabel": "Variable Interest Entities",
        "documentation": "Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined)."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r120",
      "r122"
     ]
    },
    "inva_ContingentSalesBasedMilestonePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "ContingentSalesBasedMilestonePayment",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent sales based milestone payment.",
        "label": "Contingent Sales Based Milestone Payment",
        "terseLabel": "Contingent sales based milestone payment"
       }
      }
     },
     "auth_ref": []
    },
    "inva_ContingentValueRightsLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "ContingentValueRightsLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet1": {
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.inva.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherLongtermLiabilitiesDetails": {
       "parentTag": "us-gaap_OtherLiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherLongtermLiabilitiesDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent value rights liability",
        "label": "Contingent value rights liability",
        "terseLabel": "Contingent value rights liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertibleDebtCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertibleDebtCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Debt, Current",
        "terseLabel": "Convertible subordinated notes due 2023, net of issuance costs",
        "documentation": "The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r157"
     ]
    },
    "us-gaap_ConvertibleDebtFairValueDisclosures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertibleDebtFairValueDisclosures",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet": {
       "parentTag": "us-gaap_DebtInstrumentFairValue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Debt, Fair Value Disclosures",
        "terseLabel": "2028 Notes",
        "documentation": "Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock."
       }
      }
     },
     "auth_ref": []
    },
    "inva_ConvertibleDebtInstrumentLiabilityComponentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "ConvertibleDebtInstrumentLiabilityComponentAbstract",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "n/a",
        "label": "Convertible Debt Instrument, Liability Component [Abstract]",
        "terseLabel": "Liability component"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertibleDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertibleDebtMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible debt investment",
        "label": "Convertible Debt [Member]",
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r483",
      "r484",
      "r494",
      "r495",
      "r496",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979"
     ]
    },
    "us-gaap_ConvertibleDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertibleDebtTableTextBlock",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Debt [Table Text Block]",
        "terseLabel": "Summary of Liability and Equity Components of Convertible Notes",
        "documentation": "Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount."
       }
      }
     },
     "auth_ref": []
    },
    "inva_ConvertibleNoteAndWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "ConvertibleNoteAndWarrantsMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible note and warrants.",
        "label": "Convertible Note and Warrants [Member]",
        "terseLabel": "In Carda Convertible Note",
        "verboseLabel": "Convertible note and warrants"
       }
      }
     },
     "auth_ref": []
    },
    "inva_ConvertiblePromissoryNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "ConvertiblePromissoryNoteMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertable promissory note",
        "label": "Convertible Promissory Note [Member]",
        "documentation": "Convertible promissory note member."
       }
      }
     },
     "auth_ref": []
    },
    "inva_ConvertiblePromissoryNotePurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "ConvertiblePromissoryNotePurchaseAgreementMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInGateNeurosciencesDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Promissory Note Purchase Agreement [Member]",
        "documentation": "Convertible promissory note purchase agreement [Member]",
        "terseLabel": "Convertible Promissory Note Purchase Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "inva_ConvertibleSeniorDebtFairValueDisclosures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "ConvertibleSeniorDebtFairValueDisclosures",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet": {
       "parentTag": "us-gaap_DebtInstrumentFairValue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of long-term notes which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock. Senior debt has the highest claim on the assets of the issuer in case of bankruptcy or liquidation, due within one year or the normal operating cycle, if longer. Senior note holders are paid off in full before any payments are made to debt holders having a lesser priority of repayment.",
        "label": "Convertible Senior Debt, Fair Value Disclosures",
        "terseLabel": "2025 Notes"
       }
      }
     },
     "auth_ref": []
    },
    "inva_ConvertibleSubordinatedDebtFairValueDisclosures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "ConvertibleSubordinatedDebtFairValueDisclosures",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet": {
       "parentTag": "us-gaap_DebtInstrumentFairValue",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of subordinated debt obligations which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Subordinated Debt, Fair Value Disclosures",
        "terseLabel": "2023 Notes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertibleSubordinatedDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertibleSubordinatedDebtMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Subordinated Debt [Member]",
        "terseLabel": "Convertible subordinated notes",
        "documentation": "Debt that places a lender in a lien position behind debt having a higher priority of repayment in liquidation of the entity's assets which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r199"
     ]
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfGoodsAndServicesSold",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfIncome": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of products sold (inclusive of amortization of inventory fair value adjustments, excluding amortization of intangible assets)",
        "label": "Cost of Goods and Services Sold",
        "totalLabel": "Cost of products sold (inclusive of amortization of inventory fair value adjustments, excluding depreciation and amortization of intangible assets)",
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r767"
     ]
    },
    "us-gaap_CostOfRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfRevenue",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfIncome": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureLicenseAndCollaborationArrangementsAdditionalInformationDetails",
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of license revenue",
        "label": "Cost of Revenue",
        "totalLabel": "Cost of Revenue, Total",
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r176",
      "r300",
      "r420",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r686",
      "r1169"
     ]
    },
    "inva_CostReimbursementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "CostReimbursementMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureLicenseAndCollaborationArrangementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost Reimbursement",
        "label": "Cost Reimbursement [Member]",
        "documentation": "Cost reimbursement."
       }
      }
     },
     "auth_ref": []
    },
    "inva_CostReimbursements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "CostReimbursements",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureLicenseAndCollaborationArrangementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost reimbursements",
        "label": "Cost Reimbursements",
        "documentation": "Cost reimbursements"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostsAndExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfIncome": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total expenses, net",
        "label": "Costs and Expenses",
        "verboseLabel": "Operating expenses",
        "documentation": "Total costs of sales and operating expenses for the period."
       }
      }
     },
     "auth_ref": [
      "r174"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInImaginabDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureLicenseAndCollaborationArrangementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r302",
      "r303",
      "r486",
      "r517",
      "r727",
      "r962",
      "r964"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "inva_CreditAndSecurityAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "CreditAndSecurityAgreementMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit and Security Agreement",
        "label": "Credit and Security Agreement [Member]",
        "documentation": "Credit and security agreement."
       }
      }
     },
     "auth_ref": []
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]",
        "terseLabel": "Cumulative effect period of adoption adjustment member"
       }
      }
     },
     "auth_ref": [
      "r254",
      "r308",
      "r315",
      "r321",
      "r424",
      "r430",
      "r591",
      "r592",
      "r593",
      "r626",
      "r627",
      "r652",
      "r654",
      "r655",
      "r657",
      "r658",
      "r659",
      "r665",
      "r668",
      "r670",
      "r671",
      "r722"
     ]
    },
    "srt_CumulativeEffectPeriodOfAdoptionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CumulativeEffectPeriodOfAdoptionAxis",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Axis]"
       }
      }
     },
     "auth_ref": [
      "r254",
      "r308",
      "r315",
      "r321",
      "r424",
      "r430",
      "r591",
      "r592",
      "r593",
      "r626",
      "r627",
      "r652",
      "r654",
      "r655",
      "r657",
      "r658",
      "r659",
      "r665",
      "r668",
      "r670",
      "r671",
      "r722"
     ]
    },
    "srt_CumulativeEffectPeriodOfAdoptionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CumulativeEffectPeriodOfAdoptionDomain",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Domain]"
       }
      }
     },
     "auth_ref": [
      "r254",
      "r308",
      "r315",
      "r321",
      "r424",
      "r430",
      "r591",
      "r592",
      "r593",
      "r626",
      "r627",
      "r652",
      "r654",
      "r655",
      "r657",
      "r658",
      "r659",
      "r665",
      "r668",
      "r670",
      "r671",
      "r722"
     ]
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentFederalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal",
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1104",
      "r1130",
      "r1212"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Total current",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r213",
      "r621",
      "r631",
      "r1130"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "verboseLabel": "Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "State",
        "label": "Current State and Local Tax Expense (Benefit)",
        "verboseLabel": "State",
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1104",
      "r1130",
      "r1212"
     ]
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r376"
     ]
    },
    "inva_CustomerOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "CustomerOneMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer one.",
        "label": "Customer One [Member]",
        "terseLabel": "Customer One"
       }
      }
     },
     "auth_ref": []
    },
    "inva_CustomerThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "CustomerThreeMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer three.",
        "label": "Customer Three [Member]",
        "terseLabel": "Customer Three"
       }
      }
     },
     "auth_ref": []
    },
    "inva_CustomerTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "CustomerTwoMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer two.",
        "label": "Customer Two [Member]",
        "terseLabel": "Customer Two"
       }
      }
     },
     "auth_ref": []
    },
    "inva_DebtConversionCommonStockPriceToConversionPriceRatioPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "DebtConversionCommonStockPriceToConversionPriceRatioPercentage",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of common stock price as a percentage of conversion price.",
        "label": "Debt Conversion, Common Stock Price to Conversion Price Ratio, Percentage",
        "terseLabel": "Common stock price to current conversion price ratio"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Conversion, Converted Instrument, Amount",
        "terseLabel": "Notes converted into common stock, Amount",
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r62"
     ]
    },
    "inva_DebtConversionConvertedInstrumentAverageTradePricePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "DebtConversionConvertedInstrumentAverageTradePricePercentage",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average trading price per $1,000 of Notes with respect to product of the closing common stock price and the conversion rate",
        "label": "Debt Conversion, Converted Instrument, Average Trade Price Percentage",
        "terseLabel": "Average trading price percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtConversionConvertedInstrumentSharesIssued1",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Conversion, Converted Instrument, Shares Issued",
        "terseLabel": "Debt Conversion, Converted Instrument, Shares Issued",
        "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r62"
     ]
    },
    "us-gaap_DebtCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails2": {
       "parentTag": "us-gaap_DebtLongtermAndShorttermCombinedAmount",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Debt, Current, Total",
        "label": "Debt, Current",
        "terseLabel": "Less: Current portion of long-term debt, net",
        "documentation": "Amount of debt and lease obligation, classified as current."
       }
      }
     },
     "auth_ref": [
      "r269"
     ]
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Text Block]",
        "verboseLabel": "DEBT",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r197",
      "r298",
      "r482",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r498",
      "r505",
      "r506",
      "r508"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtTables",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInGateNeurosciencesDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureNetIncomePerShareDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r157",
      "r158",
      "r223",
      "r226",
      "r304",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r489",
      "r494",
      "r495",
      "r496",
      "r497",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r702",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r1128"
     ]
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentCarryingAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails": {
       "parentTag": "us-gaap_DebtLongtermAndShorttermCombinedAmount",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtDebtMaturitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtDebtMaturitiesDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Gross",
        "terseLabel": "Total debt",
        "totalLabel": "Total",
        "verboseLabel": "Principal",
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r226",
      "r509"
     ]
    },
    "us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Convertible, Carrying Amount of Equity Component",
        "terseLabel": "Equity component, net",
        "documentation": "The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "inva_DebtInstrumentConvertibleConversionPremium": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "DebtInstrumentConvertibleConversionPremium",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage above the last reported sale price of the Company's common stock.",
        "label": "Debt Instrument, Convertible, Conversion Premium",
        "terseLabel": "Conversion premium (as a percent)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureNetIncomePerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Convertible, Conversion Price",
        "terseLabel": "Conversion price (dollars per share)",
        "verboseLabel": "Conversion price of convertible notes into common stock (in dollars per share)",
        "documentation": "The price per share of the conversion feature embedded in the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r200",
      "r485"
     ]
    },
    "us-gaap_DebtInstrumentConvertibleConversionRatio1": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentConvertibleConversionRatio1",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Convertible, Conversion Ratio",
        "terseLabel": "Conversion rate for shares of common stock per $1,000 principal",
        "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r90",
      "r203",
      "r204",
      "r485"
     ]
    },
    "us-gaap_DebtInstrumentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentDescription",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, description",
        "label": "Debt Instrument, Description",
        "documentation": "Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r90",
      "r150",
      "r157",
      "r223",
      "r226"
     ]
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInGateNeurosciencesDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible notes Face Value",
        "label": "Debt Instrument, Face Amount",
        "verboseLabel": "New principal amount convertible note",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r143",
      "r483",
      "r702",
      "r976",
      "r977"
     ]
    },
    "us-gaap_DebtInstrumentFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentFairValue",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Fair Value Disclosure",
        "totalLabel": "Total fair value of debt",
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable."
       }
      }
     },
     "auth_ref": [
      "r496",
      "r685",
      "r976",
      "r977"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Effective interest rate",
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r141",
      "r512",
      "r702"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInGateNeurosciencesDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "verboseLabel": "Debt Instrument, annual interest rate",
        "terseLabel": "Debt Instrument, annual interest rate",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r484"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtTables",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureNetIncomePerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r304",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r489",
      "r494",
      "r495",
      "r496",
      "r497",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r507",
      "r702",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r1128"
     ]
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentMaturityDate",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument maturity date",
        "label": "Debt Instrument, Maturity Date",
        "verboseLabel": "Debt instrument maturity date",
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r250",
      "r975",
      "r1214"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtTables",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInGateNeurosciencesDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureNetIncomePerShareDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r304",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r489",
      "r494",
      "r495",
      "r496",
      "r497",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r702",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r1128"
     ]
    },
    "us-gaap_DebtInstrumentPeriodicPaymentPrincipal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentPeriodicPaymentPrincipal",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInGateNeurosciencesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Principal Payment",
        "label": "Debt Instrument, Periodic Payment, Principal",
        "documentation": "Amount of the required periodic payments applied to principal."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "inva_DebtInstrumentPrincipalAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "DebtInstrumentPrincipalAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument Principal Amount",
        "label": "Debt Instrument Principal Amount",
        "terseLabel": "Total debt",
        "verboseLabel": "Principal"
       }
      }
     },
     "auth_ref": []
    },
    "inva_DebtInstrumentRatioOfRepurchasePriceToThePrincipalAmount": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "DebtInstrumentRatioOfRepurchasePriceToThePrincipalAmount",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Ratio of repurchase price to the principal amount of debt instrument that was repurchased.",
        "label": "Debt Instrument, Ratio of repurchase price to the principal amount",
        "terseLabel": "Ratio of repurchase price to the principal amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed",
        "terseLabel": "Debt instrument principal amount percentage",
        "documentation": "Percentage of principal amount of debt redeemed."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentRepurchaseAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentRepurchaseAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Repurchase Amount",
        "terseLabel": "Portion of debt retired, carrying value",
        "documentation": "Fair value amount of debt instrument that was repurchased."
       }
      }
     },
     "auth_ref": []
    },
    "inva_DebtInstrumentRepurchasePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "DebtInstrumentRepurchasePercentage",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Portion of debt Instrument, repurchased.",
        "label": "Debt Instrument, Repurchase Percentage",
        "terseLabel": "Percentage of notes repurchased"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentRepurchasedFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentRepurchasedFaceAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Repurchased Face Amount",
        "terseLabel": "Debt Instrument, Repurchased Face Amount",
        "verboseLabel": "Portion of debt retired, face value",
        "documentation": "Face (par) amount of the original debt instrument that was repurchased."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r90",
      "r91",
      "r140",
      "r141",
      "r143",
      "r149",
      "r202",
      "r204",
      "r304",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r489",
      "r494",
      "r495",
      "r496",
      "r497",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r507",
      "r702",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r1128"
     ]
    },
    "us-gaap_DebtInstrumentTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentTerm",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Term",
        "terseLabel": "Debt instrument, term",
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "inva_DebtInstrumentTransactionCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "DebtInstrumentTransactionCost",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument Transaction Cost",
        "documentation": "Debt instrument transaction cost",
        "terseLabel": "Transaction cost"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentUnamortizedDiscount",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Debt Instrument, Unamortized Discount, Total",
        "label": "Debt Instrument, Unamortized Discount",
        "verboseLabel": "Unamortized Debt discount",
        "documentation": "Amount, after accumulated amortization, of debt discount."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r143",
      "r1174"
     ]
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0,
       "order": 0.0
      },
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails": {
       "parentTag": "us-gaap_DebtLongtermAndShorttermCombinedAmount",
       "weight": -1.0,
       "order": 1.0
      },
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails": {
       "parentTag": "us-gaap_LongTermDebtCurrent",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net, Total",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "negatedLabel": "Less: Unamortized debt discount and issuance costs",
        "terseLabel": "Debt discount and issuance costs, net",
        "negatedTerseLabel": "Debt discount and issuance costs, net",
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r494",
      "r510",
      "r976",
      "r977"
     ]
    },
    "us-gaap_DebtLongtermAndShorttermCombinedAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtLongtermAndShorttermCombinedAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt, Long-Term and Short-Term, Combined Amount",
        "totalLabel": "Total debt, net",
        "terseLabel": "Total debt, net",
        "documentation": "Represents the aggregate of total long-term debt, including current maturities and short-term debt."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt [Member]",
        "terseLabel": "Debt",
        "documentation": "Contractual obligation to pay money on demand or on fixed or determinable dates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Debt Securities, Available-for-sale, Allowance for Credit Loss, Ending Balance",
        "periodStartLabel": "Debt Securities, Available-for-sale, Allowance for Credit Loss, Beginning Balance",
        "totalLabel": "Debt Securities, Available-for-sale, Allowance for Credit Loss, Total",
        "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss",
        "verboseLabel": "Credit loss",
        "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r388",
      "r436",
      "r440",
      "r441"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Table]",
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Table Text Block]",
        "terseLabel": "Schedule of amortized cost and estimated fair values for available-for-sale securities",
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r1140",
      "r1141",
      "r1142",
      "r1143",
      "r1144",
      "r1145",
      "r1146",
      "r1147",
      "r1148",
      "r1149",
      "r1150",
      "r1151"
     ]
    },
    "us-gaap_DeconsolidationGainOrLossAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeconsolidationGainOrLossAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfIncome": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": -1.0,
       "order": 5.0
      },
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deconsolidation, Gain (Loss), Amount",
        "terseLabel": "Net gain on sale of TRC",
        "negatedLabel": "Net gain on sale of TRC",
        "negatedTerseLabel": "Gain on sale of Theravance Respiratory Company, LLC (\"TRC\")",
        "documentation": "Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer."
       }
      }
     },
     "auth_ref": [
      "r116"
     ]
    },
    "inva_DecreaseToAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "DecreaseToAccumulatedDeficit",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease to accumulated deficit.",
        "label": "Decrease to Accumulated Deficit",
        "terseLabel": "Decrease to accumulated deficit"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails": {
       "parentTag": "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "negatedLabel": "Federal",
        "terseLabel": "Federal",
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1130",
      "r1211",
      "r1212"
     ]
    },
    "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredFederalStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Federal, State and Local, Tax Expense (Benefit)",
        "negatedTotalLabel": "Total",
        "totalLabel": "Total deferred",
        "documentation": "Amount of deferred federal, state, and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national, regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1205"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred Income Tax Expense (Benefit), Total",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred income taxes",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r213",
      "r248",
      "r630",
      "r631",
      "r1130"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "verboseLabel": "Deferred"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross",
        "totalLabel": "Net deferred tax (liabilities)",
        "negatedTotalLabel": "Net deferred tax (liabilities)",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r161",
      "r225",
      "r615"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred tax liabilities, net",
        "totalLabel": "Net deferred tax (liabilities)",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r605",
      "r606",
      "r796"
     ]
    },
    "us-gaap_DeferredRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredRevenue",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureLicenseAndCollaborationArrangementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred Revenue, Total",
        "label": "Deferred Revenue",
        "terseLabel": "Deferred revenue",
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r1115"
     ]
    },
    "us-gaap_DeferredRevenueCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredRevenueCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred Revenue, Current, Total",
        "label": "Deferred Revenue, Current",
        "terseLabel": "Deferred revenue",
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r1114"
     ]
    },
    "inva_DeferredRoyaltyObligationCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "DeferredRoyaltyObligationCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current portion of deferred royalty obligation.",
        "label": "Deferred Royalty Obligation, Current",
        "terseLabel": "Current portion of deferred royalty obligation"
       }
      }
     },
     "auth_ref": []
    },
    "inva_DeferredRoyaltyObligationNonCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "DeferredRoyaltyObligationNonCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherLongtermLiabilitiesDetails": {
       "parentTag": "us-gaap_OtherLiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherLongtermLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term portion of deferred royalty obligation.",
        "label": "Deferred Royalty Obligation, Non Current",
        "terseLabel": "Long-term portion of deferred royalty obligation"
       }
      }
     },
     "auth_ref": []
    },
    "inva_DeferredRoyaltyObligations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "DeferredRoyaltyObligations",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred royalty obligations",
        "label": "Deferred Royalty Obligations",
        "documentation": "Deferred royalty obligations."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails": {
       "parentTag": "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "negatedLabel": "State",
        "terseLabel": "State",
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1130",
      "r1211",
      "r1212"
     ]
    },
    "inva_DeferredTaxAssetsDeferredRoyaltyObligationNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "DeferredTaxAssetsDeferredRoyaltyObligationNet",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails2": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets deferred royalty obligation, net",
        "label": "Deferred Tax Assets Deferred Royalty Obligation, Net",
        "terseLabel": "Deferred royalty obligation, net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails2": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets before valuation allowance",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r616"
     ]
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax assets",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r1209"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails2": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": -1.0,
       "order": 0.0
      },
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Total deferred tax assets",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1209"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails2": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Total",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r1210"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails2": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r1210"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails2": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Research and development tax credit carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r106",
      "r1210"
     ]
    },
    "inva_DeferredTaxAssetsUnrealizedLossesOnInvestmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "DeferredTaxAssetsUnrealizedLossesOnInvestmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails2": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets unrealized losses on investment, net",
        "label": "Deferred Tax Assets Unrealized Losses On Investment, Net",
        "terseLabel": "Unrealized loss on investment, net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails2": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 1.0
      },
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred Tax Assets, Valuation Allowance, Total",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r617"
     ]
    },
    "inva_DeferredTaxLiabilitiesDepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "DeferredTaxLiabilitiesDepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails2": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax liabilities depreciation and amortization",
        "label": "Deferred Tax Liabilities Depreciation and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "auth_ref": []
    },
    "inva_DeferredTaxLiabilitiesInventoryFairValueAdjustment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "DeferredTaxLiabilitiesInventoryFairValueAdjustment",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails2": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax liabilities inventory fair value adjustment",
        "label": "Deferred Tax Liabilities Inventory Fair Value Adjustment",
        "terseLabel": "Inventory fair value adjustment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails2": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Unrealized Gain on Investment, net",
        "label": "Deferred Tax Liabilities, Investments",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from investments (excludes investments in subsidiaries and equity method investments)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesOther",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails2": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Other",
        "terseLabel": "Other",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r1210"
     ]
    },
    "inva_DemandLettersSentByStockholders": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "DemandLettersSentByStockholders",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of demand letters that were sent to the Company by purported stockholders.",
        "label": "Demand Letters Sent By Stockholders",
        "terseLabel": "Demand letters sent by stockholders"
       }
      }
     },
     "auth_ref": []
    },
    "inva_DenominatorAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "DenominatorAbstract",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Denominator [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "auth_ref": []
    },
    "inva_DerecognitionOfNonControllingInterestsUponAcquisitionOfEntasisMinorityInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "DerecognitionOfNonControllingInterestsUponAcquisitionOfEntasisMinorityInterest",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derecognition of non controlling interests upon acquisition of entasis minority interest.",
        "label": "Derecognition Of Non Controlling Interests Upon Acquisition Of Entasis Minority Interest",
        "terseLabel": "Derecognition of noncontrolling interests upon acquisition of Entasis noncontrolling interest"
       }
      }
     },
     "auth_ref": []
    },
    "inva_DerecognitionOfNoncontrollingInterestsUponAcquisitionOfEntasisMinorityInterestShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "DerecognitionOfNoncontrollingInterestsUponAcquisitionOfEntasisMinorityInterestShares",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derecognition of noncontrolling interests upon acquisition of Entasis noncontrolling interest (in shares)",
        "label": "Derecognition Of NonControlling Interests Upon Acquisition Of Entasis Minority Interest Shares",
        "documentation": "Derecognition of nonControlling interests upon acquisition of entasis minority interest shares."
       }
      }
     },
     "auth_ref": []
    },
    "inva_DerecognitionOfNoncontrollingInterestsUponSaleOfTrc": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "DerecognitionOfNoncontrollingInterestsUponSaleOfTrc",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derecognition of noncontrolling interestsupon sale of TRC.",
        "label": "Derecognition of Noncontrolling Interests Upon Sale of TRC",
        "terseLabel": "Derecognition of noncontrolling interests upon sale of TRC"
       }
      }
     },
     "auth_ref": []
    },
    "inva_DerecognitionOfNoncontrollingInterestsUponSaleOfTrcShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "DerecognitionOfNoncontrollingInterestsUponSaleOfTrcShares",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derecognition of noncontrolling interests upon sale of TRC (in shares)",
        "label": "Derecognition Of Noncontrolling Interests Upon Sale Of Trc Shares",
        "documentation": "Derecognition of noncontrolling interests upon sale of trc shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeCapPrice": {
     "xbrltype": "perUnitItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeCapPrice",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative, Cap Price",
        "terseLabel": "Cap price for the underlying number of shares (in dollars per share)",
        "documentation": "The cap rate on a price risk derivative such as a cap or collar. A payment or receipt is triggered if the market rate exceeds the cap rate on the contract."
       }
      }
     },
     "auth_ref": []
    },
    "inva_DescriptionOfOperationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "DescriptionOfOperationsPolicyTextBlock",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Description of Operations",
        "label": "Description of Operations [Policy Text Block]",
        "documentation": "Description of operations."
       }
      }
     },
     "auth_ref": []
    },
    "inva_DilutiveEpsOfNotes": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "DilutiveEpsOfNotes",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureNetIncomePerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to convertible notes.",
        "label": "Dilutive EPS of Notes",
        "terseLabel": "Dilutive EPS of note"
       }
      }
     },
     "auth_ref": []
    },
    "srt_DirectorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "DirectorMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationDirectorCompensationProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]",
        "terseLabel": "Non-employee director"
       }
      }
     },
     "auth_ref": [
      "r1137",
      "r1236"
     ]
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueLineItems",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureRevenueRecognitionDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfNetRevenueFromCollaborativeArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Revenue Recognition and Collaborative Arrangements",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r540",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueTable",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureRevenueRecognitionDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfNetRevenueFromCollaborativeArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation of Revenue [Table]",
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r540",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureRevenueRecognitionTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Schedule of net revenue from collaborative arrangements",
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r1176"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Text Block]",
        "verboseLabel": "STOCK-BASED COMPENSATION",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r551",
      "r556",
      "r587",
      "r588",
      "r590",
      "r994"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "inva_DividendYield": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "DividendYield",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dividend yield.",
        "label": "Dividend Yield"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r1020",
      "r1021",
      "r1034"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Financial Statement Error Correction [Flag]",
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r1020",
      "r1021",
      "r1034",
      "r1070"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r1055"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r1018"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalTaxDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Federal",
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails",
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Earnings Per Share, Basic, Total",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic net income per share attributable to Innoviva stockholders",
        "verboseLabel": "Basic net income per share",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r288",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r323",
      "r326",
      "r339",
      "r340",
      "r341",
      "r345",
      "r671",
      "r672",
      "r790",
      "r814",
      "r968"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails",
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Earnings Per Share, Diluted, Total",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted net income per share attributable to Innoviva stockholders",
        "verboseLabel": "Diluted net income per share",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r288",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r326",
      "r339",
      "r340",
      "r341",
      "r345",
      "r671",
      "r672",
      "r790",
      "r814",
      "r968"
     ]
    },
    "us-gaap_EarningsPerShareDilutedLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDilutedLineItems",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]",
        "verboseLabel": "Net Income Per Share",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r326",
      "r330",
      "r339"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureNetIncomePerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Text Block]",
        "verboseLabel": "NET INCOME PER SHARE",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r322",
      "r342",
      "r343",
      "r344"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Employee-related Liabilities, Current, Total",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued personnel-related expenses",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r589"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted-Average Amortization Period (Years)",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r589"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationCompensationAwardsDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationValuationAssumptionsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "inva_EmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "EmployeeStockPurchasePlanMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensation2012PlanAndEsppDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to the Company's Employee Stock Purchase Plan (the \"ESPP\").",
        "label": "Employee Stock Purchase Plan [Member]",
        "terseLabel": "ESPP"
       }
      }
     },
     "auth_ref": []
    },
    "inva_EmployeeStockPurchasePlanTwentyTwentyThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "EmployeeStockPurchasePlanTwentyTwentyThreeMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensation2012PlanAndEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023 ESPP",
        "label": "Employee Stock Purchase Plan Twenty Twenty Three [Member]",
        "documentation": "Employee Stock Purchase Plan Twenty Twenty Three [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "inva_EntasisLeaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "EntasisLeaseMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entasis Lease [Member]",
        "label": "Entasis Lease [Member]",
        "terseLabel": "Entasis Lease"
       }
      }
     },
     "auth_ref": []
    },
    "inva_EntasisTherapeuticsHoldingsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "EntasisTherapeuticsHoldingsIncMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsProFormaInformationDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTables",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsSummarizedFinancialDataDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsTables",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalTaxDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Entasis Therapeutics Holdings Inc.",
        "label": "Entasis Therapeutics Holdings Inc [Member]",
        "terseLabel": "Entasis",
        "verboseLabel": "Entasis Therapeutics Holdings Inc"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CIK",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1017"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Entities",
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1017"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r1017"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r1095"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1017"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r1017"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r1017"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1017"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r1096"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureNetIncomePerShareDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockholdersEquityDetails",
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r254",
      "r280",
      "r281",
      "r282",
      "r305",
      "r306",
      "r307",
      "r310",
      "r318",
      "r320",
      "r346",
      "r424",
      "r430",
      "r530",
      "r591",
      "r592",
      "r593",
      "r626",
      "r627",
      "r652",
      "r654",
      "r655",
      "r656",
      "r657",
      "r659",
      "r670",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r724",
      "r827",
      "r828",
      "r829",
      "r845",
      "r907"
     ]
    },
    "inva_EquityIncentivePlan2012Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "EquityIncentivePlan2012Member",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensation2012PlanAndEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the 2012 Equity Incentive Plan as approved by shareowners.",
        "label": "Equity Incentive Plan2012 [Member]",
        "terseLabel": "2012 Equity Incentive Plan"
       }
      }
     },
     "auth_ref": []
    },
    "inva_EquityIncentivePlansAndESPPMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "EquityIncentivePlansAndESPPMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureNetIncomePerShareAntiDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to options, Equity Incentive Plans and Employee Stock Purchase Plans.",
        "label": "Equity Incentive Plans And E S P P [Member]",
        "terseLabel": "Equity incentive plans and ESPP"
       }
      }
     },
     "auth_ref": []
    },
    "inva_EquityInvestmentsAndMoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "EquityInvestmentsAndMoneyMarketFundsMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to equity investments and money market funds.",
        "label": "Equity Investments And Money Market Funds [Member]",
        "terseLabel": "Equity investments and Money market funds"
       }
      }
     },
     "auth_ref": []
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "EquityMethodInvesteeNameDomain",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInGateNeurosciencesDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInImaginabDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInNanoliveDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r417",
      "r418",
      "r419"
     ]
    },
    "inva_EquityMethodInvestment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "EquityMethodInvestment",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity method investments",
        "label": "Equity Method Investment",
        "documentation": "Equity method investment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityMethodInvestmentOtherThanTemporaryImpairment",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investment, Other than Temporary Impairment",
        "terseLabel": "Impairment of equity investments",
        "documentation": "This item represents an other than temporary decline in value that has been recognized against an investment accounted for under the equity method of accounting. The excess of the carrying amount over the fair value of the investment represents the amount of the write down which is or was reflected in earnings. The written down value is a new cost basis with the adjusted value of the investment becoming its new carrying value subject to the equity accounting method. Evidence of a loss in value might include, but would not necessarily be limited to, absence of an ability to recover the carrying amount of the investment or inability of the investee to sustain an earnings capacity which would justify the carrying amount of the investment."
       }
      }
     },
     "auth_ref": [
      "r1156"
     ]
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInImaginabDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInNanoliveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investment, Ownership Percentage",
        "verboseLabel": "Equity investment ownership percentage",
        "terseLabel": "Equity method investment ownership percentage",
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting."
       }
      }
     },
     "auth_ref": [
      "r417"
     ]
    },
    "us-gaap_EquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityMethodInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investments",
        "terseLabel": "Total carrying value of investments",
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized."
       }
      }
     },
     "auth_ref": [
      "r358",
      "r416",
      "r1113",
      "r1157"
     ]
    },
    "us-gaap_EquityMethodInvestmentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityMethodInvestmentsPolicy",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investments [Policy Text Block]",
        "terseLabel": "Equity and Long-Term Investments",
        "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r139",
      "r418"
     ]
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquitySecuritiesFvNi",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInGateNeurosciencesDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInImaginabDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInNanoliveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Securities, FV-NI, Current",
        "terseLabel": "Equity and long-term investments at fair value",
        "verboseLabel": "Fair value of equity securities",
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current."
       }
      }
     },
     "auth_ref": [
      "r267",
      "r684",
      "r957"
     ]
    },
    "us-gaap_EquitySecuritiesFvNiRealizedGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquitySecuritiesFvNiRealizedGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Equity Securities, FV-NI, Realized Gain (Loss), Total",
        "label": "Equity Securities, FV-NI, Realized Gain (Loss)",
        "terseLabel": "Remeasurement loss",
        "documentation": "Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r815",
      "r1155"
     ]
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGain": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquitySecuritiesFvNiUnrealizedGain",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInGateNeurosciencesDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Securities, FV-NI, Unrealized Gain",
        "terseLabel": "Unrealized gain from fair value changes in equity investments",
        "verboseLabel": "Unrealized gain",
        "documentation": "Amount of unrealized gain on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r415"
     ]
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquitySecuritiesFvNiUnrealizedGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized gain loss from fair value changes in equity investments",
        "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)",
        "totalLabel": "Equity Securities, FV-NI, Unrealized Gain (Loss), Total",
        "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r816",
      "r1155"
     ]
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquitySecuritiesFvNiUnrealizedLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInGateNeurosciencesDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized loss from fair value changes in equity investments",
        "negatedLabel": "Unrealized loss from fair value changes in equity investments",
        "label": "Equity Securities, FV-NI, Unrealized Loss",
        "verboseLabel": "Unrealized loss",
        "documentation": "Amount of unrealized loss on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r415"
     ]
    },
    "us-gaap_EquitySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquitySecuritiesMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Securities [Member]",
        "terseLabel": "Equity investment",
        "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r1010",
      "r1011",
      "r1012",
      "r1241"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r1063"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r1026",
      "r1038",
      "r1048",
      "r1074"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r1023",
      "r1035",
      "r1045",
      "r1071"
     ]
    },
    "srt_EuropeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "EuropeMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Europe [Member]",
        "terseLabel": "Europe"
       }
      }
     },
     "auth_ref": [
      "r1240",
      "r1242",
      "r1243",
      "r1244"
     ]
    },
    "inva_EverestMedicinesLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "EverestMedicinesLimitedMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureLicenseAndCollaborationArrangementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Everest Medicines Limited [Member]",
        "label": "Everest Medicines Limited [Member]",
        "terseLabel": "Everest Medicines Limited"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r1069"
     ]
    },
    "inva_ExpectedHoldingPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "ExpectedHoldingPeriod",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected holding period of equity method investment.",
        "label": "Expected Holding Period",
        "terseLabel": "Expected holding period"
       }
      }
     },
     "auth_ref": []
    },
    "inva_ExtendedExpirationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "ExtendedExpirationDate",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extended expiration date.",
        "label": "Extended Expiration Date",
        "terseLabel": "Extended expiration date"
       }
      }
     },
     "auth_ref": []
    },
    "inva_FactorsAffectingComparabilityPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "FactorsAffectingComparabilityPolicyTextBlock",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Factors affecting comparability.",
        "label": "Factors Affecting Comparability Policy [Text Block]",
        "terseLabel": "Factors Affecting Comparability"
       }
      }
     },
     "auth_ref": []
    },
    "inva_FairValueAdjustmentsOfInventoryFromAcquistion": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "FairValueAdjustmentsOfInventoryFromAcquistion",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of net fair value adjustment of inventory resulting from the acquisition.",
        "label": "Fair Value Adjustments Of Inventory From Acquistion",
        "terseLabel": "Net fair value adjustment of inventory"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsSummarizedFinancialDataDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value Measurements",
        "verboseLabel": "FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r675",
      "r676",
      "r680"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsSummarizedFinancialDataDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r675",
      "r676",
      "r680"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]",
        "terseLabel": "Schedule of available-for-sale securities measured at fair value on a recurring basis",
        "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r133",
      "r134",
      "r219"
     ]
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInGateNeurosciencesDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInImaginabDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInNanoliveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "terseLabel": "Equity Investment",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByBalanceSheetGroupingTable",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInGateNeurosciencesDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInImaginabDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInNanoliveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r135",
      "r136"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r496",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r676",
      "r735",
      "r736",
      "r737",
      "r976",
      "r977",
      "r988",
      "r989",
      "r990"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r675",
      "r676",
      "r677",
      "r678",
      "r681"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Quoted Price in Active Markets for Identical Assets, Level 1",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r496",
      "r543",
      "r548",
      "r676",
      "r735",
      "r988",
      "r989",
      "r990"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Significant Other Observable Inputs, Level 2",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r496",
      "r543",
      "r548",
      "r676",
      "r736",
      "r976",
      "r977",
      "r988",
      "r989",
      "r990"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Significant Unobservable Inputs, Level 3",
        "verboseLabel": "Fair Value, Inputs, Level 3",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r496",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r676",
      "r737",
      "r976",
      "r977",
      "r988",
      "r989",
      "r990"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Fair Value, Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r496",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r735",
      "r736",
      "r737",
      "r976",
      "r977",
      "r988",
      "r989",
      "r990"
     ]
    },
    "us-gaap_FairValueMeasurementsNonrecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsNonrecurringMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Nonrecurring [Member]",
        "terseLabel": "Nonrecurring basis",
        "documentation": "Infrequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, not frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r681"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring basis",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r674",
      "r681"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r30"
     ]
    },
    "inva_FederalNetOperatingLossesEstimatedUtilizationAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "FederalNetOperatingLossesEstimatedUtilizationAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalTaxDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Federal net operating losses estimated utilization amount.",
        "label": "Federal Net Operating Losses Estimated Utilization Amount",
        "terseLabel": "Federal net operating losses estimated utilization amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsAvailableforsaleSecuritiesDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInGateNeurosciencesDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInImaginabDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInNanoliveDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r437",
      "r438",
      "r439",
      "r507",
      "r527",
      "r660",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r810",
      "r973",
      "r1105",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1151",
      "r1152",
      "r1153",
      "r1154"
     ]
    },
    "us-gaap_FinancialInstrumentsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialInstrumentsDisclosureTextBlock",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments Disclosure [Text Block]",
        "terseLabel": "EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS",
        "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Marketed products, Useful Life",
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails": {
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Accumulated amortization",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "terseLabel": "Accumulated amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r264",
      "r462"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five",
        "terseLabel": "Future amortization expense, thereafter",
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Future amortization expense, 2024",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r192"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Future amortization expense, 2028",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r192"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Future amortization expense, 2027",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r192"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Future amortization expense, 2026",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r192"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Future amortization expense, 2025",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r192"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r460",
      "r461",
      "r462",
      "r463",
      "r768",
      "r772"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r80"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsPeriodIncreaseDecrease",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsLaJollaPharmaceuticalCompanyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Finite-Lived Intangible Assets, Period Increase (Decrease), Total",
        "label": "Finite-Lived Intangible Assets, Period Increase (Decrease)",
        "terseLabel": "Measurement period adjustments for change in value of intangible assets",
        "documentation": "Amount of increase (decrease) in carrying value of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r1030",
      "r1042",
      "r1052",
      "r1078"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r1030",
      "r1042",
      "r1052",
      "r1078"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r1030",
      "r1042",
      "r1052",
      "r1078"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r1030",
      "r1042",
      "r1052",
      "r1078"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r1030",
      "r1042",
      "r1052",
      "r1078"
     ]
    },
    "inva_FuturePotentialMilestonePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "FuturePotentialMilestonePayment",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureLicenseAndCollaborationArrangementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future potential milestone payment receivable.",
        "label": "Future Potential Milestone Payment",
        "terseLabel": "Future potential milestone payment receivable"
       }
      }
     },
     "auth_ref": []
    },
    "inva_GSKMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "GSKMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureRevenueRecognitionDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfNetRevenueFromCollaborativeArrangementsDetails",
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfIncomeParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents GSK, with whom the entity has agreements and arrangements, such as those for developing and commercializing different products.",
        "label": "G S K [Member]",
        "terseLabel": "GSK"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails2": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsIspFundLpDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Changes in fair values of equity and long-term investments",
        "terseLabel": "Realized gain on equity investments",
        "totalLabel": "Gain (Loss) on Investments, Total",
        "label": "Gain (Loss) on Investments",
        "negatedLabel": "Changes in fair values of equity and long-term investments, net",
        "documentation": "Amount of realized and unrealized gain (loss) on investment."
       }
      }
     },
     "auth_ref": [
      "r180",
      "r1097"
     ]
    },
    "inva_GainLossOnOtherInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "GainLossOnOtherInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfIncome": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Changes in fair value of equity and long-term investments, net",
        "documentation": "Gain loss on other investments.",
        "label": "Gain (Loss) on Other Investments",
        "terseLabel": "Changes in fair value of other equity and long-term investments, net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfIncome": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": -1.0,
       "order": 6.0
      },
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails",
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gain (Loss) on Extinguishment of Debt, Total",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedLabel": "Loss on extinguishment of debt",
        "terseLabel": "Loss on extinguishment of debt",
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r87",
      "r88"
     ]
    },
    "inva_GateNeuroscienceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "GateNeuroscienceMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInGateNeurosciencesDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gate Neuroscience [Member]",
        "documentation": "Gate Neuroscience [Member]",
        "terseLabel": "Gate Neurosciences Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralPartnerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralPartnerMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsIspFundLpDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General Partner [Member]",
        "terseLabel": "General Partner",
        "documentation": "Party to a partnership business who has unlimited liability."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeographicConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeographicConcentrationRiskMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographic Concentration Risk [Member]",
        "terseLabel": "Geographic Concentration Risk",
        "documentation": "Reflects the percentage that a specified dollar value on the balance sheet or income statement in the period from one or more specified geographic areas is to a corresponding consolidated, segment, or product line amount. Risk is the materially adverse effects of economic decline or antagonistic political actions resulting in loss of assets, sales volume, labor supply, or source of materials and supplies in a US state or a specified country, continent, or region such as EMEA (Europe, Middle East, Africa)."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r937"
     ]
    },
    "inva_GeorgeWashingtonUniversityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "GeorgeWashingtonUniversityMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureLicenseAndCollaborationArrangementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "George Washington University.",
        "label": "George Washington University [Member]",
        "terseLabel": "George Washington University"
       }
      }
     },
     "auth_ref": []
    },
    "inva_GiaprezaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "GiaprezaMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GIAPREZA.",
        "label": "GIAPREZA [Member]",
        "terseLabel": "GIAPREZA"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Goodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails",
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Goodwill, Total",
        "periodStartLabel": "Goodwill, Beginning Balance",
        "periodEndLabel": "Goodwill, Ending Balance",
        "label": "Goodwill",
        "terseLabel": "Goodwill",
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r263",
      "r447",
      "r785",
      "r974",
      "r999",
      "r1162",
      "r1163"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureGoodwillAndIntangibleAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "GOODWILL AND INTANGIBLE ASSETS",
        "documentation": "The entire disclosure for goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r191"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Goodwill and Intangible Assets",
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r74"
     ]
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillImpairmentLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill, impairment losses",
        "label": "Goodwill, Impairment Loss",
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r448",
      "r454",
      "r459",
      "r974"
     ]
    },
    "us-gaap_GoodwillLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillLineItems",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r974"
     ]
    },
    "us-gaap_GoodwillPeriodIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillPeriodIncreaseDecrease",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsLaJollaPharmaceuticalCompanyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Goodwill, Period Increase (Decrease), Total",
        "label": "Goodwill, Period Increase (Decrease)",
        "terseLabel": "Measurement period adjustments for change in value of goodwill",
        "verboseLabel": "Decrease in goodwill",
        "documentation": "Amount of increase (decrease) of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r1161"
     ]
    },
    "inva_GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfNetRevenueFromCollaborativeArrangementsDetails": {
       "parentTag": "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfNetRevenueFromCollaborativeArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer before amortization of capitalized fees.",
        "label": "Gross Revenue from Contract with Customer, Excluding Assessed Tax, Before Amortization Of Capitalized Fees",
        "terseLabel": "Royalties"
       }
      }
     },
     "auth_ref": []
    },
    "inva_HarvardUniversityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "HarvardUniversityMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureLicenseAndCollaborationArrangementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Harvard University.",
        "label": "Harvard University [Member]",
        "terseLabel": "Harvard University"
       }
      }
     },
     "auth_ref": []
    },
    "inva_HealthCareRoyaltyPartnersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "HealthCareRoyaltyPartnersMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Health care royalty partners member.",
        "label": "Health Care Royalty Partners [Member]",
        "terseLabel": "HealthCare Royalty Partners"
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r1020",
      "r1021",
      "r1034"
     ]
    },
    "inva_ImaginabConvertibleNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "ImaginabConvertibleNoteMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ImaginAb Convertible Note",
        "label": "ImaginAb Convertible Note [Member]",
        "documentation": "ImaginAb Convertible Note."
       }
      }
     },
     "auth_ref": []
    },
    "inva_ImaginabMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "ImaginabMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInImaginabDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ImaginAb",
        "label": "Imaginab [Member]",
        "documentation": "Represents information pertaining to ImaginAb."
       }
      }
     },
     "auth_ref": []
    },
    "inva_InCardaConvertibleNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "InCardaConvertibleNoteMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In Carda Convertible note.",
        "label": "In Carda Convertible Note [Member]",
        "terseLabel": "InCarda Convertible Note"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InProcessResearchAndDevelopmentMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "In Process Research and Development [Member]",
        "terseLabel": "In-process research and development",
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process."
       }
      }
     },
     "auth_ref": []
    },
    "inva_Incarda2020WarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "Incarda2020WarrantsMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "InCarda 2020 Warrants [Member]",
        "label": "InCarda 2020 Warrants [Member]",
        "terseLabel": "Incarda 2020 Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "inva_IncardaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "IncardaMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to InCarda.",
        "label": "Incarda [Member]",
        "terseLabel": "InCarda"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfIncome": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income before income taxes",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r170",
      "r230",
      "r351",
      "r366",
      "r370",
      "r372",
      "r791",
      "r806",
      "r970"
     ]
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromEquityMethodInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfIncome": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": -1.0,
       "order": 7.0
      },
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Equity Method Investments",
        "terseLabel": "Changes in fair values of equity method investments, net",
        "negatedLabel": "Changes in fair values of equity method investments, net",
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss)."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r171",
      "r229",
      "r356",
      "r416",
      "r805"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "inva_IncomeStatementDisclosuresOfVariableInterestEntityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "IncomeStatementDisclosuresOfVariableInterestEntityAbstract",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income statements",
        "documentation": "No definition available.",
        "label": "Income Statement Disclosures of Variable Interest Entity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r464",
      "r466",
      "r891"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]",
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r466",
      "r891"
     ]
    },
    "us-gaap_IncomeStatementRelatedDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementRelatedDisclosuresAbstract",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsSummarizedFinancialDataDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Related Disclosures [Abstract]",
        "terseLabel": "Income Statement Information"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalTaxDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Axis]",
        "documentation": "Information by tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalTaxDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]",
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Text Block]",
        "verboseLabel": "INCOME TAXES",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r301",
      "r601",
      "r609",
      "r613",
      "r619",
      "r628",
      "r632",
      "r633",
      "r634",
      "r842"
     ]
    },
    "us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExaminationPenaltiesAndInterestAccrued",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalTaxDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income Tax Examination, Penalties and Interest Accrued, Total",
        "label": "Income Tax Examination, Penalties and Interest Accrued",
        "terseLabel": "Accrued interest and penalties",
        "documentation": "The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations."
       }
      }
     },
     "auth_ref": [
      "r1207"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfIncome": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0,
       "order": 1.0
      },
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails2": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0,
       "order": 3.0
      },
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails",
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total income tax expense, net",
        "negatedTotalLabel": "Total income tax expense, net",
        "terseLabel": "Income tax expense, net",
        "negatedTerseLabel": "Income tax expense, net",
        "label": "Income Tax Expense (Benefit)",
        "verboseLabel": "Income tax expense, net",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r239",
      "r249",
      "r319",
      "r320",
      "r357",
      "r607",
      "r629",
      "r817"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement period adjustments for change in value of deferred tax liabilities",
        "label": "Income Tax Expense (Benefit), Continuing Operations, Adjustment of Deferred Tax (Asset) Liability",
        "documentation": "Amount of income tax expense (benefit) from continuing operations attributable to an adjustment of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity."
       }
      }
     },
     "auth_ref": [
      "r622"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]",
        "verboseLabel": "Differences between the expected U.S. federal statutory income tax to income tax expense"
       }
      }
     },
     "auth_ref": []
    },
    "inva_IncomeTaxPayableNonCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "IncomeTaxPayableNonCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax payable non current.",
        "label": "Income Tax Payable Non Current",
        "terseLabel": "Income tax payable, long-term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r279",
      "r603",
      "r604",
      "r613",
      "r614",
      "r618",
      "r620",
      "r839"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Change in valuation allowance",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r1206"
     ]
    },
    "us-gaap_IncomeTaxReconciliationDeductionsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationDeductionsOther",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Section 250 deduction",
        "label": "Effective Income Tax Rate Reconciliation, Deduction, Other, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other deductions."
       }
      }
     },
     "auth_ref": [
      "r1206"
     ]
    },
    "us-gaap_IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Equity in Earnings (Losses) of Unconsolidated Subsidiary, Amount",
        "terseLabel": "Impact of consolidation and deconsolidation of subsidiaries",
        "negatedLabel": "Impact of consolidation and deconsolidation of subsidiaries",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to equity in earnings (loss) of unconsolidated subsidiaries exempt from income taxes."
       }
      }
     },
     "auth_ref": [
      "r1206"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "Expected tax at federal statutory rate",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r608"
     ]
    },
    "us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationMinorityInterestIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Noncontrolling Interest Income (Loss), Amount",
        "negatedTerseLabel": "Noncontrolling Interest",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to noncontrolling interest income (loss) exempt from income taxes."
       }
      }
     },
     "auth_ref": [
      "r1206"
     ]
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "terseLabel": "Other",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r1206"
     ]
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "terseLabel": "State income tax, net of federal benefit",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r1206"
     ]
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal and state research credits",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount",
        "negatedLabel": "Federal and state research credits",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit."
       }
      }
     },
     "auth_ref": [
      "r1206"
     ]
    },
    "inva_IncomeTaxesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "IncomeTaxesLineItems",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalTaxDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Taxes [Line Items]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income Taxes Paid, Net, Total",
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Cash paid for income taxes",
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "inva_IncomeTaxesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "IncomeTaxesTable",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalTaxDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of income taxes.",
        "label": "Income Taxes [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 33.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Increase (Decrease) in Accounts Payable, Total",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 24.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Receivable",
        "terseLabel": "Accounts receivable, net",
        "negatedLabel": "Accounts receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 34.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Income Taxes Payable",
        "terseLabel": "Income tax payable",
        "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 35.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Increase (Decrease) in Accrued Liabilities, Total",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued personnel-related expenses and other accrued liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInDeferredIncomeTaxes",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalTaxDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Deferred Income Taxes",
        "terseLabel": "Income tax expense recognized",
        "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 31.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Deferred Revenue",
        "terseLabel": "Deferred revenue",
        "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r951"
     ]
    },
    "inva_IncreaseDecreaseInDeferredTaxAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "IncreaseDecreaseInDeferredTaxAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsLaJollaPharmaceuticalCompanyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (decrease) in deferred tax assets",
        "label": "Increase (Decrease) In Deferred Tax Assets",
        "documentation": "Increase (Decrease) in deferred tax assets."
       }
      }
     },
     "auth_ref": []
    },
    "inva_IncreaseDecreaseInDeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "IncreaseDecreaseInDeferredTaxLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsLaJollaPharmaceuticalCompanyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Increase (decrease) in deferred tax liabilities",
        "documentation": "Increase (decrease) in deferred tax liabilities.",
        "label": "Increase (Decrease) in Deferred Tax Liabilities",
        "terseLabel": "Measurement period adjustments increase decrease in deferred tax liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInDueFromRelatedPartiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 26.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Increase (Decrease) in Due from Related Parties, Current, Total",
        "label": "Increase (Decrease) in Due from Related Parties, Current",
        "negatedLabel": "Receivables from collaborative arrangements",
        "documentation": "The aggregate increase (decrease) during the reporting period in the amount due from the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_IncreaseDecreaseInInterestPayableNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInInterestPayableNet",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 36.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Interest Payable, Net",
        "terseLabel": "Accrued interest payable",
        "documentation": "The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 27.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsLaJollaPharmaceuticalCompanyDetails",
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Increase (Decrease) in Inventories, Total",
        "label": "Increase (Decrease) in Inventories",
        "terseLabel": "Measurement period adjustments for change in value of Inventory",
        "negatedLabel": "Inventory",
        "verboseLabel": "Change in inventory",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Increase (Decrease) in Other Operating Assets, Total",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other assets",
        "documentation": "Amount of increase (decrease) in operating assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 28.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Prepaid Expense",
        "terseLabel": "Prepaid expenses",
        "negatedLabel": "Prepaid expenses",
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "inva_IncreaseInDeferredTaxAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "IncreaseInDeferredTaxAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase in deferred tax assets.",
        "label": "Increase in Deferred Tax Assets",
        "terseLabel": "Increase in Deferred Tax Assets"
       }
      }
     },
     "auth_ref": []
    },
    "inva_IncreaseToConvertibleNotes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "IncreaseToConvertibleNotes",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase to convertible notes.",
        "label": "Increase To Convertible Notes",
        "terseLabel": "Increase in convertible notes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncrementalCommonSharesAttributableToConversionOfDebtSecurities",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Incremental Common Shares Attributable to Conversion of Debt Securities, Total",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities",
        "terseLabel": "Dilutive effect",
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method."
       }
      }
     },
     "auth_ref": [
      "r335",
      "r336",
      "r341"
     ]
    },
    "inva_IncrementalCommonSharesAttributableToConversionOfDebtSecuritiesTreasuryStockMethod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "IncrementalCommonSharesAttributableToConversionOfDebtSecuritiesTreasuryStockMethod",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureNetIncomePerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the treasury stock method.",
        "label": "Incremental Common Shares Attributable To Conversion Of Debt Securities, Treasury Stock Method",
        "terseLabel": "Dilutive effect of the assumed conversion premium"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Incremental Common Shares Attributable to Share-based Payment Arrangements, Total",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements",
        "terseLabel": "Dilutive effect of options and awards granted under equity incentive plan and employee stock purchase plan",
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method."
       }
      }
     },
     "auth_ref": [
      "r327",
      "r328",
      "r329",
      "r341",
      "r555"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Indefinite-Lived Intangible Assets, Period Increase (Decrease), Total",
        "label": "Indefinite-Lived Intangible Assets, Period Increase (Decrease)",
        "terseLabel": "Measurement period adjustments for change in value of intangible assets",
        "documentation": "Amount of increase (decrease) of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit."
       }
      }
     },
     "auth_ref": [
      "r193"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r1033",
      "r1042",
      "r1052",
      "r1069",
      "r1078",
      "r1082",
      "r1090"
     ]
    },
    "inva_InnovivaCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "InnovivaCommonStockMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Innoviva's Common Stock Member",
        "label": "Innoviva Common Stock Member",
        "terseLabel": "Innoviva's Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "inva_InnovivaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "InnovivaMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Innoviva [Member]",
        "label": "Innoviva [Member]",
        "terseLabel": "Innoviva [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "inva_InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Innoviva Strategic Opportunities, LLC",
        "label": "Innoviva Strategic Opportunities Limited Liability Corporation [Member]",
        "documentation": "Represents information pertaining to Innoviva Strategic Opportunities, LLC."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r1088"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r1022",
      "r1094"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r1022",
      "r1094"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r1022",
      "r1094"
     ]
    },
    "inva_IntangibleAssetsCollaborationAgreementAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "IntangibleAssetsCollaborationAgreementAccumulatedAmortization",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration agreement, accumulated amortization",
        "label": "Intangible Assets Collaboration Agreement Accumulated Amortization",
        "documentation": "Intangible assets collaboration agreement accumulated amortization."
       }
      }
     },
     "auth_ref": []
    },
    "inva_IntangibleAssetsCollaborationAgreementGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "IntangibleAssetsCollaborationAgreementGross",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails": {
       "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible assets collaboration agreement gross.",
        "label": "Intangible Assets Collaboration Agreement Gross",
        "terseLabel": "Collaboration agreement, gross carrying amount"
       }
      }
     },
     "auth_ref": []
    },
    "inva_IntangibleAssetsCollaborationAgreementNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "IntangibleAssetsCollaborationAgreementNet",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails2": {
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible assets collaboration agreement net.",
        "label": "Intangible Assets Collaboration Agreement Net",
        "terseLabel": "Collaboration agreement, net carrying amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails": {
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets, Gross (Excluding Goodwill)",
        "terseLabel": "Total gross carrying amount",
        "totalLabel": "Total gross carrying amount",
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill."
       }
      }
     },
     "auth_ref": [
      "r263"
     ]
    },
    "inva_IntangibleAssetsInProcessResearchAndDevelopmentAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "IntangibleAssetsInProcessResearchAndDevelopmentAccumulatedAmortization",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "In-process research and development, accumulated amortization",
        "label": "Intangible Assets In Process Research And Development Accumulated Amortization",
        "documentation": "Intangible sssets in process research and development accumulated amortization."
       }
      }
     },
     "auth_ref": []
    },
    "inva_IntangibleAssetsInProcessResearchAndDevelopmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "IntangibleAssetsInProcessResearchAndDevelopmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails": {
       "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount of In-process research and development.",
        "label": "Intangible Assets In-process Research and Development, Gross",
        "terseLabel": "In-process research and development, gross carrying amount"
       }
      }
     },
     "auth_ref": []
    },
    "inva_IntangibleAssetsInProcessResearchAndDevelopmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "IntangibleAssetsInProcessResearchAndDevelopmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails2": {
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net amount of In-process research and development.",
        "label": "Intangible Assets In-process Research and Development, Net",
        "terseLabel": "In-process research and development, net carrying amount"
       }
      }
     },
     "auth_ref": []
    },
    "inva_IntangibleAssetsMarketedProductsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "IntangibleAssetsMarketedProductsAccumulatedAmortization",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amortization amount of Marketed Products.",
        "label": "Intangible Assets Marketed Products, Accumulated Amortization",
        "terseLabel": "Marketed products, Accumulated amortization"
       }
      }
     },
     "auth_ref": []
    },
    "inva_IntangibleAssetsMarketedProductsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "IntangibleAssetsMarketedProductsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails": {
       "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount of Marketed products.",
        "label": "Intangible Assets Marketed Products, Gross",
        "terseLabel": "Marketed products, gross carrying amount"
       }
      }
     },
     "auth_ref": []
    },
    "inva_IntangibleAssetsMarketedProductsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "IntangibleAssetsMarketedProductsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails2": {
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net amount of Marketed Products.",
        "label": "Intangible Assets Marketed Products, Net",
        "terseLabel": "Marketed products, net carrying amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 7.0
      },
      "http://www.inva.com/20231231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.inva.com/20231231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails",
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "totalLabel": "Net carrying amount",
        "terseLabel": "Intangible assets",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r79"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsNetExcludingGoodwillAbstract",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets, Net (Excluding Goodwill) [Abstract]",
        "terseLabel": "Intangible Assets Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestAndDividendIncomeOperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestAndDividendIncomeOperating",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfIncome": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest and dividend income",
        "label": "Interest and Dividend Income, Operating",
        "totalLabel": "Interest and Dividend Income, Operating, Total",
        "negatedLabel": "Interest and dividend income",
        "documentation": "Represents the total of interest and dividend income, including any amortization and accretion (as applicable) of discounts and premiums, earned from (1) loans and leases whether held-for-sale or held-in-portfolio; (2) investment securities; (3) federal funds sold; (4) securities purchased under agreements to resell; (5) investments in banker's acceptances, commercial paper, or certificates of deposit; (6) dividend income; or (7) other investments not otherwise specified herein."
       }
      }
     },
     "auth_ref": [
      "r232",
      "r1245"
     ]
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfIncome": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Interest Expense, Total",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense",
        "terseLabel": "Interest expense",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r234",
      "r283",
      "r355",
      "r700",
      "r892",
      "r1013",
      "r1237"
     ]
    },
    "us-gaap_InterestExpenseBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpenseBorrowings",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Interest Expense, Borrowings, Total",
        "label": "Interest Expense, Borrowings",
        "terseLabel": "Interest expense",
        "documentation": "Aggregate amount of interest expense on all borrowings."
       }
      }
     },
     "auth_ref": [
      "r233"
     ]
    },
    "us-gaap_InterestExpenseBorrowingsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpenseBorrowingsAbstract",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Expense, Borrowings [Abstract]",
        "terseLabel": "Interest expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestExpenseDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpenseDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Expense, Debt",
        "totalLabel": "Total interest and amortization expense",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt."
       }
      }
     },
     "auth_ref": [
      "r181",
      "r502",
      "r513",
      "r978",
      "r979"
     ]
    },
    "us-gaap_InterestExpenseDebtAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpenseDebtAbstract",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Expense, Debt [Abstract]",
        "terseLabel": "Interest expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestExpenseDebtExcludingAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpenseDebtExcludingAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails": {
       "parentTag": "us-gaap_InterestExpenseDebt",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails": {
       "parentTag": "us-gaap_InterestExpenseDebt",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Expense, Debt, Excluding Amortization",
        "terseLabel": "Contractual interest expense",
        "documentation": "Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs."
       }
      }
     },
     "auth_ref": [
      "r183",
      "r503",
      "r978",
      "r979"
     ]
    },
    "us-gaap_InterestExpensePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpensePolicyTextBlock",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Expense, Policy [Policy Text Block]",
        "terseLabel": "Interest Expense on Deferred Royalty Obligation",
        "documentation": "Disclosure of accounting policy for recognizing interest expense, including the method of amortizing debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Income and Interest Expense Disclosure [Table Text Block]",
        "terseLabel": "Schedule of Components of Interest Expense",
        "documentation": "Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestOnConvertibleDebtNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestOnConvertibleDebtNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest on Convertible Debt, Net of Tax",
        "terseLabel": "Add: interest expense on Notes, net of tax effect",
        "documentation": "Amount, after tax, of interest recognized on convertible debt instrument excluding interest on principal required to be paid in cash."
       }
      }
     },
     "auth_ref": [
      "r325",
      "r332",
      "r341"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r291",
      "r295",
      "r296"
     ]
    },
    "us-gaap_InterestPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails",
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Payable, Current",
        "verboseLabel": "Accrued interest payable",
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "inva_InterestRateOfDeferredRoyaltyObligation": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "InterestRateOfDeferredRoyaltyObligation",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate of deferred royalty obligation.",
        "label": "Interest Rate of Deferred Royalty Obligation",
        "terseLabel": "Percentage of interest rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryCurrentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryCurrentTable",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Current [Table]",
        "documentation": "Disclosure of information about inventory expected to be sold or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "inva_InventoryFairValueStepUpAdjustmentIncludedInCostOfProductSales": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "InventoryFairValueStepUpAdjustmentIncludedInCostOfProductSales",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory fair value step-up adjustment included in cost of products sold",
        "label": "Inventory Fair Value Step Up Adjustment Included In Cost Of Product Sales",
        "documentation": "Inventory fair value step-up adjustment included in cost of product sales."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoryNetDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoryNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods",
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r959"
     ]
    },
    "us-gaap_InventoryGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryGross",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Inventory, Gross, Total",
        "label": "Inventory, Gross",
        "terseLabel": "Inventory",
        "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r1119"
     ]
    },
    "us-gaap_InventoryLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryLineItems",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.inva.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoryNetDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoryNetDetails",
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Net",
        "totalLabel": "Total inventory",
        "terseLabel": "Inventory",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r272",
      "r956",
      "r999"
     ]
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryPolicyTextBlock",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventory",
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost."
       }
      }
     },
     "auth_ref": [
      "r240",
      "r260",
      "r271",
      "r442",
      "r443",
      "r444",
      "r766",
      "r966"
     ]
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryRawMaterialsNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoryNetDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoryNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Raw Materials, Net of Reserves",
        "terseLabel": "Raw materials",
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r961"
     ]
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryWorkInProcessNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoryNetDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoryNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work-in-process",
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r960"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsIspFundLpDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Income, Interest",
        "terseLabel": "Investment Income, Interest",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r354"
     ]
    },
    "us-gaap_InvestmentIncomeInterestAndDividend": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentIncomeInterestAndDividend",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsIspFundLpDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Income, Interest and Dividend",
        "totalLabel": "Investment Income, Interest and Dividend, Total",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r178"
     ]
    },
    "us-gaap_InvestmentIncomeInvestmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentIncomeInvestmentExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsIspFundLpDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment-related expenses, net of investment-related income",
        "label": "Investment Income, Investment Expense",
        "documentation": "Amount of expenses related to the generation of investment income."
       }
      }
     },
     "auth_ref": [
      "r182",
      "r1013",
      "r1232"
     ]
    },
    "us-gaap_InvestmentTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentTypeAxis",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Type [Axis]",
        "documentation": "Information by type of investments."
       }
      }
     },
     "auth_ref": [
      "r847",
      "r849",
      "r850",
      "r852",
      "r854",
      "r913",
      "r915",
      "r917",
      "r920",
      "r921",
      "r925",
      "r926",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932",
      "r1004"
     ]
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentTypeCategorizationMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments [Domain]",
        "terseLabel": "Investments [Domain]",
        "documentation": "Asset obtained to generate income or appreciate in value."
       }
      }
     },
     "auth_ref": [
      "r847",
      "r849",
      "r850",
      "r852",
      "r854",
      "r913",
      "r915",
      "r917",
      "r920",
      "r921",
      "r925",
      "r926",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932",
      "r1004"
     ]
    },
    "inva_IspFundLpMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "IspFundLpMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsIspFundLpDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to ISP Fund LP, an investment managed by Sarissa Capital.",
        "label": "Isp Fund Lp [Member]",
        "terseLabel": "ISP Fund LP"
       }
      }
     },
     "auth_ref": []
    },
    "country_JP": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "JP",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "JAPAN",
        "terseLabel": "Japan"
       }
      }
     },
     "auth_ref": []
    },
    "inva_LaJollaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "LaJollaMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "La Jolla",
        "documentation": "La Jolla [Member]",
        "label": "La Jolla [Member]",
        "terseLabel": "La Jolla [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "inva_LaJollaPharmaceuticalCompanyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "LaJollaPharmaceuticalCompanyMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsLaJollaPharmaceuticalCompanyDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsProFormaInformationDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTables",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalTaxDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "La jolla pharmaceutical company member.",
        "label": "La Jolla Pharmaceutical Company [Member]",
        "terseLabel": "La Jolla Pharmaceutical Company"
       }
      }
     },
     "auth_ref": []
    },
    "inva_LabaCollaborationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "LabaCollaborationMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the collaboration with GSK to develop and commercialize once-daily LABA products and combination products RELVAR.",
        "label": "Laba Collaboration [Member]",
        "terseLabel": "Long-Acting Beta2 Agonist (LABA) Collaboration"
       }
      }
     },
     "auth_ref": []
    },
    "inva_LaboratoryEquipmentFurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "LaboratoryEquipmentFurnitureAndFixturesMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory equipment, furniture and fixtures.",
        "label": "Laboratory Equipment, Furniture And Fixtures [Member]",
        "terseLabel": "Laboratory equipment furniture and fixtures"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseContractualTermAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseContractualTermAxis",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Contractual Term [Axis]",
        "documentation": "Information by contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r1102"
     ]
    },
    "us-gaap_LeaseContractualTermDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseContractualTermDomain",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Contractual Term [Domain]",
        "documentation": "Contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r1102"
     ]
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeastCostDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeastCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost",
        "totalLabel": "Total lease costs",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r713",
      "r998"
     ]
    },
    "us-gaap_LeaseCostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCostAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of Components of Lease Cost",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r1217"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legal Entity:",
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Operating Lease",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r712"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r712"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Operating Leases",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r711"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Future Minimum Lease Payments",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1218"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.inva.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total",
        "terseLabel": "Total",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r719"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r719"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r719"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r719"
     ]
    },
    "inva_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Three",
        "documentation": "Lessee, operating lease, liability, to be paid, after year three."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails2": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Less: imputed interest",
        "negatedLabel": "Less: imputed interest",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r719"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Lease term",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1216"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsIspFundLpDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Liabilities, Total",
        "label": "Liabilities",
        "verboseLabel": "Total liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r300",
      "r420",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r644",
      "r647",
      "r648",
      "r686",
      "r863",
      "r969",
      "r1015",
      "r1169",
      "r1221",
      "r1222"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails",
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r166",
      "r228",
      "r802",
      "r999",
      "r1129",
      "r1158",
      "r1215"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails",
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Liabilities and Stockholders Equity",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsSummarizedFinancialDataDetails",
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current",
        "terseLabel": "Current liabilities",
        "totalLabel": "Total current liabilities",
        "verboseLabel": "Current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r259",
      "r300",
      "r420",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r644",
      "r647",
      "r648",
      "r686",
      "r999",
      "r1169",
      "r1221",
      "r1222"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure",
        "terseLabel": "Total liabilities measured at estimated fair value",
        "totalLabel": "Total liabilities at estimated fair value",
        "documentation": "Fair value of financial and nonfinancial obligations."
       }
      }
     },
     "auth_ref": [
      "r133"
     ]
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsSummarizedFinancialDataDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Liabilities, Noncurrent, Total",
        "label": "Liabilities, Noncurrent",
        "terseLabel": "Noncurrent liabilities",
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r154",
      "r155",
      "r156",
      "r159",
      "r300",
      "r420",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r644",
      "r647",
      "r648",
      "r686",
      "r1169",
      "r1221",
      "r1222"
     ]
    },
    "inva_LicenseAndCollaborationArrangementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "LicenseAndCollaborationArrangementsDisclosureTextBlock",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureLicenseAndCollaborationArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License and collaboration arrangements disclosure.",
        "label": "License and Collaboration Arrangements Disclosure [Text Block]",
        "terseLabel": "LICENSE AND COLLABORATION ARRANGEMENTS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LicenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LicenseMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License",
        "label": "License [Member]",
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark."
       }
      }
     },
     "auth_ref": [
      "r1177"
     ]
    },
    "inva_LicenseRevenueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "LicenseRevenueMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License revenue",
        "label": "License Revenue [Member]",
        "documentation": "License revenue member"
       }
      }
     },
     "auth_ref": []
    },
    "inva_LicenseRevenueRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "LicenseRevenueRecognized",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureLicenseAndCollaborationArrangementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License revenue recognized",
        "label": "License Revenue Recognized",
        "documentation": "License revenue recognized."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LimitedPartnersContributedCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LimitedPartnersContributedCapital",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsIspFundLpDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Limited Partners' Contributed Capital",
        "terseLabel": "Contributed to partnership for investing",
        "verboseLabel": "Capital contribution",
        "documentation": "The amount of capital contributed by the limited partners."
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "us-gaap_LimitedPartnersCumulativeCashDistributions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LimitedPartnersCumulativeCashDistributions",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsIspFundLpDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Distribution from partnership",
        "label": "Limited Partners' Cumulative Cash Distributions",
        "documentation": "Aggregate cumulative cash distributions made to the limited partners."
       }
      }
     },
     "auth_ref": [
      "r206"
     ]
    },
    "inva_LimitedPartnersInitialContribution": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "LimitedPartnersInitialContribution",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsIspFundLpDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initial contribution",
        "label": "Limited Partners Initial Contribution",
        "documentation": "Limited partners initial contribution."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityCovenantTerms": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityCovenantTerms",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility, Covenant Terms",
        "terseLabel": "Debt instrument, covenant terms description",
        "documentation": "Description of the conditions for borrowing under the credit facility including the nature of any restrictions."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Term loan facility in aggregate amount",
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "us-gaap_LoanRestructuringModificationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LoanRestructuringModificationAxis",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loan Restructuring Modification [Axis]",
        "documentation": "Information by concessions made to the terms of loan contracts."
       }
      }
     },
     "auth_ref": [
      "r379",
      "r380",
      "r381",
      "r972"
     ]
    },
    "us-gaap_LoanRestructuringModificationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LoanRestructuringModificationDomain",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loan Restructuring Modification [Domain]",
        "documentation": "Concessions made to the terms of loan contracts, including but not limited to, interest rate reductions, maturity extensions, principal forgiveness, and payment deferral."
       }
      }
     },
     "auth_ref": [
      "r379",
      "r380",
      "r381",
      "r972"
     ]
    },
    "us-gaap_LoansPayableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LoansPayableMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loans Payable [Member]",
        "terseLabel": "Loans Payable [Member]",
        "documentation": "Borrowing supported by a written promise to pay an obligation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "inva_LongActingBeta2AgonistAnoroMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "LongActingBeta2AgonistAnoroMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureRevenueRecognitionDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfNetRevenueFromCollaborativeArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Long-Acting Beta2 Agonist, ANORO, which is being developed and commercialized by entering into a strategic alliance with GSK",
        "label": "Long Acting Beta2 Agonist Anoro [Member]",
        "terseLabel": "ANORO"
       }
      }
     },
     "auth_ref": []
    },
    "inva_LongActingBeta2AgonistRelvarBreoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "LongActingBeta2AgonistRelvarBreoMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureRevenueRecognitionDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfNetRevenueFromCollaborativeArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Long-Acting Beta2 Agonist, RELVAR/BREO, which is being developed and commercialized by entering into a strategic alliance with GSK",
        "label": "Long Acting Beta2 Agonist Relvar Breo [Member]",
        "terseLabel": "RELVAR/BREO"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt",
        "totalLabel": "Net carrying amount",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r226",
      "r495",
      "r511",
      "r976",
      "r977",
      "r1230"
     ]
    },
    "us-gaap_LongTermDebtByMaturityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtByMaturityAbstract",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtDebtMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Long-term debt maturities for years ending December 31:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Current Maturities",
        "totalLabel": "Net Carrying Amount",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r268"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtDebtMaturitiesDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtDebtMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Long-Term Debt, Maturity, Year One",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r304",
      "r500"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtDebtMaturitiesDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtDebtMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Long-Term Debt, Maturity, Year Five",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r304",
      "r500"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtDebtMaturitiesDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtDebtMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Long-Term Debt, Maturity, Year Four",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r304",
      "r500"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtDebtMaturitiesDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtDebtMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Long-Term Debt, Maturity, Year Three",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r304",
      "r500"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtDebtMaturitiesDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtDebtMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Long-Term Debt, Maturity, Year Two",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r304",
      "r500"
     ]
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails2": {
       "parentTag": "us-gaap_DebtLongtermAndShorttermCombinedAmount",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails",
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term debt, net of discount and issuance costs",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "totalLabel": "Total long-term debt, net",
        "verboseLabel": "Total long-term debt, net",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r270"
     ]
    },
    "us-gaap_LongTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails",
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity and long-term investments",
        "totalLabel": "Long-term Investments, Total",
        "label": "Long-Term Investments",
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle)."
       }
      }
     },
     "auth_ref": [
      "r262"
     ]
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureNetIncomePerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureNetIncomePerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]",
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r84"
     ]
    },
    "us-gaap_LossContingencyAllegations": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingencyAllegations",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingency, Allegations",
        "terseLabel": "Complaints filed by stockholders",
        "documentation": "Presents an assertion of a fact by a plaintiff in a pleading or complaint, which the plaintiff claims it will prove upon presentation of evidence at the proceeding."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r83",
      "r196"
     ]
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]"
       }
      }
     },
     "auth_ref": [
      "r376",
      "r983",
      "r1176",
      "r1233",
      "r1234"
     ]
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecuritiesPolicy",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "terseLabel": "Investments in Marketable Securities",
        "documentation": "Disclosure of accounting policy for investment classified as marketable security."
       }
      }
     },
     "auth_ref": [
      "r148"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureRevenueRecognitionDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationValuationAssumptionsDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "auth_ref": [
      "r469",
      "r470",
      "r471",
      "r472",
      "r550",
      "r765",
      "r824",
      "r855",
      "r856",
      "r914",
      "r916",
      "r918",
      "r919",
      "r927",
      "r949",
      "r950",
      "r972",
      "r980",
      "r993",
      "r1001",
      "r1173",
      "r1223",
      "r1224",
      "r1225",
      "r1226",
      "r1227",
      "r1228"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r1061"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r1061"
     ]
    },
    "inva_MeasurementPeriodAdjustmentsIncreaseDecreaseInEstimatedPurchasePrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "MeasurementPeriodAdjustmentsIncreaseDecreaseInEstimatedPurchasePrice",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in estimated purchase price during measurement period.",
        "label": "Measurement Period Adjustments, Increase Decrease In estimated Purchase Price",
        "terseLabel": "Measurement period adjustments for change in estimated purchase price"
       }
      }
     },
     "auth_ref": []
    },
    "inva_MeasurementPeriodAdjustmentsIncreaseDecreaseInLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "MeasurementPeriodAdjustmentsIncreaseDecreaseInLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsLaJollaPharmaceuticalCompanyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement period adjustments increase decrease in liabilities",
        "documentation": "Measurement period adjustments increase decrease In liabilities",
        "label": "Measurement Period Adjustments Increase Decrease In liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MembersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MembersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "LLC members' equity",
        "label": "Members' Equity",
        "totalLabel": "Members' Equity, Total",
        "documentation": "Amount of ownership interest in limited liability company (LLC), attributable to the parent entity."
       }
      }
     },
     "auth_ref": [
      "r205",
      "r347",
      "r348",
      "r349",
      "r350"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureRevenueRecognitionDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationValuationAssumptionsDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "auth_ref": [
      "r469",
      "r470",
      "r471",
      "r472",
      "r550",
      "r765",
      "r824",
      "r855",
      "r856",
      "r914",
      "r916",
      "r918",
      "r919",
      "r927",
      "r949",
      "r950",
      "r972",
      "r980",
      "r993",
      "r1001",
      "r1173",
      "r1223",
      "r1224",
      "r1225",
      "r1226",
      "r1227",
      "r1228"
     ]
    },
    "us-gaap_MinorityInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MinorityInterest",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Stockholders' Equity Attributable to Noncontrolling Interest, Ending Balance",
        "periodStartLabel": "Stockholders' Equity Attributable to Noncontrolling Interest, Beginning Balance",
        "totalLabel": "Stockholders' Equity Attributable to Noncontrolling Interest, Total",
        "label": "Equity, Attributable to Noncontrolling Interest",
        "terseLabel": "Noncontrolling interests",
        "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r227",
      "r300",
      "r420",
      "r473",
      "r475",
      "r476",
      "r477",
      "r480",
      "r481",
      "r686",
      "r801",
      "r867"
     ]
    },
    "us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders",
        "negatedTerseLabel": "Distributions to noncontrolling interests",
        "documentation": "Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders."
       }
      }
     },
     "auth_ref": [
      "r205"
     ]
    },
    "inva_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersShares",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Distributions to noncontrolling interest (in shares)",
        "documentation": "Minority interest decrease from distributions to noncontrolling interest holders shares.",
        "label": "Minority Interest Decrease From Distributions To Noncontrolling Interest Holders Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MinorityInterestPeriodIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MinorityInterestPeriodIncreaseDecrease",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Noncontrolling Interest, Period Increase (Decrease), Total",
        "label": "Noncontrolling Interest, Period Increase (Decrease)",
        "terseLabel": "Measurement period adjustments for change in value of noncontrolling interests",
        "documentation": "Net Increase or Decrease in balance of noncontrolling interest in the subsidiary during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r113"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r1081"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsAvailableforsaleSecuritiesDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r1178"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r1089"
     ]
    },
    "inva_NameOfEventAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "NameOfEventAxis",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name Of Event [Axis]",
        "label": "Name Of Event [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "inva_NameOfEventDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "NameOfEventDomain",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name Of Event [Domain]",
        "label": "Name Of Event [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]"
       }
      }
     },
     "auth_ref": [
      "r376",
      "r983",
      "r1176",
      "r1233",
      "r1234"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r1062"
     ]
    },
    "inva_NanoliveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "NanoliveMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInNanoliveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nanolive [Member]",
        "label": "Nanolive [Member]",
        "terseLabel": "Nanolive"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash used in financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r294"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r294"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r185",
      "r186",
      "r187"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsProFormaInformationDetails",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "totalLabel": "Net Income (Loss)",
        "verboseLabel": "Net income attributable to Innoviva stockholders",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r187",
      "r231",
      "r257",
      "r275",
      "r277",
      "r282",
      "r300",
      "r309",
      "r313",
      "r314",
      "r315",
      "r316",
      "r319",
      "r320",
      "r337",
      "r351",
      "r366",
      "r370",
      "r372",
      "r420",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r672",
      "r686",
      "r809",
      "r886",
      "r905",
      "r906",
      "r970",
      "r1013",
      "r1169"
     ]
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfIncome": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails",
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Income (Loss) Attributable to Noncontrolling Interest, Total",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss attributable to noncontrolling interests",
        "negatedLabel": "Net loss attributable to noncontrolling interests",
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r217",
      "r275",
      "r277",
      "r319",
      "r320",
      "r808",
      "r1123"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfIncome": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails",
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss attributable to noncontrolling interest",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "totalLabel": "Net income attributable to Innoviva stockholders",
        "verboseLabel": "Net income attributable to Innoviva stockholders, basic",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r313",
      "r314",
      "r315",
      "r316",
      "r323",
      "r324",
      "r338",
      "r341",
      "r351",
      "r366",
      "r370",
      "r372",
      "r970"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "totalLabel": "Net income attributable to Innoviva stockholders, diluted",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r325",
      "r331",
      "r332",
      "r333",
      "r334",
      "r338",
      "r341"
     ]
    },
    "inva_NetIncomeLossPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "NetIncomeLossPerShareAbstract",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Net Income (Loss) Per Share [Abstract]",
        "terseLabel": "Net income per share attributable to Innoviva stockholders"
       }
      }
     },
     "auth_ref": []
    },
    "inva_NetInvestmentRelatedIncomeExpenseEarnedInccured": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "NetInvestmentRelatedIncomeExpenseEarnedInccured",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsIspFundLpDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net investment-related income (expense) earned (incurred)",
        "label": "Net Investment Related Income Expense Earned Inccured",
        "documentation": "Net investment related income (expense) earned (inccured)."
       }
      }
     },
     "auth_ref": []
    },
    "inva_NetOperatingLossEstimatingDate": {
     "xbrltype": "gYearListItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "NetOperatingLossEstimatingDate",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalTaxDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Operating Loss Estimating Date",
        "label": "Net Operating Loss Estimating Date",
        "terseLabel": "Net operating loss estimating date"
       }
      }
     },
     "auth_ref": []
    },
    "inva_NetProceedsFromSaleOfVariableInterestEntityEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "NetProceedsFromSaleOfVariableInterestEntityEquity",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Proceeds from sale of variable interest entity equity.",
        "label": "Net Proceeds from Sale of Variable Interest Entity Equity",
        "terseLabel": "Proceeds from sale of ownership interest in TRC, net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetRentableArea": {
     "xbrltype": "areaItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetRentableArea",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Rentable Area",
        "terseLabel": "Rentable square feet",
        "documentation": "Net rentable area for properties owned."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recently Issued Accounting Pronouncements Not Yet Adopted",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "inva_NewDebtInstrumentInterestRateAfterRepurchaseOfNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "NewDebtInstrumentInterestRateAfterRepurchaseOfNotesMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "New debt instrument interest rate after repurchase of notes member.",
        "label": "New Debt Instrument Interest Rate After Repurchase Of Notes [Member]",
        "terseLabel": "New Rate [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "inva_NewPrincipalAmountMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "NewPrincipalAmountMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "New principal amount.",
        "label": "New Principal Amount [Member]",
        "terseLabel": "New Principal Amount"
       }
      }
     },
     "auth_ref": []
    },
    "inva_NonCashActivity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "NonCashActivity",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non cash activity.",
        "label": "Non Cash Activity",
        "terseLabel": "Adoption of ASU 2020-06"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r1061"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r1030",
      "r1042",
      "r1052",
      "r1069",
      "r1078"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r1059"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1058"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r1069"
     ]
    },
    "inva_NonRule10B51ArrModifiedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "NonRule10B51ArrModifiedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non Rule 10b51 Arrangement Modified",
        "label": "Non Rule 10B51 Arr Modified Flag",
        "documentation": "Non Rule 10B51 Arr Modified Flag"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r1089"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r1089"
     ]
    },
    "us-gaap_NonUsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonUsMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-US [Member]",
        "terseLabel": "Rest of the world",
        "documentation": "Countries excluding the United States of America (US)."
       }
      }
     },
     "auth_ref": [
      "r1240",
      "r1242",
      "r1243",
      "r1244"
     ]
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Supplemental Disclosure of Non-cash Investing and Financing Activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncontrollingInterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncontrollingInterestMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Noncontrolling Interest",
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r530",
      "r1132",
      "r1133",
      "r1134",
      "r1238"
     ]
    },
    "inva_NoteAmendmentAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "NoteAmendmentAgreementMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInGateNeurosciencesDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Note amendment agreement member.",
        "label": "Note Amendment Agreement [Member]",
        "terseLabel": "Note Amendment Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "inva_NumberOfBoardMembersOfInvestee": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "NumberOfBoardMembersOfInvestee",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInImaginabDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInNanoliveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of the Investee's Board members",
        "label": "Number of Board Members of the Investee",
        "documentation": "The total number of Board members of the Investee."
       }
      }
     },
     "auth_ref": []
    },
    "inva_NumberOfCommonStockIssuedDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "NumberOfCommonStockIssuedDescription",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInGateNeurosciencesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of common stock issued description",
        "label": "Number Of Common Stock Issued Description",
        "documentation": "Number of common stock issued description."
       }
      }
     },
     "auth_ref": []
    },
    "inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInImaginabDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInNanoliveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Investee's Board members currently representing the Company",
        "label": "Number of the Company's Board Members Currently Serving on the Board of Investee",
        "documentation": "The number of the Company's Board members currently serving on the Investee's Board."
       }
      }
     },
     "auth_ref": []
    },
    "inva_NumberOfCustomers": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "NumberOfCustomers",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of customers.",
        "label": "Number Of Customers",
        "terseLabel": "Number of customers"
       }
      }
     },
     "auth_ref": []
    },
    "inva_NumberOfDerivativeInstrumentsPurchased": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "NumberOfDerivativeInstrumentsPurchased",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of derivative instruments purchased.",
        "label": "Number of Derivative Instruments Purchased",
        "terseLabel": "Number of derivative instruments purchased"
       }
      }
     },
     "auth_ref": []
    },
    "inva_NumberOfSharesReceivableOnSettlementOfDerivativeInstrument": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "NumberOfSharesReceivableOnSettlementOfDerivativeInstrument",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of shares payable to the entity on settlement of derivative instruments.",
        "label": "Number of Shares Receivable on Settlement of Derivative Instrument",
        "terseLabel": "Net shares settlement payable to the entity"
       }
      }
     },
     "auth_ref": []
    },
    "inva_NumeratorAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "NumeratorAbstract",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Numerator [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "auth_ref": []
    },
    "inva_OldDebtInstrumentInterestRateBeforeRepurchaseOfNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "OldDebtInstrumentInterestRateBeforeRepurchaseOfNotesMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Old debt instrument interest rate before repurchase of notes member.",
        "label": "Old Debt Instrument Interest Rate Before Repurchase Of Notes [Member]",
        "terseLabel": "Old Rate [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "inva_OneDirectorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "OneDirectorMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One Director.",
        "label": "One Director [Member]",
        "terseLabel": "One Director"
       }
      }
     },
     "auth_ref": []
    },
    "inva_OneOfImaginabsCommonStockholderMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "OneOfImaginabsCommonStockholderMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInImaginabDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "One of ImaginAb's Common Stockholders",
        "label": "One Of Imaginabs Common Stockholder [Member]",
        "documentation": "Represents information pertaining to one of ImaginAb's common stockholders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails2": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses",
        "terseLabel": "Operating expenses",
        "totalLabel": "Total expenses",
        "verboseLabel": "Operating expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails2": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsSummarizedFinancialDataDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income (Loss)",
        "totalLabel": "Income from operations",
        "verboseLabel": "Loss from operations",
        "terseLabel": "Operating expenses",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r351",
      "r366",
      "r370",
      "r372",
      "r970"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeastCostDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeastCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Straight line operating lease costs",
        "label": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r714",
      "r998"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails2": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability",
        "totalLabel": "Total operating lease liabilities",
        "terseLabel": "Total operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r708"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current portion of lease liabilities included within Other accrued liabilities",
        "verboseLabel": "Current portion of lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r708"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r709"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherLongtermLiabilitiesDetails": {
       "parentTag": "us-gaap_OtherLiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherLongtermLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Long-term portion of lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r708"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherLongtermLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r709"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r709"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalCashFlowInformationRelatedToLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash paid for amounts included in the measurement of operating lease liabilities:",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r710",
      "r716"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset",
        "verboseLabel": "Right-of-use assets",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r707"
     ]
    },
    "inva_OperatingLeaseWeightedAverageIncrementalBorrowingRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "OperatingLeaseWeightedAverageIncrementalBorrowingRate",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease Weighted Average Incremental Borrowing Rate",
        "label": "Operating Lease Weighted Average Incremental Borrowing Rate",
        "terseLabel": "Operating lease, weighted average incremental borrowing rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Operating lease, Weighted average remaining lease term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r718",
      "r998"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalTaxDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating Loss Carryforwards, Total",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r105"
     ]
    },
    "inva_OperatingLossCarryforwardsIndefinitePeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "OperatingLossCarryforwardsIndefinitePeriod",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalTaxDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net operating loss carryforwards which can be carry forward indefinitely.",
        "label": "Operating Loss Carryforwards, Indefinite Period",
        "terseLabel": "Net operating loss carryforwards, indefinite period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OptionIndexedToIssuersEquityStrikePrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OptionIndexedToIssuersEquityStrikePrice1",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Indexed to Issuer's Equity, Strike Price",
        "terseLabel": "Strike price for the underlying number of shares (in dollars per share)",
        "documentation": "Exercise or strike price stated in the contract for options indexed to the issuer's equity shares."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r29"
     ]
    },
    "us-gaap_OptionIndexedToIssuersEquityTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OptionIndexedToIssuersEquityTypeAxis",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Indexed to Issuer's Equity, Type [Axis]",
        "documentation": "Information by type of freestanding contracts issued by an entity that are indexed to, and potentially settled in, an entity's own stock."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r131",
      "r132",
      "r218"
     ]
    },
    "us-gaap_OptionIndexedToIssuersEquityTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OptionIndexedToIssuersEquityTypeDomain",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Indexed to Issuer's Equity, Type [Domain]",
        "terseLabel": "Option Indexed to Issuer's Equity, Type [Domain]",
        "documentation": "Description of the type of freestanding contract issued by a Company that is indexed to, and potentially settled in, a Company's own stock. Specifically, the pertinent rights and privileges of the securities outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "inva_OptionPricingModelBacksolveValuationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "OptionPricingModelBacksolveValuationMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Option Pricing Model Backsolve valuation.",
        "label": "Option Pricing Model Backsolve Valuation [Member]",
        "terseLabel": "Backsolve Valuation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "verboseLabel": "DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r188",
      "r189",
      "r215"
     ]
    },
    "inva_OtherAccruedLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "OtherAccruedLiabilitiesMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Accrued Liabilities [Member]",
        "label": "Other Accrued Liabilities [Member]",
        "terseLabel": "Other Accrued Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r273",
      "r999"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other Assets, Noncurrent, Total",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r265"
     ]
    },
    "us-gaap_OtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other Liabilities, Total",
        "label": "Other Liabilities",
        "terseLabel": "Other",
        "documentation": "Amount of liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r793",
      "r859",
      "r860",
      "r1015",
      "r1236"
     ]
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other Liabilities, Current, Total",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other accrued liabilities",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r999"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.inva.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherLongtermLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherLongtermLiabilitiesDetails",
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities",
        "totalLabel": "Total other long-term liabilities",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNoncashIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 23.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other Noncash Income (Expense), Total",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Other non-cash items",
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other."
       }
      }
     },
     "auth_ref": [
      "r187"
     ]
    },
    "us-gaap_OtherNoncurrentLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNoncurrentLiabilitiesMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Noncurrent Liabilities [Member]",
        "terseLabel": "Other Noncurrent Liabilities",
        "verboseLabel": "Other Long Term Liabilities",
        "documentation": "Primary financial statement caption encompassing other noncurrent liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNoncurrentLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNoncurrentLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Noncurrent Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Other Long-term Liabilities",
        "documentation": "Tabular disclosure of other noncurrent liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails2": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfIncome": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails",
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other expense, net",
        "verboseLabel": "Other income, net",
        "totalLabel": "Other Nonoperating Income (Expense), Total",
        "label": "Other Nonoperating Income (Expense)",
        "negatedLabel": "Other expense, net",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r182"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r1061"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1028",
      "r1040",
      "r1050",
      "r1076"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1031",
      "r1043",
      "r1053",
      "r1079"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r1031",
      "r1043",
      "r1053",
      "r1079"
     ]
    },
    "inva_OutstandingStockWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "OutstandingStockWarrantMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureNetIncomePerShareAntiDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding stock warrant member",
        "label": "Outstanding Stock Warrant [Member]",
        "terseLabel": "Outstanding Stock Warrant"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OverAllotmentOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OverAllotmentOptionMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Over-Allotment Option",
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment."
       }
      }
     },
     "auth_ref": []
    },
    "inva_OwnershipInterestInConsolidatedEntities": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "OwnershipInterestInConsolidatedEntities",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ownership interest in consolidated entities.",
        "label": "Ownership Interest in Consolidated Entities",
        "terseLabel": "Ownership interest in LLC"
       }
      }
     },
     "auth_ref": []
    },
    "inva_PaionAgMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "PaionAgMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureLicenseAndCollaborationArrangementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PAION AG [Member]",
        "label": "PAION AG [Member]",
        "terseLabel": "PAION AG"
       }
      }
     },
     "auth_ref": []
    },
    "inva_ParatekPharmaceuticalsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "ParatekPharmaceuticalsIncMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureLicenseAndCollaborationArrangementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Paratek Pharmaceuticals, Inc.",
        "label": "Paratek Pharmaceuticals, Inc [Member]",
        "terseLabel": "Paratek Pharmaceuticals, Inc"
       }
      }
     },
     "auth_ref": []
    },
    "inva_PartnershipAgreementLockUpPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "PartnershipAgreementLockUpPeriod",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsIspFundLpDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The period of time in which contributors to an investment fund have waived the right of redemption, as defined in the partnership agreement.",
        "label": "Partnership Agreement, Lock-Up Period",
        "terseLabel": "Lock-up period"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r1057"
     ]
    },
    "us-gaap_PaymentOfFinancingAndStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentOfFinancingAndStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Payment of Financing and Stock Issuance Costs, Total",
        "label": "Payment of Financing and Stock Issuance Costs",
        "terseLabel": "Total issuance costs",
        "documentation": "The total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "inva_PaymentOfManagementAndIncentiveFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "PaymentOfManagementAndIncentiveFee",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsIspFundLpDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment for management and annual performance incentive fees",
        "label": "Payment of Management and Incentive fee",
        "documentation": "Payment of management and Incentive fee"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments for Repurchase of Common Stock",
        "negatedLabel": "Repurchase of common stock",
        "documentation": "The cash outflow to reacquire common stock during the period."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "inva_PaymentsForRoyaltyAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "PaymentsForRoyaltyAgreement",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments For Royalty Agreement",
        "label": "Payments For Royalty Agreement",
        "terseLabel": "Payment for royalty agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfDebtIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments of Debt Issuance Costs",
        "terseLabel": "Liability issuance costs",
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInImaginabDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInNanoliveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transaction costs to acquire equity securities",
        "label": "Payments of Stock Issuance Costs",
        "verboseLabel": "Equity issuance costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "negatedLabel": "Repurchase of shares to satisfy tax withholding",
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r290"
     ]
    },
    "us-gaap_PaymentsToAcquireEquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireEquityMethodInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of equity method investments",
        "label": "Payments to Acquire Equity Method Investments",
        "documentation": "The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_PaymentsToAcquireEquitySecuritiesFvNi": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireEquitySecuritiesFvNi",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payments to acquire equity securities",
        "label": "Payments to Acquire Equity Securities, FV-NI",
        "documentation": "Amount of cash outflow to acquire investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity."
       }
      }
     },
     "auth_ref": [
      "r238",
      "r292"
     ]
    },
    "us-gaap_PaymentsToAcquireLongtermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireLongtermInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInGateNeurosciencesDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional cash investment",
        "negatedTerseLabel": "Purchases of equity and long term investments",
        "label": "Payments to Acquire Long-Term Investments",
        "verboseLabel": "Initial contribution",
        "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, beyond the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the long-term."
       }
      }
     },
     "auth_ref": [
      "r1124"
     ]
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireMarketableSecurities",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of trading securities",
        "totalLabel": "Payments to Acquire Marketable Securities, Total",
        "label": "Payments to Acquire Marketable Securities",
        "documentation": "Amount of cash outflow for purchase of marketable security."
       }
      }
     },
     "auth_ref": [
      "r1139"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r184"
     ]
    },
    "us-gaap_PaymentsToMinorityShareholders": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToMinorityShareholders",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Noncontrolling Interests",
        "negatedLabel": "Distributions to noncontrolling interest",
        "documentation": "Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r1060"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r1060"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1059"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r1069"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r1062"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1058"
     ]
    },
    "inva_Percent2.50ConvertibleDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "Percent2.50ConvertibleDebtMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to 2.50% convertible senior notes due 2025.",
        "label": "Percent2.50 Convertible Debt [Member]",
        "terseLabel": "2025 Notes"
       }
      }
     },
     "auth_ref": []
    },
    "inva_PercentageOfEconomicInterestInPartnership": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "PercentageOfEconomicInterestInPartnership",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsIspFundLpDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Economic interest of the Partnership (in percent)",
        "documentation": "Percentage of economic interest held in Partnership.",
        "label": "Percentage of Economic Interest In Partnership"
       }
      }
     },
     "auth_ref": []
    },
    "inva_PercentageOfEconomicInterestOnFuturePaymentsUnderAgreements": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "PercentageOfEconomicInterestOnFuturePaymentsUnderAgreements",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of economic interest in any future payments made under the agreements.",
        "label": "Percentage of Economic Interest on Future Payments Under Agreements",
        "terseLabel": "Percentage of economic interest in any future payments made under the agreements"
       }
      }
     },
     "auth_ref": []
    },
    "inva_PercentageOfEstimatedVolatility": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "PercentageOfEstimatedVolatility",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of estimated volatility.",
        "label": "Percentage of Estimated Volatility",
        "terseLabel": "Estimated volatility"
       }
      }
     },
     "auth_ref": []
    },
    "inva_PercentageOfMaximumRoyaltyBasedOnAchievementOfAnnualNetProductSalesThresholds": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "PercentageOfMaximumRoyaltyBasedOnAchievementOfAnnualNetProductSalesThresholds",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureLicenseAndCollaborationArrangementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of maximum royalty based on achievement of annual net product sales thresholds.",
        "label": "Percentage Of Maximum Royalty Based On Achievement Of Annual Net Product Sales Thresholds",
        "terseLabel": "Percentage of maximum royalty based on achievement of annual net product sales thresholds"
       }
      }
     },
     "auth_ref": []
    },
    "inva_PercentageOfMinimumRoyaltyRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "PercentageOfMinimumRoyaltyRate",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureLicenseAndCollaborationArrangementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of minimum royalty rate.",
        "label": "Percentage Of Minimum Royalty Rate",
        "terseLabel": "Percentage of minimum royalty rate"
       }
      }
     },
     "auth_ref": []
    },
    "inva_PercentageOfReimbursedForDirectAndCertainIndirectManufacturingCosts": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "PercentageOfReimbursedForDirectAndCertainIndirectManufacturingCosts",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureLicenseAndCollaborationArrangementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of reimbursed for direct and certain indirect manufacturing costs.",
        "label": "Percentage Of Reimbursed For Direct And Certain Indirect Manufacturing Costs",
        "terseLabel": "Percentage of reimbursed for direct and certain indirect manufacturing costs"
       }
      }
     },
     "auth_ref": []
    },
    "inva_PercentageOfRoyaltyOnPaymentsReceivedFromSublicensees": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "PercentageOfRoyaltyOnPaymentsReceivedFromSublicensees",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureLicenseAndCollaborationArrangementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage Of Royalty On Payments Received From Sublicensees",
        "terseLabel": "Percentage of royalty on payments received from sublicensees",
        "documentation": "Represents the royalty payable as a percentage of payments received from sublicensees."
       }
      }
     },
     "auth_ref": []
    },
    "inva_PercentageOfRoyaltyPayableOnNetSales": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "PercentageOfRoyaltyPayableOnNetSales",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureLicenseAndCollaborationArrangementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the royalty payable, as a percentage of net sales.",
        "label": "Percentage Of Royalty Payable On Net Sales",
        "terseLabel": "Percentage of royalty payable on net sales"
       }
      }
     },
     "auth_ref": []
    },
    "inva_PercentageOfRoyaltyPaymentsNotEntitledToReceive": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "PercentageOfRoyaltyPaymentsNotEntitledToReceive",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of royalty payments the company is not entitled to receive.",
        "label": "Percentage of royalty payments not entitled to receive"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensation2012PlanAndEsppDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1179",
      "r1180",
      "r1181",
      "r1182",
      "r1183",
      "r1184",
      "r1185",
      "r1186",
      "r1187",
      "r1188",
      "r1189",
      "r1190",
      "r1191",
      "r1192",
      "r1193",
      "r1194",
      "r1195",
      "r1196",
      "r1197",
      "r1198",
      "r1199",
      "r1200",
      "r1201",
      "r1202",
      "r1203",
      "r1204"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensation2012PlanAndEsppDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1179",
      "r1180",
      "r1181",
      "r1182",
      "r1183",
      "r1184",
      "r1185",
      "r1186",
      "r1187",
      "r1188",
      "r1189",
      "r1190",
      "r1191",
      "r1192",
      "r1193",
      "r1194",
      "r1195",
      "r1196",
      "r1197",
      "r1198",
      "r1199",
      "r1200",
      "r1201",
      "r1202",
      "r1203",
      "r1204"
     ]
    },
    "inva_PortionOfDebtInstrumentFaceAmountExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "PortionOfDebtInstrumentFaceAmountExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Portion of debt instrument face amount, exercised.",
        "label": "Portion of Debt Instrument Face Amount, Exercised",
        "terseLabel": "Portion of debt instrument face amount, Exercised"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r515"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r865"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Preferred Stock, Shares Issued, Total",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued",
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r515"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance",
        "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r865",
      "r884",
      "r1238",
      "r1239"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Preferred Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Preferred Stock, Value, Issued, Beginning Balance",
        "totalLabel": "Preferred Stock, Value, Issued, Total",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock: $0.01 par value, 230 shares authorized, no shares issued and outstanding",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r798",
      "r999"
     ]
    },
    "inva_PreferredStockWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "PreferredStockWarrantsMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock warrants.",
        "label": "Preferred Stock Warrants Member",
        "terseLabel": "Preferred Stock Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails",
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "verboseLabel": "Prepaid expenses",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1120"
     ]
    },
    "inva_PresentationReclassificationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "PresentationReclassificationPolicyTextBlock",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Presentation reclassification.",
        "label": "Presentation Reclassification [Policy Text Block]",
        "terseLabel": "Presentation Reclassification"
       }
      }
     },
     "auth_ref": []
    },
    "inva_PriorPeriodImmaterialCorrectionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "PriorPeriodImmaterialCorrectionPolicyTextBlock",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reporting prior period immaterial correction.",
        "label": "Prior Period Immaterial Correction [Policy Text Block]",
        "terseLabel": "Prior Period Immaterial Correction"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement [Member]",
        "terseLabel": "Private Placement",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "inva_PrivatePlacementPositionsAndConvertibleNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "PrivatePlacementPositionsAndConvertibleNotesMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Private Placement Positions And Convertible Notes.",
        "label": "Private Placement Positions And Convertible Notes [Member]",
        "terseLabel": "Private Placement Positions And Convertible Notes"
       }
      }
     },
     "auth_ref": []
    },
    "inva_PrivatelyNegotiatedCappedCallOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "PrivatelyNegotiatedCappedCallOptionMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the capped call option entered in connection with the offering of convertible debt.",
        "label": "Privately Negotiated Capped Call Option [Member]",
        "terseLabel": "Privately-negotiated capped call option"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromConvertibleDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Convertible Debt",
        "terseLabel": "Proceeds from issuance of convertible notes, net of issuance costs",
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuances of common stock, net",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Debt",
        "terseLabel": "Proceeds from issuance of convertible senior notes due 2028, net of issuance costs",
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt."
       }
      }
     },
     "auth_ref": [
      "r1125"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Proceeds from Issuance or Sale of Equity, Total",
        "label": "Proceeds from Issuance or Sale of Equity",
        "terseLabel": "Gross Proceeds from sale of equity",
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r840"
     ]
    },
    "inva_ProceedsFromSaleOfEconomicInterestUnderEquityPurchaseAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "ProceedsFromSaleOfEconomicInterestUnderEquityPurchaseAgreement",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from sale of economic interest under Equity Purchase Agreement.",
        "label": "Proceeds from sale of economic interest under Equity Purchase Agreement",
        "terseLabel": "Proceeds from sale of economic interest under Equity Purchase Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProductMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product [Member]",
        "terseLabel": "Net product sales",
        "documentation": "Article or substance produced by nature, labor or machinery."
       }
      }
     },
     "auth_ref": [
      "r981"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureLicenseAndCollaborationArrangementsAdditionalInformationDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureRevenueRecognitionDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfNetRevenueFromCollaborativeArrangementsDetails",
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfIncome",
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfIncomeParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r373",
      "r767",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r953",
      "r981",
      "r1000",
      "r1103",
      "r1166",
      "r1167",
      "r1176",
      "r1233"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureLicenseAndCollaborationArrangementsAdditionalInformationDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureRevenueRecognitionDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfNetRevenueFromCollaborativeArrangementsDetails",
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfIncome",
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfIncomeParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Products and Services [Domain]"
       }
      }
     },
     "auth_ref": [
      "r373",
      "r767",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r953",
      "r981",
      "r1000",
      "r1103",
      "r1166",
      "r1167",
      "r1176",
      "r1233"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfIncome": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveIncome": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsSummarizedFinancialDataDetails",
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveIncome",
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfIncome",
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net loss",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income",
        "totalLabel": "Net income",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r257",
      "r275",
      "r277",
      "r293",
      "r300",
      "r309",
      "r319",
      "r320",
      "r351",
      "r366",
      "r370",
      "r372",
      "r420",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r642",
      "r645",
      "r646",
      "r672",
      "r686",
      "r791",
      "r807",
      "r844",
      "r886",
      "r905",
      "r906",
      "r970",
      "r996",
      "r997",
      "r1014",
      "r1123",
      "r1169"
     ]
    },
    "inva_ProfitLossShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "ProfitLossShares",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net income (in shares)",
        "label": "Profit Loss Shares",
        "documentation": "Profit Loss Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, equipment and leasehold improvements",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance",
        "totalLabel": "Property, Plant and Equipment, Net, Total",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r792",
      "r804",
      "r999"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r244",
      "r247",
      "r803"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r194"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated useful life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "inva_PropertyPlantAndEquipmentUsefulLifeTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "PropertyPlantAndEquipmentUsefulLifeTableTextBlock",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the useful life of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property, Plant and Equipment Useful Life [Table Text Block]",
        "terseLabel": "Schedule of property, equipment and leasehold improvements useful lives"
       }
      }
     },
     "auth_ref": []
    },
    "inva_PurchaseAndSaleOfOtherInvestmentsManagedByIspFundLp": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "PurchaseAndSaleOfOtherInvestmentsManagedByIspFundLp",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase and sale of other investments managed by ISP FUND LP",
        "documentation": "Purchase and sale of other investments managed by ISP FUND LP",
        "negatedLabel": "Purchase and sales of other investments managed by ISP Fund LP, net",
        "terseLabel": "Purchase and sales of other investments managed by ISP Fund LP, net"
       }
      }
     },
     "auth_ref": []
    },
    "inva_PurchaseOfEntasisNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "PurchaseOfEntasisNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase of entasis noncontrolling interest.",
        "label": "Purchase Of Entasis noncontrolling Interest",
        "negatedLabel": "Purchase of Entasis noncontrolling interest"
       }
      }
     },
     "auth_ref": []
    },
    "inva_PurchasesOfCappedCallOptionsAssociatedWithConvertibleSeniorNotes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "PurchasesOfCappedCallOptionsAssociatedWithConvertibleSeniorNotes",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchases of capped call options associated with convertible senior notes.",
        "label": "Purchases of Capped Call Options Associated with Convertible Senior Notes",
        "negatedLabel": "Purchases of capped call options associated with convertible senior notes due 2028"
       }
      }
     },
     "auth_ref": []
    },
    "inva_PurchasesOfCappedCallsInConnectionWithConvertibleSeniorNotes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "PurchasesOfCappedCallsInConnectionWithConvertibleSeniorNotes",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchases of capped calls In connection with convertible senior notes.",
        "label": "Purchases Of Capped Calls In Connection With Convertible Senior Notes",
        "terseLabel": "Purchases of capped calls in connection with convertible senior notes due 2028"
       }
      }
     },
     "auth_ref": []
    },
    "inva_PurchasesOfEquityInvestmentsManagedByIspFundLp": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "PurchasesOfEquityInvestmentsManagedByIspFundLp",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchases of Equity Investments Managed by Isp Fund Lp",
        "label": "Purchases of Equity Investments Managed by Isp Fund Lp",
        "negatedLabel": "Purchases of equity investments managed by ISP Fund LP"
       }
      }
     },
     "auth_ref": []
    },
    "inva_PurchasesOfTradingSecurityManagedByIspFundLp": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "PurchasesOfTradingSecurityManagedByIspFundLp",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchases of trading security managed by Isp fund Lp.",
        "label": "Purchases of Trading Security Managed by Isp Fund Lp",
        "negatedLabel": "Purchases of trading security managed by ISP Fund LP"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PutOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PutOptionMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Put Option [Member]",
        "terseLabel": "Stock prices above $38.00 per share",
        "documentation": "A financial contract between two parties, the buyer and the seller (writer) of the option, where the buyer has the right but not the obligation to sell a commodity or financial instrument (the underlying instrument) to the seller (writer) at a certain time for a certain price (the strike price). The seller (writer) has the obligation to purchase the underlying asset at that strike price, if the buyer exercises the option."
       }
      }
     },
     "auth_ref": [
      "r922",
      "r923",
      "r924"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r1057"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r1057"
     ]
    },
    "inva_QualifiedFinancingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "QualifiedFinancingMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Qualified Financing [Member]",
        "label": "Qualified Financing [Member]",
        "terseLabel": "Qualified Financing"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureRevenueRecognitionDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationValuationAssumptionsDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r469",
      "r470",
      "r471",
      "r472",
      "r542",
      "r550",
      "r582",
      "r583",
      "r584",
      "r738",
      "r765",
      "r824",
      "r855",
      "r856",
      "r914",
      "r916",
      "r918",
      "r919",
      "r927",
      "r949",
      "r950",
      "r972",
      "r980",
      "r993",
      "r1001",
      "r1004",
      "r1164",
      "r1173",
      "r1224",
      "r1225",
      "r1226",
      "r1227",
      "r1228"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureRevenueRecognitionDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationValuationAssumptionsDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "auth_ref": [
      "r469",
      "r470",
      "r471",
      "r472",
      "r542",
      "r550",
      "r582",
      "r583",
      "r584",
      "r738",
      "r765",
      "r824",
      "r855",
      "r856",
      "r914",
      "r916",
      "r918",
      "r919",
      "r927",
      "r949",
      "r950",
      "r972",
      "r980",
      "r993",
      "r1001",
      "r1004",
      "r1164",
      "r1173",
      "r1224",
      "r1225",
      "r1226",
      "r1227",
      "r1228"
     ]
    },
    "inva_RealizedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "RealizedLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails2": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Realized loss",
        "label": "Realized Loss",
        "terseLabel": "Realized loss"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReceivablesLongTermContractsOrPrograms": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReceivablesLongTermContractsOrPrograms",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivables, Long-Term Contracts or Programs",
        "terseLabel": "Receivables from collaboration arrangements",
        "documentation": "Amount to be collected within one year of the balance sheet date (or one operating cycle, if longer) from customers in accordance with the contractual provisions of long-term contracts or programs including amounts billed and unbilled as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r1118"
     ]
    },
    "inva_RecognitionOfNoncontrollingInterestUponInitialConsolidationOfEntasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "RecognitionOfNoncontrollingInterestUponInitialConsolidationOfEntasis",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recognition Of Noncontrolling Interest Upon Initial Consolidation Of Entasis",
        "label": "Recognition of noncontrolling interest upon initial consolidation of Entasis"
       }
      }
     },
     "auth_ref": []
    },
    "inva_RecognitionOfNoncontrollingInterestUponInitialConsolidationofEntasisShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "RecognitionOfNoncontrollingInterestUponInitialConsolidationofEntasisShares",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recognition of noncontrolling interest upon initial consolidation of Entasis (in shares)",
        "label": "Recognition Of Noncontrolling Interest Upon Initial ConsolidationOf Entasis, Shares",
        "documentation": "Recognition of noncontrolling interest upon initial consolidation of Entasis, Shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalTaxDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "terseLabel": "Uncertain Tax Positions",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r1023",
      "r1035",
      "r1045",
      "r1071"
     ]
    },
    "inva_ReductionToAdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "ReductionToAdditionalPaidInCapital",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reduction to additional paid in capital",
        "label": "Reduction to Additional Paid in Capital",
        "terseLabel": "Reduction to Additional Paid in Capital"
       }
      }
     },
     "auth_ref": []
    },
    "inva_ReductionToResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "ReductionToResearchAndDevelopmentExpense",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureLicenseAndCollaborationArrangementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reduction to Research and Development Expense",
        "label": "Reduction to Research and Development Expense",
        "terseLabel": "Reduction to research and development expense"
       }
      }
     },
     "auth_ref": []
    },
    "inva_RegulatoryMilestonePaymentsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "RegulatoryMilestonePaymentsReceivable",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureLicenseAndCollaborationArrangementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regulatory milestone payments receivable.",
        "label": "Regulatory Milestone Payments Receivable",
        "terseLabel": "Additional regulatory milestone payments receivable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsIspFundLpDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesRelatedPartyTransactionsDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureRevenueRecognitionDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfNetRevenueFromCollaborativeArrangementsDetails",
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfIncomeParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party, Type [Domain]",
        "terseLabel": "Related Party [Domain]",
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r549",
      "r725",
      "r726",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r883",
      "r885",
      "r912"
     ]
    },
    "inva_RelatedPartyTransactionCommonStockOwnershipPercentageByRelatedParty": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "RelatedPartyTransactionCommonStockOwnershipPercentageByRelatedParty",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock in the reporting entity owned by related parties.",
        "label": "Related Party Transaction, Common Stock Ownership Percentage By Related Party",
        "terseLabel": "Percentage of common stock owned by a related party"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Parties",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r889",
      "r890",
      "r891"
     ]
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsIspFundLpDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesRelatedPartyTransactionsDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureRevenueRecognitionDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfNetRevenueFromCollaborativeArrangementsDetails",
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfIncomeParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party, Type [Axis]",
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r549",
      "r725",
      "r726",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r883",
      "r885",
      "r912",
      "r1220"
     ]
    },
    "inva_RelatedPartyTransactionsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "RelatedPartyTransactionsPolicyTextBlock",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the entity's accounting policies for transactions entered with related parties.",
        "label": "Related Party Transactions [Policy Text Block]",
        "terseLabel": "Related Parties"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RepaymentsOfConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfConvertibleDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repayments of Convertible Debt",
        "terseLabel": "Payment towards convertible promissory note",
        "documentation": "The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_RepaymentsOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureLicenseAndCollaborationArrangementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty payments",
        "label": "Repayments of Debt",
        "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation."
       }
      }
     },
     "auth_ref": [
      "r1126"
     ]
    },
    "us-gaap_RepaymentsOfUnsecuredDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfUnsecuredDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails",
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repayments of Unsecured Debt",
        "negatedLabel": "Payment for repurchase of convertible subordinated notes due 2023",
        "terseLabel": "Payment for repurchase of debt instrument",
        "documentation": "The cash outflow to repay long-term debt that is not secured by collateral. Excludes repayments of tax exempt unsecured debt."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInImaginabDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureLicenseAndCollaborationArrangementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r302",
      "r303",
      "r486",
      "r517",
      "r727",
      "r963",
      "r964"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfIncome": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Research and Development Expense, Total",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r600",
      "r1229"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r599"
     ]
    },
    "inva_ResearchAndDevelopmentSupportMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "ResearchAndDevelopmentSupportMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureLicenseAndCollaborationArrangementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and Development Support [Member]",
        "label": "Research and Development Support [Member]",
        "terseLabel": "Research and Development Support"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalTaxDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research Tax Credit Carryforward [Member]",
        "terseLabel": "Research and development",
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes."
       }
      }
     },
     "auth_ref": [
      "r104"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r1024",
      "r1036",
      "r1046",
      "r1072"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r1025",
      "r1037",
      "r1047",
      "r1073"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r1032",
      "r1044",
      "r1054",
      "r1080"
     ]
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationCompensationAwardsDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock [Member]",
        "terseLabel": "RSAs",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationCompensationAwardsDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationDirectorCompensationProgramDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "RSUs",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance",
        "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance",
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r205",
      "r800",
      "r831",
      "r836",
      "r841",
      "r866",
      "r999"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r254",
      "r305",
      "r306",
      "r307",
      "r310",
      "r318",
      "r320",
      "r424",
      "r430",
      "r591",
      "r592",
      "r593",
      "r626",
      "r627",
      "r652",
      "r655",
      "r656",
      "r659",
      "r670",
      "r827",
      "r829",
      "r845",
      "r1238"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerAbstract",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails2": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfIncome": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.inva.com/20231231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfNetRevenueFromCollaborativeArrangementsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsSummarizedFinancialDataDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureLicenseAndCollaborationArrangementsAdditionalInformationDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureRevenueRecognitionDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfNetRevenueFromCollaborativeArrangementsDetails",
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total royalty revenue",
        "negatedTerseLabel": "License revenue",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Total revenue",
        "verboseLabel": "Total net revenue",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r352",
      "r353",
      "r365",
      "r368",
      "r369",
      "r373",
      "r374",
      "r376",
      "r539",
      "r540",
      "r767"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureRevenueRecognition1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Text Block]",
        "verboseLabel": "REVENUE RECOGNITION",
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts."
       }
      }
     },
     "auth_ref": [
      "r251",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r541"
     ]
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue Recognition",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r887",
      "r952",
      "r967"
     ]
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Revenues",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureLicenseAndCollaborationArrangementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue",
        "totalLabel": "Revenues, Total",
        "label": "Revenues",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r284",
      "r300",
      "r352",
      "r353",
      "r365",
      "r368",
      "r369",
      "r373",
      "r374",
      "r376",
      "r420",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r686",
      "r791",
      "r1169"
     ]
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalCashFlowInformationRelatedToLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Operating lease right-of-use assets obtained in exchange for operating lease obligations",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r717",
      "r998"
     ]
    },
    "inva_RightOfUseAssetsObtainedThroughAcquistions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "RightOfUseAssetsObtainedThroughAcquistions",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalCashFlowInformationRelatedToLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right of Use Assets Obtained Through Acquistions",
        "label": "Right of Use Assets Obtained Through Acquistions",
        "terseLabel": "Right-of-use assets obtained through acquisitions"
       }
      }
     },
     "auth_ref": []
    },
    "inva_RiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "RiskFreeInterestRate",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Risk free interest rate.",
        "label": "Risk Free Interest Rate",
        "terseLabel": "Risk free interest rate"
       }
      }
     },
     "auth_ref": []
    },
    "inva_RoyaltiesPayablePeriodAfterFirstCommercialSaleOfProduct": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "RoyaltiesPayablePeriodAfterFirstCommercialSaleOfProduct",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureLicenseAndCollaborationArrangementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalties payable period after first commercial sale of product.",
        "label": "Royalties Payable Period After First Commercial Sale Of Product",
        "terseLabel": "Royalties payable period after first commercial sale of product"
       }
      }
     },
     "auth_ref": []
    },
    "inva_RoyaltyAgreementIncreaseInMaximumPotentialPayoutPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "RoyaltyAgreementIncreaseInMaximumPotentialPayoutPercent",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty agreement increase in maximum potential payout percent.",
        "label": "Royalty Agreement Increase In Maximum Potential Payout Percent",
        "terseLabel": "Increase in maximum potential payout percent"
       }
      }
     },
     "auth_ref": []
    },
    "inva_RoyaltyAgreementMaximumPotentialPayoutPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "RoyaltyAgreementMaximumPotentialPayoutPercent",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty agreement, maximum potential payout, percent.",
        "label": "Royalty Agreement Maximum Potential Payout Percent",
        "terseLabel": "Maximum potential royalty payout"
       }
      }
     },
     "auth_ref": []
    },
    "inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentOne": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentOne",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty agreement required payment for breach of agreement payment one.",
        "label": "Royalty Agreement Required Payment For Breach Of Agreement Payment One",
        "terseLabel": "Required payment for breach of agreement, payment one"
       }
      }
     },
     "auth_ref": []
    },
    "inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentTwo",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty agreement required payment for breach of agreement payment two.",
        "label": "Royalty Agreement Required Payment For Breach Of Agreement Payment Two",
        "terseLabel": "Maximum aggregate royalty payments"
       }
      }
     },
     "auth_ref": []
    },
    "inva_RoyaltyFinancingAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "RoyaltyFinancingAgreementMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty financing agreement member.",
        "label": "Royalty Financing Agreement [Member]",
        "terseLabel": "Royalty Financing Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RoyaltyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RoyaltyMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureRevenueRecognitionDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfNetRevenueFromCollaborativeArrangementsDetails",
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfIncome",
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfIncomeParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalty [Member]",
        "terseLabel": "Royalty revenue",
        "verboseLabel": "Royalty revenue from a related party",
        "documentation": "Money for usage-based right to asset."
       }
      }
     },
     "auth_ref": [
      "r1177"
     ]
    },
    "inva_RoyaltyPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "RoyaltyPayments",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Payments",
        "label": "Royalty Payments",
        "terseLabel": "Royalty Payments"
       }
      }
     },
     "auth_ref": []
    },
    "inva_Rule10B51ArrModifiedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "Rule10B51ArrModifiedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b51Arrangement Modified",
        "label": "Rule 10b51 Arr Modified Flag",
        "documentation": "Rule 10b51 Arr Modified Flag."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r1089"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r1089"
     ]
    },
    "inva_SaleOfEquityInvestmentsManagedByIspFundLp": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "SaleOfEquityInvestmentsManagedByIspFundLp",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of equity investments managed by ISP FUND LP",
        "documentation": "Sale of equity investments managed by ISP FUND LP",
        "terseLabel": "Sales of equity investments managed by ISP Fund LP"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Number of shares to be purchased under the securities purchase agreement",
        "terseLabel": "Number of shares purchased under the securities purchase agreement",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "inva_SaleOfWarrantsNumberOfWarrantsIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "SaleOfWarrantsNumberOfWarrantsIssuedInTransaction",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Maximum number of additional shares into which warrants may be converted under the securities purchase agreement",
        "label": "Sale of Warrants, Number of Warrants Issued in Transaction",
        "documentation": "The number of warrants issued or sold by the subsidiary or equity method investee per stock transaction.",
        "terseLabel": "Number of warrants purchased under the securities purchase agreement"
       }
      }
     },
     "auth_ref": []
    },
    "inva_SalesMilestonePaymentsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "SalesMilestonePaymentsReceivable",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureLicenseAndCollaborationArrangementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales milestone payments receivable.",
        "label": "Sales Milestone Payments Receivable",
        "terseLabel": "Sales milestone payments receivable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SalesRevenueNetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SalesRevenueNetMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Benchmark [Member]",
        "terseLabel": "Net Product Sales",
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r376",
      "r1098"
     ]
    },
    "inva_SarissaCapitalManagementLpMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "SarissaCapitalManagementLpMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Sarissa Capital.",
        "label": "Sarissa Capital Management Lp [Member]",
        "terseLabel": "Sarissa Capital"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Other Accrued Liabilities",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureNetIncomePerShareAntiDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureNetIncomePerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of anti-dilutive securities",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "terseLabel": "Available-for-Sale Securities",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396"
     ]
    },
    "inva_ScheduleOfBalanceSheetInformationRelatedToOperatingLeaseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "ScheduleOfBalanceSheetInformationRelatedToOperatingLeaseTableTextBlock",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Balance sheet Information Related To Operating Lease Table Text Block",
        "label": "Schedule Of Balance sheet Information Related To Operating Lease Table Text Block",
        "terseLabel": "Schedule of Operating Lease Information Presented In Balance Sheet"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsLaJollaPharmaceuticalCompanyDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsProFormaInformationDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r109",
      "r637"
     ]
    },
    "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]",
        "terseLabel": "Schedule of Supplemental Cash Flow Information Related to Leases",
        "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureLicenseAndCollaborationArrangementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r641"
     ]
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]",
        "terseLabel": "Schedule of stock-based compensation expense included in the consolidated statements of operations by award type",
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit."
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of components of the income tax expense",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r212"
     ]
    },
    "inva_ScheduleOfConsolidatedEntitiesAndBusinessAcquisitionsByAcquisitionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "ScheduleOfConsolidatedEntitiesAndBusinessAcquisitionsByAcquisitionTable",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of consolidated entities and business acquisitions by acquisition.",
        "label": "Schedule of Consolidated Entities and Business Acquisitions by Acquisition [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Long-Term Debt Instruments [Table Text Block]",
        "terseLabel": "Schedule of Debt",
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r90",
      "r91",
      "r140",
      "r141",
      "r143",
      "r149",
      "r202",
      "r204",
      "r976",
      "r978",
      "r1131"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of deferred tax assets and deferred tax liabilities",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r211"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureNetIncomePerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of computation of basic and diluted net income per share",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1136"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEarningsPerShareDilutedByCommonClassTable",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureNetIncomePerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table]",
        "documentation": "Complete disclosure pertaining to an entity's diluted earnings per share."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r65",
      "r326",
      "r330",
      "r339"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of differences between expected U.S. federal statutory income tax to income tax expense",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r210"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "verboseLabel": "Schedule of stock-based compensation expense",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInGateNeurosciencesDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInImaginabDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInNanoliveDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r417",
      "r418",
      "r419"
     ]
    },
    "inva_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsTableTextBlock",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of finite and indefinite lived intangible assets.",
        "label": "Schedule Of Finite and Indefinite Lived Intangible Assets[Table Text Block]",
        "terseLabel": "Summary of Accumulated Amortization of Recognized Intangible Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r80",
      "r768"
     ]
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfGoodwillTable",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Goodwill [Table]",
        "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons."
       }
      }
     },
     "auth_ref": [
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r974"
     ]
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureBalanceSheetComponentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of Inventory, net",
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r167",
      "r168",
      "r169"
     ]
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Scheduled Maturities of Convertible Debt",
        "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]",
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "terseLabel": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed",
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree."
       }
      }
     },
     "auth_ref": [
      "r214"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r145",
      "r889",
      "r890",
      "r891"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Activity [Table Text Block]",
        "terseLabel": "Summary of equity award activity and related information",
        "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r26",
      "r98"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensation2012PlanAndEsppDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationCompensationAwardsDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationDirectorCompensationProgramDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r552",
      "r554",
      "r557",
      "r558",
      "r559",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "verboseLabel": "Summary of weighted-average assumptions used to calculate estimated value of stock options",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r208"
     ]
    },
    "us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfSubsidiaryOrEquityMethodInvesteeTable",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Subsidiary or Equity Method Investee [Table]",
        "documentation": "Schedule of subsidiary's sales of previously unissued stock made to investors outside the consolidated group. This includes stock issued in a business combination in exchange for shares of an acquired entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost [Table Text Block]",
        "verboseLabel": "Schedule of unrecognized stock-based compensation cost",
        "documentation": "Tabular disclosure of cost not yet recognized and weighted-average period over which cost is expected to be recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r209"
     ]
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Summary of changes in unrecognized tax benefits",
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r995",
      "r1208"
     ]
    },
    "us-gaap_ScheduleOfVariableInterestEntitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfVariableInterestEntitiesTable",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsIspFundLpDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Variable Interest Entities [Table]",
        "documentation": "Tabular disclosure of qualitative and quantitative information related to variable interests the entity holds, whether or not such variable interest entity (VIE) is included in the reporting entity's consolidated financial statements. Includes, but is not limited to, description of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a tabular comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r119",
      "r121",
      "r124",
      "r125",
      "r643",
      "r644",
      "r647",
      "r648",
      "r746",
      "r747",
      "r748"
     ]
    },
    "us-gaap_ScheduleOfVariableInterestEntitiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfVariableInterestEntitiesTextBlock",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTables",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Balance Sheets and Income Statements of VIE",
        "label": "Schedule of Variable Interest Entities [Table Text Block]",
        "documentation": "Tabular disclosure of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r119",
      "r121",
      "r124",
      "r125"
     ]
    },
    "inva_SecondNoteAmendmentAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "SecondNoteAmendmentAgreementMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInGateNeurosciencesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Second Note Amendment Agreement",
        "label": "Second Note Amendment Agreement [Member]",
        "documentation": "Second note amendment agreement."
       }
      }
     },
     "auth_ref": []
    },
    "inva_SecuredConvertibleCreditAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "SecuredConvertibleCreditAgreementMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Secured convertible credit agreement.",
        "label": "Secured Convertible Credit Agreement [Member]",
        "terseLabel": "Secured Convertible Credit Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "inva_SecuritiesPurchaseAgreementAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "SecuritiesPurchaseAgreementAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInImaginabDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInNanoliveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount the Company agreed to pay for common stock and warrants upon satisfaction of certain closing conditions under the terms of the securities purchase agreement.",
        "label": "Securities Purchase Agreement, Amount",
        "terseLabel": "Amount of securities purchase agreement",
        "verboseLabel": "Payments for acquire variable interest"
       }
      }
     },
     "auth_ref": []
    },
    "inva_SecuritiesPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "SecuritiesPurchaseAgreementMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Securities purchase agreement",
        "label": "Securities Purchase Agreement [Member]",
        "documentation": "Securities purchase agreement member."
       }
      }
     },
     "auth_ref": []
    },
    "inva_SecuritiesPurchaseAgreementNumberOfTranches": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "SecuritiesPurchaseAgreementNumberOfTranches",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of tranches in which the Company agreed to purchase common stock and warrants upon satisfaction of certain closing conditions under the terms of the securities purchase agreement.",
        "label": "Securities Purchase Agreement, Number of Tranches",
        "terseLabel": "Number of tranches",
        "verboseLabel": "Number of tranches"
       }
      }
     },
     "auth_ref": []
    },
    "inva_SecuritiesPurchaseAgreementRightsToDesignateInvesteeBoardMembersNumberOfBoardMembers": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "SecuritiesPurchaseAgreementRightsToDesignateInvesteeBoardMembersNumberOfBoardMembers",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of the investee's board members which the Company has the right to designate.",
        "label": "Securities Purchase Agreement Rights To Designate Investee Board Members Number Of Board Members",
        "terseLabel": "Number of investee's board members which may be designated by the Company"
       }
      }
     },
     "auth_ref": []
    },
    "inva_SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInImaginabDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInNanoliveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total number of shares to be purchased under the terms of a securities purchase agreement.",
        "label": "Securities Purchase Agreement, Total Number of Shares To Be Purchased Under the Agreement",
        "terseLabel": "Securities to be purchased",
        "verboseLabel": "Number of shares to be purchased under the securities purchase agreement"
       }
      }
     },
     "auth_ref": []
    },
    "inva_SecuritiesPurchaseAgreementTotalNumberOfWarrantsToBePurchasedUnderAgreement": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "SecuritiesPurchaseAgreementTotalNumberOfWarrantsToBePurchasedUnderAgreement",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of warrants to be purchased under the securities purchase agreement",
        "label": "Securities Purchase Agreement, Total Number of Warrants To Be Purchased Under Agreement",
        "documentation": "The total number of warrants to be purchased under the terms of a securities purchase agreement."
       }
      }
     },
     "auth_ref": []
    },
    "inva_SecuritiesPurchaseAgreementWarrantsNumberOfSecuritiesCalledByWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "SecuritiesPurchaseAgreementWarrantsNumberOfSecuritiesCalledByWarrants",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of additional common stock shares into which the warrants may be converted.",
        "label": "Securities Purchase Agreement, Warrants, Number of Securities Called by Warrants",
        "terseLabel": "Maximum number of additional shares into which warrants may be converted under the securities purchase agreement",
        "verboseLabel": "Maximum number of additional shares into which warrants may be converted under the securities purchase agreement"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1016"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r1019"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": [
      "r374",
      "r375",
      "r848",
      "r851",
      "r853",
      "r915",
      "r917",
      "r921",
      "r928",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r947",
      "r954",
      "r982",
      "r1004",
      "r1176",
      "r1233"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Reporting",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r374",
      "r971"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfIncome": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Selling, General and Administrative Expense, Total",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r177"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, general and administrative",
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "inva_SeniorUnsecuredConvertibleNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "SeniorUnsecuredConvertibleNotesMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureNetIncomePerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing which takes priority over other debt securities and can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Senior Unsecured Convertible Notes [Member]",
        "terseLabel": "Convertible senior notes"
       }
      }
     },
     "auth_ref": []
    },
    "inva_SeriesA1PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "SeriesA1PreferredStockMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A1 preferred stock member.",
        "label": "Series A1 preferred stock [Member]",
        "terseLabel": "Series A1 preferred stock"
       }
      }
     },
     "auth_ref": []
    },
    "inva_SeriesC2PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "SeriesC2PreferredStockMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInImaginabDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series C2 Preferred Stock",
        "label": "Series C-2 Preferred Stock [Member]",
        "documentation": "Series C-2 Preferred Stock member."
       }
      }
     },
     "auth_ref": []
    },
    "inva_SeriesCPreferredStockAndWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "SeriesCPreferredStockAndWarrantsMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to series C preferred stock and warrants.",
        "label": "Series C Preferred Stock And Warrants [Member]",
        "terseLabel": "Series C preferred stock and warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesCPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeriesCPreferredStockMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInImaginabDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInNanoliveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series C Preferred Stock [Member]",
        "terseLabel": "Series C preferred stock",
        "documentation": "Series C preferred stock."
       }
      }
     },
     "auth_ref": [
      "r1116",
      "r1117",
      "r1175"
     ]
    },
    "inva_SeriesCWarrantsAndSeriesDWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "SeriesCWarrantsAndSeriesDWarrantsMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series C warrants and Series D warrants.",
        "label": "Series C warrants and Series D warrants [Member]",
        "terseLabel": "Series C Warrants and Series D Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "inva_SeriesD1AndD2PreferredStockAndCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "SeriesD1AndD2PreferredStockAndCommonStockMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series D 1 and D 2 preferred stock and common stock.",
        "label": "Series D 1 And D 2 Preferred Stock And Common Stock Member",
        "terseLabel": "Series D 1 And D 2 Preferred Stock And Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "inva_SeriesD1PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "SeriesD1PreferredStockMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series D 1 preferred stock member.",
        "label": "Series D 1 Preferred Stock [Member]",
        "terseLabel": "Series D 1 Preferred Stock"
       }
      }
     },
     "auth_ref": []
    },
    "inva_SeriesD1WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "SeriesD1WarrantMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series D1 Warrant [Member]",
        "label": "Series D1 Warrant [Member]",
        "terseLabel": "Series D1 Warrant"
       }
      }
     },
     "auth_ref": []
    },
    "inva_SeriesD2PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "SeriesD2PreferredStockMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series D 2 preferred stock member.",
        "label": "Series D 2 Preferred Stock [Member]",
        "terseLabel": "Series D 2 Preferred Stock"
       }
      }
     },
     "auth_ref": []
    },
    "inva_SeriesD2WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "SeriesD2WarrantMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series D2 Warrant.",
        "label": "Series D2 Warrant [Member]",
        "terseLabel": "Series D2 Warrant"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesDPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeriesDPreferredStockMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series D Preferred Stock [Member]",
        "terseLabel": "Series D Preferred Stock",
        "documentation": "Series D preferred stock."
       }
      }
     },
     "auth_ref": [
      "r1116",
      "r1117",
      "r1175"
     ]
    },
    "inva_SeriesDWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "SeriesDWarrantsMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series D Warrants",
        "label": "Series D Warrants [Member]",
        "documentation": "Series D warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalEquityGrantValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalEquityGrantValue",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationDirectorCompensationProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The additional value of shares granted to newly appointed non-employee director on the date that such individual joins the Board.",
        "label": "Share Based Compensation, Arrangement by Share Based Payment Award, Additional Equity Grant Value",
        "terseLabel": "Pro rata shares grant, value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationCompensationAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Additional General Disclosures [Abstract]",
        "terseLabel": "Additional disclosures"
       }
      }
     },
     "auth_ref": []
    },
    "inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityGrantValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityGrantValue",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationDirectorCompensationProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of shares granted annually to independent directors upon re-election the to Board.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award, Annual Equity Grant, Value",
        "terseLabel": "Annual grant of shares, value"
       }
      }
     },
     "auth_ref": []
    },
    "inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveAndOverlappingOfferingPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveAndOverlappingOfferingPeriod",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensation2012PlanAndEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the consecutive and overlapping offering period for the offering of share-based payment awards.",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award Consecutive and Overlapping Offering Period",
        "terseLabel": "Total duration of consecutive and overlapping offering periods"
       }
      }
     },
     "auth_ref": []
    },
    "inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationCompensationAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee exercised the right during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercised in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationCompensationAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited (in dollars per share)",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r574"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationCompensationAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Granted (in dollars per share)",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r572"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationCompensationAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Balance at the end of the period (in dollars per share)",
        "periodStartLabel": "Balance at the beginning of the period (in dollars per share)",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r569",
      "r570"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationCompensationAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted-Average Fair Value per Share at Grant"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationCompensationAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Released RSUs and RSAs (in shares)",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r573"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationCompensationAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "terseLabel": "Total estimated fair value of equity instruments vested",
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash."
       }
      }
     },
     "auth_ref": [
      "r576"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationCompensationAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Released RSUs and RSAs (in dollars per share)",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r573"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]",
        "terseLabel": "Valuation Assumptions"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "verboseLabel": "Dividend yield",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r583"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r584"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate",
        "terseLabel": "Volatility",
        "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r582"
     ]
    },
    "inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialEquityGrantValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialEquityGrantValue",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationDirectorCompensationProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of shares granted to newly appointed non-employee director on the date that such individual joins the Board.",
        "label": "Share Based Compensation, Arrangement by Share Based Payment Award, Initial Equity Grant Value",
        "terseLabel": "One time grant of shares, value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensation2012PlanAndEsppDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationCompensationAwardsDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationDirectorCompensationProgramDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Stock-based compensation",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r552",
      "r554",
      "r557",
      "r558",
      "r559",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585"
     ]
    },
    "inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountAsContributionOfEligibleCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountAsContributionOfEligibleCompensation",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensation2012PlanAndEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount the employee may contribute of employee's eligible compensation.",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award Maximum Amount As A Contribution Of Eligible Compensation",
        "terseLabel": "Maximum value of shares an employee may purchase in a calendar year"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensation2012PlanAndEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate",
        "terseLabel": "Maximum contributions as a percentage of employee's eligible compensation",
        "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan."
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensation2012PlanAndEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Number of Shares Per Employee",
        "terseLabel": "Maximum number of shares an employee may purchase during any purchase period",
        "documentation": "The highest quantity of shares an employee can purchase under the plan per period."
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationCompensationAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised",
        "negatedLabel": "Exercised (in shares)",
        "documentation": "Number of non-option equity instruments exercised by participants."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationCompensationAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures",
        "negatedLabel": "Forfeited (in shares)",
        "documentation": "Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationCompensationAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted",
        "terseLabel": "Granted (in shares)",
        "documentation": "Net number of non-option equity instruments granted to participants."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationCompensationAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number",
        "periodEndLabel": "Balance at the end of the period (in shares)",
        "periodStartLabel": "Balance at the beginning of the period (in shares)",
        "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r21"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationCompensationAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]",
        "terseLabel": "Number of outstanding RSUs and PSUs/RSAs and PSAs",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationCompensationAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest non-option equity instruments outstanding that can be converted into shares under award activity.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Vested And Expected To Vest Outstanding, Number",
        "terseLabel": "Vested and expected to vest at the end of the period (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingWeightedAverageFairValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingWeightedAverageFairValuePerShare",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationCompensationAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Fair Value per Share of fully vested and expected to vest non-option equity instruments outstanding that can be converted into shares under award activity.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Vested And Expected To Vest Outstanding, Weighted-Average Fair Value per Share",
        "terseLabel": "Vested and expected to vest at the end of the period (in dollars per share)"
       }
      }
     },
     "auth_ref": []
    },
    "inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationDirectorCompensationProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award number of annual installments",
        "terseLabel": "Number of annual installments",
        "documentation": "The number of annual installments that RSUs granted to newly appointed independent directors will vest."
       }
      }
     },
     "auth_ref": []
    },
    "inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensation2012PlanAndEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of purchase periods having duration of six months each.",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award Number of Purchase Periods",
        "terseLabel": "Number of offering periods"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensation2012PlanAndEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares remaining available for issuance",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationCompensationAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable option",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r563"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationCompensationAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Total intrinsic value of options exercised",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r576"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationCompensationAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Forfeited (in shares)",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r567"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationCompensationAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "verboseLabel": "Granted (in shares)",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r565"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average estimated fair value of shares granted (in dollars per share)",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r575"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationCompensationAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of options outstanding",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationCompensationAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Balance at the end of the period (in shares)",
        "periodStartLabel": "Balance at the beginning of the period (in shares)",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r561",
      "r562"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationCompensationAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of outstanding options",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationCompensationAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Balance at the end of the period (in dollars per share)",
        "periodStartLabel": "Balance at the beginning of the period (in dollars per share)",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r561",
      "r562"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationCompensationAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted-Average Exercise Price of Outstanding Options"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationCompensationAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Vested and expected to vest at the end of the period (in shares)",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r577"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationCompensationAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Vested and expected to vest at the end of the period (in dollars per shares)",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r577"
     ]
    },
    "inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensation2012PlanAndEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the duration of each purchase period within each consecutive and overlapping purchase period for offering of share-based payment awards.",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award Purchase Period",
        "terseLabel": "Duration of purchase period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationCompensationAwardsDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationDirectorCompensationProgramDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationValuationAssumptionsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r557",
      "r558",
      "r559",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationCompensationAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "verboseLabel": "Exercised (in dollars per share)",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r566"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationCompensationAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited (in dollars per share)",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r567"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationCompensationAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r565"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Fair Value of Stock-Based Compensation Awards",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r551",
      "r560",
      "r579",
      "r580",
      "r581",
      "r582",
      "r585",
      "r594",
      "r595",
      "r596",
      "r597"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharePrice",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "inva_ShareRepurchaseAgreementWithGlaxoGroupLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "ShareRepurchaseAgreementWithGlaxoGroupLimitedMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share repurchase agreement with GSK",
        "label": "Share Repurchase Agreement With Glaxo Group Limited [Member]",
        "documentation": "Represents information pertaining to share repurchase agreement with Glaxo Group Limited."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareRepurchaseProgramAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareRepurchaseProgramAxis",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Repurchase Program [Axis]",
        "documentation": "Information by share repurchase program."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareRepurchaseProgramDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareRepurchaseProgramDomain",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Repurchase Program [Domain]",
        "documentation": "Name of the share repurchase program."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r581"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationCompensationAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of options exercisable",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationCompensationAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual term of options exercisable",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationCompensationAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual term of options outstanding",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r207"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationCompensationAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Total estimated fair value of options vested",
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock."
       }
      }
     },
     "auth_ref": [
      "r576"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationCompensationAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares",
        "negatedLabel": "Released RSUs/RSAs (in shares)",
        "documentation": "Number of options vested."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationCompensationAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value",
        "terseLabel": "Released RSUs/RSAs (in shares)",
        "documentation": "Weighted average grant-date fair value of options vested."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensation2012PlanAndEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Purchase price as a percentage of fair market value of stock",
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermDebtTypeAxis",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt, Type [Axis]",
        "documentation": "Information by type of short-term debt arrangement."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermDebtTypeDomain",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt, Type [Domain]",
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "inva_SoftwareAndComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "SoftwareAndComputerEquipmentMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Software and computer equipment",
        "label": "Software And Computer Equipment [Member]",
        "terseLabel": "Software and computer equipment"
       }
      }
     },
     "auth_ref": []
    },
    "inva_SpecialTermReDesignatingBoardMemberToBoardOfInvestee": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "SpecialTermReDesignatingBoardMemberToBoardOfInvestee",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Special Terms on amended and restated investor rights agreement.",
        "label": "Special Term Re Designating Board Member To Board Of Investee",
        "terseLabel": "Special terms on re-designating board member to board of investee"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalTaxDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State",
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity."
       }
      }
     },
     "auth_ref": []
    },
    "inva_StateNetOperatingLossesEstimatedUtilizationAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "StateNetOperatingLossesEstimatedUtilizationAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalTaxDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "State net operating losses estimated utilization amount.",
        "label": "State Net Operating Losses Estimated Utilization Amount",
        "terseLabel": "State net operating losses estimated utilization amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureNetIncomePerShareDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockholdersEquityDetails",
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r46",
      "r254",
      "r280",
      "r281",
      "r282",
      "r305",
      "r306",
      "r307",
      "r310",
      "r318",
      "r320",
      "r346",
      "r424",
      "r430",
      "r530",
      "r591",
      "r592",
      "r593",
      "r626",
      "r627",
      "r652",
      "r654",
      "r655",
      "r656",
      "r657",
      "r659",
      "r670",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r724",
      "r827",
      "r828",
      "r829",
      "r845",
      "r907"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r374",
      "r375",
      "r848",
      "r851",
      "r853",
      "r915",
      "r917",
      "r921",
      "r928",
      "r935",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r947",
      "r954",
      "r982",
      "r1004",
      "r1176",
      "r1233"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockholdersEquityDetails",
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfIncome",
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfIncomeParenthetical",
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "terseLabel": "Statement",
        "verboseLabel": "Subsequent Events",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r305",
      "r306",
      "r307",
      "r346",
      "r767",
      "r838",
      "r846",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r865",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r874",
      "r875",
      "r876",
      "r877",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r885",
      "r887",
      "r888",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r907",
      "r1005"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfIncome",
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfIncomeParenthetical",
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r305",
      "r306",
      "r307",
      "r346",
      "r767",
      "r838",
      "r846",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r865",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r874",
      "r875",
      "r876",
      "r877",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r885",
      "r887",
      "r888",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r907",
      "r1005"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r1027",
      "r1039",
      "r1049",
      "r1075"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of convertible subordinated notes due 2023 (in shares)",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r45",
      "r90",
      "r205",
      "r499"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture, Total",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "verboseLabel": "Exercise of stock options, and issuance of common stock units and stock awards, net of repurchase of shares to satisfy tax withholding (in shares)",
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r162",
      "r163",
      "r205"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationCompensationAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r162",
      "r163",
      "r205",
      "r566"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture, Total",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "verboseLabel": "Exercise of stock options, and issuance of common stock units and stock awards, net of repurchase of shares to satisfy tax withholding",
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r162",
      "r163",
      "r205"
     ]
    },
    "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount",
        "terseLabel": "Amount of shares repurchased",
        "documentation": "Amount remaining of a stock repurchase plan authorized."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockRepurchasedAndRetiredDuringPeriodShares",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Repurchased and Retired During Period, Shares",
        "terseLabel": "Stock repurchased and retired during period, shares",
        "documentation": "Number of shares that have been repurchased and retired during the period."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r162",
      "r163",
      "r205"
     ]
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockRepurchasedAndRetiredDuringPeriodValue",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Repurchased and Retired During Period, Value",
        "terseLabel": "Stock repurchased and retired during period, value",
        "documentation": "Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital)."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r162",
      "r163",
      "r205"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent [Abstract]",
        "verboseLabel": "Stockholders' equity:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets",
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total stockholders' equity",
        "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r113",
      "r126",
      "r254",
      "r255",
      "r281",
      "r305",
      "r306",
      "r307",
      "r310",
      "r318",
      "r424",
      "r430",
      "r530",
      "r591",
      "r592",
      "r593",
      "r626",
      "r627",
      "r652",
      "r654",
      "r655",
      "r656",
      "r657",
      "r659",
      "r670",
      "r691",
      "r692",
      "r696",
      "r724",
      "r828",
      "r829",
      "r843",
      "r867",
      "r884",
      "r908",
      "r909",
      "r933",
      "r1014",
      "r1129",
      "r1158",
      "r1215",
      "r1238"
     ]
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Text Block]",
        "terseLabel": "STOCKHOLDERS' EQUITY",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r201",
      "r299",
      "r514",
      "r516",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r528",
      "r530",
      "r661",
      "r910",
      "r911",
      "r934"
     ]
    },
    "inva_StrategicAllianceAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "StrategicAllianceAgreementMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureRevenueRecognitionDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfNetRevenueFromCollaborativeArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the strategic alliance with GSK for initiating three new full discovery programs and giving GSK option to license exclusive development and commercialization rights of products.",
        "label": "Strategic Alliance Agreement [Member]",
        "terseLabel": "Strategic alliance - MABA program"
       }
      }
     },
     "auth_ref": []
    },
    "inva_StrategicAllianceMabaProgram": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "StrategicAllianceMabaProgram",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfNetRevenueFromCollaborativeArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "strategic alliance - MABA program",
        "documentation": "strategic alliance - MABA program",
        "terseLabel": "Strategic alliance - MABA program"
       }
      }
     },
     "auth_ref": []
    },
    "inva_SubscriptionAgreementOneTimeMilestonePaymentOnCommercialSales": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "SubscriptionAgreementOneTimeMilestonePaymentOnCommercialSales",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureLicenseAndCollaborationArrangementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subscription agreement one-time milestone payment on first commercial sale",
        "label": "Subscription Agreement One-time Milestone Payment on Commercial Sales",
        "documentation": "Subscription agreement one-time milestone payment on commercial sales."
       }
      }
     },
     "auth_ref": []
    },
    "inva_SubscriptionAgreementOneTimeMilestonePaymentOnNetSales": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "SubscriptionAgreementOneTimeMilestonePaymentOnNetSales",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureLicenseAndCollaborationArrangementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subscription agreement one-time milestone payment on net sales",
        "label": "Subscription Agreement One-time Milestone Payment on Net Sales",
        "documentation": "Subscription agreement one-time milestone payment on net sales."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r697",
      "r730"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockholdersEquityDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r697",
      "r730"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued."
       }
      }
     },
     "auth_ref": [
      "r697",
      "r730"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockholdersEquityDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r697",
      "r730"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockholdersEquityDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r697",
      "r730"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureSubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Text Block]",
        "verboseLabel": "SUBSEQUENT EVENTS",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r729",
      "r731"
     ]
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiaryOrEquityMethodInvesteeLineItems",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary or Equity Method Investee [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "inva_SummaryOfSignificantAccountingPoliciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "SummaryOfSignificantAccountingPoliciesLineItems",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Summary of Significant Accounting Policies [Line Items]",
        "terseLabel": "DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "auth_ref": []
    },
    "inva_SummaryOfSignificantAccountingPoliciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "SummaryOfSignificantAccountingPoliciesTable",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to various accounting policies of the entity.",
        "label": "Summary of Significant Accounting Policies [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureBalanceSheetComponents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "BALANCE SHEET COMPONENTS",
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity."
       }
      }
     },
     "auth_ref": [
      "r1112"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r1068"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalTaxDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carryforward amount",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r105"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardAxis",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalTaxDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward [Axis]",
        "documentation": "Information by specific tax credit related to an unused tax credit."
       }
      }
     },
     "auth_ref": [
      "r104"
     ]
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardNameDomain",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalTaxDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward, Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name [Domain]",
        "documentation": "The name of the tax credit carryforward."
       }
      }
     },
     "auth_ref": [
      "r104"
     ]
    },
    "inva_TermLoanInvestmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "TermLoanInvestmentMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term Loan Investment",
        "label": "Term Loan Investment [Member]",
        "documentation": "Term loan investment."
       }
      }
     },
     "auth_ref": []
    },
    "inva_TermOfMilestonePaymentForCommercialSale": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "TermOfMilestonePaymentForCommercialSale",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureLicenseAndCollaborationArrangementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term of the milestone payment on first commercial sale",
        "label": "Term of Milestone Payment for Commercial Sale",
        "documentation": "Term of milestone payment for commercial sale."
       }
      }
     },
     "auth_ref": []
    },
    "inva_TermOfMilestonePaymentForNetSales": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "TermOfMilestonePaymentForNetSales",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureLicenseAndCollaborationArrangementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term of the milestone payment on net sales",
        "label": "Term of Milestone Payment for Net Sales",
        "documentation": "Term of milestone payment for net sales."
       }
      }
     },
     "auth_ref": []
    },
    "inva_TheravanceRespiratoryCompanyLlcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "TheravanceRespiratoryCompanyLlcMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTables",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to the variable interest entity, Theravance Respiratory Company, LLC (\"TRC\").",
        "label": "Theravance Respiratory Company Llc [Member]",
        "terseLabel": "Theravance Respiratory Company, LLC"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationDirectorCompensationProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1137",
      "r1219"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationDirectorCompensationProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Relationship to Entity [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r1060"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r1067"
     ]
    },
    "us-gaap_TradeAccountsReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TradeAccountsReceivableMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade Accounts Receivable [Member]",
        "terseLabel": "Receivables from Net Product Sales",
        "documentation": "Amount due from customers or clients for goods or services that have been delivered or sold in the normal course of business."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable [Policy Text Block]",
        "terseLabel": "Accounts Receivable",
        "documentation": "Disclosure of accounting policy for accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r235",
      "r236",
      "r237",
      "r377",
      "r378",
      "r382"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r1088"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r1090"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsAvailableforsaleSecuritiesDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInGateNeurosciencesDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInImaginabDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInNanoliveDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r507",
      "r527",
      "r660",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r810",
      "r1105",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1151",
      "r1152",
      "r1153",
      "r1154"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r1091"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r1092"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r1090"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r1090"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r1093"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r1091"
     ]
    },
    "us-gaap_TreasuryStockCommonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockCommonMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury Stock, Common [Member]",
        "terseLabel": "Treasury Stock",
        "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "us-gaap_TreasuryStockCommonShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockCommonShares",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury stock, shares",
        "label": "Treasury Stock, Common, Shares",
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "us-gaap_TreasuryStockCommonValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockCommonValue",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Treasury stock: at cost, 32,005 shares as of December 31, 2023 and 2022",
        "label": "Treasury Stock, Common, Value",
        "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r93",
      "r96"
     ]
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockSharesAcquired",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repurchase of common stock (in shares)",
        "terseLabel": "Repurchase of common stock (in shares)",
        "label": "Treasury Stock, Shares, Acquired",
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r163",
      "r205"
     ]
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Repurchase of common stock",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "negatedLabel": "Repurchase of common stock",
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r93",
      "r205"
     ]
    },
    "inva_TrelegyElliptaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "TrelegyElliptaMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureRevenueRecognitionDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfNetRevenueFromCollaborativeArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Trelegy Ellipta.",
        "label": "Trelegy Ellipta [Member]",
        "terseLabel": "TRELEGY"
       }
      }
     },
     "auth_ref": []
    },
    "inva_TwoDirectorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "TwoDirectorsMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Directors.",
        "label": "Two Directors [Member]",
        "terseLabel": "Two Directors"
       }
      }
     },
     "auth_ref": []
    },
    "inva_TwoThousandTwentyEightNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "TwoThousandTwentyEightNotesMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtTables",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty eight notes.",
        "label": "Two Thousand Twenty Eight Notes [Member]",
        "terseLabel": "2028 Notes"
       }
      }
     },
     "auth_ref": []
    },
    "inva_TwoThousandTwentyFiveNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "TwoThousandTwentyFiveNotesMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtTables",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureNetIncomePerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty five notes.",
        "label": "Two Thousand Twenty Five Notes [Member]",
        "verboseLabel": "Two Thousand Twenty Five Notes [Member]",
        "terseLabel": "2025 Notes"
       }
      }
     },
     "auth_ref": []
    },
    "inva_TwoThousandTwentyThreeNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "TwoThousandTwentyThreeNotesMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtTables",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty three notes.",
        "label": "Two Thousand Twenty Three Notes [Member]",
        "terseLabel": "2023 Notes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfAdoptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfAdoptionMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update [Domain]",
        "documentation": "Amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r309",
      "r310",
      "r311",
      "r312",
      "r321",
      "r383",
      "r384",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r465",
      "r591",
      "r592",
      "r593",
      "r624",
      "r625",
      "r626",
      "r627",
      "r638",
      "r639",
      "r640",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r682",
      "r683",
      "r687",
      "r688",
      "r689",
      "r690",
      "r698",
      "r699",
      "r703",
      "r704",
      "r705",
      "r706",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r769",
      "r770",
      "r771",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureLicenseAndCollaborationArrangementsAdditionalInformationDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureRevenueRecognitionDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfNetRevenueFromCollaborativeArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r641"
     ]
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "US",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "United States"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnamortizedDebtIssuanceExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnamortizedDebtIssuanceExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unamortized Debt Issuance Expense",
        "terseLabel": "Unamortized debt issuance cost",
        "documentation": "The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r1087"
     ]
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrealizedGainLossOnInvestments",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsIspFundLpDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Unrealized Gain (Loss) on Investments, Total",
        "label": "Unrealized Gain (Loss) on Investments",
        "verboseLabel": "Unrealized loss on other equity investments",
        "negatedLabel": "Changes in fair values of other equity and long-term investments, net",
        "documentation": "Amount of unrealized gain (loss) on investment."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "inva_UnrealizedOtherGainLossOnInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "UnrealizedOtherGainLossOnInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Changes in fair values of equity and long-term investments, net",
        "documentation": "Unrealized other gain loss on investments",
        "label": "Unrealized Other Gain Loss on Investments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalTaxDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Unrecognized Tax Benefits, Ending Balance",
        "periodStartLabel": "Unrecognized Tax Benefits, Beginning Balance",
        "label": "Unrecognized Tax Benefits",
        "terseLabel": "Unrecognized tax benefits",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r602",
      "r610"
     ]
    },
    "inva_UnrecognizedTaxBenefitsDecreaseResultingFromCurrentPeriodTaxPositionsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "UnrecognizedTaxBenefitsDecreaseResultingFromCurrentPeriodTaxPositionsNet",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalTaxDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net decrease in tax portions for 2021",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Current Period Tax Positions, Net",
        "documentation": "Net amount of decrease in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return."
       }
      }
     },
     "auth_ref": []
    },
    "inva_UnrecognizedTaxBenefitsDecreaseResultingFromPriorPeriodTaxPositionsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "UnrecognizedTaxBenefitsDecreaseResultingFromPriorPeriodTaxPositionsNet",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalTaxDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net decrease in tax portions for 2020",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions, Net",
        "documentation": "Net amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalTaxDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Current Period Tax Positions",
        "negatedLabel": "Gross decrease in tax portions from current year",
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return."
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalTaxDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Net decrease in tax portions",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns."
       }
      }
     },
     "auth_ref": [
      "r611"
     ]
    },
    "inva_UnrecognizedTaxBenefitsIncreaseResultingFromCurrentPeriodTaxPositionsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "UnrecognizedTaxBenefitsIncreaseResultingFromCurrentPeriodTaxPositionsNet",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalTaxDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrecognized tax benefits increase resulting from current period tax positions Net",
        "label": "Unrecognized Tax Benefits Increase Resulting From Current Period Tax Positions Net",
        "terseLabel": "Net increase in tax portions for 2022"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalTaxDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "terseLabel": "Net increase in tax portions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns."
       }
      }
     },
     "auth_ref": [
      "r611"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalTaxDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "terseLabel": "Unrecognized tax benefits would affect the effective income tax rate if recognized",
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate."
       }
      }
     },
     "auth_ref": [
      "r612"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Management's Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r71",
      "r72",
      "r241",
      "r242",
      "r245",
      "r246"
     ]
    },
    "us-gaap_ValuationTechniqueAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationTechniqueAxis",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Approach and Technique [Axis]",
        "documentation": "Information by valuation approach and technique."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_ValuationTechniqueDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationTechniqueDomain",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Approach and Technique [Domain]",
        "documentation": "Valuation approach and technique."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_VariableInterestEntityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableInterestEntityLineItems",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsIspFundLpDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable Interest Entity [Line Items]",
        "terseLabel": "CONSOLIDATED ENTITIES",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r643",
      "r644",
      "r647",
      "r648",
      "r746",
      "r747",
      "r748"
     ]
    },
    "us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableInterestEntityNotPrimaryBeneficiaryMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsSummarizedFinancialDataDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable Interest Entity, Not Primary Beneficiary [Member]",
        "terseLabel": "Variable Interest Entity, Not Primary Beneficiary",
        "documentation": "Variable Interest Entities (VIE) in which the entity does not have a controlling financial interest (as defined) and of which it is therefore not the primary beneficiary. VIEs of which the entity is not the primary beneficiary because it does not have the power to direct the activities of the VIE that most significantly impact the VIE's economic performance and for which it does not have the obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE are not included in the consolidated financial statements of the entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VariableInterestEntityOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableInterestEntityOwnershipPercentage",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage",
        "terseLabel": "Armata outstanding shares percentage",
        "documentation": "Percentage of the Variable Interest Entity's (VIE) voting interest owned by (or beneficial interest in) the reporting entity (directly or indirectly)."
       }
      }
     },
     "auth_ref": [
      "r123"
     ]
    },
    "us-gaap_VariableInterestEntityPrimaryBeneficiaryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableInterestEntityPrimaryBeneficiaryMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsIspFundLpDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable Interest Entity, Primary Beneficiary [Member]",
        "terseLabel": "Variable Interest Entity",
        "documentation": "Variable Interest Entities (VIE) in which the entity has a controlling financial interest (as defined) and of which it is therefore the primary beneficiary. A controlling financial interest is determined based on both: (a) the entity's power to direct activities of the VIE that most significantly impact the VIE's economic performance and (b) the entity's obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE. VIEs of which the entity is the primary beneficiary are included in the consolidated financial statements of the entity."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r643",
      "r644",
      "r647",
      "r648"
     ]
    },
    "us-gaap_VariableLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeastCostDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeastCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease costs",
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases."
       }
      }
     },
     "auth_ref": [
      "r715",
      "r998"
     ]
    },
    "us-gaap_VariableRateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableRateAxis",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable Rate [Axis]",
        "documentation": "Information by type of variable rate."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VariableRateDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableRateDomain",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable Rate [Domain]",
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index."
       }
      }
     },
     "auth_ref": []
    },
    "inva_VotingAgreementMaximumVotingRightsPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "VotingAgreementMaximumVotingRightsPercent",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of maximum voting rights",
        "label": "Voting Agreement, Maximum Voting Rights, Percent",
        "documentation": "Represents the percentage of maximum voting rights under voting agreement."
       }
      }
     },
     "auth_ref": []
    },
    "inva_WalthamMassachusettsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "WalthamMassachusettsMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Waltham Massachusetts Member",
        "label": "Waltham Massachusetts Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "terseLabel": "Warrants",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r1002",
      "r1003",
      "r1006",
      "r1007",
      "r1008",
      "r1009"
     ]
    },
    "inva_WarrantsAcquiredInSecondQuarterOf2020Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "WarrantsAcquiredInSecondQuarterOf2020Member",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to warrants acquired in the second quarter of 2020.",
        "label": "Warrants Acquired In Second Quarter Of2020 [Member]",
        "terseLabel": "Warrants acquired in second quarter of 2020"
       }
      }
     },
     "auth_ref": []
    },
    "inva_WarrantsAcquiredInSecondQuarterOf2021Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "WarrantsAcquiredInSecondQuarterOf2021Member",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to warrants acquired in the second quarter of 2021",
        "label": "Warrants Acquired In Second Quarter Of2021 [Member]",
        "terseLabel": "Warrants acquired in second quarter of 2021"
       }
      }
     },
     "auth_ref": []
    },
    "inva_WarrantsAcquiredInThirdQuarterOf2020Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "WarrantsAcquiredInThirdQuarterOf2020Member",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to warrants acquired in the third quarter of 2020.",
        "label": "Warrants Acquired In Third Quarter Of2020 [Member]",
        "terseLabel": "Warrants acquired in third quarter of 2020"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails",
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and Rights Outstanding, Term",
        "terseLabel": "Term of warrants",
        "verboseLabel": "Term of warrants",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1214"
     ]
    },
    "inva_WarrantsPurchasedIn2020Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "WarrantsPurchasedIn2020Member",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to warrants purchased in 2020.",
        "label": "Warrants Purchased In2020 [Member]",
        "terseLabel": "Warrants purchased in 2020"
       }
      }
     },
     "auth_ref": []
    },
    "inva_WarrantsPurchasedIn2021Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "WarrantsPurchasedIn2021Member",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants purchased in 2021",
        "label": "Warrants Purchased In2021 [Member]",
        "documentation": "Represents information pertaining to warrants purchased in 2021."
       }
      }
     },
     "auth_ref": []
    },
    "inva_WarrantsPurchasedIn2022Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "WarrantsPurchasedIn2022Member",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants purchased in 2022 member.",
        "label": "Warrants Purchased In 2022 [Member]",
        "terseLabel": "Warrants Purchased in 2022"
       }
      }
     },
     "auth_ref": []
    },
    "srt_WeightedAverageMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "WeightedAverageMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureStockBasedCompensationValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average [Member]",
        "terseLabel": "Weighted-average"
       }
      }
     },
     "auth_ref": [
      "r949",
      "r950",
      "r1223",
      "r1225",
      "r1228"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails",
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Shares used to compute diluted net income per share",
        "totalLabel": "Weighted-average shares used to compute diluted net income per share attributable to Innoviva stockholders",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r325",
      "r341"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Shares used to compute Innoviva basic and diluted net income per share:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "calculation": {
      "http://www.inva.com/20231231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails",
      "http://www.inva.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Shares used to compute basic net income per share",
        "verboseLabel": "Weighted-average shares used to compute basic net income per share attributable to Innoviva stockholders",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r323",
      "r341"
     ]
    },
    "inva_WithdrawalFromInvestment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "WithdrawalFromInvestment",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Withdrawal from investment",
        "label": "Withdrawal From Investment",
        "documentation": "Withdrawal From Investment"
       }
      }
     },
     "auth_ref": []
    },
    "inva_XacduroMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "XacduroMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "XACDURO",
        "label": "XACDURO [Member]",
        "documentation": "XACDURO [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "inva_XeravaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "XeravaMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "XERAVA.",
        "label": "XERAVA [Member]",
        "terseLabel": "XERAVA"
       }
      }
     },
     "auth_ref": []
    },
    "inva_ZaiLabMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20231231",
     "localname": "ZaiLabMember",
     "presentation": [
      "http://www.inva.com/20231231/taxonomy/role/DisclosureLicenseAndCollaborationArrangementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Zai Lab.",
        "label": "Zai Lab [Member]",
        "terseLabel": "Zai Lab"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "835",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482914/835-10-05-3"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "940",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "7",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-7"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "8",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-8"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21D",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-21D"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "30",
   "Topic": "350",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c),(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(1)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(2)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(3)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "SubTopic": "10",
   "Topic": "480",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481648/480-10-50-2"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2C",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2C"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)(2)",
   "SubTopic": "40",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "60",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.24)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.30)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "320",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//320/tableOfContent"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "((a)(1),(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "450",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "450",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "25",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481284/470-20-25-22"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-2"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-4"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "63",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481620/480-10-55-63"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB TOPIC 4.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-5"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481549/505-30-45-1"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-2"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-3"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-4"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "05",
   "Paragraph": "4",
   "Subparagraph": "(a)-(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479515/805-10-05-4"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "37",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479303/805-10-55-37"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-15"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-16"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-21"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1B"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2AA",
   "Subparagraph": "a",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-2AA"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-4"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-4"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-5A"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-5A"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-5A"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-6"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-9"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4I"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "40",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-4"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "40",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-11"
  },
  "r136": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-12"
  },
  "r137": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20"
  },
  "r138": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21"
  },
  "r139": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r140": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A"
  },
  "r141": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2"
  },
  "r142": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r143": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8"
  },
  "r144": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r145": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r146": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.15)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r147": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r148": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "320",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-5"
  },
  "r149": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3"
  },
  "r150": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3"
  },
  "r151": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1"
  },
  "r152": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r153": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205/tableOfContent"
  },
  "r154": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 201.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r155": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 201.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r156": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 201.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r157": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r158": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r159": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r160": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r161": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r162": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r163": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r164": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r165": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r166": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r167": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r168": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r169": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r170": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r171": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r172": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r173": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r174": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r175": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r176": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r177": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r178": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7(a),(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r179": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r180": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7(c),9(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r181": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r182": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r183": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r184": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r185": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r186": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r187": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r188": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r189": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//275/tableOfContent"
  },
  "r190": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480581/330-10-S99-2"
  },
  "r191": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//350/tableOfContent"
  },
  "r192": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r193": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r194": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r195": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r196": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r197": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//470/tableOfContent"
  },
  "r198": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481284/470-20-25-10"
  },
  "r199": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481284/470-20-25-11"
  },
  "r200": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-5"
  },
  "r201": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r202": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r203": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r204": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r205": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r206": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 4.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-5"
  },
  "r207": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r208": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r209": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r210": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r211": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r212": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r213": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r214": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1"
  },
  "r215": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//810/tableOfContent"
  },
  "r216": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r217": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r218": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-3"
  },
  "r219": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r220": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "932",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-10(c)(3)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479664/932-10-S99-1"
  },
  "r221": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "932",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-10(c)(7)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479664/932-10-S99-1"
  },
  "r222": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r223": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r224": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r225": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r226": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r227": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r228": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r229": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r230": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r231": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r232": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.1-5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r233": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.7,8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r234": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r235": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11B",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-11B"
  },
  "r236": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-15"
  },
  "r237": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "10",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-6"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "321",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479567/321-10-45-1"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "270",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-6"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//606/tableOfContent"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(210.5-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-5"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-19"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-6"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//260/tableOfContent"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-11"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-22"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-23"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-28A"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-42"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-4"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-1"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-2"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-42"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-42"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "44",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-44"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-1"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-4"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481664/323-10-45-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//330/tableOfContent"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-4"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479483/340-40-50-3"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479483/340-40-50-3"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-2"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1A"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147477123/405-50-65-1"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-15"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-9"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480454/718-10-45-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-4"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "51",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482663/740-10-55-51"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482736/825-10-45-1A"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-2"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481435/852-10-45-14"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//855/tableOfContent"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-1A"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-1A"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-1A"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "330",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482105/912-330-50-1"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(d)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(d)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(5)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column B)(Footnote 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5D",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5D",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-3"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481058/954-310-45-1"
  },
  "r937": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2"
  },
  "r938": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r939": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r940": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r941": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r942": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r943": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r944": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r945": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r946": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r947": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r948": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r949": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r950": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r951": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r952": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r953": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r954": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r955": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r956": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r957": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r958": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-8"
  },
  "r959": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r960": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r961": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r962": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16"
  },
  "r963": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21"
  },
  "r964": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22"
  },
  "r965": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r966": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r967": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r968": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r969": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r970": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r971": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47"
  },
  "r972": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r973": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8"
  },
  "r974": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24"
  },
  "r975": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r976": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r977": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r978": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E"
  },
  "r979": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F"
  },
  "r980": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r981": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r982": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r983": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r984": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r985": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r986": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r987": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r988": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r989": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r990": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r991": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11"
  },
  "r992": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6"
  },
  "r993": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r994": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r995": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482663/740-10-55-217"
  },
  "r996": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J"
  },
  "r997": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K"
  },
  "r998": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r999": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii",
   "Section": "6"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "825",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "SubTopic": "10",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(3)",
   "SubTopic": "10",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4H",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r1111": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r1112": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//210/tableOfContent"
  },
  "r1113": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r1114": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r1115": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r1116": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r1117": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r1118": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r1119": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r1120": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r1121": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r1122": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r1123": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r1124": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r1125": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r1126": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r1127": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r1128": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r1129": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r1130": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r1131": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r1132": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r1133": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r1134": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r1135": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r1136": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r1137": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13"
  },
  "r1138": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-1"
  },
  "r1139": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11"
  },
  "r1140": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r1141": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r1142": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r1143": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r1144": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r1145": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r1146": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r1147": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r1148": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r1149": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r1150": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r1151": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r1152": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r1153": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r1154": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r1155": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-4"
  },
  "r1156": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481664/323-10-45-1"
  },
  "r1157": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r1158": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r1159": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479483/340-40-50-3"
  },
  "r1160": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479483/340-40-50-3"
  },
  "r1161": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r1162": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r1163": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r1164": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r1165": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r1166": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r1167": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r1168": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r1169": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r1170": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r1171": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r1172": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r1173": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r1174": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r1175": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r1176": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r1177": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r1178": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1179": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1180": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1181": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1182": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1183": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1184": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1185": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1186": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1187": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1188": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1189": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1190": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1191": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1192": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1193": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1194": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1195": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1196": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1197": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1198": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1199": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1200": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1201": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1202": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1203": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1204": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1205": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r1206": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r1207": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r1208": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r1209": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r1210": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6"
  },
  "r1211": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r1212": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r1213": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r1214": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r1215": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r1216": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r1217": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r1218": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r1219": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r1220": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r1221": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r1222": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r1223": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r1224": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r1225": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r1226": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r1227": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r1228": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r1229": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r1230": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1231": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1232": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r1233": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r1234": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r1235": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r1236": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r1237": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r1238": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r1239": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r1240": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r1241": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r1242": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r1243": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r1244": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r1245": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "39",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480228/946-830-45-39"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>126
<FILENAME>0000950170-24-023237-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-24-023237-xbrl.zip
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M'L13X^ZK$7H:H&_BC)1KXFD><_&D-F H$8G8)G43FZ?S4!'&_<_KX=JNT&N
MKT%5'5KAD @GR'7-YISR-6CO77UB^]2M:\!8B=TUP'+8TPNF"WM9I$)I&)H$
M Y]3N][$2RG@Y ,%^)'KV620W[^6^=,*O+_#5AS+UZ3T7VR[W)+XH:!Y0;.6
MA(X[#@)NE5^6=W^"DD5[!O$I9\KL/[KG1WA9[V:)*OTAA]<J77 'K3,K*U';
MDN>!MT/Y2FQL;Y5AWA88)/CYT*LO2\$30HPT_C5E@!S*$C=@1Z2/G*Z;T ,8
M>1VA11,YBDL233)[=;HCR=8KFB_RS;!>*IA?"(WV'ND*2;&=89^;3%K?RY8!
M49AK/7R;8&J?Y'1V2.\+5NQ$B/UH[JEQ99\D((I=3HO-?6PC^SKT=>!>D;,5
M4.?E",X@%Q)<ZS64>M@_2ZQV'D^'XV_;HQSGSIH!A20'\:W*,]QT>7/&;N8T
MQI@FQIN0 3%00T4HH^%)D,\,=/40[V!I5;,(E\>ZR>I.Y:O!9(,Q,] >-_M(
M+@B5QNLN"F>?JUK.)A-\[ZME$URD,LR3QKA"==I2O5[![\&V6ID]C_11K-;S
MNMNS4(9IK;6Q3!%B/O)OX+NH&I(&M&*/T%UH%#Z#<>] $H,R-*"=7^C=5;;W
MLFD^):3!R0,E9-%JL?<I1X,JV/E\,ZY#S#*[XWF'L#R!Q11^6%)N;5'I1&2]
M"^A<(,9J)0(^12S6.4RZWUTKS%A=ZU;@CYRB1:4(R+..5N^8$(KPAWN 'S55
M56F6YABWR269HKKOM89QV3_ZMA>:?;0:BM3BBK5GY<(R8,\8#F J@-N0H,(U
ME3S\7"0J5RDKN@U:D*_"11,4+4RG@!2NO;PG56\WZ%T*N+W:DY!Y&:)[>,&4
M.J57#ZWJ<@16P\D7Y94M DN#^#X'B^Q=J(*AV] /<ZQM63X_XC=+4%9(WIDI
M[235^76*4CN*L1_"AVH?TXJS+7!/98,/%GP6ZNN&A+9$A[!:4SVL GMH4*'4
MJ2\RZ7!CRW5,KQ9_+30AGD! 2TQ>Y=#Q-\LF=$@)F!?XEYVC-.4>W\2#HZIS
M[POCW:[RF?A@I/F(3Y]E4/TE\XI4!=H?_TOCN<;63#OX+8;W9D)I^[KR0)UK
MHU0."_P"237Z5E:MK*G5Y]>7ZM*2@VTG7FNJ\[I" ;VC?2JYBY'LO(E'_46W
M'U$L&U(ML_S;?=<;*N]==BV3_MNR[=!_V+@U^4^[NG9J^_X)B3>F]_3?[0G+
MD$4H'.DW'8YT,_\*NPF+@;K7 ' 2 BR" OHY5Z P([M']I$X^)X)7TW\D(/6
M,\T%9*;#%38J'JQ3F:9?WDC6F\=<V?(#[:9EL:X!K'+@*W=,QG%27-\UX.W!
M7M*YBT)>0&]8H$FA&4I^<05N%"9E+"ORT%T2C(M\@EA&?8'!"+$'7N)(;JLZ
MO=FI3KU1F0K/@O,[MC>= .U8)O7OW!V?AX^M_DIU6VENFJ+Q]58@5,'>7=AC
M"<?5\L@U2?25&8F#NM[[,7E?Q'19W20Q7&Z/UB"]1%1\4C<Q11J5.+\HSFL2
M'A^[BB)V]*,T?WM40^P(.#KBZ^J:ZV*&Q3&+[.XNF,Z]R)2M>_JURP.JI;64
MQ[FX20P$OA%7U\&>]6+?<>>.:&[?ZJ546&_8[E4!ZZ%";W RKEYY,$]TQ<$X
MZRILT$8S0LXN\,R%!YT;!@.0$M3L<#!S%R)HN(N^KBNU$4!AD38LI;*8'[J<
M!L5)Z0V%/7[>;7K E %;I5S+7QTYCLMXQ?Z"X57L-,H>/@UU5M72^MR<NP^Y
M;/X)T5[KI:3LR(<MO,*6FF+;,SQ4K4DS>2*A%N& H4$N+SH4:(79-$J.G4?#
M.D!1H-LZ'ZNL+'UC3-]9O#L^2_"Y22FC"E% Q=2E)_E2FT1VZC %[[:IB +R
MPN:.CM:%"H)70>-\3/@+.7EF2N-\Q%IYW@TP5UQ?\;5O8DW.;\(/J,;KIQ[/
MP>=/Q#HCR3BY+*OA#+9MJ^0.S&2G0&2]DXF>:'AR/THAPGD'(XHHWNEY3)_1
M)3S2::0Q2C7)GFN4UJX69WH-&'<"7>Q< ;_)<]_,(0D>_0I"3HB<;G=&&9AA
M1Q,)QUN-P=MO7_:$Q@VMT"(YDUGS+VXEAG].R$D9]C31UA3YD'*\.JAP?J_.
MEVV3:G^55IV)!.?D+H_8YN%5>#'Z:6BM(/P2L)'+A.NM0!VH4>S40YB_^$D_
MS"\&2M'H.-=5/:)!^-H;PY@BB*9R<68@__J,8B_V7->Z];W7_B/.&/2L\.@G
M2/:I0H0"Q?Y)#NV)E=&O1[WNJOO6"7(%86)\*=5="_%C/C2DHW #0NF[/A9)
MGA:(%^X6:+F/-'2XSC$RG20FV(A8!T%9.[#&:Z7H=D#233(6BE36_3"3\^1K
MF499BO=ATD'E2;WN6GE#A2-]9)E@F0]C:[8[<>XM1]7<[MS2!6B0UBKCB.O^
M\=6T^2I 5=3B\&+'<FO$V4YG'LSB+'\@$T+YHN@+G^Y:?F>9PX4*S(EFVD)&
M7C$9SEJO<64^L/L<[7ACM]5=BYW7@#C_C,0JF))8Q(2EVM6ZK F6E:AG^=NS
M&T-O^G-/\OO*[>[OR[A/U&JM0..T23O6.@5NP1E[-#9'JFP7)FD5R[_YD5=_
MLO7#4W?F.)<P$\JL$\A^TP4I^683,]3'FTX.701^?:F>2%@-(NG2+=I9H4PD
M[M8AL,?/\.X'TR(__SKK$9\3=,ZSCUC:</L*P>&NFL\2$;Q@BH'I)MZ9PFGQ
MUZZ*;US3S<\80BMD6Q0P#,H>6#LR/&PX *9A,_*5(ACGN[-B][<Z,FRC'WR2
M4+*2GW@0KO=X^8PYOD0>T,8$:RL(E=X;]7(KFV0Y^JZ67GI6'P=KC6G2UNU_
MN/3=Z:FN,!M!0BIP.)"Y\AKP E6AV^5(XC8R")(UIJPZ?NIFYVJPK2$K>(0V
MH*^*#WJG!&$>MK093?!7H5Z4?24\5MK&U+SS"0XF>8=38=+R91GN(W:LFW":
M"0DT\7/;]$MVO9K^53DXHI_M;D'Z,Z"UOYW-]9;%2+Q$U;J_20+:."P =.^)
MH%%N2K+;(CA0!+F%9NT(-U^QK]V2Y/K-XIW7>JEPVO-ABZ^PZ_V8S2O\_SX;
M!Q,NKEB@](T[^(W6/S_[1;79(V /2G!/7W=E_M)M, 0B[Y*#:A.NS6S&.F9X
ML[LQ=P3M;94OU)<C 0M<,A4B+@I/YO7BRWBT:RQU&TZV$A36\U?>Z%Y([IR
M<[K(H(.P G+E\D-A01_AG10;E1VF!XC#:%'NM;;NMP\?4ZOG'L]TC1K.GY#A
MHK4^=LV\YVRR7Q+*]%764YK@?:JE][&W>[:+#H'Y(B58:/22%K=]V0D2%NA8
M[IN)V5UZTF#Z/,)CDW=-C//#"@ER(;LF(("DH7!\<*W. /&E?<V5=%(\K?R'
M,I&JR$N[L^Z/IHM('^VQ5Z3( (QF9O@U  MLA(Q"1T.83X= O,C56/J>O*I
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M>X0 >7=/O@E,F=Q,XUAHJO44X%;-Z:_Z\,&+DV .Q)'-$GD2+Q/69045_!I
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M3VJWT?9K^V1FK1\;4K\1AP6.SQ8':?-ZI#_;.0HW7[[1# >%<VK/:\ %ZAI
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M-(3"D)O%4W3Z#G;R;_+JNPE5E2GP,R^_9K@MTZ?ZE7<0"7(XWCH9WWE2'$H
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MY5N?2ND=N_Z%[B]T?X*..6R%E0WWG]")7@-L?5,X;])8"1\;Z!05"TH QO*
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MZ\[.F^Y^[E1U9@U>9%2+"S1/MS+< 0DA_VA_M6U6Z4?G_GC(H^H6R\,YO^C
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M6C--NMZ[9 ]A7TX-=AHU<_Q3/-?O5A7A7;$3XF,:*C;SET'HX:\_,38/M>/
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MA<^7B.C/*[VM[=W-#U=L^6O&V,(E\%=2_DY*H:4N#^)FKKAOWM(#VW]0>=9
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M[GNJ#('_];5C]D7U:^H+0;\H!:U6J%(<+3DY4'W<;%SMINS$\W_R8RG_I,I
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MK#5GZL]$1'P>H>2#X_323/^.UN6U'X'F#^;5+\\8!\_>);)DC"\?%22V+WZ
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M4]TO%4-_N$(-ID&,65]H)E6$2AX(XX%$V.8.ZYF.5;Z\+_-#?3+D;G%T#,H
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MU^U^KTI/FTZ:,,.#M1RM[KWK;.=@RI3S*)@E=S"RR>3S1=\=@D8O%_-7Z/7
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MHBM5=;J+CKJ,P7H=B+CQ.T;AMK8Z"*2PT9S/0,#*F[)T"; KJPW[Z4:'1TS
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M^LOL=S+J[X;"C7+M(ITT$H"[7$D_+,W?4[_DB1-=^UT+;P$@"= 9NB94F&\
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MZ6^=9#]!OUS_D^Q/LO_59/KHZG;^M@ON;IXC[0MK.H:_:$+FX/'-5=MWSM1
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MH?PXU\LV-+@S5*_KXD]'@Z8[XLE&0;Y++\I<S<%^=:4C]:<_,$T=[ NDHS-
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M=%9PSAHRQWM;<6P@ZK6G"6BL57AIA?!%KF!QWBX@HG+HB\4EP@CEX>.60W?
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M]4BIZ%; W$$^LU5!DPP=Y ?4Z*N1LO'-$\"#,2#20K"8-(%JEZ",-HS"OBZ
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MWH23AO7#]E>:+78YB&;K.;T+P9.V5])<A]_(;1K^1V/X \204!ED'D,;FAP
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M+29TS5P^[Y*M&^9*VVCNNKWA^Y>L5)U#;A#![E2215?#[*.)V-SKR.^[:5K
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M>O*$+HD+H/!+XS*CN5O.[& V\<L@$G-3KR2I<1K7D,QD2[6/+?I:7[7@.%6
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MW[ QN2X#)"1'0RIKHF?QZBM<=!:N[3%HFZW3IS>NKVU? @98:$!+7"^?%[1
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M4DW>\/WF"HSN%C3_X<+LQ<.LSBR-JJ^;M?"S:P8[]=3GG5C).B;7:Y2QP4L
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M2\LNE]);F=&67.+NREA_OY2Y$+*: TB'#7;S8/;C:QKSF0<H[B'/.^+5&,)
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MF=EX\*(J[=%+P,P7ZUZ?URL?>(P6;[$"LA)?[PL7^J0_BU>W@=^J]@CPVH4
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MK.X&X5,:(<K69L6*:S>-"G3"ORR9_.-\@EC^SLKA:DD[LE-3 2:9_O:ZRR]
MYIVF;%1+JGM!8VOF$6B)@\=C7L<.YX4>$99[EJ^&>*G-5F5!7OY^=Z&[L!QT
M7FW[$!=3YAIBMO][5_>LEC[S.I<EP#E96.0X+4':TC'0B_'3!*>+:2_W7/M5
M>K:$1"MR@:I*.K=M%Q.<P1\1NI4FX0]<O3<RB2 "NXJW:>2):S*F?X\JWX(
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M)B"_8C/3!\'NL<U8KJC5-2YGJS0S$*8@]HT\KQ_H9.W\1B?EW@]OF^U2Z6W
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M3".O%Q=,0_1]Z V)M+)7$]AT/^C;V;'?I\(\&]&MP@?HX6XUA[]HT(ON&J1
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MA-&.N&D38(\Z5:QWB5K B&O .)$)HG"'BVQ/#)&@]KREL]:)46$M^[-6P&P
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MB5^BZTWCF(9 OTK&GL2/?6]R*+ EA?G;K+VS$!8]Y)\ ?<#+0+8KP+NGG5<
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MP3];_LK:85_WE,Z873$*B:\H.S6,QO]]"S&,04O[4)R,""J/CP)N1^XUR\Z
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M6MIK%H>G-;UNE%N?MUN+?.I!$4L\VL.")>!=CII^,5)+=0*VO /+5D*K.$Q
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M78:D4_]R%#MY\+Q0A[GR$D^,S+RI8_N[&6*,?C#PQX>H 2%/:V'RSS#EI3,
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MWE(HW&9-E6Z<9+4\.ZSU30(F=T7V52I8M?^:66G%YY>!N*+Z\U.?L,I6SAE
M!$LR[[@SY5L\(>UX?"F5(P@U=FQ(";NL3.?VBA"-P/%(_7IHP#@H;I=!D/?$
MLJ"VV(!"Q !ONR!?>.D[)^DBH80.W2TK^AY:OZ/N-0W9%Q<AT9?Z:POI5</G
MEY** 3J/67FCBQ%2!$Q3E3-G9PSBR=L$Q196^:R?9P#.+-Q:G R/*"JV52#7
MTS+F4N"/757>--W4AU*BT?C.^)4VH@-O _1KBSDH.W\XOF0I2=LZZ]-A:_'G
MZ:Q=_@"&8[]">JT!G@VWSV*DN\OMC]@ZVPG4WQ[\MF]2Z?KA!L*NQ3?P6"^:
M3?C>NM@4Z"+LR,-W?B=<SV8F3TNS%L,>[[)!NW_N=,\:'G.SHALW8D<(^1E.
M6E-(?:P$GV!$]>))ZV>LO]9I=B']DZ+X5247?P2JM!C(URCA?6O&89NO'>#S
MC:-/RR70+&4SD#[)AX?:RI9D^,H2@LB[K4V,\;("$!Q&2O -,GM<0M]:8BJ8
MR1:_TY5F(KU5&PE9R7O0_?N8T(_;@S>$!^1Q#3 >G(&; <%^@9G O.B<;0PS
MXUM@)MOXQGR!7L-:I9(8TY,5 LQ"*3Q894T76SLP*=V2[9#&"U!5=S2<O'-,
M5B)Z?<T!'-S&)89;!R_3LXRRA<-]AQ6S4BF^*JXU&.,;4W###R'*08:8 _!
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MY9:()*FIQ (Y-BE^[.1CY,)G)\,? RF%K;B,/I$?KOW.J<"CT??Q]+$U=WI
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M^2Y\^1(>/W!Y%*Y=8CFHTLV2T6Q'QDPV KM. #8HYVS\VC#.??K]I**%3^\
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MA@'!OX<=IAR8XYZ1N\F9?@88NMR*P+12^0Q+RH":+A=!3LHN!B];^RZ)0A%
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MO'K9X[_+LH7<?O#UG)^DZH]\%6@613%F<ON$/9_8PY2(,<B"CK XF]ZC1ZZ
MAN&U-BN)W=U"CM&RE9PDFSO9/F'79"YR-3&,G< ,>O-1CP!ZT1Z:M0A6JR3!
MVC>O^$:@0NC:5O+*&OU[->_H-\,Z7@8DH8!KDEJB%VO^V=)*6NIB.,:B&::.
M7>>!I<&9I]S#!8<&']<&\'3+ GPGFQQ9J;MF84%;G#P3R/RW23C+M69 L#1?
M)PS?M?\A"\Z1_M:]-[#TMM(9\8OB-DMK(/<%3M9N;Q^BMIKTT,^GE1(BJS(1
MV@X)BS03X@&$@QJD*KLWZ\=T^@C0<O,DYVA]*K$@;F["U8K>%3VU $L$_=XW
M9:YH^N-"9"XH.UFVW(C.1[*:/%+J$:H=O+^+TESOW*^, YV2WXEUI;]Q?I1Y
MZ=H47G7I",!40O%S<JZK3J[);/"NN=G[19NB*W:H_[1%@1)3^>@CO@@&-X&6
M+PG*87^:;5<8@3R)_6SVDW7Q-;\R.P)//]++JP@Q9?[XW0Z>3+,+57YONW*Q
M^%TZ<PIF"V5S@'/0C#4Q"="6$/_=EN]\(FB"I"M6K1_TEY@V!9)0(=E,1F6+
M9!+@,)=K>\VGO$-U*%WX^-D=[-TZV[!;7XAN78! 51QU"/\)9F'U9*$N;87N
M\YIX/1UA\UMJYF=M?W,*<,F;UP[6W:)H\Z66*Y<@R%^5_K+[^#>6",UW219#
MW(MK$\@?WO-.4<"'#<*5O--4[_9+'ZDI4@E4!;&+^_R_3SW[1,TE:J]^&I&O
ML0)_-=A*RK>^R#AZ$>78/GLEL<O&[O/)C4KY;J-W=)*E4/@%6*+Y"%I>_/K0
M8$B3*V[IURE \ A?%F%/U4@%9FL5[]RL$W;_!\OP?T>W%F6+:U$0X_^DQ_O0
MMCMEW%G[3(6!OXIE1C?1.T[3$V.304?P6*<)N23]^%APW5X@(=1>(9< M'_8
M)YD]$6YY[KP0X'=I1:\2W;CWA-;2N8"X!C$J*J1=3*Z!PM"J;A9M&W#>><"4
MV5T_R(F"CZ>9E,[@"?;@2W*>;W";&NW36I;7Y]=Y/28S1OIR4<N+HQN,R6VA
M2%W1/+[%_6/T5X4BSO80C@ L$](SP^*D&02KZ3+]&D4&@;)U;[DTV.ECEU<%
M$0 5V "V5H")E+KD'^2MVOV ;,^=7INEP_N2^=HFOG>IK?APT?LM8S6PE-SZ
MH%[!'ADWQE$WE+,=Y79 "YMG^+?UQ!YNEH6*4-<%1Y[E@;E?FG8&XY7R%]J=
M=<6J[CM:?4:8\;-K)J8I\8#&I.=;16:@@>HY=Y >\OZ)#D+@WJU*^1%72COU
MS89\M*-W_UIZX*F0XQ2X>KQL-:F6MVP7:S)_")YXDN2R:8Z&BUC]"A>L'5U_
MD.WTYF,TX^+)T<!X=*^A(=D>N5CD+NQ0_2(-7"BT! ;:'Y83PO(62AUG)3-X
M&4C\0\C>"LLS>9\+?0IN*-\=2QNGEN#V:[.@_H1#&9FAP5.G!T4$SOO:&T9B
MGK;()MA"Z\-[RZ;RJO7HO QP?4IF 8K4F)+Z).W,;W&7XMB3!Y:&#D;D=4:B
M8V+\_)EXF1I5;Q'29%:<S&"H; GR2]T1P%Z+S#PP\ ?MW=]1U^V&MH<'0QT?
M9,8XQ\G<20D##OYBS*$$)F9UO)SZ,GK/_DRNEX1@E_>D'6OY-:\3&=SG/4M*
M>Y\Y<OF/#E1X+AK[O:Z.C!'5^$ MPF&QP4QY<D_C%2NCD!C#MP]/ 0)J_FVQ
M"4$RPLI^?5<M_V3-K9R6C>JQH_CGQQ)\D78GN$HG8\N<)R,T+]]X^G[?\I7>
M\<?'1K'WT=\?' #9*3B(''J,JM5%IE;>SDX*-_EQ\CT%[E]Z LX)PV$[<_*+
MG=S2Y&HY/]_%1H65OZN4IEJU@^P7F+1/[JEZD7!@^='M[-50K?><56WC[HM[
MS\)*&8=6DD>KG%WAIUYM?K2[HRS$TV/)1T (KWR&94+8J2F]\FCV7.*E[YF8
M=7PZM;GETK*7W,+!C2BY5^H<+1\BP+'O&A+EO0YNDMV':69"U_U9TB4N?-E!
M*7'RAUX?,T.+BNO'6?W8D]"+6AB-T/9(^ 'B6X!0C2[4UV(BICPL8CT[#0O!
M(\_A"W"N%;IDPR!&WHF78D-1Z?-YKBN6>PR(?)0[#6IHA62BZ+7V9^4-4M<S
MG+91*Q$LP 1*:XHPMMK6O='O!,F\Z5J,PERR;S6L&I\OGN0A-)IZYM,795Z-
MJPF ;6!N-+HVDW@O;N'NM[ 70?14BHPGW%YM,B!;V2IF:B<*(X[[0,FL+EN9
M!:0= ; ^4I1I79P)/N.VKQV\'8K@0R:_=WP8>\!6[95+K=85F^;05:GYS^4G
MQ<P\CP#2.;>V@S<2O??D!BW+1T<:@\^<>D:7HR10': W)W$A!357['#*=21[
M?1\Q'0KC+\^'=R=DE+X(+(IJ5!@$O.Q>Q(J\E@R.:5]-A52"*6,I:Z%2^ZSZ
MS-FBFZ>>:CT%"EL><PR_)M=1\9NQ!ZH<1(:EGNU"3IMW]5,(?A,X>2]4K]BP
MX:OWI>44=/'\'!>"F_IX[MZ\\H\K6Q(1FBS Z.^A3B$HV,:F25T\O%K^Y:+9
MX?JMOM'00)2'S=:^3O03_F5DW\12>$*8LJY8MG[0A]0%9.#ML0>#(/L29%4#
M<=9MCWT;"1>A#GIS)-IJJ\UX^0-KIW@]!R.T;I67>J@UVN?:.]RJNO'^1.\@
M9HG.C1#^E<4_1+*YI?JJ@EM/X)MI3C]URA]E0KBZ _37O)\K9'T&>^GW,?S?
M7;OTI&O8,/118)EHER^=GQ)%S5S<./M(A6GR1NZ;!ZH/: H%74KNJ7CDI#Y?
M1)UC]><WF?MT/O6(T+N3O:.-TK7&L-\EC[ZF% 86<M 3-AIH(40(%]32(IQ[
MJ"AG=)BP]')!IFPFU&1L:P9J]%U56\.IM3[]R?A!_393A'94P@(&2IR:.3$[
MRZ[0OJ[*&G5"8;JT'^DKD*] &8L]'VLZZE=JDG[%^IBB] *",V:&U2SZ?;2B
MXYFL$1Z>&;^%7C1.V]X44_O5@5DB>I54K("94I9N1$K79*O;*8OPB<TEWZ4:
MZB2ROS*;LS'(L9A+TPTZIAE>"9L(;MCN_?1.QNMD9(Z#?>7^DE>\^=MC>J?"
M_GAVK$O3[^G$M(ATAUCL;(3VC>/_Z$_<);=D/2J]D>^B?(U9+%9\P9HN/ 9R
MK5BA3$^[?]=[]T7=4";\(?@5PR^5NR[!"64?[57SLWQ\Q>6%^'D9GB7\!#$3
MM0JXEP,%U"^>+7I5R#A8=@3HL T\ K"RJRC*!;&=F=$5;>9;;)&@1I8NA\OG
MZGVNV5P3-9P8JP)OYX8M( 2ICF8UZ0Z#1'X!A;-Y' %"@"UQ7FI^?X>-QO!Z
MQN19B0\\*!/W\1D\W)E]6#<Z@Q$5QAXTAS-^C0(+"M=HQ/4*T_FRWA]C8R,J
MUELGMJ8TO^/B*X.-/WBN*]9NMY:W(,P.L6T:+#0"'=BM?9D?=8W$/)N5=*\Y
MO#5MX[%S!" ]V-D^SKE8NL)C-'VOD*,).WO5),2F9>A%TD"N7M3:-8\58"09
M'O]^)-26J,7HD<HJB2W]N;=NE=G*1=.KF)M>#E;+K[;'7K)F)?.%^?Z-&06\
M6)@)[N_ZDWQYQJ78+\ZPE<\VBHO )D+E^9K1-1)+]QJO18G; %:\%=*^]MEF
M,UP26KM6T<].S>GOW'DV/5'^T>" XPA@L]ET!."&D2#?O;S0O3(7'DF$_N2X
MQ6@C?@;-ZH81A)<I>]9RUT07Z+(#@OWY?BPO. I2<X*\0*KO<7[CX]&9>@BE
M1DYFV"S)?%CVNW\/I&J%_.P+>%ELF&':PC%.=<J;PQU2:E^N<DOW0O"F74%B
M:&"8*PI/6.>8E)\M[6F(_/6N?DZ(FMZYTR((U>%9[F;SO:G6(ZZ3!PA1R"C#
MEB]_=V@[9WC^"_LH:DQ[/A3>(?W0\$8VW\!_VK#__QC_;EPW4OY/6W9//2*/
MMOD?TYM_WOK_W[,%^"_'_ZR[HAVDJW)/9K_DH)Q&JD4%XH78\?$8Z:#WDU^J
M>J\Q6#=R0,^^>5Q^!)#BA8^]&[,F_V8@KQNT,1Z>\Q-;+)NEWMA8(KPF#_9%
MD;Z<W<NKMLWG&Y09H %+EGT;,;7DO2<] SF 3<78OFZ*5E<JZH32FT@+NO@Z
M<^=CQ>W< F^2K9@(67\]EF:/(F597D4W$[D_:E:.5K?P?NXO)7'C-SL?.]7[
M@0:8E<EK/9V6P JUY-+WDJNRO1;B:BN__,5/44NLABL>#:-AU8PQ#A$+VA\7
MR^;#0OX:E1VF"?JRR<QGY0NVD,2+91 $18&5G,/:<F*>$=^#@Y>V;S@[34^=
M=C:C= _2GHL$K)Q7'*A#!R,W;8J+T 3$%\;%N<$&16&8"/4%$LT.AE=[9)9<
M-1H01S[;A#D29>.%@-J!IK4)'>JG:/F"78  ![F0 +)\CW7&!DMH4_##<MJ5
M;K)\J\9>3NT'\FI-BY#F1?D?>R$,ZW9U42!%(H+-SLC9)\1;(44PZ2:8W MP
MIK+"=W;C,)5_)F6TA'JCMF.S\Z3S:LS2;@-IMHXF2V#M9;8?]G;-$]/*DOO8
M7&TMM!3ICU1WR+(C^W][:G<G$,+;ZI\,4,0Y"9*_V;(DSJD$@9M#+)@1SS/(
MY]\\AJAI[VT3T5OKC+!TAS%Y?XB@?2?)(U#_I+;R&A"*H[-A*#(E[^QL3$3,
MQN](/?*:#^!E0"]<T2%P#.,8Q/1\J)9 LMDD!* O_.#=ES9.7),WE_N@QR3?
MSR0Y?J.BBQ7!)Z"9Y,S(P'D(P[3-3%\:Y%P@1[/&LJYHIP_^G(2*ONA.Q*4Z
MVQ?OI\!T+ (%3*#:AI6MA(OG;]Y[-JB*/=F_"VV\MJXK=H_\WK;@+#6Y7[W%
M>UW=GV0)5LJ]2B!YU_S>9"OJZ;>C&,:!V"LFJ#'V(1V!IE-VO=^696<\OHR$
MB\&JN\B&BG';K#XJ4BK& C.\#+XX6NC50662^ 9J0;^-_$3V*7X"H;%0;#Y,
MDQ6KFO^R9=P ]HN[F!IR110:.T1C7YB",A:!T8SN5A=NZH OGH#'W!:&C-UZ
MD]1]Z &/TH4[>> 9=;S#H99M+<R-9%1&F+O\U]Z=B"FKX!PT>;TC\#@O*R)1
M2T8Y(9G9MP*8T0#?(P!7ZX^@ 7#1WDA(1GR+DDTN[<'EP]S VP>6)L3*,_:D
M68DA?U9HW*"6WF;92E 1+IQ%3-(8VG2I4PB=R:;DFG0PP'0$B ]%4 VV.6M6
M-T(SYYH^ 'M!$M+BK*JS1G7C=,/!/%\"(JY%ZH5?L[=9#0+RA7O/3AD9Z$UX
M[1DJ1!<?RG8^;$]F#01_B-#HCRKW #$P1)Q__6762S,]?SN=HNY*DPT_=P &
M#WHQ9]>AYH(3#<C,B1B^=^]@<-.ZD.YSV8,.]P^!KAUTIA&=NJE.,+ A)4R7
MPGUA[VZ$.!$NZ,C)6QE;(RR=L_5AJ1Y_R4ZGL_<XR*G/!+>3S<6F^FZWIQCU
M!LP"R1:?03?SI<A=PZ:.+Z8D>G:M+'50-!U*:])O"<VU8D_>JIM"*H@7;=J_
M&,(O ,;R&04 B=S?U_MOS_L? L<-TVJQPJ"7K3' -V.T"YY$3M:IY;HG)VLI
M%U/,: H P4-@/%B4FO.D+T$5>+UD=5R6KOUG2^FM# F[? 0X .$C>=8V]EV9
MZN%1)PM89WWQDP5[8XZ$ E9L(2SP0+W//7L@WD560\K7#A&#X21"SE C4!EP
MKTFVS]E2\7M>P<0(F3&::^D,K)BF0YB2#BDV&;1;R$")$QWRB*5^/6?0>>;2
M=0>WPA=$TE./WU:";-'@2;Q'5#P]C14=0DTX9[T<>8&D@2@E26_1!3;#R,R0
M(//1:U13AK6+C*Y$&'.'S6-=R;/D\*BZ[6EX1UEC&P#NND4[I8X3XVVD\">Z
M.WOZB#QKK_/Q?F*17UQD$C3?L/57ACYV<N\"0M=G-$)#)^H\)\ P@OE;<+AJ
M+/D(0+^U'G\59Q(HS@F2]R6(LWW("M(TOB+U$ZJ%%6-J^0[R+X>F3^/(#N*I
MS,?\/M+!F'C#$._)<_+/H5KPR-/]UN>*WG2I9;IDBI\MU"VT-FE;)N)JN'PI
MM%G4RW='_$I0P_(;BD/&0TFAL/I$,<=733Y#YRKZ>:D>0UV:*HUAL[I>YGAS
M[?+^+%UJGNL3OQ 3@X'QR"II[Q8>DBX'^9HCU5JHNTJCNB<H-]BK)/0B(YU[
M74"$[?"][QS2?Y:%["+&/>@2K9&Y-K^>?V_F8U94J&@( >EKW]R8)V6\%X@3
M^(@(!JS^^A>!EO_JNC@*@G?@3NS2?&909^P9<O8;=_K F+4=(B7T4A 1"),9
M\LX?W1]?E%/C/3S.<)XXY$+!26O!;3][BPZNDXB4$UOE=.V1!Z-T$2L/M17N
M2S\L6#192GP(!7'T\S6:!NBPQXU0I\=N;=,D^[RER-]>(.Y\X;L6%XNFA .9
M1R,4W*S$."+6SAUH+('\4$ "N-O6TBXJ69)Q;T1;JVU6NZ9*4YET153QU'7F
MI1.-$ 88_U)'K4!FEKJ$>8&.4GY0(1L3V3 >I%XZ8P^#W-=[!(HQDH_54?6
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MSP<'V &NC23D^4/-Q@<^;;"0R9=5%%]"E809+)W^42\ZVJQ(&!E!CD76X&J
M50_;S<87(T ]=X;1QI6) 6J:WV#-==?<=?=LE^U+DFFV'_7+L816]A>:%6W\
MCW\EA(QRO(6[^U,:^V:9+'(D-U.M@T=S5<?P&@MI.\:2<N*-&7?40TR9NDBT
M&^1H,X_ N@%'ZW(&'R$.W6UD_SE8[VHHHWB<R@(V-7(MQ,(+.<^*+?F:$QOO
M:ARX9]5$Z76%K1L\Q\XQGQ^21X&'>)^5<2]I-12RLA6<]4_FUGX\N"_\U&F3
MGTDD?[MNWIO/P^$*N9B8]FEEM,+)55M]?\SL/<\1X'1RZA&@1.4(, #M;6%3
MAD-AR;X;AZ5OPE48\%3H=<JK@K/H>D_5FY(M";I>Q=KB^2-;GHU?:K_+50CI
M1FB(]FE47B+?NT3%$]'3RJW%P2. A[#R^RV#-=8R0T]F5Y9;[IN+<B*?2II0
M7T\^R7F?DU?CNZH4Q_E(9&$#A2 :)GF!9(MM<Z4LFAI?Z0MZ1>0LH3#BE;-N
M@98Y^#CI6F=6C;,Z/4/% &_8/;RA)5EN?V08EC/V[!9S %_O<J"8)B6)QR-3
M* ^-+GOXZ?^T]YYA33!;NW 0 >F"= 14F@(!I4H+J _2I"F]1400"!"DAHXB
M(%TZ@A2E2D=*Z BA(QT2.B3TGB E0H 3]_?M_>SSGG=_WWFOZY3KG/?YD3^3
MR:Q9,VONM>Z9R9K'JKS<U7O!]@Y^)-Y<2S=K?F98S&)5OWX&<8$G>_F)A.EP
M@YN2K:$=O$STT4.4$(X9>Z]*_-N)^-6.ZWT4C$$2<>:A&<6P[NXJ\_EU%-9D
M8T1-CR%L(&[+S!* 2UIMF2Y+*BUYB/F>NN)QFNLN]5$0\0V5X-#"@+*X%1=^
M]_$%0& 3L.''[H]12?.7Z=#=2Q9]NJ+:UUY_!NDXOX63";<9)O#SN70[OG9S
M.2,Y^$I@P)Q9[G7(S#,CW]F>(,7;_]A5W(K 6@9[%.+A'<G]7P>L/8[>/KS3
MA=M2YE)&-H$7,RPG8:&P<O?^T)E5U0E:"/ZX2P;),]7@_+XGI>'-)5GP;J%4
M="E!UK<.73/1I"F4<U^(+R"78]W/  WDM!BK/I->TF.!UVX60X6DKW^XGTUC
M?P,?@OY5NL??$*GWKL[D2Y3;D,\T;B%*U)U+:$)DF/]P];)O-Y5.J:M<.KX5
M77UUKN9D86/U 6?U0');67^'M)Q85).L75K(Z+2FR^?/_I//_0M),^*',*"/
M]BR%T,6FF;#D.0J1@HJR(7V<ACTW@X7MT36F4NX_@"BO/._=O'Q\(WH^1:#
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M*IAQ[?LC!/G&V_=_6'K*+C5#8+ZJ'/1AC@=)B7W +_N(S,.O*@"7!J.W.TW
M\BW0K13=OOF;(N7?33OQ:NV[6X;-[ZXY_[QK>+C:3 H>%B&HYC>''']<5K*(
MKAZK5J1"(!H</3G<0>:4PUY*IH!EOP?85=]HK1HENLWHW#DE<<?KLH628J'P
MRJV[F^>WB$%_V0NBJ@4W@#Z*3"3]^-8VPP A^/NJ=-\>.JLZRT)(G$[(]'F.
M@GHY/M.L_[XY [W2W7+#+T$2*R..*R,QB=:79FR_MR3UP72^R[2PC//?VW+5
M+*CD!ZJAW2SFF$CZ\&YM7]%GEB=GSFG/W%=JXX[=3"P%\![\YX4>3J1Z3J)G
M]7%C.6E[Z]GTLL,M'.;YE2S%&"V30[-4[_<R?TA5818N%T1XT IME*715SSA
MIZ*8[W;8LLNFXD"F2?ESKW[OL;[V60M1"\G '@53((8HM!R/M>14Z^%Q@UJ>
M4LR=34:ZU1(W8#.%DB1KK=3NQ;$"QZ;-#ZOFGLP\N+Z]8U#CFWYZ 8@Z\8]N
MVA;Y I\3BOE8KA7*MAAN'7[I"Q90=-<N6?HD89.2]40SBE62Y(N<H=%[26HQ
MAHUX$\LN=F._TCF=PE+3VZ2]L>U[C(ER7@3^*EK!@J3@C):D!;MSUK&#0/IH
M[OO'WY]!=L]%#DL;;I/VO\+;E&X<TV5RX*XW^$=%J0>YFZ/4%Q<N3>,-;#+5
MH^<_W_N1(C:.LE !,$TI3<"'Q[Y>Z;EQ($FRV'(=6Y)V_+[&-T/NK$3JRHKC
MDX)R1>'*D19V2^E*E@*,O]6AR4WB3$:/0"I'%<3R[5*\6*7UQ-7E65RU72&V
M0;)B['CNA4[=-CZW=,U3Z"$KE:S&2B[>HAS"X=^9V8KQ=O[L,<.Q2&@YW!S7
M):=[@WXO":56^:QQ ; /L=Z?K#AMKRN.#3D9"!G/003PINA4IL8_YV(%)6VZ
MZU+P+[:2MJ'55M(T0QM;L\Z<$!X.X"NP.PK"WD7:<">EF57Q)-[=M1J/1%T*
M>C%$1UC7G?(-KR&;NE785;]O!H%,?G)9NDAM>/8F--_AR3W>[+_E_E7^?5J^
MA.8ZKZAU@P3<2%[=G[>ZD<#5+/P5E\C-)4<C#;KII^SR54!.QCIMJUC"8I@8
M$#)L#%D7JJS^,9^A O#>QX/Z!D?6FG'WLS2,>Z_^"MY=BCFD_W[ZO %4]/26
MR/S&.[,P@^)* B/V9)!]M]SRJML*NS8H:=W4.=T^=TK5WH:JDXH&0 9P,84C
MG!X"'T,6J+=T\M@'-ZPMHQR&0EJN]^=!>&8XD%]%\PKI]"8_L#2>W":-PZ6\
M0>.4(V"B6AD$P3LNP7'F*(+0CK5A3=I,1P!O\@GYT\+4TP)DLW8$ (&-#4MI
M;^&L&1FU%I]Y2QJ'A!-!5%:''G]/$NAY_,PL_\-LY8MW[@,ZF#T*$WS1R!_1
MRW.=/V2H)VC=B4.9*-9^ ;BZ20;T:&72]"JXR5/7]BMHQZ*K &UF-G2E'[UE
M>ZK8J++R56_8\(R)) [M3^LG@^Y7Y+>5H'XYTW1<ZO/_ESIE:14KXI4I'=MA
ME.)T+^SL"9]+TJ2><91P+)3T-OYMBU#$81RA'/BY^[*1%7&X]R(#./N+(9IE
M=FD)]@T19VO@I<(#<"A<]5G84YQTN<#7UR0_-*9(M'RDB+  A@&A3:^A&';G
MF?[0NV\7KK]"IG_%\TOI7)^$Q4!J.].8U>ZU'9?51@!Z<-(1\S>P9\AD./GL
M8-U/"H.B6A!C52WVP[  R%U ,:;#?VG+@I:)9(4:V]]Q)+B=!HZTA8^IWX^D
M6.9.FL1KMM5FLL08J7/[]K:BGG3O&6D1^WH<'L"A7HS_*+4C89B@W?B=3O>5
M2UFL ;:SI1%=,^HA_;-'[W0,Y7(N-$\TPE2_N[C'"Q7PR/SS'Q3O*]S@HXW-
MPNVUIH)A"QH5W+H>"/79+-/?%;/];M:/O4S[^0BY7#/.[S]PFTLU#X)W0S=.
M;?:60$XB'=+>!A9[K=?\3A;*L!0(@(?O LM+H&G=NK6RZH85!7B38D@R^4)'
MP,UD_"LAN@#30XW;I'3]".G:<Z98Y<1?%7R6EFIEEWA",GG'N'8D8YGZG?)[
M.E(K G1]C4I'E*^OO2/PO$)#'E;>2UX9M/G84%D&?8H'2^ KMJ9!5:)9?#$<
M+_4^$% YOZM&^/%#,?[B]P4^=+M=/9M=*LHR7;J&+HAPUC?9Y!9-LU!P>0$@
M($:;32, JWE8_V\PO0/..Z97,J2KUOA.)A:HUQE@KY3AHY]=-^A<NEL@+R(
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M!8#<!/__F*/F#Q3MQ(#[N"Z%,'J(7##L,'+FL,%>JY]%2/4)RN!W)ES.I5C
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M! T]2?M9W&RY/[.X[%.0IC4Z0R&V":%_A.T.;P*C(5I/U\"9H^J\0$9!'0?
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M2QWP,ET'*>%6D"(P]7;_58JO>9<9/K@*=VVKOB>.E\S/SB+-_(WD;VQ+#!>
M?AV?3/E2+_1"^+9C#:V&ENJ39J?/RT1_XTZR]9&]Z[%#\T%\:73W5$1Z2'0$
MZ=GV:TL(3M5\0O),]8\P]=3B^1YFM>-2"][VAMHWW)^+++<2+'KY:.:?N3^*
M&2?)6YQ9N-J?;ZZ)D0SG>ZBQ?;Y>S,V!\R\(%ZB/(:G^WJGMB^)"6WV%%;?)
MY7U*BVR3J"++\"DLTT1GO2U?0Y:)7K-,DZI)W7MP 0#*[BGS*%,8WJ>A/!B0
MO[]E:5:^:1H6VB)HK -$!-J8=_'>]H%*5>(T.U@Y9$+:C659X8Q"JC%UDB2S
M;XFN007X$O8"B1E#(%_/_;#YU,4U>1)G>@!XZJS;"*?Q62UV<![9,(HIH*F0
MI1C>D<)DD@5WG,N/6CA+>9?L[ @^_R9HXDUD1.M7>&\L&]&7P;HN %KXZ#R8
M#YLUQ*PNLC$S&R5F[UM*4,1%MZ1_W10';Z3\8+G#MUGB:P .UP-KX:P?AFD[
MP1G-DA;.1H@N:YQ=O>NQOX2FY3V,$A4^O=U4]>BP-5Q4-+_V^1"U^W,=C0-:
M)?,6I )C6O2[FWOS#.^'M":SZ1(;OI*D7O)Y.5;<:X75>5^>XSM@W>GTRDO
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M4VIKIT0EV2RH&W.^O[^F6Q>[Z_\93G:B2^'VBL83J8N@_&'WQFC#)/,VCB:
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M@!_5[2_;I*?2W>?^-R\ +60\4[5*/S?HS["WOT16T&_/\/PZ"#O',P7:3EX
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MON/=I(U4#_=.*2$NY\LU[.QZ/,I+BFYUB=?9+S[R4^.3YIU&D@CB.:2$1Q[
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M;$+3]Y?B:;G"Q!6V2C.#M;74]P@42#7+IW.4I\HIG]*HDNIT6:6(QE/H>?2
M0N6@3VUFM\!JI1L. >*33S0,##\S#6=#'>OJ[_3:.?(>)BQP.^L_57L): (
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M4V#J7;?Z(#V/Q!CVO8TS5D6FJLY)M8$LVKU[W6Q;P4X])Z0^I1Z:I?LH"&
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M5A[3G1 XU+_WZK4/"3YW$6-)#*-;D7@U">RY/U=3E [*QMF1<0;ADWR8\3X
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MT55;$ 83W@ 35TW[XZQ"4.KN_4U#>]AL",B <-ND;CA=R ^^EW4HK^!"X6.
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MA'%1#7H)FC/^V9.^6CN@^()-]1C&C_K0Y+H&9VH9*FT*?C](4,)FQ$;HO-0
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M?N43A4H)\:_M>+V$8ZHP4T@:V@Q%,=<!<[?]WL$U/5\.%;N3%/V133Y8M?N
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MK$0S2;:V!8L#FX%>HH'AL-M!SI,C1?Q5AO!FGNP!RPR>L=8YP8$[=4Z5)4U
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M"VC*/T_5FG2:LVI^7FBN6,?A[WDJ.8<@6H.'QWOJ8@>?58QS3[H/5C22VN"
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M<+)$H?:8A=/KUFWO$ 8]R^S_3@N:(N4B&/]I:^&<'$P(X_03MI+ _Q,+Z.Z
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M^5)&+!]V+ZQ,4K8D?BB[WNXJ#],U4H,,O$^#QFG#X@41$.4,$_3*@6I3VG%
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MS_']@;LS'$\M$9DD?(WPIY=!0"?\YYR#$F?=]Z'#IRMV6>+(584/7@J^" ?
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ME!'.N7?+WBNHXV(W.,W5HCK#5^1+D=G"S**6T[W?8;,<8S[W<AA9]DL##HD
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M3[!CV5I\O9J+3OGD67,G;AO]LH>E@GQHC_K1I^L$]EI,>0!,&76J>UJB-.
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M;7K)]<5\+:V,$DKHO$LZRK$(/_H?[+UW5%1=DS?:"-H@.6=:,A(5R:D)DD1
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MY(EB.\BN,JE*F.-:!YQ$4]7D;7#/BQH"YBX0;Z9U3N^KR[<PR M>['@VCSX
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M#B>;-!U-+2/3SX-.[-3]?-C,5:X-Z? \]7(4"Z"=93#TLHW 6/>(@M-,%>$
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M *+#J)8N:Y>9[ZW03>T\,NUZMVCREHE"[0S[.JD72S.#I5HLCO)_4FYI;JS
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M25T,&V=,]LC+[WV5=/]NG+C7!G1#AFIER^AJ2-C+;?2Y=.][<39!)>.&_2^
M]$^W+VB<14L1%]H:>1%8]4@$2GTH8X\SZ-?P1/S9QIHLEOBQ;G":'FV%OJ5.
M%E*+))=.,+>B(R_<PU0F;:$^_#*WM>;[.>M_CH-PFL?9LE+E#.N9N;F&3!NE
MN>%BUKJSS^/&9FZ\B8=U.X(]270=\;J>,ZN,'=,:&B*L'5D/ED)7HGW3OVYG
M,3W]),%!_HAMGN*L&2W]D:NE8ACE59L![,Q7@^B1FB/L[=0M#;)#_$.R]JK>
M]MGPR;[;5/&>"DH'[K)]2&1F.VC,^.914B>%N9Z8>5NH?U-ZJ%0RTP%8/F3
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M]C3%#+3/Q7X/M]=OQLH!]T@BL"BY]+AXJ6J:OD':7M*>&S\HNR6I;9<OPKT
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M]LZ6E?7SIDN#ZA_%LY[^=.-=?B/2H/R,SFU]L'::&G%CJ-D=\]E^/'!7CMW
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M?];8V\/6$64KEC?)W.]XXVW\]4M2G[?XZ]:@;RS/>P>[^>\HI-YZ(_Y.B#Q
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MSU"/%B;VK;VZ1-U]+9^KM)IDT'ZCAN%H+?$$K]]ZO$\'"]7YXK16#VNP+,?
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M+E8W\^R':\G>WB&?3XFK_RJ_H'W1)_^[\HNC1F^/QP>CUS#'P+7OC3N,$<?
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M#L,-7,\>/;C=TG/<DS;/I4&*Z() M5/.!Z'G1]QZ>J&K[!ZNK]:R">.2&9>
ML4,8&D.V.M%9#-*J.!!WCV,^SVI57:#.W&:&=-P>E5D#*_FI7"8>0M:N@Y;H
ME*S<DZ0K6]5"=%)C$Q9O+:EP4FYORAX#$<H7B<M2/AD3;H<S&5_!IQ1?\_C
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M+WYJ>P83/Y ^]50!'"T9[0.S[K3D^TJ"!J"W8-H?@F%OSZ/%W:-5%WBPZNK
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M>3RNT\:WA]GTN>HCS%MBR;KB3DX21IJQ0)]&FSK(8!_;ARX^,J=D( ^..G]
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MQB6)J.QK0$0!P%>=K@UKL%R3LLP/N:39[CY3&=?P-#(I%%MT"[GB->J:%ZM
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M"%2T-"#+%08R#^ZTT5%F.?N.I5V4YY8H)YF9]$MU/X_=2+EX_[W\@0YB3[
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MJ@9FQWAUD-18?]9E="G]#RL"Q6-],A1W ^Q6@\>";XYTYS8)^Z,3VOO!R0H
MFZY<NWNF&;U5_6_JN;GTPN1M=J+K69J$E ^5R&T/^BM^$+84-:O\7TTA,YY;
M&V]&).R!E[US=0K^W$IL7SW_=8%2T7,\[J>0RVW^55/_[.SM"._>A96>0O[)
M+=C,0YNK.P[ @XMK0!S;O_^0O\'J\S<VA9R)U#7@ELX_Y?*A3J^O 3D"6=>
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M)RGS57GO;L1['G$9?]!0QOM/P#JHSAG*H3N3UP#)U6K@.:DI%.7U3]C)!5G
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MY8]>G/-=TE? +->SU*,^N/%,F0:RNN/'6^LH/GM>H[[=@^_-<0DPVD]R*C<
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MAX(?N=Q&'C4NHH:1]'/TC@Y%K<5=MC95YL:518\7.)0\XG75:CK<,BY,(E5
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M+K%3/8A[+7M%5U+D!T]&+@+;\01;_:V9 6;Z@#CVYLGL^F/,^H&5[/MHW@9
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MXA]ECJX[/M^9MPK+;8B'7/CUT"#L86)U94V[ST&WZ-&D!1I$96]YH0(FY_<
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M0Q-L$N^.[DV[TB%^EVORWJ<1Q6;1R80WR0TWW$%+4-(ORLY,M\2!*6M,8CX
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M3=M!P+7P;R,S/:=%$N+%XK;N;0(L4]50 [TYG9&R2N[J\RY.W#J;X*<22R2
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ML!QQV?@PV6_2^2>/&&CX3U_NDT.X=^XD8)*)4-+;1'E&+I-ID8D$L"@0'U%
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MBILL.]-ZY )W<[_5'Y_*2+_ "VTTEJ?RE'P[!6Z-HT^!X#:*2P0I(JZ8XD1
MT)]\-QJ]-CYQZ"M0L^\FC@7\=S/!7B3'2)E <5QAWTNBFY'7H3V(7E]#"EE
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M?@K,T^:? M@B]!%C)O/[VU(6:DE"!AKF-#GPU:,# GTYSM!LU&G<Y\>K'.'
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M8<MS#OF[(!C.!AU*X<HF2Q@'&-\0;.B%^"VX#DC[)QZ2MK0$P>W(PVM!=*?
M.W1: .O;H$M$!8@(R2T2SRB7$VXLF?#KGW-BW0,2E=Z? ?-D..$6EJ*-]Y.Q
MZTP^DOT@JN4Z_*8,?5!V$V:YIX:G&!++6V>DQR8?C<F\#,C5"DMXGADR$@5T
M#C9!*,I#?"^<BA292W9FIL4^9%ASA-A&OE#\//BRU<HW[![LS>]' 1X=?@<4
M2>2_I[^3L%0Z1>\F;F)<XMP&U$@(HBKZWE"CD^TX;MV^&' ;^I?:S?Z/O;;A
M0+OI'_"!EADI^.1ZLB_T<7MHYOD0JE5A)=$DY"G1:K68=;?:;H('$N"N50_6
M8/%>L_+?#,N#)^IG&(W)M(^7LUQ?UE[77M<O!FRCX([51A^SS<,&U;KRWF<[
M"!X];_!M*<?@!^*.3H&/17^Z\_Y:15LL8'[W!:.OGGD]D3RZ1=0CR=S+<"*\
M,Q.Z3MI_?I/3GTV?:SF(DYC[96Z#2Z%1ZG+IN2?3_;9ZFD;\P$XC,_6>CLV9
M:KY$2491@DZ!!$>)DW>ZE+6<,J*"DMT%5*"U7(Z?6]9V;*T6E[[@$LHY P,%
M1V @0JZ0@+.U_;O,[V,(LF>2/EC12_B0IV+V: ]Y)K>Y%LX8PK^)ASY!(,Q0
M%J65W$K<^R$]'^TMVMC?O[F1LDCYCPQ+_9\S3 4=AMXVI?B> G:T9]18 0V!
M$29;9_<Y[59L,L(#6<'A#8;%:S=FC=172X1^. #Z_7!1E*6= !DBS(_)%<,.
M6YZ$SUO+MK,VQ&$T)6E_G,'.)P?T7OLI(+6]%6RW+;6*WF=/:+0T^) \P/:&
MCVF)V.%I2T]\! 6-R+[.:DS8<*R13XX_]\G$39*V ,4Y'@RK6/S$0/?ND[?P
MNF* C0<V'7B_A==%Q<1E2?6Y\R3+?+!WFHM90OD#:PUGZFHIA?J8< KP/C;O
M;*)ERD3DQ86>5*#L2XPZFLZ'=J3T1^;W(&3*G4P/?W\,^1 A,I<XLDFMH.FC
MO!UVV]20L2_^TU[6\V.Z>.2J<,L4]=E;36C2!-FD0\TWNH+YG:G)-VLUI)(&
M90CF_6RB*B=*]0<\1Q<^Q?7BV2?M=5T_UU.@19IAC[Z1V%^)R#)8?T((J;YT
MQ!(35$'CB#GB"0Y4Q*7IFS8.[F;7)2AO>Y[;2C!;"9F:7U)4;A&Z0C DOW"0
M_?EJ9E&_AFGJ0M$;V'5Y\IB,\EQ:Q'Z[9<;'ROH-'XN/#G%+'T!3#O,!'K8_
M_LG/>G3^_G6 %[A/*Y'8_=[0)_E/SB_U.?,/9!.=T2#9J57+<32>^4]15NVK
M9R,;XG\N!!RQ95B;-YI_=48PV J]7'I,S/CHMLOG%O<R_-+7/TMB<?"C^Z",
M0%.B27@#[PP$>6<'72$K]ZCK96I7'^_6>_A\U#[B8\:V\=[LT8[S?$D0P\3J
M!:N>?)>#:LM_K*]MS][)^M8:)PID)+TU1)G4E;\_^NVBGI]LY??S1E>,R@M1
MNOL@ 6)@*+%:MV5@$TG]X%*+TB!B6E<TQ%'ZWCGD9(J30>_LWS*@2WLCE:K:
MX2\$P$\!#*(69W+,)+>+LC79<]GE^DV>;!Z$CSH]/R-202UO97F>T\_HVZ<G
MC>6WABQ+TF*"^$M.@6A;F-V3&Z< DA_*9(W)78-*$Z<'M[T94"E/X][T?Q,5
M"7B#F'L\"?<\DVJ^'?Z+C4*4\J:BR11N+;K I="9 C@&%YZ&3[LG\WQBFW!G
M_#G W&/+;)^+FQU1H/E)$C"K&&J@*9JR53N?\!>G:W\PW0* @SS)YN?S5LQ]
MA,MEQAJ&KJ<8\5UAC--Z.:5R9):&;D%7K[+;P%'M=>$UGZKFJS]OQ!!R_18;
MU8PLQ"M<S",MIQ-[;L2W6-L+W[T/XB$&+?)1N9>C6?(7);^),7E65D/ 68LU
M[^P>58RBG3;.RUQY$M3]>GP[296F]4Y[D$"8LW)S>WE=+;6-9):3:S%5NB/S
M<YYFF4W7U6F683=-M*,.6I\WW7=AY-DK2OC]SI>NA[Y!V1GRNYPT821SZAWS
M$-C:_"FP?*OQ?2V,@\POS &/OCUVQB-!P]DSI?_\*X0-5X;K?@/2WTB@N(H,
MEK6ZETD%D81WM_%\[X/6!0DL?PGYE+7<(CDNLKX!*3G!:\/VW+* U]M+;>TS
M_P3<IY_$".8_'K(Q6&X3B2(A(VX)@&/3948J[ YI#ZW^BBZ*)4J/"'I?@\'N
MU$%95B-!?T8P$\VEHDY(0<*(>F$]$1FJ@#COA'+,;FWK=1TQ%G7SLQK-Z Q6
M[BV-I'LQJCI_52.C-<W6T)=N8FM#V'7A[BG@.%1!W F3<"/4.V=X+M*2S8L'
MZ7BJ2F<M!IRN]WKJ#?W:%^7:X;<;<,4QH\-ZMV6SKC0E_V-M?W"M.?0,_R1A
M1*FCN!HG*L^*)\4(V1FK'OF)7JF>OO/3U?OS1[L47<!SEN,U*-R1:-OH<%':
M]?**C$,7[-I=8/X($-C)I4B:D TH5O@,?H.;7WCH)P;CAQ4WP2-<RQ Y8N^9
M]<U$>\@W?Q'PD&+Y+!*:ZKOR "[=ZC/#1!Q5DRG:4M/K732_GQ,MF'X>\#LX
MPV09"' *E$2< CI<]O_]<CN/?\_Y2Z)W&:6+2>"0IR10]"[L0O<[L9M.,K67
M'M$9]OMIUIE51S8HY\'+;V48C(G*N<LR2+>)LL6 GTN>V\\X!40F[8[P&5WF
M"13&LQS9XC\C>29'C3Y0!J+Q0>B$U_?V+REIA2(&3VL>? Q>UNX^>M3$2!2#
M,'^W2!!8<4-7;$('6P9EVY+_96N9;.;['\X&]1J]=\RS[5Q,2AXW)]O_M,-P
M="7+:U_[I_&+VTV$(+BS/@,"ORDL!(<[<<P8OGK_XGMO+"U$OA,\7C5YMS)#
MG]I3'^DF$W.9[Z)NEW>G*B<-)*S <O6(*^DD-5J,XU91SCT/C$G^BJT50=74
MAKR&$U)J>YWH]#VO[L72\WDE<![SV3P>9Q%?KADEO*(H$UA-C$K3RO9_+C*I
MS\V;/YA#1?B;OY\(^"J>?O"PEC=]?Z%L4SX5K#VRG<DFT3F,<3J^#5=:Q(U+
MLF:9W.CG\=W2D]][=HC-A=<_JABBB/]C:]L;?ZMJL]8^IO0A )E/Z2-A@\^
MT6FP)7!;V\.MHWCS^?'04OX!B!;IO+B+#HT4:NTI@<>= A86]E==64Z!58**
MR(V']_#R6NQ! QG;9RMTX\ANOE*G[0.B[1[\9\9A!(H:>MZWB8[X&GJ>N+6O
MP9-@DY<ZXI<@8KI#TPD:+@NT([9BVU-&+3<S"J:6CUIE,;55IT!R],@BGR !
M/1RL/B&5GN@(S<B>^#LU8QB@<.-#P#=Z_ENPC\=CO_^/M"7YO]**$%S._.E)
MN,+):?YF.[L.R'*F:IMP6R)&)9]RJ<"Y#AU6Y%Y92&.??_=##] UV0W,[7:U
M8!H!M__]CB)(185/ 7A@;1?2H(N/?;MECFSGO[@R9&5<-MVI1TK$2*3?Z,+7
MW_E_QO++"\7KI#;PL5*&K6_!I4]=^-74UP<9.C/!RODEZGB>V!SBO8QGGEPI
M-@*%.<&%2M.U6S9>)HNWD3%N]SVTP/_1!;%,XT%1=42#7($+(\.WHHV)9WPJ
MK"$CBJ#WE%M4:6)X1HFA6]6&3TRGN"ISN#26F,FZ^K\\'5&BCY>+F6R!\"D3
M)YF_=V=?L&K',%D?0%N#U5:EPXD*LQ=DW>9K2 [^7F8WF_EY-ZA'4'T0<<#3
MI@_@-.<J@:_:B.+O1>!TRPQ%1W_<5%CHNGI IJ72'F%=_K/K %<'W!?S<"WC
M@H8V+J_,(/$.WY/0!(=Y-GVWRHG!__<_+7K,7FAPE7O_6N'X:]'P\K3--3IY
MU\GT/6P[U<& W+D X@3^UU/[3Y._%@C+79D8_UDX:;7>-.KS+O=6^]:?ZXW^
M'BN67O_G6RS\WVZ"PNW"/&M'XAWAB;A&;JMIO9.J[,V([NC5=_[I_C36,SD>
M)$1;BKW+%V5_LRQ.VM[:TKAK%T)+V$ FSI,D3+O5B6B[V9E:Z_^LJ.FSH-%:
M],?@T1(=]?:VWOFG\/=8?,=6>.752O63BZU],MGR.N>X?8RS/X%%50CYF>!;
M@X'WFD2)"K8B5=H</<[#?@Z;?^8$D4&Z?E\^:+B0># I%V61^PSBX7H\_A](
MS_R.\Z.G0KJA^.H@=D0WI\F!+*Q8YU@CY!1@FC"-NY<E1WW_F<;J#@D3TR!'
MB!9F(^/5G8HK.:HFMJ=OQ?YM7L&FGE.+B=KG)PW$(K85 Z&GP*]OI\ @#F6?
MR8; \%?.A,VEV3TJ?6%5:.63<'.MYIRFKOWRC,3H5A";\,4^,<>'U+Z4)3B2
MN5&'??OHC12V0_CP"O32F9A3*O%ML]MVTZ<V5\..F ?I8>$:YB113+IPU7<]
MM7<I>GRR[IN73P&K*T&K$IF\?'N%,SRD@:A=E% '3EA0QVUXNL15=NX^+:0M
MCLW?/]02<2Y8F'%WBJUL(..8/!9!$J4:V07#UO+^/=!60HXDH,DZKUTOE54>
M^Y3G&RX\F0@]0/JH;'0)/Y1.OD%Y53'R_6% L13^\<.-IY<%/JY5L,^2<N'Q
MO>@*9/BE^A?<0W_+;_$B][X[G+SE;@P/5@73PO'"_&1;8ST5X\J%)ONZX)V%
M+GKX_I:M-VX $JA+*B[N"X_D2IF:M%&I';T2(Z4O?%O7=NF]I^W@>-5XE>_E
M"89G+$46>B%O/48)C7Z(9A%0Q%YY2&(!U!CP3E@[2&<@^Y[DX=>^;J(VXC^$
M"W^^NQ#781?X-.AES09T#7\*1+[6*W=1^I9CU9MK%*#ZH\>5>L&0;VETF#J8
MT-_$/V2OPQM6R26W>-)Z*]5M?RVE5H#R\D:!+G%\BN6ILDE_L&(@*Z'PQ-2B
MGHB)+$KH:5=R:?AX"HSU9LQ8%A-@//#:0!-P>*#H3XZWI$,DPBNB^\&L4$W7
MTBB!*RF3K(SA$>:\UF".MUOON- \6/V7-R8VFPW&7X\'?SS:P,9($%'O*^"H
M+5<M97/YILO(49^],U'.29-4[(+FU*!U@506&>6Y\%M^DK4/UXSEAH-43OR]
M4 :C%%/'7/)-NXN_Y)R3?^ >^U?IT^Z(F'^BZ)63DR1"% 50[,Z6MRW]PW9<
M941=!W98WKX[7)MH%&@[DD%_# *O3.@.2;/.?(V7EWO\>T_X#K"@8#4;194=
MX;$K0P][31K%-%9FQ[N+JSL0T(W>,#:*:<G:IUD+>.*= $T3D\0>OUO/58^V
MT5_<5+DZ5R9 '>[ Y+M$@_0VF^&G XET$2X?NE7X6D"3$BBN<0J,'-<D5]LP
MC-I=\9IV;@=76*%%]L6"-)'YF2P9%\BS[2FST4O$O)!GH7WE_[9KU/.HO:PY
MZM,//XK*0N#=/\X \#TPIWA<<9;[HW27V\QB5O7X6N'P$3+5J4%'(KP_;AB:
MV>>[/_5-^?CIR2RUT;MN,YX4T*XF/I,8V 0Y5AQ]J:K1$(XIE0C5@E3;^]'_
M?.8>\/IXKB;V16SCXW#]G8*U#"(TUA>W==[)TGA'U'JBK>Q6A*BJ1"@9JZT%
M\26V=1RAH]P#];D+Q.Y5\:3?A5@_NUZK^<Z?::$")@S?:3]*K_ZQ//2W<:%X
M+;\N1:1TLKGH$>W)(FQP;"!D=IN#E''R 5UH&@0*.6DDE(=D;-P8H#!9 N]W
M.FUA9$3)'T2KW;ZFSNWZ[[^5E98YLS1/2K&@$M: .S?KI M^_^J"CLW/5IA0
M$J,1QXRZIT"FH6U.WBG0I82EUN1M<]*8VQI;&G,O>*D^BWXH??PES5=$=5-Z
M:8O!BGQ(%27G*-1OW-1\8G#LE7";Q75 0-_YZ%Y# &Z DHP4.@4:T/W!HN0U
ML7$J&Y'RI;=8P[>THO-&R].&N<<$Y8[8M]W>K-+'<H85K\8VBJ_0S'MCSD<*
M7E1_9">LI48?SM"EEN!ABW+M*%*AGJ68%#!'Y8-OG@(=L E_LUH7H:KRG"[1
M-/LY S4WC)O^JE1UK(9W,:+U 4]H@X KYU&;2,(B_L'G2M/0KI54SX'\K2>0
M<V>4GT3(.. Y+/94HZ,J?,%7QTZV.1HI9SA-RDV6F23SO7=MV>U$, $K>T)6
M>-3[C5.@LM(TST7MD8CBL-9W,=U^1B$U\[QEM;&\CQ7JQK8M7R=M]!N56=A7
MP36*BP=5L[Q[S +1JB-MZ8](%>[!?UMX-=?RR,]PL3JM4,90P]$)I5I#FX'D
MR6 ZHKR64)*?62,!>7&-*I_1FGX^CBY -/KD%LY7S#'K/K0A(-ZVT%:3R-X[
MWB21OI"$FC5U5\_U1UQ+U.)K4AP+],,-,*[NVUZSLC$R:JH*@*->CSB%/X3:
MM!WGY;I4D_45?$X!!B_#W#?Q^G1%Z].<C(*)YE I?;H,ED#MI7_*B@MO+I6#
MZQ :Y@(_C31@9<>:M>T9?ZMIH<%=<]1OF>=&.B%0<DC^=-_<\H;"!A/H>L[T
M!+W\!7\D44AER^Q:@S<^ P1/'M$G;5MV.P7Y3#J;M3F'KX0+S^_8\+3LA01Q
MOT(X2CUJ[XB*/S@0FHWSM+ 33N"8DQ17U^WU'?(#"2OYG>' #W(\P8>H%\+:
M4?FK#EW_U6JB';-P+2!C9\6ZLM>.3V'CTI[>J%=A@;V)XCHW3;W0G= 8#N2=
MY89G<TBRB08X[V_EI.5L<_R4MKJLA\C=P&FBIW6A<P:/!M]+A]'7UQJT[<%R
M"C+'TS\+"*!,Z@;@+QP6>'=BZP-N'+4^/V(MJM@N?TZCL=%$LZ9K'P6K(-DA
MFT1FK:?@MRV=_(4:PB4WW1(]:D3V!!%RSB-C@>[@F"!FEY3^A#+MFY,-;V^?
M OY*A#<#0:QOJ8#[F< EAJX@B$@D.$WA=B!*0>CDGN_3O3[ B]\\3L,4E\%I
ML0S5K*ZZL6J\\-=N ORY28NIV6L5^HUK=0P/$2<B.L!\S R*&>N*X<,+CF;5
MXA;L&.OTL8TNIA^AHRSWZ7W0)4_([CKU8ZA9U\8R'I55S"_(/,G6)L=YEHOB
M]'JB*67"!YE[U]>R0R,@[8N@($$%VK2712(MV$60,E]K'90RQ@4X8'^^6KNX
MG,Q,8\I0C7QF&^83\SQ811A$/C:'7$ULF5&H"I^TG&R:@"/&IDKD,4TTE%B/
M64$\R<+"%K_:7:'7:%)VNQ2O&^A1<R#DXHE/R49P!M(JUG;@:EZX_ES</I!5
MW5TX!2R_$[8H44<F)Q_."$E>"S=5,;K7G=-V96>2]\OZF@OW,+CVR-S^_M]3
M !.+/O&T6S"]#PH+?#S.HT4>P[D:9R80NLK%G\6\2(LVX 077*Z:1Q*N[3]<
MC?3.GNQ&WM14N,U7BG7;LNO,)Q^IO#C);.#\P@"1!^;BCK,Q:U'[40"A28B\
MHN&:?6_$ZKOQP]\F5_;_G *T.UW[*K#X$I=')'-DH"Z^IP_<FO)\I2K9N,KU
M%E6N<30PDZB]$9/*5#!GJ(&.HZI$36/7]<3C]^-C#TU(_O%043BZ4ZUR#Q6B
MX*+WJ^)S^T0L@1*C_^:FVEYS]_S+8-'O'51UXA5TGA6Y?ETM/!&A$N*V@;77
M:S\*$BWVYXEI,'><FV6=<CZP#VJID@QI21K0Y<+#.-8I'EQ-D;!H11FU5Y8G
MMZ\_R1*PBDDPV"U!$4)?!%YBV2QX?A3US5!%D 8[23=(6W$8=,-EW]XLBF T
M<OFKWZ<G/1=D*K9IYN+)6%WB#@9K*U;3-.3=(_=K[<BOG42S7;<DD%P_!P!L
MYV]5576_Q3+3W<*%\VN%>D"6B@$_GK93X%"6JGX*>"&6C2S]9^.\T1?@G7(L
M9-8YV,OGWC)Z%@U=61L5/F*>>QK^V-1I2WCA0W(>H0_6FJN0@K.POC-0F7Q=
M>R*OU!Y#L(TDZCP>RFC=?C4^'FU?9-%E1IT>V!)JP7P-B)_\$P6L!+H3)"D@
MG$-#+?W^T2V1ZEASIQ1K;Q$OH7YH4I>57*=5L::BO7?.[76ZZ-P&K1NV]8;K
M'EL/ I^H4T7A;-(%Y_X*_'C3?GZV%G',;MNF!=&=RXCTQT8%B?7\G&J^MO&\
M\HJ+?C28LZ>-=;H3D0:1(H?AWTGC/S3Q#<L\;]Q9Q_R5^0W<;G?T5#[08D$P
M%61%/SLV6H.]9((-@;]7'Q^;PX9SWX W-+X!A+N$[4PV=$LR5;DR99_0J;QO
M>IM4>#MY%?@8L[DQPEMB1.6P$X"OV314$Q5\DE,T$RM,$%[?&\9/ 4?8"#9E
MUYW'4,.6;=QV"O^X_'/!OU^UYJF@:\S$NN;6WQW9G[I#4Z%^ RM:O&<%(Q6.
M;K:<3D,AN8>7#!L1LIIZ8SZ'QM3!W:W=DE#\4K0BC $NI6FNERQ>XU*#G[X,
M.O_$8I=RWI2\)51/N=;H5'48J2'#IJ]>'8+)^VU9BXZ.E:8P#DZ\[305+W@W
M[;F@; GLNS#:$NY5I=QB[KZH_M0^@4:Q!>[>R=^41PIM3Q>H31#-_:,%.6_1
M_-13V&SK(-;7TIP2LHY>FX&=T)DGPJ^&!@U!%*6TA5_2(HL>T5PI)($ZXBD/
MQP.O_IRTFJZ)NF$OD#L6&R4J7W_$DM'[V 9A0RZ>@W-8CHF/>&O*\ 6-"+*?
MEP2O@AJ-,H,1SF#V>:^1<-C65^D*<O$I(%;=#MM;.P7*F8"9D;TU(9VV-RX%
M5WJNNE('GZ##/!(S<OR"ON-1'X7993=1@5*N"FGT5UG>#/AR+WV-RT.O#">)
MI<O]?6<YA4.7,TB<)+0+#]?+A46>"[PQ>+[6S*3<(4GUL%IHMN05+08JYM(D
M?JST!;?%8ZE7]T%YJ,_=SPWF[0EY$_0!87D$G:5J_C@%WB"DML'(%3>O+3;U
M_&.M42"V/HS@NXNRJSYCC*_04\*_@V\VF$TT!/&BOV@G*(P28KK!7T-"V;NM
MA>\S4%SD<>BHC$XH0^F8&]-)T6;<G"3@%_7FGKKC&<>ST-,#WR&A@3M4%G(Q
MWHYAX.NZ;(^STHO/4B&CA$DG# 48I)^-:GA1A"'IZ!#3PQ0DK]@I':8++9BJ
M4E2$\PMM823$QXHTO38=8F>D^,S/=P=N+W3F.\B[_3?O^3,UD\U!%+$F>9)R
MG,3#P,E0%\>:I=?V)3#@O M\ "^;DT=.!S/!S0UMC"R3:&M]VM\@$6TE!AW
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M;>G4E;2ZE.5TYPBG;\<6:,U* F.3@6G*&9[!<"]'@K"P^\;@F&X8]X$655+
M 'M45;E.YB6(84[ ;]NF(G<,NQRWG(__T/@Q77^J*%2T\K8VH,-^3Z%&F@L)
MNZNVHXC9$9L3$$.L+[M]BW?;V?H ;:8PNV3J[?QA.MG4A%86 <T1(DPQ<&S$
M8N\S;8OS-PUN=(8C A+YD$Y[%WT!GPS1F72()?P8G."L)-IHX%J8>?OP7/TN
MDB-PXX@*?) T=O%V*LWD@,/ZAJ=%^3B/$WW-2_#39^US=Y08JTGV(.6^]!S
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MB@EB_;/0"3.MBJ**WJ=Y,;Q"X32ZBOA_!?3R'!/>_%:<E@I&R5\2"@G-UJ\
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M?,=.42&1@$V7+1K<#>$&2O;KU^?2R;+\;^"\6D3V\B4\%R9U2*/B=,*?4*V
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M@-OE0:+,/@K]NA"G67#$]2FVVF@E)<"$<^-."ED (OFR_7K13I<*0X=]T@F
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M(S2+8(](CY)C);WL%;I]ZE,%($7<MI6)8!X0:X%@R/W>#J,8>8!Y1QI"0NI
MI2#"-HB7QPP:9.P'$U<<\/N\$[+.7AF]?G/#FGVU>1J>DT(N/(0G'T79B%!-
MK([$/A_\9%D:,GO);=P^T2%35\[2]H7IZ[M0;[=\%W5B$;^9-3O%%NVJC19$
M ;(K, !'7BO0DD12BGVHOED9.^"NJFGU"\%PQ#YS:'Q1OX/!0-E-(J(R.V&+
M8>5O 4LN6G*:Y1&&N>7^:=Z)D;<45X0RO;P<LO4ZW%Q9(J^TZD%-9&@Y"Z;H
MC 9KY"SL=\:.EN7LIL*=U=> G/T[C E>/@^P+-$SZ-M3RX1/0VW$VD-7GQ7P
MD^<4)+JU,"@&S>BY*I<&ZLZ097]-N13*%=\OX37;>]GP.$ZUGE+E&*E9>;1F
MJ35LN^/%45/W7OX,:4G2$,&ST-D3P*R]NT!9;M0JZ_4J0RH$@V6(+7XXRZ"@
M_]!1<5:&P45;I?ZU8#[,7@7(F E9'G&6G[Q8[^9V*:(@3H2,DO.'U%3]NLIS
MER[!66$D\_C>L[D)91 J/.U2@)?-*Z@&?0H9.K2E3T(GW3U)E&W @=:)OCG\
M";2IC!DIR+U.H\CVUI^38$B'WA6KU23LI@GNRH7R"X^/WI61UE_9J=7NTBN.
MW&MRC;] ]/A=W[G.GW-Y?0L1_SBVB"S.R277XW:G@F=\/EV$RX72] SV \89
MIP6W%+*7H9"?>38%AERM#,#2'!73;!3;R.6/8KPV@,FTSVG8ZS'"E=<CF <2
M<#]4&_Z3I 97[##^FKNE7*UPW'AH07/.8QYHI[]8/!?O/2QM')K+&+X2QR7H
M<TB!T\[\GD#D&1PN*,F_J0RNGH^T:M53^RY$KK5G:6P)9"_APJM^2\9 P]->
M[S8JZ/I+KMT\ 2#BM1/\+L5,C2LZB1S I5MD&(;4R6184W]K5M=_5/N0"[;>
M=U-F[NZ8H 2AA6@KT5-TS='RP%S/LHT;341;,HPNC[1';D^#,Q%D0 YZ;>86
M4QM?_CX7'TUFX8/C:]4)K\)W!0EJY<UM\*P#<,[9MQI5NMH6)/22'2OZ(8W]
MAJJ/@V13SOV]E.K_Q4+X!7_=757[LGO</6C7T/K$+?4G5:ZB!<18GJ46H<_]
M.PW]^JTR0TI[:X;9" ?:PA<988PFBZLB]561+/R.[M=K1IK+=%#GCQ0M>3:-
MVG2>L/OVO^T]=>Z=!W:J>:A40WMZJ(.NO"-_9WIG$])ZI)A9C[!S>SS[TFKK
M_:0?K2BZ5K$E_HLVD+JR.O)T0D)>+>6RAFZ37^C"4JGVCXZ[^PZ8575]8/X$
MEH(3+$N18!E6C2[2P9"C5T:!];PT;>XD"D"^D5U>"DCRRAGZ<'69HQ1@14']
MN6F;<;>04BCYVO,UJWT-NE!JZ5MH<1UYC+,Z4+4XR^"I>,ZM2%8)RIKMT%/(
MYN9_;<CN6H+,?9?C!\1$HJSJ*9$SZ%QOU5#W.EH5FCGB"MV[[<VIDFO%6/(0
M;F^AC(Z<54K;P/-7-IU7#!P0M7>9P;.N+;MU6S=UFV_-!@3(T'D3SD[1^IVQ
M^MJ1J2]>6L'=?9GM8_RBJ[M6@S&5X K\N']L%59VG^Z5<4KATNPHZRP^+/G;
M/NC+" WVHMEP'9L[1*7LZD+Y&WB*'YF/U9GZH":1MBE5>0/[4C;?Q\O3@@"<
MH@8QWKW\:Y'D *NA^-S"Y+,R%/_@/$^K>^%AF\[E"7>IXR7'$%.N:*\H&:
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MP>'1,>;D]$]Z80$X6/]X_1_UHKC6"_O&#9P;>'_2"PO;_4\-*&[@WA:Z2?E
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MTB'M7J6 _W4LRM,AS'AQ'5W WF8-X%$^C^-HJ'SQ[#6(6!])JU#P,]##% [
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M 6G",7/P&/_#S@BH&:JQ,$_?]FA:_5,B&WE&Y?YP[5D)V=RF*9'#06:0= R
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MFK@?$4["7-^+>1,H0MC.M=%BDI#OE]N"Y_R"E%? >\&SU5J?,OL3IJ9I5^B
M9V8][25-8JA/$^W%OO(_-8G^!;M\<)&KW'M<P-OL@["%))ZA?19$?%J&T8+'
MR.L2Q>;R9\DRZ_\\$63M\I3+4+2SPEG%]JEZ6Z*G>G%;]3Y'Q'V+\9I2":G/
MKE].4ZB%-.'3P0]7KD%"L,K?<H)#A]G$?LM;3E5DG<;KH]P+B^;"L5!DL>,9
MWB/8AL]X6JS\<?03 )G<ED;E)X%J**6_O *N ).,$1$R&DQ<.X5=([L?7T;
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MKS)<&A?!._-F!/FZ[J'Y5/%:B\!(P"[X1DM\6+;F01YU_/]&%?5;T_]9.V4
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MRU+6VNW]L?!E\O'V5YUBRZA7U$&9_%%;.?'IF<6+LYX2U_JT%\B;A'>B,I^
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MQ^SM)HS(C%L3_^BTQB')EAE,9D74I(-P*;D]7&"@YLT/Y[J)9[R.9..)D6D
MM>:L7G7ZWK:AV)EH&Y0@Z023H?Z$J$PHWYN:)[KGOMJ#B3@'^1V]75_N:LO2
M^'I,C(I!IB_??MU:O-.+!9=QLWXX^EDXIM\[KV41+9]'&UI0#1,MSS;I.*A5
MVGE^\7SNP9NI%+PZ9BJ6!4VYKB@S!O)R[QCJT912Y\* @C,Z%^G<F[7OU?7/
MJZYU^(A4Q_C,<=7/KTGU^^7/&$AYIJZ<3B[O MQ^GX?2-UP)$X\SU!4_9>?:
M^B0JFM8X=)C" A1\(282&?3B0Y+F2I>)1;_\_NDFBC.T%\UV[BF#RZQMK:%P
MJ[BNK?P/M2EPF(HK66O!TWT06T=??!A;1*DP.9OQ&2PC4 >.W>2ZB#$=2I:9
MY[Z!NEBDT)CX_+3,>@N5C:T:E15UH/I4&QPZC8Y09!>2:8K*<A]D4[T7=0<Z
MU476;DFV86L\T+<,J_GPWI6LL #9;S6.-$&?J;MPK:.&3T)G:5Z+&P<9Y4WA
MT^$/H*USN1S!7U!HL1PX4U/(K?YV_ EQ9DZ6N&0]Y/CJ6%X3=0#W@K[_CQ9U
MI1S:N3RL"&JT[7^8*$5!YIU'TQ>__P(19&(8V:A8,9<:_HK9(C2RZP<\.R;P
MQ8MK_"6O _?G^K_W-F)G?SP1WKF,>-W@/)Q;X9CC--RG4U\Q_AW.M JB6'5/
M1CC;;+T8^:#)S+,00$>H:,7OPZ.:#\I?-A0>%_HZ[\T]&/*$C/YKGPXJB/^$
MAZ#[[<ZL&=L:HDJ\S4Z9OO_\19"LAR!]YFL5L_F\:U37UPJ#WIBQ%L@$X0*H
M6/S!UNKH00J^3]OF>-]ZL6/HK%Z9I0TTTLY0=M/H5(&.VL25EV'D>_#H%L7<
MZV_.9W-A$M27=4F2 '\[EH#BVN'\L?2/=S(_@0Z?+GD,R0Q!WV]V2.(,;S35
M3B#TC^PM K5. *GG5(1ZWEE+F#8N9=&],;AN7IE1<"G"(" (?A9Y2;2HNJ>8
M1^D*95LR>82"6ES(AZEPYG4P1FY[VTES96S3%I%?9+1F=HY&]@P#ZQ$EQH!,
M+\MF&#M$/L=;U.";7L_G[3-,N:8LB1$;ZYCD_M B^-!*;]8PY8>K;4_\\VAO
MIX_.!)OIVB>M&C8/Y*7:ZF&R"-?"V4Z JGOXC5 X_09!!9-(T;$CPLY?Q6#-
MQ.OSM<*.@Y\YJ(6C*<T1FO^4C8U%+0D(/5V%#[E&6"*8KDYY/\ -*:>LWAA9
MOO^-%3&.:UMFW6+D'_\X(6\GN.<S6D/@6L],KT7/G@"L[I*L!4VG[VA=0+F2
MEK9K)#-#G]+?%Z,.. $83X#5'/?<;3"+5X!X!YQK<<Y=0GXT@/PJ1Y3UENJ3
M'0XH>JJ[^08.WJ'JT?G-HT'3X:+0,#E%;"WW6Q2/)FT_S_.0?1NN;,RC(;UA
MCZ[W]\J*;G7F%\_N'8?<YCY?5R[M%:6HFO6Q]MVILI>,+IE?LX4-Z\?QW!"7
M8,]DJH:-RJB0Q%L463@QCEPNW!?<!RW[5Y&2G<D3J VO^&M;7"J[B+K%#?V5
MPPD;AMNO<6XKT;O'N)2UJ0?UM16K GF5C6CM:#&D1JFENZ*QU[C(!UW2$R 4
M!03%YM/?]B<C16:@O]!5Q2K+^$N(,<.N7 B9F.=8(4\ESQ'%$JV$6>/(U4Q)
M-@5[\X:#9J*$X[" .#/'7*L.&ZZE"GY"\D6VLKM/P&?_[BF"Z4<U^I9+H..D
M"M>>ZRW\C[URP*N;DRAO( ^0.$T4&@9-$\K\91;3FC76_5SCQHK/ARDR84JX
M)*;T.(?B),K#N$NP5;N,3=OQI-=,U8F)Z-?))&YR(=I1'A[B2^;;=+Y )1%1
M=ZQDX.,F%[$':?V;#9AY:&';L/[5Q$C>W<K"E12'I4V/V/?AD\\%!_U"RN X
M?23#]U+>C^]FQS;5.1:H)U9'X,N77[7<23J'?!5Y/,>.]KQCA5+EIH_BT9N.
MKU:Y26V):R,O+('N=6\/\LDV1H NJNOP[?K9L"1]G1B%B>=/7V.POU%-*77?
ME415] 1X)T<TE3;KX'TH\0Z[/;$/)\ 4/\'T4RMS1V[TD;SY?'(N-^75$' Q
M%**V^_##*AVL>.E8D,SL]_B[D#%H,B\<8KF7OR<%+* BE8G=V&^-(["@QA%Y
MDW5%^P'GSK/Q$O:PTB1K.@"(K$2^ KSH5-/0- Y[BN\M=!9C=+FW:4V3BLGJ
MZ-%-^*XSY!7*_N61N&#N4V_WUACX\B5,>GZ9NU3OP8QT;+_76=9]O^%A<K68
M.H46(6O;S9"<_ "O\PKQC/=VY1&Y,8KOBTLWORVPC#NZ%3;^(+KJ\$@=^S*9
M')H^MER[Z*IZZ?Q;V)B(?IDYG8$;3*4&-0FS*L.EFV<*"_@=A'6<[@)\;,72
M(5Y<N!(=?M=B*WC:\%+\FJ=,=N#4$BII\'&_#V_*Y<<*=U"#?CG2Y^4>PFY?
MOTKG@;MTDSHPD[P^+!]V9>QSC*[<*Z;9JQ*KXN&"9!SZNY]B_*7G#=4Q=Q/*
MHL&N EDO@EB//C6J2J[![^Y:RTUET(@5.!GSJ@D[OQ:G'UKB.!9)IIKIIT%^
MH;ID%,V)'0S,$1P+4 BGL6PK\PQ=F^#R_)PX3$$1ZB0>\P7)=U>&HYAA0+EK
MP3OL12C:?KRRA7]-EAE<\_:QYJEX1 3([Z@;X5$^"]42EGXVP];><@L3OP&[
MRTU@H8W12>H[Y!5AN:?.MB"Z.P8E,QO&7A"_C4S]V-19+O*@G!/<-'W3\V[^
M<ZP_%:0_7(I".&\K:?;;BI*6SRA*2N?'GU%+M-0"!<FXNW(D#"F+1&8\YG<R
M?1)\GH=!NJ7%8^FFH1L[QH0.)%Q*[0WH,"J,^397'C<B>#$&+U=A@3O:-VJJ
M!]4]5K+R  ((%Z; G8K&=HBBR?SDH]?1K&!)C!_A>KG:9E[E+D!!QM2&MZ:"
M,5T>=U:]LZSE2L;^G:"C,G3L0RAXG40??2]TN97.P?&J^BMN34.F,;L8(OZ@
M]55NG%\-F_,;-PO;3I4MWQ5KRT^*ZJHX^\0A!0288R*OH9-909X/=<=,!H44
M?86&.L[3/L!?5W^[;W<":,AD[%:,HK]U'#6TAG$<ET '@NV'2.L(S#%<=!B:
MM7G#K,MD5"Z1ZF=WO7;<<['#1/F#C=^#1]IWN&<5!APO?^^XL#GYKU7096(O
M$5ZF9AL+5])NJJ=JM)6OY9VZ;C[,(VC*"5"0YC55US4[01)<BYT^ZN7QF<8+
MDIX107A89)Z#HEV^=S%2C7\U4J<KSJXSD7YW"B(<X)W'@)L(S>;01S[I][/W
M$(EYH7PG$P4"P'75]=6)/6Y>C&=NWNC.U\"7-5?7H6XUFHWH4VCPD/=\-A/,
MHQK":4O?\CM.<\D]0M<7<KI1_2 _8L0242%Q6C$>N+_1-WF@)D8<Y^/O-8+V
MMV9=CSR>Y#C5)R'%CU<3R<"N>6=*&^ZODUIK/BI3Z*@$Z524Y9MJEJU1N%L*
MDJ*ZHK)G"^=F0<("\V(1J5]?  ! 1K30 )?^O'6IOM'^DAEDHN_ "*GNB\"#
MW9GV2XUQ/$DA/&) N>L?9=6?=:_E5M(WD2,GBV%.WCY?*/R5N&IG7&H;7@NY
MW%>X\;P22\%8,ZLA3^IJK(Z2$_,Q'E&G&W3S\CG?(TW?F]!K=DN]W-244:C,
M] )0_/LCSJ7L.F:D7@>-;K'%O;O,_ZFJB\K[>O4U]A[V728MH'1$G7&[+EOQ
MR/#J1O>"2[><+JN#V:7[PM 'M[JKNU'$+\H%\RB'2BUT>=_,M+]?H>HB$=@T
M%JT[2Y'R*B^&]0.CPQYQSE2XKQ<NLUVO7F\HOZA Q0-$@HN2^#4?\31S571<
M'"O+H]0M7*].NV+O67Q3BY>3_=F7K>)GSH_.S)@N6Y?QA<NH,))0'31\4X+A
M'!Y[":,TNFXP"I*H _ZDZ7]P-0HIY,4ORQJPZ^0D7A6Z(4C* /'T&"!G'1!(
MRM)2$S)MC+JXQ\Q'[\!!BDDNU@,!UY@02'K6_&CY%173VR37S1IV>?EN=<<O
M0H4BJ V(S=0(5 ,LUB%9)5"0K;SL;RW@(!MQ.Z6T7(&"Q)%,0+!0VOD_E?]@
M)>W)]'\!4$L#!!0    ( !J(75B3_@-\WO<  (/* 0 2    :6UG,3$Y-3,R
M-#-?,3(N:G!G[+P'5%3+MBZ\R()$H9$,"@*"H.3<@ H(2A:0K(*D%I"<:1$!
M:9)D)>><<T8RBN30DFER$.@F-K'_WON<O<\^Y]QSW[UO_._]Y_UOKQXU1JVJ
M67/.[ZOJJIJU5C?F!V8!H%115%8$<' !  ?[ 3#3P /@"B$A$2'!%2(B(F+B
M*R2D-&2D5Z^2TE^CIJ!A9F!E869@8F+CX.=BNWF'G8F)6^SVG7L"PL+"K%P2
M,N*"TOQ"PH*_*,$A)B8FO4I*1T9&)WB#Z8;@?_O"? &HKN 1$V[@X=P$<*EP
M\*AP,)T *]9/ IQ?+^"O%PXN'CX!(=$58I*K6(%J2@ 7!P\/%Q^/@  ?'UOK
M@ZT'\*D(KMT0D">DUGQ!=-.!1M O,OT*^_WR-I#6,))#Z*7C.V(2VNMT] RW
M.+FX;_,(BXB*B4M(/GBHH*CT2%E%^ZF.KMXS?0,S\U<6EE;6-D[.+JYN[AZ>
M_N\# H,^!,.BHF-BX^(_?4[(R,S*SLG-RR^HJ*RJKJFMJV]H[^CLZN[I_?IM
M9'1L? +^8W(*L;BTO+*ZMKZQB=K;/S@\.D:?G/Z""P? P_GM^@]Q46%QX>+C
MX^$3_8(+!]?M%P$J?((; H37Y#6)7CA0WQ3TNT)S/S*]O(V874@+"7KI.$Q"
MRR&,N(7Z!=JOR/YKP-[]3R'['=C?<$T!I'@XV,[#HP)D@6-XI,:K<)Z[U6T8
M0(9 :X*NR(AAI>E$C/73$)'M49WL6EKF]AOHH+R1>BK7<1B+=^J<,,ZT3PG%
MR3KWF1'K_I >]=K7BR6E7RH!UWF(_Z4G"1A.='X ZCS9@[H/_U(IQUP[M8 !
M4MY%_,6( _@7+1[8ZC]-_&GB3Q/O@IK>"<^- "W5G9^7+U$Y6Z.]#=1E+\FG
M'/1<\0KLKUES3QMLXYR.0-L?9V& P45?E[WPW$*3DFPVZA9!KW'[;:_YDQT,
MD.QVY]J.DL!AZSE'@_KY)=>:TF\94PXH9 [;TNU\_1+>C+6X>S)Z&O_)B=40
M _RFT_D/VI6.FG?/CZ$#$;]I9M7:)S?;@J*5G5-/SM4'(G[+M#SZ3=_P1:D7
MEJ;Y_<Q-DQ???>PQ #%_- :0#3X9_EL6_I5UZKAU?Q8#2,I6[T+7&B^=?1Y_
MEX@HQ@"(6R/0-92LI.QOF1/V,Y/C2Z_6M=^=R?<(^B^"&SZ\>V\57(L!WL<K
M8X#4SO/UOV6WEO^&ZC=GP-FK3#T3&  9M2&[CTY-9OTMXQWY.ZS?O!EKZOAT
M.G]YS9CK$DJ]G_E;IC3J-T2_>_,GPW\R_"?#?S+\OY;AB+]G>$2TU*?J\N(W
M=^%#D 27P=/$&/OT],-BL%!@G89O]7Y/1[_BIKV0]X!O3BZ\^FIVT_.*LK6)
MDD"3 M7N,Z:Z(KTRY1_'N]O;8I>^T5A,7JI83K+.MU;GMZ5:3W[^RHD;='\2
M:V3SLL?TNP/4IG4%''4Y-PI=V\!V3FW5_,DIUBG;R]%&K%.#V&[/=</RDXK5
MQ0R]]Z?TG])_2O\I_:?T_WW2SIX3J;P_'P?P;9B*8 !K[+(Z:'F^I=?!$-"W
M%4D8^X%K(L=#)=1PE8<^,29J!1RN2RI(KL"G6\8QV:V>K5\**I1B:7!3U*V\
MS*E77Q09WY+=A,1<LC]ZH4"C@?-ODG 95*&7<A27V[>SX!A@&<  .^,/%N6\
M5PHP0*^:>G[!N*4.!OB8E*JM4SAM2$] HRG7#N-.P_V[Q/.L:&<'NC1W$P/(
MRWW(RW]5WE+#6,)F;JK%<XM0C9V>\RT)3\^1;G[E=]'2E=/%PH]/$8%D ,W3
MR,G9&6C>^]8A[:Q1%SI"BYI7+(MA0"!,\HWGR#4"@ ]TQ]/GXLLL0:/DJ9^Z
MI%J!/Y_5@@]W VXSS3VK\$G%46VE7)OKO"USL\DR<FE7K IE?YS6GI_*KFCT
M6;O98@!6RIA3&/_;5S1W!]XT)219-X3P']:\3*E+N\*=_<I<RNA%\VV4@?&L
M@RU5]#HWKB2/4E5#P'G]2UZN=!#;B(L>O:$>^X;"$&C]=[TZRS"(Q?2; (KT
M3+EKL/MR^9FCNSN$ZWR3\#$2  8K<T[6(308_G*JXTI&/\TV-1<#:"K0D'+G
MWZAH:A*O"L@Z)=&_8\\WHR!])XH%IH![,R,G6FV,35T0XOKLXE$>#E$V%C+/
M,],!(5+2CC$2LXX[1*][-9O) %$LR]A!PVW-:F[F=*K!EE%$QJ[[(M)JV8='
MXO7.-G1IE9IU3-,9WUF+%C!/2.!EW(ILF"-T.<1]>S,C*VI@9\9/^A;Q1J16
M&+N.U?EXE=/UXW(LKKRTPAM32Z22,&XZK)O /R8ML5GAJK!C55RITB#9O8D<
M%-&YK]A$.MH) _#9V%-">Y9\(-[74>8>GU/;0UO&-*=@AQ1TW!DPX%^F] >/
MIC7,3Y\NJ8[1O;*=B<CF')FQ%BLG ''$N;WAWWCQBB7KJ9S_2(+U3S*1NBI-
M!5P2[GS=[KV'\TRD7S<)_B(, KV$J]<WQ7^#"0[.:.\>](6)L5J%YH.KZC.]
M3#7W&DVZ5+@S\CYFP.P.#].(-!-HA$-!A,K%$MXR4.9/]7MT^6O9CV/,&F\K
M-$=^5J#C>=.![_JK.#>0 7-^TR]E&W"555Z.+",GKOUHQBZ%4,Y' ;?],'.?
MEE#@=#%>< >L^T"!\\T;S_#J.ZZU0A@@/SAQ_?;<=$")DH+,0@IUL$;^<0ZV
M@W[1%RT39) LO'5RW=&PGJB.)O&Q0]9<I_#3BF=S[6+*>-R'-]/[A4=_,$ <
MK'*52$=K?FC4'^6W5HJPGAQ!OT5;V[4I-,,.M)H<[T_?TBI>MS$?+5U114TW
M<N71&/.U<?9RIP4J_OBE]VY_^,](Y]5KG]]C#MG2URE$V)^0=QT6;6( L@0M
M]/"!3]"YA])!H8A!QZ5TYJE. GK2;K HO/?;!'0,?OM<L:'9\D+5,;731I%&
M4P'X=TDW?I^F1A+^.G,]!7,0#1B4GK]?/DTHUG4Q/2'^>BABT%Q=_O'7;]\_
M$')?4, 8^E:D]_5AWK;=3=VP<.*;]0S7]&HB+4*"B(IO*WU^1I'C;8;@97;J
MR#'DUA#]_BYSJBGZBR]QPFZGQ=RJ4(7H#N_P)2WZFXQNF_-T:%5=C\@LLVB?
M$O5\#QW%.W70FI>REEHB#WQLI<F6/P0Q3YYH$2APV^AVC\B^PL'EJ]%>0E J
M["?X)CI!G1)R3:$I('2)OL1)OHPAIQ"42?JNO6']P63[S[@=K_CV4K(I]:Q;
MR\C"93?0.+JQ0_2ZP9T1!3O8MRSD[==:=XG=U42Z"8>UK3PK(!-""F/WV!,0
M,5G+JS5W3E3.*#<KNR:?P3:\Z1&WSY7R;X+ :A["N\$)N%8&50/^C%/-D(7J
M F;\&1!CV3U(0[&AUNK#6_G#ANLFK,B4A-;7SY!$NC0UM2DT$VWO9E_<F2%]
MV12]N!N<VS">JGI-L"#I#62P2D9W]V%S^+-51YROJV6!S-^D^S=U!K70GY&S
M=VQ--2KQ^@;4>(O1JCGZZ@CC_2_A7Q:B> /A+5S8A13]>E*"X!/@"!EJH:9
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MU#PE?3"7(-1@,=.C7C7NC%5Y,X5RM#J,P+;S2JC9@M\\:%\]V%O&"7'A/MU
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M*UIKS%PN9^>)CTT]_YI@N=.FM54:[D?OBB+_@B28 3?]CBS9)=MDF/"/S:@
MN7MB>@0H26-)U>?]F74=HH[5G17E9R5]!\(%=!2?^WP@W,.:J9)7P\\4EO+T
M[8SA0PE/*%2XBQ]RUS6IL=>[L+P=H8U2>^6X-C:L (B]Q #.FN70AMMCVC@
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MG%T&W.<O%;X6I*/8A"Y9H+UL%Y#*$B'$VOD[BHE&21<PYY4]; AQ8QTZ!]I
M88!"T[32>]TN?[@M+!QZY*)1/US$OWIMT"Y\:RA2;[U(\6:> DDF0(HCC^.'
M;\Y@P(W[GD$DH+EC$-1P)^+X$WD5NJJ0FTM(";<HJ!!'CSOMRMH[WD^A6FGF
M,O)YMLYGAK=NSMT*]=(IN-)[\ZWT<?>EF+$D<14Z8VXO7XU7""$;V!]BM$FM
M4)U[$JC@>AU,5M$X!AX7)W=*HC+&IT49/BSO]--1!&AP^+!Q$VCG9_%NAL#,
MPXH;/R&4[JP/],_'JS1\8X>'Y>A%+^E'^.P4.D4UBS(S<?JMOS*H!'!H?//T
M5\]X*[&52F 5+^21,PS:_XI7;.S?,65<81L^#)SJ9M/@,-U3LDN\J5&XSE.3
MGO5C$U;H85<1L%&G,\6-RVCXZ Z"RK";BDB.1U?'A:>#[9"F2H.08-=?^#%<
M4-DBY<4E&X^M;'N#XJ>V[6(J(R@MKP4,"/1Z9O=R;U7NZ[IU39SH!+?6W*TP
M=0V>+JRIH1X'^G =TMSR(L94_'6WNTV3&;6.1 ;K>6FDL[+RH\YEX*^O(U,U
M> Z.4$:=9I_Q;FR2*2L 3DYH1OD4U=5^'!GW8F:ICE.+V/[D"D4?N6));B"G
M@3=?EYXP60'0]E>IJ$GJ)R6I8"DB,,J  7UCWC(Y-KEBKKW;6[!T(K\J.E;W
MBOL=Z3<;)+EQN8O3 RDXA:^R"-24VTLS9LSUK2I;)0YJAU>W*@ O'R#X:/&G
M:I0C' QJ)LJF'M[TPV7[R6/#C7=7$[D37Y T9\ 1- ;+MEPHOC9@+\)'62?-
MY%P2" ,4-& @16"!Y/N8M$2V33C+WH#$,Z<H7BT8D$T>_8J@=G+)3Y<_T>:Q
M*GBBQVUR\=FQ2Y=^QELA%S(BU7&)QAI]BGQ0JNU"&,F$J<"=4?;(+N>G&GC7
MA,,%&+BO$ (@G8/$ZW74U0V?E5 O2X;ER,SU5$,%6V)UYQ]75'_" H]BR2*I
M_Q__$=X?CEA-(DT<%C6Q<5@7!O"LSJ[[//O7!_HV<5$".;^<NR;.O%"@T?HO
MGU@5',>)PI&?[%[J4QZ)O(0!:T'OI,'_#WOO'1;EEB0.-R!!HDB2C(""M$C.
MH=M $DF24Z. $EIR:G*2G$% 07(6FI:<0;* Y- "DAHD"G23;/*']\Z],[,[
M&]S]9G9G?_=Y^OS3YWWK5-5;YYPZ=2HP@IZHY5E]7CU@L.S,JU?8H_$(!P!I
MO[>EB)PL0R,XK2@PIM47(I &:O?02>9[8V49U_+=#VY],;DK7)H$1(QEYI^F
MDP,?A@-VU2X9SJ[5[QV,<!#=96/88YR11&I$]-4'F9O<XWD6<,-[@R%X'S<W
MDQR&Y6A? :U>#IRJNBU<S"L@:@ NHWBJ:YE)T,.@0A\M1UH00/94:;Z)0/]1
MU)/4&(.Y;#_!%R<BN9^5FJ<&A.W4@1IQQL3\O7$!M\;4\1E5V+NZGB?-SFA,
M%^'"^TF=.LP2[U^(IFPXH.L<\%)785?L-$[H[5ZQV.?RD:7H66FRE]S,Q??B
M$O6>^G',^DDC6PU(-TN,9F:S.#A+H2,?/GQ84U$< =7Z^P2D_72\(!/?7U@
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M=\KJ74N!\XFS>4S)E!P-'*RI(FNR; %"Z-IX"4K?A\NRN*WT%2V..?:V($G
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MW#.V5%X9:9ZS>X@LLCKRK@XI..3W*\R1UGUC:-B/XJ/O8>I]Q/WE*C?>B+0
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M3%DG$OG\*!Z?GEG%0Q J"0NCF,I9(M]WT1Q2',HN]+6QFMO=9UU1.)A(.P>
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M= QY$N=(.5#'<.2$V^BVQA<<[8KS';W,0*H7+^Z 2+Q10,+Y7^P_U1UU"8&
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MH>/;B/.- <!+H'TM40.>FL%\<I.:^*YA1>%Z1*%0<2TW?I&A"RR)T< <D2M
M[&+8)$XG 2>0'#ML8)N$$(8YKK,WP)Z>I!+6*&LP'9:J0?.0/CWG1V[-F!?
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M0?)0FGYYS=L'HV9#%"0H/C_0*K!.?O%^# *[ (I4XS208E <.^_/.8$QKQ=
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M8)BVL$/EQZ4H76]^UV, <)U8I2>!"A!=55]X%3F5-T6TI$PP9WW I!<DGDY
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MYYSY=CKY'+%-];'$8@.]T#L;XU3=J/8X.[X\9XPJQ\GZ5S+HX GU[8Q7-:>
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M 6F6.#D%8O2,/$=$T)5M;F7 Y1ZJ7BO]>_9TB]I6DZ0G/(F['5<<[81O,^+
M -MKN:;:_MS1B*+IM0,*$V,1'<TX.*!9[L%#*DP8;80'/2]*LTH-BWK:>*;;
MWFE4^8T.%1:(>H4AJ:/O.8B?<V+Z=9@G$19\6XC92>+>L%D@IZ@A8#(S%I^S
M+N,\I$R"X:.816C<D6Z\L:I;GG?6@V577( #,/VI'O[B!WK_8A-';LLPK6@P
M\H]AK/YKP0QU>$KY)K8JA!SF-?7L2N0AJYT2#!-3,W0Y.I_/36-LLPWZ%\LY
MXGANN#SA3NI$8 ZI&W8:3N0"]ZFPBA%O6NVS!^YI9%Y9-]5<B"'_$J:#A!%7
M!L>9MJ+2W<4"-_*1-8LV06#)*E_QG*N$%P-N\D##*:<VL)FEJ6]!.!LJQU"U
MHZKOB.FQM\MH4=&!8-90SN8(SS[:6U<D&>>4?'>V/9\^N177#U!P0\M3>O,F
M- OR26/7DQ& X:&%3"/SA?J36:!5%IR=Y:@/C[?SDIW,.Q8F"R!E^I6LA*9*
M3@V*LH\U\,S")=F,WL[Z1_?6](_"<L!+FY'TVALPW1OB-G7-P5,2S>&= \7^
M27%FCR>]EUC/O76X*4N18B@0!P.L.X+HG/?0WD[3.3QQQ@^ST*13K]"E="='
M(M@O)5D<7)_6CZI0,DD'ZBLH5#>AL[SKPTXJL89[EXZ*"3N28')UJUPCB%XT
MQ?3=:BYEL7? 5*V'%]9T51>YQ*2Y 3C^/(R+>J'OV<L%+=THYP*$W*'A61Y8
MMD7,T=U $!3%<S6=2?#*)WI7D@=2=$)OA+:@RNG3[[Q<4OW!+]!#W@\9C8*E
M1,/=,!IX9(_\='G=K_"6NHX"IVHJ/X3+3ZS)%B\+,Q%/Z+6> HBEZWEF9Z)&
M$DNEPN=H*]*[Q()-7E[8DF8)I-ZC>!/9^<""IT%RO'W3[/RBT>!+^^!>M@74
M"T>D# @1;%-QU?7\\WP_[IWEJ@T3L]E''S\L"6$UV"ZM.W+JC,O(67:!&RL;
M0P_Z^;+N=[6S35*B\=MO)!ER)4=^Q5'4]KM0*I$1LNWXCB-98RN3!$$!V1Y4
M@E;<.BJ0"+DGN]0WK4LYGT/D-C/)OK/=Q4\+R3]!'2>=K^,F\9E#+(HQJ]^Y
M$0(XFS3)^U IOE%T9@;5RQL.ZF20: DK*AQG9CF-422GT-9%L,"3%#6>H!V<
MBG5)8>2C]?#@1"(X8-_$RR!2L<*>.>#^ YXT28ZZ,2&BR'"9'BW8LB3GANL,
M!/:J"_N.ZWE2GB'W+RS,4NVFNJ("5B?:6+LUP57^=UDCKM^YY&G)-=OO#[+W
MZ2NHZA^>HK):01*U3)0KH5W=K7%EX?O.X?#"4:&8B@)LZ]9.@.98T\6\_FDC
M>WI/V2!8O!)ZDW=CVL'@UHS5!+2=G\B @V+^YO83->_"$RZ(YY0$+J(TR;JM
M!D<#W]?MN3S<!1D5)(_G9DR(R7'FG4F,37U-"J :)':@G,%@*Y;1/;M!#E\^
MH8?H3NQV>-4(2U=<X0!*,[NSB-57IDIFYIES%9;MJHSS5OF"ZJL?](!3T(A0
M1WX_X9L7'3U8KU!W0UAU4VZ-K%8D1$RGV@3</ 500#[VJ5B"@=MU ]=X&,B8
MS5ITP1T66-MRWA-))>M;2Y$1^Y>GY(@5F<&5:-;'0CR-V+Z0]P,+R<;G 'N-
MC$:5D[R2PPZ+83Y+5>H1-)^=P^=58H];%LZU8'A]Q1^MT$1-L#\1UA-RKP69
M194R]U[RVLLD73GL3CKPNJ@G?R3P8<LD(\Q/R1[%:'9]-I!;TD)'7&:Q7]*,
M;)9='J 8@;^#$,,P;?-7V:E0A"O2?Q["-RJ$A+;-=PVO]S-X=Y:GNAG-<:)5
M,T)+;R?A)QYE(R,[6LZ6KMLU;!E-/!/B!KGV-Z.2X[78[_M?]QG"ORSN46C<
M?=  >3/M,2"FI[F806NX&:[E><DTNXX>:;\XRZ4<KQXZZ8K+SJ8'6O!7)D*0
M"[[EN2CHGDGFDQWW-971[C]/OOH]=7CO;YQLI?9.G%X^WY*'\[ZG$Y?,+9W%
M6;'_-*=G1D=D6/6.ZOO"PP"$!,;:/RN#3&(NM\AZ?@ \)FZ4JU*Z]O)-%W2"
M%!PRU$13E9":N!M?54>%-64_C('J=B1&D+,7**_%X=B1RP,6](+ U3XU 55T
MG"'S[P?FJK88\+)!J@QSJYAG6$)8!:86Z"#-1%Y.1E]/L4@WV-[GCV3,3O63
M%+1'@0U#^. %1NN@-L^7+P/9^?0G@6A2HRBSCHF#846Y6G-&^-X7&@&RT!RY
M-7;0(@M70W-\9_;$M*AMBQ#6QH'7"=W0^Z7RI+ZKKX 46(/42;D892$TUT%5
M<%U(BIC,<\<3IC[?@MR:^_-VTW'Z+#3C'E R2&OE9I?SR]"6?H#=L755 _S#
MG43F.<-K?+@R)6 ?G0X&Q[QLW/ISP/-BD\5S]A,^XR\_K=$KHFJ_>+75DT8Z
M'&)8[4TU& "OQI%*W&OH]6OEPO<!=&4%K3[X;X36MIWTOESZQ!$-#ANR"-M2
M19B1LHN> ]<.(Z'Y8%HSVW JMJ5X:<;/G;7U(TX6;,QK<MX*09=8F-$X$[[-
M$\W*!_37=FZ(XNC!-MA?84((3/$^ PZ&7+'V\_)_.6^=]H?^!?BGD+?B6D*>
M3/CVB[=CL=7@4U><A6TGU#L<#-I;7@]PG@B+6,"[, F6!=*/]&$*;F_X#=>1
MSN R$WW<8>.2VBU37KXDE JS-=^Q_,#.E56)R\"WDLPJ;OQAK74#"_*")B'W
M(*8G7:< I:CW-SZ9 UPVC=RQ I<81VT7&ZJUPBY+E]$NO.=W8U[N']E^,']%
MRG .$\53&OZ8-2%,Z"QL/"ATSNO18Q4V!&SUGLM-#X*C$>$,K],Y[2M3:,1R
M>ARK9B ?.L Y]G*63PDS'MN\$*==W-09+0,]6Y$5VNB.WY)FBFES%#X2O MY
MLR+MC3!$IPK.0&S<:P:3%>@0-W=4VOR,O([&@=[=H/?W"X5\U>@5,\G(A_;3
MA)5&<ZO'EO#>O<-6 &4M-MJMWYV955:,:/W86C:IL4,3YO7 J4R+[E-CB/=)
M'H[A2LE5(70UD64O,UJ:X81^9-M/LZ2OT.%"L-W;&-"&'2S\/%: @#%U1K1[
MV@6+4;_F9P!=BTV3JJACAI!:.!YQP4B .-2@DH$UZA10*3/=N#FY-XVHUI>3
M.NP"OY:\G*F4Z=(Z:W(*""'U$[91/[P,=/B?CPXUY:C#!Z]@JEL=N]1XO!;M
M218#9+9YU#M9R,,ZRD,2#L;G2=;(,;YJ1QRJ=6X3 92=^ Q7/YVLEP$794/'
M/CQPZT6HCI7H:51"Z!:N==Z#V+;N0%Q1]O?\N]0JL510.;@[S.M<0-CJ"=4+
M*9)M G'S25^4":D4N5V%_4CU>'QAD23]SE-)IIUCN+9Z':OX$#YP9WD,T[8&
MG)G,PDRT;$A2-P;*ZV=U:@V)4^.%%?7Y,SVSY8)MI%$/%1,7+L  Z(Q@>"H+
M"VSU3K,+I> [)U0#@@:3WC8I%]];%ZW$RL:=.J$>(4G766S*6&QPG+09V&EC
MWTQH$[UNW=!H3Z[F&0\'2#*OQV<UC%G?+6;CL"DT5"SH(@DZADXTWIM6"QUI
M,;R=I<TWQY,>UGI>MLB_4FG75B03[UB6#7+KEG]S@I7?5?,I,_Q&SYO;42PU
M>:"G42$2&XC08T':L%)D<LJ#3#(!S,Q&_4!,?$PR].:ZN->%R,6\A@+-\]W+
M1I(".Y>:(YVVN."J^3./>+2T=F9NIH?0/+O 8L@W!5B4),7 YM3)>G%?%S.&
M#KYV. 5T0*G>M!;(D52N"Y6Y5*DY7-@IO+HU>[7L!LT>JG@]@X"&<;F^$2EH
MO@IF&L(%FV"#8_#['_9X47'P\K?%G#<RZO:P][W8RN8$3-4K:K<FOJ%B=]Y;
MQA.%_- A=2YGC+]_.:H[]NW ^%D(F(7&[TCT_$QH9#]BH+]PUH>V0>[>3L<"
M;F[7SX]DM0C-\BQJ*7@FT4[::!2(T:TT<D^,,(I9UT1@9S\VU\ /]Q.IBVE+
MYVP.Q80_L1'AW4?HC_L9Y*W7N\T2/<_E%M&8@;>C]=H;_!^:2=+C7/?H0=7U
M.0?KX2V ^G>%I+^,G'W4W1:;*6/(;YE8O"EX/(F%OLZUTQ%99!2M_P[5J* T
MXNBN@OOHD@:5*S@ 4UQDGT0C\*;W8F5,"Q56T$("BS R]$0S,1(??F!4.WC@
M'A>==4V*&R5)"WE@5Z\92WPUYV(CSN/'#(!/@ZVC<@5^IFD(J_.%;H]F] HQ
M)UT2EO)'.@V$MU4RDN"#:/6V2$>H%NV0L7^Z\;NX3H\IVK"NA)Q(PMS=T&M*
MF:0\BP41[_M+)I+NYE(HM)"ZZ$I>WCP(:[>9&W&'>SE1JSDTU>T\X^=/W^[:
M[+GG5J5VQ=TL))1HK[ZY[GJ(E$NT'98X;T$_6?LGOH*[91II^74?0N8N5<=T
M>%4?JI5;Q1+I%8.'N\&+G^Y%W.HZ__@<6IT(PNNG4#+;3SRG<H&+'0;85V?$
M9+=UMU<D.UD^L:'3T8*_$R?)[4?8Q\^]#E'"!QP6ZS836CW94?&&F(+$KXCV
M^Y@^RY]>]P0[.@5JD,ZN =N/08YY4Q@4BOG>)<7#\R5?>$:<2Y&,MC:[/;RP
MP%BL7A!9Y$/F:4C$\9K5>=7)!TN@UUQM1,6A.K5CK'UJ'>EVP.H=C[D$?^(G
M]M5]%(@' O"/#?AF&%-7/N_Y+^"W2+%,F<4C+$=2LL*RAV1AGD.8?N2M2RSV
M][<R23-,EV2:3@%EO,?%/2?X-ZN+2\Q75Z0&&N$';TP-5.]W8]_FAC(L(QD7
M5* $,V<NIT2U]F:2@=",7,=\:S+L8L5Z*)8"3U"R8[HL<WF7DKB>V7,_B>IF
M- P2F(LM)SJM>VRY4 RE-N*F(5=LI-/ DPB-6118'$]<S/022+3A2IVD7[0I
M9^&V*M<H#UNBKG+<27RO<.#-/R./]"@+D\8X.V8;EVSRK5!AS13,F&46W,4*
MP,_[SS-<_/GPKL ,M&G5C;#\JAE%8X2%-I)W"<SKK+;KY,0>:OY )YHG#UD1
M^GDV*PW(3FP^"7=@)>BH#S)^.Y>L&>T)A $*T;9&U8W1(P/]B8N'KI2I>MX+
MQ0:\2%'P"G9NYL)!&;2]F3AK!-$T[BT\I:YQ%N_AR$5A7PS1;,$.8#9505^D
MM/1F?KNHLH\P+&-%.47P52SN1^-^&JZQTL#[$+),^Y"A^H$KO8"IRA*$519=
M5=43GASYR(R9IP'C]GQK)&?DG10RV'REGNP\QG74K,(N7VY.@2SZ*6#3F7Q=
MO4!!M#&<)"#6: KYR/$.)K[;AN?V+!UT/T#W70;^ZN5AOMRVZU D^,5.1N#[
M8]#YKK><)R>BF215B1)<BB1B 1?OI$XF(R<E;Z)O?;KZL)O2(F =ME?JK'0R
M66E'G()%!U)I9Z&NV9EQ)0BW>9@?(*)^_OZ+B>S19YX&.XPC%7YR+&D%C+;#
M]'?R0K<2UA]R[N0UA[-Q*T:K?] 3R_*[KGI]3<E%*C7SG=5*P,U9[L7N4(MT
M:-/%/AMD2>&XGWN\W*N<7=,<%%'XWBF ;)#AP9SI.'7[L=!(7CHX93KO0HVU
MVWXFF:9,L.;[*V-_+'?LSPD<S2$(_23YT:9A"AH)M-&^Z<<!QDW/4"OB$H%^
M@&L3'7H\NI30Z-D(O8*-2,E@A,]<@G H'V\V7+3,V"]0355KK(G\4O_FC.$<
MG1?3EA8,UKU(EO0PB=8K7T?V4&G #OM#:PHXQ?E<;=W=W"9Y?YX1A\:TU!LW
M^G (J+4M8>723,X=1#=2E+R?^G?V%K$2\<M-I-P,[96%O0=-JU>O)7DN6*=?
MQ_6&ML\+MC.4=D;ULKTZ!NYG$C9=@/!H3^X+<E!<"V<*(+E7$"*N8IFK1#$C
M$D6%3A_?3B;&:GF^$L@9B&*S& N29N6#:*F.YZ&9(JG>TQNMK#0]'<I.)Q'%
M[:-8<%6]9S>'4S4"$G4F#[05[?2(H;.#D5X7D&:!+L50? JP3Z2P\;S/Q% $
M%[,S93FZQ\G'85Q7F@(%M+.&1Q=?;1APJYS4\[6F7GZ:.) #+I-\BO5.TVAM
M%**N@8P;1K1<\EX%E>^8;F]ORM0)&WRR:EL="6^B"G=:]FC@O$*J;--@PJI8
MN3,!'U8(4<N% 7:;PY. &F.HRIA$/83"SACGO'155'T(0J"\*L,0$\)^,]Z)
M-<BTG?@672)H+8<*\/F/I%E^/],U//DK]VI16$? X ]<\]K!;UCGZV.89/:^
MF-\@3"'S5[;%5#TI+P#A>U23[X,5_3K7Q"82M#PI0&LE&1C%J\VKV2?NT#89
MZU. !.UNB;=^OP,/UPD%$?^GM>8TUIU8 ^B@W/':LCE8TT#J>^D4$/RH[\2'
M?U6!!V@(Z_U;\9B#QFQW&'I35)]A3%?]>TEJD>WE*2 ]\M/PJY:)[)?0'\53
M "%NTO&>V4"T+EX5=?R/8LQWNUQ?@)[_CI4Y"8&E<E:G@!_E[_8RE9#\J=;7
M/7RB9+?).G<1.=S$U%<*OK>IX?DF*I;$ZQ3P#]+)SGS"/1+3?ED)FQ/XV%5+
M+?&OL!>[J]C.^:HI^;$L]2!$I9TD:W;P"MVNH-$_UB7[M^G1?^_?PS]M??'?
M3A$U""#>LGZR:TX[&\?A5;[>H 1KEZCQTLL-$>EQWW>FRGQ5)DNZ,NBN\P,G
M2O_F7\F,2=?O>J#R;],1_R:O$31L=>LQ%H[YRMG#WZL!=#\%D$[9UXR8R+9+
M:1K]J<[JCPG5>IS'F<5W>/*JC8@ 6:M]^: (^O/E_1G6Y[&PO>3Z<N]K?5'$
MW[$)N)J*3O#FVV&+B!R6-I."JR,*+E:4N6P:"7V!TVJ5_JXEY<N6_P<Z["]@
MO:4)Q&E@\Z[*R(V> O%ST-]K/ X$D"D;_HOTR7C<K]&@2UU@R/J]7N-X,>SH
M?LA/0;+:Q*/\O[/#_V>L_[ZE:O+CK_J2UR>V.';VBLIR:QJ-+WZ*#?E;;-P<
M=H=1OF<=OG5%&_-F>,EP(HFSH*2CO'H&OJ[7DF0#.@4H;6T:O&4W#6/);I3X
MBBZB6Y$"4R)D_TI(3/KAY"'44&H1V' *R,B8:/C,(P5F*V^!MN&?!7Q24J6L
M.X&SIX#!P4V3+[_P"0-/SHLU?_KTQ>Y'VP]KOS 4_ZBH<,SF!=W=_3P)_87U
M..#WE/S"5HS_K>)9CQ,PSQ\?GU3-_\I__*-B#$9Z^Q2PNKI?=O(+<S'6]YJ5
M/^SSVON%#)GL>\V<;_:!FW^A5_[IR$]'_CJ. %N2+$],H89+H.9S,],;CVX\
MC<\P/.3>C:$H/YDQA<(J\^ZJ!MVR/\%O\.5PKK1DGR@YFTZ^*?$T5.)2BY1,
M\,P:3VC[?7/O_H5=_U_S#G\Z\G_#$1F^OW?D,:2FS>N&([E]I--AJ0EEJY[6
M6YZ('AR?B<&8B/[:?F>(57P^I[K#^%C210M'->??,;6D\=^[/_[7O-B?COSO
M=<024M":I#O%\\IVANKS9(F>V-(]A3#.3FWNOF>XCYM#URR'VEBR&QR6)%G.
MXNNO^0G/B]'E.?^XG]SR&P)-[HT]"F8YZC[(=(=*]KH:;-HV[D%">%]],VRO
MG[YZ1IEP3\L@\11 7JGR+-CA/:'("O*H+9U\7%SA:@V\N.)V-T^\B63!3M?\
M^V?EKU[CN9( ?"XU=GA=*RF_9FT1*Z=B*K-@XJM3C@:N30[719$"&?;!#9N^
M='=J*(H @KV91$)Z+'[0>UP"6Y]DNC;62SR(_&_A)A)2![XG 1AF5W@X.DTJ
MW 8GG6/,5[4VQ4QTC7#$N5RL>6 '+,A^*11#;N"P1GSWLO/V2F49GT55>*\0
M#"86+TTQ;)PP&/W>O%8@9*9YCKJN8%,7GM"<0EST0)0^DX0I<&Q$$/=N=R8]
M@@X3MS0]>^.]G$VG]'T7$VC[!^H;S3G<:H1/R9*'\.HA@W?\I=]BS]F)E(70
MW<1C)NAW4<U=)P<_-.].5747-AQ/AUO"O @(%N*E&2KU>/V7?(D4SB7'LBQ,
MY,<CWF[T'A5221VZG3W3=IN1<Z9_HJ>M<5T)U&>,.6BC?^T2(XA/CQ=P<XJ'
M1V7R_;[<EQD8ZU%=F1F*%98W['Y@Y!<A,*:![QOKHTM3C&J44FR@.;Q4DRZ"
M$,'8+ATU*B]O?5!R[5[N]SQA'W5O2'F^6@]\+7(QX*:16,\'QPF[IO5B:EDE
MQ7LO-,EFJ&6UT2:A<.5/D>S1120 9TWCE80E(A)E&7H+1I8 ^&SZ(EO J^YE
MYC5L!Q[LI4ZX'X%BG$'83I .K[A'P8QQN'%XKPB]$-:XIFJT7 (P!SO7BESM
MCV5:_][U XAIY._PF:KR:I_-KO^*Q>20^!V=J<+W*Y:.]#^;]R[GYL)<0B)4
M0-"HZEIQ+#^T\+1KA$*!22>#U=0_K(WV3+J[7C(&O^V Y=)HAF9#,G&3J!#6
MFA*:1_:)5;B@DV6@B?L/QHAVN9UIQ=T1.WW)T702+YJA2%^[1=/P:Y>Q#:.]
M1^8XG\AC20^"+IVM73M57579964(/\V^<)%F)HU'B7BHWE*!U$W/59?QL5>'
MY"4\>LZ\&8OQ+I"OI[H923;W^KI2F2W*M!GB82=4S"D2&]"A@6_@@J:5JTGM
M&.@(>@Q;$YHUG-0)4'%D8SL8!'782P)&]%3-M@BU9^I7+]53ZG_&BR]>2[_Z
M)KK?HB$:T@GP23C)<<YOL:Y]4,1#VM[M(Y_E?:"?^F% M(Q]B3//R]$MOY70
M@JH$B,H:$RH55@Y21[Y,>#BT003P[@?XLLC0#U+'DX6_MQV;^@KG'V0\D8.J
ML%],,#\%K'.8\_M$MDRQOUXRK,51NC HA#4!OEEP8'5/ZU!LM-+?9EX_H!<(
MC*[-AT3W.KNKY++S+J=5K;*2."V/>!"E\!1("9['$L+:K-00I?\KT8/*7] N
M7\.S=T@O<.5U_Y0K-2/U*D#T:##<YU+"J%'OE>M76@%C/&>_"L]SS"_!?>*L
MB[6@>7JSP>>JX3446*!UHITE>6]AZ8UY66GFQ(SG[85&A NBLKH;T0D%G,_L
MV&*V88W2!(J ^"$]*3=4)*3*ZJ5L740WM7-'TOS;S[BS+2+6LK#=F-"S(4!(
MO3R1Y4YHE_+XBQUPHJ\H_X"-V"K>N/$4T$'"J%YW3>G"50D>=I1\E9MS@7]T
M:WAJ*I.N6? QN;5'7NE<U65A"D]+:>:3&!0/B3V188]D\$3JRUR!9QSF5!Z<
MR*"[0QXDP(YK-^+80<77!D:[>,HP0?YN]@OT3FR#:>4^_I>QQTZDAC.1-/T7
M^%.MW,L2IU!BSRGLHC5#Y2#0L,I&*<T=]8.\=UG.,H-<\"UQ 106.%N1RP_'
M+#9]#VO"P93MY<BV94W:V??F"Z 0)"%ML-[L8)K<[]T5Z2P5N?^6;Y5DN6W^
M"D*]]B5LI>_]"''^C 8N":5IS7@6(YUWT/-2&)J?;'8PUT\Q<3@YTO$8:/JF
MA%Z6-#2 YG\^>4\/YG>_%K)OPGWI/IXYP3%X:O-5$Y^=L]]!T@)%]3&\PS83
MXS/KN,<HI/FX@_"X^&Z=%! #'S4>R0GE8K&Z3!63YR%X)_;V2$^KCKR2$);V
M>J+ Z\E[LSBU'$VB"%;T[-9J^+$,2<+397)]/,"D@?U2V 2H..W&F+4V=4_9
M5>ZUN>MX.XMIF'Z EP8$FS*'XVK[ /?UN?TN#%2G:6<UNKF<T]/.:PE^D$P'
MJKQ/T"KMAM$+=Z"]XH76ER68.;'5W,\D(8O>5:NF(6]95JF^3M;H"-%J97$.
MV8J:2;?LH[L?/_+B1 3MF ><?'#BL=Y$([K3=/8:C>4 D.>T#VDQ6:3P>$JB
MVB70U+%E;7/D[0 #03[UUW*NDGRK2ZH%1ZA&:,>5?).WD2;2STDE[]H! W="
MTL.@BU;1&ULDFPA1\2"C.9H=]RGMC\I\D6VK@?"V6HP.\U-7!P;'7<JHC4RT
M!D2J<RHA'_$EP?])70MGP/4F'GOR2R/5HK,F@^V.G#Q2Q"4;>*NFS2%N4C18
M_$0']TB\)''O-I$%<3 5GFAC=:JZB:)A4:M.)PGJJ)JI,KY2WM)WE_NC90J7
M3P%QG=#Y7$P4M]&F+D7/@R JK*I%5B!Y3K&95/(VDM*XNH)D-6 ?LXT</;!G
M#4SGF42*>5#/11''ON )-#5#IZ](R+PO81/+,\!SV<\DW=1\F=)IRA2J;_/Q
M^,UN+#AUZ%@@QZY-IM",7?1D5\?1N9,2H]=VTQ%NI<1AX79GY)B0/^*^W-;L
M9D'R=8 0UJ#A'&]!QP66#*^F-TW72#S/8JN]GNU*03%29;W4:8@G*\FQK)%.
M[?6T+TK]/HB8EWZ"W8>7@>$8F>Q;AW<'7@G2]SL?2Z?K[Q-,W&##YD:TCDN:
MC%JY3*,+3RY >U0ELP- 3E6#[]5Q(F9?#-3BU;'B8 PWC9O]=;?=.$B5 /!A
M=%IJTCQ9EGY% B!5M[NM(1GZ@F)<GU[#KRU  &F_>*4R.1IA>>%V6")@HBP0
M)8^F?63]-",=-*5ZWT^^3M&/V9>>W2\BA+KM6/"1OCB^[\HC80IY.^RPX&,)
MCR)(R#NXZ[V9AW?!*BC:8(:WF?45\7T\O:VEK #*+R7'9ZZ6(L)S(^D^;4G3
M^A'Z\TY$1_#06!G;U->CFLY&I6A3PM0_AYK[_[M^)(*M_UU^F.'(S)WMO6^Y
M8"K?L\/^((J6J%GXC2<;+-1U%2%$0D&9"-Z=C!"/:1,&H]NVX5:Q/%,>:8;3
M2M6"LP!+9C?YJ,*W8!HSAPJB%ZD/< '>S$F1(&<"!X&I#3$XUU>P<4=)-/][
MB[I;!'%NIM;H6(.\M&1K3;YM J:OZ)K7($[3GBXO+(6P1O5BC^6=MYCEQ>3I
M-<8WQ]^9BNM63E"XBO!.!$C@M[_PCVD;DD<Z/D8AC3IO?@KJ.+K]T*JUR?!@
M%K=S,,R"'1-/O<3"61&DAOY25V=*WVU6"G!H>H;B-9SE3S2@M.LQ;%AH9GSU
M^>UP%4'YQ51G"]-BAQ=?HB_"_@8$63+='7(?0/EAU1'@XP43YW5&Z5O.1_4>
MJCXX;"8KNV_LH"<<W(Y_@1"A4>X9>2=J582[[AYX *E9-K-9/V+/X$93PT6J
M&R!0V<"_5>KMM.JG?_N!S+II1<$&@Q'WM($Z.5&+#FA%KYSOV44[S1L3L:[C
M&1X6PH]L0]>=#&79207A@(/B$#+GB^G!>I'&B17H/<VLMB2$\:CSP[=9G>['
MSC&<R.A3P!<N%(XZ+3?K6>W*7X[YJOWUC@_8@(>1]=K/(Y]HHPT]U.\VP=IF
M^BZ_BJ[$6O0Q"ZWJFG BED'I<L&;0(Y>K3ZPE.R/TNI7??1*[*8FTHJ3CKCS
MES=;2J0B^NS$6;U6N+W??!)9";A) C0*,QE-W* @D' QK%HQP\59:GOI_7;@
M1- T19I)O4,EA^7I$&GT-8>"MEF)^Y6]L,?.HL52Y.:VHQV9#[+C%TN':D?>
M 3%VP !,)*(W'X+ \GHTR[W5F%^'6.]S R(5\6Y%7VD^O]>S@.:>-^&[-S_7
MJ-5.XG@C\/[!1L.Y@TPRWN%C"[=L![0]O,,Z0D3783]*13W(>+AIH(4N3T/.
MF[:SI@)*L;Y.H"G"+@:>])-:(:%YHW+XZ!Q@=WHP9)*7/)2HF1M7K#I(7\_S
MB8DZ:8S=\2T7=M+]6<AJ)Z_%_:LEK!ZC:;F\;E)6SF3VA<^-;;>$)=RFA;!F
MU[3LIG12=>.,;U=L,79Y<]:SR0)D>D"H&DGF1$8MA']AQ>&CE;,5.1;8%6PH
M)O[LM:VS$%8[)'K&"%-KS$5L5NK3]61%]3J-4Q[XU;'Z=554')4M'VN>3WIL
MGE M=?U6)M'8'SC(2_UKV%&<4^;6=0KXR*>J0Q:!E?$=R=LEXQNX]V@A^II"
MTF\@O+T#?XOPK3.^QG&SR,'0_6;:T\31Y]Q+U$ZP#MNPC1-\-&T8/T=2^^,C
M_558#G-81Y1,L)XJUQ/U?M,O<@"7=*(=*T,*_R*+E(*CCG$I5LR5_9::1//(
MW'>67_<P@.T7S5BG90ZN6RTXFN5Y-!'L""5ZR>J-8PEWK,+W[F;&*M(SK]L!
M^YMX( H:Z%OZ1.>AKF_O^X-KAW@YRH=*MJR/T/+4Q?(PP$>S\QA6K69,BG/I
M;;*W<8&@<<QN^R'#0&+SO:M<:LEE33  F@CBYV%I>R#>HTU,/+'ZZ)BUT!\Y
M#^:^_:RG!W&7C?()5EXFJ7!W$ZV_E]P5!ZD1*K^J7C_Q$7&+W%E065[S>W._
M.H19=H#XBC.AF7"$+EKF8[M-73,L\11@/[;%ZQ:*:BQ"CG8SX'9EH7C R4\3
M[@I*,Z659CS>:W"/5+O.Z(I%7;YHANN05%\[!FKI#XIE:%10?MQ=<#L:[U;@
M"$(#GW(I Y_$5U7&J;DQW.]1+>_-^6[#NRF@.:H'R0BW7.[<1](<[D)8BU.L
M <>R_!&AQ85.7)[>").QO;RQ2MNJ6&N8N3]8%P;8\6=O2[\^)*YF. @I]Y:\
M[Z/GAH*2F&UT$9YG7B 9GQ^6IF-X&-D@?40R]6ZK&[1\>$*-E@PL4I%\;'R[
M8X=G>BV3C+)J6-P ,2=?GW^V\F5-9MA[YB>>^) %S'BIG;JUTUT::^A>8H (
M/P'&YE!IS-"^=4H-K-[EPSM0[A#AG!IHHD.%]1HBIE [<G5*+#J_WN=?M%+_
M[UFM6X,_<]Q<2;E4@G1BTGO"'X:T7)SN#E*Q)WDFKE>K*<TBG(\1-D&S/'^)
M"2\/^8J&G*CKHF^H\ L:,G<G%4 OU<]H]%W*K6BP-:?.P_&U?<//78Q'-J'6
MQ+E>F:2VB\N8C/8;0XI0OZ XG6.WA>?[>[2QQ";=K^)TC\46G^TYJAEXG2Q7
MA)2]#!"7?9\N]6AH2MZJY9/>NM$)'@8JD39_D%\:[ZFFMK%_[C*0MB/6=,8^
MAB11]OH2;!5)N*BTYP5'89R^HAEOKV62DG6E4]<UQ6]-/9"R9Q8PKDY85#_O
M4&,'[[D7/F/3F @#=#5KCR %N(&!5/K4JY* "D=+W=I&#Y&HSQFE/C<:\U6+
M9-[E6) 17Q&7R)3-,A)R 1!Y9))D7OLCY!E_"H'&+U<1/"38,*I"AG_V8NFP
M- MO$4:KDX$ECZ.>2"JQ8R]_"N/5Z;/_3JF$]B.>,-!T4@Y@:S<ET11I53VQ
M&=(R.%%IEWT6>&K9\!U+0&K[P@?F2[WGVXSJ[N<A*QM>/>FVDS+<KY&+.W?M
M53I!F>12ZS;\L^D4<]SJ55R &=HYU )- Q^^]F5A6=4;9L\B,BQK\.:9Y&O!
MZL96>2HR!T, >I[83VJLBEG#0?+BC FIGH=/_VMGYHCH&8N$!U4V,, NKV#K
MY\=SO#=#LQ(C/:4E>$K1"F&C!J/(2CIWULO40V>_N(M-C&BCF90KAU]B1%B5
M]TX!I/;D$"_%CX-]L\4/*ZJ*11&5JX]HIK;F L3#[E34CIU<[A/ F?ZP<(!P
MO$T0J)=90D:*<1%Z>ET9J*8^5Q;ZQW!:_ZD$8A6RK3577]C>GO7'R;@AO21(
M@>QX]M@31PE"P $543,UCL['C,!U(V6F=:$.G_3E?2HG,TU3@P,$-720Z_CY
MD1ZL>37^1(>E^S7??_A4VY?U6MV&;]*89IV_G+?M%%+G%"">\3%GRY3[%)"N
M_DGSO5_;:N&VF:;\\C[U<H8#6N_X(_153!6D^,1;:EFA?)<HO>"L)6/2F%ZB
M?W&GV6[O*8!;<AR%^/3N%)#PWZ%:()%+U#SW:#+IR^^KC[V,AX6=Y/H9]G'P
M>],?JMY\"AG4FFG*CNK;X.G[T8SUNRK+%5H)];.6POS/$5>_6_W#2XF89.-]
MB;Z-RV<"D!4_K/[NY8&DA=O8(?_SG)^J?ZK^JZO>C:%X>0IPXI?JU,&=AYW%
MK-IGM>Z9KC^\A*S?A7/UB*[KJ:6EES!*!"E9G_1'QHV4G8U+4TUG89CC CE!
M!G J]_ML0YK8\%=W]J?JGZI_JOX+J+X;V4P-/"G\]OPM>I=O3;3T _'U4X -
MET3QZZH4*<J-LA 4-&FJ["T9Y5OI\ESUEKU29BD7'MAJZ8_  /S;P,#@B%5@
MYB_EYD_5/U7_5/T745TWR'@VO[2)"H.Z?RP8<DH0, ]&LHKD#)S=3I&1"K5%
M-P0&XI;+6NKI\1K"JI*A.A3')W])0LY]/TW!6R S!S@"XP9<D[C<LI<-^WG_
M>?]Y_Q/O7\EE3M_^/U!+ P04    "  :B%U84A?\$BC3  "O7P$ $@   &EM
M9S$Q.34S,C0S7S$S+FIP9^R\=52;7YLNG$(+%;Q(\1:7 L7="Q0H4!P2I"WN
MQ9VT4*"X%6BAN$N@2!((6K0X!/?B5B1HL.3P>]><;^:==]8G\\V:F7-.=];U
MQU[9N=9S[V<_]WW=._=^L%/87P 2-6559< M' #@ULT'@)T%* +NXN'AX]VY
MBX^/?^_>W?L$Y(0$#QX04),])":GIV%DH*>AHWO,PLO^F.DI,QT=ARCGTV?\
M0D)"C.SBTF("4KR"0@)_D=RZ=^\>P0."1X2$CP2>T#T1^/_<L*T TKLX4_B]
MN+>8 #BDMW!);V$[ (PWUWGGUM\:X)_:+1S<VW?P\._>N__@9@"4!(!S"Q<7
MYS;NG3NW;]]\&WCS/> VZ1VR)_SR> ^UW^ SN9(+?$C(N<NL4/6#0F?D@$7P
MK5OPO?N45(^H:5C9V#DXN82$143%Q"44GRLIJ[Q05=/5TS<P-#(&6EA:6=O8
MVMF[>WAZ>?OX^H5\# T+_Q01F9CT.3DE]<O7M-R\_(+"HN*2TNJ:6B@,7E>/
M:&OOZ.SJ_MG3BQP=&Y^8G)J>65I>65U;W]C<VD8='AV?G)ZASR_^LNL6 /?6
M_VS_IEVD-W;AW+Z->QO_+[MNX7C_-8#T]ITG_'AD\MKX;UP?,@E\N$NND)!3
M]>,>LZ#. <5;MY'[E"Q"2ZRHOTS[FV7_[PP+_G=9]G\9]L]VS0 (<&_=W#Q<
M4H LH L-.H KHZ.69N==0"WC=WZU^*@&6]YZ_]PQXV?'M_H-X3EPNQA:%A,,
MW+C& L*Q@!CM2S$LH$=J3/8W-SLF,K(I^+T4&$/=_0,+.":;E-V_DKVRCT/;
M,.)C </J)EA RP$6@"H]O<^!VXT%+'T+8,0"Y'G<,5A .Q;058P%A+D>@*]O
M0X<NL0!B+("F\G7N'[X_?'_X_O#]X?O#]X?O#]\?OC]\?_C^\/WA^\/WA^\/
MWQ^^/WS_._"U7:D?/&A#B(9Z!NHLOIH ^G-S5C ;LWTJL51HI5,F$I!6\I$*
M8II8CK&(,VIY+D>A[VP"P)?#<_@]1/_7!AR*[SJXHN58U["#_-8Q%O![!0M@
M.7J%!7POS[K@XCJ]C\("IKLQJNLY6, ;8]EC/?W?Y !MI?\(O/$)D:^;E*I;
M&:MXFFO>^-J1/[\K9H:[=W]4YX#JDU 5'L2S&+C0R^13 7+GJRO#/ L^TD>%
M)14JE9H:@_KO@6M@]Y9+N&?FG9N70=#]4=T1VPI=E0-MI.>=!LS\V)Y7M*][
M7[+P..6#L0\GV6]'-(X>7NZ<(\,,-ENO"1]31G)DX_P=N./1(<L/( ^4HXV7
M;.J3>HV)GP_Y:4S9F>QL5E"I'0B/@:U;P&3V OUR7HIL%N(;CRJ^VT\\**Y(
M<UZYM#-=T QZ*VV?MC7V>;]2X81"+1#8]F"U*F5;"!$?D/"PIU)JY,14V9P$
MW<S)QVH)__1%+Y-9;%<W\"H)[&IPA;P<>I7;.-O:+/0=>M#O5+%SGY=&0?2E
MJK1#"TW,UZI+VSI%)[CW%^)'I8EKK"YOQRE"K59DB;9%@Y&C!O!$MW<D9/>N
M.NT6MPW\3*OJF^I>/*$W+I&FF+J8@BJYI87'>0@-[[F4>W*PVHXE__J5U5N*
M9NP^E6$9_:6>7D>EZ^:.@SNLJW8&E_-C&9R(_-& *@I_RCL F8#<U@T)CLDZ
M@-#& -LFM:B.YKM2\G%8V=?64]7#052VY9Q25DM3%1;P0."\51(M>=*@/6B(
M8A,8..8UZ?>-5(-]7L=O&*^3?,PS@6(DA)L@6'*T&)#['4I,92M"Q6/C7BI/
M/WCW7J*F0S+:LU)=N*+*N\2>D+76D!"F2GR_/E=BL<?$R3C@MY\TA0Z/9J^3
M["YJ+@^XR[,>TH7O%RGM\C*EU9SUMX:]YNWZ<]LI4!JY(>MR"PFP)5SXSJCG
MG4L3[;!^E63\)HU?3?*+/PR\TT)[K*?4^Y[DV*?ONG1A :O$ZKQG5SP8&RVE
M-],^W>TSH1O3/)Y&K%EB4_?PSPWY4 _T&T8#Y+/ONK# @U6UTL@/VA=B2[R)
M,&H;N=I&, ;N82AM2Q5P^UV?&SY_L'P)U)QTBX9:N\2\TQ&4'7!T_NKX3DF)
MDLZH<(RL,?Q2.<.;OL-\05$/2DRY*6$Z5=LTMA3FWJKX#?-9FOX+CZ?R.,6&
M&0OZJT,^.ERC%H: .ZBF7S^9HLN]F 0V<XXPJM,D;O/3"G:G#W)<2LW?*I.D
M)3?03%X.I#))R!OU?.1,[U?Z,&LB9:4#(9P_JBB3=U_][CS3P]Y(AO2P=0A%
MG-UR!M'%(*C!2>W>XZC][[)>!<A&Q?R=#X/I@12#[6%W?<F-""4X<M_?_X-_
M-\2Q@'_E4"E.L8#8FY66Z9.*^6%H?L%9MGP?< $^=<4"$GV+P5,&6M<4%/YW
M?/X-KPO@R(W\_PVNP@+"N5,!%8MWL+/; =4"J\1MD GB3P':C.% /HFNO346
M>J>5.25.D+6P_^:[AR![F4<HC8RSR'S,F&H^:><[&?U/U]PE*,9080T+X]H)
MC\ W3]<B@DQ1>_A,WX4=&H8^I87&9&2FNSN]<7F68NRL^T;LN"+/ !7:$K9'
MUF4J@O%\?LOL;E1(IVQU99[&[+"6L:1#88MO<BXZ'3@J]3*3 <768_557=$M
MQ-:E#0$!M\/,6&IC9\Z+C$;@<6PZX;+:)M9?[< KQ-0@=/#RH+KZ@^?<]]6>
M_0[L]-,PG#9<O/A>N^XU>U'?@06T06["X=7I6,L!3QE;NSSL8*A30V14JZ[A
MF98%<P_=*-7MZ%]'9E]-9 JP -80Y9MY#FCI'XO>^VN6!B=<^,H= ^9E6A>&
MZH@Y1!:DW8T8#Q+019A0E9LXN]QPG_O%(*=QIVSCX"NG>;5%UYL WJ:RG'5!
MP7@3OB-EEYA16M?WX[  <*<7N;[_"RR Z0K<;S9HWG\3R@_%L #TBRM=+$ A
M#PM81*E<L01Q8@$YVEC /KJB+5(Z'YP0)+O.\$^C!6HEK]4P"RICM>UOF& 4
M#_;FI.T\K_&&.H F*:)EGYVC)4I.*$J,,(^33",71(>SX9FO@RPS8,'<U#.F
MA*_3MM]%>%<&B#?!X"WUET$1W)^0"C*V-<-Z'_.S:';7M.,G+$-^VX]WAU_I
M+O?U>:#H#&!>S\3 O L:LS]/RC!/#IIS$6L53=F?,D_O7E6R&<R4MP"+>P<%
M4BZN!^S 7](TU/BW6VB_RC#=7/T#EQ=B&R[F;<6;+8>"Z$5,/>.:*5',TH U
M%M#1,HMABKUK$R.B>)NX7J797EJP3:*@ KZL7A)M9I ;^J;=?;1)P2"<[\P*
M7=O;M 86P]!^;2'T(!3  GZXT9:]*!2HP4%RB.T@LP^4\VS>9#MXS93G;TW
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M"[@7_BG;-\V'AZ3VF463]D'M3&7D_'Y<E#6LSOBNA-_*&NY$_L%8"7Y'"^D
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MI6@<VZRF0<2+5V=ZYD;?6MK\0U-__'PO@%";30YGJI%ZWAKP>@3/]Q#8Q+"
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MZEDE^Z8VH3<9AXQ(RR3DC<?H#&L,?9A4&[<2.1; V.[2F#YS-NK $*Y$KD?
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M3V."G.Y^J184A"FT;BV\XX](:[84R:TH(M+.9.:#*9'/:X^]EV-&Q!4=VG_
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MV[F$[VE4OZ]HQ?TPG>G^I/N'Z=3^J@'/8V<5Y/M9!0P^=$BU%J"RR['HMS6
MI['Y]5YXD?2^!U?FC]C3/PK=?WR1))ZS<O!1\A:,[E".5_GXXC!D,@"KR6:0
MA;SYA_J3ENA.Q ZRR.WI3B!/4MD'@G T&>Y+#&!)Z!M-VO<5&-</#,1_4)L7
M!/ZD^W^C:]JV>)'6.,VA]:!O;7!HN.4VZ44:E8L8P-^!!9I;KB_2.J?6[\CS
M5O*[EJCIIJC)P[I_X KHQ+9[,2U^_ LT9/F^ E3\'B>&_TGVGY!U?=^25?S[
MU9I%;[Q4:YZ5&A8BZY(\8M5;%QX0](;Y52K_ 7OYAR#[[E,P8B^9?UB/W6S
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M(;P]+/[%]Z3#\2K%V-D%LS)<4$XZO)?D%MF&:.YRV+2^:IYQ^@O& [8),8#
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M1E9O#5Z+!C#T5-E9"0@%^0#='8MH"(S+#925L!.MIAU_6T,+U0VVSAH'6;)
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M"@T799$(X;=5HK!7)PL8"GO1[S:N#"8,1+.&=,D\4D7E9(9M@$4"*@\&H07
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MV%<HI1_'LK9$Y7STJ&T1Y]KGS[T#TY7Y&!OR7)5UYYY7\I$B6[W^ 9%;8U+
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MZ>B,-\XMOT8YX@GA<HY3RS_"&:NYV*6T%J=-<KEZ<]3*;_V*545NP6!/W\#
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MU['Z]^BOWZO]+QJ$<D=#LXPJ,M'9<H8YO,B!%FO\^2!#U=Y)60O*@\F,NN<
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MC4V=7=T]O7W]WW^,3TQ.3<_,SLVOP=8W-K>V=W;W$"<_3\_.+Y"_+G_3A0;
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MYB3#184+.P:LQGU#U=Z%I3VUS9"^.!V3^;8($4=,.^W@[+,>Y7RDWXL9(%U
MLURK>+E/8J7+8_OR;UH=EUO1)&E^KSMDY+^8F$<5@W4IJT/28XI0+"WW"U&"
M+$ZVT%;:G_=N'4VUY$R&&!N(BIEDM-?7OL]4F,6G_&CX_!FEH;+;*C/9O GT
MM[<M_MY>X1:G8ODB+)0(7_6@E[7]4&/I3YJ?(HW7".0H',C-+)Z7,#9NTJQ[
M^#Z_UPKX-F,A'SK]H,$B+DYJ6J\B]R#Q@%K6DT:F!-R,3%O=N18LC81*U,<Y
M71KBF3Q54T\!&(R\#=JPJR]SF(/'7G\X/]V$5XFTL@?UOQ$H>$,U<ZU\!XC;
ML%#;> BZQJ5YNUXM]T3C+[;+(]4+YAV661/H^PU>,&(8%H.],M'AY]E\ @=K
MRM+NQ1F!QF\*7*I_OI,X4)[4Q?@872;37VF'C%[5X*@U\E?.CXMSTH/ZDCJ,
M1+4(OD3%]M<5PE=45R\A16\$.(63[O,O6]ETNRHZF7GS6$R4&1SM3;U5=$LW
ML(W(\/IBBLL+ [%S,A!._U#=^TQ57!&SWR[+]K4>M 65HGRY:L (39S:7)FS
M#)]_O4Z3HRKSF53'C+T5@& 7[5T[)$G"UL1R*Z6L% ]^=@N2\EQ/'\W/',0>
M,V.W(&E1%49_62N%.Z*V?<2W5=/HY_=NCETA%+<'Q?_VF%3@3:2<8GDLH?U^
MY?[HK"I+-!YFM7BE2[,6AK<&W^E5\?V&C&"LX"$[W2]AT(H.MNU@MVOV $4^
M/\-N"XS=&3ITL*^PM7 O+-L&@I!WR[*!?/&@4G0G,C+ARBU3!L*W;Q7& WC$
M4,G)XQ$3"^*@#1G.\1I_*Y3N2Y^EWK(Q*Y#'I0?AH?R'WO@WF]7I]T5[NZ[G
M^^YI#$2=7_(GV0;;3ZQ&7@> \+;I@?LQ/&.WO$C&:SEW#P*::NNNC+R<BH^=
M\\3)'G!/V"WP!3B>]OY3"2KB6I\7R=K5L/"JP'7FW+'FFTAF.-TE1GLJ?W F
M^NW49-FZ*RW';$QGP<11()-W<1J]>&Z,W2K#"VF-M M/QMA,9#9<DN*4:MY?
M 2[EK:R'O9@,3<Y83G1>$XC4 R(HOFW<5U<T/1$O-S,Z<3NE:F(*I)?K[/KM
MV7-N[R/IU=*Z!-R*%I0IY(74B*$_OZ9OS\:K)>KKF&$8,"I2&H3B<^4&TZUT
MW<(K-:?;-C*[;@]]HH)(KCJ_29G< 1+\2*Z@B1HP81](0,=I42#EY%78KL'I
MI+%(E,JBK7'[?:@U]]$= ,6^XU3MN5MJ9AV+YTN@0(I1:3EGGV*C'F@<N:OQ
M0#92JN^2=UWQ6?0ZP]>8B,8D;F='_$U9G]QZ-GA$B4>Q.=#HF:VZP4--[H](
M=1-HE=]N>8JE0JA*18SW!5FTXFM0(.6T1\/U /TKV[/[.5/7,E_L.91RG+XW
MY_11NO',K[X:,Y'4#"L!5^AIA:?'(,MQX +O= ],H'D^10L0AMS:U\2^D)G8
MSJ:6IC10";%3W,N*AUVH7$#E04:Y2@Q9,KM[7J9,>WLNU#V+R&$>;F/E-%C:
MP>ZJZY!),5UKU+*P\.K%&7J,K9\IH0./]0PJ-3K\W!RZE$HQ"BLS]:;O%DTJ
MW (JG;2/J$FL+Q('0I;KX9IM7I;.N;7.++Z5(I&\SICEE%_T9_[P+^V.5-9=
M6LU3_#WEZ<]/F)_TO%Y"4G0;4&_Y'-(/Z/S._$Q$<61Z& QM5[705&$+6^I?
MX0LQ8C:I:7W,Q(7PLIZR 8W7<N\@66 F)^ >M;@OCY<FW/S;EW94)+*AW5'Y
M8E(85K)34W:O2DCE6H#A56F*&#@D Q4;ZD+@]GN!U)*)!Y6,^]SVZXPD!2ZN
MWNK&6?H-$]9A8J0?&VR@SQTZ-?+/"6AJ]=L.!JI+[@"O#NX ZL.BDTUUX<4[
MNGU4UQSF%@V ?4./*MI30P7;50O2/5*\\D.@%2KXQQ>#ZE,UQNJ^A>?%^<9P
M<S\X^$QEGPNQ_JU?_Z[1W0$\OTEJ_>+$N)G_>>\*NGL2]%V<^6A:W]<WFLF"
M>9'R\G60BUXC^\.3OF >*UP5QO>7^$['Y\Q_Q"(_^%XG(\O^Y9&HC:O2+F2Y
M=O*685^LZ'DHC8&=U(OU;VX#I!]!OX.1+XTP=-%?'6YJ3C&9ES0M#U]D")8R
M8$I97?(R"ANI@=HPEU!]*;GW.^][M%,ZGXG*YV;0"79H&5#Y7$7/ZHV3G_?1
M_;I7,5I-\D6#]0TTGPS.CD,];B171AIJ'3,[DV])8TF#[*+N %_%XI24!X;X
MO2\PT"&C$[4R"@8I:S7O:M]?1/"H,:-YQZP9Y]6^%C#G;E1T:M^V+V_6PMFO
MOT@P>6)_^SK(CZ='>_(TZI ZZ,'E ^5+[=\9A!XJ@QC! :<.RGIDU%">W2_9
M2WV0EZO)VA82'ZL0P[5E"&W/47146&-TVIKBMZ[CH[@9QU+^XFUC,(:I=+F4
M/'P5QFB_%7WH(@22"D9CAP.HQCM62<A-@03O4,Y924E1>2W*AU<:2"F6U&K#
M [!QG4Z6K*FBT>W@):2V_T$N)"3XO%(962*DX>,4-\M+:_Z%)Z4:SOD.2F#;
M4/\[Y^DOH'O?H[I#+7'<F4JL*5IU"9G5H#O6F+&$3K)RJ0.>,-"=M3$AW=2J
MX93W#,Z+/U+26DKLJNF_,#'K[(O4T:P)!?:I6-'G.P'*5Y!/I!790ZF@C@="
MXJ5OU#W9B+DXT@4A#RS3J]'S&,XK7\$+:NQ;Z;]];1V//THD-JH4V8PJ7 9+
MME0; S,V8W_@H.>*2*2=,'Z85VC?T1HU5!8(OE8D^@'\EN<3.P&9ACM'V-8@
MNB4]H8!?59Z/"O<4>1:):1CN 'C,.A"3LSO >W,\'^BSL*=?\5W[]6$M,]KP
MWNJ"145'M]>=QIKW(*P&CPVQRUXB#M7-:^X ^#9>;S7S:R0F/9U.F@U3HNEU
MKERJ'PDV#N.BOYO\4/F*FEO'C.%W%*3^>Q1\*U3#5F*@%TIC78**DEBL.R 0
MB<)SY3QOC%O%@9$+#9_#D>O Q:!6\&@+VAW@_N;V56'+Y?:MG)/<BDBZK 1A
M+.7XK)QK[*@.:R<YSPYS9"OSZ ;<8>_>.0K=-X.*5 X/'0[(&W\>_6$<1:X6
MSW8OF  (QOV=\SH$W\)+0F)P?RN+]W-OO>Y2J]<F.G*#P83KPCG&:J;EQF'*
MW(KNU?XR"-Y1WN_VGH_Z8=6VX\>.9ZQ%Z@1\W\4!,=#<3^:#^)_2#9\N8R'P
MAQCD7EJ?$%9@>2R3(A5$:Q_0#4";^T;1I@OUK:@\._L^(Q0]9-GA(K>1I?0J
MI"V*=7DVY086&-[AA:3E>??8V#8+BZ@K720N>;0,X4<EV8FWH_4OB49AT6Q=
MJ15MS5>R2^D"NHJRMN!%PA\\%OKPBIJ<OBT+H%!1,66J,RHSM!ZK.,@6P#\3
MSTLQN<!X )EI00VQLA2HX$NQY,2 9&FA'.^7^:@TH,')R'.(Q/JW]O9K;K3O
M5V6RN4WT1-C'6@@.:&&!TP_:B"<,AB77"G#;EE2L+_;3#_E3GG H/OO2*Z3>
M8 2?]UT8W#.SMLXKZ:/**_/6,QDMZYXY/RCN*J;:96).6@JD,3V:B%\98!MF
M2W4K3FB:Y/5AIC0H3P[WB%J@;@E%AV^<8 %EL1"X-5?&M<X\M+OZ(U23J+B0
M(.6SV7@E]&SK]>%"C)L9&C((IEAW]:16UOSQ!)18U:E]:Z=H@##II%:/C:T2
MDPSR8=O?$OW-JJ4>F=5KITP,R<Y>UJEJ;>MO(]U)=:GW.E5H'>.TA##2W<RI
MBUP6_7X:3Y0,I]$;4$.XRC$IJX/Z!N6.(6I&;>M;S!<]@ #0:M OJL.@):JQ
M&8E_O+Z7>Y_Z3P<VPDO_]L#&8_7W@8T,S]PMYAW@2S-3(]4Z3H'O18>,4F<G
M?5N=F3(:R[I/CX>U7,1W8-IE46>IF7(/FWY3<XRPL=A9SQ/$8^#$=L.8.]@X
MR3#"]KM>)C:6"Y,40O$Z]:Q;-'EPNB<&7\QATQT$O"67HG5Z\ I=VSA]FRJ=
M6[6 6R9B[M0NUM_B7I@P@=2[P[$C,T L6TZ/FQR! ,X'_LJS)8,EHF[.AX+&
M*_0>]$0*"N/CPWL22X)QD>)E66&M/#6C3G83E9_9O3B/,T._1LLMBB;EM19I
MY/IKMT[>LFKD:F &61G.A>R:7"8'GUY5OM->?A=OO09!ZP7Q7O.L\8EUGWB'
M,NH2:YZ;=96[-17U<+$B0PBKKJ?EWW+63R=6W '<R[-]T\QED!&W##-\[D!Z
M]WE<\I>ND%%DV)OZ-F+JS1=<+D7H:3 ^MDY9KH8P_32=$%MMFNBN!Z7(.X#>
M&+!=:;CW\MXLX(7!]Q)(]+IMI?9#9(I.(,Z"Z"A)@L3U7E8'8_2JH\HJ.5GC
M-='K'<-;9H1 UX CF\XW"%_UH>VKCM)E!BU\I-W3;Q.U-TJDM/3L]>9$8CQ/
M.N<7B?W6G**MG.U*]W]VLR=)F*[&9#C$9"!R)5J>>!#G@-JTOBOJTXK<ZR*A
MV3V?D4P*#]R+4^>Q5I(F!>?6P&-#3\L- O2/R_/?;8:22TZI_=#=-CP@Z-^\
M%H25&LD^>.<NY<98?A6(,+6A\EJ/?%]Q:!OU3-&B9AC-9J7 C0QL8H5L=/9R
M(N?A6CDFQC'9O^6?V_$=_N3A%_"4EC\'\)#G96IA0BGUS!-WZ?KV>7;)X_>'
M!ULC264DT]^R8"0?1D(<#WE/F[UG:$AZQ2L)X17U#\(K@!:<S(^63BM]9UZW
M"*[OTP/?G^%:NZ"Y %._[%^\'[ $,BA_\ =G>]=T(B*_>DS*,TM68LXHK_&4
M._K?(_0UR]<>Q%EQ_3#M%0TEP?-V5JZKKHJA3\)$[T<3F9[=\S6 KI8:.4)I
M^)CM%\4L(<,:;WCX^(5NACXU18;EF]FR)JSRJW.*B^C)I_*)M<_HE3WL9?B$
MZ459Y2#)%QG!";V=AJBZ/.$X42UK-K-38T)O?;O2R6'IDK(QK2I:OB5X!R#V
M][T52[W2G.3+PV;X@-9!E;:J0?W]EG7_@^73N@-/0O>M1N=0PVG?H/<B( %^
MMA"@E'HZ!M"<%N&4E>>O/I5@_&EAJ0ZS<;T<+/[FAQKCVQ375L[%17\E.KHG
MS'-DY^G3?;%/Z]\)'Z'I&D(@6H1(469*$E+EDHZMQTZVA)*33"+3PLW17EK>
MSKGNND+Z32\J##E^-*'9],T_DTR?E[XO@H__,60Z&2;V@;G=1"3=Q*/%L@KP
MP14RA(R&@=5U\A=!%_'/M2L_4VY#9F:LX46QI^J&WR99H^.?S!O9">>6Y6[4
MHGGP&4-'PF;$CK[$\CZ+XX$@566N);':JVLLI#A?)_!Y,K$TCKK? 2*\3,PB
M<@A\7-=>B+%/.4?ZGL=[K,9;UY/.FSU<35I-!:LY#11[2 ;@,QI<J+5$=3]=
M?OK#,WP;O5$NPK=V^I9GLD6&#LV.S$[OV(PXW*T A.>>;#(I]*-]-;F"H'V^
M-\L6(::;ZO=YG%8!*RZ36TE,=Q3?7'"Z",'90Z!%LI1[D\ MSW0]4XR,F#"9
M<'1T]!>J&[MO*7M-"/FI]4XUWSZ3OPHA$K[H13R^I:B0[F9V>)Y3X-VF 6VN
MFR:?ML;6;B5Z<1ZE+J]HP;3KLM>*9?<-['PH;)JD^SCU5]\/&Y8ZAFJI(+KS
M%::A'% KC2C< 7OK)I+#0F3#G+DJ[<7,P=I[=;%4 @.D(\MLRN'TPU9JI.S8
MHNAWN^>$%T/>Z#?;G,T4YG.(+ZZ.:X=2Z@;S_=EQ/#TX3_0C#:.27051^?0B
M>H7]'>"$H?8.X*\OV9AW!^A_,W&#4)@E[H)9+-5<XJ_NMR"3+U[?AC9(#B>W
MAQQY,A/$2#OB71I6>U^UX\'V/V\DN$<#MA^T@-<RNJE;A2# % ,NY("8VI$L
M+[($UO@!1!?LP3.2-!6NSVG\)OJUN^_UO'+H+;U&;I]G0K-R]=,Z'_'2P'MM
M]6.!E,K%6N1-O>%5RB:_ZDZV]@Y2.#-5:>*[1,%+Q*6%6:$CH//^UK&-.T#I
MB$1)B7(2MXQ3QV.,KF6!+!AG3/F!\^$ZM>J@)?'4;NJ)=\R,3EWDTRM>3^[@
MM2IBGNTL !BT5DD!=*#@UV;,-_RVMS(7R)9 L*_ARD*(YKX"T5\;$+'-GNY5
M[B'"GC >/U"3:5IYC!7_*0:<$;9:E4#IYD.M,F+BW#UP2->G%4KT$%'8HO!3
MLD[1Y\1[P$P1GW^C_0[@4/')X0V_H964J?/[4[:U0YU#0L@J$VZ90^;1B=_N
MAQE^LY$W#OA[AG6YJ W+9RQ*'7DLD=NU(CV+(SIK&2EUU/;81^ *NL4]>J/A
MZYE\!V _L;@ #^KE7*;V)IW0,[3MKZ&$9#A)W:1UOM+5SUN/M41#*W)R>0>H
M?'=._-CBF:EW1.?"6JVZ8W$W?Y)@.-$PF%?-.:E+H85V-5J@W?">9/X%XM>'
M(IYFJ Z<N("X!B%@TEHO\;XFS)RM&.R;6< 6%=6HMAU,]XUB-> F,ZMD1>3P
MAT)\1]RZB BW")Z:Y@&%9,HMQPA.MUN.R7POZTJ=8=^#DFO+"<>(O*+E'NQ=
M+Y)$91,8>U/='2!\2&8T)7#0MC^YWN3TF 89I11I-'$D.T$T" Z6E^A1CV6'
MP9H(:QA'WF=I59D)T?"MS3=WN?;(P8C3[%SS9TTM^IA.+5^Z2$Y]<PB0,@Z=
MALT81^#J/^&B9PZW\Y[0']V";T+;%M:3'LE[&'R_7QW]ZZ,*49:TUIJW<KCY
MS B^>'_%/9CP99JW$RY47?QVU @G45EM>ERXC?A!%N4E=15?H?1750YFLFO%
M0L[0X:SSX@IG(3Q;B5U]+% I?\[HXD1M:31;NV?;K&!G?<(S>O]TO35HXV0+
MMX<SS+,6G!L)PG3ML4&Z=<\;0J2IL#[5[]NYX6/^2F.8]$+82\J&N,S,-S0V
M/O3$\I^<6Q[Q"UGUC2Z:A=(>?B?$2"?;-<,).2.8\[<M7/@V&(%E]7:$:FA1
M?=M,_8$J5LSC7: Y3A)/$-VLNM0[F &MS:B;^:>9IN]2;;%M)[0304N5#RIU
MD)M!=L4.\VYSBWWB^K\@#+"6ICR2:W82EXJ5M:+K0+, (M=_G-!^*84_4GX,
M8_Y%XW0'6"Z;OBK:-3%GO0/$1QS?[ TY-P4FZLRA'3-C&@9%5MC<PN\76(2+
M!L$3HU\=G8AWJK80S7YAQO'0D.WJJE?W\&$0LEP5[*B41CB_A_)$OX+15)HN
M'(D_G.K[+J&?S%-UR92\7N[9IX>H"[>RXXHOWZ"'I,= :Q!2?0*K6]5 /_>$
M+5WT&N+$-7.2SXKK/'@5KZ0P-C-&U(YE)2WF'"0CXJ:]!$=JHWN(78?$%+E[
M25[<&SV6UK9"B'7I^'F0OT\1(\>1J/!JIW 8]=94J6T65E6P>AEG#56J*1#H
M,KHO-D:K_T1P.W5T3*2<S0B>/%?N;%GSV<6GH\Q#QV'>]!7$Q'P%*7DBXV.5
ML)JS*=%CZXU5"]1XX <4JP=NCJRP290F&<YKIF6; U7+%'@WM3A^IFY(BUFM
MT6^EV@0Z0@&JRQ: 5%5SOD>2/',MJM@? T6 1DZL++^ 2MYE66_I%&M3S7.^
MT% <FEN]()3=W6H"!UAW*8P=*>64/O%(9+WG(E/Z#FF[SB>ZO*TWSI]/VN?*
M(ZFB"1@2SE_C8=GSDN1!OC\#AL^8#^X.Q7W!W37G0"BHUD_X&PLGO<Y4.*&2
MQ#_KKQUB(FBLJ#@[39A(>D%N^ X).QD_[JZY"9DK#_FE*E'NLK_21#';&7IR
M/E=G;*I.(4=O(YUZUA81B'4[$H?,,HM[^L(96Q.OS.)MJE.X1[&Z7]D0PQOY
M(,^O#!CFWV BH_Z*+^L$RCJ(JO:J&ZCT]_;[6U^3[WDG=X_0*<(R//)J)*!O
M#T?*71EY1J7]UC0PY&N,W:-FMVTFN;]7RC*$ ,<W-TR;\:* LF0H]<I<KBZU
MZY0[>;PP-;!F"?;_ZU":IQ(9>P=@[6]-['\Q@21]/"Z+S^"=J6!V!_AP2]L%
M"WB-<I+QO;B<G*D_*\.2D^K,V>./.57TJMU"#&^YD%_6/ ICU=M6T([I74TG
M/F0X>STICVF&,144[+1BA77!3?._VNI[II^6!VB96Q#Z\]6T>2<9J!@Z5*V+
M_ 0.25_HJ J/L/Y$DXIQ'?+SBCW3D-Q>H_I6=B]>53PZR+/HP:>=DY.^@*?;
MZJO'9&TQTO0>HGG.-(YO 3A/(&LM: SSSN^@XJ]?=\7U@9O@/.IK_$5%QLB'
M6_2ELSF?"M&K.W:!LG@()LB*XU?06H1_NMK2'GNCS[@)X8Z_V$VSF]N;IIUZ
M;WHI,I\*<!?U)7;B.OU&PXE-QN*GE1#(W)CMA'"Y)LCIK#]?("&[#;T1/9-B
MJ@7HXB'5(KN^^2,Z1(?*[_P$H[;I8S>H=( =Y"SZZ<4J,3@,[IGB7':MU>HW
MH!C['>NM][K(XJZ0T4X]"0^X:L Z;_/IKPKBE3Y)IRR$->R7X+EZR&82HRQ4
M6W-<QPPMXVP?F2M'_G >F@MZZ/(B/MT0#5&J])7/,>BE%<D=@ _=JV)"^^OX
MF8R.L_7,NKKGYJBJN15"]T)%[!$01%&;$WCEU"^\(Q!@Q-27T7GQ<*%LX'TS
MY;YY_"I&SG/#6W(?FN6C7\_Z4C=::$M,[&\Y(O8N!=EI 254AR:Q$=)D,'"Q
MAV);!-XCXBE+03.J;6>/FXV<%0J6R4(X),@Z\0J]PL*YP'^O89NI96;T5@1A
M_C['^TEM&D]B(W\:]O0PS[8'S=*1:D%X&UO#9L,>5V[3,X^V?SZ +_BGXWGC
M2IB<_(XU4^+!'0"](?0@)IN<IY=$[>P.$.H;'?[VGO7)GC@>#OWP8[UWM_18
MC4NM1;8PI <)\7*X&)M7$I%^[6B%M 2\4F?B*/"D='W77+42&6K&!B.;=/_>
M)9#V4R@3M])FRM\B?S\0T/3)O+NFA:$7F#'U7?)-='G-PRW1L%BDKE?C;O4=
MH, [*&SSD7?,5/DP\^!.F\F%,[K9SHP%\7!R0!"AN=,F:A^&GCLNS;RJ1;04
M_<R!=(#70BBZLS9:D=A]&@;M@B')D0]FFV)E)M$R&TMNJ>W%3"R"7\7UW:8\
M9.9=STPWQ%N/I8ZE\\Z<T:KYK&!#$3W8%V;6%RUMGTD-=\SWQ3H@-\O69]7T
M>R'^_:GP9?59XZBW0Y]^$WSI,*+NK>J#52$INE_UW;XN8]>*'I9Y:#0S14@2
MV')I0#DOW6EU&4F[LUH?L@]40&3"IZS1& /BO%HC=C71T0U7IO6@F&)R5*0T
MM R%<&5CU\/O "T\$]#*7YQ5?US"_M.M@*V>=ZATC^SJI?X0YZU"DL79J+[P
M'Y<!=2^FRY9B*%6$ G@,JV(+_1761I"JUYQ@>S.]#8;Z\9H6[K4;MK6*6"_>
MY+&:?CS;I1<MSC P, A[(>C5GF!*)TDB?6;B:G)J14YQPHR8;GW=$4]H(K>F
MJ%-_W8%?6R?PG=."62L^G5A<PTC!&Z8'R!37TOW=;!.@4AUV$!]R?PCL3S-Y
MP"LM5LRQM.C2C!&\35O)GND1UN-F+C 8OYB,Z45;SJHAF= T:SAZT<;@'7E+
MU?>V;/BC,TV2MI#*I7Z4,1OBHBNIH354#BIT<^ N@K5X2XO\N :T/ZYD"S5J
M[ZQQ2XTRFCZUP/3FJ&TF:-C.2,:PVC7BR%7UFZ'-RP:=FV/ I6=@+"=<[.EN
MJ47PA3XA9-WEAME"7P-%=?7PP_J0:V-;6!#!4)'#^H \KEU@1%W+O7QO+^7)
MS2B5E >O-KZ>%W#8<G 4TS:9@NX !!6_/#_@:C&'NV51R+*;[<[,9#)5U6LD
MH%?,;M7S.9?S!CY>4?=RB<MY&SSL@M?C8]$M-6"'?"^SR%\#C!@VS-FJ*\#B
M+JT(]6-*7FV.MI;#ZF-*!%'JV<C:?'C5=%&3I0U_6U*>+[2(]9U[F$=.?<H]
MPZZ#>A3H0&K\O1:;MH-*I# G#W3+T% GV:*K'I9@(2'RMF)Y24U!6H+=Q#FT
M\I518DMZ(J:OWC4!S,=?)\=LI'BA[YTJFFLOS\,^H_'D]OE/?$&XB6%67F_
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M$"[ _ZJ5ILI=1_+)K5!I_J.*2_L<H^JOBJUC68Z;!;GL"N*: CB+WT<3$XT
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M).Y"<A,5\DC&:/4%=BC=!%3X) _4ZAGSV@#AB:1JH6'ZE$PHE&!1)16BC^V
MV='1K_:.%MD&S;_CB6"F=%FI9I6.<##OBE$D,3/T7Y4G@+&'9,:]W]A/Q3E3
MCVZ*UP)5?N+P5K!\+#DO7.6+B98K'<A"];EL<W@2D)91SHMEU.]_[PUP?^'F
M!7E?RQ/)R)<V;"EXH^.1T60)MFVNZ^&:?,F J>X%INT1DK(5]$"*R\/+82IH
M;%)I?G2D36;G@W&S'HNGNMW*F0I&N^F"!?5XW-GW^Z-;<IZ\-$QQSR/HU0M,
M]J<@Z*#@PCG<OC24RY?']&LS0;7WQPQ?*66 W3+GR%YG1&#,U*$"*J-/AXF+
MAWV>8+PZ36^9"C8=0FSXB&(CWAA.TV 3K+Y[/%U7*"]S+_\JVBUN#=WS(1)0
M* C*I[8UWCEM&9XF&4+P\WU_F)^OB(.RJXL\4R. E@;7E(6V!NX+=VGJ=S Y
M^GV[LMP:?^AY_@Q_*03FNCK_\@V+6:?HD +&D.:Z*MM]RH813PP_[,_OK9#Z
MD:B7Y9QN)V V+C(BCWL.'+7"=LR=GK[2UQ[PZ4#C++'6>,1QX)'#:-<:#Z4X
M6V0HK$:0&RG#,YTE*/N--J,RM RTTJW,R99!)"+SIJT4QLP0^D"*VYL0E-G@
MYJ4?[L<QZA'^I&3@6ZFU!\T=]5+9>?7086FNG4A4I)-CWX\[0?>]7@.0$BTT
MF=D-1E/7-_:=2'P4"WO/2*3]A8LE^^]IS&>Q9.[T-)_+/-W)'W\VG+^K]/7!
M:I=G"E=]QDK#]/G3C7U^ A^U2T"@W=KRIF8)JAAU]5A]SE:96V.R @,E70GD
M.'L.VV;L2O[*.O<XW:AM81[ZZ.;QY[ W?)G!!AR<1#5!+@)GYCO#J=GT2::/
MSEI/-Z$8(U529?:G))-\/9HR%/M[Z,)\W[CJ_&4'9\AM26.'>49=ODU+ 9Y#
MX8Y935TZS?!*XJ _SZ0/*F2!(+OJ[+\Y17'F'.2_CB@,^J=EK;+3H(/7H5>)
M]>_!7PJ(S?I..P,7,GRUP6G(^@:&GK^$#7D*S3*[#Z8N 36&0YICO\Q&_1^Y
M2N"?:GO#PO98A0MY;R\MK '=#-DO*:'NKR!:O_CS:Q"$+G!_N>F"?\\=_F,U
MN"M*O;^WQW]TT$T[)^>(H#_9*/2*&/Z_%]?\1T'X8M/+)W7W.<%IZ=)5%#&P
M< GX^%IF*C]W_P#7,Q#R6CNG\+SA.3SP:NV]H']$\_X(_G3E]#%3Y/\>+R"?
M[A"<A2?4;27N3:1BS\NOTI'AU]@%7-6' F;)LY"P$TB04$)Q1:DG;0BN_A=-
M?UTQ>;M^'$?^VTE.M"K("43O=CE_J=?75/H2B227T^=?EDRX3G]6+%7+1Y J
M?^D+W'Q=L5XYTLHKH3?P'45ECZ2WG:!,1===D0WU$69*(,EC@P(FP3\+I+A:
MV)\27=FP_C-&C$A3DS1SDEIY*8CI\>,7V[H^]!AN'_YL,\F^DO@$/F-;F.<A
M5XNH_*V+%V[>+N9TU8\<7&S+^J&"ODO$ 2:^,\W$P.A0UN9PQ^G'-*->(]?\
M5U6@FM\)-ZAM,SQ"T*;!I>AD43WH6+S$4V+N;4-SLC,0>!Z\+A&N:,3^[KV[
M.T*00CN2JR6S$J]':42:?73M@K!L9Y_J9YE2"8'40R"JST<V=Y6)T/_ 0>
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MV[-EQL5@T%>9)BTLY0<$PK-]9N!+ )F/L;.3K9M%L7^HF!2/BJFY\0YS1/H
M$A$Q7,3PUDX:V7\2M6R,P!Z>JF%*:S] :W4BKN6)7WQ'<YV9OXQ_F#LJAM>
MH&_>A?<T;XJXGA91LB ]1O1JR[ )F8:R'*.F.I8E.L/QIGC.&=BX^3SD+:.)
MALSVX#4S^O%O.]NA/G($ :Z,5KIQ; *(E7>;)J0MO#QHTCM&Q3\-E/'QO?3?
M)LIUQ^[D:8B2>[XW<.?:_]Y(]-6G\23I$D!R9NB*[N)0R?N& [2";K!5E86A
M.AYR[W-4F\^AD.?^.R,:@X6Q3&\.\J_6_KH0OPD?+G*E>G^W[8?J078R91>G
M-]N-%&Q4$9>U1:<7F6H\F@8RW!EV@6GQF'GG \H&C9<N1>:U6QO[;'+6 FF1
MKI< 9@\TV!B8"1T6D2)]HGW@[NZ>QMB]WFHF6=U;>BHA80JG^(D/KBNIN+.*
M,5%N<.=B2SP>::$SR\KPJ&P<T2S?ZS.P%UXU$XG639 ?F"^LH2IX2++P5??Y
M)P>*2NCR=P5/!Z"#TKS5"EW6JKG8>@*U'ZVWTH;KG"OPP;1_L6E;N*2O^XM9
ML.'FWN&/("*_4OY;^V6:D_N7 -0$]=AR6]6 ZTN/7/"HCX0SW]<&Q\?'-Y!W
M2W>BPQVK1<^K;GU;6DSX:>#<@0A<-UH_ ];&ZOAO;EO0X%7U;6C9=9\$=9?5
M'XUGG- F&,6IUI]O8$RY*\O(CH.MQ]93@*TEC):'YH'Z[D[<>PEB]L/\025(
M"FQ34VS7K4S+]P\5.];L8/*;J,ULA"\!0QC/5F0 ?[;0&H8YJ)9UF 7#VQV9
M_=-&L4,SUFS*8#!SM;/I^3)P7LK+5&1<0D7D^NY;$5^>Q=9")O^Y\FU7JN-#
MDJ:AO&@,OBLSU$C55EK5A&Q=3YH%Q]/7)NO1>8?%:)Z&V=JQOY[,'6R9 :]S
M9CTKJJ>3X:V</=:V56MR!A67I[!HQB\OB8^H;"2<+7@OULN3;P? &:\^0NMP
MV^:]&NFU?!2!M12;Y J/F.%]MQ^2R'5Q!JW35@M>(HZ<5LT^]=I\U.)I&\XQ
M)*Q.#D*A$O!Q/P.:A(>?S.7!.9N.1 [U;1QA"YUM,)7,C_K>0=T?9L;OIQB6
M1\BH.BY]'W:B:Y*KJH[&2PLM1PHGJ106#"PGGIKIU<GQW=I"EY20O%PVQIIG
M3TY)'^K$X'B]XSZ5L'N_&.HZ):NW0SAB)9;R4 FG'+]2G1C,/&%$0:UV41+]
MU8MNJ?K:[=0Y:'-3\+2,D5,3R+QG$-YQS.+#=0;JYNDODR?<I^-**Z#Y<]=,
ME]'VXO&1^<'/H;7T?.?T*<B(H)HC ?/.#&SY=&:X:FVVEN$>L8>ZVM7/XY5U
M]'>(N-**:?Z@ZWYMR2OK[)/8)6 :J8H4'F*UPMSA=SM *L/M[ /?0[GR@_^H
ML$S9Y*-X"8@&.AWE52"8T>+D5O8*:@<P_L@;R?PA=0MXH(M%T+#C.YB+Q.-?
M27.:<017&O3Q'U(,0\\<4_/YQ949U *UIADKVV Z?FSX"DW(X^LRIP>C(\P[
MF\HKCNI'ZP59VO._[I)G_WN#,#@?L&&7@+OLEP"ODNI[EP"6J;+^8C\6R&^%
M1WY"2'N9PS[<?*>W,JE$4\[ZP>]1D@+^W#<_YA*$U)A]]M+_LE*WJ_'RBF1I
M5C&YU,,O0/NPSVZT68/NS)AMSM/,(MHE$G0=^9KXP5#\YYPB\DG=*G5:,)U\
M%@FJAK2#N]Z5@:AS9R0TW\6<:BW/;4XE-F(HE7+]@T<:>D1]@&7/\//+Q]*;
MKN5Y$PE/U36@UO&47Q1'F^Z>:M\Y'%:2+$D1@3R>'$GU0&K7%)4-^#RR$DUP
M9P%T;:H.^K#G@+R4UT3*(@^S]7_&II2O&^3:C=>T.?=WU'>LZ@Z?#"WL#J,?
M7@*F2+H\#X["^;>K\:B^VW[8\*DP<#O*%3=+P(=ER0D'E]2-V\;NN6?F@-RH
M)2#DZGE/*!PRQ;G;IRJ3\K&Y TUT#-25Z383KWAJE(3#YI6V2[9)C.['.E;@
M$KR9+I#F'#TOKJ]T/2V<KL(A-1D()%]4I9<B7&O3W3DU SWD3^S;4CT\&? 1
M=?4[>=J1]X-YG)@LIK_B_'K3J>#<V8A Q?0P+$1*+-]4W/MT.RA=TY VZ[V\
M(ZD&"4.X3E50CRXNV0>/S(R<>_<81,1G]Q$/)YIA?HR1:JE'Z\RLM6 9A2''
MDF@\4["[O;/,SR^;*7%,74'=%\8_7IE;%Z<);*BIYC/*<N,R!>I'KW([Y8UV
M>>>"PY=KC02JMH:7FZX<IHISCLFK71/?;T]O&!+ ='(,12KQ>AZ7?VAQ8@O(
M18!_S&'TH:4.6EN,C[0[_0O;D6HU5RK 73<EO.AW"R.2FFXWGJ_O2/D%>[:2
M4>(X@F\/JA4<$CHWXY4Q"V=R(II]8U09$K:,PMB+VUFUNY)45J22K?5Y%!L4
M%P^PS)3Z@W1<LGVT;5WY(^UY>6%C=T.!PJ#VI"'C)TPYE(LE7:A'\V[[^)DO
M"6&?WQ%H@3NK%=+6F&A%O(*2!WPQ2^^]1M00[!<UW\9[;+UX62TDASEI\Y.%
MT]7E)9)5W5%%'8MMDO87_A4YZZT'RX4[2Q_+4'3M'R]$ (CM&E/S,.$:9>:0
M^/'(;(XE':T%-UQGM?[QJ:?+EOQPU12#\FB(6E5%'B,^N*.D1GQ"M^"]MZDU
MY!6*F&2*Q X[8%ZSLQ5N8WEDM:G/6PC;9RH1-QI[4#'->Y"GM AOMKD$5%4E
M%IK)NH-L7Z253AKMHKZEN[F[(F;J3];7O5@DX94&V)<',!XW_2?.Z>5?'#87
MOERL<5MA]5,4T.9W/*!HVSY+LB?DE#^B2E><GR:0";V]F?=:[NWTW6'CAL.[
MH'')A,=[*('I..GA*GRY.75JM>PU\E7Q"&]^B].V0D3S!WRE>B1PAR+$$".U
M5.C52+NPZN@!-(/Q>,8\](K0SJ. 61,N+6"F8YC#YGN_](PSO!X[!L/T]4T[
MZZ,US>B]OV6D4CO W6.JEKK!%9C6TC??5O4.Z7R2'%]:)-5<RTUF]\@^($[^
M7%L*DBQ\0^N7Y.ZL78RG]?,Q3@52-+8AX;"2U0RV1[^H+NCF?9 G#@GE<R6]
M-DT[>EZ$R].UK;4*'R!._ID0WP>P3A$FR#2"*2A1/'Q@(]7B*1/H(Y.##7D.
M3I;'0)T7WWGI)02[2LG*80QW-L^"GW!VD4E_FF)#Q [A]2BF08%D?^G>>7Z"
M[&I&GPZMEBYI7@(ZY&6V]4HJPU*2Y"CT9 5=IS1=(CF\TX^&GC>L@>.QOO.>
M/CJ.EA5/& H^B@S)A)X4)77)J.E/?'GRX51/M>O%G!.-04W$FM;>M<-]RCXZ
M4)/I*#)GQN.'8=*3G<F30  MZ]V;I\/R<'15'O\MD/L*_NDW8C]ASN8ETED)
ME/8'P]<0NJ5?TULL(OX7:_U9%/UUKVVSC91MBX/UUE9H+EA@;%QL7Z]-#CF(
M7CQQJSOH@,2],;\M/%'^LKC?Y5A$[?6I80V>+<V><KNM8?9:;T-6SWUR^7[Y
M"@##,"3PH.(@#V3]%: Q#UTXF"$T7TUACE^:WDRT-NV_>;ZF3F2WF>%!MZV9
M$$;-N@)6?UDA-*@OQ7%E#.CM?S,&2DNMK'NBD2D5Z.H016/?E]W@36T3S?M?
M7B6X3^5=4 UG#;(.EI ['X9$/;3\H.7BL$N<\BT*41430*JIM-16]_)@:C5Q
M[@PO7S71="CY+"FK]"5O;#=/:J#3UO;!II5VI?,A5Y@ 3C]LP.[BB7-O9D7P
M)(Y0]KO]R3?/H09+:ACQRI, ,UG;''YH:5*%*Z^A!<J_LXWI38MQG_#,1BJ#
M0D:#'U\^S.R!\WN[9.H]XF2YA#"$H_0]TQ55@A@*[X8S8&XBFMZ51 CZ[L@*
MNN=-;2#]8"VV;,K8)[4S;[0M&SO2+!K-WF<JSO+TKM"BFI2;'G%*.D7?\ZHT
M5]<#[42Z5WVHXFRGI^ NW).0]V?:MI9[M/E(TJ=^V\+&;7?LRB!D0EVBS\L%
M[A>^GSS,R#'=_F9R0+/-N_0VYF=44S9^YJJ9%=(#HK6S^=4K,FB 5K.87TI.
M"6U.7^EAU&H,"G0V):.O.U+CM_%^&]3SE'H8SAG/Q\I_/C4Y!-VE3Y*0X*5$
M#)CI#5(X=F^5(@FBV*+K[\Q()B'2CD6]$AUC5Z@ECOGAZ6\C)5^<$SN;=,>A
MC9-FJ'I@Y4Q:W'>';X7/J<EJ]UT"2OF0-)/=M=8^^U>)0 AZT^>-1T)7I:[6
MM</,G!9NL#=>C\F58ES[>VUMIC?S/<<T]_W2:O!'+J3N_9;2[VTS0=H;K XH
M5T3J,*NDIP''>L58%A8[KK2B/XJB_A!TKH*"3?[3D&.=.,:V,V^57SGGM64_
M_*N4,?%H#=P/[#HCN02P"F\/CF3HE=;>8_U3P$+Y6\#"_#<!"]ZO@(7@$O K
M8OE^";@IGE3:>*:&,4EAZ&7;)8OHC[B>#G/7U3I2*1S4X5W,=_8?:[6[V__1
MWK:[CO1,.V.E^$?NFD!)0A'#8H(8TKBWVMEFWJ5F $[V\0GM0H#Q<L,%D\P>
M(>H24&LW%!P  [TM08D\J-]X8(@O:#R8=V/=X5FL)+#)JR25Q,?&%Q]&[$E]
MT\]':\W][9DL9K'*X''K.$>'CV5-CT:O$%RSS&RT2="K8"DY:R71\9-,KSTZ
M9$I.)E\!C4HK1#.Q1(R?*?7#H2@K'D%H0IM#=+C7X_&VH 6BPXX27W'TAJF*
M+7EW#1MKS+,3D21GMP1MP^:]K*F8$):/B+B2%2I)=?2>53.=4V=;T JP9H3T
MS,@X(. 2P'0N8.H['9EEKEAD:M@"1$[=%X0F;\ S2D601$*X%JT*-#FNVIIZ
MHVZ2HO7C]I4SC;[*K7@O6.\\9J7H 6#72 E?C8CSY9#G%\:6;$J.5!B"4$8N
M\D")5W.R0QH6NL1(HE?Z1;2< Q;NG.S0/9WU5GTM(P$## 0?))H"Q$A_S_E,
M)V&+RTH6,:1&KY<P5Q?E&'^"+Z"LR%LFJ=_KYD95Z<-"KWB'IFTGNT6_MM<%
MKJS^<+>1=F9H)!%BH%8R[&]5[V.*ML'PA^\?S_L/WVZR<E@W,B?C=Z7A+RE'
M,,X/=$:.$L"\GV*=Y$T_#UC02V__Z,^LZW/9?,X>M=O_*,Y#HPE&5*VM9W2W
M<"\!:MV;JE82J^P_=D32/WN 2&T1IYQ:;NJ2T2B1CYEK>FA9XRH)_*Y &.;R
MXW7 5P<X93%*Q:GX/M>]5A$K*-,]D$V! :9+%+U8&A)HA3(P/GU";:%6LW9^
MD9>SSGSC -CU_$[$/)?((?(Q$^D.]FO7>9Q3]==E!Y#2"Q!OZAB;/]T,S6X[
M&C84M$TA(=A4+3F#L=Y^/KS=^@B1/MMD.[=_1K8GJAG56G-'BEX-VI4_7QSF
M,)%O\=I.14J\1[WL@9%QA@!3=L#UL&$M-6/WUXH[EP \$3]NL\A\::MNX'1N
MA+A(DM-;QQ?%81R." (.I(YN3O?6#8,]&3)6T"6 W"4\H/F.[](^W"E47*[E
M(H'Q(J4*<<^BB;'EE4==4T^^$1MJ!G- A@<$JT99]\]"%_PP&D BGT/-CRL$
MS# ?U3ZM5C%7I4CXH!WEAYP-(!7:%AN SM-#Z5UT%_FN+5BYNKN;D?4ZV3SL
MR7R\]5S%86$X,C[)-K-E<6PB@WLE@,*Y4;S%CDKRR*SQ3&Z 3"<(]Q:>@X]*
MQ2"O#S=;HML<QUPY\H6I:J)O1AGQZ\.5 7X%UABM+EQ],B'MNRZ.N5YT9GVF
M$O94DA]O^#!<D('X>L;Y+[I5EA_-0 MGW0CFJ#)T%5552L@F**>R H7$%D'4
MZN%+:P(MH">98\:&I1DB?; JUT@%?(2N;GY54!1KO?[UF;G7R?[7W&-3) 9J
MZ9^V'!!7^\1**RP;CQ_& E<<,D&O[VNJ-.'1 '1G2%=5TE=VC "B+&=M@X.=
MH,S3H$AEKK3"OQ@_/<X(=@])UEP5>@?7=Q]\@8X%/E='SO(2?@DPV[S*1#OI
M;*%G:J^B#A/36RJB7MM= LXXS00O =\F4[\@W'Y<2/6<+N7KYV<W9(P+5HG4
MS8EC4L_Q%\ZZF'>2/7HN M[ZO2Q\E;7!?4A<#+X@1])> GH=U7]>V?D;(Q&7
M@!51SB4P%50J2+K!S0'2Z#HO<T+2<9PH\Q<JEGT*!5FC?%U([/-JVTO DPH9
M086_/C_?B.N0XA1OK/1OR+VZ! 2NMT+VZ6/WA,/EF!I3+7Z/J_11[0WJER-_
M)9?^5P:'>2F\B7S?;XS_E9K07_EK28M^H5Y@FF#>;,8:OV%:F[DTZ^(S-/-7
M'@U*M ^%_I Q_E\$DLS_PD[TWR)K_M]P7L)&>RU,G%>.:SIWEV<?=]B5XCQ2
MN)>ORZ,:A#[UB.<J_4))87%S/^L2\#?GFO#/POV__;;_CWQ9FCWSS-2F3WM[
M\B5:I^3!''_"!AEY(%O$?5X"U0SG9;NOY?UKW0+]X>/-_D>=R?J__,W-CPH+
M1S.2&T8>>)=5E3@'=YR6[B,B\\?6*UW<45KY,>4]!# ?^TX$S,":;O7LQGS5
M-N[:JZA-CN1[3=PKI5WF-^%=UV.EB]**]QU>]I@.I-44Q9F)TL[NPXEFN1:D
M_W6Q*'\F-'7WNOE1GDHC\R[OA"]0_TR(+W.30M/P=^]^D"KO25%?*-^<V=;/
M9(I;\N(_^T1;-PT';33WJ&8C9.:GU8_45!0?LQ+ K 4[);G30.-EX<)6W@Y+
ME)*.3 <KB9"0DAH^]8?]?:P03?V[!:6HN,5@7 5(=><C8<N29 4.MF@AS'D&
MRHRU<*39!AU"-+JI?Q#-M')DA(LZ=#Y.$&Q9S,5;442,+PT3EZOJD]V/2<EM
M+++8B0IQ<EYN>W'[]5NQ59TLJ@31QX7M*YW3Y#LW->VH@CT6W_9ST]8+AR Z
MYES[QM>;]DIK3BW2^.'>N(<%)DT+77>J/5K[Q?(_^]S[WO3HBPNVC#PFIO^K
M7=Y44!2Y>>*N^370MA]-MV)'&P<"NS4,K@L6L:2XK\/Z@.F=_G?U%V!GHB8A
M0@Q2CM5?W=N :69C\\[G-Y&!;Z#*\/S-8F(&ODBX@9T,J:/#)CO_?9%\1/G*
M&Y6=_BDG/\9P=]S[46MO@8C2WOT?E#$.^6EAUG.-T35Z< ?>C>^W)YX6RM]R
MRZZ'<><)O6\+Z6+_Z0=,:$QBWBB2(6!P12IA1-Z-,.&*J[)*&T41E+IP*A>
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M=KB^XSJ^";0_@,6;!+?T#Y'.T"*4]3F;O 2>O+ZM7ZK#*%3@>$3 1%M>:5I
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M0J"CD697_>M/BT]72SB*9ZDH. VE/:QO4& IN1A[AINQQ/#5"7!J6B2\<Q-
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M?/;=X=/JIUHE4-MZ:\XZ4+&6L51>5]!^!1:$O7:)O^E//YHUDV&V8=!U]:M
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M 8QF.@"FP[%^(!LX1R_Q#K/%YX&\J+GQF4,R!/",@VZVI291>>=.@_0E /D
M^Q8?Z7Q8C&<&)G9NKE\"5#;+X7H97(DJ0*QMI- E(/\5;NL2$)> \CD[@XXV
M[XBL)=S_D_<G[T_>_V4\)FPBRD=#^N15MT;]3L.2X Q'K]#*5\A(\RBXAP6O
MP7<)"&O/F,/K\./77>WHK3^S*U'@>;%9/H+:?EBR5(]\= W.^!*@*7DV>W4
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MQ6*]_6\?*O<4%40A/Q=HQ$M#[=L/IS,:;T9OA EX*M!+8:$O1SLA1%J_C?U
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M'OT?()U_SHJ<%#HQ&);?,WO9G0<W@*<@]@LB;G7?2P#P$-IN7.8 '< M[UN
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M@$@2#-M$LZ#:N3];:A'[87&=GQ<AZVC:<ZR)3NS37XEVH.M[6_%$S<9+R+#
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M535GF2D&VL,A'9D[]P9R9>"D';&4.^>#@=HV<'-G?-%_?RLW>8X>361Z\FZ
M*X5QIN: K'D98M.4+2Y6) V >Y[5@,X.KH,X\Y[-30*97UX"'L>F*LR-.A_,
MX.L;KJ\P-I*,SWFAI_"WZ"\!;:!$=9J@2P!UM\IP"+ /Y-E)PO#CW 7\O"H
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M\[3EC5]E+#>9MBLP.TA+NEJ2Z-2LM8@_Q*]X)V*\I"_I.M>)C'2 CM5< CK
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MW!QO4*0?0VR2G&664T_D<!9I+VFW^#0(:R/WC]EICXLLJ[A/VL-HL7WHL#-
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ME;% R4.*1:Y7$I\)U356!7O\**$P\,040DSS#+#I$4SJ%!S=NK"[:<JWKBZ
MES(1TCA+HWENK]<41EDUMKT'BN ;\G+YD/JQ_^;!*I]9N-%=62-F>CS>?WI@
MZRM3XV9+5V[S5MJ.H,@1J^[)_D8-%+4F\L/0?L:J#V-/730>\?F2_;I@_KKI
M4<;<@_FWH O=O[.T]5CR?2:# 9PI^/C(.+P*]+V7Q3=CSC@$+:?FP@#9TMY
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M]?7*QW#23C%ZM@$2FFP_HQ&G?9ZR4:?H!['25V&6H5N"T_+]=/C%S[')<V<
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M5> ,.!RUZ]$^"O/R<3G82CT#E)#0V;M0YS4H+IPG.=VWM#T#R *VL4%Q/YR
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M%LPO&Q"2L%\&WR652NJ D$1)YK@ORO<SOWH00 0X3MA;*B#>2@=I&7(FTYN
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M=8K\MPQ&AW=JRB[S/6FH?Q0HK'_/F(-K6.C_:>\\HYKJTCU^:*+45XITHH*
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M=317>>9XGV7N;(78&.&U=/II($\X;ZNIA$35Z=L=EJLJ61C>O"+Z6:TO)-I
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MK/;RT0&-PCT&7EJ#[^2Y-Z%;S2_LGW.F*0_5WKM#YR615SGBOM7GEO%%6KP
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M73:?NNW+N8D$/O-$7\IL-93=HNE(AG?A9KRD;VW(_)-VFJ$MA&N/BYG.^'E
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MB1HMMH'8:T=N#J\,+]EW7!S/8G)D5>U!+BUVY;I,[Z<%ZB4D.2$6Z@0>+(V
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M_;JDZ:F)KNORWT5<NAAK'$/)_5E&?9_5MF^EA2M7?KK+MW(=T#_;V:"<MR0
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M27B^K\B@ #>G6B/"5^THXP1+OI!H6Q&7 >K5EOH*P]#7,(PD#P07>RJTXKM
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M(E'BCEHV^=[]MJ='6SA[.\\&[8MWTF[W\^/R!0Y0#Q6+^+-Y<I-R;#P#X
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MAU;8E'RX>Q1=-'/BZ)'+0Q<MYF1"MJ!J?-A/:4M1S!=* #Z@XUC3_I#=?>I
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ML$'/7KN[Z4@@C.@VE+U_XEFDJMQBS*N9TN&NFT#.UJY^(VSK< =[';A;4GP
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MJH:E+V5HV^/4WDX)<1YD_,W"@T/]>^T$@E*9-[^F+@[ZDSDAQBD 56(K^]A
M0B#&[/D3 %NQ74X9T7^ #4GL>M'3Z5A865E0GCV'#UB^O )4:)]C4.!_\>7
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M*N)L P5=VUAZ&'27=ACM*F6V"'=VMYZB6I&W\NH;P]#\GK%/W$9?A1U1OB*
M^QF;#3L\*Q0+1Z\_-E]0._E:*2^$;'O<T(Q=>\&2ZR,]N4((A>>"OCN(K"'$
M&7Z5^ZN\!@?CV?K"!3 *N=N.;ZLD5=['>R1'74YO>6E'U0U= 4+O)N:Z"9O8
M8]XBCW]< 7K[)"MYVVSB7S>[2BHGA&7JZ&DG#Z%^^:5'?Y:1S-=<B=3H.9V"
MN(%!KW3F^2""?\*AD6LF!;1Y4Z,!=_[1?F923I!_<?<:3%$?13%=UQ)-"LJ@
MGW*(&]RT%A'7O?B&"DI_@V+%T6\DPQV+X:"=;/RSSLMBVG-[<;ZVO;'W6[C@
MP-US!:&@-V.B-PMOZH@JDUK%4*WKU\F3V"7*L2 K?93>'2S93WX@B_[4_6>-
M3<6;R]-1Y7)__FMR$M6Z)N /!ITT]?+H9K[;0STF.CB&-C!/5M^.9RW-B MW
MP!32?KA\6>NG[>)6,TG#3_)(#Z7)M>K6^GBJ6[#?>A/UAY8WMUZKK2RP-#Z,
M-FS7EK*->M%HJ;[9SD3P[U:;MJU"LO*D>V5)RR_I2FX@/IP;6,GW+F.9=R=D
M!6EKF*F6#$KCTA<-%SX-^'#E+9A! \R1<6JNX;?(E&Y? 3(,1YE%_<K$ Q#D
M?+QU(1N3#B:O&QBP!UCM/2+SE^SWQX^B":JMHD46_8XVWKQQR ." JD,4L;+
M]K//,YY,%^<22A.\+3%R^<)(V\O9X?)HEU0A!^K8Y85J3!'M"*H\#PK@*]%H
MTJ^70D<*#]AW4,A8OF%Q:OB:Y6AV=\L:+Y?*&*%<+A1Q#\(\;B@K)2=3&U6X
M;=:-.97 948(D&139^RNI"RIG->QY]1H:>.(AEW!=I5N8'*U=6I%D9)HSJVL
MDTK-&1GQ%=G[NWNOFL:$LF^1$$0E:N^K.G=6/IFD&=R#K$ZU=MJITGP=8:("
M'2WQZ=6-BU+5<; HPK+R'BBGBPM31S'4E\U[W6(ZEE).LOUISF*2*!T>RO):
M_^GO/$ZS4R_D<G1=BS;=N<)$G=U/.T'N4.-=<EO>Z):PGAD?[=Q1W#&2CYE+
M(^2(^DDMF\$S9"7&@G<"X@/)(13,7[(4]?#1(?$7!,):RO>)#G%S93EY8H*+
M/G*O5?H/D3]3RXD(<1,?5':20M?4P6]L'\O1MT\['F[."-W+_"X6TW[WR>UG
MO0ZH'63-CL?\EXX[W'>MLZ$?RD<>D)XAOA,^FO)%2AW_B;C:.6!*0?-=EA,7
M0:B\B?W(PO$N"4=X^:&$D,""4A!Z\D>("-*#3/'ETNE1N79@_?@PNJGB?;37
MW((()O:;E6$[-\;+(1^2;ZPH SQ-J'MN!GH:Q7U<)$>OQ=AS8AC),]U2!_W"
M_@NLO)#7.X7XB671Q$<UH#7*3<2_]E6*&'V B *[,NY.'%F2$()U6P,S=H8\
M8CJK&$G*"$1&U;C1,$3Z,X.83K8!J,SQ676FGLF\J9T<$PX8XHK$$^=CEW9J
M>]<V63,R39(E>2;VJ[ZGU$>N<-R&2JM-"=8E.PH=,5TJT6"O52.3!?U6X+>V
MYM]=<E;%G6)TWZP8'/^^Z04#)46YA9-? 6X2#%%]6)ZF.L6-G*.(U39[BZ6M
M#%G<9<R,5^M=\Z.@V0)&COUQ%;=L%V-QV-(WR$RWAB%^/2H=X@34: G'\F5D
MDW(;8,E?X.1#$,.F&N'*B;/;.[W<!Z$'5?+JD-$>-D&.$*D/8WT']D@GV)>!
M ,D;;QHFZGUH<^W%VGEF$.2:#O/G9CU8NM>;KL^CT45?"G(]+=](FC-VW37/
M_%R(OUU>L+B3NFF'Q0H<I-FRHLM [->JXC OI\M^;2(F]KZJR'Z9HZ+U6)N.
MIH*6D(^2FMGQ55#>OIQ?B0 *G)C99A=5ND7*C1J-ZUK2FX%JN/TJ; 3.$D[)
M2D>3@X(^H]APK+Z2[ R:[+:>)'+C&YFQU9/T\=E0K2YR2\;\D\S[VY5G=6$O
MLI/&3B<+9NH2"3]2JMHCME<Z#ZX P?DF#7B&B.+53_.?%;&%%RR7*1>\WMMN
M<[YO3 A^GGE#N+WN$B05G6Y)B-;Y;Z+3:1AIMR\-4C05QLYQ&T33@UO;^6A#
M5R_[F%(#.%9YSK;2D'AYBT/3YMD<1^NJ;&D>.V]5>)\.^&'O6#IE KW(+.%I
MFL<QO=Q^9,+I"1%C][%:(52EK_[6#_==:\LLT<B5QHX&7P8P@[B*4W72</!%
MC+1AG==&.+@ VL=5\FT/QND-Z^BCM(%J6?Z*#I(ZPB*M-0KWWX[B-R?^!-V-
M3P>-8H/<"@N@9X ?I H6#5D$VRZI]F*2>*I@MUNONY.F\K[S?O ")FY-*MB7
M&@V[IJY$&0C*UEJLH1Y-](?_G&;IQ</?0:[QOUVUMB:TE6":/GP.D[L>K#WN
M>@5@L!]^.X)<^%S!<0%R9Y]&U[8*+PX]J.-A8AY4'1P9WTXY:F.T&*>UQ!NT
MSM=1*Q;Q[CNP[*;-Q)D]KY_1_5;+_SWB>8*4?&-.W$FJK^([5QTEAWM82PT?
M^C_I'F)_!3!_=_FVW?Y?7VERSNS^'26=$:A$!_QJ! SP'>/89QR7Q\1? :1.
M4G".\T27+TX?7GR$;YHS6:*S-:Q_B- #\<3^-4%ZPOXW?QY8=*"U:7@2\'>[
M%>LG?BD%]DTUZMT<BI,*F&\-[CXGA'5?M@@=5)KB48@5V,/^.Q8[8HP?0>[5
M 8Q)E^514@CW:6"*87O$%[,Q5XPC!08E$C3"N9;')\RY=EUEOP(BR-AG2>:F
MJ6)87\^8"+S1S4W]>75LM=S&'DZ=&P2G-@.Y[ZN)E;3<WS^]ATT9&9<QM\TG
M4.GASNOWVX87\R>4SDI'/(OUUSO,Y7\&CHQVCT.#!+A>FHLK3_P2.;XW<A)H
MHM;_\5HY]WC=D&4$EL(P5K2U'N6B_)ULM]_*+ TEA4.5@G.'RXR6Q7+SLZA#
MM.Z_E7JG/XH7?Q7?7TT(F1WA9&C7>"FUVR<L6V+&LS#9:'Y72CR4-,3'M 3J
M==DW*, =I8JM?T'$Y;Y1DU45T"U/Y>@[?AU6OW/R:YQ93R!0MC2F:NH!G,5T
MA\'^GFTSJH1$Z]86N([06Z'B4;%]3-U'#_$?O6>1&FW95]XUJ6,J_Y>.4W2$
M@$OJEDJ*[>.[D!AQI])AKJ[;*WU*C!:TDPZ^CX<\N!_QK]0R\DP#R8PH9FZA
M.YB-H0&&8Q58;'ZDR-;+CWQ';V7YW.59S#$6\@'ZN,M4F8%$-"_6M+2(=>I,
M\M%V080@!"K4ZPRM?3TC(%17*E#5M6]:TW5-890D%W<<Z&R#.];4>^[?@V%,
M$F@VG1!['##VOI(@ANG>0=UOF11)79!?>IH!SOY4F)D ]J_"1R6(!U6TBJ)9
MO)/YE3KC4*:*P1;>4_OURX\GGXO+P MFR^O]BC6(R_MJ^4OIE\KC_3G8N_/=
M[U)FU+JA&>NF#X?O3RI!W?-SL/8QJQ$GE7P=>(<D<,FV'M11S13*?].:^WR(
M=Z^Y^9$O)_0/Z9B YLQWZT!>.#&\B[G\1>%2YS6M3KNNWOG1+5#@DA[:?+./
M*^I72;1"RH$LC083HI19]-6%WSL2'[A[\T(TBWWTBJ:W2A#RIUJQ]D8?=ES9
M9=AYWNV[T8[8C.[SI%NT)';OF('L0?6%#/&-R=B4JJD"\-JDZQ*7P5@>8KBF
MQ^"]0E2K2ZS1L5V*;?<PS26?A.%O(9R%:M!N&^6[.4)W9XIRS>EN?"'H"4CY
M?O'MO<52ZE'V!!4#_*%4X>?L2<W64-\&2SM/E47,F.%CFG%3A<6]<S4'&0W\
M,_7QRL1G=E5E/<2=#YG[8(]MJQJG1,U57B&QKAIP*BDF]-.!TL?6V:-F,Y2E
MYR^K,BTFW9:$YS=D7\R+1ED)+3J1W.85E '^M.UHG0:^;$UZW:3WM<!Z+5@6
MK_=KTZ;P>5/3RI IBR6EY2SA_8'6Y6+0ZJ;W6/X[L^/ACY;4;UO,=>?!%W<%
MI+;1+"B2'R[>$<XZ1IAVAI;QC&[+B0=12DD^0 962?9(37QA>#:>U9V!X<X@
M>_(;/ZN##B3M,@\BXEVA-WG6<O!QO#GTBVA[7$H:KH" CCTNX=CCT+%(\BBT
M ,D1(]_A;YA8M=8["E._+STK<[T1=J!]C5 PT^6%6!I>H]%T=+OFUV,))5H$
M*D!6*\GL?3FF12+%-=O)?6[9YTN^[9^93S :'%*:M4/B"UJ\?*GM\LHXMC77
M!\^JOQT?BJZN63F;)RR'B[3I?6,XI;QH&UTH6VRKB[T8)= [MR9LEH/598I+
MW6AEE:\ EZJ0P@N?N]$K"]2XLUYR*G&29]_.%IR-/.2$:E-7UMA93#V5?GQ,
M$LYL5GH/U>AEE*.=OIRC (OH"B6)" W8R((DN=$S7W>MYOP%!9Z?78)6Y9HJ
M89F.YP)45+!:Q_F.6E_SY>5^T $!\2<U'C=W(CDGW!A;;C0K/#R-N6@\''9I
M:!>8KCS7S[B?HG \L+9$$]W"=,@^F^/LQHX<TW@1U<$Z#@W6,VW]W6'W<6%$
MZ]FKEG"=*!1)*R.'K<T/GE?8_C/1A1W?1SCQD,KLJ:-(H=<:^ #A!5P<]5^X
MK@]0/G0OAEO#L6!!<,C4AHDL-UONR/E+>L*GS:*<L+%_W4#PO\2F/7KJ]5CK
M2(T6UL=1>:=D8X[DF+DA._$YN:J4T2B5(/U$'M[[;-^[B^00&#A9JU+Y<F6(
M[UR)F9FG84ON 8NT=E&E5EZ:P?C-_84E+MU)-!6\T,Q4V4MD_*<>UE73XO2:
M:$:"A\S#W'[F>S-**X73/K:KY)K2^E.%S0BUH=:/:9%9AZ7MPGAD(7O'@ZB
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M[#]I%PUX.3Z2[/A,) :>C_TL)K$IEX 62PD\SEC_Y<A3__&)"<^\IJD<]\S
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M]V@$]]:F\34T5?(,.B:W'WST14QML?,CJL<<7-E G7MU35IKJ@O@7*\ TZE
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M(F"(1IK8YALW4?_0GZ1Y-??? %!+ P04    "  :B%U8VH1S=3#6   K,P$
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M2W\S\6UE&]EE<1TDPR/7(7)&+HEY;M0/T7Z1[!\3+/@_)=FO@OTFUP1 24B
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M=)Y&6?6@A-6\L7!=P>:;#>V1S;FXL448#J#QUX4:S\Z:K))/7*-\'K1K":O
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M40TF'CV$ \Y2A4)6R!R.0"BH^&&@]1J>\S]/NX4#LIO33K$6J%PLK1D5-OC
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M%VH*YS=/1DIC5<;QDWP4KJ2_0#*8.-2+A'2(]W*_B7NO,-5$)#0(3T;'W_R
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MQX\M#TS))Y-Z<Q(9A]>KI[\@\K_L);5_5B2), O5@XDX[CGUD_2/I#I..3:
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M(4=9J546_W/MH?/%$UWR2%3IQ(!6D#K,5:7N.%VZ[BY?<X9@Y@^_+@.DS"6
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M8GG6N$_QE]MF/V1V2N^ST9_=) 7_04\R<?=TT/BW2W3O0NY= @:3P*C[&I<
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MVG8W!LL-&OD/<6,V"%Y\-8(E!$Y6+S@A/@LS=#CWYMW+S4-)/UD[LS[Q#'D
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M^3PC-5)3%OG^>Q:A*WNWG)E)D 2M8D>#@ 162IH(J-P<^-;JH(Q=KH+$D1[
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M]OOD^OYHY'S^;#7-!PL-(+ 83I74US_',@4V3;L$Y=B(@_T2D!929G:'>_P
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M6\N*P<_12UJ^J0ZY6,2S=OKV5_F[>E=RF7QHP\OLN7-W/+4.W>(XJ;6;%<8
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MZY^0I3R1G? TP [>J]J1V3.S%T+VW1F"9$=B&R6BK:97?CJC.77A_2[]8.Y
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M .<6>IS;OF[AH+>(\><P]?+9?+8C<:Z87N@%\>-R6SS$-E%&E ;=V72+YEM
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ME,3_%K ))%G[;??\ER$7.)V_2'^M6E_@\):F9UU21SBS[\DU1AV+_@.]T3_
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M$SGQ+O(AK^=]^=F_A'H1(8Y5LU%!- )J(Y-XHF)CQQUS(+/''GL8B*_WI
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M&&A;'>F+)*,2B"UH([TJ#5,4[7XZ8_S>C?V[T_IW'HGY\UR^6VD'!!M$08.
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M>E="=OQ5, <^FE =2@$)VF+.:Q20:W9;IX1&K:]87PS3CWTY[71W^EEH.*,
M>OF23A4:(:&\I6LJ*)5&GHSQ??79\]Q"#WAZ><_T.?.^*.;BM)((#VX79[W?
MR,E<FEQW='NG2R+NIE6&SAPG6_NG^[\";P&&C8K!Q%H3+';CYQ9J'A"\S$SS
M3I^T]:UC*#OQG49 ]V-8,POTK&IZ:U?1X.[,7EF-;=TD*X-DVC&Z8SQ0"L:-
MVO*'80_#8*^$W8I(Q\]3)%-^QF8_*1G0GQ%8%4F?TI%\<6E5IOT#1DFP72/"
MX@51K@I14'DF6?,%N;A>#YI.],#]'G/0\*[HA"K8<[P3;3].4E+(+)SI1P#
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M]/XKRT4\@S $YYSUTYVX:H=^ A5].:LS=M03HUM 4,LXJ07> \@ORZ8.Q%3
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MVDF))'#/0J';SCJ23]\"(H:XSC44!%T=#X+=ZY=BOQJ\2;.(EOAL)P!(E.,
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MT^4_0Q@2CAQ??K<![]+H+!L4,-!]SO\?[5UG4!/:M@XB"(<(BO1ZI$-$BG"
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M[9YGDS=<]Y#BL<?*TXMQ=>K$JB>L_;1K[,CF)GXL0&&_=7\0"[ &HZWG:;"
M#-^%TW4LH,QT1P#$!P7K93?!,/2UX<KKZ:=79UC ]C 60#K3GGDX<(&YQ *.
M-TYHE3^)_,GV)]N?;'^R_<GV)]N?;'^R_?_)UG3IB_S&OO4OJ*9QD-)E(H-[
M6/C8A>IV[5?J;)4P^$B^T3JM_^WZ(C4:(S(M'%:BB^;[=JW%'MV+!7 +K&.:
MES'&1W-!/:@4C);QX%5@UV5)&?&EWD?QR<7"[.BC*)*_P*O_M^GFU>A166$+
M-:A':@0TY[[FLCIZJC?2DHW6Q *XX+@O[]94Z&.''\T:K /ST7QEDA5\V=$
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M3EB[C !*Y_!AV/ICUJ7L:) :0EAGI\P\2-;^_JV*LR\Q&2Y/+J61R:UVOEC
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MS$YN9 &)A)\K[6/.#4\J1ON$_,-I=Z;WV[$ (K1'?J+!^(MH'E77'-%#NJZ
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M3%\72J%:OF_F#;E7U\GS?V'MT*:O1KM)C;,;\.\1@0.$WT&PJGLUF-1#4PW
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MZ*^6];.4:Y<N]36NPWO_\G@"_PV _5?*@"<JC,1W_C\_Z$"%60X6Y(4I'Q"
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M>GLY0!Z(P,]21,P3\W<5\HZ C2CI:2<%R11]CL2=RESH-X=5 GNXF@-TLS9
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M17IRV9/Z#9IWH6.AVM; B4KT<A<P/[-P8=#5H2"<RN)AI_8ZNM+P^J'U%5%
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M?K5G&?V')1R7!'.VH6+T]C_:I7R4:9PPB?"-K2G.?'Q:'&-9@U^?7;] BFZ
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MX%5Z%.;)^0G[&=@PNWBS-D=_U'7_6M*MV\$%U4"H=)J/@X&OJ8H:C0'#WVW
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M/F>3<)K)E!Q2-Q^\@GZ-8!ET*-%?X"PUX[Z-'V-5T]EXP/C^$29'%5FN/3:
MD5[J4=H5I'-%_2\+O_]3.TW^.PXT,CW)XF'K=NO3>59S%AZT1URO8&-\?&J0
MY*L2M]SE7=!DQ?BJU)"XD(:N?>BUSD6FT:E4[N_?G> <@?..8]AW,,77M!39
MD>*O:@7_MX\,V5L]6$US=*O*M9Z)8H#71C$TD5Y["P4%XI+X$2@!<E+=1GUB
MW%NY@+QN\R>%VV@Q&JO7>FZU?0)  J.L(;QTLIG6J I7C;)J\%\H9?WC>]/^
MV?&?72;[Y9$UGT#G?4O:)R$V"GLP?%&7@..@AN=J8'CE77F,U/-/PPC7ETA]
M::9X4W(!2(P";Q7J\EM=:E2M_]T_PI^M5.%U%]R#3MWC8R_$*;[+MQ;.VSV'
MTX@3SK^=C:*W#"[5N #T= D=CJ1N1-3M[N*>'S N!8"1RGC8EYJX57>^9X1%
M(?JO_:;:"<5??="=&D#/SAJ1W_@>S_W9S=)EJ.9"<J6U]P+PK1.)<6;PTB+%
MZ;IJSU_=2 A-@T^7>PD%O;[W(3B*I$1"#Y$3_JK6_F\=/;Z\(=/B[PKWA/[J
M1.&O(1/LMO[12]^?PT4+3$9\[R'PVY"A"7_KY&\#3F+Z/6O_P5G+6O35.GZ;
M.I</P\ _V05Z..SN\X?8ZV1RK5A?^Z]*J1D>5+AQC^V*0Y:[4+)!+8+W7B-N
MD_IQX$YF/G&A(Q'P^O_)M/U6MO\9LR;KO&X>?P*V1\Y; /8=$<5K M?2\Z8O
M(XR:R[(D-(1RNK#;W]>4_%]YP[EJM//S"T!@#<\Y#"H+93_*O@!0.)J?0H3[
MEI#DA/+;1::7E<9LVKA-<5!#^B24%%2VW*G=6&\R3L@%W?,IV+1 V1#VIH:W
M5&";4L=8^_JR-P77Y\6LF>U]_-B6GUD DQW(T)!\ZI59D"^1Q8F2_#)EE3>E
M2'VLVK>:$!E53X9WNR/$)ICQZR:Y,E];9:V6PE>XA[',?-KX2N=/8_JWS:.-
MR<-!%MAE-^]-\\B?'0@LHV*Z$"F6%FE60+1?"C69?!J=X(K5]@X<'=Q@M^VV
M33GH44U86B^2WM%IN=DT;7L3@WE#C62_?6>VL%A<6W!\ 2> K"H&T)CT5I@,
M*&VM4#Q +74XZ18(L>%0-R*1;2(DTGE3]@R_.LG"_2 )FV[/Z9A5L6=]O:@M
M=DC3#PJAB0AWR-(I2:]6#Q>\ *2<@PH&\^8JMR?],V.F5$>.;!X]N))[I*))
M=Q\V-&?%(&Y7SA_>C6(5&_BT)O:YBR#^K6>)3L9?G89 XX^96!+&7J4/Y \T
MVTSA5P[X53;FL:/.1[3S;^SE3?+)% VFU0S.W_IX31.%*,)P+^F&F>\*M-B)
MKX9$6P+H";)[_\X^C?BJHV_(:N/3 4Z03&YXB-2F?+C8,FYV$LO;8E4E]$"]
MS)6"*=T&KJ9(#'I\/0]=#19G/E/RW,RHC^>^NTF6;IG][RHZ#7W7567A:R!%
MHR39I5O*AJTHA6>Y',]Z4YPZ%VO#(.E!-!W[YB: AI2R_ &1ZH'YB.:$J5F.
M)O.^9AU>[OBT\?'\9'-+2TMV3Y</[A@9=*BA*275(FDLP<[9MSE$&+S\RA02
M6CX9_?AB+)3ERZJPX57P4Z@,E/-(%5&G=$+CJ,U^61;X#P#!B,0#<-L<,FK0
M&CA6+1KV<Q:^  2WS"$J,G>2C!:11$SL&Y/3+!Q@M7F,J3Y>G.XXEY03GITY
M/563>2";EXO9\;8G[O91+V4)(M(I0_+6P60*\X  SO/\1MVR\@%G>F,#QPN
M<52;NB&&A<)*S+P>F.6Y2W)IP1ORHR0<.F>>/"#H(&I=JTE<9)]".ADG[Y"(
M<HHX.N,!"M]B)9G@Z?/A,QG\[;;>-'LF_!DJ!9&A]9EM_\E^-^:T8YY["RZ2
M2=A\&]R[LL&*.^C>99,]C@;=\<T)/<5/]5AXZ 2:;>^I38QIMO5+":3[&+X.
M#:4*#4JID%797#R4=]@,#X[=3 5C'N"C2*>7EL;L6*(5&TI)MBFOFFQZI%\
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M$&PW]NY!7_I 4H6Q#7',B_*=.27_[BT-5TXUP6D#:L+M^D_"Q"G8F$M$YZ_
MU8SIV];F-%.1)/0LL'J4-6'B&)!:^M2YB/J,0KROA=J)RN%'V;PQ6W\;4Y.(
M3H:[.3?J#_/-5F%.]&-845UOH<I<O?9^>HV5Z."E4# O8**RQ&-#OTS3R;S
M)?X9.PM/<=3*\?#C;&H2P5#R*#SJVBB,^+9VD1%<Z5!)I0QC_UP=CA>6("QR
MR/FZDTK)5/!K"P-?M72.DO(*4-&A#%Z<X;M'CLJD:6+[+^C7KO:8#7BW^\AA
MV>(W+3X%?(T 4$BC.^+ ZP9F2[R ?1 #,7>BUQ^99"V&#V]IZ\IP%J2QLQVG
MBHT1P2&CJ=L"":D@DHF)GBIC_^'P5E@@OGK-H4\"*9U[)"E*N%*&9?<5^B-'
M%_8Q,/O!Q(0<TNR0 #0("\A$2SQ[4-BR+4%0]88/\'E^^+%ANLTC L\[^H!
M1]BVMQ \5!+ 5UU<3^8HCSX%R6C/%@[B)]S6NN/M]QEP/IU]QA@_G&^*W3<R
M2NG W6@<=$.[*F;\D_=*X;@ZD)'T=-V<>A??]<.:LDT->SOGJ!GS1GJ9/0T;
M8O>H%0)XNZ<@]N=:&^B\Y40I&XI$>V'RTYD+P#%1\07@Y&M=1W$NST^40>G>
MWZ<2_J./VOZSPR&R&7AT.@">--D;0_*%]_Y3L1YZ.V4B,>B!0BG^4"28SE\
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MJ@[+,!B.IG,P!# P,%[@BL)RF@#%94-J;$7=N5>_O ]==C=I8,]8<GL'W]3
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M"-(P2'?GD,, PX?Q&N]YS[WGN^?<^GW?\%M[]MYKK>?Y/[76L];>P_GG\QG
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ML+BTO+*Z!MO=VS\X/((?([[(A0) 1?GC\Y=RX5W(=0D-#14-\XM<*)=<OC3
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MC94]N-$/?;PNYRDOF>^CIN[HESM!5AI+B=2';EK%L:0#.)<SGT)2YVH-6L;
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MNY(\&.*Y4;AX\M2%X%U'7\\C3L255=A7AOW?<#_G9WM#JI%$.%"POQZ"3D(
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M\8"IFUX"- ]!DHU)<2<:AL_ \7Z)MJY$S4]>-N:^9<TNT/Q-*B9)HJ^N?#6
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M8!^.(PI[?3<V;6Q8[OG)W&Y#J;_?2>JN ?&(P2[Q>-.:.673R[+? 3'LF&[
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MQL8OBHA<\Z@6TT(@R +(?NBQ)U5^5[E>"VT@*X)[%#T1@D=>]C?G[__T( ]
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MO=V!M/B] (6AFF,AIECFE$>U7%=>5PIOWKC(1OIHM==?3!SF8JF-(7Q?$C;
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MA-/V_!][Q$]0QJ<FN6ULMX@7:F7KZ6%^:TIPIP#*<C^N631O3AILH'^S:9M
M8D%RKMX:[RY0F^ZH0A,@FJA'7]-MI[UVQ'<42G)%KI*5:JV=_%ZR2@P<6 [S
MF5R9D>ZN-'RYI>,7A9IJ:T ]5(B[NLS)RD77%#:NS&!_<-?%P0O<7]50:^G3
M?V::K7O<#;6YQA;Z +R13+JE@,V3,R>OH0;74'@EF\1/7U.E^20LP1MM-+G4
M0I:J:G#S2EB^*\8."#?38/UZR?IAZ"9K=#T8,<[X["!/(#R(VX-M>4Q[?%:Y
MBPEC_>3DZ>Z:<79W:/?YG.3BQ4XV-,MO\\921821;[O:X#QQ,_P@N"N<>&K%
M7B!!^MFD-Y;8R8"RS<5#1]"57E^1-%U$V/HVV#'S*X+K%!#//N;LT\/TZH?R
MN<?NN3@Y$3^<LBL]ND@JLZ]OU/EARJZ!,[',-;:=S[W53^?;QWF%[91UCO,D
MB^M/28\,>RC [/=$ZM]^,7;7Q$S\+E4!04<KWTF%K^T6S6!:.7@KGJ$ GXL7
MN;'#;=ETAR A,X-C2I?A?3L)_^G%M*KC:)\&K\MWTY>6)=HJ(N9<BM[+%,T,
M;G<=X*M[$9C%'+5W;^%]S,+0B%;=='^Z6S/:PONCLW+-3T(+\LS8\B&X#UN]
M6^J9D?5V(/7^!5HKFR'-ZJWY:!/D@X,@YX=./RR@-3RZF)@Y*N7D])PZ3/%
M_WSQY)8..Q!^\.[SNBDN'K^1$->Y!)N&Y<O4JQXU^VJ$8:?0NQ,^:2$QPH "
M.:V=GD2"6$?'KE:^P%:K%J:.>F'S=C80TO"/CC22@HZ-'KO!E0<W<>^S/ M<
MJ4P64UEQ.TS,WR)0]7,\[:_ $+VE7?B<N^*[!D4%+_121W5@9;'>U>\%V9G\
MQP]S)YEVG!K\K5C9;KNV+ZJA5[Q1.GB0F4JWH5\%M_G.Q^YD*A@XN'S$&\7B
MK*%B8!+A[G*BCDB>U:%7KXU$]"S=IQ<D\9'*3OVV8/H#B1:?DNVJ@]*O''9
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MTMM_#%KE OZU0LG;Y-]\(7]HDS1[]T]Q-OWB[B5 Z1*0^LTA!KV^A4Z*_][
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M7R-/:]3[UZH88O(WHD^'#;[]%9;41R!$Y5=62F(TUVZ224$$S:^DM7+]232
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MVA>(>6N-6W7AD0X_QX0-L-P@7&GK68C?#)2/*WSQ$H!/@GWZ=95\<U2>-+.
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M^=]HJLM(#&#[U  #Z*K% !!4_U#LP(O)\?-EX?T?>E)F<TE&;WL57MH.Q "
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M=Q#HK6(+TH Z=>'O7-)2M->I.S#()WB8I--Q-CKA51[<CI 'H*="]>_%0FT
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M7^Y-'&G_V+.*?XX!D"%+^@Q:.Z96&'R^\]LUL92HJ- GZZ:XO74R6'3:!B9
M3N06;]E:'MK[S,X/V)\8838>)Z]&DU^Z;*I"\8B=[W;R*_;6]:FK%F](U4+6
MGXVZP8M+=+KHLN?V\)QZZL,3^Q7YZ]$S+2>PCA86^_2/>5PY6H$B:T+$%L@W
MO3R%>Q3*XL%+M;%R3UV7YK*0%6N!^XYBRTC_+4KG;5#3^Z1OM\DAO8/WBT'Z
MRLV3V4AWSW66.T@#Y2S$ ?^D-$Q@2V,Q5E)ZSS_K:J17#QA556+XZZLE'RYZ
M1V"R0ZUO%=<[]N,W\W[C?.>7V]_4B6@N+JBFD>PU ]6QS37B,XV:N2+W:+\]
MVR#-23?<)K"4L= ^. H2O*W'XLW70__F'<^\O.]ZVS@E\K$EYXB);?9(TN2V
M&XL&#,T(%ID%/X"J3;L=519'YXL<AC5Z!!74EDI_%HWUCZ_2,?VW[X'V^<@&
MKB4&N]:=#D5G8.JE6I\GW]A?0UOR#CGFGUW5K3=D-^;#LB5GCZBR" E)$T3)
M\#KC,8 PLM[5,YSZVX3F-"9/#8^U@F_'''AKMGTG9'V7\IW<92C./=EJRE(Z
MJREEX]7 /;/YA7F5S87%@3L0'XZ[0(TM-,>M.\"9KOW,\^KJ6GG+PB6G%=K.
M*0$K\2ROA2I.G\1JOARR%:VT\9R@>[=/*G_! -R[T@.5K236=,(6CB/DGSM]
MMEHQ4<?14.97:6),=+?Z;OZRE$X;\3)AZ <+;?V'LV,6JQ^[C7(_.>.'E ?)
M8 /^M._$:[! J7T^59*Y=C?Y5 &N['X$S@E$Y#DW3AT(WS#QX_L.G"-7/D_;
M^V03LR3/6=:MN,K ]Q *G[8/C&GF1"C?C6PR,)]7.JH62]#RB?.99NM$'W72
M(E\?R1E/Y+5]"!9L/-#)/)>IGEN_&8IT;0<^O(PXVZYK3!].OGO/]-T0W;Z5
M73Z8<+JDU53B^\[+)F(B-4+^([FXG/0C6==LIZ)=^*_Y)VQ-X8\+$G40E172
MW"<#C3T6)U76T-*0AA;MW$K[4QWZ$5L!?LC;;9SMLO+SKO @_%R5#/3(KC,[
M@>4;]28N6,XT:'5MVFPK7[*T8/EA\8\N\7^IT_O)D\U*</-!$N&PAF9EU&O;
M+T'4E0K9J6$'])]4,Q4&$KK>2,15<L5L/M'G,CBU9=_CVUVE QUKP^T;M507
M_#)V[DD*JC5+C"(9ULYK(MU2#6:J*2Y.@.=ZG]%'8C='_ED'*/-U!> @O9C#
MY5HUZ4Z)=0>#?TS6C,.8XV]6]5]K9R[ ]?'^5RT@\?[Z=M7O@H>)H:A'7D/K
M5BX(]MXLG7 )D,#91PQ @>/9,*7PZ[A$"__9V4*X7'^&!Z6-KYLW\UN"EXF)
M03.*J7 AB]9/DA40W'KY-S:"VZ?0QKA\_!^EI3:.7JMWJ@5+X)WYKD>C;E3]
MCXO>MC &6PE5N-4B+(\_TJWBPFBTKT@F.VM_>C&0D>P*[[9ZL4G;,N8<!*0$
M9)T>1P$);OL]CNFB6?'8HJ:.)"P.4;+E%I:!Y)^SAA5#"^H=E QF3,S9M\.=
MW!%9Z:QR(W\:#+(<>E_*)+(T-[K"-TMIC1 L_*Q:6;ND88I]3K300?0425XQ
MZA5?8;6H['S?S<1C3.VD LV-Y/F\)[N4:G\I27-Q1SR!>_/UTITXSV!C]8E2
MKM=</KZ-_^;M32"<%I68I78#-IYL7*#^H8BK15(4M12KC(?(;JN=FZ/>7*%#
M2D"9&/IGZ=,'+G+@B]\[THF.V!?9"N*?%LMU#$X</5_# )CKRPMGQ ]-;3$
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MH6A6#*#[ @.X*\"\YI5F+/4W1374@UT,0 D#N =9"X"$TR2^E=7@NV5C80K
M'2"4#$7F!B_\N]%8M6:FA]2C&$ O<^X9"P(?C=^$U/N;397")=*4F*U;2D6F
M<_TO33?V(HK[;S8+)H[PU54\(?#(TAM\U.W7!Q^BJ2#_UJ+])79104O7WST
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M@Y=HX$3 -Q<W'-!G KZ;/6+\9;\89WJ@?D0F3@0V25$L#Q@%7P;M4""(0,,
MWJ[).G.EK)9:0F&5P$F((0)*FD3@<!W<%OW+3AA#D8/"BTU?>KR(0! 1R(+W
MLA !PB$$F_G+;G4<88H%FA]=)*80_W@;ZU_U*J;,B'[?O\;W8W)_S\D='.N9
MK7CMZ>M@6R.Y5=9_X6%X#IDP=_']XL@R\'>NJ],'!]$_O=AL3\OYD8U:DG'F
M'90JF\$YY3_;PO\K>(.OR!E?*B;.S^A790[K-LH,YV)"#]/]-IQZ:9?R,OQI
M9R4W@Z",6/[O]8A^@W5JN11JZ\I4O;*(5*^UI31Z4T8<Y 8FN\!H:8AY7/1H
MC^^3K\;<T#<V;2JI$I2)('30]7#]UD2/6.#W^)GJD<(5@W2\W>,P$?)XK#2R
MF Y7XUKU;>=;K"L1B"^ICAP?>=T$CGQBG<B1A)J4O'ITOD^L,.YEP<1!W,10
MY&\.K\C"T9O?6<M3#[83B("R)!8/7QE>$EUCXH1WO/M  I_)B .:XNA9(G /
MH0R-HD-9W'1CTS$)^+T9%?$E^-8E&\3N+HCP7'0M$3>N0F)\H!9I+?*(P,XI
M4XMA*FE7_>MA(D4L 7_VUY+^);ZL]#\G<L[6Z2UA._#NHC@AP&X61P2^%?<:
MC C\,^=5S\?9W/%R122CEN+W%IJ8]A*!.;,!^.H*^.BXP:@DMB*$%/)0)9$>
M6X<4T%QOZ"RB?[J4%\2F8_S7*B'Y%RS7H!(/1\S=&8*O?C4]HAANQQ*! M.T
MXH_RI.CQM/LG(@!U)G'\; ,X^LCPB-+KFGA0S*E!'57WX[\WBXM()P(=33DD
MZ1Z$'YPH+K6;M6<BJ#%($QHRB4!OD&^<,==DGPY)D*O^V/3L_VWZE=:._SI;
M77C.YP;$O.!76EMW^*ML]5O\;:=_^&#=3Q^60H-QJC[L>2NA*Y4T B/D'LZ.
MX!0X+0 Y@;^.003EGK =*]/^ I]/#%A33%=NA:!Z>&$>K:&+:H/H*HO#ON2"
M:-]<:H'=13B=(O=R@B$]5!#+_W%04F[K,=5,/'.^,)]78OYL=(C'&"BB#,X,
MX]6*$=J&]S^LX-+YJBD H[!XY*_04"WF@K9Z+B_G;N_&_Y@]F>^J4^ IO27W
MP+!\++B54Y$+Y^F6IQQ:?.9N\"6O3##U5I$W"H+T%0 ='[>MJ8_PJ(G*R/#P
MCD[.D_<'%P)>%U^@%4 M[@CK?LGC%S,!UOE*T92W_*K6GR\XWMCJ6HE)N_"E
M'2";& Z %=RJP$&PXNK#5STCBQ+R-4M7QM^%57\O60^,63;Q:-?210^C\/?V
M8MEX(@?=-QIGYT]6[K"1U5MB#9H\#JKZUW<[M#H?93J7I@OV=;2OFB3HQ$#O
MSL*IE^*) .5\Y(6389J\0HGG!+6Y;@(RDX-S"Y4^U&AF(D";>F?(36;D*&7
MM5^CR3[SH)?J:#/,-1+<PN'%MB]\>&O=0Y56[<O-W6M<Y%&[GZ!ZF*)F.+/M
M06H+OQ;OUX:8](%O7WVJJ/E\'=51T,+?;":X_FEPT-"(]<"_&.LY\OQ,!-(2
M<03PKMT.^]), \>-$!U5]I&3O]/6'R/\VLC^;Y#.T=Q#]09)*%%_\*[=7V*_
M: LT=M8<Y&]_0N2TYKRNK^(]<'^]5]WX;%38& (9'A(E'&LD<P]UG7Z&D>;
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MPD 5JW<=@04CO1^4X<8T:]7#=J[7)30G1P^#@UP09;>G[$-"=G"C])],+H]
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M4ARY$_%K6AKK.*5,=] Y;QV]SNVS\L[YGCWS*^['YJB]:[B#B4\K@W'N,N,
MQZF%NRT[<\:@B) AKE^;UOCCND_W7LB<"#QA*.XT+Q*S6<ELBXQN%)YZ]>F*
M@M>5+M^U2O91AY1UBR8(!5ATQ3<=48"CRV5I"YMA16.51QX<SA&]XY7M;%R&
M?+I?^V%=Z^N9P&X@?B 2NF6.>$C^PQ/IV0%'92M&=Y!Y]-/II-?+.;$0-80O
MI -# >9U2.E07B3FCT;HH;#^V'D,TALW&?"8^@US^+AYEQH\0_/LWJI;''F8
MN$(!-(ZODH^+B(.@ZG%P_*Q%4HO94NO7K#L?2AL!I0NA(B@-@Z=\7+F$6(/
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M;^4'9/R6M7G)80R*A'\D&UII4 !/]1TN].-1R?1]P]JJIS=[V<_13IFAW.S
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M^2!CLZIV>0PQ;;B/(#17.6Z]0.36W7^J4OXN5B+]O=3,$N7'_P!02P,$%
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MW$1;20(Z^N7,42]&MEX]:FQ"QO[Q,0ZRGV2*X+YYRYQA^YDO,-/5:+]LH^G
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MC79#5J&F-QF''Q"4!=L316B8"4.VQ<@6   NP1O#!9*.^[/F3&=5J:3NS:A
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M[36FI=E@,UF\UK#U^;=5>C;B/A>75!J:37EW*!E^%C#/NKJ*8,16BT@)(@[
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M3-FF>UI.'-2.A@_91I)8-7N3ZMZ+C^^B7,V5<B>\!@0AU>$#OMW;EUVU)]<
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M,-J"]%SV;. ,?ERB;_B8]X%O$W'C8PKMT.F,7]G%UD<VE/VBG[0GWB]AUK$
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MAK\^('FO.&0C(M"!'_(!!BH[Q;@.3$_WN0M+7J&,_@&0Z?WIF'Q=F".<(I;
MHM;QZ!N:H,HUY5W&>KG5,S>O$) H8M!+,_MO[5ET%']PD-SN?&K[9&(9W)B,
M]TX\0*QIR[T=<S] KWJ'?IAD5AHM6W-8E*E[-Y&51^/-2F]D$DM&%>]_AP:@
M.<C*4WVA)36F;4KS=53TD95C8I6)/7.N!CC$>AUGY/A:ANPK%U\-QE+AM&QH
M+Q8X::')B#H0])B)#GD0-Q]VXL_]S(96>;\_:-?@WO8A8C'"P3<S&W ^96!O
MK&XS8*F%C^ZW'^P9* ;7F.3Y/?AX@P15X4N+!4J16K1Y'O;*Y7U7CQ9!W2#!
MBZ@J>(]XL)^8==C1#KACXE1;$R;^ ,7-(#MX4I(+.6 /.B5'],3A>&<*_K$8
M"_Z;,-:*N:ENCP0X=W@(M?K)OQ<H4)[YU6UAQ=Z1NQRI ()9 TEA[8-56&!'
M.M7NJJ,<J+_UZ_360+9TOL>7X0FN*9)*.?2\0\#!'E*90&(W+RC5/V\YQN&:
M<ST\W+;XB#X)G0'98[@#BW2JN2A>S3JO_1B_'=X&;RN<GE9T90DC3)(5BS/W
M>]P\NL='.>/,]5KX_H+LH+KF>")ES/OB14_0D"RD--MERCU@  ?98-,L T?@
MA?,)%5N;:UG/V3QB>.GCE EX<CU$;\GER>$ @V@F^#L6"%DS$*78G^IXZ/\H
MDL",*M_R;QKXN2ZJTLO%9+TT%(RS\N+)G'/E 9MW2%:T\M)OR:%X,K<MN'CE
MTV/Z'LS["I40VW/^@#$]"W><K#V*FBQ5'"VFP0*0I,E'AQ%^MW\.0%?_K#@A
MG5BS'D%@F %A3RX(CEV3Z6:FEX$9?1W& FWDS"@LP(R^!"^I32+E]11^VEW;
M1T\'?X5?7:K1!38M_S-\Y(\1>S:G/\;Q_3BM_MA?3V6X96FL90[<H['YWTN6
M"K3JFQ&Y=VK<Y6A)4YOT0)+]LA:E5NZ'A#M[C!:BU^[G@R4D^LTW1U175K5.
M>-6M!8^<&MS+,Z7)-(.-_T*#\,O=99F2HU<A,ZV@ ]@>-:IE%"7?/ER;I((/
M4.6EOI1:M*(D4D-\33[F9\E[TU"3-K=#"J%M'ZTU?H><$"OP&/XQXN(FM<.-
M!;PR2+I;%LY'1TN54CRSCCD2&(IUG%JM74HV[E)&QY/*_#;JWZW3^*JJ9^C#
M?'(D41:!(!SR3;.)&G4-W]$X<A4R(WC(MR"[H%%LR\%I?F?Z^6&/%\L %BAH
M#)M,63VW+/2U*)=B"Z3DLX#U()3'2EWE! R4?O"T$>.HC925F;//LS <$D"3
MN5RDC4U8^1)L<.1RHLLCL ".CI#\J-^R4?!B><$_F*42U<NEIL!1J'$T[H;J
M*_ZDFE''4HB19<Y&TFN]K8]K@!L]YNE>_%W64ST[=?/E"\T#)I4H' K(SFB"
M"D)=--+A%,V/BRT\RW[ON0H43 4M:FOW.:%)/1ARRU";[=P9E&Y$Z::X3]MA
M]M'XTJ@!>_''CXQ"[.A3+("'ML0W:8<N3T7$3,_4<L-3"0%3=U"0B\9*@KNJ
M]DRW,^GYDA#UWB9;5=F!0>0XA??T2UA++P:V)$$[&O$YKA"0I+I_]MG 0(KQ
MNEK/_64:76#YI/2ZE&.]#V\1]PD7J'8. EDY+F%8'?<2FJ)]G_2$LJ"LU+0
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MW3$I.T\OUR-+RVMZK,K<A6&MVPZ@EP9%R)V5JL3['PG;UP"W.?_-ZR-Z*NE
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M *JV[G$5OWV! 4C5G>HW5QX+EW)WM@E]M&F&&C+Z#&>KH_(OR?1:3>'! ^!
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M)-67CH:[U6W:<,YA]V$8B\^SA*.+%S\A7!?AH5L!Q[?963ZFG?3'/"?XVK.
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MG62H?%KYK)#K[:O77C1P+O+$_F >#F[58+9\>&MK:>M9;G>IOP4S=H!X)T.
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M7. *<!A^&-#PWB7N0G<G50:GB6Q"=-8H (;&NYGG)$QYD9^;>),#QP=*5[J
M(9Y-@C_:L!&3#.!5/H+(_CVIH*WC654\#=)B&VI('FIFT'_6=X-XG@4G/DN]
MQ%DYOKQS3NUU([F<" 7- H3MLZ"<\9Q!""A\@;.5,;N@&]V0MXA><&;7MK@D
MXQ+]]27FV-0%X627WL8H8+_YML\R*P*[?%=M7VTZY9^+M_\?S3)@$?P^A2\B
ML*?AT<-MS;K]+$B<$GGB3Y06AWS\!\KK?YEF#$7507!'?T'SS@P^C$O-/,<
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M)-JL(=X:9M (S(9:/)K8M*I;6^E!8%\H$64[^@\CO<)W6NSTH%?C8U)T1#>
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M0?!R#M\L#L9;N",E]UO1.A(T8ZC9P%+7RKX(]5NW"7MO3V2FWY9Y*Q6%27V
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MEBAV/4\/B96B^R+[&F'1HTW'5L6G%T^S'2,(!//2[TCL.O[;;^D194"1.0.
M5W'?R(,[3%P#&O$%$@0-QY/$?'36Z#]8MM] B##9D;-$'V.K$)Y >A1O)<=M
MI_-4'RG[S.4:$!2A!TA U)1.7JXIFN@RN3B_HM15E08V\ -V_LWK*"4@122#
M\7[(#=QK:&VPYYI%0]JBT)F.2=#:93U*S]N)2DU08XDX'EGH3K.,(%*ZS_1"
M:RK.;23PM)AP!K; OM9(<V57D=4I-0=D(7K>G[.6^@9 ;'-Y5N:4CU 23@1I
MUMG\E&)RRQR6$ST3N=2B:+& JN$L06RA<VJ"LS+!36%28(WZ=; J'L#3C!0O
M;Z'UM-1-NYIY5*$Y=G2-4/-/7H?Z=*W"B2'5KD8"3NF]9DOA>4^T#$=9$W=P
MKVO;HSJVSE?MD>8*?)-^'C[R1[>W6?CGPW?56WEU2UP$2FTHJF_"S/'^@ 7X
M">,CC]A)?R;^][]5V\_3?1TKPU34QYCW)Q5HV''F&O8XN+A91I(P;$&KY22F
M-P!V0'KXFOB#U0%C8D66TK&R,AASKGX5L[')#E #<2UZ^>>5+\KE>XT$C;'G
M?WRKRUXI8%FC_EK'XP!I1"6,626GY7\MZ/$Q84N\!\1P 38P?25!<_S3@C@E
M1=:"LZII J=K*0S!;H\/]X"-XCII_:L9Y(O=EXE?,EG/WJP%P*OYV X_ROFA
M]0 \74B#5XR)Y]P+E(5X*A+X+=Z.QL>%UDMT[MFX_ME05NXQXO6A.^($*=4(
MS=9T,3+<PQ(C K)N0V@V)]'+LEL6)R"STPG%75;0UL><KS,.GH7KV#>N!0"]
M'4'C:!AW\*6W+/_D/81O;%"+Z=K9,1-V$26YV?GCUZ!QDF[$N6_VB%8KNZSL
M8RD6/(40*5/S24H&^<JP+C89 Q%M]"1Z"A7D/P\S.Y)IX"C8V=F^%*W G^7D
MDPXBJGOZ5Z9"IF?G%W;<P#NV,ZQSK#2G6T"]#?"**%PNU TWG64L3HPRA1KZ
M!/L:'PI&'P)XVI+2$,L[83A]6X'&RN3@1V+U";#\V^4R3<-I?@M7['#>054
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MC$ST J,:M(6=LW$CR_JSRE1E@9;8K'-V*91+GS?GY$J25+RB_<*B;M_<ZNN
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MFXC4EI83L,])W3K'%"5=/<IQ$+X_K_<EK'31[XC$RT[184\O?KZES/)F[:"
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MTZ\,,*PUD/@P_I^3CE2OY84#$H2B_ZTHBAV\8);LE#-Z<M0ST$2JNK=U[B1
MB;8#)NY99?TY^UEAB@NPD/$"CVC@#%)H['H):-4-'^9[D O_:!K)I$7SI= P
MF_AO=T(B5,,6-<(NXE9>'E2@#9,V1!8;$K.>8,X'\+W9M?1E^?>HM,B'-OL8
M.I[LK]ST]HGTKABU8-Q!!)?G[!4R^;?%Q!W(SHY< JFP3Q@/-P>&$2Q7;@SG
MQ.,WLYV/X_Q$=@:BS HN5%I%^_V=M 6B2*\G]9XF]1/^D'@\FC@0*;<MQ:(2
MX<D#"N%W$TRC0SV N0$KJ74J)3C/$3C(J::BB:3MY)&.A[G@[GK^VVN@%;E5
MO0-/I;J1'>_63(LJ(LUHJPZ71^99>P82* E8/LHV*+G5 !S9IT%N]]OT<['2
M"I[O(0!J\>&VQ(&''7M?'*A65K6/3B?&RHJ([TOU2ZE 5S0R_THSJ,X:Z&I-
M5[3/MJD^;3")]_/%)%D7'A6>)!_K!J_MFSQ6*"FK"%+UVNZG:FZ\XUIZICAI
MJD^G%-<5RF[E%C6 0!+$C1.0 'N/!")XM.5HA2I/;I.)=BQ$2R#5##P6=?<P
M3\55W!8;7IXZ)U*Y)0Q7O4S%XQCP(2JYU4_CJN[).(9C0QUTD4QW$@R4)0!@
MT50[]YM>L*)Q?B80LZO[E/%YKDF(626"X4$UOO^6Q'/ L>T:,=OM(YK5L_A$
M[.U&\1]-/PCY9Q6PN480)X7;-XG2.HTPD9]Z>&A@.&+.+$QHAV+^LU.C&IFX
MR)]"LF D@7?\^]EBW)WM8Z%BDV-W%O_3')/S84%IG'\V8)YJ@5\[Q@^3<%&!
M,:V8!7P6I E-\=]Z.-I0+YB GIYN^P\'I#GG6OQUL(M=O&!&5%TN]LS$?6P:
M,3](P7X_L/9%/6D8&X6=LN.:&6D\?&&S?J@/$;H=L)AS#9,=+GI>L98-(Y@=
M7 6BBK.7]=;;K!]::[8>GR6DSIF,@=;3E5WN=,@?=>"=X:L?S@><Z6Y*;?7:
M"V;P[288/2"D/T(:1[U.&0$3)NU)H\$9BTR3+TO:R,9^N1O[(T=NVD_X2['(
M!8@K62]9W^%F>UAU_]J,S"P3%F2,NW4)4&,^C+?5/DN(R]'^1.MGY< $]]WE
MC!FOA^1NZ)2,8^_&VY1IY_1YV8GEXO;4IB=+L*^KD^9_AZ0K3S6?/N.,K6NP
M/VD"C?D(2#*^KQ)R%^C[XE$]8UEZ*L+QM7[!FX#R\%KM?4^)K.:B_L)'#(U?
MGGZA7[>Y+JDVS8:/.ALS],5*.'RS+.O/X14-.&QT7("#TI:;V'$"(W\E(V@,
M2,\5DY/#++C98F$?"#H+8S\>]F>_ )(4J.[W=&X%UR<8^SSDA$TKCG)9.I!M
M91.TWWX+?7A0-\%]M3N+]G_.=%T/RI)$[I]U<;!MIOC[]P$G>3J70" 'BNP'
M[(S\UPZ!#>W2 UUQB!Y>O(1$",2',-AF^J<!M%[QIZ;"J.$O;?N6E%@0EJ"$
M:,+?(+6@*'2C.3Y0FNAV:/N(8R^T0Y(EQ/SURHQLV=/E/5GY3K:#(MKQUVB>
MUJISVG2+J<#H[!.'>][/CVWF=Q&M8SX<Z*P4S[O%VIC\%V =!<&>G,2 =V[B
M[KQ$D@N,AYS;G/JP%[%#BXK3>K<["?SDU/I7#=R<W'(\7]94EE66)/0_"U1[
M-$YU](%(>EH\];K[RGCVPX^J>;QI;T$O@&(C(UCF1+NY^3]DD8]SDSPR^V\_
MZ;>_/ZU2X9%<,T1/G> B?,V'HV!'QF#(,5>#\T)V:DYVA3T6F#A"9C=HHB7+
M^:'D^EMJB[,WB>O\?MEE;_;!25;Y(4'..I&?:Z."&3V^/CWR'+_WM-' C44T
MQ:E_R$?0TS83WJ*R>!W7[_AUV<@>+Z+J!B_Q;<KQVRD>2XD_YQZ$M3$^E>$D
M'.'ZQ(Y.O8'$0Y;L;<!)UNNY$R4IT".I# EF"2UHLLKV.F8JT/BJJ>1WDJJE
M8L(Y9.XET"*S&+3O1"BV$B /-MK5K%2Q<X7^PB\>.]25@"LF=*#QV:+B?4XS
M;'Y)M'^ D._Q<'&,B@MXKLZKQ)THX?KD;WLXLFV]SVQJ%PLV$DP\8[X$IO+W
M@S.Z@VSMO(T.URJQE.GS4SWPHO=;U*HCNO9AD*TXD>:33:05R!VH,U]H>-C?
M5B6ZH!&[9L[WL)&D#;E'N:NRJL_R=^+:13[#DMWIF5J"F3#@'J=:>)0_KV"2
M2%DQ8L&R1'[P,/5CZ**GVG$Q#::1AZ19K-78EC[U*#'?\;;W<_M=ARD?T7,>
M2HNIB*[*LI$=\\_P:R]N0%4,6ZJ57KEY4J)ICBS5DE^,=+";,DRX]B\1]P\D
M);<UD1^>2[#LE4-%YXX'/0?/6UP"5HXV9NQ#9P>_5Z+'?=/UE7EW6#^OLOF5
M\C %I6_ F56)U,@&]:3B9%B[;H4RL"C+X ^$'A0'BSZQ..%UK5*X:!_A*YZZ
MAF(2OPXU"!H7>,I0KX":,O.39WHUT$-55-,"*D9!C)&9*CFPJDN ,D,)(C^\
M6OG#7*.V-CD:$$$R.S5W?+"?3@)V!,A%ASL,:$-%OBR';@FORRKGR!/ Q=5G
M(7*E ^43OZW>35(Y<>R)[+:=W"N8G$*:FA)^9Z.49NSPGY0EVL_]J[LI(]75
M^JW;>LR[4(%'N^MX<KD"BFIC7+\=;QPY&O%3_C1[FAU$W[UPCI8"C3@5/E$@
M<2+=X J[&&3ST=T03>I%DW^2Y$1%C#8$M+T^S:]E8+/KUE>6ZCRAQ\+B4>-^
M2^B[&3#<73<;&YX/Z [FG&>_72^(I!ZK;A['8HB0E5.>K\63E//WTQP&RWPQ
M_KX(V31R1%#J7=U9 4?%7ZVY6CSQJ]7-)@9$X(QT\&11E=IPH9/N#:MB(^VW
MGXP^70*/-[RV8]%1?IDC-HDZ ROGDH649,Z55SQ X2&TX3&F5-RV/2O V&,P
MF(T;D"YW,S;_[-6\B5"+V;A_S19?P6GQ$J!Y[TU='?_=%R]I-GGXRH?S<LPP
M;K*C#.*%0I,-O^@H=+YBM;I%<1W?>!SP%A\S_,C_]<6!7CU:HPPTN<L=U^,W
M$TX_'*F2#5"X;7F,V_X%B^K.3>6ZAR6PX/;I]!BCV0,:%K04[<-RQH#XD4*:
MAM7Z(8XY^54-MBV\(L[V$\VS2R"X$,N6U?<V(JZWX;/3C<W##N%=^8)9E\5:
MBUJC47ZFZ8J&,D/^0*,$_%P]//_Q[:$K#^=3@VJ*>(15)U/B^IYWIP9P7(;D
M+8.W#?R-O:QSM9^[F3_L(<BOT8?W&[YO0QUAP;PH3Q4O$OE[,C0ME,U&S9*S
MP8>]]J66<ZP8)R_V,QW)C&^=TTFL-SB/\'<1QT%7* %886516SW&5Y*6W)?W
MO:"P<XPP=]K16;'>F8F[QFJ8S#(/0>OQCZ=SS97Z*4:^S6PX C[.Z":T=_HR
M[,FW#9TW@Q4_)QW$LU=#/,*CUMP.&8JE!AT[#ZT9AY5#JAY1!LR&VT@H8)65
M )DK4X"T,+;*M,X*XU_NVC:PN2-0.SKE_[6:K\0*+/I^T[PQ*;DZ^0/71I5D
MU'\,?:.:GY.QBFCYHD<^KZ)#][H\3M'Z!4,"3#WB^P&;" &W0U3G>*JK2ZLQ
MDJI_"7JS/%;F2>FT;GZ\NI3]B#.+\"'[ )&MZR//UXO3/3"Q3K/0I7OA"DR!
M)!/+PH?"2S70('=T!6A17]6-;BRRY2;6EJ'+,*>+;03ROJ]N6'=Q/*R YY%I
M]*90_ZHB4Z7S0:=D=9_T=C/$(+'#F]3PYD-#K4ZN(RW>5U)V$!8\MG26J%.
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M]G41\EE;QJ58"@D[T8\N#CNFR5-:57IG/-84I,EX1S) VXY!BA_Y.A20\?I
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MPR0WT]&KJ7PO,[76<..L#U[CT,R7T=_JO!FL11*OF#,8E0:5WXL%#\4VLN$
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MPL9H!UF#'Q*Q;M=J_M(D\T^]ROD)?ND3:8NFZ#X3?Q@O.',-H*X!CR?I_->
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MVMUU@ZF@7A)XCPC<>0(<] E< YY7A5RC8].*4V,!;("&WTK 4K%5DT9&;<&
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M]7="$W9?=#XL9VLZQ=.-RX[T68>)P[X/13QZAG;-+?!W'T%Q#^#:0*JHX+P
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M6*D('/,70@JS:+R7YFO=_?-,-XW?\)T]2.AWA,>WO,ET40$'E[3^YP0/_ 1
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MZ\S47<6K>B]CLW0Y,$5FD;A9,<B:?Q)9@$RVQS.<0;[Y/^?IF2L3 <<%.;=
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M\*2ACU5F4#"M:DSI^IP=>J&3)EWAL7J5>C[P7EW#%;%LG'F!MU<T&PA V<4
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M/D]J+TN/J?MZK[^S6I_]Z#R%Z=T'#IH$0]!.U07YD8<PT-:QLZL$=1MY JL
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M\/]A<:06O(,-1I$27.OUJQ>\+D,%QGPDD=#AH2RI>3D?ZV-Y'=<!TGGB 8E
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MGT8\U[8QD;TV]<SC4LF;QTH>4VWO,YQHGL5- ;+L:LELWA2 N ,Z#I[+[J0
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MI>'QMRG MV_@[8F[U^DI0!L"W[PF0#(D$I&6RQ3@"7A1$=Z6@*^999X6ZZ$
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MS*@EHT'X)C6*.2*(KJ!HR/99*'AOD0(@'5-TA;^QJ5" :!^B*P6X:IU*+:G
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MJR-Z.??&I._:!"3# CZNO]+X"3!(!S(GRXRK/;R<2SOX6&.UC0*P*9G2$0-
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M8"L,5?I,5,BQ=3C;%S?B4DDH>*W^HYMNH,'0$U!/(5^O"-]$\>QQGV?="*$
M*9"WP:GAZ/'F2(R)^FQ&U&(5L9LWU_GHY8/MUZ_#S ?OO=+8'9;P$TBZ:;@0
M5-;ZJ>L&2WB\3N(]WVZ[YW%_I*BIDA!&Y43GHKV%M[I $ 58IV,@27K'T9+S
MF_0I@.&]<D14]J_KH:<IP)T0\!%[6LKA%5\\"*M_E!"<07[>8T<!F.!S+XDZ
MY)9=^,%I2=JB_PD S/L/.?/[._,+Q[(-KY3Y9BGBK1'4$D P)F:GP;MZ.8/
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M$JEONSWBQ;^HFY,LP!QAZ@2UZ"JZ//LC([ ^J$>A3$@UJ$]7G2!ON,M']_2
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MEWUHK_!S\S"D\ZV=G\?%U4/DQSK?H/O[02G?_+[(]S!]#L)5IW7V)7[[#>Y
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M-GDYTO:TL^1-P0RR.,FZ:X&-&-AE!K8G#"9ALP0"[&_?%WVC/"#$]*5>?TF
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MBQ>-E.XN" 4RI17 (ZY<;%&RN"WYKT1 >DA3_"V&.@W^Y30&WDV_GK.(H:2
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M,#]!2M,G6D7XA&!#+<W&=WWVGLRM7N[10?5WCS^4A.YN0 2H$Y 94 UPPY>
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M"K@<#;"(^P\?OO_?BO^;>:ZN_5<;^%>IS/]J=8TY49!JIU+"2K?JS-)D%PT
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MJN$-'H7#P(O2/DUFKZMUKZ>#>7AL,-HIGXBG%R4GH>X'MQ'@]F!V8EM34]A
MI'GWC>+._>#GSKOI31\D()>[6A(YYM,^"YYFB-Z;QAV?)A^!YM*[/*=$;I'"
MNC(<#@=B9<3K/6MNK)5!:G7I6Z1*M;\6N$].+#"\)?4@)4=DCD".5MB0664@
MI7C&.9@GH3.C[8V7EWIS2S D>WW5>KH I[79>1V9YQ7RE4%0@FX-\A(FV*)
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M!<G<1($[*)P!F6KQYTWE &(Q9#>UOCUC1Y6@DY4D5CC O0<Q6A="5RA]V_O
MO]F-[*/J@3N$J2-0_V,XF4V/(H\%3&%"5C!2H(B92#BE*^'/RAU_VY_HB5GS
MG2!&5(L>Z0@DLC3F\:92G*"'D6:?,W_N@;3 GU)@K%#EG6LXZ_*,$M25;"C<
MPY=G[R'VFJ5UY1TQ*[RP"/ SJA^KPI2]UZ+5\PHX>RY#\W)_G4_OFBW-$8B>
M^<"<+%>0\^"RV!Z))6;G6=.)+K$#I!KC\UYK@K)*10*?86I]8.:^WEH$+C.'
MU87O5C/.DQ_!XSIA8.=0@BC63/[^W2U"61^Y6E-6/7<28QRP!0>1S8;:1.%
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M9EQAS>PB(>2'U<_NWSTU%_:*DAYUQ>>^X!9(UBSWG-*"!A' _%JXAW,V?G#
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M_DV-E%-5Q_<K.&ZO/A(:BB#+>)[>A,Y8,33N<%)@6T;BQP4+&AX5.0<T\/]
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M.FVAS?0"+-+*<??KF8PF>G'Q]T>3_Q]02P,$%     @ &HA=6"_I\??$4 $
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MPJII!:_Z23YIIF1HRD7#O")&U0+NE. KO(W5P18S?]'#)*V)!BQWF4Y6W-&
M'QV2HZFR1OB+X2]*ZT+37S5HX-]_-VU[^ET(6CRG=^\F6"!64?RPX7-VQ-7)
M['=7BK<;3= @H:=/FKAELQ%BIE/[*H/!*<?2*7B66L2G\W(0@J&)T_Y!NM>Q
MW2@>]LUGA(^79WI[UQU'IEL\S+L23)CKFVK&TY^"K:I(>ULAZ;^%2YD1R6B
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M7UO".RK5G7#9?S'>WJ%ZM!-,]R7R;>2Z,+Y8C<PP8OJKC_P84FQEA].N,EP
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MF!0_PPH-O,&'I'K)>K9TPRXI.-' [X<D)\76:(#TSF\OUA:DMRQJ&:7-*N^
M!AA'(;6@>$5](HZ!1AHTP!K>O730<0,>!_]3TP!"U 32>NQE1Z&N3[1R@")!
MD%T=@QLB\<5/1&+EKE]E<:HJMMH>E^)XX'6(UG1%4V[7U)LEJI5IV*V<9--)
MFHD&]RU?")[:>=1T1%]R-V-,P 53UH"E&%#^1TOM?E03W5E9.R]F?S^,'CA9
MAWPYH[9DKO(<2G6WRT6-^3UN:DP2YLHH)V$IIV?WI]!GF:[5'1Y#./5WHH'*
MM"KSO -OEBB1G(_T=ZJ[&"F;*@*C;8%3_&9!! &XJYJV3\=RKFG95?I +P+K
MT/A4HT?\J0!WN?RCX'_XZ0?3#&MJV![N6D=N.?:S*BE<E W]1#_:\T;K\]FE
ML4%!EC[$+;7-"..WW/1U-0D*]^*&6N=).H2O"("YN%733ZL5$R79D^J/QK\_
M,[HO=UMQ^&<6C7G;3E+3BBFU-8J_+.U"-DG1+,"!]=O:TQ,S1JSS1XWF*Y @
MER52GQ=PXZ'">W7!W2@=Z*RJ.9] A!#IR&<<KZUP!SL?RF5C*\UQNP?5UAF<
MX42V'WL_%"@PKOMI <.D/DI'L*"2YOX"V]&<WNN1SN_RIGFO'1&3,"*/PPX_
MGKL"=DHBZVI-A+=BL?:J?C@>&NFV,]VRL5FA\_76+@^^UIZX4&.99F=YJ"A,
MOY6W#O/J1W2L)$.(B,5Z&!FKE3GVZ+[H=]5_TM4<^2R9K"H:G$YB,%VU+]9A
M\*K^>R$HQHKT];$=5X J'G;:][H;JU588"5ES;5;4<%)=WFV8_?0BIX%&=#;
M>U9$$I$8GH>D2#OCK5XV5.+='LJ]F@KI@.!:?_!@5JFO'=\OY>'A&M,_X#8G
MXX\5IGF_C/41KPIP^(4X[-!=I(WKO+<[ K'LZ8PMFWV-,9;\=2;;WK%F'@2S
MWL3]GW/ZVM]ZM4Y6K2?#A('[@&7C>(?)G5'86G=5!C6A];GZ317GM["(EKX:
MYEK39VN"XSZ.1]WA>!V7571V?%.SQ[/6R+KT4&; \+8C%#C==T?)[BNCFM[]
ML9G98ZMMZ;YUVCV$)NMFC5?":%_^S[*(^U9BYM<%(L*EBN,\K!.2]]O<108J
M;,12KF#<C17+3('O!25HUXPFB[,:2><%=!Q5A5CDL;UQQ"W6B3 A.!?AO.KP
MJ5';\UR"1UN^#N3V5#T+LSY=GM&4U#<FKY'X"_2),TLVY>AWO2NP\;:,,M0B
M39":#XQP&?I]MEIY@'06AV#+0]U)JOO>IO,=W>Y9'P;M.TO1,3Y$)*\P$2XD
MJZCI1MI+=\@05!;!#G'PF"*-CX:C?,16$0N5QDHB"Y*GKP@4\$K& Z.]UIK)
M$'B*54>^WTOS]:0]"VS9K9+ 7\CN4:]CI9QO[8()5P]#TH]\-^/62DD,<^('
MJ\9ZG'X H;ORM_U/9QVG70%O3V$:"8Z0212/![-L$U@YU8;1@N59360.@?QK
MI0!^/31 C=1^G'HTQE;^M>MQB7G8.SPZ]>!-R29AI&U(D'TS*<)9.J#/E8%Q
M4R-P.&T%NS%R/E:>P>LU7HXU(\LH4NW-^0(MBJ-6>K:+Y(DOM2O>GOH>X],Q
M 2X9M;()[L;"U!=JW+]NW>?^A?UC+6_/A,.FP /< :,Y#4/2Y;',VI=]=;"S
M@UU8KR_3^RH([P<:0!BX!K>@2#IK5H_F4<?U1)G@UT,%"I*U EASMDS4/B3?
M;57>2%86\SV?XGUY '4.(,2*XC WA"\%-X)R#'<-@@L)#(U*MFGX-M5WTRW2
MJDPN6ADI'8B&LR/)!KD:8].+I!2>"3^\VHK8$MR$8"%YON^*JISGY[<FCDN+
M5-48QB_^Z!9YJ'7$IP)XN0<W/_(P[)HFMLO:#>/JQ6E,U*3[+/J9^I;\6%UI
M-.18F;ME;Y/IAJ N.G36."0(Q8Y@TQC=?UB1M+EGT4Z)7R)4D.*_2PW=04F@
M@3[.>DQH_@HY90>2QE?E@WP>KO@2].M-?-+E,B?WY.T>XXO,P@D(C+B>UEXI
MI=Z6Y*[VK#1^(?89YBNBJU:0)NN$!HC%\;)G/"3;#U__J&F<.'RH;\]6&Z$P
M?UP@Y *8Z3+#Z>1K$-YKT20>#5)A[]?JZJ\EUGF)RYH]Q4G4&Z+?2#&N'I1E
MB?W04D^P% :\DE8$F2(6;X\[T,X:6ROM3:8'K:OOU\EQD*\EE+H)J+!U))!]
MW9PZ2+C_8>:2#Y>DC!/$_OL4!"# ,F,/?P3*5\2H S:/@RS<)?I8W-.)5:B,
MQY RN<7G<=Z4"PT0>KL4IA=B3.8F:G +$H0!&B"I10.)O6C@U$G;0P!^M+16
M')^0()Y*91KM\*OMDC+8B^0M+FA1T&JU!QD/"5DZNV1"12D!^Y*LLPBYM8XR
M4,2WV&Z1B>YMO6=.)"J-Q_S&.M\HBT2ULW78[X^^D<9GB,-FRO&$[!-C<J!C
MGJL;M76PVBI>Z/>CZ;8R5]O?B?RS'7;D^6T:NUC,2UAYV)I&B.+E81*3JM3S
M'\$K=QD>R'W).!63;BN.)O9H> %W33;:KH'/%WS8"2B!'3Y=U^4]6EM9#,M$
MO&A7+GX^NZ5>'V19E^31^:D"<(LXQ<X1:::1?0._-=W%R-A@S*M&56T-:TAQ
M;Z4G@=.DDTAE0M<E_WC+DP@I.7&X/U/<)DW$"0J"1:#HDP#[%KARVR)MXW.O
MJ#*F6:V5U2!:C9#1ZD#HQ-%T1"4)E=3Q=E*$NZ0)4<QQR;>=>''H<4M(')+G
M" T$[V=/"*IP[^G42;/.U\@,F&W%9GU8)NB&JY:M$&/W&%"%^5#FM5K&KLOX
MVEC.J:\);S'@>IGO2#$NY2-J9$?/&A@848>]C<W"-3IR'2EK=&41F]5[/U&B
MV^,F'J)SQN7$YX./5NPIOSCE*?0A[XX;5W];]59>PI9>U7EGZ%9^K7S2ON+4
M(=E)*D5F@"B5:X*S#H?LER 7E'X)#=-F/.+MT>GF[UTM!HL>)*Y<XS9-EF94
MUM [Q)=A4GVU'Z4"B(??C18,P9+/6EYPNR8G6'^KOS2+N[2*;J\K=M<^.@QK
M%ER27]V7$_.E>ZG&OCAK^?#Q%](&X?V4N--;'R7N=JSQ^+O2;52&&Y#V;A&,
MOX!G@ Y)H8="W(/+ ;5#\CF>H% >OWM[5RSU+HE7 C2O9 7P2=?L.^^Q._C/
MGL[6^-L767W;LN-SJU%,V?+Q^(F2@0([\IV'^ RX*N]WMZN?\@9Z,]\:PG4K
M6&.+5G((:7Z"D.FB6NUY-1E?DGP@*V!'"GDWCZLVUEBS3!7DTF0R_'K25<RE
MT1L<S3W[--'II4+_,\UN->RC8K6H1=JQ4QC)C$><4A6T0Z.J(4HPX==M3SP6
MB[M\!.NTP!D3I4>NXM'W+]QGWA5V% -O(ML36'_&XC')F,@<1:_&!Q4'[9>&
M5>WEE[(UWIHQHOJR_P# VL(6_'UB.&=;?]O!%XS3;486E/1LF=<DG?301/$:
MM)/DNQE8I.QL#A:(64)&L[!W^:F/Q'0!WA+[9]^3WW'M[W>ZG8]R[[#&5Q=$
M.QOQ(+D/L7QS>U$S/@=S+;_'WE]M4?<TO4&-.)J /E7^(A.Q&,]LTFE2Z+NN
MO73>GRYUXC!].=E,Y1']PEAT^)I1F.63W-3XHZY'$6;8*60=$^1G&(,O;ZJ:
M>+_:6%X;M3JK34Q?5KWQ9I?X Q-!6',#/*I\G7\![-1^5^37/2SY]<DQ#_YV
MG33"$;GX=ZZ.CGA?QYY^\Y]K^-$C;738H26JT[(F<4M'TD*TT"2=N<B9^*=\
MZ2M:8._A>*4:$7=A0::\90VW?:F5Y]T[V(?T:9(!=3PAA8ZE'G$F\(87(WJ[
M?L9- <\Z%"E\/#^Y]='K\J]B\F@TT"ZSQO\=;,#=+,[_O7F-N#B\MN4KHU!,
M]&<WAKT1)/\:%\BT0=0W 5,=XK]9)%X(EZ9^+35[9TT\2@+K-)V(A C[#1S6
M=?X$ =U<7#RQ]%B4&W,TB39Q7<&^R8?K=HO68Z_/A;J<V>._S>(*/"N5_8^=
MK/P(9C3P*"$+D^2+M,1.?]?]AL3 B5%61P,_4I;ZP.,<&$?9^=80YX]<_3]3
M-AP[,&W3'D:B'MBD,2;0S8AS4+P%YZ]2*YK&5=:4 B3%MF 03B.-=Z8RV"I'
MWMRIC!1GP'XNYL<'0[;-K1+P*'@ ]=1C=4]-#\FV4@F&D=HJE^EPO\+W*CME
ML:+9F?I(M0P)=:A:POIZ=B?)LXC;X-<[\]A>@"-N/B+F]%:%8"F^1\TJ;HTW
M&KA#?&+33%WUK?/^:Y]2)ZHLH;(ST,=#X]*.0WS991C^G(UT@G+LJQJ-O.OC
M&M-6(JS?'-EU:"!:OV7>84.*$70M^D"-$*S4A)LIA0::[S<E-#J?NV,48V6(
M44P,)KN[WQ3UD0!^"/QLYD4TK4+(!U[%V-26E1,)2\?RD31/@8[8S^QTS.VR
M38;J!CZ(1;BN*)9RW:2N$"YS]$<)]><)F\^OZ.8CK;&S$?Y4D8)/BRH="!02
M7L\7)C=)EQ.Q/P,T9U+2 D%*Q_OD[3HH(@0:R-CY,#_HTCTR*'#B&BLGW]?S
MIJ?)E]*$IP@3QD>LE\Y6T$!YGQ1C_JIRPQX3\:Z0Z+O*1"%X:_?BDVG.X0BB
MN\@3!.;F@A#JYI[9J<[=4WQ+X)JA,:7$;-2VQ<?G6_GT)^/II68%L\$9-CDV
M)TM+JI\-6H/68X9N^4LQLI9:)Z !0K_''D[7'=&LS;""P7/O9*9GY6E2O</V
MSK_E*0\F5_UH:EH0Q6N(1E/(^R,/9V56E^UW]#\OKY=@+%<?Q6C/?P)1GK&S
MB_KKP@HC#4QF?.!V'^*5;$15D:T)%]PBVMV*?I.00] IKT!D'3N%*$HL)<[D
MO['WGE%-==VB\$905(2(2"]!04"J-.D$1+HT44!*4!$1$) >:N@H+0("2@M*
M59I(E=X1D%XB12"$7A-J@)!\>.X[SGF>][OO.<\[QKVGW.&/_6./S)FUYEQK
MUKW6G.OR LY.W"+[3VZ%+ZD)--5RS;KC90KM_.EQM^FR0TJ9UXJY=+JZ8(02
MQ/LS 9+$*P2A03?V4Y9T,-V;@^X*?'X93%D.1?G=[KRIKIM1QAEX2&L<#-F8
M:#K>KC@D^56$A8V(<SE+T#BV[Y7WPRE.M,E>0X41F-F20_9?5(X7^7XI::(1
MZ^"M%Q.?6+6@;+P?Z\]H>A ,3&H9(M!]^(4 &608!WV_O.9,M.M]U/.,VF%'
MQ]PCU;9O%W /;8+\-\U'^YI%:*D%9AJ'=S\FRVDS7S.9TL4%W6!$Q2D5.AC/
M$,/S[)*D//;'$Y&G,8PU9:55UR]_]XZ3>_KUP9H@P6960QZ<_6$"S]4"LU^^
MC'Z:X.+!H/#"-9Z(V\F@[@MG4=A\N1N)> GE?!D965*J7>D"'\B8>T*^ OFX
M"8WWLV%X_\C91OJ[8?M U1X7?7@.?KK9N+(S:WE\/B2)ZJAJ)D9Y(DK$"F^L
MJ<2AB56_5U41:8;UPXAK9YI_?EG2M]')Q7R(&*USK#5K 2^!RY O"Q]#:JK+
MQ>K]_%4Z%NS'G_W5C UYRC_, DF0@'^0.3I1.MW%R"7A7#W5RT8J?S41=7ZN
MGL?>,YT#[Y=O=Y.B<%"-0882R\#I2!"W<'B('[2X)$*YHMYZAU'KF5;/,28]
M$#[>*[JIQ ''+J(MPT3D67/M#GN"5KS#WE_\FF@?_K0=]QKHE:9<3>X.UT&@
M<]OK>+7ZA;DM!,SNZ#SN-5'S K;CAY]XKO98X>D,\ D.6;6*=$-3JRW=-6MZ
MGTX;D4.:7<3$TV5=C>4IO>,)][T(OI6O824HZRC##!-Z7=@=SW:E=50=X+/[
MJURGPNQUPS82P"$!!WV;6),PT9DKB4VP?7&6:'M@7##=*U2V^FXBRT <V4@'
MA6"[&9',M>XPC#"B1-M%25B=V TM+GY@;@<%#PLZ<$A4557",FW)^)F"R*37
ME3BN8,/1BV&$1^C('GOHT.GOV]!O%P\&.0V:&L?57:$)C["(QL.G[QW@MA_.
M;CAD/W@,+]/RJ$X-#OHA'S'K!@F:X@I6L1#>;Q<?,^VX EO?F5&:]"YE"]*<
M_=3R$8:<(0&1@A+'3H9)1MC>C*-+L^:)KZHZ.V4HGCBGTBIQK.O_[!2\:=A]
MP?_)1U8QWOVW-)2+A@9*8 5\:9,B[V@M5SZLLH,EGBK2Q_!:^CNRUA>7U*?8
M*8?B5V#%.GB5DVU3>HL$% F=:+]R/9PA41/^$KXZ3 )$]0E72$#<@_=P%-W)
M;RS G%O=U8[6$_[)Z]=?*8W!FIBI523N:[&?NMAPP[!I%8FG-\';7'HV?:G6
M.<ND."'3[%O<U>"C*B1;X/+T5E%QFR6-6\-E.]&5H(U]G>$!^4Q/*^$.-^*J
M-XIZEOTF&%0 H?%E7$@S?N D=;<F(?+;:V3M]RD,)'PT0&@B#%^* WY*3Z.I
MSUB47.>UGF]7W*\"=W/DU,&9F.A;ETTW PG4-O9H6'D-JV?%*7'6+BE&WKB.
M#.ZY5-2SF#BU+VI=2XWTUC(4'#/]E(AG*-#,)J(Z\57\'N@B[_CC.]@O,Q5*
MZP/A\]".$S5I<AP^VQ>PR]2 4FA64EXN^T9)[/TG9/%?GF(I_-")S0]%'H=<
M(;HOTR^0 !;XG/ZONI\AD-[R3,)MWI*E$W6/6V<\"CZXE\#^KRF^)S?^ZD>>
M8@:\,PFXANJ ;""/J>W'[5,'"'19S])YAPG*MGN(2CLNNLWXZ\,<9Z27E=C9
M816A)( 7,@LZW+$\IJ?WT7'UJ#\[*"3OX#G[K7[@.-<=G,3SY'CJYB=LU8Z!
M$HL_YXDA=KIWHDYDX#ODYI2-X .>BR0 -3S=6\>_,2XW(;-NW9<DX<"Z+BW-
M10E.LX89-U=[!I?='W1KD%OKYM*07YP<4_!JS ")XJ^3 "Y$3,/J<<..%2J#
MH#IP#<?8<FQS)Y"JC_OTK.I*;X@LHC6/7B3L9/HP,X/AS;+-,J_Q-SD/"&-2
MU*WQC1UL\1;L@%='4S'=V,H4^9>A<1/,L,2,PV*E4!@3KVW3(H5_QBBX W)1
MQ2=[#"]UQ_WK2#G5VVX5\'<#,HST<CRBD66)H(KU;#XDYHTG9[>G^8X)";U)
M-WD*:563/8JZ/WV6< .[&%R4O-?%["AYQIPU/VD*H^#\XVF S&;D'M<=/%@H
MP&5VS.'1I)IX>;_-3E%W(WR+<\ER=QY,##:JU4/G@QB6#)\=(E/V'CQX4)L[
M/G;W["+'AZ)ET^<LB@GVN::;6T*9)IE3+AZ!@?%*'(9HQ(&,'CW\ASQ<VMX&
MDTN(ZR8!A^N,Q!"!W"_8IPF/, *;EUOV$.NL/VK?>6J^F=C:,7?>IUPU\M5#
MIT':JMFJU7(7_1+5C)RN[57<FW-58JKG.!%4B#4)>'BR(3ZL]I$ &^1E$^%@
M=_1$9&C$NC +C$&MXVT4<,451>&V7_RH;,!!L%:!XQ7CNSV-=>+WFA2A4L>I
M^JHB-;W@^LOQ+?I+07+9,5-/DZEB138SGZZ&=>A27B;3QAA'%)05D_]<%I"M
MS_[(%\1T<1ZK,?F#O:0#HV^)YUD_&74>N]$1=RA _U;MS+DW8'&;Q39;F.O,
M8I@\Y!.UKK+S1\OK79K>1\T<K1?<]V6*E3- $+S*;*20:Z.WW^=D[OH2O=(^
MLH?,6E@:V1G$JGE'![4C.Y1:O$G6K+ WU\^359,-+AI]QCG5C3OU^+1;-0EH
M*J9:3<Y<<1;J38$12L<T/XMN.,<TW#%*"E%DQKLVN=9-(2GB+677[4]6E+#;
MD?.,/ $_@LZ)1Z=%WD:\D+!YE4HCI<9H18=_7$8012/"ZGGZ'=P%J$&:L=Q1
M3A;!+C=EC-A?%JO&223S1MPSCFXR,F*^ -)7]4K/Q(HTHSQ++1[HP',D.A9C
M1I_SR 6(-NYE4)23@% K*\R1!;GN@!"KJ<H"=V+%42(CVU;+>Z:^\L<$FQ.Y
MVFR$[Q*1AY("#5A$RS0(QJ=Q>#^?]1TL;L5CF@MT9P^LA6R%GAV4-_ADZQWS
M?@\!N?-&VVE>L\SQ FMLC->I "G'!DPO_'!ANJLV?\_OY \A=T\42S )N (M
MO7J.ZXECU%GI I%S>(@V]BE2,C%A\4!<ZZF3K,ZB,T$AC[RG7HP$?#N> 1\2
M2,!X[.AT1\/!M23+W6T0,=3"^&4M;18L\_Y@.;O*.H?_.]YWOP:VX=P2[>/G
M[XOP%<F%M=SVX[JW7=^U4>2;-#YF&-M+#3SVO8'30;STI<WU\KR^5V-RE^KM
M@\]+7:+?Y&<PG"AJG,W=X#:B*'8Z:.=CR/XY#][J9_6/0&PV;"^R7^T0[(M0
MQ(LP3_-TJC=Q6^T;?'%T"@4U=R(RR3W94CT+(90$:>QBD&=G]GBI!83:56::
M1X%L3?$-63O!;:A(J* 6,FO_C.51YI3 =TII\X\41];.2.^=GUP60^5U/-1:
M[1O,#@M*Z(2.[@[.0UICX4*'S4+K\NHPF8P$K5H7X?E'2ZI>::A&R_/=+IOV
MKA\?*%]7M*X5)T2!'-7U>@-$G8IG<=,=/5<5A)4E8P)9Y5&B0=T-W E]NE7,
MA\-(!LA</D'Q?UU,VG$QSL%;-9M*!>\,666:GK6R^OHCK>]*NUA'G3'J%T\1
M%H/ND9ME?OG:KS6=YCO+79AN3(KV<>I3TAZIP#OE(XD-A@<LY3@IE11S/'^D
M8]3V@XDFC[PZ#=6#AFN"\/-KM69H=O'V9*WEZF+DGOMK+?FD<1<%K)_]XZEQ
M.7OI0GVZRP8OAZ7DR6*>D2?BG6?S070P 9VJ,)C_P&4J^M8K85;N3#+L2M+?
M]B0F^EY6FRM*EV'34L4MIWO%N<Q>WR5#+<KL+&X5.%C.A(>Z4ZN9K=ZL'5R,
MEPM-K3%,KV+"* 9'+,E?P6ZW3)V[I)CPO'W!X)7P4X>M&SM]CW8R:#Y5P2.3
MV4X$LL7A[A2%33H]X]G(D0BVV(.G-2?.Z3<BVY(E3:TQFHHU9$"BLB[B6LR*
MS&5F!B49W@8%5R-)$T7Z9XH\0SO&_<^SAS=2O6SM';E%4Z-K/L-ZH*-$*IB9
M\?#<L -Q),="<S_Z3<KE],63^8QDHT5"IUBQ?@-UI4%FD5NB>_FY4ZNKE9\S
M:+X<=K&KZWXM27,]W:I#%7@\R@1Y7_S6K%4V)FW&;#KL^@*[V9'YV(<8K&@G
M^8_/A.3ZG**[\' H^"NNUE\XCEDWEYGB44>BR84S C%5^VM\Y%8MX[=-0>%N
MQ_P7WPL]-"$:!&BP(5OG4!&*T>@Z,*:^Q&:VF]7K^6[(D6H42F7_L9H,5_H[
MN3 _I=UB_P+P9;S<;5Q,NN!NBBB?^8%+<3>W^HA9.?#(+OT"WB'3-MY.ZI G
MEKJ SR+MM8M"G<X#/-P=[:?2XCH-,[QS=/K-EQON6_)U&V?$-Y>3%Q_BSZ'=
MTL5=O3Y9F*E')PY.^@:S5[$KOBW6_C*T+O%348!*P*VR_-5-]<M69*J %VAM
M_L0)^9>+=--'?(7@<4:BY@<XBF!Y2(6R08,HEA7/EE25#2H.S.OQ)A-]4WK7
MK&).Z\SVG;--%Q\(2_IT0 *>7BJ8_NI76'6*4EHQ)T!X+&B*/5#=\%D&?)I^
MKJ%T_F<9"[3.6A"7/6CI^.Q=P',KYHYA6F@/A8"3T^5S:;$9JIV+P.,J'<N9
MQ9!R/U][H=-MA:B41<A8]GC10:\&Y\SB8,!->4N,#ETS_%&P^0/YM%MZU\RZ
MJ9GFR!L4 $J(DCUY*X3*'VPW[H9"V-@_E/\RNS% ^)QJXT$V[N=M_&@61+T,
MY1L$WQE9-YK]^949'5LCEMY>18&G1*>URTA20[7O! E%]W5!M(#(&9[\CY8P
M&X.RZG3M?#F!4OKLUG?=/+(7]MC SU'OI<*%X&A!1*MSMZ#QXQ_C7:\JGW2F
M1D_:<.XTT=MK#.P<4^I$Z@ZN<Y6716YT,&$FD88;=KO Y;'+M<\_S5.=(A>Y
MO\^<:Z#$#&7''B/#W$*&"BJ_;-IR)]YA3/@QG_:2G'NT\ _U7?]_":#OQ+,G
M.CD[CP3\T'6:*U].*(3/B@H%1? 5A/V5"G8OP)>(5UMFCNB'UIAY49MGNDVD
M%:$PFJG@H=$\7QEL6 HZ7KBR<&4O:>I:7;>YN4)S94+ZIUS(.V)"]BP\!,J$
M<ZSD*?YX7+E^ES_?R_"T.5E@.[45O$41QHLR) &-L22@M9\R3]G=R2V[<#'"
MFI*B'1T "66$X%:ECJ()^>E8IT )IU,3/Y4SCS.MA_([%SMKYTZ=D>8H'Y0]
M,4<*3!>?D7<TV, /&-P;CLZ!C\GL?ZRF8Q%!.\6G'YB/VT*>;17Q;"-[X[U^
M!DC/>!NK*-%O%K9-(5V?_[SVZC61,V++:6QEI@,=;:GY^K&]P-X49 IP6QVA
M]J&&'<>)!"A*084::9<5>2VPWV'WD#+\>A]E2$!]&^!S&E9_XG'S*F?"4>'$
M[FL^JJY)BN<&A6L='&8[%4]\7B?&-V_C:=>;V(H@XPI+Y-X+"U0"#QP=K34>
MOM+NY$KE#QR.AS+"_4D ,T%_M,6 !1ZTLPRX;)V=VE!> BVG!Z?GU"$M^]<(
MFN]_/MLGVHPYOA%,-W-X?@I$N2+0!T$CY>E6/Y* &0T2,/N,O%]BK$Q(N'E:
M=VCC^?N*T-O.JFSY 0J4$L<^K2R686X?)16@ZT*%%T.%&^,TEP"V^#6!@$H\
MY4R-_=M<Q)&VKRZ[JXOH:Q=(6(T>/5Y;&Y?^TBWM ?>-<PSWGTW;<T4%*!]>
M@K  @U^&'=QUQ 2.96$;#@LZ.(WH!'C'JCEE6*UG%G[B[K"OW*S%U<&^NZ5O
M\LJKK5]KD<T5H8>]75<M>H,_F."=5,H')7Z<.,?&SQ^E\,9I<A_&:1+L4W!.
MS0T7\.U+T*F)3B<_!/Z@W"%J*J6JJ6-1B0ERR;V.O(EXOGK 3<Y'HUQ(1R>[
MKO#U?7A*T ]+);C8:7<BT/\$BPHL2^-_<;KU1K P):YD4AV=ZD\?B78*)C)@
M*S(DSSY*WMI]<=>L E324)O)1#E5LP)L3[^:XJ\IJ:S U@?X]M':\W:%&A>(
MLH6]/O1LVN,M=YU2P&[A&6=4VQ.R*\S+[#UEHPM%G[+^.(:!M78$P&=LC:""
MM;B;CL*2VMEC"^::M;>1/Z.LYMDI24#!:'UVSM@JBT,[$GZJS_Y%*'=T]8T,
M$!T^'CU-LPP^*U&HKE5>7E$76C@^NG#A'/O+;M^61-YXO''%\I:V<(H]-PE8
M3;]\XL;! I&C50*@H"GF+_45R9KE MT^ZM,.-JXN4"8$E''5PC/"_<CR LSN
MR*CZ]56S5JT@M0>_.@=\E<X B6"U*HIQ)*#-^Y-O_[B:0XO;7 +XZ'KQLY.X
M41S]<0=!I9V_(DH_(OE*9[BM?J_9)>/0G1=7K/&7JR?0./VJG7+L0ZS-(M[K
M"[?<TG.#'.Z!OP\1.>&=$%3#:I?>_!V\^TGPOZ]RXK\\(O38DP#A>GA&=9K"
M7\U"_\L!EB[X,U;M;F2XW5XW5QOUH#R:3-J<-G[M'/W*<.?C&!B4.?/!57?^
MI98K@2MG,RY SJT>"I>@\ZFB^3=^%K:>_2#Y\ *,:=RXA"-A'LD@*2#DTY%.
M-UAV/0YC6EES86LBK9U[4IK;[US'<V-5/RQCT[[Q%_,)UE7VQ;?K"\UDDQ>"
ME CVF2<^M!,U3&C*0;@G>3F,NG6]7DF!;!VO3VDV_BO[SH@]QZ+>@6!:CA+=
MR][.[&,&PC91FZA\6!!Q4QM[O'L<G5'SM2(T6^,<U_?&3B &7RR!1SA.T>%#
M,V '5Y]^H7BP<DW-X_HW&K_/<#WOW;SL&-C=9VE0*?VN%1<FCA 68%Z>$K,N
MUWYX'LK5Y@0+*6Q['R]$V\?NQ1FSNXADE91SHK-+9@PN<Q'>M?*XYLSX_2J%
M%07BL>;.J>J?/C,-(;L_=1TTU-VMW$6[4V0\KLO,K7<8KIM.T>(=T,6G:_2R
MQTHM/H\[VCAL6?5S!&,SJ OM+8;D13(KWN=/4?F8?,Y1[Q3T!H Y9+;9T"Z5
MCE$SZRI52%5YFF<'/UL8_;O9AG/+_F(#,4GYW&'4LZK/D/8"-#,C=92WOV 7
M(NVSEK]UVC]/T1=_@G3Q>T9./GL2C)* 7W'^1^+C]_^6'.(E ;<DA^R3)8M?
MNFG7\1Q]/Y(<]'+Q<B@O6;.M/A-N@ZZC06E\WE;L?IYMM<WJ:L6]!6<!^G"5
MD0[RS.B/N]IQ+'J['OTQ7[K4NS(/D _M$[#&89+LH.;#CE?EEE.PS'M!VN^8
MDQ;"YZ]9<;S%<&'7+:#E,ST"K2P;:9]6X,_2RK:KJ:QX-U06Y2*LXH>VZ/MW
MF23(T& 000I=9SB3GINWXI$8#[U3*69AH446RZSM((<0B %A-BTZFGQ24I"A
MR=H6HH_3'ZM]=_&@Y(2'H^]O^I_'/U[9FS7)&2X4<K3\GMXU-5<@)E5-A*=Y
M>AAYR'+$TV>7.4^8C*N6&TO?4U* %P)>X%9KV;[VS=/+HM333Z\N*$'"J4\"
M)Q]5+U#+A.$L"7AYN(G@B2J/D!J3Z'!$PP0A-,2%.N^_?,+O7YYM>#1DB^]7
MC9-;X$5H+-0)ETM4I8(<G54AK)I"6F_Y<+SZMR-@!A,DH*/,<@,T?]=(Y?RV
MR!EXYV-<Y=%G$F"Z,X[3!C,M35W"E\X>[-IF1_.*MJ>;WSD0Z%S>I2_G'H^S
M:# 0'U\J5CC12",SQ0>$$]^]49T$G(>@W6$"1+AP _;7%[.D_]4H[]:'VGTB
MHW%0P^+6*@D@ Q/X_A[M;\W[Z.D7&[#5M?0D ))DB3]Q:=#J!.'BT_"^>13Q
M% 1O\+=>@GG_T;A_Z^$7JNJU^2=\$D"5WV2Y?7"BN (0Q,M_ZRG(+] '_S,Z
MW@)ZG@0@NXL)%'#LW[H<OC> ^OP=/KQY!6M,(%K 9[A.YO.WYH+G([:G_XS_
M9]+_UNOPGG'ZR4A_Q ?_'>6_>?>;=[]Y]S^0=Q$-%/"YN\/P-5ZI+=.=+BPR
M#$[K*X-V OT<6TFBRQJ<ZA0+"4Q]SFGU6B': _GG?S URI:Z.4@Q\A?XW_=[
M?_S/W!__!._4!2_V5?9&R-Q,+=JEI!Q^6@7^O81_MX3W7)7IFY\G<\>*IQ5E
M1!$E&_\:[0!9P(W3_YWI^N^^-?\K>#?UCR^KM)UXJGTANXAS=M7NV2/=YN83
M\LYA%>ZG7V+BI'/PD-F&4 G+L\O)#O,C79,3S9>4*GH;P7ELH^E=_KVC*XS&
M"A[_/A\%(+_7^+=\",<0-3*3Q=GRBJ)'3)Z FU-?EF3<UO^4>:),3O]J%_X_
MFC;$K2QKX[L%Y->9.*."?K59_P_G";]LT,04PS<HP4Y_&8"<]_L?O[R_1>-_
MP[O[?SY\DO/W!&'JN0AJV,4("2I[=N%9+U[M;]E7UL?.]'O-10PF7/^8TW^S
MP,?O7\^GJ-HU%5YYU-^>Y7]?R/6"0+<OKX.3*RZX/5^>5NM4LU(L^</M56@V
MU'JF[T 0>I,$>(!738?PULN'[\7[&[Z4;1Y@RTE @\ )2=:VT]MH>Q+@;TS@
M_TF?]J,+.6;J2?AU:6 ZX1>?_P!,[Q@AW/CQ."$7WA=:?'Q@B<T\$M ](9O*
M\FBK 6VT]&'M_&_DW\B_D?\[(8,$\2+6MLYH'>7<\B CEC>-C%&7SC#&J'JK
M[QFED0!%AH;]>7AS[='?75QW&A<5BOAWQ^U:L]9;*Y0C^@K!-[M^F8(_ 5>J
M,CZ\1^P::EAL1A$)Q7B#/\PQW\W X_1OW-^XOW'_K^.Z0.6'"AYC&;YR>QA]
M6[6Y<J&$CPN1K8X]TBU):F01C'M@5E/^^5KR->XMOT^;K: #WL/]8R]-PD<D
M3<-<^A)\=PWRKM#Q..F[A4[?OS>0M8=8[A_U">*/P&8?(C_S_]'1X/L#0?>K
M^6I._<;]C?L;]S\55Z"7*#IF:H;7'<@H#^*1#>%R42-K]POU]ON[XA>5ZQ?3
M.SZ8_>LWSGL>_W9>_F5S;7<3<LNDUH&X!AFMN_G'M_)<;/?0[BV;G %5^M?-
M_^B A$T'D3>E:>I"'4IH/;,J<;*=XJXHL.$.S5PUIT>T.KU*3HB2JO 'PLQL
M^^5=J&*8]50ZBX(QX80X"\OC)<B.B]%F2\,!KS?EL9<Z(8_\U6?\@'.NW<=<
M_$1+)0OSZU#M*(8H[\48Y!U401N_SB5MNO#H8;$OJ4&@6P*L;5,L7W V8<42
M^3]B0V(KWZR)/8X'"R!>V(?ASQ5:V'&<0]ZI?3QH:\QSFC=/Y1LX\"?^<8""
M4<16'RW^J-6[.+)(GG=&F^])=3EX.6F?2[31C])183M^_(L[F)9@B*5,^(B/
M/X*8#@0'NHR^I/] L8LV!M\]NQ"@D!/14XXJ.VJ@R:ECF\:)^,#+#J)$0]IU
M[;O6"&8X\"QKC^<,_GF9'XO,>557[YID7[_[#<H==_HI2PV@JIGX_;9T)IQU
M9;@_IUECIZ_'N-W-CR%/>P'I1BXLQ1.C_3820+^23H-U8TF,%72>E%Q[42K_
MJ'VP2(_R>$")_9A^[N(JDL[7&;R7% IMT1CHZ*:H+"%NK9(G-1DU\DK/W.\[
M"]MN-8(*65+"5L;Y=J\GN:>M<5(@/W:P><P$R#Z, '9E^0I +'KYIC"5N[4#
M/";E5,^B!A*5FH*VE"F\GP9(+149HCLBD.V*Y[Z,Y(X+QRQMG(H"B>J"V$N;
M"/:4'43Q48E-%IAK"P<XD;NZ(<FO$];B@)#>' KHP&: -#]\;6"#-0\U<; D
MW:]6>[?%%40O+?;-&_2H7>?%#4U<OGF9A>FX Y=VA.HT?4A)-'Y%/(&;;D,=
MK<319D[=6XEY@B^A2:*)BT8',PFYEAY')?Y,/^LHNKZI3Y##!_L43T-AGJU&
MEH]QU.%B'XH8[K,YDE<:K'^[FEF-2RQA[# #G^<NH>8W4Q'(391BV/I9OP_-
MT*?,,H!:XRP[O)%!FV7D-E>SR[_W[&5<I>D-9A/VINNY6P-A=K_G9ZB;I#DD
M])8Q7/>U0'=EWH4VC4GU*@(?^6A>,01OB3E",HU!Q^Q&/TR8#CW9*HJ]%_"S
M-*:#,TC!OI_O5%AE@2D>KEHS4EQYG#PJSIUNNO'<Y_S3P*('^*3;%2,[)$!\
MK9+?%"+J44'&%?NKR<.'Z38QF-&>CO!6NQ"]$.OZ@%96-R_71EIN954!,G@O
M75:6(53.3O8AMK?]ZN25[:[YJM[I39]^RONSFQP6>-<.#I;^*U_"GI5[W>=.
MF Q#"#,&R.X6;=2*8!0SJO5:^T[;B5R.*RQ]=<<YJG16Z85"C]W/XO::">,1
M(4>WE,O6VUQ#IP2T,O/N/CC[$[$7?L+\!M472*I:3TBTFWWV<(:VGVFS)<^*
M! 7YT@\%65J$OGWLJ/\U_*>A6?]*M!__J-SRK0Z.-*=Y@'[,X-W/ZIE3[;^D
M8K869(7I-LOOE+?^.&;1P6V[YU8!>#G$UTC?7T>8SA?+>\V2 &9\Q)$Z'NYD
M3YT6>>"ZDF3%;R9] .-B=V[B99X-4/".P$7V,1)NXUU=G=PQDB4C._;AM'5M
MR:'/SAWR[RW&]N45:^!XRO;2R4<D>\3NB3 @K_74ACQY<L5:^D1]^$?@(-3X
MAEEUA+S,<R+XZ'1^6T+-<!&&#'H'&7OYU(TSDZF>>07UO/BA%N^1Q5!?[>RB
MW"(-8 CZ\Y;@]PYR:>#YBFN VEG%1@Z,*JRH$HY+:F%QJSZ>7XCVM#EU$#^N
MRG3 V( -<EYKKU-I]N>,;%-D&-K-B^]F-#CS;#LMNA_Q79]2 7O44>DO-B*O
M8NMJ1?UEV;! 8^ KCY)V5.K.4?!VT4;],RQ/3?$#6'S;."2T(,[/1K^N2_LF
MA1$N4[-:K>\NE3!E@W\":B6YKZWXE%FTC7G2G=&=O&]'=SR^T6>:Q[C0:AQN
M*3PC'^<KZ"&W*,7Q!-L6F)3<1(F&LU87YRG.S!F_[<'T,<,P%G5#M61.M@ZY
M8YKSW1]_1C>E3 2)+MW0E3EA<M@)DY',>!* [MDM2)<R$S)6JWZMYK@V?#VP
M/M!8WC5(9LU^=,-=V\R!0\<@ZZ<M&X_+:J_^A3G_RV0N$;AH<"N8CG@E*[DA
M?,.MATYMVU3Z=.MC]=<TA'R;'?J&&>1EV%=Y8W<TA,DD*\E 95$E;T+MMDN1
MS\Q#&THVFI#' 4+VXXO1A?[<R]X>25E9]>"$>Y/FE_O,-[IMYCO IIOY/;7:
M&"$K'7P#NH_&3/O2,NKCN_YV*JFIS6$W^O<X\0Y7O+C.EW"=,D;O]MSK8;T\
M8&$U,;WB*0 $MP,VGA5S?JW$CSS*33,H=^"8_V IN8.?,?],?DWYAYCWCM/[
M(A+0Y,^5U 9E*!NQ*4GL\B)[\#!68[QQ!J.@G@VX_9\O"7=9GY(* [X$F] 8
MO3O=4D^G8_2MN0AUQJ+*14,@ZA" LRPVH&7P'TG [0T(X2P)6$45HNAQ>FT-
MV)=X_H79,VW'J$.%#S$U$_CP_B?$>V3OL-.S/,48(1OCH7(%#E:&H0!C40US
MITGEN]X>:_:# B_Q]]%@_.U:>J<+R]&W-H]YUA$6/0-Z_<Z[/1X[0%17Q(.7
MY\]H*H1Z+0;(ZWW"HUIE%XHJ3\O+.4F-/7]\'N*M;LQ;?(<-7KYNBKQ<'MY/
M9+4W=A87+*2,9Q71-P_I0\?9@4.2;?:,6Z@9N"I]2YA_Q,QW/CJD56(O?P&G
M\^=JFZ&^^:/%,<D[86*6U>/QF8']MYA*Y5W),3O3Z*+8'/,5J2\O"PLS;9^X
MCBGU+4(9<Y?WH>*#OO=Q7 ]>YOE<GQG,@+ASG5=^[KW+O#OIQT<^HL@!*X*S
MP&Y1VRV,RME>B^WO8+T$&,;D5'_:M@R$;&D+-JS6-AS2>]\'U.4')I2YMZ4U
M,N]NK,'TSVA*SCG@#%N)?"/"0@1*='GMY\ *R=U._H*IS-= N_1JCW=.?H[9
MJNS]WA3W!;_T!7&V=+,$A]RBL\L/#G53WN-Y58)U*N)8!;BMY@\& ^-T]7@_
M9M (M" ONTO@;BNRX'(B)"*/ A1[Q"Y9)=1!P/K>.&APT2K#%+B_V-VG]H A
M5J* \6.'DD)G8S$[/B%O'+_83F3I)XAS>Z)&/7G,(M]J/@ET$:.BD;OD)PK-
MQ*2=MZ2#<1D-S#B43C;>]L4(G[5FWN$FP_=3IL.;O^-ZBL-G<7Z;86OJX4_X
MVR7>U>Z^2B$C 1P-+XM-RX>%BB6JW/GF3HV:W$9/!%R,FCMTAK*ZSUIHW\/;
M.V$/01?L5F=!I6V/5[E9']^_0\Y#V&G\=:5!7D=H?:0B$INKDEK>8J9673BX
M/7<+F(2 YP.G N1 IV&#1^W>Z;G.#KD=C.&%DVWV'JT'232RKV5/LQ&MIC+Q
M:?GV_FS]CU [7D1MYH2B]7?DYSYPD^]PC5:G,:I]P1(1#MG+V *CT27:>S3U
M64?QG3FKA[[>E>'E[(KW:)(8-CF&-G+!A8!FEEWB^&BL[<?QFZL^>8DFG3M7
MBU#Q!&"8&]F(DG7[KFV+*CY+^5G:J9L;5?"79.Y?94\*1T[4)-:1 .A=.+]-
M2_$!;S7XV >T8$L"+D+FD*O3N_.\6SF^LB0@SN<]"4!])CXM)P%)EI!^"]WT
MOWIOX%]ZQK6?*-19:F3@VHRRXWYU]MB$O0WS0>IA.KY7L7S,.'(91P*:=8XT
M5B[]Y,&[:3\L$;@0^OS"C9WY5QGG>/&A.!&-4N*/D5IZT-Y#YCCIU(-8D7T$
M-Z+5. =FU9H,CW2C\K/2<>F_<^-^_=:-E=Q)HX(2[@'YNWQ/W/F[O"^>F,WB
MX"ME>LSXCN:\^4('1_D?RA W1ZX#^K[! (4/L>\,J$3)[CV)_W$7Q8L3,?&C
M0D^5^M#1IWP3;6\IE>H"K2HQ$4_C;N9C()=7D^/,F0ARMKQC!;/WP77.^ZGI
M59OXT5\=R.QS\*PJLM'$96Z/K9G**,(V)&.'(^=+/<@V^ [^498(:ZY:U7-X
MF2;1I$BEG19$Y]_OSS8@;.B7$-HP?N>Y6,'DUV\[<OHG5H0?=C3[JH0XYD2A
M<IP*N)[!++QI]R1+)2)#/8EG<3E(3#2%G9'6@$;T_*19P]2K8U#>CN0@*@(F
M1H_M6#\]JW-^K&+,4GDOEFE&@+U(=(>F.4"A*-^.<:\:BG2&^XBUV#LQQSU@
MPGZBE'Q:F[D7,)Q;CKUP\Z)CS_'X[2.?O&ZK;:H#_=-R\%?U4K@G0^8PN>97
M/ FL"=HI%>/6';.4\\E+M=0XH5KU_$D8W&QP6@-5V&3E.+?^FB;;E>@G4(S=
MBS\3BOX)T:Y0U2A\J-%H$/5:!G+7!<ZR!8^Z&$W540_"J>9[>5*[",TWML]3
MN!.80P%OIRA?/:<9$D#U<]58M.S#Q5.WZRPZFQ&..E[;ONJXG%"GG%4H;[_@
M^_[-.=7OET03)R&W3B24?\6?'^:RW08EJ_DR]*9N5LQ<A<-Y@5YF A^%F:9?
MG.)&;?ISPUQUL/Y(]$]3JDU9<*6V,V42^V>]NFWP*F&)?$)$DLJ,^J:#VH)U
MS"A35#$7&Y!A(]F#![69(J,$B\H?[/Q8VZE\4QC,P*/Y^I+4YR5(AV0'+.=!
MK<]LBF5X];WO;G[RW,D]X_#20<&=/O*3/>R&*A@W-?OQH,76]KR*TWF*& FF
M\YD9E\F:"9HXCL*9KSMI_N>^)]^HNFC'4&]B55XMF][ZD"A=M'4NLRI(!OT"
MI_%^(/S6V6^2/02UP2$3O&?1N)@CY(G7/<_)8%A'O5$)D<H.\<E7>/![<;WV
MX[WOFFL%'H@FK0A@Y[_H /"?7D>1+2)Z(^?24_Z]4@_RV_\@OLT7P+"'+F1C
M&^Z5?2Y/7YD?9R]19O9\KA4R0^-]'NTK@^-JJP:%2QQS$V1&>6Z^+H#:)/!O
M=/@^/W'9JO<V6%E9(VO>4;Q09M7DJE35%]/Q$FF\G:A'@P\VIA4KW,C89$$^
M2H=L%MRGUO?5P.=$9FMG@:B7+B78A[U%BJE^D^;<\G9KY"A?K>?H?^XK_MYT
MF<7-6J@PWFXQGV/-K[,S X0DLDX1E R+)V%6NI^K'[B?.;J3A @'+7>RN5HX
M%DPS[:9Q;-_Y.B#QB'I8B"KAM<V%&\Z).5/+4SQX"XR"MNF Q#MW!,U*G%?I
MN-E<)]4N-P#ZN$AA5:RE8SCK&>EK;%>M%R)__>,#J#EUL9=;BA'M-$44^88>
M.AE & R63Y\G]DJ-/\TJ2(JU9N).J;@]2(.I *WJPQ3W9^L:@LM>[O@QJOM)
MF[ZOM&4[\X2+$YGR<16:"0YW= >3P1_B@[!3%GK/'GVM.G_&)"9SR7FWS2LF
M=-:2@2!02@)"?*#8GPN%N68E#$FC2I]_Z &I_DHS,6_(C-O&06U(YO&QB146
MW7>7QB>I7DZ=>W/CT89F81^B:Q5;W_044LN(#>\K3CS(6R=H8C;!^,3N([!N
M#78CU)[/Y]6&(>C&3@M9NAR-S-P(<IS3!MUVLDWRWE@>4KPA6Y8]I0H.EV@-
M=HJKB*68&')LBO)Y7%N*,16$\F(E>QJZ_8X_T#[0977<:3Q\@NQ]EX6?:(6
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M4AIV.Q:Y_7:RS]F/%B&2(*>TV47642Q=K(^#YG.$HQ6,[R;L"3+T-F(@-V]
M[O*1=Q.!(,NV.+(WLF'DWL<K>Q';(H&F\M5.+2.U5=%Q?EJ>U3(RD[FABF.G
MZF[^4S<P_]/Z+!0S8PN0#X\_$ P=Q"GLOY&WGSUJ/"UO7&K\AG 2%5?(J_PJ
M)OBB8+P\AL'>?YMS;[.),Z9*7I\RWSC:5^+-"IBYUCWO]M?*GW.;[%*4[1#<
MD($%P0074YA3_RX+!C*L'+6VY.NY*I5$1=M](6_WV^0+Z56+I.9I"DA0K9A5
MK<-A]NK!?G0JND;8!X,:3@8V!'J(LN&0\^74[V9--#MR<-!8\TV$Q%,4@;K
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M;N/:S]65Q.;AOM31D(O8GI4JIJ:BJ7]0]/45KB%HT]?VT]+>/J.^.OI(LW[
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MS>XT8A"ZW0XB_0;-54\W0"[(I@7F#US)R*W;Z@K3?--%U_QD?=6J$K7]D_?
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M+$GTO+@J_^A77=I-Z1]!C%4U3;CV!?6&VO"'I1=(;YV+^U*;ZW+[!'Y7TIK
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MAD.H&>L[LA3^YC2#M:-<*VU[!PO@&, $YP9&_X1N$QIE"=&53I5,.'<B<&4
M =L?@>_9^>L"'ED7I.+HUZTNI=!?G$G759$WU%=2F8F]3KG+BRV=NC82H#C?
MI%'5:#SBZGH3\70SX8>-XJLC3XM*!/CGE50BL#\I?D)U3PR^. W?LK0^N2A(
M5MR$189M/$MW-5PVKXGM7U:YE1^W?>VI=VQAEO/''&B5&O9Z[Y18,<3WQ\E^
M3*O=H9 OHL77I_W4'%EI1(242\=XCRH;^IQC..LAFW>! F6LS_I%+W M-3I
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M4P6.2/-.J,JLZ58- DQPR17K;.B6+W%Y P<N.II/^-5X$U;;57YFT^N.JO!
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MK.G@.:M D6F,;]L:SJ5,7K&=(F%X& 2Z?8%R3GIW>8W8U80<P]887L>5:S-
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M^((/$S9\!EL]HYV)A^N1N_THX_Z0739P*_/5AOB/"HN34WGD\7$JDMQI"TG
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M^CX"XXNF=79MYGBB9AC<B?T\-G7N%"#Q 0_LUF[>B1IJ;M#+".TRYVO_[#2
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M4\HERP0S#=9-63=UGVDJ\+V!<<(SWY&\5/FEZTN[CZ8W<]_2X>)N? /FTNZ
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MZ%?3W4\FRIZU"<S>])M_0].PY%.F8.L-ZIBC=3C)_%KJLDYWQ?70$V"*@%6
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MJ*F\0=;-Y%DU'O"\_G/3P!/:;FO/UO;IE&A9PW=GY1INR/FL!9MDMN5^V>9
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M]L7=8$J<IWW+"=YIP#12/BK?T[J]MM;(,?=PACZXOE'@\K,$M5X$7O;GZG,
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M$6(2SWRP3>^Q#P?#S'<A;N"30]!%_+V[L7I"7#0ZK$SSJN,?;KXDV-THT<6
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M'/6 '   YX"I$V;R,(*@]P]02P,$%     @ &HA=6//&@V1+F0( FS # !$
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M)*5+A^[&#H-Y4%_\GN(5HC#^W"Q>/ORF(?7-H'.0538^6))!&3Q1[G3Q<T/
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M?'@$VDN7>,<04V.M@3/(V:;!J-+FWDQ\B:7>=0CSC3N&9(1"Y;<OD,Z=ID>
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M/ +L\#3;$WN225W7N!GS)V]2+ KQP:V!J&F0Z3OI^Z="D#A##GIRK)08M?;
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M*A[^22(TM/6>( [N@K:;/AA[[5E8V/9T1<R^Q':K^'8B&N:1T-8U34 EZ9E
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M%2>*+P\\>(/6P:MA,/(I,%/U;*L__7()ZB\^E.'@*19'I#W?-FOCF-EH[-%
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M86PPNW*^]>L'9UVQZ[-H8GJ[D$YVY^ ^SZ+^3KE>$D8\[#HS[S.;Y5:5?>Z
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M1\]P/)%8T++]DCOW:9 +)EHUS8L7#W\W@)L49K"01=GKW1(H*&/0;_87VOQ
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MMUZ[>##*>L;0!CR]JWH![[L04!M>R79O:C]+BU:FU17]?_M4-F62#Z4J+0%
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MHBR!_FR9)BLL>PCTB'*??V?69C'T2.7VWDANU"7]5@+X'@$0$-4>8[ZK2CU
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M5>$;*E+@E$[S23@ P Y@-:_,?3GF]LBN9X)6MP>!^0K+O QJ\B( ;HH3 !'
M?[+MC^3"$H'FFJ9L5YI:<SGJC/EH#\\X<"F)^ ?+6]WL9U097TDD ;#$AU6]
M(/<\N22S(@"8(?]H@G-%UU3_?/V/[PM\\\V9<^>9 *H%]PRD>45J)DT$@#\3
MHCOJG^W\GW+1Q]QTV 4\-SL? 9!>8D( M(6WH%3_V1Y;8^T]IP[%[5U21]$B
M?D^6(!:[3;&9_VAM.5-8>H<HP]VOTKUJ*&0#.MF"L1#!#?^3>207+ [NS&A6
MN)(5F5W 0ZGM!9Q8 O[]/YEG*1U_@_<W>'^#]S=X?X/W-WB=&;7( /?)I(0.
M-H[=RRVO@D2RF;6T1[M_$EL'V#4 E.T-'U8_#';]'Y\B^M\96&2407=!MMI2
MYZB4X?8UL;H#GSZ'8?O6**9I%<?8R;')+_^X$%)-(- /U<3;#?_A(DGECJT)
M_^T9?X?5W^#]#=[?X/T-WM_@_6^"9Q*(T369.*($#D'SH)ZI1[6C65]47=WV
M\VPW)/P<TS36-4&2Z>SO%)!*FLIT@Z+_?':R)!)_=1O.GI"6'1%7 B#3H+GS
M?[I4CT$PB?\9R @5&.'ZK]XM^7\RSJ"+-?@86X9MR&543,/6H@\IHH]GV*>"
M -@X%6@NH3:ED?S';^3]!Z<(R"\R("A4^X)ARRH=[)>7#)J*  "RTY_-$0!\
M!=W0L78$68@=K::RR^?_ZIG_WQT"P\W$!$#?,^1EF]-?#:8'H?]T@4P#\V=B
M?41+4]F#^W_J2P=W7XXZ90>]) #,O$HNF,>/N?_YRJ0_KB^^VYA6TR3Z_K]_
MON__:M!-S,$5)FQ!],T/XI]#2B5M[BEQ,HGNT#K6L.FY9ZW$+SII:1WKQ&PQ
M'!^_ KRKC3,/I_&M^TQT)-6R3 !<WVJ^<PX\3HDO.6ZZ-)V:2V:17I<C.F\/
MYDJM]_TYK$S;^N_S+DYN;;YKS[P]E".T/Q7@FVM#YC5X3?.3N+A31TN1U@1(
MPCT'5HWJ*!5MKH\THWT'T/CV](;CGX/>'><AIOSU*!F15V)\1>2&C\<E^4?(
M7W=#U;B,-\J+9<A0'!5;L1I:?TUD&BX_80]BG.>/A(KE%KY^IIUE+W&K2X/%
M,25_[]EKS5F*9Z&[A<W, UZ895,&<@/&8ZX84MWP_;RNIPMIC(N+%FERZY'T
M7]]E>[G\M0OXZ5\>NT#>^VM2?#;4@I1CP%G\4> @+?T],E2-5-/_8O:Q,?^-
MO;<.BK/9]D:'8"%8L. 0'((%=R:0X$$3W"VX#L[@">X$2- $"6[!W3T$A^#,
M#*XS6 :=R[OWD?V]^WS?/K?JWKKG5KU_=!75Q=/=:W6OW_JMGN=92VWEQ=;]
MXV9_KPYBT*(07E_ARQ+ J=K4JA=),,DCFS(1^%$XK1ROE-.AEXXVI2^'HV[B
M!W1*:26U($F@UCX-R$MS4V 9;S\8!V:_PT?@VJG[TZZ?S&DGD=MUC^,UBTIZ
M#,.PV]7%MS;WL"7D2+7_7NW18-$EW+/=8L1P3.1U<VMC5'1K3V;UBV$*FFT,
M'56<;_^PZ4600\H;&2@N+:O8%%;+1[8,&(-_2OQV/#9H]Z67KMD[36/3>$D2
MMC"A)L')P/0MG[ZH[U)5PP./K&!)@VQ"*65(!X,)+;99CZ685Q\3XYZM\]$J
M[&L5/4E1=^4OKFR8ALS5^J\/(%Z#]..D+)*U*IA\/\D_\UF*W53WVR@I8?NC
M5NOK!]&<WCTYI#.2EJ5*1;M5SBD*.%F??Y4>XI7]HG/O2;'CK'Y>7($/4FB&
MW]6""DTHQOIKG4#4UNH N,]Y95A/)[[G,?GN=WLJW_KX%68^K*:D=#< 22P'
M+&F,3;3PQVJPVYE.6N?7%:2+8?.42^R[K>5B$!&+VMOGW4^]&!O:V."G^HC4
MK-\&CFE1I,2^3MM#(TH#/CVY!C30= $_M.%).;(7_]W:+P%"<,,[)>&8\UP4
M0&'8^-P5B-FYD6+;J8\"G(%3UW2C>*,R[B76^C\;XG\V[/"[27H$ N)2L782
MW?:N/?,B$@5(2, -<$8!/FK#A/;,@>&O&N]!M>75OZZE/!XN*1  '3.RRP#)
MUEXZL;ZS* 4,^ *N9DP8)YQO!"J-[,C'2(RZ&WVCHDP_O\0CQK:0T-K2W=S#
M,B:;0ZI#YNIAG)3'@@O<Q!16)Y_&&;0, 8@/4I&5KV.)I=BU5.M: !\UY9[_
M1PU?SI;9>P,KO '6(70OZOAQICBH?@V\#;X%.&;W65F9>9]M9T;T4JT,Q"ZV
MB1O_R/ +MW2-2@70D Q^([#75JSWZ!E0)=6\-V8G'\M>D57N612@UN-W"-O)
MC\_9T958 D/8.0X.:DA0  BV#<]>.:]O[].\3'X=/-2T2.&$30E\?G:\J[5-
MEF]N&9/7*&D,:8#G1AX)AK=%'_217B;%NLK+*XA*+PA%J K.3OS]#/[A=/;O
M3\.V/B(^5^@H4RA9@?0;*\G0""C8GP.6L1&YV$<W2/HQQ8DGF.4_'DA^R-+2
M%+V*P<M52?38\QT;(-#37Q=^5_6E3:ET]_>3<(W7@?9FPN+K*$!.G;%)U[M)
MXXU<O,T$R"*R>N\"QA>E6B.+->6*=7-[E&5915E)\$U Z]?]R*7WL///0WN@
MT9(5EB&#="=,F&<]KF->LK,"A9Y3T[HZ"+^?GOV'@K'>!MZ]^IZ$$2"?&D];
MRY,YA2?CE!M,C]TOU[-H\/Q 8Z^_Y3?1<).5??.Q,9QSW&R=]AC-;&)D,8:H
M_GIJ0Y]4 A: Q!R3[:$ "VF$#XQ\G5AM+,I"8L^P<^R:60*\T)]$SR">A'A#
MLMT#6"_S'"(?I#VOX3QE-P]]<2!G/:TJY/'O_@09 UFMA61CK>EU)O]84MN+
MKE'\L?X]C1+SQ0ZAGYJ28*Z&V+-G%PD%*PXM[0V?K4KG10AK1&C0EI,# !AW
M9-/(3(AWI"1G?D,1^,+=L*Q4)(E)@,>/^%&\1*!@%C0[<X;@673:W*K*:)-3
MWN!GP1BJC76K+,)M8_(8,$Z9#Q_7TIODV?Y5%(!WR,O1:0"4"&SC:&8^Z/H'
M//X_-[*=M0<HP$:A.@I@U@P\L_+<%OIS3S@;TM$!M/N,/:\M^9^^HNR00"C<
M)-"QH@#5[?-W<?;7Q'_NV>^^L1JUY(EFKU),_%=9.*KRC@0S#T'K9-^RBU[8
MM&;\7!J-?6[\*XGB1)$6K2J;<V>XWO\0>YWV6^&W\0V3ES9.F\,UAI1)I/"N
M^/<7E8ZJMTO>5))KO6MX;9;64.-G>S YCU#J(:ND'Y/9I33$/BXRQKJ#.ZMV
M8"%2Q7&F^IY2]F$+<#E (F-+$HA0&?!>99XZY!'*AJO[DFKQ+IA3IV8]X"=A
M"C->ZV^&U"-<@H]XC+4>5GW>>"?Z*$\1AVV)+!.D;;'MW(J5)D .20^39,B3
M\89)*<LWI3_JI@W%VG__ECJ3=OAJ74<DOH-BM\&$AHX57C&3+AY(MO$^]_G#
M<>K9EG6W1'<%-DF+QD")7?&X]<DJ[@KKG$4&+F=+K7[*AJ1$"1KZT=/9J8IW
M$]( 8YFRDH;4<AXWFKX'WV2OL22(]=SFV>:C4\78!\"+C=6'$QM@#OB\3$SW
M,+23W$25MHPW@R&J^BO.8F%T:%^R#,"R>-SMC?T=)ERZ'F+8;MEC4)7.7>"\
M)5;X5$RSJ80P_$U\1-%I60<A@C!:DF]=+[X"DC8C*9YT&>.>,F!L'NC[.KO+
MZGP VR2UU@52A7GS$I[ZL^C;3NZ"EOF4V"M&VOBR&4P)?7??\^X=NQ%W+:=V
MWFF7)@*;;GH\01<2L+23FDVV)\>K49+/?%3/AXQB/88P[H3R\V\DD6Y03OVS
M,3;]G&VMQC=;1LSO^9ZN5VL)?[<*2851;$O.K?6JZ!]WX W;.7!$0WV.\J)?
MN&I^JL:6[ILGA$?T^AWF)HSU77@+)^H/,AI]MGQ&D13\6>HT''9=)Z9TVN&@
MA^7#V?4 &-42'U*FZAYG;7\J)U4>SNKR^4$U4Q89:!"B>\.7AW100 X&6?IZ
MNK,V-*D?S+K_L$H*5X.2-_@G'6<<G%U'VB"O2YF-ZL39XTV ,6 G)'S4"'/M
M)LL !?@E"[P%:!1R-'I?O-CK$#1$6A^"5Y2/;,_K&U  F:B73N:=61#%\STY
M4 9A<!M# 5*-UG] /&<K^VV,3^%3A58*XU*1=)H-#QK$@/W@8)G*9R$GX5WN
M30>?PTA?;1PY%B3&&:V<P]XJ'3RB!P7 -30VM64R:/_\7I49R;#1+75"Y <#
MY&"!8B?)[=V4VE^61$&KPG/HF^$@G_P><G>A<K>Z"II8Y:%H18MFZK 'A-C3
M]1Y4A#>9[SO/M_\(S:PJ]F.FBV^H9IP[OY,HZ@ONAZ8IQ<HW.35U40QM?]G7
M$__'_RW>2HG6VGTJUL[;;> TW\WAV=#489B"-_UI:CTRIB#VR\?=R1?E* #V
M+CW^,5C$A3=22*%QYK=H!E#H(^&GPSOZ(UBA5\8_#EC)!E'OA4&=7EX;OHFX
M8WDR%EQT9\),(>%V.[D&IVN:55G)3*G_%#]U'RPG!'/?\ DW\#C#OC^FU%K_
MZ18JK85FXJ[8-2A&5]]](X3T)8SIF"_>2VGO2+%=TD\*_4Q-'3F\ ^AF6PZD
M[B3S!!+YI&M1F7S.M^]<>!)!:2@&R!ZD;C$KOJ/O^TTV"V;/H;R[IP:8Y=ZG
MKYR)#8497OV0ER66?]X5DJ,@/2LY'<>YIHLD+(ES6G<)[^ A-P@*K^?(FS'7
M@H2)4>QFB5ZF,]O8G6WG^'0^ @MUS-W8^.>MI36&J5KPLJ@1NK:*$'A;/DV*
M!>T0.D$2*.JNRO<A:Q^J^_T??'\]J9;XL9OZ8TVDV3:-C5 K' 70S+F&DL=:
MS0@BBDR5&V+G.MQ'-)Z1 9^O;S\+HM'8UGIDDFW@*,BO'AI(_PN9JS;E<:M_
M>'ZM!/W$G$Q.G&K6KP>SM<!^(3-,8QE=="T3]*,5!7 !7BLWAT& CQL'B'/-
M6E9N*RY27!\?$'T6N<QLL:0Y_^FSW^^! M21WXQV7IS>_U'2;U NU.0A.=CM
M)]70"<,746GCQ_6/4DP9=11^D#(/KWHSUT&-Q.T5[R.GFBL2:L@5M!!URI!_
MEVS4L,4B+QO\9L*FY !\#(FX^1A'<M<J<A<\NPH&37@ZC)F^GG%R.N)QDDQ@
MLE(T4F"%@D*F79]ZW%&U5+24BGRO3AMPZ:/_,$>E%BHI!VF-8JWN:4L2\ UF
M\O PG_6E!<V+%<*+@L'<V._G^P*Y9P93&5T4&=/12,^&Z/DL=X F*]F;;5>$
M793<GLER/7J7UOJ^.MX]/%+RF_0?K,<@"3A@";AJ956IK4NYL9JE/M4+"BPS
MPZ\2VO(/?^(PAZS%SBJ)GJQ5M"M8\AHC[2#MEMU3R(3N]#>'X<(I(XDU^MH"
M;8!>UT#1 U?1;:%Y,%6,;$Q/W&V*&W.C4TW5[W!JEL$52H 9:!IH, V_*\CH
M[%4I^^6A>.;@R[W]?+$_KE4X]Y.Y;LGP[K%1;A?])?H^\!Q!?Q?J(*:L5<2\
M^D,\:W%'^O%L!Z>=@5=,@*\@"67&8:^@<PICZX."XL%GXF[]&HC<$ 1">K[W
MZG4C<?N>_)9*B>2 T3:(9":X5+T**W>=4R43&.>EY.G"A3=MU%)>_#:5;S14
M8"GZ3"(FQ@=H*^&9/6O@Q#L:PU2VD>7O2GWI75$H)FL@L</TY+0["+>-5ZHC
MM7)/0/KK4XS:(5B5[!+6#+W)\O4\&XPWW &22V3')^,F-)!08L3,R8$.MDI\
ME(;NK"B&W4%( UKV^=TG3"42DS'W&[+24,8]4B;CLZEB!'DA2F=(4[4R  HF
ME'U6%2?4[J^A3K!DWT%Z-QCBZ>\=_R: 9H&)R4P;$$\04!/]23G/;BU("$DH
M:^P-40^M4SJH<CFG=/3HYV(E'DO[?&<<3<"/A;Y- YNNL$9N0^(_$+XGC 1S
M<]A^51>:4;;6SV=^,**T'M_YPG^V:A'GEP)D \\KQ55Y.U0A/>PJ]V<]6 @%
M8-T5N?4Q00%VW*=BOWVE//4D9#*$O#)XY$.!3^?+S%U?-8IUR8.GU(87TG4Q
M]+N*Q?3A#AT;,L2IP$?^SDYP\+V*F^27+2X;+W1,-J3;?-K9[@[]@V[IA[,O
M*%G/X=BW(.63-<Q%9*XJ(K4M0SJ3R5YGQUIX&LJ-R$T-P9.7&3\_U,:8V;8I
M]I)ZXH(-YIP2LH)?? T W1;UI*7IT@NX-UNCH773!M2:.,&.'\E Z!]S9Q>>
MK"R./DYC6RZ<L8H5EMCP/+Z<KU2%MC/I(\@:(\#FZ^DQNIF.#O<PS.XLHTLO
MO*;5/$#XM1(=^COL;!S7X0G_KM)&MS]UK>%&8FR!5:CZRR:W)6RXAS6+8,%J
M)Q]_5<\X_DX@YUR5X(HY#UXHFB ^::8"-AYAYP^^,Z&@WDX";A=I]KU V@Z!
M87.+*M8S1[XW";QN@T;/V="+I<HRD=YE2OD^OQ6;M+R4Q)>&1)PPF2\) EX,
M.?J%F+ZR;VBXH\[MR^&DT&>I>9W3[-,;,NCN'I:K-K.OII&I=%1WCI% C>CL
MC3&F'J1B3?U&V9]6.DS!L[1 [:-[./&@J--O8?Z.WL?R->(XO(Z3M5VAS29M
M/2:D68,PA<8MN6*\<7/-QWUUK?^*][VD@N"JTUPNM3/8$O21;^CA[N\9^MYX
M0DG\U7)/TT7^"6Q"LH).ZP3:AH&EB-L+DSPA-F[>[]ZTX0ZK5/".#PA+]8;9
M*I</66EV;ENJG",GZEO\Q<P/W#[0IQL<23];0KX+($"'2C17C$0%#C#B>:LT
MQD+4&XT(',*0@R@ R\M7*$"5'O#,(W7BQKNNN7GBK#%T55^'H\"72I"+R"M>
M3?Q1IIARIJ-$>AM149 #^%&8ND !KAM^GY/ 62QE+I>?!Z50]C>P(-(7*L5C
M*ZBJK']DKJW;K#0J3M?W%6"V?G'>K_2%&&A#6>UV%^']-]_IO4Y"?WAK[.[J
M]#8)!7B0-Z7LKC9GYONNT)PGO=1X]_2C@,$/N*+&I@HGF>C%4.4^)+?W4YOE
M1=Q+S28?CR6;DY$!UREI-"9F,\##\4 '7"COS4<IT%U'1CL(XN7)^Y[\*C!K
MI['+J$?$%2.VH$1ZC?_T\-"8K%1)2]63V.#S!!(=TA@5-Y<..=21*3'\=LPO
MIM\-H^S%$]^(/93.BIUSZ:&E.WZ!+"RS\QXI SF9,W9,)P;Y$F'0RSX$QKF;
M$,'58\ZE='S.:D"%JH^(6/JV5%P%$M*?VK!5\BVV C]D>!ZE(%ST:V8JYXXN
MJ+%)U+X+A#LAZ-NZ2.9IKG1 4_P)0F?H$<BO][IGNJ=AE64HP!=N?]&9ITA3
M..QEM&L,IRH>Z %.M]<:7]<&Q!L&O](EN0UM00$.<7SQBNE65\T]GP-77AD%
MP?H58,9%"?7 B/F6]WZFT?643Z#C6X_E67O2 1L'6C@#XF?C[:I*('?9^:D#
MV\T[*=NH1I5YZ-O+J/K/(6+.N&R--MN[2+L;=!0@R>;M_2D8OTUR^#)K.05V
M@[=<3<NT^O^RB+#"3UNUBL32MH")B0)29H3]MYI1@."@$ZZ]W/-+%. []\O4
M'=&.6/$L\E[3"$WDG$IKYOYGI[-K"Y+GJ6M,.:[\! "*C7C8:LN2Z<,;3@3G
MLMV5<"$7>4WHR\M*<1HKWS 'PD(0"O"(Y\;X6T##ONQDNO;TIFM*WSS.$UIY
M&<QXF5Z_QT&/CNHDQC%O%&=X'8\D6>=^PTL<(I*7&;"/$JU>TRZ,X\>G%NJK
M*K7NM 86$ZW[->0LJM7X%K75C,Q-"\HK_M1NR++2%E]!Y,001H!-2^QT3BB?
MAIJNI,QPH 5+%Z#'7NN0><FML"IJ_N--Z/_O[M'/@D*!)QK PRGUK?H*!!,$
M!8CV'*>S%X_/+&B[2(YL4&2) T7.T.&BSU -(YGN#Q_ZW0KSG8,AD*B#$5DF
M@UC-_[:;495D]S#&*L@FJN;3; )7P3E;N[M*[M)U=DO"UR4P WRK E)%8+)D
M?_%NSH[G1V3A[/=64IM-MB:AS4[\#II!&"5/U3EN1(1J0\HHHS25PGI2\G.L
M/TQTYHX(F:Z+ $:X.-?'=-:-T2[$48^^ZCEX$\N.7B+T&=Z6K0*1SC<O:N&&
MBSR/6T9CXGBFWOBC[=I?1_(T)G/_RX\E%S2P$.*EL5T@_>P[8_EE8BLERA8K
M&X+G^UGW['7C7=OOU\B@(%\$Y@V'1*0).:M=$_2I0!/>::(N^NW7G/-),!W\
MK@8[(7!2*'NV3KBZ*6N8\H4W'J8871MBUV#U6=NL-7*Q%JF#T3;#Y?11]<FY
MMELL?[+B. %V,5!Y05DS)33U;(]QY@X?J9^_5P(YE+_:OGZ]_B1-EZ:1,TWC
ML:N"J>.\\!J!QR@P.L,F8O5LU<Z[IJUTF#&*% ,4%G]ITK01*+0T#AUCTD7@
M-T:T_>'V=#*)*BU5@K^VD+G]_+O7*YU" E_#&P=,\<8*V5(PH<M/&H<9*"W
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MP*V[P@5CP6@/B!:7^H45ZN]0$"<SL,6O%)(;F!OG;HI9AV\Q/B"BZRTL(MP
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M )Y%])-%EF3<OA"K[J=FGP8.:,Y^ JE:X1:P0Z\<AJ:3-%X139N3V3#,(6Q
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M^_.NPKR167P?ES0X:1/8BCHT)6#5UJ==7:Q.H7TN2K*0V?OA"GQC,L_6&_3
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M^9*<H,;#!TMESP[QQG(_)XA9&FL@IZN&OZ@4KB[\,A%,HC"Q2_J^(T^PB?'
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MVOCCJ'SV.PTT;1_JVBSV8Z,/I+<?)3!_?FWS+16)'XP9:\^]"$8!TORI1U
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MROD%'M&GPDMJ+T(E-Y#K6^ @O-^A0MW72[;^Y,VRU;4&MO7?=L+:/I!YZBQ
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MU&RVID46?ZNA2\RS/2Z\:KT1#Q5Q;C'S'W#57-E5]@XCBU_E8FO<BOR!%_@
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MX_./TFF,H'M NVQ:7K+Q--]@L,J;$&2!X137U(U>I;7YJI5 Y;0OP<WZ-,R
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M<$3(1AC^CS][[69*'H?-Y?Z.K.Z%_#KX.G@R!ABU>CC (@*53;+7^2-HJYT
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M%IV0.AK!SAAIJ?Y\8X*4A]G&NIVX68WN5:6LJ3Z+Z)@+'_2&)F <E%L#BFC
M#*\TH/P@>V<5,?/34KV6D?S+UXH^G'0MK(C)#>-.(42^Y-"5@9.9WL<E N*
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MXM).?IMH\<5.XG! /1'Z-:+Z7\]&V)$ZC=4'#$D_,BP/_/8>YL"@HD?[!]J
M(-9HD'4Q9 #L/$Z#LG\N:_=,HM-^^L.I7)=3>;P\&\2_7W3 M<H2MKA#K^7
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M"S;O)G!V3G]E\X:H69>!*PL?RC^^>6$-A*2HS+BXUPEL)^C&-7.9V_05RFH
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MI/-3KMJU%YR9@4N.<4W %YY+\3O! =R19R2L*O> ]\4+EHJ+WVC!L!W34@_
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M;YO>Z.J%!)2H#'VP@@\:0#[DB<@_X0&O']PL(VTABC2]=^R2HO/8\\;#CM<
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M&S36_ZIR[R38O1Q((23\:-"?H0+:G%=?QBSQM9;*K%2/YBU%/EHA8NV?;XC
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M!<Z:P--*J&W4BTL+Z5UF-. .?A3P#V- _F>1#QH86+E@$3NZ;D4#VX@]\\%
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M@@:H[(3X$<?GSQ*>?GZG3IY;?+0@$/K>=1$*EU2F_&XW759PJ^F(#/$<#9C
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M:!T).B*BKF<1+0#]SCK1-!>$Q0F*,HP__B6?Q,=T3(H!:J7CI/[Q!4?_1I/
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M=.]:BIUN8-(8_BD8*E0V6EBTS_UIM<.!QH6CM&5_7_/YU(SEB0/V;Y>=S<V
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MY:PQ &CG6/K'A"W!LFEW8LA=F$S4WW/;\623>>K9=??,RQG(99Z18A?3&:4
M](+( $L2GQ[OA016->4ZF/:P<]Q]O"TE@KW,R\0 DU8+&.!A3'T7&G&(10]$
MYR W>0J],2;0W[,<0WM,>I7<"P,8,F&?+;AO#& UQ6UIX *O!0.DW80;::$?
M"C<=8R^.R(V/%TG..'P9L,)YPW0.P,B%YSGJ/GJ3B8G=S:@WF?@7F1Y IPG0
MCWSXT:V(7PIXQL'8U]>"]XST:.""X"\E/%F(-/.!(PUY+X67?W2BA.JB$;T\
M O_#RG!%04&H3K51Y8%L#S^/NU8UJ-YOWV^^&"4'!R.%C=]-C_9)QDV;32U<
MFPK$X6RFO1T]DWES)3-Z*8XM>(I5@; XYYK2YL.?UMMV-XP-D/LMTU)Y!<\*
MU'$S'M8S> S%9,B?'Y^(,BS7[*AIK^8,6FOU'I,$3/,&UN/5+GR P4Q&"64N
MXZGEB<".I6%YHL<21R:#VDS$4G1;H/OPN?Z<W/EY@WIA56)F4X+R.T)J:]+S
M@GHKO,&V+G;44A]-+(J<VTHIJWE^7N%17,6ODMRI1S)2I\(O-(-<%_C0.OW\
M81TTA6N<G9'BGB7#ZQPH,#0P]4@<BT']Z>W@Q28/X4*A1:C'#7 475*9953G
ML+P+[H>.9@*4#*5$Z::X'A;V$5X*7Q)&8X!%+(A=W@$O4<9:IE+:O6%LJR@7
MOA6/$WAOT?PH77TN-FP_C7X$Q0ZG+,+J&H^$'I?PESC? ;95 G:U^T)Q_6H*
M4A5=J(=(B+2_S<C3BEKK/M$%$WYVT!U/VRY<)F/1YN*J+NC->KEE"/W"=B6O
M:645WNW YTHL;ZQR;G/N$;U!Z=54#DE1/TR?-?H,8WO&'%;3V[L6Q[6!/EL]
MC]:Z&;,>GN6U%V3257]M26.%B:(C6YFEXPV+94Z,A*TV@T.*Z*M,1''7,E/K
M%]Z;[A96TT8=NUT)?(7+KK*D]+>%;TJ'6J"LO193OH"BEWP@[1-I7QU-P2E#
MCVZ8@:98H<U@\V:Q"107T]4=,=]T9O+ZL@Z.?6&^KS6O65C>$O!%+' L,CXN
MT[)Y4\@:20SW_9R]8\SY;?A8V3QD?A>5SLJ3W[.Q=XS+D$3HA<:W7M;S>P57
MR#-G_'JH;NY":NI16BV6='_QRF >RCK:I7;814CAAW!\[(N#&\JD33S783[(
M:%S?!TA5:Y@!QSZSTC[ *!L=3 WO5[^HJ%"N'@UM#*/J^HSBA[."A$=YQT\\
MTLO+@Y4MKA,;1?:(XIK<Q !9+]U[E4>.>"D7+/5-#P;LK%JE^?1TV>#"Q  .
M/@MH;!=*0L6$B[J38%A'8^D__ZV,V.F@,PT#E%]%3' C]?P-6KR6N3U%M,^J
M)DYIN!3U7%>3B/'4U*[=<W),2CZ2.9%4;%[ /\( I.Z:,[ICO+QIB:MEK [7
MGMYBP#GDY!#AD'KOHY[BWM4&6X)0S&^Q=@\]FDF/[N*EI=7:]+G!V )S1"P$
M9\*)J@*<9\B&FF-S/@$#YP(OP)R2CFXD%ZMH$6F0LX9@2@*L%><-^[2N1E+>
M6=3&B'C3?OISS0)A@;6R!K_,MMR,D-U;?U0,R_!ON2M8%-8=1'I(STGW-#;
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MY.RRW)GIL&4:V^1;YK$'_A&.EI5TZ+(LF4'+Z8;+)*Z9'ZZGO'3QS;2MT?W
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M6+:!RN>B519+=].[2D?=N\U?2YP<8ESU=(<,T-<E3"DRQN:2C]VP%M!53_I
M3_'2AP/][IY=2.H!90D&*,;' ++%#/-S7P8JZ?/"Q]T\.N6:I.IJA^<6YB&U
M#6NSIX29-\VB:G!F! OM^[3?[\,+:%7(DD5;%\AKMA;(H:O/2C$ + #[TM'5
M9Q?-624&_%2AG#L>:[=RS./ZL<CT]$9^7#:5?[IZ=%UT2'&!]L;C%BSX>/CC
MKR90&N!-Z,>C&. $!WH)BO,W6"#  *M%ZEA3A#5'0UN&H@D7=9*$99=+GOQS
M=S-"SF*W_J:M(XW,%1@@TN4\==UZ=QL9.(&6G-B&?BZ>I6[_'BU(H6'LQ_Q'
M:T#U*$[X'"R@_H'#"M'+]S8">(_FZSNN;[",5N$?'!?Q7G4_)V%2*;1(+'^
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M/U^E.51)U(J9+VBZIM3DP4-E',N_S*^+BITM:<HDCH@%W"GR&4)Y&'ILN[9
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MA@5_::.RIZ<=/V]N?6?;H'PXLX9C$M/H!?#\]@2+H52JCJB;,T(? ?UVV)6
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M \9YC4W<I7!F'?V$UO^%[%@[[L/!8P,9'B^% 3Y<K%*Z?6!$@V S+L6MR3V
M*15Z#S";#-RQ@=X2(5255Y.ZVUCN8&%@\:J_3?'N\@S= K,GYS!)_\!/)>BV
M=:V&V,"#_:BM]/?&N!)%?O&BO0<,IG6[8@\65XH>'3LS,G+2U4TR/P^9<P3/
ML*V;SG<$-*POG)9D)$9&RHDP4*.KMWO@"R8-G\%,]";@>H67&NKBV07W !G.
M+$AQ=QH];II&C)^0;7F7UU;0H8\F9(CV>ZC$-L6@7CR4._%/W =T"E<.,A1$
M27>X&6C#^664>BY8\!Z 796$((K^'9C.PK;WP^K)>D[E@#3'MI_)6@9=H!QR
M*:5"'Y<GS:K^E%I7Q@8OGS/(5>KC+/F#WP-!8$I(Q7!!HW (<%L+[^7G:14>
MZ1;EQP& &8FX^4*G]I+KC)E#EK@.W(+)V:WF*4_3=E'<!^,N*[M2>@[Q0A0.
M7:R0"-I F06&+,W%2[4) PD#\0*#6RR=\^9-=]*G,\P^/[\=Q;<EC.4/^Y@P
M.B R^FF4]F@>G=9A2IR]KH6<CBT.+*LF^0+_IL&QF+D1_:DFKA1&32TH.)'L
MZ/M]S*[J+V4K2HV[,[PG\Y:]#^?+KSNW'N_VKGO %<.9QO4UL'%UE'80,4IA
MO ?=95D4'M@'A<OP-FQ_I1/(Q-@T<4I3W(HAMVH<RCZGO\[G[ETU7GPKWY33
M6J7JBEY/^I[=6@K4:JH[:I<14R/#J#,9W ,@!/> WX4@_\UNJ'[-HOJ6<F%"
MUN*Y#2OS;)[="G%MAD8D%,.>N'PVMZB@Q:2CP4=*[BILB=;P.;41SPH_<M-7
MX9;T?2DPR>UQC(.&=HDIQ*P992SQ7'Z(Z@O:8UDBXP4X 1ADLW%FJB6,$*K#
MS[HNA#V!Z!D)<<$?[U%5.LK>ZX.+,A+"3&/;=$>R$/1ST_':?0WBW4NXQV:T
ME#[<O3M&[U/.&M6>,FNQMG=9-CLJ-LT#$<7[#.TTLK>B @U\J\PSYSVI/&I2
M$.VJ,4N%1<&OK5VM<4;=_>\8#-/_PH6VGMEX]X $WQ[I\QWIL^<0GB8&(H?Z
M)O44,'"4=NAR[.DZ_S<9D4\C2ACD;GI4E_"U9,C!:,5<1DGZJQ( 05U;V.QL
MG2ODLWK!H7^;#YU&ZM?B9PN!J47M74@>&F#57UX7J[_OSB45&2X?-&PTJ20'
M)J5<]4%_K<#_><M_176W*:F#H9B4*EZ-X)6NW?C3+M"X.!-,;_!E([M5LB;6
M1W.Q5#>YT4B[?FEL(@;H$O=&77BEAGK=W/$LD-!0M1LY'[2CKK+!AC''Z Y_
M'HB#[.XR#@@-?0JK1VCOPZ>N,>4L!WO$Q)0B?_ODZ;!M\FN=(-&ZR1M\(HS7
MT^/%;..;OOL/ZJW 6O^78_&J^[)TNIV?F6=B4GC0*R)Y.-'YZ#I0[U2#M].A
M[F=BPF)(%*LTC\X]X(T=SZU<P1[?WWL KE2$QP5Z##N1-[ZO834S/C#+I*5=
M=2446DF0!S<$#\ <B$6OGBP7-[*Z"/4N)K/_[9UQ,,UAJF)KG$I/.<K."K#-
MTB\4:HNY!SQ]$D>8&RB95?O+;?.EX_'4=O">P[!#T;B$G$63UKC'@AV/X-W-
M&J@!9-0FJ<AZOF\B4N::&!5SYC7IEO9,F]]5N[X,?N"THQ] -.9DDTIG?Z2;
MSD0&8R:H^W[-:X822ED5GTLS:)PH-IF!)ZN1^1(32K\+Y%>!0T,%?3F3QP]Y
MG'FVWV5[[)4:_*4+%94.6X<W&CF$U3:';DEX)RA5\_A8T4:.D(NNBZ^88A1J
M*OO9@'#/4W$3PAD-@IUEQJG"SD4%M63F0%\19H:^>T"'O1D62Q[:P3A[S9O[
M\A-+.G^J#LQY:,8K6L+$N7)AP<B@1Y"OG)J%E"/F>(P>=W=TV]"4;G9!KBE9
M^6GVP*9$\T\B5*4D44G_[1[=BQ2V 6V]) <-]1".J=WI:(MC\NRV5K4%*C_J
MXI6_WH3M?BPA795'-)GT89L[#OIR[;7MZ(ART]T3RN\'OU+J4[8W1G%6A.(H
MMH.X>+#O6B'Y+ARWX_!!Z"#! NL#: 2$ENX$O(96H2@PQ5Y.NCR?$BC%K8S9
M+9ZN,\6*G9>FL*N_L5-N-C)Z_J+J1UY&I'Y;FFBC8;:^#7.5A3)KDDG*/&89
M[>$@5N3D7OJ>8#99! NK'1F@T% O:N&OYKE"P/-"4N\"1\;1=&4H)1SAF2W]
M"Y*IWXRMY4P7.(H4_=IVMB1<6_L*E4$@H#8A(4V]MDS"U>'.L[*1@Z9PJ?,U
MG&+0G>&I-$ZTCH\GLCZ0?O1=QP%(_+4H::6R7*!22"P&W.3#-&XU1?3=3]36
M$?^U[_Y<=S77$9 -$TDH,.JL?E8/3[ME]6$Y3)EZMWPR(<!E9FMC,.=#T7]V
M#\ ;J$>]CBO;I;SV"C\LMJVG>=D$[5UM.,[!M)*"HN3':S,R& AE76T;:5B:
M&WL/B__ 9L?T<PZL;RNS;\Y63J!R[0N*5VDL]?O0[8!B6@5"SMHQZT2&L!<W
MO3U&0[I]9RRR=[@0'NC9G1-\ME,L.^F5BA-/EB&U#!S X2TZ:@EOKB)VC53V
M,/O5$Y8>G>&<?QN&IE2,ZWU+0U5B,3 GJ3#Y%Q+55;Z)+N^^)/[MT*!M"9 4
M:+@':'+&(8\*"1,JX6:+7#'D7*I/.[A<"UP2)>V'H1$LDRVZ+A6&[.Q<D%Y1
MD<5HM]KUW%UT9&\K]8CVIE%/@"^-)OBI@L2HG?2@&T5!_) 5U[+-84_-B+^;
M:<B:!3-*,:3X*W9W$!:KY27,>:2&8/M[VU3:/<!R"AJZ^*5WDEKJ2E*:H;/*
M(Y#$Q+YIS=Y:[W5$6I_\+M7'>,D=>]VB]"@]C4!^UA=\=OWB== $6QC#B8@]
MPS$O)HA3HV?EA UDA&G]EX!5,C11.#\\4DWD-">=U:XTJQ5I$,;?][.S:OY>
M5(R2HU-'329K&[C!V4M@W>"B,6(KMD=?-;#HI\FO%@HR@9LK1U4>HJ0E4TE;
M"\>-;FLZL?"[)DH6O?FO AT;,X&A'H.<-*J' CK*,3$[C[+Q<:)C,>NW8K3I
M<3WPI?K6,IB'?6*! U[O^]]8"3GO[ 3IS#[45K=,GCL\25]>QQGY]HB#9$?#
MZ1ZPGMXPZ4! -2#9JI3R'L6CE18H9R+![^CB[.&%</3?=H_;@C+"7JJO9@M,
M3E+TT&YL@SU3KX_#_$0)NG:T3!?-U.C_"LV,,>%4?O#W\7$S_B3*G'U>Q)!]
MLM7:9.;*3YL:QUTYLX#[0$?* _]55Z&KQRJ&ZJ2R6B50O6G*I&#*Q:DJ&I>A
MCWK>X]4,C?"30X"9@(WAGWAL(^02CO\RI.+4N06PH8K :[U0H]/'>C,=X8[@
M_'E:[_WOB;Z$Q;O&YQ1XR:^.XHW]JOLE0I4+O)DE#><2 \D^Y$7^P8,C1R/K
MS'#M7Y^JILAZ+'"]X=G9-%-@F#(_WT[OR4M2+N>3I,9P@IN%1A(0W&0:4T;'
M)A4O,Q)&^)X0>F_D?'7XWM;:.%59W-KRJZ@Q:RA1:<DP#K@K18<&CO9@7HM9
MGTWV/)]?UAPCIF&,TP1MU=R:(#(J<4&1ZZJ-U+I7JTD8G_?*\)5<G,47(Q()
M:1R+0GP[D.;. +):%$YHBT:IAHO@1[NW@X(</^$;$;@$"3FK=/PSC2_&E=_.
MFN.QE8MYA/26EBP8 %_?1$50BLPN9@;H=(#E?4(>/*D4/<CUT!WLU?TBW_[S
M[T6A//;(UTPB-S\>='NAZ[(0,@JDA\'"GC"U\QJ_FM%743PFBR5JZ-O.[9/J
M$IF.S@J"\<O[\%[H=^9<4WF,WB"ET4MJE2#.SK<K1$6HMW%E]F^V=$/G3+!E
M.9T??:.1%:$9O7U\K7U1MBN(6:V"H2V[*Q&^5Y#UR0IGH%*TD3,33WDBH<QC
MMWAI_%@!+5!4MT]<I(?-5)THQ38'\6.3LC(Q@*2H=):[*352+T,X= ,E'>F!
M6R$8R-?S3\>C=,05 X\L59]DG,+.$_OI>T"0GV09VNG&$.E4[N7JOG'*<\BK
M@_M/((B8_"L6_16L\O%V4 I&GT!#,B^24_._[$L2"V.W&MZY,.XF18+A9-B;
M!?7FA*9__&.?2$K&6&A]%%%P2%79:5#7]!OWM-67CF6)75:JC>&!J;Z!S#,'
M\;?$07#:+0\C-]GR4L0TBY&Y4^5B.60/YU8,L>4UTZQ@8R,]ZNNLF:M5+$A'
M:4B^-6Q <)PW#:?*\1S9)<^$BE4\R%R,[%VFM(PPO&/FR(OJ5,^)?F9'O/Y?
M_/'*3+3^')D3B<%+F!\EPL]9JN\^/!Q<$NPFAY+L_?ZXU,'6YJ0YE&R0VM:4
M_YL;QKLBJOQ7)4]A8T-\OV"%X=SEZR8B(K03_$:]<;K.H;ANTES<B_%JJ6'U
MJW^@6).$4*[#6[=[0*=HB7&_/]Y5Z/(!P$31F!A'.J=-P!@"IE)K=IA>.!>;
MYI@,TI_,:]]QJ=4]9%+),9Q^^0?:D2@W2!^)PYR^.Q*UVL#3\^-Z>K=1FV1;
M,X]N2;KIJS2M[TP*9R]1RE([BQN'.XO0<)ZI$XQ"WM[!AV(FHCQ+ZH/*<#"9
M@L 6^X[,^6$<<(?'3QR1160-@9:9M.76"B;,E\!_4<,8[P'J,')5DL=)P!4'
M0A'O^LF)A<6U'4AP=P!MG'+HS'7O_J&/(WR+7:D+:T?QZAA&,3J3O*=0X)UG
MJYU9.I@J*T^N2_P_W-C\7V;AD EKB(1C&5I%.75R('LD\/PB[5F3J+@M7:QX
MW)=MBN%Q%2UM/7,?VG:*PKH86)B?</Y.S<#3Q+6G6,J'L0"ZZV#C9XNCKZI;
M)M[47$4_(WT6"+JYF=+1CF:BB\<FU])Y9!KL@-)><Q!QO)7_O9M^NA M)SDE
M-Z2U2!9$Y-15+%HIE5>D&0W%*D(IQ@I)D\MB9U8!YW?K87R&P/>D@GN/SD<(
M)24!$)M65E@@_O,N'^RBNL)!%Y?/ ^WV9,0?Y*MJHQ^=;*SOQP$1[N)4YQK$
M=DU^0X,4TU.:XJR:U)V) BOIZ:YAW.M_WH10M*ZKX1'AH^OO 4KUJ<J?H-;P
M$TL7;#FW6/$9 J!=^6\\-LAVY_*S21X_2>$(/ZU2Y>*=-8W7)$^':J2\%^)!
MJQ>LP6.$.@5YD Y$2:5\SE]3JEEW\?V5)_90Z'-/DJO)^14VPO'3Q *V_O5B
MZ5#Y3[?2R+KVJ!:UNRPO%R[*7:QAIO=/#O#Q\<\V8GO3:F,R#BA%[3G'U9.0
M!;2!G7*0P)7O_[[?%(,9,E'LCBG:"7 <^FC\$_RL<FBW>9,;1NL*6D]G$KQ^
MU.J"8M -Q(_!FQC4J*K_3+ELQYW[2CG9Y92?%8JSY^\06ZG>A@S[)B$L9N=S
M#P@7$IZ6H?<U[&W3>7_6QZ$!B+V2"BYTQ0@A_99)IM;"C;FG8R:\ZZ&<O6>7
M]/FW''8#SVM],(PC-I%LX/_IV]X7O/_#_3>#F%'I$V*4XDU]^XUV4URL] G'
MYX> ?P&]!XQ95?+? UK\.@.[ L*RQN4ISA5A(?_)&AXZZ_98:]_/B.FS9F[-
M;G[:I-_+.(U_<:"?)C-GG*!K#DM.;(?+(MP'"-%(^&-X%$81<6A0J\??-1'=
MF"B<^JHB?V#NP<=7?=,RD0[V$W)<4ZY\U9!N$,U6$?I&+/.\KX);5:-AH@ZW
M I+V9?PM4>X9TURL@\AT<$91=LGT1'I0R4QTN;PS_#.?,?K-#=#.BFQAA$F'
M"BZ[@-[>JL K&5;9=1_[)=L[?#[U@+QS!J.E9EW67WX/"S@:GUWG?)HIK4V9
M9W][$#D]-KC^;#V?@&<9/C'#1!RI&/J&7I[655FR'6QOO!- ..E$$'-1Z3=K
M=S* _,V?[X4A];GHK^ EV>']O?</@Z":,\=5_(=6.J)SB+5VBDV2J?W.KOO>
MN%KQQL&0#\=66M&B_77R6[W!7RQ?;*MC-V[PEE%AH5RWXG01=0VI;B+^!QN6
MT>X=EU)U%>7O!'06IG\I1&_B:'V)U8O<D1! U,W$] QO_JV;!.N_&8XM'B/K
M#;Q>= /&@WP[KP=;BV+*35@N<&-XIAR3Z+[C2</@>:"?[]3$=]LRGN,+;I-/
MURV8C/!$)H*8ZQL2<>,+JJH4/TZ13.EX-'GQS3W$R?]P3_5_->'YW^]@*[@E
M>KC1MY7S;=93(+1 )8?,CUQ"VH.C,OPL9.638#0._-51V-0WP"WY]K&NQD,*
MGVC28%HV, [&]$EE2SOIX+;"3[QI'DXWXU4Y%D_/&!/0L^)A@IN.T^U:V2'(
M+>&POPPDKU*HF54I]!2H.-X-QRM:&@>&G-$)FV0CA.@"9A65DLF]9[U^*N^(
MTG'"+3.49UH>K8U2[ 8/I.E.1BXO!">0HWIOVDEI/:E7+RN?(^M&0PX+&Z5>
M_VEM?E?&:*3_K/8T\[8+GLR\(F 4+&:&UO^W[)@757@/6,G!C#02R#[O:F-V
MR=_KW#^ @ G.L,PMO[F*2N(R5=KOWP/J A[DSUCK S:A[@$PSJ2&VOI9/]T+
M#0*#88K6H7*Z"M(J6UJ *KWO1H[L67EP&KQ]I)- X,.,G]T:;\W"<7-[D^O)
MX$N$HI?;'!$2*Q-O-X#-7H_!?L)/N&AP>V%';\7&._RO'>C?%O:X[O0##UY\
M!].G2/AG#-FDD].YZLYIB7T5*UO[Z8C 0KNDHFF!XXF)61=P)BA!JKQH$<A5
M\,-._U'XGC10,S$SJ2WJ4_Q.NGQO*WA^US-8P'B F.$H]L#_6_\M9S6ZM,+H
M(0;FT4:J7^S2:=_A8W4-Q_W,]F8JE@ANGX&@<<DZZ0FG_=S<RR_2/MH6YM\#
MR,/*+26BXR D^T,;"5LIFRGS_S8-PE@B]I2/[-/:Q<_,?L:IH&.84S%82)8@
M4FYXAS$?#'^3&),1MZWE1^H'.E%2H50^L([I%>G5.3WL^6QF-X&^0=A$N10H
M3-K[X-75]>1EUKS&X> _I>4@QBFE3?AX*SU6*?',N@S=WDUY;%$%I *__'GH
M3?<G8'=;XE'P'FBMRI%#7=+C%C9UXML@->@MV7:XK!.=416]NBY$0*YO$/0_
MT0;_6W<:_&=?ZZMMD[2N:_T?3E//0\ %RFL,O3\4KV/S6I:;&2CO 7W%"(WK
MRZ0K%E<+\V(1!:.W]X#7'H@M!.Z >$&[H!;**80RPX/N+AA7L'FQ!;_EQY&^
M].#"CH/BFM=M-/(>,%L6N*.FA=;0#M:L2>N$YZ_-;&,D"X[)&_NP]@)-Q:=R
MR!Y$UN<P3.O'>\ [^P%"59(7;DNLE1Z%[:L9:O)C*4I?X),U,_< Y--V!.FX
M](YSU3V@/? NQ7;_!>&OHKFKBS;&^K8TD!:^<O#YGH/<X3+V0^0J%-\# G'N
M <\-KWMF0UFJY@OL9N,7TQ@D)JRPCWO71U6:7,N'()N7[R,3"@<.\B_[^F[\
M5^:D_EY$2/6W#YU _9I;74P"0P[C0L\R*DE7XGB'?G19DQ%:VVR+G*V?])\-
M2>$CT_=R'])AZ;^Q]Y91<3;;NF@32)J@"0[!$BQX<+<0((2@">Z2($W3N$,C
MP2U @ 2W(,&#NS2>X!J\&X)+-]I  Y=OW;7W6&N?O=9W?MQ[]AAG?#_J3PVJ
MJ^:L^<SYS*+>FJ5F;/8O\VMV)8@A-P!M$>.)%NT*D_,)6Y&'7<'V#YY@JGBS
MKV]74\JN77Q_8$R590;3_I/]3?J3;S7S6]?0-7TTV.[(V.Y[A[9#\F0^#RSD
M_<%YH*9"(?JQM;CK7,S.2$;!,:#*85ATIZ]QE6Z;%[#,DEGM4KB@O,:]R_I@
MJ%-?PF6^X0)1S(#C&6!G\6.7. $Z _W!94V]>+%:4?LZX71B/8LGLJ>GW9)(
MS\5N7\"X>DK0]$$/^2)L<>2A;GW2Y[;C85UJL9U,*1=C2#A&Q+K4N//;XK;F
MY@SE2\EYGUZCW[+4#"+9#(7R/6]1]PH+V&)=73WT<R:ZG=2%H>'T&VT30="'
M;S'6\"N[C6[297FPU%[-FB"_;($L)2T!41*><V+!_&]W[[/#*Q7':.T7*?Q-
M$_59F\JKGL,I>5O>0JTU669A/"FOY4CYUI(8T_T0CE BSK#R,Z.0X[@P=V^3
M@H[EEB4K38>[N6I0M>481^V)8&CS>:O/>?ILS^5(PD3]QUL>,>G\[YX,O OQ
MY;T-%[4R5P'+-P"EKV;39UTW@'/.6WN;O47;L;<NT;OK_1%YKAN ITGTV:NG
MN6U6%[+_.Z7U*L+!T-5%_\+SU$OO?R#Y]7=1_%:J"F2ZV2__Y&((UH$),\K*
MGQY5E_*NJ"(C=]M 4,/D^2* EY$8;;4QF[FB"W2"BTFRH92>U^M+7E(?[/VN
M;J"-8.(O%\/&B45?G)5 J6_18S[6OON0\CJ,Q=Y7:+I,4AM<B+8V2*1,-?ZI
MZVV$<7C"?S_N$'@+15==6ET6:;>C&P#?B1@D L5\ R"O?6J59*[,$F*@N!G0
M&\PVJSUR&XZH_B$<??-5?<;;$Z-0GC0WJWH_Z<T!V>P7[&7J$NA<.QYTTV1&
MY@!] UA-RG5>BZFH5\&*0D#P-^?HL\@NH)&[)UZ9&J&X3)W:G1(1"WX #.B>
ML<XUF(>07Z4QM?<>+UW;0;S>!AM]2];/Z8.(@Q9*%W,23XCR)+>#[\\!ELGF
MT)_T@ 6?U</R1'A[ *E656(/36U^O3O%6AJ(*M'%N G5?[WO><:X :"=$8\6
M*WAB2CC+@.7)J87B*26@O/A:K;]52?;#/%3E@6<?X%"<MXU3!&Y2FVN3FEGB
M5&IZ%5-0;?,8RIU5P1U]1^ PMM4&I1BV>JL1NQ$H-,<D!-M>XYOY8[5!X,F!
M?B80^34K*G]RU^3PI9#HWL\Z/H*[7T*=2]7;ECL2YPK&'!W4_78%\B<P4LB9
M[C=0RRWO\C)(<?\\>)_G(UE2568 5NS"GJ2_$T80N7MAW0,O7(8["/Y."E?3
MCEW,OL+UC>LJ\M2%CT2VPWF_7RJF.%F39TPZ#SGQ#D9^FX_0V>R+@X^(#G.J
M0:EMIY?ILHQB_2YL/QD.<*P$M>E%UT&;J!SZ=SF,EP4M#K+I/4J-?T#+EI?4
M0L4*&Q*4Y*?TJIAUH0A^7G^@I\'A6WI72BW#/$NT\VKP#0!@.EB,+H'7AR?V
MS+ 7V"8N_5H<G#!4QUT(>;2.E98;G^X[.RRZS;'<G1+\'#D2YON(H$JJ)_J]
MS]@C"GQ.E^@LYPWZ#ZXESM'I;V6/;F%3_^_JJ?W-W'=-JT<P'R0UK_<JKB?+
M\U;C,)&I,E>A9;<HI.9,N<J$KCU&Q)V!H:=?W1AHH6MOQVX NT*W;C5[P,3R
M%IWG'VX H5?$$KF1G-MQ<7]V@B3!BUUE+-%MGQ]*P25'UZ930LGH.0^+<O]\
M/3>1:%^RY-GG"(3N9-F5K<2=W_-,O&YY=,MV[39J5"U6Y:>>M-7]3@F3'YMI
MFL$N^*WC'-9=!FF&?-GDB!3,H<;PG%V>G=.QIMP F"OT;@ 5M]"?<XO*M9FF
M2>=O7:^'%'X7)F<Q2J9O5? P6!#W1$.+E[;*TD!;R:N0,ZKO03+///?&&\ D
MJ[#*3L9I^_)]%NY#JD< 'HE#=LVBW_<'1=33-K[OBX]JIC-Q"D&2#ZJ*;P"X
MR1$W 'F_N*O+6YV4I!V9JDS1[3H,V!A_T,7E:W#FE^+GS+_T"(1N/KS]X^5;
M;MXS(W7WRU1MCFU!UUMU]@=YM'NF+KOB5YQV6LEMXZ='ROZ*0I9T4AD5:_.8
M@9H8ULMN[\H@NA&FNJWW_N[1A]TW@/3IE!@W?,,8Q:6NGGJ#+624F^BVDA%]
MOBM#B&MJ;%S1)HWZJ6*@I9/@1#F$-^F9X5625-CY3BK"5+5YC+?T]U0IR\O7
M.9&B-P"]["#8X;4;V;9BZ?E![B^WDQO D^TW24^=#76;M[:NK>6LVI'A:/-:
MBG,W/P5WP^++T9[%JFTH;'3"U\0%#B4@G=GM.^?6G\1HPJ4L-HU,;<Z^OR1C
M?&*<C34+F"VYYF@:#0LYSKUP'5HW%)D-^PQUZ>C=]]K;&6^<S/_V_$U4,Z0>
MG-Q*N&"Q-?PLX;M*NUO)1'$*_/-PQ4JKX8M:MTNO3VKQU98_->MO$P7?Z]P2
MM&G77!&*L.4LN?K7_/PK>N5W]'K]D@#UI8&.U>EO:)#"]71-<T+7Z4NW-$@F
M[M0IQ 0MY3)S1%];GS_KF:8UQ=@P4] <IO8=PJ_3 (YT]X7%(3;:"[S*.'[$
M3VHFZ"Y=[DVT]G^E=U,=Y)X'@=M-II^UN$9F\K7C/;O_YKQ(:'CJ"J(A7E[K
MX>T28<4B!WC0&D8_^XU\7I%'<)6RZ26BC(4C(6'[C_0YY^._P]J;?_WP8Z?;
MOWDP\O6R9^:^)O+EYF9N)"K.Z#_.%?Z7A*U"[[_4%RE/Z0W,DAE3(-^C_E?'
M!O_1*.S='NWQK^[1^/WNR;]\=9Y\6 ,.GK1ZX*1=E!O /6^7&I.1?UI7?Z9A
M:$2@2O"&/S^8"@9P]#SY]DE3(8 #9-B<]NA38TU#\I+GL)9>>A[[*5.\QICL
M(RCRBV?>=:CJK:_ OHU>B&^9.>5V<]^?V!E\W4/T.D>Y.![>E<YS$OU&IJ6I
MDDVQ/GF"GT9E7]C6F#R._3G;ZTM>W-44&W;QEO;3W(R ^D*[E N%V:8)"%M-
M.H'7QWZ-^(^.3I..HEMO[%)/*\H:_-YH-34S[4=\Y:+<%"?NJB[Z^LXGX%;S
M'7]V1!,+19\E7DU@2G:6L:$#,LCEJZ"]]F.MF?XW_[HF0P-?*U[$RM -@$DF
MLGU7S.,&D#,YA?]/!]T^L^HK2J/GOI#+[M9;OE\>_.G?+8+#MGS?X4DD>SE+
M@JCB$R7GY\0*P$*YB?&<W*C'BY&EVL'LCP/[&0\)5=V\W/R>)N^O@R( <_2Z
M/$Y;B1J:"DG[E.Z5M[+B-H-+[=P=P\%NC_J?T'Z(=-=F"!#BQ3 ;+%_=<R/&
MX$%1I7,<QJ)2!@K?$@U8.04D*"Q42!.4UU+'31_NJ#B8T91M)'O'B;5G&?S,
M3<^A=OA0^'2WJZ84(U<RJ_#;8%N73^D73ACVIH0.F.P57T)-4A?_)V/$KHJ3
MFY,77^JZE_4GI(DN%U1 4U-!L"R7U&/J#\/[MSG7_]P-WS^SBFJ?HF4[+>:4
MF11*=1K<L<*D]&^QD?<EB=3I3^A:?YZFW'<""WX<H5Y(4.S15R]BBK^5N0E+
M:/'WU-6/A26C(1=']#+7L'$:-FWB "+G#\!JC70WG6;9)=<9+'T%.WR9)Q-1
M"V\4$P6L."N7-CVUE>J8E^9#R>$PD(!PZ)<=;F-99*G-6@*[CMYBP@NSP6U'
M.3I<Z9HY=N;D#O"2)ZP[-22[MGE&Z+[9W-O>&<)0'$O"D2'T>M73W \)LX1I
MII2>D7UJ-'X%]="[17#+6'<LI>P-1A^\@61]UMM,?4Z9-MG:):'[A/E,</"I
M,G? K<1F?U9!\?]$N;1_:/>SFQMK]766$'K)VO.,,8-A]&%T"O(*9/I$NQF0
M\NFA,HIM)_L^UH>/9]4O6SGPGN8PU]V;7^!XR<-:F_&^/O7E.],F5)4.7<.3
MO-S0\ONSXS> #U&W2\D>SKD!!*I?"QG\\>[QKW]^]]@@,@FWT#72)5''_C\!
MR7H+R-FQA4JY3:PMC3%M*]5?S (_P/Q#.!5DWYS+H[7#1B/K?<JV4R.]/%)#
MNF\IDM.:!)0GZ7FD&I_#GIT0.XO5\2W]^?+OJAC\_U5PBO4JAXHWT'5:$JOD
MA?K517+K^\BB'TD+Q.'2OV[A)B4CKS3/?0/8*-P$[5UP5NQ\WU5G1P'_WF5S
M^:X=<WQ%Z->NP&"<8O9;FO'O'0SV]3> S*R<BOK-O-LAM(7=_]&3MY=\ SB:
M.!8ZO2+S<S<._H0._GN/H-_WY6MO_]"VY=RX\A^5SED/_MX15W>[)2/JHS/S
MQYHGO]R)WB"(_]XS=OH#>KYU07/I'RG=S-,YZ"OW]X[_6+LI9$QIYMVLF/I_
M)\W3B]UFX%_"_ \+$_:N.3#'C3CA;6!G127F-KF_S7!AT%/\NAO F(KAL0YY
MB7A=$XV.M.ZD4)F,*@H2:=[<<+@&MML+F.V+67.G[_UR [BO$W4#D&D_OW\#
MZ&HKR6UF7W=C[Y1CR>G4Y?ZJY0!N;M^I.BS$L!CP8JYO4V^V&P">#)QC#+IQ
M=NNJ9-"Z4Z[:-P"0]O5;ZZM$I6:,3/_YFVN2,LIK*/20] 80PH!,LFD_NN7P
M'[,PG-M-3Z^G2S!%,M]MSJ!AYPP<T"[MW%N1#ZZ?0Y%Y_SC,3U>!86X*F@0\
M5:4_N,WDF7ZKHU_5F)Y?W0#ZU:_)_G%<Q;?-O$N#BL/LZX&\Q6N&-=_B?Y8I
M[A\&DI\8DT'_6"S#+T&?=A@F+ND?9='\7Y01MV?7/AA\R1KG@8;&_WLM:%Z5
MZ9YK0*W&]F\ Q(?2MV3T0XG"#2!K&7.;Q,&5_FGH17FD3.VW&P '\6ZJU#+\
M6FDPZQ_4]/2?AYIJCRF=UIK^EOM+OW_I]W]*O\:0+KKG,UKH0A>A_#8K4&Y3
M8DVL[^:(TS[G<E%IR3II&9$R,U@>2RWZ'+%XRSLJ)/?_[+3B;PWM@/_9,IQ3
MFHJTE[C,;T !K%B2/_]2U>B_\Y[UMTX:_Z\@\9<P_]\)$WP]//S=U#/CX^]7
M<[?,&\I9B-[CD%O9X] GFE2UN&<9O8+S,?6$AO/+I/]$.JU#Z9] DWSS_XV$
M7NU_>;__J[S?7_K]2[__N_K] D6 GX#%UY_N'QZ0?HOC/F>F=:_(E\2ZY>8'
ML*Q3PN ;@"SYV)C1YW2C*HIUG:J9T"X846K4'\^C&!7^V?_/_FI_M;_:_W#3
MC?0?E6:>QDC= ' /3J6+W2PWK@J'+B5#1/8.J]+=>M4W3&9,9:XG3(\XH?/+
MUV/9N#R2?*@XU='85LHH_RE:#;_"_MA]I8\%BWV_7?'ZZ*J/A]S;[U\_%8GT
M%2A205#OK32-!Z5%%3P13! &$BG).A>*KA:^1C3HMTD;F:!-+RE?(2=#S\L4
M*C\.K=\]?YZ,1\DV'S_IA^=IV4F3%2I-X/E#:VHOO[9QDCO)LOZ3^;C@")=X
MD H],1.D%>#SMDT&^4G<V[0]W/4&\%VR@#SI/0%^P'W-V)4'ZI/>,_<19=BO
MI]IX;,0G/)?F!M\^\-*A=V!U5)YCV@@X[^5;.!ERDKG71F-S+8A<W,\IIUX/
M>E07A,OT*5MG-F1VM5CLM0M&BMW7XX[!]1@]=7V4M-&;K?Y&,5&2IV18!_7^
M;*.E0C:N):TFPW3/+4KHJG_F*G(Y9O.:J+\J@:Q6X"UN__@ZCPY62SY)L^A.
M+%Y87@3F2,-2D9#(4R4M]/G7V8A,;.=3Q_/BL[R%%0?J?8'4L%69 $'3.ZQA
M7G"4D_V18.1EP7N)1%L=G$-BML)ZM17ZJV+T05>3<.Z<?U[%K.%BN4CW872!
MM\/QR48M)"^_JC3^>],S@M)"QN#18%,QSPUX75@!ACFLAZ_V9^KD#XB+DPMS
M_GD9C\AO;ZR4D0HZ4"E21:'8?WB HJ)\J$#_0S([)!B^&OY*5E:]XGZL,]'8
M7(!$\34SFF=IJVP-)9S*_*8&X=C!4+1Z4G8#V.-DV(451_43!H0/.^C(6AYV
M#(!AT9;I,S\\JGU9)C#<?@6SAG9-P^4#[/63-,+AG'L2RH]2UJB =]71K@QX
MD'UKM,CJ#OM[C_JZ[U]R%"V>0X)4.[P)HJ^43[*)[:'T:%7!]4GB\)I5F^_A
MKTO$*Y<4W5'+M),#JS($ S[@]TU[ 8U->G.X!FXZ'U]BO<:><62B;ZS(DB;P
ME1C'0-X5&X%B!.N2$W""<+^R1]#Z[CL*C+VAO5C3J>^3P2,FS"+8:7K]0LZ2
MS!VG<GB9\[,*_5H 3&8W$G"VJ*X]<0QB;9D\,*NNTR+[(?%!0UTN4:5@VUV\
M)])DJ]YQ<:[Q\?L0&'MGYYI/)!(:F\FCZM-U35$U\:EABMSM3KC'LW/W7#,W
M,7<&[:VM/1.2T428-,GXL15^FHJ;$L<SZHMF?RZ]:T&L'&B1_I:[LXGIHCP(
M3/7CA\ '371JSX2D'USJ_3E7S0W@@9ZZ&]M"^"MLL6/J;;\P(80,_<F8U^H>
MFUQ[JF<-Z$6L82"01Z5^N(/^/B[ Z%CLI%RWMRD,)A%#@K5R):/U?>IQ$M3K
M,;@\?</)6G(#YR&F">"G7P+R-@FVJS>HO6K]1(002O"ZPVYQ'YNM#0M3(GX#
MZ).FF.#>LVZ9V7T2N2793_63^'/6$M7>@0D;"FC8B*+<W8$;OT+]6&B]4&)*
M__W35M(G5GE PEF]>&^\ @V!TX>4^W*$&4ZQ-*>\31XJB'7[%$CR[6,X90[@
MZ;#7@.0HL$G/CB+UZP>1:4J^A;F?S7G)K NETK5)W]#S,!J6E>K)VAU\4&)G
MQ/JCE"LX1LH'T2*SXA%>(;@,])S24>3;.@V] 'CAPIF'L58SHLZUB8/][TRT
M0'U*=TQ829;RG;$J?PZ^2SH<WAV4=^KS5V%X!9A'64>=-/A+;7F[9Y4;$[(B
M#F%G?&JOM9C.O3J .,^DFM9;JS#J.4KEA.0G/D)3]_%/%;^\^,+90-CJA4-S
MGJ>+_"E-@K[*W7+_WG\JK_4]X9>5\Q"-8*2[U2F0T<>RS6XCUK51J'U.<54E
M%KYW/2-5P\M!RY]GV,L !&8T5QW(,LC.H7>ZZN<*3]_5APMN0?#M]9+=?@@[
MU?KPG5(+M?TD5^'#DAU@RZ[(\.?'<(Y*\L)!?B#8Z8B=189Y0TR!-5$IT:-U
MYB!<;.Q8OV_JU.CE-RU769)23"./FZ:,YHU&&D)=PYOJU+RXM%VV!79DZ=O9
MNJ%W86ZGUBCASRR+MS:4?P=K6,PA^*CL?"UT1R7AY?[4XV22'RZ/HCF2X##7
MK6%0#T8(^08FGM)U:=C\^1W8XJ+?F 6>D3)HK3%X9\-AK-?Y_MJA:*]N1_L#
MXP5/W>X+G&&3N>FI\MO,=':!2O2"-/C\8A1HBH3(3K2(0<I:ZZ.YW?(]E%D,
MO60\ ##?O0&8,)%Z[HE4\V=?"!P4A=^\Z2M7*%66_<:)8X%=[\S:0<T[G98(
M_<=& S$!DFXW )/*&\"FP#1OIPRV[9)PPS2IGE=FU^CS]6DQO/O,D&><)&+G
MLM#+[0#I^#')-SF>B</7O5/@BM>B1SB\"8U;\6B:P^4(!JH#2:%5?%5>N<8)
M'C-M?)]U=A>RH.>E^:%4C$1*=O#C(6D9P/78](5B/->R%25?9^UR(NU8,<?L
M-I:_P-6H]Y$R"@9+54M$X<%VA=MT3Q.N"@[.HI>LXC@=')1[_>[=!?@]MD40
MTMP 7B5JUT[9KT\@%M>-\K<M7[LM_.KH:]6;..&D,QC@==WIY]FS&OZ5_5$\
MW=&+?&@!(X(\0M-<=ND\4S8O-*[_O/2V=+><6D_8*'&*,C*E0_I^+9(RS%"Y
MKBEYYV=&.7.R GYC.': . %';%MA*\!-**M\1SB3?K3"S6>=$VS[,!XI)AW@
MDQB(G@[QJNAS_^3+T?XP@6P$-Y%NQO.ZV09;0'%,TAI%,2SS8/N:M1UY%3-*
MHJ]GJT4U^\)97H+ ZJ.B^*FD:\&BJ6<<7+BB4+JB0K7<T^#:R>YP*7T$]!@G
ME$>=J7CM6$NT@VVJ!H6W55<"R6)\'B29GM% =<4Q!/ Z"Z_U4UQ>50JN:8"P
MQO9N+VT5UNMTO=018:P\"+IK&O:J5H9\7X@%]>+0.(KQD0*_;U7?80S<Y<PE
M>.* ;Z/6')UWK;(1"-V9/KH!*"@KA&'2DV_3.8O#6PN8W<2N;41!PDK'S\O=
MTD1#@CF,(9^P\87=0^DB.CL.(MTC$&7 ;G^;L5J0RG3403[_G4&IESMQ_DGK
MT@^12U_*,6:HQ>%"AQ3;=RY8D4OF34]VRT4^25)HX.+$BM!J9Y%M7D!#V_C0
MMUNH6!,Y:"Q7SKVO=1<WX<FWP"0JZO,1Z1];LG2J^XD@MAZPA*;TTTS.HM)E
M&K8OAX/Y_.=I+A-BDL$)>?'1NBK?0.+OPVP<:@TO04^!J!%&6?7LD3>[8A72
MDS)K:S45EY3SMS,,O-VMF8?2^]K.K$];J*01$_81MF;D?WG*[%OEW/HHR:%]
M]Z0'X$T1@5@F1L<J,XV=^*C\>O(HX\E'"LV=V(:SDM2"BD*;9%6O;Z:&O^;9
M^[Y(!F*)#M_SSB3&3C0:+D3.*S;-U+1"5%Z,U>+?]QT1[B57%W,*BKV'A6/E
MO8*HOG[2N0+R>_-J6M*V2-10 S&O[FP5:KD8+:=L(;H1.$H;"=@ZAE)[@KHI
M[RTK3^\Z; "R6,44#X%:E,7T)S_14;J3X&M!3PF5T$.;78>R_50?-WOF$$MG
M?"(THVZZYT2W/_5DA:28']SOWIE:2_U4CND>SD1/S;M'8L]AU,RQ6'3D?]0)
MZF$X-)7$OX5W/?2"?1-[8KMU[R0SS>Y,=T;#8+YP*=GKSI,KY17MR$,HJ3Y;
MS+60[37U9-B7/%MQKTF6.B[9S.>=BDZ3A .=-P#0#!G6PA:]"+*WU>=4BM?H
M>U,38V4(\_EGH@9@!=S@C=V%7ULQN$#5B\!CAF/H;K,H,2,@X:U'Q[W&.!(,
M/_*Z]6ZSP;Q\ONG\ZVHY/_,[?5SOU)28J#=F"NU@J*?OT*@5(?>EKO%=BEY^
MW\+U "E*K<E=5Q_*ULER>$WM<VQ5@1#-Q,"!,\$?5Z#7$]QFC6WM]4'X87KP
M^#4LJ_<X16\6/A+Q&8GTJ9\S7V1=N=UFQXK<YACCD')I&K3BW22$K9"$(,EC
MV.-G_?Q2MWMNG!5Y3"AOD*+T?:K,P0U7CE\.?Y\SMK&/EC1XTS-_VM<0?D#4
M5%!1^DN__P;@+O8.J_]D?H8>W:,[T2( 7P9NQ4BGY!G(@KF7SXI)SDNSK8(V
MUL7FQ#-AXRUO.C*YD5;N9TT;D:7E0KP/[%Q:ZDFD C.8C/OL6.4 9NZG= $
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M$'UPHPV>&8^Q[#5YA+SJJ)^J;7ZDW \<3-!LP1Y-V@:V:M08$N-A9-)T*B?
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MV$2GX[.#*S%F0O0#51IY1RF"$U:3T)U!F+BNAIO8SL]$K9<!=DG@SSJT"BR
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MV.I060DUHE?WG4O;(5PK5NQBUMMT;YPLFXYP.40/_GX/XRU<-0E\BC*,R3)
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M?TG3]^0A<II!W>DC&0H_VB/T %83V7X+B,?2NA<Y5-U;:HO9?V]5$>JWB:M
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M*_NIU"($8SIPFTS!?1RJ,V<OO#0^VU0QCT<YN3!](^<DPZ9.53ECIN"G&/=
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M1H1$_+ZS!)W?O$W%2)A:C97_.H*MU(\D&ZOR6FNXK2C!.)$['6?T;FG_N:O
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MUI#?U1OUGDEYMMIRXE$TR"O[.6]LC_=\-0Y^U][0W[7TFE_:AKMO 11H>:I
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M5D03&1<2_UMVX%#.!\ZTMO+^3)#MQW!@!7;AY32/.,?CNDC;*'6N5&C-5-C
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MUSD(D9V/OY];9/Y\/>N_ID3F;,4W09Y3_L,^^E'*U 'DD[>#6U_C!E:R>%B
MMQR;W&/>D$?\T]1JA38^*324$'>!;2)4))C=.>-*NFN%T/G<K^L6R6(^_+K9
MD"C=MXE,1+-/SF:VPF7E&-#^[PV7TBF5V>UC='#.6J)8OUZ+\\'!/KR@.09$
M8YV%0R)K*'4R9CS<VVPQ/_3V=[@V0V+,7KCHOZ[#'4!<Z?T#"-G=S!_NESR<
MMQW<=ZG[K>&_\"&(]A\^A#89YX9Y-<4S?P#L]M>_=K:^7]=&V*L#=Z:[2L\>
M..*Z@GK]!10\_T4T^,*Q2B&0!+"_-Z3(/,B2V3/*YIQ)8GRE/>Y=L1<%,4TM
MV):FN-YMTVVRIL'B:F$<?M%]U_&W+0,EJ 79"J>+L'CHDJN'",WEDSNN0ZOU
M4$ML6A1,ULLN8Z00+:9D?5/RQLO0T>M74#T\2 $*K:!>]A?08[P2?<O@;,Y=
MUSR]_*5LS[R<>P!>KYTL^Y5M_R[U]J:N9OHZ4-H4#UT8U0XV$+S<Z9[G,7@"
M^>*>W?;,2?*O[ZI _IZ\N:UN1,W>B2IY)I<:CW_A7(L>2U"0Z C8N,SE2B>I
MI7!Q)_LCJ4+NS[>I4H=RMWC,#P(?*K,Z*H6UOD2Q<(#RB""[JSLS8PR&0X:)
M/#KEXO46R>D>\CAG6PEY+-@O-W;7BMSU@HV(;.=Q^T0M_B9[/LW1U^HASW=
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M+O/)[7XH'1O_6\PR"W+__3C Q]:9E:IZ'*I:L><[L=@V4C$P69%01/?&LPY
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M?,HG/35A0B7RS<SVM3]NC^BEVO72X;@\I]1J-$O5,NJ#T..1$^*VN8*M^,>
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M? MF3E<\$3Z!_'EUL6Q&TX+XS0M\9]WA[W0U&$9Q >>G*RR0P%O*D'N[S8K
MP2($-^7B&Z/+#YC;L;OZ*06;3HDMZ5NF1JL,-J0:3U7-YHNJ$QGL#9(K-MX\
MN7DV7@E5P>1T!C@<GH EVSK3C>*.C(Q?%R9Y>$;LZ_!TRE0!GU[<2DV#?!9K
MU(I5DZ)D4J2E;XA#>199Y8Q78DX7+F^EL%*W3/Q9 I4'\ SP^]@$3RJF4(;0
M'X.<#&?YY('KTI&GKDK/T0?+F;8$6;X^$%>\\X<5Y#7-[<I\A#H%K)^O9D9[
M.O"P;R91;N6"$MK\;VH1E"I<(I$^#IR$'AM;GS<^;VQ60&TGW<\4J)23]6J;
M6B#U"_[V($CVTQC:%S4 #P(-!=G*T5C:3.D5\OH%D+:_F]#C>H>D)_HM30.K
M.(,2.%LKE(X9>^?>XX<\*879(#!ARMS&=VI#K1MPZZ0B$\1JZ"FCSTR*<Y!
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M.@+BE-4M36[;F>I:#G&T,Z],WEUHQ"# T&=S4JR^H##>TS:[W-\?4<.$6N#
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MDF$'>YEQ19FC]3MG>KI0O]5@Q]C8"8HM+VAP*SY,&2TF(]EHG"X\%TT0>PT
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M6RESU@Q]!D;ZOG$/=U%S2:H8N>]DPV0+N?PIU7O)'LL+EQI=RS@J!7H&E(:
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MGN+G4)(04MBYCN\+#5DA45LF1-]X]:G?EQBGS^4I)EV-.F=[E*=RZ.% GB%
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M=U/QNX4A _,E4?E'F/A^7Z<ZZM&L!C(F EXE)/F<1;):U9G>7OXB6C-DXYM
M:D!0=/-T%HQF_S2L6=S6F;2W.'];"OSQ65*4K>OZKP2)13-_6=;(?87G2IED
MA[K(C!"TI$=M8VN5C9730+,<)WK6UQE%_R,0ZI"IA%A3,HUU4&(Q&>R:H)AJ
M=?#<GX')H<(AT5J43AC3"MMW)H\.JRP)/>WX5ACCQH6J%O>HMXT84'RY/W2S
M?]HFMTS4SCP#B6IR!]V]=E'DXLNO8)<,G"KREO)8I1/[%+ E7R$8[6.VC$Q=
M?, D!FY-?-50C@^5)R>$.DB*L@K,*?;:#B6Q5A\*SSOX>("[IN\VZOU_NM=Y
M6!X))I02VD<TS@P3Z*6E5"=U>EWA\@]H$/B>RB-N[KHM4HJ/H;DW=F>_I/;A
MC.\[I56EHI]7^1_?6 DA#VE?O'%M:]C[R#$\_4I,WSS]+:7[LG"'>8N2,2MK
MA^WOOWR=G/V]MHSDP '(5FY2B?MQ_<DVJLPBR0MK;_,6'C!U.,^6B6SU %HH
M"LL#5% W%C"W-#>47%;88*V"Y>?7&%ZFY ;#'I<_^A;H41<5ISI_GW:799;-
M]9AZ.X,8 ^[;_^N*\FMYT2OJ3:9L$Z,Q[P,.LC;BL]D3)N*AFQ)[W0NDS19+
MJHP_H<7M*9;1GC;TU)PMPHR-U'YTKEO#+..">*XG[Y)N?[)6NR$Q51_W/L^)
MRNHLX@@+X,FQ0LAAXE3Y/(UNP-'**J,?$V<O=RL8=;BL&E%Z#&&Z73E>VJ[^
M49,K\R L0HD@O<379_'ZT7#$+2F>A,ZI*0R198CUFMI]_<9>C XMGE([P&A%
MX*>;2=Q&"5/.0YEUT'B*Y<8O/':2*YKA8W[VA9S WR.24/3DN <:$^C'!!WO
MEF)JG!+D?B5-OG4>))QH0?UE.QY0%%T+8S2YJ<0BV7A!UK18JM#;1EPJ:.BQ
MQC(5S[%FTWY5KK-,RLY[-5"AD&6L^?!Q-6ITT9ZM6E):OJJU2E[JR9<M]B2!
MA*J-EY&IZ$Y_R+Z ?N6H^Z5"QW2CAE9COR>IQYN*C]FL_ ]=(TWB(LE:R(W5
MD=I=6( (E>X^X7XI)AQ/<%8FL?YVE3&M1[$?G)_KU$;<2KTCIA">AW2,6 ^O
M$?6LE,D1YVR;]S!M=] QL2I<;]P+2S8.:U:^FA$J^&%^0:4%COJX?4<#K,&2
MP:TM'F[G0;M)3K"(_P5>XV:K+?7@_3,^J,*C^@N>H/Q.^=GB^.=;S^%S<PG#
M3/VB>S !I)&*=L\+E*O1_N1Z0(%!KWF-[L_&08"]4+-/OF/52=ZU1V#9RI]'
MR#BT5DP[Y)-<RM,D47M$+^&Q)J>_*MV&Q'''<8D*N*LG71"5G0-]J[._LJGE
M+4C*P#7F8/,A!,*++U'K;89?+HCW:^)?D$N$AO:2"G> F9'<M1D%MJK9J&!-
M%B6]R70ZZM9-%U!A[R_D-]^&!084F>IU*/_&"Z3Q6P?WXN4L4IXQ78,L/A97
MTB]*G1N?\9&TQVUAQJ2";6&WXGSS;+AY$1TW#'N;/I-K6JPXH65!;0;[8L:_
MENS!V8S)PV%Y+55O\4Q#R.]]P&_GTJV-,=WIH,(;0U\=7ZM$61%49O/.E+%^
M? SW%)<]9VHHPU\A1R?AM/8E-_S(N3R+FYNYHBID;(HU9)Z HH^>Y#X'+8#C
MR!G0KB55-%NZR'BSTF7-B7'%F?$F%K!8:#/;O9CM%1C/!;RO?EVKB:J;X>4Q
MK0MV(DD0D8.$+X?O<9?:Y32G0U=JHTAB!!Y<+R)TS7BZVLH*!6$H+PE))=UO
M5<9?>U-P(5SL'$C4?[RX7KR301I2L3_3US&Z<U.F-NOV2?[;+SPW***:0D"U
MT![ ZWU8LUH9V@K)"37NO$"@I>D@-O46S(J9&SX7YK#"B17VV1DTRQ(3;T<R
MHY[1^UM4L+'!!3^KW2^^\/=/#SC:+']D#B>L*+$,&R9[T:%SRX:6]CH+T:2E
M!J\%H!$JJE_].UE\S, _8UWC$5M;,DS&D1)*IDN\Y%]+YC,]WJ[610)&2OK!
MFJ>2R.^0I\C9<)C*$MO8NA*S,3VT=>=TVK4S_Y<S+%,>Q!+5GBYNQGC]6,6L
M@Z4;S#]>DZ:.5LW?*M*;5KEA^J0/TFSUT]-M*V#$9[VM&X('[[0B2W.V@5]F
M%&TE>$V]ES+:)Y/M@&B^1$2GCH D%V.HH;73RTRG@<WZ[K8%*DQU,Z^:ZV12
M8?D$5U_(,XPS1Y]]]2[UV@CT@[QN5 @OAZDM^]JXJ[Q>YKVMQ]'9&]YG1^:G
M-D+B.BVTZ?9?^ *'BS'E<7$Y.5IXJH;S'CWGAV6=E3CO3YX:/R6)YE)/,DE3
M8BBM;[W' B8-TX+?'5UCJ@8\Z0>P "PA>:*<>U^[,^;:T"(GX83;IA!QJ?PD
M#WM3 MN0XJ=6^>U,*R#2;?BECA0#TGWZ33/YRE<V'J,U-+?3U G-S<^O;LE;
M+X,D;I:T\$5W^DMZ'';K@=.@29XSWS)LW5:OAOCD*+SR-E4:V)86&R_GW)?N
M7""=0Q$.^KH^B[A0GV2FT=9^F63C^538J2^1F6*\_FXI#-R6S"UML%_Z94\
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MSY[AH0V^;WX:#&]= ^6]IS.A9ETGZ;?VYZ+?6H(2;6^HHSKBSJOBAKE<X/3
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MYUN(J4.'GIP6Z>=X,CQF*UJI([SUB/.T/O]F?229K&1M;I'>@\]:%U-3RJ<
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MR<VV\?ZB=*LX[\>" MW/</<K@U3G_NV+DRD^UER(L?F_/KQ'>$LD]G[!"7Z
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M<4D0,#446%>CM.+6C2C&"MC9E&!/P3S0NWJB.,?C=Y!Z:_P-5U=K"6<H$KB
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MC]<WOI<D:(.=#MC,3!8347,DJ\;(.+C40L :Q;=)^;.O7G=DYE]$)!KP))O
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M3>IA=&'5AVZL?E>]@VX )7U5KW'028 &GCK;M\";1F65+4TU^30H)ND:Y\T
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M_?T":)N67SK+[/6I7JN2\GEH'ES'D0XO_<XV+OS5CE;HS8ON&O<MYVN^X@S
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MD9C8]EQ.KD!N<AZB=7L%H1&/ 8+T02.E/Z:\A 5.7D;B=HS"D&)W<'J9$#-
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M06)R=:+?TU'R]$KS()AOP8X"OCW5?GZGLJS$4(8VLE6E*JZ7NU/"W%:.[>K
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M #[:5O8*_-FPLBYX;82!WUSZQ?M(PY!U-[!Y,B"EAG_P?]A2D(#GSP&[+A?
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MR"+HARO,AHU&63 A5RU)KZG90U&.DJ4#! /[6E*G=ELJ[#\F>3_9]'XC"7'
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M.569NOUM)T51U3%QY+2I0(^2]/7XX7VIJHL<?)P\11WL&?OUV,/ 0$JB NK
MA=Y6DBM P]U2!]%DQY.N.?2F^@MVDL_:!RM^[F#E8_^!,__PHV5.9#5^PZ:Y
M]79WG$L)F%[GY/D#&5+#_@@UQ3)6$;R"C1ND=YD5&9?9-Y]74;*TE>"(+%5W
MA.9 ^=*Y<H 7Q[.\C.^:6I'AG0+X&(OI8/X0M)";X3.1DEUXUT?^;R3O/EQR
M!!<<G2?$ P:;I@E" @/+-Q?Q/#,8</RZ#G?;+V(UAIWP,*(5W# +J#=P9AZJ
MB1C(;P#&IYEJY>LW1,R8-E&/I ZO:=*'RH<?<L">1BR^LF5Q75+!PF)K%(4"
MG(KG;0)TW"4D)V*Z74IN*6MLS>:_.XM_G?VY^1,A .=75++E\<42X?%:S(W[
M"F!CT,?%)4YX3'<:%(D/NTGP*?BW=9T="L: ]UX4)CFML ]P)5_@F.@Z5R+J
M5OXU'YCD?<D#37[4A;_6Z(FBJ\E]K8\IN)O@?':*>U_Z_)8"E7TVOUWR6E/T
MU02#<>YPI=,8T3>V-,Z'"752@B.C/H**HGT+X;N)!]ZDMC@;> T>AN;L2@I6
M^GP%>/5(I'2N48AEB)YAZ,Z4$OAF]\;:$5\8C00.%M].9'>14T502?LCO_MV
M6_V1*Y\7DEDAXRE&J6TU0NO;3ONSDA[T?E(HJ/&;BTK]7@-_QKK@[YH<EE0M
M<C#0Y7G6F5]50O(_7B29&1E<[-BE$A3^\?:L95+%C<]S"!/SWQP;2G6AN2E^
MIT^[5$"2'8\M%I42 UFC]@A%:S&'? JZ1 TRW)BE,+F:>"ZF<0++$@N.*]*!
M*<O7H^(1,?MS8\67$IS=ON?%0='<ZUFX_'XF/?3U,.*=(!VILWUC$:<&!R;?
MGQ ]+U,_C##B>#,6=&OS4L8E,+H*I7>74WIP^\#X)RIE<IXI)?V&-@5MP8JW
MW&GYY1V\#R3$7QT7$UWUJ6VZP7N'/^?=9S0SRQV=%5J**\"RE?<#5<6N@;.-
MWE+L1A;J;HB"=9U#]F 0Q(77>R6)-7;57C'MFE4:,>Q9!#>!WJR2])5,8XN,
MM:JD7F)A=8.6K91V_YVE5C<PPD9Z=G<L$Y5,NGUF4WC'1.8L5Y?#E$#H=R>U
M#8,5"-PHQ?FE5(QB/&)N-YC)K(]97"[X,P!?I-821AOLB+@QLENJ'!L#2-+-
M)6;L3%H%U'&04\RP<?J%=FD8+<)3!7K:<\O;9WEZ)C\YE!5O]@1O73[L5M+?
MW)2!-KE> 63\V-;4%=]IRTW*/4$WA4JX-,^71KIQ3_VI=E^W?@(47^B??/"L
M30# !:QR(V@VM'3B?:LMYR'?O;SXR\W1<11M>;( ;SV #=;W]^DE^;B':(F+
MN\!4U5J&YO:/B7*^"YVJUEZL2?M,)PGVN*/_X2-%2[=6'89XDY2WK\BY#\B5
M*OS^#T7[OP#<<M*D^1)D\TPCO7V62RC52S1/!+S_PNK@%T>8-J94*)?PN</(
M8CHII6C1-D$W9S!<1J2C4H\O-2_<Q)A^&#%5OF*63Y#"?B[Q^F(#W1GPE'=M
M7JVD??)-^MT1L0>V%D =0/P[&Y"\HK24>@D,HM"%U;_R2ZO;%E<YZ[LC0!VT
M$AZ>EZ.]FSV ;R$K],4]ZGGG(I/@%(KJ9Z9A\6)W*C<DEX(AV,AJ4&(<EM#]
MWNR0@8UY]N&?;\ZU?V4_AR6_BISER/7LYO)^U=R?^9,F29$3K:?0-]]9Y.9*
MEZU=]6=5M&55B*I+R&=\99P,0>"Y C#!-@LM8"MU8I<\5?C/4Y!:O$2U&OJZ
M9N@:0%PH?B-H$Q\(A#< R(",1I=,8U57@,>S _EXLBL 04_!%$=6BK&-418(
M@QI93+DS+;PT6(1\#1B^1&,$6'9W5#E.P_="[SU:X13<]+-AS0=#/-WZ=P6S
M,I?7*?*'3&"4HA4X2']*<T*CMO"R6LLANVIS>-&+E42%/;Z4/(45ZH4XY73L
MY.1Z'VHLQC7 0Z2CWZ_'YMZ[HO+AE<BA:A6T672C&_N O$=RNT#IL"^,.'9_
M5V2\WNH.1D%5#K,F0)+\'I,81MV'UHJ#H6YCN4K*->=:?JTN^$2NJP"2"[[#
MNEU'),$,P;+U>!6Q*%&I-69_O\I3TLK2YZ+LZ\"]Y[O/"V"M0J6X7,O\)((U
MBNJN$L@PX9&IGN8)),&"5^/Y33HY7J(P$ON?.],#\ \LY\*@TS\&0&*L47]?
MOPI-54&&^FF@R[EP\48ZR//P<@PXS5;HQXMU0D!<FS*_3Q&,W.T\^TF9[R6&
M!A,-#[\[-W1IM2E!@9,R![\_;76CL&FV<,BF,!5_]("$,"8+O',%V%\YF]D8
MR*>VVEFB#&B86PV!Z*6+"?>_LD@H7P40#0]ZB@_?"!,/M@,2^*\ S.TJJ 'N
M7YNX*X#+$E4+:3-5K,_LITO*P)\U\"7^RVXL95.*]NT-8UC=O>&_]KRBO_T0
M(.Q]6&\'Z)E]%;3&NJ&EZ:=OSJ?',MHFJ'!J.K]FH64LA?&QB(0AS@Q!0>__
MV?IN9,%"0XJ>I&@M6(+H8W$B?:H\#"D/P!">H6MBS%3(9WOG33LZMP<%ER:R
MQSPM7\H)\ -(Z_KD6!9MFK&'_0GH+N*M[,+78Q/D>[);]['+9<CQV4<G[."_
MQY&7%_&'H!A+]U*4"@A?U%>JUZI''0#?31]J<@BC3RR M7TLT5294Y(W '[Y
M']J._<^\@4%PE=7'.)J+2%'8D9'IFCVT]:9[,'-U#PE8>')K]B:'5[FCG_C7
MZS'E.RF@H9T,QUX!WBIS0B=5TD7N!@G-<(2BM=S-KP"^H?9(5MZ20 $XDL#'
M)8>MB9H2N3'DZ]J3F"RJS(NL#8Y<*+4L+(#J;YC@ 7E<G?792\>[+Q>H>B7=
MZX#"6<"4(5#X9\*=*:F%'+A6?^C=NKQ9 ^?"KU&B/,[+W^/(;%V(][E""S#7
M.AYU3<8GAL':TP"C$]WS.&P@9_SHPI:5;62P%A;M+"J5SS'B"Z*U&3MX(BI2
MG,YCA3*F-DZD/'?BK)A49G/V3['!+W$:@5N:FSNG2WYM] [QP^L>MG D<GVJ
M#Y8)02='M08O<79BFXJJMK C^W8!Q0/K[J;\L;X<-7S'QWL/M,EL>Z\ =%M,
M5P &7Q&:WEG#[ZBV3:H?#T:2.A_WL=[,^YU7]/5H39D"3Z\^&WPOJ&PG\(W9
M@8X/'VW<I1V#?1TEH;C6/B72^C320]&U:L=_OJGMU1LXZWN1O$QNS4REQ0]4
M?9LA@<]]P"M-.; 2*,V?,WCZ:.X5P#6]O2(V6[I'D>,!D($(Z6*I5-J?'Z_,
ME]-_?U;>+U*PKNZK(X\4][L?JHH;CB&'?^XI>A1:!,OA9&+:P:@/F6!FF3B'
M$!?JQT:#<Y=<82L@!+#:)_0$88,/P(R:V4Z^@<!='\W$9FPOC>J"28J^V:))
M:I44#A-]; YH: DF..KWS9:DZU&HW8>^K>^VR0U=8X!1%(-D9!(+?!L%!;>T
M>OV41? 7:,F?ACH-.ZZN+C9S"O>?7!J^7DXJ"/X->SJ=IX ]R<>>#RBSXL#1
MNY/=PX%-9G[C\-I1]BM _3B'$^Y:L#W_-MU8Q8Q!Q.T??10_5G"N<HM:*U;9
MR:+4B4[TYT[Z>(B'RWV:[12$%FD%(:FMG3M!DT[,X(L25HMJ/F 4>9"G4NOA
MN $9L-^#;C/SFLSO3+1;^_/9<$YQ6\#;77AOKCN0D"T@-7=VD]:_$FS1^3$S
MS[;.$&$OS\G:[.3?F[N]A-]-QJ<?)EX&<*<<'2&9G;-/HC#GMAS0('VV7,?9
M/X%1B2^%*[/&CI!&O5BYOR$W^YF517'(^+VJUXHRJ(^ZJLECIBW3ON8FTH/R
M45I N9/A,V]5,K'X-YOMMKBB/M-9*N[:M@DFR =,2.=+N\4F^EG2B/6/.*W>
M;.;(3]C]V 9VP8;O;6Z&++J0&X7C>P*>G*%[2CW<L[IE+H&1P;X3C40N/B*Y
MEA(:_'-O_]J==I&&S=-<B[TL7/W3:2E;<I=QEQD9F=3/%91PSG81WOM1P;6W
M:#B20C:)<_!(-/LCM"T-U,/B6NBI99&N%]B9BO!$]!A'_7F"2<I"VEDA$WR[
MWAY /9NC+(YVW4<S(/=VJUYJB9*C/B1I*J0A-D,4T,#HXQ9?)>! 'D=STH[Q
MQ'=@@S<#DIZ2MAA+3MJE+,<B*27&B9^U;I)WBFYGK'1I38PR7G[U3-A+#<EW
MK= 2KP#AZ#"Y9.;%W_B99=3KR9'QT7)60]3NV"2Q\ N]:YGW[5KF51,@6/TX
M5/*MK=::Z#]V4U)"NO@,H5AOECWDDM)?P.I&5]4;K@>34EGM)M@]K7B,09#<
MFDRS0;??O?OY$FXL!MJR8_<W!O7DSXVQ5K0N)V;,/E3JS/^NS7)S ?I*F\3,
M@UV4!)'28-%IAYBGL;:0A9M1^Q;9:A$Z]K.*JV_6V_9)%I&P%6NRO6W3#+0K
M^<O4:WUF<%O/!+=;,K#15_5B9F;)8H^OX7[*XZB/R1P N;N5>+:E(# 1-'1^
MG?5.GH@R2>H]A@I>$D $#7?RD_^Q"</_72#2^IN$T&7!L@F2L_M$W])&# Q)
M.(CO(%D5B539&4R?*O-/5"MJ>:$V:S!NEDOBPDUS=]*UC7(QP!B;F Y7 R(-
M)Q>VD\P:A/>9]:J_D)L"Y(<!79U:8I)6ETUZD2HI@XD2V.3KQ)N_8L<*WZI$
M> ?_.KA]>>BI8@EHT?!FDQD0(X5&/DL&3_EN%K>^WTV2XTD5V1AG-KAY4MWR
MX7[&BQOAJ6 U50H-+QI<9+?X,KLFCK/E/8>[>;'S=27_V@;CF'5AJ$7>TJ.,
MXS,4?/GF=<6]55JM9ZHTGUJ4@M"VD>T291]53&?0T;N:EGQ).D^"I <4P,$<
M'#Z0,YN:TAV_FR$E2X_\7ZU&93!3/I1/KFD$6'^J$PG6L?-%NR[3A)Z(:,[P
MYR)X5G3HO3JH P"YH$>6_\(NW#\PEJIZ@>@[DYJI*']ZIZ%)[T".$,95G K@
M'&:T\;B]=1+*:DO[2M-:N7\P5;Q5G>O!*NGO(K[;YE[33KD&9!V,-H-G"T9?
MFSOKLAP;O\$=XC4V1S35OLQ7=Y1L)CMFIZ_ZC0;)-C=3TR#O;,IRA"H:D,&]
MYE7>[A]= >*6>'&2=0M2&:64=+VQ/UX:QG[QIWSN7<IRMXWMGSA8E:J)M[F%
MO2RZFU_N6JOE2[? YS7 UT93*%A,O*O*&<((UOWY6JI*6>'BX9Y0FXY$G7F.
M=RX':*9>40OC0877&F%;KV L&I'A<[!8C/;Z^.4FHE.0.#2^#[N1J*B"GGN9
MJ3Z-;J>S_V%"69W%1UD!Z)-5JC \.9O2J\LX.%L7<G6.WN)/[_V2[.U\8X!Q
M<*N+D4!5\4JG]!<^@JS%;RZ!SU"3M3Z,^&$47QI"<68_MEW-"17"IF=FH#-:
M_/23:;32^@,$>^Q.F/:8A"I;@Y%]"C_\)?SG1+>#@QP)UULVW_\EUYK_^S#V
M_6CS775BK]%:TXZJI,XC!;D*..9;(?J=HLI<5AF@J%LZ#W4(5BO+>G-.S*8]
MN/V0ZT'_O\VX-J8,*55H%^):/@=9MGA:;_E;D^_?9[N @L'4KZ+&)9#=4K0D
M@+.V_8,:&38T@$:M^S+8%/[OSS7EGTU45'*H[OED]6IFN'Q,'>'6)JRS22U+
M<L9AVE^'(!&3G!3VXLGP]PDK\-81*"@ 3EAIXSM6>,M"$BYOZ\)D_!:7K/)L
M8#N?%S^<C@G51SM7<R<Y\^F\2'G$6W2CDH8[0CX>$,(XM*U"3V N>44_9[-S
M,F$-:4DR/VE[;3=]FXB5,4@5UQ6C:.0ETAGW12M 6+=3X[%7@Q/KZBW IF E
M7*4_@RVIH]RY]F_M\M8Y9>U(CK\0947Y);]*:>#LO_C%W[5U,'&OYYF:\ ]/
MP+%4<B$^K\]V8OUG%=.;6OCOFP[)-S3TJ[\-"_5L_.,&5+E(;SO9KF-WLLMS
MHM#V?(VB@)=2/H*<K.1GHRL5A6Z.X?0>T](8@#+U*Y^H-G&IDG8!18.QZ2GM
MXH*&CP?/,.473D[]1_=828P;B! N-O1=M?C"&FBVA1L\H]"#\IEFY=*+]R9
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M"LXQ=W9<LG1(([QD?FYUY0VZ_?S<=05Y<6L*MM+T!' 2<-?:3"OKJ&TS+EO
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ML5B5<YQ_$@$.#J.&?02\)##]7/^IS#ZOYI6OHI?^QRH#^;OGV6Z4 R@JD#'
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M<X_N[9#"U0EWDSO?*;M:B0_$S10T'PR<.#DL$ZP^36$VF'CSD,1]Z[@$A.L
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M.6O9]Z(HEVWE>)<;S5199VT&ZIZ(-=SA\%B^2[9DND?MDA67^*74!])#OK1
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M,46@7@&I;=:3@ &H(&W7'4V)]H7VTN__@'?GWM.NZKUMY+57&[%<'QTA*5B
MTAXK)J^!3C;="NYQ-M:G[_6'MB)&GIB!.KV50QR-*(R($W0"*B4 O+W/A&@\
M8U_M/+*=^_O6*  #?$JOQ5KZ!=K!['O:BCCD(P/L@SM["2.UO>BB UM/3K9"
M?3]'F<N6J50;V?GU'<A)C_#Z9+_OT\^J"KQV50\Y5 3>/.K;=!YX]$H1WTT\
M1U.WA*=E896V4CZDW?R&$R%RW)1F$U*YGQ6Y1U>SW)36Y]<.BF':D%B!4&.
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M3,S2+6*%F.[,6CK.KK!,8AU96\/JIN8^U9^VX_QC8E7Z8XGJFHZ+ 6(X-#!
MJ<4$3,6",10MT&QT$@\*8GUD8W^H1A8BH?8B)CM&D,O*??O;[7;J=7,:I)_U
M"BNID?U%35EQ\]7RYX38M?N<(MH!U:?:YHG+H'/J$Z>+0VSI>%\B"%Z+5BL-
MQZ8 "[]C(WE<I"3,52L7C.*-)$0'-FR@"<K^9=/^GT[-(Y6$'73JC%A<,< -
M2VQ4^5J*S:L"[/]U,_Y??C'(UE:I*9@5B);! $$B7[&/NX$I!FB#_MLW _[\
M"_]H?O:,[CZ-2BH&Z/CR [+)7PI9-,8 O[]K\,=3ZLT)[;U"#V*.[Y"EQZ]
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M'L<MS1'O<]R;=W7XIP*0&^&=&;?D;CLL^;'/0RBV7(:IXWDV87PWRN\3R5W
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M,DB>"+BV/M797I6"2V@JR>YX'F9W[C_.>QN5OW\%_"B] LR^\HY=Z&9"M:^
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M/U8^P,J.#4"GEMM(,)D4KC7=V_M%\R<5-HF!QW <4Y#8>#].XANU>A=?'?6
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M>H\?8Z2;ANXSM^0[-?;OV06^::<6^DENYL!F\R&Z.DG&R,RD;X,YEDW5L3;
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MM>0O-^BT-PF:W\,VNY85NL]IL)RHN_8/'03RK?E9(T(- PZ3&? CU\8 F36
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M429V<./["N^Q/%/-NN6,5F/V DRSSR:S?D8'R%^0GG3<.$^*ACL_Q[Q&TL7
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M"U\!2:%(W4OOML.4 .F#R%9!1WP(]^[+ #PO3A(?HS5<Y9&;HT; <"RZQ]D
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MI\Z'%<JXF*D4<@PQ3D]47;PD#V/A]X"0.E9DT88JN4W*(9WF 'UYUH^@!"H
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M#U.=#FE]]INO'R9RY/1#I'/.3];;J*^5,F728*F';OS=+[-(+8+R@D(FN"S
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M2/_VT#F>-+!A.M'+LSIN S00U5A'?E8;1R"=(VXMJOC<CBXAVE3TYMIVV@R
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M9WP-N["UTBTQTI]'G^9#A@91TB6KCO"[AJYE$N2&@O+7!??*!+:E$8YKFTZ
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MV J0DCECE:FJM<Q^IGAC3Q_"6$O?5N(K$7E@%.7NZ$-=G\3$^YE(6M*;8"W
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M/[/]+]O'?I'H"5K2K?A7&/M7#01.>!X@\@[$I)PJYAPED5U 71EZL4[1A(U
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MYV'L5>_GL0N\9X!<_>1[2+3K_.W!=#Q[!W/VN\)'9IWD#O8>'"1/?\;ZN2A
M2Y3=Y,EQ<Y&+1>(:C=?506UW!IUN=<1=&>4:6EB(H8*D_RU%43&L%7JK!O=Q
MKM*+^')VJ)W'H=V-+D1?4,:*6TID3S?;SR5M\%-EER9A?$(F7'Z74EK#MU])
MK\9TV.";<N.7O3UH"R)G[)=%4FLI?M2*CB#NSX/=+D&/RI!$V$V%1:U$E5Y5
M8]H)DEZ*  XN\5WI-.-PHEB-SNW.-EV_SZ9M/"VXQB+7<EA\Y91!;O[DRAE
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MM=H0Y3*?\IIH2L?$*\J?VP8*J0_6BB=O5'K\=Z/0=*=AUY>H]4!^// Y+GN
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M'*K[^5]]*?\O/?"Y4.EU\PI4F-/U1%[T:*%R@^\'XF2.G:A=\_WCR3+]02B
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MH-9WD:52X)^/PP2(-2@N[M"8P,N<*/!"[6M>7K;IV\4'P'!+,+>S2"VKL]L
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MG?I,)WM[YKH^IO4 @Y,3ICR++3!T?7">[E-VW,O[%J4-R,V3^\FOIUTJPPZ
M*V< L/-'UCL.C@!5)8U_&9 !_:="LG^MOF&CC_DIU*/V%<=.B#BN/O'6/ /2
MF-OPQF< ]Z3R^;\YG0$9S-4(U3. LZGH###31:Y>_-Q$?]Z9V#!RXUPU5KNR
MFU^=*.5-_7,JQO_"\ZGVHX##\YJW\B9JII]%G"]J:IB4=#0JV" I$4JN!C?$
MM2[%NP1S3 GO)#(>I4$^$OAP-\U)\3SZS ]%4SC'2IAM7@AO:Q@$:+,NN7:^
M#SC?J:E*V^=NN"Q?]AHSL<]W_=3II)02YN\FZT[Q(]L_JZ)V 3D4=XPOT5ML
M2<NQ+/)2>L1ZZ_VDV3S?2?N=.'89!3F%2XJ,J]ZL>X;LEW:V9>DP15KHIO*K
M7VIK1Y8=Z1_)OC'/_?E9)I1-&? P9_*@'_6GVWCPTNGCP^]6P[-*7J?;ZWGR
M3:F4_A0V#-?IDG#\6PM!W^/O5E.EQ<5-(?IGKKH8(J&I6^>*4D'W+L/6J-#V
ML3')ZPLY4;M$'O+O.Y5PF $FT>9+[>[+ GR_=*[6.DR19KDD'[:%II'M#P;'
MP8-(Q@F^N>:V1OT]@CC^'YQ5E#W*@!7*4<8B*JF)M#*U)95!"$%M@Q08"'6Q
M.NSA?%\M2KDV14'XUK+DL&-4@+W28I^>.(<]=VI-DZD?(N2P;]MG!#R/M+$?
M.][J)W)/?YUS*TMWK.DAJH.JJ!H!R[)(^IQB@M^0:#_T^2M?8X%^F3Q.RLX^
MM8O.:@\SJ4(^0^AJ<PFDV/WI1SL.'GEL;E!+GZC):YDB,8I/6];EFPY0:#G7
MD97#-SC%).OQI2H[2;($)NNOBG'G"JH"PUXQ^[!H3C>%EVEG,,I:^A)S.:L!
MX9CX4/XQJ%DV58$LC<IB 17N1%!=$$E*1@DL?W2=B.9^^3_8>^NHN)ZU77 C
MH2%H2"!H0P()2;#@;B%8"!(([@&"!;?&&G>'H,$E. 1W]^ 2" 1O7+O1!IKF
M\OODSCEG[G=FUC<S?]Q9YX]:J_;:JWM7/?NMUZKV\R8Y8VC)>T3^\8+J9BC8
M9Q!-EHJR[U&-%JU=[X4RUC>9ESG9UB3WMD!VE0VO39Q?S8TX>Q,8UB.]X9'.
M!B2CYZ'V3]J:+#XD%R2K/:3'E*-G^K(^W13=58&)W'PTNZ^NX]HF(>SJ0DIQ
M0>IJ^[L;N((3ZZZ,8[=1(JT<5]JI>;:"SQB(@[8"PM,%S<R,GQ/=/Z?H.I83
M@[BKOPVLS9QW(;OGLITJ]\7L^X;HC3=4C,#+DCW@XBH_,PHEORHS8S;C%,DC
M$;3Y><'8J^/+F&BIX)DB2%<>WA.ILU;10_BET9[VYUS/=16EY&M8?!_#>P\J
MH'+-2TD3,1NY"1<-]'J>_ETS9[#4H*/GG>,MP*(,\_/6]\ DL@UMPX782L/S
M-_-S%@WF+-V=JW5E7&:9-E_DA]KP#]!J4, 6:,3PD2 )1%*/$JW$&A?7LLZN
M(D(ZGF(P,AUM*!A[ 4T!UXY;W0)X:'*D?J=M;9'-EX.Y'LLQI_5JL ^ )]I"
MA*/T#EB8%#9P\X93*9$N-M7"IVPXUZV)G]I&<  7K_#Z!!%1"<1=*VW42%K;
MPG<NC^H:VF*KTPB:L::NLR'%=(]8N8] GOA),I.4V34)L"!@DG2D38DG2&YP
M@#!V)X-#H\6JONL6J$;5A>!3G/YFZ5-BK.MA:B_BQGC<D2ZJHQ2P)](HE7&U
MYC:1-\2VXOE#%IL&NF^?&C2[LB"8WSM:@L#2_*;1%J<^SY">X_=B\%*<YL$I
M!58!_V!^Q5YJL(\H-M*%4%2J9MH&YK<@VP%=;TIR.<5VX!K3O9Y):.\4(V(M
M7H(4J$X[AR=/#]K;NT$&*0[[_1/TMUB@-1CA<#3UG4*R_(7B61W:;(*C$KTM
M(&_;/G72SXT>KC^,S@4<-'@.?JUFWBMU2D$_0;9_',_6="JQ2TPTM'F2RP(U
MU&'*? %6A!JE7@@")^UA4+;I4TC-&#'$%2TY/]WVGM3XYIT)Y@V1($PD2,ER
MM :)OYK",E=;4B:C.KT!C'@\&R1L!FASIZ+7%KQV"\+96/>]S<?P%G99&&J]
M1'*"9,3HDU-\4%!3.A7F7SP**D/24V9_,9FLU/KB-S<#KT$2NUX@=^#$-B#U
M>X%I*3*ZDRI](2E7*AE?/H5(LTL.0VY,'#-&H$]V%"B]\WJ94,Q'D>X&H;/N
M.X)(WJ0\LR\.=E@/QPGV;3R8U\H\*>J:?U6@%& >A7,,,^4#->K*Q%\CEC*5
MVS^*6"9%;38C*]:8X#+!\T\*+**W+ 7#>VB-DW%PPQSW$OBWCEQ ].2?U9&]
ML"<DI,38YE6Q##A/G*E]MR4Z)?I% TZ77F<^7(U^BXR%WP*Z(2SVK+._\[!>
M%09^)3 >%T(<:(MAU=8VP:VV'_;2MF7G*)Y/O6D W0LE$+]@P3N4$-F!"EL<
MZWGR>0Q\I'3::RB7Z).E?'DG4OY(99 \XF%OZ$K[O67+/TD'FG]?^](1BH6T
MM@5UOZQI=3:Q*C,/CY3P1ZW'46JXB@"4%ZR:+K/R"-LUKX )OR5J.(ICH8UH
M/7'#Q[#5K?-\.X*(3Z,8F:2,'H37E17Z2=16IQI*=/[,9@!?/L)8:<<7I8!8
M];FD+N5Z8?>-LDH<[,\(#+SRP>EDJ"!HN;%J1H97[%$%ASJ-!;>1-_"ZNA9M
MZNO3;RX1@'$$[?!6_"_$A7]5^))7ZJ!>_4CD'=(=$ZXB.#5Z\AXJ*R8X,%G.
MNG\+6+2ZL2?+L"ZE4VE1$A,>O]5D;_^Y?#&($F<=A(.ZK MD_;QD=UD;@[*?
M=5H(=X^NX3PZ.<B$GO%U&5 LZ2.95,&,39\S)5)ER]G6GX6_#6]V!)=*4YC1
M^ C&6=4B#$)+A9^M[I5IH]740O&B.*5W#*H*QQC3-&*0CA+3^^UF8P\M^9ZT
M_2F58;V\%!?]H.S87QQDF^MT!K3FF/.U4V&W,2!8-WY5! \'B8B]J_U:_$-%
MPI6_FV;=Q#'M&.C5O04"=0HA0GU7TI4K<E0BHG+DK(JC'O[U/P>&"&X.\6D<
M)("(+:PBI+R;L1N\6_(:/Y>%=^VEFGMI%FHEJE] [ VQ^Z_H/G=N]&M;?)T1
MQJO4MZ8I1F\&<>F6C;HR_'>[9WQ>0"ZZ[P;!DU">F;,7FJ\MG+DSFATP1D?#
M@'4V !,F@#UMN>XSP$7AK8YA[_+9Z0Y9%<[]27G2D'C$=ESXLT@?1W/%#J3_
MJG?2TN A](55TZ,,^M8I;I&'G[PR>E&-SZ$!\<N;A(/8&/581:5*8=![\,>^
MPM3,<_/>/;L[B4)B@AN+/@M\=0LP# =.&>RH4XS=98):!4DMI'W.\F[$D1LC
MHU#C$+^ZJ;IH7B$(45[W T7]_18P@3"_G1I;\OO):!QA6A>!.!NQ^6]Q8?U'
MPXCKI8&W<$G'23U-<+)/,(30^T]K)$+',X\5'J+;UVZ!<?U6[9:"\X!;(,Z\
M_>P6>(SV.\78F:$[)JJ]\PCE48%N&E%LSY'A,"M;P"(N-G_N=>,L&PG"1_HI
MZ'HYDZE@P&J2C1 .SRN0_VC]5C.S*KAOBFTL7N"@F0P&?3".9D7R+AT+T6*]
M;4@\=[2WMW<5W6$TWGWK8UQAL^G#X]SPM/8FOX7ZWXAB+ A"PEZ3O='U :WJ
M]QS&2D_*_@S)JN:B 4 J"IZS)<NHM[:1@H2]2[%Y3*$J@X'Y50+'8!:%N/[A
M/7\F!)$_XLR6:F^^/!9NI3S-D\Q:=N9F+1QJ%+*!'4>;R3[LZ/.G*>,K1@K<
M%*=XZ07",<Y 8WI!&O>Z\OF[:)1G-!*W0JXIC+_F.IO&TC=VKB["),9!J?43
M$DO*FQB"+S7U3"%>ZDO9JX.^.>I-HUO BZ/LSS(2WGB'D (J$G#SWK^X\Z&7
M#*YQY>]<ZOR/B/) F "4T^+JSOD_A=B0S_</^&UN*C^)#+$;[B"!G!#3[B[_
M_4^<(V$'G'0A3)VSRF/6D D\PPQE;-5UK%I%Q\P6 :P$ABEZ&O*BM<RP)9#4
M+Y2D:?YNZIN&Q_B?<<U]C](P!9WIHZ#)9^D/-:L1..%F)9H"'CJ% ;'QTUB_
MKT@@HFN5Z*>6B8)*/CR-9Z 0F6=Y,3FR,D>,ID\^8DW'HT(/M,1P6 [WVQYM
M3RQF2SO':4Z?'2])FXJ%"%Q1 4=6 T],?[5;7"?$4D;%YF-0,GKF)RC*W-P"
M=PMK[VR=W&<GL^8&$?,:/3T9G!3CUE6@='WL98ZE"BL/="OWY(^9DSX>-'9(
MLJ9B6QL@2Z@\)6[>)K1%.JXQ!3G? L2]1>65QK8AW;I2PGO4XHO=F)!U&G!P
MK1XB*30X0)A/M.:<2U\2ZT7"4WK.(O[%L4:Z=$=>;\(V&F35TI\>NVT[00/I
MZNCG;@_PZ+TQ?RA+OY8&"0R, '9T\*]_( 7GD>/.(JR:OZ6C+0C'$C\JU0G@
MQV:T--*]UQA/@+D+6BPQ(O]8>HK=^S'>POYIPL;GTQ.N) IE?C3#F.2/M-/R
MO5ZT\!3JL4>>9)&.KAO5UR79)KV<%T0?2==C?8/&QNG> 9LM]HC/%UWUJ8$)
M%0&US-_K %98"6OC3YO%&"+QL7K)@2(HP0Z)#M+A0H>JABK]L-+!ABW?-_0C
MM!F7GJ2CDDFT=GLC%R+/(1U2+L>TP8!B[H<^3GZX-AL)FWA$BY>BR:W;\VQ,
MBB'"9##"!=-')#$LIVDT>;[; M_[BS-C](C5!_H3,O[U"ET',<$N!%.TT_)]
M9+3<I#,_4R2/<$@%9\XC0SM)4FF.A%N@+1!PT.=%MA="'&#*/VK@W[,W.PZH
M#/086-O$M@KNN[)+1G$*S;1W+N+,2L,%QXA*P 6\V5QZNKH]&_%N':_PMB(<
M,QPS\UVKW0S,XL?FU@]$S5(BF^U''?LX],7@'_O:7B!ZM%7B5Q%0PEQV#C/'
MF^[QR&9OPAJ,"4M1T.SIG5I9A@1W4?66?=NUS+F:/W\>QSDT,0L2H!2V$^ 9
M6-[1$'S[ ,4U?D9<NY>Z7N%6OGO/Y5*Y?9E__:61#XZ[RV5GA0*B/=RZA7+U
M6Z2*8942NGQF67CDY76Q6,HY3@M:CUT3SM1E^P"2L6O!B- OH))WY?A20[U
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M.CSG :-(AE#6B0\/Q-4P9O\J(6R&_=+6EN9!X<>_OAGTP0B#M;'> H/,L[?
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M33@=B33[09);UZ"?SGW(>O#.G,SJWM?_Y4&)_V@8_YBM:/G'RI@S"5#V.%1
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MN>#UD1IOJN%-0I:AA3)UI]K)/1)5F,<8C'53$=YX)<NXM<3!,ZF,2= GC3_
MC!;K5BG.BKHF:=9L' /"L+3XU'AM!$]P=-MK")?BY*K+)$N!V]K7;*D&T\NY
M!/LXG]Z(V$'"(W'PM6Y_C[7D-?OJ6 A;0)LJ_DL&F<6:(/M*.P>!(0*/625]
M/<3Y+;#?3@B>D.1.NHCI*&Z)]S/9N06 B_4PP*RS F/GRL#_"T_XGFG#]-$J
M:7"R+4F/9M4K3%%E"0+[Z?AM9KJUS[&FJ\NA;?=F3D/4)Z\.;PQ36#N4!+">
MGH*+]PNB)#";V+%1DO#%X  6[C*S#_[OID\+2?MV)Q%=@BWO2&)O5NPSN&;)
M?'-'^'J]PUR@#$%S,'A[\ 5K3;RTV*39J"3!L<#\(IS$B56<%*55?0L$?%M3
M\A-^S68:JK?>F"R.M&L$V6WYARP31@GL3;;>O^A: M?"$V:24Q72M-UU^(]G
MR"ZEITZ<1@\O]S+<9T%8;-77BKJOW\"D)_UL&9YH^6P[WIGX$!3R2"^S9^@.
MB^6@C"<-)\)57Y;HY_KP4?Z((640'MQ5Q98013K-4U)EZK=D]2TY=W2AN) :
MX\)4^!:HU=WR06FLW.-"1O?-M[@N/6]U&&7[DI]@_97F5=:#!!#@($B $>7X
MQ[R-,O7HW#%<IC+DV[=6UN^1&)VQ"RGB8[1R6!D"IZ6W0' &-Q+:AC=5>B;@
M](?US4\,PF&-F&(.TY48V<OJV2BWLRPBX_XV%KABY1H[@:4^::-DJ621S);<
MO9H8FXC8]/^I8W405E0%T<(86>O[<<B%]\"6994Q:)ONM"R3$-DOCI )7U:"
M;P7G-D\=&)\\GR$GBWP:CU234%92; 2-DW#I)O7HZ;,3H#S@;8TE07K/F9_Z
MB>?[Q6^6T!"L^^TJXMB' >=#=X'FC$ZHXW\&FK,)*)Q(&;\S!<M5/QYT+LOH
M<,>K0JRKPZTP)3I/S8E->$:9\6J*8@GD/.)9',5@T#QO5Y(+/UVO#XY;G]?&
M^)PGQS7?Y<9[&Z>4SZKC2=_L56=_S;8K9GS%"(;+=VM[ASS]A=(K[CQO#H^4
M_D#@BN7.),UIS8A:KZ04CK"?GH;RP/M22J#C8+HI^GI-TK6!,>]U.O81B4U3
M';HEM=\>"9:';82:WF:H5Q-J\5;#T4(TQD*+(6(7@]J;*(%JS9M<E((G38VV
M<]R?[\0R72^/=AFS"&W#4WG]3>$%'YGDJT*M)T2'&4*8DIZ8JC'7V,\6%- R
M8_4(HG-7E7R@M-55+E3E!=:V%GA*">."-ORG]$:.TP]3QY&W@-W12JN87,!G
M+YD/4<] OCYXZS<NDRBSR2-68?:LW53KW(7>K*5^>Q;).(8/%Z&GU.),=7_E
M/G8]R> G;^'08&LKLLB:V570/#N8?HPA]L0P-J9Q6XC8,[['*TJ, #V92-[T
MEMG6HM1BA&>=P^^A'6GZ;QJLIF=;-[E[>G;(YA7'W.=YSGO.ZM'><X/#*[##
MKS1;]05M N4&JZV11^$HMV*4S+0U8VU-@NA(ON2KE60X#KI]D>(0SZ5?0IRL
M[<E.);(=9AN($N"N]HK#YVML.#:X)[$@.R#&=A!"+!D$_K6 ;.Y.): CJFV6
MR)_KMB#*Y"KNQ_2EU!PD>"WHAS%6ZR!*:50*G=!_V7Y?FU9TT%HY<]4[!HPN
M8;H%RIO8(Y)N@;E;X'YMO<;\R5/Q7/[1"V69FV-M'RY1XN$KI4XAG;TB((RQ
ML4$/A2WE*KQ%8Z<$4T-C:E- :12\649-VUM371/^,$4\=_":3LO4AM88P]OW
M5S[-?XB*?4206^3F5^+NZ@!-*:4CU=ZE$MOO+9 P!).<PT5^BTNZJ?">[TRQ
M=(OV;$WZ<#L=2*X^]K%ES[S6QS]XX_8^;N$]X7Y6?'KV+UDLT<NQ)<:U'Z>T
M5K((@P/B[[M0JOK$I4E6D9&YUR$MF[]A]L"Q**1/R1G<UV1+A(Q>E0E",7V>
MN4A]L^]+>0LX@5>7*9\%X2>.NI_N3%:UD5MR(NO7ML)12L]*$_WX&6K(C]>%
M#6, H]_H+487QO%[Q'20DC<ST)>W@"&RX*.'&($%;@4C;OG:(0Q8V5<1QZ@<
MNU#$7=01[(]"$^V":9HF6_:>8+W9H[';<7@BS>"7V=Q5_YXJEVPS=*4B$OP,
MS!SUXL#9*6KMY^X:.Z>P-\G8,S=&=\^VY+(#CS4^7^[MR66IRLK9,XMTX_K*
MRD"E9+G#55FZHO,]'WPZS/+OC4@=D^>QF3]3-<<KF>Y3^XX9I9ZFEAGZ<B.!
M&AU.92Z=\@7I_KAV=A!VAI16%O$__R[AGV<^]#E@)<3A]8GS$<KR9FQ1Q_S7
MHJF=-HP^]?B)NENV!>WZP3F(Y<BS:&Q(B6QC4UTDBL%.N+D(%E!3*7_B+-!!
MYW0ZB.&S6;:(^@1_5IYFB]/Z"&9N&O3(F,$L:UZ<_L8^"IF%!R6S!-.TP5ES
MD)\%GM;Z)&\$?7$K8E=?DE%Q(/*(\ ))K;$ZS';K@]MF;)4.69]R/DA[+$(F
MT\B(<6@UUH:[XQZ@[=)8KJ]36WH7*C?4U3N_4N-<6#D%N8!^7*DIA7(.PJ+!
MYLM$^XOHP8?X!WHPIO4(@D!&)WZ1/JZG[LKWCORU[RV?>UU$G,4VJ\^N<T7X
MW9>,^TAP2CAM'-G,G(_\5G8+=(G!MW3:]):,ZE]+:Q2ZB8I[$\ZAF(N"* Y6
MHBB,9=<BWSREQ_BW<K!D&\N/.V9YE/ @PK*=SJSB"@[%LL,<40XR(I25AZV5
MXK1FW>F/T7?14_ \6\;XI4I9U2"G&:/L+2!D<J,YLUG*@Y6[1,C8U10:V#9L
M-MKY7%3O]T%J S]%!4OTFM=8T)UNV-87./[R9<Y_Q]5>'*T;F\B_X.#6J6_O
MHU9ECA6!2*B/S&FL;$7&4[;#RUHZ"Z)EG3]*KS#SO\(G2#.\7HDXV4/33[)X
M.L(/MQ1_I+)769*'S<2]>(+S>B*-2!R;G2[?WN !E EIK R/1(?F+GE;66I'
M/,>EKXG,VV@8A-4;#8Y9[GB*Y%JAP4@9J^_S+<9Z=57/Z;L=0CDUGXS-6@/V
M8 IDV6-?I\(69I@7Y]60\M2GXYPX_OH\!/O/ ,?MU[@_TUMEWFUZ&I?MB7(@
MD@)JYVH:3P^HKQ69K06I,YYG<C)S?Q,A_LD/R\*>S48*P8@"O;/[,EZT!RO,
MLNKE-@6M<8%I2#E;W)UI)09$0D=JIJ-[#<+<O0XS:;J[]:G,8O0>!#8V\'<8
M#"J-NRR\P/J]][CW@E0;PJ3?& XV$73N"8V-C:5^H*,FKUF)GIY@/SVI?ZP^
M*7'B=/FU0N0N5@I&4N-&K_)^A5$FRBVL&*.UF] BS _[SK4K?-L8V7L4!#N/
M3H?"[6V+>XG>QQ8"C_N- B0S4O3MTWX=^6BL;:V._=;T90U<^%'U\.0%DS=#
M/8LWPY&ZL#&L3+4#+3SU38T.(;O47UD@B\]-NG)&;Q*%T:_[\*]M[!0/1"H[
MZ1PM<\>58KY'Z>+W7K/P(7F];NI%7W[FS(+V4N_JD9K$#(I9>H?R3[_ G-L.
MI6HD-.!;X,9]%B'61T>XT\3H+]X:K?;+3%2MK#:+Y7WD1#2XH( Q0VBF_V[I
MXR] E#IF7#3RVY8%K+YE]0N90%W06,!5C +@ &6+4PK-$ OO)(_:R]YYS\83
M.@[SN 4()"^]Y/@O<3XAZPG4T?Q(@[_J'LL4[;^5"%1FK < P?LL4!R#'5NA
MG642GF^\#=8GU'83*=2_Z@8XW42\K"*0OBO6&E(()?\OARUF);LJNX^7/O(]
M)NH]H/:4=#<=)1XFIKC.\1%-+-P*$@IA]%-;I G[,,L_P(#36,:YB,):&2IR
M3K>\UI#GB5N3+^H6SG<_V CE/Q@536#W0YD50([$K57?:ZU*)63%/E,&\P%T
M=A!3D:MQ4"+$ML>5[AZ;#8IK[1MU$;>;F47-S;M%OA*LB*)1$4[Q=5((O;^6
MV"-/:R\$5I?J4/9.O3J::FI=RX:]/#CIO(COTC+6=YJP-^2<$M\W8ZI;[-$M
M4'TF8M"]3')H6#E=5O#TI39IK +Y:X[9*0$12>)WHXCZ4$-D;K$FDKIK4N17
M7ORSOH+"MV*N-,R#'V('UVFN FG65["F4 (V\4@&N;K&$&[; BF:V(9= D,2
M*?N+6X#8DW#E6L[YSYW'>@N8:0HTA8U:U9D_C1? 8&#$[(%C,#'.YO53]9)*
M^]_W>0'N:LE!W,E\"-U<46L+T^IEM8OL);M-\-NMXBC'V8A;P$T!T(!OYIKF
M4F>&Z@LWRS,OZGZ9.LB\B+Q7K_91C7(0FU2<UL%.KD(:/AM>P_YX3LXU>SE_
MVKYN#F=&6C+BN!2#3C\81-8):9.M&8O2?] VO1'U1T;^Y2<_.<7?<9[\PJ?8
M?OZ9MI8&^'KSELM@8<E"\_ANY^_>IGU)?.3#5+R9#@>7P=@'ZNON5$#T>: /
M'8:6_DM\GKI<:@9C$34D"NY]_\S*PG-/,[^/+^N+V7<I-Z;^G-3(@B!A?L8_
MO+G%SP%*?JS/[NYW+O]>A;X4;E@8H$8!$'T%=O_?_SX(8UV4/<X@%"H:W'$>
MM9=C\>4?1%_Z$[*10'V)"VF,_:#TWT7?)TO.YJ^BWUJ>!.U3C WQBDC?TKG:
M[O_!WGM&1=5UB;J;("!9D P%"HH*2,ZA0"6)@*CD)$F2Y%3DG). @.0D.11(
MSIDB2$Z2H0K)H4I2"05<WJ_/.*??K_OK</K><4Z/^_Y8/]88!6ON9\\]PUYK
MSFWW92$DJM];]V,@>\),PVB8%-ZTLR$E1&QBM\^C+?]ACO?/YY)#5=9R*^3+
M*4Z!1SA]4EO99/FEPH:S'R4$<_5VSM,+Q)5<%GN(XST ?$=%[.IC$B%5/+2!
MZ?3);KDR5U RQ?(RM?D[''913GM $"X/HZ?IX::_K.^=+Z.6HILT?3CTRG[_
M-'GOURW&\_1+/#FXM#@8L$P-C<88<O?8N,[MK[W[Y6RMB?,S,BNK0'59A+T"
M[F'<S!SNL8)AO09(3TK7FK\+;= .GI"Q]Y.M-8.#94Q02AUGR:XSU#HGS<,"
MD<2\G"I\/7XE4GHN+)KBJ$#ZY9L@F^ V[=/"HMNV=RGX"4EO/-QM6,-^!+!S
MQ6C1_H.9K$87+W3PBVY9PE/'%[%'0JI3J8@/:$%O-WBTTYODWOJD.H_\SHS5
M2M7'H]][U;/8[SEM#VQ&:99C!0.N4,Y*=.'32(2-;O>R"(_E3KQM9:/"G$G\
M4WM%T1W>$8?TF%P_4>@="Y_[:)'33)9QEX5]U1<4G)IU;K'M )*L0!R;1P;V
MVMH.L33>C-:T=+)MC/#\H9>T&OQHW:>AA)D28UV(1BC7(<V#S.@K<HI&0N2"
M59,I'H\HF<SB(K+Q!>?1DYWQ.S<A\ ?D4E[*4YM]$^KUHN^QY+BD+=0+,2T?
M_,09'H1_M)D!<.\+$N";P:A^@BFUH+VQH7V<[NT6]O9\K@>&DW275K[8&#TD
M&EG;FAP&G7TU?7Q,??9Z,>^Q<=;3-?\I1.(.J9P897+V<GTO610O)&:$'00:
MN\_;S5&,;:D%@K4/9[TOS:S!VE?OQA@UQ,^NR;6R:2T:1XO2K>7+@G,$%S4Y
M4!PJ8H7=WC[3TERG<I^QQ3[_OB0#<P'@M>_WR4*N&-7[2#.(D+QGGYAW#6Q0
M+'75J"=]*YT\R^"HCWD@[Y\M19]D0!Y*#>0]V$Z3 ?C??=26,&Q3R6_1ACG]
M3-HY@7M[6 -OZ3@"MSNH.N=WD%Z"Z''H$/Q1)@E8_[Z2+O)K]N_J0)CJE\#M
M&H? 5& 4-9.!NJ__Y'&+*<5%]Z>&^%,2"O7HT\"S-,>??KLQZ::(<D_5X!,F
M=C5D089[;J(RYT*1/P2D\ZAO<O260X XN74$*KDW"Q^VIO^,2%*%Z>7.#GY]
MR,R24K+YFY9U$\:CK-E\$ Y2)8^Y,V%MZ>7-PVJ'2(8L)/F;FOQ"2+X\8?2&
MDP ?+,)\GF!D?>\L<C"3;%'0.F^E8]=3^E)>XMU8\16ID"QN3/JBX2GAU><A
ML@"=BD2+NE2W'GW'D3E%#I)&BS'*@0YMH.*I(?9.-T) AP!5 #VM-MG(>-V<
M<HHXP&D7P5C@;+]<N^*AP^^*AO3DI W&!FYO//1]-3WLUN/:3H*Y8^E2.NQ>
M=)EA7,L7O,1Y&&5KK(J[SQ;ORYA:+5J-N@;\/E"_^:9K-?.J2B)\D-K@MJ$)
MID%R"QL<RD&!$4:N!@'M<\B$V,./#.UZLS2HO<0QC-0X8I2^YH,$<69H(2*B
M$#D$!V6LE9.T/(#_O@:^N2@_F&=Y>C<X7F+=$8^//]8AX/9 K[ZF=BA\I:><
M\M78F7+.UK?+;[^VB@GW"+I6_6<M<!H78=G99.^G:ZS)R"V^;:?F-RWJJ/B)
M"8-6 T1Q02>;.C/!:UG!IWGZ=4K#S_4=3O4?<@SE\7-4SE,+2@+] ^N(J*/1
M(KW%3A-SP>GOD50M=VKBQ9W5U>)5QPB/R ATAE%$O;_0NV^#9U_6/"0AG3&C
M[9#X+G\6?NF)R?5CR+8R *'??DU&V5:V(^-W8/MN/?>2-$S2N?M)J=SI)"@;
M8AJ@"N,G&>(]]'IB28FNR1I.Q%_#LWK(W7'=\.,,3')WA#R8^ZX!&B4XPZXG
M>^8R=772@1I]B]8 X;"?=,?HV#E](]+:M!R^4'H38E.XGQ1G#GPVHO-^Y](G
M%-L][_<((Z]>C8:M<ARK;0RQZE8=UKN"3W.@AE 0RF#8^C0869<>0^=\8>(@
M3#>_(HXU.0<&ZYS2_[?M!D*EJCSAO$2_5'[<*C71A^>XSU3&09'407=/FJX#
M1ZJK0DWZCMZ"C+O-@]JI.Z.X)6\4\J4'=SP"R'#5'R!/PU*5MCGRMG<+&A=G
MC.=P.1U)7YI8KN-,%I4_>83-86W!N9]75QL@PA+^3/ZN I6:O#2P2M@[A2%;
ML_EP G5APE%M:#(F^HY\NLGJWW"&L?:) *!F)N8%\_GET674==MGQ@$\8>W2
M(E2,J2II0L6DQ4^S+,Z#'G_CJ M^5=2"A$;Y'PD#9U*UCA' 9G*'SQVEPSIH
M2$V./2V/@T4ZSP$>;Y;'ED6N'Z^+'3[:2;^11JPBU,C-'@!]K'SLB"^M2\<Z
M#[5L4LG(TR%2YNN;'UQD6E9O>28X6@'L=FS<7#@5I=(D8FI]:J)KVN4VY9!G
M?O"+LG2O?%2\"*-Y93$W9[D+D2(7MTU.8]TGH[54GJUNZ!.(H.1=K-'MY5O(
M@CA(?1((-)G=*+<87]YT\'SGZS&&PW9CGFC(DJLB.P;RX$V\[!,\S;=3Y)#[
M^;E^'+*%<S*%T5(,XI"] -K>;R]R)4-+]G%H3_.K*JLG.1'5E34!$S,2>R$$
M/1:-;.F/5DWC?>FK9 &GV38<9&9>L5".^]J2D&>!>*9\_=N6DR%BHUA)%>M7
M%O,Z.W>LB KF(G_D_<IK).?^$AYE0Q+E/X!8AJI)WW)G[IU\6(@ 8T%\^)K-
MIZ3&GZI*EV5>!5\#KT"UNY\GPD8JU)2>NL:+TAUG$RNK=AK0SMC);N1G;Y\)
M2VQHL[P9OD)=<<-$RK^PA,SC!BRS1=QE>",R]:3H&' N?I1-^&G;P[L6<X;4
MFN]UMP=2U^ZIQ^LY+W:87@GL7DH-O:NQ5GXVLGPPU\]%TJ-TGY$QJAC7I53@
M-<[]")%["D;1K!&"A&$1V"4Q?^3,H<5HYJ[YX5T#*S&\+ ?G'IJ45?T1>1R'
M0_3,Y5TL@\&^4>5:)5T&!2Z;R8->7*,[/G[V3YC>RDT*-AM^VTFBGJTTMX^!
M\ZPRJV4F>D0  Z%=Y[CTIJFF.@]3DR@0W^NHBW\.!,8U.@0&CDKNK,_;!(^D
M.V_OE>=7/:+<&Z6H\927J8EZ_]YA7Z,HFV U@$$74KX/CZ&]+QT'HP]^]YH'
MP/$#]M7WG3.$!@\V#B95:^L;F\0K'D90R7\^K\9*VO$XGQY\A)UQD%"P\T9W
MP+=P?DFR^O<G 63IE[38%$7FQZN.DD\6'ID]Z:!BQ06%)$4 &[#N0_SRPP7\
M$&<HF&U]OIANQ"G*1 I=$1_Q"#N_(KGPQ^+BXKR6SL*B/H]UN'&P6@&KR%/I
M(9"JX5NYO/SM\];ZN5IQ(MT%[\Z6TB\:LOU;]AU11QI;V83U338A^:8?H67E
M%>6D_+@HCAR8ZN<HA[?NY)=9>U=OW,5=W3WEEAKZ>"=I]]^H23.>9/EAV MW
ME(JTT6[*(=LJZW%<4Q\E'?-HW\+4(F9J)HXOI:Q3RLJX;/*;?/G6UFX$\5'9
M9/&")0R<E#J_OD6B^6+B9,&L;KIF5W=+O;Y$[P4CAT?4L:"N/#(K%"/5>QQ-
M/SCRC,<T@IPQ]MF2PW[JC_\9LM>?MQ-= S]LR7;_L)@HW4O#&[7<$\8_@3XO
M-T/*;[#D1G#<"_Y7&O+=V"EA'@G*GO@>A#7L?H@&* A4&VJWJGI;1R_RBX3@
M5QB/*'&=Y:\L6Q$,1_;-<OEXL04Z.Y0[U.<N7X6KHY2=& F_*8#GW_-YD-:Z
M1@ <T;[X^GH8354:?:6/,S-US*8U8=BFQ(H/POOP5QSZ(()S-\N^F3J.%M:N
MNQ J-K+VQ'-D;0@W!<[]Y/&7*\:E:<\-@R4D<U]]F#A6EAHQN0:X6.K5?2^V
MB&=Z[[[&$RI>8R:U=GNV^V[L^&+(3^AWM6ZIE#AQ7#S'RY'!696:F(G!>09K
MBSX*6E:""#$D/G;A_R!T]@PYDK]F%^'1.IR1I[AVZ<@K$<]1P75P-U[&@)14
MM[#H&-'25%/75AL_<[#,$>DN-W<_$2<O]AD9[KNIUW@/4U:O 1*+>N-#Y3'G
M7:5// ]#YM2G0*2D?!RV$8^ $K<;DUNTJ+-H:'F:S*\C=>'.'JR?\S'P,YN9
MBO2Z!]G+1EF 3RLODR;$8D;AZYN*&+XR,EQRCXA U<F/SFELU9-EJS5UK_9#
M"+H>C;+[WSPUQ/NZW>="36&I=<GF7I0'WKE4CNW/Y)F#Q5^."Y03SI4?9XC-
M]%';["6A<(F7"YF4#7/][GSF2WQ/&!= ]ER]3&"!Y,F4SO:,QHSK:M(=W9ZJ
M M6WP8!ZR2/LS/Q\R_GAG)JI/1NHS<#23[T7;'KGJV?K1\H3QS;\+VHOA!*-
M;,RPQ"-T^\@I=QQF;LP>R(4LY$32$W&W[?YT6>;*J_%5ZG.K_LZ@ S?;SP"D
M3U4M\]TI8MSB_YN&$^KBP^S*4^9UF1>J-4VITV<+ Q)/]HE,&7-8GSCBLXZI
MW]@)T=60G64ES[!X+;,W\?+W0S3?\,C@!Q#L:_DB R#@JV!ELFO@UM@U@!(<
M4Y.FM8=P=]75WUG419O+15A\D7"4-Z+XQB.*2]YX$ZLEL =65+1QR,,7BFVB
MR\MCYVR,@10<"D5C!_^S=+?56;.;"."Y^MAQN>O23;RWH+OUZ4"](5SO\0D=
M(W/^S3W@=\XBLYBG$-L64T\,\VT_A5 1>2LP7@GFWZ3&D<7HY]T>T_V-4S5<
M8@=>)L.I2]IA9R(#Y>+B',IB$^)*#%HV-GFT"N^C[G/[ *OOCE]C_<\V+:U<
M=[$VV\E:A$L@POJSQR96,)E4WSK+,ZRIX"6_\;BI._X+C,PZ!X),?-V:U=:2
M+P>7?\TU\JK2NK!7=1[^H4Y<X$X?FHD*V>'0T.,A]]G$)/%WQ.W/HV*[ZO^X
M;P7.&2([)F_%O(NGL#_2&+S\W>PMC! Y'=:[<;16]"Y)I::G'M%?:5PGO-'F
M46)9*B3*Q+RZG8P\<G&R],$O9+'>D?IAC;W=RB8NU^T6HV[JGZ^+-?'8/M.!
M4/WPODU7*O8AH="B+LML8H^KK/RH>:@^W.2-MP). DSGYK&0<3.W+M(9L/:T
M(1FN"20C[F>B]0SL+%Q8Z+:TH:JMX>W&?4DADO>Z) (/ .P!II*7CW#X-9$;
MD="P]MKC4O%##BGMAF"] H_5N%[=^KJZR8\:1.):J_7!]I]T^ZC>D0[F1=RX
M??>5[D/B'0=T; ^(!W4KI7:J5C3*]?1@;9G(98L()\8^CWF/3$\S]]\)_MPW
M WS7\R&[5TT+UP []#E4 JF*^0QE\IW5]5T_V7+)-XQ<;[_'RM&S$!LL&!V$
M=T'\@[W E?Z(#$?+ZUER9ZKUUGE;'%ZF6LN7S;!DM=;JA)JS48\3YG]\\*<D
M[ZF.W9182M9<%I7OEF3V3<:5= W 'UU]1Y=> S+[^%>8^FO@CD&H++?5!7<#
MI_OFJ7FOX3F9!?CL9SLZ EPM]>0:&/.4N0;:N:Z!GC_JO&J]DQ>I)8XN^.'0
M2_P:YHM?*QA9YC__^S_*M.;;A@Z(0.Z7*2C-J\!YLLO?=E?W8_=&(]J/06.^
MAT.^**HM9[5]0[.S6[$2?R>-_)]D.!9[= K]=A$ R_3]X*5^#62?!EX#/KK7
M0%C>GV3P8+KKJ3GGW6DR^O=2J_U)B%;2",G2O;;5JLU_'PIH^M307NMH])_+
M???OQ8 ^SXW]"]Y?\/Z"]Q>\_[?AA4(.AF#V!:&7U27;;T.FX+IV]_F$E$=F
M[#X[Z+O]Z4_^W+BB^$!>=C;[/X#@KQO^?]<-_PO>7_#^3YF:G1M3<PT8^7[<
M:7IW4?LH::$_*CK^&KC]KQB;&[&_E]_\MHAC[$)]L+"1B<; _S^ ]?]^"G^I
MT%_P_H+WWPY>,H8O5BVRKXU/6<?B0SN9W:8B01?O[W-BPA/"O]\,DK4Q/_.1
M_M^LEJ%!KA2YB!/*O2_1#B/$4Y2\Q64,@;VYZD<:U!>1M=[Z7)$G,F0CLKD;
MT6].NP+"$-#ZNT$Z0+G3E5;6JC$&A&VM 1.W#W4LU[7R#+_5<\( GP\I2/D7
M(;-KKAF<IW'N]8Y*XM32BK<&BR5\7>37(HYEJVLUB.O&0O!9@NCN8DE2=:#S
MX(FQP2UVUFL+:0]3'M1>/!^^V_R56 DWW!B'<^_=>U/O56N<=^AZ> 8>[0F7
M^=K/I<R8B2<U?5O\V>QTK';X8XQ.?9YC^!73%K5$CP\?U$0<+"M]D3,-9KLU
MN=/87Q:MVI, #3*>]0+G#Y0S!,7H>EJL#%K>03K%D_*0VLM_U(S "*+ X:KA
M+8H5VF@Y[U<[LVL/X[BQN0IH,[*<#SH<1G/'\,??:8+AUP"=I13AA.QIP<$P
MZ\> >19Z[95Q^2-)?#A_E[Z7)LH[N'CJL(W!L/-K\?=X@<WOT?@:9G-Q,2U^
MDA=C^.7CVJGL80*'Y!;4YS-9X!0S 9_WQJ)Z+L3XSTAE0-,;]*I]%S?*8+F"
M8D.:+1V4;GR:&1LQC7G40>N6\)Y0ZQ!+X0K4$N7G244UJ(I0J"'#64 ']E;Z
M?GBU>IOK[:8=3T*0VN*J^0)^Y;"C(DJU]XRZ4+T6;><M%*/(.W :]6H\%CY7
MD^43Y)E9@[5[5P,_T,NP +W2C=HYMSU1WGAL_,DH]Q/P,A,60"IOS,':QTS!
M)2%8_#S/\MQFIK[B>_.L:O5Z[LG0)])ET2W(^JJ3-%,MU?HNRO/=N$LD@R$]
MY*4-Z<0QG*.]YC:5ZL5S)CPY]WZF:(^G[=#M-KKQPFD77?];7UEL/YI62=S"
M^:,GR!:4/12>%>FBI9*3ZR72WCA122_ZH>'7LCJKJ/J\H^AJQ1JFM!HI'WV\
MPK@U[&W\[;D ]T^]^>%8/AK8\QTRDQ7\'%R -"D"[F6$NC_9K?-93"BK8,G:
M8V^HU?E"ZB6W7B.PC\@,C5'!%QR!]NZ_E9WAM/&R7'M<(ZXT&59Q-<:F#MXG
M=J:CVV1Q%;C!H4YBKCV) 7]=M$K-']2=EV[.6#@&W-BS<>*MA^5[[:BLJ"=V
M4KF[RY]MRLFTLF?:/5%\2[=87+-N<M'<=H-30)-_U9!A>UEB#%RS=V?-V>GN
MZ2_&&M4HA&0G+KEO$8LF4C4&/^J@MB=65:AR.SED^@&_'?]J5AJ#W#(@L@DU
M>(13D=O(#$*O0A[.OG*9'#Z>/8NTBG-??DV'SY51V(8G>8[2 3U%N::LMM[=
MT8F+"Q2)H+VG/Z%\;ZL$C.U^G$VRPS%P</4(#5.I%JL]Z_;L%PC"6G=RE?B!
M..@56C<IQB5V8RWWD HN_X&.?5XS?3Q'G)2LV'J;EC6=7-Z8@.4B4)I><! R
M"\>+6X5PM2U6+R[K5^E:BZN3L(7.QO/P^V>V($F<W2:'K L7%V5L9REE*<6>
M%>+) 9^R+S(Y-E,D-.$VAH@7'L5(V9ZFD#B3G]> &5'V*QG_>T-[?:IIVYGI
M*&G0PAHSQ2(ZLP^^L2DS)>!$W/8ZXE)(').]_K@3QIJZ99W4AJIM#\50TH2U
M*%N<ZW[SFY'!S$ETI\L5$C6&T>WA2X98QUT#P3D(CE+^XA]>@JT)KVYOE XY
MU<FKODYSZM_V\W8?!CQ:J0)7#ZFWEP61QSI]::UJ7V"<JM'C"KR)(N>!Q_<;
M1RDPK_7%]1*DD1OA;G NXSLIB%J1F)4ZI@X1UJ@HDW13T".<,0LHWW@;AP%W
M>'D-,PW:RI=L%.(ZK_+K,$+NZL >7X\XP)TUWPUT'T6=LF9#[:VKT4"^\$*J
M;'_NG9O)]B6?!8Y&Q"_M-@Y(G1*=BR=W*,UP7D^F78:#P\]FV"Q$O[%/%&%_
MF*[IMD9&L]W&CUSWF,G\'F?Z=7S ;ZQAO=1U2V8T!\]/> O*W8!N="G9.1-S
M"_#B=H%3U8I_:*$DR":Y&B)_CC/")^?0)R_HVP6F*)SQ4@.'"%[BZ5-J*V!^
MP"V]>A,]TAF)'4;M[=T1=[$FT-#>)LU @<]3M>%L2N9?GA%;-B2QQ,'&E9\C
MN.FT(*S=*POT4<(4<F8*28_>47/.B>SZ^]T>$$$P]=JOT!X50V([VD :G$]/
M9#BKH"+JCX3O9,GY+$6[@,"H8&@(N*K,? (^M:#1HNL2H*TNW6F8=4O%OM>7
M0O0NUJ0E?7Y=?=[<3I+9U; ;X3 (%3+?S<HZ4S$KC""CL\R\/<F2>O"X,!4N
M<RL_H\0VWGRO1%+,]U4\%KSBZ@FD7K:./JD1N7,P^Y*63YGIAUNX(NT#UPL$
MOIW4YYLG3EV9_TW-C$"S_LL^-:[R*25.%9'!N#B8R?Y\^=A_JEG5_QC_E<8F
M%8:]*^02X-606GVKC1?Q6[S1]Z.:C1SB'<8<I5K.Z9>F3CCTF96:IJ#Y=W3F
M>R8&-],?T4FX22WM;L32:NFC"SN;8#W1QL(12D-?RH^;3288WJ]X+F89@,.N
M ?(._,FZV3M+\]T.U%Z-K\76WZ]&1:R=K$1)42 W:IV^6O'KYR]5WXI[LUBY
MCLTC7T4U:V'XBWN[_627YBJ HZ^%#+KE*@5&!Y9" LY'YMFG9%N;]:@8NEH"
M@R7B@5>7%CC021\A-+_Z-)? KFYDMX,;GPRYM3'6A_=Y[/4/6ZDK!9A\NY99
M%\\?'&2YHHQ2C/N.CQ]XQ%9P^/B)IG@946">!W:1S],]M.9W%X1] <(=I?4;
MUC=!Z?3E\)5P R:D.H9:YWO];<YQ]^*?S_2H!IA:>YV8B7$]KH%8"1OX(2=5
M_)Z6+OCM-Q[^T88[C!H&C47; Q=R#V:@#C8DF<E?O294U-7Y2/DSOZ9 8!+^
MT@Q9R'8)HFL +-R.)IS>%OH;&*?_!6;C.)8:S6'0?/$PI7C;C89=)-R>KFJ+
M@ [#49R-W<A-@E% KD0*[F8PRS<F>:9!EN7L'@69:1"^K/?1,JZ2>@*)V3>I
M1FJ$'NUZG!TTC+RO%R6[!ZNTZ^#=UXOMSB*;1^LB#AISYY(LN 1,7P]/_X@T
M_NX]P'8E@'4PI28+..FT1]V;;-'_"K&:GX8*$EU.*%!(Y\Y3[;(B/8[\%Z-,
M'3(RWJI7CCMOUY*H''#H*L@9:.L"GIX)/T@5MPT,D9.^85</T:.];@PI1FD7
M8M_KD7V%G_!ENOI\*7><F&&."UX/ZRMVLX4*\'+E'*(J^!<.?M=@%;3?!&2S
MP[9VW-0L]D^52]W-5W!NXCV8];C Y;-1]<J0\ZX-\33M9&?'GCD-9IU")[P
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M(:JZ1\D9)R%C3P0WAI14!.J$ O>"V":S5)'M ;6>WAJOC:TC>^9(JEBB%\*
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MNV#X9#TO%22\UQG=RJZ!D*;-<"_>M4<TK] V;D7>96GA@F1U)0SI\>\01B(
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M/+[4Z'>1:2)[A\>_E?-[6]1^6^1++]1Z$K\WJ<)K7(B-S&1IO7'8LFC/BFO
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M A^-7%P#V*IHM3]/_R@YJ"M>Y(S]XYNA7&O,OS>]KP%_=LRC/T__*#E8>'=
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M[8XCS\7\X6WN\4ZRW3IC#/FL2WMOE^652;^F9C<5Z)@3)4?'U^X.7Z5'Y]T
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M<6\_F!@OU4)I#]5*2*"<\Q4._C15$)B)%MDWRLVYNT)U21* A]JAI(;7GW+
M_L<?@ZF!!7T'#ZK?8_R\K8LDW_*ZW#LFEKO>9T:(;X5T@"@!/SNI%DR=6H,:
MJU&XAC-/\Y-=8+7MK:3[U$??*E2A]$/4+ZTSSO*:Z"IP%0O9:@BD-9G$,(P6
M<ZT@0HQH/7*N2*2NQ-'0>*5-8-_Y^7%*W/1M(DD@HA01&CH@"KT!D!RT.SWX
M\LFU1*/(R4"!=GZ"5&Y,[ATY4+P'S[)&ZB2?M/?R<EZC)NOL#+C6&'IWF"?J
M3IEDUB9&#\[T.IA^3V(EPROU^1P5/9=\D@F^/ ,SK/RWKHC0J7:JI)811#5L
MEG[IAW4.X#VGR6#S:L,]'6<XL3+SC<.PT,6TDXE&'#S5TVCRCA6R"9$83*[]
MJMW"')COG4^JWO,H4/!**GNL-D%B$^FF]#J\%FR>K>2XU9UMOX;6*5:)OZLE
M="3&$IV<<?&H:FRZ[\P'2Q75E]CY-N7UW8?T@R<_OV*M97/]OJ0AK4TG5N#C
MJNC04J/MH\Y?]^F'4I&6W8]/+0G<Q$X 6I2F)NCPLRCD6";Q9_E"N>,E -$/
MM"WNM)3RQ>DX#5?BJSTVEG:20JHC8Z7SWXI'C+W.KMCS-AO,I),6K?<%K3>8
MZG1FJ/A))&R!R39NT^#"5V7*Y2(SMF9;YKS!'KKVBHWZ :IP'FLE K&-G!Z"
M?G C.+AJ0?C28Y^V:]\*?#5#FHELZQ?%90C0(Y0]F8F^ 9SY@WJOI>O'(\W9
M&FU^#$Z^Y=ZV>7 #D,TJ0MT WG.BH!&KBAHJ/[B_ITA]9A-U,_=!>)SW["VT
MWF5Z\77ZH (AKG+?*"/>+1\'4X+[#4.8:X+(2#SU<5ZU>56CUQ;!@$M_ VB4
MW1+>2QL"TG6O(B-![R1W95T@>FVB?%S)&P=CP1;M_4=:XK_,@OY_=9']9Y<N
MKJ?!OTV,KTML<QVD[7^^D#<>60-_EU>D-E#XEXSH9Y7M%@5FZ,9?O2C3KK.&
M"O-W7^M?YC^E1O9;(O>FRH'0W@72)E@VVEN2R8JQ^Y"+(@295$Q:7,.<-8IJ
MZE/GHUTUV9UKC9@#5YE4_:@^(&5BC<?!0W ER6]5<>>EPD1CA/,;5QZB0T%!
MQ2[X!U91(\>$GR1K+L+ER-#ZU8X9LO@N3]=35%TJ*.&2#IP7<7BFQ>;-8ZM]
M-(3=HVQJ'<C"E?O-L7>7'8]V71O,U/!2'B_G%N8<#-T#OSS$.ZO6GA+*YKVK
M^EO=;K\021^B%"(48].;.1_U&_W5<Y4K:]0\(T4#=ZHFN_OYY5DY6R:MEBS[
MT(+8MF<\4@X>(B@CZ>#ODUS@L/)H>HJ;Q6?NDI^D_Q%-(3T7X3R3_#JS-0M1
M50$\LNUA+C).IRV=5CUN1+^)_ZC-V)0;]P2_B\? )Q.9^/ITQ,QB4(:C!<7<
MV/+,9)1U2/LR;7A<SGT0..:N@<XF7K@!) 32P#XV7>>L,%UUE&C.@@^/)&S\
MPKD60B1E\;:[D& @E])4O!-S^EG) _V=38H,V3A:X77&RJVXS^@N/[@DY)8C
M8T='XI69,)6'4FR%W >6A!0E+<S='X:=DW)LPH%F*$ATH"),TDG:I$>TE:75
M@K/<4VI@]B-'R,='[4FJ>QCA@V!RE%)IU<Y\AO%\9%4]U3NE'YNV24/-PU9'
M?.N".H'*2%$,#QEI3^$-P/XZ_%NK"41TZ-@SPGLQ8>0:LR5=7HT+N ,80(['
MUH/H'*I!!69^9SOW$F)T*RKX>_2&]E;:%Q%-*2Y2[(VHJ#G2+UVV=\^_;7B(
MG3JG%8"0D;LCQBTS& 9X7 =@.66>MD=J*(9+7"<Y,8#Y="UTP!YH#7-T"&:W
MH$"'&[?.GQ::U6BXM>FRG1MR):<FNH_+V>-.1*E5EG3/&[]=;@W:L?)BT[U=
M+J1-^ $[GJ$SCH3!=$475]42!<?O&8&V]2$(X&<4(11,@@XP3K903)Q9JJR(
M(N+I:A\$=:24\8\#XCT<MT*M4WM6:0-58:K+G2.EH64.&T,7M9IKDELIL@?)
MLN9-4%FRDR[F!;FGA>E3E[--)N:+.5)VTTMVA"S M5C 0@=R,Z[$H;+8;,?
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M5:[.1[A#)RPF@ZT6"=X@ZEU9T@9I9>W.WN>^0F\6^#'<1R+ .X)0+<]7,NS
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MCB(HB^P"QG:-?'0EQ';<*WNU]JI>&^_OJ/^.^C\A:L(<S*M(3G ?TQO%L0:
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M:*&GN;*KU#M4#2"G+&B)*C'MMP7.)N1T-YN7Y7-=U)6%3E?LA!G-@WZ@ZX<
M%X[3:HV)]GOY0$=5SLF3M@#5!]HI4NIA:_X3^)5Z%I,GP@:S#2;<Y&L?KE[N
ML>[[VQRC]83 E/99-X#LZ^3RUQ;T-9MW_=*^V7V1D[*[-,P;7;/ VS'GF/&N
M9D2'3;_J:$FBG]?/Y:!X!#@@2F):C,<)(?0<,=& ?4!?P'K6Q"OG'ENE2*[7
M2UI:T@RSOC]@0,27Y=7C'&8L?($456B46!@O\(QQ1"^]K(GRG%12&3ZC@90
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MKA)16-. 9!IC8G$-2/1MTVW&Z7FY/$9R*$F8D[^YYY&A_+56:);'1.YY2KR
MQ!_;4GW4%LD"'81P]>3L!K,]9)-1G>^D4U/6S6 >'.MUL^56*3GE<JC+(%\W
M569T5LZ6AR])L['X"1LI458LQLF/#BZ_MDIP8%NL;^EMMV4[.8A:3IOFOP!L
MBA:1BT*0>GW>SZS#HS; 3!TTM(VD&%=9$"MU/%&5YQ^"\@,D^F0OEB&N^\8;
M+E"X_89]8.WMM&.^N-[R%E:C$1A)Q TG2P5OL\!+,4R$*0>N,'R4]N([<0EM
M6S?KZ?UY1A(\4UBUW/SME,C;PL$BJRMEW07964'TM]$F-"6> @RH2D_ BGVB
M-),\:C,GM=YOS0B]1)Q9_N3]% ?]4JPUJJATWAP+$:K=;DMV-%L("?FE%O]+
MPE,B)ED;)9L1=L#AA:\*.0U:09FJE)S<RW57P7S^:XS^M=AO)IPL*;3F[?_I
MR^,9U\F.;ZDNAGL$J6V(I#P6&"0>:?ZIIJ+[E0]DG-G62%T*VE"K!/7HX^^+
M M"[@09%R%V>2D/@6<(K$V)&9%PNQ<+CO$J%N1Y:C!;*#5WY6I9C=MNEF"9-
MNN2\<\5;<2KSZ4VFV7H1P74PJ,M-WV2"9Z]<Z>Z*W-S_.F,KJP>V\,@D_TG_
MB19M/L8T"A:K:ZW6G!J,5AK!9,3$/!WZ#M-"A;40S;<-:CYY8?7JR)-)A:H!
M(2ICNLN/@YUD](TXPFOU 1>'$RY-S-^G@R*<N0>BXJYDN\TG K.Q:!?F],#P
MCZ6ZBY:I?(H_-'2DK;%[2+^0#:AU[)%M@90'#EA(U[(B()[WM!J6M%9!JTH_
MN23!D%C\SI61!I1!5'Y]G=B9 \R<3Z\"B+ !(<SUR_;/-!ASEZ3M39,BI=]H
M?<IM6=XQ@L^R-YD: 0+O\2?AHO26"W&QI-T4(@16"@G?7E>LN7(L&L2_I=FE
MPQ7^>=V/L?E=95'^+E?DI6C5*^W]>$V"ZJ$.J8H5!VQ%B7.;42\#BDM]$%S_
M';0V7<LBS87/D?/)%;+FP'YCK&939OZ,/R&<71P6TZ)TF.:E\T>:<X LK] Q
MG@S/P4$@&]=Y0[I'GO MM+# UM;WR4ZQHPVLV];VQ95NM]W5XO<2?O,,<S)B
MQ0[UV4PT.&G1P;7;-<%;(K0#TWKY2?YO3*@H@1V&1T#YK5C("O;/B9.+9E\"
MGKH62;G@G<$=F9Q@0-]MC0NI@\Y1EY7"]7M=*LDWXA:C/F;)IHYNIS^&;B%T
MEV2;:<"&^90H%4)B?&/NU);G*O8 ;\21(=PL;EJ8!9LK$\0$(QY D,L<^_AN
M/ J8Y3'G=0WD<"WIUVUV)WR9:&*S3NAT+\<JU?D[08"\V]1W\FE.5B.Y8E4Q
MNB6086S[^V-(.8/B^ 7\B.<O0=*83"-'-^_ 5_9$D:D5T*W$AS56P_3[TO6Q
M/*)4$J<D(-4$X=A=C(U?S^?VQ!^  #S.1.O%TC28?H"/X*9D^*$:C<UX3)4B
MY9<$*>?HV+SYW>)>P(%&M!KNOA:'OMQOF&\IK9:YG%LM&6/^3:,"]9M-0CUE
M/<WF]&Q8*-N+B0? G/26SMGA1G)D*-YSZ>#DZ8V)X['VK/]3!+YIOHYE<2Y#
MMQ/1AU.6;SK(9#AK)RBOBH  !X&*ILF^A7[%H*X%8CD->@WCJ!^?E -:;K&5
MT%-]B&"T84?W) L2?,7&UN"RQ/3:3-?H8DNR4JK,$+?SJ>!]C:LVNFK8Z3%&
M_HA1Y8OT DT9V/NAH1<"]AG(:&B[@-?QJ!?F<5QG.Q*U;*5"(+F;<$LEGP2>
MZ  E;=C[O;(6EES+!<3-=D'0VQ]CR(LB)<>!!"%(Q-RUXO.MP+XXC?<&_4+[
M,?EZ%"XVA6W4LIC LW#_ X8[ZZG:*,^*"[E;:^>([;I$@3%:CV*42FJK?#_2
MB0W8NS9&;;7[N13V9R?8D[1)<5^>V6;[Y&5?7O)6B=/@0,,DH#2UZT2ULS8\
M^[S#E@6Q.\)9B8;G! *,!!R.64;":G?'85VE^B0:<"L0SN+J@?H'U92A9_2+
ML;BFPJ$3P9G< ;B.?5YQ>#XL4/L(>ZUKI8EQW6:[1 M&BZB,\X:70-*!E.^A
M7+<>!G3W,WY?1$&OU0E?2R,[ ^C-D6P_>9^C.(TUK.Z 3:S'#[C5^C))U\ZE
MH,A2J\>ZN]?<ULB["@_;8 J]P*&N](<<V[_P&%[46OC%F+BV%D_T6@%7](J#
M1;U'E&)21+7PNYAF=>S!JO 7/@FI/OZ75,%C5KT3]R1P_K>1ZS8N)NH-(6N)
MZLD+\K%\/[&U6>(=DSNS<>76DBK2H?V?8#B_5&2N2=5)$_^\UUQ6EL84SB@U
M\,JL;31W7 -%-E$\?H@DU8%M3*3IQ@UA5(:1==)4T?QO0&C-;*224PAPOD2!
MI5K7PM 2/I5$E.T@JZ>1[%;2X*E.: '4N*.I )&:N+?SDM%VM.Z\Q:+_;MQ!
M['$NH:]Y@X6EX8=\W]::!\W'U4;2_KSKTTB&(=@RJ/@ZL[Z>=>^?JB9GP^VE
MH*UA\Q!=44H![A3\Z)HL->,4XQ/9<JW_?>O\._I$H@S#ZW\,H"L!T/IP]@!E
MQL17!;E9&T8**,8)F<#6%?J4==SL/:D'?X]7RTU%>9YO[HUOFTF[U3=^6Z6\
M$ =T /<+4OJ:-NU3#W99B[D>(=/1(A>?X<-]=F-VD;"D0<'%1 <QPL$73;ZV
M3##09_N<<5YF NL&&N;7FTG,^8C\4)V+W80!T>01_ZY$^&,._.;Z7F')'S9T
MQ",/4H#N)* EYR_>9?;AK.AH_[XZ,>I/8<R4!?_% QH41DLDPEY0D9[GT2Y;
M"\'5-ZA5>QZG(O=.%B'O-)+O(_$ A(S7&??42??H&RS9QS2%]VC<-ONTF-^C
MZ+]7DT;0W_ C&!\ :*)OW/V+>\6$JSC>^]W"I>,[9I0O\*12?;CSVO+OMA99
M5TLVAII$$]U<37TL!F; F,$;%UUA9LJ#7U*4&FJ7E-]^,VQMHBGDBS!M\H?(
M.S\ > CV8H]*-6AK&=_ABR1KO]>UR.=/R'1L*;WJ)!RGVO6L6[)!S/#O,(J-
M896HSC:*QOHHK18D\Y84TW<U'S/+%'%B?<7[N&3Z3H/9$,1KY40:\X<+)DDR
M[DO+LNZTWQR9W(R;BW1P5W621,NA69U"CX&F^$"(/<O387$[Z?CCZ\T+=< /
MN?CONA-8@=EE>6[$H:YJ[&E]X5#T)BA3ESA+Q\)9JO!@:7 \U'/-]1&#%Z\O
MOZ!FEX7%)MF:X[I)L1%7)<IN]<AN91:VVK^?/(+(OUZ5GUH_LV6;,E$^8:OU
MY9)E@O$Z!8A:3D+BPD&P4IV:.AC;%S^&V%ZM@[ORZ7Y&CS!,4C.DSCBX]+)8
MW"1)E)!F1[U"I0.#,DNEE(V3-$JKV2)<6ZH6)CD785BS6+K<\RQM<\2Y%5!"
MFW2+:VA%MR^W44+2DX#2^9M+;HR!.!9NW$H64^DV&<S;$6?@P[G#7\\G3EI>
MPBK8S$9'+7FR\-X8-%L8L?Y4X'C+)V02.+BY8P5<W)S1AOJ?J8O2^\\-/>:@
M]GJM&C?F(1>VE.K3KMI88B^NE0VNG?Y4K!@.@C'H7,% -D@(WI-*@1XNPK+Y
MU8!K<3]55'Y-7.Z/C<=5'W]T(IJFUT[S'&PL9',"[:?K(HK)1Z^&[TZ^ :/N
M;OTZ,&UUM;KKV<2%Y3=)VK]"&",EAYHRLR/7M=>R FB@2]]!I79GO;]RN"]P
MIA:+UL7)_-&?-<Y>9A%Y;'C0D/%ZEZ=8+=&R:5;[@J 5OJHE65>?Q4"B(E8J
M5B/4=0D; B0R%;%J//'&IU5K/IWG<Y33&<C6\\?EY4?E>76U?W%N44KH)7CR
M27D<$$#^<=A&/2DB7W07IODS\FQ5.&@ ]]-:=#%5<) G6H"@?O@J'H\^R.,-
MHO^'MJ*_(TJO+:I*:949I3L>:)E\\,8H'VZ:QQ_L1_9;NB3!EE[Z^?+O+\?X
M:,]CCRX6&L8:>)KXN]A1+;RBW:_27K7^DG:Q%:ED?GM '$%^(;!)I6XI@J^S
M.(@Z49;POH":S(0K(0BT+DY.0PZSB]K$ 9^ZR'4Z8]L9.WPJ9? .0JKD@-(4
MVZ[11M"\@*;4LJHYK"S=U2A^&QW(X'-HM./Z](/FH)MQH_5MMQ_AA B#\?/,
M,*.ZG\//$OJNG/J7OR9UK#G+PYB"(2!2[7RAG73B\6A\RD35S5'NVB]!0IC
M>AN'QY0"#5%J=YKJ+_6;OK)!6^+6FK+HG*].XI>W>4N1IR+/\_C#6ACR]U]+
M),[.,,0'Q^N TFE^CYC W=?#/HNP^;%?M#XC@2(36.9;:HHM+\E\/!'<.M=U
M!H8^[:(:!P>+TWS<^+:XH1Z3U*G&E91C&<LT]^+#^A)M"M#=)C'6 )XC!D4>
ML56*\GJ(O6FO"Y+'I!:5"IK\])%0-HSR?28N<B%ZK9=4R/H(4S=?XL(^2="*
MH"FW;*JYN?/,MZ\I3 =68OCPCY(PTPRWA9G$I7S%MA>X [#ZDNIXZ=U8] +
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M7K1  2P%\IJI@;.OL5!N-\>]T23'51/<391Y (C-Z.YPK5M5/XF'Y_S%N@G
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MT%P/.X:'%V+^(.VXC/0]UP2R;M+=6O:Q:%_MQ7=[N;FRWI5D?WM/-,<V#!3
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M][H6T@)UJWERTV>K-:3/,1C-_%3A*/-KG_/B(\_)67]E9S-LJDM^'F2BR9"
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MO:[XDE3XK,I257UYF.$<Z.-*Z!@P=MG&>KC@CWTA*@(9@]I0LDT%[4$I\7G
M^>PE@EOU'M]C51I&&G)Q1]%K)K?\NHOL1'FS8RC@&WK.(#G">J*X)#R]CKYB
MLV'-F&DV0.3]JF;2.E-/%EY;NRW_%2C\M?P2*>R90R*)V8+C/0S5=8W*8"<?
M9MZ#<<^H,;RN"/S664[_6>SISV@FD!T1,2!(3MZO_V&3J0@B1^3<,R%',4B)
MS24P(*8LBXVWV,<0Q!B!+BF)*?9,G(H]' '$0-TV.V\4R-?K].E^ H/T O&9
MZ$_"Q:YGG-KPX;]S+/6H:R=%%'%.OI?LCY=#)FIKJ'O1)CJV"( !.H.=UMR<
MQ-D5S<U,&7I/X]M$+N3A"_ /E# H?WB+\L:QWK5Z4Y60>6A=2%5]0QCA+P>N
MK=V32Q%L)X )=8[)MUC'APU>7WJH55M6[6&OKRIF$X+UU41)P ",81B[%L0=
MQ+)07!%!3Y1 /'V)S84#>*Q&BC)G45I.P8W7[Y)W<GQ]R2.M*YG[J5ODNPDT
M'.-E!CO(UW:)6XL1_&>B&&-KQR)EJ99 O(R4R._N",IZ)\PX<?$1+RJ2<:W>
M;>UN*LY=86.EO#-B-L"C_;,?GX66>IBM2QQAMW>159,+BRV/K4V_HP3$01 U
M@.LIF6!%:<<*/4PZJM9[6>^@9S^38H&D;V6#2I&S8S@IJWD:RCD 9!#J]J34
MG8U1G4D0#M,N)<23Z.<<?U1"#SL0:FG'%'U]2%%79"R223/7Q=$4)/+'Z;)S
MCPL74>$D@9YA5'M)&Z5.\R*-FG:]]\O<371%F^UV;S,KR>!RNECX+G2PHU+=
M118O/[RBZ(=AO.7/3IS'L<5G5*Y\)XF)[A<4('*X^3JFY, ?LZ"^;M73U0XZ
M+)9,RA6R'JZ<X>1NX +,2H?Y\>VG-N%F%>TOO"[RKWRJ0ONSFPQ3!VB._M95
MZ'B.GY IZ?V$DSZ6STQF0G-4XT>GF!8 .PW*4YYN4=ZT=5?E;)VNM[31XTY>
M"KE^E>&"8D SXR06#5H_)3BX$8L]"DW?^N77"8;@[O-H"C!N[<:T!"X%(1$?
M$E.-OW4(?!'!J/06.'@ZL.>9#<*:L3>"USS&<]"2A_K[[S8\I55L)]70/][A
MS)UO'9:>K-$X=0>@*;9\5";@P:!XQ;Q'9(#I"GBR]Z=[%_. <??+\ILGCBZ)
MLY1B.9/JL\>JGH3^M_;>.RK*K<D7?@"A54(#DE.K@*@(*$$R#2)9D@B()!')
M65*3DX!D 0%%HDC.&<DY1\D9NLE!NHDM--V7<\[<N>\Y[YRYL^;>^;XUW^<?
MSUJL]707NWZ_VE6U]^Y=Y?7<?;S.+CR%X=OH]]'6&><C;'JY36,R87HXQ]G
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M,$^0L$?H^D'+$MDW!$AIR33:)QLM<7J@Z6]N5TG\D\,Y\1JC,>!TW?E&5+;
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MEA*-/.BL@_8#\<RB0JJG4_,5]S:OJQ_<OGOETFL2#X_P'4^6((M=C%+19;8
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M&5%,9&@!G3)P#1,(VZO84G_49/ZQ.D8552QVOZCNG_[5-UFQZ),ZO_\ +K_
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M^2%(#9^.7 0-RE.!]_7CMOQC514AD=?ZC4X^X@ G0.'494OPB)D1_B,DJZ=
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MSCMT>C"A1H$HR2^^8CX:R(0."*/NPS@XEZ[<*'^\T7H8E:F;KS 3R_21T6R
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M /L5SNMX?SN ?SKPKN$37"<D(B8A);NJ4',#N(:'CW^- /_Z=0*"J]*@JW*
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MZU21$3F>P1B_#J*QQ"NG?509>F&^^G-=\P%WO:XR[>?0:)Z/U_XI@2Q0&YA
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MR 61)B:[A;(N99V6EMZ%P!V&+(;2X@"%?AB25QO+FX#6;R7% 1_MVM"TW#B
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M0^'\'E-S4$H[Q:H&_/Y8P >X"#C<YBZJ6(*ID.C)P7NS<C<O&P=YS^IDOE;
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MM;CGC"VQSF9^[UV?_5Z($)>!ZF >R5R6I[69#>F\\-)SVK5AUJ,%-/0*"(E
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M77R7!9RP@Y$?:V"A\7,^="JZ_OW=^B0MG@5'6Y><A@, ;'?,[+<3(Z'S%JJ
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MQ3(,GA2M,(.E\O?G1NYEXIX'K>Z3D[:.3)_ZL7OJ,)H&L?PQ;T+V?*O69-[
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MZ B'%[SG5JTUK@O69(TBTGAE0WGU\-.OP;OIJWI!YK],,8?T.@-:*Q ZR(K
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MZ5[NQ]BL5E6M[/E,LA>7BSG85:';Q$Y4$OGTZ"'[M<RL5\Y<=W=;#)5M;.[
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MA#8^H&XF382YVZM$JAM"UR@$ XV)STF>>&@;;# +9E14Q>0(<U,T(C*8#_N
MI8:J2?&\"5-UEI":HX2\?8<?5+>$\ ;F:]OHOVZF7Y8'%9O,<@YO;Y7D]&D5
MWMV;EQJX0^[B=9A!['L#>8X#0OW9U^L]\RZ;Q^PUFD;LU90]:>[$[V7?/RQ1
M4H_J4J):1C%$4(7L'+[S8*USONFT;7R;9E%H2M3_OB.H^"6&&G4M<XF*\!M#
M_BNG$O'-O"K3H-?,5VZ\Y3F6CX<M7M[T?;H4I40,?K%KW"1CE/Q2+[9<PW\#
M6H )U0:\GH09(">##I1"69Y_1PE]*N6='7Y5?4LLZ97&T1?4F@:W@$4-O(5J
M"FS:<>0M"<LQG;DV]^WX0WW%/XYW]^R<))S#YB\WHTKR"=S _9U2UVE. B-G
MPI@UPOD"/N5#'^#UTI>?0J/E29<@5%TEZ%@%'YV)$O_>C9<)1#5ORRH+S):?
MGXM\]\B@G.PQ>>:@B#_YDD,BKL^:2]4I=5R+"\.$CS940AH^]%.'OWC[(ZVI
MY;V3;GD=&0Z(76I0> 9W%-<Z2SXK,]7D.B6\UKAZ! E!H.V:POH%MTI:=!A/
M@I4Y\O\WVJ0HA\),Y"["HK#$(:D"\FSSUB?5 I*H(HJ]%:/ UB_Q4&LE=5]=
M5'4\@HJB)D3^)F7#IX5Z>E.C_G!Z,YJNLL!1CM8$%]D.^ <A4$0+-4;K(SB#
MM5^;875K0I(7FA#L1OYVQR58(8*/.S"F-!Q"X2OE")>;LU$OAZJ/B_>F;,S_
MZ'RG<4,LN*;$M6V#4H9MB#@#_5HG61TYD9RGRY]BJJ61X46,*O](L+\9.5)B
M"*\)%_+5N]#LFN.E(D?OK9[_!EUZ_BRDA;T.X_ I@XJK3*#4?V1RK_?+\%J*
M2RP'^AFC4GR"B@6T&&RCB:*;$+6O+G2O?LC\+%+GD1=3/R7Z0-XP#7SK//7"
MF8IQS%DR?JKY&%*QEWZ>9ECZ@!BZ85]P=M_VTR=ZM21EX E>A,!W@9\;#6>0
M#U+/D0F3VT\^C^.L2+FMTC-W&Y(+UNV@"N^#0PFZ\J? SH;C.XK#/,E4-GA3
MS(*M-_'Z'8&# XQB4%-]57EYRH\CV\RJ&#(MGJ)+GX[[%#XIB/YHW]>-7+V?
MP'QSA3 ;+%)6[L7-<9)!:=EF27.@RZHED5L^:%.@3)KT9?UV+R#-XQW@?<S>
MI8=.SMB42L:R7CAA]L+YPT(IFC?+Z?-BCD*G-3<N89N_RT_&;F^[E\9:4+2,
MCO:W-#U+?B8DWWF6F8H/(R,_Y3\H?9%!Q<,H=0J-F>R9_A'OD;&6<BV=YXD%
M]>K]95@X%3X%.LU*9NFX8^[:;F?*UPL?1J+3H[;Q$<?;ESA@;]L!P[<QQ:?X
M)GUI*:^"&_, -87< DF%'&C>V7AH_9NYCEAX(+NR@K<[WUD5?5(N@HIC@V43
M[=PILF;BG_C*T?&)*=UO U]D&T1.5!!E3 H7[J!Y*<A%7'CZ!6_$[6LU>0D;
MLB+ ?FS/K?2OIY,.R-6N"Z%M2THI'M-DG_\1Z:';T*0CJ@ E9J^(7/(UZMX\
MBD:&5&HE$J9J; ^RW8-D8-;PO_^=<//_O%"(_\?W0>"5U8[!< ;0%8\6&K25
MP;"CH=[+9\L-DH._+4)O!KQJBO%AIX\;Y*Q#JG=97LDVWIR7**L:G76,=__>
M:_-H#!1/Q1U;>U1Z&YG^IK*4R-9UW?LQKQ6Q>[E(_U<T4 %Z!,W8-JU\0$SJ
ML%A\CRHZN?F6W;9.ND)XM5%'30HKB:C:K-6*PB:C(9(QLI**84.1!\F0:9L^
M;>.WD^[S(?:LW%B#(P>FP2T8/" P;IM!18=2[X" T/NJ5*7VIV:OAS5:7I2'
M?!#,MG@M=R6G,BQ -D!L4&(:HXKTSUS:Q8,\-=)V8)] I_IUB.;W3\;E8-_.
MZ"G35VZ^KAP5%,RY8<'T4%)@*"Z#S9#]PERTR,8!9% L#0Z0G3Q3VE)ZL7=<
MD]K [EK#A'&HSPH0L)?<?9UG/J/V6'ZHT=XT@U>#N<02#GVSBV%<[*WT4S.U
M<Z*QXQ%T^MH7*L/VF?B@I#L2@,M;+19K=2I*(V$U=@J?3.UHF848#)]LD5T_
M47Y(-:>@4=AR19[4&1%SC:FK?\K>4W?5:/Z:&RT*EK:XZ+Y\A<I^\V,&%3_V
M*WI\^8/<F4/'F0ATFR+L*_=Z!3,."#C<-5=ZXXMG R\EGEV3DA+=($)K..?%
MQ?]XCT<1H-G:AO%2V/R<%2#OHXT,ZQS$Y[939!BK++YS=]^X>/(!@3R0MHC@
MR$%J#.@0V3N 0A6O@:C==1DVIK_E'G9RI9S=W*R*+"]R*9E]^4#](:D<U/NP
M_E_QK1M]'T8#V;4;+4_ME;6^-]/E)M;]99+\2[!#J PG[9"WH;$J\&!H*V?4
MG4*V_85:TO2TM%DFKZ8^@%"H+64L0UNAE'11JJL17!.^TJ=5PW([O/,K;E,J
M463=Q.RUZQ:[JH"7^I%2]\(IL_R%0^P_>.%VEQJRR_PNLKT81C+T'8121*.2
M:$C51/*96E^U(\$.3]:YU.<+[AF6&.CDPXL%#,?=MQ_NS*9NR_3/Z,3J)2NH
MM*WH9F(K\3HQIDBI",QKPIA8Z$<CTW44+0_*K*' 2_;ZB5XYP#=:;&,"=D,(
MAN1()J4<ARS6A%Q2IW.)^YB=@=]7:IX5(%-*-(UNGQA8\;6$Y,^;,>,%%OT6
M4!"K\D58I@A" C;M2E&/.=Q^9(PBGJEL*/?_]M+\'33UQG=.@NDZ,V%BQ?:&
M:7[\ -1@1W_Q:\-*%%^8A.56.O547N^JP+L?%BXE,H?RB\LN*@BFUQP@=$_1
M[6G'X_!*!U9U0NOZ"K5]8U=H\@K38)EEJ=6F^P,BJF ,7SY:N./SVJGG#U7>
MY;>M"P*PHN\8XL^ 9Y'YH[:4L' LE[']]+>NNJ'**BHK*]HR45T<H,!#J,R$
M &B/U0N(:R]F! &!57P=X%[B76FFLSU79TV^&G+QFB&XAX)43H_7S4; NMTP
M7I10U&L$Z8%MY3F+JQN=B?,[$Z^ $Z.D-7S =;U;#JK]C_!.V=4C4(>Y[HO[
MQXM&[1DVKHE<8>=(CFI?X@Q-. 1_75:^Z_X1TO_867E+ZQ9'8]EJD\FXKW"N
M@W=U:H']%?']]=(?T\%<)-">;Y4NNOBE]PVZ_O<%=EY<5,*36-9-3PO!6I1A
MH(>M^-EF46J#5NXUYG=[NL">KC1WB8Z:@^)96SIMHQ7-.HQO\J!?@>VSPYO1
ML9-$<FCR6S:/W6@$Y]'19?Y+28FY)K8IVB7OGS*^=7!DBA7OD\:?/2RLU%/F
M4%]ZE]Z>SN9.1?-6[VE1_I%'QPG$\SY0QUUW<DO7VJD#:E94>@7MIH7227+?
MMI@9K-EG4.V@?^ZQ]J4CSCLZMG,BB__N8^;V:/*T]($ :=,%0GM#)29W',#(
M<Y2M6U,AN<OLN:_U] 3?262?\C ;175[4EX5+O-27J$ !]@L,%-C!F_E';(;
MO@HR+.L]Z+GM\"DK0$1\C@'>R$X453H;H_:BZDQA-@=2_&7Q++W4XG"5@8,
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M!OM<080/3^U;P\#&CR>&&[._-Q4O <$;P&&/1O-1C.%"N8\*6E+M\I>]/(=
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M7OD\';;RP@,NS?FU/<J4YA)"3[6: 0-"5Q(MKUTG]@WD>K73#5BE=.V_)_7
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M)61+OGO)2]AL2HKII-H-U$/[:M;_[*M"1PU*R:$I0];J VUP5Z00>XHEF2?
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M[.4]MRE[S65?/VL*!.()] EZ\8,N3G-J59IO5"!%$I9^>0LHL6^:#X8Z9S\
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M1'6=4[GM=%'"I1&QLR3("3CG_R2@ GCP$Z2TV:,<XO++P,-Z&_JA_BDJ'P1
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MQ_O='E7B:[2@UO@Z'(@;?^8"#M/K%YA?V<OTUAMEW6SZI;CFT'I(*3#G\%3
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MVB.VW5(!^OE#!;9[=O 2=T=OT$YO>L\=VXV1F/OLA@0N.9CN@Z7N6;'ZJK
M4FQE(?6QROO\6=5[ZZ8USU'QAY<M.Q1U^:_]W;^H]'#VY0+[(A1G!2'1+@&U
M4.5IM4%KST>$ @:=K"?@#S,="(6..T"_T-2S%2A I,4MN:G#2<+\8?U<T%?I
MKZS>4AMF5K%GE6GS? OHMUY?Y@AZ]47<N>-35:_[<_A"^OGM0+#A(I81%3G_
M(IN0C/'3U/1T9U%UOU[**Y%^21&5'A!M$R[C8<[<#,AA/>&>=^B>E3H((EB1
MQ=B2,09U:LA,B/*E:&RBXW)E,>LTM-PS/4F097QX@C'N?P:O5QDI9ILDLJ!%
M.2DC5B&6Y4JDR:K-G(,8\QDKJ.)R;T_Q (ZW,]9VJY.T7KC'/&+ZTC'XAC)3
MKL^E5!/@@8D!'I;Y]@87$Y)5GJ_%'P_3Z0V9*[$M$]#@1M3'$?22HM*UOH)^
M,6_IBRY*'N .)'M;Z$WES[K;9D!_99)U]^%2E.:9H=KZ FGC+Z!3'I)B&T7,
MCC^ JRS354(0#-8F/TN&U$!B_SSAM(*+[*6#&UO<)/FZH^>_NO:;XNX JL?M
M+K  L5&U*4@]NQ%X3ZL/ FW&2HN]FF]%\UU+1[:+4A3!3/>ZOT[83]=G<3]A
MPAV2PI@13, "VM.8<E\<5<S0[30)99:AG.1G_!\6FRN'VAM6MVGX>55W]68@
MD18Q'NHX6[*-D?QEDDC3H/[*A=S^18-$$LQ>??7")J$4NN.\M<\_J.+<'9CZ
M6N/3CNCJ@+6%:K3"*A/%CFC]6?\7C1EOU$J&9T9LB=IVCGE>4&0B?51'2C:M
M-C7WU)":2EUM,X*2BM"5[4:UQ_23UKST>T/FBFO.(DZY+^M1;K 5->/(\=<Z
M5J$>]H7ENQDDL1*TO)%G,0)O);!VY)<-I!/D22(Z'^YCR)M1!6LG]$IJ?1SL
M4UVNV=:$[./&'7]_V]FPZXQRTW0*7UL<&KLV4$+Z=Z7Z3-X!M()HSD??.J%T
MOPS1ACGI-X"\R.A=\KW5^J0HO\Y#WN? C<D9GS&<J_73!(6?_]ZGJ,,=&!:6
M1AR[U:E/=+UOC/S%I_%P:0UJV\5*;\DG(C\32TPE&PU>Z'0V4<][RVM/:O:U
M[5'V*H2]N3D-&74Q-0Q#2Y:@)OI?_EA2<2CNSUP6W;PVF A)R0UKK<%*X+K2
M"\+Q> %+.QY0O2DO8'U^\^A*NTIO668AF!'?8K\+D9! \OV3:Z5'O(#I=T;B
M+V@_UOA3.)1Q5?0.\*;UA83:AN%\YBM-XI=)X2]22D<33&<[&6>=6%%197W5
M:H2&,SU;)7V#]KHI3C8S'=WCF7H(;)I,E*\Z1S_^$G!C#5KI;<Y+8B?],&EQ
M2>13D_ T!XPK:Q9-53T!'\U\=,@JOMG[S7!+ZE=E#LT4&V*^?XE>ZE3Y>_EL
M^;I!5LV69P"V'>K"@?)ZT-E8]AUR16(AS?2< C=6@@E;ZNGTV<HS9?5NVLLL
MI%)L_>B29I1!W9C#TQ[FOO=%_B6M00\M%(K]9:9X>#06OMT;4W5P/;V@SJV0
M#FXG$K-+IP&9K2@73K@L":7"UW#MH&,E!S2:HR5FSTFH7'+F&/LA1/8SWG5'
M:6FNRSW.&$IQKJ+5$?W:1&P]K:RISJAVGU1TX:Q6=@O0]^M#LYEVVG79MQ["
M.9?\R^R/26!CK[VOE7]/ QA5'5(XC#2:ZPMF+<-@%?JU3J':,M]U/KJBNI3R
M#A!,HWI&Y!&;DVW7>Q$+:<-Z;[=($HR6+EE;W2.S$#JTS-';9'%E$- D;ETR
M]P[BV'%C5JJ8UW2H\.[JH]%/;6_5L8<*E/%M>=TC7XOR90D%$F=6RK]/\TJG
M&P4\&H*]I"^IOL0:<W#(N;B@58YG_M)8#M'IJ$= ^@Y,E#VX<#IFV2Q6G^\*
MF#OD:Z2M/ITY9GX1QW(OZLC\(U)3OJMS]OTYM]2JVJC/K&4!-59T:\:80@=V
MK!.EW2UESOCXI4R6S,^F$TNK;P;?J5;Q)@L:ZB(TDG5:OP R7M+A;\]T&V:X
M7SD,?AVYU[#Q02^+_P;4@11:V0FKKCKK(O&VIRVSCGUS,#JN"2U0MR,_%DA"
MA<"RQ14":$XTPO*;9NG='GH <D B<)ZXM[ ;W\5Y#;E$%<?:YU(EK7> F%S0
M[3@B<Y^TRDM\MA4B.R:+5.JCR2D-*+%O#6A;[N%N9;6B[KDLR+JE[5R?DC="
ME*0[K8.(Y%;YFYH(*;+.MAN/!5>PNL6(4BX7U=9&W7&_<+H"A$1BST9C&,,S
M/*HBWO>'35RJ:\?H(2/"!3.YU#I8A&)4^&J^'7<+B;B:G&.E(]7#P_PJ%DF(
M.J>\/EA)ZL=YNMEFD 0_ Y,=*"=K=WX)\MWGIQ*<H-Z]TOCBEP^*HC%>'GE:
MWW@P.'4&[J+Q3C>;V6QHGG://"=0F7RC8+8 3TY.BC;!&$3-]%Q8O:R#NA.(
M1)I*,3R<LT>G25$BB*,<I"#OG(2XRBX?#;VV-P/U![+53QT>G\>P<[]_:QGY
MH8^DMQRM,<7K\?FL Z06=GP4BZ$<:QVB3[E2R)9'+W38JC_4 U;=48[L(V__
MG* /P8NYT;GA6H1/\[A#@FD^ML8.,8>PD&B?0\C_R.#<-5EM<A& WC+TE)CZ
M<\TI?@V:(@O8]$U<C./PI]T8WIX^/*09O&!YBN.T,6" \(QQ@?@SS!UQQS,_
M/-[I:M!&6<*R-1@I>,I]G%B*P9$.)^S=]F-+:UYS?'$(KW!W,/#::/+D:.E:
M;L[D6WK-TSHT%4SZ2)I:K63?10!H$LZ?N$3!TA1MW80J9D'+DE&U< [X4IQ#
ME*$.A8CX&+!WL##AXL?O1F=/*]Q2S-H^;D@QJXM)!FYS<Z@N*@[(2!74EG%O
M*Y_FU/)9H:;,.(R-9!7(M3#^C$FE_>GA8TJ%_),[G_)/<:J!<F2='L5/IZ&$
M7XR'T@>K_\W5D)*_70VQ+8@^C_W#/?LC/(5A(+A%5/F#8Y-:YFGE7+; K;RP
M]/FLU@76CW;+C4?MC/="G^\AAYEE-&3.JI9R#Q,8O'EV#-3N-70UZGS7\Z#H
M@!\Q]@%3A(G RY%9CQ?Q+JI-+)#"'V%=A"IYWMX^X991+!?5[,S36\#8#0G1
M]3&K_IHO1P4$[TN)F++P+1YX\QHA3J,<WQ"]7WY6X4KDT6H0!:>] ^ .40S6
M$">7,,C;V%F:\12#'!P0M5>KXL@R'[7^HAV<!@_@)Z.=>J<(5W-_:1$G!^I9
MNFWA%;10\OH/CPY*>IWII5=J!7E143MO0=ZNQ[O^]*FW<^S.FS@KP^1K84G#
MB\2-)TP"J>]K)#+2MNPLS&36ZX\>ZB!QBB7$/+J^")^:>@+79F^I#Q8#<A>U
MF;YH>ZF2UAJT342D"3?>DL]"_+>:TFQ>_V3H+48<^O)$! A]7V4S^;RM4QW_
MBWP+:.BY2RD1H8S8!D.*)DJ6J%^RD=DT.)FB^9#88A9+3'','M1)0N]3*191
M4L<$U/[Z4I^_3;I]A:CN2-'L7X6@H%LL;6E&6V^HZ6OYU&<SV\PP!RWZ[@ $
MG6UP+(I93N@48G\(FR9BR)RR&7'1J?U8O^$SG$(^"134Y\0L_:CA?H&G<E-N
MHL:]MZA,0S&O_ADO[PD7)RR2%;YANBM=G>3R4RJ96I09Q&R!(-QH(W5P=X,[
M>"W,U>LJ )KN?9%>\\MMT'G4O*=RL0=^)#=J.-G^JM&0,P]<)X43P&?NLJ'L
MX>TQ1#.=(%W_P?GV;&\V)?NS@(#*E!"1)PQ\MAN:5#:B8_>^GEM->VY-I>%#
MQZDP-&%R[@Z O>]0A.KMW?C.07DH+4%S7JE.*DA"MXHJ?0Q4Q_L48%NNW;-T
MC)U V39YSD5D<LVYO0P^=JEMA1#8W3Y!0")9(NUB)&>4FOM]>N>])"/GVPT+
M0 >/^+Y537>^>%2U1@Q2!_N_FK,A].POX9NPU-IO47+,B!^27+\#$(["<VGV
MJ:@N(KD'O8:R'.P_^O-)12#)IKD^:P&5=T:UW!(S)A&F/WD' M0I#8V^U7"2
MX-0>';-EPMO5!$^5*SD6'VT2VZV:3C1\V/4W1-Q>FR%%DT:8@N??D:<-JONL
M=L".E/J\NM[.OED8NR2Q,G,:R 9I1PRXW&3L&QD(8G,*XX LX#1Q\K#;D')3
M]+RYUFA.2;1KBIY3'=;(R(!'AF9?G)?1S.+/42/+M]_?+M'&O?%V710_(5U8
M>B5 V[S,U8AJJ+(PMC?(>)O=GP:=>BE<94,-9N-P8^]7O"C,:TQ 1'N?.$SQ
MS%02!P%_\A*C= V0K&M?Y5L?2_G0?N":.88X\G;>?^BZM?2QHS7C&Y1G"]'5
M:R8FR?X9N/4A2?8R8<.H5T>E&AR75=*Q3@^2:;K62WS66%B9OQ(],E5/K]G_
M\+/[L,2\14=.<!LDK+5C:V_VS&0^:7\.O/KJF]=K>+V[J:TTD9"ZW("GZ2@3
MQR</+"''HD+OC@&KY+E &M#BV_Q6Y6G;*3>>P1'@CL.9WW4'ZX9^.-T/D\8?
MIG< O,H,Z3B/,=KQ)*ZAS".""&,52S/%,(%E]%,D<Y%ECG^J>:KZ.-<J5NRT
MN[J\F9>Z,*-0(;63I<'9'>#^06M-BM'BKW#6A=O!UMR06(6;VVFEXQ9T93'"
M8[G15SK*.BHRX"AD3U>L-L8.4XG4#S'4[]FHO:R$J3IT\Z;2YJT$F@=Y?[H3
MRB3/3FT;8OW13*EG1?%BZSRMI37-D>XCDS7^=P0.I&P$B?^+N2U->=' +/;'
MHW*WLNHVXN%UL'OF]9'R'G22J@WWGB17>2;,*?)-S4/.ES\_ID=*/VWKPEX
MW@%Z=>'<LHU%95OR.=$<@@<!7)I(O#EKI-:G8_%"?NL OI>5JA>R5D.'@NI*
M>EUI@].8\WS.NWZ&:G:(IGY#X5IEY& RA(OR6-TS0W(P9XV2K66Z2.6)[:4
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MM(SB6ZTK*YGV?<YK=P4M++;HN(GKB=X;!\JNYK5TM'1T@:Z_$*P(./($V!5
M8>"QWMY!C+EKO5J[=,0B>+:Q.NWDTIHI1$UM&7<?.)Y?E2(6UO-Y$&!Z,6#[
M6]"7&98S"A?OOQV=#D]0A,F^.%#B7.PV;9MS:B 0]Q,O_YYV<0?83[YN$()$
M>H#HQ=3%%G>+L[(D AM,]WP_U%U;-@35W@$F3%VT)<']6L].Y48) N8EB2CC
MN^7KK1[!ZPW-YZA>W8Y1,1O_+B4V49XTO:T,M [+8+D>%\-WX,D#ML\+2<I]
M$^=J2V:I-WWJJ^>\WP1=M%ZT%DBMS=I6O@.TV^<".8PQ I=,9JNJF+\V-G.
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M6K#!Z<'^(B+4/EW1!>.[\2W-9!WR)/H9MP*XL> EYW.*<!?3$V?QY(_GE53
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M.<01]19V !;H\Z()IO5L3U2).I6R 'L7-5^_' B$N37MF1<CSG^C#,75OSE
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M9-_=K4-$F^&Y AZ5@+HSY&.F9%OEZBI?LZV;6NLJU]++!I%K&OZG?U_%?#M
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M ALNQMM"--%I.;W74*IJN:_G2N2%HZ@-J(*)O53^G";[WI7N!!$MG%\@2.B
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MDF<:;""_;&JB.P\ZO!A'S?"Q '=?E@PR*O?IS<BR['LH5?-SL!28?V*^:@>
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MX%?#T#!W'05"(:"\];?QV#8HFQ;3X+I*[D_+F8:K$MMS"X@PZTH/7/OWC0L
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MSD%$?X!E^!T_Y BO_D_,+X/O?\B[T/0;VIQ_X.=C^.HN_0?SF#]I4>1WK/]
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M(Y%:#-:PU^KG1X*GYA]SD%BF4\9I-V)SH%? M>H8!=W3?-VZ@6P)*TMK$;H
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M%&"V$!QM?T')M9G'B>W1:C8SB]UF)%:Q*S,C^D,U"+HEO;>=:GHKP!GUKNY
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MXF3^N(..TO".DL @O G)<8^&\IFHU1JX$>L,]?!!V?:/=_2%$HLP)(A&N]Y
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MC]#K4>.3$E@T\<=V 4O6$^/)G$.P LEF*4Q!H7CX\''%_#W3%W7)S%B+E%E
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M$NR/DOEM[/W*M*H[1F6H\;Q3'\J-JQZJ=0\-C1'PTRCU5]N!5#778<2NMX@
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M50DI_(V[WZCV,NN($  1>]!<SZ$VPVJ<38G0)IP@[@T"L-IO?7XJ=<'(CHH
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M(A[VK_-4^]VB3+8M=K79Y)V#(MC0.1\/CH4UEA$U)4:2=S$;P+0_*K1D9 2
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M0>G?M\]MSM.ZU5Y<Y#'CT;[!Z]:@S\?B&R$<97J#_[8U:"]P*35,.5"-C3-
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M/W++311:'# !E3N7C'4X4-C#Z>5CD3U1$#ZVV)Q'?LJU8AI:YH[T2.J;ZP/
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M[ ?DWN6#6(T)DA?6=*E<0XX'^'2/MZR8G1)M$R44LV?UM_Y<.TQ&'L/[:21
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MYW(X::G-/=AZQ;FGGEWCFDY4(G#'8:UEFM>L[G'Z0O:)9$W'2WW@)7H((G+
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M<+7SXF5"6*OS7!ZRW!,I4REC\_B6_" KA//_^3S#_TER-?N_ %!+ P04
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M#G3%9%%Y-'R^2S?W\S0O5_<VFF<<_V_"V0O^9/YMM]FVREIWJ4H4'E% RC*
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M0*GUP@;#M9J@+&1MIZNAC4(W"D)R$ISDWSU*(V.W"WFOLW"_Y:XZ:(!Q6Q'
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MYSGF;&F;(=SPGA;K[VDQ7(V -WHUQ!>L36T*HFB[6Q60D5QK?10)NQO_W8$
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M[@H]_[KY07>UQWZ;RN7)>:A9V(:4/43,+*K)%6^9##NW<:?WUAR*6HD0A+%
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MJ.ZXGDF9U[L0>*1J)S2]$+-XJ%]!'!I7XZ<BL9JF8SF61XEG>L"['+0G>U%
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M$>*4=!>D91;9Q(T<N$IN!<1WF4FBT(XXYR!41[VMD-6+E.,7K&N;D652QXI
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MZ+[/:&C:S)1QEKV\?A/N+_"P?*T(L58&[")T'4% H32XYQN6 -"=NWX#% Q
M8XY8 P 3\HCX%B@9K@!]0P<$@AN0]VHYE@6(K\-!8X\:&-ARX5X%Y8!ZGAZY
MOKPPG3'!?0*D@V.M#GC"$PX)?:H+"P#-Y@A, (Q 7 1,%0$(V5$(%R8LN%=!
MHR T>*!'?E^/& Y5^+X(B<7P) !: "8YP @+_8"&KA<8?/Z(?5#C NX'Q*-
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M36Y0%NA,]^FZJ(3J8WB@HO#FR00&&) QS#+"UPBG4X+;(")]==OJ*4 F,X'
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M4HM*)\!]P-RA#'1^_!.&N8BE6T:PFNOI,1R<=Z%7CQVX]Q*J?]9=:@86%V:
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MGK%*"AL,1!UY,9\Z_.N3:@_R]K<XH:EB5F=Y'(&D4B)LO_[TZ>UOAV_4+-=
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MK6B$2E]2/X"^)TIHR#.87[ZJ5$[0&U_+."O]/3O<.Y1_&N_?S$?$^3?$T Z
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M,J7MM&0&$M1H<H0:.^^<#J])<-L,X>FJR-.[Z$)ZYZ'F/S^T_D>2BMP-:;I
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M1?K<D$FWS%NM'F@"IZ8D200OF1#M.5S;@M%LB"C09!P_8\#5(+!]BJ?(6 .
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M!/ WSRTZ3/HM>2ZT(C(S25.UH^V'WP5'_I"G"FID(D!>.<6L'7I<+-;85CW
M_#_;F=%Q1%[W#J>N@E1,&/%QDJQ)D).+\8N3:+GSMMW@2A@R<.*X.H+@@3BE
M]HY'N]]%C_;VOS\Z>-QZQ<'^Z(#^LK_[_='^8_L>]]ZD7$:/O-TW2\D=+%'Z
M@5?N[!V,]K][SM)P<O9#M'.P.]J-HX/1X>-1=)G2["4E-ET^JVRJ,^CP14^W
MLX .!4^V3L@\N2Y*9OS03U.>>G3QDDRVGXDJ,M=)UO +Z./(E"*7>!P%W<0
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M[CFL,*TAV_?D\Q;E#.ZR;8EIHM=)/;W:^27YM(05-@7CC1&>CV&EM[8&!M2
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M!(X;6(==+%J9[)I<;QI$EBR7PI*BR:DXHG$5*RY;,8N<3O*UZOTY8A_H;,E
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M;"SSE,P*3MOQPU$0X^[0%S4\1K48K]+5+2^VB:Q@^H3J.CB!^.VZ&S87*6*
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M\C9BB==:2C!HVR)<8Z^T\FZG"1+(L@](<J;\ D53<[B% R9H@E*"IEN"EMT
M"FD%"9V#EKHU");.8DHNPS9T<I;.31C+S^6>Q(* O4S!T>%PD$TWX1,RGY7R
MT2@/5L=.^D,P_M^J&A_3!&UD.B0YTCMA3/=RG58][B9[4*SM/2*@*'N9TA#7
MXYVQWOJRWZDA5#',BDK\SH)\5JG2L5!UVKIBB=MF1EG#7^74@"L1: 5!OT!A
MC*)3YK&PS1-%N],30*<O?J[]:J=Y;]?VL>6$6)0" $"H,IB9/NV\;57]*VG'
M92:IL._RAK52. AL-"SKO)3Z",8)Z-Q7:=W8(JSV$<%[N;1<\A5445.UVS[K
MP7KQ @/@_$:0+_$ATUH.R9YOL<JHXX\9&ZO8.NL.)+'9$'6)(0O 1<_*2M@)
MDE8Z)VZ]*SS"2[-(2C<-G1=849(;# <OD/MA2T1>8I<'3T]G(A \.?($*[4T
M0%#BXS^T#AF]-/.I)*ZPB.V!%Y#6 X68A5UD;<'(35J95DT)EJ555G,6FBD3
M\!61JA>BP<\*F!Y03C%#M\]Q2E=6TMXEFB0[TSF6':QE0+ :5U(81&YR9>RA
MJJQ,:1F=Z!@^",_.HK@F8VZ"!-K#5NNO>_,[B)35ZY6:(*WL3$VN)=K"\5;G
MU 7LG$IE$X<T[> L64'R6%LO)^0ZS@:,T(..BVFO1FV@A41@:ON4"*ZLMN%B
M)F6RW0\E^]AJ7 AO1?U$&Z6ELQND2=(K4!BYOK@U899Z UP+&6'C\IDD?I,2
MJ/ +Z5@JV8Z!L;F#K4#'...XZ2WH_A<4*W/[;7SJCN_)Y1O5Q!'SE\GGWUR9
MO!4_=XE[TKQRHM9%(:XIJWO);J+#CVL0& 73YIM&QGJ:\$3K=%I_#Z<#N1!Y
M>W^[/MJN<I!DC9Q3^X5Z\HGG]P7!S&%W/Y3=O3]RIVQXCOAN1+#O(VRXVO=K
M#QJ&>TP X@D2$D*;IJI*N855JZI3ZR/$XB[3ZB,'41!ID!U=IIF+]ACKPW=Q
M"8ZCSQL>+.L *^A^UF:JSE<W&]I&;"12-DMIXX-@U+ MAFUAM\5!_[9@Y[5.
M/AH.G\V;DOTE)[$B2+&WS)SX!G*?<CLL\XF^;-:_I<@F6QAR!I.5/3$P,=A'
M 93&]ZOR9=(6H%N:UK9LHWY@ZB%P@OVW,R%?E[X_XJQ!=Y.I5PJ'A0LF;1:6
M!#:5L[6G^-[>Q4^P+&K;]M;#,MO5GHI=US9,E6T.%P9T0?4Y,8%'IYS0\R93
M3XZ%:&U5(,1(PX+IG$-M6296&^-+U%>T<6XNZ*^8!Q=_TFAFC^,<QNPVVO>A
M;W(G0I"@VF3FNB.'M'S>'.2J%K56(*B"J0(!7J6X@YRV64+?N^*.:VH?L;B.
MHDNIK<O6,8<,R9V=LJW9]SE!&K?OTP30YD,3:5]@!?:6K(9&0K<CWCB8<_$B
MX+D)D \ T,T=9"&B-:='(EC?Z4G=Y*Z!JXVN( 7#IZ3.VL-V?5_ZV''(:,%K
MG-/=F-[8RKI(F#00+%:(JC5YVF+?#3L[0"AL]&-5I-Q_P@NW]%MD#F@'XG*!
M:\=UR5(X;VUP&Y9BB%<G'_/6,&<D!Z,T[LGSP#%P9%<F0OW$[I-5\TM[$T0_
MT,_^"]>.[=9N>HS[2LZ%;L"GMFU_%PE&()MPQD0H]BF8'&D5(>^:,7V+YMI:
M[PF3"G1'R3$NQ]9K^;9)R&VJA28K6$?:X';E?"2CJ8R=VYUBOF/G5J>!1YM6
MTT9R)VE/3TP;.I63B6-I>BE9&[FG!EZEUUQXMZ5?)[>B%\BHJC?X>UE*PY=\
M&'B3F=&S R"Q<OFP=RZ.HW,S(V6'#K87]F X)2U) NNX@"Y.QPXUQHUYO02K
M^J6SSC[%6CR,_=6M*XQ%O/.T>6D%L1)? 0(5\TO\.XHR77"I(^U/VO+V+G)Z
MIB:O3(>5C-[TXLVXBA70N5+"(A:^TL JY),2:Z[=:'S[F9A_K5VQ.;+!HB&^
M"?:E^X4R&]'4<HTG?EO29C5=RAW)XV*2$W;4_-0(?(]W79!9M+.) XB3D->(
M%],6G)NR%!F_2>B7Y4#'^K613@<#TFE .@U(IZ^][VBA+:19DM=MMS]F+RS)
M<<HT5>,:C\,O<U@:]GH%7"0^?E@JRXDS-N;4T EOZS?''+))3):K=27P*[+@
MZ$PAOP#%]"X5/+,D?&"7RV@R< YH,?F\Z/8D:"&^^W+W;\];KHOXD5V@MSS=
M9?>3E=TW2'TBM,WQ;WD/[K#XZTE2T\>UA^Y19=9Z##LWR$OLU%F(.)MLZC'C
M#GU^K.!NF3=TFO"A0YX=L0Y&T=@M ;N2 1&LXX;W&4^&$FA>53,9?/C7MF^,
M7>Y-M ,'(9<T)SBM ]A[Y\-GA1$_DY79HFA[P!S&3 O;9?W:2#56=66R^0Z2
M&M]\J])O57E\: ,S>K@6XSX<75\7&9)"M .373@SU;1,5[<4=G@*1P\L% "E
M%S[UMKPV"79=[$O\;) N()HL2>2O-??E]5/Y>42+>KGJLRH5GSA#W"@%C!4;
M@?P09N2-8]4\&^ZV]Z+_K:V$!!^XMH$ \A?+:&Z0UIN00DW4HA523O(X\">;
MK!,>40=+\O&T:5I.FZ4T"ZI\+$U@*14CS^ NM">$W(6PN&6M4X8@<"H:T1T=
MG,"P%*'7QI412[ @K2/9_VRU+_GJ.6.!1M&99!IUBK<=)F6B,*HDUT?9N6L]
MBULK58+<B6VU@]-C$.T0[2&LU+TOE"D*;PC<)D6*MA;-SD0ND*?PZYU<Z12D
M=3CH!ZUP&)==M[<%S:O,E&;8YPJG\^0Q]"F55+&3X;SB/ER8[Y&(L/J!D4D%
M_:5EMARIQ;&#$\[>,):3"Q(NL69M_11'-\S,ZL!*\-QIJMCGAAY9\G5+J9\/
M@7?TEC;NSD'\3%([#0KY='Q'R2(O*DZ$XRT:)NW+=.M&D<_;^)8+V4%B3'3^
M&M#G]"+K>(2(B],8L&/\<GA= 1^;0U^L&UJA>E?)O2@03](9T5<'-,=8GU'T
MD^(S$8^WH;0X.M[]CF<@B$[09)B/+:5+%R!VL"S(A&E 2L>E<:F6Z+U[>XH3
MI$1,48G>)W88'N %M &9,/45S519+&W $)!OK2(,-ZO5(:$DXF#I&^Y<QR#?
MQHS '!6GXX]D)[$"K3UT.TNDW70_._PJ_62'[RQ!/N[P#:/H55%^?@XEIB0K
M0*^#I29SQW)@\AU^@;+_?=)_V>7DS QMLR;OS!\_3TX5%E&9O& P5JFVQ$)/
M+FZ/-&O31$D@$U"O0$GKMTN8J$HA2J!=_C>^VX(G[2D:ZFS'%"590QLD"R3]
M06OB#8M 3M<0=="/:+ZYDJ*1)"R\A3)L8Y![21>$BD ?@#^VC4*IU375%E<N
MJ+]UH?#2 VLQEM]83.N5GFC<N>+)=48X>7R=5EK0S&K4: +9P7S!UP"@[DQ-
M!AZN_=:N<%97?-Q,?/-!;>P \;[13N&R!0+KS2;SBB9W^Z;S6N4&WABMV))I
M'1P,LD$J,2K;CWG86^.%9KQX9<2Q@"1XBX2S)3[!HU7LHIO["]9O$%QOQRY"
MX6\YYS9/AD]R2CRLE)>:*;@$,./#LOA.-K9]LH?90/'?:;N1[Y+7G6WXR*()
M/]N._G&\I0=IZX%Q6!'OPAZN0$Z*V5H!C<EO7('0$VL1%H6Z8X,1@,L]@M(R
M_QKKJ*3HNH<)"6RS8NZ.V)BS^T&=GP3.4DL[&4GX9&'MEHO3MY?1(^7Z2M:N
M!JW+!R.\EV4Z57"8;\G"RJ(R-/\FO\*GS(*.?XKQ#$)! (^Z/R-#/V,XG">5
M0>1+\T_M:HBX+882)) 6@LSUY/K3VI&*RT\V$"=82 ]@8U7-$M+J.Q&*F0O=
MY#2[S8X%1[]#7[1:$CYLY?1>;&W!,*E!&+8G"H30U_]+N<E40L'K3GUG6]S1
M>\B$_/+*#<WU:M[_1R=D5(GH7[EHIGN'=MC\#U>WN:ZUKM-D%Z[%F]&!(G&Z
M3TG>N\6H+>1D*]IRYB8C @H:L@GH&5TZ,S[GS=/AXI7"52(GJ2N8FA=EL+5;
M*D=G9^L\2%4J#RJ(EDH[8'D"WAI6Z7 X*&=CR+J>^%@Y]+>^QH;R)= V,1+1
MT0EUTS,S$KF9!CU.^7V^]-E;WSR!MWP9L//X^ED<6C.Y1'/4][;Q$_LF=!^=
MH2B,=;@?87M@?C0Z1GDCJTK;]F##M1CRNU\YO_MDR.\.^=UO-[][O]N<R:5?
MT@7NU%EO%][WM*WA'K1E%,8M ?1%5)6+DI-E"PGY"D7%'THRCC6,T K+A82.
M+1"ZSCL.I0I]WE(U&\)4M2;.-!GUO0L06)>+K)13@#D1>1:'R9:E5QN9)#DJ
MV0^TWQ#::6AO5ZIUT\G+YD6$5!QRS\9H2-.'$_A%^EJ-1A2E?T) TL!7!N12
M@5GD;1E$ELG*0R*$/-<?;70A#F..-N1' L)5-0I8#+Y-BC^OBDHS2QH4[RMZ
M\U\2ZQTNM<,9<^E85UC+(VKRI:$AF!D[@[DQ,]M?KZATYHKYG"<KP0OF319I
M64$ER6KS*=5,O8WI5Q)W-9\2&$MQ*%+(9CB9D$"P")#ZZ;8RR+FG(0Q8>ZF+
MH 4A=1_"+600W;1!U3,),9P$2:.&S"OPO-R[+97+G/E0\I[) L=-.[60MK\+
M\.1PL64R;TV?W)8ZL5.L.$3[G=[OEN(3Y\'RD#14SA;$1JP_+$-P2:='05B=
MKY2@^F-X^>PF*9 X\?DD?9=-F]0W!FPC7_:VO=W>E^DWVC?TI#K63-\6C3,2
MUV9Q]1GE18Z-.!C"/\+.@&.=O<6M2<C>7J[JCI@:%"H(,D=9%CQV6WI0.CPF
MI[*"L049$ ?O<8+MA7HS9E]:Q=C)H72S7P_^I!--RVII3((R20NT+SW+X2-P
M+N9=<>-0R3^.S][)/]*J=:I92'SJ[[-H\DYY F3S_YZ]/$>LSB'"9<<[A<"K
MQ6$R7&D[<;I4O_J:#A&M]RZ3F;FERD D-#@^.HE;EID\#!O-H9'6)+VL490[
MY9KA6V9=*/&&'G&="SADC^.??-@;W^<3&5RH(:9&HO/;#J43-M3OY@%O2=OR
M3I#3=ZWBWK-M.'?&L\T'(]SE7*<6:RT@.M'E^,6\R1<6&]9:WO99T7>:AL7A
M(5<*SL9IPB15PB!_VXM]K?DJH5L7 OK6KV2TC_ZZVA9Z^.?IQ?CG\6^$@7%4
MD<XKW9=, A1LLZ/1T]_NA#Q]\OP.P6D0EG^.3U[^=/%^F)O.W/2FV\-&3E8/
MC:)_%22(63&CHRT76(/4)K7O]8IK(R4=P#D8H95+#F'*]RV*O"C+*Y,,[<I;
MU:)0,:383+E$M4Q=!$3B+U&O=>KU[H,^S5\:V_:W62GDL0:=P"(&TUS OJYA
M73[56,([=5J-U*,532E'02QL(OHK[KB]XD6I>CVR@"2!(158.$9IL GK2=:X
M:3HY!5,3G= V,'7JAKAMS<=3WC=[Q\^>,""=;.%,\^S6SA8W]37PU3N_))_
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M32V4IFY*UD92*\=O2G/_A3[0.:#Z;PU/O!:'\@0*^TUR4T4_.LSS&:*9B?(
M<6I$+N8S[%SDHGS8[4@Z10!2J-)NN]$NZNG/E)"3C70"JI!Y%[IN&AY4-#<S
MO@#L7>X=G2(<:+!4R/Q]+,*2D85-'Z0Q@6-[XF>JWR9-19!*9O]085%)7J<[
M']/IQTDR_<C7Q]&<](.Q+1_D5]RJEK;H-;A]Q56E,PYGAOP]J;AS)H=ZRB2O
M 'D"[%<_:I&4/&120I)^<$<"USQC0H!U-58I2?<$+Y,K*Y,/W+8@[6S%98R%
M^X==N$NN3S.NM4/5UQQ 0(@2Z.!>IW06H%TK*E3FII3:AF3-_ZT*TBW2(J(H
M _!8:8#L+MVIE,("T7(MJ[S9;A=W@9^5&?V!$PKZ2,$QX!\NA*,>AMS S^0;
M!&NY#N4!4A,S5@'2.I4^QAQ-X@"*.ZC8U! WP-KHL0N_>2&T<]J6N*!_"HYB
M#]KT,V!QF\@2,L1U4A;)C!&VO@:/9TE#)_F:E\()O#8KKG3YW',Z]P/;QXU+
M6^@/"\KHZ)XVAZ*&.6%@7%G@L^M^@N"FG7:-.;H D,::RK8H52YPRO\DJ\JV
M6*D9OLXTB*KR?-&D^82FXBZ='19M)',,K)S .*%)KV&M!<H-$5*X)DX#:EE-
M64 #N2; O(RMQ[JB?0GRMM[?>BE[A&5RDT<YS2Z\IE@G296I0MJ$>+*S 9R'
MEF5F(6LU,;QZ^<PN/6^0L$5.,.F6M(2KGV8*G.GI"C,MZ5MSVWA^388>FUYA
M UKI%FM6=DZ"CR1#TQ,C+HVI.8;7R@=+IR$?N0OX$7N644;=MXC>!%W:'G+6
M2UD!9T>3@ZEB$)3USF]5:8!C<'1 5I+O3:6HCH.0?D/TU$T4C&VD>=Z9K'?P
M7_%J U!W-&V6C5:J:C\I3(7"9K"-M!PO+>E*+8T919<JXE,ZIVL%D[;VK*L9
M]J!:EHHZG'99#EOJ)36KX@HTY0K(2$69!]\H8KBAB=,JD#6!7G+QW+Q/M['%
MC[B,VA?QYU?!:Z;KM."82=>?PB/T"VUSM2]=XN@&8)&E;!F-+IUK%.)<58("
MQ\;S.=HQ02S9L!U+U=[^[MXN&R&=IX0V,(,#:7YDPB[@(>/@4)1?^)PI6G^S
MTZA-XGO>*G5,B@9,(K':!$@JW\[)%=$/D/Q*-@TS=JP#] ]<^<KUBH+6IEG"
M,9V9V<)8*;?G0[LBRR:N=$D XD(?:SXS[1,M+AA();F.@_$;7=+H4^C:F> 0
M>:=DW&*/Q\^FH(;CUBZ H:9;Z=,6@F#C,UT /^Z-]D-NEP/X] Q\8KB\F*$(
MEY5),VLR#@/ZD<@6J;I/%M*55WSOB9BPXX?>M>J5SDV/8>_="5;5O9,7JP;$
MWY:(T, Z\+PU;.-;PU/"6EUYASA\SB+%"2FE6[RWIDG#V2\Y4?6/W%,O_(R6
M4&HLRDJ"S]7R _V;+'QNXRUH:>=?P"Z:?;!R[,I+$?\<=3K@!IGIEJI%U"ZU
M]0:L0:WM8@(%:7TUSLOVS9,:&&Q:SK&GZ H-U*B-8M:VUH*#15*B;+>F:ZQ+
M9PU,]!O8:DT0S0\2VPS_K/M3UCUA+2TXT+(]':3O&#,OC<_.(F;95+0Y3!FP
M:R-\.:T#BXI%T5_'U!P3'.YV:5W2O9/^[2BV6SSD4/)]8S['UQ[K@B-0)K5K
MWL"SZG9C-PW0N*\-C7LV0.,&:-RW"XW[5NV)* Q$J8U]AHP#4_><TQFDC4O%
M9I\RXMO^2DWMO>/C(SZ"7Y^=C\F,GEK<N.\%[$PZ2Y_GS1 UB-4W]\9'<'(F
M-@"P+>AE/G$$02V!A(SDY:I68T#^QL9 -;TR0C0U,VR)=H-1$Y,;FA][*(4G
M"T=,.=VV"2K;.JSEQ/SG/YF&R>#Z9H%%?=M[@WC>A!R21B(IR1;Z07'Y@^<A
M")A;%H!MH\.A)TV9M)PQL2-EKY);RJ["9@3S1+I2B]$520I3_J:/,R!6G(+)
M$,60;7O?VV <"\IS]05]ET*3I;;5=L<_V9PJG/I=IX7\V, 4N=4_\9Z2=3/[
MG%[NVJ&&1S $$1TQ^%CD[\A#O-TQ?-!N4LMV[.W.O#T-$A([P8ILLH5E[I@4
M'>$*D:NYCQ5Q=QNUTV\"4J(@$S2RVG)KJ./,]UV,/G@B& CEJ2-D0HFCY3G2
M^VQ(X_79A].3UTJ>4E=M2HT651OC$XT3]78T,7=!)F,[]SQ*1V84]VT-E]V)
M':@V2S14&_I2F4F@8*X*],]^K/66HJ\5JXEUB?VB\.PB'16PD0"22&^3$F@M
M.4_9@G$(7#>#I!MZ7#&9(HYO5K(>+L3GWFRU016)T9^MPX@JO$V7VZNJ8IJ*
M'X4-!I0R1SJ ^J3=CA UCJ>%#=-N3*SR1"%#(TF3B2;?.7)F9CT?UJ=-O<N6
MN#P*6D^;JR2;*Y%_^.KUR,X$>TGV_)Y#7H$RHK&5,N M@8/8B;#H0T8.?#1]
M;<U]L.'73*=T"[QV?95(W92Y65<6S23UM(H=Y_3*/,W<^Z>^BG66+).%Q.K#
M/NHTB<Y$D3@PU]'2'5K6YDPD_CYV\$5IH+C2CL9"V.;&6.8W <WKA\QT>=!!
MG V!5J!+A_FP%?<ORCD Y%L[F'U^M:[00BF/SFWJ^;)!A7:N45PKMCY4S4'=
MSZL_U7=!C*&5=9L+RB[VY=:3%*H8.K==CUTUD&3EVQ+M;ZT8P->ODS3[;!J3
M R97:38K3>Z445A1P(:Y&HK1HW:[0Y<;>\RQ[#RW]! <3 JUAH5+(HRC=V]F
M]%GASG42-K/Z5H?0-DY7#)9L&<QVO013  *Q7,XXMI9H"RF]!>A(<(.%00KK
M&N\_58M%&>AZ[NDE9<7_TQB0#LV%$B8@$ MT7:P%P'8P6]YIM^[F-RGH\]:I
M*VY("X$L0"\.X$Y >D()7)F,/[X[$BX'3I<0(8E$8;LHE\4#UP4?N);VWZ+2
M+="FLA0%U\:[CCZ'*:QVVFM$K8D$(%W>^04D,$3IQ-*MSW5A8P\#B7_#*(AJ
M6JPD:NK2]N)UM$H\ IQSN+/361!(M@Q"$NR$P#+X,LRO&VD]Q_L5*)LL!&S"
MTQQ%E[ZUH,)Q1'-MU+?;4'5/][S.M4@TDH>Y=KKFNLC@XI?KL&$AR'RYE8&3
M6D]?T[G,ZJ?0;NXWF3LAWFK+Q\TVNTDRZ/ VG>9T&2: [6.WXS8"^\YF]02E
M4 V,Q*6Q,0F9T#MIC)[^&N ]PW:/=%563#T"3#Z D]W,.=JP;]Y= B&%I0^2
MS AGL)&8]K@R!9F+V0'Q]Z0E_3X,O:3?5.31MC+@3'(=-"*<I4 029""F:(4
MW96'%--"/LW3R:S5ME1@!8:5E:ZZ.CCU55.ID$S%R@\DQB ?6S]P1?<JU<P[
M.".87$E.+4>T]!/S./VHMNY+N*Y!-MV3/4>/0.GS_='3X\>N!.+'E^<7K@9"
MF4(##IO*!1G85!"C'*&$.BSP4Z!3GU\%+8UWV'VDA 0%ODTB0Z'<^*:5RL(F
MPZ%50 *J).$M$$^"#%O6QQ8&9\)Q*51JG/X4Z#EO\_ESH*5>[%F D<:!-1$0
M#[O)E_++K#)*XRG[[*8H;8-.Y3UWYTPKEA"PURLDK,5GOY14MY8J<I6+VPS%
M)&LU% D9']+J8S?%Z^98J@N"6>;N)K:FQ;]@@%E_ <S:)4K?L]Z[ +?U\D&K
MI[->JG0!"?I<N-W/EFP*U1$!HTXHGF%/ >%FY2-/ZV"Z,26MD+7(!S[G^&CT
MED2;Y@HE"(AGV281K0TH;H)M&8VU#0//<2?R' <#\8EW08!V1DY>0S.U,#EV
M2X)[-VMFWR8E/4M02IO%YJZCA54USIV5,9!QDK!*5(WLP6!<)JPL@\X.Y<LK
MB[SB4+?UAEN8GD O+A'UJDT0?@_<SU8]5&M69JY)Q.=Y M2S]D7'HL4W"O,[
M*%Y/&?FA;):K5K-EQ4 Q&3ULK7Q1L"TG5@;'I8",6HO'0&=KQ@#!(,X?'(PZ
M*33MG>6KDT]6=D+1 O;-KI<>GX8M)"SS4PGNF8SC8'9)\22)B*U]P7\WAB$0
MK< !OKDJ+&S4%>CH>LUN6:P)C37GJA'A_CN6PQMO$()?BY (PN2N;[4MIQ<N
M3$_%M[OWC'$VNCNEK<&TEC!:K)24]MZP,59+.?1']6*$(',G_""D*#R?%CLO
M'-K!*5BB/</$  4$9G)\N-M$LM(NR;,AXV[-G? D59"V211JRIL<*3G?<4:&
M0:L8$*=)_!&Q(#@H+!!6W-D32&XVIO"X'>HB+]!DG.7A68R:%4</.$G6FM^H
M;#*Q!FP3E<V/NV':J\[$R69<)B[UI8C:Z4>[;SLOXIRIE+$91R$A]M92J>=[
M=X[R,BBOK926*$L^WNBPJ/AD6:+"E]M>-BLX[C3;&()88XG]9L?&*-VM!\3.
MUT;L' ^(G0&Q,R!V[B JZLP;K95A2R0T1P.T/GCL2[64QAU+R;N3X<WS8MIH
M344GY-6R@>CA+U(N,R&?/GK1S!:F#L#WSZPI3T]"]R0 0H(30L 2TJ7L\R9B
M*[' #1W$>[:^.>ER]N.U^KZ;OW'XUW,:;O22K!"\*0=;N! H,#.&K:*F$VCC
M!@:=D!W$@8*9=(-K6;>+9"4AL\/=[_"$I_0?[I#:,K= #IO+JH6^@!A1YV10
M<!;;VK5J^5R::2GY5CU67[^^C#WC96*KV2998VBM\MJ6LM6P8&Y0,!Y4++6@
MQM(2KMXIYCNK8@K22G6V3KPU3*Z4$'OPN]U+VM3[H:#XP(TZ8@B46'K0X'[I
MT\<&6\L[=(3-SDX))<*Z%PXNW!_.'F&6V+S0\D<._)L9FSA%[L+^ MAV(^;&
M)&I+@4T^=ES(_':CX6.[P]CX!#-:R_P;1>_1I>3:FG>6+_;D[6645E7#G*62
M&@+LG=/B9-2TV>%Q\9FVL('!R2>]V$!D/+<%]$4/)X5MB6$Q&G26[K!?VBI?
M$_FW J/P;(1RA7J$.4? =K+#C63,;$=)#(0.0'$@;-62H/'#Z?>/M;-!,H/!
MM)3$H!)*]=96>_MU(];/O,>6!UXF5$EG[6YX'Y"IM<$Q(?<W!.FE)QR0-[+7
M$U)9T.4[TP090?#(D.<P(S&AU75L6[RTWG)_UJ(";GGP+ZW]+,:K]*V![-!:
MHM*//)TT<>*@/,PWT#^T0.(DENL HQ E"YB[]5;/O2M-:"('#$1;TGT&Q,D\
ML%$V51% -CN-?> :3O$H1\,1VRREFA_B:UFM!4#&"ZBSCG]N"^R838R=#W2/
M@9H2'V*+ID+^7!AUF9L-C7E2SJK#"5Y#<0%2)-TDJ]JL*CV@,(#VL2>UA6#*
MD?:3XLIP3EIN] T IPA]SYL'WJ#M@P_T^1!!R:U<;+HNB.<%H182)A8)7D<^
M6#8YB/BQ@<7A*?S:[ -)R9$ _R@L'K,?=,MG.%NK;W8TA)8)J7.6"(E.R@K*
MVA#:%3RDAPAB0ZRNDJEK1>CSA:Q<\9"LX#R?0ZS93[ ;+I93QB7CI =:&)>D
MRTEI,.LA,T^K;H-Y8=EW;-(";YDTV<>@2G]TAT1D#WJCG.5!+.?EV>7XXFU@
M$!]S)";H81PV+D:\B9X?1A,#GB H]9RC<+"C<FNFE[?F_95>1Y!Q= _:":;3
M2G-2W;=A;)SDY\QMFJ^:VK-\GKV\'#OP.) LJZ#-A,#V+5O:%$7.LCTZ+X:J
MS:6X32"@@EK-UB%ID =C.60.O\ISH;H'0EO? )<)V(T'5G!Z@#8#MHY0;PE2
M0#.8P?U-93V.*I5<N,2'P5Q'-L L"_H8N0AF" <B3<@FCV-J><OWLF:4.NI.
M\@^3S$V= Q%PP:[7P,)BB!=M(  N^CM:,**]2J?3!Z,NHSJMZ9S_Y\]G9V?6
M'+@L6%PN+1Y@+-%<KU@$<._M(7R5OE\E%S-%5E193/ D]<)L>: 246GA[L,^
M'VU:OM4IFYLW%M*GH&5I\1&JCN^FU1YT 0[(TB1@JB[VB3Y5JGD=>#S6DFTO
M5<(Z:XW$_>\D0^7PKAY^"&,*9I0G,P[A,QX>(Y[J@=<$$H+%[\4H= X,B>JQ
M;0@6F)3MJ+G@79GO +2%_)$:>T\B5/ 4)4S@JJE6VB12A3O\E- 9YY08B>QS
M]2?Z'@&&ENF504V*'+6?5BDGBC0AI]T]]LA7SSO(!0TTA],HZXA?WL9)([W
M4"+3<+P=R?IF0KX^M_'HDD^[CNX3TW(\Z>.^5Z[!<%AU\DD < PZ[MQ<J%7%
M )S&PA>8V^Z:5M0W7<]9\FS7+13@6,_I@6_N-QWU'2CO5J;"Y%R4D]-/J]HZ
M_ON['7T-Y7^=+HI2+G;>O>/K"S2R,GR&)ZC=7@G+C_.3;'V!0P5;LG%@L%Y?
MBO8X'U]^./WI@D^"S0^QE@:<;$18TDKJ\2&Q;&![<"T#!8^>3T'2+IR3+)S!
M8>&87#FVMH(J;+6[1O9+^*7BP'"P3"9KEP;;@#M75NU(@81XM/*6!"J,U:XE
M3#O160FCH>$DR(9@.A:Q=/[WT\/=B(0C4^OK?Q]PI;H"YY3CZ8R=3O+)U=TT
M7.FE[5+#QS,B1^!!SFCK?(<ZU#8A^'Y:%RHWVD;M?'QR,KYXH:XXQPDR4]?&
M(5M?%[FV]_UG<IW2[U_0U)1E$ON@81R]Y#Y35J:T2 @Z7#K]77H8JW(7>7U:
M58G4I7'ADS,,9NY+K;??-A8ZEIF-^?J L';"9'AA\M I/;J,P:'%J&$QNR.*
MTGG<I"A4A-68F'$Z5T KW!%(@K&,:2'=3H9@R2+@FMSYYD#S39[:4?0+7%-2
M461E7-E.2O39LW0J8P(]S%)RU/PE)+*(6G$!J9H#RO;6080@*[S!U^91/9K.
ML,!0M0HXTH-*&M4(?-!M3$N(AM'G2"\TLF[TR(._H:-KW%3XFB/,H/.V]#P<
M8'.WPN8$)_?&ED1Y-.K#IAW]11GT/)8FX428$7CV_V/O39O<-K)MT;^".._T
M#3L"JE9)\JAW7T19LMKJ]J!KN=L1Y\L-D$@688$ &R"JQ/[U;Z\]9"9 L%2:
MRZH\'TY;11+(8>?./:X5I&P2,](:;O;BNZ*<="NQQ6_LL@8D';F1<:),B]#'
MK96X9GN&IXZ ^,QK_/Y15-X?WJD?_UST9?'O[%$A:.4_<>B+003%RL&!ZM?,
MD,S-C0SWU^_:Y0L!)P>[9<F*17#V^C9>'4L2^MZZ> 3Q+!BB[K+M7BBCAF+$
MY_3+!2PKE,L&Q#^;#\KYNXKCYK5YNF3G; !6G4I'/NS1N'\WE8ZDTI$;53KR
M@:;X)I?V>Q4"X(<S1.(@/."D)'?[MTD@O*&YD3(*LZ;5T,7$8IJ15 *TW@C0
M+'QCL#R!LF%$^RM!=JTDZ3AC['=^JSOO<7LU*#$?CU2/@BL$#)BBLC9]L>N!
M:G*'_ :RWULD!+@'I5]+3/S2^4):+K1X03:ZPN@($@HWX/"%[;@O9B6V!=,2
M,!Z*-/'2JZ6,@"%7&E>/T<N9,4%^2L9_U3-6#W)^9-07UMEK"34/T< CYAR'
MKH4M@E\\FYN\07/0(/T%,A)*>N+Y,:5WS]YXO+C:+;&2#(,T/!7&3VYQ5_]V
MWT;,UI.E2/")HW5M]\[-S,SFK*W4W,,G'1;'WFK@2Q8 B"Q3-NC"#T=MA6*L
M84P<*AJ;L^2RT1DR-,+!&Y/TI$)ZZCW;K>9@@3WD\RP7TK;;6R94'C,&4OG=
M"=J#;('!26A]B_6SZ:]>N/V,0(]S3$=.A@;3/2+_W.NDVCFTJ]DFPJ\'^!2+
MJ^]KG]CFO9L;VDBBT2P>RF.TZAHZ03!'4* MC>2]971\Y1:S.?NBNJI']=@M
M#^[^IH4S<YO=[59M7;6]5X.1'@Z4$'3&$(XH9Y4D=L"\&BA 5##TZA1N:$TX
M_+\@\;\\N@TWV"QY+[&$MV0%/!CD6U.^77_H8Q*X6WF>SEB[/W&+COG.3[_@
M7-K]/.J Y_3DE2=NI!432^01L]BWVYW>LR)"3D3)I43*YYXUQL1_'UU6>?:-
M_=0 !O37K+E.PQ/&'X\>(LFEV1%(^Z4\T.<E^9L1?^PKQ\CQ6\W2&DL&IY?Q
M^'MW[S^@%RUZ*6'8B_%15!M&(&,^X%X>TX[*41F$0=Z&*U,F,5F$UYO %4LT
MG@,GT=_-J).N.:9KDHIY!RJ& [1>SSR8/^1?7N,(?WVEFKE[@]7,_0>J9A[<
M_9.IF9DYW/_J?2J=VV:IOA5+<[)3;^;=<>D8RHU.R[RN.7V5)J&O?'65MGMP
MG9,\NIX2&_C<^U]Q'TCURLXW^KS^E:#:U.KE6*LJ@ @*#4A\SH9S= U^Q;+S
MS3N['IB?#J#J%BB+9\<=2UK^5&9?W/V:1K.?/B=ZQ3N\<6:N&A!H7U:]^["K
ME#37$<W%]AH"H>58FR" ]1S(I-(U1C^+L,/0Z,FEI @9>BXU#SSV3!;^Y_8D
MNW?_WOUOOKH7P.&E_W549+PIN#HM*B9/ZFM>?3&2XVB; I+2>5=8Q:^UFS("
MSCS0Q>TZ "/$R.)5I^'X97ZMN_R>WXJYN_R;:]WE"NG-:"[(OG3[GNPSI&^Y
M-Y]GX+H"T'%HB6'.AOUH2*_2T(=OG0DX?/4N[J<?5>'+&*=K\A:^R]R I5 H
M[.)7;VR2W7\'<:Z13:;HR XI0]FU.]8(/QMY2$Z3.4UGCQ[_\]=?/M9UD)RD
M=^HD'0D)G9Y^<=5Y^^):Q^TSCT=[RKW?-5K$RS%3Q$>6IIMK7!SQC:ZTT[==
M56?WL,?WI</+ UB<LO%^_XN;%0%[4W_DP\PS591^X(K2TU11FBI*;T)%Z4Z)
MUOG]*AT8 (2%QHM/[]!);P<ZL=5+5SZ4YY_>O7MR]R\/]0>@K2ZVO?NV1^\6
MZ15Z)SV<GNX%&DU54N_WK7U;OT3?*OT"R,._/'GP]5]4UN<^/WGPX*J/Z?,O
M/][/'YQ\<>_3&/S_^]==-]U'52Q?DR0"F^J<<4[NZ$E>\?_-G^1+$A71:-^*
M7L,?9D1@8N=LJK*LW1%E]?6'/HNO<<!VY:V8&NT\/OG?__7%?UT]37_SF)&P
MW3'669G993LSZO>X,&]W_<>NY[&5&P%LO9EL7+%H<M;NWK\1RY8DZH-(U!-Q
M)N:6[@;IZE?ORX=7>>]R%QX'S+=W?JH_V@)]L.ON]IW:IQS:2**21.65HO),
MHD;OSUA(TO()2<OW/EZ8!"8)S,>[B9*P?(K"DNZB)"WOZBZZPCOEH/:A>[HD
M$5DMWZE[2BOXH9(>K[G*;]]>B%'?>7#RY=??Q/]'8O>J%);DC:TH[EO)5U^X
MZU<:7.=4?*25?__''1.[WDE^9Q-]XZ-\;.*G7_Y9)YWV]SH3__K-KK!K3OO>
MGWR'7V^V-W:3N<7T#G=^I>W^]+?[]*NTRY_^+M^[EW;Y%NPR6E[O< WYNW&=
MWD-F[\_G.EVWD2<Y3LEQ>D,1>_!GG7/:WFOIY73YWH;+5_VF^<LW;?>GM=VG
MWZ1=O@6[?#_M\J>_RZ]0W2GE]&9^TW6;%)/CE!RGY#BE[3V<>,I W(K;]_Y]
MN7V_2-O]Z6_WZ6G:YENPS6F3;\$FOT)UIX33&ZTJTPHF+^73,6-?-R!\8^:<
MMO=:%DVZZF[#59?2.[=HN^^G],XMV.73E)F_!;M,.OLZZ1WZ7V!471>G]..A
M6[YWL-+_:>MJ5;<EL+MN-1+H+\-1ME#/J .0\?]$"\:,FD75]*]D98P@Q/L(
M0_S@@1%9IQ$I%DU1M^?]B/6SWS?T)3J_V<;MUFTIH*/VW_1\ )/SG]K2"1NE
M$2.>9*_&/.W=A6OF<4^_>G 4]C2B<+QL7YOOYN!Q I*,H72T"G\,7=67U5*A
M, /_^]G0[^@+59%GWW7%?ZHZSQ[1DI7T[T?KJJ'_^7[HBAZ? V'3@[[_LV'8
MY!]:>L8_Z/_EV5,:,'WK:=\5(%G]>T$RF&<_N9?5LLU9@O['%36M:IX]6U=U
MM=V"FC//GM,P"A(21__9#KMU=K;J:(KVKW_0)_2/WXKJLF@\<8/"//V#?ENV
MFY/L:;38^,X<J*S]-U:,EQ:PH2-@Z/B7A[CK$Z10%H-?EKL6N*!"7/#WHF&9
M\(0Z/Q7\CR_> -SY$U::OX'OEL;_@G:?_SM[SMRWLDW_ '/N#^WEK5>G.UNF
M2(4NAZZC;]1[9O*M>D&5-0+1SIW3GUP'I>E_C#7M77=1+5W&?^BPO?VUM$-T
MU 11;5X+Z%D_Z\YI;*PTKE KJB>\8FB[RV(OS_UUZ$G3-*1<2]<I,/M("SR_
MK';_<9UH$5$)]+]#!\;>>=6@P,%ZRD>'FA9 [HK1]$F7\,74*/D%O7'-SR4E
MUS)W<6 C-@IET+L::V[$AMW':^\Y=D?K.>)_96[>AD=WN"G@BZ:E()U)F]\[
M]T*8 APPBV<(N?EX"4=VL\;XE!CXHJ@'ERWH6AXZ48->4OH#4:$KB=:'KL*+
MHJH9LQ3?H+^Q>F2V:WH]KY@1+C"A<:1T(R'V@PSDU\.6?C$T\@.36F7"EM][
M'FTEPZ8%D%%[3O$E,TTW[45A[]<=&C.;*SWOUH%7F;2YV1-,(6#K>8S-.V*R
MSHU1/<] +GU^%5<VR\Z4%YA^VCAA&:]I40&RRZ3C$4NWSM68NO,QSW5,ESWW
M,O\@(Z&.O@2S@$P:^OF8>_J*"6=\V%1XEX50M@B!XI4#RO%\YL9@1N]+3'I=
M;?G7$2&\@'G+N'C;,+ UB?KY.BL4RIV6 K_D&1:@A^]*7L?]S P!"[X@":>3
M039@*6MWZ?COX& 7W._2_7O R>D<N+"=$.  RUM^-Q)I8;(?BR:>QLJ#L<07
M;@FJ%LAJ ]#O!1:G=- ZHJR-LQQ<SGLOAD8DC\5T+P./Q]M+#!NP\^:XF*B+
MO;'&R,:29KALZ9!B&08A6=\.T$^8**DGK'&O%.31!6*,%O2KSN'E.!"C(QO8
MV=\SP<7[LH#XD>\+#!O7_/,=P)M)CV7/=*.]K#_'RO<%79U;F%3)B(R6+BS;
M67E1]2TIK3/3 K?;=&RRQVZI= 6G[)S>Y1N7@T5"/].2&KUJ ;//<,[_U__S
M];U[=Q\^-P/&?\P?G#[\?%9*R>EIBG-YS(_/LL_L*>-OV2-R,41P2]"HA,UC
M^D#271<5'/&"324'+;;*>C]^;V'1$P:QZX $A'_B9NIW^E?,:6J]N9=N.1@U
M&11OL?SW4"E;F;YBSZJT*>7*+,EZZ/IJM9>O][V9*LQ T>[$$LAZ^G0I3F*'
M>,! =M)T8E4O9GPI)GN+BZ/P2I5ON*P<F!.J8H5[X81+ K-Y"INGNBA$S>Y@
M_9,8@91"KNU6;)Y%6]!M2:.0> KNG*1'8L2M2.DF!7)<@7AQ.[ROLA]_?"1&
MTN6:+!2S,?IA0:)=P9ST2N#@MT$/3-03?FV(O\&^$X^KR<XV<A[QSU_I4/"!
M^;':L&LUNZ4CE3;[#:_59C32X9S)YBM SY?5^E8UTW#4GCY_ECTA0X'UW_QK
M[642Q"._F1WQZ!GX63Q,$!S10JQ655TI3\U4G;"A'@^>?A#IC$W0RWX]\\.'
M+"48:1:^_KC '2$Z=3*RD[G5V<!8+K+_OG_W;D;"5V,3*W)\H1DA:5VU&,Q=
M.WC>;Y.I7Q9LGV\DS"EZ=NC(@1/U*J.$Y4E:D>QZ.&%DIY/[O*N"V[UV1;U;
M+PO$&;?K@IR;I1MV&B(F@[AJO5<"?5\B@$$_O_5,BA+"O$=Z8&:;/<UL 8\A
M["KMRG^?GMX]"9OO.9KBC14'%'=[MAHD0B-7.'MCT0U/5QO=IFMU/GO:/AK^
MVM7LR/SM^3].LF>1V.,UM1.647_\1^K%F,\/IY1/!RF^U?24\.G^VS,<\-;6
M*#^^3CP,ON$WQ0OG/4L<!GU@?"CZF5.1<7:#'D1/.L?Y+S;M@&G]&]Z=?E__
MIMK#=FZ\->3BMWR,?RIH1;/[HN#OG61GTRT;G5.<03[4Y>")75=51[85#:#;
MB<[B!R5:JP][1N^/,_.)UBK16AVM>7@'$[V"UNI/XTB\5TGX8:!/7Q6RN176
M@V3*O2^A5XUDRM=%2<[%O5$,LZXS9O0D2^$2:8?54-=W=O2R.*3]<]LX\]7]
MGSE^[/U?B6^298Y8:38T;)%T612!+3B4BGL(?-JT? 49I\@/!;M8P\;FG_/[
M?#1Z)MBN[OMYVY:!E7@-KN(X+FM9C([,;$LM632[<E*ET)"I@,!U9!U%!@--
M42,+]'D_;)$;%$<?Z0C7][#@JPNV?6^W\8K@*A*#:SZ09FA%7E"[^$-$0.0'
M41;.XZSV.2S;CCR)G$,_YS#H\#?.)$EA"/V.W3!Z2>,N-994B1\2B>OOR [4
ME;MPH]C^UC6]SZ[0-QI'8\=VTZLV,IPHPX8,0I2T*78B/_BIC@E68+6J\'E1
M<YG*]UXPU4AG\[%I8"XN8$CW10W7G!UJ>AT-\KS"'48O<$5'AJ+K. ?4+,EZ
MH!^42/ZLLT7;#+V3Q(6F'T=Y-GCN2Q+/GDZOY!1<<U%U;2/'"D4RJQ4L<UZ&
MSJW!EHI\7+%\01N#HQU)NZZ,9HE,W-D#7.][[[WAV?2?XN/IT:UK/@UXGBB6
MB<:0B%W592Q6E?X)IB0O X;.*J'KBD8$AB9]YH=6[WDRDN!2K[.X++IR$H $
M*?%82[#[8FYIM,IFMS^B=2D:R6VA",>MLN\E2DG+],MJ52T=5-'Y0/O'.52M
M1ID-]DE)E":4*O*)\$UY-1)"00810QEZ'0/X<4>G9M>1>2T/NX9Z48V H__M
M@Y-[7W[UEX>QQKES_^3+NU__Q1O[_+U7JJ&/E0QZUP''QQ(_WI'\?*]B0ZOZ
M%#47_1C)_?:I[-^5EUD4"T?Z(NTA2F#5HL0%IXSLSJJ$/HN#^C2TVGEUI EZ
M) %<L]QGOA"@V\+X<U(/8?=RR6>0OH_J#=;=HJMZ1P,NZ)T<Q4"JMAM?Q2@)
M"]OJPK96MJU,!OWX^Z<YJ;0>FA[':*EO)D5/%XH3I[JHNE!N*#J)[""Q$);5
MMK  "[3:UK7;VMFLH++(E5ZZ=##?Y&#^P+<'(J(KI]OWN]XBM_U0(GYTX6*+
M=(N:+7\[A[I;N^FBI)S5=\35-QP)ZUZXG=V#9+W0;Y85G5*.V7+\539!K0PZ
M2C#.+N02G;&!(JOKEZF59=:%E+9Q70/>?F=4$80I];MV^8*N1C'SY>F8O;@*
M\BEY%"AO44LHC^:\;7=J!.1FC"S9EI-15IT8GK9N.;VS(C,$+@YI&CGLO#E9
M[4@/L@JB>[^F_8O+7D8N!2U&YRXJM4'%&C@T,V.% QNPWHN7TJFG8N9!:;%$
MK;6B/\3:U0K<6._D*@U0LBU;9E@9JZ89V3RKH6/Q$(L+:T+_B!]L)3]: P>+
MPWPR6-:DD&T>9B*S_1:6I&W@P(>?V1>]+OSP!R=+:O@-U/#WX<(O:M1_<A$4
MMOMO<. ;F,KO?T^O/]ZCNWPK+@?X*)%+O7/%AO?J._-$'@=/A'3-"^>:6ARE
M4$>X@>HP#\B-M[\/VW_NMU^:'K3L+7*9D%0]_>JAA%"D;X1-N1 ;X9#+NB)%
M0_Y.4T)3RVVQH4=**2.,SK8[+YKJ/Z)R*HOMP/:B8=W!/40W K_=:DVM A5W
MFQEOHODJ.%=MK9D=:$9]3D_^+,Q+WXO0V57!\4A<H-"^5>^*WMU(/78K)/QW
M%P4+Z_TXG..KJ,>>RG')I8-"8L?6D;,D.Q*36LD?A2I(0%^X=5N7G)64.@1O
MOL@7R!C1+X@01\'44#1J59@]'T+W<HMZWX%E<]TV6BX>N4$[SE N?3&W^B9%
MMFD1)H)OXTO!>[+2Z+XM-&!22X)^->R&SHH:KJ[]O!42=(;6+F\"+8:JEI#,
M2,LLW+K24$UH]T#Q6+LG.]+"4Y&:"04-6H3&\2BI5.,PD[?919WL?(T:_6-K
M@4_5P>*]DJ37E0MQZLW&##IZ\F5%LLER*S*%/KIAN>:W2D!KAU#>:L_F(*1Q
M1<(@2K#DH7@7>>P:R].R)1FT@]P*=,3:YES2S&P6ML/N8,78?I5!^9G"Y*4C
M*H7B:*:3?@^(Y^AT9G5QV><:1 NF_I86?8GITMXMZ<1R+'?TNZC3 K%.G-;Y
MT+M.D1>W=[7^AN9F!Y.3"^NV[7G@'"C%L+U5/C+(>\3?SNE9C2UNW2ZY:D"V
M:"]EY9:O#PN77=#-0QM#MTPO%S.OF!GWVA4I09<%*B)*]+B,<@]EVQ2^*D'S
M%/B-Z4'9@B@1<=X6K,3H7L<C8(O+A3>-S]Y9./KT"C\$R90H5A/4Z$EV-A/3
MS>%$(3HJJQ]BH!M24]X6H%7<T(YPU'])#[>R$_9"B^9\@)_(RFU;=95W>1YI
M=.B1/";W@=492X<LAM*5:#3R71;J)M&9T*Q3F%;+I^)\O1LU7LGVA<^B^"V.
MG95H_=PB-+4S1RF8R+")Y =2TG)&#]Z%/XY,)^\E^H^ES96GS995=MZUEZ)A
M1@+$21/+D(3SHT$M\=0D:J?:3Z)W\-QZ51#ON2_@7<!/?=@$\M.X]V9AJN\@
M!?!N@E(?92G?WN6@Z[%N+_FDL';G(FQ(D_3J-<4&NNU<KRKK]6+_HJ##8YK#
MKVE0'./N;G3UWKM[[\&W'UE(7[66]]Y5-0<FITMZ&*LHAEUK-+L8"ZJ :.CX
M^IVZV).HTN-?NO*AO.KKNR=W_V+?Y]ZE;>^^[1U=(J0M; FXFT@>_5]3"+R+
MJJ\6%=KJOK7?S\#8R=N^>'!R^O4W?]&RIIDOG)Y\_>"*C[\YN7_Z]9O__/Z]
MDZ]/[_LO7 'H]_6'PO,3X;H&+_)\^=;[)(5^ERS(/]-A?TVXEE>OS"=-F'UM
MP;@>GLV?AS#[[#Q)2I*4ZTC*,P\W\X.KR\1U\<X@IIZ1JUEGOQ;5ZLBZOEH:
M/TGT5IW;GQU![+6ID#_E/?WSG<XCY68)LOJ=K?#SG=L"0.6[HN_;=%8^-?WW
MQ==I3__$IU/TWY,*(51D[]ZI_DOV'SWGIZ*KBJ9QV?^0%DQGY9/3?Z_+9O(I
M[^F?[W2*_CM;+M%(C/#Z-13@:Z(!_SF['%,K\X=H91YSR*96YM3*?'-;F?^<
M4_PPF>*;7%\\&X#\\+HNSQX].<L95Z/8;MN*VY:/=?M5'H?E[DGVS! \4$.A
MOY7FRI^Z$YM8GFG]J#;[15 ^4J.[NQJW[23[OB"-XCHT,L@HZ8D-WKR1=FZM
M'(O*T*)W+(KFA<"TRKL>=0[E)\\'>B/#/1LZSV?_?'[V.0"D,"]W 1Q<=%9&
M,^':*,?U9D74^(#F@XJD#LT2*&<#^NI_% 2(P8KPWXNJG6#]++F>15JM=]E/
MRW]43>_VV?\J-MN'5NP"L*NEH(&CUN"[MM]Q;4QC")=_([=NF_VX*T]& T7;
MK#2MG7V7E0Z]Y%+8^T/17:!(Z)_-J *.OOC3=V>C;SZ"(;&HBNBK[Z9V\E,Y
MO:/P6?;QCN_<N3T(&TPZ>B&:9\,YBM& @Q"=Y#]::5HQD#4Y #)'/<=:[W7L
M39 G^>P7:>L-MCN?OSU932\+R#,M !\&J=):%PJD-,)67/GGUZXH%8$H,##0
M Y\V[7_V&Y<]X^.59V?HFZ93\FQTW.0=SU:TU#2?'UP,&/7=<ZR'+YUD\7\F
M-8=2OE;73BOQ]*#P5_QIY(_3X7AE;.6C7&W/CEQMAYXEA.#O0XW+[?3K*XX$
MOA?8%DX?T!'I3WBBTQ/B"RMAOW:0$SX"I#E<?>E*DJGG[6K''2BLYUFLZ)'W
M\%IY]%- )V_P#/OP5#^\)[P.;4DVQ,_YZ %WO]+OG$[NLL-Q%I-+=*9O'_9W
M4=-"9L]0]4M73Y$]KVCW2?C_5="D]K2DQ7:'@^7?8#<0J8XEG>J67_!<NBKM
MGJ%U_,X.W5E)>U@QSIK'NB^D^KFQ/T)IA5WCN3X'1G\'#=$O6T&RCR^L[#GS
MDAS,\FSCP.P!Z%)R>G>#H!@^0LR$H2N>#8L:<+3R-FYN_.SL*2W!YUHB/G[<
M(T!>M%U#MR6:Q%1U7?TX6=+/$Q;U3.A'"YR]<&BE\RW0L%=5FMK=C8NR*-LM
MEW2O7715LPXXMGK:_HP^!&U<KNMPRB<5ZV/D_J//Y*K]0A%0K5+<<\\\,)0E
MG$!/W*!NP%PQ/< R8P3D2[>@8^R@,V]2G^7EY>4)>1C%"9GP'^]N.\F>CFTZ
M #KV3!T Q%JH&<;:P>[X'L#=%9L)7 @&D8&^O"R@1$7)XI'<.-#KWG#9/X-4
M,+3K_K!\&<\RV<I'H^2B?;1R;8V.H.;.$ZZ5MK8;@9#4@>-9,AP6MPZ-7X:>
M%;IJZN(RZ=*9.D-_[J)B_MM:K_^+Z)1LRXTU9=E!^DDY)>5RJ%R$1D^:-6.X
M.57)M&IH_&)HG)NEG=>[W?;;O_[5QGXC%O-WIW"[_C2N8  #XH>\U'-G$/E7
M+#AK!4^$\/TC\KQ)1YP;;#G__$Q U7YU6VYWI(<^H2.?G=[%E^Y^\_ ?>?9_
M!".75._1;_T?\IJ$W.O@.U^'!^%]WGK0=G?I1%,[PO[V7._TTR_]X\23WA_<
M3;@(.OO.BGD5>9(9M_*2?4W>/_V+KQ_X1.1CUOY:HS51'L*H:VF%J@=;W4AV
MP;^##D*Y;.@/2KHCT#$R!C&8T"\+'"?!6?3C&+UU1( 0FV1T1LY;A80\)$1C
MUVIBO<6,=/Q%-!#Q\,9T6+"0A%[2PHBX#,GKTL C3TKGP9"":Q<Q[ZP4_H04
MH/;?*BW2&URAKYGBF[]%LZK\W_]%>[/YOZ?%_^VJ_L7_714L61^6K.%H(]QO
MW_^4G9Z=9%GVZ]/G_\B>G#WZ[9=?G_\Y[8UWL![/A\T&)CX)TJ^T6=D3V:SW
MO![W;J(W5J$+EN$[V1C.FL$B Q!C[3FM0+V"M "P*]L!04YNOV6V% L\YE&P
M$RW"2ODE=%9RX@TG$0Q<@,!<U>VE82$"Z1)#J"NRCTM$]DU%UH;@.,$F\1'/
M\1P&=)P#3,%WC\M,?$_PM 4Q2G;'/7IJ08Y*$49;/UMQ0(Y+MWO(.WP'"J'_
M%I"?; [/B$/8(7W;1Y*/^R</'GSUS>DWIP^^.+W[Y?UOO@KSKA@.Z@Y/_XH9
M(T-*-_F7/D4:K:JV_=V].WWJQQ'_7[__\5]GO[ZA/34I3.H'DNEH4%^>?/7F
M">:O'CS\>%;>7[_[]?M?TJ), 'N^__''I\]^.TOK,ED74JLW;4T^8@[S[.=?
M?DUG)YV=ZZT+N08NQ#BUE(*Q,Y5V6)P;3Y4';$Q#P-G!W4;40F W-=OK:9(#
M/6H>6&#SK"[(*%HKRU<@1&5[CLR1M9+_"(2Z>9''ZST$0DL,P64Q:/@SX"MM
MBWVA .A#/^+1PO?PHK- ,RN(<#5;?VN ?S&N%D9M2%W9CGS6[))?AS%-D(*:
M>!#;KEIZ5H.(NPKX<61)!O\0]6FA2BV9@+?+!%2@),\LC! +Y-)8T2+D_?BX
M!)#W"92KAB?T$'KZ90EZ'0H]YS[PI[)U$LRAWP ;#CB& /ZAIX[H*23C=+V!
M]&$HG+H:FF@V=)K@LRFB&&-I"W:6PM\RJ14=F?\X_EY,GJPH1/GX^,FQ7+C(
M6^-#ZLITUM)9LZQ%Z18Q*)> *C=\Q3-"SK!@^#".Q]-Q<)[?)7Q%2B;UP\[_
MH0K4"OVN(Z$?%/K3!QCR*$R(*A*2<Z-Q8&;:&/OQ.1VL7H#WF-AA0:*A@6P)
M:0O"66M3TF!(R9A_@&.5L CCRODXANH4XY3K %/-J["*6&YC:KG>WC$:7#I.
MZ3C1*W%MH(0"K T>%V^P0-W.T 1[U=\->)R8?'[AHMRS6P&#%,B)C+=Z+I#N
MF4;.U);;9W1"R##5ZV;7%4TO>*;]+.62&&QX5]6LJT4E!Z$0W"FFP_$ODGLJ
M?N(UY#OU"KV77J$'J5<H]0K=A%ZA-[O* &;\=I?9W723?11.Y!50DAN.+NPD
M%VZL&.*_X'(J*R'E6A45L_.6CNXDX3/.^L OX^ W%<N].4L]&W*%+\?#WYX\
M/I-:KN]_.H,9%B6@.SY]BF+<@BYEV*U;B1VPDU2V[*;Q3RXK[V*!9>BBM5]S
MHHNA7>4.7.+VBQB*6\8F[SC$T5DI,>T"1W<8<=GM&#089(LU68G"6+= ]80%
M5/1KBD4;>W_3V$X1YE[L#I?TV'W[R>J99"S?/A7S.XYE#4X;IAX C6EQS'[U
MP9])2(4#I+%6&A^T2$EYKE,<_]ZY%^/3/WJ_QG,%X5]K85$_-/D:/%THGA#"
M\?H%?R;5X!6#>,&(W&B)LO)"!1]S&A\2+M>9B21?,QT?#/3["]>@^(-+RXY>
MS=J*9E1@C* .RM4+)N] L=O!CUB [4HOEFOE ?&M-?0RE5X4AFR%TV:Q5Z[2
MJFB8F$/(7W(YQG>$O6I;[#U9)RYK?](VC",?(_TW#D<*=4"K\4'0P_9N3\';
MFZGI''S,$&8H7M*HWP(\''TW;)4F&^*L]?]2"QO*./M]CXUE?;M?D,];[';%
M\D62L"1AP1>Z=%%\3)E_BN6_A\J:A5%$RX[/>;6<V FY%,RJV]&!YTJ"W!H:
MU\#?1O1E28*JU(9QA#G7/*I0&HG[PE%N%!?W_; Q+L-S6$9U)8$]*[*S"CSY
MM18BH_#NI@EY\O8_JBUQZ;P/*UU3_A:FM_EX0+\;2I.L29! /-_85U=C V;&
M4NM!X6(S'7K.I*!W&.YB8^0NOD14&=?YW1>0ZL&7TNL)#.>L-=KB=F&$R/;F
MX#O,.N!]"UK2+N8D.S2CF"BFT"A"KJ%YKO,'XL<2?,P.?'JTAD9%I@'WG>NZ
MBH8G,7B77S6#7!K89 HS!IN&&$*!" TIA0YN5W7\KUPN_2ORG9)=8G(F3?A_
M\JMR_4XM[3)"3OD2G@MSIVW:WC-=L4X!&R"K#2NPPB>-*[H[=&XWYFMH*0I[
M*S6W5$E[#Y>E^(KW*)46 @)H0U7NS(/RKG%ABGI"2(=7G>A.SRVE;&JNE,@(
MO?4V(((<A;:ZLF8MYW]S@U*_I8N%"Q3FHD='0[+3+0FK/[<Y)S1:R<>.)2H5
MLJ="]E2,^]:%[%DJWTX2\QH2 _)>+5*VHDG'5382=/\#>4,?+T6=3>^<-$V+
M07Y@%DA[F]:'<0^N+Q#3[\I7.98:T=AV2 R^:-I+\6/ QDW&@'=NI G^NJ;&
ML-6T 6T41ZXTY(JK#ARDXVK0N#+N6)6K;R<^#*URYV6ZO=+M]2GHHH_8>)1N
MKS^EQ'QD+ \FJ6Y:X;EN:^9&'OF945P(D=VB=E'+ +,CDZ+?,)NR9J%'^6F.
M2KWC?IW;YX/B\OZWASOIIAX@9U!K%+PCGUH*@_08>[10:+2-YF]E8V VM,.N
MKTJ_\"H((SL$QD<P-1 FK6J NS2P%_;J!TMNF.,?F@66^**8& A?\+O]2$(+
MP&(0V:G)U%%#:A?3$=^0)OV[*2'V<:0?PD#+;%$43_?>J/4H17ZUR>9(8<6]
M%*29MHPB Y4E]/'.]U>$L(L%9!Z^TV15$K\_J_@=5I](L]T&_X-07Q*?)#['
MQ6>Y+IKSJ&N[<X7 ^:/4N*S.-Y+,)V%2N&*&_8=</?KEV6-)N._6@ -?<8];
M+S)H$*7V>(M.__+CX^RSO]7M@CSLIPU94 5C8O'SZ"=-M<Q^64A['/[^XT"*
M\G'5HTS@\^Q\()6(I4K2FZ37W[T>D^ "V*1-V2^++=N+YW0%D]$N6 %=P0@%
M/IT1=21K#R4-B>UYU*#+,PV++F3!>T9O*RW:]!G'N0J :E\459=<N/'[/V?;
M.=CRA@489>\&V0DX5]@&Q"?[H7-S"4##D?# $L!_2'=;T@Y7:H>>R\Q7<9EY
M,HJ2X+Q:<#;52ZZ(8L_-:J&2Q"2)F968TBT9M+UG2A(Q=B/P!*U+4W2C/O<7
MG@8!F*XB"5,2)A:F"-S&U^'$0>\H2ZFQ;@9>%BRL.4,U?Y41EB0O29Y"=LR5
M\+F76\N0*Y@'JSH84B)8\Y<C0W8LS.YRY36D+ %GO!?@C#%#=P+.2, 9?RK@
MC'2A_%DOE"+@6R"&X\$O)%O/H!AT6S#O0]''D!G<-5)DBZXM2FN@S;;M=A"Z
MCF2P)/EB^0IIKU:[C=KFO&7RDAA8!79N?LQ,(2-YMN\Z=&YKS4"(%.^U9'#:
MSIWD,LDE1Y JW\(G52H<0V(9(5E:H!"F*#'54'_*/A]J6JNVG/E.DJPD61@H
M<J$,TV(E5=)QO=*4?Q*3)"86PC8/GC6/7F0"8FY0/ 7"1^6Q>Q%Y$FF_7;NB
MWJTE]\^P[6C^UTPI$&53=#P)XU4Z2RS])4BFNP I)7$A&MU2*D#B;&](R-.7
M.9-/*H]!JWQ*_E!@Z:L,D;4D+Z%+PI>$3Z+I'G\AZG@=PV2+-#8#W 5&QND4
M0&005HN4 $Q2]NK[-L*N$70*87N.H/6V;;]39D^/8V$ (NC*%FS15*"0I.V-
M\C1JK<TASAQ58!QGB\$?R5D%0$L2M21JIMB&)H 'M\-NR2A! K88,#N!L"6-
MM@<,%$F1)>F:ERZS[!W]J=TP6ISRL7HOX8^AJWK@2@D:+OD%[I@J8[:5MB[C
M]BUZ:-?ZQRL.HD>IJ]O+LKUL^H?TKR22223IE95"(HW;&#D8(L":)%1&%8S.
M3_"8M)>9M($!;"&$Y(QE7FG%?<]H03?M7B'6Y==0I6AOX$R&PB9K#UCP3^ M
MYX?-J#$_D")^EHQ/-^+NJ_<?" SM3X6,]3N@ZA1R/R#MD]5$/[H":5_M*N=[
M#"(>LZL:1^WK@*U@"9'&@7RFZ^!3!9UX[UOZB>)2O/=U^W2!"-[[TN6?,CA3
M$KP;O'3HOQS=*I\R7M&G?75<?YA_@I5,9_HM+I.WX*AF3),12S6L_V6U+5Z3
MJ/HJR!OQ,6X]ZHU@+60_B^<0 7N(GV#4Q^)+2!^'@ME@<?_9L%/P?,?,))5W
M*4KS\!3*6DC2.1_J%J#80O0-^-OL4-]]6%<]GE-VPSG_Y?2A.A-%D]M.YQ")
M9:5-LR%D9ZW3K9"/&  )0GM1W)CF>(9):CQF-/ 3$C[7+/?F)TD+E%&:S#A2
M_@O;M@9_=._=7'*<,*P+00N(LG$=_P%< :!C:<MJ56&5FK8A"5MUM.18=90A
MF-]=\'((--,2T?%"(=SGIC7U^CRYO5VK[$17NV$78!+&FZ<8Y\ OK/>9HY'L
MIYSTAM+1M8,>KLNVJ\N3[.=AX^B/?6"M%]"K!>,G[&0I^+<'OB.>\O31\[_^
M>/;=F4PXM:'/WD4]1,LSQD(5-HP123,V_N2T<K,K![@-%N?27> N<"^WS,I+
MRWCO[NF7)]E37YR1*V-7=' E(.NI?..4:-8,FP6=N39B5K3B\-P.3_NB JGO
MTL :, ++EDX(%O$..M?,5$@?65B%-@*1'9\K>^ZV.\<OIN'?IT-3K'8A[E:V
MRP'7**.+]>%=F$7I>MI;F47\8M:UD*!))(B9CP7Z:0-V%(:G(&D#10*]XK/^
M\YS>UZ.."@<ZIY=UKCE'E3(M<MM[<O#IZF3ZW FBA8W9AN$79!?HCH=^EVV<
MVX5QN9<8&9V!?P\%)Q$-Z87[6*>@&;FQ,V,I*@P'F/)B:X RLN8DY*+3S(\%
M+!5;7+5;Q/$X.UI>;94I\)2KZ=.N5@+=6D4]CO2DNKWDKD>2C1YK, #W#RU,
MVJVVD^]J%V7PE<+51]^/)P29P46$G1FA=VG":[(H6KJK ^+)89%&H3Q&"9G^
MCF[\W7Z+K<42 HM?+;J)(-UF$XNTR]])G8!RA<[K-WGVT[YFD[9I@1U<AM.'
M\*T94-GOU4M7%Z0\O[C_D#34>M#__&Q5\W7<,S1@UVZ1\MXY@X[<T(8!9+)J
MUH58*F2D7):.).2?SY]]+G;9JNKZ<!<C@OOX7V=/?\T>/WW^CW\^3Q?(%,3S
M:2.;Q.J&U"84W&_NHGCE)NXN6SU_\8F'75:4+9W'I0'N%>50[T*!*Y\XPZ3"
M1GLX23IQ9U7W>&A5''Y%N>$C,OE>I&V;W/MO>E(^AS*%87[V73";687;B5$S
M/>0^TMK/')F@]>[=S;,SV!K9_] *+@O#D"CAOYBG2?^:6=_G^\VB6I)#QX]\
M[)9F^>"9/U0O-L5?_^5@J!T<QFIG(*EE="BU -</ $#K,Z^-:Y-DBX'@]F+H
MTTY/=OIVW^QG9+35[$;D7OM7?3]P,&/6+H]\MB>1?GHR="TII[_^JR+C0!33
M;UVU<J2QH+,^>_+DK_]ZJM?W@2'>H[R7'9I/-6J>4/X39OL'O+O&#M>T/F)<
MZ%"<%T ,#5&LX&G6U0N7CF0ZDNE(OMVZY)KEV=!5V%424BEAK3GZKVI#[]L)
M^X\R_HRKWG)!9]A9C;E0(O3K;%6WESU3-"CWYQ[1[=YBK)=L1<K3=Z.XU B
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M39WCY:&E*D&'N5&\27J!840+X(@W4)59D>LAP#6_MP'%YNF\96 =:S-0>2-
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MG&MX-#5/U"Y-+#!'[VQUL8TL'+*%O.=^H^GWBZJ14\J? .S'4'$"F.GXYMX
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MU"-*=V9<LT(79MOM//I[/^=$602J#YP@[%8%LS[0Z=@"X87B;LI5%[/YB$W
M+C[?QG.!B5%=S8$!DGLK!#/6YNW9Q@K,BT-K<[XA$AG3!)QO_.#8M:01?7IO
M@PV7^0JAUROC$ *4?]OC$,^!NDY+>DDNIDKZ=EC49/.AW?N1\/*X[%<!:D$:
M=4<+W0O771D[/^RHLC3I<SI7<V[9]M?8X<@A1+JC)T^T%UI;.A@[_9$7CX@!
M5X/7$%QE&<CH\H70&8$<^X,A;APQ6UCXH-=.CS48GGJH#9DWN\DYC+Q+=K+[
M[+R35),L S_Z'+]M(/$X_\MNH-.ZESJTB/@OU^ VNED@?Y)PZBZDRSHZ JZY
MJ+J6GR>.;X55YL<K!1*[^ASGCG#L>1;R[VA%L/1>-^TZ#G\X*,B ^LC#HI6C
M@?6<PM((\&X_ 834Q0_ET!)S*+OA'.'Y#J8]V^SP,;N1VZW^LB3=.9YB&ZFS
MP4/ZN!J@*&D63.+7;C85214=8L==8O( _&BY=AN>&-1LX/7B6CYZ9]6_R!R]
M8PB]/\C%G,L_)09UOL\T!D4KY7OGT0/6.8D/_<;Z$ZN=QTN='YW>1-K&F-<C
M9*IP?83E0&2?5U(4L\\)Q</##M/T1X& ]MU$BU, /BB_[Y4?[JTC\%?<<ZQ;
MD%E%A2J@@_E'"1,T88+^"9<V88(F3-";NGB?;-'G>U^Z?(;RV;B^O&.K12HS
M"=])DF$9#%68S3T&?YL]+#,R(CNA/^H0OZTEDD\RF]@U\YE&12]B<ZI_9'AM
M&(&D*S%8)-@T^\<5OSX#J-#P6WH6!P':K=K,$O# .ZW"<_1#J[;%%W@P426Q
M)[D;O68[[ 08;3?IRR'[/;3FL*.)OZ*GIU84"8EOT!YRA.<WY0J.ZGPX*T5C
M&">?HI1G\(B"$WNKZU!'D&WJ5/W!;&OJN!D0R+.AWI#;U%DDX*RN74>.V&/X
M@,!V$\?OD7?\H"SP8?8\A*-^A7?W4]'0#G.L:>9G^CJXP&-'MO^9_@2)2@TU
MM^FF?-OV"/"H!3 2CF(H?A[K@L. 1>>$"MH7LQ:2?128:8T.25"&-702QR2.
MUUZ7?AUJ)[48!;9 *5EI+NS)ENNJ+CN0^2(8=7I/%>[I5[FO\5+@\[81 ,X#
MR41UJG3G^()PKF:"5GT6 K,_\:7((-LA%@;;C^MX5!/3?(95P<A#76^\,9S>
MT%I=!?7QATP1&+AX1FN[41X^=*&WUI^Q0L)U9]F63(0"%[DWA$)448V2/OO"
M+X660B%^AE:!WOCGZKTMRFV^U _*,<(><AF5Q>%S6MKEB^)<:JN4 1A-#<CR
M;-MN%S[8<<:/\X.;-D)E6K9=^<*YK>+ SAI8]#6T8B.%]8=BVM(J(5.@C=HF
MQY$%'0=G.2-VR2DV&(Y:>%U<%E+P%J'R#LV+1E.4B]IMM-JQ: Z'%)=8 J&>
MYUY(+>U..C@ H#H2?@WE&O26A*[GJ[?81M^@7'ILH*J-KJ/(M<=][F4\JD;L
M_W 49%D8=8W7L4,!Y0;O=^,'Z\F_B@4WMUX"2:!H:L9PW^Q!EN$9E7SZND9#
MW.I\O>+1&7&JQY(B/M:./PH:LRZIU';"WT%I?R0R(8ROWBG/*L\,7B[76G?!
M->-D+TBS>*)A 3&\QZAK].!D?T<!SM+)7CS1TOG?NJ)T8I4R8;=\^@L<"I:Y
MIPT3?T,BM4Y>UXT%:OR"'QPY,&L>UP\HO,Z>N^Z"@=5";U<D1(M6-B=.7\6Y
MJDG%GQ2#'5;\^2;.&,SO;6/B17>T0%>##*K[=1F?M&V9LQ<@29Y';;^A"V>9
MG9GP/Y.,G*Z1K@P^CA;GL)\!_W^PI'*<2I.5@KA<D*N"#2\=J$!ZJTJC:V.Y
MSN.$=S[6CA-P0(Y]7,AJBT\JW2FD=-";([U1$Y!$\RMCN9LI.AB56X<25Y]C
MT,>P] 6-C2ZF?%0-G;.FZ6@B[J7\;Y1[U0/:#]V%J^H:N<.)1J=']8YN$A\C
MJAK.Q7DE[U4^W=,D*E&]J ?8F M]2#^!Q 1&$->:BN0:B1B#\5U(Z)A*)BH@
MX+3;),YUK7($$=P0Y$@MPV\0C7PV/B!V#@\P7:!?F#$>_>"Z:PI<Z3/<#^,6
M-T.8"34L8N#0SC0BWKC0EW9I!H'CTB,N,%T-]6$DZ$:N8G:+3=K??('"1II&
M-;9GG0.A $(N/WR=442GROF8[.4:/-UYK6M5#D&=,Y>#Z8N1W(9+ L9MLQ94
MHB$$?[?5EEE8WTK"WM+Y3-7,'[B:^315,Z=JYE3-_#%N"CB0;#IDW,%&VV]V
M:WPW6!&;QP_?3Z^%D^R)_@ZI,T9'X,P5JK8X35)YCUZZ58+)[TN6N;F$QK/B
M?T3M>8( (:_Y.6H$G!9?DTT-C(U0>#TIV84U9&7 '<?NQKXY/I=&GJ;6-)T;
M.3EJ"HT@@Y2X7) 31ISGF&1DQ6O7&+]'_0%K[-G/>0:2!2SV[/96F\5 -KGX
MRO G4<)YKMXX_:*V5E$.]""+>&[X&GWNIR*P\H@&FG.*W*>Z319KR.,"/W$'
M:W?!/)(^/X"M*;F]WV)9TA3OJR<A,6BFXY+9"5BZF0G>..'%<R^Q%A7#<_2&
M4^[#(KFT9Z]@GCJ+&&@FEF.>K1!PU37=S8,XE\!)H)6%[N<0*'O)_4GVZX0O
M'.8(R1?IOZI?RV%8#UU9.U^ 'G8Y5/I.S1X-2_NB6X0W4..8CVTN_%-[N'2Y
M<OTE2F;)7=4!071QXL:-H=Q86RP[P"QX @&X;#8/G+Z @A*J+.W(*$\8]ESP
M[$7VMW"(AX9'$RK[P8Y4=;;:.(4-K9HO196HPX1+:=I2$/JW66V,DLW6RX:6
M ;0 H/QX)YI(-JSC)E@3*Y[01HM@KU[[6^P!_,XJF)T^C@&QRQ^JGB_7CG60
M =Q$QC<Z-2X5Y2=6FP9)Y)4&_=SXYA[:@W+4>50D0>(TGG>D, #G(=@^/MBA
MCS(-&#T [JI_DZ*$>)(*<51%"T1('$OM_0[!VYFK(2)?>'ALYO1@>"(VJ]R/
MY(@G?(/<D]LDVT]"3"WL16 95#1;5FE3IA(NC5B3ELN _L$BC+YZ_L=EP#<J
M?# L)'HT"-;$<$P^3&=^;A[W\BH@#E?2+PNZ5%9U>YG/=O%HY)##Y,?UULW;
MR/<>Q3G#X>XK#U2D+0W5,C('$?J7?=L@#Z$F'%<W2623D0W;81>07@Z/\"T\
M1V?2/Q]0OJ1;A%&Q5K[+$4AQ(-T1"P,P:?]1G2O;(C:7[45D1'@\E AECQ6J
M] =E:%L1M!-^^[KHW)KD",;9+=Z4[P_!1XOX#"B>B1=]D7"# 6E ZM ./7<&
M]:$:<=M)HGI0="]1F+0/@0.)]JAQJVH7-BV&1^7*(#4IU>;>!> _7U[(;[5R
M2X;-"KJ:=K92B)_(F5(IL!2I7N:E,%O1BI^'-EN;_)Q]'W55'8[T$+1C+@4C
M ! D[>2C_"?BOF6;P*R>4:91ILMCKUUSOEN'YJ11O%/C\MFPI>\VXP_%S8%Y
M!@5U/A1L,BDVC0^YZZURDCU31R=8WE?Z.^PA\JH<KBN>\=>C#E,$BV>8->JB
MK*(_1-^*\/*0TV$!HZ?M."'-.(3^Q<=>RMB,6F8=Y;)KM?TGR>FA&2'CA[8W
M7M(\(.A*30V3^PJ2)/D/TCTM^4@9)/Y3<R4ROY/LC&^6+;G<@Q-_&ZPI&\Z;
M1S?1467H\05%R$?RS<>;R^:6"NT(WZ]#4-EP9@X,G W7@@I6H[<M((CX2]$#
M3[2LN.)<3@2W._:Y8A[1@B'QW8,H6J0N0HD\F --K?/K(\$:N.<-Y\P]$<!X
M#^0\8*'69"D[1 ].LE\4HS*Z(X!V23>U7QZ;K"Q3A0S!<L#J:H\]S17IK26_
MFV^,:F>@E=B3MF8C/\Y(LM?#&I+'/;8348#.;>DC/T*TH6R3C$3RF%Q+4]%E
MP=:_3$,V\+!!OW.K6GH"KCN\<9J8Q'.0K(BUHEL(2EPH66%605%Y"&__M0RE
MY35MW#C7.V^Q"FCDH:FKUO?>1P3JO>=75DQ0165,D-)O:!,;@&TQ@H$H-GPZ
M: 5+M]A%>E+%D(L8&(QH0,8#)0R.ZPT-32S^BFLJ1HP(0=7._Q5%E\6VXDYP
MS[(HF^E]'-0?F/SF?.].X(#-TLN>DY#TJ[WIH791JQH?5Y#@]SPOD>#9XH2Z
MHB-05A)(9*6F2\+\AEJN%>):<55(;^\8#>Z#FZ'?W!0K](Q/]0%Z<2Z>5IG]
M]X,O[I]\D=$S:X/$;W?<>+_8,;HS(L-<48#;C;06%Q-6&T&OHD?_]^DW]\8/
MH(\;7"1U_'N-0QV(<"R?)6EJ&MP7V6?8<P6SYC_\C,\#C#6)Z'_?^_+TY.Z;
MOG;TOJ^G[_MZ\C[^.(R#WQ^^EF=(K- I1)Y# OCZJ-%3I$),']"Q[PK=Z$I9
M:GIF'@J%$3S?6OQ?W^Y?9Y80_=:Y#<?6Y+:)<8QQ)PR"J$?JX23[04Z"/4_&
M(0AK$G23V\H@NP7/OM.$3Q<-I>IL$KOL].[=OX0_APV0XTHW?CWT_(BAV1:5
M6/RH"\W)@$:LA VG0@O\#-7[;.:O,#04F9?#0RN#>S4/A>Y QU!I 61NX+#V
MV!Y:\67YAQ2KZA452TNLV*;P;JWNS(YCJ-Z:U+HYP18IS.O0'K+@6/%BCOX@
M+EU;DMIWO4JH80Y[=2SR%+2S]3+&#\(N_INL[VJU%Y]I9OT"UKL*45PO1LKS
M_%P_1IM:2+'@+^L9R<E#G:4  ;@8'3G 3<(F*"8"Q)8#FZ*N5)_K8$J<T NR
M2!(D,K>5T,^0(.H^>%''O534D8HZ4E''!X:T.FY3LS*M^BMMZ6.FLY02OLIH
MMAC.<MVBUAXQ#!E.'BGG7/Q'<2Q=-"0CSE#L*<[:51>XW' _B&G/7U2?%%A)
M%?>[P*J1*R'Z**#T@W&IN*#CQ4E%UVVD48;K_3OCX=F-;"WMQ8+YQPX]IH(H
M=6\V0'SO1^C<8R,J]RE-H<YH4<TQNB(Y1#D@I'A^CB[>G3LPBL:#VW'V-A@@
M$D/0KS 9QI3^Z7H>/SMPVU;,'NLC\I$HV44%VXMDBK/[8A-ZWA486P7^$2P(
M.7)LG,16Q/$?&4N#&5R*&,6^+4P;C>Y4O(FR!+S]]I2KJ*RNBCA< Y[_YBF,
M#T'50,)0XTB_<!:*-&K1OFT:5TMUSDAH@ FFD3#\RI'!V^Z=4S:%J"PJ"FWZ
MC=)(L-2?7$&<<0LT.O,:1!2NI"ZG$)<(\7(PT+A@!5$3V/G2)L0YYC$-+)8[
MVLF=*S8XG<J $]H.1VQ#],2M,W8[^6A7">%KO'TG&6FKQK_&;[T^F_^I&1 T
MDT>X>8B'5D W#.15#&'/"<A:(#UJQQ5Z_L&2:)$JE:GFBH10')Y*GBU2JWD?
MI5;'VFVD/(81O?D];R*M^3OM@KD%(OY;A )[T.TTKM+1]B0U'8YVJHU[TR)<
MGZA2B#SI(J26?.E8;A49DS*BW)<:D-P72-_D4<!;O%<#-Y1OB.Q<MMT+DNVE
M$XJ2*"$I19%N%/#G>L.BEL.!RRB*I:N-YGF$^=Z6=F[-T.]]WG@*W6)+,KYW
MO5'@P_PYB?TY_B>LGAILY$EK ZE<K&H ^C.?+LS0Q=6UJ"V"BJ0_MANR9L=M
M-[!DVTN81,VX@75H>J$-D"*F7,FHCO7<]9*&=2]IDMT"UJ-93IHM$LG23,#(
M#)($%K0L(FYJ$S)H*Q)::+J=Y()NM8(B37->MPN L=J.V@;&-6<5;Y_<%>3K
M2%$2%UC8TB_KBI/(#+QTT2++42L)NS"'H)W/:BK\N^(-'S=Q<0!/(XW&1.9#
M60&98MFU_F$1 J^$AA=NWRKFM%:,>\4F["7,S&2%ZA+G[\PI\Q[7!$LJCR>4
MAQF6I/Z@S\A97&/J<860);=*>C8+L^::/#L/7\".%MK4'I0KAV'UFY*+DO^.
MZ7YBE 1@$:!%6*HC#O>S'3.(6C+=C!Q^;.^=!4\_%"Z6L"1DE434NSON]6>H
M5*M+A<4&AS1DVGP5/&>K9:U&["1CCSLNB.3LP&2WPEC8S8(Q)=4$C;*$'#K'
MK^4WB@,LMDU\P\0I BY"9U=[05]!E88U<X_@U.OB=M=M/X_O]0,^KMY7)'M[
M/Y?.&4 NX>LH89XTBG"L/( B9&M%6"AI#!67"7 %:@!*R'W,1;]:,:E2UX\[
MZ6UX<3%2VYT7C5I:/1?0Q+58ODE@1^>V] 6YIK+D%.X/T$;XR7^0J=R7E>>9
M#<49S%[51N4*&J&(AV+6^=!847D4SJ@.6FOB@)E4DXKX:E1EDN,Y1%RP)8[
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M*>OV<E:6<JFXQC\@L:RMNW;+R-@2+9]Y*+M8*#Q#YDPR,(?/;;LIE&?GEMW
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M%]@6'FF>/4-2-VJ@K 4_JBH@H3E<OZ![]'M#K;KJF<IH 5#]V "JWRT J@5
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MF33312/&\':?W(HEMU'/0V)CN;U@@%X2+/%5CI5-24?+<EC*;F3VW9CEJSG
M2VT:!EHX@KTB35 ^@L2J3:AE!OJ6S->N-YZ )5$I"*T"_VU:CK#:>(K!XSH.
M2%/GB8$96W%OJMZ(P._+KNH,&SONE[B*V)C!1V\!#ZZZ>T$N)4?L7Y] \/E]
M3E,RIE%7+5UN "B%6V'G2SN&"^_2T""9:.EH%P3OF&HZ?QM*&TEYM=LU8MA%
MZN_]%R&DS X13KWTCC=H;/>MW2P+1>R^EFFJ924MP$^*EJ(NH[Q\D&]P]8)A
MW6DV#LKJC4T<"$YJA69QXP#U-F@KFJA<2T;C-C)ZXUJF3JU7(=+VC?!0'@9N
M;TK=208$ESFD=3@H'?-W8)WF^!& 7^BZ?-4\-@/,UEH#TAIH; ?S[66C@^HX
M!>>.5>T!.J.GIU\%F0C&N96>6<#FB#-W?"*%[>IRKY(UFR@2[@SR,V9F[N5Y
M8&9&SWUYX0S9M[F;"2YAO.%<'?9D?B_X9'R3J!8G**K+;RMJ;*4_-&[P%6PT
MJU@G96V7Z.JN":,1"S44P+'G(3UB3I&SMZ#.A^-PUV.BS5%^,AJWX/@NNWQ9
M<0R(M;B.QLF+N5(H@1>].*1^1,PY:_1HS2A?'LXKG3)V(WS% /S(PQ29*^6[
M!>GAV;&NNFXP!J<62:"M+(2/X<UP&@\09I-GTUEQ]S@ )]\!:*8+C\^77M&E
M\\>_AMW@JI<WW0?C[-*7J$.SLPA L78Y(6@20=:A4[A>3I!42-%LAXE)ZX/V
MKEU _SHE=BB'6N@7GW47?)MM"%,^C=EA\B'/RQQ0IV1>DU,%[?O(\R-7],))
MXLCA5DHDK<M.6P OGMQBZHO.'O" *Y,<+<U72]+C"1D=,<TZ#^&L++-1FSAB
M']5MHN<ZG;:XU(@6D<)".2IHE)TS39:?NA,QH3/EFE[*XHLP387I6'6)E2!'
M;<_!@;SEP\<HQMJ&51?02"K^XONZ>;RY;QX7:5ND;2)M&=04+G#-37*1[^>J
M_N)01(DPX60SJ7G72S1$8FGE\5XAI<^L.2]2^ *D4--&FWN$![2@=C@)W$)G
M<?\]4* ,[7,&=727PX&>"0!:RE$8&'@MHS*F#7-C!#9_?//6)V@X6_\$4?X5
M$B)D=Y1^,_+41CI.L8A70L@GI^'P"B=#Y(QJG)Z1F3./0#ER!_"0R=,.87_!
M\^)KDTRA+C^%FH20T9*"YT<7;\=H=M&P6,^V+57#1C+I@L+5#=BWP"#3;-2T
M=Z'Z?FB#=CW209"\R5.]8SIS5V:"86"?&\MBM.KT:7(2!F-CG\[6RW,>G'B*
MX\V$^3=+DR_DM;-\,Y) 5Z(9&2C!"#*IH6[3W*[A9*RVB2'L>9FY?)Z[OAI\
M-O%(T<)6LDU=S,;/$%%=2+?G#.2N.5^K($9Z/<=BZS*D>JG8$+E&G7>AEOVI
MH6<?+]"S!7KV(4#/7C+DXMM9%M;'RL^$T7CL1O6WM1K*,-#6QA$P<^?3T\=>
MLB'^H@(M/.((3%Y\#'%&2B4H):%NKQ.YA9#S3[>;_^!>$&G*>F-E.?>J0D2G
MT.\KCHL]/7RL@X]84WDJS^WJZX%]L.GM45\A:;DGV80Y[?D#;$F#=) R#9CQ
M=CC\.,L(' J;8C3#MSI+(-O?8Y[+EKSN.$V7MG+S7@?\WJZ^:!Z#S1DC5Z,R
M:K-+U)OJV71A[@$Q>SOB@79"RCJW#W$ 119+R&0B94/%;1IQIQY14J5MH]>]
MK_2@Q3$=<4K3S-E*)))Q($X<]&M%59[J>8Y@$'I>.M*C.B^'G%$D<(5C^3Y8
M9VQ[=O!+:29\O ]2VVUD'_+E\9=EC85\6H@F9Q^"*_E8\&-)UG=;1.0(L[+&
MGH59S<(Y;?EBH%>3U_G2D^O%LY?AY*&F4'XH<=$0<D@86G^8JLE&;LD[$9)9
M;:NV!1G=Z)31.I_@32$AN\]'/)LGJYD9]S"%.@CKMIOQB/'QG;]4ZH SU1VI
MG)27H"N/@:F<4/\&*D5*_PO<\"+<T"E4_\;BY+6HGY0*>[OM5A1VRY\E@-')
MC3,=\O,<8T:E.&YQ%Q;UC'6;>R8Y#S!2-YSP]#"2R*5[N5__(N/9' N-?(\D
MDSU/79L;&8?-LE'VM-J7;.'O^ UF@_=L%,LLFWKKH6V2ZT$N@^=*%N82R#B]
MW"O J_WSEU\4])^[+S\K5J_NWOWAYO]&K?K95Y_=LDLOZE0FQ,L$25' ED3_
MR^W7M^Y=%AA3E+L3^(62DW?C&@]?K+NVHL(OR;X>Q#<04Z.1^XZY\GC::%R-
MM@5T&6F\-@4+^ 93?YE3(LL;F7+NSR=QMN@<P_.0,8@1@6[;D_5KDA_1QL/C
M-,("WGCIA8(TY3GU1O 9)<?GH(P*>EX-L2<<[!(_V3_$#B\UT$6HE/6-@R36
MSJ;[<S*-Y/9'P[%(SR(]@B>38>,@/-M6&@7-V$_/H2Q.G)0?<Q(J'9G*J&<-
MR#E6YQAPP0DM<A?E;G,HJZ,;9&[>TS4:%W%GK5[#7'D8OSF.+D:"N4C<(G%,
M"$D"EE+/-VGR;*?"M LYTH)\+%2O.;$JM3OY\")0BT )[*?CT3<^[RCYVKWF
M"#FJE60@!(HYH&-$C>\JKJ$Y1+9/$KJP)Y%[J)H(/N&<"@7Y@ET[E(^=F^*Z
M#,-8)-(D4I-[G)')H=M9OF_G&Y$Y>1*.ZV9[YD'CM>&)ZC1Y>U>U'3(L<!6W
MTG.*<@V@'HO%7<3Q*07)9!KKLGU*4VZYH*=0G\BV$)LR4U2R"-@B8,( (\/T
M,JK& ]>-[ZNU,K^ WU$*U@N)]B(^6>9,N.@BCA25.D:^6E4@EJO"ZO/R0);U
M%:+6;G6WZ0O]#6-\Q:S>Z4CDA!2FJYQ]H0*E'4 )&!3NL1?1<BY=!8MTJG0F
M[JJ9=-R.!+;>9,2TC!KA8:*=GP6;U^E>-34)6Z>D&;L*W?,WYT#2RA!6!3O0
M-PZAY)BE:XXA*U&7:TORJ:$>,VOE<W6,S@B$-2L&80)%=%\"EQX$IZ1\6R7H
MJ"N99!S:JMDN+0P9N(YA0L)(!)9Z87Y)9FY4AA6/"C[4/M:1XZ3A*JO)K\_<
M$F (@1&0S]W$3X&.0X_S<JX#&!5^"5+QSQ8@N;R'2HJF/JO7A?:A<O,Q1H]V
MN_IFYGEE;"VL?U^^5^XFBH:JQ&"N<I=M8=N<RT-_OMF1!A;:]%V^2IGSD8AQ
M8I9Q?/\8V+]D\$(&%IO;'(<C$(GKAG7^1_J%8@(,9Z#D;CK3L8P,M4T&O?,7
MKO&YPT' 5\S9X$=$C)$O0B6NZ)=\DG0C) P2B10K*Y8(AH<>O8N3XSV%N"E#
M:#7K\QEU\0AP4*9J"Y*FEA5V+-UCA(Z"'J0L'+XKZ4)A 1.\;/^ G4GN8]F"
M- Z&GPWVN</[(BU5_4W;#YVGR2?K&?'/TK#RHS2L?+(TK"P-*Q]"P\IB+%Z6
ML:"_;:5I.46.7!#M+LTYT2H!DOSE%IN@;<[<O=L,L>%B!'GN-,CCDH#\@@,7
MCO:0#EZ2MXM(2CU^>R]],>A6Z -[)O<5.G?)VZW(P>UBTSI%J(9.[L#U:<YR
M)/; EQ>Y6N1*LKK,H(')MX>F$\J!A*67!I^,=,B-@JJ5=SEU2<%_QO>JNA/4
M>%6/FC0LQ;7D;A<9G)K;KME4#1G,NCF24#I*OKS'+&71F(A^A5Z%+31BP<V8
M$&:I4L319.5N5[$(H\]LXZGCQ:2'^J%J&S;,B@">N?&28D7##5+/3;LO:^UB
M*JP]CS%BM,&',V-W\EC:4D]&"JN?D(ZI.1)&#Z'EQ%/GNV.9VT=X0*U#$+DC
M81]6ZE%W,<TB(>WDKLLKG\XBFW/ON*DF'\XJN:\EC<DB<3'!V[11/MP6S[K5
M@GMN T:K=Q?ZI=+&&PXQ2W36^5LIX $]AL,!_^?^J93YX0RH9,$3>L*0.MW*
M (\BHSYW>KOZ0ZG<0-KO-QPD <H/PL]3C+N9A*H%ZCI;X3^ J_S7;RR])&_O
MP/N[>I>]H-6KN>9*-)R^U0;+5['!\E]^XY[?D6N]W=?9SK5!NYOA^2FR@>LC
MDFW3R#;X75C"4;['S>1B-L$#QY>._.G^W%7T%J&<3_0>K:<\%=-.Y1F>9E08
M:9Q-V'*/-SH.AQI*NPYH%4>C_6X\Y8&;R%^RTG9=_<)\GAC)4GOIYY_=B29[
M_>8N3=[D<F;K.=68C=WWL&YB>;H/\WW/Y8S,/,:Z83$_?"-67$VBIC)4'AL4
M2&?%B.P_,V/D#:@@=2\WYY4H5R[%2@OMG,P5*U+V%3F2 8PBK@"<'A(L^Y&D
M0*JOUX3^RD"&:I<&7HPEN 0A/G,8")48S%$'1@[ZXZ[<C*?:+]3H2] U)8/E
MX5^0_3RK66X?2G*A]Z'3LRYFUO-C]&TH^P6^O,A3)D].A,0S5U"\$RCN0ZLZ
M]YN+DY:\_H++FP\369/O#LHEBSH7"5TD]&D)W;C!S9SW*07%5&YY6F"OPQ@7
MM;<(U?.%"FX8*2G.(*@VZS'EJC??DQ3C2;O/.%YM-4-&WG1Y,I\9D/OHM@J6
M,""/N0Z&?[*/+[*WR![7!)\1.@LC=",4.[,!$( P^GLF4"-!;2N;WA<5GA^C
MR,9=!P&"0PM#VQ -2HR"&&0?E"^H.JZ'M@N6NG.&?A'B18A-@8Y!\9D0E=OP
MMP'!?RY-G!^>30MY!-_0WS<M2^TB;XN\17E+/2"7)AQ/IAYZ9M=S%0[/ H8N
M$O5")(HBAU#O>QE^&">!FD?H\N82_O;DU@F)@3)0+;*TR%+,HK08)!U#5,[J
MJF%$G8;GIHB(+2IH$9O4_9BF[SR6;4W:)G/S,ZW#0[E"-B2FL/8?UT,DMC"V
M4<9B!/EJ>/\\]+RLT^_?O7[S]2*2BTABH9'+W.5V*S12@B&>*_?2&1C#5A=K
M[@?2<5AZ)Q!69E2YP2\T"<)SYOA/'=!BVQL9%(5P(/L4H[(1J6X0U?(PZ<W"
M ;1(:1X-Q)E%.ZUP(SD7>VQM)A/SNP.#LUEHI!81RD6H!]IT[PK\%:A6(#\>
M=V]FTM2A Z?Y\5A_!_'*TGCXHS0>_G)I/%P:#Y?&P\66_"R@G&-H]T&A8>MR
M0_J%QS"0X]Q)L4<AKU9(63II%OEQ\M/RQ(1>&[5RL1'W=ML.^PB;U4IU"HU6
M^[9Y7%I=_NW_NZO/D9!D?7X"(RU#PQA)VV6P6 LN' YZ!@0Z!T_6<;S<$%RN
M@#EM%9V'B:^: K2>!]?"T,A,G'_]!H'GX]R_17O0)F1S;=QT.M_5F(9"*[P<
MW62H*)*#%F<Z\<_92V,'+@6-ZT!AHPX*X-87 P0?>&9<S5CGYB4#T 47_8P)
M60C&H;'2YE:=C4)T8=/MREYR-G804/9C^5>\"""W;Z1_"ZQI@OL.0V]= \;1
MM:Z:2&J5D7<IAPRJS1>^G+J*T%.+1:<_C4>.-:,IT6EH\WB4-C#DK?90*<3[
M *T]7@:N<F'QHI_2Z"M305Q?.!S2WB*OAE6 [%&HR,)X:.2,]K,<24KA@0^*
MGO_&[(^W,+>KMS/#5FCS#ET3)U:5FW(;T 5*"I7^;O/*+PWAU*$9TLW, )6V
M>A#4@#8>^YY%'3,_'O#(QU3RW_Z@EQOT@&J^6Z:U\]9XYC,N[&52&KG06 /$
MFF Q^G=\&<#)XG60$N3[B 7H>M,8E[H$_.CV-G!.]8*-0F^L3S3POJWIAG3S
MEZR*OMQ-QGUJ3\RTX>D'-L<D'(J=E6I^I#MD RB_;68H,"8NON)HGT9K#G3.
M2/R[>UXO2M)HA=&3'LG]U#)I3Z;Q%G*V14?/X_,O61S>Q5$!S-BBVER5J]'5
MQF/^P&@YVLS&9NT^-NU!S_+ 'GB\7"6)/@HMC+S/&F)M/B\&NK3T,'UJ7:_P
M!6Y,E_=WOMQU11*!_M2WL>*A0W'3NM$%%<B$W4>1/&?5%KK*(>RK[N!;Y<T3
MY0&T)(BLFM9#2T+ A*?:F^2&9JD&G,J56KJ6SPJI>EB!!TRD'4X@HN20-RV6
MY^E:%W!AIXYY*:NN&\(VVL-_XXW;T('9!T7W_%NL-?$CY/L0%RDP1WHQX;M3
MG$@+6>#9S$)IR%;)D;@:Z6!V?=DBKI5^_'O_:CMP'F,.14Y2:)]4%@TUY97P
M>+*?"J,7_';P,U1U37JHEZ>!\=F4R7R_Y&/[1@,T/G1CW<A!U![>26A=]SFF
MB0SM1B4?(D GIT.9)_D-;-F3!U3DLR(*P#72?&'2P?Q+%"4'H2F8#!\6VR)S
M)B9QHLV>S>U.*AITSBIP!30G8[A=O4'V2)&0[+B(WH_Q_I,^(TG) %A Z$;Q
M$),2BX&*VR8C5'G\1<W#S;?:@4GV!Z2B**8-QS5\DHF1O5U]K1])#ER SD+>
M91^<\\K=\W .>2]P0,#8,#-IG+L>3U[]]?>DF/?PCP[,%:)ZK6VA*=(H-G6H
M60K,C');OB[!CCS7F"/X66ZK]!)#)V*S:8<J8KV@R>5=_VV@ [+#X/F.,87,
M;"[ONBYE*>B8ZIJZ#H<B-^:Y"-&3]Q&%+?T%+72V-:^P.AX+G:LU\=QL\V@S
M)U:,$]N:%NA(CG&S+NHB&\G\DM6-Q@^6LVD8QB=]YV(*UB'.@ $-[4$(:1!=
M3-U-U2^3(#C,A!-=N0OM.(HH1,/MPF-H8_3 QC%D@+$B122Q%:JWH(^_!"5(
M\0VWZP/;4Y\OIKN4/447/PVI^,CB$Z,.\W^PP?SO=Z!GUR"SX2<!E&F[6*2U
M+Y"/5)X[;LKVWH[E_-2_"=]1^$K;QYR [C%7&B'3@_*INNB\_\.>^RJCE6;6
MDP1W-HVEK#<E2X5$O#S2>5-V@;E7Z)'(TVF[]%9FT/9=".^5DX[>#=T*:AM+
M46YPGPDA%7J7>*4E!2VKV,"'U!: 0Q"N??LF\^RO$//K.!RNLX."7WA_+D2Z
M>:8U)ZQX#.KKB1#39<_22+\.PN"XY9'!F7TAQ7&LAJ,LQ(?0^1,N&=>H'E^!
M9R>TNT#Q O+5-IO-O;"4X&Z/\GOM6F(UJ&GO.NS%9%,85*9T=PMG9$#Z(T2L
M8QM.@XN;+",>W\H'N4^K%VY"U=L\QYBK4_>.8CGR#>M]&LGQ,!Q UY3:A#)(
M*V(_\ISXZQ7& G)R,0JA.60*L.ZLP.H^XA+,K(+:YI'G$$;_5;2)YAM-)7V)
MK]>!YRQXWY!Y\F4=AW-::D@YU\TSC@A=M4E?M@ZGU-XWNWQ5[@]5-_#- 5KC
MN(2"@7O6L=$R(0L 9W1C*\#0DW1)YM3AS !3]I>KMNK><V^J.IZ63, SD5_2
MLSXO;32$-%PK5;_B/<7:LM9E5R3UWVQ7-_2M'KPT-7U837\ YTHM65?YF4R3
MANJX[5!WY*&SPRI^\8WW=;&$0[EYC^6T65Y'/ @5QA?MR:(28\<PC<Q)DQB.
M]/[VR&%PAO\>0?3XY"0Y$96N-4K(GJIM7Z*4P"@JZ[5]BBMH*EBTO!WYK3BE
MFNI,HIIR-WZ,F;ANDD1;'< 7 9(<?$C] PK-Z(.:\6&"(IEBL74/=9!GY8.0
M^5';2@_(Q(C96:I:RZEAQD#" 5K5/2JH/*JV&,$LFK(C[HU*L=0R;YRBH0IP
M++$+*O#'1@7^:D$%+JC #P$5^++CBJ=;P_U<KAA6[BSHUI([MRZ=+U?=\[R
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MA-CM!?.WB-(B2E@HB1$9I$/B!XZ>[B7CRS4GIIAF;SOEK+F3JCY[H^?:9L;
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MR&T.].8KG<4<K8B'(49EZV8]?X9 ^"VIF+!ZY?03EJ[NP#?XZCMZ(T;9%8=
M_^Y7* ?L0JOCQA7!\T79;^YOOBV_ R;ECM[H5FGH&-6GQP;!8'>(E2%\+Z)C
MR)N'\("%K.HV0X<S7JY);\^H@[RY5<P0(YS-48TH166ECR"-0KI[R%8P"6(W
M'WXS8WYJ#8C$IS:71\IT"8K,E@EH1,Y \.Y0B!H%D>RH3.)D[S?$?].;+D6I
ME4,MMK-*PB"&N!58CTAPBN[78J!0_TY!UIQS5KB)>#-SR8IYTL8BHLH%BSU'
M^ ] T)66H ]/Q?T44Q%][D1-U078QQ2%J6=%D$T;837SL!+SD0S.//U][306
MPT@BKI_=^Y=LH>[<7DMR&'R83] E)I=L5&B>Z9WA'B/KN]"\HM<1%U4] ^)5
MFZ<K0)U+F12]3<D9E4R![R/R:?O=<XK?%S/[G%0H93C"8]*@QAV0^MFB:!M;
M.2_1 XHE!9,^^(/D5<#Q#.R)$/.HB;3Y@//LFW#JR;SMRH>FU3:6-&1>1']U
MI7LT/W+/6)5/Z,<%/:$/7\ 9N[+%R?-.\O1<9)P?5XR#X*;P7/F63@+R,9D7
M96[6@F>RKX&&X^XW^*C*8TRO>!-TO>B@VM>C5%8Q[[2)?V6HW=UDOCO]E=L3
M.+4>40]V2MIP.I3:D>%OI=S,<D+=4=J1:%9ZDDKY!CL669YOM<:<I/D#L&U6
M7>.WR/WI$BB#'7MM"'Y.1[5/5EX;3O@/^"<+!N2GQH!\NF! %@S(!X4!^?",
MZ4\5;\Q@2&,!UJ?O8W5NC&6.0W[GNNZ]^EZ[)N=BU.&L5&J)?.(E>T*O7$(A
MP>!SWUQ: J4>+OD%P>4D&(M!A\'9WYS.R1VZ\L*8<H"[L?@3J=R^XN)W.9!G
MTO+0C*&[Z!PQ\#O[LG6_6I!09[(PT_ N[=I@(^TM3Z9-QY%]=,)0*O%OZE"(
MW(_2^:CUA,=@. 2#Y:0A(K;FR+6"/%LCN/XN^+!(+Z$[96UC>L'!(1<,'A]?
ME69I_L&WE&5,.:::@4@X($2AO:\5Y\*J[KW&H J.8$ 3V1DDOO4/L6C.V6E\
MT: 08QA$[%?P.4>;9.4J1QG29;8P+24:V3#E^. "%R2 -R86I\>TBJY*G?45
M(/[C@W&[^F,K'6=:5'2/H'U<_$JS^92H/>)%:I$**T/?")Y31XQ:?X G=<@+
MVO@S5^;;< A(">(5->VQ],VTP6'ZCP!!EZMCU1U"R=F##A %R7)O)0YPM].>
M%7ZSX$9PK[<04CTE)$HXBUW>84'?'$Y88I%P$R(1.(Y]._@$0J0!UA<L>(2#
M<D4D ?KGO\&5ILPY'E&!<X9([\:ENOP*67^! L]7FH>(C0.-;VU08Y@W,YA.
MF$5,3*%-41O(P$C3'?%@;T8Z'GIT,[0\U4(:T+7$E-_(*D\7V^&S/GA7<,JR
MNQ''Y=J#JIW3C5$MS>MQTQO<+*P=&_KB.8"%/HO#=.62R,<G!3!1(JGK262-
MZ4YU!TE1'*=7N[!$%%J[ ?/,FG'GL"R+WKSUC6J9O.HT$QX31)A_AF#S<,YS
M11L>FL-T07J(DOY^R0Z+0O&R%Y$.5R%PR\>2)!;-MZ0_9>9,>2R!KWH,W/?*
M)6W78.:S:#P(ATD2LG99\EU+?1O:X0LDHLR2B<5#:T$\)R>EFLZ(GL\&^8>8
MM:#<1ZBN"%UR)W5='@N1M/P<ZP5C8FEEAZ8#$EL5N^])'O=<MRY]R2V/FQ7:
MU=!*?!1?7';!I3SN0]D*#/+8Q/E0R;%HJV/6T,4Z/.:<E<"=!)U,36M#G,K#
MN>NUB_V!*WQ=]*#43[(%T('AI/2>P:JNUT=1*]GKFLP'$ZQ&M7';B\YPF4;E
M6_!T:\2IK%D7#VTI( SM380QXYNZ:KZ;FVY[DF7N$CL2..N#M59>]&I33^JA
M!/Z%KFH-Z#OIKP]G+0MS70!EQ:\SZ;F(L^Z&+J8OF>TVJI]+%JP3+\QCZKD0
M^&@;Y<\-^:-[;M;*!SC:7K!U:H0TA>>-)2:E<*D$$G$5#H%/]W9Z%>AUV#I+
MH-MFLJ(V#2%\4M-G-2Q/-J^ ,XL_(#Q0H23/@$-N5E8ZOMRKII&N<7M-#L9F
MTS"A! SI-G2G2D>G!<"+^F[<//L,<IN$=2_@"Z:A6HK$S&D:1^V7UU+;MZN_
M9(SE<EKQS>B,VM"&A$>@OP]CJH=<]M27<Q*8G773 DPTDP8 .L_&^B55S@7N
MP GMI4CL<=?3) "_K*#\&/X-3*)0\<!<:RC._A,SWU*W9BHBQ/)>Y+%00<&O
M75%D+E'_DOVD%*I=\%6>\D+L=#Q)2T/[.'1]HEUXS))]-HM O6[KU&5/J)@]
MV&*?2^;,\B*6J'2NE]-FN$>?TS!F!73V5@07DZE>9UPEA+[->9#C.E"R&028
MI2QN':E>X%Q+5&C=K2;4-9:J4>4?%5TLH1N]BQJE2?48W[(:'87+I?H/'4+W
M\6FVQ-(DH[26R75UJE^FMN;KZOZ;_ 0_+6*=YS+(QUNP(DDL"8Z!E?[/AE49
M_8!^NJ*Y7\!93P73'1)/,BY5DX 9041,J5Q7Q%/TPJA[ROJ<MNP46[":^NZ*
M43%YIIU#C'^T#Y,SZ0[JI!%M/A<\C_F0T-DA:AQ0Q=NG7,6I'_+$,R6<Y%-/
M<[OZHGD,GL9CY)Y% F87.MIS/(7S2."3S -FFI3Q]1.700R1.)2I;ZS)*&B8
M0Z]Y7\7$5)9#$FYI3Y*6-51&Y#-O]2BZS&5K8*!T:;#0<;R>,4[1DNAC%LEK
MAKYIZW#N5*ZEU:":G@;V#!&:B0\;6QQCQIA$C!ORE+0SC[TT/R_^\W !@WT!
MKP_-R94L@4C)0?&1?.JW38.H5Z]$)YLOQ<O///,0]?]\&@"V%NDB!-1ML(#=
M6X \/-;D772=YV=G+^B%GUBQ_^:C!;VPH!<6],('@5Z8)%2>F ,02P+W3$W8
M:+O88],>7C3X\G-EQXN51:O!<P=_PC SP'7&I%9<*G5$KG,;G/(&=(7[:EUI
M:M*A0JP9X>K+B_Q]\6YTFTYJC^/&[NC7,/V4MK,\*-VIU.;F&L+904HD@4]X
MB/,,=Y8:2:Z7BW@O+?@*6RXO9TJ9JY5/$_WK8C_+H;L+6PF%D2'M.9=TF6Y4
M:LHCTMH5\\!IU5<3YC-$P*2K.W*D S)#/R G>D)87<7.&,<>.!&_B_O[CSR
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M $Q7WXT V#L!.V1^HVQY>J4O6;F_:6J._5G7YKUCF:B3HH@NZ[P/4W4I+(B
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MT.?$="_IN>GC=#YA6V3*IZH15 3DF(BVL4!G/1S>VW@ 6LE+]B.^&GK$I*:
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MXT'^K, ?>D5P7+7=+";NQ#7F(I(YQ6E[9^(?+.!0D2\DH4]5L_.V%BH&Y61
MTD\]2B9 U/Z"2AR2_+/:MCWZY8PO_N'DR5YR\!PC($ T'3"EB1ER+R%,AD6R
M$^I^4HA= T$<X*FCAASJ/>,*4GAM^H()0R.R!L %$\@I&ZV?AU'5,B=QQ.R2
M;B3R[Z_XXL/QI]ZG_N*'O]3L_7EHB;[EX(HS.CG"!V=9FS#I<^M ';1*A(>X
M7%Q*'@"#C[>7'U%Z]?4^,=]#.KHN9= A%S>V3HK.)ZV&^ >4U;(*-%I]!]D9
MD6V-5WMW (ON_E[X8GEUL4=YP](AG*WA&2=%JU5U'72DB,R)%&+3X)AQLJZR
MV85%=E\? ZDX8*YH.H]GN6UL=[BT/"5DKM$\Q@,ZJ[H#JMD>5M$@,_<S]H7L
M:AFA;9C^N5[Q31BC*?)#8;Z4'H5Z;JT= UF0EUAWL:I_KWYAV!*RWT!LQ=<:
M-(G!W]AF0C.9CIGMB-J\E)JB+RS!WQ+\+<'?/QC\W?WYJW>+N"SB\KQ]01CU
M4!U*J&'TAC5UH[T2DD;X]XIT/SD,#$%!8#/4P!@W-9,%0JTC8,F<)"W\P+9:
M04*LAH%FU404:;:.[_8#7+&*S(Q2@V(^8A2@"H4IFI4QK 7?0#P4MG0RAW4$
M6$:>LL+4ROL:J&6C.+)!#C&OKE 88?W0/+@,O<_X/+;.'H>R-Y2C3X@K*RW#
M(1^#A-ASACUN47HR:WTLKUG9"/G4D-,<Q"L^!,?H^@+5&=#)Z2O&NLA*N=O/
M*AKEDRZ7OJAQ.'XMS+_N6*6:B8K1U!=?.]^%YRM)^B+4?VUDHJ];QSVP--*@
MD[M'Y![KS GA\^7N(IG;Q#6?K"0R=EG?94/6&8L$)CF;7:%#!^GAZ8O\II3X
MK-X,.1"*,>L\ZZWB*0KB'F':P=!N!,2U#;N@[(O:ZY'MF]P*#\#3J/AI,-7@
ML;:_64XPIGIX4GKGB/='R20]G'[/!3\VU.K^@1N2BVO&A""D"#6[[/RH*2)Z
M6H:*41[-B! DOQ80Q&R"1;;SOKH>QT,C;R1=:X2NNUBW&I7R^+UM(EM=U4YX
M4V6Z ]),Y'T+%1&W"!WBM(<(LO+9G55Y'Z2]6S1EQ(M[J1@MFA>3V).R3WK^
M)(>)NP1L2_ W;?<Q8!\CY4:U_!\;+_W)SYX.NI@C8**GPTIPTY\SQKQ;DF-Q
M?_Y2IZAR?VC6M%7!^NN\%3?UL.8.QEZ5QOJ<Y$Z_O0&8-0V&#R?2/W0Q3(_
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M_1%G'M9+\SA^5*O0TUX"3KPIGX#(?6V!8-H:[#V7]0G.KJ=[JF3C.=)[0QU
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MFY'9IZ02T0I5P4-SL^>E<SUT)BG^OJ:GTN5U*2N:FM-RN0"/G O0<[D +A?
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MCJ)'F9BCS+"_D=4RR5Y%+J:(5)#*Z@=9X,WK4HWZ!FO+&6]C# NFT3KSAD(
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MB^?=T:?AIX,CL'$./G]Z>W2FGCDY//WRX8P>^7Q\>#+$+TZ?W/YY.D7LHR8
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MRFX,+/)P-)$QB8&*;E@!TMFWU\GW7!RVS/)'G (_1D6>M\8L]!FTA;G35O=
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M@YF'1:C4;JN50"ZR@K!,-B2H! ]QB=99@EZ+C: HLI"Q/*:IJ"9@]\%4*6F
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MZI>6BPD!>MCC!#0ZSAB]]XZO'%\10'U07-#U$>(_\%Z 6X*5P#-,K"1/X-[
M)D@55B/,OCFW A>3HG)6<*,=?,/NIN5+#-H#VHLH\L7Z\A?#D0();NXU\$B1
M*:Y-%;D1%OVY1/+_)6:LCIP0P.5;%]!WPHHIXW^MI/)]NYT0EL\"]VR$28"Z
M=TY5,V4\BC,L=<)N,YB[M2C+_&Y7X5ZGN[VU+M2UM[O7W]GM;FWM;&WVNGOW
M(*YL]<GJR"H28&6.@&QM% 5**T.<V?=<93TTU(6@\@$H?!Y)*[C73(;WL72\
M(4#)S^^')V^/?[$4Q2!%^+^0TAF!.!L5$TVB-O3L8W-@4B,5I!_H<],LYG[*
M@2H$5Y41T_;*B-9RI 4,PA"[JBB4(5<Q2QFWELNAIOPCZC*6<4?>T20N2S8)
MJ9JJ<PKVYMNAJBQ)$;"QO!((U0KZ;WGAW)-.RA,[.L?_@LI&7<=(S!NG?W%N
MUQO/+FNL??4+NF8V8"K?@G-9HTIEJ)<BQ7*1"NWH$FM<2JH\! G#!2E2/OQC
M^-OQK[_#?YY3P:&[Q=?V%J=Z6[K S8US;=DNW$=6";<3/.V"APHT"_(C3V'C
M*(K3V^62"LI9/Y?)_53]<,LZ9R-I=%WS-;7/;4__K,73+Y9\*JHB1(0#:O=9
M9 D5;\,,5E9NP=HJ^'D:QQM /6$&PP,=5<43'C@I@79?/"=2UU*D'@9Y$G/A
M*HA6?Z5X""V2#XCQ6&*78%42^U86P#XECA_6[Q07((TB@=5-PK16T7A;S:KU
MX=G9\.!?JF9]W(Y8<:.#M&$=+:^R;$5]IB^^ING+%,O/L!#Y5->K_\/4:P^I
M^,WY1-?:6OY<@Q-#V:%)119'FD[95A,+:C%U&3!L0*TW!D;^*5. T-Q>;6W;
MF6:+8C=8DWY]%%8W& T,* ,(NU=;]3PVS&"3=9@*CN$]\L G4>59$<:(Y$+]
M/6#24VK+1,T]5$LE;#]J"CK)QW0N4MG-RIBZ!Y].<4/@"&IH!ZZ8ZG&+J?9<
M,94KIEJ%8JKE,]D*:Q46/O0E*!$Y0<N8+G!8]OKB-:[;VQD(K5V'U%YC8(=Z
MI*S;)Q "ND$8X)!#/?-;9E#(-8E1CSN^JCG_Q()K0)4W%!+X/ HPYY'>J9%"
MV\$6+_(L163+$6-.('5/JV0">D8^0V@DDOH:ING@\_';6JN4H"@O)@%W(+!P
MU1>M1/T6?8PML\'7LQ^R'DE$<""Y;HK\86LNN]^!6N/^[?1Z26B+]/KN#VKU
M3+::&N1H3T2+@\[FYLY>;Z^WN=7K;@_V=EZR7N_0]AW:OD.P^L&(:6M;K)\=
M#3D:NCT0:L$>VSR;YK$H495(@XE0:2P49$3MX2!(@XA#6$YT.PI; H5A\GX<
MB38R(U31.1W95B,G(HHQRDB]U^.BE/AF 2G2OF=:NGD__WXD^[<12N\%96R'
M"%469@4^$IL6GT<'IP;7M*4GH25Q]7-W"R(Z??:%ZK.NLXR3B7?7W.;[3,Z+
M/4O4H?RC6B>J/99/!=PY;5(589!C#BQFN@5S'=0^#LTH;6TP:W,RC\IVW8O%
MJI-_3OZAF]VA+SL)>!<)>$TCU'MK?ZD'&ISOH; CC0^EUHUI)6O@UQX2Q#YE
MZ:BJVB2HTI!+(SE!E#-SG&WGW').M/W8OKB^](YB[N@B,<XVW_MG@!- (CJL
M\FPJJ%PO",,LCZCG-VGD-\4A*7(Y#6)+NA-D$4O]%C2M,I-12PP7PW7Z"DP!
M*W4I:H!"".KUV$B4ZFUVO&%27E + M5\*,UT>X.Y8;ULE,B627H&TRHO*NH+
M<G.TE5:)^Q@C2DPIV\& :90IY D5<I6(_ 9UWV2-73\ (P-2 Z0 R2^>\B/R
MR/ZBNL2B%")70V)9H.":1\QBY')"V6)!336[E(,G\5AHH LU*M<CFMT:"U'P
M8<H](GS37(39>4JX&-0RC0H0Z$]\7B$;XA1&@HS&"3J]\'LU>@SG",K3A$H0
MJD)@XY8$>V&HIF+XLVHJF_A:[<4D&<EYZ\[>:YPY\ >WU1"N[;C3N-S]^>@:
MUY.V'>]XGU/78MQ1[CW&]ZW; >\/V68<6XZK3CH+NHUC!SQ0K= /3$!YS;O&
MOF*<;\X1Y9W$*2:CHVI=9 FW^=/]8PBF".0CD)TQ1)#05%4#MAAE1!#0D,].
M#O!_J%=[#>WP"1:UQLKIL/#0K.!.;W1_^2@?Y+'X$H?3/F_[%+FEICQ.959(
M@6-Z,=9AF5')!:,(C"'L%X:?.&'DA-%]QJ>++A>R\V>++"(I) &5\7)T]M0S
MLZ<>H>QZ80&XXSGGP792>@E2^L575"T$;M;ER#8:'EU*IT$>%T7@';!K]L5O
M$3]ZFZ(SLVG#Z!(+EV;&Y;[&>OKGU$14>EQZWITO00N\Z[:O5M]U*O++.(2Q
MYZJZ6BG4^VBZ]GXXU@EAC:=,;I@=JF&SH/E";AJ,S@TJQA?EK%["7Z@)PANJ
M@@KDJ8@-EUE@9H?\%-<46<B3>$&)[R*L=%?M1N-M53'/H10]#/?0H#E%8)<(
M(=L(Y.>"I]"96T)<<)9))&0#@)&@9(J$HB88%)IY$4>?L%3?M +!>2MX  U)
M4$-#I^[@)6)* Q5A'V79)#REY8PR= 5AQ3\5YF?Y&G0_OKT(L:6MDQV+9(>&
MIYB_IKP/'PX,B\]];;@<:?'J(DN2&;D%(@.G,?.;D@F_"O-XRM'6=IED/S(O
MEV2B_G#"$6:J-P&&(F;[$$]B_-_6LZ\-TOJ$'J-%;LUOSTB$6*40>(D<5;:9
M0HX\.CWVWE688':\:%A3/HL"B$$Z$OL=^+,:@*[UGO?R<?F]GGA<$+S(>!PG
M,2'GC.?$%6Q873!3U8.621,CX0,3Y)Y[">'?<MV&]>, ;QN6SHW9=]IV<!)$
MN'^O!MUN#00E)E!K)%UJ=,0?MKWSK+%%5Q3GR2<2ZI-BSU4^S0KV+/%,T>.$
MC>FY3U,!=T3.$7]YC5QH@"$?L8/S"7 B%7IPA@1B$(OP(@6F/9_!;Z(*KA)$
M49F;C:$\?<OAK)I[:46" R^$MV6$:4Q9$"(/&X<R%L+ :%FC^>A@(R0+B3^3
MS"@M)+K$G!"$3 Z*BG$'$2A0!L"P*1"A*'F_(^(-T4LKI\/=I#((*-6DXNMK
M[D2.#+@-%W\W*!4IU(Z!VRON=5^KH!HL',^1TEF"),DDM/+<W(_S;!QS3ZTF
MNU@)*?*E<@OX1$0>9]%U9R8[/A:42Q]^VZBF\D<\6 S7.DCD[Q*[6;G$%PF+
MQK(GP3?.TXGRX"I(BM8CE6!#106O5%,0WZ>QS$$A:"S2<P+*TTR!@O("-Q)S
M:01-R$>!^Y=T?(5@7 9P:"2O.*>FJ3 XR)\'OH5WNP[RQT'^K!3DSQKHO@8:
M&13?%NFL@U4!PJ08K0/[M_5ZW69GUJ:<!MDJ;WAO7'&S*?A(J]:4,&+9M*9!
M%JF*ZC%E^7&CK N1$)SO^]-_4?K(1VJQ,-#!N(7J5 U=3EW9-5UJ?E7SNM5<
MEF4B2NJ$J>_'FF(_$N65$&G+K/SY6PVNK*8.1+KR^V-4ES-U5K32'E_1K>N(
M"_MV"[S!]@9=QLW[6I]9[==X?;IP\].4@B$]-<X(> 3MR%;EGPAVSR984H.(
M^(Q1RSB,+7P1Q9&79D"QB205TKX"2__"]VC<]%R,L,<'S#52"F1CLDC!UH_I
MO92A3+R )BX8%\@CA!"^BD2V>A2U;(PWM.G09!NRL8(G>9PE<1C+1+Y#F=?<
MA(]=)SY$Z%1C6FH7)%R!8)05JC4Q/)#,BKA07M1QG()=)IF4;QK.0Y,@S_C8
M5"*.DN&CK;;ZK\EG0RDA*F>$DO-'@GJ]"NZGVE+90% 0[X?#8[X:^-% "0I@
MUT*TC@(3).A];/NAI8!*;R\D EI13::RVH#R\\=CDAD7U'HSRPF_=8($Q<#_
M##!+A1-Q,(H3=B3@W^20AHU,,K0YR8N<$1F2GV3![[0A&TGG#2>IMNT8/'LE
M, NUJ,].=<25J*_20X8U!FE!/HZPRG%C+?.8?TL5#"3?"E XJMS>&BP1L _Q
M I2D+"?^PC?GA$K++1!2#:J;44G'."#/-&_G%1YO$HM+3H8'*Z< -05U<5-M
M$<9Y6$VP:R<#W=($-64QH:!O@+[!)KKL58'3Q!7\547G?-K!**OXY,(@SV?X
MY:7R<2S8?UV2@;<%3"["LM)@BI2(GA=4(WA1!6Q"B"Z?85BB9T%-<!(@SA[0
M3*Z5CL*F,5XE/R'I0-,;K$'S4T%)+6JK:%KDQS"R;*IDF616=.R()+NBZ8=*
M^&'$ H?4/5 ;A\=]S4LD4,OCXDNB@JGK83B<H93!20:_*$!XQ6-X3TJ;%E!H
M(TLN"6M@7JI8)X,$J?;$A2R,//ZM*L# +0K$J5:ES.M\/R$38-\5IGT3NYN(
M\H+]<!9',&]9U_TI$GV01[B=$1$J][R1+O3AJ0:Q\,ZR*2B,N]VMU6KQ<"T]
M/$6FW2%Y&E4'F["!IBYO?=AZ)0]1&$D_*EWE*'XP5@I2):*[J?6>)F@+DE;I
MW-&3U<;WOK*AIR#+!#E8=?->):=,UW=Y 5.45F*AYT%:@!R&E< +@_2<.N90
MQ!5Y"@B&+B90Z?5W\M:0Z_<;=S>(<GG;8I/ -$O)ALF2A ,.)DM6KPG#R^;.
M;RY37I&H_# 4?>M#9HF@%&59= 46$FZ&5?RG0B'B>XC$!,,U]DX7&V(12WW/
M&FMN45EHV>M<V><-I4(H Q4RL+% Q=.J%)5-FLW&Q )T].,?4G66^JJMKMIW
M[D+5U?<HV16X"M279O8K1>RN)7#2/1K*,5""11?6 FP-1NHK*@?"TNY8(0Y*
M1F"#@_R&;;-5N2S6LY[>9F&D7[&205D:?W'=K-1@I.:+RP]R1$&"?U%3[S'6
M??E6)2O\=&2.!"6#C(R8BEH0=+@6J6RCDD4A+]2H2?G&D!E5POIH#Z"L(L60
ML(>:ZC/..DB*S(M!7L(IH!2,!(L>KPR^+Z"5CO<EQ9:$5%$,3^+RY%,U'9G>
MGX6@U_,>TW#&;@GPFR#D=N5P?G$4RR0;)+<&V>CSQF096[6]UB0(+H,XH8.V
M=,LX)7VRE%TSE+$B#XN+G@,YL#*8ZN^/TPM2DX&*L4TL'9%*UR&33V",\WIA
M+>/J% RE>TA2'U,!525C"?<&_$'",5?-;'%*S82B.I"UJ<9V*JP6AB?2_#SA
MZZ?4/O,357BVQC?%'U9-/ANVJE)![AILEJDCQ7M:X;TWI3B;P0I!@10-Q:_U
MX@>I;DC')?S%OS2#JTL)9::0 7$S!W8-%"8E;C0C\:725&IB  /QK)IS;L2<
M1R73# XO'FD)GPL0":GV L4EQM1C\AK0*R*,(.-<SJLDD'D-"2Y/>574VDF
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MOG3B_IOKK+@4X*D5AG?[,9BM5>BL^%Q VQ2*-F)Q,Y@PP[(A^MCJ;9H#9G/
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M5\[XRZ?7\W>RJ'W<,1-JK%%.UI>R_@X7&/,E95_TZ9/Z!6A?T(B?1/.O'O!
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MF2>IB N2Z3@GHN <4#V+2")9DB52I(*O[))[C+\*>J5?MJKVB]>TMW-%&\H
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M2.6['CP](8]RBXG$HB&(3,<]E8>*3$6:**-S$F6)/R&>$A45@N0V5ZDL8K?
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M$O"F-K8BRR21@*(.>"&88#HA,3B;B<Q2Q=D@Y7*> 7@C$8+U0.3=T<P[&R(
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M\Q?XZY<W[[]\#C[\[$;OPR]OGF'\=F)@?GP[#B;GU;318].$@?V66W#_+BT
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MPK"Y9XR(1\0[46%.E7AWFIIQ)8)K;LX_?;PY1R5J$+JXDC,4'BL=G0G@N."
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MC7#GQB]_4-KKTA<W+7_Q557,E^7U.E+ ]U04@:@V(F%.A&HF6<]+5L#T+OK
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M>$U>F!.!E[!&2Z\R"*]-W?Y7)PQUT< *<IL$:B]"'QD$AX#74>>(#F.Q4_+
M47;VSY?OZS>K]8=9P<5Z]A[/+MHDF'P.%^<S_%1,VNH$SB[2;L=?=6BSO<HA
M2!=QNVE-71-9GY$K)%F?&X//SC 6A8=D7=VZ\VI)7+(:O,\^9!FY,^+>J0.?
ME/7GJJM_;:KZJFKJ?YQ_+OI^?J6FSY=/JI+N M!-15]5$]1;5,#.N:&H *%M
M\L*<"-J,D"QFQ<&B3J"*8N"8"*"CCPQ92"+E>Z<-G 3:.)OO!J@0V@AMTQ;F
M1- 6N$_.< YRUR2J"(2 F"#SE+4HU3WK-N.\<\K 0Z"- @J4*O P 857VU7\
MGZI%F]QZ=KQKQ36[4!E9FI'K%UF:FRR-%BDH%@O$E!$4$P70F- *=9U'C2)F
MV4=BP*NWN,Y_:MKWY OEZ^U(C1H3$K1(F%.!EFH *A:!>5.QDYFO (H<K%;>
M53=8AJ3[R <X*+3L7"J"%D%K\L*<"+2BX87INOM%SE/UK[" UT*!UEH&[[+2
M76CMDP=P4&B).>.3AQ:E #Q(<G_*83M+BTVLMW:[ZP^PV&PN<!GS[N2?4OS'
MKG=D7VZR+YXG)63=O]?7X]7!U0J"XPZ<CD87)ZS'V'^*_\^+9=7 Q?)-BQ#O
M"LVN%+2W8_TY,WKJ%H<P1L*<",9LV\!;7QVE9"4H55U>S+;N[5-!5T*Q(:?^
M<_V/@3%-&".,35Z8$\$8SRHQESA(UDJ6C*V[?<,,Q***B[HDKSOG*O?/^C\X
MQOR<R\FW/Z43^Z/L_Y^\Q>6;^MZ+Y1<U )L6"6A] ;<?9N_R]NVJ9?Z_SU>C
MI>9M@!19GI'KWZ MSRT4HG/GK[E#__3QYAPW-\TKP=$C2&<2*)TY>%42F*B3
M*TP:;SL.^CYQALM.N&V X<_KU;MG.Y7_RT[CGW]6^+[.XNQ<^I$UK;G=!,]_
M)EH.2JH3H^7A6PM((Q47%J0NV$9(,W#:(7 >LI+,%1<Z?OH^X8:>:;:I=ZQ^
M][VZ </G5OEQ<8W"#H2SH>)L^,Y?3-XE$UNEE:BX3!Z"$:EE7JGJ#XHH]+T*
M$Q["^7.*G#_*;CBYZ$9+<#A;+=] A=4["G*0G2,[=SP[)YM9DDH"AMP&+WH&
MP09;MP7&I.R-PM1IVG/GM@G_L:R<W#7I?;E]F]?_-RZ6S>*]7/9OXSB?<S&R
MC0 %.(B41,J')F520DF9%626*BDMR]6[9Z;N"*+)!I,)^?Y=&(Y(2C=7AC8#
M!,J3ERJ!<EB@Y"X*%P("P]SZ0!H#(1D'.D7''$\JAWOU@3PV*-7<CZT4Y)A1
M$\H)V4>UVF*>596J;[!8OKE8;-[NND!>58>0!1N4NDW,@AV^ET.4*5KC03#K
M0"G!(&B9P2CG= [,&'FO7H\?@_/-JFR:)N9J6)[]01-?EJ=5#ZDW$)U<$KP(
M7G?JZ6 M9S)6_/CJ%"MF.:!, 9@+(H0@M"ZFCT2,'N%UNR0,P>9F;!$%(AF1
MC$AV7<MMKS-J&X%%5C?MC.G*M/J%8Q;.M^H/5?K(D2 W[&0+/B@E8A]U>I&W
MLS=U4;<-_J8NU+:M?_WK$S(G(U<O,B<WF1,4LDBO% A1-^<J1 ;.1P2KDJHN
M;\R"^SYV]4]S?8W-ZFR1=L6$S;J\7#?S\OA=JR D8T*>,*%K5.@:_)%:3E);
M] X"5Y5UN64C\^( N93!&)N,ZZ57Q$'0V T4&#,W?F35U91[0* </"@/#C*;
MF/.F^GA&8?7QF"P0%$?0S@L749OJ^O41,B ?[T0#!I0-L(\R[7)<9G6=0<3-
MVUE]YCOJ CEVW1JT)1F\R^U06:^D!1Z4!)6,!F<]!V:$EQD#%NQE7L1.M5^L
MEDVQ+XL!G_W>FAGGOD9&4.X:X?'TI3HQ/!X<7\8D7CPJJ"YVJ8XV-^!B+N""
ME5Y89T)WL-H^$8,>\'6[[ (Y5XR2"PA@DQ?F:0!L\/Z=,5ZP7 RPR*M_)TKU
M[Z*5D'TJ!7-E7NAT$=\G$G%H_TYHJG:]=_K"MY;3WB&*T4<CONCHL#K/:VP)
M.3/<;/)V<]G,88%A<;;8+O+FT?>6XNFLNSX-5KVY[9%_^T'\</.%WA;F_5WZ
M-VE^ &--UTL+><2"G=KUTD(>J6#'=;W'/(\2?9Q'B4%Z@(_C9;/]V3K'O'B/
MX2Q3N&)0NRP*5PPK7.&=L9F)!"ZIEARK+/B$#K@)"IU&GEPOR;'/E['R;Y.?
MYLM_GR\_ZOJOGU2]MV'F3$N*71 K3UVJQ,IAL5(R&6TN%7G:R<H]Z<$+J<%R
MY"(DG7/"GEJ='XN5<J[%R*:J$2N)E8-GY<%9EEQK=.(B\"C\U3&5\!%,R157
MD4?..RS;LP_Y@5A&6;,/6F8[X2C%YY6[F97UZET+ IYA6*TO)ZWC>MW.L7:M
MXLC*C%SE!FUE!N^1H_9:(1.0BXF@7+80D!4('#6W+#@TG=ZY_40OGE[D-ECC
MUWR&VYQ^P74[E7YRL5[GWLK9N)K[L<T>(N><L#EX;!X>:PPQM=G'-EJLCK;A
MU3FO+G<6&+WWI96T'2;0T _6;CE<3<XE'QG?*/66L#94K W>&V3<<Y5%!B:#
MJ^Z=0O 6-1A56)118N3V,#&-8WB#9FX=&Q<M!](N?,*ACM;U?KE=K3^0Z1J4
M9I'I&I;ITB9FXU,!K8,&Y4, [R2'PI6W+@A5Q($"&1\UO!JLOBR5F#.FR%(1
M)4]=JA.CY.&3R;ROZ,D!HE8)E%0,7*H_,JF--9X5H_5AXA9[4>R6[<?'YG53
MC((01@B[SA'S2B6, 9IS55TIVR;8&@4A*1N5YCG8SA2%?F((]W;$*"&"$B(>
M)DKPRSJ?XR+-\F4%.F4]C%VOR(;<9$,"CT4@<@C<&5 1"SB9/>C, M=&*\X/
MM)F_4L0#M<JQ<S^V$>CD"Q/'ALJQP0<]32BA6,[ 9E9];1,R.!&J\^PX!B]$
MT:R7B67]<?+F0 &?2SVR6 '%/0F4@P?EP4&6;<[!FPHEC+)"B876#S&U/(22
M'$.5^8&"!H=U^ 0;61TM-7XXT0C"92/RRUY?9$Q&KE.#-B:#][IYB-:75&V.
MMPH4*P*\BAJ"B05YD$)I=YCHQ$[)7W[L[/=XI^Q]^=YS;ZB.F6AY\E(E6@Z+
MELZQ[%0TP#33E98A0.6G ).U$#+(BKX#Q2@.2$LYEXH3+8F6IR[5B='RX#2S
MJ&10Z$$GED'E'-OP&0=.1Q:*L5&[ W5]Z(]FE.9 :0X/W)WR'#]0:\H)Z!49
MDQN-B68&46KP+GE0& 5XZ1EHG4141;/J'!^V=>0OEWK8FU=LK9NZ*2%^D3 G
MPB^-2A4L"9B)!90I$GQ  UPXK;RR E4G3:O?=H[]\LO3&#."U^2%>1KP&GS<
M,WMI;4JII675+TQQ0",0/+ID,.7@Y('[0]X9CK><]SBR#%;JH3" L,'Z(J?9
M>5YO5LME/H/U99^03_42N^EFJ\L4B*L__F+6&5FZ02DD6;IA6;JH0I B* A*
M(BBE U0E3* 53R4Q(XU1!PMC-%W_\V=5[[W%VESYD84TZ*"/H#EX:!XA;4$%
M;HN!Z"O*%%H'7F8'RE7*&2.*SYTDK]YB&WM#[6:6\;GGD\]')H:1,$^#88-W
M_+S@7,L@@&E?73<K'3A3O3^'WDN=.??=GEN]A3@.[/@);<=%RH>8WDYACGW"
M'(M&I+S94I;$(!6-K-BPK)A+)2=O)9AFEE1U^\$+*Z P-,+;R$3H!.K[ZAQY
MJ>A7@?H7N?<.\5Z2%2-DGKQ4)X;,@R,M*"U8$!QBC#M&<4"/ H1W-J8<5&$'
M2LRX#]*^4TD],I)1Y(( 1@"[;KBF+\D[EZ!PORL:*X"\_IB3J:Y7T:&$<*@F
MDOT C(HL*%OB8<((3W/)ZW5.LW5^GY<7%#X8NUX-VI0,/GS 38HL,0W61P'*
M. 2,U@.J:H*R$)F+ Q5Q?%3T7R_UO._8@>,C\[@I=D"\)%X^-"\]BZ$-F0.)
M;L?+5'FI.4CS_[/WKLUQXTC:Z/?S*QA]MB.Z(PH:WB_N=S="+=N]VG7;/I8]
ML_M^V0 !4.)TB:PFJR1K?_W)3("7NDA66U5228796+=48I$@@'SR@LPGN9"A
M"D3B>SMJS;E;O$PBRY]C\7+O5_7 \'+G>.9Z1>3E/&"*!QY8<&[",A?LORQT
M@S3S92K6B^"VU#/S>_',QBFV&Z>PZ0[?(TZPH>M+Y<SY5YOH\&#)RF&KJ:8?
M*KZGT];34CK=VCP/V?O.Y?[VZQ^(-LI=O\A#-V4\4 (LY<1C//)=EN<R#MS4
M%8G:43*#R5[24OV9?U5;+L[V)HF_0P/[CAVDP]!N\+)%R"*F1<Q#1,RP*$*9
M*;#?I03T4[)@N<P52](BS_PL]+-T=R06NT5,=^+ZL85,"YD6,BUD;K/MD!N+
MT/4"%A2 @6&D$I9Y/&,JRF/EN2J+XVRG=1_;@LQ'#7Z\'+A\S$2.8!L!DN!9
M!DC>J[DC>'OAS)KZJI1*.OF-4W<,L [NSRO+;V%5FE5I6R@"\7-79$7,I #-
M%(:!!^HIR%DJI!L4/D]DL<92_SUQ$Y#I$Q#ICT:B?[WYTJ(Z&WB=>Z'>EA,0
M>A,W#JU:LUZ A4P+F=O,T?;"S!=>SF+I<?0"D. N+UB42I7[0<0#X6XC</+H
MD.F[&&NV@1,+F18R+61N-5<X2KQ8% F+PB0%.[&0+ W2F$62>SPNI)N'<AN!
MDT>'S" .)NDNN85>#F1^=W;)INUWWXC*-V(E>Q0,H:==Z_G(ZZF\5<)P@SO%
MM+YNG:*I+YVRNE+M7PR,O$SM!+.,?_G7'_P?[G[1^Z+N]EY](^SN0#/;][4;
M^04O[*&]K]W(+W1A7];[[OI<['N.P?;(M+MM0C\N&G'!D<6]+ASUYZ*<WSB7
M:GY12V/47<)U]I#KI:?=VS*3.]N))&&0>+[/,IYP%F82(Z<R8"IUHR(+19@7
MP38.J#[R&Q*WS_6Q %%LU!L2R-])'D\'<7P&"1<O>MM;#'M!B[D?&/;L2XM5
M'B11@@F\0299J$+)>)$5R'T6)6Z8>WFQ%E[]GA.IW6+D6G UC"8P02\+)VUM
ML05,"YA/#9C2#UR1^#ES50)FH8H2EJ5AP420)4D0A;E,MY+(^]B &5K ?,1Z
MYD,(2\P;+O%LJ55BT=BDV^<G/U8U/2_5Y*=1[&5>R/R (ZV&<ED>)2'CN>1!
MI+CRHJT4,J^IIM]Y\X>:8TW)62_K6])+<33Q@A?68]H:\A8MGSU:[C[Q*TPC
MO_ D"[B+1K-0C&>!8FD8)9[,,Q&E6\F5W2&:V="M!3"[F'L*8,_>W/.*-$_B
MK&!!6F1@O\F4I6Z< DJ"41='GI#9&D!N)1*Q0W//BR:9:SDA;7;$UK,CL-O]
MM*[.&>#-I4V2>+;29+74\])219$7PD]"YL69QT(O"UE:*(_E*LV$RI,@2-;:
MDFPE*/$.A!UE??NQ<F_B>[;!O<7*O5]5BY7/"RM=*8,B5 GS@PPL>ADJEG,>
M,I>'899R[@IWK2_&5D(>.\3*8+<<E!8L+5A:L#Q$L(P#Z7F9!V"I@HB%@9NR
M-(I<YO$L](M<<=_?32+&[L RG@3)#@N"GQE6VAR,K04_1N$.!T;#SS4QVNG9
M1^<M3*#S[J-55L]*K*RR>E[*B@M7AE($C$>".IX(EH>)8%&113P.4U]FZ4.B
M("#@_%4O^1\*G2PXTE"_:ZG_]>:TG:'(OYMMB\;"FWB[Y$I[>O2U!K[%3(N9
MCX^9*8_ ' _!.N>A8F'F<I9[F<]\X7$WB-,D4.(AT9"GP\S8G62>3;:VF+GW
MJVHQ\WEAIN\661H!7$8*.^L%1<;R.$N9Y\=^D4@_EG*MY/FO!$6>#C.]#$ S
ML:!I4T-V5J%R8V,C5F<].YVU>YTB(E7XGL]2A=$'[H)^ -.<:#@3M*L]%6XS
M=O%92Z7)+;S9ED:QR=@6Q.QB[BF(/7O#.XKR+$R\A&52I(!ZN62IS#/F)EGJ
M2L615&.;P8H=@>2:V1VYMB[<(N9S6-4#0\S=)^YFF:?R",M+HHR%*N&,J]1E
M19%&(9>1+-RU(ZN'A!*LV;?W=.J''3HX@\UFDRJL!K$:Y)X:)(A4$4>>QWSI
M^2Q,$H_Q*$ZQ59R;^H5*DG#M .\O!PY0*A\S#IWXD^BE&<0V<F!1S*+8;0R9
MBKNA%X#E(\&0# .E&)>I8@5&19,@"=TX>K!G_]@HYH<3&(I%,8MBA[Z8!X)B
M,A=)&!89DP!9+!2 8FE<1"R4121C^-%=CT_^96_^T5',FX3AP=MB-A/@09D
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M^4/QI6J56#1*OE;YMNJFLWCBNSOL(_3TL&M/YRQ"6H1\?(1TO=SC>98Q+Y:
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M]DQ/@ X\!B#K&4E)73C'9U\<W_5=YL96:SPK<;%:8T=: SQZ%R3"9<KU)6B
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M+%!0%M48$L_KJFZ:"\7A^1SS@-'D08FHT?H +23YG-.RPY.O:NS) #8(*+;
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MWZ[S$PI#62V4_/FQ-LP>$%634NSUW\M]V:T>IJA49E'B9@R,+G 0BBQD7,B
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MW<HYU>>&2P4H\P&U;Y?^_*G/?K8.ZX9.PR9'?)BE0X67#>GR)-7HS372^$Z
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M)4Z)6:5>PUEC-=S0>F$Z,<<])9'NNE./=,@UVHO#H>:X&IY/L41 ,V*;G64
M\^S$"7QOOX!O9%XZ7=3+V*%GO1WUM#U@J53[SOFE<H^. F5<%FQ$= 21L*\P
MQYJ.MN&A"UW$6S8Z"-[1$<VF"SJ2T%=T$*"YU''--0%ZWJI&5\N D2G4&"KH
M1!.VSAQ@K]6--@828LU*( !04?G"#H8IX<UXE.;4F>"U;-N%:@X6&3HZ>.,!
MP-R>GGUTWB[02?K8=Q<8[6*3^X-S>%E7"EL)-'\H$/0%EFQW:0JW. P&J(>.
M ; 7+GAS"6^UT$N&W\K+FLJX80+.<7?)!=@,Y%!\7#3M8D2,\Y$W\THU1(EW
M?-XHO84I&U23W_=90;[KNX12N1*X[-R9PKZ@['U]#[TI0!AFPSTG/048N0)E
MOM [C?(X%OD_.ZQS@IA1W2>26O_!%C-3(M'-']%;E+KIS:PQA'P+HWT!??LJ
MJ5I/ ( G&N[F)5>>/:+-&*V+[HVP_'C=+K(O'Z=&&KI2?OV5U-=9N6'.@B.P
M/C%9X!S,RFZV'5E*4AP]VA-#&"=LEPV_)EN&ODXD XU"H_<K[#C9(?K*0*E6
M9/BR-I U'P(VKU@ %/RYP*6EJ%=' #'>EE0F.^5MJ^E(P"[9:#0XFTR%I=8T
MCUY)IMR,\[@H6,H+P<(L"!CW4LYX!OI1<3\LO*U4DKT%&/X[*M8/16^.CZQQ
M&S!:]UK0%OE[1YQRIP]S@&J#6":6#+:!8X@TM5';(Z\I5QT?G,$FPVE!T2/D
M&D+$0Y6.;0IX3TL#S@^G>M*YON7/G13#;[ B,ZWIB9R0RRM.+;WJ1=MK)F,7
M](\:[DM$K)NL"1CJ_%JIJKL'\2'BH\B?J-:L4@22@[4AL,7#P$FD&5C^[!K<
M#.RP@SU'[+75Z(.RFBVH;]#J1QT13^\L:%9=NH)ZZY *Q>F=*9ICQW0#(M4+
M%VUX3']/U()F?4<</%3B:%3)3<_E1U\D;;1<H'A1JH8WXN+FD=,4'W_U[X^;
M[ZB5DO=T;@UY6OXO_]^B-HV5NFKXP34H!PPG%-#)IWHWO/P@Z5]=2W\/UW+P
MZ^Y8R5^</^_8!,'MMS'?'\)I:._J>_^BV?<PR,] <9 VZ^$/H\CU@!CXS1$
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MD3)4;^8<:"G7Z.D,T*6YQ/Z>,!]:.H?YTB9X9UD62Q RFE48UF6YN-0-\.[
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M3)T)%+*6610<]J0LL1=8;<2K14T##PP!5RK$L<%(:TF14SH08QSA[,G.VL2
M2?FPTNON]9F>#[_T(-F#Y,L!2<J]BLX0%'E*52""(..#1<Q&:WSD2K*-,[U@
M#-;P,[(4&\1UJ9#&"C1][*)EC&F'\=,Y)\17.K/T(-F#9 ^2/4C>UH.K950*
M6^1HRGS FB-CB$:24ZLC#<H$>Q4D2VRMUB(@)4 %Y01 TI2R1%(+;W H)>7R
MN3I!GA5"]I$1'2^ET/0RZ"7<;MF6[M'$MWXR3\O_A#+N:9+X;K(8SU3<&2](
M*#7(-^D9XB(R9(/ 2,L@A2?>:;41I/RP11F:IB^[*LN@R8#A!T[U^RK]?']2
ML$?1'D5[%+T5BI;*.<$TPMPIQ ,' T!@B8SC.DJE""4;W4X?M@C$;E&4TG)0
MB@=._NA1M$?1'D5?,(KRB#WU4B$:N$QINP8I'33RVEBO*'=>;/BG'[;HQ(Y1
M5.)!J7&/HGW-\L?RL+P-XPG\UE<M[ROB]E/N*?JE;.\+G')/T<]Z>Y_=E/NC
MMD=5!/^9ES5X9&"FYB34/1ZK8EX%G\[;ZN[AH6D;OFP5_A<[_7.SDZO_+KM$
MWNC@KO>1O)A<@SZE9M6E0:(BQ&&/")$!<2TP4CS"/[$TFC 33+GA&+[+\5K+
MWOLU=Q_.4P_BH_@I,_G1?%;-S-@/QR>;531K'+AKF'(YX*SLLVQZ,.NW]/F#
M60@Z"BIY.J)*$<#1I%,N@F19FE28P1"^DU.NIP(S/1"\+PK<@UF_I2\ S&BI
ME;,X(,>L1-Q$,"AYX"AHI[1B04KF=W'8]$1@IN@ B[X;S7U\#7W^\UT/G=*I
MZ?!S:!*;4YKSLK9Y+W!>#-OU F=5X"C0=B/V$FDE @B<0)&5,2+OI&6<8DG\
MAL"Y6R%S-PUG,!(S:@(:LAS97_'3I5"'E'-2P>B.8DHZ^13<?#J<#9.\V94(
M(NJ!,YB?.R/TV/;LMO298AL)0D5E""*ET8@[)I$UFB*E8DF\"4IXO)M2YQW!
M-C$@2O7HUJ-;OZ7/']VPC\J7UB'"4T5:CS&R1'E0Q0R5%&MCZ4:.U-UJH7<$
MW0@%>.M;/=S'>= '*NS4>5#VSH,7QG:]"%HKBLY-D#HXQ)0)J72/ &6YE,@1
M1:+U%G-.=U,4O2LBB Q(^<"I$L^=%WIX>W9;^DSAS=&RQ%*4J1X93E$"H#1)
MS9!3@BB ,(_E1F3!W<JF]_#V;'BAA[=GMZ7/%-ZTT1H3#DJ8(!)QKP'HK//(
M,U)RID($_-M-8?6G@;>^\GH?>=!AYX'JG0<OC.UZ\;,>ZN9MX%BA4D8*FK+!
M2,G4RY,QIYRA7OBXF^+H'=&N]4"7?59"CV[]EKX =(L<L,B6 I7.E@A@B2/-
M>4!>4:JM$-*)C:Y%=ZMJWA%T4P-2]K$'/;KU6_H"T*W$1 CB&2(E!GSB0B'C
M(D,\"E#=, M4;C2VN5LY\MYUT"T^Z.,.GMIU,#E/Y%<59NP+<V&FOBI.I@9N
M\$#M/DR+\._Y<'9Y38F$X3CA4'KB^0A&F!X2SLY'D\L0BEP;H3B?3]VIJ>H+
M>@G7-^WHFW;<N?XND50ZC"*W G'E C+"6A1(27T4FMG-^KMW*;-P(RF9O_LK
M\+7_8"[3Q?M30(V3?-\NCQ#YH];C_<X[>_0PVL-H#Z/?@%$A18PB!"0(H6!B
M@,V@J/5(16<)5V60?B/0^2X%'CH%H_B!?2D]C/8PVL/H2X)1+WTI3+1( FJ"
M>DDQLBE&S3$ 0^D,QVPC6/<NI26Z!*-EKXSV42$==>W<M/9ETURNKW[9<6':
MF0XA3RA.7U1C$!EX- 03Q$2)$><V(*4L0:7@@@?E'.4[:5)W3:VFI@O(1LFF
M'1[IBH&2C]K*^KMO#-*#9P^>/7C>)+<F=9_3942>&H*XTQ*9Z%/ "^.EXXY[
MLE&;8X=5.Q\>/'4YH/Q1G3@]>/;@V8/G2P!/:J)P5)0(4ZD0ET$BJWQ$0A,5
M2TJ9Q.P!JX0^ GCR 2-]2[K'"\S91I,OJB7=X<*[4CR '^79"JZ^.5(_Y9ZB
M7\KVOL I]Q3]K+?WV4VY/\1[5+4Q]T?H_1G/U)^Q3AC7K<<?>\?&[O**% ZV
M#(C;5--4!HZTPP(Q)@R3T8IH]"Z.U-Z9Z7@X/JD^A&D;B7*ES<FO\#'X3S,S
M"]51W#\+4]BHMY/1R$RK?,O"LX%7/1OT&XX-NB<?. 7\F;DU>@SM,;3'T%N5
M=<(A4A("4L1Y0,'2(&TE0X9Z2SEVG)B=],-[,@QE>_B!6WCT&-IC:(^A+QA#
MC=<T!,80J(\4,-1R9'"D2 . DM*4KA1V%P=L3XBA](%[BCXS#.WSWA\_[SWX
M7J+U$JV7:+N0:%S0P&A4B L!5H&@*8FRA']DR81FH/<S]Q">E8:1'\>W0ON0
MD=XNZ%&T1]&'0E'/O9),"P3PEWPK7B##O4,TX*BP425V.XE:?E(49;UWI4?1
M'D5[%'TP#W6()' C4,0VU0P, 1G-2N28E#(&Z>"/A_"N/"J*/G2;Z6>&HJO^
M%?B<(F[_NUW PWG>%OC;#S]W!#:OO/NKK[OQ@NQX9DO/S[U\-/F%%[6?RTY&
M_C9SKR]-KWHUG,$HW+6KL3^>#5.I3:Q?^[;HX;*2Y^HJ 1%<LTY?&\D"C!IJ
M:E,I**/P_Q;YTNG4[UF"C>M!.PM.E)RQ4OFP"[OXDSL-?CX*@#$PT7:&RPF^
M^^)&<Q_\3]/)V9N<^6]FN:+I51 [AG'\=31QO_^A"(!,Y\EE.)V'549?=?:Q
M/<;8#QWR^.V <8Y/ Z#O:#2Y@(5)=1+.)N,Z)#_7OOP,<#V>5<5%F(9B/,EQ
M_7EMX4,Q@WO=<GU30<W- @LK*0 V.#.O0KIO.&VK<%Z85'YSDUY!).07P.W#
MB:\*F'25Y+9_M97+GVZ?'@W26D2O4RB:MS>B*[T>-C"--OV*1N9R,F]J[[ZN
MGTXPWL,_M++.);%\7H5753@W4Y#8*R[T%9?\YV$UM,/1<';YJKWC&E][_9*2
M_/#Z#W_^R@5D3WWKBF_]SO;H?1_Q#(9 ]Z1>^]^M'OB-(QCUF E.F^'#+9MM
MD>%J1YR\M $Z%@Z_JPD^:C1\RB__ZEQO52GLR;;_+@K<=<OW/\%,BW?C)"K?
M!A=2MF?!R.#NY'*3^EA=6,3'"\!_"I2Z:]&_AV3K79+MCP=)KYO,*S/VU9\>
MEEJ?$0!^*QWHY>$?Q93U8-<K##V_W)A?:,\O/;_T_')C?B$]OW0QF_4N09;=
M\:E>M[@KM7ENVC:H6#0(NJ[*;-\VJ&^,US?&N^9H6[F(2V\4"MK(U+@3$"B6
M!&%"F;=&68PWFAHS1;G%S"+'K44<A 32V!(D2NI<)*60?.-H^YZ'2/MG@)>S
M';:K&##&^@YY/<;U6_K\,2XZ4F*J#=*&EH!QQ +&88D8 !W6E,$?&QA7&A\-
MIP:1:#7BUEAD4F(_X;H4I<564-=QC!,/7<WUN;-#CW#/;DN?*<(Q%E7IG$;>
M"M#(G!#(8.L1HTJ5I>,:TXWF[5B&$(TD2%ONX1X/J$AE1)%HJK3R"O/0<833
M\H';Y7PW[/!HV9[/W^]0>P<N3.KO-.LE2M_ K6_@=M?D(T,\"5H@237HW4PQ
M!!A$$&$2I)652JC-?C,"!Z&E0 (T;<0Y-LB6V*.2:4%UD-+IC5#5CDFE4I.^
MB5NOF_=(VB/IKI#4>"%]2-E#2@?$9:1(*1,0UL:RR$KOV49Y%\^PDK3DB/N4
M^AD 4PTA E%K%*<E%IK0CB,I5;1'TAY)>R3MD71GJ9RQ+ FW&"FL0;\,3B%-
M2IJR-!4'?"22;S05UI)&![HJ(B3YCTM!D>;:((<%,9H:RR/K%I+FE!3TGS"=
M)/I1E-#7/9!V+XBC+YV5L^,F,S/JA=HS+5;0MUA[I$/.&)TKF4.!EB#8M'5(
M"1!QI%2DE(0K[#8..>^2%]PQ$X$,=%\8LC<3>D3M$777B"I<<$YBCAR7 C Q
M5=<-FB"+K3-2"2IWT_&W8XBJ65^4L,?3'D][/-TQGDK+(]'>()&<)UP%B504
M'&')2J$-QS3LI(I6U_#TH8-4GAF>;BVLU0FH7'GWSBIH;:\8MO5;6)/.K<,N
MZ^[LMDZ6)]B6E L$$!-!>U,E,@(SQ$@LK38>LTAV80]_#)_#>!YJ6!G/$H?_
M<S@[?3.O8('#] ;5KW:SE1VHG7;=9K.]HOCX[K=WA[^^@_^^.?KY\.#XX.BP
M+R07%IV\&RHJ(I!1\285@0)4KPM^[:= M)-P%M:CT1Z^*-<N%_%^!'0T+OX^
M'UT6A V*E,(]6#0VSX<;\G557)S"HET6DXMQ  DZMQ6H &9ZN;RR./[XIO@;
M;&*2]8/B_?LWQ8_I;HI?'QS_+7\BK_]49'TK5UZ;30J89Y-DN$@6-"?3D/=B
M<7=Z[KOZJ@_M5?OM58OG7@ FP"POS2A=!_K$F8&A?0[5["S7?J.8Z.+@S?YO
MB^>N7[QX$ RK"J-1,9E/\VRGU>GP/ T7AEVE>G!IHGO%?E68 KZ9CV:I9%PJ
M\E:!\I(^?_7. :SDT)WFBG&P =7\##0;6(])LP44MUMP 8N1Z]45HPG0YS0M
MW7 V@FMAB-/@0BHPUU+L*LW<@B >0 >5I2HI!ATT:,2C$<@*;Y'7FAJLE,5L
M(R2-2F<#-P0Q&T&26*>055@A7P8M+8@9+4PK%8;CS^85:)));S<GX2@VN_C!
M7.9]/IS,WC7+=#SY6"_2FJH)A+:LX(KH;4JXDNL;-3X^R_Z0*&W:D/!Y,_OB
MS/A0V,OBYT__@.&$L[,4<)LQ+Q%GE>XY_OCN_;N?_^>.([^B(5?S<[">EM,1
M>_+N"HODKY]N/8MW[]\??#C>[]=E_?U[Q3\#H,W,#!/P)VAKB2X;M54-O !P
MYZD.)B 3D-=O^Q_[95Q__Y__^O'=4;\H/<_=:%U2-87]PZ.//<7T%',SE%ZU
M7$!'";4S;KTT]BA\07X(FF-275(EW/G9^+4?5N<C<_DJ_?KZW/BDOJ^$&0WK
M=S:1.?47_P+3>Q@OV]?G6U$8^]=V\B7-(Y7P7?C,OMS0,?;MJ3]4G9[[K3S!
M8LW=U#B2DF_M=!'8= ZJ:AVSA$R$H;XRHPMS6:5:MJL[U"Y_-B2WK_U]EOC>
MCBM3G$Z3%OU?LXF[?K&O*UN9'PC*=&-WO\I%9D:@5NRD G@N)PWJ[9OZJV5]
M>/,@#I#N./8>=&:[JX"U@ZD?'!X>_7;PV_Z@.#A\LW?+)7@Z?-GQ*AP>';_[
M5!P?%6^.#C\=O3]XNW_\[FWQT\'A_N&;@_WWQ:=C^.*7=X?'GXH?$S,,Q_/@
M__18!/.TK+!T[F\5@/?V>6M/2^:50]8[B;@(%NFH4_0!%Y*4P7J]$=Q\%Y_W
MVV%E3DZFX:0Y0FN\EQGD^G8/V:$[;1RZH,Y,3L;PN+9J63)1D_MCX2*LZNX,
M5=,AHMK>>N&Y\<+WT6=ACY%O]UK@:A=]!LK[/N-%C^.1BIAO<D]7"J4^^TJP
MCS/!739;^-Z+OSY)<X7OG(CZ9@H[U<.ZUDSAF54K[LM?]^T5'EE)>(X3[CFH
M;[C0<U#/07T+ABX05-^"X5ZY&W7 VA#>GF,KR>LF8F8M0N1956-]ZK2H)Z>/
MZ^;ZQV>YW;O/O$\-%*3P"+-4:$NQB(S")9)!>)%*<%F_D6G *%8*\Q(%*U-I
M1**0M=XA*9WD3$1C2KH64_KS=%)5W\@UJ%.<AN.3_:H*\'_^V'SY:XB3G-,$
M&_*?YKCFC3G/(>G_"?ZGD/*:5N)/?_WT]J[%NK :8/[ !;N^FRRF[YI%>D3L
M$?$^B$BTHU[Z@$SI,.(\<J0B*Y&Q3+%2.L*"WT#$4HL8O0((Q QQ8R2RCL.?
ME$7#51FU\]\;(I)R@-D#5R?I$;%'Q!X1NXZ(6CAM73#(&I*R4:-!NN0&$6D-
M%B%(AS<B<S@M0W0QH& 2BEH).F*D$7D<HBREP24FWQLB,C[ 0O2(> ]/1=^T
MX5I/Q5I.PK,"I!<H?UZ@EK'[NN'**^)*BHB5(':\*)$JA4+".\:=DAS'C1)6
M02I78BL0P4GLE$GL!"H1-2;5R+6"Z/"=B1W.!X+*7NI\_QS2X^!+V.6=XZ 3
MGFBO%?(^*,29#:D7@D41]&]I2\XT41L=(!V.V@N#O#$.[O$ETD*GL'K"A#<T
ME,%^9SC(U(#CZZL$]!SRW7!(CX,O89=W[YC%1@+4,>2M8XCK=.P4O4<!:VQ*
MHJ06&T=50HJ@+!> ?H$B3E-2$946>4J9,%)%F73([PH'01_4K,?!^W@A^GB)
M:[T0-ZY@DZ:!^)Y0>O5_Y75](*X6 CB?5,.<J3P-(Y.*75X?(DUN%!?]W>'C
M4TO!OH_0B^TC9*6TP4B!L*0!K ,AD>4R(J>\-*74GOL-BT($(J+F'*E DB2U
M$BD.XI1'2CQCU'G.NRU)^[Y"+U87[;'VJ>G@Q6)M#%&ZA+7>)=SDBB(5J48D
MEEJ4Q'%6ZHUPDJBI32V$#=,1\: BV"_&(N&85<)R;X/L-M9N6"V2#C!]U%KB
M/=[V>-OC[8O#6V4]U@Q;%%3)$)>&(25)B0QF2I?.IZ[#&STRN2NI=AS%4K#D
M(S=(>Z,0%=2Z&)1U['O#6T+%0"C5 VX?T/(XKJ3<"+.I7SL,52_6^H.+[W27
M=RZ2L.'":B)0T%0B;KA%%N0**D5I=&F=951<%4F.:*&MIZ@,2J?^;0$I%32R
M92FX$R8&\KT=7-"2#H1X8!N@9Y$>"/M=[B@0.BF)BLXB4GJ3='./-,<*N<"H
MDP!XQF_X0I13P1D9D50$@%"9@+1F< ]SH-:S&(UDWQD0,EH.N'A@W;QGD1X(
M^UWN*!!*RUBIL4:8&P!" KJA842B(*U(IVF><[D1TL>T5,RRE$<#0&@$0\I3
M#FCH4QR@U$%];QDU')<#H7J-\#X.B#Z6I5G<]T"_KPJS0K:I9+U;$NY?[/3/
MS1:L_AN!GHMS,_3/$KJ>6D#UGO@7X(G_\8[-66Z9AEHRZV.,*,;4GEY8BI0L
M,7(EX0:GM/RPD89Z&S=*6R!^1=:U(O/-I)JM"L1=.>G90*4BC2_01W^S!.T^
M\J_'Y!Z3.XS)T09.!(!P!* %HR0:I(@3R!+OHC0EYW0C1_,V'IT>DWM,[C&Y
MQ^0>DV_A7.(DE,1:5$:+$?>@^"J"%3*88X\#8<)N'#?>QKG48_+W@\F/%M22
MI]&TQ<I/O8N3J5F;M [U0U:?BCO49^LF03"7;1NM7EX^N+RD>S3QJY_,4T.N
M)Y283U-W[":+T0VRV?V1LO<N.$I0,-HD X0CRPQ%VAFCK"#6^(UJC4;HX!6V
MB'(7$4]24C,-?V(1B/4T1+'A%+K#.<K.RHZI@>(/7';LJQ3T_<5R]M#:0VL/
MK?>$5AH,<=@K5'*GDK^]1#95U5+<@R7A+,!DO JM,8(VJ6E$BG&">"@I4H(;
MI$D(+'U2(G0'6ADA \$?N)9"#ZT]M/;0VD/K6I*2<3CZ4J'@?0 -U'BD7,K"
MITQ2)XT.F&^X:*1BP0L%6JM,Y6^H14H!)@=B(L.!.;Q,"NT M&HR4 ]=+/>9
M0>NJLP8^I_;1*T,_!TL&MJH= VF;6>]@-E=]7W+A_&HOS6SQ2O(](>0/WYK]
MMPK [*PE_=:F[(CM<:Y^>-VN5_8F[;13^](U=2\GTA6:KN;G &]7Z^3<9:%6
M*N;<<DA7UN<N+P?:/3X-Q67JOQLV^N\6J:=>,0WPQBJD]O$SN!;F/9SX(@)*
M%7\WX[F97A;MI;-)\??YZ!+^J+\8Y#N\F844W94^5X!.Z7/J33^Y&(=I=3H\
M+X9)6(1J!A^*XX]O]M9XKL:DPSE X-#!WW[X>><8L2,BN<6.U)>F)[_*?GEW
M?:C<_E_WBS>IBSQP?G;4?Y.KNLA .Z#6_:HP0([5?#1KZ6EDYF-W6IBQ+\SY
M^73RV8S23W4CL3ORU8.Q.F"BY*^?CMO7&JOUB]) X+OW[P\^'._WZW)E71)/
MK96Y[U>FIYBOKLMPG#'YU[U/>P/0#=( $A&]FT\GYV%07(0<N5W 0T'63\:A
MR-'<H#3\_.D?\)\D!L<GQ1^WS> 6P]M]*=- '#&!(*9+@SB.8/H%&Y&1TF%F
M"::;B7 Z6N4"ULC*LD2\%";9?P11HYG1Q#OB;QK*FC-#KC7TQ)JA5W[K>(+B
M/7RMF?<$) -7C])*^_DT[?WLJ\HHX7M97;U"0)FH&BJZ #T25 0W.1FG=2Q,
MM9I4L+P>J/%TF!0'N-R&].HF%P$NF@"'II$,81C5#!9N!E_.JQ#GHV(T_ Q/
M<).SLS!VZ;;Y^:2F^OS=U U! 6F4DD9% :W$S]VL'OI:QL.PRD.=^GJ@2;=)
M5Z:?8#KIWD6%AEK?AAGNO53E[Y\A;Q;\,9R-0MYP6+P ^P$@ V;(:,MB%;"2
MR>*H>IVPUPE[";\#G1!X"RS1R47UJNB<F 9!S#@EJ.1,($Y3!QH6#2*E%EJ4
MP7NU$4D7!1;268Z(Q!1QHB)2G&#D6(R8EI$IL=X*<L4._QSVIU,S/@D@"F9U
M;>;+CR KWH8X' ?_/GP.HZ-Q6)/<Y_-I6(AN1%=E-_U66-WU)U^/3P@_%(W4
MB\-I->N>RE82T,R8M(A8FFH7N(",)1Y9$IQDGEHGW8/1PJ=SV+,X#/Y3$CV9
M#GZ:3-^&69C"+$!I6"&6:_4ZO:;7J6\Y\+NEU=E&JP.IV\CFD]'$PG_&8=8(
MY&08=(UJ/".E)]$AJCA+K;+3&0_&"-1^H)I2>:TW#GH>&D&.+R:[0I!N 0@,
MM3"CT?4$8D$/[QZR2&)3TS*PZ4B*F1 :D,6Q@*0JN66&@^S9, 9[9-DULNP5
MGUJUOH)ICT(J$8[U:W,"UQ798WX6_! LM 9JP#JSPW%M=BU_N9C,1Q[LO^;G
M9"!.IK71-I^>3ZKZ#;/39*@U8<*PAFX^R@_:*V#QBPE</FV-O&KYI(OA#,S+
M>BS9'DF/W?3E#XIJGNS0JO>U]9KXS=\_6+%VDUD\/[\P4S"*AR'[41+)9]2H
M2:]K( KR%6LK&0I$:\0=,\A&R9$GC%'OG>!A(UB-&R\%81AAGY)>I-?(*D*0
MHI9IX>$.2F\$HOM9X"R:J>Q7'\(TA:L =AS%PS#+R *<_68)&1\:[KZI)/Y6
MO(78ZY8LGDTZ1R+*,*D)!<%*P(;C+)5A5)B!22? EB,4?MW0X($^,(LT.6I3
MH1XO'+*IK1Z74;I2QE11H"LD\DUSKTMB]X>7[G6$+9NLN1Z[QBZ:JN!L*!%)
M]@LGAB)K8HF$Q,YJ$TQN(7DE1HU$CK$02 9B$5=>(> ZE=O%2 #FZ'VYQBZK
M7/ .GC4Y&[J#)G3C:/S3? ;D_L%<)@ZJ?@6RF.Z?3$-FJ-VQ1;> $[3#5C$\
M;R9>G!D?"GN9_<_SM K%$+XUBZ4H)M,AT#K8/I=%CI($BAJ.@::RQCBO!EEZ
M@UKK@.ZJ"NB_)KGCCV_2"1N\?ASJK<\W)+7RTSF,\"C& 5S0! G>O#?8RU*<
M>H7RFG69G4XG\Y/3JP%<]3'94MG,!VS7:9N^F^JFHP;P+(#!+0-#W/* E*,>
MX1"]DUX%[LQ&W0MIG I4(&VR!Q&@54NP\TMN& TEU0*77=$E>G7S_FZ=0$V)
M4]*,3>DSWD=D?&HO84O'0M#P>:,T"@TT" L&C%?I'FX5,L9Z1,MH,"9@F'2'
M1)Z#NMD]W?*B3LRWDY%_F-A/V/RBV>K:X_52]?"T$(V/K?$/9T'4.?<PH1&[
MTGO $58B'E,).^\I8A@[X[S!1FR8K48ZN!K QH7D'HZ:(QN515YB@RDVU@CS
MD+DBMPLA$GCO^D21IXL@&J1%K8;5+"DDH)8O#Q+@CY\/]C]\?/>_O=*WX47\
MO^\^[O_6K\O&NB25]O_NOWG[:^^2W^"X=$;2.>"U-'CJK4;2&(^X\"527!I4
M^L"MY"6SFYT;(\9!:KC(R53;SFF,C/8.$>L"QUIHB1\T__EVP,O)WO55E9X2
M>#M'"\9'97B,L';)=ZPX*.:A]"A& THYM\1CLA&P*XPK-0&"B3C9>QCL/>[!
M_,/<:X)+90+O#BT0V5%:2+C9.7I@ BM'2H*,$@1Q4X)Q9X5'3$M)M0Z";#I'
M372FE%8@HI/]3R)#VBN*2D.\5Z42$NONT /MUBG]@ARFH3I/SLK/872Y5_PS
MP)RF\$>3K/4EQU:/+COG#=",AQBX0=@:F3SC%,  2(<Z[65P1D>]$4I(-=',
M*(U =7<I>"@B'1U%$D>O@F+";PH3H))DY]>1 !^'U>]+PY_LRK+7I$.4\4,G
MX[X4T2%RA1%F&/!!@NVE64K64-0HSYD/6_#!.[@$,*7TZ<C$V( T 7S005+N
MRA"IMD^RW9W:[2;3=[QAO;=Q-A4LT%I*L6O LBI&$Y<S+U:RBC+UY+R(E"S<
MY%=<3*8C?P5JGA#[7JJ'YJ<VQJE-]S;NW_-A-6Q[>[PWQ=^3_S-Y?S>2S =;
M2*2;#AY5"I7X&PD; .:#DZ!58(LBI8;P$ANA-G1+2XVU9?+MF)#B$EA A@2%
MI! L4F49B)KNZ!)$[\D.@4COX+EO$F_OX_E^W!BX#(:"M8G Z P +S@=5=J(
M0A#<&PIF+=LL!\V#+ZEGB,K<$!UL7H-3VY08;*FHI$+3#L$+WZ,=A)>.6JX*
M<\U#0#ZF-.)$#EK3@++?2I5::[%Q+*F5H\QBC61(47#42V1Y<FR NLJ)#X:;
M!RT]=3MR*#MU-OW=6Z[>**%Y=$B7J>V2S)7D!496&"X#)]9LEI.WAAA%4V2$
M=J#2<*;!BC$<$>.#3)DOSJHG,66Z=,[43<N5EY;2%.+JB,:P?UH@(R-& ;-H
M05'%)FX$4EM+?;3<(45*#?? 3JL4MJ#*6&IJ->9/L]V\4[O=6ZXO-NCB_1!(
MNPK%Q\V. "_)H >.3G4PZD(4D_D,C9IU682RU@&H_VN&8-S;NM3+YT4=M\/)
M+!1\4*3,+(I?MXN:KEI+@"I6 J&J?#%Y_>T"</]/43QZG<B'6NB-4HEI<C#)
MQ?1&X0ORPVD=]?L*=G]^-G[MA]7YR%R^2K^^OE)N$N^5P_I]3>N0^HM_ 4(-
MXV7[ZGPK"F/_VDZ^I#G $UXMJDM^N6$ISF]/^_I57E:)?7SR)EBN45E+5:>+
MMBOG(-WJCBK(1!CG*S.Z,)?5ZS_\^>H.M<N?26[[VM]GB>]-Q:8XG2;Y_%^S
MB;M^L5,3F6V+G1_H4Z&:S+"O<E#[:#@.N]B&XU0X-0G$-_57RP@W\R"2J#M<
M_J SNQ]GW5'$7C?U@\/#H]\.?ML?% >';VX;V_ET^++C53@\.G[WJ3@^*MX<
M'7XZ>G_P=O_XW=OBIX/#_<,W!_OOBT_'\,4O[PZ//Q4_)F88@N[A__18!/.T
MK+! WU6Q=_,7+<RC1DEHK2--N$AG^)0DOWON7>FY0:63NG2NU#@%:%^QCDK"
ME%5@.Y<,+"KB*5A4)9C%E-  -I64CJP%=3>*S?[8KZDUJUK-VV'E1I,*3*-C
M>-%?P3SX_0]% "/I/&F2TWG8O1CH@,)]W>[SO>+]P9MWAY_>%?N';X$;WK_?
M_^O1Q_WC@Z/#8O_CQ_W#GVLVZ.V1>L&.0/=NU>=E1MUWLCJ[7HS&VNB:F?P"
M[,%WXYFIAM5ZSJ(I1BN&G5LS[*ZQ$W_\= K(>&J&?P*=;V]0O)_YO>+'QDQL
M+FKLP#\5/QZ:RIM_ORK^%T#B3X-4EZ.:&WADRI?,J6GM8YMQ^"(D9W65Z@+F
M.OBYP*B?3U-]&3<S9WF@GWY]C][^^G'0NFCVJZ%!'TPJKN**:3A)PV^'E'Y/
M+UFP7CNXO2(GN>8'I HL5>O76;MZL!CAQ7 T*B)HS\799.D$2F^K&L^:&14.
M%.MTWE;,IJF4I(,KJS3*-Z?#L<G.I\78%^F?,.-PWIZS?S@UL!NL.(<GIK7W
MT_E)4<W/ST>7Z>?%,K452_;6QP?[G9U=/A67F9SG[4ONN,_#NM8$C![,SOJX
M9&)G!H8&,T@542;3RV4-;OC:%%5;KJ88S_-Q/[S?3>9CF%JHOK;T-EQ.DI\@
MSSG;7G6MQ_.\:MO>E^(--N:V6+?E'(%^<RYW-1DE]WURO:53Y62#I+5=%O',
MIMKF:GUMU&E)FC5</B5L>49Z4TV\PUD!V]4L)%RR96KY\"'EH$\L $#V*P)!
M-QNZW+J&%+:_;$%4:[LZ]D#_<>MM>9WR  )<M+XRJ11J7;VI<&&:*:!Q@\['
MHU!5BT&-)[.T^U5=(N=B6(7E/IR9RV)F?@]UL56 G7D$*JN+P"XV93BJB2Z]
M+.503R[&:VO;P,R2.M,R7*&\V7#%39M+%[9U9D.,M==UK4'!&N^^[+('3R=C
M87-@ 3)7KI1YG9^GOQ+VG, &G32;UKDS6U=Z96T9X(4Q59'S!JE\L(:]LX0*
M4Y*-(SC&G'/:I-0#G\YQ*$,6:S!<M+?*.*U,N5ZYI"FV,$DC 5[XI:V(W)1?
MV-'AK":=C"LNLM"I@IDVK1]682TAXV0Z6]9CN'+!8 UD4Z6%?*RSK"F]N'$:
M1BW<+O6%L^%Y&(=:BZA+?ZV4%JN^ L17Y"R\!8 4H"HET2?D;\I(A'^G:GCP
MRGRF9(I3T&%07>.L\, 36?,!%$--YZ3ZN_/%<5QA37IK%D>YL-Y:G-2U\@Q$
M['28EB35([/_ F#,4F8!HXO*U,L#,,"NW^'9Z5CPLI;L9^<A1V>U#Q_ 0*O\
M7E!&TMZXA/9ID%N'DI8T/7RQ 9.+>O4!U*=PG9DNI$'RMS8*4Z/DC0$DJBHU
MHX$;OB6 KTYZKR@^+'<]HTT]E 65M5252QV$X9D%/31[+K?J:Z8I0GY-9>]K
M:3=\.<^Z]$HU]$9TP8AKC2%]ETAD&"_3)<T=]2N'8S>?PIOVBD^YIMQ9TK56
M:HP_'>>V-/.51D.LWO]O1)&V1LBV(-*\!J!T%"DV(^U&*M"W*O%7M<4^N>^:
M HN7>:E^>KN?:.X7<YGW)C=O6"FKWSFARR5V2E.%N"H]"%VLD(W&(,=PX*7T
MS&*Y$2CEO?6IFU^9JGMPJ2VRJ2^UBCC0DC(L?=SFZFO.A3\NEF-'TK9CI397
MA&UKXT_KF1<W8>?OI8;#KAU4/^]_?/NA=T]UQ3WU59=4HN&?Z\+#^Z!'VR%8
MK*[XN"J>WZZ(YP^@@;0MZUKO4-[NA;NJ98PU?7-IW;9>LJLF['JGD,+!5<,L
M /\S 4$_FGCCAID16X-[Z459]5+EL5R-KKBQU^JK=P^:G[/NFAP RTED-XJI
M0!E+^E!" _-Y,LTB&J1B0KQ:LL_3E=G]E=[6NJFNN+^R%K5:QJS6--<7<.G-
MVKYJB2A,KH>\MH#9VS<?)ST5&#BK]B>3\60Z/0TF>UD6BE*KX34%V^IV(GG^
M\V;MABL5W9*&=RO];@](;!0^)S=FJZ,]D8+T4L'B8+PP(0:+/;TI"\!VGTQA
M\Y)N7\?PP2O"H*'PNKO0T@F=+8;:N$,1'M4*TQ7_;39A:J^>7?P*?R8^2T&(
M:R@P"^YT#(MT<KFM&N "CHA\7=T!AJX"3K(TAXEE&LY;&(1G0^]'H?UM@4<-
M'S7NS!6G86.F)>\<($AK.;<HMK**5UG_7Y-I8VI6=5C9%*:YGX]YS:#I+5;W
MJEMQR=9.T^3H78QE;:'GS8%%WL=V1S+3?&V]5Q M]R^M';+9*+XA#2UL7#.^
M;&N,-XLQ.P4F6.!1T;A<DV)YB3*/UT+-)^1*K]PK#F+2RFT8#6&;T_VS-L)T
M/IHM8/UK0+NQXXN"Z(V]FP@X-W%(MM.H>76>0+TEN?I?8U5E&V'#4=W2L$UA
M@2'"K?6)3!R.PLV>N^239)0T+MYJ^*4X W8^7<PSPWI8%:?U%'/@[>3F,NLN
M ZNI$&[Z95%:?O\DC-WE0CR_^V5_*8#?&9 -R9UQ6;< 6S^#F"=OS_5C72YA
M<_RR,K#Y['0R;;AY*5,V!63M_QA.5T*/%\Z0Q,2K8@$,D@QF/OQW'Y3X\$&)
M:EM83''3N,0^*+$/2NR#$ON@Q#XH<5=!B=DCMQ" +\B/]6$_Q^/]W+NR'GWB
M'U:"G+(*WVQ%UF7K/]Z&^:QRIZ/TS<]G]F_%C[/)2<B&1/HJV0F?AWZ>M<=&
M!<TW+CQ5[UL[<U&7H[5IZQ? G)<V;.O_W3A:Z^LN]'47;KLTS>'KPF9J.TD4
M^Z#2#NJ,2;!Z@1+_ 8JIGS01>V!L_0<TO/3YQ^34;3,FZSM6:;PX;L]UER;7
M5[H'G[=!%*ONBBWA * .UA$HG3O\BCHJPU)/.FD-XH9II#3\4YI ''-.R\TX
M=XH-L=9A9"17*<X]%8V0! DMJ4[%BJ673Q!Q0K#N9$& VI6;0RY0$X:Q'K?1
MDLE>L:CCGK[+AD0.23L!6AL7_YI/AY4?UKNW=!K5=-L&>6<G>W;"+"(QEO[E
M'/&6/6>)(D_"."<\-,$7LW:H==!D$W81OIP/&T]49CXS6QO'7K%=X"Q$1/WG
M8E3;0R=S-]A,(U>C#+=[&GO1T8N..XJ.*RB_UWR1?6F-H_1;'K^E%VV[0E-/
MM=^+V^\%2-I3\[D^9UJ)&$D.[T7X0#K#JF]<B;';)GVK;YYW?:VL'&O!>/GJ
ME1%M/<K;V3G<5\O=]0=QBUH+[3*U'=:69_=+ZEJAC.;H=[EA/VYH?Y_J2S8.
MOHL+L(Z"O5QN399HS1,;JZ=(?73/YF<IQB[IBI>]J.I%U5V69JV=%F&9[_E>
M<;P@Z@U*SM1HYL"?)J])EEAC>!.H>L-1G;)@IJ-AG4>S^EPY2,>%]66F2+=L
M/#P%QGP);CY+T:%OE^&E0.W9]$F1(.VYV=6;\\%>J_TM0B/J<\SZ!*C6\IK8
ME.1[R%^N9W4TD;&S_&$1;M'5>$+M@L>I#I^-) 456HE4- )Y++FA4F$L-DH"
M"QTMYCR@TJ>2X<):9(*@B#&+J5#,<N:O*;Q6[<I\ZF19^#I0H9I=C:NYJ01^
MNAELT2CV5Z*JOZI)W$M!R,5O>PUAQ0_]->=G.K.O\6@X!O/T<SYZ!Z+[&5 M
M*9ZPXD=N-DDKG,!RH<35"+BXXWPZ<2&D0].F^O DY7KD9(J_ Y:EY +2 GGK
M)1T#-;CZFL4NIGK&^1W9U!XFR,M!+2D1,IQ, '!7DD7^-H<A7@1 U[\%4%5/
M7=(-?P;A<9Z'N![.N!K!.!DW=<A&B^2U5)NQ=F79%$60DO%@"M/F=2DY] :+
MN8AJ6 V7O[)2QB<]*8>3Y$4O@&Q.Z_7S\VD* UJ0MQ_Z3,B3\QSLLAAR=E/G
MD!X_K-R\JM;S9YJ0EQ2B<&*FBW@@UYY!+6>838AT\^GPO"^?]NCG1&W)KV7H
MR_OA67+?=FTK7@)67O'C7;LWR[BD^HH;' NUS[KN8*AQ^FTX_$)O(5Q??[H.
M4PMF5B-ZG437!B</4\%-9*R?G*5VT?!W#$T.7KM][F#_8+%WRY3$E3#!(D>(
M#<<9WW,R_* X-L,+,QX4?YL JOX#_AD4OQAGYH/BTV0.^/N/23Z)^02@:\[A
M<WW$\HL9F<MJ".OT4_"-4*E_:<]I8/S'IV8XRIGEZ8>/X3Q'M*9?#L8^.72&
MS1'/ITDF#R"HU8M^&X;9N*G1</4!=3#C<#0\/\^D?/TI4$NJ6\Z!GFZ_EU'W
M[? 6O-;QW"H:#/:$!22T2'WBN4%*18ZT\MA[KD3T?N-X*9)2BY*C*'5$/'"P
MG[#P*#ABO/6F9,H]9FZ5>E:Y56U.:0KT;>-SW6D* VYQQ*QF.2\/,S<22Y<G
MHUL2[E>R;*]-DEZ<BG8^+]\$8RVU"@E+!>(8$S#/26K*H5@LF?-*;[1F5<Q0
M*RQ#OBR!C D'DUY*@ZRC7!I,/67K+9YSD]ZK9Z/5Q[R@Z>1A5_V^<"?IN7/J
M]PO0^1K^;?WG&^$-:^?4P_9$9:'-K=8.6"3&CR87Q6I]@2H9FQD"<L48,*D7
ME9,V9&U.]V\3[5<RL4!C^&S<9<J7#ZN'Y&GP[4%YMOZ:F/0TAY "Y=>.S*]]
MZ]))F@Z4JGS[Q+F4IA%?%3\._]3\5LU@KU$^$<\PM<QH:0[+EXDJU?RF;W\-
M+X WK)RSPY.7<?FYD, "C5OM.1TNW/(M\"!X$;SIGMAZ3;W$J%SR;VHDJ/:
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M%)%+0H&XKAKC*0<)QI%C 7(9A*LGS;N*:NIH@$"BG<4JU.I'DQN^$6%2M8W
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MKV#B8?KN2U-3=3_% %?!'YLOUYY=L;6SJV^VLJ #3/6UIU??*Q?LEL=[8.O
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MEQ(/4L$4(6RJ6B6I(Z%4>J.*[%V0???T1;X#<*^/1%;P[>D&V$1X5ZUZZ6
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M3" (E'-D+/-("UZJDPS66\5)=Q&$VU&KW4X*Z,%N*LLGE8)B(F;KY[W%II^
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MGD 8:N%%S45"F9^SV?'4\K#YS):&UB8"!MK90=._VN4[\KC<O 'ET,,R=#2
MW\B<['L*WDSGMADWN68!GE$(#YOJOV#&06":"@#2LVVW AL 5FG6]I^M<4DN
M9ZQE=L#K+0REY6/)IC>9U+ZE6NG:QDMC78AGD_H\W\K;YF0-CI=.R%E];B?%
M+G3-(9>>'<8I 70#&S 9)QB?'\=I;IORRQZI@]7PP(IDLS&'MVWK"E>D@6%4
MY:"@\I/QM! K-[F&/!-<7J*]7#8/I=HOUHC[,F=&#=:GM?0A?HJ3^FQINZ?P
M22;,!-/4]D1E&L!9'18^ERJ^@>&7,IG\,G]?3&-'(]O2WRP99F -0L?-6:J?
M3V/7&-65V2P[!3.E<;%ZRW?NK&K;CK]&3GMB6QM:J+[SMT/,IS'E2>@=KLF4
M^)HG1!F-$#2+"$&S]8@ES[2-5(FPE0&&N,A+21D*,F\SI 0P"* .,A3+**/B
M6L2-H/E]ZPA 7G[O6 Q6;<U_Y"EJ/M2OES/4@IT8?ZGM++PMSJ5YM\C_.4[K
M?]M 0J\+Z6$]6P=!>+M+&G#0JDMZ_KGN%01JWRH+2R==2[I,EU^Z[6G=],E+
M*5RV\X4U:@CX";3IM!B#W %=NG#M;&8+N7==K=@D+JZ_N-W%]YZM,<XE=9NM
M;9=696-VL[W;)D;-)6X><&RVI?">?\7,U#K.#8WSE@1KHYVO;4+/+7UMI1P,
MX)>)]7^A]_ZD!KN#WH*U@KOF6Y0[EF[L7+ -UOHTFY;YUICS7Y:KOK&4 X'H
MHQ*(TH% =" 0'0A$!P+1@4#TJ57AF1.('D^K7Z.;M6>YJ&5MU16G:AR?95Z!
M#+''.;3Y[;=7JV,#CMX?+X\*>$+ '-<)I^PRUY0[OE;8]H*=JD1S2X"[SF75
M-L7!&ZV^E4G\UK-=$$R>CINFA@DKAR.US&QMG]GJ22VNZR-IFF1!ZH!];I?-
MY\1S"-,"\RC)0)WSE+BX7=@1HI0!)R2C@^^84DH9/3)>.4&854:9RWGKU]'-
MCZ;-?+;($_X*0&=..AP6;IU];6&(7I;YM/TW138 ;\6UXPA6^UZS[A2-O@D'
M292:("QBGI/<CI602U'#3SA1X;15G.U?.);[GW_ K+S/>?APP2QP4^H ?FUC
MH.A3\<>/70#>5&$16^+6^6(6E\>YY-S;\M@-6)R'8:Z3*2F&14*<6UAB[32R
M7C!$J$TJ>A6)VNJOQH38R(E'T><S$YDO/*$48<R$8L((R;>*JC<7^VU^T?'\
M_#6L\^::Y7BW98W+WT?!GJ-<B8*>B,+N</$1@M:*Z-8I]H_);C&=Q*;00F4Y
MZEQ4NWVS]%C-N$L0]-,7:45]P-8C%R.8&Z,U,DX$I$G>24_$RBN(K^_OBRZ<
M^:O5+/V>)XEL.J9I9OTL!JDY3H=EO>WK>C*QL^9]SI*M3!&^%8G) >]548:+
MJ>ZX^$X[W5RFGEHN,$!(J25*FWXL]#>7:?X*?Q?8K1HN_VG\<TOK5W_.3(%U
MU6:/-GA2;#Z,+6=W,ZU7QEUK=&1K><=L"W\:=_>[: LM9)X.\)?KMD6;4E3=
M[9*N,NS+,X[R'UMNP7DAY[*9DVPQ"3#"/ /C,A@7-\9SD7-=[G[.RB25MR\[
M E]A+NR^>5 =^ES# I.6^18^7]IOOI0]3"LFNN6Q8%T93+.8M+0L%Q1C55QM
M8M17H/<V,]SM1%QQT.(LGK8L:S 3?3,(PC$-2AQ!N;%#7%B&+)$$8>^"4YXS
M *Z7#8+'.'%E.<("RXQ9)'S'! 0.RID0A!2*7#8(+>?:VS@_J<-%,<7Q<K)N
M#S^N.[)7]*OV],=NM_Z*T&^YW7^IM"+O+)XL=V5W; YL;BH4/<FG92VK"O)1
M#UUJN@A?[]Q1D%RY)#B2BF0J7Q*0D]0A1:P6Q@H0L"UWY&5(P22*=(P@L=Q3
M9"0EB+H(WDWR*+&^6OHN]L!^_?1NO*^2=][/JJY>5K<SYQ5EDB.O P4H(02$
MPOE@8QTM\YE:/-$M_G JK<X-,I*D -_A@#P2_"3@.\)C%^ _C[C>C/2R<.L2
M(<5SWC1<6<"2=VH=>LLH;/NG$=1[ZS@32%DCLD8HY"C!2&JCB*"1L>WS9*V6
MW'H,T)USF7OUX2<1(F(D&<X4!>NXU>]QE4;\<:G,<4\:HOI9 MTR3[?U+&D\
M US6':^9G6NIFVLSD3FTZXYR*D)S;?'C:0$U=Z]Z7-4;?JW[]MEJ=.%&/SV;
MQ%)= 9C(7E3P75$4 +=IB=4NF"&G[3GI9#F3O</@C,N@ 8<CDAQX.!9X9N%@
MB$693%0,L[25 U18)<^=0,QG:AEF.')" 22/0@;/D_;87K8!?\0S>UX$]#BM
MA>0Y5M^I^FQ#]=G7"WK>]:J>9_FR7459/G9E7@-8#DNMW+G!,#^9U8N/+5-?
MZ!+'5XM=H;^&6TW;>HTEF7=<OWQ4Z,.[6I EBK\,VL\F\/[M25 7>T&KB]9/
MO_ZCO;;8D']V%ZS.C>ZL$MBH_/%%.;$#T[)L-FORT=4YG] =YG;5#5N2\DGF
MZ$[CED2[M7;/V0[E%IF/TU(;WQ9%MI69/JY.6[FT\LMBHR[ \]V6S&9U4+D^
MAVO7FZXEQ_C:T4%G=AQ0]E*73@5_;LOSX5( G27W8W=00D>%MIKHTJVPQD\)
MGR].6R&_*D)O57154W:Z.L)[Q;7F\F(M(^TV@U7N>=:1JAV66M?+PC'N5K?-
M N0#.D(NVNJDZ]+&YEIM\6HD4YB5\JP+<1A/6_O<]O6TC8#M.5>Y'+<KG\V)
M-6^;U:GEI9UA/?T6(@AVGJFY_;(^4\]6NFY,D?(Y7C32;1]>WJWPZD" WD4C
M+,9HB3%(6N,1=S$@&Y1%P4<L=%(ZL2T2<T5P\,)$9'2FB;0!HA&M(G*.&YN$
M%%KSK3:[N@Z? 9>W9RD=3?T,Y@J 2/O?F\<A6<?AIVNYZGK)_A.ZU\V&X&,W
M(:,NQPTW7-=?NW'Q14[O&ZA^L#Y19KQ A'"=66HUB)2S2&ML75#$*KS%)W8;
MD2K5[6\O5*T5J<,+1;LL74?3-\OY6Y;"EZVH?4M=7_-$Y829"V&"X>6K9C5\
M7#I.6NS13_ODE->26#!(G&7*XXA!,*A&FAG,K0]"^JT6T+O8I[<=%%O62=S7
M3ETC*'TT3Z/N$)<-80'IL-./)6:Z.+Z@=U)B*/:PPAX9I3GB'%MD?++(^9"2
ME-$[OA<O=@0H(.4SK^-O^>C9H]7DM/SV#RHTM)>[#MW9D*N#9JOQ*3QKO@QU
MKD%$ZUFWK<19RW)QXWQ92>/EDZ.RH<\M:<-90H__XD=KF^4M:_0Z/K9?EX=>
MFI;$G*4<LWR.+: 90C*0T0&19 Q1G%MJM@Y!84X'&K'/U":9VU^ 59%:H"2Q
MQ-QK3\W6AN6^ /(UCJ>GA'YWQ,7?AG>2A')B*454&(PX)0P9AA62CGC."$U,
M;%/QWT&$'M@[W0P$XW[N!5T!;7;E/'HI0XXJ%0B8(>DQX&#J#=(&@O7D.*.)
M^(#95M7.;62H!%7;@=/K;HX^V"\/<9!('^.E%M%\W5&%<2A0HP,[]X0N;"/+
MMMX:>O.WVE%_; 4/+AB+B%/Y^&QGD$O"(JN=]!(B*VZWPJ?;=)HO3<][?Q+#
M8A*/TQ^KE/E1!CIE,Z&U/X==-O9P&M9DZ;!-Q99&P0\PB%_RX=$_5!$DZBQC
MIMDB_O 8&.K:=JE'S&I#9%Y_+NG'4IT^B]W9IDV;45XFC2]M3I?/;ICX=N?5
M8K4W/I_9:=/JWXO'!:[]Z5%K>X.K?V]GO'MZU\J;'Y\[>V&T^5,TL>?U8@YW
M_!+#R_;N!.,#_./+[@L^%S"?-?%%$\]L[D.!)W8/@">LVH\_C9MQ69GS%\MO
MK%T(5X;5-)2':#"8G/^8VY-W7T0.]'577/>Y.%!"W>HF__ZW^>RJ-^QZI#6L
MDK/^KX^S>C$-J-.D5/ZY6I/R!G/;F?VB[<_.?]@Q.653-U.<M&($,OARU8.]
M[)<_FU?%.E=+_;VZ-5OWP'ZL]Z7N$M^?CK+FUHL&]+O9:"+]VSS<9)+:07]M
MGMK5P>P)9NI6<.F*;M/+4P SGS\M;0-WG8YNV:X8^0-.SOX:G'>>SGYYZ_-A
M9:D/T[='Z;K&[!7OM&WW/$Q%\K<R<5>.^0J[]TB$$[>4QEV3^RJ38V6$4EBR
M+JI8FIL(X4VFI)/,)YB5?9NP*VX[K?OURIN"L.M=_W7/:WNENC_DJY?FISTJ
MP8ZN/188,Y8@R05'7'B'M,(4Z11HHB1HJ;921L2[$$Q(2%H.L5[0%!G&.4K)
M26*5\]R'RW';+XMF/(U-\ZH^=>-IJ2+9#N#L*H7TU1 NJS-\\.9"C^]48WC%
MS@<;8;6["_U;59C']#E+K/WL?<[O$$S;\<5),8.K>3::,WB8S384#(Z$6&1$
M/FQ$Z80<-AXE*D6*.!HLMQKQGMS#Y$,PIO-N.Z/5Y.X$"+C^./<07W/0_.T<
MCQ@)L3M%_;RT9XAU[J6$13@KWPIPEZ8=?,^ST9[!]VQ0$$1/.=<:/$[V/4DX
M9"4GB KL@TZ1.+G5_M0KWU.T>4].AHS,5VB3GI>:#,'-/8.;S&#2G<Z1\VF%
ML;WTI@Z^YMDHT>!K-@IG8N#.,8:(H2D?KTB1$Q0\" Z$!XHM>)^^^9JE'O\^
ML=-YEU(KJKPOEZ-WEQ(_+UT9HII[J5PY2 +5"2V:. 0USTUY!D>S4>7K$E>9
MM2APG\OFM(*@AB7XE[9)XZ!\W.)UN8VC*16:^_0RQRW;W?3C;[G6LZCR<?I'
M$_>:0AMBFR&VV8O2+?LC!O_R;#1F\"^;1+[2R)2Y\*P#7V$(19I1ARS66'!.
M!:=;'0!W"626BK:O6(.,N&&##QC"C?LKQM'E=J_!&3P;U1F<P88SH(GJ(!F*
M,=>'&1.0YB$@8Z0'HT],W&XI?.JLUC7MB?OR-UB.%!ZJQ8:@8V^[]H.OV8_6
MW+4KIX=Z=<=%OU6#R??DKZRP+G<<(ZHL^!X?'3+$8>2M=-$QBCW>ZD-]:G_U
MKI[Z]4W_/3DHAG=S,#RTFEW3U-5#17NTB&F]Q[7<]2X>K9N2_/IKI"S=77&/
M.I5WMA^7(_8N=1$/GF^_*DD/:-;)4"]R)/N$ON]I6G9N,AG?J1L4,0;+#$7*
M$@%N,&!DO/#(!8RI]\IPHOOF!O<;G0D\HO11'> E 7LN+G!?W?5;?O%[=X'5
M363QN_5L-^Z5[X>%?B#'_DQ>>=B.N)>ER(</+C(K3W>,[("3O\&\ZM"VOD^R
M3.P4M8!0><0\-Q5R9#U-*)"HHE,\\KC%P_O4^+9K[%C_H-/KWUNUWEN?A]##
M/O@^(.W@>+R?+?)A ''6Y).()FC)D#JTM3\[71H\T+H'4H9RQU5"5!.#.*,:
M&14IPDH#:L6<I/NU%NZ]"K?3Y=^7JOQ'J\E=6_O>\BXC+';S\CXOA1FBGGWL
MB7<N:(U<=/ YST:%!I^S<?J($DG(&! 3'D(?S?/YY%JC1)U*E), %_3*Y[1,
M*:T&WX36^[:L*=C(P=<,@<[]]>WU#HK^P=4,M5A#+=:=S^=C'!O%$/5)(0Z.
M"#E"":+1$IN23X''OB7I;GD.Q>T<EAHI^<!=BD--UE"3=;^:K"M.<1B\X%"7
M-=1E[<,E<AZEX40@'3C.[DTC0S3.A&0*4PWNDJ:^N<3]^T$B1@(_<.0VU&8-
MM5E#;=90FS749O429(M]@&SQ#5J6*QL?!N;$ 64/*'MO*%NFI#0W 27C(N(B
MG])N?4)*4VETY@1.O>M^>!?W1KK(^$B1 5[?U0G"SWG-_F,Y@=U!I_![&'_J
MB5&]].RO/N[&$P*O&[_XR2+$S<-A)_$+"B"X[<&=H*V+T^G+,&[.)O;\1?[T
MY9D-83S]N)9V'+</[D!$^X=\FN@XG2_'4+Z*XC2 ,'W)+Y./OES)U9<;"L_U
M[[][NN]W[-W]II\0MB&,6;9: ?SWDQ4&.[,?8PNOD$TPU!=V\MF>-_E$S/45
M6DY_D;VKY_X^4WQO<;;5R2Q;M7^9UW[W9.\*5,L-P;K5LV)A7P *C;,)&-Z]
M'(-;CF&M4_6J_=/%CI_]C\VS:;\[=7_(-]O?@9)[>/6C=^^._SSZ\W!4';U[
M=7#+*7@Z^[+G67AW_.'-^^K#<?7J^-W[X]^.7A]^>/.Z^O7HW>&[5T>'OU7O
M/\ ?WKYY]^%]]5-6AO%T$<//CR4P3ZL*K6?_V[H#?/@SJ2\28_<*-/=A!$]B
M];%CXZOL;-SD(\'3K#YMC_K.L+49%WP-AO+-=&Z;<5/!_\YF@#AG\*3*SN>S
ML5NTAUK/Z^5%__8OFA+ULH2[I_!1J#[7L[\ O?I8C@[(MR_GBN<K:C\NI>6?
MQ_.3ZN.L/9B\7LPJU\'LZK2>Q2JF-/9C&/CD_*#:&'DWXG&S,63X=5K/2\&Z
MS[>'T;D(>#HL ,_DX<)P2MG'V6)V5C>QN=I"/ ,Q^"/O?>?Y>5?/8Z5'55X^
MBE_^YTHT8,G6J/':J*9<1%Z.RCR6%0)HZ!=-4^2E/?A]?)E/KYJMXB3X2W5F
M9_/V9/G-Q7NV2W$(TP!SU"PFW;S$'*Z6C?P"@D;5Y[@QAR#CT_+]63V99,49
M9]<3F_+U56IA_45N,<K]!^@AA2221(20!,$VT<@I(9#S-D1%E/<YV+Y_@/YV
M/*UGX_GY43<9.R-LN1%AB^N8=?3![G,-'E]8*KAZDB<7- E6>^NH[8/J&*SH
MA?R O$SC'"3$UZ>=^0/Y.H]V5D$T!I^^CA[,-=@"1MH[Y&NS6VPM=O[RI 9[
M?-GJPW1<*8)@OL'@;PEQE<<"*S(?3\J'Y5=X@4L.IW?22PVS5@6)L*,!<>4M
M,BHQ) E-T6MI)-]J_5 $!R],1$83C[@-&GY2$-PY;FP24FC-+TOONS@_*FOT
M&TSVX2<[GN2)_E"_JD]/Z^E["*;^.@%P&&?-+^!L_9Z$F["#W;FCIQ/N@R<<
MP@."X,=W.>VE^<XOQG-XJ-_YWK_9ZN^@RK;Z_<2"P/BX*(E ")5/873GS]4W
M'T^KP\7'!=@U2EOS"('E^^/59DZUFK=L6BT8QKSCDRW?.,0VA]%+LV9DTM9;
MAJ+U8-:XQ\@X3!%/W')I53)IB_<[8J$XF$$4-=:(D\"0HS(B;92S8"4E8_X&
M6?-7ZY/S86:G35N%2?9DTRB6_31J.P3'SD%N(+KRL9>2(I6+F#&+'(&UYBR"
M,Q.,(<J\)2H?@X7E94D)1 F.N4>1,@,RQ3#XOH 1<RXQ+0.6N6/_:DDYO  $
M[\$4Q=_SS&R*1F;[#>_G@"":XW18$O;V=9[+65.^LA(<O"XX]!JYD0=T=R?]
M$XC-&6"R)K_.P86L0,0$P Q>MPMN6YAU"E, \?1D_+\K@S.>3NM/\-NG L5@
M2+G"<WX"LC8^/9O5\.=Z,<]P V+[*81D\QQD-U6S2*",JXS 9)PBFI_,(CQO
MFO\*T5X^UJ59&Y*;U8N/)_,\FJ/\T/$G$.EI!5 0 ,RX.<D=Y;,Z!^#563V;
M)T"$]:C#F/F6_WET^/L?;_Z_PSO.]*4=JV8!T[8V_?) W3UQI/C+)US_GW(4
M#<$Y6,MI=73T\ZBR9V7IRLK#!,[R4E1N A$[3#&HSF*6H^_*!H@DFS:UTL0S
MF)X*?%-=.BQA 5L8GR6C.0%460+]__?-'X=_#DNPM02@.9^L/_=Y!^+G5?0T
MSPJ13\[+F@9*=#;I-!*"H)E%UH4:;@DX8#Q-[49:4_WDCPZ/FI\/JG_F-2H4
ML*%=T"]@?N9Q<MY#TT\5QB%QI*14B#OXEPM4(RFXY(0(P I;D;OD$C-P&,@;
M#;$/=@K9R AR)BKC*79>B,NF?\WDOZJ;K] "W@X(B(->V?-EX)XU].*%5R0;
M/K]Y_M#GCOUV&8H*;R4YPZ)8Z.OB^&>;3\MYXF3'LS;;7!H;8$"MV;Q4BU6,
MWQ5-$%UVY1+TKSY'L+ .K&[(R4X8@_T8LQWH4M]-Y7(&!/Y?5+HI=R]W/"M&
MH'=A[3,0AM<W4Y95CG66/SX%SPK.M)AX<&9C<+ VY(J&TX*2^@C3@[?21JZ0
M\9DI"_.$##%@JTTBG())EG$+IM_%5B_W!WXOTW+4H1"8S_+??>5<#U0_+7>'
MN<!*+S>B1FL;8TM3GNU,?MW5Q>/I)[A5/6O/T-[>(.FC0'&%%18THI3/F^0>
M_+X&-("\Q2X3ZPMKMDZ>O(M 71:AH^E1-UM?ZT'9DJ=LXN&GZYHR^RE862IZ
M)P"!><XXD<@RQ2#PYQP9Q3@2"A,I*--:TGT(P*^[3^^YKY&YF5"07F[PC/*6
M8-[&AHF9G(]:++%I@\(.(H->VA.'A0W:!Y2(9'E3A.8&<8%X\I1JFJPU6WPF
MMQ&GPF>R;4QNV>-]RU1C+Q.-H[+%/K83<$EU2J!(E3N_Y)':;,"DSH6$<7;:
M>^D1G,24-$'1*Y*WX1@R$5P2<9%0DHQV^%ZA:)&>MQ>PK[4\AQ>@;UNR[B1.
M-[-(NI>1:UN!XQ>GBTF;61R?PK-6-0O7@.;5KO)X>FEW^ Y;U)]M6^B3PZP9
M2/H063W^BQ]-J[\OIC$O"-L,G^S79:&7!L9HYKVVX)0BA?A)YHH3PAQ28$"H
M<#:%;;@+-D2!\=%(8,(1%PH,C"(*22<2#P0[:>)#Q4\WA#;L@/30DFRXHNLB
MJ:]@GCZ'3S$)$9U'5*H(<$=!^"120#(:*X(U <NM#=;;R-/U<.>:(U9N62B"
M>PF26U2\(4[?%"@F2L%X)4?4Y8U2X0G2T0F$522"*@:.;XLU:;]2\H HII_H
M^* ZNJCI^"Y<%TB-L20J%!6VB!,.$#<8A:CW27IN(W?FLA#QJ!,8I82LSF=&
MJ2C W?F$P"X9P83GVC^8Z[HF];?[E-UO,?7WS?@K;91T)""0)0GX)Q@$(F"1
M3M) Z$4""5L!UFV$:/_^ZJ9&B/=1GK[U;(YQT@;F",(@((A[BY$--B&&<>!&
M1T,Q?UAQV7\V!_?47^TEZ@[C4"+F[MOWC,#9QN;RT$O\J+W$?.@E'GJ)AU[B
MH9=XZ"5^:E6XHI=XW0'>_)$KG-41D*S*](GQ'$-PKWS>PA ,8GT;$ Z,:"RC
MEGXK*TD)\8%%CIP*%'$J &9Q@Y$S1(BD@W)LJW?NO3^)83&)QVF;TV9Y6.]7
M&6V*.?P @_AE4ON_?J@B(+"SG >?+>(/CY$7WP>-U[YJS^K)I&UH;IOE9C%7
MYQ8X5EJL"SP#4+5>HY8[X6Y8FN;.JT6SW$69Y_Z)%JN^>-R-B/YHX9+*IYWM
M[ND=6,F/S]@%1IL_18 \ZP4@R/&7&%ZV=R<8'^ ?ER1'/A>UGS7Q11//+ "'
MN$9PMT:8]VG<C,O*G+]8?F,'$U[[$(T/..<_9@"V^R)RH*^[XKK/Q8$2ZE8W
MN8824#\HU^@5!(!W/4- ]\!VK'O>7>+[TU'6W'K1@'XW&V[R=MR4=R=_?\B9
M>C)VTEL=O+ <^0-.SOX@W$[:@,WBY(>5I#Y,WK?(@_I]GJ#SRC8G!9_X_$,$
MP (P9B,('FA-[\BU^.2",!Q6?;]]E$0]2<8C2Q5$;%)XY$*R""<1- [&,K>U
M[W^?=MF]'%8-6@P?O+G0XSVQDW(UXF1WW<"WJC##J6U/X'/>G]2S>5NL"@_]
M*W;17O2+V7!ZV_/2I,'C;'@<;P13G"/M'$><2(X<";G6V7..';$4N]YYG-S_
M/)VW5[Y=J?/[E3;OS0'M+G]\7CHS1#SW4KU#[V%>6B[#""@)A'5P.,]&>0:'
ML^YPL'+2B^20QKFO)E&%3 P)4<4C%I$9:OOM</Y8Z?#^3J?6:CB=>HAS]J!S
MR^[G\\&_/!N5&?S+AG\A+"HB*+*28,0]3DA3EB"JT8Y9C)6.6Z7(3^U?5EJ[
M)X<BY8CBW97PSTL]AMCE7EKV^RR>V7$HK/C39LB4/2/-&1S+!@6%X9:E$)$Q
MV;$H99 EEB%"E!)>R21XOP.73I/?M(H,UQ]G&H=K&F=N>:#<B,HA9S9$,GM0
MPB*<E6\%N"MO''S/L]&>P?=L-.D&&W&@'ADJ&.(\\<S49U",T7%GB2&NW[ZG
M:/.>G(S!NVG8GI>2#*'-/4.;^@S>H>55S'5H9[GM<3AA^WDIT>!IUCV-"IA:
M+!VR IP,5TXAS1Q#GA-A@TLIB"VBO:?V-$L]_GUBP=^TI6A%E?=V3/;@;X:0
MYOX:]T>>)50GM&CB$-$\-^49_,P&!8B((C@?D-'1(>XC1Y99AI((V"0NN<-;
M)^/=QL\4"I!].IGCLW+HU/3C;YE,I*CR<?I'$_>:/Z-TJ ,80IL]*-V2;6OP
M+\]&8P;_LNY?8C3*<@;1B\D'SU$)/RD>$=':,H)M2&*+?_XN<<Q2T?:U<S_B
M9-A &:*-O92"73HH9/ %ST9U!E^PT>-B*/5.@DG7F9TR,(FL-@QIP2AEU$MO
M>]=5>30-,>T^VV1?F2U!1GBH%!MBCGTHW^MMLMK!Y3P;Y1E<SL;AI]$2YH5"
MT;.<WLJ$R,Z1<OBYHSQXSTG?7,[-V91OYV34B ]%84-,L[^BL,&W[$=K[DJ6
MUD.]NN.BWXKWZWOR3\PG)9./$!(EC[BC$ TY:Y%@X&VDCT[$+6K0I_9/[^JI
M7Z\IVY=[(@\<_]R=:Z^'BO9H,=(Z]6BYZUT\6C<E^?77SC[K[HI[1!Z[DQ&V
MGMO)97+7P?/M5R7I <TZ&>I%3I8^H>][&BZUFTS&]^H& Z58)(PH\0IQ0\ \
M.4(088F*Z"*-=NL@DJ=V@_LM.-!J9,0#1V=?%;#GX@+W17J\Y1>_=Q=8W406
MOUO/=F,*XWY8Z =R[,_DE8<-B/W0;)W9\X%CZQO-JPY\POO$MS2?0*T=TBPF
MQ*TCR.I$40@!&\)PQ+)W^+;K&US_H-/KWUNUWE^O.AL:"?<!:9^]XUGM?,_B
MISA=#([G^6C.X&\VMKTUEP3<!!+)@[_!3.;N08(B"<Z[R'3DO:NTVO8W2W7^
MH]7F?:5:1IJ;P=\,@<[>ML&]GRWBQC%O@^-Y-BHT.)YUQY.$MRJ1B**B&/$0
M)#*!,R2%3#YXPSF[%T'*_ML)"_=6J\$W.8S\EK$-&3%)!V<S!#?[<C:3.I_T
MG<]/&=S-4((UE&#M@:C8RY2LIL@03Q"//B#->4#&4<*9%H;WCPC_H@1K[;-]
M<GM),0)?/=1C]2^2&NJQ+NJQKCA8>W"%0TW64).UEVY-ZA7SR2"C<TT62QRY
M8,'E84&MHY@QJ?OF%_<?P6F(X,P#1W!#7=90ES7490UU64-=U@"R^V19KFQZ
M&&AY!Y0]H.R]H>S &!:".J1D8("8I45:,H9L9IBGR9$H^I=]BOMB]*58CH1X
MX-WX[QA>P\]YS?YC.8'O8'EF8P^_A_&GGAC52\_^ZN-N/"%G5WEJ=L 8^W%/
MCO7"8]_+M^[A[3^<Q.IC1V]7V=D8%/ECE6;U:36'3XI?;L;%I-2I^LU6?Z\G
M$UN-F^IL!EHV@T=5=CZ?C=VB"$LUKU=7_=N_:$K4RY(]BZ?P8:@ %?T%.NMC
M8>//3_AD)XO"75;[L9WG2\;SDVH20=OLQSR6?-'%U^#V 3Z;U&?E#KX^!9F$
M;TY@$@ [?*[";/$1QE:'A0=<,9Z6[Z?%?#%KGPGH[7.^;;V85:XS6]5I#9_&
ME,9^#+,R.3^H-J:EFXYQLS$?\.NTGI<CTWP>. S-11A=?G(A9(,1%Y:<L\7L
MK&YB<_!<9>R/7&J5Y^==/8^5'E59,BA^^9\KN8.%66.R:[U$N8B\')5Y+"L4
MQHU?-$T1QG9AQY?I[_+AVYW?@;]49W8VSX)[>?&N7HK^S?OG-O9P]23<9B':
M2_.C7HP!98_]UT['J'[-3K3Z%1SW-&L2K$3K5F&>UJ<)C/Z.B?K:4%;0I/,>
M'3+)2ZL4)0C;X!%7@B$=3$1,A:B<$SA9<QF9.$&8=MHA+@"4<!(HLDK MRFA
M,3FIE">[D,GAQ=K#*Y<W7GO-#_"07R:U_^N'*@+4.,MJ.5O$'QY#3?<18^W)
M#R2PVJUU;&TYW+^)N=7& _2Q8$L74[L(XVSLP,*B,GU56LG-^&)"6]L'MSR/
M=M94$>8M5*^C!S< EH"1444QI47OX0>2576<RA=@1&6;SBY]SAM0\29K+UR[
M\C^U+SN4(=N!O]OIPL[.J_:FI+7=&R.MOC;2XLK*>\+%>=AK'\*E2^,-3YJ<
MC\HH.L,/P@!P<#[^%%L+$\'V-(L)3!?\6K=$XO R\(F=@P=;3$)U8N%B%^,4
M;-')&/Q86+[VFFUJX+),K_877'8V@76^XB5'%0P4'K-\8GG&J3UO)V;3[=UV
M0GP!\;$IMP"[.:]G&?:NOUW^Y,IU*<X[?PJ1 (CP^0H"7"PKC."*FY9YG?K)
M(L0+<;/AOQ?-_+2(8/LAR.8(W/:\+,!D?#IN'2_X"#N>+;'$VK? Y^0C?^;G
M\/U/\>)>R]%WXRLXHLX:!S:@C.6SG<TL7/NU.X^7!_J"6(!_FH__=R6T6WZI
MDYP<6L(PEN>LYI4-J[:"^MQ.8*2U U/0R4[^TIIHH%F<E!GT=3-_;#S1'X"^
MC$]:*]4]O0O$\N-!2O)H\Z=H8L_KQ1SN^"6&E^W="<8'^,=EY.:SX)XU\443
M 2W [*YE[=:R@)]@"4JD>OYB^8U=!6+E(8(=:/WCRQ_^]I5K(%J4UUQ"KOM<
M'RBS_H^ZYPV??DS7Y&'U@V[PW+B03W][Z</;I$>_I==;[=+(:W9I;E6%MASY
M T[.1:KQOK'!KMG[OP"_P-==1E]WEY:;E%7U81(?;U_HT>W17:M)'U*E]RFS
M/QUE]%HO&@ _S<\/*ZK?D?&[;HOZ^1F_'&(.EFX "X.^W%A?R* O?:P8^3Y[
MCOX8>!2^V2:]@<!GG\=DQNA=( XY*S'B,C&DE8F(>J<E$8$GO<73' UASBF#
M-,XD#)'#M[&(R!A+O.?2&"9NL!G2+'=#]DN#P(0::3T<.3-8LMXOZ6#)]DE%
MEK@/2N53MW0^B4L$I+6W2%+I,T>9U71K6]=P*KR1 HD$_^(I4N0$,TAZ8\$L
M4H>I?#I+QID8,:,'2W8/Q#MTV7>3^R[F;6-?GPZ@]UO4F<%5[-%5:$X]9[0
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M1RUM*EPV[9U9]9@%!@$:LI@&Q"-1R+&L$T(9P/8B6IJVZIHP4Y&PB&0T!'$
M_\A9[%&4Q":%I7)D,^3\LRST2O#?6C *B]/VKW_D#%KS>YSYRT83UCRNM '1
M=76XMEO,'.PN'7A\;?AQ2=8X+X<M3(L7R7^[;$/7>!HOV=).5SJ^7;@6-"FS
M[+8\A)E?<=)B_"SQLWA:?X(';=_7U786JM/"0-6TC)17:.%DDID1QT5F8Q7M
M;#)NQYM_!6A:9SK$Z73\"6Z2V3"[3RYN$5.).#[%*C--MO2)V1GD075*].OK
MP_R]K$?;P^R(HR&$FH9"5ME&-P#Q_XKM:#=(IS,C<5O%6DS..N*N%S-0[2LA
M=S%)2[R37VC=N_5-3PTS%+ ,@0<FT#E!!#),9L=CB*9<66_H93TEWMBH#&AG
MLN"LDI'(<,91WLZQCA@&L?R3YA+)B!(Z(G3WT5N]P\O? *XA7"CAE4'6>@D8
M)7H R0!NN"318VIHXN0^HO*HN(;W$]8,>91'?_'C:?5K=+-"OVQ:XNKO-W7B
MM140H1H46-[\81"T&F4",C1"7!(X94)MYVBMQ%%%Q)T%O<?1(<L%1TS+Z+57
MX$'8G:+=U@$\9*QK1C!O^?]]TO7O)'&2)'>:&@-Q;18+XR.RD5$4K76<9&X(
MPR^+DO00Y!)- %[DX[)9"$@+QY!FSO@DDA A]#9QPD>B?\)T_893L4PPKO@E
M@]HFT_Z/?:GUZQW"$)Q:G(O$)<8NXPJ.K$D!2>J2RXTM1&TAC-N(U!*,OIK8
MIED)S?&LQ(IONOGY/4_/A41UGS9D$WA,,S7]^WD.(8[382EWLJ\S<?BL*6;M
M=J(E#OHE56<0TQ1Q*KBT=W)"1?"):8NLUX _(\OI6G!+R1B, Q;,Q:W];,^2
MY3)R)"*EX,H4R!8!]Z=PL$)R@Z6(3X-$^[G3V ;Q%\<J5+F.KJ"AWGFBJ(04
MWBA$?$F>^H2T(@%0"C=*P]+R;7&X=:[I*^*P=$(YA/4GETZ/[OZXN[(! ;#,
M4I&;A9LX_>$_YI_K/LG#O'NKG".Z#)0+6GEK83Y6A[YLR<VX*>=B%)+RC(S'
M8;5WG3,CGW+-YO1C-<[GT"SWL<_&9S&7MI?[-_-9G'Z<G\3I\KK-S>JSB9WG
M^3RHKH3R5R6*[2K;=-H.+#\GG]Q1LEY#_K@'.HV=]"9A9!U.X-8M!!TX4B0)
MY<0('+G9RA\SC(6F5B %U@!Q0@6R%H(;BH41(J7D@QSRQ_W/'^=+BV*6>[KS
MB?V\'B[!36?Y%+[8/;(LVMK@VQZMNKU/$^?ELJL^_GQ2ET.5FCC[%)>OT(YD
M];3O-9=]3WW?4>K/*64D4HLXEC&#<8Z,2@XQKQ13*H GWB)]NK76O@=K""_T
M(<Y._XBO8S/^F(^DG7[\):_<VR)"$ ;F7XY36YD=XY-DEHXN,O^C7"L*:[C3
M/6TFFZ97.Z;6JV9%*L;ICAZJI)J;:E)G&6FN]!R9GJ,"YS&)MIGWSC<$84A2
MS",J>6X.B1(9:ST@>QV2DQKC[3#12)F<B2"97N<F%)TY$P#Y!6PLU=)BX=+E
M,/%/.RNG&A]-VV.]WDSGX_GY\><IJ/3)^*SS#0!!]N4>".VG>Z@7\USQEYLK
M;^@:X =;I<5D<H[">+*8YZ/?KQ(TN!L8TG)N7CEA+\MU>PALJ];PY\_UFLF&
MCZ[T'.MVO3V++4LY(+YO5\J-X(!XI$28V'R$9C0(\%!$U/F@F23&LJW\6K T
M"FY$EFVPO\IJT P-48W5-&$=5;1;R9"]2SF]KG"[3R+>'C<XR:<$]Q,'2RX-
M50)YXAW$J8PC+7E 2NM@==(TLBU;%URBWD2/&+/YB'>"D>8JH:@,3TIHX94;
M;-V6(.S1V$&$VHR;NYJ\>AI7UNR&%J]9N/_N8L3EZ9H9@8XOCIG\GX6=C%,Y
MT33_*>-B6!] #<NH\%: XZ)]^#(MQ)/E*2#X__MB<EX17* 5^SJT*J@)?K_]
MJ^\K&U"B\_EUP447E5R*+](XE:3^5GA1PVC'>3-@=;?_TUR*-$:KPV:I7#MM
MMDS$X\4?AT\G*46?+Q]6S$8]V'KOB],) A VHP[)("@X'0<P(ED%T,,J\"U8
M>[%%\,,M7$<M@]#/:\2# KCB0T))<6D3!Q^6FQ+7PKAEUK13CV8M?&M>Y=.?
MI_/)^7L(S4&6CJ>7X[EU+_2ZLX.WR;&>@'KTR/TL];?T_5XI#X\SCE4&9D>&
M9B-_DO>'2EIU[5L;*92U3$Q:]=6"[E^M@4^YB]H>5 [A^&>PH0!ZPJ5BK+YI
MJ.<$M-(1Q&B X" FA4P4&?=;QXSF0MDM3@7071^B\HC(W.G DT0NY6-H8C"8
M@,+'@"_#PK;5_6V<G]3AHLO] 6&A- >\1WKYXS78[Y'/Z+Y)U=3]LWA4$"^5
MDR@(!\(E+<];:0$E@9/5$9Q LEO;JS9P2?*^NXA9N"S((C<>T11B"@Z^==$2
MLQ2NU]'-+[@Z7L?&S\9GI0#TB>K EL#H D*".;A4!E;V >'75_6TD+]EWJ17
M\(?QO%IM)%0_93/8-?)>_G#5TKM6,C:J"IM3!QH_+_?/VNU6^T#)6I$XT9F-
M)1J;B[MDWC&E!$69-$DTQY?;N^CW7N:<MMWVS6$Q6_GF)UA[B+C0.6#L_D4U
M?DW,IGGC<%VTN@!G713?P34K"<O",[W8[X- )]<M]++T1_(4M)($$6TLX@9'
M9%VPB#F#N:-)6KO5-*4X<XIJB80 8\4))B"6-"!BHB3)!A/M5D[WM_$T N8L
M.OFK]>-)=F_M%M(O]6Q6?P:T^<K"F\#?]U3@P?K90I4SGW9:]N9ST%O-2NHA
M]0[J8,^9EM@AC8E"W'N9=X(C\C$RQ0#0*+(5C-Q%,C;-U#(/]@?,2BGS"OO'
M.KI7<O%CJ?JR4QAF#[,[OZ^E5DI2Y9)7;7-MSD[LU*^R)COL8ZZ$\)-%R?#E
M7)SU?K;H\C^+Z5FN4%EI169"B'G_KB1E.FO<8H'+R<'_<RDMN#CKAE%[7^+9
MMNK2+E-Q\,344I9-/Y;]07"AXVGK\Z]Z10B<IN?563UKM]/30[]QWAHOX9V+
MRQ=?PJ#K7AU,2[V85?59.]0\0%N!$\HIH)* K$J6K:TKJ^'.R[XJN*MMB2B;
M!2"AM9K[$Y@@%^,TZ]?$9@1VD=;JTE7OW[QJM^MWS$(N16HZ^ 9?:1:N\%B,
M84;.R[0L]^B;)L[7*P[R-.6ZHU"#M,X!0'4;3!"M3W/- XP_U]_"_<9A;&<P
MW(,KTI$E]S==53_%+S"4>=<@=CDEN>L-P,3%-C7=E5ODZ3EO*PC2K#Z]#&%Y
MON&EOXD>!BV/!_&_OB:;6+_3P'Q!5_YW_G60?_65/_R\A>_;=2R5:/#$TVI2
MPURL4OU7@;R,FZO?X+)O$=UI;#VQS"'E;$)<&9Q;XCD* 7N%O=;6;^]B6><2
M%KGNR^8V>OA),R41\<%'@XT/.O8 W?64*&C#$*YDIUC BZVB;P'^,2%,\ *"
M3:TR/T? 2%,F$78@'C)H@=-6Q])=1&?_\.^Z?7#2KT37"OVU[@Z\W:(<W%.<
M3 $8#Y2&D)$JB3UR!#/$,Z^/5<HAYV+N/ N";1.P<&]H3#AS"F1Z6,L$,B$R
MY+!2WG'AN=SJ0-Y<X+>=ZWP-:[NY3MF7(H R\Y/\?13L>4D-H"=*35QVWKV#
MYJVE^;JK?$3@M8YM8(KBEXQ[XW\,3/X/S^0OK^*2KFY*YC\P^0],_@.3_\#D
M/S#Y[XO)OV"$E0-\3H'^9@O:&BG[5J)JO=L^%S^-0UQC %\U4@$V<26:S(BX
MU.[E8KU23]<2H4X6.;_75I/F/J\\EED-R.83P.I+&\@U0.VV#.]@J\JB._VU
M;0=)R8Z[.@MX6W"=H<LCY &M $PV]J4K[HJZP#;AL/5"H5X?Y$'UB^V887/6
M+GZRDX5MNQ8^PW-BSE"4Q&0I65LGGOWSZ$W[REM/R&,N_6XGI>'\-$-8%Z<1
M9JP%:DO,![<XJ/X9VTG-W^A6894<S?U"LZHN1/O-XBSG/]N!P-@^Q]GR2_'3
MN%XTD_/VI2">6A1T.8L=B7NF4NC6-USP.)WE-L*0E[[TR,5P4!TO9JNFHOCE
MK!P>D;\]J6%9X*UC3M]>E Z6G,NE'=M2R5,*: ="E\=_<1 FZWU9EUR0^+7*
MW0WUOU"MV![P<%K*7JJLDAWK%ZACE;4C=JGM-O99__/7*X5!?$ZC;=I :*ES
M;>=K79[25D^V% WMS2^LTXI1#"2L/:H@%V^N:I=:#?HVB!Y\HE+E*B3#B4,\
MX(2<YP2Q0(U.7!EQ10._-5+F4T^IA$B?!Z&1C?!M*A-AA@O&TM:IIX]"]- E
M?_!M<C_T0/>)?W74/Q$Q#B<1C<LLJA*6FU/D#,]%I5@KJJCC<:L!.'@I.24$
M&0M7EJUBIY2'?\E@! G:R:U#+GHK(NR ]JE!HMB9WDD)Y8*FI"02*N3DH3-(
M:TF0$)C32#D6<JM)BGBL0(@\PC)ZQ$W( F(PPHDRCA.S@6]EAWLK);UECADM
M>0O&G^+D'(#N9'+ARS(Z[-Q425>,3T]C&+>EMKDL[OXD(SN2S1+<CL0ZYM(U
ME6G@%=(1S(3RQ&*;M+N"M.HNCF<I"X?3T K#\457T0TJX*X:ND\L<4QR6Q]X
M2NYS]CNP3"N-,959W-56R>]=#.(##-UB!U.K(H)GP@PR!4/G*:", A@.PA;R
M_?MKZ3V'_OCJDG+U0MY=:':F]:_[_<DTO90;9%0\;G)ECN]X#+JP[D+5<PJ_
M%)_D&I!\=DEIMER!U"60!M2^:-J6N%\FUO^%WON3&BY%;^-L7LXL&1>>F-,Z
MQ!)^Y0V!T](AO 7!X2_-VA!6#5L)S&W9 X81G4'4"C9]<5J>W[S8PNU7(/)E
ME<TJ0.X:JMH^ON8OE&8Q7MI2S<>O+%L"6[R?K_['P7N ][,2"YQ7Y^,XZ1JD
M9_'4C@O1S5H<V]8(=%W,$)."5<T1+?RQ[77>^',;:;3C_51/8)PE;P&^Q2]:
M5HZ-D9R,<Y=;8=U9N[I;Q1TG%RVW9<XB6/OV?)E2\W(I\OI:(8O-Z0-XO[;-
MLMLQ&EU$1Q#?KZUI&X+9ZFT6O^J5G4WJJH$(?=*N0BL3JV6&.-\MTS69#:]K
MB+PHNXJ?XE(TNVVGI1CDZR]6<E96=W-:UJ>WW&!\6@A0=C_G:_-RL3-_IPG)
M^_?Y@/2V6\7ZD\VU#>.F/#5S&BUU8R4G:5'V=;-&5@G4HGFV94$[^I%&3]B'
MM6G3ROAR:BXS%L#"[R(/':ULWNCKRM<)_I80EGS:TK 6F>L=XH\6$$T^>P7@
M/>""4 C+,Z (SB8#F"'AK>84F90#F*:09/F8(&TS_O &8>&=@PB!*[:%)=K.
MIPO6MU\_O1OOJ61(DX->,9-W)4,]3 )808W7/*,^S@&_.HT<X101@ET^SXE0
MN@4<$P#B?#@A2C@"3J;,(:V"1=0S%:)C0JBMVN\'7&PF#MBPV#=*"C(:?4H$
M!9EI*Z0+2"?AD7%6$ZJL<&&+/,H%KG10# 7*,DF*"<AZ3!&CR1-#4Y+R,1=;
MD /3P\7N9^[&**9I )7V46K$A8V9X(8AFHA.+%(&B[ZEW#QD&B?1T7823Y U
M7"'OG?1"$.OY%L'- ZXW5;TL_MS,O3QE:=C5T(I6=\,WF_LUWP!8T=%JH2V(
M*\DBSO/Q%Q$@"-@L*Y5+UJJMDPHU9]I*)Q!5#GR>X0Y$7$<DB(E!PHU,V$HW
M/:3_(@>DAR+>3Y.&$_8$;!>*)H$+$\P"]A ):6D,#I9AR;>Z&#.15\0> XS%
M8-(XS6VX\&U)J24V8*[#5BWK0X+37B[WI6SRL*O^Z"_^ZV;B8J=9+C4CLUS<
MF&LX>J>A8$,9A VNS9USEPO-91" .47N&95&;!]2C24&+<Z,D5H$Q)/@R#+
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M246)N"4>@04W2 JN'4LD.++%%7J7%,)QJ\/3CVTQ[E</!=UR.0W,+_QT7:Z
MC"3[_IS/S=3G1O4!@VG\)M=V,(U/8AJ%-L$*!Z [YL/NK00S1[U#5$3I2)1!
M\JUS]>Z2A7@$T\CH2,KO+]\PF,;!- ZF\0E,(V4^"NXD$BG;1^$4TL%I1#$Q
MF'(*,'(+-=XED?$(II'R$:6[#Q'_OM5GIVD<*A3NQPP2Y]4$A'7P/-^MZ@R>
MYTD\C[<F4<<8BD(KQ(,4R!H;4.*!Q8 E_+R7?,7OLQJ&\Q .1YB1(-]?3<.
MQ0>+.%C$ITA3.$^I51$YEYFFC=" Q8-#AG,BK/ &*[./-,7#6<2<G1#?'U_)
M8!$'BSA8Q">PB$E);;BP2$?&$<<I(.,P0UR%8"5/3K.MLMB[9"<>SB)2-E)L
MP(@WH7+JYNC=XC3.QAY^#^-/CT%X=#>K> M^HSNP.^WGS?9)Y;3>/G2+=V\O
MS8^ZCMOIS?\LQO/SZFV<G]2A.II^BLV\<#R-I]6;Z=PVX^;*J?J.B+!V3<WO
MLW$]J^9U-3^)V=J5IJI21U/5:3DY__8OFA+ULDKCJ9WZL9U49W4S+A?9::AF
ML5E,YDW^PD453I[;7Z.;+>SLO,K-DJ/J<ZRL]_4"GAVR:5O>OK+POVD5VU4Z
M;5=IO%JE@PIL9BR#?%?/8R5&51X0Q2]?K<8+-X2;%::\,J1##S=KAUA&3\G+
M47GD:3V+<.\5M=?!^L*#E8BE[ U,!EB(E<9,XA<4QK-8#&SFX%J<3E^&<7,V
ML><O\J<OSVS(M7)K#6KC=LZ[7&C[A_]>-/-Q.E].?_DJBM/PTM5?\CIF\K!5
MI]N7&QK?ZY?^H=K^[B=YA*@-&YY-<FNW__UDE4H^LQ]CFR6&V .&^L)./MOS
M)E-HK:_0<OJ+'EX]]_>9XGN;?%N=S++?_Y=Y[7=/]BX6C')#</MUJUHO%F"1
M9I/Q-.YC&3X4(CM0W5?MGRXLH7T0Q_']NL0':JC=PZL?O7MW_.?1GX>CZNC=
MJX-;3L'3V9<]S\*[XP]OWE<?CJM7Q^_>'_]V]/KPPYO7U:]'[P[?O3HZ_*UZ
M_P'^\/;-NP_OJY^R,HRGBQA^?BR!>5I5: 'QWW8YP)L_<A5N=5B[B[945,&3
M&)%**B(NF$)6:H:2U%1QX;V16T?W6J.(-"ZA?'HCX@ZB+8L90TH28Z6UUC!\
M.=IZ[T]B6$SB<?K3SL;9M!UE"00DL80''^ !OTQJ_]</583XZRS#O-DB_O"\
M8-\'0'O-XA2&![<):\!N#1J-X)>N!Z"@P[-Z5B ?P+@P#M6TGE?UYWQ54\'0
MFK@%ZS(\A'_%ZG\ !,(J5!/[$<#B1SL+D]@4O)COF^%;P8Z+V1KJ*Z@PU9-)
M_;EY\;VC\YN',M\13:TB!T;?EW'UFL^I.,!T8&3M0Z;VV7.^](&?Y*$)6=WL
M;_OB3^S#='VGW(C9K@S$B#<3PX$8<2"N&HBK!N*JH:6U5P;KN]G('+;_GV3[
M/P@I''$8>:THXM1&Y!(+".-DF;(::RVVM_\MD<8HY*(1B&M*D%,R(8MUT$HX
M''QZ@N8$04>,?G^'T#U)<\) K# T)PR>9_ \#^AYG&*46,T0(XDCSJU#&IP1
M_)0$\U(PG-(^/,_#%9X1*D:<#!YG#Y5GW]U&XE!F=JF^[&CZRLZ"_=YWL';-
MR>O%;+E_.#\9S\)J+[!.N2H,CZH/?[RJSA8S?V*;&*JK3/ MAK'_Q@E)&!A9
MC*P3$G$(&9"Q@2%NE E2$HP=OFRMB6=:FN 1(<H@'BU!.I<64RV%H((E@L/6
MQK7-F];OY[7_"VR%BS/XY<3.8G/4-(L8CJ8?9G;:M$/;L.=-N6K=D!^]^_6Z
MRF$\XM*,^%>JAQ]?4JKV3;)@O =;"3^]ROO**<YF,;L/F)E2VF>KSW8&DS'/
M!8%+P>F=W& +X24QX. C!QE@02%PU!XIKC#X?QPB89?E1D2"I6$:W#H$IMQ&
MD#5")2(^\@ ?2IGL4F[&TT_VQ?OH0;UR5</OW3P<?IS%LB_\SW:.FI4PK2Y]
M92>3&'XY7UYQ;VD2(Y#S$1.Z3\*4"P+S&.SD)G(%GW5VNOIP @'[65P )&E&
M\%=_4/W4E9MVEW3UI#]7/V6KMOE9L6E5-[6K"W-1Q+_V34*525%0$$Y%N49<
M,8.TB1$EJ8BPAD=CMRP;3MZ+"(@U6)\03\$@PT!@%4BH)R8ZF<A-)?3P-%<"
M[\2F<@.;BNL@J3CHE?C!U9-20@-/\"==(0V(6^^DP$<9M+4!*2T]XA)\52ZN
M0LIX%;2VANBMPJS;^+<B!:^CFQ]-F_ELD1=^S9.]JIM]20#NI0"4&J>+]X6)
M;.;-P<K8Y-IW,$;C3W8>)^?529R$RHWK,[!8IS"D18F+X$NG\ +G\/Y^D3$2
MW"?$3W%2GV5H-9Z>P'2%#+%@\-F^97/CX?[C^I-M_&)B9U48-Q&4#QZ=*[_&
M:P@U%^K#H+-P@C]-BVFY$SSC8YWO[B?C:1E$]\3RI6(N_S@YGY^<WG&*+\5\
MS>(LSM;F71ZHNQ:VO7W"1?\I3:*W,&$AED4H2U-V<'X>56O>@ZB7336)-L#:
MUQ]G]K3M32@@>1;M?#G)MIK%G$I!];2)\RJ>C9LZE%JY,SNKOYPW(/F5G<]R
MX5X:NQG(7-O44!U/J[\O)KGQ8M0U7Y2B\?81<7:Z*K[+Z+N+6Y86NEJ9Z!:<
M%_GMW"6(R-%T6G\"B5V]R.>3>C(Y1_7G:?:G"]>,P]C.SD>K*\M=_@O"+A H
M\*F__?;JPJ5^^*^5EP1<DD<%%Z]NG>\Y:T[&9T5(<QEGV]ZQ7B9X$6.!7GWX
MKPI>H;Q9R0[E 8>8TQJER' :J].V-*6\R.:"N!I^S2-H6SWJ&6C+89FHU[ *
M;4$+*=/)1M6T+@]K[QUCUJ,FSCYEE:FG6[?NF]4GF$CN<$ Q6)4M. ,_C@G*
M3MRFY'!T6\V/C%%A*;A]Q27.Y;@,62DYW()X%QD7DM(-J[^$GJ]:\]7\DN?W
M;9G(YM4"Q&DZGYR_;R?M>%H^/4YM\!SCAE=XW2W(ND/ &_X -=%GGY#S]$V<
M_O ?S?A+C]P!ZJ2NB-A!]<^+"MKX)<X\&.<BLE>!R Y!Q"]GXZR (.WW%*9+
M:8 \<VC\!9V,0XC3%R ;$NQ%R$<J> K>'=85614%8@D+FA*#(,0\32[AK04#
M56T<5+GQGZ<(,\ 8?9[5I8 Y56,P1^!X9^?9#'RRDT6QU;W#?,% !)I+\'DR
M$G&C+3+!!21M9(*K8(2,E[5?&R)- HM!5,Y54YN_HQ+"WA(MM-,B;&K_JVX>
M_LS3\,\\1<<I=3+]IA/ZO4$_TB-=7T&_T*:^LKQ>W7/S#-)_@$-:K35+')*Q
M0-D=*L8,W+!MNSJS)BU-WC82N3+67GVZ@A"?Q_.3E17-]\YMH#.X>9;F@CES
M.3R KM-QT]2S\VR"XY7W?K5V?1[?!4K)&M^E3G9E .BWD0'P)"8BHD/6^P"Q
M'_7(64^13X(&X1FA>(N[5@8I#,9P93Z3@AM+D7/6(/ :'(.1L/J),@#X8#<_
MX],9@8.J!%Q7R4;GTDN;S+J.J!;A-H!4;;/(:F+G5;+C6>M1GK,I^?L" #P1
M2U-2FI+ QOKQ68Z#BC25R<L?@$S/%JV-*8'#,N#9I>#59[AL:2:6MJEK26]6
M,IQ#]U5NL=N[L#F4A2&TW]K"_EW2\?56TK%KN@(7X<Z[B";_TCLS813'REB/
MK(Y@)H0@2%.I$<$JXJ"B4M9MI;(#-MHQL O,>\0UX SC/4.>*8=I!,Q@M]GT
M['F)Z#[4AZW9;N/2"P/RZZ=WXSU9"WJP>_OZ*:W%44X13:<MTT#KSK+03N$6
MI4XI2_%*;E8YA9PFL&=E=S)W\V48NI3<^6SAYV!%.I*&-F%4Y!9BZ_Q;WZ0M
M*D9C '"J 5D"T&01:<4PBHI$:9WS:;LPSS)O*+8"P&F"T#0XCS2$L0@DS7/!
M#4MJJU,TYR1;&]"41&2G]Q=IRO7M-W+O31(^PH:-M-[-K_ZD.VZ7C9:O3T_K
M:6NH1KV3D<!P-(Q8E&+*7)T!;!,#$R.C32Y&1DS<3EH';@.!6!<GQ^ [.O/:
M&?A):V)3  .7GEI&6-Y%VTUQ]Z0"DFU*Y\D.$;GLR_HG(I*FD P/*.6^<9Y9
M#QU-$?EH?=",Z4#XL&__<$*RM<?:/Q&)BFMB+$,Q0 S$$Q/(,*V1E_"  "Y(
MRBT1B90)Y6G.E>1R$*L-TLPF")DL8TKA %'4$UL1/5**C)3NOR%Y_2T8$BPD
MU3@D!($OX!$%4:^AX'JDTS+2H"F X"U#DB@)%AN42@I5RNR?2$).,NJ\$U89
M\=2^9L3 DFC<?TOR&M%M*?E&BH @!I(^".2UL( Y$@-4*QV2FCJA5$K&T,NR
MPY.56-.(!,U8EG'XCL4:4::Y<YPEC=D3RTXO"WYNYH5R+J5W ;:F)G&P)V!8
M9#$Q&,1$8>0%V!WAI51Q:S<.T*P,WF-$? #GI2,$V#I7XF0I21AKXK8"[%<3
MVS3'RR3\\>R/O$.ZS,7_/AO[N/JPZ3YM-J7E'_!C_/_9>_/F-I(C;?RK=,QK
MQSN.8'+K/C3KC9#E&:_B-YZ9M33>>/_:J%/"#@AP<4BC_?2_K,9!$$V*%P V
M@9)MFD>CNZLJZ\FC,I^,+?D(WNAUF]/L_EK(/B;35L;6[CC9%"EV=^RN5^[X
M99HLY.D%)1S:R).V:*V2UII1HD1I$'48C]Y8*=%\[>@IX9@@')UK;GD$00T%
MEWD GI)VP;&@:8?/]L!8P\Z$)6?XDGV2C_M:,[U$&VHR5\X%B-Z6(\ @P!+T
MC$1 J\4QSP/M1/VY0XV5(H-L*)J]E*&@))2P''1&;\J@]:M>$-JP7MG&:[0Y
MV=#^+5DV+?JNJ6/;Y+B^;2:KO6<>5;=RNFPFC:AK% ,5C,K)1(NPVSE"(YIK
MPB0HPO S O'7.F4A"*HU]QIOY;8WTR(4OB POJHO^7F5'O4+[BK\V7VX?J2.
MRNIJCP#;W"1W]6@WO3I3_V,K"GU;_$RES3(K--4-NGF6"+3;" 5.C4+ Y(9T
MPY!>:V<XHJ]![8IV6\;/$&,@)RY4*FM/.I5\!U]\>]XG@/SC9GK^\EQCG1AX
M5@XV+LMYR:<T_'+>_'R-1'#C/*Z)8WQ:2;FZG(P_E0S-^?3J@,4MB.N*A5<>
M/!D/F_&D^>@^I;8F<I!1\[2WR\-Y&H74C-'LZ43-KP@[SIN_N&6J;J$U3.7H
M=DFJ6.@34\G!'(S:K%TWNYX._,^WWY\U?CYKZ;+1!"VOO#SIO"A<VCZ-$KY.
M2;%<G6GB1]JDLO9]-X:X2>R(PQF7%.%F.K\L3(Z+)W]>GGLN/I0^#<;SZ?#+
M8@YPX>=NB#]-4GL<UV9_KB8O7M5UX: 'X[A! KE8A0OW^^!B?E&.N<?E'+M\
MNE24EU'B#?&5EJSCRX/;SZN\Y,4Q:OE+*IR=7TY6+?[GFB^]S1_9YL?<D.VK
MY-YETD K_&Z(8C9R96N<-[_>=<GB/'VYO[8SQ >SP5(40B$T:G,2BNV+OQR'
M]N2[9+8OY+9EDK^>!7?ABMPV+A8&]%;J)^/YAX]-<I-R"#EMYI<MEWPSN+AT
M@\DB_WG2?/Z86D&8M/FU^.>Q+TFV;I'$@Q9D@[[8Z$,K../AIY5 3A$]R\<=
M[EV<<'<-$=9;OKUJ4-R4R7GSUWFZ*25X.1L;QZL+:ORE?$YQ-D;;)8W+'*<)
MSO(T3:>+S/RK;,!!NW(WK^)T-8*?+]O'%"NY_.KOXYB&B"CAM^FX4.ZMT61)
MEH_2^ &Q[_]+7QI\Z/SB<L' WQ8++%]UXR/MS=85*85X__<"H/C]QT6.]G)'
ME[=]>J[I36S 6=(HHD?_P68#(GD-7C(.B;! N,Y9AHX+XA4SB?A2,5_8@$,F
MBY3E'$D03C!4NOE:XM'WRU$M$\]_:<?431I&(%LG#3_#'I]]'C=?<!M<$6UL
M%XP_E]HM0=;)8/I;DR<EOWV51C-9LO7VS1AS,3#J#06B SJS7GMPA+!2J>9)
M-BE[UNGY^&"9^@?.QP\X'2M2Z7_@9.S*Z.+G?8K%_[$L?QP478\(]V50G*\>
MKKK*5@LA(Z@4<053,J5;G08: ^5,*BMH)W3ZX%7_ZW(:_E^9A5TM-^F9C=U&
M.E$73&?X?D49H$9%A=%:Q3U<^&"M#(8'T,%%$%KRTLLP@6*H.[CF4=NN[_70
MA;_RK'[.WZ\FYI_K>=F5*%#&^B4,BRK!&T7ALRLE#L-255C^XE=>3K$Q/@ZF
ML_&DK1:\+CQHB*7APL2X3&@H%<ZMR[:,;>Z':!4L"AQ+$+7];M(:>%?F6.O;
M%,L3';'_79@L&W8BFH"3#_TLM. F*"6Y!\J(+5F0%APO>6DFB<PH2JK3VT+*
MLC;.$ X\)P*""0G>$@61>9JU1<7F.DDHMP0(BN7\'@WD]^D"/3[T%]^N9VU'
M:93]"A1L5U[<;J*?K$NY]'-"FLP<>@8+]VEZ4]JR+]Y(VZ7AJJ777?/*S]JB
MR-V[/B_4S>&">9XR>!-+#EHT8'-60' G,Q4-";23.!VUT$)I@GI-ET:])J$9
M:PM96(K>66*X(=7-V8.; R_#S4F"9)^#!TV)!T%8!J>H!NT(3S)PGLS396J?
M;HXXMSU2&2_%S:%4R6PL<"X128J'ZU@@H"*E7F0=,NU4;#YXU:N;T[^%Y]Q)
M&V("%DK1?5(1;&"TE#>8++U(DG7<G <O_*'<'"KZ%>*H;LZ.#L%+89CE%I3T
M)?4(@<E91X%8EZF.2MML.BFR1"96C"%?BDE%)!D,<1:L]4'0C-ZXT+UQ<UBO
M=-:]W1Q>F]L^7W-;4YO;UN:VQT/$V]^VKK6Y;<O77YO;/J2Y[2G%_&[E,/N<
MKO(Y>F=4RB0DXR8"6HH61#8,7,FL%$*B1Y2L]Z;C\E*=-4G"@R6%J8 S_"Y(
M-$F]*B6^CMLNZ\ >209$/RDI!Z,-.I&;BK^_2K_<.T&QFI8*.P\Q%$8:Z2TX
M'PM?F7>IU.&A4](IXY1&AH@>=8BQ=%X@%'P. :*14@CNM":=?/8]"DI/":PZ
M@K*F,ED1(#W?2Y[?&*IY3D!E/0=4!,_@N3?@"K&X\!F_$XZ!2AE=]D"Y3IT$
M&>*ICQFWB*:%*H%D!.'<UJA)'[TRG.9;4M7WLD]4!=1#5*VJ(*Q@&?#E<:FE
M":A/I0:G)5<^"ESY#G5]D,(H23,@$K,B* 0,*5%J3@T3/)J0;PGG[ E0>\6S
M<A>@OKEBE"L2T2N8O5=MSD;4LG?B;!Q7B04%RGH%@@53C,((">U!$X4(7G="
MZ(*$H$OW!IY+ ;_A"CS%?4")<YJQ(%.B!Q1GUDMNNWZBEZ*.9.,S:,Y*FQ8T
M_WVV%KB2(IFD"(V=Y<8/.)\S19QCI"QW H^N8"&>TC$S09/HU-SO<;G[E0EZ
MU<M@L])FP5A^&]?=3<0>7Z5S&,5KE%,;^2"W%C3\9Y^-+4J%1H_"@7&Q<.8Q
M_(YP!L9[3[QA**"=O-2'4.Q^30I_'4W2@@GN;VXP^FH#N(?*91_=E+/^K7Y4
MG#N7(W"?!(B(R^FY*$9WH8-EZ)"F3GU#CEZ0TBN(2E=<TF06+:>8Y)+D6)I-
M=3ACOK[Z.UQYTTL%=-9/#20<+2O'07*-:^ZL F,H"@,--$D13.9=>NV4</=S
M@ZL?6>D910#=*P;>\FP"CX3[>]G/>UG]/E+K/M_S<9WGZUE>5#269(&K3,HK
M$[\UG9<U9$54A^-RC)<F%YMID&?-*,W.5@F,^)SI>#B(;=K!M% ?+'(E2_ID
MVT%ZW2FD3:=K%IU;;@CN+FQS_$JW2F2?<>5JH\CTE4:1%P['\]J?:FKRFBJ>
MFI7<WL 5?T7%?$7%X]8L\0O^]^5$;G=O6_YZS<G>9S8?Y90Q HT_%W, P27:
MCQ8M"*EHR(S)*$F'S0<_(BRQ%(A*=EDY('4"J94J]KDSQ-^7FOW]&"7X.J'E
M^_%?TNJZV%83KZ_>!3NNI&>:B3[IF0UVW*7HW![(ZR6_/].6EJH14)I20"^V
M>+16 Q?&"R%B*4CID),X:Z/E :R4Z+@DEL$'%T#Q1&QP+*F4[RM$.^7W%STT
M0I:=MM;5Y-%]68 6#FG\".0J_:DVQ.U&-N92O)!0\?<9O4+2T@?T95"(2GLI
M:<%$KB"XJ+)RDE/1J7O*C)0&0QZXBAE$$ E\+*53E@9C(^>&QOZBE]5G5/9*
M0&] KVL1EEXB%KJ],E-%P$93TIU3 JM3.4L0@0:>A76=HX?"R!M#MI!HH5-"
M1PH<484.T5J+/A<S^GD0B_:UQ\!*'F[I/CE+X>.HK;6ZJ?/DJB$D?@ ?5^[T
MH0EN%-#Y:'/KY[/QX.*B-.I8]9QL/@U<<S$>ID4KRD'[^ _G_9.^H&+IRZR!
MN):NU:$099* HTZD)*C$N])'M N1.09H#R34L<&"][&P05G+2,J&=3,)5HTN
MEKSAA2JQ3&!IAKH[E[U7IM3JQ*"DU:,;.V\MIT6'S+4+%.=%9- ):?F5VD:I
MK42EWU%P9JOSABL"FFG;>65%@70#;\T-#K5WPS+3"(XIS::]<X5/P\O;6V/2
M]__^E!ZB2U2L0O&<KK\XVZ@C?KSKWVOK.(9@4R8:M.8,_?2HP7$E@45NA=,J
M4..VU8P5A.G@'2(\+\U7T3=S)*-G9T)(+ 4=KA)Q>F8=,TW.I.I5XLY7//ON
MZ60_+67.LT6/7(/7'OUT$B7X1%RQ.QR+5*,1T@D0!>9E#C2"CL4M,U*6;"X+
MRBHB>+**J7L'B';<NZ^/Z3JM;_\N7<X6H?6]8),;+4@9^R9>@DH6T.F&Y$LG
M8(X&KM.T<.PPBW(6G#2=$TQ6CBJY=J!9FS=&)3IOZ)>I3%3.)1/#WML1.[0'
M3^29D;W*NC@"C(I,4FHS!^8S"@2/# 4"?71FC2;12,5Y)S.[8M0#,>K6ZH[^
M24/ =2U4%6V>?FDT:RT7H*D,6F2OB>BT6XJ2$V64@62M00DRK+1H4J6^@TMT
MUW7FU\V>9^TY/QZE/HG(39'DZ>#W11/Z9M&1?MJZY#$5DN.%A_REJ+=[IGWV
MDI(]1T<\C0;U3B&"C-J#+_3J@F7KO=#)TXYY'1@Q-&H-W-*".M2!<]$"-\YJ
MQ[3G63P[*S=EO0KJ]).370HK(B$>@BY]_S0/I<JAK*F*.5+N>-<N1NUD>68"
M?/8EAF<#6$,8I)0404TE7;PE]>JPJ]^G\X4_;J>#;AHJVR3M)TNW=A,=_6J2
M]L%'OPWWCR:DOW9$4!GI;V.DKS'"@PW\+RFX.7K,'1GO]&A?R^B"=@?%!25G
MP0$8<=>U?VKELO3-=A%?8BW_+5W$5?Y>NS=NI^#?W,[WJ_5Z:([[;5;8\\G?
ME?W7.W=3H-+V.J"#D0E'<T\7U9_1DU3$I( "P&B7*^L!#L8!*C]T+YW,?J99
M,^VH#]1 X+K4?4L!QF8+Q.;D%7?9A&X8/:I,$TVEI:8$D25#.]_GTCC<\JB%
M=.Q>)18[JV?MDT%_6Z%/\1 WCUWO2FB^Q\GK]B/*O19]/LK#1N-57X^E/KY>
M-'D["#^4_>5H$XS?+-HR#HHZ^V4ROAA,IV,TSGX:SXI)T_RMD)O^E.:3\30,
MBODX/56KXN<13LJGA79EXBMYQU^;T>[Y],*0;Z>Y?#JTUBK>)6S<Y?+J+J-R
MEV^+I"]SE=M/;CZR/&>=N-S>O,W<04/Z$LW6I;W:1VY K[0W03A(.9)"O"_!
M$<_ <"*%%,S)V(GZ!?2YF2Y:F#)3\E8IV.@24,%XSE22X,DV2I>VI%<]2!<L
MR(.PS+3Y9353N\KLDKUB-;T*!K=R<TM:U^5'AT,*:3YKJ2MO2.V*"=%X?+FR
M2D>X(LT'].T6+F3KVA4.R@+G^,M/Z)@UTR_H'5VTV.TN43F>-4.\R621%H9C
M#(/IHDU1+'3>N 4N4>Q=^)C:!-;E YN6 V_5$RI.YA^FK;5].?T2/@[<K#!J
M%PTQ*H@U''_ 'U>Y90L*S^UN5;-%50P^(<_Q<V56_B]:TJ,/X_):RZ<NK.TV
MI0COA3MX<:\;MQZZN*78QA53:%0<Q=[S1%N54@@E\5;XDDZ;,UC#'# EG)(D
M:Z8[!WB&2AUU5$"M"B4%5X'/:%8QEFFT4B@N.KELU_?=)F%TV[<U/CP0=E?[
MUCYE$BQBH)]Q^ZV@?:$OK@[OKGE\^',K7HMN9X6M<SC( Y14E,A%Q[.M3^-W
M<?RYXTJN[K,J;7FWN.R7U65K3=%YT#+Z4M(O7R]_W;9I6[Q P/DK;=HV/K!L
M_;9LMS;.^ "\_NS:-1<)46%RMFBYMOAAI:.*D8<?!USORW$Y[RZJ<#IH!76%
M0.M1_/+ZS>K-SYOM,14G>33M3 4Z\N7]"W'U M<F;2/AL^6%K7&SVN4%2!8M
M ]#(7 2PKM]L$8 :SPM@+GO#M9&?FV>P?S;3 R3ZEI8%+HF(*EN!(DZA4V4I
M>(].%=4ZA\B)C:%#$F2D)_BI!$P4DB!:SOVCH!!RH(JK1",-MQW2X=Y8Y\"F
M^-<T#9-!V];A6:S!@O^C]N4Z6W>Y)W%WWBH9BSV$%R(:^'1C1+'DN([7WM&R
MAWI3/*0E"7U[ %?^/"S],R8+5NF 6K/ML+C^Q&(W;EJ,;Q;7O+FZIFVQO4:"
MI8?5>=WNG?YC?<7W[177[K/0D;<\K"C?#=)LW&1_D.2<7/$57Q_BU4S?!I?S
MV72&+UXV.&[,Z3Q\;&:#BW8*':KV$@F.@^%\R= ]6%H#-PZ@O-LR9AW25<OM
MS<CW\K6V9N@***_M_H65-77#MM/D=!'T*T/!W[3?;&/+Y]:]_7;PIS*4(1HO
MLT:2\B(A+4SW-LJ8)B6I>3.(F7X?3&?E@>W[+JM_SO!&>*=1:@/K(:78BF:K
M%,H'UX_X Y=7"[#PL_&3^-&V9JG5T*W:N;@<MB->N/977516FJ:,=GU/L[&H
M5SQL]^CH\3!\JMS5S\5=;2MW=>6NKMS5E;NZ<E<_]U8X<>[J@Y4+_=^2!>=G
MV^<8Q?BII_W/LNX_)#^9EY02]I6\^S8X]QJ7*[;AO-L"\.6"5DQNC.Z=%Y$I
M-9BSE;MVVVW/5CY$)_!^Z\U7-8^E*6)Q(";CB_Y%Z9-S-&IB(;'@T.U/ CPQ
MA7.$"DHB-:%+FOCT:.$/^,:[K;CN9UR^2%7OEEPGFKQ4HJ3D$Q Y.7 \9D@\
M*>))EBW?W!8MJI0EB9( 5SR!4.7XW)H(+D0C&!=:I4ZBY)Z7G-%SV<,E/T-_
M?Q ^-I.TS$%;1!_&DP'"[2*<NH"0LY)?-%E$DY9'"FZMU-P:@=H0T;)W77&I
MRC#+(8Z;?MP\_>CC"2"WS$?I$1V"0)Q@#.4E*@I>,"U\XH$0ULG3R"[P4OLA
M/"FGAH@R7I, U,B$Z$)3ZIX KJKJWX]?+\Y;?QR//A0;X2H]=U?5]?V$F?/F
M=3%GVI3*TM!N4N+VUXRD6Q14"4S-1XN4BUBMG6>Q=GX.LW&)AJJO&#OO%DW>
M'FKSW'9]U^RYXP'':OWP$(/6*4'*NE"OQHB6C.*E<#&'K C#WW3[%](D;<2+
M$A6 1I( -*$B$$:#+WD*CG0RR4Y3%?;2^A'!<.F4A"AL!*$)0P43&6AN$L^&
M,.(Z2BD3M(,IVL?)9 O"B?9(78,5ABK/I#$L'WK)=:^*0NZP?EI(*LU1KQ"D
M54U=3^\K-M&RT^51F$8Q&,]X0+%CEH$P1(,S08%S0:(CQATAG<:I2>2<@B[L
MPHD6EL< GLO"\><DX:)84[<2#E73:#>FT:G9)ZM"GF4IQ)*[Z?9I<^5LM!1=
MM.>6B\SI+V>K,H=8CA(W4GH7=1"N^7MY7O/&38;C9CJX**?(;>[8.*;A5674
MY63L5]51Y=04'^P&H^U3V^GZP-M-I_.+RT7:QQ4;\SJ9N S@K)D,IK]!1C.G
MS><Z*Q5"BS[.B[/;]M#X;*O;\P ?TK9Y7K=U7N<Q+TZI<:8&PW)0O7EF/'&#
M::E'ZG-E1S?E^NOVW54';5S8WH$LE51%YC5PW[90UP)04T>PCAIFLF$A=2I"
MM78J&FN !U% %O'5QY" 1,U))%:B%WO(_B^FEZC:S[H0(:U)DB70V17+'!?0
M,[3TB'1"!YTI[2I57OK]<%[2(TNS29L96$)+_;>.DBGN\VT5P'M9;RI[:M9U
MJS9V7!CRG&W]>MU0AE-T2XI[:DI2;PF=H=^!#@OU2HC$5*"IRTU9.K*AGPI>
M9(5.#NX)[]%1]9%)SJ(SLG!>/%M3B3[6/A5EM]7=H8>5CCHSF=#?!&E21KA2
MA:ZBM!A":8A!H6;K$I4&1E.0CH*BA7[%)@8.H1)H$D1DIKS3YN'=A8Z:7&=+
M&#[@>'O:<D:2[$@A69*V5-DX@3ZDE1I\BD0P1[V,G<.<W0O$3M&A3VG^7T&'
MK_=^67B<A^@ \WR3<TOOF153T&WM9TZ]1//&'C _N1$N_:=TJH&&S;2/91L8
M=E,YYF@SLE<$;3,Y>IMX<36IO2:%=1PU.,MM\H4M3>XY^-)SF2*J4^NEEH7%
M?HNW2!@A2FVE9-04U$?3CK,,VEF:$;\%^JH])5S$Q=62G.'D]0GFK^H0UC+S
MLCJ^9/0#5%0>'+,>+?YHT?;7O'1OT8JZF(WM<"(XJ=$.2 XHX?@92PN/0C"0
M90B)$!MY9L_"N&C[:0-\6]0YJOBT.#?MG0B82!RA"JCF$H0BOA #*R"9&&.T
MX,ETPA][%H$W__[#HT6@5_BP$@$<T)_.-S#B]:(:Z-WGP72Z77D]'.34K&@6
M[JBZOE8'O>R3T: Q.%^$K]OR1(=+,DQMV?&J<+E8#A\FX\^S\EV<ESI'?%1;
M+E7('2?S#Z5>.A2*L(45BG<8+FNVO_2P#P>S2>E -237<L *BYYM$6;4:BG@
MOVPZS7,SUUPD5OI6E2[?7ENPK!5[(P7)^$':Z=A]D#X<?0SD[;\/QVV^SKU"
M@+WM$;':\>?M?3XNJXC;BN,%G<&21K5MY+4@6"V_7WUL_;B6@?5\^3+3\=?N
MM"((7]RM'*R/%_7F'I\P7]+A%4RXG+7U0JLQMN?A2WJ]J[9A9U][G<615(\<
MR>=[E?ZQ)S/G#"II!H&*6-I#EZBN0<O.&Y^4TBS93DNU$#,W+IG2\ _]@V@#
M&!8TH D0;?+!!$X/R)Z\[15T^)-'XSYAY=O1:/P)5?ER,Z:V"':Z&'S1VYUM
MU#>1R4D22AS:?[[4Y9>N5)82 ]9IM/,<-]IUJ7<>*S*;HK([1NWIX/<>B00L
M(;VO>+DFYWY.X.PK+3C1S,F28265+\T(G"Q,CQZD8)%Y0K6FG68$3A'FB#1
MVGJ'DIKE94@052!19(]&*7]^8FC9JSZ#_:0%]T+%1+2"' I9I.*B'):AMZ ,
M=8DIJ[OJ4V5*-)42=/$K!$5/&B$S@@V$^$@-:=L!/O_J]RGI]X_7@F?;/.#W
M.0HXA2AWA\!R/6-[( 7OV"F/)05?OV0E!?\J*?BIB?.*F;LC:,_+S-UYG5M#
M^4\@XEXG33ZCH]*[^!W/,BBBRVE4*(42WJ$383-(;K)/+(LD.R'HAS@>!\C
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MVFM_] ,\2>$^Z14_^@'V6J3K:E:7I3\S?!H#[#4@[%+'O2T'#V58I[W>1S_
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M?<FTK'9P%>\*8G65#P%BD7%G.;KP4AH0E$HPC@80.@FMDN-"=(Y6E/*2Q"3
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M=*>SW[K]B9A.<.JK'8;;2>#WT+4[&^H]F2:>IS57 $#_S[]I2O'K7Z=(]BN
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MO>N3ZN^QNK#?XKI'Q>WWJ!.YNI!1Y%7V0ZGBR'CF$+4X..I9D(&V25?.+J_
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MSO#8<0QH/VL'67FX0C? =^KF6K;RRS-DIP(/QFPO)5X(RX2.!!PHL.U<6(I
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M:@\R.;&9:..;J3+^,J^+LPCM=5M%CQTC5P_I?*DR7S*>"XP5&%L-8SSG7AC
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M 3I*O043036R0><*41>DEC0)O5A&^DQ&^VE.\SY/%:^U,SRM2BI"P:RRI4>
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M &X:<WTCZ9,OS/C25$=F?"DT9CUSD^C'#4G*7&7P+0Y[<*W)_>_<N"$N:RK
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M=7NL7],2G"YXM_=;6FA\FVWQJ,'14(,T]7GDFM/PDPNY0XYEGB5)Q$+G[(T
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M QU^1_<Q1E-VO>+[[VD<ZB;%??&0WLI"A\=3(Q!)(  &HTD+J^=E:T[&P ^
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MJ@HR*6*SCSB,)A(O9" AV"I5E3=>;XQ:4-GR)),@0 *&2.HHL59S$HQ-S+G
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MTCY(/H5ZK.6D2?ZWTF7R^]?]Y-=?/X2GWOCIZR50WR]EU93 "^?ZOY.??*U
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ML0,P6C6>C*OZ:M[[-:Z2:E*O\(<EJH;_&D"RX;"Z;-[-4]U.J!_KX*<IP@2
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M<##HP51W7C\'F:I =Y/,8)%20;C#_1/+M$[G%^#;K][U;#^[VI_QJ5.W0#K
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MEL+6 :Z,77"-?[WPXB<T!I\/!YR1RPG8[!9,]?:NIIE&!'K ;O<T:277]4F
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M>T_YN4:EUOP8:7O%9>V%:[7:"Q?5BO+2LXV7'GV#YUI;/M>L&,E5] 0<QA.
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M#)A)IP%_#0?8XCLAO0\(]1D!B&P!7'ZTPU'RCGF#XN]5$'>@K"AK463-/?1
M45%4]"XCB'X%B.YWON4#:R*(?AE$W](GS_7&,])]XE<#"!+NFR,VI@FJ1B"
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M@&?:<]N'^BA[VX0GZ;*7FMYCS%X#DM">B19$QN!%GC_9G@U]_S$XD,?LM^=
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M/;J$EVI)C,5'JP(77;CJ0- %CY("#X=RIR0U%E^*,@==^-&2<!SQ;$=%Z#F
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MEM:_@IAG/<;(,-PP2C!_=SF$.84CNHIX"D@)F"&5EP^@XC9"OO1C0VCS/<K
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M*88[2P:^\Y-Y0K[2%=$,.!ZU6J8P]K2-0QGX6(SY'XV'M]9BH+)!O$CO5?0
M9=A6?\[]) /YX:15$:$VW:<2-L4E(WI:P;SCAZ$,4'ZP82:26",F#]"CWJ/:
M<8/ J+)FZ2ZCL?]4WL*+OXJ)A5Y1(J-5-W>QRSQ5A2*>RT]B/4X@IB!0M5B"
M["\H*VMT4S8)AD(1VZVRBHX\B>G)3Z?[!1Y6\UBWZ3F!,);#8P?;E>[I2W_4
M^X)%HBE5T^K?AXFV.?G^Q\\U/#KU0VOLXRBCE@L  ^74MB%O>W?XA*(5]<$1
M9V_G7.A#R S$24HPPW?XP\02"/-8S](TQBHLOK()!'G=GDXR!W5L'4QS C>A
M(HE0@#7K$<?7BJ![7-.K:)=GZ37 ,O_0#LY4TL,A:J89^Y.\-4_U]^@>T50;
M+L]0*400070!)(,/Z_Y<R&#8&)#M:AX5,+:X 9;Y$OY/J%ROK?!GC[[#Z*8X
MR0IL3#R0UG:J:NTT(Z&64G"/(*H0$+]8RD'U%V+R 3FN39<?*UAQ\8;?!"SE
M@1Y(%2E-:L.(DQC(5E*MF/RE:XGE+ZYO3S4\!JL11I-!Y^O%!M6"\EN9!;I1
M'  *>[Z^"4)\C/  3,_ S_ MRD 0DTHUYD[NS=Z_QLEO16D%/*_Y&B)(DA>E
M3ZI-3W<O.'D'2H CU8M;;S9@X@/3^5CZ$M%2Y]%LN0FPR$,# Z@I#Z\@*T='
MC@8D\Z> SB67EZT.,$3H!XQ<X(83!^4LH\'F1&:-RY X6F2X5-T6"7FX]\1@
M?H.RC3QL<(!1;,<B52LJ@3QWC^"YAF<ES8(MZ#0BE@. .%S&N?32/YR8RUCT
M"FP%J595E*,R!(BU[#P5ZS_]Q(8MTB8?PMGVPO6)12EJ>Z#"-7-A1\_$/VKP
MC+?O;_M^XI81M8A5;^(V*M=TRS7/BV >U87M]B/\_C)"F$4)2V!K%&00R<F3
M*VSG=FA&&MG)CK^IAVR;721)G)S%"<1&X9E)8#E:=K(?L$OKF-/KC :A:9.N
M##TF8 F<X0FNH#9U\()*B8,^7OCY)H4:M[N<!_[4RUJWMQ!:&V@(,S^)#RTT
M-A)Y7%C7U3=OVZX3V.9"$V(9 QW-NX;N(UT39P!1A65A!1Q&Y<_.JW*0: "P
M\D%Z61%'V"JKHQ,)]VJYNM9(I8D[X0]E8$?#"N5+L )WTR.Q0Q7 8#, 2FQ3
MM^, 0@-4OQ 3M,I@+4"K$75(\@L"\:J,:+%!T?8+2^R7Z2*6H^P1P)$R,A4"
MTV3@Y^J*:5;IN[,<L5 S->SB/4J#%=; M*Z<CE0F\(K5A8)SD"?@0Z3GEE2#
M:!>JT9[21&S4962]%O/0T,EZ"BUH&/)BD)(&MJ&/FW613SY_.>E42%GH,*!=
ME=D[YQ$OWD.!4ZC8^Y _A;36E2+>X"!"4T*$O#:$JVN[.)1O5EC 4@+;RGUQ
M2D'H$%KN$F)98<"Y4")5M7GRME,P3V<2Q.*^U ://5]L@N3PT'-E[U%#"Z$@
M$_AZH$!3GF98;4FDD0+ZME:5RB6%1*2S9O\H)\U^\;<_W=5F*/S!G?B#B(SZ
M%>M[B1]B=7"VVN*CFI+<F!?$U$$Y9/YA-)RQ6H.-J985$:JQ03#,4L%J-QJV
M'_VD4-VQ"L6_3XU\I&OO_ G'LO 3@*:1Z"T>W7>U NEI3=0B%LK$KI]:Y4HH
MTDZ*!6LSZ<<9<P U7"9EFU5M0R]WL?],GH1"SV1EJ:Q,G<UF(:!U]ZD9@0HO
M7E\CD(Z0<Q06_)6<0]1J3)(RV&U/TUH57+;I.1G->(6V!00?$M6E6K57:(FV
MRO*'O<FZ2PHG\P0EXPUJE]*B *Q0WD.6!+]1-&M5@E/K[I:O41;U2G*LB08D
M1!<W@QP+R;PH622!";='US;$)&#:7&W]9WQ//*6"G956-=2@2[;J:%O?8J(X
M*=.BGINLF5.E-05-%(MY4 ,1W\5YD&YH6!E\VQH%5M]O:M@WL^629FU6M51E
MQ'$G(I9/TJT?X=?B17.(:BW<(R9I+<C51A.PB=\CLH> 3+A?8/4A]4G\0WJZ
MK_REE56\"ZT)L"X/9Q$+%1?XNT0SH+_KZ/JV,HAU_:.FX$#Z55F*&E6,<4WW
M[&$T[$?>4G\V2E7V874[Z^L)D.T1M->5898U&SU"*@6T6I8XOLSK2Z9O.\VR
M7EQY/%>Z*EMW=XAU6!@AC!']\K:.(;'@FP<G4C>]OUU?VWX_K(5"<M3/6  N
M@,6D_CYI0W<9AAPT2X#1+H$Z32]2V][68QY#/)&8VHG%D%J-5F#H,OE;B!2H
M?(U[7D:<BGN!5O6^:AJZA L3H1W:P7QJ^PP$%ML1)-8F.&R+B(-Z%9IY=)E#
M:#<_GU4 "6/<05=RECG[)2;A=458+<TBH[^E,=6:8ESM.T] I:G:(-/V:HJR
MHS.F%) 0W/ &:<]Y")M 8K^I%$2?:-SZ+F;%0!6,6R(^$1.VJ6R'JK6[",1^
MP?S:$#8[M!T*&?C\@8%-*3[POSLMR8'^GH-#YZ6->*!J[BY.@#K*M2$/U38#
M&6!X/-Y3&#QS&+@SJ?+7NIOU])8$?SUG1:A0M**_.3<')[3M.HEGLR9;5>,"
M.IK\NE&;%,JC,LZJ9<>1(>B$J"]9@4Q%HRG@ZFKOGF:[B0@:IJM>U=J^#N4G
M*Q_B$\W7D+JQ4R2A9GWB6<:Q7G2R7+N^UN/2% "=CRE:Y^%UL$;:._) (A-X
M&5J!MT*5^R63)^OPK""J==##;(]G/T"Q@/''(T.:2[ .Z%ST,/F=N[N+A@&8
M2?IPRV4Q34.W. $-T+QF]OZ3OJP]2U9+@B@-EN0J407]##B@Y3-[[?\)+,KJ
M%Z+:8#P86*D:V[*3;<ROUWBQB?/4CU:+5SS*_@(L6P1O5%,YW=AI).\F3:L4
MI*9&M+;$S=FBDWLP2:%4BF"=TX9>MNOKC+5%XJ]0LP"X5A[6]_DFXMR5PM$(
M\>[JL2=F((1D'RUFJ+&;2[]460])GA:N_:K;]Q\^#Y5[;?!-3T8.(>J799*:
M/$%M2%@WMFWQ?7Z-,KQ8Z0.53,H 6*GORM1E+,"2^ 6I(HJ:?Y]XAIE*CFS7
MV798*;XNL;[UY?/ICU^PS'H3K_!UB582J"AC<[<BOY &E,3/B;\U8"IKNMA'
MNRIP,,@W#@\.WMXR25N(/]&%S1U&R-U-3U5!!=X.1?3*\8EG$2" ^J_/&.I!
MT$ET(47C;!-;6+8<QFM138_$9Z:UT\+4<Z0H*?9: B#W.0  H!6I'C"/Y'GI
MW:E8YZ/0I@J)D^;1@EE*43NN2T_'48XDC!CR_76858V&$S'>4_M@L&2R5Y&%
MULJ6K^SL[ODC-6'(B:$@ $+&@?X1-'><9":>L6)"R\XN09*)NH+/$&@O>N.J
MHO'4<JG4%X&FPS"OW4GUT3*^<?+V$T.ZI6<:/\ 5V"6]!>P02A-CNP7L+D>C
M*BQ[Q!VQV/B,TY0 9Q=8O#5<"_+'<RP1F&+'IC,_ZT[D,_ +"\&_8+G6^9$U
M[:> 5W2I,+\<3FPD]8%9ZO:\_@R\RA+=0=K,79Q>'#U#T1-SDHNLI6/S>[2B
MOLN&25U[K[;KZT[:Q7(W/L[+,PJZI/4HR-M:_HI9C#N^)?!SXX?UXCBR;]74
MY9OP=3!9CK:\\9/?$,'@+PWV(_@\S'-P"#7SRCXN2#I+X@C_N$2"\TX?:'$P
M&7?@014YE+IAB?*B0EK1=)@4$[,\V\0)G,X.C B=)A#_I$;W;8F4:R3@C$FY
M%PT+=7<)EHF2/36P+@/?\)9TI_-NHX1^(27*JYAX \4'28>RK@+0'0/+:!FV
MW8BNEVL#[;JZ=D-4:@"T+2#0KJ\[6#+0%.?KQY3>(_.GS >C]E7$-8/+.%'D
MURH8[D/1H2@OE'5C;P<3>90"O+K'= T@RJKWZL)#-6,"BS64(GXYFX9S45YP
MH+)3H#<OF_M-)>M;;UE6-![)V'&-GOV0B@B2C!59"]L!/;+Z\_C(XF6):.TK
M"_7LV]*;$IB&9#M,K1UZ(\*0WCOZ1*)ZL\E#,QMB(3J3<9UC"I$J%"5 F!U8
M U4,FKK9%X$K.ADUA9"84"B?FRK0O]ITFZY$H2P[NEJ19\T/63A:&5=D"M(9
M=LQ1X^@OMBAYAI"\)'Z%BWN[\Z.ZX&QJ[= ,$R\16J4TS[_RT"MM,.H>[^\(
M5[-K2E%T$6?P>HF)-K9/<I>A;4-Z\:PY4GF,1S>&?D3S4MC_ZL%H.],8Z:.<
MX05>D9@Y>1W3ZM]=YC;OXHCX>=<68Q][4G6GG/MOM)@GR<M=QPFYZW6X);H>
MM@-&_!"E==^2X,F3!HV8^K@/S0-G$);2PX < AY_P %>&"KI^A$J]Q4!Q0!.
M$JS -FN*Y^M)?0*V_-ERF>2H!["%D<#$;/G7!K@"4Z^I!9OU0.NV =$]72<R
MB4@8VVM,![4>RP?&D4?\O-5K0QN2<=MUM#Q;YN\HDI/O$5T\]CQ<QLEI@OSE
M!E\=O G[4Q,?TP)!=^F*+WX0PAG"$X2'$I2',I1 @,K'6E):0\H^1?BMAP=&
M<7[MT)[:ZUQ(.RDO%=/M_97T=R?K8=HE$I(^DUG6=)B/LJPH9*Y$;^KB;&GE
MD-#SUP@EZ2;8*0MF=>]O^QZO!4"0N&-M$4\S@$YOFK:!-6BUV'OT@J(<E8^J
M;.[*M@Z38Q*LN4 <.):9=)Y!24.7;@O57HLB'M.09VLLURI"@VU0="[NDY0V
MG<]2TG"4_'@8<Q[=HHRHS5*W69M^H]I]+[%R3QTJ2F.OT,2AH4D!#X^O0ZB'
MH/BS6(_&I!=:'<(Z A=<1F"8I,&<!1@Q@,*UUA8.H&+=\13%+W@2#Y#HCYZ#
MY7RWP]=-'A&Q]CK8XENIT,#V9W&RBZEQ3Y>AT8_D-Z$7ER5!A+^-I1]K!K?]
M&<#3!/AW=6SK)4-PYFX(J332H;>[*#>T8T96L"HRM5[CQU*W']AE?!41%UI:
M:&+5HI_MJLW9I&P;*P2]5H^)&/M)!*(246.^-ER\AQ-S*"C7X(R)H4$I+$L;
M.YO\USA>O09A2'2EZNDRHH\<1L,M;J5P[RJX:31SGD(''X2YZI6\L5,,WQH(
M+[ZE,JP>9FC%0'JKOQ!:*HWW?6BZ$U_\T(\ JQ:AC!5Z;!\XT[+S("GSYU_@
M03EI@+V8<+H/(N'N_BZ6<[X60SK8:A/ X$8JAFG;>A+])D1M\UT[U&CO+R[I
ME@,P-&$!R@#'>ZQ87]+ !]O!29W'GT(L^T/^%"<K.#A4DC<4#3#U<^<>8[GB
MK8!?%(TG J*D"1*7-'Q_WZD1M>,V)FX4-$% D0Y3&Q_K4.O9Z=1_.HI@6;DZ
M#.-7$./::H62GI-00V[\C#G617-*@79VI0):Z4?+X5N3$J,V\^ZH[>&U9@[Q
MT5@2IF'&S78N R!(34%>6_ J.L\1!)LS4?G.3^",F-#0.A&Q?[W!6D)*,+BE
MR,W<!LVD5;_W\=W?XNMW\8K"%W2#F=J8L'X.H^G<GUH#%+>!@V =!*&E55KP
MX>%7IJB><;@QNAO!L9(#\E6 :5RS<D"R](!:"Y=*0"UXF$-)F?7H=GW?'ZQ&
M(9 2'9_GS]"J\W"-6"^^8QYP<GY]@]*K[32Q"[5]W%K[_A,!/-)I?+*6HT:V
M/&S],.2V.&5P2[75N!/<H# T95I6&EE^/<6WB^3QBXB1Q.NZ2] R8'_G!6,T
M=6IL4;5[O T%11=0B 02S5;!2[#*_5!14U3>;A)(V)6$>(J)=A4)@4FJ!Z4+
M"8>J%(_@A3AJC2E.TM#R!_,52WRW*$_B=!F@:*G)*U6T=&K/!#4%/RQ;J,F\
MP=\H_$Q]%$B?I-BRLSLA DI*SM<,16&>$ R%"NY.\<>4_355"5F'T7*-!*R+
M^;5!<7C^:M;;LCIL2V[4_2W/_8:@::&R/,)L]=\Y0_AM&FS46DY/8O_03H8!
M788#S=)=+@U+5>;%5$QYO^KVH\K&L]4J =0Q^I]K_,K4+VQ]6\L?_3Q"YP&6
M6G%[]9O?;.14.$Q9VLTMTFO3\K933':A5V3]7NR>XJ*@,]GZ+QJ9MU57VVIC
M@J4%'PQ'U[&OB<R7MG-GB916";UX6X;Y"HL1! =HN\LSII?6[\'3O9R 9F^&
M''$R\:8MBJ5+6MO6RQ[^0Z.*%7]T=QWGNUU(Q X_%$,?A9A'(QY'%Q(.&7U*
MT=]S/,N+%Z:'ZZMR*=L[KU<%EBHP]"!2.RC>HL*[K#0_&#M:SU'(2GSB.$V9
M(H?_!7*H/!%!V\,Q7@"!GH8CSOU66F./NH?MC&?_3^!PN,.7\M9?(GP=+WUN
MDE5?.RUZ.7=4$%!KB/,P."3*=L,; LH+31\\U:[G^X@S #L+ 9FS%6!$B;F3
MM2HN )@U[ T8">\2M UR%0ZJN9_UO-IX'61P$TK+&LC;O#_3B\X!S-^J^^:3
M,=ZX3C_3C'U9!E5+VM0EY"D[E4K_:]' G2[/]U^P<X(!+0%E!M]8SUK#1-O>
MWT1:29G=1AN/D%O2&-+=Q2:KOZTW6FEZN#_N5Q%6ZU-2;_NDW1&7]'!YM0"<
MMW;BU3:67^5+M ),[+JR@M+"4_68X:/,'%4RS^7!9":&>:6Z!E2MW8HFQDHK
MCG&42B@M"U@O[0JA61O(\B<F*>L"I3Q(V:.KJ+B6(-R%GR[9)W8(&7>H !1J
M'Z+F\0_:ZTW:U'8V\J%2]15 V_@AO0.(VU$6AS?,&!-)R"-HV0!9: I;479Q
M#XW9 M"\" 8HB\WQ9"I3<3/KPU@^_=7-$>X[B3FJ18=1(P:9\#-/L!3Z@E\T
M1<"@M)D[O%*Q#!Q5RIER  M(10G%66K5U?;MF&\A@V2^?@BP<K,.ECY)N^"5
M;:&*+8'WDF.Z'41BI  '7M'\R\D3"2F5Q#4TFE@'PN#.1%[RH@5<K+F3^SNU
M"A=<*659M%'FFW2E,L40B7:I3CT(N1/>X?*A@<GG.5A_:!0'N8[D8HY*..].
MR+%66'YY6J%5T7@RD[]\N0U*I/*O:J]PBX[NC"/,Y;*(V1LHFZS*:-*J[Z!X
MS1I_I:R=.[L\]3C26A:Y'X+W2V>;5S5_?[Z:&_\MV.;;HC!5_I0NDX#X3H9P
MT9B&LQVR@*7W!%HKD*84C29@,BJK^LR3IOD-H7;VH'94)I)K<P: NG'"GG[M
MV].BHSMO=!E3?QDGM^A54 *2.,(_+IE-3A/+UXG&-)0\BD:GKTRA;.^,A5N4
M <8A7E7P#Z].]X\I2*?T@(']!BO]+]2-I0>K.X#01 (FBHH<!(*E5:Q$K8MU
MF 6F]3!XKMLXDL=]FEJ_O^=8#2&GPIH>94B':IB@#?\)RZWI*E@:GP=3+\OG
M]3_]Y2I/8K6P6VU@^VO9^L_X<WS28-976SC'2;[:[OP@H7&4RH 216/+BP=Z
M'H]GP%<(,UNG/$GC'J5Y"+<WA,_?8;T]8>5F\6W#JQDHJE=;HNPP2.*9%D>#
M\@;<@+FG_VN,'F_5U[;F&=-'-GH^19E_,GN.HP#"HV/=EVGNY,30+)/N.W=W
M&=%!0!:@L'$F(BT8 _3;]+2O(A(H @%,F5GK4*&:*K1&<[_)9$;HM$594^O@
M;O+ @UD4Y7Y(2Q.12#&Q8A&O4(0U("'^C+FYI"Z8(89QJ9G<PQS!1HZ?#+7:
M46GE/#I1B,TP1NGH^TP(31&TN @/I$8/T_=QGE[$W/*:TBZREN\/[&S.H[Z)
MY@)?12UOOH"AJ)EOK:.@]9B)6Z=761L&WX'/B;\M)CK+LPV8V="J;$/C6Y2K
M=SA!AQAQQ8-.,S $\'8%F]HN[\\((<NCN _2WRX3A,120F/D;TC'G7Z9"Y$W
M8[)M7ZKO[X0984^P,+9&009YQM/#@.\T.==8J(74:ZR((&T]: 8FI%&6T?$=
M,)A4'0>P#M$QR1& 4  P0LTC=<A\^WZN\<LJSAB=@JAN;Q\"G%<7J89?"O4T
MM[LX@@]5X\\]A(QSM4E0/5-J*&N?DL4[N,]$8L%<E?0OEDZWFD/J&,VDH]D(
M16(=OH$#?6GR 0=RYSSUW\[P; ,:*KZFR%T:G["ZO3,6JI&+4!)4:O.F&#1%
M,#Q87S*J "SBBS=_"Z".) X2/ZE8XC.BK0T^K+,%?8Q\ZF>E-97 H C0*TPG
M5RR'H9/+(E-@9*-A_R#'&\V_NAY.4T&TWL8I5+]2X)-H5UO?9[I*1:H2W)EX
M3H1PJ.M+'&HU";V"K7JHYF!Q!B-E 9S'RYS[4209 )4_3RWFFII4J%274I1O
MH0Q=$<W:+?ZZ+5&7ZAOSZCV )0D?KO1Q!\6[<,O/G_^@O9':]75IE*X$_]^B
MK'BKBSK(^FBK3B2<QC>""V#/M&F=EB5O:UG#^C7(-JO$?_5#"#O0)]LJVPZ4
M&VP#8X*HV\U"+C+VQAAV*BF\ZA"O7PBV,"N[1@JTQ/ KP7Y=>[T*#8SC1DJC
M%"8YT7<08]H[MG0 DTRC:*2QIGV7GJ-FT@I>)IY+> 8/)4IV?I+M;_VM7#_I
MUM=Y?-TL:N37F6'N#B3R;EW$O_0O,#O"Z+:!Q0MD&HA1J U/0A@8Y&N<)/$K
M5*M6('L>1LA=?E>P#5@%2ZAN13SNP5,.SC7J5U E>AG[N7Q4J (/GH79BQ^$
MQ*X9"[[H31RN\*S!ZKE4ORR=J-@&1&17*G$O^/"*\UST&S_")PD_=5?I[C+'
M0M=.=@P[];<MC8&="CT'RUD8!F!PN_&??!;A(!6*=.TMSVWQ&B\V<9YBR6CQ
MBC_$/4'HO(TS14YORT[#P[$N8J'8K"':^# :[I7!KXDZZKW6R*'1LP!F$10:
MHN<HK:#J'I;/3>&D9AD_K)8-E!"Z#)(T@\L+;&Q^2$N.L5A.V?$YE)1ECOZ<
MXR.\#O 9YHE5ZL]4V79J^DTQOT/U&QD!UZ6O##6:+1&UG1J!L/R.JC);X0Q?
MQ*<DGJ(HP26#ACZ8S*AE?"Z#$"4L&UA=X[+::@I7+%6OI [>]!ZE>#&7&_.U
MVXK*5$Q2# B NF9GI61-:Y.$ 5$[-? J8X_N+D!$J+[1RJVGZ3"AB'JCD;93
M5]MJB0^B^F_58@I0(4_]*INZ.(2A! UCMPF6#>^Z 9/2U&\X79!;?XM@N<[:
M8!L*SNMA@$U$$_#3:#8=%*(;/_D-D:0CH_^U75_;D,X^E,5+9^LU(LF=I!!*
MPB25%EIEI_X3@$^A-ISRW_J (7,_ZX .$9;L7WS!JJ3)5E<V=F@^-+U2 SY&
M1:)IGF9XLQ*IRM%L- $,(W4V;ROP(D/W"7UVC4I<K3^\9D_; CI^1-+49RHI
M?05)M-=. [UIZC-!*$IE]D"GKK87/UYG6-T *!):>Q$EQ2'6++^YEVTK"+LU
MYI$&L:_9R+I!G52Q[U>%H3N143W0,J^X L]9V73DD$%08N)D!UGU(#_?@\$!
M88U )4!UZSOI(+0>P6<3<0RV<?M-R2P@>ARI#F=.!^A*92K)^.K356EE'XP[
MAJP8K%/B+W1%3&*MT+A-O1QFH92%"6NY7\H$$G6/X1T,ESFDCHKV?VT<52<"
M+I,]Q&74FI;D;6VK3?X6ZQ $TD;RP$J;3"D)\.!85+D?5F4K'GY@M]"!M,P(
M<R3Z(8=6,T27M^HZ=,C&)595ND9LU/NXRU[ +_%\?8_\$$O>>#&Y+J]*6% U
MGV8NBHT" %I*SMBN1?)QL])Y$$+06UL\E*Y4)F"KNJ"FWA=4EN7 Y["::=HJ
M1;D72:=)CF6T?1GKO+KTEZA#V2MY3^<^=E:;45&ERN!:-W2V#WZ,E11?9Q\7
M&TPY&:<2*'(/5\)\_9@B:<79L4=W]S+R(%NLCD),&7P_I2-LQC.Y ?2'P!6H
M7LRN9)PQK T5+^*BR!]U0&R=R;R_S(2[ B8M6*(*LBC#J[2=C& >T!T20@HO
M*+/:JCZ"6B/+=^%7A.>,?O73#3Y861P]1@%)%H8B&JK+V=C',4( ?K[:IP)I
MN]A6U]$K/H58,-KY(94:U(NL;/M-*/"C%63O^1(J-S(KW9PL$)\>)"8W7?A)
M1'ZU!+ >^?YV(S%=J H#3H0Z>]4*3(6ET:<3=@1H[1E^W-7P:YVZ3M"-K2PQ
MVJFK;1LV;@+AC.?H!87QCB)JK^[1,Q1LC)/]31#B-8TC(G?BVYCE4DBMV0>2
MLLS1Q5N&HA6"9/* QC6>*Q(=%2W=A2+%/K[Q0=U>9L2:=!.O2!T \NUK2M89
M^TW!"(/O=3RUE*?LDYQ#$AQ##$==[2^=J%FO\U!6MBL\9?,(+8(M*@XYNZ7F
M$<>@E[K>#J,T4 B?.6YO&,,$Z'3S=9U?BMDO9&A)K>0MNT[%+PRJO(A=9RJK
MV[J[PX#G,*?F3K3<1,'?<WW8L[2Q2\QG_QE_=\\,;9"5+#4]U,9N[C5!!K^>
M[36[H6CLSGR&-9P57.!8 BKM7?2\HQ4@%=&8.;;J]3? M&O6R+O'8BV5=E/I
M0FT7=Q$%% >KF\W>T,EE48%=@C9X+H4_"((4UWB*^%_TKKZ#JQJ_\1G-1:-
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M06/W0?K;Z7Z!^_7(/JE0]("D!Q1'2D1YV,1)!M%V8!_NR0FA16,(:5[L"'R
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M>9(RV2-EI S#>W@PV^^3WTJ1-TP@3V@1GAWETQ<B(B&\=TE Z,&!16.2(.%
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M4.9T:N;W^8Q<U(U!H$/>\H"[^""IQ@=)@N*#V$MYI<XR[>I:"6CA6*\KS'8
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M8/NB"PW7Y-_$O"K;QP:1X-XH9-M CM,IC][8;;;+MH/B%G:#V+?_-K=?&S#
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MA^/1H6?[S1H?N*/=G(W$!Q[ CQP>6CM*87=5I(-C9&\5PSOJO7CHW\E#I7R
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M9V$,8=^700WGU\$4(1JA@J3&P889U"1W(O^\]1F%WL]\&%\@!^B+ @EHG:)
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M*%9M;YRFW$.]%;]^7=!R,D#)-Y.^09@JGV.!!T? H$4<KG]5W7!]MT40%C-
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M%><:YN*-L+*$\(I70+N<SY,:FYNI%1UY33U2%NABN^<QA':":?R=E(MEVUP
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M&*I;81CQ4K:/O7EL;'R445X@,E L,]L:FB9%BMT/!*Z1Y<420C-GU[= 4),
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MG[82B[I2'TOQ4"&KL9HUC:R?\E32#V758A50B8FEJA;*9PE :IQ]2^:+0AK
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M=(!3_)?W87GG/;2@!'*[&QCX$H#44D*%%/=2./2'V;+&)#ZF*&?MH_I?K&%
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M^E#-TY"^W >6VK8*_98ZH1T%"!Y%/IBGC#:8NMC["C3 !+(O@^O(\C]3'DC
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M+A ,E#[;\\L+_T$4KLB30X*7P89:39N!L,F2C3GEB%?7XG'S@,K&<0FB*/D
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M+JUJJR\MKF:='VV)T9HP5<RRF'P(^DP<H*+#,XVZ0F=1AV(XM0) UU=&\W*
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M_._+,(=B<O?T-GT/ RK>ML@"0%K 1D%MJ$P 'YC MXKE7=&_X+/!7LO[6*G
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M(Z]=:/TB02++C\0'(#4L8XFC38)_[)E:G%4C]#O" E<&%6GO?C$LO3MYQD+
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M:96Z !0]25+"S@QAMGGP_P/P$>94@][Z*T)5W94OTC$[40P>?.\?,(*WTX8
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MOX5,P]AOMWYZF*T5]]ADA2&^] 6:)U&XH@_S0QB3^YQLVP:% ATO!$( @<Y
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MHU;2=+T]_7 9MA_[NP^^K$P^%ZFF(Q?UB6'*V?J YF30[S9)% R #\6\:X6
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M8M/VP=51Q$1I[.X?=E>Z:ZD: .+"4Q*?65RH)/G>2]>MMV.D(0')X[ F_0K
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M!N^]\'LW?!O#'BZ,!V/"8P%]'@['#2N5R/$N(>;O[*^*41+0F5<80'@!\Z]
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M2UPBTA*^SM%UDJ;)!VUW3I)TZ9&78WJL)'OEG"CC>G+@7O/+AUL+_KW]KM=
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MF:@(HS(#YJ4O0^E;%<N1E -OHO)R[)3EP(\0C=2]'78 P,  Z<-=&)%T"AZ
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M*.I[*:'2;;PZW"20=78F<PI!3U+T?F4T+Y$O#91![MR5-RZC74;P\JM?^4'
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MH2\X^)HDP4<814SP*=LHVIPP0?F*"X>>P1@ST&'KELFH.7^7Q=@)EB3,Z=F
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M246N.IW$^&SS@"D^Q=EK%#( O:J696TY*A,9?=&?<[JRL-!?2?*6^KL-5&4
M$ZW*0VU#)[ZLEY@J('B;?:5O)YB09K%2C\;T71WIX@1;9O@F^QM5U]X)AEBR
M+P^_,KY+:@,GICQY]\,(E-F[) 7<W0*Q#R[AXF]&!:%A7R<879 5"=]AMAF
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M,]UG.=V3M,#^IZ\3_;_ 8@@X@XP3[)=,@-=)FB)LFU&4M#8>_])AF8"/)-]
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MY:03Q-+A5)3D)N2':&4#>FO2RXG]$19CF\])_7W\W3C?!,6-_WI 0/5)['J
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MRX[?+%2AIJT3>\(N?.E]L!N'C0W'WXL% 1&6'OUE F8<VFU#]=$;>GU$"8(
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MGT\H\VYN/#XKO"(*QC;;W&N5)DX<TJH84FO-L;9V@QD6>W?L0#5H[@0[:ED
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MX^>_)/LH ,2M52ZQ# &,QA)&<!XE)Q9A1F^_210E#'7,4AK@:&,G6*F""C1
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MG^3R!522N0','1)@6:Q9; !T.9F$"VQ++5AJ! Q5 @RFILK6)W1SX@)2DC$
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M9QEH2E2?=UH/Y<5-EJS<1*_7SBS-KIJ T;9M=RT.0"%=?-M%=[LENN75R+Z
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M4DJBTCOH(:'-<R6W)>-9[S%3W[RG>?/(V4K3L>6]6&OEA..*L\*'90')E,U
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M^#<?Q X4(<5/&WD,]4M]#$]9FCR!,P@^4>4H6@_URYAPM+G27$T>7QE$+>Z
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M\YJU30\@WKANG(%V9N2K-)?HK(J1-(("^=LHS(?_XH39#OXWB_UP7VW'!:L
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M&;^(TO4R=D+EPVM'0)V[#\;J &,*"^YZ'@[BT\LX_P9Q8IIVL0C_"R7,F')
MYIXW VL@$7H<&*345;X6?UA9Q]1^+SBM<AFN+Y8XT,U\%PPZ$B3SPNJ(--):
MURX91S5H5/Y%4]P$ACT2X_]Z_P/])S#GF=BRI#?FY$A8$]_8_$0]_NTQR,>%
M? ^[B/*<DQXE^3JO;\_FOCT_AO!N '62QB?T$31S\F&F]5C?I96]2X_?4^I]
M1^^C[P2#  ZW_PQ"$#L!%.4VWM$/?80PBK@J.4Q"?7@2&T/;4NL+OB@T@^<H
MSU%XAJ(J*,3;Y!TE2FS^CFCR.4K_!V5X=*-]Z/\.NKE;U']O=:3A>D'-"S)!
M<KP#9Q!$)W3L2EIDO:,R>YHK8\W4N\+<TU_$+3U$<?DGU.[GJ5D"?A+ZP4:Z
MU#;7WJE'CMQ^WAX86I8BL@0CG$<DA^[/^[%AS2FCW-PLJMHO V*5[RI4)7JN
M#ANKMXP!X'.8;S@(=5',ELLZTB)',1O$(D!4<V,I-(&L?D=JG$!GZW,DS":X
M+#J+(,/576MEO2S[TS+<B"9/2BD53Y/8L2U^<:L[E@QW+(J!=DI7K 4@S>?X
M]N<5;15H=U#^RP+="UMXYU*%E3Z%@V^0@KDEVRQ-4B?T_'#_#:#JE%#&.H/8
MV8/['R!V_3+!]VL4!+LH1AUE^Z(-GXBYC\URUJH7:0OA[2D:,_*7E+CKZ P]
M3'68FQ^; WA%H)!ZW,KOK"ZLYKJP6N3U)2&DMGR&H%1NEG48N+YI'Y3],_Z(
MTJ2&B>_B$K>H_][J-&V"T_3PD-4H++:X*AD%5Y+EBYKFKA?^_DPA5B,1B'S:
M/F#[BTH/('X_..6BD]KBWU%1\D#4.WB@'QP_SMF80@I7-,M%;Y?!>V3PQA!%
MX'*1^6*2Q[!X]%)A5) X W-A%EKCYSA*I%L:*%_2"]L'>S$?A,64NX^4M;8$
M2@H'4/A!^VB/+ CD1$(,LU+X0?M 9-X25/9EP"TF.C]SMV@-Q%(D U27K%8Q
M0&P2^L!&;X*H/ KP[K)KL<1\:4GC\;]>#Y'+B@]D+H7Q[2VZ5I5:P?O?L0\R
M\B7*I"B5GS0E=37SOJNG//1*-F]^ULKOOXS7["?XNN7PMJM%*<6R\REK@2,[
M,KP"),O!O^>5Z!PWS9S@'<3'3XIP'3(3^^XT)E,LR*OBB)/K2)W/SQY@\[14
MT?F9NT4L/><ABG? 1T46M:I;HM-8,U_H4Y\P>Z5(@<)]R=I;OJ$-<MZM$YB5
MN6=B'[62U<@&64VGNS8_:A^8S!NSL3SSKG.AR=FW.39Y8__Z9V/R)-F<\LE:
M1V"=^R_)GGL51O+XW4F<'[D^;1^P=OBE64FSRW!ULG)K6D:&3>BA%!?HAGF/
MT)_T7N,C)V7*W2XG!^)<Z$CI%<_]>6LU][8UL.8]JM1SXN=,>?0D7YT#25'[
M=.: ;(<OUW0#R2C_F#&8,R=J'R<6?%#(A7=37C<ZD[$DGX2R= !2TMJ(6F14
MI#P\%0Y<J1.G5F4*&91]2^).M>)PUER4(\!3NDV5(+&DH[.6*-=/\R*!Y(I(
MOVMQ7 236K-DVWA:AL9V2SDY0M;E)=TC!AAN5>VY5+/W2A.F*5PRXX<7D4K:
M>'6+FUK6[3)*%</&D*O8(T@7'Y%ANV1)+N7UK,A7X>3X7?;R!ZP[9J$:42<N
M6'=O[FJ#<%Z%A5R%V-R1:ZD2W4?.+*U,,*.#BE(<!AX=PU0S\3MV&25HIM/(
M!N3RD+H%?R^V( 1[9%&?Q2;H>JW!I!A93XN%$OYZU R2\LU+A;(>ZHFET-%N
MM?Q[NO!"9-,*GZJ8Q[J7\A\-1I_!;HH@J9LTPYM5E[UZ4%ZB]<09*^8*YSU:
M#Z9ND=>\5$?K ;?(\"J<W:DJ#KMN[G2R+]_UON[,X,>B_EZMY9'M<33"IAN3
M>AIF*)D8X.+"G^1L96W&J@R<2=36XSA_14$LP]MZILW1$J1E;JMV]<_R R+N
M0[M.NB1!E)&2KL)[%48-$49QN<'64V&Z&P8C8Y^*_9O/&3-4_EQ/XF(E4:'T
M@"M-V"6-CLV*6&[W7Y;-S-6(IQVQ]"^K6&J(6,J?=V\]'B::3<D9)M?]4B6;
M:D\ZN>ZMU?[$:G-UKK1AE#UA9(+/<C?_JGXW__=/O<U\@G]H-,#^7F+5VUET
M1/[@1L>?JB2W/Z7.CRB,CI=B$E?<<P&Q!RU:?X%QDF3' JH[D#I^</6A\%/T
MT>Z,_J-%@.!'"D(/>/]A76K8F@H:"$#6\ 6DA\B+@FA_Z1*LK#RP E^V+^,N
M;G&O?O+;0PQ0<@4 J2E]A7? %*!BORL%T@2X?]A'YY\\X!=HPO^X@@C_\>M]
M",_/!5M>OO>SY"S7CV$8G?VS@\VUCVMA'Y7U'+YDD=%U8+F@)'':  3^ZPH&
M_,>OKVA>V/WJ_CKIM#KB$'&"^';3(]C,==#%+_]-'Z7+SDS4)7AIXVN#")NQ
MHK/,=AMM4Y63\[2SMI&#VE?% W=EUYJ9BC*;[ ].RK*^.#_\8W8D<M7V[Q/)
M+4]@[P2%=((YA[@6YDH/(XSMHO+$D$^9"YR(D-VY^W^)(+?R T@<4TGY] E,
M>Z+]D'ZB6[_/8_\K!GKGGWT/A-Y4VX[]KGV0#DUC)A?@@;.89[5WFPRNXE8L
M*697?BO/K&L@D P]]2-&UQ0S:S0,#>,3.2*SWA^"H0F!3#'V+ .2;I;,'E:S
MAF&2_-D+*V2TUL6Q\0J2($\I,H7-.I4UXVKJ6,IF#8527HRU\*F TR1FL*;"
MGBNKG<B&.>MDDBS6VS9ISAH*I:RWHVJH -($IDMY0ZHNH+;%1 V;- &*.7%(
MO)5?1<HQ$PL"6%)6:DW]9M(Q&EF@9N$9.N:54$RO]_<A"N!2D\)7WDXO[^PC
M ?_.X SOS_#_,;S$2*WUO0[W)T1W-R&VU_?BFA,/.JQ1"*=$G3Z^K;:IPXD<
MH[ 5*(N==K^=9K09#H.=1OKP#9PDV>[>8^! EG/) :3YJI+;ZSN@D//EUTZ'
M=!,:EZ'VT;^4WFLJ:?Y/BGS>A28-:> 5G++8/3@H94"TCYUCG9IPDT%1+?9_
M!]ZUS>8896%*]!$=/J!>'Z+>G-E^B:0NDL-*.M_:[&.0D\\W/SU\#J#\\3F.
MLM.3?_2A?$N./1DRC"D7-_7ZP+<UC)IH_(S<P12^@&)W7T'JQ[A*;'R<@#Z$
MY"/3D"@V+KPEXEKQ0\^_UZ#B_BGA[&GXQE!]%05&,$1GI2LA+:,!6>"?^],[
M55%H8H01RY>!#<W:1)&EYPX.EPS>LNW@*6TQ./4$_%[1TH$2]3)\W3BD[78R
M$E'9=QDPLDQ;E&MQ44 QK22]1P>"\+[R-W'-8!$>8V(41K]MY^X3QM:.V<=Q
M01X,U",II.HNPH%(["22U,JYN@BI8/1+JH$WC,\_J747Z1&6MB?O._"17CUV
MT+^L?/*^<0(G=,'; 8#T"7T!$1C9>DMLKLU$B)L1]3&#TD%?IA=(/M?L@K17
M35Q+0Z9-(1M,PTDS)MPBDP.((=-++\B3AY#!"=MLVOQ2?>6_.RDL<8OUU4HP
M5Q;*RE2$;ZQM\D]1N(=@'M&\F+XUA,8:O5-"*">G/N074!*$5[,?HOA -#V&
MMPJKGR'<AYE<A]A<\FO<^_?H_1!EB1-Z[]_AER[OL#EXCE*0D)^KV9T,@;DG
M1%-1?M+O\]&>T*T3QQ=DF,Z-T%QKZ'0QAOU0KEML4\ED_@_@!.GA%EDLH@O\
MS\L+O&1"J,20B9S511NT>3;GYRATLSC.J=;Y0'%9/N'$<G>3[1H#0JA'?0T3
M +^(7)IKULS@+GP=5?/!!_\LS :[?23/L7W27Z"B[_HG)\!R!XX.DF>7T]?&
M=>,,:L<,FN3HH)%S.6'RXER0LD(]4)B&JHGR'@5*B%)EKY,AM]O7T#E&\&#_
MCB*H$A?1Y$L,CGYVW(2YR/:8)!E2?O.T$,^ [P(4'U7RII6WQ0,4/>%Q@S=Q
MI=Z0MXS51>N&5=<SA._M )%%_WT;'3^@L.0Q!1..SEH7=UM<AI055"VT2E+O
MI7ATO;XILA2FL1H2OY)ID8KB!?*8,/6= #+%*$/O&VY_I@,&4#S[Q]!%5F/P
M&(Y>!^]0BE?T"HK'IC)$["&*;^"TW,-V5S<I?X*7!<^ZQ ;4=E2J+'LH,!>*
MCS=1'$??(3\E:1[D]M(EM^+5H,1U^Q'X^]R4VYT9J[4:PJD2+5%(H6XBO2[#
M-3$B>I@@K!PW,]ZNQARV;8AU:QXWH.355?L,O]J=%V[NM.9F/ RRGHR:[X*T
MUYFY>QA1'G6:$.$>4>8*#>LMILY@PO\,,E>H^)Y,R(2T$'=N^J-,.Q" ^0*R
M" ]1UK-)[6O%\9"Q0,">:%Y$],>&1:!%>Z9H0D4ZN+,&:= 3?WT@F4\NL\:.
MW^&G26;LIQT5H!F878I3&L4?W[G[:;.E")$'N$6$ 0P7(WKO@ O$"RM%\#Q)
M+@(K/A;/\T:Z"+@8K)VL=,_=]9]?.<0]42\BAF0X&^^_G"\0, %M<,#CO%1
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M1$DQP;,R<G=]Y)=])+[G._'ES0G =I=?4332([;7MX3K1!#;V>[>8R=,(-E
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M%<#'T(USP<H)ZN?&UW[YOA$#:6;V[4DC"MGNJN-+Y?G4CAK-V4ERO5XOFR!
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M11 +[\<%^0ZU66,5;,]UM]:-M4W^%>F9V]W7!&R@S)MN/R"MA2A5UOT/]^!
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MV45Z@W#LO$;0XYH9/?0%O[7)Y1U^BA(O26IMTO2I<<SD]G*7P"#K-_< O"P
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M;Z428DLF2]2"(=HLI,QVU3,K%ZV>N/8U(ZM1ZND ^49M1*M!XOHS2!]#V!)
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M#-?C<^6/2WD_M00!7%8D.1!8DL2(*_:#XX&Y78&.\I!K/QIKS!C&OX[I2H&
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M2-S8SY\[:\/O-@3O_A%T50$Z%QHXDNS$D" ^(OIM?P]>YK2ILSMI1;TM7DD
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M;(C<X:-PGX+X>*U)B&R#=;'"AOD\*?I<&S["S3LZJ:/;4EA/]L8)G- %;P<
MTL]QE)V@:/3@A_!OOA.\I? *0-.^=4Z%=SS#FCAZ6'T>=_7,+[BYTZR,7%TG
M-=2]^VF0U\ST_+/O94[PS4\/>1@A0OO@G]ZC_%Z_$*UWHB-(-KYL0W ';UD7
MMB?;6OJ-%F4-'4WROSAQ'NY3U>LM-O0Y2E]B_^C$EZ(@N8O*NF(W8?@XVI9<
MN54A?OT&XC.<5;C?[FK.]!@F:9SEG/L=3B/!_T0U5$K]A.1CU2AL#6?WS8GA
M7-.$?,*H[2<];%<)M5]?& &&JSK\[!P!X3UEU'"3+IPT$R*G87203%'7O(\O
M6>P>G 1L]E [0AB^1ZD3/&>(5K:[W#4K>8]N0-7.^PK%LKANC2,_>8-+V;($
MN'_81^>?/. 7.P;_X[I9\!^_/H&]$Q3L#T-XN!;:.&$EP]Z!CQ3Q(2I/(S16
M04O @U?E&<0I<LFYA?_TTWH;R8R*M^M$=$ 1KGH_2_?T#Z.S?W;>TAC*&GO?
MW9Y.49QF87Z.GORCGU[#H"^W40Q_S84Z,KACAY1^B5U%J8K!4>\P<O-).?DK
MJFF/G6?WUTFG]05JSL?L2)Q8^_?I$2/<X-??M+%0Q VO(AOQ4F8VEWT^"LZ'
MI,_\^KQP\$]F'\ES+(P@;5,[W5F#T4-GI%Y7>*<\JI-:&T+#E)EC&NHU:1#X
M K[=O*TOOWI@YV2!)#%7AC1)(21L4^V&FZG\[@C\\/U[5)FR**(,II7D>50J
M?JU'/8:PT1_)4Z)WD*T@..A45)^LM+_JWX])DJ'OYP88QTT;KUTM54%XD&G%
M,><'71QK_3[)]O\LNOT_Z[Z4BSW.[59M&P&;1@8-,<DV?!+=AD^*3B&G5:::
ME"*C#\_PV@BPG!S5;-YN,]TF;8XH#:H@]&4G;8 V+-%44/OMI@.VHDS$&=P#
M/IF"2'<E.E?#1/8<I7A[!+.Y-C+ 6^NWWT,0(['X!<0N_+>S)SW5\O=7 OX[
ME'N?(H=B:\.V,T0[O .)&_LGRJ5);F_($A"P7'//&^I3I_P0"A^%4>;!<7.[
M:BGXW41Q''WWP_VM<X*_I!>2FB4RA"&[4ST@OT)U*_<1\9@'6F  0Q;YQ4ES
M"]L=G![7HEH=)+.E7R)4M.1J["L(I/AK7L4D*0'$\2K^SI)G7=V4I7-N<A,Y
ML5?PRJ1,3!Y<\K?W<+\-\U^1,:6P_>-6,FY 1:MK3H)O^H0>^H2VP$F26E+?
MQCE1W/^ 1.$G19Z.JQA?_IJ0\D<.&TNW H"<0(JY;+,T29T011Y0+B%F-\V2
MUU5\?3@_^U0AJ]/4J(E_#6/@!"CM\6?R>PU'1T,718D>X^AHF#\:OW#/WU^V
M3G@"Z$T''=!7 *5>?Q_FQ< :_/@]XKB&!HUC;02@+!?D5F(7+B]>HV-8Z*%O
M ]^6ZB GC&.MQ6CP!0*.\'>U%!N5[JXU*=&=28U&CADI)\/=M(JF8WEP&HT4
MF\9DLG'9+J4F0\L=G"<2F8) Q#JBFHP$!Y'1O57;I,/C06HI'"3?TD9&KI'>
MGY8"P^\IW[B^*&ZD%L. <3.M;J*.JZ?1BV1>T3WGT&J5+0",7B.;[[%<3*_4
MS'3ZM!R)P<%J-40LGU.C :(>!TKH2240M&\->Y?*Z7;;5/OD*D'V0T=V^6VB
M1N8\]B+ ]".NKA!A*XLEF)1NPI. 4CLEVP(.Y<C0W)N;AX:DIMB+@,EI@R9(
M B/#Y(KS[;84CDGLB@P?=,NADV\N$W>*-QE"96:QCLYH,@8C-/QV](#E":8T
ML)F?9P*=BL=5L:@*DP%4RF2F3;DZ81$>#<?QD\KC."%TVA[)N()P3 97V5%E
M6I(LKQ"EZK020IPL1VO* UH%8)D,F=(;DF!NLKP(F>H#APF!LQRQ*0]=/SC/
M9/"4'K]QSDV6%\)3*L120RPM!TZ%1BD0SFDR>LIE5/S[@^6U%B<XB=UX6\L1
M4W$$*2&^)J.E_,CA7LDMK^VIGGR*R#85,/W=;IB>A *ZE;Q-6.H2/B127 E^
MEKX1\@2A*\'+TL<.T;!X)=C9;)D>&9RO!$^;#8FL= !* +/4"#0R\8 2*"U7
MT=F)#)2@9KE6A<^6H 0IRQ4(GO0,2G"S7*/@R0"AQ 7#<CU"(,F$$O@L52-&
MY+E81)V_M^QXA)0%CUX-[)U)9?XV20+RV5?!GSX*=LSG[VW#5\1&8J3RA-YS
M!+E(^<\;5#NY1P^D\G=2OJ&_ ."(97!5"1P]OO9DZ6N5.[.KW!555FO&GL<J
M ._*X)+-1Y+&CMO-ZB?>7]L2RS+E#_#"@T273P:%9=QF20JG'M__<(,,J2CH
ML,'_\]Z='X3%#AE)V[*;-[GPMG)VULY>--=BF$]MFN*F*8UN!*)HM]$VU>T)
MQ+DLV:P0C9TPKJ5D"H#4E=^V!_BE4[Z?R3^B #$!.AUP]=-,#5"F<#D(HM%,
MVX1?XFCGIQ12:#30F*JY%N+H!PW3T(1),^D!W];^K(,R-2)L"L+Q>H318<-K
M9KXQMAEA$;T)UR#AUW+ E)];7M':9!S%O:)D&3OT!+^M^8?, 4A,-6V>O(Z:
M8C0.:[(,Q7<;5A&T'!#E=Y< XI9#.9X-\RGWEL,TEADWM4*3 _E5<Z.F"<)R
M'(:3!,[$87+(^%1@B!\2RQ^YBS[7AH\A/%Q.[)GSS#W2TX'T9#MT6/V/V1Q1
M+\1%4[K*+GGE'%$TZAE%(.'>E@F-),_B_V9.X._\VH4CW)--_<2VVE_/IGR<
M)P!9<@4R>NT&VDZ)B@C$SFF2^@GII6QC=*6_P#8 7F,>J91'?_\X>TYZ%F24
M[&B<EE'#3;IPOKSWC:4Q.JQ5VR>\G>O__(</]='8/5R>P!D$&*(4[*S1WRK(
M\M2H[\ ]A/Z_,SPA,IM+9G;;7#9#L1_HKHX\$-PX[F_P0CR#>@IDAB?06_*\
MJ64J^A.E-==/[TUEHD^\5#H1&T/_4A_#4Y8F^7G\$]6OD-9#WS+HZ?6[2R"T
MUBX+:_8D:V@LF)E@FQBA6-6IVPVZ1"CD1VALT.0'W8#Z=V%ROCUZR72%%*41
M9RLWY,9:*\@76:70VV.97PI=\!6[;0JYI K:@H-(WX);A"HA-Q9N%RCM=9?U
MIE[H[3;2=79BAKMN"OAKTULG"(!W<ZE:X%5Z&0/+%WZ;N\]EFV#VF6Y'JD2?
M0FB7G;21.";-));,^^TD ]M)+715W&^C! LJO8,2X]GFY[8-C&4R([27+?6-
M2\&!D1!'#:@$^3M!Y GM%2%/2M9!AI;00PUVGP2QP[?7QJ($TD9B61=_?T6D
M2Q,C* WU16(XE^*)(MJX$+OJ];B;WP(+-E]?173."_0G0X 6P%4JC.-M][@7
M(:K\0.MA%/[M;"24<"3.SFI>\1IY>DJ:YG[&8W:5'5[WXP1<J'F6;G>0W?J1
MAYL?OJ$:5L&+EF)L7OWDMP>H"303'.(F@VVG^?3?"9]^? _9>@0J,@!"[W]\
M$&#)K-U T94/#U=7C()_8BE;@X:0O(*K.+3=W2>I?T1F\U\B5/\PR-.5]F?,
MZF*:Y)@>0/Q^<,)W<#Q%L1-?'J&>X\?-R$,^$9(VD#Z-?E@V/+S6/V@LZ1=(
MX08)[P<_SDWG=P0V26@IVTP%%WR!%U1NTOX61RD$H4*AP@9KJN+I9Z@L-%@.
MTANNS9-N;J!PI_=Y@#<W,O%I@', G=D 7 "\!$6]HC<*Y)FZC0N'GV)S2 HH
MNZ,A._<*/'AO5)XFH'F+PC^$KG]R@L(\C%J"(^B*,]*&M3^\7V+*0#YG:J/#
M%LD1$70W@3IJBNP;;>FZ^9,4X%R:+5VT2L?G1A$N/K=BHS%DQOG*<#>N8H%9
M'KQ&([746L3Z<C:(%CCE]#8V&22NR&"ZUU7-GT0\@2W%A#\LH$:%ZF=L*0RC
M_-BP1PCGU6LT.-1[C-/;MXF$7,G!7NA,3O4Q#0(T#^=K\9*^8F')BDM'5 E+
MKIU:;5DZA5/0_;+;*=U(U[$E*. (0!X,<R(*L7 V[+W*=S%; A6-<B;"2BUY
M39C(1JFE@A(68#ELJBH(B@0AF RA<J6;=$.8#(I<A9(>\&%Y,B55;(D09V(Y
M6O(+$<F)@C$95O5F09+2;WEJ+Z42 SL@R7+TICRJ57B4R9 I.X;CWY!4P#9A
MH5S55RC&M=)RQ*2?34:$G<EP*3V7TR8QG[#6\@3O_J2(2,N16T*9=%EP*CN;
M>/N["B@F+-H]P9DDQ<I:CIRR,TF*WE6!UX2%SJ>@-$)DL>7(J2O@S17$K *]
M"<O&3\+A)K"830B9"H+C#.)6@=S?YT5LW;!RRR%3Q]VFH*V?9^ WS15%;SMX
M4Y$9+EY?"79S>0;GSB!@.XK2%09")@,E.,W@=9.6;\%VS*33%CX3A!*89O Z
MQY6)PG;PY#\ M%-C*,%G!D]*PQ)YV(ZF=&IC)A)1@IBECP1C,I8HP=%2P^[(
M)"A*H+34<DG-O:($*$LM;@))893 -D/;43?QC!+7O=D;0Q3A9JD*/R1]CA+\
M+%5313+S*,'-4M5+7O*?I5:=/3I["/G'6G9V+3N[O.*J)?%32J>T6TP,6H;N
MSY,3IQ=*=4ULLTDG^@I.77_T[J2(F\W?=RUMR_F)-7'Y6O'6NHJWXA6!WJ/4
M"=H)J]ZC&U"U\[Y".2NN6^.8N[S!UT*EAI6]) "[#>&1K.[TI/'0<(@"N*&4
MHK5<';7+5)J+=);L7+ D#J']6EO,L-IBTDK?E,D&*_L&BI B\05J%]-2WYM?
M-&G>U<R,J1AF8NVB->?T+'-.B^9>[E@\C%XU1]9 LH6D"D 5,$X8#88I_F 3
M>E2O&:@-I+(ILUJ(JO@F0ZLXRA['"$V&8\VXO"855DI!PH\2UZ3F?$8BH[&Q
M-N'RS *!)HSAMM1S2&=F*VM28$Z:8&X&T5$3)ZZRW>F,:I<U&; 9I:ZRW %/
M<PJ.-4?A(-AL#H&:<=:OI21LLCP.:DQB#LL=B1O)>U\@SGZ21/$%I?%]##]#
M")]!%D>)ZP.(=+*Z%J^NQ8MS+>Z> K(3#*'EZNYJNKNK*1XXJVNKV:ZMDBN;
M%YEQ?+?4VNN )@+U<78V9'$4%U%,0T,F320J9G/Y?L-XJ:QG5:4Z$XN-L5 /
M8^M\=B43/3VVE^,84 >0[1F("HS CWKYMK,/ ;6].I_,2DPHZG[=@<2-_5QK
M8+A>DOO)=Z*.0D\438Y>AA#U@^,"K#<XL[EVI^HZ%2U&BR<LAJOKG'Q@]4V\
MFSN">QF=CH8NJD@D,F!1><?56WGU5L8Z49",*):N?F:OWJM[KH&TI3ZY"MG^
M8#)TREUT<'8,DP'AH"66E0-7RI'3[F T,JM/KEKHR"8_\H&RAD6OGK<F7%+3
M9YXSWI=T>I>V"2F*^ZJBVZY,]G74[&-%L4V:C-K"'/HF)#;N(\=C-#;9)]2(
M"ZUIF389K'F%0ECJ'ROV-K!ZPO: FZ[DV@Q=8*?(DVUIVG^1UY1%^!'W$Q(_
M.R'44,Y@]1I>O887YS5<$3_%,Z7=8O42-MU+>$V*NWH.KTEQ9^U9N6;Q5>1C
MNY!4KJ;D15V3ALX@::C)66E-] E=/0U73\.^XF7IJJ?R,%Q3@:Z^AFLJ4./>
MR*9W\5C3@:ZNAS9 MSK>3<ZQU\2-,T[<N*8A7+"3F:6.5:9FC;/4R4A;UKA9
M^!9IRY0Y0X>CA?C*;,Z.'Z ;8A?%B1. *PBZ?66N5U0]QX<HKUI_G6-O5[NO
MWD)C:,T7<9U0=ZHT)QB>G@M]YQL]_2Z:':R/49PBQSHD2MXX"7%=PL.L[C>F
MN]]\B4)P^>+$OX'T(0L]_/L[H[&I9.VZV3$+D)D"7JI)TO:[O4'7!&0K/X;1
M.N?8UD&#?&M50=,>VQAHFG)"<R&<JR=V-_0.W@1!]!V)F_#?MS'P_)22G6;0
M4-:^(@^2T[HQ24SIQV0K,;>E1D#.TV;OF_"I;S3EB$MHEB.F^@F>)-@8#=OR
MGK<F?-Q1?49YQ4V3+?4FP]@132VWW$N'D2S&6FZ45RR5D>3A1=A,,=CVK*=E
M>V^3UD-LP\TK^CV&UTDNCMR!5'\DXB9)0+[4)]_Y\(/6Y+=A/>$-2K8 N4IS
M_BSKJ]QOZ(]1'+$,KD#&T>/KBT<[0%'['9X>Q#604$2Q\^+;FC-UJOV2U-KN
MZ?\*>:V3!1JC50K2KT_"E3]O/J!$[;BDU-GL?N8M270I^F/>I@QB'HW[+T[L
M(VY896O+YX421[[$_M&)+S<@A)(%U-;B"]5N+S[.Q/O4KCM.C$O$-)MTHL(U
MTQNSY^^[/IJMCV9KI/J\(M5'DUQ#CA87+3@[&[JX08LR0,>ZN30T[8<8_#L#
MH7NAN8UP]-2_+-S4J#R?I^<\ES5:&6'7,7O+/J+8@W=DBI*.?J28H] EMT%#
M2%[!)CXZJ?-R<.#_NB!+?=<)DL?0):=_8/0PBH"N#.D?/H@=*/:)DQ)Y#/U+
M?0Q/69H\@3,(?J;*/K0>&NN2UJ2/R)U1FQ37=G5#'#;]JX3(,*QA&AHRZ5O(
M)?=1[/_N(',^E78X.LYQ4?HM<%T?>.J""(TEWW>/R0DI?T\G\@77;:+=5&9-
MX<V&W-R_-/,[AT_HIG76O[BF;% _H/#=OK2N"RH/SB%-@]"/XJ%R-+VSY%G#
MHY>_EAT@J9YR>3CY1Q1 ,7Y/EZ.Y^NFG]H; ^$E8Q/RDAE#0:]-3Y(37.Y ,
M,[&M?FB;W*#Y^BK.2S"]E>B)%9@L[;#3SA0-@X.7B/24+9J$KA-[#D4P:370
M3[^-@_XG8=;P)S5TVLW3C=XWN%X)1'MK@_^;$\<.@>/AV\B_IE/(9R \^9Z^
M^OL#W-/2"'PAW,VT'I+G1RK&VI\7H:7D^;S$_AE^Z"5PW)Q;OT1)[H*&B*O!
M9E#=&0II#AA%:]P+E3Y-,.%TR]:4+(HR8UQKZ;323%17'F,J55#:RYZ;$Z=E
M['_]<OX$O_KU5%1:Q<Z/U4?C4]?11]7VR@DB%A7['QG\TZUS\E,G(! "NY]D
MV+_YZ<&+G>].\!!'Q^O=A(.;V-;:2# E/J78Y*+C/3'MCVBA^ERV\FJ27 0M
MP:"TC"H!H;:[F@T&V]^?VX&R%0U!=E&T% [^#+TCW 6-QH8C8R'9<;!*#R;@
MLV<T&&M$Y9K/6#.!B?F@-4F'Y>!E-#!\0;G\7E]8,9#F?F0).C3A1AT\LQ%[
ME*D<PUS&+$5S0#9LEB^:I4B,<E##'D*<VY?)X(BGG945%FEN;MHI<Z+0X_F:
M)$9PR3,:@.7EZI@6.K*S8!,U'D<V2["@R4^RP)B-M,3OP$C+CFL%A="%'>&8
MQ%KNZ?DD&HV"M>4KM.FA'+Z0+%V+(B<:#=4PJ9@0]\,$J>>-:7FB+-6&1(SG
MI^6(3:>[,QQ4+<5Q@-;.Y_]J*1Y*=?=/-H"C7W>?ME#<A$0E)CHS/)\MQT*F
M&(#SI;8\UZ,J28#BVVTY8LH=A[A\RRT%<8 8T/%>MW3A2N_[/]D CM[[7NB9
MTF08U5S_(M$-EJ?E5:W[=L(H+$=+N=Y+C?BP%+P!MQPIML1D!(SCZ%1[J,E(
MJF'J0^*#+,\DKIJYJWZ[UE$)594>0XR#,ADX,W@:[C'8\D*R2@T-].@VRY%3
M?E YPC%,AM",(SMIW2L=)8Q541^OS[G).)KPEH$+E%&!V5]G0'N<8<<FPV<&
MUR.$-*H [F\SH#N!&'$5$/Y]!A R0M>MJ^E4;C@J?_8 0/+B^-[5IQSSH^Y*
M]XTIY60+[V94LK*W5]VT1ZQN^E(YX6=&*X)$[3)MVO_42?.+ZS.(]K%S.J#0
M%E).?V+;::=<9')H3H*8JY_<5LJ4$^#^81^=?W*1\!1?BEF7_[A.NOS#KU_?
M.C-L_*"->E]!7D@1W23T#-28AK+3([W]-R4C4OVC$5#EU@AX;)$U].;2_(62
M2%1@ -.X65YH4XR;%5TF90TO<>1E;GHU$5&J.9';ZB.PZ.($*;U04[N-#G2W
M<8D7X9K -I.=Z:TOUSQD*5+WBS+8^:L&H>3)@ '4S_X5(-*#@NM]DOI'Q N:
M$WF&\N+[=Q"<P1=XP [X-+.C!YVV[$X61R=\!KS>SZ8QPT8!XB:@8NR1-(AN
M6OL?X,3OWR,I)%:-I4'8^N<+0=B"/YA&3\^ 5):)TL$$.DGAD%T=9^QHZM?U
M#2 W$?C],XB=/?B:@%T6//D[WI60^YNP)P]1AA6@AP]FVG$9P7--8[0/_EG>
M^<D'T[VJS2X%L=2EM4>T-E\DK]VKY<E--2T9'5_)SJK%LCS5&3+(]AZC$:"[
M]S&M6&CY3<N1I6MEVYFN+HQ7^X_)B^5^..,Q##=/NXA]R62 .*A!(C,L+5-&
M \(5ER]N7B01SPS8(].2UUI[VVYF]+*9]R+-RE9=B11TC%X\><^'6_6NL0#C
MK6J6AJIRRQ-]PYO)*Y9^T3+$3I.QF/9.)1HX+85(!W>I[:B6!@,**RG(XFKR
M6I6P$_QM;3(,TW*2W+1M*1RZN$9I5;<\WDR$B 98ZBU%1Q=-%:\")@=.32SA
M*!=K)L!%&S'EIGV30WHFXD\TH"V%1P=-==Z,K'/!_AQ%WG<_"#:A]QBF3KA'
M4=&EW[KG^<7<'\-=A-(9P7_H=L&NYMNC]<XK:K^=MJ?@JTM[-2F:?S6IM;;I
M5]-@ *UO@AL4\;H'5>J69TBQU[\TK=%4YT3143267P[@U*,8'L<S:,R:46:>
MVFE2]SE6*N.&*QVQJ?8)$WUS*8UE5V7FRA':]V+@ZJ>-O%$@W7;7(%&*4SJ^
MK;X:WNB^!D_PA/7NTB_.OZ+X-G"2I)\'IUO76W 4;<M]#%_BR 5)\@H2* "Y
M!\@V[U#.F>C$Y$=\?;4M[29+H-R0)!OWWYE?)([)_S,&]+UC]Y/, YZ<?R+.
MWB[O<QL=3TZ(]\7G[:61JMHT_PS2^Q]ND"'^5 NK>._X04-HIS&(^P<J5P5I
MY16XT3Y$RL>C!T^!O\L+7I;2>$%'7CN:%/Z6'1&C*+4%/-]@4.L4,] .<_-(
MDF\44FL3[Y2;R_4^H"Q)9 03EZGNZJS+Q6C7K1XAZ_7C(@D#,5:-T%B?WM4P
M@VQWG#R'T<E$ FQ.^?['"80)8 0U21I4W\Z6G)X\?RBV^5[F!&56,_Q6"XYB
MR=[C@XS&C673TC%Q,V-'LVCYF!"5D8/9M/A^7,3(P2Q9/"TR1,:(UD:&$,WQ
MK41)) .XI0Z?0HN_FL\M7^U ,WN[N@/==&TR0MPN6(SG'CT%>"9R?6=;R@VH
M<#5M: 35GMW*1"IZOHS&AB-+VC"5OYTJF,L";3E0W,;H^FSQ6(4M!V6(F;A)
M.I-:7XW&>BT]R\7'&79D'&U1#JS]> PP3'=21HMQ?TL0HY4YGQ8RM<70)PP.
M$E*SNI9TD]<N4Z5@LBF3@9C@OF<]5E@:YR%T1L:^<9B,D8JS),2O309GBO,E
M^F1D:1",P@.G-.IR\KIG N>,8"*Q-+)%-86HB[";,()%$3CJ0L4FK#JC"AME
MD4\35D51@,V@"!YCRW=P 21VV<\IINDM.QZ=^ )O&WR:B.VN807L]-4=^D0A
MZ]YN\[]-/YD4($69)U_,%'. 20-'7I% 0\P3W?QUTFE]<7[XQ^Q(G%C[]^D1
M(P0#77\ST&N$F(E7J.NT9 !G1"6#UN^2 Q?Z%DQ4:QUX57HP7-$&@8Z*9\MX
M>.2>/-<XBM?2<,J 4DQ5#(Y[";3NQ@21Y-/IB3B$D\K9>>(#P9>X?]10>@_-
MB 4.'%G+P1JQ3+$!#;PD.8EXQ$ 3'\I^]0/N;GH/&^?$.4;1<H@XIT_N;,S-
MA%.].>\E;%=K/8E%M%N\<S%;>33:AX#N68E1)2N_FXXZ9_0BF<Y&/06P6F4+
M )/7.."%A-?LT<+":F?AL:>>3Q&WU.>!==[;>KNEBQQ* 2+6 \O?Y*5 PV>J
M,/G)>2JDJ(80RQ^CA_)97D.*Y<_12IC0I)G()WR?GH(M38K=A._7"AG5I)!-
M^*(M7T2<]F3^W5RH^&U<2H1,@_6,P38U)4#9)HY3C'9*\#%8)A>S^UGG:G/C
M!$[H@K<# "D*,(S"/'S5Q,S!C^$9SBV*+[U]ZME9>PTUFHO+N=QF<8SB@"E>
M,/BVVJ9.KIK8F3>FX9HE40!<OH)[%- 9 ^@G?IPS J&19,IY</PX#UC8>/_*
MDC0/SD?A0^4W'^#=4$1:D=YPQ0:0//NV9R-^*JAPP'97"7MO4>#AEC%P)&M?
MH\B71?M2QW)GRVWR'.5NK4\PL%8U'18D)G0J+"AOR_U81Q7$3*J$/&E,+HT<
MAMR?EC_8<  R]$JV3C-\2R/WMQLG026*CBC0)E_RIS_^_.D%JHR;T+M/3B?=
M.N$;O,! ;Y*-2,2;R[7)BW/)[:S?G=ACZ9 2!C8@'(.YBH2T#+YHC;'C:X,(
MD3 S&W6GD>SJ'Y!KII?'T$6IBLX ?0P=+DK9#VH'[5!2=-56$^T3%=AS_0G&
M\]/SP>9#']T#]I+%[@'^\27V78"NI.,Q"G.>_@(%IH:NA6-\:CXH^P =3T%T
M <5%57\=[A_E"#&Z2)[AX$L$9>(";I9GV0R][1G$@7,Z^>%^N]N!&/XOA-2/
ML(J^\F].M8OOW^',+N7_1S'S [:5-(8I^_R<H>E 4;&:<PXQ-FQ'^C=,P: ]
M+ZE+[PRMEXD/64#I&5S3=_:1N+&?ZPVO4!65+;NR/F<M@-49R!LED!RJ)2I"
MD/P]4TY=.5&HS6;P+TE>A=;_R JM]C[P\Y?.YIA2#Z;XUS56:ZSEF+*V;+&I
MR(4@/@/O(8J+\K2/29*AIU0"28F/8]]I:Y/]YNSX 5+SX-(^P[Y4B5/%YZQ]
MO)!GU< 'VHPV"YAL$>8P\^$UP6MF<[IF;O3BN=Y%<"I[DU*Z^%BR8EKJ5K$E
MJTV].B&E*^(D"HT2)@,^(#),D@461ZJS>()BL6*6C<?RY<L]GQ,9G2Q_Y!M*
M<D2#E.5XF$2#1(.8Y?%M)F'<-;A9'AFG4,118K*S/-+.3+@I!C[+@_5,XAP#
MC(:6A_NIH?8!-D7+8P -XQI,0^5,O+7N_!BX:10W__821_O8.:Z>6ZOGEC&>
M6XQ$I^]^BN;\&'K^.2]!\<U/#[DW+G+,/?BG]^@>U2O#ARD-&6'2Y56GE)C(
MM=- 7UGY?/_A!RB^7NTVYKYA$>G[NH#0XW(94_*I%;AAGQKML2?[H?T1W?U.
M4+PIY=)%63]'XG,ZZ1L:HQL3J!FX*?!RN>0KG%_R^O85R^#X^NB];P@)S?'M
M3*&\:Q"W4N*C?,84)"IQ?Q.&&0II3Z#&%>0,1HFG'>8SIB!13$TM/> _L3IC
MK,X8+7Q'"/95(L6NX&PT$ER>&5@)6\CD,4@\LP0XFH.'%N16/Q$%5F:BQ#QW
MC$=H5NT 9JKP;3**9CC8=%B)R8"Q\W%3=9GJ(A6^AU>W&VGLCJ:FF0RSWK-*
M(>W5'4>Z.PY.<5X]<N2Q ()6/I-72/Q?R^JMZSOD^@YIS#ND91DDS F 7Y\6
MK7DATW]DC,\4L@GR<:$"C<6_O+E(5,K76=OB6BQ@F\L3U'<Y<GN->46A- (G
M!%%&!/^$/H+.!9FN:#U,6P:5(]#[S&<I!F3> 4& <GN#$,0.*D6_\8Y0A$Y2
ME!7]#,ISG%#/CM@8^ED"B,\^2@:.8US/47@&":JX@*Z6Y#U*BXRAU>\HZ=US
ME/X/2%^!&^U#_W?0S>:A_GNKQX.4I6"*(Y2TREH0L^?\B+R(HWF(XO)/J-W/
M4U,^?A*F' >18T"FD]5?8,G^ B9'#*]. E8 -ZN\%[J";GB5X[F#)^FUGJ*.
MFXR@&2_U5$. R?#Q\2L..P<'&E9P,SXG+YF S,9WB\OVTA(/Q"P;)CLA:+L%
M%9I,YHZWO6YN\W"=F=#-;=):)H)<D,O,M?H23<G["):TN6^"&H9H PF;P0B'
M)-0SWNFJA4Y^!%=/J]73RD9/J]4U:!#16^4:-/@(%Q:S9)NE2>J$J!CW-^#O
M#TCN.$/M=@^U67C#^&7*V=<H"'91C#K*YB7#)S)WT/4B/0MX$;D\3$6WS8_I
M?ZVWUTM-XI84<1CJM[[\CGV078.H2JOF53Q.-A_(LNE*+S_!]4W[H.Q3Q2-*
M\PB5,Q>7+$+]]^R#\#D*BU55E20@,62Y3#8-3Q?^_DPA5L,V13YM'[#]1:4'
M$+\?G'+126W8ZTA=>>#:G9."NB:R0@I7-,M%;Y?!>V3PQA#5['*1^6*2Q["P
M;:O0DR3.P!1_49O=I\<*0NWM^AQ'B72[)^5+]A4Z+A=3$C(R5;;E1Y(KML(/
MVD=[9)DF)Q)B)(?"#]H'(O/"HW)B RYDT?F9NT6L.[&Z]K1>S&*3,.5NEA/+
M,1&=H$F@(@K N\NN):SR74D:IL)Z*XA\3GP@<P\''UFBBTVIW;'_'?L@(U]C
M3(I2^4E3TLTR;YQZRD,O1?/F9ZT$_<MX,\$$7[<<WG;E&:58=CYE+7#DA]Y7
M@+P6X-_S2E2.FV9.\ [BXR=%N Z9B7UW&I,I%N15<<3)M93.YV</L'EZHNC\
MS-TBEHKV$,4[X*-2;%HU1=%IF NX^$(5:1^X+UE[1394*<Z+:0*K*/=,[*-6
ML@[6(*OI%+_F1^T#DWG=-)9GWETH-#G[-H=DJLSC>29Q#.+ZM+7 %J+4)O10
MX!FRF[Y'Z$]Z76M'3FK&FZ'4(,K]>6OEE+;B4/-%5<((\7.FV$?)5_I 4M0^
MG3D@VV%N-=U ,LH_9@SFS(G:QXD%;0^Y+&"*(:0SF36#W2(SV*TIW,Q+9S Z
M2E!H:V2%S2UUM^AL1![Z+?_TN8.]['1UTS(73."#(A*NE "3L3<CR<<$V8YL
M(%:10$E%--NU&BYU*X9&"4K9%J'XN:7ND-I8."G[*#7^R_(4<):H!S(CQI:Z
M8U.I"-QT,/>-6)-VSDJ%P 89+A7]43*Q'%^97LCB4O?"4*&XCH)<ZK[,0106
M#K\T.77J<N1AP5C-I6Z:&I%8G!_/'?_E9FLV2P(>$-J[5'!U&7TQD<1+W0)#
MY=KU<$P@V9H7HZQDL_]DP6;+EVQ'NZ>NNS6Q2*OJP"]UEX89+T>?FVXD_5+A
MUV6]'!26O]1-TBK^"0?T+W67YF#D%,X=H&*S_\N"S3;+R"F<:&"IVZ9&)N2[
M1)>*^>3/T]@T$$M%WX#G:?ZD$DO=)$/M>ZUT%$O=FSF(=6(Y,%3L])\MV&G-
M#QV,]!@J=N4O%NR*4=%W8Q-NK)LXD0S(GP%AJ5NB2S D9_%8ZDZ,D?ZTI^Q8
M[*Z9_O*K-H>)BEW_JP6[/KF,.#*ER4SJT:/5%(@E278L%KY6I"</O%:D7RO2
MKQ7I#0:.M)B:=3<8'5S7%Y >(B\*HOU%54%B@2_/ ]97/_GM(08H>@K VSM]
MA2+9%*!BORL%T@2X?]A'YY\\X!=HPO^X@@C_\>M]F$)A 'L0>S]+3L;W&(;1
MV3\[V I0N!9RJ2R)TP:%P7]=@8'_^/45[21V:MU?)YU61Q G3A#?3MLYI>3Y
MP9XO<OOIB0!S*[=_F^BH/H&]$Q0'$C,E7 O[$KOBV&.ME*K(,\_^X*0$]\7Y
MX1^S(_%8MW^?Q[7;856_1 $<+8 T/-7]2Y_ M/L/%6KJ_K=^G\?^5\?MSC_[
M'@B]J;8=^UW[(!T:C2P7X(&S6)/:KDEMUZ2V1ABRQ0T-4LS9_(JXI1M#TK+K
M!YVN'FSI.@UUQ14A:TN1)Y@K$'P4DX&EBUTS%$NX8K&VC8I>6J1D\AK73,!2
MB8)B8T+K[=]C2TU>)4%24F0;LW1'&!=8QRAF\B+ULB3L"5YJ(@Z#]!F&A=/2
M'6*=VK8IT^1%ZCVU'6%LJ='2!IU7O$5ZJ?%.FC9&;99-TQP<#U$ "2(IG#NU
M.S*F$%*T$3V33/>YH-]0VP/*[?_?WK=V-ZX<!_Z5/?Z>S;WCM9WX)'L.I9'&
M\DI#1>)XDOVR!R*:(G)!@,9#&OK7;U7CU0#Z!1 DJCDZ)_'5D-W-KNKJZGI7
MZ*7I<K-*F =8/7"LZ@('U>/G\P'E+RG[>P[XO'F#_S&$!*I&4]J^/L)/.=Y]
M$/X?\ XO#V<,C2M8"3+=.(*M:<&0CYWO*L>[71RU"IG*KW!OW+SNVR>VSY/U
MUL/LOO@U\7:ZVZN>0 P(<Y2N:LJE #+_9:X?VLY-3744IITS(RAP77N(KFM
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M:YRQ5.WB-4\B@N9K+TD.:./B]BPK5'>FD+F_&I8O'3HQG?R%>6&VO4:[1WR
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MA(.*NL"X5=2CF3"QM'/O_168G/>X]9*=M^9BBQ=BD+D7R25GVUG4^&4E%J=
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M2MH<P,-(5*U029*63*O+A@D8MZ5]3NL/T^6FD&N(6+:;8.4JPC>(<G@%RN<
M0+C"H _14'_S(TL\D/2#R$L.=[!R.J0Y6<KC37JI%RZ8BON;EP.XW*!_CM<8
M9<E;L&;I<QSZ+MF#;1(53D0S[B )GH(&$W6$U"H6"N>4938Q"FHMPZ2(9W<
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M5*7YZWBW"^JN '4,U1H@$NHAUZ&SRPT&@/%"I;2D?AZ7AMLR!X86HQRR .M
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MNF@-^AC_46=UF'IH&Q[%"HM,X)<Y5BINYL.!7JB(J\"1_)*Z5N']6"S !]?
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M\+)[B>]]^N73+W*Q1C. ) %@$Y'%&F_Q%7#D3XO7. I2D-?C)&X#9C&0)(#
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M?B5"]HK7EN?0SRT3C0]1Y^7ZIH]\5RSK#'<K58':8=%DSY<E$!_C#$/=O1#
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MAHTT8A@V0N(Z>48;+R8\O)S*B(E41#%S"4WF85TG;H(IRH,T=MU^M= :Y-I
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M83WM"V![ ,(]%'6W4?_J*.5#9I"DBBHS:A4+P8D8HKP.!$5$-\8=>>AS\!:
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MZ ^RS%@1# A=WQ@TEGV%@,4[4%(FD AVM!&48<./S+N'Y=VPS-JP9!=3KJI
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M25Q V#F5#@?&[O38E=RS*[E46/&@/>$1!5I"C6,J 4->Y\AE=S #?D-)+U9
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M'5(<K94<\13EK"@YA"7"/D\4\3?$2R$] SQ *B1H@H6+&9&K&5A$)$.VI[2
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M![!=6SB:XTSF)X=N0U^-.W_6;>17ZOX%4$L#!!0    ( !J(75BRCE^O+!H
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M,_\HFRELQS2^H2A<:2DZ[E&E4U1Y"KAR5:>>,YTB11>3-%:L@L-/V#?6N96
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M*Z^>85>9UW][]6R2Q]'K_P=02P$"% ,4    "  :B%U8(?]J,/!# @ OV0(
M$0              @ $     :6UG,3$Y-3,R-#-?,"YJ<&=02P$"% ,4
M"  :B%U8A?U][@D4 @ *B@( $0              @ $?1 ( :6UG,3$Y-3,R
M-#-?,2YJ<&=02P$"% ,4    "  :B%U8V5N5I IO  "/I0  $@
M    @ %76 0 :6UG,3$Y-3,R-#-?,3 N:G!G4$L! A0#%     @ &HA=6 /I
MZ>]!9   VI8  !(              ( !D<<$ &EM9S$Q.34S,C0S7S$Q+FIP
M9U!+ 0(4 Q0    ( !J(75B3_@-\WO<  (/* 0 2              "  0(L
M!0!I;6<Q,3DU,S(T,U\Q,BYJ<&=02P$"% ,4    "  :B%U84A?\$BC3  "O
M7P$ $@              @ $0) 8 :6UG,3$Y-3,R-#-?,3,N:G!G4$L! A0#
M%     @ &HA=6 3A]"P.G   +MH  !(              ( !:/<& &EM9S$Q
M.34S,C0S7S$T+FIP9U!+ 0(4 Q0    ( !J(75C'(7%OHYH  !0" 0 2
M          "  ::3!P!I;6<Q,3DU,S(T,U\Q-2YJ<&=02P$"% ,4    "  :
MB%U8P8V'EN^[   _$0$ $@              @ %Y+@@ :6UG,3$Y-3,R-#-?
M,38N:G!G4$L! A0#%     @ &HA=6-J$<W4PU@  *S,! !(
M ( !F.H( &EM9S$Q.34S,C0S7S$W+FIP9U!+ 0(4 Q0    ( !J(75C B/*_
M"HL  !KA   2              "  ?C "0!I;6<Q,3DU,S(T,U\Q."YJ<&=0
M2P$"% ,4    "  :B%U8%(S.8MBT  "&_0  $@              @ $R3 H
M:6UG,3$Y-3,R-#-?,3DN:G!G4$L! A0#%     @ &HA=6',$5"67KP  63@!
M !$              ( !.@$+ &EM9S$Q.34S,C0S7S(N:G!G4$L! A0#%
M  @ &HA=6*EX2RTO+ ( HRT# !(              ( ! +$+ &EM9S$Q.34S
M,C0S7S(P+FIP9U!+ 0(4 Q0    ( !J(75@6)AEQ!,8  !GE   1
M      "  5_=#0!I;6<Q,3DU,S(T,U\S+FIP9U!+ 0(4 Q0    ( !J(75@O
MZ?'WQ% ! ,!% @ 1              "  9*C#@!I;6<Q,3DU,S(T,U\T+FIP
M9U!+ 0(4 Q0    ( !J(75CSQH-D2YD" )LP P 1              "  87T
M#P!I;6<Q,3DU,S(T,U\U+FIP9U!+ 0(4 Q0    ( !J(75@1NI]\%NX  (5E
M 0 1              "  ?^-$@!I;6<Q,3DU,S(T,U\V+FIP9U!+ 0(4 Q0
M   ( !J(75C?Y3F^#DD" --  P 1              "  41\$P!I;6<Q,3DU
M,S(T,U\W+FIP9U!+ 0(4 Q0    ( !J(75CWR2 7;=<  )%I 0 1
M      "  8'%%0!I;6<Q,3DU,S(T,U\X+FIP9U!+ 0(4 Q0    ( !J(75A1
M@WR.N.0  !-D 0 1              "  1V=%@!I;6<Q,3DU,S(T,U\Y+FIP
M9U!+ 0(4 Q0    ( !J(75A8)@$R/K4% *1P10 1              "  02"
M%P!I;G9A+3(P,C,Q,C,Q+FAT;5!+ 0(4 Q0    ( !J(75B3- 7^G+<" )"@
M*0 1              "  7$W'0!I;G9A+3(P,C,Q,C,Q+GAS9%!+ 0(4 Q0
M   ( !J(75A+%.FW%04  +=U   /              "  3SO'P!I;G9A+65X
M,C%?,2YH=&U02P$"% ,4    "  :B%U8I8B0[ 8#  "0#@  #P
M    @ %^]!\ :6YV82UE>#(S7S$N:'1M4$L! A0#%     @ &HA=6"8V*$3@
M @  M P   \              ( !L?<? &EN=F$M97@R,U\R+FAT;5!+ 0(4
M Q0    ( !J(75B4FO 4+0@  /,T   /              "  ;[Z'P!I;G9A
M+65X,S%?,2YH=&U02P$"% ,4    "  :B%U8&27 GA\(  !>,@  #P
M        @ $8 R  :6YV82UE>#,Q7S(N:'1M4$L! A0#%     @ &HA=6,/0
M[3VR!0  63<   T              ( !9 L@ &EN=F$M97@S,BYH=&U02P$"
M% ,4    "  :B%U8LHY?KRP:  #$Q0  #0              @ %!$2  :6YV
@82UE>#DW+FAT;5!+!08     '@ > %L'  "8*R     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>inva-20231231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2023"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2023"
  xmlns:inva="http://www.inva.com/20231231"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="inva-20231231.xsd" xlink:type="simple"/>
    <context id="C_b6abf77e-c226-4f1c-b9e9-b0f6f21c3bb2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_d175404c-e239-4f30-bbd0-3bbf386d06ea">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:LaJollaPharmaceuticalCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-22</instant>
        </period>
    </context>
    <context id="C_35f64b46-11ed-4d73-b48d-9b0294e79c59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_ce2c65ac-3b0f-4cd6-a073-a6b687f80393">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_7b934074-97f1-4177-96bc-6664a24ee9fa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-08-07</instant>
        </period>
    </context>
    <context id="C_b697daba-e91e-4352-8b6f-532cdaacd5fa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_cdf38ae8-3488-4d9c-82c7-3e8d9ebc8c31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:NanoliveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_b8a25da7-f0c7-4777-ac22-af038c29402e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0dca3067-b301-4dc8-acf3-6ddafb2e6e93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_4e8c55ea-f6dc-4620-b986-2786c29cf612">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-08-01</instant>
        </period>
    </context>
    <context id="C_fb582b1b-defd-402a-8689-f3dd46cd150b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_175d99d3-70ac-4ebe-93be-8247d1fbe50e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:SarissaCapitalManagementLpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_eed06e0c-196c-43ba-8f27-6f6c2781e050">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_70752bbf-999a-40de-bb2c-738c0b7f7ada">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:IspFundLpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_69fb044e-5d2a-46bb-ae62-33b02683b43d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:PaionAgMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:CostReimbursementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_19a3e0c0-9301-442d-a4f9-622a1ad048d2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_4db40aa1-f9c9-4e8f-b9d8-1756f4712094">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:TheravanceRespiratoryCompanyLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-20</startDate>
            <endDate>2022-07-20</endDate>
        </period>
    </context>
    <context id="C_ed72a4a0-2d3e-42f5-b565-15482cc0126c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_6d1cd716-967a-4cec-ae43-c48297ca0a77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_a0b988e7-21ed-4760-8751-f6fa519d9c49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:EverestMedicinesLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inva:CommercialSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_c1969bd2-5e89-423e-88e9-b5564c6afe10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:GSKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_bd738e6b-a394-4de5-a04f-1f55e1ed3e59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_21e1bf8d-0dfb-436e-a0f5-40401cbd051a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_30cc733a-2659-49f2-9019-387d5263bfd5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:GateNeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_fa14f0b8-b80c-4b7b-b274-a48521a14a84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_45a2b910-f147-4239-a429-43ed79c4207b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_44f0f126-1c89-49be-aae9-85fa06e97ffc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">inva:PrivatelyNegotiatedCappedCallOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-07-31</instant>
        </period>
    </context>
    <context id="C_f0f3a5ea-44ff-44dc-9c12-7e3628fc5813">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_ce39f75c-0185-4a4f-87c1-250c81cd12eb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_cdba2e0f-32b5-4b89-bd92-54198cce3aa9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_4c92ef07-b330-4a35-9de3-b077cb45c462">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:CreditAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-10</startDate>
            <endDate>2023-07-10</endDate>
        </period>
    </context>
    <context id="C_e78c50b6-10c0-4578-be27-2aad784b619e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:LongActingBeta2AgonistAnoroMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:GSKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_f6067cb4-1702-418f-8410-c3ff025f386d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:LongActingBeta2AgonistRelvarBreoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:GSKMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inva:LabaCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_48c187f6-6fef-4cb6-83d6-250ba457d99a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_6f92e4e3-0288-40a0-9972-c89e1aac1433">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyEightNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_83a2b6b3-d55f-414b-a77a-bc247a02d235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:EverestMedicinesLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_c86331ec-9958-472c-9d3d-73034f0f043f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_9ddbdfad-57e5-479b-ba9a-8f0e252307df">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:ResearchAndDevelopmentSupportMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_1fd35541-50f5-4c16-a031-bd9cc78d2a09">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_75ab87a5-b754-4d3e-95be-4a5426c4c785">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_12a01e00-2ffc-4751-bfae-ab411878a4e9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_6f3330be-9c77-42d3-931d-990047c9e84c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">inva:NewDebtInstrumentInterestRateAfterRepurchaseOfNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-07</instant>
        </period>
    </context>
    <context id="C_1c6f694e-9295-44ca-bb54-e10942065024">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:ParatekPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_f4dfb9e5-6e91-41c1-a947-ccb6c551ac4d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ArmataTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_abc0a929-7e90-463f-b887-b58ca920de42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:HealthCareRoyaltyPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:RoyaltyFinancingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_00bcfed5-5665-4a95-a3f4-d2ac0f6fdaa3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:IspFundLpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">inva:EquityInvestmentsAndMoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_90e80338-5725-4945-ba17-420b39d8a65d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_9fea235d-92aa-406b-99d4-cef846711663">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_8b18bfe1-7298-47b5-82af-99cfcef35fce">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:LaJollaPharmaceuticalCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_f20a0f71-d04c-4707-b554-1102f62cf1a6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_5f070bd2-c0df-4242-beff-e5f9b6727217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_f018c1ca-e8f9-4a4f-9827-94816b25882f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:GateNeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:SecondNoteAmendmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-06</instant>
        </period>
    </context>
    <context id="C_85e74837-f1dd-4956-a48b-f67a1bfe07cf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_5c0f9d6a-daac-43d5-9697-46136da2e5eb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:LongActingBeta2AgonistAnoroMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:GSKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_710dc59e-981c-4ad8-987e-bb49af565884">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_09977380-7092-418e-b4d3-d48f7caaae46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_f08bc742-7ba2-448a-ba4b-b3bb674bb334">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:PutOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-01-01</startDate>
            <endDate>2013-01-31</endDate>
        </period>
    </context>
    <context id="C_c2c8ab67-08be-4854-91e3-98e911bef5b3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_4b010911-360b-4122-a51a-2daa2012b8a9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">inva:TermLoanInvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_6672ccef-5420-4f2f-9dd7-acb4111b0173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:CallOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-01-01</startDate>
            <endDate>2013-01-31</endDate>
        </period>
    </context>
    <context id="C_4e8f4a7f-a815-47e5-91cf-9d09535c48ce">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:LaJollaPharmaceuticalCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-08-31</endDate>
        </period>
    </context>
    <context id="C_f6a3bb99-253a-4791-914d-f4334dddf22a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_c2081d77-3917-481a-aad9-38a97a27b3f4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ImaginabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ConsolidatedInvesteesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_441daf0e-a05d-414c-8eaa-feeb49fa7590">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">inva:LaboratoryEquipmentFurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_4eb342bb-a67b-41a2-af3e-2b6b0a442022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_a97169bf-af91-4b94-a033-7619a6aaa930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_ad1bdaae-2e73-4919-aef7-1bf53376deb1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_ffbac92f-8341-4e52-864a-91ee3864a86e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:GSKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_569e7525-942b-48c6-9703-ac849c3d278a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:IspFundLpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_105e2ff6-b00c-4d0f-80a9-99bc41fa4247">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IncardaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_e112a83c-e5e4-49f5-9f29-958a211ef1b6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:IncardaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_9fb8ce09-b755-456a-88b1-2a93a91dc1d0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:GSKMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inva:LabaCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-12-31</instant>
        </period>
    </context>
    <context id="C_3b5f86a2-e137-470e-ae05-ea4b9e220cfa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_9c42d5a6-8705-438d-afbc-23f20a000d9b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_5d7298e5-9f61-4332-aa3f-399d8b896265">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_2e71015c-4917-4b0c-8a50-046d7e6f4812">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:LaJollaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inva:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_e3c81efe-d99a-4794-9295-046bab474ae8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_fa7ab020-0f18-40e9-ae65-5d70aca1f021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:InnovivaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_bb2dfb4c-8159-49a4-8abd-85f592b904b8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:LaJollaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-22</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_2357dcf9-e127-4ee9-a066-9899931c287f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ImaginabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:OneOfImaginabsCommonStockholderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-18</startDate>
            <endDate>2021-03-18</endDate>
        </period>
    </context>
    <context id="C_0c5dc7e3-2671-4634-a2ea-45c94c03c65f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_c104561f-a325-42f1-b855-c5fa80ede0f4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_b1399523-0285-44ab-8535-deb7616f55e6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_41328be9-6954-48ec-8905-bb9f765ccba2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_8b89681a-3d4d-4507-960c-e611eee0ae68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_2297939c-7913-4791-9563-25bbf6ee309c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inva:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_850c3b25-8c30-4a01-9de2-0ca85949a00e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:LaJollaPharmaceuticalCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_dc1e896e-f118-48b0-8cb0-89c09e214ab6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_c00f47a4-0506-4cb6-a19d-c4eb9dd56571">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ConsolidatedInvesteesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-17</instant>
        </period>
    </context>
    <context id="C_73b7ce85-a0d4-4185-bb79-15359bd6b909">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ArmataConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_e3a16997-be95-4821-b76f-a08d875b0dcf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_1ed70a12-64b7-49e4-b68e-70f274537beb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:LaJollaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inva:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_cff2e9b5-87f8-419f-9856-34ae17e4d036">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_a48b0af5-32e5-4d70-8301-ead504e49b4c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_4a4dcf17-e144-4065-bc02-636f5d4b60be">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:HarvardUniversityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_9eec32d5-1f8c-44e6-9ec4-05156ada8af3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_919c050c-8a72-41cb-a13c-102eefa52e63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_f7d458fe-e023-4486-aa27-fdd8c78f09fa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_5cb2b0db-90a2-4560-b85e-87494f6a7282">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:CommonStockAndWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_eaa09fba-b20a-4958-908d-40cfb3339c00">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyEightNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_9030a2c1-fd8e-4238-9d01-79bece46654e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IspFundLpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="C_c8d0b01f-64b8-4438-8b36-9e1b99364b0b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_77a6d898-3c41-425f-bdce-0d730d09522d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:GateNeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_6bed736f-3aa9-4d71-818d-93a8fca55527">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_a5bd2f55-3e40-4db1-9698-8e328bebe397">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_b0777350-8f02-402b-b8d8-33ebfbea0625">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_f252cf15-a5b7-46ae-b4cf-f02a7d2a1bf9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:LaJollaPharmaceuticalCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_a57ec5ea-103b-4914-89c8-f5cce009d3f2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:NanoliveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-18</startDate>
            <endDate>2022-02-18</endDate>
        </period>
    </context>
    <context id="C_702028fe-7b13-49f6-bf9a-e4aaba3364f4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_68f79cad-95a1-43ef-b218-21108e820b17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_c11bea0f-0ab6-46b3-9574-250a23feeefc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyEightNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_47540ae3-5ee1-428f-99db-8eab3bc7a785">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:HealthCareRoyaltyPartnersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_707fc4b5-3c6e-4394-b574-0e56dc4f8c0a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-11</startDate>
            <endDate>2022-07-11</endDate>
        </period>
    </context>
    <context id="C_d7474670-7c71-498e-a093-31edba908380">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IncardaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">inva:OptionPricingModelBacksolveValuationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_6e16f944-8e12-42b7-84eb-4f21d332cd44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:TrelegyElliptaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:GSKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_29193a89-f8bc-431f-9fc2-70fd8e836d0e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_109bc829-e421-4835-9aad-dedc4c375347">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:IncardaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_539783b3-bf29-4a63-8d24-99d7b7b79e81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:GSKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_3b21613e-2472-472e-b92e-7b218fb6aecc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:GateNeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:NoteAmendmentAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-13</instant>
        </period>
    </context>
    <context id="C_809b9867-b962-4553-b6ab-8ca43d28920b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_c1cee939-99f5-4170-95af-3c7cd8ef24ef">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:LicenseRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_cb4e7215-9a5e-4dd4-aeee-e50dd4e2eb6b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_5adfa42a-1fb9-4bab-ac06-149565b0b62c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">inva:EquityIncentivePlansAndESPPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_d2367046-d399-4ddc-a17e-2f5ef1165e9e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_394439fc-7c8a-4379-be01-6a604b354293">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_b628e0b4-4491-4cf0-9301-fd0c4a42318f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IncardaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">inva:OptionPricingModelBacksolveValuationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_20a1bbc0-a748-41da-a071-6972900ca7d7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:PaionAgMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_7595f3bf-096e-45fc-b68b-d690c0d2803e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:IspFundLpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">inva:EquityInvestmentsAndMoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_2bff9226-01dd-49ce-8c00-439b9b368e4f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:AstrazenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_08e9488e-214d-4494-813d-28131fd90598">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:IspFundLpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_5ca60e7e-4ba6-40eb-a454-386ec8c73923">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-09</instant>
        </period>
    </context>
    <context id="C_d7cf516f-572b-431a-8937-a3fa41621ee5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_c6dfd9f2-8eeb-44c2-9621-2be87264e608">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-17</instant>
        </period>
    </context>
    <context id="C_0fcc5eab-dacf-4fd9-9338-7ce4c19eb6f1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IncardaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:SeriesCPreferredStockAndWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_a602a058-063e-48c6-b5ce-d6c0d4fb1353">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:NanoliveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ConsolidatedInvesteesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_a69ed80b-24cf-4fb0-939b-206e1bd2ef60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:GSKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_1e700f80-a869-46a2-ac03-43bec9ff60e2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IspFundLpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_81047951-2422-46bb-a073-86b99c1cee75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:IspFundLpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">inva:EquityInvestmentsAndMoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_61ec0a88-ce56-4964-8be3-32f048a015ef">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_fdb40e49-15a5-44e8-ab56-25350fd9d665">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IncardaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_059975f4-4c4c-47fa-a5cc-efc7bf10d886">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IspFundLpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_b3da9b9d-f2ab-400a-b73e-57b287e45c47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ArmataTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">inva:TermLoanInvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_1d4ad1ec-0fb3-4d86-8793-4881afd79af0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IncardaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:SeriesA1PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-15</startDate>
            <endDate>2022-06-15</endDate>
        </period>
    </context>
    <context id="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_7b781f4e-2b96-403a-be95-189c21bfe845">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-09-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="C_60737025-6027-4430-9a69-c41773b76a7a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IncardaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ConsolidatedInvesteesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_5b63eaba-876c-4443-a190-0d776e3f0354">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_5f1754a6-1e81-4cbd-8bf9-4f5f1ce7bd5f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_c548651f-66c2-40f0-80ce-a318243d8cf7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IncardaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:SeriesCWarrantsAndSeriesDWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_0180ad0a-b06f-4e53-948d-bb80d100090e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_bcf921a3-2613-4901-bd57-bf22fbe5ef61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="C_8e426da9-946c-40b8-bd70-2a6eaa29fe3d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:LicenseRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_1d6c5f53-6c4d-4fe6-a55d-07940f638bd4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_0608758b-b85d-4f54-a373-092e1463e6e6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:CommonStockAndWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_70e1c77f-fb08-4ab9-9457-0bc05d1bd9af">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_b2abb502-4aea-4d3e-a1e8-7663f28b3e4a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:LaJollaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-22</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_dec01f12-3f85-4d42-8b61-61f857a1419a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_0e8b7755-7a30-43fc-8700-88f8cb2fb267">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_f390186b-f0e1-423b-87da-2c37deb3557f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_5610546b-710f-4b56-bca0-b9c532b6f95a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:IspFundLpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">inva:PrivatePlacementPositionsAndConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_c985f900-3058-44b4-9093-ef23d5cbfa14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="C_5294fbf9-d2f4-4cee-abd1-6e00044b2cfa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-01-01</startDate>
            <endDate>2013-01-31</endDate>
        </period>
    </context>
    <context id="C_7dd3ea38-7516-4e7e-9399-9f1920d9d119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:LicenseRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_01fb7c8c-6c66-4d02-b04d-546c5c407297">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-08-07</instant>
        </period>
    </context>
    <context id="C_9d6f1e1e-8a05-4f52-aabf-6ea93d745a22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ImaginabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_b4844c4a-5218-4a44-b32f-7a91f6ba430d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:NanoliveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-18</instant>
        </period>
    </context>
    <context id="C_ec125de3-1e4e-4a75-b4bb-7673bacb9c03">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_b58b4d47-eb88-4714-9e20-e846765b8a44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:CommonStockAndWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_a0d0f17e-db42-4983-a7d4-03a17fcfd44f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_941dd2d3-13db-4e88-a246-2446d97b2a8e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:CommonStockAndWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_1595673f-bb14-4c0c-b50c-19b1db664ef7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyEightNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_b28442af-97a1-40c6-8f0f-8d7c9d6642b5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:GateNeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_ffcfb827-8e39-4d8f-add9-6684b4c98b48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_1a69ac4e-3663-4d1d-a457-2b4890fc09f6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_059f7bf6-1ef6-49bc-9ffa-a0a2a13282ed">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="C_bc5da3bc-ba84-41b4-9714-69d7f9dcb276">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:IspFundLpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_dc664211-9a49-4cc6-b77c-b76d951d8b6a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:WarrantsPurchasedIn2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-01</instant>
        </period>
    </context>
    <context id="C_f865e077-bfae-42a2-83e9-9bbaf0133b51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inva:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_03ba9ffa-87ef-489a-a311-42db1ae05203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IspFundLpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_71266bcb-340c-4b6f-bce7-ec001e02f542">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_d5306868-e998-4382-9386-90e35c6d7f3a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ImaginabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_6c28106a-1f5c-4375-9a90-9f5d3d7fd470">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_a864ac08-9446-4d68-95de-31f94372d9f3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_d809c37b-511d-4f0b-942b-be754908ee4d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_32d8d95b-c12c-46d1-98c1-3deb4b8cb129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_5d098b39-13cc-4896-9cc3-c37b02ea18ac">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IncardaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-15</startDate>
            <endDate>2022-06-15</endDate>
        </period>
    </context>
    <context id="C_5783ed68-2473-492b-88b5-e1af30e3c0e7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:GSKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_e6d12e36-aff4-4dc6-81a3-899ea1f5910b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:LaJollaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inva:CustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_d05dfc5c-b948-4497-8849-a42784e9f325">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:LaJollaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inva:CustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_23e66452-ee29-415e-90e3-ae16681b068e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_c21ec5a1-610f-49e2-a459-1e404f26ba78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:GateNeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_825c0bd4-909c-4d86-9ae9-0ce6eb8cdcf2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:GateNeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-13</startDate>
            <endDate>2024-02-13</endDate>
        </period>
    </context>
    <context id="C_b40eac4f-f18e-4a85-95ce-6db8d48f14f2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_7bb88b87-b326-4e6e-865b-16d3ceea75e6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ArmataTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_7adc5fad-9ae2-4326-83c1-8d6394980f7e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyEightNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_0baf8d0a-a93a-4dff-b66a-e5c5efa4d6d1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IspFundLpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-30</startDate>
            <endDate>2022-03-30</endDate>
        </period>
    </context>
    <context id="C_a6dc9592-99de-4df7-8a98-ca4fcda287d2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_6c747ad1-5f7b-4926-8ac2-714e9199e239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-07</startDate>
            <endDate>2017-08-07</endDate>
        </period>
    </context>
    <context id="C_f9f2e0b5-7d3e-40a6-b5ac-2fadf0d6e6e3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_cd17c19c-ec63-4e2e-b6da-1c56d9be380d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:LaJollaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inva:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_a7bcde7c-16d0-44f6-bf9e-2ed901913ed0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ConsolidatedInvesteesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_d10e57d1-8709-4825-a966-e724f8f4633f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_17f70e4b-90ed-432b-9c5b-4b6afd7a39ac">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IncardaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_b7286a7d-74d3-4d92-a0a9-a2bb49f254d9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_bf5886d1-1be6-4c7a-bfe3-1be3dd08388d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyEightNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_e913bb79-80cf-4e4b-b05e-99a1cc469935">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:LaJollaPharmaceuticalCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_67050c7f-cb36-416c-aa88-59d5550ab95e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:CommonStockAndWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_8e8b777f-2a9d-4fa4-b2ab-fe056ae69ce8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:TheravanceRespiratoryCompanyLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_8e9e31d1-92be-49a8-9a9a-67c314bf7e73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_b14e6b43-6384-43b6-9c33-6f1a35010333">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">inva:BurlingameCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-30</instant>
        </period>
    </context>
    <context id="C_9fac3855-4b00-44d6-b70c-185ef1d1eeb0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:GateNeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-02</startDate>
            <endDate>2023-02-02</endDate>
        </period>
    </context>
    <context id="C_3596ffd8-7703-4aa7-bc48-723fa485f9cd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:LongActingBeta2AgonistRelvarBreoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:GSKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_1ba9463a-d1f5-4a30-bbac-3bc5aad6339b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ImaginabConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-23</instant>
        </period>
    </context>
    <context id="C_3325a2cf-7460-4b93-a664-ed1cbe345622">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IncardaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_140324d1-1834-455e-b137-0176d2de6d77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:IspFundLpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">inva:PrivatePlacementPositionsAndConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_bda4cb66-7959-4b7c-926d-00e33cf8a0ad">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:NanoliveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_19d44124-af4c-4c1d-92f5-962be9ea56b6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_d9c7ca7c-81fc-4272-b388-610e1b6444a8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_f86d4e5c-570c-4de9-85a1-8a94d98944a1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_13a7a85f-17d1-43df-a359-948888dae445">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-07</startDate>
            <endDate>2022-03-07</endDate>
        </period>
    </context>
    <context id="C_d98c3729-ed3e-4b22-af22-60937a83a980">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-07</instant>
        </period>
    </context>
    <context id="C_8c8eca7f-7819-48ae-9938-c3c7153ffa73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:GSKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_1c3869dc-1179-4ea1-8b03-28655253f10d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IncardaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_2ea14962-08db-4e80-a279-f2d275caee54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:IspFundLpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_195a4e8d-1787-4289-8f28-a87a026f6c66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_fe183000-a690-4df9-a845-930c3241af02">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="C_f3f69c9a-b63b-46c1-8d46-3c3cdfa265b1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_87231fad-8817-4c3e-8afb-e2378841555d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_76103f21-39aa-4d6c-bd6a-47f7c57f423e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:LongActingBeta2AgonistAnoroMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:GSKMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inva:LabaCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_2f159654-f79f-4e47-806d-ec1adbda538c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:EverestMedicinesLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_4fa6082e-52f0-4343-8a08-2384bb43f803">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IncardaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-15</startDate>
            <endDate>2022-06-15</endDate>
        </period>
    </context>
    <context id="C_0b1bdfd5-7193-40f2-af61-475bdb6831fa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IncardaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_99ee3dae-1eb1-48e4-a46a-c7e1dc1f16a3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-07-31</instant>
        </period>
    </context>
    <context id="C_89169f0d-1765-42aa-9d7f-0ca1858b85d2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IncardaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_f7344ab8-d158-462a-91a3-5ed1e74e6333">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_7b140651-bbea-4d88-8a4f-fa197b5dfa55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_046580cc-7efc-42fb-b5c6-9fa3ae87d270">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:HealthCareRoyaltyPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:RoyaltyFinancingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_0882851d-0bed-4150-b837-2e1f74d8e460">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyEightNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">inva:PrivatelyNegotiatedCappedCallOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_274e3c4f-40cb-407c-aabb-e32137ff6f9d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inva:EmployeeStockPurchasePlanTwentyTwentyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_d81eb8e0-c039-48de-a07a-d8267be56862">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:TheravanceRespiratoryCompanyLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_f20f052b-36df-4c4e-bd3b-191c89d3381d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ImaginabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:OneOfImaginabsCommonStockholderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-18</instant>
        </period>
    </context>
    <context id="C_5c9abf9d-1e31-4f48-9d0d-c57d10750153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inva:EquityIncentivePlan2012Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_11f17e9c-095d-4fae-8b57-328fa2b9ba57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IspFundLpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-30</instant>
        </period>
    </context>
    <context id="C_4c71a645-f25d-4cb5-8889-681f3449ecac">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_921dd0ce-2b9e-4442-9188-880568f7b1f1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_8438a6b5-27b4-494b-a98e-519ed66169d5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_c59027d6-af7f-4474-af78-da02d5338608">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:InnovivaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_972fc684-1125-4562-949a-c061a92ab4f3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">inva:OutstandingStockWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_a6849091-06e9-4245-b57e-57668217a80b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ImaginabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-18</instant>
        </period>
    </context>
    <context id="C_5e685cc4-011a-4588-9181-90ecb3ccceb4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_e2dfcab8-9a69-48b0-bbd8-dd20190bc830">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyEightNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">inva:PrivatelyNegotiatedCappedCallOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_308dae91-3293-4e16-bef8-42832c4675db">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_1c9ae792-bfa8-4f96-9434-ec29ab1930a2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_3f92b149-a39f-4e8f-96ab-6c3b86b4dbe7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:TrelegyElliptaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:GSKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_d68c6264-7526-47b4-8da2-c7ceccce0e57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:IncardaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_825f18bd-f7d5-4d67-9659-20286d27f1c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_b5db3709-c76a-4a08-8c44-b8f59cdb4608">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_81ea3387-bcc2-4cfe-a9e7-78fab40062ee">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_07eefa71-9b4d-4cdb-b27f-f192898d804e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">inva:EquityIncentivePlansAndESPPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_552da0c1-853f-4893-a1b0-a4223d212e95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_4aa2cab4-fd43-44e4-87cc-bff3c5ce186b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:WarrantsPurchasedIn2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_743b7286-55b6-4101-852d-19e61fad9eaf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SecuredConvertibleCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-10</instant>
        </period>
    </context>
    <context id="C_211cd3e4-b7d2-4255-9490-b9155f8d7b3d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:LaJollaPharmaceuticalCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_94027cba-de30-4b5d-a0ff-68cce2ec7cfa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ImaginabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:SeriesC2PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-14</instant>
        </period>
    </context>
    <context id="C_d3087254-4dbd-4e76-a116-2ba842506912">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">inva:OutstandingStockWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_a0e6a86f-d6b7-4f77-89aa-49a1c8b20ae6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyEightNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_fb34b57e-973b-4997-8a2c-2f01d3f8fa62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyEightNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_6f107155-7e2c-410b-87ad-9c00bd1803a3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:NanoliveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ConsolidatedInvesteesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_de46daa9-d4c7-4d11-b729-3650d5f2b9cd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:IspFundLpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">inva:EquityInvestmentsAndMoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_32088045-eb75-4318-bbdc-77c7436faa52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:LongActingBeta2AgonistRelvarBreoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:GSKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_8b957e8d-7780-431f-93e1-471c1c7babcb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_1c6acdd9-134f-4827-828c-e39c4849a9cf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:InnovivaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_5f6a168b-c6ae-4f1b-a9d6-59d531bc1b72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_33ccc9ac-1bd0-4923-b096-29db8ac98a5e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:ResearchAndDevelopmentSupportMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_9f19eb4c-29fe-474d-b77a-08e5bb571e8e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyEightNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_4f37ea9f-306f-4950-a02c-a9b920bca4f3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">inva:PrivatelyNegotiatedCappedCallOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-07-01</startDate>
            <endDate>2014-07-31</endDate>
        </period>
    </context>
    <context id="C_cd8458e6-5f79-4d96-add0-064203ed13b2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_9425c965-5f65-4fe2-b539-6c9acbd2b026">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:LaJollaPharmaceuticalCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_31fb851b-8f5e-4955-b085-ac6b0dd38b8d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inva:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_a0c44c89-e8b9-4ab7-8450-da67ef9caaa2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_a99937e1-764a-4db1-ae21-40947196ea5e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:HealthCareRoyaltyPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:RoyaltyFinancingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_f3734e2c-95b6-4b79-9206-0f8540ff6e11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:NanoliveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-18</startDate>
            <endDate>2022-02-18</endDate>
        </period>
    </context>
    <context id="C_e585cd60-cdd5-4401-bfcc-d855443a7706">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IncardaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:SeriesDWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_b2c2c1ac-728c-4d23-a024-c459443d06d0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:TheravanceRespiratoryCompanyLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_455dfd10-363e-4652-a98d-acd8423476e5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:GateNeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:NoteAmendmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-02</instant>
        </period>
    </context>
    <context id="C_51f40066-7e1b-48d8-8a38-42b77199fdd5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:GSKMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inva:LabaCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_07acd2a2-efee-41c9-bbd9-499920ef8206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ImaginabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-18</startDate>
            <endDate>2021-03-18</endDate>
        </period>
    </context>
    <context id="C_e414574e-4c06-4df7-8940-8de9bca1b108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:LaJollaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inva:CustomerThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_9c87d87f-710c-4de3-a73e-9a9094727284">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:TheravanceRespiratoryCompanyLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-20</instant>
        </period>
    </context>
    <context id="C_460b7389-fa51-4f4c-9e61-7e987dc6ad3e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:IspFundLpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_3341913e-5e8a-43b4-af63-a752924ce8bc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_833ede43-b30a-4e04-a7aa-1d2f47880788">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:LaJollaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inva:CustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_f6f51154-4209-4901-acf6-2c40992c8eb9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_b39ad5c9-17bf-4a35-b889-6bc388c60b7c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IspFundLpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_fe55bf5e-1c8a-47f4-addb-d0f1f9a5891e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
        </entity>
        <period>
            <instant>2024-02-14</instant>
        </period>
    </context>
    <context id="C_5058eabb-afd4-4dc1-a2f0-0ac8d38fabee">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_7a07a415-eb4b-4dff-ab91-19dbbfc1a7cc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:TheravanceRespiratoryCompanyLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0d916e91-2dd2-468c-ab30-e90e2ac963b9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_9d615842-43ad-4afe-b67a-2a588d4d0728">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_0651f01e-b4f6-472e-bb04-bd2532da85ee">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:GateNeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_011ae41c-ec4e-43c1-8532-003573595646">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inva:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-17</startDate>
            <endDate>2022-02-17</endDate>
        </period>
    </context>
    <context id="C_a3c920a5-17f0-4dbc-8aff-02ec45493f70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IncardaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-15</startDate>
            <endDate>2022-06-15</endDate>
        </period>
    </context>
    <context id="C_44d770d3-712a-4496-9e68-7b69a5f5d2bf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:IspFundLpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_cce222e5-dac9-4c08-abb5-d90f2a3b1707">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_966fb9ea-4c8a-4b8b-b091-d09a286a05bf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">inva:TwoDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-09</startDate>
            <endDate>2022-02-09</endDate>
        </period>
    </context>
    <context id="C_d406fd03-b3d6-41fd-b4f9-74170c936a7a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_cad461b3-85e0-44a5-b49c-2fdefdb8eb14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SecuredConvertibleCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-10</startDate>
            <endDate>2023-01-10</endDate>
        </period>
    </context>
    <context id="C_45aa5dba-bae7-468a-aac4-f6723db99993">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_6a99d93c-955d-4e2f-bcac-63e09ca2e6ef">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ImaginabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-18</startDate>
            <endDate>2021-03-18</endDate>
        </period>
    </context>
    <context id="C_28748b0b-ed6b-4f26-be07-c4b34621cb5b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-09-30</instant>
        </period>
    </context>
    <context id="C_8ee91638-15d2-4e40-b682-b93f8c3d03b7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IncardaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_3a82bed2-f816-4121-ae41-fc7fd838fa36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IncardaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:SeriesD1WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-15</instant>
        </period>
    </context>
    <context id="C_067b241e-3eec-46f9-b23d-3e9d389993c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="C_b9a1435b-0390-4e98-b9e7-4a02063789ba">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_24b1825a-6f77-49e4-828c-3e33f531af0b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_be6668a0-7dd8-4ba3-acdc-f68ede2a4466">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_dbf2c9ec-33a9-4f10-847f-e794f7585c7b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">inva:OneDirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-09</startDate>
            <endDate>2022-02-09</endDate>
        </period>
    </context>
    <context id="C_8591827b-2838-4d76-9be9-a5c2eecadbf7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IncardaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_102d957f-b55b-4b0c-b290-8ba82889bebc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_d4a6dcc0-1cdb-48e6-9838-784bbf0081bc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IncardaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-15</instant>
        </period>
    </context>
    <context id="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_2f7d8e77-eb63-419b-ad16-1ac5905b61e3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:LaJollaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inva:CustomerThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_1c07c08c-06ec-49dc-b790-0f2340f3ad4e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:WarrantsPurchasedIn2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-01</instant>
        </period>
    </context>
    <context id="C_f4a9e48d-00e5-43b6-9299-938496783a9d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:IncardaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_d4042f8a-02bc-4c92-af62-098270afe2af">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-07-01</startDate>
            <endDate>2014-07-31</endDate>
        </period>
    </context>
    <context id="C_1a6354f8-d8d6-4e39-a8ca-ea30d3d87bc6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_1a399c56-8380-4778-aa97-c511dc489262">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_36943c71-452d-4fbb-8d19-9e8b848cee67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:LaJollaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inva:CustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_ba1a82e3-49cc-4439-9ea4-1ade7ac73cb8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:LaJollaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-22</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_81c113da-ef79-4663-b552-0f93fc8926be">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:LaJollaPharmaceuticalCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_aab90c2e-843e-4eca-8999-f7ad6f6f31c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_4a240330-393d-4181-af3c-3ee7aca2c718">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IncardaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:SeriesD1WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-15</startDate>
            <endDate>2022-06-15</endDate>
        </period>
    </context>
    <context id="C_126a8e06-61fd-494c-9ffd-58ea5c0bdea5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-17</instant>
        </period>
    </context>
    <context id="C_fe573d70-749d-4747-a2aa-7a4c9cb2488c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_101e59d3-6e14-4104-a1dd-021cb423fa02">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:GateNeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:ConvertiblePromissoryNotePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-02</instant>
        </period>
    </context>
    <context id="C_87ac8e26-9a2a-47e5-973e-54a32e529605">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:TrelegyElliptaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:GSKMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inva:LabaCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_0de66d0f-6eb9-49fa-a5ec-9c7b513a7979">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inva:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-17</instant>
        </period>
    </context>
    <context id="C_2b0ee96a-cf29-4fd8-a358-2c59b280effd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:GeorgeWashingtonUniversityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_c70d2786-9128-41e1-9dae-1423ff150cb0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:GateNeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:ConvertiblePromissoryNotePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-24</startDate>
            <endDate>2021-11-24</endDate>
        </period>
    </context>
    <context id="C_5361a0f4-5547-4b13-aab7-9c5bf77f49a1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:EverestMedicinesLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inva:CommercialSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_40cc7194-3f29-4836-b18c-10aa722c5ee1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IncardaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:SeriesD1AndD2PreferredStockAndCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_1f21da09-fc29-466c-a31f-b632bcb5a795">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IncardaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:SeriesD2PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-15</startDate>
            <endDate>2022-06-15</endDate>
        </period>
    </context>
    <context id="C_653aae1f-7476-41b2-a55d-7986566e9db4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:LaJollaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inva:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_646bb33b-4ef6-4493-b542-00c92f556418">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_425efcfe-eac0-4b78-bf2f-d0ef757a0501">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:LongActingBeta2AgonistRelvarBreoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:GSKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_8c6a7bcf-3783-4f54-9341-3247cae07c70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_50bb996e-86f5-4158-a575-796da0e57247">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyEightNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_b60e6976-6149-440a-b50d-539629e77c91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">inva:OutstandingStockWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_9eac7308-f944-4333-bf01-4381430c8676">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:TheravanceRespiratoryCompanyLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_379884bb-ab3a-4a27-89b9-9b8365b16e1e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:GateNeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_bfe82950-e87e-4ffb-ad0e-84e0026f5b0c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_8e0a440d-9ea8-4152-85ec-508d2a5aa993">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_9b30963d-d42c-4ba2-85ac-e1f548c6e616">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:LaJollaPharmaceuticalCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_300582a5-75c9-4125-aa9d-205955fffcd6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-09</startDate>
            <endDate>2022-02-09</endDate>
        </period>
    </context>
    <context id="C_cd95e6eb-db30-4b57-a111-4b45da383cf5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_7087d489-2159-4c5e-b41f-f209f859c49e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyEightNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_0c62ac1f-f870-4e92-add2-b1924f35420e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:IspFundLpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">inva:EquityInvestmentsAndMoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_adc3b151-5d38-4abe-9182-9e724c5ef29b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_bd478d73-d23c-479d-ac02-32fc192ff66f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ArmataConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_74b73320-f859-4046-baa9-7350be012c10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_3810cd04-c006-4bfa-8397-c106caf901af">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_d21494bc-80c8-4b9a-af3a-b8e82bfd6caf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:IspFundLpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">inva:EquityInvestmentsAndMoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_ea704773-4bd5-40ed-9730-d6a668d17624">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:GateNeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:ConvertiblePromissoryNotePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-13</instant>
        </period>
    </context>
    <context id="C_e6805147-9eff-450d-a94b-d8e4239b1dd2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="C_fa01aae9-eeeb-459c-9277-c4cd33bb93d0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_a89fb91f-9ba5-4dc8-a73e-32d0a623c796">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="C_54ed52d3-2763-46fa-a0e9-bfeb58272692">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:GiaprezaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:LaJollaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-22</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_b6f84383-3742-4678-adab-90f14685e54b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_3b8d2e0c-b8e8-465e-b685-f60604c8c298">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2023-02-28</endDate>
        </period>
    </context>
    <context id="C_2f78a803-3fe0-4245-b906-d2b1f794b7ad">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IncardaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_29561087-beae-414b-bf9d-e689e21a5ee7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_b77a83ac-82c7-48f4-8088-fe346e76a70f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IncardaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ConsolidatedInvesteesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_825d28ed-6319-4ae7-9001-97f35281db61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:GateNeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_669beef7-e71d-4c69-83c1-57065488410a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">inva:WalthamMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_a18d4683-905b-4297-962a-d6b053b48738">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_6f7b5337-631f-48a7-b4c9-05cbb564473e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_886d4bf2-cc70-460c-8055-b20097a1c12e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_c572fa7f-d00c-4858-9672-e4e0981286bf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_983ae2b6-5a3f-48bf-90f1-b4b741cfcbbe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_3ac61c6b-9a4c-4283-b479-f0354fbd761b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-08-07</instant>
        </period>
    </context>
    <context id="C_698952c3-354e-492f-acd8-4bebed0f9f6b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">inva:PrivatelyNegotiatedCappedCallOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-01-01</startDate>
            <endDate>2013-01-31</endDate>
        </period>
    </context>
    <context id="C_29d8e0a4-1346-4e5a-9734-3d41d9fe9891">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_b022e036-d13c-4fc8-94e9-00734a572b9c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:LaJollaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inva:CustomerThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_5a9d38bb-6bc6-4e0d-b81a-0f669ce07277">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_1dbbdaf4-e472-4d57-8ddc-ea01a7242c98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_76445fe9-d438-4d1c-a28d-613fef583510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_4a4ab2a3-40c8-4d79-9cdf-f746af492718">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_e4ffec73-53e1-424c-b35f-67a5034c0026">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:GateNeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-06</startDate>
            <endDate>2023-10-06</endDate>
        </period>
    </context>
    <context id="C_c84174e9-be04-42dd-b25c-92df750b79e8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:GateNeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_d175b10d-c61c-4706-bba1-92ef6df9865b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-01</startDate>
            <endDate>2024-02-15</endDate>
        </period>
    </context>
    <context id="C_e1b05d91-a370-4fa6-955b-9c0c677f7d49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-18</instant>
        </period>
    </context>
    <context id="C_ea7c0a60-08f5-4a3e-a061-5a67602a1ec1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_bf193f24-bfbe-419c-9802-eee6070d5ad5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ImaginabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ConsolidatedInvesteesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_f3b6b1d2-3788-42e8-b1e9-0bae28c7d538">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_e05740b2-e808-41d3-b26e-897ba3aa633c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:LaJollaPharmaceuticalCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-22</startDate>
            <endDate>2022-08-22</endDate>
        </period>
    </context>
    <context id="C_f2f66487-eef9-477e-a54f-358af57f70cc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_9f56edf9-4d83-4ddd-b43e-19b470780c80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_052592af-355b-490c-9bea-1016c2ec7fe7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_c9163898-48a1-4dcb-8fe2-b46eda3de475">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_55652f07-0e2e-4bb9-b4c3-618b5066831e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_344746bb-e636-4cfa-9204-6870353b5936">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_8f8c6623-d626-4ff4-b287-9206e6e7485e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_85b04dbe-2493-4115-9d41-cfc1636e1d1c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:GateNeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-24</startDate>
            <endDate>2021-11-24</endDate>
        </period>
    </context>
    <context id="C_94c529c4-f563-461a-9da8-262bcfe8bc37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:TrelegyElliptaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:GSKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0287d352-8cf0-4411-9610-d97bd5f904bf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IspFundLpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_b57cd753-71d3-4cff-8d5a-7f32594379ed">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">inva:TermLoanInvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_a18abd1c-665b-4c52-b36b-be1bbd83b22e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_3abefe6f-631c-4640-93e2-984c5ac20007">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IspFundLpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_00500ade-f7ea-4d89-9a06-fb25d9363802">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_74708c78-45e8-4732-9508-597695b3a0d5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2013-01-31</instant>
        </period>
    </context>
    <context id="C_6c4d4181-e8c1-43dd-85b3-83b9cf5f55dd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-09</instant>
        </period>
    </context>
    <context id="C_e3491d72-ab2a-429a-8f92-dd8be751aada">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">inva:OldDebtInstrumentInterestRateBeforeRepurchaseOfNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-07</instant>
        </period>
    </context>
    <context id="C_cd9243f5-5c45-4dc0-9b92-52023672ac79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_2253537a-7271-4515-97f9-6f06ff495b9f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ImaginabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:SeriesC2PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-14</instant>
        </period>
    </context>
    <context id="C_e2357c2d-6a56-4a89-83af-cfa33770d462">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IncardaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:SeriesD1PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-15</startDate>
            <endDate>2022-06-15</endDate>
        </period>
    </context>
    <context id="C_27cbe4a1-3bff-4bc8-b808-d5e97b10b96a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:GSKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-13</startDate>
            <endDate>2022-07-13</endDate>
        </period>
    </context>
    <context id="C_0f8abff1-9020-483e-b333-8737df241e43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IncardaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:SeriesD1AndD2PreferredStockAndCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_6e065d89-351d-457c-ba2e-bc2d69edba60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_5e106938-a0b0-4aeb-9126-1ce4d5e166fa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IncardaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="C_da2e5495-b09e-47a8-9a8c-ea82f08e7ead">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">inva:OneDirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-09</startDate>
            <endDate>2022-02-09</endDate>
        </period>
    </context>
    <context id="C_c3ca1f40-a3c1-4ba0-9cd7-3d664a62262a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_ea272365-8aa7-4a80-8b19-6a8032d971c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:IspFundLpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_96f1c8f6-d5af-40ca-aebd-5dd11479b360">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_f00e797a-c719-4c90-a9dc-1bce4096970e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:GiaprezaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_64603e03-c98c-40b7-ae31-b9e79c20bc55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:LaJollaPharmaceuticalCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_0647acf4-6f5c-4d39-86c2-fb4fddd549fb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_2f32a53f-9c4b-4122-bfb3-3e89cba768ae">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_13fdb038-bf81-4c06-8c1d-9aabbf5a3705">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:IspFundLpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">inva:EquityInvestmentsAndMoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_4744817d-5145-49fb-a6a0-1308e192a8f6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_bfc65bb1-ad80-4e8a-8b46-7fb950cefb1b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inva:EmployeeStockPurchasePlanTwentyTwentyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_49ef45bd-5ceb-448c-b5bf-998ea5bcd6a4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_b4ac9910-3d92-4e1b-ac5f-f74c9dbdcfcd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_d074e316-aefd-4e82-9593-cc19fd319a60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_53420953-7564-40c6-bee0-709280cf738f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inva:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_b55f651c-8a37-4dd9-95c5-8086ccf211c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">inva:PrivatelyNegotiatedCappedCallOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2013-01-31</instant>
        </period>
    </context>
    <context id="C_47315d43-a153-47de-8273-33588b06dde8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inva:InnovivaCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-17</startDate>
            <endDate>2022-04-18</endDate>
        </period>
    </context>
    <context id="C_9125c6de-8c86-4bde-9b04-80aa987c21cc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_f526cd8e-6c2f-4f2c-bd9e-4e878cf8ba5f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:GateNeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_9f8ff2b8-4656-4ea8-955a-c60a95c6b1c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:GateNeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_e037e13e-6e91-4a72-ba0c-e61af7067b1b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_5c2cfa33-ca5f-465a-89ae-63a6b102f37a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_e3e6ec1f-49a0-4fb9-9419-c9b6fcbc8855">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_c174b897-ce7b-41b0-af4e-37c1c1527fe2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:TheravanceRespiratoryCompanyLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-20</instant>
        </period>
    </context>
    <context id="C_9d9fedca-43c3-4c3c-a148-a051b0151a35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_1dafa801-a453-4e03-925d-1453c2c0f5f6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_f0da2c05-1727-4786-acd0-b03e3dff2fa8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-10-31</endDate>
        </period>
    </context>
    <context id="C_962daa42-70a2-4386-b932-c071d02f40c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:LaJollaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inva:CustomerThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_593427ab-e2d7-4f72-ba54-456608483083">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_7cde4835-b322-4448-9e0f-120e1bccc549">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:HealthCareRoyaltyPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:RoyaltyFinancingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_acc8fa0e-9230-4a63-8d63-4ae6d91d60af">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_2e2e6b99-d8c8-44b8-aabd-25fa00182b05">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:TrelegyElliptaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:GSKMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inva:LabaCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_a332f0a6-0f9e-4712-97f0-f10d648bcf65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_d5f73726-2a05-4be7-87fa-3fd6369578ba">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_4ad76130-0d29-47d9-b811-82b396d4ef22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:LongActingBeta2AgonistAnoroMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:GSKMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inva:LabaCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_5460cef4-c4cc-4668-99ef-fb2e26f72ba2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_1007c8ce-c961-4336-8299-5ed88a88849d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">inva:LaboratoryEquipmentFurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_676e8b46-96e2-42eb-927b-d2236a78f7f0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:LongActingBeta2AgonistAnoroMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:GSKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_e4d7581f-3285-4f94-bf60-7ad14f82c23d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2013-01-31</instant>
        </period>
    </context>
    <context id="C_b5138b8b-4530-41d2-a75c-4212efb677c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_0f0e0c31-e997-4327-b909-2d345a34ba21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_e642beae-c7bf-4bc4-9ebd-c58d6623dfc5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">inva:SoftwareAndComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_98c23b09-7eaa-42d7-b41a-5b1541dea4a7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:XeravaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:LaJollaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-22</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_31010f98-5d41-43b8-8b09-e38bde00ec6d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_c21ca759-25e6-4904-91dd-c322af1eeaf5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_1cbdd9df-6a4a-4d82-9344-ffb61a7bc4cd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-17</instant>
        </period>
    </context>
    <context id="C_11c3614e-b3bf-4d55-987c-21911b9b09fc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-31</instant>
        </period>
    </context>
    <context id="C_c20721f8-5014-4577-a717-6b5f4d10b69e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:LaJollaPharmaceuticalCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_3d081474-bef5-49f9-9f8c-6d2a8ce28f36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:GateNeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_c3fa46e4-5e22-4b74-a128-70da5649065e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:CommonStockAndWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-09</startDate>
            <endDate>2022-02-09</endDate>
        </period>
    </context>
    <context id="C_51b5cb2e-4d34-4373-952e-14896dcb3ec0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_d81c2107-a7a0-4ec4-8988-fc8409645f16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:IspFundLpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_c2b5fc1d-7d57-4855-af69-696043e9626b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ImaginabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:SeriesC2PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-14</startDate>
            <endDate>2023-03-14</endDate>
        </period>
    </context>
    <context id="C_ca966b79-26e3-4d58-ae1b-26f1394533f5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:WarrantsPurchasedIn2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-01</instant>
        </period>
    </context>
    <context id="C_96fef1ab-5fb4-4957-bed2-bbcbb49272d9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_25a18144-6924-42a5-a99d-aab05e77ca53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_6d65900c-b10f-49a2-bba9-16040891a8f1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IncardaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ConvertibleNoteAndWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-09</startDate>
            <endDate>2022-03-09</endDate>
        </period>
    </context>
    <context id="C_64d5bd90-3055-4f52-b86f-cb8d0deed43e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_4c7b96af-5930-4df9-9e24-686f4186dd93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_c5f941e0-b007-4ef9-bd80-53ea1e5f382a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_96ac591a-5f0a-4705-94d6-904d91058ae4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:XeravaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_44f330d4-92f5-4b09-a61f-569ed269bd6e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyEightNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_dabbf05b-a0a7-405b-8376-1cdce909cd8e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:CreditAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-10</instant>
        </period>
    </context>
    <context id="C_3d517819-005b-4abf-9ea5-9aada251df67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">inva:TermLoanInvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_afca57b6-192a-41f3-9d82-5a1dd8586709">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:XacduroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_fa0aac3c-12ff-4c52-bf57-2b8f937d8ef4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_a7cbb363-ce02-4f94-bf8b-d70a020aba6a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:LaJollaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_1f2036f9-b56a-403d-9f98-ec7e12869b74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_2c5b2d53-225f-409f-ad02-223827b8634c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_66b50de4-9da3-415d-8893-6426c4c9c73b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_bae5ea2a-1d4e-43c0-924e-20e43f661014">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:GateNeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_3824b03b-c4bb-4202-90b1-652ccf15674b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">inva:EquityIncentivePlansAndESPPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_f0655569-45ea-4da7-be44-e42a72acf91f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_8157d7d6-196c-4c46-bf54-22f1d9546346">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:GateNeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:ConvertiblePromissoryNotePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-24</instant>
        </period>
    </context>
    <context id="C_6872c5a6-9354-4f1c-9344-b3b75b5392e8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyEightNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_29a8663f-3680-40ab-9728-c1d88380d314">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <unit id="U_Director">
        <measure>inva:Director</measure>
    </unit>
    <unit id="U_UsdItem">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>inva:Item</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_Item">
        <measure>inva:Item</measure>
    </unit>
    <unit id="U_Customer">
        <measure>inva:Customer</measure>
    </unit>
    <unit id="U_UnitedStatesOfAmericaDollarsShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_CHF">
        <measure>iso4217:CHF</measure>
    </unit>
    <unit id="U_Tranche">
        <measure>inva:Tranche</measure>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="U_Installment">
        <measure>inva:Installment</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      id="F_a7027fdd-0941-440c-9c9d-cdfbda79f29c">0001080014</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      id="F_7f36bfc1-3e2a-4e7e-8df6-9c20266e1dfa">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      id="F_ea74df07-20a7-42c8-8e36-3fab5a27a4c1">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      id="F_2d907aa0-bc18-4de5-952b-9071c0e09061">FY</dei:DocumentFiscalPeriodFocus>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      id="F_2f119708-881a-4577-8742-9ee60a34c0fc"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      id="F_118b362a-f883-4a7d-b60c-4f79a2ad6875"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:AccountingStandardsUpdateExtensibleList
      contextRef="C_0f0e0c31-e997-4327-b909-2d345a34ba21"
      id="F_f0687ae1-b6c0-4b43-81f8-6dd3b3798531">http://fasb.org/us-gaap/2023#AccountingStandardsUpdate202006Member</us-gaap:AccountingStandardsUpdateExtensibleList>
    <us-gaap:AccountingStandardsUpdateExtensibleList
      contextRef="C_bd738e6b-a394-4de5-a04f-1f55e1ed3e59"
      id="F_ef17ea9b-bf17-4735-b022-25e18ecf85bb">http://fasb.org/us-gaap/2023#AccountingStandardsUpdate202006Member</us-gaap:AccountingStandardsUpdateExtensibleList>
    <us-gaap:AccountingStandardsUpdateExtensibleList
      contextRef="C_5460cef4-c4cc-4668-99ef-fb2e26f72ba2"
      id="F_2dbed8c2-40ac-48d1-9ee8-996ed0f6f21a">http://fasb.org/us-gaap/2023#AccountingStandardsUpdate202006Member</us-gaap:AccountingStandardsUpdateExtensibleList>
    <inva:ExtendedExpirationDate
      contextRef="C_8591827b-2838-4d76-9be9-a5c2eecadbf7"
      id="F_16022dea-4c29-4456-a7e5-3f052ff36fa9">2023-03-31</inva:ExtendedExpirationDate>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      id="F_4d9e1814-d90c-438a-b69f-2d0819d5112e">http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      id="F_62616aa1-c408-4682-b198-b4aacc8031c4">http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      id="F_8a36ba82-b9a3-4b23-adb9-3d2b758e3db2">http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      id="F_fbfec351-c094-49d9-a03a-e641b11869bb">http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_b14e6b43-6384-43b6-9c33-6f1a35010333"
      id="F_7da350c6-153c-485b-808f-be5a8394009e">P36M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      id="F_4335f0ee-8c74-4e0b-beba-133f49c7dc56">http://fasb.org/us-gaap/2023#LiabilitiesAndStockholdersEquity</us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList>
    <dei:DocumentType
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      id="F_9d8199f0-bc2f-40bc-a725-ac21ef35f3f6">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      id="F_ecd0407c-f457-46aa-b4bb-58d621fdef80">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      id="F_539de6f7-1998-48fe-9568-42d1ac90c08a">2023-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      id="F_a934c2ed-de78-49cb-8600-984e39932e60">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      id="F_3a26652a-5373-4453-839b-41bc182ade18">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      id="F_c215554b-f42a-4c00-bdf7-b632754f6ddf">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      id="F_38cad768-6696-4a31-9d87-12e38ebeb9d8">000-30319</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      id="F_293de294-a3f8-45a4-bd40-37a1e489b669">INNOVIVA, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      id="F_9ffbfc6d-e491-41d4-931b-44e2d02cd28e">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      id="F_eae683bb-fd79-4a1a-b6b0-451316b0ec21">94-3265960</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      id="F_77428a60-6b8d-487f-874b-060751880f25">1350 Old Bayshore Highway, Suite 400</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      id="F_fae3ddec-42ab-484b-b3d9-de6ae72f52b9">Burlingame</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      id="F_5588472b-4fe3-4fc1-b1a5-541c869442dd">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      id="F_1cf813d5-9e16-4a73-b5df-3dcdceb90b26">94010</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      id="F_599456b4-2a75-42ec-a4fb-993d3eccf181">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      id="F_e7a8a7c3-2e1b-4386-b548-97e82f106434">238-9600</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      id="F_73daf2d8-7d19-4a61-8020-3d200a77d75a">Common Stock $0.01 Par Value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      id="F_d7416747-e3e4-4b2c-8c6a-e1c8cdd0cbd7">INVA</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      id="F_30e963d8-891d-40e6-b6b9-fec61602bd9c">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      id="F_a4fd7dfe-4dbb-4673-b271-0e3cc192a449">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      id="F_beda6eae-dc59-437c-8bbc-5ef5f597984b">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      id="F_7e0fdca1-49ff-43cc-9d91-2ae85dd1a42d">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      id="F_342fc646-5b85-4dd8-a7e0-27354d9d095a">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      id="F_fbbdce1d-ae76-4740-adc5-05012484e86e">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      id="F_7d9877bf-f4e2-42be-a37f-e766031c1201">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      id="F_e2951440-ecc7-47fe-bd6d-2a93e11d12d3">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      id="F_5da7c02c-55c2-4d54-bfc9-f52f2ef5d4e6">true</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      id="F_c7956048-bdd7-429a-b895-fa7ca6dd656e">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      id="F_e633c0ee-89ac-4494-96bc-0916e05aadbd">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_b9a1435b-0390-4e98-b9e7-4a02063789ba"
      decimals="-3"
      id="F_261b757c-58fe-45c5-994e-7d61a34ae25f"
      unitRef="U_USD">731926690000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_fe55bf5e-1c8a-47f4-addb-d0f1f9a5891e"
      decimals="INF"
      id="F_f1b95002-f83d-4e00-ac43-58a5f74ac9ab"
      unitRef="U_shares">63227333</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      id="F_8465d106-b3d9-4145-a6c8-8bf9f10c9caa">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;DOCUMENTS INCORPORATED BY REFERENCE&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;Specified portions of the registrant&#x2019;s definitive Proxy Statement to be issued in conjunction with the registrant&#x2019;s 2023 Annual Meeting of Stockholders, which is expected to be filed not later than 120 days after the registrant&#x2019;s fiscal year ended December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;, are incorporated by reference into Part III of this Annual Report. Except as expressly incorporated by reference, the registrant&#x2019;s Proxy Statement shall not be deemed to be a part of this Annual Report on Form 10-K.&lt;/span&gt;&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      id="F_2cd0b950-111d-477e-a9ba-d4c1a94c21c9">34</dei:AuditorFirmId>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_6ac4c0f1-adab-44d0-b107-740ee9ffbd09"
      unitRef="U_USD">193513000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      decimals="-3"
      id="F_0df4558c-a777-48cc-bb99-d1aa36585f0a"
      unitRef="U_USD">291049000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNet
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_33b5f858-eea1-4944-ace4-4c5f647b543b"
      unitRef="U_USD">14454000</us-gaap:AccountsReceivableNet>
    <us-gaap:AccountsReceivableNet
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      decimals="-3"
      id="F_de89055c-b8f8-4253-9f20-2b89c9c7a58d"
      unitRef="U_USD">9401000</us-gaap:AccountsReceivableNet>
    <us-gaap:ReceivablesLongTermContractsOrPrograms
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_322eff37-92f7-42d5-a81e-3575a9a6d301"
      unitRef="U_USD">69621000</us-gaap:ReceivablesLongTermContractsOrPrograms>
    <us-gaap:ReceivablesLongTermContractsOrPrograms
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      decimals="-3"
      id="F_965ef5c0-67d4-4e4e-ae5c-d8d8a75e7c0b"
      unitRef="U_USD">54672000</us-gaap:ReceivablesLongTermContractsOrPrograms>
    <us-gaap:InventoryNet
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_24c247a7-c62a-4db7-9079-2b6afbc75718"
      unitRef="U_USD">40737000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      decimals="-3"
      id="F_5d9b191c-25c9-46aa-aa60-4d4d2ce170bb"
      unitRef="U_USD">55897000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_8a92eb3a-7374-49d5-abab-d35a0ed7f881"
      unitRef="U_USD">21630000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      decimals="-3"
      id="F_d65e7613-be6a-41c8-a2cf-6ebd24df311c"
      unitRef="U_USD">29559000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_abb7edbd-0cfc-4eb1-b1b9-fb3164490e34"
      unitRef="U_USD">4264000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      decimals="-3"
      id="F_60d78822-1734-4296-b287-9edea0d28e46"
      unitRef="U_USD">2933000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_839956e0-e7f8-495d-8d9e-05b7a9b915e0"
      unitRef="U_USD">344219000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      decimals="-3"
      id="F_4f252135-c0a1-4b6a-b884-eb9c9aa08d0f"
      unitRef="U_USD">443511000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_9fbe6eec-b125-4a99-be97-75d476aa4637"
      unitRef="U_USD">483000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      decimals="-3"
      id="F_c11071e2-8ab7-40b6-9d02-a3983c6f45bb"
      unitRef="U_USD">170000</us-gaap:PropertyPlantAndEquipmentNet>
    <inva:EquityMethodInvestment
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_16c7945f-ba5c-4f33-a1b0-7627b764943c"
      unitRef="U_USD">116546000</inva:EquityMethodInvestment>
    <inva:EquityMethodInvestment
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      decimals="-3"
      id="F_8f03c343-882a-4517-a2a1-47643e212814"
      unitRef="U_USD">39154000</inva:EquityMethodInvestment>
    <us-gaap:LongTermInvestments
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_4df3af14-074c-41d1-b60c-21c7de70b9e4"
      unitRef="U_USD">444432000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      decimals="-3"
      id="F_16d5bb42-6db6-40a6-969a-3188f1dc5fdf"
      unitRef="U_USD">363859000</us-gaap:LongTermInvestments>
    <us-gaap:CapitalizedContractCostNet
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_c26af50d-4111-424d-8ba3-e214ca4a9176"
      unitRef="U_USD">83784000</us-gaap:CapitalizedContractCostNet>
    <us-gaap:CapitalizedContractCostNet
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      decimals="-3"
      id="F_f386ca52-688c-495a-8293-4ad3d9dabe3d"
      unitRef="U_USD">97607000</us-gaap:CapitalizedContractCostNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_5a82c365-03d6-43c5-ae7b-d7cf0b5d3054"
      unitRef="U_USD">2536000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      decimals="-3"
      id="F_5144fc5e-6be8-45b0-b25e-f96d260b8fe2"
      unitRef="U_USD">3265000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Goodwill
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_46d119e0-ec4e-47e4-a137-9675f05dbf47"
      unitRef="U_USD">17905000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      decimals="-3"
      id="F_d573b1e8-38a0-40af-a2e5-76655bd20267"
      unitRef="U_USD">26713000</us-gaap:Goodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_0cc8c924-4e86-4335-9871-4370d7fc5e29"
      unitRef="U_USD">230335000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      decimals="-3"
      id="F_8c013766-4a2e-4917-b877-bb13e329ee00"
      unitRef="U_USD">252919000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_48328fb6-fabf-4d3a-b47b-a552f58c9711"
      unitRef="U_USD">3267000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      decimals="-3"
      id="F_fd7317fd-fc77-4dd9-9e28-4fcdc12ef06d"
      unitRef="U_USD">4299000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_d428d075-b8f0-4e1f-b1a9-133202382fcd"
      unitRef="U_USD">1243507000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      decimals="-3"
      id="F_ff5aeb9c-1067-4b94-beb5-77e36415c02a"
      unitRef="U_USD">1231497000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_359e7c15-b159-4149-978f-577a95dae9dc"
      unitRef="U_USD">6717000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      decimals="-3"
      id="F_4a8deb03-6125-4b5a-b47c-098bf2cf4d49"
      unitRef="U_USD">2939000</us-gaap:AccountsPayableCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_0d7d98a1-27ee-478e-9485-bc56fc338b96"
      unitRef="U_USD">7020000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      decimals="-3"
      id="F_6ea1852e-b684-4c54-bf8a-0623455ea578"
      unitRef="U_USD">8022000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_936cada9-6f44-411f-a39a-4ffe197946bc"
      unitRef="U_USD">3422000</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      decimals="-3"
      id="F_7e7913e3-68d5-4cd4-97e2-89db38fd2e14"
      unitRef="U_USD">4359000</us-gaap:InterestPayableCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_f8758f3d-42db-4781-9afd-e08c09e512a9"
      unitRef="U_USD">1277000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      decimals="-3"
      id="F_18532002-cc6b-42e8-b252-9b48573e0b2f"
      unitRef="U_USD">2094000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:ConvertibleDebtCurrent
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_a76fd3ae-fe34-4598-a199-74f411f6f895"
      unitRef="U_USD">0</us-gaap:ConvertibleDebtCurrent>
    <us-gaap:ConvertibleDebtCurrent
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      decimals="-3"
      id="F_0fcc9982-4494-45ee-92ea-803b236e0116"
      unitRef="U_USD">96193000</us-gaap:ConvertibleDebtCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_ad2169d6-8d6b-4403-8ebd-b6e2a78dd286"
      unitRef="U_USD">0</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      decimals="-3"
      id="F_19b96451-d485-45c9-91bd-95a40ebcb382"
      unitRef="U_USD">154000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_0e7ff711-947b-4f6d-a2c6-880e8a43e480"
      unitRef="U_USD">19698000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      decimals="-3"
      id="F_fd08744c-ae90-4749-9ede-5acb5aa12595"
      unitRef="U_USD">21207000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_cb8dc650-0635-4172-b4ee-4050db6730e4"
      unitRef="U_USD">38134000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      decimals="-3"
      id="F_fa659918-2bdc-42e5-8a76-780ae748ee91"
      unitRef="U_USD">134968000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_90f5edf1-b300-43e6-9954-bc6611638174"
      unitRef="U_USD">446234000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      decimals="-3"
      id="F_34f01195-4314-4996-8c3c-1220bd8e0136"
      unitRef="U_USD">444180000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_17355e0a-5ce7-4b51-b12f-e7ee0d809964"
      unitRef="U_USD">71870000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      decimals="-3"
      id="F_f4aee8ce-d07e-43b6-8abc-5476afb73cf8"
      unitRef="U_USD">70918000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_38659219-d82a-4334-9485-f9a0ced5bd50"
      unitRef="U_USD">563000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      decimals="-3"
      id="F_482515ed-fac2-44fb-9a7b-b3331ff974ed"
      unitRef="U_USD">5771000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <inva:IncomeTaxPayableNonCurrent
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_2866fc83-30b2-46f3-b186-8e6083ea6723"
      unitRef="U_USD">11751000</inva:IncomeTaxPayableNonCurrent>
    <inva:IncomeTaxPayableNonCurrent
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      decimals="-3"
      id="F_a5170ea8-f03b-42ad-a929-cedcc768d520"
      unitRef="U_USD">9872000</inva:IncomeTaxPayableNonCurrent>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="2"
      id="F_89ba63b9-7f97-4418-b3e5-b9d25029efb0"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      decimals="2"
      id="F_6f702253-6e03-41a0-b4a2-534054d4342c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_1da1da43-fdbd-4701-8f82-de57eaf3ea80"
      unitRef="U_shares">230000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      decimals="-3"
      id="F_5147ddfa-f749-46af-9f69-0ffce3d25d3a"
      unitRef="U_shares">230000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      decimals="-3"
      id="F_9e42384a-1e82-4be5-8c45-929bc6cd2351"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_91661139-3a49-44a6-9bb7-551fa1260960"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      decimals="-3"
      id="F_8431bcd9-7587-48cb-8f14-0145e4d040af"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_53a6b99f-673c-43d4-90b2-748d8d96293d"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_c7a4140d-c22d-4d07-b573-8837655a8389"
      unitRef="U_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      decimals="-3"
      id="F_f370b6ed-4f10-4a9a-afe2-2bfbf925e5a4"
      unitRef="U_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="2"
      id="F_adbd1ab7-f315-4321-ad82-2fe2d1524279"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      decimals="2"
      id="F_80f550a6-2001-4446-a08a-db8cd8df1a24"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_db071206-fbb3-4422-882b-b7f1e6e5368e"
      unitRef="U_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      decimals="-3"
      id="F_7a1a3a30-b8ba-403f-b61a-eedcca4e0679"
      unitRef="U_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_32eb1f20-3dd8-4aef-9872-9cf725a9c140"
      unitRef="U_shares">63307000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_72fcb6bc-e9b2-426d-bd76-475026b64160"
      unitRef="U_shares">63307000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      decimals="-3"
      id="F_a17d3370-fd09-4e89-a0a2-c3d89a6102db"
      unitRef="U_shares">69188000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      decimals="-3"
      id="F_1d7940a8-6b79-4a28-84ee-8d2579de68aa"
      unitRef="U_shares">69188000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_1886baf2-8c65-4719-aaec-5eeeeecf1184"
      unitRef="U_USD">633000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      decimals="-3"
      id="F_1f978dac-0b72-46f9-80f4-cec896f55e4d"
      unitRef="U_USD">692000</us-gaap:CommonStockValue>
    <us-gaap:TreasuryStockCommonShares
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_c18154d3-1a3b-43c5-9522-95c2426b0538"
      unitRef="U_shares">32005000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      decimals="-3"
      id="F_b5b6c690-fce3-45aa-84cd-fd16d35b06ed"
      unitRef="U_shares">32005000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonValue
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_62544135-b6f0-424b-80f4-1c0bf87ff9b7"
      unitRef="U_USD">393829000</us-gaap:TreasuryStockCommonValue>
    <us-gaap:TreasuryStockCommonValue
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      decimals="-3"
      id="F_fe9e44ac-9207-4c4e-984c-fc569f2500d8"
      unitRef="U_USD">393829000</us-gaap:TreasuryStockCommonValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_823e248d-d81c-49d4-bcaf-e574bdd5f1ed"
      unitRef="U_USD">1093340000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      decimals="-3"
      id="F_5450d2f8-870b-420e-84ce-bb261ac31ba0"
      unitRef="U_USD">1163836000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_6059dd23-4731-486b-83bf-e91126cbc49a"
      unitRef="U_USD">-25189000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      decimals="-3"
      id="F_9e5e4bb6-6fc0-486e-82a7-5bac76b98321"
      unitRef="U_USD">-204911000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_d81d6720-2c44-4935-9ba1-a5b38168d61d"
      unitRef="U_USD">674955000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      decimals="-3"
      id="F_543be034-0332-49c5-90e4-6022c66f1ef5"
      unitRef="U_USD">565788000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_7610eb1d-937d-48ff-ade0-682be4ef1eaf"
      unitRef="U_USD">1243507000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      decimals="-3"
      id="F_af6a1759-c94a-4d6f-b1d1-b5c57d87bbcf"
      unitRef="U_USD">1231497000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="C_c1969bd2-5e89-423e-88e9-b5564c6afe10"
      decimals="-3"
      id="F_0ce36674-32d8-4f12-8b6f-3c6913d3d58a"
      unitRef="U_USD">13823000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="C_8c8eca7f-7819-48ae-9938-c3c7153ffa73"
      decimals="-3"
      id="F_b87f44a1-eb35-4eeb-99dd-2bfc63f950f8"
      unitRef="U_USD">13823000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="C_539783b3-bf29-4a63-8d24-99d7b7b79e81"
      decimals="-3"
      id="F_111332a3-5e76-4f5f-b629-f9ef59790d7a"
      unitRef="U_USD">13823000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_81ea3387-bcc2-4cfe-a9e7-78fab40062ee"
      decimals="-3"
      id="F_6ace803c-4529-4e04-ad8f-a072b40fcd8c"
      unitRef="U_USD">238846000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_cd95e6eb-db30-4b57-a111-4b45da383cf5"
      decimals="-3"
      id="F_f9f68ed6-7a62-4cfd-8614-cb403e1c5e3a"
      unitRef="U_USD">311645000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_fa01aae9-eeeb-459c-9277-c4cd33bb93d0"
      decimals="-3"
      id="F_7095efc3-5287-4b3f-aaa8-8e0cfda542c0"
      unitRef="U_USD">391866000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_48c187f6-6fef-4cb6-83d6-250ba457d99a"
      decimals="-3"
      id="F_65178307-5042-4556-84af-a9a12bf3b0c1"
      unitRef="U_USD">60617000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_809b9867-b962-4553-b6ab-8ca43d28920b"
      decimals="-3"
      id="F_07c8de9b-ad97-4a16-bd2c-a49b89ca362e"
      unitRef="U_USD">19694000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_052592af-355b-490c-9bea-1016c2ec7fe7"
      decimals="-3"
      id="F_b819c5d6-ab8c-4298-a9fe-a2f0803b64e3"
      unitRef="U_USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_c1cee939-99f5-4170-95af-3c7cd8ef24ef"
      decimals="-3"
      id="F_56a5fecd-8fa3-4eb0-a718-95f83a20e3b8"
      unitRef="U_USD">11000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_7dd3ea38-7516-4e7e-9399-9f1920d9d119"
      decimals="-3"
      id="F_8f6bb527-292e-4791-8475-efb1673bfe8b"
      unitRef="U_USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_8e426da9-946c-40b8-bd70-2a6eaa29fe3d"
      decimals="-3"
      id="F_7dd129db-f981-4e41-bc43-54119f14c358"
      unitRef="U_USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_e93661b1-366a-48ba-96e4-57963fb77fef"
      unitRef="U_USD">310463000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_2764ec9f-ffaa-4204-b689-56e049d2d76b"
      unitRef="U_USD">331339000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="-3"
      id="F_29d6158f-992d-40b2-a43f-702e42f54a0d"
      unitRef="U_USD">391866000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="C_48c187f6-6fef-4cb6-83d6-250ba457d99a"
      decimals="-3"
      id="F_0572e884-ce45-4c5d-bd3a-4d1d23cd91ee"
      unitRef="U_USD">41040000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="C_809b9867-b962-4553-b6ab-8ca43d28920b"
      decimals="-3"
      id="F_4820deb0-0128-44df-a84b-9fdd1d37d06a"
      unitRef="U_USD">13793000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="C_052592af-355b-490c-9bea-1016c2ec7fe7"
      decimals="-3"
      id="F_b5f89791-ee7b-42ec-aa72-ecb7f7b548f5"
      unitRef="U_USD">0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfRevenue
      contextRef="C_0180ad0a-b06f-4e53-948d-bb80d100090e"
      decimals="-3"
      id="F_43c9abb2-2d20-4740-af78-7412aba2ba41"
      unitRef="U_USD">1600000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="C_68f79cad-95a1-43ef-b218-21108e820b17"
      decimals="-3"
      id="F_8cc7bad5-1b56-4768-ad04-9f3494d4930e"
      unitRef="U_USD">0</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="C_b6f84383-3742-4678-adab-90f14685e54b"
      decimals="-3"
      id="F_4d596a86-a4ed-421a-adab-4a1a7da403db"
      unitRef="U_USD">0</us-gaap:CostOfRevenue>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_f9d7011a-1705-4c4b-a260-da07bbde1172"
      unitRef="U_USD">98232000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_089c0d57-158f-4111-9906-374345fc07ec"
      unitRef="U_USD">63538000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="-3"
      id="F_fdc30bb8-fe67-49f5-b550-1ce1a66ef0ca"
      unitRef="U_USD">16187000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_063b408b-c6e4-4538-b51a-bd21f960a9a2"
      unitRef="U_USD">33922000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_801ba661-b31a-43ec-8c0d-5419c16c0739"
      unitRef="U_USD">41432000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="-3"
      id="F_d2599a69-56ee-40e9-885d-2becea5b5b62"
      unitRef="U_USD">576000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_cc1f5fed-f4db-4e57-93cd-79cab0fb1da9"
      unitRef="U_USD">21784000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_eaebbf5c-cfc1-4d92-8440-b93e3704dd2f"
      unitRef="U_USD">5581000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="-3"
      id="F_a58802fd-3751-43ce-a285-b7fd9c81fec4"
      unitRef="U_USD">0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_eed60521-b4d8-4c79-987f-c6f2d7053022"
      unitRef="U_USD">0</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_54556125-635a-4603-bd79-535e11dc0d5a"
      unitRef="U_USD">266696000</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="-3"
      id="F_2101fc47-5362-4a5f-adb4-5694176d75ed"
      unitRef="U_USD">0</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_4bcf478b-80fd-4c77-affb-6f0aa266ab15"
      unitRef="U_USD">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_2d54f3d3-772f-425a-8cbe-d4004fa83642"
      unitRef="U_USD">-20662000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="-3"
      id="F_e098d7d3-ccc6-44dd-8a1e-a50d8cb4c323"
      unitRef="U_USD">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_fa210b4c-0cd5-4dcf-a3b1-1428c25729d5"
      unitRef="U_USD">77392000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_a748eb5d-49ad-44ae-bb70-794df4794da7"
      unitRef="U_USD">-161749000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="-3"
      id="F_564363d1-1724-463a-8ad2-03679528a871"
      unitRef="U_USD">84392000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <inva:GainLossOnOtherInvestments
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_9660f006-efb2-4921-9fc2-196389d0cfca"
      unitRef="U_USD">11129000</inva:GainLossOnOtherInvestments>
    <inva:GainLossOnOtherInvestments
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_b4606d6f-3471-4352-9ae5-26ff294afeb5"
      unitRef="U_USD">8462000</inva:GainLossOnOtherInvestments>
    <inva:GainLossOnOtherInvestments
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="-3"
      id="F_9517a171-742b-4eda-a0b8-e247df322ece"
      unitRef="U_USD">6638000</inva:GainLossOnOtherInvestments>
    <us-gaap:InterestAndDividendIncomeOperating
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_032dca0e-c49a-4ea2-898b-0763b64089cb"
      unitRef="U_USD">15818000</us-gaap:InterestAndDividendIncomeOperating>
    <us-gaap:InterestAndDividendIncomeOperating
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_d22e3e20-989f-469b-8738-4bab1f755d70"
      unitRef="U_USD">6369000</us-gaap:InterestAndDividendIncomeOperating>
    <us-gaap:InterestAndDividendIncomeOperating
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="-3"
      id="F_eecd894d-1783-4dc9-a87f-65245f29094d"
      unitRef="U_USD">1839000</us-gaap:InterestAndDividendIncomeOperating>
    <us-gaap:InterestExpense
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_7c455487-949c-4780-887a-bc47dcbefb3b"
      unitRef="U_USD">19157000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_2cadbd49-dc38-4f4f-b57b-c5e84f93d9c6"
      unitRef="U_USD">15789000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="-3"
      id="F_20a5e4a6-9d80-404b-9898-b705664fcee8"
      unitRef="U_USD">19070000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_696e038f-eec0-4663-ad61-37e14fb37442"
      unitRef="U_USD">-4969000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_d73394f4-0805-4db0-93f3-6d880d57b4e8"
      unitRef="U_USD">-3373000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="-3"
      id="F_b4d07642-0c47-47ce-ae82-d1c07b12bc6b"
      unitRef="U_USD">-3626000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_6e2a929b-3254-4024-b041-7a5d682848d4"
      unitRef="U_USD">116365000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_59b5bf85-5e97-4d56-840d-1295eb8403a9"
      unitRef="U_USD">44390000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="-3"
      id="F_2b3771e7-c5e7-4e29-9d91-42197d8234cf"
      unitRef="U_USD">-53410000</us-gaap:CostsAndExpenses>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_a8567a4f-eb75-4a6e-a81b-7d184520b3e6"
      unitRef="U_USD">194098000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_6e0d44ce-a6a3-4b4d-bef6-ad46212556e1"
      unitRef="U_USD">286949000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="-3"
      id="F_15aace38-5902-43cb-9905-23aeadee3ede"
      unitRef="U_USD">445276000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_ebd3a7d5-7e15-4870-8305-7cb3b9076e20"
      unitRef="U_USD">14376000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_f3564cd1-bf7a-4e1a-bac0-db0fc038d6a6"
      unitRef="U_USD">66687000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="-3"
      id="F_607fef87-2e60-44a2-8dc1-b1be42ce23fd"
      unitRef="U_USD">76439000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_48565d14-b120-4a75-840c-1d068c37fe7b"
      unitRef="U_USD">179722000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_2ed2b915-3077-4755-93f6-6f56a5a48ad6"
      unitRef="U_USD">220262000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="-3"
      id="F_978847b5-65f1-4a6f-859d-a793e634b8ee"
      unitRef="U_USD">368837000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_ae9ef733-d0d2-46ad-b1b6-c04dcc7837a5"
      unitRef="U_USD">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_143a3153-795b-42e6-a7e9-71783c6a1e42"
      unitRef="U_USD">6341000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="-3"
      id="F_1727974a-2928-4c2c-a29d-48dad8dac934"
      unitRef="U_USD">102983000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_cc800781-f4e8-4a12-aaac-07de135a0c87"
      unitRef="U_USD">179722000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_724b0e01-3065-4847-8788-0c57a2eedfc3"
      unitRef="U_USD">213921000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="-3"
      id="F_395fc31b-8b56-43b5-856e-915a125b7fb9"
      unitRef="U_USD">265854000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="2"
      id="F_1f6f9ba6-5120-4b48-b05e-61eb901841ed"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.75</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="2"
      id="F_7d8bab8e-07cf-4046-8156-8a5b62e2d381"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.07</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="2"
      id="F_eba0b338-d27e-4808-bb35-8cea8d0c27d6"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.24</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="2"
      id="F_432f13f4-cb8b-415b-a21a-ccee1eab53b6"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.2</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="2"
      id="F_82e9a375-5cac-463b-bd8b-947b49fecdf4"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.37</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="2"
      id="F_92f91e2e-396e-4e21-bc2d-1387a55f4b34"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.87</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_98d3c986-ca42-4eaf-8790-fa235f7bfd49"
      unitRef="U_shares">65435000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_c363e2cd-5311-45e6-a415-25ffa7ba2ff7"
      unitRef="U_shares">69644000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="-3"
      id="F_e25a13b3-4d61-42ac-8573-22a1bebc7456"
      unitRef="U_shares">82062000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_d09fd4c3-2e66-41b1-b461-1a807a015b2f"
      unitRef="U_shares">86876000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_d5ff2fd8-8b2d-4031-9e1b-092a54748479"
      unitRef="U_shares">95248000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="-3"
      id="F_b6349ab6-19b6-4485-8069-c8ea4a71ae31"
      unitRef="U_shares">94310000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ProfitLoss
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_aab6e11e-1469-4bce-96f0-24bd64cc91d7"
      unitRef="U_USD">179722000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_6bbe29aa-fffc-4345-a718-3be240fe4141"
      unitRef="U_USD">220262000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="-3"
      id="F_bb7f552f-d98b-4638-a5f0-9dfebcf2ac53"
      unitRef="U_USD">368837000</us-gaap:ProfitLoss>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_95dd4bc1-bf0a-435c-b41b-b97083d4d121"
      unitRef="U_USD">179722000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_2cb98452-9653-4d53-b3c9-bf8857083e20"
      unitRef="U_USD">220262000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="-3"
      id="F_92739eec-3f1d-4a51-b3d2-328787ab803c"
      unitRef="U_USD">368837000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_ab7014ea-3a72-4e2d-ba75-5521cc940cf9"
      unitRef="U_USD">0</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_38b3ef8f-9d6e-43e9-9f8b-0426668cbbc1"
      unitRef="U_USD">6341000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="-3"
      id="F_4ea68774-6c9e-403f-bfeb-b818c71d14d1"
      unitRef="U_USD">102983000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_642f9886-1ac0-47d1-8a12-809aaf22d834"
      unitRef="U_USD">179722000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_1ad9a681-78d4-4d92-abc6-19bd686ee294"
      unitRef="U_USD">213921000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="-3"
      id="F_8875eadb-2474-4fc2-a95c-fb14c775bf12"
      unitRef="U_USD">265854000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_ce39f75c-0185-4a4f-87c1-250c81cd12eb"
      decimals="INF"
      id="F_ab63fb30-dea3-49ab-9f6a-656c0af3f25a"
      unitRef="U_shares">101392000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_ce39f75c-0185-4a4f-87c1-250c81cd12eb"
      decimals="-3"
      id="F_ce148201-e9fb-4b79-a5be-ec7b9d1a5a17"
      unitRef="U_USD">1014000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_b5db3709-c76a-4a08-8c44-b8f59cdb4608"
      decimals="-3"
      id="F_fec68995-61aa-4a09-8403-373781f1fdfd"
      unitRef="U_USD">1260900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_29561087-beae-414b-bf9d-e689e21a5ee7"
      decimals="-3"
      id="F_b25f8fee-f1ca-486b-8121-abb620d79276"
      unitRef="U_USD">-722002000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_4c71a645-f25d-4cb5-8889-681f3449ecac"
      decimals="INF"
      id="F_b68ede1b-1e9f-4bf4-a940-56c80c70a626"
      unitRef="U_shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_4c71a645-f25d-4cb5-8889-681f3449ecac"
      decimals="-3"
      id="F_3d32c251-5640-4d6c-a5c9-11a4a2dc7c8b"
      unitRef="U_USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_fa14f0b8-b80c-4b7b-b274-a48521a14a84"
      decimals="-3"
      id="F_f73d69fa-5e1c-4777-b06a-a81c45a0ab02"
      unitRef="U_USD">67925000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_646bb33b-4ef6-4493-b542-00c92f556418"
      decimals="-3"
      id="F_a5076eda-6508-4f85-867b-c69b840cbe48"
      unitRef="U_USD">607837000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <inva:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersShares
      contextRef="C_ec125de3-1e4e-4a75-b4bb-7673bacb9c03"
      decimals="INF"
      id="F_fb5088f3-36af-4341-97e5-7169bb621bdb"
      unitRef="U_shares">0</inva:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersShares>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="C_ec125de3-1e4e-4a75-b4bb-7673bacb9c03"
      decimals="-3"
      id="F_f65a99f4-d638-4786-b679-50c2e5a05580"
      unitRef="U_USD">0</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="C_cb4e7215-9a5e-4dd4-aeee-e50dd4e2eb6b"
      decimals="-3"
      id="F_dbaf626b-25d1-4fd0-88c0-41503921abb3"
      unitRef="U_USD">0</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="C_ea7c0a60-08f5-4a3e-a061-5a67602a1ec1"
      decimals="-3"
      id="F_b780f6b9-c3f8-4473-bbe8-215c5e3f42c5"
      unitRef="U_USD">0</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <inva:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersShares
      contextRef="C_d7cf516f-572b-431a-8937-a3fa41621ee5"
      decimals="INF"
      id="F_1b3ecc87-dda4-4768-8036-6d51872078fc"
      unitRef="U_shares">0</inva:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersShares>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="C_d7cf516f-572b-431a-8937-a3fa41621ee5"
      decimals="-3"
      id="F_c978b0fa-7030-4a04-ab75-690f34e68426"
      unitRef="U_USD">0</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="C_23e66452-ee29-415e-90e3-ae16681b068e"
      decimals="-3"
      id="F_061100d7-21e9-4208-9294-40858bc3541e"
      unitRef="U_USD">59457000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="-3"
      id="F_9f8a4bd5-7baf-400b-af78-fff4beb9e993"
      unitRef="U_USD">59457000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <inva:ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntityShares
      contextRef="C_ec125de3-1e4e-4a75-b4bb-7673bacb9c03"
      decimals="INF"
      id="F_480d5465-7bf5-457a-92dd-f9cc6bcf3752"
      unitRef="U_shares">0</inva:ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntityShares>
    <inva:ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity
      contextRef="C_ec125de3-1e4e-4a75-b4bb-7673bacb9c03"
      decimals="-3"
      id="F_dbef375a-0735-4646-8a5e-0b9c5a439cc2"
      unitRef="U_USD">0</inva:ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity>
    <inva:ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity
      contextRef="C_cb4e7215-9a5e-4dd4-aeee-e50dd4e2eb6b"
      decimals="-3"
      id="F_f2a85f8a-a136-4a0f-9a18-d2f7ac942778"
      unitRef="U_USD">0</inva:ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity>
    <inva:ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity
      contextRef="C_ea7c0a60-08f5-4a3e-a061-5a67602a1ec1"
      decimals="-3"
      id="F_07c782f4-afcf-47f9-a70e-aec02cf625ea"
      unitRef="U_USD">0</inva:ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity>
    <inva:ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntityShares
      contextRef="C_d7cf516f-572b-431a-8937-a3fa41621ee5"
      decimals="INF"
      id="F_8fe88257-ddfa-4887-a612-2453fb9c0bbd"
      unitRef="U_shares">0</inva:ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntityShares>
    <inva:ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity
      contextRef="C_d7cf516f-572b-431a-8937-a3fa41621ee5"
      decimals="-3"
      id="F_d4a092be-77d5-4325-97cb-127c53cb615b"
      unitRef="U_USD">0</inva:ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity>
    <inva:ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity
      contextRef="C_23e66452-ee29-415e-90e3-ae16681b068e"
      decimals="-3"
      id="F_062f119a-c63a-41a2-a6ed-1eec6aeb99c3"
      unitRef="U_USD">-259000</inva:ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity>
    <inva:ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="-3"
      id="F_15a4ff0a-2f4d-4667-81b9-34bfefd9f921"
      unitRef="U_USD">-259000</inva:ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="C_ec125de3-1e4e-4a75-b4bb-7673bacb9c03"
      decimals="INF"
      id="F_2fa06984-ce02-4754-9cba-890ef461ce4d"
      unitRef="U_shares">179000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_ec125de3-1e4e-4a75-b4bb-7673bacb9c03"
      decimals="-3"
      id="F_3702c8b6-fc3e-4d6c-aa67-d602d60bf20c"
      unitRef="U_USD">2000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_cb4e7215-9a5e-4dd4-aeee-e50dd4e2eb6b"
      decimals="-3"
      id="F_aa687969-aa53-4944-8790-417d80d51dfc"
      unitRef="U_USD">1107000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_ea7c0a60-08f5-4a3e-a061-5a67602a1ec1"
      decimals="-3"
      id="F_36229718-0708-4f34-b24c-867e5ec035d3"
      unitRef="U_USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="C_d7cf516f-572b-431a-8937-a3fa41621ee5"
      decimals="INF"
      id="F_1d4819d2-f008-4c1e-a3a8-4a3d89c53ec2"
      unitRef="U_shares">0</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_d7cf516f-572b-431a-8937-a3fa41621ee5"
      decimals="-3"
      id="F_7ebf8ad6-53ec-4e7e-9008-90e987a94b4b"
      unitRef="U_USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_23e66452-ee29-415e-90e3-ae16681b068e"
      decimals="-3"
      id="F_3bd44aec-d51c-47c8-99ad-f45ded4d37ec"
      unitRef="U_USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="-3"
      id="F_36838132-ccfb-45a9-baa1-48b871c24881"
      unitRef="U_USD">1109000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="C_ec125de3-1e4e-4a75-b4bb-7673bacb9c03"
      decimals="INF"
      id="F_a7b98165-7dbe-4a37-bb60-5257c32a4bd7"
      unitRef="U_shares">32005000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="C_ec125de3-1e4e-4a75-b4bb-7673bacb9c03"
      decimals="-3"
      id="F_ecb72839-c23f-4686-8853-9412b6322551"
      unitRef="U_USD">320000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="C_cb4e7215-9a5e-4dd4-aeee-e50dd4e2eb6b"
      decimals="-3"
      id="F_8466b306-fad6-42d1-a58f-a28be4590e2c"
      unitRef="U_USD">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="C_ea7c0a60-08f5-4a3e-a061-5a67602a1ec1"
      decimals="-3"
      id="F_8bbbabec-42a4-4f10-b3b9-3d43d55b3a1b"
      unitRef="U_USD">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="C_d7cf516f-572b-431a-8937-a3fa41621ee5"
      decimals="INF"
      id="F_bc3cc2b9-6357-4bbd-9c17-660bce77ac27"
      unitRef="U_shares">-32005000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="C_d7cf516f-572b-431a-8937-a3fa41621ee5"
      decimals="-3"
      id="F_3bdbadcd-034a-4a6c-957d-d0b8e83c4a69"
      unitRef="U_USD">393829000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="C_23e66452-ee29-415e-90e3-ae16681b068e"
      decimals="-3"
      id="F_76aa2192-1161-4f6a-ba73-c4253701f85a"
      unitRef="U_USD">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="-3"
      id="F_4c1c7be4-0cfb-454d-b031-971346004891"
      unitRef="U_USD">394149000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <inva:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares
      contextRef="C_ec125de3-1e4e-4a75-b4bb-7673bacb9c03"
      decimals="INF"
      id="F_bd5e3d74-3b08-4e0f-b740-b51ced915af9"
      unitRef="U_shares">0</inva:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_ec125de3-1e4e-4a75-b4bb-7673bacb9c03"
      decimals="-3"
      id="F_ca591670-eaa6-4635-a5d7-9087097baec9"
      unitRef="U_USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_cb4e7215-9a5e-4dd4-aeee-e50dd4e2eb6b"
      decimals="-3"
      id="F_d034d5e1-5d4b-4bac-a0d8-bee59c3fc3c4"
      unitRef="U_USD">2017000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_ea7c0a60-08f5-4a3e-a061-5a67602a1ec1"
      decimals="-3"
      id="F_5a4ae9ef-f498-43eb-a222-ef781bd9c1d2"
      unitRef="U_USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <inva:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares
      contextRef="C_d7cf516f-572b-431a-8937-a3fa41621ee5"
      decimals="INF"
      id="F_b8d0ddfa-6d94-4873-a504-1ed37fb6d10b"
      unitRef="U_shares">0</inva:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_d7cf516f-572b-431a-8937-a3fa41621ee5"
      decimals="-3"
      id="F_67ffd895-342f-4c13-91f7-5fff96f86d11"
      unitRef="U_USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_23e66452-ee29-415e-90e3-ae16681b068e"
      decimals="-3"
      id="F_09b55a70-52c1-4ae6-8129-767bdc589be4"
      unitRef="U_USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="-3"
      id="F_974b865a-9565-4c37-873f-a34c0af40552"
      unitRef="U_USD">2017000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <inva:ProfitLossShares
      contextRef="C_ec125de3-1e4e-4a75-b4bb-7673bacb9c03"
      decimals="INF"
      id="F_f1d06376-9525-4d5d-a0e7-9a124404b8a4"
      unitRef="U_shares">0</inva:ProfitLossShares>
    <us-gaap:ProfitLoss
      contextRef="C_ec125de3-1e4e-4a75-b4bb-7673bacb9c03"
      decimals="-3"
      id="F_69691171-4958-454d-9c15-bf2a1c9f5c60"
      unitRef="U_USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_cb4e7215-9a5e-4dd4-aeee-e50dd4e2eb6b"
      decimals="-3"
      id="F_d7cafe7e-5926-45b6-920b-2e4b9cb63460"
      unitRef="U_USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_ea7c0a60-08f5-4a3e-a061-5a67602a1ec1"
      decimals="-3"
      id="F_c3b2c540-6a61-4683-833a-71768c733a2e"
      unitRef="U_USD">265854000</us-gaap:ProfitLoss>
    <inva:ProfitLossShares
      contextRef="C_d7cf516f-572b-431a-8937-a3fa41621ee5"
      decimals="INF"
      id="F_d278d794-ce1e-4cc7-8d5c-f10e1ff75adb"
      unitRef="U_shares">0</inva:ProfitLossShares>
    <us-gaap:ProfitLoss
      contextRef="C_d7cf516f-572b-431a-8937-a3fa41621ee5"
      decimals="-3"
      id="F_4a1d8fed-94c5-4471-a74c-4c6f764cf4af"
      unitRef="U_USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_23e66452-ee29-415e-90e3-ae16681b068e"
      decimals="-3"
      id="F_7336ae14-f1b9-40d0-b7ae-bd94b2bc7e6a"
      unitRef="U_USD">102983000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="-3"
      id="F_f636e8ad-1f93-4334-9632-655833b657a2"
      unitRef="U_USD">368837000</us-gaap:ProfitLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_b8a25da7-f0c7-4777-ac22-af038c29402e"
      decimals="INF"
      id="F_1425463b-11ff-4f54-90e8-c1dd50ae576f"
      unitRef="U_shares">69566000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_b8a25da7-f0c7-4777-ac22-af038c29402e"
      decimals="-3"
      id="F_4a6d5293-a1e6-4a20-ab98-c88e2b8d38de"
      unitRef="U_USD">696000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_c3ca1f40-a3c1-4ba0-9cd7-3d664a62262a"
      decimals="-3"
      id="F_91e38050-d8ed-4d90-9288-90f41d0e4787"
      unitRef="U_USD">1264024000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_2c5b2d53-225f-409f-ad02-223827b8634c"
      decimals="-3"
      id="F_68ac1927-8781-44a7-bacb-8783d78605a2"
      unitRef="U_USD">-456148000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_25a18144-6924-42a5-a99d-aab05e77ca53"
      decimals="INF"
      id="F_0e7de1aa-930c-4dc4-bed6-d8e1c2e64b8f"
      unitRef="U_shares">32005000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_25a18144-6924-42a5-a99d-aab05e77ca53"
      decimals="-3"
      id="F_58b38070-815a-4166-a8db-8f2f8b187b29"
      unitRef="U_USD">-393829000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_d074e316-aefd-4e82-9593-cc19fd319a60"
      decimals="-3"
      id="F_33e4149a-0b28-46a8-af8e-2d1ac68526ae"
      unitRef="U_USD">111192000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_c2c8ab67-08be-4854-91e3-98e911bef5b3"
      decimals="-3"
      id="F_be2a2a8e-7cba-4e34-b0cf-4924e7f6c58b"
      unitRef="U_USD">525935000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_983ae2b6-5a3f-48bf-90f1-b4b741cfcbbe"
      decimals="INF"
      id="F_e0d50866-8125-4de8-9155-0aa4cf11e724"
      unitRef="U_shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_983ae2b6-5a3f-48bf-90f1-b4b741cfcbbe"
      decimals="-3"
      id="F_8f086191-4163-4e18-86af-c6c648c7a6ea"
      unitRef="U_USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_4744817d-5145-49fb-a6a0-1308e192a8f6"
      decimals="-3"
      id="F_22075b8a-0e20-4961-aacc-e957deb35102"
      unitRef="U_USD">-65467000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_f2f66487-eef9-477e-a54f-358af57f70cc"
      decimals="-3"
      id="F_4a4139e8-fa2f-406f-ad61-fad1c261b616"
      unitRef="U_USD">37238000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0d916e91-2dd2-468c-ab30-e90e2ac963b9"
      decimals="INF"
      id="F_7ae938d2-1d42-40ce-9389-6bcb494fcd84"
      unitRef="U_shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0d916e91-2dd2-468c-ab30-e90e2ac963b9"
      decimals="-3"
      id="F_a18e8b4e-6edc-4086-97b4-63aeb38db126"
      unitRef="U_USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_d10e57d1-8709-4825-a966-e724f8f4633f"
      decimals="-3"
      id="F_8f980827-bf03-4ac8-ac53-4c024c638360"
      unitRef="U_USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_5058eabb-afd4-4dc1-a2f0-0ac8d38fabee"
      decimals="-3"
      id="F_9c344607-abc5-4633-ab95-a8b5745b5163"
      unitRef="U_USD">-28229000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <inva:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersShares
      contextRef="C_5f070bd2-c0df-4242-beff-e5f9b6727217"
      decimals="INF"
      id="F_5ea4bc94-3690-43ad-b4c0-2e5f867f6509"
      unitRef="U_shares">0</inva:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersShares>
    <inva:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersShares
      contextRef="C_55652f07-0e2e-4bb9-b4c3-618b5066831e"
      decimals="INF"
      id="F_54677a5a-44fc-4579-9ef6-095df61753c7"
      unitRef="U_shares">0</inva:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersShares>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="C_55652f07-0e2e-4bb9-b4c3-618b5066831e"
      decimals="-3"
      id="F_cfb5f56e-4f4d-4762-811e-974fb6465f43"
      unitRef="U_USD">0</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="C_921dd0ce-2b9e-4442-9188-880568f7b1f1"
      decimals="-3"
      id="F_e3235ef3-5c91-4f3b-aa89-029fcce7f4a7"
      unitRef="U_USD">69811000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_5df9d25a-d7c0-4dcc-b4f4-7bbeae4ed5bf"
      unitRef="U_USD">69811000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <inva:RecognitionOfNoncontrollingInterestUponInitialConsolidationofEntasisShares
      contextRef="C_5f070bd2-c0df-4242-beff-e5f9b6727217"
      decimals="INF"
      id="F_cacac36b-9e83-4970-b974-b38e8098f4df"
      unitRef="U_shares">0</inva:RecognitionOfNoncontrollingInterestUponInitialConsolidationofEntasisShares>
    <inva:RecognitionOfNoncontrollingInterestUponInitialConsolidationOfEntasis
      contextRef="C_5f070bd2-c0df-4242-beff-e5f9b6727217"
      decimals="-3"
      id="F_d424a2cb-546b-4ced-96f8-6b43db228b0c"
      unitRef="U_USD">0</inva:RecognitionOfNoncontrollingInterestUponInitialConsolidationOfEntasis>
    <inva:RecognitionOfNoncontrollingInterestUponInitialConsolidationOfEntasis
      contextRef="C_bd738e6b-a394-4de5-a04f-1f55e1ed3e59"
      decimals="-3"
      id="F_30780c8d-164c-4fb7-8a77-5a1f79e910b6"
      unitRef="U_USD">0</inva:RecognitionOfNoncontrollingInterestUponInitialConsolidationOfEntasis>
    <inva:RecognitionOfNoncontrollingInterestUponInitialConsolidationOfEntasis
      contextRef="C_5460cef4-c4cc-4668-99ef-fb2e26f72ba2"
      decimals="-3"
      id="F_e3edfd5b-b494-4546-94dc-60136c343d84"
      unitRef="U_USD">0</inva:RecognitionOfNoncontrollingInterestUponInitialConsolidationOfEntasis>
    <inva:RecognitionOfNoncontrollingInterestUponInitialConsolidationofEntasisShares
      contextRef="C_55652f07-0e2e-4bb9-b4c3-618b5066831e"
      decimals="INF"
      id="F_8e3b29ee-1dc2-488b-b250-d1e5f1119937"
      unitRef="U_shares">0</inva:RecognitionOfNoncontrollingInterestUponInitialConsolidationofEntasisShares>
    <inva:RecognitionOfNoncontrollingInterestUponInitialConsolidationOfEntasis
      contextRef="C_55652f07-0e2e-4bb9-b4c3-618b5066831e"
      decimals="-3"
      id="F_9c13da04-d511-4bcf-8d0c-93fcdd7d69ff"
      unitRef="U_USD">0</inva:RecognitionOfNoncontrollingInterestUponInitialConsolidationOfEntasis>
    <inva:RecognitionOfNoncontrollingInterestUponInitialConsolidationOfEntasis
      contextRef="C_921dd0ce-2b9e-4442-9188-880568f7b1f1"
      decimals="-3"
      id="F_61e22796-3bba-40cb-9010-f38b68410b8e"
      unitRef="U_USD">38471000</inva:RecognitionOfNoncontrollingInterestUponInitialConsolidationOfEntasis>
    <inva:RecognitionOfNoncontrollingInterestUponInitialConsolidationOfEntasis
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_4834ba7a-5ed6-44ae-95bd-78c34585faef"
      unitRef="U_USD">38471000</inva:RecognitionOfNoncontrollingInterestUponInitialConsolidationOfEntasis>
    <inva:ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntityShares
      contextRef="C_55652f07-0e2e-4bb9-b4c3-618b5066831e"
      decimals="INF"
      id="F_61eedcdd-75ea-45c3-8998-422caee86e7a"
      unitRef="U_shares">0</inva:ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntityShares>
    <inva:ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity
      contextRef="C_55652f07-0e2e-4bb9-b4c3-618b5066831e"
      decimals="-3"
      id="F_21278a54-f043-4596-b479-4e3fb1045ac4"
      unitRef="U_USD">0</inva:ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity>
    <inva:ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity
      contextRef="C_921dd0ce-2b9e-4442-9188-880568f7b1f1"
      decimals="-3"
      id="F_2642f7cc-e43f-4eb0-b58d-bcb10dc30346"
      unitRef="U_USD">-2000</inva:ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity>
    <inva:ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_25f0fcbb-3a12-487c-bd92-3090c8f66e85"
      unitRef="U_USD">-2000</inva:ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity>
    <inva:DerecognitionOfNoncontrollingInterestsUponSaleOfTrcShares
      contextRef="C_5f070bd2-c0df-4242-beff-e5f9b6727217"
      decimals="INF"
      id="F_cc0e9919-1374-4d60-9c88-c7aa9703aab6"
      unitRef="U_shares">0</inva:DerecognitionOfNoncontrollingInterestsUponSaleOfTrcShares>
    <inva:DerecognitionOfNoncontrollingInterestsUponSaleOfTrc
      contextRef="C_5f070bd2-c0df-4242-beff-e5f9b6727217"
      decimals="-3"
      id="F_6d791fe4-059e-440d-8567-43ade3591bad"
      unitRef="U_USD">0</inva:DerecognitionOfNoncontrollingInterestsUponSaleOfTrc>
    <inva:DerecognitionOfNoncontrollingInterestsUponSaleOfTrc
      contextRef="C_bd738e6b-a394-4de5-a04f-1f55e1ed3e59"
      decimals="-3"
      id="F_55db6fa4-7005-4c36-809d-ffb0dc938c4e"
      unitRef="U_USD">0</inva:DerecognitionOfNoncontrollingInterestsUponSaleOfTrc>
    <inva:DerecognitionOfNoncontrollingInterestsUponSaleOfTrc
      contextRef="C_5460cef4-c4cc-4668-99ef-fb2e26f72ba2"
      decimals="-3"
      id="F_a0a8e83f-fe64-4e40-9c6c-2d86bf03736c"
      unitRef="U_USD">78000</inva:DerecognitionOfNoncontrollingInterestsUponSaleOfTrc>
    <inva:DerecognitionOfNoncontrollingInterestsUponSaleOfTrcShares
      contextRef="C_55652f07-0e2e-4bb9-b4c3-618b5066831e"
      decimals="INF"
      id="F_64e24ebb-9452-45a4-ac1f-7c8d0d517ec4"
      unitRef="U_shares">0</inva:DerecognitionOfNoncontrollingInterestsUponSaleOfTrcShares>
    <inva:DerecognitionOfNoncontrollingInterestsUponSaleOfTrc
      contextRef="C_55652f07-0e2e-4bb9-b4c3-618b5066831e"
      decimals="-3"
      id="F_e83b21d5-316f-4076-9b25-ad9b54e2052f"
      unitRef="U_USD">0</inva:DerecognitionOfNoncontrollingInterestsUponSaleOfTrc>
    <inva:DerecognitionOfNoncontrollingInterestsUponSaleOfTrc
      contextRef="C_921dd0ce-2b9e-4442-9188-880568f7b1f1"
      decimals="-3"
      id="F_1e23d3d1-fd93-4385-b9b5-fe5ee3b3ba23"
      unitRef="U_USD">-61304000</inva:DerecognitionOfNoncontrollingInterestsUponSaleOfTrc>
    <inva:DerecognitionOfNoncontrollingInterestsUponSaleOfTrc
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_72af18d8-8420-44fd-84ec-2f472b9c4d56"
      unitRef="U_USD">-61226000</inva:DerecognitionOfNoncontrollingInterestsUponSaleOfTrc>
    <inva:DerecognitionOfNoncontrollingInterestsUponAcquisitionOfEntasisMinorityInterestShares
      contextRef="C_5f070bd2-c0df-4242-beff-e5f9b6727217"
      decimals="INF"
      id="F_b675ce08-b8d7-4573-9910-623fe7f1656e"
      unitRef="U_shares">0</inva:DerecognitionOfNoncontrollingInterestsUponAcquisitionOfEntasisMinorityInterestShares>
    <inva:DerecognitionOfNonControllingInterestsUponAcquisitionOfEntasisMinorityInterest
      contextRef="C_5f070bd2-c0df-4242-beff-e5f9b6727217"
      decimals="-3"
      id="F_b3bd7a71-7bc3-49fd-8169-468f2c57cfc2"
      unitRef="U_USD">0</inva:DerecognitionOfNonControllingInterestsUponAcquisitionOfEntasisMinorityInterest>
    <inva:DerecognitionOfNonControllingInterestsUponAcquisitionOfEntasisMinorityInterest
      contextRef="C_bd738e6b-a394-4de5-a04f-1f55e1ed3e59"
      decimals="-3"
      id="F_19eedc3f-bd71-4e36-a0e8-83af2b5b8e75"
      unitRef="U_USD">-14153000</inva:DerecognitionOfNonControllingInterestsUponAcquisitionOfEntasisMinorityInterest>
    <inva:DerecognitionOfNonControllingInterestsUponAcquisitionOfEntasisMinorityInterest
      contextRef="C_5460cef4-c4cc-4668-99ef-fb2e26f72ba2"
      decimals="-3"
      id="F_7b7f5260-e0ed-49c2-8aab-1bb425d60110"
      unitRef="U_USD">0</inva:DerecognitionOfNonControllingInterestsUponAcquisitionOfEntasisMinorityInterest>
    <inva:DerecognitionOfNoncontrollingInterestsUponAcquisitionOfEntasisMinorityInterestShares
      contextRef="C_55652f07-0e2e-4bb9-b4c3-618b5066831e"
      decimals="INF"
      id="F_dc0c8b1b-f835-4d56-8d4d-51397bf991c4"
      unitRef="U_shares">0</inva:DerecognitionOfNoncontrollingInterestsUponAcquisitionOfEntasisMinorityInterestShares>
    <inva:DerecognitionOfNonControllingInterestsUponAcquisitionOfEntasisMinorityInterest
      contextRef="C_55652f07-0e2e-4bb9-b4c3-618b5066831e"
      decimals="-3"
      id="F_707a47fb-835a-46ee-9156-90171445b869"
      unitRef="U_USD">0</inva:DerecognitionOfNonControllingInterestsUponAcquisitionOfEntasisMinorityInterest>
    <inva:DerecognitionOfNonControllingInterestsUponAcquisitionOfEntasisMinorityInterest
      contextRef="C_921dd0ce-2b9e-4442-9188-880568f7b1f1"
      decimals="-3"
      id="F_e4c5614d-790d-4617-851b-f7085547cc9b"
      unitRef="U_USD">-28009000</inva:DerecognitionOfNonControllingInterestsUponAcquisitionOfEntasisMinorityInterest>
    <inva:DerecognitionOfNonControllingInterestsUponAcquisitionOfEntasisMinorityInterest
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_61788997-53a1-40c3-9254-204b6919c618"
      unitRef="U_USD">-42162000</inva:DerecognitionOfNonControllingInterestsUponAcquisitionOfEntasisMinorityInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="C_5f070bd2-c0df-4242-beff-e5f9b6727217"
      decimals="INF"
      id="F_63e6e352-8530-40b0-941f-708a4854e660"
      unitRef="U_shares">269000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_5f070bd2-c0df-4242-beff-e5f9b6727217"
      decimals="-3"
      id="F_bee1df20-9ed5-49c2-839d-4d1426b83685"
      unitRef="U_USD">2000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_bd738e6b-a394-4de5-a04f-1f55e1ed3e59"
      decimals="-3"
      id="F_035c3a19-2104-4f54-bd23-9e13647b29db"
      unitRef="U_USD">286000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_5460cef4-c4cc-4668-99ef-fb2e26f72ba2"
      decimals="-3"
      id="F_a1efaa2a-59ca-4986-954b-31874630132f"
      unitRef="U_USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="C_55652f07-0e2e-4bb9-b4c3-618b5066831e"
      decimals="INF"
      id="F_0db8f8f7-c46d-4f1d-8bbe-0af56bd3cab7"
      unitRef="U_shares">0</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_55652f07-0e2e-4bb9-b4c3-618b5066831e"
      decimals="-3"
      id="F_9d752d02-e8ed-4a9d-98fc-fbccdce5e263"
      unitRef="U_USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_921dd0ce-2b9e-4442-9188-880568f7b1f1"
      decimals="-3"
      id="F_041aa176-7df0-48e5-b1be-c5e5330525b3"
      unitRef="U_USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_fb664234-579e-4df4-8f2f-387c9635a4cb"
      unitRef="U_USD">288000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <inva:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtInShares
      contextRef="C_5f070bd2-c0df-4242-beff-e5f9b6727217"
      decimals="INF"
      id="F_f6e9ad19-bc0f-4c43-b795-f0253d36c447"
      unitRef="U_shares">0</inva:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtInShares>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="C_5f070bd2-c0df-4242-beff-e5f9b6727217"
      decimals="-3"
      id="F_b6f659c4-207d-43ea-b683-bcd5a2325259"
      unitRef="U_USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="C_bd738e6b-a394-4de5-a04f-1f55e1ed3e59"
      decimals="-3"
      id="F_6e7d8cda-0ede-4411-9bd5-76c839bdffae"
      unitRef="U_USD">-16585000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="C_5460cef4-c4cc-4668-99ef-fb2e26f72ba2"
      decimals="-3"
      id="F_b9d0ef2f-8213-4b4a-a3dd-e3ebb9fc6808"
      unitRef="U_USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <inva:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtInShares
      contextRef="C_55652f07-0e2e-4bb9-b4c3-618b5066831e"
      decimals="INF"
      id="F_cdca65b6-4d7c-4838-9251-89f4d496b640"
      unitRef="U_shares">0</inva:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtInShares>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="C_55652f07-0e2e-4bb9-b4c3-618b5066831e"
      decimals="-3"
      id="F_c366df48-40da-4181-bea2-90a29499be32"
      unitRef="U_USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="C_921dd0ce-2b9e-4442-9188-880568f7b1f1"
      decimals="-3"
      id="F_10e75c0e-22df-446d-9164-43638799f5a9"
      unitRef="U_USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_fabb8e5d-2b52-4092-b231-d334e700e1b9"
      unitRef="U_USD">-16585000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="C_5f070bd2-c0df-4242-beff-e5f9b6727217"
      decimals="INF"
      id="F_9d9061a2-07ee-415a-ad67-0c3334c1528b"
      unitRef="U_shares">0</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
      contextRef="C_5f070bd2-c0df-4242-beff-e5f9b6727217"
      decimals="-3"
      id="F_6296ab0c-3e22-4303-b95e-a626dd506d38"
      unitRef="U_USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
      contextRef="C_bd738e6b-a394-4de5-a04f-1f55e1ed3e59"
      decimals="-3"
      id="F_9766cc9c-43dc-42a2-887f-435e66974feb"
      unitRef="U_USD">3000</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
      contextRef="C_5460cef4-c4cc-4668-99ef-fb2e26f72ba2"
      decimals="-3"
      id="F_91005394-2b51-45d0-95d2-0cfadc620c47"
      unitRef="U_USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="C_55652f07-0e2e-4bb9-b4c3-618b5066831e"
      decimals="INF"
      id="F_c5eb1507-cce0-4810-9bdf-a63a9ac1a0b4"
      unitRef="U_shares">0</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
      contextRef="C_55652f07-0e2e-4bb9-b4c3-618b5066831e"
      decimals="-3"
      id="F_81a4c356-902f-4f84-9de3-7334eb9bf44e"
      unitRef="U_USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
      contextRef="C_921dd0ce-2b9e-4442-9188-880568f7b1f1"
      decimals="-3"
      id="F_28b368eb-b589-447f-ab94-0c38e61b1505"
      unitRef="U_USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_a3fb9f17-9823-4bed-9725-13c89debffbb"
      unitRef="U_USD">3000</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="C_5f070bd2-c0df-4242-beff-e5f9b6727217"
      decimals="INF"
      id="F_3e16b625-5b1c-4a29-902a-8cf3582d5f22"
      unitRef="U_shares">647000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="C_5f070bd2-c0df-4242-beff-e5f9b6727217"
      decimals="-3"
      id="F_29bf531f-d0da-4444-b73b-f73767b14b84"
      unitRef="U_USD">6000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="C_bd738e6b-a394-4de5-a04f-1f55e1ed3e59"
      decimals="-3"
      id="F_c7bdbfbb-19a4-4207-b411-86bf692be7ea"
      unitRef="U_USD">8497000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="C_5460cef4-c4cc-4668-99ef-fb2e26f72ba2"
      decimals="-3"
      id="F_488f8e4f-b8dd-4fdf-8cf3-c4e2712a9e6f"
      unitRef="U_USD">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="C_921dd0ce-2b9e-4442-9188-880568f7b1f1"
      decimals="-3"
      id="F_40a6f8e0-4f8f-4c18-91d9-6ac4671779b3"
      unitRef="U_USD">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_bda14e28-f109-40a4-a848-56f17f70cb1f"
      unitRef="U_USD">8503000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <inva:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares
      contextRef="C_5f070bd2-c0df-4242-beff-e5f9b6727217"
      decimals="INF"
      id="F_0e066b7e-6d7f-4d4d-82e0-c3979079ef90"
      unitRef="U_shares">0</inva:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_5f070bd2-c0df-4242-beff-e5f9b6727217"
      decimals="-3"
      id="F_b15e97f1-3f64-41b1-afa7-17b558314115"
      unitRef="U_USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_bd738e6b-a394-4de5-a04f-1f55e1ed3e59"
      decimals="-3"
      id="F_45051e1c-2469-4fdb-89e4-873c9770fbd2"
      unitRef="U_USD">4225000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_5460cef4-c4cc-4668-99ef-fb2e26f72ba2"
      decimals="-3"
      id="F_6a2201b5-94f8-4539-94f7-0e3f7d530978"
      unitRef="U_USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <inva:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares
      contextRef="C_55652f07-0e2e-4bb9-b4c3-618b5066831e"
      decimals="INF"
      id="F_54c687c1-0772-4a6c-b93b-ee7e1078bce0"
      unitRef="U_shares">0</inva:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_55652f07-0e2e-4bb9-b4c3-618b5066831e"
      decimals="-3"
      id="F_c246dcd0-7c5d-455a-9e9f-52a8c618fe9c"
      unitRef="U_USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_921dd0ce-2b9e-4442-9188-880568f7b1f1"
      decimals="-3"
      id="F_19f69174-7889-4a5d-b6ff-71ec41fa0c12"
      unitRef="U_USD">3122000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_ae7773a4-bd21-4e4f-9f2d-4f2d970b6267"
      unitRef="U_USD">7347000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <inva:ProfitLossShares
      contextRef="C_5f070bd2-c0df-4242-beff-e5f9b6727217"
      decimals="INF"
      id="F_a527f1c2-2b64-449a-83e6-361bd8d9f18e"
      unitRef="U_shares">0</inva:ProfitLossShares>
    <us-gaap:ProfitLoss
      contextRef="C_5f070bd2-c0df-4242-beff-e5f9b6727217"
      decimals="-3"
      id="F_bbe72733-2508-4037-a8a5-375fd53a17b8"
      unitRef="U_USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_bd738e6b-a394-4de5-a04f-1f55e1ed3e59"
      decimals="-3"
      id="F_4e17f3dd-5e9f-40b3-ae68-6a256016bec9"
      unitRef="U_USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_5460cef4-c4cc-4668-99ef-fb2e26f72ba2"
      decimals="-3"
      id="F_657c359c-8f9c-4b47-bfd2-d6cf9feedad5"
      unitRef="U_USD">213921000</us-gaap:ProfitLoss>
    <inva:ProfitLossShares
      contextRef="C_55652f07-0e2e-4bb9-b4c3-618b5066831e"
      decimals="INF"
      id="F_218604a2-b225-4a0e-9f5a-89dec4950d9a"
      unitRef="U_shares">0</inva:ProfitLossShares>
    <us-gaap:ProfitLoss
      contextRef="C_55652f07-0e2e-4bb9-b4c3-618b5066831e"
      decimals="-3"
      id="F_c2196d9f-6b1d-428b-9935-68569d7e77fd"
      unitRef="U_USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_921dd0ce-2b9e-4442-9188-880568f7b1f1"
      decimals="-3"
      id="F_76dd6ffa-074f-4abe-9837-78a9e6d77359"
      unitRef="U_USD">6341000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_06ec7d0e-8c0d-4b83-bab8-8ba3aa7c433c"
      unitRef="U_USD">220262000</us-gaap:ProfitLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_f20a0f71-d04c-4707-b554-1102f62cf1a6"
      decimals="INF"
      id="F_02f43c37-9c34-4989-b316-11b45c762b3c"
      unitRef="U_shares">69188000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_f20a0f71-d04c-4707-b554-1102f62cf1a6"
      decimals="-3"
      id="F_f9da50ba-d5f8-4a8b-9b84-25eb0d151568"
      unitRef="U_USD">692000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_19d44124-af4c-4c1d-92f5-962be9ea56b6"
      decimals="-3"
      id="F_7d48a12b-2874-4fbd-ae50-bd1ff31475bf"
      unitRef="U_USD">1163836000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_f0655569-45ea-4da7-be44-e42a72acf91f"
      decimals="-3"
      id="F_373ee7a8-8d9c-457a-90fb-d26bac7c2ac3"
      unitRef="U_USD">-204911000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_ffcfb827-8e39-4d8f-add9-6684b4c98b48"
      decimals="INF"
      id="F_6734873e-577c-4e88-9de9-2bb3354c01cb"
      unitRef="U_shares">32005000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_ffcfb827-8e39-4d8f-add9-6684b4c98b48"
      decimals="-3"
      id="F_642a5b17-53b8-4e03-bbbf-87938c9020d2"
      unitRef="U_USD">-393829000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_2f32a53f-9c4b-4122-bfb3-3e89cba768ae"
      decimals="-3"
      id="F_5493223a-0451-4a52-8ad2-8b36b148c8fa"
      unitRef="U_USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      decimals="-3"
      id="F_0a978d70-9475-46ec-9d35-30a323353b20"
      unitRef="U_USD">565788000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="C_102d957f-b55b-4b0c-b290-8ba82889bebc"
      decimals="INF"
      id="F_b03749cb-da16-41d7-8250-23cfd7869e9d"
      unitRef="U_shares">293000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_102d957f-b55b-4b0c-b290-8ba82889bebc"
      decimals="-3"
      id="F_71f07903-3f3b-46c9-bdf7-cd89cb71e09e"
      unitRef="U_USD">3000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_ed72a4a0-2d3e-42f5-b565-15482cc0126c"
      decimals="-3"
      id="F_7e6c1272-fd25-44f4-972d-043287395982"
      unitRef="U_USD">89000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_b7286a7d-74d3-4d92-a0a9-a2bb49f254d9"
      decimals="-3"
      id="F_06eab76b-f229-4f39-a7fe-15e29f42c860"
      unitRef="U_USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="C_c104561f-a325-42f1-b855-c5fa80ede0f4"
      decimals="INF"
      id="F_ead41912-2b5c-4a71-aaff-d6bbd1aac063"
      unitRef="U_shares">0</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_c104561f-a325-42f1-b855-c5fa80ede0f4"
      decimals="-3"
      id="F_bb4bc6b3-ddd7-49a1-a55e-f0b6e7350af5"
      unitRef="U_USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_c572fa7f-d00c-4858-9672-e4e0981286bf"
      decimals="-3"
      id="F_697e4a25-abe0-40d5-a7e8-84a631dc431e"
      unitRef="U_USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_72eb33f9-0350-48c8-b550-4c2d072aa209"
      unitRef="U_USD">92000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="C_102d957f-b55b-4b0c-b290-8ba82889bebc"
      decimals="INF"
      id="F_c6c1e66d-e9d1-44e5-a74b-fc356c0f6e73"
      unitRef="U_shares">6174000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="C_102d957f-b55b-4b0c-b290-8ba82889bebc"
      decimals="-3"
      id="F_0ac62294-dd97-4105-8ef6-5961c5c737ba"
      unitRef="U_USD">62000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="C_ed72a4a0-2d3e-42f5-b565-15482cc0126c"
      decimals="-3"
      id="F_3b03654a-12f7-4b55-ae32-2a5ff628a7d0"
      unitRef="U_USD">76422000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="C_b7286a7d-74d3-4d92-a0a9-a2bb49f254d9"
      decimals="-3"
      id="F_79031a19-7dc3-4a84-9d46-bd0442d7c738"
      unitRef="U_USD">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_ddc1aad7-8b78-47bd-ba33-61c68708aa4c"
      unitRef="U_USD">76484000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <inva:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares
      contextRef="C_102d957f-b55b-4b0c-b290-8ba82889bebc"
      decimals="INF"
      id="F_025df4db-787c-42bc-916a-0d2974471f5e"
      unitRef="U_shares">0</inva:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_102d957f-b55b-4b0c-b290-8ba82889bebc"
      decimals="-3"
      id="F_c876bb32-3e52-47f2-ac57-27ec8fd07d4b"
      unitRef="U_USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_ed72a4a0-2d3e-42f5-b565-15482cc0126c"
      decimals="-3"
      id="F_8be98709-22a3-443a-82c5-3f94a3fb8e3b"
      unitRef="U_USD">5837000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_5a9d38bb-6bc6-4e0d-b81a-0f669ce07277"
      decimals="-3"
      id="F_f6b72e7a-b081-4fb3-8e12-55ff4b200d5a"
      unitRef="U_USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="C_c104561f-a325-42f1-b855-c5fa80ede0f4"
      decimals="INF"
      id="F_d7f78835-ddf5-4205-9243-19574d3bcf15"
      unitRef="U_shares">0</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_c104561f-a325-42f1-b855-c5fa80ede0f4"
      decimals="-3"
      id="F_7918e0a1-764a-4da9-901a-783dddca4df3"
      unitRef="U_USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_c572fa7f-d00c-4858-9672-e4e0981286bf"
      decimals="-3"
      id="F_46a153ac-4033-4043-a62e-5041ecb887d0"
      unitRef="U_USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_10f057e6-afb5-4297-836c-db46e7ecaa0b"
      unitRef="U_USD">5837000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <inva:ProfitLossShares
      contextRef="C_102d957f-b55b-4b0c-b290-8ba82889bebc"
      decimals="INF"
      id="F_2b59120f-993c-487f-b4df-4509c4352c11"
      unitRef="U_shares">0</inva:ProfitLossShares>
    <us-gaap:ProfitLoss
      contextRef="C_102d957f-b55b-4b0c-b290-8ba82889bebc"
      decimals="-3"
      id="F_5111e09c-ea18-415f-9dda-6e91b2013053"
      unitRef="U_USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_ed72a4a0-2d3e-42f5-b565-15482cc0126c"
      decimals="-3"
      id="F_9332b750-9fa3-4b7e-80eb-4a8a916666d6"
      unitRef="U_USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_5a9d38bb-6bc6-4e0d-b81a-0f669ce07277"
      decimals="-3"
      id="F_89efe26f-5dd3-4ce1-b0fa-7df0a64b4b79"
      unitRef="U_USD">179722000</us-gaap:ProfitLoss>
    <inva:ProfitLossShares
      contextRef="C_c104561f-a325-42f1-b855-c5fa80ede0f4"
      decimals="INF"
      id="F_c25b2150-b8cd-4692-b151-944688136dac"
      unitRef="U_shares">0</inva:ProfitLossShares>
    <us-gaap:ProfitLoss
      contextRef="C_c104561f-a325-42f1-b855-c5fa80ede0f4"
      decimals="-3"
      id="F_a6a63be3-a6b9-4732-9603-7da3263d01d6"
      unitRef="U_USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_c572fa7f-d00c-4858-9672-e4e0981286bf"
      decimals="-3"
      id="F_644d6a2e-d8c6-4b44-9d2b-8f5fcd7de068"
      unitRef="U_USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_75423b6b-61fa-446a-ac52-90d65101019c"
      unitRef="U_USD">179722000</us-gaap:ProfitLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_195a4e8d-1787-4289-8f28-a87a026f6c66"
      decimals="INF"
      id="F_6cb58af0-4ced-45e6-a047-4cbe9b11c552"
      unitRef="U_shares">63307000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_195a4e8d-1787-4289-8f28-a87a026f6c66"
      decimals="-3"
      id="F_1aafc340-64ee-4bf4-9a37-636bff73dfc8"
      unitRef="U_USD">633000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_3341913e-5e8a-43b4-af63-a752924ce8bc"
      decimals="-3"
      id="F_ad1af4c8-e805-4b36-b6f2-c1a0456e079f"
      unitRef="U_USD">1093340000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_71266bcb-340c-4b6f-bce7-ec001e02f542"
      decimals="-3"
      id="F_9884d00b-1de8-48e0-a541-b71b35840fd7"
      unitRef="U_USD">-25189000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_9125c6de-8c86-4bde-9b04-80aa987c21cc"
      decimals="INF"
      id="F_305d06d4-642f-477a-a638-65720d78e64f"
      unitRef="U_shares">32005000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_9125c6de-8c86-4bde-9b04-80aa987c21cc"
      decimals="-3"
      id="F_4f1df1c5-6348-4b00-a801-957af35b6609"
      unitRef="U_USD">-393829000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_41328be9-6954-48ec-8905-bb9f765ccba2"
      decimals="-3"
      id="F_5448a0f0-f69b-4cb0-9777-c2d2639b9827"
      unitRef="U_USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_5cb737f2-8c1a-41cf-93f4-614223b82344"
      unitRef="U_USD">674955000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_099e34d3-251a-4c11-85f7-f81213359770"
      unitRef="U_USD">179722000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_ba3feacc-98b1-4873-93e8-735b209e3a5a"
      unitRef="U_USD">220262000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="-3"
      id="F_46ac10ca-915f-4783-a5c5-ca74d3b036e8"
      unitRef="U_USD">368837000</us-gaap:ProfitLoss>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_4f717117-4f69-4734-9d4f-e77dcabd0bd4"
      unitRef="U_USD">4400000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_6d270984-0b37-4370-9285-0357130aa846"
      unitRef="U_USD">25006000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="-3"
      id="F_0e811414-44f0-4b39-96dd-5d03405611af"
      unitRef="U_USD">76432000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <inva:AmortizationOfCapitalizedFeesAndDepreciationOfPropertyAndEquipment
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_b2d9156d-5365-495e-a34d-a712c6cbbe30"
      unitRef="U_USD">13921000</inva:AmortizationOfCapitalizedFeesAndDepreciationOfPropertyAndEquipment>
    <inva:AmortizationOfCapitalizedFeesAndDepreciationOfPropertyAndEquipment
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_c6fa566a-52dc-4759-aaaf-d1d770baf660"
      unitRef="U_USD">13931000</inva:AmortizationOfCapitalizedFeesAndDepreciationOfPropertyAndEquipment>
    <inva:AmortizationOfCapitalizedFeesAndDepreciationOfPropertyAndEquipment
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="-3"
      id="F_0c085112-b065-435a-8300-a73c19b56c68"
      unitRef="U_USD">13832000</inva:AmortizationOfCapitalizedFeesAndDepreciationOfPropertyAndEquipment>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_7c6291eb-35c7-48ac-8213-ee890a331fe4"
      unitRef="U_USD">21784000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_89bfc8b7-51c3-41bf-acf7-fc95d73d202a"
      unitRef="U_USD">5581000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="-3"
      id="F_2765394e-2956-43eb-a5f5-0fa17d2a592b"
      unitRef="U_USD">0</us-gaap:AmortizationOfIntangibleAssets>
    <inva:InventoryFairValueStepUpAdjustmentIncludedInCostOfProductSales
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_08600c29-d78c-411c-8d75-99e9be3c1862"
      unitRef="U_USD">27164000</inva:InventoryFairValueStepUpAdjustmentIncludedInCostOfProductSales>
    <inva:InventoryFairValueStepUpAdjustmentIncludedInCostOfProductSales
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_6230ce41-7a5d-4f40-802b-5c9c0a0bd2de"
      unitRef="U_USD">10023000</inva:InventoryFairValueStepUpAdjustmentIncludedInCostOfProductSales>
    <inva:InventoryFairValueStepUpAdjustmentIncludedInCostOfProductSales
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="-3"
      id="F_b19d8611-315f-4f2a-baad-e1de52f13870"
      unitRef="U_USD">0</inva:InventoryFairValueStepUpAdjustmentIncludedInCostOfProductSales>
    <us-gaap:ShareBasedCompensation
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_52db40cf-cdea-402f-a66b-43789a5a2ce3"
      unitRef="U_USD">5837000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_45138f7a-096c-4e09-a7c1-75498bb93bd5"
      unitRef="U_USD">7347000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="-3"
      id="F_c61f05ed-a11d-43af-9524-5553b98e45d5"
      unitRef="U_USD">2017000</us-gaap:ShareBasedCompensation>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_91d4232f-0001-4b54-b818-85c65f8279ac"
      unitRef="U_USD">2065000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_78bb979d-bd73-441c-ae71-7dfa8fbf7bed"
      unitRef="U_USD">2055000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="-3"
      id="F_1e4d08d1-30c3-467f-9606-cf4f8c5fd953"
      unitRef="U_USD">9136000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_b9421a9a-386d-45e1-94fd-6c5d8f03697d"
      unitRef="U_USD">77392000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_83634127-35fa-4870-858a-11be4308f8b3"
      unitRef="U_USD">-161749000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="-3"
      id="F_bcd98d6c-8022-48d9-b62d-75443862c250"
      unitRef="U_USD">84392000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <inva:UnrealizedOtherGainLossOnInvestments
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_31ad1343-abe7-4f90-b7b7-1166de964adb"
      unitRef="U_USD">11129000</inva:UnrealizedOtherGainLossOnInvestments>
    <inva:UnrealizedOtherGainLossOnInvestments
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_d42433e4-e0d7-470e-9c06-75c6e6ad6bee"
      unitRef="U_USD">8462000</inva:UnrealizedOtherGainLossOnInvestments>
    <inva:UnrealizedOtherGainLossOnInvestments
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="-3"
      id="F_18c28bba-0ae6-4366-bd68-5dc8081d4ebb"
      unitRef="U_USD">4917000</inva:UnrealizedOtherGainLossOnInvestments>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_5c3dc769-2078-4420-b53e-64885eb06632"
      unitRef="U_USD">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_477103c2-a968-4071-a3db-08b2bbb255f6"
      unitRef="U_USD">-20662000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="-3"
      id="F_095ea57c-0c07-4005-a905-1ae289f8c54f"
      unitRef="U_USD">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_a23f3944-22d2-4bc0-89ca-74d44b8ce219"
      unitRef="U_USD">0</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_ed357a98-b14b-4ed9-b1f8-a133b667d68d"
      unitRef="U_USD">266696000</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="-3"
      id="F_7d089644-64a2-403f-b41a-58928ca562d2"
      unitRef="U_USD">0</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_8a479437-1b43-4d65-8791-06293eabafa3"
      unitRef="U_USD">517000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_66d1f9a4-03ff-4016-8cef-8b7392786b70"
      unitRef="U_USD">-3402000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="-3"
      id="F_66920ef6-0c13-42f5-8c73-e9dffaef28bc"
      unitRef="U_USD">259000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_9867e02d-8d42-4b47-9da8-16b4a85a1d89"
      unitRef="U_USD">5053000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_303c7ef0-4583-4139-9235-71a12bd5eeda"
      unitRef="U_USD">3525000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="-3"
      id="F_d8c7698c-1c29-42f5-829c-6fe823c1c11a"
      unitRef="U_USD">0</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInDueFromRelatedPartiesCurrent
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_a5954a02-ef6c-48e7-ba0f-b1a5170b8a6e"
      unitRef="U_USD">14949000</us-gaap:IncreaseDecreaseInDueFromRelatedPartiesCurrent>
    <us-gaap:IncreaseDecreaseInDueFromRelatedPartiesCurrent
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_a0aad8d1-7c7a-4e61-8277-e2ac999f28ca"
      unitRef="U_USD">-13319000</us-gaap:IncreaseDecreaseInDueFromRelatedPartiesCurrent>
    <us-gaap:IncreaseDecreaseInDueFromRelatedPartiesCurrent
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="-3"
      id="F_01914e2e-03b8-454a-97a5-64f0c3c3ac17"
      unitRef="U_USD">16780000</us-gaap:IncreaseDecreaseInDueFromRelatedPartiesCurrent>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_56ce69df-55b5-49bb-9831-f14978b24f2e"
      unitRef="U_USD">12004000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_99912eeb-c54d-4340-8deb-03567690f655"
      unitRef="U_USD">-280000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="-3"
      id="F_5944dacb-5138-4273-ab64-bd47c451eb76"
      unitRef="U_USD">0</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_b1cf2aa1-b186-4caf-83e9-5e0b1565411e"
      unitRef="U_USD">-7929000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_6bfbf710-7e08-46be-82bc-981ab922f506"
      unitRef="U_USD">21350000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="-3"
      id="F_e7eeb964-cac3-4b0b-8b7d-03bfd80a4e16"
      unitRef="U_USD">-203000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_1bc79fd7-4974-40f2-94c5-b6cfa1b32458"
      unitRef="U_USD">2965000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_880e84c6-0505-40bb-bc72-6e5223b36776"
      unitRef="U_USD">3341000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="-3"
      id="F_7a43b4a9-5d0e-4eec-8798-85c0bf67c58a"
      unitRef="U_USD">0</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_7506aa35-98d9-4ac2-9390-55d2c4f50367"
      unitRef="U_USD">3778000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_5a44fafd-06cf-46f3-9ba6-128549472a4e"
      unitRef="U_USD">92000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="-3"
      id="F_e9377ddd-46bd-4041-a62a-9a8d6adeb83a"
      unitRef="U_USD">-39000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_c4bb32b4-b43a-445b-accd-541dfd063664"
      unitRef="U_USD">-1498000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_884b17f6-c9cd-4a78-93e8-48b43662f9e8"
      unitRef="U_USD">11913000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="-3"
      id="F_921153b2-059c-4738-865b-8a9935e1192e"
      unitRef="U_USD">-257000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInInterestPayableNet
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_8dfed973-65ad-44b1-9272-f0a6297c02ba"
      unitRef="U_USD">-937000</us-gaap:IncreaseDecreaseInInterestPayableNet>
    <us-gaap:IncreaseDecreaseInInterestPayableNet
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_b4520b21-cccb-4531-a9a2-2987cdeb4f0e"
      unitRef="U_USD">207000</us-gaap:IncreaseDecreaseInInterestPayableNet>
    <us-gaap:IncreaseDecreaseInInterestPayableNet
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="-3"
      id="F_d9fd988d-f195-40bf-a18d-ed6b51f5bfbb"
      unitRef="U_USD">0</us-gaap:IncreaseDecreaseInInterestPayableNet>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_16dc0d05-79c2-468a-ac79-a44e1e22e127"
      unitRef="U_USD">-817000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_90cb14e2-3a82-468d-ac51-36acd4e3c721"
      unitRef="U_USD">-755000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="-3"
      id="F_01f51ba3-ea31-4207-9079-9403892d8c4e"
      unitRef="U_USD">0</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_b02fb408-a3ec-4b71-a520-bbd63080c7ea"
      unitRef="U_USD">1725000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_4ff4d9e3-edd0-4edf-bdbe-78fb9294298e"
      unitRef="U_USD">10026000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="-3"
      id="F_606c4013-3f34-45e7-91a9-e5b6e10e9669"
      unitRef="U_USD">0</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_82b0c9f6-dc1c-4431-9c3b-8cd03f2a7df6"
      unitRef="U_USD">141064000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_d1492c1b-6d1a-45e1-a6bf-58deb235a3c0"
      unitRef="U_USD">201726000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="-3"
      id="F_15716cf7-5478-42fd-8386-5da1a6fd0b4d"
      unitRef="U_USD">363813000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_e7437122-9a7a-49db-b3d3-e805f94c4bf3"
      unitRef="U_USD">0</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_eb3757df-b39d-4e4d-af9f-a9a5704b1bfd"
      unitRef="U_USD">45000000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="-3"
      id="F_d230c72b-0e7c-4e57-984f-c3977354bd89"
      unitRef="U_USD">44000000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_28561914-23a1-42e0-b574-abda35eae15a"
      unitRef="U_USD">65132000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_14852f1d-3a07-4ece-a93e-84571db9c580"
      unitRef="U_USD">0</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="-3"
      id="F_1f8b769f-38f9-45d8-8068-a9b51651cd90"
      unitRef="U_USD">15905000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireLongtermInvestments
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_ffbfc274-1691-4194-8fe1-be89ceb7337b"
      unitRef="U_USD">1218000</us-gaap:PaymentsToAcquireLongtermInvestments>
    <us-gaap:PaymentsToAcquireLongtermInvestments
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_0dd3f4e7-2399-4d4e-baa4-0a4498aa0c07"
      unitRef="U_USD">13725000</us-gaap:PaymentsToAcquireLongtermInvestments>
    <us-gaap:PaymentsToAcquireLongtermInvestments
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="-3"
      id="F_63d11917-2e35-4308-8550-1a942fbea229"
      unitRef="U_USD">6373000</us-gaap:PaymentsToAcquireLongtermInvestments>
    <inva:PurchasesOfEquityInvestmentsManagedByIspFundLp
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_ac0d4dc3-a5c1-420c-b47c-5f95a6482d98"
      unitRef="U_USD">31164000</inva:PurchasesOfEquityInvestmentsManagedByIspFundLp>
    <inva:PurchasesOfEquityInvestmentsManagedByIspFundLp
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_8a519b40-3a4e-490a-b192-2c1a036873ec"
      unitRef="U_USD">60910000</inva:PurchasesOfEquityInvestmentsManagedByIspFundLp>
    <inva:PurchasesOfEquityInvestmentsManagedByIspFundLp
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="-3"
      id="F_20f9854e-5e31-43f9-b698-1262f7d26dd3"
      unitRef="U_USD">190970000</inva:PurchasesOfEquityInvestmentsManagedByIspFundLp>
    <inva:PurchasesOfTradingSecurityManagedByIspFundLp
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_2c5ef212-8e5c-4a0c-9a51-8386728161e4"
      unitRef="U_USD">0</inva:PurchasesOfTradingSecurityManagedByIspFundLp>
    <inva:PurchasesOfTradingSecurityManagedByIspFundLp
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_55b94717-9dc8-45bd-8db9-07980deaaf9f"
      unitRef="U_USD">50000000</inva:PurchasesOfTradingSecurityManagedByIspFundLp>
    <inva:PurchasesOfTradingSecurityManagedByIspFundLp
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="-3"
      id="F_f991eb5f-3859-4e7a-ae80-ff854ad5df08"
      unitRef="U_USD">0</inva:PurchasesOfTradingSecurityManagedByIspFundLp>
    <inva:SaleOfEquityInvestmentsManagedByIspFundLp
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_35ef6511-2d12-4771-a568-443082fe774c"
      unitRef="U_USD">72500000</inva:SaleOfEquityInvestmentsManagedByIspFundLp>
    <inva:SaleOfEquityInvestmentsManagedByIspFundLp
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_eea0413d-bded-43ee-ad8e-f5ef27374065"
      unitRef="U_USD">24281000</inva:SaleOfEquityInvestmentsManagedByIspFundLp>
    <inva:SaleOfEquityInvestmentsManagedByIspFundLp
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="-3"
      id="F_dbc744f9-d737-4cee-86f5-4df5d686f09f"
      unitRef="U_USD">21440000</inva:SaleOfEquityInvestmentsManagedByIspFundLp>
    <inva:PurchaseAndSaleOfOtherInvestmentsManagedByIspFundLp
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_94919e93-b049-4186-9a4b-96df45604543"
      unitRef="U_USD">41336000</inva:PurchaseAndSaleOfOtherInvestmentsManagedByIspFundLp>
    <inva:PurchaseAndSaleOfOtherInvestmentsManagedByIspFundLp
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_ad894be0-98bf-4e65-8cf6-447ed6c48ebd"
      unitRef="U_USD">23371000</inva:PurchaseAndSaleOfOtherInvestmentsManagedByIspFundLp>
    <inva:PurchaseAndSaleOfOtherInvestmentsManagedByIspFundLp
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="-3"
      id="F_9a8f2c7f-8164-44c8-8cef-40a2ed6ce707"
      unitRef="U_USD">-279530000</inva:PurchaseAndSaleOfOtherInvestmentsManagedByIspFundLp>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_2b86fd11-a368-488e-86f9-ffba3744717f"
      unitRef="U_USD">411000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_58a0cb4a-ffe7-46d7-9f72-5ffe0bbf676a"
      unitRef="U_USD">67000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="-3"
      id="F_1e87f9f0-6889-4f20-ac9d-048350fef463"
      unitRef="U_USD">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <inva:NetProceedsFromSaleOfVariableInterestEntityEquity
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_9a23f513-0d81-466e-bf86-a42ea96e7d11"
      unitRef="U_USD">0</inva:NetProceedsFromSaleOfVariableInterestEntityEquity>
    <inva:NetProceedsFromSaleOfVariableInterestEntityEquity
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_1fac6353-e37e-4efb-8860-715da3c49ff7"
      unitRef="U_USD">248191000</inva:NetProceedsFromSaleOfVariableInterestEntityEquity>
    <inva:NetProceedsFromSaleOfVariableInterestEntityEquity
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="-3"
      id="F_ff52a95a-60fd-46fb-bd04-e35809c286f2"
      unitRef="U_USD">0</inva:NetProceedsFromSaleOfVariableInterestEntityEquity>
    <us-gaap:CashAcquiredFromAcquisition
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_498b0e35-0b0d-4349-8166-085318614adc"
      unitRef="U_USD">0</us-gaap:CashAcquiredFromAcquisition>
    <us-gaap:CashAcquiredFromAcquisition
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_ba0a6736-265c-468a-94f2-f0da8c34da57"
      unitRef="U_USD">23070000</us-gaap:CashAcquiredFromAcquisition>
    <us-gaap:CashAcquiredFromAcquisition
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="-3"
      id="F_dc60a367-9ef0-40a0-a891-9d372457e945"
      unitRef="U_USD">0</us-gaap:CashAcquiredFromAcquisition>
    <inva:CashPaidForTheAcquisitionOfLaJollaPharmaceuticalCompanyNetOfCashAcquired
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_6ce4214c-3def-49de-a706-e66d3b6f9e13"
      unitRef="U_USD">0</inva:CashPaidForTheAcquisitionOfLaJollaPharmaceuticalCompanyNetOfCashAcquired>
    <inva:CashPaidForTheAcquisitionOfLaJollaPharmaceuticalCompanyNetOfCashAcquired
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_2d17242c-3239-4e4b-95bc-ee78dfac1ada"
      unitRef="U_USD">159103000</inva:CashPaidForTheAcquisitionOfLaJollaPharmaceuticalCompanyNetOfCashAcquired>
    <inva:CashPaidForTheAcquisitionOfLaJollaPharmaceuticalCompanyNetOfCashAcquired
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="-3"
      id="F_976b0eac-d58c-4fff-a4b6-3184212d5163"
      unitRef="U_USD">0</inva:CashPaidForTheAcquisitionOfLaJollaPharmaceuticalCompanyNetOfCashAcquired>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_7bd01cfc-7ca4-4163-b54f-77708cf847cc"
      unitRef="U_USD">-66761000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_3478fb28-a218-4ea7-8cea-9e0cdc8c01ba"
      unitRef="U_USD">-56634000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="-3"
      id="F_9dd5b164-4f20-4071-8bc3-4406f8932edd"
      unitRef="U_USD">43722000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsToMinorityShareholders
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_58855024-da42-4625-9231-2cdd9e7b33c1"
      unitRef="U_USD">0</us-gaap:PaymentsToMinorityShareholders>
    <us-gaap:PaymentsToMinorityShareholders
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_0a0b3336-c609-4c97-b72d-aa4d39be37dd"
      unitRef="U_USD">69811000</us-gaap:PaymentsToMinorityShareholders>
    <us-gaap:PaymentsToMinorityShareholders
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="-3"
      id="F_b14520d9-d3df-4d70-80d5-d45d62231513"
      unitRef="U_USD">59457000</us-gaap:PaymentsToMinorityShareholders>
    <inva:PurchaseOfEntasisNoncontrollingInterest
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_d0770d03-2f07-4267-a40e-9891f0cd60f8"
      unitRef="U_USD">0</inva:PurchaseOfEntasisNoncontrollingInterest>
    <inva:PurchaseOfEntasisNoncontrollingInterest
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_22b072c0-7e29-46d1-847e-89b046776afa"
      unitRef="U_USD">43910000</inva:PurchaseOfEntasisNoncontrollingInterest>
    <inva:PurchaseOfEntasisNoncontrollingInterest
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="-3"
      id="F_90f1eed6-82df-4a3e-93c4-cc3776d16bf5"
      unitRef="U_USD">0</inva:PurchaseOfEntasisNoncontrollingInterest>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_ea4e9ff3-9cda-4aa7-97b2-7f5e8f06709b"
      unitRef="U_USD">75728000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_f0a62b60-176a-4f00-aafd-10632b0fb7b3"
      unitRef="U_USD">8503000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="-3"
      id="F_c3bf7417-e773-441a-8791-5acf3b6646cf"
      unitRef="U_USD">394149000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_a82bd7c6-7961-40c4-b73e-057aee2f32b2"
      unitRef="U_USD">77000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_d81e9a12-d118-4d18-9a81-7eb10533972d"
      unitRef="U_USD">82000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="-3"
      id="F_d9c9e230-7a0a-4c39-a078-8b27ae721a24"
      unitRef="U_USD">60000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_61dc1ae4-b5af-44b8-a444-367b54b1fd99"
      unitRef="U_USD">170000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_7b8630a3-16c8-4c45-ac0a-021e95c73488"
      unitRef="U_USD">370000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="-3"
      id="F_60a20b9f-d27d-4361-80e1-7a25f901f953"
      unitRef="U_USD">1169000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:RepaymentsOfUnsecuredDebt
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_da5a2bc6-15fe-4156-a42d-da7d756609d7"
      unitRef="U_USD">96204000</us-gaap:RepaymentsOfUnsecuredDebt>
    <us-gaap:RepaymentsOfUnsecuredDebt
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_01b1ab99-16de-4ade-bc6a-5dccd13329f3"
      unitRef="U_USD">165131000</us-gaap:RepaymentsOfUnsecuredDebt>
    <us-gaap:RepaymentsOfUnsecuredDebt
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="-3"
      id="F_42281ae2-a677-44f7-a04c-e698d429b8dd"
      unitRef="U_USD">0</us-gaap:RepaymentsOfUnsecuredDebt>
    <inva:PurchasesOfCappedCallOptionsAssociatedWithConvertibleSeniorNotes
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_3725d517-0469-46cd-9307-6733f5e6e342"
      unitRef="U_USD">0</inva:PurchasesOfCappedCallOptionsAssociatedWithConvertibleSeniorNotes>
    <inva:PurchasesOfCappedCallOptionsAssociatedWithConvertibleSeniorNotes
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_0fe3d0e3-ed3e-4fef-91ee-ded86971c4bb"
      unitRef="U_USD">21037000</inva:PurchasesOfCappedCallOptionsAssociatedWithConvertibleSeniorNotes>
    <inva:PurchasesOfCappedCallOptionsAssociatedWithConvertibleSeniorNotes
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="-3"
      id="F_69279218-b5ac-48c6-ab02-a86f98e74d63"
      unitRef="U_USD">0</inva:PurchasesOfCappedCallOptionsAssociatedWithConvertibleSeniorNotes>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_4a993779-54b0-47d7-a481-74c85a8b1569"
      unitRef="U_USD">0</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_7317e2ce-240e-4f65-9f1e-e4d7357e05bb"
      unitRef="U_USD">252536000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="-3"
      id="F_86e6394b-14b0-48c6-8880-526c0c59dc14"
      unitRef="U_USD">0</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_aa8e4d3f-b20a-4ccc-899b-2ee85d057ffb"
      unitRef="U_USD">-171839000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_716937c0-3ac9-4190-88e6-68d60b82235b"
      unitRef="U_USD">-55568000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="-3"
      id="F_8537df26-9919-49af-bcae-6195428c7b3d"
      unitRef="U_USD">-452497000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_63a8edcb-02f0-41f9-a450-08d114c1224d"
      unitRef="U_USD">-97536000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_9e3bc0f1-0ce9-4cae-bfcc-bcd901dc6079"
      unitRef="U_USD">89524000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="-3"
      id="F_47227f66-1281-4ecd-9c5d-760c3c1f13b1"
      unitRef="U_USD">-44962000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      decimals="-3"
      id="F_22d81949-6c67-4403-bbb7-c7aa8ffd801b"
      unitRef="U_USD">291049000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_c2c8ab67-08be-4854-91e3-98e911bef5b3"
      decimals="-3"
      id="F_5e452d49-ac85-472f-97b0-84dad69f03e6"
      unitRef="U_USD">201525000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_646bb33b-4ef6-4493-b542-00c92f556418"
      decimals="-3"
      id="F_ee71aee1-87de-46ac-8cd2-508403b72c29"
      unitRef="U_USD">246487000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_92d3b492-102f-4eb7-8f3f-c52e3b822d90"
      unitRef="U_USD">193513000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      decimals="-3"
      id="F_2cb8d2fd-f91e-4144-8db3-d1be81e673cf"
      unitRef="U_USD">291049000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_c2c8ab67-08be-4854-91e3-98e911bef5b3"
      decimals="-3"
      id="F_638db1cd-7a0e-48f8-bc52-deed850f7adc"
      unitRef="U_USD">201525000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_2f7d9d58-413a-49d6-bbab-e5571366aee2"
      unitRef="U_USD">11381000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_66ccbcd5-025b-4e42-ae15-dc99b80f1f63"
      unitRef="U_USD">11736000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="-3"
      id="F_bb918af0-39df-4906-bd40-6e6deab92a32"
      unitRef="U_USD">9933000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_776e6bcb-c048-4e33-8f14-2adce6352a2d"
      unitRef="U_USD">0</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_de1a6d53-dbc5-46cc-b2d7-c8f7bfd5f1ae"
      unitRef="U_USD">53855000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="-3"
      id="F_3d7f9bc3-7140-406e-bc39-dac5023eb8d2"
      unitRef="U_USD">0</us-gaap:IncomeTaxesPaidNet>
    <inva:AccruedInterestIncomeIncludedInLongTermInvestments
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_e6aa03de-c79c-4c83-952c-c90371eb6fed"
      unitRef="U_USD">2666000</inva:AccruedInterestIncomeIncludedInLongTermInvestments>
    <inva:AccruedInterestIncomeIncludedInLongTermInvestments
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_110528b5-db79-40e9-a2f6-aaa75c973c4e"
      unitRef="U_USD">0</inva:AccruedInterestIncomeIncludedInLongTermInvestments>
    <inva:AccruedInterestIncomeIncludedInLongTermInvestments
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="-3"
      id="F_a893ee63-a1b7-4857-a6f6-dacca29d3498"
      unitRef="U_USD">0</inva:AccruedInterestIncomeIncludedInLongTermInvestments>
    <inva:NonCashActivity
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_c8300200-e02d-4e64-8c3e-83229294af6f"
      unitRef="U_USD">0</inva:NonCashActivity>
    <inva:NonCashActivity
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_3408fbce-b93b-4c56-b64f-6ed4d1a3bfd3"
      unitRef="U_USD">-28228000</inva:NonCashActivity>
    <inva:NonCashActivity
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="-3"
      id="F_9264ecc6-0038-41e5-9d0f-3f3da552798b"
      unitRef="U_USD">0</inva:NonCashActivity>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      id="F_2750278b-b3ca-4ad4-a461-e6e75a001a48">&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;1.  DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Description of Operations&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Innoviva, Inc. (and where context requires, together with its subsidiaries referred to as &#x201c;Innoviva&#x201d;, the &#x201c;Company&#x201d;, or &#x201c;we&#x201d; and other similar pronouns) is a company with a portfolio of royalties and innovative healthcare assets. Our royalty portfolio contains respiratory assets partnered with Glaxo Group Limited (&#x201c;GSK&#x201d;), including RELVAR&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;/BREO&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; ELLIPTA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;(fluticasone furoate/vilanterol, &#x201c;FF/VI&#x201d;) and ANORO&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; ELLIPTA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;(umeclidinium bromide/vilanterol, &#x201c;UMEC/VI&#x201d;), and up until July 2022, TRELEGY&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; ELLIPTA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;(the combination FF/UMEC/VI). We sold our &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% ownership interest in Theravance Respiratory Company, LLC (&#x201c;TRC&#x201d;) on July 20, 2022, and are no longer entitled to receive royalties on sales of TRELEGY&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; ELLIPTA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; products. Under the Long-Acting Beta2 Agonist (&#x201c;LABA&#x201d;) Collaboration Agreement, Innoviva is entitled to receive royalties from GSK on sales of RELVAR&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;/BREO&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; ELLIPTA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; as follows: &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% on the first $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; billion of annual global net sales and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% for all annual global net sales above $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; billion; and royalties from the sales of ANORO&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; ELLIPTA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, which tier upward at a range from &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We expanded our portfolio through the acquisition of Entasis Therapeutics Holdings Inc. (&#x201c;Entasis&#x201d;) on July 11, 2022 and the acquisition of La Jolla Pharmaceutical Company (&#x201c;La Jolla&#x201d;) on August 22, 2022. Our commercial and marketed products include GIAPREZA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;(angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock, and XERAVA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; (eravacycline) for the treatment of complicated intra-abdominal infections in adults. Our new product, XACDURO&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;(formerly known as sulbactam-durlobactam or SUL-DUR), was approved by the United States Food and Drug Administration (&#x201c;FDA&#x201d;) for the treatment of hospital-acquired and ventilator-associated pneumonias caused by &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Acinetobacter&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; in adults on May 23, 2023. We commenced commercial sales of XACDURO&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; in the third quarter of 2023. Our development pipeline includes zoliflodacin, an investigational treatment for uncomplicated gonorrhea that reported positive data in a pivotal Phase 3 clinical trial on November 1, 2023. As such, we have a wholly owned robust critical care and infectious disease operating platform with a hospital focus anchored by three differentiated products with significant growth potential and a promising drug candidate.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In addition, we own other strategic healthcare assets, such as a large equity stake in Armata Pharmaceuticals, a leader in development of bacteriophages with potential use across a range of infectious and other serious diseases.  We also have economic interests in other healthcare companies.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Principles of Consolidation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The accompanying consolidated financial statements include the accounts of Innoviva, our wholly owned subsidiaries and certain variable interest entities (&#x201c;VIE&#x201d;) for which we are the primary beneficiary. All intercompany balances and transactions have been eliminated in consolidation. For consolidated entities where we own or are exposed to less than 100% of the economics, we record net income (loss) attributable to noncontrolling interest in our consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entity by the respective noncontrolling party.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Presentation Reclassification&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Amounts in equity and long-term investments reported in the Company&#x2019;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;s comparative financial statements have been reclassified to conform to the current year presentation. Certain reclassifications have been made to the consolidated statement of cash flows for the years ended December 31, 2022 and 2021 to conform to the current year&#x2019;s presentation. These reclassifications had no net effect on the net income or net cash flows from operating, investing and financing activities as previously reported.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Factors Affecting Comparability&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Our historical financial condition and results of operations for the periods presented may not be comparable, either between periods or going forward due to the factors below and as discussed in Note 5, &#x201c;Consolidated Entities and Acquisitions&#x201d;.&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Adoption of Accounting Standards Update 2020-06, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Debt-Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; (&#x201c;ASU 2020-06&#x201d;) effective January 1, 2022;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accounting consolidation of Entasis on February 17, 2022 and purchase of remaining noncontrolling interest in Entasis on July 11, 2022;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Sale of our &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% ownership interest in TRC on July 20, 2022; and&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Acquisition of La Jolla on August 22, 2022.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Use of Management&#x2019;s Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The preparation of consolidated financial statements in conformity with U.S. Generally Accepted Accounting Principles (&#x201c;U.S. GAAP&#x201d;) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ materially from those estimates. Management evaluates its significant accounting policies and estimates on an ongoing basis. We base our estimates on historical experience and other relevant assumptions that we believe to be reasonable under the circumstances. These estimates also form the basis for making judgments about the carrying values of assets and liabilities when these values are not readily apparent from other sources.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Concentrations of Credit Risk and of Significant Suppliers and Partners&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Our financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents and equity and long-term investments. Although we deposit our cash with multiple financial institutions, our deposits, at times, may exceed federally insured limits.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; We are dependent on third-party manufacturers to supply active pharmaceutical ingredients (&#x201c;API&#x201d;) and drug products for research and development and commercial programs. These programs could be adversely affected by significant interruption in the supply of API or drug products.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Currently, we derive most of our revenues from GSK and our near-term success depends in large part on GSK&#x2019;s ability to successfully develop and commercialize the products in the respiratory programs partnered with GSK. Our near-term success depends in large part upon the performance by GSK of its commercial obligations under the GSK Agreements and the commercial success of RELVAR&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;/BREO&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; ELLIPTA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and ANORO&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; ELLIPTA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. If GSK does not devote sufficient resources to the commercialization or development of these products, is unsuccessful in its efforts, or chooses to reprioritize its commercial programs, our business would be materially harmed. GSK is responsible for all clinical and other product development, regulatory, manufacturing and commercialization activities for products developed under the GSK Agreements, including RELVAR&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;/BREO&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; ELLIPTA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and ANORO&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; ELLIPTA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. Our royalty revenues may fluctuate due to a variety of factors, many of which are outside of our control. Our royalty revenues under the GSK Agreements may not meet our, analysts&#x2019; or investors&#x2019; expectations, due to a number of important factors.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We started recognizing revenue from product sales of GIAPREZA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and XERAVA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; in 2022 as a result of our acquisition of La Jolla. In the current year, we also started recognizing revenue from product sales from XACDURO&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, which was commercially launched in the third quarter of 2023. Hospitals and other healthcare organizations generally purchase our products through a network of specialty distributors. These specialty distributors, which are located in the U.S., are considered our customers for accounting purposes. We do not believe that loss of one of these distributors would significantly impact our ability to distribute our products, as we expect that sales volume would be absorbed by new or remaining distributors. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Three&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; of our customers each account for &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;31&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%, respectively, of our net product sales for the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. These same customers account for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;29&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%, respectively, of our receivables from net product sales, which are included in &#x201c;Accounts receivables, net&#x201d; in our consolidated balance sheet as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; Three of our customers each account for approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;33&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;29&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;28&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%, respectively, of our net product sales from the time of our acquisition of La Jolla through December 31, 2022. These same customers account for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;23&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;37&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;37&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%, respectively, of our receivables from net product sales, which are included in &#x201c;Accounts receivables, net&#x201d; in our consolidated balance sheet as of December 31, 2022.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Segment Reporting&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We operate in a single segment, which is to provide capital return to stockholders by maximizing the potential value of our portfolio of royalties and innovative healthcare assets. Our Chief Operating Decision Maker (&#x201c;CODM&#x201d;) is our Chief Executive Officer. The CODM allocates resources and evaluates the performance of Innoviva at the consolidated level using information about our revenues, operating results and other key financial data as needed. Our revenues are generated primarily from our collaborative arrangements and royalty payments from GSK, located in Great Britain. We also generate revenue from net product sales of GIAPREZA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, XERAVA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, and XACDURO&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Refer to Note 3, &#x201c;Revenue Recognition&#x201d;, for more information on our revenues for the periods presented. Our long-term assets are located within the United States.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Variable Interest Entities&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The primary beneficiary of a variable interest entity (&#x201c;VIE&#x201d;) is required to consolidate the assets and liabilities of the VIE. When we obtain a variable interest in another entity, we assess at the inception of the relationship and upon occurrence of certain significant events whether the entity is a VIE and, if so, whether we are the primary beneficiary of the VIE based on our power to direct the activities of the VIE that most significantly impact the VIE&#x2019;s economic performance and our obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;To assess whether we have the power to direct the activities of a VIE that most significantly impact the VIE&#x2019;s economic performance, we consider all the facts and circumstances, including our role in establishing the VIE and our ongoing rights and responsibilities. This assessment includes identifying the activities that most significantly impact the VIE&#x2019;s economic performance and identifying which party, if any, has power over those activities. In general, the parties that make the most significant decisions affecting the VIE (management and representation on the Board of Directors) and have the right to unilaterally remove those decision-makers are deemed to have the power to direct the activities of a VIE.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;To assess whether we have the obligation to absorb losses of the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE, we consider all of our economic interests that are deemed to be variable interests in the VIE. This assessment requires us to apply judgment in determining whether these interests, in the aggregate, are considered potentially significant to the VIE.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Business Combination&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;When we acquire an entity in a business combination, we recognize the fair value of all assets acquired, liabilities assumed, and any non-controlling interest in the acquiree and establish the acquisition date as the fair value measurement point. We recognize and measure goodwill as of the acquisition date, as the excess of the fair value of the consideration paid over the fair value of the identified net assets acquired. Acquisition-related expenses and related restructuring costs are expensed as incurred.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; Several valuation methods may be used to determine the fair value of assets acquired and liabilities assumed. For intangible assets, we typically use the income method. This method starts with a forecast of all of the expected future net cash flows for each asset. These cash flows are then adjusted to present value by applying an appropriate discount rate that reflects the risk factors associated with the cash flow streams. Some of the more significant estimates and assumptions inherent in the income method or other methods include the amount and timing of projected future cash flows, the discount rate selected to measure the risks inherent in the future cash flows and the assessment of the asset&#x2019;s life cycle and the competitive trends impacting the asset, including consideration of any technical, legal, regulatory, or economic barriers to entry. Determining the useful life of an intangible asset also requires judgment as different types of intangible assets will have different useful lives and certain assets may even be considered to have indefinite useful lives.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We consider all highly liquid investments purchased with a maturity of three months or less on the date of purchase to be cash equivalents. Cash equivalents are carried at cost, which approximates fair value.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Accounts Receivable&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accounts receivable are recorded net of estimates for prompt-pay discounts, chargebacks, returns and rebates. Allowances for prompt-pay discounts and chargebacks are based on contractual terms. We estimate the allowance for credit losses based on existing contractual payment terms, actual payment patterns of customers and individual customer circumstances.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Inventory&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Inventory is stated at the lower of cost or estimated net realizable value on a first-in, first-out basis. We periodically analyze inventory levels and write down inventory as cost of products sold when the following occurs: inventory has become obsolete, inventory has a cost basis in excess of its estimated net realizable value, or inventory quantities are in excess of expected product sales.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Property and Equipment&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Property and equipment, which consisted of laboratory equipment, computer equipment, software, office furniture and fixtures, and leasehold improvements, were not material as of December 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Property and equipment are stated at cost less accumulated depreciation. Property and equipment are depreciated using the straight-line method &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;over the estimated useful lives of the respective assets as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:49.17%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.66%;"&gt;&lt;/td&gt;
          &lt;td style="width:49.17%;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Shorter of remaining lease terms or useful life&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Laboratory equipment, furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#x2013; &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Software and computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Equity and Long-Term Investments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We invest from time to time in equity and debt securities of private or public companies. If we determine that we have control over these companies under either voting or VIE models, we consolidate them in our consolidated financial statements. If we determine that we do not have control over these companies under either voting or VIE models, we then determine if we have an ability to exercise significant influence via voting interests, board representation or other business relationships.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We may account for the investments where we exercise significant influence using either an equity method of accounting or at fair value by electing the fair value option under Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 825, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. If the fair value option is applied to an investment that would otherwise be accounted for under the equity method, we apply it to all our financial interests in the same entity (equity and debt, including guarantees) that are eligible items. All gains and losses from fair value changes, unrealized and realized, are presented as changes in fair values of equity method investments, net, and changes in fair values of equity and long-term investments, net, within the consolidated statements of income.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;If we conclude that we do not have an ability to exercise significant influence over an investee, we may elect to account for the security without a readily determinable fair value using the measurement alternative method under ASC 321, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Investments &#x2013; Equity Securities&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. This measurement alternative method allows us to measure the equity investment at its cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We also invest in ISP Fund LP, which investments consist of money market funds and equity and debt securities in the healthcare, pharmaceutical and biotechnology industries. Pursuant to the Partnership Agreement entered in December 2020, we became a limited partner of this partnership, and our contributions are subject to a 36-month lock-up period, which restriction prevents us from having control and access to the contributions and related investments. The lock-up period for a certain portion of our contributions expired in December 2023. Strategic Partners did not elect to make a withdrawal in 2023, thereby extending the lock-up period and withdrawal elections into subsequent years. These investments are classified as long-term investments in the consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We define fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Our valuation techniques are based on observable and unobservable inputs. Observable inputs reflect readily obtainable data from independent sources, while unobservable inputs reflect our market assumptions. We classify these inputs into the following hierarchy:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;Quoted prices for identical instruments in active markets.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;Quoted prices for similar instruments in active markets; quoted prices for identical 3or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;Unobservable inputs and little, if any, market activity for the assets.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Financial instruments include cash equivalents, accounts receivable, receivables from collaborative arrangements, accounts payable, and accrued liabilities, equity investments and convertible promissory notes. The carrying values of cash equivalents, receivables from collaborative arrangements, accounts payable, and accrued liabilities approximate their estimated fair values due to the relatively short-term nature of these instruments.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Capitalized Fees Paid&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We capitalize fees paid to licensors related to agreements for approved products or commercialized products. We capitalize these fees as capitalized fees paid (&#x201c;Capitalized Fees&#x201d;) and amortize them on a straight-line basis over their estimated useful lives upon the commercial launch of the product, shortly after its regulatory approval. The estimated useful lives of these Capitalized Fees are determined on a country-by-country and product-by-product basis, as the later of the expiration or termination of the last patent right covering the compound in such product in such country and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;15 years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; from first commercial sale of such product in such country, unless the Collaboration Agreement is terminated earlier. Consistent with our policy for classification of costs under the research and development collaborative arrangements, the amortization of these Capitalized Fees is recognized as a reduction of royalty revenue. We review our Capitalized Fees for impairment on a product-by-product basis for each major geographic area when events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. The recoverability of Capitalized Fees is measured by comparing the asset&#x2019;s carrying amount to the expected undiscounted future cash flows that the asset is expected to generate. The determination of recoverability typically requires various estimates and assumptions, including estimating the useful life over which cash flows will occur, their amount, and the asset&#x2019;s residual value, if any. We derive the required cash flow estimates from near-term forecasted product sales and long-term projected sales in the corresponding market.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Goodwill and Intangible Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Goodwill is recognized as the excess of the purchase consideration of an acquired entity over the fair value assigned to assets acquired and liabilities assumed in a business combination. Goodwill and intangible assets with indefinite useful life are not amortized and are tested for impairment at least annually on the first day of December of each year&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; or more frequently if indicators for potential impairment exist or whenever events or changes in circumstances indicate that the asset&#x2019;s carrying asset amount may not be recoverable. Intangible assets with definite useful lives are amortized on a straight-line basis over their respective remaining useful lives and are tested for impairment only if indicators for potential impairment exist or whenever events or changes in circumstances indicate that the asset&#x2019;s carrying amount may not be recoverable. Significant judgment may be involved in determining if an indicator of impairment has occurred.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Operating Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Right-of-use assets represent our right to use an underlying asset over the lease term and include any lease payments made prior to the lease commencement date and are reduced by lease incentives. Lease liabilities represent the present value of the total lease payments over the lease term, calculated using an estimated incremental borrowing rate. Lease expense is recognized on a straight-line basis over the expected lease term.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Revenue Recognition&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We apply the guidance on principal versus agent considerations under ASC Topic 606, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, to determine the appropriate treatment for the transactions between us and third parties. The classification of transactions under our arrangements is determined based on the nature and contractual terms of the arrangement along with the nature of the operations of the participants. Any consideration related to activities in which we are considered the principal, which includ&lt;/span&gt;&lt;span style="color:#252525;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;es being in control of the good or service before such good or service is transferred to the customer, are accounted for as product sales.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Revenue is recognized when our customer obtains control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. Revenue is recognized through a five-step process: (i) identify the contract with the customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price for the contract; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue as a performance obligation is satisfied.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Royalty Revenue&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We recognize the royalty revenue on net sales of products with respect to which we have contractual royalty rights in the period in which the royalties are earned. The net sales reports provided by our partner are based on its methodology and assumptions to estimate rebates and returns, which it monitors and adjusts regularly in light of contractual and legal obligations, historical trends, past experience and projected market conditions. Our partner may make significant adjustments to its sales based on actual results recorded, which could cause our royalty revenue to fluctuate. We conduct periodic royalty audits to evaluate the information provided by our partner. Royalties are recognized net of amortization of capitalized fees associated with any approval and launch milestone payments made to GSK.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Revenue from Product Sales&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; Revenue from product sales is recognized when our customers obtain control of the product and is recorded at the transaction price, net of estimates for variable consideration consisting of chargebacks, discounts, returns and rebates. Variable consideration is estimated using the expected-value amount method, which is the sum of probability-weighted amounts in a range of possible consideration amounts. Actual amounts of consideration ultimately received may differ from our estimates. If actual results vary materially from our estimates, we will adjust these estimates, which will affect revenue from product sales and earnings in the period such estimates are adjusted. These items may include:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Chargebacks: Chargebacks are discounts we provide to distributors in the event that the sales prices to end users are below the distributors&#x2019; acquisition price. This may occur due to a direct contract with a health system, a group purchasing organization (&#x201c;GPO&#x201d;) agreement or a sale to a government facility. Chargebacks are estimated based on known chargeback rates and recorded as a reduction of revenue on delivery to our customers.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Discounts: We offer customers various forms of incentives and consideration, including prompt-pay and other discounts. We estimate discounts primarily based on contractual terms. These discounts are recorded as a reduction of revenue on delivery to our customers.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Returns: We offer customers a limited right of return, generally for damaged or expired product. We estimate returns based on an internal analysis, which includes actual experience. The estimates for returns are recorded as a reduction of revenue on delivery to our customers. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Rebates: We participate in Medicaid rebate programs, which provide assistance to certain low-income patients based on each individual state&#x2019;s guidelines regarding eligibility and services. Under the Medicaid rebate programs, we pay a rebate to each participating state, generally within three months after the quarter in which product was sold. Additionally, we may offer customer incentives and consideration in the form of volume-based or other rebates. The estimates for rebates are recorded as a reduction of revenue on delivery to our customers. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We continue to assess our estimates of variable consideration as we accumulate additional historical data and will adjust these estimates accordingly.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;License Revenue&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;At the inception of a licensing arrangement that includes development and regulatory milestone payments, we evaluate whether the milestones are considered probable of being achieved and estimate the amount to be included in the transaction price. We generally recognize these milestone payments as revenues when they are achieved because there is considerable uncertainty in the research and development processes that trigger receipt of these payments under our agreements. Similarly, we recognize regulatory approval milestone payments as revenues once the product is approved by the applicable regulatory agency.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Research and Development Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Research and development expenses are recognized in the period that services are rendered or goods are received. Research and development expenses consist of salaries and benefits, laboratory supplies, facilities and other overhead costs, research-related manufacturing costs, contract service and clinical-related service costs performed by third party research organizations, research institutions and other outside service providers. Non-refundable prepayments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are recognized as an expense as the related goods are delivered or the related services are performed. We also utilize significant judgment and estimates to record accruals for estimated ongoing research costs based on the progress of the studies and progress of research manufacturing activities.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Interest Expense on Deferred Royalty Obligation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Interest expense related to the deferred royalty obligation is recognized over the expected repayment term of the deferred royalty obligation using the effective interest method. The assumptions used in determining the expected repayment term of the deferred royalty obligation require us to make estimates that could impact the effective interest rate. Each reporting period, we estimate the expected repayment term of the deferred royalty obligation based on forecasted net sales of GIAPREZA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. Changes in interest expense resulting from changes in the effective interest rate, if any, are recorded on a prospective basis. Refer to Note 12, &#x201c;Debt&#x201d;, for more information.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Fair Value of Stock&#x2011;Based Compensation Awards&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We use the Black-Scholes-Merton option pricing model to estimate the fair value of options granted under our equity incentive plans and rights to acquire stock granted under our employee stock purchase plan (&#x201c;ESPP&#x201d;). The Black-Scholes-Merton option valuation model requires the use of assumptions, including the expected term of the award and the expected stock price volatility. We use the &#x201c;simplified&#x201d; method as described in Staff Accounting Bulletin No. 107, &#x201c;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Share-Based Payment&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;,&#x201d; for the expected option term. We use our historical volatility to estimate expected stock price volatility.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Restricted stock units (&#x201c;RSUs&#x201d;) and restricted stock awards (&#x201c;RSAs&#x201d;) are measured based on the fair market values of the underlying stock on the dates of grant.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Stock-based compensation expense is calculated based on awards ultimately expected to vest and is reduced for estimated forfeitures at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differed from those estimates. Our estimated annual forfeiture rates for stock options, RSUs and RSAs are based on our historical forfeiture experience.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The estimated fair value of stock options, RSUs and RSAs is expensed on a ratable or straight-line basis over the expected term of the grant or expected term of the vesting. Compensation expense is recorded over the requisite service period based on management&#x2019;s best estimate as to whether it is probable that the shares awarded are expected to vest.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Compensation expense for purchases under the ESPP is recognized based on the fair value of the common stock on the date of offering, less the purchase discount percentage provided for in the plan.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We utilize the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and the tax basis of assets and liabilities and are measured using enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The recognition and measurement of tax benefits requires significant judgment. Our judgment might change as new information becomes available. We continue to evaluate our deferred tax assets each reporting period to determine whether adjustments to our valuation allowance are required and deferred tax assets will be realized based on the consideration of all available positive and negative evidence, including the differences between our anticipated and actual future operating results, using a &#x201c;more likely than not&#x201d; standard.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We assess all material positions taken in any income tax return, including all significant uncertain positions, in all tax years that are still subject to assessment or challenge by relevant taxing authorities. Assessing an uncertain tax position begins with the initial determination of the position&#x2019;s sustainability and is measured at the largest amount of benefit that is greater than 50% likely to be realized upon ultimate settlement. As of each balance sheet date, unresolved uncertain tax positions must be reassessed, and we determine whether the factors underlying the sustainability assertion have changed and whether the amount of the recognized tax benefit is still appropriate.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Related Parties&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Transactions with GSK were considered related party transactions up until May 2021, when we completed the share repurchase agreement with GSK to buy back all of its shares of common stock in Innoviva. GSK is no longer considered a related party after the completion of the share repurchase. Transactions with GSK are described in Note 3, &#x201c;Revenue Recognition and Collaborative Arrangements.&#x201d;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Sarissa Capital ow&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ned &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of o&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ur outstanding common stock as of December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. Transactions with Sarissa Capital are described in Note 5, &#x201c;Consolidated Entities and Acquisitions&#x201d;. Sarissa Capital is considered to be a related party because two of its principals are members of our board of directors.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Recently Issued Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In October 2023, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued ASU 2023-06, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Disclosure Improvements: Codification Amendments in Response to the SEC&#x2019;s Disclosure Update and Simplification Initiative&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The amendment modifies the disclosure or presentation requirements for a variety of topics. The effective date for each amendment will be the date on which the SEC&#x2019;s removal of that related disclosure from Regulation S-X or Regulation S-K becomes effective. The Company does not expect the adoption of the amendments to have a significant impact on its financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In November 2023, the FASB issued ASU 2023-07, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Improvements to Reportable Segment Disclosures (Topic 280).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; This ASU update requires enhanced segment disclosures, primarily related to significant segment expenses. The amendments are effective for fiscal years beginning after December 15, 2023, and interim periods beginning after December 15, 2024. The Company does not expect the adoption of the amendments to have a significant impact on its financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In December 2023, the FASB issued ASU 2023-09, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Improvements to Income Tax Disclosures (Topic 740)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The ASU requires the disclosure of income taxes paid disaggregated by jurisdiction and enhanced disclosures for the entity&#x2019;s effective tax rate reconciliation as well as other income tax related disclosures. The ASU is effective on a prospective basis for annual periods beginning after December 15, 2024. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company does not expect the adoption of the amendments to have a significant impact on its financial statements.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <inva:DescriptionOfOperationsPolicyTextBlock
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      id="F_7b7cc444-2c88-4637-bcd6-1b6a2a675f16">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Description of Operations&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Innoviva, Inc. (and where context requires, together with its subsidiaries referred to as &#x201c;Innoviva&#x201d;, the &#x201c;Company&#x201d;, or &#x201c;we&#x201d; and other similar pronouns) is a company with a portfolio of royalties and innovative healthcare assets. Our royalty portfolio contains respiratory assets partnered with Glaxo Group Limited (&#x201c;GSK&#x201d;), including RELVAR&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;/BREO&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; ELLIPTA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;(fluticasone furoate/vilanterol, &#x201c;FF/VI&#x201d;) and ANORO&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; ELLIPTA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;(umeclidinium bromide/vilanterol, &#x201c;UMEC/VI&#x201d;), and up until July 2022, TRELEGY&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; ELLIPTA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;(the combination FF/UMEC/VI). We sold our &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% ownership interest in Theravance Respiratory Company, LLC (&#x201c;TRC&#x201d;) on July 20, 2022, and are no longer entitled to receive royalties on sales of TRELEGY&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; ELLIPTA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; products. Under the Long-Acting Beta2 Agonist (&#x201c;LABA&#x201d;) Collaboration Agreement, Innoviva is entitled to receive royalties from GSK on sales of RELVAR&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;/BREO&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; ELLIPTA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; as follows: &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% on the first $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; billion of annual global net sales and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% for all annual global net sales above $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; billion; and royalties from the sales of ANORO&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; ELLIPTA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, which tier upward at a range from &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We expanded our portfolio through the acquisition of Entasis Therapeutics Holdings Inc. (&#x201c;Entasis&#x201d;) on July 11, 2022 and the acquisition of La Jolla Pharmaceutical Company (&#x201c;La Jolla&#x201d;) on August 22, 2022. Our commercial and marketed products include GIAPREZA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;(angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock, and XERAVA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; (eravacycline) for the treatment of complicated intra-abdominal infections in adults. Our new product, XACDURO&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;(formerly known as sulbactam-durlobactam or SUL-DUR), was approved by the United States Food and Drug Administration (&#x201c;FDA&#x201d;) for the treatment of hospital-acquired and ventilator-associated pneumonias caused by &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Acinetobacter&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; in adults on May 23, 2023. We commenced commercial sales of XACDURO&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; in the third quarter of 2023. Our development pipeline includes zoliflodacin, an investigational treatment for uncomplicated gonorrhea that reported positive data in a pivotal Phase 3 clinical trial on November 1, 2023. As such, we have a wholly owned robust critical care and infectious disease operating platform with a hospital focus anchored by three differentiated products with significant growth potential and a promising drug candidate.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In addition, we own other strategic healthcare assets, such as a large equity stake in Armata Pharmaceuticals, a leader in development of bacteriophages with potential use across a range of infectious and other serious diseases.  We also have economic interests in other healthcare companies.&lt;/span&gt;&lt;/p&gt;</inva:DescriptionOfOperationsPolicyTextBlock>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="C_c174b897-ce7b-41b0-af4e-37c1c1527fe2"
      decimals="2"
      id="F_8f5d0c75-3e54-4cfa-9848-e472efd28cfa"
      unitRef="U_pure">0.15</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <inva:CollaborativeArrangementRoyaltyRateDefinedLevelOne
      contextRef="C_f6067cb4-1702-418f-8410-c3ff025f386d"
      decimals="2"
      id="F_640254d7-8501-4ea0-b707-2725feb01ab5"
      unitRef="U_pure">0.15</inva:CollaborativeArrangementRoyaltyRateDefinedLevelOne>
    <inva:CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate
      contextRef="C_f6067cb4-1702-418f-8410-c3ff025f386d"
      decimals="-8"
      id="F_998046ac-17be-4028-87b5-663550d44e5d"
      unitRef="U_USD">3000000000</inva:CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate>
    <inva:CollaborativeArrangementRoyaltyRateDefinedLevelTwo
      contextRef="C_f6067cb4-1702-418f-8410-c3ff025f386d"
      decimals="2"
      id="F_71016d37-68c2-42c9-853d-f2b5325247e7"
      unitRef="U_pure">0.05</inva:CollaborativeArrangementRoyaltyRateDefinedLevelTwo>
    <inva:CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate
      contextRef="C_f6067cb4-1702-418f-8410-c3ff025f386d"
      decimals="-8"
      id="F_7f0a0c8c-60d9-456a-8c83-7ceb3e41ce31"
      unitRef="U_USD">3000000000</inva:CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate>
    <inva:CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts
      contextRef="C_4ad76130-0d29-47d9-b811-82b396d4ef22"
      decimals="3"
      id="F_19cf5fea-829d-41fa-a50e-269500fa025b"
      unitRef="U_pure">0.065</inva:CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts>
    <inva:CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts
      contextRef="C_76103f21-39aa-4d6c-bd6a-47f7c57f423e"
      decimals="2"
      id="F_76b41daf-5f41-4065-b768-a7b6a53cd714"
      unitRef="U_pure">0.10</inva:CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      id="F_47dc3248-be8d-422b-829d-29c6580d93bd">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Principles of Consolidation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The accompanying consolidated financial statements include the accounts of Innoviva, our wholly owned subsidiaries and certain variable interest entities (&#x201c;VIE&#x201d;) for which we are the primary beneficiary. All intercompany balances and transactions have been eliminated in consolidation. For consolidated entities where we own or are exposed to less than 100% of the economics, we record net income (loss) attributable to noncontrolling interest in our consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entity by the respective noncontrolling party.&lt;/span&gt;&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <inva:PresentationReclassificationPolicyTextBlock
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      id="F_af53be47-b269-4e11-8df5-b5a8d3a88818">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Presentation Reclassification&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Amounts in equity and long-term investments reported in the Company&#x2019;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;s comparative financial statements have been reclassified to conform to the current year presentation. Certain reclassifications have been made to the consolidated statement of cash flows for the years ended December 31, 2022 and 2021 to conform to the current year&#x2019;s presentation. These reclassifications had no net effect on the net income or net cash flows from operating, investing and financing activities as previously reported.&lt;/span&gt;&lt;/p&gt;</inva:PresentationReclassificationPolicyTextBlock>
    <inva:FactorsAffectingComparabilityPolicyTextBlock
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      id="F_7208c56b-8e73-4abb-8b7a-b7498c4c313c">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Factors Affecting Comparability&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Our historical financial condition and results of operations for the periods presented may not be comparable, either between periods or going forward due to the factors below and as discussed in Note 5, &#x201c;Consolidated Entities and Acquisitions&#x201d;.&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Adoption of Accounting Standards Update 2020-06, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Debt-Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; (&#x201c;ASU 2020-06&#x201d;) effective January 1, 2022;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accounting consolidation of Entasis on February 17, 2022 and purchase of remaining noncontrolling interest in Entasis on July 11, 2022;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Sale of our &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% ownership interest in TRC on July 20, 2022; and&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Acquisition of La Jolla on August 22, 2022.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;</inva:FactorsAffectingComparabilityPolicyTextBlock>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="C_c174b897-ce7b-41b0-af4e-37c1c1527fe2"
      decimals="2"
      id="F_752d2676-28b3-4d20-bbbb-39ed4e890c88"
      unitRef="U_pure">0.15</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:UseOfEstimates
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      id="F_e8d95709-9233-4f94-acd3-9f3aa79bf306">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Use of Management&#x2019;s Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The preparation of consolidated financial statements in conformity with U.S. Generally Accepted Accounting Principles (&#x201c;U.S. GAAP&#x201d;) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ materially from those estimates. Management evaluates its significant accounting policies and estimates on an ongoing basis. We base our estimates on historical experience and other relevant assumptions that we believe to be reasonable under the circumstances. These estimates also form the basis for making judgments about the carrying values of assets and liabilities when these values are not readily apparent from other sources.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      id="F_70cd2a6b-6af1-487f-a6a3-dc3b3b569723">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Concentrations of Credit Risk and of Significant Suppliers and Partners&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Our financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents and equity and long-term investments. Although we deposit our cash with multiple financial institutions, our deposits, at times, may exceed federally insured limits.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; We are dependent on third-party manufacturers to supply active pharmaceutical ingredients (&#x201c;API&#x201d;) and drug products for research and development and commercial programs. These programs could be adversely affected by significant interruption in the supply of API or drug products.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Currently, we derive most of our revenues from GSK and our near-term success depends in large part on GSK&#x2019;s ability to successfully develop and commercialize the products in the respiratory programs partnered with GSK. Our near-term success depends in large part upon the performance by GSK of its commercial obligations under the GSK Agreements and the commercial success of RELVAR&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;/BREO&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; ELLIPTA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and ANORO&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; ELLIPTA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. If GSK does not devote sufficient resources to the commercialization or development of these products, is unsuccessful in its efforts, or chooses to reprioritize its commercial programs, our business would be materially harmed. GSK is responsible for all clinical and other product development, regulatory, manufacturing and commercialization activities for products developed under the GSK Agreements, including RELVAR&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;/BREO&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; ELLIPTA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and ANORO&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; ELLIPTA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. Our royalty revenues may fluctuate due to a variety of factors, many of which are outside of our control. Our royalty revenues under the GSK Agreements may not meet our, analysts&#x2019; or investors&#x2019; expectations, due to a number of important factors.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We started recognizing revenue from product sales of GIAPREZA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and XERAVA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; in 2022 as a result of our acquisition of La Jolla. In the current year, we also started recognizing revenue from product sales from XACDURO&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, which was commercially launched in the third quarter of 2023. Hospitals and other healthcare organizations generally purchase our products through a network of specialty distributors. These specialty distributors, which are located in the U.S., are considered our customers for accounting purposes. We do not believe that loss of one of these distributors would significantly impact our ability to distribute our products, as we expect that sales volume would be absorbed by new or remaining distributors. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Three&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; of our customers each account for &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;31&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%, respectively, of our net product sales for the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. These same customers account for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;29&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%, respectively, of our receivables from net product sales, which are included in &#x201c;Accounts receivables, net&#x201d; in our consolidated balance sheet as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; Three of our customers each account for approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;33&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;29&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;28&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%, respectively, of our net product sales from the time of our acquisition of La Jolla through December 31, 2022. These same customers account for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;23&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;37&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;37&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%, respectively, of our receivables from net product sales, which are included in &#x201c;Accounts receivables, net&#x201d; in our consolidated balance sheet as of December 31, 2022.&lt;/span&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <inva:NumberOfCustomers
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="0"
      id="F_08df0bb2-419d-420c-8c31-58812f567049"
      unitRef="U_Customer">3</inva:NumberOfCustomers>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_2e71015c-4917-4b0c-8a50-046d7e6f4812"
      decimals="2"
      id="F_9f0d2626-a35a-4d73-ab4a-a5d6b6d20392"
      unitRef="U_pure">0.31</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_d05dfc5c-b948-4497-8849-a42784e9f325"
      decimals="2"
      id="F_d741bc3b-4a84-43ae-8118-1b35cfd6615b"
      unitRef="U_pure">0.27</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_962daa42-70a2-4386-b932-c071d02f40c5"
      decimals="2"
      id="F_080c047a-9518-46ab-a307-d2d7a53dc005"
      unitRef="U_pure">0.27</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_cd17c19c-ec63-4e2e-b6da-1c56d9be380d"
      decimals="2"
      id="F_cd11c345-76c6-4bee-8d20-91c0bc57d554"
      unitRef="U_pure">0.29</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_e6d12e36-aff4-4dc6-81a3-899ea1f5910b"
      decimals="2"
      id="F_3f20e9de-7d82-4914-a738-8b5986d57ba7"
      unitRef="U_pure">0.19</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_2f7d8e77-eb63-419b-ad16-1ac5905b61e3"
      decimals="2"
      id="F_412ece57-8c86-4768-8fe0-fc760b7bdec3"
      unitRef="U_pure">0.15</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_653aae1f-7476-41b2-a55d-7986566e9db4"
      decimals="2"
      id="F_7660e461-485c-430c-986a-52778a270525"
      unitRef="U_pure">0.33</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_36943c71-452d-4fbb-8d19-9e8b848cee67"
      decimals="2"
      id="F_3b93afe4-f15e-4e0e-9737-871a497390fa"
      unitRef="U_pure">0.29</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_e414574e-4c06-4df7-8940-8de9bca1b108"
      decimals="2"
      id="F_4d2478b1-a04e-4a11-ba96-3c67561423ed"
      unitRef="U_pure">0.28</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_1ed70a12-64b7-49e4-b68e-70f274537beb"
      decimals="2"
      id="F_39ae346a-6acc-478c-879c-b61e3f8348b4"
      unitRef="U_pure">0.23</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_833ede43-b30a-4e04-a7aa-1d2f47880788"
      decimals="2"
      id="F_5f015bc8-f371-4477-82b0-60cf502b9eeb"
      unitRef="U_pure">0.37</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_b022e036-d13c-4fc8-94e9-00734a572b9c"
      decimals="2"
      id="F_cfb785a2-8c9b-4af4-b6d3-af7b6931ff7d"
      unitRef="U_pure">0.37</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      id="F_2f042a3c-256e-4cd4-aa53-98d9bd532ab7">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Segment Reporting&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We operate in a single segment, which is to provide capital return to stockholders by maximizing the potential value of our portfolio of royalties and innovative healthcare assets. Our Chief Operating Decision Maker (&#x201c;CODM&#x201d;) is our Chief Executive Officer. The CODM allocates resources and evaluates the performance of Innoviva at the consolidated level using information about our revenues, operating results and other key financial data as needed. Our revenues are generated primarily from our collaborative arrangements and royalty payments from GSK, located in Great Britain. We also generate revenue from net product sales of GIAPREZA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, XERAVA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, and XACDURO&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Refer to Note 3, &#x201c;Revenue Recognition&#x201d;, for more information on our revenues for the periods presented. Our long-term assets are located within the United States.&lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationVariableInterestEntityPolicy
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      id="F_750af2c7-4413-4369-9e6b-32fd5f03b7f7">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Variable Interest Entities&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The primary beneficiary of a variable interest entity (&#x201c;VIE&#x201d;) is required to consolidate the assets and liabilities of the VIE. When we obtain a variable interest in another entity, we assess at the inception of the relationship and upon occurrence of certain significant events whether the entity is a VIE and, if so, whether we are the primary beneficiary of the VIE based on our power to direct the activities of the VIE that most significantly impact the VIE&#x2019;s economic performance and our obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;To assess whether we have the power to direct the activities of a VIE that most significantly impact the VIE&#x2019;s economic performance, we consider all the facts and circumstances, including our role in establishing the VIE and our ongoing rights and responsibilities. This assessment includes identifying the activities that most significantly impact the VIE&#x2019;s economic performance and identifying which party, if any, has power over those activities. In general, the parties that make the most significant decisions affecting the VIE (management and representation on the Board of Directors) and have the right to unilaterally remove those decision-makers are deemed to have the power to direct the activities of a VIE.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;To assess whether we have the obligation to absorb losses of the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE, we consider all of our economic interests that are deemed to be variable interests in the VIE. This assessment requires us to apply judgment in determining whether these interests, in the aggregate, are considered potentially significant to the VIE.&lt;/span&gt;&lt;/p&gt;</us-gaap:ConsolidationVariableInterestEntityPolicy>
    <us-gaap:BusinessCombinationsPolicy
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      id="F_60237007-3ab7-4e9d-9a49-1242e8557761">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Business Combination&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;When we acquire an entity in a business combination, we recognize the fair value of all assets acquired, liabilities assumed, and any non-controlling interest in the acquiree and establish the acquisition date as the fair value measurement point. We recognize and measure goodwill as of the acquisition date, as the excess of the fair value of the consideration paid over the fair value of the identified net assets acquired. Acquisition-related expenses and related restructuring costs are expensed as incurred.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; Several valuation methods may be used to determine the fair value of assets acquired and liabilities assumed. For intangible assets, we typically use the income method. This method starts with a forecast of all of the expected future net cash flows for each asset. These cash flows are then adjusted to present value by applying an appropriate discount rate that reflects the risk factors associated with the cash flow streams. Some of the more significant estimates and assumptions inherent in the income method or other methods include the amount and timing of projected future cash flows, the discount rate selected to measure the risks inherent in the future cash flows and the assessment of the asset&#x2019;s life cycle and the competitive trends impacting the asset, including consideration of any technical, legal, regulatory, or economic barriers to entry. Determining the useful life of an intangible asset also requires judgment as different types of intangible assets will have different useful lives and certain assets may even be considered to have indefinite useful lives.&lt;/span&gt;&lt;/p&gt;</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      id="F_bbe3fa22-84dd-4ed4-b1f6-a5e19d1ce9e0">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We consider all highly liquid investments purchased with a maturity of three months or less on the date of purchase to be cash equivalents. Cash equivalents are carried at cost, which approximates fair value.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      id="F_f5f60045-8b03-4671-8bad-07bd15364b07">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Accounts Receivable&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accounts receivable are recorded net of estimates for prompt-pay discounts, chargebacks, returns and rebates. Allowances for prompt-pay discounts and chargebacks are based on contractual terms. We estimate the allowance for credit losses based on existing contractual payment terms, actual payment patterns of customers and individual customer circumstances.&lt;/span&gt;&lt;/p&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      id="F_27ba5c5f-c74c-4ac2-8eb9-84e3ba818800">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Inventory&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Inventory is stated at the lower of cost or estimated net realizable value on a first-in, first-out basis. We periodically analyze inventory levels and write down inventory as cost of products sold when the following occurs: inventory has become obsolete, inventory has a cost basis in excess of its estimated net realizable value, or inventory quantities are in excess of expected product sales.&lt;/span&gt;&lt;/p&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      id="F_68f130f2-5a67-4a4c-9cf6-9b46f8ed4127">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Property and Equipment&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Property and equipment, which consisted of laboratory equipment, computer equipment, software, office furniture and fixtures, and leasehold improvements, were not material as of December 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Property and equipment are stated at cost less accumulated depreciation. Property and equipment are depreciated using the straight-line method &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;over the estimated useful lives of the respective assets as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:49.17%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.66%;"&gt;&lt;/td&gt;
          &lt;td style="width:49.17%;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Shorter of remaining lease terms or useful life&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Laboratory equipment, furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#x2013; &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Software and computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <inva:PropertyPlantAndEquipmentUsefulLifeTableTextBlock
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      id="F_28e3498e-d426-4875-940e-d44a23e1aae9">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Property and equipment are stated at cost less accumulated depreciation. Property and equipment are depreciated using the straight-line method &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;over the estimated useful lives of the respective assets as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:49.17%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.66%;"&gt;&lt;/td&gt;
          &lt;td style="width:49.17%;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Shorter of remaining lease terms or useful life&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Laboratory equipment, furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#x2013; &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Software and computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;</inva:PropertyPlantAndEquipmentUsefulLifeTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_1007c8ce-c961-4336-8299-5ed88a88849d"
      id="F_2b184ea1-eed9-43d8-8128-e1a13c46f0a1">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_441daf0e-a05d-414c-8eaa-feeb49fa7590"
      id="F_3c92dda5-0a4c-48a3-83b4-4dd8a79443c7">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_e642beae-c7bf-4bc4-9ebd-c58d6623dfc5"
      id="F_86319735-82e7-49c4-8b17-9a1a34f92f8b">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:EquityMethodInvestmentsPolicy
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      id="F_2eb58c07-7a9a-446e-88dd-ab6ce9994009">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Equity and Long-Term Investments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We invest from time to time in equity and debt securities of private or public companies. If we determine that we have control over these companies under either voting or VIE models, we consolidate them in our consolidated financial statements. If we determine that we do not have control over these companies under either voting or VIE models, we then determine if we have an ability to exercise significant influence via voting interests, board representation or other business relationships.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We may account for the investments where we exercise significant influence using either an equity method of accounting or at fair value by electing the fair value option under Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 825, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. If the fair value option is applied to an investment that would otherwise be accounted for under the equity method, we apply it to all our financial interests in the same entity (equity and debt, including guarantees) that are eligible items. All gains and losses from fair value changes, unrealized and realized, are presented as changes in fair values of equity method investments, net, and changes in fair values of equity and long-term investments, net, within the consolidated statements of income.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;If we conclude that we do not have an ability to exercise significant influence over an investee, we may elect to account for the security without a readily determinable fair value using the measurement alternative method under ASC 321, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Investments &#x2013; Equity Securities&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. This measurement alternative method allows us to measure the equity investment at its cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We also invest in ISP Fund LP, which investments consist of money market funds and equity and debt securities in the healthcare, pharmaceutical and biotechnology industries. Pursuant to the Partnership Agreement entered in December 2020, we became a limited partner of this partnership, and our contributions are subject to a 36-month lock-up period, which restriction prevents us from having control and access to the contributions and related investments. The lock-up period for a certain portion of our contributions expired in December 2023. Strategic Partners did not elect to make a withdrawal in 2023, thereby extending the lock-up period and withdrawal elections into subsequent years. These investments are classified as long-term investments in the consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;</us-gaap:EquityMethodInvestmentsPolicy>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      id="F_e09aa6ff-8afc-4933-a18a-a9eadea24f10">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We define fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Our valuation techniques are based on observable and unobservable inputs. Observable inputs reflect readily obtainable data from independent sources, while unobservable inputs reflect our market assumptions. We classify these inputs into the following hierarchy:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;Quoted prices for identical instruments in active markets.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;Quoted prices for similar instruments in active markets; quoted prices for identical 3or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;Unobservable inputs and little, if any, market activity for the assets.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Financial instruments include cash equivalents, accounts receivable, receivables from collaborative arrangements, accounts payable, and accrued liabilities, equity investments and convertible promissory notes. The carrying values of cash equivalents, receivables from collaborative arrangements, accounts payable, and accrued liabilities approximate their estimated fair values due to the relatively short-term nature of these instruments.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <inva:CapitalizedFeesPaidPolicyTextBlock
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      id="F_96873202-6912-4d6a-b263-9f78d2ceea15">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Capitalized Fees Paid&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We capitalize fees paid to licensors related to agreements for approved products or commercialized products. We capitalize these fees as capitalized fees paid (&#x201c;Capitalized Fees&#x201d;) and amortize them on a straight-line basis over their estimated useful lives upon the commercial launch of the product, shortly after its regulatory approval. The estimated useful lives of these Capitalized Fees are determined on a country-by-country and product-by-product basis, as the later of the expiration or termination of the last patent right covering the compound in such product in such country and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;15 years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; from first commercial sale of such product in such country, unless the Collaboration Agreement is terminated earlier. Consistent with our policy for classification of costs under the research and development collaborative arrangements, the amortization of these Capitalized Fees is recognized as a reduction of royalty revenue. We review our Capitalized Fees for impairment on a product-by-product basis for each major geographic area when events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. The recoverability of Capitalized Fees is measured by comparing the asset&#x2019;s carrying amount to the expected undiscounted future cash flows that the asset is expected to generate. The determination of recoverability typically requires various estimates and assumptions, including estimating the useful life over which cash flows will occur, their amount, and the asset&#x2019;s residual value, if any. We derive the required cash flow estimates from near-term forecasted product sales and long-term projected sales in the corresponding market.&lt;/span&gt;&lt;/p&gt;</inva:CapitalizedFeesPaidPolicyTextBlock>
    <inva:CapitalizedFeePaidEstimatedUsefulLife
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      id="F_ebd92070-d818-4ceb-b80e-4a89028114fc">P15Y</inva:CapitalizedFeePaidEstimatedUsefulLife>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      id="F_d887635f-29a6-4e91-8d64-6c2fa3e8b97b">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Goodwill and Intangible Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Goodwill is recognized as the excess of the purchase consideration of an acquired entity over the fair value assigned to assets acquired and liabilities assumed in a business combination. Goodwill and intangible assets with indefinite useful life are not amortized and are tested for impairment at least annually on the first day of December of each year&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; or more frequently if indicators for potential impairment exist or whenever events or changes in circumstances indicate that the asset&#x2019;s carrying asset amount may not be recoverable. Intangible assets with definite useful lives are amortized on a straight-line basis over their respective remaining useful lives and are tested for impairment only if indicators for potential impairment exist or whenever events or changes in circumstances indicate that the asset&#x2019;s carrying amount may not be recoverable. Significant judgment may be involved in determining if an indicator of impairment has occurred.&lt;/span&gt;&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      id="F_45994672-35c0-45c0-a2eb-d03c927a3b71">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Operating Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Right-of-use assets represent our right to use an underlying asset over the lease term and include any lease payments made prior to the lease commencement date and are reduced by lease incentives. Lease liabilities represent the present value of the total lease payments over the lease term, calculated using an estimated incremental borrowing rate. Lease expense is recognized on a straight-line basis over the expected lease term.&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      id="F_fbfd1e4c-e97e-4272-bb50-f1cd739e15fc">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Revenue Recognition&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We apply the guidance on principal versus agent considerations under ASC Topic 606, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, to determine the appropriate treatment for the transactions between us and third parties. The classification of transactions under our arrangements is determined based on the nature and contractual terms of the arrangement along with the nature of the operations of the participants. Any consideration related to activities in which we are considered the principal, which includ&lt;/span&gt;&lt;span style="color:#252525;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;es being in control of the good or service before such good or service is transferred to the customer, are accounted for as product sales.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Revenue is recognized when our customer obtains control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. Revenue is recognized through a five-step process: (i) identify the contract with the customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price for the contract; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue as a performance obligation is satisfied.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Royalty Revenue&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We recognize the royalty revenue on net sales of products with respect to which we have contractual royalty rights in the period in which the royalties are earned. The net sales reports provided by our partner are based on its methodology and assumptions to estimate rebates and returns, which it monitors and adjusts regularly in light of contractual and legal obligations, historical trends, past experience and projected market conditions. Our partner may make significant adjustments to its sales based on actual results recorded, which could cause our royalty revenue to fluctuate. We conduct periodic royalty audits to evaluate the information provided by our partner. Royalties are recognized net of amortization of capitalized fees associated with any approval and launch milestone payments made to GSK.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Revenue from Product Sales&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; Revenue from product sales is recognized when our customers obtain control of the product and is recorded at the transaction price, net of estimates for variable consideration consisting of chargebacks, discounts, returns and rebates. Variable consideration is estimated using the expected-value amount method, which is the sum of probability-weighted amounts in a range of possible consideration amounts. Actual amounts of consideration ultimately received may differ from our estimates. If actual results vary materially from our estimates, we will adjust these estimates, which will affect revenue from product sales and earnings in the period such estimates are adjusted. These items may include:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Chargebacks: Chargebacks are discounts we provide to distributors in the event that the sales prices to end users are below the distributors&#x2019; acquisition price. This may occur due to a direct contract with a health system, a group purchasing organization (&#x201c;GPO&#x201d;) agreement or a sale to a government facility. Chargebacks are estimated based on known chargeback rates and recorded as a reduction of revenue on delivery to our customers.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Discounts: We offer customers various forms of incentives and consideration, including prompt-pay and other discounts. We estimate discounts primarily based on contractual terms. These discounts are recorded as a reduction of revenue on delivery to our customers.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Returns: We offer customers a limited right of return, generally for damaged or expired product. We estimate returns based on an internal analysis, which includes actual experience. The estimates for returns are recorded as a reduction of revenue on delivery to our customers. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Rebates: We participate in Medicaid rebate programs, which provide assistance to certain low-income patients based on each individual state&#x2019;s guidelines regarding eligibility and services. Under the Medicaid rebate programs, we pay a rebate to each participating state, generally within three months after the quarter in which product was sold. Additionally, we may offer customer incentives and consideration in the form of volume-based or other rebates. The estimates for rebates are recorded as a reduction of revenue on delivery to our customers. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We continue to assess our estimates of variable consideration as we accumulate additional historical data and will adjust these estimates accordingly.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;License Revenue&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;At the inception of a licensing arrangement that includes development and regulatory milestone payments, we evaluate whether the milestones are considered probable of being achieved and estimate the amount to be included in the transaction price. We generally recognize these milestone payments as revenues when they are achieved because there is considerable uncertainty in the research and development processes that trigger receipt of these payments under our agreements. Similarly, we recognize regulatory approval milestone payments as revenues once the product is approved by the applicable regulatory agency.&lt;/span&gt;&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      id="F_8fe11a65-c96b-4a35-a205-c955a291a15a">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Research and Development Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Research and development expenses are recognized in the period that services are rendered or goods are received. Research and development expenses consist of salaries and benefits, laboratory supplies, facilities and other overhead costs, research-related manufacturing costs, contract service and clinical-related service costs performed by third party research organizations, research institutions and other outside service providers. Non-refundable prepayments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are recognized as an expense as the related goods are delivered or the related services are performed. We also utilize significant judgment and estimates to record accruals for estimated ongoing research costs based on the progress of the studies and progress of research manufacturing activities.&lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:InterestExpensePolicyTextBlock
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      id="F_674ad6c0-0f51-41fb-ab78-32d3358e9c48">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Interest Expense on Deferred Royalty Obligation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Interest expense related to the deferred royalty obligation is recognized over the expected repayment term of the deferred royalty obligation using the effective interest method. The assumptions used in determining the expected repayment term of the deferred royalty obligation require us to make estimates that could impact the effective interest rate. Each reporting period, we estimate the expected repayment term of the deferred royalty obligation based on forecasted net sales of GIAPREZA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. Changes in interest expense resulting from changes in the effective interest rate, if any, are recorded on a prospective basis. Refer to Note 12, &#x201c;Debt&#x201d;, for more information.&lt;/span&gt;&lt;/p&gt;</us-gaap:InterestExpensePolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      id="F_0d447386-b511-4236-95ea-236d9a7671a8">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Fair Value of Stock&#x2011;Based Compensation Awards&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We use the Black-Scholes-Merton option pricing model to estimate the fair value of options granted under our equity incentive plans and rights to acquire stock granted under our employee stock purchase plan (&#x201c;ESPP&#x201d;). The Black-Scholes-Merton option valuation model requires the use of assumptions, including the expected term of the award and the expected stock price volatility. We use the &#x201c;simplified&#x201d; method as described in Staff Accounting Bulletin No. 107, &#x201c;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Share-Based Payment&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;,&#x201d; for the expected option term. We use our historical volatility to estimate expected stock price volatility.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Restricted stock units (&#x201c;RSUs&#x201d;) and restricted stock awards (&#x201c;RSAs&#x201d;) are measured based on the fair market values of the underlying stock on the dates of grant.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Stock-based compensation expense is calculated based on awards ultimately expected to vest and is reduced for estimated forfeitures at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differed from those estimates. Our estimated annual forfeiture rates for stock options, RSUs and RSAs are based on our historical forfeiture experience.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The estimated fair value of stock options, RSUs and RSAs is expensed on a ratable or straight-line basis over the expected term of the grant or expected term of the vesting. Compensation expense is recorded over the requisite service period based on management&#x2019;s best estimate as to whether it is probable that the shares awarded are expected to vest.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Compensation expense for purchases under the ESPP is recognized based on the fair value of the common stock on the date of offering, less the purchase discount percentage provided for in the plan.&lt;/span&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      id="F_64c72857-68f1-43d2-bb76-0335abec8aff">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We utilize the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and the tax basis of assets and liabilities and are measured using enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The recognition and measurement of tax benefits requires significant judgment. Our judgment might change as new information becomes available. We continue to evaluate our deferred tax assets each reporting period to determine whether adjustments to our valuation allowance are required and deferred tax assets will be realized based on the consideration of all available positive and negative evidence, including the differences between our anticipated and actual future operating results, using a &#x201c;more likely than not&#x201d; standard.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We assess all material positions taken in any income tax return, including all significant uncertain positions, in all tax years that are still subject to assessment or challenge by relevant taxing authorities. Assessing an uncertain tax position begins with the initial determination of the position&#x2019;s sustainability and is measured at the largest amount of benefit that is greater than 50% likely to be realized upon ultimate settlement. As of each balance sheet date, unresolved uncertain tax positions must be reassessed, and we determine whether the factors underlying the sustainability assertion have changed and whether the amount of the recognized tax benefit is still appropriate.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <inva:RelatedPartyTransactionsPolicyTextBlock
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      id="F_82807c29-eedd-4d77-9512-f02652bc2d62">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Related Parties&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Transactions with GSK were considered related party transactions up until May 2021, when we completed the share repurchase agreement with GSK to buy back all of its shares of common stock in Innoviva. GSK is no longer considered a related party after the completion of the share repurchase. Transactions with GSK are described in Note 3, &#x201c;Revenue Recognition and Collaborative Arrangements.&#x201d;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Sarissa Capital ow&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ned &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of o&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ur outstanding common stock as of December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. Transactions with Sarissa Capital are described in Note 5, &#x201c;Consolidated Entities and Acquisitions&#x201d;. Sarissa Capital is considered to be a related party because two of its principals are members of our board of directors.&lt;/span&gt;&lt;/p&gt;</inva:RelatedPartyTransactionsPolicyTextBlock>
    <inva:RelatedPartyTransactionCommonStockOwnershipPercentageByRelatedParty
      contextRef="C_175d99d3-70ac-4ebe-93be-8247d1fbe50e"
      decimals="3"
      id="F_b23bbcc6-6ff7-4df7-84d9-a66bd22d97a1"
      unitRef="U_pure">0.115</inva:RelatedPartyTransactionCommonStockOwnershipPercentageByRelatedParty>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      id="F_29d6250d-2087-410c-901a-06da38b802bb">&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Recently Issued Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In October 2023, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued ASU 2023-06, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Disclosure Improvements: Codification Amendments in Response to the SEC&#x2019;s Disclosure Update and Simplification Initiative&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The amendment modifies the disclosure or presentation requirements for a variety of topics. The effective date for each amendment will be the date on which the SEC&#x2019;s removal of that related disclosure from Regulation S-X or Regulation S-K becomes effective. The Company does not expect the adoption of the amendments to have a significant impact on its financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In November 2023, the FASB issued ASU 2023-07, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Improvements to Reportable Segment Disclosures (Topic 280).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; This ASU update requires enhanced segment disclosures, primarily related to significant segment expenses. The amendments are effective for fiscal years beginning after December 15, 2023, and interim periods beginning after December 15, 2024. The Company does not expect the adoption of the amendments to have a significant impact on its financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In December 2023, the FASB issued ASU 2023-09, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Improvements to Income Tax Disclosures (Topic 740)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The ASU requires the disclosure of income taxes paid disaggregated by jurisdiction and enhanced disclosures for the entity&#x2019;s effective tax rate reconciliation as well as other income tax related disclosures. The ASU is effective on a prospective basis for annual periods beginning after December 15, 2024. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company does not expect the adoption of the amendments to have a significant impact on its financial statements.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      id="F_2211db62-b1a5-43a2-a723-e35e93a52a25">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2.  NET INCOME PER SHARE&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Basic net income per share attributable to Innoviva stockholders is computed by dividing net income attributable to Innoviva stockholders by the weighted-average number of shares of common stock outstanding. Diluted net income per share attributable to Innoviva stockholders is computed by dividing net income attributable to Innoviva stockholders by the weighted-average number of shares of common stock and dilutive potential common stock equivalents then outstanding. Dilutive potential common stock equivalents include the assumed exercise, vesting and issuance of employee stock awards using the treasury stock method, as well as common stock issuable upon assumed conversion of our convertible subordinated notes due 2023 (the &#x201c;2023 Notes&#x201d;) up until its maturity date on January 15, 2023, our convertible senior notes due 2025 (the &#x201c;2025 Notes&#x201d;), and our convertible senior notes due 2028 (the &#x201c;2028 Notes&#x201d;) using the if-converted method.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The 2025 Notes are convertible, based on the applicable conversion rate, into cash, shares of our common stock or a combination thereof, at our election. Our current intent is to settle the principal amount of th&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;e 2025 Notes in cash upon conversion. The impact of the assumed conversion premium to diluted net income per share was historically computed using the treasury stock method until the adoption of ASU 2020-06. As the average market price per share of our common stock as reported on The Nasdaq Global Select Market was lower than the initial conversion price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17.26&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share, there was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; dilutive effect of the assumed conversion premium for the year ended December 31, 2021.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table shows the computation of basic and diluted net income per share for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023, 2022 and 2021:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.311%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.481%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.75%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.481%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.75%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.481%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.75%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands except per share data)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Numerator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net income attributable to Innoviva stockholders, basic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;179,722&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;213,921&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;265,854&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Add: interest expense on 2023 Notes, net of tax effect&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;89&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,439&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,736&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Add: interest expense on 2025 Notes, net of tax effect&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,116&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,583&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Add: interest expense on 2028 Notes, net of tax effect&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,377&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,626&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net income attributable to Innoviva stockholders, diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;191,304&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;225,569&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;270,590&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Denominator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Weighted-average shares used to compute basic net income&lt;br/&gt;&#160;&#160;&#160;per share attributable to Innoviva stockholders&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;65,435&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;69,644&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;82,062&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Dilutive effect of 2023 Notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;187&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,188&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,189&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Dilutive effect of 2025 Notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,150&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,150&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Dilutive effect of 2028 Notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,955&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,158&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Dilutive effect of options and awards granted under equity&lt;br/&gt;&#160;&#160;&#160;incentive plan and employee stock purchase plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;149&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;108&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;59&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Weighted-average shares used to compute diluted net income&lt;br/&gt;&#160;&#160;&#160;per share attributable to Innoviva stockholders&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;86,876&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;95,248&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;94,310&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net income per share attributable to Innoviva stockholders&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Basic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.75&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.07&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.20&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.37&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.87&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Anti&#x2011;dilutive Securities&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following common stock equivalents were not included in the computation of diluted net income per share because their effect was anti&#x2011;dilutive for the periods presented:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.8%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.2%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.2%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.799999999999999%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding options and awards granted under equity incentive&lt;br/&gt;&#160;&#160;&#160;plan and employee stock purchase plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,333&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;648&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;979&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding stock warrant&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;591&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;282&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,924&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;930&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;979&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="C_fa0aac3c-12ff-4c52-bf57-2b8f937d8ef4"
      decimals="2"
      id="F_886bd5c7-8216-45d9-a953-ca1cc69addbf"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">17.26</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <inva:IncrementalCommonSharesAttributableToConversionOfDebtSecuritiesTreasuryStockMethod
      contextRef="C_e3e6ec1f-49a0-4fb9-9419-c9b6fcbc8855"
      decimals="0"
      id="F_ed457491-7443-4b22-8862-a2487aa82607"
      unitRef="U_shares">0</inva:IncrementalCommonSharesAttributableToConversionOfDebtSecuritiesTreasuryStockMethod>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      id="F_bd18c9a0-14ee-4a92-a6fe-23533efc6046">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table shows the computation of basic and diluted net income per share for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023, 2022 and 2021:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.311%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.481%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.75%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.481%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.75%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.481%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.75%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands except per share data)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Numerator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net income attributable to Innoviva stockholders, basic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;179,722&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;213,921&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;265,854&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Add: interest expense on 2023 Notes, net of tax effect&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;89&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,439&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,736&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Add: interest expense on 2025 Notes, net of tax effect&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,116&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,583&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Add: interest expense on 2028 Notes, net of tax effect&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,377&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,626&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net income attributable to Innoviva stockholders, diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;191,304&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;225,569&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;270,590&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Denominator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Weighted-average shares used to compute basic net income&lt;br/&gt;&#160;&#160;&#160;per share attributable to Innoviva stockholders&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;65,435&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;69,644&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;82,062&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Dilutive effect of 2023 Notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;187&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,188&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,189&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Dilutive effect of 2025 Notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,150&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,150&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Dilutive effect of 2028 Notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,955&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,158&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Dilutive effect of options and awards granted under equity&lt;br/&gt;&#160;&#160;&#160;incentive plan and employee stock purchase plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;149&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;108&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;59&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Weighted-average shares used to compute diluted net income&lt;br/&gt;&#160;&#160;&#160;per share attributable to Innoviva stockholders&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;86,876&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;95,248&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;94,310&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net income per share attributable to Innoviva stockholders&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Basic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.75&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.07&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.20&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.37&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.87&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_762629b2-5320-4034-bdc1-29fdc72694ea"
      unitRef="U_USD">179722000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_47185b1f-c5c0-487b-bc92-0f0d611754d1"
      unitRef="U_USD">213921000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="-3"
      id="F_3347a5de-bb92-4ea1-bc86-94fdb3fe7f64"
      unitRef="U_USD">265854000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:InterestOnConvertibleDebtNetOfTax
      contextRef="C_1d6c5f53-6c4d-4fe6-a55d-07940f638bd4"
      decimals="-3"
      id="F_0fedaeda-5eea-460b-8778-ce0aff33825c"
      unitRef="U_USD">89000</us-gaap:InterestOnConvertibleDebtNetOfTax>
    <us-gaap:InterestOnConvertibleDebtNetOfTax
      contextRef="C_394439fc-7c8a-4379-be01-6a604b354293"
      decimals="-3"
      id="F_554101ee-8eee-4e32-abbc-bddd568d0604"
      unitRef="U_USD">2439000</us-gaap:InterestOnConvertibleDebtNetOfTax>
    <us-gaap:InterestOnConvertibleDebtNetOfTax
      contextRef="C_a0c44c89-e8b9-4ab7-8450-da67ef9caaa2"
      decimals="-3"
      id="F_9ab0ca4c-65c4-4eb5-b14a-5662a7470ebe"
      unitRef="U_USD">4736000</us-gaap:InterestOnConvertibleDebtNetOfTax>
    <us-gaap:InterestOnConvertibleDebtNetOfTax
      contextRef="C_d9c7ca7c-81fc-4272-b388-610e1b6444a8"
      decimals="-3"
      id="F_dda584a0-7f9a-4c50-88ed-768905fe65e9"
      unitRef="U_USD">5116000</us-gaap:InterestOnConvertibleDebtNetOfTax>
    <us-gaap:InterestOnConvertibleDebtNetOfTax
      contextRef="C_a18abd1c-665b-4c52-b36b-be1bbd83b22e"
      decimals="-3"
      id="F_4ecffe49-3301-4887-9d55-bffb82d8ea2a"
      unitRef="U_USD">4583000</us-gaap:InterestOnConvertibleDebtNetOfTax>
    <us-gaap:InterestOnConvertibleDebtNetOfTax
      contextRef="C_8b89681a-3d4d-4507-960c-e611eee0ae68"
      decimals="-3"
      id="F_c2f023c5-84bc-449f-a2e0-74d1a029bc4a"
      unitRef="U_USD">0</us-gaap:InterestOnConvertibleDebtNetOfTax>
    <us-gaap:InterestOnConvertibleDebtNetOfTax
      contextRef="C_6f92e4e3-0288-40a0-9972-c89e1aac1433"
      decimals="-3"
      id="F_b7bdb5f5-5425-45d8-bb3b-ec0d1550d608"
      unitRef="U_USD">6377000</us-gaap:InterestOnConvertibleDebtNetOfTax>
    <us-gaap:InterestOnConvertibleDebtNetOfTax
      contextRef="C_eaa09fba-b20a-4958-908d-40cfb3339c00"
      decimals="-3"
      id="F_24d8fca1-f4c0-4161-adeb-3bfbadf4873e"
      unitRef="U_USD">4626000</us-gaap:InterestOnConvertibleDebtNetOfTax>
    <us-gaap:InterestOnConvertibleDebtNetOfTax
      contextRef="C_50bb996e-86f5-4158-a575-796da0e57247"
      decimals="-3"
      id="F_497f880b-c292-4094-aa19-742b9f2e8aeb"
      unitRef="U_USD">0</us-gaap:InterestOnConvertibleDebtNetOfTax>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_ad61e599-77d3-46f3-be60-97e76d1dc984"
      unitRef="U_USD">191304000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_a58cc639-04c8-4e48-a607-ac49f7881217"
      unitRef="U_USD">225569000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="-3"
      id="F_4f0d2d78-2e47-4fea-89e9-d9abd824cd6e"
      unitRef="U_USD">270590000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_1f811c0d-117e-4960-84f0-8f5a913aea57"
      unitRef="U_shares">65435000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_ee9f6274-f28d-40fa-a601-755a5fe6a147"
      unitRef="U_shares">69644000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="-3"
      id="F_2598cb0e-c3b7-4afd-b4e4-e9c8983e773d"
      unitRef="U_shares">82062000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="C_1d6c5f53-6c4d-4fe6-a55d-07940f638bd4"
      decimals="-3"
      id="F_8b3af0d7-986e-4ae2-b7ff-dc7b342071dd"
      unitRef="U_shares">187000</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="C_394439fc-7c8a-4379-be01-6a604b354293"
      decimals="-3"
      id="F_1e68f8a1-15a9-4c37-ba92-88f51dae86d0"
      unitRef="U_shares">6188000</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="C_a0c44c89-e8b9-4ab7-8450-da67ef9caaa2"
      decimals="-3"
      id="F_0df8d5bc-149a-4d00-b18d-a5a27209ab24"
      unitRef="U_shares">12189000</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="C_d9c7ca7c-81fc-4272-b388-610e1b6444a8"
      decimals="-3"
      id="F_d4ae79ec-38ae-4166-be57-c181fbdb0442"
      unitRef="U_shares">11150000</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="C_a18abd1c-665b-4c52-b36b-be1bbd83b22e"
      decimals="-3"
      id="F_c2550765-ade0-4b8d-b793-c8618a7cd077"
      unitRef="U_shares">11150000</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="C_8b89681a-3d4d-4507-960c-e611eee0ae68"
      decimals="-3"
      id="F_9a99014c-4617-4d95-abcd-d315438efc25"
      unitRef="U_shares">0</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="C_6f92e4e3-0288-40a0-9972-c89e1aac1433"
      decimals="-3"
      id="F_25dbe408-57f2-4ca0-874a-533c8ca2d6df"
      unitRef="U_shares">9955000</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="C_eaa09fba-b20a-4958-908d-40cfb3339c00"
      decimals="-3"
      id="F_f4143b56-5cb5-4334-944e-d8229b667c6a"
      unitRef="U_shares">8158000</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="C_50bb996e-86f5-4158-a575-796da0e57247"
      decimals="-3"
      id="F_501661d3-150d-4468-acf3-4f68ca03e278"
      unitRef="U_shares">0</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_a51727c0-f4b6-48ce-a6bb-e152df693b17"
      unitRef="U_shares">149000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_676ff6ee-6112-4f75-82bd-8fcb1485e7d4"
      unitRef="U_shares">108000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="-3"
      id="F_d7d56afb-7b14-4520-b65b-c3ecc7ca4032"
      unitRef="U_shares">59000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_7e4fa101-3650-44be-88b1-56464e8cc244"
      unitRef="U_shares">86876000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_c812195f-d2a1-4c97-afd8-90345c4c4d10"
      unitRef="U_shares">95248000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="-3"
      id="F_2af6c265-0278-47e7-b8df-6918f5223703"
      unitRef="U_shares">94310000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="2"
      id="F_5080eb5e-4b9a-47e4-9c06-336a37fb6fa9"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.75</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="2"
      id="F_90ef21ee-81cd-425a-9b73-a2db240c41a7"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.07</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="2"
      id="F_ad92ee33-b672-42b4-a0f2-924015a5c56b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.24</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="2"
      id="F_462e32f8-466d-4625-8255-8753693c593c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.2</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="2"
      id="F_d4d87396-efbd-42d6-a4dc-2e0f80a850c0"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.37</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="2"
      id="F_9ef1e4a6-f0b3-4fee-a935-c3777fe7c935"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.87</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      id="F_2232223b-d5c9-4377-a7d3-fec6543358de">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following common stock equivalents were not included in the computation of diluted net income per share because their effect was anti&#x2011;dilutive for the periods presented:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.8%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.2%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.2%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.799999999999999%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding options and awards granted under equity incentive&lt;br/&gt;&#160;&#160;&#160;plan and employee stock purchase plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,333&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;648&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;979&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding stock warrant&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;591&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;282&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,924&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;930&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;979&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_3824b03b-c4bb-4202-90b1-652ccf15674b"
      decimals="-3"
      id="F_8cf05da8-e9a7-40cd-bf51-0123dba8b00f"
      unitRef="U_shares">1333000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_5adfa42a-1fb9-4bab-ac06-149565b0b62c"
      decimals="-3"
      id="F_fc15029a-9a25-401b-bf07-3f510923bf0f"
      unitRef="U_shares">648000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_07eefa71-9b4d-4cdb-b27f-f192898d804e"
      decimals="-3"
      id="F_33f85cc9-db6b-4c66-a0bd-328855c4902a"
      unitRef="U_shares">979000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_b60e6976-6149-440a-b50d-539629e77c91"
      decimals="-3"
      id="F_da1d1e96-7295-4383-bac1-13785cb78684"
      unitRef="U_shares">591000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_d3087254-4dbd-4e76-a116-2ba842506912"
      decimals="-3"
      id="F_ad67de70-389e-47f2-88ae-09ab3f35dd3b"
      unitRef="U_shares">282000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_972fc684-1125-4562-949a-c061a92ab4f3"
      decimals="-3"
      id="F_9f5514b0-8099-4ec8-9152-dd784a111742"
      unitRef="U_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_fffcc53c-e259-49bc-8699-1581571480cf"
      unitRef="U_shares">1924000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_6cecc704-c476-4233-be91-b0bca7862710"
      unitRef="U_shares">930000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="-3"
      id="F_7b4f19da-649a-48e7-8f64-073569a402e5"
      unitRef="U_shares">979000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      id="F_d10b5246-f64f-4285-a603-31f5b9ad03f1">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;3.  REVENUE RECOGNITION&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Net Revenue from Collaboration Arrangement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On July 13, 2022, Innoviva&#x2019;s wholly owned subsidiary, Innoviva TRC Holdings, LLC (&#x201c;ITH&#x201d;) entered into an equity purchase agreement (&#x201c;TRC Equity Purchase Agreement&#x201d;) with Royalty Pharma Investments 2019 ICAV (&#x201c;Royalty Pharma&#x201d;) to sell our ownership interest in TRC. As a result of the sale of our ownership interest in TRC, which was consummated on July 20, 2022, we are no longer entitled to receive &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of royalty payments made by GSK stemming from sales of TRELEGY&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; ELLIPTA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. We retained our royalty rights with respect to RELVAR&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;/BREO&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; ELLIPTA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and ANORO&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; ELLIPTA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Net revenue recognized under our GSK Agreements was as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.311%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.481%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.75%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.481%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.75%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.481%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.75%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Royalties &#x2013; RELVAR/BREO&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;208,042&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;215,034&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;234,066&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Royalties &#x2013; ANORO&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;44,627&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;38,405&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;44,935&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Royalties &#x2013; TRELEGY&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;72,029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;126,688&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total royalties&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;252,669&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;325,468&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;405,689&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: amortization of capitalized&lt;br/&gt;&#160;&#160;&#160;fees paid&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,823&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,823&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,823&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total royalty revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;238,846&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;311,645&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;391,866&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;   The year ended December 31, 2022 represents the period from January 1, 2022 to July 20, 2022, the date of the sale of our ownership interest in TRC.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;LABA Collaboration&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As a result of the launch and approval of RELVAR&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;/BREO&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; ELLIPTA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and ANORO&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; ELLIPTA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; in the U.S., Japan and Europe, we paid milestone fees to GSK totaling $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;220.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million during the year ended December 31, 2014. The milestone fees paid to GSK were recognized as capitalized fees paid, which are being amortized over their estimated useful lives commencing upon the commercial launch of the product. The amortization is recorded as a reduction to the royalties from GSK.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We are entitled to receive annual royalties from GSK on sales of RELVAR&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;/BREO&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; ELLIPTA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; as follows: &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% on the first $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; billion of annual global net sales and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% for all annual global net sales above $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; billion. Sales of single&#x2011;agent LABA medicines and combination medicines would be combined for the purposes of this royalty calculation. For other products combined with a LABA from the LABA Collaboration, such as ANORO&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; ELLIPTA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, royalties are upward tiering and range from &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We are also entitled to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of royalty payments made by GSK under its agreements originally entered into with us, and since assigned to TRC in connection with the Spin-Off, including TRELEGY&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; ELLIPTA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; through July 20, 2022, which royalties were upward tiering and ranged from &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Net Product Sales&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Net product sales were $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;60.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, consisting of net sales of GIAPREZA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, XERAVA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, and XACDURO&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; for $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;41.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively. We derived approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;91&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of our net product sales for the same period from customers located in the U.S. and the rest of the world, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;From the date of acquisition of La Jolla to December 31, 2022, net product sales were $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, consisting of net sales of GIAPREZA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and XERAVA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; for $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively. We derived approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;96&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of our net product sales for the same period from customers located in the U.S. and the rest of the world, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;License Revenue&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Refer to the out-license agreement with Zai Lab and Everest in Note 4, &#x201c;License and Collaboration Arrangements&#x201d;.&lt;/span&gt;&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <inva:PercentageOfRoyaltyPaymentsNotEntitledToReceive
      contextRef="C_27cbe4a1-3bff-4bc8-b808-d5e97b10b96a"
      decimals="2"
      id="F_7b758520-64e9-4fa6-b6db-d992a088b034"
      unitRef="U_pure">0.15</inva:PercentageOfRoyaltyPaymentsNotEntitledToReceive>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      id="F_9d253d8c-bdc7-46eb-9f93-f246715ebd92">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Net revenue recognized under our GSK Agreements was as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.311%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.481%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.75%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.481%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.75%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.481%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.75%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Royalties &#x2013; RELVAR/BREO&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;208,042&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;215,034&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;234,066&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Royalties &#x2013; ANORO&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;44,627&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;38,405&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;44,935&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Royalties &#x2013; TRELEGY&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;72,029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;126,688&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total royalties&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;252,669&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;325,468&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;405,689&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: amortization of capitalized&lt;br/&gt;&#160;&#160;&#160;fees paid&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,823&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,823&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,823&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total royalty revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;238,846&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;311,645&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;391,866&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;   The year ended December 31, 2022 represents the period from January 1, 2022 to July 20, 2022, the date of the sale of our ownership interest in TRC.&lt;/span&gt;&lt;/p&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <inva:GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees
      contextRef="C_32088045-eb75-4318-bbdc-77c7436faa52"
      decimals="-3"
      id="F_f05da76d-03bd-483f-a805-7e6d68725bd1"
      unitRef="U_USD">208042000</inva:GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees>
    <inva:GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees
      contextRef="C_3596ffd8-7703-4aa7-bc48-723fa485f9cd"
      decimals="-3"
      id="F_19c2d7de-a5c0-44f4-8f35-ab38357c13ed"
      unitRef="U_USD">215034000</inva:GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees>
    <inva:GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees
      contextRef="C_425efcfe-eac0-4b78-bf2f-d0ef757a0501"
      decimals="-3"
      id="F_96c9bcea-ba1f-42fa-954a-17ba06ee7c02"
      unitRef="U_USD">234066000</inva:GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees>
    <inva:GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees
      contextRef="C_e78c50b6-10c0-4578-be27-2aad784b619e"
      decimals="-3"
      id="F_a8d81c52-1b7f-4d65-8568-6dc34c8740f0"
      unitRef="U_USD">44627000</inva:GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees>
    <inva:GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees
      contextRef="C_5c0f9d6a-daac-43d5-9697-46136da2e5eb"
      decimals="-3"
      id="F_c6d19d98-dde8-43be-a11b-f17b7b543918"
      unitRef="U_USD">38405000</inva:GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees>
    <inva:GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees
      contextRef="C_676e8b46-96e2-42eb-927b-d2236a78f7f0"
      decimals="-3"
      id="F_10a79183-dbc3-4918-bfdd-e090a5187961"
      unitRef="U_USD">44935000</inva:GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees>
    <inva:GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees
      contextRef="C_6e16f944-8e12-42b7-84eb-4f21d332cd44"
      decimals="-3"
      id="F_b77bea76-072e-4367-b47f-c8d7a579d4d8"
      unitRef="U_USD">0</inva:GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees>
    <inva:GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees
      contextRef="C_3f92b149-a39f-4e8f-96ab-6c3b86b4dbe7"
      decimals="-3"
      id="F_fef7ca76-dc12-4482-8f29-1f59651c4359"
      unitRef="U_USD">72029000</inva:GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees>
    <inva:GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees
      contextRef="C_94c529c4-f563-461a-9da8-262bcfe8bc37"
      decimals="-3"
      id="F_8bd0930b-e853-47a3-8715-a03895cd09ab"
      unitRef="U_USD">126688000</inva:GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees>
    <inva:GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees
      contextRef="C_c1969bd2-5e89-423e-88e9-b5564c6afe10"
      decimals="-3"
      id="F_0a46b916-e927-4a4b-bbcf-565a95bcb326"
      unitRef="U_USD">252669000</inva:GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees>
    <inva:GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees
      contextRef="C_8c8eca7f-7819-48ae-9938-c3c7153ffa73"
      decimals="-3"
      id="F_c7718fcb-15da-47ad-9408-ce32c7969ad9"
      unitRef="U_USD">325468000</inva:GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees>
    <inva:GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees
      contextRef="C_539783b3-bf29-4a63-8d24-99d7b7b79e81"
      decimals="-3"
      id="F_7b335909-04aa-4116-a317-e7b61d33d447"
      unitRef="U_USD">405689000</inva:GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="C_c1969bd2-5e89-423e-88e9-b5564c6afe10"
      decimals="-3"
      id="F_953bdfff-ff9b-46b2-8750-c514a013ede2"
      unitRef="U_USD">13823000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="C_8c8eca7f-7819-48ae-9938-c3c7153ffa73"
      decimals="-3"
      id="F_fbe41650-f196-4afa-81c6-b1dcf7a54420"
      unitRef="U_USD">13823000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="C_539783b3-bf29-4a63-8d24-99d7b7b79e81"
      decimals="-3"
      id="F_741e51bb-5fb0-4d89-8108-a040d0e136b6"
      unitRef="U_USD">13823000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_a69ed80b-24cf-4fb0-939b-206e1bd2ef60"
      decimals="-3"
      id="F_cddcec21-ea9a-4af4-b3a2-9caa8b61badd"
      unitRef="U_USD">238846000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_ffbac92f-8341-4e52-864a-91ee3864a86e"
      decimals="-3"
      id="F_2ea1c0d8-54c8-46b5-b0c0-84d040cbef6f"
      unitRef="U_USD">311645000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_5783ed68-2473-492b-88b5-e1af30e3c0e7"
      decimals="-3"
      id="F_8ac0fd58-edde-4fad-8c67-b2372c7a9e04"
      unitRef="U_USD">391866000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CapitalizedContractCostGross
      contextRef="C_9fb8ce09-b755-456a-88b1-2a93a91dc1d0"
      decimals="-5"
      id="F_1e1c1ae1-395a-40f7-bebf-a77c03b102d9"
      unitRef="U_USD">220000000</us-gaap:CapitalizedContractCostGross>
    <inva:CollaborativeArrangementRoyaltyRateDefinedLevelOne
      contextRef="C_f6067cb4-1702-418f-8410-c3ff025f386d"
      decimals="2"
      id="F_11023421-5436-4265-83fa-1596965edd86"
      unitRef="U_pure">0.15</inva:CollaborativeArrangementRoyaltyRateDefinedLevelOne>
    <inva:CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate
      contextRef="C_f6067cb4-1702-418f-8410-c3ff025f386d"
      decimals="-8"
      id="F_51c0337b-1b2a-47ce-ab1d-b1ec73d2bc7c"
      unitRef="U_USD">3000000000</inva:CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate>
    <inva:CollaborativeArrangementRoyaltyRateDefinedLevelTwo
      contextRef="C_f6067cb4-1702-418f-8410-c3ff025f386d"
      decimals="2"
      id="F_d315d1fc-2843-4317-b200-95ac7358d994"
      unitRef="U_pure">0.05</inva:CollaborativeArrangementRoyaltyRateDefinedLevelTwo>
    <inva:CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate
      contextRef="C_f6067cb4-1702-418f-8410-c3ff025f386d"
      decimals="-8"
      id="F_71b8c505-4141-469e-ac3e-7854b3a44369"
      unitRef="U_USD">3000000000</inva:CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate>
    <inva:CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts
      contextRef="C_4ad76130-0d29-47d9-b811-82b396d4ef22"
      decimals="3"
      id="F_28409b73-e199-4c3a-bf74-d1332ddc64ef"
      unitRef="U_pure">0.065</inva:CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts>
    <inva:CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts
      contextRef="C_76103f21-39aa-4d6c-bd6a-47f7c57f423e"
      decimals="2"
      id="F_8a37912e-71fa-434b-b803-83665e12379c"
      unitRef="U_pure">0.10</inva:CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts>
    <inva:PercentageOfEconomicInterestOnFuturePaymentsUnderAgreements
      contextRef="C_51f40066-7e1b-48d8-8a38-42b77199fdd5"
      decimals="2"
      id="F_928ecbe5-11fc-41a2-baf5-670cb9aea5eb"
      unitRef="U_pure">0.15</inva:PercentageOfEconomicInterestOnFuturePaymentsUnderAgreements>
    <inva:CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts
      contextRef="C_87ac8e26-9a2a-47e5-973e-54a32e529605"
      decimals="3"
      id="F_c2a719e0-c7e3-4b4e-8c2d-0efdc7d8e4ca"
      unitRef="U_pure">0.065</inva:CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts>
    <inva:CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts
      contextRef="C_2e2e6b99-d8c8-44b8-aabd-25fa00182b05"
      decimals="2"
      id="F_7e2a50b5-bbc8-4ddf-ad63-4b5c3ee9d630"
      unitRef="U_pure">0.10</inva:CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_a7cbb363-ce02-4f94-bf8b-d70a020aba6a"
      decimals="-5"
      id="F_12f0c5dd-bb35-4f3e-8dd2-300cacda0a6c"
      unitRef="U_USD">60600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_f00e797a-c719-4c90-a9dc-1bce4096970e"
      decimals="-5"
      id="F_b2ed2db9-7aad-46d5-847a-5de4b7453b59"
      unitRef="U_USD">41300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_96ac591a-5f0a-4705-94d6-904d91058ae4"
      decimals="-5"
      id="F_adf8a4ff-defa-4848-ae5d-ffa82b4b1d01"
      unitRef="U_USD">17300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_afca57b6-192a-41f3-9d82-5a1dd8586709"
      decimals="-5"
      id="F_3608c151-a861-4a5f-ab6d-3977299e61eb"
      unitRef="U_USD">2000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_29193a89-f8bc-431f-9fc2-70fd8e836d0e"
      decimals="2"
      id="F_934efe4a-0ba7-48d2-9461-2c9d7eca9f96"
      unitRef="U_pure">0.91</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_adc3b151-5d38-4abe-9182-9e724c5ef29b"
      decimals="2"
      id="F_819ef480-0301-478b-93b1-282a8d43deeb"
      unitRef="U_pure">0.09</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_b2abb502-4aea-4d3e-a1e8-7663f28b3e4a"
      decimals="-5"
      id="F_85684c5e-6bec-4ec7-a80b-f22a1450a681"
      unitRef="U_USD">19700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_54ed52d3-2763-46fa-a0e9-bfeb58272692"
      decimals="-5"
      id="F_05ea2058-d91e-4e0e-8cbf-ee64da28a436"
      unitRef="U_USD">14200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_98c23b09-7eaa-42d7-b41a-5b1541dea4a7"
      decimals="-5"
      id="F_380494ee-df55-4e0e-992e-0e7978599960"
      unitRef="U_USD">5500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_ba1a82e3-49cc-4439-9ea4-1ade7ac73cb8"
      decimals="2"
      id="F_da8694fc-959b-4708-a060-b6a47e41bab6"
      unitRef="U_pure">0.96</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_bb2dfb4c-8159-49a4-8abd-85f592b904b8"
      decimals="2"
      id="F_45b22d6a-c190-4996-a7f0-e03fb6840aff"
      unitRef="U_pure">0.04</us-gaap:ConcentrationRiskPercentage1>
    <inva:LicenseAndCollaborationArrangementsDisclosureTextBlock
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      id="F_491467b6-21ea-48ae-9d4a-5c795cc59005">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;4. LICENSE AND COLLABORATION ARRANGEMENTS&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Out-License Agreements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Zai Lab&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Entasis entered into a license and collaboration agreement with Zai Lab (Shanghai) Co., Ltd. (&#x201c;Zai Lab&#x201d;) (Nasdaq: ZLAB), pursuant to which Zai Lab licensed exclusive rights to durlobactam and SUL-DUR, in the Asia-Pacific region (&#x201c;the Zai Agreement&#x201d;). Under the terms of the Zai Agreement, Zai Lab will fund most of the registrational clinical trial costs in China for SUL-DUR, with the exception of Phase 3 patient drug supply of licensed products. Zai Lab will conduct development activities and plan and obtain regulatory approval in a specified number of countries in the Asia-Pacific region beyond China after receipt of regulatory approval of a licensed product in China. Zai Lab is also solely responsible for commercializing licensed products in the Asia-Pacific region and will commercialize licensed products for which it has obtained regulatory approval. We are obligated to supply Zai Lab with the licensed products for clinical development and, if the licensed product is approved, for commercial use for a certain period unless Zai Lab notifies otherwise. Zai Lab may take over manufacturing responsibilities for its own commercialization activities within a specified time period following the effective date of the Zai Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We ar&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;e eligible to receive up to an aggregate of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;91.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in research and development support payments and development, regulatory and sales milestone payments related to SUL-DUR, imipenem and other combinations with the licensed products. Zai Lab will pay us a tiered royalty equal to from a high-single digit to low-double digit percentage based on annual net sales of licensed products in the territory, subject to specified reductions for the market entry of competing products, loss of patent coverage of licensed products and for payments owed to third parties for additional rights necessary to commercialize licensed products in the territory.  Payments received for research support and reimbursable clinical trial costs are recorded as a reduction to research and development expense during the period in which the qualifying expenses are incurred. Such amounts recorded &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;for the year ended December 31, 2023 and from the date of acquisition of Entasis to December 31, 2022 are not material. Following the approval of XACDURO&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; by the FDA in May 2023, we recognized $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in license revenue for the year ended December 31, 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;GARDP&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Entasis entered into a collaboration agreement with the Global Antibiotic Research and Development Partnership (&#x201c;GARDP&#x201d;) for the development, manufacture and commercialization of the product candidate zoliflodacin in certain countries (&#x201c;the GARDP Collaboration Agreement&#x201d;). Under the terms of the GARDP Collaboration Agreement, GARDP will use commercially reasonable endeavors to perform and fully fund the Phase 3 registrational trial, including the manufacture and supply of the product candidate containing zoliflodacin, in uncomplicated gonorrhea. We recorded reimbursements from GARDP under this agreement as reduction to research and development expense. Relevant amounts for the year ended December 31, 2023 and from the date of acquisition of Entasis to December 31, 2022 are not material.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In addition, under the GARDP Collaboration Agreement, GARDP was granted a worldwide, fully paid, exclusive and royalty-free license, with the right to sublicense, to use our zoliflodacin technology in connection with GARDP&#x2019;s development, manufacture and commercialization of zoliflodacin in low-income and specified middle-income countries. We retained commercial rights in all other countries worldwide, including the major markets in North America, Europe and Asia-Pacific. We also retained the right to use and grant licenses to our zoliflodacin technology to perform our obligations under the GARDP Collaboration Agreement and for any purpose other than gonorrhea or community-acquired indications. If we believe that the results of the Phase 3 registrational trial of zoliflodacin would be supportive of an application for marketing approval, we are obligated to use our best efforts to file an application for marketing approval with the FDA within six months of the completion of the trial and to use commercially reasonable endeavors to file an application for marketing approval with the European Medicines Agency (&#x201c;EMA&#x201d;). Each party is responsible for using commercially reasonable efforts to obtain marketing authorizations for the product candidate in their respective territories.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;PAION AG&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Pursuant to the PAION AG and PAION Deutschland GmbH (together and individually &#x201c;PAION&#x201d;) License, La Jolla granted PAION an exclusive license to commercialize GIAPREZA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and XERAVA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; in the European Economic Area, the United Kingdom and Switzerland (collectively, the &#x201c;PAION Territory&#x201d;). We are entitled to receive potential commercial milestone payments of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;109.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and double-digit tiered royalty payments. Royalties payable in a given jurisdiction under the PAION License will be subject to reduction on account of generic competition and after patent expiration in that jurisdiction. Pursuant to the PAION License, PAION will be solely responsible for the future development and commercialization of GIAPREZA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and XERAVA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; in the PAION Territory. PAION is required to use commercially reasonable efforts to commercialize GIAPREZA&#xae; and XERAVA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; in the PAION Territory. We have not recognized any revenue from PAION related to commercial milestones from the date of acquisition of La Jolla to December 31, 2023. Royalty revenue recognized under this agreement for the year ended December 31, 2023 and from the date of acquisition of La Jolla to December 31, 2022 are not material.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;La Jolla also entered into the PAION commercial supply agreement (the &#x201c;PAION Supply Agreement&#x201d;) whereby La Jolla will supply PAION a minimum quantity of GIAPREZA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and XERAVA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; through July 13, 2024. The PAION supply agreement will automatically renew until the earlier of July 13, 2027, or until a new supply agreement is executed. During the initial term of the supply agreement, we will be reimbursed for direct and certain indirect manufacturing costs at cost. We recognized $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in cost reimbursements under this agreement for the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023. Amounts recognized under this agreement from the date of acquisition of La Jolla to December 31, 2022 were not material.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;PAION AG and PAION Deutschland GmbH filed for insolvency in Germany on October 27, 2023 and the insolvency proceedings were opened on January 1, 2024. PAION announced on December 22, 2023 that it concluded negotiations with Humanwell Healthcare Group and entered into an agreement on the sale of the essential business operations of PAION AG and PAION Deutschland GmbH with the approval of the insolvency administrator in both procedures. La Jolla did not oppose the sale and is in discussions with the acquirer regarding the continued business relationship.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Everest Medicines Limited&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Pursuant to the Everest Medicines Limited (&#x201c;Everest&#x201d;) License, La Jolla granted Everest an exclusive license to develop and commercialize XERAVA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; for the treatment of complicated intra-abdominal infections (&#x201c;cIAI&#x201d;) and other indications in mainland China, Taiwan, Hong Kong, Macau, South Korea, Singapore, the Malaysian Federation, the Kingdom of Thailand, the Republic of Indonesia, the Socialist Republic of Vietnam and the Republic of the Philippines (collectively, the &#x201c;Everest Territory&#x201d;). &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Under the Everest License, we recognized $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in license revenue for the year ended December 31, 2023 as a result of an achievement of a regulatory milestone during the period. We are eligible to receive additional sales milestone payments of up to an aggregate of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We are also entitled to receive tiered royalties from Everest at percentages in the low double digits on sales, if any, in the Everest Territory of products containing eravacycline. Royalties are payable with respect to each jurisdiction in the Everest Territory until the latest to occur of: (i) the last-to-expire of specified patent rights in such jurisdiction in the Everest Territory; (ii) expiration of marketing or regulatory exclusivity in such jurisdiction in the Everest Territory; or (iii) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; years after the first commercial sale of a product in such jurisdiction in the Everest Territory. Royalty revenue recognized under this agreement for the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. Royalty revenue recognized &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;from the date of acquisition of La Jolla to December 31, 2022 is not material.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;La Jolla also entered into the Everest commercial supply agreement (the &#x201c;Everest Supply Agreement&#x201d;) whereby La Jolla will supply Everest a minimum quantity of XERAVA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; through December 31, 2023 and will transfer to Everest certain XERAVA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;-related manufacturing know-how. We were eligible to be reimbursed for direct and certain indirect manufacturing costs at &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;110&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of cost through December 31, 2023. We recognized $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in revenue under this agreement for the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and from the acquisition of La Jolla to December 31, 2022, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;In-License Agreements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;George Washington University&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Pursuant to the George Washington University (&#x201c;GW&#x201d;) License, GW exclusively licensed to La Jolla certain intellectual property rights relating to GIAPREZA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, including the exclusive rights to certain issued patents and patent applications covering GIAPREZA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. Under the GW License, we are obligated to use commercially reasonable efforts to develop, commercialize, market and sell GIAPREZA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. We are obligated to pay a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% royalty on net sales of GIAPREZA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% on payments received from sublicensees. The obligation to pay royalties under this agreement extends through the last-to-expire patent covering GIAPREZA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We recognized $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million for the year ended December 31, 2023 under this agreement. Amounts recognized f&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;rom the date of acquisition of La Jolla to December 31, 2022 were not material.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Harvard University&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Pursuant to the Harvard University (&#x201c;Harvard&#x201d;) License, Harvard exclusively licensed to La Jolla certain intellectual property rights relating to tetracycline-based products, including XERAVA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, including the exclusive rights to certain issued patents and patent applications covering such products. Under the Harvard License, we are obligated to use commercially reasonable efforts to develop, commercialize, market and sell tetracycline-based products, including XERAVA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. For each product covered by the Harvard License, we are obligated to make certain payments for the following: (i) up to approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million upon the achievement of certain clinical development and regulatory milestones; (ii) a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% royalty on direct U.S. net sales of XERAVA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;; (iii) a single-digit tiered royalty on direct ex-U.S. net sales of XERAVA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, starting at a minimum royalty rate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%, with step-ups to a maximum royalty of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% based on the achievement of annual net product sales thresholds; and (iv) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% on payments received from sublicensees. The obligation to pay royalties under this agreement extends through the last-to-expire patent covering tetracycline-based products, including XERAVA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; For the year ended December 31, 2023, we recognized $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million as cost of license revenue under this agreement as a result of the license revenue we earned under the out-licensing agreement with Everest for the same period. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;From the date of acquisition of La Jolla to December 31, 2022, amounts recognized under this agreement were not material.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Paratek Pharmaceuticals, Inc.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Pursuant to the Paratek Pharmaceuticals, Inc. (&#x201c;Paratek&#x201d;) License, Paratek non-exclusively licensed to La Jolla certain intellectual property rights relating to XERAVA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, including non-exclusive rights to certain issued patents and patent applications covering XERAVA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. We are obligated to pay Paratek a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.25&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% royalty based on direct U.S. net sales of XERAVA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. Our obligation to pay royalties with respect to the licensed product is retroactive to the date of the first commercial sale of XERAVA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;and shall continue until there are no longer any valid claims of the Paratek patents, which expired in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;October 2023&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. For the year ended December 31, 2023 and from the date of acquisition of La Jolla to December 31, 2022, amounts recognized under this agreement were not material.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Business Transfer and Subscription Agreement with AstraZeneca&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Entasis entered into a Business Transfer and Subscription Agreement with AstraZeneca, AstraZeneca UK Limited and AstraZeneca Pharmaceuticals LP (collectively, &#x201c;AstraZeneca&#x201d;) (the &#x201c;AstraZeneca Agreement&#x201d;) in 2015, which was amended and restated through 2018, pursuant to which Entasis obtained, among other things, worldwide rights to durlobactam and zoliflodacin. Under the AstraZeneca Agreement, we are obligated to pay AstraZeneca a one-time milestone payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million within &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;three months&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; of achieving a specified cumulative net sales milestone for durlobactam. We are also obligated to pay AstraZeneca a one-time milestone payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million within &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;two years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; of achieving the first commercial sale of zoliflodacin. Additionally, we are obligated to pay AstraZeneca tiered, single-digit royalties on the annual worldwide net sales of durlobactam and, the lesser of tiered, single-digit royalties on the worldwide annual net sales of zoliflodacin and a specified share of the royalties we receive from sublicensees of zoliflodacin. Royalties on sales of zoliflodacin do not include sales by GARDP in low-income and specified middle-income countries as discussed above. Our obligation to make these royalty payments expires with respect to each product on a country-by-country basis upon the later of (i) the 10-year anniversary of the first commercial sale of a product in each such country or (ii) when the last patent right covering a product expires in each such country.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Royalty expense on durlobactam arising from our net sales of XACDURO&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; for the year ended December 31, 2023 was immaterial.&lt;/span&gt;&lt;/p&gt;</inva:LicenseAndCollaborationArrangementsDisclosureTextBlock>
    <inva:FuturePotentialMilestonePayment
      contextRef="C_33ccc9ac-1bd0-4923-b096-29db8ac98a5e"
      decimals="-5"
      id="F_c5d8bb5e-faf3-43da-89cc-40dcb126a516"
      unitRef="U_USD">91000000</inva:FuturePotentialMilestonePayment>
    <inva:LicenseRevenueRecognized
      contextRef="C_9ddbdfad-57e5-479b-ba9a-8f0e252307df"
      decimals="-5"
      id="F_470c8928-485d-4308-bfaa-c30e457d3b07"
      unitRef="U_USD">3000000</inva:LicenseRevenueRecognized>
    <inva:FuturePotentialMilestonePayment
      contextRef="C_20a1bbc0-a748-41da-a071-6972900ca7d7"
      decimals="-5"
      id="F_f9f8a305-47ba-4a39-8939-5ae1c3cc9705"
      unitRef="U_USD">109500000</inva:FuturePotentialMilestonePayment>
    <us-gaap:Revenues
      contextRef="C_69fb044e-5d2a-46bb-ae62-33b02683b43d"
      decimals="-5"
      id="F_9ced0058-bf18-48b7-8fa6-d074a278006b"
      unitRef="U_USD">1300000</us-gaap:Revenues>
    <inva:LicenseRevenueRecognized
      contextRef="C_2f159654-f79f-4e47-806d-ec1adbda538c"
      decimals="-5"
      id="F_2ea0d13e-696b-484a-88f4-98d0dd486fdd"
      unitRef="U_USD">8000000</inva:LicenseRevenueRecognized>
    <inva:SalesMilestonePaymentsReceivable
      contextRef="C_83a2b6b3-d55f-414b-a77a-bc247a02d235"
      decimals="-5"
      id="F_aeabb2b8-6b26-4001-ae12-4a83f53cd89c"
      unitRef="U_USD">20000000</inva:SalesMilestonePaymentsReceivable>
    <inva:RoyaltiesPayablePeriodAfterFirstCommercialSaleOfProduct
      contextRef="C_2f159654-f79f-4e47-806d-ec1adbda538c"
      id="F_f8cd0749-629d-404c-aa59-38f8ffa9b14e">P10Y</inva:RoyaltiesPayablePeriodAfterFirstCommercialSaleOfProduct>
    <us-gaap:Revenues
      contextRef="C_2f159654-f79f-4e47-806d-ec1adbda538c"
      decimals="-5"
      id="F_d2e69ce3-a072-4acd-bb4d-3c9f8acd7a89"
      unitRef="U_USD">1400000</us-gaap:Revenues>
    <inva:PercentageOfReimbursedForDirectAndCertainIndirectManufacturingCosts
      contextRef="C_a0b988e7-21ed-4760-8751-f6fa519d9c49"
      decimals="2"
      id="F_708156e9-488f-4fa6-8346-3e098328d3ea"
      unitRef="U_pure">1.10</inva:PercentageOfReimbursedForDirectAndCertainIndirectManufacturingCosts>
    <us-gaap:Revenues
      contextRef="C_a0b988e7-21ed-4760-8751-f6fa519d9c49"
      decimals="-5"
      id="F_8779320b-069f-48d8-8eec-7fdc7f94fead"
      unitRef="U_USD">2400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_5361a0f4-5547-4b13-aab7-9c5bf77f49a1"
      decimals="-5"
      id="F_f2590fe0-9128-4cfd-9f4e-674a914142ee"
      unitRef="U_USD">800000</us-gaap:Revenues>
    <inva:PercentageOfRoyaltyPayableOnNetSales
      contextRef="C_2b0ee96a-cf29-4fd8-a358-2c59b280effd"
      decimals="2"
      id="F_f29d2c6f-86e9-45a4-a6e9-f6e300790834"
      unitRef="U_pure">0.06</inva:PercentageOfRoyaltyPayableOnNetSales>
    <inva:PercentageOfRoyaltyOnPaymentsReceivedFromSublicensees
      contextRef="C_2b0ee96a-cf29-4fd8-a358-2c59b280effd"
      decimals="2"
      id="F_0ecf2817-bad3-4550-8023-f0e239444832"
      unitRef="U_pure">0.15</inva:PercentageOfRoyaltyOnPaymentsReceivedFromSublicensees>
    <inva:AccruedRoyaltyObligations
      contextRef="C_2b0ee96a-cf29-4fd8-a358-2c59b280effd"
      decimals="-5"
      id="F_d570177c-c96a-4d74-a735-e6f6605a0a4f"
      unitRef="U_USD">2500000</inva:AccruedRoyaltyObligations>
    <inva:ClinicalDevelopmentAndRegulatoryMilestonesAmountPayable
      contextRef="C_4a4dcf17-e144-4065-bc02-636f5d4b60be"
      decimals="-5"
      id="F_0aec8e11-9d90-476c-9414-77217ebd3725"
      unitRef="U_USD">15100000</inva:ClinicalDevelopmentAndRegulatoryMilestonesAmountPayable>
    <inva:PercentageOfRoyaltyPayableOnNetSales
      contextRef="C_4a4dcf17-e144-4065-bc02-636f5d4b60be"
      decimals="2"
      id="F_a6afe523-8212-4d94-8667-126dae3b56cb"
      unitRef="U_pure">0.05</inva:PercentageOfRoyaltyPayableOnNetSales>
    <inva:PercentageOfMinimumRoyaltyRate
      contextRef="C_4a4dcf17-e144-4065-bc02-636f5d4b60be"
      decimals="3"
      id="F_bbe8463d-8a50-4278-9180-96b8f5bba597"
      unitRef="U_pure">0.045</inva:PercentageOfMinimumRoyaltyRate>
    <inva:PercentageOfMaximumRoyaltyBasedOnAchievementOfAnnualNetProductSalesThresholds
      contextRef="C_4a4dcf17-e144-4065-bc02-636f5d4b60be"
      decimals="3"
      id="F_6226b28b-3130-4532-9f7f-56fc64e9d4c2"
      unitRef="U_pure">0.075</inva:PercentageOfMaximumRoyaltyBasedOnAchievementOfAnnualNetProductSalesThresholds>
    <inva:PercentageOfRoyaltyOnPaymentsReceivedFromSublicensees
      contextRef="C_4a4dcf17-e144-4065-bc02-636f5d4b60be"
      decimals="2"
      id="F_bc2b50fe-f3b7-418e-b91f-3f32fa7a4411"
      unitRef="U_pure">0.20</inva:PercentageOfRoyaltyOnPaymentsReceivedFromSublicensees>
    <us-gaap:CostOfRevenue
      contextRef="C_4a4dcf17-e144-4065-bc02-636f5d4b60be"
      decimals="-5"
      id="F_388cda57-c631-4829-8bfc-f5cd35a8408b"
      unitRef="U_USD">1200000</us-gaap:CostOfRevenue>
    <inva:PercentageOfRoyaltyPayableOnNetSales
      contextRef="C_1c6f694e-9295-44ca-bb54-e10942065024"
      decimals="4"
      id="F_bce8215b-1510-4cdf-8b5d-9d910b935257"
      unitRef="U_pure">0.0225</inva:PercentageOfRoyaltyPayableOnNetSales>
    <inva:ClaimExpirationDate
      contextRef="C_1c6f694e-9295-44ca-bb54-e10942065024"
      id="F_74217e46-2d1f-46a3-b56f-e778cc36373e">2023-10</inva:ClaimExpirationDate>
    <inva:SubscriptionAgreementOneTimeMilestonePaymentOnNetSales
      contextRef="C_2bff9226-01dd-49ce-8c00-439b9b368e4f"
      decimals="-5"
      id="F_d164b6ea-beb3-4a8e-a4de-8a8dba709268"
      unitRef="U_USD">5000000</inva:SubscriptionAgreementOneTimeMilestonePaymentOnNetSales>
    <inva:TermOfMilestonePaymentForNetSales
      contextRef="C_2bff9226-01dd-49ce-8c00-439b9b368e4f"
      id="F_5159c828-3599-4442-aff7-b15fca04de4f">P3M</inva:TermOfMilestonePaymentForNetSales>
    <inva:SubscriptionAgreementOneTimeMilestonePaymentOnCommercialSales
      contextRef="C_2bff9226-01dd-49ce-8c00-439b9b368e4f"
      decimals="-5"
      id="F_38d2f6dd-6b05-4a87-ad24-11d91a657b78"
      unitRef="U_USD">10000000</inva:SubscriptionAgreementOneTimeMilestonePaymentOnCommercialSales>
    <inva:TermOfMilestonePaymentForCommercialSale
      contextRef="C_2bff9226-01dd-49ce-8c00-439b9b368e4f"
      id="F_874230e9-c5c4-40a8-8d34-2e030acc69c6">P2Y</inva:TermOfMilestonePaymentForCommercialSale>
    <inva:ConsolidatedEntitiesAndAcquisitionsTextBlock
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      id="F_9a0e3283-2790-4dd2-998f-d09a43402847">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;5. CONSOLIDATED ENTITIES AND ACQUISITIONS&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Consolidated Entities&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Theravance Respiratory Company, LLC&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Up until July 20, 2022, we consolidated TRC under the VIE model as we determined that TRC was a VIE and we were the primary beneficiary of the entity because we had the power to direct the economically significant activities of TRC and the obligation to absorb losses of, or the right to receive benefits from, TRC. We held &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% ownership interest of TRC. The primary source of revenue for TRC is the royalties generated from the net sales of TRELEGY&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; ELLIPTA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; by GSK.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As discussed in Note 3, &#x201c;Revenue Recognition&#x201d;, on July 13, 2022, ITH entered into the TRC Equity Purchase Agreement to sell our ownership interest in TRC. Upon the closing of the transaction on July 20, 2022, we received $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;277.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in cash from Royalty Pharma. We are also entitled to receive up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in contingent sales-based milestone payments in the future. In connection with the closing of the transaction, we also received our portion of TRC&#x2019;s remaining cash balance of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million from Royalty Pharma rather than through a cash distribution from TRC.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Prior to the closing of the transaction and as part of the agreement, TRC distributed its ownership interests and investments in InCarda Therapeutics (&#x201c;InCarda&#x201d;), Inc., ImaginAb, Inc. (&#x201c;ImaginAb&#x201d;), Gate Neurosciences (&#x201c;Gate&#x201d;), Inc. and Nanolive SA (&#x201c;Nanolive&#x201d;), which had a total carrying value of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;39.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, to ITH. We accounted for the transaction similar to an upstream sale between a parent and a VIE under ASC 810-10. As such, ITH recorded the transferred investments at their respective carrying values and no gain or loss was recognized in the consolidated statement of income.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The summarized financial information of TRC &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;for the relevant periods through the sale date in 2022 are presented as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Income statements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:61.232%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.78%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.603%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.78%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.603%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;min-width:fit-content;"&gt;&#160;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Royalty revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;72,029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;126,688&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;332&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,956&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Income from operations&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;71,697&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;122,732&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other income, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Realized loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;39,386&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Income tax expense, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Changes in fair values of equity and&lt;br/&gt;&#160;&#160;&#160;long-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,884&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,541&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net income&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;23,438&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;121,191&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;   The year ended December 31, 2022 represents the period from January 1, 2022 to July 20, 2022, the date of the sale of our ownership interest in TRC.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;ISP Fund LP&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In December 2020, Innoviva Strategic Partners LLC, our wholly owned subsidiary (&#x201c;Strategic Partners&#x201d;), contributed $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;300.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million to ISP Fund LP (the &#x201c;Partnership&#x201d;) for investing in &#x201c;long&#x201d; positions in the healthcare, pharmaceutical and biotechnology sectors and became a limited partner. The general partner of the Partnership (&#x201c;General Partner&#x201d;) is an affiliate of Sarissa Capital.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Partnership Agreement provides for Sarissa Capital to receive management fees from the Partnership, payable quarterly in advance, measured based on the Net Asset Value of Strategic Partners&#x2019; capital account in the Partnership. In addition, General Partner is entitled to an annual performance fee based on the Net Profits of the Partnership during the annual measurement period.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Partnership Agreement includes a lock-up period of thirty-six months after which Strategic Partners is entitled to make withdrawals from the Partnership as of such lock-up expiration date and each anniversary thereafter, subject to certain limitations. The lock-up period for the initial contribution of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;190.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;which excludes the amount discussed below, expired in December 2023. Strategic Partners did not elect to make a withdrawal in 2023, thereby extending the lock-up period and withdrawal elections into subsequent years.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In May 2021, Strategic Partners received a distribution of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;110.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million from the Partnership to provide funding to Innoviva for a strategic repurchase of shares held by GSK. On March 30, 2022, Strategic Partners made an additional capital contribution of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;110.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million to the Partnership pursuant to the letter agreement entered into between Strategic Partners, the Partnership and Sarissa Capital Fund GP LP on May 20, 2021. The capital contribution is subject to a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;36-month&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; lock up period from the contribution date.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We consolidate ISP Fund LP under the VIE model as we have determined that ISP Fund LP is a VIE and we are the primary beneficiary of the entity via our related party relationships with Sarissa Capital entities. Our maximum exposure to loss is equal to the amount we invested in the entity.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ISP Fund LP is determined to be an investment company under ASC 946, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Financial Services &#x2013; Investment Companies&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, as it meets all fundamental characteristics of an investment company, and its activities are consistent with those of an investment company. Since ISP Fund LP is subject to investment company industry specific guidance, we have retained the industry-specific guidance applied by the Partnership. In addition, as our investment in the Partnership is a passive investment for the Company and is not part of our main operations, the investments are presented as part of &#x201c;Equity and long-term investments&#x201d; in our consolidated balance sheets. We report in our consolidated statements of income any investment gains and losses by the Partnership as part of &#x201c;Changes in fair value of equity and long-term investments, net&#x201d;, any interest and dividend income as part of &#x201c;Interest and dividend income&#x201d; and any investment expenses as part of &#x201c;Other expense, net&#x201d;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, we continued to hold &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the economic interest of Partnership. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023 and 2022, total assets of the Partnership were $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;311.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;320.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively, of which the majority was attributable to equity and long-term investments. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023 and 2022, total liabilities of the Partnership w&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ere $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; mill&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ion and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively. The Partnership&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2019;s assets can only be used to settle its own obligations. During the year ended December 31, 2023, the Partnership incurred&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;million in net investment-related expenses, generated $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million interest income, recorded $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in net realized losses and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in net unrealized losses as changes in fair values of equity and long-term investments, net, in the consolidated statement of income. During the year ended December 31, 2022, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;the Partnership incurred $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in net investment-related expenses, generated $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million interest income, recorded $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in net realized gains and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in net unrealized losses as changes in fair values of equity and long-term investments, net, in the consolidated statement of income. During the year ended December 31, 2021, the Partnership incurred $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in net investment-related expense, generated $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million interest and dividend income, and recorded net $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million realized gains and net $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million unrealized losses as changes in fair values of equity and long-term investments, net, in the consolidated statement of income. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We account for the long-term investments held by ISP Fund LP as of December 31, 2023 and 2022 as equity investments measured at fair value and the investment in convertible notes as of December 31, 2022 as trading security.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Acquisitions&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Entasis Therapeutics Holdings Inc.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We started investing in Entasis in 2020 as part of our capital allocation strategy of deploying cash generated from royalty income and investing in different life sciences companies. Entasis at the time was an advanced, late clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products. Effective in June 2020, after certain conditions were met with respect to the sales of Entasis equity shares, Innoviva had the right to designate &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;two&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; members to Entasis&#x2019; board. Our investment in Entasis consisted of shares of common stock and warrants to purchase shares of Entasis common stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The fair value of Entasis&#x2019; common stock was measured based on its closing market price at each balance sheet date. We used the Black-Scholes-Merton pricing model to estimate the fair value of the warrants.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On February 17, 2022, Innoviva Strategic Opportunities, LLC (&#x201c;ISO&#x201d;)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; entered into a securities purchase agreement with Entasis pursuant to which ISO purchased a convertible promissory note for a total purchase price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. The note bore an annual interest rate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.59&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% and was due to mature and become payable on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;August 18, 2022&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; unless it was converted at a conversion price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.48&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; before the maturity date. With this financing, we determined that we had both (i) the power to direct the economically significant activities of Entasis and (ii) the obligation to absorb the losses, or the right to receive the benefits, that could potentially be significant to Entasis and therefore, we were the primary beneficiary of Entasis. Accordingly, we consolidated Entasis&#x2019; financial position and results of operations effective on February 17, 2022. Our equity ownership interest remained at &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;59.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% as of February 17, 2022, and the fair values of our holdings of Entasis common stock and warrants were remeasured and estimated at $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;64.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;31.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The remeasurement resulted in a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million loss in the first quarter of 2022 which was included in changes in fair values of equity method investments, net, in the consolidated statement of income for the year ended December 31, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We completed our acquisition of Entasis&#x2019; minority interest on July 11, 2022. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; payments were made toward the convertible promissory note through the date of acquisition of Entasis. In connection with the acquisition, all of the Entasis warrants were replaced with Innoviva warrants (the &#x201c;Replacement Warrants&#x201d;) of equivalent value and bearing the same terms. The Replacement Warrants are classified as equity.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We recognized the difference between the acquisition price and the carrying value of the acquired minority interest on July 11, 2022 in our additional paid-in capital.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The fair values assigned to assets acquired and liabilities assumed as of February 17, 2022 were based on management&#x2019;s best estimates and assumptions. After the acquisition in July 2022, we adjusted the purchase price allocation based on new and additional information related to product sales forecast provided by Entasis and deferred tax liabilities.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;During the year ended December 31, 2022, we recorded measurement period adjustments of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million decrease in goodwill, primarily related to a decrease in estimated purchase price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, an increase in noncontrolling interests of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, and an increase in intangible assets of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. The cumulative impact of the measurement period adjustments included in the consolidated net income for the year ended December 31, 2022 was not material.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In February 2023, we recorded a measurement period adjustment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million increase in goodwill, primarily related to a decrease in intangible assets of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and an increase in deferred tax liabilities of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. The measurement period adjustment did not impact the consolidated net income for the year ended December 31, 2023.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table represents the adjusted fair values of the assets acquired and liabilities assumed by us in the transaction:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.444%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.8%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.757%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;February 17, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;23,070&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Prepaid expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,554&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,959&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;185&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;959&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Goodwill&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,493&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Intangible assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;106,700&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;302&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total assets acquired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;150,222&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accounts payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,583&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued personnel-related expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,058&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other accrued liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,096&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,769&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total liabilities assumed&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,506&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total assets acquired, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;134,716&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The goodwill arising from the acquisition of Entasis is primarily attributable to Entasis&#x2019; assembled workforce and the value associated with growing our business more efficiently. The goodwill from this acquisition is not expected to be deductible for tax purposes.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Refer to Note 8, &#x201c;Goodwill and Intangible Assets&#x201d;, for more discussion on the intangible assets recognized as part of this acquisition.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As a result of the consolidation, we recognized a non-controlling interest of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;38.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million as of February 17, 2022. Our consolidated net income for the year ended December 31, 2022 included the net loss attributable to noncontrolling interest since the consolidation date until the date of acquisition of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;La Jolla Pharmaceutical Company&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On August 22, 2022, ISO acquired La Jolla for a total consideration of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;206.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. ISO acquired La Jolla at a price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.23&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share. La Jolla is dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases. La Jolla brought to Innoviva an established product portfolio, including GIAPREZA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock and XERAVA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; (eravacycline) for the treatment of complicated intra-abdominal infections (cIAIs). We incurred approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in acquisition-related costs in connection with this acquisition during the year ended December 31, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The fair values assigned to assets acquired and liabilities assumed as of August 22, 2022 were based on management&#x2019;s best estimates and assumptions.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;During the year ended December 31, 2022, we recorded measurement period adjustments of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million increase in goodwill, primarily related to a decrease in inventory and intangible assets of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively, and an increase in deferred tax liabilities of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, partially offset by a decrease in other long-term liabilities of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. The cumulative impact of the measurement period adjustments included in the consolidated net income for the year ended December 31, 2022 was not material.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In June 2023, we recorded a measurement period adjustment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million decrease in goodwill, primarily related to an increase in deferred tax assets of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and a decrease in deferred tax liabilities of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. In August 2023, we recorded a measurement period adjustment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million increase in goodwill, primarily related to a decrease in deferred tax assets of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and an increase in deferred tax liabilities of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. The cumulative impact of the measurement period adjustments included did not impact the consolidated net income for the year ended December 31, 2023.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table represents the adjusted fair values of assets acquired and liabilities assumed by us in the transaction:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.444%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.8%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.757%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;August 22, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;47,415&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Short-term marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;471&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accounts receivable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,876&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Inventory&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;66,200&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Prepaid expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,261&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;907&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;226&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Goodwill&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,411&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Intangible assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;151,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,461&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;710&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total assets acquired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;287,951&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accounts payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,237&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,849&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other accrued liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,362&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other long-term liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;65,944&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total liabilities assumed&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;81,392&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total assets acquired, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;206,559&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The goodwill arising from the acquisition of La Jolla is primarily attributable to La Jolla&#x2019;s assembled workforce and the value associated with leveraging the workforce to develop and commercialize new drug products in the future and growing our business more efficiently. The goodwill from this acquisition is not expected to be deductible for tax purposes.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Refer to Note 8, &#x201c;Goodwill and Intangible Assets&#x201d;, for more discussion on the intangible assets recognized as part of this acquisition.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Pro Forma Financial Information&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table presents certain unaudited pro-forma financial information for the years ended December 31, 2022 and 2021 as if the consolidation of Entasis and La Jolla occurred on January 1, 2021. The unaudited pro forma financial information is presented for informational purposes only, and is not indicative of the results of operations that would have been achieved if the acquisitions had taken place on January 1, 2021, or of results that may occur in the future. The unaudited pro forma financial information combines the historical results of the Entasis and La Jolla with the Company&#x2019;s consolidated historical results and includes certain adjustments including, but not limited to, fair value adjustments to equity investments in Entasis&#x2019; common stock and warrants, fair value adjustments to inventory, amortization of intangible assets, and interest expense on deferred royalty obligations and acquisition-related costs.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:53.88%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.26%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:18.799999999999997%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.26%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:18.799999999999997%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;357,880&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;435,398&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net income&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;204,987&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;281,719&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net income attributable to Innoviva stockholders&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;214,390&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;197,535&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</inva:ConsolidatedEntitiesAndAcquisitionsTextBlock>
    <inva:OwnershipInterestInConsolidatedEntities
      contextRef="C_9eac7308-f944-4333-bf01-4381430c8676"
      decimals="2"
      id="F_0565eeaa-14fc-4105-b44d-2a1384f965c8"
      unitRef="U_pure">0.15</inva:OwnershipInterestInConsolidatedEntities>
    <inva:ProceedsFromSaleOfEconomicInterestUnderEquityPurchaseAgreement
      contextRef="C_9c87d87f-710c-4de3-a73e-9a9094727284"
      decimals="-5"
      id="F_5d669584-4a16-43df-99b6-20165e629f13"
      unitRef="U_USD">277500000</inva:ProceedsFromSaleOfEconomicInterestUnderEquityPurchaseAgreement>
    <inva:ContingentSalesBasedMilestonePayment
      contextRef="C_4db40aa1-f9c9-4e8f-b9d8-1756f4712094"
      decimals="-5"
      id="F_c77a662a-0621-4eb3-ac39-eb72ccd64478"
      unitRef="U_USD">50000000</inva:ContingentSalesBasedMilestonePayment>
    <inva:CashDistributionReceived
      contextRef="C_4db40aa1-f9c9-4e8f-b9d8-1756f4712094"
      decimals="-5"
      id="F_078fcb7a-3864-44ee-824e-36be1a16ba0c"
      unitRef="U_USD">4400000</inva:CashDistributionReceived>
    <us-gaap:EquityMethodInvestments
      contextRef="C_9c87d87f-710c-4de3-a73e-9a9094727284"
      decimals="-5"
      id="F_1d6e1856-9f40-4f9c-8300-cf537fcb38c9"
      unitRef="U_USD">39400000</us-gaap:EquityMethodInvestments>
    <us-gaap:ScheduleOfVariableInterestEntitiesTextBlock
      contextRef="C_8e8b777f-2a9d-4fa4-b2ab-fe056ae69ce8"
      id="F_8900d24b-05a0-4198-9a12-e0b2ee276469">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The summarized financial information of TRC &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;for the relevant periods through the sale date in 2022 are presented as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Income statements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:61.232%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.78%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.603%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.78%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.603%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;min-width:fit-content;"&gt;&#160;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Royalty revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;72,029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;126,688&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;332&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,956&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Income from operations&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;71,697&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;122,732&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other income, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Realized loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;39,386&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Income tax expense, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Changes in fair values of equity and&lt;br/&gt;&#160;&#160;&#160;long-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,884&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,541&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net income&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;23,438&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;121,191&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;   The year ended December 31, 2022 represents the period from January 1, 2022 to July 20, 2022, the date of the sale of our ownership interest in TRC.&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfVariableInterestEntitiesTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_b2c2c1ac-728c-4d23-a024-c459443d06d0"
      decimals="-3"
      id="F_10f70c8e-4f7f-4ca3-b77a-59255ab84f38"
      unitRef="U_USD">72029000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_7a07a415-eb4b-4dff-ab91-19dbbfc1a7cc"
      decimals="-3"
      id="F_4c0cd5e1-664c-4c03-a810-77e21e9e9a94"
      unitRef="U_USD">126688000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:OperatingExpenses
      contextRef="C_9eac7308-f944-4333-bf01-4381430c8676"
      decimals="-3"
      id="F_19514078-4d7f-46e4-9ec3-6baa01d8bc45"
      unitRef="U_USD">-332000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_d81eb8e0-c039-48de-a07a-d8267be56862"
      decimals="-3"
      id="F_71a44ba5-c899-4022-994d-2aa0cc5643bf"
      unitRef="U_USD">-3956000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_9eac7308-f944-4333-bf01-4381430c8676"
      decimals="-3"
      id="F_9f51a90b-d5b3-4baf-a592-557db4d38798"
      unitRef="U_USD">71697000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_d81eb8e0-c039-48de-a07a-d8267be56862"
      decimals="-3"
      id="F_7f3cb076-04b4-4d3d-87b1-c333b3e454e0"
      unitRef="U_USD">122732000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_9eac7308-f944-4333-bf01-4381430c8676"
      decimals="-3"
      id="F_c2d29a19-daed-4394-b61e-859713cd07bf"
      unitRef="U_USD">10000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_d81eb8e0-c039-48de-a07a-d8267be56862"
      decimals="-3"
      id="F_2f21832c-338f-4281-9f6b-759b8af2cef9"
      unitRef="U_USD">0</us-gaap:OtherNonoperatingIncomeExpense>
    <inva:RealizedLoss
      contextRef="C_9eac7308-f944-4333-bf01-4381430c8676"
      decimals="-3"
      id="F_f2a97274-1f4f-460d-ae0c-feb28444b496"
      unitRef="U_USD">-39386000</inva:RealizedLoss>
    <inva:RealizedLoss
      contextRef="C_d81eb8e0-c039-48de-a07a-d8267be56862"
      decimals="-3"
      id="F_e46ed95f-8618-4b08-972d-9ee0c9d9fd5d"
      unitRef="U_USD">0</inva:RealizedLoss>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_9eac7308-f944-4333-bf01-4381430c8676"
      decimals="-3"
      id="F_fd0c3223-a52a-48b1-a54d-d2343a4454e1"
      unitRef="U_USD">1000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_d81eb8e0-c039-48de-a07a-d8267be56862"
      decimals="-3"
      id="F_080bc88e-12ec-4149-90d5-7bd8a47674c7"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:GainLossOnInvestments
      contextRef="C_9eac7308-f944-4333-bf01-4381430c8676"
      decimals="-3"
      id="F_f02c3cdb-acc9-4cbf-9957-678c00ecf7f0"
      unitRef="U_USD">-8884000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="C_d81eb8e0-c039-48de-a07a-d8267be56862"
      decimals="-3"
      id="F_e8d2f2cc-27a9-4411-9bd6-36f1e69c07d7"
      unitRef="U_USD">-1541000</us-gaap:GainLossOnInvestments>
    <us-gaap:ProfitLoss
      contextRef="C_9eac7308-f944-4333-bf01-4381430c8676"
      decimals="-3"
      id="F_e397c611-ef5b-4261-b926-3631409061a6"
      unitRef="U_USD">23438000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_d81eb8e0-c039-48de-a07a-d8267be56862"
      decimals="-3"
      id="F_43adfe2b-634e-4aed-8e25-0f6e4e580cb0"
      unitRef="U_USD">121191000</us-gaap:ProfitLoss>
    <us-gaap:LimitedPartnersContributedCapital
      contextRef="C_1e700f80-a869-46a2-ac03-43bec9ff60e2"
      decimals="-5"
      id="F_7fdbffc2-128f-47d4-a23f-3d31b2874a80"
      unitRef="U_USD">300000000</us-gaap:LimitedPartnersContributedCapital>
    <inva:LimitedPartnersInitialContribution
      contextRef="C_059975f4-4c4c-47fa-a5cc-efc7bf10d886"
      decimals="-5"
      id="F_f5e048ab-9eec-4e63-9a25-d200726c9f15"
      unitRef="U_USD">190000000</inva:LimitedPartnersInitialContribution>
    <us-gaap:LimitedPartnersCumulativeCashDistributions
      contextRef="C_9030a2c1-fd8e-4238-9d01-79bece46654e"
      decimals="-5"
      id="F_69fcbab7-42fe-4ba2-8211-853ec6669c3b"
      unitRef="U_USD">110000000</us-gaap:LimitedPartnersCumulativeCashDistributions>
    <us-gaap:LimitedPartnersContributedCapital
      contextRef="C_11f17e9c-095d-4fae-8b57-328fa2b9ba57"
      decimals="-5"
      id="F_e6b3f107-faa4-4f27-a236-560d92621265"
      unitRef="U_USD">110000000</us-gaap:LimitedPartnersContributedCapital>
    <inva:PartnershipAgreementLockUpPeriod
      contextRef="C_0baf8d0a-a93a-4dff-b66a-e5c5efa4d6d1"
      id="F_5952750a-4747-4048-8cdc-ba21ff28db50">P36M</inva:PartnershipAgreementLockUpPeriod>
    <inva:PercentageOfEconomicInterestInPartnership
      contextRef="C_059975f4-4c4c-47fa-a5cc-efc7bf10d886"
      decimals="2"
      id="F_979e7540-9f16-4721-8b5a-6067157efbda"
      unitRef="U_pure">1</inva:PercentageOfEconomicInterestInPartnership>
    <us-gaap:Assets
      contextRef="C_b39ad5c9-17bf-4a35-b889-6bc388c60b7c"
      decimals="-5"
      id="F_7e09e334-d1c2-4af9-8ac1-b3bdc917a5ed"
      unitRef="U_USD">311800000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_3abefe6f-631c-4640-93e2-984c5ac20007"
      decimals="-5"
      id="F_5cd98a1e-8b67-472d-a3d5-19ddd1f3398f"
      unitRef="U_USD">320600000</us-gaap:Assets>
    <us-gaap:Liabilities
      contextRef="C_b39ad5c9-17bf-4a35-b889-6bc388c60b7c"
      decimals="-5"
      id="F_addc67ae-9328-46b8-93f8-b7ad4c0d6bd7"
      unitRef="U_USD">100000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_3abefe6f-631c-4640-93e2-984c5ac20007"
      decimals="-5"
      id="F_5c36a5fe-b2c3-4311-966b-4cb72c1e5891"
      unitRef="U_USD">1600000</us-gaap:Liabilities>
    <inva:NetInvestmentRelatedIncomeExpenseEarnedInccured
      contextRef="C_059975f4-4c4c-47fa-a5cc-efc7bf10d886"
      decimals="-5"
      id="F_34474073-836e-4ded-b229-5b44072f0e9c"
      unitRef="U_USD">4300000</inva:NetInvestmentRelatedIncomeExpenseEarnedInccured>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_059975f4-4c4c-47fa-a5cc-efc7bf10d886"
      decimals="-5"
      id="F_0b2c65ea-8032-4d62-8963-32f321cf6967"
      unitRef="U_USD">6300000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:GainLossOnInvestments
      contextRef="C_059975f4-4c4c-47fa-a5cc-efc7bf10d886"
      decimals="-5"
      id="F_561de82e-5ef2-4244-9a3c-8543ec66908b"
      unitRef="U_USD">2400000</us-gaap:GainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="C_059975f4-4c4c-47fa-a5cc-efc7bf10d886"
      decimals="-5"
      id="F_32e0511f-7e5c-44fc-94c1-94e0f20b7ce7"
      unitRef="U_USD">6700000</us-gaap:UnrealizedGainLossOnInvestments>
    <inva:NetInvestmentRelatedIncomeExpenseEarnedInccured
      contextRef="C_03ba9ffa-87ef-489a-a311-42db1ae05203"
      decimals="-5"
      id="F_d8a82c50-5826-4025-8d04-322b9936a799"
      unitRef="U_USD">5200000</inva:NetInvestmentRelatedIncomeExpenseEarnedInccured>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_03ba9ffa-87ef-489a-a311-42db1ae05203"
      decimals="-5"
      id="F_97ecde06-8713-4737-a93e-23658bfa9fc6"
      unitRef="U_USD">2000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:GainLossOnInvestments
      contextRef="C_03ba9ffa-87ef-489a-a311-42db1ae05203"
      decimals="-5"
      id="F_b0accbe7-c0cf-4ba7-8bf5-7123d0002c14"
      unitRef="U_USD">6800000</us-gaap:GainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="C_03ba9ffa-87ef-489a-a311-42db1ae05203"
      decimals="-5"
      id="F_5a051022-3b58-4384-a4a0-44ecf8d09a85"
      unitRef="U_USD">9900000</us-gaap:UnrealizedGainLossOnInvestments>
    <inva:NetInvestmentRelatedIncomeExpenseEarnedInccured
      contextRef="C_0287d352-8cf0-4411-9610-d97bd5f904bf"
      decimals="-5"
      id="F_91ea76ab-7fa6-43a6-946b-ecf55e6b3895"
      unitRef="U_USD">3600000</inva:NetInvestmentRelatedIncomeExpenseEarnedInccured>
    <us-gaap:InvestmentIncomeInterestAndDividend
      contextRef="C_0287d352-8cf0-4411-9610-d97bd5f904bf"
      decimals="-5"
      id="F_dba588e7-5ff7-45ef-b8ee-8f9ed2dd98f8"
      unitRef="U_USD">1800000</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:GainLossOnInvestments
      contextRef="C_0287d352-8cf0-4411-9610-d97bd5f904bf"
      decimals="-5"
      id="F_193b980a-a50d-4a50-9018-2ad221f1d1b7"
      unitRef="U_USD">10500000</us-gaap:GainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="C_0287d352-8cf0-4411-9610-d97bd5f904bf"
      decimals="-5"
      id="F_d5fee99c-b330-4f90-af14-b9125f109617"
      unitRef="U_USD">2400000</us-gaap:UnrealizedGainLossOnInvestments>
    <inva:SecuritiesPurchaseAgreementRightsToDesignateInvesteeBoardMembersNumberOfBoardMembers
      contextRef="C_8f8c6623-d626-4ff4-b287-9206e6e7485e"
      decimals="0"
      id="F_dfe2b84f-232e-435e-94ac-3fc38ae275d6"
      unitRef="U_Director">2</inva:SecuritiesPurchaseAgreementRightsToDesignateInvesteeBoardMembersNumberOfBoardMembers>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="C_0de66d0f-6eb9-49fa-a5ec-9c7b513a7979"
      decimals="-5"
      id="F_63d68d0c-8ac9-4c47-9d3c-f6d2bbc21be4"
      unitRef="U_USD">15000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="C_0de66d0f-6eb9-49fa-a5ec-9c7b513a7979"
      decimals="4"
      id="F_1f229d5a-3c41-4cbf-bfe8-4c0f25b8a743"
      unitRef="U_pure">0.0059</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="C_011ae41c-ec4e-43c1-8532-003573595646"
      id="F_6ff7305f-44a8-48b8-ac53-12af7ec7e17f">2022-08-18</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="C_0de66d0f-6eb9-49fa-a5ec-9c7b513a7979"
      decimals="2"
      id="F_872cd0ac-bee1-4988-9b5d-812ad2f1a615"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.48</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="C_c00f47a4-0506-4cb6-a19d-c4eb9dd56571"
      decimals="3"
      id="F_5b38513e-6e0b-45a3-a161-0cbdb7c43d0c"
      unitRef="U_pure">0.599</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="C_c6dfd9f2-8eeb-44c2-9621-2be87264e608"
      decimals="-5"
      id="F_d647bf54-6717-401d-b62b-71a859a50505"
      unitRef="U_USD">64500000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="C_126a8e06-61fd-494c-9ffd-58ea5c0bdea5"
      decimals="-5"
      id="F_3bc72364-c8d2-4955-9d85-48ea3c3f10f2"
      unitRef="U_USD">31400000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="C_a864ac08-9446-4d68-95de-31f94372d9f3"
      decimals="-5"
      id="F_2ccab435-7a95-4957-b210-6897152e3380"
      unitRef="U_USD">7800000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="C_707fc4b5-3c6e-4394-b574-0e56dc4f8c0a"
      decimals="-3"
      id="F_346d8b38-1fbd-43d4-8033-3e6f9e7303f3"
      unitRef="U_USD">0</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:GoodwillPeriodIncreaseDecrease
      contextRef="C_710dc59e-981c-4ad8-987e-bb49af565884"
      decimals="-5"
      id="F_3eeea199-6a9c-4bed-ad7a-dce058f78f3a"
      unitRef="U_USD">-4700000</us-gaap:GoodwillPeriodIncreaseDecrease>
    <inva:MeasurementPeriodAdjustmentsIncreaseDecreaseInEstimatedPurchasePrice
      contextRef="C_710dc59e-981c-4ad8-987e-bb49af565884"
      decimals="-5"
      id="F_acf239c5-1148-4a38-adba-880abd71a70b"
      unitRef="U_USD">-1400000</inva:MeasurementPeriodAdjustmentsIncreaseDecreaseInEstimatedPurchasePrice>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease
      contextRef="C_710dc59e-981c-4ad8-987e-bb49af565884"
      decimals="-5"
      id="F_b7c861aa-d43f-4ae0-9828-83904acd56c7"
      unitRef="U_USD">1700000</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease
      contextRef="C_710dc59e-981c-4ad8-987e-bb49af565884"
      decimals="-5"
      id="F_920c87ec-9784-440a-9cfa-bcdff66ecb4a"
      unitRef="U_USD">2500000</us-gaap:IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease>
    <us-gaap:GoodwillPeriodIncreaseDecrease
      contextRef="C_3b8d2e0c-b8e8-465e-b685-f60604c8c298"
      decimals="-5"
      id="F_f3ba2403-4fa8-411a-888d-1f991744a29d"
      unitRef="U_USD">1200000</us-gaap:GoodwillPeriodIncreaseDecrease>
    <us-gaap:IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease
      contextRef="C_3b8d2e0c-b8e8-465e-b685-f60604c8c298"
      decimals="-5"
      id="F_61241a22-2590-4213-9307-6b1c4312f351"
      unitRef="U_USD">-800000</us-gaap:IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease>
    <inva:IncreaseDecreaseInDeferredTaxLiabilities
      contextRef="C_3b8d2e0c-b8e8-465e-b685-f60604c8c298"
      decimals="-5"
      id="F_b277d103-6c0f-42c9-89ed-fb432f1cd03c"
      unitRef="U_USD">400000</inva:IncreaseDecreaseInDeferredTaxLiabilities>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="C_8f8c6623-d626-4ff4-b287-9206e6e7485e"
      id="F_a54dbd9a-1b7a-47b9-bf5a-a8b6c68614a7">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table represents the adjusted fair values of the assets acquired and liabilities assumed by us in the transaction:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.444%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.8%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.757%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;February 17, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;23,070&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Prepaid expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,554&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,959&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;185&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;959&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Goodwill&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,493&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Intangible assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;106,700&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;302&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total assets acquired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;150,222&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accounts payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,583&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued personnel-related expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,058&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other accrued liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,096&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,769&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total liabilities assumed&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,506&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total assets acquired, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;134,716&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="C_1cbdd9df-6a4a-4d82-9344-ffb61a7bc4cd"
      decimals="-3"
      id="F_83d339a1-6454-45cb-8702-8fd2f21d8671"
      unitRef="U_USD">23070000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets
      contextRef="C_1cbdd9df-6a4a-4d82-9344-ffb61a7bc4cd"
      decimals="-3"
      id="F_2c0f211a-95a0-478f-b09c-f265fe0e9065"
      unitRef="U_USD">5554000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther
      contextRef="C_1cbdd9df-6a4a-4d82-9344-ffb61a7bc4cd"
      decimals="-3"
      id="F_5ec24488-b0a0-4f5b-a641-250cd8fe1b63"
      unitRef="U_USD">1959000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
      contextRef="C_1cbdd9df-6a4a-4d82-9344-ffb61a7bc4cd"
      decimals="-3"
      id="F_bed4bb33-192f-4382-b52a-40d14d20af5b"
      unitRef="U_USD">185000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <inva:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets
      contextRef="C_1cbdd9df-6a4a-4d82-9344-ffb61a7bc4cd"
      decimals="-3"
      id="F_6bf47e06-d4c6-4f87-a63f-a68af80d7ce0"
      unitRef="U_USD">959000</inva:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets>
    <us-gaap:Goodwill
      contextRef="C_1cbdd9df-6a4a-4d82-9344-ffb61a7bc4cd"
      decimals="-3"
      id="F_87696f4c-9aba-4912-832b-a0805442542c"
      unitRef="U_USD">11493000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
      contextRef="C_1cbdd9df-6a4a-4d82-9344-ffb61a7bc4cd"
      decimals="-3"
      id="F_82f28d63-ee54-499d-84dd-996c1cb19e51"
      unitRef="U_USD">106700000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets
      contextRef="C_1cbdd9df-6a4a-4d82-9344-ffb61a7bc4cd"
      decimals="-3"
      id="F_a5ab4c8c-27aa-4ceb-91b0-ca6beb320c07"
      unitRef="U_USD">302000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
      contextRef="C_1cbdd9df-6a4a-4d82-9344-ffb61a7bc4cd"
      decimals="-3"
      id="F_5eeda392-7a15-4cd0-9c5c-bd002cc79418"
      unitRef="U_USD">150222000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable
      contextRef="C_1cbdd9df-6a4a-4d82-9344-ffb61a7bc4cd"
      decimals="-3"
      id="F_f0b72a82-4e04-4784-ac2f-d1e7eb74e4ea"
      unitRef="U_USD">1583000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <inva:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedPersonnelRelatedExpenses
      contextRef="C_1cbdd9df-6a4a-4d82-9344-ffb61a7bc4cd"
      decimals="-3"
      id="F_7924b47f-2819-4328-97e2-078f0f041f63"
      unitRef="U_USD">1058000</inva:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedPersonnelRelatedExpenses>
    <inva:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAccruedLiabilities
      contextRef="C_1cbdd9df-6a4a-4d82-9344-ffb61a7bc4cd"
      decimals="-3"
      id="F_975f56ed-35c2-4842-9688-f2b7f241d975"
      unitRef="U_USD">5096000</inva:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAccruedLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="C_1cbdd9df-6a4a-4d82-9344-ffb61a7bc4cd"
      decimals="-3"
      id="F_ac340973-2cf7-4cbd-b121-2ea1affcfd4e"
      unitRef="U_USD">7769000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
      contextRef="C_1cbdd9df-6a4a-4d82-9344-ffb61a7bc4cd"
      decimals="-3"
      id="F_44e69415-8d40-4d88-9180-25070284092f"
      unitRef="U_USD">15506000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="C_1cbdd9df-6a4a-4d82-9344-ffb61a7bc4cd"
      decimals="-3"
      id="F_6ff7849d-f9be-450a-9acf-782698ec24f8"
      unitRef="U_USD">134716000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:MinorityInterest
      contextRef="C_1cbdd9df-6a4a-4d82-9344-ffb61a7bc4cd"
      decimals="-5"
      id="F_6dfdf5f6-111f-4d18-b755-bcade717cccd"
      unitRef="U_USD">38500000</us-gaap:MinorityInterest>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_710dc59e-981c-4ad8-987e-bb49af565884"
      decimals="-5"
      id="F_293aa7d6-0b2d-47ca-97f3-612fec869643"
      unitRef="U_USD">13600000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="C_e05740b2-e808-41d3-b26e-897ba3aa633c"
      decimals="-5"
      id="F_96f8aca3-eacd-44c0-9b02-4f4a46a7f9fc"
      unitRef="U_USD">206600000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="C_d175404c-e239-4f30-bbd0-3bbf386d06ea"
      decimals="2"
      id="F_67be033a-b16e-43e8-9533-23ca17d4bb06"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">6.23</us-gaap:BusinessAcquisitionSharePrice>
    <us-gaap:AcquisitionCosts
      contextRef="C_64603e03-c98c-40b7-ae31-b9e79c20bc55"
      decimals="-5"
      id="F_62700df4-7667-4b67-bd28-65464115f4ad"
      unitRef="U_USD">5300000</us-gaap:AcquisitionCosts>
    <us-gaap:GoodwillPeriodIncreaseDecrease
      contextRef="C_64603e03-c98c-40b7-ae31-b9e79c20bc55"
      decimals="-5"
      id="F_dca6ae47-9c82-404f-9198-69f14203e6e6"
      unitRef="U_USD">3700000</us-gaap:GoodwillPeriodIncreaseDecrease>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="C_64603e03-c98c-40b7-ae31-b9e79c20bc55"
      decimals="-5"
      id="F_4707052e-f63f-4c28-800d-ca0b0c075a90"
      unitRef="U_USD">-7700000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease
      contextRef="C_64603e03-c98c-40b7-ae31-b9e79c20bc55"
      decimals="-5"
      id="F_d3c43416-a373-4344-9734-570165238862"
      unitRef="U_USD">-1500000</us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease>
    <inva:IncreaseDecreaseInDeferredTaxLiabilities
      contextRef="C_64603e03-c98c-40b7-ae31-b9e79c20bc55"
      decimals="-5"
      id="F_b05ad8cd-f163-4ad2-b125-4fc2282faa95"
      unitRef="U_USD">2600000</inva:IncreaseDecreaseInDeferredTaxLiabilities>
    <inva:MeasurementPeriodAdjustmentsIncreaseDecreaseInLiabilities
      contextRef="C_64603e03-c98c-40b7-ae31-b9e79c20bc55"
      decimals="-5"
      id="F_541eff81-ec71-47c3-9e28-1be121f98b0d"
      unitRef="U_USD">-8300000</inva:MeasurementPeriodAdjustmentsIncreaseDecreaseInLiabilities>
    <us-gaap:GoodwillPeriodIncreaseDecrease
      contextRef="C_c20721f8-5014-4577-a717-6b5f4d10b69e"
      decimals="-5"
      id="F_983cc8a2-be22-4682-913b-7e0325bafd90"
      unitRef="U_USD">-13100000</us-gaap:GoodwillPeriodIncreaseDecrease>
    <inva:IncreaseDecreaseInDeferredTaxAssets
      contextRef="C_c20721f8-5014-4577-a717-6b5f4d10b69e"
      decimals="-5"
      id="F_4ef55ebc-267e-4a78-85fd-6e9a5da9d06c"
      unitRef="U_USD">10500000</inva:IncreaseDecreaseInDeferredTaxAssets>
    <inva:IncreaseDecreaseInDeferredTaxLiabilities
      contextRef="C_c20721f8-5014-4577-a717-6b5f4d10b69e"
      decimals="-5"
      id="F_177def64-2b39-45c1-8eb5-07e15273ecee"
      unitRef="U_USD">-2600000</inva:IncreaseDecreaseInDeferredTaxLiabilities>
    <us-gaap:GoodwillPeriodIncreaseDecrease
      contextRef="C_4e8f4a7f-a815-47e5-91cf-9d09535c48ce"
      decimals="-5"
      id="F_5c19a1e7-e70a-4141-bd97-2ccf6c4ae4b9"
      unitRef="U_USD">3000000</us-gaap:GoodwillPeriodIncreaseDecrease>
    <inva:IncreaseDecreaseInDeferredTaxAssets
      contextRef="C_4e8f4a7f-a815-47e5-91cf-9d09535c48ce"
      decimals="-5"
      id="F_48976b1d-19a6-46d9-8cea-8f691ef1d1dd"
      unitRef="U_USD">-2400000</inva:IncreaseDecreaseInDeferredTaxAssets>
    <inva:IncreaseDecreaseInDeferredTaxLiabilities
      contextRef="C_4e8f4a7f-a815-47e5-91cf-9d09535c48ce"
      decimals="-5"
      id="F_9b6ad3b1-08f6-4ca0-adaf-300d498e9204"
      unitRef="U_USD">600000</inva:IncreaseDecreaseInDeferredTaxLiabilities>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="C_211cd3e4-b7d2-4255-9490-b9155f8d7b3d"
      id="F_9619c407-67cc-4053-a7ad-0d31806e86c0">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table represents the adjusted fair values of assets acquired and liabilities assumed by us in the transaction:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.444%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.8%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.757%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;August 22, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;47,415&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Short-term marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;471&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accounts receivable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,876&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Inventory&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;66,200&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Prepaid expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,261&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;907&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;226&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Goodwill&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,411&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Intangible assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;151,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,461&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;710&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total assets acquired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;287,951&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accounts payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,237&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,849&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other accrued liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,362&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other long-term liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;65,944&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total liabilities assumed&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;81,392&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total assets acquired, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;206,559&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="C_d175404c-e239-4f30-bbd0-3bbf386d06ea"
      decimals="-3"
      id="F_4f2c1f9c-a27c-465c-bdfa-0f5d80d9a3bc"
      unitRef="U_USD">47415000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities
      contextRef="C_d175404c-e239-4f30-bbd0-3bbf386d06ea"
      decimals="-3"
      id="F_4c953744-8bb4-4164-b1d7-aec440b1a20b"
      unitRef="U_USD">471000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables
      contextRef="C_d175404c-e239-4f30-bbd0-3bbf386d06ea"
      decimals="-3"
      id="F_07b6c5fb-808c-4f27-9edf-274e05e392ab"
      unitRef="U_USD">5876000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory
      contextRef="C_d175404c-e239-4f30-bbd0-3bbf386d06ea"
      decimals="-3"
      id="F_013e7152-a610-4c0f-823f-b18b3a0078ed"
      unitRef="U_USD">66200000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets
      contextRef="C_d175404c-e239-4f30-bbd0-3bbf386d06ea"
      decimals="-3"
      id="F_b94a3fde-9910-4779-a1a3-11775c76f54b"
      unitRef="U_USD">1261000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther
      contextRef="C_d175404c-e239-4f30-bbd0-3bbf386d06ea"
      decimals="-3"
      id="F_5dae0d2c-9253-44f4-9c89-eeeb4ba191bb"
      unitRef="U_USD">907000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
      contextRef="C_d175404c-e239-4f30-bbd0-3bbf386d06ea"
      decimals="-3"
      id="F_7d02a06b-a5f4-47b7-83b3-c415adbffd55"
      unitRef="U_USD">13000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <inva:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets
      contextRef="C_d175404c-e239-4f30-bbd0-3bbf386d06ea"
      decimals="-3"
      id="F_95e5dbcd-98eb-4ce4-a3a3-f5d09f464b03"
      unitRef="U_USD">226000</inva:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets>
    <us-gaap:Goodwill
      contextRef="C_d175404c-e239-4f30-bbd0-3bbf386d06ea"
      decimals="-3"
      id="F_ee97a437-896e-4267-874e-188a310adf52"
      unitRef="U_USD">6411000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
      contextRef="C_d175404c-e239-4f30-bbd0-3bbf386d06ea"
      decimals="-3"
      id="F_4922cb69-48a6-4d36-a893-8532232c6cac"
      unitRef="U_USD">151000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets
      contextRef="C_d175404c-e239-4f30-bbd0-3bbf386d06ea"
      decimals="-3"
      id="F_6ea13c57-ec3b-4cd9-8bb1-e808b24dcc41"
      unitRef="U_USD">7461000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets
      contextRef="C_d175404c-e239-4f30-bbd0-3bbf386d06ea"
      decimals="-3"
      id="F_3cf76fce-48fc-4b23-8baa-533bb6ceb5e0"
      unitRef="U_USD">710000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
      contextRef="C_d175404c-e239-4f30-bbd0-3bbf386d06ea"
      decimals="-3"
      id="F_3d2205f0-21c7-491d-bb11-13f25ebe2ea4"
      unitRef="U_USD">287951000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable
      contextRef="C_d175404c-e239-4f30-bbd0-3bbf386d06ea"
      decimals="-3"
      id="F_327e038b-83ef-4ab1-a8f2-ddd09130e064"
      unitRef="U_USD">1237000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue
      contextRef="C_d175404c-e239-4f30-bbd0-3bbf386d06ea"
      decimals="-3"
      id="F_68461bf3-5fcf-4036-83b1-e1dbcbe38e4c"
      unitRef="U_USD">2849000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue>
    <inva:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAccruedLiabilities
      contextRef="C_d175404c-e239-4f30-bbd0-3bbf386d06ea"
      decimals="-3"
      id="F_f5ca7f1e-e720-4dd6-9d43-656fcdc9443b"
      unitRef="U_USD">11362000</inva:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAccruedLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther
      contextRef="C_d175404c-e239-4f30-bbd0-3bbf386d06ea"
      decimals="-3"
      id="F_0c6ffa82-91c1-4ecd-844d-9b21438594ab"
      unitRef="U_USD">65944000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
      contextRef="C_d175404c-e239-4f30-bbd0-3bbf386d06ea"
      decimals="-3"
      id="F_42c73cf9-98c7-43f4-bdac-e052ab203368"
      unitRef="U_USD">81392000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="C_d175404c-e239-4f30-bbd0-3bbf386d06ea"
      decimals="-3"
      id="F_d330552b-76d3-4f6a-8633-a92532fb1e5b"
      unitRef="U_USD">206559000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:BusinessAcquisitionProFormaInformationTextBlock
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      id="F_82217721-0adc-4753-8d9e-37de7bb50fa9">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table presents certain unaudited pro-forma financial information for the years ended December 31, 2022 and 2021 as if the consolidation of Entasis and La Jolla occurred on January 1, 2021. The unaudited pro forma financial information is presented for informational purposes only, and is not indicative of the results of operations that would have been achieved if the acquisitions had taken place on January 1, 2021, or of results that may occur in the future. The unaudited pro forma financial information combines the historical results of the Entasis and La Jolla with the Company&#x2019;s consolidated historical results and includes certain adjustments including, but not limited to, fair value adjustments to equity investments in Entasis&#x2019; common stock and warrants, fair value adjustments to inventory, amortization of intangible assets, and interest expense on deferred royalty obligations and acquisition-related costs.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:53.88%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.26%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:18.799999999999997%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.26%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:18.799999999999997%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;357,880&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;435,398&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net income&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;204,987&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;281,719&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net income attributable to Innoviva stockholders&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;214,390&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;197,535&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:BusinessAcquisitionProFormaInformationTextBlock>
    <us-gaap:BusinessAcquisitionsProFormaRevenue
      contextRef="C_e913bb79-80cf-4e4b-b05e-99a1cc469935"
      decimals="-3"
      id="F_9eecbd1b-ba60-46f3-879e-2cb8615d4f80"
      unitRef="U_USD">357880000</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaRevenue
      contextRef="C_9425c965-5f65-4fe2-b539-6c9acbd2b026"
      decimals="-3"
      id="F_3f4cd773-8589-485d-88ca-626ce038a829"
      unitRef="U_USD">435398000</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss
      contextRef="C_e913bb79-80cf-4e4b-b05e-99a1cc469935"
      decimals="-3"
      id="F_842c4329-80c7-474b-9ffc-3c57313f8b10"
      unitRef="U_USD">204987000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss
      contextRef="C_9425c965-5f65-4fe2-b539-6c9acbd2b026"
      decimals="-3"
      id="F_ae7f430a-8088-4a61-8065-4be78029acc3"
      unitRef="U_USD">281719000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_e913bb79-80cf-4e4b-b05e-99a1cc469935"
      decimals="-3"
      id="F_d2bef76e-8cab-4cf9-b38e-d76e324a92a9"
      unitRef="U_USD">214390000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_9425c965-5f65-4fe2-b539-6c9acbd2b026"
      decimals="-3"
      id="F_659718fa-0c58-461c-9ae8-1ad69690d799"
      unitRef="U_USD">197535000</us-gaap:NetIncomeLoss>
    <us-gaap:FinancialInstrumentsDisclosureTextBlock
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      id="F_9c01bd6c-a34a-4be5-96a6-fcec29d0860c">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;6. EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Equity and Other Investments in Armata&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;During the first quarter of 2020, Innoviva acquired &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,710,800&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock as well as warrants to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,710,800&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; additional shares of common stock of Armata Pharmaceuticals, Inc. (&#x201c;Armata&#x201d;) for approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in cash. Armata is a clinical stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;During the first quarter of 2021, ISO entered into a securities purchase agreement with Armata to acquire &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,153,847&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of Armata common stock and warrants to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,153,847&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; additional shares of Armata common stock for approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. Armata also entered into a voting agreement with the Company and ISO, pursuant to which the Company and ISO agreed not to vote or take any action by written consent with respect to any common shares held by the Company and ISO that represent, in the aggregate, more than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;49.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the total number of shares of Armata&#x2019;s common stock for voting on the matters related to election or removal of Armata&#x2019;s board members. The voting agreement will expire the earlier of the second anniversary of the agreement effective date and approval by the FDA of any of Armata&#x2019;s product candidates for marketing and commercial distribution. During the fourth quarter of 2021, ISO also purchased an additional &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,212,122&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of Armata common stock for approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On February 9, 2022, ISO entered into a securities purchase agreement with Armata to acquire &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of Armata common stock and warrants to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,500,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; additional shares of common stock with an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share for $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;45.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. The investment closed in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;two&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; tranches on February 9, 2022 and March 31, 2022. The investment is intended to aid Armata in advancing its clinical pipeline and strengthening its bacteriophage platform. On February 9, 2022, Armata also entered a second amended and restated voting agreement with the Company and ISO, pursuant to which the Company and ISO agreed not to vote or take any action by written consent with respect to any common shares held by the Company and ISO that represent, in the aggregate, more than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;49.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the total number of shares of Armata&#x2019;s common stock for voting on the matters related to election or removal of Armata&#x2019;s board members or amend the bylaws of Armata to reduce the maximum number of directors or set the number of directors who may serve on the board of Armata. The voting agreement will expire the earlier of the second anniversary of the agreement effective date and approval by the FDA of any of Armata&#x2019;s product candidates for marketing and commercial distribution. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In addition, as of February 9, 2022, Armata entered into an amended and restated investor rights agreement with the Company and ISO, pursuant to which for as long as the Company and ISO hold at least &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the outstanding shares of Armata&#x2019;s common stock on a fully-diluted, the Company and ISO shall have the right to designate two directors to Armata&#x2019;s board of directors, and for so long as the Company and ISO hold at least &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%, but less than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%, of the outstanding shares of Armata&#x2019;s common stock on a fully-diluted basis, the Company and ISO shall have the right to designate one director to Armata&#x2019;s board of directors, subject to certain conditions and qualifications set forth in the amended and restated investor rights agreement.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; On July 10, 2023, Armata entered into an amendment to the amended and restated investor rights agreement with the Company and ISO, pursuant to which the Company and ISO agreed that the voting agreement will expire on the earlier of the fifth anniversary of the original agreement's effective date, January 26, 2021, or the approval by the FDA of any of Armata&#x2019;s product candidates for marketing and commercial distribution. A&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;s of December 31, 2023,&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;three&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; of the eight &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;members of Armata&#x2019;s board of directors are also members of the board of directors of Innoviva. As of December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and 2022, we owned approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;69.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of Armata&#x2019;s common stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On January 10, 2023, we entered into a Secured Convertible Credit Agreement (the &#x201c;Credit Agreement&#x201d;) with Armata, under which we invested in a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;one-year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; convertible note (the &#x201c;Armata Convertible Note&#x201d;) in an aggregate amount of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;30.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million at an interest rate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% per annum.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; Pursuant to the Credit Agreement, the balance on the Armata Convertible Note, including all accrued and unpaid interest thereon, will convert into shares of Armata's common stock upon the occurrence of a qualified financing, as defined in the Credit Agreement. Any portion of the balance on the Armata Convertible Note, including all accrued and unpaid interest thereon, may also be converted into shares of Armata's common stock at our option once a registration statement covering the resale of such securities has been declared effective by the SEC. The Armata Convertible Note is secured by substantially all of the assets of Armata and its domestic and foreign material subsidiaries. On July 10, 2023, ISO and Armata executed an amendment to the Armata Convertible Note extending the maturity date from January 10, 2024 to January 10, 2025.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On July 10, 2023, ISO and Armata entered into a Credit and Security Agreement (the &#x201c;Credit and Security Agreement"), under which we extended a term loan to Armata (the &#x201c;Armata Term Loan&#x201d;) in an aggregate amount of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. The Armata Term Loan is subject to an interest rate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% per annum and is due to mature on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;January 10, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The Credit and Security Agreement is secured by substantially all of the assets of Armata and its domestic and foreign material subsidiaries.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The investments in Armata's common stock and warrants provide Innoviva and ISO the ability to have significant influence, but not control over Armata&#x2019;s operations. Armata&#x2019;s business and affairs are managed under the direction of its board of directors, which Innoviva and ISO do not control. Based on our evaluation, we determined that Armata is a VIE, but Innoviva and ISO are not the primary beneficiaries of the VIE. We have not provided financial or other support that we were not previously contractually required to provide during the periods presented. Our maximum exposure to loss is equal to the amount we invested in the entity.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We account for Armata&#x2019;s common stock and warrants under the equity method using the fair value option. The fair value of Armata&#x2019;s common stock is measured based on its closing market price. The warrants purchased in 2020, 2021 and 2022 have an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.87&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.25&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share, respectively. All warrants are exercisable immediately within &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; from the issuance date of the warrants and include a cashless exercise option. We use the Black-Scholes-Merton pricing model to estimate the fair value of these warrants with the following input assumptions: Armata&#x2019;s closing market price on the valuation date, the risk-free interest rate computed based on the U.S. Treasury yield, the remaining contractual term as the expected term, and the expected stock price volatility calculated based on the historical volatility of the common stock of Armata and its peer companies. We account for the Armata Convertible Note as a trading security, measured at fair value using a Monte Carlo simulation model with the probability of certain qualified events and the assumptions of risk-free rate, volatility of stock price and timing of certain qualified events. We account for the Armata Term Loan as a trading security, measured at fair value using an income approach based on the discounted value of expected future cash flows.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;the fair values of our holdings of Armata common stock, warrants, the Armata Convertible Note and the Armata Term Loan were estimated at $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;81.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;35.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;51.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. As of December 31, 2022 the fair values of our holdings of Armata common stock and warrants were estimated at $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;31.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;For the Armata common stock and warrants, we recorded $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;77.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million unrealized gains, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;152.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million unrealized losses and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;78.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million unrealized gains as changes in fair values of equity method investments, net, in the consolidated statements of income for the years ended December 31, 2023, 2022 and 2021, respectively. For the Armata Convertible Note and Term Loan, we recorded $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million unrealized gain, respectively, as changes in fair values of equity and long-term investments, net, in the consolidated statement of income for year ended December 31, 2023.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The summarized financial information, including the portion we do not own, is presented for Armata on a one quarter lag as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Balance Sheet Information&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:53.88%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.26%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:18.799999999999997%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.26%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:18.799999999999997%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;September 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;36,585&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;33,245&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Noncurrent assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;76,176&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;59,636&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21,884&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,004&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Noncurrent liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;103,263&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;40,300&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Income Statement Information&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.311%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.481%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.75%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.481%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.75%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.481%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.75%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Twelve Months Ended&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;September 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,052&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,446&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,989&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Loss from operations&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;41,639&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;32,666&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24,227&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;59,512&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;32,650&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;23,732&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Equity Method Investment in Entasis&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Prior to the consolidation of Entasis&#x2019; financial position and results of operations in February 2022, we accounted for Entasis as an equity method investment. Refer to Note 5, &#x201c;Consolidated Entities and Acquisitions&#x201d;, for more information.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The summarized financial information, including the portion we did not own, is presented for Entasis on a one quarter lag regardless of the date of our investments as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Income Statement Information&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:71.98%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:25.02%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Twelve Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Loss from operations&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;52,323&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;125,413&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Equity Investment in InCarda&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;During the third quarter of 2020, TRC purchased &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20,469,432&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of Series C preferred stock and a warrant to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,117,358&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; additional shares of Series C preferred stock of InCarda Therapeutics, Inc. (&#x201c;InCarda&#x201d;) (the &#x201c;InCarda 2020 Warrant&#x201d;) for $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, which included $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of transaction costs. InCarda is a privately held biopharmaceutical company focused on developing inhaled therapies for cardiovascular diseases. The investment is intended to fund the ongoing clinical development of InRhythm&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;TM&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; (flecainide for inhalation), InCarda&#x2019;s lead program, for the treatment of a recent-onset episode of paroxysmal atrial fibrillation. On July 20, 2022, under the terms of the TRC Equity Purchase Agreement, TRC transferred to Innoviva&#x2019;s wholly-owned subsidiary, Innoviva TRC Holdings, LLC (&#x201c;ITH&#x201d;) all of TRC&#x2019;s ownership interests and investments in InCarda. ITH has the right to designate one member to InCarda&#x2019;s board of directors. As of December 31, 2023, no ITH designee is serving on InCarda&#x2019;s &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;six&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;-member board. We did not exercise the InCarda 2020 Warrant which expired in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_16022dea-4c29-4456-a7e5-3f052ff36fa9;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;March 2023&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and wrote off its carrying value of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million during 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On March 9, 2022, TRC entered into a Note and Warrant Purchase Agreement (the &#x201c;InCarda Agreement&#x201d;) with InCarda to acquire a convertible promissory note (the &#x201c;InCarda Convertible Note&#x201d;) and warrants (the &#x201c;InCarda 2022 Warrant&#x201d;) for $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million.  The InCarda 2022 Warrant expires on March 9, 2027 and is measured at fair value.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On June 15, 2022, the principal amount and the accrued interest of the InCarda Convertible Note were converted into equity securities. In addition, TRC participated in InCarda&#x2019;s Series D preferred stock financing by investing $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. In connection with the new round of financing, InCarda recapitalized its equity structure resulting in TRC owning &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,093,886&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of InCarda&#x2019;s common stock, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;37,350&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of its Series A-1 preferred stock, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20,469,432&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of its Series C preferred stock, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,771,780&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of its Series D-1 preferred stock, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,369,802&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of its Series D-2 preferred stock, a warrant to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,117,358&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of its Series C preferred stock at $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.73&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share and a warrant to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,490,033&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of its Series D-1 preferred stock at $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.20&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023 and 2022, we held &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of InCarda equity ownership, respectively. Our investment in InCarda does not provide us with the ability to control or have significant influence over InCarda&#x2019;s operations. Based on our evaluation, we determined that InCarda is a VIE, but we are not the primary beneficiary of the VIE. We have not provided financial or other support that we were not previously contractually required to provide during the periods presented. Our maximum exposure to loss is equal to the amount we invested in the entity.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We account for our investments in InCarda under the measurement alternative. Under the measurement alternative, the equity investment is initially recorded at its allocated cost, but the carrying value may be adjusted through earnings upon an impairment or when there is an observable price change involving the same or a similar investment with the same issuer. Due to InCarda&#x2019;s equity recapitalization in the second quarter of 2022, TRC reassessed the value of its investments in InCarda using the Option Pricing Model Backsolve valuation methodology. Key assumptions used in the valuation model included an expected holding period of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;two years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, a risk free interest rate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%, a dividend yield of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% and an estimated volatility of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;122.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%. The estimated volatility was calculated based on the historical volatility of a selected peer group of public companies comparable to InCarda. We recognized an impairment charge of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million during the second quarter of 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Due to certain changes in InCarda&#x2019;s business operations during the second quarter of 2023, ITH reassessed the value of its investments in InCarda using the Option Pricing Model methodology. Key assumptions used in the valuation model included an expected holding period of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;two years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, a risk-free interest rate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%, a dividend yield of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% and an estimated volatility of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;114.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%. The estimated volatility was calculated based on the historical volatility of a selected peer group of public companies comparable to InCarda. We recognized an impairment charge of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million during the second quarter of 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023, we recorded $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in fair value of InCarda&#x2019;s Series C preferred stock and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in fair value of Series D warrants&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2022, we recorded $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in fair value of InCarda&#x2019;s Series C preferred stock and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in fair value of Series C warrants and Series D warrants&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. As of December 31, 2023 and 2022, we recognized $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively, for InCarda&#x2019;s Series D-1 preferred stock, Series D-2 preferred stock, and common stock using the measurement alternative. We recorded $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; milli&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;on unrealized loss as changes in fair values of equity and long-term investments, net, in the consolidated statements of income for the years ended December 31, 2023, 2022, 2021, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Equity Investment in ImaginAb&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On March 18, 2021, TRC entered into a securities purchase agreement with ImaginAb, Inc. (&#x201c;ImaginAb&#x201d;) to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,051,724&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of ImaginAb Series C preferred stock for $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. On the same day, TRC also entered into a securities purchase agreement with one of ImaginAb&#x2019;s common stockholders to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,097,157&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of ImaginAb common stock for $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. ImaginAb is a privately held biotechnology company focused on clinically managing cancer and autoimmune diseases via molecular imaging. $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million was incurred for investment due diligence costs and execution and recorded as part of the equity investment in the consolidated balance sheets.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On July 20, 2022, under the terms of the TRC Equity Purchase Agreement, TRC transferred to ITH all of TRC&#x2019;s ownership interests and investments in ImaginAb.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On March 14, 2023, ITH entered into a securities purchase agreement with ImaginAb to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;270,568&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of ImaginAb Series C-2 preferred stock for $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. On September 14, 2023, ITH entered into a securities purchase agreement with ImaginAb to purchase another &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;405,852&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of ImaginAb Series C-2 preferred stock for $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. As of December 31, 2023, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; of ImaginAb&#x2019;s six board members was designated by ITH. As of December 31, 2023 and 2022, we held &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%, respectively, of ImaginAb equity ownership.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; Our investment in ImaginAb does not provide us with the ability to control or have significant influence over ImaginAb&#x2019;s operations. Based on our evaluation, we determined that ImaginAb is a VIE, but we are not the primary beneficiary of the VIE. We have not provided financial or other support that we were not previously contractually required to provide during the periods presented. Our maximum exposure to loss is equal to the amount we invested in the entity.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Because ImaginAb&#x2019;s equity securities are not publicly traded and do not have a readily determinable fair value, we account for our investment in ImaginAb&#x2019;s Series C preferred stock and common stock using the measurement alternative. As of December 31, 2023 &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;and 2022, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively, was recorded as equity and long-term investments in the consolidated balance sheets, respectively, and there was no change to the fair value of our investment in ImaginAb.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Convertible Promissory Note in Gate Neurosciences&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On November 24, 2021, TRC entered into a Convertible Promissory Note Purchase Agreement with Gate to acquire a convertible promissory note (the &#x201c;Gate Convertible Note&#x201d;) with a principal amount of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. Gate is a privately held biopharmaceutical company focused on developing the next generation of targeted nervous system therapies, leveraging precision medicine approaches to develop breakthrough drugs for psychiatric and neurologic diseases. The investment is intended to fund Gate's ongoing development and research. The Gate Convertible Note bears an annual interest rate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% and will convert into shares of common stock of Gate upon a qualified event or into shares of shadow preferred stock of Gate (&#x201c;Shadow Preferred&#x201d;) upon a qualified financing. A qualifying event can be a qualified initial price offering, a qualified merger, or a merger with a special-purpose acquisition company (&#x201c;SPAC&#x201d;). Shadow Preferred means preferred stock having identical rights, preferences and restrictions as the preferred stock that would be issued in a qualified financing.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The number of common stock shares to be issued in a qualified event shall be equal to the amount due on the conversion date divided by the lesser of a capped conversion price (the &#x201c;Capped Conversion Price&#x201d;) and the qualified event price (the &#x201c;Qualified Event Price&#x201d;). The Capped Conversion Price is calculated as $50.0 million divided by the number of shares of common stock outstanding at such time on a fully diluted basis. The Qualified Event Price is the price per share determined by the qualified event. A qualified financing is a sale or series of sales of preferred stock where (i) at least 50 percent of counterparties are not existing shareholders, (ii) net proceeds to Gate are at least $35.0 million, and (iii) the stated or implied equity valuation of Gate is at least $80.0 million. &lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On July 20, 2022, under the terms of the TRC Equity Purchase Agreement, TRC transferred to ITH all of TRC's debt investments in Gate.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On February 2, 2023, ITH entered into a Note Amendment Agreement with Gate to amend the Gate Convertible Note. Pursuant to the Note Amendment Agreement, the principal amount of the Gate Convertible Note was increased from $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, which represents the original principal, accrued interest as of the amendment date and an additional cash investment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. All other material terms of the Gate Convertible Note were unchanged.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On October 6, 2023, ITH entered into a Second Note Amendment Agreement with Gate to amend the Note Amendment Agreement. Pursuant to the Second Note Amendment Agreement, the principal amount of the Gate Convertible Note was increased from $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, which represents the amended principal as of February 2, 2023, accrued interest as of the second amendment date and an additional cash investment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. All other material terms of the Gate Convertible Note were unchanged.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We have accounted for the Gate Convertible Note as a trading security, measured at fair value using a Monte Carlo simulation model with the probability of certain qualified events and the assumptions of equity value of Gate, risk-free rate, expected stock price, volatility of its peer companies, and the time until a financing is raised. As of December 31, 2023 &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;and 2022, the fair value of the Gate Convertible Note was estimated at $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;28.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively, and recorded as equity and long-term investments in the consolidated balance sheets. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We recorded $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of unrealized loss, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of unrealized gain, and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of unrealized loss as changes in fair values of other equity and long-term investments, net, in the consolidated statements of income for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023, 2022 and 2021, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Equity Investment in Nanolive&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On February 18, 2022, TRC entered into an investment and shareholders agreement with Nanolive to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18,750,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of Nanolive Series C preferred stock for $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million (equivalent to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million CHF). Nanolive SA is a Swiss privately held life sciences company focused on developing breakthrough imaging solutions that accelerate research in growth industries such as drug discovery and cell therapy. $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million was incurred for investment due diligence costs and execution and recorded as part of the equity and long-term investment in the consolidated balance sheets. On July 20, 2022, under the terms of the TRC Equity Purchase Agreement, TRC transferred to ITH all of TRC&#x2019;s ownership interests and investments in Nanolive. ITH has the right to designate one member to Nanolive&#x2019;s board. ITH also has the right to designate another member, who will be mutually acceptable to ITH and another stockholder, to Nanolive&#x2019;s board. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; Innoviva designee is serving on Nanolive&#x2019;s &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;six&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;-member board. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, we held &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of Nanolive equity ownership, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Our investment in Nanolive does not provide us with the ability to control or have significant influence over Nanolive&#x2019;s operations. Based on our evaluation, we determined that Nanolive is a VIE, but we are not the primary beneficiary of the VIE. We have not provided financial or other support that we were not previously contractually required to provide during the periods presented. Our maximum exposure to loss is equal to the amount we invested in the entity.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Because Nanolive&#x2019;s equity securities are not publicly traded and do not have a readily determinable fair value, we account for our investment in Nanolive&#x2019;s Series C preferred stock using the measurement alternative. As of December 31, 2023 and 2022,&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of investment in Nanolive was recorded as equity and long-term investments in the consolidated balance sheets, and there was no change to the carrying amount of our investment.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Available-for-Sale Securities&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The estimated fair value of available-for-sale securities is based on quoted market prices for these or similar investments that were based on prices obtained from a commercial pricing service. Available-for-sale securities are summarized below:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:36.867%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.56%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.222000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.56%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.222000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.56%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.222000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.56%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.222000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amortized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unrealized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unrealized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Estimated&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;170,706&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;170,706&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;170,706&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;170,706&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"&gt;&lt;span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:9pt;font-family:Times New Roman;transform-origin:top left;min-width:3.333%;display:inline-flex;justify-content:flex-start;"&gt;(1)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Money market funds are included in cash and cash equivalents in the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:36.867%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.56%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.222000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.56%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.222000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.56%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.222000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.56%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.222000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amortized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unrealized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unrealized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Estimated&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;263,469&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;263,469&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;263,469&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;263,469&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"&gt;&lt;span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:9pt;font-family:Times New Roman;transform-origin:top left;min-width:3.333%;display:inline-flex;justify-content:flex-start;"&gt;(1)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Money market funds are included in cash and cash equivalents in the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023 and 2022, all available-for-sale securities were money market funds, and there was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; credit loss recognized.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Fair Value Measurements&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Our available-for-sale securities, equity and long-term investments and contingent value rights are measured at fair value on a recurring basis and our debt is carried at amortized cost basis.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:36.867%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.56%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.222000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.56%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.222000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.56%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.222000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.56%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.222000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Estimated Fair Value Measurements as of December 31, 2023 Using:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Quoted Price&lt;br/&gt;in Active&lt;br/&gt;Markets for&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Significant&lt;br/&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Significant&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Identical&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Observable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unobservable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Types of Instruments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Inputs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Inputs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;"&gt;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;170,706&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;170,706&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Investments held by ISP Fund LP &lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;251,207&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;60,605&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;311,812&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Equity investment - Armata Common Stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;81,249&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;81,249&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Equity investment - Armata Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;35,297&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;35,297&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Convertible debt investment - Armata Note&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;51,883&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;51,883&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Term loan investment - Armata Term Loan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27,044&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27,044&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Convertible debt investment - Gate Note&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27,972&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27,972&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total assets measured at estimated fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;503,162&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;35,297&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;167,504&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;705,963&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;"&gt;Liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Debt&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2025 Notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;200,407&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;200,407&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2028 Notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;227,070&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;227,070&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;Total fair value of debt&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;427,477&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;427,477&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Contingent value rights&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;359&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;359&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total liabilities at estimated fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;427,477&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;359&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;427,836&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"&gt;&lt;span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:9pt;font-family:Times New Roman;transform-origin:top left;min-width:3.333%;display:inline-flex;justify-content:flex-start;"&gt;(1)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The investments held by ISP Fund LP, consisted of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;248.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in equity investments, which included private placement positions of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;60.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;62.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in money market funds. A certain portion of the total capital contribution of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;300.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million is no longer subject to a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;36-month&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; lock-up period from the date of such capital contribution. However, we did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;t elect to make a withdrawal in 2023, thereby extending the lock-up period and withdrawal elections into subsequent years. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:36.867%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.56%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.222000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.56%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.222000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.56%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.222000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.56%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.222000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Estimated Fair Value Measurements as of December 31, 2022 Using:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Quoted Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;in Active&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Significant&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Markets for&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Significant&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Identical&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Observable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unobservable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Types of Instruments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Inputs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Inputs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;"&gt;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;263,469&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;263,469&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Investments held by ISP Fund LP &lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;265,982&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;54,578&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;320,560&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Equity investment - Armata Common Stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;31,095&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;31,095&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Equity investment - Armata Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,059&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,059&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Equity investment - InCarda Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;605&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;605&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Convertible debt investment - Gate Note&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,700&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,700&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total assets measured at estimated fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;560,546&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,059&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;70,883&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;639,488&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;"&gt;Debt&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2023 Notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;96,089&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;96,089&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2025 Notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;197,807&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;197,807&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2028 Notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;211,768&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;211,768&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total fair value of debt&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;505,664&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;505,664&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Contingent value rights&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;595&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;595&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total liabilities at estimated fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;505,664&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;595&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;506,259&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"&gt;&lt;span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:9pt;font-family:Times New Roman;transform-origin:top left;min-width:3.333%;display:inline-flex;justify-content:flex-start;"&gt;(1)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The investments held by ISP Fund LP, consisted of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;295.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in equity investments, which included private placement positions and convertible notes of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;54.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in money market funds. Our total capital contribution of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;300.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million was subject to a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;36-month&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; lock-up period from the date of such capital contributions.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The fair values of our equity investments in Armata&#x2019;s common stock and publicly traded investments held by ISP Fund LP are based on the quoted prices in active markets and are classified as Level 1 financial instruments. The fair values in the warrants in Armata classified within Level 2 are based upon observable inputs that may include benchmark yields, reported trades, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids, offers, and reference data including market research publications.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The InCarda Warrants, the Gate Convertible Note, the Armata Convertible Note, the Armata Term Loan, private placement positions and convertible notes held by ISP Fund LP, and contingent value rights are classified as Level 3 financial instruments as these securities are not publicly traded and the assumptions used in the valuation model for valuing these securities are based on significant unobservable and observable inputs including those of publicly traded peer companies.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The fair values of our 2025 Notes and 2028 Notes are based on recent trading prices of the respective instruments. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The fair values of our 2023 Notes, which were fully paid off in January 2023, were also based on their trading prices.&lt;/span&gt;&lt;/p&gt;</us-gaap:FinancialInstrumentsDisclosureTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="C_21e1bf8d-0dfb-436e-a0f5-40401cbd051a"
      decimals="INF"
      id="F_9ac9cac2-de37-49ef-b7f0-75f42ea0ef18"
      unitRef="U_shares">8710800</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <inva:SaleOfWarrantsNumberOfWarrantsIssuedInTransaction
      contextRef="C_4aa2cab4-fd43-44e4-87cc-bff3c5ce186b"
      decimals="0"
      id="F_e839077f-756a-433c-993a-74c87486419e"
      unitRef="U_shares">8710800</inva:SaleOfWarrantsNumberOfWarrantsIssuedInTransaction>
    <inva:SecuritiesPurchaseAgreementAmount
      contextRef="C_5cb2b0db-90a2-4560-b85e-87494f6a7282"
      decimals="-5"
      id="F_ce353fc5-74ca-4884-b7d0-2d5489c9f883"
      unitRef="U_USD">25000000</inva:SecuritiesPurchaseAgreementAmount>
    <inva:SecuritiesPurchaseAgreementTotalNumberOfWarrantsToBePurchasedUnderAgreement
      contextRef="C_49ef45bd-5ceb-448c-b5bf-998ea5bcd6a4"
      decimals="INF"
      id="F_15f23262-e4f7-4b16-b01f-458b875b0393"
      unitRef="U_shares">6153847</inva:SecuritiesPurchaseAgreementTotalNumberOfWarrantsToBePurchasedUnderAgreement>
    <inva:SecuritiesPurchaseAgreementTotalNumberOfWarrantsToBePurchasedUnderAgreement
      contextRef="C_29a8663f-3680-40ab-9728-c1d88380d314"
      decimals="INF"
      id="F_3f56dd32-67d0-47f4-a8e5-8bdf49095656"
      unitRef="U_shares">6153847</inva:SecuritiesPurchaseAgreementTotalNumberOfWarrantsToBePurchasedUnderAgreement>
    <inva:SecuritiesPurchaseAgreementAmount
      contextRef="C_b58b4d47-eb88-4714-9e20-e846765b8a44"
      decimals="-5"
      id="F_6de8779f-cd07-4033-91aa-39596db1e5c8"
      unitRef="U_USD">20000000</inva:SecuritiesPurchaseAgreementAmount>
    <inva:VotingAgreementMaximumVotingRightsPercent
      contextRef="C_e037e13e-6e91-4a72-ba0c-e61af7067b1b"
      decimals="3"
      id="F_c03d3710-a02d-4e17-b39f-c5797495ea2f"
      unitRef="U_pure">0.495</inva:VotingAgreementMaximumVotingRightsPercent>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="C_1c9ae792-bfa8-4f96-9434-ec29ab1930a2"
      decimals="INF"
      id="F_93928661-faf1-4515-9360-e8918247ac92"
      unitRef="U_shares">1212122</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <inva:SecuritiesPurchaseAgreementAmount
      contextRef="C_1c9ae792-bfa8-4f96-9434-ec29ab1930a2"
      decimals="-5"
      id="F_14575c79-aac6-47ec-8b33-461ec0292f41"
      unitRef="U_USD">4000000</inva:SecuritiesPurchaseAgreementAmount>
    <inva:SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement
      contextRef="C_5ca60e7e-4ba6-40eb-a454-386ec8c73923"
      decimals="INF"
      id="F_c8a58389-d3f5-4328-979d-92e1e5d42357"
      unitRef="U_shares">9000000</inva:SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement>
    <inva:SecuritiesPurchaseAgreementTotalNumberOfWarrantsToBePurchasedUnderAgreement
      contextRef="C_6c4d4181-e8c1-43dd-85b3-83b9cf5f55dd"
      decimals="INF"
      id="F_f64b8299-39a6-49ce-ae32-eaab41485d94"
      unitRef="U_shares">4500000</inva:SecuritiesPurchaseAgreementTotalNumberOfWarrantsToBePurchasedUnderAgreement>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_6c4d4181-e8c1-43dd-85b3-83b9cf5f55dd"
      decimals="INF"
      id="F_542a0965-600b-4614-a9fd-62bfbc469171"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <inva:SecuritiesPurchaseAgreementAmount
      contextRef="C_c3fa46e4-5e22-4b74-a128-70da5649065e"
      decimals="-5"
      id="F_25dcf38a-ac83-4e35-8beb-f9900d053bee"
      unitRef="U_USD">45000000</inva:SecuritiesPurchaseAgreementAmount>
    <inva:SecuritiesPurchaseAgreementNumberOfTranches
      contextRef="C_e037e13e-6e91-4a72-ba0c-e61af7067b1b"
      decimals="0"
      id="F_e7565c97-1c88-47cf-871d-a449784904ee"
      unitRef="U_Tranche">2</inva:SecuritiesPurchaseAgreementNumberOfTranches>
    <inva:VotingAgreementMaximumVotingRightsPercent
      contextRef="C_300582a5-75c9-4125-aa9d-205955fffcd6"
      decimals="3"
      id="F_e0b6c9f0-ab0f-43ab-a0e2-61241950e49f"
      unitRef="U_pure">0.495</inva:VotingAgreementMaximumVotingRightsPercent>
    <inva:SpecialTermReDesignatingBoardMemberToBoardOfInvestee
      contextRef="C_300582a5-75c9-4125-aa9d-205955fffcd6"
      id="F_42231e2a-406e-43d4-97fb-3c77377d04e0">In addition, as of February 9, 2022, Armata entered into an amended and restated investor rights agreement with the Company and ISO, pursuant to which for as long as the Company and ISO hold at least 12.5% of the outstanding shares of Armata&#x2019;s common stock on a fully-diluted, the Company and ISO shall have the right to designate two directors to Armata&#x2019;s board of directors, and for so long as the Company and ISO hold at least 8%, but less than 12.5%, of the outstanding shares of Armata&#x2019;s common stock on a fully-diluted basis, the Company and ISO shall have the right to designate one director to Armata&#x2019;s board of directors, subject to certain conditions and qualifications set forth in the amended and restated investor rights agreement.</inva:SpecialTermReDesignatingBoardMemberToBoardOfInvestee>
    <us-gaap:VariableInterestEntityOwnershipPercentage
      contextRef="C_966fb9ea-4c8a-4b8b-b091-d09a286a05bf"
      decimals="3"
      id="F_d591f73c-2640-41e6-9aac-5e8dfb680071"
      unitRef="U_pure">0.125</us-gaap:VariableInterestEntityOwnershipPercentage>
    <us-gaap:VariableInterestEntityOwnershipPercentage
      contextRef="C_da2e5495-b09e-47a8-9a8c-ea82f08e7ead"
      decimals="2"
      id="F_954a0e66-01ac-47e9-9f0e-2bcd83619a34"
      unitRef="U_pure">0.08</us-gaap:VariableInterestEntityOwnershipPercentage>
    <us-gaap:VariableInterestEntityOwnershipPercentage
      contextRef="C_dbf2c9ec-33a9-4f10-847f-e794f7585c7b"
      decimals="3"
      id="F_e6469275-c1cb-4a34-864d-788da8f82e31"
      unitRef="U_pure">0.125</us-gaap:VariableInterestEntityOwnershipPercentage>
    <inva:NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee
      contextRef="C_4a4ab2a3-40c8-4d79-9cdf-f746af492718"
      decimals="0"
      id="F_d559132b-6d52-4ab8-9fa7-2ba7bf208c59"
      unitRef="U_Director">3</inva:NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="C_a7bcde7c-16d0-44f6-bf9e-2ed901913ed0"
      decimals="3"
      id="F_c41ab8b1-32dc-4ef7-9e55-b0ab398457ac"
      unitRef="U_pure">0.694</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:DebtInstrumentDescription
      contextRef="C_cad461b3-85e0-44a5-b49c-2fdefdb8eb14"
      id="F_251c67b6-d5bc-46a4-a44d-f50fa8eba7fa">On January 10, 2023, we entered into a Secured Convertible Credit Agreement (the &#x201c;Credit Agreement&#x201d;) with Armata, under which we invested in a one-year convertible note (the &#x201c;Armata Convertible Note&#x201d;) in an aggregate amount of $30.0 million at an interest rate of 8.0% per annum.</us-gaap:DebtInstrumentDescription>
    <us-gaap:DebtInstrumentTerm
      contextRef="C_cad461b3-85e0-44a5-b49c-2fdefdb8eb14"
      id="F_5f418be5-e9ae-4b6d-a421-e6f81f28da8e">P1Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="C_743b7286-55b6-4101-852d-19e61fad9eaf"
      decimals="-5"
      id="F_64fd8761-189a-490e-abda-3b904b2f6aa8"
      unitRef="U_USD">30000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="C_743b7286-55b6-4101-852d-19e61fad9eaf"
      decimals="3"
      id="F_0c43860b-8017-4cc6-a0ee-cee373de7719"
      unitRef="U_pure">0.08</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="C_dabbf05b-a0a7-405b-8376-1cdce909cd8e"
      decimals="-5"
      id="F_80ac1a3b-7baf-4790-91a4-dd0c70c88ac1"
      unitRef="U_USD">25000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="C_dabbf05b-a0a7-405b-8376-1cdce909cd8e"
      decimals="2"
      id="F_3559dc50-4870-47d0-8236-0bbbf6d850f7"
      unitRef="U_pure">0.14</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="C_4c92ef07-b330-4a35-9de3-b077cb45c462"
      id="F_56e2760c-b103-4262-a77b-bbe5ca6d5356">2025-01-10</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_ca966b79-26e3-4d58-ae1b-26f1394533f5"
      decimals="2"
      id="F_cf2676d0-941b-4d0f-bc41-3d298f4795ee"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.87</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_dc664211-9a49-4cc6-b77c-b76d951d8b6a"
      decimals="2"
      id="F_9b0f5e9b-cd06-4d42-b949-9c087272b4ef"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_1c07c08c-06ec-49dc-b790-0f2340f3ad4e"
      decimals="2"
      id="F_2452ff76-57d3-42b9-8861-55042e240564"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="C_ca966b79-26e3-4d58-ae1b-26f1394533f5"
      id="F_6676608e-44a7-4487-8ec6-7c1a0af8bd94">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="C_dc664211-9a49-4cc6-b77c-b76d951d8b6a"
      id="F_cf3f401e-4741-4c07-bd3a-390026042e7c">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="C_1c07c08c-06ec-49dc-b790-0f2340f3ad4e"
      id="F_a0bf8b7e-9513-4377-b4fd-f26730d5a6a4">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="C_6f7b5337-631f-48a7-b4c9-05cbb564473e"
      decimals="-5"
      id="F_ea64263f-2e2c-4d15-9377-bdbaf907cf0a"
      unitRef="U_USD">81200000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="C_f390186b-f0e1-423b-87da-2c37deb3557f"
      decimals="-5"
      id="F_a529c840-0f44-4cb8-b142-110bef451224"
      unitRef="U_USD">35300000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="C_bd478d73-d23c-479d-ac02-32fc192ff66f"
      decimals="-5"
      id="F_c32ecff1-d6a9-46bd-8f5c-9ba8127a5bd0"
      unitRef="U_USD">51900000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="C_f4dfb9e5-6e91-41c1-a947-ccb6c551ac4d"
      decimals="-5"
      id="F_97382db8-ce68-45ae-9f03-2f18f3e23127"
      unitRef="U_USD">27000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="C_8438a6b5-27b4-494b-a98e-519ed66169d5"
      decimals="-5"
      id="F_8ea858a5-6168-4496-9e1f-78da67bfaa73"
      unitRef="U_USD">31100000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="C_19a3e0c0-9301-442d-a4f9-622a1ad048d2"
      decimals="-5"
      id="F_0f0c1f3e-e9f9-453a-875f-86990da30648"
      unitRef="U_USD">8100000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGain
      contextRef="C_0608758b-b85d-4f54-a373-092e1463e6e6"
      decimals="-5"
      id="F_9ed3512b-bd3a-4b7b-b6d5-d6543b769583"
      unitRef="U_USD">77400000</us-gaap:EquitySecuritiesFvNiUnrealizedGain>
    <us-gaap:EquitySecuritiesFvNiUnrealizedLoss
      contextRef="C_67050c7f-cb36-416c-aa88-59d5550ab95e"
      decimals="-5"
      id="F_3869fed2-7247-46e0-a469-22ebc2f3e6b7"
      unitRef="U_USD">152500000</us-gaap:EquitySecuritiesFvNiUnrealizedLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGain
      contextRef="C_941dd2d3-13db-4e88-a246-2446d97b2a8e"
      decimals="-5"
      id="F_a8dc1659-7eda-4bf4-9d19-149bd19db4b0"
      unitRef="U_USD">78700000</us-gaap:EquitySecuritiesFvNiUnrealizedGain>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGain
      contextRef="C_73b7ce85-a0d4-4185-bb79-15359bd6b909"
      decimals="-5"
      id="F_65841340-dfa5-491b-98df-01b9e3560927"
      unitRef="U_USD">21800000</us-gaap:EquitySecuritiesFvNiUnrealizedGain>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGain
      contextRef="C_7bb88b87-b326-4e6e-865b-16d3ceea75e6"
      decimals="-5"
      id="F_7781aebf-db9e-4f67-a4b4-d93c65df7ecb"
      unitRef="U_USD">2000000</us-gaap:EquitySecuritiesFvNiUnrealizedGain>
    <us-gaap:ScheduleOfVariableInterestEntitiesTextBlock
      contextRef="C_e037e13e-6e91-4a72-ba0c-e61af7067b1b"
      id="F_caa5c2ed-e4ce-417b-805e-fab30250493d">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The summarized financial information, including the portion we do not own, is presented for Armata on a one quarter lag as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Balance Sheet Information&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:53.88%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.26%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:18.799999999999997%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.26%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:18.799999999999997%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;September 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;36,585&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;33,245&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Noncurrent assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;76,176&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;59,636&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21,884&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,004&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Noncurrent liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;103,263&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;40,300&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Income Statement Information&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.311%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.481%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.75%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.481%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.75%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.481%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.75%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Twelve Months Ended&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;September 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,052&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,446&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,989&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Loss from operations&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;41,639&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;32,666&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24,227&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;59,512&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;32,650&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;23,732&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfVariableInterestEntitiesTextBlock>
    <us-gaap:AssetsCurrent
      contextRef="C_4a4ab2a3-40c8-4d79-9cdf-f746af492718"
      decimals="-3"
      id="F_9fbc5032-dd6c-432f-9a15-705c8cc1dc4c"
      unitRef="U_USD">36585000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_6bed736f-3aa9-4d71-818d-93a8fca55527"
      decimals="-3"
      id="F_632e256c-0cfe-4c83-be2a-574f7b3ec0e6"
      unitRef="U_USD">33245000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="C_4a4ab2a3-40c8-4d79-9cdf-f746af492718"
      decimals="-3"
      id="F_ca3800af-4529-4ede-91cd-d15552aaf914"
      unitRef="U_USD">76176000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="C_6bed736f-3aa9-4d71-818d-93a8fca55527"
      decimals="-3"
      id="F_4fb798bc-3351-4b12-a251-f87815b43485"
      unitRef="U_USD">59636000</us-gaap:AssetsNoncurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_4a4ab2a3-40c8-4d79-9cdf-f746af492718"
      decimals="-3"
      id="F_54fe305d-2c18-413e-b072-7709b4df6b18"
      unitRef="U_USD">21884000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_6bed736f-3aa9-4d71-818d-93a8fca55527"
      decimals="-3"
      id="F_c6df6857-2c83-41e3-93fa-4bf6d7afe8f4"
      unitRef="U_USD">7004000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="C_4a4ab2a3-40c8-4d79-9cdf-f746af492718"
      decimals="-3"
      id="F_4e1e851d-0837-4c90-b41c-79eaf73050e4"
      unitRef="U_USD">103263000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="C_6bed736f-3aa9-4d71-818d-93a8fca55527"
      decimals="-3"
      id="F_f530192f-a129-4cc5-a810-b6df92651682"
      unitRef="U_USD">40300000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_a48b0af5-32e5-4d70-8301-ead504e49b4c"
      decimals="-3"
      id="F_2645524a-5d36-47bd-b51b-2095b81a7751"
      unitRef="U_USD">4052000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_9c42d5a6-8705-438d-afbc-23f20a000d9b"
      decimals="-3"
      id="F_1970b7b8-42ea-4604-ade9-7b94a51e7b08"
      unitRef="U_USD">5446000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_e3c81efe-d99a-4794-9295-046bab474ae8"
      decimals="-3"
      id="F_11d66f51-cc9f-48c3-a10f-24e39abce7e7"
      unitRef="U_USD">3989000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_a48b0af5-32e5-4d70-8301-ead504e49b4c"
      decimals="-3"
      id="F_1d439cfe-f7e6-4a1c-9899-6548b3f1db1c"
      unitRef="U_USD">-41639000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_9c42d5a6-8705-438d-afbc-23f20a000d9b"
      decimals="-3"
      id="F_589da5ba-4ef9-4a60-82cb-25e6b1e6d64d"
      unitRef="U_USD">-32666000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_e3c81efe-d99a-4794-9295-046bab474ae8"
      decimals="-3"
      id="F_23ce54b6-5fba-45b7-8db8-20190242a1cc"
      unitRef="U_USD">-24227000</us-gaap:OperatingIncomeLoss>
    <us-gaap:ProfitLoss
      contextRef="C_a48b0af5-32e5-4d70-8301-ead504e49b4c"
      decimals="-3"
      id="F_ca9f2b33-e587-4d65-a9ad-f4d3ed069adc"
      unitRef="U_USD">-59512000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_9c42d5a6-8705-438d-afbc-23f20a000d9b"
      decimals="-3"
      id="F_5bc22a7e-bb51-4958-8ddb-94415a5c9079"
      unitRef="U_USD">-32650000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_e3c81efe-d99a-4794-9295-046bab474ae8"
      decimals="-3"
      id="F_f768945a-8e34-40fd-9b03-47dda64fb831"
      unitRef="U_USD">-23732000</us-gaap:ProfitLoss>
    <us-gaap:ScheduleOfVariableInterestEntitiesTextBlock
      contextRef="C_a97169bf-af91-4b94-a033-7619a6aaa930"
      id="F_7e7dc1ee-7f7e-4537-a683-f682745cc966">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The summarized financial information, including the portion we did not own, is presented for Entasis on a one quarter lag regardless of the date of our investments as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Income Statement Information&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:71.98%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:25.02%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Twelve Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Loss from operations&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;52,323&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;125,413&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfVariableInterestEntitiesTextBlock>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_e3a16997-be95-4821-b76f-a08d875b0dcf"
      decimals="-3"
      id="F_d565b1b0-c872-42ae-bf3d-00fa37a80885"
      unitRef="U_USD">-52323000</us-gaap:OperatingIncomeLoss>
    <us-gaap:ProfitLoss
      contextRef="C_e3a16997-be95-4821-b76f-a08d875b0dcf"
      decimals="-3"
      id="F_b7321a83-31f4-44ab-8565-44f53c6530ff"
      unitRef="U_USD">-125413000</us-gaap:ProfitLoss>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="C_1c3869dc-1179-4ea1-8b03-28655253f10d"
      decimals="INF"
      id="F_561308d0-ab56-4b1b-9ad3-4979d66100b0"
      unitRef="U_shares">20469432</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <inva:SecuritiesPurchaseAgreementWarrantsNumberOfSecuritiesCalledByWarrants
      contextRef="C_5e106938-a0b0-4aeb-9126-1ce4d5e166fa"
      decimals="INF"
      id="F_0a5b1194-4e49-43d7-875c-74703210de13"
      unitRef="U_shares">5117358</inva:SecuritiesPurchaseAgreementWarrantsNumberOfSecuritiesCalledByWarrants>
    <inva:SecuritiesPurchaseAgreementAmount
      contextRef="C_0fcc5eab-dacf-4fd9-9338-7ce4c19eb6f1"
      decimals="-5"
      id="F_79fe5249-7248-4739-89ee-f6715a94e9a0"
      unitRef="U_USD">15800000</inva:SecuritiesPurchaseAgreementAmount>
    <inva:DebtInstrumentTransactionCost
      contextRef="C_1c3869dc-1179-4ea1-8b03-28655253f10d"
      decimals="-5"
      id="F_ce6d8aad-786c-46a1-9a6a-79c7d88a9186"
      unitRef="U_USD">800000</inva:DebtInstrumentTransactionCost>
    <inva:NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee
      contextRef="C_3325a2cf-7460-4b93-a664-ed1cbe345622"
      decimals="0"
      id="F_10164b0d-eda7-4ea3-9301-4c19affb0eb1"
      unitRef="U_Director">6</inva:NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee>
    <inva:CarryingValueWroteOffWarrantExercise
      contextRef="C_89169f0d-1765-42aa-9d7f-0ca1858b85d2"
      decimals="-5"
      id="F_d9321537-4f96-498a-9dbd-6ae3547d956e"
      unitRef="U_USD">100000</inva:CarryingValueWroteOffWarrantExercise>
    <inva:SecuritiesPurchaseAgreementAmount
      contextRef="C_6d65900c-b10f-49a2-bba9-16040891a8f1"
      decimals="-5"
      id="F_c1ef15eb-accd-462c-bac2-cf52d5c3120d"
      unitRef="U_USD">700000</inva:SecuritiesPurchaseAgreementAmount>
    <us-gaap:PaymentsToAcquireEquitySecuritiesFvNi
      contextRef="C_5d098b39-13cc-4896-9cc3-c37b02ea18ac"
      decimals="-5"
      id="F_974079ac-a8ed-4551-8268-107e0d7e77ab"
      unitRef="U_USD">2300000</us-gaap:PaymentsToAcquireEquitySecuritiesFvNi>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="C_a3c920a5-17f0-4dbc-8aff-02ec45493f70"
      decimals="INF"
      id="F_e732ed37-8ca1-423e-8730-e71e6abbcf85"
      unitRef="U_shares">4093886</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="C_1d4ad1ec-0fb3-4d86-8793-4881afd79af0"
      decimals="INF"
      id="F_d30e931a-fef5-4ddc-a396-6eafbee319e6"
      unitRef="U_shares">37350</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="C_1c3869dc-1179-4ea1-8b03-28655253f10d"
      decimals="INF"
      id="F_62fdf94d-fb94-4b51-b2fe-ceacd8338d14"
      unitRef="U_shares">20469432</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="C_e2357c2d-6a56-4a89-83af-cfa33770d462"
      decimals="INF"
      id="F_e74819a3-edeb-4f35-9388-c6000dd37664"
      unitRef="U_shares">8771780</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="C_1f21da09-fc29-466c-a31f-b632bcb5a795"
      decimals="INF"
      id="F_056280df-d651-470f-921a-6b86e2d827e0"
      unitRef="U_shares">3369802</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="C_4fa6082e-52f0-4343-8a08-2384bb43f803"
      decimals="INF"
      id="F_098b6cd5-c85a-4df3-8c6b-682b577ff992"
      unitRef="U_shares">5117358</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_d4a6dcc0-1cdb-48e6-9838-784bbf0081bc"
      decimals="2"
      id="F_829f46b8-9261-4700-8c70-c50df5c667e1"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.73</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="C_4a240330-393d-4181-af3c-3ee7aca2c718"
      decimals="INF"
      id="F_9d3e7903-0deb-4641-825a-23db895553f0"
      unitRef="U_shares">2490033</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_3a82bed2-f816-4121-ae41-fc7fd838fa36"
      decimals="2"
      id="F_18f36aac-db97-4fc4-90fe-4cf21a2b3c1d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.2</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="C_60737025-6027-4430-9a69-c41773b76a7a"
      decimals="3"
      id="F_97bb2bb8-6a77-4f71-8862-6c86fe8d953f"
      unitRef="U_pure">0.081</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="C_b77a83ac-82c7-48f4-8088-fe346e76a70f"
      decimals="3"
      id="F_f159f5f6-5289-4904-8c01-3186a82380e6"
      unitRef="U_pure">0.09</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <inva:ExpectedHoldingPeriod
      contextRef="C_b628e0b4-4491-4cf0-9301-fd0c4a42318f"
      id="F_f51d4db1-f9f8-4eb7-b523-e02c037ff5cd">P2Y</inva:ExpectedHoldingPeriod>
    <inva:RiskFreeInterestRate
      contextRef="C_b628e0b4-4491-4cf0-9301-fd0c4a42318f"
      decimals="3"
      id="F_adc21b81-07ce-4b7b-a002-dacb0f8efb2c"
      unitRef="U_pure">0.032</inva:RiskFreeInterestRate>
    <inva:DividendYield
      contextRef="C_b628e0b4-4491-4cf0-9301-fd0c4a42318f"
      decimals="3"
      id="F_6f97445d-6ed1-4ee8-8707-1dc132569411"
      unitRef="U_pure">0</inva:DividendYield>
    <inva:PercentageOfEstimatedVolatility
      contextRef="C_b628e0b4-4491-4cf0-9301-fd0c4a42318f"
      decimals="3"
      id="F_c995c83c-7cad-4753-944e-625cd373d796"
      unitRef="U_pure">1.22</inva:PercentageOfEstimatedVolatility>
    <us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment
      contextRef="C_2f78a803-3fe0-4245-b906-d2b1f794b7ad"
      decimals="-5"
      id="F_38c6653b-1209-4899-a3ff-08e4f215cda7"
      unitRef="U_USD">9000000</us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment>
    <inva:ExpectedHoldingPeriod
      contextRef="C_d7474670-7c71-498e-a093-31edba908380"
      id="F_f342b3ef-b8d4-4bd8-9ff6-0b1f26d80c1b">P2Y</inva:ExpectedHoldingPeriod>
    <inva:RiskFreeInterestRate
      contextRef="C_d7474670-7c71-498e-a093-31edba908380"
      decimals="3"
      id="F_e40fbfcb-710b-402f-a617-7a03e5c33e8b"
      unitRef="U_pure">0.049</inva:RiskFreeInterestRate>
    <inva:DividendYield
      contextRef="C_d7474670-7c71-498e-a093-31edba908380"
      decimals="3"
      id="F_61165f89-3354-47ce-a2c0-6d11b4f7cf1e"
      unitRef="U_pure">0</inva:DividendYield>
    <inva:PercentageOfEstimatedVolatility
      contextRef="C_d7474670-7c71-498e-a093-31edba908380"
      decimals="3"
      id="F_33a59cde-2c60-4e6d-9c21-8af8f5b4e526"
      unitRef="U_pure">1.142</inva:PercentageOfEstimatedVolatility>
    <us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment
      contextRef="C_105e2ff6-b00c-4d0f-80a9-99bc41fa4247"
      decimals="-5"
      id="F_9a8ed939-65bb-46c0-a9a1-09af17d679f8"
      unitRef="U_USD">2900000</us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="C_17f70e4b-90ed-432b-9c5b-4b6afd7a39ac"
      decimals="-5"
      id="F_5e45238d-1059-4f82-a862-44559ce9bb8e"
      unitRef="U_USD">4800000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="C_e585cd60-cdd5-4401-bfcc-d855443a7706"
      decimals="-5"
      id="F_971466cb-dc0f-45b9-abd5-3fbae21da5bb"
      unitRef="U_USD">100000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="C_0b1bdfd5-7193-40f2-af61-475bdb6831fa"
      decimals="-5"
      id="F_862cb3b8-aaeb-4bf8-a4a2-6ef46cc137ec"
      unitRef="U_USD">6800000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="C_c548651f-66c2-40f0-80ce-a318243d8cf7"
      decimals="-5"
      id="F_06c4942f-2171-458c-9057-a7536bd4bdb3"
      unitRef="U_USD">600000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="C_40cc7194-3f29-4836-b18c-10aa722c5ee1"
      decimals="-5"
      id="F_8a36e2c6-69b6-42c8-9c5d-e7a38d44cb76"
      unitRef="U_USD">2700000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="C_0f8abff1-9020-483e-b333-8737df241e43"
      decimals="-5"
      id="F_61a0f8bf-7323-495b-bf99-3654e8e601d6"
      unitRef="U_USD">3200000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="C_89169f0d-1765-42aa-9d7f-0ca1858b85d2"
      decimals="-5"
      id="F_1147bfca-8add-452a-8032-8bbb0b828bf1"
      unitRef="U_USD">3100000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedLoss
      contextRef="C_fdb40e49-15a5-44e8-ab56-25350fd9d665"
      decimals="-5"
      id="F_d633aafd-3be4-4d65-b34b-4b822125bbed"
      unitRef="U_USD">8700000</us-gaap:EquitySecuritiesFvNiUnrealizedLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedLoss
      contextRef="C_8ee91638-15d2-4e40-b682-b93f8c3d03b7"
      decimals="-5"
      id="F_4a1ab563-537b-4a96-881d-31c1e54c8f3e"
      unitRef="U_USD">700000</us-gaap:EquitySecuritiesFvNiUnrealizedLoss>
    <inva:SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement
      contextRef="C_a6849091-06e9-4245-b57e-57668217a80b"
      decimals="INF"
      id="F_6a68847f-adfc-435a-894b-561cf225d500"
      unitRef="U_shares">4051724</inva:SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement>
    <inva:SecuritiesPurchaseAgreementAmount
      contextRef="C_6a99d93c-955d-4e2f-bcac-63e09ca2e6ef"
      decimals="-5"
      id="F_27912b1f-6711-41e3-8797-348b444d4899"
      unitRef="U_USD">4700000</inva:SecuritiesPurchaseAgreementAmount>
    <inva:SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement
      contextRef="C_f20f052b-36df-4c4e-bd3b-191c89d3381d"
      decimals="INF"
      id="F_ce75bc49-9557-4e59-8d36-cad6f6a53147"
      unitRef="U_shares">4097157</inva:SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement>
    <inva:SecuritiesPurchaseAgreementAmount
      contextRef="C_2357dcf9-e127-4ee9-a066-9899931c287f"
      decimals="-5"
      id="F_44e5f160-9d80-4eee-97e0-804c1c3f49a3"
      unitRef="U_USD">1300000</inva:SecuritiesPurchaseAgreementAmount>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_07acd2a2-efee-41c9-bbd9-499920ef8206"
      decimals="-5"
      id="F_c6d0de17-0a5a-4da6-9f0e-3a9910c6e3a3"
      unitRef="U_USD">400000</us-gaap:PaymentsOfStockIssuanceCosts>
    <inva:SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement
      contextRef="C_94027cba-de30-4b5d-a0ff-68cce2ec7cfa"
      decimals="INF"
      id="F_dcc9ef07-7732-42d7-a365-2d394a76c18a"
      unitRef="U_shares">270568</inva:SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement>
    <inva:SecuritiesPurchaseAgreementAmount
      contextRef="C_c2b5fc1d-7d57-4855-af69-696043e9626b"
      decimals="-5"
      id="F_33f9e097-b7bd-40d5-be0a-499a2d17bbd0"
      unitRef="U_USD">600000</inva:SecuritiesPurchaseAgreementAmount>
    <inva:SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement
      contextRef="C_2253537a-7271-4515-97f9-6f06ff495b9f"
      decimals="INF"
      id="F_4152cd33-ebea-43a2-a713-9429be0ca58d"
      unitRef="U_shares">405852</inva:SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement>
    <inva:SecuritiesPurchaseAgreementAmount
      contextRef="C_c2b5fc1d-7d57-4855-af69-696043e9626b"
      decimals="-5"
      id="F_d25119f3-2bf1-43d2-9727-29870d85633b"
      unitRef="U_USD">600000</inva:SecuritiesPurchaseAgreementAmount>
    <inva:NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee
      contextRef="C_d5306868-e998-4382-9386-90e35c6d7f3a"
      decimals="0"
      id="F_d2cc1d17-7c0f-4ac2-9934-715c74fb7044"
      unitRef="U_Director">1</inva:NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="C_c2081d77-3917-481a-aad9-38a97a27b3f4"
      decimals="3"
      id="F_fda0b1d8-6fce-4d7b-ba69-42f9bb47eb1a"
      unitRef="U_pure">0.124</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="C_bf193f24-bfbe-419c-9802-eee6070d5ad5"
      decimals="3"
      id="F_5494d00b-c794-473c-a4a7-486dfd13a3d0"
      unitRef="U_pure">0.127</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="C_d5306868-e998-4382-9386-90e35c6d7f3a"
      decimals="-5"
      id="F_4980b7c7-7f03-427c-a4fd-7608ecded216"
      unitRef="U_USD">7600000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="C_9d6f1e1e-8a05-4f52-aabf-6ea93d745a22"
      decimals="-5"
      id="F_27a1bc18-c37f-4554-89f9-09feb63af8ca"
      unitRef="U_USD">6400000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="C_c70d2786-9128-41e1-9dae-1423ff150cb0"
      decimals="-5"
      id="F_b67b8c4a-efd0-4495-a0b2-83054542a5d4"
      unitRef="U_USD">15000000</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="C_8157d7d6-196c-4c46-bf54-22f1d9546346"
      decimals="2"
      id="F_96eecc59-84bf-4cff-982a-264a650f727d"
      unitRef="U_pure">0.08</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <inva:NumberOfCommonStockIssuedDescription
      contextRef="C_85b04dbe-2493-4115-9d41-cfc1636e1d1c"
      id="F_ae4db676-60a6-4591-bbf9-177fcd309dcc">The number of common stock shares to be issued in a qualified event shall be equal to the amount due on the conversion date divided by the lesser of a capped conversion price (the &#x201c;Capped Conversion Price&#x201d;) and the qualified event price (the &#x201c;Qualified Event Price&#x201d;). The Capped Conversion Price is calculated as $50.0 million divided by the number of shares of common stock outstanding at such time on a fully diluted basis. The Qualified Event Price is the price per share determined by the qualified event. A qualified financing is a sale or series of sales of preferred stock where (i) at least 50 percent of counterparties are not existing shareholders, (ii) net proceeds to Gate are at least $35.0 million, and (iii) the stated or implied equity valuation of Gate is at least $80.0 million. </inva:NumberOfCommonStockIssuedDescription>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_8157d7d6-196c-4c46-bf54-22f1d9546346"
      decimals="-5"
      id="F_eaa1d709-e2ca-45e4-b08a-891410d18cd6"
      unitRef="U_USD">15000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_455dfd10-363e-4652-a98d-acd8423476e5"
      decimals="-5"
      id="F_7e1eb564-9720-4fea-a3df-e3e60b0f5665"
      unitRef="U_USD">21500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:PaymentsToAcquireLongtermInvestments
      contextRef="C_9fac3855-4b00-44d6-b70c-185ef1d1eeb0"
      decimals="-5"
      id="F_392bd5b6-bc4c-422d-ad61-b4274be3c002"
      unitRef="U_USD">5000000</us-gaap:PaymentsToAcquireLongtermInvestments>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_101e59d3-6e14-4104-a1dd-021cb423fa02"
      decimals="-5"
      id="F_3cdc77ee-ef75-44dd-bf63-6f0fcf6024dd"
      unitRef="U_USD">21500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_f018c1ca-e8f9-4a4f-9827-94816b25882f"
      decimals="-5"
      id="F_4c835a65-d49d-4702-b7d2-738e3f8020a2"
      unitRef="U_USD">27700000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:PaymentsToAcquireLongtermInvestments
      contextRef="C_e4ffec73-53e1-424c-b35f-67a5034c0026"
      decimals="-5"
      id="F_dc8b23c2-7292-4807-a8c6-aac52ca3a008"
      unitRef="U_USD">5000000</us-gaap:PaymentsToAcquireLongtermInvestments>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="C_77a6d898-3c41-425f-bdce-0d730d09522d"
      decimals="-5"
      id="F_1516d2b7-3b60-4e74-882d-9a1828f82ce0"
      unitRef="U_USD">28000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="C_30cc733a-2659-49f2-9019-387d5263bfd5"
      decimals="-5"
      id="F_4598e52e-7fa4-4141-b265-05a47c7f1108"
      unitRef="U_USD">15700000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNiUnrealizedLoss
      contextRef="C_0651f01e-b4f6-472e-bb04-bd2532da85ee"
      decimals="-5"
      id="F_313f8f75-8c59-4274-94d2-1b644e26c1e3"
      unitRef="U_USD">400000</us-gaap:EquitySecuritiesFvNiUnrealizedLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGain
      contextRef="C_c21ec5a1-610f-49e2-a459-1e404f26ba78"
      decimals="-5"
      id="F_7f25e588-58ef-496a-aa2a-81b6dc69a1a3"
      unitRef="U_USD">600000</us-gaap:EquitySecuritiesFvNiUnrealizedGain>
    <us-gaap:EquitySecuritiesFvNiUnrealizedLoss
      contextRef="C_c21ec5a1-610f-49e2-a459-1e404f26ba78"
      decimals="-5"
      id="F_50fa0bf1-59d0-4a46-a957-bed042a1b5d5"
      unitRef="U_USD">800000</us-gaap:EquitySecuritiesFvNiUnrealizedLoss>
    <inva:SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement
      contextRef="C_b4844c4a-5218-4a44-b32f-7a91f6ba430d"
      decimals="INF"
      id="F_a3aa22fa-45e9-4453-b193-1bf119b5757f"
      unitRef="U_shares">18750000</inva:SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement>
    <inva:SecuritiesPurchaseAgreementAmount
      contextRef="C_a57ec5ea-103b-4914-89c8-f5cce009d3f2"
      decimals="-5"
      id="F_f6c16d6b-a29b-47d9-b473-63e761adf89a"
      unitRef="U_USD">9800000</inva:SecuritiesPurchaseAgreementAmount>
    <inva:SecuritiesPurchaseAgreementAmount
      contextRef="C_a57ec5ea-103b-4914-89c8-f5cce009d3f2"
      decimals="-5"
      id="F_f8d0a016-1735-460b-be06-0f0888743e88"
      unitRef="U_CHF">9000000</inva:SecuritiesPurchaseAgreementAmount>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_f3734e2c-95b6-4b79-9206-0f8540ff6e11"
      decimals="-5"
      id="F_29e67c17-ea57-4849-8135-41f6eccccf81"
      unitRef="U_USD">700000</us-gaap:PaymentsOfStockIssuanceCosts>
    <inva:NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee
      contextRef="C_cdf38ae8-3488-4d9c-82c7-3e8d9ebc8c31"
      decimals="INF"
      id="F_2aa87ec2-c14d-44ee-b483-6b8be6672e97"
      unitRef="U_Director">0</inva:NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee>
    <inva:NumberOfBoardMembersOfInvestee
      contextRef="C_cdf38ae8-3488-4d9c-82c7-3e8d9ebc8c31"
      decimals="0"
      id="F_fe5010ab-bb93-4bd9-9108-9a7103a387a4"
      unitRef="U_Director">6</inva:NumberOfBoardMembersOfInvestee>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="C_a602a058-063e-48c6-b5ce-d6c0d4fb1353"
      decimals="3"
      id="F_072a5807-56b1-43a5-938b-542d2b01771b"
      unitRef="U_pure">0.153</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="C_6f107155-7e2c-410b-87ad-9c00bd1803a3"
      decimals="3"
      id="F_b46de076-fc7f-4634-81bc-9681ae269797"
      unitRef="U_pure">0.155</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="C_cdf38ae8-3488-4d9c-82c7-3e8d9ebc8c31"
      decimals="-5"
      id="F_3f5c6074-b3c9-4aba-829f-538fbe2f4e58"
      unitRef="U_USD">10600000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="C_bda4cb66-7959-4b7c-926d-00e33cf8a0ad"
      decimals="-5"
      id="F_74fb4169-b481-413e-aa30-8e2d175b7e7f"
      unitRef="U_USD">10600000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      id="F_3766c498-0bcd-4acf-bfa9-a652c6e82ecc">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The estimated fair value of available-for-sale securities is based on quoted market prices for these or similar investments that were based on prices obtained from a commercial pricing service. Available-for-sale securities are summarized below:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:36.867%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.56%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.222000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.56%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.222000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.56%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.222000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.56%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.222000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amortized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unrealized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unrealized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Estimated&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;170,706&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;170,706&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;170,706&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;170,706&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"&gt;&lt;span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:9pt;font-family:Times New Roman;transform-origin:top left;min-width:3.333%;display:inline-flex;justify-content:flex-start;"&gt;(1)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Money market funds are included in cash and cash equivalents in the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:36.867%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.56%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.222000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.56%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.222000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.56%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.222000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.56%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.222000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amortized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unrealized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unrealized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Estimated&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;263,469&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;263,469&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;263,469&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;263,469&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"&gt;&lt;span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:9pt;font-family:Times New Roman;transform-origin:top left;min-width:3.333%;display:inline-flex;justify-content:flex-start;"&gt;(1)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Money market funds are included in cash and cash equivalents in the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_f86d4e5c-570c-4de9-85a1-8a94d98944a1"
      decimals="-3"
      id="F_b9ac7d88-0ec7-4a44-b18b-b9ac67c540d1"
      unitRef="U_USD">170706000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_f86d4e5c-570c-4de9-85a1-8a94d98944a1"
      decimals="-3"
      id="F_26a4b48a-8a57-4a41-bd9e-43886a8b595b"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_f86d4e5c-570c-4de9-85a1-8a94d98944a1"
      decimals="-3"
      id="F_4a70ed61-c9ff-4827-8179-ace3ddd3bf0d"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_f86d4e5c-570c-4de9-85a1-8a94d98944a1"
      decimals="-3"
      id="F_e2184934-bd84-4125-9424-85c04dca4927"
      unitRef="U_USD">170706000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_287da742-b209-48b2-9599-c3abb9941dd3"
      unitRef="U_USD">170706000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_d97563a5-dac2-4b2c-9903-8ae2ccf68d28"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_9ee341c7-3961-4f76-af83-81db2b050ae4"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_9b43ccbf-ace8-4b70-88f8-0b99711bcb15"
      unitRef="U_USD">170706000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_a0d0f17e-db42-4983-a7d4-03a17fcfd44f"
      decimals="-3"
      id="F_5b257131-c564-45cc-91a5-088cab24c28e"
      unitRef="U_USD">263469000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_a0d0f17e-db42-4983-a7d4-03a17fcfd44f"
      decimals="-3"
      id="F_64e8fe2d-9ccc-4d48-a246-d18907408dd4"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_a0d0f17e-db42-4983-a7d4-03a17fcfd44f"
      decimals="-3"
      id="F_e248727d-972b-4bb6-ab0b-09782adb2852"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_a0d0f17e-db42-4983-a7d4-03a17fcfd44f"
      decimals="-3"
      id="F_35d88796-82fe-4251-9612-1a4e04f63d2e"
      unitRef="U_USD">263469000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      decimals="-3"
      id="F_b7eab255-6060-4634-aa12-a62bd9f9e168"
      unitRef="U_USD">263469000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      decimals="-3"
      id="F_a51b749c-6ae2-4d0d-baa4-ad8ddca62d00"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      decimals="-3"
      id="F_47800e7c-af7c-408c-873c-4cf8d0a580bc"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      decimals="-3"
      id="F_900b0718-f17a-4754-b039-e3e3f6a66900"
      unitRef="U_USD">263469000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_9c1eaf19-5d49-4e10-aa6c-c3f28bf7e427"
      unitRef="U_USD">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      decimals="-3"
      id="F_0ceb0bd1-76d0-4545-b7be-9b75590587ce"
      unitRef="U_USD">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      id="F_17bca1d5-c0e6-4c3c-a110-9993c8b8d90e">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Our available-for-sale securities, equity and long-term investments and contingent value rights are measured at fair value on a recurring basis and our debt is carried at amortized cost basis.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:36.867%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.56%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.222000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.56%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.222000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.56%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.222000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.56%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.222000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Estimated Fair Value Measurements as of December 31, 2023 Using:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Quoted Price&lt;br/&gt;in Active&lt;br/&gt;Markets for&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Significant&lt;br/&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Significant&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Identical&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Observable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unobservable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Types of Instruments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Inputs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Inputs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;"&gt;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;170,706&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;170,706&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Investments held by ISP Fund LP &lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;251,207&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;60,605&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;311,812&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Equity investment - Armata Common Stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;81,249&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;81,249&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Equity investment - Armata Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;35,297&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;35,297&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Convertible debt investment - Armata Note&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;51,883&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;51,883&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Term loan investment - Armata Term Loan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27,044&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27,044&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Convertible debt investment - Gate Note&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27,972&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27,972&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total assets measured at estimated fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;503,162&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;35,297&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;167,504&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;705,963&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;"&gt;Liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Debt&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2025 Notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;200,407&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;200,407&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2028 Notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;227,070&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;227,070&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;Total fair value of debt&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;427,477&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;427,477&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Contingent value rights&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;359&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;359&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total liabilities at estimated fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;427,477&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;359&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;427,836&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"&gt;&lt;span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:9pt;font-family:Times New Roman;transform-origin:top left;min-width:3.333%;display:inline-flex;justify-content:flex-start;"&gt;(1)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The investments held by ISP Fund LP, consisted of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;248.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in equity investments, which included private placement positions of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;60.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;62.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in money market funds. A certain portion of the total capital contribution of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;300.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million is no longer subject to a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;36-month&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; lock-up period from the date of such capital contribution. However, we did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;t elect to make a withdrawal in 2023, thereby extending the lock-up period and withdrawal elections into subsequent years. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:36.867%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.56%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.222000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.56%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.222000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.56%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.222000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.56%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.222000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Estimated Fair Value Measurements as of December 31, 2022 Using:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Quoted Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;in Active&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Significant&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Markets for&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Significant&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Identical&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Observable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unobservable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Types of Instruments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Inputs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Inputs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;"&gt;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;263,469&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;263,469&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Investments held by ISP Fund LP &lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;265,982&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;54,578&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;320,560&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Equity investment - Armata Common Stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;31,095&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;31,095&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Equity investment - Armata Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,059&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,059&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Equity investment - InCarda Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;605&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;605&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Convertible debt investment - Gate Note&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,700&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,700&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total assets measured at estimated fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;560,546&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,059&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;70,883&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;639,488&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;"&gt;Debt&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2023 Notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;96,089&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;96,089&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2025 Notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;197,807&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;197,807&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2028 Notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;211,768&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;211,768&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total fair value of debt&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;505,664&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;505,664&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Contingent value rights&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;595&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;595&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total liabilities at estimated fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;505,664&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;595&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;506,259&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"&gt;&lt;span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:9pt;font-family:Times New Roman;transform-origin:top left;min-width:3.333%;display:inline-flex;justify-content:flex-start;"&gt;(1)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The investments held by ISP Fund LP, consisted of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;295.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in equity investments, which included private placement positions and convertible notes of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;54.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in money market funds. Our total capital contribution of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;300.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million was subject to a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;36-month&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; lock-up period from the date of such capital contributions.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_5e685cc4-011a-4588-9181-90ecb3ccceb4"
      decimals="-3"
      id="F_6d4fd783-ff34-4a94-99d3-408891549f33"
      unitRef="U_USD">170706000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_c5f941e0-b007-4ef9-bd80-53ea1e5f382a"
      decimals="-3"
      id="F_18593713-57ed-4b50-bc90-ed0a6b10dc97"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_31010f98-5d41-43b8-8b09-e38bde00ec6d"
      decimals="-3"
      id="F_46e1034c-66f9-4f1b-84a9-df1d75fcecbb"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_c21ca759-25e6-4904-91dd-c322af1eeaf5"
      decimals="-3"
      id="F_3f6865c3-54a3-4389-ba1e-3552c012b26c"
      unitRef="U_USD">170706000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_569e7525-942b-48c6-9703-ac849c3d278a"
      decimals="-3"
      id="F_640cced8-8c0d-4ecb-b7e5-b8a0e34874d2"
      unitRef="U_USD">251207000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_d21494bc-80c8-4b9a-af3a-b8e82bfd6caf"
      decimals="-3"
      id="F_b935334f-0493-4661-b36b-bead7c670f68"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_7595f3bf-096e-45fc-b68b-d690c0d2803e"
      decimals="-3"
      id="F_22478cef-8f79-4fb5-9e36-deaf9b1d90f8"
      unitRef="U_USD">60605000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_13fdb038-bf81-4c06-8c1d-9aabbf5a3705"
      decimals="-3"
      id="F_163fe0cd-4268-4bdf-8328-6e0ab0363e8f"
      unitRef="U_USD">311812000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_9f56edf9-4d83-4ddd-b43e-19b470780c80"
      decimals="-3"
      id="F_926336ea-4816-4d18-b707-61b4578c0b3a"
      unitRef="U_USD">81249000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_9d9fedca-43c3-4c3c-a148-a051b0151a35"
      decimals="-3"
      id="F_6c37fcd5-7e41-4773-940f-80bae2065315"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_a18d4683-905b-4297-962a-d6b053b48738"
      decimals="-3"
      id="F_d58bd632-297a-4028-843b-bc0bdfc5fed4"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_51b5cb2e-4d34-4373-952e-14896dcb3ec0"
      decimals="-3"
      id="F_17062d09-f91b-41b5-868f-aa1f688f683b"
      unitRef="U_USD">81249000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_5f6a168b-c6ae-4f1b-a9d6-59d531bc1b72"
      decimals="-3"
      id="F_b3b6233b-1d63-406a-835b-b9b6e151b613"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_1a6354f8-d8d6-4e39-a8ca-ea30d3d87bc6"
      decimals="-3"
      id="F_3ef17bf4-1732-47e0-9ad2-5137735f4051"
      unitRef="U_USD">35297000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_64d5bd90-3055-4f52-b86f-cb8d0deed43e"
      decimals="-3"
      id="F_735fa536-272e-48e9-a5cc-5fd80c31bbed"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_45a2b910-f147-4239-a429-43ed79c4207b"
      decimals="-3"
      id="F_fbddb451-b161-421e-bd94-935fb1e7f561"
      unitRef="U_USD">35297000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_9fea235d-92aa-406b-99d4-cef846711663"
      decimals="-3"
      id="F_dd912b58-29c2-4422-9d89-e200a754d98c"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_ad1bdaae-2e73-4919-aef7-1bf53376deb1"
      decimals="-3"
      id="F_fe596701-6d46-468e-9e99-20193bd523f7"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_c9163898-48a1-4dcb-8fe2-b46eda3de475"
      decimals="-3"
      id="F_9a271439-ef47-42af-b7a6-a3db60a36c56"
      unitRef="U_USD">51883000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_8b957e8d-7780-431f-93e1-471c1c7babcb"
      decimals="-3"
      id="F_c24bb2e3-87e0-4419-8e9c-8e06f4715566"
      unitRef="U_USD">51883000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_b3da9b9d-f2ab-400a-b73e-57b287e45c47"
      decimals="-3"
      id="F_71fb031a-ce16-4607-badb-8f4ddbd216cd"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_b57cd753-71d3-4cff-8d5a-7f32594379ed"
      decimals="-3"
      id="F_24b37d32-67c4-4885-8747-569383971955"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_4b010911-360b-4122-a51a-2daa2012b8a9"
      decimals="-3"
      id="F_08bf71d5-d43d-438f-9561-cbb4c533b6bb"
      unitRef="U_USD">27044000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_3d517819-005b-4abf-9ea5-9aada251df67"
      decimals="-3"
      id="F_bd7e535d-1cf1-4d79-a58c-2ea0ec435f92"
      unitRef="U_USD">27044000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_b28442af-97a1-40c6-8f0f-8d7c9d6642b5"
      decimals="-3"
      id="F_8f57c6d3-ea73-4ffa-a4dc-ef6e6c00e245"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_f526cd8e-6c2f-4f2c-bd9e-4e878cf8ba5f"
      decimals="-3"
      id="F_bc363f24-6946-4640-81d4-04ed59be1f2d"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_379884bb-ab3a-4a27-89b9-9b8365b16e1e"
      decimals="-3"
      id="F_f3176264-d32b-43d2-ada9-d508c897dae8"
      unitRef="U_USD">27972000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_bae5ea2a-1d4e-43c0-924e-20e43f661014"
      decimals="-3"
      id="F_17255b89-d487-44de-8a56-076d0c70b2d4"
      unitRef="U_USD">27972000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_1a399c56-8380-4778-aa97-c511dc489262"
      decimals="-3"
      id="F_d0c41cd4-8ca7-4d51-928c-30575a503886"
      unitRef="U_USD">503162000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_c8d0b01f-64b8-4438-8b36-9e1b99364b0b"
      decimals="-3"
      id="F_d2b4a620-c952-405d-b00c-c2f864bc4474"
      unitRef="U_USD">35297000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_702028fe-7b13-49f6-bf9a-e4aaba3364f4"
      decimals="-3"
      id="F_4a371282-3d28-41f1-b10f-fb93d416dac6"
      unitRef="U_USD">167504000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_acc8fa0e-9230-4a63-8d63-4ae6d91d60af"
      decimals="-3"
      id="F_dd38df39-be3a-416b-be8b-e9141a4db40e"
      unitRef="U_USD">705963000</us-gaap:AssetsFairValueDisclosure>
    <inva:ConvertibleSeniorDebtFairValueDisclosures
      contextRef="C_b697daba-e91e-4352-8b6f-532cdaacd5fa"
      decimals="-3"
      id="F_592ad3ff-d267-4ed0-aa12-1bb1126ffa22"
      unitRef="U_USD">0</inva:ConvertibleSeniorDebtFairValueDisclosures>
    <inva:ConvertibleSeniorDebtFairValueDisclosures
      contextRef="C_1dbbdaf4-e472-4d57-8ddc-ea01a7242c98"
      decimals="-3"
      id="F_9d1d4112-6de6-4fa5-b7e8-21836e0725af"
      unitRef="U_USD">200407000</inva:ConvertibleSeniorDebtFairValueDisclosures>
    <inva:ConvertibleSeniorDebtFairValueDisclosures
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_65e8acca-db38-42d4-96e6-4d098081beca"
      unitRef="U_USD">0</inva:ConvertibleSeniorDebtFairValueDisclosures>
    <inva:ConvertibleSeniorDebtFairValueDisclosures
      contextRef="C_12a01e00-2ffc-4751-bfae-ab411878a4e9"
      decimals="-3"
      id="F_5d9e3ccd-ab76-431c-8f7b-c29c8e3baf67"
      unitRef="U_USD">200407000</inva:ConvertibleSeniorDebtFairValueDisclosures>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="C_b697daba-e91e-4352-8b6f-532cdaacd5fa"
      decimals="-3"
      id="F_24ab3e6a-15ad-49ec-a791-91f0b012b51e"
      unitRef="U_USD">0</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="C_d809c37b-511d-4f0b-942b-be754908ee4d"
      decimals="-3"
      id="F_bf8d27f0-9bb2-41b0-8572-d2c30ad0891f"
      unitRef="U_USD">227070000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="C_0e8b7755-7a30-43fc-8700-88f8cb2fb267"
      decimals="-3"
      id="F_ca6f6cd8-b07a-4bbd-9537-74987c92bef4"
      unitRef="U_USD">0</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="C_12a01e00-2ffc-4751-bfae-ab411878a4e9"
      decimals="-3"
      id="F_b2fb31ce-17dd-4f34-a228-4d291cedf0b3"
      unitRef="U_USD">227070000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:DebtInstrumentFairValue
      contextRef="C_b697daba-e91e-4352-8b6f-532cdaacd5fa"
      decimals="-3"
      id="F_417a3f83-c0b3-4c7c-b7a5-bf9fd5965ede"
      unitRef="U_USD">0</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="C_d809c37b-511d-4f0b-942b-be754908ee4d"
      decimals="-3"
      id="F_4561ab40-b068-422f-b7bc-2b076340fcec"
      unitRef="U_USD">427477000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="C_0e8b7755-7a30-43fc-8700-88f8cb2fb267"
      decimals="-3"
      id="F_7eee3b92-a798-4882-b825-74ddd16afe2a"
      unitRef="U_USD">0</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="C_12a01e00-2ffc-4751-bfae-ab411878a4e9"
      decimals="-3"
      id="F_89970358-edb1-48a3-aee1-a13be0efeaec"
      unitRef="U_USD">427477000</us-gaap:DebtInstrumentFairValue>
    <inva:ContingentValueRightsLiability
      contextRef="C_74b73320-f859-4046-baa9-7350be012c10"
      decimals="-3"
      id="F_f8a64d0b-4e94-4170-bbec-04f71b904ddd"
      unitRef="U_USD">0</inva:ContingentValueRightsLiability>
    <inva:ContingentValueRightsLiability
      contextRef="C_d809c37b-511d-4f0b-942b-be754908ee4d"
      decimals="-3"
      id="F_30c35ce1-82c0-427d-ad05-bd2fdf4eb028"
      unitRef="U_USD">0</inva:ContingentValueRightsLiability>
    <inva:ContingentValueRightsLiability
      contextRef="C_1dafa801-a453-4e03-925d-1453c2c0f5f6"
      decimals="-3"
      id="F_8d303717-78d2-4f23-bdaf-078f33d332f5"
      unitRef="U_USD">359000</inva:ContingentValueRightsLiability>
    <inva:ContingentValueRightsLiability
      contextRef="C_f7d458fe-e023-4486-aa27-fdd8c78f09fa"
      decimals="-3"
      id="F_34cd0973-2233-4132-b402-b3cf40c7f429"
      unitRef="U_USD">359000</inva:ContingentValueRightsLiability>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_74b73320-f859-4046-baa9-7350be012c10"
      decimals="-3"
      id="F_84918b1d-460b-47e7-bdf8-f10e925bac0e"
      unitRef="U_USD">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_d809c37b-511d-4f0b-942b-be754908ee4d"
      decimals="-3"
      id="F_9cbb6bb4-fb04-4332-8c86-905e06496680"
      unitRef="U_USD">427477000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_1dafa801-a453-4e03-925d-1453c2c0f5f6"
      decimals="-3"
      id="F_a9dcbda3-7044-4a23-ba44-ae21d6a525f6"
      unitRef="U_USD">359000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_f7d458fe-e023-4486-aa27-fdd8c78f09fa"
      decimals="-3"
      id="F_28bc960d-d14d-47c3-9784-aed048363a4f"
      unitRef="U_USD">427836000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_08e9488e-214d-4494-813d-28131fd90598"
      decimals="-5"
      id="F_a0e347eb-99aa-437e-ad46-4cb50eaa1373"
      unitRef="U_USD">248500000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_5610546b-710f-4b56-bca0-b9c532b6f95a"
      decimals="-5"
      id="F_5f8c1571-9f4c-4eda-ade7-9761134b8465"
      unitRef="U_USD">60600000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_ea272365-8aa7-4a80-8b19-6a8032d971c0"
      decimals="-5"
      id="F_90a60e5c-4b32-46c7-8263-4ff0b82e7275"
      unitRef="U_USD">62900000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LimitedPartnersContributedCapital
      contextRef="C_bc5da3bc-ba84-41b4-9714-69d7f9dcb276"
      decimals="-5"
      id="F_b0006e36-35db-438b-aaab-1625e15887f7"
      unitRef="U_USD">300000000</us-gaap:LimitedPartnersContributedCapital>
    <inva:PartnershipAgreementLockUpPeriod
      contextRef="C_70752bbf-999a-40de-bb2c-738c0b7f7ada"
      id="F_682ea2de-3876-4f8f-8634-46d4810ee084">P36M</inva:PartnershipAgreementLockUpPeriod>
    <inva:WithdrawalFromInvestment
      contextRef="C_70752bbf-999a-40de-bb2c-738c0b7f7ada"
      decimals="-3"
      id="F_90a798ce-d1fa-420a-8d7a-49f3a9dc17ca"
      unitRef="U_USD">0</inva:WithdrawalFromInvestment>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_be6668a0-7dd8-4ba3-acdc-f68ede2a4466"
      decimals="-3"
      id="F_286af3e8-03af-4dfb-b52b-74d4fb73f81e"
      unitRef="U_USD">263469000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_29d8e0a4-1346-4e5a-9734-3d41d9fe9891"
      decimals="-3"
      id="F_f1d2d04c-d672-4ae7-b449-16be6028657e"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_f6a3bb99-253a-4791-914d-f4334dddf22a"
      decimals="-3"
      id="F_f5185b53-9452-4367-92ef-72f96dadd147"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_24b1825a-6f77-49e4-828c-3e33f531af0b"
      decimals="-3"
      id="F_4be73e97-3670-4a91-bbaa-20aaba8b2f00"
      unitRef="U_USD">263469000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_81047951-2422-46bb-a073-86b99c1cee75"
      decimals="-3"
      id="F_642b9e4b-f8ea-48f4-9e68-c69a54e91074"
      unitRef="U_USD">265982000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_00bcfed5-5665-4a95-a3f4-d2ac0f6fdaa3"
      decimals="-3"
      id="F_007ca7f4-d174-4a7c-a703-836236edbe52"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0c62ac1f-f870-4e92-add2-b1924f35420e"
      decimals="-3"
      id="F_16adad2a-1e35-499c-8549-470982d5bd2a"
      unitRef="U_USD">54578000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_de46daa9-d4c7-4d11-b729-3650d5f2b9cd"
      decimals="-3"
      id="F_8a869d89-7a7a-45db-ada7-7a991d2546c3"
      unitRef="U_USD">320560000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_fe573d70-749d-4747-a2aa-7a4c9cb2488c"
      decimals="-3"
      id="F_67646e81-ba7b-4418-b15b-f12f8b0823ca"
      unitRef="U_USD">31095000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_5c2cfa33-ca5f-465a-89ae-63a6b102f37a"
      decimals="-3"
      id="F_974fe0a0-0c59-4d2a-ac5f-566b6dc55ca4"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_85e74837-f1dd-4956-a48b-f67a1bfe07cf"
      decimals="-3"
      id="F_702cf89d-d3a3-4575-aaa7-449f730d1c6d"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_35f64b46-11ed-4d73-b48d-9b0294e79c59"
      decimals="-3"
      id="F_49ddd7ca-b9eb-4a90-93dd-c8ac8f0bdcbc"
      unitRef="U_USD">31095000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_1f2036f9-b56a-403d-9f98-ec7e12869b74"
      decimals="-3"
      id="F_f8562e75-3573-4f9f-8045-70ff1c9c717f"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_66b50de4-9da3-415d-8893-6426c4c9c73b"
      decimals="-3"
      id="F_fd23a935-a558-4115-8a1c-47e476ea344a"
      unitRef="U_USD">8059000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_f6f51154-4209-4901-acf6-2c40992c8eb9"
      decimals="-3"
      id="F_cf44bd73-c9a3-4eea-bca5-2631979a8b8b"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_6e065d89-351d-457c-ba2e-bc2d69edba60"
      decimals="-3"
      id="F_2d7deb3c-f6da-46c5-adb8-0c019fb6165d"
      unitRef="U_USD">8059000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_f4a9e48d-00e5-43b6-9299-938496783a9d"
      decimals="-3"
      id="F_5b34893e-f7f3-4d1e-a7b4-93dfa52c2771"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_e112a83c-e5e4-49f5-9f29-958a211ef1b6"
      decimals="-3"
      id="F_0cfa3877-5005-406a-82fc-5e871e40cd2b"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_d68c6264-7526-47b4-8da2-c7ceccce0e57"
      decimals="-3"
      id="F_c90d0199-0a0e-45ea-9c85-9d661c80fd6c"
      unitRef="U_USD">605000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_109bc829-e421-4835-9aad-dedc4c375347"
      decimals="-3"
      id="F_a75ac58c-7546-45bd-bbb5-c024080f98fd"
      unitRef="U_USD">605000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_3d081474-bef5-49f9-9f8c-6d2a8ce28f36"
      decimals="-3"
      id="F_3c8089b1-d952-4259-9f7c-b5d7221ba929"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_c84174e9-be04-42dd-b25c-92df750b79e8"
      decimals="-3"
      id="F_d8135559-e564-4e12-9218-e7b5445cb556"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_825d28ed-6319-4ae7-9001-97f35281db61"
      decimals="-3"
      id="F_65e2036f-0e58-4c6f-a3b6-1650fa2b3cf6"
      unitRef="U_USD">15700000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_9f8ff2b8-4656-4ea8-955a-c60a95c6b1c1"
      decimals="-3"
      id="F_e01c7de6-2529-4e16-ba0a-ee28c8dc3641"
      unitRef="U_USD">15700000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0647acf4-6f5c-4d39-86c2-fb4fddd549fb"
      decimals="-3"
      id="F_4ec0538e-a183-4e20-8162-a781ac683c56"
      unitRef="U_USD">560546000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_d2367046-d399-4ddc-a17e-2f5ef1165e9e"
      decimals="-3"
      id="F_b892ae12-65d9-437e-901b-bcdbab2736b9"
      unitRef="U_USD">8059000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_dc1e896e-f118-48b0-8cb0-89c09e214ab6"
      decimals="-3"
      id="F_9978330a-a1e0-4ba5-99f3-2d409d9cd256"
      unitRef="U_USD">70883000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_825f18bd-f7d5-4d67-9659-20286d27f1c0"
      decimals="-3"
      id="F_b45f594e-51e3-4456-8b7b-15c3217d768e"
      unitRef="U_USD">639488000</us-gaap:AssetsFairValueDisclosure>
    <inva:ConvertibleSubordinatedDebtFairValueDisclosures
      contextRef="C_c86331ec-9958-472c-9d3d-73034f0f043f"
      decimals="-3"
      id="F_44a7684e-ec11-4dc4-848f-8799426c8aa4"
      unitRef="U_USD">0</inva:ConvertibleSubordinatedDebtFairValueDisclosures>
    <inva:ConvertibleSubordinatedDebtFairValueDisclosures
      contextRef="C_dec01f12-3f85-4d42-8b61-61f857a1419a"
      decimals="-3"
      id="F_c55c9a2c-1409-47b1-8c4a-e21937939e27"
      unitRef="U_USD">96089000</inva:ConvertibleSubordinatedDebtFairValueDisclosures>
    <inva:ConvertibleSubordinatedDebtFairValueDisclosures
      contextRef="C_b1399523-0285-44ab-8535-deb7616f55e6"
      decimals="-3"
      id="F_7efb727b-ece1-4cd3-a513-007890eacfde"
      unitRef="U_USD">0</inva:ConvertibleSubordinatedDebtFairValueDisclosures>
    <inva:ConvertibleSubordinatedDebtFairValueDisclosures
      contextRef="C_d406fd03-b3d6-41fd-b4f9-74170c936a7a"
      decimals="-3"
      id="F_c627209e-d75c-4e6a-9408-d72732f00814"
      unitRef="U_USD">96089000</inva:ConvertibleSubordinatedDebtFairValueDisclosures>
    <inva:ConvertibleSeniorDebtFairValueDisclosures
      contextRef="C_c86331ec-9958-472c-9d3d-73034f0f043f"
      decimals="-3"
      id="F_d4c2329e-733a-4717-8575-de6e9b7e617a"
      unitRef="U_USD">0</inva:ConvertibleSeniorDebtFairValueDisclosures>
    <inva:ConvertibleSeniorDebtFairValueDisclosures
      contextRef="C_dec01f12-3f85-4d42-8b61-61f857a1419a"
      decimals="-3"
      id="F_fb741ad5-96ef-445a-92b6-309946c3176c"
      unitRef="U_USD">197807000</inva:ConvertibleSeniorDebtFairValueDisclosures>
    <inva:ConvertibleSeniorDebtFairValueDisclosures
      contextRef="C_b1399523-0285-44ab-8535-deb7616f55e6"
      decimals="-3"
      id="F_a5d11fc4-82bb-4b00-b1e4-85ede6904016"
      unitRef="U_USD">0</inva:ConvertibleSeniorDebtFairValueDisclosures>
    <inva:ConvertibleSeniorDebtFairValueDisclosures
      contextRef="C_d406fd03-b3d6-41fd-b4f9-74170c936a7a"
      decimals="-3"
      id="F_7cf2bc54-bf20-4d11-b78e-1c5dfa01a815"
      unitRef="U_USD">197807000</inva:ConvertibleSeniorDebtFairValueDisclosures>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="C_c86331ec-9958-472c-9d3d-73034f0f043f"
      decimals="-3"
      id="F_712778a4-be60-4c64-9e15-f8d2d2d8b653"
      unitRef="U_USD">0</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="C_dec01f12-3f85-4d42-8b61-61f857a1419a"
      decimals="-3"
      id="F_b6c1a9f6-9df3-4645-9a54-275640e2ab3a"
      unitRef="U_USD">211768000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="C_b1399523-0285-44ab-8535-deb7616f55e6"
      decimals="-3"
      id="F_e4dcf57d-e979-4f94-a11e-68df29740c51"
      unitRef="U_USD">0</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="C_d406fd03-b3d6-41fd-b4f9-74170c936a7a"
      decimals="-3"
      id="F_ed9b801c-6154-4ea9-954a-42db2b4ab1ee"
      unitRef="U_USD">211768000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:DebtInstrumentFairValue
      contextRef="C_c86331ec-9958-472c-9d3d-73034f0f043f"
      decimals="-3"
      id="F_2a26bc5b-c6c4-4752-b041-e69f3ce8793d"
      unitRef="U_USD">0</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="C_dec01f12-3f85-4d42-8b61-61f857a1419a"
      decimals="-3"
      id="F_538e3495-3ed2-4ff0-a9fd-91a7f57f7862"
      unitRef="U_USD">505664000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="C_b1399523-0285-44ab-8535-deb7616f55e6"
      decimals="-3"
      id="F_256cf4fa-aba2-4323-9a2e-fe8c730b3fc6"
      unitRef="U_USD">0</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="C_d406fd03-b3d6-41fd-b4f9-74170c936a7a"
      decimals="-3"
      id="F_7e366394-addb-4771-aae1-ee261f8bcf92"
      unitRef="U_USD">505664000</us-gaap:DebtInstrumentFairValue>
    <inva:ContingentValueRightsLiability
      contextRef="C_76445fe9-d438-4d1c-a28d-613fef583510"
      decimals="-3"
      id="F_d7d442b1-2e94-4d0c-bdaa-01a94b916a8d"
      unitRef="U_USD">0</inva:ContingentValueRightsLiability>
    <inva:ContingentValueRightsLiability
      contextRef="C_344746bb-e636-4cfa-9204-6870353b5936"
      decimals="-3"
      id="F_7c1b951d-b971-45e6-a3a2-45fbbcc563c8"
      unitRef="U_USD">0</inva:ContingentValueRightsLiability>
    <inva:ContingentValueRightsLiability
      contextRef="C_593427ab-e2d7-4f72-ba54-456608483083"
      decimals="-3"
      id="F_7652e3e7-3d3e-4473-8674-6403b51aae7d"
      unitRef="U_USD">595000</inva:ContingentValueRightsLiability>
    <inva:ContingentValueRightsLiability
      contextRef="C_9d615842-43ad-4afe-b67a-2a588d4d0728"
      decimals="-3"
      id="F_3023a1e1-772a-4ea8-b210-34baa44fe992"
      unitRef="U_USD">595000</inva:ContingentValueRightsLiability>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_76445fe9-d438-4d1c-a28d-613fef583510"
      decimals="-3"
      id="F_be7fbe7a-9081-40fa-b64b-317eee1b6879"
      unitRef="U_USD">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_344746bb-e636-4cfa-9204-6870353b5936"
      decimals="-3"
      id="F_6081934f-07a3-41bb-a614-2a4d19488d6e"
      unitRef="U_USD">505664000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_593427ab-e2d7-4f72-ba54-456608483083"
      decimals="-3"
      id="F_95b03b45-4f61-4df5-97c6-d588f88fa59f"
      unitRef="U_USD">595000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_9d615842-43ad-4afe-b67a-2a588d4d0728"
      decimals="-3"
      id="F_c24c0054-198d-4133-b239-71538de799c1"
      unitRef="U_USD">506259000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_44d770d3-712a-4496-9e68-7b69a5f5d2bf"
      decimals="-5"
      id="F_4e1639e8-ea07-437b-af4d-0747aeabe994"
      unitRef="U_USD">295400000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_140324d1-1834-455e-b137-0176d2de6d77"
      decimals="-5"
      id="F_3fc536e8-cd2c-40b8-89d8-d86fae92ab64"
      unitRef="U_USD">54600000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_2ea14962-08db-4e80-a279-f2d275caee54"
      decimals="-5"
      id="F_9b04e254-d076-4265-960b-cce81bdbabcc"
      unitRef="U_USD">25100000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LimitedPartnersContributedCapital
      contextRef="C_460b7389-fa51-4f4c-9e61-7e987dc6ad3e"
      decimals="-2"
      id="F_28b158c2-c17a-4709-a8e1-0316a16ee710"
      unitRef="U_USD">300000</us-gaap:LimitedPartnersContributedCapital>
    <inva:PartnershipAgreementLockUpPeriod
      contextRef="C_d81c2107-a7a0-4ec4-8988-fc8409645f16"
      id="F_786a8a9d-babc-4ba1-b400-bd668a9f7f70">P36M</inva:PartnershipAgreementLockUpPeriod>
    <inva:CapitalizedFeesPaidDisclosureTextBlock
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      id="F_fdd4a155-309a-4dde-9813-cef9edc61d23">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;7. CAPITALIZED FEES PAID&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Capitalized fees paid, which consist of registrational and launch-related milestone fees paid to GSK, were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.311%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.481%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.749%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.481%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.75%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.481%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.75%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amortization period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;United States&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2013-2030&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;120,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;120,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Europe&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2013-2029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;60,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;60,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Japan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2013-2029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;40,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;40,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Gross carrying value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;220,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;220,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accumulated amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;136,216&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;122,393&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net carrying value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;83,784&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;97,607&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;These milestone fees are amortized over their estimated useful lives commencing upon the commercial launch of the product in their respective regions with the amortization recorded as a reduction in revenue from collaborative arrangements. As of December 31, 2023, the weighted average remaining amortization period wa&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;s &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;6.2&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Additional information regarding these milestone fees is included in Note 3, &#x201c;Revenue Recognition&#x201d;. Amortization for each of the years ended December 31, 2023, 2022 and 2021 was &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The remaining estimated amortization is &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; for each of the years from 2024 to 2027, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million for the year 2028, and&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; thereafter.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</inva:CapitalizedFeesPaidDisclosureTextBlock>
    <us-gaap:CapitalizedContractCostTableTextBlock
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      id="F_9b205584-ae22-46d4-80f3-9d9d4e6e5696">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Capitalized fees paid, which consist of registrational and launch-related milestone fees paid to GSK, were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.311%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.481%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.749%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.481%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.75%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.481%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.75%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amortization period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;United States&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2013-2030&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;120,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;120,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Europe&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2013-2029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;60,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;60,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Japan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2013-2029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;40,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;40,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Gross carrying value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;220,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;220,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accumulated amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;136,216&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;122,393&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net carrying value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;83,784&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;97,607&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:CapitalizedContractCostTableTextBlock>
    <us-gaap:CapitalizedContractCostGross
      contextRef="C_0dca3067-b301-4dc8-acf3-6ddafb2e6e93"
      decimals="-3"
      id="F_5b3f8b79-aee6-41e3-9e91-e18334634e6a"
      unitRef="U_USD">120000000</us-gaap:CapitalizedContractCostGross>
    <us-gaap:CapitalizedContractCostGross
      contextRef="C_b0777350-8f02-402b-b8d8-33ebfbea0625"
      decimals="-3"
      id="F_4a746f43-2f79-43e7-994e-40a20ef26e91"
      unitRef="U_USD">120000000</us-gaap:CapitalizedContractCostGross>
    <us-gaap:CapitalizedContractCostGross
      contextRef="C_9eec32d5-1f8c-44e6-9ec4-05156ada8af3"
      decimals="-3"
      id="F_95f447d7-78dc-409d-a6ff-de85877826cb"
      unitRef="U_USD">60000000</us-gaap:CapitalizedContractCostGross>
    <us-gaap:CapitalizedContractCostGross
      contextRef="C_5d7298e5-9f61-4332-aa3f-399d8b896265"
      decimals="-3"
      id="F_a21e1668-80a6-4dc8-87c5-f39ef4c779d1"
      unitRef="U_USD">60000000</us-gaap:CapitalizedContractCostGross>
    <us-gaap:CapitalizedContractCostGross
      contextRef="C_ce2c65ac-3b0f-4cd6-a073-a6b687f80393"
      decimals="-3"
      id="F_748b1cab-650f-4566-9ea5-f4d85232eae3"
      unitRef="U_USD">40000000</us-gaap:CapitalizedContractCostGross>
    <us-gaap:CapitalizedContractCostGross
      contextRef="C_cd8458e6-5f79-4d96-add0-064203ed13b2"
      decimals="-3"
      id="F_adf2f105-1d35-4d7f-9cb7-c29fe1506a15"
      unitRef="U_USD">40000000</us-gaap:CapitalizedContractCostGross>
    <us-gaap:CapitalizedContractCostGross
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_450762cc-1ad5-4676-b57d-498534b63e41"
      unitRef="U_USD">220000000</us-gaap:CapitalizedContractCostGross>
    <us-gaap:CapitalizedContractCostGross
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      decimals="-3"
      id="F_6af88f74-d5b3-4f68-9a3b-10ceba811f96"
      unitRef="U_USD">220000000</us-gaap:CapitalizedContractCostGross>
    <us-gaap:CapitalizedContractCostAccumulatedAmortization
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_94bd15dc-6cf0-4094-a260-0c44987cd46b"
      unitRef="U_USD">136216000</us-gaap:CapitalizedContractCostAccumulatedAmortization>
    <us-gaap:CapitalizedContractCostAccumulatedAmortization
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      decimals="-3"
      id="F_8dfd5dd2-e092-489f-99ef-6d506134387b"
      unitRef="U_USD">122393000</us-gaap:CapitalizedContractCostAccumulatedAmortization>
    <us-gaap:CapitalizedContractCostNet
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_6b811829-e2f2-4282-9ee2-5a69f33621b7"
      unitRef="U_USD">83784000</us-gaap:CapitalizedContractCostNet>
    <us-gaap:CapitalizedContractCostNet
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      decimals="-3"
      id="F_9b5ab1b7-995a-4964-aa15-12fc69a90614"
      unitRef="U_USD">97607000</us-gaap:CapitalizedContractCostNet>
    <inva:CapitalizedFeesPaidWeightedAverageUsefulLife
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      id="F_beb5e9c4-ed8c-4782-8ca6-bd6927d247f3">P6Y2M12D</inva:CapitalizedFeesPaidWeightedAverageUsefulLife>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="C_81ea3387-bcc2-4cfe-a9e7-78fab40062ee"
      decimals="-5"
      id="F_5a607ae6-e230-4765-bca7-1281aeef1e58"
      unitRef="U_USD">13800000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="C_cd95e6eb-db30-4b57-a111-4b45da383cf5"
      decimals="-5"
      id="F_c4c68f29-ee54-4a60-aa3c-73710af8c287"
      unitRef="U_USD">13800000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="C_fa01aae9-eeeb-459c-9277-c4cd33bb93d0"
      decimals="-5"
      id="F_e6d0940a-362f-40d4-90c8-006b117c953a"
      unitRef="U_USD">13800000</us-gaap:CapitalizedContractCostAmortization>
    <inva:CapitalizedFeesPaidRemainingEstimatedAmortizationNextTwelveMonths
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-5"
      id="F_cfa76036-2f56-473d-b2e1-b3e376a66303"
      unitRef="U_USD">13800000</inva:CapitalizedFeesPaidRemainingEstimatedAmortizationNextTwelveMonths>
    <inva:CapitalizedFeesPaidRemainingEstimatedAmortizationYearTwo
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-5"
      id="F_2251e42f-d132-41aa-80d4-1ddaae8e6f2e"
      unitRef="U_USD">13800000</inva:CapitalizedFeesPaidRemainingEstimatedAmortizationYearTwo>
    <inva:CapitalizedFeesPaidRemainingEstimatedAmortizationYearthree
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-5"
      id="F_16d463be-e07e-490c-b561-41f58a9cce43"
      unitRef="U_USD">13800000</inva:CapitalizedFeesPaidRemainingEstimatedAmortizationYearthree>
    <inva:CapitalizedFeesPaidRemainingEstimatedAmortizationYearFour
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-5"
      id="F_a3fbce11-8a41-4fdc-85e7-bfbf0f514840"
      unitRef="U_USD">13800000</inva:CapitalizedFeesPaidRemainingEstimatedAmortizationYearFour>
    <inva:CapitalizedFeesPaidRemainingEstimatedAmortizationYearFive
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-5"
      id="F_4564357e-549d-44b5-8e5d-3be78dc9c78a"
      unitRef="U_USD">13700000</inva:CapitalizedFeesPaidRemainingEstimatedAmortizationYearFive>
    <inva:CapitalizedFeesPaidRemainingEstimatedAmortizationAfterYearFive
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-5"
      id="F_1142369f-e146-4772-8122-dcf9df3e096a"
      unitRef="U_USD">14800000</inva:CapitalizedFeesPaidRemainingEstimatedAmortizationAfterYearFive>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      id="F_921c4e0c-9a12-4bee-a458-e44e418ff557">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;8. GOODWILL AND INTANGIBLE ASSETS&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Goodwill and intangible assets acquired are recognized at fair value as of the acquisition date. The carrying amount of goodwill as of December 31, 2023 and 2022 was &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;26.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively. We have &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;t recognized any impairment losses related to goodwill and intangible assets during the periods presented.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Intangible assets with definite lives are amortized over their estimated useful lives. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The carrying basis and accumulated amortization of recognized intangible assets as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022 were as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11pt;font-family:'Calibri',sans-serif;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:36.86%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.56%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.24%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.56%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.56%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.56%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="12" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Useful Life&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Accumulated&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Net Carrying&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Marketed products&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;219,700&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25,204&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;194,496&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;In-process research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,600&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,600&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Collaboration agreement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;35,400&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,161&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;33,239&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;257,700&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27,365&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;230,335&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:36.86%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.56%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.24%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.56%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.56%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.56%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="12" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Useful Life&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Accumulated&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Net Carrying&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Marketed products&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;151,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,581&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;145,419&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;In-process research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;72,100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;72,100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Collaboration agreement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;35,400&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;35,400&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;258,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,581&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;252,919&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Intangible assets recognized as a result of the acquisition of Entasis amounted to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;106.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, which consisted of Entasis&#x2019; in-process research and development related to its antibacterial therapeutic product candidates and a collaboration agreement amounting to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;71.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;35.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively. Following the FDA approval of XACDURO&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; in May 2023, we started amortizing $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;68.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of the then in-process research and development as a marketed product, as well as the collaboration agreement, over their estimated useful lives. The useful life of the remaining in-process research and development of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million will be determined upon commercialization of the underlying product candidate; thus, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; amortization expense for this intangible asset was recognized &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;for the periods presented.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Intangible assets recognized as a result of the acquisition of La Jolla amounting to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;151.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million pertain to product rights and developed technologies on La Jolla&#x2019;s currently marketed products. These are intangible assets with determinable lives and are amortized over their estimated useful lives.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We recognized amortization expense of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and 2022, respectively. Future amortization expense is expected to be $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million for each of the years from 2024 to 2028 and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;98.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million thereafter.&lt;/span&gt;&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:Goodwill
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-5"
      id="F_4bef471e-f308-4778-aaa4-cc38b16e8dbd"
      unitRef="U_USD">17900000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      decimals="-5"
      id="F_266ce74b-de2b-495f-ac26-4a6ca264193e"
      unitRef="U_USD">26700000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_a5bd1532-c79d-4274-9c3b-2a0db2c3d6d2"
      unitRef="U_USD">0</us-gaap:GoodwillImpairmentLoss>
    <inva:ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsTableTextBlock
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      id="F_fc9e1147-6d55-42d2-acfa-78a3d9ac51d7">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The carrying basis and accumulated amortization of recognized intangible assets as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022 were as follows:&lt;/span&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:36.86%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.56%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.24%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.56%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.56%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.56%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="12" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Useful Life&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Accumulated&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Net Carrying&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Marketed products&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;219,700&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25,204&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;194,496&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;In-process research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,600&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,600&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Collaboration agreement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;35,400&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,161&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;33,239&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;257,700&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27,365&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;230,335&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:36.86%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.56%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.24%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.56%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.56%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.56%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="12" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Useful Life&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Accumulated&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Net Carrying&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Marketed products&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;151,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,581&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;145,419&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;In-process research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;72,100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;72,100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Collaboration agreement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;35,400&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;35,400&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;258,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,581&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;252,919&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</inva:ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="C_90e80338-5725-4945-ba17-420b39d8a65d"
      id="F_b7bd33d9-7335-4e47-b29f-82958a7fa4a7">P8Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="C_6d1cd716-967a-4cec-ae43-c48297ca0a77"
      id="F_31083c62-6cd9-43e6-9680-8fa420fb43a8">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <inva:IntangibleAssetsMarketedProductsGross
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_b6d8b8eb-1948-4eaf-aeb4-6282a0a5fe4d"
      unitRef="U_USD">219700000</inva:IntangibleAssetsMarketedProductsGross>
    <inva:IntangibleAssetsMarketedProductsAccumulatedAmortization
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_8a6e4bf6-f919-4d5e-a8c5-c28896121c9f"
      unitRef="U_USD">-25204000</inva:IntangibleAssetsMarketedProductsAccumulatedAmortization>
    <inva:IntangibleAssetsMarketedProductsNet
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_a6ca964b-b3f6-47c1-b7e5-fb2b0900e039"
      unitRef="U_USD">194496000</inva:IntangibleAssetsMarketedProductsNet>
    <inva:IntangibleAssetsInProcessResearchAndDevelopmentGross
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_224e5497-33ce-4da8-b40f-3a17ea729467"
      unitRef="U_USD">2600000</inva:IntangibleAssetsInProcessResearchAndDevelopmentGross>
    <inva:IntangibleAssetsInProcessResearchAndDevelopmentAccumulatedAmortization
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_c868d534-08c1-4a61-8b32-95d92d11fc9a"
      unitRef="U_USD">0</inva:IntangibleAssetsInProcessResearchAndDevelopmentAccumulatedAmortization>
    <inva:IntangibleAssetsInProcessResearchAndDevelopmentNet
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_393a1d81-55d7-407c-a273-2de0e122c44e"
      unitRef="U_USD">2600000</inva:IntangibleAssetsInProcessResearchAndDevelopmentNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      id="F_0c167f9c-a339-40e7-b02e-9335f42a3f59">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <inva:IntangibleAssetsCollaborationAgreementGross
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_dab77d17-373a-4338-bb2e-df50d59f3e49"
      unitRef="U_USD">35400000</inva:IntangibleAssetsCollaborationAgreementGross>
    <inva:IntangibleAssetsCollaborationAgreementAccumulatedAmortization
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_ed2f3a8f-64c4-4efb-a498-0a90182743cf"
      unitRef="U_USD">-2161000</inva:IntangibleAssetsCollaborationAgreementAccumulatedAmortization>
    <inva:IntangibleAssetsCollaborationAgreementNet
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_13312e85-2b95-4fdf-b2b6-1b384f1ad19e"
      unitRef="U_USD">33239000</inva:IntangibleAssetsCollaborationAgreementNet>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_849cc4e0-5fe6-429c-9fa4-f4db47ea0ddc"
      unitRef="U_USD">257700000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_45b48927-22ff-4403-92b9-509ec52a1bf3"
      unitRef="U_USD">-27365000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_0ea77f82-6b50-4327-94a6-49fcbe36f818"
      unitRef="U_USD">230335000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="C_cd9243f5-5c45-4dc0-9b92-52023672ac79"
      id="F_fe07f1fa-33d0-4a01-a391-900dbf3ba0a1">P8Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="C_6d1cd716-967a-4cec-ae43-c48297ca0a77"
      id="F_6a4ab856-c446-41f2-ab23-162c16656ce4">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <inva:IntangibleAssetsMarketedProductsGross
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      decimals="-3"
      id="F_233a3454-f80f-4aa8-ba20-ef13085837fb"
      unitRef="U_USD">151000000</inva:IntangibleAssetsMarketedProductsGross>
    <inva:IntangibleAssetsMarketedProductsAccumulatedAmortization
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      decimals="-3"
      id="F_3cb4cfe6-3775-4bb1-a783-3d5c94426035"
      unitRef="U_USD">-5581000</inva:IntangibleAssetsMarketedProductsAccumulatedAmortization>
    <inva:IntangibleAssetsMarketedProductsNet
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      decimals="-3"
      id="F_5cbf0a69-2153-452f-a302-9c94cf6c5384"
      unitRef="U_USD">145419000</inva:IntangibleAssetsMarketedProductsNet>
    <inva:IntangibleAssetsInProcessResearchAndDevelopmentGross
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      decimals="-3"
      id="F_4cfa7373-e265-435a-b2ab-57f9886acb68"
      unitRef="U_USD">72100000</inva:IntangibleAssetsInProcessResearchAndDevelopmentGross>
    <inva:IntangibleAssetsInProcessResearchAndDevelopmentAccumulatedAmortization
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      decimals="-3"
      id="F_e115b030-3f16-429f-b168-252f960e9e49"
      unitRef="U_USD">0</inva:IntangibleAssetsInProcessResearchAndDevelopmentAccumulatedAmortization>
    <inva:IntangibleAssetsInProcessResearchAndDevelopmentNet
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      decimals="-3"
      id="F_7e2c1076-18ab-4bbc-9556-d8c752e96a27"
      unitRef="U_USD">72100000</inva:IntangibleAssetsInProcessResearchAndDevelopmentNet>
    <inva:IntangibleAssetsCollaborationAgreementGross
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      decimals="-3"
      id="F_348030ff-bc3f-4dc4-93f2-2533716f4ec0"
      unitRef="U_USD">35400000</inva:IntangibleAssetsCollaborationAgreementGross>
    <inva:IntangibleAssetsCollaborationAgreementAccumulatedAmortization
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      decimals="-3"
      id="F_08ea668c-50d6-4d51-a5a3-270d00709582"
      unitRef="U_USD">0</inva:IntangibleAssetsCollaborationAgreementAccumulatedAmortization>
    <inva:IntangibleAssetsCollaborationAgreementNet
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      decimals="-3"
      id="F_8e8faa89-49a4-4597-9e87-c54de793e6d4"
      unitRef="U_USD">35400000</inva:IntangibleAssetsCollaborationAgreementNet>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      decimals="-3"
      id="F_a9e71439-4d46-48fd-924b-894fa89b0cec"
      unitRef="U_USD">258500000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      decimals="-3"
      id="F_3599a021-6b00-433b-bd8e-7870a3ef5264"
      unitRef="U_USD">-5581000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      decimals="-3"
      id="F_b06d1916-ebea-472c-a019-2a703961e301"
      unitRef="U_USD">252919000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
      contextRef="C_8c6a7bcf-3783-4f54-9341-3247cae07c70"
      decimals="-5"
      id="F_9caa7bd0-d6d3-42b9-8d77-984b94720e7f"
      unitRef="U_USD">106700000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
      contextRef="C_f9f2e0b5-7d3e-40a6-b5ac-2fadf0d6e6e3"
      decimals="-5"
      id="F_55a358e1-7819-45a2-9475-cdbb4ff7a47d"
      unitRef="U_USD">71300000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
      contextRef="C_0c5dc7e3-2671-4634-a2ea-45c94c03c65f"
      decimals="-5"
      id="F_cdb9f03d-122e-419c-9112-423275e49580"
      unitRef="U_USD">35400000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_059f7bf6-1ef6-49bc-9ffa-a0a2a13282ed"
      decimals="-5"
      id="F_1ad0c74d-0639-4735-afa3-1315d4bc9a85"
      unitRef="U_USD">68700000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetResidualValue
      contextRef="C_067b241e-3eec-46f9-b23d-3e9d389993c0"
      decimals="-5"
      id="F_4f11930f-9df5-4f41-894b-07b98b151ff9"
      unitRef="U_USD">2600000</us-gaap:AcquiredFiniteLivedIntangibleAssetResidualValue>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_308dae91-3293-4e16-bef8-42832c4675db"
      decimals="-3"
      id="F_79b9e9d8-7f39-42b6-aa62-ff626d383c03"
      unitRef="U_USD">0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
      contextRef="C_9b30963d-d42c-4ba2-85ac-e1f548c6e616"
      decimals="-5"
      id="F_ee0943fc-452a-4848-a988-132cca52d3c3"
      unitRef="U_USD">151000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_f0f3a5ea-44ff-44dc-9c12-7e3628fc5813"
      decimals="-5"
      id="F_f09b66e6-3b19-493a-8756-04446a2e875a"
      unitRef="U_USD">21800000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_45aa5dba-bae7-468a-aac4-f6723db99993"
      decimals="-5"
      id="F_3623d45a-afb5-4d6f-bc0d-9e9c4fd7e517"
      unitRef="U_USD">5600000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="C_9b30963d-d42c-4ba2-85ac-e1f548c6e616"
      decimals="-5"
      id="F_965900c8-fe92-4a35-be11-8d021dc20450"
      unitRef="U_USD">25800000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="C_9b30963d-d42c-4ba2-85ac-e1f548c6e616"
      decimals="-5"
      id="F_3c0390cc-3da9-4e43-9e78-0e6d8d902ab4"
      unitRef="U_USD">25800000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="C_9b30963d-d42c-4ba2-85ac-e1f548c6e616"
      decimals="-5"
      id="F_8b0f0a2a-48ea-4589-a8ba-a0876bf1bcd8"
      unitRef="U_USD">25800000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="C_9b30963d-d42c-4ba2-85ac-e1f548c6e616"
      decimals="-5"
      id="F_677f31d2-2071-47e4-82c9-cd894bc3b687"
      unitRef="U_USD">25800000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="C_9b30963d-d42c-4ba2-85ac-e1f548c6e616"
      decimals="-5"
      id="F_2ff5ac30-9726-4498-911a-b34b372955cf"
      unitRef="U_USD">25800000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
      contextRef="C_9b30963d-d42c-4ba2-85ac-e1f548c6e616"
      decimals="-5"
      id="F_ef823452-8b1a-4631-b21c-f0400696cae5"
      unitRef="U_USD">98700000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      id="F_f2a8e4d5-5364-4e53-8ecb-1cceab476f49">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;9. BALANCE SHEET COMPONENTS&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Inventory&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11pt;font-family:'Calibri',sans-serif;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Inventory consisted of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.313%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.843%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.843%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Raw materials&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,257&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,757&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Work-in-process&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,670&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25,052&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Finished goods&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,810&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25,088&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total inventory&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;40,737&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;55,897&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and 2022, total inventory included net fair value adjustments resulting from the acquisition of La Jolla of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;23.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;49.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, which will be recognized as cost of products sold when sales occur in future periods. The fair value adjustments recorded as part of cost of products sold amounted to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;million and&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Other Accrued Liabilities&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Other accrued liabilities consisted of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.313%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.843%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.843%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued contract manufacturing expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,966&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,382&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued clinical expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;591&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;692&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued research expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;185&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;349&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued professional services&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,876&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,977&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_4d9e1814-d90c-438a-b69f-2d0819d5112e;"&gt;&lt;span style="-sec-ix-hidden:F_62616aa1-c408-4682-b198-b4aacc8031c4;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Current portion of lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,207&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,316&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Royalty obligation payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,928&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Current portion of deferred royalty obligation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,639&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued license fees and royalties&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,575&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;943&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,370&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,909&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total other accrued liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19,698&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21,207&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Other Long-Term Liabilities&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11pt;font-family:'Calibri',sans-serif;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Other long-term liabilities consisted of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.313%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.843%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.843%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Long-term portion of deferred royalty obligation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;69,876&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;67,947&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_8a36ba82-b9a3-4b23-adb9-3d2b758e3db2;"&gt;&lt;span style="-sec-ix-hidden:F_fbfec351-c094-49d9-a03a-e641b11869bb;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Long-term portion of lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,635&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,376&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Contingent value rights liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;359&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;595&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total other long-term liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;71,870&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;70,918&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      id="F_dc3edbb6-eeda-4e39-ab00-99c32828f53d">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Inventory consisted of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.313%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.843%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.843%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Raw materials&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,257&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,757&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Work-in-process&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,670&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25,052&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Finished goods&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,810&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25,088&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total inventory&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;40,737&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;55,897&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_9f14deaf-5d36-43cd-be8c-b9e820ee89f4"
      unitRef="U_USD">11257000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      decimals="-3"
      id="F_e4f00795-6977-43a1-9d19-a38b0ce30381"
      unitRef="U_USD">5757000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_9aec7400-8b94-4fa4-9bc9-d6923e71d9ea"
      unitRef="U_USD">15670000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      decimals="-3"
      id="F_58019c96-bf9e-4f62-9dca-d9c61f8dc59b"
      unitRef="U_USD">25052000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_c9d841cc-09fe-4e5a-9d36-bc190b858331"
      unitRef="U_USD">13810000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      decimals="-3"
      id="F_02953bfa-f7ff-4cf8-8d36-878c2a5b5778"
      unitRef="U_USD">25088000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_f4e0fa86-0391-4712-885a-ab724a935b78"
      unitRef="U_USD">40737000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      decimals="-3"
      id="F_19bec129-7853-4c19-8338-eb406206a9ce"
      unitRef="U_USD">55897000</us-gaap:InventoryNet>
    <inva:FairValueAdjustmentsOfInventoryFromAcquistion
      contextRef="C_850c3b25-8c30-4a01-9de2-0ca85949a00e"
      decimals="-5"
      id="F_dc61f6d5-a21e-4db7-9546-1c27b25c97f3"
      unitRef="U_USD">23000000</inva:FairValueAdjustmentsOfInventoryFromAcquistion>
    <inva:FairValueAdjustmentsOfInventoryFromAcquistion
      contextRef="C_f252cf15-a5b7-46ae-b4cf-f02a7d2a1bf9"
      decimals="-5"
      id="F_8b0f9a60-24d2-4a2f-aaa3-21895c15717c"
      unitRef="U_USD">49500000</inva:FairValueAdjustmentsOfInventoryFromAcquistion>
    <inva:AmortizationOfFairValueAdjustmentsOfCostOfProductsSold
      contextRef="C_81c113da-ef79-4663-b552-0f93fc8926be"
      decimals="-5"
      id="F_19870bd0-9eaf-444d-b6a8-27dfb75abe0c"
      unitRef="U_USD">27200000</inva:AmortizationOfFairValueAdjustmentsOfCostOfProductsSold>
    <inva:AmortizationOfFairValueAdjustmentsOfCostOfProductsSold
      contextRef="C_8b18bfe1-7298-47b5-82af-99cfcef35fce"
      decimals="-5"
      id="F_37d35905-65ad-4e2f-bfb2-dafb09d23b47"
      unitRef="U_USD">10000000</inva:AmortizationOfFairValueAdjustmentsOfCostOfProductsSold>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      id="F_fa224706-4186-46bc-88fc-93c730720f65">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Other accrued liabilities consisted of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.313%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.843%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.843%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued contract manufacturing expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,966&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,382&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued clinical expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;591&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;692&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued research expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;185&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;349&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued professional services&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,876&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,977&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_4d9e1814-d90c-438a-b69f-2d0819d5112e;"&gt;&lt;span style="-sec-ix-hidden:F_62616aa1-c408-4682-b198-b4aacc8031c4;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Current portion of lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,207&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,316&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Royalty obligation payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,928&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Current portion of deferred royalty obligation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,639&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued license fees and royalties&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,575&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;943&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,370&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,909&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total other accrued liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19,698&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21,207&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <inva:AccruedContractManufacturingLiability
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_5f11a578-aa4c-461c-aacf-353cc99fb8ca"
      unitRef="U_USD">1966000</inva:AccruedContractManufacturingLiability>
    <inva:AccruedContractManufacturingLiability
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      decimals="-3"
      id="F_498709cf-9571-442e-a433-fd2d2afaa5f5"
      unitRef="U_USD">8382000</inva:AccruedContractManufacturingLiability>
    <inva:AccruedClinicalLiability
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_c23a3ffb-0b29-4973-8b8a-6cbe43957d41"
      unitRef="U_USD">591000</inva:AccruedClinicalLiability>
    <inva:AccruedClinicalLiability
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      decimals="-3"
      id="F_340574a2-fc6e-46b9-abae-895ceaac7ef1"
      unitRef="U_USD">692000</inva:AccruedClinicalLiability>
    <inva:AccruedResearchLiability
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_3d6947b6-6d97-46de-993b-fb80faad00bc"
      unitRef="U_USD">185000</inva:AccruedResearchLiability>
    <inva:AccruedResearchLiability
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      decimals="-3"
      id="F_adec6c6d-0b89-45b0-af49-1a59447515a5"
      unitRef="U_USD">349000</inva:AccruedResearchLiability>
    <inva:AccruedProfessionalServices
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_cf0d0519-d2ca-4528-ad81-72bd6862f587"
      unitRef="U_USD">8876000</inva:AccruedProfessionalServices>
    <inva:AccruedProfessionalServices
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      decimals="-3"
      id="F_962f46d8-bea2-4d27-a6e6-de888e6a24cf"
      unitRef="U_USD">3977000</inva:AccruedProfessionalServices>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_980dcfb9-9399-42f4-b97d-458cf5331949"
      unitRef="U_USD">1207000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      decimals="-3"
      id="F_c5bc1d83-a00f-4f4e-b937-a194d941526a"
      unitRef="U_USD">1316000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_97f26be4-0d40-476f-b72a-c8a76153516f"
      unitRef="U_USD">1928000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      decimals="-3"
      id="F_a668cd0e-f41f-4450-9cef-d3e2932f98a7"
      unitRef="U_USD">0</us-gaap:AccruedRoyaltiesCurrent>
    <inva:DeferredRoyaltyObligationCurrent
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_8a5db259-321a-44b9-9737-bfb1f9597b30"
      unitRef="U_USD">0</inva:DeferredRoyaltyObligationCurrent>
    <inva:DeferredRoyaltyObligationCurrent
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      decimals="-3"
      id="F_1791c14d-e871-4d03-b597-b05a2f65df42"
      unitRef="U_USD">2639000</inva:DeferredRoyaltyObligationCurrent>
    <inva:AccruedLicenseFeesAndRoyalties
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_f8c246f1-8a66-4775-a17f-71ea5ada1501"
      unitRef="U_USD">1575000</inva:AccruedLicenseFeesAndRoyalties>
    <inva:AccruedLicenseFeesAndRoyalties
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      decimals="-3"
      id="F_1ee633d9-ca9b-4008-9dc8-e166b84f713c"
      unitRef="U_USD">943000</inva:AccruedLicenseFeesAndRoyalties>
    <us-gaap:OtherLiabilities
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_d0010a82-06e4-4745-b7b3-d296ef19b229"
      unitRef="U_USD">3370000</us-gaap:OtherLiabilities>
    <us-gaap:OtherLiabilities
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      decimals="-3"
      id="F_ef841dfb-a14b-495f-930b-2a3cbddb7138"
      unitRef="U_USD">2909000</us-gaap:OtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_905a4e5c-0d1f-41f2-914f-d39852545f3f"
      unitRef="U_USD">19698000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      decimals="-3"
      id="F_6e736dff-17c4-4e5f-8d78-bbd27ca7af94"
      unitRef="U_USD">21207000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:OtherNoncurrentLiabilitiesTableTextBlock
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      id="F_574ebbdd-c8c0-4903-acf8-2555a066bd3d">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Other long-term liabilities consisted of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.313%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.843%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.843%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Long-term portion of deferred royalty obligation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;69,876&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;67,947&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_8a36ba82-b9a3-4b23-adb9-3d2b758e3db2;"&gt;&lt;span style="-sec-ix-hidden:F_fbfec351-c094-49d9-a03a-e641b11869bb;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Long-term portion of lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,635&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,376&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Contingent value rights liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;359&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;595&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total other long-term liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;71,870&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;70,918&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:OtherNoncurrentLiabilitiesTableTextBlock>
    <inva:DeferredRoyaltyObligationNonCurrent
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_6241912c-3d39-424d-a60b-45eba89f440d"
      unitRef="U_USD">69876000</inva:DeferredRoyaltyObligationNonCurrent>
    <inva:DeferredRoyaltyObligationNonCurrent
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      decimals="-3"
      id="F_f4404e89-27c3-4e8e-8364-0ce1093f907c"
      unitRef="U_USD">67947000</inva:DeferredRoyaltyObligationNonCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_eb1a5710-e43e-413a-86c2-20cbbc788fc9"
      unitRef="U_USD">1635000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      decimals="-3"
      id="F_e5bd16f6-1687-4dd3-8e8d-c58608fdf048"
      unitRef="U_USD">2376000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <inva:ContingentValueRightsLiability
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_04058619-6b30-4bde-a95b-14fedca33c46"
      unitRef="U_USD">359000</inva:ContingentValueRightsLiability>
    <inva:ContingentValueRightsLiability
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      decimals="-3"
      id="F_9f832710-b60e-4094-a95e-6d25399295d2"
      unitRef="U_USD">595000</inva:ContingentValueRightsLiability>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_d45f20c9-3169-4c42-9ad4-4c5a8f7b7e35"
      unitRef="U_USD">71870000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      decimals="-3"
      id="F_bf98f80c-a20a-476c-930b-f89136c9c9b1"
      unitRef="U_USD">70918000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      id="F_06ff81a8-e489-45fa-ac44-4fedaa7fb9d8">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;10. STOCK&#x2011;BASED COMPENSATION&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Equity Incentive Plans&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In May 2012, we adopted the 2012 Equity Incentive Plan (the &#x201c;2012 Plan&#x201d;). The 2012 Plan provides for the grant of incentive stock options, nonstatutory stock options, RSAs, RSUs and Stock Appreciation Rights to employees, non-employee directors and consultants. As of December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, total shares remaining available for issuance under the 2012 Plan were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,924,185&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Under the 2004 Employee Stock Purchase Plan (the &#x201c;2004 ESPP&#x201d;), our employees may purchase common stock through payroll deductions at a price equal to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;85&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the lower of the fair market value of the stock at the beginning of the offering period or at the end of each applicable purchase period. The 2004 ESPP provided for consecutive and overlapping offering periods of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;24 months&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; in duration, with each offering period composed of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;four&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; consecutive &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;six-month&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; purchase periods. The purchase periods ended on either May 15 or November 15. The 2004 ESPP contributions were limited to a maximum of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of an employee&#x2019;s eligible compensation. The maximum number of shares that an employee may purchase in any purchase period was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,500&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. An employee may not purchase shares with a value greater than $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; in any calendar year.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On April 13, 2023, the Board of Directors adopted the 2023 ESPP (the &#x201c;2023 ESPP&#x201d;). The 2023 ESPP, which supersedes the 2004 ESPP, was approved by the Company&#x2019;s stockholders on May 22, 2023. Under the 2023 ESPP, eligible employees may purchase common stock through payroll deductions at a price equal to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;85&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the lower of the fair market value of the stock at the beginning or end of each applicable purchase period. The 2023 ESPP provides for offering periods of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;six months&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, which ends on either May 15 or November 15. The 2023 ESPP contributions are limited to a maximum of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of an employee&#x2019;s eligible compensation. The maximum number of shares that an employee may purchase in any purchase period is &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,500&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. An employee may not purchase shares with a value greater than $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; in any calendar year. A total of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million shares of our common stock was reserved and available for issuance under the 2023 ESPP.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, total shares remaining available for issuance under the 2023 ESPP were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,500,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Director Compensation Program&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Our non-employee directors receive compensation for services provided as a director. Each member of our board of directors who is not an employee receives both cash and equity compensation for services as a director, member of a committee of the board of directors, lead independent director and chairman, as applicable. In October 2017, both the cash and equity components of the compensation program were amended, effective immediately (the &#x201c;October 2017 Amendments&#x201d;).&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Each of our independent directors receives periodic automatic grants of equity awards under a program implemented under the 2012 Plan. These grants are non&#x2011;discretionary. Only our independent directors or affiliates of such directors are eligible to receive automatic grants under the 2012 Plan. Under the program, each individual who first became a non-employee director will, on the date such individual joins the board of directors, automatically be granted a one&#x2011;time grant of RSUs covering a number of shares of our common stock calculated as $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;125,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; ($&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;250,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; prior to the October 2017 Amendments) divided by our common stock closing share price on the date of grant as reported on The Nasdaq Global Select Market, rounded down to the nearest whole share (the &#x201c;Initial RSUs&#x201d;), plus a one&#x2011;time grant of RSUs covering a number of shares of our common stock calculated as $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;225,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; ($&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;250,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; prior to the October 2017 Amendments) divided by our common stock closing share price on the date of grant as reported on The Nasdaq Global Select Market, which would be pro-rated for the number of whole months remaining until the anniversary of the prior year&#x2019;s stockholders&#x2019; meeting, rounded down to the nearest whole share (the &#x201c;Pro Rata RSUs&#x201d;). The Initial RSUs vest in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;two&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; equal annual installments, while Pro Rata RSUs vest in a single installment at the sooner of the next annual stockholder meeting or the one-year grant anniversary, in each case subject to the non-employee director&#x2019;s continuous service through the applicable vesting date.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Annually, upon his or her re&#x2011;election to the board of directors at the Annual Meeting of Stockholders, each non-employee director is automatically granted an RSU covering a number of shares of our common stock calculated as $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;225,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; ($&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;250,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; prior to the October 2017 Amendments) divided by our common stock closing share price on the date of grant as reported on The Nasdaq Global Select Market, rounded down to the nearest whole share. These RSUs will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the non-employee director&#x2019;s continuous service through the applicable vesting date. Following the amendment to our non-employee director compensation program, both the annual RSUs and Initial RSUs described above remained unchanged with the exception that the number of shares of our common stock subject to each award has been reduced.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;These RSUs will vest in full upon the director&#x2019;s death, the occurrence of a change in control or, with respect to awards made after the October 2017 Amendments, the director&#x2019;s disability before the director&#x2019;s service terminates. Director RSUs carry dividend equivalent rights to be credited with an amount equal to all cash dividends paid on the underlying shares of common stock while unvested. Dividend equivalents are subject to the same terms and conditions, including vesting, as the RSUs to which they attach and are paid in cash upon vesting.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Stock&#x2011;Based Compensation Expense&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Stock&#x2011;based compensation expense is included in the consolidated statements of income as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.01%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.203%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.203%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.583%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Selling, general and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,645&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,305&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,017&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,192&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,042&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,837&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,347&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,017&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Stock&#x2011;based compensation expense included in the consolidated statements of income by award type is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.311%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.481%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.75%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.481%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.75%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.481%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.75%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,980&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,057&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;490&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;RSUs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,663&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,053&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,280&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;RSAs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;168&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;194&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;200&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;ESPP&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;26&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;43&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;47&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,837&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,347&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,017&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023, the unrecognized stock-based compensation cost and the estimated weighted-average amortization period were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:60.2%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.82%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:16.08%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.36%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:16.54%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unrecognized Compensation Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted-Average Amortization Period (Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,861&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.9&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;RSUs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,430&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.4&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;RSAs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;220&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.9&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total unrecognized compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,511&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Compensation Awards&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11pt;font-family:'Calibri',sans-serif;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table summarizes equity award activity under the 2012 Plan and prior plans and related information:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:32.386%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.642%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.02%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:7.7219999999999995%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.642%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.02%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:7.7219999999999995%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.642%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.02%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.182%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands, except per share data)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Number of outstanding options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted-Average Exercise Price of Outstanding Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Number of outstanding RSUs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted-Average Fair Value per Share at Grant&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Number of outstanding RSAs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted-Average Fair Value per Share at Grant&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance as of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;948&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15.56&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;518&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12.16&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;30&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14.97&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;828&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12.77&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;389&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12.85&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12.98&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Released RSUs and RSAs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;284&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12.42&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15.02&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;275&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15.22&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;141&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11.98&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,499&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14.09&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;482&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12.62&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14.93&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Vested and expected to vest &lt;br/&gt;&#160;&#160;&#160;as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,499&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14.09&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;482&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12.62&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the aggregate intrinsic value of options outstanding and options exercisable was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2022, the aggregate intrinsic value of options outstanding and options exercisable was not material. As of December 31, 2023, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;519,165&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; options were exercisable. The weighted average remaining contractual term of options outstanding was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;7.96&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; years and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;8.01&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; years as of December 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The total intrinsic value of the options exercised was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;t material for the year ended December 31, 2023, 2022 and 2021. The total estimated fair value of options vested was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million for the years ended December 31, 2023 and 2021, respectively. The total estimated fair value of options vested was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;t material for the year ended December 31, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The total estimated fair value of RSUs vested was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million for the years December 31, 2023, 2022 and 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The total estimated fair value of RSAs vested was not material for the year ended December 31, 2023, 2022, and 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Valuation Assumptions&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Black-Scholes-Merton&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; assumptions used in calculating the estimated value of stock options granted by Innoviva on the date of grant were as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.311%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.481%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.748999999999999%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.481%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.748999999999999%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.481%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.748999999999999%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.09&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.04&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.11&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;37.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;38.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;44.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Weighted-average estimated fair value of stock options granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.57&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.43&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.84&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_5c9abf9d-1e31-4f48-9d0d-c57d10750153"
      decimals="INF"
      id="F_25096e86-be07-4e4f-b8fa-3cf2e3cb6739"
      unitRef="U_shares">2924185</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="C_53420953-7564-40c6-bee0-709280cf738f"
      decimals="2"
      id="F_39b87b14-80d5-4628-a876-15d602e094d8"
      unitRef="U_pure">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveAndOverlappingOfferingPeriod
      contextRef="C_53420953-7564-40c6-bee0-709280cf738f"
      id="F_246c326c-ab98-46d6-9328-a54386ef4f48">P24M</inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveAndOverlappingOfferingPeriod>
    <inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods
      contextRef="C_53420953-7564-40c6-bee0-709280cf738f"
      decimals="0"
      id="F_a8a15ac9-14ac-45ce-95fc-7f0da4b518f2"
      unitRef="U_Item">4</inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods>
    <inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod
      contextRef="C_53420953-7564-40c6-bee0-709280cf738f"
      id="F_b0500d38-ae42-4a47-9915-d7d5f0dc05c7">P6M</inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate
      contextRef="C_f865e077-bfae-42a2-83e9-9bbaf0133b51"
      decimals="2"
      id="F_89abb7dd-6a2c-4fc8-bda9-8f2ef8d54278"
      unitRef="U_pure">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee
      contextRef="C_53420953-7564-40c6-bee0-709280cf738f"
      decimals="INF"
      id="F_1b648a63-314a-42ec-a86b-c91c0801f476"
      unitRef="U_shares">2500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee>
    <inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountAsContributionOfEligibleCompensation
      contextRef="C_53420953-7564-40c6-bee0-709280cf738f"
      decimals="-3"
      id="F_d5429b78-e7ab-482b-985c-ed2f287cc89c"
      unitRef="U_USD">25000000</inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountAsContributionOfEligibleCompensation>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="C_274e3c4f-40cb-407c-aabb-e32137ff6f9d"
      decimals="2"
      id="F_12ab4973-24fc-4d98-abe2-9df9487ce5fc"
      unitRef="U_pure">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveAndOverlappingOfferingPeriod
      contextRef="C_274e3c4f-40cb-407c-aabb-e32137ff6f9d"
      id="F_d84885ff-a19b-48f9-b100-ba5f87e3320b">P6M</inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveAndOverlappingOfferingPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate
      contextRef="C_bfc65bb1-ad80-4e8a-8b46-7fb950cefb1b"
      decimals="2"
      id="F_b82281e0-e74e-4bae-a502-d6eabe0482ab"
      unitRef="U_pure">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee
      contextRef="C_274e3c4f-40cb-407c-aabb-e32137ff6f9d"
      decimals="INF"
      id="F_c467acbe-9ae7-4670-8547-5ee36a0b4c86"
      unitRef="U_shares">2500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee>
    <inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountAsContributionOfEligibleCompensation
      contextRef="C_274e3c4f-40cb-407c-aabb-e32137ff6f9d"
      decimals="-3"
      id="F_2605b439-660a-48a2-b950-f892df258edf"
      unitRef="U_USD">25000000</inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountAsContributionOfEligibleCompensation>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_bfc65bb1-ad80-4e8a-8b46-7fb950cefb1b"
      decimals="INF"
      id="F_031e54d0-3646-41d3-8807-e8f3fa26348b"
      unitRef="U_shares">2500000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_bfc65bb1-ad80-4e8a-8b46-7fb950cefb1b"
      decimals="INF"
      id="F_a42b442e-88fe-4556-b55b-543cf1b6a120"
      unitRef="U_shares">2500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialEquityGrantValue
      contextRef="C_f0da2c05-1727-4786-acd0-b03e3dff2fa8"
      decimals="0"
      id="F_f6475233-99a5-42a1-9a5f-11908568190a"
      unitRef="U_USD">125000</inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialEquityGrantValue>
    <inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialEquityGrantValue
      contextRef="C_7b781f4e-2b96-403a-be95-189c21bfe845"
      decimals="0"
      id="F_99780f76-5f60-4f33-99b8-688501dcd4ce"
      unitRef="U_USD">250000</inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialEquityGrantValue>
    <inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalEquityGrantValue
      contextRef="C_f0da2c05-1727-4786-acd0-b03e3dff2fa8"
      decimals="0"
      id="F_55824172-3088-4061-aea9-8e5d6877388b"
      unitRef="U_USD">225000</inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalEquityGrantValue>
    <inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalEquityGrantValue
      contextRef="C_7b781f4e-2b96-403a-be95-189c21bfe845"
      decimals="0"
      id="F_8f9db4d8-f7b8-45dc-b5d3-c949e30e1023"
      unitRef="U_USD">250000</inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalEquityGrantValue>
    <inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments
      contextRef="C_bcf921a3-2613-4901-bd57-bf22fbe5ef61"
      decimals="INF"
      id="F_7b107d20-441c-4a9e-bd0e-7d18b63e0d3d"
      unitRef="U_Installment">2</inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments>
    <inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityGrantValue
      contextRef="C_11c3614e-b3bf-4d55-987c-21911b9b09fc"
      decimals="0"
      id="F_d17950a4-fe6e-4a82-a3d7-a0b1920c59e6"
      unitRef="U_USD">225000</inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityGrantValue>
    <inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityGrantValue
      contextRef="C_28748b0b-ed6b-4f26-be07-c4b34621cb5b"
      decimals="0"
      id="F_0d18f1e7-186e-4e08-907b-3f6f3b370d45"
      unitRef="U_USD">250000</inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityGrantValue>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      id="F_825a894a-bf5a-4cb0-83d1-610f7471e575">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Stock&#x2011;based compensation expense is included in the consolidated statements of income as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.01%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.203%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.203%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.583%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Selling, general and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,645&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,305&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,017&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,192&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,042&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,837&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,347&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,017&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_3810cd04-c006-4bfa-8397-c106caf901af"
      decimals="-3"
      id="F_8c42dfa1-f53a-4990-9805-30a9f5161df9"
      unitRef="U_USD">4645000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_a6dc9592-99de-4df7-8a98-ca4fcda287d2"
      decimals="-3"
      id="F_4ab60342-b2ee-4617-b3ab-14f98150502c"
      unitRef="U_USD">5305000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_00500ade-f7ea-4d89-9a06-fb25d9363802"
      decimals="-3"
      id="F_f83383c1-8cd1-4f72-92d2-a854e663d83e"
      unitRef="U_USD">2017000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_75ab87a5-b754-4d3e-95be-4a5426c4c785"
      decimals="-3"
      id="F_3b862451-0441-4a1f-bb5f-1635634e4423"
      unitRef="U_USD">1192000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_cdba2e0f-32b5-4b89-bd92-54198cce3aa9"
      decimals="-3"
      id="F_338902bf-f653-4158-854e-43ea6083a48c"
      unitRef="U_USD">2042000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_b6abf77e-c226-4f1c-b9e9-b0f6f21c3bb2"
      decimals="-3"
      id="F_79704afe-af46-4a69-90b4-b7c36057cfd2"
      unitRef="U_USD">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_62172a6e-2be8-4e17-9cf4-f64ba96eb65d"
      unitRef="U_USD">5837000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_c5c2e9dd-c794-4e66-8f50-acbf58a8203e"
      unitRef="U_USD">7347000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="-3"
      id="F_e31d4c4d-10bd-4606-b09f-10d972a61d7e"
      unitRef="U_USD">2017000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      id="F_27494baa-3da4-4847-bf8b-a7a1de0f28da">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Stock&#x2011;based compensation expense included in the consolidated statements of income by award type is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.311%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.481%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.75%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.481%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.75%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.481%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.75%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,980&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,057&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;490&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;RSUs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,663&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,053&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,280&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;RSAs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;168&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;194&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;200&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;ESPP&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;26&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;43&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;47&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,837&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,347&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,017&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_1fd35541-50f5-4c16-a031-bd9cc78d2a09"
      decimals="-3"
      id="F_fb813e96-95fe-41d7-96fb-d4469abee4db"
      unitRef="U_USD">1980000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_b40eac4f-f18e-4a85-95ce-6db8d48f14f2"
      decimals="-3"
      id="F_76c74957-1ed7-4d07-acd1-d6ffc431017b"
      unitRef="U_USD">3057000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_7b140651-bbea-4d88-8a4f-fa197b5dfa55"
      decimals="-3"
      id="F_2345b731-a606-4e6b-a317-e945276878b6"
      unitRef="U_USD">490000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_f3f69c9a-b63b-46c1-8d46-3c3cdfa265b1"
      decimals="-3"
      id="F_07cd61a7-bc57-4aaf-9692-31c065ee990f"
      unitRef="U_USD">3663000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_a332f0a6-0f9e-4712-97f0-f10d648bcf65"
      decimals="-3"
      id="F_679a9c37-96a5-4657-9f27-d15fc21dde81"
      unitRef="U_USD">4053000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_4eb342bb-a67b-41a2-af3e-2b6b0a442022"
      decimals="-3"
      id="F_9fb5c905-b605-48d2-9239-8ff290c399ed"
      unitRef="U_USD">1280000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_fb582b1b-defd-402a-8689-f3dd46cd150b"
      decimals="-3"
      id="F_ffa024ce-c52e-4c3e-956c-11d5208c8ad2"
      unitRef="U_USD">168000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_b4ac9910-3d92-4e1b-ac5f-f74c9dbdcfcd"
      decimals="-3"
      id="F_06aa5e75-0fad-4d19-a51a-01d67f73576c"
      unitRef="U_USD">194000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_70e1c77f-fb08-4ab9-9457-0bc05d1bd9af"
      decimals="-3"
      id="F_7186cfc6-967b-485c-8bd8-6261631949ff"
      unitRef="U_USD">200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_53420953-7564-40c6-bee0-709280cf738f"
      decimals="-3"
      id="F_b529cdca-9fd8-4608-a482-fb9897704808"
      unitRef="U_USD">26000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_31fb851b-8f5e-4955-b085-ac6b0dd38b8d"
      decimals="-3"
      id="F_4cb78605-b808-4a71-8e2b-146d7a26eaac"
      unitRef="U_USD">43000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_2297939c-7913-4791-9563-25bbf6ee309c"
      decimals="-3"
      id="F_8350c294-8cdc-4d0f-b636-9cc3d29b13e7"
      unitRef="U_USD">47000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_dd2f6f15-2b30-444f-bc3d-b82009169a9b"
      unitRef="U_USD">5837000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_54b49c22-4de8-454b-b926-a9cbb534f347"
      unitRef="U_USD">7347000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="-3"
      id="F_a73bcec2-3fae-4bfa-859f-5cb126d13963"
      unitRef="U_USD">2017000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      id="F_e7eedd67-af55-417a-af70-810307361e3f">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023, the unrecognized stock-based compensation cost and the estimated weighted-average amortization period were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:60.2%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.82%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:16.08%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.36%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:16.54%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unrecognized Compensation Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted-Average Amortization Period (Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,861&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.9&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;RSUs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,430&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.4&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;RSAs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;220&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.9&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total unrecognized compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,511&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_6c28106a-1f5c-4375-9a90-9f5d3d7fd470"
      decimals="-3"
      id="F_5537f60a-e69e-4eb6-9f62-4c09dfab5876"
      unitRef="U_USD">4861000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_1fd35541-50f5-4c16-a031-bd9cc78d2a09"
      id="F_64ed0e0b-149d-43c4-9bdf-5515a0bc1cf1">P2Y10M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_3b5f86a2-e137-470e-ae05-ea4b9e220cfa"
      decimals="-3"
      id="F_25874670-cca4-4af4-8c11-f997fe4e1e03"
      unitRef="U_USD">4430000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_f3f69c9a-b63b-46c1-8d46-3c3cdfa265b1"
      id="F_ab4ef592-f345-4f95-a2ee-be76090adde8">P2Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_f3b6b1d2-3788-42e8-b1e9-0bae28c7d538"
      decimals="-3"
      id="F_c6cd01f3-2440-4bc9-939b-ba9ccd7781cc"
      unitRef="U_USD">220000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_fb582b1b-defd-402a-8689-f3dd46cd150b"
      id="F_dc406b22-b1b1-4d35-ad92-4c90a54d09ba">P1Y10M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_29a1849b-149a-4a73-bc63-5816436d6531"
      unitRef="U_USD">9511000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      id="F_51a9a1f7-5778-4852-acc2-4a99267e3a1d">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table summarizes equity award activity under the 2012 Plan and prior plans and related information:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:32.386%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.642%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.02%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:7.7219999999999995%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.642%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.02%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:7.7219999999999995%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.642%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.02%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.182%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands, except per share data)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Number of outstanding options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted-Average Exercise Price of Outstanding Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Number of outstanding RSUs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted-Average Fair Value per Share at Grant&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Number of outstanding RSAs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted-Average Fair Value per Share at Grant&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance as of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;948&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15.56&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;518&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12.16&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;30&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14.97&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;828&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12.77&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;389&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12.85&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12.98&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Released RSUs and RSAs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;284&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12.42&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15.02&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;275&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15.22&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;141&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11.98&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,499&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14.09&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;482&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12.62&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14.93&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Vested and expected to vest &lt;br/&gt;&#160;&#160;&#160;as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,499&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14.09&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;482&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12.62&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_886d4bf2-cc70-460c-8055-b20097a1c12e"
      decimals="-3"
      id="F_1699a7dc-5004-4b3a-aecc-12272be43fd8"
      unitRef="U_shares">948000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_886d4bf2-cc70-460c-8055-b20097a1c12e"
      decimals="2"
      id="F_6c8d7e05-3a22-4c21-b8c0-e89b7321f9a5"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">15.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="C_cff2e9b5-87f8-419f-9856-34ae17e4d036"
      decimals="-3"
      id="F_e38ca905-3ac9-4daf-b117-026e91972df6"
      unitRef="U_shares">518000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_cff2e9b5-87f8-419f-9856-34ae17e4d036"
      decimals="2"
      id="F_6b10463e-118c-4da3-aab9-308b667254de"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">12.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="C_8e0a440d-9ea8-4152-85ec-508d2a5aa993"
      decimals="-3"
      id="F_5687c969-a4d5-490f-96d4-a0d70cbe75b9"
      unitRef="U_shares">30000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_8e0a440d-9ea8-4152-85ec-508d2a5aa993"
      decimals="2"
      id="F_d8ef4316-0b0d-449e-bdcc-40dda8c866a1"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">14.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_1fd35541-50f5-4c16-a031-bd9cc78d2a09"
      decimals="-3"
      id="F_1ca81e62-5e2c-4308-97bf-7a1ef22208a2"
      unitRef="U_shares">828000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_1fd35541-50f5-4c16-a031-bd9cc78d2a09"
      decimals="2"
      id="F_2290e929-82cd-43b8-82bd-453a3c3f615c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">12.77</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="C_f3f69c9a-b63b-46c1-8d46-3c3cdfa265b1"
      decimals="-3"
      id="F_ce41e84e-dbad-4c6e-99b5-1392413b080e"
      unitRef="U_shares">389000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_f3f69c9a-b63b-46c1-8d46-3c3cdfa265b1"
      decimals="2"
      id="F_69bf4fad-de8a-48df-8bef-501fd67b187b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">12.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="C_fb582b1b-defd-402a-8689-f3dd46cd150b"
      decimals="-3"
      id="F_7d6895fa-7d8f-4f5e-b6f6-868f19d39913"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_fb582b1b-defd-402a-8689-f3dd46cd150b"
      decimals="0"
      id="F_b32d5a95-6acb-4031-b304-29e73439ba59"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_1fd35541-50f5-4c16-a031-bd9cc78d2a09"
      decimals="-3"
      id="F_bcdd82f5-d40e-43eb-b799-705e315e0976"
      unitRef="U_shares">2000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_1fd35541-50f5-4c16-a031-bd9cc78d2a09"
      decimals="2"
      id="F_d5f99c69-2ec5-490f-ad68-28d79c052eec"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">12.98</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="C_f3f69c9a-b63b-46c1-8d46-3c3cdfa265b1"
      decimals="-3"
      id="F_0ed13725-6002-484c-a65b-de0b587cc2fb"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_f3f69c9a-b63b-46c1-8d46-3c3cdfa265b1"
      decimals="0"
      id="F_313216b2-4f56-4e05-a6f8-04c85ca3fd34"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0</inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="C_fb582b1b-defd-402a-8689-f3dd46cd150b"
      decimals="-3"
      id="F_454a0886-edeb-4f21-adfb-3ce83b68eeae"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_fb582b1b-defd-402a-8689-f3dd46cd150b"
      decimals="0"
      id="F_2c210651-13a9-4ecc-b307-195f3ebc6150"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0</inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="C_1fd35541-50f5-4c16-a031-bd9cc78d2a09"
      decimals="-3"
      id="F_27961c4f-22fe-4e4e-9a59-ac46f7c70135"
      unitRef="U_shares">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="C_1fd35541-50f5-4c16-a031-bd9cc78d2a09"
      decimals="0"
      id="F_70b66271-a461-4d90-a2cf-075959133da6"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_f3f69c9a-b63b-46c1-8d46-3c3cdfa265b1"
      decimals="-3"
      id="F_7598cb2a-ee13-4893-b274-6dc77e2d67c7"
      unitRef="U_shares">284000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_f3f69c9a-b63b-46c1-8d46-3c3cdfa265b1"
      decimals="2"
      id="F_9a98928f-7c3b-4be5-b271-2e695b9b9aac"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">12.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_fb582b1b-defd-402a-8689-f3dd46cd150b"
      decimals="-3"
      id="F_e6469af1-5921-4e91-aad7-b3554c57c7bd"
      unitRef="U_shares">14000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_fb582b1b-defd-402a-8689-f3dd46cd150b"
      decimals="2"
      id="F_042aedb0-14ce-4754-a20e-dcdc0609822f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">15.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_1fd35541-50f5-4c16-a031-bd9cc78d2a09"
      decimals="-3"
      id="F_5d1d58b1-aa2b-4f7f-8f3e-68ee975320d4"
      unitRef="U_shares">275000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_1fd35541-50f5-4c16-a031-bd9cc78d2a09"
      decimals="2"
      id="F_9fa58380-a18c-4c52-ae2f-faed246284d4"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">15.22</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures
      contextRef="C_f3f69c9a-b63b-46c1-8d46-3c3cdfa265b1"
      decimals="-3"
      id="F_973d2a14-25a1-48f8-b71c-a2f9cd1e9b6f"
      unitRef="U_shares">141000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="C_f3f69c9a-b63b-46c1-8d46-3c3cdfa265b1"
      decimals="2"
      id="F_38c0a7ab-efc9-4347-a7f1-86de0e4eea05"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">11.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures
      contextRef="C_fb582b1b-defd-402a-8689-f3dd46cd150b"
      decimals="-3"
      id="F_5d994358-7849-499f-94c4-77faf7875e42"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="C_fb582b1b-defd-402a-8689-f3dd46cd150b"
      decimals="0"
      id="F_186db3df-f11f-4fb3-9288-d5a03799f322"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_6c28106a-1f5c-4375-9a90-9f5d3d7fd470"
      decimals="-3"
      id="F_2d5a620d-de0b-4f36-a2b7-07f07b51f380"
      unitRef="U_shares">1499000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_6c28106a-1f5c-4375-9a90-9f5d3d7fd470"
      decimals="2"
      id="F_42018a6d-ac7d-4860-a070-fb325b5fcff1"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">14.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="C_3b5f86a2-e137-470e-ae05-ea4b9e220cfa"
      decimals="-3"
      id="F_f738106f-187a-4c8f-8ae0-4351177ffe36"
      unitRef="U_shares">482000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_3b5f86a2-e137-470e-ae05-ea4b9e220cfa"
      decimals="2"
      id="F_25b843ad-a1e5-4734-a37e-996ce3fada4b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">12.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="C_f3b6b1d2-3788-42e8-b1e9-0bae28c7d538"
      decimals="-3"
      id="F_eef61b42-6e00-4d64-ba8a-c770f809692a"
      unitRef="U_shares">16000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_f3b6b1d2-3788-42e8-b1e9-0bae28c7d538"
      decimals="2"
      id="F_63ba7b47-1b9e-47c2-93a2-d5f8d8c093da"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">14.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="C_6c28106a-1f5c-4375-9a90-9f5d3d7fd470"
      decimals="-3"
      id="F_f2aee846-3679-4e3a-9be6-2caa3a3fad1a"
      unitRef="U_shares">1499000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="C_6c28106a-1f5c-4375-9a90-9f5d3d7fd470"
      decimals="2"
      id="F_cfe3d378-82a2-4a93-9f28-410cfda92a68"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">14.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingNumber
      contextRef="C_3b5f86a2-e137-470e-ae05-ea4b9e220cfa"
      decimals="-3"
      id="F_4773acf5-7081-4cbc-94e5-d1f54f31645e"
      unitRef="U_shares">482000</inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingNumber>
    <inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingWeightedAverageFairValuePerShare
      contextRef="C_3b5f86a2-e137-470e-ae05-ea4b9e220cfa"
      decimals="2"
      id="F_646f528f-a63d-409c-8f53-defaef7556dc"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">12.62</inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingWeightedAverageFairValuePerShare>
    <inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingNumber
      contextRef="C_f3b6b1d2-3788-42e8-b1e9-0bae28c7d538"
      decimals="0"
      id="F_74543118-2be4-4ed9-8a54-5892278a56f4"
      unitRef="U_shares">0</inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingNumber>
    <inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingWeightedAverageFairValuePerShare
      contextRef="C_f3b6b1d2-3788-42e8-b1e9-0bae28c7d538"
      decimals="0"
      id="F_5176867a-4b83-45e4-89de-244758b2c4df"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0</inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingWeightedAverageFairValuePerShare>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_6c28106a-1f5c-4375-9a90-9f5d3d7fd470"
      decimals="-5"
      id="F_ec962339-4e78-403b-9834-c2147714856a"
      unitRef="U_USD">3600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_6c28106a-1f5c-4375-9a90-9f5d3d7fd470"
      decimals="-5"
      id="F_2ffa1bc9-1623-4bab-a77a-7c0d83a6aff7"
      unitRef="U_USD">800000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_6c28106a-1f5c-4375-9a90-9f5d3d7fd470"
      decimals="0"
      id="F_7ef1477d-9d14-4ea1-aca6-8c1678e0d4ce"
      unitRef="U_shares">519165</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_1fd35541-50f5-4c16-a031-bd9cc78d2a09"
      id="F_7414926f-ed91-4f8d-ac4d-d065d42e819d">P7Y11M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_b40eac4f-f18e-4a85-95ce-6db8d48f14f2"
      id="F_71be8666-502e-4e51-89df-fe50d750db66">P8Y3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_1fd35541-50f5-4c16-a031-bd9cc78d2a09"
      decimals="-6"
      id="F_a025dbaa-aa7c-4bbd-91fe-b81f59ac718e"
      unitRef="U_USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_b40eac4f-f18e-4a85-95ce-6db8d48f14f2"
      decimals="-6"
      id="F_6349e2a5-dce6-4ba0-9be1-e9fed92ffacb"
      unitRef="U_USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_7b140651-bbea-4d88-8a4f-fa197b5dfa55"
      decimals="-6"
      id="F_15f2f2cc-450a-448e-9b9a-fe6daf93765d"
      unitRef="U_USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="C_1fd35541-50f5-4c16-a031-bd9cc78d2a09"
      decimals="-5"
      id="F_60116b46-2e06-46d2-991f-3950808d714c"
      unitRef="U_USD">1900000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="C_7b140651-bbea-4d88-8a4f-fa197b5dfa55"
      decimals="-5"
      id="F_fae3e3f7-841f-4c9d-a6c1-28f08a773df3"
      unitRef="U_USD">600000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="C_b40eac4f-f18e-4a85-95ce-6db8d48f14f2"
      decimals="-6"
      id="F_6f2290d1-f3d7-4c1c-a9da-0d2ea81702e8"
      unitRef="U_USD">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="C_f3f69c9a-b63b-46c1-8d46-3c3cdfa265b1"
      decimals="-5"
      id="F_4b819e10-c195-4599-bfb2-6cec2bc6b88f"
      unitRef="U_USD">3900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="C_a332f0a6-0f9e-4712-97f0-f10d648bcf65"
      decimals="-5"
      id="F_89376dc9-ad99-4cd7-b476-c8c0a202e88f"
      unitRef="U_USD">2300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="C_4eb342bb-a67b-41a2-af3e-2b6b0a442022"
      decimals="-5"
      id="F_d6c3745c-472b-4828-9654-58806b5c2de6"
      unitRef="U_USD">1100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      id="F_7ba97f2c-5c0b-40c8-a706-3e4a2d60eba6">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; assumptions used in calculating the estimated value of stock options granted by Innoviva on the date of grant were as follows:&lt;/span&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.311%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.481%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.748999999999999%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.481%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.748999999999999%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.481%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.748999999999999%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.09&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.04&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.11&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;37.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;38.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;44.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Weighted-average estimated fair value of stock options granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.57&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.43&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.84&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_1c6acdd9-134f-4827-828c-e39c4849a9cf"
      decimals="3"
      id="F_5eaa8900-abcd-4fe1-9761-894a8a82ff55"
      unitRef="U_pure">0.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_c59027d6-af7f-4474-af78-da02d5338608"
      decimals="3"
      id="F_93009f1d-c05d-4b53-aeeb-a5d3d22f123b"
      unitRef="U_pure">0.036</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_fa7ab020-0f18-40e9-ae65-5d70aca1f021"
      decimals="3"
      id="F_0f80bf81-b666-413f-a024-7404e635da5a"
      unitRef="U_pure">0.011</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_1c6acdd9-134f-4827-828c-e39c4849a9cf"
      id="F_88663f6c-a64b-47da-84c2-606d908d59ee">P6Y1M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_c59027d6-af7f-4474-af78-da02d5338608"
      id="F_36fd9fb2-657f-4f20-960c-6ab4c1299bcd">P6Y14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_fa7ab020-0f18-40e9-ae65-5d70aca1f021"
      id="F_d9f039bf-23c1-4d04-84d2-a9c1394ccc59">P6Y1M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="C_1c6acdd9-134f-4827-828c-e39c4849a9cf"
      decimals="3"
      id="F_cfb9d116-50bb-4f73-bb8e-2e2aedd51c76"
      unitRef="U_pure">0.378</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="C_c59027d6-af7f-4474-af78-da02d5338608"
      decimals="3"
      id="F_f90fad7e-f19e-4a10-a253-d895a3847e66"
      unitRef="U_pure">0.386</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="C_fa7ab020-0f18-40e9-ae65-5d70aca1f021"
      decimals="3"
      id="F_f86b5d2b-7804-4f9f-a1a9-8e31a0bec3a4"
      unitRef="U_pure">0.449</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_1c6acdd9-134f-4827-828c-e39c4849a9cf"
      decimals="3"
      id="F_63b28a3b-34da-4d58-a199-1507d7952cf7"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_c59027d6-af7f-4474-af78-da02d5338608"
      decimals="3"
      id="F_d0d90b90-55c7-47eb-a9df-beb16955f9db"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_fa7ab020-0f18-40e9-ae65-5d70aca1f021"
      decimals="3"
      id="F_e3fe1e8f-32c7-4bae-8b5d-3a7000a32153"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_1c6acdd9-134f-4827-828c-e39c4849a9cf"
      decimals="2"
      id="F_ae9708c7-de97-4070-a7ff-440d90a6f453"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_c59027d6-af7f-4474-af78-da02d5338608"
      decimals="2"
      id="F_9106b0b3-e1bd-4f4e-ae75-b3d05f30eadc"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">6.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_fa7ab020-0f18-40e9-ae65-5d70aca1f021"
      decimals="2"
      id="F_ab2cdf34-7fa3-49fd-8c67-21ca827a3e67"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      id="F_cc9ad91a-2b2b-4267-b845-fec36e9dee27">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;11. &lt;/span&gt;&lt;span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Stockholders&#x2019; Equity&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On October 31, 2022, our board of directors authorized a share repurchase program under which we may repurchase up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;100.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of our outstanding shares of common stock. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The repurchase program authorizes the repurchase by the Company of its common stock in open market transactions, including pursuant to a trading plan in accordance with Rule 10b-18 promulgated under the Securities Exchange Act of 1934, as amended (the &#x201c;Exchange Act&#x201d;) privately negotiated transactions, in block trades, accelerated share repurchase transactions, exchange transactions, or any combination thereof or by other means in accordance with federal securities laws. The authorization permits the Company to repurchase shares of its common stock from time to time at management&#x2019;s discretion. Repurchases may also be made pursuant to a trading plan under Rule 10b5-1 under the Exchange Act, which would permit shares to be repurchased when the Company might otherwise be precluded from doing so because of self-imposed trading blackout periods or other regulatory restrictions. The actual means and timing of any shares purchased under the program will depend on a variety of factors, including ongoing assessments of the capital needs of the business, the market price of our common stock, prevailing stock prices, general market conditions and other considerations. This program has no termination date, may be suspended or discontinued at any time at our discretion, and does not obligate us to acquire any amount of common stock. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;From program inception through December 31, 2022, we repurchased &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;647,394&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares in the open market at an average price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13.13&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share for a total amount of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. For the year ended&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; December 31, 2023, we repurchased &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,173,565&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares in the open market at an average price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12.39&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share for a total amount of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;76.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. Subsequent to December 31, 2023 and through February 15, 2024, we have repurchased &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;131,826&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares in the open market at an average price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15.93&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share for a total amount of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. All of the repurchased shares were retired.&lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
      contextRef="C_c985f900-3058-44b4-9093-ef23d5cbfa14"
      decimals="-5"
      id="F_1ed4741a-e219-4a0a-942b-c8c602aa4dad"
      unitRef="U_USD">100000000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="C_5f070bd2-c0df-4242-beff-e5f9b6727217"
      decimals="INF"
      id="F_c14eb4f6-0ccd-4858-a83b-408d72b6d578"
      unitRef="U_shares">647394</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <inva:CommonStockAcquiredAverageCostPerShare
      contextRef="C_5f070bd2-c0df-4242-beff-e5f9b6727217"
      decimals="2"
      id="F_244eca2f-dff9-44f5-930e-67e01f23671b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">13.13</inva:CommonStockAcquiredAverageCostPerShare>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="C_5f070bd2-c0df-4242-beff-e5f9b6727217"
      decimals="-5"
      id="F_8e29ce8f-aff0-4fbf-af12-354a977efd55"
      unitRef="U_USD">8500000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="C_102d957f-b55b-4b0c-b290-8ba82889bebc"
      decimals="0"
      id="F_d797fcfa-2701-45a7-984b-ee570d0ae783"
      unitRef="U_shares">6173565</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <inva:CommonStockAcquiredAverageCostPerShare
      contextRef="C_102d957f-b55b-4b0c-b290-8ba82889bebc"
      decimals="2"
      id="F_9684f598-7013-4ade-a431-7776a27c6ed0"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">12.39</inva:CommonStockAcquiredAverageCostPerShare>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="C_102d957f-b55b-4b0c-b290-8ba82889bebc"
      decimals="-5"
      id="F_228f960b-88c7-47ca-8117-83e8d11169d8"
      unitRef="U_USD">76500000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="C_d175b10d-c61c-4706-bba1-92ef6df9865b"
      decimals="INF"
      id="F_44eb9190-4410-4c4e-a0e7-a6a62b8d6260"
      unitRef="U_shares">131826</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <inva:CommonStockAcquiredAverageCostPerShare
      contextRef="C_d175b10d-c61c-4706-bba1-92ef6df9865b"
      decimals="2"
      id="F_a48ffd31-fdfc-4308-8d66-a701beb105d6"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">15.93</inva:CommonStockAcquiredAverageCostPerShare>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="C_d175b10d-c61c-4706-bba1-92ef6df9865b"
      decimals="-5"
      id="F_940af20c-ffd7-4cb2-9886-841f04c088a9"
      unitRef="U_USD">2100000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      id="F_ce958e7c-bfd2-4be6-b740-8748ef1ca634">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;12. DEBT&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Our debt consists of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.313%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.843%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.843%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2023 Notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;96,204&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2025 Notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;192,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;192,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2028 Notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;261,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;261,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total debt&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;453,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;549,704&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;Less: Unamortized debt discount and issuance costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,266&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,331&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total debt, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;446,234&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;540,373&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;Less: Current portion of long-term debt, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;96,193&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total long-term debt, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;446,234&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;444,180&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Convertible Subordinated Notes Due 2023&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In January 2013, we completed an underwritten public offering of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;287.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million aggregate principal amount of our 2023 Notes, which matured on January 15, 2023. The 2023 Notes bore interest at the rate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.125&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% per year that is payable semi-annually in arrears in cash on January 15 and July 15 of each year, beginning on July 15, 2013.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The 2023 Notes were convertible, at the option of the holder, into shares of our common stock at an initial conversion rate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;35.9903&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares per $1,000 principal amount of the 2023 Notes, subject to adjustment in certain circumstances, which represented an initial conversion price of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27.79&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In connection with the offering of the 2023 Notes, we entered into &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;two&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; privately negotiated capped call option transactions with a single counterparty. The capped call option transaction was an integrated instrument consisting of a call option on our common stock purchased by us with a strike price equal to the initial conversion price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27.79&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share for the underlying number of shares and a cap price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;38.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share, both of which were subject to adjustments consistent with the 2023 Notes. The cap component was economically equivalent to a call option sold by us for the underlying number of shares with an initial strike price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;38.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share. As an integrated instrument, the settlement of the capped call coincided with the due date of the convertible debt. Upon settlement, we would receive from our hedge counterparty a number of shares of our common shares that would range from &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;zero&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, if the stock price was below $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27.79&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share, to a maximum of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,779,659&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares, if the stock price was above $38.00 per share. However, if the market price of our common stock, as measured under the terms of the capped call transactions, exceeded $38.00 per share, there was no incremental anti-dilutive benefit from the capped call.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As a result of the partial conversion by certain holders of the 2023 Notes in July 2014, and dividends declared and paid in 2014 and 2015, the conversion rate with respect to our 2023 Notes was adjusted in total to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50.5818&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of our common stock per $1,000 principal amount of the 2023 Notes, which represented a conversion price of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19.77&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share. As a result of the conversion rate adjustments, the capped call strike price and cap price were also adjusted to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19.77&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27.04&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;For the year ended December 31, 2016, we retired a portion of our 2023 Notes with a face value of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and carrying value of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million by way of purchase in the open market.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On March 7, 2022, we used $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;165.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million from the sale of the 2028 Notes to repurchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;60&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the 2023 Notes with a face value of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;144.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. The carrying value of the repurchased 2023 Notes was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;144.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. Accrued interest was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and unamortized debt issuance costs were $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million on the date of repurchase. We recognized a loss on the extinguishment of the 2023 Notes of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in other expense, net, in the consolidated statement of operations. The repurchase reduced the outstanding principal balance to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;96.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and unamortized debt issuance costs to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. The annual effective interest rate of the 2023 Notes changed from &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.36&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.37&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On April 18, 2022, certain 2023 Notes holders converted their notes of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; thousand into Innoviva&#x2019;s common stock. The outstanding principal balance was reduced slightly to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;96.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Our outstanding 2023 Notes balance consisted of the following as of December 31, 2022:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:77%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.98%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:19.02%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Principal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;96,204&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Debt issuance costs, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net carrying amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;96,193&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The remaining balance of the 2023 Notes in the amount of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;96.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million was fully paid upon the maturity date in January 2023.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table sets forth total interest expense recognized related to the 2023 Notes for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023, 2022 and 2021:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.311%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.481%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.75%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.481%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.75%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.481%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.75%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Contractual interest expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;85&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,617&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,121&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Amortization of debt issuance costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;302&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;580&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total interest and amortization expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;96&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,919&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,701&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Convertible Senior Notes Due 2025&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On August 7, 2017, we completed a private placement of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;192.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million aggregate principal amount of our 2025 Notes. The proceeds include the 2025 Notes sold pursuant to the $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million over-allotment option granted by us to the initial purchasers, which option was exercised in full. The 2025 Notes were sold in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act. The 2025 Notes are senior unsecured obligations and bear interest at a rate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% per year, payable semi-annually in arrears on February 15 and August 15 of each year, beginning on February 15, 2018.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The 2025 Notes are convertible, based on the applicable conversion rate, into cash, shares of our common stock or a combination thereof, at our election. The initial conversion rate for the 2025 Notes is &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;57.9240&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of our common stock per $1,000 principal amount of the 2025 Notes (which is equivalent to an initial conversion price of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17.26&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share), representing a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;30.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% conversion premium over the last reported sale price of the Company&#x2019;s common stock on August 1, 2017, which was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13.28&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share. The conversion rate is subject to customary anti-dilution adjustments in certain circumstances. The 2025 Notes will mature on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;August 15, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, unless repurchased or converted in accordance with their terms prior to such date. Prior to February 15, 2025, the 2025 Notes will be convertible at the option of the holders only upon the occurrence of specified events and during certain periods, as described below. From, and including, February 15, 2025, until the close of business on the second scheduled trading day immediately preceding the maturity date, the 2025 Notes will be convertible at any time.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Holders of the 2025 Notes may convert all or a portion of their 2025 Notes prior to the close of business on February 15, 2025 only under the following circumstances:&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;after September 30, 2017, if our closing common stock price for at least 20 days out of the most recent 30 consecutive trading days of the preceding quarter is greater than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;130&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the current conversion price of the 2025 Notes;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;for five consecutive business days, if the average trading price per $1,000 of Notes during the prior 10 consecutive trading days is less than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;98&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the product of our closing common stock price and the conversion rate of the 2025 Notes on such day; and,&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;upon the occurrence of specified corporate events, including certain distributions, the occurrence of a fundamental changes (as defined in the indenture governing the 2025 Notes) or a transaction resulting in our common stock converting into other securities or property or assets. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On or after February 15, 2025, holders of the 2025 Notes may convert their 2025 Notes at any time until the close of business on the second scheduled trading day immediately preceding the maturity date of the 2025 Notes.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In the event of default or a fundamental change (as defined above), holders of the 2025 Notes may require us to repurchase all or a portion of their 2025 Notes at price equal to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the principal amount of the 2025 Notes, plus any accrued and unpaid interest.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Effective January 1, 2022, we adopted ASU 2020-06 using a modified retrospective method, under which financial results reported in prior periods were not adjusted.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; Prior to the adoption of ASU 2020-06, we separately accounted for the liability and equity components of the 2025 Notes by allocating the proceeds between the liability component and the embedded conversion option (&#x201c;equity component&#x201d;) due to our ability to settle the conversion obligation of the 2025 Notes in cash, common stock or a combination of cash and common stock, at our option. The carrying amount of the liability component was calculated by measuring the fair value of a similar liability that does not have an associated convertible feature using the income approach. The allocation was performed in a manner that reflected our non-convertible debt borrowing rate for similar debt. The equity component of the 2025 Notes of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;67.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million was recognized as a debt discount and represents the difference between the proceeds from the issuance of the 2025 Notes and the fair value of the liability of the 2025 Notes on the date of issuance. The excess of the principal amount of the liability component over its carrying amount (&#x201c;debt discount&#x201d;) was amortized to interest expense using the effective interest method over the term of the 2025 Notes. The equity component was not remeasured as long as it continued to meet the conditions for equity classification. Additionally, we separated the total issuance costs of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million incurred into liability and equity components in proportion to the allocation of the initial proceeds, resulting in liability issuance costs of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and equity issuance costs of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. Issuance costs attributable to the liability component were amortized on a straight-line basis, which approximated the effective interest rate method, to interest expense over the term of the 2025 Notes. The issuance costs attributable to the equity component were netted against the equity component in additional paid-in capital. The annual effective interest rate of the liability component of the 2025 Notes was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.87&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Upon adoption of ASU 2020-06 on January 1, 2022, we combined the liability and equity components of the 2025 Notes assuming that the instrument was accounted for as a single liability from inception to the date of adoption. We similarly combined the liability and equity components of the issuance costs. The issuance costs are presented as a deduction from the outstanding principal balance of the 2025 Notes and are amortized on a straight-line basis over the term of the 2025 Notes under the effective interest rate method. As of January 1, 2022, the annual effective interest rate on the 2025 Notes was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.88&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%. Beginning January 1, 2022, the annual effective interest rate on the 2025 Notes is &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.88&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Our outstanding 2025 Notes balances consisted of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:53.88%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.26%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:18.799999999999997%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.26%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:18.799999999999997%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Principal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;192,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;192,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Debt discount and issuance costs, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,205&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,917&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net carrying amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;191,295&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;190,583&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table sets forth total interest expense recognized related to the 2025 Notes for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023, 2022 and 2021:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.01%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.203%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.203%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.583%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Contractual interest expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,813&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,813&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,813&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Amortization of debt issuance costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;712&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;692&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;657&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Amortization of debt discount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,898&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total interest and amortization expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,525&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,505&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,368&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Convertible Senior Notes Due 2028&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In March 2022, we completed a private placement of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;261.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million aggregate principal amount of our 2028 Notes, which will mature on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;March 15, 2028&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The proceeds include the 2028 Notes sold pursuant to the $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;45.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million over-allotment option granted by us to the initial purchasers, of which $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;36.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million was exercised. The 2028 Notes were sold in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The net proceeds from the sale of the $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;261.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million aggregate principal amount of 2028 Notes were approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;252.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million after deducting the initial purchasers&#x2019; discounts and commissions and our estimated offering expenses. We used approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of the net proceeds from the offering to fund the cost of entering into the capped call transactions described below. In addition, we used $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;165.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of the remaining net proceeds to repurchase $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;144.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million aggregate principal amount of the 2023 Notes in separate and individually negotiated transactions with certain holders of the 2023 Notes, which closed concurrently with the issuance of the 2028 Notes. We expect to use the remaining net proceeds for general corporate purposes.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The 2028 Notes bear interest at an annual rate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.125&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% that is payable semi-annually in arrears in cash on March 15 and September 15 of each year, beginning on September 15, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The 2028 Notes are convertible, based on the applicable conversion rate, into cash, shares of our common stock or a combination thereof, at our election. The initial conversion rate was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;38.1432&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares per $1,000 principal amount of the 2028 Notes, subject to customary anti-dilution adjustment in certain circumstances, which represented an initial conversion price of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;26.22&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Prior to September 15, 2027, the 2028 Notes will be convertible at the option of the holders only upon the occurrence of specified events and during certain periods, and will be convertible on or after September 15, 2027, at any time until the close of business on the second scheduled trading day immediately preceding the maturity date of the 2028 Notes.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Holders of the 2028 Notes may convert all or a portion of their 2028 Notes prior to the close of business on September 15, 2027, only under the following circumstances:&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;after March 31, 2022, if our closing common stock price for at least 20 days out of the most recent 30 consecutive trading days of the preceding quarter is greater than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;130&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the current conversion price of the 2028 Notes;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;for five consecutive business days, if the average trading price per $1,000 of Notes during the prior 10 consecutive trading days is less than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;98&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the product of our closing common stock price and the conversion rate of the 2028 Notes on such day; and,&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;upon the occurrence of specified corporate events, including certain distributions, the occurrence of a fundamental changes (as defined in the indenture governing the 2028 Notes) or a transaction resulting in our common stock converting into other securities or property or assets.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On or after September 15, 2027, holders of the 2028 Notes may convert their 2028 Notes at any time until the close of the business on the second day immediately preceding the maturity date of the 2028 Notes.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The 2028 Notes will be redeemable, in whole or in part, at our option at any time, and from time to time, on or after March 20, 2025, and on or before the 75th scheduled trading day immediately before the maturity date but only if the last reported sale price per share of our common stock exceeds 130% of the conversion price for a specified period of time. The redemption price will be equal to the principal amount of the 2028 Notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date. In addition, calling any 2028 Note for redemption will constitute a make-whole fundamental change (as defined in the indenture governing the 2028 Notes) with respect to that 2028 Note, in which case the conversion rate applicable to the conversion of that 2028 Note will be increased in certain circumstances if it is converted after it is called for redemption.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;If we undergo a fundamental change, subject to certain conditions, holders may require us to purchase for cash all or any portion of their 2028 Notes. The fundamental change purchase price will be &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the principal amount of the 2028 Notes to be purchased plus any accrued and unpaid interest to, but excluding, the fundamental change purchase date.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The indenture governing the 2028 Notes contains customary terms and covenants, including a merger covenant and that upon certain events of default occurring and continuing, either the Trustee or the holders of at least 25% of the aggregate principal amount of the outstanding Notes may declare 100% of the principal of, and accrued and unpaid interest, if any, on, all the Notes to be due and payable immediately.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In connection with the offering of the 2028 Notes, we entered into privately negotiated capped call transactions. The cap price of the capped call transaction is initially $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;33.9850&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;share and is subject to certain adjustments under the terms of the capped call transactions. The capped call transactions cover, subject to customary adjustments, the number of shares of common stock initially&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;underlying &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;the 2028 Notes. The capped call transactions are expected generally to reduce potential dilution to our common stock upon conversion of the 2028 Notes or at our election (subject to certain conditions) offset any cash payments we are required to make in excess of the aggregate principal amount of converted 2028 Notes, as the case may be, with such reduction or offset subject to a cap.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The annual effective interest rate on the 2028 Notes is &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.70&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11pt;font-family:'Calibri',sans-serif;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Our outstanding 2028 Notes balance consisted of th&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;e following:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.313%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.843%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.843%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Principal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;261,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;261,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Debt discount and issuance costs, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,061&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,403&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net carrying amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;254,939&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;253,597&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table sets forth total interest expense recognized related to the 2028 Notes for the year ended December 31, 2023 and from the issuance through December 31, 2022:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.313%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.843%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.843%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Date of Issuance through&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Contractual interest expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,546&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,514&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Amortization of debt discount and issuance costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,342&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,061&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total interest and amortization expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,888&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,575&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Debt Maturities&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The aggregate scheduled maturities of our convertible debt as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.444%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.8%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.757%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Year ending December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;192,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;261,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;453,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Deferred Royalty Obligation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As part of our acquisition of La Jolla, we recorded the fair value of its deferred royalty obligation in connection with La Jolla&#x2019;s royalty financing agreement (&#x201c;La Jolla Royalty Agreement&#x201d;) with HealthCare Royalty Partners (&#x201c;HCR&#x201d;). Under the terms of the La Jolla Royalty Agreement, HCR is entitled to receive quarterly royalties on worldwide net sales of GIAPREZA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; until either January 1, 2031 or when the maximum aggregate royalty payments have been made, whichever occurs first. Quarterly payments to HCR under the Royalty Agreement start at a maximum royalty rate, with step-downs based on the achievement of annual net product sales thresholds. The current maximum royalty rate is &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Starting January 1, 2024, the maximum royalty rate was increased to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% based on the terms of the Agreement.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; The La Jolla Royalty Agreement is subject to maximum aggr&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;egate royalty payments to HCR of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;225.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;For the years ended December 31, 2023, we recognized interest expense of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million on the deferred royalty obligation. From the date of our acquisition of La Jolla through December 31, 2022, we recognized interest expense of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million on the deferred royalty obligation. The carrying value of the deferred royalty obligation as of December 31, 2023 and 2022 was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;69.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;70.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively, (refer to Note 9 &#x201c;Balance Sheet Components&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x201d;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;). During the year ended December 31, 2023, we made royalty payments to HCR of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. From the date of acquisition of La Jolla through December 31, 2022, we made royalty payments to HCR of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The deferred royalty obligation was valued using Level 3 inputs, and its carrying value as of December 31, 2023 and 2022 approximates fair value. The fair value of the deferred royalty obligation was calculated as the&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;discounted &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;deferred royalty obligations based on revenue projections for GIAPREZA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. As of December 31, 2023, the annual effective interest rate of the deferred royalty obligation is &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16.46&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Under the terms of the La Jolla Royalty Agreement, if we are unable to meet certain obligations, including the obligation to use commercially reasonable and diligent efforts to commercialize GIAPREZA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, HCR would have the right to terminate the La Jolla Royalty Agreement and demand payment of either $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;125.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million or $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;225.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million (depending on which obligation we have failed to meet) less aggregate royalties already paid to HCR. As of December 31, 2023, inclusive of the aggregate royalties paid to HCR by La Jolla under the La Jolla Royalty Agreement prior to our acquisition, La Jolla paid $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;aggregate royalties to HCR. In the event that we fail to pay such amount if and when due in a timely manner, HCR would have the right to foreclose on the GIAPREZA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;-related assets. HCR has no recourse against any asset other than GIAPREZA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Certain contract provisions within the La Jolla Royalty Agreement that could result in an acceleration of amounts due under the La Jolla Royalty Agreement are recognized as embedded derivatives that require bifurcation from the deferred royalty obligation and fair value recognition. We determined the fair value of each derivative by assessing the probability of each event occurring, as well as the potential repayment amounts and timing of such repayments that would result under various scenarios. As a result of this assessment, we determined that the fair value of the embedded derivatives is immaterial and, therefore, not recognized as of December 31, 2023 and 2022. We estimate the fair value of the embedded derivatives for each reporting period until either the features lapse or the La Jolla Royalty Agreement is terminated, whichever occurs first. Any material change in the fair value of the embedded derivatives will be recorded as either a gain or loss in the consolidated statements of income.&lt;/span&gt;&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      id="F_fa8a086a-ba1f-4100-821f-2910de74f0cb">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Our debt consists of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.313%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.843%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.843%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2023 Notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;96,204&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2025 Notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;192,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;192,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2028 Notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;261,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;261,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total debt&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;453,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;549,704&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;Less: Unamortized debt discount and issuance costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,266&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,331&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total debt, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;446,234&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;540,373&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;Less: Current portion of long-term debt, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;96,193&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total long-term debt, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;446,234&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;444,180&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <inva:DebtInstrumentPrincipalAmount
      contextRef="C_1a69ac4e-3663-4d1d-a457-2b4890fc09f6"
      decimals="-3"
      id="F_ec5a7034-ddd2-4c3b-b872-2bf46636c227"
      unitRef="U_USD">0</inva:DebtInstrumentPrincipalAmount>
    <inva:DebtInstrumentPrincipalAmount
      contextRef="C_96fef1ab-5fb4-4957-bed2-bbcbb49272d9"
      decimals="-3"
      id="F_8b8c2db5-7a67-4d6c-b975-8f8870765436"
      unitRef="U_USD">96204000</inva:DebtInstrumentPrincipalAmount>
    <inva:DebtInstrumentPrincipalAmount
      contextRef="C_aab90c2e-843e-4eca-8999-f7ad6f6f31c9"
      decimals="-3"
      id="F_c56d8e0b-3749-4fb2-b162-4ec7a3a25ea4"
      unitRef="U_USD">192500000</inva:DebtInstrumentPrincipalAmount>
    <inva:DebtInstrumentPrincipalAmount
      contextRef="C_87231fad-8817-4c3e-8afb-e2378841555d"
      decimals="-3"
      id="F_0d33f5e0-8fc0-4a58-8986-e8c6e1756765"
      unitRef="U_USD">192500000</inva:DebtInstrumentPrincipalAmount>
    <inva:DebtInstrumentPrincipalAmount
      contextRef="C_c11bea0f-0ab6-46b3-9574-250a23feeefc"
      decimals="-3"
      id="F_f56738c2-2627-42c5-87bc-a5d708a35222"
      unitRef="U_USD">261000000</inva:DebtInstrumentPrincipalAmount>
    <inva:DebtInstrumentPrincipalAmount
      contextRef="C_fb34b57e-973b-4997-8a2c-2f01d3f8fa62"
      decimals="-3"
      id="F_913a9942-aa1a-4499-b39f-0c13d6eb0623"
      unitRef="U_USD">261000000</inva:DebtInstrumentPrincipalAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_880047d0-f190-47a0-92b1-a6c0c988b595"
      unitRef="U_USD">453500000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      decimals="-3"
      id="F_bac5e71d-16f8-4c04-9040-bc6fcdb09360"
      unitRef="U_USD">549704000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_2c26d5c8-a2e1-4411-9152-96405e2e4efa"
      unitRef="U_USD">7266000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      decimals="-3"
      id="F_8a81f3e7-69fc-4ed2-992c-0f834e07c505"
      unitRef="U_USD">9331000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtLongtermAndShorttermCombinedAmount
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_215c19c4-a3be-43ea-8fde-4875b3959577"
      unitRef="U_USD">446234000</us-gaap:DebtLongtermAndShorttermCombinedAmount>
    <us-gaap:DebtLongtermAndShorttermCombinedAmount
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      decimals="-3"
      id="F_44daf669-171c-437c-860b-34ecaee45ab1"
      unitRef="U_USD">540373000</us-gaap:DebtLongtermAndShorttermCombinedAmount>
    <us-gaap:DebtCurrent
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_328b2d75-568c-4e96-af39-fefde12f8390"
      unitRef="U_USD">0</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      decimals="-3"
      id="F_75078810-d1f7-4cd1-bb52-d895d3068f06"
      unitRef="U_USD">96193000</us-gaap:DebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_55caac61-d6cc-4ab9-b787-d4c560453742"
      unitRef="U_USD">446234000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      decimals="-3"
      id="F_9eec5908-1155-4308-ada4-62c6b55e84ad"
      unitRef="U_USD">444180000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_74708c78-45e8-4732-9508-597695b3a0d5"
      decimals="-5"
      id="F_3fe221d0-9a35-4c33-a500-02c836838d89"
      unitRef="U_USD">287500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="C_74708c78-45e8-4732-9508-597695b3a0d5"
      decimals="5"
      id="F_0cc62baf-bcd7-4934-a838-d8e2bbf4b99a"
      unitRef="U_pure">0.02125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="C_5294fbf9-d2f4-4cee-abd1-6e00044b2cfa"
      decimals="4"
      id="F_3c244d44-f5a4-40cf-8651-2e6cc845a6a6"
      unitRef="U_pure">35.9903</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="C_e4d7581f-3285-4f94-bf60-7ad14f82c23d"
      decimals="2"
      id="F_80c8a85c-0889-4309-b2d3-f4276c7bd987"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">27.79</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <inva:NumberOfDerivativeInstrumentsPurchased
      contextRef="C_b55f651c-8a37-4dd9-95c5-8086ccf211c2"
      decimals="0"
      id="F_eac88c43-42e2-4f56-b5cb-04d6c3a172e0"
      unitRef="U_Item">2</inva:NumberOfDerivativeInstrumentsPurchased>
    <us-gaap:OptionIndexedToIssuersEquityStrikePrice1
      contextRef="C_698952c3-354e-492f-acd8-4bebed0f9f6b"
      decimals="2"
      id="F_7778c823-134a-4a23-b452-d0dff7954d8c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">27.79</us-gaap:OptionIndexedToIssuersEquityStrikePrice1>
    <us-gaap:DerivativeCapPrice
      contextRef="C_b55f651c-8a37-4dd9-95c5-8086ccf211c2"
      decimals="2"
      id="F_66599239-a8db-41e9-af5d-640b05003b62"
      unitRef="U_UsdItem">38</us-gaap:DerivativeCapPrice>
    <us-gaap:DerivativeCapPrice
      contextRef="C_b55f651c-8a37-4dd9-95c5-8086ccf211c2"
      decimals="2"
      id="F_cab36d97-5eb7-4b91-a78b-09e4f7ce7843"
      unitRef="U_UsdItem">38</us-gaap:DerivativeCapPrice>
    <inva:NumberOfSharesReceivableOnSettlementOfDerivativeInstrument
      contextRef="C_6672ccef-5420-4f2f-9dd7-acb4111b0173"
      decimals="0"
      id="F_9cfbc176-81d8-4e30-bbf7-93617c4a5270"
      unitRef="U_shares">0</inva:NumberOfSharesReceivableOnSettlementOfDerivativeInstrument>
    <us-gaap:OptionIndexedToIssuersEquityStrikePrice1
      contextRef="C_698952c3-354e-492f-acd8-4bebed0f9f6b"
      decimals="2"
      id="F_8dfa07ab-b7f3-44f1-aa20-b94a5218fd38"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">27.79</us-gaap:OptionIndexedToIssuersEquityStrikePrice1>
    <inva:NumberOfSharesReceivableOnSettlementOfDerivativeInstrument
      contextRef="C_f08bc742-7ba2-448a-ba4b-b3bb674bb334"
      decimals="0"
      id="F_a1aa7d29-71ab-43b1-9ab5-41b9a74a44be"
      unitRef="U_shares">2779659</inva:NumberOfSharesReceivableOnSettlementOfDerivativeInstrument>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="C_d4042f8a-02bc-4c92-af62-098270afe2af"
      decimals="4"
      id="F_0e676deb-4658-414f-9ee1-dc3d434585c5"
      unitRef="U_pure">50.5818</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="C_99ee3dae-1eb1-48e4-a46a-c7e1dc1f16a3"
      decimals="2"
      id="F_c52b8164-9349-42a8-a045-e38b4dfcb8f2"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">19.77</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:OptionIndexedToIssuersEquityStrikePrice1
      contextRef="C_4f37ea9f-306f-4950-a02c-a9b920bca4f3"
      decimals="2"
      id="F_c02b2c83-ce65-4bf3-9ba5-1d04a78167a8"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">19.77</us-gaap:OptionIndexedToIssuersEquityStrikePrice1>
    <us-gaap:DerivativeCapPrice
      contextRef="C_44f0f126-1c89-49be-aae9-85fa06e97ffc"
      decimals="2"
      id="F_8a004d60-618c-49db-ab6d-e61d79f33592"
      unitRef="U_UsdItem">27.04</us-gaap:DerivativeCapPrice>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="C_fe183000-a690-4df9-a845-930c3241af02"
      decimals="-5"
      id="F_fb43f992-a007-47a7-98d2-514e1175e16f"
      unitRef="U_USD">14100000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:DebtInstrumentRepurchaseAmount
      contextRef="C_fe183000-a690-4df9-a845-930c3241af02"
      decimals="-5"
      id="F_29f523a3-1462-4bea-9917-42d40bdcc1b3"
      unitRef="U_USD">13900000</us-gaap:DebtInstrumentRepurchaseAmount>
    <us-gaap:RepaymentsOfUnsecuredDebt
      contextRef="C_13a7a85f-17d1-43df-a359-948888dae445"
      decimals="-5"
      id="F_c1d1e3f3-b51d-4492-afda-3b3abe1ca8ca"
      unitRef="U_USD">165600000</us-gaap:RepaymentsOfUnsecuredDebt>
    <inva:DebtInstrumentRepurchasePercentage
      contextRef="C_13a7a85f-17d1-43df-a359-948888dae445"
      decimals="2"
      id="F_994d6106-be21-4196-be1f-58eb5d69f225"
      unitRef="U_pure">0.60</inva:DebtInstrumentRepurchasePercentage>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="C_d98c3729-ed3e-4b22-af22-60937a83a980"
      decimals="-5"
      id="F_71a61ed1-a3c6-4847-94d6-c8af665024a3"
      unitRef="U_USD">144800000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:DebtInstrumentRepurchaseAmount
      contextRef="C_d98c3729-ed3e-4b22-af22-60937a83a980"
      decimals="-5"
      id="F_336b518d-48ba-428f-ae82-d0c621143608"
      unitRef="U_USD">144500000</us-gaap:DebtInstrumentRepurchaseAmount>
    <us-gaap:InterestPayableCurrent
      contextRef="C_d98c3729-ed3e-4b22-af22-60937a83a980"
      decimals="-5"
      id="F_6223e942-a3f1-419f-9a24-7217dd742534"
      unitRef="U_USD">400000</us-gaap:InterestPayableCurrent>
    <us-gaap:UnamortizedDebtIssuanceExpense
      contextRef="C_d98c3729-ed3e-4b22-af22-60937a83a980"
      decimals="-5"
      id="F_678f9f36-927f-4887-9aae-cc374c67458d"
      unitRef="U_USD">300000</us-gaap:UnamortizedDebtIssuanceExpense>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="C_13a7a85f-17d1-43df-a359-948888dae445"
      decimals="-5"
      id="F_f090e74a-1554-4bfc-ae58-b219672ab00e"
      unitRef="U_USD">20700000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <inva:DebtInstrumentPrincipalAmount
      contextRef="C_d98c3729-ed3e-4b22-af22-60937a83a980"
      decimals="-5"
      id="F_64c4fae7-bfe1-416b-9f70-2b350f7bfa49"
      unitRef="U_USD">96200000</inva:DebtInstrumentPrincipalAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="C_d98c3729-ed3e-4b22-af22-60937a83a980"
      decimals="-5"
      id="F_0f36d212-9a21-4c28-9a5f-b507eb2fc793"
      unitRef="U_USD">200000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="C_e3491d72-ab2a-429a-8f92-dd8be751aada"
      decimals="4"
      id="F_3a1441c3-450f-435d-b971-426307f308b1"
      unitRef="U_pure">0.0236</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="C_6f3330be-9c77-42d3-931d-990047c9e84c"
      decimals="4"
      id="F_2cad4fe6-37d9-4994-b951-51af8dd8dfc9"
      unitRef="U_pure">0.0237</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="C_47315d43-a153-47de-8273-33588b06dde8"
      decimals="-2"
      id="F_77b69027-cbea-4c0b-924c-5b5d4d852895"
      unitRef="U_USD">3000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <inva:DebtInstrumentPrincipalAmount
      contextRef="C_e1b05d91-a370-4fa6-955b-9c0c677f7d49"
      decimals="-5"
      id="F_2b222747-6f28-436e-8902-2ebfc7cd8963"
      unitRef="U_USD">96200000</inva:DebtInstrumentPrincipalAmount>
    <us-gaap:ConvertibleDebtTableTextBlock
      contextRef="C_1d6c5f53-6c4d-4fe6-a55d-07940f638bd4"
      id="F_e8f947f8-c1c5-4b86-9310-f2859d6c945d">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Our outstanding 2023 Notes balance consisted of the following as of December 31, 2022:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:77%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.98%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:19.02%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Principal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;96,204&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Debt issuance costs, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net carrying amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;96,193&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ConvertibleDebtTableTextBlock>
    <inva:DebtInstrumentPrincipalAmount
      contextRef="C_96fef1ab-5fb4-4957-bed2-bbcbb49272d9"
      decimals="-3"
      id="F_e255a58d-7039-478f-ac53-d46a5e2541a3"
      unitRef="U_USD">96204000</inva:DebtInstrumentPrincipalAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="C_96fef1ab-5fb4-4957-bed2-bbcbb49272d9"
      decimals="-3"
      id="F_ca74bb45-a323-42e1-ac24-92a435ec2efa"
      unitRef="U_USD">11000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:LongTermDebtCurrent
      contextRef="C_96fef1ab-5fb4-4957-bed2-bbcbb49272d9"
      decimals="-3"
      id="F_9e3581cd-17ce-4d08-ab3b-09d6738af8c7"
      unitRef="U_USD">96193000</us-gaap:LongTermDebtCurrent>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_61ec0a88-ce56-4964-8be3-32f048a015ef"
      decimals="-5"
      id="F_4ca80bf7-6bb7-470c-a74e-b6063ff60158"
      unitRef="U_USD">96200000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock
      contextRef="C_1d6c5f53-6c4d-4fe6-a55d-07940f638bd4"
      id="F_5e80ee9a-b12b-4154-9a51-275422fce683">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table sets forth total interest expense recognized related to the 2023 Notes for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023, 2022 and 2021:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.311%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.481%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.75%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.481%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.75%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.481%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.75%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Contractual interest expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;85&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,617&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,121&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Amortization of debt issuance costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;302&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;580&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total interest and amortization expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;96&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,919&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,701&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="C_f7344ab8-d158-462a-91a3-5ed1e74e6333"
      decimals="-3"
      id="F_c07f93c0-e538-4a92-8b06-1e026412f0e7"
      unitRef="U_USD">85000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="C_a5bd2f55-3e40-4db1-9698-8e328bebe397"
      decimals="-3"
      id="F_fd65225a-2f6c-4499-9cca-b906266314fe"
      unitRef="U_USD">2617000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="C_4c7b96af-5930-4df9-9e24-686f4186dd93"
      decimals="-3"
      id="F_90962992-1453-42ac-b5b4-7d347dc96dcc"
      unitRef="U_USD">5121000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="C_f7344ab8-d158-462a-91a3-5ed1e74e6333"
      decimals="-3"
      id="F_9947f9b6-1319-4f10-9442-3c96c06e2229"
      unitRef="U_USD">11000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="C_a5bd2f55-3e40-4db1-9698-8e328bebe397"
      decimals="-3"
      id="F_4a8ce0e4-70fa-460b-ac2e-4a45a9ee4e6e"
      unitRef="U_USD">302000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="C_4c7b96af-5930-4df9-9e24-686f4186dd93"
      decimals="-3"
      id="F_e87dd506-613c-41e5-bf06-53c9b3bd0d18"
      unitRef="U_USD">580000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:InterestExpenseDebt
      contextRef="C_f7344ab8-d158-462a-91a3-5ed1e74e6333"
      decimals="-3"
      id="F_b8d4e722-c3bd-4a7b-8801-0adbd6d729bf"
      unitRef="U_USD">96000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="C_a5bd2f55-3e40-4db1-9698-8e328bebe397"
      decimals="-3"
      id="F_fa75a407-a58d-438c-b7fc-c8fc9c9a81c0"
      unitRef="U_USD">2919000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="C_4c7b96af-5930-4df9-9e24-686f4186dd93"
      decimals="-3"
      id="F_be7af684-75e4-473b-acb2-8ddcbcb2e34c"
      unitRef="U_USD">5701000</us-gaap:InterestExpenseDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_01fb7c8c-6c66-4d02-b04d-546c5c407297"
      decimals="-5"
      id="F_2f953245-339a-4593-9918-614fd1aa9f20"
      unitRef="U_USD">192500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_3ac61c6b-9a4c-4283-b479-f0354fbd761b"
      decimals="-5"
      id="F_cb7df1d5-02db-451e-8193-8e633c9ebd23"
      unitRef="U_USD">17500000</us-gaap:DebtInstrumentFaceAmount>
    <inva:PortionOfDebtInstrumentFaceAmountExercised
      contextRef="C_3ac61c6b-9a4c-4283-b479-f0354fbd761b"
      decimals="-5"
      id="F_6d9f9034-1a6c-4330-b251-dde402764f91"
      unitRef="U_USD">17500000</inva:PortionOfDebtInstrumentFaceAmountExercised>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="C_01fb7c8c-6c66-4d02-b04d-546c5c407297"
      decimals="3"
      id="F_b584955e-aa41-422c-ada2-c8ec1bcf877f"
      unitRef="U_pure">0.025</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="C_6c747ad1-5f7b-4926-8ac2-714e9199e239"
      decimals="4"
      id="F_cc68a917-4dd7-45ac-95e6-2dbc73af8c94"
      unitRef="U_pure">57.924</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="C_7b934074-97f1-4177-96bc-6664a24ee9fa"
      decimals="2"
      id="F_dc011ca6-5953-44f1-b660-8fba7ef4f07f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">17.26</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <inva:DebtInstrumentConvertibleConversionPremium
      contextRef="C_7b934074-97f1-4177-96bc-6664a24ee9fa"
      decimals="3"
      id="F_d8209cf8-0bc8-428a-989e-8793da566d81"
      unitRef="U_pure">0.30</inva:DebtInstrumentConvertibleConversionPremium>
    <us-gaap:SharePrice
      contextRef="C_4e8c55ea-f6dc-4620-b986-2786c29cf612"
      decimals="2"
      id="F_1d0de603-0d3a-469c-a40a-ae047bc15c46"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">13.28</us-gaap:SharePrice>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="C_6c747ad1-5f7b-4926-8ac2-714e9199e239"
      id="F_e761b618-6f74-4d00-b319-55dc3aaaa1fb">2025-08-15</us-gaap:DebtInstrumentMaturityDate>
    <inva:DebtConversionCommonStockPriceToConversionPriceRatioPercentage
      contextRef="C_d9c7ca7c-81fc-4272-b388-610e1b6444a8"
      decimals="2"
      id="F_361ad168-60a0-4fef-811d-09c2e2a68fb8"
      unitRef="U_pure">1.30</inva:DebtConversionCommonStockPriceToConversionPriceRatioPercentage>
    <inva:DebtConversionConvertedInstrumentAverageTradePricePercentage
      contextRef="C_d9c7ca7c-81fc-4272-b388-610e1b6444a8"
      decimals="2"
      id="F_f34abc0c-97fc-4530-acac-75dc986bff0f"
      unitRef="U_pure">0.98</inva:DebtConversionConvertedInstrumentAverageTradePricePercentage>
    <inva:DebtInstrumentRatioOfRepurchasePriceToThePrincipalAmount
      contextRef="C_bfe82950-e87e-4ffb-ad0e-84e0026f5b0c"
      decimals="2"
      id="F_cadca6db-3a81-4e0d-844c-dc84defaa481"
      unitRef="U_pure">1</inva:DebtInstrumentRatioOfRepurchasePriceToThePrincipalAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="C_5b63eaba-876c-4443-a190-0d776e3f0354"
      decimals="-5"
      id="F_a119c076-3fcb-4315-8e2c-4e3ed9d2eed9"
      unitRef="U_USD">67300000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:PaymentOfFinancingAndStockIssuanceCosts
      contextRef="C_d9c7ca7c-81fc-4272-b388-610e1b6444a8"
      decimals="-5"
      id="F_c6604ce3-ef80-4c7d-9546-2cada20f428a"
      unitRef="U_USD">5400000</us-gaap:PaymentOfFinancingAndStockIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="C_d9c7ca7c-81fc-4272-b388-610e1b6444a8"
      decimals="-5"
      id="F_1611ed7e-0b9a-41e7-9350-bb8f17ffab01"
      unitRef="U_USD">3500000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_d9c7ca7c-81fc-4272-b388-610e1b6444a8"
      decimals="-5"
      id="F_3c3eb0f8-a7ad-45bb-a8ac-986a9880c50c"
      unitRef="U_USD">1900000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="C_96f1c8f6-d5af-40ca-aebd-5dd11479b360"
      decimals="4"
      id="F_e0d57e38-00fd-404d-9fd8-17fe0f1ddf46"
      unitRef="U_pure">0.0887</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="C_a89fb91f-9ba5-4dc8-a73e-32d0a623c796"
      decimals="4"
      id="F_2a62bc1a-cd04-4822-9432-05ed6346a4dd"
      unitRef="U_pure">0.0288</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="C_e6805147-9eff-450d-a94b-d8e4239b1dd2"
      decimals="4"
      id="F_3dc619e1-a033-4f91-a47b-f9c96304afd1"
      unitRef="U_pure">0.0288</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:ConvertibleDebtTableTextBlock
      contextRef="C_d9c7ca7c-81fc-4272-b388-610e1b6444a8"
      id="F_0b4381c8-8b34-4c30-a4b6-766e0be51a3f">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Our outstanding 2025 Notes balances consisted of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:53.88%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.26%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:18.799999999999997%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.26%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:18.799999999999997%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Principal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;192,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;192,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Debt discount and issuance costs, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,205&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,917&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net carrying amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;191,295&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;190,583&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ConvertibleDebtTableTextBlock>
    <inva:DebtInstrumentPrincipalAmount
      contextRef="C_aab90c2e-843e-4eca-8999-f7ad6f6f31c9"
      decimals="-3"
      id="F_c72d48b0-98f2-4cae-80cb-b81bc30f1516"
      unitRef="U_USD">192500000</inva:DebtInstrumentPrincipalAmount>
    <inva:DebtInstrumentPrincipalAmount
      contextRef="C_87231fad-8817-4c3e-8afb-e2378841555d"
      decimals="-3"
      id="F_06e6178f-a61c-4481-a353-e6d4c134d3f5"
      unitRef="U_USD">192500000</inva:DebtInstrumentPrincipalAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="C_aab90c2e-843e-4eca-8999-f7ad6f6f31c9"
      decimals="-3"
      id="F_bed37f89-c575-4d45-ab96-edeca82d2673"
      unitRef="U_USD">1205000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="C_87231fad-8817-4c3e-8afb-e2378841555d"
      decimals="-3"
      id="F_745fb5a1-ca61-4b7b-b9d3-09c21797bd2d"
      unitRef="U_USD">1917000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:LongTermDebt
      contextRef="C_aab90c2e-843e-4eca-8999-f7ad6f6f31c9"
      decimals="-3"
      id="F_6b3ff789-89b0-4e20-80ae-e926aafc74df"
      unitRef="U_USD">191295000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="C_87231fad-8817-4c3e-8afb-e2378841555d"
      decimals="-3"
      id="F_4cee7335-3cb7-4bb3-9098-134c79623e86"
      unitRef="U_USD">190583000</us-gaap:LongTermDebt>
    <us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock
      contextRef="C_d9c7ca7c-81fc-4272-b388-610e1b6444a8"
      id="F_08c14028-c203-4bad-a6c8-1df895dc6ee6">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table sets forth total interest expense recognized related to the 2025 Notes for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023, 2022 and 2021:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.01%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.203%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.203%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.583%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Contractual interest expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,813&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,813&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,813&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Amortization of debt issuance costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;712&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;692&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;657&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Amortization of debt discount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,898&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total interest and amortization expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,525&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,505&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,368&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="C_bfe82950-e87e-4ffb-ad0e-84e0026f5b0c"
      decimals="-3"
      id="F_25d65c4f-bb98-4082-9510-29b17a96a5ad"
      unitRef="U_USD">4813000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="C_32d8d95b-c12c-46d1-98c1-3deb4b8cb129"
      decimals="-3"
      id="F_14f0624a-5b37-4353-86df-1e90dbf4882b"
      unitRef="U_USD">4813000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="C_e3e6ec1f-49a0-4fb9-9419-c9b6fcbc8855"
      decimals="-3"
      id="F_5af7e1b6-5577-4852-a1d1-1e5751ffa349"
      unitRef="U_USD">4813000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="C_bfe82950-e87e-4ffb-ad0e-84e0026f5b0c"
      decimals="-3"
      id="F_d63c43b6-93c9-4697-9fa2-4f761394c185"
      unitRef="U_USD">712000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="C_32d8d95b-c12c-46d1-98c1-3deb4b8cb129"
      decimals="-3"
      id="F_ea2bfe28-5996-424a-9624-327d497fbe9d"
      unitRef="U_USD">692000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="C_e3e6ec1f-49a0-4fb9-9419-c9b6fcbc8855"
      decimals="-3"
      id="F_93e7059f-53fe-4ff4-9d0c-bce6652c58d9"
      unitRef="U_USD">657000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="C_bfe82950-e87e-4ffb-ad0e-84e0026f5b0c"
      decimals="-3"
      id="F_ff3a466e-7eaa-431f-98b5-02a26d4e1e22"
      unitRef="U_USD">0</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="C_32d8d95b-c12c-46d1-98c1-3deb4b8cb129"
      decimals="-3"
      id="F_f0176460-942a-43dd-bf59-169736db24bc"
      unitRef="U_USD">0</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="C_e3e6ec1f-49a0-4fb9-9419-c9b6fcbc8855"
      decimals="-3"
      id="F_f74ed6c1-9395-4764-9cf4-b7a3754e2f3d"
      unitRef="U_USD">7898000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:InterestExpenseDebt
      contextRef="C_bfe82950-e87e-4ffb-ad0e-84e0026f5b0c"
      decimals="-3"
      id="F_e410d43f-3d93-49b3-9c3c-ce22adb8f109"
      unitRef="U_USD">5525000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="C_32d8d95b-c12c-46d1-98c1-3deb4b8cb129"
      decimals="-3"
      id="F_11c8a395-d2d0-417e-b963-5c3a3857c2f2"
      unitRef="U_USD">5505000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="C_e3e6ec1f-49a0-4fb9-9419-c9b6fcbc8855"
      decimals="-3"
      id="F_fc4f7d9d-64ec-4725-8a4a-8755f7291765"
      unitRef="U_USD">13368000</us-gaap:InterestExpenseDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_6872c5a6-9354-4f1c-9344-b3b75b5392e8"
      decimals="-5"
      id="F_7aae06a5-df6f-4874-ae2c-0ea625d8d878"
      unitRef="U_USD">261000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="C_a0e6a86f-d6b7-4f77-89aa-49a1c8b20ae6"
      id="F_59170e43-d667-4e24-b275-75aacd90dd32">2028-03-15</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_7087d489-2159-4c5e-b41f-f209f859c49e"
      decimals="-5"
      id="F_c09beff9-120c-4eac-b888-43c9f23a1cb1"
      unitRef="U_USD">45000000</us-gaap:DebtInstrumentFaceAmount>
    <inva:PortionOfDebtInstrumentFaceAmountExercised
      contextRef="C_7087d489-2159-4c5e-b41f-f209f859c49e"
      decimals="-5"
      id="F_ae3ff1c5-ddf9-434d-aa12-9839a294b711"
      unitRef="U_USD">36000000</inva:PortionOfDebtInstrumentFaceAmountExercised>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_6872c5a6-9354-4f1c-9344-b3b75b5392e8"
      decimals="-5"
      id="F_e9c5b2f8-6ee9-4e43-9116-767b3f001251"
      unitRef="U_USD">261000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="C_a0e6a86f-d6b7-4f77-89aa-49a1c8b20ae6"
      decimals="-5"
      id="F_635fc246-6c33-4855-8cd2-dad7bb5602da"
      unitRef="U_USD">252600000</us-gaap:ProceedsFromConvertibleDebt>
    <inva:PurchasesOfCappedCallsInConnectionWithConvertibleSeniorNotes
      contextRef="C_0882851d-0bed-4150-b837-2e1f74d8e460"
      decimals="-5"
      id="F_1bb96a0b-c393-4653-8f54-519e9ba6b4db"
      unitRef="U_USD">21000000</inva:PurchasesOfCappedCallsInConnectionWithConvertibleSeniorNotes>
    <us-gaap:RepaymentsOfUnsecuredDebt
      contextRef="C_cce222e5-dac9-4c08-abb5-d90f2a3b1707"
      decimals="-5"
      id="F_5b7e4b18-e899-415c-af4a-5fcbb96cf872"
      unitRef="U_USD">165600000</us-gaap:RepaymentsOfUnsecuredDebt>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="C_eed06e0c-196c-43ba-8f27-6f6c2781e050"
      decimals="-5"
      id="F_cb16d33d-9d1b-4d76-b9fc-3d4d80bda161"
      unitRef="U_USD">144800000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="C_bf5886d1-1be6-4c7a-bfe3-1be3dd08388d"
      decimals="5"
      id="F_a31b8813-7fee-4d2e-896a-9ba39fe3ecf0"
      unitRef="U_pure">0.02125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="C_44f330d4-92f5-4b09-a61f-569ed269bd6e"
      decimals="4"
      id="F_f719f987-dd86-420a-bb6e-7a6485ef407d"
      unitRef="U_pure">38.1432</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="C_7adc5fad-9ae2-4326-83c1-8d6394980f7e"
      decimals="2"
      id="F_a2137393-4e88-48b3-984c-016886019ede"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">26.22</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <inva:DebtConversionCommonStockPriceToConversionPriceRatioPercentage
      contextRef="C_a0e6a86f-d6b7-4f77-89aa-49a1c8b20ae6"
      decimals="2"
      id="F_fa80e96a-a03a-4289-bf7f-3f1d434737ea"
      unitRef="U_pure">1.30</inva:DebtConversionCommonStockPriceToConversionPriceRatioPercentage>
    <inva:DebtConversionConvertedInstrumentAverageTradePricePercentage
      contextRef="C_a0e6a86f-d6b7-4f77-89aa-49a1c8b20ae6"
      decimals="2"
      id="F_0c26ec3c-7148-477d-9406-aae5ac69c096"
      unitRef="U_pure">0.98</inva:DebtConversionConvertedInstrumentAverageTradePricePercentage>
    <inva:DebtInstrumentRatioOfRepurchasePriceToThePrincipalAmount
      contextRef="C_a0e6a86f-d6b7-4f77-89aa-49a1c8b20ae6"
      decimals="2"
      id="F_f329e02d-c6b5-46cd-8c05-6d02a562b184"
      unitRef="U_pure">1</inva:DebtInstrumentRatioOfRepurchasePriceToThePrincipalAmount>
    <us-gaap:LineOfCreditFacilityCovenantTerms
      contextRef="C_6f92e4e3-0288-40a0-9972-c89e1aac1433"
      id="F_e865c4e6-9fbd-431d-b34c-cc95e55b8b7c">The indenture governing the 2028 Notes contains customary terms and covenants, including a merger covenant and that upon certain events of default occurring and continuing, either the Trustee or the holders of at least 25% of the aggregate principal amount of the outstanding Notes may declare 100% of the principal of, and accrued and unpaid interest, if any, on, all the Notes to be due and payable immediately.</us-gaap:LineOfCreditFacilityCovenantTerms>
    <us-gaap:DerivativeCapPrice
      contextRef="C_e2dfcab8-9a69-48b0-bbd8-dd20190bc830"
      decimals="4"
      id="F_589df2ee-2c98-4bea-9258-d56ab07689f5"
      unitRef="U_UsdItem">33.985</us-gaap:DerivativeCapPrice>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="C_c11bea0f-0ab6-46b3-9574-250a23feeefc"
      decimals="4"
      id="F_ae011e47-6c0e-4c12-86bb-e41fed86c937"
      unitRef="U_pure">0.027</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:ConvertibleDebtTableTextBlock
      contextRef="C_6f92e4e3-0288-40a0-9972-c89e1aac1433"
      id="F_59143c81-782e-4967-8f50-e9fc69973a57">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Our outstanding 2028 Notes balance consisted of th&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;e following:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.313%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.843%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.843%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Principal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;261,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;261,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Debt discount and issuance costs, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,061&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,403&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net carrying amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;254,939&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;253,597&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ConvertibleDebtTableTextBlock>
    <inva:DebtInstrumentPrincipalAmount
      contextRef="C_c11bea0f-0ab6-46b3-9574-250a23feeefc"
      decimals="-3"
      id="F_891e0afe-003d-4f50-8c3d-1956061a34e3"
      unitRef="U_USD">261000000</inva:DebtInstrumentPrincipalAmount>
    <inva:DebtInstrumentPrincipalAmount
      contextRef="C_fb34b57e-973b-4997-8a2c-2f01d3f8fa62"
      decimals="-3"
      id="F_25a0e1dd-ae3e-4a86-88c1-76e165f33497"
      unitRef="U_USD">261000000</inva:DebtInstrumentPrincipalAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="C_c11bea0f-0ab6-46b3-9574-250a23feeefc"
      decimals="-3"
      id="F_3423bdd8-dca1-46d1-bb93-4a1073626699"
      unitRef="U_USD">6061000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="C_fb34b57e-973b-4997-8a2c-2f01d3f8fa62"
      decimals="-3"
      id="F_d719cd5b-cc1f-419e-9245-6a9f3a0d3aac"
      unitRef="U_USD">7403000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:LongTermDebt
      contextRef="C_c11bea0f-0ab6-46b3-9574-250a23feeefc"
      decimals="-3"
      id="F_d268a315-a9d4-4355-9473-630ba2fd1e73"
      unitRef="U_USD">254939000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="C_fb34b57e-973b-4997-8a2c-2f01d3f8fa62"
      decimals="-3"
      id="F_352f3d8e-1ffd-48d7-a530-6ea77910939e"
      unitRef="U_USD">253597000</us-gaap:LongTermDebt>
    <us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock
      contextRef="C_6f92e4e3-0288-40a0-9972-c89e1aac1433"
      id="F_8a971575-7c20-4cfb-bce0-f291770bd156">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table sets forth total interest expense recognized related to the 2028 Notes for the year ended December 31, 2023 and from the issuance through December 31, 2022:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.313%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.843%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.843%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Date of Issuance through&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Contractual interest expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,546&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,514&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Amortization of debt discount and issuance costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,342&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,061&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total interest and amortization expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,888&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,575&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="C_9f19eb4c-29fe-474d-b77a-08e5bb571e8e"
      decimals="-3"
      id="F_99e87089-2733-482b-86f2-fb95cf93c5e2"
      unitRef="U_USD">5546000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="C_1595673f-bb14-4c0c-b50c-19b1db664ef7"
      decimals="-3"
      id="F_32a3895b-df6f-4722-ba1b-fa8a9867cea0"
      unitRef="U_USD">4514000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="C_9f19eb4c-29fe-474d-b77a-08e5bb571e8e"
      decimals="-3"
      id="F_bd559644-15a4-4679-a2c3-c6616e5bb490"
      unitRef="U_USD">1342000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="C_1595673f-bb14-4c0c-b50c-19b1db664ef7"
      decimals="-3"
      id="F_108e2988-9a62-4086-a92e-80fee9ee57e0"
      unitRef="U_USD">1061000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:InterestExpenseDebt
      contextRef="C_9f19eb4c-29fe-474d-b77a-08e5bb571e8e"
      decimals="-3"
      id="F_53b0c67e-090d-47cd-a4d2-f84c42707df1"
      unitRef="U_USD">6888000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="C_1595673f-bb14-4c0c-b50c-19b1db664ef7"
      decimals="-3"
      id="F_79c0a96b-b9ed-43de-b41b-28de0266cdb6"
      unitRef="U_USD">5575000</us-gaap:InterestExpenseDebt>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      id="F_efe95fd0-6b2f-4269-aeb5-245dfeeb4e53">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The aggregate scheduled maturities of our convertible debt as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.444%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.8%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.757%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Year ending December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;192,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;261,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;453,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_c83c3f98-5561-471a-9b96-3a4b19da82fa"
      unitRef="U_USD">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_2f9f31e7-b197-4a90-850f-f0ab03920a9a"
      unitRef="U_USD">192500000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_205f4cf8-dfd9-4d56-98e9-93f4bc23172a"
      unitRef="U_USD">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_9d1a8422-edb0-4ace-96ae-629bbd1b04c8"
      unitRef="U_USD">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_b0ca7900-0b8e-4ae9-916a-56add4eb2346"
      unitRef="U_USD">261000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_34f8728f-772a-416a-a036-b6bd1d1aed75"
      unitRef="U_USD">453500000</us-gaap:DebtInstrumentCarryingAmount>
    <inva:RoyaltyAgreementMaximumPotentialPayoutPercent
      contextRef="C_47540ae3-5ee1-428f-99db-8eab3bc7a785"
      decimals="2"
      id="F_e244f9fc-2891-40b9-9bef-163739f814ef"
      unitRef="U_pure">0.14</inva:RoyaltyAgreementMaximumPotentialPayoutPercent>
    <inva:RoyaltyAgreementIncreaseInMaximumPotentialPayoutPercent
      contextRef="C_47540ae3-5ee1-428f-99db-8eab3bc7a785"
      decimals="2"
      id="F_6601824d-b285-4a61-b866-0ec48258d069"
      unitRef="U_pure">0.18</inva:RoyaltyAgreementIncreaseInMaximumPotentialPayoutPercent>
    <inva:RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentTwo
      contextRef="C_47540ae3-5ee1-428f-99db-8eab3bc7a785"
      decimals="-5"
      id="F_0a631d63-7063-4a98-98a8-d5e97c66677a"
      unitRef="U_USD">225000000</inva:RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentTwo>
    <us-gaap:InterestExpenseBorrowings
      contextRef="C_a99937e1-764a-4db1-ae21-40947196ea5e"
      decimals="-5"
      id="F_ac1df2eb-161a-4280-add1-8e04fe805781"
      unitRef="U_USD">6500000</us-gaap:InterestExpenseBorrowings>
    <us-gaap:InterestExpenseBorrowings
      contextRef="C_abc0a929-7e90-463f-b887-b58ca920de42"
      decimals="-5"
      id="F_f0fb4fca-b836-44e0-a371-887cfbcb5893"
      unitRef="U_USD">1800000</us-gaap:InterestExpenseBorrowings>
    <inva:DeferredRoyaltyObligations
      contextRef="C_7cde4835-b322-4448-9e0f-120e1bccc549"
      decimals="-5"
      id="F_81db57c7-3087-4663-bd45-55a33e96d461"
      unitRef="U_USD">69900000</inva:DeferredRoyaltyObligations>
    <inva:DeferredRoyaltyObligations
      contextRef="C_046580cc-7efc-42fb-b5c6-9fa3ae87d270"
      decimals="-5"
      id="F_9692aec1-2f92-4b70-86d7-978ebbf3aa16"
      unitRef="U_USD">70600000</inva:DeferredRoyaltyObligations>
    <inva:RoyaltyPayments
      contextRef="C_a99937e1-764a-4db1-ae21-40947196ea5e"
      decimals="-5"
      id="F_7cad6a2d-fea6-47ac-9a69-8cb76069695b"
      unitRef="U_USD">5400000</inva:RoyaltyPayments>
    <inva:RoyaltyPayments
      contextRef="C_abc0a929-7e90-463f-b887-b58ca920de42"
      decimals="-5"
      id="F_49c49ec4-e2bd-4fd1-b6fd-755a21122836"
      unitRef="U_USD">1000000</inva:RoyaltyPayments>
    <inva:InterestRateOfDeferredRoyaltyObligation
      contextRef="C_a99937e1-764a-4db1-ae21-40947196ea5e"
      decimals="4"
      id="F_b4c501df-2806-491d-8f19-6be77571165f"
      unitRef="U_pure">0.1646</inva:InterestRateOfDeferredRoyaltyObligation>
    <inva:RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentOne
      contextRef="C_47540ae3-5ee1-428f-99db-8eab3bc7a785"
      decimals="-5"
      id="F_97e7cc18-6045-4cc9-b34d-2e1f547ae367"
      unitRef="U_USD">125000000</inva:RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentOne>
    <inva:RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentTwo
      contextRef="C_47540ae3-5ee1-428f-99db-8eab3bc7a785"
      decimals="-5"
      id="F_d612a0ab-2c0a-480d-994a-e1b11f4daa13"
      unitRef="U_USD">225000000</inva:RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentTwo>
    <inva:PaymentsForRoyaltyAgreement
      contextRef="C_47540ae3-5ee1-428f-99db-8eab3bc7a785"
      decimals="-5"
      id="F_dfb7d166-1e3d-46e1-b060-f80a71d63a0e"
      unitRef="U_USD">18100000</inva:PaymentsForRoyaltyAgreement>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      id="F_d86927fb-decb-4a8c-8b28-8ca796d0a490">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;13. COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Operating Lease&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We have operating leases for our corporate headquarters, office spaces and laboratory facilities.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Our operating leases include a facility lease consisting of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20,062&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; square feet of office and laboratory space in Waltham, Massachusetts. Effective April 2022, we exercised our renewal option for to extend the lease term for three additional years through December 2025.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In 2019, we entered into an operating lease for our headquarters in Burlingame, California for approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,111&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; rentable square feet. The lease commenced in November 2019 with an initial term of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_7da350c6-153c-485b-808f-be5a8394009e;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;thirty-six&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; calendar months, which was subsequently amended to expire in December 2027.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The components of lease costs are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.313%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.843%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.843%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Straight line operating lease costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,428&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,585&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Variable lease costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;189&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;155&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total lease costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,617&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,740&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Supplemental cash flow information related to leases are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.313%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.843%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.843%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cash paid for amounts included in the measurement of &lt;br/&gt;&#160;&#160;&#160;operating lease liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,542&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;790&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating lease right-of-use assets obtained in exchange &lt;br/&gt;&#160;&#160;&#160;for operating lease obligations&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,323&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Right-of-use assets obtained through acquisitions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,185&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023, our operating leases have weighted-average remaining term of approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2.3&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; years and the weighted-average discount rate on our operating lease liabilities was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We have not presented the comparative information above for the year ended December 31, 2021 as our operating lease during this year was not material.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Future minimum lease payments on our operating leases as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.444%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.8%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.757%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Year ending December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,373&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,428&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;143&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;149&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,093&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;251&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;    &lt;/span&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_4335f0ee-8c74-4e0b-beba-133f49c7dc56;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;  Total operating lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,842&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Legal Proceedings&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;From time to time, the Company is involved in legal proceedings in the ordinary course of its business. We are not currently a party to any material legal proceedings except as discussed below.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On February 15, 2022, La Jolla received a paragraph IV notice of certification (the &#x201c;First Notice Letter&#x201d;) from Gland Pharma Limited (&#x201c;Gland&#x201d;) advising that Gland had submitted an Abbreviated New Drug Application (&#x201c;ANDA&#x201d;) to the FDA seeking approval to manufacture, use or sell a generic version of GIAPREZA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; in the U.S. prior to the expiration of U.S. Patent Nos.: 9,220,745; 9,572,856; 9,867,863; 10,028,995; 10,335,451; 10,493,124; 10,500,247; 10,548,943; 11,096,983; and 11,219,662 (the &#x201c;GIAPREZA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; Patents&#x201d;), which are listed in the FDA&#x2019;s Approved Drug Products with Therapeutic Equivalence Evaluations (the &#x201c;Orange Book&#x201d;). The First Notice Letter alleges that the GIAPREZA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; Patents are invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of the generic product described in Gland&#x2019;s ANDA.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On March 29, 2022, La Jolla filed a complaint for patent infringement of the GIAPREZA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; Patents against Gland and certain related entities in the United States District Court for the District of New Jersey in response to Gland&#x2019;s ANDA filing. In accordance with the Hatch-Waxman Act, because GIAPREZA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; is a new chemical entity and La Jolla filed a complaint for patent infringement within 45 days of receipt of the First Notice Letter, the FDA cannot approve Gland&#x2019;s ANDA any earlier than 7.5 years from the approval of the GIAPREZA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; NDA unless the District Court finds that all of the asserted claims of the patents-in-suit are invalid, unenforceable and/or not infringed.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On February 22, 2023, La Jolla received a paragraph IV notice of certification (the &#x201c;Second Notice Letter&#x201d;) from Gland advising that Gland had amended its ANDA filing to include a paragraph IV certification alleging that all claims of the newly-issued and Orange Book-listed U.S. Patent No. 11,559,559 (&#x201c;the &#x2019;559 Patent&#x201d;), which covers GIAPREZA&#xae;, are invalid, unenforceable and/or not infringed.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On March 22, 2023, La Jolla filed a First Amended Complaint in this litigation adding Gland&#x2019;s marketing and distribution partners for its ANDA angiotensin II product, Fresenius Kabi USA LLC and Fresenius Kabi SwissBiosim GmbH (collectively, the &#x201c;Fresenius Kabi Defendants&#x201d;), as co-defendants. On April 7, 2023, La Jolla filed a Second Amended Complaint in response to the Second Notice Letter, adding claims that the manufacture, use, sale, offer for sale, or import of Gland&#x2019;s ANDA angiotensin II product will infringe the &#x2019;559 Patent. On November 14, 2023, La Jolla filed a Third Amended Complaint adding additional infringement claims against the Fresenius Kabi Defendants. We intend to vigorously enforce our intellectual property rights relating to GIAPREZA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Fact discovery is set to conclude on February 29, 2024 and expert discovery will be complete by July 12, 2024. A trial date has not yet been set in this matter.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Given the early stage of this matter, we cannot reasonably estimate a potential future loss or a range of potential future losses, if any, and have not recorded a contingent liability accrual as of December 31, 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Indemnifications and Other Contingencies&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In the ordinary course of business, we may provide indemnifications of varying scope and terms to vendors, directors, officers, and other parties with respect to certain matters, including, but not limited to, losses arising out of breach of such agreements, services to be provided by us, our negligence or willful misconduct, violations of law, or intellectual property infringement claims made by third parties. In addition, we have entered into indemnification agreements with directors and certain officers and employees that will require us, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors, officers, or employees. No material demands have been made upon us to provide indemnification under such agreements, and thus, there are no claims that we are aware of that could have a material effect in our consolidated financial statements. We also maintain director and officer insurance, which may cover certain liabilities arising from our obligation to indemnify our directors. To date, we have not incurred any material costs and, as of December 31, 2023, we have not accrued any liabilities in the consolidated financial statements as a result of these provisions.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="C_669beef7-e71d-4c69-83c1-57065488410a"
      decimals="INF"
      id="F_4d5e831e-7356-4e50-9e37-980a43ed330d"
      unitRef="U_sqft">20062</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:NetRentableArea
      contextRef="C_b14e6b43-6384-43b6-9c33-6f1a35010333"
      decimals="INF"
      id="F_7b37f5db-77bf-403d-b066-d4c6715e30eb"
      unitRef="U_sqft">2111</us-gaap:NetRentableArea>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      id="F_b5147742-247f-4521-b9f4-672ab51afec1">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The components of lease costs are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.313%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.843%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.843%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Straight line operating lease costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,428&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,585&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Variable lease costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;189&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;155&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total lease costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,617&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,740&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_f28a1787-7b21-43b4-8ad6-6977f7f2ee53"
      unitRef="U_USD">1428000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_78e75855-de36-4672-ba3a-7f61275dd001"
      unitRef="U_USD">1585000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_714c2965-70ed-42bf-9d74-7852b7f9f81d"
      unitRef="U_USD">189000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_417a283d-c157-42af-ad3b-fef7a437e490"
      unitRef="U_USD">155000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_e079b7f4-f058-419b-b41d-1379ce4c99fb"
      unitRef="U_USD">1617000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_6e9d1d1a-0dae-420e-9eec-d96faaa22122"
      unitRef="U_USD">1740000</us-gaap:LeaseCost>
    <us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      id="F_dc7a1280-1b19-4982-89fc-ef961e4a6c53">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Supplemental cash flow information related to leases are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.313%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.843%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.843%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cash paid for amounts included in the measurement of &lt;br/&gt;&#160;&#160;&#160;operating lease liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,542&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;790&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating lease right-of-use assets obtained in exchange &lt;br/&gt;&#160;&#160;&#160;for operating lease obligations&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,323&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Right-of-use assets obtained through acquisitions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,185&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_95d54c3e-61d5-46d0-8778-350b1b293063"
      unitRef="U_USD">1542000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_a56bcd41-ca7d-41c9-ae0a-96d514786613"
      unitRef="U_USD">790000</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_67651e79-7caa-483a-8146-b345a86cd55d"
      unitRef="U_USD">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_65fbaebb-c969-4f74-8401-3d99075400ba"
      unitRef="U_USD">3323000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <inva:RightOfUseAssetsObtainedThroughAcquistions
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_8a26630c-6581-4943-a94b-169a91ff761d"
      unitRef="U_USD">0</inva:RightOfUseAssetsObtainedThroughAcquistions>
    <inva:RightOfUseAssetsObtainedThroughAcquistions
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_e2d60dd3-9141-44b4-aab1-efbfef1a4bac"
      unitRef="U_USD">1185000</inva:RightOfUseAssetsObtainedThroughAcquistions>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      id="F_414ba284-c4ca-4eed-867a-f3107230dda8">P2Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <inva:OperatingLeaseWeightedAverageIncrementalBorrowingRate
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="3"
      id="F_b5c7853c-4ecb-409e-805a-d70207dfb13c"
      unitRef="U_pure">0.076</inva:OperatingLeaseWeightedAverageIncrementalBorrowingRate>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      id="F_2629987c-d234-4d83-9b43-64349c24656b">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Future minimum lease payments on our operating leases as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.444%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.8%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.757%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Year ending December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,373&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,428&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;143&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;149&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,093&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;251&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;    &lt;/span&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_4335f0ee-8c74-4e0b-beba-133f49c7dc56;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;  Total operating lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,842&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_1bff0ed9-9c13-4ad8-9c8d-8f4cca630dba"
      unitRef="U_USD">1373000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_5013ae42-f574-49cf-bf04-bcb7bf1df8eb"
      unitRef="U_USD">1428000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_9fd43e5c-734d-491a-a079-3d411b31ff1b"
      unitRef="U_USD">143000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <inva:LesseeOperatingLeaseLiabilityToBePaidAfterYearThree
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_cd930406-6595-4ea7-94aa-8b5d618f887a"
      unitRef="U_USD">149000</inva:LesseeOperatingLeaseLiabilityToBePaidAfterYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_7159a43c-b3e1-4c1d-8c95-9ad811936b69"
      unitRef="U_USD">3093000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_e012dab2-3069-4c99-ad22-b9558f62002f"
      unitRef="U_USD">251000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_82e888a1-4fa5-40f2-a4dc-801b92a5a357"
      unitRef="U_USD">2842000</us-gaap:OperatingLeaseLiability>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      id="F_a4456011-4edd-4155-8c71-a146cbcec95a">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;14. INCOME TAXES&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Income tax expense consists of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.311%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.481%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.75%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.481%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.75%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.481%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.75%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,799&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;40,822&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,177&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;464&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,976&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;41,286&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,594&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;26,026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;70,893&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,194&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;625&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,539&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total deferred&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,400&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25,401&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;76,432&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;vertical-align:bottom;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total income tax expense, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,376&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;66,687&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;76,439&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The impacts of the differences between the expected U.S. federal statutory income tax to our income tax expense are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.311%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.481%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.75%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.481%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.75%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.481%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.75%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected tax at federal statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;40,747&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;58,928&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;93,507&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;State income tax, net of federal benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,433&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,414&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;848&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Federal and state research credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,582&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,453&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,260&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Section 250 deduction&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,274&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Noncontrolling interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,468&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21,626&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Impact of consolidation and deconsolidation of subsidiaries&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,897&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,219&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;125&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,129&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,167&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,180&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,321&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total income tax expense, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,376&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;66,687&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;76,439&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Significant components of our deferred tax assets and deferred tax liabilities are as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:56.36%;"&gt;&lt;/td&gt;
        &lt;td style="width:2%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:17.82%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:17.82%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;182,013&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;149,646&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development tax credit carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21,357&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21,230&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Unrealized loss on investment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,032&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred royalty obligation, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18,084&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17,404&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,467&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,527&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total deferred tax assets before valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;227,921&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;202,839&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;169,249&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;144,808&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;58,672&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;58,031&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Depreciation and amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;39,064&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50,587&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Unrealized gain on investment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,747&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Inventory fair value adjustment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,424&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,410&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;805&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;563&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,771&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We record deferred tax assets if the realization of such assets is more likely than not to occur. Significant management judgment is required in determining whether a valuation allowance against the deferred tax assets is required. We have considered all available evidence, both positive and negative, such as our historical operating results and predictability of future taxable income, in making such determination. We are also required to exercise significant management&#x2019;s judgment in forecasting future taxable income. Specifically, we evaluate the following criteria when considering a valuation allowance:&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;the history of tax net operating losses in recent years;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;predictability of operating results;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;profitability for a sustained period of time; and&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;level of profitability on a quarterly basis.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023, we had federal net operating loss carryforwards of approximately &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;543.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, which will expire beginning 2034. As of December 31, 2023, we also had state net operating loss carryforwards of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; billion&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, which will expire beginning 2029 and state research tax credits of approximately &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;33.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, which do not expire.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Utilization of net operating loss and tax credit carryforwards may be subject to a substantial annual limitation due to ownership change limitations provided by the Internal Revenue Code and similar state provisions. Annual limitations may result in expiration of net operating loss and tax credit carryforwards before some or all of such amounts have been utilized.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We conducted an Internal Revenue Code of 1986, as amended, Section 382 (&#x201c;Section 382&#x201d;) analysis of the Company through December 31, 2022 to determine whether an ownership change had occurred since inception. The Section 382 study concluded that it is more likely than not that the Company did not experience an ownership change during the testing period. If we ever undergo an ownership change, the utilization of the pre-ownership change net operating loss carryforwards or pre-ownership change tax attributes, such as research tax credits, to offset the post-ownership change income may be subject to an annual limitation, pursuant to Sections 382 and 383 of the Internal Revenue Code of 1986, as amended. Similar rules may apply under state tax laws.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As a result of the acquisition of Entasis, we conducted a study of Entasis&#x2019; ownership changes and estimated that we will be able to utilize $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;155.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of its federal net operating losses, which are subject to annual limitations.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As a result of the acquisition of La Jolla, we also performed an analysis of its ownership changes and estimated that we will be able to utilize $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;309.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of its federal net operating losses, which are subject to annual limitations.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Our policy is to recognize interest and/or penalties related to income tax matters in income tax expense. As of December 31, 2023 and 2022, we had &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; accrued interest or penalties due to the Company&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2019;s net operating losses available to offset any tax adjustments.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Uncertain Tax Positions&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;A reconciliation of the beginning and ending balances of the total amounts of unrecognized tax benefits are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:76.46%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.34%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:19.2%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Unrecognized tax benefits as of December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,185&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net decrease in tax portions for 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;313&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Unrecognized tax benefits as of December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,872&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net increase in tax portions for 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,452&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Unrecognized tax benefits as of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16,324&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net increase in tax portions for 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,119&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Unrecognized tax benefits as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19,443&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We are subject to taxation in the U.S. and various state jurisdictions. The tax years 2006 through 2013, 2015 and forward remain open to examination by the federal and most state tax authorities due to net operating loss and overall credit carryforward positions.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In December 2021, the Organization for Economic Cooperation and Development (&#x201c;OECD&#x201d;) enacted model rules for a new global minimum tax framework (&#x201c;BEPS Pillar Two&#x201d;), and various governments around the world have enacted, or are in the process of enacting legislation. We are in the process of evaluating whether and when these new rules may come into effect and apply to us.  We plan to treat the tax if any as a period cost. We do not believe that the Pillar Two rules apply to us yet.  As such, the potential future quantitative impact of the enacted or substantively enacted legislation is not yet reasonably estimable.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      id="F_d81c565b-640d-4b3c-b235-f608c4a72dab">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Income tax expense consists of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.311%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.481%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.75%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.481%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.75%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.481%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.75%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,799&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;40,822&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,177&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;464&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,976&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;41,286&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,594&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;26,026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;70,893&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,194&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;625&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,539&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total deferred&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,400&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25,401&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;76,432&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;vertical-align:bottom;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total income tax expense, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,376&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;66,687&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;76,439&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_cae0bbd3-a340-465d-92b9-6294c965c36c"
      unitRef="U_USD">7799000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_3b00f08d-e101-4de2-bddc-fac52396cc34"
      unitRef="U_USD">40822000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="-3"
      id="F_ed9158b9-43cb-4145-b6f8-aec6907b5360"
      unitRef="U_USD">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_e107cc8e-42be-4532-9be9-a8a30fc8d31e"
      unitRef="U_USD">2177000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_b5edd728-145e-4e6f-848b-3e5b96badc2e"
      unitRef="U_USD">464000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="-3"
      id="F_b69e5108-f291-485f-9e6e-d13719aec7a4"
      unitRef="U_USD">7000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_240ed584-a314-4381-aa37-dea1225f1d1b"
      unitRef="U_USD">9976000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_6f7928d5-8cc3-4720-be3d-d0ee3ea854a9"
      unitRef="U_USD">41286000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="-3"
      id="F_52d44819-85c0-483b-b1db-9261a2421112"
      unitRef="U_USD">7000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_a8ca3586-0255-45c2-b40b-144033664eea"
      unitRef="U_USD">6594000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_6148e256-6808-4395-8df5-ed5f8c17fc35"
      unitRef="U_USD">26026000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="-3"
      id="F_38cc2855-f555-498f-9382-5d78b98171da"
      unitRef="U_USD">70893000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_8430ea7c-47f5-46ee-9693-516b4c1a5b22"
      unitRef="U_USD">-2194000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_8eb00778-a9b1-47b8-b5c4-9e622694f588"
      unitRef="U_USD">-625000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="-3"
      id="F_51155404-2c99-4457-b8f6-e261565c9469"
      unitRef="U_USD">5539000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_fd698089-9069-4a10-a5a6-865e6e4c80b8"
      unitRef="U_USD">4400000</us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_d9b3c4d8-eda9-4825-935f-328c1b70d0c7"
      unitRef="U_USD">25401000</us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="-3"
      id="F_52193b2f-eb58-4877-af65-6b7a6f09da93"
      unitRef="U_USD">76432000</us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_b031e1ae-b46c-4960-b9ab-7f12945b9024"
      unitRef="U_USD">14376000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_27ac999d-61c5-4b6f-b305-80b5b80bbea3"
      unitRef="U_USD">66687000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="-3"
      id="F_fd0e3767-896d-4dcb-827b-b27a60a95179"
      unitRef="U_USD">76439000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      id="F_304f787d-b60f-4005-b3b6-0ffac4a484b6">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The impacts of the differences between the expected U.S. federal statutory income tax to our income tax expense are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.311%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.481%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.75%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.481%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.75%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.481%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.75%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected tax at federal statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;40,747&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;58,928&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;93,507&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;State income tax, net of federal benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,433&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,414&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;848&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Federal and state research credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,582&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,453&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,260&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Section 250 deduction&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,274&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Noncontrolling interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,468&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21,626&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Impact of consolidation and deconsolidation of subsidiaries&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,897&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,219&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;125&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,129&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,167&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,180&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,321&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total income tax expense, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,376&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;66,687&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;76,439&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_f010d9f0-353a-4a0b-8b54-e10adbb743e0"
      unitRef="U_USD">40747000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_8fcd81fe-abd8-4445-93eb-a664702e4cb9"
      unitRef="U_USD">58928000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="-3"
      id="F_7b507b21-de11-40a0-84e5-cf4efb1da214"
      unitRef="U_USD">93507000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_4c4d1508-9912-47dd-aa6b-89230195599d"
      unitRef="U_USD">1433000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_dc74d82a-55af-4cf6-a0e7-9b65a8a73966"
      unitRef="U_USD">-1414000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="-3"
      id="F_5b43c2d3-0942-4eac-b141-132f4da191df"
      unitRef="U_USD">848000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_a4671c0b-4c4f-43c7-878a-e80f1da27b29"
      unitRef="U_USD">-1582000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_5224486e-c2b1-4ffb-871e-e6ed0afa192b"
      unitRef="U_USD">-2453000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="-3"
      id="F_74abf689-d52c-4069-868b-0bde4c390cb8"
      unitRef="U_USD">1260000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationDeductionsOther
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_8a6461b2-ae92-44fe-bf66-c4b474a4d15c"
      unitRef="U_USD">15274000</us-gaap:IncomeTaxReconciliationDeductionsOther>
    <us-gaap:IncomeTaxReconciliationDeductionsOther
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_374a9e6d-e5b9-4c14-b5df-e80e23e6c922"
      unitRef="U_USD">0</us-gaap:IncomeTaxReconciliationDeductionsOther>
    <us-gaap:IncomeTaxReconciliationDeductionsOther
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="-3"
      id="F_79118a2a-45e0-4ab0-bce5-9191a3a0b35b"
      unitRef="U_USD">0</us-gaap:IncomeTaxReconciliationDeductionsOther>
    <us-gaap:IncomeTaxReconciliationMinorityInterestIncomeExpense
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_14f47642-bb3b-4d47-82c8-2408656fb0ca"
      unitRef="U_USD">0</us-gaap:IncomeTaxReconciliationMinorityInterestIncomeExpense>
    <us-gaap:IncomeTaxReconciliationMinorityInterestIncomeExpense
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_40e810a8-830f-4a0c-8a9c-a37ebae4e8d3"
      unitRef="U_USD">-7468000</us-gaap:IncomeTaxReconciliationMinorityInterestIncomeExpense>
    <us-gaap:IncomeTaxReconciliationMinorityInterestIncomeExpense
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="-3"
      id="F_f9360b69-e56e-4c71-a7b0-c05733fe7457"
      unitRef="U_USD">21626000</us-gaap:IncomeTaxReconciliationMinorityInterestIncomeExpense>
    <us-gaap:IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_c9d37bb1-2d12-4b62-8833-6d7b95215eaf"
      unitRef="U_USD">0</us-gaap:IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary>
    <us-gaap:IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_85d4fcee-0037-4de1-bb9b-8a2e5994c1ff"
      unitRef="U_USD">-8897000</us-gaap:IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary>
    <us-gaap:IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="-3"
      id="F_11b12143-fe96-4e91-bd5a-b907ecabc32a"
      unitRef="U_USD">0</us-gaap:IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_1fe5b857-ff9d-425f-8c4e-258c66188b9d"
      unitRef="U_USD">1219000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_ee8db7f3-73ed-4be2-bdbb-860707e1c6f1"
      unitRef="U_USD">-125000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="-3"
      id="F_441f228b-36ef-400f-862a-48d33de974ce"
      unitRef="U_USD">1129000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_3bf0413b-1753-492c-a020-fc4e7f6f245c"
      unitRef="U_USD">-12167000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_fffb7dca-c234-4d19-ae37-2829c3835079"
      unitRef="U_USD">13180000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="-3"
      id="F_5111b844-1563-4a41-83a1-41cad1559818"
      unitRef="U_USD">1321000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_2993d321-025b-46e6-8a5e-531c3bd54201"
      unitRef="U_USD">14376000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_5f70aded-57ec-444e-8e64-4af20a597208"
      unitRef="U_USD">66687000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="-3"
      id="F_758d085a-a9d5-4f6a-a516-06bfff3b1e91"
      unitRef="U_USD">76439000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      id="F_fee71e65-1ad7-4401-9973-4245d9ffb94f">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Significant components of our deferred tax assets and deferred tax liabilities are as follows:&lt;/span&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:56.36%;"&gt;&lt;/td&gt;
        &lt;td style="width:2%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:17.82%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:17.82%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;182,013&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;149,646&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development tax credit carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21,357&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21,230&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Unrealized loss on investment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,032&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred royalty obligation, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18,084&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17,404&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,467&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,527&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total deferred tax assets before valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;227,921&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;202,839&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;169,249&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;144,808&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;58,672&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;58,031&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Depreciation and amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;39,064&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50,587&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Unrealized gain on investment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,747&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Inventory fair value adjustment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,424&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,410&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;805&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;563&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,771&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_a68e1546-b23e-41e2-8edb-6fbe1bc56e3d"
      unitRef="U_USD">182013000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      decimals="-3"
      id="F_9ba58509-077c-4d13-8a9a-7c14c9bc8c1b"
      unitRef="U_USD">149646000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_16fa89d1-46d8-4804-bfd1-2c3f31764b5b"
      unitRef="U_USD">21357000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      decimals="-3"
      id="F_af802ca1-3a41-4b0a-b52d-0cccc570495a"
      unitRef="U_USD">21230000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <inva:DeferredTaxAssetsUnrealizedLossesOnInvestmentNet
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_3d7d346b-8390-4f16-8ee4-853618f4a727"
      unitRef="U_USD">0</inva:DeferredTaxAssetsUnrealizedLossesOnInvestmentNet>
    <inva:DeferredTaxAssetsUnrealizedLossesOnInvestmentNet
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      decimals="-3"
      id="F_3ff87072-0b88-4c22-a4d5-5c6f2f7dff82"
      unitRef="U_USD">6032000</inva:DeferredTaxAssetsUnrealizedLossesOnInvestmentNet>
    <inva:DeferredTaxAssetsDeferredRoyaltyObligationNet
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_81da5f42-0b6e-45c7-82fc-85dc4df3e182"
      unitRef="U_USD">18084000</inva:DeferredTaxAssetsDeferredRoyaltyObligationNet>
    <inva:DeferredTaxAssetsDeferredRoyaltyObligationNet
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      decimals="-3"
      id="F_3e01b464-f506-47a3-b005-114c52b717fb"
      unitRef="U_USD">17404000</inva:DeferredTaxAssetsDeferredRoyaltyObligationNet>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_1ff7badb-7d28-4ff4-b342-a90806de2f0b"
      unitRef="U_USD">6467000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      decimals="-3"
      id="F_81f0a9a5-8def-4380-ad8a-9ae00c81c76d"
      unitRef="U_USD">8527000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_2105104e-8753-47dd-8ed8-5d3623582346"
      unitRef="U_USD">227921000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      decimals="-3"
      id="F_a14a5fff-b4af-41b3-ab52-d5e8bf4e48d4"
      unitRef="U_USD">202839000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_28ad28c8-736f-48a4-8571-49da3b912dc8"
      unitRef="U_USD">169249000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      decimals="-3"
      id="F_eeddd89c-577f-4dd4-8407-fc9c27fe976f"
      unitRef="U_USD">144808000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_0286f692-ae0b-4775-b71f-973a2fb1ace4"
      unitRef="U_USD">58672000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      decimals="-3"
      id="F_75489f29-e08c-48d3-ae16-6b3dee39ac1d"
      unitRef="U_USD">58031000</us-gaap:DeferredTaxAssetsNet>
    <inva:DeferredTaxLiabilitiesDepreciationAndAmortization
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_fe6da3dc-0e84-4852-9311-f9192c8b1624"
      unitRef="U_USD">-39064000</inva:DeferredTaxLiabilitiesDepreciationAndAmortization>
    <inva:DeferredTaxLiabilitiesDepreciationAndAmortization
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      decimals="-3"
      id="F_4859a712-3da0-475a-af4e-f9a181a27b70"
      unitRef="U_USD">-50587000</inva:DeferredTaxLiabilitiesDepreciationAndAmortization>
    <us-gaap:DeferredTaxLiabilitiesInvestments
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_334ccf84-c8ef-4e20-81e5-43785a6ebf7c"
      unitRef="U_USD">13747000</us-gaap:DeferredTaxLiabilitiesInvestments>
    <us-gaap:DeferredTaxLiabilitiesInvestments
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      decimals="-3"
      id="F_41e7df49-c874-41bf-862b-6482fd980bcc"
      unitRef="U_USD">0</us-gaap:DeferredTaxLiabilitiesInvestments>
    <inva:DeferredTaxLiabilitiesInventoryFairValueAdjustment
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_1651f3c2-c3d1-4f7d-a7a6-1d0353e6b22a"
      unitRef="U_USD">-6424000</inva:DeferredTaxLiabilitiesInventoryFairValueAdjustment>
    <inva:DeferredTaxLiabilitiesInventoryFairValueAdjustment
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      decimals="-3"
      id="F_562d2225-5687-4373-96c0-712ac451728d"
      unitRef="U_USD">-12410000</inva:DeferredTaxLiabilitiesInventoryFairValueAdjustment>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_1ccb0ca0-a8d6-4e6b-8386-1252ab6253e2"
      unitRef="U_USD">0</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      decimals="-3"
      id="F_f9d451df-8648-46bd-b3c5-e790ce70c3d0"
      unitRef="U_USD">-805000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_ff4be056-754f-4e7f-b0c9-6558242306ba"
      unitRef="U_USD">563000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      decimals="-3"
      id="F_4490f298-8e3b-4436-b079-58a89e034338"
      unitRef="U_USD">5771000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_552da0c1-853f-4893-a1b0-a4223d212e95"
      decimals="-5"
      id="F_81ac6b5d-e388-4636-b05e-87fc45efd0f7"
      unitRef="U_USD">543500000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_5f1754a6-1e81-4cbd-8bf9-4f5f1ce7bd5f"
      decimals="-8"
      id="F_a8c2120b-b196-4bb2-9b80-f8f56dc66af2"
      unitRef="U_USD">1000000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_8e9e31d1-92be-49a8-9a9a-67c314bf7e73"
      decimals="-5"
      id="F_fbab969c-a360-4a7f-8adb-c7fe38f24ab9"
      unitRef="U_USD">33300000</us-gaap:TaxCreditCarryforwardAmount>
    <inva:FederalNetOperatingLossesEstimatedUtilizationAmount
      contextRef="C_09977380-7092-418e-b4d3-d48f7caaae46"
      decimals="-5"
      id="F_5ed97001-680f-41fb-938f-eb4d14751420"
      unitRef="U_USD">155600000</inva:FederalNetOperatingLossesEstimatedUtilizationAmount>
    <inva:FederalNetOperatingLossesEstimatedUtilizationAmount
      contextRef="C_9b30963d-d42c-4ba2-85ac-e1f548c6e616"
      decimals="-5"
      id="F_f526b038-626c-46ab-89f9-d1d19ee1cbf9"
      unitRef="U_USD">309500000</inva:FederalNetOperatingLossesEstimatedUtilizationAmount>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_d707e5a3-fea6-464f-bd99-31fd83fc546b"
      unitRef="U_USD">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      decimals="-3"
      id="F_e2480865-8173-4b25-955f-a854f1b74535"
      unitRef="U_USD">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      id="F_d109e6dd-7872-45ea-ab18-5cb6587c55d4">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;A reconciliation of the beginning and ending balances of the total amounts of unrecognized tax benefits are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:76.46%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.34%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:19.2%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Unrecognized tax benefits as of December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,185&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net decrease in tax portions for 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;313&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Unrecognized tax benefits as of December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,872&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net increase in tax portions for 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,452&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Unrecognized tax benefits as of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16,324&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net increase in tax portions for 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,119&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Unrecognized tax benefits as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19,443&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_646bb33b-4ef6-4493-b542-00c92f556418"
      decimals="-3"
      id="F_5279e76e-ddf3-4596-affe-d78519e490bd"
      unitRef="U_USD">15185000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_6bb9d5ad-dd77-4e1c-9c70-326cd71ad19b"
      decimals="-3"
      id="F_66d4f817-b7ba-4935-a175-1f96945f8fc8"
      unitRef="U_USD">313000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_c2c8ab67-08be-4854-91e3-98e911bef5b3"
      decimals="-3"
      id="F_e732bbbc-53f6-405a-a931-71b96be1fe93"
      unitRef="U_USD">14872000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_2a658234-c59b-4b8b-b3e3-f2816b3aeccb"
      decimals="-3"
      id="F_33419dca-cd50-4d3c-9c45-9be7f3912a5c"
      unitRef="U_USD">1452000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_919c050c-8a72-41cb-a13c-102eefa52e63"
      decimals="-3"
      id="F_95c4c416-662c-4c9e-b750-ee7a08bab147"
      unitRef="U_USD">16324000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      decimals="-3"
      id="F_55629020-4237-4ba8-9c41-02deaa428553"
      unitRef="U_USD">3119000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_89447e67-fc05-4e77-9ac9-db6d75b7d66e"
      decimals="-3"
      id="F_17040fe0-7815-4fda-8ee2-2339bc4bade4"
      unitRef="U_USD">19443000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      id="F_ed2bb416-e5ab-4d76-bca2-773282e576b4">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;15. SUBSEQUENT EVENTS&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On February 13, 2024, ITH entered into a Third Note Amendment Agreement with Gate to amend the Gate Convertible Note. Pursuant to the Third Note Amendment Agreement, the principal amount of the Gate Convertible Note was increased from $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;33.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, which represents the principal and accrued interest as of the amendment date and an additional cash investment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. All other material terms of the Gate Convertible Note were unchanged.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On February 23, 2024, ITH purchased a subordinated convertible promissory note (the &#x201c;ImaginAb Convertible Note&#x201d;) from ImaginAb for a total purchase price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. The ImaginAb Convertible Note bears an annual interest of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% and shall be due and payable upon the earlier to occur of January 31, 2025 and certain events defined in the ImaginAb Convertible Note. Under certain circumstances, the ImaginAb Convertible Note is convertible at the option of ITH into ImaginAb&#x2019;s equity securities at defined conversion prices. The ImaginAb Convertible Note is subordinate to certain existing indebtedness of ImaginAb as defined in the ImaginAb Convertible Note.&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_ea704773-4bd5-40ed-9730-d6a668d17624"
      decimals="-5"
      id="F_ff961027-d441-4045-9603-ba80fea6416e"
      unitRef="U_USD">27700000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_3b21613e-2472-472e-b92e-7b218fb6aecc"
      decimals="-5"
      id="F_dd992304-852d-4b12-b9d1-de1e03725b42"
      unitRef="U_USD">33500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:PaymentsToAcquireLongtermInvestments
      contextRef="C_825c0bd4-909c-4d86-9ae9-0ce6eb8cdcf2"
      decimals="-5"
      id="F_3b127812-7f71-4b32-9902-796fd7ca45f2"
      unitRef="U_USD">5000000</us-gaap:PaymentsToAcquireLongtermInvestments>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="C_1ba9463a-d1f5-4a30-bbac-3bc5aad6339b"
      decimals="-5"
      id="F_1e265029-1ed9-4a12-a74e-975d953f6153"
      unitRef="U_USD">2700000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="C_1ba9463a-d1f5-4a30-bbac-3bc5aad6339b"
      decimals="2"
      id="F_470017ab-b51e-40e4-9a3e-96c1804827e1"
      unitRef="U_pure">0.10</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <dei:AuditorName
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      id="F_47568f74-f4b9-4b5a-908a-352d18716ad9">Deloitte &amp; Touche LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="C_b5138b8b-4530-41d2-a75c-4212efb677c1"
      id="F_c1246bbf-3a43-430f-addb-10571caa5744">San Jose, California</dei:AuditorLocation>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="C_d5f73726-2a05-4be7-87fa-3fd6369578ba"
      id="F_d7a62b0f-0b0c-4521-b31a-3153357f191b">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag
      contextRef="C_d5f73726-2a05-4be7-87fa-3fd6369578ba"
      id="F_27712b0b-3359-4939-92dd-bd559b24e741">false</ecd:NonRule10b51ArrAdoptedFlag>
    <inva:Rule10B51ArrModifiedFlag
      contextRef="C_d5f73726-2a05-4be7-87fa-3fd6369578ba"
      id="F_1bba5060-2cd3-4d71-b702-cdec62395141">false</inva:Rule10B51ArrModifiedFlag>
    <inva:NonRule10B51ArrModifiedFlag
      contextRef="C_d5f73726-2a05-4be7-87fa-3fd6369578ba"
      id="F_f521b277-acbb-4d90-bf98-bc45f037f7a8">false</inva:NonRule10B51ArrModifiedFlag>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="C_d5f73726-2a05-4be7-87fa-3fd6369578ba"
      id="F_f85b2d46-3cb9-4f9e-89c9-5b3cd1546844">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag
      contextRef="C_d5f73726-2a05-4be7-87fa-3fd6369578ba"
      id="F_2d7d9811-ad17-480c-9299-717f1011ae72">false</ecd:NonRule10b51ArrTrmntdFlag>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#F_fd0c3223-a52a-48b1-a54d-d2343a4454e1"
          xlink:label="F_fd0c3223-a52a-48b1-a54d-d2343a4454e1"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_f02c3cdb-acc9-4cbf-9957-678c00ecf7f0"
          xlink:label="F_f02c3cdb-acc9-4cbf-9957-678c00ecf7f0"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_f2a97274-1f4f-460d-ae0c-feb28444b496"
          xlink:label="F_f2a97274-1f4f-460d-ae0c-feb28444b496"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_c2d29a19-daed-4394-b61e-859713cd07bf"
          xlink:label="F_c2d29a19-daed-4394-b61e-859713cd07bf"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_e397c611-ef5b-4261-b926-3631409061a6"
          xlink:label="F_e397c611-ef5b-4261-b926-3631409061a6"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_9f51a90b-d5b3-4baf-a592-557db4d38798"
          xlink:label="F_9f51a90b-d5b3-4baf-a592-557db4d38798"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_10f70c8e-4f7f-4ca3-b77a-59255ab84f38"
          xlink:label="F_10f70c8e-4f7f-4ca3-b77a-59255ab84f38"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_19514078-4d7f-46e4-9ec3-6baa01d8bc45"
          xlink:label="F_19514078-4d7f-46e4-9ec3-6baa01d8bc45"
          xlink:type="locator"/>
        <link:footnote id="FNT_e66ad88b-f785-4158-ae1c-5740243b0d71" xlink:label="FNT_e66ad88b-f785-4158-ae1c-5740243b0d71" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><xhtml:span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">(1)</xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">   The year ended December 31, 2022 represents the period from January 1, 2022 to July 20, 2022, the date of the sale of our ownership interest in TRC.</xhtml:span></xhtml:p></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_fd0c3223-a52a-48b1-a54d-d2343a4454e1"
          xlink:to="FNT_e66ad88b-f785-4158-ae1c-5740243b0d71"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_f02c3cdb-acc9-4cbf-9957-678c00ecf7f0"
          xlink:to="FNT_e66ad88b-f785-4158-ae1c-5740243b0d71"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_f2a97274-1f4f-460d-ae0c-feb28444b496"
          xlink:to="FNT_e66ad88b-f785-4158-ae1c-5740243b0d71"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_c2d29a19-daed-4394-b61e-859713cd07bf"
          xlink:to="FNT_e66ad88b-f785-4158-ae1c-5740243b0d71"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_e397c611-ef5b-4261-b926-3631409061a6"
          xlink:to="FNT_e66ad88b-f785-4158-ae1c-5740243b0d71"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_9f51a90b-d5b3-4baf-a592-557db4d38798"
          xlink:to="FNT_e66ad88b-f785-4158-ae1c-5740243b0d71"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_10f70c8e-4f7f-4ca3-b77a-59255ab84f38"
          xlink:to="FNT_e66ad88b-f785-4158-ae1c-5740243b0d71"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_19514078-4d7f-46e4-9ec3-6baa01d8bc45"
          xlink:to="FNT_e66ad88b-f785-4158-ae1c-5740243b0d71"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#F_64e8fe2d-9ccc-4d48-a246-d18907408dd4"
          xlink:label="F_64e8fe2d-9ccc-4d48-a246-d18907408dd4"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_e2184934-bd84-4125-9424-85c04dca4927"
          xlink:label="F_e2184934-bd84-4125-9424-85c04dca4927"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_e248727d-972b-4bb6-ab0b-09782adb2852"
          xlink:label="F_e248727d-972b-4bb6-ab0b-09782adb2852"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_35d88796-82fe-4251-9612-1a4e04f63d2e"
          xlink:label="F_35d88796-82fe-4251-9612-1a4e04f63d2e"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_5b257131-c564-45cc-91a5-088cab24c28e"
          xlink:label="F_5b257131-c564-45cc-91a5-088cab24c28e"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_b9ac7d88-0ec7-4a44-b18b-b9ac67c540d1"
          xlink:label="F_b9ac7d88-0ec7-4a44-b18b-b9ac67c540d1"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_4a70ed61-c9ff-4827-8179-ace3ddd3bf0d"
          xlink:label="F_4a70ed61-c9ff-4827-8179-ace3ddd3bf0d"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_26a4b48a-8a57-4a41-bd9e-43886a8b595b"
          xlink:label="F_26a4b48a-8a57-4a41-bd9e-43886a8b595b"
          xlink:type="locator"/>
        <link:footnote id="FNT_30a29ac4-a358-403f-922e-b22439018a34" xlink:label="FNT_30a29ac4-a358-403f-922e-b22439018a34" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Money market funds are included in cash and cash equivalents in the consolidated balance sheets.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_64e8fe2d-9ccc-4d48-a246-d18907408dd4"
          xlink:to="FNT_30a29ac4-a358-403f-922e-b22439018a34"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_e2184934-bd84-4125-9424-85c04dca4927"
          xlink:to="FNT_30a29ac4-a358-403f-922e-b22439018a34"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_e248727d-972b-4bb6-ab0b-09782adb2852"
          xlink:to="FNT_30a29ac4-a358-403f-922e-b22439018a34"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_35d88796-82fe-4251-9612-1a4e04f63d2e"
          xlink:to="FNT_30a29ac4-a358-403f-922e-b22439018a34"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_5b257131-c564-45cc-91a5-088cab24c28e"
          xlink:to="FNT_30a29ac4-a358-403f-922e-b22439018a34"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_b9ac7d88-0ec7-4a44-b18b-b9ac67c540d1"
          xlink:to="FNT_30a29ac4-a358-403f-922e-b22439018a34"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_4a70ed61-c9ff-4827-8179-ace3ddd3bf0d"
          xlink:to="FNT_30a29ac4-a358-403f-922e-b22439018a34"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_26a4b48a-8a57-4a41-bd9e-43886a8b595b"
          xlink:to="FNT_30a29ac4-a358-403f-922e-b22439018a34"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#F_b935334f-0493-4661-b36b-bead7c670f68"
          xlink:label="F_b935334f-0493-4661-b36b-bead7c670f68"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_640cced8-8c0d-4ecb-b7e5-b8a0e34874d2"
          xlink:label="F_640cced8-8c0d-4ecb-b7e5-b8a0e34874d2"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_163fe0cd-4268-4bdf-8328-6e0ab0363e8f"
          xlink:label="F_163fe0cd-4268-4bdf-8328-6e0ab0363e8f"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_22478cef-8f79-4fb5-9e36-deaf9b1d90f8"
          xlink:label="F_22478cef-8f79-4fb5-9e36-deaf9b1d90f8"
          xlink:type="locator"/>
        <link:footnote id="FNT_24bb9798-5eb0-4e31-b65e-3441d7813ebf" xlink:label="FNT_24bb9798-5eb0-4e31-b65e-3441d7813ebf" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The investments held by ISP Fund LP, consisted of $</xhtml:span><xhtml:span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">248.5</xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in equity investments, which included private placement positions of $</xhtml:span><xhtml:span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">60.6</xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, and $</xhtml:span><xhtml:span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">62.9</xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in money market funds. A certain portion of the total capital contribution of $</xhtml:span><xhtml:span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">300.0</xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million is no longer subject to a </xhtml:span><xhtml:span style="font-size:10pt;font-family:Times New Roman;"><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">36-month</xhtml:span></xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> lock-up period from the date of such capital contribution. However, we did </xhtml:span><xhtml:span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t elect to make a withdrawal in 2023, thereby extending the lock-up period and withdrawal elections into subsequent years. </xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_b935334f-0493-4661-b36b-bead7c670f68"
          xlink:to="FNT_24bb9798-5eb0-4e31-b65e-3441d7813ebf"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_640cced8-8c0d-4ecb-b7e5-b8a0e34874d2"
          xlink:to="FNT_24bb9798-5eb0-4e31-b65e-3441d7813ebf"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_163fe0cd-4268-4bdf-8328-6e0ab0363e8f"
          xlink:to="FNT_24bb9798-5eb0-4e31-b65e-3441d7813ebf"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_22478cef-8f79-4fb5-9e36-deaf9b1d90f8"
          xlink:to="FNT_24bb9798-5eb0-4e31-b65e-3441d7813ebf"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#F_8a869d89-7a7a-45db-ada7-7a991d2546c3"
          xlink:label="F_8a869d89-7a7a-45db-ada7-7a991d2546c3"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_16adad2a-1e35-499c-8549-470982d5bd2a"
          xlink:label="F_16adad2a-1e35-499c-8549-470982d5bd2a"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_007ca7f4-d174-4a7c-a703-836236edbe52"
          xlink:label="F_007ca7f4-d174-4a7c-a703-836236edbe52"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_642b9e4b-f8ea-48f4-9e68-c69a54e91074"
          xlink:label="F_642b9e4b-f8ea-48f4-9e68-c69a54e91074"
          xlink:type="locator"/>
        <link:footnote id="FNT_4e3e88eb-3c93-45b2-a2dc-9cb89ab6791d" xlink:label="FNT_4e3e88eb-3c93-45b2-a2dc-9cb89ab6791d" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The investments held by ISP Fund LP, consisted of $</xhtml:span><xhtml:span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">295.4</xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in equity investments, which included private placement positions and convertible notes of $</xhtml:span><xhtml:span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">54.6</xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, and $</xhtml:span><xhtml:span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">25.1</xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in money market funds. Our total capital contribution of $</xhtml:span><xhtml:span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">300.0</xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million was subject to a </xhtml:span><xhtml:span style="font-size:10pt;font-family:Times New Roman;"><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">36-month</xhtml:span></xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> lock-up period from the date of such capital contributions.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_8a869d89-7a7a-45db-ada7-7a991d2546c3"
          xlink:to="FNT_4e3e88eb-3c93-45b2-a2dc-9cb89ab6791d"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_16adad2a-1e35-499c-8549-470982d5bd2a"
          xlink:to="FNT_4e3e88eb-3c93-45b2-a2dc-9cb89ab6791d"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_007ca7f4-d174-4a7c-a703-836236edbe52"
          xlink:to="FNT_4e3e88eb-3c93-45b2-a2dc-9cb89ab6791d"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_642b9e4b-f8ea-48f4-9e68-c69a54e91074"
          xlink:to="FNT_4e3e88eb-3c93-45b2-a2dc-9cb89ab6791d"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
